FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Kino, H
   Ito, Y
   Akutsu, H
   Tanaka, S
   Hara, T
   Ishikawa, E
   Miyamoto, H
   Matsumaru, Y
   Matsumura, A
AF Kino, Hiroyoshi
   Ito, Yoshiro
   Akutsu, Hiroyoshi
   Tanaka, Shuho
   Hara, Takuma
   Ishikawa, Eiichi
   Miyamoto, Hidetaka
   Matsumaru, Yuji
   Matsumura, Akira
TI Combined Endoscopic Endonasal and Bilateral Subfrontal Approach for a
   Nonfunctioning Pituitary Adenoma Associated with an Internal Carotid
   Artery-Superior Hypophyseal Artery Aneurysm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral aneurysm; Endoscopic endonasal approach; Pituitary adenoma
ID MACROADENOMA; RESECTION
AB BACKGROUND: An aneurysm embedded in a pituitary adenoma is rare, and treatment for both the aneurysm and pituitary adenoma is complex and controversial.
   CASE DESCRIPTION: A 53-year-old woman presented with a visual field defect. Magnetic resonance imaging showed a pituitary adenoma and coexistence of an aneurysm located at the orifice of the superior hypophyseal artery (SHA) from the internal carotid artery (ICA). The aneurysm was embedded in the pituitary adenoma; therefore, obliteration of the aneurysm was needed prior to tumor removal to prevent intraoperative rupture of the aneurysm. Although endovascular coil embolization was tried first, it was not successful. A combined endoscopic endonasal approach and transcranial approach was performed for simultaneous tumor removal and aneurysm clipping. A bilateral subfrontal approach was selected for aneurysm clipping because, using this approach, the parent artery was safely controlled from the ipsilateral trajectory, whereas exposure and clipping of the aneurysm were easily done from the contralateral trajectory. Additionally, the supine head position without rotation is comfortable for endoscopic endonasal surgery. The tumor was totally removed, and the aneurysm was safely and completely obliterated with a clip. The patient's postoperative course was uneventful, and her visual disturbance improved.
   CONCLUSIONS: A combined endoscopic endonasal and bilateral subfrontal approach is effective for a pituitary adenoma associated with an ICA-SHA aneurysm.
C1 [Kino, Hiroyoshi; Ito, Yoshiro; Akutsu, Hiroyoshi; Hara, Takuma; Ishikawa, Eiichi; Matsumaru, Yuji; Matsumura, Akira] Univ Tsukuba, Fac Med, Dept Neurosurg, Tsukuba, Ibaraki, Japan.
   [Tanaka, Shuho; Miyamoto, Hidetaka] Univ Tsukuba, Fac Med, Dept Otolaryngol, Tsukuba, Ibaraki, Japan.
RP Ito, Y (reprint author), Univ Tsukuba, Fac Med, Dept Neurosurg, Tsukuba, Ibaraki, Japan.
EM yoshiro@md.tsukuba.ac.jp
CR Choi HS, 2013, J KOREAN NEUROSURG S, V54, P250, DOI 10.3340/jkns.2013.54.3.250
   Chuang CC, 2006, CEREBROVASC DIS, V21, P142, DOI 10.1159/000090450
   De Jesus O, 1999, SURG NEUROL, V51, P477, DOI 10.1016/S0090-3019(98)00137-2
   Horiuchi T, 2015, J NEUROSURG, V123, P460, DOI 10.3171/2014.12.JNS141218
   Kassam AB, 2007, J NEUROSURG, V107, P1047, DOI 10.3171/JNS-07/11/1047
   Kinouchi H, 2002, J NEUROSURG, V96, P1000, DOI 10.3171/jns.2002.96.6.1000
   Komotar RJ, 2012, PITUITARY, V15, P150, DOI 10.1007/s11102-011-0359-3
   Matsuyama Takeshi, 1993, Neurological Surgery, V21, P171
   NAKAO S, 1981, J NEUROSURG, V54, P532, DOI 10.3171/jns.1981.54.4.0532
   Oh MC, 2012, J NEUROSURG, V116, P942, DOI 10.3171/2011.12.JNS11875
   Ohki M, 1999, No To Shinkei, V51, P895
   Pant B, 1997, NEUROSURG REV, V20, P13, DOI 10.1007/BF01390519
   Sade B, 2004, J NEUROSURG, V100, P557, DOI 10.3171/jns.2004.100.3.0557
   Seda L, 2008, ARQ NEURO-PSIQUIAT, V66, P99, DOI 10.1590/S0004-282X2008000100026
   Serra C, 2019, ACTA NEUROCHIR, V161, P197, DOI 10.1007/s00701-018-3728-0
   Serrano LE, 2019, NEUROSURG REV, V42, P877, DOI 10.1007/s10143-018-01063-3
   Sheikh B, 2000, ACTA NEUROCHIR, V142, P33, DOI 10.1007/s007010050004
   Soni A, 2008, PITUITARY, V11, P307, DOI 10.1007/s11102-007-0063-5
   Tanaka Y, 2002, J NEUROSURG, V96, P649, DOI 10.3171/jns.2002.96.4.0649
   Tayebi Meybodi A, 2018, J NEUROSURG, P1
   WAKAI S, 1979, SURG NEUROL, V12, P503
   Wang Chia-Sheng, 2009, Cases J, V2, P6459, DOI 10.4076/1757-1626-2-6459
   Xia XW, 2012, J CLIN NEUROSCI, V19, P1437, DOI 10.1016/j.jocn.2011.11.032
   Yamada S, 2012, CASE REP NEUROL MED, DOI 10.1155/2012/891847
   Yang MY, 2005, J CLIN NEUROSCI, V12, P477, DOI 10.1016/j.jocn.2004.05.020
   YAPOR WY, 1991, J NEUROSURG, V74, P501, DOI 10.3171/jns.1991.74.3.0501
   Yu K, 2011, BRIT J NEUROSURG, V25, P432, DOI 10.3109/02688697.2010.509521
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 297
EP 301
DI 10.1016/j.wneu.2019.10.159
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200185
PM 31698130
DA 2020-05-12
ER

PT J
AU Bustillo, MA
   Hussain, I
   Virk, MS
   Fu, KM
   Scharoun, JH
AF Bustillo, Maria A.
   Hussain, Ibrahim
   Virk, Michael S.
   Fu, Kai-Ming
   Scharoun, Jacques H.
TI Scoliosis Correction with One Ventricle: A Multispecialty Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Fontan; Scoliosis; Single ventricle
ID FONTAN CIRCULATION; PULMONARY; ADOLESCENT; MANAGEMENT
AB BACKGROUND: Patients with single-ventricle congenital heart disease may present for scoliosis correction. These patients undergo a series of cardiac operations that create a novel circulation that has a significant impact on the management of their spinal surgery.
   CASE DESCRIPTION: A 21-year-old man with severe scoliosis presented for posterior T4-L3 spinal fusion. He was born with complex congenital heart disease that resulted in his having a single functioning ventricle. He underwent a series of operations culminating in a Fontan procedure to palliate his heart disease. Both the surgical procedure and the anesthetic plan were modified based on his abnormal physiology, which led to a successful correction with no complications.
   CONCLUSIONS: Patients who have undergone a Fontan procedure can successfully unuergo a lengthy scoliosis correction, but it requires multidisciplinary planning.
C1 [Bustillo, Maria A.; Scharoun, Jacques H.] Weill Cornell Med Coll, Dept Anesthesiol, New York, NY 10065 USA.
   [Bustillo, Maria A.; Hussain, Ibrahim; Virk, Michael S.; Fu, Kai-Ming] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA.
RP Scharoun, JH (reprint author), Weill Cornell Med Coll, Dept Anesthesiol, New York, NY 10065 USA.
EM jhs2001@med.cornell.edu
OI Scharoun, Jacques/0000-0002-7166-6593
CR Currigan DA, 2014, ANESTHESIOLOGY, V121, P930, DOI 10.1097/ALN.0000000000000430
   Evans S, 2014, BONE JOINT J, V96B, P94, DOI 10.1302/0301-620X.96B1.32581
   Files MD, 2018, AM J PHYSIOL-HEART C, V315, pH1779, DOI 10.1152/ajpheart.00336.2018
   Gewillig M, 2016, HEART, V102, P1081, DOI 10.1136/heartjnl-2015-307467
   Goobie SM, 2018, J BONE JOINT SURG AM, V100, P2024, DOI 10.2106/JBJS.18.00314
   Hedequist DJ, 2006, SPINE, V31, P202, DOI 10.1097/01.brs.0000195162.14945.91
   Herrera-Soto JA, 2007, SPINE, V32, P1998, DOI 10.1097/BRS.0b013e318131b225
   Honda T, 2016, ANN THORAC SURG, V102, P1596, DOI 10.1016/j.athoracsur.2016.03.101
   Jolley M, 2015, ANESTH ANALG, V121, P172, DOI 10.1213/ANE.0000000000000717
   Palmon SC, 1998, ANESTH ANALG, V87, P1175, DOI 10.1097/00000539-199811000-00037
   Vischoff D, 2001, PAEDIATR ANAESTH, V11, P607, DOI 10.1046/j.1460-9592.2001.00715.x
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 302
EP 307
DI 10.1016/j.wneu.2019.11.004
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200186
PM 31715418
DA 2020-05-12
ER

PT J
AU Mattei, TA
   Teasdale, GM
AF Mattei, Tobias A.
   Teasdale, Graham M.
TI The Story of the Development and Adoption of the Glasgow Coma Scale:
   Part I, The Early Years
SO WORLD NEUROSURGERY
LA English
DT Article
DE Coma scales; Glasgow Coma Scale; Glasgow Coma Scale Score; GCS; History
   of neurosurgery; Medical coma; Traumatic brain injury
ID IMPAIRED CONSCIOUSNESS; BRAIN-DAMAGE; HEAD-INJURY; PREDICTION; PROGNOSIS
AB The Glasgow Coma Scale and its derived Score have been adopted worldwide for assessing the degree of impaired responsiveness in traumatic brain injury and other kinds of acute brain damage. In this historical vignette, we describe how the foundations for their enduring success were laid during their initial development. To provide a unique additional background and context, the material from interviews with one of the originators of the scale was brought together with information from key publications in the early years after the first description of the scale in 1974. This historical investigation shows how the contents of the eye, verbal, and motor components of the scale were assembled through analysis of previous systems, guided by early clinimetric principles. Its reproducibility as a tool for clinical communication was confirmed through innovative studies of interobserver variability. To test its validity, international collaborations linking units in Britain, the Netherlands, and the United States were pursued. These collaborations were accompanied by the creation of the total Glasgow Coma Score with a 6-point motor subdivision. The observation that outcomes after severe head injury were similar in the different countries, despite marked variations in management, stimulated controversy that promoted further interest in traumatic brain injury research and a recommendation for the worldwide use of the scale as a common severity marker. Inclusion of the scale in major developments such as the Advanced Trauma Life Support (AILS) and the National Traumatic Coma Databank cemented its influential position in clinical care and research for the succeeding decades.
C1 [Mattei, Tobias A.] St Louis Univ, Div Neurosurg, St Louis, MO 63103 USA.
   [Teasdale, Graham M.] Univ Glasgow, Neurosurg, Glasgow, Lanark, Scotland.
RP Mattei, TA (reprint author), St Louis Univ, Div Neurosurg, St Louis, MO 63103 USA.
EM tobias.mattei@health.slu.edu
CR Ablin G, 1967, WORLD DIRECTORY NEUR
   BARLOW P, 1984, J MICROCOMPUT APPL, V7, P271, DOI 10.1016/0745-7138(84)90059-9
   BATES D, 1977, ANN NEUROL, V2, P211, DOI 10.1002/ana.410020306
   BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491
   Bryan J, 2002, TRAUMA, V4, P91, DOI DOI 10.1191/1460408602TA2330A
   CHAMPION HR, 1990, J TRAUMA, V30, P539, DOI 10.1097/00005373-199005000-00003
   CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008
   Collicott P E, 1979, Nebr Med J, V64, P279
   COLLICOTT PE, 1980, JAMA-J AM MED ASSOC, V243, P1156
   Davis DP, 2006, J TRAUMA, V60, P985, DOI 10.1097/01.ta.0000205860.96209.1c
   Feinstein AR, 1967, CLIN JUDGEMENT
   FISHER CM, 1969, ACTA NEUROL SCAND, VS 45, P5
   FOULKES MA, 1991, J NEUROSURG S, V75, pS
   Green SM, 2011, ANN EMERG MED, V58, P427, DOI 10.1016/j.annemergmed.2011.06.009
   Jennett B, 1975, J R Coll Physicians Lond, V9, P231
   Jennett B, 1972, Clin Neurosurg, V19, P200
   JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291
   JENNETT B, 1972, LANCET, V1, P734
   JENNETT B, 1975, LANCET, V1, P480
   JENNETT B, 1977, LANCET, V1, P878
   JENNETT B, 1976, LANCET, V1, P1031
   Jennett B., 1984, HIGH TECHNOLOGY MED
   JENNETT WB, 1965, BRIT MED J, V1, P1215, DOI 10.1136/bmj.1.5444.1215
   KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008
   LANGFITT TW, 1978, J NEUROSURG, V48, P673, DOI 10.3171/jns.1978.48.5.0673
   LEVY DE, 1981, ANN INTERN MED, V94, P293, DOI 10.7326/0003-4819-94-3-293
   MacEwen W, 1811, LANCET, V118, P581
   Majerus S, 2005, PROG BRAIN RES, V150, P397, DOI 10.1016/S0079-6123(05)50028-1
   MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276
   MCKISSOCK W, 1960, LANCET, V2, P167
   MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289
   MURRAY GD, 1986, STAT MED, V5, P403, DOI 10.1002/sim.4780050504
   MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P
   Plum F, 1972, Contemp Neurol Ser, V10, P1
   Ponce FA, 2014, J NEUROSURG, V120, P1252, DOI 10.3171/2014.2.JNS14358a
   REILLY PL, 1975, LANCET, V2, P375
   Reith FCM, 2017, NEUROSURGERY, V80, P829, DOI 10.1093/neuros/nyw178
   Rowbottham GFR, 1964, ACUTE INJURIES HEAD
   SEGATORE M, 1992, HEART LUNG, V21, P548
   Styner JK, 2006, SURG-J R COLL SURG E, V4, P163, DOI 10.1016/S1479-666X(06)80087-9
   TEASDALE G, 1978, ANESTHESIOLOGY, V49, P225, DOI 10.1097/00000542-197809000-00023
   TEASDALE G, 1983, LANCET, V2, P678
   TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603
   TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862
   TEASDALE G, 1974, LANCET, V2, P81
   Teasdale G, 1975, Nurs Times, V71, P972
   Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13
   TEASDALE GM, 1974, J NEUROL NEUROSUR PS, V37, P1286
   TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457
   Teasdale GM, 2000, INTENS CARE MED, V26, P153, DOI 10.1007/s001340050037
   Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6
NR 51
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 311
EP 322
DI 10.1016/j.wneu.2019.10.193
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200188
PM 31712114
DA 2020-05-12
ER

PT J
AU Das, KK
   Attri, G
   Singh, S
   Bhaisora, KS
   Verma, P
   Jaiswal, S
   Jaiswal, A
   Behari, S
AF Das, Kuntal Kanti
   Attri, Gagandeep
   Singh, Suyash
   Bhaisora, Kamlesh Singh
   Verma, Pawan
   Jaiswal, Sushila
   Jaiswal, Awadeshkumar
   Behari, Sanjay
TI Intradural Extramedullary Nonconus Nonfilum Spinal Ependymomas: Report
   of a Rare Variant and Newer Insights into Their Histogenesis with
   Proposal of a Classification Scheme and a Management Algorithm Based on
   a Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Exophytic growth; Outcome; Pathology; Radiology; Spinal ependymoma;
   Surgery
ID CENTRAL-NERVOUS-SYSTEM; OF-THE-LITERATURE; ANAPLASTIC EPENDYMOMA;
   METASTASES; GLIOMAS; TUMORS; ROOT
AB BACKGROUND: Ependymomas are common intramedullary spinal tumors but there are scattered reports of this tumor presenting with exophytic growth patterns masquerading as intradural extramedullary (IDEM) tumors. Such IDEM ependymomas are seldom suspected preoperatively and it is only during surgery that their existence is revealed. Little is known of such rare growth patterns of an otherwise common intramedullary spinal cord tumor, their characteristics, and their management considerations.
   METHODS: We present a case of an exophytic dorsal ependymoma with a stalk like attachment to the spinal cord and the surgical management in a 24-year old woman. An extensive literature search was carried out on all prominent databases to find out similar cases reported earlier. We excluded filum/conus ependymoma, purely extradural spinal ependymoma as well as the extraspinal ependymomas. Details of each case reported before were obtained and tabulated.
   RESULTS: IDEM ependymomas have been reported in 54 patients so far, including the present case. Four patterns of growth emerged from the literature review: intramedullary ependymoma with exophytic component (group I, n = 9), exophytic IDEM ependymoma without intramedullary component (group II, a = 6), IDEM ependymoma arising from nerve roots (group III, n = 7), and pure IDEM ependymoma (group IV, n = 32). Except in group I, IDEM ependymoma affects females more frequently, without any specific age predilection. Thoracic spinal cord/canal is the most common location across all groups. Multifocal disease, craniospinal dissemination, and recurrences tend to be maximum in group IV.
   CONCLUSIONS: IDEM ependymomas are more common in thoracic segment of the cord and broadly divisible into 4 subgroups. We suggest a subpial origin of group II IDEM ependymomas. We also advocate proliferation index estimation in grade II ependymomas to enable formulation of an optimal management plan.
C1 [Das, Kuntal Kanti; Attri, Gagandeep; Singh, Suyash; Bhaisora, Kamlesh Singh; Verma, Pawan; Jaiswal, Sushila; Jaiswal, Awadeshkumar; Behari, Sanjay] Sanjay Gandhi Post Grad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
   [Verma, Pawan; Jaiswal, Sushila] Sanjay Gandhi Post Grad Inst Med Sci, Dept Pathol, Lucknow, Uttar Pradesh, India.
RP Das, KK (reprint author), Sanjay Gandhi Post Grad Inst Med Sci, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
EM kkdas@sgpgi.ac.in
CR Benzagmout M, 2008, SURG NEUROL, V70, P536, DOI 10.1016/j.surneu.2007.05.055
   Bonfield CM, 2011, NEUROSURGERY, V68, pE831, DOI 10.1227/NEU.0b013e318209257e
   Celano E, 2016, J NEURO-ONCOL, V128, P377, DOI 10.1007/s11060-016-2135-8
   Cerase A, 2006, J NEUROSURG-SPINE, V5, P476, DOI 10.3171/spi.2006.5.5.476
   Chakravorty Ananya, 2017, J Spine Surg, V3, P727, DOI 10.21037/jss.2017.11.10
   Chamberlain Marc C, 2003, Curr Neurol Neurosci Rep, V3, P193, DOI 10.1007/s11910-003-0078-x
   Cheng C. H., 1996, Annals Academy of Medicine Singapore, V25, P869
   Cicero G, 2015, ACTA MEDICA MEDITERR, V31, P1229
   COOPER IS, 1951, SURG GYNECOL OBSTET, V92, P183
   Das Kuntal Kanti, 2017, Asian J Neurosurg, V12, P224, DOI 10.4103/1793-5482.144151
   Duffau H, 2000, SPINE, V25, P1993, DOI 10.1097/00007632-200008010-00021
   EDELSON RN, 1972, NEUROLOGY, V22, P1222, DOI 10.1212/WNL.22.12.1222
   Evzikov G Yu, 2018, Zh Vopr Neirokhir Im N N Burdenko, V82, P48, DOI 10.17116/neiro201882348
   Fasoli F, 2008, NEURORADIOL J, V21, P239, DOI 10.1177/197140090802100214
   Fotakopoulos George, 2014, J Med Case Rep, V8, P438, DOI 10.1186/1752-1947-8-438
   Fuentes Rodriguez N, 2004, REV CUB MED MILITAR, V33
   Funao H, 2016, SPINE J, V16, pE535, DOI 10.1016/j.spinee.2016.01.203
   Gardner L, 2013, NEUROL INDIA, V61, P687, DOI 10.4103/0028-3886.125386
   Gonzalez Feria L, 1971, Arch Neurobiol (Madr), V34, P325
   Graca J, 2006, AM J NEURORADIOL, V27, P818
   Guarnieri G, 2014, NEURORADIOL J, V27, P179, DOI 10.15274/NRJ-2014-10018
   Guppy Kern H, 2011, Surg Neurol Int, V2, P119, DOI 10.4103/2152-7806.84246
   Ha Seung Man, 2012, Korean J Spine, V9, P250, DOI 10.14245/kjs.2012.9.3.250
   Hentschel SJ, 2004, ACTA NEUROCHIR, V146, P1047, DOI 10.1007/s00701-004-0275-7
   HIDA K, 1994, PARAPLEGIA, V32, P52, DOI 10.1038/sc.1994.9
   Honda A, 2017, EUR SPINE J, V26, pS222, DOI 10.1007/s00586-017-5055-1
   ISHIKAWA T, 1988, Neurological Surgery, V16, P1339
   Iunes EA, 2011, J NEUROSURG-SPINE, V14, P65, DOI 10.3171/2010.9.SPINE09963
   Jung TY, 2018, J KOREAN NEUROSURG S, V61, P312, DOI 10.3340/jkns.2018.0003
   KATOH S, 1995, SPINE, V20, P2036, DOI 10.1097/00007632-199509150-00017
   Khatri Deepak, 2019, Asian J Neurosurg, V14, P329, DOI 10.4103/ajns.AJNS_225_18
   Kim Byung Soo, 2013, Korean J Spine, V10, P177, DOI 10.14245/kjs.2013.10.3.177
   Kinsman MJ, 2011, CLIN NEUROL NEUROSUR, V113, P661, DOI 10.1016/j.clineuro.2011.02.021
   Klekamp J, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.5.FOCUS15161
   Krishnan SS, 2012, J NEUROSCI RURAL PRA, V3, P366, DOI 10.4103/0976-3147.102630
   LI MH, 1992, ACTA RADIOL, V33, P207
   Liao DY, 2018, WORLD NEUROSURG, V111, P139, DOI 10.1016/j.wneu.2017.12.069
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Marchesini N, 2019, BRIT J NEUROSURG, DOI 10.1080/02688697.2019.1630551
   Moriwaki T, 2013, ASIAN SPINE J, V7, P139, DOI 10.4184/asj.2013.7.2.139
   Morselli C, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.07.027
   MOSER FG, 1992, NEUROSURGERY, V31, P962, DOI 10.1227/00006123-199211000-00024
   Oh MC, 2013, NEURO-ONCOLOGY, V15, P208, DOI 10.1093/neuonc/nos286
   Oliver B, 1981, Arch Neurobiol (Madr), V44, P215
   Oral S, 2018, TURK NEUROSURG, V28, P158, DOI 10.5137/1019-5149.JTN.14780-15.2
   Orozco LD, 2011, J CLIN NEUROSCI, V18, P1262, DOI 10.1016/j.jocn.2011.01.017
   Palejwala SK, 2014, CUREUS, V6, pe191
   Payer M, 1999, J CLIN NEUROSCI, V6, P344, DOI 10.1016/S0967-5868(99)90061-9
   Perez-Bovet J, 2013, NEUROSURGERY, V72, pE497, DOI 10.1227/NEU.0b013e31827d102e
   Pomeraniec IJ, 2015, J CLIN NEUROSCI, V22, P1871, DOI 10.1016/j.jocn.2015.06.015
   Robles SG, 2005, SPINE, V30, pE251, DOI 10.1097/01.brs.0000161008.13441.7b
   Ruda R, 2018, NEURO-ONCOLOGY, V20, P445, DOI 10.1093/neuonc/nox166
   Sahu RK, 2015, J PEDIATR NEUROSCI, V10, P214, DOI 10.4103/1817-1745.165660
   Schuurmans M, 2006, J NEURO-ONCOL, V79, P57, DOI 10.1007/s11060-005-9114-9
   Severino M, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.04.002
   SHAW EG, 1986, INT J RADIAT ONCOL, V12, P323, DOI 10.1016/0360-3016(86)90345-7
   Singh S, 2018, WORLD NEUROSURG, V113, P184, DOI 10.1016/j.wneu.2018.02.048
   Son DW, 2011, J KOREAN NEUROSURG S, V50, P57, DOI 10.3340/jkns.2011.50.1.57
   Suri Vaishali S, 2004, Indian J Cancer, V41, P66
   Suzuki S, 2001, Brain Tumor Pathol, V18, P151, DOI 10.1007/BF02479429
   Terao Tohru, 2016, NMC Case Rep J, V3, P91, DOI 10.2176/nmccrj.cr.2015-0295
   Tripathy P, 2011, NEUROL NEUROCHIR POL, V45, P397
   Vats A, 2015, J CRANIOVERTEBRAL JU, V6, P134, DOI 10.4103/0974-8237.161596
   VENKATARAMANA NK, 1990, ACTA NEUROCHIR, V107, P44, DOI 10.1007/BF01402611
   Vural M, 2010, J NEUROSURG-SPINE, V12, P467, DOI 10.3171/2009.11.SPINE08780
   WAGLE WA, 1988, J COMPUT ASSIST TOMO, V12, P705, DOI 10.1097/00004728-198807000-00045
   Weinstein GM, 2016, CASE REP PATHOL, DOI 10.1155/2016/3534791
   Wolfla CE, 1997, J NEUROSURG, V87, P643, DOI 10.3171/jns.1997.87.4.0643
NR 69
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 323
EP 336
DI 10.1016/j.wneu.2019.10.152
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200189
PM 31682991
DA 2020-05-12
ER

PT J
AU Christodoulides, I
   Lavrador, JP
   Bodi, I
   Laxton, R
   Gullan, R
   Bhangoo, R
   Vergani, F
   Ashkan, K
AF Christodoulides, Ioannis
   Lavrador, Jose Pedro
   Bodi, Istvan
   Laxton, Ross
   Gullan, Richard
   Bhangoo, Ranjeev
   Vergani, Francesco
   Ashkan, Keyoumars
TI Transformation of Grade II to Grade III Rhabdoid-Papillary Meningioma:
   Is Stereotactic Radiosurgery the Culprit? A Case Report and Literature
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Meningioma; Rhabdoid papillary lesion; Stereotactic radiosurgery;
   Surgery; TERT
ID GAMMA-KNIFE SURGERY; MALIGNANT-TRANSFORMATION; ADJUVANT RADIOTHERAPY;
   PITUITARY-ADENOMA; TUMOR-CONTROL; RECURRENT; BRAIN; CLASSIFICATION;
   EPIDEMIOLOGY; GUIDELINES
AB BACKGROUND: In the management of meningiomas, single-fraction stereotactic radiosurgery (SRS) is an established alternative treatment to surgical resection. However, its effects on tumorigenesis and malignant transformation are still uncertain.
   CASE DESCRIPTION: We have described a grade II parafalcine meningioma was initially surgically resected (Simpson 2 clearance) and then managed with a single dose of SRS on recurrence. The tumor recurred again 7 years later, with histological features of a grade III rhabdoid-papillary lesion, with local brain invasion.
   CONCLUSION: To the best of our knowledge, this is the first report to describe malignant transformation of a grade II to grade III meningioma after SRS to date.
C1 [Christodoulides, Ioannis; Lavrador, Jose Pedro; Gullan, Richard; Bhangoo, Ranjeev; Vergani, Francesco; Ashkan, Keyoumars] Kings Coll Hosp Fdn Trust, Dept Neurosurg, London, England.
   [Bodi, Istvan; Laxton, Ross] Kings Coll Hosp Fdn Trust, Dept Neuropathol, London, England.
RP Christodoulides, I (reprint author), Kings Coll Hosp Fdn Trust, Dept Neurosurg, London, England.
EM ychristodoulides@gmail.com
CR Aras Y, 2013, NEUROL NEUROCHIR POL, V47, P80, DOI 10.5114/ninp.2013.32932
   Biczok A, 2018, J NEURO-ONCOL, V139, P671, DOI 10.1007/s11060-018-2912-7
   Bloch O, 2012, J NEURO-ONCOL, V107, P13, DOI 10.1007/s11060-011-0720-4
   Breen P, 1998, J NEUROSURG, V89, P933, DOI 10.3171/jns.1998.89.6.0933
   CAHAN WG, 1948, CANCER, V1, P3, DOI 10.1002/1097-0142(194805)1:1<3::AID-CNCR2820010103>3.0.CO;2-7
   Chopra R, 2007, INT J RADIAT ONCOL, V68, P845, DOI 10.1016/j.ijrobp.2007.01.001
   Claus EB, 2005, NEUROSURGERY, V57, P1088, DOI 10.1227/01.NEU.0000188281.91351.B9
   Comey CH, 1998, J NEUROSURG, V89, P653, DOI 10.3171/jns.1998.89.4.0653
   DiBiase SJ, 2004, INT J RADIAT ONCOL, V60, P1515, DOI 10.1016/j.ijrobp.2004.05.073
   Durand A, 2009, J NEURO-ONCOL, V95, P367, DOI 10.1007/s11060-009-9934-0
   Erfurth EM, 2001, CLIN ENDOCRINOL, V55, P613, DOI 10.1046/j.1365-2265.2001.01385.x
   Flannery TJ, 2017, J NEUROSURG, V127, P67, DOI 10.3171/2009.8.JNS09695
   Galani V, 2017, CLIN NEUROL NEUROSUR, V158, P119, DOI 10.1016/j.clineuro.2017.05.002
   Germano IM, 2018, NEUROSURGERY, V82, pE49, DOI 10.1093/neuros/nyx515
   Goldbrunner R, 2016, LANCET ONCOL, V17, pE383, DOI 10.1016/S1470-2045(16)30321-7
   Goutagny S, 2014, BRAIN PATHOL, V24, P184, DOI 10.1111/bpa.12110
   Hwang KL, 2017, CHIN CLIN ONCOL, V6, DOI 10.21037/cco.2017.06.09
   Iwami K, 2015, BRAIN TUMOR PATHOL, V32, P137, DOI 10.1007/s10014-014-0190-4
   Jenkinson MD, 2016, J CLIN NEUROSCI, V28, P87, DOI 10.1016/j.jocn.2015.09.021
   JONES A, 1991, CLIN ENDOCRINOL, V35, P379, DOI 10.1111/j.1365-2265.1991.tb03554.x
   Kaul D, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-78
   Kitamura Y, 2013, J NEUROSURG, V119, P494, DOI 10.3171/2013.1.JNS121533
   Kondziolka D, 1998, NEUROSURGERY, V43, P405, DOI 10.1097/00006123-199809000-00001
   Kondziolka D, 2008, NEUROSURGERY, V62, P53, DOI 10.1227/01.NEU.0000311061.72626.0D
   KRUSE F, 1960, NEUROLOGY, V10, P197, DOI 10.1212/WNL.10.2.197
   Kshettry VR, 2015, NEURO-ONCOLOGY, V17, P1166, DOI 10.1093/neuonc/nov069
   Lee HS, 2012, J KOREAN NEUROSURG S, V51, P98, DOI 10.3340/jkns.2012.51.2.98
   LEMAY DR, 1989, SURG NEUROL, V31, P365, DOI 10.1016/0090-3019(89)90068-2
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Mason WP, 2002, J NEUROSURG, V97, P341, DOI 10.3171/jns.2002.97.2.0341
   Mattozo CA, 2007, J NEUROSURG, V106, P846, DOI 10.3171/jns.2007.106.5.846
   MCLEAN CA, 1990, J NEUROSURG, V73, P946, DOI 10.3171/jns.1990.73.6.0946
   Minniti G, 2005, J CLIN ENDOCR METAB, V90, P800, DOI 10.1210/jc.2004-1152
   Moradi A, 2008, J CLIN NEUROSCI, V15, P1370, DOI 10.1016/j.jocn.2007.12.005
   Ngwenya LB, 2012, J NEUROSURG, V117, P666, DOI 10.3171/2012.2.JNS12182
   Osipov V, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-34
   Palma L, 1997, J NEUROSURG, V86, P793, DOI 10.3171/jns.1997.86.5.0793
   Pasquier D, 2008, INT J RADIAT ONCOL, V71, P1388, DOI 10.1016/j.ijrobp.2007.12.020
   Patel TR, 2014, WORLD NEUROSURG, V81, P594, DOI 10.1016/j.wneu.2013.10.043
   Perry A, 1999, CANCER, V85, P2046, DOI 10.1002/(SICI)1097-0142(19990501)85:9<2046::AID-CNCR23>3.0.CO;2-M
   Pollock BE, 2003, INT J RADIAT ONCOL, V55, P1000, DOI 10.1016/S0360-3016(02)04356-0
   Pollock BE, 2017, INT J RADIAT ONCOL, V97, P919, DOI 10.1016/j.ijrobp.2017.01.004
   Qiu LH, 2014, EXP THER MED, V7, P1393, DOI 10.3892/etm.2014.1550
   Regis J, 2010, J NEUROSURG, V113, P105, DOI 10.3171/2010.8.GKS101058
   Riemenschneider MJ, 2006, LANCET NEUROL, V5, P1045, DOI 10.1016/S1474-4422(06)70625-1
   Rogers L, 2015, J NEUROSURG, V122, P4, DOI 10.3171/2014.7.JNS131644
   RON E, 1988, NEW ENGL J MED, V319, P1033, DOI 10.1056/NEJM198810203191601
   Starke RM, 2014, WORLD NEUROSURG, V82, P395, DOI 10.1016/j.wneu.2013.02.008
   Starke RM, 2012, J NEUROSURG, V116, P588, DOI 10.3171/2011.11.JNS11530
   Tao CY, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-238
   Walcott BP, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00227
   Wang CY, 2017, NEURO-ONCOLOGY, V19, P1263, DOI 10.1093/neuonc/nox007
   Wolf A, 2019, LANCET ONCOL, V20, P159, DOI 10.1016/S1470-2045(18)30659-4
   Yang SY, 2008, J NEUROL NEUROSUR PS, V79, P574, DOI 10.1136/jnnp.2007.121582
NR 54
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 337
EP 342
DI 10.1016/j.wneu.2019.11.019
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200190
PM 31715408
DA 2020-05-12
ER

PT J
AU Lotfinia, I
   Mahdkhah, A
AF Lotfinia, Iraj
   Mahdkhah, Ata
TI Spinal Textiloma After Diskectomy: A Case Report and Review of the
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Foreign bodies; Lumbar spine; Textilomas
ID RETAINED SURGICAL SPONGE; FOREIGN-BODY GRANULOMA; POSTERIOR LUMBAR
   SURGERY; PARASPINAL TEXTILOMA; GOSSYPIBOMA; MIMICKING; CT; LAMINECTOMY;
   DIAGNOSIS; MR
AB BACKGROUND: Spinal masses can be diagnosed by clinical and radiographic examinations. Infrequently, pseudotumors may be due to retained masses after surgical interventions. In fact, these spinal or paraspinal expansions are caused by iatrogenic foreign bodies. Pseudotumors are mentioned as textilomas.
   CASE DESCRIPTION: We present a case of a patient with a history of lumbar diskectomy in the L2-L3 segments performed in 2017. A 53-year-old woman was admitted with the complaint of persistent mechanical lower back and leg pain for 2 months.
   CONCLUSIONS: There are no specific clinical and paraclinical manifestations for retained surgical foreign bodies. The number of cases of textilomas associated with spinal surgery are few in comparison with abdominal or thoracic interventions. It is better to integrate textiloma in the differential diagnosis of soft-tissue masses in the paraspinal region with surgical history. Although the definitive treatment of textilomas is surgical elimination of the foreign body, exact evaluation of surgical site before its closure is essential to prevent these cases.
C1 [Lotfinia, Iraj] Tabriz Univ Med Sci, Dept Neurosurg, Tabriz, Iran.
   [Mahdkhah, Ata] Urmia Univ Med Sci, Dept Neurosurg, Orumiyeh, Iran.
RP Mahdkhah, A (reprint author), Urmia Univ Med Sci, Dept Neurosurg, Orumiyeh, Iran.
EM amahdkhah@gmail.com
CR Akhaddar A, 2012, WORLD NEUROSURG, V77, P375, DOI 10.1016/j.wneu.2011.07.017
   Atabey C, 2009, NEUROL INDIA, V57, P320, DOI 10.4103/0028-3886.53289
   Aydogan M, 2007, SPINE J, V7, P618, DOI 10.1016/j.spinee.2006.08.004
   Bani-Hani Kamal E, 2005, Asian J Surg, V28, P109, DOI 10.1016/S1015-9584(09)60273-6
   Chater-Cure G, 2009, NEUROCIRUGIA, V20, P44
   CHOI BI, 1988, AM J ROENTGENOL, V150, P1047, DOI 10.2214/ajr.150.5.1047
   De Winter F, 2002, CLIN NUCL MED, V27, P132, DOI 10.1097/00003072-200202000-00014
   Dewachter P, 2011, JBR-BTR, V94, P118, DOI 10.5334/jbr-btr.531
   EBNER F, 1985, NEURORADIOLOGY, V27, P354, DOI 10.1007/BF00339572
   Erdem G, 2010, DIAGN INTERV RADIOL, V16, P10, DOI 10.4261/1305-3825.DIR.1183-07.1
   GIFFORD RRM, 1973, JAMA-J AM MED ASSOC, V223, P1040, DOI 10.1001/jama.1973.03220090060018
   Gupta R, 2015, IJSS J SURG, V1, P10
   HOYLAND JA, 1988, J BONE JOINT SURG BR, V70, P659
   Jakab E, 1996, YALE J BIOL MED, V69, P477
   Kaiser CW, 1996, ANN SURG, V224, P79, DOI 10.1097/00000658-199607000-00012
   Karabekir HS, 2007, NEUROSCIENCES, V12, P163
   Karcnik TJ, 1997, CLIN IMAG, V21, P269, DOI 10.1016/S0899-7071(96)00025-3
   Kim HS, 2007, AM J NEURORADIOL, V28, P709
   Kobayashi Takashi, 2014, J Med Case Rep, V8, P311, DOI 10.1186/1752-1947-8-311
   Kopka L, 1996, J COMPUT ASSIST TOMO, V20, P919, DOI 10.1097/00004728-199611000-00009
   Kothbauer KF, 2001, J NEUROSURG, V95, P503, DOI 10.3171/jns.2001.95.3.0503
   Kucukyuruk B, 2010, J NEUROSCI RURAL PRA, V1, P102, DOI 10.4103/0976-3147.71725
   Lee Sungjoon, 2016, Korean J Spine, V13, P160, DOI 10.14245/kjs.2016.13.3.160
   Marquardt G, 2001, NEUROSURG REV, V24, P41, DOI 10.1007/PL00011966
   Naama O, 2010, J NEURORADIOLOGY, V37, P131, DOI 10.1016/j.neurad.2009.04.003
   Okten Ali Ihsan, 2006, Eur Spine J, V15 Suppl 5, P626
   Opsenak R, 2016, CESK SLOV NEUROL N, V79, P715
   Rajkovic Z, 2010, PAIN MED, V11, P1777, DOI 10.1111/j.1526-4637.2010.00969.x
   Ribalta T, 2004, ARCH PATHOL LAB MED, V128, P749
   Rohde V, 1999, BRIT J NEUROSURG, V13, P417
   Sahin S, 2013, BALK MED J, V30, P422, DOI 10.5152/balkanmedj.2013.8732
   Sahin-Akyar G, 1997, Australas Radiol, V41, P288, DOI 10.1111/j.1440-1673.1997.tb00675.x
   SHEWARD SE, 1986, J COMPUT ASSIST TOMO, V10, P343, DOI 10.1097/00004728-198603000-00038
   STOLL A, 1988, SURG NEUROL, V30, P235, DOI 10.1016/0090-3019(88)90278-9
   Taylor F H, 1994, J Thorac Imaging, V9, P56, DOI 10.1097/00005382-199420000-00010
   Turgut M, 2005, NEUROL MED-CHIR, V45, P209, DOI 10.2176/nmc.45.209
   VANGOETHEM JWM, 1991, J COMPUT ASSIST TOMO, V15, P1000, DOI 10.1097/00004728-199111000-00018
   WILLIAMS RG, 1978, RADIOLOGY, V129, P323, DOI 10.1148/129.2.323
   Ziyal IM, 1997, J NEUROSURG, V87, P473, DOI 10.3171/jns.1997.87.3.0473
NR 39
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 343
EP 347
DI 10.1016/j.wneu.2019.08.227
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200191
PM 31520757
DA 2020-05-12
ER

PT J
AU Yang, SJ
   You, RJ
   Wu, WF
   Wei, ZS
   Hong, MF
   Peng, ZX
AF Yang, Sujuan
   You, Rongjiao
   Wu, Weifeng
   Wei, Zhisheng
   Hong, Mingfan
   Peng, Zhongxing
TI Dural Arteriovenous Fistula Complicated with Cerebral Venous Sinus
   Thrombosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral venous sinus thrombosis; Digital subtraction angiography; Dural
   arteriovenous fistula
ID DIAGNOSIS; MANAGEMENT
AB BACKGROUND: Cerebral venous sinus thrombosis (CVST) is always confused with dural arteriovenous fistula (DAVF) in clinical practice; however, both of them are very rare cerebral vascular diseases. In this report, we provide one case of DAVF combined with CVST.
   CASE DESCRIPTION: A 75-year-old woman complained of headache with nausea and vomiting for 4 days. Magnetic resonance venography revealed filling defect in the torcular, left transverse, and sigmoid sinus, which strongly suggested sinus thrombosis. The patient underwent anticoagulation treatment for 9 days. However, the manifestation was not alleviated, magnetic resonance imaging detected the lesion was enlarged, and the midline shifted to the left. Digital subtraction angiography examination detected that one fistula classified as Borden type IA was fed by the left superficial temporal artery and drained into the left transverse and sigmoid sinus. Endovascular embolization with ethylene vinyl alcohol was conducted.
   CONCLUSIONS: Follow-up at 6 months indicated that the patient recovered without any sequelae.
C1 [Yang, Sujuan; You, Rongjiao; Wu, Weifeng; Wei, Zhisheng; Hong, Mingfan; Peng, Zhongxing] Guangdong Pharmaceut Univ, Dept Neurol, Affiliated Hosp 1, Guangzhou, Peoples R China.
RP Peng, ZX (reprint author), Guangdong Pharmaceut Univ, Dept Neurol, Affiliated Hosp 1, Guangzhou, Peoples R China.
EM pzx802@163.com
OI Yang, Sujuan/0000-0003-0925-4501
FU Science and Technology Project of Yuexiu District, Guangzhou, China
   [2017-WS-010]
FX This report is supported by the Science and Technology Project of Yuexiu
   District, Guangzhou, China (2017-WS-010).
CR Capecchi M, 2018, J THROMB HAEMOST, V16, P1918, DOI 10.1111/jth.14210
   Chen JG, 2017, J CLIN NEUROSCI, V44, P225, DOI 10.1016/j.jocn.2017.06.011
   Ferro JM, 2004, STROKE, V35, P664, DOI 10.1161/01.STR.0000117571.76197.26
   Ferro JM, 2017, EUR STROKE J, V2, P195, DOI 10.1177/2396987317719364
   Gupta Ak, 2009, Indian J Radiol Imaging, V19, P43, DOI 10.4103/0971-3026.45344
   Kwon BJ, 2005, AM J NEURORADIOL, V26, P2500
   Lee SK, 2017, J NEUROINTERV SURG, V9, P516, DOI 10.1136/neurintsurg-2015-012116
   Maali L, 2017, NEUROL SCI, V38, P1963, DOI 10.1007/s10072-017-3082-7
   Gatto LAM, 2019, PEDIATR NEUROSURG, V54, P66, DOI 10.1159/000494563
   Miller TR, 2015, STROKE, V46, P2017, DOI 10.1161/STROKEAHA.115.008228
   Narvid J, 2011, AM J NEURORADIOL, V32, P446, DOI 10.3174/ajnr.A2328
   Noguchi K, 2010, AM J NEURORADIOL, V31, P1903, DOI 10.3174/ajnr.A2231
   Padilha Igor Gomes, 2019, J Neuroradiol, DOI 10.1016/j.neurad.2019.06.004
   Pekkola J, 2011, ACTA RADIOL, V52, P442, DOI 10.1258/ar.2011.100433
   Rammos S, 2014, NEUROSURG CLIN N AM, V25, P539, DOI 10.1016/j.nec.2014.04.010
   Sebire G, 2005, BRAIN, V128, P477, DOI 10.1093/brain/awh412
   Simon S, 2009, J NEUROSURG, V110, P514, DOI 10.3171/2008.7.JNS08253
   Stam J, 2005, NEW ENGL J MED, V352, P1791, DOI 10.1056/NEJMra042354
   Tsai LK, 2004, J NEUROL NEUROSUR PS, V75, P1639, DOI 10.1136/jnnp.2003.026583
   Walcott BP, 2013, J NEUROINTERV SURG, V5, P6, DOI 10.1136/neurintsurg-2011-010169
NR 20
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 348
EP 352
DI 10.1016/j.wneu.2019.10.075
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200192
PM 31639507
DA 2020-05-12
ER

PT J
AU Casillo, SM
   Luy, DD
   Goldschmidt, E
AF Casillo, Stephanie M.
   Luy, Diego D.
   Goldschmidt, Ezequiel
TI A History of the Lobes of the Brain
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral lobes; Felix Vicq d'Azyr; Francois Chaussier; Francois Leuret;
   Louis Pierre Gratiolet; Thomas Willis
ID ANATOMY
AB The division of the cerebrum into 5 lobes is widely accepted in the scientific community. Despite this, a history of the lobes of the brain has not been discussed in the literature. Therefore, this article recounts this history with emphasis on the contributions of Thomas Willis (1664), Felix Vicq d'Azyr (1796), Johann-Christian Reil (1796), Francois Chaussier (1807), and Louis Pierre Gratiolet and Francois Leuret (1857) into one of the most widely accepted concepts in neuroanatomy.
C1 [Goldschmidt, Ezequiel] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA 15260 USA.
   [Casillo, Stephanie M.; Luy, Diego D.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
RP Goldschmidt, E (reprint author), Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA 15260 USA.
EM goldschmidted@upmc.edu
OI Casillo, Stephanie/0000-0002-6154-5050
CR Binder DK, 2007, NEUROSURGERY, V61, P1091, DOI 10.1227/01.neu.0000303205.15489.23
   Brogna C, 2012, NEUROSURGERY, V70, P1265, DOI 10.1227/NEU.0b013e31824008e7
   CAPUTI F, 1995, J NEUROSURG, V83, P933, DOI 10.3171/jns.1995.83.5.0933
   Caron L, 2015, MED HIST, V59, P525, DOI 10.1017/mdh.2015.45
   Changeux JP, 2008, NEURONAL MAN BIOL MI
   Chaussier F., 1807, EXPOSITION SOMMAIRE
   Collice M, 2008, NEUROSURGERY, V63, P623, DOI 10.1227/01.NEU.0000327693.86093.3F
   Doty RW, 2007, NEUROSCIENCE, V147, P561, DOI 10.1016/j.neuroscience.2007.02.046
   Feindel W, 2004, BRAIN, V127, P2373
   Feindel W, 1978, T WILLIS ANATOMY BRA
   Filley Christopher M, 2010, Handb Clin Neurol, V95, P557, DOI 10.1016/S0072-9752(08)02135-0
   Finger S., 1994, ORIGINS NEUROSCIENCE
   Finger Stanley, 2000, MINDS BRAIN HIST PIO
   Gratiolet LP, 1854, MEMOIRES PLIS CEREBR
   Jakob C., 1899, ATLAS GESUNDEN KRANK
   Krudop WA, 2015, PSYCHOPATHOLOGY, V48, P222, DOI 10.1159/000381986
   Leuret F, 1857, ANATOMIE COMP SYSTEM, V2, P111
   MEYER A, 1965, Med Hist, V9, P1
   O'Connor JPB, 2003, J ROY SOC MED, V96, P139, DOI 10.1258/jrsm.96.3.139
   Parent A, 2014, NEUROSCI MED, V5, P1, DOI DOI 10.4236/nm.2014.51001
   Parent A, 2007, CAN J NEUROL SCI, V34, P30, DOI 10.1017/S0317167100018722
   Parent A, 2016, CAN J NEUROL SCI, V43, P596, DOI 10.1017/cjn.2016.14
   Pearce JMS, 2006, EUR NEUROL, V56, P262, DOI 10.1159/000096679
   Pessoa L, 2015, J COMP NEUROL, V523, P2495, DOI 10.1002/cne.23840
   Rengachary SS, 2008, J NEUROSURG, V109, P765, DOI 10.3171/JNS/2008/109/10/0765
   Rolando L, 1829, TURIN MEMORIE REGIA, V35, P103
   Standring S, 2016, J ANAT, V229, P32, DOI 10.1111/joa.12473
   Swanson LW, 2000, TRENDS NEUROSCI, V23, P519, DOI 10.1016/S0166-2236(00)01639-8
   Swanson LW, 2014, NEUROANATOMICAL TERM
   TAMRAZ J, 2006, ATLAS REGIONAL ANATO
   Tubbs RS, 2001, CHILD NERV SYST, V27, P1031
   Uddin LQ, 2017, J CLIN NEUROPHYSIOL, V34, P300, DOI 10.1097/WNP.0000000000000377
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 353
EP 360
DI 10.1016/j.wneu.2019.10.155
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200193
PM 31682988
DA 2020-05-12
ER

PT J
AU Martinez-Perez, R
   Hardesty, DA
   Palmer, J
   Zachariah, M
   Otto, BA
   Carrau, RL
   Prevedello, DM
AF Martinez-Perez, Rafael
   Hardesty, Douglas A.
   Palmer, Joshua
   Zachariah, Marcus
   Otto, Bradley A.
   Carrau, Ricardo L.
   Prevedello, Daniel M.
TI Remote Leptomeningeal Dissemination in Olfactory Neuroblastoma Mimicking
   Multiple Parasagittal Meningiomas: Diagnostic and Therapeutic Challenge
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dural invasion; Endonasal; Endoscopic; Esthesioneuroblastoma;
   Extradural; Metastases
ID ESTHESIONEUROBLASTOMA; TUMOR
AB BACKGROUND: Olfactory neuroblastoma (ON) is a highly aggressive and locally recurrent neoplasm. Distant systemic metastases are not uncommon, but remote leptomeningeal dissemination is extremely rare.
   CASE DESCRIPTION: We report 2 cases of ON previously treated with endoscopic endonasal radical surgical resection and radiotherapy. After a relatively long period of disease-free survival, multiple leptomeningeal lesions were seen around the sagittal sinus giving a radiologic appearance of parasagittal meningiomas. Both patients underwent surgery and multimodal treatment with radiotherapy and chemotherapy for the disseminated disease. Pathologic examination confirmed the parasagittal lesions as metastatic ON.
   CONCLUSIONS: A high suspicion of secondary disease should be maintained in patients with previous history of ON and parasagittal leptomeningeal enhancing lesion, particularly when multiple lesions are detected around the sagittal sinus. Radical resection and multimodal treatment are warranted to improve long-term outcome. Understanding the venous drainage route as a potential pathway for remote seeding from the primary site of disease has therapeutic implications. We postulate that en-bloc tumor resection and proximal sagittal sinus ligation might reduce potential for leptomeningeal metastasis.
C1 [Martinez-Perez, Rafael; Hardesty, Douglas A.; Zachariah, Marcus; Otto, Bradley A.; Carrau, Ricardo L.; Prevedello, Daniel M.] Ohio State Univ, Dept Neurol Surg, Wexner Med Ctr, Columbus, OH 43210 USA.
   [Hardesty, Douglas A.; Otto, Bradley A.; Carrau, Ricardo L.; Prevedello, Daniel M.] Ohio State Univ, Dept Head & Neck Surg, Wexner Med Ctr, Columbus, OH 43210 USA.
   [Palmer, Joshua] Ohio State Univ, Dept Oncol Radiotherapy, Wexner Med Ctr, Columbus, OH 43210 USA.
RP Prevedello, DM (reprint author), Ohio State Univ, Dept Neurol Surg, Wexner Med Ctr, Columbus, OH 43210 USA.; Prevedello, DM (reprint author), Ohio State Univ, Dept Head & Neck Surg, Wexner Med Ctr, Columbus, OH 43210 USA.
EM Daniel.prevedello@osumc.edu
RI Martinez-Perez, Rafael/E-2408-2014
OI Martinez-Perez, Rafael/0000-0002-2896-2346
CR Broich G, 1997, ANTICANCER RES, V17, P2683
   Broski SM, 2012, J NUCL MED, V53, P1200, DOI 10.2967/jnumed.112.102897
   Chamberlain MC, 2002, CANCER, V95, P243, DOI 10.1002/cncr.10679
   Eisen MD, 1996, AM J NEURORADIOL, V17, P1937
   Howell MC, 2011, AM J NEURORADIOL, V32, P929, DOI 10.3174/ajnr.A2401
   Jiang W, 2016, J NEURO-ONCOL, V126, P201, DOI 10.1007/s11060-015-1935-6
   Kim YS, 2016, WORLD NEUROSURG, V96, DOI 10.1016/j.wneu.2016.08.126
   Laigle-Donadey F, 2005, J NEURO-ONCOL, V75, P57, DOI 10.1007/s11060-004-8098-1
   Levine PA, 2009, LARYNGOSCOPE, V119, P3, DOI 10.1002/lary.20047
   Sindou MP, 2006, J NEUROSURG, V105, P514, DOI 10.3171/jns.2006.105.4.514
   Sivakumar Walavan, 2015, Surg Neurol Int, V6, pS628, DOI 10.4103/2152-7806.170464
   Snyderman CH, 2010, SKULL BASE-INTERD AP, V20, P309, DOI 10.1055/s-0030-1253583
   Theilgaard SA, 2003, ACTA OTO-LARYNGOL, V123, P433, DOI 10.1080/00016480310001295
NR 13
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 361
EP 364
DI 10.1016/j.wneu.2019.11.042
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200194
PM 31734430
DA 2020-05-12
ER

PT J
AU Sindou, M
   Dumot, C
AF Sindou, Marc
   Dumot, Chloe
TI Planning of Endocranial Supratentorial Basal Cistern and Skull Base
   Approaches Depending on Venous Patterns Using a Topogram
SO WORLD NEUROSURGERY
LA English
DT Article
DE Basal cistern approaches; Cerebral hemispheric venous drainage; Digital
   subtraction angiography; Intracranial venous system; Skull base
   approaches; Topogram; Venous MRI
ID PREOPERATIVE EVALUATION; MICROSURGICAL ANATOMY; MR VENOGRAPHY; VEINS;
   ANGIOGRAPHY
AB BACKGROUND: Because damage or sacrifice of venous drainage during supratentorial basal cistern and skull base approaches may have severe and harmful consequences, methods to identify preoperatively veins at risk are of paramount importance. Among methods, a codified assessment with a venous topogram is helpful, with practical implications.
   METHODS: This technical note describes how to construct an easy-to-use topogram. Three regions of interest are defined as triangles. The anterior triangle corresponds to the anterior frontal veins draining to the superior sagittal sinus at risk during anterior cerebral fossa surgery, the middle triangle corresponds to the anterior sylvian veins draining to the cavernous sinus at risk during pterional approaches, and the inferior triangle corresponds to the inferior cerebral veins draining to the transverse sinus at risk in subtemporal approaches and temporal lobe surgery.
   RESULTS: Depending on predominance of the drainage, 4 situations were defined: an anterior, an inferior, and a middle predominance or equilibrium between the 3 triangles. These anatomic features have important practical implications in skull base and basal cistern approaches.
   CONCLUSIONS: This is, to our knowledge, the only toprogram described in the scientific literature. Any well-defined approach should be adapted to the individual patient according not only to location and type of lesion but also to the venous drainage to be encountered along the way.
C1 [Sindou, Marc; Dumot, Chloe] Univ Claude Bernard Lyon 1, Lyon, France.
   [Sindou, Marc] Grp ELSAN, Clin Breteche, Nantes, France.
   [Dumot, Chloe] Hosp Civils Lyon, Hop Pierre Wertheimer, Lyon, France.
RP Dumot, C (reprint author), Univ Claude Bernard Lyon 1, Lyon, France.; Dumot, C (reprint author), Hosp Civils Lyon, Hop Pierre Wertheimer, Lyon, France.
EM chloe.dumot@chu-lyon.fr
CR Acerbi F, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.4.FOCUS18120
   Acerbi F, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.3.FOCUS1862
   Al-Mefty O, 1996, SURG INTRACRANIAL VE
   Ayanzen RH, 2000, AM J NEURORADIOL, V21, P74
   Bozzao A, 2005, EUR RADIOL, V15, P1790, DOI 10.1007/s00330-005-2788-8
   Cheng L, 2016, J CLIN NEUROSCI, V31, P1, DOI 10.1016/j.jocn.2015.11.033
   Elhammady MS, 2015, WORLD NEUROSURG, V83, P320, DOI 10.1016/j.wneu.2013.06.003
   Ferroli P, 2011, WORLD NEUROSURG, V75, P122, DOI 10.1016/j.wneu.2010.09.011
   Ferroli P, 2011, J NEUROSURG, V115, P18, DOI 10.3171/2011.3.JNS10620
   Hakuba A., 1996, SURG INTRACRANIAL VE
   Jang WY, 2012, BRIT J NEUROSURG, V26, P705, DOI 10.3109/02688697.2012.690914
   Kageyama Yusuke, 1992, Neurologia Medico-Chirurgica, V32, P733, DOI 10.2176/nmc.32.733
   Lee JM, 2005, SURG NEUROL, V64, P128, DOI 10.1016/j.surneu.2004.10.029
   Liauw L, 2000, RADIOLOGY, V214, P678, DOI 10.1148/radiology.214.3.r00mr41678
   Linda W, 2015, J NEUROSURG, V123, P1, DOI 10.3171/2014.10.JNS141055
   Loubeyre P, 1999, MAGN RESON IMAGING, V17, P1227, DOI 10.1016/S0730-725X(99)00054-5
   Lovblad KO, 2002, NEURORADIOLOGY, V44, P681, DOI 10.1007/s00234-002-0751-9
   MATSUSHIMA T, 1983, J NEUROSURG, V59, P63, DOI 10.3171/jns.1983.59.1.0063
   Nagata T, 2013, WORLD NEUROSURG, V79, P116, DOI 10.1016/j.wneu.2011.05.022
   Nakase H, 2005, ACTA NEUROCHIR, V147, P621, DOI 10.1007/s00701-005-0501-y
   Ohnishi H, 1996, SURGERY OF THE INTRACRANIAL VENOUS SYSTEM, P380
   Ohnishi H, 1996, SURGERY OF THE INTRACRANIAL VENOUS SYSTEM, P386
   OKA K, 1985, NEUROSURGERY, V17, P711, DOI 10.1227/00006123-198511000-00003
   Rhoton AL, 2007, NEUROSURGERY, V61, P1, DOI 10.1227/01.NEU.0000280027.92382.2B
   Sindou M, 2005, ACT NEUR S, V94, P167
   Sindou M, 2000, ADV TECH STAND NEUR, V26, P131
   Wangaryattawanich P, 2016, RADIOGRAPHICS, V36, P244, DOI 10.1148/rg.2016150084
   Yasargil MG, 1984, MICROSURGICAL ANATOM
   Zhong J, 2008, NEUROL RES, V30, P697, DOI 10.1179/174313208X289624
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 365
EP 371
DI 10.1016/j.wneu.2019.11.009
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200195
PM 31715402
DA 2020-05-12
ER

PT J
AU Han, MS
   Moon, KS
   Lee, KH
   Jang, WY
   Kim, SK
   Jung, S
AF Han, Moon-Soo
   Moon, Kyung-Sub
   Lee, Kyung-Hwa
   Jang, Woo-Youl
   Kim, Seul-Kee
   Jung, Shin
TI Intracranial Inflammatory Pseudotumor Associated with Idiopathic
   Hypertrophic Pachymeningitis Mimicking Malignant Tumor or High-Grade
   Meningioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Idiopathic hypertrophic pachymeningitis; Ig4; Meningioma; Pseudotumor;
   Tumefactive fibroinflammatory lesion
AB BACKGROUND: Idiopathic hypertrophic pachymeningitis (IHP) is a rare clinical disease characterized by inflammatory fibrosis, which causes diffuse thickening of the dura mater. The inflammatory fibrosis will be locally invasive in nature but will be characterized by a benign histological appearance, known as an inflammatory pseudotumor. We present the case of a patient with an infiltrative lesion involving the right frontal convexity diagnosed as IHP, which had been suspected to be a malignant tumor or high-grade meningioma from the preoperative radiological findings.
   CASE DESCRIPTION: A 59-year-old man was admitted to our hospital because of a temporary loss of consciousness. Contrast-enhanced magnetic resonance imaging (MRI) of the brain showed a 30-mm x 12-mm mass located in the right frontal convexity. The lesion had an isointensity to high-intensity signal with moderate periregional edema on T2-weighted MRI, and homogeneous enhancement, including a necrotic portion with a long dural tail along the right frontal convexity, after contrast-enhanced MRI. Thus, our preliminary diagnosis was high-grade meningioma or a malignant tumor. We decided to surgically remove the tumor. Intraoperatively, the lesion appeared as a dural-based yellowish mass with partial infiltration of the cortex. Histopathological examination of the lesion revealed thickened meninges with marked fibroinflammatory changes. The inflammatory changes extended into the underlying brain parenchyma and were centered in the perivascular spaces. The lesion showed abundant lymphoplasmacytic infiltration with fibrosis. Immunohistochemistry revealed mixed T and B lymphocytes and plasma cells. Only a small number of IgG4-positive cells were identified. From these findings, we finally concluded that the diagnosis was IHP. The patient did not receive any further steroid therapy, because the patient had no evidence of systemic autoimmune disease. A follow-up brain MRI scan was performed 6 month after surgery, which revealed no recurrence of the lesion.
   CONCLUSIONS: Surgical treatment can he the first treatment option when the lesion is not localized to a critical portion of the brain. Thus, it might be possible to arrive at a definitive diagnosis histologically and determine additional treatment strategies. Also, if the surgeons are confident that the IHP has been removed completely, additional steroid therapy might not be necessary.
C1 [Han, Moon-Soo; Moon, Kyung-Sub; Jang, Woo-Youl; Jung, Shin] Chonnam Natl Univ, Hwasun Hosp & Med Sch, Dept Neurosurg, Res Inst Med Sci, Gwangju, Jeollanam Do, South Korea.
   [Lee, Kyung-Hwa] Chonnam Natl Univ, Hwasun Hosp & Med Sch, Dept Pathol, Res Inst Med Sci, Gwangju, Jeollanam Do, South Korea.
   [Kim, Seul-Kee] Chonnam Natl Univ, Hwasun Hosp & Med Sch, Dept Diagnost Radiol, Res Inst Med Sci, Gwangju, Jeollanam Do, South Korea.
RP Moon, KS (reprint author), Chonnam Natl Univ, Hwasun Hosp & Med Sch, Dept Neurosurg, Res Inst Med Sci, Gwangju, Jeollanam Do, South Korea.
EM moonks@chonnam.ac.kr
CR ARBER DA, 1995, HUM PATHOL, V26, P1093, DOI 10.1016/0046-8177(95)90271-6
   Arrese T, 2005, NEUROCIRUGIA, V16, P63
   Cacao G, 2019, NEUROL SCI, V40, P543, DOI 10.1007/s10072-018-3689-3
   Holodny AI, 2001, AM J NEURORADIOL, V22, P876
   Hosler MR, 2007, J NEURO-OPHTHALMOL, V27, P95, DOI 10.1097/WNO.0b013e318064c53a
   Huang YY, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007549
   HYTIROGLOU P, 1992, HEAD NECK-J SCI SPEC, V14, P230, DOI 10.1002/hed.2880140311
   Jang Y, 2017, J CLIN NEUROL, V13, P155, DOI 10.3988/jcn.2017.13.2.155
   Kupersmith MJ, 2004, NEUROLOGY, V62, P686, DOI 10.1212/01.WNL.0000113748.53023.B7
   Lee Young-Sub, 2014, Brain Tumor Res Treat, V2, P87, DOI 10.14791/btrt.2014.2.2.87
   Lok JYC, 2015, HONG KONG MED J, V21, P360, DOI 10.12809/hkmj144295
   Margoni M, 2019, NEUROL SCI, V40, P2193, DOI 10.1007/s10072-019-03954-9
   Okano A, 2015, WORLD NEUROSURG, V83, DOI 10.1016/j.wneu.2015.02.011
   Sylaja PN, 2002, NEUROL INDIA, V50, P53
   Tang HL, 2018, WORLD NEUROSURG, V118, P71, DOI 10.1016/j.wneu.2018.06.174
   Uchida H, 2018, CLIN NEUROL NEUROSUR, V168, P30, DOI 10.1016/j.clineuro.2018.02.035
   Umegaki Sho, 2018, No Shinkei Geka, V46, P147, DOI 10.11477/mf.1436203691
   Wang YJ, 2004, HEADACHE, V44, P916, DOI 10.1111/j.1526-4610.2004.04175.x
   WOLD LE, 1983, AM J SURG PATHOL, V7, P477, DOI 10.1097/00000478-198307000-00010
   Yao AH, 2019, WORLD NEUROSURG, V127, P534, DOI 10.1016/j.wneu.2019.04.006
   Yonekawa T, 2014, J NEUROL NEUROSUR PS, V85, P732, DOI 10.1136/jnnp-2013-306410
NR 21
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 372
EP 376
DI 10.1016/j.wneu.2019.10.172
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200196
PM 31704361
DA 2020-05-12
ER

PT J
AU Messina, R
   Bozzi, MT
   Chiumarulo, L
   Tacconi, L
   Signorelli, F
AF Messina, Raffaella
   Bozzi, Maria Teresa
   Chiumarulo, Luigi
   Tacconi, Leonello
   Signorelli, Francesco
TI Ruptured Tentorial Arteriovenous Fistula: Endoscopic-Assisted
   Microsurgical Disconnection Using Indocyanine Green Videoangiography
   Guidance
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dural arteriovenous fistula; Flow dynamics; Indocyanine green;
   Tentorium; Videoangiography
C1 [Messina, Raffaella; Bozzi, Maria Teresa; Signorelli, Francesco] Univ Aldo Moro Bari, Dept Basic Med Sci Neurosci & Sense Organs, Div Neurosurg, Bari, Italy.
   [Chiumarulo, Luigi] Univ Aldo Moro Bari, Dept Basic Med Sci Neurosci & Sense Organs, Div Neuroradiol, Bari, Italy.
   [Tacconi, Leonello] Univ Hosp, Div Neurosurg, Trieste, Italy.
RP Signorelli, F (reprint author), Univ Aldo Moro Bari, Dept Basic Med Sci Neurosci & Sense Organs, Div Neurosurg, Bari, Italy.
EM francesco.signorelli@uniba.it
OI tacconi, leonello/0000-0003-3915-5635; Signorelli,
   Francesco/0000-0002-5040-1916; Messina, Raffaella/0000-0002-2819-3938
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 377
EP 377
DI 10.1016/j.wneu.2019.11.024
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200197
PM 31726094
DA 2020-05-12
ER

PT J
AU Hara, T
   Iwamuro, H
   Ohara, Y
   Matsuoka, H
   Kikuchi, N
   Kimura, T
   Arai, H
   Mizuno, J
AF Hara, Takeshi
   Iwamuro, Hirokazu
   Ohara, Yukoh
   Matsuoka, Hidenori
   Kikuchi, Naoko
   Kimura, Takaoki
   Arai, Hajime
   Mizuno, Junichi
TI Efficacy of Atlantoaxial Transarticular Screw Fixation Using
   Navigation-Guided Drill: Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intraoperative navigation; Navigation-guided drill; Transarticular screw
AB BACKGROUND: Atlantoaxial transarticular screw fixation (TASF) is a procedure that involves inserting screws vertically into the articular processes of C1 and C2. However, this procedure is associated with a risk of injury to surrounding structures including the vertebral artery, carotid artery, pharynx, and spinal cord by misinserting K-wires or screws. This study was performed to evaluate the risk of TASF using 3-dimensional navigation-guided drilling and screw insertion tract creation.
   METHODS: Three patients underwent the surgical procedure using a navigation system guided by intraoperative computed tomography. The insertion tract of the screw was created using the navigation system to avoid penetration of the C1 anterior arch or damage to the vertebral artery. A blunt-tipped guide wire was used, which was safe to advance to the cortex of the anterior arch of C1.
   RESULTS: There were no complications or instrument failures in any of the surgeries. In each case, the total radiation dose delivered was 5.31-7.02 mGy, and total radiation exposure time was 55.6-106.8 seconds. Bone fusion was achieved in all cases.
   CONCLUSIONS: TASF using a navigation system for drilling is useful for accurate placement of K-wire and preventing damage of the vital structures, lowering the risk of the procedure.
C1 [Hara, Takeshi; Iwamuro, Hirokazu; Ohara, Yukoh; Arai, Hajime] Juntendo Univ, Dept Neurosurg, Tokyo, Japan.
   [Matsuoka, Hidenori; Kikuchi, Naoko; Kimura, Takaoki; Mizuno, Junichi] Shin Yurigaoka Gen Hosp, Kawasaki, Kanagawa, Japan.
RP Hara, T (reprint author), Juntendo Univ, Dept Neurosurg, Tokyo, Japan.
EM tkhara@juntendo.ac.jp
CR Dusad T, 2018, ASIAN SPINE J, V12, P710, DOI 10.31616/asj.2018.12.4.710
   Huang KY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005100
   Kaneyama S, 2014, J NEUROSURG-SPINE, V21, P231, DOI 10.3171/2014.3.SPINE13730
NR 3
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 378
EP 382
DI 10.1016/j.wneu.2019.10.176
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200198
PM 31698122
DA 2020-05-12
ER

PT J
AU Zhang, XL
   Wang, JJ
   Guo, Y
   Dong, S
   Shi, W
   Wang, GQ
   Zhang, HF
   Wang, GH
AF Zhang, Xiaolei
   Wang, James Jin
   Guo, Yi
   Dong, Sheng
   Shi, Wei
   Wang, Guoqin
   Zhang, Huifang
   Wang, Guihuai
TI Sudden Aggravated Radicular Pain Caused by Hemorrhagic Spinal
   Angiolipomas After Back Massage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intratumoral hemorrhage; Radicular compression; Spinal angiolipomas;
   Spinal cord compression
AB BACKGROUND: Spinal angiolipomas (SALs) are benign tumors that usually present a slow progressive spinal cord or radicular compression. Acute myelopathy or acute aggravated radicular syndrome are exceedingly rare.
   CASE DESCRIPTION: The authors report an original case with sudden aggravated radicular pain caused by hemorrhagic SALs. A 54-year-old woman presented with a 2-month history of mild back pain, and the pain was significantly aggravated after a therapeutic back massage. Neurologic examination showed pain and hyperalgesia between T4 and T7 dermatome, from back to front, just like a band. Spinal magnetic resonance imaging (MRI) showed a dorsally located epidural lesion (T4-T6) and a small intratumoral hemorrhage at the lower part of the tumor. A bilateral T4-T6 laminectomy was performed to achieve total excision of the tumors. Histologic examination showed that the tumors were composed of mature adipose tissue and vascular tissue as angiolipomas. The postoperative course was uneventful with complete neurologic recovery 4 days after the surgery. MRI at 1-year follow-up indicated no recurrence.
   CONCLUSIONS: SALs are unusual benign tumors that are composed of mature tissue and abnormal blood vessels; sudden aggravated spinal cord or radicular compression syndrome is rare. MRI is the best choice in the diagnosis of SALs. Surgery may be performed in different ways depending on the type of SALs, and the prognosis is generally good.
C1 [Zhang, Xiaolei; Wang, James Jin; Guo, Yi; Dong, Sheng; Shi, Wei; Wang, Guoqin; Zhang, Huifang; Wang, Guihuai] Tsinghua Univ, Dept Neurosurg, Sch Clin Med, Beijing Tsinghua Changgung Hosp, Beijing, Peoples R China.
RP Wang, GH (reprint author), Tsinghua Univ, Dept Neurosurg, Sch Clin Med, Beijing Tsinghua Changgung Hosp, Beijing, Peoples R China.
EM wghneurosurgeon@126.com
OI Zhang, Xiaolei/0000-0002-6431-0169
FU Beijing Tsinghua Changgung Hospital Fund [12017C1026]
FX This work was supported by the Beijing Tsinghua Changgung Hospital Fund
   (12017C1026).
CR Akhaddar A, 2008, EUR SPINE J, V17, pS296, DOI 10.1007/s00586-008-0591-3
   Berenbruch K., 1890, FALL MULTIPLEN ANGIO
   Fukui MB, 1999, AM J NEURORADIOL, V20, P1365
   Gelabert-Gonzalez M, 2009, EUR SPINE J, V18, P324, DOI 10.1007/s00586-008-0858-8
   HADDAD FS, 1986, SURG NEUROL, V26, P473, DOI 10.1016/0090-3019(86)90261-2
   Jea Andrew, 2005, Neurosurgery, V56, pE1156
   Labram EK, 1999, BRIT J NEUROSURG, V13, P25, DOI 10.1080/02688699944140
   LIN JJ, 1974, CANCER-AM CANCER SOC, V34, P720, DOI 10.1002/1097-0142(197409)34:3<720::AID-CNCR2820340331>3.0.CO;2-K
   PREUL MC, 1993, J NEUROSURG, V78, P280, DOI 10.3171/jns.1993.78.2.0280
   Provenzale JM, 1996, AM J NEURORADIOL, V17, P713
   VONHANWEHR R, 1985, NEUROSURGERY, V16, P406, DOI 10.1227/00006123-198503000-00023
   Wang P, 2011, EUR SPINE J, V20, pS176, DOI 10.1007/s00586-010-1484-9
   Yen HL, 2008, J CLIN NEUROSCI, V15, P1170, DOI 10.1016/j.jocn.2007.07.084
NR 13
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 383
EP 387
DI 10.1016/j.wneu.2019.11.005
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200199
PM 31733392
DA 2020-05-12
ER

PT J
AU Panagopoulos, D
   Apostolopoulou, K
   Themistocleous, M
AF Panagopoulos, Dimitrios
   Apostolopoulou, Katerina
   Themistocleous, Marios
TI Severe Neuromuscular Scoliosis Implicated by Dysfunction of Intrathecal
   Baclofen Pump: Case Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cerebrospinal fluid blockage; Intrathecal baclofen pump; Neuromuscular
   scoliosis
ID CEREBRAL-PALSY; SPINAL-FUSION; NATURAL-HISTORY; COMPLICATIONS;
   IMPLANTATION; MANAGEMENT; SPASTICITY; CHILDREN; THERAPY
AB BACKGROUND: Complex spinal deformities are a common issue in pediatric patients with an underlying neurologic diagnosis or syndrome. Management of neuromuscular scoliosis is an awesome responsibility, because these patients present with the most challenging pathologies of the deformed spine. Along with surgical correction of the underlying deformity, an intrathecal baclofen (ITB) pump is considered effective in managing the associated spasticity.
   CASE DESCRIPTION: We present the case of an 11-year-old female who sustained an episode of severe ischemic encephalopathy accompanied by hydrocephalus and severe spastic quadriplegia. An ITB pump was inserted to manage spasticity. Two years later, a very severe decompensated spinal curvature developed. In addition, malfunction of the pump was noted, and the decision was made to perform revision along with open hemilaminectomy at the L3-4 level. The inability of cerebrospinal fluid (CSF) to access the pump was verified intraoperatively, with the absence of CSF glow through the intrathecal space demonstrating blockage of CSF flow.
   CONCLUSIONS: The association of cerebral palsy and relevant disorders with the relentless progression of scoliosis is analyzed, along with the possible offending mechanisms. The efficacy of an ITB pump in controlling intractable spasticity associated with neuromuscular scoliosis is reviewed, as well as its potential to accentuate the clinical progression of neuromuscular scoliosis. Although this is an extremely infrequent situation, we must always bear in mind the possibility that malfunction of an ITS pump could be related to obstruction of CSF flow, owing to the extreme severity of the curves established during the course of, most likely untreated, neuromuscular scoliosis.
C1 [Panagopoulos, Dimitrios; Apostolopoulou, Katerina; Themistocleous, Marios] Pediat Hosp Athens, Neurosurg Dept, Athens, Greece.
RP Panagopoulos, D (reprint author), Pediat Hosp Athens, Neurosurg Dept, Athens, Greece.
EM dimpanayop@gmail.com
CR ALBRIGHT AL, 1991, JAMA-J AM MED ASSOC, V265, P1418, DOI 10.1001/jama.265.11.1418
   Arishima H, 2015, NEUROMODULATION, V18, P214, DOI 10.1111/ner.12203
   Borowski A, 2008, SPINE, V33, P1995, DOI 10.1097/BRS.0b013e31817bab42
   Burn SC, 2010, J NEUROSURG-PEDIATR, V5, P195, DOI 10.3171/2009.9.PEDS08460
   Cloake Thomas, 2016, J Spine Surg, V2, P299, DOI 10.21037/jss.2016.09.05
   Dickey MP, 2013, PEDIATR INFECT DIS J, V32, P715, DOI 10.1097/INF.0b013e318287f02a
   Dziurzynski K, 2006, CHILD NERV SYST, V22, P270, DOI 10.1007/s00381-004-1129-6
   Gooch JL, 2004, DEV MED CHILD NEUROL, V46, P548, DOI 10.1017/S001216220400091X
   Halawi MJ, 2015, ORTHOPEDICS, V38, pE452, DOI 10.3928/01477447-20150603-50
   Imrie MN, 2010, ORTHOP CLIN N AM, V41, P531, DOI 10.1016/j.ocl.2010.06.008
   Koop SE, 1991, SCOL RES SOC ANN M S
   Lonstein JE, 2012, SPINE, V37, P583, DOI 10.1097/BRS.0b013e318225ebd5
   Lynn AK, 2009, PM&R, V1, P834, DOI 10.1016/j.pmrj.2009.07.016
   Majd ME, 1997, SPINE, V22, P1461, DOI 10.1097/00007632-199707010-00007
   Motta F, 2014, J NEUROSURG-PEDIATR, V13, P301, DOI 10.3171/2013.11.PEDS13253
   Murphy RF, 2019, CURR REV MUSCULOSKE, V12, P220, DOI 10.1007/s12178-019-09552-8
   Noordeen MHH, 1997, J BONE JOINT SURG BR, V79B, P53, DOI 10.1302/0301-620X.79B1.6699
   Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x
   PENN RD, 1985, LANCET, V2, P125
   Sasaki N, 2016, NEUROMODULATION, V19, P664, DOI 10.1111/ner.12449
   Scannell B, 2015, PHYS MED REH CLIN N, V26, P79, DOI 10.1016/j.pmr.2014.09.003
   Senaran H, 2007, SPINE, V32, P2348, DOI 10.1097/BRS.0b013e3181557252
   Shilt JS, 2008, J PEDIATR ORTHOPED, V28, P684, DOI 10.1097/BPO.0b013e318183d591
   WALKER KR, 2017, SPINE DEFORM, V5, P424
NR 24
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 390
EP 395
DI 10.1016/j.wneu.2019.11.027
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200201
PM 31733394
DA 2020-05-12
ER

PT J
AU Longatti, P
   Fiorindi, A
   Bruscella, S
   Cappabianca, P
AF Longatti, Pierluigi
   Fiorindi, Alessandro
   Bruscella, Sara
   Cappabianca, Paolo
TI Development of Cerebral Endoscopy in Italy: Background, Narration, and
   Legacy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral endoscopy; Hydrocephalus; Neuroendoscopy; Neurosurgical
   history; Technical development; Third ventriculostomy
ID 3RD VENTRICULOSTOMY; NEUROENDOSCOPY; INNOVATION; SURGERY; NEUROSURGERY;
   HISTORY; FENESTRATION
AB Bibliometric analysis shows that neuroendoscopy (NE) overcame its pioneering phase in the late 1980s, and became a significant technological and clinical innovation in the early 1990s. During those years the charge-coupled device digital video cameras were introduced and videoendoscopy had its decisive breakthrough, laying the foundation for NE take-off. NE can be considered an early product of artificial intelligence, as much as neuroimaging and neuro- navigation. In Italy, cerebral NE started in 1993 and, despite a couple of years of relative delay, gained ground rapidly thanks also to the personal contribution of Michelangelo Gangemi (1949-2017), to whose memory this article is dedicated. In this paper we try to re-create the history of Italian NE through original documents and other testimonials, in the context of the general worldwide development of NE. The modality of its rapid diffusion throughout our peninsula seems a good paradigm of how cooperation without unnecessary competition can be rewarding and constructive.
C1 [Longatti, Pierluigi; Fiorindi, Alessandro] Univ Padua, Treviso Hosp, Neurosurg Unit, Treviso, Italy.
   [Bruscella, Sara; Cappabianca, Paolo] Univ Napoli Federico II, Div Neurosurg, Naples, Italy.
   [Fiorindi, Alessandro] Univ Brescia, Neurosurg Unit, Spedali Civili, Brescia, Italy.
RP Fiorindi, A (reprint author), Univ Padua, Treviso Hosp, Neurosurg Unit, Treviso, Italy.; Fiorindi, A (reprint author), Univ Brescia, Neurosurg Unit, Spedali Civili, Brescia, Italy.
EM alessandro.fiorindi@asst-spedalicivili.it
CR Auer M, 1988, ADV NEUROSURG, V16, P52
   BAUER BL, 1994, ACT NEUR S, V61, P1
   Berci G, 1988, Surg Endosc, V2, P227, DOI 10.1007/BF00705327
   Broggi G, 2000, ACTA NEUROCHIR, V142, P893, DOI 10.1007/s007010070075
   CAEMAERT J, 1992, ACTA NEUROCHIR, V119, P68, DOI 10.1007/BF01541784
   Cappabianca P, 2008, NEUROSURGERY, V62, P575, DOI [10.1227/01.NEU.0000297107.42131.DF, 10.1227/01.neu.0000316262.74843.dd]
   Cappabianca P, 2017, ACTA NEUROCHIR, V159, P2243, DOI 10.1007/s00701-017-3344-4
   Choi JU, 1999, YONSEI MED J, V40, P600, DOI 10.3349/ymj.1999.40.6.600
   Cinalli G, 1999, J NEUROSURG, V90, P448, DOI 10.3171/jns.1999.90.3.0448
   Decq P, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.034
   Demerdash A, 2017, BRIT J NEUROSURG, V31, P28, DOI 10.1080/02688697.2016.1245848
   Di Ieva A, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.09.005
   Ferrer E, 1997, ACTA NEUROCHIR, V139, P12, DOI 10.1007/BF01850862
   Finger T, 2017, ACTA NEUROCHIR, V159, P1033, DOI 10.1007/s00701-017-3152-x
   FUKUSHIMA T, 1973, J NEUROSURG, V38, P251, DOI 10.3171/jns.1973.38.2.0251
   Gaab MR, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.032
   Gangemi M, 1996, MINIM INVAS NEUROSUR, V39, P7, DOI 10.1055/s-2008-1052207
   Gangemi M, 1997, SURG NEUROL, V47, P134, DOI 10.1016/S0090-3019(96)00367-9
   Gangemi M, 2000, MINIM INVAS NEUROSUR, V43, P153, DOI 10.1055/s-2000-12262
   Gangemi M, 1999, MINIM INVAS NEUROSUR, V42, P128, DOI 10.1055/s-2008-1053384
   Gangemi M, 2008, NEUROSURGERY, V63, P62, DOI 10.1227/01.NEU.0000319522.34196.7B
   Gangemil M, 2007, MINIM INVAS NEUROSUR, V50, P265, DOI 10.1055/s-2007-990305
   Grant JA, 1996, NEUROSURGERY, V39, P1232, DOI 10.1097/00006123-199612000-00030
   Griffith H B, 1986, Adv Tech Stand Neurosurg, V14, P2
   Grunert P, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.6.FOCUS09123
   Hughes-Hallett A, 2014, ANN SURG, V260, P205, DOI 10.1097/SLA.0000000000000662
   JONES RFC, 1990, NEUROSURGERY, V26, P86, DOI 10.1227/00006123-199001000-00012
   LEWIS AI, 1995, J NEUROSURG, V82, P780, DOI 10.3171/jns.1995.82.5.0780
   Li CZ, 2018, WORLD NEUROSURG, V110, P270, DOI 10.1016/j.wneu.2017.11.103
   Longatti P, 2006, CHILD NERV SYST, V22, P1263, DOI 10.1007/s00381-006-0105-8
   Longatti Pierluigi, 2020, J Neurosurg Sci, V64, P221, DOI 10.23736/S0390-5616.19.04651-4
   Manwaring KH, 1992, NEUROENDOSCOPY, VI
   Marcus HJ, 2015, J NEUROSURG, V123, P174, DOI 10.3171/2014.12.JNS141422
   Matsumoto S, 1991, HYDROCEPHALUS PATHOG, P679
   Meakins JL, 2002, AM J SURG, V183, P399, DOI 10.1016/S0002-9610(02)00825-5
   Melikian A G, 1997, Zh Vopr Neirokhir Im N N Burdenko, P22
   Mohanty A, 1996, PEDIATR NEUROSURG, V25, P248, DOI 10.1159/000121133
   Nicolato A, 2004, MINIM INVAS NEUROSUR, V47, P32, DOI 10.1055/s-2003-812467
   OKA K, 1993, NEUROSURGERY, V33, P236, DOI 10.1227/00006123-199308000-00009
   Oppido PA, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.1.FOCUS10326
   Prevedello DM, 2007, J NEUROSURG, V107, P206, DOI 10.3171/JNS-07/07/0206
   Rampini P, 1998, PEDIATR NEUROSURG, V29, P102, DOI 10.1159/000028698
   Riskin DJ, 2006, ANN SURG, V244, P686, DOI 10.1097/01.sla.0000242706.91771.ce
   Schmitt PJ, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.6.FOCUS12136
   Smith GE, 2010, REV MOD PHYS, V82, P2307, DOI 10.1103/RevModPhys.82.2307
   Tai-Tong W, 1996, CHILD NERV SYST, V12, P487
   Tomasello F., 1994, 43 ANN M IT SOC NEUR, P291
   Valenzuela S, 1999, CHILD NERV SYST, V15, P457, DOI 10.1007/s003810050439
   VRIES JK, 1978, SURG NEUROL, V9, P165
   Zada G, 2013, WORLD NEUROSURG, V79, pS3, DOI 10.1016/j.wneu.2013.02.001
   Zagzoog N, 2019, J NEUROSURG-PEDIATR, V23, P145, DOI 10.3171/2018.2.PEDS17354
NR 51
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 396
EP 401
DI 10.1016/j.wneu.2019.10.165
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200202
PM 31698127
DA 2020-05-12
ER

PT J
AU Zhang, D
   Barata, A
   Pires, P
   Soares, P
   Marques, L
AF Zhang, Ding
   Barata, Antonio
   Pires, Pedro
   Soares, Pedro
   Marques, Luis
TI Transposition of Superior Cerebellar Artery for Microvascular
   Decompression in Trigeminal Neuralgia Using an In Situ Superior Petrosal
   Vein Sling Technique
SO WORLD NEUROSURGERY
LA English
DT Article
DE Microvascular decompression; Sling; Superior cerebellar artery; Superior
   petrosal vein; Transposition; Trigeminal neuralgia
ID EXPERIENCE; SACRIFICE
AB BACKGROUND: Several microvascular decompression technical variations for the treatment of medically refractory trigeminal neuralgia have been proposed that can be categorized generally as interposition and transposition techniques. These latter approaches, so-called slinging techniques, have been increasing in popularity, because they can possibly reduce the long-term recurrence rates by preventing the formation of fibrosis and granulomas at the decompression site. We have reported a technique for transposition of the superior cerebellar artery for microvascular decompression in trigeminal neuralgia using the superior petrosal vein as an in situ sling to anchor and reroute the artery away from the nerve.
   METHODS: We have presented a technical report with illustrative intraoperative images and video from 2 cases of trigeminal neuralgia in which the superior petrosal vein was used as a simple and straightforward in situ sling for transposition of the superior cerebellar artery.
   RESULTS: The technique was applied successfully in 2 patients with complete and immediate remission of trigeminal neuralgia, without surgical morbidity.
   CONCLUSION: The most frequent neurovascular conflict in trigeminal neuralgia involves the superior cerebellar artery, and the strategic location of the superior petrosal vein relative to this neurovascular complex allows for its use as a natural in situ sling that reroutes the artery and prevents its recoil against the nerve. This technique can be added to the increasing armamentarium of transposition techniques for microvascular decompression, with the advantage of simplicity and no requirement for a complex prosthesis to secure the transposition.
C1 [Zhang, Ding; Barata, Antonio; Marques, Luis] Egas Moniz Hosp, Hosp Ctr West Lisbon, Dept Neurosurg, Lisbon, Portugal.
   [Pires, Pedro; Soares, Pedro] Egas Moniz Hosp, Hosp Ctr West Lisbon, Dept Neuroradiol, Lisbon, Portugal.
RP Zhang, D (reprint author), Egas Moniz Hosp, Hosp Ctr West Lisbon, Dept Neurosurg, Lisbon, Portugal.
EM ding_zhang10@hotmail.com
OI Zhang, Ding/0000-0002-2385-6720; Calvao-Pires, Pedro/0000-0002-3486-2317
CR Barker FG, 1996, NEW ENGL J MED, V334, P1077, DOI 10.1056/NEJM199604253341701
   di Russo P, 2019, OPER NEUROSURG, V17, P193, DOI 10.1093/ons/opy325
   FUKUSHIMA T, 1982, Neurological Surgery, V10, P1257
   Gonzalez-Quarante LH, 2017, WORLD NEUROSURG, V106, P775, DOI 10.1016/j.wneu.2017.07.110
   Holste K, 2020, NEUROSURGERY, V86, P182, DOI 10.1093/neuros/nyz075
   JANNETTA PJ, 1967, J NEUROSURG, V26, P159, DOI 10.3171/jns.1967.26.1part2.0159
   Krayenbuhl H, 1976, PROG NEUROL SURG, V7, P180
   Liebelt BD, 2017, WORLD NEUROSURG, V104, P788, DOI 10.1016/j.wneu.2017.05.098
   Masuoka J, 2011, NEUROSURG REV, V34, P373, DOI 10.1007/s10143-011-0310-0
   McLaughlin MR, 1999, J NEUROSURG, V90, P1, DOI 10.3171/jns.1999.90.1.0001
   Melvill RL, 1996, J NEUROSURG, V84, P127, DOI 10.3171/jns.1996.84.1.0127
   Meybodi AT, 2014, ACTA NEUROCHIR, V156, P1181, DOI 10.1007/s00701-014-2092-y
   Mitsos AP, 2008, NEUROSURG REV, V31, P327, DOI 10.1007/s10143-008-0144-6
   Ohta M, 2008, NEUROL MED-CHIR, V48, P30, DOI 10.2176/nmc.48.30
   Otani N, 2018, J NEUROSURG, V128, P1522, DOI 10.3171/2017.1.JNS161243
   Pathmanaban ON, 2017, WORLD NEUROSURG, V103, P84, DOI 10.1016/j.wneu.2017.03.117
   RHOTON AL, 2000, NEUROSURGERY S, V47, pS6
   Rogers CL, 2000, INT J RADIAT ONCOL, V47, P1013, DOI 10.1016/S0360-3016(00)00513-7
   Sade B, 2010, NEUROSURGERY CASE RE, P76
   Sade B, 2014, NEUROSURG CLIN N AM, V25, P743, DOI 10.1016/j.nec.2014.06.007
   Sindou M, 2008, NEUROSURGERY, V63, P341, DOI 10.1227/01.NEU.0000327022.79171.D6
   Skrap M, 2010, NEUROSURGERY, V66, P88, DOI 10.1227/01.NEU.0000367556.35258.FA
   Steinberg JA, 2019, J NEUROSURG, V130, P1315, DOI 10.3171/2017.10.JNS17971
   Tatli M, 2008, ACTA NEUROCHIR, V150, P243, DOI 10.1007/s00701-007-1488-3
   Xia Y, 2010, ACUPUNCTURE THERAPY FOR NEUROLOGICAL DISEASES: A NEUROBIOLOGICAL VIEW, P1, DOI 10.1007/978-3-642-10857-0
   ZHANG KW, 1990, ANN OTO RHINOL LARYN, V99, P129, DOI 10.1177/000348949009900210
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 402
EP 407
DI 10.1016/j.wneu.2019.11.029
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200203
PM 31733391
DA 2020-05-12
ER

PT J
AU Nisson, PL
   Link, TW
   Carnevale, J
   Virk, MS
   Greenfield, JP
AF Nisson, Peyton L.
   Link, Thomas W.
   Carnevale, Joseph
   Virk, Michael S.
   Greenfield, Jeffrey P.
TI Primary Aneurysmal Bone Cyst of the Thoracic Spine: A Pediatric Case
   Report
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysmal bone cyst; Case report; Pediatric; Spine; Surgery; Thoracic
ID PUBERTAL CHANGES; MOBILE SPINE; USP6; ONCOGENES; ETIOLOGY; PATTERN
AB BACKGROUND: To date, only a few documented cases exist of complete or near-complete paraplegia of the lower extremities following collapse of a vertebral body secondary to an aneurysmal bone cyst. We describe the preceding symptoms associated with this catastrophic event along with surgical management and recovery.
   CASE DESCRIPTION: A previously healthy, 13-year-old girl had experienced months of ongoing back pain with associated posture change. After collapsing at home in the bathroom, she was brought in by emergency medical services and presented to the neurosurgery service with an American Spinal Injury Association A spinal cord injury. Imaging revealed a collapsed T4 vertebral body including expanded and fluid-filled posterior elements and severe kyphotic spine angulation resulting in cord compression corresponding to her sensory and motor deficits. She underwent emergent surgery for spinal cord decompression with a T2-T4 laminectomy, transpedicular tumor resection, and T1-7 instrumented fusion. The patient tolerated the procedure well postoperatively. At 9 months after the event, she is ambulating independently without the use of crutches or a cane and has regained full strength for all muscle groups of her lower extremities.
   CONCLUSIONS: The unique combination of back pain and posture change symptoms in an otherwise healthy pediatric patient should heighten clinical suspicion for a possible aneurysmal bone cyst of the spine when formulating a differential diagnosis. Additionally, despite the clinical severity at presentation, patients may still experience significant recovery following expeditious surgical intervention.
C1 [Nisson, Peyton L.] Cedars Sinai Med Ctr, Dept Neurosurg, Los Angeles, CA 90048 USA.
   [Nisson, Peyton L.; Link, Thomas W.; Carnevale, Joseph; Virk, Michael S.; Greenfield, Jeffrey P.] Weill Cornell Med Brain & Spine Ctr, Dept Neurol Surg, New York, NY 10021 USA.
RP Greenfield, JP (reprint author), Weill Cornell Med Brain & Spine Ctr, Dept Neurol Surg, New York, NY 10021 USA.
EM jpgreenf@med.cornell.edu
OI Link, Thomas/0000-0003-1325-8847; Greenfield,
   Jeffrey/0000-0003-1904-1040
CR AHO HJ, 1982, VIRCHOWS ARCH A, V395, P169, DOI 10.1007/BF00429610
   Alberti C, 2011, CLIN CHEM, V57, P1424, DOI 10.1373/clinchem.2011.169466
   AMELI NO, 1985, J NEUROSURG, V63, P685, DOI 10.3171/jns.1985.63.5.0685
   Amendola L, 2013, EUR SPINE J, V22, P533, DOI 10.1007/s00586-012-2566-7
   Barbanti-Brodano G, 2017, EUR SPINE J, V26, pS158, DOI 10.1007/s00586-017-4978-x
   BONAKDARPOUR A, 1978, RADIOLOGY, V126, P75, DOI 10.1148/126.1.75
   Boriani S, 2001, SPINE, V26, P27, DOI 10.1097/00007632-200101010-00007
   Boriani S, 2010, EUR SPINE J, V19, P231, DOI 10.1007/s00586-009-1137-z
   CAPANNA R, 1985, J BONE JOINT SURG AM, V67A, P527, DOI 10.2106/00004623-198567040-00004
   CHIGIRA M, 1983, J BONE JOINT SURG BR, V65, P633
   COHEN J, 1977, ORTHOP CLIN N AM, V8, P715
   COHEN J, 1970, J BONE JOINT SURG AM, VA 52, P1493, DOI 10.2106/00004623-197052070-00030
   de Kleuver M, 1998, J PEDIATR ORTHOP B, V7, P286, DOI 10.1097/01202412-199810000-00006
   Deo SD, 2005, SPINE, V30, pE80, DOI 10.1097/01.brs.0000152094.20585.c0
   Docquier PL, 2005, J BONE JOINT SURG AM, V87A, P2253, DOI 10.2106/JBJS.D.02540
   FARSETTI P, 1990, ARCH ORTHOP TRAUM SU, V109, P221, DOI 10.1007/BF00453145
   Guseva NV, 2017, GENE CHROMOSOME CANC, V56, P266, DOI 10.1002/gcc.22432
   HAY MC, 1978, J BONE JOINT SURG BR, V60, P406
   Jaffe HL, 1942, ARCH SURG-CHICAGO, V44, P1004, DOI 10.1001/archsurg.1942.01210240043003
   Jaiswal A, 2013, BMJ CASE REP, V2013
   KYRIAKOS M, 1991, CANCER-AM CANCER SOC, V68, P1770, DOI 10.1002/1097-0142(19911015)68:8<1770::AID-CNCR2820680821>3.0.CO;2-7
   Leithner A, 1999, CLIN ORTHOP RELAT R, P176
   MACCARTY CS, 1961, J NEUROSURG, V18, P671, DOI 10.3171/jns.1961.18.5.0671
   MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291, DOI 10.1136/adc.44.235.291
   MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13
   MCDONALD P, 1992, CLIN ORTHOP RELAT R, P127
   Mehta V, 2017, CUREUS, V9, DOI 10.7759/cureus.1208
   Miu A, 2015, J Med Life, V8, P509
   MOHAN V, 1989, ARCH ORTHOP TRAUM SU, V108, P390, DOI 10.1007/BF00932454
   NEER CS, 1973, CLIN ORTHOP RELAT R, P40
   Novais EN, 2011, J BONE JOINT SURG AM, V93A, P1534, DOI 10.2106/JBJS.J.01430
   Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827
   Oliveira AM, 2004, AM J PATHOL, V165, P1773, DOI 10.1016/S0002-9440(10)63432-3
   Papagelopoulos PJ, 1998, SPINE, V23, P621, DOI 10.1097/00007632-199803010-00018
   Pauli C, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-17
   RAFTOPOULOS C, 1994, CHILD NERV SYST, V10, P464, DOI 10.1007/BF00303615
   ROSMAN MA, 1978, CAN J SURG, V21, P181
   SCAGLIETTI O, 1982, CLIN ORTHOP RELAT R, P33
   SCHAFFER L, 1985, SPINE, V10, P390, DOI 10.1097/00007632-198505000-00017
   SHACKED I, 1981, PARAPLEGIA, V19, P294, DOI 10.1038/sc.1981.56
   Shiels WE, 2013, CLIN ORTHOP RELAT R, V471, P2675, DOI 10.1007/s11999-013-3043-2
   SZENDROI M, 1992, J CANCER RES CLIN, V119, P61, DOI 10.1007/BF01209491
   TILLMAN BP, 1968, MAYO CLIN PROC, V43, P478
   Van Arsdale W W, 1893, Ann Surg, V18, P8, DOI 10.1097/00000658-189307000-00002
   Zileli M, 2013, EUR SPINE J, V22, P593, DOI 10.1007/s00586-012-2510-x
NR 45
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 408
EP 414
DI 10.1016/j.wneu.2019.10.151
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200204
PM 31678311
DA 2020-05-12
ER

PT J
AU Telfeian, AE
   Oyelese, A
   Fridley, J
   Moldovan, K
   Gokaslan, ZL
AF Telfeian, Albert E.
   Oyelese, Adetokunbo
   Fridley, Jared
   Moldovan, Krisztina
   Gokaslan, Ziya L.
TI Transforaminal Endoscopic Approach for Lumbar Extraforaminal Synovial
   Cysts: Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic spine surgery; Extraforaminal; Lumbar spine; Minimally
   invasive; Synovial cyst; Transforaminal
ID JUXTAFACET CYSTS
AB OBJECTIVE: Lumbar facet cysts are commonly seen in degenerative lumbar conditions causing stenosis and radiculopathy. Extraforaminal lumbar facet cysts are a rare entity and present a surgical challenge because of their location. Transforaminal endoscopic spine surgery is an emerging technique in spine surgery but has never been described as a treatment option for lumbar radiculopathy in the setting of extraforaminal lumbar facet cyst.
   METHODS: A technique for the transforaminal endoscopic treatment of an extraforaminal lumbar facet cyst is presented in 2 patients. We retrospectively reviewed 321 cases of patients who underwent transforaminal endoscopic surgery in a 4-year period with a minimum followup of 2 years.
   RESULTS: A series of 2 patients who underwent transforaminal endoscopic foraminotomy and cyst resection procedures for extraforaminal lumbar facet cysts between 2014 and 2017 is presented: A 51-year-old woman with a right L4-5 extraforaminal cyst improved from a preoperative visual analog scale (VAS) of 7 and Oswestry disability index (OM) of 26 to a 1-year postoperative VAS score of 2 and ODI of 4; and a 71-year-old woman with a left L5-S1 extraforaminal cyst improved from a preoperative VAS of 7 and ODI of 30 to a 1-year postoperative VAS score of 2 and ODI of 6.
   CONCLUSIONS: Transforaminal endoscopic surgery for a lumbar radiculopathy in the setting of an extraforaminal lumbar facet cyst is presented as a unique minimally invasive approach for the treatment of extraforaminal lumbar facet cyst that avoids facet resection and fusion.
C1 [Telfeian, Albert E.; Oyelese, Adetokunbo; Fridley, Jared; Moldovan, Krisztina; Gokaslan, Ziya L.] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Dept Neurosurg, Providence, RI 02903 USA.
RP Telfeian, AE (reprint author), Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Dept Neurosurg, Providence, RI 02903 USA.
EM atelfeian@lifespan.org
CR EYSTER EF, 1989, NEUROSURGERY, V24, P112
   Kemaloglu S, 2001, SPINAL CORD, V39, P399, DOI 10.1038/sj.sc.3101170
   Kim JU, 2008, NEUROL MED-CHIR, V48, P578, DOI 10.2176/nmc.48.578
   Manabe M, 2006, J SPINAL DISORD TECH, V19, P447, DOI 10.1097/00024720-200608000-00013
   MAUPIN WB, 1989, AM J ROENTGENOL, V153, P1231, DOI 10.2214/ajr.153.6.1231
   Oertel MF, 2006, SURG NEUROL, V66, P197, DOI 10.1016/j.surneu.2005.11.026
   ONOFRIO BM, 1988, NEUROSURGERY, V22, P642, DOI 10.1227/00006123-198804000-00004
   PENDLETON B, 1983, NEUROSURGERY, V13, P322, DOI 10.1227/00006123-198309000-00021
   Phuong LK, 2002, NEUROSURGERY, V51, P505, DOI 10.1097/00006123-200208000-00038
   Sabo RA, 1996, J NEUROSURG, V85, P560, DOI 10.3171/jns.1996.85.4.0560
   Spinner RJ, 2010, J NEUROSURG-SPINE, V12, P96, DOI 10.3171/2009.7.SPINE09257
   Campa-Santamarina JT, 2015, CUREUS, V7, DOI 10.7759/cureus.362
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 415
EP 419
DI 10.1016/j.wneu.2019.11.033
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200205
PM 31733383
DA 2020-05-12
ER

PT J
AU Asuzu, DT
   Kumar, J
   Capek, S
   Park, MS
AF Asuzu, David T.
   Kumar, Jeyan
   Capek, Stepan
   Park, Min S.
TI Fulminant Reversible Cerebral Vasoconstriction Syndrome After Carotid
   Endarterectomy for Asymptomatic Stenosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid endarterectomy; Ischemic stroke; Vasospasm
ID BLOOD-FLOW; FEATURES
AB BACKGROUND: Reversible cerebral vasoconstriction syndrome (RCVS) is a rare complication after carotid endarterectomy (CEA). Only a limited number of prior cases of RCVS have been reported after CEA for asymptomatic carotid stenosis.
   CASE DESCRIPTION: In this report we present an unusual case of RCVS associated with multifocal intraparenchymal hemorrhage, subarachnoid hemorrhage, subdural hematoma, and ischemic stroke after CEA for asymptomatic carotid stenosis. We review preexisting studies and draw correlations with implications for understanding the mechanisms of RCVS.
   CONCLUSIONS: A high index of suspicion should be maintained in post-CEA patients presenting with headaches or focal neurologic deficits, and vigilance with serial vascular imaging may help minimize long-term complications.
C1 [Asuzu, David T.; Kumar, Jeyan; Capek, Stepan; Park, Min S.] Univ Virginia, Dept Neurosurg, Charlottesville, VA 22904 USA.
   [Asuzu, David T.] NINDS, Surg Neurol Branch, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
RP Park, MS (reprint author), Univ Virginia, Dept Neurosurg, Charlottesville, VA 22904 USA.
EM MP2TQ@hscmail.mcc.virginia.edu
CR Bodenant M, 2010, CASE REP NEUROL, V2, P80, DOI 10.1159/000315865
   Calabrese LH, 2007, ANN INTERN MED, V146, P34, DOI 10.7326/0003-4819-146-1-200701020-00007
   Causey MW, 2016, J VASC SURG, V64, P1847, DOI 10.1016/j.jvs.2016.01.020
   Chen SP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018024
   Dodick DW, 1999, CEPHALALGIA, V19, P118, DOI 10.1046/j.1468-2982.1999.019002118.x
   Ducros A, 2012, LANCET NEUROL, V11, P906, DOI 10.1016/S1474-4422(12)70135-7
   Ducros A, 2010, STROKE, V41, P2505, DOI 10.1161/STROKEAHA.109.572313
   Farooq Muhammad U, 2016, Exp Transl Stroke Med, V8, P7, DOI 10.1186/s13231-016-0021-2
   Katz BS, 2014, JAMA NEUROL, V71, P68, DOI 10.1001/jamaneurol.2013.4639
   LopezValdes E, 1997, NEUROLOGY, V49, P303, DOI 10.1212/WNL.49.1.303
   Singhal AB, 2016, ANN NEUROL, V79, P882, DOI 10.1002/ana.24652
   SUNDT TM, 1981, MAYO CLIN PROC, V56, P533
   Topcuoglu MA, 2016, STROKE, V47, P1742, DOI 10.1161/STROKEAHA.116.013136
   WALTZ AG, 1968, NEUROLOGY, V18, P613, DOI 10.1212/WNL.18.7.613
   Wu TY, 2011, J CLIN NEUROSCI, V18, P1725, DOI 10.1016/j.jocn.2011.03.018
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 423
EP 426
DI 10.1016/j.wneu.2019.11.032
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200207
PM 31733386
DA 2020-05-12
ER

PT J
AU Rubio, RR
   Dubnicoff, T
   Rutledge, WC
   Abla, AA
AF Rubio, Roberto Rodriguez
   Dubnicoff, Todd
   Rutledge, W. Caleb
   Abla, Adib A.
TI Combined Pterional Transsylvian and Bifrontal Interhemispheric Approach
   to Ruptured Subcallosal and Pericallosal Brain Arteriovenous
   Malformation with Skeletonization of the Entire A2 ACA Segment
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D video; Anterior cerebral artery; Arteriovenous malformation;
   Bifrontal; Interhemispheric; Pterional; Ruptured; Second segment;
   Transsylvian
C1 [Rubio, Roberto Rodriguez; Abla, Adib A.] Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.
   [Rubio, Roberto Rodriguez; Dubnicoff, Todd; Rutledge, W. Caleb; Abla, Adib A.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
   [Rubio, Roberto Rodriguez] Univ Calif San Francisco, Dept Otolaryngol Head & Neck Surg, San Francisco, CA 94143 USA.
RP Abla, AA (reprint author), Univ Calif San Francisco, Skull Base & Cerebrovasc Lab, San Francisco, CA 94143 USA.; Abla, AA (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
EM adib.abla@ucsf.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 427
EP 427
DI 10.1016/j.wneu.2019.11.059
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200208
PM 31756504
DA 2020-05-12
ER

PT J
AU Monteiro, J
   Santiago, B
   Manilha, R
   Viegas, C
   Oliveira, A
   Sa, MCE
AF Monteiro, Joana
   Santiago, Bruno
   Manilha, Rui
   Viegas, Catarina
   Oliveira, Ana
   Cunha e Sa, Manuel
TI Adult Atypical Teratoid/Rhabdoid Tumor in the Pineal Region: Case Report
   and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Adult; Pineal region; Teratoid rhabdoid tumor
ID CENTRAL-NERVOUS-SYSTEM; TERATOID RHABDOID TUMOR; MULTIMODAL THERAPY;
   AT/RT; INFANCY
AB BACKGROUND: Atypical teratoid/rhabdoid tumor (AT/RT) is a malignant embryonal central nervous system tumor with a poor prognosis. Its occurrence in the pineal region is extremely rare, with only 6 cases in adults reported so far.
   CASE DESCRIPTION: We report on a puerperal woman with an AT/RT in the pineal region. Total tumor resection was performed. Definitive diagnosis was confirmed by the loss of nuclear INI1/SMARCB1 staining. The patient underwent radiotherapy and chemotherapy with no evidence of recurrence at 31 months after surgery.
   CONCLUSIONS: This case highlights the importance of immunohistochemistry in the diagnosis of the disease and the importance of an aggressive treatment.
C1 [Monteiro, Joana; Santiago, Bruno; Manilha, Rui; Viegas, Catarina; Cunha e Sa, Manuel] Hosp Garcia de Orta, Dept Neurosurg, Almada, Portugal.
   [Oliveira, Ana] Hosp Garcia de Orta, Dept Pathol, Almada, Portugal.
RP Monteiro, J (reprint author), Hosp Garcia de Orta, Dept Neurosurg, Almada, Portugal.
EM joanaratmonteiro@gmail.com
OI Monteiro, Joana/0000-0002-1822-0090
CR Arslanoglu A, 2004, AM J NEURORADIOL, V25, P476
   Benesch M, 2014, BONE MARROW TRANSPL, V49, P370, DOI 10.1038/bmt.2013.208
   Biegel Jaclyn A., 2002, Cancer Research, V62, P323
   Biswas A, 2016, CANCER MANAG RES, V8, P115, DOI 10.2147/CMAR.S83472
   Biswas A, 2009, CHILD NERV SYST, V25, P1495, DOI 10.1007/s00381-009-0903-x
   D'cunja J, 2007, EUR J CANCER, V43, P1581, DOI 10.1016/j.ejca.2007.03.003
   Dardis C, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00247
   Erickson ML, 2005, J NEURO-ONCOL, V74, P311, DOI 10.1007/s11060-004-7560-4
   Fruhwald MC, EUROPEAN RHABDOID RE
   Gessl M, 2003, BRAIN PATHOL, V13, P409
   Han L, 2011, AM J NEURORADIOL, V32, P103, DOI 10.3174/ajnr.A2361
   Ho DMT, 2000, ACTA NEUROPATHOL, V99, P482, DOI 10.1007/s004010051149
   Ingold B, 2006, ACTA NEUROPATHOL, V111, P56, DOI 10.1007/s00401-005-1112-7
   Jin SM, 2015, FOLIA NEUROPATHOL, V53, P80, DOI 10.5114/fn.2015.49977
   Johann PD, 2016, CANCER CELL, V29, P379, DOI 10.1016/j.ccell.2016.02.001
   Kawaguchi T, 2004, ACTA NEUROCHIR, V146, P1033, DOI 10.1007/s00701-004-0313-5
   Kuge A, 2012, BRAIN TUMOR PATHOL, V29, P177, DOI 10.1007/s10014-011-0075-8
   Liebigt S, 2017, J NEUROL SURG PART A, V78, P92, DOI 10.1055/s-0036-1583180
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Makuria AT, 2008, J NEURO-ONCOL, V88, P321, DOI 10.1007/s11060-008-9571-z
   Meyers SP, 2006, AM J NEURORADIOL, V27, P962
   Mirone G, 2009, J CLIN NEUROSCI, V16, P1495, DOI 10.1016/j.jocn.2009.02.011
   Park Hae Gi, 2014, Brain Tumor Res Treat, V2, P108, DOI 10.14791/btrt.2014.2.2.108
   Raisanen J, 2005, BRAIN PATHOL, V15, P23
   Raisanen J, 2004, DIAGN CYTOPATHOL, V31, P60, DOI 10.1002/dc.20064
   RORKE LB, 1995, J NEURO-ONCOL, V24, P21, DOI 10.1007/BF01052653
   Samaras V, 2009, CLIN NEUROPATHOL, V28, P1
   Shonka Nicole A, 2011, J Clin Med Res, V3, P85, DOI 10.4021/jocmr535w
   Slavc I, 2014, CANCER MED-US, V3, P91, DOI 10.1002/cam4.161
   Souki C, 2014, CLIN NEUROPATHOL, V33, P245, DOI 10.5414/NP300683
   Sugita Y, 1999, PATHOL INT, V49, P1114, DOI 10.1046/j.1440-1827.1999.00988.x
   Takei H, 2010, J NEUROSURG, V113, P374, DOI 10.3171/2009.10.JNS09964
   Valencia-Moya A, 2016, NEUROCIRUGIA, V27, P87, DOI 10.1016/j.neucir.2015.01.003
   Wu WW, 2016, WORLD NEUROSURG, V85, P197, DOI 10.1016/j.wneu.2015.08.076
NR 34
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 428
EP 433
DI 10.1016/j.wneu.2019.11.075
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200209
PM 31759153
DA 2020-05-12
ER

PT J
AU Zhou, SZ
   Zhu, YF
   Xu, J
   Tao, RJ
   Yuan, SH
AF Zhou, Shizhen
   Zhu, Yufang
   Xu, Jun
   Tao, Rongjie
   Yuan, Shuanghu
TI Rare NF1 Gene Mutation in Chinese Patient with Neurofibromatosis Type 1
   and Anaplastic Astrocytoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anaplastic astrocytoma; Gene mutation; Neurofibromatosis type 1
ID INDIVIDUALS; GLIOMAS; AGE-10; TUMORS
AB BACKGROUND: Neurofibromatosis type 1 (NF1), a dysregulated neuro-cutaneous disorder, is an autosomal dominant genetic disease caused by mutations in the NF1 gene. Anaplastic astrocytoma is rare in NF1 patients, and research has proposed that high-grade astrocytomas could be due to larger germ-line mutations in NF1.We present a clinical and molecular study of a Chinese family with NF1.
   CASE DESCRIPTION: A 28-year-old male patient with NF1 presents with headache, vertigo, and dizziness. Histopathologic examination and molecular features identified a cerebellar anaplastic astrocytoma, IDH-wildtype. The patient underwent gross total resection of the lesion and received radiotherapy and chemotherapy. A rare splice error mutation (c.4110+945A>G) in intron 23-2 of NF1 was identified by next-generation sequencing in the proband. Sanger sequencing identified and confirmed it in some affected family members.
   CONCLUSIONS: We present a unique case of NF1 with anaplastic astrocytoma that revealed a rare splice error mutation in the NF1 gene in the family.
C1 [Zhou, Shizhen; Zhu, Yufang; Xu, Jun; Tao, Rongjie; Yuan, Shuanghu] Shandong Univ, Shandong Canc Hosp, Jinan, Shandong, Peoples R China.
   [Zhou, Shizhen; Zhu, Yufang; Xu, Jun; Tao, Rongjie; Yuan, Shuanghu] Shandong Acad Med Sci, Jinan, Shandong, Peoples R China.
RP Yuan, SH (reprint author), Shandong Univ, Shandong Canc Hosp, Jinan, Shandong, Peoples R China.; Yuan, SH (reprint author), Shandong Acad Med Sci, Jinan, Shandong, Peoples R China.
EM yuanshuanghu@sina.com
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [NSFC81872475]
FX This study was partially funded by Natural Science Foundation of China
   (NSFC81872475).
CR Banerjee S, 2016, J CLIN NEUROSCI, V31, P182, DOI 10.1016/j.jocn.2015.12.034
   Brinckmann A, 2007, ELECTROPHORESIS, V28, P4295, DOI 10.1002/elps.200700118
   Brokinkel B, 2013, J NEUROL SURG PART A, V74, pE203, DOI 10.1055/s-0033-1342938
   Campian J, 2017, J CLIN ONCOL, V35, P2378, DOI 10.1200/JCO.2016.71.7199
   Cimino Patrick J, 2018, Handb Clin Neurol, V148, P799, DOI 10.1016/B978-0-444-64076-5.00051-X
   Fortunato JT, 2018, ANTICANCER RES, V38, P4897, DOI 10.21873/anticanres.12804
   Gutmann DH, 2003, NEUROLOGY, V61, P1397, DOI 10.1212/WNL.61.10.1397
   Gutmann DH, 2002, NEUROLOGY, V59, P759, DOI 10.1212/WNL.59.5.759
   LISTERNICK R, 1994, J PEDIATR-US, V125, P63, DOI 10.1016/S0022-3476(94)70122-9
   Rodriguez FJ, 2008, J NEUROPATH EXP NEUR, V67, P240, DOI 10.1097/NEN.0b013e318165eb75
NR 10
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 434
EP 437
DI 10.1016/j.wneu.2019.10.126
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200210
PM 31678437
DA 2020-05-12
ER

PT J
AU Grewal, SS
   Domingo, RA
   Wharen, RE
AF Grewal, Sanjeet S.
   Domingo, Ricardo A.
   Wharen, Robert E., Jr.
TI Left Radiofrequency Thalamotomy for Drug-Refractory Essential Tremor
SO WORLD NEUROSURGERY
LA English
DT Article
DE Essential tremor; Radiofrequency; Stereotactic and stimulation;
   Thalamotomy
C1 [Grewal, Sanjeet S.; Domingo, Ricardo A.; Wharen, Robert E., Jr.] Mayo Clin, Dept Neurol Surg, Jacksonville, FL 32224 USA.
RP Wharen, RE (reprint author), Mayo Clin, Dept Neurol Surg, Jacksonville, FL 32224 USA.
EM wharen.robert@mayo.edu
OI Grewal, Sanjeet/0000-0002-4307-7062
CR Miller TR, 2019, NEURORADIOL J, V32, P401, DOI 10.1177/1971400919870180
   Shanker V, 2019, CURR NEUROL NEUROSCI, V19, P66
   Walters H, 2019, CURR NEUROL NEUROSCI, V19, DOI 10.1007/s11910-019-0975-2
NR 3
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 438
EP 438
DI 10.1016/j.wneu.2019.10.180
PG 1
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200211
PM 31704356
DA 2020-05-12
ER

PT J
AU Walton, A
   Mecklosky, J
   Carr, C
   Scullen, T
   Mathkour, M
   Werner, C
   Amenta, PS
AF Walton, Alice
   Mecklosky, Jessica
   Carr, Christopher
   Scullen, Tyler
   Mathkour, Mansour
   Werner, Cassidy
   Amenta, Peter S.
TI Cauda Equina Syndrome Secondary to Diffuse Infiltration of the Cauda
   Equina by Acute Myeloid Leukemia: Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Acute myeloid leukemia; Cauda equina infiltration; Cauda equina syndrome
ID CENTRAL-NERVOUS-SYSTEM; ADULT PATIENTS; INVOLVEMENT; MANIFESTATION; CNS
AB BACKGROUND: Cauda equina syndrome (CES) results from the dysfunction of lumbar, sacral, and coccygeal rootlets composing the cauda equina. The underlying etiology is most commonly compression secondary to a large herniated lumbosacral disk; however, any pathology affecting the rootlets can result in the syndrome.
   METHODS: We present a rare case of CES secondary to neoplastic poly-radiculities in a patient with acute myelogenous leukemia (AML) and review the pertinent literature. A 72-year-old male with a medical history of AML presented with 2 weeks of difficulty ambulating, followed by acute-onset low back pain radiating to the buttocks bilaterally.
   RESULTS: Imaging of the lumbar spine demonstrated diffuse enhancement and thickening of the cauda equina rootlets. Lumbar puncture showed numerous blasts with monocytoid features consistent with AML, and the patient was diagnosed with polyradiculopathy of the cauda equina secondary to diffuse metastatic infiltration.
   CONCLUSIONS: Central nervous system involvement of leukemia is poorly understood, even though such lesions are not uncommon in advanced disease. As treatment has improved, many types of leukemia, such as AML, are believed to be curable, and patients with the disease are living longer. With improved survival, it is reasonable to suspect that such involvement by AML may become more common. Our patient is a classic presentation of CES secondary to diffuse infiltration by AML and serves as an example of this rare manifestation of hematologic malignancy.
C1 [Walton, Alice; Mecklosky, Jessica; Carr, Christopher; Scullen, Tyler; Mathkour, Mansour; Werner, Cassidy; Amenta, Peter S.] Tulane Univ Med Ctr Hosp & Clin, Dept Neurosurg, New Orleans, LA 70112 USA.
RP Amenta, PS (reprint author), Tulane Univ Med Ctr Hosp & Clin, Dept Neurosurg, New Orleans, LA 70112 USA.
EM peter.amenta@gmail.com
RI Mathkour, Mansour/N-7878-2015
OI Mathkour, Mansour/0000-0002-1913-3677
CR Abbott BL, 2003, LEUKEMIA, V17, P2090, DOI 10.1038/sj.leu.2403131
   Alakel N, 2017, CANCER MANAG RES, V9, DOI 10.2147/CMAR.S125259
   AZZARELLI B, 1977, ARCH PATHOL LAB MED, V101, P203
   Bennett Shelby J, 2016, Pract Neurol, V16, P35, DOI 10.1136/practneurol-2015-001236
   Buakhao Jitsuda, 2011, Journal of the Medical Association of Thailand, V94, P1271
   Cheng CL, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1376-9
   Del Principe MI, 2018, SEMIN HEMATOL, V55, P209, DOI 10.1053/j.seminhematol.2018.02.006
   Deschler B, 2006, CANCER-AM CANCER SOC, V107, P2099, DOI 10.1002/cncr.22233
   Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184
   LEVINE GA, 1973, CANCER-AM CANCER SOC, V31, P959, DOI 10.1002/1097-0142(197304)31:4<959::AID-CNCR2820310430>3.0.CO;2-5
   Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407
   Onal IK, 2006, J NATL MED ASSOC, V98, P808
   PETURSSON SR, 1981, CANCER, V47, P346, DOI 10.1002/1097-0142(19810115)47:2<346::AID-CNCR2820470223>3.0.CO;2-U
   Pui CH, 2008, LANCET ONCOL, V9, P257, DOI 10.1016/S1470-2045(08)70070-6
   Quaile A, 2019, INT ORTHOP, V43, P957, DOI 10.1007/s00264-018-4208-0
   Shihadeh F, 2011, CANCER, V118, P112
   Wilson R, 2018, PEDIATR DRUGS, V20, P293, DOI 10.1007/s40272-018-0298-9
   Yao H, 2018, NATURE, V560, P55, DOI 10.1038/s41586-018-0342-5
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 439
EP 442
DI 10.1016/j.wneu.2019.11.068
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200212
PM 31759146
DA 2020-05-12
ER

PT J
AU Silva, NA
   Goldstein, IM
AF Silva, Nicole A.
   Goldstein, Ira M.
TI Obstruction of Ventriculoperitoneal Shunt After Myelography-Report of a
   Unique Case and Its Treatment
SO WORLD NEUROSURGERY
LA English
DT Article
DE CSF loculation; CT myelogram; Hydrocephalus; Lumbar puncture;
   Malfunction; Myelography; Obstruction; Shunt pumping; Shunt tap;
   Ventriculomegaly; Ventriculoperitoneal shunt
ID HYDROCEPHALUS; COMPLICATIONS
AB BACKGROUND: Myelography, frequently supplanted by noninvasive, efficient magnetic resonance imaging, remains a useful technique when evaluating the spinal canal in nerve root avulsion, radiation therapy treatment planning, cerebrospinal fluid (CSF) loculation, and CSF leak. Myelography is achieved through a lumbar puncture and instillation of nonionic, water-soluble intrathecal iohexol (Omnipaque, GE Healthcare, Marlborough, Massachusetts, USA) contrast. The aim of the study was to highlight a possible complication of obstruction of a shunt valve due to an increased viscosity of the CSF after intrathecal Omnipaque contrast administration during myelography.
   CASE DESCRIPTION: The authors report a case of myelography that resulted in obstruction of a ventriculoperitoneal (VP) shunt. A 23-year-old female with significant medical history of neurofibromatosis type I, obstructive hydrocephalus, anterior cervical diskectomy and fusion, and VP shunt placement underwent diagnostic computed tomography after myelography with Omnipaque contrast to assess possible CSF loculation and cord impingement from her cervical instrumentation. The patient experienced somnolence after myelography from obstruction of the VP shunt, with marked ventriculomegaly demonstrated by computed tomography of the head. A shunt tap and shunt pumping regimen resulted in resolution of the obstruction and hydrocephalus, with return to neurologic baseline.
   CONCLUSIONS: This is a recent case of VP shunt obstruction after myelography, of which previous cases reported are decades old. A shunt pumping regimen may be a nonoperative, effective mean for similar mechanical obstructions of VP shunts for restoration of flow and patency of the shunt system in these patients. We encourage physicians to consider the possibility of shunt obstruction after diagnostic myelography. Caution and close observation should be considered in patients undergoing myelography with a programmable VP shunt.
C1 [Silva, Nicole A.; Goldstein, Ira M.] Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07103 USA.
RP Goldstein, IM (reprint author), Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07103 USA.
EM goldstir@njms.rutgers.edu
CR Eberhardt K, 2014, NEURORADIOLOGY, V56, P1069, DOI 10.1007/s00234-014-1433-0
   Gnanalingham KK, 2004, BRIT J NEUROSURG, V18, P303, DOI 10.1080/02688690410001732814
   GUPTA SR, 1985, COMPUT RADIOL, V9, P359, DOI 10.1016/0730-4862(85)90122-2
   JENSEN F, 1979, NEURORADIOLOGY, V18, P139
   Jorgensen Julianne, 2016, Critical Reviews in Biomedical Engineering, V44, P91, DOI 10.1615/CritRevBiomedEng.2016017149
   KRUDY AG, 1992, AM J ROENTGENOL, V159, P1315, DOI 10.2214/ajr.159.6.1442408
   MASON MS, 1962, J NEUROSURG, V19, P302, DOI 10.3171/jns.1962.19.4.0302
   Morgalla M, 2018, J NEUROL SURG PART A, V79, P316, DOI 10.1055/s-0037-1618563
   Ozdoba C, 2011, RADIOL RES PRACT, V2011, DOI 10.1155/2011/329017
   PANG DL, 1994, NEUROSURGERY, V35, P643, DOI 10.1227/00006123-199410000-00010
   Pomerantz SR, 2016, HAND CLINIC, V135, P193, DOI 10.1016/B978-0-444-53485-9.00010-6
   Rodriguez D, 2016, AM J ROENTGENOL, V206, P20, DOI 10.2214/AJR.15.14664
   Tseng SH, 1997, NEURORADIOLOGY, V39, P863, DOI 10.1007/s002340050522
NR 13
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 443
EP 447
DI 10.1016/j.wneu.2019.11.067
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200213
PM 31756508
DA 2020-05-12
ER

PT J
AU Khalighinejad, F
   Hajizadeh, M
   Mokhtari, A
   Rakhshan, R
   Hajizadeh, M
   Rezvani, M
AF Khalighinejad, Farnaz
   Hajizadeh, Mahsa
   Mokhtari, Ali
   Rakhshan, Reza
   Hajizadeh, Majid
   Rezvani, Majid
TI Spinal Intradural Extramedullary Dermoid Cyst
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dermoid cyst; Intradural extramedullary; Spinal; Teratoma
ID TERATOMA
AB BACKGROUND: Dermoid cysts are benign congenital tumors that develop early in life. These tumors are classified by the presence of all 3 germ layers. Spinal intradural extramedullary teratoma is a rare disease, which is more common in children under 5 years of age than in adults.
   CASE DESCRIPTION: A 12-year-old girl with a dermoid cyst at the lower lumbar level presented with 2-month low back pain and intermittent lower extremity radicular symptoms on the right side. Magnetic resonance imaging scan of the spine revealed an intradural extramedullary mass lesion at L4-5. Surgical excision of the cyst was successfully performed. Surgical and histopathologic findings confirmed extramedullary ruptured matured teratoma. Postoperatively, the patient had remarkable clinical improvement.
   CONCLUSIONS: Although dermoid cysts are uncommon, they should be considered in the differential diagnosis of spinal lesions in patients with lower back pain. It can be successfully treated with surgical excision.
C1 [Khalighinejad, Farnaz] Univ Massachusetts, Med Sch, Worcester, MA 01605 USA.
   [Hajizadeh, Mahsa] Isfahan Univ Med Sci, Isfahan Res Comm Pathol, Esfahan, Iran.
   [Mokhtari, Ali; Rezvani, Majid] Isfahan Univ Med Sci, Dept Neurosurg, Esfahan, Iran.
   [Rakhshan, Reza] Isfahan Univ Med Sci, Dept Pathol, Esfahan, Iran.
   [Hajizadeh, Majid] Abadan Univ Med Sci, Dept Radiol, Abadan, Iran.
RP Hajizadeh, M (reprint author), Isfahan Univ Med Sci, Isfahan Res Comm Pathol, Esfahan, Iran.
EM Mahsahjizadeh@gmail.com
CR Choi JS, 2018, ARCH PLAST SURG-APS, V45, P512, DOI 10.5999/aps.2018.00017
   Danison Aaron P, 2018, Asian J Neurosurg, V13, P1182, DOI 10.4103/ajns.AJNS_370_16
   Jayasuriya Nadeena Sri Swarnagupta, 2017, J Med Case Rep, V11, P11, DOI 10.1186/s13256-016-1186-y
   Kabbasch C, 2014, NEURORADIOL J, V27, P759, DOI 10.15274/NRJ-2014-10089
   Mpayo LL, 2014, PEDIATR NEUROL, V50, P655, DOI 10.1016/j.pediatrneurol.2014.02.005
   Pandey Sharad, 2015, Asian J Neurosurg, V10, P133, DOI 10.4103/1793-5482.161181
   Stevens QEJ, 2006, J SPINAL DISORD TECH, V19, P213, DOI 10.1097/01.bsd.0000188664.54014.c4
   Sung KS, 2008, J KOREAN NEUROSURG S, V44, P334, DOI 10.3340/jkns.2008.44.5.334
   Triantafyllidi E, 2018, CLIN NEUROL NEUROSUR, V175, P54, DOI 10.1016/j.clineuro.2018.10.010
   Turan N, 2016, WORLD NEUROSURG, V87, DOI 10.1016/j.wneu.2015.10.053
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 448
EP 451
DI 10.1016/j.wneu.2019.11.073
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200214
PM 31759148
DA 2020-05-12
ER

PT J
AU Yokoya, S
   Hino, A
   Oka, H
AF Yokoya, Shigeomi
   Hino, Akihiko
   Oka, Hideki
TI Rare Spontaneous Disappearance of Intracranial Aneurysm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Spontaneous disappearance; Unruptured clinoid segment aneurysm
ID POSTERIOR CEREBRAL-ARTERY; SPONTANEOUS THROMBOSIS
AB An unruptured anterior circulation, nongiant saccular cerebral aneurysm (located at the clinoid segment [C3] of the internal carotid artery [ICA] and growing into the carotid cave) was detected at a medical checkup and diagnosed from subsequent examinations. The aneurysm was observed and followed up with radiologic examinations. An examination performed 12 years after diagnosis revealed the disappearance of the aneurysm. This observation should be kept in mind, that it is possible for an unruptured aneurysm to undergo spontaneous thrombosis without any intervention.
C1 [Yokoya, Shigeomi; Hino, Akihiko; Oka, Hideki] Imperial Gift Fdn Inc, Saiseikai Shiga Hosp, Dept Neurosurg, Ritto, Shiga, Japan.
RP Yokoya, S (reprint author), Imperial Gift Fdn Inc, Saiseikai Shiga Hosp, Dept Neurosurg, Ritto, Shiga, Japan.
EM yokoya@ks.kyorin-u.ac.jp
CR Choi CY, 2012, J KOREAN NEUROSURG S, V52, P243, DOI 10.3340/jkns.2012.52.3.243
   HODOZUKA A, 1991, Neurologia Medico-Chirurgica, V31, P966, DOI 10.2176/nmc.31.966
   Kondo A, 2003, NEUROL SURG TOKYO, V31, P189
   Little AS, 2007, NEUROSURGERY, V61, P1139, DOI 10.1227/01.neu.0000306091.30517.e7
   Moron F, 2005, AM J NEURORADIOL, V26, P58
   Ohta H, 2001, ACTA NEUROCHIR, V143, P837, DOI 10.1007/s007010170039
   Peltier J, 2008, CHILD NERV SYST, V24, P1483, DOI 10.1007/s00381-008-0670-0
   Pop R, 2015, BMJ CASE REP, V2015
   Yamada Y, 2010, SURG CEREB STROKE JP, V38, P114
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 452
EP 453
DI 10.1016/j.wneu.2019.11.085
PG 2
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200215
PM 31765869
DA 2020-05-12
ER

PT J
AU Chu, YLE
   Tsang, ACO
   Tsang, FCP
   Lee, R
   Lui, WM
AF Chu, Yin Lun Edward
   Tsang, Anderson Chun-on
   Tsang, Frederick Chun-Pong
   Lee, Raymand
   Lui, Wai Man
TI Endovascular Intervention for Early Postoperative Stenosis of
   Extracranial-Intracranial Bypass Graft: Case Report and Review of the
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Angioplasty; Early postoperative period; Endovascular intervention;
   Graft stenosis; Graft vasospasm; High-flow EC-IC bypass; Stent
ID RADIAL ARTERY GRAFTS; MANAGEMENT; ANEURYSMS
AB BACKGROUND: Bypass graft stenosis following extracranial-intracranial bypass surgery carries significant risks for morbidity and mortality. In case of graft failure, treatment options include surgical revision and endovascular intervention. Whereas endovascular intervention following coronary artery bypass is well established, the role of endovascular therapy in cerebral bypass conduits is rarely reported. We present a case of extracranial-intracranial bypass graft stenosis in the early postoperative period that was successfully treated by endovascular angioplasty and stenting.
   CASE DESCRIPTION: A middle-aged patient presented with a malignant skull base tumor with internal carotid artery invasion. Extracranial-intracranial bypass surgery was performed for flow preservation before tumor removal. Autologous radial artery was used as the bypass graft conduit. Symptomatic graft stenosis was encountered in the immediate postoperative period. Treatments in the form of intra-arterial vasodilator infusion and balloon angioplasty led to only minor flow improvement. The narrowing was eventually salvaged by endovascular stenting. Good clinical and radiologic outcomes were achieved at 6-month follow-up.
   CONCLUSIONS: Endovascular intervention is a feasible treatment option in management of graft stenosis after cerebral revascularization surgery. Our case adds evidence to the safety and role of endovascular intervention in early cerebral bypass conduit failure. In addition, endovascular stenting can be considered as a salvage option for cases that are refractory to angioplasty.
C1 [Chu, Yin Lun Edward; Lee, Raymand] Queen Mary Hosp, Dept Radiol, Hong Kong, Peoples R China.
   [Tsang, Anderson Chun-on; Tsang, Frederick Chun-Pong; Lui, Wai Man] Queen Mary Hosp, Dept Surg, Div Neurosurg, Hong Kong, Peoples R China.
RP Chu, YLE (reprint author), Queen Mary Hosp, Dept Radiol, Hong Kong, Peoples R China.
EM edchu.radiology@gmail.com
OI Chu, Edward Yin Lun/0000-0001-6831-6966
CR Chen C, 2019, BRIT J NEUROSURG, DOI 10.1080/02688697.2019.1621986
   Goube P, 2010, EUR J CARDIO-THORAC, V37, P697, DOI 10.1016/j.ejcts.2009.06.058
   Natarajan SK, 2010, NEUROSURGERY, V67, P794, DOI 10.1227/01.NEU.0000374724.78276.A6
   Qahwash OM, 2012, J NEUROSURG, V116, P201, DOI 10.3171/2011.8.JNS11747
   Ramanathan D, 2011, AM J NEURORADIOL, V32, P1415, DOI 10.3174/ajnr.A2565
   Ramanathan D, 2012, NEUROSURGERY, V70, P1442, DOI 10.1227/NEU.0b013e31824c046f
   Sekhar LN, 2001, NEUROSURGERY, V49, P646, DOI 10.1097/00006123-200109000-00023
   Sharma AK, 2003, CATHETER CARDIO INTE, V59, P172, DOI 10.1002/ccd.10527
   Sia SF, 2013, J CLIN NEUROSCI, V20, P1, DOI 10.1016/j.jocn.2012.05.007
   Sia SF, 2011, NEUROSURGERY, V69, P308, DOI 10.1227/NEU.0b013e318214b300
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 460
EP 464
DI 10.1016/j.wneu.2019.11.006
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200218
PM 31715412
DA 2020-05-12
ER

PT J
AU Bot, GM
   Zhao, XC
   McElenney, BK
   Meybodi, AT
   Belykh, E
   Lawton, MT
   Preul, MC
AF Bot, Gyang Markus
   Zhao, Xiaochun
   McElenney, Brenna K.
   Meybodi, Ali Tayebi
   Belykh, Evgenii
   Lawton, Michael T.
   Preul, Mark C.
TI Comparative Analysis of Continuous Suturing, Interrupted Suturing, and
   Cyanoacrylate-Based Lid Techniques for End-to-End Microvascular
   Anastomosis: Laboratory Investigation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anastomosis; Continuous suture; Flow; Glue; Interrupted suture; Leak;
   Microsurgical; Patency
ID SAPHENOUS-VEIN GRAFT; VESSELS; BYPASS
AB BACKGROUND: Mastery of the microsurgical anastomosis is an indispensable component of neurosurgical training. However, in many resource-limited countries, the training, materials, and equipment to obtain these surgical and decision making skills are severely lacking. This study aimed to compare different suturing techniques for microvascular anastomosis and to complete a comparative assessment of the performance of a young neurosurgeon when using the various techniques.
   METHODS: We compared 3 end-to-end suturing techniques for microvascular anastomosis: interrupted suturing, continuous suturing, and a 2-octyl-cyanoacrylate-based lid technique using an umbilical artery model. We assessed the subjective difficulty of the suturing technique, the time needed to perform the procedure, and the flow rate and leakage of the vessel after each technique. This study was designed to use materials that would be available in developing countries. Surgical apparatus used, such as operating microscopes, were first-generation technology, and testing procedures were designed for neurosurgical residents in developing countries.
   RESULTS: The mean times to complete the anastomosis were 20.7 +/- 7.7 minutes for the interrupted technique, 26.4 +/- 7.7 minutes for the continuous technique, and 12.5 +/- 2.5 minutes for the lid technique; these values were significantly different (P< 0.01). The differences among the 3 techniques in leakage and flow rates and subjective difficulty in performance were not significant.
   CONCLUSIONS: Suturing time was the only statistically significant difference among the 3 anastomotic techniques, with the lid technique apparently the quickest to perform. Such techniques can be designed to assess microsurgical abilities and help neurosurgery residents in developing countries improve their surgical skills and techniques.
C1 [Bot, Gyang Markus; Zhao, Xiaochun; Meybodi, Ali Tayebi; Belykh, Evgenii; Lawton, Michael T.; Preul, Mark C.] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Loyal & Edith Davis Neurosurg Res Lab, Phoenix, AZ 85013 USA.
   [Bot, Gyang Markus] Jos Univ Teaching Hosp, Dept Surg, Neurosurg Div, Jos, Nigeria.
   [McElenney, Brenna K.] Univ Arizona, Coll Med, Phoenix, AZ USA.
RP Preul, MC (reprint author), St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Loyal & Edith Davis Neurosurg Res Lab, Phoenix, AZ 85013 USA.
EM Neuropub@barrowneuro.org
RI Belykh, Evgenii/O-8279-2017
OI Belykh, Evgenii/0000-0003-2060-5739
FU American Association of Neurological Surgeons; Barrow Neurological
   Foundation; Newsome Chair in Neurosurgery Research
FX Gyang Markus Bot, MD, an international visiting neurosurgeon from
   Nigeria, was funded in part by the American Association of Neurological
   Surgeons for 2017 and 2018 to work under Drs. Michael Lawton and Mark
   Preul at The Loyal and Edith Davis Neurosurgical Research Laboratory of
   the Barrow Neurological Institute. The study was funded in part by the
   Barrow Neurological Foundation and the Newsome Chair in Neurosurgery
   Research held by Dr. Preul. Dermabond tissue glue was donated by
   Ethicon, Inc. (Somerville, New Jersey, USA), a Johnson & Johnson, Inc.
   company, and was an expired batch (expiration January 2017). Ethicon had
   no role in study design, study conduct, manuscript preparation, or
   submission for publication.
CR Abla AA, 2011, J NEUROSURG, V115, P1231, DOI 10.3171/2011.7.JNS102013
   Aihara M, 2013, ACTA NEUROCHIR, V155, P607, DOI 10.1007/s00701-013-1644-x
   Alghoul MS, 2011, MICROSURG, V31, P72, DOI 10.1002/micr.20813
   Allouni A, 2014, J HAND MICROSURG, V6, P110, DOI 10.1007/s12593-014-0142-6
   Ang ESW, 2001, J RECONSTR MICROSURG, V17, P193
   Belykh E, 2016, J NEUROSURG, V125, P915, DOI 10.3171/2015.8.JNS151346
   Belykh E, 2014, WORLD NEUROSURG, V82, P20, DOI 10.1016/j.wneu.2014.01.018
   Bot G M, 2010, J Surg Tech Case Rep, V2, P44, DOI 10.4103/2006-8808.63727
   Bot GM, 2018, OPER NEUROSURG, V15, pE60, DOI 10.1093/ons/opy014
   Byvaltsev VA, 2018, MINIM INVASIVE SURG, V2018, DOI 10.1155/2018/6130286
   Chen YX, 2001, J HAND SURG-AM, V26A, P530, DOI 10.1053/jhsu.2001.22933
   Cobbett J, 1967, Br J Plast Surg, V20, P16, DOI 10.1016/S0007-1226(67)80003-1
   Goldstein M, 1979, J Microsurg, V1, P70
   JACOBSON JH, 1962, DIS CHEST, V41, P220, DOI 10.1378/chest.41.2.220
   JENKINS JD, 1967, BRIT J SURG, V54, P558, DOI 10.1002/bjs.1800540614
   LITTLE JR, 1978, J NEUROSURG, V48, P1042, DOI 10.3171/jns.1978.48.6.1042
   Meybodi AT, 2017, WORLD NEUROSURG, V107, P935, DOI 10.1016/j.wneu.2017.06.066
   Meybodi AT, 2017, WORLD NEUROSURG, V107, P925, DOI 10.1016/j.wneu.2017.06.067
   MOSCONA AR, 1978, ISRAEL J MED SCI, V14, P979
   Purdy P, 2002, AM J NEURORADIOL, V23, P748
   SEKHAR LN, 1990, J NEUROSURG, V72, P35, DOI 10.3171/jns.1990.72.1.0035
   Simsek T, 2006, J RECONSTR MICROSURG, V22, P631, DOI 10.1055/s-2006-956237
   SPETZLER RF, 1990, J NEUROSURG, V73, P496, DOI 10.3171/jns.1990.73.4.0496
   TAKENAKA H, 1992, SURG TODAY, V22, P46, DOI 10.1007/BF00326125
   Takeuchi Satoru, 2015, Surg Neurol Int, V6, P95, DOI 10.4103/2152-7806.157949
   Ulusoy MG, 2009, J PLAST RECONSTR AES, V62, P1205, DOI 10.1016/j.bjps.2007.12.085
   Wolfe SQ, 2005, SKULL BASE-INTERD AP, V15, P71, DOI 10.1055/s-2005-868164
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 465
EP 471
DI 10.1016/j.wneu.2019.11.054
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200219
PM 31734417
DA 2020-05-12
ER

PT J
AU Fujita, T
   Iwamoto, Y
   Takeuchi, H
   Tsujino, H
   Hashimoto, N
AF Fujita, Tomoaki
   Iwamoto, Yoshihiro
   Takeuchi, Hayato
   Tsujino, Hitoshi
   Hashimoto, Naoya
TI Lumbar Subdural Hematoma Detected After Surgical Treatment of Chronic
   intracranial Subdural Hematoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bridging vein; Intracranial chronic subdural hematoma; Magnetic
   resonance imaging; Migration; Spinal subdural hematoma
ID CRANIOTOMY; SPACE; MR
AB BACKGROUND: Spinal subdural hematoma (SSDH), which can cause lower back pain, leg pain, and leg weakness, is rare and will usually be associated with a bleeding tendency, trauma, spinal vascular malformation, intraspinal tumor, or iatrogenic invasion. Only a few cases of SSDH after intracranial chronic subdural hematoma (CSDH) have been reported. We report a case of lumbar SSDH in the absence of predisposing factors after reoperation for recurrent intracranial CSDH, which improved with conservative treatment.
   CASE DESCRIPTION: Approximately 1 month after falling, a 63-year-old woman was experiencing left hemiparesis and impaired orientation that was diagnosed as right intracranial CSDH using computed tomography. Surgical treatment of the CSDH led to immediate improvement of her symptoms. On postoperative day 29, the right CSDH had recurred with left hemiparesis, and successful reoperation relieved the symptoms within a few hours post-operatively. However, 1 day after the second operation, very small acute subdural hematomas in regions along the left tentorium cerebelli and left falx cerebri were found on computed tomography. On day 31, she complained of sitting-induced bilateral radiating lower limb pain. Magnetic resonance imaging on day 34 showed an acute SSDH at the L4-L5 level and a sacral perineural cyst filled with hematoma, although her radiating pain was showing improvement. She was treated conservatively and was discharged without symptoms on day 44.
   CONCLUSIONS: Although SSDH is rare, it is important for neurosurgeons and physicians to consider the possibility of a SSDH when lower limb pain or paresis occurs after procedures that will result in rapid intracranial pressure alterations such as drainage of an intracranial CSDH.
C1 [Fujita, Tomoaki; Iwamoto, Yoshihiro; Takeuchi, Hayato; Tsujino, Hitoshi] Kyoto Yamashiro Gen Med Ctr, Dept Neurosurg, Kyoto, Japan.
   [Hashimoto, Naoya] Kyoto Prefectural Univ, Dept Neurosurg, Grad Sch Med Sci, Kyoto, Japan.
RP Fujita, T (reprint author), Kyoto Yamashiro Gen Med Ctr, Dept Neurosurg, Kyoto, Japan.
EM friendautumn@gmail.com
CR Adhiyaman V, 2002, POSTGRAD MED J, V78, P71, DOI 10.1136/pmj.78.916.71
   Bahl A, 2012, J PEDIATR NEUROSCI, V7, P106, DOI 10.4103/1817-1745.102568
   Boe Chelsea C, 2017, J Spine Surg, V3, P112, DOI 10.21037/jss.2017.03.01
   Braun P, 2007, EUR J RADIOL, V64, P119, DOI 10.1016/j.ejrad.2007.02.014
   Doll A, 2000, J NEURORADIOLOGY, V27, P192
   Hagihara N, 2010, NEUROL MED-CHIR, V50, P333, DOI 10.2176/nmc.50.333
   Ji GY, 2013, J KOREAN NEUROSURG S, V54, P515, DOI 10.3340/jkns.2013.54.6.515
   Kokubo R, 2014, J NEUROSURG-SPINE, V20, P157, DOI 10.3171/2013.10.SPINE13346
   Lecouvet FE, 2003, J COMPUT ASSIST TOMO, V27, P530, DOI 10.1097/00004728-200307000-00013
   Lee JI, 2003, ACTA NEUROCHIR, V145, P411, DOI 10.1007/s00701-003-0025-2
   Lee TH, 2007, CLIN NEUROL NEUROSUR, V109, P282, DOI 10.1016/j.clineuro.2006.11.004
   Moon KS, 2007, J CLIN NEUROSCI, V14, P283, DOI 10.1016/j.jocn.2005.11.016
   Morishige M, 2007, ACTA NEUROCHIR, V149, P1081, DOI 10.1007/s00701-007-1256-4
   Moscovici S, 2011, J CLIN NEUROSCI, V18, P563, DOI 10.1016/j.jocn.2010.07.116
   Moser Manuel, 2015, NMC Case Rep J, V2, P114, DOI 10.2176/nmccrj.2014-0377
   Mursch K, 2007, CLIN NEUROL NEUROSUR, V109, P442, DOI 10.1016/j.clineuro.2007.02.001
   Ohta H, 2001, NEUROL SURG TOKYO, V29, P53
   Paisan GM, 2017, WORLD NEUROSURG, V108, DOI 10.1016/j.wneu.2017.08.189
   PAUL LW, 1946, RADIOLOGY, V46, P139, DOI 10.1148/46.2.139
   POST MJD, 1994, AM J NEURORADIOL, V15, P1895
   Reina MA, 2002, ANESTH ANALG, V94, P991
   ROSCOE MWA, 1984, SPINE, V9, P672, DOI 10.1097/00007632-198410000-00003
   RUSSELL NA, 1983, SURG NEUROL, V20, P133, DOI 10.1016/0090-3019(83)90464-0
   Wu RH, 2017, BMC SURG, V17, DOI 10.1186/s12893-017-0303-1
   Yamaguchi S, 2005, NEUROL MED-CHIR, V45, P645, DOI 10.2176/nmc.45.645
   Yang MS, 2009, J FORMOS MED ASSOC, V108, P258, DOI 10.1016/S0929-6646(09)60061-9
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 472
EP 476
DI 10.1016/j.wneu.2019.11.053
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200220
PM 31756510
DA 2020-05-12
ER

PT J
AU Sun, SW
   Li, YP
   Zhang, HZ
   Gao, H
   Zhou, XM
   Xu, Y
   Yan, K
   Wang, XD
AF Sun, Shuwen
   Li, Yuping
   Zhang, Hengzhu
   Gao, Heng
   Zhou, Xinmin
   Xu, Yu
   Yan, Ke
   Wang, Xiaodong
TI Neuroendoscopic Surgery versus Craniotomy for Supratentorial
   Hypertensive Intracerebral Hemorrhage: A Systematic Review and
   Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Craniotomy; Hemorrhage; Meta-analysis; Neuroendoscopy
ID ENDOSCOPIC HEMATOMA EVACUATION; INTRAVENTRICULAR HEMORRHAGE;
   STEREOTACTIC ASPIRATION; MANAGEMENT; EFFICACY; STROKE; SAFETY; TUMORS
AB BACKGROUND: No consensus has been achieved on the superiority between neuroendoscopy (NE) and craniotomy (CT) for the treatment of supratentorial hypertensive intracerebral hemorrhage (HICH). The purpose of this study is to analyze the efficacy and safety of NE versus CT for supratentorial HICH.
   METHODS: A systematic search of English databases (PubMed, Embase, the Cochrane Library, and Web of Science) was performed to identify related studies reported from September 1994 to June 2019. The Newcastle-Ottawa Scale and the Cochrane Reviewer's Handbook 5.0.0 were separately used to evaluate the quality of the included observational studies and randomized controlled trials. RevMan 5.3 software was adopted to conduct the meta-ana lysis. The outcome measures included the primary and secondary outcomes. Subgroup analysis was performed to explore the impact of year of publication, initial Glasgow Coma Scale (GCS) score, age, time to surgery, hematoma volume, and surgical methods on the outcome measures.
   RESULTS: Fifteen studies (3 randomized controlled trials and 12 observational studies), comprising 1859 patients with supratentorial HICH, were included in this meta-analysis. The pooled results showed that NE could increase the good functional outcome (GFO) (P < 0.0003) and hematoma evacuation rate (P = 0.0007) and reduce the mortality (P < 0.00001), blood loss (P = 0.004), operation time (P < 0.00001), hospital stays (P = 0.006), and intensive care unit stays (P < 0.0001) compared with CT. In addition, NE could also have a positive effect on preventing postoperative infection (P< 0.00001) and total complications (P < 0.00001). However, in postoperative rebleeding incidence (P = 0.12), no obvious difference was found between the 2 groups. Publication bias was low regarding GFO, mortality, and hematoma evacuation rate. Subgroup analysis suggested that year of publication, initial GCS score, age, hematoma volume, and surgical methods did not affect the hematoma evacuation rate significantly. The difference in mortality was not statistically significant in the subgroup of hematoma volume <50 mL (P = 0.44) and initial GCS score >8 ( P = 0.09). In addition, the data suggested that time to surgery and surgical methods might be the important factors affecting GFO and mortality.
   CONCLUSIONS: NE might be a safer and more effective surgical method than CT in the treatment of patients with supratentorial HICH. However, because of the existence of some limitations, the safety and validity of NE were weakened. More high-quality trials should be included to verify our conclusion.
C1 [Sun, Shuwen; Gao, Heng; Zhou, Xinmin; Xu, Yu] Southeast Univ, Affiliated Jiangyin Hosp, Dept Neurosurg, Med Coll, Jiangyin, Peoples R China.
   [Li, Yuping; Zhang, Hengzhu; Yan, Ke; Wang, Xiaodong] Yangzhou Univ, Dept Neurosurg, Clin Med Coll, Yangzhou, Jiangsu, Peoples R China.
RP Zhang, HZ (reprint author), Yangzhou Univ, Dept Neurosurg, Clin Med Coll, Yangzhou, Jiangsu, Peoples R China.
EM zhanghengzhu@sina.com
OI Sun, Shuwen/0000-0002-2492-1483; Ke, Yan/0000-0002-1534-0011
FU Natural Science Foundation of Yangzhou [2017114]
FX This study was funded by the Natural Science Foundation of Yangzhou (No.
   2017114).
CR Arboix A, 2002, ACTA NEUROL SCAND, V105, P282, DOI 10.1034/j.1600-0404.2002.1o170.x
   Cai Q, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008435
   Chen QW, 2015, STROKE, V46, P2902, DOI 10.1161/STROKEAHA.115.009713
   Chi FL, 2014, WORLD J EMERG MED, V5, P203, DOI [10.5847/wjem.j.issn.1920-8642.2014.03.008, 10.5847/wjem.j.1920-8642.2014.03.008]
   Cho DY, 2006, SURG NEUROL, V65, P547, DOI 10.1016/j.surneu.2005.09.032
   Chrastina J, 2014, J NEUROL SURG PART A, V75, P110, DOI 10.1055/s-0032-1320032
   Conner AK, 2017, WORLD NEUROSURG, V106, P707, DOI 10.1016/j.wneu.2017.06.181
   Eroglu U, 2018, WORLD NEUROSURG, V114, pE60, DOI 10.1016/j.wneu.2018.02.056
   Feng Y, 2016, TURK NEUROSURG, V26, P84, DOI 10.5137/1019-5149.JTN.12669-14.0
   Fu CH, 2019, WORLD NEUROSURG, V122, pE995, DOI 10.1016/j.wneu.2018.10.192
   Gaab MR, 2011, WORLD NEUROSURG, V75, P206, DOI 10.1016/j.wneu.2010.10.003
   Glaucia FC, 2014, APPL ENG AGRIC, V18, P727
   Gui CJ, 2019, PAK J MED SCI, V35, P377, DOI 10.12669/pjms.35.2.463
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hu YZ, 2013, J ZHEJIANG UNIV-SC B, V14, P496, DOI 10.1631/jzus.B1200332
   Huang Y, 2014, CHIN J PRACT NERV DI, V17, P1
   Juttler Eric, 2007, Expert Rev Neurother, V7, P1401, DOI 10.1586/14737175.7.10.1401
   Koschnitzky JE, 2018, FLUIDS BARRIERS CNS, V15, DOI 10.1186/s12987-018-0096-3
   Krishnamurthi RV, 2013, LANCET GLOB HEALTH, V1, pE259, DOI 10.1016/S2214-109X(13)70089-5
   Kuo LT, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.2.FOCUS10313
   Lan Q, 2006, SURG NEUROL, V66, P2, DOI 10.1016/j.surneu.2006.06.039
   Lee MH, 2014, CHILD NERV SYST, V30, P1055, DOI 10.1007/s00381-014-2367-x
   Li YQ, 2017, WORLD NEUROSURG, V105, P332, DOI 10.1016/j.wneu.2017.05.134
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Lord AS, 2014, STROKE, V45, P3535, DOI 10.1161/STROKEAHA.114.006435
   Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1
   Meretoja A, 2012, STROKE, V43, P2592, DOI 10.1161/STROKEAHA.112.661603
   Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b
   Mottolese C, 2015, NEUROCHIRURGIE, V61, P155, DOI 10.1016/j.neuchi.2013.12.008
   Naftel RP, 2011, J NEUROSURG-PEDIATR, V7, P104, DOI 10.3171/2010.10.PEDS10338
   Nakano T, 2003, MINIM INVAS NEUROSUR, V46, P278
   Qiu YM, 2003, CHINESE MED J-PEKING, V116, P195
   Simernitskiy B P, 2015, Zh Vopr Neirokhir Im N N Burdenko, V79, P64, DOI 10.17116/neiro201579264-74
   Souweidane MM, 2005, NEUROSURGERY, V57, P312, DOI 10.1227/01.NEU.0000176641.17216.FB
   Sufianov AA, 2018, NEUROSURG REV, V41, P851, DOI 10.1007/s10143-017-0934-9
   Sun GQ, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014123
   Tang YP, 2018, BMC NEUROL, V18, DOI 10.1186/s12883-018-1138-9
   van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0
   Wang WH, 2015, J CHIN MED ASSOC, V78, P101, DOI 10.1016/j.jcma.2014.08.013
   Wu JL, 2017, CHIN J PRACT NERV DI, V20, P7
   Xiang H, 2018, WORLD NEUROSURG, V111, P335
   Xu XH, 2015, ACAD J CHIN PLA MED, V4, P309
   Xu XH, 2018, J NEUROSURG, V128, P553, DOI 10.3171/2016.10.JNS161589
   Yamahata H, 2014, NEUROSURG REV, V37, P629, DOI 10.1007/s10143-014-0562-6
   Yamashiro S, 2015, NEUROL MED-CHIR, V55, P819, DOI 10.2176/nmc.oa.2014-0136
   Yao Z, 2018, WORLD NEUROSURG, V113, P348, DOI 10.1016/j.wneu.2018.02.022
   Ye ZPP, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007876
   Zhang HZ, 2014, BIOMED RES INT, DOI 10.1155/2014/898762
   Zhang Y, 2008, J BENGBU MED COLL, V33, P423
   Zheng J, 2016, MED, V95, P3024
   Zheng JS, 2010, J CRANIOFAC SURG, V21, P1210, DOI 10.1097/SCS.0b013e3181e17d17
   Zhou HG, 2011, J NEUROL, V258, P661, DOI 10.1007/s00415-011-5902-7
   Zhu HW, 2012, TURK NEUROSURG, V22, P294, DOI 10.5137/1019-5149.JTN.5136-11.1
   王建清, 2007, [中华神经外科杂志, Chinese Journal of Neurosurgery], V23, P572
NR 54
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 477
EP 488
DI 10.1016/j.wneu.2019.10.115
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200221
PM 31669683
DA 2020-05-12
ER

PT J
AU Chiang, LJ
   Wang, CK
   Tsai, HW
   Lee, JS
AF Chiang, Liang-Jui
   Wang, Chien-Kuo
   Tsai, Hung-Wen
   Lee, Jung-Shun
TI Diagnostic Dilemma in Discriminating Between Spinal Neurenteric Cysts
   and Simple Arachnoid Cysts Based on Embryogenesis and Surgical
   Correlation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arachnoid cyst; Intradural spinal cyst; Neurenteric cyst
ID SUBARACHNOID HEMORRHAGE; MALFORMATIONS; MANAGEMENT; CORD
AB BACKGROUND: Neurenteric cyst (NEC) is a rare intradural spinal tumor, but a correct preoperative diagnosis remains challenging. A misdiagnosis of arachnoid cyst (AC) often leads to conflicting surgical management and significantly higher recurrence.
   CASE DESCRIPTION: We report the case of a 26-year-old woman who presented with progressive spastic quadriparesis with myelopathy below the C4 level, which was caused by a ventral intradural extramedullary cystic tumor at the C3-4 level. Magnetic resonance images showed the cystic content as identical to cerebrospinal fluid, which prompted the tentative diagnosis of spinal AC. Surgical fenestration was scheduled. However, intraoperative findings of a thick-walled cyst and severe adhesion to the neural structure without a history of trauma and inflammation were more compatible with the pathogenesis of an NEC. Because of the high recurrence rate after an incomplete resection of an NEC, we did a complete resection of the cyst with adhesive rootlets instead. Pathology analysis and immunohistochemical staining confirmed the diagnosis of an endodermal-derived NEC.
   CONCLUSIONS: NECs must be differentiated from ACs because they are different diseases and require different surgical management. In cases with clear cystic content, however, the diagnosis is likely to be AC, but a thick cystic wall and structural adhesions should suggest the differential diagnosis of NEC. Gross total removal of NECs should be attempted to reduce NEC recurrence.
C1 [Chiang, Liang-Jui; Lee, Jung-Shun] Natl Cheng Kung Univ, Sect Neurosurg, Dept Surg, Natl Cheng Kung Univ Hosp, Tainan, Taiwan.
   [Wang, Chien-Kuo] Natl Cheng Kung Univ, Dept Diagnost Radiol, Natl Cheng Kung Univ Hosp, Tainan, Taiwan.
   [Tsai, Hung-Wen] Natl Cheng Kung Univ, Dept Pathol, Natl Cheng Kung Univ Hosp, Tainan, Taiwan.
   [Lee, Jung-Shun] Natl Cheng Kung Univ, Dept Cell Biol & Anat, Coll Med, Tainan, Taiwan.
RP Lee, JS (reprint author), Natl Cheng Kung Univ, Sect Neurosurg, Dept Surg, Natl Cheng Kung Univ Hosp, Tainan, Taiwan.
EM nslee1218@gmail.com
CR AGNOLI AL, 1984, J NEUROSURG, V61, P834, DOI 10.3171/jns.1984.61.5.0834
   Basaran R, 2015, BRIT J NEUROSURG, V29, P285, DOI 10.3109/02688697.2014.976175
   BENTLEY JFR, 1960, ARCH DIS CHILD, V35, P76, DOI 10.1136/adc.35.179.76
   Bond AE, 2012, J NEUROSURG-PEDIATR, V9, P432, DOI 10.3171/2012.1.PEDS11391
   Chen CT, 2016, WORLD NEUROSURG, V96, P85, DOI 10.1016/j.wneu.2016.08.089
   Chen CT, 2016, ACTA NEUROCHIR, V158, P1325, DOI 10.1007/s00701-016-2828-y
   Choi DY, 2015, J KOREAN NEUROSURG S, V57, P135, DOI 10.3340/jkns.2015.57.2.135
   Garg K, 2017, BRIT J NEUROSURG, V31, P172, DOI 10.1080/02688697.2016.1229747
   Garg N, 2008, BRIT J NEUROSURG, V22, P241, DOI 10.1080/02688690701818919
   Kazan S, 1999, J NEUROSURG, V91, P211, DOI 10.3171/spi.1999.91.2.0211
   Kikkawa Yuichiro, 2012, Surg Neurol Int, V3, P78, DOI 10.4103/2152-7806.98518
   Kriss TC, 1997, SPINE, V22, P568, DOI 10.1097/00007632-199703010-00023
   Lee HJ, 2001, PEDIATR NEUROSURG, V35, P181, DOI 10.1159/000050419
   Li ZX, 2019, EUR J RADIOL OPEN, V6, P231, DOI 10.1016/j.ejro.2019.06.001
   Menezes AH, 2006, NEUROSURGERY, V58, P97, DOI 10.1227/01.NEU.0000192160.79897.25
   Nottmeier EW, 2009, J NEUROSURG-SPINE, V11, P344, DOI 10.3171/2009.3.SPINE08844
   OSENBACH RK, 1992, NEUROSURGERY, V30, P35, DOI 10.1227/00006123-199201000-00007
   Paleologos TS, 2000, BRIT J NEUROSURG, V14, P185
   PALMA L, 1976, ACTA NEUROCHIR, V33, P283, DOI 10.1007/BF01886676
   Preece MT, 2006, AM J NEURORADIOL, V27, P1211
   Ramli N, 2001, BRIT J RADIOL, V74, P862, DOI 10.1259/bjr.74.885.740862
   Savage JJ, 2010, J CRANIOVERTEBRAL JU, V1, P58, DOI 10.4103/0974-8237.65484
   Tumialan LM, 2005, J NEUROSURG, V103, P1088, DOI 10.3171/jns.2005.103.6.1088
   VINTERS HV, 1981, CAN J NEUROL SCI, V8, P159, DOI 10.1017/S0317167100043092
   Wang LA, 2011, NEUROSURGERY, V68, P44, DOI 10.1227/NEU.0b013e3181fc5ee0
   Wang MY, 2003, SURG NEUROL, V60, P49, DOI 10.1016/S0090-3019(03)00149-6
   Weng Jian-Cong, 2020, Neurosurgery, V86, P548, DOI 10.1093/neuros/nyz143
   Wester K, 2018, ARACHNOID CYSTS: EPIDEMIOLOGY, BIOLOGY, AND NEUROIMAGING, P1
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 489
EP 494
DI 10.1016/j.wneu.2019.11.069
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200222
PM 31756499
DA 2020-05-12
ER

PT J
AU Marrero, JAM
   Marrero, AEM
   Berenguer, JLP
   Alvarez, EL
   Corona, JM
   Feliciano, C
AF Monserrate Marrero, Jorge A.
   Monserrate Marrero, Andres E.
   Perez Berenguer, Juan L.
   Labat Alvarez, Eduardo
   Corona, Juan M.
   Feliciano, Caleb
TI Cerebellar Arteriovenous Malformation with Coexistent Hemangioblastoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Case report; Cerebellar arteriovenous malformation; Hemangioblastoma
ID EXPRESSION; MODEL
AB BACKGROUND: This is a case of a man aged 40 years with a past medical history of smoking, hypertension, polycythemia vera, intellectual disability, and schizophrenia who presented with generalized headaches, progressive loss of balance, and visual disturbance for 1 month.
   CASE DESCRIPTION: Head computed tomography and magnetic resonance imaging revealed a right cerebellar hematoma associated to heterogenous lesion with cystic components and flow-voids in the right cerebellar hemisphere. A ventriculoperitoneal shunt was placed with partial improvement of symptoms. Further vascular studies confirmed presence of a vascular nidus with significant arteriovenous shunting. The patient later required intervention for cerebellar arteriovenous malformation (AVM) removal. Microscopic evaluation of the lesion showed the AVM nidus, as well as large, vacuolated stromal cells and numerous thin-walled vessels. Immunostaining with inhibin and S-100 highlighted the stromal cells with numerous lipid-containing vacuoles. The earlier mentioned findings were consistent with the diagnosis of an AVM with coexistent hemangioblastoma of the right cerebellar hemisphere.
   CONCLUSIONS: Coexistence of hemangioblastomas and AVMs are extremely rare, and only 3 cases have been reported previously in the literature.
C1 [Monserrate Marrero, Jorge A.] Univ Puerto Rico, Sch Med, Med Sci Campus, San Juan, PR 00936 USA.
   [Monserrate Marrero, Andres E.; Corona, Juan M.; Feliciano, Caleb] Univ Puerto Rico, Sect Neurol Surg, Med Sci Campus, San Juan, PR 00936 USA.
   [Perez Berenguer, Juan L.] Univ Puerto Rico, Dept Pathol, Med Sci Campus, San Juan, PR 00936 USA.
   [Labat Alvarez, Eduardo] Univ Puerto Rico, Dept Neuroradiol, Med Sci Campus, San Juan, PR 00936 USA.
RP Marrero, AEM (reprint author), Univ Puerto Rico, Sect Neurol Surg, Med Sci Campus, San Juan, PR 00936 USA.
EM andres.monserrate@upr.edu
CR Bao LY, 2017, SCI REP-UK, V7, DOI 10.1038/srep44899
   Bennett EE, 2016, INT J SURG CASE REP, V23, P47, DOI 10.1016/j.ijscr.2016.03.024
   Glasker S, 2006, CANCER RES, V66, P4167, DOI 10.1158/0008-5472.CAN-05-3505
   Huang J, 2017, ANN NEUROL, V82, P371, DOI 10.1002/ana.25015
   Kritikos ME, 2018, CUREUS, V10, DOI 10.7759/cureus.2890
   Li PC, 2018, NEUROL RES, V40, P122, DOI 10.1080/01616412.2017.1405574
   Louis DN, 2016, WHO CLASSIFICATION T
   Ma DX, 2016, TUMOR BIOL, V37, P3765, DOI 10.1007/s13277-015-4200-x
   Ma DX, 2011, CANCER BIOL THER, V12, P727, DOI 10.4161/cbt.12.8.16598
   Ma DX, 2011, CARCINOGENESIS, V32, P102, DOI 10.1093/carcin/bgq214
   MEDVEDEV YA, 1991, J NEUROSURG, V75, P121, DOI 10.3171/jns.1991.75.1.0121
   Papagiannaki C, 2017, J NEUROINTERV SURG, V9, P204, DOI 10.1136/neurintsurg-2015-012173
   Park DM, 2017, PLOS MED, V4, pe60
   Ramey WL, 2014, CLIN NEUROL NEUROSUR, V126, P126, DOI 10.1016/j.clineuro.2014.08.029
   RAYNOR RB, 1965, ARCH NEUROL-CHICAGO, V12, P39, DOI 10.1001/archneur.1965.00460250043006
   Shively SB, 2011, MODERN PATHOL, V24, P1023, DOI 10.1038/modpathol.2011.61
NR 16
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 495
EP 500
DI 10.1016/j.wneu.2019.10.197
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200223
PM 31712111
DA 2020-05-12
ER

PT J
AU Aten, Q
   Killeffer, J
   Seaver, C
   Reier, L
AF Aten, Quentin
   Killeffer, James
   Seaver, Chad
   Reier, Louis
TI Causes, Complications, and Costs Associated will External Ventricular
   Drainage Catheter Obstruction
SO WORLD NEUROSURGERY
LA English
DT Review
DE External ventricular drain; Infection; Obstruction; Ventriculostomy
ID INTRAVENTRICULAR HEMORRHAGE; INTRACEREBRAL HEMORRHAGE; RISK-FACTORS;
   INFECTION-RATES; MANAGEMENT; PRESSURE; IMPACT; PLACEMENT; FREQUENCY;
   ACCURACY
AB Ventricular catheter obstructions in patients treated with external ventricular drains (EVDs) have the potential to substantially impact the cost of patient care. There is a paucity of literature that directly addresses catheter obstruction over large numbers of patients with EVDs in multiple centers. Contemporary literature was reviewed to characterize causes, complications, and costs of EVD catheter obstruction. Data from published studies of EVD complications were compiled to estimate the rate of EVD catheter replacement and quantify the correlation between catheter replacement and infection. In these studies, the average number of catheters placed per patient with an EVD was 1.26, indicating a relatively high rate of replacement. Obstructions because of thrombosis and catheter malposition were identified as frequent causes of EVD replacement. Patients who underwent replacement had a 29% rate of ventriculostomy-related infection compared with 6% in those who had no replacement. The estimated diagnostic, procedural, and material cost of EVD replacement is in the range of approximately $1300-$3200 per replacement. The diagnosis and treatment of ventricular catheter obstruction, along with associated complications, creates a substantial cost burden. Further research should focus on strategies to reduce the incidence of ventricular catheter obstruction.
C1 [Aten, Quentin; Seaver, Chad] Arkis BioSci Inc, Knoxville, TN USA.
   [Killeffer, James] Univ Tennessee, Dept Surg, Grad Sch Med, Div Neurosurg, Knoxville, TN 37996 USA.
   [Reier, Louis] Lincoln Mem Univ, DeBusk Coll Osteopath Med, Harrogate, TN USA.
RP Killeffer, J (reprint author), Univ Tennessee, Dept Surg, Grad Sch Med, Div Neurosurg, Knoxville, TN 37996 USA.
EM jakilleffer@gmail.com
CR Abdelmalik PA, 2017, SEMIN RESP CRIT CARE, V38, P745, DOI 10.1055/s-0037-1607991
   Arabi Y, 2005, AM J INFECT CONTROL, V33, P137, DOI 10.1016/j.ajic.2004.11.008
   Blegvad C, 2013, ACTA NEUROCHIR, V155, P1763, DOI 10.1007/s00701-013-1729-6
   BORGBJERG BM, 1995, ACTA NEUROCHIR, V136, P189, DOI 10.1007/BF01410625
   Camacho EF, 2011, INFECTION, V39, P47, DOI 10.1007/s15010-010-0073-5
   Cevik S, 2016, INT J CLIN MED, V7, P84
   Chi H, 2010, INT J INFECT DIS, V14, pE216, DOI 10.1016/j.ijid.2009.04.006
   Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126
   Dasic D, 2006, BRIT J NEUROSURG, V20, P296, DOI 10.1080/02688690600999901
   Dey M, 2015, NEUROSURGERY, V76, P291, DOI 10.1227/NEU.0000000000000624
   Engelhard HH, 2003, SURG NEUROL, V60, P15, DOI 10.1016/S0090-3019(03)00144-7
   Fargen KM, 2016, J NEUROSURG, V124, P1805, DOI 10.3171/2015.5.JNS15299
   Fargen KM, 2016, ACTA NEUROCHIR, V158, P271, DOI 10.1007/s00701-015-2688-x
   Fried HI, 2016, NEUROCRIT CARE, V24, P61, DOI 10.1007/s12028-015-0224-8
   Galarza M, 2015, CHILD NERV SYST, V31, P873, DOI 10.1007/s00381-015-2651-4
   Galarza M, 2014, CHILD NERV SYST, V30, P105, DOI 10.1007/s00381-013-2226-1
   Gardner PA, 2009, J NEUROSURG, V110, P1021, DOI 10.3171/2008.9.JNS17661
   Gilard V, 2017, WORLD NEUROSURG, V97, P117, DOI 10.1016/j.wneu.2016.09.105
   Guiza F, 2015, INTENS CARE MED, V41, P1067, DOI 10.1007/s00134-015-3806-1
   Hagel S, 2014, Interdiscip Perspect Infect Dis, V2014, P708531, DOI 10.1155/2014/708531
   Halpern NA, 2010, CRIT CARE MED, V38, P65, DOI 10.1097/CCM.0b013e3181b090d0
   Harris CA, 2012, NEUROSURGERY, V70, P1589, DOI 10.1227/NEU.0b013e318244695f
   Harrop JS, 2010, NEUROSURGERY, V67, P187, DOI 10.1227/01.NEU.0000370247.11479.B6
   Hinson HE, 2010, CURR NEUROL NEUROSCI, V10, P73, DOI 10.1007/s11910-010-0086-6
   Hoefnagel D, 2008, ACTA NEUROCHIR, V150, P209, DOI 10.1007/s00701-007-1458-9
   Hsieh CT, 2011, ACTA NEUROL BELG, V111, P22
   Hsieh PC, 2008, NEUROSURG CLIN N AM, V19, P401, DOI 10.1016/j.nec.2008.07.013
   Hu WJ, 2001, BLOOD, V98, P1231, DOI 10.1182/blood.V98.4.1231
   Jamjoom AAB, 2018, J NEUROL NEUROSUR PS, V89, P120, DOI 10.1136/jnnp-2017-316415
   Kakarla UK, 2008, NEUROSURGERY, V63, P162, DOI 10.1227/01.NEU.0000312390.83127.7F
   Kawoos U, 2015, INT J MOL SCI, V16, P28979, DOI 10.3390/ijms161226146
   Kleindorfer D, 2017, STROKE, V48, P2000, DOI 10.1161/STROKEAHA.116.015822
   Kocan Mary Jo, 2002, Crit Care Nurse, V22, P70
   Lo CH, 2007, J NEUROSURG, V106, P378, DOI 10.3171/jns.2007.106.3.378
   Maniker AH, 2006, NEUROSURGERY, V59, P419, DOI 10.1227/01.NEU.0000222817.99752.E6
   McLaughlin N, 2012, ACTA NEUROCHIR, V154, P761, DOI 10.1007/s00701-012-1276-6
   Miller C, 2017, J NEUROSURG, V126, P289, DOI 10.3171/2015.12.JNS152341
   Muralidharan Rajanandini, 2015, Surg Neurol Int, V6, pS271, DOI 10.4103/2152-7806.157620
   Mustanoja S, 2015, INT J STROKE, V10, P576, DOI 10.1111/ijs.12437
   Muttaiyah S, 2010, J CLIN NEUROSCI, V17, P296, DOI 10.1016/j.jocn.2009.06.016
   Nyquist PA, 2009, INTRACEREBRAL HEMORR, P176
   Ortolano F, 2017, ACTA NEUROCHIR, V159, P1981, DOI 10.1007/s00701-017-3291-0
   Park P, 2004, NEUROSURGERY, V55, P594, DOI 10.1227/01.NEU.0000134289.04500.EE
   Park YG, 2011, J KOREAN NEUROSURG S, V50, P317, DOI 10.3340/jkns.2011.50.4.317
   Pershad J, 2017, PEDIATRICS, V140
   Phan K, 2016, J CLIN NEUROSCI, V32, P95, DOI 10.1016/j.jocn.2016.03.019
   Pople I, 2012, NEUROSURGERY, V71, P6, DOI 10.1227/NEU.0b013e3182544e31
   Rahman M, 2012, JT COMM J QUAL PATIE, V38, P459, DOI 10.1016/S1553-7250(12)38061-6
   Ramanan M, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-014-0712-z
   Rivero-Garvia M, 2011, ACTA NEUROCHIR, V153, P647, DOI 10.1007/s00701-010-0905-1
   Root BK, 2016, WORLD NEUROSURG, V86, P306, DOI [10.1016/J.WNEU.2015.09.032, 10.1016/j.wneu.2015.09.032]
   Rosenbaum BP, 2014, J CLIN NEUROSCI, V21, P623, DOI 10.1016/j.jocn.2013.09.001
   Schmidt DR, 2009, BIOLOGICAL INTERACTIONS ON MATERIALS SURFACES: UNDERSTANDING AND CONTROLLING PROTEIN, CELL, AND TISSUE RESPONSES, P1, DOI 10.1007/978-0-387-98161-1_1
   Sivaraman B, 2010, BIOMATERIALS, V31, P832, DOI 10.1016/j.biomaterials.2009.10.008
   Steiner T, 2006, NEUROSURGERY, V59, P767, DOI 10.1227/01.NEU.0000232837.34992.32
   Sussman ES, 2014, J NEUROSURG, V120, P931, DOI 10.3171/2013.12.JNS131685
   Szumilas M, 2010, J CAN ACAD CHILD ADO, V19, P227
   Weisenberg SH, 2016, J NEUROSURG, V125, P1504, DOI 10.3171/2015.12.JNS151181
   Wong GKC, 2002, J NEUROL NEUROSUR PS, V73, P759, DOI 10.1136/jnnp.73.6.759
   Xu LC, 2014, COLLOID SURFACE B, V124, P49, DOI 10.1016/j.colsurfb.2014.09.040
   Zabramski JM, 2003, J NEUROSURG, V98, P725, DOI 10.3171/jns.2003.98.4.0725
   Ziai WC, 2012, CRIT CARE MED, V40, P1601, DOI 10.1097/CCM.0b013e318241e380
   Zygourakis CC, 2017, J NEUROSURG, V126, P558, DOI 10.3171/2016.1.JNS152242
NR 63
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 501
EP 506
DI 10.1016/j.wneu.2019.10.105
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200224
PM 31669535
DA 2020-05-12
ER

PT J
AU Mirza, AB
   Akhbari, M
   Lavrador, JP
   Maratos, EC
AF Mirza, Asfand Baig
   Akhbari, Melika
   Lavrador, Jose P.
   Maratos, Eleni C.
TI Atypical Cauda Equina Syndrome with Lower Limb Clonus: A Literature
   Review and Case Report
SO WORLD NEUROSURGERY
LA English
DT Review
DE Atypical; Cauda equina; Clonus; Review; Spine; Syndrome
ID SYNDROME SECONDARY; HERNIATION; STANDARDS; CARE
AB BACKGROUND: Cauda equina syndrome (CES) is a neurosurgical emergency warranting urgent surgical decompression. Treatment delay may precipitate permanent adverse neurological sequelae. CES is a clinical diagnosis, corroborated by radiological findings. Atypical presentations should be acknowledged to avoid inappropriately rejected diagnoses.
   CASE DESCRIPTION: We report the case of a woman exhibiting bilateral lower limb weakness, perineal numbness, sphincter disturbance, and lower limb clonus. Classically, CES displays lower motor neuron signs in the lower limbs. The presence of clonus, an upper motor neuron sign, brought the diagnosis into doubt. The history included chronic fatigue, difficulty mobilizing, and intermittent blurred vision. A lumbosacral magnetic resonance imaging (MRI) scan demonstrated a large disc prolapse at L5/S1. The cord was not low-lying or tethered. Therefore, the possibility of second diagnoses, including of inflammatory or demyelinating nature, was raised. An urgent MRI scan of the brain and cervicothoracic cord identified no other lesions. On balance, the clinical presentation could overwhelmingly be attributed to the L5/S1 disc prolapse. Given the time-critical nature of cauda equina (CE) compression, an urgent laminectomy and discectomy was offered with continued postoperative investigation of the clonus. Intraoperatively, significant CE compression was found. The operation proceeded uneventfully and the patient recovered fully. In the immediate postoperative period, the clonus persisted yet subsequently resolved completely.
   CONCLUSIONS: We conclude that the clonus was attributable to CE compression and not a second pathology. The corresponding neuroanatomical correlate remains nondelineated. The presence of clonus does not preclude a diagnosis of CES. If the clinicoradiological information otherwise correlate, surgery should not be delayed while alternative diagnoses are sought. The literature is also reviewed.
C1 [Mirza, Asfand Baig; Lavrador, Jose P.; Maratos, Eleni C.] Kings Coll Hosp NHS Fdn Trust, Dept Neurosurg, London, England.
   [Akhbari, Melika] Kings Coll London, GKT Sch Med Educ, London, England.
RP Akhbari, M (reprint author), Kings Coll London, GKT Sch Med Educ, London, England.
EM melika.akhbari@kcl.ac.uk
OI Akhbari, Melika/0000-0001-7634-2515
CR Ahn UM, 2000, SPINE, V25, P1515, DOI 10.1097/00007632-200006150-00010
   AlTahan HA, 2018, AM J CASE REP, V19, P694, DOI 10.12659/AJCR.908793
   Balasubramanian K, 2010, BRIT J NEUROSURG, V24, P383, DOI 10.3109/02688697.2010.505987
   Bang Jin Hyuk, 2015, Korean J Neurotrauma, V11, P175, DOI 10.13004/kjnt.2015.11.2.175
   Caputo L, 2002, J CAN CHIROPR ASS, V46, P31
   Celik EC, 2012, J BACK MUSCULOSKELET, V25, P1, DOI 10.3233/BMR-2011-0303
   Galano E., 2009, Annals of Physical and Rehabilitation Medicine, V52, P687, DOI 10.1016/j.rehab.2009.10.001
   Gardner A, 2011, EUR SPINE J, V20, P690, DOI 10.1007/s00586-010-1668-3
   Germon T, 2015, SPINE J, V15, p2S, DOI 10.1016/j.spinee.2015.01.006
   HURME M, 1983, ANN CHIR GYNAECOL FE, V72, P33
   Jeon Joon Bok, 2016, Korean J Spine, V13, P124, DOI 10.14245/kjs.2016.13.3.124
   Lavy C, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b936
   NHS Litigation Authority, 2016, 2016 SAF PUBL
   Olivero WC, 2009, J SPINAL DISORD TECH, V22, P202, DOI 10.1097/BSD.0b013e31817baad8
   Podnar S, 2007, MUSCLE NERVE, V35, P529, DOI 10.1002/mus.20696
   Pronin S, 2019, SPINE, V44, P1238, DOI 10.1097/BRS.0000000000003045
   Society of British Neurological Surgeons, 2009, STAND CAR EST SUSP C
   Society of British Neurological Surgeons, 2015, SBNS CAR QUAL STAT
   Sreeram SC, 2017, INT J BASIC CLIN PHA, V6, P1820
   Srikandarajah N, 2018, SPINE, V43, pE1005, DOI 10.1097/BRS.0000000000002605
   Todd NV, 2016, BRIT J NEUROSURG, V30, P518, DOI 10.1080/02688697.2016.1187254
   Todd NV, 2015, BRIT J NEUROSURG, V29, P630, DOI 10.3109/02688697.2015.1054364
   Todd NV, 2005, BRIT J NEUROSURG, V19, P301, DOI 10.1080/02688690500305324
   Widge AS, 2009, J NEUROSURG-SPINE, V10, P257, DOI 10.3171/2008.12.SPINE08389
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 507
EP 509
DI 10.1016/j.wneu.2019.10.198
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200225
PM 31715419
DA 2020-05-12
ER

PT J
AU Jumah, F
   Quinoa, T
   Akel, O
   Shah, S
   Narayan, V
   Adeeb, N
   Gupta, G
   Nanda, A
AF Jumah, Fareed
   Quinoa, Travis
   Akel, Omar
   Shah, Smit
   Narayan, Vinayak
   Adeeb, Nimer
   Gupta, Gaurav
   Nanda, Anil
TI The Origins of Eponymous Aneurysm Clips: A Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aneurysm; Clip; History; Innovations; Pioneers
ID SMALL VESSEL SURGERY; INTERNAL CAROTID-ARTERY; INTRACRANIAL ANEURYSM;
   CLINICAL-APPLICATION; TITANIUM; SYSTEM; REPAIR; HISTORY; GRAFTS;
   YASARGIL,M.GAZI
AB Aneurysm clips are indispensable tools in the armamentarium of vascular neurosurgeons. The history of the development of aneurysm clips is witness to ingenuity and tenacity in treating a potentially devastating disease. Few know the stories of their innovators and the inspiration behind their designs. Hence, we present this historical vignette in an attempt to shed more light on the pioneers who shaped the evolution of aneurysm clips as we know them. A comprehensive literature search was performed using PubMed, Google Scholar, Google Books, and library historical archives, as well as personal communications with relatives, colleagues, and institutions of the surgeon-designers. We present the following aneurysm clip innovators and chronicle their biographies and contributions: Herbert Olivecrona (1891-1980), Frank Mayfield (1908-1991), Charles Drake (1920- 1998), Joseph McFadden (1920- present), Thoralf Sundt Jr. (1930- 1992), William M. Lougheed (1923- -2004), William B. Scoville (1906- 1984), Milton D. Heifetz (1921-2015), Gazi Yasargil (1925-present), Kenichiro Sugita (1932-1994), and Robert Spetzler (1944-present). Although this compilation of eponymous clips is by no means complete, we hope that it provides an informative historical perspective and an inspiration for aspiring neurosurgeons. The history of aneurysm surgery, an entity once deemed inoperable, teaches us the importance of innovation in medicine.
C1 [Jumah, Fareed; Quinoa, Travis; Akel, Omar; Shah, Smit; Narayan, Vinayak; Gupta, Gaurav; Nanda, Anil] Rutgers Robert Wood Johnson Med Sch & Univ Hosp, Dept Neurosurg, New Brunswick, NJ 08901 USA.
   [Adeeb, Nimer] Ochsner Louisiana State Univ Hosp, Dept Neurosurg, Shreveport, LA USA.
RP Nanda, A (reprint author), Rutgers Robert Wood Johnson Med Sch & Univ Hosp, Dept Neurosurg, New Brunswick, NJ 08901 USA.
EM an651@rwjms.rutgers.edu
RI Gupta, Gaurav/AAL-3349-2020; Jumah, Fareed.rizq@gmail.com/AAG-7529-2020
OI Gupta, Gaurav/0000-0002-9442-6007; 
CR Adamson T. M., 2016, SURG NEUROL INT, V7
   Al-Mefty O, 1999, NEUROSURGERY, V45, P1019, DOI 10.1097/00006123-199911000-00013
   Al-Shatoury HA, 2000, SURG NEUROL, V54, P465
   ALEXANDER E, 1974, J NEUROSURG, V41, P1, DOI 10.3171/jns.1974.41.1.0001
   Ammar A, 1999, NEUROL RES, V21, P8, DOI 10.1080/01616412.1999.11740884
   Annese J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4122
   BOTTERELL EH, 1956, J NEUROSURG, V13, P1, DOI 10.3171/jns.1956.13.1.0001
   BOTTERELL EH, 1982, SURG NEUROL, V17, P81, DOI 10.1016/S0090-3019(82)80025-6
   Burtscher IM, 1998, ACTA RADIOL, V39, P70
   Cohen-Gadol AA, 2004, J NEUROSURG, V101, P547, DOI 10.3171/jns.2004.101.3.0547
   Cushing H, 1911, ANN SURG, V54, P1, DOI 10.1097/00000658-191107000-00002
   Dandy WE, 1938, ANN SURG, V107, P654, DOI 10.1097/00000658-193805000-00003
   Del Maestro RF, 2000, J NEUROSURG, V92, P1056, DOI 10.3171/jns.2000.92.6.1056
   Dossani RH, 2015, WORLD NEUROSURG, V84, P1127, DOI 10.1016/j.wneu.2015.04.031
   Dott Norman M, 1933, Edinb Med J, V40, pT219
   Drake C G, 1969, Clin Neurosurg, V16, P114
   DREW JH, 1953, J NEUROSURG, V10, P439, DOI 10.3171/jns.1953.10.4.0439
   DUANE W, 1950, J NEUROSURG, V7, P92, DOI 10.3171/jns.1950.7.1.0092
   Dujovny M, 2010, NEUROL RES, V32, P1011, DOI 10.1179/016164110X12807570509817
   Findlay JM, 2005, CAN J NEUROL SCI, V32, P129, DOI 10.1017/S031716710001903X
   FINDLAY JM, 1993, CAN J NEUROL SCI, V20, P337
   Fox AJ, 1999, AM J NEURORADIOL, V20, P358
   FOX JL, 1976, STROKE, V7, P489, DOI 10.1161/01.STR.7.5.489
   Hamby W., 1969, PROGR NEUROLOGICAL S, V3, P1
   He L, 2016, WORLD NEUROSURG, V96, P454, DOI 10.1016/j.wneu.2016.09.053
   Heifetz L., 2015, AANS NEUROSURGEON, P24
   Heifetz M., MY INVOLVEMENT INTRA
   Heifetz M D, 1969, J Neurosurg, V30, P753, DOI 10.3171/jns.1969.30.6.0753
   Heifetz MD, 1975, RIGHT DIE NEUROSURGE
   Henn JS, 2002, J NEUROSURG, V96, P144, DOI 10.3171/jns.2002.96.1.0144
   HOOK O, 1963, ACTA NEUROL SCAND, V39, P271
   Kato Y, 1996, MINIM INVAS NEUROSUR, V39, P82, DOI 10.1055/s-2008-1052223
   KELLY PJ, 1989, SURG NEUROL, V31, P169, DOI 10.1016/0090-3019(89)90111-0
   KELLY PJ, 1993, J NEUROSURG, V78, P1, DOI 10.3171/jns.1993.78.1.0001
   KHODADAD G, 1966, J NEUROSURG, V24, P855, DOI 10.3171/jns.1966.24.5.0855
   KHODADAD G, 1966, J NEUROSURG, V24, P61, DOI 10.3171/jns.1966.24.1.0061
   KHODADAD G, 1964, J NEUROSURG, V21, P552, DOI 10.3171/jns.1964.21.7.0552
   Kobayashi M, 2015, INT J IMPLANT DENT, V1, DOI 10.1186/s40729-015-0032-0
   Kobayashi S, 1984, Neurosurg Rev, V7, P75, DOI 10.1007/BF01780687
   Kobayashi S, 2011, WORLD NEUROSURG, V75, P354, DOI 10.1016/j.wneu.2011.01.030
   Krammer MJ, 2010, NEUROSURGERY, V66, pONSE336, DOI 10.1227/01.NEU.0000369644.26132.56
   Lai LT, 2017, WORLD NEUROSURG, V102, P673, DOI 10.1016/j.wneu.2017.02.006
   Laws E, CYBER MUSEUM NEUROSU
   Lawton MT, 1996, NEUROSURGERY, V38, P1170, DOI 10.1097/00006123-199606000-00026
   Lawton MT, 1996, NEUROSURGERY, V38, P1158, DOI 10.1097/00006123-199606000-00022
   Lippi D, 1990, Med Secoli, V2, P1
   LJUNGGREN B, 1993, J NEUROSURG, V78, P142, DOI 10.3171/jns.1993.78.1.0142
   Ljunggren B., 1990, GREAT MEN SICK BRAIN
   Lochhead RA, 2010, WORLD NEUROSURG, V74, P71, DOI 10.1016/j.wneu.2010.07.011
   LOUGHEED WM, 1971, J NEUROSURG, V34, P114, DOI 10.3171/jns.1971.34.1.0114
   LOUGHEED WM, 1965, J NEUROSURG, V22, P397, DOI 10.3171/jns.1965.22.4.0397
   Louw DF, 2003, J NEUROSURG, V98, P638, DOI 10.3171/jns.2003.98.3.0638
   Louw DF, 2001, NEUROSURG FOCUS, V11, P1
   Lovato RM, 2016, INDIAN J SURG, V78, P77, DOI 10.1007/s12262-015-1421-6
   Lysholm E., 1935, ACTA RADIOL S, V24, P1
   Lysholm E, 1938, BRIT J RADIOL, V11, P273
   MAYFIELD FH, 1971, J NEUROSURG, V35, P97, DOI 10.3171/jns.1971.35.1.0097
   McFadden JT, 2012, J NEUROSURG, V117, P1, DOI 10.3171/2012.1.JNS111786
   MCFADDEN JT, 1989, J NEUROSURG, V71, P293, DOI 10.3171/jns.1989.71.2.0293
   McFadden JT, 2003, J NEUROSURG, V99, P1114
   McKenzie K, 1927, SURG GYNECOL OBSTET, V45, P549
   MIXTER WJ, 1934, NEW ENGL J MED, V211, P210, DOI DOI 10.1056/NEJM193408022110506
   NORLEN G, 1953, J NEUROSURG, V10, P404, DOI 10.3171/jns.1953.10.4.0404
   OLIVECRONA H, 1967, J NEUROSURG, V26, P6, DOI 10.3171/jns.1967.26.1part1.0006
   Olivecrona H, 1967, J NEUROSURG, V26, P99
   Olivecrona H, 1927, CHIRURG BEHANDLUNG G
   OLIVECRONA H, 1957, CONGENITAL ARTERIOVE
   Papadopoulos MC, 2004, NEUROSURGERY, V54, P966, DOI 10.1227/01.NEU.0000116140.53925.03
   Park PJ, 2010, NEUROSURGERY, V66, pONS300, DOI 10.1227/01.NEU.0000369923.05148.67
   Peerless SJ, 1998, NEUROSURGERY, V43, P1322
   Ponce FA, 2011, J NEUROSURG, V114, P877, DOI 10.3171/2010.9.JNS091178
   Robert, 2017, COMMUNICATION   0315
   SCOVILLE WB, 1966, J NEUROSURG, V25, P97
   SCOVILLE WB, 1960, AM J PSYCHIAT, V117, P525, DOI 10.1176/ajp.117.6.525
   SCOVILLE WB, 1949, J NEUROSURG, V6, P65, DOI 10.3171/jns.1949.6.1.0065
   Sekula RF, 2006, NEUROSURGERY, V59, P168, DOI 10.1227/01.NEU.0000220058.17532.B5
   SHAHBABIAN S, 1978, J NEUROSURG, V49, P935, DOI 10.3171/jns.1978.49.6.0935
   Shellock FG, 1998, RADIOLOGY, V206, P838, DOI 10.1148/radiology.206.3.9494511
   Shibuya M, 1966, LIFE K SUGITA MEMORY
   SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476
   SUGITA K, 1984, J NEUROSURG, V60, P145, DOI 10.3171/jns.1984.60.1.0145
   SUGITA K, 1982, J NEUROSURG, V57, P240, DOI 10.3171/jns.1982.57.2.0240
   Sugita K, 1985, MICRONEUROSURGICAL A
   SUNDT TM, 1972, J NEUROSURG, V37, P753, DOI 10.3171/jns.1972.37.6.0753
   SUNDT TM, 1969, J NEUROSURG, V31, P59, DOI 10.3171/jns.1969.31.1.0059
   SUNDT TM, 1967, J NEUROSURG, V27, P477, DOI 10.3171/jns.1967.27.6.0477
   Sutherland GR, 2008, NEUROSURGERY, V62, P400, DOI 10.1227/01.NEU.0000313104.34038.CC
   Takayasu M, 2000, ACTA NEUROCHIR, V142, P159, DOI 10.1007/s007010050018
   Tew JM, 1999, NEUROSURGERY, V45, P1010, DOI 10.1097/00006123-199911000-00010
   TEW JM, 1991, J NEUROSURG, V75, P347, DOI 10.3171/jns.1991.75.3.0347
   vanLoon JJL, 1997, NEUROSURGERY, V41, P851, DOI 10.1097/00006123-199710000-00016
   von Holst H, 1977, Acta Neurochir (Wien), V38, P101
   Wichmann W, 1997, AM J NEURORADIOL, V18, P939
   William Beecher Scoville M.D, 1984, HARTFORD HOSP B
   Yasargil M, 1969, MICROSURGERY APPL NE
   YASARGIL MG, 1977, SURG NEUROL, V8, P331
NR 96
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 518
EP 531
DI 10.1016/j.wneu.2019.09.061
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200229
PM 31542444
DA 2020-05-12
ER

PT J
AU North, RY
   Verla, T
   Bartlett, E
   Reece, E
   Weiner, HL
   Ropper, AE
AF North, Robert Y.
   Verla, Terence
   Bartlett, Erica
   Reece, Edward
   Weiner, Howard L.
   Ropper, Alexander E.
TI Giant Symptomatic Meningocele as a Delayed, Adult Complication of
   Lipomyelomeningocele
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult spina bifida; Lipomyelomeningocele; Meningocele
ID SPINA-BIFIDA
AB BACKGROUND: An expanding cohort of patients with spina bifida live well into adulthood and pose complex management challenges due to unique combinations of adult health issues overlying congenital problems.
   CASE DESCRIPTION: We present a case of a 45-year-old woman with an expanding, disfiguring, painful lumbar meningocele more than 40 years after her only surgery as a 3-year-old child. A team of pediatric and adult neurosurgeons as well as plastic/reconstructive surgeons successfully performed surgery to obliterate the meningocele, with preservation of her baseline functional status, and no evidence of recurrence after more than 1 year of follow-up.
   CONCLUSIONS: Symptomatic meningocele may present in a long-delayed fashion in adult patients with a history of spina bifida. Surgical treatment may provide symptomatic benefit.
C1 [North, Robert Y.; Verla, Terence; Weiner, Howard L.; Ropper, Alexander E.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
   [Bartlett, Erica; Reece, Edward] Baylor Coll Med, Div Plast Surg, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.
   [Weiner, Howard L.] Texas Childrens Hosp, Div Pediat Neurosurg, Dept Surg, Houston, TX 77030 USA.
RP North, RY (reprint author), Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
EM north@bcm.edu
CR Bowman RM, 2001, PEDIATR NEUROSURG, V34, P114, DOI 10.1159/000056005
   Davis BE, 2005, PEDIATR NEUROSURG, V41, P186, DOI 10.1159/000086559
   Dillon CM, 2000, EUR J PEDIATR SURG, V10, P33, DOI 10.1055/s-2008-1072412
   Mukherjee S, 2007, THESCIENTIFICWORLDJO, V7, P1890, DOI 10.1100/tsw.2007.179
   Piatt JH, 2016, J NEUROSURG-SPINE, V25, P69, DOI 10.3171/2015.9.SPINE15771
   Roach JW, 2011, CLIN ORTHOP RELAT R, V469, P1246, DOI 10.1007/s11999-010-1594-z
NR 6
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 532
EP 535
DI 10.1016/j.wneu.2019.11.086
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200230
PM 31760189
DA 2020-05-12
ER

PT J
AU Detiger, SE
   Karim, F
   Monserez, D
   Verdijk, R
   van Hagen, M
   Paridaens, D
   van Laar, J
AF Detiger, Sanne Emilie
   Karim, Faiz
   Monserez, Dominiek
   Verdijk, Robert
   van Hagen, Martin
   Paridaens, Dion
   van Laar, Jan
TI IgG4-Related Disease of Skull Base: Case Series of 3 Patients with
   Headache
SO WORLD NEUROSURGERY
LA English
DT Article
DE IgG4-related disease; Serum IgG4; Skull base
ID NECK
AB BACKGROUND: IgG4-related disease (IgG4-RD) is an immune-mediated, systemic, fibroinflammatory disease. IgG4-RD may manifest in almost every part of the human body. Here, we describe 3 patients with a skull base manifestation of IgG4-RD that mimicked malignancy.
   CASE DESCRIPTION: Patient 1, a 73-year-old male, presented with a mass in the left nasopharynx and clivus. Patient 2, a 73-year-old male, presented with a mass in the left petrous bone and clivus with involvement of the left jaw joint. Patient 3, a 50-year-old male, presented with a lytic lesion of the clivus and sphenoid bone. All patients complained of headache and hearing loss. Serum IgG4 was normal, and imaging did not show systemic manifestation. Histology established the diagnosis of IgG4-RD. Two patients were treated successfully with prednisolone, hydroxychloroquine, and radiotherapy. One patient is monitored without treatment.
   CONCLUSIONS: The described cases emphasize the broad clinical spectrum of IgG4-RD. The diagnostic workup may be challenging, and serum IgG4 may be normal, as demonstrated in these cases. Careful histopathologic examination of the tissues remains essential. Timely diagnosis of IgG4-RD is important to prevent secondary organ damage in patients with active disease.
C1 [Detiger, Sanne Emilie; Paridaens, Dion] Rotterdam Eye Hosp, Rotterdam, Netherlands.
   [Karim, Faiz; van Hagen, Martin; van Laar, Jan] Erasmus MC, Sect Clin Immunol, Dept Internal Med & Immunol, Rotterdam, Netherlands.
   [Monserez, Dominiek] Erasmus MC, Dept Otorhinolaryngol & Head & Neck Surg, Rotterdam, Netherlands.
   [Verdijk, Robert] Erasmus MC, Dept Pathol, Sect Ophthalm Pathol, Rotterdam, Netherlands.
   [Paridaens, Dion] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Karim, Faiz] Groene Hart Hosp, Dept Internal Med, Gouda, Netherlands.
RP Detiger, SE (reprint author), Rotterdam Eye Hosp, Rotterdam, Netherlands.
EM s.detiger@oogziekenhuis.nl
OI Verdijk, Robert M/0000-0003-1437-214X
CR Cain RB, 2014, OTOLARYNG HEAD NECK, V151, P496, DOI 10.1177/0194599814533648
   Deshpande V, 2015, HEAD NECK PATHOL, V9, P24, DOI 10.1007/s12105-015-0620-6
   Fujita A, 2012, RADIOGRAPHICS, V32, P1945, DOI 10.1148/rg.327125032
   Karim AF, 2018, NETH J MED, V76, P275
   Karim AF, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/6103064
   Karim F, 2017, NEW ENGL J MED, V376, P599, DOI 10.1056/NEJMc1614275
   Katsura M, 2012, NEURORADIOLOGY, V54, P873, DOI 10.1007/s00234-012-1012-1
   Khosroshahi A, 2015, ARTHRITIS RHEUMATOL, V67, P1688, DOI 10.1002/art.39132
   Lin YH, 2015, OCUL IMMUNOL INFLAMM, V23, P162, DOI 10.3109/09273948.2014.928735
NR 9
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 536
EP 539
DI 10.1016/j.wneu.2019.10.111
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200231
PM 31669684
DA 2020-05-12
ER

PT J
AU Moon, SJ
   Han, MS
   Lee, GJ
   Lee, SK
   Moon, BJ
   Lee, JK
AF Moon, Sung-Jun
   Han, Moon-Soo
   Lee, Gwang-Jun
   Lee, Seul-Kee
   Moon, Bong Ju
   Lee, Jung-Kil
TI Unexpected Intradural Lumbar Disk Herniation Found During Transforaminal
   Endoscopic Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic diskectomy; Intradural disk herniation; Microscopic
   diskectomy
ID DIAGNOSIS
AB BACKGROUND: Intradural disk herniation (IDH) is defined as the displacement of the intervertebral disk nucleus pulposus into the dural sac. In this lumbar lesion, the affected level differs from that of a traditional extradural herniation: 55% of cases occur at the level of 14-5, 16% at L3-4, and 10% at L5-S1. Upper lumbar IDH is extremely rare. We present a case of an IDH at the level of L2-3 that was diagnosed during endoscopic surgery.
   CASE DESCRIPTION: A 65-year-old male patient presented with severe radiating pain in the anterior right thigh that was accompanied by a tingling sensation in the right calf and difficulty in walking. Physical examination showed normal strength. Bladder and bowel function was normal, but mild hypesthesia of the L3 sensory dermatome was observed. Magnetic resonance imaging revealed a herniated disk at the level of L2-L3 that was compressing the right side of the dura. A percutaneous transforaminal endoscopic lumbar diskectomy was planned. After foraminoplasty, no ruptured disk fragments could be found. During dissection of the adhesion between the dura and protruded disk, the dura was torn. Interestingly, through this dural opening, multiple fragmented disk portions were visualized among the nerve rootlets. We removed some of the soft disk material; however, complete removal of the disk fragments was predicted to damage the rootlets, and we decided to convert to microscopic surgery. The disk fragments were successfully removed via durotomy under microscopic assistance. The incised dorsal dura was primarily sutured with continuous stitches, and the defect on the ventrolateral side of the dura was patched and sealed using a harvested inner ligamentum flavum and Gelfoam (Pfizer, New York, New York, USA). After the operation, the patient's symptoms improved. There was no cerebrospinal fluid leakage.
   CONCLUSIONS: If there is any preoperative clinical or radiologic suspicion of IDH, a microscopic surgical approach should be considered to be the first-line option, as this is a safe and effective method for achieving IDH removal and dura repair without a postoperative neurologic deficit. Even during endoscopic surgery, if the surgeon expects even minor complications, we suggest converting to open surgery. In addition, the adequate sealing of the dura may be sufficient to prevent cerebrospinal fluid leakage, without the need for dural suture and lumbar drainage.
C1 [Moon, Sung-Jun] Buk Gu Wooridul Spine Hosp, Dept Neurosurg, Gwangju, South Korea.
   [Han, Moon-Soo; Lee, Gwang-Jun; Lee, Seul-Kee; Moon, Bong Ju; Lee, Jung-Kil] Chonnam Natl Univ, Dept Neurosurg, Med Sch, Gwangju, South Korea.
   [Han, Moon-Soo; Lee, Gwang-Jun; Lee, Seul-Kee; Moon, Bong Ju; Lee, Jung-Kil] Res Inst Med Sci, Gwangju, South Korea.
RP Lee, JK (reprint author), Chonnam Natl Univ, Dept Neurosurg, Med Sch, Gwangju, South Korea.; Lee, JK (reprint author), Res Inst Med Sci, Gwangju, South Korea.
EM jkl@chonnam.ac.kr
CR Choi JY, 2007, SPINE J, V7, P111, DOI 10.1016/j.spinee.2006.02.025
   D'Andrea G, 2004, NEUROSURG REV, V27, P75, DOI 10.1007/s10143-003-0296-3
   Dandy WE, 1942, ANN SURG, V115, P514, DOI 10.1097/00000658-194204000-00004
   Ducati LG, 2013, EUR SPINE J, V22, pS404, DOI 10.1007/s00586-012-2516-4
   Floeth Frank, 2012, Eur Spine J, V21 Suppl 4, pS453, DOI 10.1007/s00586-011-2073-2
   Han IH, 2009, J KOREAN NEUROSURG S, V46, P168, DOI 10.3340/jkns.2009.46.2.168
   Jang JW, 2010, SPINE, V35, pE726, DOI 10.1097/BRS.0b013e3181c64ca7
   Kim HS, 2018, WORLD NEUROSURG, V119, P163, DOI 10.1016/j.wneu.2018.07.244
   Kobayashi K, 2014, CLIN NEUROL NEUROSUR, V125, P47, DOI 10.1016/j.clineuro.2014.06.033
   Lee JS, 2006, J KOREAN MED SCI, V21, P778, DOI 10.3346/jkms.2006.21.4.778
   Singh PK, 2012, ASIAN SPINE J, V6, P145, DOI 10.4184/asj.2012.6.2.145
   YILDIZHAN A, 1991, ACTA NEUROCHIR, V110, P160, DOI 10.1007/BF01400685
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 540
EP 543
DI 10.1016/j.wneu.2019.11.121
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200232
PM 31786381
DA 2020-05-12
ER

PT J
AU Takebayashi, K
   Ishikawa, T
   Murakami, M
   Funatsu, T
   Ishikawa, T
   Taira, T
   Kawamata, T
AF Takebayashi, Kento
   Ishikawa, Tomomi
   Murakami, Masato
   Funatsu, Takayuki
   Ishikawa, Tasuya
   Taira, Takaomi
   Kawamata, Takakazu
TI Isolated Posterior Spinal Artery Aneurysm Presenting with Spontaneous
   Thrombosis After Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Posterior spinal artery aneurysm; Radiculopial artery; Subarachnoid
   hemorrhage
ID DISSECTING ANEURYSM
AB BACKGROUND: The cause of subarachnoid hemorrhage is more likely to be intracranial than spinal. Bleeding, although common with spinal arteriovenous malformations and spinal cord tumors, rarely occurs with ruptured isolated spinal artery aneurysms. Here, we report a case of isolated thoracic posterior spinal artery aneurysm presenting with thrombosis after subarachnoid hemorrhage.
   CASE DESCRIPTION: A 67-year-old woman presented with sudden-onset nausea and low back and right thigh pain that worsened with movement. Computed tomography (CT) and magnetic resonance imaging (MRI) scans of the head suggested a small subarachnoid hemorrhage in the high-convexity sulcus, and lumbar puncture showed bloody cerebrospinal fluid. There was no apparent intracranial aneurysm on CT angiography; however, spinal MRI showed a lesion on the right side of the spinal cord at Th10. Contrast-enhanced CT showed an enhancing lesion at this site on day 7 that was not present on day 15. Selective right Th10 intercostal artery angiography on day 22 showed no evidence of aneurysm. The lesion was suspected to be a thrombotic spinal artery aneurysm. Given the unclear natural history of this entity, surgery was performed on day 36. After right Th10 hemilaminectomy and opening the dura, the arachnoid and adhesions were found to be thickened. A fusiform-shaped thrombosed aneurysm continuous with the radiculopial artery was removed. The patient was discharged without neurologic deterioration.
   CONCLUSIONS: Isolated spinal artery aneurysm is a rare cause of subarachnoid hemorrhage. It is expected that additional cases will clarify the natural history and indications for treatment.
C1 [Takebayashi, Kento; Ishikawa, Tomomi; Murakami, Masato; Funatsu, Takayuki; Ishikawa, Tasuya; Taira, Takaomi; Kawamata, Takakazu] Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan.
RP Takebayashi, K (reprint author), Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan.
EM tikurin0221@yahoo.co.jp
CR Bell DL, 2014, J CLIN NEUROSCI, V21, P1273, DOI 10.1016/j.jocn.2014.01.002
   Caglar YS, 2005, J CLIN NEUROSCI, V12, P603, DOI 10.1016/j.jocn.2004.08.022
   Dabus G, 2018, J NEUROINTERV SURG, V10, P451, DOI 10.1136/neurintsurg-2017-013566
   Geibprasert S, 2010, INTERV NEURORADIOL, V16, P183, DOI 10.1177/159101991001600211
   Horio Y, 2015, NEUROL MED-CHIR, V55, P915, DOI 10.2176/nmc.cr.2015-0210
   Ikeda S, 2016, SPINE J, V16, pE215, DOI 10.1016/j.spinee.2015.11.015
   Johnson Jeremiah, 2015, J Neurointerv Surg, V7, pe23, DOI 10.1136/neurintsurg-2014-011248.rep
   Kim HJ, 2012, NEUROSURGERY, V71, pE749, DOI 10.1227/NEU.0b013e31825ea539
   Kocak A, 2006, BRIT J NEUROSURG, V20, P241, DOI 10.1080/02688690600852704
   Nemecek AN, 2006, J NEUROSURG-SPINE, V5, P555, DOI 10.3171/spi.2006.5.6.555
   Ronchetti G, 2015, NEUROCRIT CARE, V22, P299, DOI 10.1007/s12028-014-0009-5
   Sato K, 2012, NEUROSURGERY, V71, pE1053, DOI 10.1227/NEU.0b013e3182647be4
   Takata M, 2016, SPINE, V41, pE46, DOI 10.1097/BRS.0000000000001081
   Van Es ACGM, 2013, INTERV NEURORADIOL, V19, P60, DOI 10.1177/159101991301900109
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 544
EP 547
DI 10.1016/j.wneu.2019.11.118
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200233
PM 31786383
DA 2020-05-12
ER

PT J
AU Akhunbay-Fudge, CY
   Chakrabarty, A
   Derham, C
   Pal, D
AF Akhunbay-Fudge, Christopher Yusuf
   Chakrabarty, Arundhati
   Derham, Christopher
   Pal, Debasish
TI Thoracic Intradural Extramedullary Ependymoma with Anaplastic
   Transformation: Case Report and Discussion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anaplastic; Ependymoma; Extramedullary; Intradural
ID GRADE II EPENDYMOMA; SPINAL EPENDYMOMA; MALIGNANT-TRANSFORMATION
AB BACKGROUND: Intradural extramedullary spinal ependymomas arising from outside the region of the conus medullaris are rare clinical entities, and anaplastic transformation of these lesions is even more exceptional.
   CASE DESCRIPTION: We report on a case of an intradural extramedullary T5-T6 ependymoma that underwent gross total resection. Histologic analysis of the initial tumor revealed a World Health Organization grade 2 ependymoma. Two years after initial surgical resection,there was radiologic recurrence and a re-do resection was performed with subsequent spinal stabilization. Histologic analysis of the recurrent tumor revealed a World Health Organization grade 3 ependymoma. After surgery the patient received radiotherapy, and he remains disease free at 2 years following his second surgery. In addition, we employed carbon fiber screws and rods for stabilization in his second operation to reduce artefact on follow-up imaging.
   CONCLUSIONS: We advocate that primary spinal ependymomas should be within the differential of intradural extramedullary lesions arising outside the region of the conus medullaris.
C1 [Akhunbay-Fudge, Christopher Yusuf; Derham, Christopher; Pal, Debasish] Leeds Teaching Hosp NHS Trust, Dept Neurosurg, Leeds, W Yorkshire, England.
   [Chakrabarty, Arundhati] Leeds Teaching Hosp NHS Trust, Dept Histopathol, Leeds, W Yorkshire, England.
RP Akhunbay-Fudge, CY (reprint author), Leeds Teaching Hosp NHS Trust, Dept Neurosurg, Leeds, W Yorkshire, England.
EM Christopher.akhunbay-fudge@nhs.net
CR Benzagmout M, 2008, SURG NEUROL, V70, P536, DOI 10.1016/j.surneu.2007.05.055
   Celano E, 2016, J NEURO-ONCOL, V128, P377, DOI 10.1007/s11060-016-2135-8
   Cerase A, 2006, J NEUROSURG-SPINE, V5, P476, DOI 10.3171/spi.2006.5.5.476
   Chakravorty Ananya, 2017, J Spine Surg, V3, P727, DOI 10.21037/jss.2017.11.10
   Duffau H, 2000, SPINE, V25, P1993, DOI 10.1097/00007632-200008010-00021
   Guppy Kern H, 2011, Surg Neurol Int, V2, P119, DOI 10.4103/2152-7806.84246
   Honda A, 2017, EUR SPINE J, V26, pS222, DOI 10.1007/s00586-017-5055-1
   Hong S, 2013, J KOREAN NEUROSURG S, V54, P521, DOI 10.3340/jkns.2013.54.6.521
   Iunes EA, 2011, J NEUROSURG-SPINE, V14, P65, DOI 10.3171/2010.9.SPINE09963
   KATOH S, 1995, SPINE, V20, P2036, DOI 10.1097/00007632-199509150-00017
   Kim Byung Soo, 2013, Korean J Spine, V10, P177, DOI 10.14245/kjs.2013.10.3.177
   Kinsman MJ, 2011, CLIN NEUROL NEUROSUR, V113, P661, DOI 10.1016/j.clineuro.2011.02.021
   Moriwaki T, 2013, ASIAN SPINE J, V7, P139, DOI 10.4184/asj.2013.7.2.139
   Robles SG, 2005, SPINE, V30, pE251, DOI 10.1097/01.brs.0000161008.13441.7b
   Sarikafa S, 2015, J NEUROL SURG REP, V76, P151, DOI 10.1055/s-0035-1549311
   Schuurmans M, 2006, J NEURO-ONCOL, V79, P57, DOI 10.1007/s11060-005-9114-9
   Takeda N, 2017, BRIT J NEUROSURG, V31, P270, DOI 10.1080/02688697.2016.1187251
   Wu J, 2016, NEURO-ONCOLOGY, V18, P902, DOI 10.1093/neuonc/now016
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 549
EP 554
DI 10.1016/j.wneu.2019.11.122
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200235
PM 31786385
DA 2020-05-12
ER

PT J
AU Zhong, BL
   Shao, ZW
   Pan, HT
AF Zhong, Binlong
   Shao, Zengwu
   Pan, Haitao
TI Intraspinal Canal Schwannoma with Extensive Calcification: Case Report
   and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Calcification; Intraspinal; Schwannoma
ID CAUDA-EQUINA; DEFICIT
AB BACKGROUND: Schwannomas are the most common benign tumors in the intraspinal location, with slow-growing and nonaggressive features. Calcification is not a common histopathological and radiological feature in schwannoma.
   CASE DESCRIPTION: We report the case of a 43-year-old man with soreness in the lower back, left buttock, and lower limb of 1 month's duration. On magnetic resonance imaging and computed tomography, an intradural mass with extensive calcification was found at the L1-L2 level. The tumor was completely resected, with sacrifice of 1 nerve root. Postoperatively, his symptoms were relieved, and no dysfunction of the lower limbs and sphincter was observed. Pathologically, the tumor was diagnosed as a schwannoma with extensive calcification. At the 7-month follow-up examination, no complaints were found.
   CONCLUSION: Although intraspinal schwannoma with extensive calcification is rare, which increases the difficulty of an accurate diagnosis preoperatively, the tumor can be completely removed with or without excision of the nonfunctional nerve roots.
C1 [Zhong, Binlong; Shao, Zengwu; Pan, Haitao] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed, Wuhan, Peoples R China.
RP Pan, HT (reprint author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed, Wuhan, Peoples R China.
EM phtsuperman@163.com
OI Zhong, Binlong/0000-0002-3087-7626
CR BONSTELLE CT, 1976, NEURORADIOLOGY, V10, P231, DOI 10.1007/BF00327569
   CERVONI L, 1994, ACTA NEUROCHIR, V127, P199, DOI 10.1007/BF01808766
   Chavez JA, 2015, CLIN NEUROPATHOL, V34, P47, DOI 10.5414/NP300781
   DROSS PE, 1985, AM J NEURORADIOL, V6, P967
   GRAHAM DI, 1972, J NEUROSURG, V36, P487, DOI 10.3171/jns.1972.36.4.0487
   Hayashi F, 2009, SPINE J, V9, P19
   Hung CH, 2008, KAOHSIUNG J MED SCI, V24, P212, DOI 10.1016/S1607-551X(08)70120-7
   Hyun SJ, 2012, J KOREAN NEUROSURG S, V51, P105, DOI 10.3340/jkns.2012.51.2.105
   Jagannatha AT, 2016, J PEDIATR NEUROSCI, V11, P319, DOI 10.4103/1817-1745.199474
   Jinnai T, 2005, NEUROSURGERY, V56, P510, DOI 10.1227/01.NEU.0000153752.59565.BB
   KIM P, 1989, J NEUROSURG, V71, P810, DOI 10.3171/jns.1989.71.6.0810
   Ledbetter LN, 2019, RADIOL CLIN N AM, V57, P341, DOI 10.1016/j.rcl.2018.09.007
   Lenzi J, 2017, NEUROL RES INT, V2017, DOI 10.1155/2017/3568359
   SCHIMMEL DH, 1974, NEURORADIOLOGY, V8, P55, DOI 10.1007/BF00339803
   Shikata J, 1989, Nihon Geka Hokan, V58, P140
   TEKKOK IH, 1993, PARAPLEGIA, V31, P678, DOI 10.1038/sc.1993.109
NR 16
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 555
EP 559
DI 10.1016/j.wneu.2019.11.099
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200236
PM 31778833
DA 2020-05-12
ER

PT J
AU Shirokane, K
   Tamaki, T
   Kim, K
   Morita, A
AF Shirokane, Kazutaka
   Tamaki, Tomonori
   Kim, Kyongsong
   Morita, Akio
TI Subarachnoid Hemorrhage Attributable to Bilateral Aplastic or Twiglike
   Middle Cerebral Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aplastic middle cerebral artery; EC-IC bypass; Subarachnoid hemorrhage;
   Tetralogy of Fallot; Twiglike middle cerebral artery
ID MOYAMOYA-DISEASE; TETRALOGY; ANOMALIES; FALLOT
AB BACKGROUND: Aplastic or twiglike middle cerebral artery (MCA), a congenital anomaly related to the abnormal development of the MCA, is rare. It is usually unilateral; bilateral lesions are extremely rare. An aplastic or twiglike MCA may lead to cerebral ischemic stroke, intracranial hemorrhage, and subarachnoid hemorrhage (SAH). In patients with ischemic stroke due to hemodynamic stress, extracranial-intracranial (EC-IC) bypass surgery is indicated. As hemodynamic stress may also elicit SAH, it is important to select the appropriate treatment. EC-IC bypass surgery was successful in a patient with bilateral aplastic or twiglike MCA who suffered SAH due to hemodynamic stress.
   CASE DESCRIPTION: A 64-year-old female with a history of surgery for tetralogy of Fallot experienced SAH in the left sylvian fissure. As angiography showed a bilateral aplastic or twiglike MCA and single photon emission computed tomography revealed a decrease in the cerebral blood flow in the left MCA territory, we attributed her SAH to hemodynamic stress due to the decreased blood flow in the MCA territory and to the vulnerability of abnormal vessels as are seen in moyamoya disease. We performed EC-IC bypass surgery to reduce hemodynamic stress. A cerebral angiogram obtained 2 weeks post-operatively revealed sufficient blood flow in the MCA territory from the superficial temporal artery used for bypass. In the course of 2-year follow-up she remained stroke free.
   CONCLUSIONS: The presence of aplastic or twiglike MCA may lead to stroke due to hemodynamic stress. EC-IC bypass surgery may help to prevent stroke recurrence and SAH.
C1 [Shirokane, Kazutaka; Tamaki, Tomonori] Tama Nagayama Hosp, Nippon Med Sch, Dept Neurosurg, Tokyo, Japan.
   [Kim, Kyongsong] Chiba Hokusoh Hosp, Nippon Med Sch, Dept Neurosurg, Chiba, Japan.
   [Morita, Akio] Nippon Med Coll Hosp, Dept Neurosurg, Bunkyo Ku, Tokyo, Japan.
RP Shirokane, K (reprint author), Tama Nagayama Hosp, Nippon Med Sch, Dept Neurosurg, Tokyo, Japan.
EM kazutaka-shirokane@nms.ac.jp
CR Akkan K, 2015, EUR J RADIOL, V84, P2013, DOI 10.1016/j.ejrad.2015.06.012
   Ali H, 2018, CUREUS, V10, DOI 10.7759/cureus.2714
   Fiorda-Diaz J, 2017, FRONT SURG, V4, DOI 10.3389/fsurg.2017.00072
   Iida Yu, 2017, NMC Case Rep J, V4, P79, DOI 10.2176/nmccrj.cr.2016-0240
   Imaizumi S, 2001, ACTA NEUROCHIR, V143, P625, DOI 10.1007/s007010170069
   Ishikawa T, 1997, STROKE, V28, P1170, DOI 10.1161/01.STR.28.6.1170
   Kuroda S, 2015, NEUROL MED-CHIR, V55, P796, DOI 10.2176/nmc.oa.2015-0044
   Liu HM, 2005, CEREBROVASC DIS, V20, P1, DOI 10.1159/000086119
   Lutz T, 2018, CLIN NEURORADIOL, V28, P441, DOI 10.1007/s00062-017-0613-9
   Matsunaga Y, 2018, J STROKE CEREBROVASC, V27, pE78, DOI 10.1016/j.jstrokecerebrovasdis.2017.12.004
   Miura Shinichi, 2018, Brain Nerve, V70, P1033, DOI 10.11477/mf.1416201125
   Miyamoto S, 2014, STROKE, V45, P1415, DOI 10.1161/STROKEAHA.113.004386
   Rodriguez-Hernandez A, 2011, NEUROSURG REV, V34, P517, DOI 10.1007/s10143-011-0342-5
   Sakai Kosuke, 2018, No Shinkei Geka, V46, P713, DOI 10.11477/mf.1436203799
   Seo BS, 2012, NEUROSURGERY, V70, P1472, DOI 10.1227/NEU.0b013e318246a510
   Suteu CC, 2016, J CARDIAC SURG, V31, P461, DOI 10.1111/jocs.12770
   Tashiro R, 2016, J STROKE CEREBROVASC, V25, pE77, DOI 10.1016/j.jstrokecerebrovasdis.2016.03.029
   Uchino A, 2017, SURG RADIOL ANAT, V39, P1161, DOI 10.1007/s00276-017-1848-5
   Uchiyama N, 2017, NEUROL MED-CHIR, V57, P261, DOI 10.2176/nmc.ra.2017-0043
   Uchiyama Taku, 2016, No Shinkei Geka, V44, P143, DOI 10.11477/mf.1436203246
   Uda K, 2019, J NEUROSURG, V130, P1367, DOI 10.3171/2017.10.JNS171523
   Yamamoto S, 2019, WORLD NEUROSURG, V122, pE253, DOI 10.1016/j.wneu.2018.10.001
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 560
EP 563
DI 10.1016/j.wneu.2019.10.054
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200237
PM 31629144
DA 2020-05-12
ER

PT J
AU Wang, Y
AF Wang, Yi
TI Contralateral Sudden Sensorineural Hearing Loss After Vestibular
   Schwannoma Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complication; Contralateral; Endolymphatic hydrops; Sudden sensorineural
   hearing loss; Vestibular schwannoma
ID ACOUSTIC NEUROMA; FACIAL PALSY; EAR; REMOVAL; TUMOR
AB BACKGROUND: Contralateral sudden sensorineural hearing loss (SNHL) after vestibular schwannoma (VS) surgery is extremely rare, and the mechanism of hearing loss remains unclear. This report aims to provide details of a new case of contralateral SNHL after VS resection, discuss the possible causes of SNHL, and review the relevant literature.
   CASE DESCRIPTION: A 32-year-old woman developed sudden, profound SNHL after VS surgery. She gradually recovered partial hearing after 6 months of steroid, vasodilator, and neurotrophic therapy.
   CONCLUSIONS: Compensatory endolymphatic hydrops caused by the loss of cerebrospinal fluid might be responsible for this case of sudden SNHL following VS surgery.
C1 [Wang, Yi] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Otorhinolaryngol, Beijing, Peoples R China.
RP Wang, Y (reprint author), Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Otorhinolaryngol, Beijing, Peoples R China.
EM ywin6727@yahoo.com
CR CHOVANES GI, 1986, NEUROSURGERY, V19, P452, DOI 10.1227/00006123-198609000-00021
   CLEMIS JD, 1982, LARYNGOSCOPE, V92, P76
   da la Cruz M, 1998, J LARYNGOL OTOL, V112, P769, DOI 10.1017/S0022215100141635
   Deeb RH, 2015, ENT-EAR NOSE THROAT, V94, P28
   DEKEYSER J, 1983, J NEUROL NEUROSUR PS, V46, P687, DOI 10.1136/jnnp.46.7.687
   FORTNUM HM, 1992, ARCH DIS CHILD, V67, P1128, DOI 10.1136/adc.67.9.1128
   Garcia-Cabo P, 2019, ACTA OTORRINOLAR ESP, V70, P165, DOI [10.1016/j.otorri.2018.03.007, 10.1016/j.otoeng.2018.03.006]
   GLODDEK B, 1994, CLIN EXP IMMUNOL, V97, P133
   Harada K, 1990, Nihon Jibiinkoka Gakkai Kaiho, V93, P1864
   KYLEN P, 1977, ACTA OTO-LARYNGOL, V84, P393, DOI 10.3109/00016487709123982
   LUSTIG LR, 1995, OTOLARYNG HEAD NECK, V113, P276, DOI 10.1016/S0194-5998(95)70118-4
   Plans G, 2007, NEUROSURGERY, V61, P878, DOI 10.1227/01.NEU.0000280056.00899.FC
   PLASSE HM, 1981, LARYNGOSCOPE, V91, P101
   Shuto T, 2011, NEUROL MED-CHIR, V51, P434, DOI 10.2176/nmc.51.434
   Togashi S, 2014, J CLIN NEUROSCI, V21, P863, DOI 10.1016/j.jocn.2013.06.019
   TOS M, 1989, J LARYNGOL OTOL, V103, P845, DOI 10.1017/S0022215100110278
   Tripathi M, 2018, WORLD NEUROSURG, V117, P74, DOI 10.1016/j.wneu.2018.05.245
   Walsted A, 2000, EUR ARCH OTO-RHINO-L, V257, P124, DOI 10.1007/s004050050207
   Walsted A, 2000, ACTA OTO-LARYNGOL, P95
   Warade A, 2016, INT J SURG CASE REP, V29, P47, DOI 10.1016/j.ijscr.2016.10.032
NR 20
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 564
EP 568
DI 10.1016/j.wneu.2019.11.092
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200238
PM 31765866
DA 2020-05-12
ER

PT J
AU Ghaffarpasand, F
   Dadgostar, E
   Ilami, G
   Shoaee, F
   Niakan, A
   Aghabaklou, S
   Ghadimi, M
   Goudarzi, S
   Dehghankhalili, M
   Alavi, MH
AF Ghaffarpasand, Fariborz
   Dadgostar, Ehsan
   Ilami, Ghazal
   Shoaee, Fatemeh
   Niakan, Amin
   Aghabaklou, Sara
   Ghadimi, Maryam
   Goudarzi, Sogand
   Dehghankhalili, Maryam
   Alavi, Mohammad Hesam
TI Intravenous Acetaminophen (Paracetamol) for Postcraniotomy Pain:
   Systematic Review and Meta-Analysis of Randomized Controlled Trials
SO WORLD NEUROSURGERY
LA English
DT Review
DE Acetaminophen; Craniotomy; Meta-analysis; Postoperative pain
ID POSTOPERATIVE PAIN; CRANIOTOMY; MANAGEMENT
AB BACKGROUND: Acute pain control after supratentorial craniotomy is considered among the most important indicators of postoperative recovery. The aim of this study was to determine the effects of intravenous acetaminophen on postcraniotomy pain.
   METHODS: We searched databases including Embase, Scopus, Medline, Cochrane Library, and Web of Science until April 2019. Cochran Q test and I-2 statistic were used to assess the heterogeneity across included clinical trials. Standardized mean difference (SMD) and 95% confidence interval (CI) were used to estimate pooled effect sizes.
   RESULTS: Out of 479 reports, 5 randomized controlled trials met the inclusion criteria and were appropriate for our meta-analysis, which included a total of 2635 patients. The pooled results of included clinical trials indicated that paracetamol intake significantly decreased rescue dose (SMD, -0.67; 95% CI, -1.15 to - 0.19; P < 0.01; I-2 = 90.0%), total dosage of rescue (SMD, -0.78; 95% CI, -1.18 to - 0.37; P < 0.01; I-2 = 86.0%), intensive care unit length of stay (SMD, -0.24; 95% CI, -0.44 to -0.04; P = 0.01; I-2= 0.0%), and visual analog scale score (SMD, -0.16; 95% CI, -0.31 to -0.00; P = 0.04; I-2 = 71.7%) and increased patient satisfaction (SMD, 0.28; 95% CI, 0.14-0.43; P< 0.01; I-2 = 10.2%) among patients with craniotomy. Time to rescue (SMD, 0.21; 95% CI, -0.42 to 0.85; P = 0.51; I-2 = 94.3%) and hospital length of stay (SMD, -0.04; 95% CI, -0.24 to 0.16; P = 0.69; I-2 = 0.0%) did not significantly change after paracetamol intake.
   CONCLUSIONS: The results of this systematic review and meta-analysis indicate that preoperative intravenous administration of acetaminophen is associated with decreased postoperative pain, need for rescue analgesics, and dosages of analgesics after craniotomy surgery.
C1 [Ghaffarpasand, Fariborz; Ilami, Ghazal] Shiraz Univ Med Sci, Res Ctr Neuromodulat & Pain, Shiraz, Iran.
   [Niakan, Amin; Alavi, Mohammad Hesam] Shiraz Univ Med Sci, Trauma Res Ctr, Shiraz, Iran.
   [Dehghankhalili, Maryam] Shiraz Univ Med Sci, Student Res Comm, Shiraz, Iran.
   [Dadgostar, Ehsan] Food & Drug Adm, Halal Res Ctr IRI, Tehran, Iran.
   [Aghabaklou, Sara] Univ Southern Calif, Dept Prevent Med, Los Angeles, CA 90007 USA.
   [Ghadimi, Maryam] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA.
   [Goudarzi, Sogand] Harvard Univ, Beth Israel Deaconess Med Sch, Dept Med, Div Cardiovasc Med, Boston, MA USA.
   [Shoaee, Fatemeh] Shiraz Kowsar Hosp, Dept Obstet & Gynecol, Shiraz, Iran.
RP Niakan, A (reprint author), Shiraz Univ Med Sci, Trauma Res Ctr, Shiraz, Iran.
EM aminniakan@yahoo.com
RI Ghaffarpasand, Fariborz/I-4204-2019
OI Ghaffarpasand, Fariborz/0000-0002-1721-9987
CR Artime CA, 2018, J NEUROSURG ANESTH, V30, P231, DOI 10.1097/ANA.0000000000000461
   Botting RM, 2000, CLIN INFECT DIS, V31, pS202, DOI 10.1086/317520
   Bronco A, 2014, PEDIATR ANESTH, V24, P781, DOI 10.1111/pan.12351
   Burbridge MA, 2019, CUREUS, V11, DOI 10.7759/cureus.3863
   Dilmen OK, 2016, CLIN NEUROL NEUROSUR, V146, P90, DOI 10.1016/j.clineuro.2016.04.026
   Duggan ST, 2009, DRUGS, V69, P101, DOI 10.2165/00003495-200969010-00007
   Dunn LK, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0693-y
   Gottschalk A, 2007, J NEUROSURG, V106, P210, DOI 10.3171/jns.2007.106.2.210
   Greenberg S, 2018, WORLD NEUROSURG, V109, pE554, DOI 10.1016/j.wneu.2017.10.021
   Haldar R, 2015, BIOMED RES INT, DOI 10.1155/2015/509164
   Hassani Ebrahim, 2015, Adv Biomed Res, V4, P64, DOI 10.4103/2277-9175.152610
   Hoefnagel A, 2015, J ANESTH CLIN RES, V6, P2
   Jahr JS, 2013, AM J THER, V20, P189, DOI 10.1097/MJT.0b013e31828900cb
   Lutman B, 2018, CURR PAIN HEADACHE R, V22, DOI 10.1007/s11916-018-0722-4
   McNicol ED, 2011, BRIT J ANAESTH, V106, P764, DOI 10.1093/bja/aer107
   McNicol ED, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007126.pub3
   Memis D, 2010, J CRIT CARE, V25, P458, DOI 10.1016/j.jcrc.2009.12.012
   Mordhorst C, 2010, J NEUROSURG ANESTH, V22, P202, DOI 10.1097/ANA.0b013e3181df0600
   Prabhakar H, 2019, TXB NEUROANESTHESIA, P319
   Sivakumar W, 2019, J NEUROSURG, V130, P766, DOI 10.3171/2017.10.JNS171464
   Smyth MD, 2004, J NEUROSURG, V100, P183, DOI 10.3171/ped.2004.100.2.0183
   Verchere E, 2002, J NEUROSURG ANESTH, V14, P96, DOI 10.1097/00008506-200204000-00002
   Vijayan R, 2017, CHALLENGING TOPICS N, P139
   Xing F, 2019, BMC ANESTHESIOL, V19, DOI 10.1186/s12871-019-0722-x
NR 24
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 569
EP 576
DI 10.1016/j.wneu.2019.11.066
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200239
PM 31756498
DA 2020-05-12
ER

PT J
AU Kuwano, A
   Arai, K
   Aihara, Y
   Kawamata, T
AF Kuwano, Atsushi
   Arai, Koji
   Aihara, Yasuo
   Kawamata, Takakazu
TI A Case of Infratentorial Meningioma Causing Spontaneous Downbeat
   Nystagmus: Case Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Downbeat nystagmus; Infratentorial meningioma; Vermian compression
ID UPBEAT
AB BACKGROUND: Spontaneous downbeat nystagmus is a finding that raises suspicions of a central nervous system disorder. Vermis and lower brainstem lesions are considered to be responsible, but the exact mechanism is still controversial. We observed a rare case of spontaneous downbeat nystagmus caused by an infratentorial meningioma.
   CASE DESCRIPTION: A 50-year-old woman was incidentally diagnosed with infratentorial tumor. Later, she suffered from oscillopsia and the symptom disturbed her daily life especially while driving. Magnetic resonance imaging showed a tumor of approximately 30 mm in diameter at the dorsal midline of the posterior fossa. The tumor was compressing the cerebellar vermis and was apparently responsible for the symptoms that affected her daily life; therefore, we decided to perform tumor removal. The postoperative course was uneventful, and the spontaneous downbeat nystagmus completely disappeared.
   CONCLUSIONS: Vertical nystagmus is a finding that raises suspicion of a central nervous system disorder, and requires detailed examination. In addition, in case of vertical nystagmus because of tumor compression of the vermis, removal of the tumor can be an effective treatment.
C1 [Kuwano, Atsushi; Arai, Koji] Isesaki Sawa Med Assoc Hosp, Dept Neurosurg, Gunnma, Japan.
   [Kuwano, Atsushi; Arai, Koji; Aihara, Yasuo; Kawamata, Takakazu] Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan.
RP Kuwano, A (reprint author), Isesaki Sawa Med Assoc Hosp, Dept Neurosurg, Gunnma, Japan.; Kuwano, A (reprint author), Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan.
EM kuwano.atsushi@twmu.ac.jp
CR BALOH RW, 1981, NEUROLOGY, V31, P304, DOI 10.1212/WNL.31.3.304
   COGAN DG, 1954, AMA ARCH OPHTHALMOL, V52, P13
   COGAN DG, 1968, ARCH OPHTHALMOL-CHIC, V80, P757
   DIETERICH M, 1991, J NEUROL NEUROSUR PS, V54, P627, DOI 10.1136/jnnp.54.7.627
   Ichijo H, 1992, EQUILIBR RES, V51, P473
   Jorgensen JS, 2016, OPEN OPHTHALMOL J, V10, P126, DOI 10.2174/1874364101610010126
   Marti S, 2008, EXP BRAIN RES, V188, P613, DOI 10.1007/s00221-008-1396-7
   ROUSSEAUX M, 1991, J NEUROL NEUROSUR PS, V54, P367, DOI 10.1136/jnnp.54.4.367
   Tarnutzer AA, 2018, CURR OPIN NEUROL, V31, P74, DOI 10.1097/WCO.0000000000000517
   Wagner JN, 2008, J NEUROL NEUROSUR PS, V79, P672, DOI 10.1136/jnnp.2007.126284
   Yokota J-I, 2017, EQUILIBRIUM RES, V76, P17
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 577
EP 579
DI 10.1016/j.wneu.2019.11.140
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200240
PM 31790839
DA 2020-05-12
ER

PT J
AU Bender, MT
   Zarrin, DA
   Jiang, BW
   Campos, JK
   Lin, LM
   Young, RW
   Colby, GP
   Coon, AL
AF Bender, Matthew T.
   Zarrin, David A.
   Jiang, Bowen
   Campos, Jessica K.
   Lin, Li-Mei
   Young, Robert W.
   Colby, Geoffrey P.
   Coon, Alexander L.
TI Aspirin Monotherapy in Flow Diversion of Selected Internal Carotid
   Artery Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aspirin; Flow diversion; Pipeline embolization device;
   Single-antiplatelet therapy
ID PIPELINE EMBOLIZATION DEVICE; CEREBRAL ANEURYSMS
AB BACKGROUND: Dual antiplatelet therapy has been adopted as the standard of care for intracranial stenting, including flow diversion of cerebral aneurysms, to reduce the risk of acute and delayed ischemic complications.
   CASE DESCRIPTION: This is a report of 2 cases in which patients who underwent flow diversion of unruptured internal carotid artery aneurysms were treated with aspirin monotherapy. Neither patient tolerated dual antiplatelet therapy, one because of nosebleeds due to hereditary hemorrhagic telangiectasia and one because of an unnamed bleeding disorder. The lesions-a previously coiled, recanalizing dorsal internal carotid artery aneurysm and a small superior hypophyseal aneurysm-were each treated with a single Pipeline Flex embolization device and were completely occluded with normal-appearing parent vessel on 12-month follow-up digital subtraction angiography.
   CONCLUSIONS: This is the first report of patients electively treated with flow diversion using Pipeline Flex embolization device on aspirin monotherapy in the literature.
C1 [Bender, Matthew T.] Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA.
   [Zarrin, David A.; Jiang, Bowen; Campos, Jessica K.; Young, Robert W.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
   [Lin, Li-Mei] Univ Calif Irvine, Dept Neurosurg, Orange, CA 92668 USA.
   [Colby, Geoffrey P.] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA USA.
   [Coon, Alexander L.] Carondelet Neurol Inst, Dept Neurosurg, Tucson, AZ USA.
RP Bender, MT (reprint author), Univ Rochester, Med Ctr, Dept Neurosurg, Rochester, NY 14642 USA.
EM matthew_bender@urmc.rochester.edu
CR Adeeb N, 2017, STROKE, V48, P1322, DOI 10.1161/STROKEAHA.116.015308
   Bender MT, 2019, NEUROSURGERY, V84, P206, DOI 10.1093/neuros/nyy076
   Bender MT, 2019, NEUROSURGERY, V85, P543, DOI 10.1093/neuros/nyy395
   Bender MT, 2018, NEUROSURGERY, V83, P692, DOI 10.1093/neuros/nyx484
   Bender MT, 2017, J NEUROINTERV SURG, V9, P978, DOI 10.1136/neurintsurg-2016-012618
   Colby GP, 2017, J NEUROINTERV SURG, V9, P679, DOI 10.1136/neurintsurg-2016-012946
   Griessenauer CJ, 2017, NEUROSURGERY, V80, P579, DOI 10.1227/NEU.0000000000001377
   Hanel RA, 2017, BMJ CASE REP, V2017
   Jiang B, 2018, STROKE VASC NEUROL, V3, P169, DOI 10.1136/svn-2018-000150
   Levine GN, 2012, CATHETER CARDIO INTE, V79, P453, DOI 10.1002/ccd.23438
   Manning NW, 2019, J NEUROINTERV SURG, V11, P694, DOI 10.1136/neurintsurg-2018-014363
   Woodall MN, 2014, J NEUROSURG, V120, P87, DOI 10.3171/2013.10.JNS122402
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 580
EP 583
DI 10.1016/j.wneu.2019.06.161
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200241
PM 31254705
DA 2020-05-12
ER

PT J
AU Barrie, U
   Elguindy, M
   Pernik, M
   Adeyemo, E
   Aoun, SG
   Hall, K
   Reyes, VP
   El Ahmadieh, TY
   Bagley, CA
AF Barrie, Umaru
   Elguindy, Mahmoud
   Pernik, Mark
   Adeyemo, Emmanuel
   Aoun, Salah G.
   Hall, Kristen
   Reyes, Valery Peinado
   El Ahmadieh, Tarek Y.
   Bagley, Carlos A.
TI Intramedullary Spinal Metastatic Renal Cell Carcinoma: Systematic Review
   of Disease Presentation, Treatment, and Prognosis with Case Illustration
SO WORLD NEUROSURGERY
LA English
DT Review
DE Intramedullary metastasis; Intramedullary tumor; Renal carcinoma
   survival; Renal cell carcinoma; Spinal metastasis; Systematic review
ID CORD METASTASIS; 1ST MANIFESTATION; RADIOTHERAPY; DIAGNOSIS
AB OBJECTIVE: Renal cell carcinoma (RCC) metastases to the intramedullary spinal cord carry a grim prognosis. The purpose of this review is to provide the reader with a comprehensive and systematic review of the current literature, and to present an illustrative case that would aid in the future management of similar scenarios.
   METHODS: A systematic review of the literature using the PubMed electronic database was made according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Only human clinical reports of intramedullary RCC metastasis were included. We also present an illustrative case that was treated at our institution.
   RESULTS: We identified 23 reports with a total of 31 patients. Of the tumors, 47% were located at the cervical level. Brain metastases were present in 41% of cases. Limb weakness (72%), urinary incontinence (41%), dysesthesia (47%), and localized spinal pain (38%) were the most frequently reported symptoms. Surgical resection alone was used in 34% of cases, followed by a combination of surgery and radiotherapy (31%), and radiotherapy alone (25%). Spinal metastases were detected an average of 321 months after the diagnosis of RCC, and mean patient survival after that was 8 months (range, 0-65 months). Reported survival after radiotherapy appeared to be the longest (11.2 months) compared with surgery (9.1 months) and combination therapy (5 months).
   CONCLUSIONS: Intramedullary spinal metastatic RCC is a rare entity with debilitating neurologic potential. Survival appears to be affected by the treatment method but is also likely influenced by the stage of discovery of the disease.
C1 [Barrie, Umaru; Elguindy, Mahmoud; Pernik, Mark; Adeyemo, Emmanuel; Aoun, Salah G.; Hall, Kristen; Reyes, Valery Peinado; El Ahmadieh, Tarek Y.; Bagley, Carlos A.] Univ Texas Southwestern, Dept Neurol Surg, Dallas, TX 75390 USA.
RP Aoun, SG (reprint author), Univ Texas Southwestern, Dept Neurol Surg, Dallas, TX 75390 USA.
EM Salah.aoun@utsouthwestern.edu
OI Barrie, Umaru/0000-0002-0365-7070
CR Altinoz MA, 2005, J NEUROSURG-SPINE, V3, P495, DOI 10.3171/spi.2005.3.6.0495
   Asadi Mehrnaz, 2009, Cases J, V2, P7805, DOI 10.4076/1757-1626-2-7805
   Ateaque A, 2000, BRIT J NEUROSURG, V14, P474
   de la Riva AG, 2005, NEUROCIRUGIA, V16, P359
   De Meerleer G, 2014, LANCET ONCOL, V15, pE170, DOI 10.1016/S1470-2045(13)70569-2
   Donovan DJ, 2006, SPINE, V31, pE460, DOI 10.1097/01.brs.0000222022.67502.4e
   Fakih M, 2001, ANN ONCOL, V12, P1173, DOI 10.1023/A:1011693212682
   Gao J, 2014, TURK NEUROSURG, V24, P294, DOI 10.5137/1019-5149.JTN.7805-13.0
   Gaylor JB, 1938, J NEUROL PSYCHIATRY, V1, P301, DOI 10.1136/jnnp.1.4.301
   Hashii H, 2011, J RADIAT RES, V52, P641, DOI 10.1269/jrr.10187
   Hrabalek L, 2010, BIOMED PAP, V154, P117, DOI 10.5507/bp.2010.018
   Islam MR, 2016, BANGLADESH CRIT CARE, V4, P51
   Jayasundera MV, 1997, EUR J CANCER, V33, P508, DOI 10.1016/S0959-8049(97)89034-X
   Kalayci M, 2004, ACTA NEUROCHIR, V146, P1347, DOI 10.1007/s00701-004-0386-1
   KAWAKAMI Y, 1973, ACTA NEUROPATHOL, V26, P253, DOI 10.1007/BF00684435
   Kaya RA, 2003, NEUROL MED-CHIR, V43, P612, DOI 10.2176/nmc.43.612
   Komura S, 2011, EUR J ORTHOP SURG TR, V21, P597, DOI 10.1007/s00590-011-0764-3
   Malik MT, 2018, NEUROLOGY, V90, pE911, DOI 10.1212/WNL.0000000000005072
   Nomoto Yusuke, 2016, Rinsho Shinkeigaku, V56, P348, DOI 10.5692/clinicalneurol.cn-000850
   Parikh S, 2009, CLIN NEUROL NEUROSUR, V111, P858, DOI 10.1016/j.clineuro.2009.06.008
   Park J, 2013, J KOREAN MED SCI, V28, P1253, DOI 10.3346/jkms.2013.28.8.1253
   Payer S, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.5.FOCUS15149
   Poggi MM, 2001, CLIN NUCL MED, V26, P837, DOI 10.1097/00003072-200110000-00006
   Saeed Hayder, 2017, Hematol Oncol Stem Cell Ther, V10, P143, DOI 10.1016/j.hemonc.2017.07.003
   Schiff D, 1996, NEUROLOGY, V47, P906, DOI 10.1212/WNL.47.4.906
   Schijns OEMG, 2000, CLIN NEUROL NEUROSUR, V102, P249, DOI 10.1016/S0303-8467(00)00106-2
   Soga H, 2016, WORLD J CLIN UROL, V5, P72
   Strickland BA, 2018, J NEUROSURG-SPINE, V28, P79, DOI 10.3171/2017.5.SPINE161161
   Tsai Tai-Hsin, 2016, Spinal Cord Ser Cases, V2, P15026, DOI 10.1038/scsandc.2015.26
   WEITZNER S, 1969, NEUROLOGY, V19, P674, DOI 10.1212/WNL.19.7.674
   Weng YX, 2018, BIOMED RES INT, DOI 10.1155/2018/7485020
   Zakaria Z, 2012, BMJ CASE REP, V2012
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 584
EP 593
DI 10.1016/j.wneu.2019.11.056
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200242
PM 31734421
DA 2020-05-12
ER

PT J
AU Zeng, X
   Zhan, Q
   Gao, Y
   Cui, NH
   Dong, MH
   Feng, LQ
   Chu, LZ
   Liu, J
AF Zeng, Xi
   Zhan, Qi
   Gao, Yuan
   Cui, Naihao
   Dong, Minghao
   Feng, Luqian
   Chu, Liangzhao
   Liu, Jian
TI The Coexistence of Gliosarcoma and Arteriovenous Malformation with the
   BRAF V600E Mutation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous malformation; BRAF V600E; Gliosarcoma
ID MIMICKING; PITFALLS
AB BACKGROUND: The authors report a case of a woman aged 33 years who suffered from the combination of primary gliosarcoma and arteriovenous malformation as the first clinical presentation of intracranial hemorrhage.
   CASE DESCRIPTION: Subsequently, gene examination rarely finds BRAF V600E mutation in the surgical specimen. The lesion was not completely identified with magnetic resonance imaging and digital subtraction angiography.
   CONCLUSIONS: This case illustrates the occult and unusual feature of gliosarcoma. The pathogenesis of such coexistence might be related to underlying genetic alterations.
C1 [Zeng, Xi; Zhan, Qi; Gao, Yuan; Cui, Naihao; Liu, Jian] Guizhou Med Univ, Guiyang, Guizhou, Peoples R China.
   [Dong, Minghao; Feng, Luqian; Chu, Liangzhao] Guizhou Med Univ, Dept Neurosurg, Affiliated Hosp, Guiyang, Guizhou, Peoples R China.
RP Liu, J (reprint author), Guizhou Med Univ, Guiyang, Guizhou, Peoples R China.
EM luzicaipseudonym@outlook.com
FU Program for Changjiang Scholars and Innovative Research Team in
   UniversityProgram for Changjiang Scholars & Innovative Research Team in
   University (PCSIRT) [IRT13058]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [81560409]; Program
   for Provincial Science and Technology [LH-2016-7236]
FX This work was supported in part by the Program for Changjiang Scholars
   and Innovative Research Team in University (IRT13058), National Natural
   Science Foundation of China (81560409), and the Program for Provincial
   Science and Technology (LH-2016-7236).
CR Alexandrescu S, 2016, BRAIN PATHOL, V26, P215, DOI 10.1111/bpa.12295
   Cachia D, 2015, J NEURO-ONCOL, V125, P401, DOI 10.1007/s11060-015-1930-y
   Castelli J, 2016, J NEURO-ONCOL, V129, P85, DOI 10.1007/s11060-016-2142-9
   Cho SY, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.9
   Gmeiner M, 2013, CLIN NEUROL NEUROSUR, V115, P501, DOI 10.1016/j.clineuro.2012.12.009
   Handong W, 2018, CHIN J CLIN NEUROSUR, V23, P69
   Jain A, 2017, WORLD NEUROSURG, V106, P30, DOI [10.1016/j.WNEU.2017.06.073, 10.1016/j.wneu.2017.06.073]
   Khanna R, 2019, INTERDISCIP NEUROSUR, V16, P3, DOI 10.1016/j.inat.2018.10.014
   Le Guennec L, 2015, J NEUROIMAGING, V25, P1053, DOI 10.1111/jon.12220
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Mano Y, 2014, CHILD NERV SYST, V30, P1753, DOI 10.1007/s00381-014-2465-9
   Naganska E, 2013, FOLIA NEUROPATHOL, V51, P269, DOI 10.5114/fn.2013.37712
   Oh JE, 2016, BRAIN PATHOL, V26, P517, DOI 10.1111/bpa.12328
   Schindler G, 2014, J CLIN NEUROSCI, V21, P1945, DOI 10.1016/j.jocn.2014.03.034
   Shelly D, 2016, NEUROL INDIA, V64, P115, DOI 10.4103/0028-3886.173668
   Smith DR, 2018, J NEURO-ONCOL, V137, P303, DOI 10.1007/s11060-017-2718-z
   Wang LM, 2017, J CLIN PATHOL, V70, P1079, DOI 10.1136/jclinpath-2017-204620
   XiangWen L, 2013, CHIN J PRACT NERV DI, V16, P32
   Yamamoto J, 2014, BRAIN TUMOR PATHOL, V31, P215, DOI 10.1007/s10014-013-0171-z
   Zhenping C, 2019, J PRACT ONCOL, V34, P11
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 594
EP 597
DI 10.1016/j.wneu.2019.11.079
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200243
PM 31759151
DA 2020-05-12
ER

PT J
AU Wahood, W
   Yolcu, YU
   Kerezoudis, P
   Goyal, A
   Alvi, MA
   Freedman, BA
   Bydon, M
AF Wahood, Waseem
   Yolcu, Yagiz Ugur
   Kerezoudis, Panagiotis
   Goyal, Anshit
   Alvi, Mohammed Ali
   Freedman, Brett A.
   Bydon, Mohamad
TI Artificial Discs in Cervical Disc Replacement: A Meta-Analysis for
   Comparison of Long-Term Outcomes
SO WORLD NEUROSURGERY
LA English
DT Review
DE ASD; Bryan; CDR; Discover; Heterotopic ossification; Mobi-C;
   Prestige-LP; ProDisc-C; Reoperation
ID ADJACENT-SEGMENT DEGENERATION; HETEROTOPIC OSSIFICATION; SINGLE-LEVEL;
   FOLLOW-UP; CLINICAL-OUTCOMES; RADIOGRAPHIC OUTCOMES; RADIOLOGICAL
   ANALYSIS; MOBI-C; ARTHROPLASTY; FUSION
AB BACKGROUND: Cervical disc replacement (CDR) has emerged as an alternative to anterior cervical discectomy and fusion for the surgical treatment of degenerative cervical disc disease. Although comparison of the 2 techniques has been studied in the literature, a thorough assessment of all artificial discs between each has not been performed. The objective of the present study was to examine the long-term outcomes of 5 artificial discs.
   METHODS: An electronic literature search was conducted for studies of CDR devices for all years available. Only articles in English were included. Heterotopic ossification, adjacent segment disease, and reoperation comprised the primary outcomes of interest. Pooled descriptive statistics with effect size (ES) and 95% confidence interval were used to synthesize the outcomes for each device.
   RESULTS: Sixty-five studies (n = 5785) were included in the analysis. Comparison of the incidence of grade III/IV heterotopic ossification showed a significant variability between the 5 devices (P < 0.001) with ProDisc-C (ES, 38%; 95% confidence interval [CI], 24%-54%) having the highest incidence rate. Overall rate of adjacent segment disease was 14% (95% CI, 7%-23%) with significant associated heterogeneity (P < 0.001). Regarding 2-year reoperation risk, the overall incidence rate was 2% (95% CI, 1%-3%), with nonsignificant variability between devices (P = 0.63). The highest rate was observed in the Discover group (ES, 4%; 95% CI, 0%-13%).
   CONCLUSIONS: The results of the present meta-analysis indicate that surgical and clinical outcomes may differ among different CDR devices. These findings may assist surgeons in tailoring their decision making to specific patient profiles. Future multicenter efforts are needed to validate associations found in this study.
C1 [Wahood, Waseem; Yolcu, Yagiz Ugur; Kerezoudis, Panagiotis; Goyal, Anshit; Alvi, Mohammed Ali; Bydon, Mohamad] Mayo Clin, Neuroinformat Lab, Rochester, MN 55905 USA.
   [Wahood, Waseem; Yolcu, Yagiz Ugur; Kerezoudis, Panagiotis; Goyal, Anshit; Alvi, Mohammed Ali; Bydon, Mohamad] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Freedman, Brett A.] Mayo Clin, Dept Orthoped Surg, Rochester, MN USA.
RP Bydon, M (reprint author), Mayo Clin, Neuroinformat Lab, Rochester, MN 55905 USA.; Bydon, M (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
EM bydon.mohamad@mayo.edu
CR Anderson PA, 2003, SPINE, V28, pS186, DOI 10.1097/01.BRS.0000092212.42388.79
   Anderson PA, 2008, SPINE, V33, P1305, DOI 10.1097/BRS.0b013e31817329a1
   Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
   Bae HW, 2015, SPINE, V40, P759, DOI 10.1097/BRS.0000000000000887
   Beaurain J, 2009, EUR SPINE J, V18, P841, DOI 10.1007/s00586-009-1017-6
   Bland JM, 1998, BRIT MED J, V316, P129
   Burkus JK, 2014, J NEUROSURG-SPINE, V21, P516, DOI 10.3171/2014.6.SPINE13996
   Burkus JK, 2010, J NEUROSURG-SPINE, V13, P308, DOI 10.3171/2010.3.SPINE09513
   Cao JM, 2011, J CLIN NEUROSCI, V18, P1308, DOI 10.1016/j.jocn.2011.01.034
   Chang HK, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2016.10.FOCUS16411
   Chen F, 2013, ARCH ORTHOP TRAUM SU, V133, P473, DOI 10.1007/s00402-013-1689-6
   Chen Y, 2013, ORTHOPEDICS, V36, pE958, DOI 10.3928/01477447-20130624-29
   Cheng L, 2009, INT ORTHOP, V33, P1347, DOI 10.1007/s00264-008-0655-3
   Chin KR, 2017, SPINE, V42, pE567, DOI 10.1097/BRS.0000000000001936
   Chung SB, 2012, ACTA NEUROCHIR, V154, P1017, DOI 10.1007/s00701-012-1309-1
   Deeks J J, 2003, Health Technol Assess, V7, piii
   Delamarter RB, 2013, SPINE, V38, P711, DOI 10.1097/BRS.0b013e3182797592
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Donk RD, 2018, CLIN SPINE SURG, V31, pE50, DOI 10.1097/BSD.0000000000000551
   Donk RD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183603
   Du JJ, 2011, SPINE J, V11, P281, DOI 10.1016/j.spinee.2011.01.037
   Duggal Neil, 2004, Neurosurg Focus, V17, pE9
   Fay LY, 2014, EUR SPINE J, V23, P627, DOI 10.1007/s00586-013-3123-8
   FREEMAN MF, 1950, ANN MATH STAT, V21, P607, DOI 10.1214/aoms/1177729756
   Gao FQ, 2015, SPINE, V40, P1816, DOI 10.1097/BRS.0000000000001138
   Gao XL, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009671
   Goffin J, 2010, J NEUROSURG-SPINE, V12, P261, DOI 10.3171/2009.9.SPINE09129
   Gornet MF, 2017, J NEUROSURG-SPINE, V26, P653, DOI 10.3171/2016.10.SPINE16264
   Gornet MF, 2017, SPINE, V42, P366, DOI 10.1097/BRS.0000000000001745
   Gornet MF, 2015, J NEUROSURG-SPINE, V23, P558, DOI 10.3171/2015.1.SPINE14589
   Guerin P, 2012, J SPINAL DISORD TECH, V25, P10, DOI 10.1097/BSD.0b013e31820f916c
   Guyer RD, 2003, SPINE, V28, pS15, DOI 10.1097/00007632-200308011-00004
   Hacker RJ, 2006, J NEUROSURG-SPINE, V4, P189, DOI 10.3171/spi.2006.4.2.189
   Heidecke V, 2008, ACTA NEUROCHIR, V150, P453, DOI 10.1007/s00701-008-1552-7
   Heller JG, 2009, SPINE, V34, P101, DOI 10.1097/BRS.0b013e31818ee263
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hisey MS, 2016, INT J SPINE SURG, V10, DOI 10.14444/3010
   Hisey MS, 2014, INT J SPINE SURG, V8, DOI 10.14444/1007
   Hisey MS, 2015, J SPINAL DISORD TECH, V28, pE237, DOI 10.1097/BSD.0000000000000185
   Hou Y, 2016, BONE JOINT J, V98B, P829, DOI 10.1302/0301-620X.98B6.36381
   Huppert J, 2011, EUR SPINE J, V20, P1417, DOI 10.1007/s00586-011-1722-9
   Kelly MP, 2015, J NEUROSURG-SPINE, V23, P484, DOI 10.3171/2015.1.SPINE14985
   Kerezoudis P, 2018, OPER NEUROSURG, V15, pE40, DOI 10.1093/ons/opy181
   Kettler A, 2006, EUR SPINE J, V15, P705, DOI 10.1007/s00586-005-0954-y
   Kim KS, 2016, CLIN SPINE SURG, V29, pE309, DOI 10.1097/BSD.0000000000000054
   Kim SH, 2015, EUR SPINE J, V24, P2872, DOI 10.1007/s00586-015-3849-6
   Kuang L, 2016, CLIN SPINE SURG, V29, P372
   Lei T, 2016, INT ORTHOP, V40, P1197, DOI 10.1007/s00264-015-3098-7
   Leung C, 2005, NEUROSURGERY, V57, P759, DOI 10.1227/01.NEU.0000175856.31210.58
   Li J, 2013, EUR SPINE J, V22, P2303, DOI 10.1007/s00586-013-2897-z
   Liu JJ, 2016, GLOB SPINE J, V6, P563, DOI 10.1055/s-0035-1570086
   Liu SC, 2016, J CLIN NEUROSCI, V27, P102, DOI 10.1016/j.jocn.2015.05.072
   Malham GM, 2014, J CLIN NEUROSCI, V21, P949, DOI 10.1016/j.jocn.2013.09.013
   McAfee PC, 2003, J SPINAL DISORD TECH, V16, P384, DOI 10.1097/00024720-200308000-00010
   Mehren C, 2006, SPINE, V31, P2802, DOI 10.1097/01.brs.0000245852.70594.d5
   Miao JH, 2018, CLIN SPINE SURG, V31, pE204, DOI 10.1097/BSD.0000000000000604
   Miyazaki M, 2008, J SPINAL DISORD TECH, V21, P288, DOI 10.1097/BSD.0b013e31813c0e59
   Mostofi Keyvan, 2016, Eur J Orthop Surg Traumatol, V26, P805, DOI 10.1007/s00590-016-1801-z
   Munigangaiah S, 2014, J ORTHOP SURG-HONG K, V22, P364, DOI 10.1177/230949901402200320
   Nunley PD, 2018, NEUROSURGERY, V83, P1087, DOI 10.1093/neuros/nyx579
   Park JY, 2013, EUR SPINE J, V22, P1078, DOI 10.1007/s00586-012-2613-4
   Park JH, 2008, J KOREAN NEUROSURG S, V44, P217, DOI 10.3340/jkns.2008.44.4.217
   Pointillart V, 2018, INT ORTHOP, V42, P851, DOI 10.1007/s00264-017-3745-2
   ROBINSON RA, 1955, B JOHNS HOPKINS HOSP, V96, P223
   Rozankovic M, 2017, CLIN SPINE SURG, V30, pE515, DOI 10.1097/BSD.0000000000000170
   Sasso RC, 2011, ORTHOPEDICS, V34, P889, DOI [10.3928/01477447-20110922-24, 10.3928/01477447-20101221-17]
   Sasso RC, 2007, SPINE, V32, P2933, DOI 10.1097/BRS.0b013e31815d0034
   Sasso RC, 2007, J SPINAL DISORD TECH, V20, P481, DOI 10.1097/BSD.0b013e3180310534
   Sasso WR, 2016, SPINE, V21, P21
   Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.i4086, 10.1136/bmj.g7647]
   Shang ZK, 2017, MED SCI MONITOR, V23, P5254, DOI 10.12659/MSM.904863
   Shi S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159761
   Skeppholm M, 2015, SPINE J, V15, P1284, DOI 10.1016/j.spinee.2015.02.039
   Staudt MD, 2018, NEUROSURG REV, V41, P399, DOI 10.1007/s10143-016-0765-0
   Suk KS, 2015, J SPINAL DISORD TECH, V28, pE449, DOI 10.1097/BSD.0000000000000256
   Sundseth J, 2017, EUR SPINE J, V26, P1225, DOI 10.1007/s00586-016-4922-5
   Tu TH, 2012, J NEUROSURG-SPINE, V16, P601, DOI 10.3171/2012.3.SPINE11436
   Tu TH, 2011, J NEUROSURG-SPINE, V14, P457, DOI 10.3171/2010.11.SPINE10444
   Turel MK, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2016.11.FOCUS16414
   Walraevens J, 2010, NEUROSURGERY, V67, P679, DOI 10.1227/01.NEU.0000377039.89725.F3
   Wilson EB, 1927, J AM STAT ASSOC, V22, P209, DOI 10.2307/2276774
   Yan SZ, 2017, MED SCI MONITOR, V23, P2692, DOI 10.12659/MSM.905178
   Yang SD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16670-1
   Yang YC, 2009, INT ORTHOP, V33, P1037, DOI 10.1007/s00264-008-0571-6
   Yi S, 2010, SPINE, V35, P1556, DOI 10.1097/BRS.0b013e3181c6526b
   Yi S, 2009, SURG NEUROL, V72, P325, DOI 10.1016/j.surneu.2009.02.013
   Zhang HX, 2014, INT ORTHOP, V38, P2533, DOI 10.1007/s00264-014-2497-5
   Zhang HX, 2014, ORTHOPEDICS, V37, P771, DOI 10.3928/01477447-20141023-50
   Zhang XS, 2012, SPINE, V37, P433, DOI 10.1097/BRS.0b013e31822699fa
   Zhang Zhenxiang, 2014, Eur J Orthop Surg Traumatol, V24 Suppl 1, pS275, DOI 10.1007/s00590-014-1424-1
   Zhang ZX, 2013, ARCH ORTHOP TRAUM SU, V133, P1061, DOI 10.1007/s00402-013-1772-z
   Zheng BL, 2017, BMC SURG, V17, DOI 10.1186/s12893-017-0316-9
NR 92
TC 0
Z9 0
U1 5
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 598
EP +
DI 10.1016/j.wneu.2019.10.032
PG 21
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200244
PM 31627001
DA 2020-05-12
ER

PT J
AU Westman, M
   Takala, R
   Rahi, M
   Ikonen, TS
AF Westman, Marjut
   Takala, Riikka
   Rahi, Melissa
   Ikonen, Tuija S.
TI The Need for Surgical Safety Checklists in Neurosurgery Now and in the
   Future-A Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Neurosurgery; Patient safety; Surgical checklist; Systematic review
ID STANDARDIZED PROTOCOL; ADVERSE EVENTS; IMPLEMENTATION; INFECTION;
   COMMUNICATION; COMPLICATIONS; METAANALYSIS; EXPERIENCE; REDUCTION;
   MORBIDITY
AB Safety checklists have been studied among various surgical patient groups, but evidence of their benefits in neurosurgery remains sparse. Since the implementation of the World Health Organization's Surgical Safety Checklist, their use has become widespread. The aim of this review was to systematically review the state of the literature on surgical safety checklists in neurosurgery. Also, in the new era of robotics and artificial intelligence, there is a need to re-evaluate patient safety procedures in neurosurgery. A systematic review was conducted on PubMed, Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials, Embase, and MEDLINE for articles published between 2008 and 2016 using MeSH (medical subject heading) terms and keywords describing postoperative complications and surgical adverse events, and some additional searches were carried out until January 2019. Twenty-six original studies or reviews were eligible for this review. They were categorized into studies with patient-related outcomes, personnel-related outcomes, or previous reviews. Checklist use in neurosurgery was found to reduce hospital-acquired infectious complications and to enhance operating room safety culture. Checklists seem to improve patient safety in neurosurgery, although the amount of evidence is still limited. Despite their shortcomings, checklists are here to stay, and new research is required to update checklists to meet the requirements of the transforming working environment of the neurosurgery operating room.
C1 [Westman, Marjut] Univ Turku, Fac Med, Turku, Finland.
   [Ikonen, Tuija S.] Univ Turku, Fac Med, Publ Hlth, Turku, Finland.
   [Takala, Riikka] Turku Univ Hosp, Perioperat Serv, Intens Care Med & Pain Management, Turku, Finland.
   [Rahi, Melissa] Turku Univ Hosp, Dept Neurosurg, Div Clin Neurosci, Turku, Finland.
RP Westman, M (reprint author), Univ Turku, Fac Med, Turku, Finland.
EM marjut.westman@gmail.com
OI Takala, Riikka/0000-0001-6342-0043
CR Belykh E, 2019, WORLD NEUROSURG, V123, P390, DOI 10.1016/j.wneu.2018.11.135
   Bergs J, 2014, BRIT J SURG, V101, P150, DOI 10.1002/bjs.9381
   Borchard A, 2012, ANN SURG, V256, P925, DOI 10.1097/SLA.0b013e3182682f27
   Crawford R, 2017, SURG HAVE ADMITTED R
   de Jager E, 2016, WORLD J SURG, V40, P1842, DOI 10.1007/s00268-016-3519-9
   de Vries EN, 2010, NEW ENGL J MED, V363, P1928, DOI 10.1056/NEJMsa0911535
   Fargen KM, 2013, J NEUROINTERV SURG, V5, P497, DOI 10.1136/neurintsurg-2012-010430
   Flint AC, 2013, NEUROSURGERY, V72, P993, DOI 10.1227/NEU.0b013e31828e8dfd
   Fourcade A, 2012, BMJ QUAL SAF, V21, P191, DOI 10.1136/bmjqs-2011-000094
   Harrop JS, 2010, NEUROSURGERY, V67, P187, DOI 10.1227/01.NEU.0000370247.11479.B6
   Haugen AS, 2015, ANN SURG, V261, P821, DOI 10.1097/SLA.0000000000000716
   Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119
   Hommelstad J, 2013, ACTA NEUROCHIR, V155, P523, DOI 10.1007/s00701-012-1574-z
   Kable AK, 2002, INT J QUAL HEALTH C, V14, P269, DOI 10.1093/intqhc/14.4.269
   Ko HCH, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-211
   Kubilay Z, 2013, J NEUROSURG, V118, P514, DOI 10.3171/2012.11.JNS121336
   Lee RP, 2018, NEUROSURGERY, V83, P508, DOI 10.1093/neuros/nyx478
   Lepanluoma M, 2014, SCAND J SURG, V103, P66, DOI 10.1177/1457496913482255
   Lepanluoma M, 2015, J NEUROSURG, V123, P145, DOI 10.3171/2014.12.JNS141077
   Lyons MK, 2010, AM J MED QUAL, V25, P285, DOI 10.1177/1062860610363305
   Lyons VE, 2014, WESTERN J NURS RES, V36, P245, DOI 10.1177/0193945913505782
   Magill ST, 2017, WORLD NEUROSURG, V107, P597, DOI 10.1016/j.wneu.2017.08.090
   McLaughlin N, 2014, WORLD NEUROSURG, V82, P567, DOI 10.1016/j.wneu.2013.07.074
   O'Leary JD, 2016, CAN MED ASSOC J, V188, pE191, DOI 10.1503/cmaj.151333
   Oszvald A, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.8.FOCUS12261
   Patel J, 2014, INT J SURG, V12, P1317, DOI 10.1016/j.ijsu.2014.10.031
   Rahman M, 2012, JT COMM J QUAL PATIE, V38, P459, DOI 10.1016/S1553-7250(12)38061-6
   Russ S, 2013, ANN SURG, V258, P856, DOI 10.1097/SLA.0000000000000206
   Russ SJ, 2015, ANN SURG, V261, P81, DOI 10.1097/SLA.0000000000000793
   Ryan SL, 2014, J NEUROSURG-PEDIATR, V14, P259, DOI 10.3171/2014.5.PEDS1448
   Santana HT, 2016, J INFECT PUBLIC HEAL, V9, P586, DOI 10.1016/j.jiph.2015.12.019
   Schwab Klaus, 2017, 4 IND REVOLUTION
   Sewell M, 2011, INT ORTHOP, V35, P897, DOI 10.1007/s00264-010-1112-7
   Tang R, 2014, ANZ J SURG, V84, P148, DOI 10.1111/ans.12168
   Thimbleby H, 2013, J PUBLIC HEALTH RES, V2, P160, DOI 10.4081/jphr.2013.e28
   Thomassen O, 2014, ACTA ANAESTH SCAND, V58, P5, DOI 10.1111/aas.12207
   Treadwell JR, 2014, BMJ QUAL SAF, V23, P299, DOI 10.1136/bmjqs-2012-001797
   Vats A, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5433
   Westman M, 2018, J CLIN NEUROSCI, V53, P188, DOI 10.1016/j.jocn.2018.04.076
   Wong JM, 2016, WORLD NEUROSURG, V92, P491, DOI 10.1016/j.wneu.2016.06.064
   Zuckerman SL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12257
NR 41
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 614
EP +
DI 10.1016/j.wneu.2019.09.140
PG 18
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200245
PM 31589982
DA 2020-05-12
ER

PT J
AU Chen, PA
   Chen, YC
   Wei, KC
   Chen, KT
AF Chen, Po-An
   Chen, Yi-Chun
   Wei, Kuo-Chen
   Chen, Ko-Ting
TI Awake Craniotomy for a Left Pan-Hippocampal Diffuse Low-Grade Glioma in
   a Deaf and Mute Patient Using Sign Language
SO WORLD NEUROSURGERY
LA English
DT Article
DE Awake craniotomy; Functional magnetic resonance imaging; Hippocampal
   glioma; Sign language; Transcortical approach
ID SUPRACEREBELLAR-TRANSTENTORIAL APPROACH; SURGICAL TECHNIQUE; RESECTION;
   SURGERY; TUMORS; AREAS
AB BACKGROUND: Awake craniotomy is becoming an essential technique, especially for intrinsic brain tumors which have no clear margins and where extent of resection (EOR) matters. However, intraoperative monitoring for awaken patients requires voice feedback in regular settings. Resection of hippocampal glioma is challenging because of its deep-seated location, its extension in an anterior-posterior axis, and being covered with eloquent cortex. We present a native deaf and mute patient, who has been diagnosed of a left pan-hippocampal glioma, who underwent an awake craniotomy using sign language during intraoperative monitoring.
   CASE DESCRIPTION: The patient was a 58-year-old, right-handed, native deaf and mute woman who was diagnosed with a left pan-hippocampal glioma. Magnetic resonance imaging (MRI) revealed an intrinsic, nonenhanced, expansile lesion involving the pan-hippocampus. Functional MRI preferred a right hemisphere-dominant pattern. Neuropsychologic testing was normal. An awake craniotomy was successfully performed using sign language to preserve her remaining sole method of communication. A standard sleep-awake-sleep protocol with a transmiddle temporal gyrus (2.5 x 1 cm gyrectomy) approach was performed after a negative mapping result. More than 90% EOR was achieved with only a 0.7 cm(3) residual tumor at the hippocampal tail. The pathology was anaplastic ganglioglioma, Ki-67 70%, and World Health Organization grade III. Her postoperative neuropsychologic status was the same as preoperative condition.
   CONCLUSIONS: We demonstrated using sign language for intraoperative monitoring is feasible in a native deaf and mute patient. We also showed a navigation-assisted minimal transcortical approach to achieve >90% EOR for a pan-hippocampal glioma in a single-stage operation.
C1 [Chen, Po-An; Wei, Kuo-Chen; Chen, Ko-Ting] Chang Gung Mem Hosp Linkou, Dept Neurosurg, Taoyuan, Taiwan.
   [Chen, Yi-Chun] Chang Gung Mem Hosp Linkou, Dept Neurol, Taoyuan, Taiwan.
   [Chen, Ko-Ting] Chang Gung Univ, PhD Program Biomed Engn, Taoyuan, Taiwan.
RP Chen, KT (reprint author), Chang Gung Mem Hosp Linkou, Dept Neurosurg, Taoyuan, Taiwan.; Chen, KT (reprint author), Chang Gung Univ, PhD Program Biomed Engn, Taoyuan, Taiwan.
EM chenkoting@gmail.com
OI Chen, Ko-Ting/0000-0002-6795-5974
CR Black DF, 2017, AM J NEURORADIOL, V38, pE65, DOI 10.3174/ajnr.A5345
   Chaddad-Neto F, 2019, OPER NEUROSURG, V16, pE83, DOI 10.1093/ons/opy294
   Chang WH, 2018, J NEURO-ONCOL, V139, P215, DOI 10.1007/s11060-018-2863-z
   Duffau H, 2018, NEUROSURG REV, V41, P689, DOI 10.1007/s10143-017-0937-6
   Duffau H, 2018, NEUROSURG REV, V41, P133, DOI 10.1007/s10143-017-0918-9
   Fernandez-Miranda JC, 2018, OPER NEUROSURG, V15, pE79, DOI 10.1093/ons/opy106
   Hamer PCD, 2012, J CLIN ONCOL, V30, P2559, DOI 10.1200/JCO.2011.38.4818
   Hanalioglu S, 2017, SURG GIANT UNUSUAL T
   Hervey-Jumper SL, 2015, J NEUROSURG, V123, P325, DOI 10.3171/2014.10.JNS141520
   Iijima K, 2017, ACTA NEUROCHIR, V159, P177, DOI 10.1007/s00701-016-3035-6
   Izci Y, 2009, SURG NEUROL, V72, P509, DOI 10.1016/j.surneu.2009.01.025
   Ma RC, 2018, WORLD NEUROSURG, V117, pE238, DOI 10.1016/j.wneu.2018.06.006
   Martino J, 2017, WORLD NEUROSURG, V105, DOI 10.1016/j.wneu.2017.05.170
   Metellus P, 2017, WORLD NEUROSURG, V98, DOI 10.1016/j.wneu.2016.08.098
   Que MC, 2018, NEURAL PLAST, V2018, DOI 10.1155/2018/9456891
   Rabinowitch Ithai, 2016, Commun Integr Biol, V9, pe1158378, DOI 10.1080/19420889.2016.1158378
   Reisch R, 2009, MINIM INVAS NEUROSUR, V52, P163, DOI 10.1055/s-0029-1238285
   Roux FE, 2003, NEUROSURGERY, V53, P1342, DOI 10.1227/01.NEU.0000093424.71086.8F
   Roux FE, 2003, NEUROSURGERY, V52, P1335, DOI 10.1227/01.NEU.0000064803.05077.40
   Russell SM, 2002, NEUROSURGERY, V50, P978, DOI 10.1097/00006123-200205000-00010
   Sanai N, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.12.FOCUS09266
   Schramm J, 2008, ACTA NEUROCHIR, V150, P857, DOI 10.1007/s00701-008-0013-7
   SMITH KA, 1995, J NEUROSURG, V82, P940, DOI 10.3171/jns.1995.82.6.0940
   Trumpp NM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198894
   Ture U, 2012, J NEUROSURG, V116, P773, DOI 10.3171/2011.12.JNS11791
   Uchiyama N, 2001, NEUROSURGERY, V49, P1470, DOI 10.1097/00006123-200112000-00036
   Uribe JS, 2009, J NEUROSURG, V110, P137, DOI 10.3171/2008.4.17508
   Wang YC, 2019, J NEURO-ONCOL, V142, P577, DOI 10.1007/s11060-019-03131-0
   YASARGIL MG, 1992, ACTA NEUROCHIR, V116, P147, DOI 10.1007/BF01540867
   Yonekawa Y, 2001, J NEUROSURG, V94, P339, DOI 10.3171/jns.2001.94.2.0339
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 629
EP +
DI 10.1016/j.wneu.2019.11.129
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200246
PM 31790835
DA 2020-05-12
ER

PT J
AU Inukai, M
   Shibahara, I
   Hotta, M
   Miyasaka, K
   Sato, S
   Hide, T
   Saegusa, M
   Kumabe, T
AF Inukai, Madoka
   Shibahara, Ichiyo
   Hotta, Masatoshi
   Miyasaka, Kazuhiro
   Sato, Sumito
   Hide, Takuichiro
   Saegusa, Makoto
   Kumabe, Toshihiro
TI Case of Calcifying Pseudoneoplasms of the Neuraxis Coexisting with
   Interhemispheric Lipoma and Agenesis of the Corpus Callosum: Involvement
   of Infiltrating Macrophages
SO WORLD NEUROSURGERY
LA English
DT Article
DE Agenesis of corpus callosum; Calcifying pseudoneoplasms of the neuraxis;
   Lipoma; Macrophage; Methionine positron emission tomography
ID PSEUDOTUMOR; COLLISION; TUMOR; AXIS
AB BACKGROUND: Calcifying pseudoneoplasm of the neuraxis (CAPNON) is a rare clinical entity. We report an unusual case of intraparenchymal bifrontal CAPNON coexisting with interhemispheric lipoma and agenesis of the corpus callosum.
   CASE DESCRIPTION: A 64-year-old woman presented with slight weakness of her left leg. Computed tomography and magnetic resonance imaging showed massive nodular intraparenchymal calcifications at both sides of the interhemispheric lipoma associated with partial agenesis of the corpus callosum. Enhancement was observed at the periphery and within the calcification. Massive perifocal edema was also demonstrated. The enhanced lesion with calcification was partially resected. Histologic analysis of the resected specimen disclosed nodular calcification with fibro-osseous components and histiocytic reaction, consistent with CAPNON. A high ratio of M2 macrophages was observed among the infiltrating macrophages. C-11-methionine positron emission tomography demonstrated high uptake of the tracer at the lesion corresponding to the calcified lesion on computed tomography. Postoperatively, massive perifocal edema was decreased and maintained without progression for a year.
   CONCLUSIONS: The high M2 macrophage activity verified by histopathologic analysis suggests that CAPNON is not a silent but a more active, tumefactive disease involving the immune response. This hypothesis may be supported by the high uptake of C-11-methionine positron emission tomography.
C1 [Inukai, Madoka; Saegusa, Makoto] Kitasato Univ, Dept Pathol, Sch Med, Sagamihara, Kanagawa, Japan.
   [Shibahara, Ichiyo; Miyasaka, Kazuhiro; Sato, Sumito; Hide, Takuichiro; Kumabe, Toshihiro] Kitasato Univ, Dept Neurosurg, Sch Med, Sagamihara, Kanagawa, Japan.
   [Hotta, Masatoshi] Natl Ctr Global Hlth & Med, Dept Radiol, Tokyo, Japan.
RP Shibahara, I (reprint author), Kitasato Univ, Dept Neurosurg, Sch Med, Sagamihara, Kanagawa, Japan.
EM shibahar@med.kitasato-u.ac.jp
CR Abdaljaleel M, 2017, NEUROPATHOLOGY, V37, P233, DOI 10.1111/neup.12349
   Aiken AH, 2009, AM J NEURORADIOL, V30, P1256, DOI 10.3174/ajnr.A1505
   Barber SM, 2018, WORLD NEUROSURG, V115, P309, DOI 10.1016/j.wneu.2018.04.175
   BERTONI F, 1990, J NEUROSURG, V72, P42, DOI 10.3171/jns.1990.72.1.0042
   Brasiliense LB, 2017, CUREUS, V9, DOI 10.7759/cureus.1044
   Delgado AF, 2018, BRIT J RADIOL, V91, DOI 10.1259/bjr.20170426
   Duque SG, 2016, CLIN NEUROL NEUROSUR, V143, P116, DOI 10.1016/j.clineuro.2016.02.025
   Hide T, 2018, EBIOMEDICINE, V30, P94, DOI 10.1016/j.ebiom.2018.02.024
   Higa N, 2017, NEUROPATHOLOGY, V37, P446, DOI 10.1111/neup.12384
   Hubbard M, 2015, NEUROPATHOLOGY, V35, P452, DOI 10.1111/neup.12198
   Kracht LW, 2003, EUR J NUCL MED MOL I, V30, P868, DOI 10.1007/s00259-003-1148-7
   Li G, 2017, J THORAC CARDIOV SUR, V153, P1318, DOI 10.1016/j.jtcvs.2017.01.052
   Nakajima R, 2017, JPN J RADIOL, V35, P279, DOI 10.1007/s11604-017-0638-7
   Ni JJ, 2015, J NEUROSCI, V35, P12488, DOI 10.1523/JNEUROSCI.1599-15.2015
   Paolini MA, 2018, NEUROPATHOLOGY, V38, P535, DOI 10.1111/neup.12500
   Qian J, 1999, AM J SURG PATHOL, V23, P1270, DOI 10.1097/00000478-199910000-00013
   Rodriguez FJ, 2008, ACTA NEUROPATHOL, V115, P363, DOI 10.1007/s00401-007-0286-6
   Safaee MM, 2018, J NEUROSURG-PEDIATR, V22, P528, DOI 10.3171/2018.5.PEDS18104
   Salim AA, 2012, PATHOLOGY, V44, P657, DOI 10.1097/PAT.0b013e32835a00ef
   Shimony N, 2014, ACTA NEUROCHIR, V156, P1115, DOI 10.1007/s00701-014-2066-0
   Shioi A, 2018, J ATHEROSCLER THROMB, V25, P294, DOI 10.5551/jat.RV17020
   Stienen MN, 2013, ACTA NEUROCHIR, V155, P9, DOI 10.1007/s00701-012-1502-2
   Tabu K, 2016, STEM CELLS, V34, P1151, DOI 10.1002/stem.2299
   Takeya M, 2016, PATHOL INT, V66, P491, DOI 10.1111/pin.12440
   Tsugu H, 1999, NEUROL MED-CHIR, V39, P762, DOI 10.2176/nmc.39.762
   Yan X, 2011, CLIN NEUROPATHOL, V30, P197, DOI 10.5414/NP300360
   Zhang Y, 2017, CELL TISSUE RES, V369, P273, DOI 10.1007/s00441-017-2598-8
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 635
EP +
DI 10.1016/j.wneu.2019.10.182
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200247
PM 31704362
DA 2020-05-12
ER

PT J
AU Hoda, H
   Takami, H
   Graffeo, CS
   Hanakawa, K
   Komiyama, M
   Murao, M
   Ide, T
AF Hoda, Hidenori
   Takami, Hirokazu
   Graffeo, Christopher S.
   Hanakawa, Kazuo
   Komiyama, Masaki
   Murao, Masahiko
   Ide, Takafumi
TI Sumo-Associated Traumatic Vertebral Artery Dissection Precipitating
   Subarachnoid Hemorrhage in Association with Bifid Origins of the
   Posterior Inferior Cerebellar Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arterial dissection; Collateral artery; Posterior inferior cerebellar
   artery; Traumatic subarachnoid hemorrhage; Vertebral artery
ID CERVICAL-SPINE FRACTURE; BASKETBALL GAME; STROKE; ANEURYSM; INJURY;
   INFARCTION; CHILDREN
AB BACKGROUND: Traumatic vertebral artery dissection (tVAD) is frequently accompanied by cerebellar infarction, but subarachnoid hemorrhage (SAH) is rare.
   CASE DESCRIPTION: We report a unique case of tVAD precipitating SAH, from which the patient fully recovered, most likely because of the protective effects of an anomalously duplicated posterior inferior cerebellar artery (PICA)origin. A 17-year-old Sumo wrestler experienced a brief loss of consciousness after an attack by an opponent to his neck. Head computed tomography imaging demonstrated diffuse posterior fossa SAH; cerebral angiography demonstrated left vertebral artery (VA) occlusion, which was thought to be most likely attributable to tVAD. Angiography revealed distal PICA reconstitution, supplied by collateral arterial flow from the meningeal branch of the proximal ipsilateral VA. An external ventricular drain was placed acutely for treatment of SAH-induced hydrocephalus; however, the patient had an otherwise uneventful course, and remained without clinical evidence of ischemic infarct. A repeat imaging confirming a probable duplicated PICA origin from the VA, distal to the tVAD-associated thrombosis.
   CONCLUSIONS: Of particular interest, the patient's abnormal anatomy may have been a mixed blessing, with a more fragile bifid PICA potentially underlying the unexpected development of SAH, whereas the sister branch simultaneously spared him a potentially catastrophic infarction via arterial collateralization.
C1 [Hoda, Hidenori; Takami, Hirokazu; Hanakawa, Kazuo; Murao, Masahiko; Ide, Takafumi] Tokyo Metropolitan Bokutoh Hosp, Dept Neurosurg, Tokyo, Japan.
   [Hoda, Hidenori] Tokyo Metropolitan Bokutoh Hosp, Trauma & Crit Care Ctr, Tokyo, Japan.
   [Takami, Hirokazu; Graffeo, Christopher S.] Mayo Clin, Dept Neurol Surg, Rochester, MN USA.
   [Komiyama, Masaki] Osaka City Gen Hosp, Dept Neurointervent, Osaka, Japan.
RP Hoda, H (reprint author), Tokyo Metropolitan Bokutoh Hosp, Dept Neurosurg, Tokyo, Japan.; Hoda, H (reprint author), Tokyo Metropolitan Bokutoh Hosp, Trauma & Crit Care Ctr, Tokyo, Japan.
EM hoda-tmhp@umin.ac.jp
OI Hoda, Hidenori/0000-0002-4283-4412
CR Aljishi M, 2018, BMJ CASE REP, V2018
   Berne JD, 2009, J TRAUMA, V67, P1333, DOI 10.1097/TA.0b013e31818888c7
   Bhogal P, 2015, INTERV NEURORADIOL, V21, P750, DOI 10.1177/1591019915609137
   Biffl WL, 2000, ANN SURG, V231, P672, DOI 10.1097/00000658-200005000-00007
   Cheon JE, 2001, PEDIATR RADIOL, V31, P163, DOI 10.1007/s002470000391
   Chojdak-Lukasiewicz J, 2014, NEUROL INDIA, V62, P711, DOI 10.4103/0028-3886.149455
   De Giorgio F, 2004, MED SCI LAW, V44, P80, DOI 10.1258/rsmmsl.44.1.80
   Debehnke Daniel J., 1994, Journal of Emergency Medicine, V12, P27, DOI 10.1016/0736-4679(94)90008-6
   DEEN HG, 1992, SPINE, V17, P230, DOI 10.1097/00007632-199202000-00019
   deSouza RM, 2011, EUR SPINE J, V20, P1405, DOI 10.1007/s00586-011-1862-y
   Do FF, 2000, PEDIATR EMERG CARE, V16, P184, DOI 10.1097/00006565-200006000-00014
   FLETCHER J, 1995, BRIT J SPORT MED, V29, P143, DOI 10.1136/bjsm.29.2.143
   Fragoso YD, 2016, ARQ NEURO-PSIQUIAT, V74, P275, DOI 10.1590/0004-282X20150150
   Graffeo CS, 2017, WORLD NEUROSURG, V105, P1009, DOI 10.1016/j.wneu.2017.05.150
   Gupta V, 2015, CASE REP NEUROL MED, DOI 10.1155/2015/182875
   Halfpap JP, 2016, J ORTHOP SPORT PHYS, V46, P929, DOI 10.2519/jospt.2016.0416
   HILTONJONES D, 1985, J NEUROL, V232, P137, DOI 10.1007/BF00313888
   Hutchinson PJ, 2000, J NEUROL NEUROSUR PS, V68, P98, DOI 10.1136/jnnp.68.1.98
   ISHIKAWA T, 1992, NEUROSURGERY, V31, P365, DOI 10.1227/00006123-199208000-00026
   Karnik R, 2000, ACTA NEUROL SCAND, V101, P70, DOI 10.1034/j.1600-0404.2000.00010.x
   Koh JS, 2012, J KOREAN NEUROSURG S, V51, P40, DOI 10.3340/jkns.2012.51.1.40
   Konno K, 2001, J NEUROL, V248, P816, DOI 10.1007/s004150170102
   LANNUZEL A, 1994, NEUROPEDIATRICS, V25, P106, DOI 10.1055/s-2008-1071595
   LATCHAW RE, 1974, NEURORADIOLOGY, V8, P141, DOI 10.1007/BF00341593
   Low A, 2011, BMJ CASE REP, V2011
   Malek AM, 2000, J TRAUMA, V48, P143, DOI 10.1097/00005373-200001000-00027
   Maroon JC, 2007, SURG NEUROL, V67, P163, DOI 10.1016/j.surneu.2006.03.045
   McCrory P, 2000, J CLIN NEUROSCI, V7, P298, DOI 10.1054/jocn.1999.0189
   Mohaghegh S, 2015, ASIAN J SPORTS MED, V6
   Opeskin K, 1998, AM J FOREN MED PATH, V19, P206, DOI 10.1097/00000433-199809000-00002
   Pacei F, 2014, NEUROL SCI, V35, P331, DOI 10.1007/s10072-013-1555-x
   Padget Dorcas Hager, 1948, CONTRIBUTIONS TO EMBRYOLOGY [CARNEGIE INST OF WASHINGTON PUBL], V32, P205
   Trivelato FP, 2011, INTERV NEURORADIOL, V17, P351, DOI 10.1177/159101991101700312
   Rodriguez MFM, 2016, SPORTS HEALTH, V8, P53, DOI 10.1177/1941738114547347
   Rogers L, 1979, Am J Sports Med, V7, P352, DOI 10.1177/036354657900700609
   Sahjpaul RL, 1998, J NEUROSURG, V89, P822, DOI 10.3171/jns.1998.89.5.0822
   Sepelyak K, 2010, EUR J PEDIATR, V169, P557, DOI 10.1007/s00431-009-1066-1
   SHETH RD, 1994, CLIN PEDIATR, V33, P503, DOI 10.1177/000992289403300811
   Simon LV, 2012, VERTEBRAL ARTERY INJ
   Slowey M, 2012, EMERG MED AUSTRALAS, V24, P203, DOI 10.1111/j.1742-6723.2011.01496.x
   Suzuki S, 2018, J CLIN NEUROSCI, V47, P137, DOI 10.1016/j.jocn.2017.10.008
   Tekin S, 1997, PEDIATR NEUROL, V16, P67, DOI 10.1016/S0887-8994(96)00252-4
   TRAMO MJ, 1985, STROKE, V16, P1039, DOI 10.1161/01.STR.16.6.1039
   Uchiyama T, 2015, INTERV NEURORADIOL, V21, P451, DOI 10.1177/1591019915590363
   Wechsler B, 2001, AM J PHYS MED REHAB, V80, P608, DOI 10.1097/00002060-200108000-00012
   Yamada SM, 2014, CLIN J SPORT MED, V24, P155, DOI 10.1097/01.jsm.0000432859.64058.d7
NR 46
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP 641
EP +
DI 10.1016/j.wneu.2019.09.164
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200248
PM 31610246
DA 2020-05-12
ER

PT J
AU Addepalli, A
   Benton, J
   Zhu, SY
   Mann, SK
   Fall, MP
   Cox, A
   Essibayi, MA
   Unda, SR
   Brook, A
   Lee, SK
   Ramos, RD
   Altschul, DJ
AF Addepalli, Aravind
   Benton, Joshua
   Zhu, Shaoyu
   Mann, Shira Kaye
   Fall, Mame P.
   Cox, Andrew
   Essibayi, Muhammed Amir
   Unda, Santiago Rene
   Brook, Allan
   Lee, Seon-Kyu
   Ramos, Rafael De La Garza
   Altschul, David J.
TI Risk of Ipsilateral Deep Vein Thrombosis After Use of AngioSeal Closure
   Device in Aneurysmal Subarachnoid Hemorrhage Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; AngioSeal; Closure device; Deep vein thrombosis; Subarachnoid
   hemorrhage
ID CARDIAC-CATHETERIZATION; VENOUS THROMBOEMBOLISM; ARTERIAL HEMOSTASIS;
   MANUAL COMPRESSION; COMPLICATIONS; CORONARY
AB BACKGROUND: Deep vein thrombosis (DVT) is a known complication in patients with aneurysmal subarachnoid hemorrhage (aSAH). This study investigated the association between use of the AngioSeal (St. Jude Medical, Minnetonka, MN) vascular closure device and the risk of ipsilateral and any DVT event after angiography in patients with aSAH.
   METHODS: We conducted a review of our institutional cerebral angiography database for the years 2005-2018 to identify all adult patients who underwent angiography for aSAH. We compared the incidence of DVT (occurring within 14 days) between aSAH patients who underwent manual compression versus the AngioSeal closure device.
   RESULTS: A total of 459 aSAH patients underwent angiography; 262 underwent manual compression (57.1%) and 197 received AngioSeal (42.9%). There was a 3.4% rate of ipsilateral DVT in the manual compression group and 7.6% in the AngioSeal closure device group (chi 2 test, P = 0.04). Similarly, the rate of any DVT was 8.8% for manual compression and 16.8% for patients who received AngioSeal (chi 2 test, P = 0.01). On multivariate analysis, AngioSeal remained a significant independent predictor of ipsilateral DVT (odds ratio 2.4, P = 0.04) and any DVT (odds ratio 2.3, P = 0.01).
   CONCLUSIONS: In aSAH patients undergoing cerebral angiographic procedures with access through the femoral artery, the use of AngioSeal closure device was found to be associated with a significantly increased risk of ipsilateral DVT within 14 days.
C1 [Addepalli, Aravind; Benton, Joshua; Zhu, Shaoyu; Mann, Shira Kaye; Fall, Mame P.; Cox, Andrew; Ramos, Rafael De La Garza; Altschul, David J.] Albert Einstein Coll Med, Montefiore Med Ctr, Leo M Davidoff Dept Neurosurg, New York, NY 10461 USA.
   [Brook, Allan; Lee, Seon-Kyu] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Radiol, New York, NY USA.
   [Essibayi, Muhammed Amir] Firat Univ, Grad Sch Med Sci, Elazig, Turkey.
   [Unda, Santiago Rene] Natl Univ La Rioja, Hlth & Sci Dept, La Rioja, Argentina.
RP Altschul, DJ (reprint author), Albert Einstein Coll Med, Montefiore Med Ctr, Leo M Davidoff Dept Neurosurg, New York, NY 10461 USA.
EM daltschu@montefiore.org
RI Essibayi, Muhammed Amir/AAK-2800-2020
OI Essibayi, Muhammed Amir/0000-0001-8325-2382; Unda,
   Santiago/0000-0001-7319-6794; Altschul, David/0000-0002-5130-1378
CR AKER UT, 1994, CATHETER CARDIO DIAG, V31, P228, DOI 10.1002/ccd.1810310314
   Alshehri AM, 2015, INT J ANGIOL, V24, P133, DOI 10.1055/s-0035-1547449
   [Anonymous], 2019, ANGIO SEAL PREMARKET
   [Anonymous], 2016, ANGIO SEAL
   Applegate RJ, 2010, J INVASIVE CARDIOL, V22, P420
   Cox Tiffany, 2015, Surg Technol Int, V27, P32
   Dauerman HL, 2007, J AM COLL CARDIOL, V50, P1617, DOI 10.1016/j.jacc.2007.07.028
   Gregory D, 2013, J INTERV CARDIOL, V26, P630, DOI 10.1111/joic.12070
   KENSEY KR, 1994, J INVASIVE CARDIOL, V6, P273
   Kshettry VR, 2014, J CLIN NEUROSCI, V21, P282, DOI 10.1016/j.jocn.2013.07.003
   KUSSMAUL WG, 1995, J AM COLL CARDIOL, V25, P1685, DOI 10.1016/0735-1097(95)00101-9
   Liang CW, 2015, J NEUROSURG, V123, P891, DOI 10.3171/2014.12.JNS141288
   Miao W, 2018, WORLD NEUROSURG, V110, pE46, DOI 10.1016/j.wneu.2017.09.200
   Modi Sachin, 2013, Indian J Radiol Imaging, V23, P134, DOI 10.4103/0971-3026.116566
   Nash JE, 1999, HERZ, V24, P597, DOI 10.1007/BF03044483
   Peltonen S, 1997, J NEUROSURG, V87, P207, DOI 10.3171/jns.1997.87.2.0207
   Ray WZ, 2009, J NEUROSURG, V110, P1010, DOI 10.3171/2008.9.JNS08107
   Schulz-Schupke S, 2015, JAMA-J AM MED ASSOC, V313, P855, DOI 10.1001/jama.2015.427
   Sen AN, 2016, NEUROPHOTONICS, V3, DOI 10.1117/1.NPh.3.3.031409
   Serrone JC, 2013, WORLD NEUROSURG, V80, P859, DOI 10.1016/j.wneu.2013.01.012
   Tellez A, 2010, EUROINTERVENTION, V5, P731, DOI 10.4244/EIJV5I6A120
   Upponi SS, 2007, EUR J RADIOL, V61, P332, DOI 10.1016/j.ejrad.2006.09.007
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E162
EP E165
DI 10.1016/j.wneu.2019.09.170
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200020
PM 31605856
DA 2020-05-12
ER

PT J
AU Ahmadvand, S
   Dayyani, M
   Etemadrezaie, H
   Ghorbanpour, A
   Zarei, R
   Shahriyari, A
   Emadzadeh, M
   Ganjeifar, B
   Zabihyan, S
AF Ahmadvand, Saba
   Dayyani, Mojtaba
   Etemadrezaie, Hamid
   Ghorbanpour, Ahmad
   Zarei, Reyhaneh
   Shahriyari, Ali
   Emadzadeh, Maryam
   Ganjeifar, Babak
   Zabihyan, Samira
TI Rate and Risk Factors of Early Ventriculoperitoneal Shunt Revision: A
   Five-Year Retrospective Analysis of a Referral Center
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult; Complication; Hydrocephalus; Pediatrics; Revision;
   Ventriculoperitoneal shunt
ID CEREBROSPINAL-FLUID SHUNT; FAILURE RATE; PLACEMENT; COMPLICATIONS;
   SURVIVAL; PREDICTORS; INFECTION; CATHETER; SURGERY; EPIDEMIOLOGY
AB BACKGROUND: Cerebral shunts are the mainstay treatment of hydrocephalus. Because most previous studies have focused on factors related to long-term outcomes of shunt surgery, we aimed to assess the rates and causes of 30-day ventriculoperitoneal shunt (VPS) failure in a single referral center over 5 years in both adult and pediatric patients.
   METHODS: Patients who underwent VPS surgery from February 2012 to February 2017 in Ghaem Teaching Hospital, Mashhad, Iran were evaluated retrospectively through clinical history, operative reports, imaging studies, and follow-up notes. Data of 12 possible factors related to shunt failure were collected comprising age, gender, household income, level of education, cause of hydrocephalus, causes of revision, type of failure, anatomic site, duration of operation, time of surgery, surgeons' level of expertise, and Glasgow Coma Scale (GCS) score.
   RESULTS: Among 403 VPS placements, 121 VPS revisions were performed, and 82 eligible patients were included in the study (57.3% male and 42.7% female). The 30-day shunt failure rate was 24.4% among all revisions. Obstruction and malposition were the most common causes of early revisions. Six factors were statistically significant in the univariate analysis. After adjustment in a logistic regression model, 2 factors, namely surgeons' level of expertise (odds ratio, 10.33; 95% confidence interval, 1.08-98.80) and anatomic site of the shunt (odds ratio, 10.28; 95% confidence interval, 1.21- 87.35) were associated with early shunt revision.
   CONCLUSIONS: Shunt surgeries performed by junior residents and shunts placed in the frontal site were associated with early shunt failure.
C1 [Ahmadvand, Saba; Zarei, Reyhaneh; Shahriyari, Ali] Islamic Azad Univ Mashhad, Fac Med, Mashhad, Razavi Khorasan, Iran.
   [Dayyani, Mojtaba; Etemadrezaie, Hamid; Ghorbanpour, Ahmad; Ganjeifar, Babak; Zabihyan, Samira] Mashhad Univ Med Sci, Ghaem Teaching Hosp, Fac Med, Dept Neurosurg, Mashhad, Razavi Khorasan, Iran.
   [Emadzadeh, Maryam] Mashhad Univ Med Sci, Fac Med, Clin Res Unit, Mashhad, Razavi Khorasan, Iran.
RP Zabihyan, S (reprint author), Mashhad Univ Med Sci, Ghaem Teaching Hosp, Fac Med, Dept Neurosurg, Mashhad, Razavi Khorasan, Iran.
EM zabihyan@yahoo.com
CR Agarwal Nitin, 2017, J Indian Assoc Pediatr Surg, V22, P155, DOI 10.4103/0971-9261.207624
   Al-Tamimi YZ, 2014, NEUROSURGERY, V74, P29, DOI 10.1227/NEU.0000000000000196
   Anderson IA, 2019, J NEUROSURG, V130, P145, DOI 10.3171/2017.8.JNS17399
   BORGBJERG BM, 1995, ACTA NEUROCHIR, V136, P1, DOI 10.1007/BF01411427
   Cheng H, 2018, J SURG RES, V229, P134, DOI 10.1016/j.jss.2018.03.022
   Crowley RW, 2014, WORLD NEUROSURG, V81, P397, DOI 10.1016/j.wneu.2013.01.039
   Dewan MC, 2019, J NEUROSURG, V130, P1065, DOI 10.3171/2017.10.JNS17439
   Dickerman RD, 2005, J CLIN NEUROSCI, V12, P781, DOI 10.1016/j.jocn.2004.12.005
   Farahmand D, 2009, J NEUROL NEUROSUR PS, V80, P1248, DOI 10.1136/jnnp.2007.141416
   GEORGE R, 1979, J NEUROSURG, V51, P804, DOI 10.3171/jns.1979.51.6.0804
   Gonzalez DO, 2017, PEDIATR NEUROSURG, V52, P6, DOI 10.1159/000447410
   IGNELZI RJ, 1975, J NEUROSURG, V42, P679, DOI 10.3171/jns.1975.42.6.0679
   Khan Farid, 2015, Surg Neurol Int, V6, P25, DOI 10.4103/2152-7806.151388
   Khan F, 2013, CHILD NERV SYST, V29, P791, DOI 10.1007/s00381-012-2004-5
   Kim Ho Soo, 2015, Korean J Neurotrauma, V11, P58, DOI 10.13004/kjnt.2015.11.2.58
   Martin K, 2011, J PEDIATR SURG, V46, P2146, DOI 10.1016/j.jpedsurg.2011.07.001
   McClinton D, 2001, PEDIATR INFECT DIS J, V20, P593, DOI 10.1097/00006454-200106000-00009
   McGirt MJ, 2007, CHILD NERV SYST, V23, P289, DOI 10.1007/s00381-006-0226-0
   McGirt MJ, 2003, CLIN INFECT DIS, V36, P858, DOI 10.1086/368191
   McGirt MJ, 2002, PEDIATR NEUROSURG, V36, P248, DOI 10.1159/000058428
   MEDINA SAP, 2017, COCHRANE DB SYST REV, V2017
   Merkler AE, 2017, WORLD NEUROSURG, V98, P654, DOI 10.1016/j.wneu.2016.10.136
   Nassar B.R., 2016, GERONTOL GERIATR MED, V2
   Paff M, 2018, INTERDISCIP NEUROSUR, V13, P66, DOI 10.1016/j.inat.2018.04.004
   Pan P, 2018, J PEDIATR NEUROSCI, V13, P176, DOI 10.4103/jpn.JPN_29_18
   Prusseit J, 2009, PEDIATR NEUROSURG, V45, P325, DOI 10.1159/000257520
   Recinos PF, 2013, J NEUROSURG-PEDIATR, V11, P558, DOI 10.3171/2013.1.PEDS1254
   Reddy GK, 2014, WORLD NEUROSURG, V81, P404, DOI 10.1016/j.wneu.2013.01.096
   Reddy GK, 2012, CLIN NEUROL NEUROSUR, V114, P1211, DOI 10.1016/j.clineuro.2012.02.050
   Reddy GK, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.10.034
   Rossi NB, 2016, J NEUROSURG-PEDIATR, V17, P249, DOI 10.3171/2015.5.PEDS15118
   Shah SS, 2008, NEUROSURGERY, V62, P1095, DOI 10.1227/01.neu.0000325871.60129.23
   Shao Y, 2011, MINIM INVAS NEUROSUR, V54, P44, DOI 10.1055/s-0031-1271680
   SHURTLEFF DB, 1985, PEDIATR NEUROSCI, V12, P49, DOI 10.1159/000120218
   Tormenti MJ, 2011, J NEUROSURG-PEDIATR, V8, P390, DOI 10.3171/2011.7.PEDS115
   Vinchon M, 2006, CHILD NERV SYST, V22, P692, DOI 10.1007/s00381-005-0037-8
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
   Whitehead WE, 2017, J NEUROSURG-PEDIATR, V19, P157, DOI 10.3171/2016.8.PEDS16229
   Wu Y, 2007, NEUROSURGERY, V61, P557, DOI 10.1227/01.NEU.0000290903.07943.AF
NR 39
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E505
EP E511
DI 10.1016/j.wneu.2019.10.108
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200061
PM 31669687
DA 2020-05-12
ER

PT J
AU Alexopoulos, G
   Prim, M
   Khan, M
   Quadri, N
   Urquiaga, JF
   El Tecle, N
   Coppens, J
AF Alexopoulos, Georgios
   Prim, Michael
   Khan, Maheen
   Quadri, Nabiha
   Urquiaga, Jorge F.
   El Tecle, Najib
   Coppens, Jeroen
TI Minimally Invasive Evacuation of Severe Intraventricular Hemorrhage
   Using the BrainPath Endoport-Assisted Microsurgical System
SO WORLD NEUROSURGERY
LA English
DT Article
DE BrainPath; Endoport-assisted microsurgical device; Endoport system;
   Neuroendoscopic evacuation of intraventricular hemorrhage; Severe
   intraventricular hemorrhage; Spontaneous intracerebral hemorrhage
ID INTRACEREBRAL HEMORRHAGE; ENDOSCOPIC SURGERY; GRAEB; NEUROENDOSCOPY;
   PREDICTION; MANAGEMENT; SCORE
AB OBJECTIVE: We present the application of the BrainPath endoport-assisted microsurgical device (EAMD) as a treatment modality for patients with severe intraventricular hemorrhage (IVH) secondary to spontaneous supratentorial intracerebral hemorrhage (sICH).
   METHODS: Patients with severe secondary IVH (defined as Graeb score [GS] >6) who presented to Saint Louis University Hospital, St. Louis, Missouri, United States, from 2017 to 2019 were treated with the minimally invasive approach for IVH evacuation using the atraumatic BrainPath aspiration system.
   RESULTS: Three patients (2 men and 1 woman) with a mean age of 54 years were included in this study. The mean preoperative GS was 10.0 with a modified GS of 23.3. The mean postoperative GS was 4.0 (P = 0.001) with a modified GS of 10.67 (P = 0.001). There were no complications related to the surgery itself in any of the reported cases.
   CONCLUSIONS: BrainPath EAMD evacuation of severe IVH secondary to sICH appears to be a safe and effective treatment modality that significantly increases the extent of IVH clearance, which could also lead to improved long-term patient outcomes.
C1 [Alexopoulos, Georgios; Prim, Michael; Khan, Maheen; Quadri, Nabiha; Urquiaga, Jorge F.; El Tecle, Najib; Coppens, Jeroen] St Louis Univ Hosp, Dept Neurosurg, St Louis, MO 63110 USA.
RP Alexopoulos, G (reprint author), St Louis Univ Hosp, Dept Neurosurg, St Louis, MO 63110 USA.
EM alexopoulos_george@hotmail.com
OI el Tecle, Najib/0000-0002-5242-1646; Alexopoulos,
   Georgios/0000-0002-6225-3033
CR Arboix A, 2012, ISRN NEUROL, V2012
   Chen CJ, 2016, CASE REP NEUROL MED, DOI 10.1155/2016/8654262
   Chen CC, 2011, WORLD NEUROSURG, V75, P264, DOI 10.1016/j.wneu.2010.07.041
   Chen PW, 2012, NEUROL INDIA, V59, P861
   Czorlich P, 2015, ACTA NEUROCHIR, V157, P409, DOI 10.1007/s00701-014-2334-z
   Di Rienzo Alessandro, 2020, Neurosurg Rev, V43, P695, DOI 10.1007/s10143-019-01110-7
   Ding Dale, 2017, J Cerebrovasc Endovasc Neurosurg, V19, P101, DOI 10.7461/jcen.2017.19.2.101
   Ding DL, 2015, J CLIN NEUROSCI, V22, P1025, DOI 10.1016/j.jocn.2015.01.004
   Du B, 2018, NEURAL REGEN RES, V13, P999, DOI 10.4103/1673-5374.233442
   Du B, 2018, BRAIN INJURY, V32, P1142, DOI 10.1080/02699052.2018.1469042
   Fiorella D, 2015, J NEUROINTERV SURG, V7, P752, DOI 10.1136/neurintsurg-2014-011358
   Flint AC, 2008, NEUROCRIT CARE, V8, P330, DOI 10.1007/s12028-008-9070-2
   Gilard V, 2017, WORLD NEUROSURG, V97, P117, DOI 10.1016/j.wneu.2016.09.105
   Hansen BM, 2016, NEUROEPIDEMIOLOGY, V46, P43, DOI 10.1159/000442575
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   Herrick DB, 2014, NEUROCRIT CARE, V21, P426, DOI 10.1007/s12028-014-9959-x
   Kiymaz N, 2005, ADV THER, V22, P447, DOI 10.1007/BF02849864
   Li YP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080599
   McLaughlin N, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.022
   Morgan TC, 2013, STROKE, V44, P635, DOI 10.1161/STROKEAHA.112.670653
   Nishikawa T, 2009, CLIN NEUROL NEUROSUR, V111, P450, DOI 10.1016/j.clineuro.2009.01.005
   Roeder SS, 2019, CEREBROVASC DIS, V47, P245, DOI 10.1159/000501027
   Sacco S, 2009, STROKE, V40, P394, DOI 10.1161/STROKEAHA.108.523209
   Song P, 2018, CURR MED SCI, V38, P880, DOI 10.1007/s11596-018-1957-3
   Tan LA, 2016, J CLIN NEUROSCI, V27, P53, DOI 10.1016/j.jocn.2015.08.037
   Trifan G, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00217
   Witsch J, 2015, NEUROLOGY, V84, P989, DOI 10.1212/WNL.0000000000001344
   Yogendrakumar V, 2019, NEUROLOGY, V93, pE879, DOI 10.1212/WNL.0000000000008007
   Zaidi HA, 2015, WORLD NEUROSURG, V84, P1191, DOI 10.1016/j.wneu.2015.06.015
   Zhang ZQ, 2007, CEREBROVASC DIS, V24, P91, DOI 10.1159/000103122
NR 30
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E540
EP E548
DI 10.1016/j.wneu.2019.10.135
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200065
PM 31678444
DA 2020-05-12
ER

PT J
AU Alford, EN
   Rotman, LE
   Shank, CD
   Agee, BS
   Markert, JM
AF Alford, Elizabeth N.
   Rotman, Lauren E.
   Shank, Christopher D.
   Agee, Bonita S.
   Markert, James M.
TI Independent Validation of the Colloid Cyst Risk Score to Predict
   Symptoms and Hydrocephalus in Patients with Colloid Cysts of the Third
   Ventricle
SO WORLD NEUROSURGERY
LA English
DT Article
DE Colloid cyst; Forecasting; Reproducibility of results; Validation study
ID NATURAL-HISTORY; TRANSCALLOSAL; DETERIORATION; MORBIDITY; TUMORS
AB BACKGROUND: The Colloid Cyst Risk Score (CCRS) was devised to identify patients with symptomatic colloid cyst and stratify risk of hydrocephalus. The CCRS considers patient age, presence of headache, colloid cyst diameter, fluid-attenuated inversion recovery hyperintensity, and location within the third ventricle.
   OBJECTIVE: The purpose of this study was to independently evaluate the validity of the CCRS.
   METHODS: Patients with a colloid cyst of the third ventricle were identified retrospectively from institutional billing records and radiology report archives. Patients without a confirmed diagnosis of colloid cyst of the third ventricle or magnetic resonance imaging of the brain were excluded. Data were collected via retrospective chart review.
   RESULTS: One hundred and fifty-six patients met inclusion and exclusion criteria. In our cohort, the CCRS stratified symptomatic patients and patients with hydrocephalus across all scores (P< 0.001). From CCRS 2 to 5, the percentage of symptomatic patients increased from 13% to 100%, whereas the percentage of patients with hydrocephalus increased from 8% to 83%. Simple logistic regression showed that total CCRS, headache, axial diameter, fluid-attenuated inversion recovery hyperintensity, and risk zone were all highly predictive of symptomatic status and hydrocephalus (P< 0.001). Logistic regression with receiver operating curves for the CCRS showed an area under the curve of 0.914 for symptomatic colloid cysts and an area under the curve of 0.892 for colloid cysts with hydrocephalus.
   CONCLUSIONS: Our data analysis validates the predictive value of the CCRS for both symptomatic status and hydrocephalus and supports the use of the CCRS in risk stratification and clinical decision making.
C1 [Alford, Elizabeth N.; Rotman, Lauren E.; Shank, Christopher D.; Agee, Bonita S.; Markert, James M.] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA.
RP Alford, EN (reprint author), Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL 35294 USA.
EM ekuhn@uabmc.edu
CR Beaumont TL, 2016, J NEUROSURG, V125, P1420, DOI 10.3171/2015.11.JNS151396
   Brunori A, 2018, WORLD NEUROSURG, V117, pE457, DOI 10.1016/j.wneu.2018.06.051
   Greenberg MS, 2016, HDB NEUROSURGERY
   Hamer PCD, 2002, J NEUROSURG, V96, P1041, DOI 10.3171/jns.2002.96.6.1041
   Hassaneen W, 2010, J CLIN NEUROSCI, V17, P830, DOI 10.1016/j.jocn.2009.12.007
   Horn EM, 2008, NEUROSURGERY, V62, P1076, DOI [10.1227/01.NEU.0000255409.61398.EA, 10.1227/01.neu.0000333773.43445.7b]
   LITTLE JR, 1974, J NEUROSURG, V40, P230, DOI 10.3171/jns.1974.40.2.0230
   Milligan BD, 2010, NEUROSURGERY, V67, P1483, DOI 10.1227/NEU.0b013e3181f7eb68
   O'Neill AH, 2018, J CLIN NEUROSCI, V53, P122, DOI 10.1016/j.jocn.2018.04.061
   Pollock BE, 2000, NEUROSURGERY, V46, P1077, DOI 10.1097/00006123-200005000-00010
   RYDER JW, 1986, J NEUROSURG, V64, P216, DOI 10.3171/jns.1986.64.2.0216
   Sheikh AB, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.06.024
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E747
EP E753
DI 10.1016/j.wneu.2019.10.188
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200087
PM 31706971
DA 2020-05-12
ER

PT J
AU Ammanuel, SG
   Edwards, CS
   Alhadi, R
   Hervey-Jumper, SL
AF Ammanuel, Simon G.
   Edwards, Caleb S.
   Alhadi, Rasheed
   Hervey-Jumper, Shawn L.
TI Readability of Online Neuro-Oncology-Related Patient Education Materials
   from Tertiary-Care Academic Centers
SO WORLD NEUROSURGERY
LA English
DT Article
DE Health literacy; Neuro-oncology; Patient education
ID HEALTH LITERACY; AMERICAN ACADEMY; INTERNET; INFORMATION; OUTCOMES;
   SURGERY; QUALITY
AB BACKGROUND: The Internet has become a popular resource for patients to research diagnosed or suspected medical diseases. Medical institutions provide comprehensive online education resources about various conditions to the general public. The U.S. National Institutes of Health and American Medical Association recommend that patient education materials aimed at the general population should be written at or below eighth-grade reading level. The goal of this study is to assess the readability of patient education materials for central nervous system tumors across tertiary-care institutions.
   METHODS: Patient education materials were collected from National Cancer Institute designated cancer centers in October 2019. Materials were analyzed by Flesch-Kincaid Grade Level (FKGL) and Flesch Reading Ease (FRE) score using Microsoft Office Word software. Subgroups were formed based on regions in the United States (Northeast, Southeast, Midwest, Southwest, and West) as well as diagnostic and treatment information.
   RESULTS: A total of 180 documents were collected across 50 institutions. Overall median FKGL was 12.5, and median FRE was 38.2. Median FKGL for diagnostic information was 11.6 and FRE was 43.0, whereas median FKGL for treatment information was 12.9 and median FRE was 34.3. No statistically significant differences were seen for both FKGL and FRE among geographic regions (P > 0.05).
   CONCLUSIONS: Online neuro-oncology patient education materials from tertiary institutions are written above recommended reading levels. Future efforts should be taken to improve the readability of brain tumor-specific patient education materials, particularly with information relating to treatment.
C1 [Ammanuel, Simon G.; Edwards, Caleb S.; Alhadi, Rasheed; Hervey-Jumper, Shawn L.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA.
RP Hervey-Jumper, SL (reprint author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94110 USA.
EM shawn.hervey-jumper@ucsf.edu
CR Agarwal N, 2014, J NEUROSURG-SPINE, V21, P468, DOI 10.3171/2014.5.SPINE13600
   Agarwal N, 2013, J CLIN NEUROSCI, V20, P1357, DOI 10.1016/j.jocn.2012.10.047
   Ayoub S, 2019, OCUL IMMUNOL INFLAMM, V27, P399, DOI 10.1080/09273948.2017.1413396
   Berkman ND, 2011, ANN INTERN MED, V155, P97, DOI 10.7326/0003-4819-155-2-201107190-00005
   Betschart P, 2017, INT UROL NEPHROL, V49, P2111, DOI 10.1007/s11255-017-1695-7
   Boztas N, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008526
   Cherla DV, 2014, ENDOCR PRACT, V20, P1044, DOI 10.4158/EP14114.OR
   Cotugna N, 2005, J COMMUN HEALTH, V30, P213, DOI 10.1007/s10900-004-1959-x
   COUPER MP, 2010, MED DECIS MAKING, V30, P106, DOI DOI 10.1177/0272989X10377661
   DeWalt DA, 2004, J GEN INTERN MED, V19, P1228, DOI 10.1111/j.1525-1497.2004.40153.x
   Echeverri M, 2018, INT J ENV RES PUB HE, V15, P1
   Eltorai AEM, 2016, SPINE, V41, P1041, DOI 10.1097/BRS.0000000000001446
   Eltorai AEM, 2015, CLIN ORTHOP RELAT R, V473, P1181, DOI 10.1007/s11999-014-4071-2
   Flesch R, 1948, J APPL PSYCHOL, V32, P221, DOI 10.1037/h0057532
   Fox S, 2013, PSYCHOL BEHAV ASPECT, P135
   Garcia M, 2018, J NEUROSURG-PEDIATR, V21, P535, DOI 10.3171/2017.10.PEDS17177
   Gupta R, 2016, J NEUROSURG, V127, P1
   Hadden K, 2016, J HAND SURG-AM, V41, P825, DOI 10.1016/j.jhsa.2016.05.006
   Hargrave DR, 2006, NEURO-ONCOLOGY, V8, P175, DOI 10.1215/15228517-2005-008
   Hendriks EJ, 2018, HUM BRAIN MAPP, V39, P2064, DOI 10.1002/hbm.23986
   Kincaid JP, 1975, DERIVATION NEW READA
   Kugar MA, 2017, J SURG RES, V218, P43, DOI 10.1016/j.jss.2017.05.033
   Langford AT, J CANCER EDUC, DOI [10.1007/s13187-019-1482-5, DOI 10.1007/S13187-019-1482-5,]
   Medlock S, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.3749
   National Institutes of Health, 2013, WST4282013, P1
   Ostrom QT, 2018, NEURO-ONCOLOGY, V20, P1, DOI 10.1093/neuonc/noy131
   Roberts H, 2016, J BONE JOINT SURG AM, V98, DOI 10.2106/JBJS.15.00658
   Rosenberg SA, 2018, PRACT RADIAT ONCOL, V7, P57
   Ryu JH, 2016, SPINE, V41, pE561, DOI 10.1097/BRS.0000000000001321
   Sabharwal S, 2008, CLIN ORTHOP RELAT R, V466, P1245, DOI 10.1007/s11999-008-0193-8
   Saeed F, 2017, WORLD NEUROSURG, V97, P312, DOI 10.1016/j.wneu.2016.10.001
   Schmitt Paul J, 2013, World Neurosurg, V80, pe33, DOI 10.1016/j.wneu.2011.09.007
   Schoof ML, 2014, FAM MED, V46, P291
   Serper M, 2014, HEALTH SERV RES, V49, P1249, DOI 10.1111/1475-6773.12154
   Siegel C, 2018, SEMIN ONCOL NURS, V34, P513, DOI 10.1016/j.soncn.2018.10.014
   Stringer T, 2018, PEDIATR DERMATOL, V35, P800, DOI 10.1111/pde.13682
   Vernon J, 2007, LOW HLTH LITERACY IM
   Walsh TM, 2008, RESP CARE, V53, P1310
   Weiss BD, HLTH LITERACY MANUAL
   Williams AM, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0315-0
NR 40
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E1108
EP E1114
DI 10.1016/j.wneu.2019.11.109
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200129
PM 31785430
DA 2020-05-12
ER

PT J
AU Badhiwala, JH
   Ellenbogen, Y
   Khan, O
   Nouri, A
   Jiang, F
   Wilson, JRF
   Jaja, B
   Witiw, CD
   Nassiri, F
   Fehlings, MG
   Wilson, JR
AF Badhiwala, Jetan H.
   Ellenbogen, Yosef
   Khan, Omar
   Nouri, Aria
   Jiang, Fan
   Wilson, Jamie R. F.
   Jaja, Blessing
   Witiw, Christopher D.
   Nassiri, Farshad
   Fehlings, Michael G.
   Wilson, Jefferson R.
TI Comparison of the Inpatient Complications and Health Care Costs of
   Anterior versus Posterior Cervical Decompression and Fusion in Patients
   with Multilevel Degenerative Cervical Myelopathy: A Retrospective
   Propensity Score-Matched Analysis
SO WORLD NEUROSURGERY
LA English
DT Article; Proceedings Paper
CT Global Spine Congress
CY MAY 15-18, 2019
CL Toronto, CANADA
SP AO Spine
DE Anterior cervical discectomy and fusion; Cervical laminectomy; Cervical
   spondylotic myelopathy; Degenerative cervical myelopathy; Evidence-based
   medicine; Posterior cervical decompression and fusion; Spinal fusion
ID SURGICAL DECOMPRESSION; NATIONAL TRENDS; OUTCOMES; SURGERY; EFFICACY;
   SAFETY
AB BACKGROUND: The optimal surgical approach for multilevel degenerative cervical myelopathy (DCM) is unclear, and there is significant variation in practice patterns. We sought to compare inpatient complications and costs of anterior (ACDF) versus posterior cervical decompression and fusion (PCDF).
   METHODS: Patients who underwent multilevel ACDF or PCDF for DCM were identified from the National Inpatient Sample for 2004-2014 using ICD-9-CM codes. Propensity score matching was performed with age, sex, comorbidities, hospital bed size, and use of intraoperative monitoring as covariates. Hospitalization charges/costs, length of stay (LOS), discharge disposition, and inpatient morbidity/mortality were compared between matched ACDF and PCDF groups.
   RESULTS: Propensity score matching generated a cohort of 13,884 patients (n = 6,942 ACDF; n = 6,942 PCDF). PCDF was associated with greater LOS (mean difference [MD] +1.7 days, P < 0.001) and less frequent routine discharge home (odds ratio [OR] 0.26, P < 0.01). With regard to complications, PCDF had a higher rate of myocardial infarction (OR 1.6, P = 0.007), pulmonary embolism (OR 2.6, P = 0.009), deep vein thrombosis (OR 3.7, P < 0.001), neurological complications (OR 1.7, P = 0.037), hardware-related complications (OR 2.7, P < 0.001), wound infection/breakdown (OR 6.8, P < 0.001), and cerebrospinal fluid leak (OR 1.7, P = 0.011). By contrast, rates of postoperative hematoma (OR 0.61, P = 0.007), hoarseness (OR 0.13, P < 0.001), and dysphagia (OR 0.20, P < 0.001) were higher after ACDF. Mortality was comparable. Hospital charges (MD + $26,259, P < 0.001) and costs (MD +$7,728, P < 0.001) were significantly higher for PCDF.
   CONCLUSIONS: At a national level, for multilevel DCM, we found PCDF to be associated with greater LOS, in-hospital costs, and general medical and surgical complications. ACDF carried higher risk of postoperative hematoma, hoarseness, and dysphagia.
C1 [Badhiwala, Jetan H.; Khan, Omar; Nouri, Aria; Jiang, Fan; Wilson, Jamie R. F.; Jaja, Blessing; Witiw, Christopher D.; Nassiri, Farshad; Fehlings, Michael G.; Wilson, Jefferson R.] Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada.
   [Jiang, Fan] Univ Toronto, Dept Surg, Div Orthopaed Surg, Toronto, ON, Canada.
   [Ellenbogen, Yosef] McMaster Univ, Michael G DeGroote Sch Med, Hamilton, ON, Canada.
RP Wilson, JR (reprint author), Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada.
EM WilsonJeff@smh.ca
OI Jiang, Fan/0000-0002-7673-0267; Nouri, Aria/0000-0002-4965-3059
CR Asher AL, 2019, NEUROSURGERY, V84, P919, DOI 10.1093/neuros/nyy144
   Badhiwala JH, 2018, SPINE J, V18, P2220, DOI 10.1016/j.spinee.2018.05.009
   Badhiwala JH, 2019, NEUROSURGERY, V84, P890, DOI 10.1093/neuros/nyy133
   CDC/National Center for Health Statistics, 2015, ICD 9 CM ADD CONV TA
   Davies BM, 2018, BMJ-BRIT MED J, P360
   Fehlings MG, 2017, GLOB SPINE J, V7, p70S, DOI 10.1177/2192568217701914
   Fehlings MG, 2015, SPINE, V40, P1322, DOI 10.1097/BRS.0000000000000988
   Fehlings MG, 2013, SPINE, V38, P2247, DOI 10.1097/BRS.0000000000000047
   Fehlings MG, 2013, J BONE JOINT SURG AM, V95A, P1651, DOI 10.2106/JBJS.L.00589
   Ghogawala Z, 2011, NEUROSURGERY, V68, P622, DOI 10.1227/NEU.0b013e31820777cf
   HCUP, 2017, HCUP NIS DAT DOC
   Karadimas SK, 2013, SPINE, V38, pS21, DOI 10.1097/BRS.0b013e3182a7f2c3
   Kato S, 2017, J BONE JOINT SURG AM, V99, P1013, DOI 10.2106/JBJS.16.00882
   Kato S, 2016, CURR REV MUSCULOSKE, V9, P263, DOI 10.1007/s12178-016-9348-5
   Kwee MM, 2015, INT SURG, V100, P292, DOI 10.9738/INTSURG-D-13-00256.1
   Kwon BK, 2007, J NEUROSURG-SPINE, V7, P1, DOI 10.3171/SPI-07/07/001
   Lawrence BD, 2013, SPINE, V38, pS173, DOI 10.1097/BRS.0b013e3182a7eaaf
   Liu T, 2011, J SPINAL DISORD TECH, V24, P213, DOI 10.1097/BSD.0b013e3181e9f294
   Luo JQ, 2015, EUR SPINE J, V24, P1621, DOI 10.1007/s00586-015-3911-4
   Memtsoudis SG, 2011, CLIN ORTHOP RELAT R, V469, P649, DOI 10.1007/s11999-010-1549-4
   Mobley SR, 2007, HEAD NECK-J SCI SPEC, V29, P1041, DOI 10.1002/hed.20650
   Nouri A, 2015, SPINE, V40, pE675, DOI 10.1097/BRS.0000000000000913
   Passias PG, 2017, J CLIN NEUROSCI, V42, P75, DOI 10.1016/j.jocn.2017.04.017
   Qian L, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/s13018-014-0063-x
   Sebastian A, 2016, SPINE J, V16, P504, DOI 10.1016/j.spinee.2015.12.009
   Seng CS, 2013, SPINE J, V13, P723, DOI 10.1016/j.spinee.2013.02.038
   Veeravagu A, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.3.FOCUS1669
   Vonck CE, 2018, GLOB SPINE J, V8, P244, DOI 10.1177/2192568217722562
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E112
EP E119
DI 10.1016/j.wneu.2019.09.132
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200016
PM 31574327
DA 2020-05-12
ER

PT J
AU Becker, D
   Scherer, M
   Neher, P
   Jungk, C
   Jesser, J
   Pfluger, I
   Brinster, R
   Bendszus, M
   Bruckner, T
   Maier-Hein, K
   Unterberg, A
AF Becker, Daniela
   Scherer, Moritz
   Neher, Peter
   Jungk, Christine
   Jesser, Jessica
   Pflueger, Irada
   Brinster, Regina
   Bendszus, Martin
   Bruckner, Thomas
   Maier-Hein, Klaus
   Unterberg, Andreas
TI Going Beyond Diffusion Tensor Imaging Tractography in Eloquent Glioma
   Surgery-Hiqh-Resolution Fiber Tractography: Q-Ball or Constrained
   Spherical Deconvolution?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Glioma surgery; High-resolution fiber tractography; Q-ball imaging
ID HIGH-GRADE GLIOMAS; CORTICOSPINAL TRACT; MRI TRACTOGRAPHY; BRAIN;
   TRACKING; ORIENTATIONS
AB OBJECTIVE: As a result of the resolution of intravoxel fiber crossing, high-resolution fiber tractography (HRFT) provides advantages over conventional diffusion tensor imaging (DTI) for fiber tractography (FT). Nevertheless, neurosurgically applied FT is still predominantly based on DTI. Although the application of HRFT is evolving, there is still a lack of data about which method should be preferred. With this prospectively designed study, we present our initial experience comparing an analytical Q-ball imaging (QBI) approach with constrained spherical deconvolution (CSD) and conventional DTI-FT considering a particularly neurosurgical perspective.
   METHODS: For 18 patients with eloquent gliomas in the dominant hemisphere, probabilistic FT based on QBI, CSD, and DTI was performed for the major components of the language-associated pathways using a routine diffusion-weighted sequence. Quantitative analysis evaluated tract density, tract volume (TV), tract length (TL), number of fibers, and tract surface (TS) of the fiber object.
   RESULTS: Both HRFT models showed a significantly larger mean TV, TL, and TS compared with DTI (for QBI vs. DTI: TV (P = 0.0000), TL (P = 0.0048), and TS (P = 0.0129); for CSD vs. DTI: TV (P = 0.0000), TL (P = 0.0008), and TS (P = 0.0010)). However, results of QBI versus CSD did not differ significantly for these variables: TV (P = 0.1415), TL (P = 0.2837), and TS (P = 0.3692). Bland-Altman analysis supports these findings, suggesting systematically higher values for TV, TL, and TS with HRFT but no relevant differences of either QBI or CSD. Neither tumor volume nor peritumoral edema influenced FT results.
   CONCLUSIONS: Our quantitative analysis showed no significant differences regarding TV, TL, and TS for the HRFT methods; however, it suggested advantages over DTI-FT in terms of the display of marginal and terminal fibers. In our recently established setting, QBI-FT shows greater potential for integration into the clinical workflow.
C1 [Becker, Daniela; Scherer, Moritz; Jungk, Christine; Unterberg, Andreas] Heidelberg Univ, Dept Neurosurg, Heidelberg, Germany.
   [Jesser, Jessica; Pflueger, Irada; Bendszus, Martin] Heidelberg Univ, Dept Neuroradiol, Heidelberg, Germany.
   [Neher, Peter; Brinster, Regina; Bruckner, Thomas] Heidelberg Univ, Inst Med Biometry & Biostat, Heidelberg, Germany.
   [Maier-Hein, Klaus] German Canc Res Ctr, Div Med Image Comp, Heidelberg, Germany.
RP Becker, D (reprint author), Heidelberg Univ, Dept Neurosurg, Heidelberg, Germany.
EM daniela.becker@med.uni-heidelberg.de
RI Maier-Hein, Klaus/M-6250-2016
OI Maier-Hein, Klaus/0000-0002-6626-2463
CR Abhinav K, 2015, NEURO-ONCOLOGY, V17, P1199, DOI 10.1093/neuonc/nov113
   Aganj I, 2009, 2009 IEEE INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING: FROM NANO TO MACRO, VOLS 1 AND 2, P1398, DOI 10.1109/ISBI.2009.5193327
   Assaf Y, 2004, MAGN RESON MED, V52, P965, DOI 10.1002/mrm.20274
   BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1
   Becker Daniela, 2019, J Neurosurg Sci, DOI 10.23736/S0390-5616.19.04782-9
   Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018
   Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609
   Bucci M, 2013, NEUROIMAGE-CLIN, V3, P361, DOI 10.1016/j.nicl.2013.08.008
   Caverzasi E, 2016, J NEUROSURG, V125, P33, DOI 10.3171/2015.6.JNS142203
   Descoteaux M, 2007, MAGN RESON MED, V58, P497, DOI 10.1002/mrm.21277
   Descoteaux M, 2009, IEEE T MED IMAGING, V28, P269, DOI 10.1109/TMI.2008.2004424
   DOUEK P, 1991, J COMPUT ASSIST TOMO, V15, P923, DOI 10.1097/00004728-199111000-00003
   Frank LR, 2002, MAGNET RESON MED, V47, P1083, DOI 10.1002/mrm.10156
   Fritzsche K, 2010, CEUR WORKSHOP P, V574, P246
   Fritzsche KH, 2012, METHOD INFORM MED, V51, P441, DOI 10.3414/ME11-02-0031
   Funk P, 1915, MATH ANN, V77, P129, DOI 10.1007/BF01456824
   Garyfallidis E, 2014, FRONT NEUROINFORM, V8, DOI 10.3389/fninf.2014.00008
   Kaden E, 2016, NEUROIMAGE, V139, P346, DOI 10.1016/j.neuroimage.2016.06.002
   Kinoshita M, 2005, NEUROIMAGE, V25, P424, DOI 10.1016/j.neuroimage.2004.07.076
   Kuhnt D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070973
   Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3
   Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781
   Mormina E, 2015, AM J NEURORADIOL, V36, P1853, DOI 10.3174/ajnr.A4368
   Mormina E, 2016, NEURORADIOLOGY, V58, P1067, DOI 10.1007/s00234-016-1732-8
   Nabavi A, 2001, NEUROSURGERY, V48, P787, DOI 10.1097/00006123-200104000-00019
   Negwer C, 2017, J NEUROSURG, V126, P1006, DOI 10.3171/2016.2.JNS152382
   Neher PF, 2015, MED IMAGE ANAL, V26, P287, DOI 10.1016/j.media.2015.10.011
   Pasternak O, 2009, MAGN RESON MED, V62, P717, DOI 10.1002/mrm.22055
   Rit S, 2014, J PHYS CONF SER, V489, DOI 10.1088/1742-6596/489/1/012079
   Sollmann N, 2018, NEUROSURG FOCUS, V44, DOI [10.3171/2018.3.FOCUS1838, 10.3171/2018.10.FocusVid.1873]
   Tournier JD, 2007, NEUROIMAGE, V35, P1459, DOI 10.1016/j.neuroimage.2007.02.016
   Tournier JD, 2004, NEUROIMAGE, V23, P1176, DOI 10.1016/j.neuroimage.2004.07.037
   Tuch DS, 2002, MAGNET RESON MED, V48, P577, DOI 10.1002/mrm.10268
   Tuch DS, 2003, NEURON, V40, P885, DOI 10.1016/S0896-6273(03)00758-X
   Tuch DS, 2004, MAGNET RESON MED, V52, P1358, DOI 10.1002/mrm.20279
   Wilkins B, 2015, NEUROIMAGE, V109, P341, DOI 10.1016/j.neuroimage.2014.12.060
   Wu JS, 2015, HUM BRAIN MAPP, V36, P4972, DOI 10.1002/hbm.22991
   Zhan W, 2006, J MAGN RESON, V183, P193, DOI 10.1016/j.jmr.2006.08.005
NR 38
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E596
EP E609
DI 10.1016/j.wneu.2019.10.138
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200073
PM 31678440
DA 2020-05-12
ER

PT J
AU Bohl, MA
   Sethi, R
   Leveque, JC
AF Bohl, Michael A.
   Sethi, Rajiv
   Leveque, Jean-Christophe
TI Incidence and Clinical Risk of Cement Extravasation in Adult Patients
   Undergoing Prophylactic Vertebroplasty During Surgical Spine
   Reconstruction
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult; Bone cements; Osteotomy; Vertebroplasty
ID PERCUTANEOUS VERTEBROPLASTY; PULMONARY-EMBOLISM; CARDIAC PERFORATION;
   RARE COMPLICATION; DEFORMITY SURGERY; BONE-CEMENT; LEAKAGE;
   POLYMETHYLMETHACRYLATE; METASTASES; AUGMENTATION
AB OBJECTIVE: To measure the incidence and severity of cement extravasation in adult patients undergoing prophylactic vertebroplasty as part of a spinal reconstruction procedure.
   METHODS: Consecutive adult patients treated with prophylactic vertebroplasty during a spinal reconstruction procedure were reviewed over a 46-month period. Patients without a postoperative computed tomography scan were excluded. Spine reconstruction was defined as any procedure involving >= 6 levels of fusion or a 3-column osteotomy. Cement extravasation was graded using a novel grading system. Fisher exact tests were performed to identify independent predictors of cement extravasation.
   RESULTS: Inclusion and exclusion criteria were met by 34 patients comprising 112 vertebral bodies (VB). All 34 patients (100%) had computed tomography evidence of cement extravasation. Of 112 VBs, 103 (92.0%) demonstrated cement extravasation. Thirteen VBs (11.6%) in 9 patients (26.5%) had cement extending to the vena cava or end-organs or cement causing spinal canal stenosis (grade 4 and 5 extravasation). No permanent clinical sequelae were found in these 9 patients. Upper thoracic vertebrae (C7-T6) had significantly higher rates of grade 4 and 5 extravasation than lower thoracic-lumbar vertebrae (T7-L5) (P = 0.004).
   CONCLUSIONS: Although no patients in this study experienced known long-term consequences of prophylactic vertebroplasty, 26.5% of patients had cement extravasation that threatened end-organs or neural elements. These results prompted us to change our practice from cementing upper thoracic VBs to using hooks instead. Cement injection is associated with serious risks and should be performed selectively. Larger prospective studies are needed to verify these results.
C1 [Bohl, Michael A.] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
   [Bohl, Michael A.; Sethi, Rajiv; Leveque, Jean-Christophe] Virginia Mason Med Ctr, Neurosci Inst, Seattle, WA 98101 USA.
RP Bohl, MA (reprint author), St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.; Bohl, MA (reprint author), Virginia Mason Med Ctr, Neurosci Inst, Seattle, WA 98101 USA.
EM Michael.Bohl@bnaneuro.net
CR Alvarez L, 2003, EUR SPINE J, V12, P356, DOI 10.1007/s00586-003-0525-z
   Athreya S, 2009, CARDIOVASC INTER RAD, V32, P817, DOI 10.1007/s00270-009-9550-6
   Barragan-Campos HM, 2006, RADIOLOGY, V238, P354, DOI 10.1148/radiol.2381040841
   Barzilai O, 2019, OPER NEUROSURG, V16, P593, DOI 10.1093/ons/opy186
   Becker S, 2007, J Orthop Surg (Hong Kong), V15, P222
   Calmels V, 2007, AM J NEURORADIOL, V28, P570
   Chen HL, 2002, ANESTH ANALG, V95, P1060, DOI 10.1097/00000539-200210000-00049
   Chen Lih-Huei, 2004, Chang Gung Med J, V27, P261
   Chung Seung-Eun, 2006, Eur Spine J, V15 Suppl 5, P590, DOI 10.1007/s00586-005-0037-0
   Corcos G, 2014, SPINE, V39, pE332, DOI 10.1097/BRS.0000000000000134
   Cotten A, 1996, RADIOLOGY, V200, P525, DOI 10.1148/radiology.200.2.8685351
   Fuentes S, 2010, NEUROCHIRURGIE, V56, P8, DOI 10.1016/j.neuchi.2009.12.001
   Ghobrial GM, 2017, SPINE J, V17, P1499, DOI 10.1016/j.spinee.2017.05.015
   Han S, 2019, WORLD NEUROSURG, V124, pE436, DOI 10.1016/j.wneu.2018.12.113
   Harrington KD, 2001, J BONE JOINT SURG AM, V83A, P1070, DOI 10.2106/00004623-200107000-00014
   Howe CR, 2011, SPINE, V36, P1397, DOI 10.1097/BRS.0b013e3181f453e2
   Jaeblon T, 2010, J AM ACAD ORTHOP SUR, V18, P297, DOI 10.5435/00124635-201005000-00006
   Kim SY, 2005, AM J ROENTGENOL, V185, P1245, DOI 10.2214/AJR.04.1443
   Lador R, 2010, SPINE J, V10, P1118, DOI 10.1016/j.spinee.2010.09.020
   Lim KJ, 2007, ANESTH ANALG, V104, P924, DOI 10.1213/01.ane.0000256974.84535.7a
   Monticelli F, 2005, FORENSIC SCI INT, V149, P35, DOI 10.1016/j.forsciint.2004.06.010
   Moussazadeh N, 2015, SPINE J, V15, P1609, DOI 10.1016/j.spinee.2015.03.037
   Nieuwenhuijse MJ, 2010, SPINE, V35, pE1037, DOI 10.1097/BRS.0b013e3181ddd262
   Passias PG, 2016, J BONE JOINT SURG AM, V98, P536, DOI 10.2106/JBJS.14.01126
   Pichelmann MA, 2010, SPINE, V35, P219, DOI 10.1097/BRS.0b013e3181c91180
   Rollinghoff M, 2009, MINIM INVAS NEUROSUR, V52, P233, DOI 10.1055/s-0029-1243631
   Sabuncuoglu H, 2008, ACTA NEUROCHIR, V150, P811, DOI 10.1007/s00701-008-1503-3
   Schwab FJ, 2012, EUR SPINE J, V21, P2603, DOI 10.1007/s00586-012-2370-4
   Scroop R, 2002, AM J NEURORADIOL, V23, P868
   Semaan H, 2018, ACTA RADIOL, V59, P861, DOI 10.1177/0284185117732599
   Son KH, 2008, EUR J CARDIO-THORAC, V33, P507, DOI 10.1016/j.ejcts.2007.11.027
   Soroceanu A, 2015, SPINE, V40, P1414, DOI 10.1097/BRS.0000000000001020
   Street JT, 2012, SPINE J, V12, P22, DOI 10.1016/j.spinee.2011.12.003
   Stricker K, 2004, ANESTH ANALG, V98, P1184, DOI 10.1213/01.ANE.0000104585.83801.C5
   Teng MMH, 2006, AM J NEURORADIOL, V27, P224
   Tozzi P, 2002, ANN THORAC SURG, V74, P1706, DOI 10.1016/S0003-4975(02)03962-0
   Trumm CG, 2012, SKELETAL RADIOL, V41, P1391, DOI 10.1007/s00256-012-1365-x
   Tsai YD, 2010, SPINE, V35, pE134, DOI 10.1097/BRS.0b013e3181b52221
   Wang Li-jun, 2012, Orthop Surg, V4, P182, DOI 10.1111/j.1757-7861.2012.00193.x
   Yang JY, 2019, SPINE, V44, P777, DOI 10.1097/BRS.0000000000002955
   Yeom JS, 2003, J BONE JOINT SURG BR, V85B, P83, DOI 10.1302/0301-620X.85B1.13026
   Yoo KY, 2004, SPINE, V29, pE294, DOI 10.1097/01.BRS.0000131211.87594.B0
   Zaccheo M. V., 2008, AM J EMERG MED, V26
   Zhan Y, 2017, WORLD NEUROSURG, V101, P633, DOI 10.1016/j.wneu.2017.01.124
NR 44
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E928
EP E936
DI 10.1016/j.wneu.2019.11.034
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200108
PM 31733390
DA 2020-05-12
ER

PT J
AU Bonney, PA
   Fujii, T
   Jarvis, CA
   Pham, MH
   Giannotta, SL
AF Bonney, Phillip A.
   Fujii, Tats
   Jarvis, Casey A.
   Pham, Martin H.
   Giannotta, Steven L.
TI Surgical Closed Suction Drain Use After Craniotomy for Evacuation of
   Supratentorial Epidural Hematomas: A Case Series of Radiographic and
   Clinical Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Craniotomy; Drain; Epidural hematoma; Neurosurgery; Surgical outcomes;
   Traumatic brain injury
ID RISK-FACTORS; HYPOTENSION; INFECTION
AB BACKGROUND: Surgical closed suction drain (SCSDs) are used in a variety of surgical disciplines to prevent postoperative fluid collections. Use of SCSDs has not been well studied in the neurosurgical literature. Practice patterns have varied within our institution with respect to SCSDs after craniotomies for neurotrauma. In this study we describe SCSD use for patients undergoing evacuation of supratentorial epidural hematomas (EDHs) and examine the effect on patient outcomes and length of hospital stay.
   METHODS: We performed a retrospective review of craniotomies for supratentorial EDH performed at our Level I trauma center between May 2015 and May 2018. Imaging and clinical data were obtained from chart review.
   RESULTS: Fifty-two patients with EDH received operations from 8 attending surgeons. The number of drains used was 0 or 1 in 36 cases and 2 or more in 16 cases. Drain location was subgaleal in 25 cases, epidural in 8 cases, and both subgaleal and epidural in 13 cases. Attending preference (P < 0.001) but not hematoma size was associated with use of an epidural drain and use of 2 or more drains. After controlling for age, initial neurologic exam, and presence of other injuries, use of more drains was associated with longer intensive care unit lengths of stay. Drain use pattern was not associated with patient outcome measures, and no return to the operating room was necessary for residual or recurrent EDH.
   CONCLUSIONS: Use of fewer SCSDs did not affect radiographic outcome after evacuation of epidural hematomas but was associated with decreased intensive care unit length of stay.
C1 [Bonney, Phillip A.; Fujii, Tats; Jarvis, Casey A.; Giannotta, Steven L.] Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90007 USA.
   [Pham, Martin H.] Univ Calif San Diego, Dept Neurosurg, San Diego, CA 92103 USA.
RP Bonney, PA (reprint author), Univ Southern Calif, Keck Sch Med, Dept Neurol Surg, Los Angeles, CA 90007 USA.
EM phil.alan.bonney@gmail.com
OI Jarvis, Casey/0000-0001-9598-6615
CR Chan KW, 2000, SURG NEUROL, V54, P444, DOI 10.1016/S0090-3019(00)00323-2
   Choi H, 2013, J NEUROSURG-PEDIATR, V12, P181, DOI 10.3171/2013.4.PEDS12505
   Choi Su Yong, 2015, J Cerebrovasc Endovasc Neurosurg, V17, P194, DOI 10.7461/jcen.2015.17.3.194
   Fujii T, 2016, J CLIN NEUROSCI, V31, P152, DOI 10.1016/j.jocn.2016.03.007
   JACKSON FE, 1971, SURGERY, V70, P578
   Karamchandani K, 2006, BRIT J ANAESTH, V96, P608, DOI 10.1093/bja/ael063
   Kim T, 2013, ACTA NEUROCHIR, V155, P2165, DOI 10.1007/s00701-013-1833-7
   Krpata DM, 2017, J GASTROINTEST SURG, V21, P2083, DOI 10.1007/s11605-017-3601-0
   Meguro T, 2007, NEUROL MED-CHIR, V47, P314, DOI 10.2176/nmc.47.314
   Parker MJ, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001825.pub2
   Schipmann S, 2016, WORLD NEUROSURG, V95, P178, DOI 10.1016/j.wneu.2016.07.093
   TOLEDO E, 1980, ACTA NEUROCHIR, V52, P55, DOI 10.1007/BF01400947
   Watanabe J, 2017, INT J COLORECTAL DIS, V32, P391, DOI 10.1007/s00384-016-2687-2
   Zhang GM, 2009, SURG NEUROL, V72, P138, DOI 10.1016/j.surneu.2008.06.014
   Zhang QY, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011290
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E460
EP E468
DI 10.1016/j.wneu.2019.10.098
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200055
PM 31669243
DA 2020-05-12
ER

PT J
AU Bora, SK
   Suri, A
   Khadgawat, R
   Tandon, N
   Suri, V
   Sharma, MC
   Satyarthee, G
   Singh, M
   Tandon, V
   Agarwal, D
   Kumar, R
   Chandra, PS
   Gurjar, HK
   Borkar, S
   Gupta, DK
   Singh, PK
   Kale, SS
AF Bora, Santanu Kumar
   Suri, Ashish
   Khadgawat, Rajesh
   Tandon, Nikhil
   Suri, Vaishali
   Sharma, Mehar Chand
   Satyarthee, Gurudutt
   Singh, Manmohan
   Tandon, Vivek
   Agarwal, Deepak
   Kumar, Rajinder
   Chandra, P. Sarat
   Gurjar, Hitesh Kumar
   Borkar, Sachin
   Gupta, Deepak Kumar
   Singh, Pankaj Kumar
   Kale, Shashank Sharad
TI Management of Cushing's Disease: Changing Trend from Microscopic to
   Endoscopic Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE ACTH; Cushing disease; Endonasal; Endoscopy; Hypercortisolism;
   Remission; Transsphenoidal
ID TRANSSPHENOIDAL SURGERY; PITUITARY SURGERY; CAVERNOUS SINUS;
   RISK-FACTORS; MICROSURGERY; COMPLICATIONS; ADENOMAS
AB BACKGROUND: Cushing's disease (CD) is a spectrum of clinical manifestations due to adrenocorticotropic hormone-secreting pituitary adenoma. Transsphenoidal adenomectomy remains the standard treatment. There has been a paradigm shift from microscopic to endoscopic transsphenoidal surgery in recent years. However, the efficacy of endoscopic transsphenoidal surgery has not been established. Therefore, it is of interest to determine the superiority of endoscopic transsphenoidal surgery, if any, over microscopic surgery.
   OBJECTIVE: To assess the efficacy of endoscopic endonasal transsphenoidal surgery for the treatment of CD and to determine the factors affecting remission.
   METHODS: Patients undergoing surgery for CD from 2009 to 2017 were analyzed retrospectively. Transsphenoidal resection was the preferred treatment, with recent trends in favor of the endonasal endoscopic skull base approach. Postoperative cortisol level of <2 mu g/dL was taken as remission and value between 2 and 5 mu g/dL as possible remission.
   RESULTS: In total, 104 patients operated primarily for CD were included for analysis; 47 patients underwent microscopic surgery, 55 endoscopic surgery, and 2 were operated transcranially. Remission was achieved in 76.47% of patients. In univariate analysis, factors significantly associated with remission were 1) type of surgery (P = 0.01); remission in endoscopy surgery (88.23%) is better than microscopy (56.6%); 2) postoperative day 1 morning cortisol (P = 0.004); and 3) postoperative day 1 morning ACTH (P = 0.015). In multivariate analysis, only postoperative day 1 cortisol was found to be significant predictor of remission (P = 0.02).
   CONCLUSIONS: Postoperative plasma cortisol level is a strong independent predictor of remission. Remission provided by endoscopy is significantly better than the microscopic approach.
C1 [Bora, Santanu Kumar; Suri, Ashish; Satyarthee, Gurudutt; Singh, Manmohan; Tandon, Vivek; Agarwal, Deepak; Kumar, Rajinder; Chandra, P. Sarat; Gurjar, Hitesh Kumar; Borkar, Sachin; Gupta, Deepak Kumar; Singh, Pankaj Kumar; Kale, Shashank Sharad] All India Inst Med Sci, Neurosci Ctr, Dept Neurosurg, New Delhi, India.
   [Khadgawat, Rajesh] All India Inst Med Sci, Dept Endocrine & Metab, New Delhi, India.
   [Tandon, Nikhil; Suri, Vaishali; Sharma, Mehar Chand] All India Inst Med Sci, Dept Pathol, New Delhi, India.
RP Suri, A (reprint author), All India Inst Med Sci, Neurosci Ctr, Dept Neurosurg, New Delhi, India.
EM surineuro@gmail.com
CR Alfieri A, 2001, NEUROSURGERY, V49, P354, DOI 10.1097/00006123-200108000-00017
   Ammini AC, 2011, HORM-INT J ENDOCRINO, V10, P222, DOI 10.14310/horm.2002.1312
   BLACK PM, 1987, NEUROSURGERY, V20, P920, DOI 10.1227/00006123-198706000-00017
   BUCHFELDER M, 1993, AM J NEURORADIOL, V14, P1183
   Chen JCT, 2003, J NEUROSURG, V98, P967, DOI 10.3171/jns.2003.98.5.0967
   Cho DY, 2002, SURG NEUROL, V58, P371, DOI 10.1016/S0090-3019(02)00892-3
   Esposito F, 2006, J CLIN ENDOCR METAB, V91, P7, DOI 10.1210/jc.2005-1204
   Estrada J, 2001, J CLIN ENDOCR METAB, V86, P5695, DOI 10.1210/jc.86.12.5695
   Frank G, 2006, NEUROENDOCRINOLOGY, V83, P240, DOI 10.1159/000095534
   GOLD EM, 1979, ANN INTERN MED, V90, P829, DOI 10.7326/0003-4819-90-5-829
   Hammer GD, 2004, J CLIN ENDOCR METAB, V89, P6348, DOI 10.1210/jc.2003-032180
   Jho HD, 2001, J NEURO-ONCOL, V54, P187, DOI 10.1023/A:1012969719503
   Jho HD, 2001, MINIM INVAS NEUROSUR, V44, P1, DOI 10.1055/s-2001-13590
   Knappe U J, 1996, Acta Neurochir Suppl, V65, P31
   KNOSP E, 1993, NEUROSURGERY, V33, P610, DOI 10.1227/00006123-199310000-00008
   Laws ER, 2012, BRAIN TUMORS ENCY AP, P692
   Netea-Maier RT, 2006, EUR J ENDOCRINOL, V154, P675, DOI 10.1530/eje.1.02133
   Nishioka H, 2005, ACTA NEUROCHIR, V147, P1163, DOI 10.1007/s00701-005-0586-3
   Rees DA, 2002, CLIN ENDOCRINOL, V56, P541, DOI 10.1046/j.1365-2265.2002.01511.x
   Seiler RW, 2000, J NEUROSURG, V93, P762, DOI 10.3171/jns.2000.93.5.0762
   Semple PL, 1999, J NEUROSURG, V91, P175, DOI 10.3171/jns.1999.91.2.0175
   Shiley SG, 2003, LARYNGOSCOPE, V113, P1283, DOI 10.1097/00005537-200308000-00003
   Shimon I, 2002, NEUROSURGERY, V51, P57, DOI 10.1097/00006123-200207000-00008
   Sonino N, 1996, J CLIN ENDOCR METAB, V81, P2647, DOI 10.1210/jc.81.7.2647
   Swearingen B, 1999, ANN INTERN MED, V130, P821, DOI 10.7326/0003-4819-130-10-199905180-00015
   TINDALL GT, 1990, J NEUROSURG, V72, P363, DOI 10.3171/jns.1990.72.3.0363
   TYRRELL JB, 1994, ENDOCRIN METAB CLIN, V23, P925, DOI 10.1016/S0889-8529(18)30075-6
   Vance ML, 2003, ENDOCRIN METAB CLIN, V32, P355, DOI 10.1016/S0889-8529(03)00003-3
   White DR, 2004, LARYNGOSCOPE, V114, P1945, DOI 10.1097/01.mlg.0000147925.04605.cc
NR 29
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E46
EP E54
DI 10.1016/j.wneu.2019.08.165
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200008
PM 31491582
DA 2020-05-12
ER

PT J
AU Borg, A
   Jaunmuktane, Z
   Dorward, N
AF Borg, Anouk
   Jaunmuktane, Zane
   Dorward, Neil
TI Tumors of the Neurohypophysis: One Unit's Experience and Literature
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Granular cell tumor; Neurohypophysis; Pituicytoma; Sellar region;
   Spindle cell oncocytoma; Transsphenoidal surgery
ID GRANULAR-CELL TUMOR; CENTRAL-NERVOUS-SYSTEM; ADENOHYPOPHYSIS REPORT;
   PILOCYTIC ASTROCYTOMA; PITUICYTOMA REPORT; PITUITARY-ADENOMA; CASE
   SERIES; ONCOCYTOMA; SELLAR; CLASSIFICATION
AB OBJECTIVE: To evaluate and understand the clinical behavior and radiologic correlates of tumors originating from the posterior pituitary gland. To review the management strategy for these rare tumors and add to the limited existing literature.
   METHODS: Retrospective review of 8 cases (5 pituicytomas, 2 spindle cell oncocytomas, and 1 granular cell tumor) managed at our institution between 2004 and 2019. The patients' clinical course, histologic features, and radiologic findings were reviewed. Their management andlong-term follow-up is presented and compared with the literature.
   RESULTS: Long-term follow- up ranged from 1 to 9 years. There was 1 recurrence in a patient with spindle cell oncocytoma, and this was treated with radiotherapy. The endoscopically managed cases resulted in complete tumor excision with no recurrence.
   CONCLUSIONS: Epidemiologic data on primary tumors of the neurohypophysis is limited because of the rarity of these tumors. This study adds to the literature that these tumors behave as World Health Organization grade I tumors, although close follow-up is recommended as a few cases have shown recurrence. The endoscopic approach resulted in better gross total tumor resection rate in this series.
C1 [Borg, Anouk; Dorward, Neil] Natl Hosp Neurol & Neurosurg, Victor Horsley Dept Neurosurg, Queen Sq, London, England.
   [Jaunmuktane, Zane] Univ Coll London Hosp, Natl Hosp Neurol & Neurosurg, Div Neuropathol, London, England.
   [Jaunmuktane, Zane] UCL, Inst Neurol, Queen Sq, London, England.
RP Borg, A (reprint author), Natl Hosp Neurol & Neurosurg, Victor Horsley Dept Neurosurg, Queen Sq, London, England.
EM anoukmt@yahoo.com
OI Borg, Anouk/0000-0002-2171-1026
CR Aquilina K, 2006, BRIT J NEUROSURG, V20, P51, DOI 10.1080/02688690600600996
   BECKER DH, 1981, NEUROSURGERY, V8, P173, DOI 10.1227/00006123-198102000-00006
   Bello CT, 2018, ENDOCRINOL DIAB META, DOI 10.1530/EDM-17-0178
   Benites PR, 2005, VIRCHOWS ARCH, V447, P649, DOI 10.1007/s00428-005-1229-z
   Billeci D, 2017, J CLIN NEUROSCI, V39, P39, DOI 10.1016/j.jocn.2017.02.017
   Borges MT, 2011, J NEURO-ONCOL, V101, P145, DOI 10.1007/s11060-010-0229-2
   Brandao Rafael Augusto Castro Santiago, 2010, Surg Neurol Int, V1, P79, DOI 10.4103/2152-7806.73802
   Brat DJ, 2007, BRAIN PATHOL, V17, P319, DOI 10.1111/j.1750-3639.2007.00082.x
   Brat DJ, 2000, AM J SURG PATHOL, V24, P362, DOI 10.1097/00000478-200003000-00004
   Buhl R, 2001, NEURORADIOLOGY, V43, P309, DOI 10.1007/s002340000507
   Cambiaso P, 2015, PEDIATRICS, V136, pE1632, DOI 10.1542/peds.2015-0638
   CAMPBELL RL, 1966, J NEUROSURG, V25, P208, DOI 10.3171/jns.1966.25.2.0208
   Cenacchi G, 2001, ULTRASTRUCT PATHOL, V25, P309, DOI 10.1080/019131201753136331
   Cha Seung Heon, 2017, Brain Tumor Research and Treatment, V5, P110
   Chakraborti S, 2013, PATHOL RES PRACT, V209, P52, DOI 10.1016/j.prp.2012.10.006
   Chang TW, 2018, BRIT J NEUROSURG, V32, P501, DOI 10.1080/02688697.2018.1472212
   Chu J, 2011, Br J Radiol, V84, pe55, DOI 10.1259/bjr/16529716
   CONE L, 1990, AM J NEURORADIOL, V11, P403
   Cossu G, 2018, ONCOL LETT, V16, P643, DOI 10.3892/ol.2018.8625
   CUSICK JF, 1982, J NEUROSURG, V56, P594, DOI 10.3171/jns.1982.56.4.0594
   Dahiya S, 2005, ACTA NEUROPATHOL, V110, P97, DOI 10.1007/s00401-005-1009-5
   Demssie YN, 2011, PITUITARY, V14, P367, DOI 10.1007/s11102-009-0170-6
   DORON Y, 1965, J NEUROSURG, V22, P95, DOI 10.3171/jns.1965.22.1.0095
   Ellis JA, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.09.011
   Romero-Rojas AE, 2011, BRAIN TUMOR PATHOL, V28, P359, DOI 10.1007/s10014-011-0051-3
   Feng M, 2014, PITUITARY, V17, P399, DOI 10.1007/s11102-013-0515-z
   Feng Z, 2018, BRIT J NEUROSURG, P1
   Figarella-Branger D, 2002, ACTA NEUROPATHOL, V104, P313, DOI 10.1007/s00401-002-0557-1
   Fujisawa H, 2012, NEUROL MED-CHIR, V52, P594, DOI 10.2176/nmc.52.594
   Furtado SV, 2010, J CLIN NEUROSCI, V17, P938, DOI 10.1016/j.jocn.2009.09.047
   Gagliardi F, 2016, PITUITARY, V19, P277, DOI 10.1007/s11102-016-0704-7
   Grote A, 2010, CLIN NEUROPATHOL, V29, P127
   Guadagno E, 2016, ULTRASTRUCT PATHOL, V40, P121, DOI 10.3109/01913123.2016.1157662
   Guerrero-Perez F, 2019, REV ENDOCR METAB DIS, V20, P219, DOI 10.1007/s11154-019-09484-1
   Guerrero-Perez F, 2019, ENDOCRINE, V63, P36, DOI 10.1007/s12020-018-1774-2
   Guo XP, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003062
   Hagel C, 2017, PITUITARY, V20, P211, DOI 10.1007/s11102-016-0762-x
   Han F, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009745
   Hasiloglu ZI, 2016, CLIN RADIOL, V71, DOI 10.1016/j.crad.2016.04.022
   HURLEY TR, 1994, NEUROSURGERY, V35, P314, DOI 10.1227/00006123-199408000-00021
   Huynh N, 2012, CASE REP OPHTHALM, V3, P190, DOI 10.1159/000339242
   Ida CM, 2013, ENDOCR PATHOL, V24, P149, DOI 10.1007/s12022-013-9254-y
   Iglesias A, 2000, EUR RADIOL, V10, P1871, DOI 10.1007/s003300000488
   Inoue R, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0655-x
   Islamian AP, 2012, PITUITARY, V15, P227, DOI 10.1007/s11102-011-0317-0
   JI CH, 1995, NEURORADIOLOGY, V37, P451
   Jiang BY, 2018, NEUROPATHOLOGY, V38, P293, DOI 10.1111/neup.12448
   Karamchandani J, 2012, CAN J NEUROL SCI, V39, P835, DOI 10.1017/S0317167100015717
   Kasashima S, 2000, PATHOL INT, V50, P568, DOI 10.1046/j.1440-1827.2000.01080.x
   Katsuta T, 2003, J NEUROSURG, V98, P404, DOI 10.3171/jns.2003.98.2.0404
   Kim YG, 2015, CHILD NERV SYST, V31, P985, DOI 10.1007/s00381-015-2668-8
   Kloub O, 2005, AM J SURG PATHOL, V29, P247, DOI 10.1097/01.pas.0000147400.87767.f6
   Kobayashi TK, 2006, CYTOPATHOLOGY, V17, P153, DOI 10.1111/j.1365-2303.2006.00298.x
   Kong XY, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005657
   Kosuge Yasushi, 2012, J Med Case Rep, V6, P306, DOI 10.1186/1752-1947-6-306
   Koutourousiou M, 2013, J NEUROL SURG PART B, V74, P1, DOI 10.1055/s-0032-1329619
   Kwon MJ, 2011, PATHOL INT, V61, P598, DOI 10.1111/j.1440-1827.2011.02708.x
   Law-ye B, 2018, WORLD NEUROSURG, V109, P304, DOI 10.1016/j.wneu.2017.10.036
   Lee CC, 2004, J FORMOS MED ASSOC, V103, P58
   Lefevre E, 2018, PITUITARY, V21, P507, DOI 10.1007/s11102-018-0905-3
   Li Z, 2009, PATHOLOGY, V41, P505, DOI 10.1080/00313020903041119
   LIMA A, 1960, J NEUROSURG, V17, P778, DOI 10.3171/jns.1960.17.4.0778
   LISS L, 1958, ARCH NEURO PSYCHIATR, V80, P567, DOI 10.1001/archneurpsyc.1958.02340110037005
   Liu HL, 2017, CHINESE MED J-PEKING, V130, P741, DOI 10.4103/0366-6999.201605
   Losa M, 2000, J NEUROSURG, V93, P121, DOI 10.3171/jns.2000.93.1.0121
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Manoranjan B, 2017, J CLIN NEUROSCI, V43, P134, DOI 10.1016/j.jocn.2017.05.017
   Mao ZG, 2011, ONCOL LETT, V2, P37, DOI 10.3892/ol.2010.209
   MASSIE AP, 1979, J PATHOL, V129, P53, DOI 10.1002/path.1711290202
   Matyja E, 2010, FOLIA NEUROPATHOL, V48, P175
   Menon G, 2008, BRIT J NEUROSURG, V22, P126, DOI 10.1080/02688690701604566
   Mete O, 2013, AM J SURG PATHOL, V37, P1694, DOI 10.1097/PAS.0b013e31829723e7
   Mlika M, 2011, J MED CASE REPORTS, V5
   Mu QC, 2015, MOL MED REP, V12, P871, DOI 10.3892/mmr.2015.3476
   Mumert ML, 2011, J NEUROSURG, V114, P325, DOI 10.3171/2010.5.JNS1058
   Nagata Y, 2018, WORLD NEUROSURG, V114, pE1225, DOI 10.1016/j.wneu.2018.03.180
   Nakasu Y, 2006, NEUROL MED-CHIR, V46, P152, DOI 10.2176/nmc.46.152
   Neidert MC, 2016, HUM PATHOL, V47, P138, DOI 10.1016/j.humpath.2015.08.017
   Newnham HH, 2008, NEW ENGL J MED, V359, P2824, DOI 10.1056/NEJMicm067848
   Nishio S, 1998, CLIN NEUROL NEUROSUR, V100, P144, DOI 10.1016/S0303-8467(98)00017-1
   Ogiwara Hideki, 2011, Surg Neurol Int, V2, P116, DOI 10.4103/2152-7806.83932
   Orrego JJ, 2009, PITUITARY, V12, P371, DOI 10.1007/s11102-009-0185-z
   Osman M, 2017, AM J CASE REP, V18, DOI 10.12659/AJCR.903702
   Peron S, 2017, WORLD NEUROSURG, V105, DOI 10.1016/j.wneu.2017.06.171
   Phillips JJ, 2010, ARCH PATHOL LAB MED, V134, P1063, DOI 10.1043/2009-0167-CR.1
   Piccirilli M, 2014, TUMORI J, V100, pE160, DOI [10.1177/1636.17940, 10.1700/1636.17940]
   Polasek JB, 2018, J NEURO-ONCOL, V140, P181, DOI 10.1007/s11060-018-2986-2
   Policarpio-Nicolas MLC, 2008, DIAGN CYTOPATHOL, V36, P58, DOI 10.1002/dc.20646
   Popovic V, 2007, ENDOCR PATHOL, V18, P91, DOI 10.1007/s12022-007-0013-9
   Rhee JS, 2002, ANN OTO RHINOL LARYN, V111, P754, DOI 10.1177/000348940211100818
   Rivero-Celada D, 2012, NEUROCIRUGIA, V23, P165, DOI 10.1016/j.neucir.2012.03.001
   Roncaroli F, 2002, AM J SURG PATHOL, V26, P1048, DOI 10.1097/00000478-200208000-00010
   ROSSI ML, 1987, J NEUROSURG, V67, P768, DOI 10.3171/jns.1987.67.5.0768
   Rotman JA, 2014, CLIN IMAG, V38, P499, DOI 10.1016/j.clinimag.2014.03.003
   Saiegh L, 2013, NEUROENDOCRINOL LETT, V34, P331
   Salge-Arrieta FJ, 2019, J ENDOCRINOL INVEST, V42, P371, DOI 10.1007/s40618-018-0923-z
   Sali A, 2017, NEUROPATHOLOGY, V37, P535, DOI 10.1111/neup.12393
   Schaller B, 1998, NEUROSURGERY, V42, P166, DOI 10.1097/00006123-199801000-00036
   Schultz AB, 2001, ARCH PATHOL LAB MED, V125, P527
   Secci F, 2012, ACTA NEUROCHIR, V154, P649, DOI 10.1007/s00701-011-1235-7
   Shenoy AS, 2013, INDIAN J PATHOL MICR, V56, P180, DOI 10.4103/0377-4929.118695
   Shibuya M, 2018, BRAIN TUMOR PATHOL, V35, P62, DOI 10.1007/s10014-018-0311-6
   Shizukuishi T, 2014, JPN J RADIOL, V32, P179, DOI 10.1007/s11604-013-0279-4
   Singh G, 2012, CLIN NEUROL NEUROSUR, V114, P267, DOI 10.1016/j.clineuro.2011.10.014
   Sosa S, 2018, MEDICINA-BUENOS AIRE, V78, P33
   Teti C, 2015, PITUITARY, V18, P592, DOI 10.1007/s11102-014-0612-7
   Tian YJ, 2013, CLIN NEUROL NEUROSUR, V115, P1943, DOI 10.1016/j.clineuro.2013.07.032
   Ulm AJ, 2004, NEUROSURGERY, V54, P753, DOI 10.1227/01.NEU.0000108983.50966.B7
   Vajtai I, 2011, ACTA NEUROPATHOL, V122, P253, DOI 10.1007/s00401-011-0835-x
   Vellutini Eduardo de Arnaldo Silva, 2018, Surg Neurol Int, V9, P145, DOI 10.4103/sni.sni_319_17
   Vuong HG, 2016, PATHOL RES PRACT, V212, P222, DOI 10.1016/j.prp.2015.07.014
   Wang JM, 2016, NEUROPATHOLOGY, V36, P432, DOI 10.1111/neup.12291
   Witte Hanno M, 2018, Br J Neurosurg, P1, DOI 10.1080/02688697.2018.1533107
   Yang GZ, 2017, INT J SURG PATHOL, V25, P751, DOI 10.1177/1066896917712861
   Yang XY, 2016, ONCOL LETT, V12, P3417, DOI 10.3892/ol.2016.5119
   Yilmaz O, 2012, CHILD NERV SYST, V28, P11, DOI 10.1007/s00381-011-1634-3
   Yoshida K, 2018, WORLD NEUROSURG, V119, P201, DOI 10.1016/j.wneu.2018.07.245
   Zhang Y, 2018, WORLD NEUROSURG, V118, pE621, DOI 10.1016/j.wneu.2018.07.004
   Zunarelli E, 2011, PATHOLOGY, V43, P389, DOI 10.1097/PAT.0b013e32834687b3
   Zygourakis CC, 2015, PITUITARY, V18, P150, DOI 10.1007/s11102-014-0568-7
NR 121
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E968
EP E978
DI 10.1016/j.wneu.2019.11.043
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200113
PM 31734425
DA 2020-05-12
ER

PT J
AU Borghei-Razavi, H
   Sharma, M
   Emch, T
   Krivosheya, D
   Lee, B
   Muhsen, B
   Prayson, R
   Obuchowski, N
   Barnett, GH
   Vogelbaum, MA
   Chao, ST
   Suh, JH
   Mohammadi, AM
   Angelov, L
AF Borghei-Razavi, Hamid
   Sharma, Mayur
   Emch, Todd
   Krivosheya, Daria
   Lee, Bryan
   Muhsen, Baha'eddin
   Prayson, Richard
   Obuchowski, Nancy
   Barnett, Gene H.
   Vogelbaum, Michael A.
   Chao, Samuel T.
   Suh, John H.
   Mohammadi, Alireza M.
   Angelov, Lilyana
TI Pathologic Correlation of Cellular Imaging Using Apparent Diffusion
   Coefficient Quantification in Patients with Brain Metastases After Gamma
   Knife Radiosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Apparent diffusion coefficient; Brain metastasis; Gamma knife
   radiosurgery; Pathologic correlation
ID HIGH-GRADE GLIOMAS; INTRAVOXEL INCOHERENT MOTION; STEREOTACTIC
   RADIOSURGERY; RADIATION NECROSIS; TUMOR PROGRESSION; MR SPECTROSCOPY;
   LOCAL-CONTROL; FOLLOW-UP; FDG-PET; DIFFERENTIATION
AB OBJECTIVE: To evaluate the role of apparent diffusion coefficient (ADC) in differentiating radiation necrosis (RN) from recurrent tumor after Gamma Knife radiosurgery (GKRS) for brain metastases (BMs).
   METHODS: Forty-one patients with BM who underwent surgical intervention after GKRS at Cleveland Clinic (2006-2017) were included in this retrospective study. The ADC values of the growing lesions and the contralateral hemisphere were calculated using picture archiving and communication system. These values were correlated to the percentage of RN identified on pathologic evaluation of the surgical specimen.
   RESULTS: The median age of the patients was 59 years (range, 25-86 years), and lung cancer (63.4%) was the most common malignancy. Median initial (pre-GKRS) target volume of the lesions was 5.4 cc (range, 0.135-45.6 cc), and median GKRS dose was 18.0 Gy. Surgical resection or biopsy was performed at a median of 176 days after GKRS. Two variables were statistically significant predictors of predominate RN (75%-100%) in the surgical specimen: 1) ADC of the lesion on the preresection magnetic resonance imaging (MRI) and 2) initial pre-GKRS target volume. ADC >1.5 x 10(-3) mm(2)/s within the lesion on MRI predicted significant RN on pathologic evaluation of the lesion (P < 0.05). Similarly, when the target volume before GKRS was large (>10 cc), the risk of identifying significant necrosis in the pathologic specimen was elevated (P < 0.05).
   CONCLUSIONS: Our data suggest that the combination of lesion ADC on MRI prior to surgical intervention and the initial target volume can predict RN with reasonable accuracy.
C1 [Borghei-Razavi, Hamid; Sharma, Mayur; Krivosheya, Daria; Lee, Bryan; Muhsen, Baha'eddin; Barnett, Gene H.; Vogelbaum, Michael A.; Mohammadi, Alireza M.; Angelov, Lilyana] Cleveland Clin, Dept Neurosurg, Cleveland, OH 44106 USA.
   [Emch, Todd] Cleveland Clin, Dept Neuroradiol, Cleveland, OH 44106 USA.
   [Prayson, Richard] Cleveland Clin, Dept Neuropathol, Cleveland, OH 44106 USA.
   [Obuchowski, Nancy] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA.
   [Chao, Samuel T.; Suh, John H.] Cleveland Clin, Dept Radiat Oncol, Cleveland, OH 44106 USA.
   [Borghei-Razavi, Hamid; Sharma, Mayur; Krivosheya, Daria; Lee, Bryan; Muhsen, Baha'eddin; Vogelbaum, Michael A.; Chao, Samuel T.; Suh, John H.; Mohammadi, Alireza M.; Angelov, Lilyana] Cleveland Clin, Rose Ella Burkhart Brain Tumor & Neurooncol Ctr, Cleveland, OH 44106 USA.
RP Angelov, L (reprint author), Cleveland Clin, Dept Neurosurg, Cleveland, OH 44106 USA.; Angelov, L (reprint author), Cleveland Clin, Rose Ella Burkhart Brain Tumor & Neurooncol Ctr, Cleveland, OH 44106 USA.
EM angelol@ccf.org
RI Sharma, Mayur/B-3228-2018
OI Sharma, Mayur/0000-0001-6481-7819
CR Al Sayyari A, 2010, AM J NEURORADIOL, V31, P1049, DOI 10.3174/ajnr.A2011
   Alattar AA, 2019, WORLD NEUROSURG, V128, P134, DOI 10.1016/j.wneu.2019.04.200
   Ali MA, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.7.FOCUS16227
   Alkonyi B, 2012, J NUCL MED, V53, P1058, DOI 10.2967/jnumed.111.097881
   Aoyama H, 2006, JAMA-J AM MED ASSOC, V295, P2483, DOI 10.1001/jama.295.21.2483
   Bisdas S, 2011, ACAD RADIOL, V18, P575, DOI 10.1016/j.acra.2011.01.018
   Bulakbasi N, 2003, AM J NEURORADIOL, V24, P225
   Camargo A, 2017, AM J NEURORADIOL, V38, P1200, DOI 10.3174/ajnr.A5144
   Chao ST, 2013, INT J RADIAT ONCOL, V87, P449, DOI 10.1016/j.ijrobp.2013.05.015
   Chiang IC, 2009, BRIT J RADIOL, V82, P813, DOI 10.1259/bjr/90100265
   Chuang CC, 2012, J NEUROSURG, V117, P63, DOI 10.3171/2012.7.GKS121003
   Detsky JS, 2017, J NEURO-ONCOL, V134, P433, DOI 10.1007/s11060-017-2545-2
   El Kady RM, 2011, AM J ROENTGENOL, V196, pW280, DOI 10.2214/AJR.10.4706
   Ellingson BM, 2015, NEURO-ONCOLOGY, V17, P1188, DOI 10.1093/neuonc/nov095
   Ganz J, 2009, ACTA NEUROCHIR, V151, P9, DOI 10.1007/s00701-008-0174-4
   Gavrilovic IT, 2005, J NEURO-ONCOL, V75, P5, DOI 10.1007/s11060-004-8093-6
   Guo AC, 2002, RADIOLOGY, V224, P177, DOI 10.1148/radiol.2241010637
   Hagmann P, 2006, RADIOGRAPHICS, V26, pS205, DOI 10.1148/rg.26si065510
   Hein PA, 2004, AM J NEURORADIOL, V25, P201
   Inano R, 2014, NEUROIMAGE-CLIN, V5, P396, DOI 10.1016/j.nicl.2014.08.001
   Kapadia A, 2017, J NEURO-ONCOL, V135, P119, DOI 10.1007/s11060-017-2556-z
   Kapsalaki EZ, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/6/E7
   Kilburn JM, 2014, J NEURO-ONCOL, V117, P167, DOI 10.1007/s11060-014-1373-x
   Kim DY, 2014, AM J NEURORADIOL, V35, P2082, DOI 10.3174/ajnr.A3995
   Kim JM, 2017, J NEURO-ONCOL, V133, P357, DOI 10.1007/s11060-017-2442-8
   Knitter JR, 2018, AM J ROENTGENOL, V211, P168, DOI 10.2214/AJR.17.18890
   Kwee TC, 2008, EUR RADIOL, V18, P1937, DOI 10.1007/s00330-008-0968-z
   Lee CC, 2014, J NEURO-ONCOL, V118, P351, DOI 10.1007/s11060-014-1439-9
   Lin NU, 2015, LANCET ONCOL, V16, pE270, DOI 10.1016/S1470-2045(15)70057-4
   Minniti G, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-48
   Ozsunar Y, 2010, ACAD RADIOL, V17, P282, DOI 10.1016/j.acra.2009.10.024
   Patchell RA, 2003, CANCER TREAT REV, V29, P533, DOI 10.1016/S0305-7372(03)00105-1
   Peng LK, 2018, INT J RADIAT ONCOL, V102, P1236, DOI 10.1016/j.ijrobp.2018.05.041
   SCHWARTZ RB, 1991, AM J NEURORADIOL, V12, P1187
   Server A, 2011, EUR J RADIOL, V80, P462, DOI 10.1016/j.ejrad.2010.07.017
   Shah R, 2012, RADIOGRAPHICS, V32, P1343, DOI 10.1148/rg.325125002
   Sharma M, 2017, WORLD NEUROSURG, V106, P666, DOI 10.1016/j.wneu.2017.07.048
   Sharma M, 2017, CANCER MED-US, V6, P2076, DOI 10.1002/cam4.1149
   Sharma P, 2017, CHIN CLIN ONCOL, V6, DOI [10.21037/cco.2016.12.01, 10.21037/cco.2017.06.26]
   Shaw E, 2000, INT J RADIAT ONCOL, V47, P291, DOI 10.1016/S0360-3016(99)00507-6
   Sneed PK, 2015, J NEUROSURG, V123, P373, DOI 10.3171/2014.10.JNS141610
   Soon YY, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009454.pub2
   Stelzer Keith J, 2013, Surg Neurol Int, V4, pS192, DOI 10.4103/2152-7806.111296
   Tie J, 2008, J CLIN NEUROSCI, V15, P1327, DOI 10.1016/j.jocn.2007.12.008
   Tihan T, 2006, HUM PATHOL, V37, P272, DOI 10.1016/j.humpath.2005.11.010
   Tomura N, 2017, AM J NEURORADIOL, V38, P1520, DOI 10.3174/ajnr.A5252
   Trifiletti DM, 2017, J NEURO-ONCOL, V134, P289, DOI 10.1007/s11060-017-2519-4
   Varma A, 2006, NEUROSURGERY, V59, P1030, DOI 10.1227/01.NEU.0000245596.46581.B2
   Vermoolen MA, 2012, INSIGHTS IMAGING, V3, P395, DOI 10.1007/s13244-012-0175-y
   Vogelbaum MA, 2006, J NEUROSURG, V104, P907, DOI 10.3171/jns.2006.104.6.907
   Zhang ZJ, 2018, EUR RADIOL, V28, P2255, DOI 10.1007/s00330-017-5154-8
NR 51
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E903
EP E912
DI 10.1016/j.wneu.2019.11.037
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200105
PM 31733389
DA 2020-05-12
ER

PT J
AU Caffo, M
   Cardali, SM
   Raffa, G
   Caruso, G
   Barresi, V
   Ricciardo, G
   Gorgoglione, N
   Granata, F
   Germano, A
AF Caffo, Maria
   Cardali, Salvatore M.
   Raffa, Giovanni
   Caruso, Gerardo
   Barresi, Valeria
   Ricciardo, Giuseppe
   Gorgoglione, Nicola
   Granata, Francesca
   Germano, Antonino
TI The Value of Preoperative Planning Based on Navigated Transcranical
   Magnetic Stimulation for Surgical Treatment of Brain Metastases Located
   in the Perisylvian Area
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain metastases; Cortical mapping; Eloquent areas; Navigated
   transcranial magnetic stimulation; Sylvian area
ID DTI FIBER TRACKING; LANGUAGE PATHWAYS; GLIOMA SURGERY; CORTICAL
   STIMULATION; MOTOR; DIFFUSION; TUMORS; TRACT; TOOL; TRACTOGRAPHY
AB BACKGROUND: Brain metastases are the most common neoplasms in adults. When brain metastases are located in eloquent areas, their treatment still seems controversial and not clearly defined. It is therefore essential to provide correct preoperative planning to better define extension and characterization of brain metastasis.
   METHODS: We retrospectively looked for the tumor database of our institution, patients with single brain metastasis, located in the sylvian area, who underwent resection with the support of intraoperative neurophysiologic monitoring between 2008 and 2018.
   RESULTS: We retrieved data for 30 adults, each with a single brain metastasis that was located in the sylvian area, including the insula and the lower portion of the motor cortex. Neuronavigation and the intraoperative visualization of the navigated transcranial magnetic stimulation-based reconstruction of functional networks were used to delineate the ideal trajectory toward the lesion. The Karnofsky Performance Status significantly improved in the postoperative period.
   CONCLUSIONS: The correct planning of brain metastasis allows more secure removal of the neoplastic lesion, avoiding and/or reducing the appearance of neurologic deficits. Navigated transcranial magnetic stimulation represents a new method that can promote a more complete and safer resection of the metastatic lesion in eloquent areas. An optimal surgical result, in the absence of postoperative neurologic deficits, allows the patient to undertake adjuvant therapy able to prolong survival.
C1 [Caffo, Maria; Cardali, Salvatore M.; Raffa, Giovanni; Caruso, Gerardo; Ricciardo, Giuseppe; Gorgoglione, Nicola; Germano, Antonino] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Unit Neurosurg, Messina, Italy.
   [Granata, Francesca] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Italy.
   [Barresi, Valeria] Univ Verona, Dept Diagnost & Publ Hlth, Verona, Italy.
RP Caruso, G (reprint author), Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Unit Neurosurg, Messina, Italy.
EM gcaruso@unime.it
RI Raffa, Giovanni/K-7972-2016
OI Raffa, Giovanni/0000-0001-8623-4964
CR Altieri Roberto, 2018, Surg Technol Int, V33, P353
   Bello L, 2007, NEUROSURGERY, V60, P67, DOI 10.1227/01.NEU.0000249206.58601.DE
   Bello L, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.12.FOCUS09240
   BERGER MS, 1992, STEREOT FUNCT NEUROS, V58, P153, DOI 10.1159/000098989
   Berman J, 2009, MAGN RESON IMAGING C, V17, P205, DOI 10.1016/j.mric.2009.02.002
   Bongetta D, 2016, WORLD NEUROSURG, V88, P54, DOI 10.1016/j.wneu.2016.01.017
   Bongetta D, 2016, ACTA NEUROCHIR, V158, P325, DOI 10.1007/s00701-015-2654-7
   Bozzao A, 2010, EUR RADIOL, V20, P2475, DOI 10.1007/s00330-010-1806-7
   Caffo M, 2013, INT J MOL SCI, V14, P2135, DOI 10.3390/ijms14012135
   Compston A, 2010, BRAIN, V133, P2835, DOI 10.1093/brain/awq274
   Conti A, 2014, OPER NEUROSURG, V10, P542, DOI 10.1227/NEU.0000000000000502
   Corina DP, 2010, BRAIN LANG, V115, P101, DOI 10.1016/j.bandl.2010.04.001
   De Benedictis A, 2010, NEUROSURGERY, V66, P1074, DOI 10.1227/01.NEU.0000369514.74284.78
   Della Pappa GM, 2019, WORLD NEUROSURG, V128, P547, DOI 10.1016/j.wneu.2019.05.142
   Della Pepa GM, 2019, WORLD NEUROSURG, V131, P18, DOI 10.1016/j.wneu.2019.07.165
   Della Pepa GM, 2018, ACTA NEUROCHIR, V160, P1873, DOI 10.1007/s00701-018-3628-3
   Della Pepa GM, 2018, ACTA NEUROCHIR, V160, P1259, DOI 10.1007/s00701-018-3541-9
   Della Pepa GM, 2019, WORLD NEUROSURG, V129, P401
   Essayed WI, 2017, NEUROIMAGE-CLIN, V15, P659, DOI 10.1016/j.nicl.2017.06.011
   Frey D, 2012, NEUROIMAGE, V62, P1600, DOI 10.1016/j.neuroimage.2012.05.059
   Frey D, 2014, NEURO-ONCOLOGY, V16, P1365, DOI 10.1093/neuonc/nou110
   Hendrix P, 2016, CLIN ANAT, V29, P925, DOI 10.1002/ca.22765
   Hwang TL, 1996, CANCER, V77, P1551
   Ibrahim AS, 2013, EGYPT J RADIOL NUC M, V44, P297, DOI 10.1016/j.ejrnm.2013.02.011
   Kalkanis SN, 2010, J NEURO-ONCOL, V96, P33, DOI 10.1007/s11060-009-0061-8
   Keles GE, 2004, J NEUROSURG, V100, P369, DOI 10.3171/jns.2004.100.3.0369
   Krieg SM, 2017, ACTA NEUROCHIR, V159, P1187, DOI 10.1007/s00701-017-3187-z
   Krieg SM, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00261
   Krieg SM, 2014, NEURO-ONCOLOGY, V16, P1274, DOI 10.1093/neuonc/nou007
   Krieg SM, 2014, NEUROIMAGE, V100, P219, DOI 10.1016/j.neuroimage.2014.06.016
   Kyritsis AP, 2012, CANCER CHEMOTH PHARM, V69, P1, DOI 10.1007/s00280-011-1775-9
   Lin XL, 2015, J CLIN ONCOL, V33, P3475, DOI 10.1200/JCO.2015.60.9503
   Lu S, 2003, AM J NEURORADIOL, V24, P937
   Mourad AF, 2017, EGYPT J RADIOL NUC M, V48, P661, DOI 10.1016/j.ejrnm.2017.04.002
   Nimsky C, 2005, RADIOLOGY, V234, P218, DOI 10.1148/radiol.2341031984
   Nimsky C, 2005, NEUROSURGERY, V56, P130, DOI 10.1227/01.NEU.0000144842.18771.30
   Nimsky C, 2007, NEUROSURGERY, V61, P178, DOI [10.1227/01.NEU.0000144842.18771.30, 10.1227/01.neu.0000279214.00139.3b]
   Orringer DA, 2012, EXPERT REV MED DEVIC, V9, P491, DOI [10.1586/ERD.12.42, 10.1586/erd.12.42]
   Pascual-Leone A, 1999, PHILOS T R SOC B, V354, P1229, DOI 10.1098/rstb.1999.0476
   Pascual-Leone A, 2000, CURR OPIN NEUROBIOL, V10, P232, DOI 10.1016/S0959-4388(00)00081-7
   PATCHELL RA, 1990, NEW ENGL J MED, V322, P494, DOI 10.1056/NEJM199002223220802
   Picht T, 2016, J NEURO-ONCOL, V126, P535, DOI 10.1007/s11060-015-1993-9
   Picht T, 2013, NEUROSURGERY, V72, P808, DOI 10.1227/NEU.0b013e3182889e01
   Picht T, 2012, NEUROSURGERY, V70, P1248, DOI 10.1227/NEU.0b013e318243881e
   Picht T, 2011, NEUROSURGERY, V69, P581, DOI 10.1227/NEU.0b013e3182181b89
   Picht T, 2009, NEUROSURGERY, V65, P93, DOI 10.1227/01.NEU.0000348009.22750.59
   Raffa G, 2017, NAVIGATED TRANSCRANI, P97
   Raffa Giovanni, 2019, J Neurosurg, P1, DOI 10.3171/2019.3.JNS183411
   Raffa G, 2019, J NEUROSURG SCI, V63, P670, DOI 10.23736/S0390-5616.19.04710-6
   Raffa G, 2019, WORLD NEUROSURG, V128, pE378, DOI 10.1016/j.wneu.2019.04.158
   Raffa G, 2019, CLIN NEUROL NEUROSUR, V180, P7, DOI 10.1016/j.clineuro.2019.03.003
   Raffa G, 2018, CLIN NEUROL NEUROSUR, V168, P127, DOI 10.1016/j.clineuro.2018.03.009
   Raffa G, 2018, NEUROSURGERY, V83, P768, DOI 10.1093/neuros/nyx554
   Raffa G, 2017, ACTA NEUROCHIR SUPPL, V124, P251, DOI 10.1007/978-3-319-39546-3_37
   Raffa G, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00552
   Rizzo V, 2014, NEUROSCI LETT, V583, P136, DOI 10.1016/j.neulet.2014.09.017
   Romano A, 2011, NEUROSURGERY, V69, P696, DOI 10.1227/NEU.0b013e31821a8555
   Rosenstock T, 2017, J NEUROSURG, V126, P1227, DOI 10.3171/2016.4.JNS152896
   Rosset A, 2004, J DIGIT IMAGING, V17, P205, DOI 10.1007/s10278-004-1014-6
   Sanai N, 2008, NEW ENGL J MED, V358, P18, DOI 10.1056/NEJMoa067819
   Scerrati A, 2014, CLIN NEUROL NEUROSUR, V124, P106, DOI 10.1016/j.clineuro.2014.06.032
   Schwendner MJ, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00424
   Scibilia A, 2018, NEUROL RES, V40, P241, DOI 10.1080/01616412.2018.1429203
   Scibilia A, 2017, ACTA NEUROCHIR SUPPL, V124, P263, DOI 10.1007/978-3-319-39546-3_38
   Scibilia A, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS16141
   Sjobakk TE, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-141
   Soffietti R, 2017, NEURO-ONCOLOGY, V19, P162, DOI 10.1093/neuonc/now241
   Sollmann N, 2016, J NEUROSCI METH, V267, P45, DOI 10.1016/j.jneumeth.2016.04.002
   Sperduto PW, 2012, J CLIN ONCOL, V30, P419, DOI 10.1200/JCO.2011.38.0527
   Treglia G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194669
   VECHT CJ, 1993, ANN NEUROL, V33, P583, DOI 10.1002/ana.410330605
   Yen PS, 2009, SURG NEUROL, V72, P464, DOI 10.1016/j.surneu.2009.05.008
NR 72
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E442
EP E452
DI 10.1016/j.wneu.2019.10.090
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200053
PM 31655240
DA 2020-05-12
ER

PT J
AU Caplan, IF
   Glauser, G
   Goodrich, S
   Chen, HI
   Lucas, TH
   Lee, JYK
   McClintock, SD
   Malhotra, NR
AF Caplan, Ian F.
   Glauser, Gregory
   Goodrich, Stephen
   Chen, H. Isaac
   Lucas, Timothy H.
   Lee, John Y. K.
   McClintock, Scott D.
   Malhotra, Neil R.
TI Undiagnosed Obstructive Sleep Apnea as Predictor of 90-Day Readmission
   for Brain Tumor Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; Discharge predictive tool; Hospital readmissions; STOP-Bang
   questionnaire
ID STOP-BANG QUESTIONNAIRE; 30-DAY READMISSION; POSTOPERATIVE
   COMPLICATIONS; SURGERY PATIENTS; CRANIOTOMY; SCREEN; RISK; CARE; HOME;
   TOOL
AB BACKGROUND: Previously undiagnosed obstructive sleep apnea (OSA) is a known contributor to negative postoperative outcomes. The STOP-Bang questionnaire is a screening tool for OSA that has been validated in both medical and surgical populations. The authors have previously studied this screening tool in a brain tumor population at 30 days. The present study seeks to investigate the effectiveness of this questionnaire, for predicting 90-day readmissions in a population of brain tumor patients with previously undiagnosed OSA.
   METHODS: Included for analysis were all patients undergoing craniotomy for supratentorial neoplasm at a multihospital, single academic medical center. Data were collected from supratentorial craniotomy cases for which the patient was alive at 90 days after surgery (n = 238). Simple logistic regression analyses were used to assess the ability of the STOP-Bang questionnaire and subsequent single variables to accurately predict patient outcomes at 90 days.
   RESULTS: The sample included 238 brain tumor admissions, of which 50% were female (n = 119). The average STOP-Bang score was 1.95 +/- 1.24 (range 0-7). A 1-unit higher increase in STOP-Bang score accurately predicted 90-day readmissions (odds ratio [OR] = 1.65, P = 0.001), 30- to 90-day emergency department visits (OR = 1.85, P < 0.001), and 30- to 90-day reoperation (OR = 2.32, P < 0.001) with fair accuracy as confirmed by the receiver operating characteristic (C-statistic = 0.65-0.76). However, the STOP-Bang questionnaire did not correlate with home discharge (P = 0.315).
   CONCLUSIONS: The results of this study suggest that undiagnosed OSA, as evaluated by the STOP-Bang questionnaire, is an effective predictor of readmission risk and health system utilization in a brain tumor craniotomy population with previously undiagnosed OSA.
C1 [Caplan, Ian F.; Glauser, Gregory; Chen, H. Isaac; Lucas, Timothy H.; Lee, John Y. K.; Malhotra, Neil R.] Hosp Univ Penn, Dept Neurosurg, 3400 Spruce St, Philadelphia, PA 19104 USA.
   [Goodrich, Stephen] Univ Penn, McKenna EpiLog Fellowship Populat Hlth, Philadelphia, PA 19104 USA.
   [Goodrich, Stephen; McClintock, Scott D.] West Chester Univ, West Chester Stat Inst, W Chester, PA USA.
   [Goodrich, Stephen; McClintock, Scott D.] West Chester Univ, Dept Math, W Chester, PA USA.
RP Malhotra, NR (reprint author), Hosp Univ Penn, Dept Neurosurg, 3400 Spruce St, Philadelphia, PA 19104 USA.
EM NRM@uphs.upenn.edu
OI Goodrich, Stephen/0000-0001-9225-3627
FU Kevin and Bernadette McKenna Family Research Fund
FX Support was received from the Kevin and Bernadette McKenna Family
   Research Fund.
CR American Cancer Society, 2018, KEY STAT BRAIN SPIN
   Axon RN, 2011, JAMA-J AM MED ASSOC, V305, P504, DOI 10.1001/jama.2011.72
   Berger I, 2019, NEUROSURGERY, V85, pE902, DOI 10.1093/neuros/nyz161
   Caplan Ian F, 2019, J Neurosurg, P1, DOI 10.3171/2019.4.JNS1968
   Chudeau N, 2016, ANAESTH CRIT CARE PA, V35, P347, DOI 10.1016/j.accpm.2016.01.006
   Chung F, 2012, BRIT J ANAESTH, V108, P768, DOI 10.1093/bja/aes022
   Chung F, 2008, ANESTHESIOLOGY, V108, P812, DOI 10.1097/ALN.0b013e31816d83e4
   Chung F, 2008, ANESTHESIOLOGY, V108, P822, DOI 10.1097/ALN.0b013e31816d91b5
   Chung F, 2016, CHEST, V149, P631, DOI 10.1378/chest.15-0903
   Chung F, 2014, J CLIN SLEEP MED, V10, P951, DOI 10.5664/jcsm.4022
   Cohen JB, 2017, PLAST RECONSTR SURG, V139, P257, DOI 10.1097/PRS.0000000000002848
   Corso RM, 2014, MINERVA ANESTESIOL, V80, P877
   Dasenbrock HH, 2017, NEUROSURGERY, V80, P551, DOI 10.1093/neuros/nyw062
   Dickinson H, 2015, J NEUROSURG, V122, P61, DOI 10.3171/2014.8.JNS1498
   Donoho DA, 2018, J NEURO-ONCOL, V136, P87, DOI 10.1007/s11060-017-2625-3
   Finkel KJ, 2009, SLEEP MED, V10, P753, DOI 10.1016/j.sleep.2008.08.007
   Gawande A., 2018, NEW YORKER
   Guralnick AS, 2012, J CLIN SLEEP MED, V8, P501, DOI 10.5664/jcsm.2140
   Hosmer D., 2000, APPL LOGISTIC REGRES, P143, DOI DOI 10.1002/0471722146
   Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563
   Kaw R, 2006, CHEST, V129, P198, DOI 10.1378/chest.129.1.198
   Kocher RP, 2011, JAMA-J AM MED ASSOC, V306, P1794, DOI 10.1001/jama.2011.1561
   Kulkarni GV, 2014, AM J SURG, V207, P436, DOI 10.1016/j.amjsurg.2013.09.018
   Lockhart EM, 2013, SLEEP MED, V14, P407, DOI 10.1016/j.sleep.2012.10.018
   Lonjaret L, 2017, ANAESTH CRIT CARE PA, V36, P213, DOI 10.1016/j.accpm.2016.06.012
   Marcus LP, 2014, J NEUROSURG, V120, P1201, DOI 10.3171/2014.1.JNS131264
   Memtsoudis SG, 2018, ANESTH ANALG, V127, P967, DOI 10.1213/ANE.0000000000003434
   Missios S, 2017, J NEUROSURG, V127, P1213, DOI 10.3171/2016.9.JNS161575
   Moghavem N, 2015, J NEUROSURG, V123, P189, DOI 10.3171/2014.12.JNS14447
   Nagappa M, 2017, ANESTH ANALG, V125, P1301, DOI 10.1213/ANE.0000000000002344
   Nuno M, 2014, NEUROSURGERY, V74, P196, DOI 10.1227/NEU.0000000000000243
   Pace A, 2012, J PALLIAT MED, V15, P225, DOI 10.1089/jpm.2011.0306
   Piazza M, 2019, NEUROSURGERY, V85, P50, DOI 10.1093/neuros/nyy197
   Sah HK, 2017, J CLIN ANESTH, V42, P31, DOI 10.1016/j.jclinane.2017.08.010
   Seet E, 2015, SINGAP MED J, V56, P212, DOI 10.11622/smedj.2015034
   Senders JT, 2018, NEUROSURGERY, V83, P1249, DOI 10.1093/neuros/nyy001
   Sharma A, 2017, EPILEPSY RES, V129, P37, DOI 10.1016/j.eplepsyres.2016.11.009
   Vasu TS, 2010, ARCH OTOLARYNGOL, V136, P1020, DOI 10.1001/archoto.2010.1020
   Young T, 1997, SLEEP, V20, P705, DOI 10.1093/sleep/20.9.705
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E979
EP E984
DI 10.1016/j.wneu.2019.11.050
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200114
PM 31734423
DA 2020-05-12
ER

PT J
AU Chalouhi, N
   Sweid, A
   Al Saiegh, F
   Mahtabfar, A
   Ghosh, R
   Mouchtouris, N
   Khanna, O
   Romo, V
   Tjoumakaris, S
   Gooch, R
   Rosenwasser, RH
   Jabbour, P
AF Chalouhi, Nohra
   Sweid, Ahmad
   Al Saiegh, Fadi
   Mahtabfar, Aria
   Ghosh, Ritam
   Mouchtouris, Nikolaos
   Khanna, Omaditya
   Romo, Victor
   Tjoumakaris, Stavropoula
   Gooch, Reid
   Rosenwasser, Robert H.
   Jabbour, Pascal
TI Initial Experience with Transradial Intraoperative Angiography in
   Aneurysm Clipping: Technique, Feasibility, and Case Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Angiogram; Clip ligation; Endovascular; Transradial
ID ACCESS
AB BACKGROUND: The transradial approach has slowly been gaining momentum in neuroendovascular procedures. We sought to assess its feasibility and safety and present a case series of transradial intraoperative angiography (IOA) during microsurgical clip ligation of intracranial aneurysms.
   METHODS: The setup and technique for transradial intraoperative angiography are described. Data on 10 consecutive patients undergoing IOA through the radial artery are presented.
   RESULTS: All target vessels were successfully catheterized transradially, and conversion to the transfemoral access was not required in any of the cases. There was no access-site complication, such as hand ischemia, hematoma, or radial artery spasm. There were also no thromboembolic events causing a stroke. The average time for the IOA was 9.3 minutes.
   CONCLUSIONS: Our initial experience shows the transradial approach for IOA in clip ligation of aneurysms to be feasible and safe, with potential advantages over transfemoral IOA.
C1 [Chalouhi, Nohra; Sweid, Ahmad; Al Saiegh, Fadi; Mahtabfar, Aria; Ghosh, Ritam; Mouchtouris, Nikolaos; Khanna, Omaditya; Tjoumakaris, Stavropoula; Gooch, Reid; Rosenwasser, Robert H.; Jabbour, Pascal] Thomas Jefferson Univ Hosp, Dept Neurol Surg, Philadelphia, PA 19107 USA.
   [Romo, Victor] Thomas Jefferson Univ Hosp, Dept Anesthesiol, Philadelphia, PA 19107 USA.
RP Jabbour, P (reprint author), Thomas Jefferson Univ Hosp, Dept Neurol Surg, Philadelphia, PA 19107 USA.
EM Pascal.jabbour@jefferson.edu
OI Mouchtouris, Nikolaos/0000-0001-9495-9391; Sweid,
   Ahmad/0000-0002-2652-2451
CR Ando G, 2015, ANN INTERN MED, V163, P932, DOI 10.7326/M15-1277
   Chalouhi N, 2012, NEUROSURGERY, V71, P1162, DOI 10.1227/NEU.0b013e318271ebfc
   Chiang VL, 2002, J NEUROSURG, V96, P988, DOI 10.3171/jns.2002.96.6.0988
   Hamon M, 2013, EUROINTERVENTION, V8, P1242, DOI 10.4244/EIJV8I11A192
   Kumar R, 2009, NEUROCRIT CARE, V11, P299, DOI 10.1007/s12028-009-9229-5
   Mann JT, 1996, J INVASIVE CARDIOL, V8, pD40
   Mehta SR, 2012, J AM COLL CARDIOL, V60, P2490, DOI 10.1016/j.jacc.2012.07.050
   Osbun JW, 2020, J NEUROINTERV SURG, V12, P170, DOI 10.1136/neurintsurg-2019-015207
   Raabe A, 2003, NEUROSURGERY, V52, P132, DOI 10.1097/00006123-200301000-00017
   Snelling BM, 2018, J NEUROINTERV SURG, V10, P874, DOI 10.1136/neurintsurg-2017-013584
   Snelling BM, 2018, J NEUROINTERV SURG, V10, P493, DOI 10.1136/neurintsurg-2017-013295
   Tang G, 2002, J NEUROSURG, V96, P993, DOI 10.3171/jns.2002.96.6.0993
   Zussman BM, 2019, J NEUROINTERV SURG, V11, P1235, DOI 10.1136/neurintsurg-2019-014920
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E554
EP E558
DI 10.1016/j.wneu.2019.10.130
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200067
PM 31678443
DA 2020-05-12
ER

PT J
AU Chen, D
   Bhambhvani, HP
   Hom, J
   Mahoney, M
   Wintermark, M
   Sharp, C
   Ratliff, J
   Chen, YR
AF Chen, Doris
   Bhambhvani, Hriday P.
   Hom, Jason
   Mahoney, Megan
   Wintermark, Max
   Sharp, Christopher
   Ratliff, John
   Chen, Yi-Ren
TI Effect of Electronic Clinical Decision Support on Imaging for the
   Evaluation of Acute Low Back Pain in the Ambulatory Care Setting
SO WORLD NEUROSURGERY
LA English
DT Article
DE Best practice alert; CT; Inappropriate imaging; Low back pain; MRI;
   X-ray
AB OBJECTIVES: To assess the effectiveness of a clinical decision support tool consisting of an electronic medical record best practice alert (BPA) on the frequency of lumbar imaging in patients with acute low back pain in the ambulatory care setting, and to explore why providers order imaging outside of clinical guidelines.
   METHODS: On March 23, 2016, we implemented a BPA pop-up alert that informed the ordering physician of the Choosing Wisely recommendation to not order imaging within the first 6 weeks of low back pain in the absence of red flags. We calculated imaging rates 1 year before and after implementation of the BPA. To override the BPA, providers could ignore the alert or explain their rationale for ordering imaging using either preset options or a free-text submission. We tracked preset options and manually reviewed 125 free-text submissions.
   RESULTS: Significant decreases in both total imaging rate (9.6% decrease; P = 0.02) and magnetic resonance imaging rate (14.9% decrease; P < 0.01) were observed after implementation of the BPA. No change was found in the rates of X-ray or computed tomography scan orders. Almost two-thirds (64%) of the providers used preset options in overriding the BPA, and 36% of the providers entered a free-text submission. Among those providers using a free-text submission, 56% entered a non-guideline-supported rationale.
   CONCLUSIONS: The present study demonstrates the effectiveness of a simple, low-cost clinical decision support tool in reducing imaging rates for patients with acute low back pain. We also identify reasons why providers order imaging outside of clinical guidelines.
C1 [Chen, Doris; Mahoney, Megan; Sharp, Christopher] Stanford Univ, Sch Med, Dept Med, Div Primary Care & Populat Hlth, Stanford, CA 94305 USA.
   [Bhambhvani, Hriday P.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
   [Hom, Jason] Stanford Univ, Sch Med, Dept Med, Div Hosp Med, Stanford, CA 94305 USA.
   [Wintermark, Max] Stanford Univ, Sch Med, Dept Radiol, Stanford, CA 94305 USA.
   [Ratliff, John; Chen, Yi-Ren] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.
RP Bhambhvani, HP (reprint author), Stanford Univ, Sch Med, Stanford, CA 94305 USA.
EM hriday@stanford.edu
OI Ratliff, John/0000-0003-3452-1907
CR American Board of Internal Medicine Foundation, CHOOS WIS PROM CONV
   American Board of Internal Medicine Foundation, SOC CHOOS WIS
   Balague F, 2012, LANCET, V379, P482, DOI 10.1016/S0140-6736(11)60610-7
   Blackmore CC, 2011, J AM COLL RADIOL, V8, P19, DOI 10.1016/j.jacr.2010.07.009
   Centers for Medicare and Medicaid Services (CMS), APPR US CRIT PROGR
   Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006
   Davis Patricia C, 2009, J Am Coll Radiol, V6, P401, DOI 10.1016/j.jacr.2009.02.008
   Ferrari R, 2016, CAN FAM PHYSICIAN, V62, pE129
   Horn J, 2016, J AM COLL RADIOL, V13, P1385, DOI 10.1016/j.jacr.2016.06.043
   Jenkins HJ, 2015, CAN MED ASSOC J, V187, P401, DOI 10.1503/cmaj.141183
   Kim LH, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.3676
   Palen TE, 2019, AM J ROENTGENOL, V213, P1015, DOI 10.2214/AJR.19.21511
   Pham HH, 2009, ARCH INTERN MED, V169, P972, DOI 10.1001/archinternmed.2009.78
   Srinivas SV, 2012, ARCH INTERN MED, V172, P1016, DOI 10.1001/archinternmed.2012.1838
   Stanford Health Care, PRIC TRANSP CHARG DE
NR 15
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E874
EP E877
DI 10.1016/j.wneu.2019.11.031
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200101
PM 31733384
DA 2020-05-12
ER

PT J
AU Chen, W
   Wang, XY
   Liu, FJ
   Tian, Y
   Chen, J
   Li, GP
   You, C
AF Chen, Wei
   Wang, Xiaoyu
   Liu, Fujun
   Tian, Yuan
   Chen, Jing
   Li, Guoping
   You, Chao
TI The Predictive Role of Postoperative Neutrophil to Lymphocyte Ratio for
   30-Day Mortality After Intracerebral Hematoma Evacuation
SO WORLD NEUROSURGERY
LA English
DT Article
DE 30-day mortality; Hematoma evacuation; Inflammation; Intracerebral
   hemorrhage; Neutrophil-to-lymphocyte ratio; Postoperative
ID HEMORRHAGE
AB OBJECTIVE: To evaluate whether the postoperative neutrophil-to-lymphocyte ratio (NLR) is a prognostic marker for patients with intracerebral hemorrhage (ICH) undergoing surgical hematoma evacuation.
   METHODS: This retrospective cohort study was conducted to identify patients with ICH who underwent hematoma evacuation between January 2013 and December 2018. Data on demographics, clinical features, laboratory tests (admission and postoperative), and imaging information were collected. The associations between variables and 30-day mortality were assessed by multivariable logistic regression analysis. The predictive power of independent predictors was evaluated by receiver operating characteristic (ROC) curve analysis.
   RESULTS: A total of 380 patients were included. Multivariable analysis identified admission Glasgow Coma Scale score (odds ratio [OR], 0.61; 95% confidence interval [CI], 0.53-0.70; P< 0.001) and initial hematoma volume (OR, 1.01; 95% CI, 1.01-1.02; P = 0.022) were independently associated with 30-day mortality. With regard to laboratory biomarkers, postoperative NLR (OR, 1.04; 95% CI, 1.01-1.08; P = 0.014) was independently correlated with 30-day death, but admission NLR (OR, 1.00; 95% CI, 0.97-1.03; P = 0.944) was not. The best predictive cutoff point of 12.97 for postoperative NLR (area under the ROC curve, 0.606; P = 0.006) for predicting 30-day mortality was determined by ROC analysis.
   CONCLUSIONS: In patients with ICH undergoing hematoma evacuation, admission Glasgow Coma Scale score, initial hematoma volume, and postoperative NLR were independently associated with 30-day mortality. Postoperative NLR may be a prognostic marker in surgical ICH patients, and future studies are needed to confirm this finding.
C1 [Chen, Wei; Wang, Xiaoyu; Liu, Fujun; Tian, Yuan; Chen, Jing; Li, Guoping; You, Chao] Sichuan Univ, Dept Neurosurg, West China Hosp, Chengdu, Sichuan, Peoples R China.
RP You, C (reprint author), Sichuan Univ, Dept Neurosurg, West China Hosp, Chengdu, Sichuan, Peoples R China.
EM chao_y2019@126.com
FU Support Project Funding of Science and Technology Department of Sichuan
   Province [2016FZ0119, 2010FZ0045]
FX This study was funded by the Support Project Funding of Science and
   Technology Department of Sichuan Province (Grants 2016FZ0119 and
   2010FZ0045).
CR Aronowski J, 2011, STROKE, V42, P1781, DOI 10.1161/STROKEAHA.110.596718
   Dirnagl U, 2007, STROKE, V38, P770, DOI 10.1161/01.STR.0000251441.89665.bc
   Felberg RA, 2002, ANN NEUROL, V51, P517, DOI 10.1002/ana.10160
   Giede-Jeppe A, 2017, CEREBROVASC DIS, V44, P26, DOI 10.1159/000468996
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304
   Lattanzi S, 2017, ONCOTARGET, V8, P57489, DOI 10.18632/oncotarget.15423
   Lattanzi S, 2016, STROKE, V47, P1654, DOI 10.1161/STROKEAHA.116.013627
   Qin J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211833
   Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8
   Tao CY, 2017, BIOMARK MED, V11, P33, DOI 10.2217/bmm-2016-0187
   Wang F, 2019, CNS NEUROSCI THER, V25, P30, DOI 10.1111/cns.12977
   Wang F, 2018, NEUROTOX RES, V34, P347, DOI 10.1007/s12640-018-9890-6
   Wang F, 2016, J STROKE CEREBROVASC, V25, P182, DOI 10.1016/j.jstrokecerebrovasdis.2015.09.013
   Wang ZG, 2019, J INT MED RES, V47, P2970, DOI 10.1177/0300060519847866
   Ye ZPP, 2017, ONCOTARGET, V8, P90380, DOI 10.18632/oncotarget.20120
   Zahorec R, 2001, Bratisl Lek Listy, V102, P5
   Zhang F, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016120
   Zhang F, 2019, WORLD NEUROSURG, V125, pE651, DOI 10.1016/j.wneu.2019.01.143
   Zhang F, 2018, WORLD NEUROSURG, V119, pE956, DOI 10.1016/j.wneu.2018.08.010
   Zhou Y, 2014, PROG NEUROBIOL, V115, P25, DOI 10.1016/j.pneurobio.2013.11.003
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E631
EP E635
DI 10.1016/j.wneu.2019.10.154
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200077
PM 31682990
DA 2020-05-12
ER

PT J
AU Chen, WL
   Lei, CX
   Liu, PH
   Liu, YF
   Guo, XP
   Kong, ZR
   Wang, YK
   Dai, CX
   Wang, YN
   Ma, WB
   Wang, Y
AF Chen, Wenlin
   Lei, Chuxiang
   Liu, Penghao
   Liu, Yifan
   Guo, Xiaopeng
   Kong, Ziren
   Wang, Yuekun
   Dai, Congxin
   Wang, Yaning
   Ma, Wenbin
   Wang, Yu
TI Progress and Prospects of Recurrent Glioma: A Recent Scientometric
   Analysis of the Web of Science in 2019
SO WORLD NEUROSURGERY
LA English
DT Article
DE Citation classics; Citations; Glioma recurrence; Recurrent glioma;
   Scientometric analysis
ID PHASE-II TRIAL; BEVACIZUMAB PLUS IRINOTECAN; MOST-CITED ARTICLES;
   CITATION-CLASSICS; NEUROONCOLOGY; TEMOZOLOMIDE
AB BACKGROUND: Most patients with glioma experience recurrence and have a poor prognosis. Scientometric analysis is effective and widely used to summarize the most influential studies within a certain field. We present the first scientometric analysis of recurrent glioma.
   METHODS: We conducted a generalized search for articles on recurrent glioma in the Web of Science database and evaluated the top 100 most cited articles among 4651 articles.
   RESULTS: The number of citations from the top 100 cited articles on recurrent glioma ranged from 149 to 1471; most of these articles were published in oncology-specific journals (66) and were submitted by institutions in the United States (n = 67). The top-cited articles consisted of 98 articles and 2 literature reviews. Articles were classified into 4 major categories based on subject matter: 82 pertained to treatment, 6 pertained to genetic mechanisms, 7 pertained to diagnosis, and 5 pertained to prognosis. Treatment-related articles were subdivided into the following 7 categories: targeted therapy (n = 21), chemotherapy (n = 20), immunotherapy (n = 12), combination therapy (n = 12), radiotherapy (n = 9), surgical resection = 6), a new therapy (physiotherapy) (n = 1), and treatment summary (n = 1).
   CONCLUSIONS: The results of the analysis indicated that the core problem is the treatment of recurrent glioma. Although the number of citations on targeted therapy and combination therapy has increased in recent years, the proportion of randomized controlled trials, basic medical research, literature reviews, and meta-analyses is relatively low; thus, there is an urgent need to conduct these types of studies on recurrent glioma.
C1 [Chen, Wenlin; Liu, Penghao; Liu, Yifan; Guo, Xiaopeng; Kong, Ziren; Wang, Yuekun; Dai, Congxin; Wang, Yaning; Ma, Wenbin; Wang, Yu] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Lei, Chuxiang] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Vasc Surg, Beijing, Peoples R China.
RP Wang, Y (reprint author), Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM ywang@pumch.cn
OI Liu, Penghao/0000-0002-9100-1580
FU Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences
   [2016-I2M-2-001]; PUMCH Science Fund for Junior Faculty
   [pumch-2016-2.19]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [3332018029]
FX This work was supported by the Chinese Academy of Medical Sciences
   Innovation Fund for Medical Sciences (grant number 2016-I2M-2-001); the
   2016 PUMCH Science Fund for Junior Faculty (grant number
   pumch-2016-2.19); and the Fundamental Research Funds for the Central
   Universities (grant number 3332018029).
CR Alfaifi A, 2018, WORLD NEUROSURG, V111, pE454, DOI 10.1016/j.wneu.2017.12.090
   Almutairi O, 2017, WORLD NEUROSURG, V107, P1025, DOI 10.1016/j.wneu.2017.08.021
   Belter CW, 2015, J MED LIBR ASSOC, V103, P219, DOI 10.3163/1536-5050.103.4.014
   BREM H, 1995, LANCET, V345, P1008, DOI 10.1016/S0140-6736(95)90755-6
   Cohen J, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS16158
   Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721
   Grosu AL, 2005, INT J RADIAT ONCOL, V63, P511, DOI 10.1016/j.ijrobp.2005.01.056
   Guo XP, 2018, WORLD NEUROSURG, V116, pE1153, DOI 10.1016/j.wneu.2018.05.189
   Hachem LD, 2017, NEURO-ONCOLOGY, V19, P1158, DOI 10.1093/neuonc/nox053
   Kim Y, 2017, EUR NEUROL, V78, P210, DOI 10.1159/000479626
   Kreisl TN, 2009, J CLIN ONCOL, V27, P740, DOI 10.1200/JCO.2008.16.3055
   Kumar AA, 2017, WORLD NEUROSURG, V108, DOI 10.1016/j.wneu.2017.08.136
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   McNeill KA, 2016, NEUROL CLIN, V34, P981, DOI 10.1016/j.ncl.2016.06.014
   National Comprehensive Cancer Network, CENTR NERV SYST CANC
   Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009
   SHRIEVE DC, 1995, NEUROSURGERY, V36, P275, DOI 10.1227/00006123-199502000-00006
   Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069
   Vredenburgh JJ, 2007, J CLIN ONCOL, V25, P4722, DOI 10.1200/JCO.2007.12.2440
   Vredenburgh JJ, 2007, CLIN CANCER RES, V13, P1253, DOI 10.1158/1078-0432.CCR-06-2309
   Weller M, 2013, NEURO-ONCOLOGY, V15, P4, DOI 10.1093/neuonc/nos273
   Yung WKA, 1999, J CLIN ONCOL, V17, P2762, DOI 10.1200/JCO.1999.17.9.2762
   Yung WKA, 2000, BRIT J CANCER, V83, P588, DOI 10.1054/bjoc.2000.1316
NR 23
TC 1
Z9 1
U1 6
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E387
EP E399
DI 10.1016/j.wneu.2019.10.078
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200047
PM 31639500
DA 2020-05-12
ER

PT J
AU Chiba, K
   Aihara, Y
   Masui, K
   Abe, K
   Komori, T
   Kawamata, T
AF Chiba, Kentaro
   Aihara, Yasuo
   Masui, Kenta
   Abe, Kayoko
   Komori, Takashi
   Kawamata, Takakazu
TI Pulvinar Locus is Highly Relevant to Patients' Outcomes in Surgically
   Resected Thalamic Gliomas in Children
SO WORLD NEUROSURGERY
LA English
DT Article
DE BRAF V600E; H3F3A; Histology; Pulvinar; Thalamic glioma
ID HIGH-GRADE GLIOMAS; TUMORS; ASTROCYTOMA; TRIAL; TEMOZOLOMIDE; MUTATIONS;
   LOMUSTINE; IMPACT
AB OBJECTIVE: Thalamic gliomas in children are less suitable for surgical resection because of their location. In cases of unavoidable resection, careful surgical planning in addition to histology and extent of resection affects prognosis.
   METHODS: A cohort of 10 pediatric patients with thalamic glioma underwent surgical resection at our department. The predominant location of tumor origins in the thalamus was defined in imaging studies. Histopathology was determined (retrospectively in a subset) according to the World Health Organization classification 2016, including the newly established type of "diffuse midline glioma, H3 K27M-mutant."
   RESULTS: Three low-grade gliomas (grade I/II) and 7 high-grade gliomas (grade III/IV) were identified. The mean follow-up period was 49.8 months. All 3 low-grade gliomas did not recur (progression-free survival, 58.3 months). Six of 7 high-grade gliomas recurred, and the patients died of the primary disease (overall survival, 28.1 months). Poor outcomes, especially when located at the pulvinar region, were noticeable, with strong predictive power for poor prognosis (P = 0.0018). The presence of H3 K27M mutation and pulvinar location were closely associated (P = 0.0036). Four of 5 patients with pulvinar region tumors developed dissemination and died of the primary disease.
   CONCLUSIONS: Pulvinar location is specifically associated with a high rate of malignancy in histology, the presence of H3 K27M mutation, and dissemination at an early disease stage. This association suggests that a distinct biological profile affects prognosis depending on location within the thalamus, especially the pulvinar. We report that tumor location is highly relevant to prognosis and should be taken into consideration when planning treatment.
C1 [Chiba, Kentaro; Aihara, Yasuo; Kawamata, Takakazu] Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan.
   [Masui, Kenta; Komori, Takashi] Tokyo Womens Med Univ, Dept Pathol 1, Tokyo, Japan.
   [Abe, Kayoko] Tokyo Womens Med Univ, Dept Radiol, Tokyo, Japan.
RP Aihara, Y (reprint author), Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan.
EM yaihara@twmu.ac.jp
FU Department of Neurosurgery, Tokyo Women's Medical University
FX This study was supported by research funds from the Department of
   Neurosurgery, Tokyo Women's Medical University.
CR Aihara K, 2014, NEURO-ONCOLOGY, V16, P140, DOI 10.1093/neuonc/not144
   Benarroch EE, 2015, NEUROLOGY, V84, P738, DOI 10.1212/WNL.0000000000001276
   Broadway SJ, 2011, J NEUROSURG-PEDIATR, V7, P589, DOI 10.3171/2011.4.PEDS119
   Broniscer A, 2018, BRAIN PATHOL, V28, P112, DOI 10.1111/bpa.12484
   Cao L, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0487-x
   Cohen KJ, 2011, NEURO-ONCOLOGY, V13, P317, DOI 10.1093/neuonc/noq191
   Colosimo C, 2002, CHILD NERV SYST, V18, P426, DOI 10.1007/s00381-002-0607-y
   Eisenstat DD, 2015, J NEURO-ONCOL, V121, P573, DOI 10.1007/s11060-014-1669-x
   Faury D, 2007, J CLIN ONCOL, V25, P1196, DOI 10.1200/JCO.2006.07.8626
   FINLAY JL, 1995, J CLIN ONCOL, V13, P112, DOI 10.1200/JCO.1995.13.1.112
   Jakacki RI, 2008, NEURO-ONCOLOGY, V10, P569, DOI 10.1215/15228517-2008-019
   Kramm CM, 2011, NEURO-ONCOLOGY, V13, P680, DOI 10.1093/neuonc/nor045
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Moshel YA, 2007, NEUROSURGERY, V61, P66, DOI 10.1227/01.neu.0000279725.13521.a3
   Moshel YA, 2009, J NEUROSURG-PEDIATR, V4, P495, DOI 10.3171/2009.7.PEDS09128
   Ozek MM, 2002, CHILD NERV SYST, V18, P450, DOI 10.1007/s00381-002-0608-x
   Parekh C, 2011, J NEURO-ONCOL, V103, P673, DOI 10.1007/s11060-010-0444-x
   Pollack IF, 2010, J NEURO-ONCOL, V99, P155, DOI 10.1007/s11060-010-0297-3
   Puget S, 2007, J NEUROSURG, V106, P354, DOI 10.3171/ped.2007.106.5.354
   Ryall S, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0353-0
   Schwartzentruber J, 2012, NATURE, V482, P226, DOI 10.1038/nature10833
   SPOSTO R, 1989, J NEURO-ONCOL, V7, P165, DOI 10.1007/BF00165101
   Steinbok P, 2016, CHILD NERV SYST, V32, P269, DOI 10.1007/s00381-015-2968-z
   Wong TT, 2016, CHILD NERV SYST, V32, P1895, DOI 10.1007/s00381-016-3148-5
NR 24
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E530
EP E539
DI 10.1016/j.wneu.2019.10.116
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200064
PM 31704359
DA 2020-05-12
ER

PT J
AU Cordeiro, JG
   Diaz, A
   Davis, JK
   Di Luca, DG
   Farooq, G
   Luca, CC
   Jagid, JR
AF Cordeiro, Joacir Graciolli
   Diaz, Anthony
   Davis, Jenna Kylene
   Di Luca, Daniel Garbin
   Farooq, Ghulam
   Luca, Corneliu C.
   Jagid, Jonathan Russell
TI Safety of Noncontrast Imaging-Guided Deep Brain Stimulation Electrode
   Placement in Parkinson Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Contrast; Deep brain stimulation (DBS); Hemorrhage; Parkinson disease
   (PD); Safety
ID SUBTHALAMIC NUCLEUS; CONTRAST-MEDIA; HEMORRHAGE; COMPLICATIONS;
   NEUROSURGERY; IMPLANTATION; PALLIDOTOMY; RISKS; TERM
AB BACKGROUND: Deep brain stimulation (DBS) is considered standard of care for the treatment of medically refractory Parkinson disease (PD). The placement of brain electrodes is performed using contrast imaging to enhance blood vessel identification during stereotactic planning. We present our experience with a series of patients implanted using noncontrast imaging.
   METHODS: All cases of DBS surgery for PD performed between 2012 and 2018 with noncontrast imaging were retrospectively reviewed. Clinical features, postoperative imaging, and complications were analyzed.
   RESULTS: A total of 287 deep-seated electrodes were implanted in 152 patients. Leads were placed at the subthalamic nucleus and globus pallidus internus in 258 and 29 hemispheres, respectively. We identified 2 cases of intracranial hemorrhage (0.7%).
   CONCLUSIONS: DBS lead placement can be performed without the use of intravenous contrast with a postoperative intracranial hemorrhage rate comparable with other reported series.
C1 [Cordeiro, Joacir Graciolli; Diaz, Anthony; Davis, Jenna Kylene; Jagid, Jonathan Russell] Univ Miami, Miller Sch Med, Dept Neurosurg, Miami, FL 33136 USA.
   [Di Luca, Daniel Garbin; Luca, Corneliu C.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Farooq, Ghulam] Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
RP Jagid, JR (reprint author), Univ Miami, Miller Sch Med, Dept Neurosurg, Miami, FL 33136 USA.
EM jjagid@med.miami.edu
RI Di Luca, Daniel/T-6211-2018
OI Di Luca, Daniel/0000-0002-1356-4919
CR Aviles-Olmos I, 2014, J NEUROL NEUROSUR PS, V85, P1419, DOI 10.1136/jnnp-2013-306907
   Barnes SRS, 2009, MAGN RESON IMAGING C, V17, P47, DOI 10.1016/j.mric.2008.12.002
   Benabid AL, 2000, NEUROLOGY, V55, pS40
   Beric A, 2001, STEREOT FUNCT NEUROS, V77, P73, DOI 10.1159/000064600
   Binder DK, 2005, NEUROSURGERY, V56, P722, DOI 10.1227/01.NEU.0000156473.57196.7E
   Bjorklund A, 2010, PROG BRAIN RES, V184, P311, DOI [10.1016/S0079-6123(16)8401-6, 10.1016/S0079-6123(10)84016-6]
   Blaser LS, 2015, EUR J CLIN PHARMACOL, V71, P209, DOI 10.1007/s00228-014-1781-z
   Brockow K, 2005, ALLERGY, V60, P150, DOI 10.1111/j.1398-9995.2005.00745.x
   Brodsky MA, 2017, NEUROLOGY, V89, P1944, DOI 10.1212/WNL.0000000000004630
   Clement Olivier, 2018, EClinicalMedicine, V1, P51, DOI 10.1016/j.eclinm.2018.07.002
   DePaoli Damon, 2019, J Neurosurg, P1, DOI 10.3171/2019.1.JNS182600
   Elias WJ, 2009, J NEUROSURG, V110, P201, DOI 10.3171/2008.7.17625
   Falowski S, 2012, STEREOT FUNCT NEUROS, V90, P173, DOI 10.1159/000338254
   Gorgulho A, 2005, J NEUROSURG, V102, P888, DOI 10.3171/jns.2005.102.5.0888
   Halefoglu AM, 2018, WORLD J RADIOL, V10, P30, DOI 10.4329/wjr.v10.i4.30
   Hamani C, 2008, NEUROSURGERY, V62, P863, DOI [10.1227/01.NEU.0000159714.28232.C4, 10.1227/01.neu.0000316288.75736.1c]
   Hariz MI, 1999, STEREOT FUNCT NEUROS, V72, P157, DOI 10.1159/000029720
   Hertel Frank, 2006, Neurosurgery, V59, pE1138
   Hu XW, 2010, PARKINSONISM RELAT D, V16, P96, DOI 10.1016/j.parkreldis.2009.07.013
   Jonker PKC, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.8.FOCUS13289
   KATAYAMA H, 1990, RADIOLOGY, V175, P621, DOI 10.1148/radiology.175.3.2343107
   Kenney C, 2007, J NEUROSURG, V106, P621, DOI 10.3171/jns.2007.106.4.621
   Krauss P, 2018, WORLD NEUROSURG, V120, pE991, DOI 10.1016/j.wneu.2018.08.210
   Kruger MT, 2018, NEURORADIOLOGY, V60, P1151, DOI 10.1007/s00234-018-2079-0
   Kumar R, 1998, NEUROLOGY, V51, P850, DOI 10.1212/WNL.51.3.850
   Lasser EC, 1997, RADIOLOGY, V203, P605, DOI 10.1148/radiology.203.3.9169676
   Leung AM, 2012, CURR OPIN ENDOCRINOL, V19, P414, DOI 10.1097/MED.0b013e3283565bb2
   Lieberman PL, 1999, CLIN REV ALLERG IMMU, V17, P469, DOI 10.1007/BF02737651
   Limousin P, 1999, J NEUROL NEUROSUR PS, V66, P289, DOI 10.1136/jnnp.66.3.289
   Lozano CS, 2019, J NEUROSURG, V130, P1847, DOI 10.3171/2018.2.JNS172186
   Machado A, 2006, MOVEMENT DISORD, V21, pS247, DOI 10.1002/mds.20959
   Martin AJ, 2017, STEREOT FUNCT NEUROS, V95, P307, DOI 10.1159/000479287
   Obeso JA, 2001, NEW ENGL J MED, V345, P956, DOI 10.1056/nejmoa000827
   Palur RS, 2002, J NEUROSURG, V96, P1058, DOI 10.3171/jns.2002.96.6.1058
   Pan KM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175688
   Paschen Steffen, 2018, Prog Neurol Surg, V33, P80, DOI 10.1159/000480910
   Prince MR, 2011, AM J ROENTGENOL, V196, pW138, DOI 10.2214/AJR.10.4885
   Reinacher PC, 2019, OPER NEUROSURG, V17, P497, DOI 10.1093/ons/opz015
   YOUSEM DM, 1989, AM J NEURORADIOL, V10, P1151
   Zekaj Edvin, 2019, Asian J Neurosurg, V14, P538, DOI 10.4103/ajns.AJNS_136_18
   Zrinzo L, 2012, J NEUROSURG, V116, P84, DOI 10.3171/2011.8.JNS101407
   Zsigmond P, 2017, STEREOT FUNCT NEUROS, V95, P392, DOI 10.1159/000484944
NR 42
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E1008
EP E1014
DI 10.1016/j.wneu.2019.11.071
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200118
PM 31756502
DA 2020-05-12
ER

PT J
AU Delion, M
   Klinger, E
   Bernard, F
   Aubin, G
   Ter Minassian, A
   Menei, P
AF Delion, Matthieu
   Klinger, Evelyne
   Bernard, Florian
   Aubin, Ghislaine
   Ter Minassian, Aram
   Menei, Philippe
TI Immersing Patients in a Virtual Reality Environment for Brain Mapping
   During Awake Surgery: Safety Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Awake surgery; Brain mapping; Neurosurgery; Social cognition; Virtual
   reality
ID MOTION SICKNESS; INTRAOPERATIVE SEIZURES; CORTICAL STIMULATION; VIDEO
   GAMES; HEART-RATE; CRANIOTOMY; VARIABILITY; NEGLECT; CORTEX
AB BACKGROUND: Brain mapping by direct electrical stimulation during awake craniotomy is now a standard procedure that reduces the risk of permanent neurologic deficits. Virtual reality technology immerses the patient in a virtually controlled, interactive world, offering a unique opportunity to develop innovative tasks for perioperative mapping of complex cognitive functions. The objective of this prospective single-center study was to evaluate the tolerance and safety of a virtual reality headset (VRH) and immersive virtual experiences in patients undergoing awake craniotomy and brain mapping by direct electrical stimulation.
   METHODS: The study included 30 patients with a brain tumor near the language area. Language mapping was performed with a naming task, DO 80, presented on a digital tablet and then in two-dimensional and three-dimensional formats through a VRH. During wound closure, different virtual reality experiences were proposed to the patient, offering different types of virtual motion or interaction with an avatar piloted by a neuropsychologist.
   RESULTS: Two patients could not use the VRH owing to technical issues. No procedure was aborted, no patient experienced virtual reality sickness and all patients reported they would repeat the procedure. Despite a high rate of intraoperative focal seizures, there was no argument to attribute the seizures to VRH use.
   CONCLUSIONS: This study shows that it is possible during awake brain surgery to immerse the patient in a virtual environment and to interact with the patient, opening the field of new brain mapping procedures for complex cognitive functions.
C1 [Delion, Matthieu; Bernard, Florian; Menei, Philippe] Univ Hosp Angers, Dept Neurosurg, Angers, France.
   [Aubin, Ghislaine] Univ Hosp Angers, Dept Neurol, Angers, France.
   [Ter Minassian, Aram] Univ Hosp Angers, Dept Anesthesia Crit Care & Emergency, Angers, France.
   [Klinger, Evelyne] Univ Bordeaux, French Inst Res Handicap IFRH, EA4136, Bordeaux, France.
   [Aubin, Ghislaine] Univ Angers, Univ Nantes, Lab Psychol Pays de la Loire LUNAM UPRES EA 4638, INSERM, Angers, France.
   [Ter Minassian, Aram] Univ Angers, Univ Nantes, LARIS EA 7315, Image Signal & Sci Vivant,INSERM, Angers, France.
   [Menei, Philippe] Univ Angers, Univ Nantes, CRCINA, INSERM, Angers, France.
   [Aubin, Ghislaine] Reg Ctr Funct Rehabil, Dept Rehabil Med, Neurepsycho Unit, Angers, France.
RP Menei, P (reprint author), Univ Hosp Angers, Dept Neurosurg, Angers, France.; Menei, P (reprint author), Univ Angers, Univ Nantes, CRCINA, INSERM, Angers, France.
EM phmenei@chu-angers.fr
OI menei, philippe/0000-0002-2794-1316
CR Bernard F, 2018, J MED INTERNET RES, V20, DOI 10.2196/10332
   Bernard F, 2018, WORLD NEUROSURG, V118, P348, DOI 10.1016/j.wneu.2018.05.024
   Bernardo A, 2017, WORLD NEUROSURG, V106, P1015, DOI 10.1016/j.wneu.2017.06.140
   Besharati TL, 2015, J NEUROSURG, V123, P206, DOI DOI 10.3171/2014.9.JNS141001
   Buker TJ, 2012, HUM FACTORS, V54, P235, DOI 10.1177/0018720811428734
   Chen W, 2015, BRAIN RES BULL, V113, P17, DOI 10.1016/j.brainresbull.2015.01.007
   Conner AK, 2016, CUREUS, V8, DOI 10.7759/cureus.883
   Conte V, 2015, MINERVA ANESTESIOL, V81, P379
   de Borst AW, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00576
   de Ribaupierre S, 2017, HEALTHC TECHNOL LETT, V4, P151, DOI 10.1049/htl.2017.0077
   Duffau H, 2003, J NEUROSURG, V98, P764, DOI 10.3171/jns.2003.98.4.0764
   Eseonu CI, 2018, J NEUROL SURG PART A, V79, P239, DOI 10.1055/s-0037-1617759
   Freyschlag CF, 2014, J NEUROSURG SCI, V58, P199
   Giussani C, 2010, J NEUROSURG, V112, P520, DOI 10.3171/2009.5.JNS081522
   Hoffman HG, 2000, CLIN J PAIN, V16, P244, DOI 10.1097/00002508-200009000-00010
   Kim YY, 2005, PSYCHOPHYSIOLOGY, V42, P616, DOI 10.1111/j.1469-8986.2005.00349.x
   Kitabayashi Tomohiro, 2012, No Shinkei Geka, V40, P1087
   Konstantatos AH, 2009, BURNS, V35, P491, DOI 10.1016/j.burns.2008.08.017
   Lemee JM, 2018, WORLD NEUROSURG, V118, P360, DOI 10.1016/j.wneu.2018.07.099
   Malinska M, 2015, INT J OCCUP SAF ERGO, V21, P47, DOI 10.1080/10803548.2015.1017964
   Mazerand E, 2017, WORLD NEUROSURG, V97, P424, DOI 10.1016/j.wneu.2016.10.031
   Mazur T, 2018, WORLD NEUROSURG, V110, P414, DOI 10.1016/j.wneu.2017.11.132
   Merhi O, 2007, HUM FACTORS, V49, P920, DOI 10.1518/001872007X230262
   Mosadeghi S, 2016, JMIR MENT HEALTH, V3, DOI 10.2196/mental.5801
   Nalivaiko E, 2015, PHYSIOL BEHAV, V151, P583, DOI 10.1016/j.physbeh.2015.08.043
   Nossek E, 2013, NEUROSURGERY, V73, P135, DOI 10.1227/01.neu.0000429847.91707.97
   Ohyama S, 2007, AURIS NASUS LARYNX, V34, P303, DOI 10.1016/j.anl.2007.01.002
   Ojemann JG, 2002, J NEUROSURG, V97, P33, DOI 10.3171/jns.2002.97.1.0033
   Pouratian N, 2004, J NEUROSURG, V101, P458, DOI 10.3171/jns.2004.101.3.0458
   Roux FE, 2011, NEUROSURGERY, V69, P1218, DOI 10.1227/NEU.0b013e31822aefd2
   Sallard E, 2012, NEUROCASE, V18, P80, DOI 10.1080/13554794.2011.556127
   Sanai N, 2008, NEW ENGL J MED, V358, P18, DOI 10.1056/NEJMoa067819
   Sharples S, 2008, DISPLAYS, V29, P58, DOI 10.1016/j.displa.2007.09.005
   Shoja MM, 2007, CHILD NERV SYST, V23, P265, DOI 10.1007/s00381-006-0285-2
   Trenite DGAKN, 2002, EPILEPTIC DISORD, V4, P121
   Vallar G, 2014, HUM BRAIN MAPP, V35, P1334, DOI 10.1002/hbm.22257
   Vilasboas T, 2017, WORLD NEUROSURG, V103, P449, DOI 10.1016/j.wneu.2017.04.021
   Wager M, 2013, NEUROSURGERY S, V72, P180
   Wager M, 2013, NEUROSURGERY, V72, P169, DOI 10.1227/NEU.0b013e31827bf1d6
   Wang YC, 2019, J NEURO-ONCOL, V142, P577, DOI 10.1007/s11060-019-03131-0
NR 40
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E937
EP E943
DI 10.1016/j.wneu.2019.11.047
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200109
PM 31734424
DA 2020-05-12
ER

PT J
AU Delman, C
   Cage, JM
   Lause, G
   Roberto, R
   Gupta, MC
   Klineberg, E
AF Delman, Connor
   Cage, J. Matthew
   Lause, Greg
   Roberto, Rolando
   Gupta, Munish C.
   Klineberg, Eric
TI Anterior and Posterior Fusion for Large, Rigid Idiopathic Scoliosis:
   Does Implant Density Matter?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anchor density; Anterior release; Curves; Idiopathic scoliosis; Implant
   density; Rigid
ID PEDICLE SCREW INSTRUMENTATION; SAGITTAL PLANE CORRECTION; HALO-FEMORAL
   TRACTION; CURVE-CORRECTION; CLINICAL-OUTCOMES; SPINAL-FUSION; ONLY
   SURGERY; RELEASE; FIXATION; DEFORMITY
AB BACKGROUND: Despite advancements in surgical techniques, controversy remains regarding the optimal implant density for the correction of idiopathic scoliosis. Recent evidence has suggested that equivalent radiographic and clinical outcomes can be achieved with lower implant densities for those with moderate curves and good flexibility. Among the experts, the consensus has continued that higher implant densities should be used for larger, stiffer curves. The purpose of the present study was to compare the radiographic results between high-implant density (HID) and low-implant density (LID) constructs in patients with large (>65 degrees), rigid (<50% flexibility) curves who had undergone anterior release and posterior spinal fusion.
   METHODS: We reviewed the idiopathic scoliosis cases performed at a single institution from 2006 to 2014. Only those meeting the inclusion criteria were selected. The patients were divided into HID and LID groups. The postoperative radiographs were compared for coronal correction, thoracic kyphosis, pelvic tilt, lumbar lordosis, and sagittal vertical axis.
   RESULTS: A statistically significant improvement in coronal correction was detected in the HID group at all follow-up points (final follow-up: HID, 81.1% vs. LID, 70.4%; P = 0.01). When preoperative thoracic kyphosis was considered, no differences were found between the 2 groups. No differences were found in the other sagittal parameters.
   CONCLUSION: In patients with large, rigid idiopathic scoliosis undergoing anterior release and posterior spinal fusion, a small, but statistically, significant improvement in the coronal Cobb angle was seen. It remains to be determined whether this small difference in radiographic correction will have any influence on the clinical outcome.
C1 [Delman, Connor; Roberto, Rolando; Klineberg, Eric] Univ Calif Davis, Dept Orthopaed Surg, Sacramento, CA 95817 USA.
   [Cage, J. Matthew; Lause, Greg] Tripler Army Med Ctr, Dept Orthopaed Surg, Honolulu, HI 96859 USA.
   [Roberto, Rolando; Klineberg, Eric] Shriners Hosp Children, Dept Orthopaed Surg, Sacramento, CA USA.
   [Gupta, Munish C.] Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO USA.
RP Cage, JM (reprint author), Tripler Army Med Ctr, Dept Orthopaed Surg, Honolulu, HI 96859 USA.
EM jmatthew.cage@gmail.com
CR Arlet V, 2004, EUR SPINE J, V13, P740, DOI 10.1007/s00586-004-0729-x
   Arlet V, 2000, EUR SPINE J, V9, pS17, DOI 10.1007/s005860000186
   Aubin CE, 2007, EUR SPINE J, V16, P57, DOI 10.1007/s00586-006-0063-6
   Bharucha NJ, 2013, SPINE J, V13, P375, DOI 10.1016/j.spinee.2012.05.029
   Burton DC, 2005, SPINE, V30, P1979, DOI 10.1097/01.brs.0000176196.94565.d6
   Cao Y, 2014, SPINE, V39, pE800, DOI 10.1097/BRS.0000000000000342
   Chen JY, 2013, SPINE, V38, pE946, DOI 10.1097/BRS.0b013e318297bfd4
   Clements DH, 2009, SPINE, V34, P2147, DOI 10.1097/BRS.0b013e3181adb35d
   D'Andrea LP, 2000, SPINE, V25, P1795, DOI 10.1097/00007632-200007150-00010
   de Kleuver M, 2014, EUR SPINE J, V23, P2603, DOI 10.1007/s00586-014-3356-1
   Di Silvestre M, 2008, EUR SPINE J, V17, P1336, DOI 10.1007/s00586-008-0731-9
   Dobbs MB, 2006, SPINE, V31, P2400, DOI 10.1097/01.brs.0000240212.31241.8e
   Ferrero E, 2014, EUR SPINE J, V23, P2635, DOI 10.1007/s00586-014-3566-6
   FON GT, 1980, AM J ROENTGENOL, V134, P979, DOI 10.2214/ajr.134.5.979
   Goldberg CJ, 2008, PEDIATR SURG INT, V24, P129, DOI 10.1007/s00383-007-2016-5
   Gotfryd Alberto Ofenhejm, 2013, Spine Deform, V1, P272, DOI 10.1016/j.jspd.2013.05.004
   Harrington PR, 2002, J BONE JOINT SURG AM, V84A, P316, DOI 10.2106/00004623-200202000-00020
   Hempfing A, 2007, EUR SPINE J, V16, P515, DOI 10.1007/s00586-006-0229-2
   Kemppainen John W, 2016, Spine Deform, V4, P33, DOI 10.1016/j.jspd.2015.07.010
   Ketenci IE, 2016, SPINE, V41, P134, DOI 10.1097/BRS.0000000000001182
   Kim YJ, 2004, SPINE, V29, P2040, DOI 10.1097/01.brs.0000138268.12324.1a
   Larson AN, 2016, J NEUROSURG-SPINE, V24, P116, DOI 10.3171/2015.4.SPINE131119
   Larson A Noelle, 2013, Spine Deform, V1, P237, DOI 10.1016/j.jspd.2013.05.009
   Larson AN, 2014, SPINE, V39, P571, DOI 10.1097/BRS.0000000000000204
   Lenke LG, 2004, SPINE, V29, P2055, DOI 10.1097/01.brs.0000138274.09504.38
   Li JF, 2016, CLIN SPINE SURG, V29, pE434, DOI 10.1097/BSD.0000000000000129
   Li M, 2009, J SPINAL DISORD TECH, V22, P251, DOI 10.1097/BSD.0b013e3181884940
   Li Y., 2018, ANN OPER RES, V1, P1, DOI DOI 10.29140/ice.v1n1.28
   Lowenstein JE, 2007, SPINE, V32, P448, DOI 10.1097/01.brs.0000255030.78293.fd
   Luhmann SJ, 2005, SPINE, V30, P2061, DOI 10.1097/01.brs.0000179299.78791.96
   Luo M, 2017, MEDICINE, V96, P7337
   Mac-Thiong JM, 2017, SPINE J, V17, P663, DOI 10.1016/j.spinee.2016.11.012
   Mehrpour S, 2017, ARCH ORTHOP TRAUM SU, V137, P457, DOI 10.1007/s00402-017-2642-x
   Morr S, 2015, EUR SPINE J, V24, P1473, DOI 10.1007/s00586-015-3769-5
   Quan GMY, 2010, SPINE, V35, P562, DOI 10.1097/BRS.0b013e3181b4af34
   Roach JW, 1999, ORTHOP CLIN N AM, V30, P353, DOI 10.1016/S0030-5898(05)70092-4
   Roussouly P, 2010, EUR SPINE J, V19, P1824, DOI 10.1007/s00586-010-1476-9
   Ruf M, 2013, SPINE, V38, pE1662, DOI 10.1097/BRS.0000000000000030
   Rushton PRP, 2016, EUR SPINE J, V25, P3324, DOI 10.1007/s00586-015-4335-x
   Sanders JO, 2011, SPINE, V36, pE1402, DOI 10.1097/BRS.0b013e31822815ff
   Sariyilmaz K, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009581
   Shen MK, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1695-x
   Shi ZC, 2015, J SPINAL DISORD TECH, V28, pE454, DOI 10.1097/BSD.0b013e3182a2658a
   Sucato DJ, 2010, SPINE, V35, P2186, DOI 10.1097/BRS.0b013e3181feab19
   Suk SI, 2007, EUR SPINE J, V16, P1359, DOI 10.1007/s00586-007-0334-x
   Tannous OO, 2018, GLOB SPINE J, V8, P114, DOI 10.1177/2192568217735507
   Vigneswaran HT, 2015, J NEUROSURG-PEDIATR, V16, P322, DOI 10.3171/2015.3.PEDS14649
   Weinstein SL, 2008, LANCET, V371, P1527, DOI 10.1016/S0140-6736(08)60658-3
   Yang S, 2011, EUR SPINE J, V20, P1039, DOI 10.1007/s00586-011-1808-4
   Zhang HQ, 2012, CHINESE MED J-PEKING, V125, P1297, DOI 10.3760/cma.j.issn.0366-6999.2012.07.020
   Zhang HQ, 2011, INT ORTHOP, V35, P1037, DOI 10.1007/s00264-010-1111-8
NR 51
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E37
EP E45
DI 10.1016/j.wneu.2019.08.123
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200007
PM 31470168
DA 2020-05-12
ER

PT J
AU Deng, HP
   Lu, B
   Yin, CX
   Xu, YL
   Ding, Y
   Mi, YR
   Xu, P
AF Deng, Heping
   Lu, Bo
   Yin, Chunxia
   Xu, Yali
   Ding, Yang
   Mi, Yaru
   Xu, Ping
TI The Effectiveness of Ultrasonography in the Diagnosis of Spontaneous
   Hourglasslike Constriction of Peripheral Nerve in the Upper Extremity
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hourglasslike constriction; Median nerve; Musculocutaneous nerve;
   Peripheral nerve; Radial nerve; Spontaneous; Ultrasonography
ID SUPRASCAPULAR NERVE; NEUROPATHY; TORSION; PALSY
AB OBJECTIVE: To investigate the ultrasonographic characteristics in hourglasslike constriction of peripheral nerve in the upper extremity and to evaluate the value of ultrasonography in the diagnosis.
   METHODS: Nineteen patients with hourglasslike constriction of peripheral nerve in the upper extremity underwent ultrasonography and the results were compared with surgery. The ultrasonographic characteristics, the accurate rate, and the relation between the ultrasonography and surgery were analyzed.
   RESULTS: There were 22 affected nerves involved in 19 patients, including 17 radial neuropathies, 4 median neuropathies, and 1 musculocutaneous neuropathy. The accuracy rate of ultrasonography in diagnosing hourglasslike constriction of upper limb nerve was 87.93%. Ultrasonography showed that the constriction sites were completely consistent with the operation. The ultrasonography characteristics of hourglasslike constriction of upper limb nerves were hourglasslike nerve incompleteness or complete constriction, and the nerves at both ends were thickened, and no compression structure was seen around. All lesions with complete constriction diagnosed by ultrasonography were treated with resection of the lesion with or without graft. In addition, 71.43% with incomplete constriction were treated with neurolysis, and 28.57% with resection of the lesion with direct repair.
   CONCLUSIONS: Ultrasonography could be used as a routine noninvasive examination for hourglasslike constriction of upper limb nerves. Ultrasonography suggests that resection of the lesion rather than neurolysis should be considered in the treatment of complete constriction. For patients with clinical symptoms, ultrasonography showed local nerve enlargement but no constriction; clinicians should be prompted to explore carefully during operation to avoid missing nerve hourglasslike constriction.
C1 [Deng, Heping; Yin, Chunxia; Mi, Yaru; Xu, Ping] Hebei Med Univ, Dept Ultrasonog, Affiliated Hosp 3, Shijiazhuang, Hebei, Peoples R China.
   [Lu, Bo; Xu, Yali] Hebei Med Univ, Dept Orthopaed, Affiliated Hosp 3, Shijiazhuang, Hebei, Peoples R China.
   [Ding, Yang] Hebei Med Univ, Dept Pathol, Affiliated Hosp 3, Shijiazhuang, Hebei, Peoples R China.
RP Deng, HP (reprint author), Hebei Med Univ, Dept Ultrasonog, Affiliated Hosp 3, Shijiazhuang, Hebei, Peoples R China.
EM denghepingmm@126.com
CR Abe T, 1966, RINSHO SEIKEI GEKA, V1, P617
   Aranyi Z, 2017, MUSCLE NERVE, V56, P1054, DOI 10.1002/mus.25708
   Aranyi Z, 2015, MUSCLE NERVE, V52, P503, DOI 10.1002/mus.24615
   Druzhinin D S, 2018, Zh Nevrol Psikhiatr Im S S Korsakova, V118, P10, DOI 10.17116/jnevro201811810110
   El Sayed L, 2018, HAND SURG REHABIL, V37, P114, DOI 10.1016/j.hansur.2017.11.005
   Endo Y, 2015, SKELETAL RADIOL, V44, P457, DOI 10.1007/s00256-014-2006-3
   Englert H M, 1976, Handchirurgie, V8, P61
   Fernandez E, 2001, J NEUROSURG, V94, P627, DOI 10.3171/jns.2001.94.4.0627
   [顾玉东 Gu Yudong], 2005, [中华手外科杂志, Chinese Journal of Hand Surgery], V21, P193
   Heiling B, 2018, CLIN NEUROL NEUROSUR, V172, P160, DOI 10.1016/j.clineuro.2018.07.006
   Kim DH, 2019, SKELETAL RADIOL, V48, P1451, DOI 10.1007/s00256-019-03174-4
   Lundborg G, 2003, J HAND SURG-AM, V28A, P212, DOI 10.1053/jhsu.2003.50040
   McGraw I, 2019, J HAND SURG-EUR VOL, V44, P310, DOI 10.1177/1753193418813788
   Nakagawa Y, 2018, NEUROSURGERY, V82, pE1, DOI 10.1093/neuros/nyx171
   Nakashima Y, 2014, ULTRASOUND MED BIOL, V40, P1718, DOI 10.1016/j.ultrasmedbio.2013.12.011
   Noda Y, 2017, J NEUROL SCI, V377, P1, DOI 10.1016/j.jns.2017.03.037
   Oberlin C, 2006, J HAND SURG-AM, V31A, P1100, DOI 10.1016/j.jhsa.2006.03.007
   Pan YW, 2014, NEUROSURGERY, V75, P10, DOI 10.1227/NEU.0000000000000350
   Qi HT, 2013, CLIN RADIOL, V68, pE479, DOI 10.1016/j.crad.2013.03.021
   Vigasio A, 2018, J SHOULDER ELB SURG, V27, pE29, DOI 10.1016/j.jse.2017.08.021
   Wang Y, 2019, J LOW FREQ NOISE V A, V38, P1008, DOI 10.1177/1461348418795813
   [吴可晚 Wu Kewan], 2010, [中华手外科杂志, Chinese Journal of Hand Surgery], V26, P261
   Wu P, 2014, NEUROSURGERY, V75, P250, DOI 10.1227/NEU.0000000000000424
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E103
EP E111
DI 10.1016/j.wneu.2019.09.111
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200015
PM 31568902
DA 2020-05-12
ER

PT J
AU Dodier, P
   Auzinger, T
   Mistelbauer, G
   Wang, WT
   Ferraz-Leite, H
   Gruber, A
   Marik, W
   Winter, F
   Fischer, G
   Frischer, JM
   Bavinzski, G
AF Dodier, Philippe
   Auzinger, Thomas
   Mistelbauer, Gabriel
   Wang, Wei-Te
   Ferraz-Leite, Heber
   Gruber, Andreas
   Marik, Wolfgang
   Winter, Fabian
   Fischer, Gerrit
   Frischer, Josa M.
   Bavinzski, Gerhard
TI Novel Software-Derived Workflow in Extracranial-Intracranial Bypass
   Surgery Validated by Transdural Indocyanine Green Videoangiography
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral revascularization; EC-IC bypass surgery; Flow augmentation;
   Flow replacement; STA-MCA bypass; Transdural ICG-VA; Virtual planning
ID SUPERFICIAL TEMPORAL ARTERY; RECONSTRUCTION; OCCLUSION; RESECTION;
   REVASCULARIZATION; NEURONAVIGATION; IDENTIFICATION; REGISTRATION;
   ASSOCIATION; ANGIOGRAPHY
AB BACKGROUND: The introduction of image-guided methods to bypass surgery has resulted in optimized preoperative identification of the recipients and excellent patency rates. However, the recently presented methods have also been resource-consuming. In the present study, we have reported a cost-efficient planning workflow for extracranial-intracranial (EC-IC) revascularization combined with transdural indocyanine green videoangiography (tICG-VA).
   METHODS: We performed a retrospective review at a single tertiary referral center from 2011 to 2018. A novel software-derived workflow was applied for 25 of 92 bypass procedures during the study period. The precision and accuracy were assessed using tICG-VA identification of the cortical recipients and a comparison of the virtual and actual data. The data from a control group of 25 traditionally planned procedures were also matched.
   RESULTS: The intraoperative transfer time of the calculated coordinates averaged 0.8 minute (range, 0.4-1.9 minutes). The definitive recipients matched the targeted branches in 80%, and a neighboring branch was used in 16%. Our workflow led to a significant craniotomy size reduction in the study group compared with that in the control group (P = 0.005). tICG-VA was successfully applied in 19 cases. An average of 2 potential recipient arteries were identified transdurally, resulting in tailored durotomy and 3 craniotomy adjustments. Follow-up patency results were available for 49 bypass surgeries, comprising 54 grafts. The overall patency rate was 91% at a median follow-up period of 26 months. No significant difference was found in the patency rate between the study and control groups (P = 0.317).
   CONCLUSIONS: Our clinical results have validated the presented planning and surgical workflow and support the routine implementation of tICG-VA for recipient identification before durotomy.
C1 [Dodier, Philippe; Wang, Wei-Te; Ferraz-Leite, Heber; Winter, Fabian; Frischer, Josa M.; Bavinzski, Gerhard] Med Univ Vienna, Dept Neurosurg, Vienna, Austria.
   [Marik, Wolfgang] Med Univ Vienna, Dept Radiol, Vienna, Austria.
   [Auzinger, Thomas] IST Austria, Comp Graph & Digital Fabricat Grp, Klosterneuburg, Austria.
   [Mistelbauer, Gabriel] Otto von Guericke Univ, Inst Simulat & Graph, Magdeburg, Germany.
   [Gruber, Andreas] Kepler Univ Hosp, Univ Clin Neurosurg, Linz, Austria.
   [Fischer, Gerrit] Univ Hosp Saarland, Dept Neurosurg, Homburg, Germany.
   [Fischer, Gerrit] Univ Saarland, Med Fac, Homburg, Germany.
RP Dodier, P (reprint author), Med Univ Vienna, Dept Neurosurg, Vienna, Austria.
EM philippe.dodier@meduniwien.ac.at
OI Marik, Wolfgang/0000-0002-1193-0970; Winter, Fabian/0000-0003-0695-7877;
   Dodier, Philippe/0000-0002-8850-8321
CR Almefty RO, 2015, WORLD NEUROSURG, V84, P15, DOI 10.1016/j.wneu.2015.03.005
   Anchieta MVM, 2016, INT J COMPUT ASS RAD, V11, P1919, DOI 10.1007/s11548-016-1415-2
   BARNETT HJM, 1985, NEW ENGL J MED, V313, P1191, DOI 10.1056/nejm198511073131904
   Bavinzski G, 2011, J NEUROL NEUROCHIR P, V12, P284
   BESL PJ, 1992, IEEE T PATTERN ANAL, V14, P239, DOI 10.1109/34.121791
   Broeckx CE, 2017, WORLD NEUROSURG, V108, P225, DOI 10.1016/j.wneu.2017.08.177
   Bruneau M, 2015, OPER NEUROSURG, V11, P484, DOI 10.1227/NEU.0000000000000971
   Burkhardt JK, 2019, WORLD NEUROSURG, V125, pE408, DOI 10.1016/j.wneu.2019.01.089
   Cabrilo I, 2015, WORLD NEUROSURG, V83, P596, DOI 10.1016/j.wneu.2014.12.020
   CHEN Y, 1992, IMAGE VISION COMPUT, V10, P145, DOI 10.1016/0262-8856(92)90066-C
   Coppens JR, 2008, J NEUROSURG, V109, P553, DOI 10.3171/JNS/2008/109/9/0553
   d'Avella E, 2013, ACTA NEUROCHIR, V155, P415, DOI 10.1007/s00701-012-1617-5
   Della Puppa A, 2014, ACTA NEUROCHIR, V156, P1761, DOI 10.1007/s00701-014-2164-z
   Esposito G, 2016, STROKE, V47, P282, DOI 10.1161/STROKEAHA.115.008220
   Fischer G, 2016, WORLD NEUROSURG, V88, P97, DOI 10.1016/j.wneu.2015.12.029
   Fischer G, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS0917
   Grubb RL, 2013, J NEUROSURG, V118, P25, DOI 10.3171/2012.9.JNS12551
   Gruber A, 2012, AJNR Am J Neuroradiol, V33, pE36, DOI 10.3174/ajnr.A2424
   Ha Mahnjeong, 2016, J Cerebrovasc Endovasc Neurosurg, V18, P239, DOI 10.7461/jcen.2016.18.3.239
   Kaku Y, 2008, ACT NEUR S, V103, P83
   Kikuta K, 2008, NEUROSURGERY, V62, P1434, DOI [10.1227/01.NEU.0000232775.06672.F4, 10.1227/01.neu.0000333807.64530.39]
   Komotar RJ, 2012, NEUROSURGERY, V70, pN22, DOI 10.1227/01.neu.0000414948.56225.36
   Lawton MT, 1996, NEUROSURGERY, V38, P83, DOI 10.1097/00006123-199601000-00020
   Nakagawa I, 2010, ACTA NEUROCHIR, V152, P1535, DOI 10.1007/s00701-010-0681-y
   Pena-Tapia PG, 2008, J NEUROSURG, V108, P655, DOI 10.3171/JNS/2008/108/4/0655
   Riva M, 2015, NEUROSURG REV, V38, P373, DOI 10.1007/s10143-015-0612-8
   Schick U, 1996, ACTA NEUROCHIR, V138, P938, DOI 10.1007/BF01411282
   SCHMIEDEK P, 1994, J NEUROSURG, V81, P236, DOI 10.3171/jns.1994.81.2.0236
   Standhardt H, 2004, INTERV NEURORADIOL, V10, P257, DOI 10.1177/159101990401000309
   SUNDT TM, 1985, MAYO CLIN PROC, V60, P230, DOI 10.1016/S0025-6196(12)60315-2
   Tanabe N, 2017, ACTA NEUROCHIR, V159, P567, DOI 10.1007/s00701-016-3060-5
   Ueba T, 2013, J NEUROSURG, V118, P632, DOI 10.3171/2012.11.JNS121113
   VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604
   Wanebo JE, 2004, NEUROSURGERY, V55, P395, DOI 10.1227/01.NEU.0000129549.99061.94
   Wathen C, 2016, NEUROSURGERY, V79, P889, DOI 10.1227/NEU.0000000000001357
   YASARGIL MG, 1970, SURGERY, V67, P221
   Yokota H, 2017, WORLD NEUROSURG, V106, P446, DOI 10.1016/j.wneu.2017.07.004
NR 37
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E892
EP E902
DI 10.1016/j.wneu.2019.11.038
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200104
PM 31733380
DA 2020-05-12
ER

PT J
AU Du, CF
   Liu, CJ
   Huang, YP
   Wang, X
AF Du, Cheng-Fei
   Liu, Chun-Jie
   Huang, Yun-Peng
   Wang, Xin
TI Effect of Spiral Nucleus Implant Parameters on the Compressive
   Biomechanics of Lumbar Intervertebral Disc
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biomechanics; Finite element; Lumbar spine; Nucleus replacement; Spiral
   implant
ID LOW-BACK-PAIN; FINITE-ELEMENT; MECHANICAL-BEHAVIOR; PULPOSUS; SPINE;
   PROSTHESIS; REMOVAL
AB OBJECTIVE: To determine the effect of spiral nucleus implant parameters on the biomechanical behavior of the lumbar intervertebral disc after nucleus replacement under compressive loading.
   METHODS: A finite element (FE) model of nucleus replacement in the L4-5 intervertebral disc was constructed. The effects of a spiral implant parameters, such as elasticity, size, and friction property, on the biomechanical behavior of the disc under a compressive load were determined. The effect of an implant with a sharp edge on disc biomechanics was also examined. The stress distribution and contact pressure on the endplate and AF, axial stiffness of disc, and annular bulge of the nucleus replacement models were investigated.
   RESULTS: Axial stiffness, annular bulge, and contact pressure were all insensitive to friction properties. Insertion of the spiral implant reversed the changes in the AF and endplates due to the removal of the nucleus. There was a positive correlation between axial stiffness and elasticity with implant size. Annular bulge was positively correlated with size but negatively correlated with elasticity. Compared with the base model, the implant with a sharp edge caused a decrease in disc axial stiffness but an increase in contact pressure on the AF in an annular bulge in the sagittal and coronal axis, respectively.
   CONCLUSIONS: A spiral implant may provide similar biomechanical behavior as a normal disc during compressive loading, with an optimal modulus of approximately 7 MPa. The spiral implant should fully conform to the nucleus cavity during replacement for the best biomechanical results.
C1 [Du, Cheng-Fei; Liu, Chun-Jie; Wang, Xin] Tianjin Univ Technol, Tianjin Key Lab Adv Mechatron Syst Design & Intel, Sch Mech Engn, Tianjin, Peoples R China.
   [Du, Cheng-Fei; Liu, Chun-Jie; Wang, Xin] Tianjin Univ Technol, Natl Demonstrat Ctr Expt Mech & Elect Engn Educ, Tianjin, Peoples R China.
   [Huang, Yun-Peng] Fujian Med Univ, Dept Orthoped, Affiliated Hosp 1, Fuzhou, Peoples R China.
RP Wang, X (reprint author), Tianjin Univ Technol, Tianjin Key Lab Adv Mechatron Syst Design & Intel, Sch Mech Engn, Tianjin, Peoples R China.; Wang, X (reprint author), Tianjin Univ Technol, Natl Demonstrat Ctr Expt Mech & Elect Engn Educ, Tianjin, Peoples R China.
EM wangxin_tju@hotmail.com
OI Du, Cheng-Fei/0000-0001-7486-1848
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [11432016, 11602172]; Natural Science Foundation of
   Fujian Province, ChinaNatural Science Foundation of Fujian Province
   [2019J01451]
FX This work was supported by the National Natural Science Foundation of
   China (Grants 11432016 and 11602172) and the Natural Science Foundation
   of Fujian Province, China (Grant 2019J01451).
CR Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140-6736(99)01312-4
   Bao QB, 1996, BIOMATERIALS, V17, P1157, DOI 10.1016/0142-9612(96)84936-2
   Dahl MC, 2010, SPINE, V35, P1445, DOI 10.1097/BRS.0b013e3181bef192
   Du CF, 2015, IFMBE PROC, V51, P326, DOI 10.1007/978-3-319-19387-8_78
   Du CF, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-0980-4
   Edwards WT, 2001, SPINE, V26, P1753
   Fan W, 2018, J MECH BEHAV BIOMED, V78, P342, DOI 10.1016/j.jmbbm.2017.11.040
   FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506
   Goins Maurice L, 2005, Spine J, V5, p317S, DOI 10.1016/j.spinee.2005.02.021
   Huang JY, 2015, COMPUT METHOD BIOMEC, V18, P1516, DOI 10.1080/10255842.2014.921815
   Husson JL, 2003, J SPINAL DISORD TECH, V16, P405, DOI 10.1097/00024720-200308000-00013
   Joshi A, 2009, J BIOMED MATER RES B, V90B, P596, DOI 10.1002/jbm.b.31322
   Korge A, 2002, EUR SPINE J, V11, pS149, DOI 10.1007/s00586-002-0444-4
   LIN HS, 1978, J BONE JOINT SURG AM, V60, P41, DOI 10.2106/00004623-197860010-00006
   Luoma K, 2000, SPINE, V25, P487, DOI 10.1097/00007632-200002150-00016
   Meakin JR, 2001, J MATER SCI-MATER M, V12, P207, DOI 10.1023/A:1008954813910
   PANJABI MM, 1984, SPINE, V9, P707, DOI 10.1097/00007632-198410000-00010
   Ray CD, 2002, EUR SPINE J, V11, pS137, DOI 10.1007/s00586-002-0425-7
   Rundell SA, 2009, SPINE, V34, P2022, DOI 10.1097/BRS.0b013e3181af1d5a
   Schmidt H, 2014, COMPUT METHOD BIOMEC, V17, P1762, DOI 10.1080/10255842.2013.766722
   Strange DGT, 2010, SPINE J, V10, P602, DOI 10.1016/j.spinee.2010.04.015
   Veliskova P, 2018, J BIOMECH, V70, P16, DOI 10.1016/j.jbiomech.2017.10.032
   Walker BF, 2000, J SPINAL DISORD, V13, P205, DOI 10.1097/00002517-200006000-00003
   Weinstein JN, 2006, SPINE, V31, P2707, DOI 10.1097/01.brs.0000248132.15231.fe
   Yao J, 2006, BIOMATERIALS, V27, P377, DOI 10.1016/j.biomaterials.2005.06.036
NR 25
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E878
EP E884
DI 10.1016/j.wneu.2019.11.030
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200102
PM 31733385
DA 2020-05-12
ER

PT J
AU Fan, YG
   Wang, J
   Cai, M
   Xia, L
   Wang, XD
AF Fan, Yonggang
   Wang, Jie
   Cai, Mandi
   Xia, Lei
   Wang, Xudong
TI The Correlation Between Postoperative Cervical Sagittal Alignment and
   Spine Sagittal Alignment in Adolescent Idiopathic Scoliosis: A
   Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adolescent idiopathic scoliosis; Cervical alignment; Meta-analysis;
   Thoracic kyphosis
ID SURGERY; OBESITY
AB OBJECTIVE: To perform a meta-analysis exploring the correlation between cervical lordosis (CL) and sagittal spine alignment in patients with adolescent idiopathic scoliosis (AIS) after surgery for determining a surgical strategy.
   METHODS: We searched 3 electronic databases for studies discussing the correlation between CL and spine sagittal alignment in patients with AIS. Studies reported from the inception of the database to June 2019 were retrieved without any language restrictions. Summary correlation coefficient (r) values were extracted from each study, and 95% confidence intervals (CIs) were calculated. In addition, we conducted subgroup analyses in different curve type subgroups with at least 2 studies.
   RESULTS: Ten relevant studies involving 539 patients were evaluated in this meta-analysis. The Pearson correlation (r) for CL and the T1 slope was -0.69; (95% CI, -0.79 to -0.54). The fixed-effects summary correlation between CL and thoracic kyphosis in patients was moderate (r = -0.40; 95% CI, -0.48 to -0.31). In addition, the fixed-effects summary correlations between CL and lumbar lordosis (r = 0.19; 95% CI, 0.07-0.30), pelvic incidence (r = -0.08; 95% CI, -0.20 to 0.04), pelvic tilt (r = -0.06; 95% CI, -0.18 to 0.06), and sacral slope (r = -0.06; 95% CI, -0.18 to 0.06) in patients were weak.
   CONCLUSIONS: There is a strong negative correlation between CL and the T1 slope in patients with AIS. Given the lack of robust clinical evidence, these findings warrant verification by large prospective registries and randomized trials with long follow-up periods.
C1 [Fan, Yonggang; Wang, Jie; Cai, Mandi; Xia, Lei; Wang, Xudong] Zhengzhou Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Zhengzhou, Henan, Peoples R China.
RP Xia, L (reprint author), Zhengzhou Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Zhengzhou, Henan, Peoples R China.
EM xialeigu1@126.com
CR Charles YP, 2015, SPINE, V40, pE419, DOI 10.1097/BRS.0000000000000767
   CHENG JC, 2015, NAT REV DIS PRIMERS, V1, DOI DOI 10.1038/NRDP.2015.30
   Choi J, 2013, OBES REV, V14, P232, DOI 10.1111/obr.12003
   COCHRAN T, 1983, SPINE, V8, P576, DOI 10.1097/00007632-198309000-00003
   Hiyama A, 2016, EUR SPINE J, V25, P3226, DOI 10.1007/s00586-016-4701-3
   Hwang SW, 2011, J NEUROSURG-SPINE, V15, P491, DOI 10.3171/2011.6.SPINE1012
   Katsuura A, 2001, EUR SPINE J, V10, P320, DOI 10.1007/s005860000243
   Legarreta CA, 2014, SPINE, V39, P1330, DOI 10.1097/BRS.0000000000000403
   Luo SG, 2018, CLIN NEUROL NEUROSUR, V171, P21, DOI 10.1016/j.clineuro.2018.04.019
   Ma ZX, 2016, INT ORTHOP, V40, P659, DOI 10.1007/s00264-015-2914-4
   Miyazaki M, 2008, SPINE, V33, pE870, DOI 10.1097/BRS.0b013e3181839733
   Pesenti S, 2016, EUR SPINE J, V25, P424, DOI 10.1007/s00586-015-4244-z
   STOKES IAF, 1987, J ORTHOP RES, V5, P102, DOI 10.1002/jor.1100050113
   Wang F, 2017, SPINE, V42, pE539, DOI 10.1097/BRS.0000000000001906
   Weinstein SL, 2008, LANCET, V371, P1527, DOI 10.1016/S0140-6736(08)60658-3
   Yagi Mitsuru, 2014, Spine Deform, V2, P122, DOI 10.1016/j.jspd.2013.11.002
   Yan P, 2018, WORLD NEUROSURG, V120, pE333, DOI 10.1016/j.wneu.2018.08.071
   Youn MS, 2016, EUR SPINE J, V25, P3114, DOI 10.1007/s00586-016-4488-2
   Zhang Z, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008799
   Zhao J, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009764
   Zhu C, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1590-5
NR 21
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E311
EP E316
DI 10.1016/j.wneu.2019.10.064
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200038
PM 31634621
DA 2020-05-12
ER

PT J
AU Farrokhi, F
   Buchlak, QD
   Sikora, M
   Esmaili, N
   Marsans, M
   McLeod, P
   Mark, J
   Cox, E
   Bennett, C
   Carlson, J
AF Farrokhi, Farrokh
   Buchlak, Quinlan D.
   Sikora, Matt
   Esmaili, Nazanin
   Marsans, Maria
   McLeod, Pamela
   Mark, Jamie
   Cox, Emily
   Bennett, Christine
   Carlson, Jonathan
TI Investigating Risk Factors and Predicting Complications in Deep Brain
   Stimulation Surgery with Machine Learning Algorithms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Data imputation; Deep brain stimulation; Gradient boosting machines;
   Machine learning; Neurosurgery; Risk stratification; Supervised learning
ID SUBTHALAMIC NUCLEUS; PARKINSONS-DISEASE; NEURAL-NETWORK; SPINE SURGERY;
   MISSING DATA; CLASSIFICATION; READMISSIONS; IMPROVEMENT; OUTCOMES;
   MODELS
AB BACKGROUND: Deep brain stimulation (DBS) surgery is an option for patients experiencing medically resistant neurologic symptoms. DBS complications are rare; finding significant predictors requires a large number of surgeries. Machine learning algorithms may be used to effectively predict these outcomes. The aims of this study were to 1) investigate preoperative clinical risk factors and 2) build machine learning models to predict adverse outcomes.
   METHODS: This multicenter registry collected clinical and demographic characteristics of patients undergoing DBS surgery (n = 501) and tabulated occurrence of complications. Logistic regression was used to evaluate risk factors. Supervised learning algorithms were trained and validated on 70% and 30%, respectively, of both over-sampled and original registry data. Performance was evaluated using area under the receiver operating characteristics curve (AUC), sensitivity, specificity, and accuracy.
   RESULTS: Logistic regression showed that the risk of complication was related to the operating institution in which the surgery was performed (odds ratio [OR] = 0.44, confidence interval [CI] = 0.25-0.78), body mass index (OR = 0.94, CI = 0.89-0.99), and diabetes (OR = 2.33, CI = 1.18-4.60). Patients with diabetes were almost 3x more likely to return to the operating room (OR = 2.78, CI = 1.31-5.88). Patients with a history of smoking were 4x more likely to experience postoperative infection (OR = 4.20, CI = 1.21-14.61). Supervised learning algorithms demonstrated high discrimination performance when predicting any complication (AUC = 0.86), a complication within 12 months (AUC = 0.91), return to the operating room (AUC = 0.88), and infection (AUC = 0.97). Age, body mass index, procedure side, gender, and a diagnosis of Parkinson disease were influential features.
   CONCLUSIONS: Multiple significant complication risk factors were identified, and supervised learning algorithms effectively predicted adverse outcomes in DBS surgery.
C1 [Farrokhi, Farrokh; Sikora, Matt; Marsans, Maria] Virginia Mason Med Ctr, Neurosci Inst, Seattle, WA 98101 USA.
   [McLeod, Pamela; Carlson, Jonathan] Inland Neurosurg & Spine Associates, Spokane, WA USA.
   [Mark, Jamie] Selkirk Neurol, Spokane, WA USA.
   [Cox, Emily] Providcncc Med Res Ctr, Providence Hlth & Serv, Spokane, WA USA.
   [Buchlak, Quinlan D.; Esmaili, Nazanin; Bennett, Christine] Univ Notre Dame Australia, Sch Med, Sydney, NSW, Australia.
   [Esmaili, Nazanin] Univ Technol Sydney, Fac Engn & IT, Ultimo, NSW, Australia.
   [Esmaili, Nazanin] Univ Toronto, Dept Med, Toronto, ON, Canada.
RP Buchlak, QD (reprint author), Univ Notre Dame Australia, Sch Med, Sydney, NSW, Australia.
EM quinlan.buchlak1@my.nd.edu.au
CR Abouzari M, 2009, NEUROSURG REV, V32, P479, DOI 10.1007/s10143-009-0215-3
   Akins PT, 2015, SPINE, V40, P1022, DOI 10.1097/BRS.0000000000000916
   Angeles P, 2017, INT C REHAB ROBOT, P1512, DOI 10.1109/ICORR.2017.8009462
   Bates DW, 2003, NEW ENGL J MED, V348, P2526, DOI 10.1056/NEJMsa020847
   Batista GEAPA, 2003, APPL ARTIF INTELL, V17, P519, DOI 10.1080/08839510390219309
   Bauer JM, 2019, J AM ACAD ORTHOP SUR, V27, pE408, DOI 10.5435/JAAOS-D-17-00717
   Baumgarten C, 2016, J MED IMAGING, V3, DOI 10.1117/1.JMI.3.2.025001
   Bekelis K, 2014, SPINE J, V14, P1247, DOI 10.1016/j.spinee.2013.08.009
   Bilimoria KY, 2013, J AM COLL SURGEONS, V217, P833, DOI 10.1016/j.jamcollsurg.2013.07.385
   Boachie-Adjei Oheneba, 2014, Spine Deform, V2, P340, DOI 10.1016/j.jspd.2014.05.004
   Brown I, 2012, EXPERT SYST APPL, V39, P3446, DOI 10.1016/j.eswa.2011.09.033
   Buchlak QD, 2016, CURR REV MUSCULOSKEL, V9
   Buchlak QD, 2017, ADULT LUMBAR SCOLIOS, P61
   Buchlak Quinlan D, 2019, Neurosurg Rev, DOI 10.1007/s10143-019-01163-8
   Buchlak QD, 2018, J CLIN NEUROSCI, V57, P26, DOI 10.1016/j.jocn.2018.08.051
   Buchlak QD, 2017, J CLIN NEUROSCI, V43, P247, DOI 10.1016/j.jocn.2017.06.012
   Carlson JD, 2017, OPER NEUROSURG, V13, P96, DOI 10.1227/NEU.0000000000001326
   Chawla NV, 2010, DATA MINING AND KNOWLEDGE DISCOVERY HANDBOOK, SECOND EDITION, P875, DOI 10.1007/978-0-387-09823-4_45
   Chawla NV, 2002, J ARTIF INTELL RES, V16, P321, DOI 10.1613/jair.953
   Chen TQ, 2016, KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P785, DOI 10.1145/2939672.2939785
   Cooney MT, 2009, J AM COLL CARDIOL, V54, P1209, DOI 10.1016/j.jacc.2009.07.020
   Copeland M, 2015, MICROSOFT AZURE, P3, DOI DOI 10.1007/978-1-4842-1043-7_1
   Dalbhanjan P., 2015, OVERVIEW DEPLOYMENT, P1
   Esmaili N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206274
   Fan JL, 2018, ENERG CONVERS MANAGE, V164, P102, DOI 10.1016/j.enconman.2018.02.087
   Figee M, 2013, NAT NEUROSCI, V16, P386, DOI 10.1038/nn.3344
   Flora ED, 2010, MOVEMENT DISORD, V25, P1550, DOI 10.1002/mds.23195
   Friedman JH, 2001, ANN STAT, V29, P1189, DOI 10.1214/aos/1013203451
   Gabb GM, 2016, MED J AUSTRALIA, V205, P85, DOI 10.5694/mja16.00526
   Grigsby J, 1998, EPILEPSIA, V39, P61, DOI 10.1111/j.1528-1157.1998.tb01275.x
   Hardaway FA, 2017, NEUROSURGERY, V83, P540
   He HB, 2009, IEEE T KNOWL DATA EN, V21, P1263, DOI 10.1109/TKDE.2008.239
   Herzog J, 2004, MOVEMENT DISORD, V19, P1050, DOI 10.1002/mds.20056
   Horton NJ, 2007, AM STAT, V61, P79, DOI 10.1198/000313007X172556
   Hu KJ, 2017, WORLD NEUROSURG, V98, P365, DOI 10.1016/j.wneu.2016.10.138
   Japkowicz N, 1995, INT JOINT CONF ARTIF, P518
   Japkowicz N., 2002, Intelligent Data Analysis, V6, P429
   Japkowicz N., 2000, P INT C ART INT JUL
   Kalakoti P, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.3.FOCUS1547
   Kawamoto K, 2005, BMJ-BRIT MED J, V330, P765, DOI 10.1136/bmj.38398.500764.8F
   Khor S, 2018, JAMA SURG, V153, P634, DOI 10.1001/jamasurg.2018.0072
   Kim JS, 2018, SPINE DEFORM, V6, P762, DOI DOI 10.1016/J.JSPD.2018.03.003
   Kleiner-Fisman G, 2006, MOVEMENT DISORD, V21, pS290, DOI 10.1002/mds.20962
   Kostoglou K, 2017, IEEE T BIO-MED ENG, V64, P1123, DOI 10.1109/TBME.2016.2591827
   Kotsiantis S., 2006, COMPUT SCI ENG, V30, P25
   Kubat M, 1998, MACH LEARN, V30, P195, DOI 10.1023/A:1007452223027
   Li X., 2014, IEEE T SYST MAN CY B
   Little S, 2013, ANN NEUROL, V74, P449, DOI 10.1002/ana.23951
   Lu J, 2016, BBA-GEN SUBJECTS, V1860, P2664, DOI 10.1016/j.bbagen.2016.05.019
   Matias CM, 2018, J NEUROSURG, V129, P1572, DOI 10.3171/2017.7.JNS171166
   Mazurowski MA, 2008, NEURAL NETWORKS, V21, P427, DOI 10.1016/j.neunet.2007.12.031
   Miocinovic S, 2013, JAMA NEUROL, V70, P163, DOI 10.1001/2013.jamaneurol.45
   Mueller J, 2008, MOVEMENT DISORD, V23, P131, DOI 10.1002/mds.21783
   Murphy ME, 2017, NEUROSURGERY, V81, P638, DOI 10.1093/neuros/nyx057
   Odekerken VJJ, 2013, LANCET NEUROL, V12, P37, DOI 10.1016/S1474-4422(12)70264-8
   Patel JL, 2007, CURR CLIN PHARMACOL, V2, P217, DOI 10.2174/157488407781668811
   Raghunathan T. E., 2001, SURV METHODOL, V27, P85, DOI DOI 10.1002/SIM.1186
   Raschka S., 2017, PYTHON MACHINE LEARN
   Rawi R, 2018, BIOINFORMATICS, V34, P1092, DOI 10.1093/bioinformatics/btx662
   Rodriguez-Oroz MC, 2005, BRAIN, V128, P2240, DOI 10.1093/brain/awh571
   Rumalla K, 2018, CLIN NEUROL NEUROSUR, V171, P129, DOI 10.1016/j.clineuro.2018.06.013
   Saad F, 2016, PROBABILISTIC DATA A, P1
   Sahin Y, 2013, EXPERT SYST APPL, V40, P5916, DOI 10.1016/j.eswa.2013.05.021
   Schlaepfer TE, 2013, BIOL PSYCHIAT, V73, P1204, DOI 10.1016/j.biopsych.2013.01.034
   Schrock LE, 2015, MOVEMENT DISORD, V30, P448, DOI 10.1002/mds.26094
   Seiffert C, 2010, IEEE T SYST MAN CY A, V40, P185, DOI 10.1109/TSMCA.2009.2029559
   Senders JT, 2018, NEUROSURGERY, V83, P181, DOI 10.1093/neuros/nyx384
   Senders JT, 2018, WORLD NEUROSURG, V109, P476, DOI 10.1016/j.wneu.2017.09.149
   Sethi R, 2017, J NEUROSURG-SPINE, V26, P744, DOI 10.3171/2016.11.SPINE16537
   Sethi Rajiv K, 2014, Spine Deform, V2, P95, DOI 10.1016/j.jspd.2013.12.002
   Sethi RK, 2018, SEMIN SPINE SURG, V30, P111
   Shi HY, 2013, J NEUROSURG, V118, P746, DOI 10.3171/2013.1.JNS121130
   Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393
   Steyerberg EW, 2007, J CLIN EPIDEMIOL, V60, P979, DOI 10.1016/j.jclinepi.2007.03.003
   Stopa BM, 2019, WORLD NEUROSURG, V126, pE190, DOI 10.1016/j.wneu.2019.01.292
   Taghva A, 2011, WORLD NEUROSURG, V75, P758, DOI 10.1016/j.wneu.2010.11.008
   Taghva A, 2010, NEUROSURGERY, V66, P108, DOI 10.1227/01.NEU.0000365369.48392.E8
   Tanaka M, 2018, WORLD NEUROSURG, V114, pE518, DOI 10.1016/j.wneu.2018.03.021
   Touzani S, 2018, ENERG BUILDINGS, V158, P1533, DOI 10.1016/j.enbuild.2017.11.039
   Valsky D, 2017, MOVEMENT DISORD, V32, P70, DOI 10.1002/mds.26806
   Wong S, 2009, J NEURAL ENG, V6, DOI 10.1088/1741-2560/6/2/026006
   Yanamadala V, 2017, SPINE, V42, pE1016, DOI 10.1097/BRS.0000000000002065
   Yanamadala Vijay, 2017, Instr Course Lect, V66, P379
   Zaidel A, 2009, MOVEMENT DISORD, V24, P1785, DOI 10.1002/mds.22674
   Zhang YR, 2015, TRANSPORT RES C-EMER, V58, P308, DOI 10.1016/j.trc.2015.02.019
   Zhou JJ, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.5.FOCUS18161
   Zrinzo L, 2012, J NEUROSURG, V116, P84, DOI 10.3171/2011.8.JNS101407
NR 87
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E325
EP E338
DI 10.1016/j.wneu.2019.10.063
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200040
PM 31634625
DA 2020-05-12
ER

PT J
AU Fatima, N
   Meola, A
   Pollom, E
   Chang, SD
   Soltys, S
AF Fatima, Nida
   Meola, Antonio
   Pollom, Erqi
   Chang, Steven D.
   Soltys, Scott
TI Stereotactic Radiosurgery for Large Benign Intracranial Tumors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cyberknife radiosurgery; Large benign intracranial tumor; Stereotactic
   radiosurgery
ID GAMMA-KNIFE RADIOSURGERY; SKULL BASE MENINGIOMAS; FOLLOW-UP;
   RADIOTHERAPY; PRESERVATION; SURGERY; RISK
AB BACKGROUND: Historically, it is stated that large intracranial tumors, herein defined as a maximum dimension of >= 3 cm or tumor volume >= 14.2 cm(3), are not candidates for stereotactic radiosurgery (SRS). We report outcomes of patients with large benign intracranial tumors treated with SRS.
   METHODS: With institutional review board approval, we retrospectively identified 74 patients with large benign intracranial tumors (59 meningiomas, 9 vestibular schwannomas, and 6 glomus jugulare tumors) treated with robotic SRS (2007-2018). Patients received definitive SRS in 47.3% of the cases, adjuvant to surgical resection in 44.6%, and salvage after past radiation treatment in 8.1%. A median tumor volume of 16.0 cm(3) (range, 10.1-65.5 cm(3)) received a median dose of 24.0 Gy (range, 14.0-30.0 Gy) in a median of 3 fractions (range, 1-5), for a median single fraction equivalent dose (with alpha/beta of 3) of 14.8 Gy (range, 11.3-18.0 Gy). The Kaplan-Meier estimate of tumor local control (LC) was calculated from date of SRS.
   RESULTS: With a median clinical follow-up of 32.8 months (range, 0.6-125.9 months) and median radiologic follow-up of 28.5 months (range, 0.6-121.4 months), LC was 96.5% (95% confidence interval, 92.4%-100%) at 3 years and 91.7% (95% confidence interval, 87.6%-95.7%) at 5 years. Adverse radiation effect (ARE) was seen in 10 patients (13.5%) at a median of 13.5 months (range, 7.8-34.5 months). ARE occurred in 9% of those with prior treatment compared with 5% who were radiation-naive (P = 0.23). With 236.4 person-years of follow-up, no secondary malignancies were seen.
   CONCLUSIONS: Despite the historical adage, we find that SRS provides high rates of LC for these large tumors, with rates of ARE similar to historical reports of SRS for smaller benign tumors.
C1 [Fatima, Nida; Meola, Antonio; Chang, Steven D.] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.
   [Pollom, Erqi; Soltys, Scott] Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA USA.
RP Meola, A (reprint author), Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.
EM Ameola@stanford.edu
OI Meola, Antonio/0000-0003-2426-2884; Fatima, Nida/0000-0002-0976-888X
CR al-Mefty O, 1991, Acta Neurochir Suppl (Wien), V53, P92
   Bari M E, 2003, J Pak Med Assoc, V53, P147
   Combs SE, 2013, RADIOTHER ONCOL, V106, P186, DOI 10.1016/j.radonc.2012.07.008
   Erridge SC, 2009, RADIOTHER ONCOL, V93, P597, DOI 10.1016/j.radonc.2009.09.011
   Eustacchio S, 2002, ACT NEUR S, V84, P71
   Fatima N, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2019.3.FOCUS1970
   Ganz J, 2009, ACTA NEUROCHIR, V151, P1, DOI 10.1007/s00701-008-0166-4
   Gilbo P, 2014, CANCER-AM CANCER SOC, V120, P3738, DOI 10.1002/cncr.28923
   Gonzalez-Darder JM, 2004, NEUROCIRUGIA, V15, P439
   Haselsberger K, 2009, J NEUROL NEUROSUR PS, V80, P1172, DOI 10.1136/jnnp.2008.156745
   Kondziolka D, 1999, J NEUROSURG, V91, P44, DOI 10.3171/jns.1999.91.1.0044
   Kondziolka D, 2008, NEUROSURGERY, V62, P53, DOI 10.1227/01.NEU.0000311061.72626.0D
   Minniti G, 2005, J CLIN ENDOCR METAB, V90, P800, DOI 10.1210/jc.2004-1152
   Niranjan A, 2008, NEUROSURGERY, V63, P1054, DOI 10.1227/01.NEU.0000335783.70079.85
   Ojemann SG, 2000, J NEUROSURG, V93, P62, DOI 10.3171/jns.2000.93.supplement_3.0062
   Pendl G, 2000, J NEUROSURG, V93, P107, DOI 10.3171/jns.2000.93.supplement_3.0107
   Pollock BE, 2003, INT J RADIAT ONCOL, V55, P1000, DOI 10.1016/S0360-3016(02)04356-0
   Pollock BE, 2004, NEUROSURG FOCUS, V17, P63, DOI [10.3171/foc.2004.17.2.10, DOI 10.3171/FOC.2004.17.2.10]
   Rashid A, 2012, J RADIOSURGERY SBRT, V2, P29
   Rowe J, 2007, NEUROSURGERY, V60, P60, DOI 10.1227/01.NEU.0000255492.34063.32
   Ruess D, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0805-0
   Starke RM, 2015, J NEUROSURG, V122, P363, DOI 10.3171/2014.10.JNS14198
   Tuniz F, 2009, NEUROSURGERY, V65, P898, DOI 10.1227/01.NEU.0000359316.34041.A8
   Wolf A, 2019, LANCET ONCOL, V20, P159, DOI 10.1016/S1470-2045(18)30659-4
   정영조, 2004, [Journal of Korean Neurosurgical Society, 대한신경외과학회지], V36, P206
NR 25
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E172
EP E180
DI 10.1016/j.wneu.2019.10.005
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200022
PM 31605862
DA 2020-05-12
ER

PT J
AU Flores, G
   Amaral-Nieves, N
   de Jesus, A
   Feliciano, C
AF Flores, Gabriel
   Amaral-Nieves, Natalie
   de Jesus, Aixa
   Feliciano, Caleb
TI Descriptive Study of Aneurysmal and Nonaneurysmal Subarachnoid
   Hemorrhage and the Role of Confirmative Digital Subtraction Angiography
   in Patients with Nonaneurysmal Subarachnoid in Puerto Rico
SO WORLD NEUROSURGERY
LA English
DT Article
DE CTA; DSA; Perimesencephalic; Subarachnoid hemorrhage
ID PERIMESENCEPHALIC HEMORRHAGE; RISK; SERIES
AB BACKGROUND: Cerebrovascular disease is the fifth cause of mortality in Puerto Rico. There is no descriptive study for the presentation of spontaneous subarachnoid hemorrhage (SAH) in our institution. Therefore, our primary aim was to perform a retrospective analysis of adult patients with spontaneous SAH and assess the need for digital subtraction angiography (DSA) after initially aneurysm-negative computed tomography angiography (CTA) in nonaneurysmal SAH, specifically perimesencephalic SAH (PM-SAH).
   METHODS: Medical records of 324 adult patients with aneurysmal and nonaneurysmal SAH treated at the Puerto Rico Medical Center from 2015 to 2018 were retrospectively analyzed. Demographics, past medical history, clinical characteristics, and imaging information were extracted.
   RESULTS: Acute hydrocephalus, mortality at 30 days, prevalence of diffuse SAH pattern, and Fisher and World Federation of Neurosurgical Societies grades >2 on initial examination were higher in the aneurysmal SAH subgroup. Patients with nonaneurysmal SAH had a significantly higher prevalence of chronic kidney disease and diabetes mellitus. Of the patients with nonaneurysmal PM-SAH with initial aneurysm-negative CTA, 100% were subsequently confirmed by DSA.
   CONCLUSIONS: Patients in the aneurysmal SAH subgroup correlated with an increased disease burden. Furthermore, this study shows that in our population, patients with nonaneurysmal PM-SAH with a low Fisher and World Federation of Neurosurgical Societies grade and with comorbid diabetes mellitus and chronic kidney disease may not need DSA after a negative initial CTA result.
C1 [Flores, Gabriel; de Jesus, Aixa; Feliciano, Caleb] Univ Puerto Rico, Sch Med, Dept Surg, Sect Neurosurg, Med Sci Campus, San Juan, PR 00936 USA.
   [Amaral-Nieves, Natalie] Univ Puerto Rico, Sch Med, Med Sci Campus, San Juan, PR 00936 USA.
RP Flores, G (reprint author), Univ Puerto Rico, Sch Med, Dept Surg, Sect Neurosurg, Med Sci Campus, San Juan, PR 00936 USA.
EM gabriel.a.flores@upr.edu
CR Coelho Luís Guilherme Bastos Silva Aguiar, 2016, Rev. bras. ter. intensiva, V28, P141, DOI 10.5935/0103-507X.20160028
   Elhadi AM, 2015, J NEUROSURG, V122, P663, DOI 10.3171/2014.10.JNS14175
   Feigin VL, 2005, STROKE, V36, P2773, DOI 10.1161/01.STR.0000190838.02954.e8
   Fowler MJ, 2008, CLIN DIABETES, V26, P77, DOI [DOI 10.2337/DIACLIN.26.2.77, 10.2337/diaclin.26.2.77]
   Harbaugh RE, 2003, NEUROSURGERY, V53
   Heit JJ, 2016, AM J NEURORADIOL, V37, P297, DOI 10.3174/ajnr.A4503
   Kalra VB, 2014, STROKE, V45, P3576, DOI 10.1161/STROKEAHA.114.006679
   Konczalla J, 2015, EUR J NEUROL, V22, P1329, DOI 10.1111/ene.12762
   Konczalla J, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-140
   Korja M, 2017, J NEUROSURG, V127, P748, DOI 10.3171/2016.9.JNS161085
   Mensing LA, 2018, STROKE, V49, P1363, DOI 10.1161/STROKEAHA.117.019843
   Potter CA, 2016, RADIOLOGY, V281, P858, DOI 10.1148/radiol.2016152402
   Redekop G, 1998, J NEUROSURG, V89, P539, DOI 10.3171/jns.1998.89.4.0539
   Skodvin TO, 2017, STROKE, V48, P880, DOI 10.1161/STROKEAHA.116.015288
   The Royal College of Surgeons of England, NAT STUD SUB HEM
   Tominari S, 2015, ANN NEUROL, V77, P1050, DOI 10.1002/ana.24400
   VANGIJN J, 1985, NEUROLOGY, V35, P493, DOI 10.1212/WNL.35.4.493
NR 17
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E481
EP E486
DI 10.1016/j.wneu.2019.10.104
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200058
PM 31672662
DA 2020-05-12
ER

PT J
AU Gadjradj, PS
   Ogenio, K
   Voigt, I
   Harhangi, BS
AF Gadjradj, Pravesh S.
   Ogenio, Kennedy
   Voigt, Istifari
   Harhangi, Biswadjiet S.
TI Ergonomics and Related Physical Symptoms Among Neurosurgeons
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ergonomics; Neurosurgery; Occupational injury
ID MUSCULOSKELETAL DISORDERS; OPERATING-ROOM; RISK-FACTORS; NECK PAIN;
   SURGEONS; RATES
AB OBJECTIVE: Work-related musculoskeletal disorders (WMSDs) among neurosurgeons can lead to consequences for themselves, the hospital, and society. In the current study, the working conditions of neurosurgeons from an ergonomic point of view is evaluated, together with WMSD.
   METHODS: Members of the Congress of Neurological Surgeons were surveyed with an online survey covering 1) demographics, 2) working conditions, 3) ergonomic features during 3 neurosurgical procedures, and 4) whether they experienced WMSD. Multivariate logistic regression analysis was performed to identify factors associated with experiencing WMSD.
   RESULTS: hi total, 417 replies were received. Respondents had a mean tenure of 21.9 years. In total, 33.1% stated that the operating room is furnished ergonomically and 90.7% stated that ergonomics is an underexposed field in neurosurgery. The majority of the respondents (73.6%) had experienced WMSD. Performing long procedures and spine surgery were mentioned most often as cause for WMSD. Due to WMSD, 11.3% of the respondents had to take time off work, and 14.2% considered changing their career. Analgesics were mostly used as treatment for WMSD (42.9%) and 7.4% underwent surgery. Having a tenure <= 15 years and having the operating room furnished ergonomically were associated with less WMSD in univariate analysis, whereas only a tenure <15 years was in multivariate analysis (odds ratio 0.27; 95% confidence interval 0.085-0.831).
   CONCLUSIONS: Despite only a minority of the surgeons taking time off due to WMSD, the majority suffers from WMSD. Education of residents in ergonomics to prevent WMSD in their later careers and ergonomic furnishing of surgical instrumentation and operating rooms seem to be areas for improvement.
C1 [Gadjradj, Pravesh S.; Voigt, Istifari] Leiden Univ, Dept Neurosurg, Med Ctr, Leiden, Netherlands.
   [Ogenio, Kennedy] Sint Elisabeth Hosp, Dept Neurosurg, Willemstad, Curacao.
   [Ogenio, Kennedy; Harhangi, Biswadjiet S.] Erasmus MC Univ Med Ctr Rotterdam, Dept Neurosurg, Rotterdam, Netherlands.
RP Gadjradj, PS (reprint author), Leiden Univ, Dept Neurosurg, Med Ctr, Leiden, Netherlands.
EM p.gadjradj@erasmusmc.nl
CR Alleblas CCJ, 2017, ANN SURG, V266, P905, DOI 10.1097/SLA.0000000000002223
   Alsabah S, 2019, SURG ENDOSC, V33, P1818, DOI 10.1007/s00464-018-6460-1
   Auerbach JD, 2011, SPINE, V36, pE1715, DOI 10.1097/BRS.0b013e31821cd140
   Baum GR, 2017, J NEUROSURG, V127, P1190, DOI 10.3171/2016.9.JNS16367
   Cagnie B, 2007, EUR SPINE J, V16, P679, DOI 10.1007/s00586-006-0269-7
   Centers for Disease Control and Prevention, 2018, WORK REL MUSC DIS ER
   Davern M, 2013, HEALTH SERV RES, V48, P905, DOI 10.1111/1475-6773.12070
   Dewan MC, 2017, J NEUROSURG, V126, P1772, DOI 10.3171/2016.4.JNS16245
   Epstein S, 2019, ANN SURG, V269, P778, DOI 10.1097/SLA.0000000000002592
   Epstein S, 2018, JAMA SURG, V153, DOI 10.1001/jamasurg.2017.4947
   Fisher SM, 2018, PLAST RECONSTR SURG, V142, P1380, DOI 10.1097/PRS.0000000000004923
   Hoe VCW, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008570.pub3
   Hoy DG, 2010, BEST PRACT RES CL RH, V24, P783, DOI 10.1016/j.berh.2011.01.019
   Janki S, 2017, SURG ENDOSC, V31, P2457, DOI 10.1007/s00464-016-5247-5
   Khansa I, 2018, PLAST RECONSTR SURG, V141, p165E, DOI 10.1097/PRS.0000000000003961
   Lee GI, 2017, SURG ENDOSC, V31, P1697, DOI 10.1007/s00464-016-5160-y
   Livingston EH, 2012, ARCH SURG-CHICAGO, V147, P110, DOI 10.1001/archsurg.2011.2169
   Mulimani P, 2018, COCHRANE DB SYST REV, V10
   Park A, 2010, J AM COLL SURGEONS, V210, P306, DOI 10.1016/j.jamcollsurg.2009.10.017
   Rosenblatt PL, 2013, J MINIM INVAS GYN, V20, P744, DOI 10.1016/j.jmig.2013.07.006
   Ho TVT, 2018, LARYNGOSCOPE, V128, P632, DOI 10.1002/lary.26859
   van Schalkwyk RD, 2017, INT J OCCUP SAF ERGO, V23, P297, DOI 10.1080/10803548.2016.1216356
   Wang J, 2017, INT J ENV RES PUBLIC, V14
   Yang HO, 2015, SPINE, V40, P184, DOI 10.1097/BRS.0000000000000700
NR 24
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E432
EP E441
DI 10.1016/j.wneu.2019.10.093
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200052
PM 31655238
DA 2020-05-12
ER

PT J
AU Gagliardi, F
   Boari, N
   Piloni, M
   Bailo, M
   Caputy, AJ
   Mortini, P
AF Gagliardi, Filippo
   Boari, Nicola
   Piloni, Martina
   Bailo, Michele
   Caputy, Anthony J.
   Mortini, Pietro
TI Temporal Galeofascial Flap for Reconstruction After Transmaxillary
   Approaches to the Clival Region
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clivus; Galeal-pericranial flap; Skull base reconstruction; Temporal
   muscle fascia; Transmaxillary approaches
ID SKULL BASE RECONSTRUCTION; LE-FORT-I; PERICRANIAL FLAP; SUBTOTAL
   MAXILLECTOMY; SURGICAL ANATOMY; MYOFASCIAL FLAP; CRANIAL-BASE; ANTERIOR;
   CLOSURE; MAXILLOTOMY
AB BACKGROUND: A paramount concern after transmaxillary approaches has been skull base reconstruction. Regional pedicled flaps represent the best reconstructive option. We have described a technique to harvest a lateral-based multilayered vascularized flap for skull base reconstruction after resection of large tumors using the transmaxillary transpterygoid approach (TMTPA).
   METHODS: We performed a cadaver study using the TMTPA to harvest the combined temporal galeofascial flap (CTGF). The first layer, with major sealing capabilities, is composed by a temporoparietal galeal-pericranial flap. The second layer is composed by temporal muscle fascia to provide mechanical support for flap dural engrafting.
   RESULTS: The CTGF provides excellent coverage of both the clival dural lining and the ipsilateral pterygopalatine fossa structures (x1.6). The CTGF is pliable and easy to harvest. It offers great flexibility in flap content and design, providing a large quantity of vascularized tissue. The vascular pedicle derives from the superficial temporal vessels, which can ensure flap trophism.
   CONCLUSIONS: CTGF represents an effective option as regional multilayered pedicled flap for skull base reconstruction after resection of clival tumors using the TMTPA. The flap pedicle, owing to its anatomical location, will often be preserved even after repeated microsurgical or endoscopic procedures, providing a technical alternative for reconstruction even in patients who have undergone multiple surgeries with low residual availability of regional flaps.
C1 [Gagliardi, Filippo; Boari, Nicola; Piloni, Martina; Bailo, Michele; Mortini, Pietro] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Neurosurg & Gamma Knife Radiosurg, Milan, Italy.
   [Caputy, Anthony J.] George Washington Univ, Dept Neurol Surg, Washington, DC USA.
RP Gagliardi, F (reprint author), Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Dept Neurosurg & Gamma Knife Radiosurg, Milan, Italy.
EM gagliardi.filippo@hsr.it
RI Bailo, Michele/M-3599-2016
OI Bailo, Michele/0000-0003-4151-2873
CR ARGENTA LC, 1985, PLAST RECONSTR SURG, V76, P695, DOI 10.1097/00006534-198511000-00007
   Boari N, 2016, J NEUROSURG, V125, P450, DOI 10.3171/2015.6.JNS142370
   Boari N, 2010, J NEUROSURG, V113, P1011, DOI 10.3171/2010.4.JNS091887
   COCKE EW, 1990, ARCH OTOLARYNGOL, V116, P92
   DROMMER RB, 1986, J MAXILLOFAC SURG, V14, P119, DOI 10.1016/S0301-0503(86)80275-2
   DUFOURMENTEL C, 1958, Ann Chir Plast, V3, P311
   FUKUTA K, 1994, PLAST RECONSTR SURG, V94, P794, DOI 10.1097/00006534-199411000-00007
   Gagliardi F, 2017, WORLD NEUROSURG, V107, P477, DOI 10.1016/j.wneu.2017.08.022
   Gagliardi F, 2016, WORLD NEUROSURG, V95, P246, DOI 10.1016/j.wneu.2016.08.034
   Gagliardi F, 2015, ACTA NEUROCHIR, V157, P597, DOI 10.1007/s00701-014-2340-1
   Gagliardi F, 2014, J CRANIO MAXILL SURG, V42, P1000, DOI 10.1016/j.jcms.2014.01.024
   Gagliardi F, 2013, ACTA NEUROCHIR, V155, P1849, DOI 10.1007/s00701-013-1845-3
   Gagliardi F, 2013, NEUROSURG REV, V36, P513, DOI 10.1007/s10143-013-0463-0
   Gagliardi F, 2012, J CRANIOFAC SURG, V23, P1468, DOI 10.1097/SCS.0b013e31825a6497
   Gagliardi F, 2012, NEUROSURG REV, V35, P1, DOI 10.1007/s10143-011-0354-1
   Gagliardi F, 2011, J CRANIOFAC SURG, V22, P1015, DOI 10.1097/SCS.0b013e31821015b5
   Georgantopoulou A, 2003, BRIT J PLAST SURG, V56, P10, DOI 10.1016/S0007-1226(03)00013-4
   Hanasono MM, 2011, PLAST RECONSTR SURG, V128, P675, DOI 10.1097/PRS.0b013e318221dcef
   Harvey RJ, 2012, LARYNGOSCOPE, V122, P452, DOI 10.1002/lary.22475
   Hitotsumatsu T, 2000, NEUROSURGERY, V46, P1416, DOI 10.1097/00006123-200006000-00025
   IRISH JC, 1994, HEAD NECK-J SCI SPEC, V16, P3, DOI 10.1002/hed.2880160103
   JACKSON IT, 1986, PLAST RECONSTR SURG, V77, P905, DOI 10.1097/00006534-198606000-00005
   JAMES D, 1991, NEUROSURGERY, V29, P411, DOI 10.1227/00006123-199109000-00012
   JOHNS ME, 1981, LARYNGOSCOPE, V91, P952
   Kadri PAS, 2004, J NEUROSURG, V100, P517, DOI 10.3171/jns.2004.100.3.0517
   Kwon D, 2017, SEMIN PLAST SURG, V31, P189, DOI 10.1055/s-0037-1607273
   Kyoshima K, 2002, NEUROSURGERY, V50, P813, DOI 10.1097/00006123-200204000-00023
   MOLONEY F, 1981, J ORAL SURG, V39, P731
   MUNOZ FI, 1990, J CRANIO MAXILL SURG, V18, P158, DOI 10.1016/S1010-5182(05)80511-6
   Noone MC, 2002, OTOLARYNG HEAD NECK, V127, P494, DOI 10.1067/mhn.2002.129737
   Sabit I, 2002, SURG NEUROL, V58, P21, DOI 10.1016/S0090-3019(02)00764-4
   Safavi-Abbasi S, 2016, J NEUROSURG, V125, P419, DOI 10.3171/2015.5.JNS15529
   Sharma RK, 1996, PLAST RECONSTR SURG, V97, P25, DOI 10.1097/00006534-199601000-00003
   Smith JE, 2004, OTOLARYNG HEAD NECK, V130, P704, DOI 10.1016/j.otohns.2004.01.004
   To EWH, 2001, BRIT J PLAST SURG, V54, P457
   TOLHURST DE, 1991, PLAST RECONSTR SURG, V87, P603, DOI 10.1097/00006534-199104000-00001
   UTTLEY D, 1989, J NEUROSURG, V71, P705, DOI 10.3171/jns.1989.71.5.0705
   Zanation AM, 2009, LARYNGOSCOPE, V119, P13, DOI 10.1002/lary.20022
   Zoller JE, 2001, J CRANIO MAXILL SURG, V29, P159, DOI 10.1054/jcms.2001.0208
NR 39
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E68
EP E74
DI 10.1016/j.wneu.2019.09.038
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200010
PM 31526880
DA 2020-05-12
ER

PT J
AU Ganau, M
   Gallinaro, P
   Cebula, H
   Scibilia, A
   Todeschi, J
   Gubian, A
   Nannavecchia, B
   Signorelli, F
   Pop, R
   Coca, HA
   Proust, F
   Chibbaro, S
AF Ganau, Mario
   Gallinaro, Paolo
   Cebula, Helene
   Scibilia, Antonino
   Todeschi, Julien
   Gubian, Arthur
   Nannavecchia, Beniamino
   Signorelli, Francesco
   Pop, Raoul
   Coca, Hugo-Andres
   Proust, Francois
   Chibbaro, Salvatore
TI Intracranial Metastases from Prostate Carcinoma: Classification,
   Management, and Prognostication
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chronic subdural hematoma; Dura-mater based lesion; Meningioma;
   Metastasis; Prostate carcinoma; Vault osteolytic lesion
ID SUBDURAL-HEMATOMA; BRAIN METASTASIS; RADIOSURGICAL OPTIONS; MIMICKING
   MENINGIOMA; DURAL METASTASIS; CURRENT TENETS; ADENOCARCINOMA;
   NEUROONCOLOGY; SECONDARY; TUMOR
AB BACKGROUND: Prostate carcinomas rarely metastasize to the central nervous system but, when they do, dural localizations are as common as and far more aggressive than intraparenchymal ones. Those metastases can be further classified according to their extension toward the subdural or extradural space and can frequently simulate other pathologic conditions including chronic subdural hematomas, abscess, and primary bone tumors. Beside the challenges of the preoperative differential diagnostic and complexity of surgical planning and operative excision, subdural metastases seem to carry a much poorer prognosis.
   METHODS: A series of consecutive patients admitted during a 12-year period through our oncall pathway for subdural/extradural collections or intraparenchymal lesions found, on histologic analysis, to represent intracranial prostate cancer metastases was retrospectively reviewed.
   RESULTS: A total of 19 patients were included, but only 3 were diagnosed with small cell prostate carcinoma, while the majority had a primary prostate adenocarcinoma. Metastases could be classified as pure subdural space lesions, dural-based lesions, extradural/bony lesions, and pure intraparenchymal lesions. All patients with subdural metastases and 3 out of 5 patients with dural-based lesions required an emergency intervention due to rapidly deteriorating neurologic status. The mean follow-up in our series was 37 months; only subdural localizations had a remarkably unfavorable outcome.
   CONCLUSIONS: Supported by our experience and the review of the literature, we suggest that a low threshold for contrast-enhanced computed tomography/magnetic resonance imaging is advisable in case of suspicious subdural collection, even in an emergency setting, for patients with previous medical history of prostate cancer.
C1 [Ganau, Mario; Gallinaro, Paolo; Cebula, Helene; Scibilia, Antonino; Todeschi, Julien; Gubian, Arthur; Nannavecchia, Beniamino; Coca, Hugo-Andres; Proust, Francois; Chibbaro, Salvatore] Hautepierre Univ Hosp, Dept Neurosurg, Strasbourg, France.
   [Pop, Raoul] Hautepierre Univ Hosp, Dept Neuroradiol, Strasbourg, France.
   [Signorelli, Francesco] Bari Univ Hosp, Dept Neurosurg, Bari, Italy.
RP Gallinaro, P (reprint author), Hautepierre Univ Hosp, Dept Neurosurg, Strasbourg, France.
EM paolo.gallinaro88@gmail.com
RI Chibbaro, Salvatore/AAI-6368-2020
CR Behrens B, 2001, NEURORADIOLOGY, V43, P162, DOI 10.1007/s002340000509
   Boukas Alexandros, 2015, Surg Neurol Int, V6, P30, DOI 10.4103/2152-7806.151713
   Brown PD, 2016, JAMA-J AM MED ASSOC, V316, P401, DOI 10.1001/jama.2016.9839
   BUCCI MN, 1986, J UROLOGY, V135, P803, DOI 10.1016/S0022-5347(17)45861-7
   CATANE R, 1976, CANCER, V38, P2583, DOI 10.1002/1097-0142(197612)38:6<2583::AID-CNCR2820380652>3.0.CO;2-D
   CHENG CLY, 1988, J NEUROSURG, V68, P642, DOI 10.3171/jns.1988.68.4.0642
   Cheng YK, 2009, J CLIN NEUROSCI, V16, P1084, DOI 10.1016/j.jocn.2008.08.008
   Churilla TM, 2017, INT J RADIAT ONCOL, V99, P1173, DOI 10.1016/j.ijrobp.2017.07.045
   Davis JN, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-275
   Dorsi MJ, 2010, CLIN NEUROL NEUROSUR, V112, P501, DOI 10.1016/j.clineuro.2010.02.009
   Erasmus CE, 2002, CAN J NEUROL SCI, V29, P375, DOI 10.1017/S0317167100002250
   Ganau L, 2012, AVIAT SPACE ENVIR MD, V83, P899, DOI 10.3357/ASEM.3331.2012
   Ganau M., 2018, MEDICINES, V5, P1
   Ganau M, 2015, TUMORI J, V101, P57, DOI 10.5301/tj.5000215
   Ganau M, 2014, Tumori J, V100, P459, DOI 10.1700/1636.17912
   Ganau M, 2012, CASE REP SURG, DOI 10.1155/2012/614321
   Ganau M, 2012, HELL J NUCL MED, V15, P184, DOI 10.1967/s002449910051
   Houssem Abid, 2018, Asian J Neurosurg, V13, P851, DOI 10.4103/ajns.AJNS_325_16
   Ishii N, 2007, NEUROL SURG TOKYO, V35, P511
   Johnson MD, 2002, HUM PATHOL, V33, P1211, DOI 10.1053/hupa.2002.129200
   Kleinschmidt-DeMasters BK, 2001, ARCH PATHOL LAB MED, V125, P880
   KWEE IL, 1983, NEUROSURGERY, V13, P584, DOI 10.1227/00006123-198311000-00018
   Lath C O, 2005, Australas Radiol, V49, P497, DOI 10.1111/j.1440-1673.2005.01473.x
   LEECH RW, 1974, J NEUROSURG, V41, P610, DOI 10.3171/jns.1974.41.5.0610
   Long MA, 1999, BRIT J RADIOL, V72, P933, DOI 10.1259/bjr.72.862.10673942
   LYNES WL, 1986, UROLOGY, V28, P280, DOI 10.1016/0090-4295(86)90005-1
   Lyons MK, 2006, NEUROLOGIST, V12, P48, DOI 10.1097/01.nrl.0000186809.04283.17
   Nzokou A, 2015, J NEUROL SURG REP, V76, P123, DOI 10.1055/s-0035-1549224
   O'Meara C, 2012, J SURG CASE REP
   Patil Shashikant, 2010, J La State Med Soc, V162, P203
   RAO KG, 1982, UROLOGY, V19, P433
   Sahin F, 2006, J CLIN NEUROSCI, V13, P259, DOI 10.1016/j.jocn.2005.03.033
   Sutton MA, 1996, UROLOGY, V48, P789, DOI 10.1016/S0090-4295(96)00238-5
   Sweets T, 2009, UROLOGY, V73, DOI 10.1016/j.urology.2008.03.025
   Tagle P, 2002, SURG NEUROL, V58, P241, DOI 10.1016/S0090-3019(02)00831-5
   TASAKI K, 1990, Neurological Surgery, V18, P539
   TAYLOR HG, 1984, CANCER, V53, P2728, DOI 10.1002/1097-0142(19840615)53:12<2728::AID-CNCR2820531231>3.0.CO;2-X
   Tomlin JM, 2002, SURG NEUROL, V58, P329, DOI 10.1016/S0090-3019(02)00835-2
   Tremont-Lukats IW, 2003, CANCER, V98, P363, DOI 10.1002/cncr.11522
   Varlet G, 2001, REV NEUROL-FRANCE, V157, P1543
NR 40
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E559
EP E565
DI 10.1016/j.wneu.2019.10.125
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200068
PM 31678450
DA 2020-05-12
ER

PT J
AU Goel, A
   Patil, A
   Shah, A
   Dandpat, S
   Rai, S
   Ranjan, S
AF Goel, Atul
   Patil, Abhinandan
   Shah, Abhidha
   Dandpat, Saswat
   Rai, Survendra
   Ranjan, Shashi
TI Os Odontoideum: Analysis of 190 Surgically Treated Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atlantoaxial fixation; Atlantoaxial instability; Basilar invagination;
   Os odontoideum
ID BASILAR INVAGINATION; ATLANTOAXIAL INSTABILITY; OUTCOME ANALYSIS;
   FIXATION; DISLOCATION; REDUCTION; PLATE; MASS
AB OBJECTIVE: The aim of this study was to report an experience with 190 cases of os odontoideum over 20 years. The management outcome following atlantoaxial fixation was analyzed.
   METHODS: From January 2000 to September 2018, 190 patients with os odontoideum were surgically treated. There were 113 male patients and 77 female patients; average age was 24 years (range, 2-68 years).The patients were divided into 3 groups depending on the nature of atlantoaxial dislocation (group 1, mobile and partially or completely reducible atlantoaxial dislocation; group 2, fixed or irreducible atlantoaxial dislocation; group 3, presence of basilar invagination). There were 65 pediatric patients (<18 years old). All patients underwent atlantoaxial joint manipulation and lateral mass plate and screw fixation. The goal of surgery was segmental atlantoaxial arthrodesis. No transoral or posterior foramen magnum bone decompression was done. Occipital bone was not included in the fixation construct.
   RESULTS: On direct bone handling and observation, atlantoaxial joint pathologic hyperactivity related instability was identified in all patients. Atlantoaxial segmental stabilization resulted in clinical symptomatic and neurologic improvement in 100% of patients.
   CONCLUSIONS: Os odontoideum signifies chronic or long-standing atlantoaxial instability. Segmental atlantoaxial fixation is a reliable form of surgical treatment. Bone decompression is not necessary. Inclusion of occipital bone and subaxial vertebrae in the fixation construct is not necessary.
C1 [Goel, Atul; Patil, Abhinandan; Shah, Abhidha; Dandpat, Saswat; Rai, Survendra; Ranjan, Shashi] KEM Hosp & Seth GS Med Coll, Dept Neurosurg, Parel, India.
   [Goel, Atul] Lilavati Hosp & Res Ctr, Mumbai, Maharashtra, India.
RP Goel, A (reprint author), KEM Hosp & Seth GS Med Coll, Dept Neurosurg, Parel, India.; Goel, A (reprint author), Lilavati Hosp & Res Ctr, Mumbai, Maharashtra, India.
EM atulgoel62@hotmail.com
CR Dai LY, 2000, SURG NEUROL, V53, P106, DOI 10.1016/S0090-3019(99)00184-6
   Dlouhy BJ, 2017, J NEUROSURG-SPINE, V27, P20, DOI 10.3171/2016.11.SPINE16733
   FIELDING JW, 1980, J BONE JOINT SURG AM, V62, P376, DOI 10.2106/00004623-198062030-00007
   Fujiwara A, 2003, SPINE, V28, P1601, DOI 10.1097/00007632-200307150-00023
   Giacomini C., 1886, GIOR ACCAD MED TORIN, V49, P24
   Goel A, 2005, J NEUROSURG-SPINE, V2, P505, DOI 10.3171/spi.2005.2.4.0505
   Goel A, 2004, J NEUROSURG-SPINE, V1, P281, DOI 10.3171/spi.2004.1.3.0281
   GOEL A, 1994, ACTA NEUROCHIR, V129, P47, DOI 10.1007/BF01400872
   Goel A, 1998, J NEUROSURG, V88, P962, DOI 10.3171/jns.1998.88.6.0962
   Goel A, 2002, NEUROSURGERY, V51, P1351, DOI 10.1097/00006123-200212000-00004
   Goel A, 2007, J NEUROSURG-SPINE, V7, P90, DOI 10.3171/SPI-07/07/090
   Goel Atul, 2019, Oper Neurosurg (Hagerstown), DOI 10.1093/ons/opz289
   Goel A, 2018, WORLD NEUROSURG, V110, P558, DOI 10.1016/j.wneu.2017.08.192
   Goel A, 2018, WORLD NEUROSURG, V110, P533, DOI 10.1016/j.wneu.2017.07.007
   Goel A, 2017, J CRANIOVERTEBRAL JU, V8, P295, DOI 10.4103/jcvjs.JCVJS_132_17
   Goel A, 2017, WORLD NEUROSURG, V99, P164, DOI 10.1016/j.wneu.2016.11.093
   Goel A, 2016, WORLD NEUROSURG, V95, P375, DOI 10.1016/j.wneu.2016.08.026
   Goel A, 2015, NEUROSURGERY, V77, P296, DOI 10.1227/NEU.0000000000000761
   Goel A, 2015, J CRANIOVERTEBRAL JU, V6, P6, DOI 10.4103/0974-8237.151578
   Goel A, 2015, NEUROL INDIA, V63, P7, DOI 10.4103/0028-3886.152657
   Goel A, 2015, J NEUROSURG-SPINE, V22, P116, DOI 10.3171/2014.10.SPINE14176
   Goel A, 2014, J CRANIOVERTEBRAL JU, V5, P3, DOI 10.4103/0974-8237.135206
   Goel A, 2009, J NEUROSURG-SPINE, V10, P220, DOI 10.3171/2008.12.SPINE08499
   HUSKISSON EC, 1982, J RHEUMATOL, V9, P768
   KIRLEW KA, 1993, SKELETAL RADIOL, V22, P525
   MCRAE DL, 1960, AMER J ROENTGENOL RA, V84, P3
   MORGAN MK, 1989, J NEUROSURG, V70, P636, DOI 10.3171/jns.1989.70.4.0636
   SCHULER TC, 1991, J PEDIATR ORTHOPED, V11, P222, DOI 10.1097/01241398-199103000-00017
   Shah A, 2016, WORLD NEUROSURG, V91, P419, DOI 10.1016/j.wneu.2016.04.050
   STILLWELL WT, 1978, CLIN ORTHOP RELAT R, P71
   Tang XS, 2018, EUR SPINE J, V27, pS259, DOI 10.1007/s00586-017-5116-5
   WOLLIN DG, 1963, J BONE JOINT SURG AM, V45, P1459, DOI 10.2106/00004623-196345070-00011
   Wu XH, 2018, J NEUROSURG-SPINE, V28, P131, DOI 10.3171/2017.5.SPINE161211
NR 33
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E512
EP E523
DI 10.1016/j.wneu.2019.10.107
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200062
PM 31669688
DA 2020-05-12
ER

PT J
AU Goethe, E
   LoPresti, MA
   Zhao, M
   Brayton, A
   Gadgil, N
   Pan, IW
   Lam, S
AF Goethe, Eric
   LoPresti, Melissa A.
   Zhao, Michelle
   Brayton, Alison
   Gadgil, Nisha
   Pan, I. W.
   Lam, Sandi
TI Quality of Life in Pediatric Neurosurgery: Comparing Parent and Patient
   Perceptions
SO WORLD NEUROSURGERY
LA English
DT Article
DE Health-related Quality of Life; Pediatric neurosurgery; Patient
   perceptions; Quality of life
AB BACKGROUND: In the pediatric neurosurgical population, understanding how to mitigate the effects of disease on children's physical ability, social and psychological well-being, and education can have lasting effects on their development and family. Understanding parents' perceptions of their children's health-related quality of life (HRQoL) is crucial in proper counseling, management of expectations, establishment of a healthy patient/parent-physician relationship, and understanding the role and impact of health care. In this study we sought to examine the differences between patient and parent perceptions of HRQoL and the factors that influence these differences.
   METHODS: A standardized survey (PedsQL Inventory) to assess physical, psychological, and social function and school performance was administered to both parents and patients in a general pediatric neurosurgery outpatient clinic from 2015-2018.
   RESULTS: 197 encounters with 179 patients occurred in the study period. There were 105 male and 92 female patients across various ethnic backgrounds. The most common diagnoses were tumor (23.4%) and vascular malformation (16.2%). Parent overall scores were lower than their children's (72.5 vs. 76.4, P < 0.01). Parent scores of physical function (74.3 vs. 78.7, P < 0.01) and overall psychosocial function (71.5 vs. 75.3, P < 0.01) were also lower. Parent scores in all domains of the PedsQL were correlated with overall score difference (P< 0.01), but only child scores of overall psychosocial (P < 0.03) and school function (P < 0.04) were correlated with overall score difference.
   CONCLUSIONS: Parents have more negative assessments of their children's HRQoL compared with their children in all domains assessed by the PedsQL. Further research is needed to identify factors that contribute to these discrepancies.
C1 [Goethe, Eric; LoPresti, Melissa A.; Gadgil, Nisha; Lam, Sandi] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
   [Goethe, Eric; LoPresti, Melissa A.; Brayton, Alison; Gadgil, Nisha; Pan, I. W.; Lam, Sandi] Texas Childrens Hosp, Div Neurosurg, Houston, TX 77030 USA.
   [LoPresti, Melissa A.; Zhao, Michelle] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA.
RP Lam, S (reprint author), Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.; Lam, S (reprint author), Texas Childrens Hosp, Div Neurosurg, Houston, TX 77030 USA.
EM sandilam@gmail.com
OI Pan, I-Wen/0000-0002-2781-2629
CR Bandayrel K, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/s12955-014-0110-7
   Desai VR, 2019, WORLD NEUROSURG, V122, P252, DOI 10.1016/j.wneu.2018.10.194
   Ellert U, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-102
   Hansen D, 2016, J NEUROSURG-PEDIATR, V18, P480, DOI 10.3171/2016.3.PEDS15641
   Holland AA, 2015, APPL NEUROPSYCH-CHIL, V4, P249, DOI 10.1080/21622965.2014.892427
   Sousa MAP, 2017, ARCH ARGENT PEDIATR, V115, P541, DOI [10.5546/aap.2017.eng.541, 10.5546/aap.2017.541]
   Puka K, 2015, EPILEPSIA, V56, P873, DOI 10.1111/epi.13004
   Quitmann Julia, 2013, Pediatr Endocrinol Rev, V11, P147
   Rajmil L, 2013, HEALTH QUAL LIFE OUT, V11, DOI 10.1186/1477-7525-11-101
   Rowland MP, 2012, J BLIND INNOV RES, V2
   Schmidt LB, 2018, CLIN EPIDEMIOL, V10, P1721, DOI 10.2147/CLEP.S178757
   Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006
   Vetter TR, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-85
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E306
EP E310
DI 10.1016/j.wneu.2019.10.037
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200037
PM 31654773
DA 2020-05-12
ER

PT J
AU Gong, S
   Tao, YQ
   Jin, H
   Sun, X
   Liu, Y
   Wang, SM
   Xu, MT
   Yang, XW
   Wang, Y
   Yuan, LJ
   Song, WL
AF Gong, Shun
   Tao, Yingqun
   Jin, Hai
   Sun, Xiao
   Liu, Yang
   Wang, Shimiao
   Xu, Menting
   Yang, Xingwang
   Wang, Yu
   Yuan, Lijia
   Song, Weilong
TI Assessment of Deep Brain Stimulation Implantation Surgery: A Practical
   Scale
SO WORLD NEUROSURGERY
LA English
DT Article
DE Assessment; Deep brain stimulation; Multivariate regression testing;
   Prognosis; Scale
ID SUBTHALAMIC NUCLEUS; BILATERAL STIMULATION; TARGETING ACCURACY;
   INTRACRANIAL AIR; SHIFT
AB BACKGROUND: Patients requiring deep brain stimulation (DBS) will undergo extensive preoperative and postoperative evaluations. However, the field lacks a robust scoring system for quantifying the outcomes of DBS surgery. We sought to determine whether a practical scale could assess the outcomes of DBS surgery and the clinical significance.
   METHODS: A retrospective study was performed of the data from 150 patients who had undergone DBS from February 2017 to February 2019. An independence analysis and multivariate testing were used to identify significant independent predictors. The scale scores were computed by summing across the weighted predictors. The correlation between the scale scores and the intraoperative electrophysiological signal length (IESL), DBS power-on voltage, improvement rate in the unified Parkinson disease rating scale (UPDRS) and UPDRS part III (UPDRS III) scores was analyzed. Receiver operating characteristics curve analysis was used to quantify the discriminative capacity of the scale for predicting the prognosis.
   RESULTS: Listwise exclusion of patients with incomplete data sets yielded a final sample of 130 patients with Parkinson disease who had undergone bilateral DBS. Multivariate testing identified 3 independent predictors of the prognosis, including electrode implantation duration, postoperative pneumocephalus volume, and electrode fusion error. The scale scores correlated significantly with the subthalamic nucleus DBS power-on voltage (r = - 0.4063; P < 0.0001), globus pallidus internus DBS power-on voltage (r = -0.4723; P = 0.0014), and improvement rate of the UPDRS (r = 0.3490; P< 0.0001) and UPDRS III (r = 0.6623; P < 0.0001) scores. However, the scale scores did not significantly correlate with the subthalamic nucleus IESL and globus pallidus internus IESL. Receiver operating characteristics curve analysis revealed impressive outcome discrimination for the UPDRS and UPDRS III scores (UPDRS: area under the curve, 0.62, P = 0.0219; UPDRS III: area under the curve, 0.85, P < 0.0001).
   CONCLUSIONS: We have introduced a novel practical scale capable of assessing the outcomes of DBS surgery and predicting the prognosis of patients after DBS surgery.
C1 [Gong, Shun; Tao, Yingqun; Jin, Hai; Sun, Xiao; Liu, Yang; Wang, Shimiao; Xu, Menting; Yang, Xingwang; Wang, Yu; Yuan, Lijia; Song, Weilong] Peoples Liberat Army Inst Neurol, Gen Hosp Northern Theater Command, Original Gen Hosp Shenyang Mil Area Command, Dept Neurosurg, Shenyang, Peoples R China.
RP Tao, YQ (reprint author), Peoples Liberat Army Inst Neurol, Gen Hosp Northern Theater Command, Original Gen Hosp Shenyang Mil Area Command, Dept Neurosurg, Shenyang, Peoples R China.
EM yingquntao@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81870890]; Key Program of Scientific Natural
   Funding of Liaoning Province [20170540935]
FX The present study was supported by the National Natural Science
   Foundation of China (grant 81870890) and Key Program of Scientific
   Natural Funding of Liaoning Province (grant 20170540935). The funding
   source had no role in the design or performance of the present study;
   collection, management, analysis, or interpretation of the data;
   preparation, review, or approval of the report; or the decision to
   submit the report for publication.
CR Aum DJ, 2018, FRONT BIOSCI-LANDMRK, V23, P162, DOI 10.2741/4586
   Azmi H, 2011, STEREOT FUNCT NEUROS, V89, P246, DOI 10.1159/000327916
   Bentley JN, 2017, STEREOT FUNCT NEUROS, V95, P6, DOI 10.1159/000452843
   Burchiel KJ, 2013, J NEUROSURG, V119, P301, DOI 10.3171/2013.4.JNS122324
   Choi KS, 2018, BRAIN STIMUL, V11, P445, DOI 10.1016/j.brs.2017.12.001
   Dafsari HS, 2016, BRAIN STIMUL, V9, P78, DOI 10.1016/j.brs.2015.08.005
   Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281
   Elias WJ, 2007, J NEUROSURG, V107, P983, DOI 10.3171/JNS-07/11/0983
   Ho AL, 2019, OPER NEUROSURG, V17, P424, DOI 10.1093/ons/opy395
   Holden MS, 2018, INT J COMPUT ASS RAD, V13, P1129, DOI 10.1007/s11548-018-1753-3
   Ivan ME, 2014, J NEUROSURG, V121, P149, DOI 10.3171/2014.3.JNS121312
   Krack P, 2003, NEW ENGL J MED, V349, P1925, DOI 10.1056/NEJMoa035275
   Li Z, 2016, STEREOT FUNCT NEUROS, V94, P351, DOI 10.1159/000449206
   Patel NK, 2002, STEREOT FUNCT NEUROS, V78, P132, DOI 10.1159/000068964
   Patel NK, 2003, J NEUROL NEUROSUR PS, V74, P1631, DOI 10.1136/jnnp.74.12.1631
   Picillo M, 2016, BRAIN STIMUL, V9, P425, DOI 10.1016/j.brs.2016.02.004
   Polanski WH, 2018, INT J QUAL HEALTH C, V30, P760, DOI 10.1093/intqhc/mzy129
   Roth A, 2018, J CLIN NEUROSCI, V57, P1, DOI 10.1016/j.jocn.2018.08.039
   Sasaki T, 2018, NEUROL MED-CHIR, V58, P199, DOI 10.2176/nmc.oa.2017-0242
   Sharim J, 2015, NEUROMODULATION, V18, P574, DOI 10.1111/ner.12328
   Sillay KA, 2013, ANN BIOMED ENG, V41, P293, DOI 10.1007/s10439-012-0650-0
   Southwell DG, 2016, STEREOT FUNCT NEUROS, V94, P102, DOI 10.1159/000443407
   van den Munckhof P, 2010, NEUROSURGERY, V67, P49, DOI 10.1227/01.NEU.0000370597.44524.6D
   Winkler D, 2013, STEREOT FUNCT NEUROS, V91, P392, DOI 10.1159/000351522
   Xu F, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.4.FOCUS1815
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E1121
EP E1129
DI 10.1016/j.wneu.2019.11.117
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200131
PM 31786379
DA 2020-05-12
ER

PT J
AU Guedes, F
   Brown, RS
   Torrao, FJL
   Siquara-de-Sousa, AC
   Amorim, RMP
AF Guedes, Fernando
   Brown, Rosana Siqueira
   Lourenco Torrao-Junior, Francisco Jose
   Siquara-de-Sousa, Ana Caroline
   Pires Amorim, Rogerio Martin
TI Nondiscogenic Sciatica: What Clinical Examination and Imaging Can Tell
   Us?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Nondiscogenic sciatic neuropathy; Sciatica; Sciatic nerve; Sciatic tumor
ID MAGNETIC-RESONANCE NEUROGRAPHY; PIRIFORMIS SYNDROME; NERVE SCHWANNOMA;
   DISC HERNIATION; RARE CAUSE; DIAGNOSIS; ENDOMETRIOSIS; MRI
AB OBJECTIVE: Lesions affecting the sciatic nerve (SN) can mimic lumbar radiculopathy. In patients presenting with sciatica, approximately 10% have a nondiscogenic etiology. Through neurological examination and imaging, it may be possible to confirm nondiscogenic sciatica (NDS). This study aims to present a series of 6 patients with infragluteal NDS, highlighting clinical and imaging aspects that may suggest this diagnosis.
   METHODS: This is a retrospective study of 6 patients treated for NDS from 2010 to 2018. The mean and median ages were 41.2 and 38.5 years, respectively, with all patients female.
   RESULTS: All patients presented with sciatic pain, tenderness to deep infragluteal palpation, and a positive Tinel's sign related to the SN. Four patients were referred for surgical treatment, whereas 1 underwent pharmacological therapy and 1 underwent incisional biopsy and radiotherapy. In our series, 6 different causes for NDS were diagnosed: 1 nontumorous cause: extrauterine endometriosis and 5 tumors: metastasis from rectal adenocarcinoma, low-grade sarcoma, schwannoma, high-grade sarcoma, and myxoma.
   CONCLUSIONS: Differentiating between discogenic and NDS can be challenging for clinicians. When patients present with sciatic pain, a Tinel's sign related to the SN elicited at the deep infragluteal region, tenderness to deep infragluteal palpation, occasionally with an SN motor deficit and imaging findings of the lumbar spine that do not justify a discogenic source, the cause should be considered nondiscogenic and they should be scheduled for magnetic resonance imaging of the gluteal and pelvic region.
C1 [Guedes, Fernando; Brown, Rosana Siqueira; Lourenco Torrao-Junior, Francisco Jose; Pires Amorim, Rogerio Martin] Fed Univ Rio de Janeiro State UNIRIO, Gaffree E Guinle Univ Hosp, Sch Med, Dept Surg,Div Neurosurg, Rio De Janeiro, Brazil.
   [Siquara-de-Sousa, Ana Caroline] Fluminense Fed Univ, Antonio Pedro Univ Hosp, Pathol Dept, Niteroi, RJ, Brazil.
RP Guedes, F (reprint author), Fed Univ Rio de Janeiro State UNIRIO, Gaffree E Guinle Univ Hosp, Sch Med, Dept Surg,Div Neurosurg, Rio De Janeiro, Brazil.
EM neuroguedes@yahoo.com.br
CR Ailianou A, 2012, BRIT J RADIOL, V85, P672, DOI 10.1259/bjr/84443179
   Al Nezari NH, 2013, SPINE J, V13, P657, DOI 10.1016/j.spinee.2013.02.007
   Arooj S, 2014, J PAK MED ASSOC, V64, P949
   Blanchard C, 2008, REV MED INTERNE, V29, P748, DOI 10.1016/j.revmed.2008.01.008
   Capek S, 2015, J NEUROSURG, V122, P778, DOI 10.3171/2014.12.JNS141339
   Cass SP, 2015, CURR SPORT MED REP, V14, P41, DOI 10.1249/JSR.0000000000000110
   Ceccaroni M, 2011, J SPINAL DISORD TECH, V24, P474, DOI 10.1097/BSD.0b013e31820fc53b
   De Sousa ACS, 2015, CLIN ANAT, V28, P1029, DOI 10.1002/ca.22617
   Ergun T, 2010, BRIT J RADIOL, V83, P791, DOI 10.1259/bjr/76002141
   Eroglu U, 2014, TURK NEUROSURG, V24, P120, DOI 10.5137/1019-5149.JTN.7915-13.0
   Filler AG, 2005, J NEUROSURG-SPINE, V2, P99, DOI 10.3171/spi.2005.2.2.0099
   Floyd JR, 2011, J NEUROSURG-SPINE, V14, P281, DOI 10.3171/2010.10.SPINE09162
   Guedes-Correa JF, 2018, REV BRAS NEUROL, V54, P39
   Haspolat Y, 2013, CASE REP ORTHOP, V2013, P1
   Hebert-Blouin MN, 2010, ACTA NEUROCHIR, V152, P1567, DOI 10.1007/s00701-010-0682-x
   Hopayian K, 2010, EUR SPINE J, V19, P2095, DOI 10.1007/s00586-010-1504-9
   Jankovic D, 2013, CAN J ANESTH, V60, P1003, DOI 10.1007/s12630-013-0009-5
   Jiang H, 2014, JBJS CASE CONNECT, V4, pe11
   Koes BW, 2007, BMJ-BRIT MED J, V334, P1313, DOI 10.1136/bmj.39223.428495.BE
   Kulcu DG, 2008, J CLIN NEUROSCI, V15, P1246, DOI 10.1016/j.jocn.2008.01.017
   Lewis AM, 2006, ARCH NEUROL-CHICAGO, V63, P1469, DOI 10.1001/archneur.63.10.1469
   Mannan K, 2008, J BONE JOINT SURG BR, V90B, P98, DOI 10.1302/0301-620X.90B1.19832
   Mansukhani SA, 2015, J ORTHOP SURG-HONG K, V23, P259, DOI 10.1177/230949901502300232
   Michel F., 2013, Annals of Physical and Rehabilitation Medicine, V56, P300, DOI 10.1016/j.rehab.2013.03.006
   Munakomi Sunil, 2017, F1000Res, V6, P267, DOI 10.12688/f1000research.11108.1
   Omezzine SJ, 2009, ORTHOP TRAUMATOL-SUR, V95, P543, DOI 10.1016/j.otsr.2009.05.007
   Pham M, 2010, FERTIL STERIL, V94, DOI 10.1016/j.fertnstert.2009.12.046
   Rhanim Abdelkarim, 2013, J Clin Orthop Trauma, V4, P89, DOI 10.1016/j.jcot.2013.04.001
   Ropper AH, 2015, NEW ENGL J MED, V372, P1240, DOI 10.1056/NEJMra1410151
   de Sousa ACS, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.6.FOCUS15208
   Uppal J, 2017, WORLD NEUROSURG, V97, DOI 10.1016/j.wneu.2016.09.111
   van der Windt DAWM, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007431.pub2
   Vilos GA, 2002, J AM ASSOC GYN LAP, V9, P145, DOI 10.1016/S1074-3804(05)60122-3
   Vroomen PCAJ, 1999, J NEUROL, V246, P899, DOI 10.1007/s004150050480
   WEWERS ME, 1990, RES NURS HEALTH, V13, P227, DOI 10.1002/nur.4770130405
   Yoshimoto M, 2009, J SPINAL DISORD TECH, V22, P328, DOI 10.1097/BSD.0b013e31817dc46d
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E1053
EP E1061
DI 10.1016/j.wneu.2019.11.083
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200123
PM 31760186
DA 2020-05-12
ER

PT J
AU Hamzaoglu, V
   Beger, O
   Erdogan, O
   Kara, E
   Vayisoglu, Y
   Taghipour, P
   Ozalp, H
   Karatas, D
   Avci, E
   Dagtekin, A
   Bagdatoglu, C
   Ozturk, AH
   Talas, DU
AF Hamzaoglu, Vural
   Beger, Orhan
   Erdogan, Osman
   Kara, Engin
   Vayisoglu, Yusuf
   Taghipour, Pourya
   Ozalp, Hakan
   Karatas, Derya
   Avci, Emel
   Dagtekin, Ahmet
   Bagdatoglu, Celal
   Ozturk, Ahmet Hakan
   Talas, Derya Umit
TI Radioanatomlc Assessment of the Geniculate Ganglior Dehiscence and
   Dimension. A Cadaveric Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cadaver; Computed tomography; Dehiscence; Geniculate ganglion
ID SUPERIOR CANAL DEHISCENCE; COMPUTED-TOMOGRAPHY; FACIAL-NERVE;
   MORPHOMETRIC PROPERTIES; MICROSURGICAL ANATOMY; AREA; CHILDREN; FETAL
AB OBJECTIVE: The main aim of this study placed on cadavers was to compare the data related to geniculate ganglion (GG) dehiscence and dimension obtained from computed tomography (CT) with dissection values.
   METHODS: This study was conducted on 20 temporal -nes obtained from 10 cadavers (4 female, 6 male) aged between 45 and 92 (71.50 +/- 15.98) years. All the measurements related to GG dimension were performed with a CT scanner and microdissection.
   RESULTS: The size of GG including its area, length, and width did not show statistically significant differences in terms of sex, side, and assessment method (CT and cadaveric dissections). The dehiscent GG was observed in 6 (30%) and 5 (25%) out of 20 temporal bones in CT and cadaveric dissections, respectively. The presence and absence of GG dehiscence in CT and dissection were similar in 75%.
   CONCLUSIONS: Our findings based on dissection data suggest that radiologic evaluation of dehiscent GG detection might be erroneous by 25%, which highlights that surgeons should be careful when lifting the dura to prevent GG injury during middle cranial fossa surgical approaches. On the other hand, there was no statistical difference between CT and dissection measurements related to GG dimension.
C1 [Hamzaoglu, Vural; Ozalp, Hakan; Karatas, Derya; Avci, Emel; Dagtekin, Ahmet; Bagdatoglu, Celal] Mersin Univ, Dept Neurosurg, Fac Med, Mersin, Turkey.
   [Beger, Orhan; Ozturk, Ahmet Hakan] Mersin Univ, Dept Anat, Fac Med, Mersin, Turkey.
   [Erdogan, Osman] Sanliurfa Training & Res Hosp, Dept Otorhinolaryngol, Sanliurfa, Turkey.
   [Kara, Engin] Mersin Univ, Dept Radiol, Fac Med, Mersin, Turkey.
   [Vayisoglu, Yusuf; Talas, Derya Umit] Mersin Univ, Dept Otorhinolaryngol, Fac Med, Mersin, Turkey.
   [Taghipour, Pourya] Mersin Univ, Fac Med, Mersin, Turkey.
RP Beger, O (reprint author), Mersin Univ, Dept Anat, Fac Med, Mersin, Turkey.
EM obeger@gmail.com
RI Beger, Orhan/W-8481-2018; Erdogan, Osman/N-8052-2018; TAGHIPOUR,
   POURYA/AAK-2674-2020
OI Beger, Orhan/0000-0002-4932-8758; Erdogan, Osman/0000-0001-9384-7881;
   TAGHIPOUR, POURYA/0000-0002-3442-4069; Hamzaoglu,
   Vural/0000-0003-0249-7711
CR Ames JA, 2012, INT J PEDIATR OTORHI, V76, P1214, DOI 10.1016/j.ijporl.2012.04.021
   Aristegui M, 2019, ANAT REC, V302, P588, DOI 10.1002/ar.23923
   BAXTER A, 1971, Journal of Laryngology and Otology, V85, P587, DOI 10.1017/S0022215100073849
   Beger O, 2019, INT J PEDIATR OTORHI, V124, P59, DOI 10.1016/j.ijporl.2019.05.039
   Celik O, 2017, BRAZ J OTORHINOLAR, V83, P261, DOI 10.1016/j.bjorl.2016.03.016
   Chopra R, 2003, SURG RADIOL ANAT, V24, P348, DOI 10.1007/s00276-002-0076-8
   Dalchow CV, 2013, EUR ARCH OTO-RHINO-L, V270, P511, DOI 10.1007/s00405-012-2022-7
   de Arriba A, 2013, ACTA OTORRINOLAR ESP, V64, P240, DOI 10.1016/j.otorri.2012.01.008
   DOBOZI M, 1975, ACTA OTO-LARYNGOL, V80, P116, DOI 10.3109/00016487509121309
   GE XX, 1981, ANN OTO RHINOL LARYN, V90, P1
   HALL GM, 1969, ARCH OTOLARYNGOL, V90, P568
   Himi T, 2000, ORL J OTO-RHINO-LARY, V62, P316, DOI 10.1159/000027776
   HOUSE WF, 1965, ARCHIV OTOLARYNGOL, V81, P506
   Isaacson B, 2007, OTOL NEUROTOL, V28, P107, DOI 10.1097/01.mao.0000235968.53474.77
   Jufas N, 2017, J OTOLARYNGOL-HEAD N, V46, DOI 10.1186/s40463-017-0231-1
   Kalcioglu MT, 2019, EUR ARCH OTO-RHINO-L, V276, P79, DOI 10.1007/s00405-018-5198-7
   Kansu L, 2012, INT J PEDIATR OTORHI, V76, P772, DOI 10.1016/j.ijporl.2012.03.003
   Kurt H, 2014, OR SURG OR MED OR PA, V117, pE280, DOI 10.1016/j.oooo.2014.01.011
   Lee HK, 2003, ANN OTO RHINOL LARYN, V112, P531, DOI 10.1177/000348940311200609
   Lee HK, 2000, ANN OTO RHINOL LARYN, V109, P255, DOI 10.1177/000348940010900303
   Lookabaugh S, 2015, OTOL NEUROTOL, V36, P118, DOI 10.1097/MAO.0000000000000523
   Migirov L, 2009, EUR ARCH OTO-RHINO-L, V266, P657, DOI 10.1007/s00405-008-0804-8
   Mu XF, 2012, ACAD RADIOL, V19, P971, DOI 10.1016/j.acra.2012.03.025
   Nomiya S, 2011, EUR ARCH OTO-RHINO-L, V268, P1267, DOI 10.1007/s00405-011-1510-5
   RHOTON AL, 1968, J NEUROSURG, V28, P48, DOI 10.3171/jns.1968.28.1.0048
   Sagardoy T, 2017, CLIN OTOLARYNGOL, V42, P461, DOI 10.1111/coa.12629
   Sayit AT, 2019, BRAZ J OTORHINOLAR, V85, P365, DOI 10.1016/j.bjorl.2018.03.005
   Sequeira SM, 2011, OTOL NEUROTOL, V32, P1500, DOI 10.1097/MAO.0b013e318238280c
   Talas DU, 2019, INT J PEDIATR OTORHI, V116, P7, DOI 10.1016/j.ijporl.2018.10.012
   Tavassolie TS, 2012, OTOL NEUROTOL, V33, P215, DOI 10.1097/MAO.0b013e318241c23b
   Yetiser Sertac, 2012, Int J Otolaryngol, V2012, P679708, DOI 10.1155/2012/679708
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E913
EP E919
DI 10.1016/j.wneu.2019.11.036
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200106
PM 31733393
DA 2020-05-12
ER

PT J
AU Hou, XF
   Lu, SB
   Wang, BB
   Kong, C
   Hu, HL
AF Hou, Xiaofei
   Lu, Shibao
   Wang, Baobao
   Kong, Chao
   Hu, Hailiang
TI Morphologic Characteristics of the Deep Cervical Paraspinal Muscles in
   Patients with Single-Level Cervical Spondylotic Myelopathy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spondylotic myelopathy; Fat infiltration; MRI; Paraspinal
   muscles
ID LONGUS-COLLI; MULTIFIDUS; ATROPHY; SPINE
AB OBJECTIVE: This study aimed to compare morphologic changes of deep paraspinal muscles at C4-7 in patients with C5-6 single-level cervical spondylotic myelopathy (CSM), and to evaluate the relationship between morphologic changes and the level of spinal cord compression.
   METHODS: The study included 15 patients with C5-6 single-level CSM and 15 age- and sex-matched healthy subjects. Cross-sectional area (CSA) and functional CSA of the bilateral longus capitis (LCap), longus colli (LC), multifidus (MF), semispinalis cervicis (SSC), semispinalis capitis, splenius capitis, and splenius cervicis were measured on preoperative magnetic resonance images at C4-7, and calculated as ratios with respect to the corresponding vertebral body CSA.
   RESULTS: The mean maximum spinal cord compression was 22.30% in the CSM group. At the cranial level (C4-5), the CSM group had more fat infiltration in the MF and SSC (P < 0.05). At the spinal cord compression segment and caudal adjacent segment (C5-6 and C6-7), the degree of fat infiltration of all paravertebral muscles was aggravated, accompanied by atrophy of LCap, LC, and MF (P < 0.05). Compared between different levels, fat infiltration in the MF at C5-6 was greater than adjacent levels.
   CONCLUSIONS: In patients with C5-6 single-level CSM, fat infiltration and atrophy of deep paraspinal muscles, especially the Leap, LC, and MF, mainly occurred in the level of spinal cord compression and caudal adjacent level. In the cranial adjacent segment, the degree of MF and SSC fat infiltration in patients with CSM was also aggravated. This may suggest that multiple mechanisms are involved in paraspinal muscles degeneration in CSM.
C1 [Hou, Xiaofei; Lu, Shibao; Wang, Baobao; Kong, Chao; Hu, Hailiang] Capital Med Univ, Dept Orthopaed, Xuanwu Hosp, Beijing, Peoples R China.
RP Lu, SB (reprint author), Capital Med Univ, Dept Orthopaed, Xuanwu Hosp, Beijing, Peoples R China.
EM spinelsb@sina.com
FU Beijing Natural Science FoundationBeijing Natural Science Foundation
   [7174366]
FX This study was supported by the Beijing Natural Science Foundation
   (7174366).
CR Anderson JS, 2005, SPINE, V30, pE86, DOI 10.1097/01.brs.0000153700.97830.02
   Arimi SA, 2018, PAIN MED, V19, P2077, DOI 10.1093/pm/pnx331
   Au J, 2016, CLIN ANAT, V29, P643, DOI 10.1002/ca.22731
   Boyd-Clark LC, 2002, SPINE, V27, P694, DOI 10.1097/00007632-200204010-00005
   Boyd-Clark LC, 2001, J ANAT, V199, P709, DOI 10.1046/j.1469-7580.2001.19960709.x
   Cloney M, 2018, J CLIN NEUROSCI, V57, P208, DOI 10.1016/j.jocn.2018.03.028
   Elliott JM, 2011, SPINE, V36, pS205, DOI 10.1097/BRS.0b013e3182387f57
   Fortin M, 2017, SPINE, V42, P232, DOI 10.1097/BRS.0000000000001704
   Fortin M, 2012, PHYS THER, V92, P853, DOI 10.2522/ptj.20110380
   Hayashi N, 2002, RADIOLOGY, V223, P397, DOI 10.1148/radiol.2232010857
   Kang JI, 2013, ANN REHABIL MED-ARM, V37, P498, DOI 10.5535/arm.2013.37.4.498
   Kim WH, 2011, J KOREAN NEUROSURG S, V50, P201, DOI 10.3340/jkns.2011.50.3.201
   Lin IS, 2019, J NEUROENG REHABIL, V16, DOI 10.1186/s12984-019-0564-2
   Machino M, 2016, SPINE, V41, P476, DOI 10.1097/BRS.0000000000001237
   MAYOUXBENHAMOU MA, 1994, SURG RADIOL ANAT, V16, P367, DOI 10.1007/BF01627655
   Okada E, 2011, EUR SPINE J, V20, P1567, DOI 10.1007/s00586-011-1774-x
   Rezasoltani A, 2012, J BACK MUSCULOSKELET, V25, P67, DOI 10.3233/BMR-2012-0303
   Thakar S, 2014, J NEUROSURG-SPINE, V21, P223, DOI 10.3171/2014.4.SPINE13627
   Wei LX, 2018, WORLD NEUROSURG, V118, pE505, DOI 10.1016/j.wneu.2018.06.224
   Wesselink E, 2019, CHIROPR MAN THER, V27, DOI 10.1186/s12998-019-0234-2
   Yoon SY, 2018, CLIN ANAT, V31, P710, DOI 10.1002/ca.23074
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E166
EP E171
DI 10.1016/j.wneu.2019.09.162
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200021
PM 31605863
DA 2020-05-12
ER

PT J
AU Hu, S
   Ma, Q
   Li, B
   Wu, QQ
   Han, RZ
AF Hu, Si
   Ma, Qiang
   Li, Bin
   Wu, QianQian
   Han, RuiZhang
TI Association of Hypothyroidism with Hypertensive Intracerebral
   Hemorrhage: A Case-Control Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hypertension; Hypertensive intracerebral hemorrhage; Hypothyroidism;
   Risk factor
ID DISEASE; RISK
AB BACKGROUND: Hypothyroidism is widely thought to cause vascular endothelial disorders and atherosclerosis. The purpose of this study was to explore whether patients with hypertension and hypothyroidism may have a higher incidence of hypertensive intracerebral hemorrhage.
   METHODS: Cases of hypertensive intracerebral hemorrhage collected from the neurology department and neurosurgery department of our hospital from January 1, 2018, to December 31, 2018, were retrospectively collected. A case-control study was conducted on an equal number of patients with hypertension without hypertensive intracerebral hemorrhage randomly selected through age matching in the same period. The history of hypothyroidism and other common risk factors at admission was recorded.
   RESULTS: A total of 231 patients with hypertensive intracerebral hemorrhage were included and 231 patients with hypertension were selected for control subjects according to the age matching and random screening principles. Hypothyroidism was present in 54 patients (23.4%) and 33 matched controls (14.3%). Multivariate logistic regression analysis showed that hypothyroidism was an independent risk factor for hypertensive intracerebral hemorrhage (odds ratio, 2.29; 95% confidence interval, 1.38-3.79; P = 0.001).
   CONCLUSIONS: Hypothyroidism may be independently associated with hypertensive intracerebral hemorrhage. In view of the known pathophysiologic relationship between hypothyroidism and vascular endothelial dysfunction and atherosclerosis, further research and exploration are necessary.
C1 [Hu, Si; Ma, Qiang; Li, Bin; Han, RuiZhang] 98th Hosp Chinese Peoples Liberat Army, Dept Neurosurg, Huzhou, Zhejiang, Peoples R China.
   [Wu, QianQian] 98th Hosp Chinese Peoples Liberat Army, Dept Neurol, Huzhou, Zhejiang, Peoples R China.
RP Han, RZ (reprint author), 98th Hosp Chinese Peoples Liberat Army, Dept Neurosurg, Huzhou, Zhejiang, Peoples R China.
EM 196671693@163.com
CR Ashizawa K, 2010, CLIN ENDOCRINOL, V72, P689, DOI 10.1111/j.1365-2265.2009.03697.x
   Asvold BO, 2007, EUR J ENDOCRINOL, V156, P707, DOI 10.1530/eje.1.02333e
   Cappola AR, 2003, J CLIN ENDOCR METAB, V88, P2438, DOI 10.1210/jc.2003-030398
   Cini G, 2009, BIOMED PHARMACOTHER, V63, P742, DOI 10.1016/j.biopha.2009.08.003
   Ding W, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012446
   Greenberg SM, 1997, STROKE, V28, P1418, DOI 10.1161/01.STR.28.7.1418
   Kahaly GJ, 2005, ENDOCR REV, V26, P704, DOI 10.1210/er.2003-0033
   Klein I, 2016, CURR PROB CARDIOLOGY, V41, P65, DOI 10.1016/j.cpcardiol.2015.04.002
   La Vignera S, 2012, J ENDOCRINOL INVEST, V35, P96, DOI 10.3275/8190
   Labovitz DL, 2005, NEUROLOGY, V65, P518, DOI 10.1212/01.wnl.0000172915.71933.00
   Liotta EM, 2013, J STROKE CEREBROVASC, V22, P1151, DOI 10.1016/j.jstrokecerebrovasdis.2012.11.015
   Mayer O, 2006, VASC HEALTH RISK MAN, V2, P499, DOI 10.2147/vhrm.2006.2.4.499
   Papaioannou GI, 2004, METABOLISM, V53, P278, DOI 10.1016/j.metabol.2003.10.003
   Tang YP, 2018, BMC NEUROL, V18, DOI 10.1186/s12883-018-1138-9
   Thabet AM, 2017, HAND CLINIC, V140, P177, DOI 10.1016/B978-0-444-63600-3.00011-8
   Thrift AG, 1999, EPIDEMIOLOGY, V10, P307, DOI 10.1097/00001648-199905000-00020
   Williams B, 2018, EUR HEART J, V39, P3021, DOI 10.1093/eurheartj/ehy339
   Ziai WC, 2013, STROKE, V44, pS74, DOI 10.1161/STROKEAHA.111.000662
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E8
EP E11
DI 10.1016/j.wneu.2019.08.041
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200003
PM 31421295
DA 2020-05-12
ER

PT J
AU Huang, YH
   Lien, FC
   Chao, LY
   Lin, CH
   Chen, SH
AF Huang, Yi-Hung
   Lien, Fang-Chieh
   Chao, Lin-Yu
   Lin, Chang-Hao
   Chen, Shih-Hao
TI Full Endoscopic Uniportal Unilateral Laminotomy for Bilateral
   Decompression in Degenerative Lumbar Spinal Stenosis: Highlight of
   Ligamentum Flavum Detachment and Survey of Efficacy and Safety in 2
   Years of Follow-up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic surgery; Lumbar spinal stenosis; Uniportal; Unilateral
   laminotomy bilateral decompression
ID TECHNICAL NOTE; INTERLAMINAR
AB OBJECTIVE: Conventional laminectomy for spine decompression involves inherent complications resulting from perioperative traumatization of posterior structures. Minimally invasive decompression was developed to address these issues. Full endoscopic spine surgery has shifted the paradigm from disc pathology to spinal stenosis by overcoming the limitation of bony procedures with evolving endoscopic instruments. However, a steep learning curve restricts the development of endoscopic decompression. The purpose of this study is to describe full endoscopic uniportal unilateral laminotomy for bilateral decompression through the interlaminar approach and to evaluate its efficacy and safety in 2 years of follow-up.
   METHODS: A total of 106 patients (45 men, 61 women) with degeneration lumbar stenosis involving 165 segments were enrolled from April 2015 to June 2017, and treated by full endoscopic uniportal unilateral laminotomy for bilateral decompression. We made an 8-mm incision and used a general-size endoscope (working channel 4.3 mm) to avoid neurological compromise during the demonstration.
   RESULTS: The visual analogue scale (VAS) results for back pain revealed a significant reduction from preoperative 6.8 = 2.1 to 1.7 +/- 1.7 after 2 years (P < 0.001). The VAS results for leg pain revealed a significant reduction from preoperative 7.6 +/- 1.3 to 1.3 +/- 1.6 after 2 years (P < 0.001). The Oswestry Disability Index showed significant improvement from preoperative 62.0 +/- 13.9 to 14.6 +/- 15.7 after 2 years (P < 0.001). The average operation time was 68.9 +/- 10.0 minutes per level. One case had iatrogenic durotomy, 1 case underwent revision surgery due to incomplete decompression, and 2 cases had delayed wound healing.
   CONCLUSIONS: This procedure obtained successful and satisfactory outcomes for patients, and was more feasible for surgeons.
C1 [Huang, Yi-Hung; Lien, Fang-Chieh; Chao, Lin-Yu; Lin, Chang-Hao] Ditmanson Med Fdn Chia Yi Christian Hosp, Dept Orthopaed, Chiayi, Taiwan.
   [Huang, Yi-Hung] Chia Nan Univ Pharm & Sci, Dept Sports Management, Tainan, Taiwan.
   [Chen, Shih-Hao] Buddhist Tzu Chi Gen Hosp, Dept Orthopaed Surg, Taipei, Taiwan.
   [Chen, Shih-Hao] Tzu Chi Univ, Hualien, Taiwan.
RP Chen, SH (reprint author), Buddhist Tzu Chi Gen Hosp, Dept Orthopaed Surg, Taipei, Taiwan.; Chen, SH (reprint author), Tzu Chi Univ, Hualien, Taiwan.
EM cychaudiofan@gmail.com
OI Lin, Chang-Hao/0000-0002-8344-0751
CR Ahn Y, 2014, EXPERT REV MED DEVIC, V11, P605, DOI 10.1586/17434440.2014.940314
   Amundsen T, 2000, SPINE, V25, P1424, DOI 10.1097/00007632-200006010-00016
   Celik SE, 2010, J SPINAL DISORD TECH, V23, P229, DOI 10.1097/BSD.0b013e3181a3d889
   Choi G, 2006, NEUROSURGERY, V58, P59, DOI 10.1227/01.NEU.0000192713.95921.4A
   Choi G, 2014, J SPINE, V3, P182
   Eum JH, 2016, J NEUROSURG-SPINE, V24, P602, DOI 10.3171/2015.7.SPINE15304
   Fischgrund JS, 1997, SPINE, V22, P2807, DOI 10.1097/00007632-199712150-00003
   Gibson JNA, 2005, SPINE, V30, P2312, DOI 10.1097/01.brs.0000182315.88558.9c
   Heo DH, 2018, WORLD NEUROSURG, V120, pE684, DOI 10.1016/j.wneu.2018.08.144
   Hu Serena S, 2008, Instr Course Lect, V57, P431
   Ito F, 2019, NEUROSPINE, V16, P41, DOI 10.14245/ns.1836320.160
   Kambin P, 1996, J NEUROSURG, V84, P462, DOI 10.3171/jns.1996.84.3.0462
   Kim HS, 2017, WORLD NEUROSURG, V103, P201, DOI 10.1016/j.wneu.2017.03.130
   Kim JE, 2018, J ORTHOP, V15, P366, DOI 10.1016/j.jor.2018.01.039
   Knaub Mark A, 2005, Instr Course Lect, V54, P313
   Knight MTN, 2001, J CLIN LASER MED SUR, V19, P73, DOI 10.1089/104454701750285395
   Komp M, 2015, PAIN PHYSICIAN, V18, P61
   Komp M, 2011, J SPINAL DISORD TECH, V24, P281, DOI 10.1097/BSD.0b013e3181f9f55e
   Lee CH, 2018, SPINE, V43, P1756, DOI 10.1097/BRS.0000000000002708
   Overdevest GM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010036.pub2
   Ruetten S, 2009, J NEUROSURG-SPINE, V10, P476, DOI 10.3171/2008.7.17634
   Soliman HM, 2015, SPINE J, V15, P2282, DOI 10.1016/j.spinee.2015.07.009
   Thome C, 2005, J NEUROSURG-SPINE, V3, P129, DOI 10.3171/spi.2005.3.2.0129
   WHITECLOUD TS, 1994, SPINE, V19, P531, DOI 10.1097/00007632-199403000-00007
NR 24
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E672
EP E681
DI 10.1016/j.wneu.2019.10.162
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200083
PM 31698129
DA 2020-05-12
ER

PT J
AU Huang, YM
   Xu, WH
   Chen, Q
   Lan, ZB
AF Huang, Yuming
   Xu, Weihong
   Chen, Qing
   Lan, Zhibin
TI Treatment of Typical Enneking Stage 3 Thoracic Aggressive Vertebral
   Hemangiomas with Pain and Neurologic Deficits: Results After at Least 36
   Months of Follow-Up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aggressive vertebral hemangioma; Enneking stage; Frankel grade;
   Neurologic deficits; Pain; VAS
ID EPIDURAL HEMANGIOMAS; SURGICAL-MANAGEMENT; NATURAL-HISTORY;
   VERTEBROPLASTY; COMPRESSION
AB OBJECTIVE: To evaluate the efficiency of a comprehensive treatment strategy for patients with Enneking stage 3 thoracic aggressive vertebral hemangioma (AVH).
   METHODS: A retrospective analysis of radiographic and clinical outcomes was performed for 17 patients who received treatment for Enneking stage 3 thoracic AVH accompanied by pain and neurologic deficits between January 2010 and February 2015. A visual analog scale (VAS) was used to clinically evaluate the level of pain. Neurologic examinations were performed to assess the patients' sensory symptoms, motor deficits, and Frankel grade.
   RESULTS: The average operative time was 181.8 +/- 37.1 minutes, and the average intraoperative blood loss was 1226.5 +/- 151.2 ml (range, 900-1450 ml). All patients underwent preoperative embolization to minimize intraoperative blood loss. All patients experienced immediate pain relief and resolution of their neurologic symptoms. All 17 patients achieved Frankel grade D at the final follow-up; moreover, they reported that their pain was relieved (mean VAS score, 2.82 +/- 0.81; P < 0.05) and their neurologic deficits had resolved. No surgery-related complications were noted. No patients exhibited signs of recurrence.
   CONCLUSIONS: We recommend a comprehensive treatment strategy for patients with Enneking stage 3 thoracic AVH that includes preoperative embolization, vertebroplasty, posterior decompression, and internal fixation. We recommend that absorbable gelatin sponge particles be used for intraoperative embolization prior to the injection of bone cement, which may significantly reduce intraoperative bleeding, operative time, and occurrence of surgery-related complications.
C1 [Huang, Yuming] Xiamen Univ, Orthoped Dept, Fuzhou Hosp 2, Fuzhou, Peoples R China.
   [Xu, Weihong; Chen, Qing] Fujian Med Univ, Dept Spine Surg, Affiliated Hosp 1, Fuzhou, Peoples R China.
   [Lan, Zhibin] Fujian Tradit Chinese Med Univ, Spinal Surg Dept, Quanzhou Orthoped Tratenatol Hosp, Quanzhou, Peoples R China.
RP Lan, ZB (reprint author), Fujian Tradit Chinese Med Univ, Spinal Surg Dept, Quanzhou Orthoped Tratenatol Hosp, Quanzhou, Peoples R China.
EM 1691452213@qq.com
OI Huang, Yuming/0000-0002-7693-6417; Lan, Zhibin/0000-0001-8610-7244
CR Acosta FL, 2006, NEUROSURGERY, V58, P287, DOI 10.1227/01.NEU.0000194846.55984.C8
   Acosta FL, 2008, NEUROSURG CLIN N AM, V19, P17, DOI 10.1016/j.nec.2007.09.010
   Acosta FL, 2011, J SPINAL DISORD TECH, V24, P268, DOI 10.1097/BSD.0b013e3181efe0a4
   Alexander J, 2010, SPINE, V35, pE917, DOI 10.1097/BRS.0b013e3181ddfb24
   Chen L, 2007, CHINESE MED J-PEKING, V120, P1136, DOI 10.1097/00029330-200707010-00004
   ENNEKING WF, 1986, CLIN ORTHOP RELAT R, P9
   FOX MW, 1993, J NEUROSURG, V78, P36, DOI 10.3171/jns.1993.78.1.0036
   Goldstein CL, 2015, SPINE, V40, P656, DOI 10.1097/BRS.0000000000000840
   Hadjipavlou A, 2007, J BONE JOINT SURG BR, V89B, P495, DOI 10.1302/0301-620X.89B4.18121
   Hu W, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012775
   Kato S, 2010, J ORTHOP SCI, V15, P350, DOI 10.1007/s00776-010-1483-z
   KRUEGER EG, 1961, J NEUROSURG, V18, P331, DOI 10.3171/jns.1961.18.3.0331
   LAVI E, 1986, J NEUROL NEUROSUR PS, V49, P709, DOI 10.1136/jnnp.49.6.709
   Lowe LH, 2012, SEMIN ROENTGENOL, V47, P106, DOI 10.1053/j.ro.2011.11.002
   MCALLISTER VL, 1975, BRAIN, V98, P71, DOI 10.1093/brain/98.1.71
   Muhmer M, 2014, EUR SPINE J, V23, P404, DOI 10.1007/s00586-013-3045-5
   NGUYEN JP, 1987, SURG NEUROL, V27, P391, DOI 10.1016/0090-3019(87)90020-6
   Ogawa R, 2015, CASE REP ORTHOP, V2015, P724364
   Pastushyn AI, 1998, SURG NEUROL, V50, P535, DOI 10.1016/S0090-3019(98)00007-X
   Urrutia J, 2011, J CLIN NEUROSCI, V18, P209, DOI 10.1016/j.jocn.2010.05.022
   Vasudeva VS, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS16169
   Wang B, 2018, MED SCI MONITOR, V24, P6840, DOI 10.12659/MSM.910439
   Wang B, 2018, SPINE J, V18, P1128, DOI 10.1016/j.spinee.2017.11.003
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E642
EP E648
DI 10.1016/j.wneu.2019.10.158
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200079
PM 31689570
DA 2020-05-12
ER

PT J
AU Ikawa, F
   Michihata, N
   Iihara, K
   Akiyama, Y
   Morita, A
   Fushimi, K
   Yasunaga, H
   Kurisu, K
AF Ikawa, Fusao
   Michihata, Nobuaki
   Iihara, Koji
   Akiyama, Yasuhiko
   Morita, Akio
   Fushimi, Kiyohide
   Yasunaga, Hideo
   Kurisu, Kaoru
TI Risk Management of Aneurysmal Subarachnoid Hemorrhage by Age and
   Treatment Method from a Nationwide Database in Japan
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysmal subarachnoid hemorrhage; Elderly; Endovascular coiling;
   Nationwide database; Outcome at discharge; Surgical clipping
ID RUPTURED CEREBRAL ANEURYSMS; ENDOVASCULAR COILING; DOUBLE-BLIND;
   VASOSPASM; PREDICTION; CILOSTAZOL; MORTALITY; OUTCOMES
AB OBJECTIVE: There has been no precise guide for treatment management of aneurysmal subarachnoid hemorrhage (aSAH) based on the patient's age and treatment method. This study clarifies each risk management for aSAH according to age and treatment method listed in a nationwide database.
   METHODS: We compared 2 groups of patients (nonelderly, <65 years; elderly, >= 65 years) who underwent surgical clipping or endovascular coiling and were registered in a nationwide database in Japan from 2010 to 2015. The odds ratio (OR) and 95% confidence interval (CI) of each risk factor were calculated through multivariate logistic regression analysis for poor outcome according to a modified Rankin Scale score >2 at discharge for each group.
   RESULTS: In all groups, the risk factors for poor outcome were older age, male sex, neurologic grade on admission, diabetes mellitus, and use of anticoagulation drugs. Inverse risk factors were a high-volume hospital, academic hospital, hypertension, and use of an antiplatelet drug (OR, 0.63-0.81; 95% CI, 0.56-0.88). Chronic heart disease was also a risk factor, but use of a statin drug (OR, 0.85-0.87; 95% CI, 0.76-0.97) and location other than on the anterior communicating artery (OR, 0.74-0.80; 95% CI, 0.67-0.91) were inverse risks in both the elderly and the endovascular coiling groups.
   CONCLUSIONS: Management for patients with aneurysmal subarachnoid hemorrhage was recommended in high-volume and academic institutes with the administration of antiplatelet drugs and consideration of several risk factors. Elderly patients undergoing endovascular coiling might be better given a statin drug, and patients with chronic heart failure or an anterior communicating artery aneurysm should be treated more carefully.
C1 [Ikawa, Fusao; Kurisu, Kaoru] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan.
   [Michihata, Nobuaki; Yasunaga, Hideo] Univ Tokyo, Sch Publ Hlth, Dept Clin Epidemiol & Hlth Econ, Tokyo, Japan.
   [Iihara, Koji] Kyushu Univ, Grad Sch Med Sci, Dept Neurosurg, Fukuoka, Japan.
   [Akiyama, Yasuhiko] Shimane Univ, Dept Neurosurg, Fac Med, Izumo, Shimane, Japan.
   [Morita, Akio] Nippon Med Coll Hosp, Dept Neurol Surg, Tokyo, Japan.
   [Fushimi, Kiyohide] Tokyo Med & Dent Univ, Dept Hlth Policy & Informat, Grad Sch Med, Tokyo, Japan.
RP Ikawa, F (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan.
EM fikawa-nsu@umin.ac.jp
OI Yasunaga, Hideo/0000-0002-6017-469X; Ikawa, Fusao/0000-0003-4205-1490
FU Japan Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [17K10829]
FX This work was supported by the Japan Society for the Promotion of
   Science, Grant-in-Aid for Scientific Research (C) 17K10829.
CR Andaluz N, 2008, J NEUROSURG, V108, P1163, DOI 10.3171/JNS/2008/108/6/1163
   Chotai S, 2013, NEUROL MED-CHIR, V53, P157, DOI 10.2176/nmc.53.157
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Cross DT, 2003, J NEUROSURG, V99, P810, DOI 10.3171/jns.2003.99.5.0810
   Dasenbrock H, 2019, J NEUROSURG, V131, P426, DOI 10.3171/2018.3.JNS173057
   De Marchis GM, 2017, CLIN NEUROL NEUROSUR, V157, P82, DOI 10.1016/j.clineuro.2017.04.009
   Dorhout Mees SM, 2007, COCHRANE DB SYST REV
   Eskesen V, 1987, Br J Neurosurg, V1, P455, DOI 10.3109/02688698708999636
   Gordon EH, 2017, EXP GERONTOL, V89, P30, DOI 10.1016/j.exger.2016.12.021
   Hamdan A, 2014, J NEUROSURG, V121, P1367, DOI 10.3171/2014.7.JNS132318
   Iihara K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096819
   Ikawa Fusao, 2020, Neurosurg Rev, V43, P655, DOI 10.1007/s10143-019-01096-2
   Ikawa F, 2018, NEUROSURG REV, V41, P567, DOI 10.1007/s10143-017-0894-0
   Jaja BNR, 2015, J NEUROSURG, V122, P644, DOI 10.3171/2014.10.JNS132694
   Ma BX, 2018, ANN MED, V50, P402, DOI 10.1080/07853890.2018.1471217
   Matsuda N, 2016, CEREBROVASC DIS, V42, P97, DOI 10.1159/000445509
   Mocco J, 2006, NEUROSURGERY, V59, P529, DOI 10.1227/01.NEU.0000228680.22550.A2
   Molyneux AJ, 2015, LANCET, V385, P691, DOI 10.1016/S0140-6736(14)60975-2
   Nagahama Y, 2018, J NEUROSURG, V129, P702, DOI 10.3171/2017.5.JNS17831
   OHTA T, 1986, J NEUROSURG, V64, P420, DOI 10.3171/jns.1986.64.3.0420
   Ono K, 2007, NEUROL MED-CHIR, V47, P291, DOI 10.2176/nmc.47.291
   Oravec CS, 2018, NEUROSURGERY, V82, P728, DOI 10.1093/neuros/nyx328
   Proust F, 2010, J NEUROSURG, V112, P1200, DOI 10.3171/2009.10.JNS08754
   Rinaldo L, 2016, J CLIN NEUROSCI, V34, P108, DOI 10.1016/j.jocn.2016.05.006
   Rosen DS, 2005, NEUROCRIT CARE, V2, P110, DOI 10.1385/NCC:2:2:110
   Rosengart AJ, 2007, STROKE, V38, P2315, DOI 10.1161/STROKEAHA.107.484360
   Sadamasa N, 2014, J NEUROINTERV SURG, V6, P664, DOI 10.1136/neurintsurg-2013-010951
   Schlenk F, 2009, NEUROCRIT CARE, V11, P56, DOI 10.1007/s12028-009-9222-z
   Senbokuya N, 2013, J NEUROSURG, V118, P121, DOI 10.3171/2012.9.JNS12492
   Shen Y, 2018, WORLD NEUROSURG, V119, pE527, DOI 10.1016/j.wneu.2018.07.196
   Shigematsu K, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002736
   To MS, 2018, WORLD NEUROSURG, V113, P153, DOI 10.1016/j.wneu.2018.01.184
   Vaartjes I, 2009, CEREBROVASC DIS, V28, P564, DOI 10.1159/000247600
   Wilson TJ, 2014, J NEUROINTERV SURG, V6, P175, DOI 10.1136/neurintsurg-2013-010714
   Yasunaga H, 2013, ASIAN PAC J DIS MANA, V7, P19, DOI DOI 10.7223/APJDM.7.19
   Zhang F, 2017, J CRANIOFAC SURG, V28, pE535, DOI 10.1097/SCS.0000000000003818
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E55
EP E67
DI 10.1016/j.wneu.2019.09.015
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200009
PM 31521760
DA 2020-05-12
ER

PT J
AU Inci, S
   Akbay, A
   Aslan, T
AF Inci, Servet
   Akbay, Atilla
   Aslan, Tuley
TI The Longest Angiographic and Clinical Follow-Up of Microsurgically
   Treated Giant Intracranial Aneurysms: Experience with 70 Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Giant aneurysm; Late angiography; Long-term follow-up; Microsurgery
ID DIGITAL-SUBTRACTION-ANGIOGRAPHY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY;
   PIPELINE EMBOLIZATION DEVICE; SURGICAL-TREATMENT; FLOW-DIVERSION;
   CEREBRAL ANEURYSMS; MANAGEMENT; RISK; COMPLICATIONS; RECURRENCE
AB BACKGROUND: Giant intracranial aneurysms (GIAs), if left untreated, have an extremely poor natural history. Despite many reports about the surgical treatment of GIAs, their long-term clinical and angiographic results are unclear. To our knowledge, this study reports the longest clinical and angiographic follow-up of microsurgically treated GIAs in the English literature.
   METHODS: Between January 1997 and December 2017, 70 patients with giant anterior circulation aneurysms treated using microsurgery were retrospectively reviewed. The applied microsurgical techniques and especially long-term clinical and angiographic follow-up data were evaluated.
   RESULTS: The mean aneurysm size was 29.2 mm (range, 25-58 mm). The aneurysm neck was occluded in 61 patients (87.2%). Nine aneurysms were clipped using an aneurysm clip compression technique. In 8 patients (11.4%), the aneurysm neck was found smaller at surgery than expected according to angiographic findings.
   Postoperative angiograms showed complete occlusion in 52 of 61 patients (85.2%). The treatment results at discharge were excellent-good (modified Rankin Scale score <= 2) in 75.3% of the patients. The overall mortality was 7.6%. At long-term clinical follow-up (mean, 105.2 months), 48 patients (78.6%) showed excellent-good outcome. At late angiographic follow-up (mean, 98.0 months), no recurrence was seen in patients with complete aneurysm closure.
   CONCLUSIONS: Most giant anterior circulation aneurysms can be successfully clipped, with acceptable morbidity and mortality. Some giant aneurysms have a smaller neck than expected. The aneurysm clip compression technique is useful in clipping of GIAs. This longest clinical and angiographic follow-up in the literature shows that clip ligation has excellent durability in GIAs, also.
C1 [Inci, Servet; Akbay, Atilla; Aslan, Tuley] Hacettepe Univ, Dept Neurosurg, Sch Med, Ankara, Turkey.
RP Inci, S (reprint author), Hacettepe Univ, Dept Neurosurg, Sch Med, Ankara, Turkey.
EM sinci@hacettepe.edu.tr
CR Akyuz M, 2004, ACTA NEUROCHIR, V146, P245, DOI 10.1007/s00701-003-0206-z
   Al-Mufti F, 2019, INTERV NEUROL, V8, P38, DOI 10.1159/000489016
   AUSMAN JI, 1990, SURG NEUROL, V34, P8, DOI 10.1016/0090-3019(90)90166-M
   Barrow DL, 2004, NEUROL INDIA, V52, P156
   Berge J, 2011, AM J NEURORADIOL, V32, P1930, DOI 10.3174/ajnr.A2710
   Burkhardt JK, 2017, WORLD NEUROSURG, V106, P74, DOI [10.1016/j.WNEU.2017.06.110, 10.1016/j.wneu.2017.06.110]
   Cantore G, 2008, NEUROSURGERY, V63, P279, DOI 10.1227/01.NEU.0000313122.58694.91
   Chalouhi N, 2014, AM J NEURORADIOL, V35, P546, DOI 10.3174/ajnr.A3696
   Cruz JP, 2012, AM J NEURORADIOL, V33, P603, DOI 10.3174/ajnr.A3065
   David CA, 1999, J NEUROSURG, V91, P396, DOI 10.3171/jns.1999.91.3.0396
   de Korte AM, 2018, WORLD NEUROSURG, V120, pE802, DOI 10.1016/j.wneu.2018.08.169
   Dehdashti AR, 2006, J NEUROSURG, V104, P395, DOI 10.3171/jns.2006.104.3.395
   Dolati P, 2015, WORLD NEUROSURG, V84, P1362, DOI 10.1016/j.wneu.2015.06.027
   Familiari P, 2015, NEUROSURGERY, V77, P733, DOI 10.1227/NEU.0000000000000917
   GALZIO RJ, 1994, NEW TRENDS IN MANAGEMENT OF CEREBRO-VASCULAR MALFORMATIONS, P203
   Gewirtz RJ, 1996, SURG NEUROL, V45, P409, DOI 10.1016/0090-3019(95)00437-8
   Giombini S, 1988, Acta Neurochir Suppl (Wien), V42, P71
   Golitz P, 2014, NEUROSURGERY, V74, P606, DOI 10.1227/NEU.0000000000000326
   Guedon A, 2016, J NEUROSURG, V29, P1
   HAMBURGER C, 1992, NEUROSURG REV, V15, P97, DOI 10.1007/BF00313502
   Hampton T, 2011, J NEUROINTERV SURG, V3, P167, DOI 10.1136/jnis.2010.002873
   Handa H, 1982, Neurosurg Rev, V5, P169, DOI 10.1007/BF01742680
   HOSOBUCHI Y, 1979, J NEUROSURG, V51, P743, DOI 10.3171/jns.1979.51.6.0743
   Inci S, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.04.039
   Jabbarli R, 2016, J NEUROSURG, V125, P1249, DOI 10.3171/2015.10.JNS151536
   Kivisaari RP, 2004, NEUROSURGERY, V55, P1015, DOI 10.1227/01.NEU.0000141043.07303.60
   Kodama N, 1982, Neurosurg Rev, V5, P155, DOI 10.1007/BF01742678
   Kulcsar Z, 2011, AM J NEURORADIOL, V32, P20, DOI 10.3174/ajnr.A2370
   Lawton MT, 1998, NEUROSURG CLIN N AM, V9, P725, DOI 10.1016/S1042-3680(18)30225-0
   LIN T, 1989, J NEUROSURG, V70, P556, DOI 10.3171/jns.1989.70.4.0556
   Lylyk P, 2009, NEUROSURGERY, V64, P632, DOI 10.1227/01.NEU.0000339109.98070.65
   McAuliffe W, 2012, AM J NEURORADIOL, V33, P164, DOI 10.3174/ajnr.A2727
   Morita A, 2012, NEW ENGL J MED, V366, P2474, DOI 10.1056/NEJMoa1113260
   Murayama Y, 2016, STROKE, V47, P365, DOI 10.1161/STROKEAHA.115.010698
   Nakase H, 2006, NEUROL MED-CHIR, V46, P379, DOI 10.2176/nmc.46.379
   Nanda A, 2014, WORLD NEUROSURG, V81, P752, DOI 10.1016/j.wneu.2012.12.010
   O'Kelly CJ, 2013, AM J NEURORADIOL, V34, P381, DOI 10.3174/ajnr.A3224
   Parkinson RJ, 2008, NEUROSURGERY, V62, P1336, DOI [10.1227/01.NEU.0000237410.32115.C9, 10.1227/01.neu.0000333798.67209.1f]
   Pasqualin A, 1988, Acta Neurochir Suppl (Wien), V42, P60
   Peerless SJ, 1990, NEUROLOGICAL SURG CO, P1742
   Piepgras DG, 1998, J NEUROSURG, V88, P430, DOI 10.3171/jns.1998.88.3.0430
   Rouchaud A, 2016, NEURORADIOLOGY, V58, P171, DOI 10.1007/s00234-015-1615-4
   Sharma BS, 2008, CLIN NEUROL NEUROSUR, V110, P674, DOI 10.1016/j.clineuro.2008.04.001
   Sindou R, 1998, ACTA NEUROCHIR, V140, P1153, DOI 10.1007/s007010050230
   SOLOMON RA, 1992, NEUROSURG QUART, V2, P1
   Spetzler RF, 2001, NEUROSURGERY, V49, P902, DOI 10.1097/00006123-200110000-00022
   Sughrue ME, 2011, NEUROSURGERY, V69, P1261, DOI 10.1227/NEU.0b013e31822bb8a6
   SUNDT TM, 1979, J NEUROSURG, V51, P731, DOI 10.3171/jns.1979.51.6.0731
   SYMON L, 1984, J NEUROSURG, V61, P1009, DOI 10.3171/jns.1984.61.6.1009
   Tan LA, 2015, J NEUROINTERV SURG, V7, P217, DOI 10.1136/neurintsurg-2014-011111
   Thaker NG, 2012, J NEUROINTERV SURG, V4, P219, DOI 10.1136/neurintsurg-2011-010025
   Thornton J, 2000, NEUROSURGERY, V46, P1294, DOI 10.1097/00006123-200006000-00003
   Tsutsumi K, 2001, STROKE, V32, P1191, DOI 10.1161/01.STR.32.5.1191
   VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Wolfe Stacey Quintero, 2006, Clin Neurosurg, V53, P157
   Xu L, 2017, WORLD NEUROSURG, V102, P293, DOI 10.1016/j.wneu.2017.03.055
   YASARGIL MG, 1984, MICRONEUROSURGERY, V2
NR 58
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E412
EP E421
DI 10.1016/j.wneu.2019.10.085
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200050
PM 31655236
DA 2020-05-12
ER

PT J
AU Inoue, T
   Soshi, S
   Kubota, M
   Marumo, K
AF Inoue, Takeshi
   Soshi, Shigeru
   Kubota, Makoto
   Marumo, Keishi
TI Efficacy of Laminoplasty in Improving Sensory Disturbances in Patients
   with Cervical Spondylotic Myelopathy: A Prospective Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical spondylotic myelopathy; JOACMEQ; Laminoplasty; Numbness;
   PainVision; Sensory disturbance; SF-36
ID OPEN-DOOR LAMINOPLASTY; EVALUATION QUESTIONNAIRE JOACMEQ;
   QUALITY-OF-LIFE; OSSIFICATION; LAMINECTOMY; DIAGNOSIS; PAIN
AB OBJECTIVE: Upper extremity sensory disturbances are primary symptoms that affect the quality of life (QOL) of patients with cervical spondylotic myelopathy. Although laminoplasty is 1 of the surgical options, its effects on sensory disturbances have remained unclear. We aimed to determine whether surgical intervention would improve the sensory disturbances of patients with cervical spandylotic myelopathy.
   METHODS: We conducted a prospective clinical trial of 101 patients who had undergone open door laminoplasty. For an objective sensory assessment, we measured the current perception thresholds (CPTs) in the patients' forearms and palms using PainVision PS-2100. For a subjective sensory assessment, numbness in the upper extremities was rated using a visual analog scale (VAS). Using the VAS scores, the patients were divided into those with improvement and without improvement. Their self-reported 36-item short-form health survey and Japanese Orthopaedic Association cervical myelopathy evaluation questionnaire scores were compared.
   RESULTS: The postoperative CPTs in relationship to the preoperative CPTs at 3, 6, and 12 months was 99.3%, 981%, and 93.8% in the forearm and 93.6%, 90.6%, and 87.8% in the palm, respectively. The corresponding postoperative numbness VAS scores were 63.8%, 50.5%, and 48.0%. At 12 months postoperatively, the 36-item short-form health survey physical and role component summary scores, cervical spine function effectiveness rates, upper and lower extremity function, and QOL items in the Japanese Orthopaedic Association cervical myelopathy evaluation questionnaire were significantly higher in the improvement group.
   CONCLUSIONS: Our findings have indicated that improvement in postoperative subjective sensory disturbances will occur relatively earlier and will be significantly greater than the improvement in objective sensory disturbances. Furthermore, improvement in the subjective sensory disturbances contributes to functional spinal cord recovery and patients' health-related QOL.
C1 [Inoue, Takeshi; Soshi, Shigeru; Kubota, Makoto; Marumo, Keishi] Jikei Univ, Dept Orthopaed Surg, Sch Med, Tokyo, Japan.
RP Inoue, T (reprint author), Jikei Univ, Dept Orthopaed Surg, Sch Med, Tokyo, Japan.
EM inoue@jikei.ac.jp
CR Bakhsheshian J, 2017, GLOB SPINE J, V7, P572, DOI 10.1177/2192568217699208
   BENZEL EC, 1991, J SPINAL DISORD, V4, P286, DOI 10.1097/00002517-199109000-00005
   Chiba K, 2006, SPINE, V31, P2998, DOI 10.1097/01.brs.0000250307.78987.6b
   Cho SK, 2018, J AM ACAD ORTHOP SUR, V26, pE142, DOI 10.5435/JAAOS-D-16-00242
   Flanigan DC, 2015, J AM ACAD ORTHOP SUR, V23, P563, DOI 10.5435/JAAOS-D-14-00225
   Fujiwara H, 2018, CLIN SPINE SURG, V31, pE245, DOI 10.1097/BSD.0000000000000619
   Fukui M, 2009, J ORTHOP SCI, V14, P348, DOI 10.1007/s00776-009-1337-8
   Gautschi OP, 2016, ACTA NEUROCHIR, V158, P1875, DOI 10.1007/s00701-016-2899-9
   Heller JG, 2001, SPINE, V26, P1330, DOI 10.1097/00007632-200106150-00013
   Hilton B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207709
   HIRABAYASHI K, 1981, SPINE, V6, P354, DOI 10.1097/00007632-198107000-00005
   HIRABAYASHI K, 1983, SPINE, V8, P693, DOI 10.1097/00007632-198310000-00003
   ITOH T, 1985, SPINE, V10, P729, DOI 10.1097/00007632-198510000-00007
   Katims JJ, 1998, PAIN DIGEST, V8, P219
   Kaye ID, 2018, CLIN SPINE SURG, V31, P1, DOI 10.1097/BSD.0000000000000600
   NATHAN PW, 1986, BRAIN, V109, P1003, DOI 10.1093/brain/109.5.1003
   NURICK S, 1972, BRAIN, V95, P101, DOI 10.1093/brain/95.1.101
   NURICK S, 1972, BRAIN, V95, P87
   Ohtori S, 2014, ASIAN SPINE J, V8, P793, DOI 10.4184/asj.2014.8.6.793
   Seichi A, 2006, SPINE, V31, P1338, DOI 10.1097/01.brs.0000219475.21126.6b
   Seichi A, 2001, SPINE, V26, P479, DOI 10.1097/00007632-200103010-00010
   Singh A, 2006, SPINE, V31, P639, DOI 10.1097/01.brs.0000202744.48633.44
   Tanaka N, 2014, J ORTHOP SCI, V19, P33, DOI 10.1007/s00776-013-0494-y
   Visser MA, 2019, PAIN MED, V20, P826, DOI 10.1093/pm/pny107
   Wang D, 2017, BIOMED RES INT, DOI 10.1155/2017/5670219
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Zhou FF, 2014, CHINESE MED J-PEKING, V127, P2659, DOI 10.3760/cma.j.issn.0366-6999.20132020
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E581
EP E588
DI 10.1016/j.wneu.2019.10.141
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200071
PM 31678439
DA 2020-05-12
ER

PT J
AU Joswig, H
   Staudt, MD
   MacDougall, KW
   Parrent, AG
AF Joswig, Holger
   Staudt, Michael D.
   MacDougall, Keith W.
   Parrent, Andrew G.
TI Effect of Training on Percutaneous Glycerol Rhizotomy for Trigeminal
   Neuralgia: A Long-Term, Retrospective Comparison of Staff Neurosurgeon
   and Trainee Complications and Efficacy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Education; Glycerol rhizotomy; Pain; Training; Trigeminal
   neuralgia
ID SURGICAL EDUCATION; MICROVASCULAR DECOMPRESSION; CEREBROSPINAL-FLUID;
   RESIDENTS; RADIATION; EXPOSURE
AB OBJECTIVE: The role of trainee involvement in lesioning procedures for trigeminal neuralgia (TN) has not yet been investigated in reported studies. The objective of the present study was to compare the complications and efficacy of percutaneous glycerol rhizotomy (GR) when performed by staff neurosurgeons and trainees.
   METHODS: A retrospective medical record analysis of 165 patients with medically refractory TN who had undergone 293 GR procedures by either a staff attending (n = 156) or trainee (n = 137) from 2007 to 2018 was performed. The data were analyzed with respect to procedure time, fluoroscopy time and radiation exposure, complication rates and outcomes.
   RESULTS: No difference was found in procedure duration between the teaching and nonteaching cases and only a nonsignificant trend was found toward a longer fluoroscopy time for the latter. The initial response rates to GR were equal for staff attending (88.7%) and trainee (872%) cases (P = 0.708). Similarly, no statistically significant difference (P = 0.48) was found between the median time to recurrence for the staff attending cases (1.6 +/- 0.3 years) compared with that of the trainee cases (1.7 +/- 0.3 years). The overall incidence of complications was low (7.5%). The occurrence of facial hypoesthesia correlated with the amount of glycerol injected (P< 0.01).
   CONCLUSIONS: GR for the treatment of TN can safely be performed by senior residents and fellows under supervision.
C1 [Joswig, Holger; Staudt, Michael D.; MacDougall, Keith W.; Parrent, Andrew G.] Western Univ, London Hlth Sci Ctr, Dept Clin Neurol Sci, Div Neurosurg, London, ON, Canada.
   [Joswig, Holger] Ernst von Bergmann Hosp, Dept Neurosurg, Potsdam, Germany.
RP Joswig, H (reprint author), Western Univ, London Hlth Sci Ctr, Dept Clin Neurol Sci, Div Neurosurg, London, ON, Canada.; Joswig, H (reprint author), Ernst von Bergmann Hosp, Dept Neurosurg, Potsdam, Germany.
EM holger.joswig@gmail.com
OI Joswig, Holger/0000-0003-3540-3910
CR Asplund P, 2016, NEUROSURGERY, V78, P421, DOI 10.1227/NEU.0000000000001059
   Bydon M, 2015, J NEUROSURG, V122, P955, DOI 10.3171/2014.11.JNS14890
   Chen H Isaac, 2010, Clin Neurosurg, V57, P129
   Cruccu G, 2008, EUR J NEUROL, V15, P1013, DOI 10.1111/j.1468-1331.2008.02185.x
   Holden MS, 2018, INT J COMPUT ASS RAD, V13, P1129, DOI 10.1007/s11548-018-1753-3
   Jagia M, 2004, REGION ANESTH PAIN M, V29, P592, DOI 10.1016/j.rapm.2004.08.013
   Joswig H, 2017, J NEUROL SURG PART A, V78, P460, DOI 10.1055/s-0037-1599056
   Joswig H, 2017, WORLD NEUROSURG, V102, P117, DOI 10.1016/j.wneu.2017.02.128
   Joswig H, 2016, WORLD NEUROSURG, V91, P81, DOI 10.1016/j.wneu.2016.03.081
   Joswig H, 2016, ACTA NEUROCHIR, V158, P357, DOI 10.1007/s00701-015-2667-2
   KONDZIOLKA D, 1994, CAN J NEUROL SCI, V21, P137, DOI 10.1017/S0317167100049076
   Kruger MT, 2018, STEREOT FUNCT NEUROS, V96, P190, DOI 10.1159/000489581
   Kundu B, 2018, HEADACHE, V58, P1675, DOI 10.1111/head.13425
   Li Y, 2000, Stud Health Technol Inform, V70, P175
   Lopez BC, 2004, NEUROSURGERY, V54, P973, DOI 10.1227/01.NEU.0000114867.98896.F0
   Macki M, 2018, WORLD NEUROSURG, V114, pE70, DOI 10.1016/j.wneu.2018.02.068
   Maldaner N, 2018, ACTA NEUROCHIR, V160, P901, DOI 10.1007/s00701-017-3458-8
   Noorani I, 2019, NEUROSURGERY, V85, pE684, DOI 10.1093/neuros/nyz103
   Pandia MP, 2008, REGION ANESTH PAIN M, V33, P222, DOI 10.1016/j.rapm.2007.02.013
   Phan K, 2016, J CLIN NEUROSCI, V29, P7, DOI 10.1016/j.jocn.2015.11.027
   Pickett GE, 2005, NEUROSURGERY, V56, P537, DOI 10.1227/01.NEU.0000153907.43563.FF
   Rogers CL, 2000, INT J RADIAT ONCOL, V47, P1013, DOI 10.1016/S0360-3016(00)00513-7
   Shakur SF, 2015, OPER NEUROSURG, V11, P420, DOI 10.1227/NEU.0000000000000853
   Singer G, 2005, J AM ACAD ORTHOP SUR, V13, P69, DOI 10.5435/00124635-200501000-00009
   Staudt M, 2018, DIAGNOSIS MANAGEMENT, P221
   Staudt Michael D, 2019, J Neurosurg, P1, DOI 10.3171/2019.1.JNS183093
   Stienen MN, 2016, ACTA NEUROCHIR, V158, P17, DOI 10.1007/s00701-015-2633-z
   Stienen MN, 2015, WORLD NEUROSURG, V84, P1589, DOI 10.1016/j.wneu.2015.07.030
   Stienen MN, 2015, ACTA NEUROCHIR, V157, P1395, DOI 10.1007/s00701-015-2396-6
   Stienen MN, 2014, ACTA NEUROCHIR, V156, P1205, DOI 10.1007/s00701-014-2070-4
   Tatli M, 2008, ACTA NEUROCHIR, V150, P243, DOI 10.1007/s00701-007-1488-3
   The Accreditation Council for Graduate Medical Education, NEUR SURG MIL
   The Royal College of Physicians and Surgeons of Canada, OBJ TRAIN SPEC NEUR
   Udupi BP, 2012, NEUROSURGERY, V70, P407, DOI 10.1227/NEU.0b013e318233a85f
   Wallach J, 2018, J CLIN NEUROSCI, V55, P13, DOI 10.1016/j.jocn.2018.06.010
   Wang DD, 2013, J CLIN NEUROSCI, V20, P1538, DOI 10.1016/j.jocn.2012.12.026
   Zaidi HA, 2016, WORLD NEUROSURG, V86, P220, DOI 10.1016/j.wneu.2015.09.059
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E1001
EP E1007
DI 10.1016/j.wneu.2019.11.058
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200117
PM 31756505
DA 2020-05-12
ER

PT J
AU Kalidindi, KKV
   Bhat, MR
   Mannem, A
   Chhabra, HS
AF Kalidindi, Kalyan Kumar Varma
   Bhat, Mohd Rafiq
   Mannem, Abhishek
   Chhabra, Harvinder Singh
TI Conservative Management for Late Presenting Dural Tears After Spine
   Surgery: An Institutional Experience and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Conservative management; Late presenting dural tears; Literature review;
   Spine surgery
ID INCIDENTAL DUROTOMY; LUMBAR SPINE; DELAYED PRESENTATION; PROTOCOL
AB BACKGROUND: Symptoms and evidence of cerebrospinal fluid (CSF) leak after an uneventful intraoperative and immediate postoperative course are a rare entity in spine surgery. The literature is sparse on the description of such late presenting dural tears (LPDTs). They may need further admissions, wound management, and additional surgical procedures that add to the morbidity of the patient.
   METHODS: A retrospective review of spine surgeries done at our institute for degenerative spinal conditions between January 2017 and January 2018 was conducted. A mini meta-analysis was performed on studies comparing conservative and surgical management of LPDTs.
   RESULTS: Among 1929 patients, 6 cases (5 lumbar and 1 cervical) had an LPDT. Five of them had a CSF fistula and 1 patient had a pseudomeningocele. Two patients with CSF fistula were complicated by superficial surgical site infection (SSI). There was additional evidence of pneumocephalus and pneumorachis in 1 case. The SSI was managed by bedside debridement, regular dressing, and culture-sensitive antibiotics. CSF fistulas were managed by deep suturing, and pseudomeningocele was managed by excision of the sac and plication of the neck. All the patients had a good to an excellent outcome at the end of a 1-year follow-up.
   CONCLUSIONS: One should be aware of the possibility of LPDTs. A combination of history, clinical examination, and imaging may aid in the diagnosis. It can be associated with complications like CSF fistula, pseudomeningocele, SSI, pneumocephalus, or pneumorachis. Conservative trial can have good to excellent outcomes in the management of such cases though there is insufficient evidence to establish it.
C1 [Kalidindi, Kalyan Kumar Varma; Bhat, Mohd Rafiq; Mannem, Abhishek; Chhabra, Harvinder Singh] Indian Spinal Injuries Ctr, Dept Spine Serv, New Delhi, India.
RP Kalidindi, KKV (reprint author), Indian Spinal Injuries Ctr, Dept Spine Serv, New Delhi, India.
EM kalyanvarmambbs@gmail.com
CR Akyuz O, 2016, POL J RADIOL, V81, P34, DOI 10.12659/PJR.895570
   Bosacco SJ, 2001, CLIN ORTHOP RELAT R, P238
   Brookfield Kathleen, 2008, Orthopedics, V31, P816
   Cammisa FP, 2000, SPINE, V25, P2663, DOI 10.1097/00007632-200010150-00019
   Dannawi Z, 2014, BMJ CASE REP, V2014
   Durand WM, 2018, SPINE J, V18, P2043, DOI 10.1016/j.spinee.2018.04.004
   EISMONT FJ, 1981, J BONE JOINT SURG AM, V63, P1132, DOI 10.2106/00004623-198163070-00010
   Epstein Nancy E, 2013, Surg Neurol Int, V4, pS301, DOI 10.4103/2152-7806.111427
   Guerin P, 2012, INJURY, V43, P397, DOI 10.1016/j.injury.2010.12.014
   Hershman S, 2013, BULL HOSP JT DIS, V71, P231
   Khan MH, 2006, SPINE, V31, P2609, DOI 10.1097/01.brs.0000241066.55849.41
   Khazim R, 2015, EUR SPINE J, V24, P2069, DOI 10.1007/s00586-015-3830-4
   Kundu A, 2008, CAN J ANAESTH, V55, P696, DOI 10.1007/BF03017746
   Lauer K K, 1992, J Clin Anesth, V4, P45, DOI 10.1016/0952-8180(92)90120-P
   Le AX, 2001, SPINE, V26, P115, DOI 10.1097/00007632-200101010-00020
   McMahon P, 2012, J NEUROSURG-SPINE, V17, P30, DOI 10.3171/2012.3.SPINE11939
   Rampersaud YR, 2006, SPINE, V31, P1503, DOI 10.1097/01.brs.0000220652.39970.c2
   Saxler G, 2005, SPINE, V30, P2298, DOI 10.1097/01.brs.0000182131.44670.f7
   Tafazal SI, 2005, EUR SPINE J, V14, P287, DOI 10.1007/s00586-004-0821-2
   Tosun B, 2012, ASIAN SPINE J, V6, P157, DOI 10.4184/asj.2012.6.3.157
   Wang JC, 1998, J BONE JOINT SURG AM, V80A, P1728, DOI 10.2106/00004623-199812000-00002
   Wolff S, 2012, ORTHOP TRAUMATOL-SUR, V98, P879, DOI 10.1016/j.otsr.2012.06.016
NR 22
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E82
EP E92
DI 10.1016/j.wneu.2019.09.067
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200012
PM 31542441
DA 2020-05-12
ER

PT J
AU Kan, I
   Ishibashi, T
   Sakuta, K
   Fujimura, S
   Yuki, I
   Kaku, S
   Kodama, T
   Kato, N
   Nishimura, K
   Aoki, K
   Sasaki, Y
   Karagiozov, K
   Murayama, Y
AF Kan, Issei
   Ishibashi, Toshihiro
   Sakuta, Kenichi
   Fujimura, Soichiro
   Yuki, Ichiro
   Kaku, Shogo
   Kodama, Tomonobu
   Kato, Naoki
   Nishimura, Kengo
   Aoki, Ken
   Sasaki, Yuichi
   Karagiozov, Kostadin
   Murayama, Yuichi
TI Preoperative Light Transmission Aggregometry Values Predict for
   Thromboembolic Complications After Stent-Assisted Coil Embolization
SO WORLD NEUROSURGERY
LA English
DT Article
DE Antiplatelet therapy; Light transmission aggregometry; Stent-assisted
   coil embolization
ID TREATMENT PLATELET REACTIVITY; INTRACRANIAL ANEURYSMS; DEVICE PLACEMENT;
   FUNCTION TESTS; CLOPIDOGREL; EVENTS; VARIABILITY; STANDARD
AB OBJECTIVE: Risk control of thromboembolic complications (TECs) during stent-assisted coil embolization (SACE) for unruptured intracranial aneurysms (UIAs) is crucial for satisfactory treatment outcomes. We retrospectively evaluated the data from our cohort of SACE for UIAs to analyze the role of anatomical, clinical, and stent type-related factors to determine the optimal preoperative values of light transmission aggregometry (LTA) for TEC prevention.
   METHODS: From July 2015 to May 2018, we retrospectively analyzed the data from 132 patients with SACE-treated UIAs at our hospital. Data regarding the aneurysm location, maximum diameter, stent type used, preoperative LTA value, and ischemic and hemorrhagic complications were collected. Aspirin 100 mg and clopidogrel 75 mg were started 7 days before surgery, with a "boost" dose (an additional 75 mg of clopidogrel for an LTA value >60%) added after August 2016 to address clopidogrel resistance. After multivariate analysis, we developed our original combined parameter termed the thromboembolic predictor (TEP). Receiver operating characteristic (ROC) analysis for TEP and each significant variable was performed.
   RESULTS: TECs were confirmed in 5 of the 132 patients (3.8%) and hemorrhagic complications in 9 of the 132 patients (6.8%). From the multivariate analysis results, the LTA value and maximum diameter were chosen as significant variables and included in the TEP. ROC analysis of the LTA value revealed a sensitivity and specificity of 0.866 and 0.600, respectively (area under the curve, 0.747), with a cutoff of 62%. TEP permitted the establishment of an optimal LTA value according to the aneurysm maximum diameter to predict for TECs. The complication rate for the Neuroform EZ, Enterprise, Neuroform Atlas, and LVIS stents was 2.9%, 10.5%, 1.4%, and 14.3%, respectively.
   CONCLUSIONS: The preoperative LTA value contributes to the prediction of TECs after SACE for UIAs. The TEP (relating the LTA cutoff to aneurysm size) allows for improved antiplatelet therapy adjustment before SACE to reduce TECs.
C1 [Kan, Issei; Ishibashi, Toshihiro; Yuki, Ichiro; Kaku, Shogo; Kodama, Tomonobu; Kato, Naoki; Nishimura, Kengo; Aoki, Ken; Sasaki, Yuichi; Karagiozov, Kostadin; Murayama, Yuichi] Jikei Univ Hosp, Dept Neurosurg, Tokyo, Japan.
   [Sakuta, Kenichi] Jikei Univ Hosp, Dept Neurol, Tokyo, Japan.
   [Fujimura, Soichiro] Jikei Univ, Dept Innovat Med Informat Technol, Sch Med, Tokyo, Japan.
   [Fujimura, Soichiro] Tokyo Univ Sci, Grad Sch Mech Engn, Tokyo, Japan.
RP Kan, I (reprint author), Jikei Univ Hosp, Dept Neurosurg, Tokyo, Japan.
EM isseikan@gmail.com
OI Kan, Issei/0000-0003-4829-4784; NISHIMURA, KENGO/0000-0001-7898-663X;
   Yuki, Ichiro/0000-0002-7673-9085; Ishibashi,
   Toshihiro/0000-0003-1044-5604
CR Adeeb N, 2018, WORLD NEUROSURG, V113, P47, DOI 10.1016/j.wneu.2018.02.014
   Adeeb N, 2017, STROKE, V48, P1322, DOI 10.1161/STROKEAHA.116.015308
   Almandoz JED, 2014, J NEUROINTERV SURG, V6, P767, DOI 10.1136/neurintsurg-2013-010976
   Almandoz JED, 2013, J NEUROINTERV SURG, V5, pIII3, DOI 10.1136/neurintsurg-2012-010582
   Derdeyn CP, 2002, J NEUROSURG, V96, P837, DOI 10.3171/jns.2002.96.5.0837
   Femia EA, 2012, PLATELETS, V23, P7, DOI 10.3109/09537104.2011.596592
   Feng MT, 2016, WORLD NEUROSURG, V93, P271, DOI 10.1016/j.wneu.2016.06.014
   Flechtenmacher N, 2015, AM J NEURORADIOL, V36, P1953, DOI 10.3174/ajnr.A4388
   Gupta R, 2016, WORLD NEUROSURG, V96, P285, DOI 10.1016/j.wneu.2016.09.013
   Hwang G, 2015, JAMA NEUROL, V72, P764, DOI 10.1001/jamaneurol.2015.0654
   Jeong YH, 2012, J THROMB HAEMOST, V10, P487, DOI 10.1111/j.1538-7836.2011.04604.x
   Kang HS, 2010, AM J NEURORADIOL, V31, P1206, DOI 10.3174/ajnr.A2051
   Kang HS, 2010, NEUROSURGERY, V67, P1371, DOI 10.1227/NEU.0b013e3181efe3ef
   Kim KS, 2018, J NEUROSURG, V129, P890, DOI 10.3171/2017.5.JNS162307
   Lee SJ, 2013, CLIN RADIOL, V68, P256, DOI 10.1016/j.crad.2012.07.017
   Paniccia R, 2007, J THROMB HAEMOST, V5, P1839, DOI 10.1111/j.1538-7836.2007.02656.x
   Paniccia R, 2015, VASC HEALTH RISK MAN, V11, P133, DOI 10.2147/VHRM.S44469
   Phan K, 2016, J CLIN NEUROSCI, V31, P15, DOI 10.1016/j.jocn.2016.01.035
   Piotin M, 2010, STROKE, V41, P110, DOI 10.1161/STROKEAHA.109.558114
   Tan LA, 2015, J NEUROINTERV SURG, V7, P217, DOI 10.1136/neurintsurg-2014-011111
   Taylor LI, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1746
   ten Brinck MFM, 2019, NEUROSURGERY, V84, P179, DOI 10.1093/neuros/nyy048
   Ulfert C, 2018, J NEUROINTERV SURG, V10, P1192, DOI 10.1136/neurintsurg-2017-013516
   Wong P, 2015, NEUROL RES, V37, P998, DOI 10.1179/1743132815Y.0000000084
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E731
EP E738
DI 10.1016/j.wneu.2019.10.179
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200085
PM 31704360
DA 2020-05-12
ER

PT J
AU Kaushik, A
   Dwarakanath, TA
   Bhutani, G
   Srinivas, D
AF Kaushik, Abhishek
   Dwarakanath, T. A.
   Bhutani, Gaurav
   Srinivas, Dwarakanath
TI Robot-Based Autonomous Neuroregistration and Neuronavigation:
   Implementation and Case Studies
SO WORLD NEUROSURGERY
LA English
DT Article
DE Autonomous neuroregistration; Image-guided surgery; Neuronavigation;
   Robot-based neurosurgery
ID REGISTRATION; ACCURACY; LOCALIZATION; CT
AB BACKGROUND: To conduct an autonomous robot-based neurosurgical procedure in the least time with high accuracy. Further, to analyze and validate the method.
   METHODS: The coordinates of the markers and the region of interest in the medical image space are measured , Subsequently, in the real patient space, a set of algorithms plans the robot motion. The surgical robot attached with a camera autonomously navigates toward the fiducial markers to measure the coordinates and conduct the neuroregistration. The robot also facilitates the precise constrained guiding path to navigate the surgical tool to reach the region of interest (target) selected in the image.
   RESULTS: The phantom was registered within 1 mm accuracy in all cases for all poses. High-precision navigation to the target in all poses was shown.
   CONCLUSIONS: The robot is successful in conducting hands-off neuroregistration and neuronavigation. The accuracy is considerably higher, and the time taken is lesser relative to the manual procedure.
C1 [Kaushik, Abhishek; Dwarakanath, T. A.] Homi Bhabha Natl Inst, Dept Engn Sci, Mumbai, Maharashtra, India.
   [Dwarakanath, T. A.; Bhutani, Gaurav] Bhabha Atom Res Ctr, Div Remote Handling & Robot, Mumbai, Maharashtra, India.
   [Srinivas, Dwarakanath] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India.
RP Kaushik, A (reprint author), Homi Bhabha Natl Inst, Dept Engn Sci, Mumbai, Maharashtra, India.
EM kaushik.or.abhishek@gmail.com
OI Kaushik, Abhishek/0000-0001-6004-7220
CR [Anonymous], 2011, DIG IM COMM MED DI 3
   Bhutani G., 2015, THESIS
   Cardinale F, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.2.FOCUS16539
   Dawson-Howe K., 2014, PRACTICAL INTRO COMP
   Du J, 2006, INT J COMPUT MATH, V83, P49, DOI 10.1080/00207160500112944
   Dwarakanath S, 2019, LECT N MECH ENG, P49, DOI 10.1007/978-981-10-8597-0_5
   Eljamel MS, 2007, INT J MED ROBOT COMP, V3, P372, DOI 10.1002/rcs.153
   Grimm F, 2015, J NEUROSURG, V123, P737, DOI 10.3171/2014.12.JNS141781
   Guo ZY, 2018, WORLD NEUROSURG, V116, P77, DOI 10.1016/j.wneu.2018.04.155
   Hartley R. I., 2004, MULTIPLE VIEW GEOMET
   Heinig M, 2012, INT J COMPUT ASS RAD, V7, P911, DOI 10.1007/s11548-012-0676-7
   Kaushik A, 2019, LECT N MECH ENG, P27, DOI 10.1007/978-981-10-8597-0_3
   Kaushik A, 2018, INT J COMPUT ASS RAD, V13, P1807, DOI 10.1007/s11548-018-1826-3
   Korsager AS, 2016, J APPL CLIN MED PHYS, V17, P294, DOI 10.1120/jacmp.v17i3.6088
   Meng FL, 2018, INT J COMPUT ASS RAD, V13, P253, DOI 10.1007/s11548-017-1675-5
   Mordvintsev A, 2013, POSE ESTIMATION OPEN
   Pianykh OS, 2011, DIGITAL IMAGING COMM
   Poggi S, 2003, PHYS MED BIOL, V48, P2199, DOI 10.1088/0031-9155/48/14/311
   Salma A, 2012, COMPUT AIDED SURG, V17, P172, DOI 10.3109/10929088.2012.691992
   Stieglitz LH, 2013, NEUROSURGERY, V72, P796, DOI 10.1227/NEU.0b013e318287072d
   Suligoj F, 2017, IEEE ACCESS, V5, P12265, DOI 10.1109/ACCESS.2017.2718621
   Wang MN, 2009, PATTERN RECOGN LETT, V30, P414, DOI 10.1016/j.patrec.2008.11.001
   West JB, 2001, NEUROSURGERY, V48, P810, DOI 10.1097/00006123-200104000-00023
   WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004
NR 24
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E256
EP E271
DI 10.1016/j.wneu.2019.10.041
PG 16
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200032
PM 31629139
DA 2020-05-12
ER

PT J
AU Knio, ZO
   VanHorn, TA
   O'Gara, TJ
AF Knio, Ziyad O.
   VanHorn, Trent A.
   O'Gara, Tadhg J.
TI Should the EuroQol-Five Dimensions Replace the Oswestry Disability Index
   When Tracking Lumbar Tubular Microdecompression Outcomes?
SO WORLD NEUROSURGERY
LA English
DT Article
DE EQ-5D; Health state; Oswestry Disability Index; Patient-reported
   outcomes measures
ID LEG-PAIN-SCORES; BACK
AB OBJECTIVE: Patient-reported outcomes measures (PROMs) are critical in evaluating the effectiveness of surgical spine interventions. The Oswestry Disability Index (ODI) is commonly used but tedious to administer routinely. The EuroGol-5 Dimensions (EQ-5D) questionnaire is easier to administer but not traditionally used to measure spine surgical results. This study aimed to investigate the correlation of commonly administered PROMs in lumbar tubular microdecompression patients, and to consider whether ODI could be predicted from remaining PROMs.
   METHODS: This study examined 304 index lumbar tubular microdecompression patients with PROMs collected at routine intervals. Spearman correlation coefficients were calculated for each pairwise combination of the following PROMs: ODI, EQ-5D index, leg pain visual analog scale (VAS), low back pain VAS, health state item. Linear regression modeling was conducted to predict ODI from the remaining four PROMs.
   RESULTS: The patients had a mean age of 65.55 +/- 12.97 years and 46.4% were male. Each combination of PROMs demonstrated a statistically significant pairwise correlation (P< 0.001). ODI showed strong correlation with EQ-5D index (r = -0.77), leg pain VAS (r = 0.73), and back pain VAS (r = 0.65), but weak correlation with health state item (r = -0.33). Forwards stepwise model selection yielded a multiple linear regression model including all four PROMs predictors, with an adjusted R2 of 0.690. There was strong correlation between predicted and observed ODI (r = 0.83, P < 0.001).
   CONCLUSIONS: ODI can be predicted from EQ-5D, leg and low back pain VAS, and health state items with moderate accuracy. The added utility of capturing ODI routinely may not out-weigh the challenges in doing so.
C1 [Knio, Ziyad O.; VanHorn, Trent A.; O'Gara, Tadhg J.] Wake Forest Sch Med, Dept Orthopaed Surg, Winston Salem, NC 27101 USA.
   [O'Gara, Tadhg J.] Wake Forest Sch Med, Dept Neurosurg, Winston Salem, NC 27101 USA.
RP O'Gara, TJ (reprint author), Wake Forest Sch Med, Dept Orthopaed Surg, Winston Salem, NC 27101 USA.; O'Gara, TJ (reprint author), Wake Forest Sch Med, Dept Neurosurg, Winston Salem, NC 27101 USA.
EM togara@wakehealth.edu
OI Knio, Ziyad/0000-0001-5696-873X
CR Carreon LY, 2014, SPINE, V39, P678, DOI 10.1097/BRS.0000000000000220
   Chung AS, 2017, SPINE, V42, P1096, DOI 10.1097/BRS.0000000000001990
   Copay AG, 2008, SPINE J, V8, P968, DOI 10.1016/j.spinee.2007.11.006
   Fairbank JCT, 2000, SPINE, V25, P2940, DOI 10.1097/00007632-200011150-00017
   Ferreira LN, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0491-x
   Habibzadeh F, 2016, BIOCHEM MEDICA, V26, P297, DOI 10.11613/BM.2016.034
   Johnsen LG, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-148
   Kovacs FM, 2004, SPINE, V29, P206, DOI 10.1097/01.BRS.0000107235.47465.08
   Kovacs FM, 2013, SPINE, V38, P1523, DOI 10.1097/BRS.0b013e31829cb804
   McCaffery M, 1993, PAIN CLIN MANUAL NUR
   Mehra A, 2008, ANN ROY COLL SURG, V90, P497, DOI 10.1308/003588408X300984
   Mueller B, 2013, SPINE, V38, P757, DOI 10.1097/BRS.0b013e31827ab803
   Payakachat N, 2015, PHARMACOECONOMICS, V33, P1137, DOI 10.1007/s40273-015-0295-6
   ROLAND M, 1983, SPINE, V8, P145, DOI 10.1097/00007632-198303000-00005
   Selivanova A, 2018, PHARMACOECONOMICS, V36, P715, DOI 10.1007/s40273-018-0647-0
   Shaw JW, 2005, MED CARE, V43, P203, DOI 10.1097/00005650-200503000-00003
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E566
EP E571
DI 10.1016/j.wneu.2019.10.124
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200069
PM 31678442
DA 2020-05-12
ER

PT J
AU Kong, CC
   Guo, ZL
   Xu, XL
   Yu, YB
   Yang, WQ
   Wang, Q
   Zhang, L
AF Kong, Chen-Chen
   Guo, Zhuang-Li
   Xu, Xiao-Li
   Yu, Yan-Bing
   Yang, Wen-Qiang
   Wang, Qi
   Zhang, Li
TI Delayed Facial Palsy After Microvascular Decompression for Hemifacial
   Spasm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Delayed facial palsy; Hemifacial spasm; Microvascular decompression;
   Risk factors
AB OBJECTIVE: We explored the risk factors for the occurrence of delayed facial paralysis (DFP) after microvascular decompression (MVD) for hemifacial spasm (HFS).
   METHODS: A retrospective study was conducted of 636 patients who had undergone MVD for HFS by the same neurosurgery department of China-Japan Friendship Hospital from January 2006 to May 2016. Of the 636 patients, 50 (7.9%) had presented with DFP, which had developed from 2 to 60 days postoperatively (average, 12.9 +/- 10.0005 days). All 50 patients with DFP had recovered completely within 10-300 days (average, 88.7 +/- 61.389 days) after the onset of DFP. We randomly selected 100 patients from the 586 patients without DFP as the control group. Univariate and multivariate logistic analyses were used to analyze the risk factors involved in the occurrence of DFP.
   RESULTS: Univariate analysis showed that the disease course was the only factor associated with the development of DFP (P = 0.003). Furthermore, on multivariate logistic analysis, the course of HFS was the only risk factor associated with the development of DFP (P = 0.01). Additionally, the Spearman test revealed a positive correlation between the onset of DFP and the duration of the DFP symptoms (r(s) = 0.682; P < 0.001).
   CONCLUSION: Although DFP frequently occurred after MVD, it can recover spontaneously. The longer the course of HFS, the more frequently DFP will occur after MUD. The earlier that DFP develops, the shorter will be the time to recovery.
C1 [Kong, Chen-Chen; Xu, Xiao-Li; Yu, Yan-Bing; Yang, Wen-Qiang; Wang, Qi; Zhang, Li] China Japan Friendship Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Guo, Zhuang-Li] Qingdao Univ, Affiliated Hosp, Dept Rehabil, Qingdao, Peoples R China.
RP Zhang, L (reprint author), China Japan Friendship Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM allan189@163.com
CR BADEMOSI O, 1987, African Journal of Medicine and Medical Sciences, V16, P197
   Dou NN, 2014, J CRANIOFAC SURG, V25, P907, DOI 10.1097/SCS.0000000000000567
   Furukawa K, 2003, NEUROL SURG TOKYO, V31, P899
   Gianoli GJ, 2002, OTOLARYNG HEAD NECK, V127, P427, DOI 10.1067/mhn.2002.129817
   Guthikonda B, 2015, NEUROSURGERY, V66, pE846
   Guthikonda B, 2010, NEUROSURGERY, V66, pE845, DOI 10.1227/01.NEU.0000367637.09010.41
   Han JS, 2012, J KOREAN NEUROSURG S, V52, P288, DOI 10.3340/jkns.2012.52.4.288
   Jin YC, 2015, NEUROSURG REV, V38, P567, DOI 10.1007/s10143-015-0622-6
   Kim BTHS, 1999, J KOREAN NEUROSURG S, V28, P1332
   Liu LX, 2016, ACTA NEUROCHIR, V158, P379, DOI 10.1007/s00701-015-2652-9
   Lovely TJ, 1998, SURG NEUROL, V50, P449, DOI 10.1016/S0090-3019(97)00314-5
   Lv MY, 2017, BRIT J NEUROSURG, V31, P322, DOI 10.1080/02688697.2017.1297368
   Martinez ARM, 2014, ARQ NEURO-PSIQUIAT, V72, P119, DOI 10.1590/0004-282X20130227
   Mauriello JA, 1996, CLIN NEUROL NEUROSUR, V98, P213, DOI 10.1016/0303-8467(96)00025-X
   Na BS, 2018, J CLIN NEUROL, V14, P303, DOI 10.3988/jcn.2018.14.3.303
   Olson S, 2005, J CLIN NEUROSCI, V12, P787, DOI 10.1016/j.jocn.2005.08.001
   Rhee DJ, 2006, ACTA NEUROCHIR, V148, P839, DOI 10.1007/s00701-006-0847-9
   Samii M, 2002, NEUROSURGERY, V50, P712, DOI 10.1097/00006123-200204000-00005
   Savadi-Oskouei D, 2008, EUR NEUROL, V60, P253, DOI 10.1159/000151701
   Scheller C, 2004, ZBL NEUROCHIR, V65, P103, DOI 10.1055/s-2004-816268
   Thirumala PD, 2011, J CLIN NEUROPHYSIOL, V28, P56, DOI 10.1097/WNP.0b013e3182051300
   Zhang X, 2017, J CRANIOFAC SURG, V28, pE579, DOI 10.1097/SCS.0000000000003900
NR 22
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E12
EP E15
DI 10.1016/j.wneu.2019.08.105
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200004
PM 31465849
DA 2020-05-12
ER

PT J
AU Kumar, C
   Dietz, N
   Sharma, M
   Wang, DZ
   Ugiliweneza, B
   Boakye, M
AF Kumar, Chitra
   Dietz, Nicholas
   Sharma, Mayur
   Wang, Dengzhi
   Ugiliweneza, Beatrice
   Boakye, Maxwell
TI Long-Term Comparison of Health Care Utilization and Reoperation Rates in
   Patients Undergoing Cervical Disc Arthroplasty and Anterior Cervical
   Discectomy and Fusion for Cervical Degenerative Disc Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE ACDF; CDA; Reoperation; Single-level degenerative disc disease;
   Utilization
ID LEVEL INTRADISCAL PRESSURE; SINGLE-LEVEL; FOLLOW-UP; DECOMPRESSION;
   REPLACEMENT; ARTHRODESIS; OUTCOMES; TRENDS
AB BACKGROUND: Thus study was a retrospective cohort analysis. Anterior cervical discectomy and fusion (ACDF) has been the gold-standard procedure for single-level degenerative disc disease (DDD). Recently, cervical disc arthroplasty (CDA) has become increasingly prevalent as an alternative intervention.
   OBJECTIVE: To examine the long-term costs and reoperation rates associated with CDA and ACDF for the treatment of single-level DDD.
   METHODS: In the present study, we performed a retrospective cohort analysis using the MarketScan database of patients who underwent either ACDF or CDA between 2007 and 2011 and had 5 years postsurgery follow-up. Outcomes related to the health care utilization, cost, and reoperation were analyzed after propensity score matching (PSM).
   RESULTS: Of 12,434 patients, 12,099 underwent ACDF and 335 CDA. Length of hospital stay and initial hospitalization cost was higher after ACDF compared with CDA. More patients undergoing CDA had early physical therapy compared with patients undergoing ACDF (CDA 30.15% vs. ACDF 22.39%; P = 0.0176). Five years after surgery, there was no significant difference in overall payments between patients undergoing ACDF and patients undergoing CDA. Reoperation rates were comparable at 5 years after the index procedure (CDA 8.06% vs. ACDF 9.25%; P = 0.5862). Patients who underwent ACDF showed decreased use of tramadol after surgery (15.09% before surgery vs. 9.55% after surgery; P < 0.0001).
   CONCLUSIONS: We found no difference in health care utilization between ACDF and CDA procedures for DDD 5 years after surgery. Also, there was no difference in reoperation rates during the study period. ACDF resulted in significant reduction in overall opioid use after versus before procedure.
C1 [Kumar, Chitra] Princeton Univ, Princeton, NJ 08544 USA.
   [Dietz, Nicholas; Sharma, Mayur; Wang, Dengzhi; Ugiliweneza, Beatrice; Boakye, Maxwell] Univ Louisville, Dept Neurosurg, Louisville, KY 40292 USA.
RP Kumar, C (reprint author), Princeton Univ, Princeton, NJ 08544 USA.
EM chitra.dileepkumar@gmail.com
RI Sharma, Mayur/B-3228-2018
OI Sharma, Mayur/0000-0001-6481-7819; Dietz, Nicholas/0000-0001-5822-1680
CR Bergstralh E, MATCH MACROCOMPUTERI
   BOHLMAN HH, 1993, J BONE JOINT SURG AM, V75A, P1298, DOI 10.2106/00004623-199309000-00005
   Bydon Mohamad, 2014, Surg Neurol Int, V5, pS74, DOI 10.4103/2152-7806.130676
   Cheng L, 2011, CLIN ORTHOP RELAT R, V469, P3408, DOI 10.1007/s11999-011-2039-z
   Cloward RB, 2007, J NEUROSURG-SPINE, V6, P496, DOI 10.3171/spi.2007.6.5.496
   Cohen J., 1988, STAT POWER ANAL BEHA
   Connolly J, 2017, SPINE, V42, P1405, DOI 10.1097/BRS.0000000000002133
   Delamarter RB, 2013, SPINE, V38, P711, DOI 10.1097/BRS.0b013e3182797592
   Dmitriev AE, 2005, SPINE, V30, P1165, DOI 10.1097/01.brs.0000162441.23824.95
   Duffy FJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00527
   Eck JC, 2002, SPINE, V27, P2431, DOI 10.1097/00007632-200211150-00003
   Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004
   Faries D, 2010, ANAL OBSERVATIONAL H
   Fehlings MG, 2009, J NEUROSURG-SPINE, V11, P97, DOI 10.3171/2009.5.SPINE09210
   Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365
   Ghobrial GM, 2019, NEUROSURGERY, V84, P347, DOI 10.1093/neuros/nyy118
   Goz V, 2014, J SPINE, V3, P178
   Heller JG, 2009, SPINE, V34, P101, DOI 10.1097/BRS.0b013e31818ee263
   Hilibrand Alan S, 2004, Spine J, V4, p190S, DOI 10.1016/j.spinee.2004.07.007
   Hu Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149312
   Jiang H, 2012, ARCH ORTHOP TRAUM SU, V132, P141, DOI 10.1007/s00402-011-1401-7
   Kaiser MG, 2002, NEUROSURGERY, V50, P229, DOI 10.1097/00006123-200202000-00001
   Laratta JL, 2018, GLOB SPINE J, V8, P78, DOI 10.1177/2192568217701095
   MacDowall A, 2020, J NEUROSURG-SPINE, V32, P344, DOI [10.3171/2018.9.SPINE18659, 10.3171/2019.9.SPINE19787]
   Matsunaga S, 1999, SPINE, V24, P670, DOI 10.1097/00007632-199904010-00011
   Matz PG, 2009, J NEUROSURG-SPINE, V11, P174, DOI 10.3171/2009.3.SPINE08720
   Peng CWB, 2009, SPINE J, V9, P551, DOI 10.1016/j.spinee.2009.03.008
   Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83
   Qureshi SA, 2013, J CLIN NEUROSCI, V20, P1723, DOI 10.1016/j.jocn.2013.03.002
   Radcliff K, 2015, SPINE, V40, P521, DOI 10.1097/BRS.0000000000000822
   Robertson JT, 2005, J NEUROSURG-SPINE, V3, P417, DOI 10.3171/spi.2005.3.6.0417
   Saifi C, 2018, SPINE J, V18, P1022, DOI 10.1016/j.spinee.2017.10.072
   Sasso WR, 2017, SPINE, V42, P209, DOI 10.1097/BRS.0000000000001746
   Sawilowsky SS, 2009, J MOD APPL STAT METH, V8, P597, DOI 10.22237/jmasm/1257035100
   Sharma M, 2018, J NEUROSURG-SPINE, V29, P271, DOI 10.3171/2018.1.SPINE171258
   Shillingford Jamal, 2017, J Spine Surg, V3, P641, DOI 10.21037/jss.2017.12.04
   Sullivan Gail M, 2012, J Grad Med Educ, V4, P279, DOI 10.4300/JGME-D-12-00156.1
   Tracey RW, 2014, J CLIN NEUROSCI, V21, P1905, DOI 10.1016/j.jocn.2014.05.007
   Warren D, 2013, INT J SPINE SURG, V7, DOI 10.1016/j.ijsp.2013.05.001
   Yue WM, 2005, SPINE, V30, P2138, DOI 10.1097/01.brs.0000180479.63092.17
NR 40
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E855
EP E865
DI 10.1016/j.wneu.2019.11.012
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200099
PM 31733395
DA 2020-05-12
ER

PT J
AU Labaran, LA
   Vatani, J
   Bell, J
   Puvanesarajah, V
   Sequeira, S
   Raad, M
   Jain, A
   Hassanzadeh, H
AF Labaran, Lawal A.
   Vatani, Jasmine
   Bell, Joshua
   Puvanesarajah, Varun
   Sequeira, Sean
   Raad, Micheal
   Jain, Amit
   Hassanzadeh, Hamid
TI Outcomes Following Posterior Lumbar Fusion in Patients with Polycythemia
   Vera
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bleeding disorder; Complications; PLF; Polycythemia vera; Posterior
   lumbar fusion; Spine fusion; Spine surgery
ID ADVERSE PERIOPERATIVE OUTCOMES; ESSENTIAL THROMBOCYTHEMIA; HEMATOLOGIC
   MALIGNANCIES; THROMBOEMBOLIC EVENTS; RISK-FACTORS; COMPLICATIONS;
   SURGERY; THROMBOSIS; INFECTION; MORTALITY
AB BACKGROUND: Polycythemia vera (PV) is a chronic myeloproliferative neoplasm that is associated with increased risk for venous and arterial thromboembolism. The aim of this study was to evaluate outcomes following elective posterior lumbar fusion (PLF) and/or posterior interbody fusion (PLIF) among patients with PV.
   METHODS: Using PearlDiver retrospective national database, Medicare patients <85 years old who underwent elective primary PLF (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 81.07) and/or PLIF (ICD-9-CM code 81.08) for degenerative lumbar spine pathologies during 2006-2013 were identified. Patients included in the PLF and/or PLIF cohort were separated into patients with a prior diagnosis of PV (ICD-9-CM code 238.4) and a control cohort of patients without PV. Comparisons of postoperative outcomes were made between the PV patient group and matched control group. Significance was set at 0.05.
   RESULTS: Selected study participants included 1491 patients with PV and 29,056 patients in the matched control group. Patients with PV had a significantly increased rate of 90-day acute pulmonary embolism (1.9% vs. 1.2%, odds ratio [OR] 1.65, 95% confidence interval [CI] 1.10-2.38, P = 0.010), 90-day lower extremity deep vein thrombosis (3.4% vs. 1.9%, OR 1.81, 95% CI 1.33-2.40, P < 0.001), and 1-year diagnosis of surgical site infection (5.4% vs. 4.2%, OR 1.30, 95% CI 1.02-1.63, P = 0.027) compared with patients without PV. Nonetheless, PV was not associated with other major medical complications, including stroke, myocardial infarction, and mortality, following PLF and/or PLIF.
   CONCLUSIONS: Patients with PV undergoing elective PLF and/or PLIF have a significantly increased risk for pulmonary embolism, lower extremity deep vein thrombosis, and surgical site infection.
C1 [Labaran, Lawal A.; Vatani, Jasmine; Bell, Joshua; Sequeira, Sean; Hassanzadeh, Hamid] Univ Virginia, Dept Orthopaed Surg, Charlottesville, VA 22903 USA.
   [Puvanesarajah, Varun; Raad, Micheal; Jain, Amit] Johns Hopkins Univ Hosp, Dept Orthopaed Surg, Baltimore, MD 21287 USA.
RP Hassanzadeh, H (reprint author), Univ Virginia, Dept Orthopaed Surg, Charlottesville, VA 22903 USA.
EM HH4XD@hscmail.mcc.virginia.edu
OI Labaran, Lawal/0000-0002-8224-9517
CR Amin R, 2018, SPINE, V43, P617, DOI 10.1097/BRS.0000000000002393
   Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544
   BARABAS AP, 1973, BRIT J SURG, V60, P183, DOI 10.1002/bjs.1800600305
   Chahoud J, 2014, FRONT MED-LAUSANNE, V1, DOI 10.3389/fmed.2014.00007
   De Stefano V, 2008, HAEMATOLOGICA, V93, P372, DOI 10.3324/haematol.12053
   De Stefano V, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0101-8
   Entezami P, 2019, WORLD NEUROSURG, V125, P354, DOI 10.1016/j.wneu.2019.01.258
   Fang A, 2005, SPINE, V30, P1460, DOI 10.1097/01.brs.0000166532.58227.4f
   Fineberg SJ, 2013, SPINE, V38, P1154, DOI 10.1097/BRS.0b013e318286b7c0
   FITTS WT, 1960, ANN SURG, V152, P548, DOI 10.1097/00000658-196015230-00016
   Kwaan HC, 2003, SEMIN THROMB HEMOST, V29, P451
   Lee MJ, 2014, SPINE J, V14, P2112, DOI 10.1016/j.spinee.2013.12.026
   Ma XM, 2008, AM J HEMATOL, V83, P359, DOI 10.1002/ajh.21129
   McCrath DJ, 2005, ANESTH ANALG, V100, P1576, DOI 10.1213/01.ANE.0000155290.86795.12
   McMullin MFF, 2019, BRIT J HAEMATOL, V184, P161, DOI 10.1111/bjh.15647
   Memtsoudis SG, 2011, SPINE, V36, P1867, DOI 10.1097/BRS.0b013e3181c7decc
   Newman JM, 2018, J KNEE SURG, V31, P291, DOI 10.1055/s-0037-1603335
   Newman JM, 2017, J ARTHROPLASTY, V32, P2436, DOI 10.1016/j.arth.2017.03.002
   Oz BS, 2007, J CARDIAC SURG, V22, P420, DOI 10.1111/j.1540-8191.2007.00438.x
   Passias PG, 2018, GLOB SPINE J, V8, P218, DOI 10.1177/2192568217718817
   Pumberger M, 2012, EUR SPINE J, V21, P1633, DOI 10.1007/s00586-012-2298-8
   Puvanesarajah V, 2018, SPINE, V43, P16, DOI 10.1097/BRS.0000000000001771
   Puvanesarajah V, 2016, SPINE, V41, pE1063, DOI 10.1097/BRS.0000000000001550
   Qureshi R, 2017, SPINE, V42, P1865, DOI 10.1097/BRS.0000000000002248
   Raedler Lisa A, 2014, Am Health Drug Benefits, V7, pS36
   RIGBY PG, 1960, ARCH INTERN MED, V106, P622, DOI 10.1001/archinte.1960.03820050034007
   Ruggeri M, 2008, BLOOD, V111, P666, DOI 10.1182/blood-2007-07-102665
   Schoenfeld AJ, 2013, SPINE, V38, P1892, DOI 10.1097/BRS.0b013e31829fc3a0
   Tefferi A, 2019, AM J HEMATOL, V94, P133, DOI 10.1002/ajh.25303
   Tefferi A, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-017-0042-7
   WASSERMAN LR, 1963, NEW ENGL J MED, V269, P1226, DOI 10.1056/NEJM196312052692302
   WASSERMAN LR, 1964, ANN NY ACAD SCI, V115, P122, DOI 10.1111/j.1749-6632.1964.tb50658.x
   Weingarten TN, 2015, TRANSFUSION, V55, P1090, DOI 10.1111/trf.13006
   Wolach B, 1998, BLOOD CELL MOL DIS, V24, P544, DOI 10.1006/bcmd.1998.0218
   Wu JC, 2012, EUR SPINE J, V21, P2680, DOI 10.1007/s00586-012-2405-x
   Yi S, 2006, YONSEI MED J, V47, P326, DOI 10.3349/ymj.2006.47.3.326
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E372
EP E378
DI 10.1016/j.wneu.2019.10.071
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200045
PM 31639499
DA 2020-05-12
ER

PT J
AU Lan, Q
   Zhu, Q
   Xu, L
   Xu, T
AF Lan, Qing
   Zhu, Qing
   Xu, Liang
   Xu, Tao
TI Application of 3D-Printed Craniocerebral Model in Simulated Surgery for
   Complex Intracranial Lesions
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D printing; Aneurysm; Brain tumor; Keyhole; Neurosurgery; Simulated
   surgery
ID SKULL BASE; EXPERIENCE
AB OBJECTIVE: To demonstrate the use of 3-dimensional (3D)-printed intracranial lesion models for complex neurosurgery to increase the success rate of clinical surgeries via practice in simulated surgeries.
   METHODS: We collected computed tomographic, magnetic resonance (MR), and computed tomographic images from patients with intracranial tumor or aneurysm, conducted multimodal image reconstruction, and then constructed a 3D-printed model with the skull base, cerebral arteries, and brain tumor or aneurysm. Forty-nine simulated surgeries were carried out on the model under a microscope, and actual surgery was carried out after validation and accumulation of experience.
   RESULTS: The 3D-printed brain tumor models were used to design the surgical route, to simulate piecemeal resection of tumors through keyhole approach, and to verify the extent of tumor resection. A drill was used for bone flap removal and milling of bony structures such as the anterior clinoid process, tuberculum sellae, petrous apex, and internal acoustic meatus. The tumors were removed by laser knife and cavitron ultrasonic aspiration. The 3D-printed aneurysm models were used to assess the feasibility of different keyhole approaches and to select the aneurysm clip. Actual surgery was based on the results of the simulated surgery. Postoperative MR image review showed that 84% (21/25) of patients had total tumor resection and 16% (4/25) subtotal resection. Digital subtraction angiography confirmed complete clipping of all aneurysms (24 cases/39 aneurysms).
   CONCLUSIONS: 3D-printed craniocerebral models provide effective simulated surgery conditions for keyhole surgeries of complex brain tumors or aneurysms and aid in preoperative surgical design, accumulation of surgical experience, and validation of surgical outcomes.
C1 [Lan, Qing; Zhu, Qing; Xu, Liang] Soochow Univ, Dept Neurosurg, Affiliated Hosp 2, Suzhou, Peoples R China.
   [Xu, Tao] Tsinghua Univ, Biomfg Ctr, Dept Mech Engn, Beijing, Peoples R China.
RP Lan, Q (reprint author), Soochow Univ, Dept Neurosurg, Affiliated Hosp 2, Suzhou, Peoples R China.
EM szlq006@163.com
FU Health Department of Jiangsu Province as a Jiangsu Medical Innovation
   Team and Leading Talent Project [LJ201150]; Jiangsu Science and
   Technology Department as a Jiangsu Clinical Cutting-Edge Technology,
   Social Development Project [BE2016668]
FX Supported by the Health Department of Jiangsu Province as a Jiangsu
   Medical Innovation Team and Leading Talent Project (LJ201150) and by the
   Jiangsu Science and Technology Department as a Jiangsu Clinical
   Cutting-Edge Technology, Social Development Project (BE2016668).
CR Altieri R, 2017, NEUROSURG REV, V40, P231, DOI 10.1007/s10143-016-0754-3
   Burks JD, 2018, NEUROSURGERY, V82, P388, DOI 10.1093/neuros/nyx213
   Chepelev Leonid, 2018, 3D Print Med, V4, P11, DOI 10.1186/s41205-018-0030-y
   Chivukula VK, 2019, J CLIN NEUROSCI, V61, P153, DOI 10.1016/j.jocn.2018.10.103
   Conner AK, 2018, J NEUROSURG, V128, P1388, DOI 10.3171/2016.12.JNS162168
   Fischer G, 2011, NEUROSURGERY, V68, DOI 10.1227/NEU.0b013e31820934ca
   Fischer Gerrit, 2011, Neurosurgery, V68, P45, DOI 10.1227/NEU.0b013e31820934ca
   Gargiulo P, 2017, J HEALTHC ENG, DOI 10.1155/2017/1439643
   Hoshide R, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2017.11.FOCUS17607
   Huang X, 2019, PITUITARY, V22, P46, DOI 10.1007/s11102-018-0927-x
   Kondo K, 2019, WORLD NEUROSURG, V127, pE609, DOI 10.1016/j.wneu.2019.03.219
   Lan Q, 2006, SURG NEUROL, V66, P2, DOI 10.1016/j.surneu.2006.06.039
   Lan Q, 2016, WORLD NEUROSURG, V91, P434, DOI 10.1016/j.wneu.2016.04.069
   Lan Q, 2015, WORLD NEUROSURG, V84, P1758, DOI 10.1016/j.wneu.2015.07.046
   Lin JY, 2018, WORLD NEUROSURG, V120, pE142, DOI 10.1016/j.wneu.2018.07.236
   Mashiko T, 2015, WORLD NEUROSURG, V83, P351, DOI 10.1016/j.wneu.2013.10.032
   Oishi M, 2013, J NEUROSURG, V119, P94, DOI 10.3171/2013.3.JNS121109
   Reisch R, 2005, NEUROSURGERY, V57, P242, DOI 10.1227/01.NEU.0000178353.42777.2C
   Wang JL, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011103
   Zheng JP, 2018, WORLD NEUROSURG, V111, pE773, DOI 10.1016/j.wneu.2017.12.169
NR 20
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E761
EP E770
DI 10.1016/j.wneu.2019.10.191
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200089
PM 31712116
DA 2020-05-12
ER

PT J
AU Lee, JA
   Kong, DS
   Lee, S
   Park, SK
   Park, K
AF Lee, Jeong-A
   Kong, Doo-Sik
   Lee, Seunghoon
   Park, Sang-Ku
   Park, Kwan
TI Clinical Outcome After Microvascular Decompression According to the
   Progression Rates of Hemifacial Spasm
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hemifacial spasm; Microvascular decompression; Outcome; Progression
   rate; Symptom progression
ID INDENTATION; NERVE
AB OBJECTIVE: The progression rate for clinical manifestations in hemifacial spasm (HFS) varies; however, little is known about the factors contributing to this. The purpose of this study was to identify independent factors affecting the rate of symptom progression and to evaluate clinical outcomes according to progression rates.
   METHODS: The study enrolled 1335 patients who underwent microvascular decompression for HFS between July 2004 and January 2015. We assessed detailed history, clinical manifestations, and outcomes. Based on the duration and severity of symptoms, patients were classified into rapidly progressive and slowly progressive groups. We identified predisposing factors affecting the differences between the 2 groups and evaluated the clinical outcome in each group.
   RESULTS: Of 1335 patients with HFS, 825 (61.8%) were classified as rapidly progressive, and 510 (38.2%) were classified as slowly progressive. In univariable and multivariable analyses, younger age at surgery, older age at symptom onset, and absence of intraoperative facial nerve indentation were significant predisposing factors for rapid progression. The rapidly progressive group had worse outcomes than the slowly progressive group following microvascular decompression.
   CONCLUSIONS: In this study, patients with rapidly progressive HFS had worse clinical outcomes. Therefore, patients with rapidly progressive symptoms should be warned in advance that the prognosis may be worse after microvascular decompression. This study is also useful to understand the differences in symptom progression rates in HFS in order to inform patients about symptom progression.
C1 [Lee, Jeong-A; Kong, Doo-Sik; Lee, Seunghoon; Park, Kwan] Sungkyunkwan Univ, Samsung Med Ctr, Dept Neurosurg, Sch Med, Seoul, South Korea.
   [Park, Sang-Ku] Sungkyunkwan Univ, Samsung Med Ctr, Dept Neurol, Sch Med, Seoul, South Korea.
RP Park, K (reprint author), Sungkyunkwan Univ, Samsung Med Ctr, Dept Neurosurg, Sch Med, Seoul, South Korea.
EM kwanpark@skku.edu
OI Park, Sang-Ku/0000-0002-0546-9014
CR BARKER FG, 1995, J NEUROSURG, V82, P201, DOI 10.3171/jns.1995.82.2.0201
   Cheng J, 2015, WORLD NEUROSURG, V84, P920, DOI 10.1016/j.wneu.2015.04.040
   Conte A, 2015, MOV DISORD CLIN PRAC, V2, P53, DOI 10.1002/mdc3.12106
   JANNETTA PJ, 1980, ANN SURG, V192, P518, DOI 10.1097/00000658-198010000-00010
   Jo KW, 2013, NEUROSURG REV, V36, P297, DOI 10.1007/s10143-012-0420-3
   Kotterba S, 2000, ACTA NEUROL SCAND, V101, P305, DOI 10.1034/j.1600-0404.2000.90281a.x
   Lee JA, 2012, STEREOT FUNCT NEUROS, V90, P16, DOI 10.1159/000330396
   Lee JA, 2019, WORLD NEUROSURG, V125, pE797, DOI 10.1016/j.wneu.2019.01.172
   Lee JA, 2017, STEREOT FUNCT NEUROS, V95, P21, DOI 10.1159/000453276
   Lefaucheur JP, 2018, NEUROCHIRURGIE, V64, P87, DOI 10.1016/j.neuchi.2017.12.004
   Li ST, 2016, WORLD NEUROSURG, V92, P218, DOI 10.1016/j.wneu.2016.05.012
   Lv MY, 2017, BRIT J NEUROSURG, V31, P322, DOI 10.1080/02688697.2017.1297368
   Miller LE, 2012, BRIT J NEUROSURG, V26, P438, DOI 10.3109/02688697.2011.641613
   Na BS, 2018, J CLIN NEUROL, V14, P303, DOI 10.3988/jcn.2018.14.3.303
   Park JS, 2008, ACTA NEUROCHIR, V150, P235, DOI 10.1007/s00701-007-1457-x
   Ryu H, 1998, ACTA NEUROCHIR, V140, P1173, DOI 10.1007/s007010050233
   Sindou M, 2018, NEUROCHIRURGIE, V64, P106, DOI 10.1016/j.neuchi.2018.01.001
   Tan EK, 2006, ACTA NEUROL SCAND, V114, P59, DOI 10.1111/j.1600-0404.2006.00650.x
   Xu YP, 2013, EUR REV MED PHARMACO, V17, P2974
NR 19
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E985
EP E990
DI 10.1016/j.wneu.2019.11.052
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200115
PM 31734426
DA 2020-05-12
ER

PT J
AU Li, ZF
   Wang, SL
   Jiao, XZ
   Wei, GX
AF Li, Zhifeng
   Wang, Senlin
   Jiao, Xuzhang
   Wei, Guangxin
TI Genetic Association of Angiotensin-Converting Enzyme I/D Polymorphism
   with Intracranial Hemorrhage: An Updated Meta-analysis of 39
   Case-Control Studies
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angiotensin-converting enzyme (ACE); I/D polymorphism; Intracranial
   hemorrhage (ICH); Meta-analysis
ID ACE GENE; INSERTION/DELETION POLYMORPHISM; INTRACEREBRAL HEMORRHAGE;
   SUBARACHNOID HEMORRHAGE; RISK-FACTORS; POPULATION; RS4646994; SYSTEM
AB BACKGROUND: Genetic association studies about associations between angiotensin-converting enzyme (ACE) polymorphisms and intracranial hemorrhage (ICH) generated conflicting results. In this study, a meta-analysis was performed to better assess the relationship between ACE polymorphisms and ICH.
   METHODS: PubMed, Medline, Embase, and CNKI were searched for eligible studies. We calculated odds ratios (ORs) and 95% confidence intervals (CIs) to evaluate associations between ACE polymorphisms and ICH.
   RESULTS: A total of 39 studies with 3839 cases and 5353 controls were analyzed. Pooled analyses showed that ACE insertion/deletion (I/D) polymorphism was significantly associated with ICH in the overall population (dominant model: P < 0.0001, OR = 0.70, 95% CI 0.60-0.82, I-2 = 58%; recessive model: P < 0.0001, OR = 1.95, 95% CI 1.57-2.43, I-2 = 66%; allele model: P < 0.0001, OR = 0.68, 95% CI 0.60-0.78, I-2 = 75%). Further subgroup analyses yielded similar significant results in individuals of East Asian and South Asian descent, but not in individuals of European descent.
   CONCLUSIONS: This meta-analysis suggests that ACE I/D polymorphism might affect individual susceptibility to ICH in both East Asians and South Asians. These results indicate that this polymorphism could be used to identify individuals at higher susceptibility to ICH in Asians.
C1 [Li, Zhifeng; Jiao, Xuzhang] Changyi Peoples Hosp, Dept Neurosurg, Changyi, Shandong, Peoples R China.
   [Wang, Senlin] Changyi Peoples Hosp, Dept Neurosurg 2, Changyi, Shandong, Peoples R China.
   [Wei, Guangxin] Weifang Peoples Hosp, Brain Hosp, Dept Neurosurg, Weifang, Shandong, Peoples R China.
RP Wei, GX (reprint author), Weifang Peoples Hosp, Brain Hosp, Dept Neurosurg, Weifang, Shandong, Peoples R China.
EM guangxinwei650218@163.com
CR Ajala AR, 2012, AM J HYPERTENS, V25, P827, DOI 10.1038/ajh.2012.50
   Andrew C, 1996, ELECTROEN CLIN NEURO, V98, P144
   Atadzhanov M, 2013, NEUROL INT, V5, P69, DOI 10.4081/ni.2013.e20
   Atlas SA, 2007, J MANAGE CARE PHARM, V13, pS9, DOI 10.18553/jmcp.2007.13.s8-b.9
   Backhaus R, 2015, NEUROREPORT, V26, P81, DOI 10.1097/WNR.0000000000000304
   Badran DI, 2015, GENET TEST MOL BIOMA, V19, P258, DOI 10.1089/gtmb.2014.0326
   Caceres JA, 2012, EMERG MED CLIN N AM, V30, P771, DOI 10.1016/j.emc.2012.06.003
   Cai KH, 2006, CHIN J NEUROL, V5, P778
   Chen CM, 2008, EUR J NEUROL, V15, P1206, DOI 10.1111/j.1468-1331.2008.02294.x
   Chowdhury A, 2000, OPT LETT, V25, P832, DOI 10.1364/OL.25.000832
   Das S, 2015, NEUROL SCI, V36, P137, DOI 10.1007/s10072-014-1880-8
   Dikmen M, 2006, ARQ NEURO-PSIQUIAT, V64, P211
   Fassot C, 2001, J PHYSIOL-LONDON, V535, P533, DOI 10.1111/j.1469-7793.2001.00533.x
   Freeman WD, 2012, NEUROL CLIN, V30, P211, DOI 10.1016/j.ncl.2011.09.002
   Gao BF, 2010, SHANDONG MED J, V50, P39
   [龚洁 GONG Jie], 2005, [南京医科大学学报. 自然科学版, Acta Universitatis Medicinalis Nanjing], V25, P890
   Griessenauer CJ, 2018, J NEUROSURG, V128, P1
   Huang Y, 2014, J RENIN-ANGIO-ALDO S, V15, P32, DOI 10.1177/1470320313481838
   Kalita J, 2011, NEUROL INDIA, V59, P41, DOI 10.4103/0028-3886.76856
   Kraft P, 2007, HUM HERED, V63, P111, DOI 10.1159/000099183
   Krishnan K, 2018, INT J STROKE, V13, P362, DOI 10.1177/1747493017744463
   Kumar A, 2014, NEUROL SCI, V35, P1983, DOI 10.1007/s10072-014-1877-3
   [李昕 Li Cuan], 2005, [中华检验医学杂志, Chinese Journal of Laboratory Medicine], V28, P825
   Li F, 2010, J MED RES, V39, P37
   Li HQ, 2010, CHIN J EPIDEMIOL, V33, P23
   Liang Y, 2001, J BRAIN NEUROL DIS, V9, P65
   Lin SH, 2000, OPT LETT, V25, P1582, DOI 10.1364/OL.25.001582
   Lu J, 2007, HARBIN MED, V27, P1
   Misra UK, 2012, NEUROL SCI, V33, P1071, DOI 10.1007/s10072-011-0903-y
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Nakata Y, 1997, AM J HYPERTENS, V10, P1391, DOI 10.1016/S0895-7061(97)90510-0
   Nie Y, 2000, J APOPL NERV DIS, V17, P41
   Pan Q, 2004, CHINA J MODERN MED, V14, P50
   Pannu H, 2005, J NEUROSURG, V103, P92, DOI 10.3171/jns.2005.103.1.0092
   Qian M, 2003, J CLIN NEUROL, V16, P291
   Qin HJ, 2013, NEUROL RES, V35, P545, DOI 10.1179/1743132813Y.0000000184
   Ren Q, 2017, J STROKE NEUROL DIS, V34, P884
   [尚蔚 Shang Wei], 2004, [中风与神经疾病杂志, Journal of Apoplexy and Nervous Diseases], V21, P388
   Slowik A, 2004, NEUROLOGY, V63, P359, DOI 10.1212/01.WNL.0000130200.12993.0C
   Song Y, 2015, J RENIN-ANGIO-ALDO S, V16, P1125, DOI 10.1177/1470320314545557
   Staalso JM, 2011, J NEUROSURG ANESTH, V23, P304, DOI 10.1097/ANA.0b013e318225c979
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Sun HY, 2008, CHIN J CEREBROVASC D, V5, P150
   Sun JH, 2016, BLOOD PRESSURE, V25, P117, DOI 10.3109/08037051.2015.1110923
   Sun Y, 2013, PLOS ONE, V8
   Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4
   Wang Yi-ming, 2004, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V21, P156
   Wu S, 2017, MOL NEUROBIOL, V54, P2435, DOI 10.1007/s12035-016-9823-4
   Xie X, 2017, SCAND J IMMUNOL, V86, P50, DOI 10.1111/sji.12560
   Xu H, 2011, INT J CEREBROVASC DI, V19, P101
   Xu X, 2001, STROKE NERV DIS, V8, P84
   Yang JH, 2012, N PHARM, V9, P54
   Yang ZJ, 2001, CHIN J PRACT INT MED, V21, P608
   Zhang C, 2000, J MED COLL QINGDAO U, V36, P85
   Zhang YD, 2004, J BRAIN NERV DIS, V12, P323
   Zhao W, 2007, CHIN J GERIATR HEART, V9, P826
   Zhao YY, 2005, J TROP MED, V5, P593
   Zhou C, 2000, J CLIN NEUROL, V13, P143
   姚丽芬, 2002, [中国急救医学, Chinese Journal of Critical Care Medicine], V22, P585
NR 59
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E1
EP E7
DI 10.1016/j.wneu.2019.06.104
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200002
PM 31233928
DA 2020-05-12
ER

PT J
AU Liao, Yh
   Ye, RP
   Tang, Q
   Tang, C
   Ma, F
   Luo, N
   Zhong, DJ
AF Liao, Yehui
   Ye, Rupei
   Tang, Qiang
   Tang, Chao
   Ma, Fei
   Luo, Ning
   Zhong, Dejun
TI Is It Necessary to Perform the Second Surgery Stage of Anterior
   Debridement in the Treatment of Spinal Tuberculosis?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Long-segment; Posterior instrument; Single stage; Surgical treatment;
   Tuberculous spondylitis
ID LUMBAR INTERBODY FUSION; POSTERIOR INSTRUMENTATION; SURGICAL-TREATMENT;
   TRANSPEDICULAR DECOMPRESSION; NEUROLOGICAL DEFICITS; POTTS-DISEASE;
   SINGLE; THORACOLUMBAR; SPONDYLITIS; MANAGEMENT
AB OBJECTIVE: In this retrospective comparative study, the efficacy and clinical outcomes of long posterior instrumentation, with or without laminectomy, were evaluated and the necessity of the second stage of anterior debridement in the treatment of spinal tuberculosis (TB) was discussed.
   METHODS: This retrospective study included 41 patients who were diagnosed with spinal TB between January 2010 and June 2016. A total of 18 patients had received long posterior instrumentation, with or without laminectomy (group A), whereas the other 23 patients had posterior instrumentation plus anterior debridement and autogenous bone grafting (group B). The surgical information, clinical effectiveness, laboratory tests, and imaging results were compared between the 2 groups.
   RESULTS: One patient in group B died. Sinus drainage and incomplete bone fusion were discovered 1 year postoperatively. TB symptoms were significantly improved after surgery compared with those before surgery (P < 0.05), and there was no significant difference in the treatment efficacy between the 2 groups at the final follow-ups (P > 0.05). Compared with those of group B, the surgical time, bed-rest time, and hospitalization time of group A were all significantly shorter (P< 0.05), whereas the times before abscesses disappeared, bone graft fusion, and erythrocyte sedimentation rate returning to normal were all significantly longer (P< 0.05).
   CONCLUSIONS: Single-stage long posterior instrumentation, with or without laminectomy, is a safe, effective, and feasible method for the treatment of spinal TB. The second stage of anterior debridement surgery may not be necessary for every spinal TB treatment.
C1 [Liao, Yehui; Tang, Qiang; Tang, Chao; Ma, Fei; Luo, Ning; Zhong, Dejun] Southwest Med Univ, Dept Spine Surg, Affiliated Hosp, Luzhou, Peoples R China.
   [Ye, Rupei] Southwest Med Univ, Dept Pathol, Affiliated Hosp, Luzhou, Peoples R China.
RP Zhong, DJ (reprint author), Southwest Med Univ, Dept Spine Surg, Affiliated Hosp, Luzhou, Peoples R China.
EM zdj_1974@163.com
FU youth research fund of Southwest Medical University, China
   [2017-ZRQN-071]
FX The work was supported by the youth research fund of Southwest Medical
   University, China (number 2017-ZRQN-071).
CR Benli IT, 2007, CLIN ORTHOP RELAT R, P108, DOI 10.1097/BLO.0b013e318065b70d
   CHEN WJ, 1995, ACTA ORTHOP SCAND, V66, P137, DOI 10.3109/17453679508995507
   Churchyard G, 2017, J INFECT DIS, V216, pS629, DOI 10.1093/infdis/jix362
   Cousins S, 2018, LANCET INFECT DIS, V18, P147, DOI 10.1016/S1473-3099(18)30005-7
   Darbyshire J, 1998, J BONE JOINT SURG BR, V80B, P456
   Echazarreta A, 2018, BIOMEDICA, V38, P180, DOI 10.7705/biomedica.v38i0.3904
   El-Sharkawi MM, 2012, INT ORTHOP, V36, P315, DOI 10.1007/s00264-011-1401-9
   Flamme CH, 2005, SPINE, V30, pE352, DOI 10.1097/01.brs.0000168551.60385.b3
   Fukuta S, 2003, SPINE, V28, pE302, DOI 10.1097/00007632-200308010-00025
   Garg B, 2012, INDIAN J ORTHOP, V46, P165, DOI 10.4103/0019-5413.93682
   HODGSON AR, 1994, CLIN ORTHOP RELAT R, P16
   Huang QS, 2009, INT ORTHOP, V33, P1385, DOI 10.1007/s00264-009-0758-5
   Jain AK, 2004, J BONE JOINT SURG BR, V86B, P1027, DOI 10.1302/0301-620X.86B7.14546
   Laheri VJ, 2001, SPINAL CORD, V39, P429, DOI 10.1038/sj.sc.3101185
   Lee SH, 2006, J SPINAL DISORD TECH, V19, P595, DOI 10.1097/01.bsd.0000211241.06588.7b
   Lee TC, 1999, J NEUROSURG, V91, P163, DOI 10.3171/spi.1999.91.2.0163
   Lieng Q, 2019, WORLD NEUROSURG, V123, P29, DOI 10.1016/j.wneu.2018.11.199
   Liu JM, 2015, WORLD NEUROSURG, V83, P1157, DOI 10.1016/j.wneu.2015.01.041
   Liu Z, 2016, CLIN NEUROL NEUROSUR, V141, P111, DOI 10.1016/j.clineuro.2016.01.002
   Luo CK, 2016, SPINE J, V16, P154, DOI 10.1016/j.spinee.2013.11.014
   Moon MS, 1997, SPINE, V22, P1791, DOI 10.1097/00007632-199708010-00022
   Pang XY, 2013, ARCH ORTHOP TRAUM SU, V133, P765, DOI 10.1007/s00402-013-1722-9
   Rajasekaran S, 2006, J PEDIATR ORTHOPED, V26, P716, DOI 10.1097/01.bpo.0000230326.21707.71
   Trecarichi EM, 2012, EUR REV MED PHARMACO, V16, P58
   Turgut M, 2001, NEUROSURG REV, V24, P8, DOI 10.1007/PL00011973
   Wang ST, 2016, BONE JOINT J, V98B, P834, DOI 10.1302/0301-620X.98B6.36472
   Wang XB, 2012, INT ORTHOP, V36, P373, DOI 10.1007/s00264-011-1389-1
   Watts HG, 1996, J BONE JOINT SURG AM, V78A, P288, DOI 10.2106/00004623-199602000-00019
   World Health Organization, 2004, GLOB TUB CONTR, P22
   World Health Organization, 2016, WHOHTMTB201613
   Wu P, 2015, EUR J TRAUMA EMERG S, V41, P189, DOI 10.1007/s00068-014-0421-8
   Wu WJ, 2018, WORLD NEUROSURG, V110, pE842, DOI 10.1016/j.wneu.2017.11.126
   Xu Z, 2015, SPINAL CORD, V53, P482, DOI 10.1038/sc.2014.252
   Yang JS, 2019, WORLD NEUROSURG, V122, pE1472, DOI 10.1016/j.wneu.2018.11.087
   Zeng H, 2015, ACTA ORTHOP TRAUMATO, V49, P513, DOI 10.3944/AOTT.2015.14.0037
   Zeng YP, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891-019-2466-7
   Zhang HQ, 2013, ARCH ORTHOP TRAUM SU, V133, P333, DOI 10.1007/s00402-012-1669-2
   Zhang ZH, 2016, J ORTHOP SURG RES, V11, DOI 10.1186/s13018-016-0385-y
   Zhong WY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119759
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E956
EP E967
DI 10.1016/j.wneu.2019.11.044
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200112
PM 31756501
DA 2020-05-12
ER

PT J
AU Lin, TT
   Wang, ZY
   Chen, G
   Liu, WG
AF Lin, Taotao
   Wang, Zhenyu
   Chen, Gang
   Liu, Wenge
TI Predictive Effect of Cervical Sagittal Parameters on Conservative
   Treatment of Single-Segment Cervical Spondylotic Radiculopathy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical sagittal parameters; Conservative treatment; Single-segment
   cervical spondylotic radiculopathy
ID ALIGNMENT; EPIDEMIOLOGY; IMPACT; SLOPE
AB OBJECTIVE: To explore whether the cervical sagittal parameters affect the conservative treatment of single-segment cervical spondylotic radiculopathy and whether the conservative treatment of single-segment cervical spondylotic radiculopathy can be predicted by cervical sagittal parameters.
   METHODS: Cervical spondylotic radiculopathy is currently treated with a stepwise approach, and conservative treatment is recommended. However, there is insufficient evidence to support the efficacy of conservative treatment. Between January 2013 and January 2018, 121 patients with single-segment cervical spondylotic radiculopathy were enrolled in this study. The inclusion criteria included complete cervical lateral radiographs. The following radiographic parameters were measured: C0-2 Cobb angle; C2-7 Cobb angle (CL), C7 slope (C7S), neck tilt (NT), thoracic inlet angle (TIA), T1 slope (T1S), C2-7 sagittal vertical axis (SVA), cervical tilt, cranial tilt, and cervical curvature index (CCI). Cervical spine function and quality of life were assessed using a visual analog scale (VAS) and the Neck Disability Index (NDI). According to the therapeutic effect, the patients were divided into group A (effective conservative treatment group) and group B (ineffective conservative treatment group). Effective conservative treatment was defined as conservative treatment for 3 months (1 nonsteroidal analgesic and 1 neurotrophic drug, supplemented by cervical traction and a neck support brace) resulting in a 60% reduction in NDI score. The Pearson correlation coefficient was used to calculate the correlation between each sagittal parameter and functional score. Logistic regression analysis and receiver operating characteristic (ROC) curve analysis were used to determine independent risk factors and critical values.
   RESULTS: In the effective conservative treatment group (group A), the pretreatment NDI score was significantly positively correlated with the pretreatment VAS score and negatively correlated with CL, C7S, TIA, T1S, cervical tilt, and CCI. In the ineffective conservative treatment group (group B), the pretreatment NDI score was significantly positively correlated with the pretreatment VAS score and NT, and negatively correlated with age, CL, C7S, T1S, cervical tilt, and CCI. Based on logistic regression analysis and ROC curve analysis, we found that a larger C2-7 Cobb angle before treatment was the sole independent risk factor for conservative treatment (P < 0.001). Patients with a C2-7 Cobb angle >7.7 degrees had a greater likelihood of receiving effective conservative treatment.
   CONCLUSIONS: In patients with single-segment cervical spondylotic radiculopathy, a larger C2-7 Cobb angle before treatment was the sole independent risk factor for effective conservative treatment (P< 0.001). Conservative treatment was more likely to be effective when the C2-7 Cobb angle is >7.7 degrees.
C1 [Lin, Taotao; Wang, Zhenyu; Chen, Gang; Liu, Wenge] Fujian Med Univ, Dept Orthoped, Union Hosp, Fuzhou, Peoples R China.
RP Liu, WG (reprint author), Fujian Med Univ, Dept Orthoped, Union Hosp, Fuzhou, Peoples R China.
EM 530378270@qq.com
CR ABUMI K, 1990, SPINE, V15, P1142, DOI 10.1097/00007632-199011010-00011
   Albert TJ, 1998, SPINE, V23, P2738, DOI 10.1097/00007632-199812150-00014
   Corey DL, 2014, MED CLIN N AM, V98, P791, DOI 10.1016/j.mcna.2014.04.001
   Fehlings MG, 2009, J NEUROSURG-SPINE, V11, P97, DOI 10.3171/2009.5.SPINE09210
   Grob D, 2007, EUR SPINE J, V16, P669, DOI 10.1007/s00586-006-0254-1
   Hyun SJ, 2016, SPINE, V41, pE396, DOI 10.1097/BRS.0000000000001264
   Kandziora F, 2001, SPINE, V26, P1850, DOI 10.1097/00007632-200109010-00007
   McAviney J, 2005, J MANIP PHYSIOL THER, V28, P187, DOI 10.1016/j.jmpt.2005.02.015
   Nicholson KJ, 2018, SPINE, V43, P883, DOI 10.1097/BRS.0000000000002478
   Patwardhan AG, 2015, SPINE, V40, P783, DOI 10.1097/BRS.0000000000000877
   Scardino FB, 2010, EUR SPINE J, V19, P699, DOI 10.1007/s00586-009-1267-3
   Schoenfeld AJ, 2012, J SPINAL DISORD TECH, V25, P17, DOI 10.1097/BSD.0b013e31820d77ea
   Shimizu K, 2005, SPINE, V30, P2388, DOI 10.1097/01.brs.0000184378.67465.5c
   Tamai K, 2018, SPINE, V43, P520, DOI 10.1097/BRS.0000000000002371
   Tang JA, 2012, NEUROSURGERY, V71, P662, DOI 10.1227/NEU.0b013e31826100c9
   Woods BI, 2015, J SPINAL DISORD TECH, V28, pE251, DOI 10.1097/BSD.0000000000000284
   Yu M, 2015, EUR SPINE J, V24, P1265, DOI 10.1007/s00586-015-3832-2
   Yu R, 2016, J ALZHEIMERS DIS, V50, P133, DOI 10.3233/JAD-150751
NR 18
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E1028
EP E1036
DI 10.1016/j.wneu.2019.11.081
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200120
PM 31759147
DA 2020-05-12
ER

PT J
AU Liu, JP
   Feng, HL
AF Liu, Jinping
   Feng, Hailong
TI Oblique Lateral Interbody Fusion (OLIF) with Supplemental Anterolateral
   Screw and Rod Instrumentation: A Preliminary Clinical Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterolateral instrumentation; Lumbar degenerative disease; Oblique
   lateral interbody fusion; Surgical treatment
ID DECOMPRESSION; COMPLICATIONS; FIXATION; PLATE; CAGE
AB OBJECTIVE: This study aimed to evaluate the technical details, clinical effectiveness, and complications of oblique lateral interbody fusion supplemented with anterolateral screw-rod instrumentation in managing degenerative lumbar diseases.
   METHODS: The clinical data of 14 patients with lumbar degenerative diseases who underwent oblique lateral interbody fusion and anterolateral screw-rod instrumentation in the Department of Neurosurgery, Sichuan Provincial People's Hospital, from April 2015 to May 2018, were retrospectively analyzed. The duration of operation, estimated blood loss, radiological exposure, length of hospital stay, and complications were recorded. The visual analog scale score, Oswestry Disability Index, and radiologic parameters were evaluated before and after surgery.
   RESULTS: The diagnosis included degenerative/isthmic spondylolisthesis (grade I), degenerative lumbar stenosis, disc hernia with instability, and adjacent segment disease. The follow-up period was 12-45 months. The clinical symptoms improved significantly after the operation according to the visual analog scale and Oswestry Disability Index scores. The average operation time, blood loss, and length of hospital stay were 72.50 +/- 21.46 minutes, 53.21 +/- 19.07 mL, and 5.57 +/- 2.21 days, respectively. The postoperative radiographic examination demonstrated increased intervertebral height and foramen area (P< 0.05). The radiologic fusion rate was 95% at the last follow-up; cage subsidence was found in 1 case. No major complications, such as vascular injury, ureteral injury, or infection, occurred.
   CONCLUSIONS: As an alternative method of instrumentation, anterolateral screw-rod fixation minimized the total operation time, blood loss, radiological exposure, and soft tissue disruption, and realized 1-stage intervertebral fusion and instrumentation through a single small incision.
C1 [Liu, Jinping; Feng, Hailong] Univ Elect Sci & Technol China, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Sch Med, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
RP Feng, HL (reprint author), Univ Elect Sci & Technol China, Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Sch Med, Dept Neurosurg, Chengdu, Sichuan, Peoples R China.
EM ryanfeng_nspine@163.com
CR Abe K, 2017, SPINE, V42, P55, DOI 10.1097/BRS.0000000000001650
   Blizzard DJ, 2018, SPINE, V43, P440, DOI 10.1097/BRS.0000000000002330
   Cappuccino A, 2010, SPINE, V35, pS361, DOI 10.1097/BRS.0b013e318202308b
   Caputo AM, 2013, J CLIN NEUROSCI, V20, P1558, DOI 10.1016/j.jocn.2012.12.024
   Choi YH, 2017, J KOREAN NEUROSURG S, V60, P755, DOI 10.3340/jkns.2017.0606.003
   DiGiorgio AM, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.5.FOCUS17168
   Fujibayashi S, 2015, SPINE, V40, pE175, DOI 10.1097/BRS.0000000000000703
   Gragnaniello Cristian, 2016, J Spine Surg, V2, P256, DOI 10.21037/jss.2016.11.02
   Kepler CK, 2011, J SPINAL DISORD TECH, V24, P363, DOI 10.1097/BSD.0b013e3181fee8b6
   Kim Jin-Sung, 2016, Neurosurgery, V63 Suppl 1, P190, DOI 10.1227/01.neu.0000489803.65103.84
   Kim SM, 2005, J NEUROSURG-SPINE, V2, P62, DOI 10.3171/spi.2005.2.1.0062
   Le Huec JC, 2002, EUR SPINE J, V11, P130, DOI 10.1007/s005860100316
   Marchi L, 2013, J NEUROSURG-SPINE, V19, P110, DOI 10.3171/2013.4.SPINE12319
   Mayer HM, 1997, SPINE, V22, P691, DOI 10.1097/00007632-199703150-00023
   Nayak AN, 2013, SPINE J, V13, P1331, DOI 10.1016/j.spinee.2013.03.048
   Ohtori S, 2015, ASIAN SPINE J, V9, P565, DOI 10.4184/asj.2015.9.4.565
   Reis MT, 2016, J NEUROSURG-SPINE, V25, P720, DOI 10.3171/2016.4.SPINE151386
   ROCKOFF SD, 1969, CALC TISS RES, V3, P163, DOI 10.1007/BF02058659
   Sato J, 2017, EUR SPINE J, V26, P671, DOI 10.1007/s00586-015-4170-0
   Silvestre C, 2012, ASIAN SPINE J, V6, P89, DOI 10.4184/asj.2012.6.2.89
   Wang K, 2019, BIOMED RES INT, DOI 10.1155/2019/5672162
   Xu DS, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.03.24
   Xu J, 2019, WORLD NEUROSURG, V128, pE315, DOI 10.1016/j.wneu.2019.04.142
   Zhang YH, 2017, GLOB SPINE J, V7, P657, DOI 10.1177/2192568217716149
NR 24
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E944
EP E950
DI 10.1016/j.wneu.2019.11.046
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200110
PM 31734420
DA 2020-05-12
ER

PT J
AU Liu, M
   Yang, ZK
   Yan, YF
   Shen, X
   Yao, HB
   Fei, L
   Wang, ES
AF Liu, Meng
   Yang, Zhi-Kun
   Yan, Yu-Feng
   Shen, Xiao
   Yao, Hui-Bin
   Fei, Li
   Wang, Er-Song
TI Optic Nerve Sheath Measurements by Computed Tomography to Predict
   Intracranial Pressure and Guide Surgery in Patients with Traumatic Brain
   Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Computed tomography; Intracranial pressure; Optic nerve sheath diameter;
   Traumatic brain injury
ID DECOMPRESSIVE CRANIECTOMY; DIAMETER
AB BACKGROUND: Research has shown that the optic nerve sheath diameter (ONSD) is a good predictor of intracranial pressure (ICP) and may predict the need for surgery in patients with head injury. The objective was to test the value of ONSD in predicting the requirement for surgery in patients with traumatic brain injury (TBI).
   METHODS: In this retrospective cohort study, we first verified the correlation between ICP and ONSD using data from 62 patients with TBI who had undergone ICP monitoring. Second, we analyzed head computed tomography images from patients with TBI who were admitted to the emergency department where patients had been divided into surgery or conservative treatment groups, dependent on the assessment of a neurosurgeon. The correlation between ICP and ONSD was measured using linear regression analysis. Biologistic and receiver operating characteristic curve analyses were used to test the diagnostic value of ONSD to predict surgery.
   RESULTS: ONSD was significantly correlated with ICP (r = 0.606; P < 0.01), and there was a significant linear regression equation (<(y)over cap> = 0.071 x ICP + 3.533; P < 0.01), with ONSD predicting the requirement for surgery in patients with TBI (area under the curve, 0.920; P < 0.01; 95% confidence interval, 0.877-0.962).
   CONCLUSIONS: ONSD measured via head computed tomography correlates with ICP and can predict the requirement for surgery in patients with TBI following admission to the emergency department.
C1 [Liu, Meng; Yang, Zhi-Kun; Yan, Yu-Feng; Shen, Xiao; Yao, Hui-Bin; Fei, Li; Wang, Er-Song] Fudan Univ, Jinshan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
RP Wang, ES (reprint author), Fudan Univ, Jinshan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
EM wersong@aliyun.com
CR Bekerman I, 2016, AM J EMERG MED, V34, P2336, DOI 10.1016/j.ajem.2016.08.045
   Bekerman I, 2016, J CLIN NEUROSCI, V30, P106, DOI 10.1016/j.jocn.2016.01.018
   Bekerman I, 2016, J NEUROIMAGING, V26, P309, DOI 10.1111/jon.12322
   Cecil S, 2011, CRIT CARE NURSE, V31, P25, DOI 10.4037/ccn2010226
   Chauvet D, 2010, NEUROSURG REV, V33, P287, DOI 10.1007/s10143-010-0261-x
   Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077
   Goel RS, 2008, INJURY, V39, P519, DOI 10.1016/j.injury.2007.09.029
   Honeybul S, 2017, J CLIN NEUROSCI, V43, P11, DOI 10.1016/j.jocn.2017.04.032
   Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215
   Kazdal H, 2016, WORLD NEUROSURG, V85, P292, DOI [10.1016/j.WNEU.2015.10.015, 10.1016/j.wneu.2015.10.015]
   Kimberly HH, 2008, ACAD EMERG MED, V15, P201, DOI 10.1111/j.1553-2712.2007.00031.x
   Kimberly HH, 2008, CRIT CARE, V12, DOI 10.1186/cc7008
   Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668
   Mehan ND, 2016, CURR SURG REP, V4, DOI 10.1007/s40137-016-0151-4
   Miller MT, 2004, J TRAUMA, V56, P967, DOI 10.1097/01.TA.0000123699.16465.8B
   Moretti R, 2009, NEUROCRIT CARE, V11, P406, DOI 10.1007/s12028-009-9250-8
   Sekhon MS, 2014, INTENS CARE MED, V40, P1267, DOI 10.1007/s00134-014-3392-7
   Vaiman M, 2016, J CLIN NEUROSCI, V34, P177, DOI 10.1016/j.jocn.2016.06.008
   Vaiman M, 2014, HEAD FACE MED, V10, DOI 10.1186/1746-160X-10-32
NR 19
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E317
EP E324
DI 10.1016/j.wneu.2019.10.065
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200039
PM 31629929
DA 2020-05-12
ER

PT J
AU Lorente, L
   Martin, MM
   Ramos, L
   Argueso, M
   Caceres, JJ
   Sole-Violan, J
   Jimenez, A
AF Lorente, Leonardo
   Martin, Maria M.
   Ramos, Luis
   Argueso, Monica
   Caceres, Juan J.
   Sole-Violan, Jordi
   Jimenez, Alejandro
TI High Serum Tissue Inhibitor of Matrix Metalloproteinase-1 Levels and
   Mortality in Patients with Spontaneous Intracerebral Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Mortality; Patients; Spontaneous intracerebral hemorrhage; TIMP-1
ID TEMPORAL PROFILE; MATRIX-METALLOPROTEINASE-9; MARKERS; MMP-9
AB BACKGROUND: Matrix metalloproteinase (MMP)-9, a member of the endoproteinase family, is involved in the neuroinflammation of spontaneous intracerebral hemorrhage (SIH). High circulating MMP-9 levels have been associated with poor functional outcome in patients with SIH. The objectives of this study were to determine whether serum MMP-9 and tissue inhibitor of matrix metalloproteinases (TIMP)-1 levels in SIH patients were higher in nonsurviving than surviving patients, if they were associated with early mortality, and if they could be used as biomarkers of prognosis.
   METHODS: This observational prospective study included patients with severe supratentorial SIH (defined as Glasgow Coma Scale <9) from 6 Spanish Intensive Care Units. Serum MMP-9 and TIMP-1 levels were determined at the time of severe SIH diagnosis. Thirty-day mortality was the endpoint study.
   RESULTS: Nonsurviving patients (n = 46) showed higher serum TIMP-1 (P < 0.001) and MMP-9 levels (P = 0.01) than surviving patients (n = 54). The area under the curve by serum TIMP-1 levels for the prediction of 30-day mortality was 74% (95% confidence interval = 64% - 82%; P< 0.001). Multiple logistic regression analysis showed an association between serum TIMP-1 levels >223 ng/ml and 30-day mortality (odds ratio = 13.993; 95% confidence interval = 2.864-68.356; P = 0.001) after controlling for intracerebral hemorrhage score, glycemia, midline shift, and early evacuation of SIH. There was an association between circulating levels of TIMP-1 and MMP-9 (rho = 0.25; P = 0.01).
   CONCLUSIONS: The novel aspects our study include that serum TIMP-1 and MMP-9 levels in SIH patients were higher in nonsurviving than in surviving patients and that serum TIMP-1 levels were associated with early mortality and could he used as biomarkers for predicting mortality.
C1 [Lorente, Leonardo] Hosp Univ Canarias, Intens Care Unit, Tenerife, Spain.
   [Jimenez, Alejandro] Hosp Univ Canarias, Res Unit, Tenerife, Spain.
   [Martin, Maria M.] Hosp Univ Nuestra Senora Candelaria, Intens Care Unit, Santa Cruz De Tenerife, Spain.
   [Ramos, Luis] Hosp Gen La Palma, Intens Care Unit, Brena Alta, La Palma, Spain.
   [Argueso, Monica] Hosp Clin Univ Valencia, Intens Care Unit, Valencia, Spain.
   [Caceres, Juan J.] Hosp Insular, Intens Care Unit, Las Palmas Gran Canaria, Spain.
   [Sole-Violan, Jordi] Hosp Univ Dr Negrin, Intens Care Unit, Las Palmas Gran Canaria, Spain.
RP Lorente, L (reprint author), Hosp Univ Canarias, Intens Care Unit, Tenerife, Spain.
EM lorentemartin@msn.com
CR Abilleira S, 2003, J NEUROSURG, V99, P65, DOI 10.3171/jns.2003.99.1.0065
   Alvarez-Sabin J, 2004, STROKE, V35, P1316, DOI 10.1161/01.STR.0000126827.69286.90
   BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401
   Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763
   Castellazzi M, 2010, ACTA NEUROCHIR SUPPL, V106, P137, DOI 10.1007/978-3-211-98811-4_24
   Chang JJ, 2017, EUR J NEUROL, V24, P1384, DOI 10.1111/ene.13403
   Chang JJ, 2014, J STROKE CEREBROVASC, V23, P2498, DOI 10.1016/j.jstrokecerebrovasdis.2014.07.005
   Chen S, 2015, TRANSL STROKE RES, V6, P4, DOI 10.1007/s12975-014-0384-4
   Cui JJ, 2012, CELL BIOCHEM BIOPHYS, V62, P87, DOI 10.1007/s12013-011-9264-7
   Dang BQ, 2017, CURR DRUG TARGETS, V18, P1358, DOI 10.2174/1389450118666170427151657
   Delgado P, 2007, NEUROLOGIA, V22, P448
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891
   Howe MD, 2019, J STROKE CEREBROVASC, V28, P1718, DOI 10.1016/j.jstrokecerebrovasdis.2019.02.014
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Lee JM, 2005, J NEUROL SCI, V229, P249, DOI 10.1016/j.jns.2004.11.041
   Li N, 2013, STROKE, V44, P658, DOI 10.1161/STROKEAHA.112.673590
   Lorente L, 2018, WORLD NEUROSURG, V113, pE542, DOI 10.1016/j.wneu.2018.02.085
   Lorente L, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0364-7
   Lorente L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094370
   Mittal MK, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00210
   Mracsko E, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00388
   Petrovska-Cvetkovska Dragana, 2014, Pril (Makedon Akad Nauk Umet Odd Med Nauki), V35, P39
   Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108
   TEASDALE G, 1974, LANCET, V2, P81
   Wu GF, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0287-3
   Yang QW, 2016, INT J NEUROSCI, V126, P213, DOI 10.3109/00207454.2015.1007372
   Yang R, 2017, DIS MODEL MECH, V10, P337, DOI 10.1242/dmm.027268
   YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E476
EP E480
DI 10.1016/j.wneu.2019.10.106
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200057
PM 31669537
DA 2020-05-12
ER

PT J
AU Mallepally, AR
   Tandon, V
   Chhabra, HS
AF Mallepally, Abhinandan Reddy
   Tandon, Vikas
   Chhabra, Harvinder Singh
TI Adjacent Level Tuberculous Spondylodiscitis Leading to Proximal
   Junctional Kyphosis: Rare and Unusual Presentation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adjacent segment; Proximal junctional kyphosis; Tuberculosis
ID RISK-FACTORS; VERTEBRAL OSTEOMYELITIS; INFECTIONS; FRACTURE; PATIENT;
   INSTRUMENTATION; SYSTEM
AB BACKGROUND: Vertebral osteomyelitis manifesting as a compression fracture misdiagnosed in the setting of steroid-induced or senile osteoporosis is very rare, although such patients are prone to infection or reactivation, as their immune system is exhausted. Spondylo-discitis occurring at adjacent levels following instrumented spinal fusion leading to pathologic fracture and proximal junctional failure, especially caused by tuberculosis, to our knowledge, has not been discussed in the literature.
   METHODS: In case 1, a 61-year-old woman with osteoporotic T12 collapse was treated with corpectomy, anterior reconstruction, and posterior fixation from T9-L2. Initial biopsy and culture were normal. She presented 4 months later with compression fracture of T8; T8 corpectomy with anterior reconstruction and proximal extension of the construct was performed. In case 2, a 65-year-old woman with multiple comorbidities and osteoporotic L1 compression fracture was treated with L1 corpectomy, anterior reconstruction, and posterior instrumentation from T11-L3. She presented 4 months later with T10 vertebral body acute collapse; 2-stage anterior corpectomy and reconstruction was performed. In both cases, probing the affected vertebral body yielded pus. Pus and bone tissue samples sent for culture and histopathologic examination were positive for tuberculosis suggesting tuberculous spondylitis in both cases.
   RESULTS: In both patients, tuberculous spondylodiscitis at the proximal adjacent level was diagnosed <1 year after the initial spinal surgery. Neither patient had a previous history of pulmonary or extrapulmonary tuberculosis. They were successfully treated with antituberculous therapy and proximal extension of the construct with anterior reconstruction.
   CONCLUSIONS: Adjacent segment spondylodiscitis should be suspected and intraoperative biopsy must be considered for histopathologic and microbiologic examination to rule out subclinical infection in immunosuppressed patients with multiple comorbidities. Management should be individualized, considering the context of infection, causative organism, extent of bone destruction, and neurologic involvement.
C1 [Mallepally, Abhinandan Reddy; Tandon, Vikas; Chhabra, Harvinder Singh] Indian Spinal Injuries Ctr, Dept Spine Serv, New Delhi, India.
RP Mallepally, AR (reprint author), Indian Spinal Injuries Ctr, Dept Spine Serv, New Delhi, India.
EM mabhi28@gmail.com
OI mallepally, abhinandan reddy/0000-0001-8153-7499
CR Abdelrahman H, 2013, SPINE J, V13, P1809, DOI 10.1016/j.spinee.2013.05.053
   ALLEN EH, 1978, CLIN RADIOL, V29, P31, DOI 10.1016/S0009-9260(78)80161-5
   Atsatt RF, 1939, J BONE JOINT SURG AM, V21, P346
   Cardo D, 2004, AM J INFECT CONTROL, V32, P470, DOI 10.1016/j.ajic.2004.10.001
   Cierny G, 2003, CLIN ORTHOP RELAT R, P7, DOI 10.1097/01.blo.0000088564.81746.62
   Currie S, 2011, CLIN RADIOL, V66, P778, DOI 10.1016/j.crad.2011.02.016
   Di Capua J, 2018, GLOB SPINE J, V8, P615, DOI 10.1177/2192568218761361
   Etebar S, 1999, J NEUROSURG, V90, P163, DOI 10.3171/spi.1999.90.2.0163
   Farah K, 2018, NEUROCHIRURGIE, V64, P53, DOI 10.1016/j.neuchi.2017.09.003
   FORSYTHE M, 1978, ORTHOP CLIN N AM, V9, P1039
   Hostin R, 2013, SPINE, V38, P1008, DOI 10.1097/BRS.0b013e318271319c
   Hu XB, 2015, J SPINAL DISORD TECH, V28, P31, DOI 10.1097/BSD.0b013e3182694f73
   Kulkarni Arvind Gopalrao, 2006, Eur Spine J, V15 Suppl 5, P559, DOI 10.1007/s00586-005-0003-x
   Lange T, 2010, SPINE, V35, pE804, DOI 10.1097/BRS.0b013e3181d56955
   Macnab I, 1978, MACN, P39
   Maruo K, 2013, SPINE, V38, pE1469, DOI 10.1097/BRS.0b013e3182a51d43
   MCHENRY MC, 1988, ARCH INTERN MED, V148, P417, DOI 10.1001/archinte.148.2.417
   MODIC MT, 1985, RADIOLOGY, V157, P157, DOI 10.1148/radiology.157.1.3875878
   Nagoshi N, 2018, CASE REP ORTHOP, V2018
   VENGER BH, 1986, NEUROSURGERY, V18, P461, DOI 10.1227/00006123-198604000-00013
   Wang JJ, 2010, INJURY, V41, P415, DOI 10.1016/j.injury.2010.01.001
   Watanabe K, 2010, SPINE, V35, P138, DOI 10.1097/BRS.0b013e3181c8f35d
   Yagi M, 2012, SPINE, V37, P1479, DOI 10.1097/BRS.0b013e31824e4888
   Yagi M, 2011, SPINE, V36, pE60, DOI 10.1097/BRS.0b013e3181eeaee2
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E808
EP E814
DI 10.1016/j.wneu.2019.11.007
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200094
PM 31715405
DA 2020-05-12
ER

PT J
AU Mattioli, F
   Ghirelli, M
   Trebbi, M
   Silvestri, M
   Presutti, L
   Fermi, M
AF Mattioli, Francesco
   Ghirelli, Michael
   Trebbi, Marco
   Silvestri, Martina
   Presutti, Livio
   Fermi, Matteo
TI Improvement of Swallowing Function After Surgical Treatment of Diffuse
   Idiopathic Skeletal Hyperostosis: Our Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior surgical approaches; Cervical spine; Deglutition disorders;
   Diffuse idiopathic skeletal hyperostosis
ID CERVICAL-SPINE; DYSPHAGIA; RELIABILITY; VALIDITY
AB OBJECTIVE: To investigate the swallowing improvement in patients who underwent a transcervical prevascular retrovisceral approach for symptomatic cervical diffuse idiopathic skeletal hyperostosis (DISH), by means of the 10-item Eating Assessment Tool (EAT-10) questionnaire.
   METHODS: Retrospective observational study of 21 patients treated with a transcervical anterior prevascular retrovisceral approach for symptomatic DISH with dysphagia as the primary symptom. All patients underwent videofluoroscopic study of swallowing before surgery and the EAT-10 questionnaire before and after the surgical procedure.
   RESULTS: A statistically significant (P < 0.001) improvement in the postoperative EAT-10 score was reported. Sixteen out of 21 patients (76.2%) had their symptoms completely resolved, with an EAT-10 score less than 3. These results were not influenced by age and sex nor by presence of tracheostomy. The preoperative EAT-10 score was consistently related to postoperative outcome. Patients with mild and moderate dysphagia had better Delta in EAT-10 scores than patients with severe and very severe dysphagia (P = 0.02).
   CONCLUSIONS: Surgical management seems to be effective in resolving swallowing disorders related to this disease in a consistent percentage of patients. This evidence is supported by the statistically significant improvement in EAT-10 scores after treatment. Moreover, it might be postulated that early intervention can guarantee higher success rate because patients with severe and very severe dysphagia had significantly smaller improvement.
C1 [Mattioli, Francesco; Ghirelli, Michael; Trebbi, Marco; Silvestri, Martina; Presutti, Livio; Fermi, Matteo] Univ Hosp Modena, Otorhinolaryngol Head & Neck Surg Dept, Modena, Italy.
RP Ghirelli, M (reprint author), Univ Hosp Modena, Otorhinolaryngol Head & Neck Surg Dept, Modena, Italy.
EM michael.ghirelli@gmail.com
OI Fermi, Matteo/0000-0002-2727-0321
CR Abdel-Aziz M, 2018, CURR OPIN OTOLARYNGO, V26, P375, DOI 10.1097/MOO.0000000000000488
   Abdel-Aziz M, 2017, ACTA OTO-LARYNGOL, V137, P623, DOI 10.1080/00016489.2016.1272136
   Bakker JT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188414
   Belafsky PC, 2008, ANN OTO RHINOL LARYN, V117, P919, DOI 10.1177/000348940811701210
   BEYELER C, 1992, BRIT J RHEUMATOL, V31, P319
   Carlson ML, 2011, DYSPHAGIA, V26, P34, DOI 10.1007/s00455-009-9264-6
   Ebraheim NA, 2000, SPINE, V25, P1603, DOI 10.1097/00007632-200007010-00002
   Ebraheim NA, 1997, SPINE, V22, P2664
   FORESTIER J, 1950, ANN RHEUM DIS, V9, P321, DOI 10.1136/ard.9.4.321
   Ghirelli M, 2017, ATLAS CRANIOCERVICAL, P129
   Jung A, 2010, NEUROSURGERY, V67, P10, DOI 10.1227/01.NEU.0000370203.26164.24
   Miyamoto K, 2009, EUR SPINE J, V18, P1652, DOI 10.1007/s00586-009-1133-3
   Oppenlander ME, 2009, SURG NEUROL, V72, P266, DOI 10.1016/j.surneu.2008.08.081
   Park MK, 2018, EUR SPINE J, V27, pS330, DOI 10.1007/s00586-017-5236-y
   Presutti L, 2010, ANN OTO RHINOL LARYN, V119, P602, DOI 10.1177/000348941011900906
   RESNICK D, 1976, RADIOLOGY, V119, P559, DOI 10.1148/119.3.559
   SAFFOURI MH, 1974, ANN OTO RHINOL LARYN, V83, P65, DOI 10.1177/000348947408300111
   Schindler A, 2013, ANN OTO RHINOL LARYN, V122, P717, DOI 10.1177/000348941312201109
   Seidler TO, 2009, EUR ARCH OTO-RHINO-L, V266, P285, DOI 10.1007/s00405-008-0735-4
   SHERK HH, 1983, LARYNGOSCOPE, V93, P168
   Vengust R, 2010, EUR SPINE J, V19, pS130, DOI 10.1007/s00586-009-1159-6
   Verlaan JJ, 2011, SPINE J, V11, P1058, DOI 10.1016/j.spinee.2011.09.014
   von der Hoeh NH, 2015, EUR SPINE J, V24, pS489, DOI 10.1007/s00586-014-3507-4
NR 23
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E29
EP E36
DI 10.1016/j.wneu.2019.08.124
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200006
PM 31470164
DA 2020-05-12
ER

PT J
AU Mazzatenta, D
   Zoli, M
   Guaraldi, F
   Ambrosi, F
   Fustini, MF
   Pasquini, E
   Asioli, S
   Zucchelli, M
AF Mazzatenta, Diego
   Zoli, Matteo
   Guaraldi, Federica
   Ambrosi, Francesca
   Fustini, Marco Faustini
   Pasquini, Ernesto
   Asioli, Sofia
   Zucchelli, Mino
TI Outcome of Endoscopic Endonasal Surgery in Pediatric Craniopharyngiomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic endonasal approach; Hypothalamus; Pediatric
   craniopharyngioma; Pituitary function
ID BETA-CATENIN ACCUMULATION; CHILDHOOD CRANIOPHARYNGIOMA; TRANSSPHENOIDAL
   APPROACH; RESECTION; CLASSIFICATION; MANAGEMENT; TUMORS; SUPRASELLAR;
   RECURRENCE; SERIES
AB BACKGROUND: In the last years, few reports have shown the feasibility of the endoscopic endonasal approach (EEA) for craniopharyngiomas in pediatric patients. For these tumors, recent studies have suggested less aggressive surgery, favoring the preservation of the patient's quality of life.
   OBJECTIVE: The aim of this study was to assess the outcome of the EEA in a large series with specific attention on the long-term functional sequelae.
   MATERIALS: All consecutive pediatric craniopharyngiomas operated on through this approach since 2000 were included in the study. Preoperative and postoperative operative clinical, radiologic, and pathologic features were retrieved from patient records (mean follow-up, 72 +/- 67 months).
   RESULTS: The series included 25 patients (12 female; mean age, 8.9 +/- 4.1 years). Most of the tumors presented with a supradiaphragmatic extension (88%). Removal was radical in 23 patients (92%). Complications consisted of 6 cerebrospinal fluid leaks (24%). One patient (4%) died of postoperative respiratory complications. Most patients (92%) developed panhypopituitarism and visual disturbances normalized or improved in 6 patients (43%). At follow-up, 9 patients (36%) were overweight/obese (6 were already overweight before surgery). The tumor recurrence rate was 19%.
   CONCLUSIONS: EEA can be an effective approach for midline craniopharyngiomas in children older than 3 years. It gives a satisfactory exposure of the suprasellar region and an adequate assessment of the brain-tumor interface. Its main limitations are age-related anatomic features of nasal/paranasal sinuses and the risk of cerebrospinal fluid leak.
C1 [Mazzatenta, Diego; Zoli, Matteo; Guaraldi, Federica; Fustini, Marco Faustini] IRCCS Ist Sci Neurol Bologna, Ctr Diag & Treatment Pituitary & Skull Base Tumor, Pituitary Unit, Bologna, Italy.
   [Mazzatenta, Diego; Zoli, Matteo; Guaraldi, Federica] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy.
   [Ambrosi, Francesca; Asioli, Sofia] Univ Bologna, Dept Biomed & Neuromuscular Sci, Sect Anat Pathol M Malpighi, Bellaria Hosp, Bologna, Italy.
   [Pasquini, Ernesto] Bellaria Hosp, Dept Ear Nose & Throat Dis, Bologna, Italy.
   [Zucchelli, Mino] Bellaria Hosp, Div Pediat Neurosurg, Dept Neurosurg, Bologna, Italy.
RP Zoli, M (reprint author), IRCCS Ist Sci Neurol Bologna, Ctr Diag & Treatment Pituitary & Skull Base Tumor, Pituitary Unit, Bologna, Italy.; Zoli, M (reprint author), Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy.
EM matteo.zoli4@unibo.it
OI Asioli, Sofia/0000-0002-5035-2448; zucchelli, mino/0000-0002-7494-355X;
   Guaraldi, Federica/0000-0001-8416-1669
CR Alalade AF, 2018, J NEUROSURG-PEDIATR, V21, P72, DOI 10.3171/2017.7.PEDS17295
   Ali ZS, 2013, CHILD NERV SYST, V29, P2065, DOI 10.1007/s00381-013-2153-1
   Barazi SA, 2013, BRIT J NEUROSURG, V27, P374, DOI 10.3109/02688697.2012.741739
   Buslei R, 2005, ACTA NEUROPATHOL, V109, P589, DOI 10.1007/s00401-005-1004-x
   Buslei R, 2007, ACTA NEUROPATHOL, V113, P585, DOI 10.1007/s00401-006-0184-3
   Cacciari E, 2006, J ENDOCRINOL INVEST, V29, P581, DOI 10.1007/BF03344156
   Cagnazzo F, 2018, J NEUROL SURG PART A, V79, P247, DOI 10.1055/s-0037-1607195
   Carpentieri SC, 2001, NEUROSURGERY, V49, P1053, DOI 10.1097/00006123-200111000-00005
   Cavallo LM, 2014, J NEUROSURG, V121, P100, DOI 10.3171/2014.3.JNS131521
   CAVAZZUTI V, 1983, J NEUROSURG, V59, P409, DOI 10.3171/jns.1983.59.3.0409
   Coury JR, 2020, NEUROSURG REV, V43, P41, DOI 10.1007/s10143-018-0978-5
   Cushing H, 1921, PITUITARY BODY ITS D
   DeVile CJ, 1996, J NEUROSURG, V85, P73, DOI 10.3171/jns.1996.85.1.0073
   Elowe-Gruau E, 2013, J CLIN ENDOCR METAB, V98, P2376, DOI 10.1210/jc.2012-3928
   Foschi M, 2017, AUTON NEUROSCI-BASIC, V208, P126, DOI 10.1016/j.autneu.2017.08.006
   Frank G, 2006, NEUROSURGERY, V59, P75, DOI 10.1227/01.NEU.0000219897.98238.A3
   Gardner PA, 2008, J NEUROSURG, V108, P1043, DOI 10.3171/JNS/2008/108/5/1043
   Hadad G, 2006, LARYNGOSCOPE, V116, P1882, DOI 10.1097/01.mlg.0000234933.37779.e4
   Hayward R, 1999, CHILD NERV SYST, V15, P764, DOI 10.1007/s003810050468
   HOFFMAN HJ, 1992, J NEUROSURG, V76, P47, DOI 10.3171/jns.1992.76.1.0047
   Hofmann BM, 2006, AM J SURG PATHOL, V30, P1595, DOI 10.1097/01.pas.0000213328.64121.12
   Jane JA, 2010, J NEUROSURG-PEDIATR, V5, P49, DOI 10.3171/2009.7.PEDS09252
   Kassam AB, 2008, J NEUROSURG, V108, P715, DOI 10.3171/JNS/2008/108/4/0715
   KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016
   Komotar RJ, 2012, WORLD NEUROSURG, V77, P329, DOI 10.1016/j.wneu.2011.07.011
   Koutourousiou M, 2013, J NEUROSURG, V119, P1194, DOI 10.3171/2013.6.JNS122259
   Kutteh WH, 2018, J OBSTET GYNAECOL, V38, P878, DOI 10.1080/01443615.2017.1398222
   Leng LZ, 2012, NEUROSURGERY, V70, P110, DOI 10.1227/NEU.0b013e31822e8ffc
   Locatelli D, 2010, INT J PEDIATR OTORHI, V74, P1298, DOI 10.1016/j.ijporl.2010.08.009
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Madsen PJ, 2019, J NEUROSURG-PEDIATR, V24, P236, DOI 10.3171/2019.4.PEDS18612
   Ohmori K, 2007, PEDIATR NEUROSURG, V43, P265, DOI 10.1159/000103306
   Pascual JM, 2013, NEUROSURG REV, V36, P337, DOI 10.1007/s10143-012-0439-5
   Patel VS, 2017, WORLD NEUROSURG, V108, P6, DOI 10.1016/j.wneu.2017.08.058
   Puget S, 2007, J NEUROSURG, V106, P3, DOI 10.3171/ped.2007.106.1.3
   Sainte-Rose C, 2005, CHILD NERV SYST, V21, P691, DOI 10.1007/s00381-005-1209-2
   Sankhla SK, 2015, J PEDIATR NEUROSCI, V10, P308, DOI 10.4103/1817-1745.174457
   Shen L, 2015, NEUROL SCI, V36, P1859, DOI 10.1007/s10072-015-2269-z
   Smith TR, 2016, J NEUROSURG-PEDIATR, V18, P408, DOI 10.3171/2016.4.PEDS16112
   WEINER HL, 1994, NEUROSURGERY, V35, P1001, DOI 10.1227/00006123-199412000-00001
   Yamada S, 2018, J NEUROSURG-PEDIATR, V21, P549, DOI 10.3171/2017.10.PEDS17254
   Yang I, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09307
   Zacharin M, 2015, BEST PRACT RES CL EN, V29, P367, DOI 10.1016/j.beem.2015.01.002
   Zoli M, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.9.FOCUS16317
   Zoli M, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14317
NR 45
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E277
EP E288
DI 10.1016/j.wneu.2019.10.039
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200034
PM 31629927
DA 2020-05-12
ER

PT J
AU Mbabuike, N
   Shakur, SF
   Gassie, K
   Srinivasan, V
   Mascitelli, J
   Abla, A
   Duckworth, E
   Kan, P
   Zenonos, GA
   Schirmer, C
   Charbel, FT
   de Olivera, E
   Morcos, JJ
   Lawton, M
   Tawk, RG
AF Mbabuike, Nnenna
   Shakur, Sophia F.
   Gassie, Kelly
   Srinivasan, Visish
   Mascitelli, Justin
   Abla, Adib
   Duckworth, Edward
   Kan, Peter
   Zenonos, Georgios A.
   Schirmer, Clemens
   Charbel, Fady T.
   de Olivera, Evandro
   Morcos, Jacques J.
   Lawton, Michael
   Tawk, Rabih G.
TI Microsurgical Management of Intracranial Aneurysms After Failed Flow
   Diversion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysms; Bailout; Flow diversion; Microsurgery; Operative; Treatment
ID THROMBOSED ANEURYSM; GIANT ANEURYSM; ARTERY; BYPASS; OCCLUSION; DEVICE;
   EFFICACY
AB BACKGROUND: Flow diversion has become increasingly popular tor treatment of cerebral aneurysms in the past few years. In an increasing number of patients with aneurysms, flow diversion (FD) has failed, with a paucity of reported data regarding salvage treatment for these challenging cases.
   METHODS: We present a multicenter series of 13 aneurysms for which FD failed and that were subsequently treated with open surgery. We also present a review of the reported data regarding operative management of aneurysms after unsuccessful FD.
   RESULTS: Twelve patients with 13 aneurysms were included in the present study. All 12 patients had undergone surgery after FD because of persistent aneurysm filling, mass effect, or aneurysm rupture. The patients underwent aneurysm clipping and parent vessel reconstruction, decompression of the aneurysm mass, occlusion of proximal flow to the aneurysm, or aneurysm trapping with or without extracranial-intracranial artery bypass.
   CONCLUSIONS: Aneurysms for which FD fails present variety of unique and challenging management situations that will likely be encountered with increased frequency, given the popularity of FD. Microsurgical salvage options require require individualized care tailored to the underlying pathological features, patient characteristics, and surgical expertise.
C1 [Mbabuike, Nnenna; Gassie, Kelly; de Olivera, Evandro; Tawk, Rabih G.] Mayo Clin Florida, Dept Neurosurg, Jacksonville, FL 32224 USA.
   [Shakur, Sophia F.; Charbel, Fady T.] Univ Illinois, Dept Neurosurg, Coll Med Chicago, Chicago, IL USA.
   [Srinivasan, Visish; Duckworth, Edward; Kan, Peter] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
   [Mascitelli, Justin; Lawton, Michael] Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
   [Schirmer, Clemens] Geisinger Med Ctr, Dept Neurosurg, Danville, PA 17822 USA.
   [Abla, Adib] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA.
   [de Olivera, Evandro] Inst Neurol Sci, Sao Paulo, Brazil.
   [Zenonos, Georgios A.; Morcos, Jacques J.] Univ Miami, Dept Neurosurg, Miami, FL USA.
RP Tawk, RG (reprint author), Mayo Clin Florida, Dept Neurosurg, Jacksonville, FL 32224 USA.
EM Tawk.rabih@mayo.edu
OI Schirmer, Clemens/0000-0003-1743-8781
CR Abla AA, 2014, J NEUROSURG-PEDIATR, V14, P31, DOI 10.3171/2014.4.PEDS13213
   AOKI N, 1988, NEUROSURGERY, V22, P564, DOI 10.1227/00006123-198803000-00021
   BATJER HH, 1990, NEUROSURGERY, V26, P695, DOI 10.1227/00006123-199004000-00025
   Becske T, 2017, J NEUROSURG, V127, P81, DOI 10.3171/2015.6.JNS15311
   Bell RS, 2011, NEUROSURGERY, V68, P1056, DOI 10.1227/NEU.0b013e31820d5396
   Bowers CA, 2015, ACTA NEUROCHIR, V157, P2071, DOI 10.1007/s00701-015-2593-3
   Charbel Fady T, 2005, Neurosurgery, V56, P186
   Cherian J, 2018, OPER NEUROSURG, V14, P288, DOI 10.1093/ons/opx119
   Daou B, 2017, J NEUROSURG, V126, P564, DOI 10.3171/2016.2.JNS152544
   Ding Dale, 2014, J Cerebrovasc Endovasc Neurosurg, V16, P26, DOI 10.7461/jcen.2014.16.1.26
   Ding Dale, 2013, J Cerebrovasc Endovasc Neurosurg, V15, P241, DOI 10.7461/jcen.2013.15.3.241
   Gressot LV, 2016, WORLD NEUROSURG, V93, DOI 10.1016/j.wneu.2016.06.131
   HALBACH VV, 1994, J NEUROSURG, V80, P659, DOI 10.3171/jns.1994.80.4.0659
   Hampton T, 2011, J NEUROINTERV SURG, V3, P167, DOI 10.1136/jnis.2010.002873
   HEROS RC, 1984, NEUROSURGERY, V15, P572, DOI 10.1227/00006123-198410000-00020
   Iihara K, 2003, J NEUROSURG, V98, P407, DOI 10.3171/jns.2003.98.2.0407
   Kallmes DF, 2017, J NEUROSURG, V127, P775, DOI 10.3171/2016.8.JNS16467
   Kan P, 2017, J NEUROSURG, V126, P1894, DOI 10.3171/2016.6.JNS16402
   Kan P, 2016, J NEUROINTERV SURG, V8, P945, DOI 10.1136/neurintsurg-2015-011959
   Matsuda Y, 2018, J NEUROINTERV SURG, V10, P162, DOI 10.1136/neurintsurg-2016-012969
   POZZATI E, 1982, J NEUROSURG, V57, P566, DOI 10.3171/jns.1982.57.4.0566
   Puri AS, 2016, NEURORADIOLOGY, V58, P267, DOI 10.1007/s00234-015-1630-5
   Rustemi O, 2016, NEUROSURGERY, V78, P332, DOI 10.1227/NEU.0000000000001074
   Shapiro M, 2017, J NEUROSURG, V126, P578, DOI 10.3171/2015.12.JNS152065
   Tawk Rabih G, 2006, Neurosurgery, V58, pE1217, DOI 10.1227/01.NEU.0000215995.09860.0A
   WHITTLE IR, 1982, J NEUROL NEUROSUR PS, V45, P1040, DOI 10.1136/jnnp.45.11.1040
   Zhao M, 2000, MAGN RESON IMAGING, V18, P697, DOI 10.1016/S0730-725X(00)00157-0
NR 27
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E16
EP E28
DI 10.1016/j.wneu.2019.08.121
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200005
PM 31470147
DA 2020-05-12
ER

PT J
AU McIntyre, M
   Gandhi, C
   Dragonette, J
   Schmidt, M
   Cole, C
   Santarelli, J
   Lehrer, R
   Al-Mufti, F
   Bowers, CA
AF McIntyre, Matthew
   Gandhi, Chirag
   Dragonette, James
   Schmidt, Meic
   Cole, Chad
   Santarelli, Justin
   Lehrer, Rachel
   Al-Mufti, Fawaz
   Bowers, Christian A.
TI Increasing Frailty Predicts Worse Outcomes and Increased Complications
   After Angiogram-Negative Subarachnoid Hemorrhages
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angiogram-negative; Complications; Frailty; Modified frailty index;
   Mortality; Subarachnoid hemorrhage
ID POSTOPERATIVE OUTCOMES; MORBIDITY; INDEX; MORTALITY; RISK; MODEL
AB BACKGROUND: The effect of frailty on outcomes after angiogram-negative subarachnoid hemorrhages (ANSAH) is currently unknown. We investigated frailty's effects on ANSAH outcomes, including mortality and in-hospital complications.
   METHODS: Patients from 2014 to 2018 with nontraumatic subarachnoid hemorrhage and cerebral angiograms with an unidentifiable hemorrhage source were retrospectively reviewed. The cohort was divided into nonfrail (modified frailty index [mFI] = 0) and frail (mFI >= 1) groups based on pre-hemorrhage characteristics. Primary outcomes were mortality rate and discharge location. Multivariate logistic regression analyses determined predictors of ANSAH severity and primary endpoints. Receiver operating characteristic curves were used to discriminate risks for primary endpoints comparing mFI, Hunt and Hess and Fisher scores, and age.
   RESULTS: We included 75 patients with a mean age of 55.4 +/- 1.5 years, comprising 42 (56%) women, and 41 (54.7%) with perimesencephalic bleeds. A total of 32 of 75 (42.7%) patients were classified as frail. Frail individuals were 6.2 times less likely to he discharged home (odds ratio [OR] = 0.16; 95% confidence interval [CI]: 0.05-0.5; P = 0.001) and all mortalities occurred in frail patients (12.5% [n = 4 of 32]; P = 0.030). The only independent predictor of mortality was higher mFl (OR = 5.4; 95% CI: 1.5-19.1; P = 0.009), and lower mFI best predicted discharge home (OR = 0.39; 95% CI: 0.17-0.88; P = 0.023). Receiver operating characteristic analysis showed that mFI best predicted both mortality (area under the curve = 0.9718; P = 0.002) and discharge home (area under the curve = 0.7998; P < 0.001).
   CONCLUSIONS: Frail ANSAH patients have poorer outcomes and increased mortality compared with non-frail patients. Although prospective study is needed, this information significantly impacts our understanding of ANSAH outcomes and frailty should be used for prognostication as it was a better predictor than Hunt and Hess or Fisher scores.
C1 [McIntyre, Matthew; Dragonette, James] New York Med Coll, Sch Med, Valhalla, NY 10595 USA.
   [Gandhi, Chirag; Schmidt, Meic; Cole, Chad; Santarelli, Justin; Lehrer, Rachel; Al-Mufti, Fawaz; Bowers, Christian A.] Westchester Med Ctr, Dept Neurosurg, Valhalla, NY 10595 USA.
RP Bowers, CA (reprint author), Westchester Med Ctr, Dept Neurosurg, Valhalla, NY 10595 USA.
EM Christian.Bowers@wmchealth.org
OI Bowers, Christian/0000-0001-6299-503X; Al-Mufti,
   Fawaz/0000-0003-4461-7005
CR Abdallah A, 2018, INDIAN J NEUROSURG, V7, P116, DOI 10.1055/s-0038-1668493
   Adams P, 2013, JAMA OTOLARYNGOL, V139, P783, DOI 10.1001/jamaoto.2013.3969
   Akcakaya MO, 2017, TURK NEUROSURG, V27, P732, DOI 10.5137/1019-5149.JTN.18359-16.2
   Al-Mufti F, 2018, NEUROSURGERY, V82, P359, DOI 10.1093/neuros/nyx188
   Alfieri A, 2008, J NEUROSURG, V109, P1019, DOI 10.3171/JNS.2008.109.12.1019
   Asilturk M, 2018, NEUROL NEUROCHIR POL, V52, P15, DOI 10.1016/j.pjnns.2017.09.005
   Bakker NA, 2014, J NEUROSURG, V120, P99, DOI 10.3171/2013.9.JNS131337
   Bashir A, 2018, NEURORADIOL J, V31, P244, DOI 10.1177/1971400917743100
   Boswell S, 2013, J STROKE CEREBROVASC, V22, P750, DOI 10.1016/j.jstrokecerebrovasdis.2012.02.001
   Burke T, 2018, NEUROPSYCHOL REV, V28, P453, DOI 10.1007/s11065-018-9389-1
   Canneti B, 2015, J STROKE CEREBROVASC, V24, P2484, DOI 10.1016/j.jstrokecerebrovasdis.2015.06.011
   Dalbjerg SM, 2013, CLIN NEUROL NEUROSUR, V115, P1304, DOI 10.1016/j.clineuro.2012.12.014
   Ellis JA, 2014, NEUROSURGERY, V75, P530, DOI 10.1227/NEU.0000000000000490
   Gupta SK, 2009, SURG NEUROL, V71, P566, DOI 10.1016/j.surneu.2008.04.021
   Hui FK, 2011, NEUROSURGERY, V68, P125, DOI 10.1227/NEU.0b013e3181fd82b6
   Hui FK, 2009, NEUROCRIT CARE, V11, P64, DOI 10.1007/s12028-009-9203-2
   Imaoka Y, 2018, CLIN NEUROL NEUROSUR, V175, P137, DOI 10.1016/j.clineuro.2018.11.004
   Isobe N, 2018, WORLD NEUROSURG, V119, pE167, DOI 10.1016/j.wneu.2018.07.080
   Kang P, 2016, NEUROCRIT CARE, V24, P104, DOI 10.1007/s12028-015-0152-7
   Kaufmann TJ, 2007, RADIOLOGY, V243, P812, DOI 10.1148/radiol.2433060536
   Khan AA, 2013, CLIN NEUROL NEUROSUR, V115, P1470, DOI 10.1016/j.clineuro.2013.02.002
   Kim SE, 2018, WORLD NEUROSURG, V119, pE216, DOI 10.1016/j.wneu.2018.07.119
   Konczalla J, 2015, NEUROSURG REV, V38, P121, DOI 10.1007/s10143-014-0568-0
   Lakomkin N, 2019, SPINE, V44, pE782, DOI 10.1097/BRS.0000000000002970
   Lantigua H, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1036-0
   Lee SU, 2018, WORLD NEUROSURG, V115, pE558, DOI 10.1016/j.wneu.2018.04.096
   Leven DM, 2017, GLOB SPINE J, V7, P529, DOI 10.1177/2192568217700099
   Lin N, 2012, NEUROCRIT CARE, V16, P389, DOI 10.1007/s12028-012-9680-6
   RINKEL GJE, 1991, LANCET, V338, P964, DOI 10.1016/0140-6736(91)91836-J
   Robinson TN, 2009, ANN SURG, V250, P449, DOI 10.1097/SLA.0b013e3181b45598
   Sarabia R, 2010, NEUROCIRUGIA, V21, P441
   Saxton A, 2011, ANN SURG, V253, P1223, DOI 10.1097/SLA.0b013e318214bce7
   Seib CD, 2018, JAMA SURG, V153, P160, DOI 10.1001/jamasurg.2017.4007
   Shin JI, 2017, SPINE, V42, P304, DOI 10.1097/BRS.0000000000001755
   Sprenker C, 2015, J CRIT CARE, V30, P216
   Tsiouris A, 2013, J SURG RES, V183, P40, DOI 10.1016/j.jss.2012.11.059
   Velanovich V, 2013, J SURG RES, V183, P104, DOI 10.1016/j.jss.2013.01.021
   Yagi M, 2018, SPINE, V43, P1259, DOI 10.1097/BRS.0000000000002596
   Yue Q, 2016, WORLD NEUROSURG, V95, P253, DOI 10.1016/j.wneu.2016.08.020
   Zhong WY, 2014, TURK NEUROSURG, V24, P327, DOI 10.5137/1019-5149.JTN.7253-12.1
NR 40
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E181
EP E188
DI 10.1016/j.wneu.2019.10.003
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200023
PM 31605860
DA 2020-05-12
ER

PT J
AU Mehbodniya, A
   Moghavvemi, M
   Narayanan, V
   Muthusamy, KA
   Hamdi, M
   Waran, V
AF Mehbodniya, Amirhossein
   Moghavvemi, Mahmoud
   Narayanan, Vairavan
   Muthusamy, Kalai A.
   Hamdi, Mohammad
   Waran, Vicknes
TI Identifying the Sources of Error When Using 3-Dimensional Printed Head
   Models with Surgical Navigation
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D printing in medicine; Image-guided surgery; Surgical simulation
ID ACCURACY
AB OBJECTIVES: The evaluation of sources of error when preparing, printing, and using 3-dimensional (3D) printed head models for training purposes.
   METHODS: Two 3D printed models were designed and fabricated using actual patient imaging data with reference marker points embedded artificially within these models that were then registered to a surgical navigation system using 3 different methods. The first method uses a conventional manual registration, using the actual patient's imaging data. The second method is done by directly scanning the created model using intraoperative computed tomography followed by registering the model to a new imaging dataset manually. The third is similar to the second method of scanning the model but eventually uses an automatic registration technique. The errors for each experiment were then calculated based on the distance of the surgical navigation probe from the respective positions of the embedded marker points.
   RESULTS: Errors were found in the preparation and printing techniques, largely depending on the orientation of the printed segment and postprocessing, but these were relatively small. Larger errors were noted based on a couple of variables: if the models were registered using the original patient imaging data as opposed to using the imaging data from directly scanning the model (1.28 mm vs. 1.082 mm), and the accuracy was best using the automated registration techniques (0.74 mm).
   CONCLUSION: Spatial accuracy errors occur consistently in every 3D fabricated model. These errors are derived from the fabrication process, the image registration process, and the surgical process of registration.
C1 [Mehbodniya, Amirhossein] Univ Malaya, Fac Engn, Dept Elect Engn, Kuala Lumpur, Malaysia.
   [Moghavvemi, Mahmoud] Univ Malaya, Fac Engn, Ctr Res Appl Elect, Dept Elect Engn, Kuala Lumpur, Malaysia.
   [Narayanan, Vairavan; Muthusamy, Kalai A.; Waran, Vicknes] Univ Malaya, Fac Med, Dept Surg, Kuala Lumpur, Malaysia.
   [Hamdi, Mohammad] Univ Malaya, Ctr Adv Mfg & Mat Proc, Dept Mech Engn, Kuala Lumpur, Malaysia.
   [Moghavvemi, Mahmoud] Univ Sci & Culture, Tehran, Iran.
RP Waran, V (reprint author), Univ Malaya, Fac Med, Dept Surg, Kuala Lumpur, Malaysia.
EM cmvwaran@gmail.com
RI NARAYANAN, VAIRAVAN/B-9191-2010
OI NARAYANAN, VAIRAVAN/0000-0002-1118-5042
FU Malaysia's Ministry of Science,Technology and Innovation under
   ScienceFund [03-01-03-SF1219]
FX This study was funded by Malaysia's Ministry of Science,Technology and
   Innovation under ScienceFund grant number 03-01-03-SF1219.
CR Baskaran V, 2016, FRONT NEUROANAT, V10, DOI 10.3389/fnana.2016.00069
   Costa Anthony Beardsworth, 2016, Neurosurgery, V63 Suppl 1, P198, DOI 10.1227/01.neu.0000489824.15381.09
   Craven CL, 2018, J NEUROSURG-PEDIATR, V21, P329, DOI 10.3171/2017.8.PEDS17287
   Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001
   George E, 2017, RADIOGRAPHICS, V37, P1424, DOI 10.1148/rg.2017160165
   Labadie Robert F, 2005, Curr Opin Otolaryngol Head Neck Surg, V13, P27, DOI 10.1097/00020840-200502000-00008
   Narayanan V, 2015, EUR ARCH OTO-RHINO-L, V272, P753, DOI 10.1007/s00405-014-3300-3
   Rybicki FJ, 2017, 3D PRINTING MED PRAC
   Salmi M, 2013, J CRANIO MAXILL SURG, V41, P603, DOI 10.1016/j.jcms.2012.11.041
   Shakir HJ, 2017, NEUROSURGERY, V80, P3, DOI 10.1093/neuros/nyw001
   Sipos EP, 2015, J RADIOL NURS, V34, P73
   Stelter K, 2012, COMPUT AIDED SURG, V17, P153, DOI 10.3109/10929088.2012.668937
   Tokuda J, 2009, INT J MED ROBOT COMP, V5, P423, DOI 10.1002/rcs.274
   Uhl E, 2009, NEUROSURGERY, V64, P231, DOI 10.1227/01.NEU.0000340785.51492.B5
   Vercruyssen M, 2014, PERIODONTOL 2000, V66, P228, DOI 10.1111/prd.12046
   Waran V, 2014, J NEUROSURG, V120, P489, DOI 10.3171/2013.11.JNS131066
   Waran V, 2015, SIMUL HEALTHC, V10, P43, DOI 10.1097/SIH.0000000000000060
   Waran V, 2012, J CLIN NEUROSCI, V19, P574, DOI 10.1016/j.jocn.2011.07.031
NR 18
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E379
EP E386
DI 10.1016/j.wneu.2019.10.080
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200046
PM 31639505
DA 2020-05-12
ER

PT J
AU Mena, LPDR
   Monroy-Sosa, A
   Chakravarthi, SS
   Gonen, L
   Epping, A
   Khalili, S
   Smithee, W
   Kassam, M
   Celix, JM
   Kura, B
   Jennings, J
   Rovin, RA
   Fukui, MB
   Kassam, AB
AF Mena, Laila Perez de San Roman
   Monroy-Sosa, Alejandro
   Chakravarthi, Srikant S.
   Gonen, Lior
   Epping, Austin
   Khalili, Sammy
   Smithee, William
   Kassam, Mikaeel
   Celix, Juanita M.
   Kura, Bhavani
   Jennings, Jonathan
   Rovin, Richard A.
   Fukui, Melanie B.
   Kassam, Amin B.
TI An Anatomically-Based Endoscopic Endonasal Model to Navigate the
   Anterior Ventral Skull Base
SO WORLD NEUROSURGERY
LA English
DT Article
DE Critical oblique foramen line (COFL); Endoscopic endonasal approach
   (EEA); Orbito-sellar line (OSL); Paramedial anterior line (PAL); Sellar
   and parasellar; Skull base
ID SPHENOID SINUS; ANATOMY; REGION
AB BACKGROUND: Endoscopic endonasal approaches to access the sellar and parasellar regions are challenging in the face of anatomical variations or pathologic conditions. We propose an anatomically-based model including the orbitosellar line (OSL), critical oblique foramen line (COFL), and paramedial anterior line (PAL) facilitating safe, superficial-to-deep dissection triangulating upon the medial opticocarotid recess.
   METHODS: Five cadaveric heads were dissected to systematically expose the OSL, COFL, and PAL, illustrated with image guidance. Application of the coordinate system and a 6-step dissection sequence is described.
   RESULTS: The coordinate system consists of 1) the OSL, connecting a) the anterior orbital point, junction of the anterior buttress of the middle turbinate with the agger nasi region, located 34.3 +/- 0.9 mm above the intersection of the vertical plane of the lacrimal crest, and the orthogonal plane of the maxillo-ethmoidal suture; b) the posterior orbital point, junction of the optic canal with the lamina papyracea, located 4 +/- 0.7 mm below the posterior ethmoidal artery; and c) the medial opticocarotid recess; 2) COFL (15 +/- 2.8 mm), connecting the palatovaginal canal, vidian canal, and foramen rotundum; and 3) PAL (39 +/- 0.06 mm), connecting the vidian canal with the posterior ethmoidal artery.
   CONCLUSIONS: OSL, COFL, and PAL form an anatomically-based model for the systematic exposure when accessing the parasellar and sellar regions. Preliminary anatomical data suggest that this model may be of value when normal anatomy is distorted by pathology or anatomic variations.
C1 [Mena, Laila Perez de San Roman; Monroy-Sosa, Alejandro; Chakravarthi, Srikant S.; Epping, Austin; Khalili, Sammy; Celix, Juanita M.; Kura, Bhavani; Jennings, Jonathan; Rovin, Richard A.; Fukui, Melanie B.] Aurora St Lukes Med Ctr, Aurora Neurosci Innovat Inst, Milwaukee, WI USA.
   [Gonen, Lior] Shaare Zedek Med Ctr, Jerusalem, Israel.
   [Smithee, William] Univ Texas Med Branch, Sch Med, Galveston, TX 77555 USA.
   [Kassam, Mikaeel; Kassam, Amin B.] Neeka Hlth Enterprises, Milwaukee, WI 53217 USA.
RP Kassam, AB (reprint author), Neeka Hlth Enterprises, Milwaukee, WI 53217 USA.
EM amin@neekahealth.com
OI Monroy Sosa, Alejandro/0000-0001-7107-6166
CR Amin SM, 2010, SKULL BASE-INTERD AP, V20, P421, DOI 10.1055/s-0030-1261262
   Attia M, 2012, NEUROSURGERY, V71, P58, DOI 10.1227/NEU.0b013e318258e23d
   Cappabianca P, 2004, NEUROSURGERY, V55, P933, DOI 10.1227/01.NEU.0000137330.02549.0D
   Cappabianca P, 2008, ADV TECH STAND NEURO, V33, P151, DOI 10.1007/978-3-211-72283-1_4
   Elias WJ, 2000, OPERATIVE NEUROSURGI, P373
   FUJII K, 1979, J NEUROSURG, V50, P31, DOI 10.3171/jns.1979.50.1.0031
   Galletti B, 2019, AURIS NASUS LARYNX, V46, P520, DOI 10.1016/j.anl.2018.11.004
   Kassam Amin, 2005, Neurosurg Focus, V19, pE4
   Kassam Amin, 2005, Neurosurg Focus, V19, pE3
   Kassam AB, 2011, J NEUROSURG, V114, P1544, DOI 10.3171/2010.10.JNS09406
   Labib MA, 2014, OPER NEUROSURG, V10, P448, DOI 10.1227/NEU.0000000000000362
   Labib MA, 2013, NEUROSURGERY, V72, P66, DOI 10.1227/NEU.0b013e318271f614
   Liu JK, 2001, J NEUROSURG, V95, P1083, DOI 10.3171/jns.2001.95.6.1083
   Mahmoud M, 2010, NEUROSURGERY, V67, P108, DOI 10.1227/01.NEU.0000383153.75695.24
   Osawa S, 2009, NEUROSURGERY, V64, P385, DOI 10.1227/01.NEU.0000338945.54863.D9
   Ozcan T, 2010, WORLD NEUROSURG, V73, P326, DOI 10.1016/j.wneu.2010.01.015
   Peris-Celda M, 2013, NEUROSURGERY, V73, P117, DOI 10.1227/NEU.0000000000000184
   RHOTON AL, 1979, SURG NEUROL, V12, P63
   Toh ST, 2007, ARCH OTOLARYNGOL, V133, P1153, DOI 10.1001/archotol.133.11.1153
   Wang J, 2010, NEUROSURGERY, V66, P797, DOI 10.1227/01.NEU.0000367619.24800.B1
   Wang X, 2017, J CRANIOFAC SURG, V28, pE554, DOI 10.1097/SCS.0000000000003859
   WILSON CB, 1978, J NEUROSURG, V48, P13, DOI 10.3171/jns.1978.48.1.0013
   Yilmazlar S, 2012, J CRANIO MAXILL SURG, V40, pE198, DOI 10.1016/j.jcms.2011.10.008
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E422
EP E431
DI 10.1016/j.wneu.2019.10.091
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200051
PM 31655241
DA 2020-05-12
ER

PT J
AU Munier, SM
   Ginalis, EE
   Desai, AN
   Danish, SF
AF Munier, Sean M.
   Ginalis, Elizabeth E.
   Desai, Akshay N.
   Danish, Shabbar F.
TI Understanding the Relationship Between Real-Time Thermal Imaging and
   Thermal Damage Estimate During Magnetic Resonance-Guided Laser
   Interstitial Thermal Therapy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Laser interstitial thermal therapy; LITT; Magnetic resonance thermal
   imaging; Magnetic resonance thermometry; Thermal ablation parameters
ID ABLATION; TISSUE
AB OBJECTIVE: Magnetic resonance-guided laser interstitial thermal therapy is a minimally invasive procedure that uses intraoperative magnetic resonance thermometry (MRT) to generate a thermal damage estimate (TDE) of the ablative area. This study aimed to compare areas produced by the MRT heat map with the system-generated TDE produced by Visualase software.
   METHODS: All ablations were performed using the Visualase laser ablation system. MRT heat map and TDE were quantified using MATLAB version R2014a. TDE was compared with the summed area of green, yellow, and red areas (heat map 63.9 [HM63.9]) and the summed area of light blue, green, yellow, and red areas (heat map 50.4 [HM50.4]) produced by the MRT heat map.
   RESULTS: Fifty-six patients undergoing magnetic resonance-guided laser interstitial thermal therapy were examined. Mean TDE produced was 236 mm2 (SEM = 9.5). Mean HM63.9 was 231 mm2 (SEM = 8.7), and mean HM50.4 was 370 mm2 (SEM = 12.8). There was no significant difference between TDE and HM63.9 (P = 0.51). There was a significant difference between TDE and HM50.4 (P < 0.001) and between HM63.9 and HM50.4 (P < 0.001).
   CONCLUSIONS: The system-generated TDE consistently remains contained within the boundaries of the MRT heat map. At standard factory settings, TDE and the area produced within the periphery of HM63.9 are similar in magnitude. The light blue portion of the MRT heat map may serve as an additional means of predicting when critical structures may be at risk during laser ablation if exposed to further thermal stress.
C1 [Munier, Sean M.; Ginalis, Elizabeth E.; Desai, Akshay N.; Danish, Shabbar F.] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Neurosurg, New Brunswick, NJ 08903 USA.
RP Munier, SM (reprint author), Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Neurosurg, New Brunswick, NJ 08903 USA.
EM sm1676@rwjms.rutgers.edu
CR Curry DJ, 2012, EPILEPSY BEHAV, V24, P408, DOI 10.1016/j.yebeh.2012.04.135
   Dewhirst MW, 2003, INT J HYPERTHER, V19, P267, DOI 10.1080/0265673031000119006
   Esquenazi Y, 2014, EPILEPSY RES, V108, P547, DOI 10.1016/j.eplepsyres.2014.01.009
   Gonzalez-Martinez J, 2014, OPER NEUROSURG, V10, P167, DOI 10.1227/NEU.0000000000000286
   Jethwa PR, 2012, NEUROSURGERY, V71, P133, DOI 10.1227/NEU.0b013e31826101d4
   McDannold N, 2005, INT J HYPERTHER, V21, P533, DOI 10.1080/02656730500096073
   MCGAHAN JP, 1995, ACAD RADIOL, V2, P61, DOI 10.1016/S1076-6332(05)80248-X
   McNichols RJ, 2004, LASER SURG MED, V34, P48, DOI 10.1002/lsm.10243
   Munier SM, 2019, J NEUROSURG, V131, P1958, DOI 10.3171/2018.7.JNS18886
   Patel NV, 2018, OPER NEUROSURG, V15, P179, DOI 10.1093/ons/opx191
   Patel NV, 2015, J NEUROSURG-PEDIATR, V15, P363, DOI 10.3171/2014.10.PEDS13698
   Pearce J, 2011, INT J HYPERTHER, V27, P741, DOI 10.3109/02656736.2011.580822
   Rieke V, 2008, J MAGN RESON IMAGING, V27, P376, DOI 10.1002/jmri.21265
   Riordan M, 2014, TRANSL PEDIATR, V3, P229, DOI 10.3978/j.issn.2224-4336.2014.07.07
   Sun XNR, 2015, NEUROSURGERY, V77, P51, DOI 10.1227/NEU.0000000000000732
   THOMSEN S, 1991, PHOTOCHEM PHOTOBIOL, V53, P825, DOI 10.1111/j.1751-1097.1991.tb09897.x
   Willie JT, 2014, NEUROSURGERY, V74, P569, DOI 10.1227/NEU.0000000000000343
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E1093
EP E1098
DI 10.1016/j.wneu.2019.11.110
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200127
PM 31785432
DA 2020-05-12
ER

PT J
AU O'Connor, KP
   Hathidara, MY
   Danala, G
   Xu, C
   McCoy, TM
   Sidorov, EV
   Zheng, B
   Bohnstedt, BN
   Ray, B
AF O'Connor, Kyle P.
   Hathidara, Mausaminben Y.
   Danala, Gopichandh
   Xu, Chao
   McCoy, Tressie M.
   Sidorov, Evgeny, V
   Zheng, Bin
   Bohnstedt, Bradley N.
   Ray, Bappaditya
TI Predicting Clinical Outcome After Mechanical Thrombectomy: The GADIS
   (Gender, Age, Diabetes Mellitus History, Infarct Volume, and Sex) Score
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute ischemic stroke; Endovascular thrombectomy; Image segmentation;
   Large vessel occlusion; Outcome scale
ID ISCHEMIC-STROKE; ENDOVASCULAR TREATMENT; THERAPY; REPERFUSION;
   MORTALITY; ISCORE
AB OBJECTIVE: To investigate predictive factors and develop an outcome assessment tool to determine clinical outcome after endovascular mechanical thrombectomy (EMT) in patients presenting with large vessel occlusion (LVO).
   METHODS: A retrospective analysis was carried out of a prospective cohort of patients presenting with LVO who underwent EMT after adoption of an expanded time window of <= 24 hours. Final cerebral infarction volume (CIV) after EMT was estimated using magnetic resonance imaging segmentation software. Stepwise linear regression models were used to identify factors that determined clinical outcome and to develop a predictive scale.
   RESULTS: Ninety patients underwent EMT over 19 months (68 within 6 hours and 22 between 6 and 24 hours). Clinical outcome determined using modified Rankin Scale (mRS) score at discharge and 3 months was no different among these subcohorts. A threshold of 16.99 mL of CIV, using the Youden index, resulted in a sensitivity of 90.5% and specificity of 58.1% for predicting mRS score of 0-2. A regression model identified gender, age, diabetes mellitus status, CIV, and smoking status as outcome determinants, which were used to develop the GADIS (Gender, Age, Diabetes Mellitus History, Infarct Volume, and Sex) scoring system to predict good clinical outcome. Using the GADIS score, <6 predicted mRS score 0-2 at discharge with a sensitivity of 83.3% and specificity of 80.6%.
   CONCLUSIONS: The GADIS score for patients with LVO-related acute ischemic stroke includes CIV after EMT and helps in early short-term prognostication. It is not intended to predict preintervention patient selection or outcome prediction.
C1 [O'Connor, Kyle P.; McCoy, Tressie M.; Bohnstedt, Bradley N.] Oklahoma Univ, Coll Med, Hlth Sci Ctr, Dept Neurosurg, Oklahoma City, OK USA.
   [Hathidara, Mausaminben Y.; Sidorov, Evgeny, V; Ray, Bappaditya] Oklahoma Univ, Coll Med, Hlth Sci Ctr, Dept Neurol, Oklahoma City, OK 73106 USA.
   [Xu, Chao] Oklahoma Univ, Coll Publ Hlth, Dept Biostat & Epidemiol, Hlth Sci Ctr, Oklahoma City, OK USA.
   [Danala, Gopichandh; Zheng, Bin] Univ Oklahoma, Dept Elect Engn, Norman, OK 73019 USA.
RP Ray, B (reprint author), Oklahoma Univ, Coll Med, Hlth Sci Ctr, Dept Neurol, Oklahoma City, OK 73106 USA.
EM Bappaditya.Ray@utsouthwestern.edu
OI Ray, Bappaditya/0000-0001-8623-0920
CR Abdul-Rahim AH, 2016, STROKE, V47, P74, DOI 10.1161/STROKEAHA.115.009898
   Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   Albers GW, 2016, ANN NEUROL, V79, P76, DOI 10.1002/ana.24543
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Boers AMM, 2018, J NEUROINTERV SURG, V10, P1137, DOI 10.1136/neurintsurg-2017-013724
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Carbone F, 2019, TRANSL STROKE RES, V10, P178, DOI 10.1007/s12975-018-0637-8
   Chen R, 2016, AM J MED SCI, V351, P380, DOI 10.1016/j.amjms.2016.01.011
   De Marchis GM, 2019, NEUROLOGY, V92, pE1517, DOI 10.1212/WNL.0000000000007177
   Desai SM, 2019, J STROKE CEREBROVASC, V28, DOI 10.1016/j.jstrokecerebrovasdis.2019.104315
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Grapow MTR, 2006, J THORAC CARDIOV SUR, V132, P5, DOI 10.1016/j.jtcvs.2006.03.035
   Hill Michael D, 2014, Handb Clin Neurol, V126, P167, DOI 10.1016/B978-0-444-53480-4.00012-6
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Kernan WN, 2000, STROKE, V31, P456, DOI 10.1161/01.STR.31.2.456
   Kwok CS, 2013, STROKE, V44, P2010, DOI 10.1161/STROKEAHA.113.001148
   Lansberg MG, 2015, NEUROLOGY, V85, P708, DOI 10.1212/WNL.0000000000001853
   Lei CY, 2014, STROKE, V45, P1689, DOI 10.1161/STROKEAHA.113.004352
   Liggins JTP, 2015, INT J STROKE, V10, P705, DOI 10.1111/ijs.12207
   Luitse MJA, 2012, LANCET NEUROL, V11, P261, DOI 10.1016/S1474-4422(12)70005-4
   Malhotra K, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00651
   MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Ntaios G, 2012, NEUROLOGY, V78, P1916, DOI 10.1212/WNL.0b013e318259e221
   O'Donnell MJ, 2012, ARCH INTERN MED, V172, P1548, DOI 10.1001/2013.jamainternmed.30
   Saposnik G, 2012, STROKE, V43, P1315, DOI 10.1161/STROKEAHA.111.646265
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Schnabel RB, 2015, LANCET, V386, P154, DOI 10.1016/S0140-6736(14)61774-8
   Smith EE, 2017, CIRCULATION, V136, P2303, DOI 10.1161/CIRCULATIONAHA.117.031097
   Sung SF, 2014, J STROKE CEREBROVASC, V23, P1634, DOI 10.1016/j.jstrokecerebrovasdis.2014.01.010
   Wheeler HM, 2015, INT J STROKE, V10, P723, DOI 10.1111/ijs.12436
   Zaidat OO, 2012, NEUROLOGY, V79, pS35, DOI 10.1212/WNL.0b013e31826957ef
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E1130
EP E1142
DI 10.1016/j.wneu.2019.11.127
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200132
PM 31786382
DA 2020-05-12
ER

PT J
AU Ogihara, S
   Yamazaki, T
   Shiibashi, M
   Maruyama, T
   Chikuda, H
   Miyoshi, K
   Inanami, H
   Oshima, Y
   Azuma, S
   Kawamura, N
   Yamakawa, K
   Hara, N
   Morii, J
   Okazaki, R
   Takeshita, Y
   Sato, K
   Tanaka, S
   Saita, K
AF Ogihara, Satoshi
   Yamazaki, Takashi
   Shiibashi, Michio
   Maruyama, Toru
   Chikuda, Hirotaka
   Miyoshi, Kota
   Inanami, Hirohiko
   Oshima, Yasushi
   Azuma, Seiichi
   Kawamura, Naohiro
   Yamakawa, Kiyofumi
   Hara, Nobuhiro
   Morii, Jiro
   Okazaki, Rentaro
   Takeshita, Yujiro
   Sato, Kei
   Tanaka, Sakae
   Saita, Kazuo
TI Risk Factor Analysis of Deep Surgical Site Infection After Posterior
   Instrumented Fusion Surgery for Spinal Trauma: A Multicenter
   Observational Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE American Society of Anesthesiologists; Instrumentation; Posterior
   fusion; Risk factor; Spinal trauma; Surgical site infection
ID OPERATING-ROOM; RELIABILITY; QUALITY; PATIENT; AIR
AB BACKGROUND: Surgical site infection (SSI) is a dire complication in spinal surgeries, resulting in reoperation, prolonged hospitalization, and increased expenses. Patients with traumatized spine have been reported to have a high risk of postoperative SSI. Precise identification of risk factors associated with SSI can be helpful in its prevention. However, there are only a limited number of studies investigating risk factors of SSI after posterior instrumented fusion for traumatized spine.
   METHODS: From July 2010 to June 2015, we conducted an observational study on deep SSI after posterior instrumented fusion surgery for spinal trauma in adult patients at 10 research hospitals. Detailed clinical data were prospectively collected using a standardized data collection chart and were retrospectively analyzed. SSI was diagnosed based on the definition by the Centers for Disease Control and Prevention.
   RESULTS: A total of 623 consecutive adult patients were enrolled in this study, of which 20 (3.2%) developed deep SSI. According to multivariate regression analysis, surgery at academic hospitals (P = 0.004) and an American Society of Anesthesiologists (ASA) score >= 3 (P = 0.017) were independent predictors of deep SSI after posterior instrumented fusion surgery for spinal trauma.
   CONCLUSIONS: The complexity of patients and resident involvement in surgeries may be greater at academic than at nonacademic hospitals. ASA score can be considered as an accessible and comprehensive tool for surgeons to preoperatively gauge the potential risk of SSI, a complex clinical entity. The results of this study can improve clinicians' risk perception in those undergoing posterior fusion for spinal trauma.
C1 [Ogihara, Satoshi; Sato, Kei; Saita, Kazuo] Saitama Med Univ, Dept Orthopaed Surg, Saitama, Japan.
   [Shiibashi, Michio] Saitama Med Univ, Informat Technol Ctr, Saitama, Japan.
   [Yamazaki, Takashi; Hara, Nobuhiro] Musashino Red Cross Hosp, Dept Orthopaed, Tokyo, Japan.
   [Yamazaki, Takashi; Hara, Nobuhiro] Musashino Red Cross Hosp, Dept Surg, Tokyo, Japan.
   [Maruyama, Toru] Saitama Rehabil Ctr, Saitama, Japan.
   [Chikuda, Hirotaka] Gunma Univ, Fac Med, Gunma, Japan.
   [Miyoshi, Kota; Takeshita, Yujiro] Yokohama Rosai Hosp, Yokohama, Kanagawa, Japan.
   [Inanami, Hirohiko] Iwai Orthopaed Med Hosp, Tokyo, Japan.
   [Oshima, Yasushi; Tanaka, Sakae] Univ Tokyo, Fac Med, Tokyo, Japan.
   [Azuma, Seiichi; Okazaki, Rentaro] Saitama Red Cross Hosp, Saitama, Japan.
   [Kawamura, Naohiro] Japanese Red Cross Med Ctr, Dept Spine & Orthopaed Surg, Tokyo, Japan.
   [Yamakawa, Kiyofumi] Tokyo Metropolitan Komagome Hosp, Dept Orthopaed Surg & Musculoskeletal Oncol, Tokyo, Japan.
   [Morii, Jiro] Sanraku Hosp, Dept Orthopaed Surg, Tokyo, Japan.
RP Ogihara, S (reprint author), Saitama Med Univ, Dept Orthopaed Surg, Saitama, Japan.
EM sogihara@saitama-med.ac.jp
OI Oshima, Yasushi/0000-0003-4696-1846; Ogihara,
   Satoshi/0000-0002-1814-3195
CR Andersson AE, 2012, AM J INFECT CONTROL, V40, P750, DOI 10.1016/j.ajic.2011.09.015
   Birgand G, 2015, INFECT CONT HOSP EP, V36, P93, DOI 10.1017/ice.2014.9
   Blam OG, 2003, SPINE, V28, P1475, DOI 10.1097/00007632-200307010-00022
   Chen YC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182614
   Cooper K, 2016, J CLIN NEUROSCI, V23, P123, DOI 10.1016/j.jocn.2015.08.023
   Dubory A, 2015, EUR SPINE J, V24, P543, DOI 10.1007/s00586-014-3523-4
   Gruskay J, 2012, SPINE, V37, P1170, DOI 10.1097/BRS.0b013e3182407859
   Ishii M, 2013, GLOB SPINE J, V3, P95, DOI 10.1055/s-0033-1343072
   Kao LS, 2011, J AM COLL SURGEONS, V213, P231, DOI 10.1016/j.jamcollsurg.2011.04.004
   Kobayashi K, 2018, EUR SPINE J, V27, P1698, DOI 10.1007/s00586-018-5513-4
   Koutsoumbelis S, 2011, J BONE JOINT SURG AM, V93A, P1627, DOI 10.2106/JBJS.J.00039
   Lai Q, 2017, J ORTHOP SURG RES, V12, DOI 10.1186/s13018-017-0612-1
   Lonjon G, 2012, ORTHOP TRAUMATOL-SUR, V98, P788, DOI 10.1016/j.otsr.2012.07.006
   Mangram AJ, 1999, INFECT CONT HOSP EP, V20, P250, DOI 10.1086/501620
   Maragakis LL, 2009, ANESTHESIOLOGY, V110, P556, DOI 10.1097/ALN.0b013e3181974be7
   Ogihara S, 2015, J ORTHOP SCI, V20, P71, DOI 10.1007/s00776-014-0669-1
   OWENS WD, 1978, ANESTHESIOLOGY, V49, P239, DOI 10.1097/00000542-197810000-00003
   Parker SL, 2011, MINIM INVAS NEUROSUR, V54, P33, DOI 10.1055/s-0030-1269904
   Phan K, 2015, EUR SPINE J, V24, P1017, DOI 10.1007/s00586-015-3903-4
   Phan K, 2019, SPINE J, V19, P1905, DOI 10.1016/j.spinee.2019.07.006
   REA GL, 1995, J SPINAL DISORD, V8, P368
   Rechtine GR, 2001, J ORTHOP TRAUMA, V15, P566, DOI 10.1097/00005131-200111000-00006
   Sankar A, 2014, BRIT J ANAESTH, V113, P424, DOI 10.1093/bja/aeu100
   Scaltriti S, 2007, J HOSP INFECT, V66, P320, DOI 10.1016/j.jhin.2007.05.019
   Schoenfeld AJ, 2013, SPINE J, V13, P1171, DOI 10.1016/j.spinee.2013.02.071
   Veeravagu A, 2009, SPINE, V34, P1869, DOI 10.1097/BRS.0b013e3181adc989
   Watanabe M, 2010, J NEUROSURG-SPINE, V12, P540, DOI 10.3171/2009.11.SPINE09308
   Wathen C, 2016, NEUROSURGERY, V79, P889, DOI 10.1227/NEU.0000000000001357
NR 28
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E524
EP E529
DI 10.1016/j.wneu.2019.10.117
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200063
PM 31669691
DA 2020-05-12
ER

PT J
AU Oishr, Y
   Tamura, R
   Takahashi, S
   Morimoto, Y
   Sato, M
   Horikoshi, T
   Hassaan, S
   Yoshida, K
   Toda, M
AF Oishr, Yumiko
   Tamura, Ryota
   Takahashi, Satoshi
   Morimoto, Yukina
   Sato, Mizuto
   Horikoshi, Tomo
   Hassaan, Shady
   Yoshida, Kazunari
   Toda, Masahiro
TI A Comparative Study Between Traditional Microscopic Surgeries and
   Endoscopic Endonasal Surgery for Skull Base Chordomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chordoma; Clivus; Endoscopic endonasal approach; Skull base
ID CLIVAL CHORDOMAS; PHASE-II; RESECTION; MANAGEMENT; EVOLUTION
AB BACKGROUND: Skull base chordomas (SBCs) are rare clinically aggressive neoplasms, developing local recurrences after surgical resection. Although SBCs have traditionally been resected by craniotomy or microscopic transsphenoidal surgery (TSS), the recent development of the endoscopic endonasal approach (EEA) has revolutionized treatment strategies through minimally invasive techniques. This study aimed to evaluate clinical outcomes after traditional microsurgeries or EEAs for SBCs.
   METHODS: The present retrospective study investigated 66 patients with primary SBCs who underwent surgery between 1977 and 2019. Resection was performed via EEA in 17 cases, craniotomy in 23, transoral approach in 8, TSS in 12, staged surgery in 4, and others in 2. The median follow-up period for progression-free survival (PFS) was 19.5 months.
   RESULTS: There were no significant differences in preoperative tumor volume or resection rate among these approaches. The incidence of postoperative cranial nerve palsy was significantly lower in EEA than that in craniotomy (P < 0.05). Although total resection was observed in 4 cases of EEA expanding into the superior and inferior part of the clivus, no cases of transoral approach or TSS achieved total resection for both parts. No significant difference in PFS was found among these approaches. Multivariate analysis showed that being female and the absence of radiotherapy were significantly associated with shorter PFS (P < 0.05 and P < 0.001, respectively). The resection rate was not associated with PFS.
   CONCLUSIONS: EEA is a less invasive surgical approach for SBCs. The development of surgical instruments and postoperative radiotherapy will further improve patients' outcomes.
C1 [Oishr, Yumiko; Tamura, Ryota; Takahashi, Satoshi; Morimoto, Yukina; Hassaan, Shady; Yoshida, Kazunari; Toda, Masahiro] Keio Univ, Dept Neurosurg, Sch Med, Shinjuku Ku, Tokyo, Japan.
   [Sato, Mizuto; Horikoshi, Tomo] Tochigi Med Ctr, Dept Neurosurg, Utsunomiya, Tochigi, Japan.
   [Hassaan, Shady] Assiut Univ, Dept Neurosurg, Assiut Governorate, Egypt.
RP Toda, M (reprint author), Keio Univ, Dept Neurosurg, Sch Med, Shinjuku Ku, Tokyo, Japan.
EM todam@keio.jp
OI Toda, Masahiro/0000-0003-2700-1620; Takahashi,
   Satoshi/0000-0002-0168-1261
CR Ahmed AT, 2018, SPINE, V43, pE1157, DOI 10.1097/BRS.0000000000002638
   Aktas U, 2013, J CRANIO MAXILL SURG, V41, P457, DOI 10.1016/j.jcms.2012.11.011
   Aldana PR, 2012, NEUROSURGERY, V71, P308, DOI 10.1227/NEU.0b013e318266e488
   Alonso WA, 1968, LARYNGOSCOPE, V14, P65
   Boari N, 2016, J NEUROSURG, V125, P450, DOI 10.3171/2015.6.JNS142370
   Bompas E, 2015, ANN ONCOL, V26, P2168, DOI 10.1093/annonc/mdv300
   Carrabba G, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.12.E7
   Conger A, 2019, J NEUROSURG, V130, P861, DOI 10.3171/2017.11.JNS172141
   de Almeida JR, 2009, LARYNGOSCOPE, V119, P239, DOI 10.1002/lary.20108
   Dehdashti AR, 2008, NEUROSURGERY, V63, P299, DOI 10.1227/01.NEU.0000316414.20247.32
   Elhadi AM, 2015, OPER NEUROSURG, V11, P69, DOI 10.1227/NEU.0000000000000601
   Fraser JF, 2010, J NEUROSURG, V112, P1061, DOI 10.3171/2009.7.JNS081504
   Gondim JA, 2010, PITUITARY, V13, P68, DOI 10.1007/s11102-009-0195-x
   Gui SB, 2016, NEUROSURG REV, V39, P321, DOI 10.1007/s10143-015-0696-1
   HARDY J, 1965, J NEUROSURG, V23, P612, DOI 10.3171/jns.1965.23.6.0612
   Hwang PY, 2007, NEUROSURGERY, V61, P212, DOI 10.1227/01.neu.0000303219.55393.fe
   Ikeda T, 1992, Nihon Jibiinkoka Gakkai Kaiho, V95, P214
   Jahangiri A, 2015, NEUROSURGERY, V76, P179, DOI 10.1227/NEU.0000000000000611
   Jho HD, 1997, ACTA NEUROCHIR, V139, P343, DOI 10.1007/BF01808831
   Kim GG, 2013, ADV OTO-RHINO-LARYNG, V74, P71, DOI 10.1159/000342282
   Komotar RJ, 2011, WORLD NEUROSURG, V76, P318, DOI 10.1016/j.wneu.2011.02.026
   KONDZIOLKA D, 1991, NEUROSURGERY, V29, P38, DOI 10.1227/00006123-199107000-00007
   Koutourousiou M, 2012, NEUROSURGERY, V71, P614, DOI 10.1227/NEU.0b013e31825ea3e0
   Lebellec L, 2016, ONCOTARGET, V7, P73984, DOI 10.18632/oncotarget.12172
   Lobo Bjorn, 2015, Surg Neurol Int, V6, P82, DOI 10.4103/2152-7806.157442
   McMaster ML, 2001, CANCER CAUSE CONTROL, V12, P1, DOI 10.1023/A:1008947301735
   Muto J, 2016, J NEUROSURG, V125, P1171, DOI 10.3171/2015.8.JNS15302
   ROTH JA, 1977, LARYNGOSCOPE, V87, P47
   Saito K, 2012, ACTA NEUROCHIR, V154, P879, DOI 10.1007/s00701-012-1317-1
   Schwartz TH, 2019, J NEUROSURG, V130, P337, DOI 10.3171/2018.10.JNS182154
   Scopel TF, 2012, LARYNGOSCOPE, V122, P751, DOI 10.1002/lary.22448
   Shidoh S, 2014, NEUROL MED-CHIR, V54, P991, DOI 10.2176/nmc.st.2014-0135
   Shimony N, 2017, ACTA NEUROCHIR, V159, P1835, DOI 10.1007/s00701-016-3032-9
   Stacchiotti S, 2012, J CLIN ONCOL, V30, P914, DOI 10.1200/JCO.2011.35.3656
   Tamura R, 2016, NEUROSURG REV, V39, P297, DOI 10.1007/s10143-015-0688-1
   Tomio R, 2015, J NEUROSURG, V122, P499, DOI 10.3171/2014.10.JNS132437
   Truong HQ, 2019, J NEUROSURG, V131, P141, DOI 10.3171/2018.2.JNS173126
   Walcott BP, 2012, LANCET ONCOL, V13, pE69, DOI 10.1016/S1470-2045(11)70337-0
   Zhou JP, 2018, WORLD NEUROSURG, V117, P46, DOI 10.1016/j.wneu.2018.05.209
   Zoli M, 2018, J NEUROSURG, V128, P329, DOI 10.3171/2016.11.JNS162082
   ZOLTAN L, 1960, J NEUROSURG, V17, P888, DOI 10.3171/jns.1960.17.5.0888
NR 41
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E1099
EP E1107
DI 10.1016/j.wneu.2019.11.113
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200128
PM 31785435
DA 2020-05-12
ER

PT J
AU Otani, N
   Mori, K
   Wada, K
   Tomiyama, A
   Toyooka, T
   Takeuchi, S
   Nakao, Y
   Yamamoto, T
   Arai, H
AF Otani, Naoki
   Mori, Kentaro
   Wada, Kojiro
   Tomiyama, Arata
   Toyooka, Terushige
   Takeuchi, Satoru
   Nakao, Yasuaki
   Yamamoto, Takuji
   Arai, Hajime
TI Limited Indications for Clipping Surgery of Paraclinoid Aneurysm Based
   on Long-Term Visual Morbidity
SO WORLD NEUROSURGERY
LA English
DT Article
DE Extradural temporopolar approach; Paraclinoid aneurysm; Visual morbidity
ID EXTRADURAL TEMPOROPOLAR APPROACH; CAROTID-ARTERY ANEURYSMS; OPHTHALMIC
   SEGMENT; ENDOVASCULAR TREATMENT; INTRACRANIAL ANEURYSMS; FLOW-DIVERSION;
   MICROSURGICAL TREATMENT; CEREBRAL ANEURYSMS; NATURAL-HISTORY;
   RISK-FACTORS
AB OBJECTIVE: Clipping of paraclinoid aneurysm is still challenging because of poor visual morbidity. The extradural temporopolar approach was applied to clip paraclinoid aneurysms, with the expectation of reducing visual morbidity. Factors related to poor visual morbidity were evaluated, to assess the results for clipping of paraclinoid aneurysms.
   METHODS: A series of 40 unruptured paraclinoid aneurysms in 38 patients were clipped via extradural temporopolar approach. Preoperative and postoperative states of visual cognitive function and radiological outcomes were investigated. Aneurysms were classified into dorsal type or non-dorsal type, and small (<9 mm) or not-small (>= 9 mm), respectively, to identify factors correlated with visual morbidity.
   RESULTS: Complete clipping rate was 90.0% without any recurrence (mean: 5.2 years). Visual morbidity was unexpectedly high at 28.9%, including 2.7% of blindness immediately after the operation, and 23.7% and 2.7% at the final examination (mean: 3.6 years). Multivariate analysis showed aneurysm size was significantly correlated with worse visual outcome. Visual morbidity was 13.3% and 11.1% for dorsal and the non-dorsal small aneurysms, respectively, and all these cases showed visual field defect limited to the nasal quadrant without decreased visual acuity. In contrast, the non-dorsal not-small aneurysms showed significantly worse visual morbidity (60%) with decreased visual acuity.
   CONCLUSIONS: Clipping via extradural temporopolar approach can achieve durable treatment for small unruptured paraclinoid aneurysms with acceptable visual morbidity. Visual morbidity of the not-small non-dorsal type, however, was poor. The indications for clipping of paraclinoid aneurysm should be limited to small aneurysms, especially the dorsal type in young patients.
C1 [Otani, Naoki; Mori, Kentaro; Wada, Kojiro; Tomiyama, Arata; Toyooka, Terushige; Takeuchi, Satoru] Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama, Japan.
   [Mori, Kentaro] Tokyo Gen Hosp, Tokyo, Japan.
   [Nakao, Yasuaki; Yamamoto, Takuji] Juntendo Univ, Shizuoka Hosp, Izunokuni, Shizuoka, Japan.
   [Arai, Hajime] Juntendo Univ Hosp, Tokyo, Japan.
RP Otani, N (reprint author), Natl Def Med Coll, Dept Neurosurg, Tokorozawa, Saitama, Japan.
EM naotani@ndmc.ac.jp
CR Asaid M, 2017, WORLD NEUROSURG, V106, P322, DOI [10.1016/J.WNEU.2017.06.135, 10.1016/j.wneu.2017.06.135]
   Barami K, 2003, SKULL BASE-INTERD AP, V13, P31, DOI 10.1055/s-2003-37551
   BATJER HH, 1994, J NEUROSURG, V80, P650, DOI 10.3171/jns.1994.80.4.0650
   Brinjikji W, 2016, AM J NEURORADIOL, V37, P1673, DOI 10.3174/ajnr.A4807
   Brinjikji W, 2013, STROKE, V44, P442, DOI 10.1161/STROKEAHA.112.678151
   Burrows AM, 2016, AM J NEURORADIOL, V37, P1866, DOI 10.3174/ajnr.A4835
   Colli BO, 2013, NEUROSURG REV, V36, P99, DOI 10.1007/s10143-012-0415-0
   Daou B, 2019, J NEUROSURG, V130, P1376, DOI 10.3171/2017.12.JNS163090
   DAY AL, 1990, J NEUROSURG, V72, P677, DOI 10.3171/jns.1990.72.5.0677
   DAY JD, 1994, J NEUROSURG, V81, P230, DOI 10.3171/jns.1994.81.2.0230
   DEOLIVEIRA E, 1995, ACTA NEUROCHIR, V136, P204, DOI 10.1007/BF01410627
   DOLENC VV, 1985, J NEUROSURG, V62, P667, DOI 10.3171/jns.1985.62.5.0667
   Figueiredo EG, 2010, NEUROSURG REV, V33, P27, DOI 10.1007/s10143-009-0224-2
   FOX JL, 1988, NEUROSURGERY, V22, P32, DOI 10.1227/00006123-198801000-00005
   Fulkerson DH, 2009, NEUROSURGERY, V64, P218, DOI 10.1227/01.NEU.0000337127.73667.80
   Hayakawa M, 2000, J NEUROSURG, V93, P561, DOI 10.3171/jns.2000.93.4.0561
   Hoh BL, 2001, NEUROSURGERY, V48, P78, DOI 10.1097/00006123-200101000-00014
   Iihara K, 2003, J NEUROSURG, V99, P241, DOI 10.3171/jns.2003.99.2.0241
   Javalkar V, 2011, J CLIN NEUROSCI, V18, P13, DOI 10.1016/j.jocn.2010.06.020
   Kamide T, 2018, J NEUROSURG, V129, P1511, DOI 10.3171/2017.7.JNS17673
   Kanagalingam S, 2012, J NEURO-OPHTHALMOL, V32, P27, DOI 10.1097/WNO.0b013e31823b6c60
   Kikuta Ken-Ichiro, 2016, Acta Neurochir Suppl, V123, P41, DOI 10.1007/978-3-319-29887-0_6
   Kim LJ, 2014, NEUROSURGERY, V74, P51, DOI 10.1227/NEU.0000000000000192
   KOBAYASHI S, 1989, J NEUROSURG, V70, P216, DOI 10.3171/jns.1989.70.2.0216
   KOTHANDARAM P, 1971, J NEUROSURG, V34, P544, DOI 10.3171/jns.1971.34.4.0544
   Kumon Y, 1997, SURG NEUROL, V48, P465, DOI 10.1016/S0090-3019(97)00175-4
   Lai LT, 2013, J CLIN NEUROSCI, V20, P1127, DOI 10.1016/j.jocn.2012.12.004
   Lanzino G, 2012, AM J NEURORADIOL, V33, P2158, DOI 10.3174/ajnr.A3207
   Matano F, 2016, WORLD NEUROSURG, V85, P169, DOI 10.1016/j.wneu.2015.08.068
   Matsukawa H, 2016, WORLD NEUROSURG, V91, P183, DOI 10.1016/j.wneu.2016.04.004
   Murayama Y, 1999, J NEUROSURG, V90, P207, DOI 10.3171/jns.1999.90.2.0207
   Nanda A, 2011, NEUROSURGERY, V68, P355, DOI 10.1227/NEU.0b013e3182039819
   Nonaka T, 2007, SURG NEUROL, V67, P612, DOI 10.1016/j.surneu.2006.08.074
   NUTIK S, 1978, J NEUROSURG, V48, P526, DOI 10.3171/jns.1978.48.4.0526
   Oh SY, 2015, CLIN NEUROL NEUROSUR, V128, P72, DOI 10.1016/j.clineuro.2014.11.008
   Otani N, 2018, J NEUROL SURG PART B, V79, pS347, DOI 10.1055/s-0038-1654703
   Otani Naoki, 2016, Surg Neurol Int, V7, pS454, DOI 10.4103/2152-7806.185774
   Pasqualin Alberto, 2016, Acta Neurochir Suppl, V123, P33, DOI 10.1007/978-3-319-29887-0_5
   Raco A, 2008, J NEUROSURG, V108, P1200, DOI 10.3171/JNS/2008/108/6/1200
   Roy D, 1997, AM J NEURORADIOL, V18, P1207
   Silva MA, 2019, J NEUROSURG, V130, P1505, DOI 10.3171/2018.1.JNS171774
   Silva MA, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1718
   Toyooka T, 2017, OPER NEUROSURG, V13, P224, DOI 10.1227/NEU.0000000000001324
   Wang Y, 2013, ACTA NEUROCHIR, V155, P2019, DOI 10.1007/s00701-013-1830-x
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Yeon JY, 2012, ACTA NEUROCHIR, V154, P2163, DOI 10.1007/s00701-012-1509-8
   Zanaty M, 2015, NEUROSURGERY, V76, P286, DOI 10.1227/NEU.0000000000000607
   Zhu Y, 2015, WORLD NEUROSURG, V84, P1726, DOI 10.1016/j.wneu.2015.07.036
NR 48
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E153
EP E161
DI 10.1016/j.wneu.2019.09.147
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200019
PM 31629143
DA 2020-05-12
ER

PT J
AU Ovalioglu, AO
   Ovalioglu, TC
   Arslan, S
   Canaz, G
   Aydin, AE
   Sar, M
   Emel, E
AF Ovalioglu, Aysegul Ozdemir
   Ovalioglu, Talat Cem
   Arslan, Sema
   Canaz, Gokhan
   Aydin, Aysegul Esen
   Sar, Mehmet
   Emel, Erhan
TI Effects of Erythrosine on Neural Tube Development in Early Chicken
   Embryos
SO WORLD NEUROSURGERY
LA English
DT Article
DE Embryology; Erythrosine; Neural tube defect; Spina bifida
ID FOLIC-ACID; TERM TOXICITY; DEFECTS; RISK;
   2',4',5',7'-TETRAIODOFLUORESCEIN; WOMEN
AB OBJECTIVE: Erythrosine (E127), a synthetic food dye containing iodine and sodium, has often been used inside packaged foods and beverages in Turkey and many other countries. We evaluated the effects of erythrosine on neural tube development in early-stage chicken embryos.
   METHODS: The study included 4 groups, with a total of - embryos: a control group, a normal saline group, a half-dose group, and a high-dose group. After 30 hours of incubation, saline and erythrosine solution was injected under the embryonic discs. At the end of 72 hours, the embryos were excised and evaluated macroscopically and histopathologically.
   RESULTS: Neural tube defects were detected in the erythrosine-administered groups with statistically significant differences. In contrast, the embryos in the control and saline groups displayed normal development.
   CONCLUSIONS: Erythrosine increased the risk of neural defects in early-stage chicken embryos, even at half of the approved dose.
C1 [Ovalioglu, Aysegul Ozdemir; Ovalioglu, Talat Cem; Aydin, Aysegul Esen; Emel, Erhan] Marmara Univ, Bakirkoy Res & Training Hosp Neurol Neurosurg & P, Dept Neurosurg, Istanbul, Turkey.
   [Sar, Mehmet] Marmara Univ, Bakirkoy Res & Training Hosp Neurol Neurosurg & P, Dept Pathol, Istanbul, Turkey.
   [Arslan, Sema] Marmara Univ, Bakirkoy Res & Training Hosp Neurol Neurosurg & P, Dept Biochem, Istanbul, Turkey.
   [Canaz, Gokhan] Arnavutkoy State Hosp, Dept Neurosurg, Istanbul, Turkey.
RP Canaz, G (reprint author), Arnavutkoy State Hosp, Dept Neurosurg, Istanbul, Turkey.
EM gokhancanaz@gmail.com
CR Aguilar F, 2011, EFSA J, V9, DOI 10.2903/j.efsa.2011.1854
   Amchova P, 2015, REGUL TOXICOL PHARM, V73, P914, DOI 10.1016/j.yrtph.2015.09.026
   Baines J., 2000, WHO FOOD ADDITIVE SE
   BUTTERWORTH KR, 1976, FOOD COSMET TOXICOL, V14, P525, DOI 10.1016/S0015-6264(76)80001-6
   Canaz H, 2018, CHILD NERV SYST, V34, P1367, DOI 10.1007/s00381-018-3731-z
   Christianson A., 2005, MARCH DIMES GLOBAL R
   COLLINS TFX, 1993, FOOD CHEM TOXICOL, V31, P161, DOI 10.1016/0278-6915(93)90089-H
   Frey L, 2003, EPILEPSIA, V44, P4, DOI 10.1046/j.1528-1157.44.s3.2.x
   GARDNER DF, 1987, TOXICOL APPL PHARM, V91, P299, DOI 10.1016/0041-008X(87)90052-4
   HANSEN WH, 1973, FOOD COSMET TOXICOL, V11, P535, DOI 10.1016/S0015-6264(73)80324-4
   JENNINGS AS, 1990, TOXICOL APPL PHARM, V103, P549, DOI 10.1016/0041-008X(90)90327-Q
   Kaufman BA, 2004, PEDIATR CLIN N AM, V51, P389, DOI 10.1016/S0031-3955(03)00207-4
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   LAFFERMAN JA, 1979, SCIENCE, V205, P410, DOI 10.1126/science.451609
   Lamers Y, 2018, AM J CLIN NUTR, V108, P1357, DOI 10.1093/ajcn/nqy212
   MAILMAN RB, 1980, SCIENCE, V207, P535, DOI 10.1126/science.7352264
   Merinas-Amo R, 2019, FOODS, V8, DOI 10.3390/foods8050176
   Ray JG, 2005, OBSTET GYNECOL, V105, P261, DOI 10.1097/01.AOG.0000151988.84346.3e
   Shaw GM, 2003, AM J CLIN NUTR, V78, P972
   SHAYWITZ BA, 1977, J PEDIATR-US, V90, P67, DOI 10.1016/S0022-3476(77)80766-X
   Tuncbilek E, 1999, TURKISH J PEDIATR, V41, P299
   World Health Organization, 2019, EV CERT FOOD ADD 86
   Yerby MS, 2003, EPILEPSIA, V44, P33, DOI 10.1046/j.1528-1157.2003.t01-1-44703.x-i1
NR 23
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E822
EP E825
DI 10.1016/j.wneu.2019.11.017
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200096
PM 31715407
DA 2020-05-12
ER

PT J
AU Pavese, N
   Tai, YF
   Yousif, N
   Nandi, D
   Bain, PG
AF Pavese, Nicola
   Tai, Yen F.
   Yousif, Nada
   Nandi, Dipankar
   Bain, Peter G.
TI Traditional Trial and Error versus Neuroanatomic 3-Dimensional Image
   Software-Assisted Deep Brain Stimulation Programming in Patients with
   Parkinson Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Deep brain stimulation; Parkinson disease; Subthalamic; Visual software
AB BACKGROUND: Programming deep brain stimulation (DBS) settings in patients with Parkinson disease (PD) is challenging and time consuming because of the vast number of possible parameter combinations. This results in long sessions that can be exhausting for the patients and physicians. GUIDE (Boston Scientific) is a 3-dimensional neuroanatomic visual software that precisely visualizes the location of the DBS electrode in the subthalamic nucleus (STN). The objective of this paper is to compare the duration and clinical effects of traditional trial and error versus GUIDE-assisted DBS programming in 10 patients with PD treated with STN DBS.
   METHODS: For each patient, neurostimulation parameters were selected with GUIDE to create a stimulation field encompassing the dorsal part of the STN. On programming day, each patient was assessed with both traditional and GUIDE approaches using a crossover design. For GUIDE-assisted sessions, the patients were programmed directly with the DBS settings obtained with the stimulated field model, and if necessary, parameters were adjusted to achieve optimal clinical response. Clinical improvement was assessed with Unified Parkinson's Disease Rating Scale scores for limb bradykinesia, tremor, and rigidity.
   RESULTS: In 7 patients, DBS settings obtained with GUIDE led to suboptimal clinical improvement and mild adjustments were required. After these adjustments, the magnitude of clinical improvement with the 2 approaches was comparable (P = 0.8219). Programming time with GUIDE was significantly shorter than with the traditional programming approach (P < 0.0001).
   CONCLUSIONS: Visualization of stimulation fields with GUIDE provides useful information to achieve a clinical improvement comparable with that obtained with the traditional trial and error approach, but with shorter and more efficient programming sessions.
C1 [Pavese, Nicola] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne, Tyne & Wear, England.
   [Pavese, Nicola] Aarhus Univ, Inst Clin Med, Aarhus, Denmark.
   [Pavese, Nicola; Tai, Yen F.; Yousif, Nada; Nandi, Dipankar; Bain, Peter G.] Imperial Coll London, Div Brain Sci, London, England.
   [Yousif, Nada] Univ Hertfordshire, Sch Engn & Comp Sci, Hatfield, Herts, England.
RP Pavese, N (reprint author), Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne, Tyne & Wear, England.; Pavese, N (reprint author), Aarhus Univ, Inst Clin Med, Aarhus, Denmark.; Pavese, N (reprint author), Imperial Coll London, Div Brain Sci, London, England.
EM nicola.pavese@newcastle.ac.uk
OI Pavese, Nicola/0000-0002-6801-6194
CR Aziz TZ, 2001, STEREOT FUNCT NEUROS, V77, P87, DOI 10.1159/000064602
   Benabid AL, 2009, LANCET NEUROL, V8, P67, DOI 10.1016/S1474-4422(08)70291-6
   Castrioto Anna, 2013, Handb Clin Neurol, V116, P129, DOI 10.1016/B978-0-444-53497-2.00011-5
   Fahn S, 1987, RECENT DEV PARKINSON, V2, P293
   Picillo M, 2016, BRAIN STIMUL, V9, P425, DOI 10.1016/j.brs.2016.02.004
   Pourfar MH, 2015, STEREOT FUNCT NEUROS, V93, P231, DOI 10.1159/000375172
   Shukla AW, 2017, PARKINSONS DIS-US, V2017, DOI 10.1155/2017/8492619
   Volkmann J, 2006, MOVEMENT DISORD, V21, pS284, DOI 10.1002/mds.20961
   Volkmann Jens, 2016, Neurosurgery, V63 Suppl 1, P211, DOI 10.1227/01.neu.0000489863.00935.ea
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E98
EP E102
DI 10.1016/j.wneu.2019.09.106
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200014
PM 31568905
DA 2020-05-12
ER

PT J
AU Pham, TB
   Srinivas, S
   Martin, JR
   Brandel, MG
   Wali, AR
   Rennert, RC
   Steinberg, JA
   Santiago-Dieppa, DR
   Costantini, TW
   Khalessi, AA
AF Pham, Tammy B.
   Srinivas, Shanmukha
   Martin, Joel R.
   Brandel, Michael G.
   Wali, Arvin R.
   Rennert, Robert C.
   Steinberg, Jeffrey A.
   Santiago-Dieppa, David R.
   Costantini, Todd W.
   Khalessi, Alexander A.
TI Risk Factors for Urinary Tract Infection or Pneumonia After Admission
   for Traumatic Subdural Hematoma at a Level I Trauma Center: Large
   Single-Institution Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Neurosurgical outcomes; Pneumonia; Subdural hematoma; Urinary tract
   infection
ID VENTILATOR-ASSOCIATED PNEUMONIA; CLINICAL-PRACTICE GUIDELINES;
   BRAIN-INJURY; DISEASES SOCIETY; UNITED-STATES; MORTALITY; EPIDEMIOLOGY;
   MORBIDITY; PROGRAM; ADULTS
AB BACKGROUND: The development of infections such as urinary tract infections (UTIs) or pneumonia after a traumatic subdural hematoma (tSDH) can worsen patient outcomes and increase healthcare costs. We herein identify clinical parameters that influence the risk of infections after tSDH.
   METHODS: This single-institution retrospective cohort study examined the incidence and risk factors for UTI and pneumonia among tSDH patients from 1990 to 2015. Multivariate logistic regression assessed the impact of various demographic and clinical variables on these outcomes.
   RESULTS: 3024 patients with tSDHs were identified (73.1% male); Of those, 208 (6.9%) experienced a UTI and 434 (14.4%) experienced pneumonia. Of the 559 patients (18.5%) who underwent a craniotomy and/or craniectomy for evacuation of a tSDH, 62 (11.1%) experienced a UTI and 222 (39.7%) experienced pneumonia. Risk factors for both pneumonia and UTI included length of stay (LOS) >= 7 days (odds ratio [OR] = 6.0, P < 0.001; OR = 11.2, P < 0.001), intensive care unit LOS >= 7 days (OR = 8.1, P < 0.001; OR = 1.7, P = 0.012), and mechanical ventilation >= 14 days (OR = 3.4, P < 0.001; OR = 1.8, P = 0.007). Craniotomy/craniectomy increased the risk of pneumonia (OR = 1.4, P = 0.019) but not UTI. Glasgow Coma Scale (GCS) >= 13 was associated with a decreased pneumonia risk (OR = 0.5, P = 0.003), and male gender (OR = 0.5, P < 0.001) and age <60 (OR = 0.6, P < 0.001) were associated with a decreased UTI risk.
   CONCLUSIONS: Patients with prolonged hospitalizations and/or intensive care unit stays were more likely to experience UTIs and pneumonia. Male gender and younger age were protective against UTI, and higher GCS was protective against pneumonia. These data may aid the identification and treatment of at-risk populations after admission for a tSDH.
C1 [Pham, Tammy B.; Srinivas, Shanmukha; Martin, Joel R.; Brandel, Michael G.; Wali, Arvin R.; Rennert, Robert C.; Steinberg, Jeffrey A.; Santiago-Dieppa, David R.; Khalessi, Alexander A.] Univ Calif San Diego, Dept Neurol Surg, La Jolla, CA 92093 USA.
   [Costantini, Todd W.] Univ Calif San Diego, Dept Surg, La Jolla, CA 92093 USA.
RP Khalessi, AA (reprint author), Univ Calif San Diego, Dept Neurol Surg, La Jolla, CA 92093 USA.
EM akhalessi@ucsd.edu
CR Abulhasan YB, 2018, AM J INFECT CONTROL, V46, P656, DOI 10.1016/j.ajic.2017.12.001
   Centers for Disease Control and Prevention (CDC), 2013, NAT HEALTHC SAF NETW
   Drakulovic MB, 1999, LANCET, V354, P1851, DOI 10.1016/S0140-6736(98)12251-1
   Foxman B, 2003, INFECT DIS CLIN N AM, V17, P227, DOI 10.1016/S0891-5520(03)00005-9
   Ham J, 2001, CRIT CARE, V5, P73400
   Hawe CS, 2009, INTENS CARE MED, V35, P1180, DOI 10.1007/s00134-009-1461-0
   Hooton TM, 2010, CLIN INFECT DIS, V50, P625, DOI 10.1086/650482
   Kalil AC, 2016, CLIN INFECT DIS, V63, pE61, DOI 10.1093/cid/ciw353
   Karhade AV, 2017, WORLD NEUROSURG, V97, P205, DOI 10.1016/j.wneu.2016.09.056
   Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894
   Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002
   Lukasiewicz AM, 2016, J NEUROSURG, V124, P760, DOI 10.3171/2015.2.JNS142721
   Magill SS, 2014, NEW ENGL J MED, V370, P1198, DOI 10.1056/NEJMoa1306801
   Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765
   Morris AC, 2011, CRIT CARE MED, V39, P2218, DOI 10.1097/CCM.0b013e3182227d52
   Muscedere JG, 2010, CLIN INFECT DIS, V51, pS120, DOI 10.1086/653060
   Nicolle LE, 2014, ANTIMICROB RESIST IN, V3, DOI 10.1186/2047-2994-3-23
   Orlando A, 2017, WORLD NEUROSURG, V107, P94, DOI [10.1016/J.WNEU.2017.07.130, 10.1016/j.wneu.2017.07.130]
   [R-Core-Team Computing R.F. f.S], 2014, R LANG ENV STAT COMP
   Rennert RC, 2019, WORLD NEUROSURG, V122, pE619, DOI 10.1016/j.wneu.2018.10.114
   Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009
   Ryan CG, 2012, J TRAUMA ACUTE CARE, V73, P1348, DOI 10.1097/TA.0b013e31826fcb30
   Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586
   Saint S, 2016, NEW ENGL J MED, V374, P2111, DOI 10.1056/NEJMoa1504906
   Shirawi N, 2006, CRIT CARE, V10, DOI 10.1186/cc3828
   Tallon JM, 2008, CAN J SURG, V51, P339
   Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1
   Tuttle JC, 2017, J CLIN OUTCOMES MANA, P24
   WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212
NR 29
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E754
EP E760
DI 10.1016/j.wneu.2019.10.192
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200088
PM 31712113
DA 2020-05-12
ER

PT J
AU Raghavan, A
   Smith, G
   Onyewadume, L
   Peck, MR
   Herring, E
   Pace, J
   Rogers, M
   Momotaz, H
   Hoffer, SA
   Hu, Y
   Liu, HY
   Tatsuoka, C
   Sajatovic, M
   Sloan, AE
AF Raghavan, Alankrita
   Smith, Gabriel
   Onyewadume, Louisa
   Peck, Matthew R.
   Herring, Eric
   Pace, Jonathan
   Rogers, Matt
   Momotaz, Hasina
   Hoffer, Seth Alan
   Hu, Yin
   Liu, Hongyan
   Tatsuoka, Curtis
   Sajatovic, Martha
   Sloan, Andrew E.
TI Morbidity and Mortality After Burr Hole Craniostomy Versus Craniotomy
   for Chronic Subdural Hematoma Evacuation: A Single-Center Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chronic subdural hematoma; Craniotomy; Craniostomy; Reoperation
ID PORT SYSTEM; ELDERLY-PATIENTS; TOTAL HIP; PREDICTORS; RECURRENCE;
   MANAGEMENT; RISK; DRAINAGE; SURVIVAL; OUTCOMES
AB BACKGROUND: Chronic subdural hematomas (cSDHs) are common neurosurgical pathological entities and typically occur after trauma in elderly patients. The 2 most commonly used strategies for treatment have included burr hole drainage and craniotomy with decompression. However, the choice of these procedures has remained controversial and has been primarily determined by surgeon preference. We designed a matched-cohort analysis to compare these 2 procedures and identify the risk factors associated with the postoperative outcomes. Thus, we compared the rates of reoperation and mortality for patients who had undergone craniotomy versus burr hole evacuation for cSDH.
   METHODS: A retrospective review examining the data from 299 consecutive patients with cSHDs from 2002 to 2015 was performed. We compared the following endpoints between the 2 procedures: 30-day mortality, discharge to a skilled nursing facility, and the need for reoperation. We also compared the potential risk factors in the patients with different primary outcomes.
   RESULTS: Patients undergoing craniotomy had a decreased need for reoperation compared with patients treated with burr hole evacuation (7.5% vs. 15.7%; P = 0.044). Older age was associated with both increased disposition to a nursing facility and increased 30-day mortality in both groups. Increased 30-day mortality was associated with aspirin usage in patients who had undergone craniotomy and with warfarin (Coumadin) in patients who had undergone burr hole evacuation.
   CONCLUSIONS: Our study identified an increased need for reoperation for patients treated with burr hole evacuation compared with those undergoing craniotomy. Older age and low Glasgow coma scale scores were associated with worse outcomes in both groups. Certain methods of anticoagulation were also associated with worse outcomes, which varied between the 2 groups. We recommend that surgeons individualize the choice of procedure according to the specific patient characteristics with consideration of these findings.
C1 [Raghavan, Alankrita; Smith, Gabriel; Onyewadume, Louisa; Peck, Matthew R.; Herring, Eric; Pace, Jonathan; Hoffer, Seth Alan; Hu, Yin; Tatsuoka, Curtis; Sloan, Andrew E.] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA.
   [Smith, Gabriel; Pace, Jonathan; Hoffer, Seth Alan; Hu, Yin; Sloan, Andrew E.] Univ Hosp Cleveland, Med Ctr, Dept Neurosurg, Cleveland, OH 44106 USA.
   [Sajatovic, Martha] Univ Hosp Cleveland, Med Ctr, Dept Neurol, Cleveland, OH 44106 USA.
   [Sajatovic, Martha] Univ Hosp Cleveland, Med Ctr, Dept Psychiat, Cleveland, OH 44106 USA.
   [Sajatovic, Martha] Univ Hosp Cleveland, Med Ctr, Neurol & Behav Outcomes Ctr, Cleveland, OH 44106 USA.
   [Rogers, Matt] Travis Airforce Base, David Grant Med Ctr, Fairfield, CA USA.
   [Momotaz, Hasina; Liu, Hongyan] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA.
RP Sloan, AE (reprint author), Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA.; Sloan, AE (reprint author), Univ Hosp Cleveland, Med Ctr, Dept Neurosurg, Cleveland, OH 44106 USA.
EM Andrew.sloan@uhhospitals.org
OI Smith, Gabriel/0000-0002-8400-0176
FU Department of Neurosurgery, University Hospitals Cleveland Medical
   Center; National Institutes of HealthUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA [RO1CA217956,
   U01CA236215]; Peter D. Cristal Chair; Center of Excellence for
   Translational Neuro-Oncology; Kimble Family Foundation; Gerald Kaufman
   Fund for Glioma Research; Ferry Family Foundation at the University
   Hospitals of Cleveland
FX This project was sponsored by the Junior Faculty Mentorship Program in
   the Department of Neurosurgery, University Hospitals Cleveland Medical
   Center (to A.E.S.). A.E.S. was also supported by the National Institutes
   of Health (grants RO1CA217956 and U01CA236215), Peter D. Cristal Chair,
   Center of Excellence for Translational Neuro-Oncology, Kimble Family
   Foundation, Gerald Kaufman Fund for Glioma Research, and Ferry Family
   Foundation at the University Hospitals of Cleveland.
CR Adhiyaman V, 2017, QJM-INT J MED, V110, P375, DOI [10.1093/qjmed/hcw231, 10.1093/qjmed/hcx143]
   Christopher E, 2019, NEUROSURG REV, V42, P427, DOI 10.1007/s10143-018-0979-4
   Drapkin AJ, 2014, WORLD NEUROSURG, V81, pE20, DOI 10.1016/j.wneu.2012.01.027
   El-Kadi H, 2000, NEUROSURG CLIN N AM, V11, P553, DOI 10.1016/S1042-3680(18)30122-0
   Bae ME, 2011, ACTA NEUROCHIR, V153, P1097, DOI 10.1007/s00701-010-0903-3
   FOGELHOLM R, 1975, J NEUROSURG, V42, P43, DOI 10.3171/jns.1975.42.1.0043
   Guilfoyle MR, 2017, ACTA NEUROCHIR, V159, P903, DOI 10.1007/s00701-017-3095-2
   Huang YH, 2014, INJURY, V45, P1327, DOI 10.1016/j.injury.2014.02.023
   Jamsen E, 2013, ANN RHEUM DIS, V72, P1975, DOI 10.1136/annrheumdis-2012-202064
   Javadi A, 2011, WORLD NEUROSURG, V75, P731, DOI 10.1016/j.wneu.2010.11.042
   Kamenova M, 2016, NEUROSURGERY, V79, P715, DOI 10.1227/NEU.0000000000001393
   Karibe H, 2017, NEUROL MED-CHIR, V57, P418, DOI 10.2176/nmc.st.2017-0058
   Lega BC, 2010, J NEUROSURG, V113, P615, DOI 10.3171/2009.9.JNS08825
   Leroy HA, 2015, J CLIN NEUROSCI, V22, P1895, DOI 10.1016/j.jocn.2015.03.064
   Liu WM, 2014, J NEUROSURG, V121, P665, DOI 10.3171/2014.5.JNS132715
   Lukasiewicz AM, 2016, J NEUROSURG, V124, P760, DOI 10.3171/2015.2.JNS142721
   Mascarenhas L, 2012, NEUROCHIRURGIE, V58, P47, DOI 10.1016/j.neuchi.2011.09.005
   Motoie R, 2018, WORLD NEUROSURG, V118, pE87, DOI 10.1016/j.wneu.2018.06.124
   Muzii V F, 2005, J Neurosurg Sci, V49, P41
   Muzii VF, 2005, J NEUROSURG SCI, V49, P6
   Nathan S, 2017, NEUROLOGY, V88, P1889, DOI 10.1212/WNL.0000000000003918
   Nilsdotter AK, 2002, RHEUMATOLOGY, V41, P1261, DOI 10.1093/rheumatology/41.11.1261
   Okada Y, 2007, BRAIN TUMOR PATHOL, V24, P15, DOI 10.1007/s10014-007-0213-5
   Oyama H, 2011, NEUROL MED-CHIR, V51, P825, DOI 10.2176/nmc.51.825
   Peng DQ, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011402.pub2
   Rahman M, 2015, WORLD NEUROSURG, V84, P41, DOI 10.1016/j.wneu.2015.02.016
   Regan JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115085
   REYMOND MA, 1992, NEUROSURG REV, V15, P21, DOI 10.1007/BF02352062
   Rughani AI, 2010, J NEUROSURG, V113, P609, DOI 10.3171/2009.11.JNS091244
   Safain M, 2013, J NEUROSURG, V118, P694, DOI 10.3171/2012.11.JNS12689
   Santarius T, 2009, LANCET, V374, P1067, DOI 10.1016/S0140-6736(09)61115-6
   Schwarz F, 2015, CLIN NEUROL NEUROSUR, V138, P66, DOI 10.1016/j.clineuro.2015.08.002
   Shabani S, 2016, WORLD NEUROSURG, V96, P66, DOI 10.1016/j.wneu.2016.08.075
   Singh AK, 2014, NEUROL INDIA, V62, P169, DOI 10.4103/0028-3886.132364
   Singla A, 2013, CLIN NEUROL NEUROSUR, V115, P425, DOI 10.1016/j.clineuro.2012.06.005
   Soleman J, 2017, SWISS MED WKLY, V147, DOI 10.4414/smw.2017.14398
   Uno M, 2017, NEUROL MED-CHIR, V57, P402, DOI 10.2176/nmc.ra.2016-0337
   Won SY, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.7.FOCUS17417
   Xu FF, 2014, BRAIN INJURY, V28, P1121, DOI 10.3109/02699052.2014.910702
NR 39
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E196
EP E203
DI 10.1016/j.wneu.2019.10.023
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200025
PM 31605846
DA 2020-05-12
ER

PT J
AU Ranson, WA
   Neifert, SN
   Cheung, ZB
   Mikhail, CM
   Caridi, JM
   Cho, SK
AF Ranson, William A.
   Neifert, Sean N.
   Cheung, Zoe B.
   Mikhail, Christopher M.
   Caridi, John M.
   Cho, Samuel K.
TI Predicting In-Hospital Complications After Anterior Cervical Discectomy
   and Fusion: A Comparison of the Elixhauser and Charlson Comorbidity
   Indices
SO WORLD NEUROSURGERY
LA English
DT Article
DE ACDF; Anterior cervical discectomy and fusion; Charlson; Comorbidity;
   Complication; Elixhauser
ID TOTAL JOINT ARTHROPLASTY; PERIOPERATIVE COMPLICATIONS; RISK-ADJUSTMENT;
   PREOPERATIVE ANEMIA; ADMINISTRATIVE DATA; OUTCOMES; MORTALITY; DISEASE;
   SURGERY; UNDERWEIGHT
AB OBJECTIVE: The objective of this study was to determine the ability of the Elixhauser Comorbidity Index (ECI) and Charlson Comorbidity Index (CCI) to predict postoperative complications after anterior cervical discectomy and fusion (ACDF).
   METHODS: This was a retrospective study of ACDF hospitalizations in the National Inpatient Sample from 2013 to 2014. The ECI and CCI were calculated, and patients who experienced postoperative complications were identified. The ability of these indexes to predict complications was compared using the c statistic (area under the receiver operating characteristic curve [AUC]). In addition, the CCI and ECI were compared with a base model that included age, sex, race, and primary payer.
   RESULTS: A total of 261,780 patients were included. Patients who experienced a complication were more often male (P < 0.0001) and older (P < 0.0001). They also had a higher comorbidity burden as assessed by both the ECI (P< 0.0001) and the CCI (P < 0.0001). The ECI was superior in predicting airway complications (AUC, 0.81 vs. 0.75; P < 0.0001), hemorrhagic anemia (AUC, 0.67 vs. 0.63; P = 0.0015), pulmonary embolism (AUC, 0.91 vs. 0.77; P < 0.0001), wound dehiscence (AUC, 0.80 vs. 0.55; P = 0.0080), sepsis (AUC, 0.87 vs. 0.82; P = 0.0001), and septic shock (AUC, 0.94 vs. 0.83; P< 0.0001). The CCI was not found to be superior to the ECI for predicting any complications. Both were excellent for predicting mortality (ECI AUC, 0.87; CCI AUC, 0.90).
   CONCLUSIONS: The ECI was superior to the CCI in predicting 6 of 15 complications in this study. Both are excellent tools for predicting mortality after ACDF.
C1 [Ranson, William A.; Cheung, Zoe B.; Mikhail, Christopher M.; Cho, Samuel K.] Mt Sinai Hosp, Dept Orthopaed, New York, NY 10029 USA.
   [Neifert, Sean N.; Caridi, John M.] Mt Sinai Hosp, Dept Neurosurg, New York, NY 10029 USA.
RP Cho, SK (reprint author), Mt Sinai Hosp, Dept Orthopaed, New York, NY 10029 USA.
EM Samuel.cho@mountsinai.org
CR Alvarez AP, 2016, ADV ORTHOP, V2016, DOI 10.1155/2016/7268985
   Anoushiravani AA, 2016, J ARTHROPLASTY, V31, P1407, DOI 10.1016/j.arth.2015.12.053
   Bovonratwet P, 2019, SPINE, V44, P543, DOI 10.1097/BRS.0000000000002885
   Bronheim RS, 2018, SPINE, V43, P239, DOI 10.1097/BRS.0000000000002301
   Cairns MA, 2018, J BONE JOINT SURG AM, V100, P269, DOI 10.2106/JBJS.17.00327
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chitale R, 2015, J SPINAL DISORD TECH, V28, P126, DOI 10.1097/BSD.0b013e318270dad7
   Chu YT, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-140
   Chughtai M, 2019, SPINE J, V19, P597, DOI 10.1016/j.spinee.2018.09.011
   Daley J, 2001, ANNU REV MED, V52, P275, DOI 10.1146/annurev.med.52.1.275
   De la Garza-Ramos R, 2016, NEUROL RES, V38, P117, DOI 10.1080/01616412.2016.1138669
   DeFrances Carol J, 2008, Natl Health Stat Report, P1
   DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8
   Di Capua J, 2017, GLOB SPINE J, V7, P425, DOI 10.1177/2192568217699383
   Dias Celso Garreta Prats, 2017, Rev. bras. ortop., V52, P575, DOI 10.1016/j.rboe.2017.08.007
   Dobran M, 2017, Surg Neurol Int, V8, P212, DOI 10.4103/sni.sni_222_17
   Echt M, 2018, WORLD NEUROSURG, V116, pE824, DOI 10.1016/j.wneu.2018.05.103
   Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004
   Farley JF, 2006, AM J MANAG CARE, V12, P110
   Gagne JJ, 2011, J CLIN EPIDEMIOL, V64, P749, DOI 10.1016/j.jclinepi.2010.10.004
   Glassman SD, 2007, SPINE, V32, P2764, DOI 10.1097/BRS.0b013e31815a7644
   Goyal A, 2018, CLIN NEUROL NEUROSUR, V177, P27
   Grendar J, 2012, ARCH SURG-CHICAGO, V147, P126, DOI 10.1001/archsurg.2011.296
   Healy MA, 2016, JAMA SURG, V151, P823, DOI 10.1001/jamasurg.2016.0773
   IEZZONI LI, 1992, JAMA-J AM MED ASSOC, V267, P2197, DOI 10.1001/jama.267.16.2197
   Kalakoti P, 2019, SPINE, V44, P334, DOI 10.1097/BRS.0000000000002825
   Kapadia BH, 2019, CLIN SPINE SURG, V32, pE86, DOI 10.1097/BSD.0000000000000732
   Kim CY, 2018, J SHOULDER ELB SURG, V27, P1748, DOI 10.1016/j.jse.2018.03.001
   Lieffers JR, 2011, CANCER-AM CANCER SOC, V117, P1957, DOI 10.1002/cncr.25653
   Menendez ME, 2015, INT ORTHOP, V39, P1307, DOI 10.1007/s00264-015-2702-1
   Menendez ME, 2015, SPINE, V40, P809, DOI 10.1097/BRS.0000000000000892
   Menendez ME, 2014, CLIN ORTHOP RELAT R, V472, P2878, DOI 10.1007/s11999-014-3686-7
   Moore BJ, 2017, MED CARE, V55, P698, DOI 10.1097/MLR.0000000000000735
   Nahhas Cindy R, 2018, J Spine Surg, V4, P233, DOI 10.21037/jss.2018.05.11
   Narain AS, 2018, J NEUROSURG-SPINE, V28, P160, DOI 10.3171/2017.6.SPINE17288
   Nunley PD, 2017, NEUROSURG FOCUS, V43, DOI 10.3171/2017.7.FOCUS17278
   Phan K, 2017, GLOB SPINE J, V7, P441, DOI 10.1177/2192568217699404
   Pine M, 2007, JAMA-J AM MED ASSOC, V297, P71, DOI 10.1001/jama.297.1.71
   Poses RM, 1996, J CLIN EPIDEMIOL, V49, P743, DOI 10.1016/0895-4356(96)00021-2
   Powell H, 2001, J CLIN EPIDEMIOL, V54, P687, DOI 10.1016/S0895-4356(00)00364-4
   Preen DB, 2004, J CLIN EPIDEMIOL, V57, P1295, DOI 10.1016/j.jclinepi.2004.03.016
   Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83
   Ranson WA, 2018, GLOB SPINE J, V8, P834, DOI 10.1177/2192568218775960
   Sayeed Z, 2016, J ARTHROPLASTY, V31, P2085, DOI 10.1016/j.arth.2016.03.015
   Seicean A, 2013, SPINE, V38, P1331, DOI 10.1097/BRS.0b013e3182912c6b
   Sivaganesan A, 2019, SPINE, V44, P588, DOI 10.1097/BRS.0000000000002883
   Song KJ, 2014, ASIAN SPINE J, V8, P531, DOI 10.4184/asj.2014.8.4.531
   Southern DA, 2004, MED CARE, V42, P355, DOI 10.1097/01.mlr.0000118861.56848.ee
   Sugawara T, 2015, NEUROL MED-CHIR, V55, P540, DOI 10.2176/nmc.ra.2014-0403
   Tseng VL, 2012, JAMA-J AM MED ASSOC, V308, P493, DOI 10.1001/jama.2012.9014
   Virk SS, 2019, SPINE, V44, pE33, DOI 10.1097/BRS.0000000000002766
   Weiler C, 2012, Eur Spine J, V21 Suppl 6, pS810, DOI 10.1007/s00586-011-1922-3
   Zaki O, 2019, SPINE, V44, P762, DOI 10.1097/BRS.0000000000002937
NR 53
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E487
EP E496
DI 10.1016/j.wneu.2019.10.102
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200059
PM 31669536
DA 2020-05-12
ER

PT J
AU Raz, E
   Dehkharghani, S
   Shapiro, M
   Nossek, E
   Jain, R
   Zhang, C
   Ishida, K
   Tanweer, O
   Peschillo, S
   Nelson, PK
AF Raz, Eytan
   Dehkharghani, Seena
   Shapiro, Maksim
   Nossek, Erez
   Jain, Rajan
   Zhang, Cen
   Ishida, Koto
   Tanweer, Omar
   Peschillo, Simone
   Nelson, Peter Kim
TI Possible Empirical Evidence of Glymphatic System on Computed Tomography
   After Endovascular Perforations
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular; Extravasation; Glymphatic; Stroke; Subarachnoid hemorrhage
ID INTERSTITIAL FLUID; CLEARANCE; PATHWAY
AB BACKGROUND: The glial-lymphatic pathway is a fluid-clearance pathway consisting of a para-arterial route for the flow of cerebrospinal fluid along perivascular spaces and subsequently toward the brain interstitium. In this case series, we aim to investigate an empirical demonstration of glymphatic clearance of extravasated iodine following perforation incurred during endovascular therapy on serial computed tomography.
   METHODS: Six consecutive cases of endovascular pertoration during thrombectomy performed between 2005 and 2018 were retrospectively collected by searching our internal database of total 446 thrombectomies. Two cases were excluded because care was withdrawn shortly following the procedure and no follow-up imaging was available. One case was excluded because a ventricular drain was placed. Three cases were hence included in this analysis.
   RESULTS: All 3 cases demonstrated progressive absorption of contrast by the brain parenchyma with eventual contrast disappearance.
   CONCLUSIONS: We described a likely in vivo computed tomography correlate of the glymphatic system in a cohort of patients who sustained intraprocedural extravasation during thrombectomy for acute ischemic stroke.
C1 [Raz, Eytan; Dehkharghani, Seena; Shapiro, Maksim; Jain, Rajan; Nelson, Peter Kim] NYU Langone Hlth, Dept Radiol, New York, NY 10016 USA.
   [Nossek, Erez; Jain, Rajan; Tanweer, Omar; Nelson, Peter Kim] NYU Langone Hlth, Dept Neurosurg, New York, NY USA.
   [Zhang, Cen; Ishida, Koto] NYU Langone Hlth, Dept Neurol, New York, NY USA.
   [Peschillo, Simone] Univ Catania, Dept Neurosurg, Catania, Sicily, Italy.
RP Raz, E (reprint author), NYU Langone Hlth, Dept Radiol, New York, NY 10016 USA.
EM eytan.raz@gmail.com
OI Peschillo, Simone/0000-0002-3920-8517; Zhang, Cen/0000-0003-2661-8469;
   Ishida, Koto/0000-0003-3856-9684; Dehkharghani,
   Seena/0000-0002-3141-1094; Jain, Rajan/0000-0002-4879-0457
CR Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   de Leon MJ, 2017, J NUCL MED, V58, P1471, DOI 10.2967/jnumed.116.187211
   Dreha-Kulaczewski S, 2015, J NEUROSCI, V35, P2485, DOI 10.1523/JNEUROSCI.3246-14.2015
   Golanov EV, 2018, J CEREBR BLOOD F MET, V38, P793, DOI 10.1177/0271678X17701157
   Goulay R, 2017, STROKE, V48, P2301, DOI 10.1161/STROKEAHA.117.017014
   Iliff JJ, 2013, J NEUROSCI, V33, P18190, DOI 10.1523/JNEUROSCI.1592-13.2013
   Iliff JJ, 2013, J CLIN INVEST, V123, P1299, DOI 10.1172/JCI67677
   Mokin M, 2017, J NEUROINTERV SURG, V9, P922, DOI 10.1136/neurintsurg-2016-012707
   Nedergaard M, 2013, SCIENCE, V340, P1529, DOI 10.1126/science.1240514
   Pfaff J, 2016, AM J NEURORADIOL, V37, P2066, DOI 10.3174/ajnr.A4862
   Rasmussen MK, 2018, LANCET NEUROL, V17, P1016, DOI 10.1016/S1474-4422(18)30318-1
   Ringstad G, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121537
   Ringstad G, 2017, BRAIN, V140, P2691, DOI 10.1093/brain/awx191
   Taoka T, 2017, JPN J RADIOL, V35, P172, DOI 10.1007/s11604-017-0617-z
   Watts R, 2019, AM J NEURORADIOL, V40, P648, DOI 10.3174/ajnr.A5931
   WINKLER SS, 1980, J COMPUT ASSIST TOMO, V4, P191, DOI 10.1097/00004728-198004000-00011
   Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224
   Yang LJ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-107
NR 19
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E400
EP E404
DI 10.1016/j.wneu.2019.10.089
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200048
PM 31655242
DA 2020-05-12
ER

PT J
AU Rentenberger, C
   Okano, I
   Salzmann, SN
   Winter, F
   Plais, N
   Burkhard, MD
   Shue, J
   Sama, AA
   Cammisa, FP
   Girardi, FP
   Hughes, AP
AF Rentenberger, Colleen
   Okano, Ichiro
   Salzmann, Stephan N.
   Winter, Fabian
   Plais, Nicolas
   Burkhard, Marco D.
   Shue, Jennifer
   Sama, Andrew A.
   Cammisa, Frank P.
   Girardi, Federico P.
   Hughes, Alexander P.
TI Perioperative Risk Factors for Early Revisions in Stand-Alone Lateral
   Lumbar Interbody Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bone mineral density; Foraminal stenosis; Revision; Stand-alone lateral
   lumbar interbody fusion; Subsidence
ID CLINICAL-EVALUATION; SUBSIDENCE; OUTCOMES; SURGERY; DECOMPRESSION;
   STENOSIS; LEVEL; CAGES; QCT; DXA
AB BACKGROUND: Lateral lumbar interbody fusion can be performed without supplemental posterior instrumentation. Previous reports have shown favorable results with standalone lateral lumbar interbody fusion (SA-LLIF); however, a reoperation rate of up to 26% has been reported. It remains unclear what perioperative factors are associated with early failure after SA-LLIF. The objective of this study is to determine perioperative factors that increase the risk of early revisions after SA-LLIF.
   METHODS: Data of consecutive patients with SA-LLIF were reviewed. All revisions or recommendations for revision surgery within 12 months after the LLIF procedure were documented. As potential contributors, operative levels, preoperative clinical diagnosis, number of fusion levels, and the average L1/L2 quantitative computed tomography-volumetric bone mineral density value were obtained along with other demographic factors. Cage subsidence (grade 0-III as per Marchi et al.), was also evaluated in patients who had radiographs/computed tomography between 6 and 12 months postoperatively (n = 122). Logistic regression analyses were conducted.
   RESULTS: Of 133 eligible patients, 21 (15.8%) underwent revision surgery and 4 (3.0%) were recommended for revision surgery within 1 year primarily because of neurologic symptoms or pain (68%). Baseline demographics showed no significant difference between the revision and the nonrevision group. The average number of levels levels fused was 2.12 (revision group) and 2.14 (nonrevision group) (P = 0.55). Significantly more patients in the revision group had the diagnosis of foraminal stenosis (64.0% vs. 39.8%; P = 0.04).
   CONCLUSIONS: Patients with foraminal stenosis were more likely to have early revision surgery after SA-LLIF primarily because of neurologic symptoms/pain. This information can assist in preoperative discussions and management of patient expectations.
C1 [Rentenberger, Colleen; Okano, Ichiro; Salzmann, Stephan N.; Winter, Fabian; Shue, Jennifer; Sama, Andrew A.; Cammisa, Frank P.; Girardi, Federico P.; Hughes, Alexander P.] Hosp Special Surg, New York, NY 10021 USA.
   [Plais, Nicolas] Hosp Univ San Cecilio, Granada, Spain.
   [Burkhard, Marco D.] Waid Spital, Zurich, Switzerland.
RP Hughes, AP (reprint author), Hosp Special Surg, New York, NY 10021 USA.
EM hughesa@hss.edu
OI Okano, Ichiro/0000-0003-1741-5176; Winter, Fabian/0000-0003-0695-7877;
   Plais, nicolas/0000-0003-2303-6084
CR Ahmadian A, 2015, J CLIN NEUROSCI, V22, P740, DOI 10.1016/j.jocn.2014.08.036
   Aichmair A, 2017, SPINE, V42, pE515, DOI 10.1097/BRS.0000000000001871
   Aichmair A, 2013, SPINE, V38, pE1483, DOI 10.1097/BRS.0b013e3182a3d1b4
   Alimi M, 2018, CLIN SPINE SURG, V31, pE42, DOI 10.1097/BSD.0000000000000507
   Alimi M, 2014, J NEUROSURG-SPINE, V20, P623, DOI 10.3171/2014.1.SPINE13569
   American College of Radiology, 2014, ACR SPR SSR PRACT PA
   Brown JK, 2017, J CLIN DENSITOM, V20, P216, DOI 10.1016/j.jocd.2015.11.001
   CANN CE, 1980, J COMPUT ASSIST TOMO, V4, P493, DOI 10.1097/00004728-198008000-00018
   Castro C, 2014, CLIN ORTHOP RELAT R, V472, P1776, DOI 10.1007/s11999-013-3263-5
   Cummock MD, 2011, J NEUROSURG-SPINE, V15, P11, DOI 10.3171/2011.2.SPINE10374
   Formica M, 2017, EUR SPINE J, V26, P464, DOI 10.1007/s00586-017-5115-6
   Kim HJ, 2015, EUR SPINE J, V24, P388, DOI 10.1007/s00586-014-3592-4
   Kotwal S, 2015, J SPINAL DISORD TECH, V28, P119, DOI 10.1097/BSD.0b013e3182706ce7
   Lang G, 2017, WORLD NEUROSURG, V104, P644, DOI 10.1016/j.wneu.2017.05.035
   Le TV, 2012, SPINE, V37, P1268, DOI 10.1097/BRS.0b013e3182458b2f
   Macki M, 2019, WORLD NEUROSURG, V122, P599, DOI 10.1016/j.wneu.2018.11.121
   Malham GM, 2015, J NEUROSURG-SPINE, V23, P589, DOI 10.3171/2015.1.SPINE14566
   Malham GM, 2015, EUR SPINE J, V24, pS339, DOI 10.1007/s00586-015-3807-3
   MARCHI LUIS, 2016, Coluna/Columna, V15, P226, DOI 10.1590/S1808-185120161503162720
   Marchi L, 2013, J NEUROSURG-SPINE, V19, P110, DOI 10.3171/2013.4.SPINE12319
   Marchi Luis, 2012, ScientificWorldJournal, V2012, P456346, DOI 10.1100/2012/456346
   Nemani VM, 2014, SPINE, V39, pE326, DOI 10.1097/BRS.0000000000000141
   Oh KW, 2017, CLIN SPINE SURG, V30, pE683, DOI 10.1097/BSD.0000000000000315
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Pickhardt PJ, 2015, J CLIN DENSITOM, V18, P5, DOI 10.1016/j.jocd.2014.03.002
   Pimenta L, 2013, J NEUROL SURG PART A, V74, P343, DOI 10.1055/s-0032-1333420
   Pimenta L, 2012, SCI WORLD J, DOI 10.1100/2012/381814
   Rodgers W, 2007, US MUSCULOSKELET REV, V2, P28
   Salzmann SN, 2019, SPINE J, V19, P695, DOI 10.1016/j.spinee.2018.10.007
   Salzmann SN, 2017, CURR REV MUSCULOSKE, V10, P539, DOI 10.1007/s12178-017-9444-1
   Shepherd JA, 2015, J CLIN DENSITOM, V18, P274, DOI 10.1016/j.jocd.2015.06.013
   STEIGER P, 1990, RADIOLOGY, V175, P537, DOI 10.1148/radiology.175.2.2326479
   Summers RM, 2011, J COMPUT ASSIST TOMO, V35, P212, DOI 10.1097/RCT.0b013e3182032537
   Tempel ZJ, 2018, J NEUROSURG-SPINE, V28, P50, DOI 10.3171/2017.5.SPINE16427
   Tempel ZJ, 2015, EUR SPINE J, V24, pS414, DOI 10.1007/s00586-015-3844-y
   Tohmeh AG, 2014, SPINE, V39, pE1582, DOI 10.1097/BRS.0000000000000645
   Tokuhashi Y, 2009, ORTHOPEDICS, V32, P877
   Wang L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06608-y
   Wang TY, 2017, WORLD NEUROSURG, V106, P819, DOI 10.1016/j.wneu.2017.07.045
   Watanabe K, 2011, J SPINAL DISORD TECH, V24, P137, DOI 10.1097/BSD.0b013e3181e1cd99
NR 40
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E657
EP E663
DI 10.1016/j.wneu.2019.10.164
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200081
PM 31698117
DA 2020-05-12
ER

PT J
AU Ridwan, S
   Grote, A
   Simon, M
AF Ridwan, Sami
   Grote, Alexander
   Simon, Matthias
TI Safety and Efficacy of Negative Pressure Wound Therapy for Deep Spinal
   Wound Infections After Dural Exposure, Durotomy, or Intradural Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dura; NPWT; Revision surgery; Spinal surgery; Spinal infection; Spine;
   VAC
ID VACUUM-ASSISTED-CLOSURE; CEREBELLAR HEMORRHAGE; POSTOPERATIVE
   INFECTIONS; LUMBAR SPINE; RISK-FACTORS; MANAGEMENT; FUSION;
   INSTRUMENTATION; COMPLICATIONS; IRRIGATION
AB BACKGROUND: Negative pressure wound therapy (NPWT) for deep spinal wound infections after exposure or opening of the dura can carry significant risks (i.e., cerebrospinal fluid infections and fistulas). In the present study, we reviewed a fairly large and recent experience with such patients.
   METHODS: We identified 25 patients with exposure and/or incision of the dura who had undergone NPWT from January 2014 to June 2018 for deep spinal wound infections. The demographic data, specifics of primary surgery and NPWT (i.e., dressing changes, duration, time required for wound healing), patients' clinical course, outcomes, and microbiological findings were studied. Application of a Granufoam vacuum dressing with a continuous negative pressure of 60 mm Hg was performed after proper debridement.
   RESULTS: Of the 25 patients, 13 were women and 12 were men (median age, 69 years). They had primarily undergone treatment for spinal tumors (n = 7), infections and degenerative disease (n = 8 each), or fractures (n = 2), with instrumentation in 18 patients (72%). The dura was exposed in all 25 patients and had been incised in 10 (40%) patients (intended incision, 3; accidental incision, 7). Most patients had been treated for a lumbar wound infection (64%). A microorganism was detected in 84% of the cases, with Staphylococcus aureus accounting for most of the infections (48%). NPWT was concluded after a median of 4 dressing changes (range, 2-14) and 19 days (range, 10-70), with no implant removal required in any patient. NPWT application was observed to be safe without cerebrospinal fluid-related complications. The presence of comorbidities (28% had diabetes) had no effect on the treatment results.
   CONCLUSIONS: NPWT can be safely applied for deep spinal wound infections after dura exposure or durotomy during previous spine surgery.
C1 [Ridwan, Sami; Grote, Alexander; Simon, Matthias] Bethel Clin, Dept Neurosurg, Bielefeld, Germany.
RP Ridwan, S (reprint author), Bethel Clin, Dept Neurosurg, Bielefeld, Germany.
EM sami.ridwan@yahoo.de
CR Alpert HW, 2014, J PEDIATR ORTHOPED, V34, P613, DOI 10.1097/BPO.0000000000000145
   ANDREWS RT, 1995, AM J NEURORADIOL, V16, P1312
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chen SH, 2015, EUR SPINE J, V24, P561, DOI 10.1007/s00586-014-3636-9
   Cheng MT, 2005, SPINE, V30, P1689, DOI 10.1097/01.brs.0000171907.60775.85
   Contractor D, 2008, J ORTHOP TRAUMA, V22, pS167, DOI 10.1097/BOT.0b013e318188e295
   Dersch T, 1994, 4 ANN M WOUND HEAL S
   Friedman JA, 2002, NEUROSURGERY, V50, P1361, DOI 10.1097/00006123-200206000-00030
   Gobel F, 1999, Z ORTHOP GRENZGEB, V137, P371, DOI 10.1055/s-2008-1039729
   Guerin P, 2012, INJURY, V43, P397, DOI 10.1016/j.injury.2010.12.014
   Horn PL, 2007, ORTHOP NURS, V26, P317, DOI 10.1097/01.NOR.0000295960.94450.69
   Jones GA, 2007, J NEUROSURG-SPINE, V6, P407, DOI 10.3171/spi.2007.6.5.407
   Kalevski S K, 2010, Asian J Neurosurg, V5, P54
   Karaaslan F, 2015, INT MED CASE REP J, V8, P7, DOI 10.2147/IMCRJ.S76214
   Kim JI, 2010, J SPINAL DISORD TECH, V23, P258, DOI 10.1097/BSD.0b013e3181a9452c
   Kurtz SM, 2012, J NEUROSURG-SPINE, V17, P342, DOI 10.3171/2012.7.SPINE12203
   Labler L, 2006, EUR SPINE J, V15, P1388, DOI 10.1007/s00586-006-0164-2
   Lee R, 2018, EUR SPINE J, V27, P2536, DOI 10.1007/s00586-018-5612-2
   Leitner L, 2018, EUR SPINE J, V27, P2529, DOI 10.1007/s00586-018-5592-2
   Mehbod AA, 2005, J SPINAL DISORD TECH, V18, P14, DOI 10.1097/01.bsd.0000133493.32503.d3
   Mendonca Derick A, 2006, Int Wound J, V3, P261, DOI 10.1111/j.1742-481X.2006.00266.x
   MIKAWA Y, 1994, SPINE, V19, P1169, DOI 10.1097/00007632-199405001-00015
   Mithani SK, 2006, NEUROSURG QUART, V16, P9, DOI 10.1097/01.wnq.0000203020.93797.ed
   Mithani SK, 2008, CONT SPINE SURG, V9, P1
   Morykwas MJ, 1997, ANN PLAS SURG, V38, P553, DOI 10.1097/00000637-199706000-00001
   Olsen MA, 2003, J NEUROSURG, V98, P149, DOI 10.3171/spi.2003.98.2.0149
   Ousey KJ, 2013, SPINE J, V13, P1393, DOI 10.1016/j.spinee.2013.06.040
   Pawar AY, 2016, ASIAN SPINE J, V10, P176, DOI 10.4184/asj.2016.10.1.176
   Picada R, 2000, J SPINAL DISORD, V13, P42, DOI 10.1097/00002517-200002000-00009
   Ploumis A, 2008, J SPINAL DISORD TECH, V21, P320, DOI 10.1097/BSD.0b013e318141f99d
   Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433
   Runkel N, 2011, INJURY, V42, pS1, DOI 10.1016/S0020-1383(11)00041-6
   Scuderi GJ, 2005, MED SCI MONITOR, V11, pCR64
   Smits AJ, 2017, EUR SPINE J, V26, P1525, DOI 10.1007/s00586-016-4883-8
   STOLKE D, 1989, SPINE, V14, P56, DOI 10.1097/00007632-198901000-00011
   Stromqvist F, 2010, EUR SPINE J, V19, P439, DOI 10.1007/s00586-009-1236-x
   Takai K, 2019, WORLD NEUROSURG, V121, pE700, DOI 10.1016/j.wneu.2018.09.193
   Tsubouchi N, 2018, EUR SPINE J, V27, P2481, DOI 10.1007/s00586-017-5294-1
   Voskuijl T, 2014, CLIN ORTHOP RELAT R, V472, P1638, DOI 10.1007/s11999-013-3394-8
   Wang JC, 1998, J BONE JOINT SURG AM, V80A, P1728, DOI 10.2106/00004623-199812000-00002
   Yao R, 2018, GLOB SPINE J, V8, p5S, DOI 10.1177/2192568218799056
   Yuan W, 2018, SPINE, V43, pE1089, DOI 10.1097/BRS.0000000000002615
   Yuan-Innes M J, 2001, Spine (Phila Pa 1976), V26, pE30
NR 43
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E624
EP E630
DI 10.1016/j.wneu.2019.10.146
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200076
PM 31678318
DA 2020-05-12
ER

PT J
AU Roa, JA
   Ortega-Gutierrez, S
   Martinez-Galdamez, M
   Maud, A
   Dabus, G
   Pazour, A
   Dandapat, S
   Arteaga, MS
   Fernandez, JG
   Paez-Granda, D
   Kalousek, V
   Pons, RB
   Mowla, A
   Duckwiler, G
   Szeder, V
   Jabbour, P
   Hasan, DM
   Samaniego, EA
AF Roa, Jorge A.
   Ortega-Gutierrez, Santiago
   Martinez-Galdamez, Mario
   Maud, Alberto
   Dabus, Guilherme
   Pazour, Avery
   Dandapat, Sudeepta
   Schuller Arteaga, Miguel
   Galvan Fernandez, Jorge
   Paez-Granda, Diego
   Kalousek, Vladimir
   Barranco Pons, Roger
   Mowla, Ashkan
   Duckwiler, Gary
   Szeder, Viktor
   Jabbour, Pascal
   Hasan, David M.
   Samaniego, Edgar A.
TI Transcirculation Approach for Endovascular Embolization of Intracranial
   Aneurysms, Arteriovenous Malformations, and Dural Fistulas: A
   Multicenter Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular device; Endovascular embolization; Endovascular
   intervention; Intracranial aneurysm; Neurointerventional technique;
   Transcirculation approach
ID NEUROFORM STENT DEPLOYMENT; ASSISTED COIL EMBOLIZATION; INFERIOR
   CEREBELLAR ARTERY; WIDE-NECKED ANEURYSMS; BASILAR APEX; PLACEMENT;
   DEVICE
AB BACKGROUND: Unfavorable anatomy can preclude traditional anterograde endovascular interventions. Transcirculation approaches, which consist of primary catheterization of a target artery from the contralateral side or opposite cerebral circulation, can provide alternative pathways for successful treatment of these patients. We aimed to assess the safety, efficacy, and outcomes of endovascular embolization through transcirculation approaches.
   METHODS: Nine centers provided retrospective data on patients who underwent transcirculation procedures for embolization of intracranial aneurysms (IAs), dural arteriovenous fistulas (dAVFs), and arteriovenous malformations (AVMs). Raymond-Roy Occlusion Classification (RROC) grades and degree of obliteration were used to evaluate treatment success. Minor/major complications and clinical/angiographic outcomes were also assessed. A review of the literature reporting patients who underwent transcirculation embolizations was also performed.
   RESULTS: Forty patients were included in the study (34 IAs, 3 AVMs, and 3 dAVFs). Most IAs (22/34, 64.7%) were treated electively. Three AVMs and 2 dAVFs presented ruptured. RROC grade I-II was achieved in 97% of IAs. All AVMs and dAVFs were completely obliterated. One patient developed a transient arterial thrombus that was successfully treated with intravenous tirofiban. The most common indications for a transcirculation approach were difficult access angle of the target lesion (42.5%) and occlusion of the parent artery (27.5%). The review of the literature pooled 152 IAs treated via transcirculation approaches. Most common locations were the basilar tip (27%), posterior inferior cerebellar artery (25%), and internal carotid artery (15.1%). The posterior communicating artery was crossed in 60 (39.5%), anterior communicating artery in 48 (31.6%), and vertebral artery in 37 (24.3%) patients. Primary coiling alone was performed in 22 (14.5%), stent-assisted coiling in 67 (44.1%), balloon-assisted coiling in 36 (23.7%), stent-assisted coiling + balloon-assisted coiling in 20 (13.2%) and flow diversion in 7 (4.6%) patients. After intervention, 142 (93.4%) IAs achieved successful RROC grades I-II. Two major complications (1.3%) leading to death were reported, both of which were intraprocedural aneurysmal ruptures with massive subarachnoid hemorrhage and herniation. After a mean angiographic follow-up of 11.3 months, only 6/108 (5.6%) IAs showed intrasaccular filling/recurrence.
   CONCLUSIONS: Transcirculation approaches seem to be safe and effective in the treatment of IAs, dAVFs, and AVMs. The most common indication for a transcirculation approach is the presence of a difficult angle to access the target lesion and occlusion of the parent artery.
C1 [Roa, Jorge A.; Ortega-Gutierrez, Santiago; Pazour, Avery; Dandapat, Sudeepta; Samaniego, Edgar A.] Univ Iowa Hosp & Clin, Dept Neurol, Iowa City, IA 52242 USA.
   [Roa, Jorge A.; Ortega-Gutierrez, Santiago; Hasan, David M.; Samaniego, Edgar A.] Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
   [Ortega-Gutierrez, Santiago; Samaniego, Edgar A.] Univ Iowa Hosp & Clin, Dept Radiol, Iowa City, IA 52242 USA.
   [Martinez-Galdamez, Mario; Schuller Arteaga, Miguel; Galvan Fernandez, Jorge] Hosp Clin Univ, Dept Intervent Neuroradiol & Endovasc Neurosurg, Valladolid, Spain.
   [Maud, Alberto] Texas Tech Univ Hlth Sci Ctr El Paso, Dept Neurol, El Paso, TX USA.
   [Dabus, Guilherme] Miami Cardiac & Vasc Inst, Miami, FL USA.
   [Paez-Granda, Diego] Virgen de la Arrixaca Univ Hosp, Dept Neurol, Murcia, Spain.
   [Kalousek, Vladimir] Univ Clin Hosp Ctr Sestre Milosrdnice, Zagreb, Croatia.
   [Barranco Pons, Roger] Dept Neurointervent Radiol, Barcelona, Spain.
   [Mowla, Ashkan; Duckwiler, Gary; Szeder, Viktor] Univ Calif Los Angeles, Div Intervent Neuroradiol, Dept Radiol, Los Angeles, CA USA.
   [Jabbour, Pascal] Thomas Jefferson Univ Hosp, Dept Neurosurg, Philadelphia, PA 19107 USA.
RP Samaniego, EA (reprint author), Univ Iowa Hosp & Clin, Dept Neurol, Iowa City, IA 52242 USA.; Samaniego, EA (reprint author), Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.; Samaniego, EA (reprint author), Univ Iowa Hosp & Clin, Dept Radiol, Iowa City, IA 52242 USA.
EM edgarsama@gmail.com
OI Dandapat, Sudeepta/0000-0003-3744-7845; Roa, Jorge/0000-0003-4987-8853
CR Agarwal N, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.11.FOCUS13331
   Ahmed ME, 2014, CAN J NEUROL SCI, V41, P193, DOI 10.1017/S0317167100016577
   Albuquerque FC, 2011, NEUROSURGERY, V68, P820, DOI 10.1227/NEU.0b013e3182077f17
   BENNDORF G, 2006, NEUROSURGERY, V58, DOI DOI 10.1227/01.NEU.0000205287.06739.E1
   Blackburn SL, 2013, J NEUROINTERV SURG, V5, P212, DOI 10.1136/neurintsurg-2012-010301
   Cho YD, 2013, NEURORADIOLOGY, V55, P733, DOI 10.1007/s00234-013-1163-8
   Cross DT, 2005, AM J NEURORADIOL, V26, P2578
   Fitzpatrick D, 2006, J VASC INTERV RADIOL, V17, P1687, DOI 10.1097/01.RVI.0000236820.37414.EF
   GURIAN JH, 1995, NEUROSURGERY, V37, P1216, DOI 10.1227/00006123-199512000-00025
   Heye S, 2015, J NEUROINTERV SURG, V7, P824, DOI 10.1136/neurintsurg-2014-011417
   Jeon Se-Il, 2012, J Cerebrovasc Endovasc Neurosurg, V14, P223, DOI 10.7461/jcen.2012.14.3.223
   Joshi KC, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2019.1.FocusVid.18444
   Kelly ME, 2007, NEUROSURGERY, V61, P249, DOI 10.1227/01.neu.0000303977.04128.3e
   Kitahara T, 2017, INTERV NEURORADIOL, V23, P117, DOI 10.1177/1591019916685080
   Kwon HJ, 2018, AM J NEURORADIOL, V39, P2297, DOI 10.3174/ajnr.A5875
   Moret J, 2000, AM J NEURORADIOL, V21, P262
   Mulder MJHL, 2015, INTERV NEURORADIOL, V21, P715, DOI 10.1177/1591019915609122
   Dang NV, 2014, INTERV NEURORADIOL, V20, P482, DOI 10.15274/NRJ-2014-10021
   Park Jeong Woo, 2016, J Cerebrovasc Endovasc Neurosurg, V18, P124, DOI 10.7461/jcen.2016.18.2.124
   Pride GL, 2009, J NEUROINTERV SURG, V1, P132, DOI 10.1136/jnis.2009.000182
   Roh HG, 2012, KOREAN J RADIOL, V13, P510, DOI 10.3348/kjr.2012.13.4.510
   Rotta MA, 2017, BRAZ NEUROSURG, V36, P128, DOI 10.1055/s-0035-1570116
   Samaniego EA, 2018, INTERV NEUROL, V7, P271, DOI 10.1159/000487545
   Samaniego EA, 2016, J NEUROINTERV SURG, V8, P1030, DOI 10.1136/neurintsurg-2015-012070
   Siddiqui MA, 2009, NEURORADIOLOGY, V51, P411, DOI 10.1007/s00234-009-0517-8
   Trivelato FP, 2017, CLIN NEURORADIOL, V27, P57, DOI 10.1007/s00062-015-0414-y
   Valle-Giler EP, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.2.FOCUS16485
   Zanaty M, 2019, WORLD NEUROSURG, V130, P201, DOI 10.1016/j.wneu.2019.07.027
NR 28
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E1015
EP E1027
DI 10.1016/j.wneu.2019.11.078
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200119
PM 31759150
DA 2020-05-12
ER

PT J
AU Dantas, FLR
   Dantas, F
   Caires, ACV
   Fonseca, GD
   Cariri, GA
   Botelho, RV
AF Rolemberg Dantas, Fernando Luiz
   Dantas, Francois
   Vieira Caires, Antonio Carlos
   Fonseca Filho, Gilberto de Almeida
   Cariri, Gustavo Agra
   Botelho, Ricardo Vieira
TI The Results of Microsurgery without Fusion for Lumbar Synovial Cysts: A
   Case Series of 50 Patients
SO WORLD NEUROSURGERY
LA English
DT Article
DE Fusion; Lumbar synovial cysts; Microsurgery; Spondylolisthesis
ID TERM-FOLLOW-UP; SURGICAL-TREATMENT; FACET JOINT; SPINE; MANAGEMENT;
   RESECTION; PATHOGENESIS; DIAGNOSIS; PREVALENCE; EXPERIENCE
AB OBJECTIVES: The treatments described for spinal synovial cysts range from percutaneous puncture to arthrodesis. There is a fear of postoperative instability after surgical resection of cysts, mainly when they are associated with degenerative spondylolisthesis. The objective of the article is to address the postoperative instability and recurrence rate of the symptoms after microsurgery without fusion.
   METHODS: We report a consecutive series of 50 patients with lumbar synovial cysts operated on with microsurgery without arthrodesis. Functional status was assessed postoperatively by the MacNab success scale and by self-assessment using the Weiner scale, the 36-item short-form health survey (SF-36), and the Oswestry scale. The presence of preoperative and postoperative instability was determined with static and dynamic lumbar spine X-rays before surgery and in the last follow-up at 2 years to evaluate the presence of spondylolisthesis before and after surgery. Facet inclination angle and stage of disc degeneration at the level of the cysts were evaluated. Disc degeneration was defined by the modified Pfirrmann grading system.
   RESULTS: The mean Oswestry index was 12 +/- 12.6% (median 8, 0-53). Based on the MacNab scale, 98% were considered excellent and good. The Weiner scale showed that low back pain was present in 16% of patients postoperatively. There was significant improvement of leg strength and pain in 96% and 94%, respectively. Only 3 patients were reoperated on with late fusion. Total surgical resection was obtained in all cases, with a late fusion rate of only 6% and no recurrence at the operated site.
   CONCLUSIONS: The microsurgical treatment for synovial cysts without arthrodesis presented excellent and good results in the majority of cases. It is necessary to carry out prospective randomized studies to clarify the best therapeutic options.
C1 [Rolemberg Dantas, Fernando Luiz; Dantas, Francois; Vieira Caires, Antonio Carlos; Fonseca Filho, Gilberto de Almeida; Cariri, Gustavo Agra] Biocor Inst, Dept Neurosurg, Belo Horizonte, MG, Brazil.
   [Rolemberg Dantas, Fernando Luiz; Botelho, Ricardo Vieira] IAMSPE, Postgrad Hlth Sci, Sao Paulo, Brazil.
   [Dantas, Francois] Fac Ciencias Med Minas Gerais, Feluma Postgrad, Belo Horizonte, MG, Brazil.
RP Dantas, FLR (reprint author), Biocor Inst, Dept Neurosurg, Belo Horizonte, MG, Brazil.; Dantas, FLR (reprint author), IAMSPE, Postgrad Hlth Sci, Sao Paulo, Brazil.
EM frdantas@uai.com.br
CR Amoretti N, 2012, EUR RADIOL, V22, P2836, DOI 10.1007/s00330-012-2533-z
   Apostolaki E, 2000, EUR RADIOL, V10, P615, DOI 10.1007/s003300050973
   Ayberk G, 2008, NEUROL MED-CHIR, V48, P298, DOI 10.2176/nmc.48.298
   Bahuleyan B, 2013, WORLD NEUROSURG, V79, P277, DOI 10.1016/j.wneu.2012.11.007
   Birch BD, 2016, WORLD NEUROSURG, V94, P188, DOI 10.1016/j.wneu.2016.06.125
   Boviatsis EJ, 2008, EUR SPINE J, V17, P831, DOI 10.1007/s00586-007-0563-z
   Bruder M, 2017, J NEUROSURG-SPINE, V27, P256, DOI 10.3171/2016.12.SPINE16756
   Bydon A, 2010, SPINE J, V10, P820, DOI 10.1016/j.spinee.2010.04.010
   Campbell R, 2018, WORLD NEUROSURG, V119, pE502, DOI 10.1016/j.wneu.2018.07.190
   Campbell RJ, 2017, WORLD NEUROSURG, V98, P492, DOI 10.1016/j.wneu.2016.11.044
   Deinsberger R, 2006, J SPINAL DISORD TECH, V19, P155, DOI 10.1097/01.bsd.0000188660.31212.83
   Denis DR, 2016, INT J SPINE SURG, V10, DOI 10.14444/3037
   Domenicucci M, 2017, WORLD J ORTHOP, V8, P697, DOI 10.5312/wjo.v8.i9.697
   Doyle AJ, 2004, SPINE, V29, P874, DOI 10.1097/00007632-200404150-00010
   Epstein NE, 2012, SURG NEUROL INT S3, V3, P157
   Ewald C, 2005, ZBL NEUROCHIR, V66, P147, DOI 10.1055/s-2005-836475
   EYSTER EF, 1989, NEUROSURGERY, V24, P112
   Fairbank J C, 1980, Physiotherapy, V66, P271
   Ganau M, 2013, NEUROL MED-CHIR, V53, P95, DOI 10.2176/nmc.53.95
   Griffith JF, 2007, SPINE, V32, pE708, DOI 10.1097/BRS.0b013e31815a59a0
   Guo MC, 2019, WORLD NEUROSURG, V130, pE680, DOI 10.1016/j.wneu.2019.06.188
   Gupta A, 2010, SPINE J, V10, P817, DOI 10.1016/j.spinee.2010.05.010
   HEARY RF, 1992, NEUROSURGERY, V30, P415, DOI 10.1227/00006123-199203000-00018
   Houten JK, 2003, J NEUROSURG, V99, P235, DOI 10.3171/spi.2003.99.2.0235
   Howington JU, 1999, J NEUROSURG, V91, P193, DOI 10.3171/spi.1999.91.2.0193
   Huang AJ, 2017, SKELETAL RADIOL, V46, P75, DOI 10.1007/s00256-016-2513-5
   James A, 2012, J SPINAL DISORD TECH, V25, pE13, DOI 10.1097/BSD.0b013e31822ac4e5
   Janssen SJ, 2018, CLIN SPINE SURG, V31, pE296, DOI 10.1097/BSD.0000000000000648
   Kaufmann AM, 1996, CAN J NEUROL SCI, V23, P227, DOI 10.1017/S0317167100038579
   Knafo S, 2015, J SPINAL DISORD TECH, V28, P211, DOI 10.1097/BSD.0b013e31827179c8
   Komp M, 2014, SURG INNOV, V21, P605, DOI 10.1177/1553350614525668
   Kulkarni AG, 2017, GLOB SPINE J, V7, P629, DOI 10.1177/2192568217700103
   KURZ LT, 1985, J BONE JOINT SURG AM, V67A, P865, DOI 10.2106/00004623-198567060-00006
   Kusakabe T, 2006, J NEUROSURG-SPINE, V5, P398, DOI 10.3171/spi.2006.5.5.398
   LEMISH W, 1989, SPINE, V14, P1378, DOI 10.1097/00007632-198912000-00016
   MACNAB I, 1971, J BONE JOINT SURG AM, VA 53, P891, DOI 10.2106/00004623-197153050-00004
   Metellus P, 2006, ACTA NEUROCHIR, V148, P47, DOI 10.1007/s00701-005-0650-z
   Meyerding HW, 1932, SURG GYNECOL OBSTET, V54, P371
   Oertel JM, 2017, WORLD NEUROSURG, V103, P122, DOI 10.1016/j.wneu.2017.02.075
   ONOFRIO BM, 1988, NEUROSURGERY, V22, P642, DOI 10.1227/00006123-198804000-00004
   Pulhorn H, 2012, BRIT J NEUROSURG, V26, P123, DOI 10.3109/02688697.2011.595847
   Ramhmdani S, 2019, WORLD NEUROSURG, V122, pE1059, DOI 10.1016/j.wneu.2018.10.228
   Rhee J, 2012, J NEUROSURG-SPINE, V17, P453, DOI 10.3171/2012.8.SPINE12101
   Sandhu FA, 2004, NEUROSURGERY, V54, P107, DOI 10.1227/01.NEU.0000097269.79994.2F
   Scholz C, 2017, CLIN NEUROL NEUROSUR, V153, P35, DOI 10.1016/j.clineuro.2016.12.008
   Shah Rinoo V, 2003, Spine J, V3, P479, DOI 10.1016/S1529-9430(03)00148-7
   Shuang F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111695
   Campa-Santamarina JT, 2015, CUREUS, V7, DOI 10.7759/cureus.362
   Vergara P, 2017, WORLD NEUROSURG, V108, P555, DOI 10.1016/j.wneu.2017.09.039
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Weiner BK, 2007, J ORTHOP SURG RES, V2, P2, DOI DOI 10.1186/1749-799X-2-5
   Wilby MJ, 2009, SPINE, V34, P2518, DOI 10.1097/BRS.0b013e3181b22bd0
   Xu RS, 2010, SPINE, V35, P1044, DOI 10.1097/BRS.0b013e3181bdafed
   YARDE WL, 1995, SURG NEUROL, V43, P459, DOI 10.1016/0090-3019(95)80090-4
NR 54
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E783
EP E789
DI 10.1016/j.wneu.2019.11.003
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200091
PM 31726093
DA 2020-05-12
ER

PT J
AU Carabias, CS
   Gomez, PA
   Panero, I
   Eiriz, C
   Castano-Leon, AM
   Egea, J
   Lagares, A
AF Sanchez Carabias, Cristina
   Gomez, Pedro A.
   Panero, Irene
   Eiriz, Carla
   Maria Castano-Leon, Ana
   Egea, Javier
   Lagares, Alfonso
CA I 12 Neurotraumatology Grp Collabo
TI Chitinase-3-Like Protein 1, Serum Amyloid A1, C-Reactive Protein, and
   Procalcitonin Are Promising Biomarkers for Intracranial Severity
   Assessment of Traumatic Brain Injury: Relationship with Glasgow Coma
   Scale and Computed Tomography Volumetry
SO WORLD NEUROSURGERY
LA English
DT Article
DE Biomarkers; CT volumetry; Glasgow Coma Scale; Intracranial hemorrhage;
   Traumatic brain injury
ID FIBRILLARY ACIDIC PROTEIN; NEURON-SPECIFIC ENOLASE; INTRACEREBRAL
   HEMORRHAGE; NEUROBIOCHEMICAL MARKERS; PROGNOSTIC VALUE; SUBARACHNOID
   HEMORRHAGE; CEREBRAL-ISCHEMIA; DIAGNOSTIC MARKER; TEMPORAL PROFILE;
   PLASMA-LEVELS
AB OBJECTIVE: The volume and location of intracranial hematomas are well-known prognostic factors for traumatic brain injury. The aim of this study was to determine the relationship of serum biomarkers sloop, glial fibrillary acidic protein, neuron-specific enolase, total tau, phosphorylated neurofilament heavy chain, serum amyloid A1 (SAA1), C-reactive protein, procalcitonin (PCT), and chitinase-3-like protein 1 (YKL-40) with traumatic brain injury severity and the amount and location of hemorrhagic traumatic lesions.
   METHODS: A prospective observational cohort of 115 patients with a Glasgow Coma Scale (GCS) score of 3-15 were evaluated. Intracranial lesion volume was measured from the semiautomatic segmentation of hematoma on computed tomography using Analyze software. The establishment of possible biomarker cutoff points for intracranial lesion detection was estimated using the Youden Index (J) obtained from the area under the receiver operating characteristic curve.
   RESULTS: SAA1, YKL-40, PCT, and S100 beta showed the most robust association with level of consciousness, both with total GCS and motor score. Biomarkers significantly correlated with volumetric measurements of subdural hematoma, traumatic subarachnoid hemorrhage, intraparenchymal hemorrhage, intraventricular hemorrhage, and total amount of bleeding. The type of intracranial hemorrhage was associated with various release patterns of neurobiochemical markers.
   CONCLUSIONS: YKL-40, SAA1, C-reactive protein, and PCT combined with S100 beta were the most promising biomarkers to determine the presence, location, and extent of traumatic intracranial lesions. Combination of biomarkers further increased the discriminatory capacity for the detection of intracranial bleeding.
C1 [Sanchez Carabias, Cristina; Lagares, Alfonso] Hosp 12 Octubre I 12, Inst Invest, Neurotraumatol & Subarachnoid Hemorrhage Res Unit, Madrid, Spain.
   [Gomez, Pedro A.; Panero, Irene; Eiriz, Carla; Maria Castano-Leon, Ana; Lagares, Alfonso] Hosp Univ 12 Octubre, Dept Neurosurg, Madrid, Spain.
   [Gomez, Pedro A.; Panero, Irene; Eiriz, Carla; Maria Castano-Leon, Ana; Lagares, Alfonso] Univ Complutense Madrid, Fac Med, Dept Surg, Madrid, Spain.
   [Egea, Javier] Univ La Princesa, Inst Invest Sanitaria Hosp, Mol Neuroinflammat & Neuronal Plastic Res Lab, Hosp Univ Santa Cristina,Res Unit, Madrid, Spain.
   [I 12 Neurotraumatology Grp Collabo] Hosp Univ 12 Octubre, Dept Intens Care Med, Madrid, Spain.
RP Carabias, CS (reprint author), Hosp 12 Octubre I 12, Inst Invest, Neurotraumatol & Subarachnoid Hemorrhage Res Unit, Madrid, Spain.
EM csanchezcarabias@gmail.com
RI ; Gomez, Pedro/E-2411-2014
OI Lagares, Alfonso/0000-0003-3996-0554; /0000-0002-3321-983X;
   Castano-Leon, Ana M/0000-0002-7918-5049; Gomez,
   Pedro/0000-0002-4185-5238
FU Fondo de Investigaciones Sanitarias (FIS) (ISCIII/FEDER) [PI18/01387,
   PI14/01457]; Programa Miguel Servet [CP14/00008]; Fundacion Mutua
   MadrilenaInstituto de Salud Carlos III [PI16/00735]
FX This work was supported by grants from Fondo de Investigaciones
   Sanitarias (FIS) (ISCIII/FEDER) (grant numbers PI18/01387, PI14/01457)
   to A.L.; Programa Miguel Servet (grant number CP14/00008); and Fundacion
   Mutua Madrilena (grant number PI16/00735) to J.E.
CR Al Nimer F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132177
   Aly H, 2011, J PERINATOL, V31, P263, DOI 10.1038/jp.2010.130
   Anada RP, 2018, ELECTROPHORESIS, V39, P2308, DOI 10.1002/elps.201700407
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653
   Bogoslovsky T, 2017, J NEUROTRAUM, V34, P66, DOI 10.1089/neu.2015.4333
   Bonneh-Barkay D, 2010, J NEUROTRAUM, V27, P1215, DOI 10.1089/neu.2010.1310
   Brea D, 2009, ATHEROSCLEROSIS, V205, P561, DOI 10.1016/j.atherosclerosis.2008.12.028
   CHESNUT RM, 1994, NEUROSURGERY, V34, P840, DOI 10.1227/00006123-199405000-00008
   De Vos A, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0945-8
   Deng SX, 2013, BMC ANESTHESIOL, V13, DOI 10.1186/1471-2253-13-48
   Deng WJ, 2015, CELL MOL NEUROBIOL, V35, P355, DOI 10.1007/s10571-014-0131-0
   Di Napoli M, 2014, STROKE, V45, P59, DOI 10.1161/STROKEAHA.113.001721
   Di Napoli M, 2012, NEUROLOGY, V79, P690, DOI 10.1212/WNL.0b013e318264e3be
   Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F
   Fassbender K, 1997, J NEUROL SCI, V148, P101, DOI 10.1016/S0022-510X(96)05351-8
   Foerch C, 2012, CLIN CHEM, V58, P237, DOI 10.1373/clinchem.2011.172676
   Fountas KN, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS08311
   Fullerton HJ, 2016, STROKE, V47, P2221, DOI 10.1161/STROKEAHA.116.013719
   Gao WM, 2014, PEDIATR RES, V76, P280, DOI 10.1038/pr.2014.86
   Gatson JW, 2014, J NEUROSURG, V121, P1232, DOI 10.3171/2014.7.JNS132474
   Han Yong Y, 2002, Pediatr Crit Care Med, V3, P39, DOI 10.1097/00130478-200201000-00010
   Hergenroeder G, 2008, J NEUROTRAUM, V25, P79, DOI 10.1089/neu.2007.0386
   Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113
   Hu YY, 2010, SHOCK, V33, P134, DOI 10.1097/SHK.0b013e3181ad5c88
   Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558
   Jiang YX, 2014, CLIN BIOCHEM, V47, P302, DOI 10.1016/j.clinbiochem.2014.09.015
   Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008
   Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4
   Lagares A, 2015, NEUROSURGERY, V77, P898, DOI 10.1227/NEU.0000000000000927
   Li GZ, 2018, NEUROSCI LETT, V662, P242, DOI 10.1016/j.neulet.2017.10.040
   Liliang PC, 2010, J SURG RES, V160, P302, DOI 10.1016/j.jss.2008.12.022
   Lopponen P, 2014, J NEUROSURG, V121, P1374, DOI 10.3171/2014.7.JNS132678
   Luger S, 2017, CLIN CHEM, V63, P377, DOI 10.1373/clinchem.2016.263335
   Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d
   MABE H, 1991, SURG NEUROL, V36, P170, DOI 10.1016/0090-3019(91)90108-L
   Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286
   Majdan M, 2015, J NEUROTRAUM, V32, P101, DOI 10.1089/neu.2014.3438
   Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029
   Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363
   Naghibi T, 2017, J CLIN DIAGN RES, V11, pPC6, DOI 10.7860/JCDR/2017/19132.9198
   Nylen K, 2007, STROKE, V38, P1489, DOI 10.1161/STROKEAHA.106.478362
   O'Connor E, 2004, ANAESTH INTENS CARE, V32, P465, DOI 10.1177/0310057X0403200402
   Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883
   Olivecrona Z, 2015, BRAIN INJURY, V29, P446, DOI 10.3109/02699052.2014.989403
   Park HK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032847
   Petzold A, 2011, BRAIN, V134, P464, DOI 10.1093/brain/awq360
   Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297
   Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180
   Rothoerl RD, 2006, J NEUROSURG ANESTH, V18, P68, DOI 10.1097/01.ana.0000181693.30750.af
   Sauerland S, 2003, J NEUROTRAUM, V20, P953, DOI 10.1089/089771503770195803
   Shahim P, 2017, NEUROLOGY, V88, P1400, DOI 10.1212/WNL.0000000000003816
   SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367
   Sogut O, 2010, J INT MED RES, V38, P1708, DOI 10.1177/147323001003800516
   Stelzl T, 1995, Eur J Emerg Med, V2, P24, DOI 10.1097/00063110-199503000-00006
   TEASDALE G, 1974, LANCET, V2, P81
   Tian D, 2015, NEUROREPORT, V26, P33, DOI 10.1097/WNR.0000000000000298
   Unden J, 2005, BRIT J NEUROSURG, V19, P43, DOI 10.1080/02688690500089381
   Vos PE, 2006, EUR J NEUROL, V13, P632, DOI 10.1111/j.1468-1331.2006.01332.x
   Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2
   Wunderlich MT, 2006, CLIN NEUROL NEUROSUR, V108, P558, DOI 10.1016/j.clineuro.2005.12.006
   Wunderlich MT, 2004, J NEUROL SCI, V227, P49, DOI 10.1016/j.jns.2004.08.005
   Yuh EL, 2012, J NEUROTRAUM, V29, P735, DOI 10.1089/neu.2011.2008
   Zanier ER, 2011, J NEUROL NEUROSUR PS, V82, P157, DOI 10.1136/jnnp.2009.177667
   Zhang LJ, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-130
   Zurek J, 2011, BRAIN INJURY, V25, P221, DOI 10.3109/02699052.2010.541895
NR 66
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E120
EP E143
DI 10.1016/j.wneu.2019.09.143
PG 24
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200017
PM 31606503
DA 2020-05-12
ER

PT J
AU Saraceno, G
   Agosti, E
   Qiu, J
   Buffoli, B
   Ferrari, M
   Raffetti, E
   Belotti, F
   Ravanelli, M
   Mattavelli, D
   Schreiber, A
   Hirtler, L
   Rodella, LF
   Maroldi, R
   Nicolai, P
   Gentili, F
   Kucharczyk, W
   Fontanella, MM
   Doglietto, F
AF Saraceno, Giorgio
   Agosti, Edoardo
   Qiu, Jimmy
   Buffoli, Barbara
   Ferrari, Marco
   Raffetti, Elena
   Belotti, Francesco
   Ravanelli, Marco
   Mattavelli, Davide
   Schreiber, Alberto
   Hirtler, Lena
   Rodella, Luigi F.
   Maroldi, Roberto
   Nicolai, Piero
   Gentili, Fred
   Kucharczyk, Walter
   Fontanella, Marco M.
   Doglietto, Francesco
TI Quantitative Anatomical Comparison of Anterior, Anterolateral and
   Lateral, Microsurgical and Endoscopic Approaches to the Middle Cranial
   Fossa
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopy; Middle cranial fossa; Quantification; Transcranial;
   Transnasal; Transorbital
ID PTERIONAL CRANIOTOMY; SURGICAL EXPOSURE; TRIGEMINAL NERVE;
   QUANTIFICATION; SEGMENT
AB OBJECTIVE: To quantitatively compare different microsurgical and endoscopic approaches to the middle cranial fossa in a preclinical setting with a novel, computer-based research method.
   METHODS: Different approaches were performed bilaterally in 5 head and neck specimens that underwent high-resolution computed tomography scans: 5 transcranial anterolateral (supraorbital, mini-pterional, pterional, pterional-transzygomatic, fronto-temporal-orbito-zygomatic) without and with anterior clinoidectomy; 2 trans- cranial lateral (subtemporal and subtemporal- transzygomatic); 2 endoscopic transnasal (transpterygoid, transpterygoid to infratemporal fossa); 2 endoscopic transorbital (superior eyelid and inferolateral), and endoscopic transmaxillary. A dedicated navigation system was used to quantify surgical working volumes and exposure of different areas of the middle cranial fossa (Approach-Viewer, part of GTx-Eyes II, University Health Network, Toronto, Canada). Statistical analysis was performed using a mixed linear model with bootstrap resampling.
   RESULTS: Endoscopic transnasal and fronto-temporal-orbito-zygomatic approaches with anterior clinoidectomy showed the largest surgical volumes. Endoscopic approaches allowed a wider exposure of medial anatomical surfaces (e.g., the petrous apex) compared with transcranial ones. Transcranial approaches with larger craniotomies allowed the widest exposure of superomedial anatomical structures (e.g., roof of cavernous sinus). The resection of the zygomatic arch allowed exposure of more medial surfaces with an inferior to superior trajectory.
   CONCLUSIONS: This study implemented a novel neuronavigation-based research method to quantitatively compare different approaches to the middle cranial fossa; its results might guide, after consideration of clinical implications, the choice of the neurosurgical approach to different areas of this complex skull base region.
C1 [Saraceno, Giorgio; Agosti, Edoardo; Belotti, Francesco; Fontanella, Marco M.; Doglietto, Francesco] Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Neurosurg, Brescia, Italy.
   [Ferrari, Marco; Mattavelli, Davide; Schreiber, Alberto; Nicolai, Piero] Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Otorhinolaryngol, Brescia, Italy.
   [Ravanelli, Marco; Maroldi, Roberto] Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Radiol, Brescia, Italy.
   [Qiu, Jimmy] Univ Hlth Network, TECHNA Inst, Toronto, ON, Canada.
   [Buffoli, Barbara; Rodella, Luigi F.] Univ Brescia, Dept Clin & Expt Sci, Sect Anat & Physiopathol, Brescia, Italy.
   [Raffetti, Elena] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden.
   [Hirtler, Lena] Med Univ Vienna, Ctr Anat & Cell Biol, Div Anat, Vienna, Austria.
   [Gentili, Fred] Univ Toronto, Toronto Western Hosp, Dept Neurosurg, Toronto, ON, Canada.
   [Kucharczyk, Walter] Univ Hlth Network, Dept Med Imaging, Div Neuroradiol, Toronto, ON, Canada.
RP Doglietto, F (reprint author), Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Neurosurg, Brescia, Italy.
EM francesco.doglietto@unibs.it
RI Ferrari, Marco/AAC-7179-2019; Saraceno, Giorgio/AAL-3322-2020; Buffoli,
   Barbara/E-9934-2010
OI Ferrari, Marco/0000-0002-4023-0121; Saraceno,
   Giorgio/0000-0002-6711-0824; Buffoli, Barbara/0000-0002-8531-7730;
   Schreiber, Alberto/0000-0002-1580-3928; Raffetti,
   Elena/0000-0001-8742-3986; Belotti, Francesco/0000-0003-4293-9668
CR Almeida JP, 2018, J NEUROSURG, V128, P1885, DOI 10.3171/2017.3.JNS163110
   Belotti F, 2018, WORLD NEUROSURG, V109, pE281, DOI 10.1016/j.wneu.2017.09.165
   Campero A, 2010, J CLIN NEUROSCI, V17, P1428, DOI 10.1016/j.jocn.2010.03.023
   Cinalli G, 2005, EXPERT REV MED DEVIC, V2, P351, DOI 10.1586/17434440.2.3.351
   Dallan I, 2015, WORLD NEUROSURG, V84, P97, DOI 10.1016/j.wneu.2015.02.034
   Daly MJ, 2011, PROC SPIE, V7964, DOI 10.1117/12.878976
   DeMonte F, 2011, AL MEFTYS MENINGIOMA
   Doglietto F, 2016, NEUROSURG REV, V39, P357, DOI 10.1007/s10143-015-0694-3
   Doglietto Francesco, 2019, Acta Neurochir Suppl, V125, P37, DOI 10.1007/978-3-319-62515-7_6
   Doglietto F, 2018, WORLD NEUROSURG, V113, pE659, DOI 10.1016/j.wneu.2018.02.118
   Doglietto Francesco, 2017, World J Methodol, V7, P139, DOI 10.5662/wjm.v7.i4.139
   DOLENC VV, 1994, ACTA NEUROCHIR, V130, P55, DOI 10.1007/BF01405503
   Ferrari M, 2019, HEAD NECK-J SCI SPEC, V41, P642, DOI 10.1002/hed.25378
   Ferrari M, 2016, WORLD NEUROSURG, V90, P403, DOI 10.1016/j.wneu.2016.03.017
   Figueiredo EG, 2007, NEUROSURGERY, V61, P256, DOI 10.1227/01.neu.0000303978.11752.45
   Figueiredo EG, 2006, NEUROSURGERY, V59, P212, DOI 10.1227/01.NEU.0000223365.55701.F2
   Jagersberg M, 2017, WORLD NEUROSURG, V101, P710, DOI 10.1016/j.wneu.2017.02.011
   Jeon C, 2019, J NEUROSURG, V131, P1126, DOI 10.3171/2018.6.JNS181099
   Kassam AB, 2009, NEUROSURGERY, V64, pS71, DOI 10.1227/01.NEU.0000335162.36862.54
   Lehmberg J, 2014, ACTA NEUROCHIR, V156, P415, DOI 10.1007/s00701-013-1960-1
   Locateli D, 2016, J NEUROSURG SCI, V60, P514
   McCulloch P, 2009, LANCET, V374, P1105, DOI 10.1016/S0140-6736(09)61116-8
   Muto J, 2010, NEUROSURGERY, V67, P291, DOI 10.1227/01.NEU.0000382967.84940.52
   Osawa S, 2008, NEUROSURGERY, V63, P210, DOI 10.1227/01.NEU.0000327037.75571.10
   Oyama K, 2017, NEUROL MED-CHIR, V57, P534, DOI 10.2176/nmc.ra.2017-0039
   Paturet G, 1951, TRAITE ANATOMIE HUMA
   PERNECZKY A, 1999, KEYHOLE CONCEPT NEUR
   Phuong HL, 2004, J CLIN NEUROSCI, V11, P283, DOI 10.1016/j.jocn.2003.08.005
   Ramakrishna R, 2016, J CLIN NEUROSCI, V24, P99, DOI 10.1016/j.jocn.2015.07.021
   Raza SM, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.7.FOCUS14341
   Rhoton AL, 2002, NEUROSURGERY, V51, pS303, DOI 10.1227/01.NEU.0000028329.38986.47
   Rhoton AL, 2002, NEUROSURGERY, V51, pS335, DOI 10.1227/01.NEU.0000028680.51299.00
   Rhoton AL, 2002, NEUROSURGERY, V51, pS375, DOI 10.1227/01.NEU.0000028833.01529.E7
   Rhoton AL, 2000, NEUROSURGERY, V47, pS29, DOI 10.1097/00006123-200009001-00010
   RUBINSTEIN D, 1994, RADIOLOGY, V193, P155, DOI 10.1148/radiology.193.1.8090884
   Rychen J, 2018, WORLD NEUROSURG, V113, P163, DOI 10.1016/j.wneu.2018.02.016
   Schreiber A, 2017, WORLD NEUROSURG, V100, P44, DOI 10.1016/j.wneu.2016.12.094
   Schreiber A, 2017, INT FORUM ALLERGY RH, V7, P199, DOI [10.1002/alr.21857, 10.1002/alr.22001]
   Spiriev T, 2016, J NEUROL SURG PART B, V77, P199, DOI 10.1055/s-0035-1564590
   Tang CT, 2013, NEUROSURG REV, V36, P403, DOI 10.1007/s10143-012-0447-5
   Truong HQ, 2019, J NEUROSURG, V130, P227, DOI 10.3171/2017.8.JNS171308
   Tubbs RS, 2007, CLIN ANAT, V20, P131, DOI 10.1002/ca.20255
   Tullos HJ, 2018, WORLD NEUROSURG, V117, pE637, DOI 10.1016/j.wneu.2018.06.103
   Ustun ME, 2006, SKULL BASE-INTERD AP, V16, P39, DOI 10.1055/s-2006-931622
   van Furth WR, 2006, NEUROSURGERY, V58, P103, DOI 10.1227/01.NEU.0000197050.70397.C1
   Van Rompaey J, 2014, EUR ARCH OTO-RHINO-L, V271, P787, DOI 10.1007/s00405-013-2581-2
   Van Rompaey J, 2013, J NEUROL SURG PART B, V74, P331, DOI 10.1055/s-0033-1342989
   Welling LC, 2015, J NEUROSURG, V122, P1012, DOI 10.3171/2014.11.JNS146
   Yasargil M. G., 1984, MICRONEUROSURGERY
   Zoli M, 2018, ACTA NEUROCHIR, V160, P2349, DOI 10.1007/s00701-018-3708-4
NR 50
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E682
EP E730
DI 10.1016/j.wneu.2019.10.178
PG 49
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200084
PM 31731015
DA 2020-05-12
ER

PT J
AU Sarmento, SA
   Rabelo, NN
   Figueiredo, EG
AF Sarmento, Stenio Abrantes
   Rabelo, Nicollas Nunes
   Figueiredo, Eberval Gadelha
TI Minimally Invasive Technique (Nummular Craniotomy) for Mesial Temporal
   Lobe Epilepsy: A Comparison of 2 Approaches
SO WORLD NEUROSURGERY
LA English
DT Article
DE Epilepsy surgery techniques; Keyhole approach; Mesial temporal lobe
   epilepsy; Nummular craniotomy; Seizure outcome
ID SELECTIVE AMYGDALOHIPPOCAMPECTOMY; SURGICAL-TREATMENT; SURGERY; TRIAL
AB OBJECTIVE: To describe our series of a minimally invasive technique using a small scalp incision and keyhole craniotomy for the removal of mesial temporal lobe structures through a transcortical approach in patients with medically intractable mesial temporal lobe epilepsy (MILE). Studies that directly compare the clinical outcomes between minimally invasive and conventional techniques are scarce, and this information is lacking in the literature.
   METHODS: The study enrolled 73 consecutive patients with refractory MILE and unilateral hippocampal sclerosis; 30 patients were operated on with standard frontotemporal craniotomy between 2010 and 2013 and 43 patients were operated with a minimally invasive craniotomy (nummular craniotomy) between 2014 and 2016. The preoperative evaluation included clinical history, physical examination, video-electroencephalography, neuropsychologic assessment, and magnetic resonance imaging including thinsection coronal sequences.
   RESULTS: There were no deaths in either group. Postoperative complications in the standard frontotemporal craniotomy group included temporal muscle atrophy (n = 4; 13.3%), cerebrospinal fluid leakage (n = 1; 3.3%), and wound infection (n = 1; 3.3%). No complications were observed in the keyhole craniotomy group. There was no between-group difference in postoperative seizure control. The mean Engel class I seizure-free outcome was 90.4% in the standard frontotemporal craniotomy group and 90.7% in the nummular craniotomy group (P > 0.05). Lengths of hospitalization (2.81 vs. 4.37 days, P< 0.001) and operative time (85.79 vs. 142.73 minutes, P < 0.001) were lower in the keyhole than in the standard frontotemporal craniotomy group, respectively.
   CONCLUSIONS: The nummular technique was associated with faster recovery, early hospital discharge, and fewer complications than the standard technique. No differences were observed in postoperative seizure control. Keyhole craniotomy is a safe, easy, and effective treatment option for medically intractable MTLE.
C1 [Sarmento, Stenio Abrantes] Inst Cerebro, Joao Pessoa, Paraiba, Brazil.
   [Sarmento, Stenio Abrantes] Epilepsy Surg Program, Joao Pessoa, Paraiba, Brazil.
   [Sarmento, Stenio Abrantes] Nova Esperanca Med Sch, Joao Pessoa, Paraiba, Brazil.
   [Sarmento, Stenio Abrantes] Univ Fed Paraiba, Joao Pessoa, Paraiba, Brazil.
   [Rabelo, Nicollas Nunes; Figueiredo, Eberval Gadelha] Univ Sao Paulo, Dept Neurosurg, Sao Paulo, Brazil.
RP Figueiredo, EG (reprint author), Univ Sao Paulo, Dept Neurosurg, Sao Paulo, Brazil.
EM ebgadelha@yahoo.com
RI Figueiredo, Eberval Gadelha/H-3488-2012
CR Vanegas MAA, 2017, EPILEPSIA, V58, P10, DOI 10.1111/epi.13684
   Binder DK, 2006, CHILD NERV SYST, V22, P960, DOI 10.1007/s00381-006-0131-6
   Boling W, 2010, J CLIN NEUROSCI, V17, P1180, DOI 10.1016/j.jocn.2010.01.030
   Flores JAC, 2017, ARQ NEURO-PSIQUIAT, V75, P801, DOI [10.1590/0004-282X20170141, 10.1590/0004-282x20170141]
   Duckworth EAM, 2008, NEUROSURGERY, V63, P156
   Figueiredo EG, 2010, NEUROSURGERY, V66, P45, DOI 10.1227/01.NEU.0000350981.36623.8B
   HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x
   Hori T, 2007, J NEUROSURG, V106, P134, DOI 10.3171/jns.2007.106.1.134
   Kehlet H, 2008, ANN SURG, V248, P189, DOI 10.1097/SLA.0b013e31817f2c1a
   Kucukyuruk Baris, 2012, Epilepsy Res Treat, V2012, P769825, DOI 10.1155/2012/769825
   Little AS, 2009, J NEUROSURG, V111, P1263, DOI 10.3171/2008.10.17673
   Lutz MT, 2004, EPILEPSIA, V45, P809, DOI 10.1111/j.0013-9580.2004.54003.x
   Miyagi Y, 2003, NEUROSURGERY, V52, P1117, DOI 10.1227/01.NEU.0000058464.75451.C1
   Niemeyer P., 1958, TEMPORAL LOBE EPILEP, P461
   Olivier A, 2000, CAN J NEUROL SCI, V27, pS68, DOI 10.1017/S031716710000069X
   Olivier A, 2012, TECHNIQUES IN EPILEPSY SURGERY: THE MNI APPROACH, P97
   Park TS, 1996, J NEUROSURG, V85, P1172, DOI 10.3171/jns.1996.85.6.1172
   SHIMIZU H, 1989, NEUROSURGERY, V25, P798, DOI 10.1227/00006123-198911000-00017
   SPENCER DD, 1992, EPILEPSY SURGERY, P533
   Wen HT, 1999, NEUROSURGERY, V45, P549, DOI 10.1097/00006123-199909000-00028
   Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501
   WIESER HG, 1982, SURG NEUROL, V17, P445, DOI 10.1016/S0090-3019(82)80016-5
   Yang PF, 2016, J NEUROSURG, V125, P67, DOI 10.3171/2015.6.JNS1583
   Yang PF, 2016, NEUROSURG REV, V39, P99, DOI 10.1007/s10143-015-0657-8
   Yasargil M G, 1985, Adv Tech Stand Neurosurg, V12, P93
   Yasargil MG, 2010, J NEUROSURG, V112, P168, DOI 10.3171/2008.12.JNS081112
NR 26
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E636
EP E641
DI 10.1016/j.wneu.2019.10.160
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200078
PM 31689571
DA 2020-05-12
ER

PT J
AU Schuss, P
   Hadjiathanasiou, A
   Ilic, I
   Brandecker, S
   Guresir, A
   Vatter, H
   Guresir, E
AF Schuss, Patrick
   Hadjiathanasiou, Alexis
   Ilic, Inja
   Brandecker, Simon
   Gueresir, Agi
   Vatter, Hartmut
   Gueresir, Erdem
TI Risk of Rebleeding in Patients Suffering From Ruptured Brain
   Arteriovenous Malformations Undergoing Subacute Treatment: A
   Single-Center Series and Systematic Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brain arteriovenous malformation; Rebleeding; Subacute management
ID MANAGEMENT; HEMORRHAGE
AB INTRODUCTION: The optimal timing for treatment of ruptured brain arteriovenous malformation (BAVM) is still controversial. The present study aims to determine safety of subacute BAVM management in clinically stable patients by identifying the rate of rebleeding.
   METHODS: Patients presenting from 2000 to 2018 with ruptured BAVM who were scheduled for BAVM treatment at least 4 weeks after initial hemorrhage were included in the present study. After neurological rehabilitation of the patient and decreased hemorrhage-induced brain swelling, subacute treatment for the ruptured BAVM was carried out. Primary outcome of the present series was defined as treatment failure resulting from rehemorrhage caused by the ruptured BAVM in patients previously labeled eligible for subacute BAVM treatment. Additionally, we performed a systematic review of the contemporary peer-reviewed literature concerning treatment strategy in patients with ruptured BAVM.
   RESULTS: Fifty-five patients suffering from ruptured BAVM were considered eligible for subacute BAVM treatment at our institution. No patient suffered from early rebleeding before definitive BAVM treatment in our institutional group. Our own patient data were then pooled with data from the literature, resulting in 166 patients suffering from ruptured BAVM who underwent subacute BAVM treatment. Of these, 1 patient (0.6%) suffered from rehemorrhage during the recovery period 130 days after initial BAVM rupture.
   CONCLUSIONS: The present series and systematic re-view revealed a rehemorrhage rate of 0.6% in patients suffering from ruptured BAVM who underwent subacute treatment. Therefore, subacute treatment of patients with ruptured BAVM seems safe after application of rigorous treatment algorithms to sort out patients with higher risk for rehemorrhage.
C1 [Schuss, Patrick; Hadjiathanasiou, Alexis; Ilic, Inja; Brandecker, Simon; Gueresir, Agi; Vatter, Hartmut; Gueresir, Erdem] Rheinische Friedrich Wilhelms Univ, Dept Neurosurg, Bonn, Germany.
RP Schuss, P (reprint author), Rheinische Friedrich Wilhelms Univ, Dept Neurosurg, Bonn, Germany.
EM patrick.schuss@ukbonn.de
RI guresir, erdem/AAL-4484-2020
OI guresir, erdem/0000-0002-6624-6885
CR Aoun SG, 2012, NEUROSURG CLIN N AM, V23, P87, DOI 10.1016/j.nec.2011.09.013
   Beecher JS, 2018, J NEUROSURG, V128, P999, DOI 10.3171/2017.1.JNS16745
   Bir SC, 2016, J CLIN NEUROSCI, V23, P95, DOI 10.1016/j.jocn.2015.05.041
   COOK DJ, 1992, CHEST, V102, pS305
   Derdeyn CP, 2017, STROKE, V48, pE200, DOI 10.1161/STR.0000000000000134
   Downer JJ, 2011, NEURORADIOL J, V24, P879, DOI 10.1177/197140091102400609
   Friedlander RM, 2007, NEW ENGL J MED, V356, P2704, DOI 10.1056/NEJMcp067192
   FULTS D, 1984, NEUROSURGERY, V15, P658, DOI 10.1227/00006123-198411000-00003
   GRAF CJ, 1983, J NEUROSURG, V58, P331, DOI 10.3171/jns.1983.58.3.0331
   Hadjiathanasiou A, 2018, NEUROSURG REV, V41, P649, DOI 10.1007/s10143-017-0909-x
   Hafez A, 2017, ACTA NEUROCHIR, V159, P2103, DOI 10.1007/s00701-017-3315-9
   JAFAR JJ, 1994, NEUROSURGERY, V34, P8
   Kim H, 2014, NEUROLOGY, V83, P590, DOI 10.1212/WNL.0000000000000688
   Shotar E, 2017, CEREBROVASC DIS, V44, P304, DOI 10.1159/000479120
   SPETZLER RF, 1986, J NEUROSURG, V65, P476, DOI 10.3171/jns.1986.65.4.0476
   Stapf C, 2006, NEUROLOGY, V66, P1350, DOI 10.1212/01.wnl.0000210524.68507.87
   Starke RM, 2009, BRIT J NEUROSURG, V23, P376, DOI 10.1080/02688690902977662
   Xu F, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.6.FOCUS14178
   Zacharia BE, 2012, CURR ATHEROSCLER REP, V14, P335, DOI 10.1007/s11883-012-0257-9
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E610
EP E615
DI 10.1016/j.wneu.2019.10.148
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200074
PM 31678312
DA 2020-05-12
ER

PT J
AU Shah, A
   Jhawar, SS
   Nunez, M
   Goel, A
   Goel, A
AF Shah, Abhidha
   Jhawar, Sukhdeep Singh
   Nunez, Maximilliano
   Goel, Aimee
   Goel, Atul
TI Brainstem Anatomy: A Study on the Basis of the Pattern of Fiber
   Organization
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brainstem; Fiber dissection; Fiber organization; White fibers
ID MICROSURGICAL ANATOMY
AB OBJECTIVE: A focused dissection of the brainstem was performed to study the various fiber bundles and gray matter nuclei of the brainstem and to decipher the intricate anatomy.
   METHODS: Ten formalin-fixed cadaveric human brains were procured. The fiber dissection techniques described by Klingler were then adopted to study the anatomy. The primary dissection tools used were thin handmade wooden spatulas and fine jeweler's forceps. The fibers were dissected layer by layer with the use of magnification.
   RESULTS: The brainstem dissection was performed from the dorsal, ventral, and lateral aspects to provide a 3-dimensional perspective of the internal architecture. We have presented a novel classification of the brainstem white matter in accordance with the internal organization. The fiber tracts of the brainstem can be divided into short projection fibers, long projection fibers, traversing fibers, and association fibers. From our dissection findings, we divided these white fibers of the brainstem into 3 zones from laterally to medially. The first or outermost zone consists of short projection fibers connecting the brainstem to the cerebellum and adjacent thalamic nuclei. The second zone or the middle zone lies medial to the first zone and consists of traversing and long projection fibers. These consist of both ascending and descending fibers. The third zone or the innermost zone consists of the brainstem association fibers.
   CONCLUSIONS: This division of the fiber bundles into zones will help neurosurgeons in understanding the course and anatomy of the fibers, which can be cumbersome to remember when only studying the sectional anatomy of the brainstem.
C1 [Shah, Abhidha; Jhawar, Sukhdeep Singh; Goel, Atul] King Edward Mem Hosp, Dept Neurosurg, Bombay, Maharashtra, India.
   [Shah, Abhidha; Jhawar, Sukhdeep Singh; Goel, Atul] Seth GS Med Coll, Mumbai, Maharashtra, India.
   [Nunez, Maximilliano] Dr Nestor Carlos Kirchner Hosp, El Cruce High Complex Hosp, Florencio Varela, Argentina.
   [Goel, Aimee] Charing Cross Hosp, London, England.
RP Shah, A (reprint author), King Edward Mem Hosp, Dept Neurosurg, Bombay, Maharashtra, India.; Shah, A (reprint author), Seth GS Med Coll, Mumbai, Maharashtra, India.
EM abhidha@gmail.com
CR Akiyama O, 2018, J NEUROSURG, V129, P740, DOI 10.3171/2017.5.JNS17251
   Goel A, 2014, ACTA NEUROCHIR, V156, P825, DOI 10.1007/s00701-013-1990-8
   Klingler J, 1935, SCHWEIZ ARCH NEUROL, V36, P247
   Parraga RG, 2016, J NEUROSURG, V124, P1377, DOI 10.3171/2015.4.JNS132778
   Shah A, 2019, WORLD NEUROSURG, V125, pE620, DOI 10.1016/j.wneu.2019.01.139
   Shah A, 2012, J CLIN NEUROSCI, V19, P289, DOI 10.1016/j.jocn.2011.04.039
   Yagmurlu K, 2014, NEUROSURGERY S4, V10, p:619
   Yagmurlu K, 2014, OPER NEUROSURG, V10, P602, DOI 10.1227/NEU.0000000000000466
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E826
EP E846
DI 10.1016/j.wneu.2019.11.016
PG 21
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200097
PM 31715404
DA 2020-05-12
ER

PT J
AU Shakir, HJ
   Cappuzzo, JM
   Shallwani, H
   Kwasnicki, A
   Bullis, C
   Wang, JF
   Hess, RM
   Levy, EI
AF Shakir, Hakeem J.
   Cappuzzo, Justin M.
   Shallwani, Hussain
   Kwasnicki, Amanda
   Bullis, Carli
   Wang, Jiefei
   Hess, Ryan M.
   Levy, Elad, I
TI Relationship of Grit and Resilience to Burnout Among US Neurosurgery
   Residents
SO WORLD NEUROSURGERY
LA English
DT Article
DE Burnout; Grit; Resilience; Survey
ID WORK-LIFE BALANCE; SATISFACTION; PHYSICIANS; STRESS; SCALE
AB INTRODUCTION: Studies have begun investigating grit (continued fortitude in the face of hardship) and resilience (ability to recover from a setback) and their relationship to burnout (emotional exhaustion [EE] caused by prolonged stress or frustration) within medicine. We investigated the prevalence of burnout among neurosurgery residents and aimed to determine the relationship among burnout, grit, and resilience.
   METHODS: We surveyed U.S. neurosurgical residents to perform a discretional analysis of prevalence of burnout. Multivariate analysis was performed to determine which variables were associated with higher and lower levels of EE, depersonalization (DP), personal accomplishment (PA), burnout, grit, and resilience.
   RESULTS: Of 1385 U.S. neurosurgery residents, 427 (30.8%) responded to our survey. Burnout prevalence was 33.0% (95% confidence interval, 28.6%-37.7%). High grit was associated with U.S. graduates (P = 0.006), married residents (P = 0.025), and fewer social/personal stressors (P = 0.003). Lower resilience was associated with female sex (P = 0.006), whereas higher resilience was associated with international medical graduates (P = 0.017) and fewer social/personal stressors (P = 0.005). High burnout was associated with greater social/personal stressors (P = 0.002), clinical rotations (P = 0.001), and lack of children (P = 0.016). There were positive correlations between EE and DP and among PA, grit, and resilience. There were negative correlations for EE and DP with PA, grit, and resilience and between grit/resilience and burnout.
   CONCLUSIONS: There is an inverse relationship between grit/resilience and burnout. Increased social/personal stressors are associated with increased levels of burnout and decreased grit and resilience. Grit and resilience are higher when social and personal stressors are decreased, indicating that these characteristics may fluctuate over time.
C1 [Shakir, Hakeem J.; Cappuzzo, Justin M.; Shallwani, Hussain; Wang, Jiefei; Hess, Ryan M.; Levy, Elad, I] Univ Buffalo, Jacobs Sch Med, Dept Neurosurg, Buffalo, NY 14260 USA.
   [Levy, Elad, I] Univ Buffalo, Jacobs Sch Med, Dept Radiol, Buffalo, NY 14260 USA.
   [Shakir, Hakeem J.; Cappuzzo, Justin M.; Shallwani, Hussain; Wang, Jiefei; Hess, Ryan M.; Levy, Elad, I] Gates Vasc Inst Kaleida Hlth, Dept Neurosurg, Buffalo, NY 14203 USA.
   [Kwasnicki, Amanda] Univ Illinois, Dept Neurosurg, Chicago, IL USA.
   [Bullis, Carli] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97201 USA.
   [Wang, Jiefei] Univ Buffalo, Dept Biostat, Buffalo, NY USA.
   [Levy, Elad, I] Univ Buffalo, Canon Stroke & Vasc Res Ctr, Buffalo, NY 14260 USA.
RP Levy, EI (reprint author), Univ Buffalo, Jacobs Sch Med, Dept Neurosurg, Buffalo, NY 14260 USA.; Levy, EI (reprint author), Univ Buffalo, Jacobs Sch Med, Dept Radiol, Buffalo, NY 14260 USA.; Levy, EI (reprint author), Gates Vasc Inst Kaleida Hlth, Dept Neurosurg, Buffalo, NY 14203 USA.; Levy, EI (reprint author), Univ Buffalo, Canon Stroke & Vasc Res Ctr, Buffalo, NY 14260 USA.
EM elevy@ubns.com
CR Attenello FJ, 2018, J NEUROSURG, V129, P1349, DOI 10.3171/2017.9.JNS17996
   Burkhart RA, 2014, SURGERY, V155, P1014, DOI 10.1016/j.surg.2014.01.015
   Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113
   Cornum R, 2011, AM PSYCHOL, V66, P4, DOI 10.1037/a0021420
   Dam Aaron, 2019, AEM Educ Train, V3, P14, DOI 10.1002/aet2.10311
   Duckworth AL, 2007, J PERS SOC PSYCHOL, V92, P1087, DOI 10.1037/0022-3514.92.6.1087
   Duckworth AL, 2009, J PERS ASSESS, V91, P166, DOI 10.1080/00223890802634290
   Dyrbye LN, 2014, ACAD MED, V89, P443, DOI 10.1097/ACM.0000000000000134
   Eley DS, 2013, PEERJ, V1, DOI 10.7717/peerj.216
   Elmore LC, 2016, J AM COLL SURGEONS, V223, P440, DOI 10.1016/j.jamcollsurg.2016.05.014
   Gopal R, 2005, ARCH INTERN MED, V165, P2595, DOI 10.1001/archinte.165.22.2595
   Halliday L, 2017, POSTGRAD MED J, V93, P389, DOI 10.1136/postgradmedj-2015-133919
   Hurst C, 2013, BMC MED EDUC, V13, DOI 10.1186/1472-6920-13-96
   Lacy BE, 2018, CLIN GASTROENTEROL H, V16, P311, DOI 10.1016/j.cgh.2017.06.043
   Lebares CC, 2018, J AM COLL SURGEONS, V226, P80, DOI 10.1016/j.jamcollsurg.2017.10.010
   MASLACH C, 1981, J OCCUP BEHAV, V2, P99, DOI 10.1002/job.4030020205
   Maslach C, 1996, MASLACH BURNOUT INVE
   Masten A. S., 2002, HDB POSITIVE PSYCHOL, P74, DOI DOI 10.1093/OXFORDHB/9780195187243.013.0012
   Reivich KJ, 2011, AM PSYCHOL, V66, P25, DOI 10.1037/a0021897
   Robertson-Kraft C, 1970, TEACH COLL REC, P116
   Salles A, 2014, AM J SURG, V207, P251, DOI 10.1016/j.amjsurg.2013.09.006
   Shakir HJ, 2018, NEUROSURGERY, V83, P582, DOI 10.1093/neuros/nyx494
   Shanafelt TD, 2015, MAYO CLIN PROC, V90, P1600, DOI 10.1016/j.mayocp.2015.08.023
   Shanafelt TD, 2012, ARCH INTERN MED, V172, P1377, DOI 10.1001/archinternmed.2012.3199
   Shanafelt TD, 2009, ANN SURG, V250, P463, DOI 10.1097/SLA.0b013e3181ac4dfd
   Sood A, 2014, EXPLORE-NY, V10, P358, DOI 10.1016/j.explore.2014.08.002
   Vassar L., ACGME SEEKS TRANSFOR
NR 27
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E224
EP E236
DI 10.1016/j.wneu.2019.10.043
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200028
PM 31629138
DA 2020-05-12
ER

PT J
AU Shirahata, T
   Okano, I
   Salzmann, SN
   Sax, OC
   Shue, J
   Sama, AA
   Cammisa, FP
   Toyone, T
   Inagaki, K
   Hughes, AP
   Girardi, FP
AF Shirahata, Toshiyuki
   Okano, Ichiro
   Salzmann, Stephan N.
   Sax, Oliver C.
   Shue, Jennifer
   Sama, Andrew A.
   Cammisa, Frank P.
   Toyone, Tomoaki
   Inagaki, Katsunori
   Hughes, Alexander P.
   Girardi, Federico P.
TI Association Between Surgical Level and Early Postoperative Thigh
   Symptoms Among Patients Undergoing Standalone Lateral Lumbar Interbody
   Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior thigh pain; Anterior thigh paresthesia; Anterior thigh symptom;
   Lateral lumbar interbody fusion; LLIF; Neurological complication;
   Standalone
ID RETROPERITONEAL TRANSPSOAS APPROACH; COMPLICATIONS; PLEXUS; INJURY;
   OUTCOMES; SURGERY; NERVE
AB BACKGROUND: Lateral lumbar interbody fusion (LLIF) has often been associated with postoperative lumbar plexus symptoms, including pain, paresthesia, and motor deficits in the lower extremities, especially the anterior thigh regions. Previous studies have suggested that LLIF procedures at L4-L5 will be associated with a greater motor deficit rate than other levels. However, it is unclear which level has the greatest risk of pain and paresthesia. The purpose of the present retrospective observational study was to investigate the difference in the incidence of early postoperative thigh symptoms (pain and paresthesia) stratified by procedure level among patients who had undergone standalone LLIF.
   METHODS: We reviewed the data from consecutive patients who had undergone LLIF at a single academic institution. A total of 285 standalone LLIF cases without preoperative motor deficits were identified. The incidence of postoperative thigh pain and paresthesia at the 6-week postoperative follow-up examination was assessed at all levels from T12-L1 to L4-L5.
   RESULTS: A total of 81 patients (28.4%) had anterior thigh pain and 62 (21.8%) had anterior thigh paresthesia. The presence of >= 3 levels fused (odds ratio [OR], 2.96; P = 0.004) and surgery at L2-L3 (OR, 2.59; P = 0.001) were significant risk factors for postoperative anterior thigh paresthesia on univariate analysis but were not associated with anterior thigh pain. Multivariate analyses demonstrated that only surgery L2-L3 was an independent risk factor for anterior thigh paresthesia (OR, 2.09; P = 0.049).
   CONCLUSIONS: Our results have demonstrated that standalone LLIF at the L2-L3 was significantly associated with a greater incidence of postoperative anterior thigh paresthesia but that the incidence of postoperative thigh pain showed no significant association with any operative level.
C1 [Shirahata, Toshiyuki; Okano, Ichiro; Salzmann, Stephan N.; Sax, Oliver C.; Shue, Jennifer; Sama, Andrew A.; Cammisa, Frank P.; Hughes, Alexander P.; Girardi, Federico P.] Hosp Special Surg, Spine Care Inst, 535 E 70th St, New York, NY 10021 USA.
   [Shirahata, Toshiyuki; Toyone, Tomoaki; Inagaki, Katsunori] Showa Univ, Dept Orthoped Surg, Sch Med, Tokyo, Japan.
RP Shirahata, T (reprint author), Hosp Special Surg, Spine Care Inst, 535 E 70th St, New York, NY 10021 USA.; Shirahata, T (reprint author), Showa Univ, Dept Orthoped Surg, Sch Med, Tokyo, Japan.
EM tahs.s2003@gmail.com
OI Okano, Ichiro/0000-0003-1741-5176
CR Abel NA, 2018, NEUROSURG REV, V41, P457, DOI 10.1007/s10143-017-0863-7
   Aichmair A, 2017, SPINE, V42, pE515, DOI 10.1097/BRS.0000000000001871
   Aichmair A, 2013, SPINE, V38, pE1483, DOI 10.1097/BRS.0b013e3182a3d1b4
   Cummock MD, 2011, J NEUROSURG-SPINE, V15, P11, DOI 10.3171/2011.2.SPINE10374
   Formica M, 2017, EUR SPINE J, V26, P464, DOI 10.1007/s00586-017-5115-6
   Gautschi OP, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.7.FOCUS11168
   Grimm BD, 2016, CLIN SPINE SURG, V29, pE151, DOI 10.1097/BSD.0000000000000121
   Grunert P, 2017, WORLD NEUROSURG, V105, P519, DOI 10.1016/j.wneu.2017.06.027
   Hijji FY, 2017, SPINE J, V17, P1412, DOI 10.1016/j.spinee.2017.04.022
   Kotwal S, 2015, J SPINAL DISORD TECH, V28, P119, DOI 10.1097/BSD.0b013e3182706ce7
   Le TV, 2013, SPINE, V38, pE13, DOI 10.1097/BRS.0b013e318278417c
   Lykissas MG, 2014, SPINE J, V14, P749, DOI 10.1016/j.spinee.2013.06.066
   Moro T, 2003, SPINE, V28, P423, DOI 10.1097/00007632-200303010-00002
   Ng CLL, 2015, EUR SPINE J, V24, pS361, DOI 10.1007/s00586-015-3876-3
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Pumberger M, 2012, EUR SPINE J, V21, P1192, DOI 10.1007/s00586-011-2087-9
   Rodgers WB, 2011, SPINE, V36, P26, DOI 10.1097/BRS.0b013e3181e1040a
   Salzmann SN, 2017, CURR REV MUSCULOSKE, V10, P539, DOI 10.1007/s12178-017-9444-1
   Sofianos DA, 2012, CLIN ORTHOP RELAT R, V470, P1621, DOI 10.1007/s11999-011-2088-3
   Tormenti MJ, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09263
   Uribe JS, 2010, J NEUROSURG-SPINE, V13, P260, DOI 10.3171/2010.3.SPINE09766
   Wong OF, 2013, HONG KONG MED J, V19, P416, DOI 10.12809/hkmj133793
   Yang SH, 2005, SPINE, V30, pE547, DOI 10.1097/01.brs.0000178821.14102.9d
   Yuan PS, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749-799X-9-20
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E885
EP E891
DI 10.1016/j.wneu.2019.11.025
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200103
PM 31733379
DA 2020-05-12
ER

PT J
AU Shofty, B
   Mauda-Havakuk, M
   Ben-Sira, L
   Bokstein, F
   Lidar, Z
   Salame, K
   Korn, A
   Constantini, S
AF Shofty, Ben
   Mauda-Havakuk, Michal
   Ben-Sira, Liat
   Bokstein, Felix
   Lidar, Zvi
   Salame, Khalil
   Korn, Akiva
   Constantini, Shlomi
TI Surgical Management of "Kissing" Spinal Plexiform Neurofibromas in
   Neurofibromatosis Tyne 1 Patient
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intradural; Kissing; Neurofibroma; Neurofibromatosis; NF1
ID TYPE-1
AB BACKGROUND: "Kissing" neurofibromas (KNs) are a unique group of spinal tumors found in neurofibromatosis type 1 (NF1) patients. These are bilateral neurofibromas that approximate each other at the same level, with significant impingement compression of the cord or thecal sac. The best management options and surgical strategies for NF1 patients with KN have not been standardized.
   METHODS: We conducted a retrospective study evaluating adult NF1 patients with KN. All patients are followed routinely at the Gilbert Israeli NF Center. Patients' files were reviewed for natural history, imaging features, surgical technique, and surgical outcome.
   RESULTS: Twelve patients with at least 1 pair of KN were identified (6 females). Median age at spinal presentation was 24 (range 17-48). KNSs were located at the cervical (n = 8) and lumbar (n = 8) region, with no thoracic involvement. Seven of the 12 patients were operated; all underwent surgery due to cervical compression with progressive myelopathy. Four patients remained asymptomatic during the follow-up period. Three patients underwent multiple operations. Operative outcome was favorable in 71% of patients, with marked overall motor improvement or stabilization of neurologic deterioration. Two patients who entered surgery with a low functional reserve deteriorated after surgery.
   CONCLUSIONS: In our series, KN caused progressive cord compression in 7 of the 8 patients with cervical tumors. No intervention was needed for lumbar tumors. Cervical tumors should be followed closely, with a low threshold for intervention. NF1 patients harboring KN should be followed both clinically and radiologically for life.
C1 [Shofty, Ben; Lidar, Zvi; Salame, Khalil; Korn, Akiva] Tel Aviv Med Ctr & Sch Med, Dept Neurosurg, Tel Aviv, Israel.
   [Shofty, Ben; Mauda-Havakuk, Michal; Ben-Sira, Liat; Bokstein, Felix; Lidar, Zvi; Salame, Khalil; Korn, Akiva; Constantini, Shlomi] Tel Aviv Univ, Tel Aviv, Israel.
   [Shofty, Ben; Mauda-Havakuk, Michal; Ben-Sira, Liat; Bokstein, Felix; Constantini, Shlomi] Tel Aviv Med Ctr & Sch Med, Gilbert Israeli Neurofibromatosis Ctr, Tel Aviv, Israel.
   [Constantini, Shlomi] Tel Aviv Med Ctr & Sch Med, Dept Pediat Neurosurg, Tel Aviv, Israel.
RP Constantini, S (reprint author), Tel Aviv Univ, Tel Aviv, Israel.; Constantini, S (reprint author), Tel Aviv Med Ctr & Sch Med, Gilbert Israeli Neurofibromatosis Ctr, Tel Aviv, Israel.; Constantini, S (reprint author), Tel Aviv Med Ctr & Sch Med, Dept Pediat Neurosurg, Tel Aviv, Israel.
EM sconsts@netvision.net.il
CR Bigder M, 2017, WORLD NEUROSURG, V108, DOI 10.1016/j.wneu.2017.08.139
   Dombi E, 2016, NEW ENGL J MED, V375, P2550, DOI 10.1056/NEJMoa1605943
   Gutmann DH, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.4
   Leonard JR, 2007, J NEUROL NEUROSUR PS, V78, P1404, DOI 10.1136/jnnp.2007.121509
   Mauda-Havakuk M, 2017, AM J NEURORADIOL, V38, P1869, DOI 10.3174/ajnr.A5338
   Montemurro Nicola, 2014, Evid Based Spine Care J, V5, P136, DOI 10.1055/s-0034-1387805
   Murovic Judith A, 2006, Neurosurg Focus, V20, pE1
   Pandey S, 2017, MALAYS J MED SCI, V24, P117, DOI 10.21315/mjms2017.24.1.13
   Restrepo CS, 2005, J COMPUT ASSIST TOMO, V29, P532, DOI 10.1097/01.rct.0000163705.21892.23
   Ruggieri M, 2015, CLIN GENET, V87, P401, DOI 10.1111/cge.12498
   Shofty B, 2015, SEMIN PEDIATR NEUROL, V22, P234, DOI 10.1016/j.spen.2015.10.007
   Taleb FS, 2011, J NEUROSURG-SPINE, V14, P356, DOI 10.3171/2010.9.SPINE09242
   Thakker SD, 1999, NEURORADIOLOGY, V41, P625, DOI 10.1007/s002340050814
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E1143
EP E1147
DI 10.1016/j.wneu.2019.11.124
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200133
PM 31786384
DA 2020-05-12
ER

PT J
AU Smith, ZA
   Weber, KA
   Paliwal, M
   Hopkins, BS
   Barry, AJ
   Cantrell, D
   Ganju, A
   Koski, TR
   Parrish, TB
   Dhaher, Y
AF Smith, Zachary A.
   Weber, Kenneth A., II
   Paliwal, Monica
   Hopkins, Benjamin S.
   Barry, Alexander J.
   Cantrell, Donald
   Ganju, Aruna
   Koski, Tyler R.
   Parrish, Todd B.
   Dhaher, Yasin
TI Magnetic Resonance Imaging Atlas-Based Volumetric Mapping of the
   Cervical Cord Gray Matter in Cervical Canal Stenosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical cord compression; CSM; Gray matter; Myelopathy; Spinal Cord
   Toolbox; Spine; Volumetric spinal cord mapping
ID SPINAL-CORD; SPONDYLOTIC MYELOPATHY; NATURAL-HISTORY; PATHOPHYSIOLOGY
AB BACKGROUND: White matter volume loss may be an anatomic driver in the development of clinical symptoms in cervical spondylotic myelopathy (CSM). Considerably less attention has been devoted to gray matter (GM) injury. Newly developed atlas-based mapping techniques may allow evaluation of GM cord volume alterations in CSM.
   METHODS: There were 29 subjects evaluated: 15 patients with CSM (61.1 +/- 8.7 years old) and 14 age-matched control subjects (56.1 +/- 5.3 years old). All subjects underwent 3T magnetic resonance imaging of the cervical spine. Post-processing with the Spinal Cord Toolbox (v3.0) provided GM volumetric analysis. Clinical scores collected included modified Japanese Orthopaedic Association, neck and arm numeric rating scales, Nurick Scale, and Neck Disability Index. All volumes were normalized to account for anatomic variability.
   RESULTS: Normalized mean ventral GM volume in the compression region was significantly lower in patients compared with control subjects (1.103 +/- 0.21 vs. 1.35 +/- 0.32, P = 0.027). Normalized mean dorsal volume in the compression region was decreased in patients compared with control subjects (0.90 +/- 0.17 vs. 1.04 +/- 0.15, P = 0.049). GM volumes were associated with clinical scores, including Neck Disability Index, arm numeric rating scale, modified Japanese Orthopaedic Association, and Nurick Scale scores (P = 0.022, P = 0.004, P = 0.027, and P = 0.016).
   CONCLUSIONS: GM volume loss may be evaluated through atlas-based post-processing techniques and may correlate with clinical symptoms in CSM.
C1 [Smith, Zachary A.; Paliwal, Monica; Hopkins, Benjamin S.; Ganju, Aruna; Koski, Tyler R.] Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Chicago, IL 60611 USA.
   [Cantrell, Donald; Parrish, Todd B.] Northwestern Univ, Feinberg Sch Med, Dept Radiol, Chicago, IL 60611 USA.
   [Weber, Kenneth A., II] Stanford Univ, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Palo Alto, CA 94304 USA.
   [Barry, Alexander J.] Shirley Ryan Abil Lab, Arms Hands Lab, Chicago, IL USA.
   [Dhaher, Yasin] Univ Texas Southwestern Med Ctr Dallas, Dept Phys Med & Rehabil, Dallas, TX 75390 USA.
RP Smith, ZA (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Chicago, IL 60611 USA.
EM zsmith1@nm.org
OI Barry, Alexander/0000-0002-0904-155X; Parrish, Todd/0000-0002-1184-1572
FU NIDA NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Drug Abuse
   (NIDA) [T32 DA035165]; NINDS NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Neurological Disorders & Stroke (NINDS) [K23 NS091430, K23
   NS104211]
CR Bakhsheshian J, 2017, GLOB SPINE J, V7, P572, DOI 10.1177/2192568217699208
   Cloney MB, 2018, SPINE, V43, P675, DOI 10.1097/BRS.0000000000002470
   De Leener B, 2018, NEUROIMAGE, V165, P170, DOI 10.1016/j.neuroimage.2017.10.041
   De Leener B, 2017, NEUROIMAGE, V145, P24, DOI 10.1016/j.neuroimage.2016.10.009
   Fehlings MG, 1998, SPINE, V23, P2730, DOI 10.1097/00007632-199812150-00012
   Gibson J, 2018, YALE J BIOL MED, V91, P43
   Grabher P, 2017, J NEUROTRAUM, V34, P2329, DOI 10.1089/neu.2017.4980
   Grabher P, 2016, SCI REP-UK, V6, DOI 10.1038/srep24636
   Harrop JS, 2010, SPINE, V35, P620, DOI 10.1097/BRS.0b013e3181b723af
   Hopkins BS, 2019, WORLD NEUROSURG, V127, pE436, DOI 10.1016/j.wneu.2019.03.165
   Hopkins BS, 2018, SPINE, V43, pE1204, DOI 10.1097/BRS.0000000000002667
   Houten JK, 2008, J NEUROSURG-SPINE, V9, P237, DOI 10.3171/SPI/2008/9/9/237
   Karadimas SK, 2013, SPINE, V38, pS21, DOI 10.1097/BRS.0b013e3182a7f2c3
   Levy S, 2015, NEUROIMAGE, V119, P262, DOI 10.1016/j.neuroimage.2015.06.040
   Liu HW, 2017, NEUROLOGY, V89, P602, DOI 10.1212/WNL.0000000000004197
   Martin AR, 2016, NEUROIMAGE-CLIN, V10, P192, DOI 10.1016/j.nicl.2015.11.019
   Matz PG, 2009, J NEUROSURG-SPINE, V11, P104, DOI 10.3171/2009.1.SPINE08716
   Nemani VM, 2015, SPINE, V40, P6, DOI 10.1097/BRS.0000000000000659
   Smith ZA, 2019, PLOS ONE, V14
   Wen CY, 2014, RADIOLOGY, V270, P197, DOI 10.1148/radiol.13121885
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E497
EP E504
DI 10.1016/j.wneu.2019.10.109
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200060
PM 31669690
DA 2020-05-12
ER

PT J
AU Song, KJ
   Choi, BW
   Ham, DH
   Kim, HJ
AF Song, Kyung-Jin
   Choi, Byung-Wan
   Ham, Dong Hun
   Kim, Hyeong Jik
TI Prognosis of Hardware-Related Problems in Anterior Cervical Discectomy
   and Fusion with Cage and Plate Constructs
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cervical discectomy and fusion; Cage and plate; Hardware
   problem; Prognosis
ID INTERNAL-FIXATION; SPINE; STABILIZATION; COMPLICATIONS; MANAGEMENT;
   ALLOGRAFT
AB OBJECTIVE: To analyze hardware-related problems and their prognoses after anterior cervical discectomy and fusion (ACDF) using cages and plates for degenerative and traumatic cervical disc diseases.
   METHODS: The study included 808 patients who underwent anterior cervical discectomy and fusion for degenerative and traumatic disc diseases with >1 year of follow-up. We investigated time of onset and progression of problems associated with instrumentation and cage usage. The mean follow-up time was 3.4 years. Type of plate, range and level of fusion, patient factors (age, sex, body mass index, and bone mineral density), and local kyphosis were evaluated.
   RESULTS: Complications were found in 132 cases (16.5%), including subsidence in 69 cases, plate loosening in 8 cases, screw loosening in 8 cases, screw breakage in 1 case, and multiple complications in 36 cases. In 3 cases, additional posterior cervical surgery was performed. One case needed hardware revision. There were no esophageal, tracheal, or neurovascular structural injuries secondary to metal failure. There were no significant differences in type of plate, level of surgery, or patient factors. The greater the number of fusion segments, the greater the incidence of complications (P = 0.001). The clinical outcomes improved regardless of the complications (P = 0.083).
   CONCLUSIONS: Most hardware-related complications are not symptomatic and can be treated conservatively. Only a few cases need revision surgery. Precise surgical techniques are needed in multilevel anterior cervical discectomy and fusion (>3 levels) because of the increased complication rate.
C1 [Song, Kyung-Jin; Ham, Dong Hun; Kim, Hyeong Jik] Chonbuk Natl Univ, Dept Orthopaed Surg, Med Sch, Jeonju, South Korea.
   [Choi, Byung-Wan] Inje Univ, Haeundae Paik Hosp, Dept Orthoped Surg, Busan, South Korea.
RP Choi, BW (reprint author), Inje Univ, Haeundae Paik Hosp, Dept Orthoped Surg, Busan, South Korea.
EM alla1013@naver.com
CR BANWART JC, 1995, SPINE, V20, P1055, DOI 10.1097/00007632-199505000-00012
   BOHLER J, 1980, J TRAUMA, V20, P203
   Bolesta MJ, 2000, SPINE, V25, P2040, DOI 10.1097/00007632-200008150-00007
   Bolesta MJ, 2000, SPINE, V25, P2045
   CASPAR W, 1989, NEUROSURGERY, V25, P491, DOI 10.1227/00006123-198910000-00001
   Daffner Scott D, 2009, Instr Course Lect, V58, P689
   Fogel GR, 2010, SPINE J, V10, P417, DOI 10.1016/j.spinee.2010.02.004
   Fraser JF, 2007, J NEUROSURG-SPINE, V6, P298, DOI 10.3171/spi.2007.6.4.298
   Kandziora F, 2005, INJURY, V36, P27, DOI 10.1016/j.injury.2005.06.012
   Kim YS, 2018, J CLIN NEUROSCI, V47, P341, DOI 10.1016/j.jocn.2017.10.022
   Kwon BK, 2007, NEUROSURGERY, V60, P118, DOI 10.1227/01.NEU.0000249222.57709.59
   Lowery GL, 1998, SPINE, V23, P181, DOI 10.1097/00007632-199801150-00006
   McCullen GM, 2000, SPINE, V25, P643, DOI 10.1097/00007632-200003010-00020
   Oliver JD, 2018, SPINE, V43, pE413, DOI 10.1097/BRS.0000000000002441
   Orlando ER, 2003, SPINE, V28, pE290, DOI 10.1097/00007632-200308010-00023
   Park JY, 2016, J CLIN NEUROSCI, V33, P83, DOI 10.1016/j.jocn.2016.01.042
   Park JB, 2005, J BONE JOINT SURG AM, V87A, P558, DOI 10.2106/JBJS.C.01555
   POMPILI A, 2002, SPINE, V27, P499, DOI DOI 10.1097/01.BRS.0000035309.04502.52
   Reidy D, 2004, J SPINAL DISORD TECH, V17, P117, DOI 10.1097/00024720-200404000-00008
   Rhee JM, 2007, J AM ACAD ORTHOP SUR, V15, P640, DOI 10.5435/00124635-200711000-00002
   Schroeder GD, 2017, CLIN SPINE SURG, V30, P20, DOI 10.1097/BSD.0000000000000453
   SMITH GW, 1958, J BONE JOINT SURG AM, V40, P607, DOI 10.2106/00004623-195840030-00009
   Song KJ, 2010, EUR SPINE J, V19, P1677, DOI 10.1007/s00586-010-1283-3
   Song KJ, 2009, SPINE, V34, P2886, DOI 10.1097/BRS.0b013e3181b64f2c
   Xie N, 2008, INT ORTHOP, V32, P649, DOI 10.1007/s00264-007-0369-y
   Yue WM, 2005, SPINE, V30, P2138, DOI 10.1097/01.brs.0000180479.63092.17
   Yue WM, 2005, EUR SPINE J, V14, P677, DOI 10.1007/s00586-004-0849-3
   Zaveri GR, 2001, J SPINAL DISORD, V14, P10, DOI 10.1097/00002517-200102000-00003
NR 28
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E249
EP E255
DI 10.1016/j.wneu.2019.10.042
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200031
PM 31629142
DA 2020-05-12
ER

PT J
AU Suzuki, K
   Kurashima, A
   Abe, K
   Ishikawa, T
   Yamaguchi, K
   Kawamata, T
   Yaguchi, A
   Sakai, S
AF Suzuki, Kazufumi
   Kurashima, Aoi
   Abe, Kayoko
   Ishikawa, Tatsuya
   Yamaguchi, Koji
   Kawamata, Takakazu
   Yaguchi, Arino
   Sakai, Shuji
TI Dual-Phase Computed Tomography Angiography Enhances Detection of
   Contrast Extravasation in Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Contrast extravasation; CT angiography; Subarachnoid hemorrhage; Subpial
   hematoma
ID PREDICTS HEMATOMA EXPANSION; IN-HOSPITAL MORTALITY; SPOT SIGN; CT
   ANGIOGRAPHY; INTRACEREBRAL HEMATOMA; ANEURYSM
AB BACKGROUND: Contrast-enhanced computed tomography angiography (CTA) can be used to detect contrast extravasation in intracerebral hemorrhage. However, investigation for contrast extravasation in subarachnoid hemorrhage (SAH) is insufficient. We evaluated the efficacy of dual-phase CTA to improve evaluation of contrast extravasation in SAH.
   METHODS: We retrospectively evaluated 35 patients with SAH who underwent contrast-enhanced dual-phase CTA within 24 hours from onset. The second-phase scan was performed 8 or 15 seconds following the usual CTA. The frequency of contrast extravasation was compared between phases. We also recorded the time from onset, coma level, interventional treatment, and early mortality.
   RESULTS: Of 35 patients (22.9%) with SAH, 8 showed contrast extravasation in the second phase compared with 3 in the first phase. Contrast extravasation was correlated with clinical coma level (P < 0.05), and all contrast extravasation was found within 6 hours from onset. Early mortality, treatment decision, and hematoma distribution type did not correlate with existence of contrast extravasation. We also observed 4 cases of secondary subpial hematoma due to SAH, with 3 showing extravasation in both phases.
   CONCLUSIONS: Dual-phase CTA with a short interval enhances detection frequency of contrast extravasation in SAH and might he a better evaluation tool for SAH.
C1 [Suzuki, Kazufumi; Abe, Kayoko; Sakai, Shuji] Tokyo Womens Med Univ, Dept Diagnost Imaging & Nucl Med, Tokyo, Japan.
   [Ishikawa, Tatsuya; Yamaguchi, Koji; Kawamata, Takakazu] Tokyo Womens Med Univ, Dept Neurosurg, Tokyo, Japan.
   [Yaguchi, Arino] Tokyo Womens Med Univ, Dept Crit Care & Emergency Med, Tokyo, Japan.
   [Kurashima, Aoi] Tokyo Womens Med Univ, Sch Med, Tokyo, Japan.
RP Suzuki, K (reprint author), Tokyo Womens Med Univ, Dept Diagnost Imaging & Nucl Med, Tokyo, Japan.
EM kasuzuki-rad@umin.ac.jp
RI Suzuki, Kazufumi/Q-9218-2016
OI Suzuki, Kazufumi/0000-0002-5895-956X; Ishikawa,
   Tatsuya/0000-0003-3553-6510
CR Almandoz JED, 2012, J NEUROINTERV SURG, V4, P442, DOI 10.1136/neurintsurg-2011-010061
   Almandoz JED, 2010, STROKE, V41, P54, DOI 10.1161/STROKEAHA.109.565382
   Brouwers HB, 2013, STROKE, V44, P1590, DOI 10.1161/STROKEAHA.111.000586
   Demchuk AM, 2012, LANCET NEUROL, V11, P307, DOI 10.1016/S1474-4422(12)70038-8
   Goldstein JN, 2007, NEUROLOGY, V68, P889, DOI 10.1212/01.wnl.0000257087.22852.21
   Hilditch CA, 2016, BMJ CASE REP, V2016
   Koculym A, 2013, AM J NEURORADIOL, V34, P965, DOI 10.3174/ajnr.A3338
   Nakatsuka M, 2002, NEURORADIOLOGY, V44, P25, DOI 10.1007/s002340100689
   Niikawa S, 1998, NEUROL MED-CHIR, V38, P844, DOI 10.2176/nmc.38.844
   Rodriguez-Luna D, 2017, RADIOLOGY, V285, P932, DOI 10.1148/radiol.2017162839
   Ryu CW, 2005, J COMPUT ASSIST TOMO, V29, P677, DOI 10.1097/01.rct.0000176015.75169.12
   Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018
   Suzuki K, 2012, AM J NEURORADIOL, V33, P1374, DOI 10.3174/ajnr.A2981
   Suzuki K, 2015, NEURORADIOL J, V28, P337, DOI 10.1177/1971400915576664
   Suzuki K, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2013.02.014
   Takagi K, 1998, NEUROL SURG TOKYO, V26, P509
   TOKUDA Y, 1995, SURG NEUROL, V43, P272, DOI 10.1016/0090-3019(95)80013-7
   Tsukabe A, 2014, NEURORADIOLOGY, V56, P1039, DOI 10.1007/s00234-014-1430-3
   Wada R, 2007, STROKE, V38, P1257, DOI 10.1161/01.STR.0000259633.59404.f3
   Wu TC, 2018, ACTA RADIOL, V59, P485, DOI 10.1177/0284185117718401
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E237
EP E242
DI 10.1016/j.wneu.2019.10.046
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200029
PM 31629136
DA 2020-05-12
ER

PT J
AU Tai, AX
   Herur-Raman, A
   Jean, WC
AF Tai, Alexander X.
   Herur-Raman, Aalap
   Jean, Walter C.
TI The Benefits of Progressive Occipital Condylectomy in Enhancing the Far
   Lateral Approach to the Foramen Magnum
SO WORLD NEUROSURGERY
LA English
DT Article
DE Condylectomy; Far lateral approach; Foramen magnum; Transcondylar;
   Vertebrobasilar junction
ID TRANSCONDYLAR APPROACH; INSTABILITY
AB BACKGROUND: The portion of the occipital condyle that is safe to remove remains controversial in the transcondylar approach. We aimed to correlate the gain in exposure with incremental removal of the occipital condyle to determine if there is a point where further drilling yields diminishing gains.
   METHODS: Virtual reality rendering of the skull was generated from 25 subjects with no posterior fossa pathology. A suboccipital far lateral craniotomy was done in virtual reality space, stopping at the posterior edge of the occipital condyle. Angular measurements of surgical corridor were taken at this point and after removal of 25% and 50% of the condyle. Two surgical targets were used: at the anterior midline of the foramen magnum and the vertebrobasilar junction.
   RESULTS: Progressive removal of the occipital condyle increased exposure to both targets in a linear fashion. For the midline of the foramen magnum, the working angle increased from 12 degrees to 18 degrees for quarter condylectomy and then to 25 degrees for half condylectomy. The corridor to the vertebrobasilar junction was much tighter, and the angle increased from 5.5 degrees to 9 degrees for quarter condylectomy and then to 12 degrees for half condylectomy. The gain in exposure for the low target was greater than for the high target (P < 0.001).
   CONCLUSIONS: Progressive removal of the occipital condyle yielded a linear increase in exposure without an ideal point beyond which the drilling was futile. However, the impact of condylectomy was greater for our low target compared with our high target.
C1 [Tai, Alexander X.] Medstar Georgetown Univ Hosp, Dept Neurosurg, Washington, DC 20007 USA.
   [Herur-Raman, Aalap] Surg Theater, Mayfield Village, OH USA.
   [Jean, Walter C.] George Washington Univ Hosp, Dept Neurosurg, Washington, DC USA.
RP Tai, AX (reprint author), Medstar Georgetown Univ Hosp, Dept Neurosurg, Washington, DC 20007 USA.
EM axt2@georgetown.edu
RI Jean, Walter/L-2780-2019
OI Jean, Walter/0000-0001-6774-2066; Tai, Alexander/0000-0003-3800-6101
CR Au K, 2019, SKULL BASE SURG STRA, P332
   Cardoso AC, 2015, CLIN ANAT, V28, P683, DOI 10.1002/ca.22551
   Dowd GC, 1999, NEUROSURGERY, V45, P95, DOI 10.1097/00006123-199907000-00023
   Flores BC, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.10.FOCUS13332
   GEORGE B, 1988, SURG NEUROL, V29, P484, DOI 10.1016/0090-3019(88)90145-0
   HEROS RC, 1986, J NEUROSURG, V64, P559, DOI 10.3171/jns.1986.64.4.0559
   Kooshkabadi A, 2015, NEUROSURGERY, V77, P888, DOI 10.1227/NEU.0000000000000922
   Kshettry VR, 2017, J NEUROSURG, V127, P829, DOI 10.3171/2016.7.JNS16293
   [刘建军 Liu Jianjun], 2007, [低温物理学报, Chinese Journal of Low Temperature Physics], V29, P1
   Mazur MD, 2017, NEUROSURGERY, V80, P140, DOI 10.1093/neuros/nyw002
   Muthukumar N, 2005, ACTA NEUROCHIR, V147, P889, DOI 10.1007/s00701-005-0555-x
   RHOTON AL, 2000, NEUROSURGERY S3, V47, pS19
   Seoane P, 2017, NEUROSURGERY, V81, P268, DOI 10.1093/neuros/nyw136
   Spektor S, 2000, J NEUROSURG, V92, P824, DOI 10.3171/jns.2000.92.5.0824
   Wen HT, 1997, J NEUROSURG, V87, P555, DOI 10.3171/jns.1997.87.4.0555
   Wu AH, 2010, NEUROSURGERY, V66, pONS191, DOI [10.1227/01.NEU.0000369704.49958.5B, 10.1227/10.NEU.0000369704.49958.5B]
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E144
EP E152
DI 10.1016/j.wneu.2019.09.152
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200018
PM 31605848
DA 2020-05-12
ER

PT J
AU Tang, ZJ
   Yang, K
   Zhong, M
   Yang, RJ
   Zhang, JS
   Jiang, QH
   Liu, HY
AF Tang, Zhiji
   Yang, Kun
   Zhong, Ming
   Yang, Ruijin
   Zhang, Jinshi
   Jiang, Qiuhua
   Liu, Hongyi
TI Predictors of 30-Day Mortality in Traumatic Brain-Injured Patients after
   Primary Decompressive Craniectomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Mortality; Predictors; Primary decompressive craniectomy; Traumatic
   brain injury
ID PROGRESSIVE HEMORRHAGIC INJURY; CHINESE MILITARY HOSPITALS; ASSOCIATION;
   EPIDEMIOLOGY; COAGULATION; HYPOTENSION; CRANIOTOMY; INPATIENTS;
   CHILDREN; OUTCOMES
AB OBJECTIVE: Primary decompressive craniectomy (DC) is an important therapeutic technique for severe head-injured patients with space-occupying lesions in emergency situations, hut these patients are still at high risk for unfavorable outcomes. This study aimed to investigate the predictors of 30-day mortality in adult patients undergoing primary DC after traumatic brain injury (TBI).
   METHODS: All adult patients (>= 18 years of age) who underwent primary DC from January 2012 to March 2019 were included. Demographic, clinical, surgical, and laboratory variables were collected for analysis. Early mortality was defined as 30-day mortality after DC. First, a univariate analysis (P < 0.05) was used to compare survivors and nonsurvivors. Multivariate logistic regression analysis was used to identify the predictors of 30-day mortality for patients who underwent primary DC.
   RESULTS: A total of 387 patients were enrolled in the study. The 30-day mortality was 31.52% (122/387). The median age at presentation was 49 years (interquartile range, 38-60), and 316 (81.65%) patients were male. In the multivariate logistic regression analysis, the factors associated with 30-day mortality included age (odds ratio [OK 1.068; 95% confidence interval [CI], 1.040-1.096; P < 0.001), bilateral unreactive pupils (OR, 12.734; 95% CI, 4.129-39.270; P < 0.001), subdural hemorrhage (OR, 3.468; 95% CI, 1.305-9.218; P < 0.013), completely effaced basal cistern (OR, 3.52; 95% CI, 1.568-7.901; P = 0.002), intraoperative hypotension (OR, 11.532; 95% CI, 4.222-31.499; P < 0.001), preoperative activated partial thromboplastin time (OR, 6.905; 95% CI, 2.055-23.202; P = 0.002), and Injury Severity Score (OR, 1.081; 95% CI, 1.031-1.133; P = 0.002).
   CONCLUSIONS: In patients undergoing primary DC after traumatic brain injury, the predictors of 30-day mortality include age, bilateral unreactive pupils, subdural hemorrhage, completely effaced basal cistern, intraoperative hypotension, preoperative activated partial thromboplastin time, and Injury Severity Score.
C1 [Tang, Zhiji; Yang, Ruijin; Zhang, Jinshi; Jiang, Qiuhua] Ganzhou Peoples Hosp, Dept Neurosurg, Ganzhou, Jiangxi, Peoples R China.
   [Tang, Zhiji; Yang, Kun; Liu, Hongyi] Nanjing Med Univ, Affiliated Brain Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China.
   [Zhong, Ming] Huichang Cty Peoples Hosp, Dept Neurosurg, Ganzhou, Jiangxi, Peoples R China.
RP Jiang, QH (reprint author), Ganzhou Peoples Hosp, Dept Neurosurg, Ganzhou, Jiangxi, Peoples R China.
EM jiangqh1968@126.com
FU Science & Technology Program of Health Commission of Jiangxi Province
   [20197373]
FX This study was funded by the Science & Technology Program of Health
   Commission of Jiangxi Province (number 20197373).
CR Ahmed N, 2017, J NEUROL SURG PART A, V78, P453, DOI 10.1055/s-0036-1593978
   Al-Jishi A, 2011, CAN J NEUROL SCI, V38, P612, DOI 10.1017/S0317167100012154
   BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001
   Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033
   Chen SH, 2011, J TRAUMA, V71, P1632, DOI 10.1097/TA.0b013e3182367b3c
   Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077
   Gouello G, 2014, SCI WORLD J, DOI 10.1155/2014/207585
   Huang YH, 2013, J NEUROSURG, V118, P1329, DOI 10.3171/2013.1.JNS121775
   Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215
   Jamous M, 2010, EUR J TRAUMA EMERG S, V36, P465, DOI 10.1007/s00068-010-0002-4
   Josan VA, 2006, CHILD NERV SYST, V22, P1268, DOI 10.1007/s00381-006-0064-0
   Juratli TA, 2014, J NEUROTRAUM, V31, P1521, DOI 10.1089/neu.2013.3241
   Kolias AG, 2016, BRIT J NEUROSURG, V30, P246, DOI 10.3109/02688697.2016.1159655
   Kolias AG, 2013, NAT REV NEUROL, V9, P405, DOI 10.1038/nrneurol.2013.106
   Kramer AH, 2016, NEUROCRIT CARE, V25, P10, DOI 10.1007/s12028-015-0232-8
   Li YM, 2017, J CLIN NEUROSCI, V44, P107, DOI 10.1016/j.jocn.2017.05.026
   Li YM, 2015, BRAIN INJURY, V29, P981, DOI 10.3109/02699052.2014.989405
   Lichte P, 2015, EUR J MED RES, V20, DOI 10.1186/s40001-015-0159-8
   Manuel Vinas-Rios Juan, 2015, Asian J Neurosurg, V10, P190, DOI 10.4103/1793-5482.161171
   Mao X, 2015, THER CLIN RISK MANAG, V11, P1627, DOI 10.2147/TCRM.S89820
   Mhanna MJ, 2015, J NEUROSURG-PEDIATR, V16, P508, DOI 10.3171/2014.10.PEDS14117
   Miller P, 2006, ANESTH ANALG, V103, P869, DOI 10.1213/01.ane.0000237327.12205.dc
   Mohindra S, 2008, SURG NEUROL, V69, P474, DOI 10.1016/j.surneu.2007.02.031
   Nakae Ryuta, 2017, Surg Neurol Int, V8, P214, DOI 10.4103/sni.sni_56_17
   Nakae R, 2016, J NEUROTRAUM, V33, P688, DOI 10.1089/neu.2015.4039
   Nambiar M, 2015, CRIT CARE RESUSC, V17, P67
   Nardi G, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0817-9
   Ostermann RC, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0975-y
   Park Jun-Hee, 2014, Korean J Neurotrauma, V10, P112, DOI 10.13004/kjnt.2014.10.2.112
   Picetti E, 2017, ACTA NEUROCHIR, V159, P615, DOI 10.1007/s00701-017-3118-z
   Potts MB, 2008, ACTA NEUROCHIR SUPPL, V102, P109, DOI 10.1007/978-3-211-85578-2_22
   Spaite DW, 2017, ANN EMERG MED, V70, P522, DOI 10.1016/j.annemergmed.2017.03.027
   Strnad M, 2016, WIEN KLIN WOCHENSCHR, V129, P1
   Tang ZJ, 2018, WORLD NEUROSURG, V119, pE389, DOI 10.1016/j.wneu.2018.07.173
   Tapper Julius, 2017, Surg Neurol Int, V8, P141, DOI 10.4103/sni.sni_453_16
   TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691
   Utter GH, 2011, J NEUROTRAUM, V28, P155, DOI 10.1089/neu.2010.1451
   Vilcinis R, 2017, WORLD NEUROSURG, V101, P335, DOI 10.1016/j.wneu.2017.02.010
   Watts Hannah F, 2012, J Emerg Trauma Shock, V5, P131, DOI 10.4103/0974-2700.96481
   Wen L, 2011, BRAIN INJURY, V25, P1318, DOI 10.3109/02699052.2011.608214
   Wettervik TS, 2018, ACTA NEUROCHIR, V160, P229, DOI 10.1007/s00701-017-3418-3
   White CL, 2009, J TRAUMA, V67, P508, DOI 10.1097/TA.0b013e3181b2519f
   Yang CJ, 2011, J TRAUMA, V71, pE132, DOI 10.1097/TA.0b013e31820ea36b
   Yuan F, 2012, J NEUROTRAUM, V29, P2137, DOI 10.1089/neu.2011.2233
   Yuan Q, 2016, J NEUROTRAUM, V33, P1279, DOI 10.1089/neu.2015.4205
   Zhang K, 2016, BRIT J NEUROSURG, V30, P251, DOI 10.3109/02688697.2016.1139052
   Zygun DA, 2004, NEUROSURGERY, V55, P877, DOI 10.1227/01.NEU.0000137658.14906.E4
NR 47
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E298
EP E305
DI 10.1016/j.wneu.2019.10.053
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200036
PM 31629151
DA 2020-05-12
ER

PT J
AU Tao, YQ
   Huang, CN
   Li, FC
   Chen, QX
AF Tao, Yiqing
   Huang, Chunneng
   Li, Fangcai
   Chen, Qixin
TI Magnetic Resonance Imaging Study of Oblique Corridor and Trajectory to
   L1-L5 Intervertebral Disks in Lateral Position
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lateral position; Lumbar interbody fusion; Magnetic resonance imaging;
   Oblique corridor; Retroperitoneal vessel; Trajectory
ID LUMBAR INTERBODY FUSION; RETROPERITONEAL TRANSPSOAS APPROACH; SURGICAL
   APPROACH; PSOAS MUSCLE; COMPLICATIONS; SPINE; ANATOMY; PLEXUS
AB OBJECTIVE: This study investigated the retroperitoneal oblique corridor and trajectory of L1-L5 as the lateral surgical access to the intervertebral disks in the Chinese population and detected the potential relationship between the corridor or trajectory and vertebral parameters, including disk axis, psoas muscle, and retroperitoneal vessel.
   METHODS: Seventy magnetic resonance imaging studies performed from January 2017 to January 2019 were investigated. The oblique corridor was defined as the distance between the left lateral border of the retroperitoneal vessel and the anterior border of psoas. The trajectory was defined as the distance between the retroperitoneal vessel and lumbar plexus.
   RESULTS: The oblique corridor analysis to L1-L5 disks have the following mean distances: L1-2 13.36 mm, L2-3 13.36 mm, L3-4 12.37 mm, and L4-5 10.36 mm. There was no difference in the L1- L5 corridor between genders. And the position of retroperitoneal vessel was negatively correlated with the corridor width. The trajectory measurements to L1-L5 disks have the following mean distances: L1-2 27.44 mm, L2-3 30.86 mm, L3 - 4 30.73 mm, and L4-5 24.36 mm. Moreover, the vertebral parameters, including the disk axis and psoas muscle, were positively correlated with the trajectory width. Otherwise, the position of retroperitoneal vessel was negatively correlated with the trajectory width.
   CONCLUSIONS: Compared with previous studies, the safe surgical area of the Chinese is generally smaller than that of Caucasian. The position of the retroperitoneal vessel is the vital potential to limit the corridor and trajectory. Preoperative assessment of vertebral parameters, especially vascular structure, is essential for planning surgical process.
C1 [Tao, Yiqing; Li, Fangcai; Chen, Qixin] Zhejiang Univ, Affiliated Hosp 2, Dept Orthoped, Sch Med, Hangzhou, Zhejiang, Peoples R China.
   [Huang, Chunneng] Zhejiang Univ, Affiliated Hangzhou Peoples Hosp 1, Dept Orthoped, Sch Med, Hangzhou, Zhejiang, Peoples R China.
RP Chen, QX (reprint author), Zhejiang Univ, Affiliated Hosp 2, Dept Orthoped, Sch Med, Hangzhou, Zhejiang, Peoples R China.
EM zrcqx@zju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81401011, 81472114, 81572177, 81772379]; China
   Postdoctoral Science FoundationChina Postdoctoral Science Foundation
   [2017M612011]; Nature Science Foundation of Zhejiang ProvinceNatural
   Science Foundation of Zhejiang Province [LQ18H060003]; National Health
   Commission Science Foundation of China [WKJ-ZJ-1903]
FX This study was partly supported by grants from the National Natural
   Science Foundation of China (81401011, 81472114, 81572177, and
   81772379); China Postdoctoral Science Foundation (2017M612011); Nature
   Science Foundation of Zhejiang Province (LQ18H060003); and National
   Health Commission Science Foundation of China (WKJ-ZJ-1903).
CR Abe K, 2017, SPINE, V42, P55, DOI 10.1097/BRS.0000000000001650
   Ahmadian A, 2013, J NEUROSURG-SPINE, V18, P289, DOI 10.3171/2012.11.SPINE12755
   Aichmair Alexander, 2015, J Spinal Disord Tech, V28, P71, DOI 10.1097/BSD.0000000000000067
   Anand N, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09278
   Campbell PG, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2017.10.FOCUS17566
   Capener N, 1935, Proc R Soc Med, V28, P1369
   Cummock MD, 2011, J NEUROSURG-SPINE, V15, P11, DOI 10.3171/2011.2.SPINE10374
   Davis TT, 2014, J NEUROSURG-SPINE, V21, P785, DOI 10.3171/2014.7.SPINE13564
   Davis TT, 2011, J BONE JOINT SURG AM, V93A, P1482, DOI 10.2106/JBJS.J.00962
   Fujibayashi S, 2017, SPINE, V42, P1478, DOI 10.1097/BRS.0000000000002139
   Graham RB, 2014, NEUROSURG CLIN N AM, V25, P219, DOI 10.1016/j.nec.2013.12.002
   Guerin P, 2011, SURG RADIOL ANAT, V33, P665, DOI 10.1007/s00276-011-0798-6
   Hijji FY, 2017, SPINE J, V17, P1412, DOI 10.1016/j.spinee.2017.04.022
   Hu WK, 2011, EUR SPINE J, V20, P557, DOI 10.1007/s00586-010-1609-1
   Hussain NS, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.8.FOCUS11165
   Isaacs RE, 2010, SPINE, V35, pS322, DOI 10.1097/BRS.0b013e3182022e04
   Kepler CK, 2011, EUR SPINE J, V20, P550, DOI 10.1007/s00586-010-1593-5
   Kotwal S, 2015, J SPINAL DISORD TECH, V28, P119, DOI 10.1097/BSD.0b013e3182706ce7
   Kulkarni SS, 2003, EUR SPINE J, V12, P48, DOI 10.1007/s00586-002-0460-4
   Le TV, 2012, SPINE, V37, P1268, DOI 10.1097/BRS.0b013e3182458b2f
   Lehmen JA, 2015, EUR SPINE J, V24, pS287, DOI 10.1007/s00586-015-3886-1
   Li JXJL, 2018, WORLD NEUROSURG, V111, pE678, DOI 10.1016/j.wneu.2017.12.136
   Liu LH, 2014, INDIAN J ORTHOP, V48, P178, DOI 10.4103/0019-5413.128762
   Mayer HM, 1997, SPINE, V22, P691, DOI 10.1097/00007632-199703150-00023
   Mehta VA, 2011, NEUROL RES, V33, P38, DOI 10.1179/016164110X12681290831289
   Mobbs Ralph J, 2015, J Spine Surg, V1, P2, DOI 10.3978/j.issn.2414-469X.2015.10.05
   Molinares DM, 2016, J NEUROSURG-SPINE, V24, P248, DOI 10.3171/2015.3.SPINE13976
   Nourian AA, 2016, SPINE, V41, pE73, DOI 10.1097/BRS.0000000000001160
   Oliveira L, 2010, SPINE, V35, pS331, DOI 10.1097/BRS.0b013e3182022db0
   Ozgur Burak M, 2006, Spine J, V6, P435, DOI 10.1016/j.spinee.2005.08.012
   Phan K, 2016, J CLIN NEUROSCI, V31, P23, DOI 10.1016/j.jocn.2016.02.030
   Pimenta L, 2012, SCI WORLD J, DOI 10.1100/2012/381814
   Rodgers W B, 2010, SAS J, V4, P63, DOI 10.1016/j.esas.2010.03.001
   Rodgers WB, 2011, SPINE, V36, P26, DOI 10.1097/BRS.0b013e3181e1040a
   Rodgers WB, 2010, J SPINAL DISORD TECH, V23, P393, DOI 10.1097/BSD.0b013e3181b31729
   Saraph V, 2004, EUR SPINE J, V13, P425, DOI 10.1007/s00586-004-0722-4
   Sekharappa V, 2013, EUR SPINE J, V22, P2039, DOI 10.1007/s00586-013-2748-y
   Tormenti MJ, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09263
   Uribe JS, 2010, J NEUROSURG-SPINE, V13, P260, DOI 10.3171/2010.3.SPINE09766
   Wang MY, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.1.FOCUS09286
   Xu ZK, 2019, WORLD NEUROSURG, V126, pE860, DOI 10.1016/j.wneu.2019.03.001
   Yusof MI, 2014, SPINE, V39, pE811, DOI 10.1097/BRS.0000000000000368
   Zhang F, 2017, EUR SPINE J, V26, P646, DOI 10.1007/s00586-016-4645-7
   Zhuang ZR, 2011, SPINE, V36, pE1547, DOI 10.1097/BRS.0b013e318210f063
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E616
EP E623
DI 10.1016/j.wneu.2019.10.147
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200075
PM 31678316
DA 2020-05-12
ER

PT J
AU Tardivo, V
   Labidi, M
   Passeri, T
   Bernat, AL
   Zenga, F
   Voormolen, E
   Penet, N
   Froelich, S
AF Tardivo, Valentina
   Labidi, Moujahed
   Passeri, Thibault
   Bernat, Anne Laure
   Zenga, Francesco
   Voormolen, Eduard
   Penet, Nicolas
   Froelich, Sebastien
TI From the Occipital Condyle to the Sphenoid Sinus: Extradural Extension
   of the Far Lateral Transcondylar Approach with Endoscopic Assistance
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chordoma; Craniovertebral junction; Endoscopic assistance; Far lateral;
   Transcondylar approach
ID CRANIOVERTEBRAL JUNCTION; ENDONASAL APPROACH
AB BACKGROUND: Surgical management of extensive skull base tumors, such as chordoma and chondrosarcoma, remains very challenging. The need for gross total removal to improve survival must be weighed against the risk of injury to neurovascular structures and the loss of stability at the craniovertebral junction. In cases of tumors that are already compromising craniovertebral junction stability, the occipital condyle can be exploited as a deep keyhole to reach the clivus, petrous apex, and sphenoid sinus.
   METHODS: We performed an anatomic study on 7 cadaveric specimens to describe the main landmarks and boundaries of the corridor. We also provide a clinical case to demonstrate the feasibility of the approach.
   RESULTS: In all specimens, using the space provided by the condyle, it was possible to drill the petrous bone up to the posterior wall of the sphenoid sinus following the direction of the inferior petrosal sinus. To successfully complete the approach, after the hypoglossal canal was exposed, endoscopic assistance was needed to overcome the narrowing of the visual field provided by the microscope.
   CONCLUSIONS: In cases of invasive skull base tumor involving the craniovertebral junction and affecting its stability, the occipital condyle can be exploited as a deep keyhole to the homolateral and contralateral petrous apex, clivus, and sphenoid sinus.
C1 [Tardivo, Valentina; Labidi, Moujahed; Passeri, Thibault; Bernat, Anne Laure; Voormolen, Eduard; Penet, Nicolas; Froelich, Sebastien] Paris VII Diderot Univ, Lariboisiere Hosp, Dept Neurosurg, Paris, France.
   [Tardivo, Valentina] Univ Torino, Dept Surg Sci, Turin, Italy.
   [Zenga, Francesco] Univ Torino, Div Neurosurg, Dept Neurosci, Turin, Italy.
   [Labidi, Moujahed] Ctr Hosp Univ Montreal, Div Neurosurg, Montreal, PQ, Canada.
RP Tardivo, V (reprint author), Paris VII Diderot Univ, Lariboisiere Hosp, Dept Neurosurg, Paris, France.; Tardivo, V (reprint author), Univ Torino, Dept Surg Sci, Turin, Italy.
EM tardivo.valentina@gmail.com
OI Labidi, Moujahed/0000-0002-7496-8327; Tardivo,
   Valentina/0000-0001-6609-7018
CR Aldana PR, 2012, NEUROSURGERY, V71, P308, DOI 10.1227/NEU.0b013e318266e488
   Bejjani GK, 2000, SURG NEUROL, V54, P109, DOI 10.1016/S0090-3019(00)00255-X
   Benet A, 2014, WORLD NEUROSURG, V81, P385, DOI 10.1016/j.wneu.2013.01.091
   BERTALANFFY H, 1991, NEUROSURGERY, V29, P815, DOI 10.1227/00006123-199112000-00002
   Bhatki AM, 2010, ORAL MAXIL SURG CLIN, V22, P157, DOI 10.1016/j.coms.2009.10.005
   Bruneau M, 2006, NEUROSURGERY, V58, P29, DOI 10.1227/01.NEU.0000193930.74183.42
   Chau AMT, 2010, J CLIN NEUROSCI, V17, P1463, DOI 10.1016/j.jocn.2010.04.007
   Chotai S, 2014, CLIN NEUROL NEUROSUR, V121, P1, DOI 10.1016/j.clineuro.2014.03.004
   de Lara D, 2014, WORLD NEUROSURG, V82, pS121, DOI 10.1016/j.wneu.2014.07.036
   Dehdashti AR, 2008, NEUROSURGERY, V63, P299, DOI 10.1227/01.NEU.0000316414.20247.32
   Fish U, 1980, ACTA NEUROCHIR, V51, P259
   Fraser JF, 2010, J NEUROSURG, V112, P1061, DOI 10.3171/2009.7.JNS081504
   Fukushima T, 1996, MANUAL SKULL BASE DI
   Gardner PA, 2013, NEUROSURGERY, V73, P261, DOI 10.1227/01.neu.0000430821.71267.f2
   GEORGE B, 1995, SKULL BASE SURG, V5, P9, DOI 10.1055/s-2008-1058945
   George B, 2001, OPER TECH NEUROSURG, P168
   Hakuba Akira, 1993, P671
   Hanakita S, 2018, J NEUROL SURG PART B, V79, pS371, DOI 10.1055/s-0038-1667018
   HEROS RC, 1986, J NEUROSURG, V64, P559, DOI 10.3171/jns.1986.64.4.0559
   Kassam AB, 2008, J NEUROSURG, V108, P177, DOI 10.3171/JNS/2008/108/01/0177
   Kshettry VR, 2017, J NEUROSURG, V127, P829, DOI 10.3171/2016.7.JNS16293
   Labidi M, 2019, ENDOSCOPIC KEYHOLE C, P101
   Labidi M, 2018, WORLD NEUROSURG, V7, P31183
   Pant H, 2010, SKULL BASE-INTERD AP, V20, P35, DOI 10.1055/s-0029-1242983
   Perez-Orribo L, 2013, NEUROSURGERY, V72, P1021, DOI 10.1227/NEU.0b013e31828d6231
   Prevedello DM, 2010, ACTA NEUROCHIR, V152, P1223, DOI 10.1007/s00701-009-0563-3
   Stacchiotti S, 2015, LANCET ONCOL, V16, pE71, DOI 10.1016/S1470-2045(14)71190-8
   Velat GJ, 2012, WORLD NEUROSURG, V77, P619, DOI 10.1016/j.wneu.2011.04.009
   Vescan AD, 2007, LARYNGOSCOPE, V117, P1338, DOI 10.1097/MLG.0b013e31806146cd
   Vishteh AG, 1999, J NEUROSURG, V90, P91, DOI 10.3171/spi.1999.90.1.0091
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E771
EP E782
DI 10.1016/j.wneu.2019.10.190
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200090
PM 31734422
DA 2020-05-12
ER

PT J
AU Tasiou, A
   Tzerefos, C
   Alleyne, CH
   Boccardi, E
   Karlsson, B
   Kitchen, N
   Spetzler, RF
   Tolias, CM
   Fountas, KN
AF Tasiou, Anastasia
   Tzerefos, Christos
   Alleyne, Cargill H., Jr.
   Boccardi, Edoardo
   Karlsson, Bengt
   Kitchen, Neil
   Spetzler, Robert F.
   Tolias, Christos M.
   Fountas, Kostas N.
TI Arteriovenous Malformations: Congenital or Acquired Lesions?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acquired lesions; Cerebral arteriovenous malformations; Congenital
   lesions; De novo formation; Socioeconomic ramifications
ID TERM-FOLLOW-UP; NATURAL-HISTORY; FAMILIAL OCCURRENCE; SERIAL
   ANGIOGRAPHY; MOYAMOYA-DISEASE; GROWTH-FACTOR; BRAIN; CHILD; RECURRENCE;
   HEMORRHAGE
AB OBJECTIVE: Arteriovenous malformations (AVMs) were believed to be congenital. However, an increasing number of de novo AVM cases have questioned this doctrine.
   METHODS: A consensus meeting of international experts attempted to establish a consensus on the nature of these relatively rare but challenging vascular lesions. In addition, an extensive search of the subject was performed using the PubMed medical database.
   RESULTS: All participants agreed that genetic factors may play a role in the pathogenesis of AVMs. All but 1 participant believed that an underlying genetic predisposition may be detected later on in a patient's life, whereas genetic variations may contribute to sporadic AVM formation. The presence of genetic variations alone may not be enough for an AVM formation. A second hit is probably required. This consensus opinion is also supported by our literature search.
   CONCLUSIONS: We discuss the literature on the genetics of AVMs and compare it with the consensus meeting outcomes. The congenital or noncongenital character of intracranial AVMs has an impact on the understanding their biological behavior, as well as their efficient short-term and long-term management.
C1 [Tasiou, Anastasia; Tzerefos, Christos; Fountas, Kostas N.] Univ Thessaly, Univ Hosp Larissa, Sch Med, Dept Neurosurg, Larisa, Greece.
   [Alleyne, Cargill H., Jr.] Univ Neurosci Augusta Back, Augusta, GA USA.
   [Boccardi, Edoardo] Osped Niguarda Ca Granda, Dept Diagnost & Intervent Neuroradiol, Milan, Italy.
   [Karlsson, Bengt] Natl Univ Singapore Hosp, Dept Surg, Div Neurosurg, Singapore, Singapore.
   [Kitchen, Neil] Natl Hosp Neurol & Neurosurg, Victor Horsley Dept Neurosurg, Queen Sq, London, England.
   [Spetzler, Robert F.] Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
   [Tolias, Christos M.] Kings Coll Hosp London, Dept Neurovasc Surg, London, England.
RP Tasiou, A (reprint author), Univ Thessaly, Univ Hosp Larissa, Sch Med, Dept Neurosurg, Larisa, Greece.
EM ttasiou@yahoo.com
OI Tasiou, Anastasia/0000-0002-8853-540X
CR Achrol AS, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.2.FOCUS0926
   Akimoto H, 2003, NEUROSURGERY, V52, P228, DOI 10.1097/00006123-200301000-00030
   Alvarez H, 2012, J NEUROSURG-PEDIATR, V9, P327, DOI 10.3171/2011.12.PEDS11312
   Andaluz N, 2004, SURG NEUROL, V62, P324, DOI 10.1016/j.surneu.2003.11.030
   Bai YH, 2012, CHILD NERV SYST, V28, P1981, DOI 10.1007/s00381-012-1878-6
   BROWN RD, 1988, J NEUROSURG, V68, P352, DOI 10.3171/jns.1988.68.3.0352
   Bulsara KR, 2002, NEUROSURGERY, V50, P1137, DOI 10.1097/00006123-200205000-00036
   Chen YM, 2008, NEUROSURGERY, V62, P1340, DOI 10.1227/01.neu.0000333306.64683.b5
   CRAWFORD PM, 1986, J NEUROL NEUROSUR PS, V49, P1, DOI 10.1136/jnnp.49.1.1
   da Costa L, 2009, STROKE, V40, P100, DOI 10.1161/STROKEAHA.108.524678
   Dalton A, 2018, BRIT J NEUROSURG, V32, P305, DOI 10.1080/02688697.2018.1478060
   Delev D, 2017, J NEUROSURG, V126, P1552, DOI 10.3171/2016.3.JNS151731
   Di Rocco C, 2006, CHILD NERV SYST, V22, P909, DOI 10.1007/s00381-006-0143-2
   Dogan SN, 2019, WORLD NEUROSURG, V126, P257, DOI 10.1016/j.wneu.2019.02.226
   Duong DH, 1999, NEW ENGL J MED, V340, P1812
   Friedman JA, 2000, J NEUROSURG, V93, P1058, DOI 10.3171/jns.2000.93.6.1058
   Fujimura M, 2014, J NEUROSURG-PEDIATR, V13, P647, DOI 10.3171/2014.3.PEDS13610
   FULTS D, 1984, NEUROSURGERY, V15, P658, DOI 10.1227/00006123-198411000-00003
   Fuse T, 2001, NEUROL MED-CHIR, V41, P83, DOI 10.2176/nmc.41.83
   Gabriel EM, 1996, J NEUROSURG, V84, P879, DOI 10.3171/jns.1996.84.5.0879
   Gonzalez LF, 2005, J NEUROSURG, V102, P726, DOI 10.3171/jns.2005.102.4.0726
   GRAF CJ, 1983, J NEUROSURG, V58, P331, DOI 10.3171/jns.1983.58.3.0331
   Gross BA, 2013, J NEUROSURG, V118, P437, DOI 10.3171/2012.10.JNS121280
   Harris OA, 2000, NEUROL RES, V22, P473
   Hernesniemi JA, 2008, NEUROSURGERY, V63, P823, DOI 10.1227/01.NEU.0000330401.82582.5E
   Herzig R, 2000, EUR J NEUROL, V7, P95, DOI 10.1046/j.1468-1331.2000.00007.x
   Humphreys RP, 1996, PEDIATR NEUROSURG, V25, P277, DOI 10.1159/000121140
   Jeffree RL, 2009, PEDIATR NEUROSURG, V45, P296, DOI 10.1159/000235604
   Kader A, 1996, J NEUROSURG, V85, P14, DOI 10.3171/jns.1996.85.1.0014
   KADOYA C, 1994, SURG NEUROL, V42, P234, DOI 10.1016/0090-3019(94)90269-0
   Karlsson B, 1997, MINIM INVAS NEUROSUR, V40, P40, DOI 10.1055/s-2008-1053413
   Karlsson B, 2018, J NEUROSURG, V129, P10, DOI 10.3171/2018.7.GKS181278
   Kilbourn KJ, 2014, NEUROSURG REV, V37, P685, DOI 10.1007/s10143-014-0557-3
   Kim H, 2014, NEUROLOGY, V83, P590, DOI 10.1212/WNL.0000000000000688
   Kim H, 2011, ACTA NEUROCHIR SUPPL, V111, P83, DOI 10.1007/978-3-7091-0693-8_14
   Kim H, 2009, CEREBROVASC DIS, V27, P176, DOI 10.1159/000185609
   Kim H, 2009, STROKE, V40, pS95, DOI 10.1161/STROKEAHA.108.533216
   Koch MJ, 2016, J CLIN NEUROSCI, V28, P162, DOI 10.1016/j.jocn.2015.11.021
   Komiyama M, 2016, NEUROL MED-CHIR, V56, P317, DOI 10.2176/nmc.ra.2016-0051
   KRAYENBUHL HA, 1977, ACTA NEUROCHIR, V36, P215, DOI 10.1007/BF01405393
   Larsen PD, 1997, PEDIATR NEUROL, V17, P74, DOI 10.1016/S0887-8994(97)00007-6
   Lasjaunias P, 1997, Interv Neuroradiol, V3, P275
   Leblanc GG, 2009, STROKE, V40, pE694, DOI 10.1161/STROKEAHA.109.563692
   Leblanc R, 1996, J NEUROSURG, V85, P1135, DOI 10.3171/jns.1996.85.6.1135
   Lindqvist M, 2000, NEUROSURGERY, V46, P803, DOI 10.1097/00006123-200004000-00006
   Lo Presti A, 2018, ACTA NEUROCHIR, V160, P2191, DOI 10.1007/s00701-018-3668-8
   Lv XL, 2018, NEURORADIOL J, V31, P224, DOI 10.1177/1971400918759811
   Mahajan A, 2010, NEUROSURG REV, V33, P115, DOI 10.1007/s10143-009-0227-z
   Markham L, 2015, J NEUROL NEUROSCI, V6, P36
   Mathon B, 2013, NEUROLOGY, V81, P398, DOI 10.1212/WNL.0b013e31829c5cd5
   Mckinney JS, 2008, J NEUROSURG, V109, P1098, DOI 10.3171/JNS.2008.109.12.1098
   MENDELOW AD, 1987, J NEUROL NEUROSUR PS, V50, P980, DOI 10.1136/jnnp.50.8.980
   Mikhak B, 2011, CEREBROVASC DIS, V31, P338, DOI 10.1159/000322601
   Miller BA, 2014, J NEUROSURG-PEDIATR, V14, P418, DOI 10.3171/2014.7.PEDS1431
   Miyasaka Y, 2003, J NEUROSURG, V98, P190, DOI 10.3171/jns.2003.98.1.0190
   Morales-Valero SF, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.6.FOCUS14234
   Morgan MK, 2017, ACTA NEUROCHIR, V159, P1457, DOI 10.1007/s00701-017-3217-x
   Morgan MK, 2012, J NEUROSURG, V117, P934, DOI 10.3171/2012.8.JNS12351
   MORIOKA T, 1988, NEUROSURGERY, V23, P101, DOI 10.1227/00006123-198807000-00018
   Mullan S, 1996, J NEUROSURG, V85, P1, DOI 10.3171/jns.1996.85.1.0001
   Nakamura M, 2016, NEUROSURGERY, V78, pE596, DOI 10.1227/NEU.0000000000001025
   Neil Jayson A, 2014, Surg Neurol Int, V5, P148, DOI 10.4103/2152-7806.142796
   Nussbaum ES, 1998, NEUROSURGERY, V43, P347, DOI 10.1097/00006123-199808000-00103
   O'Shaughnessy BA, 2005, J NEUROSURG, V102, P238, DOI 10.3171/jns.2005.102.2.0238
   Ogilvy CS, 2001, CIRCULATION, V103, P2644
   ONDRA SL, 1990, J NEUROSURG, V73, P387, DOI 10.3171/jns.1990.73.3.0387
   Ozsarac Murat, 2012, J Emerg Med, V43, pe17, DOI 10.1016/j.jemermed.2009.05.035
   Pabaney AH, 2016, WORLD NEUROSURG, V96, DOI 10.1016/j.wneu.2016.09.062
   PARKINSON D, 1980, J NEUROSURG, V53, P285, DOI 10.3171/jns.1980.53.3.0285
   Pawlikowska L, 2005, STROKE, V36, P2278, DOI 10.1161/01.STR.0000182253.91167.fa
   PEETERS FLM, 1982, NEURORADIOLOGY, V23, P113, DOI 10.1007/BF00367248
   Petridis AK, 2016, ACTA NEUROCHIR, V158, P791, DOI 10.1007/s00701-016-2727-2
   PORTER AJ, 1969, BRIT J RADIOL, V42, P667, DOI 10.1259/0007-1285-42-501-667
   Potter CA, 2009, J NEUROINTERV SURG, V1, P151, DOI 10.1136/jnis.2009.000299
   Reck SD, 2005, J NEURO-OPHTHALMOL, V25, P205, DOI 10.1097/01.wno.0000177301.82963.9f
   Rodriguez-Arias C, 2000, CHILD NERV SYST, V16, P363, DOI 10.1007/s003810050532
   Salman RAS, 2014, JAMA-J AM MED ASSOC, V311, P1661, DOI 10.1001/jama.2014.3200
   Santos R, 2018, WORLD NEUROSURG, V111, P341, DOI 10.1016/j.wneu.2017.12.145
   Schmit BP, 1996, J NEUROSURG, V84, P677, DOI 10.3171/jns.1996.84.4.0677
   Shi S, 2018, J NEUROSURG, V128, P506, DOI 10.3171/2016.9.JNS161710
   Shidoh Satoka, 2017, NMC Case Rep J, V4, P89, DOI 10.2176/nmccrj.cr.2016-0272
   Shimoda Y, 2016, J NEUROSURG-PEDIATR, V17, P330, DOI 10.3171/2015.7.PEDS15245
   Song JK, 2007, J NEUROSURG, V106, P384, DOI 10.3171/ped.2007.106.5.384
   Sonstein WJ, 1996, J NEUROSURG, V85, P838, DOI 10.3171/jns.1996.85.5.0838
   Stevens J, 2009, AM J NEURORADIOL, V30, P111, DOI 10.3174/ajnr.A1255
   Sturiale CL, 2013, BRAIN, V136, P665, DOI 10.1093/brain/aws180
   Su H, 2010, AM J PATHOL, V176, P1018, DOI 10.2353/ajpath.2010.090453
   van Beijnum J, 2007, J NEUROL NEUROSUR PS, V78, P1213, DOI 10.1136/jnnp.2006.112227
   WALTIMO O, 1973, J NEUROL SCI, V19, P21, DOI 10.1016/0022-510X(73)90052-X
   WILLINSKY RA, 1990, NEURORADIOLOGY, V32, P207, DOI 10.1007/BF00589113
   Wu J, 2014, CHILD NERV SYST, V30, P1277, DOI 10.1007/s00381-014-2413-8
   Yasargil MG, 1987, AVM BRAIN HIST EMBRY
   Yeo JJY, 2015, CHILD NERV SYST, V31, P609, DOI 10.1007/s00381-014-2609-y
NR 93
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E799
EP E807
DI 10.1016/j.wneu.2019.11.001
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200093
PM 31715403
DA 2020-05-12
ER

PT J
AU Tawk, RG
   Akinduro, OO
   Grewal, SS
   Brasiliense, L
   Grand, W
   Grotenhuis, A
AF Tawk, Rabih G.
   Akinduro, Oluwaseun O.
   Grewal, Sanjeet S.
   Brasiliense, Leonardo
   Grand, Walter
   Grotenhuis, Andre
TI Endoscopic Transforaminal Transchoroidal Approach to the Third Ventricle
   for Cystic and Solid Tumors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Choroidal fissure; Colloid cyst; Endoscope; Third ventricle;
   Transchoroidal
ID VENTRICULAR COLLOID CYSTS; LATERAL TRANSCALLOSAL APPROACH; MICROSURGICAL
   TREATMENT; CHOROIDAL FISSURE; FORNIX DAMAGE; RESECTION; EXPERIENCE;
   MANAGEMENT; REMOVAL; ANATOMY
AB BACKGROUND: Endoscopic access to the third ventricle is limited by the confinements of the foramen of Monro and can be aided by opening of the choroidal fissure.
   OBJECTIVE: We describe the endoscopic transforaminal transchoroidal (ETTC) approach to the third ventricle with opening of the choroidal fissure to enlarge the posterior foramen of Monro for treatment of various third ventricular diseases.
   METHODS: We completed a retrospective review of a prospectively collected database at 3 tertiary academic facilities. The search included patients who underwent endoscopic transcranial procedures between 2005 and 2018. All 13 patients included in this study were treated using the ETTC approach for lesions in the third ventricle using a rigid 6-mm working endoscope.
   RESULTS: There were 7 women and 6 men with a mean age of 44 years (standard deviation, 16 years). Third ventricular diseases included colloid cyst, craniopharyngioma, anaplastic astrocytoma, subependymal giant cell astrocytoma, metastatic lung adenocarcinoma, and lymphoma. Resection was complete in 7 patients and near complete in 4. Two patients had biopsy of a thalamic tumor and third ventriculostomy. The mean follow-up time was 44 months (standard deviation, 36 months; range, 9-121 months). There were no intraoperative or postoperative complications related to the approach.
   CONCLUSIONS: ETTC approach is a safe and effective method for enlargement of the foramen of Monro. The approach improves maneuverability of the endoscope and allows a broad range of movement and increased angulation within the foramen of Monro. Attention to anatomy is paramount to avoid injury to the venous structures and fornix.
C1 [Tawk, Rabih G.; Akinduro, Oluwaseun O.; Grewal, Sanjeet S.] Mayo Clin, Dept Neurosurg, Jacksonville, FL 32224 USA.
   [Grand, Walter] Univ Buffalo, Dept Neurosurg, Buffalo, NY USA.
   [Brasiliense, Leonardo] Univ Arizona, Dept Neurosurg, Tucson, AZ USA.
   [Grotenhuis, Andre] Radboud Univ Nijmegen, Dept Neurosurg, Nijmegen, Netherlands.
RP Tawk, RG (reprint author), Mayo Clin, Dept Neurosurg, Jacksonville, FL 32224 USA.
EM Tawk.Rabih@mayo.edu
CR Agha RA, 2018, INT J SURG, V60, P279, DOI 10.1016/j.ijsu.2018.10.031
   Anderson RCE, 2003, NEUROSURG CLIN N AM, V14, P509, DOI 10.1016/S1042-3680(03)00054-8
   Desai KI, 2002, SURG NEUROL, V57, P295, DOI 10.1016/S0090-3019(02)00701-2
   FORNARI M, 1981, J NEUROSURG, V54, P64, DOI 10.3171/jns.1981.54.1.0064
   Greenlee JDW, 2008, NEUROSURGERY, V63, P51, DOI [10.1227/01.NEU.0000297004.20222.ED, 10.1227/01.neu.0000317373.00018.6f]
   Grondin RT, 2007, CAN J NEUROL SCI, V34, P197, DOI 10.1017/S0317167100006041
   Hernesniemi J, 1996, SURG NEUROL, V45, P2, DOI 10.1016/0090-3019(95)00379-7
   Hernesniemi J, 2008, SURG NEUROL, V69, P447, DOI 10.1016/j.surneu.2007.11.005
   Hernesniemi J, 2008, SURG NEUROL, V69, P455, DOI 10.1016/j.surneu.2007.12.004
   Horn EM, 2007, NEUROSURGERY, V60, P613, DOI 10.1227/01.NEU.0000255409.61398.EA
   Iacoangeli M, 2014, J NEUROSURG, V120, P1471, DOI 10.3171/2014.1.JNS131102
   Ibanez-Botella G, 2014, NEUROSURG REV, V37, P227, DOI 10.1007/s10143-014-0529-7
   Ibrahim I, 2009, BRIT J HOSP MED, V70, P478, DOI 10.12968/hmed.2009.70.8.43545
   JEEVES MA, 1979, J NEUROL NEUROSUR PS, V42, P134, DOI 10.1136/jnnp.42.2.134
   Jin BZ, 2015, J NEUROSURG SCI, V59, P19
   Kasowski HJ, 2005, NEUROSURGERY, V57, P361, DOI 10.1227/01.NEU.0000176652.59747.40
   Kern KC, 2012, NEUROIMAGE, V59, P2932, DOI 10.1016/j.neuroimage.2011.09.071
   Kwok SC, 2010, HIPPOCAMPUS, V20, P413, DOI 10.1002/hipo.20643
   LAVYNE MH, 1983, NEUROSURGERY, V12, P86, DOI 10.1227/00006123-198301000-00013
   LEWIS AI, 1994, J NEUROSURG, V81, P174, DOI 10.3171/jns.1994.81.2.0174
   Mathiesen T, 1997, J NEUROSURG, V86, P5, DOI 10.3171/jns.1997.86.1.0005
   Milligan BD, 2010, NEUROSURGERY, V67, P1483, DOI 10.1227/NEU.0b013e3181f7eb68
   Mishra S, 2010, NEUROL INDIA, V58, P412, DOI 10.4103/0028-3886.66222
   NAGATA S, 1988, SURG NEUROL, V30, P3, DOI 10.1016/0090-3019(88)90180-2
   Rodziewicz GS, 2000, NEUROSURGERY, V46, P655, DOI 10.1097/00006123-200003000-00025
   Symss NP, 2011, NEUROL INDIA, V59, P53, DOI 10.4103/0028-3886.84334
   Ulm AJ, 2009, J NEUROSURG, V111, P600, DOI 10.3171/2008.7.JNS08124
   Viale GL, 2001, NEUROSURGERY, V49, P986
   Araujo JLV, 2017, J NEUROSURG, V127, P209, DOI 10.3171/2016.8.JNS16403
   Wen HT, 1998, NEUROSURGERY, V42, P1205, DOI 10.1097/00006123-199806000-00001
   Winkler PA, 2000, NEUROSURGERY, V46, P879, DOI 10.1097/00006123-200004000-00020
   Wu AH, 2010, NEUROSURGERY, V66, pONS221, DOI 10.1227/01.NEU.0000369920.68166.6C
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E453
EP E459
DI 10.1016/j.wneu.2019.10.099
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200054
PM 31669244
DA 2020-05-12
ER

PT J
AU Telfeian, AE
   Shen, J
   Ali, R
   Oyelese, A
   Fridley, J
   Gokaslan, ZL
AF Telfeian, Albert E.
   Shen, Jian
   Ali, Rohaid
   Oyelese, Adetokunbo
   Fridley, Jared
   Gokaslan, Ziya L.
TI Incidence and Implications of Incidental Durotomy in Transforaminal
   Endoscopic Spine Surgery: Case Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE CSF leak; Durotomy; Endoscopic spine surgery; Minimally invasive spine;
   Transforaminal
ID DURAL TEARS; LUMBAR SPINE
AB OBJECTIVE: To evaluate the incidence and outcomes of incidental durotomy in transforaminal endoscopic spine surgery.
   METHODS: Transforaminal lumbar endoscopic procedures were performed by 2 surgeons in 907 patients over a period of 4 years from 2014 to 2018. Patient data were evaluated retrospectively in these patients with a minimum follow-up of 1 year.
   RESULTS: In 907 patients over 4 years there were 5 durotomies: 4 incidental and 1 intentional. The rate for incidental durotomy was therefore 0.4%. There were no adverse outcomes from the incidental durotomies, and only 1 patient noted a headache.
   CONCLUSIONS: Incidental durotomy is a rare complication or transforaminal lumbar endoscopic spine surgery and appears to occur more likely in patients who have undergone previous spine surgery at the site of the endoscopic procedure, not unexpectantly. Glues, patches, and bedrest were among the various methods used after durotomy. In this series there were no cases of symptomatic spinal fluid leakage or pseudomeningocele seen. Only 20% of patients who had durotomies noted a headache in the immediate postoperative period.
C1 [Telfeian, Albert E.; Ali, Rohaid; Oyelese, Adetokunbo; Fridley, Jared; Gokaslan, Ziya L.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Shen, Jian] Mohawk Valley Orthoped, Amsterdam, NY USA.
RP Telfeian, AE (reprint author), Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
EM ATelfeian@Lifespan.org
OI Shen, Jian/0000-0001-6283-9715
CR Ahn Y, 2011, EUR SPINE J, V20, P58, DOI 10.1007/s00586-010-1493-8
   Cammisa FP, 2000, SPINE, V25, P2663, DOI 10.1097/00007632-200010150-00019
   Epstein NE, 2007, J SPINAL DISORD TECH, V20, P380, DOI 10.1097/BSD.0b013e31802dabd2
   JONES AAM, 1989, SPINE, V14, P443, DOI 10.1097/00007632-198904000-00021
   Matsumoto M, 2010, J ORTHOP SCI, V15, P92, DOI 10.1007/s00776-009-1428-6
   Saxler G, 2005, SPINE, V30, P2298, DOI 10.1097/01.brs.0000182131.44670.f7
   Schroeder GD, 2016, SPINE, V41, P1548, DOI 10.1097/BRS.0000000000001583
   Sen RD, 2018, WORLD NEUROSURG, V120, pE1054, DOI 10.1016/j.wneu.2018.09.009
   Sencer A, 2014, WORLD NEUROSURG, V82, P884, DOI 10.1016/j.wneu.2014.05.032
   Soma K, 2019, SPINE J, V19, P1559, DOI 10.1016/j.spinee.2019.04.015
   Tsutsumimoto T, 2014, BONE JOINT J, V96B, P641, DOI 10.1302/0301-620X.96B5.32957
   Wang JC, 1998, J BONE JOINT SURG AM, V80A, P1728, DOI 10.2106/00004623-199812000-00002
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E951
EP E955
DI 10.1016/j.wneu.2019.11.045
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200111
PM 31734429
DA 2020-05-12
ER

PT J
AU Terakado, T
   Nakai, Y
   Ikeda, G
   Uemura, K
   Matsumaru, Y
   Ishikawa, E
   Matsumura, A
AF Terakado, Toshitsugu
   Nakai, Yasunobu
   Ikeda, Go
   Uemura, Kazuya
   Matsumaru, Yuji
   Ishikawa, Eiichi
   Matsumura, Akira
TI Effectiveness of Low-Dose Intravenous Fentanyl for Postoperative
   Headache Management After Neck Clipping of Ruptured Intracranial
   Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm clipping; Fentanyl; Headache; Subarachnoid hemorrhage
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SUBARACHNOID HEMORRHAGE; MAGNESIUM;
   POLYMORPHISM; GABAPENTIN; MODEL; PAIN
AB BACKGROUND: After subarachnoid hemorrhage (SAH), headache management is often difficult owing to the need to use multiple analgesic drugs. Fentanyl is an opioid we can use after surgery, and it can decrease pain post SAH. The aim of this study was to investigate the effectiveness and safety of fentanyl for management of headache after SAH.
   METHODS: Twenty-two patients who underwent surgical clipping for ruptured intracranial aneurysms and complained of severe headache after the surgery were enrolled. Among them, 9 patients were given fentanyl combined with other analgesic drugs. The numeric rating scale score and dietary intake were measured in the acute phase after the SAH.
   RESULTS: The numeric rating scale scores were significantly lower in the fentanyl ( + ) group. The maximum numeric rating scale decreased to <5 points within 16.5 +/- 2.9 days in the fentanyl ( - ) group and within 12.0 +/- 2.6 days in the fentanyl ( + ) group. The median numeric rating scale decreased to <5 points over 14.0 +/- 4.2 days in the fentanyl ( - ) group and >7.7 +/- 3.8 days in the fentanyl ( + ) group. At day 14, the fentanyl ( + ) group showed significantly better dietary intake than that of the fentanyl ( - ) group.
   CONCLUSIONS: Using fentanyl after surgical clipping for ruptured intracranial aneurysms might decrease headache and produce few adverse effects. Adequate headache control showed improved dietary intake after SAH.
C1 [Terakado, Toshitsugu; Nakai, Yasunobu; Ikeda, Go; Uemura, Kazuya] Univ Tsukuba, Tsukuba Med Ctr Hosp, Dept Neurosurg, Tsukuba, Ibaraki, Japan.
   [Matsumaru, Yuji; Ishikawa, Eiichi; Matsumura, Akira] Univ Tsukuba, Fac Med, Dept Neurosurg, Tsukuba, Ibaraki, Japan.
RP Terakado, T (reprint author), Univ Tsukuba, Tsukuba Med Ctr Hosp, Dept Neurosurg, Tsukuba, Ibaraki, Japan.
EM toshi_0211jp@yahoo.co.jp
CR Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608
   Bonnet U, 2017, EUR NEUROPSYCHOPHARM, V27, P1185, DOI 10.1016/j.euroneuro.2017.08.430
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Dhakal LP, 2015, NEUROCRIT CARE, V22, P414, DOI 10.1007/s12028-014-0086-5
   Dreier JP, 2000, J NEUROSURG, V93, P658, DOI 10.3171/jns.2000.93.4.0658
   FACCHINETTI F, 1991, HEADACHE, V31, P298, DOI 10.1111/j.1526-4610.1991.hed3105298.x
   Fassbender K, 2000, STROKE, V31, P2971, DOI 10.1161/01.STR.31.12.2971
   Frazier JL, 2004, J NEUROSURG, V101, P93, DOI 10.3171/jns.2004.101.1.0093
   Fukuda K, 2009, PAIN, V147, P194, DOI 10.1016/j.pain.2009.09.004
   Glisic EK, 2016, AM J CRIT CARE, V25, P136, DOI 10.4037/ajcc2016486
   Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016
   INAGAWA T, 1995, STROKE, V26, P761, DOI 10.1161/01.STR.26.5.761
   Japanese Society of Clinicalcytology, 2015, JAP GUID MAN STROK 2, P18
   Kita Y, 1999, INT J EPIDEMIOL, V28, P1059, DOI 10.1093/ije/28.6.1059
   Lotsch J, 2006, BEHAV NEUROSCI, V120, P1218, DOI 10.1037/0735-7044.120.6.1218
   Magalhaes JE, 2013, HEADACHE, V53, P1613, DOI 10.1111/head.12165
   Mees SMD, 2010, J NEUROL NEUROSUR PS, V81, P490, DOI 10.1136/jnnp.2009.181404
   Mees SMD, 2012, LANCET, V380, P44, DOI 10.1016/S0140-6736(12)60724-7
   Morad AH, 2016, HEADACHE, V56, P1617, DOI 10.1111/head.12908
   Muroi C, 2014, NEUROCRIT CARE, V20, P240, DOI 10.1007/s12028-013-9930-2
   Naganuma Masaki, 2008, J Stroke Cerebrovasc Dis, V17, P334, DOI 10.1016/j.jstrokecerebrovasdis.2008.04.009
   Niemi T, 1999, J NEUROSURG ANESTH, V11, P188, DOI 10.1097/00008506-199907000-00006
   Patel R, 2016, PHARMACOL RES PERSPE, V4, DOI 10.1002/prp2.205
   Rasouli J, 2019, J CLIN NEUROSCI, V68, P9, DOI 10.1016/j.jocn.2019.07.057
   Rocha PAS, 2015, HEADACHE, V55, P733, DOI 10.1111/head.12563
   Shimony N, 2016, J NEUROSURG, V125, P1513, DOI 10.3171/2015.10.JNS151516
   Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010
   Steiner T, 2013, CEREBROVASC DIS, V35, P93, DOI 10.1159/000346087
   Strassman AM, 2006, J NEUROPHYSIOL, V95, P1298, DOI 10.1152/jn.01293.2005
   van den Bergh WM, 2006, STROKE, V37, P2326, DOI 10.1161/01.STR.0000236841.16055.0f
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E339
EP E345
DI 10.1016/j.wneu.2019.10.062
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200041
PM 31634620
DA 2020-05-12
ER

PT J
AU Tsuyuguchi, S
   Sugiyama, K
   Kinoshita, Y
   Kolakshyapati, M
   Takayasu, T
   Usui, S
   Takano, M
   Yonezawa, U
   Taguchi, A
   Amatya, VJ
   Takeshima, Y
   Kurisu, K
   Yamasaki, F
AF Tsuyuguchi, Sayuru
   Sugiyama, Kazuhiko
   Kinoshita, Yasuyuki
   Kolakshyapati, Manish
   Takayasu, Takeshi
   Usui, Satoshi
   Takano, Motoki
   Yonezawa, Ushio
   Taguchi, Akira
   Amatya, Vishwa Jeet
   Takeshima, Yukio
   Kurisu, Kaoru
   Yamasaki, Fumiyuki
TI Primary and Recurrent Growing Teratoma Syndrome in Central Nervous
   System Nongerminomatous Germ Cell Tumors: Case Series and Review of the
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Central nervous system germ cell tumor; Growing teratoma syndrome;
   Immature teratoma; Mature teratoma; Nongerminomatous germ cell tumor
ID IMMATURE TERATOMA; NEOADJUVANT CHEMOTHERAPY; 2ND-LOOK SURGERY; PINEAL;
   METASTASES; MANAGEMENT; RESECTION; OVARY
AB BACKGROUND: The term "growing teratoma syndrome (GTS)" has been used as follows: patients with germ cell tumor (GET) who present with enlarging original/metastatic masses during or after appropriate systemic chemotherapy despite normalized serum markers. In other words, the definition of the term GTS is not fully established. We analyzed and reviewed our case series regarding GTS that developed after the treatment of central nervous system (CNS) nongerminoatous germ cell tumors (NGGCTs).
   METHODS: Our institutional review board approved this retrospective study. Between 2003 and 2018, we treated 16 patients (16 males; age ranging from 5.4 to 51.9 years, median 13.8) with CNS-NGGCT at our institution. We reviewed those patients and also reviewed the literature about GTS of CNS. We defined primary GTS (p-GTS) as the enlargement of cyst size and/or solid tumor occurred during treatment in the absence of marker elevation, and recurrent GTS (r-GTS) as the enlargement of teratoma after complete response of initial tumors.
   RESULTS: Among 16 patients with CNS-NGGCT, we surgically confirmed mature/immature teratoma components in 15 patients. Two patients underwent surgical removal of tumor before neoadjuvant therapy, and among the rest 14 patients, 6 developed p-GTS, and 2 patients underwent salvage surgery during chemo-/chemoradiotherapy. Those with histologic diagnosis of immature teratoma during salvage surgery had a shorter interval from the initiation of chemoradiotherapy compared with mature teratoma (P< 0.05). One patient developed r-GTS. In the literature review, most of the p-GTS consisted of enlargement with the multicystic component. Histologic diagnosis of immature teratoma during salvage surgery was observed in earlier stages of chemoradiotherapy (P < 0.05, log-rank test). Previous history of p-GTS might be a risk factor of r-GTS.
   CONCLUSIONS: The incidence of p-GTS, enlargement of the cystic component during treatment, is not rare. Physicians need to be aware of this important phenomenon.
C1 [Tsuyuguchi, Sayuru; Kinoshita, Yasuyuki; Kolakshyapati, Manish; Takayasu, Takeshi; Usui, Satoshi; Takano, Motoki; Yonezawa, Ushio; Taguchi, Akira; Kurisu, Kaoru; Yamasaki, Fumiyuki] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan.
   [Amatya, Vishwa Jeet; Takeshima, Yukio] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Pathol, Hiroshima, Japan.
   [Sugiyama, Kazuhiko] Hiroshima Univ Hosp, Dept Clin Oncol, Hiroshima, Japan.
   [Sugiyama, Kazuhiko] Hiroshima Univ Hosp, Neurooncol Program, Hiroshima, Japan.
   [Kolakshyapati, Manish] B&B Hosp, Dept Neurosurg, Gwarko, Lalitpur, Nepal.
RP Yamasaki, F (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan.
EM fyama@hiroshima-u.ac.jp
FU Japan Society for the promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [16K10757]
FX This study was partially supported by Japan Society for the promotion of
   Science Grant-in-Aid for Scientific Research (C) (Grant-in-aid no.
   16K10757).
CR Amsalem H, 2004, GYNECOL ONCOL, V92, P357, DOI 10.1016/j.ygyno.2003.10.024
   Bi WL, 2005, NEUROSURGERY, V56, P188, DOI 10.1227/01.NEU.0000144847.91050.B1
   CALDAS C, 1992, GYNECOL ONCOL, V47, P385, DOI 10.1016/0090-8258(92)90145-9
   CHEN LT, 1990, CHEST, V98, P231, DOI 10.1378/chest.98.1.231
   Committee of Brain Tumor Registry of Japan, 2003, NEUROL MED CHIR TOKY, V43, P1
   DEARNALEY DP, 1990, INT J RADIAT ONCOL, V18, P773, DOI 10.1016/0360-3016(90)90396-2
   Denaro L, 2010, ACTA NEUROCHIR, V152, P1943, DOI 10.1007/s00701-010-0807-2
   DISAIA PJ, 1977, OBSTET GYNECOL, V49, P346
   Friedman JA, 2001, NEUROSURGERY, V48, P518, DOI 10.1097/00006123-200103000-00011
   Glass T, 2014, CHILD NERV SYST, V30, P953, DOI 10.1007/s00381-013-2295-1
   Goldman S, 2015, J CLIN ONCOL, V33, P2464, DOI 10.1200/JCO.2014.59.5132
   Hanna A, 2000, NEUROCHIRURGIE, V46, P568
   Hirano H, 2008, NERVOUS SYST CHILD, V33, P329
   HOFFMAN HJ, 1991, J NEUROSURG, V74, P545, DOI 10.3171/jns.1991.74.4.0545
   Isaka T, 2003, NERV SYST CHILD, V28, P359
   JEFFERY GM, 1991, BRIT J UROL, V67, P195, DOI 10.1111/j.1464-410X.1991.tb15109.x
   Kanamori M, 2018, J NEURO-ONCOL, V138, P601, DOI 10.1007/s11060-018-2827-3
   KATTAN J, 1993, GYNECOL ONCOL, V49, P395, DOI 10.1006/gyno.1993.1147
   Khoo B, 2017, J SURG CASE REP, DOI 10.1093/jscr/rjx038
   Kim CY, 2011, J NEURO-ONCOL, V101, P109, DOI 10.1007/s11060-010-0238-1
   Kitahara T, 2016, TOHOKU J EXP MED, V238, P273, DOI 10.1620/tjem.238.273
   Kong DS, 2009, J NEUROSURG-PEDIATR, V3, P392, DOI 10.3171/2009.1.PEDS0857
   Kurata A, 2010, INT J GYNECOL PATHOL, V29, P438, DOI 10.1097/PGP.0b013e3181cef16b
   Kuwayama Kazuyuki, 2014, No Shinkei Geka, V42, P859
   LEE ACW, 1995, MED PEDIATR ONCOL, V24, P53, DOI 10.1002/mpo.2950240112
   LOGOTHETIS CJ, 1982, CANCER, V50, P1629, DOI 10.1002/1097-0142(19821015)50:8<1629::AID-CNCR2820500828>3.0.CO;2-1
   LORIGAN JG, 1988, AM J ROENTGENOL, V151, P325, DOI 10.2214/ajr.151.2.325
   Matsutani M, 1998, Neurosurg Focus, V5, pe7
   Moiyadi A, 2010, ACTA NEUROCHIR, V152, P137, DOI 10.1007/s00701-009-0332-3
   Myers MH, 2017, ANN NEUROSCI, V24, P12, DOI 10.1159/000464418
   Noudel R, 2008, J NEUROSURG-PEDIATR, V2, P331, DOI 10.3171/PED.2008.2.11.331
   OCallaghan AM, 1997, CANCER, V80, P942, DOI 10.1002/(SICI)1097-0142(19970901)80:5<942::AID-CNCR16>3.0.CO;2-W
   Ogiwara H, 2015, NEUROSURGERY, V76, P658, DOI 10.1227/NEU.0000000000000697
   Oya S, 2014, CHILD NERV SYST, V30, P1455, DOI 10.1007/s00381-014-2396-5
   PANICEK DM, 1990, RADIOLOGY, V175, P499, DOI 10.1148/radiology.175.2.2158120
   Peltier J, 2008, J NEURO-ONCOL, V90, P111, DOI 10.1007/s11060-008-9640-3
   RUSTIN GJS, 1986, CANCER, V57, P2108
   Yagi K, 2004, NEUROL MED-CHIR, V44, P33, DOI 10.2176/nmc.44.33
   Zhang XM, 2013, J CLIN NEUROSCI, V20, P75, DOI 10.1016/j.jocn.2012.05.021
   Zheludkova O G, 2015, Zh Vopr Neirokhir Im N N Burdenko, V79, P69, DOI 10.17116/neiro201579369-74
NR 40
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E360
EP E371
DI 10.1016/j.wneu.2019.10.074
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200044
PM 31751614
DA 2020-05-12
ER

PT J
AU Tuleasca, C
   Paddick, I
   Hopewell, JW
   Jones, B
   Millar, WT
   Hamdi, H
   Porcheron, D
   Levivier, M
   Regis, J
AF Tuleasca, Constantin
   Paddick, Ian
   Hopewell, John W.
   Jones, Bleddyn
   Millar, William T.
   Hamdi, Hussein
   Porcheron, Denis
   Levivier, Marc
   Regis, Jean
TI Establishment of a Therapeutic Ratio for Gamma Knife Radiosurgery of
   Trigeminal Neuralgia: The Critical Importance of Biologically Effective
   Dose Versus Physical Dose
SO WORLD NEUROSURGERY
LA English
DT Article
DE BED; Biologically effective dose; Radiation dose; Radiosurgery;
   Therapeutic ratio; Trigeminal neuralgia
ID STEREOTACTIC RADIOSURGERY; PROSPECTIVE SERIES; SURGERY; OUTCOMES; PAIN;
   MULTIPLE; EFFICACY; IMPACT; CELLS
AB OBJECTIVE: How variations of treatment time affect the safety and efficacy of Gamma Knife (GK) radiosurgery is a matter of considerable debate. With the relative simplicity of treatment planning for trigeminal neuralgia (TN), this question has been addressed in a group of these patients. Using the concept of the biologically effective dose (BED), the effect of the two key variables, dose and treatment time, were considered.
   METHODS: A retrospective analysis was performed of 408 TN cases treated from 1997 to 2010. Treatment involved the use of a single 4 mm isocenter. If conditions allowed, the isocenter was placed at a median distance of 7.5 mm from the emergence of the trigeminal nerve from the brain stem. The effects were assessed in terms of the incidence of the complication, hypoesthesia, and in terms of efficacy using the incidence of pain free after 30 days and 1 and 2 years. These responses were evaluated with respect to both the physical dose and the BED, the latter using a biexponential repair model.
   RESULTS: RE-evaluation showed that the prescription doses, at the 100% isodose, varied from 75 to 97.9 Gy, delivered in 25-135 minutes. The relationship between the physical dose and the incidence of hypoesthesia was not significant; the overall incidence was similar to 20%. However, a clear relationship was found between the BED and the incidence of hypoesthesia, with the incidence increasing from <5% after a BED of similar to 1800 Gy(2.47) to 42% after similar to 2600 Gy(2.47). Efficacy, in terms of freedom from pain, was similar to 90%, irrespective of the BED (1550-2600 Gy(2.47)) at 1 and 2 years. The data suggested that "pain free" status developed more slowly at lower BED values.
   CONCLUSIONS: These results strongly suggest that safety and efficacy might be better achieved by prescribing a specific BED instead of a physical dose. A dose and time to BED conversion table has been prepared to enable iso-BED prescriptions. This finding could dramatically change dose-planning strategies in the future. However, this concept requires validation for other indications for which more complex dose planning is required.
C1 [Tuleasca, Constantin; Levivier, Marc] Cent Univ Hosp, Neurosurg Serv, Lausanne, Switzerland.
   [Tuleasca, Constantin; Levivier, Marc] Cent Univ Hosp, Gamma Knife Ctr, Lausanne, Switzerland.
   [Tuleasca, Constantin; Levivier, Marc] Univ Lausanne, Fac Biol & Med, Lausanne, Switzerland.
   [Tuleasca, Constantin] Swiss Fed Inst Technol, Signal Proc Lab, Lausanne, Switzerland.
   [Tuleasca, Constantin] Sorbonne Univ, Fac Med, Paris, France.
   [Tuleasca, Constantin] CHU Bicetre, Hop Univ Paris Sud, AP HP, Paris, France.
   [Paddick, Ian] Natl Hosp Neurol & Neurosurg, Gamma Knife Ctr, London, England.
   [Hopewell, John W.; Jones, Bleddyn] Univ Oxford, Green Templeton Coll, Oxford, England.
   [Jones, Bleddyn] Univ Oxford, CRUK MRC Oxford Inst Radiat Oncol, Gray Lab, Oxford, England.
   [Millar, William T.] Gartnavel Hosp, Beatson Oncol Ctr, Glasgow, Lanark, Scotland.
   [Hamdi, Hussein; Porcheron, Denis; Regis, Jean] Ctr Hosp Univ La Timone, Funct & Stereotax Neurosurg Serv, Marseille, France.
   [Hamdi, Hussein; Porcheron, Denis; Regis, Jean] Ctr Hosp Univ La Timone, Gamma Knife Unit, Marseille, France.
   [Hamdi, Hussein] Tanta Univ Hosp, Neurosurg Dept, Tanta, Egypt.
RP Hopewell, JW (reprint author), Univ Oxford, Green Templeton Coll, Oxford, England.
EM john.hopewell@gtc.ox.ac.uk
OI TULEASCA, Constantin/0000-0001-6776-1486
CR Arai Y, 2010, J NEUROSURG, V113, P168, DOI 10.3171/2010.7.GKS101049
   Balamucki CJ, 2006, J NEUROSURG, V105, P730, DOI 10.3171/jns.2006.105.5.730
   BEDFORD JS, 1973, RADIAT RES, V54, P316, DOI 10.2307/3573709
   Deeks J J, 2003, Health Technol Assess, V7, piii
   Ergina PL, 2009, LANCET, V374, P1097, DOI 10.1016/S0140-6736(09)61086-2
   FINNEY DJ, 1949, ANN APPL BIOL, V36, P187, DOI 10.1111/j.1744-7348.1949.tb06408.x
   FINNEY DJ, 1948, BIOMETRIKA, V35, P191, DOI 10.2307/2332639
   Flickinger JC, 1997, INT J RADIAT ONCOL, V38, P485, DOI 10.1016/S0360-3016(97)89481-3
   Flickinger JC, 2001, INT J RADIAT ONCOL, V51, P449, DOI 10.1016/S0360-3016(01)01606-6
   Goetsch SJ, 2002, INT J RADIAT ONCOL, V54, P300, DOI 10.1016/S0360-3016(02)02905-X
   Goldstein A, 1968, PRINCIPLES DRUG ACTI, P295
   Hallgren S, 2019, J RADIOSURGERY SBRT, V6, P1
   Hopewell JW, 2013, J RADIOSURGERY SBRT, V2, P251
   Hopewell JW, 2012, PROG NEUROL SURG, V25, P39, DOI 10.1159/000331173
   Kondziolka D, 1998, PROG NEUROL, V14, P21
   Kondziolka D, 1996, J NEUROSURG, V84, P940, DOI 10.3171/jns.1996.84.6.0940
   Kondziolka D, 2010, J NEUROSURG, V112, P758, DOI 10.3171/2009.7.JNS09694
   Lee JYK, 2015, J NEUROSURG, V123, P961, DOI 10.3171/2014.12.JNS142013
   Massager N, 2006, INT J RADIAT ONCOL, V65, P1200, DOI 10.1016/j.ijrobp.2006.01.043
   Millar WT, 2015, PHYS MEDICA, V31, P627, DOI 10.1016/j.ejmp.2015.04.008
   MILLAR WT, 1993, INT J RADIAT BIOL, V64, P275, DOI 10.1080/09553009314551431
   Pop LAM, 2000, RADIOTHER ONCOL, V55, P301, DOI 10.1016/S0167-8140(00)00205-X
   Regis J, 2014, CONTROVERSIES STEREO, P120
   Regis J, 2016, J NEUROSURG, V124, P1079, DOI 10.3171/2015.2.JNS142144
   Regis J, 2016, STEREOT FUNCT NEUROS, V94, P24, DOI 10.1159/000443529
   Tuleasca C, 2014, J NEUROSURG, V121, P210, DOI 10.3171/2014.8.GKS141487
   Tuleasca C, 2014, STEREOT FUNCT NEUROS, V92, P203, DOI 10.1159/000362173
   Tuleasca C, 2014, STEREOT FUNCT NEUROS, V92, P170, DOI 10.1159/000362172
   Tuleasca C, 2012, J NEUROSURG, V117, P181, DOI 10.3171/2012.8.GKS121015
   Young B, 2013, J NEUROSURG, V119, P1166, DOI 10.3171/2013.1.JNS12875
NR 30
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E204
EP E213
DI 10.1016/j.wneu.2019.10.021
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200026
PM 31606504
DA 2020-05-12
ER

PT J
AU Tyagi, G
   Sadashiva, N
   Konar, S
   Aravinda, HR
   Saini, J
   Shukla, D
   Devi, BI
AF Tyagi, Gaurav
   Sadashiva, Nishanth
   Konar, Subhas
   Aravinda, Hanumanthapura Ramalingaiah
   Saini, Jitender
   Shukla, Dhaval
   Devi, Bhagavatula Indira
TI Persistent Trigeminal Artery: Neuroanatomic and Clinical Relevance
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cavernous ICA; Fetal brain circulation; Intracranial aneurysm;
   Persistent trigeminal artery; Trigeminal neuralgia
ID COIL EMBOLIZATION; ARTERIOVENOUS-MALFORMATION; VARIANT ANEURYSM;
   CAROTID-ARTERY; NEURALGIA; BRANCHES; SEGMENTS
AB INTRODUCTION: Persistent trigeminal artery (PTA) is the most common remnant of primitive circulation communicating the developing carotid and vertebrobasilar junction. Although discovered incidentally, an altered hemodynamic may lead to an increased association of aneurysms, vascular malformations, and stroke. Neurosurgeons should be aware of the presence and significance of PTA when interpreting imaging and planning interventions.
   METHODS: We retrospectively reviewed all magnetic resonance angiography and cerebral digital subtraction angiography performed between 2012 and 2017 for the presence of PTA. The radiologic and anatomic details were noted and analyzed along with the clinical profiles. We categorized the radiologic findings with respect to the available classification systems. A review of the available literature was done comparing our results.
   RESULTS: We found 33 cases of incidentally detected PTA. The average age of the patients was 45.42 years. The lateral surface of the proximal cavernous internal carotid artery was the most common origin (n = 23). Only 3 cases had a medial/transsellar course. Most cases were Saltzman/Weon type I (19/33). Intracranial aneurysms were associated with 6 patients (18.18%). Trigeminal neuralgia (TN) was a presenting feature in 5 patients. None had a direct neurovascular conflict at the root entry zone.
   CONCLUSIONS: Our study is one of the largest to describe the incidence of PTA. We emphasized the importance of PTA to the neurosurgeons; increased association of aneurysms, as a route for intervention in occlusive disease of the posterior fossa; risk of injury and bleeding during transsphenoidal surgery; and the association with TN. However, we found that only PTA variants are likely to be associated with TN because of their cisternal course causing NV conflict.
C1 [Tyagi, Gaurav; Sadashiva, Nishanth; Konar, Subhas; Shukla, Dhaval; Devi, Bhagavatula Indira] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India.
   [Aravinda, Hanumanthapura Ramalingaiah; Saini, Jitender] Natl Inst Mental Hlth & Neurosci, Dept Neuroradiol & Intervent Radiol, Bangalore, Karnataka, India.
RP Sadashiva, N (reprint author), Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore, Karnataka, India.
EM nishanth46@gmail.com
RI ; Sadashiva, Nishanth/J-9587-2015
OI Shukla, Dhaval/0000-0001-7613-1929; Sadashiva,
   Nishanth/0000-0003-0509-4993
CR Alcala-Cerra Gabriel, 2012, Surg Neurol Int, V3, P111, DOI 10.4103/2152-7806.101798
   Ali S, 2008, NEUROSURGERY, V62, P746, DOI [10.1227/01.NEU.0000297127.23313.C6, 10.1227/01.neu.0000317327.17225.f8]
   Azab W, 2012, TURK NEUROSURG, V22, P399, DOI 10.5137/1019-5149.JTN.4427-11.1
   Bosco D, 2010, NEUROL SCI, V31, P657, DOI 10.1007/s10072-010-0342-1
   Bouthillier A, 1996, NEUROSURGERY, V38, P425, DOI 10.1097/00006123-199603000-00001
   Boyko OB, 1996, NEURORADIOLOGY, V38, P11, DOI 10.1007/BF00593207
   Chen WH, 2015, CLIN NEURORADIOL, V25, P207, DOI 10.1007/s00062-014-0314-6
   Choudhri O, 2015, J CLIN NEUROSCI, V22, P409, DOI 10.1016/j.jocn.2014.06.007
   Cloft HJ, 1999, J NEUROSURG, V90, P865, DOI 10.3171/jns.1999.90.5.0865
   Conforti R, 2012, NEUROL SCI, V33, P1455, DOI 10.1007/s10072-012-0942-z
   DAVIS RA, 1956, ANN SURG, V143, P641, DOI 10.1097/00000658-195605000-00010
   de Bondt BJ, 2007, NEURORADIOLOGY, V49, P23, DOI 10.1007/s00234-006-0150-8
   Goyal M, 2001, RADIOLOGY, V220, P618, DOI 10.1148/radiol.2202991498
   Harman M, 2004, EUROP J RADIOL EXTRA, V51, P65
   INOUE T, 1990, NEUROSURGERY, V26, P903, DOI 10.1227/00006123-199006000-00001
   Ishikawa T, 2017, WORLD NEUROSURG, V108, DOI 10.1016/j.wneu.2017.09.033
   Kai Y, 2011, NEUROL MED-CHIR, V51, P361, DOI 10.2176/nmc.51.361
   Kalidindi RS, 2005, CLIN RADIOL, V60, P515, DOI 10.1016/j.crad.2004.09.004
   Kim MJ, 2015, SURG RADIOL ANAT, V37, P69, DOI 10.1007/s00276-014-1318-2
   Ladner TR, 2013, BMJ CASE REP, V2013
   LEE KS, 1989, J NEUROSURG, V70, P271, DOI 10.3171/jns.1989.70.2.0271
   Mohanty CB, 2011, BRIT J NEUROSURG, V25, P736, DOI 10.3109/02688697.2011.554583
   MORITA A, 1989, J NEUROSURG, V70, P415, DOI 10.3171/jns.1989.70.3.0415
   Murai S, 2019, ACTA NEUROCHIR, V161, P407, DOI 10.1007/s00701-018-3767-6
   Nishio A, 2001, NEUROL MED-CHIR, V41, P446, DOI 10.2176/nmc.41.446
   O'uchi E, 2010, NEURORADIOLOGY, V52, P1111, DOI 10.1007/s00234-010-0669-6
   OHSHIRO S, 1993, NEUROSURGERY, V32, P144, DOI 10.1227/00006123-199301000-00025
   Padget Dorcas Hager, 1948, CONTRIBUTIONS TO EMBRYOLOGY [CARNEGIE INST OF WASHINGTON PUBL], V32, P205
   Panda A, 2013, CASE REP OTOLARYNGOL, DOI 10.1155/2013/275820
   PARKINSON D, 1974, J NEUROSURG, V40, P244, DOI 10.3171/jns.1974.40.2.0244
   Quain R, 1840, PROV MED SURG J, V1, P203
   Salas E, 1998, NEUROSURGERY, V43, P557, DOI 10.1097/00006123-199809000-00082
   SALTZMAN GF, 1959, ACTA RADIOL, V51, P329, DOI 10.3109/00016925909171103
   Schlamann M, 2006, NEURORADIOLOGY, V48, P931, DOI 10.1007/s00234-006-0149-1
   Son B, 2013, CLIN NEURORADIOL, V23, P45, DOI 10.1007/s00062-011-0114-1
   Suttner N, 2000, NEUROSURGERY, V47, P428, DOI 10.1097/00006123-200008000-00030
   SUTTON D, 1950, BRIT J RADIOL, V23, P617, DOI 10.1259/0007-1285-23-274-617
   Takigawa T, 2014, INTERV NEURORADIOL, V20, P295, DOI 10.15274/NRJ-2014-10053
   Tamura Y, 2003, NEUROSURGERY, V52, P1217, DOI 10.1227/01.NEU.0000058023.55777.44
   Tubbs RS, 2007, CLIN ANAT, V20, P596, DOI 10.1002/ca.20434
   Tubbs RS, 2007, CLIN ANAT, V20, P367, DOI 10.1002/ca.20386
   Tubbs RS, 2011, J NEUROSURG, V114, P1127, DOI 10.3171/2010.11.JNS101527
   Uchino A, 2014, NEURORADIOL J, V27, P697, DOI 10.15274/NRJ-2014-10093
   Warnke JP, 2009, CENT EUR NEUROSURG, V70, P207, DOI 10.1055/s-0028-1093354
   Weon YC, 2011, ACTA RADIOL, V52, P1043, DOI 10.1258/ar.2011.110191
NR 45
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E214
EP E223
DI 10.1016/j.wneu.2019.10.025
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200027
PM 31627002
DA 2020-05-12
ER

PT J
AU Uno, J
   Kameda, K
   Otsuji, R
   Ren, N
   Nagaoka, S
   Maeda, K
   Ikai, Y
   Gi, H
AF Uno, Junji
   Kameda, Katsuharu
   Otsuji, Ryosuke
   Ren, Nice
   Nagaoka, Shintaro
   Maeda, Kazushi
   Ikai, Yoshiaki
   Gi, Hidefuku
TI Mechanical Thrombectomy for Basilar Artery Occlusion Compared with
   Anterior Circulation Stroke
SO WORLD NEUROSURGERY
LA English
DT Article
DE Basilar artery occlusion; Cerebrovascular disease/stroke; Mechanical
   thrombectomy; Posterior circulation; Revascularization; Stroke
ID ACUTE ISCHEMIC-STROKE; ENDOVASCULAR TREATMENT; PREDICTORS; PERFUSION;
   INTRAARTERIAL; THROMBOLYSIS; REPERFUSION; OUTCOMES; THERAPY;
   RECANALIZATION
AB OBJECTIVE: To investigate the clinical effectiveness of mechanical thrombectomy (MT) for basilar artery occlusion (BAO) and to ascertain whether outcomes for patients with BAO were comparable to those with anterior circulation large vessel occlusion (ACS).
   METHODS: A total of 345 patients who underwent MT between 2011 and 2018 were grouped by occlusion site (295 patients with ACS and 50 patients with BAO). Patients' baseline characteristics, procedural times, complications, symptomatic intracranial hemorrhage, modified Rankin Scale score, and mortality at 90 days were analyzed.
   RESULTS: Male preponderance (66.0% vs. 48.8%; P = 0.0316), younger age (72.5 years [interquartile range (IQR), 64.75-78.5 years] vs. 77 years [IQR 69-84 years]; P = 0.0297), higher National Institutes of Health Stroke Scale score (24.5 [IQR, 13-32] vs. 18 [IQR 13-22]; P = 0.0015) and higher reperfusion rate (100% vs. 84.7%; P = 0.0010) were observed in patients with BAO. We found no significant difference in favorable outcomes (modified Rankin Scale score <= 2) between patients with BAO and patients with ACS (64.3% vs. 49.3%; P = 0.0914). In multivariate analysis, Alberta Stroke Program Early Computed Tomography Score (odds ratio [OR], 1.282; 95% confidence interval [CI], 1.090-1.524; P = 0.0024), time from onset to reperfusion (OTR) (OR, 0.9950; 95% CI, 0.992-0.998; P = 0.0008), successful reperfusion (OR, 6.953; 95% CI, 1.576-48.729; P = 0.0092), and hemorrhagic complication (OR, 0.352; 95% CI, 0.151-0.797; P = 0.0122) were associated with a favorable outcome at 90 days in patients with ACS. In patients with BAO, only OTR (OR, 0.9879; 95% CI, 0.974-0.999; P = 0.0314) was associated with a favorable outcome at 90 days.
   CONCLUSIONS: MT may be considered the standard care for patients with BAO. OTR was the only common significant predictor for favorable outcomes in both patient cohorts.
C1 [Uno, Junji; Kameda, Katsuharu; Otsuji, Ryosuke; Ren, Nice; Nagaoka, Shintaro; Maeda, Kazushi; Ikai, Yoshiaki; Gi, Hidefuku] Baba Mem Hosp, Dept Neurosurg, Osaka, Japan.
RP Uno, J (reprint author), Baba Mem Hosp, Dept Neurosurg, Osaka, Japan.
EM babahpns@silver.ocn.ne.jp
CR Alawieh A, 2018, J NEUROINTERV SURG, V10, P735, DOI 10.1136/neurintsurg-2017-013420
   Albers GW, 2018, NEW ENGL J MED, V378, P708, DOI 10.1056/NEJMoa1713973
   Alemseged F, 2019, INT J STROKE, V14, P540, DOI 10.1177/1747493017744465
   Arenillas JF, 2018, J CEREBR BLOOD F MET, V38, P1839, DOI 10.1177/0271678X17740293
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Bouslama M, 2017, STROKE, V48, P3252, DOI 10.1161/STROKEAHA.117.018270
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Alonso GC, 2017, SUSTAINABILITY-BASEL, V9, DOI 10.3390/su9071173
   Consoli A, 2016, J NEUROINTERV SURG, V8, P1211, DOI 10.1136/neurintsurg-2015-012155
   Dornak T, 2015, Clin Radiol, V70, pe20, DOI 10.1016/j.crad.2015.01.008
   Giorgianni A, 2018, J STROKE CEREBROVASC, V27, P2367, DOI 10.1016/j.jstrokecerebrovasdis.2018.04.022
   Gory B, 2018, CEREBROVASC DIS, V45, P61, DOI 10.1159/000486690
   Gory B, 2016, J NEUROL NEUROSUR PS, V87, P520, DOI 10.1136/jnnp-2014-310250
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Higashida RT, 2003, STROKE, V34, pE109, DOI 10.1161/01.STR.0000082721.62796.09
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Khatri P, 2014, LANCET NEUROL, V13, P567, DOI 10.1016/S1474-4422(14)70066-3
   Kumar G, 2015, J NEUROINTERV SURG, V7, P868, DOI 10.1136/neurintsurg-2014-011418
   Lindsberg PJ, 2006, STROKE, V37, P922, DOI 10.1161/01.STR.0000202582.29510.6b
   Meinel TR, 2019, J NEUROINTERV SURG, V11, P1174, DOI 10.1136/neurintsurg-2018-014516
   Mokin M, 2016, STROKE, V47, P782, DOI 10.1161/STROKEAHA.115.011598
   Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442
   Pallesen LP, 2015, J NEUROIMAGING, V25, P384, DOI 10.1111/jon.12130
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Sheth SA, 2015, ANN NEUROL, V78, P584, DOI 10.1002/ana.24474
   Shi ZS, 2014, STROKE, V45, P1977, DOI 10.1161/STROKEAHA.114.005603
   Singer OC, 2015, ANN NEUROL, V77, P415, DOI 10.1002/ana.24336
   Strbian D, 2013, ANN NEUROL, V73, P688, DOI 10.1002/ana.23904
   Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4
   Weber R, 2019, EUR J NEUROL, V26, P299, DOI 10.1111/ene.13809
NR 30
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E469
EP E475
DI 10.1016/j.wneu.2019.10.097
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200056
PM 31669246
DA 2020-05-12
ER

PT J
AU Venable, GT
   Dave, P
   Gordon, WE
   Fraser, BD
   Wallace, DA
   Mangham, W
   Taylor, DR
   Khan, NR
   Michael, LM
   Vaughn, BN
   Klimo, P
AF Venable, Garrett T.
   Dave, Pooja
   Gordon, William E.
   Fraser, Brittany D.
   Wallace, David A.
   Mangham, William
   Taylor, Douglas R.
   Khan, Nickalus R.
   Michael, L. Madison, II
   Vaughn, Brandy N.
   Klimo, Paul, Jr.
TI Application of the Preventable Shunt Revision Rate to an Adult
   Population
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult; Hydrocephalus; Preventable shunt revision rate; Quality; Shunt
   malfunction
ID HYDROCEPHALUS; RISK; REOPERATIONS; NEUROSURGERY; MANAGEMENT
AB BACKGROUND: The preventable shunt revision rate (PSRR) was recently introduced in pediatric hydrocephalus as a quality metric for shunt surgery. We evaluated the PSRR in an adult hydrocephalus population.
   METHODS: All ventricular shunt operations (January 1, 2013 to March 31, 2018) performed at a university-based teaching hospital were included. For any index surgery (de novo or revision) resulting in reoperation within 90 days, the index surgery details were collected, and a consensus decision was reached regarding whether the failure had been potentially avoidable. Preventable failure was defined as failure due to infection, malposition, disconnection, migration, or kinking. The 90-day shunt failure rate and PSRR were calculated. Bivariate analyses were performed to evaluate the individual effects of each independent variable on preventable shunt failure.
   RESULTS: A total of 318 shunt operations had been performed in 245 patients. Most patients were women (62%), with a median age of 48.2 years (interquartile range, 31.2-63.2 years). Most had had ventriculoperitoneal shunts placed (86.5%), and just more than one half were new shunts (51.6%). A total of 53 cases (16.7%) in 42 patients experienced shunt failure within 90 days of the index operation. Of these, 27 failures (8.5% of the total cases; 51% of the failures) were considered potentially preventable. The most common reasons were infection (37%; n = 10) and malposition of the proximal and distal catheters (both 25.9%; n = 7). Age was the only statistically significant difference between the 2 groups, with the patients experiencing preventable shunt failure older than those without preventable shunt failure (51.4 vs. 37.1 years; P = 0.017).
   CONCLUSIONS: The 90-day PSRR can be applied to an adult population and serve as a quality metric.
C1 [Venable, Garrett T.; Gordon, William E.; Mangham, William; Taylor, Douglas R.; Khan, Nickalus R.; Michael, L. Madison, II; Klimo, Paul, Jr.] Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, Memphis, TN 38163 USA.
   [Fraser, Brittany D.; Wallace, David A.] Univ Tennessee, Ctr Hlth Sci, Coll Med, Memphis, TN 38163 USA.
   [Dave, Pooja] Rhodes Coll, Memphis, TN 38112 USA.
   [Michael, L. Madison, II; Klimo, Paul, Jr.] Semmes Murphey Clin, Memphis, TN 38120 USA.
   [Vaughn, Brandy N.; Klimo, Paul, Jr.] Le Bonheur Childrens Hosp, Memphis, TN 38103 USA.
RP Klimo, P (reprint author), Univ Tennessee, Ctr Hlth Sci, Dept Neurosurg, Memphis, TN 38163 USA.; Klimo, P (reprint author), Semmes Murphey Clin, Memphis, TN 38120 USA.; Klimo, P (reprint author), Le Bonheur Childrens Hosp, Memphis, TN 38103 USA.
EM pklimo@semmes-murphey.com
CR Agarwal N, 2019, J NEUROSURG, V131, P1668, DOI 10.3171/2018.5.JNS18519
   Al-Holou WN, 2019, J NEUROSURG, V131, P1062, DOI 10.3171/2018.5.JNS18506
   Anderson IA, 2019, J NEUROSURG, V130, P145, DOI 10.3171/2017.8.JNS17399
   Barton SE, 2013, J NEUROSURG-PEDIATR, V11, P392, DOI 10.3171/2013.1.PEDS12362
   Beez T, 2018, WORLD NEUROSURG, V109, pE404, DOI 10.1016/j.wneu.2017.09.193
   Bohl Michael A, 2016, Neurosurgery, V63 Suppl 1, P91, DOI 10.1227/NEU.0000000000001295
   Dave P, 2019, NEUROSURGERY, V84, P788, DOI 10.1093/neuros/nyy263
   Erps A, 2018, PEDIATR INT, V60, P1056, DOI 10.1111/ped.13709
   Farahmand D, 2009, J NEUROL NEUROSUR PS, V80, P1248, DOI 10.1136/jnnp.2007.141416
   Gassas A, 2006, PEDIATR NEUROSURG, V42, P95, DOI 10.1159/000090462
   Halfon P, 2007, J CLIN EPIDEMIOL, V60, P56, DOI 10.1016/j.jclinepi.2006.03.013
   Khan Farid, 2015, Surg Neurol Int, V6, P25, DOI 10.4103/2152-7806.151388
   Lee RP, 2018, NEUROSURGERY, V83, P508, DOI 10.1093/neuros/nyx478
   McDowell MM, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e01099
   McLaughlin N, 2015, J NEUROSURG, V123, P198, DOI 10.3171/2014.9.JNS14666
   Merkler AE, 2017, WORLD NEUROSURG, V98, P654, DOI 10.1016/j.wneu.2016.10.136
   Omrani O, 2018, CHILD NERV SYST, V34, P2407, DOI 10.1007/s00381-018-3953-0
   Oravec CS, 2018, NEUROSURGERY, V82, P728, DOI 10.1093/neuros/nyx328
   PUCA A, 1991, NEUROSURGERY, V29, P822, DOI 10.1227/00006123-199112000-00003
   Reddy GK, 2011, NEUROSURGERY, V69, P774, DOI 10.1227/NEU.0b013e31821ffa9e
   Simon TD, 2014, J PEDIATR-US, V164, P1462, DOI 10.1016/j.jpeds.2014.02.013
   Venable GT, 2016, J NEUROSURG-PEDIATR, V18, P7, DOI 10.3171/2015.12.PEDS15388
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E815
EP E821
DI 10.1016/j.wneu.2019.11.018
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200095
PM 31715417
DA 2020-05-12
ER

PT J
AU von Glinski, A
   Elia, C
   Ansari, D
   Yilmaz, E
   Takayanagi, A
   Norvell, DC
   Pierre, CA
   Abdul-Jabbar, A
   Chapman, JR
   Oskouian, R
AF von Glinski, Alexander
   Elia, Christopher
   Ansari, Darius
   Yilmaz, Emre
   Takayanagi, Ariel
   Norvell, Daniel C.
   Pierre, Clifford A.
   Abdul-Jabbar, Amir
   Chapman, Jens R.
   Oskouian, Rod J.
TI Complications and Mortality in Octogenarians Undergoing Lumbopelvic
   Fixation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lumbopelyic fixation; Morbidity; Mortality; Octogenarian; Spine surgery
ID LUMBAR SPINAL STENOSIS; ILIAC SCREW FIXATION; QUALITY-OF-LIFE;
   HOUNSFIELD UNITS; ADULT; SURGERY; PREDICTORS; RATES
AB BACKGROUND: Advancements in modern medicine have led to longer life expectancy. Literature on spinopelvic fixation in elderly patients is limited. We investigated morbidity and mortality in octogenarians who underwent spinopelvic fixation.
   METHODS: A retrospective chart review was conducted of patients who underwent spinopelvic fixation from January 2014 through December 2018 at a single institution. Patients were grouped into the octogenarian group (OG), 80-89 years old, and comparison group (CG), 40-50 years old. Demographics; pathology; Charlson Comorbidity Index; Hounsfield units; surgery details; and clinical data including complications, intensive care unit and length of hospital stay, and mortality were collected and compared.
   RESULTS: Inclusion criteria were met by 26 patients (OG: n = 14; CG: n = 12). Diagnoses in the OG were deformity (42.9%), pseudarthrosis (35.7%), fracture (7.1%), infection (7.1%), and tumor (7.1%). The only significant differences in baseline patient characteristics were that Charlson Comorbidity Index was significantly higher in the OG (6.0 +/- 1.4) compared with the CG (1.1 +/- 1.0) (P< 0.001) and the OG had lower Hounsfield units (P < 0.001), indicating poorer hone quality. More patients in the CG underwent staged and anterior approaches compared with the OG (P = 0.031). Major and minor complication rates were 57.1% and 42.9%, respectively, in the OG (P = 0.98) and 25% and 25% in the CG (P = 0.34). Mortality rate was 14.3%.
   CONCLUSIONS: With an aging population, the number of patients requiring spinopelvic fixation will continue to grow. Spine surgeons must carefully weigh benefits and risks in patients with multiple comorbidities.
C1 [von Glinski, Alexander; Elia, Christopher; Ansari, Darius; Yilmaz, Emre; Pierre, Clifford A.; Abdul-Jabbar, Amir; Chapman, Jens R.; Oskouian, Rod J.] Swedish Neurosci Inst, Seattle, WA 98122 USA.
   [von Glinski, Alexander] Swedish Med Ctr, Hansjorg Wyss Hip & Pelv Ctr, Seattle, WA 98104 USA.
   [von Glinski, Alexander; Elia, Christopher; Ansari, Darius; Pierre, Clifford A.; Abdul-Jabbar, Amir; Oskouian, Rod J.] Seattle Sci Fdn, Seattle, WA 98122 USA.
   [von Glinski, Alexander; Yilmaz, Emre] Ruhr Univ Bochum, BG Univ Hosp Bergmannsheil, Dept Trauma Surg, Bochum, Germany.
   [Elia, Christopher; Takayanagi, Ariel] Riverside Univ Hlth Syst, Dept Neurosurg, Moreno Valley, CA USA.
   [Norvell, Daniel C.] Spectrum Res Inc, Washington, DC USA.
RP von Glinski, A (reprint author), Swedish Neurosci Inst, Seattle, WA 98122 USA.; von Glinski, A (reprint author), Swedish Med Ctr, Hansjorg Wyss Hip & Pelv Ctr, Seattle, WA 98104 USA.; von Glinski, A (reprint author), Seattle Sci Fdn, Seattle, WA 98122 USA.; von Glinski, A (reprint author), Ruhr Univ Bochum, BG Univ Hosp Bergmannsheil, Dept Trauma Surg, Bochum, Germany.
EM AlexvonGlinski@gmail.com
CR Blecher R, 2019, SPINE, V44, P291, DOI 10.1097/BRS.0000000000002819
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Deyo RA, 2010, JAMA-J AM MED ASSOC, V303, P1259, DOI 10.1001/jama.2010.338
   Elder BD, 2017, SPINE, V42, pE142, DOI 10.1097/BRS.0000000000001722
   Guler UO, 2015, EUR SPINE J, V24, P1085, DOI 10.1007/s00586-014-3615-1
   Ilyas H, 2015, J SPINAL DISORD TECH, V28, pE199, DOI 10.1097/BSD.0000000000000222
   Ishida W, 2017, GLOB SPINE J, V7, P672, DOI 10.1177/2192568217700111
   Issa K, 2018, CLIN SPINE SURG, V31, pE102, DOI 10.1097/BSD.0000000000000597
   Jazini E, 2017, J ORTHOP TRAUMA, V31, P37, DOI 10.1097/BOT.0000000000000703
   Katz JN, 1999, SPINE, V24, P2229, DOI 10.1097/00007632-199911010-00010
   Lopez AD, 2006, DIS CONTROL PRIORITI
   Mi J, 2017, CLIN SPINE SURG, V30, pE1130, DOI 10.1097/BSD.0000000000000490
   Murphy ME, 2017, J NEUROSURG-SPINE, V26, P353, DOI 10.3171/2016.8.SPINE16616
   Netuveli G, 2006, J EPIDEMIOL COMMUN H, V60, P357, DOI 10.1136/jech.2005.040071
   Netuveli G, 2008, BRIT MED BULL, V85, P113, DOI 10.1093/bmb/ldn003
   Nguyen JH, 2019, J NEUROSURG-SPINE, V30, P635, DOI 10.3171/2018.9.SPINE18239
   Passias PG, 2017, SPINE DEFORM, V5, P342, DOI [10.1016/j.jspd.2017.02.002, DOI 10.1016/J.JSPD.2017.02.002]
   Poorman GW, 2018, INT J SPINE SURG, V12, P617, DOI 10.14444/5076
   Schreiber JJ, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.5.FOCUS1483
   Schreiber Joseph J, 2014, HSS J, V10, P25, DOI 10.1007/s11420-013-9367-3
   Schreiber JJ, 2011, J BONE JOINT SURG AM, V93A, P1057, DOI 10.2106/JBJS.J.00160
   Tadokoro K, 2005, SPINE, V30, P2458, DOI 10.1097/01.brs.0000184692.71897.a2
   Wang MY, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15180
   Zheng FY, 2001, J SPINAL DISORD, V14, P518, DOI 10.1097/00002517-200112000-00011
NR 24
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E272
EP E276
DI 10.1016/j.wneu.2019.10.040
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200033
PM 31629134
DA 2020-05-12
ER

PT J
AU von Glinski, A
   Yilmaz, E
   Ishak, B
   Ramey, W
   Jack, A
   Iwanaga, J
   Abdul-Jabbar, A
   Oskouian, R
   Tubbs, RS
   Chapman, JR
AF von Glinski, Alexander
   Yilmaz, Emre
   Ishak, Basem
   Ramey, Wyatt
   Jack, Andrew
   Iwanaga, Joe
   Abdul-Jabbar, Amir
   Oskouian, Rod J.
   Tubbs, R. Shane
   Chapman, Jens R.
TI Neurovascular Relations in Modified Iliac Screws and Traditional Iliac
   Screw: Anatomic Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Iliac screws; Lumbopelvic fixation; Modified insertion point;
   Neurovascular injuries; Supragluteal artery
ID UNSTABLE SACRUM FRACTURES; TRIANGULAR OSTEOSYNTHESIS; FIXATION; ADULT;
   INSTRUMENTATION
AB BACKGROUND: This study describes a modified iliac screw technique and compares it with the traditional iliac screw in regard to neurovascular structures at risk. Few studies have detailed the insertion point's surrounding anatomy and its relationship to vulnerable neurovascular structures when this modified technique is used. Therefore we describe our modified iliac screw entry and trajectory and detail the surrounding anatomy and neurovascular structures at risk with this technique in comparison with the "gold standard" trajectory.
   METHODS: The traditional iliac screw (TS) and modified iliac screw (MS) were placed into 12 fresh-frozen adult cadavers (3 female, 9 male). We measured the screw-to-supragluteal artery, vein, and nerve (SGANV) bundle and screw-to-sciatic notch distances. Further, we dissected the medial cortical border of the iliac screw to identify its final position with respect to the surrounding anatomy.
   RESULTS: No medial or lateral cortical breaches were visualized after screw placement. The MS was 18.31 mm from the greater sciatic foramen compared with 18.65 mm with the TS. The smallest distance from the MS to the greater sciatic foramen was 13.9 mm compared with 14.8 mm with the TS, an insignificant difference. The SGANV bundle-to-MS distance was 20.6 mm, and SGANV bundle-to-TS distance was 20.77 mm, again an insignificant difference.
   CONCLUSIONS: Using the modified iliac screw technique does not change the intraosseous pathway (and thus bone purchase) with respect to the distance between the screw and neurovascular structures at risk.
C1 [von Glinski, Alexander; Ishak, Basem; Ramey, Wyatt; Jack, Andrew; Abdul-Jabbar, Amir; Oskouian, Rod J.; Tubbs, R. Shane; Chapman, Jens R.] Swedish Med Ctr, Swedish Neurosci Inst, Seattle, WA 98122 USA.
   [von Glinski, Alexander; Ishak, Basem; Iwanaga, Joe; Abdul-Jabbar, Amir; Oskouian, Rod J.; Chapman, Jens R.] Seattle Sci Fdn, Seattle, WA 98122 USA.
   [von Glinski, Alexander] Swedish Med Ctr, Hansjorg Wyss Hip & Pelv Ctr, Seattle, WA 98122 USA.
   [von Glinski, Alexander; Yilmaz, Emre] Ruhr Univ Bochum, BG Univ Hosp Bergmannsheil, Dept Trauma Surg, Bochum, Germany.
   [Tubbs, R. Shane] St Georges Univ, Dept Anat Sci, St Georges, Grenada.
RP von Glinski, A (reprint author), Swedish Med Ctr, Swedish Neurosci Inst, Seattle, WA 98122 USA.; von Glinski, A (reprint author), Swedish Med Ctr, Hansjorg Wyss Hip & Pelv Ctr, Seattle, WA 98122 USA.; von Glinski, A (reprint author), Ruhr Univ Bochum, BG Univ Hosp Bergmannsheil, Dept Trauma Surg, Bochum, Germany.
EM alexvonglinski@gmail.com
CR ALLEN BL, 1984, SPINE, V9, P388, DOI 10.1097/00007632-198405000-00011
   Berry J L, 2001, Spine (Phila Pa 1976), V26, pE143, DOI 10.1097/00007632-200104010-00002
   Collinge C, 2005, J ORTHOP TRAUMA, V19, P96, DOI 10.1097/00005131-200502000-00005
   Edwards CC, 2004, SPINE, V29, P1996, DOI 10.1097/01.brs.0000138272.54896.33
   Ilyas H, 2015, J SPINAL DISORD TECH, V28, pE199, DOI 10.1097/BSD.0000000000000222
   Ishida W, 2017, GLOB SPINE J, V7, P672, DOI 10.1177/2192568217700111
   JOSTEN C, 1994, CHIRURG, V65, P970
   Kakkos SK, 2008, J VASC SURG, V47, P1074, DOI 10.1016/j.jvs.2007.11.005
   Kebaish KM, 2010, SPINE, V35, P2245, DOI 10.1097/BRS.0b013e3181f5cfae
   Lippert H, 2007, LEHRBUCH ANATOMIE, P123
   LUQUE ER, 1982, CLIN ORTHOP RELAT R, P192
   Nguyen JH, 2019, J NEUROSURG-SPINE, V30, P635, DOI 10.3171/2018.9.SPINE18239
   Protas M, 2017, SPINE SCH, V1, P30
   Schildhauer TA, 1998, J ORTHOP TRAUMA, V12, P307, DOI 10.1097/00005131-199806000-00002
   Schildhauer TA, 2003, J ORTHOP TRAUMA, V17, P22, DOI 10.1097/00005131-200301000-00004
   Schildhauer TA, 2002, J SPINAL DISORD TECH, V15, P199, DOI 10.1097/00024720-200206000-00005
   Schildhauer TA, 2006, J ORTHOP TRAUMA, V20, P447, DOI 10.1097/00005131-200608000-00001
   Schunke M., 2007, PROMETHEUS ALLGEMEIN, P2
NR 18
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E93
EP E97
DI 10.1016/j.wneu.2019.09.090
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200013
PM 31562967
DA 2020-05-12
ER

PT J
AU Wakuta, N
   Abe, H
   Fukuda, K
   Nonaka, M
   Morishita, T
   Arima, H
   Inoue, T
AF Wakuta, Naoki
   Abe, Hiroshi
   Fukuda, Kenji
   Nonaka, Masani
   Morishita, Takashi
   Arima, Hisatomi
   Inoue, Tooru
TI Feasibility and Safety of Endoscopic Procedure in Burr-Hole Surgery for
   Chronic Subdural Hematoma in Patients of Very Advanced Age
SO WORLD NEUROSURGERY
LA English
DT Article
DE Burr-hole surgery; Chronic subdural hematoma; Endoscopic procedure;
   Extremely aged patients; Recurrent risk
ID INDEPENDENT PREDICTORS; RECURRENCE; COMPLICATIONS; EVACUATION; OUTCOMES;
   MANAGEMENT
AB OBJECTIVE: The usefulness of endoscopic procedures for chronic subdural hematoma (CSDH) has been described, but the indications in patients of very advanced age have not been analyzed. The aim of this study was to evaluate the feasibility, safety, and usefulness of introduction of an endoscopic procedure for such patients.
   METHODS: We retrospectively analyzed the data of 540 CSDHs treated by burr-hole surgery with endoscopic examination. The safety of the endoscopic procedure was assessed according to postoperative complications, morbidity, and mortality. The outcome was evaluated by statistical comparison among 4 different age-groups, and the recurrence rate and risk factors for recurrence was investigated in patients of very advanced age.
   RESULTS: Postoperative complications occurred in 7 cases (1.5%). The 6-month morbidity and mortality were 13.5% and 4.5%. No complications, morbidity, or mortality associated with the additional endoscopic procedure occurred even in patients of very advanced age. The endoscopic features of trabecular structures and residual septa separating the cavity were also risk factors for recurrence in patients of very advanced age. Releasing of the septa showed the possibility of decreasing the risk of recurrence to 6.6% in patients aged >= 85 years as well as in younger patients. There were some inevitable problems such as prolongation of the surgical time and inadequate endoscopic surgical skill.
   CONCLUSIONS: An endoscopic procedure for CSDH can be safely indicated and useful even in patients aged >= 85 years. However, clinicians should carefully select the patients based on clinical information associated with risk factors for recurrence.
C1 [Wakuta, Naoki; Abe, Hiroshi; Fukuda, Kenji; Nonaka, Masani; Morishita, Takashi; Inoue, Tooru] Fukuoka Univ, Fukuoka Univ Hosp, Dept Neurosurg, Fukuoka, Japan.
   [Wakuta, Naoki; Abe, Hiroshi; Fukuda, Kenji; Nonaka, Masani; Morishita, Takashi; Inoue, Tooru] Fukuoka Univ, Sch Med, Fukuoka, Japan.
   [Arima, Hisatomi] Fukuoka Univ, Fac Med, Dept Prevent Med & Publ Hlth, Fukuoka, Japan.
RP Wakuta, N (reprint author), Fukuoka Univ, Fukuoka Univ Hosp, Dept Neurosurg, Fukuoka, Japan.; Wakuta, N (reprint author), Fukuoka Univ, Sch Med, Fukuoka, Japan.
EM nwakuta@fukuoka-u.ac.jp
OI Morishita, Takashi/0000-0002-0789-7776
CR Asano Y, 1992, No To Shinkei, V44, P827
   Bartek J, 2017, WORLD NEUROSURG, V106, P609, DOI 10.1016/j.wneu.2017.07.044
   Berhouma M, 2014, ACTA NEUROCHIR, V156, P2359, DOI 10.1007/s00701-014-2219-1
   Borger V, 2012, ACTA NEUROCHIR, V154, P1549, DOI 10.1007/s00701-012-1434-x
   Brennan PM, 2017, J NEUROSURG, V127, P732, DOI 10.3171/2016.8.JNS16134
   Chari A, 2016, J NEUROTRAUM, V33, P1212, DOI 10.1089/neu.2015.3983
   Frontera JA, 2011, CRIT CARE MED, V39, P1619, DOI 10.1097/CCM.0b013e3182186ed6
   Gelabert-Gonzalez M, 2005, CLIN NEUROL NEUROSUR, V107, P223, DOI 10.1016/j.clineuro.2004.09.015
   Han MH, 2017, J NEUROSURG, V127, P1117, DOI 10.3171/2016.8.JNS16867
   Hellwig D, 1996, SURG NEUROL, V45, P272, DOI 10.1016/0090-3019(95)00417-3
   Huang YH, 2013, INT J SURG, V11, P544, DOI 10.1016/j.ijsu.2013.05.007
   Jones S, 1999, AGE AGEING, V28, P519, DOI 10.1093/ageing/28.6.519
   Jung YG, 2015, J KOREAN NEUROSURG S, V57, P266, DOI 10.3340/jkns.2015.57.4.266
   Ibanez FAL, 2011, WORLD NEUROSURG, V75, P709, DOI 10.1016/j.wneu.2010.11.010
   Lega BC, 2010, J NEUROSURG, V113, P615, DOI 10.3171/2009.9.JNS08825
   Leroy HA, 2015, J CLIN NEUROSCI, V22, P1895, DOI 10.1016/j.jocn.2015.03.064
   Lindvall P, 2009, J CLIN NEUROSCI, V16, P1287, DOI 10.1016/j.jocn.2009.01.001
   Liu WM, 2014, J NEUROSURG, V121, P665, DOI 10.3171/2014.5.JNS132715
   Majovsky M, 2016, ACTA NEUROCHIR, V158, P1987, DOI 10.1007/s00701-016-2902-5
   Miranda LB, 2011, J NEUROSURG, V114, P72, DOI 10.3171/2010.8.JNS10298
   Mobbs R, 2009, J CLIN NEUROSCI, V16, P701, DOI 10.1016/j.jocn.2008.06.023
   Nakaguchi H, 2001, J NEUROSURG, V95, P256, DOI 10.3171/jns.2001.95.2.0256
   Oishi M, 2001, NEUROL MED-CHIR, V41, P382, DOI 10.2176/nmc.41.382
   Okada Y, 2002, SURG NEUROL, V57, P405, DOI 10.1016/S0090-3019(02)00720-6
   Ooba S, 2006, NEUROL SURG TOKYO, V34, P273
   Ramachandran R, 2007, SURG NEUROL, V67, P367, DOI 10.1016/j.surneu.2006.07.022
   Rust T, 2006, J CLIN NEUROSCI, V13, P823, DOI 10.1016/j.jocn.2004.12.013
   Santarius T, 2009, LANCET, V374, P1067, DOI 10.1016/S0140-6736(09)61115-6
   Schoedel P, 2016, WORLD NEUROSURG, V94, P465, DOI 10.1016/j.wneu.2016.07.027
   Shiomi N, 2002, NEUROL SURG TOKYO, V30, P717
   Sjavik K, 2017, J NEUROSURG, V23, P1, DOI DOI 10.3171/2016.12.JNS161713
   Stippler M, 2013, NEUROL RES, V35, P243, DOI 10.1179/1743132813Y.0000000163
   Tabuchi Sadaharu, 2014, J Clin Med Res, V6, P379, DOI 10.14740/jocmr1907w
   Teo C, 1996, CHILD NERV SYST, V12, P248
   Toi H, 2018, J NEUROSURG, V128, P222, DOI 10.3171/2016.9.JNS16623
   Torihashi K, 2008, NEUROSURGERY, V63, P1125, DOI 10.1227/01.NEU.0000335782.60059.17
   Uno M, 2017, NEUROL MED-CHIR, V57, P402, DOI 10.2176/nmc.ra.2016-0337
   Wakuta N, 2019, WORLD NEUROSURG, V124, pE241, DOI 10.1016/j.wneu.2018.12.078
   Wang K, 2017, TURK NEUROSURG, V27, P60, DOI 10.5137/1019-5149.JTN.14519-15.1
   Yamamoto H, 2003, J NEUROSURG, V98, P1217, DOI 10.3171/jns.2003.98.6.1217
NR 40
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E1037
EP E1046
DI 10.1016/j.wneu.2019.11.080
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200121
PM 31759155
DA 2020-05-12
ER

PT J
AU Wang, TW
   Yang, YP
   Xu, XK
   Niu, XD
   Yang, RH
   Gao, T
   Kong, L
   Mao, Q
   Qiu, YM
AF Wang, Tianwei
   Yang, Yanping
   Xu, Xiaoke
   Niu, Xiaodong
   Yang, Renhao
   Gao, Ting
   Kong, Lin
   Mao, Qing
   Qiu, Yongming
TI An Integrative Survival Analysis for Multicentric Low-Grade Glioma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Multicentric low-grade glioma; Oligodendroglioma; Progression-free
   survival; Prognosis
ID CEREBRAL GLIOMAS; ASTROCYTOMA; CEREBELLAR; PATIENT; MANAGEMENT
AB OBJECTIVE: This study aimed to perform a survival pis of patients with multicentric low-grade gliomas (MLGGs) and to assess the influence of various prognostic factors on progression-free survival (PFS) and overall survival.
   METHODS: A literature search on Web of Science and PubMed was performed for literature in English published from 1963 to September 2018. Detailed information including demographics, clinical characteristics, treatments, critical events, and time to events for survival analysis were extracted from the included articles.
   RESULTS: A total of 36 cases from published articles were selected for analysis. Univariate analysis showed that age (31 years or >= 31 years), grade (pure low grade/ low and high grade) and glioma type (astrocytoma/oligodendroglioma) had a significant relationship with PFS. Cox regression analysis showed that tumor grade was an independent prognostic factor for PFS. No factors correlated with overall survival.
   CONCLUSIONS: This integrative analysis of MLGGs patients revealed that age younger than 31 years, pure MLGG, and oligodendroglioma were significantly associated with improved PFS, and pure MLGGs was an independent prognostic factors for PFS.
C1 [Wang, Tianwei; Yang, Renhao; Qiu, Yongming] Shanghai Jiao Tong Univ, Renji Hosp, Dept Neurosurg, Sch Med, Shanghai, Peoples R China.
   [Yang, Yanping] Xi An Jiao Tong Univ, Xian Cent Hosp, Dept Neurosurg, Sch Med, Xian, Shaanxi, Peoples R China.
   [Xu, Xiaoke; Gao, Ting] Xi An Jiao Tong Univ, Xian Cent Hosp, Dept Neurol, Sch Med, Xian, Shaanxi, Peoples R China.
   [Niu, Xiaodong; Mao, Qing] Sichuan Univ, West China Hosp, Dept Neurosurg, Chengdu, Peoples R China.
   [Kong, Lin] Fudan Univ, Shanghai Proton & Heavy Ion Ctr, Dept Radiat Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China.
RP Qiu, YM (reprint author), Shanghai Jiao Tong Univ, Renji Hosp, Dept Neurosurg, Sch Med, Shanghai, Peoples R China.
EM qiuzhouba@126.com
FU National Natural Science FoundationNational Natural Science Foundation
   of China [81874215]
FX This study was funded by the National Natural Science Foundation
   (project no. 81874215).
CR Ampil F, 2007, J NEURO-ONCOL, V85, P353, DOI 10.1007/s11060-007-9413-4
   BARNARD RO, 1987, CANCER, V60, P1519, DOI 10.1002/1097-0142(19871001)60:7<1519::AID-CNCR2820600719>3.0.CO;2-1
   BATZDORF U, 1963, J NEUROSURG, V20, P122, DOI 10.3171/jns.1963.20.2.0122
   Chaichana KL, 2010, J NEUROSURG, V112, P10, DOI 10.3171/2008.10.JNS08608
   Claus EB, 2005, CANCER-AM CANCER SOC, V103, P1227, DOI 10.1002/cncr.20867
   Corrivetti F, 2017, WORLD NEUROSURG, V97, DOI 10.1016/j.wneu.2016.10.025
   di Russo P, 2013, ACTA NEUROCHIR, V155, P2245, DOI 10.1007/s00701-013-1892-9
   Duffau H, 2015, NEURO-ONCOLOGY, V17, P332, DOI 10.1093/neuonc/nou153
   Franco CMR, 2000, ARQ NEURO-PSIQUIAT, V58, P150, DOI 10.1590/S0004-282X2000000100023
   Grosu F, 2017, ROM J MORPHOL EMBRYO, V58, P207
   Harrison RA, 2016, NEURO-ONCOLOGY, V18, P172
   Hefti M, 2010, CENT EUR NEUROSURG, V71, P20, DOI 10.1055/s-0029-1241190
   Inoue A, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0907-4
   Kaku S, 2004, NEUROL SURG TOKYO, V32, P501
   Kato T, 1999, NEUROL MED CHIR, V30, P604
   Ma SP, 2015, J CLIN NEUROSCI, V22, P418, DOI 10.1016/j.jocn.2014.08.003
   MAMELAK AN, 1994, J NEUROSURG, V81, P24, DOI 10.3171/jns.1994.81.1.0024
   PHILIPPON JH, 1993, NEUROSURGERY, V32, P554
   PINEDA A, 1964, J NEUROSURG, V21, P805, DOI 10.3171/jns.1964.21.9.0805
   Pulido PG, 2013, SEIZURE-EUR J EPILEP, V22, P480, DOI 10.1016/j.seizure.2013.02.018
   Saikali S, 2005, J NEUROSURG, V102, P376, DOI 10.3171/jns.2005.102.2.0376
   Sakai K, 2011, BRAIN TUMOR PATHOL, V28, P151, DOI 10.1007/s10014-010-0015-z
   Salunke P, 2010, NEUROL INDIA, V58, P651, DOI 10.4103/0028-3886.68696
   Salvati M, 2003, NEUROSURG REV, V26, P275, DOI 10.1007/s10143-003-0276-7
   Sanai N, 2008, NEUROSURGERY, V62, P753, DOI 10.1227/01.neu.0000318159.21731.cf
   Sim KB, 1999, CHILD NERV SYST, V15, P477, DOI 10.1007/s003810050443
   SOLITARE GB, 1962, J NEUROSURG, V19, P1079, DOI 10.3171/jns.1962.19.12.1079
   SOLOMON A, 1969, J NEUROSURG, V31, P87, DOI 10.3171/jns.1969.31.1.0087
   Sridharan V, 2015, WORLD NEUROSURG, V84, P1045, DOI 10.1016/j.wneu.2015.05.021
   Terakawa Y, 2013, J NEUROSURG, V118, P1169, DOI 10.3171/2013.2.JNS121747
   Tsutsumi S, 2009, J CLIN NEUROSCI, V16, P1086, DOI 10.1016/j.jocn.2008.07.089
   van Veelen MLC, 1998, J NEUROL NEUROSUR PS, V64, P581, DOI 10.1136/jnnp.64.5.581
   Vergani F, 2009, ACTA NEUROCHIR, V151, P1699, DOI 10.1007/s00701-009-0306-5
   Wang TW, 2018, WORLD NEUROSURG, V112, pE269, DOI 10.1016/j.wneu.2018.01.035
NR 34
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E189
EP E195
DI 10.1016/j.wneu.2019.10.001
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200024
PM 31605855
DA 2020-05-12
ER

PT J
AU Wen, JK
   Shi, CG
   Yu, L
   Wang, S
   Xi, YH
   Ye, XJ
AF Wen, Jiankun
   Shi, Changgui
   Yu, Lei
   Wang, Shuang
   Xi, Yanhai
   Ye, Xiaojian
TI Unilateral Versus Bilateral Percutaneous Pedicle Screw Fixation in
   Oblique Lumbar Interbody Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bilateral pedicle screw; Fusion rate; Lumbar spine; Oblique lumbar
   interbody fusion; Unilateral pedicle screw
ID BIOMECHANICAL ANALYSIS; COMPLICATIONS; ADJACENT; SPONDYLOLISTHESIS;
   INSTRUMENTATION; IMMOBILIZATION; MIGRATION; SEGMENTS; DISEASES
AB OBJECTIVE: To compare clinical and radiologic outcomes of unilateral pedicle screw (UPS) and bilateral pedicle screw (BPS) fixations after single-level oblique lateral interbody fusion procedures.
   METHODS: This retrospective study included 74 patients receiving single-level oblique lateral interbody fusion at L3-4 or L4-5 (June 2014 to June 2017). These patients were divided into BPS (n = 36) and UPS (n = 38) groups. Perioperative outcomes included operative time, blood loss, medical expenses, and complication rates. Radiologic outcomes included fusion rates and cage subsidence rates. Clinical outcomes included disability measured by the Oswestry Disability Index and pain measured by the visual analog scale.
   RESULTS: The operative time was significantly shorter in the UPS group (76.2 +/- 4.4 minutes) compared with the BPS group (127.0 +/- 5.6 minutes, P < 0.001). There was a significant between-group difference in medical expenses ($11,044.8 +/- $470.7 in UPS group vs. $15,018.4 +/- $547.1 in BPS, P< 0.001). Blood loss and hospital stay did not differ between groups. Oswestry Disability Index and visual analog scale scores significantly decreased in both groups at different time points postoperatively compared with preoperatively. The UPS group had lower Oswestry Disability Index and visual analog scale scores than the BPS group at 7 days postoperatively, but no between-group difference was found after 1-month follow-up. Fusion rate was 86.8% in UPS group and 91.7% in BPS group (P> 0.05). Cage subsidence rates did not differ between groups.
   CONCLUSIONS: Oblique lateral interbody fusion with UPS fixation is an effective and reliable option for single-level lumbar diseases. Compared with BPS fixation, it resulted in less blood loss, required less operative time, and had comparable effects on radiologic and clinical outcomes.
C1 [Wen, Jiankun; Shi, Changgui; Yu, Lei; Wang, Shuang; Xi, Yanhai; Ye, Xiaojian] Second Mil Med Univ, Changzheng Hosp, Dept Spine Surg, Shanghai, Peoples R China.
RP Ye, XJ (reprint author), Second Mil Med Univ, Changzheng Hosp, Dept Spine Surg, Shanghai, Peoples R China.
EM xjyespine@smmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81802120, 81772445]; Shanghai Sailing Program
   [18YF1423100]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81802120 to C. Shi, Grant No. 81772445 to X. Ye) and
   Shanghai Sailing Program (Grant No. 18YF1423100 to C. Shi).
CR Abbasi A, 2019, CUREUS, V11, DOI 10.7759/cureus.4029
   Abe K, 2017, SPINE, V42, P55, DOI 10.1097/BRS.0000000000001650
   Aoki Y, 2010, J NEUROSURG-SPINE, V13, P381, DOI 10.3171/2010.3.SPINE09590
   BRIDWELL KH, 1993, J SPINAL DISORD, V6, P461, DOI 10.1097/00002517-199306060-00001
   Burton D, 2005, SPINE, V30, P2765, DOI 10.1097/01.brs.0000190814.11514.5e
   CAPPUCCINO A, 2010, SPINE PHILA PA 197 S, V35, pS36
   Chen C, 2015, J ORTHOP SURG RES, V10, DOI 10.1186/s13018-015-0253-1
   Chen HH, 2005, SPINE, V30, pE92, DOI 10.1097/01.brs.0000153703.80747.16
   Choi UY, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.2.FOCUS12398
   Dahdaleh NS, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.5.FOCUS13171
   Duncan JW, 2013, EUR SPINE J, V22, P439, DOI 10.1007/s00586-012-2458-x
   Fernandez-Fairen M, 2007, SPINE, V32, P395, DOI 10.1097/01.brs.0000255023.56466.44
   Fujibayashi S, 2017, SPINE, V42, P1478, DOI 10.1097/BRS.0000000000002139
   GOEL VK, 1991, SPINE PHILA PA 197 S, V16, pS15
   HA KY, 1993, J SPINAL DISORD, V6, P99
   Han YC, 2014, EUR SPINE J, V23, P974, DOI 10.1007/s00586-014-3221-2
   Hu XQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087501
   Jang JS, 2005, J NEUROSURG-SPINE, V3, P218, DOI 10.3171/spi.2005.3.3.0218
   Lee MJ, 2012, SPINE, V37, pS40, DOI 10.1097/BRS.0b013e31826ca9b1
   Lin B, 2013, ORTHOPEDICS, V36, pE1071, DOI 10.3928/01477447-20130724-26
   Lin GX, 2018, WORLD NEUROSURG, V119, pE898, DOI 10.1016/j.wneu.2018.08.003
   Liu XL, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1387-6
   Liu Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111979
   Marchi L, 2013, J NEUROSURG-SPINE, V19, P110, DOI 10.3171/2013.4.SPINE12319
   MARDJETKO SM, 1994, SPINE, V19, pS2256, DOI 10.1097/00007632-199410151-00002
   MCAFEE PC, 1989, SPINE, V14, P919, DOI 10.1097/00007632-198909000-00003
   MCAFEE PC, 1991, SPINE PHILA PA 197 S, V16, pS19
   McKissack HM, 2019, ASIAN SPINE J, V13, P325, DOI 10.31616/asj.2018.0087
   NAGATA H, 1993, SPINE, V18, P2471, DOI 10.1097/00007632-199312000-00017
   Sato J, 2017, EUR SPINE J, V26, P671, DOI 10.1007/s00586-015-4170-0
   Shen XL, 2016, CLIN SPINE SURG, V29, pE1, DOI 10.1097/BSD.0000000000000042
   Shono Y, 1998, SPINE, V23, P1550, DOI 10.1097/00007632-199807150-00009
   Silvestre C, 2012, ASIAN SPINE J, V6, P89, DOI 10.4184/asj.2012.6.2.89
   Slucky Andrew V, 2006, Spine J, V6, P78, DOI 10.1016/j.spinee.2005.08.003
   Suk KS, 2000, SPINE, V25, P1843
   Toyone T, 2010, SPINE J M ABSTRACTS, V27
   Tuttle Jonathan, 2006, Neurosurg Focus, V20, pE5
   Xiao SW, 2015, EUR SPINE J, V24, P764, DOI 10.1007/s00586-014-3717-9
   Xie YZ, 2012, ORTHOPEDICS, V35, pE1517, DOI 10.3928/01477447-20120919-22
   Xue HM, 2012, SPINE J, V12, P209, DOI 10.1016/j.spinee.2012.01.010
   YUAN HA, 1994, SPINE, V19, pS2279
   Yucesoy K, 2008, J NEUROSURG-SPINE, V8, P44, DOI 10.3171/SPI-08/01/044
   Zhang K, 2014, INT ORTHOP, V38, P111, DOI 10.1007/s00264-013-2026-y
NR 43
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E920
EP E927
DI 10.1016/j.wneu.2019.11.035
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200107
PM 31733381
DA 2020-05-12
ER

PT J
AU Wu, K
   Zhao, YW
   Feng, ZY
   Hu, XJ
   Chen, Z
   Wang, Y
AF Wu, Kai
   Zhao, Yuwei
   Feng, Zhiyun
   Hu, Xiaojian
   Chen, Zhong
   Wang, Yue
TI Stepwise Local Anesthesia for Percutaneous Endoscopic Interlaminar
   Discectomy: Technique Strategy and Clinical Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE General anesthesia; Interlaminar discectomy; Local anesthesia; Lumbar
   disc herniation; Percutaneous endoscopic lumbar discectomy;
   Transforaminal discectomy
ID LUMBAR DISC HERNIATION; COMPLICATION; INJECTION; EXCISION; BLOCK
AB BACKGROUND: Due to suboptimal pain control under conventional local anesthesia, percutaneous endoscopic interlaminar discectomy is typically performed under general anesthesia. The purpose of this study was to develop a stepwise approach of local anesthesia for endoscopic interlaminar discectomy and evaluate its efficacy.
   METHODS: A stepwise local anesthesia was developed, which mainly includes 3 steps: conventional local anesthesia from skin to laminae, epidural injection, and nerve root block. From June 2015 to May 2017, consecutive patients who underwent endoscopic interlaminar discectomy were included. Local anesthesia or general anesthesia was used based on patients' preference. Anesthetic effectiveness was evaluated as excellent, good, or poor, and adverse events were recorded. Hospitalization expense was compared between the 2 groups. Clinical outcomes were assessed using the Visual Analog Scale and the Oswestry Disability Index.
   RESULTS: There were 98 patients included in the study. Among them, 48 received stepwise local anesthesia and the other 50 received general anesthesia. In the stepwise local anesthesia group, 40 (83.3%) patients rated anesthetic effectiveness as excellent, 7 (14.6%) as good, and 1 (2.1%) as poor. Nine patients had complications that may be associated with local anesthesia, including dyspnea, temporary paresis of legs, and temporary worsened dysesthesia or numbness in legs. After surgery, the patients' leg pain and Oswestry Disability Index significantly improved in both groups. On average, hospitalization expense was approximately 20% less when local anesthesia was used, as compared with using general anesthesia.
   CONCLUSIONS: The stepwise local anesthesia can achieve satisfactory pain control and seems to be a good choice for endoscopic interlaminar discectomy.
C1 [Wu, Kai; Zhao, Yuwei; Feng, Zhiyun; Hu, Xiaojian; Chen, Zhong; Wang, Yue] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Orthoped Surg,Spine Lab, Hangzhou, Peoples R China.
RP Wang, Y (reprint author), Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Orthoped Surg,Spine Lab, Hangzhou, Peoples R China.
EM wangyuespine@zju.edu.cn
OI Wu, Kai/0000-0001-9730-5289
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81772382]; Science and Technology Department of
   Zhejiang Province [2016C33G2011213]; Technology Program of Traditional
   Chinese Medicine Department of Zhejiang Province [2017ZZ011]
FX This work was supported by the National Natural Science Foundation of
   China (no. 81772382); Science and Technology Department of Zhejiang
   Province (2016C33G2011213); and the Technology Program of Traditional
   Chinese Medicine Department of Zhejiang Province (major program,
   2017ZZ011).
CR Alvi MA, 2018, WORLD NEUROSURG, V114, P391, DOI 10.1016/j.wneu.2018.02.156
   BARUTELL C, 1980, ANAESTHESIA, V35, P365, DOI 10.1111/j.1365-2044.1980.tb05119.x
   Choi G, 2006, NEUROSURGERY, V58, P59, DOI 10.1227/01.NEU.0000192713.95921.4A
   Choi KC, 2013, PAIN PHYSICIAN, V16, P547
   Choquet O, 2014, REGION ANESTH PAIN M, V39, P306, DOI 10.1097/AAP.0000000000000095
   Constant I, 1998, BRIT J ANAESTH, V80, P294
   Fardon DF, 2014, SPINE J, V14, P2525, DOI 10.1016/j.spinee.2014.04.022
   Gadjradj PS, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.10.FOCUS15484
   Hansen Tom G, 2004, Expert Rev Neurother, V4, P781, DOI 10.1586/14737175.4.5.781
   Hara K, 2012, REGION ANESTH PAIN M, V37, P289, DOI 10.1097/AAP.0b013e31824bde5c
   KAMBIN P, 1986, CLIN ORTHOP RELAT R, P37
   Kamper SJ, 2014, EUR SPINE J, V23, P1021, DOI 10.1007/s00586-013-3161-2
   Li XH, 2016, J CLIN NEUROSCI, V33, P19, DOI 10.1016/j.jocn.2016.01.043
   Li ZZ, 2015, CLIN NEUROL NEUROSUR, V133, P40, DOI 10.1016/j.clineuro.2015.03.003
   Morau D, 2010, REGION ANESTH PAIN M, V35, P559, DOI 10.1097/AAP.0b013e3181fa6b60
   Nie HF, 2016, SPINE, V41, pB30, DOI 10.1097/BRS.0000000000001810
   Ruan WF, 2016, INT J SURG, V31, P86, DOI 10.1016/j.ijsu.2016.05.061
   Ruetten S, 2006, MINIM INVAS NEUROSUR, V49, P80, DOI 10.1055/s-2006-932172
   Shah S, 2005, ANESTH ANALG, V100, P1515, DOI 10.1213/01.ANE.0000150613.23987.92
   Stark RH, 1996, J HAND SURG-AM, V21A, P391, DOI 10.1016/S0363-5023(96)80350-9
   Tran DQH, 2011, REGION ANESTH PAIN M, V36, P548, DOI 10.1097/AAP.0b013e318235f566
   Tsou Paul Moody, 2002, Spine J, V2, P41, DOI 10.1016/S1529-9430(01)00153-X
   Wang XD, 2014, CHILD NERV SYST, V30, P897, DOI 10.1007/s00381-013-2320-4
   Yeung AT, 2002, SPINE, V27, P722, DOI 10.1097/00007632-200204010-00009
NR 24
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E346
EP E352
DI 10.1016/j.wneu.2019.10.061
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200042
PM 31634623
DA 2020-05-12
ER

PT J
AU Wu, YY
   Guo, XY
   Chen, K
   He, FD
   Quan, JR
AF Wu, Yan-Yan
   Guo, Xuan-Yan
   Chen, Kai
   He, Fan-Ding
   Quan, Jie-Rong
TI Feasibility and Reliability of an Ultrasound Examination to Diagnose
   Piriformis Syndrome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Diagnostic performance; Piriformis; Piriformis syndrome; Sciatic nerve;
   Ultrasound
ID MUSCLE SYNDROME; SCIATIC-NERVE; ULTRASONOGRAPHY; MANAGEMENT; ANATOMY
AB OBJECTIVE: We explored the diagnostic performance of ultrasound examinations in the diagnosis of piriformis syndrome (PS).
   METHODS: In our single-center retrospective study, 52 patients with a diagnosis of PS and 50 healthy volunteers were enrolled to undergo ultrasound examination of the piriformis and sciatic nerve. The thicknesses of the piriformis and the diameter of the sciatic nerve were measured to compare the differences between the patients with PS and healthy volunteers. The diagnostic performance of ultrasound examinations was assessed by constructing a receiver operating characteristic curve and calculating the area under the curve.
   RESULTS: In patients with PS, the piriformis and sciatic nerve were enlarged on the abnormal side compared with the asymptomatic side, accompanied by a decreased echo intensity and an unclear perineurium. In addition, the piriformis thickness and sciatic nerve diameter of those with PS were significantly greater than were those of the healthy volunteers. The diagnostic performance of ultrasonography was significant. The area under the receiver operating characteristic curve for piriformis thickness and sciatic nerve diameter to discriminate between the abnormal and asymptomatic sides was 0.778 and 0.871, respectively.
   CONCLUSION: Ultrasound examinations can assist in the clinical diagnosis of PS and have the potential to be an alternative method for the diagnosis of PS for most musculoskeletal clinicians.
C1 [Guo, Xuan-Yan] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Ultrason Dept, Chengdu, Peoples R China.
   Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Chengdu, Peoples R China.
RP Guo, XY (reprint author), Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Ultrason Dept, Chengdu, Peoples R China.
EM guoxuanyan88@yeah.net
CR Benson ER, 1999, J BONE JOINT SURG AM, V81A, P941, DOI 10.2106/00004623-199907000-00006
   Burke CJ, 2019, ULTRASOUND Q, V35, P125, DOI 10.1097/RUQ.0000000000000360
   Chen J, 2018, J MED ULTRASOUND, V26, P85, DOI 10.4103/JMU.JMU_6_17
   Chen J, 2017, J ULTRASON, V17, P160, DOI 10.15557/JoU.2017.0024
   Chiou Hong-Jen, 2003, Radiographics, V23, pe15
   DEYO RA, 1992, JAMA-J AM MED ASSOC, V268, P760, DOI 10.1001/jama.268.6.760
   Feigenbaum F, 2012, SPINE SURG TECHNIQUE, P1135
   Hernando MF, 2015, SKELETAL RADIOL, V44, P919, DOI 10.1007/s00256-015-2124-6
   Fishman LM, 2019, MUSCLE NERVE, V59, P395, DOI 10.1002/mus.26417
   Fishman LM, 2017, MUSCLE NERVE, V56, P258, DOI 10.1002/mus.25504
   Goedee HS, 2013, EUR J NEUROL, V20, P1342, DOI 10.1111/ene.12182
   Grechenig W, 2000, BIOMED TECH, V45, P298, DOI 10.1515/bmte.2000.45.11.298
   [贺亭 He Ting], 2016, [中华超声影像学杂志, Chinese Journal of Ultrasonography], V25, P61
   Hopayian Kevork, 2018, Eur J Orthop Surg Traumatol, V28, P155, DOI 10.1007/s00590-017-2031-8
   Jankovic D, 2013, CAN J ANESTH, V60, P1003, DOI 10.1007/s12630-013-0009-5
   Lento PH, 2008, CURR REV MUSCULOSKE, V1, P24, DOI 10.1007/s12178-007-9002-3
   Michel F., 2013, Annals of Physical and Rehabilitation Medicine, V56, P371, DOI 10.1016/j.rehab.2013.04.003
   Michel F., 2013, Annals of Physical and Rehabilitation Medicine, V56, P300, DOI 10.1016/j.rehab.2013.03.006
   Miller TA, 2012, CAN J NEUROL SCI, V39, P577, DOI 10.1017/S0317167100015298
   Park CH, 2011, KOREAN J PAIN, V24, P87, DOI 10.3344/kjp.2011.24.2.87
   Poliak-Tunis M., 2019, PAIN REV GUIDE, P703
   Siddiq Md Abu Bakar, 2017, Eur J Orthop Surg Traumatol, V27, P193, DOI 10.1007/s00590-016-1853-0
   Stacy MR, 2017, ADV WOUND CARE, V6, P241, DOI 10.1089/wound.2016.0716
   Vassalou EE, 2018, EUR RADIOL, V28, P447, DOI 10.1007/s00330-017-4982-x
   Zhang WH, 2019, MUSCLE NERVE, V59, P411, DOI 10.1002/mus.26418
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E1085
EP E1092
DI 10.1016/j.wneu.2019.11.098
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200126
PM 31778837
DA 2020-05-12
ER

PT J
AU Wutte, C
   Becker, J
   Klein, B
   Mach, O
   Panzer, S
   Stuby, FM
   Strowitzki, M
   Maier, D
   Thome, C
   Grassner, L
AF Wutte, Christof
   Becker, Johannes
   Klein, Barbara
   Mach, Orpheus
   Panzer, Stephanie
   Stuby, Fabian Maria
   Strowitzki, Martin
   Maier, Doris
   Thome, Claudius
   Grassner, Lukas
TI Early Decompression (< 8 Hours) Improves Functional Bladder Outcome and
   Mobility After Traumatic Thoracic Spinal Cord Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Decompression; Outcome; Spinal cord injury; Surgery; Thoracic
ID SURGICAL DECOMPRESSION; INTRASPINAL PRESSURE; INDEPENDENCE MEASURE;
   NEUROLOGICAL RECOVERY; STABILIZATION; SCIM; COMPRESSION; DUROPLASTY;
   PRIORITIES; PATIENT
AB BACKGROUND: There is accumulating evidence of a potential beneficial effect of early surgical intervention after acute cervical spinal cord injury (SCI). However, around one third of all SC's affect the thoracic spine. This cohort has not been extensively investigated, mainly because of less sensitive clinical readout measures. Apart from regaining full sensorimotor function, improvements in bladder and bowel management remain of the highest priority for patients with chronic paraplegia. Therefore, this study investigates the effect of early decompression (here defined as <8 hours) versus delayed management on neurologic and functional outcome.
   METHODS: We retrospectively analyzed data from the institutional database, in which follow-up data were collected prospectively according to the European Multicenter Study about Spinal Cord Injury standards. Within a 13-year period, we identified 43 patients who met inclusion and exclusion criteria. Of these, 32 (74%) were managed surgically within the first 8 hours. There was a trend toward a higher rate of patients with clinically complete SCI in the early group at baseline.
   RESULTS: After 1 year, we did not observe a benefit on the neurologic outcome as assessed via the American Spinal Injury Association Impairment Scale grade. Functional outcome was evaluated using the Spinal Cord Independence Measure (SCIM). The early decompressed group demonstrated significantly improved SCIM 6 i.e., bladder management) (P < 0.045) and SCIM 9-11 subitems (i.e., mobility, transfer) (P < 0.019).
   CONCLUSIONS: Early decompression was an independent predictor for improved functional bladder outcome and mobility after 1 year. This effect needs to be studied in future prospective, multicenter studies.
C1 [Wutte, Christof; Becker, Johannes; Mach, Orpheus; Stuby, Fabian Maria; Maier, Doris; Grassner, Lukas] Ctr Spinal Cord Injuries, Trauma Ctr Murnau, Murnau, Germany.
   [Wutte, Christof; Strowitzki, Martin] Trauma Ctr Murnau, Dept Neurosurg, Murnau, Germany.
   [Panzer, Stephanie] Trauma Ctr Murnau, Dept Radiol, Murnau, Germany.
   [Becker, Johannes; Panzer, Stephanie] Trauma Ctr Murnau, Inst Biomech, Murnau, Germany.
   [Becker, Johannes; Panzer, Stephanie] Paracelsus Med Univ, Salzburg, Austria.
   [Klein, Barbara; Grassner, Lukas] Paracelsus Med Univ, Inst Mol Regenerat Med, Salzburg, Austria.
   [Klein, Barbara; Grassner, Lukas] SCI TReCS Spinal Cord Injury & Tissue Regenerat C, Salzburg, Austria.
   [Thome, Claudius; Grassner, Lukas] Med Univ Innsbruck, Dept Neurosurg, Innsbruck, Austria.
RP Grassner, L (reprint author), Ctr Spinal Cord Injuries, Trauma Ctr Murnau, Murnau, Germany.; Grassner, L (reprint author), Paracelsus Med Univ, Inst Mol Regenerat Med, Salzburg, Austria.; Grassner, L (reprint author), SCI TReCS Spinal Cord Injury & Tissue Regenerat C, Salzburg, Austria.; Grassner, L (reprint author), Med Univ Innsbruck, Dept Neurosurg, Innsbruck, Austria.
EM lukas.grassner@googlemail.com
CR Ahuja CS, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.18
   Aimetti AA, 2019, SPINAL CORD, V57, P753, DOI 10.1038/s41393-019-0299-8
   Anderson KD, 2004, J NEUROTRAUM, V21, P1371, DOI 10.1089/neu.2004.21.1371
   Badhiwala JH, 2019, J NEUROSURG-SPINE, V30, P1, DOI 10.3171/2018.9.SPINE18682
   Bourassa-Moreau E, 2016, J NEUROTRAUM, V33, P301, DOI 10.1089/neu.2015.3957
   Bransford RJ, 2012, J NEUROSURG-SPINE, V17, P52, DOI 10.3171/2012.6.AOSPINE1287
   Carlson GD, 2003, J BONE JOINT SURG AM, V85A, P86, DOI 10.2106/00004623-200301000-00014
   Carlson GD, 1997, J NEUROTRAUM, V14, P951, DOI 10.1089/neu.1997.14.951
   Catz A, 1997, SPINAL CORD, V35, P850, DOI 10.1038/sj.sc.3100504
   Catz A, 2001, DISABIL REHABIL, V23, P263
   ELKHOURY GY, 1993, AM J ROENTGENOL, V160, P95, DOI 10.2214/ajr.160.1.8416656
   Fehlings MG, 1999, SPINE, V24, P605, DOI 10.1097/00007632-199903150-00023
   Fehlings MG, 2017, GLOB SPINE J, V7, p195S, DOI 10.1177/2192568217706367
   Fehlings MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032037
   Fekete C, 2013, SPINAL CORD, V51, P40, DOI 10.1038/sc.2012.87
   Furlan JC, 2013, J NEUROTRAUM, V30, P487, DOI 10.1089/neu.2012.2539
   Gallagher MJ, 2019, J NEUROTRAUM, V36, P919, DOI 10.1089/neu.2018.5961
   Grassner L, 2018, J NEUROTRAUM, V35, P403, DOI 10.1089/neu.2017.5215
   Grassner L, 2019, WORLD NEUROSURG, V131, pE586, DOI 10.1016/j.wneu.2019.08.009
   Grassner L, 2016, NEURAL REGEN RES, V11, P1928, DOI 10.4103/1673-5374.197132
   Grassner L, 2017, EUR SPINE J, V26, P20, DOI 10.1007/s00586-016-4769-9
   Grassner L, 2016, J NEUROTRAUM, V33, P1658, DOI 10.1089/neu.2015.4325
   Harrop JS, 2011, SPINE, V36, P21, DOI 10.1097/BRS.0b013e3181fd6b36
   Jug M, 2015, J NEUROTRAUM, V32, P1385, DOI 10.1089/neu.2014.3767
   Khorasanizadeh M, 2019, J NEUROSURG-SPINE, V30, P683, DOI 10.3171/2018.10.SPINE18802
   KRENGEL WF, 1993, SPINE, V18, P2080, DOI 10.1097/00007632-199310001-00027
   Lidal IB, 2007, J REHABIL MED, V39, P145, DOI 10.2340/16501977-0017
   Mchenry TP, 2006, J BONE JOINT SURG AM, V88A, P997, DOI 10.2106/JBJS.E.00560
   Panicker JN, 2015, LANCET NEUROL, V14, P720, DOI 10.1016/S1474-4422(15)00070-8
   Pavese C, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002041
   Phang I, 2016, J NEUROSURG-SPINE, V25, P398, DOI 10.3171/2016.1.SPINE151317
   Phang I, 2015, NEUROCRIT CARE, V23, P414, DOI 10.1007/s12028-015-0153-6
   Phang I, 2015, J NEUROTRAUM, V32, P865, DOI 10.1089/neu.2014.3668
   Rahimi-Movaghar V, 2005, J SPINAL CORD MED, V28, P415, DOI 10.1080/10790268.2005.11753841
   Ryken TC, 2013, NEUROSURGERY, V72, P84, DOI 10.1227/NEU.0b013e318276ee16
   Saadoun S, 2016, BRIT J NEUROSURG, V30, P1
   Schinkel C, 2006, J TRAUMA, V61, P156, DOI 10.1097/01.ta.0000222669.09582.ec
   Simpson LA, 2012, J NEUROTRAUM, V29, P1548, DOI 10.1089/neu.2011.2226
   ter Wengel PV, 2019, J NEUROTRAUM, V36, P835, DOI 10.1089/neu.2018.5974
   ter Wengel PV, 2019, J NEUROTRAUM, V36, P2609, DOI 10.1089/neu.2018.6277
   Tykocki T, 2017, WORLD NEUROSURG, V105, P145, DOI 10.1016/j.wneu.2017.05.138
   Wilson JR, 2018, J NEUROTRAUM, V35, P2554, DOI 10.1089/neu.2017.5535
   Wilson JR, 2017, GLOB SPINE J, V7, p95S, DOI 10.1177/2192568217701716
   Wutte C, 2019, J NEUROTRAUM, V36, P2020, DOI 10.1089/neu.2018.6146
   Zariffa J, 2011, SPINAL CORD, V49, P463, DOI 10.1038/sc.2010.140
NR 45
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E847
EP E854
DI 10.1016/j.wneu.2019.11.015
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200098
PM 31715410
DA 2020-05-12
ER

PT J
AU Xiang, YL
   Zhang, TT
   Li, YX
   Liu, JJ
   Xu, HL
   He, WW
   Chen, Q
   Yang, YJ
AF Xiang, Yilan
   Zhang, Tingting
   Li, Yanxuan
   Liu, Jinjin
   Xu, Haoli
   He, Wenwen
   Chen, Qian
   Yang, Yunjun
TI Comparison of Ultra-Early Hematoma Growth and Common Noncontrast
   Computed Tomography Features in Predicting Hematoma Enlargement in
   Patients with Soontaneous Intracerebral Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE CT; Hematoma; Spontaneous intracerebral hemorrhage; Ultra-early hematoma
   growth
ID BLACK-HOLE SIGN; ANGIOGRAPHY SPOT SIGN; BLEND SIGN; EXPANSION; CT;
   HYPODENSITIES; VOLUME; BLOOD
AB OBJECTIVE: Ultra-early hematoma growth (uHG), the black hole sign, and the blend sign are common predictors of hematoma enlargement (HE). This study aimed to develop a new diagnostic criterion for predicting HE using uHG and to compare the accuracy of uHG, the black hole sign, and the blend sign in predicting HE in patients with spontaneous intracerebral hemorrhage (sICH).
   METHODS: We retrospectively analyzed data of 920 patients with sICH from August 2013 to January 2018. Receiver operating characteristic curves were plotted to determine the optimal threshold values of uHG to predict HE. The effects of the black hole sign, blend sign, and uHG on HE were assessed using univariate and multivariate logistic regression models, and their prediction accuracies were analyzed using receiver operator analyses.
   RESULTS: The black hole sign was identified in 131 patients, the blend sign in 163 patients, and uHG >6.46 mL/h in 441 patients. Logistic analysis showed that the black hole sign, blend sign, and uHG >6.46 mL/h were independent predictors of HE. The sensitivity values of uHG >6.46 mL/h, the black hole sign, and the blend sign were 70.43%, 24.19%, and 36.56%, respectively, and specificity values were 57.77%, 88.28%, and 87.06%, respectively. uHG had the greatest area under the curve. The black hole and blend signs were more commonly found in patients with uHG >6.46 mL/h (P < 0.001).
   CONCLUSIONS: uHG >6.46 mL/h was the optimal predictor used for identifying patients at high risk of developing HE. A greater uHG value was associated with an increased prevalence of the black hole and blend signs.
C1 [Xiang, Yilan; Zhang, Tingting; Li, Yanxuan; Liu, Jinjin; Xu, Haoli; He, Wenwen; Chen, Qian; Yang, Yunjun] Wenzhou Med Univ, Affiliated Hosp 1, Dept Radiol, Wenzhou, Zhejiang, Peoples R China.
RP Yang, YJ (reprint author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Radiol, Wenzhou, Zhejiang, Peoples R China.
EM yyjunjim@163.com
FU Science and Technology Planning Projects of Wenzhou [Y20180112]; Health
   Foundation for Creative Talents in Zhejiang Province; Project Foundation
   for the College Young and Middle-aged Academic Leader of Zhejiang
   Province
FX Funded by the Science and Technology Planning Projects of Wenzhou (grant
   no. Y20180112), Health Foundation for Creative Talents in Zhejiang
   Province, and Project Foundation for the College Young and Middle-aged
   Academic Leader of Zhejiang Province.
CR Anderson CS, 2013, NEW ENGL J MED, V368, P2355, DOI 10.1056/NEJMoa1214609
   Barras CD, 2009, STROKE, V40, P1325, DOI 10.1161/STROKEAHA.108.536888
   Blacquiere D, 2015, STROKE, V46, P3111, DOI 10.1161/STROKEAHA.115.010566
   Boulouis G, 2016, STROKE, V47, P2511, DOI 10.1161/STROKEAHA.116.014425
   BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987
   Brouwers HB, 2013, CEREBROVASC DIS, V35, P195, DOI 10.1159/000346599
   Brouwers HB, 2012, STROKE, V43, P2120, DOI 10.1161/STROKEAHA.112.659094
   Falcone GJ, 2013, JAMA NEUROL, V70, P988, DOI 10.1001/jamaneurol.2013.98
   FISHER CM, 1971, J NEUROPATH EXP NEUR, V30, P536, DOI 10.1097/00005072-197107000-00015
   Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304
   Li Q, 2018, CEREBROVASC DIS, V45, P48, DOI 10.1159/000486163
   Li Q, 2017, STROKE, V48, P3019, DOI 10.1161/STROKEAHA.117.017985
   Li Q, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183082
   Li Q, 2016, STROKE, V47, P1777, DOI 10.1161/STROKEAHA.116.013186
   Li Q, 2015, STROKE, V46, P2119, DOI 10.1161/STROKEAHA.115.009185
   Li RL, 2017, BIOSCI TRENDS, V11, P682, DOI 10.5582/bst.2017.01283
   Lou M, 2010, STROKE, V41, P34, DOI 10.1161/STROKEAHA.109.564955
   Marti-Fabregas J, 2013, EUR NEUROL, V70, P175, DOI 10.1159/000351246
   Morotti A, 2018, STROKE, V49, P2067, DOI 10.1161/STROKEAHA.118.022010
   NEW PFJ, 1976, RADIOLOGY, V121, P635, DOI 10.1148/121.3.635
   Ovesen C, 2014, STROKE, V45, P994, DOI 10.1161/STROKEAHA.113.003608
   Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8
   Rodriguez-Luna D, 2011, NEUROLOGY, V77, P1599, DOI 10.1212/WNL.0b013e3182343387
   Rodriguez-Luna D, 2016, NEUROLOGY, V87, P357, DOI 10.1212/WNL.0000000000002897
   Sato S, 2014, NEUROLOGY, V83, P2232, DOI 10.1212/WNL.0000000000001076
   Schlunk F, 2015, TRANSL STROKE RES, V6, P257, DOI 10.1007/s12975-015-0410-1
   Sporns PB, 2017, J STROKE, V19, P333, DOI 10.5853/jos.2016.02061
   van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0
   Yaghi S, 2014, INT J NEUROSCI, V124, P890, DOI 10.3109/00207454.2014.887716
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E75
EP E81
DI 10.1016/j.wneu.2019.09.053
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200011
PM 31648055
DA 2020-05-12
ER

PT J
AU Xie, L
   Wang, HL
   Jiang, JY
AF Xie, Lin
   Wang, Hongli
   Jiang, Jianyuan
TI Does Radiotherapy with Surgery Improve Survival and Decrease Progression
   to Multiple Myeloma in Patients with Solitary Plasmacytoma of Bone of
   the Spine?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Propensity score matched; Radiotherapy; Solitary plasmacytoma of bone;
   Surgery; Survival
AB OBJECTIVE: To investigate the outcomes of radiotherapy with or without surgery during treatment of patients with solitary plasmacytoma of bone (SBP) of the spine.
   METHODS: Patients diagnosed with SBP of the spine treated with radiotherapy with or without surgery were identified and extracted from the SEER database. Propensity score matched (PSM) analysis was performed to balance patient characteristics between radiotherapy alone and radiotherapy with surgery groups. Patients in different age-groups were stratified and analyzed.
   RESULTS: A total of 1275 patients with SBP of the spine treated with radiotherapy with or without surgery were extracted from the SEER database. Before PSM, the unadjusted Kaplan-Meier curve showed that the radiotherapy with surgery group had worse overall survival than did the radiotherapy without surgery group (both P < 0.05), whereas the difference of overall survival was attenuated after PSM. Stratified analysis found that the radiotherapy with surgery group had less progression to multiple myeloma for young patients (age <45 years) with SBP of the spine than did the radiotherapy without surgery group.
   CONCLUSIONS: The results of our study suggest that radiotherapy with surgery may show less progression to multiple myeloma for younger patients with SBP of the spine.
C1 [Xie, Lin; Wang, Hongli; Jiang, Jianyuan] Fudan Univ, Huashan Hosp, Dept Orthoped, Shanghai, Peoples R China.
RP Jiang, JY (reprint author), Fudan Univ, Huashan Hosp, Dept Orthoped, Shanghai, Peoples R China.
EM 18111220066@fudan.edu.cn
CR Abd El-Fattah M, 2017, BRIT J HAEMATOL, V179, P161, DOI 10.1111/bjh.14189
   Albano D, 2018, EUR J NUCL MED MOL I, V45, P77, DOI 10.1007/s00259-017-3810-5
   Caers J, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-017-0549-1
   de Waal EGM, 2016, BRIT J HAEMATOL, V175, P661, DOI 10.1111/bjh.14291
   Dimopoulos MA, 2000, BLOOD, V96, P2037
   HOLLAND J, 1992, CANCER, V69, P1513, DOI 10.1002/1097-0142(19920315)69:6<1513::AID-CNCR2820690633>3.0.CO;2-X
   Huang WD, 2010, SPINE, V35, pE278, DOI 10.1097/BRS.0b013e3181c9b431
   Jawad MU, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-41
   Reed V, 2011, CANCER-AM CANCER SOC, V117, P4468, DOI 10.1002/cncr.26031
   Song KH, 2018, CLIN ORTHOP RELAT R, V476, P987, DOI 10.1007/s11999.0000000000000152
   Song KH, 2018, INT ORTHOP, V42, P2941, DOI 10.1007/s00264-018-3942-7
   Song KH, 2018, SPINE, V43, pE1281, DOI 10.1097/BRS.0000000000002688
   Suh YG, 2012, ANN HEMATOL, V91, P1785, DOI 10.1007/s00277-012-1510-6
   Thumallapally N, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-3015-5
   Tomita K, 2006, J ORTHOP SCI, V11, P3, DOI 10.1007/s00776-005-0964-y
   Tutar S, 2016, SPINE J, V16, pE485, DOI 10.1016/j.spinee.2016.01.016
   Warsame R, 2012, AM J HEMATOL, V87, P647, DOI 10.1002/ajh.23201
   Weberpals J, 2017, HAEMATOLOGICA, V102, pE229, DOI 10.3324/haematol.2016.157768
   Yang JS, 2013, J KOREAN NEUROSURG S, V54, P426, DOI 10.3340/jkns.2013.54.5.426
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E790
EP E798
DI 10.1016/j.wneu.2019.11.002
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200092
PM 31715413
DA 2020-05-12
ER

PT J
AU Yamada, T
   Natori, Y
AF Yamada, Tetsuhisa
   Natori, Yoshihiro
TI Prospective Study on the Efficacy of Orally Administered Tranexamic Acid
   and Goreisan for the Prevention of Recurrence After Chronic Subdural
   Hematoma Burr Hole Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chronic subdural hematoma; Goreisan; Recurrence; Tranexamic acid
ID COMPLICATIONS
AB OBJECTIVE: This prospective study investigated whether tranexamic acid and Goreisan effectively prevent recurrence after burr hole surgery for chronic subdural hematoma.
   METHODS: A total of 297 patients with chronic subdural hematoma underwent initial burr hole surgery at our hospital from April 2014 to March 2018. Of these, 206 patients (250 hematomas) consented to participate in this study. Patients were randomly divided into the non-administration, tranexamic acid, and Goreisan groups based on age. The oral administration intervention was implemented from the day after surgery, after which there was a 3-month follow-up. Recurrence rates were measured, and head computed tomography scan was used to measure the volume of residual hematoma 1 day, 1 week, and 1, 2, and 3 months after surgery.
   RESULTS: A total of 193 patients (232 hematomas) were followed-up for 3 months (82 hematomas in the nonadministration group, 72 hematomas in the tranexamic acid group, and 78 hematomas in the Goreisan group). There were no significant between-group differences in demographic characteristics, current drug treatment, comorbidities, hematoma, operation side (bilateral or unilateral), preoperative hematoma volume, and recurrence rates. At 1, 2, and 3 months, the residual hematoma volume was significantly smaller in the tranexamic acid group than in the other 2 groups.
   CONCLUSIONS: Oral administration of tranexamic acid or Goreisan does not minimize recurrence after chronic subdural hematoma burr hole surgery; however, tranexamic acid can reduce the hematoma volume.
C1 [Yamada, Tetsuhisa] Iizuka Hosp, Dept Emergency Med, Fukuoka, Japan.
   [Natori, Yoshihiro] Iizuka Hosp, Dept Neurosurg, Fukuoka, Japan.
RP Yamada, T (reprint author), Iizuka Hosp, Dept Emergency Med, Fukuoka, Japan.
EM tyamadah4@aih-net.com
CR Bartek J, 2017, WORLD NEUROSURG, V106, P609, DOI 10.1016/j.wneu.2017.07.044
   Castle NA, 2005, DRUG DISCOV TODAY, V10, P485, DOI 10.1016/S1359-6446(05)03390-8
   Isohama Y, 2011, SCI KAMPO MED, V35, P186
   Isohama Y, 2018, FARUMASHIA, V54, P139
   Kageyama H, 2013, J NEUROSURG, V119, P332, DOI 10.3171/2013.3.JNS122162
   Kaneshiro Yuta, 2019, Surg Neurol Int, V10, P18, DOI 10.4103/sni.sni_108_18
   Karibe Hiroshi, 2011, No Shinkei Geka, V39, P1149
   Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256
   Miyagami M, 2009, NEUROL SURG TOKYO, V37, P765
   Mori K, 2001, NEUROL MED-CHIR, V41, P371, DOI 10.2176/nmc.41.371
   Nagashima H, 2010, JPN J NEUROSURG TOKY, V19, P845
   Ohnishi N., 2000, Journal of Traditional Medicines, V17, P131
   OKAMOTO SHOKUKE, 1959, KEIO JOUR MED, V8, P247
   OKAMOTO SHOSUKE, 1962, KEIO JOUR MED, V11, P105
   Shiomi N, 2001, NEUROL SURG TOKYO, V29, P39
   Takayama Motoharu, 2012, No Shinkei Geka, V40, P871
   Tsushima S, 2013, JAPAN J NEUROSURG, V22, P625
   Verkman AS, 2002, EXP NEPHROL, V10, P235
   Wakabayashi Yukihiro, 2012, No Shinkei Geka, V40, P967
   Yamada T, 2015, NEUROTRAUMATOLOGY, V38, P71
   Yamada T, 2018, NEUROTRAUMATOLOGY, V41, P16
   Yamada T, 2013, JPN J NEUROSURG TOKY, V22, P125
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E549
EP E553
DI 10.1016/j.wneu.2019.10.134
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200066
PM 31678452
DA 2020-05-12
ER

PT J
AU Yamagami, K
   Hatano, T
   Nakahara, I
   Ishii, A
   Ando, M
   Chihara, H
   Ogura, T
   Suzuki, K
   Kondo, D
   Kamata, T
   Higashi, E
   Sakai, S
   Sakamoto, H
   Iihara, K
   Nagata, I
AF Yamagami, Keitaro
   Hatano, Taketo
   Nakahara, Ichiro
   Ishii, Akira
   Ando, Mitsushige
   Chihara, Hideo
   Ogura, Takenori
   Suzuki, Keita
   Kondo, Daisuke
   Kamata, Takahiko
   Higashi, Eiji
   Sakai, Shota
   Sakamoto, Hiroki
   Iihara, Koji
   Nagata, Izumi
TI Long-term Outcomes After Intraprocedural Aneurysm Rupture During Coil
   Embolization of Unruptured Intracranial Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Coil embolization; Endovascular neurosurgery; Intraprocedural rupture;
   Long-term outcomes; Unruptured intracranial aneurysm
ID GUGLIELMI DETACHABLE COILS; CEREBRAL ANEURYSMS; RISK; MANAGEMENT;
   THERAPY; SINGLE; PREDICTORS; SAFETY
AB BACKGROUND: The long-term outcomes of patients with intraprocedural aneurysm rupture (IPR) during endovascular coiling of unruptured intracranial aneurysms (UIAs) remain unclear. We investigated the long-term outcomes and predictors of neurological outcomes in patients who sustained IPR during coil embolization of UIAs.
   METHODS: We retrospectively analyzed the medical record of 312 untreated UIAs in 284 patients who underwent endovascular coiling between April 2013 and July 2018.
   RESULTS: The mean follow-up period for the entire cohort was 25.6 months. Twelve patients (3.8%) experienced IPR. The mean aneurysm size in the IPR cohort was significantly smaller than that in the no-IPR cohort (P = 0.045). The IPR cohort had a higher percentage of earlier subarachnoid hemorrhage from another aneurysm (P = 0.019), anterior communicating artery (AComA) aneurysm (P < 0.001), and basilar artery (BA) aneurysm (P = 0.022) than the no-IPR cohort. Neurologic deterioration was observed in 3 patients. The morbidity and mortality rates of the IPR cohort were 25% and 8.3%, respectively. Patients with IPR during coil embolization for AComA aneurysm did not develop neurological deterioration. Two of the 3 patients (66.7%) with a BA aneurysm had neurological deterioration. The proportion of patients with an mRS score of 0-2 at the last follow-up did not differ between the 2 cohorts (P = 0.608).
   CONCLUSIONS: The proportion of functionally independent patients did not differ between patients with and without IPR. Patients with BA aneurysms who developed an IPR tended to exhibit more unfavorable clinical courses than patients with AcomA aneurysms.
C1 [Yamagami, Keitaro; Hatano, Taketo; Ando, Mitsushige; Chihara, Hideo; Ogura, Takenori; Suzuki, Keita; Kondo, Daisuke; Kamata, Takahiko; Higashi, Eiji; Sakai, Shota; Sakamoto, Hiroki; Nagata, Izumi] Kokura Mem Hosp, Stroke Ctr, Dept Neurosurg, Kitakyushu, Fukuoka, Japan.
   [Yamagami, Keitaro; Iihara, Koji] Kyushu Univ, Grad Sch Med Sci, Dept Neurosurg, Fukuoka, Fukuoka, Japan.
   [Nakahara, Ichiro] Fujita Hlth Univ, Dept Comprehens Strokol, Sch Med, Toyoake, Aichi, Japan.
   [Ishii, Akira] Kyoto Univ, Dept Neurosurg, Grad Sch Med, Kyoto, Japan.
RP Yamagami, K (reprint author), Kokura Mem Hosp, Stroke Ctr, Dept Neurosurg, Kitakyushu, Fukuoka, Japan.; Yamagami, K (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Neurosurg, Fukuoka, Fukuoka, Japan.
EM yamagami.keitaro.twins@gmail.com
RI ; Nakahara, Ichiro/G-3259-2010
OI Chihara, Hideo/0000-0001-8767-6617; Nakahara, Ichiro/0000-0001-8909-2949
CR Algra AM, 2019, JAMA NEUROL, V76, P282, DOI 10.1001/jamaneurol.2018.4165
   Almekhlafi MA, 2020, J NEUROINTERV SURG, V12, P298, DOI 10.1136/neurintsurg-2019-015173
   Birknes JK, 2006, NEUROSURGERY, V59, P43, DOI 10.1227/01.NEU.0000219220.25721.B9
   Brisman JL, 2005, NEUROSURGERY, V57, P1103, DOI 10.1227/01.NEU.0000185631.20246.1A
   Cho SH, 2017, WORLD NEUROSURG, V105, P177, DOI 10.1016/j.wneu.2017.05.147
   Cloft HJ, 2002, AM J NEURORADIOL, V23, P1706
   Darsaut TE, 2017, J NEUROL NEUROSUR PS, V88, P663, DOI 10.1136/jnnp-2016-315433
   Doerfler A, 2001, AM J NEURORADIOL, V22, P1825
   Elijovich L, 2008, STROKE, V39, P1501, DOI 10.1161/STROKEAHA.107.504670
   Fan LH, 2017, J NEUROINTERV SURG, V9, P370, DOI 10.1136/neurintsurg-2016-012335
   Gonzalez N, 2008, STROKE, V39, P2776, DOI 10.1161/STROKEAHA.107.505222
   Greving JP, 2014, LANCET NEUROL, V13, P59, DOI 10.1016/S1474-4422(13)70263-1
   Huang MC, 2011, STROKE, V42, P1730, DOI 10.1161/STROKEAHA.110.603803
   Kang DH, 2014, J NEUROSURG, V121, P605, DOI 10.3171/2014.5.JNS132107
   Kawabata S, 2018, J NEUROINTERV SURG, V10, P362, DOI 10.1136/neurintsurg-2017-013156
   Kocur D, 2018, CLIN NEUROL NEUROSUR, V10, P362
   Levy E, 2001, NEUROSURGERY, V49, P807, DOI 10.1097/00006123-200110000-00005
   Lin N, 2018, J NEUROINTERV SURG, V10, pI69, DOI 10.1136/jnis.2011.004978.rep
   McDougall CG, 2012, J NEUROSURG, V116, P135, DOI 10.3171/2011.8.JNS101767
   Molyneux A, 2012, LANCET, V11, P304
   Neidert MC, 2018, NEUROSURGERY, V83, P1286, DOI 10.1093/neuros/nyx609
   Nishikawa Y, 2013, J STROKE CEREBROVASC, V22, P650, DOI 10.1016/j.jstrokecerebrovasdis.2012.02.008
   Park YK, 2018, WORLD NEUROSURG, V114, pE605, DOI 10.1016/j.wneu.2018.03.040
   Phillips TJ, 2012, AM J NEURORADIOL, V33, P1225, DOI 10.3174/ajnr.A3166
   Pierot L, 2008, STROKE, V39, P2497, DOI 10.1161/STROKEAHA.107.512756
   Santillan A, 2012, AM J NEURORADIOL, V33, P2017, DOI 10.3174/ajnr.A3061
   Schuette AJ, 2011, NEUROSURGERY, V68, P731, DOI 10.1227/NEU.0b013e3182077373
   Shigematsu T, 2013, STROKE, V44, P2735, DOI 10.1161/STROKEAHA.111.000609
   Sluzewski M, 2001, J NEUROSURG, V94, P238, DOI 10.3171/jns.2001.94.2.0238
   Stapleton CJ, 2015, J NEUROSURG, V122, P128, DOI 10.3171/2014.9.JNS14616
   Tokunaga K, 2019, WORLD NEUROSURG, V130, pE457, DOI 10.1016/j.wneu.2019.06.114
   Tummala RP, 2001, NEUROSURGERY, V49, P1059, DOI 10.1097/00006123-200111000-00007
   van Rooij WJ, 2009, AM J NEURORADIOL, V30, P835, DOI 10.3174/ajnr.A1429
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E289
EP E297
DI 10.1016/j.wneu.2019.10.038
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200035
PM 31629140
DA 2020-05-12
ER

PT J
AU Yang, CX
   Wang, X
   Tang, XL
   Wang, RZ
   Bao, XJ
AF Yang, Chengxian
   Wang, Xue
   Tang, Xiaoli
   Wang, Renzhi
   Bao, Xinjie
TI Stem-Cell Research of Parkinson Disease: Bibliometric Analysis of
   Research Productivity from 1999 to 2018
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bibliometric analysis; Parkinson disease; Publications; Stem cells;
   VOSviewer
ID DOPAMINERGIC-NEURONS; ECONOMIC BURDEN; RAT MODEL; TRANSPLANTATION;
   SURVIVAL; PROGENITORS
AB OBJECTIVE: Although the overall publication trends in Parkinson disease (PD) and characteristics of top-cited articles have been reported, there was only 1 literature analysis published in 2012 with a special focus on stem cells. It is necessary to evaluate and update the global publication trends in stem cell research of PD.
   METHODS: We identified the publications designated as "article" about stem-cell research of PD between 1999 and 2018 in the Web of Science Core Collection. We used HistCite to analyze annual outputs, journals, countries/regions, and institutions every 5 years and visualized global collaborations between publications by VOSviewer. Moreover, to track the growing hotspots, MeSH terms of each publication were obtained by Medical Text Indexer according to the title and abstract.
   RESULTS: We described the publication trends and topic hotspots of stem-cell research of PD by bibliometric analysis of 1709 papers. Researchers showed growing interest in publishing relevant scientific literature in journals associated with stem cells or multidisciplinary science. Stem cell research of PD was more common in developed countries and regions. The United States of America was the most contributive country throughout, accounting for 33% of total publications and ranking first in all 5-year periods. Harvard University was the most productive institution in this area, ranking first during 1999-2003, 2004-2008, and 2009-2013. The application of induced pluripotent stem cells was at the forefront of cell therapies for PD.
   CONCLUSIONS: These bibliometric findings suggest that stem cell research consistently promotes the understanding and treatment of PD.
C1 [Yang, Chengxian; Wang, Renzhi; Bao, Xinjie] Peking Union Med Coll Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Wang, Xue; Tang, Xiaoli] Peking Union Med Coll, Inst Med Informat & Lib, Beijing, Peoples R China.
   [Wang, Xue; Tang, Xiaoli] Chinese Acad Med Sci, Beijing, Peoples R China.
RP Bao, XJ (reprint author), Peking Union Med Coll Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM baoxinjie1@pumch.cn
FU National Key R&D Program of China [2018YFA0108602, 2018YFA0108600];
   Beijing Municipal Natural Science FoundationBeijing Natural Science
   Foundation [7182134]; CAMS Initiative for Innovative Medicine (CAMS-I2M)
   [2016-I2M-1-017, 2016-I2M-3-018]; CAMS Young Talents Award Project
   [2018RC320003]; Beijing Nova ProgramBeijing Municipal Science &
   Technology Commission [Z181100006218003]
FX This work was supported by the National Key R&D Program of China
   (2018YFA0108602, 2018YFA0108600); Beijing Municipal Natural Science
   Foundation (7182134); CAMS Initiative for Innovative Medicine (CAMS-I2M)
   (2016-I2M-1-017, 2016-I2M-3-018); CAMS Young Talents Award Project
   (2018RC320003); and Beijing Nova Program (Z181100006218003).
CR Araujo R, 2017, J PARKINSON DIS, V7, P81, DOI 10.3233/JPD-179000
   Barker RA, 2017, CELL STEM CELL, V21, P569, DOI 10.1016/j.stem.2017.09.014
   Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099
   Brederlau A, 2006, STEM CELLS, V24, P1433, DOI 10.1634/stemcells.2005-0393
   Doi D, 2014, STEM CELL REP, V2, P337, DOI 10.1016/j.stemcr.2014.01.013
   Dorsey ER, 2018, LANCET NEUROL, V17, P939, DOI 10.1016/S1474-4422(18)30295-3
   Elkouzi A, 2019, NAT REV NEUROL, V15, P204, DOI 10.1038/s41582-019-0155-7
   Findley Leslie J, 2011, J Med Econ, V14, P130, DOI 10.3111/13696998.2010.551164
   Grealish S, 2014, CELL STEM CELL, V15, P653, DOI 10.1016/j.stem.2014.09.017
   Gu Q, 2017, STEM CELL REP, V9, P366, DOI 10.1016/j.stemcr.2017.04.017
   Kalia LV, 2015, LANCET, V386, P896, DOI 10.1016/S0140-6736(14)61393-3
   Kikuchi T, 2017, NATURE, V548, P592, DOI 10.1038/nature23664
   Kikuchi T, 2011, J PARKINSON DIS, V1, P395, DOI 10.3233/JPD-2011-11070
   Kowal SL, 2013, MOVEMENT DISORD, V28, P311, DOI 10.1002/mds.25292
   Li RH, 2012, NEURAL REGEN RES, V7, P1272, DOI 10.3969/j.issn.1673-5374.2012.16.010
   Mendez I, 2008, NAT MED, V14, P507, DOI 10.1038/nm1752
   National Institutes of Health, 2019, EST FUND VAR RES CON
   Redmond DE, 2007, P NATL ACAD SCI USA, V104, P12175, DOI 10.1073/pnas.0704091104
   Ren ZH, 2009, SCI CHINA SER C, V52, P610, DOI 10.1007/s11427-009-0090-8
   Robert C, 2019, PARKINSONISM RELAT D, V61, P10, DOI 10.1016/j.parkreldis.2018.11.011
   Samata B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13097
   Sonntag KC, 2018, PROG NEUROBIOL, V168, P1, DOI 10.1016/j.pneurobio.2018.04.005
   Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634
   Takagi Y, 2005, J CLIN INVEST, V115, P102, DOI 10.1172/JCI200521137
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   The Michael J, 2019, MICH J
   Wagner J, 1999, NAT BIOTECHNOL, V17, P653
   Wang YK, 2018, STEM CELL REP, V11, P171, DOI 10.1016/j.stemcr.2018.05.010
   Winter Y, 2010, NEURODEGENER DIS, V7, P365, DOI 10.1159/000302644
   Xue JH, 2018, NEUROL SCI, V39, P1537, DOI 10.1007/s10072-018-3450-y
   Yamabe K, 2018, J MED ECON, V21, P1206, DOI 10.1080/13696998.2018.1522638
   Yang JX, 2017, PARKINSONS DIS-US, V2017, DOI 10.1155/2017/8762939
   Zhang ZX, 2005, LANCET, V365, P595, DOI 10.1016/S0140-6736(05)70801-1
   Zuo FX, 2017, STEM CELLS, V35, P1519, DOI 10.1002/stem.2616
NR 34
TC 0
Z9 0
U1 9
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E405
EP E411
DI 10.1016/j.wneu.2019.10.087
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200049
PM 31655231
DA 2020-05-12
ER

PT J
AU Yang, HZ
   Wang, BB
   Zou, XB
   Ge, S
   Chen, YY
   Zhang, S
   Ni, L
   Li, HR
   Yang, JC
   Ma, XY
AF Yang, Haozhi
   Wang, Binbin
   Zou, Xiaobao
   Ge, Su
   Chen, Yuyue
   Zhang, Shuang
   Ni, Ling
   Li, Hengrui
   Yang, Jincheng
   Ma, Xiangyang
TI Safe Limit of Shortening of the Spinal Cord in Thoracolumbar Bivertebral
   Column Resections: An Experimental Study in Goats
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bivertebral column resection; Safe limit of shortening; Somatosensory
   evoked potential; Spinal cord injury; Thoracolumbar
ID INJURY; OSTEOTOMY; SURGERY; MOTOR
AB OBJECTIVE: To clarify the safe limit of shortening of the spinal cord in thoracolumbar bivertebral column resection in a goat model.
   METHODS: Ten healthy goats were selected for the experiment. Radiographs were taken before surgery to measure the height of T13, L1, and the initial osteotomy segment (distance from the lower end plate of T12 to the upper end plate of L2). A procedure of thoracolumbar bivertebral column resection (T13 and L1) was completed under the monitoring of somatosensory evoked potential (SSEP) monitoring. The SSEP measured after vertebral resection was set as the baseline. SSEPs decreased by 50% from the baseline amplitude and/or delayed by 10% relative to the baseline peak latency were set as positive results, indicating spinal cord injury. The initial height of the osteotomy gap was measured first and the spinal column was gradually shortened until the SSEP monitoring did not show a positive result. Then the height of the osteotomy gap was recorded again. The safe limit of shortening was measured and recorded when any morphologic change of the spinal cord was observed. Hindlimb function was evaluated by the Tarlov scores on day 2 postoperatively.
   RESULTS: The safe limit of shortening of the spinal cord in thoracolumbar bivertebral columns resection was 35.2 +/- 2.6 mm, which was roughly equal to 127.6% of the mean osteotomy vertebral height and 57.1% of the initial osteotomy gap height. Pearson correlation test showed that the safe limit of shortening of the spinal cord was correlated with the height of T13, the height of L1, the mean height of T13 and 11, and the height of the initial osteotomy gap.
   CONCLUSIONS: The safe limit of shortening distance of the bivertebral column resection was roughly equal to 127.6% of the mean osteotomy vertebral height and 57.1% of the initial osteotomy gap height with good correlation. Moreover, the safe limit of shortening distance of the bivertebral column resection was longer than that in single vertebral column resection. Increasing the number of vertebrae resected may prevent spinal cord injury because of excessive shortening.
C1 [Yang, Haozhi; Wang, Binbin; Zou, Xiaobao; Ge, Su; Chen, Yuyue; Zhang, Shuang; Ni, Ling; Li, Hengrui; Ma, Xiangyang] Southern Theatre Command PLA, Gen Hosp, Dept Orthoped, Guangzhou, Peoples R China.
   [Yang, Haozhi] Southern Med Univ, Dept Orthoped, Affiliated Hosp 3, Guangzhou, Peoples R China.
   [Zou, Xiaobao; Zhang, Shuang; Ma, Xiangyang] Southern Med Univ, Grad Sch, Guangzhou, Peoples R China.
   [Yang, Jincheng] Southern Med Univ, Dept Orthoped, Nanfang Hosp, Guangzhou, Peoples R China.
RP Ma, XY (reprint author), Southern Theatre Command PLA, Gen Hosp, Dept Orthoped, Guangzhou, Peoples R China.; Ma, XY (reprint author), Southern Med Univ, Grad Sch, Guangzhou, Peoples R China.
EM maxy1001@126.com
OI Yang, Haozhi/0000-0002-0298-5179
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81672232]
FX This work was supported by the National Natural Science Foundation of
   China (81672232).
CR Akar I, 2017, ANN VASC SURG, V42, P285, DOI 10.1016/j.avsg.2016.12.016
   Chandanwale A S, 2008, J Orthop Surg (Hong Kong), V16, P277
   Flouty O, 2012, PHYSIOL MEAS, V33, P2003, DOI 10.1088/0967-3334/33/12/2003
   Gurer B, 2015, INJURY, V46, P240, DOI 10.1016/j.injury.2014.11.002
   Hamzaoglu A, 2011, SPINE, V36, pE340, DOI 10.1097/BRS.0b013e3182015712
   Hilibrand AS, 2004, J BONE JOINT SURG AM, V86A, P1248, DOI 10.2106/00004623-200406000-00018
   Ji L, 2013, SPINAL CORD, V51, P134, DOI 10.1038/sc.2012.99
   Jorge A, 2019, J CLIN NEUROPHYSIOL, V36, P155, DOI 10.1097/WNP.0000000000000563
   Kawahara N, 2005, SPINE, V30, P613, DOI 10.1097/01.brs.0000155407.87439.a2
   Kawahara N, 2001, SPINE, V26, P391, DOI 10.1097/00007632-200102150-00016
   Lenke LG, 2010, CLIN ORTHOP RELAT R, V468, P687, DOI 10.1007/s11999-009-1037-x
   Maier SP, 2014, SPINE, V39, P881, DOI 10.1097/BRS.0000000000000304
   Modi HN, 2011, J BONE JOINT SURG AM, V93A, P1781, DOI [10.2106/JBJS.J.01794, 10.2106/JBJS.I.01794]
   Ore CLD, 2018, WORLD NEUROSURG, V119, pE551, DOI 10.1016/j.wneu.2018.07.209
   Qin J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052910
   Qiu F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127624
   Schwartz DM, 2007, J BONE JOINT SURG AM, V89A, P2440, DOI 10.2106/Jl3JS.F01476
   Singh PM, 2017, VET ANAESTH ANALG, V44, P1149, DOI 10.1016/j.vaa.2017.01.002
   Strahm C, 2003, SPINAL CORD, V41, P483, DOI 10.1038/sj.sc.3101493
   Teng WN, 2017, J FORMOS MED ASSOC, V116, P606, DOI 10.1016/j.jfma.2016.10.001
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E589
EP E595
DI 10.1016/j.wneu.2019.10.140
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200072
PM 31678449
DA 2020-05-12
ER

PT J
AU Yang, JS
   Liu, JJ
   Liu, P
   Zhang, ZX
   Liu, TJ
   Tuo, Y
   Yan, L
   Zhang, ZP
   Zhang, HP
   Chen, H
   Hao, DJ
AF Yang, Jun-Song
   Liu, Ji-Jun
   Liu, Peng
   Zhang, Zhen-Xing
   Liu, Tuan-Jiang
   Tuo, Yuan
   Yan, Liang
   Zhang, Zheng-Ping
   Zhang, Hai-Ping
   Chen, Hao
   Hao, Ding-Jun
TI Can Posterior Ligament Structure Be Functionally Healed After Anterior
   Reduction and Fusion Surgery in Patients with Traumatic Subaxial
   Cervical Fracture-Dislocations?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior reduction; Ligamentous injury; Subaxial cervical spine injury
ID SCREW FIXATION; SPINE; DECOMPRESSION; STABILIZATION; SUBLUXATION; DISC
AB BACKGROUND: Selection of approach for subaxial cervical fracture-dislocation (SCFD) is controversial. The questions of whether a posterior ligamentous structure (PLS) can be functionally healed in patients with SCFD and how long this healing process takes are critical in these patients.
   METHODS: This study retrospectively enrolled 394 patients with SCFD who underwent anterior decompression, reduction, and fusion between January 2002 and December 2017. The definition of functional healing of PLS was based on evaluations of clinical function and radiographic stability of PLS.
   RESULTS: Follow-up was available for 354 patients (89.8%). The PLS of 339 cases was functionally healed at the first follow-up interval without any posterior surgical intervention. No hardware failure or progressive cervical kyphosis was observed at further follow-up. At 12 months postoperatively, interbody fusion was satisfactory. However, the other 15 patients experienced nonhealing PLS at 8 weeks postoperatively and developed cervical deformity at further follow-up. Five patients refused revision surgery; the other 10 patients obtained solid fusion after revision surgeries.
   CONCLUSIONS: Among 354 patients with SCFD and treated by single anterior reduction and fixation, simple PLS injury without any bony instability at the posterior column of the cervical spine can be functionally healed in 95.8% of patients by external fixation for 8 weeks. Whether this finding is applicable to various types of SCFD should be verified in further prospective studies with larger samples.
C1 [Hao, Ding-Jun] Xi An Jiao Tong Univ, Honghui Hosp, Dept Spine Surg, Xian, Shaanxi, Peoples R China.
   Xi An Jiao Tong Univ, Hlth Sci Ctr, Xian, Shaanxi, Peoples R China.
RP Hao, DJ (reprint author), Xi An Jiao Tong Univ, Honghui Hosp, Dept Spine Surg, Xian, Shaanxi, Peoples R China.
EM dingjun.hao@qq.com
OI liu, peng/0000-0003-3453-2278; chen, hao/0000-0002-7122-9027
FU National Natural Science Foundation of China, ChinaNational Natural
   Science Foundation of China [81830077]
FX This work was supported by a grant from the National Natural Science
   Foundation of China, China (No. 81830077 to D.-J. Hao).
CR Abumi K, 2000, J NEUROSURG, V92, P30, DOI 10.3171/spi.2000.92.1.0030
   Abumi K, 2012, SPINE, V37, pE349, DOI 10.1097/BRS.0b013e318239cf1f
   de Oliveira J C, 1979, Spine (Phila Pa 1976), V4, P195
   EISMONT FJ, 1991, J BONE JOINT SURG AM, V73A, P1555, DOI 10.2106/00004623-199173100-00014
   Eubanks AC, 2010, SPINE J, V10, P230, DOI 10.1016/j.spinee.2009.12.025
   Feng GJ, 2012, SPINE, V37, P2082, DOI 10.1097/BRS.0b013e31825ee846
   Gelb DE, 2013, NEUROSURGERY, V72, P187, DOI 10.1227/NEU.0b013e318276f637
   GOFFIN J, 1989, NEUROSURGERY, V25, P865, DOI 10.1227/00006123-198912000-00003
   Goradia D, 2007, AM J NEURORADIOL, V28, P209
   KOTANI Y, 1994, SPINE, V19, P2529, DOI 10.1097/00007632-199411001-00007
   Lawrence JE, 2017, BONE JOINT J, V99B, P87, DOI 10.1302/0301-620X.99B1.BJJ-2016-0452.R1
   Nakashima H, 2011, EUR SPINE J, V20, P387, DOI 10.1007/s00586-010-1589-1
   Park JH, 2015, J NEUROSURG-SPINE, V23, P35, DOI 10.3171/2014.11.SPINE14805
   Reindl R, 2006, SPINE, V31, P648, DOI 10.1097/01.brs.0000202811.03476.a0
   ROBERTSON PA, 1992, J BONE JOINT SURG BR, V74, P224
   Theodotou CB, 2019, NEUROSURGERY, V84, P388, DOI 10.1093/neuros/nyy032
   Vaccaro AR, 2007, SPINE, V32, P2365, DOI 10.1097/BRS.0b013e3181557b92
   Vaccaro AR, 2016, EUR SPINE J, V25, P2173, DOI 10.1007/s00586-015-3831-3
   Wang M, 2016, EUR SPINE J, V25, P2302, DOI 10.1007/s00586-016-4524-2
   Westin O, 2016, ORTHOP J SPORTS MED, V4, DOI 10.1177/2325967116667920
   Zhang ZF, 2016, SPINE, V41, pE403, DOI 10.1097/BRS.0000000000001260
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E243
EP E248
DI 10.1016/j.wneu.2019.10.045
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200030
PM 31629147
DA 2020-05-12
ER

PT J
AU Yang, XS
   Liu, X
   Liang, C
   Yu, M
   Liu, XG
   Liu, ZJ
AF Yang, Xiaosong
   Liu, Xiao
   Liang, Chen
   Yu, Miao
   Liu, Xiaoguang
   Liu, Zhongjun
TI Three-Dimensional Analysis of the Radiological Risk Factors for
   Progression of the Thoracic Ossification of the Posterior Longitudinal
   Ligament After Posterior Decompression and Stabilization
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ossification of the posterior longitudinal ligament; Progression; Risk
   factors; Thoracic spine; Three-dimensional analysis
ID CERVICAL-SPINE; LAMINOPLASTY; MULTICENTER; SURGERY; GROWTH; FUSION;
   VOLUME
AB BACKGROUND: Although research shows that the ossified masses of ossification of the posterior longitudinal ligament (OPLL) continue to grow postoperatively, information regarding thoracic OPLL (T-OPLL) is lacking. To date, no study has investigated the progression of T-OPLL within each motion segment. The purpose of this study was to analyze the progression of T-OPLL in each motion segment using a 3-dimensional measurement and evaluate whether the type of T-OPLL and surgical methods affect its progression postoperatively.
   METHODS: Clinical data from 20 patients (101 segments) with thoracic myelopathy secondary to OPLL were evaluated retrospectively. All patients underwent posterior decompression (laminectomy and stabilization or circumferential decompression [CD] and stabilization) at a single center. The 3-dimensional measurement of OPLL volume was performed using computed tomography scans. The ossified masses were classified into 2 types based on the fusion of each segment at the intervertebral space: type 1 = complete bridging (fused); type 2 = not fused. Statistical analyses were performed to determine the degree of T-OPLL progression according to the types and surgical methods.
   RESULTS: Mean OPLL progression was significantly higher in type 2. The mean annual growth rates of OPLL (AGRO) for groups 1 and 2 were 6.21% +/- 6.11% per year and 23.50% +/- 11.34% per year, respectively (P < 0.01). Further, no statistically significant differences were seen between the fixed and non-fixed groups (P = 0.23), and CD and non-CD segments (P = 0.56).
   CONCLUSIONS: The mean AGRO does not decrease even after stabilization and CD. Type 2 intervertebral space was a risk factor for T-OPLL progression. Cases of type 2 without CD need close follow-up.
C1 [Yang, Xiaosong; Liu, Xiao; Yu, Miao; Liu, Xiaoguang; Liu, Zhongjun] Peking Univ, Orthopaed Dept, Hosp 3, Beijing, Peoples R China.
   [Liang, Chen] Peking Univ, Ctr Pain Med, Hosp 3, Beijing, Peoples R China.
RP Liu, XG (reprint author), Peking Univ, Orthopaed Dept, Hosp 3, Beijing, Peoples R China.
EM drlxgpku@163.com
CR Boody BS, 2019, INT ORTHOP, V43, P797, DOI 10.1007/s00264-018-4106-5
   Chiba K, 2005, J NEUROSURG-SPINE, V3, P17, DOI 10.3171/spi.2005.3.1.0017
   Fargen KM, 2012, J NEUROSURG-SPINE, V17, P512, DOI 10.3171/2012.9.SPINE12548
   Fujimori T, 2014, SPINE J, V14, P1991, DOI 10.1016/j.spinee.2013.11.054
   Fujimori T, 2012, J NEUROSURG-SPINE, V16, P289, DOI 10.3171/2011.11.SPINE11502
   Hori T, 2007, SPINE, V32, pE551, DOI 10.1097/BRS.0b013e31814614f3
   Iwasaki M, 2002, J NEUROSURG, V96, P180, DOI 10.3171/spi.2002.96.2.0180
   Izumi T, 2013, EUR SPINE J, V22, P2569, DOI 10.1007/s00586-013-2989-9
   Katsumi K, 2016, EUR SPINE J, V25, P1634, DOI 10.1007/s00586-015-4328-9
   Lee DH, 2018, SPINE J, V18, P1116, DOI 10.1016/j.spinee.2017.10.069
   Lee JJ, 2018, SPINE J, V18, P1779, DOI 10.1016/j.spinee.2018.03.002
   Liu X, 2014, CHINESE MED J-PEKING, V127, P3371, DOI 10.3760/cma.j.issn.0366-6999.20140557
   Matsumoto M, 2011, J NEUROSURG-SPINE, V15, P380, DOI 10.3171/2011.6.SPINE10816
   Matsuyama Y, 2009, EUR SPINE J, V18, P943, DOI 10.1007/s00586-009-0956-2
   McClendon J, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2010.12.FOCUS10282
   Seichi A, 2010, J NEUROSURG-SPINE, V13, P47, DOI 10.3171/2010.3.SPINE09680
   Shin DA, 2017, J KOREAN NEUROSURG S, V60, P441, DOI 10.3340/jkns.2015.0708.014
   Shingyouchi Y, 1996, SPINE, V21, P2474, DOI 10.1097/00007632-199611010-00013
   Song J, 2006, SPINAL CORD, V44, P576, DOI 10.1038/sj.sc.3101881
   Sugita S, 2014, J NEUROSURG-SPINE, V21, P773, DOI 10.3171/2014.7.SPINE131191
   Takahata M, 2008, SPINE, V33, P1199, DOI 10.1097/BRS.0b013e3181714515
   TSUYAMA N, 1984, CLIN ORTHOP RELAT R, P71
   Wang L, 2019, WORLD NEUROSURG, V126, P593, DOI 10.1016/j.wneu.2019.03.229
   Yamazaki M, 2006, SPINAL CORD, V44, P130, DOI 10.1038/sj.sc.3101807
   Yamazaki M, 2006, SPINE, V31, P1452, DOI 10.1097/01.brs.0000220834.22131.fb
   Yamazaki M, 2010, EUR SPINE J, V19, P691, DOI 10.1007/s00586-009-1266-4
NR 26
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E739
EP E746
DI 10.1016/j.wneu.2019.10.189
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200086
PM 31706973
DA 2020-05-12
ER

PT J
AU Yang, XL
   Wang, YM
   Sun, XF
   Bai, XY
   Cui, Q
   Zhu, H
   Qian, J
   Chen, YD
   Sun, SJ
   Ji, N
   Liu, YB
AF Yang, Xueliang
   Wang, Yaming
   Sun, Xuefei
   Bai, Xueyan
   Cui, Qu
   Zhu, Hong
   Qian, Jun
   Chen, Yuedan
   Sun, Shengjun
   Ji, Nan
   Liu, Yuanbo
TI STAT3 Activation Is Associated with Interleukin-10 Expression and
   Survival in Primary Central Nervous System Lymphoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE IL-10; Phosphorylation; Primary central nervous system lymphoma;
   Prognosis; STAT3
ID B-CELL LYMPHOMA; CEREBROSPINAL-FLUID INTERLEUKIN-10; PRIMARY CNS
   LYMPHOMA; POOR-PROGNOSIS; IL-10; CHEMOTHERAPY; INHIBITOR; BIOMARKER; ABC
AB BACKGROUND: The findings from several studies have confirmed that signal transducer and activator of transcription 3 (STAT3) is constitutively phosphorylated in primary central nervous system lymphoma (PCNSL). However, the underlying mechanism and prognostic significance of STAT3 activation have not yet been clarified.
   METHODS: The expression of STAT3, phosphorylated STAT3 (p-STAT3), and interleukin (IL)-10 was examined in 32 PCNSL samples using immunohistochemistry. The relationship between IL-10 expression and STAT3 phosphorylation was determined. In addition, the associations of the expression of these proteins with the clinical factors and survival were analyzed.
   RESULTS: Expression of STAT3, p-STAT3, and IL-10 was detected in 28 (87.5%), 17 (53.1%), and 25 (78.1%) samples, respectively. IL-10 expression was significantly associated with STAT3 phosphorylation in PCNSL (P = 0.033). STAT3 phosphorylation and IL-10 expression were associated with the presence of multiple brain lesions (P = 0.004 and P = 0.027, respectively), suggesting that STAT3 activation might enhance the intracranial spread of tumors in PCNSL. The 2-year overall survival and progression-free survival (PFS) rates were 67.8% and 35.5%, respectively. Kaplan-Meier survival analysis demonstrated that STAT3 phosphorylation, IL-10 expression, and multiple brain lesions were significantly associated with PFS in those with PCNSL (P = 0.009, P = 0.030, and P = 0.040, respectively). However, Cox regression analysis indicated that only STAT3 phosphorylation was significantly associated with shorter PFS (hazard ratio, 3.22; 95% confidence interval, 1.24-8.37; P = 0.016).
   CONCLUSION: Our results have indicated that STAT3 activation is closely related to IL-10 expression and that p-STAT3 might be a novel biomarker predictive of poor survival in those with PCNSL.
C1 [Yang, Xueliang; Sun, Xuefei; Bai, Xueyan; Cui, Qu; Zhu, Hong; Qian, Jun; Chen, Yuedan; Liu, Yuanbo] Capital Med Univ, Beijing Tiantan Hosp, Dept Hematol, Beijing, Peoples R China.
   [Wang, Yaming] Capital Med Univ, Xuanwu Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Sun, Shengjun] Capital Med Univ, Beijing Tiantan Hosp, Neuroimaging Ctr, Beijing, Peoples R China.
   [Ji, Nan] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Liu, YB (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Hematol, Beijing, Peoples R China.
EM yuanbol@ccmu.edu.cn
CR Aigner P, 2019, CYTOKINE, V118, P27, DOI 10.1016/j.cyto.2018.07.014
   Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501
   Batchelor T, 2006, J CLIN ONCOL, V24, P1281, DOI 10.1200/JCO.2005.04.8819
   Beguelin W, 2015, LEUKEMIA, V29, P1684, DOI 10.1038/leu.2015.57
   Camilleri-Broet S, 2006, BLOOD, V107, P190, DOI 10.1182/blood-2005-03-1024
   Campo E, 2011, BLOOD, V117, P5019, DOI 10.1182/blood-2011-01-293050
   Devarajan E, 2009, CURR MOL MED, V9, P626, DOI 10.2174/156652409788488720
   Ding BB, 2008, BLOOD, V111, P1515, DOI 10.1182/blood-2007-04-087734
   Geng LY, 2017, ONCOTARGET, V8, P48701, DOI 10.18632/oncotarget.9792
   Gupta M, 2012, BLOOD, V120, P4400, DOI 10.1182/blood-2012-05-428466
   Gupta M, 2012, BLOOD, V119, P2844, DOI 10.1182/blood-2011-10-388538
   Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545
   Huang X, 2013, J CLIN ONCOL, V31, P4520, DOI 10.1200/JCO.2012.45.6004
   Jahnke K, 2006, J NEURO-ONCOL, V80, P159, DOI 10.1007/s11060-006-9165-6
   Kamran MZ, 2013, BIOMED RES INT, DOI 10.1155/2013/421821
   Kishimoto W, 2016, CANCER MED-US, V5, P3235, DOI 10.1002/cam4.930
   Komohara Y, 2011, J CLIN EXP HEMATOP, V51, P93, DOI 10.3960/jslrt.51.93
   Langner-Lemercier S, 2016, NEURO-ONCOLOGY, V18, P1297, DOI 10.1093/neuonc/now033
   Lech-Maranda E, 2006, EUR CYTOKINE NETW, V17, P60
   Lech-Maranda E, 2004, BLOOD, V103, P3529, DOI 10.1182/blood-2003-06-1850
   Ma J, 2015, ONCOTARGET, V6, P43881, DOI 10.18632/oncotarget.6316
   Mendez JS, 2018, NEURO-ONCOLOGY, V20, P687, DOI 10.1093/neuonc/nox187
   Mizowaki T, 2015, J NEURO-ONCOL, V124, P165, DOI 10.1007/s11060-015-1843-9
   Morichika K, 2019, CANCER SCI, V110, P2982, DOI 10.1111/cas.14114
   Munoz J, 2014, ONCOLOGIST, V19, P536, DOI 10.1634/theoncologist.2013-0407
   Nguyen-Them L, 2016, EUR J CANCER, V61, P69, DOI 10.1016/j.ejca.2016.03.080
   Ok CY, 2014, CLIN CANCER RES, V20, P5113, DOI 10.1158/1078-0432.CCR-14-0683
   Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914
   Rubenstein JL, 2013, BLOOD, V121, P4740, DOI 10.1182/blood-2013-01-476333
   Ruggieri S, 2017, ONCOTARGET, V8, P31254, DOI 10.18632/oncotarget.16115
   Saini U, 2017, ONCOGENE, V36, P168, DOI 10.1038/onc.2016.197
   Sasagawa Y, 2015, J NEURO-ONCOL, V121, P177, DOI 10.1007/s11060-014-1622-z
   Sasayama T, 2012, NEURO-ONCOLOGY, V14, P368, DOI 10.1093/neuonc/nor203
   Scuto A, 2011, CANCER RES, V71, P3182, DOI 10.1158/0008-5472.CAN-10-2380
   Song Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep38671
   Sun XF, 2017, ONCOTARGET, V8, P49156, DOI 10.18632/oncotarget.17101
   Tong MT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182282
   Vajpayee N, 2010, J NEURO-ONCOL, V100, P249, DOI 10.1007/s11060-010-0188-7
   Wu ZL, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-31
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E1077
EP E1084
DI 10.1016/j.wneu.2019.11.100
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200125
PM 31778838
DA 2020-05-12
ER

PT J
AU Ying, JY
   Yuan, TY
   Jin, L
   Li, CZ
   Gui, SB
   Wang, R
   Zuo, ZT
   Zhang, YZ
AF Ying, Jianyou
   Yuan, Taoyang
   Jin, Lu
   Li, Chuzhong
   Gui, Songbai
   Wang, Rui
   Zuo, Zhentao
   Zhang, Yazhuo
TI Brain Morphometric and Functional Magnetic Resonance Imaging Study on
   Patients with Visual Field Defects Resulting from Suprasellar Tumors:
   Preoperative and Postoperative Assessment
SO WORLD NEUROSURGERY
LA English
DT Article
DE Amplitude of low frequency fluctuation (ALFF); Suprasellar tumors;
   Visual field defects (VFD); Voxel-based morphometry (VBM)
ID GRAY-MATTER; ORGANIZATION; ACTIVATION; SURGERY; CORTEX
AB OBJECTIVE: The aim of this study was to investigate the structural and functional changes in the visual cortex in patients with suprasellar tumor with recovery of visual field defects at different times before and after surgical decompression of the optic nerves.
   METHODS: Twenty-one patients with suprasellar tumor with visual field defects were scanned with structural images and resting-state functional magnetic resonance imaging at 1 week preoperation, 1 week postoperation, and 1 month postoperation. Paired-sample t test was performed on the gray matter volume (GMV) within the occipital cortex, and the significance level was set at false discovery rate (FDR)-adjusted P < 0.05 voxel level to define the region of interest (ROI). One-way analysis of variance was performed on GMV and amplitude of low frequency fluctuation (ALFF) within the ROI. Pearson coefficients were calculated between changes of GMV and ALFF within the ROI and clinical factors.
   RESULTS: The GMV in the bilateral pericalcarine cortex increased significantly at 1 month postoperation compared with the preoperative period (FDR-adjusted P < 0.05), with correlation to visual field defects. ALFF values in the bilateral pericalcarine cortex at 1 month postoperation were significantly higher than preoperative values.
   CONCLUSIONS: The postoperative visual improvement can be reflected in the increased GMV and ALFF of the bilateral pericalcarine cortex at 1 month postoperation, which suggests that an experience-dependent plasticity of the visual cortex was induced by an increase in sensory input.
C1 [Ying, Jianyou; Yuan, Taoyang; Li, Chuzhong; Wang, Rui; Zhang, Yazhuo] Capital Med Univ, Beijing Neurosurg Inst, Beijing Tiantan Hosp, Beijing, Peoples R China.
   [Jin, Lu; Gui, Songbai; Zhang, Yazhuo] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Zuo, Zhentao] Chinese Acad Sci, Inst Biophys, State Key Lab Brain & Cognit Sci, Beijing, Peoples R China.
   [Zuo, Zhentao] Chinese Acad Sci, CAS Ctr Excellence Brain Sci & Intelligence Techn, Beijing, Peoples R China.
   [Zuo, Zhentao] Univ Chinese Acad Sci, Sino Danish Coll, Beijing, Peoples R China.
   [Zhang, Yazhuo] Beijing Inst Brain Disorders Brain Tumor Ctr, Beijing, Peoples R China.
   [Zhang, Yazhuo] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
RP Zhang, YZ (reprint author), Capital Med Univ, Beijing Neurosurg Inst, Beijing Tiantan Hosp, Beijing, Peoples R China.; Zhang, YZ (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.; Zhang, YZ (reprint author), Beijing Inst Brain Disorders Brain Tumor Ctr, Beijing, Peoples R China.; Zhang, YZ (reprint author), China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
EM zyz2004520@yeah.net
OI KANG, JIE/0000-0002-2079-6742
FU Ministry of Science and Technology of ChinaMinistry of Science and
   Technology, China [2015CB351701]; National Natural Science Foundation of
   China of ChinaNational Natural Science Foundation of China [91132302];
   Beijing Municipal Science and Technology CommissionBeijing Municipal
   Science & Technology Commission [Z171100000117002]
FX This work was supported in part by the Ministry of Science and
   Technology of China (2015CB351701), the National Natural Science
   Foundation of China of China (91132302), & the Beijing Municipal Science
   and Technology Commission (Z171100000117002).
CR Anurova I, 2015, CEREB CORTEX, V25, P2035, DOI 10.1093/cercor/bhu009
   Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582
   Bitter T, 2010, BRAIN RES, V1347, P42, DOI 10.1016/j.brainres.2010.06.003
   Bitter T, 2010, CHEM SENSES, V35, P407, DOI 10.1093/chemse/bjq028
   Boucard CC, 2009, BRAIN, V132, P1898, DOI 10.1093/brain/awp119
   Chouinard PA, 2012, J NEUROSURG, V117, P218, DOI 10.3171/2012.4.JNS112158
   DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0
   Dayan E, 2011, NEURON, V72, P443, DOI 10.1016/j.neuron.2011.10.008
   Draganski B, 2008, BEHAV BRAIN RES, V192, P137, DOI 10.1016/j.bbr.2008.02.015
   Driemeyer J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002669
   Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201
   Gaser C, 2003, ANN NY ACAD SCI, V999, P514, DOI 10.1196/annals.1284.062
   Gilbert CD, 2012, NEURON, V75, P250, DOI 10.1016/j.neuron.2012.06.030
   Glasser MF, 2013, NEUROIMAGE, V80, P105, DOI 10.1016/j.neuroimage.2013.04.127
   Hajiabadi M, 2016, J NEUROSURG, V125, P759, DOI 10.3171/2015.6.JNS1546
   Ilg R, 2008, J NEUROSCI, V28, P4210, DOI 10.1523/JNEUROSCI.5722-07.2008
   Karstensen HG, 2018, BRAIN IMAGING BEHAV, V12, P1569, DOI 10.1007/s11682-017-9817-5
   Kerrison JB, 2000, AM J OPHTHALMOL, V130, P813, DOI 10.1016/S0002-9394(00)00539-0
   Lovden M, 2010, PSYCHOL BULL, V136, P659, DOI 10.1037/a0020080
   Okamoto Y, 2010, INVEST OPHTH VIS SCI, V51, P3405, DOI 10.1167/iovs.09-3763
   Pascual-Leone A, 2005, ANNU REV NEUROSCI, V28, P377, DOI 10.1146/annurev.neuro.27.070203.144216
   Paul DA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010798
   Plank T, 2011, NEUROIMAGE, V56, P1556, DOI 10.1016/j.neuroimage.2011.02.055
   Qian HY, 2015, CHINESE MED J-PEKING, V128, P1171, DOI 10.4103/0366-6999.156106
   Qian HY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160119
   Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041
   Shao YB, 2013, EUR J NEUROSCI, V38, P3456, DOI 10.1111/ejn.12349
   Siuda-Krzywicka K, 2016, ELIFE, V5, DOI 10.7554/eLife.10762
   Song GD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13214-5
   Speckter H, 2019, J NEURO-ONCOL, V142, P275, DOI 10.1007/s11060-019-03092-4
   Thomas C, 2013, NEUROIMAGE, V73, P225, DOI 10.1016/j.neuroimage.2012.03.069
   Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073
   Yang M, 2014, HEARING RES, V316, P37, DOI 10.1016/j.heares.2014.07.006
   Zatorre RJ, 2012, NAT NEUROSCI, V15, P528, DOI 10.1038/nn.3045
   Zhao C, 2018, PROG NEURO-PSYCHOPH, V83, P27, DOI 10.1016/j.pnpbp.2017.12.017
NR 35
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E353
EP E359
DI 10.1016/j.wneu.2019.10.060
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200043
PM 31634624
DA 2020-05-12
ER

PT J
AU Yoon, HK
   Oh, H
   Lee, HC
   Cho, WS
   Kim, JE
   Park, JW
   Choi, H
   Park, HP
AF Yoon, Hyun-Kyu
   Oh, Hyongmin
   Lee, Hyung-Chul
   Cho, Won-Sang
   Kim, Jeong Eun
   Park, Jae Won
   Choi, Hongyoon
   Park, Hee-Pyoung
TI Effect of Sevoflurane Postconditioning on the Incidence of Symptomatic
   Cerebral Hyperperfusion After Revascularization Surgery in Adult
   Patients with Moyamoya Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Moyamoya disease; Revascularization; Risk factor; Sevoflurane
   postconditioning; Symptomatic cerebral hyperperfusion
ID EXTRACRANIAL-INTRACRANIAL BYPASS; BRAIN-BARRIER DISRUPTION; ARTERY
   ANASTOMOSIS; NITRIC-OXIDE; SURGICAL REVASCULARIZATION; NEUROLOGIC
   DETERIORATION; OXIDATIVE STRESS; ISCHEMIA; PROPOFOL; INHIBITION
AB OBJECTIVE: Various experimental studies have reported neuroprotective effects of sevoflurane postconditioning against cerebral ischemia-reperfusion injury. We therefore investigated its neuroprotective effects on hyperperfusion-related transient neurologic deterioration, called symptomatic cerebral hyperperfusion (SCH), and also identified predictive factors for SCH in patients with moyamoya disease after revascularization surgery.
   METHODS: A total of 152 adult patients with moyamoya disease undergoing anastomosis of the superficial temporal artery to middle cerebral artery were randomly allocated into 2 groups. The postconditioning group (group S, n = 76) inhaled sevoflurane of 1 minimum alveolar concentration for 15 minutes immediately after reperfusion and then washed it out slowly for 15 minutes. The control group (group C, n = 76) received no intervention. The incidence of SCH was compared between the 2 groups.
   RESULTS: The incidence of SCH was not significantly different between groups S and C (53.3% vs. 43.4%, respectively; P = 0.291). The incidence of postoperative complications and the Glasgow Outcome Scale score at hospital discharge also did not differ significantly. Predictive factors for SCH included a decreased vascular reserve in preoperative single-photon emission computed tomography scan (odds ratio [OR], 7.18; 95% confidence interval [CI],1.78-29.02; P = 0.006), an operation performed on the dominant hemisphere (OR, 3.32; 95% CI, 1.57-6.98; P = 0.002), temporal occlusion time (OR, 1.06; 95% CI, 1.01-1.11; P = 0.017), and intraoperative minimum partial pressure of carbon dioxide (PaCO2) (OR, 0.86; 95% CI, 0.78-0.94; P = 0.001).
   CONCLUSIONS: Sevoflurane postconditioning did not reduce the incidence of SCH after revascularization surgery in patients with moyamoya disease. Rather, a decreased vascular reserve, operation on the dominant hemisphere, increased temporal occlusion time, and decreased intraoperative minimum PaCO2 were associated with SCH in these patients.
C1 [Yoon, Hyun-Kyu; Oh, Hyongmin; Lee, Hyung-Chul; Park, Hee-Pyoung] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Anesthesiol & Pain Med, Seoul, South Korea.
   [Cho, Won-Sang; Kim, Jeong Eun] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Neurosurg, Seoul, South Korea.
   [Choi, Hongyoon] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Nucl Med, Seoul, South Korea.
   [Park, Jae Won] Catholic Univ Korea, Bucheon St Marys Hosp, Dept Neurosurg, Bucheon, South Korea.
RP Park, HP (reprint author), Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Anesthesiol & Pain Med, Seoul, South Korea.
EM hppark@snu.ac.kr
OI Choi, Hongyoon/0000-0002-8895-2449; Yoon, hyun-kyu/0000-0001-5424-3559;
   Park, Hee-Pyoung/0000-0002-4772-0780
CR AGARDH CD, 1991, INT J DEV NEUROSCI, V9, P127, DOI 10.1016/0736-5748(91)90003-5
   Bastola P, 2015, INDIAN J ANAESTH, V59, P287, DOI 10.4103/0019-5049.156868
   Battisti-Charbonney A, 2011, J PHYSIOL-LONDON, V589, P3039, DOI 10.1113/jphysiol.2011.206052
   Beck-Schimmer B, 2012, ANN SURG, V256, P837, DOI 10.1097/SLA.0b013e318272df7c
   Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124
   Conti A, 2006, BRIT J ANAESTH, V97, P333, DOI 10.1093/bja/ael169
   Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127
   del Zoppo GJ, 2003, J CEREBR BLOOD F MET, V23, P879, DOI 10.1097/01.WCB.0000078322.96027.78
   Fan YY, 2017, NEUROCHEM INT, V107, P43, DOI 10.1016/j.neuint.2017.01.006
   Fearon WF, 2008, CIRCULATION, V117, P2577, DOI 10.1161/CIRCULATIONAHA.108.772491
   Forstermann U, 2010, PFLUG ARCH EUR J PHY, V459, P923, DOI 10.1007/s00424-010-0808-2
   Fujimura M, 2007, SURG NEUROL, V67, P273, DOI 10.1016/j.surneu.2006.07.017
   Fujimura M, 2014, NEUROSURGERY, V74, P163, DOI 10.1227/NEU.0000000000000238
   Fujimura M, 2011, NEUROSURGERY, V68, P957, DOI 10.1227/NEU.0b013e318208f1da
   Fujimura M, 2009, SURG NEUROL, V71, P442, DOI 10.1016/j.surneu.2008.02.031
   Gasche Y, 2001, J CEREBR BLOOD F MET, V21, P1393, DOI 10.1097/00004647-200112000-00003
   Hellstrom J, 2011, ACTA ANAESTH SCAND, V55, P460, DOI 10.1111/j.1399-6576.2011.02405.x
   Hwang JW, 2013, BRIT J ANAESTH, V110, P773, DOI 10.1093/bja/aes470
   Hwang JW, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112347
   Kang HS, 2010, J NEUROL NEUROSUR PS, V81, P673, DOI 10.1136/jnnp.2009.191817
   Kim JE, 2008, CEREBROVASC DIS, V25, P580, DOI 10.1159/000132205
   Kim JE, 2014, NEUROL RES, V36, P407, DOI 10.1179/1743132814Y.0000000351
   Kim JS, 2016, J STROKE, V18, P2, DOI 10.5853/jos.2015.01627
   Kim T, 2016, J NEUROSURG, V124, P1788, DOI 10.3171/2015.6.JNS151105
   Kottenberg E, 2014, J THORAC CARDIOV SUR, V147, P376, DOI 10.1016/j.jtcvs.2013.01.005
   Kuroda S, 1997, CLIN NEUROSCI, V4, P199
   Kuwabara Y, 1997, STROKE, V28, P701, DOI 10.1161/01.STR.28.4.701
   Latour LL, 2004, ANN NEUROL, V56, P468, DOI 10.1002/ana.20199
   Lee H, 2015, BRIT J ANAESTH, V114, P307, DOI 10.1093/bja/aeu268
   Matta BF, 1999, ANESTHESIOLOGY, V91, P677, DOI 10.1097/00000542-199909000-00019
   Miyamoto S, 2014, STROKE, V45, P1415, DOI 10.1161/STROKEAHA.113.004386
   Ohue S, 2008, SURG NEUROL, V69, P281, DOI 10.1016/j.surneu.2007.01.047
   Rodriguez-Gonzalez R, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-87
   Seo JH, 2013, BRIT J ANAESTH, V110, P988, DOI 10.1093/bja/aet009
   SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165
   Steurer MP, 2012, CRIT CARE, V16, DOI 10.1186/cc11676
   Toda N, 2009, PHARMACOL REV, V61, P62, DOI 10.1124/pr.108.000547
   Uchino H, 2016, STROKE, V47, P1930, DOI 10.1161/STROKEAHA.116.013304
   Uchino H, 2014, ACTA NEUROCHIR, V156, P1753, DOI 10.1007/s00701-014-2161-2
   Uchino H, 2012, STROKE, V43, P2610, DOI 10.1161/STROKEAHA.112.654723
   Wang JK, 2010, BRAIN RES, V1357, P142, DOI 10.1016/j.brainres.2010.08.009
   White RP, 2000, CLIN SCI, V99, P555, DOI 10.1042/CS20000064
   Yamato M, 2003, FREE RADICAL BIO MED, V35, P1619, DOI 10.1016/j.freeradbiomed.2003.09.013
   Zhang Y, 2011, NAT MED, V17, P341, DOI 10.1038/nm.2296
   Zhao M, 2019, J NEUROSURG, V130, P531, DOI 10.3171/2017.10.JNS171749
   Zhao WG, 2013, BRIT J NEUROSURG, V27, P321, DOI 10.3109/02688697.2012.757294
NR 46
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E991
EP E1000
DI 10.1016/j.wneu.2019.11.055
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200116
PM 31734419
DA 2020-05-12
ER

PT J
AU Yun, R
   Sciubba, DM
   Lewin, JJ
   Streiff, MB
   Haut, ER
   Lau, BD
   Shermock, KM
   Kraus, PS
   Popoola, VO
   Dalpoas, SE
AF Yun, Regina
   Sciubba, Daniel M.
   Lewin, John J.
   Streiff, Michael B.
   Haut, Elliott R.
   Lau, Brandyn D.
   Shermock, Kenneth M.
   Kraus, Peggy S.
   Popoola, Victor O.
   Dalpoas, Stacy Elder
TI Defects in Processes of Care for Pharmacologic Prophylaxis Are Common
   Among Neurosurgery Patients Who Develop In-Hospital Postoperative Venous
   Thromboembolism
SO WORLD NEUROSURGERY
LA English
DT Article
DE Heparin; Neurosurgery; Perioperative; Venous thromboembolism; VTE
   algorithm; VTE prophylaxis
ID TRAUMATIC BRAIN-INJURY; INTRACRANIAL HEMORRHAGE; MOLECULAR-WEIGHT;
   PREVENTION; RISK; HEPARIN; COMPLICATIONS; POPULATION; SURGERY
AB BACKGROUND: Venous thromboembolism (VTE) is a cause of considerable morbidity and mortality in hospitalized patients. An evidence-based algorithm was developed and implemented at our institution to guide perioperative VTE prophylaxis management.
   OBJECTIVE: We evaluated compliance with prescription of risk-appropriate VTE prophylaxis and administration of prescribed VTE prophylaxis in neurosurgery patients.
   METHODS: This was a retrospective analysis of postoperative neurosurgery patients at a single institution with subsequent diagnosis of acute VTE during their inpatient stay. Descriptive statistics were used to characterize pharmacologic VTE prophylaxis and prescribing patterns.
   RESULTS: The incidence of VTE in our neurosurgery population was 248/13,913 (1.8%). Of the 123 patients, the median time to VTE diagnosis was 96 hours after surgery (interquartile range [IQR], 58-188 hours). A total of 108 patients (87.8%) were prescribed risk-appropriate VTE prophylaxis, among whom 61 (56.5%) received all doses as prescribed. Fifty-three patients (43.1%) missed >= 1 dose of prescribed prophylaxis and the median missed doses was 3 (IQR, 0-3). The median time to first dose of pharmacologic VTE prophylaxis was 42 hours (IQR, 28-51). More than half (n = 63, 51.2%) of the VTE risk assessments contained >= 1 error, of which 15 (23.8%) would have resulted in a change in recommendation.
   CONCLUSIONS: Our evidence-based VTE prophylaxis algorithm was not accurately completed in more than half of patients. Many patients who developed VTE had a defect in their VTE prophylaxis management during their inpatient stay. Research to improve optimal VTE prevention practice in neurosurgery patients is needed.
C1 [Yun, Regina; Lewin, John J.; Shermock, Kenneth M.; Kraus, Peggy S.; Dalpoas, Stacy Elder] Johns Hopkins Univ Hosp, Dept Pharm, Baltimore, MD 21287 USA.
   [Sciubba, Daniel M.] Johns Hopkins Univ Hosp, Dept Neurosurg, Baltimore, MD 21287 USA.
   [Streiff, Michael B.] Johns Hopkins Univ, Sch Med, Div Hematol, Dept Med, Baltimore, MD USA.
   [Streiff, Michael B.; Haut, Elliott R.; Lau, Brandyn D.; Shermock, Kenneth M.; Kraus, Peggy S.; Popoola, Victor O.] Johns Hopkins Univ, Sch Med, Armstrong Inst Patient Safety & Qual, Baltimore, MD USA.
   [Haut, Elliott R.] Johns Hopkins Univ, Sch Med, Dept Surg, Div Acute Care Surg, Baltimore, MD 21205 USA.
   [Lewin, John J.; Haut, Elliott R.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA.
   [Lau, Brandyn D.] Johns Hopkins Univ, Sch Med, Russell H Morgan Dept Radiol & Radiol Sci, Baltimore, MD USA.
   [Lau, Brandyn D.] Johns Hopkins Univ, Sch Med, Div Hlth Sci Informat, Baltimore, MD USA.
   [Haut, Elliott R.; Lau, Brandyn D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA.
RP Dalpoas, SE (reprint author), Johns Hopkins Univ Hosp, Dept Pharm, Baltimore, MD 21287 USA.
EM selder5@jhmi.edu
FU Patient-Centered Outcomes Research Institute entitled "Preventing Venous
   Thromboembolism: Empowering Patients and Enabling Patient-Centered Care
   via Health Information Technology [CE-12-11-4489]; "Preventing Venous
   Thromboembolism (VTE): Engaging Patients to Reduce Preventable Harm from
   Missed/Refused Doses of VTE Prophylaxis" [DI-1603-34596]; Agency for
   Healthcare Research and QualityUnited States Department of Health &
   Human ServicesAgency for Healthcare Research & Quality [1R01HS024547];
   National Institutes of Health National Heart, Lung, and Blood
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R21HL129028, PCS-1511-32745]
FX E.R.H is/was primary investigator of contracts from Patient-Centered
   Outcomes Research Institute entitled "Preventing Venous Thromboembolism:
   Empowering Patients and Enabling Patient-Centered Care via Health
   Information Technology" (CE-12-11-4489) and "Preventing Venous
   Thromboembolism (VTE): Engaging Patients to Reduce Preventable Harm from
   Missed/Refused Doses of VTE Prophylaxis" (DI-1603-34596); primary
   investigator of a grant from the Agency for Healthcare Research and
   Quality (1R01HS024547) entitled "Individualized Performance Feedback on
   Venous Thromboembolism Prevention Practice"; co-investigator on a grant
   from the National Institutes of Health National Heart, Lung, and Blood
   Institute (R21HL129028) entitled "Analysis of the Impact of Missed Doses
   of Venous Thromboembolism Prophylaxis"; he is supported by a contract
   from The PatientCentered Outcomes Research Institute "A Randomized
   Pragmatic Trial Comparing the Complications and Safety of Blood Clot
   Prevention Medicines Used in Orthopedic Trauma Patients"
   (PCS-1511-32745); he receives royalties from Lippincott Williams &
   Wilkins for the book Avoiding Common ICU Errors. He was the paid author
   of a paper commissioned by the National Academies of Medicine entitled
   "Military Trauma Care's Learning Health System: The Importance of Data
   Driven Decision Making," which was used to support the report titled "A
   National Trauma Care System: Integrating Military and Civilian Trauma
   Systems to Achieve Zero Preventable Deaths After Injury." Results
   presented in part at Society of Critical Care Medicine Annual Conference
   2017, Honolulu, Hawaii, January 24, 2017 (Snapshot Platform
   Presentation).
CR Angelli G, 1998, NEW ENGL J MED, V339, P80
   Brandes AA, 1997, EUR J CANCER, V33, P1592, DOI 10.1016/S0959-8049(97)00167-6
   Browd SR., 2004, NEUROSURG FOCUS, V17, pE1, DOI DOI 10.3171/F0C.2004.17.4.1
   Byrne JP, 2016, J AM COLL SURGEONS, V223, P621, DOI 10.1016/j.jamcollsurg.2016.06.382
   Cage TA, 2009, J NEURO-ONCOL, V93, P151, DOI 10.1007/s11060-009-9886-4
   Collen JF, 2008, CHEST, V134, P237, DOI 10.1378/chest.08-0023
   DePasse JM, 2015, WORLD J ORTHOP, V6, P351, DOI 10.5312/wjo.v6.i3.351
   Dickinson LD, 1998, NEUROSURGERY, V43, P1074, DOI 10.1097/00006123-199811000-00039
   Elder S, 2016, J PATIENT SAF, V12, P63, DOI 10.1097/PTS.0000000000000086
   Freeman AL, 2010, EXPERT REV CARDIOVAS, V8, P1711, DOI [10.1586/erc.10.160, 10.1586/ERC.10.160]
   Gould MK, 2012, CHEST, V141, pE227S, DOI 10.1378/chest.11-2297
   Haut ER, 2015, JAMA SURG, V150, P912, DOI 10.1001/jamasurg.2015.1340
   Haut ER, 2012, ARCH SURG-CHICAGO, V147, P901, DOI 10.1001/archsurg.2012.2024
   Imberti D, 2009, THROMB RES, V124, P667, DOI [10.1016/j.thromres.2009.04.021, 10.1016/j.thromres.2009.08.006]
   Iorio A, 2000, ARCH INTERN MED, V160, P2327, DOI 10.1001/archinte.160.15.2327
   Kim JYS, 2015, JAMA SURG, V150, P110, DOI 10.1001/jamasurg.2014.1841
   King CS, 2007, CHEST, V131, P507, DOI 10.1378/chest.06-1861
   Kwee MM, 2015, INT SURG, V100, P292, DOI 10.9738/INTSURG-D-13-00256.1
   Lau BD, 2018, CIRCULATION, V137, P1278, DOI 10.1161/CIRCULATIONAHA.116.026897
   Lau BD, 2016, J SURG RES, V205, P179, DOI 10.1016/j.jss.2016.06.024
   Lau BD, 2016, AM J MED QUAL, V31, P448, DOI 10.1177/1062860615583547
   Lau BD, 2015, JAMA SURG, V150, P813, DOI 10.1001/jamasurg.2015.0891
   Nurmohamed MT, 1996, THROMB HAEMOSTASIS, V75, P233
   Phelan HA, 2012, J TRAUMA ACUTE CARE, V73, P1434, DOI 10.1097/TA.0b013e31825ac49e
   Shermock KM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066311
   Smith TR, 2015, J CLIN NEUROSCI, V22, P519, DOI 10.1016/j.jocn.2014.10.003
   Sogaard KK, 2014, CIRCULATION, V130, P829, DOI 10.1161/CIRCULATIONAHA.114.009107
   Stein PD, 2006, AM J MED, V119, P60, DOI 10.1016/j.amjmed.2005.06.058
   STREIFF MB, 2012, BMJ-BRIT MED J, V344, DOI DOI 10.1136/BMJ.E3935
   Streiff MB, 2016, J HOSP MED, V11, pS8, DOI 10.1002/jhm.2657
   Sweetland S, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4583
   Tsuda Y, 2013, J ORTHOP SCI, V18, P613, DOI 10.1007/s00776-013-0401-6
   Walsh D C, 2001, Curr Opin Pulm Med, V7, P326, DOI 10.1097/00063198-200109000-00013
   Wang Chih-Ping, 2016, Taiwan J Ophthalmol, V6, P96, DOI 10.1016/j.tjo.2015.05.002
   Zeidan AM, 2013, AM J HEMATOL, V88, P545, DOI 10.1002/ajh.23450
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E664
EP E671
DI 10.1016/j.wneu.2019.10.163
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200082
PM 31698120
DA 2020-05-12
ER

PT J
AU Zanaty, M
   Roa, JA
   Tjoumakaris, SI
   Jabbour, P
   Mouchtouris, N
   Sweid, A
   Ortega-Gutierrez, S
   Ishii, D
   Limaye, K
   Asi, K
   Samaniego, EA
   Hasan, DM
AF Zanaty, Mario
   Roa, Jorge A.
   Tjoumakaris, Stavropoula, I
   Jabbour, Pascal
   Mouchtouris, Nikolaos
   Sweid, Ahmad
   Ortega-Gutierrez, Santiago
   Ishii, Daizo
   Limaye, Kaustubh
   Asi, Khaled
   Samaniego, Edgar A.
   Hasan, David M.
TI Off-Label Use of the WEB Device
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Embolization; Endovascular; Off-label; Subarachnoid
   hemorrhage; WEB
ID DUAL ANTIPLATELET THERAPY; FLOW-DISRUPTION; ANEURYSMS; TIROFIBAN; SAFETY
AB OBJECTIVE: We present our initial experience with the off-label use of the Woven EndoBridge (WEB) device.
   METHODS: We performed a retrospective study from 2 institutions of patients with intracranial aneurysms who underwent treatment with the WEB device alone or in conjunction with stenting and/or coiling in an off-labeled location.
   RESULTS: Eleven patients with 12 aneurysms were included. Four (30.8%) aneurysms presented ruptured. Off-labeled locations included 3 aneurysms in the posterior communicating artery, 3 in the supraclinoid ophthalmic artery, 2 in the pericallosal artery, 2 in the posterior inferior cerebellar artery, 1 at the verte-brobasilar junction, and 1 in the cavernous internal carotid artery. Mean dome-to-neck ratio was 1.91 +/- 0.9. Average duration of the procedure was 63.9 +/- 29.6 minutes. Femoral route was used in 61.5%, and radial access in 48.5% of cases. Five procedures (41.7%) were performed under monitored anesthesia care. We had 1.33 attempts per aneurysm. WEB embolization was supplemented with coiling in 2 cases (16.67%) and stenting in 1 case (8.3%). Based on the O'Kelly-Marotta ("OKM") grading scale, we report a rate of 0% for grade 1, 33.3% for grade 2, and 33.3% for grade 3. Postprocedural occlusion was complete in 4 (33.3%) and adequate in 8 (66.6%) patients. No procedure-related deaths or symptomatic complications were reported.
   CONCLUSIONS: The WEB device was successfully deployed in off-labeled locations, including posterior communicating artery, ophthalmic artery, and pericallosal aneurysms. The efficacy of this usage must be evaluated in multicenter prospective studies, but our preliminary results are promising. Correct characterization of the aneurysm size/morphology, as well as awareness of possible adjunct treatments, are crucial for successful intervention.
C1 [Zanaty, Mario; Ishii, Daizo; Hasan, David M.] Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
   [Roa, Jorge A.] Univ Iowa Hosp & Clin, Dept Neurol & Neurosurg, Iowa City, IA 52242 USA.
   [Ortega-Gutierrez, Santiago; Samaniego, Edgar A.] Univ Iowa Hosp & Clin, Dept Neurol Neurosurg & Radiol, Iowa City, IA 52242 USA.
   [Limaye, Kaustubh; Asi, Khaled] Univ Iowa Hosp & Clin, Dept Neurol, Iowa City, IA 52242 USA.
   [Tjoumakaris, Stavropoula, I; Jabbour, Pascal; Mouchtouris, Nikolaos; Sweid, Ahmad] Thomas Jefferson Univ Hosp, Dept Neurosurg, Philadelphia, PA 19107 USA.
RP Hasan, DM (reprint author), Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
EM david-hasan@uiowa.edu
OI Mouchtouris, Nikolaos/0000-0001-9495-9391; Limaye,
   Kaustubh/0000-0002-7280-7407; Roa, Jorge/0000-0003-4987-8853; Sweid,
   Ahmad/0000-0002-2652-2451
FU NINDS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS) [R01 NS107293]
CR AJNR News Digest, 2015, WEB FLOW DISR AN TRE
   Arthur AS, 2019, J NEUROINTERV SURG, V11, P924, DOI 10.1136/neurintsurg-2019-014815
   Caroff J, 2014, NEURORADIOLOGY, V56, P755, DOI 10.1007/s00234-014-1390-7
   Chalouhi N, 2016, NEUROSURGERY, V78, P670, DOI 10.1227/NEU.0000000000001071
   Hudson JS, 2019, NEUROSURGERY, V84, P479, DOI 10.1093/neuros/nyy127
   Hudson JS, 2018, J NEUROSURG, V129, P916, DOI 10.3171/2017.5.JNS17642
   Khanna O, 2019, STROKE, V50, P2587, DOI 10.1161/STROKEAHA.119.025811
   Lawson A, 2018, J NEUROSURG, V128, P144, DOI 10.3171/2016.9.JNS152849
   Nagahama Y, 2018, J NEUROSURG, V129, P702, DOI 10.3171/2017.5.JNS17831
   O'Kelly CJ, 2010, INTERV NEURORADIOL, V16, P133, DOI 10.1177/159101991001600204
   Papagiannaki C, 2014, AM J NEURORADIOL, V35, P2106, DOI 10.3174/ajnr.A4028
   Pierot L, 2012, AM J NEURORADIOL, V33, P1232, DOI 10.3174/ajnr.A3191
   Pierot L, 2012, AM J NEURORADIOL, V33, P469, DOI 10.3174/ajnr.A2771
   Pierot L, 2008, STROKE, V39, P2497, DOI 10.1161/STROKEAHA.107.512756
   Pierot L, 2018, J NEUROINTERV SURG, V10, P553, DOI 10.1136/neurintsurg-2017-013448
   Pierot L, 2013, NEUROSURGERY, V73, P27, DOI 10.1227/01.neu.0000429860.04276.c1
   Samaniego EA, 2019, STROKE VASC NEUROL, V4, P36, DOI 10.1136/svn-2018-000192
   US Food and Drug Administration, PREM APPR PMA
   Zanaty M, 2019, WORLD NEUROSURG, V130, P201, DOI 10.1016/j.wneu.2019.07.027
   Zanaty M, 2016, WORLD NEUROSURG, V96, P31, DOI 10.1016/j.wneu.2016.08.050
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E1047
EP E1052
DI 10.1016/j.wneu.2019.11.076
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200122
PM 31759154
DA 2020-05-12
ER

PT J
AU Zappa, F
   Mattavelli, D
   Madoglio, A
   Rampinelli, V
   Ferrari, M
   Tampalini, F
   Fontanella, M
   Nicolai, P
   Doglietto, F
   Agosti, E
   Battaglia, P
   Biroli, A
   Bresson, D
   Castelnuovo, P
   Fiorindi, A
   Herman, P
   Karligkiotis, A
   Locatelli, D
   Pozzi, F
   Saraceno, G
   Schreiber, A
   Verillaud, B
   Zanoni, MT
AF Zappa, Francesca
   Mattavelli, Davide
   Madoglio, Alba
   Rampinelli, Vittorio
   Ferrari, Marco
   Tampalini, Fabio
   Fontanella, Marco
   Nicolai, Piero
   Doglietto, Francesco
   Agosti, Edoardo
   Battaglia, Paolo
   Biroli, Antonio
   Bresson, Damien
   Castelnuovo, Paolo
   Fiorindi, Alessandro
   Herman, Philippe
   Karligkiotis, Apostolos
   Locatelli, Davide
   Pozzi, Fabio
   Saraceno, Giorgio
   Schreiber, Alberto
   Verillaud, Benjamin
   Zanoni, Mario Turri
CA PEER Res Grp
TI Hybrid Robotics for Endoscopic Skull Base Surgery: Preclinical
   Evaluation and Surgeon First Impression
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscope holder; Endoscopy; Preclinical; Robotics; Skull base surgery;
   Transsphenoidal
ID SKILLS; SINUS; NAVIGATION; HOLDERS
AB BACKGROUND: A robotic endoscope holder theoretically provide various advantages in transnasal endoscopic skull base surgery, but only recently has a robotic system become commercially available. The objective of this study was to provide a preclinical evaluation of potential advantages and surgeon first impression of this robotic hybrid solution.
   METHODS: Thirty skull base surgeons, attending the Joint European Diploma of Endoscopic Skull Base Surgery 2018-2019 in Paris, France, were enrolled. A questionnaire, mainly concerning personal surgical experience and habits, was administered. The test phase consisted of 2 different dry-lab tasks, performed with and without EndoscopeRobot, according to randomization and on 2 different days. A modified NASA Task Load Index test was subsequently administered via e-mail to all participants. Completion times and modified Global Evaluative Assessment of Robotic Skills in Endoscopy scores of the videotaped tasks were recorded.
   RESULTS: Nineteen otorhinolaryngologic surgeons and 11 neurosurgeons, with different surgical habits and endoscopic experience, were enrolled. No one appeared unfavorable a priori to robotic endoscopic surgery. Although the robot did not provide an advantage in the simple grasping task 1, a trend toward better completion times and efficacy was evident in the bimanual task 2, when performed with the robot and bimanually. According to the modified NASA Task Load Index test, surgeons felt more successful with the robot in task 2, finding it less stressful and mentally demanding.
   CONCLUSIONS: Endoscopic skull base surgeons seem to view a hybrid robotic solution positively. EndoscopeRobot seems to provide a benefit to the single surgeon with experience in bimanual endoscopic surgery. Further preclinical and clinical evaluation of this technology is necessary.
C1 [Zappa, Francesca; Madoglio, Alba; Fontanella, Marco; Doglietto, Francesco] Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Neurosurg, Brescia, Italy.
   [Mattavelli, Davide; Rampinelli, Vittorio; Ferrari, Marco; Nicolai, Piero] Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Otorhinolaryngol, Brescia, Italy.
   [Tampalini, Fabio] Univ Brescia, Dept Informat Engn, Adv Robot Lab, Brescia, Italy.
   [Agosti, Edoardo] Univ Insubria, Otorhinolaryngol, Varese, Italy.
   [Agosti, Edoardo] Univ Insubria, Neurosurg, Varese, Italy.
   [Agosti, Edoardo] Henri Mondor Univ Hosp, Neurosurg, Creteil, France.
   [Agosti, Edoardo] Lariboisiere Univ Hosp, Dept Otorhinolaryngol, Paris, France.
   [Agosti, Edoardo] Paris Diderot Univ, Paris, France.
RP Doglietto, F (reprint author), Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Neurosurg, Brescia, Italy.
EM francesco.doglietto@unibs.it
RI Verillaud, Benjamin/AAM-5105-2020; Ferrari, Marco/AAC-7179-2019;
   Saraceno, Giorgio/AAL-3322-2020; Locatelli, Davide/AAH-5844-2020;
   Fiorindi, Alessandro/AAA-1597-2020
OI Ferrari, Marco/0000-0002-4023-0121; Saraceno,
   Giorgio/0000-0002-6711-0824; Locatelli, Davide/0000-0003-1163-9611;
   Fiorindi, Alessandro/0000-0003-2917-367X; Doglietto,
   Francesco/0000-0002-7438-0734; Schreiber, Alberto/0000-0002-1580-3928;
   Turri-Zanoni, Mario/0000-0002-3678-9088
CR Blanco RGF, 2013, J LAPAROENDOSC ADV S, V23, P776, DOI 10.1089/lap.2012.0573
   Dixon BJ, 2014, LARYNGOSCOPE, V124, P853, DOI 10.1002/lary.24385
   Eichhorn KWG, 2011, ACTA NEUROCHIR SUPPL, V109, P237, DOI 10.1007/978-3-211-99651-5_37
   Kun Y, 2019, J SURG EDUC, V76, P362, DOI 10.1016/j.jsurg.2018.08.017
   Lin ZH, 2013, IEEE T BIO-MED ENG, V60, P977, DOI 10.1109/TBME.2012.2230260
   Nimsky C, 2004, MINIM INVAS NEUROSUR, V47, P41, DOI 10.1055/s-2003-812465
   O'Malley BW, 2007, INT J RADIAT ONCOL, V69, pS125, DOI 10.1016/j.ijrobp.2007.06.028
   Ogiwara T, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS16498
   Paraskevopoulos D, 2018, WORLD NEUROSURG, V111, pE632, DOI 10.1016/j.wneu.2017.12.142
   Paraskevopoulos D, 2016, WORLD NEUROSURG, V89, P343, DOI 10.1016/j.wneu.2016.01.052
   Rampinelli V, 2017, WORLD NEUROSURG, V105, P223, DOI 10.1016/j.wneu.2017.05.130
   Rangarajan S, 2017, OTOLARYNG CLIN N AM, V50, P633, DOI 10.1016/j.otc.2017.01.013
   SHAH J, 2015, AM J ROBOT SURG, V1, P12
   Singh R, 2016, WORLD NEUROSURG, V86, P259, DOI 10.1016/j.wneu.2015.09.045
   Suh IH, 2012, J ROBOT SURG, V6, P301, DOI 10.1007/s11701-011-0312-5
   Takeshita N, 2018, ENDOSC INT OPEN, V6, pE1065, DOI 10.1055/a-0640-3123
   Trevillot V, 2013, EUR ANN OTORHINOLARY, V130, P201, DOI 10.1016/j.anorl.2012.03.010
   Wurm J, 2005, INT J MED ROBOT COMP, V1, P42, DOI 10.1002/rcs.26
NR 18
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E572
EP E580
DI 10.1016/j.wneu.2019.10.142
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200070
PM 31678446
DA 2020-05-12
ER

PT J
AU Zhang, H
   Ma, L
   Shu, C
   Dong, LQ
   Ma, YQ
   Zhou, Y
AF Zhang, Hui
   Ma, Li
   Shu, Cheng
   Dong, Lian-qiang
   Ma, Ya-qun
   Zhou, Yan
TI Spinal Clear Cell Meningiomas: Clinical Features and Factors Predicting
   Recurrence
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clear cell meningiomas; Clinical feature; Prognostic factor; Recurrence;
   Spine
ID MR-IMAGING FINDINGS; CAUDA-EQUINA; DESCRIPTIVE EPIDEMIOLOGY;
   PROGNOSTIC-FACTORS; VARIANT; TUMORS; CLASSIFICATION; MANAGEMENT;
   RESECTION; OUTCOMES
AB OBJECTIVE: As a World Health Organization grade II tumor of the nervous system, clear cell meningioma (CCM) is an uncommon histologic variant of meningioma. Spinal CCMs are even rarer, with <100 spinal CCMs reported in the English literature. We present this study to characterize clinical manifestations of spinal CCMs and determine the factors predicting recurrence.
   METHODS: A literature search was performed for relevant case reports and series in PubMed and Embase until September 1, 2019. These articles were reviewed to identify clinical features, treatment modalities, and prognosis of patients with spinal CCMs.
   RESULTS: Eighty-four spinal CCMs were analyzed. Of these patients, 36 (42.9%) were young (age <= 18 years), and the mean age at resection was 24 years. Fifty-three patients (63.1%) were female and 31 (36.9%) were male. Most of the tumors (56/84, 66.7%) were located in the lumbar region. In 31 patients (36.9%) >2 segments in the craniocaudal direction were involved (number of involved segments >= 3 levels). Gross tumor resection was performed in 77 patients (91.7%). Twenty patients (23.8%) showed radiographic evidence of recurrence during follow-up. Recurrence-free survival at 1, 5, and 10 years after resection of spinal CCM was 87%, 71%, and 47%, respectively. Multivariate analysis showed that age <= 18 years (hazard ratio [HR], 3.64; P = 0.024), subtotal resection (HR, 3.43; P = 0.031), and segments involving >= 3 levels (HR, 5.66; P = 0.002) were associated with increased recurrence.
   CONCLUSIONS: Spinal CCMs have their own unique clinical features compared with conventional spinal meningiomas and intracranial CCMs. Spinal CCMs have a predilection to affect younger patients, are prone to appear in the lumbar region, and have a high recurrence rate. Age <= 18 years, subtotal resection, and involvement of long segments (>= 3 levels) are positive predictors of recurrence.
C1 [Zhang, Hui; Shu, Cheng; Dong, Lian-qiang; Zhou, Yan] Air Force Med Ctr Chinese PLA, Dept Neurosurg, Beijing, Peoples R China.
   [Ma, Li; Ma, Ya-qun] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 7, Dept Anesthesiol, Beijing, Peoples R China.
RP Ma, YQ (reprint author), Chinese Peoples Liberat Army Gen Hosp, Med Ctr 7, Dept Anesthesiol, Beijing, Peoples R China.
EM ma_yq126@126.com
CR Alameda F, 1999, ULTRASTRUCT PATHOL, V23, P51
   Balogun JA, 2013, PEDIATR NEUROSURG, V49, P311, DOI 10.1159/000366452
   Boet R, 2004, J CLIN NEUROSCI, V11, P432, DOI 10.1016/j.jocn.2003.10.014
   Carra S, 2003, PEDIATR NEUROSURG, V38, P162, DOI 10.1159/000068815
   Chen MH, 2004, J CLIN NEUROSCI, V11, P665, DOI 10.1016/j.jocn.2003.10.024
   Colen CB, 2009, J NEUROSURG-PEDIATR, V3, P57, DOI 10.3171/2008.10.17668
   Dubois A, 1998, NEURORADIOLOGY, V40, P743, DOI 10.1007/s002340050676
   Duong LM, 2012, CANCER-AM CANCER SOC, V118, P4220, DOI 10.1002/cncr.27390
   Epstein NE, 2005, J SPINAL DISORD TECH, V18, P539, DOI 10.1097/01.bsd.0000173314.98401.b5
   Evans LT, 2015, J NEUROSURG-PEDIATR, V16, P296, DOI 10.3171/2015.3.PEDS14417
   Gilard V, 2018, J NEURO-ONCOL, V140, P49, DOI 10.1007/s11060-018-2929-y
   Greene S, 2008, PEDIATR NEUROSURG, V44, P9, DOI 10.1159/000110656
   Heth JA, 2000, J NEUROSURG, V93, P317, DOI 10.3171/spi.2000.93.2.0317
   Holtzman RNN, 1996, J NEUROSURG, V84, P264, DOI 10.3171/jns.1996.84.2.0264
   Hua LY, 2018, J NEURO-ONCOL, V140, P639, DOI 10.1007/s11060-018-2993-3
   Inoue T, 2018, ACTA NEUROCHIR, V160, P2321, DOI 10.1007/s00701-018-3727-1
   Jain D, 2007, J NEURO-ONCOL, V81, P315, DOI 10.1007/s11060-006-9237-7
   Jallo GI, 2001, NEUROSURGERY, V48, P218, DOI 10.1097/00006123-200101000-00042
   Jia Y, 2005, CHINESE MED J-PEKING, V118, P348
   Kamp MA, 2019, NEUROSURG REV, V42, P835, DOI 10.1007/s10143-018-0963-z
   Kawasaki Yukari, 2018, Br J Neurosurg, P1, DOI 10.1080/02688697.2018.1429565
   Kim CH, 2016, EUR SPINE J, V25, P4025, DOI 10.1007/s00586-015-4306-2
   Ko JK, 2011, J KOREAN NEUROSURG S, V49, P71, DOI 10.3340/jkns.2011.49.1.71
   Kobayashi Y, 2013, J ORTHOP SCI, V18, P861, DOI 10.1007/s00776-012-0217-9
   Kotecha RS, 2011, LANCET ONCOL, V12, P1229, DOI 10.1016/S1470-2045(11)70275-3
   Kshettry VR, 2015, SPINE, V40, pE886, DOI 10.1097/BRS.0000000000000974
   Li JH, 2019, WORLD NEUROSURG, V122, pE415, DOI 10.1016/j.wneu.2018.10.064
   Li P, 2016, ACTA NEUROCHIR, V158, P67, DOI 10.1007/s00701-015-2635-x
   Liu PI, 2005, SURG NEUROL, V63, P285, DOI 10.1016/j.surneu.2004.03.013
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Maiti TK, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS16163
   Maiuri F, 2011, CLIN NEUROL NEUROSUR, V113, P34, DOI 10.1016/j.clineuro.2010.08.017
   Matsui H, 1998, NEUROSURG REV, V21, P171, DOI 10.1007/BF02389326
   Meguins LC, 2014, CHIRURG TURIN, V27, P337
   Nakajima H, 2009, MINIM INVAS NEUROSUR, V52, P32, DOI 10.1055/s-0028-1085455
   Nakamura M, 2012, SPINE, V37, pE617, DOI 10.1097/BRS.0b013e31824167f1
   Oviedo A, 2005, PEDIATR DEVEL PATHOL, V8, P386, DOI 10.1007/s10024-005-0119-3
   Park HC, 2000, CHILD NERV SYST, V16, P607, DOI 10.1007/PL00007302
   Park SH, 2006, ACTA NEUROCHIR, V148, P463, DOI 10.1007/s00701-005-0695-z
   Payano M, 2004, APMIS, V112, P141, DOI 10.1111/j.1600-0463.2004.apm1120209.x
   Pimentel J, 1998, CLIN NEUROPATHOL, V17, P141
   Postalci L, 2011, TURK NEUROSURG, V21, P449, DOI [10.5137/1019-5149.JTN .3518-10.2, 10.5137/1019-5149.JTN.3518-10.2]
   Prayson RA, 2010, APPL IMMUNOHISTO M M, V18, P422, DOI 10.1097/PAI.0b013e3181dd35d2
   Raco A, 2017, NEUROSURGERY, V80, P602, DOI 10.1093/neuros/nyw092
   Ravindra VM, 2016, NEUROSURG CLIN N AM, V27, P195, DOI 10.1016/j.nec.2015.11.010
   Ruttledge Martin H, 2005, Neurosurg Focus, V19, pE6
   Schwake M, 2018, J CLIN NEUROSCI, V57, P86, DOI 10.1016/j.jocn.2018.08.030
   Smith MJ, 2017, HISTOPATHOLOGY, V70, P814, DOI 10.1111/his.13135
   Sun SQ, 2015, NEUROSURGERY, V76, P739, DOI 10.1227/NEU.0000000000000720
   Tao XG, 2018, WORLD NEUROSURG, V111, pE880, DOI 10.1016/j.wneu.2017.12.173
   Tauziede-Espariat A, 2018, BRAIN PATHOL, V28, P466, DOI 10.1111/bpa.12524
   Tsuda K, 2014, NEUROL MED-CHIR, V54, P907, DOI 10.2176/nmc.oa.2013-0311
   Vural M, 2007, CHILD NERV SYST, V23, P225, DOI 10.1007/s00381-006-0181-9
   Wang XQ, 2014, J COMPUT ASSIST TOMO, V38, P200, DOI 10.1097/RCT.0000000000000018
   Wang XQ, 2012, CHILD NERV SYST, V28, P129, DOI 10.1007/s00381-011-1570-2
   Wu L, 2019, J CLIN NEUROSCI, V69, P55, DOI 10.1016/j.jocn.2019.08.037
   Wu L, 2017, J NEURO-ONCOL, V133, P347, DOI 10.1007/s11060-017-2441-9
   Wu TT, 2010, PATHOL RES PRACT, V206, P349, DOI 10.1016/j.prp.2009.06.015
   Yang Jian, 2018, J Orthop Sci, DOI 10.1016/j.jos.2018.11.006
   Ye JL, 2016, J NEURO-ONCOL, V128, P349, DOI 10.1007/s11060-016-2119-8
   Yu KB, 2002, KOREAN J RADIOL, V3, P125, DOI 10.3348/kjr.2002.3.2.125
   Zhang H, 2017, WORLD NEUROSURG, V97, P693, DOI 10.1016/j.wneu.2016.10.010
   Zhang J, 2013, CLIN NEUROL NEUROSUR, V115, P371, DOI 10.1016/j.clineuro.2012.05.031
   ZORLUDEMIR S, 1995, AM J SURG PATHOL, V19, P493, DOI 10.1097/00000478-199505000-00001
NR 64
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E1062
EP E1076
DI 10.1016/j.wneu.2019.11.093
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200124
PM 31765868
DA 2020-05-12
ER

PT J
AU Zhao, Y
   Chen, L
   Zhang, JS
   You, N
   Liu, YY
   Yao, AH
   Zhao, K
   Zhang, J
   Xu, BN
AF Zhao, Yue
   Chen, Li
   Zhang, Jiashu
   You, Na
   Liu, Yuyang
   Yao, Anhui
   Zhao, Kai
   Zhang, Jun
   Xu, Bainan
TI Duraplasty with Cervical Fascia Autograft to Reduce Postoperative
   Complications of Posterior Fossa Tumor Surgery with Suboccipital Midline
   Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebrospinal fluid leak; Meningitis; Posterior fossa tumor;
   Pseudomeningocele; Suboccipital midline approach
ID CEREBROSPINAL-FLUID LEAK; HYDROGEL DURAL SEALANT; CRANIOTOMY;
   MANAGEMENT; INFECTION; CLOSURE
AB BACKGROUND: The suboccipital midline approach is common dealing with posterior fossa tumors but has a high risk of postoperative complications, such as pseudomeningocele, cerebrospinal fluid (CSF) leak, and meningitis. Neurosurgeons used various kinds of method to lower its rate.
   METHODS: A retrospective, single-center review of patients diagnosed with posterior fossa tumor underwent a suboccipital midline approach. Compare the rates of pseudomeningocele, CSF leak, and meningitis between 2 groups (artificial dura mater or cervical fascia autograft). We get the cervical fascia autograft from the superficial layer of deep cervical fascia just above the trapezius.
   RESULTS: Our retrospective review involved 123 patients matching the inclusion criteria between January 2009 and April 2019. The complication rate of pseudomeningocele, CSF leak and meningitis were 8.9%, 4.9%, and 17.9%, respectively. The presence of pseudomeningocele or CSF leak for group "artificial" was 11 of 75 (14.67%) and for group "autograft" it was 3 of 48 (6.25%). The rate of meningitis for group "artificial" (24.0%, 18 of 75) was significantly higher (P = 0.027) than the one for group "autograft" (8.33%, 4 of 48). Multivariate regression analysis suggested that the age was negatively correlated with postoperative pseudomeningocele or CSF leak (P = 0.006), with meningitis (P< 0.001). Using cervical fascia autograft decreased the rate of meningitis (P = 0.021) while showing no statistically significant clinical impact on pseudomeningocele or CSF leak.
   CONCLUSIONS: Applying the cervical fascia autograft to reconstruct the dura during posterior fossa surgery is a simple and effective method to reduce the rate of meningitis as compared with artificial dura mater.
C1 [Zhao, Yue; Zhang, Jiashu; You, Na; Liu, Yuyang; Yao, Anhui; Zhao, Kai; Zhang, Jun; Xu, Bainan] Chinese Peoples Liberat Army Gen Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Chen, Li] Peoples Hosp Qinghai Prov, Dept Radiol, Xining, Qinghai, Peoples R China.
RP Xu, BN (reprint author), Chinese Peoples Liberat Army Gen Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM xubn301@yeah.net
OI Yue, Zhao/0000-0002-9694-9872
CR Abla AA, 2010, J CRANIOVERTEBRAL JU, V1, P29, DOI 10.4103/0974-8237.65479
   Altaf I, 2016, PAK J MED SCI, V32, P1439, DOI 10.12669/pjms.326.9956
   Cosgrove GR, 2007, J NEUROSURG, V106, P52, DOI 10.3171/jns.2007.106.1.52
   Dubey A, 2009, SURG NEUROL, V72, P369, DOI 10.1016/j.surneu.2009.04.001
   Felbaum DR, 2016, CUREUS, V8, DOI 10.7759/cureus.946
   Hadanny A, 2016, WORLD NEUROSURG, V89, P193, DOI 10.1016/j.wneu.2016.01.076
   Horan TC, 2008, AM J INFECT CONTROL, V36, P309, DOI 10.1016/j.ajic.2008.03.002
   Jito J, 2014, NEUROL MED-CHIR, V54, P634, DOI 10.2176/nmc.cr2013-0010
   Kawai H, 2014, NEUROL RES, V36, P866, DOI 10.1179/1743132814Y.0000000342
   Korinek AM, 2006, NEUROSURGERY, V59, P126, DOI 10.1227/01.NEU.0000220477.47323.92
   Kourbeti IS, 2015, J NEUROSURG, V122, P1113, DOI 10.3171/2014.8.JNS132557
   Kushel Y, 2019, WORLD NEUROSURG, V129, pE171, DOI 10.1016/j.wneu.2019.05.091
   Lassen B, 2012, NEUROSURGERY, V70, P936, DOI 10.1227/NEU.0b013e31823bcc61
   Malliti M, 2004, NEUROSURGERY, V54, P599, DOI 10.1227/01.NEU.0000108640.45371.1A
   Marx S, 2018, ACTA NEUROCHIR, V160, P1063, DOI 10.1007/s00701-018-3496-x
   Mazzola Catherine A, 2003, Neurosurg Focus, V15, pE3
   Moskowitz SI, 2009, NEUROSURGERY, V64, pS28, DOI 10.1227/01.NEU.0000334414.79963.59
   Steinbok P, 2007, CHILD NERV SYST, V23, P171, DOI 10.1007/s00381-006-0234-0
   Than KD, 2008, NEUROSURGERY, V63, P182, DOI 10.1227/01.NEU.0000313116.28200.67
   Tu A, 2014, CHILD NERV SYST, V30, P1791, DOI 10.1007/s00381-014-2501-9
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E1115
EP E1120
DI 10.1016/j.wneu.2019.11.106
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200130
PM 31785439
DA 2020-05-12
ER

PT J
AU Zhong, WY
   Du, YM
   Guo, QL
   Tan, XJ
   Li, T
   Chen, C
   Liu, M
   Shen, J
   Su, WD
   Wang, DH
   Wang, YY
AF Zhong, Weiying
   Du, Yiming
   Guo, Qinglong
   Tan, Xianjun
   Li, Tao
   Chen, Chao
   Liu, Ming
   Shen, Jie
   Su, Wandong
   Wang, Donghai
   Wang, Yunyan
TI The Clinical and Morphologic Features Related to Aneurysm Wall
   Enhancement and Enhancement Pattern in Patients with Anterior
   Circulation Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysmal wall enhancement; Inflammation; Magnetic resonance imaging;
   Unruptured intracranial aneurysm
ID INTRACRANIAL ANEURYSMS; RUPTURE; RISK
AB BACKGROUND: Aneurysm wall enhancement (AWE) may predict rupture-prone intracranial aneurysms (IAs). However, the clinical and morphologic risk factors related to AWE have not been well described. Furthermore, the risk factors related to enhancement patterns have never been studied, especially in patients with anterior circulation aneurysms. Therefore, we aimed to investigate the risk factors related to wall enhancement and the enhancement patterns in anterior circulation unruptured aneurysms.
   METHODS: One hundred patients (median age, 59 years; 68% female) with 113 anterior circulation unruptured aneurysms were included in this prospective study. Clinical and morphologic risk factors related to wall enhancement and circumferential enhancement were analyzed using univariate and multivariate analyses.
   RESULTS: There were 33 symptomatic unruptured IAs (292%) and 50 IAs with AWE (44.2%) (partial [n = 16] and circumferential [n = 34]). Univariate analysis showed that symptomatic IAs and morphologic factors (irregular shape, size, width, dome depth, size ratio, aspect ratio, and bottleneck) correlated with wall enhancement. Furthermore, female sex, blood parameters (cholesterol and low-density lipoprotein), and morphologic factors (size and dome depth) correlated with wall enhancement patterns (P <0.05). Multivariate analysis showed that size was the most important factor in wall enhancement (P = 0.06; odds ratio, 3.758) and a trend for symptomatic IAs (P = 0.033; odds ratio, 2.426). Female sex was the most important factor in circumferential enhancement (P = 0.017; odds ratio, 7.276).
   CONCLUSIONS: AWE was strongly associated with aneurysm size and was observed more frequently in symptomatic unruptured IAs. Sex hormones and atherosclerotic factors may be involved in circumferential enhancement. However, further studies should be performed to investigate the pathologic mechanisms for pattern of enhancement.
C1 [Zhong, Weiying; Tan, Xianjun; Li, Tao; Chen, Chao; Liu, Ming; Shen, Jie; Su, Wandong; Wang, Donghai; Wang, Yunyan] Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan, Peoples R China.
   [Zhong, Weiying; Tan, Xianjun; Li, Tao; Chen, Chao; Liu, Ming; Shen, Jie; Su, Wandong; Wang, Donghai; Wang, Yunyan] Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan, Peoples R China.
   [Zhong, Weiying; Chen, Chao; Liu, Ming; Shen, Jie; Su, Wandong; Wang, Donghai; Wang, Yunyan] Shandong Key Lab Brain Funct Remodeling, Jinan, Peoples R China.
   [Du, Yiming] Yinan Cty Peoples Hosp, Dept Pharm, Linyi, Shandong, Peoples R China.
   [Guo, Qinglong] Caoxian Panshi Hosp, Dept Neurosurg, Heze, Peoples R China.
RP Wang, YY (reprint author), Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan, Peoples R China.; Wang, YY (reprint author), Shandong Univ, Inst Brain & Brain Inspired Sci, Jinan, Peoples R China.; Wang, YY (reprint author), Shandong Key Lab Brain Funct Remodeling, Jinan, Peoples R China.
EM wangyunyan0618@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81701160]
FX This research was supported by a grant from the National Natural Science
   Foundation of China (no. 81701160).
CR Backes D, 2018, NEUROSURGERY, V83, P719, DOI 10.1093/neuros/nyx487
   Fennell VS, 2016, FRONT SURG, V3, DOI 10.3389/fsurg.2016.00043
   Harrod CG, 2006, MED HYPOTHESES, V66, P736, DOI 10.1016/j.mehy.2005.09.051
   Hu P, 2016, NEURORADIOLOGY, V58, P979, DOI 10.1007/s00234-016-1729-3
   Ishibashi T, 2009, STROKE, V40, P313, DOI 10.1161/STROKEAHA.108.521674
   Ishii D, 2019, J STROKE CEREBROVASC, V28, P2221, DOI 10.1016/j.jstrokecerebrovasdis.2019.05.002
   Juvela S, 2001, STROKE, V32, P485, DOI 10.1161/01.STR.32.2.485
   Kwon OK, 2019, NEUROIMAG CLIN N AM, V29, P255, DOI 10.1016/j.nic.2019.01.004
   Liu P, 2016, INTERV NEURORADIOL, V22, P501, DOI 10.1177/1591019916653252
   Lv N, 2019, NEUROSURGERY, V84, pE385, DOI 10.1093/neuros/nyy310
   Lv N, 2018, WORLD NEUROSURG, V114, pE338, DOI 10.1016/j.wneu.2018.02.182
   Matouk CC, 2013, NEUROSURGERY, V72, P492, DOI 10.1227/NEU.0b013e31827d1012
   Matsushige T, 2019, STROKE, V50, P1891, DOI 10.1161/STROKEAHA.119.025245
   Matsushige T, 2019, WORLD NEUROSURG, V127, pE578, DOI 10.1016/j.wneu.2019.03.209
   Nagahata S, 2016, CLIN NEURORADIOL, V26, P277, DOI 10.1007/s00062-014-0353-z
   Omodaka S, 2018, NEUROSURGERY, V82, P638, DOI 10.1093/neuros/nyx267
   Petridis AK, 2018, CLINICS PRACT, V8, P73, DOI 10.4081/cp.2018.1089
   Vergouwen MDI, 2019, AM J NEURORADIOL, V40, P1112, DOI 10.3174/ajnr.A6105
   Wang Guang-Xian, 2019, Acad Radiol, V26, pe292, DOI 10.1016/j.acra.2018.12.004
   Zhu CC, 2018, EUR RADIOL, V28, P5019, DOI 10.1007/s00330-018-5522-z
   Zolnourian A, 2019, WORLD NEUROSURG, V127, P414, DOI 10.1016/j.wneu.2019.04.130
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E649
EP E656
DI 10.1016/j.wneu.2019.10.156
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200080
PM 31689567
DA 2020-05-12
ER

PT J
AU Zhou, ZQ
   Jin, ZG
   Zhang, P
   Shan, BC
   Zhou, ZT
   Zhang, YZ
   Deng, YK
   Zhou, XZ
AF Zhou, Zhiqiang
   Jin, Zhigao
   Zhang, Peng
   Shan, Bingchen
   Zhou, Zhentao
   Zhang, Yingzi
   Deng, Yekun
   Zhou, Xiaozhong
TI Correlation Between Dural Sac Size in Dynamic Magnetic Resonance Imaging
   and Clinical Symptoms in Patients with Lumbar Spinal Stenosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Claudication distance; Correlation; LSS; Standing MRI; VAS of leg pain
ID COMPUTED-TOMOGRAPHY; MRI; DISC; DECOMPRESSION; MYELOGRAPHY; DISABILITY;
   LOAD; PAIN; CT
AB OBJECTIVE: To assess the dynamic change of the dural sac size in patients with lumbar spinal stenosis (LSS) from supine to standing position and their correlation with clinical symptoms.
   METHODS: A total of 110 patients with LSS were prospectively enrolled to undergo both supine (0 degrees) and standing (78 degrees) magnetic resonance imaging (MRI). Dural sac cross-sectional area (DCSA) and dural sac anteroposterior diameter (DAPD) at the most constricted spinal level in supine and standing MRI were measured and compared. Clinical symptoms were assessed by duration of disease, claudication distance, visual analog scale (VAS) score of leg pain, and Chinese Oswestry Disability Index score of low back pain. The correlation between the parameters and clinical symptoms was analyzed by Pearson correlation coefficient (r).
   RESULTS: Mean minimum DCSA and DAPD in the standing position were significantly smaller (both P< 0.01) than in the supine position. DCSA and DAPD in standing MRI and their changes had better correlation with the intermittent claudication distance and VAS score of leg pain than in the supine position. A more than 15 mm(2) reduction of DSCA was observed in patients with shorter claudication distance and more severe VAS score of leg pain (both P < 0.01).
   CONCLUSIONS: Dural sac size on MRI was reduced significantly from supine to standing position. Standing MRI and the changes of DCSA significantly correlated with claudication distance and VAS score of leg pain in patients with LSS. Therefore, standing MRI provides more radiologic information correlating with clinical symptoms in patients with LSS than supine MRI.
C1 [Zhou, Zhiqiang; Jin, Zhigao; Zhang, Peng; Shan, Bingchen; Zhou, Zhentao; Zhang, Yingzi; Deng, Yekun; Zhou, Xiaozhong] Soochow Univ, Dept Orthoped, Affiliated Hosp 2, Suzhou, Peoples R China.
RP Zhou, XZ (reprint author), Soochow Univ, Dept Orthoped, Affiliated Hosp 2, Suzhou, Peoples R China.
EM drzhouxz@163.com
CR Ali HI, 2015, EGYPT J RADIOL NUC M, V46, P1065, DOI 10.1016/j.ejrnm.2015.06.002
   Arun R, 2009, SPINE, V34, P2324, DOI 10.1097/BRS.0b013e3181b4df92
   Danielson BI, 1998, ACTA RADIOL, V39, P604, DOI 10.3109/02841859809175484
   Felix ZF, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-89
   Foris LA, 2018, SPINAL STENOSIS NEUR
   Hansen BB, 2017, SPINE, V42, P662, DOI 10.1097/BRS.0000000000001889
   Hebelka H, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0727-z
   Hiwatashi A, 2004, AM J NEURORADIOL, V25, P170
   Iwahashi H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160002
   Jones ADR, 2014, EUR SPINE J, V23, P135, DOI 10.1007/s00586-013-2964-5
   Kanno H, 2016, AM J NEURORADIOL, V37, P730, DOI 10.3174/ajnr.A4582
   Kanno H, 2018, SPINE J, V18, P726, DOI 10.1016/j.spinee.2017.08.251
   Kanno H, 2012, SPINE, V37, P207, DOI 10.1097/BRS.0b013e3182134e73
   Kimura S, 2001, SPINE, V26, P2596, DOI 10.1097/00007632-200112010-00014
   Kuittinen P, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-247
   Lafian AM, 2018, RHEUM DIS CLIN N AM, V44, P501, DOI 10.1016/j.rdc.2018.03.008
   Lang G, 2018, CUREUS, V10, DOI 10.7759/cureus.2440
   Lurie JD, 2009, SPINE, V34, P701, DOI 10.1097/BRS.0b013e31819b390e
   Manenti G, 2003, IN VIVO, V17, P413
   Moon ES, 2005, YONSEI MED J, V46, P806, DOI 10.3349/ymj.2005.46.6.806
   Ogikubo O, 2007, SPINE, V32, P1423, DOI 10.1097/BRS.0b013e318060a5f5
   Oguz H, 2007, EUR SPINE J, V16, P913, DOI 10.1007/s00586-007-0317-y
   Sirvanci M, 2008, EUR SPINE J, V17, P679, DOI 10.1007/s00586-008-0646-5
   Thome C, 2005, J NEUROSURG-SPINE, V3, P129, DOI 10.3171/spi.2005.3.2.0129
   Vitzthum HE, 2000, J NEUROSURG, V93, P58, DOI 10.3171/spi.2000.93.1.0058
   Wang YC, 2008, J FORMOS MED ASSOC, V107, P334, DOI 10.1016/S0929-6646(08)60095-9
   Weber C, 2016, SPINE, V41, pE78, DOI 10.1097/BRS.0000000000001166
   Willen J, 1997, SPINE, V22, P2968, DOI 10.1097/00007632-199712150-00021
   Willen J, 2001, SPINE, V26, P2607, DOI 10.1097/00007632-200112010-00016
   Willen J, 2008, SPINE, V33, pE109, DOI 10.1097/BRS.0b013e318163f9ab
NR 30
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD FEB
PY 2020
VL 134
BP E866
EP E873
DI 10.1016/j.wneu.2019.11.011
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KK6VS
UT WOS:000512878200100
PM 31715409
DA 2020-05-12
ER

PT J
AU Akbora, HD
   Kunter, I
   Ercetin, T
   Elagoz, AM
   Cicek, BA
AF Akbora, Hasan Deniz
   Kunter, Imge
   Ercetin, Tugba
   Elagoz, Ali Murat
   Cicek, Burak Ali
TI Determination of tetrodotoxin (TTX) levels in various tissues of the
   silver cheeked puffer fish (Lagocephalus sceleratus (Gmelin, 1789)) in
   Northern Cyprus Sea (Eastern Mediterranean)
SO TOXICON
LA English
DT Article
DE Lagocephalus sceleratus; Silver cheeked pufferfish; Tetrodotoxin; TTX;
   ELISA; North Cyprus; Eastern Mediterranean
ID TOXICITY
AB Lagocephalus sceleratus from the family Tetraodontidae, which is originated from the Red Sea, started to migrate to Mediterranean waters after the opening of the Suez Channel in 1869. Since they do not have any predators in the Mediterranean Sea, their population increased in number very fast. Different tissues of L. sceleratus have tetrodotoxin (TTX). TTX is a non-protein, heat resistant molecule which binds to voltage-gated sodium channels of musculatory and nervous system. Ingestion of the fish can cause a wide variety of effects from mild toxications to death. This study is the first toxicity report of L. sceleratus for Cyprus. Due to the lack of data on toxicity levels of L. sceleratus, and some cases of poising after the ingestion of the fish were the reasons for the start of this work. 24 L. sceleratus were sampled from 3 different areas to represent Northern Cyprus, during one year period. 16 fish samples selected and grouped into 4 fishes per season for toxicity assay. TTX levels from liver, gonad, intestine, muscle and skin tissue homogenate were analyzed with TTX ELISA. Totally 80 tissues were analyzed, 40% of them were above the toxic limit (2.2 mu g/g). Most toxic tissue, according to the seasonal average, was found in the summer season and was determined as; Liver = 13.48 mu g/g. Most toxic three fishes were found to be female with a length of 45-60 cm. TTX distribution among tissues have similarities with previously published studies from different regions.
C1 [Akbora, Hasan Deniz; Cicek, Burak Ali] Eastern Mediterranean Univ, Fac Arts & Sci, Dept Biol Sci, Via Mersin 10, TR-99628 Famagusta, North Cyprus, Turkey.
   [Kunter, Imge; Ercetin, Tugba] Eastern Mediterranean Univ, Fac Pharm, Via Mersin 10, TR-99628 Famagusta, North Cyprus, Turkey.
   [Elagoz, Ali Murat] Univ Ghent, Marine Biol Res Grp, Krijgslaan 281, B-9000 Ghent, Belgium.
RP Akbora, HD (reprint author), Eastern Mediterranean Univ, Fac Arts & Sci, Dept Biol Sci, Via Mersin 10, TR-99628 Famagusta, North Cyprus, Turkey.
EM hasan.deniz@emu.edu.tr; imge.kunter@emu.edu.tr;
   tugba.ercetin@emu.edu.tr; ali.elagoz@imbrsea.eu; burak.cicek@emu.edu.tr
OI ELAGOZ, ALI MURAT/0000-0002-1639-0619; Akbora, Hasan
   Deniz/0000-0002-6647-866X
CR Alcaraz A, 1999, FORENSIC SCI INT, V99, P35, DOI 10.1016/S0379-0738(98)00171-6
   Aydin M, 2011, TURK J FISH AQUAT SC, V11, P569, DOI 10.4194/1303-2712-v11_4_10
   Azman AMN, 2014, SAINS MALAYS, V43, P1003
   Bane V, 2014, TOXINS, V6, P693, DOI 10.3390/toxins6020693
   Bentur Y, 2008, TOXICON, V52, P964, DOI 10.1016/j.toxicon.2008.10.001
   Boustany L, 2015, CAH BIOL MAR, V56, P137
   Campbell S, 2009, NAT PROD RES, V23, P1630, DOI 10.1080/14786410903003780
   Chua H.H., 2009, FAMILY AFFAIR, V64, P181
   EastMed, 2010, SUBR TECHN M LESS MI
   Eisenman Arie, 2008, AM J EMERG MED, P6
   El-Sayed M, 2003, ECOTOX ENVIRON SAFE, V56, P367, DOI 10.1016/S0147-6513(02)00142-2
   Golani Daniel, 2005, Zoology in the Middle East, V36, P27
   Hwang DF, 2007, ADV FOOD NUTR RES, V52, P141, DOI 10.1016/S1043-4526(06)52004-2
   Jen HC, 2008, J CHROMATOGR B, V871, P95, DOI 10.1016/j.jchromb.2008.06.030
   Kalogirou S, 2013, MEDITERR MAR SCI, V14, P251, DOI 10.12681/mms.364
   Katikou P, 2009, TOXICON, V54, P50, DOI 10.1016/j.toxicon.2009.03.012
   Khalaf G., 2014, J EARTH SCI ENG, V4, P236
   Kheifets Julia, 2012, Case Rep Crit Care, V2012, P782507, DOI 10.1155/2012/782507
   Kosker AR, 2016, FOOD CHEM, V210, P332, DOI 10.1016/j.foodchem.2016.04.122
   Man CN, 2010, J CHROMATOGR A, V1217, P7455, DOI 10.1016/j.chroma.2010.09.064
   *NAT CTR BIOT INF, 2019, PUBCHEM DAT TETR
   Noguchi T, 2001, J TOXICOL-TOXIN REV, V20, P1, DOI 10.1081/TXR-100103080
   Noguchi T, 2006, COMP BIOCHEM PHYS D, V1, P153, DOI 10.1016/j.cbd.2005.11.003
   Nzoughet JK, 2013, FOOD CHEM, V136, P1584, DOI 10.1016/j.foodchem.2012.01.109
   Ozbay T., 2015, MERSIN KORFEZINDE DA
   Oztiirk-Golani B., 2006, FISHES E MEDITERRANE
   Por F.D., 1978, LESSEPSIAN MIGRATION, DOI [10.1007/978-3-642-66728-2, DOI 10.1007/978-3-642-66728-2]
   Rodriguez P, 2012, FOOD CHEM, V132, P1103, DOI 10.1016/j.foodchem.2011.11.081
   ROUSOU M, 2014, SEXUALITY EARLY DEV, V1, P35, DOI DOI 10.3354/SEDA000005
   Sabrah M. M., 2006, EGYPTIAN J AQUATIC R, V32, P283
   Ulman A, 2015, ENVIRON DEV SUSTAIN, V17, P801, DOI 10.1007/s10668-014-9576-z
   Woodward R.B., 1964, STRUCTURE TETRODOTOX, P49, DOI 10.3358/sh okueishi.3.209
   Yaglioglu Deniz, 2011, Biharean Biologist, V5, P159
   Yu C-H., 2007, DETECTION BIOSYNTHES
NR 34
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2020
VL 175
BP 1
EP 6
DI 10.1016/j.toxicon.2019.12.002
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KR8GN
UT WOS:000517854100001
PM 31833474
DA 2020-05-12
ER

PT J
AU Bisneto, PF
   Alcantara, JA
   da Silva, IM
   Sachett, JDG
   Bernarde, PS
   Monteiro, WM
   Kaefer, IL
AF Bisneto, Pedro Ferreira
   Alcantara, Joao Arthur
   da Silva, Iran Mendonca
   Goncalves Sachett, Jacqueline de Almeida
   Bernarde, Paulo Sergio
   Monteiro, Wuelton Marcelo
   Kaefer, Igor Luis
TI Coral snake bites in Brazilian Amazonia: Perpetrating species,
   epidemiology and clinical aspects
SO TOXICON
LA English
DT Review
DE Brazil; Elapidae; Envenomings; Micrurus; Serpentes; Snakebite
ID MICRURUS-FULVIUS-FULVIUS; BIOLOGICAL CHARACTERIZATION; CROSS-REACTIVITY;
   VENOM; STATE; ENVENOMATION; ELAPIDAE; NEUTRALIZATION; ACCIDENTS;
   COLOMBIA
AB Coral snakes constitute a relatively diverse and little known group of venomous snakes. So far, data for this kind of snakebite in the Amazon region are based only on case reports. This study takes advantage of novel data from the Brazilian Health Ministry database from 2010 to 2015 and presents a review of the cases reported in the literature regarding the Amazonian biome both from Brazil and nearby countries. Thirty-four cases reported in the database were used in the study, representing 0.05% of the snakebites in Brazilian Amazonia for that period. The incidence rate was 0.123 cases/100,000 inhabitants/year. The most affected group is that of working age men, suggesting occupational risk. Most of bites were on lower limbs. Pain, edema and paresthesia were the most common symptoms. Systemic symptoms not usually associated with coral snakes envenomings, such as coagulopathy and thrombocytopenia, have been reported in Amazonia. Five patients received less antivenom than indicated by the Health Ministry. Based on these results, we recommend the execution of educational programs to avoid such accidents and to teach both the general public and health professionals the correct treatment for the bites. We also suggest that the covering of Intensive Care Units in the region needs to be improved to avoid deaths.
C1 [Bisneto, Pedro Ferreira; Kaefer, Igor Luis] Univ Fed Amazonas UFAM, Inst Ciencias Biol, Programa Posgrad Zool, Av Gen Rodrigo Octavio 1200,Coroado 1, BR-69067005 Manaus, Amazonas, Brazil.
   [Alcantara, Joao Arthur; da Silva, Iran Mendonca; Goncalves Sachett, Jacqueline de Almeida; Monteiro, Wuelton Marcelo] Univ Estado Amazonas UEA, Escola Super Ciencias Saude, Programa Posgrad Med Trop, Av Carvalho Leal 1777, BR-69065001 Manaus, Amazonas, Brazil.
   [Alcantara, Joao Arthur; da Silva, Iran Mendonca; Monteiro, Wuelton Marcelo] Fundacao Med Trop Dr Heitor Vieira Dourado FMT HV, Diretoria Ensino & Pesquisa, Av Pedro Teixeira W-N, BR-69040000 Manaus, Amazonas, Brazil.
   [Goncalves Sachett, Jacqueline de Almeida] Fundacao Alfredo Matta FUAM, Diretoria Ensino & Pesquisa, Av Codajas 24, BR-69065130 Manaus, Amazonas, Brazil.
   [Bernarde, Paulo Sergio] Univ Fed Acre UFAC, Lab Herpetol, Ctr Multidisciplinar, Campus Floresta,Estr Canela Fina,Km 12,Lote 245, BR-69895000 Cruzeiro Do Sul, Acre, Brazil.
RP Bisneto, PF (reprint author), Univ Fed Amazonas UFAM, Inst Ciencias Biol, Programa Posgrad Zool, Av Gen Rodrigo Octavio 1200,Coroado 1, BR-69067005 Manaus, Amazonas, Brazil.
EM pedro.fbisneto@hotmail.com
RI Kaefer, Igor L/A-3413-2009
OI Kaefer, Igor L/0000-0001-6515-0278; Sergio Bernarde,
   Paulo/0000-0002-2191-7817; Sachett, Jacqueline/0000-0002-4443-7496
FU FAPEAM (Fundacao de Amparo a Pesquisa do Estado do Amazonas); Brazilian
   CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico)National Council for Scientific and Technological
   Development (CNPq)
FX PFB thanks FAPEAM (Fundacao de Amparo a Pesquisa do Estado do Amazonas)
   for a scholarship grant; WMM and ILK thank Brazilian CNPq (Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico) for productivity
   grants. The authors also thank Gabriel Masseli and Sergio Marques de
   Souza for providing photographs and two anonymous reviewers for
   observations that helped to improve this manuscript.
CR Aird S.D., 1993, TOXICON, V31, P108
   AlapeGiron A, 1996, FEBS LETT, V380, P29, DOI 10.1016/0014-5793(95)01543-4
   Albuquerque PLMM, 2013, REV INST MED TROP SP, V55, P347, DOI 10.1590/S0036-46652013000500009
   Alcantara JA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208532
   Almeida P.C., 2016, COBRAS CORAIS BRASIL, P168
   Alves EC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202361
   AMIB-Associacao de Medicine Intensive Brasileira, 2016, CENS AMIB 2016
   [Anonymous], 2016, SINAN SIST NAC AGR N
   BARROS ACS, 1994, TOXICON, V32, P445, DOI 10.1016/0041-0101(94)90296-8
   Bemarde O.S., 2014, SERPENTES PECONHENTA
   Bernarde PS, 2018, SALAMANDRA, V54, P249
   Borges C.C., 1999, VERREV SOC BRAS MED, V32, P637, DOI [10.1590/S0037-86821999000600005, DOI 10.1590/S0037-86821999000600005]
   BRASIL, 2001, MAN DIAGN TRAT AC AN
   BRASIL, 2014, PROT CLIN AC SERP FA
   BRAZIL OV, 1987, REV I MED TROP, V29, P119, DOI 10.1590/S0036-46651987000300001
   Bucaretchi F., 2016, COBRAS CORAIS BRASIL, P346
   Bucaretchi Fábio, 2006, Rev. Inst. Med. trop. S. Paulo, V48, P141, DOI 10.1590/S0036-46652006000300005
   Bucaretchi F, 2016, CLIN TOXICOL, V54, P222, DOI 10.3109/15563650.2015.1135337
   Campbell J.A., 2004, VENOMOUS REPTILES W, VI
   Canas CA, 2017, J VENOM ANIM TOXINS, V23, DOI 10.1186/s40409-017-0100-4
   Casais-e-Silva L.L., 2009, GAZ MED BAHIA, V79, P26
   Chen MY, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2007JD009132
   Ciscotto PHC, 2011, J PROTEOMICS, V74, P1810, DOI 10.1016/j.jprot.2011.07.011
   COELHO LK, 1992, HUM EXP TOXICOL, V11, P135, DOI 10.1177/096032719201100213
   Correa-Netto C, 2011, J PROTEOMICS, V74, P1795, DOI 10.1016/j.jprot.2011.04.003
   Cuellar Gordo Leydy Constanza, 2016, Rev. Cienc. Salud, V14, P161, DOI 10.12804/revsalud14.02.2016.02
   Currie BJ, 2006, TOXICON, V48, P941, DOI 10.1016/j.toxicon.2006.07.015
   da Silva AM, 2019, TOXICON, V166, P34, DOI 10.1016/j.toxicon.2019.05.008
   da Silva IM, 2018, TOXICON, V141, P51, DOI 10.1016/j.toxicon.2017.11.012
   Pardal PPD, 2010, REV INST MED TROP SP, V52, P333, DOI 10.1590/S0036-46652010000600009
   de Roodt AR, 2013, REV INST MED TROP SP, V55, P13, DOI 10.1590/S0036-46652013000100003
   Feitosa EL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132237
   Feitosa ES, 2015, REV SOC BRAS MED TRO, V48, P34, DOI 10.1590/0037-8682-0105-2013
   Fiszon Judith Tiomny, 2008, Rev. bras. epidemiol., V11, P114
   Fontana M.D., 1984, MEM I BUTANTAN, V47, P13
   Gutierrez J.M., 2016, COBRAS CORAIS BRASIL, P302
   GUTIERREZ JM, 1992, TOXICON, V30, P1299, DOI 10.1016/0041-0101(92)90446-C
   Gutierrez JM, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.79, 10.1038/nrdp.2017.63]
   Harrison RA, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000569
   Heckmann X, 2017, Bull Soc Pathol Exot, V110, P276, DOI 10.1007/s13149-017-0567-9
   IBGE-Institute Brasileiro de Geografia E Estatistica, 2018, CAR GER POP RES ARN
   JAMIESON R, 1989, MED J AUSTRALIA, V150, P698, DOI 10.5694/j.1326-5377.1989.tb136764.x
   KITCHENS CS, 1987, JAMA-J AM MED ASSOC, V258, P1615, DOI 10.1001/jama.258.12.1615
   Leon G, 2013, TOXICON, V76, P63, DOI 10.1016/j.toxicon.2013.09.010
   Lima JS, 2009, REV SOC BRAS MED TRO, V42, P561, DOI 10.1590/S0037-86822009000500015
   Lomonte B, 2016, TOXICON, V122, P7, DOI 10.1016/j.toxicon.2016.09.008
   Manock SR, 2008, T ROY SOC TROP MED H, V102, P1127, DOI 10.1016/j.trstmh.2008.03.026
   Marques Otavio Augusto Vuolo, 2009, Biota Neotrop., V9, P139, DOI 10.1590/S1676-06032009000200014
   Martins Marcio, 1999, Herpetological Natural History, V6, P78
   Masseli G.S., 2018, HERPETOL REV, V1, P134
   Melgarejo A.R., 2009, ANIMAIS PECONHENTOS, P42
   Mendonca-da-Silva I, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006068
   Moreno E, 2005, REV SOC BRAS MED TRO, V38, P15, DOI 10.1590/S0037-86822005000100004
   Nascimento S P, 2000, Cad Saude Publica, V16, P271
   Norris RL, 2005, WILD ENVIRON MED, V16, P16, DOI 10.1580/PR12-04.1
   Ocampo-Trujillo Bernardo, 2016, Rev. colomb. anestesiol., V44, P161
   Olamendi-Portugal T, 2008, PROTEOMICS, V8, P1919, DOI 10.1002/pmic.200700668
   Oliveira FD, 2017, REV SOC BRAS MED TRO, V50, P365, DOI 10.1590/0037-8682-0408-2016
   Oliveira S.S., 2018, CLIN TOXINOLOGY AUST, V1, P73, DOI DOI 10.1007/978-94-007-6288-6_61-2
   OteroPatine R, 2018, CLIN TOXICOLOGY AUST, V1, P3, DOI DOI 10.1007/978-94-017-7438-3_41
   Pardal PPD, 2004, T ROY SOC TROP MED H, V98, P28, DOI 10.1016/S0035-9203(03)00005-1
   Paula Neto J. B., 2005, J. Venom. Anim. Toxins incl. Trop. Dis, V11, P422, DOI 10.1590/S1678-91992005000400004
   Roriz KRPS, 2018, REV SOC BRAS MED TRO, V51, P338, DOI 10.1590/0037-8682-0489-2017
   Pierini SV, 1996, TOXICON, V34, P225, DOI 10.1016/0041-0101(95)00125-5
   PIFANO C, 1986, MED CRIT VENEZ, V1, P96
   de Roodt AR, 2012, TOXICON, V59, P356, DOI 10.1016/j.toxicon.2011.11.009
   Santos HLR, 2019, ACTA TROP, V191, P69, DOI 10.1016/j.actatropica.2018.12.030
   Rey-Suarez P, 2016, J PROTEOMICS, V136, P262, DOI 10.1016/j.jprot.2016.02.006
   Rey-Suarez P, 2012, TOXICON, V60, P851, DOI 10.1016/j.toxicon.2012.05.023
   Rey-Suarez P, 2011, J PROTEOMICS, V75, P655, DOI 10.1016/j.jprot.2011.09.003
   Risk J.Y., 2016, COBRAS CORAIS BRASIL, P380
   ROZE JA, 1996, CORAL SNAKES AM BIOL
   Santos M.C., 1995, SERPENTES INTERESSE, P64
   Sanz L, 2019, J PROTEOMICS, V200, P90, DOI 10.1016/j.jprot.2019.03.014
   Sanz L, 2016, TOXINS, V8, DOI 10.3390/toxins8060178
   Silva Jr N.J., 2016, COBRAS CORAIS BRASIL, P46
   Silva Jr N.J., 2009, ANIMAIS PECONHENTOS, P116
   SINAN- Sistema Nacional de Agravos de Notificacio, 2015, SINAN SIST NAC AGR N
   Solorzano A., 1998, REV BIOL TROP, V36, P235
   Souza AD, 2018, TOXICON, V145, P15, DOI 10.1016/j.toxicon.2018.02.041
   Strauch MA, 2018, J VENOM ANIM TOXINS, V24, DOI 10.1186/s40409-018-0148-9
   Tanaka GD, 2016, TOXICON, V117, P59, DOI 10.1016/j.toxicon.2016.03.020
   Tanaka GD, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000622
   Terra ALC, 2015, TOXICON, V103, P1, DOI 10.1016/j.toxicon.2015.06.011
   Vital Brazil Oswaldo, 1996, Revista do Instituto de Medicina Tropical de Sao Paulo, V38, P61, DOI 10.1590/S0036-46651996000100012
   Waldez Fabiano, 2009, Acta Amaz., V39, P681, DOI 10.1590/S0044-59672009000300025
   Wen F.H., 2009, ANIMAIS PECONHENTOS, P432
   Wen FH, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003701
   Wood A, 2013, CLIN TOXICOL, V51, P783, DOI 10.3109/15563650.2013.828841
NR 89
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2020
VL 175
BP 7
EP 18
DI 10.1016/j.toxicon.2019.11.011
PG 12
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KR8GN
UT WOS:000517854100002
PM 31785286
DA 2020-05-12
ER

PT J
AU Fortner, GA
   Devlin, JJ
   McGowan, AJ
   Boboc, M
   Natarajan, R
   Zarow, GJ
AF Fortner, Grady A.
   Devlin, John J.
   McGowan, Andrew J.
   Boboc, Michael
   Natarajan, Ramesh
   Zarow, Gregory J.
TI Comparison of thromboelastography versus conventional coagulation tests
   in simulated Crotalus atrox envenomation using human blood
SO TOXICON
LA English
DT Article
DE Snakebite; Rattlesnake; Venom; Thromboelastography; Venom-induced
   consumptive coagulopathy
ID RAPID THROMBELASTOGRAPHY; POINT; COAGULOPATHY; SNAKEBITE; COST;
   TRANSFUSION; HEMOSTASIS; PERSISTENT; MANAGEMENT; RECURRENT
AB Introduction: Pit viper bites are a source of significant morbidity and mortality. Pit viper bites can cause venom-induced consumptive coagulopathy (VICC), typically evaluated with laboratory-based conventional coagulation tests (CCTs). However, CCTs require a laboratory and average 1 h to conduct. Thromboelastography (TEG) provides real-time, point-of-care tests of coagulation that are fast and require no separate laboratory facilities, which could be advantageous in both hospital and austere settings. However, the relative efficacy of TEG versus CCTs was unclear, particularly at low venom concentrations. Therefore, the objectives of this study were to test human blood with various concentrations of pit viper venom using CCTs and TEG to determine dose-dependent changes, lowest observed effect concentration (LOEC), and sensitivity to detecting samples out of normal diagnostic range.
   Methods: Blood samples from 20 volunteers were mixed with varying concentrations of western diamond back rattlesnake (Crotalus atrox) venom based on the mouse LD50(IV) (none, 0.5%, 1%, 2%, 33%, 66%, and 100% LD50(IV)). Samples were split and assessed with both CCTs including prothrombin time (PT), international normalized ratio (INR), partial thromboplastin time (PTT), fibrinogen, and D-dimer, along with TEG measures of reaction time (R), kinetic time (K), rate of clot formation (alpha-angle), and clot strength (MA). Data were analyzed as dose-dependent concentration-based changes in raw values and in percent of samples exceeding diagnostic thresholds using ANOVA and nonparametric statistics at the p < .05 threshold.
   Results: All evaluations showed significant concentration-dependent changes, and 100% of samples exceeded diagnostic thresholds at 33%LD50(IV) and above, save D-dimer. At 0.5%LD50(IV), R, K, alpha-angle, PT, and INR were significantly different from controls, and at 1%LD50(IV), mean values exceeded diagnostic thresholds for R, K, alpha-angle, MA, PT, and INR, but not for PTT, D-dimer, or fibrinogen. At 2%LD50(IV), 100% of samples were out of normal range for K, alpha-angle, and PT.
   Conclusion: TEG is effective in coagulopathy evaluations of in vitro simulated pit viper envenomation. At low venom concentrations, TEG performed as well or better than the majority of CCTs. These findings provide empirical evidence supporting the use of TEG to rapidly and accurately evaluate VICC.
C1 [Fortner, Grady A.; Devlin, John J.; McGowan, Andrew J.; Boboc, Michael; Natarajan, Ramesh; Zarow, Gregory J.] Naval Med Ctr Portsmouth, Combat Trauma Res Grp, Portsmouth, VA USA.
   [Boboc, Michael; Natarajan, Ramesh] GDIT, Fairfax, VA USA.
   [Zarow, Gregory J.] Emergency Statistician, Idyllwild, CA USA.
RP Fortner, GA (reprint author), POB 25578, Barrigada, GU 96921 USA.
EM grady.a.fortner2.mil@mail.mil
CR Alves EC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202361
   Armentano RA, 2014, J VET EMERG CRIT CAR, V24, P144, DOI 10.1111/vec.12139
   Asha SE, 2014, EMERG MED J, V31, P714, DOI 10.1136/emermed-2013-202632
   Bagcchi S, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5313
   Berling I, 2015, TRANSFUS MED REV, V29, P82, DOI 10.1016/j.tmrv.2014.09.005
   Boyer LV, 1999, ARCH INTERN MED, V159, P706, DOI 10.1001/archinte.159.7.706
   Cao DZ, 2018, TOXICON, V151, P29, DOI 10.1016/j.toxicon.2018.06.079
   Cohen J, 2019, TRANSFUSION, V59, P1601, DOI 10.1111/trf.15176
   CONSROE P, 1992, J WILDERNESS MED, V3, P162, DOI 10.1580/0953-9859-3.2.162
   Cotton BA, 2011, J TRAUMA, V71, P407, DOI 10.1097/TA.0b013e31821e1bf0
   Crochemore T, 2017, EINSTEIN-SAO PAULO, V15, P380, DOI [10.1590/S1679-45082017MD3130, 10.1590/s1679-45082017md3130]
   DAMBISYA YM, 1994, TOXICON, V32, P1619, DOI 10.1016/0041-0101(94)90320-4
   de Queiroz MR, 2017, TOXICON, V133, P33, DOI 10.1016/j.toxicon.2017.04.013
   Debono J, 2019, COMP BIOCHEM PHYS C, V225, DOI 10.1016/j.cbpc.2019.108567
   Debono J, 2019, TOXICOL IN VITRO, V58, P195, DOI 10.1016/j.tiv.2019.03.038
   Debono J, 2019, TOXICOL IN VITRO, V55, P62, DOI 10.1016/j.tiv.2018.11.008
   Doran CM, 2010, J TRAUMA, V69, pS40, DOI 10.1097/TA.0b013e3181e4257b
   Florkowski C, 2017, CRIT REV CL LAB SCI, V54, P471, DOI 10.1080/10408363.2017.1399336
   Gilcher R.O., 2011, ROSSIS PRINCIPLES TR, P625, DOI [10.1002/9781444303513, DOI 10.1002/9781444303513]
   Gummin DD, 2018, CLIN TOXICOL, V56, P1213, DOI 10.1080/15563650.2018.1533727
   Habib AG, 2018, TOXICON, V150, P115, DOI 10.1016/j.toxicon.2018.05.009
   Hadley GP, 1999, T ROY SOC TROP MED H, V93, P177, DOI 10.1016/S0035-9203(99)90300-0
   Haemoscope Corporation, 2007, TEG 5000 THROMB US M
   Hawkins Robert C, 2007, Clin Biochem Rev, V28, P179
   Holcomb JB, 2012, ANN SURG, V256, P476, DOI 10.1097/SLA.0b013e3182658180
   Hyatt CE, 2016, TOP COMPANION ANIM M, V31, P11, DOI 10.1053/j.tcam.2016.05.002
   Isbister GK, 2013, QJM-INT J MED, V106, P925, DOI 10.1093/qjmed/hct102
   Isbister GK, 2010, SEMIN THROMB HEMOST, V36, P444, DOI 10.1055/s-0030-1254053
   Kang AM, 2020, J MED TOXICOL, V16, P24, DOI 10.1007/s13181-019-00729-8
   Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218
   Kitchens CS, 2008, J MED TOXICOL, V4, P180, DOI 10.1007/BF03161198
   Larreche S, 2018, BLOOD COAGUL FIBRIN, V29, P196, DOI 10.1097/MBC.0000000000000702
   Lee-Lewandrowski E, 2009, CLIN LAB MED, V29, P479, DOI 10.1016/j.cll.2009.07.001
   Nagel SS, 2014, J VET EMERG CRIT CAR, V24, P662, DOI 10.1111/vec.12236
   Nielsen VG, 2018, BASIC CLIN PHARMACOL, V122, P157, DOI 10.1111/bcpt.12848
   Nystrup KB, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-52
   PANDYA BV, 1984, BIOCHEMISTRY-US, V23, P460, DOI 10.1021/bi00298a010
   Pecoraro V, 2014, CLIN CHEM LAB MED, V52, P313, DOI 10.1515/cclm-2013-0386
   Roeloffzen WWH, 2010, ANESTH ANALG, V110, P987, DOI 10.1213/ANE.0b013e3181d31e91
   Roszko PJD, 2017, CLIN TOXICOL, V55, P229, DOI 10.1080/15563650.2016.1263857
   Seifert SA, 2011, CLIN TOXICOL, V49, P324, DOI 10.3109/15563650.2011.566883
   Slagboom J, 2017, BRIT J HAEMATOL, V177, P947, DOI 10.1111/bjh.14591
   Wada H, 2018, THROMB J, V16, DOI 10.1186/s12959-018-0168-2
   Whiting P, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19580
   Witham WR, 2015, WILD ENVIRON MED, V26, P211, DOI 10.1016/j.wem.2014.11.019
NR 45
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2020
VL 175
BP 19
EP 27
DI 10.1016/j.toxicon.2019.12.001
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KR8GN
UT WOS:000517854100003
PM 31833475
DA 2020-05-12
ER

PT J
AU Ben Salah-Abbes, J
   Belgacem, H
   Ezzdini, K
   Abdel-Wahhab, MA
   Abbes, S
AF Ben Salah-Abbes, Jalila
   Belgacem, Hela
   Ezzdini, Khawla
   Abdel-Wahhab, Mosaad A.
   Abbes, Samir
TI Zearalenone nephrotoxicity: DNA fragmentation, apoptotic gene expression
   and oxidative stress protected by Lactobacillus plantarum MON03
SO TOXICON
LA English
DT Article
DE Lactic acid bacteria; Zearalenone; Oxidative stress; Pro-inflammatory
   cytokines; Apoptotic genes expression; Prevention
ID AFLATOXIN B-1; TOXICITY; LIVER; IMMUNOTOXICITY; OCHRATOXIN; EXPOSURE;
   CLAY; PERFORMANCE; ABILITY; DAMAGE
AB The present study was conducted to determine the abilities of the living Lactobacillus plantation MON03 cells to degrade Zearalenone (ZEN) in liquid medium, and to elucidate the preventive effect in ZEN-contaminated balb/c mice showing kidney damage. The DNA fragmentation, Bcl-2 and Bax gene expression, caspase-3 activity, mRNA level of inflammation-regulating cytokines and histology of kidney tissues were examined. Female Balb/c mice were divided into four groups (10/group) and treated daily for 2 wk by oral gavage with lactic acid bacteria (L. plantarum MON03) 2 x 10(9) CFU/L, similar to 2 mg/kg only, ZEN (40 mg/kg BW) only, ZEN (40 mg/kg BW) + lactic acid bacteria (L. plantarum MON03, 2 x 10(9) CFU/L, similar to 2 mg/kg). Control group received vehicle. At the end of experiment, the kidney was collected for the determination of DNA fragmentation, Bcl-2 and Bax gene expression,caspase-3 activity, Malondialdehyde (MDA), and glutathione peroxidase (GSH-Px) content, as well as for any alterations in expression of total antioxidant activity (TAC) and mRNA levels of inflammation-regulating cytokines (e.g., IL-10, IL-6, TNF-alpha).
   The results indicated that, kidney cells exposure to ZEN led to increased caspase-3 activity, MDA, and IL-10, IL-6, TNF-alpha and Bax mRNA levels, but decreased TAC content and down-regulated expression of GSH-Px and CAT and Bcl-2 mRNA. Co-treatment with ZEN plus LP suppressed the levels of DNA fragmentation; normalized kidney MDA and increased CAT levels, up-regulated expression of GSH-Px and CAT, and normalized mRNA levels of the analyzed cytokines. It's concluded that ZEN might have toxic effects in kidney. Further, it can be seen that use of LP induced protective effects against the oxidative stress and kidney toxicity of ZEN in part through adhesion (and so likely diminished bioavailability).
C1 [Ben Salah-Abbes, Jalila; Belgacem, Hela; Ezzdini, Khawla; Abbes, Samir] Univ Monastir, Lab Genet Biodivers & Bioresources Valorisat, Monastir, Tunisia.
   [Abdel-Wahhab, Mosaad A.] Natl Res Ctr, Food Toxicol & Contaminants Dept, Cairo, Egypt.
   [Abbes, Samir] Univ Jendouba, Higher Inst Biotechnol Beja, Jendouba, Tunisia.
RP Abbes, S (reprint author), Univ Monastir, Lab Genet Biodivers & Bioresources Valorisat, Monastir, Tunisia.
EM samir.abbes@isbb.rnu.tn
FU Tunisian Ministry of Higher Education and Scientific Research
   (Laboratory of Genetic, Biodiversity and Bioresources Valorisation,
   University of Monastir, Monastir, Tunisia); Higher Institute of
   Biotechnology of Beja (Animal Biotechnology Department); National
   Research center, EgyptNational Research Centre (NRC)
FX The work was supported by Tunisian Ministry of Higher Education and
   Scientific Research (Laboratory of Genetic, Biodiversity and
   Bioresources Valorisation, University of Monastir, Monastir, Tunisia),
   the Higher Institute of Biotechnology of Beja (Animal Biotechnology
   Department) and The National Research center, Egypt.
CR Abbes S, 2006, INT IMMUNOPHARMACOL, V6, P1251, DOI 10.1016/j.intimp.2006.03.012
   Abbes S, 2016, J IMMUNOTOXICOL, V13, P46, DOI 10.3109/1547691X.2014.997905
   Abbes S, 2013, IMMUNOPHARM IMMUNOT, V35, P341, DOI 10.3109/08923973.2013.772194
   Abbes S, 2012, IMMUNOPHARM IMMUNOT, V34, P944, DOI 10.3109/08923973.2012.674139
   Ali-Vehmas T., 2010, TRANSBOUND EMERA DIS, V45, P453
   Alshannaq A., 2017, INT J ENVIRON RES, V13, P14
   Belgacem H, 2019, MUTAT RES-GEN TOX EN, V840, P11, DOI 10.1016/j.mrgentox.2018.12.008
   Ben Salah-Abbes J, 2009, MUTAT RES-GEN TOX EN, V677, P59, DOI 10.1016/j.mrgentox.2009.05.017
   Ben Salah-Abbes J, 2009, TOXICON, V53, P525, DOI 10.1016/j.toxicon.2009.01.013
   Ben Salah-Abbes J, 2008, J PHARM PHARMACOL, V60, P761, DOI 10.1211/jpp.60.6.0012
   Ben Salem I, 2015, ENVIRON SCI POLLUT R, V22, P19069, DOI 10.1007/s11356-015-5086-2
   Bol EK, 2016, FOOD CHEM TOXICOL, V89, P85, DOI 10.1016/j.fct.2016.01.013
   Carninci P, 2000, GENOME RES, V10, P1617, DOI 10.1101/gr.145100
   Chen FL, 2015, INT J MOL SCI, V16, P19780, DOI 10.3390/ijms160819780
   Corrin B., 1981, J CLIN PATHOL, V520
   Delattre J., 2007, RADICAUX LIB STRESS
   Denli M, 2015, J ANIM SCI, V93, P637, DOI 10.2527/jas.2014-7356
   Edwards SG, 2017, FOOD ADDIT CONTAM A, V34, P2230, DOI 10.1080/19440049.2017.1372639
   El-Sawi N. M., 2012, The Journal of American Science, V8, P378
   Ghali R, 2008, FOOD CONTROL, V19, P921, DOI 10.1016/j.foodcont.2007.09.003
   Gibb RK, 1997, GYNECOL ONCOL, V65, P13, DOI 10.1006/gyno.1997.4637
   Hamed AM, 2017, FOOD ADDIT CONTAM A, V34, P2033, DOI 10.1080/19440049.2017.1368722
   Ismail T.A., 2014, AM J PHARM TOXICOL, V9, P29
   Jebali R, 2015, J IMMUNOTOXICOL, V12, P290, DOI 10.3109/1547691X.2014.973622
   Kabak B, 2006, CRIT REV FOOD SCI, V46, P593, DOI 10.1080/10408390500436185
   Koraichi F, 2012, TOXICOL LETT, V211, P246, DOI 10.1016/j.toxlet.2012.04.001
   Krol A, 2018, ANAL BIOANAL CHEM, V410, P943, DOI 10.1007/s00216-017-0555-8
   Lee A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182220
   Lin CC, 1998, J PHARM PHARMACOL, V50, P789, DOI 10.1111/j.2042-7158.1998.tb07141.x
   Liu WF, 2002, J BIOL CHEM, V277, P8273, DOI 10.1074/jbc.M110768200
   Mary VS, 2012, TOXICOLOGY, V302, P299, DOI 10.1016/j.tox.2012.08.012
   Raben N, 1996, HUM MOL GENET, V5, P995, DOI 10.1093/hmg/5.7.995
   Raju MVLN, 2000, BRIT POULTRY SCI, V41, P640, DOI 10.1080/713654986
   Ricardo S.D., 2008, J CLIN INVESTIG
   Schoemaker MH, 2002, J HEPATOL, V36, P742, DOI 10.1016/S0168-8278(02)00063-6
   Shetty PH, 2007, INT J FOOD MICROBIOL, V113, P41, DOI 10.1016/j.ijfoodmicro.2006.07.013
   Smith M.C., 2016, TOXINS BASEL
   Soliman MM, 2015, INT J IMMUNOPATH PH, V28, P508, DOI 10.1177/0394632015575950
   Styriak I, 2001, Mycotoxin Res, V17 Suppl 1, P24, DOI 10.1007/BF03036705
   Tatay E, 2018, TOXICOL MECH METHOD, V28, P239, DOI 10.1080/15376516.2017.1395501
   Tinyiro SE, 2011, FOLIA MICROBIOL, V56, P321, DOI 10.1007/s12223-011-0047-8
   Umekawa T, 2004, J AM SOC NEPHROL, V15, P635, DOI 10.1097/01.ASN.0000113321.49771.2D
   van der Hoeven JAB, 2003, TRANSPLANTATION, V76, P1150, DOI 10.1097/01.TP.0000080983.14161.95
   WALLER RA, 1969, J AM STAT ASSOC, V64, P1484, DOI 10.2307/2286085
   Wang N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32006-z
   Wiame I, 2000, BIOTECHNIQUES, V29, P252, DOI 10.2144/00292bm11
   Zinedine A, 2007, FOOD CHEM TOXICOL, V45, P1, DOI 10.1016/j.fct.2006.07.030
NR 47
TC 1
Z9 1
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2020
VL 175
BP 28
EP 35
DI 10.1016/j.toxicon.2019.12.004
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KR8GN
UT WOS:000517854100004
PM 31830485
DA 2020-05-12
ER

PT J
AU Li, XD
   Brunner, C
   Wu, YF
   Leka, O
   Schneider, G
   Kammerer, RA
AF Li, Xiaodan
   Brunner, Cyrill
   Wu, Yufan
   Leka, Oneda
   Schneider, Gisbert
   Kammerer, Richard A.
TI Structural insights into the interaction of botulinum neurotoxin a with
   its neuronal receptor SV2C
SO TOXICON
LA English
DT Article
DE Botulinum neurotoxin; Synaptic vesicle glycoprotein 2; Protein receptor;
   Crystal structure; Surface plasmon resonance; Mutagenesis; Biophysics;
   Plasticity; Protein-protein interactions; Protein-carbohydrate
   interactions
ID CRYSTAL-STRUCTURE; PROTEIN-RECEPTOR; BACILLUS-THURINGIENSIS;
   SYNAPTOTAGMIN-I; TOXIN; BINDING; IDENTIFICATION; BLOCKADE; DOMAIN
AB A dual-receptor interaction with a polysialoganglioside and synaptic vesicle glycoprotein 2 (SV2) is required for botulinum neurotoxin A (BoNT) toxicity. Here, we review what is currently known about the BoNT/A-SV2 interaction based on structural studies. Currently, five crystal structures of the receptor-binding domain (Hc) of BoNT subtypes A1 and A2 complexed to the large luminal domain (LD4) of SV2C have been determined. On the basis of the available structures, we will discuss the importance of protein-protein and protein-carbohydrate interactions for BoNT/A toxicity as well as the high plasticity of BoNT/A for receptor recognition by tolerating a variety of side-chain interactions at the interface. A plausible explanation how receptor-binding specificity of BoNT/A may be achieved without an extensive and conserved side chain-side chain interaction network will be provided.
C1 [Li, Xiaodan; Wu, Yufan; Leka, Oneda; Kammerer, Richard A.] Paul Scherrer Inst, Div Biol & Chem, Lab Biomol Res, CH-5232 Villigen, Switzerland.
   [Brunner, Cyrill; Schneider, Gisbert] Swiss Fed Inst Technol, Dept Chem & Appl Biosci, RETHINK, Vladimir Prelog Weg 4, CH-8093 Zurich, Switzerland.
RP Kammerer, RA (reprint author), Paul Scherrer Inst, Div Biol & Chem, Lab Biomol Res, CH-5232 Villigen, Switzerland.
EM richard.kammerer@psi.ch
OI Kammerer, Richard/0000-0003-4570-5197; li, xiaodan/0000-0001-8647-7317;
   Schneider, Gisbert/0000-0001-6706-1084
FU Swiss National Science FoundationSwiss National Science Foundation
   (SNSF) [31003A_163449, 31003A_170028]
FX This work was supported by grants 31003A_163449 and 31003A_170028 of the
   Swiss National Science Foundation to R.A.K. and X.L., respectively.
CR Bartholome O, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00148
   Benoit RM, 2017, SCI REP-UK, V7, DOI 10.1038/srep43588
   Benoit RM, 2015, TOXICON, V107, P25, DOI 10.1016/j.toxicon.2015.08.002
   Benoit RM, 2014, NATURE, V505, P108, DOI 10.1038/nature12732
   Berntsson RPA, 2013, STRUCTURE, V21, P1602, DOI 10.1016/j.str.2013.06.026
   Binz T, 2013, CURR TOP MICROBIOL, V364, P139, DOI 10.1007/978-3-642-33570-9_7
   Chai Q, 2006, NATURE, V444, P1096, DOI 10.1038/nature05411
   Colasante C, 2013, MOL NEUROBIOL, V48, P120, DOI 10.1007/s12035-013-8423-9
   Contreras E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10732-w
   Dong M, 2006, SCIENCE, V312, P592, DOI 10.1126/science.1123654
   Dong M, 2019, ANNU REV BIOCHEM, V88, P811, DOI 10.1146/annurev-biochem-013118-111654
   Dong M, 2008, MOL BIOL CELL, V19, P5226, DOI 10.1091/mbc.E08-07-0765
   Dressler D, 2012, CURR OPIN MICROBIOL, V15, P325, DOI 10.1016/j.mib.2012.05.012
   Evidente VGH, 2010, CURR NEUROL NEUROSCI, V10, P338, DOI 10.1007/s11910-010-0129-z
   Fischer A, 2012, J BIOL CHEM, V287, P1657, DOI 10.1074/jbc.C111.319400
   Fotinou C, 2001, J BIOL CHEM, V276, P32274, DOI 10.1074/jbc.M103285200
   Fu ZJ, 2009, BIOCHEMISTRY-US, V48, P5631, DOI 10.1021/bi9002138
   Gardner AP, 2018, TOXINS, V10, DOI 10.3390/toxins10070268
   GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630
   Gustafsson R, 2018, TOXINS, V10, DOI 10.3390/toxins10040153
   Hill KK, 2007, J BACTERIOL, V189, P818, DOI 10.1128/JB.01180-06
   Jin RS, 2006, NATURE, V444, P1092, DOI 10.1038/nature05387
   Johnson E.A., 2008, BOTULISM HDB CLIN NE, V91, P333
   Kammerer RA, 2014, TRENDS BIOCHEM SCI, V39, P517, DOI 10.1016/j.tibs.2014.08.009
   Kroken AR, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00795-16
   Kumaran D, 2009, J MOL BIOL, V386, P233, DOI 10.1016/j.jmb.2008.12.027
   Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338
   LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0
   Mahrhold S, 2013, BIOCHEM J, V453, P37, DOI 10.1042/BJ20130391
   Mansfield MJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37647-8
   Montal M, 2010, ANNU REV BIOCHEM, V79, P591, DOI 10.1146/annurev.biochem.051908.125345
   Montecucco C, 2004, TRENDS MICROBIOL, V12, P442, DOI 10.1016/j.tim.2004.08.002
   Pantano S, 2014, CELL MOL LIFE SCI, V71, P793, DOI 10.1007/s00018-013-1380-7
   Peck MW, 2017, TOXINS, V9, DOI 10.3390/toxins9010038
   Pellete S, 2015, TOXICON, V107, P37, DOI 10.1016/j.toxicon.2015.06.021
   Peng LS, 2012, J CELL SCI, V125, P3233, DOI 10.1242/jcs.103564
   Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5591, DOI 10.1073/pnas.042681399
   Pier CL, 2011, FEBS LETT, V585, P199, DOI 10.1016/j.febslet.2010.11.045
   Pirazzini M, 2017, PHARMACOL REV, V69, P200, DOI 10.1124/pr.116.012658
   Rossetto O, 2014, NAT REV MICROBIOL, V12, P535, DOI 10.1038/nrmicro3295
   Rummel A, 2004, J BIOL CHEM, V279, P30865, DOI 10.1074/jbc.M403945200
   Schmitt J, 2010, BIOCHEMISTRY-US, V49, P5200, DOI 10.1021/bi100412v
   Swaminathan S, 2000, NAT STRUCT BIOL, V7, P693, DOI 10.1038/78005
   TAHIROV TH, 1995, J MOL BIOL, V250, P354, DOI 10.1006/jmbi.1995.0382
   Takamori S, 2006, CELL, V127, P831, DOI 10.1016/j.cell.2006.10.030
   Torii Y, 2011, TOXICON, V57, P93, DOI 10.1016/j.toxicon.2010.10.009
   Whitemarsh RCM, 2013, INFECT IMMUN, V81, P3894, DOI 10.1128/IAI.00536-13
   Yao GR, 2016, NAT STRUCT MOL BIOL, V23, P656, DOI 10.1038/nsmb.3245
   Yeh FL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001207
   Zhang N, 2015, J NEUROSCI, V35, P2492, DOI 10.1523/JNEUROSCI.4248-14.2015
   Zhang SC, 2018, CELL HOST MICROBE, V23, P169, DOI 10.1016/j.chom.2017.12.018
   Zhang SC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14130
   Zornetta I, 2016, SCI REP-UK, V6, DOI 10.1038/srep30257
NR 53
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2020
VL 175
BP 36
EP 43
DI 10.1016/j.toxicon.2019.11.010
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KR8GN
UT WOS:000517854100005
PM 31783045
OA Bronze
DA 2020-05-12
ER

PT J
AU Lu, N
   Ling, L
   Guan, T
   Wang, LT
   Wang, D
   Zhou, JH
   Ruan, T
   Shen, X
   Li, XM
   Sun, YM
   Lei, HT
AF Lu, Ning
   Ling, Li
   Guan, Tian
   Wang, Lanteng
   Wang, Dian
   Zhou, Jiahui
   Ruan, Ting
   Shen, Xing
   Li, Xiangmei
   Sun, Yuanming
   Lei, Hongtao
TI Broad-specificity ELISA with a heterogeneous strategy for sensitive
   detection of microcystins and nodularin
SO TOXICON
LA English
DT Article
DE Microcystin-LR; ELISA; Heterogeneous coating; Broad-specificity
ID ON PHOTOELECTROCHEMICAL IMMUNOASSAY; LINKED-IMMUNOSORBENT-ASSAY;
   SOLID-PHASE DISPERSION; NATURAL BLOOMS; LR; CYANOBACTERIA; VALIDATION;
   LAKE; IMMUNOSENSORS; DIAGNOSIS
AB A highly sensitive and broadly specific competitive indirect enzyme-linked immunosorbent assay (ciELISA) method was developed for the simultaneous detection of nine microcystins (MCs) and nodularin (NOD) using MC-LR-keyhole limpet hemocyanin (KLH) for New Zealand white rabbit immunization to produce antibodies. The MC-LR-bovine serum albumin (BSA) and NOD-BSA coating antigens were compared and heterogeneous coating strategy was found to significantly improve the sensitivity of detection, as evident from the appropriate structure. Comparison of the half-maximum inhibitory concentration (IC50) with MC-LR and MC-LR-BSA coating techniques (0.29 ng/mL) revealed the superior performance of 0.054 ng/mL for NOD-BSA coating. NOD-BSA was selected as the coating antigen, because it showed ultrahigh sensitivity for the detection of MC-LR with a limit of detection (LOD) of 0.0016 ng/mL, which was below the maximum residue level (MRL) of 1 ng/mL. In addition, high reproducibility, good stability, and acceptable spiked sample detection, as validated by liquid chromatography tandem mass spectrometry (LC-MS/MS), indicated the possible application of this method for the analysis of MCs and NOD in water sample.
C1 [Lu, Ning; Ling, Li; Guan, Tian; Wang, Lanteng; Wang, Dian; Zhou, Jiahui; Ruan, Ting; Shen, Xing; Li, Xiangmei; Sun, Yuanming; Lei, Hongtao] South China Agr Univ, Coll Food Sci, Key Lab Food Qual & Safety Guangdong Prov, Guangzhou 510642, Peoples R China.
RP Lei, HT (reprint author), South China Agr Univ, Coll Food Sci, Key Lab Food Qual & Safety Guangdong Prov, Guangzhou 510642, Peoples R China.
EM hongtao@scau.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31871883, 31701703, 31601555, 71633002]; Science
   and Technology Planning Project of Guangdong Province and Guangzhou
   [2017B020207010, 201803020026, 201807010109]
FX This work was supported by the National Natural Science Foundation of
   China (31871883, 31701703, 31601555, 71633002), Science and Technology
   Planning Project of Guangdong Province and Guangzhou (2017B020207010,
   201803020026, 201807010109).
CR Aguete EC, 2001, CHROMATOGRAPHIA, V53, pS254, DOI 10.1007/BF02490338
   Akter S, 2016, ANAL CHEM, V88, P10080, DOI 10.1021/acs.analchem.6b02470
   Baldia SF, 2003, FISHERIES SCI, V69, P110, DOI 10.1046/j.1444-2906.2003.00594.x
   Bury NR, 1996, J EXP BIOL, V199, P1319
   Bury NR, 1997, J FISH DIS, V20, P209, DOI 10.1046/j.1365-2761.1997.00292.x
   Camean A, 2005, J ANAL APPL PYROL, V74, P19, DOI 10.1016/j.jaap.2004.09.007
   Camean A, 2004, ANAL BIOANAL CHEM, V380, P537, DOI 10.1007/s00216-004-2755-2
   Campas M, 2007, BIOSENS BIOELECTRON, V22, P1034, DOI 10.1016/j.bios.2006.04.025
   Chen JH, 2016, J AGR FOOD CHEM, V64, P2772, DOI 10.1021/acs.jafc.6b00039
   Chen K, 2012, ENVIRON SCI TECHNOL, V46, P11955, DOI 10.1021/es302327w
   Devlin S, 2014, TALANTA, V122, P8, DOI 10.1016/j.talanta.2013.12.065
   Fastner J, 1999, ARCH HYDROBIOL, V145, P147
   Fu XW, 2013, J NANOSCI NANOTECHNO, V13, P8245, DOI 10.1166/jnn.2013.7936
   Guan M, 2004, CLIN DIAGN LAB IMMUN, V11, P699, DOI 10.1128/CDLI.11.4.699-703.2004
   Han SM, 2007, ANAL CHIM ACTA, V587, P1, DOI 10.1016/j.aca.2007.01.028
   Hu CL, 2009, TALANTA, V80, P407, DOI 10.1016/j.talanta.2009.06.044
   Jia JM, 2014, SCI TOTAL ENVIRON, V487, P224, DOI 10.1016/j.scitotenv.2014.04.037
   Kaloudis T, 2013, J HAZARD MATER, V263, P105, DOI 10.1016/j.jhazmat.2013.07.036
   Kim IS, 2015, J IND ENG CHEM, V29, P375, DOI 10.1016/j.jiec.2015.04.018
   Lin YX, 2017, ANAL CHEM, V89, P5637, DOI 10.1021/acs.analchem.7b00942
   Lin YX, 2016, ANAL CHEM, V88, P7858, DOI 10.1021/acs.analchem.6b02124
   Ling JJ, 2019, BIOSENS BIOELECTRON, V127, P167, DOI 10.1016/j.bios.2018.12.012
   Luo ZB, 2018, ANAL CHEM, V90, P9568, DOI 10.1021/acs.analchem.8b02421
   Moreno IM, 2011, ENVIRON TOXICOL, V26, P45, DOI 10.1002/tox.20528
   Masango M, 2008, WATER RES, V42, P3241, DOI 10.1016/j.watres.2007.10.033
   Metcalf JS, 2002, J WATER SUPPLY RES T, V51, P145
   Oh HM, 2000, APPL ENVIRON MICROB, V66, P176, DOI 10.1128/AEM.66.1.176-179.2000
   Oplatowska M, 2011, ANAL CHIM ACTA, V698, P51, DOI 10.1016/j.aca.2011.04.047
   Pei XM, 2013, ANAL CHIM ACTA, V758, P1, DOI 10.1016/j.aca.2012.10.060
   Pestana CJ, 2014, J CHROMATOGR B, V965, P61, DOI 10.1016/j.jchromb.2014.06.012
   Poon KF, 2001, ENVIRON TOXICOL CHEM, V20, P1648, DOI [10.1897/1551-5028(2001)020&lt;1648:DOMICB&gt;2.0.CO;2, 10.1002/etc.5620200805]
   Roche PW, 1999, INT J LEPROSY, V67, P279
   Rodriguez EM, 2008, WATER RES, V42, P1744, DOI 10.1016/j.watres.2007.10.039
   Ruiz MJ, 2005, J CHROMATOGR A, V1073, P257, DOI 10.1016/j.chroma.2004.08.128
   Ruvieri Valter, 2004, Revista do Instituto Adolfo Lutz, V63, P220
   Thanh SD, 2010, NOVA HEDWIGIA, V90, P433, DOI 10.1127/0029-5035/2010/0090-0433
   Tsutsumi T, 2000, FOOD CHEM TOXICOL, V38, P593, DOI 10.1016/S0278-6915(00)00044-2
   WHO (World Health Organization), 1996, GUID DRINK WAT QUAL, V2
   Yang XC, 2017, SECUR COMMUN NETW, P1, DOI 10.1155/2017/5084636
   Zastepa A, 2017, LAKE RESERV MANAGE, V33, P433, DOI 10.1080/10402381.2017.1384415
   Zeck A, 2001, ANAL CHIM ACTA, V441, P1, DOI 10.1016/S0003-2670(01)01092-3
   Zhang HJ, 2013, AQUAT TOXICOL, V140, P11, DOI 10.1016/j.aquatox.2013.05.009
NR 42
TC 0
Z9 0
U1 7
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2020
VL 175
BP 44
EP 48
DI 10.1016/j.toxicon.2019.12.003
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KR8GN
UT WOS:000517854100006
PM 32056695
DA 2020-05-12
ER

PT J
AU Sousa, ML
   Ribeiro, T
   Vasconcelos, V
   Linder, S
   Urbatzka, R
AF Sousa, Maria Ligia
   Ribeiro, Tiago
   Vasconcelos, Vitor
   Linder, Stig
   Urbatzka, Ralph
TI Portoamides A and B are mitochondrial toxins and induce cytotoxicity on
   the proliferative cell layer of in vitro microtumours
SO TOXICON
LA English
DT Article
DE Cyanobacteria; Natural compounds; Mitochondria; Spheroid
ID INDUCED APOPTOSIS; BRENTUXIMAB VEDOTIN; DOLASTATIN 10; CANCER-CELLS;
   MARINE; CYANOBACTERIA; MECHANISMS; ANALOG
AB Cyanobacteria are known to produce many toxins and other secondary metabolites. The study of their specific mode of action may reveal the biotechnological potential of such compounds. Portoamides A and B (PAB) are cyclic peptides isolated from the cyanobacteria Phormidium sp. due to their growth repression effect on microalgae and were shown to be cytotoxic against certain cancer cell lines. In the present work, viability was assessed on HCT116 colon cancer cells grown as monolayer culture and as multicellular spheroids (MTS), non-carcinogenic cells and on zebrafish larvae. HCT116 cells and epithelial RPE-1(hTERT) cells showed very similar degrees of sensitivities to PAB. PAB were able to penetrate the MTS, showing a four-fold high IC50 compared to monolayer cultures. The toxicity of PAB was similar at 4 degrees C and 37 degrees C suggesting energy-independent uptake. PAB exposure decreased ATP production, mitochondrial maximal respiration rates and induced mitochondrial membrane hyperpolarization. PAB induced general organelle stress response, indicated by an increase of the mitochondrial damage sensor PINK-1, and of phosphorylation of eIF2 alpha, characteristic for endoplasmic reticulum stress. In summary, these findings show general toxicity of PAB on immortalized cells, cancer cells and zebrafish embryos, likely due to mitochondrial toxicity.
C1 [Sousa, Maria Ligia; Ribeiro, Tiago; Vasconcelos, Vitor; Urbatzka, Ralph] Interdisciplinary Ctr Marine & Environm Res, CIIMAR, Porto, Portugal.
   [Sousa, Maria Ligia; Ribeiro, Tiago; Vasconcelos, Vitor] Univ Porto, FCUP Fac Sci, Porto, Portugal.
   [Linder, Stig] Karolinska Inst, Canc Ctr Karolinska, Dept Oncol & Pathol, Stockholm, Sweden.
   [Linder, Stig] Linkoping Univ, Dept Med & Hlth Sci, Linkoping, Sweden.
RP Urbatzka, R (reprint author), Interdisciplinary Ctr Marine & Environm Res, CIIMAR, Porto, Portugal.
EM rurbatzka@ciimar.up.pt
RI ; Urbatzka, Ralph/G-8907-2013
OI Ribeiro, Tiago/0000-0002-2457-8339; Urbatzka, Ralph/0000-0001-7476-9195;
   Sousa, Maria Ligia/0000-0003-0012-7493
FU project CYANCAN - Uncovering the cyanobacterial chemical diversity: the
   search for novel anticancer compounds [PTDC/MEDQUI/30944/2017]; NORTE
   2020; Portugal 2020; European Union through the ERDFEuropean Union (EU);
   Foundation for Science and Technology [UID/Multi/04423/2019];
   FCTPortuguese Foundation for Science and Technology
   [SFRH/BPD/112287/2015, SFRH/BD/108314/2015]; CancerfondenSwedish Cancer
   Society; VetenskapsradetSwedish Research Council; Radiumhemmets
   forskningsfonder; Knut och Alice Wallenbergs stiftelseKnut & Alice
   Wallenberg Foundation;  [SFRH/BD/139131/2018]
FX This research was supported the project CYANCAN - Uncovering the
   cyanobacterial chemical diversity: the search for novel anticancer
   compounds (reference PTDC/MEDQUI/30944/2017) co-financed by NORTE 2020,
   Portugal 2020 and the European Union through the ERDF, and by Foundation
   for Science and Technology through national funds and strategic fund
   UID/Multi/04423/2019. Ralph Urbatzka was supported by the FCT postdoc
   grant SFRH/BPD/112287/2015, Maria Ligia Sousa by the FCT PhD grant
   SFRH/BD/108314/2015 and Tiago Ribeiro by SFRH/BD/139131/2018. SL was
   supported by Cancerfonden, Vetenskapsradet, Radiumhemmets
   forskningsfonder and Knut och Alice Wallenbergs stiftelse.
CR Antunes J, 2019, MAR DRUGS, V17, DOI 10.3390/md17020111
   Ashkenazi A, 2008, NAT REV DRUG DISCOV, V7, P1001, DOI 10.1038/nrd2637
   Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100
   Chari RVJ, 2014, ANGEW CHEM INT EDIT, V53, P3796, DOI 10.1002/anie.201307628
   D'Arcy P, 2011, NAT MED, V17, P1636, DOI 10.1038/nm.2536
   Dahms HU, 2006, BIOFOULING, V22, P317, DOI 10.1080/08927010600967261
   de Claro RA, 2012, CLIN CANCER RES, V18, P5845, DOI 10.1158/1078-0432.CCR-12-1803
   Freitas S, 2016, MAR DRUGS, V14, DOI 10.3390/md14090158
   Freitas S, 2016, TOXICON, V119, P140, DOI 10.1016/j.toxicon.2016.05.016
   Friedrich J, 2007, J BIOMOL SCREEN, V12, P925, DOI 10.1177/1087057107306839
   GERWICK WH, 1994, J ORG CHEM, V59, P1243, DOI 10.1021/jo00085a006
   GOLAKOTI T, 1995, J AM CHEM SOC, V117, P12030, DOI 10.1021/ja00154a002
   HAMMES WP, 1974, ANTIMICROB AGENTS CH, V6, P722, DOI 10.1128/AAC.6.6.722
   Harrigan GG, 1998, J NAT PROD, V61, P1075, DOI 10.1021/np980321c
   He H, 2015, SCI REP-UK, V5, DOI 10.1038/srep13543
   Herrmann R, 2008, J BIOMOL SCREEN, V13, P1, DOI 10.1177/1087057107310442
   Katz J, 2011, CLIN CANCER RES, V17, P6428, DOI 10.1158/1078-0432.CCR-11-0488
   Khaled AR, 2001, J BIOL CHEM, V276, P6453, DOI 10.1074/jbc.M006391200
   KOBAYASHI M, 1994, TETRAHEDRON LETT, V35, P7969, DOI 10.1016/S0040-4039(00)78398-5
   Kondejewski LH, 1996, INT J PEPT PROT RES, V47, P460
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Leao PN, 2010, P NATL ACAD SCI USA, V107, P11183, DOI 10.1073/pnas.0914343107
   Leao PN, 2009, EUR J PHYCOL, V44, P347, DOI 10.1080/09670260802652156
   Li JZ, 2006, J BIOL CHEM, V281, P7260, DOI 10.1074/jbc.M509868200
   Luesch H, 2001, J NAT PROD, V64, P907, DOI 10.1021/np010049y
   Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893
   Mittapalli RK, 2019, J CLIN PHARMACOL, V59, P1225, DOI 10.1002/jcph.1418
   Mootz HD, 1997, J BACTERIOL, V179, P6843, DOI 10.1128/jb.179.21.6843-6850.1997
   Morrison K, 2016, MOL CANCER THER, V15, P1301, DOI 10.1158/1535-7163.MCT-15-0570
   Morschhauser F, 2019, LANCET HAEMATOL, V6, pE254, DOI 10.1016/S2352-3026(19)30026-2
   Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298
   Newman DJ, 2017, MAR DRUGS, V15, DOI 10.3390/md15040099
   Nunnari J, 2012, CELL, V148, P1145, DOI 10.1016/j.cell.2012.02.035
   PAGE EH, 1986, J AM ACAD DERMATOL, V14, P785, DOI 10.1016/S0190-9622(86)70094-7
   Pereira AR, 2012, CHEMBIOCHEM, V13, P810, DOI 10.1002/cbic.201200007
   Perry SW, 2011, BIOTECHNIQUES, V50, P98, DOI 10.2144/000113610
   Pitaval A, 2010, J CELL BIOL, V191, P303, DOI 10.1083/jcb.201004003
   Ribeiro D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187665
   Salvador-Reyes LA, 2015, NAT PROD REP, V32, P478, DOI 10.1039/c4np00104d
   Sanchez-Alcazar JA, 2000, CELL DEATH DIFFER, V7, P1090, DOI 10.1038/sj.cdd.4400740
   Scarlett JL, 2000, FEBS LETT, V475, P267, DOI 10.1016/S0014-5793(00)01681-1
   SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290
   Tan LT, 2013, DRUG DISCOV TODAY, V18, P863, DOI 10.1016/j.drudis.2013.05.010
   Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124
   Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365
   Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107
   Weiswald LB, 2015, NEOPLASIA, V17, P1, DOI 10.1016/j.neo.2014.12.004
   Wijffels RH, 2013, CURR OPIN BIOTECH, V24, P405, DOI 10.1016/j.copbio.2013.04.004
NR 48
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2020
VL 175
BP 49
EP 56
DI 10.1016/j.toxicon.2019.12.159
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KR8GN
UT WOS:000517854100007
PM 31887317
DA 2020-05-12
ER

PT J
AU Killi, N
   Bonello, G
   Mariottini, GL
   Pardini, P
   Pozzolini, M
   Cengiz, S
AF Killi, Nurcin
   Bonello, Guido
   Mariottini, Gian Luigi
   Pardini, Patrizia
   Pozzolini, Marina
   Cengiz, Sibel
TI Nematocyst types and venom effects of Aurelia aurita and Velella velella
   from the Mediterranean Sea
SO TOXICON
LA English
DT Article
DE Cnidaria; Jellyfish; Venom; Nematocysts; Morphology; Cytotoxicity
ID NOCTILUCA FORSKAL CNIDARIA; JELLYFISH ENVENOMATION; TOXINS; PROTEINS;
   CYANEA
AB Natural substances produced by venomous marine organisms are thought to be possible sources of useful compounds and new drugs having the potential to open new ways for pharmacology, nutrition and environmental applications. In this framework, cnidarians are very interesting being widely distributed and all are venomous organisms; so, a deep knowledge of their occurrence, morphology of venomous structures and of effects of venoms at cellular level is fundamental to evaluate the possible utilization of venomous compounds or extracts. In this research, the morphology and occurrence of nematocysts in two cnidarian species (Aurelia aurita, Velella velella), and the preliminary evaluation of the cytotoxicity of V. velella crude extract, of which cytotoxicity on cell cultures at present is unknown, were considered. The specimens were sampled in Gulluk Bay, South-western coast of Turkey, and in the Gulf of Genova, Northwestern coast of Italy. Six nematocyst types (a-isorhiza, A-isorhiza, o-isorhiza, eurytele, polyspiras, birhopaloid) having different sizes, were observed in A. aurita, and two types (eurytele and stenotele) in V. velella. The crude extract from V. velella showed cytotoxic activity against cultured fibroblasts L929 at high doses, while inducing cell proliferation at low doses. The protein content in the extract increased remarkably after disruption of nematocysts.
C1 [Killi, Nurcin; Cengiz, Sibel] Mugla Sitki Kocman Univ, Fac Fisheries, Dept Basic Sci, TR-48000 Mugla, Turkey.
   [Bonello, Guido; Mariottini, Gian Luigi; Pardini, Patrizia; Pozzolini, Marina] Univ Genoa, Dept Earth Environm & Life Sci, I-16132 Genoa, Italy.
RP Mariottini, GL (reprint author), Univ Genoa, Dept Earth Environm & Life Sci, I-16132 Genoa, Italy.
EM Gian.Luigi.Mariottini@unige.it
FU Scientific Research Projects Office of Mugla Sstlu Korman University
   [17/114]
FX A part of this study was created from MSc thesis of Sibel Cengiz
   (Supervisor: Nurcin Killi) and supported by Scientific Research Projects
   Office of Mugla Sstlu Korman University with the Research Project No.
   17/114.
CR Allavena A, 1998, TOXICON, V36, P933, DOI 10.1016/S0041-0101(97)00171-2
   Andreev YA, 2012, TOXICON, V60, P109, DOI 10.1016/j.toxicon.2012.04.029
   Bayazit V, 2004, SAUDI MED J, V25, P156
   BENMEIR P, 1990, BURNS, V16, P471, DOI 10.1016/0305-4179(90)90080-G
   Benoit Evelyne, 1998, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V192, P409
   BERESS L, 1975, TOXICON, V13, P359, DOI 10.1016/0041-0101(75)90196-8
   Boero F., 2013, REV JELLYFISH BLOOMS, P92
   Bonello G., 2017, JELLYFISH ECOLOGY DI, P219
   BORENFREUND E, 1988, TOXICOL IN VITRO, V2, P1, DOI 10.1016/0887-2333(88)90030-6
   Bosmans F, 2007, TOXICON, V49, P550, DOI 10.1016/j.toxicon.2006.11.029
   Brinkman DL, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1568-3
   Brinkman DL, 2014, J BIOL CHEM, V289, P4798, DOI 10.1074/jbc.M113.534149
   Brinkman DL, 2009, TOXICON, V54, P1162, DOI 10.1016/j.toxicon.2009.02.006
   Burnett J.W., 1991, JELLYFISH BLOOMS MED, P227
   Burnett JW, 2009, TOXICON, V54, P1201, DOI 10.1016/j.toxicon.2009.02.020
   BURNETT JW, 1988, TOXICON, V26, P215, DOI 10.1016/0041-0101(88)90174-2
   Burnett JW, 2001, HYDROBIOLOGIA, V451, P1, DOI 10.1023/A:1011883019506
   CALDER DR, 1971, T AM MICROSC SOC, V90, P269, DOI 10.2307/3225186
   Cengiz S., 2019, THESIS, V2019, P58
   Chen WF, 2012, N-S ARCH PHARMACOL, V385, P265, DOI 10.1007/s00210-011-0710-2
   Condon RH, 2013, P NATL ACAD SCI USA, V110, P1000, DOI 10.1073/pnas.1210920110
   CUSHING DH, 1990, ADV MAR BIOL, V26, P249, DOI 10.1016/S0065-2881(08)60202-3
   Diochot S, 2007, TOXICON, V49, P271, DOI 10.1016/j.toxicon.2006.09.026
   Diochot S, 2003, MOL PHARMACOL, V64, P59, DOI 10.1124/mol.64.1.59
   Endean R., 1981, P46
   Fenner PJ, 1998, J TRAVEL MED, V5, P135, DOI 10.1111/j.1708-8305.1998.tb00487.x
   HAMILTON MA, 1977, ENVIRON SCI TECHNOL, V11, P714, DOI 10.1021/es60130a004
   Helmholz H, 2010, DEV HYDROBIOL, V212, P223, DOI 10.1007/s10750-010-0216-9
   Kideys AE, 2000, J MARINE SYST, V24, P355, DOI 10.1016/S0924-7963(99)00095-0
   KIHARA H, 1988, JPN J PHYSIOL, V38, P839, DOI 10.2170/jjphysiol.38.839
   Killi N, 2018, RESULTS PROBL CELL D, V65, P477, DOI 10.1007/978-3-319-92486-1_21
   Kirkpatrick P.A., 1984, Synopses of the British Fauna New Series, P1
   Kokelj F., 1990, DERMATOL VENEREOL, V125, P575
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lee H, 2011, TOXICON, V58, P277, DOI 10.1016/j.toxicon.2011.06.007
   Liao QW, 2019, DRUG DISCOV TODAY, V24, P189, DOI 10.1016/j.drudis.2018.08.011
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Manuele M., 2019, THESIS, P91
   Marchini B, 2004, RIV BIOL-BIOL FORUM, V97, P505
   Mariottini Gian L., 2015, Central Nervous System Agents in Medicinal Chemistry, V15, P74
   Mariottini GL, 2016, MAR DRUGS, V14, DOI 10.3390/md14030048
   Mariottini GL, 2010, MAR DRUGS, V8, P1122, DOI 10.3390/md8041122
   Mariottini GL, 2002, TOXICON, V40, P695, DOI 10.1016/S0041-0101(01)00262-8
   MARISCAL RN, 1974, COELENTERATE BIOL RE, P129, DOI DOI 10.1016/B978-0-12-512150-7.50008-6
   Mayer AMS, 1998, LIFE SCI, V62, pPL401, DOI 10.1016/S0024-3205(98)00229-X
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nicholas Y.W.L., 2012, CONTRIBUTIONS MARINE, P57
   Ostman C, 1997, SCI MAR, V61, P313
   Ostman C, 2000, SCI MAR, V64, P31
   Pennington MW, 2015, MAR DRUGS, V13, P529, DOI 10.3390/md13010529
   Purcell JE, 2015, J PLANKTON RES, V37, P1056, DOI 10.1093/plankt/fbv031
   Purcell JE, 2012, HYDROBIOLOGIA, V690, P47, DOI 10.1007/s10750-012-1052-x
   Radwan FFY, 2001, TOXICON, V39, P245, DOI 10.1016/S0041-0101(00)00121-5
   Rocha J, 2011, MAR DRUGS, V9, P1860, DOI 10.3390/md9101860
   RUSSELL F. S., 1939, JOUR MARINE BIOL ASSOC UNITED KINGDOM, V23, P347
   Schuchert P, 2010, REV SUISSE ZOOL, V117, P337
   Smith JJ, 2007, TOXICON, V49, P159, DOI 10.1016/j.toxicon.2006.09.020
   Suput D, 2009, TOXICON, V54, P1190, DOI 10.1016/j.toxicon.2009.03.001
   Tibballs J, 2006, TOXICON, V48, P830, DOI 10.1016/j.toxicon.2006.07.020
   UNEP, 1991, MAP TECHNICAL REPORT, V47
   UNEP, 1984, WORKSH JELL BLOOMS M
   Vaissiere R., 1984, WORKSH JELL BLOOMS M, P149
   Carneiro RFV, 2011, J APPL TOXICOL, V31, P720, DOI 10.1002/jat.1620
   Wanke E, 2007, TOXICON, V49, P239, DOI 10.1016/j.toxicon.2006.09.025
   Weill R., 1930, Bulletin Biologique de la France et de la Belgique, V64, P141
   Yoffe B, 2004, BURNS, V30, P503, DOI 10.1016/j.burns.2004.01.013
   Yu HH, 2005, BIOORG MED CHEM LETT, V15, P4949, DOI 10.1016/j.bmcl.2005.08.015
   Zaharenko AJ, 2011, J NAT PROD, V74, P378, DOI 10.1021/np100738m
NR 68
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2020
VL 175
BP 57
EP 63
DI 10.1016/j.toxicon.2019.12.155
PG 7
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KR8GN
UT WOS:000517854100008
PM 32056696
DA 2020-05-12
ER

PT J
AU Dressler, D
AF Dressler, Dirk
TI Therapeutically relevant features of botulinum toxin drugs
SO TOXICON
LA English
DT Article
DE Botulinum toxin; Pharmaceutical preparation; Clinical pharmacology;
   Future development
ID ONABOTULINUMTOXINA BOTOX(A(R)); CERVICAL DYSTONIA; INCOBOTULINUMTOXINA;
   XEOMIN(R); BOTOX(R); THERAPY
AB Botulinum toxin (BT) drugs were introduced in the late 1980s. They are now used worldwide in a large number of indications. This huge market and its future opportunities have attracted a number of companies about to enter the competition with projects to develop new BT drugs. We want to outline features of BT drugs that are relevant for their therapeutic use and - with that - are also relevant to compare and to evaluate new BT drugs and to guide their further development.
   BT drugs may vary in their content of botulinum neurotoxin, complexing proteins and excipients. Their manufacturing is complex and directly influences core features of the final drug. It includes breeding, purification, botulinum neurotoxin activation, stabilisation, potency control, labelling and testing, specific biological activity and packaging. The manufacturer's support concerning product documentation and support, reliability of drug supply, counterfeit protection and - last but not least - competitive pricing is also important. Further developments include the indication spectrum, the market penetration, the drug's duration of action, liquid preparations, transdermal applications, improving antigenicity and a bio-similarity registration process. Most projects, however, will try to produce Botox (R) analogs at reduced sale prices.
C1 [Dressler, Dirk] Hannover Med Sch, Dept Neurol, Movement Disorders Sect, Carl Neuberg Str 1, D-30625 Hannover, Germany.
RP Dressler, D (reprint author), Hannover Med Sch, Dept Neurol, Movement Disorders Sect, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM dressler.dirk@mh-hannover.de
CR [Anonymous], 2008, EUROPEAN PHARMACOPOE, P1327
   Dressler D, 2006, EUR J NEUROL, V13, P11, DOI 10.1111/j.1468-1331.2006.01439.x
   Dressler D, 2012, EUR J NEUROL, V19, P385, DOI 10.1111/j.1468-1331.2011.03559.x
   Dressler D, 2009, EUR J NEUROL, V16, P2, DOI 10.1111/j.1468-1331.2009.02877.x
   Dressler D., 2018, TREATMENT DYSTONIA
   Dressler D, 2016, TOXICON, V123, pS23
   Dressler D, 2018, J NEURAL TRANSM, V125, P1351, DOI 10.1007/s00702-018-1897-x
   Dressler D, 2017, J NEURAL TRANSM, V124, P1223, DOI 10.1007/s00702-017-1767-y
   Dressler Dirk, 2017, J Clin Mov Disord, V4, P6, DOI 10.1186/s40734-017-0049-z
   Dressler D, 2016, J NEURAL TRANSM, V123, P527, DOI 10.1007/s00702-016-1522-9
   Dressler D, 2014, J NEURAL TRANSM, V121, P29, DOI 10.1007/s00702-013-1076-z
   Dressler D, 2012, J NEURAL TRANSM, V119, P13, DOI 10.1007/s00702-011-0719-1
   European Pharmacopoeia 6 .0, 2008, EUROPEAN PHARMACOPOE, V5, p[571, 3]
   Frevert J, 2010, BIOL-TARGETS THER, V4, P325, DOI 10.2147/BTT.S14902
   Jankovic J, 2003, NEUROLOGY, V60, P1186, DOI 10.1212/01.WNL.0000055087.96356.BB
   Lee JC, 2005, MICROBIOL-SGM, V151, P3739, DOI 10.1099/mic.0.28421-0
   MARION MH, 1995, J NEUROL NEUROSUR PS, V59, P102, DOI 10.1136/jnnp.59.1.102
   Rystedt A, 2015, CLIN NEUROPHARMACOL, V38, P170, DOI 10.1097/WNF.0000000000000101
   Scaglione F, 2016, TOXINS, V8, pE65, DOI DOI 10.3390/T0XINS8030065
NR 19
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD FEB
PY 2020
VL 175
BP 64
EP 68
DI 10.1016/j.toxicon.2019.12.005
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KR8GN
UT WOS:000517854100009
PM 32056697
OA Bronze
DA 2020-05-12
ER

PT J
AU Amor, N
   Farjallah, S
   Merella, P
   Alagaili, AN
   Mohammed, OB
AF Amor, Nabil
   Farjallah, Sarra
   Merella, Paolo
   Alagaili, Abdulaziz N.
   Mohammed, Osama B.
TI Multilocus approach reveals discordant molecular markers and corridors
   for gene flow between North African populations of Fasciola hepatica
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Fasciola hepatica; Fasciola gigantica; Genetic diversity; Gene flow;
   Tunisia; Algeria
ID INTERMEDIATE FORMS; ENDEMIC AREA; PHYLOGENETIC ANALYSIS; MOUTH-DISEASE;
   RIBOSOMAL DNA; F GIGANTICA; NUCLEAR; SEQUENCES; FLUKES; CATTLE
AB Fasciolosis is a foodborne trematodosis characterised by a worldwide distribution. Various approaches have been developed for the study of the causative agents of this parasitic infection: Fasciola hepatica, Fasciola gigantica and the aspermic intermediated forms (hybrid and introgressed). In the present study, novel and common molecular markers (pepck and pold, ITS, CO1, ND1 and CO1-trnT-rrnL) were used to characterise Fasciola flukes from the Tunisian-Algerian border, to estimate the gene flow between these populations and to evaluate the reliability of different molecular markers. All nuclear and mitochondrial markers, apart from pepck, supported the monophyly of the studied flukes identified as F. hepatica. Multiplex PCR for pepck revealed three different genotypes corresponding to F. hepatica (pepck-Fh), F. gigantica (pepck-Fg) and the aspermic Fasciola flukes (pepck-Fh/Fg). Sequence analysis of pepck revealed high polymorphism, length variation, within this intronic marker. The observed inconsistencies were due to the position of the forward primer within the intronic region. Pepck sequences showed different level of heterozygosity and homozygosity with length polymorphisms in the introns. Pepck multiplex PCR patterns could not differentiate between Fasciola species. All studies based on only pepck multiplex PCR with mitochondrial markers should be revised. Nuclear and mitochondrial markers revealed an important gene flow between Tunisian and Algerian populations of F. hepatica. The combination of nuclear and mitochondrial sequence analysis is still the best method to distinguish these taxa. Effective measures are needed in order to better control cross-country illegal trade of vector.
C1 [Amor, Nabil; Alagaili, Abdulaziz N.; Mohammed, Osama B.] King Saud Univ, Dept Zool, KSU Mammals Res Chair, Riyadh 11451, Saudi Arabia.
   [Amor, Nabil; Farjallah, Sarra] Tunis El Manor Univ, Lab Biodivers Parasitol & Aquat Ecosyst LR18ES05, Tunis 2092, Tunisia.
   [Merella, Paolo] Univ Sassari, Dipartimento Med Vet, Parassitol & Malattie Parassitarie, Via Vienna 2, I-07100 Sassari, Italy.
RP Amor, N (reprint author), King Saud Univ, Coll Sci, Dept Zool, KSU Mammals Res Chair, POB 2455, Riyadh 11451, Saudi Arabia.
EM namor@ksu.edu.sa
RI Amor, Nabil/G-3698-2019
OI Amor, Nabil/0000-0003-3815-5465
FU Vice Deanship of Research Chairs, Deanship of Scientific Research of the
   King Saud University, Kingdom of Saudi Arabia
FX The project was financially supported by the Vice Deanship of Research
   Chairs, Deanship of Scientific Research of the King Saud University,
   Kingdom of Saudi Arabia.
CR Valero MA, 2018, INFECT GENET EVOL, V64, P231, DOI 10.1016/j.meegid.2018.06.032
   Valero M, 2016, T ROY SOC TROP MED H, V110, P55, DOI 10.1093/trstmh/trv110
   ADLARD RD, 1993, INT J PARASITOL, V23, P423, DOI 10.1016/0020-7519(93)90022-Q
   Afshan K, 2014, J HELMINTHOL, V88, P417, DOI 10.1017/S0022149X13000369
   Alasaad S, 2007, PARASITOL RES, V101, P1245, DOI 10.1007/s00436-007-0628-2
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Amer S, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1898-2
   Amor N, 2011, EXP PARASITOL, V128, P196, DOI 10.1016/j.exppara.2011.03.011
   Aryaeipour M, 2017, IRAN J PUBLIC HEALTH, V46, P318
   Ashrafi K, 2006, PARASITOL INT, V55, P249, DOI 10.1016/j.parint.2006.06.003
   Ashrafi K, 2015, INFECT GENET EVOL, V31, P95, DOI 10.1016/j.meegid.2015.01.009
   Bandelt HJ, 1999, MOL BIOL EVOL, V16, P37, DOI 10.1093/oxfordjournals.molbev.a026036
   Beltran M, 2002, MOL BIOL EVOL, V19, P2176, DOI 10.1093/oxfordjournals.molbev.a004042
   Bouguedour R, 2016, REV SCI TECH OIE, V35, P757, DOI 10.20506/rst.35.3.2566
   BOWLES J, 1992, MOL BIOCHEM PARASIT, V54, P165, DOI 10.1016/0166-6851(92)90109-W
   Carnevale S, 2017, VET PARASITOL, V245, P34, DOI 10.1016/j.vetpar.2017.08.006
   Chikowore T.J., 2019, ONDERSTEPOORT J VET, V18, pe1, DOI [10.4102/ojvr.v86i1.1706.86, DOI 10.4102/OJVR.V86I1.1706.86]
   Chougar L, 2019, PARASITOL RES, V118, P1179, DOI 10.1007/s00436-019-06270-5
   Cole R, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3137-5
   Creer S, 2006, SYST BIOL, V55, P57, DOI 10.1080/10635150500431213
   Creer S, 2007, EVOL BIOINFORM, V3, P99
   Darriba D, 2012, NAT METHODS, V9, P772, DOI 10.1038/nmeth.2109
   Dunn AM, 1978, VET HELMINTHOLOGY
   Excoffier L, 2005, EVOL BIOINFORM, V1, P47, DOI 10.1177/117693430500100003
   Farjallah S, 2013, EXP PARASITOL, V135, P471, DOI 10.1016/j.exppara.2013.08.006
   Farjallah S, 2009, PARASITOL RES, V105, P1617, DOI 10.1007/s00436-009-1601-z
   Friesen Vicki, 2000, P274
   Friesen VL, 1997, MOL ECOL, V6, P1047, DOI 10.1046/j.1365-294X.1997.00277.x
   Fu YX, 1997, GENETICS, V147, P915
   Giribet G, 1999, MOL PHYLOGENET EVOL, V13, P132, DOI 10.1006/mpev.1999.0643
   Hamed N, 2014, REV MED VET-TOULOUSE, V165, P49
   Hayashi K, 2018, J VET MED SCI, V80, P98, DOI 10.1292/jvms.17-0406
   Hayashi K, 2016, J VET MED SCI, V78, P1529, DOI 10.1292/jvms.16-0126
   Hayashi K, 2016, PARASITOL INT, V65, P424, DOI 10.1016/j.parint.2016.06.004
   Howe KL, 2017, MOL BIOCHEM PARASIT, V215, P2, DOI 10.1016/j.molbiopara.2016.11.005
   Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754
   Ichikawa-Seki M, 2017, PARASITOL INT, V66, P519, DOI 10.1016/j.parint.2017.04.005
   Ichikawa-Seki M, 2017, PARASITOLOGY, V144, P206, DOI 10.1017/S003118201600161X
   Ichikawa-Seki M, 2017, PARASITOL INT, V66, P893, DOI 10.1016/j.parint.2016.10.010
   Itagaki T, 1998, INT J PARASITOL, V28, P777, DOI 10.1016/S0020-7519(98)00037-X
   Itagaki T, 2005, PARASITOLOGY, V131, P679, DOI 10.1017/S0031182005008292
   Kardjadj M, 2018, VET ITAL, V54, P5, DOI 10.12834/VetIt.928.4711.2
   Le TH, 2008, INT J PARASITOL, V38, P725, DOI 10.1016/j.ijpara.2007.10.003
   LESSA EP, 1992, MOL BIOL EVOL, V9, P323
   Librado P, 2009, BIOINFORMATICS, V25, P1451, DOI 10.1093/bioinformatics/btp187
   Loeurng V, 2019, VET PARASITOL, V273, P45, DOI 10.1016/j.vetpar.2019.07.013
   Marcilla A, 2002, MOL CELL PROBE, V16, P327, DOI 10.1006/mcpr.2002.0429
   Mas-Coma S, 2009, ADV PARASIT, V69, P41, DOI 10.1016/S0065-308X(09)69002-3
   McNulty SN, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006537
   Mekroud A, 2004, PARASITOL RES, V92, P502, DOI 10.1007/s00436-004-1072-1
   Mohanta UK, 2014, PARASITOL RES, V113, P2493, DOI 10.1007/s00436-014-3898-5
   Okonechnikov K, 2012, BIOINFORMATICS, V28, P1166, DOI 10.1093/bioinformatics/bts091
   Ouchene-Khelifi NA, 2018, TROP BIOMED, V35, P181
   PALUMBI SR, 1994, MOL BIOL EVOL, V11, P426
   Peng M, 2009, PARASITOL RES, V105, P809, DOI 10.1007/s00436-009-1459-0
   Periago MV, 2008, INFECT GENET EVOL, V8, P51, DOI 10.1016/j.meegid.2007.10.001
   Pons J, 2006, CLADISTICS, V22, P144, DOI 10.1111/j.1096-0031.2006.00088.x
   Rokni MB, 2010, IRAN RED CRESCENT ME, V12, P27
   Rouhani Soheila, 2017, Pak J Biol Sci, V20, P204, DOI 10.3923/pjbs.2017.204.209
   Ryman N, 2009, MOL ECOL, V18, P2084, DOI 10.1111/j.1365-294X.2009.04187.x
   Samuel AR, 1999, EPIDEMIOL INFECT, V122, P529, DOI 10.1017/S0950268899002265
   Shoriki T, 2016, PARASITOL INT, V65, P180, DOI 10.1016/j.parint.2015.12.002
   SLADE RW, 1994, MOL BIOL EVOL, V11, P341
   Sota T, 2003, MOL PHYLOGENET EVOL, V26, P139, DOI 10.1016/S1055-7903(02)00311-1
   Soulsby E.J.L., 1982, HELMINTH ARTHROPOD P
   Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446
   TAJIMA F, 1989, GENETICS, V123, P585
   TERASAKI K, 1982, JPN J VET SCI, V44, P223
   Terasaki K, 1998, J VET MED SCI, V60, P1305, DOI 10.1292/jvms.60.1305
   Le TH, 2012, J CLIN MICROBIOL, V50, P1178, DOI 10.1128/JCM.06277-11
   Thang TN, 2019, PARASITOL INT, V72, DOI 10.1016/j.parint.2019.101930
   Yamaguti S., 1958, SYSTERMA HELMINTHUM, VI
   Zhu XQ, 2007, PARASITOL RES, V101, P1703, DOI 10.1007/s00436-007-0699-0
NR 73
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD FEB
PY 2020
VL 278
AR UNSP 109035
DI 10.1016/j.vetpar.2020.109035
PG 11
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KR8FZ
UT WOS:000517852700015
PM 32014829
DA 2020-05-12
ER

PT J
AU Baran, AI
   Jahanghiri, F
   Hajipour, N
   Sparagano, OAE
   Norouzi, R
   Moharramnejad, S
AF Baran, Abbas Imani
   Jahanghiri, Farzad
   Hajipour, Nasser
   Sparagano, Olivier Andre Ettore
   Norouzi, Roghayeh
   Moharramnejad, Sajjad
TI In vitro acaricidal activity of essential oil and alcoholic extract of
   Trachyspermum ammi against Dermanyssus gallinae
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Ajowan; Acaricidal activity; Dermanussus gallinae; In vitro;
   Trachyspermum ammi
ID POULTRY RED MITE; PLANT ESSENTIAL OILS; L. ESSENTIAL OIL;
   CARUM-COPTICUM; FUMIGANT TOXICITY; HAEMONCHUS-CONTORTUS; AMERICAN
   COCKROACH; GABA RECEPTOR; THYMOL; REPELLENT
AB This study aimed to assess in vitro acaricidal activity of essential oil (EO) and alcoholic extracts (AE) of Ajowan against D. gallinae. Using contact and spraying bioassays, different doses of EO and AE were tested. Cypermethrin and thymol (positive controls), and ethanol and distilled water (negative controls) were also tested. The results indicated that effects were method and dose dependent. Statistical analysis showed a highly significant difference for contact and spraying bioassays and various doses of EO and AE (p < 0.0001) as, the spraying method was more effective than the contact method for acaricidal activity at 24 h post treatment (PT). In this method, Cypermethrin, EO and thymol caused over 90 % mite mortality at 50 mu gcm(-2), while AE caused this rate at 150 mu gcm(-2). In the contact bioassay, all tests produced low mortality rates except for Cypermethrin. Thymol was the main constituent of EO (Area = 42.26 %) and AE (Area = 45.8 %). Results of the present study indicated that Ajowan had a satisfactory acaricidal effect against D. gallinae in vitro. It was also found that the spraying method could be used to control the D. gallinae as the most appropriate method.
C1 [Baran, Abbas Imani; Jahanghiri, Farzad; Hajipour, Nasser; Norouzi, Roghayeh] Univ Tabriz, Fac Vet Med, Dept Pathobiol, Tabriz, Iran.
   [Sparagano, Olivier Andre Ettore] City Univ Hong Kong, Jockey Club Coll Vet Med & Life Sci, Dept Infect Dis & Publ Hlth, Hong Kong, Peoples R China.
   [Moharramnejad, Sajjad] AREEO, Crop & Hort Sci Res Dept, Ardabil Agr & Nat Resources Res & Educ Ctr, Moghan, Iran.
RP Baran, AI (reprint author), Univ Tabriz, Fac Vet Med, Dept Pathobiol, Tabriz, Iran.
EM a.imani@tabrizu.ac.ir; weftra2naa@gmail.com; n.hajipour@tabrizu.ac.ir;
   Olivier.sparagano@cityu.edu.hk; r.norouzi@tabrizu.ac.ir;
   smoharranejad@gmail.com
OI Imani Baran, Abbas/0000-0003-1207-1837; Sparagano,
   Olivier/0000-0003-3141-310X
FU Faculty of Veterinary Medicine, University of Tabriz, Iran [D-43-8705];
   Faculty of Veterinary Medicine; University of Tabrizfor
FX This paper was related to the research project under No. D-43-8705 at
   the Faculty of Veterinary Medicine, University of Tabriz, Iran. The
   authors would like to thank the Deputy Dean for Research of the Faculty
   of Veterinary Medicine and the Vice Chancellor for Research of the
   University of Tabrizfor providing financial support and the facilities
   needed to perform this research project. Moreover, the authors would
   like to thank Mr. Kanaani (expert of the analytical chemistry laboratory
   of the Faculty of Chemistry, University of Tabriz) for GC-MS and HPLC
   analysis, Dr. a. Bavili (Professor of analytical chemistry at the
   Faculty of Pharmacy, Faculty of Medical Sciences, University of Tabriz)
   for preparation of thymol (marker) and Dr. Razban Haghighi (a botanist
   from the Agriculture and Natural Recourses Research Center (ANRRC) of
   East Azerbaijan Province, Iran) for confirmation and identification of
   T. cunmi seeds.
CR Ahn YJ, 2006, ADV PHYTOMED, V3, P269
   Al-Mekhlafi FA, 2018, SAUDI J BIOL SCI, V25, P52, DOI 10.1016/j.sjbs.2017.02.010
   Ali W, 2012, VET PARASITOL, V187, P341, DOI 10.1016/j.vetpar.2012.01.014
   Araujo LX, 2015, PARASITOL RES, V114, P3271, DOI 10.1007/s00436-015-4547-3
   Calderone NW, 1997, J ECON ENTOMOL, V90, P1080, DOI 10.1093/jee/90.5.1080
   Camarda A, 2018, MED VET ENTOMOL, V32, P290, DOI 10.1111/mve.12296
   Chaubey M.K., 2018, CURR LIFE SCI, V4, P10
   Dehghani-Saman A., 2015, J HERBMED PHARM, V4, P81
   Dhaiwal K, 2017, J FOOD BIOCHEM, V41, DOI 10.1111/jfbc.12364
   Enan EE, 2005, INSECT BIOCHEM MOLEC, V35, P309, DOI 10.1016/j.ibmb.2004.12.007
   Enan EE, 2005, ARCH INSECT BIOCHEM, V59, P161, DOI 10.1002/arch.20076
   Erler F, 2007, IOBC WPRS B, V30, P281
   Ferreira LE, 2016, VET PARASITOL, V228, P70, DOI 10.1016/j.vetpar.2016.08.011
   George DR, 2008, VET PARASITOL, V155, P333, DOI 10.1016/j.vetpar.2008.05.005
   George DR, 2010, VET PARASITOL, V169, P222, DOI 10.1016/j.vetpar.2009.12.038
   George DR, 2010, MED VET ENTOMOL, V24, P9, DOI 10.1111/j.1365-2915.2009.00856.x
   George DR, 2010, MED VET ENTOMOL, V24, P1, DOI 10.1111/j.1365-2915.2009.00855.x
   George DR, 2009, VET PARASITOL, V162, P129, DOI 10.1016/j.vetpar.2009.02.009
   George DR, 2009, VET PARASITOL, V161, P276, DOI 10.1016/j.vetpar.2009.01.010
   Ghrabi-Gammar Z, 2009, IND CROP PROD, V30, P441, DOI 10.1016/j.indcrop.2009.07.001
   Gorji S.F., 2014, IRAN PARASITOL RES, V113, P1209
   Goudarzi GR, 2011, J AGR SCI TECH-IRAN, V13, P203
   Harrington DWJ, 2011, WORLD POULTRY SCI J, V67, P83, DOI 10.1017/S0043933911000079
   Isman MB, 2006, ANNU REV ENTOMOL, V51, P45, DOI 10.1146/annurev.ento.51.110104.151146
   Kim HK, 2018, EXP APPL ACAROL, V74, P403, DOI 10.1007/s10493-018-0249-8
   Kim JR, 2016, EXP APPL ACAROL, V68, P485, DOI 10.1007/s10493-015-0005-2
   Kim SI, 2004, VET PARASITOL, V120, P297, DOI 10.1016/j.vetpar.2003.12.016
   Kim SI, 2007, VET PARASITOL, V145, P377, DOI 10.1016/j.vetpar.2006.12.021
   Kostyukovsky M, 2002, PEST MANAG SCI, V58, P1101, DOI 10.1002/ps.548
   Mahmoodi Leila, 2014, Archives of Phytopathology and Plant Protection, V47, P1291, DOI 10.1080/03235408.2013.840101
   Mathew N, 2008, MOLECULES, V13, P2156, DOI 10.3390/molecules13092156
   Matos RS, 2019, TICKS TICK-BORNE DIS, V10, P314, DOI 10.1016/j.ttbdis.2018.11.003
   Maurer V, 2009, EXP APPL ACAROL, V48, P31, DOI 10.1007/s10493-009-9254-2
   Moazeni M, 2012, VET PARASITOL, V187, P203, DOI 10.1016/j.vetpar.2011.12.025
   Moreno FC, 2012, VET PARASITOL, V187, P237, DOI 10.1016/j.vetpar.2011.12.040
   Na YE, 2011, VET PARASITOL, V178, P324, DOI 10.1016/j.vetpar.2011.01.034
   Nechita IS, 2015, VET PARASITOL, V214, P348, DOI 10.1016/j.vetpar.2015.10.014
   Pandey SK, 2009, PARASITOL RES, V105, P507, DOI 10.1007/s00436-009-1429-6
   Park HM, 2011, J MED ENTOMOL, V48, P405, DOI 10.1603/ME10108
   Park IK, 2007, J NEMATOL, V39, P275
   Andre WPP, 2017, REV BRAS PARASITOL V, V26, P323, DOI [10.1590/S1984-29612017056, 10.1590/s1984-29612017056]
   Priestley CM, 2003, BRIT J PHARMACOL, V140, P1363, DOI 10.1038/sj.bjp.0705542
   Seo SM, 2012, J AGR FOOD CHEM, V60, P5909, DOI 10.1021/jf301296d
   Seo SM, 2009, J AGR FOOD CHEM, V57, P6596, DOI 10.1021/jf9015416
   Shojaaddini Mohammad, 2008, Journal of Plant Protection Research, V48, P411, DOI 10.2478/v10045-008-0050-5
   Sonar PK, 2016, PHARM BIOL, V54, P494, DOI 10.3109/13880209.2015.1050116
   Sparagano O, 2013, TRANSBOUND EMERG DIS, V60, P150, DOI 10.1111/tbed.12138
   Stefanidesova K, 2017, TICKS TICK-BORNE DIS, V8, P780, DOI 10.1016/j.ttbdis.2017.06.003
   Sylejmani D, 2016, AVIAN DIS, V60, P454, DOI 10.1637/11327-111415-Reg
   Szczepanik M, 2012, ALLELOPATHY J, V30, P129
   Tabari MA, 2017, PARASITOL RES, V116, P1545, DOI 10.1007/s00436-017-5431-0
   Tabari MA, 2015, PARASITOL RES, V114, P3801, DOI 10.1007/s00436-015-4610-0
   Tong F, 2010, PESTIC BIOCHEM PHYS, V98, P317, DOI 10.1016/j.pestbp.2010.07.003
   Torabi-Pour H, 2017, J HERB MED PHARM, V6, P185
   Youssefi MR, 2019, MOLECULES, V24, DOI 10.3390/molecules24101867
   Zhu L, 2013, J ETHNOPHARMACOL, V148, P311, DOI 10.1016/j.jep.2013.04.034
NR 56
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD FEB
PY 2020
VL 278
AR UNSP 109030
DI 10.1016/j.vetpar.2020.109030
PG 7
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KR8FZ
UT WOS:000517852700014
PM 32007678
DA 2020-05-12
ER

PT J
AU Ceylan, O
   Sevinc, F
AF Ceylan, Onur
   Sevinc, Ferda
TI Endemic instability of ovine babesiosis in Turkey: A country-wide
   sero-epidemiological study
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Babesia ovis; ELISA; IFAT; Sheep; Endemic status
ID MOLECULAR-DETECTION; SHEEP; SEROPREVALENCE; INFECTION; THEILERIA;
   DIAGNOSIS; REGION; IDENTIFICATION; PIROPLASMOSIS; PREVALENCE
AB Ovine babesiosis is an endemic tick-borne disease of small ruminants in the Middle East, European, and some African and Asian countries, including Turkey. This study assessed whether the endemic status of this disease was stable or instable, which is important for disease control efforts. For this aim, 4115 sheep blood samples were collected from 81 cities in the seven geographical regions of Turkey. The diagnosis of Babesia ovis was made using microscopic and serological techniques. Thin blood smears were prepared from anticoagulated venous blood. Serum samples were screened for specific antibodies using an enzyme-linked immunosorbent assay (ELISA) and indirect fluorescent antibody test (IFAT). Recombinant Babesia ovis secreted antigen 1 (rBoSA1) was used in the ELISA. The antigen slides used in the IFAT were prepared from the B. ovis-infected blood at a high level of parasitemia (5 %). The animals were divided into three groups according to their age: group I (one to six months), group II (6-12 months), and group III (older than one year). The endemic status of B. ovis was determined according to the inoculation rate (h value) calculations. Babesia spp. merozoites were observed in 40 (0.97 %) of the slides. Seropositivity rates were 29.89 % (1230/4115) and 49.16 % (2023/4115) by the ELISA and IFAT, respectively. According to the IFAT results, 31.7 %, 33.6 %, and 52.8 % of the animals were seropositive in groups I, II, and III respectively. The inoculation rates of the animals indicated that the endemic status of ovine babesiosis was mostly instable throughout the country. Endemic stability was found only in group I from four regions (Central Anatolia, Eastern Anatolia, Aegean, and Mediterranean). Based on these results, the risk of clinical infection due to tick infestation was high when the maternal immunity and non-specific age resistance weakens or disappears. Thus, vaccination is needed to protect sheep against B. ovis infections in Turkey.
C1 [Ceylan, Onur; Sevinc, Ferda] Selcuk Univ, Fac Vet Med, Dept Parasiyol, Konya, Turkey.
RP Ceylan, O (reprint author), Selcuk Univ, Fac Vet Med, Dept Parasiyol, Konya, Turkey.
EM onurceylan@selcuk.edu.tr
OI Ceylan, Onur/0000-0002-3514-5221
FU Academic Staff Training Program Coordination Unit, Selcuk University in
   Turkey [2015-OYP-109]
FX This study was derived from the PhD thesis prepared by the first author
   under the supervision of the second author. Financial support was
   supplied by the Academic Staff Training Program Coordination Unit,
   Selcuk University in Turkey (Number of project: 2015-OYP-109). The
   authors would like to thank Associate Professor Mustafa Agah Tekindal
   for statistical analysis, and Research Assistant Ceylan Ceylan and
   Research Assistant Ali Uslu for their help during sample collection.
CR Ahmed JS, 2006, ANN NY ACAD SCI, V1081, P498, DOI 10.1196/annals.1373.074
   Aktas M, 2001, TURK J VET ANIM SCI, V25, P241
   Aktas M, 2007, PARASITOL RES, V100, P797, DOI 10.1007/s00436-006-0345-2
   Altay K, 2017, MANAS J AGR VET LIFE, V7, P30
   Bruning A, 1996, BRIT VET J, V152, P139, DOI 10.1016/S0007-1935(96)80070-4
   Cakmak A, 1991, AU VET FAK DERG, V38, P242
   Carletti T, 2016, TICKS TICK-BORNE DIS, V7, P85, DOI 10.1016/j.ttbdis.2015.09.002
   Cicek H, 2004, TURK J VET ANIM SCI, V28, P683
   Dumanli N, 1997, TURK J VET ANIM SCI, V21, P183
   DUZGUN A, 1991, VET PARASITOL, V39, P225, DOI 10.1016/0304-4017(91)90039-X
   Ekici O.D., 2011, J AVKAE, V1, P24
   Ekici OD, 2012, VET PARASITOL, V188, P372, DOI 10.1016/j.vetpar.2012.04.001
   Emre Z, 2001, TURK J VET ANIM SCI, V25, P759
   Erster O, 2015, VET PARASITOL, V214, P282, DOI 10.1016/j.vetpar.2015.09.013
   Ferrer D, 1998, VET PARASITOL, V79, P275, DOI 10.1016/S0304-4017(98)00175-7
   Geleta A.R., 2005, THESIS
   Guan GQ, 2012, PARASITOL INT, V61, P532, DOI 10.1016/j.parint.2012.04.004
   HABELA M, 1990, VET PARASITOL, V35, P233, DOI 10.1016/0304-4017(90)90058-J
   HABELA M, 1990, VET PARASITOL, V35, P1, DOI 10.1016/0304-4017(90)90111-N
   HAGHI SMM, 2013, RES MOL MED, V1, P35
   Hashemzadeh F, 2006, IRAN J VET RES, V7, P53
   Hay S I, 2001, Trends Parasitol, V17, P310, DOI 10.1016/S1471-4922(01)02008-6
   Healer J., 2016, Molecular parasitology: protozoan parasites and their molecules, P509
   Hussein N.M., 2017, UPPER EGYPT ARCH PAR, V1
   Inci A, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005021
   Jonsson NN, 2012, TRENDS PARASITOL, V28, P85, DOI 10.1016/j.pt.2011.12.002
   MAHONEY DF, 1972, AUST VET J, V48, P292, DOI 10.1111/j.1751-0813.1972.tb05160.x
   Ozubek S, 2017, J MED ENTOMOL, V54, P212, DOI 10.1093/jme/tjw134
   Papadopoulos B, 1996, VET PARASITOL, V63, P41, DOI 10.1016/0304-4017(95)00878-0
   Renneker S, 2013, TRANSBOUND EMERG DIS, V60, P113, DOI 10.1111/tbed.12148
   Rjeibi MR, 2016, ONDERSTEPOORT J VET, V83, DOI 10.4102/ojvr.v83i1.1040
   Sayin F., 1997, Parassitologia (Rome), V39, P153
   Schnittger L, 2012, INFECT GENET EVOL, V12, P1788, DOI 10.1016/j.meegid.2012.07.004
   Sevinc F., 1996, Veteriner Bilimleri Dergisi, V12, P73
   Sevinc F., 2015, Eurasian Journal of Veterinary Sciences, V31, P132
   Sevinc F, 2007, VET PARASITOL, V149, P65, DOI 10.1016/j.vetpar.2007.07.014
   Sevinc F, 2015, VET PARASITOL, V214, P213, DOI 10.1016/j.vetpar.2015.09.022
   Sevinc F, 2015, J CLIN MICROBIOL, V53, P1531, DOI 10.1128/JCM.03219-14
   Sevinc F, 2013, VET PARASITOL, V198, P391, DOI 10.1016/j.vetpar.2013.09.012
   Sevinc F, 2013, VET PARASITOL, V191, P35, DOI 10.1016/j.vetpar.2012.07.025
   Shahzad W, 2013, IRAN J PARASITOL, V8, P570
   Shayan P, 2007, PARASITOL RES, V101, P1029, DOI 10.1007/s00436-007-0581-0
   Smit R, 2016, EXPERT REV VACCINES, V15, P5, DOI 10.1586/14760584.2016.1111142
   Uilenberg G, 2006, VET PARASITOL, V138, P3, DOI 10.1016/j.vetpar.2006.01.035
   YERUHAM I, 1995, VET PARASITOL, V60, P349, DOI 10.1016/0304-4017(95)00783-7
   Yeruham I, 1998, VET PARASITOL, V74, P153, DOI 10.1016/S0304-4017(97)00143-X
   Zhou M, 2017, TICKS TICK-BORNE DIS, V8, P246, DOI 10.1016/j.ttbdis.2016.11.006
NR 47
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD FEB
PY 2020
VL 278
AR UNSP 109034
DI 10.1016/j.vetpar.2020.109034
PG 7
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KR8FZ
UT WOS:000517852700008
PM 31991285
DA 2020-05-12
ER

PT J
AU Costa, FS
   Rodrigues, VF
   de Rezende, MC
   Rodrigues-Oliveira, JL
   Coelho, PMZ
   Negrao-Correa, D
AF Costa, Fernanda S.
   Rodrigues, Vanessa Fernandes
   de Rezende, Michelle Carvalho
   Rodrigues-Oliveira, Jailza Lima
   Coelho, Paulo M. Z.
   Negrao-Correa, Deborah
TI The effect of maternal Strongyloides venezuelensis infection on mice
   offspring susceptibility and immune response
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Strongyloides venezuelensis; Transmammary transmission in mice;
   Protective immunity
ID TRANSMAMMARY TRANSMISSION; PROTECTIVE IMMUNITY; SUDDEN-DEATH;
   STERCORALIS; RATTI; EOSINOPHILS; INNATE; LARVAE; ELIMINATION; PAPILLOSUS
AB Species of Strongyloides infect a wide range of hosts worldwide. Due to their complex life cycle, it is hard to control the transmission of these parasites. Several species show evidence of vertical transmission; however, the impact of this transmission route on the susceptibility of the offspring has been poorly investigated. Herein, we used Strongyloides venezuelensis infected mice to evaluate transplacental and transmammary parasite transmission and their effect on the susceptibility of offspring. Swiss female mice were infected at the end of the gestation or during the breastfeeding period, and their offspring were examined for the presence of the parasite one week after infection of the mother. Our data showed that female mice infected with S. venezuelensis during gestation did not transmit the parasite to their offspring. On the other hand, all newborn mice breastfeeding in S. venezuelensis infected females got infected. To evaluate the effect of early exposure to the parasite on susceptibility and immune response of the hosts, the offspring of each experimental group (non-infected, gestation-infected, and breastfeeding-infected mothers) received anti-helminth treatment after parasite evaluation and were subcutaneously infected with S. venezuelensis upon reaching adulthood. Mice from the group of breastfeeding-infected mothers showed lower susceptibility to S. venezuelensis in adulthood in comparison with mice from non infected mothers. The low parasite burden was accompanied by earlier eosinophil and neutrophil activation in the gut and higher serum levels of IgE. In contrast, S. venezuelensis infection in adult mice born from gestation-infected mothers presented with more worms in the intestine and lower levels of parasite-reactive IgM in serum in comparison with mice born from non-infected mothers, thus suggesting that early exposure to parasite antigens may modulate the protective immune response. Altogether, our data confirmed transmammary, but not transplacental, transmission of S. venezuelensis in mice and demonstrated that early exposure to the parasite and/or their antigens has an important effect on host susceptibility to a later infection.
C1 [Costa, Fernanda S.; Rodrigues, Vanessa Fernandes; de Rezende, Michelle Carvalho; Rodrigues-Oliveira, Jailza Lima; Negrao-Correa, Deborah] Univ Fed Minas Gerais, Dept Parasitol, Biol Sci Inst, Belo Horizonte, MG, Brazil.
   [Costa, Fernanda S.; Coelho, Paulo M. Z.] Fundacao Oswaldo Cruz, Lab Schistosomiasis, Rene Rachou Res Ctr, Belo Horizonte, MG, Brazil.
RP Negrao-Correa, D (reprint author), Univ Fed Minas Gerais, ICB, Dept Parasitol, Av Presidente Antonio Carlos 6627,Campus Pampulha, BR-31270901 Belo Horizonte, MG, Brazil.
EM denegrao@icb.ufmg.br
RI Rodrigues, Vanessa/AAJ-9451-2020
OI Rodrigues, Vanessa Fernandes/0000-0003-3037-4161; Negrao-Correa,
   Deborah/0000-0001-7670-5216
FU Conselho Nacional de Desenvolvimento Cientffico e Tecnologico
   (CNPq-Brazil)National Council for Scientific and Technological
   Development (CNPq) [481035/2012-5]; Fundacao de Amparo a Pesquisa do
   Estado de Minas Gerais (FAPEMIG-Brazil)Minas Gerais State Research
   Foundation (FAPEMIG) [PPM -00500-15]; Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES -Brazil, Basic Parasitology Program)
   [23038.005297/2011-39]
FX This study was supported by the Conselho Nacional de Desenvolvimento
   Cientffico e Tecnologico (CNPq-Brazil, grant #481035/2012-5), Fundacao
   de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG-Brazil, grant
   #PPM -00500-15), and Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES -Brazil, Basic Parasitology Program, grant
   #23038.005297/2011-39). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Aguiar PD, 2015, PARASITOL INT, V64, P145, DOI 10.1016/j.parint.2014.04.010
   Barcante JMP, 2003, PARASITOL RES, V89, P89, DOI 10.1007/s00436-002-0719-z
   Ben Nouir N, 2012, VACCINE, V30, P4971, DOI 10.1016/j.vaccine.2012.05.046
   Breloer M, 2017, PARASITOLOGY, V144, P295, DOI 10.1017/S0031182016000111
   Brigandi RA, 1996, EXP PARASITOL, V82, P279, DOI 10.1006/expr.1996.0035
   BROWN RC, 1977, AM J TROP MED HYG, V26, P215, DOI 10.4269/ajtmh.1977.26.215
   Carvalho EM, 2004, PARASITE IMMUNOL, V26, P487, DOI 10.1111/j.0141-9838.2004.00726.x
   Concha R, 2005, J CLIN GASTROENTEROL, V39, P203, DOI 10.1097/01.mcg.0000152779.68900.33
   DAWKINS HJS, 1982, J HELMINTHOL, V56, P23, DOI 10.1017/S0022149X00034957
   DAWKINS HJS, 1981, INT J PARASITOL, V11, P89, DOI 10.1016/0020-7519(81)90031-X
   Dillard KJ, 2007, ACTA VET SCAND, V49, DOI 10.1186/1751-0147-49-37
   El-Malky M, 2003, PARASITOL INT, V52, P71, DOI 10.1016/S1383-5769(02)00086-7
   Fernandes A, 2008, PARASITE IMMUNOL, V30, P139, DOI 10.1111/j.1365-3024.2007.01009.x
   Galioto AM, 2006, INFECT IMMUN, V74, P5730, DOI 10.1128/IAI.01958-05
   Herbert DR, 2000, J IMMUNOL, V165, P4544, DOI 10.4049/jimmunol.165.8.4544
   IVEY CL, 1995, J CLIN INVEST, V95, P2720, DOI 10.1172/JCI117974
   JACOBS DE, 1987, J VET PHARMACOL THER, V10, P23, DOI 10.1111/j.1365-2885.1987.tb00072.x
   Jaleta TG, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005752
   KAWANABE M, 1988, PARASITOL RES, V75, P50, DOI 10.1007/BF00931190
   Klement P, 1996, LAB ANIM SCI, V46, P286
   Labes EM, 2011, PARASITOLOGY, V138, P1417, DOI 10.1017/S0031182011001284
   Ligas JA, 2003, INFECT IMMUN, V71, P6835, DOI 10.1128/IAI.71.12.6835-6843.2003
   Lyons E., 1969, BLOOD HORSE, V95, P2270
   Lyons E. T., 1970, Modern Veterinary Practice, V51
   LYONS ET, 1973, J PARASITOL, V59, P780, DOI 10.2307/3278405
   MANDLER R, 1993, J IMMUNOL, V150, P407
   Matsumoto M, 2016, PARASITOL INT, V65, P506, DOI 10.1016/j.parint.2016.02.005
   Matsumoto M, 2013, INFECT IMMUN, V81, P2518, DOI 10.1128/IAI.00285-13
   Miller FL, 2017, VET PARASITOL, V248, P1, DOI 10.1016/j.vetpar.2017.10.010
   Moncol D J, 1966, Vet Med Small Anim Clin, V61, P583
   Mukai K, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00053-17
   Nagayasu E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05049-x
   Nakamura Y, 2002, J HELMINTHOL, V76, P59, DOI 10.1079/JOH200196
   NAKANISHI N, 1993, VET PARASITOL, V47, P67, DOI 10.1016/0304-4017(93)90176-N
   Negrao-Correa D, 2004, INFECT IMMUN, V72, P1135, DOI 10.1128/IAI.72.2.1135-1142.2004
   Negrao-Correa D, 2006, INT J PARASITOL, V36, P1185, DOI 10.1016/j.ijpara.2006.05.005
   NOLAN TJ, 1981, P HELM SOC WASH, V48, P8
   NWAORGU O C, 1990, Revue d'Elevage et de Medecine Veterinaire des Pays Tropicaux, V43, P503
   O'Connell AE, 2011, INFECT IMMUN, V79, P2770, DOI 10.1128/IAI.00931-10
   Olsen A, 2009, T ROY SOC TROP MED H, V103, P967, DOI 10.1016/j.trstmh.2009.02.013
   PARSONS JC, 1987, VET CLIN N AM-SMALL, V17, P1307, DOI 10.1016/S0195-5616(87)50004-3
   Paula FM, 2011, PARASITOLOGY, V138, P1331, DOI 10.1017/S003118201100120X
   Porto AF, 2001, PARASITE IMMUNOL, V23, P503, DOI 10.1046/j.1365-3024.2001.00407.x
   Puthiyakunnon S, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003018
   Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720
   Sasaki Y, 2005, J EXP MED, V202, P607, DOI 10.1084/jem.20042202
   SCHAD GA, 1989, J PARASITOL, V75, P740, DOI 10.2307/3283059
   Schaer Fabian, 2013, PLoS Neglected Tropical Diseases, V7, P1
   Schilter HC, 2010, PARASITE IMMUNOL, V32, P184, DOI 10.1111/j.1365-3024.2009.01176.x
   SETASUBAN P, 1980, Southeast Asian Journal of Tropical Medicine and Public Health, V11, P535
   SETASUBAN P, 1975, Southeast Asian Journal of Tropical Medicine and Public Health, V6, P608
   Shoop WL, 2002, J PARASITOL, V88, P536, DOI 10.1645/0022-3395(2002)088[0536:TTOSSI]2.0.CO;2
   Siddiqui AA, 2001, CLIN INFECT DIS, V33, P1040, DOI 10.1086/322707
   STEWART TB, 1976, AM J VET RES, V37, P541
   STRATH M, 1985, J IMMUNOL METHODS, V83, P209, DOI 10.1016/0022-1759(85)90242-X
   SWERCZEK TW, 1971, AM J VET RES, V32, P89
   TAIRA N, 1991, VET PARASITOL, V39, P313, DOI 10.1016/0304-4017(91)90048-Z
   Thamsborg SM, 2017, PARASITOLOGY, V144, P274, DOI 10.1017/S0031182016001116
   Vadlamudi Raja S, 2006, Clin Mol Allergy, V4, P8, DOI 10.1186/1476-7961-4-8
   Viney M.E., 2007, STRONGYLOIDES SPP WO, P1, DOI DOI 10.1895/WORMBOOK.1.141.1
   WILSON PAG, 1976, PARASITOLOGY, V72, P355, DOI 10.1017/S0031182000049556
   WILSON PAG, 1977, PARASITOLOGY, V75, P233, DOI 10.1017/S0031182000062375
   Wulcan JM, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3592-7
   Yasuda K, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00118
   ZAMIRDIN M, 1974, PARASITOLOGY, V69, P445, DOI 10.1017/S0031182000063113
NR 65
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD FEB
PY 2020
VL 278
AR UNSP 109037
DI 10.1016/j.vetpar.2020.109037
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KR8FZ
UT WOS:000517852700011
PM 32004853
DA 2020-05-12
ER

PT J
AU Ferreira, LL
   de Oliveira, JG
   Silva, FD
   Ferraz, ALL
   Mascarin, GM
AF Ferreira, Lorena Lopes
   de Oliveira Filho, Jaires Gomes
   Silva, Fernanda de Oliveira
   Lacerda Ferraz, Ana Livia
   Mascarin, Gabriel Moura
TI Attract or repel Amblyomma sculptum ticks: Screening of semiochemicals
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Amblyomma cajennense sensu lato; Attractant; Field trial; Repellent;
   Alternative tick control; Y-tube olfactometer
ID AGGREGATION-ATTACHMENT PHEROMONE; TROPICAL BONT TICK; BROWN DOG TICK;
   VARIEGATUM FABRICIUS IXODIDAE; SANGUINEUS SENSU-LATO; ACARI IXODIDAE;
   OLFACTORY RECEPTORS; BREATH COMPONENTS; A-VARIEGATUM; HOST-ODOR
AB Amblyomma sculptum is a tick of medical-veterinary importance. Areas with high infestations need to be monitored, and parasitized hosts treated accordingly. Carbon dioxide (CO2) traps and acaricides are commonly deployed as control measures, although with some disadvantages such as high costs, challenging logistics and vertebrate intoxication. Semiochemicals have the potential to improve tick attraction to traps and monitoring devices and alleviate the burden of A. sculptum infestations. Four concentrations (10, 5, 2.5 and 1.25 %) of 13 semiochemical candidates (CO2 only at 5 % as the standard, benzaldehyde, benzoic acid, salicylic acid, 2,6 diclorophenol, R-limonene, S-limonene, methyl salicylate, 1-octen-3-ol, acetone, ammonium hydroxide, isobutyric acid and lactic acid) were tested on unfed A. sculptum nymphs and adults using a Y-tube olfactometer to evaluated repellence and attraction behaviors. All stages tested were attracted to CO2, whereas nymphs were repelled by benzaldehyde and R-limonene, both at 10 %, and isobutyric acid at 5 and 10 %. Nymphs were attracted by methyl salicylate, benzoic acid and salicylic acid, all at 1.25 %, and by ammonium hydroxide at 2.5 %. Males were attracted by benzoic acid at 2.5 %, while females were repelled by benzaldehyde at 5 %. Mixtures with the attractive compounds achieved no attraction response. The compounds that caused attractiveness in the olfactometer assay (CO2, methyl salicylate, benzoic acid, salicylic acid and ammonium hydroxide) were placed randomly in traps in a grassland plot naturally infested with A. sculptum in triplicate. Notably, dry ice (CO2) remained the best at luring ticks in the field (P < 0.001). Benzoic acid should be further investigated since attractant activity was strongly confirmed in both laboratory and field tests. On the other hand, isobutyric acid and R-limonene could be better exploited due to their repellent role revealed by the lab assay, which makes them worthwhile molecules as natural repellents for the management of this tick.
C1 [Ferreira, Lorena Lopes] Escola Vet, Campus Pampulha,Ave Antonio Carlos 6627,CP 567, BR-31270901 Belo Horizonte, MG, Brazil.
   [de Oliveira Filho, Jaires Gomes; Silva, Fernanda de Oliveira] Univ Fed Goias, Escola Vet & Zootecnia, Campus Samambaia,Ave Esperanca S-N,Campus Univ, BR-74690900 Goiania, Go, Brazil.
   [Lacerda Ferraz, Ana Livia] Clarion Biociencias Ltda, Rua 11,Qd 7 Lt 47 55, Aparecida De Goiania, Go, Brazil.
   [Mascarin, Gabriel Moura] Empresa Brasileira Pesquisa Agr, Embrapa Meio Ambiente, Rodovia SP 340,Km 127,5,CP 69, BR-13820000 Jaguariuna, SP, Brazil.
RP Ferreira, LL (reprint author), Escola Vet, Campus Pampulha,Ave Antonio Carlos 6627,CP 567, BR-31270901 Belo Horizonte, MG, Brazil.
EM loren4_lopes@hotmail.com; jaires_filho@hotmail.com;
   oliveiras.fer@outlook.com; ferrazal.vet@gmail.com;
   gabriel.mascarin@embrapa.br
OI Lopes Ferreira, Lorena/0000-0003-0813-3054
FU National Council of Technological and Scientific Development (CNPq),
   BrazilNational Council for Scientific and Technological Development
   (CNPq) [2012-7, 2014-0]
FX We thank the National Council of Technological and Scientific
   Development (CNPq), Brazil, for its financial support (Grant no.
   #/2012-7 and #/2014-0). Special thanks to Professor Ligia Miranda
   Ferreira Borges for the chemical ecology support and to provide the
   structure used in this work at Laboratorio de Ecologia Quimica de
   Carrapatos, Centro de Parasitologia Veterinaria, EVZ/UFG.
CR Apps P.J., 1998, J VET RES, V55, P135
   Araújo Rachel Paes de, 2015, Cad. saúde colet., V23, P354, DOI 10.1590/1414-462X201500040094
   Barros-Battesti D.M., 2006, CARRAPATOS IMPORTANC
   BERGER RS, 1972, SCIENCE, V177, P704, DOI 10.1126/science.177.4050.704
   Bernier U.R., 2006, INSECT REPELLENTS PR, P77
   Bissinger B.W., 2014, BIOL TICKS, V2, P383
   Louly CCB, 2008, MEM I OSWALDO CRUZ, V103, P60, DOI 10.1590/S0074-02762008000100009
   Carnohan LP, 2017, TICKS TICK-BORNE DIS, V8, P226, DOI 10.1016/j.ttbdis.2016.11.003
   Carr AL, 2013, MED VET ENTOMOL, V27, P86, DOI 10.1111/j.1365-2915.2012.01024.x
   CLIFFORD CM, 1960, J PARASITOL, V46, P567, DOI 10.2307/3274939
   Cancado PHD, 2008, PARASITOL RES, V103, P371, DOI 10.1007/s00436-008-0982-8
   Dantas-Torres F, 2013, EXP APPL ACAROL, V61, P119, DOI 10.1007/s10493-013-9671-0
   Dautel H, 2004, INT J MED MICROBIOL, V293, P182, DOI 10.1016/S1433-1128(04)80037-8
   de Oliveira JG, 2017, TICKS TICK-BORNE DIS, V8, P139, DOI 10.1016/j.ttbdis.2016.10.010
   DIEHL PA, 1991, J CHEM ECOL, V17, P833, DOI 10.1007/BF01395594
   Borges LMF, 2015, TICKS TICK-BORNE DIS, V6, P676, DOI 10.1016/j.ttbdis.2015.05.014
   Ferreira LL, 2019, TICKS TICK-BORNE DIS, V10, P621, DOI 10.1016/j.ttbdis.2019.02.006
   Gachoka K.K., 2012, INT J ACAROL, V1, P1
   Gachoka KK, 2011, REV BRAS PARASITOL V, V20, P347, DOI 10.1590/S1984-29612011000400017
   Geier M, 1999, CHEM SENSES, V24, P647, DOI 10.1093/chemse/24.6.647
   Grenacher S, 2001, EXP APPL ACAROL, V25, P641, DOI 10.1023/A:1016145805759
   Guerenstein PG, 2009, ACTA TROP, V110, P148, DOI 10.1016/j.actatropica.2008.09.019
   Hink W.F., 1990, Patent, Patent No. [4,933, 371, 4933371]
   Jaleta KT, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1386-3
   Klessig DF, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00206
   Labruna MB, 2009, ANN NY ACAD SCI, V1166, P156, DOI 10.1111/j.1749-6632.2009.04516.x
   Logan JG, 2007, PEST MANAG SCI, V63, P647, DOI 10.1002/ps.1408
   LUSBY WR, 1991, EXP APPL ACAROL, V13, P143, DOI 10.1007/BF01193665
   Martins TF, 2010, TICKS TICK-BORNE DIS, V1, P75, DOI 10.1016/j.ttbdis.2010.03.002
   McMahon C, 2002, NATURWISSENSCHAFTEN, V89, P311, DOI 10.1007/s00114-002-0317-z
   McMahon C, 2001, J CHEM ECOL, V27, P471, DOI 10.1023/A:1010328720035
   Borges LMF, 2007, VET PARASITOL, V147, P155, DOI 10.1016/j.vetpar.2007.02.037
   Nava S, 2014, TICKS TICK-BORNE DIS, V5, P252, DOI 10.1016/j.ttbdis.2013.11.004
   NCBI-National Center for Biotechnology Information, 2017, PUBCHEM COMP DAT
   NORVAL RAI, 1992, EXP APPL ACAROL, V16, P237, DOI 10.1007/BF01193806
   NORWOOD DM, 1992, ARCH ENVIRON HEALTH, V47, P309, DOI 10.1080/00039896.1992.9938367
   Oliveira PR, 2003, MED VET ENTOMOL, V17, P412, DOI 10.1111/j.1365-2915.2003.00459.x
   Osterkamp J, 1999, J COMP PHYSIOL A, V185, P59, DOI 10.1007/s003590050366
   Pedro T.B., 2016, REV BRAS MED VET S3, V38, P80
   Pellegrino AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075004
   Phillips M, 1999, J CHROMATOGR B, V729, P75, DOI 10.1016/S0378-4347(99)00127-9
   Pohlit AM, 2011, PLANTA MED, V77, P618, DOI 10.1055/s-0030-1270949
   R Core Team, 2018, R LANG ENV STAT COMP
   Ramos VD, 2017, TICKS TICK-BORNE DIS, V8, P506, DOI 10.1016/j.ttbdis.2017.02.011
   Sato Tayra Pereira, 2019, Revista de Patologia Tropical, V48, P161, DOI 10.5216/rpt.v48i3.59123
   SCHONI R, 1984, J INSECT PHYSIOL, V30, P613, DOI 10.1016/0022-1910(84)90045-3
   Smallegange RC, 2010, ECOL CONT VECTOR-BOR, V2, P143
   Soares SF, 2012, ACTA TROP, V124, P192, DOI 10.1016/j.actatropica.2012.08.007
   Sonenshine DE, 2006, ANNU REV ENTOMOL, V51, P557, DOI 10.1146/annurev.ento.51.110104.151150
   Sonenshine DE, 2004, PARASITOLOGY, V129, pS405, DOI 10.1017/S003118200400486X
   Sonenshine DE, 2003, J MED ENTOMOL, V40, P849, DOI 10.1603/0022-2585-40.6.849
   SONENSHINE DE, 1985, ANNU REV ENTOMOL, V30, P1, DOI 10.1146/annurev.en.30.010185.000245
   Sonenshine DE, 2014, BIOL TICKS, V1
   STEULLET P, 1994, J COMP PHYSIOL A, V174, P27, DOI 10.1007/BF00192003
   STEULLET P, 1992, J COMP PHYSIOL A, V170, P665, DOI 10.1007/BF00198976
   Superintendencia de Vigilancia em Sande (SUVISA), 2016, FEBR MAC
   Van Duijvendijk G, 2017, MED VET ENTOMOL, V31, P220, DOI 10.1111/mve.12214
   Venables W.N., 2002, MODERN APPL STAT S
   Vieira A.M.L., 2004, MANUAL VIGILANCIA AC
   Wilkins Jr J.S., 1999, Patent, Patent No. [5,951,992, 5951992]
   Xu Pingxi, 2015, F1000Res, V4, P156, DOI 10.12688/f1000research.6646.1
   Yates F, 1934, JR STATIST SOC     S, V1, P217, DOI DOI 10.2307/2983604
   YUNKER CE, 1992, EXP APPL ACAROL, V13, P295, DOI 10.1007/BF01195086
NR 63
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD FEB
PY 2020
VL 278
AR UNSP 109036
DI 10.1016/j.vetpar.2020.109036
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KR8FZ
UT WOS:000517852700009
PM 32004852
DA 2020-05-12
ER

PT J
AU Francis, EK
   McKay-Demeler, J
   Calvani, NED
   McDonell, D
   Slapeta, J
AF Francis, Emily Kate
   McKay-Demeler, Janina
   Calvani, Nichola Eliza Davies
   McDonell, Denise
   Slapeta, Jan
TI Which larvae are they? Use of single larva for the molecular
   confirmation of Cooperia pectinata and Cooperia punctata in Australian
   cattle
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Faecal egg count; Flotation; Larval culture; Molecular diagnostics;
   MT-PCR; Species-specific; Iodine staining
ID GASTROINTESTINAL NEMATODE INFECTIONS; BEEF-CATTLE; ANTHELMINTIC
   RESISTANCE; DIAGNOSIS; EFFICACY; IDENTIFICATION; DIVERSITY; ONCOPHORA;
   HELMINTH; CALVES
AB In Australia, Cooperia spp. are often overshadowed by parasites believed to be more pathogenic production limiting nematodes. A rise in anthelmintic resistance and reports of reduced growth rates attributed to infection with Cooperia spp. in Europe increases the need to be able to monitor the presence of C. pectinata, C. punctata and C. oncophora in Australian cattle. Here, we present the first molecular confirmation of C. pectinata and C. punctata in Australian cattle using ITS2 rDNA and COXII mtDNA. Cultured larvae were morphologically differentiated to the genus level with the aid of iodine solution and their DNA was screened using a cattle nematode MT-PCR panel. By isolating individual iodine stained and morphologically identified nematode larvae, we demonstrated the presence of C. pectinata and C. punctata using a generic ITS2 rDNA qPCR assay following DNA amplicon sequencing. A novel suite of COXII mtDNA species/genus-specific PCR assays for Cooperia speciation from complex nematode samples enabled us to detect all three species (C. oncophora, C. pectinata, C. punctata) in Australia cattle samples. Our approach, utilising traditional techniques coupled with the manipulation of individual nematode larvae, provides a foundation for the inclusion of Cooperia spp. into existing high throughput molecular diagnostic panels for cattle nematode surveillance.
C1 [Francis, Emily Kate; Calvani, Nichola Eliza Davies; McDonell, Denise; Slapeta, Jan] Univ Sydney, Fac Sci, Sydney Sch Vet Sci, Sydney, NSW 2006, Australia.
   [McKay-Demeler, Janina] Dawbuts Pty Ltd, 9 Mitchell St, Camden, NSW 2570, Australia.
RP Slapeta, J (reprint author), Fac Sci, Sydney Sch Vet Sci, Sydney, NSW 2006, Australia.
EM jan.slapeta@sydney.edu.au
OI Calvani, Nichola/0000-0002-8787-6755; Slapeta, Jan/0000-0003-1459-9117
FU Honours program, Faculty of Science, The University of Sydney
FX The study was in part funded by the Honours program 2019 by the Faculty
   of Science, The University of Sydney. We thank Maira N. Meggiolaro and
   the Veterinary Pathology Diagnostic Services, The University of Sydney
   for excellent technical support and access to the instrumentation, Phil
   Stein (Dawbuts) for larva identification and Dr Florian Roeber for
   discussion and insight.
CR Avramenko RW, 2017, INT J PARASITOL, V47, P893, DOI 10.1016/j.ijpara.2017.06.006
   Candy PM, 2018, VET PARASITOL, V251, P56, DOI 10.1016/j.vetpar.2017.12.023
   Cotter JL, 2015, VET PARASITOL, V207, P276, DOI 10.1016/j.vetpar.2014.11.019
   Cringoli G, 2017, NAT PROTOC, V12, P1723, DOI 10.1038/nprot.2017.067
   Demeler J, 2009, VET PARASITOL, V160, P109, DOI 10.1016/j.vetpar.2008.10.030
   Findley K, 2013, NATURE, V498, P367, DOI 10.1038/nature12171
   Gasser RB, 1997, MOL CELL PROBE, V11, P201, DOI 10.1006/mcpr.1997.0106
   HENDERSON AWK, 1978, TROP ANIM HEALTH PRO, V10, P63, DOI 10.1007/BF02235308
   Koppelstaetter C, 2005, MECH AGEING DEV, V126, P1331, DOI 10.1016/j.mad.2005.08.003
   Lyndal-Murphy M, 2010, VET PARASITOL, V168, P146, DOI 10.1016/j.vetpar.2009.10.016
   LyndalMurphy M., 1987, AUSTR STANDARD DIAGN, P1
   MAFF/ADAS, 1986, MAN VET PAR LAB TECH, V418, P1
   Marin I, 2001, BIOTECHNIQUES, V30, P88, DOI 10.2144/01301st05
   Ramunke S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200390
   Rashid MH, 2019, PARASITOL RES, V118, P891, DOI 10.1007/s00436-019-06235-8
   Rashid MH, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2963-9
   Redman E, 2019, VET PARASITOL, V275, DOI 10.1016/j.vetpar.2019.108933
   Rehbein S, 1999, PARASITOL RES, V85, P783, DOI 10.1007/s004360050632
   Rendell DK, 2010, AUST VET J, V88, P504, DOI 10.1111/j.1751-0813.2010.00648.x
   Roeber F, 2017, VET PARASITOL, V239, P62, DOI 10.1016/j.vetpar.2017.04.011
   Roeber F, 2014, VET PARASITOL, V205, P619, DOI 10.1016/j.vetpar.2014.08.005
   Stromberg BE, 2012, VET PARASITOL, V183, P284, DOI 10.1016/j.vetpar.2011.07.030
   Taylor L, 2014, VET PARASITOL, V204, P269, DOI 10.1016/j.vetpar.2014.04.029
   van Wyk JA, 2004, VET PARASITOL, V119, P277, DOI 10.1016/j.vetpar.2003.11.012
   Vlaminck J, 2015, INT J PARASITOL, V45, P209, DOI 10.1016/j.ijpara.2014.11.001
   Waghorn TS, 2019, NEW ZEAL VET J, V67, P40, DOI 10.1080/00480169.2018.1532849
   Whitlock J.H., 1960, J VET PARASITISMS, P1
   WINKS R, 1970, AUST VET J, V46, P8, DOI 10.1111/j.1751-0813.1970.tb14872.x
NR 28
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD FEB
PY 2020
VL 278
AR UNSP 109033
DI 10.1016/j.vetpar.2020.109033
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KR8FZ
UT WOS:000517852700006
PM 32006906
DA 2020-05-12
ER

PT J
AU Gonzalez-Miguel, J
   Becerro-Recio, D
   Sotillo, J
   Simon, F
   Siles-Lucas, M
AF Gonzalez-Miguel, Javier
   Becerro-Recio, David
   Sotillo, Javier
   Simon, Fernando
   Siles-Lucas, Mar
TI Set up of an in vitro model to study early host-parasite interactions
   between newly excysted juveniles of Fasciola hepatica and host
   intestinal cells using a quantitative proteomics approach
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Fasciola hepatica; Newly excysted juveniles; Host's intestinal
   epithelium; In vitro model; Co-culture
ID STATISTICAL-MODEL; INFECTION; PROTEINS; MODULATION; PEPTIDASES;
   ACTIVATION; CANDIDATES; RESISTANCE; TEGUMENT; IMMUNITY
AB Fasciola hepatica is the causative agent of fasciolosis, a parasitic zoonosis of global distribution causing significant economic losses in animal production and a human public health problem in low-income countries. Hosts are infected by ingestion of aquatic plants carrying metacercariae. Once ingested, the juvenile parasites excyst in the small intestine and, after crossing it, they follow a complex migratory route that lead the parasites to their definitive location in the bile ducts. Despite being a critical event in the progression of the infection, the available data on the cross-talk relationships between the parasite and the host at an early stage of the infection are scarce. The objective of the present work is to characterize the proteomic changes occurring in both the parasite and the host, through the development of a novel in vitro model, to shed light on the molecular pathways of communication between the newly excysted juveniles (NEJ) from F. hepatica and the host's intestinal epithelium. For this, in vitro excystation of F. hepatica metacercariae was carried out and NEJ were obtained. Additionally, optimal conditions of growth and expansion of mouse primary small intestinal epithelial cells (MPSIEC) in culture were fine-tuned. Tegumentary and somatic parasite antigens (NEJ-Teg and NEJ-Som), as well as host cell protein lysate (MPSIEC-Lys) were obtained before and after 24 h co-culture of NEJ with MPSIEC. We used an isobaric tags for relative and absolute quantitation (iTRAQ)-based strategy to detect 191 and 62 up-regulated, and 112 and 57 down-regulated proteins in the NEJ-Teg and NEJ-Som extracts, respectively. Similarly, 87 up-regulated and 73 down-regulated proteins in the MPSIEC-Lys extract were identified. Taking into account the biological processes in which these proteins were involved, interesting mechanisms related to parasite development, invasion and evasion, as well as manipulation of the host intestinal epithelial cell adhesion, immunity and apoptosis pathways, among others, could be inferred, taking place at the host-parasite interface. The further understanding of these processes could constitute promising therapeutic targets in the future against fasciolosis.
C1 [Gonzalez-Miguel, Javier; Becerro-Recio, David; Siles-Lucas, Mar] CSIC, Inst Nat Resources & Agrobiol IRNASA, Sustainable Dev Dept, C Cordel de Merinas 52, Salamanca 37008, Spain.
   [Gonzalez-Miguel, Javier] Sechenov Univ, Martsinovsky Inst Med Parasitol Trop & Vector Bor, Moscow, Russia.
   [Sotillo, Javier] Inst Salud Carlos III, Ctr Nacl Microbiol, Madrid, Spain.
   [Sotillo, Javier] James Cook Univ, Ctr Mol Therapeut, Australian Inst Trop Hlth & Med, Cairns, Qld, Australia.
   [Simon, Fernando] Univ Salamanca, Fac Pharm, Lab Parasitol, Salamanca 37007, Spain.
RP Gonzalez-Miguel, J (reprint author), CSIC, Inst Nat Resources & Agrobiol IRNASA, Sustainable Dev Dept, C Cordel de Merinas 52, Salamanca 37008, Spain.; Gonzalez-Miguel, J (reprint author), Sechenov Univ, Martsinovsky Inst Med Parasitol Trop & Vector Bor, Moscow, Russia.
EM javier.gonzalez@irnasa.csic.es
RI Gonzalez-Miguel, Javier/A-4922-2019
OI Gonzalez-Miguel, Javier/0000-0003-4279-4761
FU Ministry MINECO, Spain [AGL2015-67023-C2-2-R]; JIN project "ULYSSES" -
   Ministerio de Ciencia, Innovation y Universidades (MCIU)
   [RTI2018-093463-J-100]; Agenda Estatal de Investigation (AEI); Fondo
   Europeo de Desarrollo Regional (FEDER, UE); Instituto de Salud Carlos
   IIIInstituto de Salud Carlos III [CP17III/00002];  [PT13/0001]
FX This work has been financed by Ministry MINECO, Spain (Project nb.
   AGL2015-67023-C2-2-R). Protein Identification by LC/MS/MS was carried
   out in the 'CI3MS0 PROTEIN CHEMISTRY FACILITY' that belongs to
   ProteoRed, PRB2-ISCTIL supported by grant PT13/0001. JGM is supported by
   the JIN project "ULYSSES" (RTI2018-093463-J-100) funded by Ministerio de
   Ciencia, Innovation y Universidades (MCIU), Agenda Estatal de
   Investigation (AEI) and Fondo Europeo de Desarrollo Regional (FEDER,
   UE). JS is a Miguel Servet Fellow funded by Instituto de Salud Carlos
   III (CP17III/00002).
CR Allaire JM, 2018, TRENDS IMMUNOL, V39, P677, DOI 10.1016/j.it.2018.04.002
   Alonso R, 2015, INT J BIOL SCI, V11, P546, DOI 10.7150/ijbs.11084
   Asif M., 2017, INT J BIOORG CHEM, V2, P146
   Barr F, 2010, CURR OPIN CELL BIOL, V22, P461, DOI 10.1016/j.ceb.2010.04.007
   BENNETT CE, 1975, EXP PARASITOL, V38, P38, DOI 10.1016/0014-4894(75)90036-3
   Bhoj VG, 2009, NATURE, V458, P430, DOI 10.1038/nature07959
   Bidula S, 2019, J IMMUNOL RES, DOI 10.1155/2019/3205072
   Brennan GP, 2007, EXP MOL PATHOL, V82, P104, DOI 10.1016/j.yexmp.2007.01.009
   Briehl MM, 1997, ONCOL RES, V9, P281
   Brubaker PL, 2012, ENDOCRINOLOGY, V153, P2945, DOI 10.1210/en.2012-1549
   Cestari I, 2013, MOL IMMUNOL, V53, P328, DOI 10.1016/j.molimm.2012.08.015
   Chandra Rashmi, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P63, DOI 10.1097/MED.0b013e3280122850
   Coakley G, 2016, MOL BIOCHEM PARASIT, V208, P33, DOI 10.1016/j.molbiopara.2016.06.003
   Conesa A, 2005, BIOINFORMATICS, V21, P3674, DOI 10.1093/bioinformatics/bti610
   Corvan SM, 2015, VET PARASITOL, V207, P285, DOI 10.1016/j.vetpar.2014.10.012
   Cwiklinski K, 2019, ADV PARASIT, V104, P113, DOI 10.1016/bs.apar.2019.01.001
   Cwiklinski K, 2018, INT J PARASITOL, V48, P321, DOI 10.1016/j.ijpara.2017.12.001
   Cwiklinski K, 2018, MOL CELL PROTEOMICS, V17, P792, DOI [10.1074/mcp.ra117.000445, 10.1074/mcp.RA117.000445]
   Cwiklinski K, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0632-2
   Dalton JP, 2013, VET PARASITOL, V195, P272, DOI 10.1016/j.vetpar.2013.04.008
   Di Genova BM, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00256
   Dominguez MF, 2018, VET PARASITOL, V258, P46, DOI 10.1016/j.vetpar.2018.06.011
   Ebner F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01868
   Efstathiou JA, 1998, AM J PATHOL, V153, P341, DOI 10.1016/S0002-9440(10)65576-9
   Feather CM, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2513-x
   Garcia-Campos A, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004688
   Garcia-Campos A, 2016, PARASITOLOGY, V143, P24, DOI 10.1017/S0031182015001481
   Goto Y, 2013, IMMUNOL CELL BIOL, V91, P204, DOI 10.1038/icb.2012.80
   Grevelding CG, 2018, TRENDS PARASITOL, V34, P246, DOI 10.1016/j.pt.2017.12.001
   Hernandez-Gonzalez A, 2010, MOL BIOCHEM PARASIT, V172, P121, DOI 10.1016/j.molbiopara.2010.04.003
   Hirst NL, 2016, INT J PARASITOL, V46, P425, DOI 10.1016/j.ijpara.2015.12.001
   Hooper LV, 2015, ADV IMMUNOL, V126, P129, DOI 10.1016/bs.ai.2014.11.003
   Huan YH, 1999, J CLIN INVEST, V104, P1459, DOI 10.1172/JCI5111
   Kasny M, 2009, ADV PARASIT, V69, P205, DOI 10.1016/S0065-308X(09)69004-7
   Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h
   Kelley JM, 2016, TRENDS PARASITOL, V32, P458, DOI 10.1016/j.pt.2016.03.002
   Kocher T, 2009, J PROTEOME RES, V8, P4743, DOI 10.1021/pr900451u
   Li J, 2016, CELL MOL IMMUNOL, V13, P560, DOI 10.1038/cmi.2016.40
   Maizels RM, 1991, PARASITE ANTIGENS PA
   Manning G, 2002, TRENDS BIOCHEM SCI, V27, P514, DOI 10.1016/S0968-0004(02)02179-5
   Mas-Coma S, 2014, ADV EXP MED BIOL, V766, P77, DOI 10.1007/978-1-4939-0915-5_4
   Moazeni M, 2016, EXP PARASITOL, V169, P81, DOI 10.1016/j.exppara.2016.07.010
   Morphew RM, 2013, VET PARASITOL, V191, P379, DOI 10.1016/j.vetpar.2012.08.029
   Mulvenna J, 2010, INT J PARASITOL, V40, P543, DOI 10.1016/j.ijpara.2009.10.002
   Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261
   Nguyen TGT, 2011, ACTA TROP, V117, P19, DOI 10.1016/j.actatropica.2010.09.003
   Piedrafita D, 2001, PARASITE IMMUNOL, V23, P473, DOI 10.1046/j.1365-3024.2001.00404.x
   Poole RK, 2005, BIOCHEM SOC T, V33, P176, DOI 10.1042/BST0330176
   Prashar A, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00435
   Ravida A, 2016, MOL CELL PROTEOMICS, V15, P3139, DOI 10.1074/mcp.M116.059774
   Ren Yushan, 2014, Virologica Sinica, V29, P25, DOI 10.1007/s12250-014-3421-2
   Ressurreicao M, 2016, SCI REP-UK, V6, DOI 10.1038/srep35614
   Robinson MW, 2008, MOL CELL PROTEOMICS, V7, P1111, DOI 10.1074/mcp.M700560-MCP200
   Roditi I, 2016, MOL BIOCHEM PARASIT, V208, P16, DOI 10.1016/j.molbiopara.2016.05.008
   Ryan LA, 2008, MOL BIOCHEM PARASIT, V159, P73, DOI 10.1016/j.molbiopara.2008.02.001
   Schweizer G, 2005, VET REC, V157, P188, DOI 10.1136/vr.157.7.188
   Shadforth IP, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-145
   Shevchenko A, 2001, ELECTROPHORESIS, V22, P1194, DOI 10.1002/1522-2683()22:6<1194::AID-ELPS1194>3.0.CO;2-A
   Skelly PJ, 2006, ADV PARASIT, V63, P185, DOI 10.1016/S0065-308X(06)63003-0
   Stack C, 2011, ADV EXP MED BIOL, V712, P116, DOI 10.1007/978-1-4419-8414-2_8
   Stutzer C, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00067
   Taman A, 2009, MOL BIOCHEM PARASIT, V168, P24, DOI 10.1016/j.molbiopara.2009.06.003
   Toet H, 2014, INT J PARASITOL, V44, P915, DOI 10.1016/j.ijpara.2014.07.011
   van Milligen FJ, 1998, J IMMUNOL METHODS, V213, P183, DOI 10.1016/S0022-1759(98)00026-X
   WIEST PM, 1992, AM J TROP MED HYG, V46, P358, DOI 10.4269/ajtmh.1992.46.358
   Zhou Y, 2015, CELL MICROBIOL, V17, P26, DOI 10.1111/cmi.12384
NR 66
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD FEB
PY 2020
VL 278
AR UNSP 109028
DI 10.1016/j.vetpar.2020.109028
PG 9
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KR8FZ
UT WOS:000517852700007
PM 31986420
DA 2020-05-12
ER

PT J
AU Kumar, R
   Sharma, AK
   Ghosh, S
AF Kumar, Rinesh
   Sharma, Anil Kumar
   Ghosh, Srikant
TI Menace of acaricide resistance in cattle tick, Rhipicephalus microplus
   in India: Status and possible mitigation strategies
SO VETERINARY PARASITOLOGY
LA English
DT Review
DE Acaricides; Contributing factors; India; Rhipicephalus microplus;
   Resistance; Resistance mechanisms
ID IN-FIELD POPULATIONS; SODIUM-CHANNEL GENE; BOOPHILUS-MICROPLUS;
   HYALOMMA-ANATOLICUM; SYNTHETIC PYRETHROIDS; AMITRAZ RESISTANCE;
   DELTAMETHRIN RESISTANCE; 1ST REPORT; DISCRIMINATING CONCENTRATIONS;
   ORGANOPHOSPHATE RESISTANCE
AB Livestock in general and dairy sector in particular plays a vital role in the Indian economy and in the socioeconomic development of millions of people. Rhipicephalus microplus, a one-host and the most prevalent cattle tick in various agro climatic zones of India. This tick species is responsible for severe economic losses to livestock owners both through the direct effects of blood sucking, injection of toxins and indirectly by transmitting pathogens. Due to inadvertent and indiscriminate use of chemicals to kill ticks, field tick population has developed resistance to almost all chemicals that are used to manage them. The intention of this review is to provide the current status of resistance in ticks, the possible mechanisms of resistance operating in the tick population, factors contributing to the development of resistance and the managemental strategies.
C1 [Kumar, Rinesh; Sharma, Anil Kumar; Ghosh, Srikant] ICAR Indian Vet Res Inst, Div Parasitol, Bareilly 243122, Uttar Pradesh, India.
   [Kumar, Rinesh] Coll Vet & Anim Sci, Dept Parasitol, Rewa, Madhya Pradesh, India.
RP Ghosh, S (reprint author), ICAR Indian Vet Res Inst, Div Parasitol, Bareilly 243122, Uttar Pradesh, India.
EM sghoshtick@gmail.com
FU Indian Council of Agricultural Research, New DelhiIndian Council of
   Agricultural Research (ICAR); National Agricultural Science Fund
   [NASF/ABA-6015/2016-17/357, NFBSFARA/BSA4004/2013-14]
FX The authors are grateful to Indian Council of Agricultural Research, New
   Delhi for funding through National Agricultural Science Fund [Grant
   number NASF/ABA-6015/2016-17/357 and NFBSFARA/BSA4004/2013-14].
CR Abdullah Swaid, 2013, Acarina, V21, P84
   Ahanger RR, 2015, EXP APPL ACAROL, V67, P467, DOI 10.1007/s10493-015-9960-x
   Andreotti R, 2011, REV BRAS PARASITOL V, V20, P127, DOI 10.1590/S1984-29612011000200007
   Baffi MA, 2008, MOL BIOCHEM PARASIT, V160, P70, DOI 10.1016/j.molbiopara.2008.03.009
   Baffi MA, 2007, VET PARASITOL, V148, P301, DOI 10.1016/j.vetpar.2007.06.016
   BANSAL GC, 2005, P NAT ACAD SCI INDIA, V75, P134
   Baron S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131341
   Basu A. K., 1997, Journal of Veterinary Parasitology, V11, P183
   Baxter GD, 1998, INSECT BIOCHEM MOLEC, V28, P581, DOI 10.1016/S0965-1748(98)00034-4
   Castro-Janer E, 2010, VET PARASITOL, V173, P300, DOI 10.1016/j.vetpar.2010.06.036
   Castro-Janer E, 2009, VET PARASITOL, V162, P120, DOI 10.1016/j.vetpar.2009.02.013
   CHAUDHURI R. P., 1964, BULL ENTOMOL RES, V55, P405, DOI 10.1017/S0007485300049555
   Chen AC, 2007, VET PARASITOL, V148, P379, DOI 10.1016/j.vetpar.2007.06.026
   Chen AC, 2009, J ECON ENTOMOL, V102, P373, DOI 10.1603/029.102.0148
   Chhabra M. B., 1998, Journal of Veterinary Parasitology, V12, P3
   Chigure GM, 2018, INT J ACAROL, V44, P28, DOI 10.1080/01647954.2017.1400588
   Corley SW, 2013, P NATL ACAD SCI USA, V110, P16772, DOI 10.1073/pnas.1309072110
   Crampton AL, 1999, EXP APPL ACAROL, V23, P897, DOI 10.1023/A:1006245800759
   DAHD, 2015, 19 LIV CENS 2012 ALL, P20
   DAHD, 2018, NAT ACT PLAN DAIR DE, P13
   De La Fuente J, 2000, ANN NY ACAD SCI, V916, P617
   Dutta S, 2017, EXP APPL ACAROL, V71, P291, DOI 10.1007/s10493-017-0111-4
   Enayati AA, 2010, PESTIC BIOCHEM PHYS, V97, P243, DOI 10.1016/j.pestbp.2010.03.003
   EVANS PD, 1980, NATURE, V287, P60, DOI 10.1038/287060a0
   FAO, 2004, MOD 1 TICKS AC RES D, P25
   Faza AP, 2013, EXP PARASITOL, V134, P519, DOI 10.1016/j.exppara.2013.04.006
   Fular A, 2018, TICKS TICK-BORNE DIS, V9, P1184, DOI 10.1016/j.ttbdis.2018.04.014
   Gaur R, 2017, EXP APPL ACAROL, V73, P115, DOI 10.1007/s10493-017-0175-1
   Gaur RS, 2016, EXP APPL ACAROL, V69, P487, DOI 10.1007/s10493-016-0046-1
   Geary TG, 2005, TRENDS PARASITOL, V21, P530, DOI 10.1016/j.pt.2005.08.014
   Ghosh S, 2007, EXP APPL ACAROL, V43, P137, DOI 10.1007/s10493-007-9100-3
   Ghosh S., 2014, STUDY HERBAL ACARICI
   Ghosh SK, 1997, INDIAN VET J, V74, P250
   Ghosh S, 2007, PARASITOL RES, V101, pS207, DOI 10.1007/s00436-007-0684-7
   Ghosh S, 2017, PESTIC BIOCHEM PHYS, V138, P66, DOI 10.1016/j.pestbp.2017.03.002
   Ghosh S, 2015, TICKS TICK-BORNE DIS, V6, P668, DOI 10.1016/j.ttbdis.2015.05.013
   Ghosh S, 2014, J VECTOR DIS, V51, P259
   Godara R, 2019, TROP ANIM HEALTH PRO, V51, P1203, DOI 10.1007/s11250-019-01810-8
   He HQ, 1999, BIOCHEM BIOPH RES CO, V261, P558, DOI 10.1006/bbrc.1999.1076
   Hernandez R, 1999, J MED ENTOMOL, V36, P764, DOI 10.1093/jmedent/36.6.764
   Hernandez R, 2000, INSECT BIOCHEM MOLEC, V30, P969, DOI 10.1016/S0965-1748(00)00069-2
   Hollingworth R.M., 1982, INSECTICIDE MODE ACT, P189
   Jamroz RC, 2000, J INSECT PHYSIOL, V46, P685, DOI 10.1016/S0022-1910(99)00157-2
   Jani B. M., 1991, Journal of Veterinary Parasitology, V5, P136
   Jongejan F, 2004, PARASITOLOGY, V129, pS3, DOI 10.1017/S0031182004005967
   Jonsson NN, 2007, VET PARASITOL, V146, P193, DOI 10.1016/j.vetpar.2007.03.006
   Jonsson NN, 2010, INT J PARASITOL, V40, P1659, DOI 10.1016/j.ijpara.2010.07.006
   Jonsson N, 2018, FRONT BIOSCI-LANDMRK, V23, P796, DOI 10.2741/4617
   Jonsson NN, 2000, VET PARASITOL, V88, P79, DOI 10.1016/S0304-4017(99)00189-2
   Jyothimol G, 2014, VET PARASITOL, V204, P433, DOI 10.1016/j.vetpar.2014.04.028
   Jyoti, 2016, J Parasit Dis, V40, P694, DOI 10.1007/s12639-014-0562-z
   Jyoti, 2015, Toxicol Int, V22, P125, DOI 10.4103/0971-6580.172274
   Jyoti, 2016, VET PARASITOL, V216, P108, DOI 10.1016/j.vetpar.2015.12.004
   Jyoti, 2014, J Parasit Dis, V38, P343, DOI 10.1007/s12639-013-0322-5
   Jyoti, 2012, INDIAN VET J, V89, P23
   Katuri R N, 2017, J Parasit Dis, V41, P713, DOI 10.1007/s12639-016-0872-4
   Kaur D., 2017, INT J FAUNA BIOL STU, V4, P112
   Khajuria V, 2014, INDIAN VET J, V91, P21
   Khan M.H., 1990, REV BRAS PARASITOL, V4, P9
   Klafke GM, 2017, J MED ENTOMOL, V54, P1639, DOI 10.1093/jme/tjx060
   Klafke G, 2017, TICKS TICK-BORNE DIS, V8, P73, DOI 10.1016/j.ttbdis.2016.09.019
   Klafke GM, 2006, VET PARASITOL, V142, P386, DOI 10.1016/j.vetpar.2006.07.001
   Klafke GM, 2019, INT J PARASITOL-DRUG, V9, P100, DOI 10.1016/j.ijpddr.2019.03.001
   Klafke GM, 2010, VET PARASITOL, V168, P97, DOI 10.1016/j.vetpar.2009.10.003
   Kumar R, 2013, ACTA TROP, V125, P237, DOI 10.1016/j.actatropica.2012.10.006
   Kumar S.S., 2017, Journal of Entomology and Zoology Studies, V5, P580
   Kumar S, 2016, INDIAN J ANIM SCI, V86, P14
   Kumar S, 2015, TICKS TICK-BORNE DIS, V6, P383, DOI 10.1016/j.ttbdis.2015.03.003
   Kumar S, 2014, EXP APPL ACAROL, V63, P413, DOI 10.1007/s10493-014-9789-8
   Kumar S, 2011, VET PARASITOL, V181, P274, DOI 10.1016/j.vetpar.2011.04.030
   KUNZ SE, 1994, REV SCI TECH OIE, V13, P1249, DOI 10.20506/rst.13.4.816
   Lenka D R, 2016, Vet Parasitol Reg Stud Reports, V5, P37, DOI 10.1016/j.vprsr.2016.09.002
   Li AY, 2007, PEST MANAG SCI, V63, P882, DOI 10.1002/ps.1417
   Li AY, 2005, J ECON ENTOMOL, V98, P552, DOI 10.1603/0022-0493-98.2.552
   Lovis L, 2012, INT J PARASITOL-DRUG, V2, P216, DOI 10.1016/j.ijpddr.2012.08.001
   Martins JR, 2001, VET REC, V149, P64
   Mendes M. C., 2007, Arqivos do Instituto Biologico Sao Paulo, V74, P81
   Mendes M.C., 2010, 13 INT C AC REC, P152
   Miller RJ, 1999, J MED ENTOMOL, V36, P533, DOI 10.1093/jmedent/36.5.533
   Miller RJ, 2002, J MED ENTOMOL, V39, P645, DOI 10.1603/0022-2585-39.4.645
   Minjauw B, 2003, RES REPORT
   Morgan JAT, 2009, INT J PARASITOL, V39, P775, DOI 10.1016/j.ijpara.2008.12.006
   Nagar G., 2016, INT J SCI ENV TECH, V5, P3440
   Nagar G, 2018, EXP APPL ACAROL, V75, P319, DOI 10.1007/s10493-018-0265-8
   Nandi A, 2018, VET PARASITOL, V250, P30, DOI 10.1016/j.vetpar.2017.12.009
   Nandi A, 2015, EXP APPL ACAROL, V66, P141, DOI 10.1007/s10493-015-9884-5
   Pasay C, 2008, MED VET ENTOMOL, V22, P82, DOI 10.1111/j.1365-2915.2008.00716.x
   Perez-Cogollo LC, 2010, VET PARASITOL, V172, P109, DOI 10.1016/j.vetpar.2010.04.030
   Perez-Cogollo LC, 2010, VET PARASITOL, V168, P165, DOI 10.1016/j.vetpar.2009.10.021
   Pradeep BS, 2012, INDIAN J ANIM RES, V46, P248
   RATH SS, 2006, J INSECT SCI, V19, P74
   Ravindran R, 2014, TROP BIOMED, V31, P449
   Reck J, 2014, VET PARASITOL, V201, P128, DOI 10.1016/j.vetpar.2014.01.012
   Rodriguez-Vivas RI, 2018, PARASITOL RES, V117, P3, DOI 10.1007/s00436-017-5677-6
   Sabatini GA, 2001, VET PARASITOL, V95, P53, DOI 10.1016/S0304-4017(00)00406-4
   Sharma AK, 2012, VET PARASITOL, V188, P337, DOI 10.1016/j.vetpar.2012.03.050
   Sharma N, 2018, INT J ACAROL, V44, P268, DOI 10.1080/01647954.2018.1513559
   Shyma K P, 2015, J Parasitol Res, V2015, P506586, DOI 10.1155/2015/506586
   Shyma KP, 2013, INDIAN J ANIM SCI, V83, P591
   Singh N.K., 2015, Journal of Parasitic Diseases, V39, P49, DOI 10.1007/s12639-013-0280-y
   Singh NK, 2014, SCI WORLD J, DOI 10.1155/2014/594398
   Singh N. K., 2010, Journal of Veterinary Parasitology, V24, P207
   Singh NK, 2014, TICKS TICK-BORNE DIS, V5, P90, DOI 10.1016/j.ttbdis.2013.08.002
   Singh NK, 2015, VET PARASITOL, V214, P192, DOI 10.1016/j.vetpar.2015.09.014
   Singh NK, 2014, VET PARASITOL, V204, P330, DOI 10.1016/j.vetpar.2014.05.035
   Sinha S. R. P., 2010, Journal of Veterinary Parasitology, V24, P75
   Soundararajan C, 2006, INDIAN VET J, V83, P1258
   Srivastava P. K., 2001, Indian Veterinary Medical Journal, V25, P293
   STONE B. F., 1962, Bulletin of Entomological Research, V53, Pt. 3, P563, DOI 10.1017/S000748530004832X
   Stone NE, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0456-z
   Stutzer C, 2013, INT J PARASITOL, V43, P541, DOI 10.1016/j.ijpara.2013.01.009
   Sungirai M, 2018, TICKS TICK-BORNE DIS, V9, P2, DOI 10.1016/j.ttbdis.2017.10.017
   Taylor MA, 2001, VET J, V161, P253, DOI 10.1053/tvjl.2000.0549
   Temeyer KB, 2004, J MED ENTOMOL, V41, P259, DOI 10.1603/0022-2585-41.3.259
   Temeyer KB, 2007, J MED ENTOMOL, V44, P1013, DOI 10.1603/0022-2585(2007)44[1013:RAMIBY]2.0.CO;2
   Temeyer KB, 2013, PESTIC BIOCHEM PHYS, V106, P118, DOI 10.1016/j.pestbp.2013.01.005
   Temeyer KB, 2009, J MED ENTOMOL, V46, P1355, DOI 10.1603/033.046.0614
   van Wyk RDJ, 2016, TICKS TICK-BORNE DIS, V7, P586, DOI 10.1016/j.ttbdis.2016.01.007
   Vatsya S, 2011, INT J ACAROL, V37, P405, DOI 10.1080/01647954.2010.521518
   Velusamy R, 2014, VET WORLD, V7, P574, DOI 10.14202/vetworld.2014.574-578
   Yessinou RE, 2018, TICKS TICK-BORNE DIS, V9, P665, DOI 10.1016/j.ttbdis.2018.02.013
NR 121
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD FEB
PY 2020
VL 278
AR UNSP 108993
DI 10.1016/j.vetpar.2019.108993
PG 10
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KR8FZ
UT WOS:000517852700001
PM 31954273
DA 2020-05-12
ER

PT J
AU Mantilla-Montelongo, G
   Castaneda-Ramirez, GS
   Can-Celis, A
   Chan-Perez, JI
   Sandoval-Castro, CA
   Torres-Acosta, JFD
AF Mantilla-Montelongo, Gabriela
   Sarahi Castaneda-Ramirez, Gloria
   Can-Celis, Alhely
   Israel Chan-Perez, Jose
   Alfredo Sandoval-Castro, Carlos
   de Jesus Torres-Acosta, Juan Felipe
TI Optimal age of Trichostrongylus colubriformis larvae (L-3) for the in
   vitro larval exsheathment inhibition test under tropical conditions
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Trichostrongylus colubriformis; Larval exsheathment inhibition test;
   Optimal age; Anthelmintic activity; Small ruminants; Plant extracts
ID HAEMONCHUS-CONTORTUS; GASTROINTESTINAL NEMATODES; INFECTIVE LARVAE;
   RESISTANCE; MIGRATION; EXTRACTS; ANTHELMINTICS
AB This study identified the optimal age of Trichostrongylus colubnformis larvae (L-3) under tropical conditions for the in vitro evaluation of plant extracts using the larval exsheathment inhibition test (LEIT). Two T. colubriformis isolates with different anthelmintic (AH) susceptibility status were used for this study. The L-3 of both isolates were maintained on refrigeration (4-5 degrees C) until use. For the LEIT, the isolates were tested every week during 16 weeks, using a stock solution of Acacia pennatula acetone:water extract at different dilutions (80-1200 mu g/mL). Respective positive controls (levamisole 12.5 mM) and negative controls (PBS) were included. Effective concentrations 50 % (EC50), 90 % (EC90) and respective 95 % confidence intervals (95 %CI) for exsheathment inhibition were calculated at 60 min after exposure to chlorine solution. Motility of L-3 (migration percentages (M %)) was recorded weekly using the larval migration test (LMT) as an indicator of L-3 fitness over time. No correlation was found between L-3 age or M% and the extract's EC50 or EC90 values. However, the EC50 values for the A. pennatula extract ranged from 80 to 200 mu g/mL from weeks 2-10. Beyond week 12, larval exsheathment was irregular, with higher EC50 and EC90 values and wider 95 %CI. The M% decreased below 85 % on week 7 for Paraiso isolate, and on week 10 for FMVZ isolate. A linear negative relationship was observed between the age of L-3 and M% for both T. colubriformis isolates. The relationship (slope) for both isolates was similar therefore a single linear equation was estimated describing all M% data (r(2) = 0.771, df = 164, P < 0.05). Thus, when using these T. colubriformis isolates under our tropical conditions for the evaluation of AH activity of plant extracts with LEIT, the optimal age of L-3 is between weeks 2-7, when M% remained above 85 %. The latter may ensure consistent and reproducible exsheathment results for T. colubriformis. Each laboratory must identify optimal conditions to perform the LEIT.
C1 [Mantilla-Montelongo, Gabriela] Univ Autonoma Yucatan, CONACYT, Fac Med Vet & Zootecnia, Km 15-5 Carretera Merida Xmatkuil, Merida 97100, Yucatan, Mexico.
   [Sarahi Castaneda-Ramirez, Gloria; Can-Celis, Alhely; Israel Chan-Perez, Jose; Alfredo Sandoval-Castro, Carlos; de Jesus Torres-Acosta, Juan Felipe] Univ Autonoma Yucatan, Fac Med Vet & Zootecnia, CCBA, Km 15-5 Carretera Merida Xmatkuil, Merida 97100, Yucatan, Mexico.
RP Torres-Acosta, JFD (reprint author), Univ Autonoma Yucatan, Fac Med Vet & Zootecnia, CCBA, Km 15-5 Carretera Merida Xmatkuil, Merida 97100, Yucatan, Mexico.
EM maria.mancilla@correo.uady.mx; carlos.sandoval@correo.uady.mx;
   tacosta@correo.uady.mx
RI Sandoval-Castro, Carlos Alfredo/A-8097-2008
OI Sandoval-Castro, Carlos Alfredo/0000-0003-2778-8240; Torres-Acosta, Juan
   Felipe de Jesus/0000-0003-3724-3391; Mancilla-Montelongo,
   Gabriela/0000-0001-6481-6496
FU CONACYTConsejo Nacional de Ciencia y Tecnologia (CONACyT)
   [CB-2013-01/221041]; Catedras CONACYT Programme [692]
FX This work was financed by project CONACYT: CB-2013-01/221041. G.
   Mancilla-Montelongo thanks the Catedras CONACYT Programme (Project
   number 692).
CR Alonso-Diaz MA, 2008, VET PARASITOL, V153, P187, DOI 10.1016/j.vetpar.2008.01.011
   [Anonymous], 2020, GRAPHPAD PRISM VERS
   Barrau E, 2005, PARASITOLOGY, V131, P531, DOI 10.1017/S0031182005008024
   Brunet S, 2008, VET PARASITOL, V157, P81, DOI 10.1016/j.vetpar.2008.07.013
   Brunet S, 2011, PARASITOL INT, V60, P419, DOI 10.1016/j.parint.2010.09.011
   Castaneda-Ramirez GS, 2018, PARASITOL RES, V117, P3979, DOI 10.1007/s00436-018-6107-0
   Castaneda-Ramirez GS, 2017, VET PARASITOL, V243, P130, DOI 10.1016/j.vetpar.2017.06.019
   Chan-Perez JI, 2017, VET PARASITOL, V240, P11, DOI 10.1016/j.vetpar.2017.04.023
   Chylinski C, 2015, PARASITOL RES, V114, P715, DOI 10.1007/s00436-014-4238-5
   Demeler J, 2010, VET PARASITOL, V170, P61, DOI 10.1016/j.vetpar.2010.01.032
   Garate-Gallardo L, 2015, PARASITE, V22, DOI 10.1051/parasite/2015019
   Giraldo O, 2018, PEERJ, V6, DOI 10.7717/peerj.4795
   Hoste H, 2016, ADV PARASIT, V93, P239, DOI 10.1016/bs.apar.2016.02.025
   Jackson F, 2010, IN VITRO SCREENING OF PLANT RESOURCES FOR EXTRA-NUTRITIONAL ATTRIBUTES IN RUMINANTS: NUCLEAR AND RELATED METHODOLOGIES, P25, DOI 10.1007/978-90-481-3297-3_3
   Jaimez-Rodriguez PR, 2019, TROP ANIM HEALTH PRO, V51, P2243, DOI 10.1007/s11250-019-01928-9
   LeOra Software, 2004, PROBIT LOGIT ANAL LE
   Love SCJ, 2003, GROSS PATHOLOGY RUMI, V350, P309
   Mancilla G., 2019, REV LATINOAM QUIM, V47, P71
   Marie-Magdeleine C, 2014, RES VET SCI, V96, P127, DOI 10.1016/j.rvsc.2013.12.004
   Martinez-Ortiz-de-Montellano C, 2013, EXP PARASITOL, V133, P281, DOI 10.1016/j.exppara.2012.11.024
   Mendez-Ortiz FA, 2019, TROP ANIM HEALTH PRO, V51, P1591, DOI 10.1007/s11250-019-01855-9
   Ministry of Agriculture Fisheries and Food (MAFF), 1986, MAN VET PAR LAB TECH, V418, P160
   O'Connor LJ, 2006, VET PARASITOL, V142, P1, DOI 10.1016/j.vetpar.2006.08.035
   de Montellano CMO, 2007, VET PARASITOL, V146, P66, DOI 10.1016/j.vetpar.2007.02.012
   Ortiz-Ocampo G. I., 2016, Tropical and Subtropical Agroecosystems, V19, P41
   Quijada J, 2015, J AGR FOOD CHEM, V63, P6346, DOI 10.1021/acs.jafc.5b00831
   R Core Team, 2018, R LANG ENV STAT COMP
   RABEL B, 1994, INT J PARASITOL, V24, P671, DOI 10.1016/0020-7519(94)90119-8
   Torres-Acosta JFJ, 2012, VET PARASITOL, V189, P89, DOI 10.1016/j.vetpar.2012.03.037
   Torres-Acosta JFJ, 2004, VET PARASITOL, V124, P217, DOI 10.1016/j.vetpar.2004.07.009
   Troell K, 2006, PARASITOLOGY, V132, P403, DOI 10.1017/S0031182005009182
   WAGLAND BM, 1992, INT J PARASITOL, V22, P1183, DOI 10.1016/0020-7519(92)90040-R
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD FEB
PY 2020
VL 278
AR UNSP 109027
DI 10.1016/j.vetpar.2020.109027
PG 6
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KR8FZ
UT WOS:000517852700005
PM 31981859
DA 2020-05-12
ER

PT J
AU Marjanovic, DS
   Zdravkovic, N
   Milovanovic, M
   Trailovic, JN
   Robertson, AP
   Todorovic, Z
   Trailovic, SM
AF Marjanovic, Djordje S.
   Zdravkovic, Nemanja
   Milovanovic, Mirjana
   Trailovic, Jelena Nedeljkovic
   Robertson, Alan P.
   Todorovic, Zoran
   Trailovic, Sasa M.
TI Carvacrol acts as a potent selective antagonist of different types of
   nicotinic acetylcholine receptors and enhances the effect of monepantel
   in the parasitic nematode Ascaris suum
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Carvacrol; Monepantel; A. suum; nAChR
ID ANTHELMINTIC DRUG DISCOVERY; MECHANISM
AB The neuromuscular system of parasitic nematodes has proven to be an efficient pharmacological target for antihelmintics. Some of the most frequently used antiparasitic drugs are agonists or antagonists of nicotinic acetylcholine receptors (nAChRs). The antinematodal mechanism of action of carvacrol involves the inhibition of parasite muscle contraction. We have examined the interaction of carvacrol with antinematodal drugs that are agonists of different subtypes of nAChRs and monepantel, which is a non-competitive antagonist of this receptor in A. suum. Additionally, we investigated the effect of carvacrol on the muscle type of nAChRs in the mammalian host. As orthosteric agonists of nAChR, pyrantel, morantel and befinijum lead to dose-dependent contractions of the neuromuscular preparation of Ascaris suum. Carvacrol 100 mu M decreased the E-max of pyrantel, morantel and bephenium by 29%, 39% and 12 %, 39 % and 12 % respectively. The EC50 ratio was 3.43, 2.95 and 2.47 for pyrantel, morantel and bephinium, respectively. Carvacrol 300 u mu M reduces the E-max of pyrantel, morantel and bephenium by 71%, 80% and 75 %, 80 % and 75 % respectively. The EC50 ratio for pyrantel, morantel and bephenium was 3.88, 3.19 and 4.83 respectively. Furthermore, carvacrol enhances the inhibitory effect of monepantel on A. mum contractions, which may have an effective clinical application. On the other hand, tested concentrations of carvacrol did not significantly affect the EFS-induced contractions of the rat diaphragm, indicating a lack of interaction with the postsynaptic nAChR at the muscle end plate in mammals, but the highest concentration (300 mu M) caused a clear tetanic fade. Carvacrol exhibited a time and dose-dependent effect on the Rota-rod performances of rats with a high value of the ED50 (421.6 mg/kg). In our research, carvacrol dominantly exhibited characteristics of a non-competitive antagonist of nAChR in A. suum, and enhances the inhibitory effect of monepantel. The combination of monepantel and carvacrol may be clinically very effective, and the carvacrol molecule itself can be used as a promising platform for the development of new anthelmintic drugs.
C1 [Marjanovic, Djordje S.; Zdravkovic, Nemanja; Milovanovic, Mirjana; Trailovic, Jelena Nedeljkovic; Trailovic, Sasa M.] Univ Belgrade, Fac Vet Med, Bulevar Oslobodjenja 18, Belgrade 11000, Serbia.
   [Robertson, Alan P.] Iowa State Univ, Coll Vet Med, Ames, IA 50011 USA.
   [Todorovic, Zoran] Univ Belgrade, Fac Med, Doktora Subotica 8, Belgrade 11000, Serbia.
RP Trailovic, SM (reprint author), Univ Belgrade, Fac Vet Med, Bulevar Oslobodjenja 18, Belgrade 11000, Serbia.
EM drdjolevet@yahoo.com; nemanja.zdravkovich@gmail.com; miram@vet.bg.ac.rs;
   tjelena@vet.bg.ac.rs; alanr@iastate.edu; zoran.todorovic@med.bg.ac.rs;
   sasa@vet.bg.ac.rs
OI Todorovic, Zoran/0000-0001-8869-9976
FU Ministry of Education, Science and Technological Development Republic of
   Serbia [TR31087]
FX This study was supported by the Ministry of Education, Science and
   Technological Development Republic of Serbia, Grant No TR31087.
CR Abongwa M, 2018, INT J PARASITOL-DRUG, V8, P36, DOI 10.1016/j.ijpddr.2017.12.001
   Abongwa M, 2017, ACTA VET-BEOGRAD, V67, P137, DOI 10.1515/acve-2017-0013
   Adams R.H., 2001, VET PHARM THERAPEUTI, P947
   Anderson R. C., 2000, NEMATODE PARASITES V
   ASCHER P, 1979, J PHYSIOL-LONDON, V295, P139, DOI 10.1113/jphysiol.1979.sp012958
   COLQUHOUN L, 1991, J EXP BIOL, V158, P509
   da Silva FF, 2018, REV BRAS PARASITOL V, V27, P423, DOI [10.1590/S1984-296120180071, 10.1590/s1984-296120180071]
   DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322
   Geary TG, 2015, J PARASITOL, V101, P125, DOI 10.1645/14-703.1
   GURNEY AM, 1984, BRIT J PHARMACOL, V82, P623, DOI 10.1111/j.1476-5381.1984.tb10801.x
   JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x
   Kaminsky R, 2008, PARASITOL RES, V103, P931, DOI 10.1007/s00436-008-1080-7
   Klowden MJ., 2007, PHYSL SYSTEMS INSECT
   Komuniecki R, 2012, MOL BIOCHEM PARASIT, V183, P1, DOI 10.1016/j.molbiopara.2012.02.001
   Lei J, 2010, BIOCHEM PHARMACOL, V79, P1062, DOI 10.1016/j.bcp.2009.11.002
   Martin RJ, 2004, INT J PARASITOL, V34, P1083, DOI 10.1016/j.ijpara.2004.04.014
   Martin RJ, 1998, INT J PARASITOL, V28, P849, DOI 10.1016/S0020-7519(98)00048-4
   Papke RL, 2001, J PHARMACOL EXP THER, V297, P646
   Paterson S, 2007, P ROY SOC B-BIOL SCI, V274, P1467, DOI 10.1098/rspb.2006.0433
   Ploeger HW, 2018, VET PARASITOL, V262, P11, DOI 10.1016/j.vetpar.2018.09.007
   Puttachary S, 2013, MOL BIOCHEM PARASIT, V188, P79, DOI 10.1016/j.molbiopara.2013.02.004
   Richmond JE, 1999, NAT NEUROSCI, V2, P791, DOI 10.1038/12160
   Robertson AP, 2002, J PHARMACOL EXP THER, V302, P853, DOI 10.1124/jpet.102.034272
   Roepstorff A, 2011, VET PARASITOL, V180, P72, DOI 10.1016/j.vetpar.2011.05.029
   Stemmelin J, 2008, NEUROPSYCHOPHARMACOL, V33, P574, DOI 10.1038/sj.npp.1301424
   Thamsborg SM, 2013, ASCARIS: THE NEGLECTED PARASITE, P363, DOI 10.1016/B978-0-12-396978-1.00014-8
   Trailovic SM, 2015, PARASITOL RES, V114, P3059, DOI 10.1007/s00436-015-4508-x
   Trailovic SM, 2011, RES VET SCI, V91, P426, DOI 10.1016/j.rvsc.2010.09.016
   Umetsu S, 2014, WORLD J GASTROENTERO, V20, P14058, DOI 10.3748/wjg.v20.i38.14058
NR 29
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD FEB
PY 2020
VL 278
AR UNSP 109031
DI 10.1016/j.vetpar.2020.109031
PG 11
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KR8FZ
UT WOS:000517852700012
PM 32032866
DA 2020-05-12
ER

PT J
AU Nawaz, M
   Malik, I
   Hameed, M
   Kuthu, ZH
   Zhou, JL
AF Nawaz, Mohsin
   Malik, Irfan
   Hameed, Mudassar
   Kuthu, Zulfiqar Hussain
   Zhou, Jinlin
TI Modifications of histones in parasites as drug targets
SO VETERINARY PARASITOLOGY
LA English
DT Review
DE Post-translational modifications; Histone acetylases; Histone
   methyltransferase; Plasmodium
ID DEACETYLASE INHIBITORS; GENE-EXPRESSION; ANTIMALARIAL ACTIVITY;
   SCHISTOSOMA-MANSONI; PLASMODIUM-FALCIPARUM; METHYLTRANSFERASE
   INHIBITORS; EPIGENETIC REGULATION; ANTIGENIC VARIATION;
   CHROMATIN-STRUCTURE; MODIFYING ENZYMES
AB Post-translational modifications of histones and histone modifying enzymes play important roles in gene regulations and other physiological processes in parasites. Inhibitors of such modifying enzymes could be useful as novel therapeutics against parasitic diseases or as chemical probes for investigation of epigenetics. Development of parasitic histone modulators has got rapid expansion in the last few years. A number of highly potent and selective compounds have been reported, together with extensive preclinical studies of their biological activity. Some of these compounds have been widely used in humans targeting cancer and are found non-toxic. This review summarizes the antiparasitic activities of histone and histone modifying enzymes inhibitors evaluated in last few years. As the current chemotherapy against parasites is still not satisfactory, therefore, such compounds represents good starting points for the discovery of effective antiparasitic drugs.
C1 [Nawaz, Mohsin; Malik, Irfan; Hameed, Mudassar; Kuthu, Zulfiqar Hussain; Zhou, Jinlin] Chinese Acad Agr Sci, Shanghai Vet Res Inst, Key Lab Anim Parasitol, Minist Agr, Shanghai 200241, Peoples R China.
RP Zhou, JL (reprint author), Chinese Acad Agr Sci, Shanghai Vet Res Inst, Key Lab Anim Parasitol, Minist Agr, Shanghai 200241, Peoples R China.
EM jinlinzhou@shvri.ac.cn
FU National Key Research and Development Program of China [2018YFC0840403]
FX National Key Research and Development Program of China (2018YFC0840403)
CR Agbor-Enoh S, 2009, ANTIMICROB AGENTS CH, V53, P1727, DOI 10.1128/AAC.00729-08
   Alsford S, 2004, MOL MICROBIOL, V53, P365, DOI 10.1111/j.1365-2958.2004.04151.x
   Alsford S, 2007, MOL MICROBIOL, V63, P724, DOI 10.1111/j.1365-2958.2006.05553.x
   Anderson L, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005539
   Andrews KT, 2008, ANTIMICROB AGENTS CH, V52, P1454, DOI 10.1128/AAC.00757-07
   Andrews KT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031847
   Aragon AD, 2009, MOL BIOCHEM PARASIT, V164, P57, DOI 10.1016/j.molbiopara.2008.11.007
   Azzi A, 2009, EXP PARASITOL, V121, P288, DOI 10.1016/j.exppara.2008.11.010
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   BASCH PF, 1991, SCHISTOSOMES DEV REP
   Batugedara G, 2017, TRENDS PARASITOL, V33, P364, DOI 10.1016/j.pt.2016.12.004
   Bougdour A, 2009, J EXP MED, V206, P953, DOI 10.1084/jem.20082826
   Bouzid M, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-213
   Brien GL, 2016, CANCER CELL, V29, P464, DOI 10.1016/j.ccell.2016.03.007
   Cabezas-Cruz A, 2016, EPIGENETICS-US, V11, P303, DOI 10.1080/15592294.2016.1163460
   Caccio S. M., 2005, Parassitologia (Rome), V47, P185
   Calo E, 2013, MOL CELL, V49, P825, DOI 10.1016/j.molcel.2013.01.038
   Campo VA, 2017, INT J PARASITOL-DRUG, V7, P23, DOI 10.1016/j.ijpddr.2016.12.003
   Campos EI, 2010, NAT STRUCT MOL BIOL, V17, P1343, DOI 10.1038/nsmb.1911
   Carey N, 2006, CURR OPIN PHARMACOL, V6, P369, DOI 10.1016/j.coph.2006.03.010
   Carranza PG, 2016, INT J BIOCHEM CELL B, V81, P32, DOI 10.1016/j.biocel.2016.10.010
   Carrozza MJ, 2003, TRENDS GENET, V19, P321, DOI 10.1016/S0168-9525(03)00115-X
   Chaal BK, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000737
   Chakrabarty SP, 2009, BIOORGAN MED CHEM, V17, P8060, DOI 10.1016/j.bmc.2009.10.003
   Chan A., 2019, 775734 BIORXIV
   Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5
   Chua MJ, 2017, INT J PARASITOL-DRUG, V7, P42, DOI 10.1016/j.ijpddr.2016.12.005
   Chung D, 2002, TRENDS MOL MED, V8, pS10, DOI 10.1016/S1471-4914(02)02303-1
   Cioli D, 2004, INT J PARASITOL, V34, P979, DOI 10.1016/j.ijpara.2004.05.001
   Cioli D, 2014, MOL BIOCHEM PARASIT, V195, P23, DOI 10.1016/j.molbiopara.2014.06.002
   Colley DG, 2014, LANCET, V383, P2253, DOI 10.1016/S0140-6736(13)61949-2
   Copeland RA, 2009, NAT REV DRUG DISCOV, V8, P724, DOI 10.1038/nrd2974
   Cui LW, 2010, EUKARYOT CELL, V9, P1138, DOI 10.1128/EC.00036-10
   Cui L, 2008, EUKARYOT CELL, V7, P1200, DOI 10.1128/EC.00063-08
   Cui L, 2007, EUKARYOT CELL, V6, P1219, DOI 10.1128/EC.00062-07
   Cui L, 2007, ANTIMICROB AGENTS CH, V51, P488, DOI 10.1128/AAC.01238-06
   Dalmasso M.C., 2011, FRONT BIOSCI, V16, P105
   Deribe YL, 2010, NAT STRUCT MOL BIOL, V17, P666, DOI 10.1038/nsmb.1842
   Doenhoff MJ, 2008, CURR OPIN INFECT DIS, V21, P659, DOI 10.1097/QCO.0b013e328318978f
   Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859
   Dow GS, 2008, ANTIMICROB AGENTS CH, V52, P3467, DOI 10.1128/AAC.00439-08
   Dubois F, 2009, MOL BIOCHEM PARASIT, V168, P7, DOI 10.1016/j.molbiopara.2009.06.001
   Duraisingh MT, 2016, CELL HOST MICROBE, V19, P629, DOI 10.1016/j.chom.2016.04.020
   Fan J, 2015, ACS CHEM BIOL, V10, P95, DOI 10.1021/cb500846u
   Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Frew AJ, 2009, CANCER LETT, V280, P125, DOI 10.1016/j.canlet.2009.02.042
   Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097
   Gray D.J., 2011, BMJ-BRIT MED J, V342, pd2651
   Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173
   Gregoretti IV, 2004, J MOL BIOL, V338, P17, DOI 10.1016/j.jmb.2004.02.006
   Guarente L, 2000, GENE DEV, V14, P1021
   Guerra CA, 2008, PLOS MED, V5, P300, DOI 10.1371/journal.pmed.0050038
   Guidi A, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3268-8
   Guimaraes-Costa AB, 2009, P NATL ACAD SCI USA, V106, P6748, DOI 10.1073/pnas.0900226106
   Guo FG, 2018, J INFECT DIS, V217, P1110, DOI 10.1093/infdis/jix689
   Gupta A.P., 2013, PLOS PATHOG, V9
   Gupta AP, 2017, EPIGENET CHROMATIN, V10, DOI 10.1186/s13072-017-0147-z
   Hailu GS, 2017, J MED CHEM, V60, P4780, DOI 10.1021/acs.jmedchem.6b01595
   Haines LR, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000373
   Hoffman K. A., 1989, Veterinary Technician, V10, P124
   Hotez P.J., 2010, MANIFESTO ADV CONTRO
   Hotez PJ, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000412
   Imai S, 2000, NATURE, V403, P795
   Jeffers V, 2017, MICROBIOL MOL BIOL R, V81, DOI [10.1128/mmbr.00047-16, 10.1128/MMBR.00047-16]
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jiang LB, 2013, NATURE, V499, P223, DOI 10.1038/nature12361
   Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93
   Joshi MB, 1999, MOL BIOCHEM PARASIT, V99, P11, DOI 10.1016/S0166-6851(98)00177-7
   Kristeleit Rebecca, 2004, Expert Opin Emerg Drugs, V9, P135, DOI 10.1517/eoed.9.1.135.32947
   Kunz W, 2001, TRENDS PARASITOL, V17, P227, DOI 10.1016/S1471-4922(01)01893-1
   Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145
   Legartova S, 2013, EPIGENOMICS-UK, V5, P379, DOI [10.2217/EPI.13.38, 10.2217/epi.13.38]
   Lijscher A., 2005, RES SUST SYST INT SC
   Lopez-Rubio JJ, 2007, MOL MICROBIOL, V66, P1296, DOI 10.1111/j.1365-2958.2007.06009.x
   LOVERDE PT, 1991, PARASITOL TODAY, V7, P303, DOI 10.1016/0169-4758(91)90263-N
   Lucius R., 2016, BIOL PARASITES, V52
   Malmquist NA, 2015, ANTIMICROB AGENTS CH, V59, P950, DOI 10.1128/AAC.04419-14
   Malmquist NA, 2012, P NATL ACAD SCI USA, V109, P16708, DOI 10.1073/pnas.1205414109
   Marfurt J, 2011, ANTIMICROB AGENTS CH, V55, P961, DOI 10.1128/AAC.01220-10
   Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4
   Martinez-Iglesias O, 2008, CLIN TRANSL ONCOL, V10, P395, DOI 10.1007/s12094-008-0221-x
   Miao J, 2010, MOL MICROBIOL, V78, P883, DOI 10.1111/j.1365-2958.2010.07371.x
   Miller RH, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003469
   Munkhjargal T, 2012, VET PARASITOL, V190, P423, DOI 10.1016/j.vetpar.2012.06.026
   Mwangi IN, 2014, INT J PARASITOL-DRUG, V4, P296, DOI 10.1016/j.ijpddr.2014.09.006
   N'Goran EK, 2001, TROP MED INT HEALTH, V6, P817, DOI 10.1046/j.1365-3156.2001.00785.x
   Najdrowski M, 2007, PARASITOL RES, V101, P161, DOI 10.1007/s00436-006-0437-z
   Ngwa CJ, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00320
   Ngwa CJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205087
   Noh M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022077
   Nyamjargal T., 2013, MONG J AGR SCI, V11, P24
   Ogata T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179884
   Oger F, 2008, BIOCHEM BIOPH RES CO, V377, P1079, DOI 10.1016/j.bbrc.2008.10.090
   Organization WH, 2016, WORLD MAL REP 2015
   Papageorgiou FT, 2002, INFECT IMMUN, V70, P6976, DOI 10.1128/IAI.70.12.6976-6986.2002
   Patel V, 2009, J MED CHEM, V52, P2185, DOI 10.1021/jm801654y
   Pereira ASA, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006873
   Petter M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001292
   Pica-Mattoccia L, 2004, INT J PARASITOL, V34, P527, DOI 10.1016/j.ijpara.2003.12.003
   Pierce RJ, 2012, CURR PHARM DESIGN, V18, P3567, DOI 10.2174/138161212801327248
   Pradel G., 2016, ADV INFECT DIS, V6, P82, DOI [10.4236/aid.2016.62011, DOI 10.4236/AID.2016.62011]
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Roquis D, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007066
   Sahoo N., 2002, Journal of Veterinary Parasitology, V16, P61
   Salusso A, 2017, FEBS J, V284, P2396, DOI 10.1111/febs.14131
   Santos JD, 2019, PARASITOLOGY, V146, P543, DOI 10.1017/S0031182018001828
   Scherf A, 2008, ANNU REV MICROBIOL, V62, P445, DOI 10.1146/annurev.micro.61.080706.093134
   Schmidt I, 2016, BIOORGAN MED CHEM, V24, P3636, DOI 10.1016/j.bmc.2016.06.003
   Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874
   Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Slifko TR, 2000, INT J PARASITOL, V30, P1379, DOI 10.1016/S0020-7519(00)00128-4
   Sonda S, 2010, MOL MICROBIOL, V76, P48, DOI 10.1111/j.1365-2958.2010.07062.x
   Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Striepen B, 2013, NATURE, V503, P189, DOI 10.1038/503189a
   Strobl JS, 2007, J PARASITOL, V93, P694, DOI 10.1645/GE-1043R.1
   Sumanadasa SDM, 2012, ANTIMICROB AGENTS CH, V56, P3849, DOI 10.1128/AAC.00030-12
   Talbert PB, 2012, EPIGENET CHROMATIN, V5, DOI 10.1186/1756-8935-5-7
   Talbert PB, 2010, NAT REV MOL CELL BIO, V11, P264, DOI 10.1038/nrm2861
   Tan MJ, 2011, CELL, V146, P1015, DOI 10.1016/j.cell.2011.08.008
   Thepparit C, 2010, MICROBIOL-SGM, V156, P2855, DOI 10.1099/mic.0.041400-0
   Trelle MB, 2009, J PROTEOME RES, V8, P3439, DOI 10.1021/pr9000898
   Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433
   Urban CF, 2006, CELL MICROBIOL, V8, P668, DOI 10.1111/j.1462-5822.2005.00659.x
   Vanagas L, 2012, EXPERT REV ANTI-INFE, V10, P1189, DOI [10.1586/ERI.12.100, 10.1586/eri.12.100]
   Vannier E, 2015, LANCET INFECT DIS, V15, P137, DOI 10.1016/S1473-3099(14)71062-X
   Vilcinskas A, 2016, ZOOLOGY, V119, P273, DOI 10.1016/j.zool.2016.05.004
   Wang YW, 2011, INFECT IMMUN, V79, P1124, DOI 10.1128/IAI.00658-10
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   White NJ, 2004, J CLIN INVEST, V113, P1084, DOI 10.1172/JCI200421682
   Wigle T.J., 2011, CURR CHEM GENOMICS, V5, P48
   Xargay-Torrent S, 2011, CLIN CANCER RES, V17, P3956, DOI 10.1158/1078-0432.CCR-10-3412
   Xu K, 2011, OXID MED CELL LONGEV, V2011, DOI 10.1155/2011/143269
   Yang XJ, 2008, MOL CELL, V31, P449, DOI 10.1016/j.molcel.2008.07.002
   Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689
NR 137
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD FEB
PY 2020
VL 278
AR UNSP 109029
DI 10.1016/j.vetpar.2020.109029
PG 9
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KR8FZ
UT WOS:000517852700002
PM 31978703
DA 2020-05-12
ER

PT J
AU Tuersong, W
   He, L
   Zhu, T
   Yang, X
   Zhang, ZZ
   Ahmad, AA
   Di, WD
   Wang, CQ
   Zhou, CX
   Liu, H
   Chen, J
   Hu, M
AF Tuersong, Waresi
   He, Li
   Zhu, Tao
   Yang, Xin
   Zhang, Zongze
   Ahmad, Awais Ali
   Di, Wenda
   Wang, Chunqun
   Zhou, Caixian
   Liu, Hui
   Chen, Jian
   Hu, Min
TI Development and evaluation of a loop-mediated isothermal amplification
   (LAMP) assay for the detection of the E198A SNP in the isotype-1
   beta-tubulin gene of Haemonchus contortus populations in China
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Haemonchus contortus; Loop-mediated isothermal amplification (LAMP);
   Benzimidazole resistance; Single nucleotide polymorphisms (SNP)
ID ANTHELMINTIC RESISTANCE; BENZIMIDAZOLE RESISTANCE; SHEEP; MUTATION;
   REVEALS; COST
AB Haernonchus contortus is one of the most important gastrointestinal nematodes of small ruminants around the world, seriously hampering the healthy development of the sheep industry. The control of this parasite mainly depends on anthelmintics, however, drug resistance of H. contortus has become a serious problems worldwide. Previous studies demonstrated that the E198A (GAA to GCA), a single nucleotide polymorphism (SNP) in the isotype-1 beta-tubulin gene is associated with benzimidazole resistance in H. contortus. However, only PCR-RFLP and ARMS-PCR methods have been previously used for the detection of the E198A mutation. In the present study, a loop-mediated isothermal amplification (LAMP) assay was established for rapid detection of the E198A SNP in H. contortus. The results showed that optimization of LAMP reaction reagents and conditions could achieve this. The resulting amplicons were visualized by adding hydroxynaphthol blue dye (HNB) prior to amplification. The color of LAMP products amplified without DNA or from DNA from worms with the E198A homozygous susceptible genotype was still violet, but the products with DNA from worms with the E198A heterozygous genotype or the E198A resistant homozygous genotype changed to sky blue. The specificity of this method was further verified by sequencing, which confirmed the successful LAMP detection of the E198A mutation with high specificity. In conclusion, the developed LAMP method has high specificity and good reproducibility for screening the E198A SNP of isotype-1 beta-tubulin gene of H. contortus of field samples without using sophisticated equipment, providing useful technique for the rapid detection and thus prevention and control of benzimidazole resistant H. contortus infections.
C1 [Tuersong, Waresi; He, Li; Zhu, Tao; Yang, Xin; Zhang, Zongze; Ahmad, Awais Ali; Di, Wenda; Wang, Chunqun; Zhou, Caixian; Liu, Hui; Chen, Jian; Hu, Min] Huazhong Agr Univ, Coll Vet Med, State Key Lab Agr Microbiol, Wuhan 430070, Peoples R China.
   [He, Li] Hubei Univ Med, Sch Basic Med Sci, Shiyan 442000, Peoples R China.
   [Yang, Xin] South China Agr Univ, Coll Vet Med, Key Lab Zoonosis, Minist Agr, Guangzhou 510642, Peoples R China.
RP Hu, M (reprint author), Huazhong Agr Univ, Coll Vet Med, State Key Lab Agr Microbiol, Wuhan 430070, Peoples R China.
EM mhu@mail.hzau.edu.cn
FU National Key Research and Development Program of China [2018YFD0501600];
   National Key Basic Research Program (973 Program) of ChinaNational Basic
   Research Program of China [2015CB150300]
FX This study was supported by the "National Key Research and Development
   Program of China" (2018YFD0501600) and the "National Key Basic Research
   Program (973 Program) of China" (Grant No. 2015CB150300) to M.H.
CR Ahmad AA, 2019, GENES-BASEL, V10, DOI 10.3390/genes10020107
   Bartram DJ, 2012, VET PARASITOL, V186, P151, DOI 10.1016/j.vetpar.2011.11.030
   Besier RB, 2016, ADV PARASIT, V93, P95, DOI 10.1016/bs.apar.2016.02.022
   [薄新文 Bo Xinwen], 2005, [中国农业科学, Scientia Agricultura Sinica], V38, P826
   Cai Kui-zheng, 2009, Zhongguo Shouyi Kexue, V39, P685
   Chaudhry U, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1624-0
   Gasser RB, 2006, NAT PROTOC, V1, P3121, DOI 10.1038/nprot.2006.485
   Gawande SP, 2019, J VIROL METHODS, V270, P21, DOI 10.1016/j.jviromet.2019.04.018
   Ghisi M, 2007, VET PARASITOL, V144, P313, DOI 10.1016/j.vetpar.2006.10.003
   Hao C., 2007, THESIS
   Hoberg EP, 2016, ADV PARASIT, V93, P1, DOI 10.1016/bs.apar.2016.02.021
   Jackson F, 2000, PARASITOLOGY, V120, pS95, DOI 10.1017/S0031182099005740
   Kaplan RM, 2012, VET PARASITOL, V186, P70, DOI 10.1016/j.vetpar.2011.11.048
   Kotze AC, 2016, ADV PARASIT, V93, P397, DOI 10.1016/bs.apar.2016.02.012
   Kotze AC, 2014, INT J PARASITOL-DRUG, V4, P164, DOI 10.1016/j.ijpddr.2014.07.007
   Lambert Sabrina Mota, 2017, Vet Parasitol Reg Stud Reports, V8, P28, DOI 10.1016/j.vprsr.2017.01.006
   LICHTENFELS JR, 1994, J PARASITOL, V80, P107, DOI 10.2307/3283353
   Muchiut SM, 2018, VET PARASITOL, V254, P43, DOI 10.1016/j.vetpar.2018.03.004
   McLeod R S., 2004, ACIAR MONOGRAPH, V113, P23
   Miller CM, 2012, VET PARASITOL, V186, P376, DOI 10.1016/j.vetpar.2011.11.063
   Mori Y, 2001, BIOCHEM BIOPH RES CO, V289, P150, DOI 10.1006/bbrc.2001.5921
   Mori Y, 2009, J INFECT CHEMOTHER, V15, P62, DOI 10.1007/s10156-009-0669-9
   Papadopoulos E, 2012, VET PARASITOL, V189, P85, DOI 10.1016/j.vetpar.2012.03.036
   Redman E, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003494
   Rufener L, 2009, MOL BIOCHEM PARASIT, V168, P120, DOI 10.1016/j.molbiopara.2009.07.002
   Shen DD, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1838-4
   Siddique M.P., 2019, INT MICROBIOL, DOI [10.1007/s10123-01900079-z, DOI 10.1007/S10123-01900079-Z]
   Tiwari J, 2006, VET PARASITOL, V138, P301, DOI 10.1016/j.vetpar.2006.02.003
   Wang CQ, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01509
   Yang X, 2017, J PARASITOL, V103, P161, DOI 10.1645/16-157
   Yuan W, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003062
   Zhang ZZ, 2018, VET PARASITOL, V252, P127, DOI 10.1016/j.vetpar.2018.01.021
   Zhang ZZ, 2016, INT J PARASITOL-DRUG, V6, P199, DOI 10.1016/j.ijpddr.2016.10.001
NR 33
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD FEB
PY 2020
VL 278
AR UNSP 109040
DI 10.1016/j.vetpar.2020.109040
PG 5
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KR8FZ
UT WOS:000517852700013
PM 32007679
DA 2020-05-12
ER

PT J
AU Voinot, M
   Cazapal-Monteiro, C
   Hernandez, JA
   Palomero, AM
   Arroyo, FL
   Sanchis, J
   Pedreira, J
   Sanchez-Andrade, R
   Paz-Silva, A
   Arias, MS
AF Voinot, Mathilde
   Cazapal-Monteiro, Cristiana
   Angel Hernandez, Jose
   Miguel Palomero, Antonio
   Leonardo Arroyo, Fabian
   Sanchis, Jaime
   Pedreira, Jose
   Sanchez-Andrade, Rita
   Paz-Silva, Adolfo
   Sol Arias, Maria
TI Integrating the control of helminths in dairy cattle: Deworming,
   rotational grazing and nutritional pellets with parasiticide fungi
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Biological control; Ruminants; Mucor circinelloides; Duddingtonia
   flagrans; Chlamydospores; Sustainability
ID BIOLOGICAL-CONTROL; DUDDINGTONIA-FLAGRANS; GASTROINTESTINAL NEMATODES;
   CALICOPHORON-DAUBNEYI; FIELD-EVALUATION; PASTURE; INFECTION; EFFICACY;
   HORSES; SHEEP
AB Thirty-two Friesian cattle under a leaders/followers four-day rotation and passing eggs of trematodes and gastrointestinal nematodes (GIN) were studied in two trials for the integrated control of these helminths over two years. In the first trial, the effect of rotational pasturing was assessed on a group of leaders (milking cows, G-L1) and followers (dried-off cows and heifers, G-F1) supplemented daily with commercial nutritional pellets. In the second trial, leaders (G-L2) and followers (G-F2) were maintained under a rotational pasturing regime; the cows received daily commercial pelleted feed and heifers pellets manufactured with a blend of parasiticide fungi (3 x 10(5) chlamydospores of both Mucor circinelloides and Duddingtonia flagrans/kg pellet). Deworming via closantel and albendazole was performed in cows in each trial at the beginning of their drying periods, and fourteen days later, the fecal egg-count reductions (FECR) of Calicophoron daubneyi and GIN were from 94 to 100% (average 98 %), while the percentages of reduction of cattle shedding eggs (CPCR) were from 50 to 100% (average 77 % and 82 %, respectively). The heifers were dewormed one time only, at the beginning of each trial, and the values of FECR and CPCR were 100 % against C. daubneyi and 96 % and 83 %, respectively, against GIN. Over a period of 24 months, significantly higher numbers of helminth egg-output were observed in G-L1, with the lowest numbers in G-F2. C. daubneyi egg output was reduced by 5 % (G-L1) and 42 % (G-F1) at the end of trial 1 and by 83 % (G-L2) and 100 % (G-F2) at the end of trial 2; the numbers of GIN egg-output decreased by 13 % (G-L1) and 18 % (G-F1) at the end of trial 1, and by 72 % (G-L2) and 85 % (G-F2) at the end of trial 2. No adverse effects were detected in cattle taking pellets enriched with fungal spores (G-F2). It is concluded that long-term ingestion of spores of M. circinelloides and D. flagrans provides a valuable tool to improve the effect of rotational grazing and to lessen the risk of infection by C. daubneyi and GIN in dairy cattle, and accordingly, the performance of integrated control programs.
C1 [Voinot, Mathilde; Cazapal-Monteiro, Cristiana; Angel Hernandez, Jose; Miguel Palomero, Antonio; Leonardo Arroyo, Fabian; Sanchez-Andrade, Rita; Paz-Silva, Adolfo; Sol Arias, Maria] Santiago de Compostela Univ, Vet Fac, Anim Pathol Dept, Control Parasites Grp COPAR,GI 2120, Lugo 27002, Spain.
   [Sanchis, Jaime] Univ La Republ Reg Norte, Vet Fac, Parasit Dis, Salto 50000, Uruguay.
   [Pedreira, Jose] Fatro Iberica SL, Barcelona 08960, Spain.
RP Paz-Silva, A (reprint author), Santiago de Compostela Univ, Vet Fac, Anim Pathol Dept, Control Parasites Grp COPAR,GI 2120, Lugo 27002, Spain.
EM adolfo.paz@usc.es
FU Ministerio de Economia y Competitividad, Spain [AGL201234355,
   CTM2015-65954-R]; FEDEREuropean Union (EU); Ramon y Cajal (Spanish
   Ministry of Economy and Competitiveness); Xunta de Galicia, SpainXunta
   de Galicia
FX This study was partly supported by the Research Projects AGL201234355
   and CTM2015-65954-R (Ministerio de Economia y Competitividad, Spain;
   FEDER). Dr. Maria Sol Arias Vazquez is a recipient of a Ramon y Cajal
   (Spanish Ministry of Economy and Competitiveness) contract, and Dr.
   Cristiana F. Cazapal-Monteiro is a recipient of a postdoctoral research
   fellowship (Xunta de Galicia, Spain). We thank "Granxa Gayoso"
   (Diputacion Provincial de Lugo, Spain) for their support in culturing
   the parasiticide fungi.
CR Saumell CA, 2015, REV IBEROAM MICOL, V32, P252, DOI 10.1016/j.riam.2014.09.003
   Hernndez JA, 2018, VECTOR-BORNE ZOONOT, V18, P690, DOI 10.1089/vbz.2018.2296
   Hernandez JA, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2827-3
   Hernandez JA, 2016, VET PARASITOL, V229, P37, DOI 10.1016/j.vetpar.2016.09.014
   Araújo Jackson Victor de, 2004, Cienc. Rural, V34, P457, DOI 10.1590/S0103-84782004000200019
   Arias MS, 2013, VET PARASITOL, V197, P126, DOI 10.1016/j.vetpar.2013.06.011
   Arias MS, 2013, BIOMED RES INT, DOI 10.1155/2013/567876
   Arias M.S., 2015, J SCI TECHNOL ENV, V1, P1
   Arroyo FL, 2016, BIOL CONTROL, V92, P38, DOI 10.1016/j.biocontrol.2015.09.007
   Arroyo F, 2017, J PARASITOL, V103, P199, DOI 10.1645/16-76
   Assis RCL, 2013, VET PARASITOL, V193, P134, DOI 10.1016/j.vetpar.2012.12.005
   Cazapal-Monteiro CF, 2015, PARASITOL RES, V114, P2443, DOI 10.1007/s00436-015-4440-0
   Chandrawathani P, 2004, VET PARASITOL, V120, P177, DOI 10.1016/j.vetpar.2003.12.014
   Cortinas FJ, 2015, BIOCONTROL SCI TECHN, V25, P1443, DOI 10.1080/09583157.2015.1062843
   Craig T.M., 2009, FOOD ANIMAL PRACTICE, P78, DOI DOI 10.1016/B978-141603591-6.10022-3
   da Silva ME, 2014, VET RES COMMUN, V38, P101, DOI 10.1007/s11259-014-9590-5
   Demeler J, 2009, VET PARASITOL, V160, P109, DOI 10.1016/j.vetpar.2008.10.030
   Dias AS, 2013, PARASITOL RES, V112, P2131, DOI 10.1007/s00436-013-3372-9
   Dimander SO, 2003, VET PARASITOL, V111, P193, DOI 10.1016/S0304-4017(02)00380-1
   Flack S., 2016, ART SCI GRAZING, P240
   Francisco I, 2009, VET PARASITOL, V164, P357, DOI 10.1016/j.vetpar.2009.06.018
   GRONVOLD J, 1993, J HELMINTHOL, V67, P31, DOI 10.1017/S0022149X00012827
   Healey K, 2018, VET PARASITOL, V258, P124, DOI 10.1016/j.vetpar.2018.06.017
   Hertzberg H, 2007, REV SUISSE AGRIC, V39, P89
   Jobim MB, 2008, CIENC RURAL, V38, P2256, DOI 10.1590/S0103-84782008000800026
   Kumar Niranjan, 2013, J Parasit Dis, V37, P151, DOI 10.1007/s12639-012-0215-z
   Larsson A, 2006, VET PARASITOL, V142, P197, DOI 10.1016/j.vetpar.2006.07.017
   Luns FD, 2018, BIOMED RES INT, DOI 10.1155/2018/2934674
   Malrait K, 2015, VET PARASITOL, V207, P134, DOI 10.1016/j.vetpar.2014.10.033
   Mendoza-de Gives P, 2018, VET PARASITOL, V263, P66, DOI 10.1016/j.vetpar.2018.10.001
   Moazeni M, 2010, IRAN J VET RES, V11, P168
   Nogareda C, 2006, J VET MED B, V53, P439, DOI 10.1111/j.1439-0450.2006.00979.x
   Nzalawahe J, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2965-7
   Perez DOO, 2017, EXP PARASITOL, V175, P74, DOI 10.1016/j.exppara.2017.02.009
   ROLFE PF, 1993, AUST VET J, V70, P265, DOI 10.1111/j.1751-0813.1993.tb08047.x
   Santurio JM, 2009, VET PARASITOL, V164, P344, DOI 10.1016/j.vetpar.2009.05.012
   Smith M.C., 2009, GOAT MED
   Szmidt-Adjide V, 2000, VET PARASITOL, V87, P133, DOI 10.1016/S0304-4017(99)00168-5
   Thornton PK, 2010, PHILOS T R SOC B, V365, P2853, DOI 10.1098/rstb.2010.0134
   Thrusfield M, 2007, VET EPIDEMIOLOGY, P624
   Torres-Acosta JFJ, 2008, SMALL RUMINANT RES, V77, P159, DOI 10.1016/j.smallrumres.2008.03.009
   Undersander D., 2002, PASTURES PROFIT GUID
   van Wyk JA, 2013, ONDERSTEPOORT J VET, V80, DOI 10.4102/ojvr.v80i1.539
NR 43
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD FEB
PY 2020
VL 278
AR UNSP 109038
DI 10.1016/j.vetpar.2020.109038
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KR8FZ
UT WOS:000517852700010
PM 32000048
DA 2020-05-12
ER

PT J
AU Zecca, IB
   Hodo, CL
   Slack, S
   Auckland, L
   Rodgers, S
   Killets, KC
   Saunders, AB
   Hamer, SA
AF Zecca, Italo B.
   Hodo, Carolyn L.
   Slack, Sarah
   Auckland, Lisa
   Rodgers, Sandy
   Killets, Keswick C.
   Saunders, Ashley B.
   Hamer, Sarah A.
TI Prevalence of Trypanosoma cruzi infection and associated histologic
   findings in domestic cats (Felis catus)
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Trypanosome cruzi; Cat; Serology; PCR; Chagas disease; Texas
ID CHAGAS-DISEASE; TRIATOMINE VECTORS; IMMUNODEFICIENCY VIRUS;
   BARTONELLA-HENSELAE; WILD CARNIVORES; TEXAS; MYOCARDITIS; DOGS;
   TRANSMISSION; BLOOD
AB Trypanosoma cruzi is a zoonotic protozoan parasite transmitted by triatomines that infects a wide range of mammals. South Texas is a hotspot for triatomines, T. cruzi-infected dogs and wildlife, and local transmission to humans also occurs. However, little is known about the infection of domestic cats (Fells califs) in the United States. Given the role cats play in the ecology of T. cruzi in Mexico and South America, we hypothesized that T. cruzi infection occurs in cats from south Texas, sometimes associated with cardiac pathology. In 2017, 167 euthanized cats from a south Texas shelter were sampled across winter, spring, and summer. We collected whole blood and hearts from all cats, with additional tissues from a subset. Serum samples were screened for T cruzi antibodies using two independent rapid immunochromatographic tests and an indirect fluorescent antibody test. Cats were considered seropositive if they were positive on at least two independent serological tests. Blood clot, heart tissue and other tissues were subjected to qPCR for parasite detection and discrete typing unit (DTU) determination. Tissues from selected seropositive or PCR-positive animals and a subset of negative animals were processed routinely for histopathology and examined by a board-certified pathologist. A total of 19 cats (11.4%) were seropositive and three cats (1.8%) - one of which was seropositive - had one or more PCR-positive tissues. Infected tissues included heart, bicep femoris muscle, sciatic nerve, esophagus, and mesentery. Genotyping of the parastite to the level of DTU showed that exclusively DTU TcI was present, despite past studies showing both TcI and TcIV in vectors of the region. Eight of 19 (42.1%) seropositive cats exhibited lymphoplasmacytic inflammation, sometimes with fibrosis, in cardiac tissue compared to 28.6% of 28 seronegative cats (P = 0.10). Domestic cats are affected hosts in the eco-epidemiology of Chagas disease. Future prospective studies are needed to understand disease progression. Veterinarians in the southern United States should consider T. cruzi in their index of suspicion in cats with exposure to vectors and undetermined cardiac abnormalities.
C1 [Zecca, Italo B.; Hodo, Carolyn L.; Slack, Sarah; Auckland, Lisa; Killets, Keswick C.; Saunders, Ashley B.; Hamer, Sarah A.] Texas A&M Univ, Coll Vet Med & Biomed Sci, College Stn, TX 77840 USA.
   [Hodo, Carolyn L.] Univ Texas MD Anderson Canc Ctr, Michele E Keeling Ctr Comparat Med & Res, 650 Cool Water Dr, Bastrop, TX 78602 USA.
   [Rodgers, Sandy] Texas A&M Univ, Vet Med Diagnost Lab, 483 Agron Rd, College Stn, TX 77843 USA.
RP Hamer, SA (reprint author), Texas A&M Univ, Coll Vet Med & Biomed Sci, College Stn, TX 77840 USA.
EM shamer@cvm.tamu.edu
FU Texas AgriLife/Texas Veterinary Medical Diagnostic Laboratory Seed Grant
   program; AgriLife Insect Vector grant
FX We thank Bailee Ethridge and Dr. Erin Edwards for assistance in the
   field and with tissue prepartion. We thank Carlos Rodriguez for his help
   with serological testing. We thank shelter veterinary medical personnel
   and staff for assistance. The shelter staff and veterinary medical
   personnel gained no financial benefits for their participation. The
   Texas AgriLife/Texas Veterinary Medical Diagnostic Laboratory Seed Grant
   program and the AgriLife Insect Vector grant provided financial support.
   The CVM Diversity Fellowship (Zecca) and Boehringer Ingelheim Veterinary
   Scholars Program (Slack) provided student support.
CR Andrade ZA, 1997, AM J TROP MED HYG, V57, P328, DOI 10.4269/ajtmh.1997.57.328
   Barbabosa-Pliego A, 2009, AM J TROP MED HYG, V81, P390, DOI 10.4269/ajtmh.2009.81.390
   Beard CB, 2003, EMERG INFECT DIS, V9, P103, DOI 10.3201/eid0901.020217
   Bern C, 2009, CLIN INFECT DIS, V49, pE52, DOI 10.1086/605091
   Bryan LK, 2016, VET PARASITOL, V216, P13, DOI 10.1016/j.vetpar.2015.11.016
   Case JB, 2006, J FELINE MED SURG, V8, P111, DOI 10.1016/j.jfms.2005.10.004
   Chu K, 2009, JAVMA-J AM VET MED A, V234, P1023, DOI 10.2460/javma.234.8.1023
   Cura CI, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003765
   Curtis-Robles R, 2018, INFECT GENET EVOL, V58, P171, DOI 10.1016/j.meegid.2017.12.016
   Curtis-Robles R, 2018, AM J TROP MED HYG, V98, P113, DOI 10.4269/ajtmh.17-0526
   Curtis-Robles R, 2017, AM J TROP MED HYG, V96, P805, DOI 10.4269/ajtmh.16-0789
   Curtis-Robles R, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005298
   Curtis-Robles R, 2016, INT J PARASITOL-PAR, V5, P117, DOI 10.1016/j.ijppaw.2016.04.001
   Da Silva AS, 2010, RES VET SCI, V88, P281, DOI 10.1016/j.rvsc.2009.08.011
   *DEV COR TEAM, 2008, R LANG ENV STAT COMP
   Duffy T, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002000
   Eloy L.J., 2012, ISRN VET SCI, V2012
   Foley JE, 1998, VET QUART, V20, P1
   Gorchakov R, 2016, J MED ENTOMOL, V53, P911, DOI 10.1093/jme/tjw040
   Gurtler RE, 2007, PARASITOLOGY, V134, P69, DOI 10.1017/S0031182006001259
   GURTLER RE, 1993, T ROY SOC TROP MED H, V87, P12, DOI 10.1016/0035-9203(93)90400-K
   HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S
   Hodo C.L., 2020, J WILDL DIS, V56
   Hodo CL, 2019, J VET INTERN MED, V33, P158, DOI 10.1111/jvim.15352
   Hodo CL, 2017, ILAR J, V58, P379, DOI 10.1093/ilar/ilx020
   Jimenez-Coello M, 2012, ZOONOSES PUBLIC HLTH, V59, P102, DOI 10.1111/j.1863-2378.2012.01463.x
   Kjos SA, 2013, J MED ENTOMOL, V50, P1126, DOI 10.1603/ME12242
   Kutt AS, 2012, J ZOOL, V287, P292, DOI 10.1111/j.1469-7998.2012.00915.x
   Lages-Silva E, 2001, AM J TROP MED HYG, V65, P435, DOI 10.4269/ajtmh.2001.65.435
   Lazarte Raul A., 2012, Morbidity and Mortality Weekly Report, V61, P477
   Levy JK, 2006, JAVMA-J AM VET MED A, V228, P371, DOI 10.2460/javma.228.3.371
   LEWINSOHN R, 1981, J ROY SOC MED, V74, P451, DOI 10.1177/014107688107400612
   Loyd KAT, 2013, BIOL CONSERV, V160, P183, DOI 10.1016/j.biocon.2013.01.008
   Rolim VM, 2016, J COMP PATHOL, V154, P3, DOI 10.1016/j.jcpa.2015.10.180
   Meurs KM, 2000, CARDIOVASC PATHOL, V9, P119, DOI 10.1016/S1054-8807(00)00031-4
   Meyers AC, 2019, J VET INTERN MED, V33, P1695, DOI 10.1111/jvim.15516
   Montgomery SP, 2014, AM J TROP MED HYG, V90, P814, DOI 10.4269/ajtmh.13-0726
   MOTT KE, 1978, AM J TROP MED HYG, V27, P1123, DOI 10.4269/ajtmh.1978.27.1123
   Nieto PD, 2009, VET PARASITOL, V165, P241, DOI 10.1016/j.vetpar.2009.07.010
   Nogueira-Paiva NC, 2014, MEM I OSWALDO CRUZ, V109, P51, DOI 10.1590/0074-0276130216
   Pinto CM, 2012, INFECT GENET EVOL, V12, P1328, DOI 10.1016/j.meegid.2012.04.013
   Rocha FL, 2013, PARASITOLOGY, V140, P160, DOI 10.1017/S0031182012001539
   Simpson KE, 2005, J FELINE MED SURG, V7, P203, DOI 10.1016/j.jfms.2004.08.004
   Tenney TD, 2014, EMERG INFECT DIS, V20, P1323, DOI 10.3201/eid2008.131843
   US Census Bureau, 2014, STAT COUNT QUICKF HI
   Varanat M, 2012, VET PATHOL, V49, P608, DOI 10.1177/0300985811404709
   Vera-Cruz JM, 2003, PARASITOL RES, V89, P480, DOI 10.1007/s00436-002-0787-0
   Villalba-Aleman E, 2019, PARASITOLOGY, V146, P983, DOI 10.1017/S0031182019000210
   Sanchez FDV, 2019, HIST ACTUAL ONLINE, P179
   Vitt JP, 2016, J VET INTERN MED, V30, P1210, DOI 10.1111/jvim.13967
   Waleckx E, 2014, EMERG INFECT DIS, V20, P2141, DOI 10.3201/eid2012.131576
   WINCKER P, 1994, AM J TROP MED HYG, V51, P771, DOI 10.4269/ajtmh.1994.51.771
   Zingales B, 2009, MEM I OSWALDO CRUZ, V104, P1051, DOI 10.1590/S0074-02762009000700021
   Zingales B, 2014, MEM I OSWALDO CRUZ, V109, P828, DOI 10.1590/0074-0276140156
NR 54
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD FEB
PY 2020
VL 278
AR UNSP 109014
DI 10.1016/j.vetpar.2019.109014
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KR8FZ
UT WOS:000517852700003
PM 31972512
DA 2020-05-12
ER

PT J
AU Zhao, PF
   Li, YC
   Zhou, YQ
   Zhao, JL
   Fang, R
AF Zhao, Pengfei
   Li, Yuncan
   Zhou, Yanqin
   Zhao, Junlong
   Fang, Rui
TI In vivo immunoprotective comparison between recombinant protein and DNA
   vaccine of Eimeria tenella surface antigen 4
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE E. tenella; Recombinant EtSAG4 protein; pEGFP-N1-EtSAG4 plasmid;
   Immunoprotective
ID PROTECTIVE IMMUNITY; ANTICOCCIDIAL DRUGS; TOXOPLASMA-GONDII;
   COCCIDIOSIS; GAMMA; INHIBITION; RESISTANCE; CHICKENS; MAXIMA
AB Eimeria tenella, belonging to protozoon, is the causative agent of cecal coccidiosis in chicken and causes enormous impacts for poultry industry. The surface antigens of apicomplexan parasites function as attachment and invasion in host-parasite interaction. Meanwhile, host immune response is triggered as a result of parasitic invasion. Immunogenicity and potency as a vaccinal candidate antigen of E. tenella surface antigen 4 (EtSAG4) have been unknown. Therefore, a gene segment of E. tenella EtSAG4 was amplified and transplanted to pET28a prokaryotic vector for recombinant protein expression. Similarly, pEGFP-N1 eukaryotic vectors with EtSAG4 gene segment (pEGFP-N1-EtSAG4) amplified in 293 T cells as DNA vaccines. Reverse transcription-polymerase chain reaction (RT-PCR) assay and western blot analysis were used to demonstrate successful expressions of EtSAG4 in Escherichia coli or 293 T cells. Subsequently, animal experiments (72 cobb broilers) were performed to evaluate immunoprotective between recombinant protein and DNA vaccine of E. tenella EtSAG4 using different immunizing doses (50 or 100 mu g), respectively. Serum from chickens infected with E. tenella identified recombinant EtSAG4 (rEtSAG4) protein. Chickens vaccinated with either rEtSAG4 protein or pEGFP-N1-EtSAG4 plasmids both shown a significant increase in concentration of IFN-gamma (p < 0.05) compared with control groups indicating production of cell-mediated immunity. Besides, pEGFP-N1-EtSAG4 plasmids motivated more intense immune responses for immunoglobulin Y (IgY) and interleukin 17 (IL-17) (p < 0.05) contrast to control groups. However, there was no increase in concentration of interleukin 10 (IL-10) and interleukin 4 (IL-4) for both rEtSAG4 protein and pEGFP-N1-EtSAG4 plasmids. Chickens vaccinated with rEtSAG4 protein or pEGFP-N1-EtSAG4 plasmids both show higher weight, lower oocyst output and mean lesion scores compared with infection control groups. The highest anticoccidial index (ACI) value of immunized groups was 168.24 from EGFP-N1-EtSAG4 plasmids (100 mu g) group. Generally, EGFP-N1-EtSAG4 plasmids as DNA vaccines provided a more effective immunoprotective for chickens against E. tenalla than that of rEtSAG4 protein as subunit vaccines. EtSAG4 is a promising candidate antigen gene for development of coccidiosis vaccine.
C1 [Zhao, Pengfei; Zhou, Yanqin; Zhao, Junlong; Fang, Rui] Huazhong Agr Univ, Coll Vet Med, State Key Lab Agr Microbiol, Wuhan 430070, Hubei, Peoples R China.
   [Li, Yuncan] Tibet Agr & Anim Husb Univ, Coll Anim Sci & Technol, Nyingchi 860000, Tibet, Peoples R China.
RP Fang, R (reprint author), Huazhong Agr Univ, Coll Vet Med, State Key Lab Agr Microbiol, Wuhan 430070, Hubei, Peoples R China.
EM pengfeizhao0513@163.com; 2577907129@qq.com; yanqinzhou@mail.hzau.edu.cn;
   zhaojunlong@mail.hzau.edu.cn; fangrui19810705@163.com
FU national key research and development program [2016YFD0501303];
   Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [2662015PY048]
FX We would like to thank professor Shijun Li for providing space for
   animal experiments and guidance from professor Rui Fang, Junlong Zhao,
   Yanqin Zhou. This study was supported by the national key research and
   development program (2016YFD0501303) and the Fundamental Research Funds
   for the Central Universities (Grant No. 2662015PY048).
CR Blake DP, 2015, P NATL ACAD SCI USA, V112, pE5343, DOI 10.1073/pnas.1506468112
   Blake DP, 2014, TRENDS PARASITOL, V30, P12, DOI 10.1016/j.pt.2013.10.003
   Bussiere FI, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2622-1
   Chapman HD, 2014, INT J PARASITOL-DRUG, V4, P214, DOI 10.1016/j.ijpddr.2014.10.002
   Chapman HD, 1998, INT J PARASITOL, V28, P1141, DOI 10.1016/S0020-7519(98)00024-1
   CHAPMAN HD, 1975, PARASITOLOGY, V71, P41, DOI 10.1017/S0031182000053130
   Clark EL, 2016, INT J PARASITOL, V46, P537, DOI 10.1016/j.ijpara.2016.05.006
   Debock I, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00393
   Dimier IH, 1998, AVIAN DIS, V42, P239, DOI 10.2307/1592473
   Dimier IH, 1997, IMMUNOL CELL BIOL, V75, P511, DOI 10.1038/icb.1997.80
   Ding X., 2005, VACCINE, V23
   Geriletu, 2011, VET PARASITOL, V177, P6, DOI 10.1016/j.vetpar.2010.11.041
   Hoan T.D., 2015, 13 S VET PAR BRANCH
   Jahn D, 2009, PARASITOL RES, V105, P655, DOI 10.1007/s00436-009-1437-6
   JOHNSON J, 1970, EXP PARASITOL, V28, P30, DOI 10.1016/0014-4894(70)90063-9
   Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710
   Lee SH, 2009, VET PARASITOL, V163, P123, DOI 10.1016/j.vetpar.2009.04.020
   Lekutis C, 2001, INT J PARASITOL, V31, P1285, DOI 10.1016/S0020-7519(01)00261-2
   LILLEHOJ HS, 1987, INFECT IMMUN, V55, P1616, DOI 10.1128/IAI.55.7.1616-1621.1987
   Liu YL, 2013, PARASITOL RES, V112, P251, DOI 10.1007/s00436-012-3132-2
   LONG P L, 1976, Folia Veterinaria Latina, V6, P201
   MOREHOUSE NF, 1970, EXP PARASITOL, V28, P25, DOI 10.1016/0014-4894(70)90062-7
   Nielsen HV, 1999, INFECT IMMUN, V67, P6358
   OVINGTON KS, 1995, INT J PARASITOL, V25, P1331, DOI 10.1016/0020-7519(95)00069-E
   Ramly N.Z., 2013, ACTA CRYSTALLOGR, P69
   Reid AJ, 2014, GENOME RES, V24, P1676, DOI 10.1101/gr.168955.113
   Rothwell L, 2000, AVIAN PATHOL, V29, P333, DOI 10.1080/03079450050118467
   Shirley KW., 2007, VACCINE, V25
   Shirley MW, 2005, ADV PARASIT, V60, P285, DOI 10.1016/S0065-308X(05)60005-X
   SMITH RR, 1975, POULTRY SCI, V54, P2081, DOI 10.3382/ps.0542081
   Tabares E, 2004, MOL BIOCHEM PARASIT, V135, P123, DOI 10.1016/j.molbiopara.2004.01.013
   Towbin H., 1979, BIOTECHNOLOGY, V102, P459
   Hoan TD, 2016, EXP PARASITOL, V162, P7, DOI 10.1016/j.exppara.2015.12.015
   WALLACH M, 1992, INFECT IMMUN, V60, P2036, DOI 10.1128/IAI.60.5.2036-2039.1992
   Wiedmer S, 2017, PARASITE, V24, DOI 10.1051/parasite/2017049
   Yock-Ping C., 2011, PLOS ONE, V6
   Yun CH, 2000, DEV COMP IMMUNOL, V24, P303, DOI 10.1016/S0145-305X(99)00080-4
   Zhang ZC, 2016, VET PARASITOL, V215, P96, DOI 10.1016/j.vetpar.2015.10.028
   Zhang ZC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115411
   Zhao GH, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-175
NR 40
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD FEB
PY 2020
VL 278
AR UNSP 109032
DI 10.1016/j.vetpar.2020.109032
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA KR8FZ
UT WOS:000517852700004
PM 31981858
DA 2020-05-12
ER

PT J
AU Abed, SA
   Settar, A
   Chetehouna, K
   Kadiri, MS
   El Tabach, E
   Gascoin, N
AF Akridiss Abed, S.
   Settar, A.
   Chetehouna, K.
   Kadiri, M. S.
   El Tabach, E.
   Gascoin, N.
TI Numerical study on a porous material subject to SiC particles
   deposition, using OpenFOAM and sensitivity analysis technique: Effect of
   clogging evolution on the thermal performances
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Transpiration cooling; Porous media; Particle clogging; OpenFOAM;
   Numerical heat transfer; Global sensitivity analysis
ID HEAT-TRANSFER; MEDIA; CONDUCTIVITY; MODEL; TEMPERATURE; CONVECTION;
   TRANSPORT; FLOW
AB The high thermal load endured by scramjets can cause many damages to the combustion chamber walls of the engine which requires an efficient cooling of the latter. The method of transpiration cooling has shown to be an efficient technique of heat management, by sending a cold fluid through the porous walls of the combustion chamber to cool them. Various parameters could affect the hydrodynamic and thermal behaviours involved at the porous wall, such as the thermal conductivities, the material porosity, the velocity of the flow and other inputs. The present work consists of two-dimensional numerical study of the thermal behaviour of bronze-based porous medium (BR30) using an OpenFOAM house-code. The porous matrix is crossed by water as fluid cooling in laminar flow, while, constant temperatures are applied in contact of combustion chamber. The Local Thermal Non-Equilibrium (LTNE) is considered in the internal field. The developed code was validated against both experimental and numerical results from the literature. Afterwards, two clogged porous media (clogging level of 21% and 32%) are investigated from the thermal and hydrodynamic point of view. Then after, both porous mediums are compared to the nominal configuration (without clogging). The results have shown that the clogging of the material affected not only the hydrodynamic behaviour of the flow but also the thermal properties of the material. Moreover, it has been shown that the clogged materials heated quicker and more that the clean one, while the two clogged materials didn't show a noticeable difference. To understand the effect of different parameters affecting the cooling system efficiency, a global sensitivity analysis is then conducted to determine the most important parameter by varying each one in a range of 10%. The solid thermal conductivity as well as the fluid velocity are the most influencing parameters on the temperature. The interaction of the parameters has also been studied and shown that the interactions of the fluid velocity, solid thermal conductivity as well as the porosity with other parameters have more effect on the resulting temperature. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Akridiss Abed, S.; Settar, A.; Chetehouna, K.; Gascoin, N.] Univ Orleans, Ctr Val Loire, PRISME, INSA,EA 4229, F-18020 Bourges, France.
   [Akridiss Abed, S.; Kadiri, M. S.] Univ Sultan Moulay Slimane, ENSA Khouribga, LIPIM Lab, Khouribga, Morocco.
   [El Tabach, E.] Univ Orleans, IUT Bourges, PRISME, EA 4229, F-18020 Bourges, France.
RP Abed, SA (reprint author), Univ Orleans, Ctr Val Loire, PRISME, INSA,EA 4229, F-18020 Bourges, France.
EM safaa.akridiss-abed@utc.fr
RI Gascoin, Nicolas/K-6151-2013; SETTAR, Abdelhakim/J-7793-2016
OI Gascoin, Nicolas/0000-0002-6434-5716; SETTAR,
   Abdelhakim/0000-0002-2147-880X
CR Adou J. K., 2015, Case Studies in Fire Safety, V4, P11, DOI 10.1016/j.csfs.2015.05.003
   Akridiss S, 2018, EXP THERM FLUID SCI, V98, P112, DOI 10.1016/j.expthermflusci.2018.05.017
   Akridiss S, 2018, AEROSP SCI TECHNOL, V78, P553, DOI 10.1016/j.ast.2018.05.006
   Alem A., 2009, C INT SOLS NON SAT E
   Alomar OR, 2015, INT J THERM SCI, V94, P228, DOI 10.1016/j.ijthermalsci.2015.03.007
   Andoh YH, 2003, APPL THERM ENG, V23, P1947, DOI 10.1016/S1359-4311(03)00145-5
   Benamar A, 2007, CR GEOSCI, V339, P674, DOI 10.1016/j.crte.2007.07.012
   Biasi V., 2013, TRANSFERTS CHALEUR M
   Boudenne A., 2003, ETUDE EXPT THEORIQUE
   Calmidi VV, 1999, J HEAT TRANS-T ASME, V121, P466, DOI 10.1115/1.2826001
   Das M.K., 2018, MODELING TRANSPORT P, P15, DOI DOI 10.1007/978-3-319-69866-3_2
   Dehghan M, 2014, ENERG CONVERS MANAGE, V85, P264, DOI 10.1016/j.enconman.2014.05.074
   Feng YJ, 2007, J POROUS MEDIA, V10, P551, DOI 10.1615/JPorMedia.v10.i6.30
   Feng Y, 2017, APPL THERM ENG, V119, P650, DOI 10.1016/j.applthermaleng.2017.03.010
   Gascoin N, 2011, INT J MULTIPHAS FLOW, V37, P24, DOI 10.1016/j.ijmultiphaseflow.2010.09.001
   Gascoin N, 2012, J POROUS MEDIA, V15, P705, DOI 10.1615/JPorMedia.v15.i8.10
   Gascoin N, 2008, FUEL PROCESS TECHNOL, V89, P1416, DOI 10.1016/j.fuproc.2008.07.004
   Goupy J., 2006, TUTORIEL PLANS EXPER
   Greenshields C. J., 2017, OPENFOAM USER GUIDE
   HASSELMAN DPH, 1987, J COMPOS MATER, V21, P508, DOI 10.1177/002199838702100602
   Ikni T, 2013, CR GEOSCI, V345, P392, DOI 10.1016/j.crte.2013.09.001
   Jasak H., 2007, INT WORKSH COUPL MET, V1000, P1
   Jopek H., 2012, CONVECT CONDUCT HEAT, DOI [10.5772/24531, DOI 10.5772/24531]
   Kasaeian A, 2017, INT J HEAT MASS TRAN, V107, P778, DOI 10.1016/j.ijheatmasstransfer.2016.11.074
   Khan W., 2014, INT J PURE APPL MATH, V96, P235
   Lachaud J, 2014, J THERMOPHYS HEAT TR, V28, P191, DOI 10.2514/1.T4262
   Langener T, 2012, INT J THERM SCI, V54, P70, DOI 10.1016/j.ijthermalsci.2011.10.018
   Langener T, 2011, AIAA J, V49, P1409, DOI 10.2514/1.J050698
   Mahmoudi Y, 2011, INT J THERM SCI, V50, P2386, DOI 10.1016/j.ijthermalsci.2011.07.008
   Martin H., 20 NAT HEAT TRANSF C, P21
   Mohamed D., 2014, MODELE PROPAGATION F
   Morio J, 2011, EUR J PHYS, V32, P1577, DOI 10.1088/0143-0807/32/6/011
   Nield D.A., 2006, J HEAT TRANSFER, V137, DOI [10.1115/1.3449990, DOI 10.1115/1.3449990]
   Pavlyukevich N.V., 2011, TRANSPIRATION COOLIN, DOI [10.1615/AtoZ.t.transpiration, DOI 10.1615/ATOZ.T.TRANSPIRATION]
   Polezhaev J, 1997, ENERG CONVERS MANAGE, V38, P1123, DOI 10.1016/S0196-8904(96)00142-2
   Rahli O, 2011, NUMER HEAT TR A-APPL, V59, P349, DOI 10.1080/10407782.2011.549081
   Rahli O., 1997, ETUDE MILIEUX POREUX
   Richardson S.M., A TO Z GUIDE THERMOD, DOI [10.1615/AtoZ.f.flow_of_fluids, DOI 10.1615/ATOZ.F.FLOW_OF_FLUIDS]
   Romagnosi L, 2013, ENERG CONVERS MANAGE, V68, P63, DOI 10.1016/j.enconman.2012.12.023
   Saito MB, 2010, INT J HEAT MASS TRAN, V53, P2424, DOI 10.1016/j.ijheatmasstransfer.2010.01.041
   Saltelli A., 2004, RELIAB ENG SYST SAFE, DOI [10.1002/0470870958, DOI 10.1002/0470870958]
   Saltelli A., 2014, GLOBAL SENSITIVITY A
   Settar A, 2015, MECH IND, V16, DOI 10.1051/meca/2015035
   Settar A, 2018, INT J HYDROGEN ENERG, V43, P12386, DOI 10.1016/j.ijhydene.2018.04.215
   Settar A, 2015, INT J HYDROGEN ENERG, V40, P8966, DOI 10.1016/j.ijhydene.2015.04.100
   Shirvan KM, 2017, INT J THERM SCI, V121, P124, DOI 10.1016/j.ijthermalsci.2017.07.008
   Soulaine C., 2013, INITIATION CFD OPEN, V1
   Taddeo L., 2015, 20 AIAA INT SPAC PLA, DOI [10.2514/6.2015-3664, DOI 10.2514/6.2015-3664]
   Tosun I., 2007, MODELING TRANSPORT P, P59, DOI [10.1016/B978-044453021-9/50005-1, DOI 10.1016/B978-044453021-9/50005-1]
   Vadasz P., 2015, FLUID FLOW HEAT TRAN, P1, DOI [10.1007/978-3-319-20056-9, DOI 10.1007/978-3-319-20056-9]
   Vu T.L., 2012, MODELISATIONS SIMULA
   Wijaya I, 2017, J PHYS CONF SER, V877, DOI 10.1088/1742-6596/877/1/012056
   Wong MB, 2003, STRUCT DES TALL SPEC, V12, P83, DOI 10.1002/tal.214
   Xin CY, 2014, ENERG CONVERS MANAGE, V78, P1, DOI 10.1016/j.enconman.2013.10.047
   Xu HJ, 2019, CHEM ENG SCI, V195, P462, DOI 10.1016/j.ces.2018.09.045
   Zhou X., 2013, CHOICE REV, DOI [10.5860/choice.45-5931, DOI 10.5860/CHOICE.45-5931]
   Zukauskas A., 1972, ADV HEAT TRANSFER, V8, P93, DOI [10.1016/50065-2717(081/0038-8, DOI 10.1016/S0065-2717(08)70038-8]
NR 57
TC 0
Z9 0
U1 25
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115321
DI 10.1016/j.ces.2019.115321
PG 12
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600014
DA 2020-05-12
ER

PT J
AU Avila, M
   Fletcher, DF
   Poux, M
   Xuereb, C
   Aubin, J
AF Avila, M.
   Fletcher, D. F.
   Poux, M.
   Xuereb, C.
   Aubin, J.
TI Predicting power consumption in continuous oscillatory baffled reactors
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CFD; Energy dissipation rate; Dimensionless power density
ID HEAT-TRANSFER; SUSPENSION POLYMERIZATION; FLOW; CRYSTALLIZATION;
   DISSIPATION
AB Continuous oscillatory baffled reactors (COBRs) have been proven to intensify processes, use less energy and produce fewer wastes compared with stirred tanks. Prediction of power consumption in these devices has been based on simplistic models developed for pulsed columns with single orifice baffles several decades ago and are limited to certain flow conditions. This work explores the validity of existing models to estimate power consumption in a COBR using CFD simulation to analyse power density as a function of operating conditions (covering a range of net flow and oscillatory Reynolds numbers: Re-ne(t) = 6 - 27/Re-o = 24 - 96) in a COBR with a single orifice baffle geometry. Comparison of computed power dissipation with that predicted by the empirical quasi-steady flow models shows that this model is not able to predict correctly the values when the flow is not fully turbulent, which is common when operating COBRs. It has been demonstrated that dimensionless power density is inversely proportional to the total flow Reynolds number in laminar flow and constant in turbulent flow, as is the case for flow in pipes and stirred tanks. For the geometry studied here (P/V)* = 330/Re-T in laminar flow and (P/V)* = 1.92 in turbulent flow. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Avila, M.; Poux, M.; Xuereb, C.; Aubin, J.] Univ Toulouse, CNRS, INPT, Lab Genie Chim,UPS, Toulouse, France.
   [Fletcher, D. F.] Univ Sydney, Sch Chem & Biomol Engn, Sydney, NSW 2006, Australia.
RP Aubin, J (reprint author), Lab Genie Chim, 4 Allee Emile Monso,BP-84234, F-31432 Toulouse 4, France.
EM joelle.aubincano@ensiacet.fr
RI ; Fletcher, David Frederick/F-5524-2011
OI Aubin, Joelle/0000-0001-6230-5158; Fletcher, David
   Frederick/0000-0003-2221-4192
CR Abbott MSR, 2013, INTERFACE FOCUS, V3, DOI 10.1098/rsfs.2012.0036
   Abbott MSR, 2014, CHEM ENG RES DES, V92, P1969, DOI 10.1016/j.cherd.2014.01.020
   Agnew LR, 2017, CRYST GROWTH DES, V17, P2418, DOI 10.1021/acs.cgd.6b01831
   Ahmed SMR, 2017, CHEM ENG TECHNOL, V40, P907, DOI 10.1002/ceat.201600480
   BAIRD MHI, 1995, [No title captured], V73, P503
   BRUNOLD CR, 1989, CHEM ENG SCI, V44, P1227, DOI 10.1016/0009-2509(89)87022-8
   Gonzalez-Juarez D, 2018, APPL THERM ENG, V141, P494, DOI 10.1016/j.applthermaleng.2018.05.115
   Gough P, 1997, J CHEM TECHNOL BIOT, V69, P321, DOI 10.1002/(SICI)1097-4660(199707)69:3<321::AID-JCTB717>3.0.CO;2-Q
   Harvey AP, 2001, IND ENG CHEM RES, V40, P5371, DOI 10.1021/ie0011223
   JEALOUS AC, 1955, IND ENG CHEM, V47, P1168
   Jimeno G, 2018, CHEM ENG PROCESS, V134, P153, DOI 10.1016/j.cep.2018.11.002
   Johansen FC, 1930, P R SOC LOND A-CONTA, V126, P231, DOI 10.1098/rspa.1930.0004
   Lawton S, 2009, ORG PROCESS RES DEV, V13, P1357, DOI 10.1021/op900237x
   Liu SJ, 2001, CAN J CHEM ENG, V79, P100, DOI 10.1002/cjce.5450790115
   Lobry E, 2015, CHEM ENG J, V259, P505, DOI 10.1016/j.cej.2014.08.014
   MACKLEY MR, 1995, CHEM ENG SCI, V50, P2211, DOI 10.1016/0009-2509(95)00088-M
   Mazubert A, 2015, CHEM ENG TECHNOL, V38, P2161, DOI 10.1002/ceat.201500138
   Mazubert A, 2014, GREEN PROCESS SYNTH, V3, P419, DOI 10.1515/gps-2014-0057
   Ni X, 2000, CHEM ENG SCI, V55, P3195, DOI 10.1016/S0009-2509(99)00577-1
   Ni X, 1999, CHEM ENG SCI, V54, P841, DOI 10.1016/S0009-2509(98)00279-6
   Ni X, 2001, AICHE J, V47, P1746, DOI 10.1002/aic.690470807
   Ni XW, 2004, CRYST GROWTH DES, V4, P1129, DOI 10.1021/cg049827l
   Phan AN, 2011, CHEM ENG PROCESS, V50, P254, DOI 10.1016/j.cep.2011.02.004
   Reis N, 2006, BIOTECHNOL BIOENG, V95, P744, DOI 10.1002/bit.21035
   Reis N, 2004, CHEM ENG SCI, V59, P4967, DOI 10.1016/j.ces.2004.09.013
   Soufi MD, 2017, FUEL PROCESS TECHNOL, V167, P641, DOI 10.1016/j.fuproc.2017.07.030
   Stephens GG, 2002, EXP THERM FLUID SCI, V25, P583, DOI 10.1016/S0894-1777(01)00098-X
   Stonestreet P, 2002, CHEM ENG RES DES, V80, P31, DOI 10.1205/026387602753393204
   Stonestreet P, 1999, CHEM ENG RES DES, V77, P671, DOI 10.1205/026387699526809
   Zheng MZ, 2007, PHYS FLUIDS, V19, DOI 10.1063/1.2799553
NR 30
TC 0
Z9 0
U1 13
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115310
DI 10.1016/j.ces.2019.115310
PG 11
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600007
DA 2020-05-12
ER

PT J
AU Bai, YG
   Pei, XP
   Zhao, B
   Xu, K
   Zhai, KK
   Wang, C
   Zhang, F
   Tan, Y
   Zhang, BC
   Wang, YC
   Wang, PX
AF Bai, Yungang
   Pei, Xiaopeng
   Zhao, Bin
   Xu, Kun
   Zhai, Kankan
   Wang, Chao
   Zhang, Fan
   Tan, Ying
   Zhang, Baichao
   Wang, Yinchuan
   Wang, Pixin
TI Multiple pickering high internal phase emulsions stabilized by modified
   diatomite particles via one-step emulsification process
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Diatomite particles; Pickering double emulsions; Porous polymer
   particles
ID TEMPLATED POROUS POLYMERS; NANOPARTICLES; ADSORPTION
AB Conventional approaches to generating double emulsions are cumbersome, complicated, and based on a two-step emulsification process using a combination of two distinctive surfactants. In this work, the surface properties of diatomite particles were successfully tailored by chemical modification with palmitoyl chloride. The properties of the resulting diatomite particles changed from the original hydrophilicity to hydrophobicity, leading to straightforward stabilization of oil-in-water-in-oil (O/W/O) Pickering double emulsions by a one-step emulsification process. Pickering double high internal phase emulsions (HIPEs) with an internal phase up to 80 vol% could be produced solely using the modified diatomite particles. The water-in-oil (W/O) droplet sizes of these HIPEs were much larger than the droplets of conventional nanoparticle-stabilized Pickering HIPEs. Furthermore, using the O/W/O Pickering double emulsions as templates, the porous polymer particles were fabricated. In addition, it was demonstrated that the wide particle size distribution of diatomite particles and modified heterogeneity were the reasons for the formation of multiple emulsions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bai, Yungang; Pei, Xiaopeng; Xu, Kun; Zhai, Kankan; Wang, Chao; Zhang, Fan; Tan, Ying; Zhang, Baichao; Wang, Yinchuan; Wang, Pixin] Chinese Acad Sci, Changchun Inst Appl Chem, Key Lab Polymer Ecomat, Changchun 130022, Jilin, Peoples R China.
   [Bai, Yungang; Pei, Xiaopeng; Zhai, Kankan; Wang, Chao; Zhang, Fan; Wang, Pixin] Univ Sci & Technol China, Hefei 230026, Anhui, Peoples R China.
   [Zhao, Bin] Xinjiang Oilfield Co, Res Inst Explorat & Dev, Hami 839000, Peoples R China.
RP Xu, K; Tan, Y (reprint author), 5625 Renmin St, Changchun 130022, Jilin, Peoples R China.
EM xukun@ciac.ac.cn; tanying@ciac.ac.cn
OI Tan, Ying/0000-0003-3442-6328
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51673191, 21774124, U1762106]; Jilin Province
   Science and Technology Development Project Foundation [20180201071GX];
   Special Funds for High Technology Industrialization of Scientific and
   Technological Cooperation between Jilin and the Chinese Academy of
   Sciences [2018SYHZ0008]; Capital Care Foundation in Jilin Province
   Budget [2019C049-10]
FX Financial support from the National Natural Science Foundation of China
   (grant no. 51673191, 21774124, U1762106), the Jilin Province Science and
   Technology Development Project Foundation (grant no. 20180201071GX),
   Special Funds for High Technology Industrialization of Scientific and
   Technological Cooperation between Jilin and the Chinese Academy of
   Sciences (grant no. 2018SYHZ0008) and Capital Care Foundation in Jilin
   Province Budget (grant no. 2019C049-10) are gratefully acknowledged.
CR Arab M, 2019, INT J BIOL MACROMOL, V121, P691, DOI 10.1016/j.ijbiomac.2018.10.114
   Binks BP, 2003, CHEM COMMUN, P2540, DOI 10.1039/b308998c
   Carrillo CA, 2015, J COLLOID INTERF SCI, V445, P166, DOI 10.1016/j.jcis.2014.12.028
   Cohen N, 2013, J POLYM SCI POL CHEM, V51, P4369, DOI 10.1002/pola.26851
   Cunha AG, 2014, LANGMUIR, V30, P9327, DOI 10.1021/la5017577
   Desire CT, 2018, EUR POLYM J, V102, P56, DOI 10.1016/j.eurpolymj.2018.02.002
   Dickinson E, 2011, FOOD BIOPHYS, V6, P1, DOI 10.1007/s11483-010-9188-6
   Estrada-Fernandez AG, 2018, J FOOD ENG, V221, P35, DOI 10.1016/j.jfoodeng.2017.10.006
   Ikem VO, 2008, ANGEW CHEM INT EDIT, V47, P8277, DOI 10.1002/anie.200802244
   Jiao B, 2018, ANGEW CHEM INT EDIT, V57, P9274, DOI 10.1002/anie.201801350
   Koroleva MY, 2018, COLLOID J+, V80, P272, DOI 10.1134/S1061933X18030079
   Lee EJ, 2017, BIOPROC BIOSYST ENG, V40, P1701, DOI 10.1007/s00449-017-1825-8
   Lee J, 2018, LANGMUIR, V34, P11843, DOI 10.1021/acs.langmuir.8b02576
   Lei L, 2016, J COLLOID INTERF SCI, V483, P232, DOI 10.1016/j.jcis.2016.08.034
   Li ZF, 2011, COLLOID POLYM SCI, V289, P489, DOI 10.1007/s00396-010-2362-z
   Li ZF, 2010, LANGMUIR, V26, P5088, DOI 10.1021/la903546g
   Li ZF, 2009, ANGEW CHEM INT EDIT, V48, P8490, DOI 10.1002/anie.200902103
   Mu Y, 2018, MICROPOR MESOPOR MAT, V267, P203, DOI 10.1016/j.micromeso.2018.03.037
   Ning Y, 2013, CHEM COMMUN, V49, P8761, DOI 10.1039/c3cc45323e
   Pei XP, 2017, POLYMER, V108, P78, DOI 10.1016/j.polymer.2016.11.035
   Pei XP, 2016, POLYM CHEM-UK, V7, P3325, DOI 10.1039/c6py00341a
   Sheng GD, 2012, J ENVIRON RADIOACTIV, V113, P108, DOI 10.1016/j.jenvrad.2012.05.011
   Silverstein MS, 2017, POLYMER, V126, P261, DOI 10.1016/j.polymer.2017.07.046
   Silverstein MS, 2014, POLYMER, V55, P304, DOI 10.1016/j.polymer.2013.08.068
   Silverstein MS, 2014, PROG POLYM SCI, V39, P199, DOI 10.1016/j.progpolymsci.2013.07.003
   Sung MR, 2015, J FOOD ENG, V155, P16, DOI 10.1016/j.jfoodeng.2015.01.007
   Tan H, 2017, SOFT MATTER, V13, P3871, DOI 10.1039/c7sm00706j
   Tan Y, 2012, CARBOHYD POLYM, V88, P1358, DOI 10.1016/j.carbpol.2012.02.018
   Thompson KL, 2015, LANGMUIR, V31, P4137, DOI 10.1021/acs.langmuir.5b00741
   Wong LLC, 2011, MACROMOL RAPID COMM, V32, P1563, DOI 10.1002/marc.201100382
   Xu HY, 2016, LANGMUIR, V32, P38, DOI 10.1021/acs.langmuir.5b03037
   Yang Y, 2013, CHEM COMMUN, V49, P7144, DOI 10.1039/c3cc42270d
   Zheng XH, 2014, MACROMOLECULES, V47, P6847, DOI 10.1021/ma501253u
NR 33
TC 0
Z9 0
U1 56
U2 56
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115341
DI 10.1016/j.ces.2019.115341
PG 9
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600032
DA 2020-05-12
ER

PT J
AU Cornejo, I
   Nikrityuk, P
   Hayes, RE
AF Cornejo, Ivan
   Nikrityuk, Petr
   Hayes, Robert E.
TI The influence of channel geometry on the pressure drop in automotive
   catalytic converters: Model development and validation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CFD; Monolith; Permeability; Pressure drop; Catalytic converter; Channel
   shape
ID MONOLITH CATALYSTS; SIMULATION; DESIGN
AB This paper presents a detailed physics based model for the pressure drop through a honeycomb substrate for several channel shapes and void fractions. A CFD-based computational model of a single channel is used to study the pressure drop when flow is entering, passing through and leaving the substrate. An extensive set of 3D computational experiments covering square, hexagonal and triangular channel cross-sections, void fractions from 0.39 to 0.84 and channel Re from 95 to 1284 is used. It is shown that altering the void fraction changes the pressure drop at the inlet and outlet of the substrate, however, its effect on the friction factor inside the substrate is minor. The resulting model can be used either as a semi-empirical lumped model for pressure drop and in 3D full-scale simulations with a porous medium representing the substrate. A validation for the velocity profile in a full scale monolith with experimental data available in the literature is carried out and an excellent agreement is observed. The proposed model significantly improves the prediction of the flow distribution across the substrate, which has remained unaddressed historically by existing models and is the most important effect required to make accurate predictions of heat distribution, conversion efficiency and others in full-scale simulations. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Cornejo, Ivan; Nikrityuk, Petr; Hayes, Robert E.] Univ Alberta, Dept Chem & Mat Engn, Edmonton, AB, Canada.
   [Cornejo, Ivan] Univ Tecn Federico Santa Maria, Dept Ingn Quim & Ambiental, Valparaiso, Chile.
RP Hayes, RE (reprint author), Univ Alberta, Dept Chem & Mat Engn, Edmonton, AB, Canada.
EM bob.hayes@ualberta.ca
FU Becas-Chile (CONICYT) scholarshipComision Nacional de Investigacion
   Cientifica y Tecnologica (CONICYT); Natural Sciences and Engineering
   Research Council of CanadaNatural Sciences and Engineering Research
   Council of Canada; Compute Ontario; Compute Canada
FX I. Cornejo acknowledges the receipt of a Becas-Chile (CONICYT)
   scholarship. Other funding was provided by the Natural Sciences and
   Engineering Research Council of Canada. This research was enabled in
   part by support provided by Compute Ontario (computeontario.ca) and
   Compute Canada (www.computecanada.ca).
CR [Anonymous], 2017, ANSYS FLUENT 18 2 SO
   Ansys Fluent Ansys, 2017, ANS FLUENT ANS 18 2, V390, P1
   Benjamin S.F., 1996, EXPT PREDICTIVE STUD
   Benjamin SF, 2001, P I MECH ENG C-J MEC, V215, P379, DOI 10.1243/0954406011520779
   Bergman T. L., 2011, FUNDAMENTALS HEAT MA
   Bertrand F, 2012, CATAL TODAY, V188, P80, DOI 10.1016/j.cattod.2011.12.011
   Chen JW, 2008, APPL CATAL A-GEN, V345, P1, DOI 10.1016/j.apcata.2008.04.010
   Clarkson R.J., 1995, THESIS
   Cornejo I., 2017, EMISS CONTROL SCI TE, V3, P302, DOI DOI 10.1007/s40825-017-0070-6
   Cornejo I, 2019, CHEM ENG RES DES, V147, P232, DOI 10.1016/j.cherd.2019.05.017
   Cornejo I, 2019, INT J THERM SCI, V138, P235, DOI 10.1016/j.ijthermalsci.2018.12.044
   Cornejo I, 2018, CHEM ENG RES DES, V140, P308, DOI 10.1016/j.cherd.2018.10.028
   Cornejo I, 2018, CHEM ENG SCI, V187, P107, DOI 10.1016/j.ces.2018.04.041
   Cornejo I, 2018, CHEM ENG SCI, V175, P377, DOI 10.1016/j.ces.2017.10.004
   Cornejo Ivan, 2019, CANAD J CHEM ENG
   Dai CN, 2013, CHEM ENG SCI, V100, P342, DOI 10.1016/j.ces.2013.02.066
   Ekstrom F., 2002, TECHNICAL REPORT
   Grimm M, 2008, COMPUT CHEM ENG, V32, P552, DOI 10.1016/j.compchemeng.2007.03.020
   Hayes RE, 2012, CATAL TODAY, V188, P94, DOI 10.1016/j.cattod.2012.03.015
   Joao Regufe Maria, 2019, MICROPOR MESOPOR MAT
   Kim YD, 2007, INT J AUTO TECH-KOR, V8, P563
   Kim YD, 2009, CHEM ENG SCI, V64, P1373, DOI 10.1016/j.ces.2008.11.020
   Kim YD, 2009, ENVIRON ENG SCI, V26, P1171, DOI 10.1089/ees.2008.0088
   Kostoglou M, 2011, COMPUT CHEM ENG, V35, P1915, DOI 10.1016/j.compchemeng.2011.03.019
   Kumar A, 2010, COMPUT CHEM ENG, V34, P135, DOI 10.1016/j.compchemeng.2009.05.018
   Lai M.-C., 1991, SAE T, P241
   Lobo OJ, 2018, PHYS FLUIDS, V30, DOI 10.1063/1.5018160
   MENTER FR, 1994, AIAA J, V32, P1598, DOI 10.2514/3.12149
   Patankar S.V., 1980, NUMERICAL HEAT TRANS
   Quintanilla A, 2018, APPL CATAL B-ENVIRON, V235, P246, DOI 10.1016/j.apcatb.2018.04.066
   Roy S, 2019, CHEM ENG SCI, V200, P27, DOI 10.1016/j.ces.2018.12.053
   SHAH RK, 1978, J FLUID ENG-T ASME, V100, P177, DOI 10.1115/1.3448626
   Thakkar H, 2018, CHEM ENG J, V348, P109, DOI 10.1016/j.cej.2018.04.178
   Wendland Daniel W, 1986, SAE T, P729
   White F. M., 2009, FLUID MECH
NR 35
TC 0
Z9 0
U1 7
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115317
DI 10.1016/j.ces.2019.115317
PG 12
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600013
DA 2020-05-12
ER

PT J
AU Dong, TW
   Jiang, SL
   Wu, JC
   Liu, HS
   He, YD
AF Dong, Tianwen
   Jiang, Shunliang
   Wu, Jianchun
   Liu, Hesheng
   He, Yadong
TI Simulation of flow and mixing for highly viscous fluid in a twin screw
   extruder with a conveying element using parallelized smoothed particle
   hydrodynamics
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Smoothed particle hydrodynamics; Highly viscous fluid; Twin screw
   extruder; Parallel computing; Flow and mixing
ID NUMERICAL-SIMULATION; MESHLESS METHODS; SPH; IMPLEMENTATION; SINGLE
AB For simulation of the flow in twin screw extrusion, there are several challenges for mesh-based methods, such as complex geometry, moving boundary and partially filled regions. Smooth particle hydrodynamics (SPH) is a kind of meshless particle algorithm that is very suitable in the simulation of these problems. However, due to the high viscosity of polymer limits the time step, the simulation efficiency of SPH is very low. In this paper, we used a parallelized SPH algorithm based on graphics processing units (GPU) to simulate the full filled and partially filled flows of highly viscous fluid in a conveying element. Firstly, in order to verify the results of the SPH simulation, the results for the full filled case simulated by SPH, FEM and FVM were compared and it showed that they are consistent with each other. Consequently, we investigated the mixing process of two kinds of color particles in the conveying element respectively for full filled and half filled cases. We found a better mixing occurs in some regions with the increase of revolution. We also tracked the motion trajectory of two rows of particles and analyze the mixing behavior of these particles in depth. Our results show that by using this parallelized SPH, the computational efficiency can be greatly improved while the hardware cost is low. This work laid a foundation for further study of real extrusion process. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Dong, Tianwen; Wu, Jianchun; Liu, Hesheng] Shangrao Normal Univ, Jiangxi Prov Key Lab Polymer Preparat & Proc, Shangrao 334001, Peoples R China.
   [Jiang, Shunliang] Nanchang Univ, Sch Informat Engn, Nanchang 330031, Jiangxi, Peoples R China.
   [He, Yadong] Beijing Univ Chem Technol, Coll Mech & Elect Engn, Beijing 100029, Peoples R China.
RP Dong, TW (reprint author), Shangrao Normal Univ, Jiangxi Prov Key Lab Polymer Preparat & Proc, Shangrao 334001, Peoples R China.
EM tianwendong@live.cn
FU Science and Technology Project of Jiangxi Education Department
   [GJJ14718]; Natural Science Foundation of Jiangxi ProvinceNatural
   Science Foundation of Jiangxi Province [20181BAB211011]
FX This work was supported by the Science and Technology Project of Jiangxi
   Education Department (Grant No. GJJ14718) and the Natural Science
   Foundation of Jiangxi Province (Grant No. 20181BAB211011). The authors
   would like to thank DualSPHysics team for providing DualSPHysics code.
CR Barcarolo DA, 2014, J COMPUT PHYS, V273, P640, DOI 10.1016/j.jcp.2014.05.040
   Bayyeya MA, 2008, J MATER PROCESS TECH, V197, P221, DOI 10.1016/j.jmatprotec.2007.06.028
   Belytschko T, 1996, COMPUT METHOD APPL M, V139, P3, DOI 10.1016/S0045-7825(96)01078-X
   Bierdel M., 2008, COROTATING TWIN SCRE
   Colagrossi A, 2003, J COMPUT PHYS, V191, P448, DOI 10.1016/S0021-9991(03)00324-3
   Connelly RK, 2007, J FOOD ENG, V79, P956, DOI 10.1016/j.jfoodeng.2006.03.017
   Crespo AJC, 2015, COMPUT PHYS COMMUN, V187, P204, DOI 10.1016/j.cpc.2014.10.004
   Crespo AC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020685
   Cummins SJ, 1999, J COMPUT PHYS, V152, P584, DOI 10.1006/jcph.1999.6246
   Dalrymple RA, 2001, COASTAL DYNAMICS '01: PROCEEDINGS, P779
   Dominguez JM, 2013, COMPUT PHYS COMMUN, V184, P1848, DOI 10.1016/j.cpc.2013.03.008
   Dong TW, 2013, CMES-COMP MODEL ENG, V95, P339
   Eitzlmayr A, 2015, CHEM ENG SCI, V134, P861, DOI 10.1016/j.ces.2015.04.055
   Eitzlmayr A, 2015, CHEM ENG SCI, V134, P880, DOI 10.1016/j.ces.2015.05.035
   Fard AS, 2012, INT J NUMER METH FL, V68, P1031, DOI 10.1002/fld.2595
   GINGOLD RA, 1977, MON NOT R ASTRON SOC, V181, P375, DOI 10.1093/mnras/181.3.375
   He QL, 2017, COMPUT MATH APPL, V73, P109, DOI 10.1016/j.camwa.2016.11.005
   Hughes JP, 2010, J HYDRAUL RES, V48, P105, DOI 10.1080/00221686.2010.9641251
   Ilince F, 2010, INT POLYM PROC, V25, P275, DOI 10.3139/217.2351
   Khalifeh A, 2005, J NON-NEWTON FLUID, V126, P7, DOI 10.1016/j.jnnfm.2004.12.002
   LAWAL A, 1995, POLYM ENG SCI, V35, P1325, DOI 10.1002/pen.760351702
   Lee ES, 2008, J COMPUT PHYS, V227, P8417, DOI 10.1016/j.jcp.2008.06.005
   Leimkuhler B.J., 1996, INTEGRATION METHODS, DOI [10.1007/978-1-4612-4066-2_10, DOI 10.1007/978-1-4612-4066-2_10]
   LUCY LB, 1977, ASTRON J, V82, P1013, DOI 10.1086/112164
   Molteni D, 2009, COMPUT PHYS COMMUN, V180, P861, DOI 10.1016/j.cpc.2008.12.004
   MONAGHAN JJ, 1992, ANNU REV ASTRON ASTR, V30, P543, DOI 10.1146/annurev.aa.30.090192.002551
   MONAGHAN JJ, 1994, J COMPUT PHYS, V110, P399, DOI 10.1006/jcph.1994.1034
   MONAGHAN JJ, 1985, ASTRON ASTROPHYS, V149, P135
   Monaghan JJ, 1999, J WATERW PORT C-ASCE, V125, P145, DOI 10.1061/(ASCE)0733-950X(1999)125:3(145)
   Morris JP, 1997, J COMPUT PHYS, V136, P214, DOI 10.1006/jcph.1997.5776
   Moulinec C, 2008, CMES-COMP MODEL ENG, V25, P133
   Nguyen VP, 2008, MATH COMPUT SIMULAT, V79, P763, DOI 10.1016/j.matcom.2008.01.003
   Ottino J.M., 2011, KINEMATICS MIXING ST
   Pokriefke G., 2004, INT C FEM TECHN ANSY
   Prakash M, 2009, J MATER PROCESS TECH, V209, P3396, DOI 10.1016/j.jmatprotec.2008.07.055
   Robinson M, 2008, AICHE J, V54, P1987, DOI 10.1002/aic.11530
   SIBILLA S, 2007, P SPHERIC 2 INT WORK
   Sun XS, 2016, CHEM ENG SCI, V139, P221, DOI 10.1016/j.ces.2015.09.031
   Tadmor Z., 2006, PRINCIPLE POLYM PROC
   Vergnes B, 1998, POLYM ENG SCI, V38, P1781, DOI 10.1002/pen.10348
   Vikhansky A, 2002, CHEM ENG SCI, V57, P2719, DOI 10.1016/S0009-2509(02)00122-7
   Wittek P, 2018, CHEM ENG SCI, V187, P256, DOI 10.1016/j.ces.2018.05.007
   Xu BP, 2018, ADV POLYM TECH, V37, P2215, DOI 10.1002/adv.21880
   Zhu XZ, 2009, J MATER PROCESS TECH, V209, P3289, DOI 10.1016/j.jmatprotec.2008.07.045
NR 44
TC 0
Z9 0
U1 21
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115311
DI 10.1016/j.ces.2019.115311
PG 16
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600008
DA 2020-05-12
ER

PT J
AU Ebadi, M
   Moshksayan, K
   Kashaninejad, N
   Saidi, MS
   Nguyen, NT
AF Ebadi, Milad
   Moshksayan, Khashayar
   Kashaninejad, Navid
   Saidi, Mohammad Said
   Nam-Trung Nguyen
TI A tool for designing tree-like concentration gradient generators for
   lab-on-a-chip applications
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Tree-like concentration gradient generator; Open-source CGG;
   Fluorescence measurement; Microfluidics; CFD
ID MICROFLUIDIC DEVICE; CHEMOTAXIS; GROWTH; DIFFERENTIATION; FABRICATION;
   SPHEROIDS; DIFFUSION; CELLS
AB Concentration gradient generators (CGGs) help biologists to perform large scale, fast and high-throughput experiments. This paper introduces a design tool called Tree-like Concentration gradient generator Design Tool (TCDT). The performance of this tool is validated both numerically and experimentally. Three CGGs were fabricated using three different fabrication methods and design parameters. The performance of these devices was examined using the measurement of fluorescent and dye intensity. The performance of the design tool for non-linear and multi-drug concentration gradient generations was investigated as well. In addition, a method was developed to investigate the multi-drug concentration effect, which can be the starting point for off-the-shelf usage of the CGGs in personalized medicine. Experimental data, as well as numerical results, confirmed that the output concentrations of the CGGs were within five percent of the values predicted by the design tool. This open-source software is available online for public use. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ebadi, Milad; Moshksayan, Khashayar; Saidi, Mohammad Said] Sharif Univ Technol, Dept Mech Engn, Tehran 11155, Iran.
   [Kashaninejad, Navid; Nam-Trung Nguyen] Griffith Univ, Queensland Micro & Nanotechnol Ctr, Nathan Campus,170 Kessels Rd, Brisbane, Qld 4111, Australia.
RP Saidi, MS (reprint author), Sharif Univ Technol, Dept Mech Engn, Tehran 11155, Iran.; Nguyen, NT (reprint author), Griffith Univ, Queensland Micro & Nanotechnol Ctr, Nathan Campus,170 Kessels Rd, Brisbane, Qld 4111, Australia.
EM mssaidi@sharif.edu; nam-trung.nguyen@griffith.edu.au
RI Nguyen, Nam-Trung/A-4180-2008; Kashaninejad, Navid/L-9228-2016
OI Nguyen, Nam-Trung/0000-0003-3626-5361; Kashaninejad,
   Navid/0000-0002-4385-7771
CR Abhyankar VV, 2006, LAB CHIP, V6, P389, DOI 10.1039/b514133h
   [Anonymous], 2017, SERIAL DILUTION USIN, P21
   BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453
   Bui MPN, 2011, ANAL CHEM, V83, P1603, DOI 10.1021/ac102472a
   Cengel Y. A., 2010, FLUID MECH
   Chang CW, 2014, LAB CHIP, V14, P3762, DOI 10.1039/c4lc00732h
   Chang TC, 2014, LAB CHIP, V14, P4540, DOI 10.1039/c4lc00642a
   Chiang HC, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-216
   Chung BG, 2005, LAB CHIP, V5, P401, DOI 10.1039/b417651k
   CRANK J., 1979, MATH DIFFUSION
   Diao JP, 2006, LAB CHIP, V6, P381, DOI 10.1039/b511958h
   DiCicco M, 2014, BIOCHIP J, V8, P282, DOI 10.1007/s13206-014-8406-6
   Gao YD, 2012, MICROFLUID NANOFLUID, V12, P887, DOI 10.1007/s10404-011-0908-0
   Gendron PO, 2008, J FLUORESC, V18, P1093, DOI 10.1007/s10895-008-0357-7
   Girod B., 1999, VISION MODELLING VIS
   Glawdel T, 2009, LAB CHIP, V9, P3243, DOI 10.1039/b911412m
   GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992
   Harrison H, 2015, ANALYST, V140, P2869, DOI [10.1039/c5an00105f, 10.1039/C5AN00105F]
   Heo YS, 2010, HUM REPROD, V25, P613, DOI 10.1093/humrep/dep449
   Hong B, 2016, BIOMED MICRODEVICES, V18, DOI 10.1007/s10544-016-0054-2
   Hu C., 2017, BIOCH ANAL BIOCH, V6, DOI [10.4172/2161-1009.1000320, DOI 10.4172/2161-1009.1000320]
   Huang CH, 2017, MICROFLUID NANOFLUID, V21, DOI 10.1007/s10404-017-1922-7
   Jain M, 2010, BIOMICROFLUIDICS, V4, DOI 10.1063/1.3368991
   Jang YH, 2011, LAB CHIP, V11, P3277, DOI 10.1039/c1lc20449a
   Jeon NL, 2000, LANGMUIR, V16, P8311, DOI 10.1021/la000600b
   Jeon NL, 2002, NAT BIOTECHNOL, V20, P826, DOI 10.1038/nbt712
   Jin D, 2016, RSC ADV, V6, P29598, DOI 10.1039/c6ra01456a
   Kashaninejad N, 2016, MICROMACHINES-BASEL, V7, DOI 10.3390/mi7080130
   Keenan TM, 2008, LAB CHIP, V8, P34, DOI 10.1039/b711887b
   Kendig S., 2003, MICROELECTRONICS PRO
   Kilinc D, 2016, INTEGR BIOL-UK, V8, P39, DOI 10.1039/c5ib00209e
   Kothapalli CR, 2011, LAB CHIP, V11, P497, DOI 10.1039/c01c00240b
   Kwapiszewska K, 2016, AIMS BIOPHYS, V3, P553, DOI 10.3934/biophy.2016.4.553
   Lee JM, 2011, ELECTROPHORESIS, V32, P3133, DOI 10.1002/elps.201100161
   Lee K, 2010, MICROFLUID NANOFLUID, V8, P677, DOI 10.1007/s10404-009-0500-z
   Ligrani Phillip M., 1994, STUDY DEAN VORTEX DE, P1
   Lim W, 2018, MOLECULES, V23, DOI 10.3390/molecules23123355
   Lin F, 2004, LAB CHIP, V4, P164, DOI 10.1039/b313600k
   Liu MC, 2008, SENSOR ACTUAT B-CHEM, V129, P826, DOI 10.1016/j.snb.2007.09.074
   Mark D, 2012, LAB CHIP, V12, P2464, DOI 10.1039/c2lc00043a
   Moshksayan Khashayar, 2018, Inventions, V3, DOI 10.3390/inventions3030043
   Moshksayan K, 2018, SENSOR ACTUAT B-CHEM, V263, P151, DOI 10.1016/j.snb.2018.01.223
   Nguyen NT, 2012, MICRO NANO TECHNOL, P321, DOI 10.1016/B978-1-4377-3520-8.00009-7
   Nguyen NT, 2012, MICRO NANO TECHNOL, P9, DOI 10.1016/B978-1-4377-3520-8.00002-4
   Nguyen B, 2016, LAB CHIP, V16, P2785, DOI 10.1039/c6lc00619a
   Park JY, 2007, LAB CHIP, V7, P1673, DOI 10.1039/b710777c
   Python, 2019, SOFTW FDN PYTH LANG
   Ramesan S, 2016, LAB CHIP, V16, P2820, DOI 10.1039/c5lc00937e
   Rao S. S., 1996, ENG OPTIMIZATION THE
   Ren YK, 2019, ELECTROPHORESIS, V40, P979, DOI 10.1002/elps.201800325
   Rismanian M, 2019, CHEM ENG SCI, V195, P120, DOI 10.1016/j.ces.2018.11.041
   Ruppen J, 2015, LAB CHIP, V15, P3076, DOI 10.1039/c5lc00454c
   Shames I., 2003, MECH FLUIDS
   Toh AGG, 2014, MICROFLUID NANOFLUID, V16, P1, DOI 10.1007/s10404-013-1236-3
   Tretkoff E., 2005, APS NEWS, V14
   Truskey G.A., 2004, TRANSPORT PHENOMENA
   Walker GM, 2005, LAB CHIP, V5, P611, DOI 10.1039/b417245k
   Wang CJ, 2008, LAB CHIP, V8, P227, DOI 10.1039/b713945d
   Wang F., 2009, COLD SPRING HARBOR P, V1
   Yang CG, 2011, LAB CHIP, V11, P3305, DOI 10.1039/c1lc20123a
   Ye NN, 2007, LAB CHIP, V7, P1696, DOI 10.1039/b711513j
   Zheng TF, 2019, ELECTROPHORESIS, DOI 10.1002/elps.201900315
   ZICHA D, 1991, J CELL SCI, V99, P769
   Zigmond SH H.J., 1973, J EXP MED, V137, P23
NR 64
TC 1
Z9 1
U1 36
U2 36
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115339
DI 10.1016/j.ces.2019.115339
PG 14
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600030
DA 2020-05-12
ER

PT J
AU Ebneyamini, A
   Grace, J
   Lim, CJ
   Ellis, N
   Elnashaie, SSEH
   Mahecha-Botero, A
AF Ebneyamini, A.
   Grace, J.
   Lim, C. J.
   Ellis, N.
   Elnashaie, S. S. E. H.
   Mahecha-Botero, A.
TI Simulation of autothermal hydrogen-producing limestone calcination for
   calcium looping in turbulent fluidized bed reactors
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Calcium looping; Sorbent-enhanced reforming; Sorbent regeneration;
   Fluidized bed reactor; Reactor modeling; Hydrogen
ID CO2 CAPTURE; CARBONATION/CALCINATION CYCLE; SORBENTS; METHANE; KINETICS
AB This paper investigates the performance of combining limestone calcination with catalytic methane reforming and combustion in turbulent fluidized bed membrane reactors. The equilibrium performance of the process was evaluated using Aspen simulation, with a unique correlation to estimate the required gaseous feed composition for autothermal and complete sorbent regeneration at operating temperatures of 800-900 degrees C. A one-dimensional, isothermal, steady-state kinetic model is then employed to study the performance of the four-in-one (combustion + reforming + calcination + optional membrane separation) integrated process under turbulent fluidization conditions. The simulation results demonstrate the high potential of this novel sorbent regeneration technique for autothermal, rapid and hydrogen-producing limestone calcination. The performance is shown to depend strongly on the sorbent/total gas molar feed ratio, operating temperature, operating pressure and sorbent residence time. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ebneyamini, A.; Grace, J.; Lim, C. J.; Ellis, N.; Elnashaie, S. S. E. H.; Mahecha-Botero, A.] Univ British Columbia, Dept Chem & Biol Engn, Vancouver, BC V6T 1Z3, Canada.
RP Ebneyamini, A (reprint author), Univ British Columbia, Dept Chem & Biol Engn, Vancouver, BC V6T 1Z3, Canada.
EM aebneyam@mail.ubc.ca
FU Natural Science and Engineering Research Council of Canada
   (NSERC)Natural Sciences and Engineering Research Council of Canada
FX The authors acknowledge the financial support of the Natural Science and
   Engineering Research Council of Canada (NSERC) via their CREATE and
   Discovery Grant programs.
CR Abanades JC, 2002, CHEM ENG J, V90, P303, DOI 10.1016/S1385-8947(02)00126-2
   Abba I.A., 2001, THESIS
   Anderson DM, 2015, IND ENG CHEM RES, V54, P8422, DOI 10.1021/acs.iecr.5b01879
   Andres MB, 2011, INT J HYDROGEN ENERG, V36, P4038, DOI 10.1016/j.ijhydene.2010.09.091
   Benguerba Y, 2015, REACT KINET MECH CAT, V115, P483, DOI 10.1007/s11144-015-0849-9
   Bi HT, 2000, CHEM ENG SCI, V55, P4789, DOI 10.1016/S0009-2509(00)00107-X
   Butler J., 2013, THESIS
   Chen YM, 2014, IND ENG CHEM RES, V53, P6230, DOI 10.1021/ie500294k
   Chen ZX, 2008, CHEM ENG SCI, V63, P170, DOI 10.1016/j.ces.2007.09.031
   Chen Z, 2009, ENERG FUEL, V23, P1437, DOI 10.1021/ef800779k
   Davis M.E., 2003, FUNDAMENTALS CHEM RE, DOI [10.1021/ed043pA758.1, DOI 10.1021/ED043PA758.1]
   Ebneyamini A., 2017, THESIS, DOI [10.20381/ruor-20323, DOI 10.20381/RUOR-20323]
   Ebneyamini A, 2019, IND ENG CHEM RES, V58, P8636, DOI 10.1021/acs.iecr.9b00668
   Ebneyamini A, 2017, J MEMBRANE SCI, V543, P361, DOI 10.1016/j.memsci.2017.08.064
   Elnashaie S., 2007, NUMERICAL TECHNIQUES
   Jakobsen JP, 2009, ENRGY PROCED, V1, P725, DOI 10.1016/j.egypro.2009.01.096
   Johnsen K, 2006, CHEM ENG SCI, V61, P1195, DOI 10.1016/j.ces.2005.08.022
   Johnsen K., 2006, THESIS
   Johnsen K, 2006, IND ENG CHEM RES, V45, P4133, DOI 10.1021/ie0511736
   Leimert JM, 2017, PROCESSES, V5, DOI 10.3390/pr5040082
   Leimert JM, 2016, INT J HYDROGEN ENERG, V41, P9355, DOI 10.1016/j.ijhydene.2016.04.073
   Manovic V, 2010, INT J ENV RES PUB HE, V7, P3129, DOI 10.3390/ijerph7083129
   Martinez I, 2013, CHEM ENG J, V215, P174, DOI 10.1016/j.cej.2012.09.134
   Romeo LM, 2008, ENERG CONVERS MANAGE, V49, P2809, DOI 10.1016/j.enconman.2008.03.022
   Sakadjian BB, 2007, IND ENG CHEM RES, V46, P35, DOI 10.1021/ie060214a
   Salaudeen SA, 2018, J CO2 UTIL, V23, P179, DOI 10.1016/j.jcou.2017.11.012
   Senthoorselvan S, 2009, J ENG GAS TURB POWER, V131, DOI 10.1115/1.2969090
   Steib M., 2018, THESIS
   Thompson ML, 1999, CHEM ENG SCI, V54, P2175, DOI 10.1016/S0009-2509(98)00354-6
   Ylatalo J, 2013, FUEL, V113, P770, DOI 10.1016/j.fuel.2012.11.041
NR 30
TC 0
Z9 0
U1 9
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115353
DI 10.1016/j.ces.2019.115353
PG 15
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600038
DA 2020-05-12
ER

PT J
AU Ghosh, S
   Viswanathan, NN
   Ballal, NB
AF Ghosh, Snigdha
   Viswanathan, Nurni N.
   Ballal, N. B.
TI Shape and maximum volume of static holdup in between two vertical
   spheres: A modeling study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Static liquid holdup; Bond number; Modified Bond number; Axisymmetric
   liquid-vapor interface; Young- Laplace equation
ID TRICKLE-BED REACTORS; LIQUID HOLDUP; SURFACE-TENSION; ENERGY; BRIDGE;
   DROP
AB Static liquid holdup is one of the important parameters in packed bed operations. Packed bed can be fundamentally imagined as an aggregate of two-sphere contacts and liquid is potentially held at the contact points. Between two vertical spheres, existing literature report maximum volume of films either as the geometric limit while solving Young-Laplace equation or the stability limit of static liquid holdup in the presence of asymmetric perturbation. However, it is of fundamental interest to find out the maximum limit of stability of the liquid without any asymmetric perturbation. This work shows a limit, below the geometrical limit of the system, beyond which liquid cannot be stable due to the gravitational force. Axisymmetric film shapes of a given volume, derived using Young- Laplace equation with different boundary conditions, are tested with total energy minimization principle to define the stability limit. Further, a correlation for maximum static liquid holdup is reported with respect to a modified Bond number. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ghosh, Snigdha; Viswanathan, Nurni N.; Ballal, N. B.] Indian Inst Technol, Dept Met Engn & Mat Sci, Mumbai 400076, Maharashtra, India.
RP Ghosh, S (reprint author), Indian Inst Technol, Dept Met Engn & Mat Sci, Mumbai 400076, Maharashtra, India.
EM snigdha_ghosh@iitb.ac.in
CR BAYRAMLI E, 1987, J COLLOID INTERF SCI, V116, P490, DOI 10.1016/0021-9797(87)90145-7
   BIKERMAN JJ, 1950, J COLL SCI IMP U TOK, V5, P349, DOI 10.1016/0095-8522(50)90059-6
   CHARPENTIER JC, 1975, AICHE J, V21, P1213, DOI 10.1002/aic.690210626
   DERAMOS AL, 1993, LANGMUIR, V9, P3691
   Extrand CW, 1998, J COLLOID INTERF SCI, V207, P11, DOI 10.1006/jcis.1998.5743
   Fukutake T., 1982, ISIJ INT, V22, P355
   GARDNER GC, 1956, CHEM ENG SCI, V5, P101, DOI 10.1016/0009-2509(56)80026-2
   Hanstead A.R., 2000, MEASUREMENT STATIC L, V418, DOI [10.1016/0021-9797(90)90361-Q, DOI 10.1016/0021-9797(90)90361-Q]
   Husslage WM, 2005, METALL MATER TRANS B, V36, P765, DOI 10.1007/s11663-005-0080-6
   Macdougall G, 1942, PROC R SOC LON SER-A, V180, P0151, DOI 10.1098/rspa.1942.0031
   MAO ZS, 1993, CHEM ENG SCI, V48, P2697, DOI 10.1016/0009-2509(93)80182-P
   MAZZONE DN, 1986, J COLLOID INTERF SCI, V113, P544, DOI 10.1016/0021-9797(86)90187-6
   Megias-Alguacil D, 2009, AICHE J, V55, P1103, DOI 10.1002/aic.11726
   MICHAEL DH, 1981, ANNU REV FLUID MECH, V13, P189, DOI 10.1146/annurev.fl.13.010181.001201
   SAEZ AE, 1990, J COLLOID INTERF SCI, V140, P408, DOI 10.1016/0021-9797(90)90361-Q
   SAEZ AE, 1991, AICHE J, V37, P1733, DOI 10.1002/aic.690371117
   SHULMAN HL, 1955, AICHE J, V1, P247, DOI 10.1002/aic.690010219
   STANDISH N, 1968, CHEM ENG SCI, V23, P945, DOI 10.1016/0009-2509(68)80035-1
   Tadmor R, 2004, LANGMUIR, V20, P7659, DOI 10.1021/la049410h
   Turner G.A., 1959, T I CHEM ENG-LOND, V37, P324, DOI [10.1145/2505515.2507827, DOI 10.1145/2505515.2507827]
   Xiong W, 2012, METALL MATER TRANS B, V43, P562, DOI 10.1007/s11663-011-9628-9
NR 21
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115332
DI 10.1016/j.ces.2019.115332
PG 8
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600023
DA 2020-05-12
ER

PT J
AU Gu, WQ
   Yan, SL
   Bai, ZS
AF Gu, Wenquan
   Yan, Shenglin
   Bai, Zhishan
TI A study on a droplet impact on a fiber during coalescence-separation:
   Phenomena and models
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Coalescence; Droplets impact; Fibers; Threshold velocity
ID WATER DROPLETS; OIL; EMULSION; BED; COLLECTION; REMOVAL
AB Droplets impact on fibers occurred in liquid phase plays a vital role in the coalescence-separation applications, however, the mechanism and details are still unclear. Here we investigated the impact process through energy conversion and impact dynamics and two models are established to determine the threshold velocities of capture. The adhering phenomenon is observed when the impact velocity is smaller than the minimum threshold velocity V-c1. The droplet may be captured by fibers when the impact velocity is larger than V-c1 and smaller than the maximum threshold velocity V-c2. These two velocities limit a range in which the droplet may be captured by fibers are significant to facilitate the optimization of coalescence separation. This study opens up opportunities for understanding the details of coalescence separation as well as improving efficiency of industrial applications. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gu, Wenquan; Yan, Shenglin; Bai, Zhishan] East China Univ Sci & Technol, Sch Mech & Power Engn, Shanghai 200237, Peoples R China.
RP Bai, ZS (reprint author), East China Univ Sci & Technol, Sch Mech & Power Engn, Shanghai 200237, Peoples R China.
EM baizs@ecust.edu.cn
FU National Natural Science Foundation of China, ChinaNational Natural
   Science Foundation of China [51578239]; Scientific Research Projects of
   Shanghai, China [17DZ1202802]
FX This work was supported by the National Natural Science Foundation of
   China, China (51578239) and Scientific Research Projects of Shanghai,
   China (17DZ1202802).
CR Agarwal S, 2013, IND ENG CHEM RES, V52, P13164, DOI 10.1021/ie4018995
   Bansal S, 2011, J HAZARD MATER, V190, P45, DOI 10.1016/j.jhazmat.2011.01.134
   Bussmann M., 1997, ASME FLUIDS ENG DIV
   CARROLL BJ, 1976, J COLLOID INTERF SCI, V57, P488, DOI 10.1016/0021-9797(76)90227-7
   Chawaloesphonsiya N, 2014, SEP SCI TECHNOL, V49, P2960, DOI 10.1080/01496395.2014.943768
   Comtet J, 2016, SOFT MATTER, V12, P149, DOI 10.1039/c5sm02037a
   Contal P, 2004, J AEROSOL SCI, V35, P263, DOI 10.1016/j.jaerosci.2003.07.003
   DEAR JP, 1988, J APPL PHYS, V63, P1015, DOI 10.1063/1.340000
   Dressaire E, 2016, SOFT MATTER, V12, P200, DOI 10.1039/c5sm02246k
   Han Q, 2017, J DISPER SCI TECHNOL, V38, P1523, DOI 10.1080/01932691.2016.1259073
   Hung LS, 2002, INT J MULTIPHAS FLOW, V28, P93, DOI 10.1016/S0301-9322(01)00061-1
   Hung LS, 1999, INT J MULTIPHAS FLOW, V25, P1545, DOI 10.1016/S0301-9322(98)00085-8
   Kim SG, 2016, PHYS FLUIDS, V28, DOI 10.1063/1.4945103
   Kundu P, 2013, SEP PURIF TECHNOL, V118, P519, DOI 10.1016/j.seppur.2013.07.041
   LEVIN Z, 1971, PHILOS TR R SOC S-A, V269, P555, DOI 10.1098/rsta.1971.0052
   Liang GT, 2014, EXP THERM FLUID SCI, V52, P97, DOI 10.1016/j.expthermflusci.2013.09.001
   Liang GT, 2013, EXP THERM FLUID SCI, V51, P18, DOI 10.1016/j.expthermflusci.2013.06.012
   Lorenceau E, 2004, J COLLOID INTERF SCI, V279, P192, DOI 10.1016/j.jcis.2004.06.054
   Lorenceau E, 2009, EUR PHYS J-SPEC TOP, V166, P3, DOI 10.1140/epjst/e2009-00868-0
   Maiti S, 2011, COLLOID SURFACE A, V389, P291, DOI 10.1016/j.colsurfa.2011.07.041
   Patel SU, 2014, SEP PURIF TECHNOL, V126, P62, DOI 10.1016/j.seppur.2014.02.009
   Piroird K, 2009, J COLLOID INTERF SCI, V334, P70, DOI 10.1016/j.jcis.2009.03.004
   Shanyengana ES, 2003, J WATER SUPPLY RES T, V52, P237
   Shin C, 2006, J DISPER SCI TECHNOL, V27, P517, DOI 10.1080/01932690500374276
   Sokolovic RMS, 2007, SEP PURIF TECHNOL, V56, P79, DOI 10.1016/j.seppur.2007.01.028
   Sokolovic RMS, 1997, IND ENG CHEM RES, V36, P4949
   Sokolovic RMS, 2003, IND ENG CHEM RES, V42, P3098, DOI 10.1021/ie020361i
   Viswanadam G, 2013, SEP PURIF TECHNOL, V104, P81, DOI 10.1016/j.seppur.2012.11.020
   Zheng YM, 2010, NATURE, V463, P640, DOI 10.1038/nature08729
   Zhou YB, 2009, IND ENG CHEM RES, V48, P1660, DOI 10.1021/ie8012242
NR 30
TC 0
Z9 0
U1 20
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115337
DI 10.1016/j.ces.2019.115337
PG 6
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600028
DA 2020-05-12
ER

PT J
AU He, Y
   Bayly, AE
   Hassanpour, A
   Fairweather, M
   Muller, F
AF He, Yi
   Bayly, Andrew E.
   Hassanpour, Ali
   Fairweather, Michael
   Muller, Frans
TI Flow behaviour of an agitated tubular reactor using a novel dynamic mesh
   based CFD model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CFD; Fluid-structure interaction; Agitated tubular reactor; Dynamic
   meshing approach; Reynolds stress model; Process intensification
ID STIRRED-TANK; NUMERICAL-SIMULATION; FLUID-FLOWS; COMPLEX; DEM;
   POLYMERIZATION; PREDICTION; SUSPENSION; BOUNDARIES; SYSTEMS
AB Agitated tubular reactor (ATR) is an intensified continuous reactor in which radial mixing is decoupled from axial flow. This study proposed a novel CFD model to study fluid dynamics and mixing mechanisms in the ATR system. It combines a soft-sphere collision model with a dynamic meshing approach to tackle structure-structure and fluid-structure interactions (FSI) simultaneously. Its ability to handle FSI is validated on the sedimentation of a large sphere in a quiescent fluid. A periodic motion of the agitator was predicted, which is mainly driven by collision with the external oscillating tube. The fluid motion is complex, with vortex structures forming behind the agitator at its highest point; and the highest fluid velocities seen as fluid is squeezed under the agitator. Three Reynolds stress models were evaluated and the pressure-strain term shows little influence on the agitator's motion. Viscous dissipation was found to be the main mechanism for energy dissipation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [He, Yi; Bayly, Andrew E.; Hassanpour, Ali; Fairweather, Michael; Muller, Frans] Univ Leeds, Sch Chem & Proc Engn, Leeds LS2 9JT, W Yorkshire, England.
RP He, Y (reprint author), Univ Leeds, Sch Chem & Proc Engn, Leeds LS2 9JT, W Yorkshire, England.
EM y.he1@leeds.ac.uk
OI Bayly, Andrew/0000-0001-6354-9015; Hassanpour, Ali/0000-0002-7756-1506
FU European Commission under the H2020 SPIRE programme
   [SPIRE-082015-680565]
FX The authors would like to thank the European Commission for supporting
   this work as part of the research project "Intensified by Design (R) for
   the intensification of processes involving solids handling"(IbD (R)),
   under the H2020 SPIRE programme (SPIRE-082015-680565). This work was
   undertaken on ARC3, part of the high performance computing facilities at
   the University of Leeds, UK.
CR ABRAHAM FF, 1970, PHYS FLUIDS, V13, P2194, DOI 10.1063/1.1693218
   BAKKER A, 1994, CHEM ENG RES DES, V72, P594
   Balaras E, 2004, COMPUT FLUIDS, V33, P375, DOI 10.1016/S0045-7930(03)00058-6
   Bathe KJ, 1999, COMPUT STRUCT, V72, P1, DOI 10.1016/S0045-7949(99)00042-5
   Browne DL, 2011, ORG PROCESS RES DEV, V15, P693, DOI 10.1021/op2000223
   Brucato A, 1998, CHEM ENG SCI, V53, P3653, DOI 10.1016/S0009-2509(98)00149-3
   Cheng YG, 2005, ANN BIOMED ENG, V33, P567, DOI 10.1007/s10439-005-4388-9
   DAVID R, 1991, CHEM ENG SCI, V46, P205, DOI 10.1016/0009-2509(91)80130-Q
   Derksen JJ, 2012, AICHE J, V58, P3266, DOI 10.1002/aic.13889
   Derksen JJ, 2003, AICHE J, V49, P2700, DOI 10.1002/aic.690491104
   Fadlun EA, 2000, J COMPUT PHYS, V161, P35, DOI 10.1006/jcph.2000.6484
   Gasparini G, 2012, ORG PROCESS RES DEV, V16, P1013, DOI 10.1021/op2003612
   Hartmann H, 2006, AICHE J, V52, P3696, DOI 10.1002/aic.10997
   Harvey AP, 2003, J CHEM TECHNOL BIOT, V78, P338, DOI 10.1002/jctb.782
   He Y, 2018, POWDER TECHNOL, V333, P219, DOI 10.1016/j.powtec.2018.04.034
   He Y, 2015, INT J MINER PROCESS, V142, P73, DOI 10.1016/j.minpro.2015.05.005
   He Y, 2018, POWDER TECHNOL, V325, P620, DOI 10.1016/j.powtec.2017.11.045
   Jaensson NO, 2016, J NON-NEWTON FLUID, V235, P125, DOI 10.1016/j.jnnfm.2016.07.008
   JAISINGHANI R, 1977, CHEM ENG SCI, V32, P811, DOI 10.1016/0009-2509(77)80067-5
   Jones E, 2012, CHEM ENG RES DES, V90, P726, DOI 10.1016/j.cherd.2012.01.018
   Kasat GR, 2008, CHEM ENG SCI, V63, P3877, DOI 10.1016/j.ces.2008.04.018
   Kerdouss F, 2006, CHEM ENG SCI, V61, P3313, DOI 10.1016/j.ces.2005.11.061
   KRESTA SM, 1991, AICHE J, V37, P448, DOI 10.1002/aic.690370314
   MINDLIN RD, 1953, J APPL MECH-T ASME, V20, P327
   Ng K, 2000, CHEM ENG RES DES, V78, P334, DOI 10.1205/026387600527446
   Ni X, 2001, AICHE J, V47, P1746, DOI 10.1002/aic.690470807
   Pan CM, 2008, CHINESE J CHEM ENG, V16, P693, DOI 10.1016/S1004-9541(08)60142-1
   PESKIN CS, 1972, J COMPUT PHYS, V10, P252, DOI 10.1016/0021-9991(72)90065-4
   QUIRK JJ, 1994, COMPUT FLUIDS, V23, P125, DOI 10.1016/0045-7930(94)90031-0
   Rutherford K, 1996, AICHE J, V42, P332, DOI 10.1002/aic.690420204
   Singh KK, 2007, CHEM ENG SCI, V62, P1308, DOI 10.1016/j.ces.2006.10.028
   SPEZIALE CG, 1991, J FLUID MECH, V227, P245, DOI 10.1017/S0022112091000101
   Taghavi M, 2011, CHEM ENG RES DES, V89, P280, DOI 10.1016/j.cherd.2010.07.006
   ten Cate A, 2002, PHYS FLUIDS, V14, P4012, DOI 10.1063/1.1512918
   TEZDUYAR TE, 1992, COMPUT METHOD APPL M, V94, P339, DOI 10.1016/0045-7825(92)90059-S
   Udaykumar HS, 1996, INT J NUMER METH FL, V22, P691, DOI 10.1002/(SICI)1097-0363(19960430)22:8<691::AID-FLD371>3.0.CO;2-U
   Villone MM, 2011, COMPUT FLUIDS, V42, P82, DOI 10.1016/j.compfluid.2010.11.009
   Wilcox DC, 1998, TURBULENCE MODELING
   Zadghaffari R, 2009, COMPUT CHEM ENG, V33, P1240, DOI 10.1016/j.compchemeng.2009.01.017
   Zhou YC, 1999, PHYSICA A, V269, P536, DOI 10.1016/S0378-4371(99)00183-1
   Zhu HP, 2007, CHEM ENG SCI, V62, P3378, DOI 10.1016/j.ces.2006.12.089
NR 41
TC 0
Z9 0
U1 14
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115333
DI 10.1016/j.ces.2019.115333
PG 16
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600024
DA 2020-05-12
ER

PT J
AU Jiang, XF
   Xu, EL
   Wua, GG
   Li, HZ
AF Jiang, Xiaofeng
   Xu, Enle
   Wua, Guoguang
   Li, Huai Z.
TI Drop impact on superhydrophobic surface with protrusions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Drop impact; Superhydrophobic; Protrusion; Deformation; Breakup
ID LOW-FRICTION; DEPOSITION; DYNAMICS
AB The phenomenon of drop impact is of significant importance to many engineering applications. In this work, water drops impact on superhydrophobic surfaces with or without protrusions were experimentally investigated under relatively low We numbers, using a high-speed camera. The focus was given to the spreading, bouncing and breakup behaviors on three different protrusions (semicircle, equilateral triangle and square). Our results show that the presence of protrusions not only alters the impact dynamics but also drastically affect the drop deformation. It was found that water drops persist the memory of the protrusions' geometry during the rebounding process and the hierarchical structure of protrusion surfaces leads drops to bounce off and break up more easily. A dimensionless analysis reveals that the protrusion with different geometries distinctly enhances the expanding process and reduces the contact time compared to the planar surface. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jiang, Xiaofeng; Xu, Enle; Wua, Guoguang] China Univ Min & Technol, Sch Chem Engn & Technol, Xuzhou 221116, Jiangsu, Peoples R China.
   [Jiang, Xiaofeng; Li, Huai Z.] Univ Lorraine, CNRS, Lab React & Proc Engn, 1 Rue Grandville,BP 20451, F-54001 Nancy, France.
RP Li, HZ (reprint author), Univ Lorraine, CNRS, Lab React & Proc Engn, 1 Rue Grandville,BP 20451, F-54001 Nancy, France.
EM Huai-Zhi.Li@univ-lorraine.fr
RI Li, Huai/S-2162-2019
OI Li, Huai/0000-0001-7129-6660
FU Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [2019QNA09]
FX This work is supported by the Fundamental Research Funds for the Central
   Universities (No. 2019QNA09).
CR Arogeti M, 2019, CHEM ENG SCI, V193, P89, DOI 10.1016/j.ces.2018.08.013
   Bergeron V, 2000, NATURE, V405, P772, DOI 10.1038/35015525
   Bhat M, 2019, CHEM ENG SCI, V202, P95, DOI 10.1016/j.ces.2019.03.017
   Bird JC, 2013, NATURE, V503, P385, DOI 10.1038/nature12740
   Chen JY, 2016, COMPOS SCI TECHNOL, V122, P1, DOI 10.1016/j.compscitech.2015.11.015
   Clanet C, 2004, J FLUID MECH, V517, P199, DOI 10.1017/S0022112004000904
   Cottin-Bizonne C, 2003, NAT MATER, V2, P237, DOI 10.1038/nmat857
   Dupeux G, 2011, PHYS REV LETT, V107, DOI 10.1103/PhysRevLett.107.114503
   Gauthier A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9001
   George JE, 2016, MATER DESIGN, V100, P8, DOI 10.1016/j.matdes.2016.03.104
   Jiang XF, 2017, ADV MATER INTERFACES, V4, DOI 10.1002/admi.201700516
   LeClear S, 2016, J COLLOID INTERF SCI, V461, P114, DOI 10.1016/j.jcis.2015.09.026
   Lei W, 2014, APPL THERM ENG, V62, P507, DOI 10.1016/j.applthermaleng.2013.10.019
   Liu YH, 2014, NAT PHYS, V10, P515, DOI [10.1038/NPHYS2980, 10.1038/nphys2980]
   Lunkad SF, 2007, CHEM ENG SCI, V62, P7214, DOI 10.1016/j.ces.2007.07.036
   Lv CJ, 2016, APPL PHYS LETT, V108, DOI 10.1063/1.4945662
   Malla LK, 2017, LANGMUIR, V33, P9620, DOI 10.1021/acs.langmuir.7b02183
   Mertaniemi H, 2011, ADV MATER, V23, P2911, DOI 10.1002/adma.201100461
   Patil ND, 2016, EXP THERM FLUID SCI, V74, P195, DOI 10.1016/j.expthermflusci.2015.12.006
   Pepper RE, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.2969755
   Richard D, 2000, EUROPHYS LETT, V50, P769, DOI 10.1209/epl/i2000-00547-6
   Sampath S, 2001, MAT SCI ENG A-STRUCT, V304, P144, DOI 10.1016/S0921-5093(00)01464-7
   Shen Y, 2015, APPL PHYS LETT, V107, DOI 10.1063/1.4931095
   Song MR, 2017, NPG ASIA MATER, V9, DOI 10.1038/am.2017.122
   Tsai PC, 2009, LANGMUIR, V25, P12293, DOI 10.1021/la900330q
   van Dam DB, 2004, PHYS FLUIDS, V16, P3403, DOI 10.1063/1.1773551
   Wang N, 2015, APPL SURF SCI, V355, P226, DOI 10.1016/j.apsusc.2015.06.203
   Wang Z., 2007, APPL PHYS LETT, V91
   Wijewardana NS, 2016, GEODERMA, V264, P150, DOI 10.1016/j.geoderma.2015.10.020
   Yanashima R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045893
   Yarin AL, 2006, ANNU REV FLUID MECH, V38, P159, DOI 10.1146/annurev.fluid.38.050304.092144
   Zhang M., 2016, BIOTRIBOLOGY, V5, P31, DOI DOI 10.1016/J.BI0TRI.2015.08.002
   Zhang R, 2014, PHYS FLUIDS, V26, DOI 10.1063/1.4892083
NR 33
TC 0
Z9 0
U1 15
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115351
DI 10.1016/j.ces.2019.115351
PG 8
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600036
DA 2020-05-12
ER

PT J
AU Korhonen, M
   Puisto, A
   Alava, M
   Maloney, T
AF Korhonen, Marko
   Puisto, Antti
   Alava, Mikko
   Maloney, Thaddeus
TI The effect of pressure pulsing on the mechanical dewatering of nanofiber
   suspensions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Computational fluid dynamics; Dewatering; Darcy's law; Pressure
   optimization; Nanocellulose
ID WATER REMOVAL; NANOCELLULOSE; PERMEABILITY; MEDIA; FLOW
AB Dewatering processes are invariably encountered in the chemical manufacturing and processing of various bioproducts. In this study, Computational Fluid Mechanics (CFD) simulations and theory are utilized to model and optimize the dewatering of commercial nanofiber suspensions. The CFD simulations are based on the volume-averaged Navier-Stokes equations, while the analytical model is deduced from the empirical Darcy's law for dewatering flows. The results are successfully compared to experimental data on commercial cellulose suspensions obtained with a Dynamic Drainage Analyzer (DDA). Both the CFD simulations and the analytical model capture the dewatering flow profiles of the commercial suspensions in an experiment using a constant pressure profile. However, a temporally varying pressure profile offers a superior dewatering performance, as indicated by both the simulations and the analytical model. Finally, the analytical model also predicts an optimized number of pressure pulses, minimizing the time required to completely dewater the suspension. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Korhonen, Marko; Puisto, Antti; Alava, Mikko] Aalto Univ, Dept Appl Phys, POB 11100, FI-00076 Aalto, Finland.
   [Maloney, Thaddeus] Aalto Univ, Dept Bioprod & Biosyst, POB 16300, FI-0076 Aalto, Finland.
RP Korhonen, M (reprint author), Aalto Univ, Dept Appl Phys, POB 11100, FI-00076 Aalto, Finland.
EM marko.korhonen@aalto.fi; antti.puisto@aalto.fi; mikko.alava@aalto.fi;
   thaddeus.maloney@aalto.fi
RI Alava, Mikko/G-2202-2013; Maloney, Thad C/E-6752-2014
OI Alava, Mikko/0000-0001-9249-5079; Maloney, Thad C/0000-0003-4524-5370
FU Jane and Aatos Erkko Foundation via the NANOFORM project; Academy of
   FinlandAcademy of Finland [278367]
FX We wish to thank the Jane and Aatos Erkko Foundation for their financial
   support via the NANOFORM project and the Aalto Science-IT project for
   the high-performance computational resources. The financial support of
   the Academy of Finland (Project No. 278367) is also greatly appreciated.
CR Alava M, 2006, REP PROG PHYS, V69, P669, DOI 10.1088/0034-4885/69/3/R03
   ANDERSON TB, 1967, IND ENG CHEM FUND, V6, P527, DOI 10.1021/i160024a007
   Boluk Y, 2011, COLLOID SURFACE A, V377, P297, DOI 10.1016/j.colsurfa.2011.01.003
   Britt K., 1980, J TECH ASS PULP PAPE
   BRITT KW, 1986, TAPPI J, V69, P76
   BRITT KW, 1973, TAPPI, V56, P46
   BRITT KW, 1976, TAPPI, V59, P67
   BRITT KW, 1985, TAPPI J, V68, P104
   Dimic-Misic K, 2013, CELLULOSE, V20, P1853, DOI [10.1007/s10570-013-0076-3, 10.1007/s10570-013-9964-9]
   Guo ZL, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.036304
   Hubbe MA, 2007, BIORESOURCES, V2, P500
   JACKSON GW, 1986, CAN J CHEM ENG, V64, P364, DOI 10.1002/cjce.5450640302
   Kargarzadeh H, 2017, POLYMER, V132, P368, DOI 10.1016/j.polymer.2017.09.043
   Kim JH, 2015, INT J PR ENG MAN-GT, V2, P197, DOI 10.1007/s40684-015-0024-9
   Koponen A, 1998, PHYS REV LETT, V80, P716, DOI 10.1103/PhysRevLett.80.716
   Koponen A, 2016, DRY TECHNOL, V34, P1521, DOI 10.1080/07373937.2015.1132427
   KRIEGER IM, 1959, T SOC RHEOL, V3, P137, DOI 10.1122/1.548848
   Liimatainen H, 2009, BIORESOURCES, V4, P321
   Lomine F, 2013, INT J NUMER ANAL MET, V37, P577, DOI 10.1002/nag.1109
   Masoodi R, 2010, AICHE J, V56, P2257, DOI 10.1002/aic.12163
   Narsilio GA, 2009, COMPUT GEOTECH, V36, P1200, DOI 10.1016/j.compgeo.2009.05.006
   Neyens E, 2003, J HAZARD MATER, V98, P51, DOI 10.1016/S0304-3894(02)00320-5
   Patist A, 2008, INNOV FOOD SCI EMERG, V9, P147, DOI 10.1016/j.ifset.2007.07.004
   Puisto A, 2012, NORD PULP PAP RES J, V27, P277, DOI 10.3183/NPPRJ-2012-27-02-p277-281
   Rusche H., 2003, THESIS
   Schmid CF, 2000, J RHEOL, V44, P781, DOI 10.1122/1.551116
   Soltani P, 2014, POWDER TECHNOL, V254, P44, DOI 10.1016/j.powtec.2014.01.001
   Weller HG, 1998, COMPUT PHYS, V12, P620, DOI 10.1063/1.168744
   Wu RM, 1998, WATER RES, V32, P760, DOI 10.1016/S0043-1354(97)00320-5
NR 29
TC 1
Z9 1
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115267
DI 10.1016/j.ces.2019.115267
PG 8
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600004
DA 2020-05-12
ER

PT J
AU Lashina, EA
   Slavinskaya, EM
   Chumakova, NA
   Stadnichenko, AI
   Salanov, AN
   Chumakov, GA
   Boronin, AI
AF Lashina, E. A.
   Slavinskaya, E. M.
   Chumakova, N. A.
   Stadnichenko, A. I.
   Salanov, A. N.
   Chumakov, G. A.
   Boronin, A. I.
TI Inverse temperature hysteresis and self-sustained oscillations in CO
   oxidation over Pd at elevated pressures of reaction mixture: Experiment
   and mathematical modeling
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Inverse hysteresis; Self-sustained oscillations; Surface oxide;
   Isothermal lumped model; Phase transition
ID CARBON-MONOXIDE OXIDATION; RANGE 1-150 TORR; KINETIC OSCILLATIONS;
   METHANE OXIDATION; CATALYTIC-PROPERTIES; PALLADIUM OXIDATION; PD/AL2O3
   CATALYSTS; SUBSURFACE OXYGEN; SURFACE-STRUCTURE; SINGLE-CRYSTALS
AB Studying the kinetics of CO oxidation over Pd foil at elevated CO and O-2 pressures, we observed an inverse hysteresis: CO conversion was much lower under sample cooling than under foil heating. It was established that under heating the oxidation of metallic palladium to bulk palladium oxide occurred through formation of the palladium surface oxide. Under cooling the bulk oxide reduced directly to metallic species, and in this case some self-sustained oscillations of reaction rate were observed. The catalytic scheme including main various oxygen states of the palladium surface and bulk with transitions between them under reaction conditions in heating/cooling catalytic cycle was proposed. On the base of this scheme the kinetic model of CO oxidation reaction was developed. Both most important mechanisms: Langmuir - Hinshelwood and Mars - van Krevelen, were involved for description of the observed kinetic nonlinear phenomena. The performed simulations demonstrated the capability of this model to describe well the inverse hysteresis of CO oxidation rate together with its oscillatory behavior at constant temperature within the hysteresis loop. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lashina, E. A.; Slavinskaya, E. M.; Chumakova, N. A.; Stadnichenko, A. I.; Salanov, A. N.; Boronin, A. I.] Boreskov Inst Catalysis, 5 Acad Lavrentiev Ave, Novosibirsk 630090, Russia.
   [Chumakov, G. A.] Sobolev Inst Math, 4 Acad Koptyug Ave, Novosibirsk 630090, Russia.
   [Lashina, E. A.; Slavinskaya, E. M.; Chumakova, N. A.; Stadnichenko, A. I.; Chumakov, G. A.; Boronin, A. I.] Novosibirsk State Univ, 2 Pirogova Str, Novosibirsk 630090, Russia.
RP Boronin, AI (reprint author), Boreskov Inst Catalysis, 5 Acad Lavrentiev Ave, Novosibirsk 630090, Russia.
EM boronin@catalysis.ru
RI ; Boronin, Andrei/E-9471-2012
OI Lashina, Elena/0000-0002-8379-2511; Boronin, Andrei/0000-0003-1172-8745
FU Boreskov Institute of Catalysis SB RAS [AAAA-A17-117041710084-2,
   AAAA-A17-117041710076-7]; Sobolev Institute of Mathematics SB RAS
   [I.1.5.3]
FX This work was conducted within the framework of budget projects No.
   AAAA-A17-117041710084-2 and No. AAAA-A17-117041710076-7 for Boreskov
   Institute of Catalysis SB RAS and No. I.1.5.3 for Sobolev Institute of
   Mathematics SB RAS.
CR Abedi A, 2012, CATAL LETT, V142, P930, DOI 10.1007/s10562-012-0861-x
   Amin A, 2014, APPL CATAL A-GEN, V478, P91, DOI 10.1016/j.apcata.2014.03.032
   [Anonymous], 1998, ENG CHEM REACTIONS
   BASSETT MR, 1990, J CHEM PHYS, V93, P811, DOI 10.1063/1.459451
   Boubnov A, 2013, TOP CATAL, V56, P333, DOI 10.1007/s11244-013-9976-6
   Briggs D., 1990, PRACTICAL SURFACE AN
   Bychkov VY, 2016, APPL CATAL A-GEN, V522, P40, DOI 10.1016/j.apcata.2016.04.024
   Bychkov VY, 2009, SURF SCI, V603, P1680, DOI 10.1016/j.susc.2008.10.060
   CAMPBELL CT, 1977, J PHYS CHEM-US, V81, P491, DOI 10.1021/j100520a024
   Carlsson PA, 2006, PHYS CHEM CHEM PHYS, V8, P2703, DOI 10.1039/b602958b
   Casapu M, 2017, ACS CATAL, V7, P343, DOI 10.1021/acscatal.6b02709
   Chiang YJ, 2013, J PHYS CHEM C, V117, P15593, DOI 10.1021/jp402074w
   Dadi RK, 2016, CHEM ENG J, V297, P325, DOI 10.1016/j.cej.2016.03.139
   Duan ZY, 2014, ACS CATAL, V4, P3435, DOI 10.1021/cs5006025
   Dubbe H, 2016, TOP CATAL, V59, P1054, DOI 10.1007/s11244-016-0589-8
   Dunnen A.D., 2016, J CHEM PHYS, V144
   EISWIRTH M, 1986, SURF SCI, V177, P90, DOI 10.1016/0039-6028(86)90259-1
   Elokhin VI, 1998, KINET CATAL+, V39, P246
   Ertl G., 1990, ADV CATAL, V37, P213
   Ertl G., 2014, NOBEL LECT REACTIONS
   FARRAUTO RJ, 1995, APPL CATAL B-ENVIRON, V6, P263, DOI 10.1016/0926-3373(95)00015-1
   Farrauto RJ, 2012, SCIENCE, V337, P659, DOI 10.1126/science.1226310
   Fernandes VR, 2016, ACS CATAL, V6, P4154, DOI 10.1021/acscatal.6b00658
   Gabasch H, 2006, SURF SCI, V600, P2980, DOI 10.1016/j.susc.2006.05.029
   Grunwaldt JD, 2007, CHEM COMMUN, P4635, DOI 10.1039/b710222d
   Gustafson J, 2014, SCIENCE, V343, P758, DOI 10.1126/science.1246834
   Gustafson J, 2018, ACS CATAL, V8, P4438, DOI 10.1021/acscatal.8b00498
   Han JY, 2006, SURF SCI, V600, P2730, DOI 10.1016/j.susc.2006.04.040
   Han JY, 2006, SURF SCI, V600, P2752, DOI 10.1016/j.susc.2006.04.042
   Han JY, 2004, J CATAL, V225, P7, DOI 10.1016/j.jcat.2004.03.035
   HARTMANN N, 1994, CATAL LETT, V28, P373, DOI 10.1007/BF00806068
   Hauptmann W, 2009, APPL CATAL B-ENVIRON, V93, P22, DOI 10.1016/j.apcatb.2009.09.008
   Hendriksen BLM, 2010, NAT CHEM, V2, P730, DOI 10.1038/nchem.728
   Hendriksen BLM, 2004, SURF SCI, V552, P229, DOI 10.1016/j.susc.2004.01.025
   IMBIHL R, 1985, J CHEM PHYS, V83, P1578, DOI 10.1063/1.449834
   IMBIHL R, 1995, CHEM REV, V95, P697, DOI 10.1021/cr00035a012
   IMBIHL R, 1993, PROG SURF SCI, V44, P185, DOI 10.1016/0079-6816(93)90086-B
   Ivanova AS, 2010, APPL CATAL B-ENVIRON, V97, P57, DOI 10.1016/j.apcatb.2010.03.024
   Jaeger NI, 2003, KINET CATAL+, V44, P183, DOI 10.1023/A:1023396227142
   Kaichev VV, 2016, J CATAL, V334, P23, DOI 10.1016/j.jcat.2015.11.009
   Keren I, 2000, CHEM ENG SCI, V55, P1461, DOI 10.1016/S0009-2509(99)00424-8
   Kibis LS, 2009, APPL SURF SCI, V255, P9248, DOI 10.1016/j.apsusc.2009.07.011
   Kibis LS, 2012, J PHYS CHEM C, V116, P19342, DOI 10.1021/jp305166k
   Kota AS, 2017, CHEM ENG SCI, V166, P320, DOI 10.1016/j.ces.2017.02.050
   KRISCHER K, 1992, J CHEM PHYS, V96, P9161, DOI 10.1063/1.462226
   Kurkina ES, 2005, KINET CATAL+, V46, P453, DOI 10.1007/s10975-005-0098-4
   Lashina EA, 2012, CHEM ENG SCI, V83, P149, DOI 10.1016/j.ces.2012.03.020
   Lashina EA, 2009, CHEM ENG J, V154, P82, DOI 10.1016/j.cej.2009.02.017
   Latkin EI, 2000, J MOL CATAL A-CHEM, V158, P161, DOI 10.1016/S1381-1169(00)00061-3
   Laurin M, 2005, J CHEM PHYS, V123, DOI 10.1063/1.1949167
   Li JH, 2015, CATAL TODAY, V258, P169, DOI 10.1016/j.cattod.2015.04.035
   Lundgren E, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.246103
   Lundgren E, 2017, ACCOUNTS CHEM RES, V50, P2326, DOI 10.1021/acs.accounts.7b00281
   Marin G., 2011, KINETICS CHEM REACTI
   Matera S, 2015, ACS CATAL, V5, P4514, DOI 10.1021/acscatal.5b00858
   Mehar V, 2018, ACS CATAL, V8, P8553, DOI 10.1021/acscatal.8b02191
   Moulder JF, 1992, HDB XRAY PHOTOELECTR
   Murzin D., 2005, CATALYTIC KINETICS
   Myshlyavtsev AV, 2010, APPL SURF SCI, V256, P5376, DOI 10.1016/j.apsusc.2009.12.084
   Oh SH, 2007, J CATAL, V245, P35, DOI 10.1016/j.jcat.2006.09.016
   Onderwaater WG, 2017, CATAL STRUCT REACT, V3, P89, DOI 10.1080/2055074X.2017.1280641
   Pillo T, 1997, J PHYS-CONDENS MAT, V9, P3987, DOI 10.1088/0953-8984/9/19/018
   Rogal J, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.155410
   Royer S, 2011, CHEMCATCHEM, V3, P24, DOI 10.1002/cctc.201000378
   SANDER M, 1991, SURF SCI, V251, P921, DOI 10.1016/0039-6028(91)91125-H
   Seriani N, 2009, J CHEM PHYS, V131, DOI 10.1063/1.3187935
   SHEINTUCH M, 1977, CATAL REV, V15, P107, DOI 10.1080/03602457708081723
   Shipilin M, 2015, J PHYS CHEM C, V119, P15469, DOI 10.1021/acs.jpcc.5b04400
   Slavinskaya EM, 2015, APPL CATAL B-ENVIRON, V166, P91, DOI 10.1016/j.apcatb.2014.11.015
   Slavinskaya EM, 2011, APPL CATAL A-GEN, V401, P83, DOI 10.1016/j.apcata.2011.05.001
   Slinko M. M., 1994, OSCILLATING HETEROGE
   SLINKO MG, 1978, CATAL REV, V17, P119, DOI 10.1080/03602457808080880
   Stonkus OA, 2014, CHEMCATCHEM, V6, P2115, DOI 10.1002/cctc.201402108
   Stotz H, 2019, J CATAL, V370, P152, DOI 10.1016/j.jcat.2018.12.007
   Suprun EA, 2017, KINET CATAL+, V58, P92, DOI 10.1134/S0023158417010116
   Svintsitskiy DA, 2011, APPL SURF SCI, V257, P8542, DOI 10.1016/j.apsusc.2011.05.012
   Svintsitskiy DA, 2016, CHEMCATCHEM, V8, P3546, DOI 10.1002/cctc.201600802
   Titkov AI, 2006, SURF SCI, V600, P4119, DOI 10.1016/j.susc.2006.01.131
   Todorova M, 2003, SURF SCI, V541, P101, DOI 10.1016/S0039-6028(03)00873-2
   TURNER JE, 1981, SURF SCI, V103, P54, DOI 10.1016/0039-6028(81)90099-6
   van Rijn R, 2011, PHYS CHEM CHEM PHYS, V13, P13167, DOI 10.1039/c1cp20989b
   van Spronsen MA, 2017, CHEM SOC REV, V46, P4347, DOI 10.1039/c7cs00045f
   VISHNEVSKII AL, 1989, DOKL AKAD NAUK SSSR+, V304, P641
   Wang D, 2019, APPL CATAL A-GEN, V572, P44, DOI 10.1016/j.apcata.2018.12.022
   Weaver JF, 2017, ACS CATAL, V7, P7319, DOI 10.1021/acscatal.7b02570
   Weaver JF, 2013, CHEM REV, V113, P4164, DOI 10.1021/cr300323w
   Westerstrom R, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.125431
   Yablonskii G., 1991, SERIES MONOGRAPHS CO, V32
   Yuranov I, 2000, CHEM ENG SCI, V55, P2827, DOI 10.1016/S0009-2509(99)00557-6
   Zemlyanov D, 2013, TOP CATAL, V56, P885, DOI 10.1007/s11244-013-0052-z
   Zhang F, 2014, J PHYS CHEM C, V118, P28647, DOI 10.1021/jp509383v
   Zhang XL, 2003, APPL CATAL A-GEN, V240, P183, DOI 10.1016/S0926-860X(02)00422-2
   Zhdanov V.P., 2007, ELEMENTARY PHYSICOCH
   Zhdanov VP, 1999, SURF SCI, V426, P345, DOI 10.1016/S0039-6028(99)00328-3
   Zorn K, 2011, J PHYS CHEM C, V115, P1103, DOI 10.1021/jp106235x
NR 95
TC 0
Z9 0
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115312
DI 10.1016/j.ces.2019.115312
PG 15
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600009
DA 2020-05-12
ER

PT J
AU Li, C
   Teng, XN
   Peng, HD
   Yi, XP
   Zhuang, YP
   Zhang, SL
   Xia, JY
AF Li, Chao
   Teng, Xiaonuo
   Peng, Huadong
   Yi, Xiaoping
   Zhuang, Yingping
   Zhang, Siliang
   Xia, Jianye
TI Novel scale-up strategy based on three-dimensional shear space for
   animal cell culture
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Shear rate; Animal cell culture; Scale-up; Computational fluid dynamics;
   Stirred tank bioreactor
ID COMPUTATIONAL FLUID-DYNAMICS; ENERGY-DISSIPATION RATE; LARGE-EDDY
   SIMULATIONS; STIRRED-TANK; INSECT CELLS; RUSHTON TURBINE; MASS-TRANSFER;
   HOLD-UP; FLOW; BIOREACTOR
AB Animal cell cultivations are widely used for producing antibodies, vaccines, and recombinant protein drugs. However, the extreme sensitivity of animal cells to hydrodynamic stress often hinders its scale-up in large-scale stirred tank bioreactors. This study introduced a new scale-up strategy based on three-dimensional (3D) shear space for large-scale animal cell culture. First, the shear environments of bioreactors ranging from lab-scale (7.5 and 42 L) to industrial-scale (30, 90, 350, and 1000 L) were quantitatively analyzed through computational fluid dynamics (CFD) methods and successfully validated by particle image velocimetry (PIV) experiments. Moreover, the quantitative relationships between shear parameters (including shear rates in the impeller and tank zone, overall average shear rate, and maximum shear rate) and impeller tip velocity were established. In addition, a correlation analysis between shear-related parameters and viable cell densities in Spodoptera frugiperda Sf9 cultivations indicated that shear rates in the impeller and tank zone, and the overall average shear rate were the three key shear parameters required for scale-up. Further, an optimized 3D operation space for shear rate was established according to the three key shear parameters obtained under preferable operation conditions in lab-scale bioreactors. Based on the results, agitation rates in large-scale bioreactors were determined using the proposed correlation. Ultimately, we achieved successful scale-up of Spodoptera frugiperda Sf9 in industrial bioreactors with volumes up to 1000 L using this strategy. Thus, this study introduces a highly efficient and economical scale-up strategy for shear-sensitive cells. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Li, Chao; Teng, Xiaonuo; Yi, Xiaoping; Zhuang, Yingping; Zhang, Siliang; Xia, Jianye] East China Univ Sci & Technol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China.
   [Peng, Huadong] Imperial Coll London, Dept Bioengn, London SW7 2AZ, England.
   [Peng, Huadong] Imperial Coll London, Ctr Synthet Biol, London SW7 2AZ, England.
RP Xia, JY (reprint author), East China Univ Sci & Technol, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China.
EM jyxia@ecust.edu.cn
RI Peng, Huadong/G-1357-2015
OI Peng, Huadong/0000-0003-0635-0493
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21506052]; Fundamental Research Funds for the
   Central UniversitiesFundamental Research Funds for the Central
   Universities [22221818014]
FX This work was supported by the National Natural Science Foundation of
   China [grant number 21506052] and the Fundamental Research Funds for the
   Central Universities [grant number 22221818014].
CR Borys BS, 2018, BIOCHEM ENG J, V133, P157, DOI 10.1016/j.bej.2018.02.005
   Bustamante MCC, 2013, CHEM ENG SCI, V90, P92, DOI 10.1016/j.ces.2012.12.028
   Campesi A, 2009, BIOPROC BIOSYST ENG, V32, P241, DOI 10.1007/s00449-008-0242-4
   Chalmers JJ, 2015, CURR OPIN CHEM ENG, V10, P94, DOI 10.1016/j.coche.2015.09.005
   Collignon ML, 2016, BIOCHEM ENG J, V108, P30, DOI 10.1016/j.bej.2015.10.020
   Delafosse A, 2015, CHEM ENG SCI, V134, P457, DOI 10.1016/j.ces.2015.05.045
   Garcia-Ochoa F, 2015, CHEM ENG SCI, V122, P491, DOI 10.1016/j.ces.2014.10.016
   Garcia-Ochoa F, 2009, BIOTECHNOL ADV, V27, P153, DOI 10.1016/j.biotechadv.2008.10.006
   Gelves R, 2014, BIOPROC BIOSYST ENG, V37, P365, DOI 10.1007/s00449-013-1001-8
   Ghorai S, 2006, CHEM ENG PROCESS, V45, P55, DOI 10.1016/j.cep.2005.05.006
   Hogue MM, 2015, CHEM ENG SCI, V137, P752, DOI 10.1016/j.ces.2015.06.056
   Kelly WJ, 2008, BIOTECHNOL APPL BIOC, V49, P225, DOI 10.1042/BA20070177
   Lara AR, 2006, MOL BIOTECHNOL, V34, P355, DOI 10.1385/MB:34:3:355
   Li ZP, 2011, CHEM ENG SCI, V66, P1219, DOI 10.1016/j.ces.2010.12.024
   Liu Y, 2016, BIOCHEM ENG J, V114, P212, DOI 10.1016/j.bej.2016.07.006
   Liu Y, 2016, BIOCHEM ENG J, V113, P66, DOI 10.1016/j.bej.2016.06.001
   Lu HZ, 2015, BIOPROC BIOSYST ENG, V38, P917, DOI 10.1007/s00449-014-1337-8
   Luo HP, 2008, CHEM ENG SCI, V63, P3057, DOI 10.1016/j.ces.2008.03.015
   Luo J. Y., 1994, EUR C MIX IM S
   Ma NN, 2002, BIOTECHNOL BIOENG, V80, P428, DOI 10.1002/bit.10387
   Mollet M, 2004, BIOTECHNOL PROGR, V20, P1437, DOI 10.1021/bp0498488
   Mollet M, 2008, BIOTECHNOL BIOENG, V100, P260, DOI 10.1002/bit.21762
   Mollet M, 2007, BIOTECHNOL BIOENG, V98, P772, DOI 10.1002/bit.21476
   Rayat ACME, 2016, CURR OPIN CHEM ENG, V14, P150, DOI 10.1016/j.coche.2016.09.012
   Perez JAS, 2006, CHEM ENG J, V124, P1, DOI 10.1016/j.cej.2006.07.002
   Schmid G, 1996, CYTOTECHNOLOGY, V20, P43, DOI 10.1007/BF00350388
   Sieck JB, 2013, J BIOTECHNOL, V164, P41, DOI 10.1016/j.jbiotec.2012.11.012
   Singh H, 2011, CHEM ENG SCI, V66, P5976, DOI 10.1016/j.ces.2011.08.018
   Surrao DC, 2016, BIOTECHNOL BIOENG, V113, P2725, DOI 10.1002/bit.26040
   Taghavi M, 2011, CHEM ENG RES DES, V89, P280, DOI 10.1016/j.cherd.2010.07.006
   Takors R, 2012, J BIOTECHNOL, V160, P3, DOI 10.1016/j.jbiotec.2011.12.010
   Tescione L, 2015, BIOTECHNOL BIOENG, V112, P84, DOI 10.1002/bit.25330
   TRINH K, 1994, BIOTECHNOL BIOENG, V43, P37, DOI 10.1002/bit.260430106
   Unadkat H, 2011, CHEM ENG SCI, V66, P5374, DOI 10.1016/j.ces.2011.07.046
   van Oers MM, 2015, J GEN VIROL, V96, P6, DOI 10.1099/vir.0.067108-0
   Wang G, 2015, ENG LIFE SCI, V15, P20, DOI 10.1002/elsc.201400172
   Wang H, 2018, BIOPROC BIOSYST ENG, V41, P1371, DOI 10.1007/s00449-018-1964-6
   Wang Y, 2009, BIOTECHNOL ADV, V27, P989, DOI 10.1016/j.biotechadv.2009.05.022
   Weidner T, 2017, Z NATURFORSCH C, V72, P429, DOI 10.1515/znc-2017-0066
   Wu BX, 2012, BIOTECHNOL BIOENG, V109, P804, DOI 10.1002/bit.24345
   Wu J, 2006, AICHE J, V52, P2323, DOI 10.1002/aic.10857
   Xie MH, 2013, CHEM ENG TECHNOL, V36, P115, DOI 10.1002/ceat.201200318
   Xie MH, 2014, IND ENG CHEM RES, V53, P5941, DOI 10.1021/ie400831s
   Zhu H, 2009, CHEM ENG RES DES, V87, P307, DOI 10.1016/j.cherd.2008.08.013
NR 44
TC 0
Z9 0
U1 27
U2 27
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115329
DI 10.1016/j.ces.2019.115329
PG 10
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600020
DA 2020-05-12
ER

PT J
AU Li, L
   Zhao, SC
   Xin, Z
AF Li, Lu
   Zhao, Shicheng
   Xin, Zhong
TI Three-solvent spherical crystallization method with a model drug:
   Clopidogrel hydrogen sulfate
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Spherical crystallization; Spherical agglomeration; QESD; Diffusion
ID ACID FINE PARTICLES; AGGLOMERATED CRYSTALS; PARAMETERS; SUSPENSION;
   GLYCINE; DESIGN
AB A novel three-solvent spherical crystallization method for producing monodisperse spherical particles with potential use in industry has been presented in this work. By combining the advantages of quasi-emulsion solvent diffusion (QESD) and spherical agglomeration (SA) method, the new approach adds another solvent as diffusion agent which can form a partially miscible zone with good and poor solvents in their phase diagram, changing the diffusion driving force into the transformation of composition point of solvent system from immiscible to miscible region in phase diagram of solvents system. This study presents a detailed process and characterization of obtained spheres in terms of size distribution and morphologies by using clopidogrel hydrogen sulfate (CHS) as a model drug. The effects of process parameters on spheres size and morphology are also investigated experimentally. The results show that particles of defined size and morphology can be prepared precisely by tuning the process conditions. Furthermore, the morphologies exhibit a continuous structural transition from polycrystalline to single crystal. This approach overcomes the shortage of QESD requiring large amount of poor solvent, and also breaks through the main difficulty of selecting suitable bridging liquid of SA method. Although CHS is used as model drug, this method is easily generalized to other drugs. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Li, Lu; Zhao, Shicheng; Xin, Zhong] East China Univ Sci & Technol, Dept Prod Engn, Shanghai Key Lab Multiphase Mat Chem Engn, Shanghai 200237, Peoples R China.
RP Xin, Z (reprint author), East China Univ Sci & Technol, Dept Prod Engn, Shanghai 200237, Peoples R China.
EM xzh@ecust.edu.cn
FU Nature Science Foundation of ChinaNational Natural Science Foundation of
   China [2147605, 21878089, 21606084]; National Key R&D Program of China
   [2016YFB0302201]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [22221818010]
FX This work was financially supported by the Nature Science Foundation of
   China (Grants 2147605, 21878089 and 21606084), National Key R&D Program
   of China (2016YFB0302201) and the Fundamental Research Funds for the
   Central Universities (22221818010).
CR Blandin AF, 2003, POWDER TECHNOL, V130, P316, DOI 10.1016/S0032-5910(02)00210-3
   Bousquet A., 2002, POLYMORPHIC CLOPIDOG
   Chadwick K, 2009, ORG PROCESS RES DEV, V13, P1284, DOI 10.1021/op900123n
   Chow AHL, 1996, DRUG DEV IND PHARM, V22, P357, DOI 10.3109/03639049609042001
   Dickie Jennifer S, 2006, Am J Cardiovasc Drugs, V6, P407, DOI 10.2165/00129784-200606060-00008
   Garg N, 2011, EXPERT OPIN PHARMACO, V12, P1781, DOI 10.1517/14656566.2011.587118
   Gu TH, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201700797
   Holan J, 2015, CHEM ENG SCI, V128, P36, DOI 10.1016/j.ces.2015.01.045
   Kalny M, 2017, CRYST GROWTH DES, V17, P3700, DOI 10.1021/acs.cgd.7b00303
   Katta J, 2008, INT J PHARM, V348, P61, DOI 10.1016/j.ijpharm.2007.07.006
   KAWASHIMA Y, 1982, SCIENCE, V216, P1127, DOI 10.1126/science.216.4550.1127
   Kawashima Y, 2003, POWDER TECHNOL, V130, P283, DOI 10.1016/S0032-5910(02)00206-1
   KAWASHIMA Y, 1984, POWDER TECHNOL, V39, P41, DOI 10.1016/0032-5910(84)85018-4
   KAWASHIMA Y, 1995, PHARMACEUT RES, V12, P1040, DOI 10.1023/A:1016266600113
   Krishna E.H., 2012, ASIAN J PHARM CLIN R, V5, P114
   Kumar S, 2008, PHARM DEV TECHNOL, V13, P559, DOI 10.1080/10837450802310180 
   Maghsoodi M, 2011, PHARM DEV TECHNOL, V16, P474, DOI 10.3109/10837450.2010.492218
   Pitt K, 2018, POWDER TECHNOL, V326, P327, DOI 10.1016/j.powtec.2017.11.052
   Subero-Couroyer C, 2006, POWDER TECHNOL, V161, P98, DOI 10.1016/j.powtec.2005.08.014
   Tahara K, 2015, CRYST GROWTH DES, V15, P5149, DOI 10.1021/acs.cgd.5b01159
   Thati J, 2012, EUR J PHARM SCI, V45, P657, DOI 10.1016/j.ejps.2012.01.006
   Thati J, 2011, EUR J PHARM SCI, V42, P365, DOI 10.1016/j.ejps.2011.01.001
   Toldy AI, 2014, CRYST GROWTH DES, V14, P3485, DOI 10.1021/cg5004337
   Toldy AI, 2012, CRYST GROWTH DES, V12, P3977, DOI 10.1021/cg300413s
   Wang X, 2006, CRYST GROWTH DES, V6, P2214, DOI 10.1021/cg0503043
   Zhang HT, 2010, IND ENG CHEM RES, V49, P1402, DOI 10.1021/ie901001c
NR 26
TC 0
Z9 0
U1 18
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115001
DI 10.1016/j.ces.2019.05.037
PG 8
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600001
DA 2020-05-12
ER

PT J
AU Lin, RN
   Wang, K
   Liu, L
   Zhang, YX
   Dong, SH
AF Lin, Ruinan
   Wang, Ke
   Liu, Li
   Zhang, Yongxue
   Dong, Shaohua
TI Study on the characteristics of interfacial waves in annular flow by
   image analysis
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Interfacial wave; Image analysis; Annular flow; Flow pattern transition
ID GAS-LIQUID FLOW; DISTURBANCE WAVES; CHURN FLOW; HUGE WAVE; 2-PHASE FLOW;
   ENTRAINMENT; FILM; VISUALIZATION; RIPPLES; MODEL
AB Various scales of interfacial waves in length and amplitude are usually present at the gas-liquid interface. Complete knowledge of the interfacial waves is of great importance for the characterization of mass, momentum and energy exchange in annular flow. In this paper, an image analysis approach for interfacial wave recognition by detecting the spatiotemporal evolution of liquid film is introduced. Based on the image analysis, the identification and the characteristics of the interfacial waves are carefully investigated. The results indicate that the flow patterns identification and the pressure gradient are related to the characteristics and behaviors of interfacial waves. Remarkably, the analysis reveals that the orientation of interfacial waves is the significant criteria in flow patterns identification, and disturbance waves play the dominant role in pressure gradient. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lin, Ruinan; Wang, Ke; Zhang, Yongxue] China Univ Petr, Beijing Key Lab Proc Fluid Filtrat & Separat, Beijing, Peoples R China.
   [Liu, Li] Shanghai Jiao Tong Univ, Sch Nucl Sci & Engn, Shanghai, Peoples R China.
   [Dong, Shaohua] China Univ Petr, Pipeline Res Ctr, Beijing, Peoples R China.
RP Wang, K (reprint author), China Univ Petr, Beijing Key Lab Proc Fluid Filtrat & Separat, Beijing, Peoples R China.; Dong, SH (reprint author), China Univ Petr, Pipeline Res Ctr, Beijing, Peoples R China.
EM wang_ke@cup.edu.cn; shdong@cup.edu.cn
RI ; Wang, Ke/L-1921-2015
OI Wang, Cong/0000-0002-4781-5165; Wang, Ke/0000-0002-7447-2356
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51706245]; Science Foundation of China University
   of Petroleum, Beijing [2462016YJRC029]
FX The authors gratefully acknowledge research support from the National
   Natural Science Foundation of China under Grant No. 51706245 and the
   Science Foundation of China University of Petroleum, Beijing No.
   2462016YJRC029.
CR Al-Sarkhi A, 2012, AICHE J, V58, P1018, DOI 10.1002/aic.12653
   Alamu M.B., 2010, INVESTIGATION PERIOD
   Alekseenko SV, 2008, MICROGRAVITY SCI TEC, V20, P271, DOI 10.1007/s12217-008-9028-1
   Alekseenko S, 2012, EXP FLUIDS, V53, P77, DOI 10.1007/s00348-011-1200-5
   Alekseenko SV, 2015, INT J MULTIPHAS FLOW, V77, P65, DOI 10.1016/j.ijmultiphaseflow.2015.08.007
   Alekseenko SV, 2014, INT J MULTIPHAS FLOW, V67, P122, DOI 10.1016/j.ijmultiphaseflow.2014.07.009
   Arai T, 2015, EXP THERM FLUID SCI, V60, P337, DOI 10.1016/j.expthermflusci.2014.05.018
   ASALI JC, 1993, INT J MULTIPHAS FLOW, V19, P229, DOI 10.1016/0301-9322(93)90001-B
   Ayati AA, 2017, PHYS FLUIDS, V29, DOI 10.1063/1.4985717
   Azzopardi BJ, 2004, INT J MULTIPHAS FLOW, V30, P89, DOI 10.1016/j.ijmultiphaseflow.2003.11.001
   Azzopardi BJ, 1997, INT J MULTIPHAS FLOW, V23, P1
   AZZOPARDI BJ, 1986, NUCL ENG DES, V92, P121, DOI 10.1016/0029-5493(86)90240-2
   Barbosa JR, 2001, INT J MULTIPHAS FLOW, V27, P2105, DOI 10.1016/S0301-9322(01)00048-9
   Belt RJ, 2010, INT J MULTIPHAS FLOW, V36, P570, DOI 10.1016/j.ijmultiphaseflow.2010.03.004
   Cuadros JL, 2019, NUCL ENG DES, V346, P112, DOI 10.1016/j.nucengdes.2019.03.008
   Da Riva E, 2009, CHEM ENG SCI, V64, P3753, DOI 10.1016/j.ces.2009.04.049
   Dasgupta A, 2017, EXP THERM FLUID SCI, V81, P147, DOI 10.1016/j.expthermflusci.2016.10.012
   de Jong P, 2003, INT J MULTIPHAS FLOW, V29, P1203, DOI 10.1016/S0301-9322(03)00085-5
   Han HW, 2006, NUCL ENG DES, V236, P2580, DOI 10.1016/j.nucengdes.2006.03.015
   Hewitt G.F., 1970, ANN 2 PHASE FLOW
   Hewitt G.F., 1962, M2159 UKAEA AERE
   Hewitt GF, 2012, ENERG FUEL, V26, P4067, DOI 10.1021/ef3002422
   Holowach MJ, 2002, INT J HEAT FLUID FL, V23, P807, DOI 10.1016/S0142-727X(02)00194-7
   Isaenkov SV, 2019, INT J MULTIPHAS FLOW, V111, P62, DOI 10.1016/j.ijmultiphaseflow.2018.11.010
   Kaji R, 2010, INT J MULTIPHAS FLOW, V36, P303, DOI 10.1016/j.ijmultiphaseflow.2009.11.010
   Li Liu, 2018, Journal of Shanghai Jiaotong University (Science), V23, P34, DOI 10.1007/s12204-018-2020-z
   Liu L., INT J MULTIPH FLOW, V122
   Liu L, 2019, CHEM ENG SCI, V199, P588, DOI 10.1016/j.ces.2019.01.037
   MCQUILLAN KW, 1985, INT J MULTIPHAS FLOW, V11, P741, DOI 10.1016/0301-9322(85)90022-9
   Omebere-Iyar NK, 2007, CHEM ENG RES DES, V85, P180, DOI 10.1205/cherd05059
   Owen D., 1986, EXPT THEORETICAL ANA
   Pan LM, 2015, INT J HEAT MASS TRAN, V89, P165, DOI 10.1016/j.ijheatmasstransfer.2015.05.073
   Parsi M, 2015, INT J MULTIPHAS FLOW, V73, P155, DOI 10.1016/j.ijmultiphaseflow.2015.03.019
   Parsi M, 2015, CHEM ENG SCI, V130, P221, DOI 10.1016/j.ces.2015.03.033
   Ryu SH, 2011, NUCL ENG DES, V241, P3890, DOI 10.1016/j.nucengdes.2011.07.006
   Sawant P, 2008, NUCL ENG DES, V238, P3528, DOI 10.1016/j.nucengdes.2008.06.013
   Schubring D, 2010, INT J MULTIPHAS FLOW, V36, P385, DOI 10.1016/j.ijmultiphaseflow.2010.01.003
   SEKOGUCHI K, 1989, INT J MULTIPHAS FLOW, V15, P295, DOI 10.1016/0301-9322(89)90002-5
   Sharaf S, 2016, INT J MULTIPHAS FLOW, V78, P88, DOI 10.1016/j.ijmultiphaseflow.2015.09.005
   TAYLOR NH, 1963, CHEM ENG SCI, V18, P537
   Vasques J, 2018, EXP THERM FLUID SCI, V97, P484, DOI 10.1016/j.expthermflusci.2018.03.020
   Waltrich PJ, 2013, INT J MULTIPHAS FLOW, V57, P38, DOI 10.1016/j.ijmultiphaseflow.2013.06.008
   Wang K., 2017, CHEM ENG SCI, V79, P19
   Wang K, 2013, CHEM ENG SCI, V104, P638, DOI 10.1016/j.ces.2013.09.022
   Wang K, 2012, CHEM ENG SCI, V79, P19, DOI 10.1016/j.ces.2012.05.011
   Wolf A, 2001, CHEM ENG SCI, V56, P3221, DOI 10.1016/S0009-2509(00)00546-7
   Zhao YJ, 2013, INT J MULTIPHAS FLOW, V55, P111, DOI 10.1016/j.ijmultiphaseflow.2013.04.001
NR 47
TC 1
Z9 1
U1 9
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115336
DI 10.1016/j.ces.2019.115336
PG 12
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600027
DA 2020-05-12
ER

PT J
AU Lopez-Zamora, S
   de Lasa, H
AF Lopez-Zamora, S.
   de Lasa, H.
TI A Mid-Infrared Region (MIR) lumped Group Contribution based method for
   monitoring light gases and gasolines in Fluid Catalytic Cracking
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Gasoline; Light gases; Group Contribution Method; MIR; Fluid Catalytic
   Cracking
ID ABSORPTION; DIFFUSION; KINETICS; OIL
AB A lumped Group Contribution Method (GCM) is applied in the 3200-2800 cm(-1) Mid-Infrared Region (MIR) to determine lumped Fluid Catalytic Cracking (FCC) product fractions. This GCM based on molecular functionality, predicts hydrocarbon absorption MIR spectra. In this analysis, lumps considered for light gases (LG) are paraffins (n-paraffins and iso-paraffins) and olefins. As well, lumps for gasolines include n-paraffins, iso-paraffins, olefins, naphthenes and aromatics (FIONA). To accomplish this, a sampling system, designated as CREC-MIR Hydrocarbons Sampling System (CREC-MIRHSS) is considered. The method is validated using data from Kraemer (1991) obtained in a CREC Riser Simulator and a constrained nonlinear multivariable minimization. This leads to minimum deviations of 2.47% of the Root Mean Squared Error of Prediction (RMSEP) for paraffins and olefins in LG. This also gives minimum deviations in the gasoline of 1.11% for n-paraffins, of 1.34% for iso-paraffins, 5.97% for olefins, 2.12% for naphthenes and 6.92% for aromatics. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lopez-Zamora, S.] Univ Nacl Colombia Sede Medellin, Fac Minas Bioproc & Flujos React, Medellin, Colombia.
   [de Lasa, H.] Univ Western Ontario, Dept Chem & Biochem Engn, Chem Reactor Engn Ctr, London, ON, Canada.
RP de Lasa, H (reprint author), Univ Western Ontario, Dept Chem & Biochem Engn, Chem Reactor Engn Ctr, London, ON, Canada.
EM hdelasa@uwo.ca
FU Colombian Science Foundation (COLCIENCIAS)Departamento Administrativo de
   Ciencia, Tecnologia e Innovacion Colciencias; Colombian State Oil
   Company (ECOPETROL S.A.) [0423 2013]; Emerging Leaders in the Americas
   (ELAP) Canadian Exchange Program; Natrural Sciences and Engineering
   Research Council (NSERC), Canada
FX The authors would like to acknowledge the financial support of the
   Colombian Science Foundation (COLCIENCIAS), the Colombian State Oil
   Company (ECOPETROL S.A.) under contract No. 0423 2013, the Emerging
   Leaders in the Americas (ELAP) Canadian Exchange Program and the
   Natrural Sciences and Engineering Research Council (NSERC), Canada. We
   would also like to thank Florencia de Lasa for her assistance with the
   technical drawing of some of the figures and for the editing of this
   manuscript.
CR Al-Khattaf S, 2001, CAN J CHEM ENG, V79, P341, DOI 10.1002/cjce.5450790306
   Al-Sabawi M, 2006, IND ENG CHEM RES, V45, P1583, DOI 10.1021/ie050683x
   Aponte Y, 2016, FUEL, V186, P222, DOI 10.1016/j.fuel.2016.08.020
   BILOUS O, 1956, AICHE J, V2, P117, DOI 10.1002/aic.690020124
   de Lasa H., 1998, Fiber Optic Sensor for Sensing Particle Movement in a Catalytic Reactor, Patent No. 5749291
   de Lasa H., 2019, [Reactor and multifunctional riser and downer simulator incorporating the same, US], Patent No. 10220363
   de Lasa H.I., 1992, US Patent, Patent No. 5102628
   Hayes DJM, 2015, FUEL, V150, P261, DOI 10.1016/j.fuel.2015.01.094
   Hong Z, 2011, P COMBUST INST, V33, P309, DOI 10.1016/j.proci.2010.05.101
   International A., 2012, E1655052012 INT A
   JAYNES DN, 1969, APPL OPTICS, V8, P1741, DOI 10.1364/AO.8.001741
   Klingbeil AE, 2006, MEAS SCI TECHNOL, V17, P1950, DOI 10.1088/0957-0233/17/7/038
   Klingbeil A.E., 2007, MID 1R LASER ABSORPT
   Kraemer D.W., 1991, MODELLING CATALYTIC
   KRAEMER DW, 1990, CHEM ENG SCI, V45, P2447, DOI 10.1016/0009-2509(90)80127-Z
   Lopez-Zamora S, 2018, CHEM ENG SCI, V192, P788, DOI 10.1016/j.ces.2018.08.021
   Lopez-Zamora S., 2019, IN SITU CHARACTERIZA
   Mevel R, 2012, CHEM PHYS LETT, V531, P22, DOI 10.1016/j.cplett.2012.01.069
   Nocedal J, 2006, SPRINGER SER OPER RE, P1, DOI 10.1007/978-0-387-40065-5
   OLSON DB, 1978, APPL SPECTROSC, V32, P489, DOI 10.1366/000370278774330892
   Pereira P., 2000, COMBINED STEAM CONVE
   Porter J.M., 2009, LASER BASED DIAGNOST
   Sadeghbeigi R, 2012, FLUID CATALYTIC CRACKING HANDBOOK: AN EXPERT GUIDE TO THE PRACTICAL OPERATION, DESIGN, AND OPTIMIZATION OF FCC UNITS, 3RD EDITION, P1
   Sharma RC, 2014, SPECTROCHIM ACTA A, V128, P176, DOI 10.1016/j.saa.2014.02.065
   Sharpe SW, 2004, APPL SPECTROSC, V58, P1452, DOI 10.1366/0003702042641281
   Stritzke F, 2015, APPL PHYS B-LASERS O, V119, P143, DOI 10.1007/s00340-015-6073-5
   Tomita E, 2003, MEAS SCI TECHNOL, V14, P1357, DOI 10.1088/0957-0233/14/8/322
   Workman J.J., 2007, HDB NEAR INFRARED AN, P123
NR 28
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115324
DI 10.1016/j.ces.2019.115324
PG 11
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600016
DA 2020-05-12
ER

PT J
AU Magnone, E
   Park, YG
   Chae, JW
   Kim, MK
   Lee, HJ
   Park, JH
AF Magnone, Edoardo
   Park, Yu Gang
   Chae, Jin Woong
   Kim, Min Kwang
   Lee, Hong Joo
   Park, Jung Hoon
TI High-performance low-temperature catalytic deoxidation of landfill gas
   based on Pd-decorated La0.8Sr0.2Co0.2Fe0.8O3-delta oxide
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Greenhouse gas; Catalyst; Oxidation; Catalytic deoxidation; Pd-decorated
   La(0.8)Sr(0.2)Co(0.2)Fe(0.8)O(3-delta )catalysts; Light-off temperature
ID WASTE
AB An efficient Pd-decorated La0.8Sr0.2Co0.2Fe0.8O3-delta (LSCFO) catalyst for the catalytic deoxidation of landfill gas (LFG) at low temperature has been developed. Synergism between the Pd coating and the LSCFO substrate in inducing the catalytic deoxygen reaction (CDR) was observed. The results demonstrated that the Pd-decorated LSCFO catalysts studied showed excellent deoxygen performances and a low light-off temperature of about 225 degrees C, which is lower than the typical temperatures used in conventional catalytic deoxygen processes (T > 300 degrees C). A probable cause of this synergism may be the cooperative action when the Pd catalyst was coated on an active deoxygen substrate. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Magnone, Edoardo; Park, Yu Gang; Chae, Jin Woong; Kim, Min Kwang; Lee, Hong Joo; Park, Jung Hoon] Dongguk Univ, Wonheung Gwan F619,30 Pildong Ro 1gil, Seoul 100715, South Korea.
RP Park, JH (reprint author), Dongguk Univ, Wonheung Gwan F619,30 Pildong Ro 1gil, Seoul 100715, South Korea.
EM pjhoon@dongguk.edu
OI Magnone, Edoardo/0000-0002-1333-4339; Park, Jung
   Hoon/0000-0002-8410-8005
FU 'Global Top Environment R&D Program' in the 'R&D Center for reduction of
   Non-CO2 Greenhouse gases' (Development and demonstration of oxygen
   removal technology of landfill gas) - Korea Ministry of Environment (ME)
   [2017002410012]
FX The project is supported by the 'Global Top Environment R&D Program' in
   the 'R&D Center for reduction of Non-CO2 Greenhouse gases' (Development
   and demonstration of oxygen removal technology of landfill gas) funded
   by Korea Ministry of Environment (ME) (2017002410012).
CR Ferreira AFP, 2015, CHEM ENG SCI, V124, P79, DOI 10.1016/j.ces.2014.06.014
   Ghorbel L, 2014, ENVIRON TECHNOL, V35, P372, DOI 10.1080/09593330.2013.828778
   Gong HJ, 2015, FUEL, V144, P43, DOI 10.1016/j.fuel.2014.12.019
   Gong HJ, 2014, FUEL, V120, P179, DOI 10.1016/j.fuel.2013.12.002
   Havas D, 2017, SEP SCI TECHNOL, V52, P186, DOI 10.1080/01496395.2016.1218515
   He PJ, 2005, ENVIRON TECHNOL, V26, P373, DOI 10.1080/09593332608618553
   Kim JR, 2017, J IND ENG CHEM, V47, P214, DOI 10.1016/j.jiec.2016.11.034
   Kim MK, 2019, KOREAN J CHEM ENG, V36, P1201, DOI 10.1007/s11814-019-0300-4
   Ko JH, 2015, CRIT REV ENV SCI TEC, V45, P2043, DOI 10.1080/10643389.2015.1010427
   Kwak TH, 2006, KOREAN J CHEM ENG, V23, P954, DOI 10.1007/s11814-006-0014-2
   Lawson P. S., 1989, International Journal of Ambient Energy, V10, P195
   Lichti KA, 1999, MATER HIGH TEMP, V16, P109, DOI 10.3184/096034099783641146
   Magnone E, 2016, FUEL, V183, P34, DOI 10.1016/j.fuel.2016.06.027
   Yang ZY, 2019, FUEL, V249, P161, DOI 10.1016/j.fuel.2019.03.113
NR 14
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115352
DI 10.1016/j.ces.2019.115352
PG 4
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600037
DA 2020-05-12
ER

PT J
AU Mangili, PV
   Prata, DM
AF Mangili, Patrick V.
   Prata, Diego M.
TI Preliminary design of sustainable industrial process alternatives based
   on eco-efficiency approaches: The maleic anhydride case study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Computational simulation; Maleic anhydride; Process design; Process
   economics; Safety metrics; Sustainability indicators
ID ENVIRONMENTAL-IMPACT ASSESSMENT; CHEMICAL-PROCESSES; INDICATORS;
   OXIDATION; PERFORMANCE; FRAMEWORK; ENERGY; BUTANE
AB The increasing need for mitigating environmental impacts has led the industries to develop more sustainable processes, which may represent an arduous task since economic, safety, social and environmental factors must be considered. Hence, this paper demonstrates the relevance of using sustainability indicators in developing cleaner industrial processes. Such metrics were used to design a more sustainable butane-based maleic anhydride manufacturing technology, which was compared to the benzene-based route in terms of economic, safety and environmental indicators. The analysis showed that, although the latter consumes approximately 2.8% less water, generates about 3.1% less wastewater and is 70 times less hazardous in terms of fire/explosion risks, the former is not only 33.8% more profitable but also consumes 28% less energy and, consequently, emits approximately 42.9% less CO2. After grouping the fifteen sustainability metrics in a composite evaluation index, the butane-based process proved to be about 34% more eco-efficient than the benzene-based technology. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Mangili, Patrick V.; Prata, Diego M.] Univ Fed Fluminense, Dept Chem & Petr Engn, BR-24210240 Niteroi, RJ, Brazil.
RP Mangili, PV (reprint author), Univ Fed Fluminense, Dept Chem & Petr Engn, BR-24210240 Niteroi, RJ, Brazil.
EM pmangili@id.uff.br
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES)CAPES [001]
FX This study was financed in part by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 001.
CR American Industrial Hygiene Association, 2011, CURR ERPGTM VAL
   Azapagic A., 2011, SUSTAINABLE DEV PRAC
   Banco Central do Brasil, 2018, INT RAT
   Bare JC, 2000, INT J LIFE CYCLE ASS, V5, P319, DOI 10.1007/BF02978665
   Bicalho T, 2017, J CLEAN PROD, V156, P888, DOI 10.1016/j.jclepro.2017.03.229
   Chen H, 2004, IND ENG CHEM RES, V43, P535, DOI 10.1021/ie0304356
   Daful AG, 2017, CHEM ENG SCI, V162, P53, DOI 10.1016/j.ces.2016.12.054
   Deloitte, 2017, INT TAX BRAZ HIGHL 2
   Dong Y, 2016, CHEM ENG SCI, V142, P299, DOI 10.1016/j.ces.2015.12.004
   Fermeglia M, 2009, AICHE J, V55, P1065, DOI 10.1002/aic.11730
   Goedkoop M, 2001, ECOINDICATOR 99 DAMA, V36A
   Independent Chemical Information System, 2018, IND CHEM PRIC A Z
   International Energy Agency, 2005, EN STAT MAN
   Junqueira PG, 2018, CHEM ENG PROCESS, V130, P309, DOI 10.1016/j.cep.2018.06.010
   Kralisch D, 2015, GREEN CHEM, V17, P123, DOI 10.1039/c4gc01153h
   Lesser D, 2017, CHEM ENG SCI, V172, P559, DOI 10.1016/j.ces.2017.06.049
   Malow M., 1985, ENVIRON PROG, V4, P151, DOI [10.1002/ep.670040307, DOI 10.1002/EP.670040307]
   Mangili PV, 2019, COMPUT CHEM ENG, V130, DOI 10.1016/j.compchemeng.2019.106558
   Mangili PV, 2019, CHEM ENG PROCESS, V135, P93, DOI 10.1016/j.cep.2018.11.020
   Mangili PV, 2018, CHEM ENG PROCESS, V123, P100, DOI 10.1016/j.cep.2017.10.022
   Maussner J, 2018, CHEM ENG SCI, V192, P306, DOI 10.1016/j.ces.2018.06.079
   MCTIC-Ministerio da Ciencia Tecnologia Inovacoes e Comunicacoes, 2019, MET AN DESP FAT EM M
   Lainez JM, 2008, COMPUT-AIDED CHEM EN, V25, P1131
   Morales-Mora MA, 2012, PROCESS SAF ENVIRON, V90, P27, DOI 10.1016/j.psep.2011.10.002
   Patel AD, 2012, ENERG ENVIRON SCI, V5, P8430, DOI 10.1039/c2ee21581k
   Patel C, 2012, PROCESS SAF ENVIRON, V90, P255, DOI [10.1016/j.psep.2012.04.002, 10.1016/j.psep.2011.06.015]
   Penney WR, 2012, CHEM PROCESS EQUIPME
   Pereira CP, 2018, BRAZ J CHEM ENG, V35, P69, DOI 10.1590/0104-6632.20180351s20160370
   Ruiz-Mercado GJ, 2012, IND ENG CHEM RES, V51, P2329, DOI 10.1021/ie200755k
   Schwarz J.M., 2001, ENV QUALITY MANAGEME, V11, P75, DOI 10.1002/tqem.1307
   SEEG-Sistema de Estimativa de Emissao de Gases do Efeito Estufa, 2018, NOV MET SET EN
   Seider W.D., 2017, PRODUCT PROCESS DESI
   SHARMA RK, 1991, AICHE J, V37, P39, DOI 10.1002/aic.690370103
   Smith R., 2016, CHEM PROCESS DESIGN
   Smith RL, 2015, COMPUT CHEM ENG, V81, P272, DOI 10.1016/j.compchemeng.2015.04.020
   Technobell Technology, 2018, CHEM PROC TECHN MAL
   The British Standards Institution, 2012, 140452012 ISO BSI ST
   The Chemical Company, 2016, EPCA SPEC ED CRIT RA
   Towler G.P., 2013, CHEM ENG DESIGN PRIN
   Trivedi BC, 1982, MALEIC ANHYDRIDE
   Turton R, 2018, ANAL SYNTHESIS DESIG
   United Nations Conference on Trade and Development (UNCTAD), 2004, MAN PREP US EC IND
   Uraz C, 2007, CHEM ENG TECHNOL, V30, P1708, DOI 10.1002/ceat.200700249
   Valenzuela-Venegas G, 2016, J CLEAN PROD, V133, P99, DOI 10.1016/j.jclepro.2016.05.113
   Warnasooriya S, 2017, PROCESS SAF ENVIRON, V105, P224, DOI 10.1016/j.psep.2016.11.010
   Yao Y, 2018, J CLEAN PROD, V172, P768, DOI 10.1016/j.jclepro.2017.10.125
   Zamagni A, 2012, INT J LIFE CYCLE ASS, V17, P373, DOI 10.1007/s11367-012-0389-8
NR 47
TC 1
Z9 1
U1 16
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115313
DI 10.1016/j.ces.2019.115313
PG 17
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600010
DA 2020-05-12
ER

PT J
AU Maussner, J
   Freund, H
AF Maussner, Johannes
   Freund, Hannsjoerg
TI Multi-objective reactor design under uncertainty: A decomposition
   approach based on cubature rules
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Multi-objective optimization; Optimization under uncertainty;
   Model-based reactor design; Cubature rule; Maleic anhydride synthesis
ID DYNAMIC OPTIMIZATION; MULTICRITERIA OPTIMIZATION; ROBUST OPTIMIZATION;
   DECISION-SUPPORT; HEAT-TRANSFER; STRATEGIES; OXIDATION; SYSTEMS; FLUID;
   BED
AB Model-based strategies for chemical reactor design proved to be a reliable tool for the systematic design of resource and energy efficient chemical reactors. The adequacy and accuracy of the underlying model equations (e.g. reaction kinetics and kinetics for heat and mass transport) are crucial for the success of such design approaches. However, the models used in chemical engineering are typically based on experimental data and predictive expressions for the fundamental phenomena and thus the respective model parameters are inevitably subject to uncertainty. Therefore, consideration of parametric uncertainty in the design strategy is necessary to obtain reliable chemical reactor designs. Moreover, the design of chemical reactors involves almost always multiple conflicting objectives which poses an additional challenge.
   In the present work, we propose an efficient reactor design strategy to tackle the combined challenges of parametric uncertainty and multiple conflicting objectives. The approach combines a scalarization method with a cubature rule to efficiently determine robust compromise solutions. The cubature rule is used to approximate the first two statistical moments of the objectives and of all critical inequality constraints. The approximation of the statistical moments is performed separate from the optimization problem. This leads to an iterative approach with improved computational performance. The proposed approach is illustrated and compared to an existing approach from literature by studying three different reactor design case studies, namely the optimization of a batch, semi-batch and multi-tubular fixed-bed reactor.
   The results of the newly proposed reactor design approach and the existing method from literature are in very good agreement for all considered case studies. The advantage of the new approach is a significantly lower computational effort compared to the existing method. This is especially visible for the more complex case studies with a higher number of uncertain parameters. The advantage of the approach proposed in the present work is thus particularly relevant and important for the application to complex reactor design tasks such as, e.g., the design of polymerization reactors or multi-phase reactors. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Maussner, Johannes; Freund, Hannsjoerg] Friedrich Alexander Univ Erlangen Nurnberg FAU, Lehrstuhl Chem Reakt Tech, Cauerstr 3, D-91058 Erlangen, Germany.
RP Freund, H (reprint author), Friedrich Alexander Univ Erlangen Nurnberg FAU, Lehrstuhl Chem Reakt Tech, Cauerstr 3, D-91058 Erlangen, Germany.
EM hannsjoerg.freund@fau.de
FU German Research Foundation (DFG) within the framework of its "Excellence
   Initiative"German Research Foundation (DFG)
FX The authors gratefully acknowledge the funding of the German Research
   Foundation (DFG), which, within the framework of its "Excellence
   Initiative", supports the Cluster of Excellence "Engineering of Advanced
   Materials" at the Friedrich-Alexander-Univer sitat Erlangen-Nurnberg
   (www.eam.fau.de).
CR ALSALEH MA, 1988, CHEM ENG J BIOCH ENG, V37, P35, DOI 10.1016/0300-9467(88)80004-2
   Bartl M, 2011, AICHE J, V57, P2185, DOI 10.1002/aic.12437
   BAUER R, 1976, CHEM-ING-TECH, V48, P227, DOI 10.1002/cite.330480309
   Bernardo FP, 2015, J COMPUT APPL MATH, V280, P110, DOI 10.1016/j.cam.2014.11.053
   Bhaskar V, 2000, REV CHEM ENG, V16, P1
   Bhatia T, 1996, IND ENG CHEM RES, V35, P2234, DOI 10.1021/ie950701i
   Biegler LT, 2007, CHEM ENG PROCESS, V46, P1043, DOI 10.1016/j.cep.2006.06.021
   Biegler LT, 2010, MOS-SIAM SER OPTIMIZ, V10, pXIII, DOI 10.1137/1.9780898719383
   Bortz M, 2017, IND ENG CHEM RES, V56, P12672, DOI 10.1021/acs.iecr.7b02539
   Bortz M, 2014, COMPUT CHEM ENG, V60, P354, DOI 10.1016/j.compchemeng.2013.09.015
   Calverley EM, 2012, CHEM ENG SCI, V80, P393, DOI 10.1016/j.ces.2012.06.047
   Cools R., 1997, Acta Numerica, V6, P1, DOI 10.1017/S0962492900002701
   COOLS R, 1993, J COMPUT APPL MATH, V48, P309, DOI 10.1016/0377-0427(93)90027-9
   Das I, 1998, SIAM J OPTIMIZ, V8, P631, DOI 10.1137/S1052623496307510
   Diehl M, 2006, MATH PROGRAM, V107, P213, DOI 10.1007/s10107-005-0685-1
   Dixon AG, 1996, CHEM ENG PROCESS, V35, P323, DOI 10.1016/0255-2701(96)80012-2
   Emenike VN, 2019, COMPUT CHEM ENG, V121, P232, DOI 10.1016/j.compchemeng.2018.10.006
   ERGUN S, 1949, IND ENG CHEM, V41, P1179, DOI 10.1021/ie50474a011
   ERGUN S, 1952, CHEM ENG PROG, V48, P89
   FOURER R, 1990, MANAGE SCI, V36, P519, DOI 10.1287/mnsc.36.5.519
   Freund H, 2011, CHEM-ING-TECH, V83, P420, DOI 10.1002/cite.201000195
   Ganzer G., 2019, CHEM ENG SCI UNPUB
   GEE DA, 1988, BIOTECHNOL BIOENG, V31, P224, DOI 10.1002/bit.260310308
   GROSSMANN IE, 1978, AICHE J, V24, P1021, DOI 10.1002/aic.690240612
   Grossmann IE, 2016, COMPUT CHEM ENG, V91, P3, DOI 10.1016/j.compchemeng.2016.03.002
   HAIMES YY, 1971, IEEE T SYST MAN CYB, VSMC1, P296
   HALEMANE KP, 1983, AICHE J, V29, P425, DOI 10.1002/aic.690290312
   Hancock BJ, 2013, STRUCT MULTIDISCIP O, V48, P763, DOI 10.1007/s00158-013-0925-6
   Julier S., 1996, TECH REP
   JULIER SJ, 1995, PROCEEDINGS OF THE 1995 AMERICAN CONTROL CONFERENCE, VOLS 1-6, P1628
   Kaiser NM, 2016, COMPUT CHEM ENG, V94, P45, DOI 10.1016/j.compchemeng.2016.06.008
   Kameswaran S, 2008, COMPUT OPTIM APPL, V41, P81, DOI 10.1007/s10589-007-9098-9
   Kawajiri Y, 2006, AICHE J, V52, P1343, DOI 10.1002/aic.10736
   Kim IY, 2006, STRUCT MULTIDISCIP O, V31, P105, DOI 10.1007/s00158-005-0557-6
   Li P, 2008, COMPUT CHEM ENG, V32, P25, DOI 10.1016/j.compchemeng.2007.05.009
   Logist F, 2012, COMPUT CHEM ENG, V37, P191, DOI 10.1016/j.compchemeng.2011.11.002
   Logist F, 2009, CHEM ENG SCI, V64, P2527, DOI 10.1016/j.ces.2009.01.054
   Logist F, 2011, CHEM ENG SCI, V66, P4670, DOI 10.1016/j.ces.2011.06.018
   Logist F, 2010, STRUCT MULTIDISCIP O, V42, P591, DOI 10.1007/s00158-010-0506-x
   Lu J, 2004, SIAM J SCI COMPUT, V26, P613, DOI 10.1137/S1064827503426863
   Marler RT, 2004, STRUCT MULTIDISCIP O, V26, P369, DOI 10.1007/s00158-003-0368-6
   MARTIN H, 1993, CHEM-ING-TECH, V65, P1468, DOI 10.1002/cite.330651206
   Maussner J, 2018, CHEM ENG SCI, V192, P306, DOI 10.1016/j.ces.2018.06.079
   Maussner J, 2018, CHEM ENG SCI, V183, P329, DOI 10.1016/j.ces.2018.02.002
   Messac A, 2003, STRUCT MULTIDISCIP O, V25, P86, DOI 10.1007/s00158-002-0276-1
   Mitsos A, 2018, COMPUT CHEM ENG, V113, P209, DOI 10.1016/j.compchemeng.2018.03.013
   Nie YS, 2013, IND ENG CHEM RES, V52, P15311, DOI 10.1021/ie4005699
   Nimmegeers P, 2019, CHEM-ING-TECH, V91, P349, DOI 10.1002/cite.201800082
   Noeres C, 2004, CHEM ENG PROCESS, V43, P421, DOI 10.1016/j.cep.2003.05.001
   OHNO H, 1976, BIOTECHNOL BIOENG, V18, P847, DOI 10.1002/bit.260180607
   PISTIKOPOULOS EN, 1995, COMPUT CHEM ENG, V19, pS553, DOI 10.1016/0098-1354(95)00119-M
   Puschke J., 2018, COMPUT CHEM ENG
   Rossner N., 2010, IFAC P, V11, P7, DOI DOI 10.3182/20100707-3-BE-2012.0035
   Sahinidis NV, 2004, COMPUT CHEM ENG, V28, P971, DOI 10.1016/j.compchemeng.2003.09.017
   Sanchis J, 2008, STRUCT MULTIDISCIP O, V36, P537, DOI 10.1007/s00158-007-0185-4
   Schwarz H., 1997, THESIS
   Sen M, 2013, ADV POWDER TECHNOL, V24, P51, DOI 10.1016/j.apt.2012.02.001
   SHARMA RK, 1991, AICHE J, V37, P39, DOI 10.1002/aic.690370103
   Shi J, 2016, COMPUT CHEM ENG, V95, P260, DOI 10.1016/j.compchemeng.2016.08.002
   Lopez-Saucedo ES, 2016, CHEM ENG RES DES, V111, P83, DOI 10.1016/j.cherd.2016.04.005
   Srinivasan B, 2003, COMPUT CHEM ENG, V27, P27, DOI 10.1016/S0098-1354(02)00117-5
   Stroud A., 1971, APPROXIMATE CALCULAT
   Telen D, 2015, J PROCESS CONTR, V33, P140, DOI 10.1016/j.jprocont.2015.06.011
   Tsotsas E., 2013, VDI WARMEATLAS, P1517, DOI [10.1007/978-3-642-19981-3_102, DOI 10.1007/978-3-642-19981-3_102]
   Vallerio M, 2016, CHEM ENG SCI, V140, P201, DOI 10.1016/j.ces.2015.09.012
   Vallerio M, 2015, COMPUT CHEM ENG, V82, P186, DOI 10.1016/j.compchemeng.2015.07.004
   Vallerio M, 2015, EXPERT SYST APPL, V42, P7710, DOI 10.1016/j.eswa.2015.05.038
   Verma SK, 2017, COMPUT CHEM ENG, V106, P23, DOI 10.1016/j.compchemeng.2017.05.015
   Wachsen O, 2015, CHEM-ING-TECH, V87, P683, DOI 10.1002/cite.201400142
   Wachter A, 2006, MATH PROGRAM, V106, P25, DOI 10.1007/s10107-004-0559-y
   Wendt M, 2002, IND ENG CHEM RES, V41, P3621, DOI 10.1021/ie010649s
   Xie X., 2018, PROCESSES, V6
   Xie XZ, 2019, CHEM ENG SCI, V207, P805, DOI 10.1016/j.ces.2019.06.023
   ZEHNER P, 1972, CHEM-ING-TECH, V44, P1303, DOI 10.1002/cite.330442305
NR 74
TC 0
Z9 0
U1 7
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115304
DI 10.1016/j.ces.2019.115304
PG 16
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600006
DA 2020-05-12
ER

PT J
AU Molteni, M
   Donazzi, A
AF Molteni, Matteo
   Donazzi, Alessandro
TI Model analysis of atmospheric non-thermal plasma for methane abatement
   in a gas phase dielectric barrier discharge reactor
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Methane abatement; Dielectric barrier discharge; Non-thermal plasma;
   Modeling
ID CROSS-SECTIONS; CATALYTIC-OXIDATION; ELECTRON COLLISIONS; PRESSURE;
   CHEMISTRY; DEPOSITION; CONVERSION; OXYGEN; WATER; C-2
AB A physical model of a non-thermal plasma reactor for the abatement of CH4 emissions is presented. The model includes mass balances for neutral, charged and radical species, the enthalpy balance for the gas phase and specific equations for electron temperature and density. The kinetic scheme of CH4 abatement couples the GRI-Mech set of radical reactions (325 steps) with ten sets of plasma reactions (108 steps), which comprise elastic collisions, direct ionization, dissociative ionization, excitation and attachment reactions. The model is validated based on literature results that explore the effects of Specific Input Energy, gas temperature and H2O addition. The results highlight that dissociative electron-impact reactions produce chemically active OH and O radicals, which boost CH4 conversion, making H2O a key abatement promoter in the plasma process. The heating effect induced by electron collisions is relevant, suggesting that an accurate control of thermal insulation is crucial to characterize the reactor performance. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Molteni, Matteo; Donazzi, Alessandro] Politecn Milan, Dipartimento Energia, Via Lambruschini 4, I-20156 Milan, Italy.
RP Donazzi, A (reprint author), Politecn Milan, Dipartimento Energia, Via Lambruschini 4, I-20156 Milan, Italy.
EM alessandro.donazzi@polimi.it
CR Adamovich IV, 2009, PHYS PLASMAS, V16, DOI 10.1063/1.3264740
   Affonso Nobrega P, 2018, PLASMA SCI TECHNOL, V20, DOI 10.1088/2058-6272/aab301
   Benalcazar P, 2017, GOSPOD SUROWCAMI MIN, V33, P29, DOI 10.1515/gospo-2017-0042
   BOEUF JP, 1987, PHYS REV A, V36, P2782, DOI 10.1103/PhysRevA.36.2782
   Bogaerts A, 2010, PURE APPL CHEM, V82, P1283, DOI 10.1351/PAC-CON-09-09-20
   BURCH R, 1995, APPL CATAL A-GEN, V123, P173, DOI 10.1016/0926-860X(94)00251-7
   BUURON AJM, 1995, DIAM RELAT MATER, V4, P1271, DOI 10.1016/0925-9635(95)00303-7
   Da Costa P, 2008, APPL CATAL B-ENVIRON, V84, P214, DOI 10.1016/j.apcatb.2008.04.013
   Danko S, 2013, PLASMA SOURCES SCI T, V22, DOI 10.1088/0963-0252/22/5/055009
   De Bie C, 2011, PLASMA PROCESS POLYM, V8, P1033, DOI 10.1002/ppap.201100027
   De Bie C, 2011, PLASMA SOURCES SCI T, V20, DOI 10.1088/0963-0252/20/2/024008
   DeFilippo AC, 2016, COMBUST FLAME, V172, P38, DOI 10.1016/j.combustflame.2016.07.005
   DOTAN I, 1982, J CHEM PHYS, V76, P4972, DOI 10.1063/1.442843
   Eckert Z, 2018, J PHYS D APPL PHYS, V51, DOI 10.1088/1361-6463/aad2b1
   ELIASSON B, 1991, IEEE T PLASMA SCI, V19, P1063, DOI 10.1109/27.125031
   ELIASSON B, 1987, J PHYS D APPL PHYS, V20, P1421, DOI 10.1088/0022-3727/20/11/010
   ELIASSON B, 1991, IEEE T PLASMA SCI, V19, P309, DOI 10.1109/27.106829
   Engeln R, 1999, CHEM PHYS LETT, V310, P405, DOI 10.1016/S0009-2614(99)00810-6
   Gordillo-Vazquez FJ, 2004, PLASMA SOURCES SCI T, V13, P50, DOI 10.1088/0963-0252/13/1/007
   Goyette A.R.K.A.N., 1975, SPECTROSCOPIC DETERM
   Hagelaar GJM, 2005, PLASMA SOURCES SCI T, V14, P722, DOI 10.1088/0963-0252/14/4/011
   Hurlbatt A, 2017, PLASMA PROCESS POLYM, V14, DOI 10.1002/ppap.201600138
   Huu TP, 2015, CATAL TODAY, V257, P86, DOI 10.1016/j.cattod.2015.03.001
   International Energy Agency, 2017, INTR SCOP WORLD EN O, P33, DOI [10.1787/weo-2017-en, DOI 10.1787/WEO-2017-EN]
   Itikawa Y, 2005, J PHYS CHEM REF DATA, V34, P1, DOI 10.1063/1.1799251
   Itikawa Y, 2002, J PHYS CHEM REF DATA, V31, P749, DOI 10.1063/1.1481879
   Jo S, 2015, CHEM ENG SCI, V130, P101, DOI 10.1016/j.ces.2015.03.019
   Jo S, 2013, PHYS PLASMAS, V20, DOI 10.1063/1.4818795
   Kemaneci E, 2015, J PHYS D APPL PHYS, V48, DOI 10.1088/0022-3727/48/43/435203
   Konnov AA, 2009, COMBUST FLAME, V156, P2093, DOI 10.1016/j.combustflame.2009.03.016
   Lampert JK, 1997, APPL CATAL B-ENVIRON, V14, P211, DOI 10.1016/S0926-3373(97)00024-6
   Lefkowitz JK, 2015, PHILOS T R SOC A, V373, DOI 10.1098/rsta.2014.0333
   Lieberman MA, 2005, PRINCIPLES OF PLASMA DISCHARGES AND MATERIALS PROCESSING, 2ND EDITION, P87
   Marques R, 2008, APPL CATAL B-ENVIRON, V82, P50, DOI 10.1016/j.apcatb.2007.12.024
   McBride J., 1993, 4513NASATM4513, V4513, P98
   Metcalfe WK, 2013, INT J CHEM KINET, V45, P638, DOI 10.1002/kin.20802
   MEULENBROEKS RFG, 1994, PHYS REV E, V49, P4397, DOI 10.1103/PhysRevE.49.4397
   Mfopara A, 2009, PLASMA CHEM PLASMA P, V29, P91, DOI 10.1007/s11090-008-9164-9
   Monahan DD, 2008, PLASMA SOURCES SCI T, V17, DOI 10.1088/0963-0252/17/4/045003
   MONCHICK L, 1961, J CHEM PHYS, V35, P1676, DOI 10.1063/1.1732130
   MORGAN WL, 1992, PLASMA CHEM PLASMA P, V12, P477, DOI 10.1007/BF01447255
   NGV Global-CNG LNG Natural Gas Vehicles, NGV GLOBAL CNG LNG N
   Ogata A, 1998, PLASMA CHEM PLASMA P, V18, P363, DOI 10.1023/A:1021897419040
   PAI ST, 1992, J APPL PHYS, V71, P5820, DOI 10.1063/1.350476
   Park S, 2017, TOP CATAL, V60, P735, DOI 10.1007/s11244-017-0778-0
   PASSCHIER JDP, 1993, J APPL PHYS, V74, P3744, DOI 10.1063/1.354487
   Pham H. T., 2017, TOP CATAL, V60, P326
   Pringle KJ, 2004, PLASMA CHEM PLASMA P, V24, P421, DOI 10.1007/s11090-004-2277-x
   RAKSHIT AB, 1981, J CHEM PHYS, V74, P2853, DOI 10.1063/1.441404
   Takaki K, 2004, IEEE T PLASMA SCI, V32, P2175, DOI 10.1109/TPS.2004.837614
   Takaki K, 2004, IEEE T DIELECT EL IN, V11, P481, DOI 10.1109/tdei.2004.1306726
   Thorsteinsson E.G., 2010, PLASMA SOURCES SCI T, V19, DOI [10.1088/0963-0252/19/5/055008055008, DOI 10.1088/0963-0252/19/5/055008055008]
   VIALLE M, 1991, J PHYS D APPL PHYS, V24, P301, DOI 10.1088/0022-3727/24/3/011
   WYATT JR, 1975, J CHEM PHYS, V62, P2555, DOI 10.1063/1.430836
   Yamamoto T, 1999, J HAZARD MATER, V67, P165, DOI 10.1016/S0304-3894(99)00038-2
   Zhang YR, 2016, APPL CATAL B-ENVIRON, V185, P56, DOI 10.1016/j.apcatb.2015.12.009
NR 56
TC 0
Z9 0
U1 18
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115340
DI 10.1016/j.ces.2019.115340
PG 16
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600031
DA 2020-05-12
ER

PT J
AU Nazari, M
   Rashidi, S
   Esfahani, JA
AF Nazari, Morteza
   Rashidi, Saman
   Esfahani, Javad Abolfazli
TI Effects of flexibility of conductive plate on efficiency of an
   induced-charge electrokinetic micro-mixer under constant and
   time-varying electric fields-A comprehensive parametric study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Electrokinetic; Micro-mixer; Flexible conductive plate; Mixing
   efficiency; Constant and time-varying electric fields
ID HEAT-TRANSFER; FLOW; DRIVEN; MICROFLUIDICS; MICROMIXERS; CHIP; CFD;
   MICROCHANNEL; SIMULATION; NANOFLUID
AB In this study, an induced-charge electrokinetic micro-mixer with a flexible conductive plate is simulated. The plate can be deformed under the influences of the hydrodynamic and electrostatic forces. A comprehensive parametric investigation is conducted on this micro-mixer. The influences of various parameters including usage of flexible and non-flexible plate, constant and time-varying electric fields, alternating electric field amplitude, average electric field intensity, Young's modulus of conductive plate, conductive plate length, and conductive plate displacement on the concentration field, pressure field, velocity field, and mixing efficiency are investigated. The results showed that the mixing efficiency of micro-mixer is greater for lower value of Young's modulus. The flexible conductive plate, which is subjected to a time-varying electric field, contributes to the mixing in two ways: (1) by inducing vortices on the conductive surfaces of the plate, (2) by oscillating the conductive plate, which acts as a stirrer and increases the mixing efficiency. The micro-mixer with flexible conductive plate under time-varying electric field has better mixing efficiency as compared with the other cases. The vortices created around the flexible plate are larger than the vortices of the non-flexible plate due to plate deformation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Nazari, Morteza; Esfahani, Javad Abolfazli] Ferdowsi Univ Mashhad, Dept Mech Engn, Mashhad 917751111, Razavi Khorasan, Iran.
   [Rashidi, Saman] Semnan Univ, Fac New Sci & Technol, Dept Energy, Semnan, Iran.
RP Esfahani, JA (reprint author), Ferdowsi Univ Mashhad, Dept Mech Engn, Mashhad 917751111, Razavi Khorasan, Iran.
EM Abolfazl@um.ac.ir
RI ; Esfahani, Javad A./S-5005-2017
OI Rashidi, Saman/0000-0001-6266-920X; Esfahani, Javad
   A./0000-0001-6395-8089
CR Ansari MA, 2012, CHEM ENG J, V181, P846, DOI 10.1016/j.cej.2011.11.113
   Aoki N, 2006, CHEM ENG J, V118, P189, DOI 10.1016/j.cej.2006.02.011
   Azimi S, 2017, PHYS FLUIDS, V29, DOI 10.1063/1.4975982
   Azimi S, 2016, MICROFLUID NANOFLUID, V20, DOI 10.1007/s10404-016-1786-2
   Bhatti MM, 2017, J MOL LIQ, V230, P237, DOI 10.1016/j.molliq.2017.01.033
   Chen JJ, 2011, CHEM ENG SCI, V66, P2164, DOI 10.1016/j.ces.2011.02.022
   Chen XY, 2017, ANAL CHIM ACTA, V964, P142, DOI 10.1016/j.aca.2017.01.066
   Chen Y., 2018, ANAL CHIM ACTA
   Coleman JT, 2005, MICROFLUID NANOFLUID, V1, P319, DOI 10.1007/s10404-005-0034-y
   Cortes-Quiroz CA, 2010, CHEM ENG J, V160, P852, DOI 10.1016/j.cej.2010.02.029
   Daghighi Y., 2011, LAB CHIP MICROVALVE, P2929
   Daghighi Y, 2013, ANAL CHIM ACTA, V763, P28, DOI 10.1016/j.aca.2012.12.010
   Dittrich PS, 2006, NAT REV DRUG DISCOV, V5, P210, DOI 10.1038/nrd1985
   DONEA J, 1982, COMPUT METHOD APPL M, V33, P689, DOI 10.1016/0045-7825(82)90128-1
   Ebrahimi S, 2014, INT J HEAT MASS TRAN, V75, P565, DOI 10.1016/j.ijheatmasstransfer.2014.04.004
   Ellahi R, 2019, SYMMETRY-BASEL, V11, DOI 10.3390/sym11081038
   Feng HC, 2016, CHEM ENG SCI, V142, P12, DOI 10.1016/j.ces.2015.11.023
   Ghaemmaghami AM, 2012, DRUG DISCOV TODAY, V17, P173, DOI 10.1016/j.drudis.2011.10.029
   Guo ZH, 2019, CHEM ENG SCI, V197, P357, DOI 10.1016/j.ces.2018.12.034
   Gutierrez E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025534
   Hardt S, 2006, MICROFLUID NANOFLUID, V2, P237, DOI 10.1007/s10404-005-0071-6
   He M., 2019, MICROSYST TECHNOL, V2
   Helisaz H, 2018, CHEM ENG SCI, V191, P358, DOI 10.1016/j.ces.2018.06.077
   Hessel V, 2005, CHEM ENG SCI, V60, P2479, DOI 10.1016/j.ces.2004.11.033
   Hu H. H., 1992, Theoretical and Computational Fluid Dynamics, V3, P285, DOI 10.1007/BF00717645
   HUGHES TJR, 1981, COMPUT METHOD APPL M, V29, P329, DOI 10.1016/0045-7825(81)90049-9
   Hussain F, 2018, APPL SCI-BASEL, V8, DOI 10.3390/app8020275
   Jhorar R, 2018, INDIAN J PHYS, V92, P1229, DOI 10.1007/s12648-018-1215-3
   Kang K, 2014, 2014 INTERNATIONAL CONFERENCE ON WIRELESS COMMUNICATION AND SENSOR NETWORK (WCSN), P5, DOI 10.1109/WCSN.2014.8
   Kazemi Z, 2017, CHEM ENG PROCESS, V121, P188, DOI 10.1016/j.cep.2017.08.015
   Khetani SR, 2008, NAT BIOTECHNOL, V26, P120, DOI 10.1038/nbt1361
   Knight J, 2002, NATURE, V418, P474, DOI 10.1038/418474a
   Lee CY, 2018, SENSOR ACTUAT B-CHEM, V259, P677, DOI 10.1016/j.snb.2017.12.034
   Lu LH, 2002, J MICROELECTROMECH S, V11, P462, DOI 10.1109/JMEMS.2002.802899
   Ma YB, 2008, J MICROMECH MICROENG, V18, DOI 10.1088/0960-1317/18/4/045015
   Mahian O., 2018, RECENT ADV MODELING
   Nazari M, 2020, INT J HEAT MASS TRAN, V146, DOI 10.1016/j.ijheatmasstransfer.2019.118892
   Nazari M, 2019, INT COMMUN HEAT MASS, V108, DOI 10.1016/j.icheatmasstransfer.2019.104293
   Palchesko RN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051499
   Qaderi A, 2019, CHEM ENG SCI, V199, P463, DOI 10.1016/j.ces.2019.01.034
   Rashidi A, 2014, KSCE J CIV ENG, V18, P1580, DOI 10.1007/s12205-014-0354-0
   Rashidi A, 2016, KSCE J CIV ENG, V20, P1178, DOI 10.1007/s12205-015-0726-0
   Rashidi A, 2011, J CONSTR ENG M, V137, P17, DOI 10.1061/(ASCE)CO.1943-7862.0000200
   Rashidi S, 2018, CHEM ENG PROCESS, V126, P108, DOI 10.1016/j.cep.2018.02.021
   Rife JC, 2000, SENSOR ACTUAT A-PHYS, V86, P135, DOI 10.1016/S0924-4247(00)00433-7
   Rios A, 2012, ANAL CHIM ACTA, V740, P1, DOI 10.1016/j.aca.2012.06.024
   Shamloo A., 2017, CHEM ENG PROCESS PRO
   Shi HB, 2019, CHEM ENG SCI, V207, P672, DOI 10.1016/j.ces.2019.07.004
   Shirvan KM, 2017, POWDER TECHNOL, V313, P99, DOI 10.1016/j.powtec.2017.02.065
   Shirvan KM, 2017, INT J HEAT MASS TRAN, V107, P1110, DOI 10.1016/j.ijheatmasstransfer.2016.11.022
   Sikanen T, 2008, MICROFLUID NANOFLUID, V5, P479, DOI 10.1007/s10404-008-0260-1
   Stroock AD, 2002, ANAL CHEM, V74, P5306, DOI 10.1021/ac0257389
   Suzuki H, 2002, PROC IEEE MICR ELECT, P40, DOI 10.1109/MEMSYS.2002.984076
   Tian JD, 2004, NATURE, V432, P1050, DOI 10.1038/nature03151
   Tsai JH, 2002, SENSOR ACTUAT A-PHYS, V97-8, P665, DOI 10.1016/S0924-4247(02)00031-6
   Valipour MS, 2014, J HEAT TRANS-T ASME, V136, DOI 10.1115/1.4026371
   Vatankhah P, 2018, ANAL CHIM ACTA, V1022, P96, DOI 10.1016/j.aca.2018.03.039
   Veenstra TT, 1999, J MICROMECH MICROENG, V9, P199, DOI 10.1088/0960-1317/9/2/323
   Wang L, 2012, CHEM ENG SCI, V81, P157, DOI 10.1016/j.ces.2012.07.004
   Wu MH, 2010, LAB CHIP, V10, P939, DOI 10.1039/b921695b
   Wu ZM, 2008, ELECTROCHIM ACTA, V53, P5827, DOI 10.1016/j.electacta.2008.03.039
   Wu ZM, 2008, MICROFLUID NANOFLUID, V5, P65, DOI 10.1007/s10404-007-0227-7
   Yaralioglu GG, 2004, ANAL CHEM, V76, P3694, DOI 10.1021/ac035220k
   Yoshimura M, 2019, MICROFLUID NANOFLUID, V23, DOI 10.1007/s10404-019-2201-6
   Yousif MA, 2019, HEAT TRANSF RES, V50, P649, DOI 10.1615/HeatTransRes.2018025568
   Zhao H, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.066217
   Zhao W, 2017, CHEM ENG SCI, V165, P113, DOI 10.1016/j.ces.2017.02.027
NR 67
TC 0
Z9 0
U1 7
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115335
DI 10.1016/j.ces.2019.115335
PG 21
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600026
DA 2020-05-12
ER

PT J
AU Ojha, DP
   Kim, HJ
AF Ojha, Devi Prashad
   Kim, Han Joo
TI Investigation of photocatalytic activity of ZnO promoted hydrothermally
   synthesized ZnWO4 nanorods in UV-visible light irradiation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE ZnWO4; ZnO; Photocatalysis; Salicylic acid; Nanorod
ID COMPOSITE; PHOTOLUMINESCENCE; NANOCOMPOSITES; DEGRADATION; PERFORMANCE;
   BINARY
AB Hydrothermally synthesized Zinc tungstate (ZnWO4, ZWO) nanorod with high aspect ratio is coupled with ZnO to design a photoactive ZnO/ZWO heterostructure. The morphological characterizations and surface measurements indicated ZnO nanoparticles embedded over well crystallized ZnWO4 nanorods thereby increasing specific surface area. The kinetic studies of the salicylic acid photodegradation showed the enhanced photoactivity of ZnO/ZWO heterostructure as compared to the individual nanostructures. This is attributed to the selective photoexcitation of the semiconductors that prolonged the lifetime of the charged species further confirmed by the conductivity measurements and trapping experiments. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ojha, Devi Prashad; Kim, Han Joo] Chonbuk Natl Univ, Dept Convergence Technol Engn, Jeonju 561756, South Korea.
   [Kim, Han Joo] Chonbuk Natl Univ, Ecofriendly Machine Parts Design Ctr, Jeonju 561756, South Korea.
RP Kim, HJ (reprint author), Chonbuk Natl Univ, Dept Convergence Technol Engn, Jeonju 561756, South Korea.
EM devuojha@jbnu.ac.kr; khanjoo@jbnu.ac.kr
FU National Research foundation (NRF) by Ministry of Education, Science,
   Technology (MEST), Republic of Korea [2017-R1C1B2011968]
FX This work was supported by National Research foundation (NRF) by
   Ministry of Education, Science, Technology (MEST), Republic of Korea via
   Project no. 2017-R1C1B2011968. We would like to acknowledge Centre for
   Chonbuk University Research Facility (CURF) for providing all the
   equipment needed for the analysis.
CR Almeida MAP, 2012, CRYSTENGCOMM, V14, P7127, DOI 10.1039/c2ce25771h
   Amouzegar Z, 2015, CERAM INT, V41, P1743, DOI 10.1016/j.ceramint.2014.09.119
   Chen DM, 2014, DALTON T, V43, P13105, DOI 10.1039/c4dt01347f
   Chen F, 2019, ANGEW CHEM INT EDIT, V58, P10061, DOI 10.1002/anie.201901361
   Chen F, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201804284
   Fujishima A, 2007, INT J HYDROGEN ENERG, V32, P2664, DOI 10.1016/j.ijhydene.2006.09.009
   Ge L, 2011, APPL CATAL B-ENVIRON, V108, P100, DOI 10.1016/j.apcatb.2011.08.014
   Hamrouni A, 2015, J PHOTOCH PHOTOBIO A, V309, P47, DOI 10.1016/j.jphotochem.2015.05.001
   He GL, 2015, APPL SURF SCI, V351, P474, DOI 10.1016/j.apsusc.2015.05.159
   Huang BR, 2013, SURF COAT TECH, V231, P289, DOI 10.1016/j.surfcoat.2012.05.006
   Huang GL, 2007, MAT SCI ENG B-SOLID, V139, P201, DOI 10.1016/j.mseb.2007.02.009
   Huang HW, 2017, ANGEW CHEM INT EDIT, V56, P11860, DOI 10.1002/anie.201706549
   Jiang XW, 2016, CERAM INT, V42, P15160, DOI 10.1016/j.ceramint.2016.05.098
   Jin LM, 2019, ADV MATER, V31, DOI 10.1002/adma.201807079
   Kubacka A, 2012, CHEM REV, V112, P1555, DOI 10.1021/cr100454n
   Lavat AE, 2008, CERAM INT, V34, P2147, DOI 10.1016/j.ceramint.2007.09.003
   Li MT, 2019, CERAM INT, V45, P10746, DOI 10.1016/j.ceramint.2019.02.148
   Lowry GV, 2016, ENVIRON SCI-NANO, V3, P953, DOI 10.1039/c6en00136j
   Nakata K, 2012, J PHOTOCH PHOTOBIO C, V13, P169, DOI 10.1016/j.jphotochemrev.2012.06.001
   OI T, 1980, APPL PHYS LETT, V36, P278, DOI 10.1063/1.91452
   Ojha DP, 2019, COMPOS PART B-ENG, V160, P277, DOI 10.1016/j.compositesb.2018.10.039
   Ojha DP, 2018, CHEM PHYS LETT, V712, P83, DOI 10.1016/j.cplett.2018.09.070
   Pant B, 2016, J ALLOY COMPD, V671, P51, DOI 10.1016/j.jallcom.2016.02.067
   Pietruszka R, 2014, MAT SCI SEMICON PROC, V25, P190, DOI 10.1016/j.mssp.2013.11.026
   Rao AN, 2009, J HAZARD MATER, V166, P1357, DOI 10.1016/j.jhazmat.2008.12.051
   Shi R, 2010, APPL CATAL B-ENVIRON, V100, P173, DOI 10.1016/j.apcatb.2010.07.027
   Su YG, 2012, J PHYS CHEM C, V116, P18508, DOI 10.1021/jp3052505
   Thomas A, 2015, CHEMSUSCHEM, V8, P1652, DOI 10.1002/cssc.201500383
   Wang H, 2019, APPL CATAL B-ENVIRON, V245, P290, DOI 10.1016/j.apcatb.2018.12.051
   Wen FS, 2002, MATER LETT, V55, P152, DOI 10.1016/S0167-577X(01)00638-3
   Wu Z, 2017, ADV SCI, V4, DOI 10.1002/advs.201600382
   Yang ZM, 2014, J MATER CHEM A, V2, P1750, DOI 10.1039/c3ta14286h
   Yu CL, 2009, MATER SCI ENG B-ADV, V164, P16, DOI 10.1016/j.mseb.2009.06.008
   Yu HB, 2019, SMALL, V15, DOI 10.1002/smll.201901008
   Zhang J., 2018, J PHOTOCHEM PHOTOB C
NR 35
TC 1
Z9 1
U1 23
U2 23
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115338
DI 10.1016/j.ces.2019.115338
PG 7
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600029
DA 2020-05-12
ER

PT J
AU Paul, D
   Singh, S
   Mishra, S
AF Paul, Deepraj
   Singh, Suneet
   Mishra, Surendra
TI Stability analysis of parallel channels in flow boiling system: Flow
   maldistribution and density wave oscillations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Stability; Flow maldistribution; Density wave oscillations; Hopf
   bifurcation; Symmetry-break
ID 2-PHASE FLOW; NONLINEAR DYNAMICS; INSTABILITIES; PIPES
AB In a flow boiling thermal-hydraulic system, Density wave oscillations (DWO) and Flow maldistribution (FMD) are two important instability phenomena. These instabilities can lead to undesirable consequences of system operation. Thermal-hydraulic system with an odd number of channels behave differently as compared to an even number of channels. Following FMD for a two channel system, it leads to a new steady state operating condition. Here, one channel receives higher flowrate and another channel receives lower flowrate for a forced flow system. It may be possible that the new operating point is in a DWO zone. Post FMD, the individual flowrate of the channel starts to oscillate. It shall be noted that under constant mass flowrate condition, such local behaviour in the channels will be difficult to detect. For a twin-channel forced flow system, DWO which may be observed with/without FMD is related to out-of-phase oscillations only. It is thus interesting to study the interaction of DWO and FMD phenomena for a tri-channel flow boiling system. Symmetry breaking transition in the context of excursion instability (i.e., Ledinegg instability) is analyzed in this work. Here, a two and three channel system is used to analyze the two phenomena, FMD and DWO. The difference between the two and three channel flow boiling system is brought out in this work. Unlike two channel system, it is observed that a region in three channel system exists where both symmetrical and asymmetrical equilibrium solutions are unstable. Further, post FMD the solution starts to oscillate but the total system inflow and outflow remains constant. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Paul, Deepraj; Singh, Suneet] Indian Inst Technol, Dept Energy Sci & Engn, Mumbai, Maharashtra, India.
   [Paul, Deepraj; Mishra, Surendra] Nucl Power Corp India Ltd, Mumbai, Maharashtra, India.
RP Singh, S (reprint author), Indian Inst Technol, Dept Energy Sci & Engn, Mumbai, Maharashtra, India.
EM suneet.singh@iitb.ac.in
CR Baikin M, 2011, INT J HEAT MASS TRAN, V54, P4448, DOI 10.1016/j.ijheatmasstransfer.2011.04.034
   BOURE JA, 1973, NUCL ENG DES, V25, P165, DOI 10.1016/0029-5493(73)90043-5
   Ruspini LC, 2014, INT J HEAT MASS TRAN, V71, P521, DOI 10.1016/j.ijheatmasstransfer.2013.12.047
   CLAUSSE A, 1990, HEAT TRANSFER 1990, VOLS 1-7, P3
   Dhooge A, 2003, ACM T MATH SOFTWARE, V29, P141, DOI 10.1145/779359.779362
   Dorao CA, 2015, CHEM ENG SCI, V134, P767, DOI 10.1016/j.ces.2015.03.040
   Goswami N, 2014, CHEM ENG SCI, V110, P119, DOI 10.1016/j.ces.2014.01.020
   Heinrich M, 2010, NEW J PHYS, V12, DOI 10.1088/1367-2630/12/11/113030
   Kakac S, 2008, INT J HEAT MASS TRAN, V51, P399, DOI 10.1016/j.ijheatmasstransfer.2007.09.026
   Kashyap AM, 2018, CHEM ENG J, V337, P642, DOI 10.1016/j.cej.2017.12.128
   Koji A., 1971, B JSME, V14, P837
   Kuznetsov Y.A., 2004, APPL MATH SCI
   Lee JD, 2005, NUCL ENG DES, V235, P2358, DOI 10.1016/j.nucengdes.2005.05.031
   Lee JD, 1999, NUCL ENG DES, V192, P31, DOI 10.1016/S0029-5493(99)00085-0
   Lee JD, 2019, INT J HEAT MASS TRAN, V129, P903, DOI 10.1016/j.ijheatmasstransfer.2018.10.006
   Lee JD, 2016, ANN NUCL ENERGY, V94, P814, DOI 10.1016/j.anucene.2016.04.044
   Lin YN, 1998, NUCL ENG DES, V179, P31, DOI 10.1016/S0029-5493(97)00242-2
   Minzer U, 2004, INT J MULTIPHAS FLOW, V30, P763, DOI 10.1016/j.ijmultiphaseflow.2004.04.006
   Minzer U, 2006, CHEM ENG SCI, V61, P7249, DOI 10.1016/j.ces.2006.08.026
   Mishra AM, 2016, APPL THERM ENG, V98, P1189, DOI 10.1016/j.applthermaleng.2015.11.118
   Pandey V, 2017, CHEM ENG SCI, V168, P204, DOI 10.1016/j.ces.2017.04.041
   Paruya S, 2016, CHEM ENG SCI, V140, P123, DOI 10.1016/j.ces.2015.09.037
   Paul S, 2014, INT J HEAT MASS TRAN, V69, P151, DOI 10.1016/j.ijheatmasstransfer.2013.10.012
   Rahman ME, 2018, CHEM ENG SCI, V192, P176, DOI 10.1016/j.ces.2018.07.013
   RIZWANUDDIN, 1986, NUCL ENG DES, V93, P1, DOI 10.1016/0029-5493(86)90190-1
   SAHA P, 1976, J HEAT TRANS-T ASME, V98, P616, DOI 10.1115/1.3450609
   Strogatz S. H., 2000, NONLINEAR DYNAMICS C
   Taitel Y, 2011, INT J MULTIPHAS FLOW, V37, P469, DOI 10.1016/j.ijmultiphaseflow.2011.01.002
   Van Oevelen T, 2017, INT J HEAT MASS TRAN, V107, P557, DOI 10.1016/j.ijheatmasstransfer.2016.11.050
   Vandewalle LA, 2019, CHEM ENG SCI, V199, P635, DOI 10.1016/j.ces.2018.08.053
   Xia GL, 2016, NUCL ENG DES, V305, P604, DOI 10.1016/j.nucengdes.2016.04.016
NR 31
TC 0
Z9 0
U1 7
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115316
DI 10.1016/j.ces.2019.115316
PG 12
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600012
DA 2020-05-12
ER

PT J
AU Pio, G
   Salzano, E
AF Pio, Gianmaria
   Salzano, Ernesto
TI Implementation of gas-phase kinetic model for the optimization of the
   ethylene oxide production
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Ethylene oxide; Partial oxidation; Runaway; Low temperature; Process
   intensification
ID LAMINAR BURNING VELOCITY; SELECTIVE OXIDATION; RUNAWAY DETECTION;
   LOW-TEMPERATURE; FLAMMABILITY; MIXTURES; REACTORS; EPOXIDATION;
   PARAMETERS; CRITERION
AB The direct epoxidation of light olefins is a key process of the chemical industry. However, several concerns regarding industrial and safety aspects, such as the occurrence of runaway reactions and the relevance of side reactions reducing process selectivity, are still under investigation.
   To this aim, a reactor operation diagram was obtained under process relevant conditions, allowing for the identification of runaway, hot spots and pseudo adiabatic operation regions by using several criteria and kinetic models. Indeed, catalytic only or complete (catalytic + non-catalytic) kinetic mechanisms were adopted to this aim. The selection of different runaway criteria was found to be negligible on the region boundaries. On the contrary, significant discrepancies were observed for hot spot region boundaries and between catalytic and complete models.
   An in-depth analysis, based on thermodynamic and kinetic models, was performed to individuate the optimized operative conditions. Flammability limits were estimated by applying the limiting laminar burning velocity theory, in case of different inert composition and initial temperature.
   The results indicate that a decrease in the operative temperature has the potential to either reduce the capital costs or increase process safety. Furthermore, the proposed approach can be intended as a supporting procedure for the selection of process alternatives and reactor design. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Pio, Gianmaria; Salzano, Ernesto] Univ Bologna, Dipartimento Ingn Civile Chim Ambientale & Mat, Via Terracini 28, I-40131 Bologna, Italy.
RP Salzano, E (reprint author), Univ Bologna, Dipartimento Ingn Civile Chim Ambientale & Mat, Via Terracini 28, I-40131 Bologna, Italy.
EM ernesto.salzano@unibo.it
RI ; Salzano, Ernesto/A-2854-2008
OI Pio, Gianmaria/0000-0002-0770-1710; Salzano, Ernesto/0000-0002-3238-2491
CR Bertolino A, 2019, COMBUST FLAME, V207, P120, DOI 10.1016/j.combustflame.2019.05.036
   Bolk JW, 1999, AICHE J, V45, P2419, DOI 10.1002/aic.690451115
   Chase Jr. M.W., 1998, J PHYS CHEM REF DATA, V9
   Chen CC, 2018, CHEM ENG SCI, V185, P84, DOI 10.1016/j.ces.2018.04.011
   Copelli S, 2014, J LOSS PREVENT PROC, V28, P92, DOI 10.1016/j.jlp.2013.05.004
   Ghanta M, 2013, IND ENG CHEM RES, V52, P18, DOI 10.1021/ie301601y
   Goodwin D. G., 2003, OPEN SOURCE EXTENSIB
   Groppi G, 2001, CATAL TODAY, V69, P63, DOI 10.1016/S0920-5861(01)00356-X
   Hertzberg M., 1984, THEORY FLAMMABILITY
   Khan FI, 2004, J HAZARD MATER, V108, P147, DOI 10.1016/j.jhazmat.2004.01.011
   Lei Y, 2010, SCIENCE, V328, P224, DOI 10.1126/science.1185200
   Liu JY, 2018, POWDER TECHNOL, V329, P19, DOI 10.1016/j.powtec.2018.01.066
   Liu JR, 2017, THERMOCHIM ACTA, V652, P85, DOI 10.1016/j.tca.2017.03.008
   Mc Guire White, 2008, LIQUEFIED GAS HANDLI, P9
   MORBIDELLI M, 1988, CHEM ENG SCI, V43, P91, DOI 10.1016/0009-2509(88)87129-X
   Nonaka HOB, 2016, FUEL, V182, P382, DOI 10.1016/j.fuel.2016.05.098
   Oliveira APS, 2017, MOL CATAL, V436, P29, DOI 10.1016/j.mcat.2017.04.007
   Ozbek MO, 2013, CATAL LETT, V143, P131, DOI 10.1007/s10562-012-0957-3
   Pekalski AA, 2002, J HAZARD MATER, V93, P93, DOI 10.1016/S0304-3894(02)00041-9
   Peschel A, 2011, CHEM ENG SCI, V66, P6453, DOI 10.1016/j.ces.2011.08.054
   Pio G, 2019, COMBUST SCI TECHNOL, V191, P1541, DOI 10.1080/00102202.2018.1564746
   Pio G, 2019, FUEL, V254, DOI 10.1016/j.fuel.2019.05.150
   Pio G, 2018, J LOSS PREVENT PROC, V56, P424, DOI 10.1016/j.jlp.2018.10.002
   Pio G, 2018, PROCESS SAF ENVIRON, V119, P131, DOI 10.1016/j.psep.2018.07.024
   Pio G, 2019, J HAZARD MATER, V362, P224, DOI 10.1016/j.jhazmat.2018.09.018
   Pio G, 2018, ENERG FUEL, V32, P8830, DOI 10.1021/acs.energyfuels.8b01796
   Pio G, 2018, IND ENG CHEM RES, V57, P7130, DOI 10.1021/acs.iecr.8b01377
   Rebsdat S, 2012, ULLMANNS ENCY IND CH, DOI [10.1002/14356007.a10, DOI 10.1002/14356007.A10]
   Salmi T, 2013, CHEM ENG SCI, V87, P306, DOI 10.1016/j.ces.2012.10.016
   Strozzi F, 1999, AICHE J, V45, P2429, DOI 10.1002/aic.690451116
   Varma A., 1999, CAMBRIDGE SERIES CHE, DOI [10.1017/CBO9780511721779, DOI 10.1017/CBO9780511721779]
   WESTERTERP KR, 1984, CHEM ENG SCI, V39, P245, DOI 10.1016/0009-2509(84)80024-X
   Zabetakis MG, 1958, S INT COMBUST, V7, P484, DOI DOI 10.1016/S0082-0784(58)80082-X
NR 33
TC 0
Z9 0
U1 12
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115331
DI 10.1016/j.ces.2019.115331
PG 7
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600022
DA 2020-05-12
ER

PT J
AU de Menezes, DES
   Pessoa, PD
   Fuentes, MDR
AF Sanches de Menezes, Davi Eber
   Pessoa Filho, Pedro de Alcantara
   Robustillo Fuentes, Maria Dolores
TI Use of 1-butyl-3-methylimidazolium-based ionic liquids as methane
   hydrate inhibitors at high pressure conditions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Ionic liquids; Methane; Hydrates; Inhibitors; High-pressure calorimetry
ID UNSTIRRED GAS/LIQUID SYSTEM; DUAL FUNCTION INHIBITORS; PHASE-EQUILIBRIA;
   FLOW ASSURANCE; MICELLE FORMATION; CHLORIDE; WATER; CO2; BROMIDE;
   TETRAFLUOROBORATE
AB The performance of 1-Butyl-3-methylimidazolium chloride ([BMIM][Cl]) and 1-Butyl-3-methyl-imidazolium bromide ([BMIM][Br]) as methane hydrate inhibitors is evaluated in this work. New hydrate dissociation data were obtained through high-pressure calorimetry for aqueous solutions with inhibitor mole fractions of 1.0%, 5.0%, 10.0%, and 15.0% and pressures from 9.6 to 100 MPa. Challenging situations from the experimental point of view were also explored. These ionic liquids are known to be both kinetic and thermodynamic inhibitors, but they promote hydrate growth at mole fractions of 1% and 5% in the pressure range studied. The effectiveness of these ionic liquids as thermodynamic inhibitors at high pressures is compared to that of methanol, a commercial inhibitor commonly used in the oil and gas industry. [BMIM][Cl] is more effective than [BMIM][Br] and methanol, considering equimolar aqueous solutions, even though methanol is more effective for solutions with the same mass fraction. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sanches de Menezes, Davi Eber; Pessoa Filho, Pedro de Alcantara; Robustillo Fuentes, Maria Dolores] Univ Sao Paulo, Engn Sch, Dept Chem Engn, Av Prof Luciano Gualberto 380, BR-05508010 Sao Paulo, SP, Brazil.
RP Fuentes, MDR (reprint author), Univ Sao Paulo, Engn Sch, Dept Chem Engn, Av Prof Luciano Gualberto 380, BR-05508010 Sao Paulo, SP, Brazil.
EM mariadolores.robustillo@usp.br
OI Pessoa Filho, Pedro de Alcantara/0000-0003-4315-7238
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2014/02140-7, 2014/25740-0, 2015/23148-9, 2017/01351-2]; CAPESCAPES
   [001]; CNPqNational Council for Scientific and Technological Development
   (CNPq) [306184/2017-6]
FX The authors thank FAPESP (processes 2014/02140-7, 2014/25740-0,
   2015/23148-9, 2017/01351-2), CAPES (finance code 001) and CNPq (process
   306184/2017-6) for financial support. The help of Dr. Larissa C. B.
   Almeida Bessa is gratefully acknowledged.
CR Altamash T, 2018, J NAT GAS SCI ENG, V58, P59, DOI 10.1016/j.jngse.2018.08.002
   Amtawong J, 2016, J PHYS CHEM LETT, V7, P2346, DOI 10.1021/acs.jpclett.6b00982
   Angell CA, 2007, ACCOUNTS CHEM RES, V40, P1228, DOI 10.1021/ar7001842
   Bhattacharjee G, 2017, IND ENG CHEM RES, V56, P3687, DOI 10.1021/acs.iecr.7b00328
   Blesic M, 2007, GREEN CHEM, V9, P481, DOI 10.1039/b615406a
   Bobev S, 2004, AM MINERAL, V89, P1208
   Cha MJ, 2016, FLUID PHASE EQUILIBR, V413, P2, DOI 10.1016/j.fluid.2015.08.010
   Cha M, 2013, CHEM ENG SCI, V99, P184, DOI 10.1016/j.ces.2013.05.060
   Chen Q, 2008, J NAT GAS CHEM, V17, P264, DOI 10.1016/S1003-9953(08)60061-4
   Chong ZR, 2016, APPL ENERG, V162, P1633, DOI 10.1016/j.apenergy.2014.12.061
   Dalmazzone D., 2017, GAS HYDRATES FUNDAME
   Dalmazzone D, 2009, CHEM ENG SCI, V64, P2020, DOI 10.1016/j.ces.2009.01.028
   Daraboina N, 2013, ENERG FUEL, V27, P5779, DOI 10.1021/ef401042h
   Deschamps J, 2010, J CHEM ENG DATA, V55, P3395, DOI 10.1021/je100146b
   Di Profio P, 2005, CHEM ENG SCI, V60, P4141, DOI 10.1016/j.ces.2005.02.051
   dos Santos LC, 2015, IND ENG CHEM RES, V54, P6812, DOI 10.1021/acs.iecr.5b01410
   Dunaeva AN, 2010, SOLAR SYST RES+, V44, P202, DOI 10.1134/S0038094610030044
   Dupont J, 2004, J BRAZIL CHEM SOC, V15, P341, DOI 10.1590/S0103-50532004000300002
   DYADIN YA, 1987, J STRUCT CHEM+, V28, P394, DOI 10.1007/BF00753818
   Dyadin YA, 1996, NGH '96 - 2ND INTERNATIONAL CONFERENCE ON NATURAL GAS HYDRATES, PROCEEDINGS, P67
   Farhadian A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46274-w
   Gupta A, 2008, CHEM ENG SCI, V63, P5848, DOI 10.1016/j.ces.2008.09.002
   Haghighi H, 2009, FLUID PHASE EQUILIBR, V276, P24, DOI 10.1016/j.fluid.2008.10.006
   Hu Y, 2017, J CHEM ENG DATA, V62, P1910, DOI 10.1021/acs.jced.7b00292
   Jager MD, 2001, FLUID PHASE EQUILIBR, V185, P89, DOI 10.1016/S0378-3812(01)00459-9
   JAGER MD, 2001, [No title captured]
   Jeffrey G. A., 1984, J INCLUSION PHENOM, V1, P211, DOI DOI 10.1007/BF00656757)
   KE M., 2004, SPE87563MS, DOI [10.2118/87563-MS, DOI 10.2118/87563-MS]
   KE W, 2013, [No title captured], V7, P432
   Kelland MA, 2006, ENERG FUEL, V20, P825, DOI 10.1021/ef050427x
   Kim KS, 2011, CHEM COMMUN, V47, P6341, DOI 10.1039/c0cc05676f
   Kinnari K, 2015, J CHEM ENG DATA, V60, P437, DOI 10.1021/je500783u
   Kobori T, 2015, CRYST GROWTH DES, V15, P3862, DOI 10.1021/acs.cgd.5b00484
   Koh CA, 2002, FLUID PHASE EQUILIBR, V194, P143, DOI 10.1016/S0378-3812(01)00660-4
   Koh CA, 2011, ANNU REV CHEM BIOMOL, V2, P237, DOI 10.1146/annurev-chembioeng-061010-114152
   Kouakou AC, 2013, FUEL, V109, P297, DOI 10.1016/j.fuel.2013.01.036
   Kumar A, 2015, IND ENG CHEM RES, V54, P12217, DOI 10.1021/acs.iecr.5b03476
   Le Parlouer P, 2004, J THERM ANAL CALORIM, V78, P165, DOI 10.1023/B:JTAN.0000042164.19602.7e
   Lee W, 2016, ENERG FUEL, V30, P3879, DOI 10.1021/acs.energyfuels.6b00271
   Li SF, 2010, J CHEM ENG DATA, V55, P3212, DOI 10.1021/je100059h
   McLaurin G, 2014, ANGEW CHEM INT EDIT, V53, P10429, DOI 10.1002/anie.201403638
   Miskolczy Z, 2004, CHEM PHYS LETT, V400, P296, DOI 10.1016/j.cplett.2004.10.127
   Mohammadi AH, 2005, AICHE J, V51, P2825, DOI 10.1002/aic.10526
   Mohammadi AH, 2010, IND ENG CHEM RES, V49, P925, DOI 10.1021/ie901357m
   Nakamura T, 2003, CHEM ENG SCI, V58, P269, DOI 10.1016/S0009-2509(02)00518-3
   Nakano S, 1999, J CHEM ENG DATA, V44, P254, DOI 10.1021/je980152y
   Nishikawa K, 2007, J PHYS CHEM B, V111, P4894, DOI 10.1021/jp0671852
   Okutani K, 2008, CHEM ENG SCI, V63, P183, DOI 10.1016/j.ces.2007.09.012
   Qureshi MF, 2016, ENERG FUEL, V30, P3541, DOI 10.1021/acs.energyfuels.5b03001
   Rae PJ, 2004, POLYMER, V45, P7615, DOI 10.1016/j.polymer.2004.08.064
   Richard AR, 2013, CHEM ENG SCI, V87, P270, DOI 10.1016/j.ces.2012.10.021
   RIGBY HA, 1949, NATURE, V164, P583, DOI 10.1038/164583a0
   Rustandi A, 2012, MAKARA J TECHNOL, V16, P57
   Sabil KM, 2015, J CHEM THERMODYN, V84, P7, DOI 10.1016/j.jct.2014.12.017
   Sahle CJ, 2013, P NATL ACAD SCI USA, V110, P6301, DOI 10.1073/pnas.1220301110
   Sami NA, 2013, INT J SCI ENG RES, V4
   de Menezes DES, 2019, CHEM ENG SCI, V208, DOI 10.1016/j.ces.2019.08.007
   de Menezes DES, 2018, BRAZ J CHEM ENG, V35, P403, DOI 10.1590/0104-6632.20180352s20160329
   Sanz E, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.255701
   Shen XD, 2016, J MOL LIQ, V223, P672, DOI 10.1016/j.molliq.2016.08.111
   Shin K, 2013, P NATL ACAD SCI USA, V110, P8437, DOI 10.1073/pnas.1302812110
   Sloan ED, 2011, NATURAL GAS HYDRATES IN FLOW ASSURANCE, P1
   Sloan ED, 2008, CHEM IND-SER, V119, P1
   Sowa B, 2015, ENERG FUEL, V29, P6259, DOI 10.1021/acs.energyfuels.5b01391
   Sowa B, 2014, ENERG FUEL, V28, P6877, DOI 10.1021/ef501701y
   Sun Z., 2004, J NAT GAS CHEM, V13, P107
   Sun ZG, 2003, ENERG CONVERS MANAGE, V44, P2733, DOI 10.1016/S0196-8904(03)00048-7
   Tariq M, 2016, RSC ADV, V6, P23827, DOI 10.1039/c6ra00170j
   Tariq M, 2014, IND ENG CHEM RES, V53, P17855, DOI 10.1021/ie503559k
   VANDERWAALS JH, 1959, ADV CHEM PHYS, V2, P1
   Vorotyntsev VM, 2011, RUSS CHEM REV+, V80, P971, DOI 10.1070/RC2011v080n10ABEH004176
   Wallqvist A., 1992, J CHEM PHYS, V96
   Wang LJ, 2013, ADV MATER RES-SWITZ, V616-618, P1202, DOI 10.4028/www.scientific.net/AMR.616-618.1202
   Watanabe K, 2005, CHEM ENG SCI, V60, P4846, DOI 10.1016/j.ces.2005.03.043
   Xiao CW, 2010, CHEM ENG SCI, V65, P3080, DOI 10.1016/j.ces.2010.01.033
   Xiao CW, 2009, CHEM ENG SCI, V64, P1522, DOI 10.1016/j.ces.2008.12.031
   Xu CG, 2013, ENERGY, V59, P719, DOI 10.1016/j.energy.2013.07.056
   Yang S, 2000, THESIS
   Zare M, 2015, J MOL LIQ, V204, P236, DOI 10.1016/j.molliq.2015.01.034
   Zare M, 2013, FLUID PHASE EQUILIBR, V341, P61, DOI 10.1016/j.fluid.2012.12.024
   Zhang JS, 2007, J COLLOID INTERF SCI, V315, P313, DOI 10.1016/j.jcis.2007.06.049
   Zhong Y, 2000, CHEM ENG SCI, V55, P4175, DOI 10.1016/S0009-2509(00)00072-5
NR 82
TC 0
Z9 0
U1 13
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115323
DI 10.1016/j.ces.2019.115323
PG 11
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600015
DA 2020-05-12
ER

PT J
AU Shi, XQ
   Chen, Y
   Zhang, X
   Long, XW
   Qian, JS
AF Shi, Xueqiang
   Chen, Yuan
   Zhang, Xuan
   Long, Xuwei
   Qian, Jieshu
TI Biomass rhamnolipid modified poly(vinylidene fluoride) membrane with
   significantly improved surface hydrophilicity and enhanced antifouling
   performance
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Poly(vinylidene fluoride); Rhamnolipid; Biomass; Surface grafting;
   Hydrophilicity
ID GRAFTED PVDF MEMBRANE; ULTRAFILTRATION MEMBRANES; ZWITTERIONIC POLYMER;
   FERMENTATION BROTH; WATER; BIOSURFACTANT; PURIFICATION; FABRICATION;
   STRATEGY; PROGRESS
AB Membrane fouling could result in severe decline of performance and increase of operation cost. Therefore, it is of great practical significance to enhance the antifouling property through improving the hydrophilicity of the membrane surface. In this work, we report the first attempt of chemically grafting the industrialized biosurfactant rhamnolipid onto the surface of poly(vinylidene fluoride) (PVDF) membranes. Results showed that the hydrophilicity of the PVDF membrane was greatly improved through surface grafting. In the subsequent filtration experiments toward both BSA solution and surfactin fermentation broth, the rhamnolipid-modified membranes exhibited much better antifouling performances. Further analysis showed that the grafting of rhamnolipid improved the antifouling properties mainly through reducing the total fouling and especially the irreversible fouling. We reckon our work as an important contribution to the design of membrane with enhanced antifouling performance. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shi, Xueqiang; Chen, Yuan; Zhang, Xuan; Long, Xuwei; Qian, Jieshu] Nanjing Univ Sci & Technol, Sch Environm & Biol Engn, Key Lab New Membrane Mat, Minist Ind & Informat Technol, Nanjing 210094, Jiangsu, Peoples R China.
RP Long, XW; Qian, JS (reprint author), Nanjing Univ Sci & Technol, Sch Environm & Biol Engn, Key Lab New Membrane Mat, Minist Ind & Informat Technol, Nanjing 210094, Jiangsu, Peoples R China.
EM chewayron@njust.edu.cn; qianjieshu@njust.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51573079]; Fundamental Research Funds for the
   Central UniversitiesFundamental Research Funds for the Central
   Universities [30918012201]; Nanjing University of Science and
   TechnologyNanjing University of Science & Technology
FX The authors thank the financial support from National Natural Science
   Foundation of China (51573079), Fundamental Research Funds for the
   Central Universities (30918012201) from Nanjing University of Science
   and Technology.
CR Aghajani M, 2018, ENG LIFE SCI, V18, P272, DOI 10.1002/elsc.201700070
   Ameduri B, 2009, CHEM REV, V109, P6632, DOI 10.1021/cr800187m
   Bhattachatjee S, 2016, ENVIRON SCI TECHNOL, V50, P1812, DOI 10.1021/acs.est.5b05074
   Chang Y, 2009, J MEMBRANE SCI, V345, P160, DOI 10.1016/j.memsci.2009.08.039
   Chen HL, 2007, J MEMBRANE SCI, V299, P114, DOI 10.1016/j.memsci.2007.04.031
   Chen HL, 2008, J MEMBRANE SCI, V325, P599, DOI 10.1016/j.memsci.2008.08.017
   Chen L, 2018, CHEM ENG J, V347, P695, DOI 10.1016/j.cej.2018.04.086
   Chiang YC, 2009, J MEMBRANE SCI, V339, P151, DOI 10.1016/j.memsci.2009.04.044
   Cui JY, 2019, SEP PURIF TECHNOL, V209, P434, DOI 10.1016/j.seppur.2018.03.054
   Cui Z, 2014, PROG POLYM SCI, V39, P164, DOI 10.1016/j.progpolymsci.2013.07.008
   Davenport DM, 2017, SEP PURIF TECHNOL, V189, P389, DOI 10.1016/j.seppur.2017.08.034
   Fu WG, 2019, J MEMBRANE SCI, V572, P453, DOI 10.1016/j.memsci.2018.11.022
   Hinman SS, 2017, ACS APPL MATER INTER, V9, P1029, DOI 10.1021/acsami.6b11556
   Huang X, 2015, CHEM ENG J, V273, P421, DOI 10.1016/j.cej.2015.03.086
   Isa MHM, 2007, J MEMBRANE SCI, V296, P51, DOI 10.1016/j.memsci.2007.03.023
   Janshoff A, 2015, BBA-MOL CELL RES, V1853, P2977, DOI 10.1016/j.bbamcr.2015.05.029
   Kang GD, 2014, J MEMBRANE SCI, V463, P145, DOI 10.1016/j.memsci.2014.03.055
   Kim LH, 2015, BIOFOULING, V31, P211, DOI 10.1080/08927014.2015.1022724
   Kim Y, 2012, CHEM COMMUN, V48, P693, DOI 10.1039/c1cc16217a
   Leitermann Frank, 2008, J Biol Eng, V2, P13, DOI 10.1186/1754-1611-2-13
   Li MZ, 2012, J MEMBRANE SCI, V405, P141, DOI 10.1016/j.memsci.2012.02.062
   Li RJ, 2018, J COLLOID INTERF SCI, V531, P493, DOI 10.1016/j.jcis.2018.07.090
   Liang S, 2013, ACS APPL MATER INTER, V5, P6694, DOI 10.1021/am401462e
   Liu F, 2011, J MEMBRANE SCI, V375, P1, DOI 10.1016/j.memsci.2011.03.014
   Liu GS, 2018, BIOTECHNOL BIOENG, V115, P796, DOI 10.1002/bit.26517
   Liu J, 2013, IND ENG CHEM RES, V52, P18392, DOI 10.1021/ie403456n
   Liu Y, 2013, DESALINATION, V316, P127, DOI 10.1016/j.desal.2013.02.004
   Long XW, 2014, J MEMBRANE SCI, V457, P113, DOI 10.1016/j.memsci.2014.01.044
   Masuelli MA, 2012, J MEMBRANE SCI, V389, P91, DOI 10.1016/j.memsci.2011.10.019
   McKeating KS, 2019, ACS SENSORS, V4, P1774, DOI 10.1021/acssensors.9b00257
   Ozdemir G, 2004, COLLOID SURFACE B, V39, P1, DOI 10.1016/j.colsurfb.2004.08.006
   Pendergast MM, 2011, ENERG ENVIRON SCI, V4, P1946, DOI 10.1039/c0ee00541j
   Qin AW, 2015, ACS APPL MATER INTER, V7, P8427, DOI 10.1021/acsami.5b00978
   Rajati H, 2018, CHEM ENG SCI, V185, P92, DOI 10.1016/j.ces.2018.04.006
   Rana D, 2010, CHEM REV, V110, P2448, DOI 10.1021/cr800208y
   Rana D, 2011, J MEMBRANE SCI, V367, P110, DOI 10.1016/j.memsci.2010.10.050
   Reis RS, 2011, BIORESOURCE TECHNOL, V102, P6377, DOI 10.1016/j.biortech.2011.03.074
   Shen LG, 2018, SEP PURIF TECHNOL, V207, P83, DOI 10.1016/j.seppur.2018.06.044
   Sun HY, 2019, CHEM ENG SCI, V209, DOI 10.1016/j.ces.2019.115186
   Sun M, 2018, ENVIRON SCI TECHNOL, V52, P8674, DOI 10.1021/acs.est.8b01916
   Venault A, 2016, CHEM ENG SCI, V142, P97, DOI 10.1016/j.ces.2015.11.041
   Wang KY, 2011, CHEM ENG SCI, V66, P2421, DOI 10.1016/j.ces.2011.03.001
   Xu ZH, 2005, J MEMBRANE SCI, V255, P125, DOI 10.1016/j.memsci.2005.02.001
   Zdziennicka A, 2018, INT J ADHES ADHES, V84, P275, DOI 10.1016/j.ijadhadh.2018.04.005
   Zhang PY, 2013, CHEM ENG SCI, V97, P296, DOI 10.1016/j.ces.2013.03.058
   Zhao XZ, 2015, ACS APPL MATER INTER, V7, P17947, DOI 10.1021/acsami.5b04648
   Zhou Q, 2014, DESALINATION, V337, P6, DOI 10.1016/j.desal.2014.01.006
   Zhu YZ, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201804121
   Zhu YZ, 2013, J MATER CHEM A, V1, P5758, DOI 10.1039/c3ta01598j
NR 49
TC 0
Z9 0
U1 20
U2 20
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115330
DI 10.1016/j.ces.2019.115330
PG 10
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600021
DA 2020-05-12
ER

PT J
AU Shrestha, S
   Kuang, SB
   Yu, AB
   Zhou, ZY
AF Shrestha, S.
   Kuang, S. B.
   Yu, A. B.
   Zhou, Z. Y.
TI Effect of van der Waals force on bubble dynamics in bubbling fluidized
   beds of ellipsoidal particles
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Non-spherical particles; van der Waals force; Bubble dynamics; CFD-DEM
ID ELEMENT METHOD SIMULATION; GROUP-A PARTICLES; GAS-SOLID FLOW;
   NONSPHERICAL PARTICLES; INTERPARTICLE FORCES; NUMERICAL-SIMULATION;
   PARTICULATE SYSTEMS; FINE POWDERS; PART I; BEHAVIOR
AB This paper presents a numerical analysis of the combined effect of cohesive van der Waals force and particle shape on bubble dynamics in gas fluidization. The van der Waals force is incorporated into the CFDDEM model and the magnitude varies from 0 to 20 times Hamaker constant (H-a = 2.1 x 10 (-21) J), representing non-cohesive to highly cohesive particles. Particles with aspect ratios at 0.5 (oblate), I (spherical) and 2 (prolate) are employed to represent disc-like, spherical and rod-like particles, respectively. The results show that under the influence of cohesive force, features such as bubble splitting and coalescence are affected significantly by aspect ratios of ellipsoidal particles. With the increase of Hamaker constant, bubble size and rising velocity decrease, and the bubble shape becomes irregular and vertically oblong. Moreover, the increase of van der Waals force leads to the transformation to non-bubbling fluidization for ellipsoids, but channelling occurs for spheres. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shrestha, S.; Kuang, S. B.; Yu, A. B.; Zhou, Z. Y.] Monash Univ, Dept Chem Engn, ARC Res Hub Computat Particle Technol, Clayton, Vic 3800, Australia.
RP Zhou, ZY (reprint author), Monash Univ, Dept Chem Engn, ARC Res Hub Computat Particle Technol, Clayton, Vic 3800, Australia.
EM zongyan.zhou@monash.edu
RI Yu, Aibing/A-6054-2008; Kuang, Shibo/H-4935-2013
OI Yu, Aibing/0000-0002-5139-0657; Kuang, Shibo/0000-0002-2969-9420;
   Shrestha, Siddhartha/0000-0002-9445-2854; Zhou,
   Zongyan/0000-0002-0480-7173
FU Australian Research Council Industrial Transformation Research Hubs
   SchemeAustralian Research Council [IH140100035]; Australian
   GovernmentAustralian Government
FX The authors are grateful for the financial support from Australian
   Research Council Industrial Transformation Research Hubs Scheme (Project
   Number IH140100035). This research was under-taken with the assistance
   of resources from the National Computational Infrastructure (NCI), which
   is supported by the Australian Government.
CR Andreux R, 2008, AICHE J, V54, P406, DOI 10.1002/aic.11390
   Babadi M, 2006, J COMPUT PHYS, V219, P770, DOI 10.1016/j.jcp.2006.04.014
   BOLAND D, 1972, POWDER TECHNOL, V5, P289, DOI 10.1016/0032-5910(72)80033-0
   Busciglio A, 2008, CHEM ENG J, V140, P398, DOI 10.1016/j.cej.2007.11.015
   Chen AH, 2006, AICHE J, V52, P174, DOI 10.1002/aic.10609
   Chen X, 2017, ADV POWDER TECHNOL, V28, P820, DOI 10.1016/j.apt.2016.12.008
   CLIFT R, 1972, CHEM ENG SCI, V27, P2309, DOI 10.1016/0009-2509(72)85111-X
   Davidson J.F., 1963, FLUIDIZED PARTICLES
   Davidson J. F., 1961, T I CHEM ENG-LOND, V39, P223
   DIFELICE R, 1994, INT J MULTIPHAS FLOW, V20, P153, DOI 10.1016/0301-9322(94)90011-6
   Feng YQ, 2004, IND ENG CHEM RES, V43, P8378, DOI 10.1021/ie049387v
   Gan JQ, 2017, CHEM ENG SCI, V163, P11, DOI 10.1016/j.ces.2017.01.020
   Gan JQ, 2016, CHEM ENG SCI, V156, P64, DOI 10.1016/j.ces.2016.09.017
   Gan JQ, 2016, AICHE J, V62, P62, DOI 10.1002/aic.15050
   GELDART D, 1984, POWDER TECHNOL, V37, P25, DOI 10.1016/0032-5910(84)80003-0
   GELDART D, 1978, POWDER TECHNOL, V19, P133, DOI 10.1016/0032-5910(78)80084-9
   Gu YL, 2016, POWDER TECHNOL, V296, P17, DOI 10.1016/j.powtec.2015.09.037
   Hilton JE, 2010, CHEM ENG SCI, V65, P1584, DOI 10.1016/j.ces.2009.10.028
   Holzer A, 2008, POWDER TECHNOL, V184, P361, DOI 10.1016/j.powtec.2007.08.021
   Hou QF, 2012, CHEM ENG SCI, V84, P449, DOI 10.1016/j.ces.2012.08.051
   Hou QF, 2012, AICHE J, V58, P1422, DOI 10.1002/aic.12700
   Huang JK, 2018, CHEM ENG RES DES, V136, P687, DOI 10.1016/j.cherd.2018.04.028
   Kobayashi T, 2013, POWDER TECHNOL, V248, P143, DOI 10.1016/j.powtec.2013.02.028
   Kuang SB, 2008, IND ENG CHEM RES, V47, P470, DOI 10.1021/ie070991q
   Kunii D., 1991, FLUIDIZATION ENG
   LaMarche CQ, 2017, CHEM ENG J, V310, P259, DOI 10.1016/j.cej.2016.10.119
   Launder B. E., 1974, Computer Methods in Applied Mechanics and Engineering, V3, P269, DOI 10.1016/0045-7825(74)90029-2
   Lettieri P, 2001, POWDER TECHNOL, V120, P34, DOI 10.1016/S0032-5910(01)00344-8
   Li TW, 2017, ADV POWDER TECHNOL, V28, P2961, DOI 10.1016/j.apt.2017.09.003
   Liu BQ, 2008, PARTICUOLOGY, V6, P125, DOI 10.1016/j.cpart.2007.07.005
   Lu G, 2015, CHEM ENG SCI, V127, P425, DOI 10.1016/j.ces.2014.11.050
   Ma JL, 2019, CHEM ENG J, V359, P1024, DOI 10.1016/j.cej.2018.11.082
   Ma JL, 2016, IND ENG CHEM RES, V55, P624, DOI 10.1021/acs.iecr.5b02789
   Mikami T, 1998, CHEM ENG SCI, V53, P1927, DOI 10.1016/S0009-2509(97)00325-4
   Nan WG, 2016, ADV POWDER TECHNOL, V27, P2265, DOI 10.1016/j.apt.2016.08.015
   Nieuwland JJ, 1996, CHEM ENG SCI, V51, P4087, DOI 10.1016/0009-2509(96)00260-6
   Okhovat M., 2018, J CHEM PETROL ENG, V52, P93
   Pandit JK, 2007, CHEM ENG SCI, V62, P159, DOI 10.1016/j.ces.2006.08.013
   Pandit JK, 2005, POWDER TECHNOL, V160, P7, DOI 10.1016/j.powtec.2005.04.044
   Pinson D, 1998, J PHYS D APPL PHYS, V31, P457, DOI 10.1088/0022-3727/31/4/016
   Raganati F, 2018, CHEM ENG RES DES, V133, P347, DOI 10.1016/j.cherd.2018.03.034
   Rhodes MJ, 2001, CHEM ENG SCI, V56, P69, DOI 10.1016/S0009-2509(00)00427-9
   ROWE PN, 1976, CHEM ENG SCI, V31, P1179, DOI 10.1016/0009-2509(76)85027-0
   Seville JPK, 2000, POWDER TECHNOL, V113, P261, DOI 10.1016/S0032-5910(00)00309-0
   Shabanian J, 2017, CHEM ENG J, V313, P580, DOI 10.1016/j.cej.2016.12.061
   Shabanian J, 2016, INT J CHEM REACT ENG, V14, P433, DOI 10.1515/ijcre-2014-0106
   Shabanian J, 2015, CHEM ENG J, V259, P135, DOI 10.1016/j.cej.2014.07.117
   Shabanian J, 2014, CHEM ENG SCI, V119, P261, DOI 10.1016/j.ces.2014.08.037
   Shrestha S, 2018, POWDER TECHNOL, V339, P70, DOI 10.1016/j.powtec.2018.08.001
   Shrestha Siddhartha, 2017, EPJ Web of Conferences, V140, DOI 10.1051/epjconf/201714015026
   Shrestha S., 2019, POWDER TECHNOL
   Shrestha S., 2018, POWDER TECHNOL
   Shrestha S, 2019, AICHE J, V65, DOI 10.1002/aic.16736
   Shrestha S, 2019, CHEM ENG SCI, V201, P448, DOI 10.1016/j.ces.2019.02.030
   Tian FG, 2018, GRANUL MATTER, V20, DOI 10.1007/s10035-018-0836-8
   TSUKADA M, 1990, POWDER TECHNOL, V63, P69, DOI 10.1016/0032-5910(90)80008-M
   Wang TY, 2016, POWDER TECHNOL, V301, P927, DOI 10.1016/j.powtec.2016.07.005
   Xu BH, 1997, CHEM ENG SCI, V52, P2785, DOI 10.1016/S0009-2509(97)00081-X
   Yang WJ, 2014, IND ENG CHEM RES, V53, P8245, DOI 10.1021/ie404158e
   Ye M, 2004, POWDER TECHNOL, V139, P129, DOI 10.1016/j.powtec.2003.10.012
   Yu AB, 2003, J CHEM TECHNOL BIOT, V78, P111, DOI 10.1002/jctb.788
   Yu AB, 2003, POWDER TECHNOL, V130, P70, DOI 10.1016/S0032-5910(02)00228-0
   Zhou ZY, 2011, CHEM ENG SCI, V66, P6128, DOI 10.1016/j.ces.2011.08.041
   Zhou ZY, 2009, AICHE J, V55, P868, DOI 10.1002/aic.11823
   Zhou ZY, 2011, IND ENG CHEM RES, V50, P9787, DOI 10.1021/ie200862n
   Zhu HP, 2007, CHEM ENG SCI, V62, P3378, DOI 10.1016/j.ces.2006.12.089
   Zhu HP, 2008, CHEM ENG SCI, V63, P5728, DOI 10.1016/j.ces.2008.08.006
NR 67
TC 0
Z9 0
U1 25
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115343
DI 10.1016/j.ces.2019.115343
PG 17
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600034
DA 2020-05-12
ER

PT J
AU Siegel, RA
   Wu, D
AF Siegel, Ronald A.
   Wu, Di
TI Examination of a Shannon entropy-like figure of merit for controlled
   release of drugs and other molecules
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Controlled release; Figure of merit; Entropy; Shannon; Kullback-Leibler;
   3-D printing
ID OPTIMIZATION; SOLUTE
AB We propose a figure of merit, based on temporal entropy, to evaluate the degree to which a controlled drug release system is able to adhere to its target release pattern. This criterion can be used, for example, to design multilayered drug release systems whose release flux optimally tracks the target pattern. Such multilayered systems are produced by sequential polymerization, sequential spraying, 3D printing, and other additive manufacturing techniques. After calculating this figure of merit for certain canonical controlled release mechanisms, with zero-order release as the target pattern, we optimize the pattern of initial drug concentrations in a multilayer system with respect to the figure of merit. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Siegel, Ronald A.] Univ Minnesota, Dept Pharmaceut, Minneapolis, MN 55455 USA.
   [Siegel, Ronald A.] Univ Minnesota, Dept Biomed Engn, Minneapolis, MN 55455 USA.
   [Wu, Di] Univ Minnesota, Dept Math, Minneapolis, MN 55455 USA.
RP Siegel, RA (reprint author), Univ Minnesota, Dept Pharmaceut, Minneapolis, MN 55455 USA.; Siegel, RA (reprint author), Univ Minnesota, Dept Biomed Engn, Minneapolis, MN 55455 USA.
EM siege017@umn.edu
CR Baker R.W., 1975, CONTROLLED RELEASE B, V47, P15
   Carslaw HS, 1986, CONDUCTION HEAT SOLI
   Cho Y, 2015, ENTROPY-SWITZ, V17, P102, DOI 10.3390/e17010102
   Crank J., 1975, MATH DIFFUSION, P414, DOI DOI 10.1016/0306-4549(77)90072-X
   Devanga-Chinta D, 2010, DRUG DEV IND PHARM, V36, P200, DOI 10.3109/03639040903497059
   Georgiadis MC, 2001, J CONTROL RELEASE, V77, P273, DOI 10.1016/S0168-3659(01)00510-7
   Havil J, 2003, GAMMA: EXPLORING EULERS CONSTANT, P1
   HIGUCHI T, 1961, J PHARM SCI, V50, P874, DOI 10.1002/jps.2600501018
   Hivechi A, 2019, MAT SCI ENG C-MATER, V94, P929, DOI 10.1016/j.msec.2018.10.037
   Jonathan G, 2016, INT J PHARMACEUT, V499, P376, DOI 10.1016/j.ijpharm.2015.12.071
   Khaled SA, 2014, INT J PHARMACEUT, V461, P105, DOI 10.1016/j.ijpharm.2013.11.021
   KIM C, 1999, CONTROLLED RELEASE D
   KORSMEYER RW, 1983, INT J PHARM, V15, P25, DOI 10.1016/0378-5173(83)90064-9
   Kosmidis K, 2003, J CHEM PHYS, V119, P6373, DOI 10.1063/1.1603731
   KULLBACK S, 1951, ANN MATH STAT, V22, P79, DOI 10.1214/aoms/1177729694
   KYDONIEUS AF, 1992, TREATISE CONTROLLED
   LEE P I, 1986, Journal of Controlled Release, V4, P1, DOI 10.1016/0168-3659(86)90027-1
   Lu SX, 1998, AICHE J, V44, P1689, DOI 10.1002/aic.690440720
   Lu SX, 2000, J PHARM SCI, V89, P45, DOI 10.1002/(SICI)1520-6017(200001)89:1<45::AID-JPS5>3.0.CO;2-8
   Mathiowitz E., 1999, ENCY CONTROLLED DRUG, P1057
   Nauman EB, 2010, CHEM ENG SCI, V65, P923, DOI 10.1016/j.ces.2009.09.043
   PAUL DR, 1976, J MEMBRANE SCI, V1, P33, DOI 10.1016/S0376-7388(00)82256-5
   PEPPAS NA, 1985, PHARM ACTA HELV, V60, P110
   Presse S, 2013, REV MOD PHYS, V85, P1115, DOI 10.1103/RevModPhys.85.1115
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168-3659(87)90034-4
   SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x
   Siegel RA, 2000, J CONTROL RELEASE, V69, P109, DOI 10.1016/S0168-3659(00)00292-3
   Siegel RA, 2012, ADV DEL SCI TECHNOL, P19, DOI 10.1007/978-1-4614-0881-9_2
   Siepmann J, 2001, ADV DRUG DELIVER REV, V48, P229, DOI 10.1016/S0169-409X(01)00116-8
   THEEUWES F, 1975, J PHARM SCI, V64, P1987, DOI 10.1002/jps.2600641218
NR 30
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115315
DI 10.1016/j.ces.2019.115315
PG 10
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600011
DA 2020-05-12
ER

PT J
AU Silvi, LD
   Saha, A
   Chandraker, DK
   Ghosh, S
   Das, AK
AF Silvi, Liril D.
   Saha, Avik
   Chandraker, Dinesh K.
   Ghosh, Sumana
   Das, Arup K.
TI Numerical analysis of pre-dryout sequences through the route of
   interfacial evolution in annular gas-liquid two-phase flow with phase
   change
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Annular flow; Boiling; Merging; Bubble; Bursting; Rewetting; Two-phase
   flow; Dryout; Nucleation
ID HEAT-TRANSFER; SUBCHANNEL ANALYSIS; BUBBLE; PREDICTION; SIMULATION;
   VALIDATION; 3-FLUID; FLUID; VAPOR; FIDAS
AB Numerical modeling of two-phase annular flow boiling has been carried out inside a tube using volume of fluid based computational multifluid dynamics. The proposed numerical methodology has been validated with available experimental results from literature. The stages of bubble nucleation, growth, merging, bursting, droplet entrainment, film rewetting, and dryout has been clearly visualized for diabatic annular mist flow. Plots of liquid phase fraction and average heat transfer coefficient were plotted which shows decreasing trends with axial space. Effect of different degrees of superheats and gas-liquid velocities at a higher working pressure of 40 bar have been studied, which can be commonly observed in boiling water reactor (BWR) conditions. Dryout is found to happen early in the axial length if the degree of superheat and flow velocities increases. The chaotic interfacial behavior has been analyzed with mean, standard deviation and attractor plot of space time-varying values of liquid phase fraction. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Silvi, Liril D.; Ghosh, Sumana] Indian Inst Technol, Dept Chem Engn, Roorkee, Uttar Pradesh, India.
   [Saha, Avik; Das, Arup K.] Indian Inst Technol, Dept Mech Engn, Roorkee, Uttar Pradesh, India.
   [Chandraker, Dinesh K.] Bhabha Atom Res Ctr, Reactor Engn Div, Mumbai, Maharashtra, India.
RP Ghosh, S (reprint author), Indian Inst Technol, Dept Chem Engn, Roorkee, Uttar Pradesh, India.
EM silviliril@gmail.com; aviksaha129@gmail.com; dineshkc@barc.gov.in;
   ghoshfch@iitr.ac.in; akdasfme@iitr.ac.in
FU Board of Research in Nuclear Science, Department of Atomic Energy,
   Mumbai, IndiaBoard of Research in Nuclear Sciences (BRNS) [36
   (1)/14/55/2016-BRNS/36/28]
FX The present research work is funded by project no. 36
   (1)/14/55/2016-BRNS/36/28 sponsored by Board of Research in Nuclear
   Science, Department of Atomic Energy, Mumbai, India.
CR Adamsson C, 2011, NUCL ENG DES, V241, P2843, DOI 10.1016/j.nucengdes.2011.01.033
   Albadawi A, 2013, INT J MULTIPHAS FLOW, V53, P11, DOI 10.1016/j.ijmultiphaseflow.2013.01.005
   ANDREANI M, 1994, INT J MULTIPHAS FLOW, V20, P1, DOI 10.1016/0301-9322(94)90069-8
   Anglart H., 1997, 8 INT TOP M NUCL REA
   Barbosa JR, 2003, INT J HEAT MASS TRAN, V46, P5153, DOI 10.1016/S0017-9310(03)00255-2
   Becker K.M., 1983, KTHNEL33 ROYAL I TEC
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   Chi-Liang Yu, 1977, International Journal of Heat and Mass Transfer, V20, P827, DOI 10.1016/0017-9310(77)90112-0
   Collier JG, 1994, CONVECTIVE BOILING C
   DELVALLE VH, 1985, INT J HEAT MASS TRAN, V28, P1907, DOI 10.1016/0017-9310(85)90213-3
   El-Genk MS, 2001, INT J HEAT MASS TRAN, V44, P2809, DOI 10.1016/S0017-9310(00)00326-4
   Emonot P, 2011, NUCL ENG DES, V241, P4476, DOI 10.1016/j.nucengdes.2011.04.049
   Gluck M, 2007, NUCL ENG DES, V237, P655, DOI 10.1016/j.nucengdes.2006.08.011
   Hoyer N, 1998, INT J MULTIPHAS FLOW, V24, P319, DOI 10.1016/S0301-9322(97)00057-8
   ISHII M, 1990, NUCL ENG DES, V121, P349, DOI 10.1016/0029-5493(90)90017-R
   Jayanti S, 1997, INT J HEAT MASS TRAN, V40, P2445, DOI 10.1016/S0017-9310(96)00288-8
   Klostermann J, 2013, INT J NUMER METH FL, V71, P960, DOI 10.1002/fld.3692
   Kumar P, 2016, PHYS FLUIDS, V28, DOI 10.1063/1.4954999
   LAFAURIE B, 1994, J COMPUT PHYS, V113, P134, DOI 10.1006/jcph.1994.1123
   Li D, 2007, J HEAT TRANS-T ASME, V129, P864, DOI 10.1115/1.2717942
   Li HP, 2016, INT J HEAT MASS TRAN, V99, P839, DOI 10.1016/j.ijheatmasstransfer.2016.04.021
   Li HP, 2016, NUCL ENG DES, V303, P17, DOI 10.1016/j.nucengdes.2016.04.001
   Marek R, 2001, INT J HEAT MASS TRAN, V44, P39, DOI 10.1016/S0017-9310(00)00086-7
   Mukherjee A, 2004, J HEAT TRANS-T ASME, V126, P1023, DOI 10.1115/1.1834614
   Pandey V, 2018, J HEAT TRANS-T ASME, V140, DOI 10.1115/1.4041088
   PLESSET MS, 1954, J APPL PHYS, V25, P493, DOI 10.1063/1.1721668
   Samkhaniani N, 2017, HEAT MASS TRANSFER, V53, P2885, DOI 10.1007/s00231-017-2031-6
   Sato Y, 2015, J COMPUT PHYS, V300, P20, DOI 10.1016/j.jcp.2015.07.046
   SUGAWARA S, 1990, NUCL ENG DES, V120, P147, DOI 10.1016/0029-5493(90)90369-9
   SUGAWARA S, 1991, NUCL ENG DES, V132, P253, DOI 10.1016/0029-5493(91)90269-N
   Tanasawa I., 1991, ADV HEAT TRANSFER, P55, DOI DOI 10.1016/S0065-2717(08)70334-4
   Tong LS., 2018, BOILING HEAT TRANSFE
   Utaka Y, 2013, INT J HEAT MASS TRAN, V57, P222, DOI 10.1016/j.ijheatmasstransfer.2012.10.031
   Valette M, 2011, NUCL ENG DES, V241, P4487, DOI 10.1016/j.nucengdes.2011.04.019
   VAN LEER B, 1974, J COMPUT PHYS, V14, P361
   Weller H.G., 2008, 4 TRHGW OPENCFD LTD
   Yang JF, 2017, NUCL ENG DES, V321, P190, DOI 10.1016/j.nucengdes.2016.10.054
NR 37
TC 0
Z9 0
U1 14
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115356
DI 10.1016/j.ces.2019.115356
PG 16
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600040
DA 2020-05-12
ER

PT J
AU Song, WL
   Hou, YL
   Chen, ZH
   Cai, DL
   Qian, WZ
AF Song, Wenlong
   Hou, Yilin
   Chen, Zhaohui
   Cai, Dali
   Qian, Weizhong
TI Process simulation of the syngas-to-aromatics processes: Technical
   economics aspects
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Syngas to aromatics; Process simulation; Economics analysis; Energy
   consumption
ID SYNTHESIS GAS; DIRECT CONVERSION; METHANOL; FUELS; HYDROCARBONS;
   PYROLYSIS; CATALYST; PERFORMANCE; SELECTIVITY; SCALE
AB Direct conversion of syngas-to-aromatics (STA) is an increasing vital catalytic field that still contains much uncertainty. For the first time, we report the process simulation of STA via direct routes and indirect STA (syngas first to produce methanol, then methanol being converted into aromatics). The conversion of CO was selected as the sensitivity indicator for the evaluation of energy consumption and economic aspects. A low conversion of CO resulted in a low yield (and low partial pressure) of aromatics and an increasing difficulty in separating them from unreacted syngas and light hydrocarbons. The associated increased investment and operational costs were analyzed quantitatively. Direct STA shows obvious advantages in operational cost savings and in construction costs when the conversion of CO was higher than 66-72% when compared with the indirect STA route. The simulation results provide new insights into the upper limits of the process of developing catalysts. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Song, Wenlong; Hou, Yilin; Chen, Zhaohui; Cai, Dali; Qian, Weizhong] Tsinghua Univ, Dept Chem Engn, Beijing 100084, Peoples R China.
RP Qian, WZ (reprint author), Tsinghua Univ, Dept Chem Engn, Beijing 100084, Peoples R China.
EM qianwz@tsinghua.edu.cn
RI Qian, Weizhong/AAK-8321-2020
OI Qian, Weizhong/0000-0002-1684-1061; Cai, Dali/0000-0001-5611-323X
FU National key R&D program of China [2017YFB0602204]
FX The author is grateful to the financial support of National key R&D
   program of China (2017YFB0602204).
CR Adebajo MO, 2003, CATAL COMMUN, V4, P71, DOI 10.1016/S1566-7367(02)00259-5
   Brown TR, 2015, BIORESOURCE TECHNOL, V178, P166, DOI 10.1016/j.biortech.2014.09.053
   Brown TR, 2013, BIOFUEL BIOPROD BIOR, V7, P235, DOI 10.1002/bbb.1387
   BRUCE LA, 1984, APPL CATAL, V9, P351, DOI 10.1016/0166-9834(84)80006-8
   Carrasco JL, 2017, FUEL, V193, P477, DOI 10.1016/j.fuel.2016.12.063
   Chen ZH, 2019, CHEM ENG SCI, V204, P1, DOI 10.1016/j.ces.2019.04.013
   Corsaro A, 2014, PETROL SCI TECHNOL, V32, P2722, DOI 10.1080/10916466.2014.901350
   De Maria R, 2013, INT J CHEM REACT ENG, V11, DOI 10.1515/ijcre-2013-0061
   Dincer I., 2014, PROGR EXERGY ENERGY
   FUJIMOTO K, 1984, J CATAL, V87, P136, DOI 10.1016/0021-9517(84)90176-3
   Guan N, 1996, CATAL TODAY, V30, P207, DOI 10.1016/0920-5861(96)00014-4
   Han YY, 2009, CHINESE J CHEM ENG, V17, P108, DOI 10.1016/S1004-9541(09)60041-0
   Inui T., 1987, STUD SURF SCI CATAL, V34, P639
   Larson E.D., 2010, ENERGY ENV SCI, V3
   Larson ED, 2009, BIOFUEL BIOPROD BIOR, V3, P174, DOI 10.1002/bbb.137
   Li MR, 2016, FUEL, V168, P68, DOI 10.1016/j.fuel.2015.11.076
   Liu H., 2001, COMP LURGI ICI LOW P
   Lu P, 2018, APPL ENERG, V209, P1, DOI 10.1016/j.apenergy.2017.10.068
   Ma YH, 2016, RSC ADV, V6, P81198, DOI 10.1039/c6ra19035a
   Ma YH, 2016, RSC ADV, V6, P74797, DOI 10.1039/c6ra19073a
   Preciado JE, 2012, ENERGIES, V5, P4924, DOI 10.3390/en5124924
   Qian WZ, 2017, MULTIPHASE REACTOR ENGINEERING FOR CLEAN AND LOW-CARBON ENERGY APPLICATIONS, P295
   Salkuyeh YK, 2015, ENERGIES, V8, P3739, DOI 10.3390/en8053739
   Sorunmu Y, 2018, ACS SUSTAIN CHEM ENG, V6, P10001, DOI 10.1021/acssuschemeng.8b01266
   Sorunmu YE, 2017, ACS SUSTAIN CHEM ENG, V5, P8804, DOI 10.1021/acssuschemeng.7b01609
   Spath P., 2005, BIOMASS HYDROGEN PRO
   Su C, 2016, CATAL TODAY, V264, P63, DOI 10.1016/j.cattod.2015.09.022
   Talmadge M., 2013, SYNGAS UPGRADING HYD
   Tian T, 2010, ACTA PHYS-CHIM SIN, V26, P3305, DOI 10.3866/PKU.WHXB20101228
   VARMA RL, 1987, IND ENG CHEM RES, V26, P183, DOI 10.1021/ie00062a001
   Wang DS, 2002, CHINESE J CATAL+, V23, P333
   Wang N, 2016, CHEM COMMUN, V52, P2011, DOI 10.1039/c5cc08471g
   Wang T, 2014, CATAL TODAY, V233, P8, DOI 10.1016/j.cattod.2014.02.007
   Yang JH, 2017, CHEM COMMUN, V53, P11146, DOI 10.1039/c7cc04768a
   Zeng DF, 2007, MICROPOR MESOPOR MAT, V98, P214, DOI 10.1016/j.micromeso.2006.09.012
   Zhang JG, 2015, ACS CATAL, V5, P2982, DOI 10.1021/acscatal.5b00192
   Zhang QD, 2013, J IND ENG CHEM, V19, P975, DOI 10.1016/j.jiec.2012.11.019
NR 37
TC 1
Z9 1
U1 11
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115328
DI 10.1016/j.ces.2019.115328
PG 10
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600019
DA 2020-05-12
ER

PT J
AU Tao, HL
   Lin, S
   Lian, C
   Li, CZ
   Liu, HL
AF Tao, Haolan
   Lin, Sen
   Lian, Cheng
   Li, Chunzhong
   Liu, Honglai
TI Microscopic insights into the ion transport in graphene-based membranes
   with different interlayer spacing distributions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Ion transport; Graphene oxide membranes; Interlayer spacing
   distribution; Poisson-Nernst-Planck; Navier-Stokes equations
ID WATER; PERMEATION; REDUCTION; STORAGE
AB The ion transport in nanoscale pores/channels are totally different to that in the macroscopic level. Here, a combined method based on the Poisson-Nernst-Planck (PNP) and Navier-Stokes (NS) equations is applied to study the ion transport in graphene oxide membranes (GOMs) with different interlayer spacing distributions by controlling the offset angle of the middle nanosheet of the model. The layered membrane with suitable interlayer spacing distribution has strong electrical double layer (EDL) overlapping and relatively weak spatial confinement, which improves the ion selectivity and water permeation. This phenomenon can be further understood by analyzing microscopic properties including the local density and flux profiles with considering the effects of surface charge and bulk concentration. This work could provide macroscopic insights into the ionic flow in laminar GOMs at a different angle and possible improvement of the GOMs performances. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tao, Haolan; Lian, Cheng; Li, Chunzhong; Liu, Honglai] East China Univ Sci & Technol, Shanghai Engn Res Ctr Hierarch Nanomat, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.
   [Tao, Haolan; Lian, Cheng; Li, Chunzhong; Liu, Honglai] East China Univ Sci & Technol, Sch Chem & Mol Engn, Shanghai 200237, Peoples R China.
   [Lin, Sen] East China Univ Sci & Technol, Natl Engn Res Ctr Integrated Utilizat Salt Lake R, Shanghai 200237, Peoples R China.
   [Lian, Cheng] Univ Utrecht, Ctr Extreme Matter & Emergent Phenomena, Inst Theoret Phys, Princetonpl 5, NL-3584 CC Utrecht, Netherlands.
   [Li, Chunzhong] East China Univ Sci & Technol, Shanghai Engn Res Ctr Hierarch Nanomat, Sch Chem Engn, Key Lab Ultrafine Mat,Minist Educ, Shanghai 200237, Peoples R China.
RP Lian, C; Liu, HL (reprint author), East China Univ Sci & Technol, Shanghai Engn Res Ctr Hierarch Nanomat, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.; Lian, C; Liu, HL (reprint author), East China Univ Sci & Technol, Sch Chem & Mol Engn, Shanghai 200237, Peoples R China.; Lian, C (reprint author), Univ Utrecht, Ctr Extreme Matter & Emergent Phenomena, Inst Theoret Phys, Princetonpl 5, NL-3584 CC Utrecht, Netherlands.
EM liancheng@ecust.edu.cn; hlliu@ecust.edu.cn
RI Li, Chunzhong/B-1103-2015
OI Li, Chunzhong/0000-0001-7897-5850; Lin, Sen/0000-0002-9495-423X; Lian,
   Cheng/0000-0002-9016-832X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [91834301, 21808055]; Shanghai Sailing Program
   [18YF1405400]; EU-FET NANOPHLOW [REP-766972-1]
FX This work was sponsored by the National Natural Science Foundation of
   China (No. 91834301 and 21808055), the Shanghai Sailing Program
   (18YF1405400). C. Lian acknowledges the EU-FET project NANOPHLOW
   (REP-766972-1).
CR Bai H, 2011, ADV MATER, V23, P1089, DOI 10.1002/adma.201003753
   Bocquet L, 2010, CHEM SOC REV, V39, P1073, DOI 10.1039/b909366b
   Candelaria SL, 2012, NANO ENERGY, V1, P195, DOI 10.1016/j.nanoen.2011.11.006
   Chen H, 2008, ADV MATER, V20, P3557, DOI 10.1002/adma.200800757
   Cheng C, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501272
   Cheng LJ, 2010, CHEM SOC REV, V39, P923, DOI 10.1039/b822554k
   Compton S.T., 2010, SMALL, V6, P711, DOI DOI 10.1002/SMLL.200901934
   Daiguji H, 2005, NANO LETT, V5, P2274, DOI 10.1021/nl051646y
   Daiguji H, 2004, NANO LETT, V4, P2315, DOI 10.1021/nl0489945
   Daiguji H, 2010, CHEM SOC REV, V39, P901, DOI 10.1039/b820556f
   Dreyer DR, 2010, CHEM SOC REV, V39, P228, DOI 10.1039/b917103g
   Eijkel JCT, 2010, CHEM SOC REV, V39, P957, DOI 10.1039/b913776a
   Gomez-Navarro C, 2010, NANO LETT, V10, P1144, DOI 10.1021/nl9031617
   Huang HB, 2014, J MATER CHEM A, V2, P13772, DOI 10.1039/c4ta02359e
   Huang HB, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3979
   Huang Y, 2015, ADV MATER INTERFACES, V2, DOI 10.1002/admi.201400433
   Hung WS, 2014, CHEM MATER, V26, P2983, DOI 10.1021/cm5007873
   Kim SJ, 2010, CHEM SOC REV, V39, P912, DOI 10.1039/b822556g
   Lian C, 2019, ACS NANO, V13, P8185, DOI 10.1021/acsnano.9b03303
   Lian C, 2019, AICHE J, V65, P804, DOI 10.1002/aic.16467
   Lian C, 2017, J PHYS CHEM C, V121, P14010, DOI 10.1021/acs.jpcc.7b02827
   Liu C., 2011, AIP ADV, V1
   Liu GP, 2015, CHEM SOC REV, V44, P5016, DOI 10.1039/c4cs00423j
   Maier J, 2005, NAT MATER, V4, P805, DOI 10.1038/nmat1513
   Mouterde T, 2019, NATURE, V567, P87, DOI 10.1038/s41586-019-0961-5
   Nair RR, 2012, SCIENCE, V335, P442, DOI 10.1126/science.1211694
   Nguyen B.H., 2016, ADV NAT SCI NANOSCI, V7
   Pei SF, 2012, CARBON, V50, P3210, DOI 10.1016/j.carbon.2011.11.010
   Qiu L, 2011, CHEM COMMUN, V47, P5810, DOI 10.1039/c1cc10720h
   Schoch RB, 2008, REV MOD PHYS, V80, P839, DOI 10.1103/RevModPhys.80.839
   Stankovich S, 2007, CARBON, V45, P1558, DOI 10.1016/j.carbon.2007.02.034
   Suss ME, 2015, ENERG ENVIRON SCI, V8, P2296, DOI [10.1039/C5EE00519A, 10.1039/c5ee00519a]
   Wei N, 2014, ACS APPL MATER INTER, V6, P5877, DOI 10.1021/am500777b
   Yeh HC, 2014, ISR J CHEM, V54, P1533, DOI 10.1002/ijch.201400079
   Zeng H., 2017, P NATL ACAD SCI USA, V114, P3358
   Zhan C, 2017, ADV SCI, V4, DOI 10.1002/advs.201700059
   Zhang MC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09286-8
NR 37
TC 0
Z9 0
U1 28
U2 28
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115354
DI 10.1016/j.ces.2019.115354
PG 7
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600039
DA 2020-05-12
ER

PT J
AU Tomadakis, M
   Fuselier, K
   Almeer, F
   Ferguson, A
   Cowdrick, V
AF Tomadakis, Manolis
   Fuselier, Katie
   Almeer, Fahad
   Ferguson, Ashley
   Cowdrick, Victoria
TI Transport through random bimodal and multimodal fiber structures
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bimodal and multimodal; Fibrous media; Transport properties; Theoretical
   models; Computer simulation; Experimental data
ID C/C COMPOSITE PREFORM; HYDRAULIC PERMEABILITY; KNUDSEN DIFFUSIVITIES;
   REGIME DIFFUSION; FIBRIN NETWORKS; ORIENTATION; PERFORMANCE; TRANSITION;
   PARTICLE; FILTERS
AB Random walk simulation results are reported for the transport and structural properties of random bimodal fibrous media for a range of values of the porosity, relative fiber size, and relative fiber density. Analytical expressions are derived for the mean intercept length of random bimodal and multimodal fiber structures, and are validated through simulations. A fiber dispersity factor emerges from the derivations, accounting for the deviation of the mean intercept length of such structures from that of unimodal fiber beds of the same porosity. Tortuosity factors in all diffusion regimes for in-plane and transverse flow through bimodal fibrous media of moderate or high porosity are practically independent of the relative fiber size and density and equal to those reported earlier for beds of unimodal fibers. The same holds for the formation factor of such structures, accounting for the dimensionless effective bulk diffusivity, thermal and electrical conductivity, magnetic permeability, dielectric constant and refractive index. The dimensionless viscous permeability of bimodal and multimodal fiber structures of moderate or high porosity may be obtained from that of unimodal fiber structures through simple multiplication by the square of the dispersity factor. This result is in line with a multitude of experimental data of the literature. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tomadakis, Manolis; Fuselier, Katie; Almeer, Fahad; Ferguson, Ashley; Cowdrick, Victoria] Florida Inst Technol, Coll Engn & Sci, Chem Engn Program, 150 West Univ Blvd, Melbourne, FL 32901 USA.
RP Tomadakis, M (reprint author), Florida Inst Technol, Coll Engn & Sci, Chem Engn Program, 150 West Univ Blvd, Melbourne, FL 32901 USA.
EM tomadaki@fit.edu
CR Arambakam R, 2012, INT J HEAT MASS TRAN, V55, P7234, DOI 10.1016/j.ijheatmasstransfer.2012.07.049
   Brown RC, 2001, POWDER TECHNOL, V118, P3, DOI 10.1016/S0032-5910(01)00288-1
   Choi HJ, 2017, AEROSOL AIR QUAL RES, V17, P1052, DOI 10.4209/aaqr.2016.06.0256
   Clague DS, 1997, PHYS FLUIDS, V9, P1562, DOI 10.1063/1.869278
   Coindreau O, 2005, J MATER RES, V20, P2328, DOI 10.1557/JMR.2005.0311
   COLEMAN R, 1969, J APPL PROBAB, V6, P430, DOI 10.2307/3212012
   Das D, 2012, J DISPER SCI TECHNOL, V33, P1225, DOI 10.1080/01932691.2011.590437
   ETHIER CR, 1991, AICHE J, V37, P1227, DOI 10.1002/aic.690370812
   Gervais PC, 2012, CHEM ENG SCI, V73, P239, DOI 10.1016/j.ces.2012.01.040
   Happel J., 1965, LOW REYNOLDS NUMBER
   Luu HT, 2017, ACTA ACUST UNITED AC, V103, P1050, DOI 10.3813/AAA.919134
   Hogrel JY, 2008, BIOMED SIGNAL PROCES, V3, P118, DOI 10.1016/j.bspc.2007.06.004
   HUANG Y, 1994, J BIOMECH ENG-T ASME, V116, P430, DOI 10.1115/1.2895794
   JOHNSON DL, 1986, PHYS REV LETT, V57, P2564, DOI 10.1103/PhysRevLett.57.2564
   Johnson EM, 1996, AICHE J, V42, P1220, DOI 10.1002/aic.690420504
   Kahl C, 2018, COMPOS PART A-APPL S, V111, P54, DOI 10.1016/j.compositesa.2018.05.014
   KALOS MH, 1986, MONTE CARLO METHODS, V1
   Lara-Padilla H, 2017, MATERIALS, V10, DOI 10.3390/ma10060640
   Mattern KJ, 2008, AICHE J, V54, P32, DOI 10.1002/aic.11350
   Mei Y, 2013, J APPL POLYM SCI, V128, P1089, DOI [10.1002/app.38296, 10.1002/APP.38296]
   Nordson, 2004, WHATS NEW BIC, P26
   Pant HR, 2013, J MEMBRANE SCI, V429, P225, DOI 10.1016/j.memsci.2012.11.025
   POLLARD WG, 1948, PHYS REV, V73, P762, DOI 10.1103/PhysRev.73.762
   Pradhan AK, 2017, J TEXT I, V108, P788, DOI 10.1080/00405000.2016.1191720
   Sakano T, 2000, SEP PURIF TECHNOL, V19, P145, DOI 10.1016/S1383-5866(99)00086-6
   SHAH GA, 1982, BIOPOLYMERS, V21, P1037, DOI 10.1002/bip.360210604
   SHAH GA, 1987, THROMB RES, V45, P257, DOI 10.1016/0049-3848(87)90193-9
   SJOSTRAN.J, 1969, ACTA ANAT, V74, P532
   Tafreshi HV, 2009, CHEM ENG SCI, V64, P1154, DOI 10.1016/j.ces.2008.11.013
   Tomadakis M.M., 1994, AICHE ANN M
   TOMADAKIS MM, 1993, J CHEM PHYS, V98, P616, DOI 10.1063/1.464604
   TOMADAKIS MM, 1993, AICHE J, V39, P397, DOI 10.1002/aic.690390304
   Tomadakis MM, 2005, J COMPOS MATER, V39, P163, DOI 10.1177/00219983050464338
   Tomadakis MM, 2005, J CHEM PHYS, V122, DOI 10.1063/1.1854130
   TOMADAKIS MM, 1991, AICHE J, V37, P1175, DOI 10.1002/aic.690370807
   TOMADAKIS MM, 1993, CHEM ENG SCI, V48, P3323, DOI 10.1016/0009-2509(93)80149-K
   TOMADAKIS MM, 1991, AICHE J, V37, P74, DOI 10.1002/aic.690370107
   Vignoles GL, 2007, J MATER RES, V22, P1537, DOI [10.1557/JMR.2007.0216, 10.1557/jmr.2007.0216]
   Yang H, 2018, CHEM ENG SCI, V192, P634, DOI 10.1016/j.ces.2018.08.006
   Zhang SC, 2016, ACS APPL MATER INTER, V8, P8086, DOI 10.1021/acsami.6b00359
NR 40
TC 0
Z9 0
U1 9
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115298
DI 10.1016/j.ces.2019.115298
PG 14
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600005
DA 2020-05-12
ER

PT J
AU Torres, JJ
   Tinjaca, CD
   Alvarez, OA
   Gomez, JM
AF Torres, Juan J.
   Tinjaca, Cristhian D.
   Alvarez, Oscar A.
   Gomez, Jorge M.
TI Optimization proposal for emulsions formulation considering a multiscale
   approach
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Emulsion Formulation; Integrated Product Design; Pyomo; Multiscale
   Properties
ID CHEMICAL-PRODUCT DESIGN; DECISION-MAKING; FRAMEWORK; COEFFICIENT;
   FRICTION; MODEL
AB The design of higher value-added products involves the evaluation of different formulation alternatives, while simultaneously addressing product structure and functionalities, manufacturing process, and market requirements. Mathematical programming approaches have proven to be suitable means to reduce experimentation resources and development time; however, the integration of the diverse design variables and constraints establish a challenging modeling task that includes the implementation of multiple simulation software. This paper presents an optimization proposal for emulsions formulation considering a multiscale approach based on mathematical programming and independent modular representation of the (1) product structure and properties, (2) consumer requirements and (3) product market performance. This proposal was developed in Pyomo in order to provide a generic, highly configurable and modular open-source environment for the solution of multiscale design problems, allowing the combination of diverse mathematical models. Two emulsion design cases are presented to highlight the application of the optimization model to find the best formulation related to multiscale properties. The first case consists of the maximization of consumer preference, while the second case involves the maximization of economic revenue. According to the optimization proposal implementation, the results show that the economic-driven formulation offers a better balance between revenue and consumer preference. The Pyomo code is available upon request. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Torres, Juan J.; Tinjaca, Cristhian D.; Alvarez, Oscar A.; Gomez, Jorge M.] Univ Los Andes, Chem Engn Dept, Prod & Proc Design Grp, Carrera 1 18-10, Bogota 111711, Colombia.
RP Gomez, JM (reprint author), Univ Los Andes, Chem Engn Dept, Prod & Proc Design Grp, Carrera 1 18-10, Bogota 111711, Colombia.
EM jj.torres1443@uniandes.edu.co; cd.tinjaca521@uniandes.edu.co;
   oalvarez@uniandes.edu.co; jorgomez@uniandes.edu.co
OI Alvarez Solano, Oscar Alberto/0000-0002-5486-5240; Gomez, Jorge
   Mario/0000-0002-2018-4121
CR Acosta EJ, 2008, COLLOID SURFACE A, V320, P193, DOI 10.1016/j.colsurfa.2008.01.049
   Bagajewicz M, 2011, AICHE J, V57, P160, DOI 10.1002/aic.12242
   Bagajewicz MJ, 2007, AICHE J, V53, P3155, DOI 10.1002/aic.11332
   Bernal L., 2016, LIB UNIANDES FINAL P
   Bernardo FP, 2017, COMPUT-AIDED CHEM EN, V39, P347, DOI 10.1016/B978-0-444-63683-6.00012-5
   Bernardo FP, 2015, AICHE J, V61, P802, DOI 10.1002/aic.14681
   Camarda KV, 1999, COMPUT CHEM ENG, V23, pS467, DOI 10.1016/S0098-1354(99)80115-X
   Cheng YS, 2009, COMPUT CHEM ENG, V33, P1097, DOI 10.1016/j.compchemeng.2008.10.010
   Constantinou L, 2007, COMPUT-AIDED CHEM EN, V23, P87, DOI 10.1016/S1570-7946(07)80006-X
   Conte E, 2011, AICHE J, V57, P2431, DOI 10.1002/aic.12458
   Cussler E.L., 2011, CHEM PRODUCT DESIGN
   DAVIES JT, 1985, CHEM ENG SCI, V40, P839, DOI 10.1016/0009-2509(85)85036-3
   El-Hamouz A, 2009, CHEM ENG TECHNOL, V32, P1203, DOI 10.1002/ceat.200900038
   Fedorova M, 2015, COMPUT CHEM ENG, V83, P232, DOI 10.1016/j.compchemeng.2015.02.010
   Fung KY, 2016, COMPUT CHEM ENG, V91, P15, DOI 10.1016/j.compchemeng.2016.03.009
   Gani R, 2004, COMPUT CHEM ENG, V28, P2441, DOI 10.1016/j.compchemeng.2004.08.010
   Greth G. G., 1961, J APPL POLYM SCI, V5, P135
   Hart W.E., 2017, PYOMO OPTIMIZATION M
   Hedonic Rosen S., 1974, J POLIT EC, V82
   Heintz J, 2014, COMPUT IND, V65, P505, DOI 10.1016/j.compind.2014.01.010
   Heitzig M, 2014, COMPUT CHEM ENG, V71, P677, DOI 10.1016/j.compchemeng.2014.07.016
   Hill M, 2004, AICHE J, V50, P1656, DOI 10.1002/aic.10293
   HINZE JO, 1955, AICHE J, V1, P289, DOI 10.1002/aic.690010303
   Kalakul S., 2016, VPPD LAB CHEM PRODUC, DOI [10.1016/B978-0-444-63683-6.00003-4, DOI 10.1016/B978-0-444-63683-6.00003-4]
   Klatt KU, 2009, COMPUT CHEM ENG, V33, P536, DOI 10.1016/j.compchemeng.2008.09.002
   Kraus R, 2012, COMPUT-AIDED CHEM EN, V31, P155
   Mattei M, 2014, FLUID PHASE EQUILIBR, V362, P288, DOI 10.1016/j.fluid.2013.10.030
   Mattei M, 2013, IND ENG CHEM RES, V52, P12236, DOI 10.1021/ie4016232
   MORALES H, 2019, [No title captured], DOI DOI 10.1080/10852352.2019.1664712
   NACHT S, 1981, J SOC COSMET CHEM, V32, P55
   Ng KA, 2004, COMPUT CHEM ENG, V29, P51, DOI 10.1016/j.compchemeng.2004.07.029
   Gallo-Molina JP, 2017, IND ENG CHEM RES, V56, P7757, DOI 10.1021/acs.iecr.7b02246
   Pal R, 2001, CHEM ENG J, V81, P15, DOI 10.1016/S1385-8947(00)00174-1
   Pamies R, 2008, COLLOID POLYM SCI, V286, P1223, DOI 10.1007/s00396-008-1902-2
   Pradilla D, 2018, LANGMUIR, V34, P9489, DOI 10.1021/acs.langmuir.8b01393
   Pradilla D, 2015, CHEM ENG RES DES, V95, P162, DOI 10.1016/j.cherd.2014.10.016
   PRINCEN HM, 1989, J COLLOID INTERF SCI, V128, P176, DOI 10.1016/0021-9797(89)90396-2
   Rosen MJ, 2004, SURFACTANTS INTERFAC, V40, DOI [10.1016/0166-6622(89)80030-7, DOI 10.1016/0166-6622(89)80030-7]
   Salager J.-L., 2001, TECH INGENIEUR PRINC
   Salager JL, 1999, SURF SCI SERIES, V82, P253
   Seider WD, 2009, COMPUT CHEM ENG, V33, P930, DOI 10.1016/j.compchemeng.2008.10.019
   Sivamani RK, 2003, SKIN RES TECHNOL, V9, P227, DOI 10.1034/j.1600-0846.2003.02366.x
   Smith BV, 2010, COMPUT CHEM ENG, V34, P857, DOI 10.1016/j.compchemeng.2010.02.039
   Tcholakova S, 2011, LANGMUIR, V27, P14783, DOI 10.1021/la203474b
   Toropova AP, 2013, J MATH CHEM, V51, P1684, DOI 10.1007/s10910-013-0177-0
   Villadsen J, 1997, CHEM ENG SCI, V52, P2857, DOI 10.1016/S0009-2509(97)00125-5
   Wang ZW, 2005, J DISPER SCI TECHNOL, V26, P441, DOI 10.1081/DIS-200054572
   Watson JP, 2012, MATH PROGRAM COMPUT, V4, P109, DOI 10.1007/s12532-012-0036-1
   Weininger Weininger D., 1988, J CHEM INF MODEL, V1988, P31
   Wibowo C, 2001, AICHE J, V47, P2746, DOI 10.1002/aic.690471214
NR 50
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115326
DI 10.1016/j.ces.2019.115326
PG 12
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600017
DA 2020-05-12
ER

PT J
AU Viswanathan, H
AF Viswanathan, H.
TI Oscillatory motion and merging responses of primary and satellite
   droplets from Newtonian liquid jets
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Liquid jet; VOF; Coalescence of drops; Air-entrapment; Merging of
   satellite drops; Reflexive-like separation
ID CAPILLARY INSTABILITY; BREAKUP; COALESCENCE; COLLISION; VOLUME; DROPS;
   TRANSITION; SEPARATION; SIMULATION; STABILITY
AB Numerical simulations of laminar Newtonian liquid jets are presented that divulge several breakup and merging responses for both primary and satellite droplets. Using an axisymmetric VOF model, we predict the presence of surface oscillations of droplets disintegrated from jets, which at times lead to merging of droplets when travelling downstream. Our simulations indicate that when primary droplets undergo merging, they exhibit characteristics such as (i) permanent and (ii) partial coalescence. We find that the partial coalescence of droplets can lead to a reflexive-like separation and then show re-merge responses. The formation of an air-bubble during the merging of binary droplets is predicted. Characteristics such as forward, rear, and simultaneous merging patterns of satellites with primary droplets are captured in our numerical simulations. Furthermore, a new merging pattern is reported wherein, satellites formed from the swellings of the jet can be absorbed back into the moving core of the liquid jet. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Viswanathan, H.] Sheffield Hallam Univ, Dept Engn & Math, Howard St, Sheffield S1 1WB, S Yorkshire, England.
RP Viswanathan, H (reprint author), Sheffield Hallam Univ, Dept Engn & Math, Howard St, Sheffield S1 1WB, S Yorkshire, England.
EM h.viswanathan@shu.ac.uk
FU ANSYS Academic Research Partnership Grant
FX This work was supported by ANSYS Academic Research Partnership Grant.
CR ASHGRIZ N, 1990, J FLUID MECH, V221, P183, DOI 10.1017/S0022112090003536
   BECKER E, 1991, J FLUID MECH, V231, P189, DOI 10.1017/S0022112091003361
   Borthakur MP, 2017, PHYS REV E, V96, DOI 10.1103/PhysRevE.96.013115
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   BRAZIERSMITH PR, 1972, PROC R SOC LON SER-A, V326, P393, DOI 10.1098/rspa.1972.0016
   Chakraborty I, 2016, INT J MULTIPHAS FLOW, V84, P54, DOI 10.1016/j.ijmultiphaseflow.2016.04.002
   CHANDRASEKHAR S, 1961, HYDRODYNAMIC HYDROMA, pCH12
   CHAUDHARY KC, 1980, J FLUID MECH, V96, P287, DOI 10.1017/S0022112080002121
   Clanet C, 1999, J FLUID MECH, V383, P307, DOI 10.1017/S0022112098004066
   Delteil J, 2011, COMPUT FLUIDS, V50, P10, DOI 10.1016/j.compfluid.2011.05.010
   Driessen T, 2014, J FLUID MECH, V749, P275, DOI 10.1017/jfm.2014.178
   EGGERS J, 1994, J FLUID MECH, V262, P205, DOI 10.1017/S0022112094000480
   GARCIA FJ, 1994, PHYS FLUIDS, V6, P2676, DOI 10.1063/1.868157
   GOEDDE EF, 1970, J FLUID MECH, V40, P495, DOI 10.1017/S0022112070000289
   HIRT CW, 1981, J COMPUT PHYS, V39, P201, DOI 10.1016/0021-9991(81)90145-5
   Krishnan KG, 2015, INT J MULTIPHAS FLOW, V77, P171, DOI 10.1016/j.ijmultiphaseflow.2015.08.003
   LEIB SJ, 1986, J FLUID MECH, V168, P479, DOI 10.1017/S0022112086000472
   Mashayek F, 2003, INT J HEAT MASS TRAN, V46, P77, DOI 10.1016/S0017-9310(02)00256-9
   Moallemi N, 2016, PHYS FLUIDS, V28, DOI 10.1063/1.4938095
   Munnannur A, 2007, INT J MULTIPHAS FLOW, V33, P873, DOI 10.1016/j.ijmultiphaseflow.2007.03.003
   NAYFEH AH, 1970, PHYS FLUIDS, V13, P841, DOI 10.1063/1.1693025
   Nikolopoulos N, 2011, INT J HEAT MASS TRAN, V54, P678, DOI 10.1016/j.ijheatmasstransfer.2010.09.002
   Orme M, 1997, PROG ENERG COMBUST, V23, P65, DOI 10.1016/S0360-1285(97)00005-1
   Pan Y, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.2009527
   Pan Y, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2194936
   PIMBLEY WT, 1977, IBM J RES DEV, V21, P21, DOI 10.1147/rd.211.0021
   Plateau J.A.F., 1873, STATIQUE EXPT THEORI
   Premnath KN, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.2148987
   Qian J, 1997, J FLUID MECH, V331, P59, DOI 10.1017/S0022112096003722
   Rayleigh L., 1882, P ROY SOC LONDON, V34, P130
   Rayleigh L., 1879, P LOND MATH SOC, V10, P4, DOI DOI 10.1112/PLMS/S1-10.1.4
   Rivero-Rodriguez J, 2017, COMPUT FLUIDS, V154, P132, DOI 10.1016/j.compfluid.2017.05.020
   RUTLAND DF, 1970, CHEM ENG SCI, V25, P1689, DOI 10.1016/0009-2509(70)80060-4
   Sallam KA, 2002, INT J MULTIPHAS FLOW, V28, P427, DOI 10.1016/S0301-9322(01)00067-2
   Sauter US, 2005, J FLUID MECH, V533, P237, DOI 10.1017/S002211200500412X
   Savart F., 1833, ANN CHIM PHYS, V53, P337
   Sunol F, 2015, PHYS FLUIDS, V27, DOI 10.1063/1.4927365
   Tomotika S., 1935, Proceedings of the Royal Society of London, Series A (Mathematical and Physical Sciences), V150, P322, DOI 10.1098/rspa.1935.0104
   VASSALLO P, 1991, P ROY SOC LOND A MAT, V433, P269, DOI 10.1098/rspa.1991.0047
   Viswanathan H, 2019, INT J MULTIPHAS FLOW, V112, P269, DOI 10.1016/j.ijmultiphaseflow.2018.09.016
   Xiao F, 2016, COMPUT FLUIDS, V136, P402, DOI 10.1016/j.compfluid.2016.06.021
   Xie L, 2017, PHYS FLUIDS, V29, DOI 10.1063/1.4991578
   Youngs D., 1982, NUMERICAL METHODS FL, P273, DOI DOI 10.1007/S11433-009-0265-0
   YUEN MC, 1968, J FLUID MECH, V33, P151, DOI 10.1017/S0022112068002429
NR 44
TC 0
Z9 0
U1 14
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115334
DI 10.1016/j.ces.2019.115334
PG 11
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600025
DA 2020-05-12
ER

PT J
AU Wang, T
   Xie, TL
   Xu, C
AF Wang, Tao
   Xie, Tingliang
   Xu, Cong
TI Numerical investigations of micro-SLM extraction/stripping in a spiral
   channel
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Supported liquid membrane; In situ microextraction/stripping; Mass
   transfer mechanism; Numerical simulation; Dean flow
ID SUPPORTED-LIQUID-MEMBRANE; MASS-TRANSFER; METAL-IONS; WASTE-WATER;
   TRANSPORT; MICROEXTRACTION; ENHANCEMENT; TECHNOLOGY; SEPARATION
AB Micro-supported liquid membrane (micro-SLM) extraction/stripping has attracted significant research attention because of its advantages. For both design and optimization purpose, a deep understanding of the mass transfer mechanisms in the micro-SLM process is of vital importance. However, the interplay between the channel diffusion, channel convection, and membrane transfer at the microscale results in complicated mass transfer patterns. The underlying mechanisms of these patterns are still unclear. In the present study, a comprehensive 3D numerical simulation was established to investigate the mass transfer behaviors in a spiral micro-SLM device. Five different mass transfer mechanisms were determined and explained in detail. Two dimensionless numbers were defined to differentiate between these mass transfer mechanisms and to generate a mechanism zoning map. The proposed model and the zoning map are very useful in predicting the mass transfer behaviors of the micro-SLM extraction/stripping process in both a laboratory environment and the industry. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Tao; Xie, Tingliang; Xu, Cong] Tsinghua Univ, Inst Nucl & New Energy Technol, Collaborat Innovat Ctr Adv Nucl Energy Technol, Beijing 100084, Peoples R China.
   [Wang, Tao; Xie, Tingliang] Tsinghua Univ, Inst Nucl & New Energy Technol, Collaborat Innovat Ctr Adv Nucl Energy Technol, Chengfu Rd,POB 1021, Beijing 102201, Peoples R China.
RP Xu, C (reprint author), Tsinghua Univ, Inst Nucl & New Energy Technol, Collaborat Innovat Ctr Adv Nucl Energy Technol, Chengfu Rd,POB 1021, Beijing 102201, Peoples R China.
EM tao-wang17@mails.tsinghua.edu.cn; xtl15@mails.tsinghua.edu.cn;
   c-xu@mail.tsinghua.edu.cn
OI Xu, Cong/0000-0002-5426-9721
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21776152, 21576149]
FX This work was supported by the National Natural Science Foundation of
   China (No. 21776152 and No. 21576149).
CR Alhusseini A, 2000, MATH COMPUT MODEL, V32, P465, DOI 10.1016/S0895-7177(00)00145-X
   Allahyari SA, 2016, J MEMBRANE SCI, V520, P374, DOI 10.1016/j.memsci.2016.08.009
   Ata ON, 2007, HYDROMETALLURGY, V87, P148, DOI 10.1016/j.hydromet.2007.02.008
   Bahlake A, 2016, HEAT MASS TRANSFER, V52, P1295, DOI 10.1007/s00231-015-1635-y
   Breembroek GRM, 1998, J MEMBRANE SCI, V146, P185, DOI 10.1016/S0376-7388(98)00099-4
   Cai ZX, 2006, ANAL CHIM ACTA, V556, P151, DOI 10.1016/j.aca.2005.06.028
   CHAUDRY MA, 1991, J RADIOAN NUCL CH AR, V148, P15, DOI 10.1007/BF02060542
   DEHAAN AB, 1989, J MEMBRANE SCI, V45, P281, DOI 10.1016/S0376-7388(00)80520-7
   Di Carlo D, 2009, LAB CHIP, V9, P3038, DOI 10.1039/b912547g
   Elhassadi AA, 1999, SEPAR SCI TECHNOL, V34, P305, DOI 10.1081/SS-100100652
   Gelfgat AY, 2003, PHYS FLUIDS, V15, P330, DOI 10.1063/1.1532732
   Ghambarian M, 2012, MICROCHIM ACTA, V177, P271, DOI 10.1007/s00604-012-0773-x
   Gjelstad A, 2007, J CHROMATOGR A, V1157, P38, DOI 10.1016/j.chroma.2007.05.007
   Haddadi B, 2018, J MEMBRANE SCI, V563, P199, DOI 10.1016/j.memsci.2018.05.040
   Harrington PJ, 2001, J MEMBRANE SCI, V192, P83, DOI 10.1016/S0376-7388(01)00485-9
   HILL C, 1994, J INCLUS PHENOM MOL, V19, P399, DOI 10.1007/BF00708996
   Hylton K, 2008, ANAL CHIM ACTA, V607, P45, DOI 10.1016/j.aca.2007.11.039
   Jonsson JA, 1999, TRAC-TREND ANAL CHEM, V18, P318, DOI 10.1016/S0165-9936(99)00102-8
   Jonsson JA, 2000, J CHROMATOGR A, V902, P205, DOI 10.1016/S0021-9673(00)00922-5
   Kandwal P, 2011, CHEM ENG J, V174, P110, DOI 10.1016/j.cej.2011.08.057
   Kocherginsky NM, 2007, SEP PURIF TECHNOL, V53, P171, DOI 10.1016/j.seppur.2006.06.022
   Kou DW, 2004, J CHROMATOGR A, V1055, P63, DOI 10.1016/j.chroma.2004.09.022
   Lee JY, 2008, ANAL CHIM ACTA, V624, P253, DOI 10.1016/j.aca.2008.06.050
   Lozano LJ, 2011, J MEMBRANE SCI, V376, P1, DOI 10.1016/j.memsci.2011.03.036
   Mahmud H, 2000, J MEMBRANE SCI, V179, P29, DOI 10.1016/S0376-7388(00)00381-1
   Mallubhotla H, 1999, J MEMBRANE SCI, V153, P259, DOI 10.1016/S0376-7388(98)00255-5
   Mansour M, 2017, CHEM ENG SCI, V172, P250, DOI 10.1016/j.ces.2017.06.015
   Martinez J, 2018, CHEM ENG SCI, V191, P134, DOI 10.1016/j.ces.2018.06.018
   McNeil MV, 2018, CHEM ENG SCI, V191, P479, DOI 10.1016/j.ces.2018.06.058
   Namiesnik J, 2005, ANAL BIOANAL CHEM, V381, P279, DOI 10.1007/s00216-004-2830-8
   Nivedita N, 2017, SCI REP-UK, V7, DOI 10.1038/srep44072
   Nuri Ata Osman, 2005, HYDROMETALLURGY, V80, P155
   Okubo A., 1984, DIFFUSION MASS TRANS
   Pabby AK, 2013, J MEMBRANE SCI, V430, P263, DOI 10.1016/j.memsci.2012.11.060
   Panja S, 2012, DESALINATION, V285, P213, DOI 10.1016/j.desal.2011.10.004
   Pedersen-Bjergaard S, 2008, J CHROMATOGR A, V1184, P132, DOI 10.1016/j.chroma.2007.08.088
   Petersen NJ, 2010, MICROFLUID NANOFLUID, V9, P881, DOI 10.1007/s10404-010-0603-6
   Prechtl C, 2017, CHEM ENG TECHNOL, V40, P670, DOI 10.1002/ceat.201600395
   Ren ZQ, 2007, CHEM ENG SCI, V62, P6090, DOI 10.1016/j.ces.2007.06.005
   Sun H, 2017, CHEM ENG RES DES, V123, P277, DOI 10.1016/j.cherd.2017.05.009
   Tang YX, 2013, PROCESS BIOCHEM, V48, P1980, DOI 10.1016/j.procbio.2013.09.006
   Teng T., 2012, J MEMBR SCI TECHNOL, V2, P1
   Valenzuela F, 2002, J MEMBRANE SCI, V204, P385, DOI 10.1016/S0376-7388(02)00067-4
   Vatankhah P, 2018, ANAL CHIM ACTA, V1022, P96, DOI 10.1016/j.aca.2018.03.039
   Vernekar PV, 2013, CHEM ENG RES DES, V91, P141, DOI 10.1016/j.cherd.2012.06.019
   Wang XY, 2005, ANAL CHIM ACTA, V543, P92, DOI 10.1016/j.aca.2005.04.033
   Wannachod T, 2014, CHEM ENG J, V248, P158, DOI 10.1016/j.cej.2014.03.024
   Xia HM, 2018, MICROSYST TECHNOL, V24, P1253, DOI 10.1007/s00542-017-3496-4
   YUSUF A, 2018, [No title captured], V22, DOI DOI 10.4314/JASEM.V22I5.18
   Zidi C, 2010, J MEMBRANE SCI, V360, P334, DOI 10.1016/j.memsci.2010.05.027
NR 50
TC 0
Z9 0
U1 9
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115344
DI 10.1016/j.ces.2019.115344
PG 14
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600035
DA 2020-05-12
ER

PT J
AU Wang, YJ
   Biegler, LT
   Patel, M
   Wassick, J
AF Wang, Yajun
   Biegler, Lorenz T.
   Patel, Mukund
   Wassick, John
TI Robust optimization of solid-liquid batch reactors under parameter
   uncertainty
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Batch processes; Optimal control; Robust optimization; Parameter
   uncertainty; Global solution
ID DYNAMIC OPTIMIZATION; ONLINE OPTIMIZATION; MODEL; DESIGN; APPROXIMATION
AB Unknown parameters in batch process models can be estimated as uncertainties owing to model mismatch, measurement errors and even the absence of variable measurements. Applying a model-based dynamic optimization with the estimated parameter values is likely to violate path and end-point constraints. This work aims at developing a robust off-line optimization strategy to overcome model uncertainty and improve control feasibility. First, model parameter uncertainty is quantified by the likelihood confidence region from parameter estimation. A two-stage multi-scenario approach is performed to enhance robustness of optimal solutions by adding worst-case scenarios to the optimal control problem. Detailed formulations of two stages for batch process optimal control under multiple scenarios and feasibility evaluation over the uncertainty space are introduced. Additionally, to avoid local solutions at the feasibility stage, we develop a multi-start approach to solve nonlinear programming problems starting from extreme points on the hyper-elliptical confidence region. This robust optimization approach is applied to case studies of industrial solid-liquid batch reactors. The results indicate the proposed approach is able to enhance robustness of optimal control and prevent hard constraint violations within a few iterations. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Yajun; Biegler, Lorenz T.] Carnegie Mellon Univ, Chem Engn Dept, Pittsburgh, PA 15213 USA.
   [Patel, Mukund; Wassick, John] DowDuPont Inc, Midland, MI 48640 USA.
RP Biegler, LT (reprint author), Carnegie Mellon Univ, Chem Engn Dept, Pittsburgh, PA 15213 USA.
EM lb01@andrew.cmu.edu
CR Abel O, 2003, J PROCESS CONTR, V13, P703, DOI 10.1016/S0959-1524(03)00002-7
   Albuquerque JS, 1997, AICHE J, V43, P986, DOI 10.1002/aic.690430414
   Biegler LT, 2010, MOS-SIAM SER OPTIMIZ, V10, pXIII, DOI 10.1137/1.9780898719383
   Bryson A. E., 1975, APPL OPTIMAL CONTROL
   Chen Z, 2012, IEEE T SMART GRID, V3, P1822, DOI 10.1109/TSG.2012.2212729
   Diehl M, 2006, MATH PROGRAM, V107, P213, DOI 10.1007/s10107-005-0685-1
   HALEMANE KP, 1983, AICHE J, V29, P425, DOI 10.1002/aic.690290312
   Holtorf F, 2019, J PROCESS CONTR, V80, P167, DOI 10.1016/j.jprocont.2019.05.007
   Li P, 2008, COMPUT CHEM ENG, V32, P25, DOI 10.1016/j.compchemeng.2007.05.009
   Nagy ZK, 2007, J PROCESS CONTR, V17, P229, DOI 10.1016/j.jprocont.2006.10.008
   Nagy ZK, 2004, J PROCESS CONTR, V14, P411, DOI 10.1016/j.jprocont.2003.07.004
   Puschke J, 2017, COMPUT CHEM ENG, V98, P161, DOI 10.1016/j.compchemeng.2016.12.004
   Rooney WC, 2001, AICHE J, V47, P1794, DOI 10.1002/aic.690470811
   Rossi F, 2016, AICHE J, V62, P3264, DOI 10.1002/aic.15346
   Samsatli NJ, 1998, AICHE J, V44, P1993, DOI 10.1002/aic.690440907
   Shi J, 2016, COMPUT CHEM ENG, V95, P260, DOI 10.1016/j.compchemeng.2016.08.002
   Srinivasan B, 2003, COMPUT CHEM ENG, V27, P1, DOI 10.1016/S0098-1354(02)00116-3
   Terwiesch P., 1994, Journal of Process Control, V4, P238, DOI 10.1016/0959-1524(94)80045-6
   Vin JP, 2001, IND ENG CHEM RES, V40, P4543, DOI 10.1021/ie0007724
   Visser E, 2000, J PROCESS CONTR, V10, P399, DOI 10.1016/S0959-1524(00)00015-9
   Wang LM, 2018, INT J SYST SCI, V49, P324, DOI 10.1080/00207721.2017.1402215
   Wang LM, 2017, IND ENG CHEM RES, V56, P10099, DOI 10.1021/acs.iecr.7b00525
   Wang YJ, 2018, CHEM ENG SCI, V187, P455, DOI 10.1016/j.ces.2018.05.040
   Zavala VA, 2008, CHEM ENG SCI, V63, P4834, DOI 10.1016/j.ces.2007.05.022
   Zhou Z, 2013, APPL ENERG, V103, P135, DOI 10.1016/j.apenergy.2012.09.019
NR 25
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115170
DI 10.1016/j.ces.2019.115170
PG 15
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600003
DA 2020-05-12
ER

PT J
AU Wang, YN
   Cao, LL
   Vanierschot, M
   Cheng, ZF
   Blanpain, B
   Guo, MX
AF Wang, Yannan
   Cao, Lingling
   Vanierschot, Maarten
   Cheng, Zhongfu
   Blanpain, Bart
   Guo, Muxing
TI Modelling of gas injection into a viscous liquid through a top-submerged
   lance
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Top injection flow; Viscous liquid; VOF-RNG/LES; Subgrid scale model;
   Model validation; Flow characteristics
ID NUMERICAL-SIMULATION; FLUID-FLOW; SLAG; TURBULENCE; BATH; HYDRODYNAMICS;
   BEHAVIOR
AB The hydrodynamics of a gas-viscous liquid flow is numerically studied by coupling the Volume of Fluid (VOF) method with the Renormalization Group (RNG) k e model or Large Eddy Simulation (LES) (VOFRNG or VOF-LES). The simulations are validated by Particle Imaging Velocimetry (PIV) measurements. Averaged flow features are predicted by 2D and 3D VOF-RNG/LES models. Only the 3D VOF-LES model predicts the velocity fluctuation well. The Dynamic Smagorinsky-Lilly (DSL) Subgrid-scale model slightly outperforms the Wall-Adapting Local Eddy-Viscosity (WALE) subgrid-scale model. Subsequently, flow characteristics of a gas-viscous liquid flow are studied by the validated 3D VOF-LES-DSL model under industrially relevant conditions. Gas penetration depth, flow velocity attenuation, surface sloshing and slag splashing are quantitatively described. The flow regime is identified through the pressure data monitored in the lance and its Fast Fourier Transform (FFT) results. The study of the coherent structures shows strong vortices in the top part of the slag pot. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Yannan; Cao, Lingling; Cheng, Zhongfu; Blanpain, Bart; Guo, Muxing] Katholieke Univ Leuven, Dept Mat Engn, B-3000 Leuven, Belgium.
   [Vanierschot, Maarten] Katholieke Univ Leuven, Mech Engn Technol Cluster TC, Campus Grp T Leuven, B-3000 Leuven, Belgium.
RP Wang, YN (reprint author), Katholieke Univ Leuven, Dept Mat Engn, B-3000 Leuven, Belgium.
EM yannan.wang@kuleuven.be
FU Grant IWT project [140514]
FX The authors gratefully acknowledge the computational support from HPC
   (KU Leuven) and financial support from Grant IWT project 140514
   (Flanders). Yannan Wang and Lingling Cao also would like to express
   their gratitude to the China Scholarship Council (CSC). Yannan Wang
   thank Daniele Obiso from TU Freiberg for his helpful suggestion in
   computing the time-averaged velocity of the liquid phase in the VOF
   model.
CR ANSYS Inc, 2015, ANS THEOR GUID 16 2
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   BRIGHAM EO, 1988, FAST FOURIER TRANSFO
   CHONG MS, 1990, PHYS FLUIDS A-FLUID, V2, P765, DOI 10.1063/1.857730
   COOLEY JW, 1969, IEEE T EDUC, VE 12, P27, DOI 10.1109/TE.1969.4320436
   Crowe CT, 1996, ANNU REV FLUID MECH, V28, P11, DOI 10.1146/annurev.fl.28.010196.000303
   Dippenaar R, 2005, IRONMAK STEELMAK, V32, P35, DOI 10.1179/174328105X15805
   Falcon E, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.094503
   Fulgosi M, 2003, J FLUID MECH, V482, P319, DOI 10.1017/S0022112003004154
   GERMANO M, 1991, PHYS FLUIDS A-FLUID, V3, P1760, DOI 10.1063/1.857955
   HOEFELE EO, 1979, METALL TRANS B, V10, P631, DOI 10.1007/BF02662566
   Hou Q, 2005, ISIJ INT, V45, P325, DOI 10.2355/isijinternational.45.325
   Huda N, 2012, METALL MATER TRANS B, V43, P39, DOI 10.1007/s11663-011-9558-6
   Huda N, 2010, METALL MATER TRANS B, V41, P35, DOI 10.1007/s11663-009-9316-1
   Hunt JCR, 1988, STUDYING TURBULENCE, V1, P193, DOI DOI 10.1017/S002211200800236X
   Hussain F., 1991, LUML S STUD TURB, P157, DOI [10.1007/978-1-4612-2792-211, DOI 10.1007/978-1-4612-2792-211]
   Hussain F., 1987, TURBULENCE MANAGEMEN, P445
   Hutton R. E., 1964, J APPL MECH, V31, P123
   IGUCHI M, 1994, ISIJ INT, V34, P973, DOI 10.2355/isijinternational.34.973
   IGWE BUN, 1973, METALL TRANS, V4, P1887, DOI 10.1007/BF02665417
   JEONG J, 1995, J FLUID MECH, V285, P69, DOI 10.1017/S0022112095000462
   Jha PK, 2003, INT J NUMER METHOD H, V13, P964, DOI 10.1108/09615530310501920
   Lakehal D, 2002, J TURBUL, V3
   Lamb H, 1932, HYDRODYNAMICS
   Launder B. E., 1974, Computer Methods in Applied Mechanics and Engineering, V3, P269, DOI 10.1016/0045-7825(74)90029-2
   Lee MS, 2003, SCAND J METALL, V32, P281, DOI 10.1034/j.1600-0692.2003.00653.x
   LEHRER LH, 1968, IND ENG CHEM PROC DD, V7, P226, DOI 10.1021/i260026a012
   LILLY DK, 1992, PHYS FLUIDS A-FLUID, V4, P633, DOI 10.1063/1.858280
   Liovic P, 2002, APPL MATH MODEL, V26, P113, DOI 10.1016/S0307-904X(01)00051-8
   Liovic P, 2007, INT J HEAT FLUID FL, V28, P127, DOI 10.1016/j.ijheatfluidflow.2006.03.003
   Madarame H, 2002, J FLUID STRUCT, V16, P417, DOI 10.1006/jfls.2000.0428
   MAZUMDAR D, 1985, METALL TRANS B, V16, P83, DOI 10.1007/BF02657492
   MIKHAIL SA, 1995, THERMOCHIM ACTA, V263, P87, DOI 10.1016/0040-6031(94)02413-I
   Morsi YS, 2000, CAN METALL QUART, V39, P87
   Motz H, 2001, WASTE MANAGE, V21, P285, DOI 10.1016/S0956-053X(00)00102-1
   Nicoud F, 1999, FLOW TURBUL COMBUST, V62, P183, DOI 10.1023/A:1009995426001
   Obiso D, 2019, METALL MATER TRANS B, V50, P2403, DOI 10.1007/s11663-019-01630-z
   PAN Y, 2010, J COMP MULTIFLOWS, V2, P151, DOI DOI 10.1260/1757-482X.2.3.151
   Ruzicka MC, 1997, INT J MULTIPHAS FLOW, V23, P671, DOI 10.1016/S0301-9322(97)00009-8
   Santos RM, 2012, CHEM ENG J, V203, P239, DOI 10.1016/j.cej.2012.06.155
   Sattar MA, 2014, CHEM ENG SCI, V107, P165, DOI 10.1016/j.ces.2013.11.037
   SCHWARZ MP, 1991, ISIJ INT, V31, P947, DOI 10.2355/isijinternational.31.947
   SCHWARZ MP, 1990, CHEM ENG SCI, V45, P1765, DOI 10.1016/0009-2509(90)87054-V
   Schwarze R, 2001, MODEL SIMUL MATER SC, V9, P279, DOI 10.1088/0965-0393/9/4/303
   Singh V, 2007, ISIJ INT, V47, P1605, DOI 10.2355/isijinternational.47.1605
   Smagorinsky J., 1963, MON WEATHER REV, V91, P99, DOI [10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, DOI 10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, 10.1175/1520-0493(1963)091, 10.1175/1520-0493(1963)091<less than>0099:GCEWTP<greater than>2.3.CO;2]
   Sutherland W, 1893, PHILOS MAG, V36, P507, DOI [DOI 10.1080/14786449308620508, 10.1080/14786449308620508]
   VANDOORMAAL JP, 1984, NUMER HEAT TRANSFER, V7, P147, DOI 10.1080/10407798408546946
   Vanierschot M, 2014, CHEM ENG SCI, V113, P88, DOI 10.1016/j.ces.2014.04.006
   Wang G, 2010, J HAZARD MATER, V184, P555, DOI 10.1016/j.jhazmat.2010.08.071
   Wang YN, 2018, CHEM ENG SCI, V192, P1091, DOI 10.1016/j.ces.2018.08.045
   Wei JH, 1999, IRONMAK STEELMAK, V26, P363, DOI 10.1179/030192399677239
   Yakhot V., 1986, Journal of Scientific Computing, V1, P3, DOI 10.1007/BF01061452
   Yang H., 2017, 12 INT C CFD OIL GAS, P355
   Youngs D., 1982, NUMERICAL METHODS FL, P273, DOI DOI 10.1007/S11433-009-0265-0
   Zhao HL, 2016, INT J MIN MET MATER, V23, P1369, DOI 10.1007/s12613-016-1360-7
   Zhao HL, 2017, INT J CHEM REACT ENG, V15, DOI 10.1515/ijcre-2016-0139
   ZHAO YF, 1990, METALL TRANS B, V21, P997, DOI 10.1007/BF02670270
NR 58
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115359
DI 10.1016/j.ces.2019.115359
PG 20
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600041
DA 2020-05-12
ER

PT J
AU Xu, D
   Ma, K
   Chen, L
   Hu, YJ
   Jiang, H
   Li, CZ
AF Xu, Da
   Ma, Kun
   Chen, Ling
   Hu, Yanjie
   Jiang, Hao
   Li, Chunzhong
TI MXene interlayer anchored Fe3O4 nanocrystals for ultrafast Li-ion
   batteries
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fe3O4 nanocrystals; MXene; 2D space confinement; High-rate; Li-ion
   batteries
ID ANODE MATERIAL; LITHIUM; NANOPARTICLES; MICROSPHERES; ARCHITECTURE;
   STORAGE
AB Balancing energy density and charging rate has been identified as a great challenge for Li-ion batteries (LIBs), which mainly hinges on developing high-performance electrode materials. Herein, we have developed nove Fe3O4@Ti3C2 hybrids, in which the Fe3O4 nanocrystals are well-anchored between Ti 3 C 2 interlayers with the assistance of the synergistic effects of 2D physical confinement and Ti-O-Fe covalent bonds. Such structural design can address the dispersion and volume change of nanocrystals during continuous charge/discharge with the enhancement of structural stability and the exposure of abundant active sites for each component. Meantime, the charge polarization caused by the Ti-O-Fe covalent bonds greatly accelerates the lithiation reaction kinetics and electrons transfer. These advantages endow the Fe3O4@Ti3C2 hybrids with a very high specific capacity of 1172 mAh g(-1) and a rapid charging capability of 366 mAh g(-1) in 66 s. A 90% capacity retention can be maintained even through 1000 cycles at 5 A g(-1). More impressively, we can also achieve a free-standing electrode by a simple vacuum filtering, exhibiting a high areal capacity of 4.2 mAh cm(-2) at 4.4 mg cm(-2) almost without sacrificing gravimetric capacity. The present 2D confined strategy provides a new notion to construct satisfactory electrodes for energy storage. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xu, Da; Ma, Kun; Jiang, Hao; Li, Chunzhong] East China Univ Sci & Technol, Sch Chem Engn, Minist Educ, Key Lab Ultrafine Mat, Shanghai 200237, Peoples R China.
   [Xu, Da; Chen, Ling; Hu, Yanjie; Jiang, Hao; Li, Chunzhong] East China Univ Sci & Technol, Shanghai Engn Res Ctr Hierarch Nanomat, Sch Mat Sci & Engn, Shanghai 200237, Peoples R China.
RP Jiang, H; Li, CZ (reprint author), East China Univ Sci & Technol, Sch Chem Engn, Minist Educ, Key Lab Ultrafine Mat, Shanghai 200237, Peoples R China.; Jiang, H; Li, CZ (reprint author), East China Univ Sci & Technol, Shanghai Engn Res Ctr Hierarch Nanomat, Sch Mat Sci & Engn, Shanghai 200237, Peoples R China.
EM jianghao@ecust.edu.cn; czli@ecust.edu.cn
RI Li, Chunzhong/B-1103-2015
OI Li, Chunzhong/0000-0001-7897-5850
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21975074, 91534202, 91834301]; Basic Research
   Program of Shanghai [17JC1402300]; Shanghai Scientific and Technological
   Innovation Project [18JC1410500]; National Program for Support of
   Top-Notch Young Professionals; Fundamental Research Funds for the
   Central UniversitiesFundamental Research Funds for the Central
   Universities [222201718002]
FX This work was supported by the National Natural Science Foundation of
   China (21975074, 91534202, and 91834301), the Basic Research Program of
   Shanghai (17JC1402300), the Shanghai Scientific and Technological
   Innovation Project (18JC1410500), the National Program for Support of
   Top-Notch Young Professionals, and the Fundamental Research Funds for
   the Central Universities (222201718002).
CR Armand M, 2008, NATURE, V451, P652, DOI 10.1038/451652a
   Brezesinski T, 2010, NAT MATER, V9, P146, DOI [10.1038/nmat2612, 10.1038/NMAT2612]
   Chao DL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12122
   Chen DY, 2011, ACS APPL MATER INTER, V3, P3078, DOI 10.1021/am200592r
   Du LY, 2017, NANOSCALE, V9, P14376, DOI 10.1039/c7nr05362b
   Fu CP, 2015, J MATER CHEM A, V3, P14245, DOI 10.1039/c5ta02210j
   He CN, 2013, ACS NANO, V7, P4459, DOI 10.1021/nn401059h
   Hu MM, 2018, ACS NANO, V12, P3578, DOI 10.1021/acsnano.8b00676
   Lee SH, 2013, NANO LETT, V13, P4249, DOI 10.1021/nl401952h
   Li J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09931-2
   Li J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07831-5
   Li L, 2015, ADV ENERGY MATER, V5, DOI 10.1002/aenm.201500171
   Li WY, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201705937
   Liu BQ, 2018, ADV ENERGY MATER, V8, DOI 10.1002/aenm.201702347
   Liu JL, 2018, GREEN ENERGY ENVIRON, V3, P20, DOI 10.1016/j.gee.2017.10.001
   Liu JL, 2018, ADV SCI, V5, DOI 10.1002/advs.201700322
   Liu SH, 2016, CHEMELECTROCHEM, V3, P38, DOI 10.1002/celc.201500410
   Liu Z, 2016, ADV ENERGY MATER, V6, DOI 10.1002/aenm.201502318
   Lu FF, 2017, ADV MATER INTERFACES, V4, DOI 10.1002/admi.201700639
   Ma K, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201804306
   Malik R, 2010, NANO LETT, V10, P4123, DOI 10.1021/nl1023595
   Meng RJ, 2018, ADV ENERGY MATER, V8, DOI 10.1002/aenm.201801514
   Muller GA, 2015, NANO LETT, V15, P1911, DOI 10.1021/nl504764m
   Peng LL, 2018, ACS NANO, V12, P820, DOI 10.1021/acsnano.7b08186
   Sathish M, 2012, J POWER SOURCES, V217, P85, DOI 10.1016/j.jpowsour.2012.05.099
   Shi Y, 2017, ADV MATER, V29, DOI 10.1002/adma.201603922
   Simon P, 2014, SCIENCE, V343, P1210, DOI 10.1126/science.1249625
   Tan QW, 2019, J MATER CHEM A, V7, P744, DOI 10.1039/c8ta09797f
   Tian RY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09792-9
   Wang B, 2013, ANGEW CHEM INT EDIT, V52, P4165, DOI 10.1002/anie.201300190
   Wang HW, 2017, ADV MATER, V29, DOI 10.1002/adma.201702093
   Wang YS, 2018, J MATER CHEM A, V6, P11189, DOI 10.1039/c8ta00122g
   Xiong QQ, 2012, J PHYS CHEM C, V116, P6495, DOI 10.1021/jp3002178
   Xu JS, 2012, ACS APPL MATER INTER, V4, P4752, DOI 10.1021/am301123f
   Xu L, 2018, GREEN ENERGY ENVIRON, V3, P156, DOI 10.1016/j.gee.2018.01.005
   Yan J, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201701264
   Yun S, 2019, ADV ENERGY MATER, V9, DOI 10.1002/aenm.201802816
   Zhang X, 2015, MATER LETT, V157, P63, DOI 10.1016/j.matlet.2015.05.047
   Zhao L, 2015, ACS APPL MATER INTER, V7, P9709, DOI 10.1021/acsami.5b01503
   Zhu CB, 2017, SCIENCE, V358, DOI 10.1126/science.aao2808
   Zhuo LH, 2013, J MATER CHEM A, V1, P3954, DOI 10.1039/c3ta01388j
NR 41
TC 0
Z9 0
U1 110
U2 110
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115342
DI 10.1016/j.ces.2019.115342
PG 8
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600033
DA 2020-05-12
ER

PT J
AU Zhang, ZJ
   Chan, LLT
   Chen, JH
   Shao, ZJ
AF Zhang, Zhengjiang
   Chan, Lester Lik Teck
   Chen, Junghui
   Shao, Zhijiang
TI Correntropy based data reconciliation and gross error detection for
   bilinear systems
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Chemical processes; Correntropy; Data reconciliation; Gross error;
   Robust estimator
ID ROBUST DATA RECONCILIATION; ESTIMATORS; FRAMEWORK
AB Data reconciliation and gross error detection plays an important role in the process control as measured signals are often contaminated by measurement errors. The simultaneous reconciliation of flow rate and composition measurements results in nonlinear constraints. A Correntropy based data reconciliation and gross error detection method is proposed for the type of bilinear systems with specific to the flow rate and measurement composition. Correntropy is a robust estimator and is effective in reducing the effect of gross errors. Moreover, unmeasured variables can be effectively identified. The Correntropy based data reconciliation and gross error detection method is applied to the mineral processing plant and air separation process for application. Results demonstrate that the proposed method can overcome the weakness of being sensitive to the effect of gross errors. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Zhengjiang] Wenzhou Univ, Coll Math Phys & Elect Informat Engn, Wenzhou 325035, Peoples R China.
   [Chan, Lester Lik Teck; Chen, Junghui] Chung Yuan Christian Univ, Dept Chem Engn, Taoyuan 32023, Taiwan.
   [Shao, Zhijiang] Zhejiang Univ, Inst Ind Control, State Key Lab Ind Control Technol, Hangzhou 310027, Zhejiang, Peoples R China.
RP Chen, JH (reprint author), Chung Yuan Christian Univ, Dept Chem Engn, Taoyuan 32023, Taiwan.
EM jason@wavenet.cycu.edu.tw
RI Zhang, Zhengjiang/H-9667-2015; Chen, Junghui/A-9496-2015
OI Zhang, Zhengjiang/0000-0001-6018-5527; Chen, Junghui/0000-0002-9994-839X
FU Ministry of Science and Technology, R.O.C. [MOST
   106-2221-E-033-060-MY3]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [61703309]; National
   Key R&D Program of China [2017YFB0603703]
FX The authors would like to gratefully acknowledge Ministry of Science and
   Technology, R.O.C. (MOST 106-2221-E-033-060-MY3), the National Natural
   Science Foundation of China (No. 61703309), and the National Key R&D
   Program of China (2017YFB0603703) for the financial support.
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Albuquerque JS, 1996, AICHE J, V42, P2841, DOI 10.1002/aic.690421014
   Alhaj-Dibo M, 2008, CONTROL ENG PRACT, V16, P159, DOI 10.1016/j.conengprac.2007.01.003
   Alighardashi H, 2017, IND ENG CHEM RES, V56, P14530, DOI 10.1021/acs.iecr.7b02930
   Arora N, 2001, COMPUT CHEM ENG, V25, P1585, DOI 10.1016/S0098-1354(01)00721-9
   Buzzi-Ferraris G, 2011, COMPUT CHEM ENG, V35, P388, DOI 10.1016/j.compchemeng.2010.11.004
   Chen JH, 2013, CHEM ENG SCI, V104, P1019, DOI 10.1016/j.ces.2013.09.034
   CROWE CM, 1986, AICHE J, V32, P616, DOI 10.1002/aic.690320410
   do Valle EC, 2018, COMPUT CHEM ENG, V111, P134, DOI 10.1016/j.compchemeng.2018.01.002
   Erdogmus D, 2002, IEEE T SIGNAL PROCES, V50, P1780, DOI 10.1109/TSP.2002.1011217
   Kim M, 2008, INT J REFRIG, V31, P790, DOI 10.1016/j.ijrefrig.2007.11.008
   Liu WF, 2007, IEEE T SIGNAL PROCES, V55, P5286, DOI 10.1109/TSP.2007.896065
   Llanos CE, 2017, IND ENG CHEM RES, V56, P9617, DOI 10.1021/acs.iecr.7b00726
   Llanos CE, 2015, IND ENG CHEM RES, V54, P5096, DOI 10.1021/ie504735a
   MCCORMICK GP, 1976, MATH PROGRAM, V10, P147, DOI 10.1007/BF01580665
   Munoz JC, 2012, CHEMOMETR INTELL LAB, V111, P53, DOI 10.1016/j.chemolab.2011.11.007
   Narasimhan S, 2000, DATA RECONCILIATION
   Ozyurt DB, 2004, COMPUT CHEM ENG, V28, P381, DOI 10.1016/j.compchemeng.2003.07.001
   Prata DM, 2010, CHEM ENG SCI, V65, P4943, DOI 10.1016/j.ces.2010.05.017
   Ragot J, 2005, AICHE J, V51, P1569, DOI 10.1002/aic.10412
   ROUSSEEUW P, 1987, ROBUST REGRESSION OU
   Rousseeuw P.J., 1985, ABSTRACTS IMS B, V14, P399
   SERTH RW, 1987, CHEM ENG COMMUN, V51, P89, DOI 10.1080/00986448708911836
   SMITH HW, 1973, CIM BULL, V66, P97
   Soderstrom TA, 2001, CONTROL ENG PRACT, V9, P869, DOI 10.1016/S0967-0661(01)00056-9
   Venkataraman P., 2009, APPL OPTIMIZATION MA
   Wang D, 2003, IND ENG CHEM RES, V42, P3075, DOI 10.1021/ie0206655
   Wu SX, 2016, NEUROCOMPUTING, V175, P808, DOI 10.1016/j.neucom.2015.10.093
   Xia R, 2018, POLYM ENG SCI, V58, P2071, DOI 10.1002/pen.24818
   Xie S, 2019, CONTROL ENG PRACT, V83, P203, DOI 10.1016/j.conengprac.2018.11.006
   Yamamura K., 1988, INT CHEM ENG, V28, P91
   Zhang ZJ, 2010, COMPUT CHEM ENG, V34, P154, DOI 10.1016/j.compchemeng.2009.09.007
NR 32
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 2
PY 2020
VL 212
AR 115327
DI 10.1016/j.ces.2019.115327
PG 14
WC Engineering, Chemical
SC Engineering
GA JV0CP
UT WOS:000502034600018
DA 2020-05-12
ER

PT J
AU Grodeland, G
   Fossum, E
   Bogen, B
AF Grodeland, Gunnveig
   Fossum, Even
   Bogen, Bjarne
TI Targeting of HA to chemokine receptors induces strong and cross-reactive
   T cell responses after DNA vaccination in pigs
SO VACCINE
LA English
DT Article
DE DNA vaccine; Influenza; Chemokine receptor; APC-targeting; Pig
ID MOLECULES; HEMAGGLUTININ; EXPRESSION; EFFICACY; VACCINES
AB Efficient influenza vaccination of pigs can reduce disease burdens for the swine industry, but also represents an important measure for reducing the risk from novel viral reassortments that pose pandemic threats to the human population. Here, we have vaccinated pigs with a DNA vaccine encoding influenza virus hemagglutinin (HA) linked to the chemokine MIP1 alpha that bind chemokine receptors 1, 3, and 5 expressed on antigen presenting cells (APC). Such MIP1 alpha targeting of HA to APC enhanced induction of HA reactive antibodies, particularly IgG2. In addition, the MIP1 alpha- HA vaccine induced strong T cell responses that could cross-react with different influenza subtypes. Thus, the strategy of targeting HA to chemokine receptors could be important for inducing broad protection against antigenically diverse influenza strains in pigs. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 Univ Oslo, Inst Clin Med, KG Jebsen Ctr Influenza Vaccine Res, N-0027 Oslo, Norway.
   Oslo Univ Hosp, N-0027 Oslo, Norway.
RP Grodeland, G (reprint author), Univ Oslo, Inst Immunol, Sognsvannsveien 20, N-0027 Oslo, Norway.
EM gunnveig.grodeland@medisin.uio.no
OI Grodeland, Gunnveig/0000-0001-6285-3162
CR Bemelin-Cottet C, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00641
   Boudreau CM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00440
   Butler JE, 2009, IMMUNOGENETICS, V61, P209, DOI 10.1007/s00251-008-0336-9
   Crawley A, 2003, VACCINE, V21, P2911, DOI 10.1016/S0264-410X(03)00142-7
   Eriksson P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29578-1
   Fossum E, 2015, EUR J IMMUNOL, V45, P624, DOI 10.1002/eji.201445080
   Fredriksen AB, 2007, BLOOD, V110, P1797, DOI 10.1182/blood-2006-06-032938
   Grodeland G, 2016, J IMMUNOL, V197, P3575, DOI 10.4049/jimmunol.1600893
   Grodeland G, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00367
   Grodeland G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080008
   Grodeland G, 2013, J IMMUNOL, V191, P3221, DOI 10.4049/jimmunol.1300504
   He P, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0088-z
   Khiabanian H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007366
   Khurana S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006366
   Kirkpatrick E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28706-1
   Liu MA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020037
   Nelli RK, 2010, BMC VET RES, V6, DOI 10.1186/1746-6148-6-4
   Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948
   Norderhaug L, 1997, J IMMUNOL METHODS, V204, P77, DOI 10.1016/S0022-1759(97)00034-3
   Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X
   Ruffini PA, 2010, VACCINE, V29, P191, DOI 10.1016/j.vaccine.2010.10.057
   STAUDT LM, 1983, J EXP MED, V157, P687, DOI 10.1084/jem.157.2.687
   Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803
   Wang JM, 1998, INT J CANCER, V75, P900, DOI 10.1002/(SICI)1097-0215(19980316)75:6<900::AID-IJC13>3.0.CO;2-6
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1280
EP 1285
DI 10.1016/j.vaccine.2019.11.084
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900002
PM 31836256
OA Other Gold
DA 2020-05-12
ER

PT J
AU Poh, ZW
   Wang, ZZ
   Kumar, SR
   Yong, HY
   Prabakaran, M
AF Poh, Zhong Wee
   Wang, Zhenzhang
   Kumar, Subaschandrabose Rajesh
   Yong, Hui Yee
   Prabakaran, Mookkan
TI Modification of neutralizing epitopes of hemagglutinin for the
   development of broadly protective H9N2 vaccine
SO VACCINE
LA English
DT Article
DE H9N2; Baculoviral display HA; Neutralizing epitope; Monovalent vaccine
   strain
ID AVIAN INFLUENZA-VIRUS; HUMAN INFECTION; CHINA; EVOLUTION
AB The H9N2 avian influenza viruses cause significant economic losses in poultry worldwide and could potentially cause human pandemic. Currently, the available vaccines have limited efficacy due to antigenic drift of H9N2. To improve vaccine efficacy, we developed monovalent vaccine strain via the modification of neutralizing epitopes on hemagglutinin (HA) to broaden the protection against H9N2 viruses. In this study, single and multiple mutation were introduced to amino acid at position 148,150 (site I) and 183, 186, 188 (site II) on the full-length HA gene of H9N2 strain (A/Hong Kong/33982/2009). These mutant HA constructs were displayed on the baculovirus surface (BacH9), and evaluated for their cross-protective efficacy against H9N2 viruses in a mouse model. Our findings indicate that mice immunized with multiple BacH9 mutant constructs (148-150 183 and 186) induced cross-protective immunity against circulating H9N2 in the viral challenge study and prove to be a promising vaccine candidate for H9N2. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Poh, Zhong Wee; Wang, Zhenzhang; Kumar, Subaschandrabose Rajesh; Yong, Hui Yee; Prabakaran, Mookkan] Natl Univ Singapore, Temasek Life Sci Lab, 1 Res Link, Singapore 117604, Singapore.
RP Prabakaran, M (reprint author), Natl Univ Singapore, Temasek Life Sci Lab, 1 Res Link, Singapore 117604, Singapore.
EM prabakar@tll.org.sg
OI Prabakaran, Mookkan/0000-0002-9816-5908
FU Temasek Life Sciences Laboratory, SingaporeNational University of
   Singapore
FX We are grateful for the financial support received from Temasek Life
   Sciences Laboratory, Singapore. We thank Subramanian Kabilan and Govind
   Govindarajan for animal work.
CR CHAMBERS TM, 1988, VIROLOGY, V167, P414, DOI 10.1016/0042-6822(88)90103-1
   Cong YL, 2007, J GEN VIROL, V88, P2035, DOI 10.1099/vir.0.82783-0
   Huang YW, 2015, J MED VIROL, V87, P1641, DOI 10.1002/jmv.24231
   Kaverin NV, 2004, J VIROL, V78, P240, DOI 10.1128/JVI.78.1.240-249.2004
   Lee DH, 2013, CLIN EXP VACCINE RES, V2, P26, DOI 10.7774/cevr.2013.2.1.26
   Okamatsu M, 2008, ARCH VIROL, V153, P2189, DOI 10.1007/s00705-008-0243-2
   Park KJ, 2011, J GEN VIROL, V92, P36, DOI 10.1099/vir.0.024992-0
   Peacock T, 2016, SCI REP-UK, V6, DOI 10.1038/srep18745
   Peiris JSM, 2001, J VIROL, V75, P9679, DOI 10.1128/JVI.75.20.9679-9686.2001
   Prabakaran M, 2008, VIROLOGY, V380, P412, DOI 10.1016/j.virol.2008.08.002
   Prabakaran M, 2010, J VIROL, V84, P11822, DOI 10.1128/JVI.00891-10
   Prabakaran M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005672
   Qi XF, 2016, VET RES, V47, DOI 10.1186/s13567-016-0322-4
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rueda P, 2000, VACCINE, V19, P726, DOI 10.1016/S0264-410X(00)00259-0
   Sealy JE, 2019, EMERG INFECT DIS, V25, P63, DOI 10.3201/eid2501.180616
   Sun YP, 2015, PROTEIN CELL, V6, P18, DOI 10.1007/s13238-014-0111-7
   Sun YP, 2011, P NATL ACAD SCI USA, V108, P4164, DOI 10.1073/pnas.1019109108
   Wang ZY, 2019, VACCINE, V37, P1736, DOI 10.1016/j.vaccine.2019.02.012
   WEBSTER RG, 1991, VACCINE, V9, P303, DOI 10.1016/0264-410X(91)90055-B
   Yokoyama WM, 2006, CURR PROTOC CYTOM
   Yuan RY, 2017, J INFECTION, V74, P422, DOI 10.1016/j.jinf.2017.01.003
   Zhang PH, 2008, J GEN VIROL, V89, P3102, DOI 10.1099/vir.0.2008/005652-0
NR 23
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1286
EP 1290
DI 10.1016/j.vaccine.2019.11.080
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900003
PM 31924429
DA 2020-05-12
ER

PT J
AU Nnaji, CA
   Shey, MS
   Adetokunboh, OO
   Wiysonge, CS
AF Nnaji, Chukwudi A.
   Shey, Muki S.
   Adetokunboh, Olatunji O.
   Wiysonge, Charles S.
TI Immunogenicity and safety of fractional dose yellow fever vaccination: A
   systematic review and meta-analysis
SO VACCINE
LA English
DT Review
DE Yellow fever; Vaccination; Fractional dose; Dose-sparing;
   Immunogenicity; Safety
ID SERIOUS ADVERSE EVENTS; CASE DEFINITIONS; GUIDELINES; COLLECTION; 17D;
   VIRUS
AB Background: Recent upsurges in yellow fever outbreaks are increasing the demand for yellow fever vaccine, while enormously straining global vaccine supply. Fractional dose yellow fever vaccination is being considered as a dose-sparing strategy to address current vaccine shortages. This systematic review and meta-analysis aimed to assess the effects of fractional dose yellow fever vaccination, in comparison with those of standard dose vaccination.
   Methods: We registered this review on the International Prospective Register of Systematic Reviews (PROSPERO, registration number: CRD42018084214), developed the protocol in line with the Preferred Reporting Items for Systematic Review and Meta-Analyses Protocols (PRISMA-P) and synthesised the evidence in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA). We stratified meta-analyses by vaccine dose.
   Results: We retrieved 2524 records from the literature search, eleven of them potentially eligible. From these studies, we included eight eligible trials, with a total of 2371 participants. Seroconversion rates at four to five weeks following vaccination were similar between participants who received standard doses and participants who received fractional doses containing one-third (547 participants: risk ratio [RR] 1.02, 95% confidence interval [CI] 1.00-1.04), one-fifth (155 participants: RR 1.00, 95% CI 0.98-1.03), one-tenth (890 participants: RR 0.99, 95% CI 0.96-1.01), and one-fiftieth (661 participants: RR 0.97, 95% CI 0.92-1.02) of the standard dose. However, the rates of seroconversion were substantially lower among participants who received fractional doses containing one-hundredth and lower fractions of the standard dose. Immunogenicity similarly persisted 8-10 years following both fractional and standard dose vaccination. Minor adverse events following vaccination did not differ across doses, and no serious adverse events were reported in any study arm.
   Conclusions: These findings support the use of fractional dosing as a strategy for mitigating vaccine short-ages. The strategy should be specifically considered for individuals who are young, immuno-competent and well nourished. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Nnaji, Chukwudi A.; Wiysonge, Charles S.] Univ Cape Town, Sch Publ Hlth & Family Med, Cape Town, South Africa.
   [Nnaji, Chukwudi A.; Adetokunboh, Olatunji O.; Wiysonge, Charles S.] South African Med Res Council, Cochrane South Africa, Cape Town, South Africa.
   [Shey, Muki S.] Univ Cape Town, Dept Med, Cape Town, South Africa.
   [Shey, Muki S.] Univ Cape Town, Wellcome Ctr Infect Dis Res Africa CIDRI Africa, Cape Town, South Africa.
   [Adetokunboh, Olatunji O.] Stellenbosch Univ, DST NRF Ctr Excellence Epidemiol Modelling & Anal, Stellenbosch, South Africa.
   [Adetokunboh, Olatunji O.; Wiysonge, Charles S.] Stellenbosch Univ, Dept Global Hlth, Stellenbosch, South Africa.
RP Nnaji, CA (reprint author), Univ Cape Town, Sch Publ Hlth & Family Med, Cape Town, South Africa.
EM nnjchu001@myuct.ac.za
RI Nnaji, Chukwudi A/C-4019-2018; Adetokunboh, Olatunji/O-7224-2018; Shey,
   Muki/M-1273-2016
OI Wiysonge, Charles/0000-0002-1273-4779; Nnaji,
   Chukwudi/0000-0002-4132-1922; Adetokunboh, Olatunji/0000-0002-4608-3951;
   Shey, Muki/0000-0002-8776-4737
FU South African Medical Research Council; National Research Foundation of
   South AfricaNational Research Foundation - South Africa [106035, 108571,
   111678]; Wellcome Trust Intermediate Fellowship in Public Health and
   Tropical MedicineWellcome Trust [211360/Z/18/Z]
FX This work is sponsored partly by the South African Medical Research
   Council and the National Research Foundation of South Africa (Grant
   Numbers: 106035, 108571 and 111678). MSS is supported by Wellcome Trust
   Intermediate Fellowship in Public Health and Tropical Medicine (Grant
   number 211360/Z/18/Z).
CR Barnett ED, 2007, CLIN INFECT DIS, V44, P850, DOI 10.1086/511869
   Booth A, 2012, SYST REV, V1, DOI 10.1186/2046-4053-1-2
   Camacho LAB, 2004, REV SAUDE PUBL, V38, P671, DOI 10.1590/S0034-89102004000500009
   Campi-Azevedo AC, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-391
   Casey RM, 2018, N ENGL J MED
   Domingo C, LANCET INFECT DIS
   FINNEY DJ, 1995, J CLIN EPIDEMIOL, V48, P87, DOI 10.1016/0895-4356(94)00096-9
   Fox JP, 1943, AM J HYG, V38, P113, DOI 10.1093/oxfordjournals.aje.a118875
   FREESTONE DS, 1977, J BIOL STAND, V5, P181, DOI 10.1016/S0092-1157(77)80003-6
   Gavi, 2017, YELL FEV SUPPL PROC
   Gershman MD, 2012, VACCINE, V30, P5038, DOI 10.1016/j.vaccine.2012.04.067
   Gotuzzo E, 2013, AM J TROP MED HYG, V89, P434, DOI 10.4269/ajtmh.13-0264
   Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE
   Hickling J, 2013, YELLOW FEVER VACCINA
   Higgins JP, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Jacobson RA, 2007, VACCINE, V25, P3153, DOI 10.1016/j.vaccine.2007.01.047
   Jean K, 2016, AM J TROP MED HYG, V95, P1435, DOI 10.4269/ajtmh.16-0401
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Lindsey NP, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw045
   LOPES OD, 1988, J BIOL STAND, V16, P77
   Lyman Gary H, 2005, BMC Med Res Methodol, V5, P14, DOI 10.1186/1471-2288-5-14
   Martins RD, 2018, VACCINE, V36, P4112, DOI 10.1016/j.vaccine.2018.05.041
   Martins RM, 2013, HUM VACC IMMUNOTHER, V9, P879, DOI 10.4161/hv.22982
   Melsen WG, 2014, CLIN MICROBIOL INFEC, V20, P123, DOI 10.1111/1469-0691.12494
   Monath TP, 2005, HUM VACCINES, V1, P207, DOI 10.4161/hv.1.5.2221
   Monath TP, 2016, LANCET, V387, P1599, DOI 10.1016/S0140-6736(16)30195-7
   Monath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030
   Norrby E, 2007, J EXP MED, V204, P2779, DOI 10.1084/jem.20072290
   Nzolo D, 2017, SAFETY PROFILE FRACT
   Roukens AH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001993
   Roukens AH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027753
   Roukens AH, 2009, VACCINE, V27, P2408, DOI 10.1016/j.vaccine.2009.02.049
   Roukens AHE, 2018, ANN INTERN MED, V169, P761, DOI 10.7326/M18-1529
   Ruggeberg JU, 2007, VACCINE, V25, P5675, DOI 10.1016/j.vaccine.2007.02.064
   Sejvar JJ, 2007, VACCINE, V25, P5771, DOI 10.1016/j.vaccine.2007.04.060
   Sejvar JJ, 2011, VACCINE, V29, P599, DOI 10.1016/j.vaccine.2010.06.003
   Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.i4086, 10.1136/bmj.g7647]
   The Nordic Cochrane Centre. The Cochrane Collaboration, 2014, REV MAN REVMAN REVMA
   Thomas RE, 2016, DRUG DES DEV THER, V10, P3345, DOI 10.2147/DDDT.S99600
   Thomas RE, 2013, VACCINE, V31, P6201, DOI 10.1016/j.vaccine.2013.10.050
   Thomas RE, 2011, VACCINE, V29, P4544, DOI 10.1016/j.vaccine.2011.04.055
   WHO, 2015, VACCINE, V33, P76, DOI 10.1016/j.vaccine.2014.05.040
   Wiysonge CS, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-3
   World Health Organization, PROCEEDING, V23, P12
   World Health Organization (WHO), 2016, WHOYFSAGE161
   World Health Organization (WHO), 2008, REQ BIOL SUBST
   World Hlth Org, 2017, VACCINE, V35, P5753, DOI 10.1016/j.vaccine.2017.05.069
NR 48
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1291
EP 1301
DI 10.1016./j.vaccine.2019.12.018
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900004
PM 31859201
DA 2020-05-12
ER

PT J
AU Whitworth, HS
   Gallagher, KE
   Howard, N
   Mounier-Jack, S
   Mbwanji, G
   Kreimer, AR
   Basu, P
   Kelly, H
   Drolet, M
   Brisson, M
   Watson-Jones, D
AF Whitworth, Hilary S.
   Gallagher, Katherine E.
   Howard, Natasha
   Mounier-Jack, Sandra
   Mbwanji, Gladys
   Kreimer, Aimee R.
   Basu, Partha
   Kelly, Helen
   Drolet, Melanie
   Brisson, Marc
   Watson-Jones, Deborah
TI Efficacy and immunogenicity of a single dose of human papillomavirus
   vaccine compared to no vaccination or standard three and two-dose
   vaccination regimens: A systematic review of evidence from clinical
   trials
SO VACCINE
LA English
DT Review
DE Human papillomavirus; Vaccine; Dosage; Efficacy; Immunogenicity
ID BIVALENT HPV VACCINE; COSTA-RICA VACCINE; AS04-ADJUVANTED VACCINE;
   DOUBLE-BLIND; INFECTION; IMPACT; RESPONSES; IMMUNITY; DESIGN; CANCER
AB Objectives: This study aimed to systematically review the literature on the efficacy and immunogenicity of single-dose HPV vaccination compared to no vaccination or multi-dose schedules among vaccine trial participants.
   Methods: Medline, EMBASE, Global Health Database and Cochrane Central Register of Controlled Trials were searched for publications and conference abstracts (dated January 1999 -August 2018) using MeSH and non-MeSH terms for human papillomavirus AND vaccines AND (immunogenicity OR efficacy/effectiveness) AND dosage. Search results were screened against pre-specified eligibility criteria. Data were extracted from included articles, and a narrative synthesis conducted on efficacy against HPV16/18 infection and humoral immunogenicity.
   Results: Seven of 6,523 unique records identified were included in the review. Six were nested observational studies of participants randomised to receive two or three doses in three large HPV vaccine trials, in which some participants did not complete their allocated schedules. One small pilot study prospectively allocated participants to receive one or no vaccine dose. Frequency of HPV16/18 infection was low (e.g. <1% for 12-month-persistent infection) in all vaccinated participants up to seven years post vaccination and did not significantly differ by number of doses (p > 0.05 in all cases). Frequency of infection was significantly lower in one-dose recipients compared to unvaccinated controls (p < 0.01 for all infection endpoints in each study). HPV16/18 seropositivity rates were high in all HPV vaccine recipients (100% in three of four studies reporting this endpoint), though antibody levels were lower with one compared to two or three doses.
   Conclusions: This review supports the premise that one HPV vaccine dose may be as effective in preventing HPV infection as multi -dose schedules in healthy young women. However, it also highlights the paucity of available evidence from purpose-designed, prospectively-randomised trials. Results from ongoing clinical trials assessing the efficacy and immunogenicity of single-dose HPV vaccination compared to currently-recommended schedules are awaited. 2019 The Authors. Published by Elsevier Ltd.
C1 [Whitworth, Hilary S.; Kelly, Helen; Watson-Jones, Deborah] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England.
   [Gallagher, Katherine E.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, London, England.
   [Howard, Natasha; Mounier-Jack, Sandra] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, London, England.
   [Whitworth, Hilary S.; Mbwanji, Gladys; Watson-Jones, Deborah] Natl Inst Med Res, Mwanza Intervent Trials Unit, Mwanza, Tanzania.
   [Kreimer, Aimee R.] NCI, NIH, Bethesda, MD 20892 USA.
   [Basu, Partha] WHO, Int Agcy Res Canc, Lyon, France.
   [Drolet, Melanie; Brisson, Marc] Univ Laval, Ctr Rech CHU Quebec, Quebec City, PQ, Canada.
   [Brisson, Marc] Laval Univ, Dept Social & Prevent Med, Quebec City, PQ, Canada.
RP Whitworth, HS (reprint author), LSHTM, Keppel St, London WC1E 7HT, England.
EM hilary.whitworth@lshtm.ac.uk
OI Basu, Partha/0000-0003-0124-4050; Howard, Natasha/0000-0003-4174-7349
FU PATH on behalf of the Single-Dose HPV Vaccine Evaluation Consortium
   [GAT.2233-01625422-SUB]; Harvard University (Harvard); London School of
   Hygiene & Tropical Medicine (LSHTM); PATHUnited States Agency for
   International Development (USAID); US National Cancer Institute
   (NCI)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI);
   University of British Columbia, Canada (UBC); Universite Laval, Quebec
   (CHU); University of Witwatersrand Reproductive Health and HIV Institute
   (Wits RHI); US Centers for Disease Control and Prevention (CDC)United
   States Department of Health & Human ServicesCenters for Disease Control
   & Prevention - USA
FX Financial support for this project was provided by PATH on behalf of the
   Single-Dose HPV Vaccine Evaluation Consortium (grant ID
   GAT.2233-01625422-SUB), which includes Harvard University (Harvard),
   London School of Hygiene & Tropical Medicine (LSHTM), PATH, US National
   Cancer Institute (NCI), University of British Columbia, Canada (UBC),
   CHU de Quebec-Universite Laval, Quebec (CHU), University of
   Witwatersrand Reproductive Health and HIV Institute (Wits RHI), and the
   US Centers for Disease Control and Prevention (CDC).
CR [Anonymous], 2014, Wkly Epidemiol Rec, V89, P465
   Aranda S, 2017, INT J GYNECOL OBSTET, V138, P4, DOI 10.1002/ijgo.12182
   Basu P, 2016, HUM VACC IMMUNOTHER, V12, P1394, DOI 10.1080/21645515.2016.1146429
   Beachler DC, 2016, J INFECT DIS, V213, P1444, DOI 10.1093/infdis/jiv753
   Brisson M, 2016, LANCET PUBLIC HEALTH, V1, pE8, DOI 10.1016/S2468-2667(16)30001-9
   Cuschieri K, 2016, BRIT J CANCER, V114, P1261, DOI 10.1038/bjc.2016.97
   Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055
   Gallagher KE, 2018, VACCINE, V36, P4761, DOI 10.1016/j.vaccine.2018.02.003
   Ghebreyesus TA, 2018, CERVICAL CANC NCD WE
   Gilca V, 2019, HUM VACC IMMUNOTHER, V15, P1
   Gilca V, 2019, HUM VACC IMMUNOTHER, V15, P503, DOI 10.1080/21645515.2018.1522469
   Hall MT, 2019, LANCET PUBLIC HEALTH, V4, pE19, DOI 10.1016/S2468-2667(18)30183-X
   Herrero R, 2008, VACCINE, V26, P4795, DOI 10.1016/j.vaccine.2008.07.002
   Higgins JP, 2010, STAT METHODS GROUP C, P1
   Joura EA, 2015, NEW ENGL J MED, V372, P711, DOI 10.1056/NEJMoa1405044
   Kavanagh K, 2014, BRIT J CANCER, V110, P2804, DOI 10.1038/bjc.2014.198
   Kreimer AR, 2018, VACCINE, V36, P4774, DOI 10.1016/j.vaccine.2017.12.078
   Kreimer AR, 2015, LANCET ONCOL, V16, P775, DOI 10.1016/S1470-2045(15)00047-9
   Kreimer AR, 2011, JNCI-J NATL CANCER I, V103, P1444, DOI 10.1093/jnci/djr319
   LaMontagne DS, 2014, VACCINE, V32, P6303, DOI 10.1016/j.vaccine.2014.08.071
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Markowitz LE, 2018, VACCINE, V36, P4806, DOI 10.1016/j.vaccine.2018.01.057
   Paovonen J, 2009, LANCET, V374, P301, DOI 10.1016/S0140-6736(09)61248-4
   PATH, 2018, GLOB HPV VACC INTR O
   Pinto LA, 2018, VACCINE, V36, P4792, DOI 10.1016/j.vaccine.2017.11.089
   Safaeian M, 2016, CANCER PREV RES, V9, P116, DOI 10.1158/1940-6207.CAPR-15-0373
   Safaeian M, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx158
   Safaeian M, 2013, CANCER PREV RES, V6, P1242, DOI 10.1158/1940-6207.CAPR-13-0203
   Sampson JN, 2018, CONTEMP CLIN TRIALS, V68, P35, DOI 10.1016/j.cct.2018.02.010
   Sankaranarayanan R, 2018, VACCINE, V36, P4783, DOI 10.1016/j.vaccine.2018.02.087
   Sankaranarayanan R, 2016, LANCET ONCOL, V17, P67, DOI 10.1016/S1470-2045(15)00414-3
   Scherer EM, 2016, EBIOMEDICINE, V10, P55, DOI 10.1016/j.ebiom.2016.06.042
   Schiller JT, 2012, VACCINE, V30, pF123, DOI 10.1016/j.vaccine.2012.04.108
   Signorelli C, 2017, EPIDEMIOL INFECT, V145, P1962, DOI [10.1017/s0950268817000747, 10.1017/S0950268817000747]
   Simms KT, 2019, LANCET ONCOL, V20, P394, DOI 10.1016/S1470-2045(18)30836-2
   Single-Dose HPV vaccine evaluation consortium, 2018, GEN SUMM CURR PUBL E
   Stanley M, 2018, VACCINE, V36, P4759, DOI 10.1016/j.vaccine.2018.02.076
   Toh ZQ, 2017, CLIN INFECT DIS, V64, P852, DOI 10.1093/cid/ciw865
   Toh ZQ, 2015, VACCINE, V33, P5042, DOI 10.1016/j.vaccine.2015.07.102
   World Health Organization lAfRoC, 2018, GLOBOCAN 2018
NR 40
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1302
EP 1314
DI 10.1016/j.vaccine.2019.12.017
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900005
PM 31870572
OA Green Accepted, Other Gold
DA 2020-05-12
ER

PT J
AU Nguyen-Huu, NH
   Thilly, N
   Derrough, T
   Sdona, E
   Claudot, F
   Pulcini, C
   Agrinier, N
AF Ngoc-Ha Nguyen-Huu
   Thilly, Nathalie
   Derrough, Tarik
   Sdona, Emmanouela
   Claudot, Frederique
   Pulcini, Celine
   Agrinier, Nelly
CA HPV Policy Working Grp
TI Human papillomavirus vaccination coverage, policies, and practical
   implementation across Europe
SO VACCINE
LA English
DT Review
DE Human papillomavirus vaccination; Vaccination coverage rate; European
   Union; Vaccination strategies; Systematic review
ID HPV VACCINATION; PROGRAMS; ADOLESCENTS; CRISIS; IMPACT
AB Background: Our objectives were to describe Human Papillomavirus vaccination coverage rates (HPV-VCR), policies, and practical steps for programme implementation that may be linked to high uptake in the population targeted by routine programmes across 30 European Union/European Economic Area Member States and Switzerland.
   Methods: Information from institutional websites and from articles indexed in Medline between 01/2006 and 01/2017 was reviewed and extracted using a standardised form. In 12/2017, a cross-sectional survey was administered to national experts, in order to update the compiled information.
   Results: Data were available in 31 countries, and validated by national experts in 28 of them. National vaccination programmes targeted girls 9-15 years of age in 30 countries and boys in 11 countries. HPV-VCR in girls was monitored in 25 countries: VCR was reported >= 71%(high) in ten countries, 51-70% in seven, 31-50% in four, and <= 30%(very low) in four. In high VCR countries, HPV vaccination was mainly delivered through school health services, and invitation and reminders to attend for vaccination were used. In areas with very low VCR, vaccination tended to be opportunistic and no reminders were used.
   Conclusion: According to our findings, school delivery within structured vaccination programmes and the use of reminders tended to be associated with highest HPV-VCR. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ngoc-Ha Nguyen-Huu; Thilly, Nathalie; Claudot, Frederique; Pulcini, Celine; Agrinier, Nelly] Univ Lorraine, Apemac, F-54000 Nancy, France.
   [Thilly, Nathalie] Univ Lorraine, CHRU Nancy, Plateforme Aide Rech Clin, F-54000 Nancy, France.
   [Derrough, Tarik; Sdona, Emmanouela] European Ctr Dis Prevent & Control, Stockholm, Sweden.
   [Pulcini, Celine] Univ Lorraine, CHRU Nancy, Infect Dis Dept, F-54000 Nancy, France.
   [Agrinier, Nelly] Univ Lorraine, CHRU Nancy, INSERM, CIC,Epidemiol Clin, F-54000 Nancy, France.
RP Agrinier, N (reprint author), Univ Lorraine, CHRU Nancy, INSERM, Hop Brabois,CIC Epidemiol Clin 1433, Allee Morvan, F-54000 Vandoeuvre Les Nancy, France.
EM n.agrinier@chru-nancy.fr
OI Nguyen-Huu, Ngoc-Ha/0000-0003-3633-438X
CR [Anonymous], EXPERT REV VACCINES, V17, DOI 10.1080/14760584.2018.1548282?scroll=top&needAccess.true
   [Anonymous], 2017, PREV CONTR HPV REL C
   [Anonymous], VACC SCHED
   [Anonymous], 2011, VACCINATION CERVICAL
   [Anonymous], ANN HPV VACC COV 201
   ANTSZ, PROT CERV CANC QUEST
   Barnard M, 2019, PREV MED REP, V14, DOI DOI 10.1016/J.PMEDR2019.100884
   Bocquier A, 2018, VACCINE, V36, P7666, DOI 10.1016/j.vaccine.2018.10.085
   Brotherton JML, 2013, MED J AUSTRALIA, V199, P614, DOI 10.5694/mja13.10272
   Corcoran B, 2018, LANCET, V391, P2103, DOI 10.1016/S0140-6736(18)30854-7
   Craciun C, 2012, VACCINE, V30, P6789, DOI 10.1016/j.vaccine.2012.09.016
   Derrough T, 2017, EUROSURVEILLANCE, V22, P10, DOI [10.2807/1560-7917.ES.2017.22.17.30519, 10.2807/1560-7917.es.2017.22.17.30519]
   Drolet M, 2019, LANCET, V394, P497, DOI 10.1016/S0140-6736(19)30298-3
   Drolet M, 2015, LANCET INFECT DIS, V15, P565, DOI 10.1016/S1473-3099(14)71073-4
   Elfstrom KM, 2015, VACCINE, V33, P1673, DOI 10.1016/j.vaccine.2015.02.028
   Fiks AG, 2013, PEDIATRICS, V131, P1114, DOI 10.1542/peds.2012-3122
   Gargano JW, 2018, CLIN INFECT DIS, DOI [10.1093/cid/civ707, DOI 10.1093/CID/CIV707]
   Garland SM, 2016, CLIN INFECT DIS, V63, P519, DOI 10.1093/cid/ciw354
   Gautier A, 2016, B EPIDEMIOL HEBD 201, P28, DOI DOI 10.1016/S0992-5945(17130241-6
   Herweijer E, 2016, INT J CANCER, V138, P2867, DOI 10.1002/ijc.30035
   King LA, 2008, EURO SURVEILL, V13
   Lutringer-Magnin D, 2011, VACCINE, V29, P5322, DOI 10.1016/j.vaccine.2011.05.006
   Mammas IN, 2016, J PEDIATR ADOL GYNEC, V29, P362, DOI 10.1016/j.jpag.2015.12.007
   Marlow LAV, 2007, VACCINE, V25, P1945, DOI 10.1016/j.vaccine.2007.01.059
   Musto R, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-640
   Niccolai LM, 2015, JAMA PEDIATR, V169, P686, DOI 10.1001/jamapediatrics.2015.0310
   Patel C., 2018, EUROSURVEILLANCE, V23, DOI [10.7807/1560-7917Fs701R23411700737, DOI 10.7807/1560-7917FS701R23411700737]
   Poljak M, 2013, VACCINE, V31, pH59, DOI 10.1016/j.vaccine.2013.03.029
   Rieck T, 2014, VACCINE, V32, P5564, DOI 10.1016/j.vaccine.2014.07.105
   Safon M-O, 2017, PROTECTION SOCIALE C
   Sander BB, 2012, VACCINE, V30, P1425, DOI 10.1016/j.vaccine.2011.11.097
   Sante Publique France, 2011, PAP HUM DONN COUV VA
   St Sauver JL, 2016, PREV MED, V89, P327, DOI 10.1016/j.ypmed.2016.02.039
   Suppli CH, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6268-x
   Vorsters A, 2018, VACCINE, V36, P5219, DOI 10.1016/j.vaccine.2018.06.066
   Walling EB, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-3863
   World Health Organization, IMM COV
   Wymann MN, 2018, INT J PUBLIC HEALTH, V63, P105, DOI 10.1007/s00038-017-1050-x
NR 38
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1315
EP 1331
DI 10.1016/j.vaccine.2019.11.081
PG 17
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900006
PM 31836255
DA 2020-05-12
ER

PT J
AU Huang, CY
   Fu, XF
   Zhou, YG
   Mi, FF
   Tian, G
   Liu, XX
   Wu, J
   Ding, C
   Yan, DY
   Li, LJ
   Yang, SG
AF Huang, Chenyang
   Fu, Xiaofang
   Zhou, Yuging
   Mi, Fenfang
   Tian, Guo
   Liu, Xiaoxiao
   Wu, Jie
   Ding, Cheng
   Yan, Danying
   Li, Lanjuan
   Yang, Shigui
TI Comparison of the immunogenicity and safety of quadrivalent and
   tetravalent influenza vaccines in children and adolescents
SO VACCINE
LA English
DT Review
DE Quadrivalent inactivated influenza vaccine; Trivalent inactivated
   influenza vaccine; Immunogenicity; Safety
ID INACTIVATED QUADRIVALENT; HONG-KONG; COST-EFFECTIVENESS; UNITED-STATES;
   DOUBLE-BLIND; AGE; TRIAL; RECOMMENDATIONS; SURVEILLANCE; IMMUNIZATION
AB Background: Children and adolescents are susceptible to influenza. Vaccination is the most important strategy for preventing influenza, yet there are few studies on the immunogenicity and safety of quadrivalent inactivated influenza vaccine (QIV) containing two A strains (H1N1 and H3N2) and two B lineages (Victoria and Yamagata). Therefore, to further clarify the immunogenicity and safety of QIV in children and adolescents, a meta-analysis was performed to provide a reference for the development of influenza prevention strategies.
   Methods: PubMed, EMBASE and Cochrane Library were searched for articles published as of February 12, 2019. Random clinical trials comparing the immunogenicity and safety of QIV and TIV among children and adolescents were selected. The main outcomes were comparisons of immunogenicity (seroprotection rate [SPR] and seroconversion rate [SCR] and adverse events using risk ratios (RRs). The meta-analysis was performed using random-effects models.
   Results: Among the 6 months up to 3 years group, QIV showed a higher SPR for B lineages than for TIV-B/Yamagata, with pooled RRs of 3.07 (95% CI: 2.58-3.66) and 1.06 (95% CI: 1.01-1.11), respectively. For the 3 years through 18 years, QIV had a higher SCR and SPR for the Yamagata lineage than for TIV-B/Victoria, with pooled RRs of 2.30 (95% CI: 1.83-2.88) and 1.16 (95% CI: 1.03-1.30), respectively. Compared to TIVB/Yamagata, a higher SCR and SPR for the Victoria lineage was found for QIV, with RRs of 3.09 (95% CI: 1.99-4.78) and 1.72 (95% CI: 1.22-2.41), respectively. Regarding adverse events, only pain was more frequently reported for QIV than TN; the RR was 1.09 (95% CI: 1.02-1.17).
   Conclusions: The immunogenicity of QIV for common ingredients was similar to that of TIV, but the former exhibited significantly higher immunogenicity for the unique lineage. QIV also had the same reliable safety as TN. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Huang, Chenyang; Fu, Xiaofang; Zhou, Yuging; Tian, Guo; Liu, Xiaoxiao; Wu, Jie; Ding, Cheng; Yan, Danying; Li, Lanjuan; Yang, Shigui] Zhejiang Univ, State Key Lab Diag & Treatment Infect Dis, Collaborat Innovat Ctr Diag & Treatment Infect Di, Coll Med,Affiliated Hosp 1, Hangzhou 310003, Peoples R China.
   [Mi, Fenfang] Zhejiang Chinese Med Univ, Hangzhou 310053, Peoples R China.
RP Yang, SG (reprint author), Zhejiang Univ, State Key Lab Diag & Treatment Infect Dis, Collaborat Innovat Ctr Diag & Treatment Infect Di, Coll Med,Affiliated Hosp 1, Hangzhou 310003, Peoples R China.
EM yangshigui@zju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81672005, U1611264, 81001271, 81721091];
   Mega-Project of National Science and Technology for the 12th and 13th
   Five-Year Plan of China [2018ZX10715-014-002, 2014ZX10004008]
FX This study was supported by grants from the National Natural Science
   Foundation of China (81672005, U1611264, 81001271, 81721091), the
   Mega-Project of National Science and Technology for the 12th and 13th
   Five-Year Plan of China (2018ZX10715-014-002 and 2014ZX10004008).
CR Administration U. S. F. a. D, 2018, FLUZ QUADR
   Ambrose CS, 2012, HUM VACC IMMUNOTHER, V8, P81, DOI 10.4161/hv.8.1.17623
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461
   [Anonymous], 2019, WEEKLY EPIDEMIOLOGIC, V94
   [Anonymous], 2009, MON B
   Belshe RB, 2010, VACCINE, V28, pD45, DOI 10.1016/j.vaccine.2010.08.028
   CDC, UPD INFL VACC REC 20
   Chan PKS, 2013, CLIN INFECT DIS, V56, P677, DOI 10.1093/cid/cis885
   Claeys C, 2018, LANCET
   Claeys C, 2019, PEDIATR INFECT DIS J, V38, P1
   Del Giudice G, 2017, NPJ AGING MECH DIS, V4, DOI 10.1038/s41514-017-0020-0
   Dolin R, 2013, J INFECT DIS, V208, P539, DOI 10.1093/infdis/jit264
   Domachowske JB, 2013, J INFECT DIS, V207, P1878, DOI 10.1093/infdis/jit091
   Gianchecchi E, 2016, FUTURE VIROL, V11, P379, DOI 10.2217/fvl-2016-0012
   Greenberg DP, 2014, PEDIATR INFECT DIS J, V33, P630, DOI 10.1097/INF.0000000000000254
   Grohskopf LA, 2019, MMWR RECOMM REP, V68, P1, DOI 10.15585/mmwr.rr6803a1
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Janjua NZ, 2012, J INFECT DIS, V205, P1858, DOI 10.1093/infdis/jis283
   Lafond KE, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001977
   Langley JM, J INFECT DIS, DOI [10.1093/infdishit263, DOI 10.1093/INFDISHIT263]
   Langley JM, 2015, J PEDIAT INF DIS SOC, V4, P242, DOI 10.1093/jpids/piu098
   Lee J, 2018, J KOREAN MED SCI, V33, DOI 10.3346/jkms.2018.33.e100
   Maldonado YA, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-2478
   Matias G, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1939-7
   Matias G, 2014, INFLUENZA OTHER RESP, V8, P507, DOI 10.1111/irv.12258
   Meier G, 2015, J MED ECON, V18, P746, DOI 10.3111/13696998.2015.1044456
   Moa AM, 2016, VACCINE, V34, P4092, DOI 10.1016/j.vaccine.2016.06.064
   Moore DL, 2018, PAED CHILD HEALT-CAN, V23, P565, DOI 10.1093/pch/pxy150
   Pepin S, 2019, VACCINE, V37, P1876, DOI 10.1016/j.vaccine.2018.11.074
   Pepin S, 2016, HUM VACC IMMUNOTHER, V12, P3072, DOI 10.1080/21645515.2016.1212143
   Rasmussen SA, 2012, AM J OBSTET GYNECOL, V207, pS3, DOI 10.1016/j.ajog.2012.06.068
   Regan AK, 2015, VACCINE, V33, P6149, DOI 10.1016/j.vaccine.2015.10.005
   Review Manager (RevMan) [Computer program], 2014, REV MAN REVMAN
   RijuRaya DS, 2017, REV VALUE QUADRIVALE, V13, P1640
   Sentinel C., 2018, SENTINEL C INFLUENZA
   Thommes EW, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1193-4
   Tricco AC, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-153
   Van Bellinghen LA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098437
   Wang L, 2016, J PEDIAT INF DIS SOC, V5, P170, DOI 10.1093/jpids/piv041
   Wang SY, 2017, EXPERT REV VACCINES, V16, P1155, DOI 10.1080/14760584.2017.1374181
   World Health Organization, 2018, INFL SEAS
   Wu P, 2012, J INFECT DIS, V206, P1862, DOI 10.1093/infdis/jis628
   You JHS, 2015, HUM VACC IMMUNOTHER, V11, P564, DOI 10.1080/21645515.2015.1011016
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1332
EP 1344
DI 10.1016/j.vaccine.2019.11.071
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900007
PM 31948819
DA 2020-05-12
ER

PT J
AU Orumaa, M
   Kjaer, SK
   Dehlendorff, C
   Munk, C
   Olsen, AO
   Hansen, BT
   Campbell, S
   Nygard, M
AF Orumaa, Madleen
   Kjaer, Susanne K.
   Dehlendorff, Christian
   Munk, Christian
   Olsen, Anne Olaug
   Hansen, Bo T.
   Campbell, Suzanne
   Nygard, Mari
TI The impact of HPV multi-cohort vaccination: Real-world evidence of
   faster control of HPV-related morbidity
SO VACCINE
LA English
DT Article
DE Real-world data; Immunization Program; Condylomata Acuminata; Human
   Papillomavirus Recombinant; Vaccine Quadrivalent; Papillomavirus
   Infections/prevention & control; Multi-cohort vaccination
ID HUMAN-PAPILLOMAVIRUS VACCINATION; CATCH-UP VACCINATION; GENITAL WARTS;
   NATURAL-HISTORY; DANISH WOMEN; FOLLOW-UP; POPULATION; LESIONS; BURDEN;
   IMPLEMENTATION
AB Background: In 2009, both Norway and Denmark initiated routine quadrivalent human papillomavirus vaccination (qHPV) for 12-year-old girls; however, Denmark also introduced free-of-charge multi-cohort vaccination for older age groups in 2008. We aim to describe trends in genital warts (GWs) incidence rates (IRs) among men and women and qHPV vaccine coverage among women in Norway and Denmark in 2006-2015.
   Methods: We linked multiple national health registries in Norway and Denmark via national personal identifiers to access data on GWs incidence and qHPV vaccination among women and men aged 12-35 years residing in Norway and Denmark in 2006-2015. We calculated age-specific and age-standardized GWs IRs, GWs IR trends before (2006-2009) and after (2009-2015) the implementation of qHPV vaccination, and qHPV vaccine coverage among women.
   Results: In Norway and Denmark together, there were more than 200,000 cases of incident GWs and over 710,000 girls got at least one dose of qHPV vaccine during the study period. The total qHPV coverage in Norway and Denmark in 2015 was among women aged 12-35 years 24% and 70%, respectively. GWs IRs in Norway and Denmark decreased annually in 2009-2015 among women by 4.8% (95% confidence interval: 4.3 to 5.3) and 18.0% (95%Cl: 17.5 to 18.6), respectively, and among men 1.9% (95%Cl: 1.4 to 2.4) and 10.7% (95%Cl: 10.3 to 11.2), respectively. In Denmark, GWs IRs decreased rapidly among both sexes and all age groups after qHPV vaccination, while Norway showed only a modest decrease.
   Conclusion: Rapid decline in HPV-related morbidity is feasible with high coverage of multi-cohort vaccination. However, the decision to vaccinate a single cohort of 12-years-old girls only will postpone HPV-related disease control by at least a decade. Thus countries planning HPV vaccination programs should also initiate multi-cohort vaccination for faster disease control. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Orumaa, Madleen; Hansen, Bo T.; Campbell, Suzanne; Nygard, Mari] Oslo Univ Hosp, Canc Registry Norway, Dept Res, HPV Related Epidemiol Res Unit, POB 5313 Majorstuen, N-0304 Oslo, Norway.
   [Kjaer, Susanne K.; Munk, Christian] Danish Canc Soc, Unit Virus Lifestyle & Genes, Res Ctr, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.
   [Dehlendorff, Christian] Danish Canc Soc, Unit Stat & Phannacoepidemiol, Res Ctr, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.
   [Olsen, Anne Olaug] Univ Oslo, Inst Hlth & Soc, Dept Community Med & Global Hlth, Forskningsveien 3A, N-0373 Oslo, Norway.
RP Nygard, M (reprint author), Oslo Univ Hosp, Canc Registry Norway, Dept Res, HPV Related Epidemiol Res Unit, POB 5313 Majorstuen, N-0304 Oslo, Norway.
EM mari.nygard@kreftregisteret.no
OI Nygard, Mari/0000-0002-4100-4855; Campbell, Suzanne/0000-0003-0818-9752;
   Orumaa, Madleen/0000-0001-6849-202X
CR Andersen JS, 2011, SCAND J PUBLIC HEALT, V39, P34, DOI 10.1177/1403494810394718
   [Anonymous], 2017, ANN REPORT
   Baandrup L, 2013, SEX TRANSM DIS, V40, P130, DOI 10.1097/OLQ.0b013e31827bd66b
   Baldur-Felskov B, 2014, CANCER CAUSE CONTROL, V25, P915, DOI 10.1007/s10552-014-0392-4
   Blomberg M, 2013, CLIN INFECT DIS, V57, P929, DOI 10.1093/cid/cit436
   Bollerup S, 2016, SEX TRANSM DIS, V43, P238, DOI 10.1097/OLQ.0000000000000418
   Brisson M, 2011, SEX TRANSM INFECT, V87, P41, DOI 10.1136/sti.2010.044412
   Burger EA, 2015, J INFECT DIS, V211, P206, DOI 10.1093/infdis/jiu413
   Chow EPF, 2015, SEX TRANSM INFECT, V91, P214, DOI 10.1136/sextrans-2014-051813
   Couto E, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-867
   de la Cour CD, 2019, CANCER MED-US, V8, P839, DOI 10.1002/cam4.1961
   de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716
   Derkay CS, 2008, LARYNGOSCOPE, V118, P1236, DOI 10.1097/MLG.0b013e31816a7135
   Dillner J, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3493
   Donovan B, 2011, LANCET INFECT DIS, V11, P39, DOI 10.1016/S1473-3099(10)70225-5
   Drolet M, 2019, LANCET, V394, P497, DOI 10.1016/S0140-6736(19)30298-3
   Drolet M, 2017, J INFECT DIS, V216, P1205, DOI 10.1093/infdis/jix476
   Drolet M, 2015, LANCET INFECT DIS, V15, P565, DOI 10.1016/S1473-3099(14)71073-4
   Elfstrom KM, 2016, J INFECT DIS, V213, P199, DOI 10.1093/infdis/jiv368
   Garland SM, 2009, J INFECT DIS, V199, P805, DOI 10.1086/597071
   Guan P, 2012, INT J CANCER, V131, P2349, DOI 10.1002/ijc.27485
   Guleria S, 2017, ACTA OBSTET GYN SCAN, V96, P286, DOI 10.1111/aogs.13088
   Gupta G, 2016, VACCINE, V34, P4724, DOI 10.1016/j.vaccine.2016.07.051
   Hansen BT, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019005
   Hansen BT, 2010, PREV MED, V51, P68, DOI 10.1016/j.ypmed.2010.03.014
   Kildemoes HW, 2011, SCAND J PUBLIC HEALT, V39, P38, DOI 10.1177/1403494810394717
   Kirkwood BR, 2003, ESSENTIAL MED STAT
   Kjaer SK, 2018, CLIN INFECT DIS, V66, P339, DOI 10.1093/cid/cix797
   Kjaer SK, 2007, J INFECT DIS, V196, P1447, DOI 10.1086/522863
   Lehtinen M, 2018, INT J CANCER, V142, P949, DOI 10.1002/ijc.31119
   Lehtinen M, 2015, CURR OPIN OBSTET GYN, V27, P326, DOI 10.1097/GCO.0000000000000208
   Leval A, 2012, J INFECT DIS, V206, P860, DOI 10.1093/infdis/jis405
   Liu G, 2015, SEX TRANSM DIS, V42, P20, DOI 10.1097/OLQ.0000000000000231
   Mariani L, 2015, ADV THER, V32, P10, DOI 10.1007/s12325-015-0178-4
   McCredie MRE, 2008, LANCET ONCOL, V9, P425, DOI 10.1016/S1470-2045(08)70103-7
   Nygard M, 2015, CLIN VACCINE IMMUNOL, V22, P943, DOI 10.1128/CVI.00133-15
   Nygard M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088323
   Pan American Health Organization, 2019, UPD SUPPL HPV VACC P
   Park IU, 2015, CLIN INFECT DIS, V61, pS849, DOI 10.1093/cid/civ813
   Pottegard A, 2017, INT J EPIDEMIOL, V46, P798, DOI 10.1093/ije/dyw213
   Schellenbacher C, 2017, VIRUS RES, V231, P166, DOI 10.1016/j.virusres.2016.11.020
   Schiller JT, 2015, LANCET ONCOL, V16, pE217, DOI 10.1016/S1470-2045(14)71179-9
   Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125
   Schmidt M, 2014, EUR J EPIDEMIOL, V29, P541, DOI 10.1007/s10654-014-9930-3
   Serrano B, 2018, BEST PRACT RES CL OB, V47, P14, DOI 10.1016/j.bpobgyn.2017.08.006
   Steben M, 2018, J MED VIROL, V90, P592, DOI 10.1002/jmv.24968
   Stigum H, 2010, ARCH SEX BEHAV, V39, P907, DOI 10.1007/s10508-009-9494-6
   Svahn MF, 2016, SCAND J PUBLIC HEALT, V44, P551, DOI 10.1177/1403494816653669
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   WHO, 2019, DRAFT GLOB STRAT EL
   Wiley DJ, 2002, CLIN INFECT DIS, V35, pS210, DOI 10.1086/342109
   Winer RL, 2005, J INFECT DIS, V191, P731, DOI 10.1086/427557
   Woestenberg PJ, 2017, J INFECTION, V74, P393, DOI 10.1016/j.jinf.2017.01.007
   World Health Organization, 2014, COMPR CERV CANC CONT
NR 54
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1345
EP 1351
DI 10.1016/j.vaccine.2019.12.016
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900008
PM 31917039
OA Other Gold
DA 2020-05-12
ER

PT J
AU Anwari, P
   Debellut, F
   Vodicka, E
   Clark, A
   Farewar, F
   Zhwak, ZA
   Nazary, D
   Pecenka, C
   LaMontagne, DS
   Safi, N
AF Anwari, Palwasha
   Debellut, Frederic
   Vodicka, Elisabeth
   Clark, Andrew
   Farewar, Farhad
   Zhwak, Zubiada A.
   Nazary, Dastagger
   Pecenka, Clint
   LaMontagne, D. Scott
   Safi, Najibullah
TI Potential health impact and cost-effectiveness of bivalent human
   papillomavirus (HPV) vaccination in Afghanistan
SO VACCINE
LA English
DT Article
DE Human papillomavirus; HPV vaccine; Cervical cancer; Cost-effectiveness
   analysis; Afghanistan
ID THRESHOLDS
AB Introduction: Human papillomavirus (HPV) vaccination has not been introduced in many countries in South-Central Asia, including Afghanistan, despite the sub-region having the highest incidence rate of cervical cancer in Asia. This study estimates the potential health impact and cost-effectiveness of HPV vaccination in Afghanistan to inform national decision-making.
   Method: An Excel-based static cohort model was used to estimate the lifetime costs and health outcomes of vaccinating a single cohort of 9-year-old girls in the year 2018 with the bivalent HPV vaccine, compared to no vaccination. We also explored a scenario with a catch-up campaign for girls aged 10-14 years. Input parameters were based on local sources, published literature, or assumptions when no data was available. The primary outcome measure was the discounted cost per disability-adjusted life-year (DALY) averted, evaluated from both government and societal perspectives.
   Results: Vaccinating a single cohort of 9-year-old girls against HPV in Afghanistan could avert 1718 cervical cancer cases, 125 hospitalizations, and 1612 deaths over the lifetime of the cohort. The incremental cost-effectiveness ratio was US$426 per DALY averted from the government perspective and US$400 per DALY averted from the societal perspective. The estimated annual cost of the HPV vaccination program (US$3,343,311) represents approximately 3.53% of the country's total immunization budget for 2018 or 0.13% of total health expenditures.
   Conclusion: In Afghanistan, HPV vaccine introduction targeting a single cohort is potentially cost-effective (0.7 times the GDP per capita of $586) from both the government and societal perspective with additional health benefits generated by a catch-up campaign, depending on the government's willingness to pay for the projected health outcomes. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Anwari, Palwasha] Afghanistan Natl Immunizat Tech Advisory Grp, Dist 10, Kabul, Afghanistan.
   [Debellut, Frederic] PATH, Rue Varembe 7, CH-1202 Geneva, Switzerland.
   [Vodicka, Elisabeth; Pecenka, Clint; LaMontagne, D. Scott] PATH, 2201 Westlake Ave,Suite 200, Seattle, WA 98121 USA.
   [Clark, Andrew] London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.
   [Farewar, Farhad] Minist Publ Hlth, Hlth Econ & Financing Directorate, Masood Sq,Dist 10, Kabul, Afghanistan.
   [Zhwak, Zubiada A.] Kabul Univ Med Sci Abu Ali Ibn Sina, Univ Area, Dist 3, Kabul, Afghanistan.
   [Nazary, Dastagger] Minist Publ Hlth, Expanded Program Immunizat, St 13,Dist 10, Kabul, Afghanistan.
   [Safi, Najibullah] WHO, UNOCA Compound, Jalalabad Rd,Dist 9, Kabul, Afghanistan.
RP Debellut, F (reprint author), PATH, Rue Varembe 7, CH-1202 Geneva, Switzerland.
OI Debellut, Frederic/0000-0002-3027-2838
FU Bill & Melinda Gates Foundation, Seattle, WAGates Foundation
   [OPP1147721]
FX This work was supported by the Bill & Melinda Gates Foundation, Seattle,
   WA [grant number OPP1147721].
CR Adhanom Ghebreyesus Tedros, 2018, CERV CANC NCD WE CAN
   Anwari P, 2018, VACCINE, V36, P7769, DOI 10.1016/j.vaccine.2017.10.058
   Berkhof J, 2013, VACCINE, V31, pH71, DOI 10.1016/j.vaccine.2013.04.086
   Bertram MY, 2016, B WORLD HEALTH ORGAN, V94, P925, DOI 10.2471/BLT.15.164418
   Burger EA, 2018, VACCINE, V36, P4823, DOI 10.1016/j.vaccine.2018.04.061
   Campos NG, 2017, INT J GYNECOL OBSTET, V138, P47, DOI 10.1002/ijgo.12184
   Campos NG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164000
   Campos NG, 2015, INT J CANCER, V137, P893, DOI 10.1002/ijc.29438
   Campos NG, 2014, AM J EPIDEMIOL, V180, P545, DOI 10.1093/aje/kwu159
   Canfell K, 2011, VACCINE, V29, P2487, DOI 10.1016/j.vaccine.2010.12.085
   de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716
   Engelgau MM, 2011, DIR DEV, P1
   GHO, PRIM SEC PREV CANC R
   Goldie SJ, 2008, VACCINE, V26, P4080, DOI 10.1016/j.vaccine.2008.04.053
   Herrero R, 2009, J INFECT DIS, V199, P919, DOI 10.1086/597308
   Islamic Republic of Afghanistan Central Statistics Organization, AFGH LIV COND SURV 2
   Jenkins D, 2008, GYNECOL ONCOL, V110, pS18, DOI 10.1016/j.ygyno.2008.06.027
   Jit M, 2014, LANCET GLOB HEALTH, V2, pE406, DOI 10.1016/S2214-109X(14)70237-2
   Lehtinen M, 2012, LANCET ONCOL, V13, P89, DOI 10.1016/S1470-2045(11)70286-8
   Marseille E, 2015, B WORLD HEALTH ORGAN, V93, P118, DOI 10.2471/BLT.14.138206
   Marth C, 2017, ANN ONCOL, V28, P72, DOI 10.1093/annonc/mdx220
   Neumann PJ, COST EFFECTIVENESS H
   Ng CJ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1615-0
   Onarheim KH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150120
   Prinja S, 2017, CANCER-AM CANCER SOC, V123, P3253, DOI 10.1002/cncr.30734
   Salomon JA, 2015, LANCET GLOB HEALTH, V3, pE712, DOI 10.1016/S2214-109X(15)00069-8
   Sankaranarayanan R, 2011, IARC SCI PUBLICATION, V162
   Sankaranarayanan R, 2018, VACCINE, V36, P4783, DOI 10.1016/j.vaccine.2018.02.087
   Shrestha Aamod Dhoj, 2018, Asian Pac J Cancer Prev, V19, P319
   UN Population Division, WORLD POP PROSP 2017
   UNICEF, AUT AD SYR SAF BOX P
   Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741
   *WHO, WORLD HLTH REP 2002
   WHO IARC, 2018, CANC FACT SHEETS CER, V876
   Woods B, 2016, VALUE HEALTH, V19, P929, DOI 10.1016/j.jval.2016.02.017
   World Health Organization, MON VACC WAST COUNTR
   World Health Organization, 2019, VACC NAT IMM PROGR U
   World Health Organization, 2017, WEEKL EP REC HUM PAP
   World Health Organization, WHO PREQ VACC
   World Health Organization, HUM PAP HPV CERV CAN
   Yaghoubi Mohsen, 2018, Value Health Reg Issues, V15, P112, DOI 10.1016/j.vhri.2018.03.001
NR 41
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1352
EP 1362
DI 10.1016/j.vaccine.2019.12.013
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900009
PM 31870571
OA Other Gold, Green Accepted, Green Published
DA 2020-05-12
ER

PT J
AU Coudeville, L
   Baurin, N
   Shepard, DS
AF Coudeville, Laurent
   Baurin, Nicolas
   Shepard, Donald S.
TI The potential impact of dengue vaccination with, and without,
   pre-vaccination screening
SO VACCINE
LA English
DT Article
DE Seroscreening; Serotesting; Dengue fever; Vaccination;
   Cost-effectiveness; Serostatus
ID BENEFITS; BURDEN; RISKS; AREAS
AB Background: The World Health Organization defined a 'screen and vaccinate' strategy as its recommended policy for the licensed dengue vaccine (Dengvaxia, Sanofi Pasteur), so that only individuals with previous dengue infection are vaccinated. The objectives of the present study were to build upon a recently published analysis of the benefits and risks associated with dengue vaccination to evaluate the public health impact and cost-effectiveness of a screen and vaccinate strategy.
   Methods: The current analysis was based on a previously reported transmission model and added, for the screening part, three rapid diagnostic tests with identical specificity (99%) but alternative sensitivities (50-70-90%) in the detection of prior dengue infection. The impact of a screen-and-vaccinate strategy considered nine settings representing different levels of transmission intensity. Outcomes (dengue-related hospitalizations, severe dengue, and symptomatic dengue) were assessed according to the level of transmission setting. The cost-effectiveness of vaccination in 10 endemic countries was also assessed.
   Results: Although associated, in most cases, with a lower population impact than a 'no-screening' approach, a screen and vaccinate strategy is more effective in reducing the number of hospitalized and severe cases prevented per vaccination performed and generates positive health benefits for individuals screened and subsequently vaccinated. As a result, this intervention is cost-effective in all countries considered except for very low transmission settings. The overall population impact of a screen and vaccinate approach is also likely to be improved by the use of several rounds of screening (up to 48% reduction in dengue hospitalization over 10 years with 5 rounds).
   Conclusions: WHO recommended option of a screen and vaccinate policy is likely to have a positive impact both at the individual and population level across a wide range of transmission settings and has the potential to be as, if not more, cost-effective than a no screening strategy. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Coudeville, Laurent; Baurin, Nicolas] Sanofi Pasteur, Vaccinat Value Modelling, Lyon, France.
   [Shepard, Donald S.] Brandeis Univ, Heller Sch Social Policy & Management, Waltham, MA USA.
RP Coudeville, L (reprint author), Sanofi Pasteur, 14 Espace Henry Vallee, F-69007 Lyon, France.
EM Laurent.Coudeville@sanofi.com
FU Sanofi Pasteur
FX This study was funded by Sanofi Pasteur.
CR Alhoot MA, 2013, INT J MED SCI, V10, P719, DOI 10.7150/ijms.5037
   Amin L, 2015, SCI ENG ETHICS, V21, P655, DOI 10.1007/s11948-014-9557-5
   Arslan A, 2016, J VECTOR DIS, V53, P136
   Beatty PR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3787
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Bonaparte M, 2019, J TRAVEL MED, V26, DOI 10.1093/jtm/taz078
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   Coudeville L, 2018, EXPERT REV VACCINES, V17, P753, DOI 10.1080/14760584.2018.1503955
   Coudeville L, 2016, VACCINE, V34, P6426, DOI 10.1016/j.vaccine.2016.08.050
   Espana G, 2018, BIORXIV
   Ferguson NM, 2016, SCIENCE, V353, P1033, DOI 10.1126/science.aaf9590
   Flasche S, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002181
   Guy B, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029462
   Guzman MG, 2013, ARCH VIROL, V158, P1445, DOI 10.1007/s00705-013-1645-3
   Lee TH, 2017, EXPERT REV ANTI-INFE, V15, P67, DOI 10.1080/14787210.2017.1248405
   Orellano P, 2018, VACCINE, V36, P979, DOI 10.1016/j.vaccine.2018.01.007
   Paixao ES, 2015, REV SOC BRAS MED TRO, V48, P399, DOI 10.1590/0037-8682-0145-2015
   Shepard DS, 2016, LANCET INFECT DIS, V16, P935, DOI 10.1016/S1473-3099(16)00146-8
   Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820
   Turner HC, 2018, T R SOC TROP MED HYG
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   WHO, 2019, COST EFF STRAT PLANN
   Wilder-Smith A, 2019, VACCINE, V37, P5137, DOI 10.1016/j.vaccine.2019.07.016
   World Health Organization, 2018, WKLY EPIDEMIOL REC, V93, P329
   Zeng W, 2018, VACCINE, V36, P413, DOI 10.1016/j.vaccine.2017.11.064
NR 25
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1363
EP 1369
DI 10.1016/j.vaccine.2019.12.012
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900010
PM 31879126
OA Other Gold
DA 2020-05-12
ER

PT J
AU Rao, S
   Ziniel, SI
   Khan, I
   Dempsey, A
AF Rao, Suchitra
   Ziniel, Sonja I.
   Khan, Isra'a
   Dempsey, Amanda
TI Be inFLUential: Evaluation of a multifaceted intervention to increase
   influenza vaccination rates among pediatric inpatients
SO VACCINE
LA English
DT Article
DE Influenza vaccination; Inpatient; Standing orders; Clinical decision
   support; Pediatric vaccination
ID STANDING-ORDERS; PNEUMOCOCCAL VACCINATION; COST-EFFECTIVENESS;
   IMMUNIZATION; CHILDREN; CARE; STRATEGIES; REMINDERS
AB Background and Objective: Annual influenza vaccination is recommended for individual >= 6 months of age, yet vaccination rates remain below national targets in the US. Hospitalization provides another medical setting for influenza vaccination, but the effectiveness of inpatient interventions has not been well studied. Our objective was to evaluate the effectiveness of a multifaceted intervention to increase influenza vaccination rates among pediatric inpatients.
   Methods: We conducted a pre-post interventional study on medical inpatient units at Children's Hospital Colorado from September 2016-April 2017 (pre-intervention) and September 2017-April 2018 (intervention). The intervention targeted nurses (web-based education modules, huddles and reminders) and providers (vaccination lists in the electronic health record, reminders, vaccination reports and financial incentives for residents). Outcomes were influenza vaccine ordering rates, and influenza vaccination rates at discharge. We analyzed data using descriptive statistics, bivariate and logistic regression.
   Results: Among 4,050 inpatients in 2016-2017 and 4,523 inpatients in 2017 aged >= 6 months, vaccination status was documented for 2,902/4,050 (71.7%) and 3,431/4,523 (75.9%) children aged > 6 months of age hospitalized during the study period. The vaccine ordering rate among eligible children was 28.8% in the pre-intervention season versus 50.2% in the intervention season (p < 0.001). The intervention was associated with 1.23 (95% CI 1.11-1.35) times higher odds of appropriate vaccination screening on admission, 2.27 (95% CI 2.01-2.56) times higher odds of a vaccination being ordered, and 1.39 (95% CI 1.27-1.53) times higher odds of a child being vaccinated against influenza at discharge (all p < 0.001). Residents (56%) and medical providers (39%) were more likely to order vaccines compared with nurses (5%), p = 0.014).
   Conclusion: A multifaceted intervention targeting nurses, residents and providers comprising education, visual reminders, vaccination reports and financial incentives is an effective way of improving influenza vaccine ordering, resulting in higher inpatient influenza vaccination rates. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Rao, Suchitra] Univ Colorado, Sch Med, Dept Pediat Infect Dis Hosp Med & Epidemiol, Box 055,13123 E 16th Ave, Aurora, CO 80045 USA.
   [Rao, Suchitra; Ziniel, Sonja I.; Khan, Isra'a] Childrens Hosp Colorado, Box 055,13123 E 16th Ave, Aurora, CO 80045 USA.
   [Ziniel, Sonja I.; Khan, Isra'a] Univ Colorado, Sch Med, Dept Pediat Hosp Med, Aurora, CO USA.
   [Dempsey, Amanda] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA.
   [Dempsey, Amanda] Adult & Child Ctr Hlth Outcomes Res & Delivery Sc, Aurora, CO USA.
RP Rao, S (reprint author), Univ Colorado, Sch Med, Dept Pediat Infect Dis Hosp Med & Epidemiol, Box 055,13123 E 16th Ave, Aurora, CO 80045 USA.; Rao, S (reprint author), Childrens Hosp Colorado, Box 055,13123 E 16th Ave, Aurora, CO 80045 USA.
EM suchitra.rao@childrenscolorado.org
CR Albert SM, 2012, BMC FAM PRACT, V13, DOI 10.1186/1471-2296-13-22
   Baskin E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192594
   Brady MT, 2012, PEDIATRICS, V130, P780, DOI 10.1542/peds.2012-2308
   Cohen ES, 2015, BMJ QUAL SAF, V24, P221, DOI 10.1136/bmjqs-2014-003556
   Conway SP, 1999, ARCH DIS CHILD, V81, P422, DOI 10.1136/adc.81.5.422
   Coyle CM, 2004, INFECT CONT HOSP EP, V25, P904, DOI 10.1086/502317
   CROUSE BJ, 1994, J FAM PRACTICE, V38, P258
   Dexter PR, 2001, NEW ENGL J MED, V345, P965, DOI 10.1056/NEJMsa010181
   Dexter PR, 2004, JAMA-J AM MED ASSOC, V292, P2366, DOI 10.1001/jama.292.19.2366
   Donato AA, 2007, INFECT CONT HOSP EP, V28, P219, DOI 10.1086/511797
   Freedman JL, 2015, PEDIATRICS, V135, pE540, DOI 10.1542/peds.2014-0943
   Gerard MN, 2008, J AM MED INFORM ASSN, V15, P776, DOI 10.1197/jamia.M2698
   GRAHN H, 1989, J BIOMOL STRUCT DYN, V6, P1135, DOI 10.1080/07391102.1989.10506541
   Guide TC, 2014, VACCINATION PROGRAMS
   Hammer LD, 2010, PEDIATRICS, V125, P1295, DOI 10.1542/peds.2010-0743
   Handley MA, 2018, ANNU REV PUBL HEALTH, V39, P5, DOI 10.1146/annurev-publhealth-040617-014128
   HOEY JR, 1982, CAN MED ASSOC J, V127, P27
   Honeycutt AA, 2007, VACCINE, V25, P1484, DOI 10.1016/j.vaccine.2006.10.029
   Lawson F, 2000, J GERONTOL A-BIOL, V55, pM522, DOI 10.1093/gerona/55.9.M522
   Nowalk MP, 2016, ACAD PEDIATR, V16, P57, DOI 10.1016/j.acap.2015.03.010
   Nowalk MP, 2014, J HEALTHC QUAL, V36, P5, DOI 10.1111/jhq.12020
   Nowalk MP, 2014, AM J PREV MED, V47, P435, DOI 10.1016/j.amepre.2014.07.003
   Nowalk MP, 2012, VACCINE, V30, P5978, DOI 10.1016/j.vaccine.2012.07.023
   Parmelli E, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-33
   Prevention CfDCa, 2019, FLU VACC COV US 2016
   Rao Suchitra, 2018, Pediatr Qual Saf, V3, pe102, DOI 10.1097/pq9.0000000000000102
   Rao S, 2018, INFLUENZA OTHER RESP, V12, P416, DOI 10.1111/irv.12482
   Rao Suchitra, 2016, Hosp Pediatr, V6, P513, DOI 10.1542/hpeds.2015-0112
   Rees S, 2011, J NURS CARE QUAL, V26, P358, DOI 10.1097/NCQ.0b013e31821fb6bb
   Samad L, 2006, BMJ-BRIT MED J, V332, P1312, DOI 10.1136/bmj.332.7553.1312
   Sand KL, 2007, J AM GERIATR SOC, V55, P1741, DOI 10.1111/j.1532-5415.2007.01422.x
   Sokos DR, 2007, AM J HEALTH-SYST PH, V64, P1096, DOI 10.2146/ajhp060321
   Teufel RJ, 2008, J HOSP MED, V3, P134, DOI 10.1002/jhm.286
   Trick WE, 2009, INFECT CONT HOSP EP, V30, P86, DOI 10.1086/593121
   Walton S, 2007, ARCH DIS CHILD, V92, P620, DOI 10.1136/adc.2006.104778
NR 35
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1370
EP 1377
DI 10.1016/j.vaccine.2019.12.010
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900011
PM 31862197
DA 2020-05-12
ER

PT J
AU Markkula, J
   Hemming-Harlo, M
   Vesikari, T
AF Markkula, Jukka
   Hemming-Harlo, Maria
   Vesikari, Timo
TI Shedding of oral pentavalent bovine-human reassortant rotavirus vaccine
   indicates high uptake rate of vaccine and prominence of G-type G1
SO VACCINE
LA English
DT Article
DE Rotavirus; Oral vaccine; RotaTeq (R); Shedding; RV5
ID FINNISH CHILDREN; STRAINS; SAFETY; GASTROENTERITIS; EFFICACY; INFANTS;
   IMMUNIZATION; INFECTION; PROGRAM
AB Background: Live oral pentavalent bovine-human reassortant rotavirus (RV) vaccine, RotaTeq (R), contains bovine rotaviruses reassorted with human G-types G1, G2, G3 and G4, and P-type P[8]. Shedding of RotaTeq (R) vaccine, as studied by RT-PCR, has been shown to be more common than initially reported, and may include formation of vaccine-derived double-reassortant G1 P[8] RVs. We studied the extent and duration of RotaTeq (R) vaccine virus shedding, genotypes shed, and clinical symptoms associated with shedding.
   Material and methods: We enrolled a total of 301 infants who received RotaTeq (R) vaccine according to Finnish schedule at 2,3 and 5 months of age. Stool samples were collected 5-10 days after the first and 0-7 days before the third dose of the vaccine. Additional stool samples 6 and 12 weeks later were collected if the second stool sample was positive. All stools were studied with RT-PCR for RV VP7, VP4 and VP6. Parents filled a symptom diary for a week after each vaccine dose.
   Results: We found that 93% of the vaccinees shed vaccine related viral particles in one sample taken 5-10 days after the first dose, indicating that stool shedding is very common and may be regarded as a marker of successful vaccination. Genotype G1 was the predominant genotype in shedding, often in association with Pin and the only genotype found in long-term shedding. Also G4 was commonly detected whereas other vaccine G-types and bovine-type P[5] were not.
   Conclusions: Shedding of RotaTeq (R) vaccine-derived viruses is a sign for successful vaccination. Intense shedding of G1 with or without P[8]reflects effective multiplication and may be an important factor in the induction of protective immunity. Shedding of G1 containing vaccine viruses may be prolonged up to 8 months of age. These results suggest that the pentavalent vaccine functions largely like a monovalent G1 vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Markkula, Jukka; Hemming-Harlo, Maria; Vesikari, Timo] Tampere Univ, Vaccine Res Ctr, Biokatu 10, Tampere 33520, Finland.
   [Hemming-Harlo, Maria] Tampere Univ Hosp, Dept Pediat, Tampere 33521, Finland.
RP Markkula, J (reprint author), Biokatu 10, Tampere 33520, Finland.
EM jukka.markkula@tuni.fi; maria.hemming-har-lo@tuni.fi;
   timo.vesikari@tuni.fi
CR [Anonymous], 2018, LANCET INFECT DIS, DOI [10.1016/51473- 3099(18)30362-1., DOI 10.1016/51473-3099(18)30362-1]
   Bautista-Marquez A, 2016, VACCINE, V34, P5284, DOI 10.1016/j.vaccine.2016.09.006
   Block SL, 2007, PEDIATRICS, V119, P11, DOI 10.1542/peds.2006-2058
   Boom JA, 2012, J INFECT DIS, V206, P1275, DOI 10.1093/infdis/jis490
   Bowen MD, 2016, J INFECT DIS, V214, P732, DOI 10.1093/infdis/jiw233
   Dennehy PH, 2007, INT J INFECT DIS, V11, pS36, DOI 10.1016/S1201-9712(07)60020-4
   Donato CM, 2012, J INFECT DIS, V206, P377, DOI 10.1093/infdis/jis361
   Giaquinto C, 2007, J INFECT DIS, V195, pS36, DOI 10.1086/516716
   Hemming M, 2014, PEDIATR INFECT DIS J, V33, P655, DOI 10.1097/INF.0000000000000221
   Hemming M, 2012, PEDIATR INFECT DIS J, V31, P992, DOI 10.1097/INF.0b013e31825d611e
   Hemming-Harlo M, 2017, J PEDIATR INFECT DIS, V6, P317, DOI 10.1093/jpids/piw061
   Higashimoto Y, 2018, J CLIN MICROBIOL, V56, DOI [10.1128/JCM.00035-18, 10.1128/jcm.00035-18]
   Hsieh YC, 2014, VACCINE, V32, P1199, DOI 10.1016/j.vaccine.2013.08.041
   Lappalainen S, 2017, J MED VIROL, V89, P239, DOI 10.1002/jmv.24636
   Leino T, 2017, VACCINE, V35, P5611, DOI 10.1016/j.vaccine.2017.08.052
   Leino T, 2012, VACCINE, V31, P176, DOI 10.1016/j.vaccine.2012.10.068
   Liu GF, 2017, HUM VACC IMMUNOTHER, V13, P2357, DOI [10.1080/21645515.2017.1365208, 10.1080/21645515.2017.1356522]
   Markkula J, 2017, INFECT DIS-NOR, V49, P388, DOI 10.1080/23744235.2016.1275773
   Markkula J, 2015, PEDIATR INFECT DIS J, V34, P296, DOI 10.1097/INF.0000000000000579
   Matson DO, 2014, HUM VACC IMMUNOTHER, V10
   Matthijnssens J, 2008, J VIROL, V82, P3204, DOI 10.1128/JVI.02257-07
   Merck, ROTATEQ PRESCR INF
   Patel M, 2013, J INFECT DIS, V208, P284, DOI 10.1093/infdis/jit166
   Patel NC, 2010, NEW ENGL J MED, V362, P314, DOI 10.1056/NEJMoa0904485
   Payne DC, 2010, PEDIATRICS, V125, pE438, DOI 10.1542/peds.2009-1901
   Rasanen S, 2011, SCAND J INFECT DIS, V43, P58, DOI 10.3109/00365548.2010.508462
   Richardson S, 1998, LANCET, V351, P1844, DOI 10.1016/S0140-6736(97)11257-0
   Roczo-Farkas S, 2017, COMMUN DIS INTELL, V41, pE455
   Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434
   RUUSKA T, 1990, SCAND J INFECT DIS, V22, P259, DOI 10.3109/00365549009027046
   Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664
   Ward RL, 1997, J INFECT DIS, V176, P570, DOI 10.1086/514076
   Ye SF, 2018, CLIN INFECT DIS, V66, P1411, DOI 10.1093/cid/cix1022
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1378
EP 1383
DI 10.1016/j.vaccine.2019.12.007
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900012
PM 31862199
DA 2020-05-12
ER

PT J
AU Pastural, E
   McNeil, SA
   MacKinnon-Cameron, D
   Ye, LY
   Langley, JM
   Stewart, R
   Martin, LH
   Hurley, GJ
   Salehi, S
   Penfound, TA
   Halperin, S
   Dale, JB
AF Pastural, Elodie
   McNeil, Shelly A.
   MacKinnon-Cameron, Donna
   Ye, Lingyun
   Langley, Joanne M.
   Stewart, Robert
   Martin, Luis H.
   Hurley, Gregory J.
   Salehi, Sanaz
   Penfound, Thomas A.
   Halperin, Scott
   Dale, James B.
TI Safety and immunogenicity of a 30-valent M protein-based group a
   streptococcal vaccine in healthy adult volunteers: A randomized,
   controlled phase I study
SO VACCINE
LA English
DT Article
DE Streptococcus pyogenes; Streptococcal vaccines; Multivalent vaccine;
   Phase I clinical trial; Group A Streptococcus; M protein; Bacterial
   vaccines; Bactericidal activity; Opsonophagocytosis; Strep A vaccine;
   StreptAnova (TM)
ID RECOMBINANT; BURDEN
AB Background: Streptococcus pyogenes (group A Streptococcus, Strep A) is a widespread pathogen that continues to pose a significant threat to human health. The development of a Strep A vaccine remains an unmet global health need. One of the major vaccine strategies is the use of M protein, which is a primary virulence determinant and protective antigen. Multivalent recombinant M protein vaccines are being developed with N-terminal M peptides that contain opsonic epitopes but do not contain human tissue cross-reactive epitopes.
   Methods: We completed a Phase I trial of a recombinant 30-valent M protein-based Strep A vaccine (Strep A vaccine, StreptAnova (TM)) comprised of four recombinant proteins containing N-terminal peptides from 30 M proteins of common pharyngitis and invasive and/or rheumatogenic serotypes, adjuvanted with aluminum hydroxide. The trial was observer-blinded and randomized in a 2:1 ratio for intramuscular administration of Strep A vaccine or an alum-based comparator in healthy adult volunteers, at 0, 30 and 180 days. Primary outcome measures were assessments of safety, including assays for antibodies that cross-reacted with host tissues, and immunogenicity assessed by ELISA with the individual vaccine peptides and by opsonophagocytic killing (OPK) assays in human blood.
   Results: Twenty-three Strep A-vaccinated participants and 13 controls completed the study. The Strep A vaccine was well-tolerated and there was no clinical evidence of autoimmunity and no laboratory evidence of tissue cross-reactive antibodies. The vaccine was immunogenic and elicited significant increases in geometric mean antibody levels to 24 of the 30 component M antigens by ELISA. Vaccine-induced OPK activity was observed against selected M types of Strep A in vaccinated participants that seroconverted to specific M peptides.
   Conclusion: The Strep A vaccine was well tolerated and immunogenic in healthy adults, providing strong support for further clinical development. (C) 2019 Published by Elsevier Ltd.
C1 [Pastural, Elodie; Martin, Luis H.] Pan Prov Vaccine Enterprise Inc PREVENT, Saskatoon, SK, Canada.
   [McNeil, Shelly A.; MacKinnon-Cameron, Donna; Ye, Lingyun; Langley, Joanne M.; Halperin, Scott] Dalhousie Univ, Canadian Ctr Vaccinol, IWK Hlth Ctr, Nova Scotia Hlth Author, Halifax, NS, Canada.
   [McNeil, Shelly A.] Dalhousie Univ, Div Infect Dis, Dept Med, Halifax, NS, Canada.
   [Langley, Joanne M.; Halperin, Scott] Dalhousie Univ, Div Infect Dis, Dept Pediat, Halifax, NS, Canada.
   [Stewart, Robert] Dalhousie Univ, Div Cardiol, Dept Med, Halifax, NS, Canada.
   [Hurley, Gregory J.; Salehi, Sanaz; Penfound, Thomas A.; Dale, James B.] Univ Tennessee, Ctr Hlth Sci, Dept Med, Div Infect Dis, Memphis, TN 38163 USA.
RP McNeil, SA (reprint author), QEII Victoria Gen Site, Div Infect Dis, Room 5077 Dickson Bldg,5780 Univ Ave, Halifax, NS B3H 1V7, Canada.
EM Shelly.McNeil@nshealth.ca
FU Pan-Provincial Vaccine Enterprise Inc. (PREVENT), Canada; Vaxent, LLC,
   United States; National Institutes of Health, United States (NIAID)
   [HHSN2722012000031]; US Public Health Service, United States (NIH) [R01
   AI-010085, R01 AI -132117]
FX Financial support was provided by Pan-Provincial Vaccine Enterprise Inc.
   (PREVENT), Canada and Vaxent, LLC, United States. The sponsors provided
   the study vaccine and provided some input into the study design. Tissue
   cross-reactive antibody assays were performed under a contract from the
   National Institutes of Health, United States (NIAID Contract
   HHSN2722012000031), to Dr. Mast at the Blood Research Institute at the
   Blood Center of Wisconsin. Dr. Dale received funds from the US Public
   Health Service, United States (NIH grants R01 AI-010085 and R01 AI
   -132117).
CR Carapetis JR, 2005, LANCET INFECT DIS, V5, P685, DOI 10.1016/S1473-3099(05)70267-X
   Choi YJ, 2010, APPL ENVIRON MICROB, V76, P5058, DOI 10.1128/AEM.00413-10
   Dale JB, 2017, VACCINE, V35, P19, DOI 10.1016/j.vaccine.2016.11.065
   Dale JB, 2013, VACCINE, V31, P1576, DOI 10.1016/j.vaccine.2013.01.019
   Dale JB, 2011, VACCINE, V29, P8175, DOI 10.1016/j.vaccine.2011.09.005
   Dale JB, 1999, VACCINE, V17, P193, DOI 10.1016/S0264-410X(98)00150-9
   Dale JB, 1999, INFECT DIS CLIN N AM, V13, P227, DOI 10.1016/S0891-5520(05)70052-0
   Dale JB, 1996, VACCINE, V14, P944, DOI 10.1016/0264-410X(96)00050-3
   DALE JB, 1993, J IMMUNOL, V151, P2188
   Engel ME, 2014, PEDIATR INFECT DIS J, V33, P208, DOI 10.1097/INF.0b013e3182a5c32a
   Frost HR, 2017, CLIN INFECT DIS, V65, P1523, DOI 10.1093/cid/cix599
   Giersing BK, 2016, VACCINE, V34, P2865, DOI 10.1016/j.vaccine.2016.02.078
   Hall MA, 2004, INFECT IMMUN, V72, P2507, DOI 10.1128/IAI.72.5.2507-2512.2004
   Hu MC, 2002, INFECT IMMUN, V70, P2171, DOI 10.1128/IAI.70.4.2171-2177.2002
   Kotloff KL, 2004, JAMA-J AM MED ASSOC, V292, P709, DOI 10.1001/jama.292.6.709
   LANCEFIELD RC, 1957, J EXP MED, V106, P525, DOI 10.1084/jem.106.4.525
   MASSELL BF, 1969, J AMER MED ASSOC, V207, P1115, DOI 10.1001/jama.207.6.1115
   MASSELL BF, 1968, APPL MICROBIOL, V16, P509, DOI 10.1128/AEM.16.3.509-518.1968
   McNeil S, 2005, INT C SER, V1289, P303, DOI DOI 10.1016/J.ICS.2005.12.002
   McNeil SA, 2005, CLIN INFECT DIS, V41, P1114, DOI 10.1086/444458
   Salehi S, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00617-18
   Sanderson-Smith M, 2014, J INFECT DIS, V210, P1325, DOI 10.1093/infdis/jiu260
   Sekuloski S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198658
   Sheel M, 2016, EXPERT REV VACCINES, V15, P227, DOI 10.1586/14760584.2016.1116946
   STOLLERMAN GH, 1967, ARTHRITIS RHEUM-US, V10, P245, DOI 10.1002/art.1780100311
   Tapia MD, 2015, PEDIATR INFECT DIS J, V34, P463, DOI 10.1097/INF.0000000000000608
   Vekemans J, 2019, CLIN INFECT DIS, V69, P877, DOI 10.1093/cid/ciy1143
   Watkins DA, 2017, NEW ENGL J MED, V377, P713, DOI 10.1056/NEJMoa1603693
NR 28
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1384
EP 1392
DI 10.1016/j.vaccine.2019.12.005
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900013
PM 31843270
DA 2020-05-12
ER

PT J
AU Lutz, CS
   Fink, RV
   Cloud, AJ
   Stevenson, J
   Kim, D
   Fiebelkorn, AP
AF Lutz, Chelsea S.
   Fink, Rebecca V.
   Cloud, Ann J.
   Stevenson, John
   Kim, David
   Fiebelkorn, Amy Parker
TI Factors associated with perceptions of influenza vaccine safety and
   effectiveness among adults, United States, 2017-2018
SO VACCINE
LA English
DT Article
DE Adult vaccination; Influenza; Influenza vaccination; Vaccine
   perceptions; Vaccine safety; Vaccine effectiveness
ID SEASONAL INFLUENZA; BEHAVIOR; IMMUNIZATION; ATTITUDES; METAANALYSIS;
   RATIONALE; COVERAGE; BELIEFS; WHITE; RATES
AB Background: Annual vaccination against seasonal influenza is widely recognized as the primary intervention method in preventing morbidity and mortality from influenza, but coverage among adults is suboptimal in the United States. Safety and effectiveness perceptions regarding vaccines are consistently cited as factors that influence adults' decisions to accept or reject vaccination. Therefore, we conducted this analysis in order to understand sociodemographic, attitude, and knowledge factors associated with these perceptions for influenza vaccine among adults in three different age groups.
   Methods: Probability-based Internet panel surveys using nationally representative samples of adults aged >= 19 years in the United States were conducted during February-March of 2017 and 2018. We asked respondents if they believed the influenza vaccine was safe and effective. We calculated prevalence ratios using chi-square and pairwise t-tests to determine associations between safety and effectiveness beliefs and sociodemographic variables for adults aged 19-49, 50-64, and >= 65 years.
   Results: Survey completion rates were 58.2% (2017) and 57.2% (2018); we analyzed 4597 combined responses. Overall, most adults reported the influenza vaccine was safe (86.3%) and effective (73.0%). However, fewer younger adults reported positive perceptions compared with older age groups. Respondents who believed the vaccine was safe also reported it was effective.
   Conclusions: Generally, adults perceived the influenza vaccine as safe and effective. Considering this, any improvements to these perceptions would likely be minor and have a limited effect on coverage. Future research to understand why, despite positive perceptions, adults are still choosing to forego the vaccine may be informative. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lutz, Chelsea S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.
   [Lutz, Chelsea S.] US DOE, Oak Ridge Inst Sci & Educ, Washington, DC 20585 USA.
   [Lutz, Chelsea S.; Stevenson, John; Kim, David; Fiebelkorn, Amy Parker] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Fink, Rebecca V.] Westat Corp, Rockville, MD USA.
   [Fink, Rebecca V.; Cloud, Ann J.] Abt Associates Inc, Cambridge, MA USA.
   [Kim, David] US Dept HHS, Div Vaccines, Off Infect Dis & HIV AIDS, Off Assistant Secretary Hlth, Washington, DC 20201 USA.
RP Lutz, CS (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.; Lutz, CS (reprint author), US DOE, Oak Ridge Inst Sci & Educ, Washington, DC 20585 USA.; Lutz, CS (reprint author), Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
EM nfi5@cdc.gov; RebeccaV_Fink@abtassoc.com; Ann_Cloud@abtassoc.com;
   ddk5@cdc.gov; dez8@cdc.gov
OI Lutz, Chelsea/0000-0002-5706-2144
FU U.S. Centers for Disease Control and PreventionUnited States Department
   of Health & Human ServicesCenters for Disease Control & Prevention - USA
FX This work was funded by the U.S. Centers for Disease Control and
   Prevention. This project was also supported in part by an appointment to
   the Research Participation Program for the Centers for Disease Control
   and Prevention, National Center for Immunization and Respiratory
   Diseases, Immunization Services Division, administered by the Oak Ridge
   Institute of Science and Education, US Department of Energy, United
   States through an agreement between the CDC. The findings and
   conclusions in this article are those of the authors and do not
   necessarily represent the official position of the Centers for Disease
   Control and Prevention.
CR Abbas KM, 2018, PEERJ, V6, DOI 10.7717/peerj.5171
   Battaglia D. I., 2009, SURVEY PRACTICE, V2, P1, DOI [DOI 10.29115/SP-2009-0019, 10.29115/SP-2009-0019]
   Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8
   Centers for Disease Control and Prevention, 2015, NAT HLTH INT SURV
   Centers for Disease Control and Prevention, 2016, ADULTVAXVIEW VACC CO
   Centers for Disease Control and Prevention, 2016, NAT HLTH INT SURV
   Centers for Disease Control and Prevention, 2004, SEASONAL INFLUENZA V
   Centers for Disease Control and Prevention, FLU VAX VIEW PRIOR F
   Centers for Disease Control and Prevention, 2017, EST INFL COV AD US
   Centers for Disease Control and Prevention, PEOPL 65 YEARS OLD I
   Centers for Disease Control and Prevention, 2016, FLU VACCINATION COVE
   Chi RC, 2004, AM J MED SCI, V327, P113, DOI 10.1097/00000441-200403000-00001
   Deiss RG, 2015, VACCINE, V33, P7160, DOI 10.1016/j.vaccine.2015.11.004
   Ding H, 2017, MMWR-MORBID MORTAL W, V66, P1016, DOI 10.15585/mmwr.mm6638a2
   EICKHOFF TC, 1971, J INFECT DIS, V123, P446, DOI 10.1093/infdis/123.4.446
   Fiore Anthony E., 2010, Morbidity and Mortality Weekly Report, V59, P1
   FRANCIS T, 1967, ARCH ENVIRON HEALTH, V14, P747, DOI 10.1080/00039896.1967.10664832
   Fuchs Joerg, 2006, Pharmacy Pract (Granada), V4, P163, DOI 10.4321/s1885-642x2006000400003
   Kim S, 2017, HEALTH COMMUN, P1, DOI [10.1080/10410236.2017.1384351, DOI 10.1080/10410236.20171384351]
   Kostova D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066312
   Lin CJ, 2010, VACCINE, V28, P7706, DOI 10.1016/j.vaccine.2010.07.009
   Lindley MC, 2006, AM J PREV MED, V31, P281, DOI 10.1016/j.amepre.2006.06.025
   Lu PJ, 2017, VACCINE, V35, P3104, DOI 10.1016/j.vaccine.2017.04.028
   Lu PJ, 2015, AM J PREV MED, V49, pS412, DOI 10.1016/j.amepre.2015.03.005
   Malosh R, 2014, VACCINE, V32, P1841, DOI 10.1016/j.vaccine.2014.01.075
   Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046
   Nadler JL, 2016, MMWR-MORBID MORTAL W, V65, P101, DOI 10.15585/mmwr.mm6505a1
   Nyhan B, 2015, VACCINE, V33, P459, DOI 10.1016/j.vaccine.2014.11.017
   Padilla ME, 2018, J PHARM PRACT, DOI [10.177/0897190018810595, DOI 10.1177/0897190018810595897190018810595]
   Quinn SC, 2018, SSM-POPUL HLTH, V4, P25, DOI 10.1016/j.ssmph.2017.11.003
   Quinn SC, 2017, VACCINE, V35, P7154, DOI 10.1016/j.vaccine.2017.10.083
   Quinn SC, 2017, VACCINE, V35, P1167, DOI 10.1016/j.vaccine.2016.12.046
   Reed C, 2015, PLOS ONE, V10, DOI [10.1371tjourrtalpone01183690118369, DOI 10.1371/TJOURRTALPONE011836,4E0118369]
   Rondy M, 2017, J INFECTION, V75, P381, DOI 10.1016/j.jinf.2017.09.010
   Santibanez TA, 2010, AM J HEALTH BEHAV, V34, P77
   Sawyer SM, 2012, LANCET, V379, P1630, DOI 10.1016/S0140-6736(12)60072-5
   Talbot HK, 2011, J INFECT DIS, V203, P500, DOI 10.1093/infdis/jiq076
   U.S. Census Bureau, 2016, CURR POP SURV
   U.S. Census Bureau, 2017, CURR POP SURV
   United States Census Bureau, 2016, AM COMM SURV ACS
   Uyeki TM, 2017, ANN INTERN MED, V167, pITC33, DOI 10.7326/AITC201709050
   Wheelock A, 2013, EXPERT REV VACCINES, V12, P893, DOI 10.1586/14760584.2013.814841
   Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1
   Wooten KG, 2012, VACCINE, V30, P6927, DOI 10.1016/j.vaccine.2012.08.036
   Wray RJ, 2007, J FAM PRACTICE, V56, P925
   Xie H, 2015, SCI REP-UK, V5, DOI 10.1038/srep15279
   Yeager DS, 2011, PUBLIC OPIN QUART, V75, P709, DOI 10.1093/poq/nfr020
NR 47
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1393
EP 1401
DI 10.1016/j.vaccine.2019.12.004
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900014
PM 31883808
DA 2020-05-12
ER

PT J
AU Perry, M
   McGowan, A
   Roberts, R
   Cottrell, S
AF Perry, Malone
   McGowan, Anne
   Roberts, Richard
   Cottrell, Simon
TI Timeliness and equity of infant pertussis vaccination in wales: Analysis
   of the three dose primary course
SO VACCINE
LA English
DT Article
DE Pertussis vaccine; Socioeconomic factors; Whooping cough; Vaccination;
   Immunisation; Child
ID IMMUNIZATION; CHILDREN; ENGLAND; RECORDS; DELAY
AB Infants aged under one year are at the highest risk of severe complications or death from pertussis infection. Prompt vaccination with a three dose course at two, three and four months of age decreases the amount of time they are vulnerable following waning of maternal antibodies. In Wales, uptake of all three doses of the primary course of pertussis containing vaccine is high. However, timeliness and equity at a population level have not been previously reported.
   This analysis included 163,733 children born from 1st January 2013 to 31st December 2017. In this cohort 87.9% received the first dose of a pertussis containing vaccine by 12 weeks of age, 87.1% had received all three doses by 24 weeks of age, and 96.3% received three doses by 52 weeks of age.
   Differences in uptake between those living in the most deprived and least deprived quintiles of Lower Super Output Area (LSOA) were smaller than differences in timeliness, but statistically significant. In 2017 the difference in timely uptake between those living in the most and least deprived quintiles was 4%, 5% and 7% for doses one, two and three respectively. There was a difference of 10% in the proportion of infants receiving all three primary vaccinations on time between the most and least deprived quintile of LSOAs.
   Consideration is needed on interventions that will help improve timeliness such as enhanced follow up of defaulters, electronic communication between primary care data systems, enhanced health visitor intervention and opportunistic vaccination in those who fail to attend scheduled vaccination appointments. There is also the need for routine monitoring of timeliness and further research into what influences delayed vaccination. Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.
C1 [Perry, Malone] Publ Hlth Wales, Vaccine Preventable Dis Programme, 2 Capital Quarter,Tyndall St, Cardiff CF10 4BZ, S Glam, Wales.
   Publ Hlth Wales, Communicable Dis Surveillance Ctr, 2 Capital Quarter,Tyndall St, Cardiff CF10 4BZ, S Glam, Wales.
RP Perry, M (reprint author), Publ Hlth Wales, Vaccine Preventable Dis Programme, 2 Capital Quarter,Tyndall St, Cardiff CF10 4BZ, S Glam, Wales.
EM Malorie.Perry@wales.nhs.uk; Anne.McGowan2@wales.nhs.uk;
   Richard.Roberts3@wales.nhs.uk; Simon.Cottrell@wales.nhs.uk
CR Amirthalingam G, 2013, EUROSURVEILLANCE, V18, P19, DOI 10.2807/1560-7917.ES2013.18.38.20587
   Bouziri A, 2010, Med Trop (Mars), V70, P245
   Campbell H, 2018, J MED MICROBIOL, V67, P1426, DOI 10.1099/jmm.0.000829
   Campbell H, 2012, EMERG INFECT DIS, V18, P38, DOI 10.3201/eid1801.110784
   CDC, 2015, PERT OUTBR TRENDS
   CDC MMWR, 2003, SURV SAF IMM VACC AD
   Curran D, 2016, PEDIATR INFECT DIS J, V35, P542, DOI 10.1097/INF.0000000000001071
   Dabrera G, 2015, CLIN INFECT DIS, V60, P333, DOI 10.1093/cid/ciu821
   Dayan GH, 2006, AM J EPIDEMIOL, V163, P561, DOI 10.1093/aje/kwj074
   Deane GB, 2015, THESIS
   DIETZ VJ, 1993, PEDIATR INFECT DIS J, V12, P353, DOI 10.1097/00006454-199304000-00022
   Dombkowski KJ, 2004, PUBLIC HEALTH REP, V119, P144, DOI 10.1177/003335490411900207
   Dombkowski KJ, 2002, AM J PREV MED, V23, P36, DOI 10.1016/S0749-3797(02)00442-7
   ECDC, 2019, VACC SCHED
   Edwards KM, 2003, VACCINE, V21, P3483, DOI 10.1016/S0264-410X(03)00356-6
   Friederichs V, 2006, ARCH DIS CHILD, V91, P465, DOI 10.1136/adc.2005.085944
   Government of Western Australia, 2012, ONG PERT EP W AUSTR
   Grant CC, 2003, BRIT MED J, V326, P852, DOI 10.1136/bmj.326.7394.852
   Hull BP, 2006, VACCINE, V24, P4403, DOI 10.1016/j.vaccine.2006.02.049
   Institute of Environmental Science and Research Ltd, 2013, PERT REP WEEKS 22 23
   Kmietowicz Z, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e5008
   Miller E, 1999, BIOLOGICALS, V27, P79, DOI 10.1006/biol.1999.0184
   Moore HC, 2018, VACCINE, V36, P4062, DOI 10.1016/j.vaccine.2018.05.084
   Nilsson L, 2012, VACCINE, V30, P3239, DOI 10.1016/j.vaccine.2011.10.089
   Public Health England, 2018, ENH PERT SURV
   Public Health England, 2016, PERT GREEN BOOK CHAP
   Public Health Wales, COV PERT INFL VACC P
   Public Health Wales Health Protection Division, 2019, 130 COVER PUBL HLTH
   Rybak A, 2019, ARCH PEDIATRIE, V26, P56, DOI 10.1016/j.arcped.2018.11.011
   Strine TW, 2003, AM J PREV MED, V25, P45, DOI 10.1016/S0749-3797(03)00093-X
   Tiley KS, 2018, VACCINE, V36, P6726, DOI 10.1016/j.vaccine.2018.09.032
   Tozzi AE, 2003, PEDIATRICS, V112, P1069, DOI 10.1542/peds.112.5.1069
   Walton S, 2017, VACCINE, V35, P7166, DOI 10.1016/j.vaccine.2017.10.085
   Welsh Government, 2012, TEMP PROGR PERT WHOO
   Welsh Government, 2015, WELSH IND MULT DEPR
NR 35
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1402
EP 1407
DI 10.1016/j.vaccine.2019.12.001
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900015
PM 31839466
DA 2020-05-12
ER

PT J
AU Ali, D
   Levin, A
   Abdulkarim, M
   Tijjani, U
   Ahmed, B
   Namalam, F
   Oyewole, F
   Dougherty, L
AF Ali, Disha
   Levin, Ann
   Abdulkarim, Masduq
   Tijjani, Usman
   Ahmed, Bakoji
   Namalam, Faruk
   Oyewole, Femi
   Dougherty, Leanne
TI A cost-effectiveness analysis of traditional and geographic information
   system-supported microplanning approaches for routine immunization
   program management in northern Nigeria
SO VACCINE
LA English
DT Article
DE Immunization; Microplanning; GIS; Mapping; Costing; Nigeria; Sub-Saharan
   Africa
ID CHILDHOOD IMMUNIZATION; VACCINATION COVERAGE; INTERVENTIONS;
   ELIMINATION; REMINDERS; SERVICES; BURDEN
AB Effective RI microplanning requires accurate population estimates and maps showing health facilities and locations of villages and target populations. Traditional microplanning relies on census figures to project target populations and on community estimates of distances, while GIS microplanning uses satellite imagery to estimate target populations and spatial analyses to estimate distances. This paper estimates the cost-effectiveness of geographical information systems (GIS)-based microplanning for routine immunization (RI) programming in two states in northern Nigeria.
   For our cost-effectiveness analysis, we captured the cost of all inputs for both approaches to capture the incremental cost of GIS over traditional microplanning and present the incremental cost-effectiveness ratios for each vaccine-preventable illness, death, and disability-adjusted life year (DALY) averted.
   We considered two scenarios for estimating vaccine requirements for each microplanning approach, one based on administrative vaccination coverage rates and one based on National Nutrition and Health Survey rates. With the administrative rates, GIS microplanning projected approximately 194,000 and 157,000 more required vaccinations than traditional microplanning in Bauchi and Sokoto States; with the survey rates, the additional number of vaccinations required was nearly 113,000 in Bauchi and about 47,000 in Sokoto. For each state under each scenario, we present numbers of and costs per measles and pertussis cases, deaths, and DALYs averted by the additional vaccinations, as well as annual costs.
   As expected, GIS-based microplanning incurs higher costs than traditional microplanning, due mainly to the additional vaccinations required for populations previously unreached. Our estimates of cost per DALY averted suggest, however, that GIS microplanning is more cost-effective than traditional microplanning in both states under both coverage scenarios and that the higher costs incurred by GIS microplanning are worth adopting. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Ali, Disha] JSI, MCSP, 2733 Crystal Dr 4th Floor, Arlington, VA 22202 USA.
   [Levin, Ann] MCSP, 6414 Hollins Dr, Bethesda, MD 20817 USA.
   [Abdulkarim, Masduq] JSI, MCSP, New GRA, Adjacent River Edge Reso, Bauchi, Nigeria.
   [Tijjani, Usman] JSI, MCSP, Block 14 Shehu Kangiwa Secretariat Ahmad Daku Rd, Sokoto, Nigeria.
   [Ahmed, Bakoji] Primary Hlth Care Dev Agcy, Dis Control & Immunizat Unit, Bello Kirfi Rd,Off Murtala Muhammed Rd, Bauchi, Bauchi State, Nigeria.
   [Namalam, Faruk] Sokoto State Primary Hlth Care Dev Agcy, Planning Res & Stat, Block 14 Shehu Kangiwa Secretariat,Ahmad Daku Rd, Gwadabawa, Sokoto State, Nigeria.
   [Oyewole, Femi] JSI, MCSP, Plot 448 Reuben Okoya St, Abuja, Nigeria.
   [Dougherty, Leanne] JSI, MCSP, 2733 Crystal Dr 4th Floor, Arlington, VA 22202 USA.
RP Dougherty, L (reprint author), JSI, MCSP, 2733 Crystal Dr 4th Floor, Arlington, VA 22202 USA.
EM Disha_Ali@jsi.com; ann@levinmorgan.com; leanne_dougherty@hotmail.com
FU American people through the United States Agency for International
   Development (USAID)United States Agency for International Development
   (USAID) [AID-OAA-A-14-00028]
FX This manuscript is made possible by the generous support of the American
   people through the United States Agency for International Development
   (USAID) under the terms of the Cooperative Agreement AID-OAA-A-14-00028.
   The contents are the responsibility of the Maternal and Child Survival
   Program and do not necessarily reflect the views of USAID or the United
   States Government.
CR Abubakar A, 2019, PAN AFR MED J, V32, DOI [10.11604/pami.supp.2019.32.1.13352, DOI 10.11604/PAMI.SUPP.2019.32.1.13352]
   Adeloye D, 2017, VACCINE, V35, P2871, DOI 10.1016/j.vaccine.2017.04.034
   [Anonymous], 2019, OUTBREAK NEWS TODAY
   Barau I, 2014, J INFECT DIS, V210, pS102, DOI 10.1093/infdis/jiu010
   Bertram MY, 2016, B WORLD HEALTH ORGAN, V94, P925, DOI 10.2471/BLT.15.164418
   Bharti N, 2016, SCI REP, V6, DOI [10.1038/crep34541, DOI 10.1038/CREP34541]
   Checchi F, 2013, INT J HEALTH GEOGR, V12, DOI 10.1186/1476-072X-12-4
   Crowcroft NS, 2003, LANCET INFECT DIS, V3, P413, DOI 10.1016/S1473-3099(03)00669-8
   Domek GJ, 2016, VACCINE, V34, P2437, DOI 10.1016/j.vaccine.2016.03.065
   Dougherty L, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2019-001606
   Dunkle SE, 2014, J INFECT DIS, V210, pS523, DOI 10.1093/infdis/jiu373
   Egunsola O, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027825
   Eze GU, 2015, AMELIORER PERFORMANC, V34, P8
   Feldstein LR, 2017, GLOBAL ROUTINE VACCI, V2017
   Gammino VM, 2014, J INFECT DIS, V210, pS98, DOI 10.1093/infdis/jit285
   Geng F, 2017, HEALTH POLICY PLANN, V32, P1174, DOI 10.1093/heapol/czx067
   Gibson DG, 2017, LANCET GLOB HEALTH, V5, pE428, DOI [10.1016/S2214-109X(17)30072-4, 10.1016/s2214-109x(17)30072-4]
   Gidado SO, 2014, J INFECT DIS, V210, pS118, DOI 10.1093/infdis/jiu197
   Ibrahim B, 2019, PAN AFRICAN MED J, V32
   Kamadjeu R, 2009, INT J HEALTH GEOGR, V8, DOI 10.1186/1476-072X-8-4
   Kamanga A, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0831-z
   Kazi AM, 2017, INT J MED INFORM, V107, P48, DOI 10.1016/j.ijmedinf.2017.09.004
   Kelly GC, 2011, GEOSPATIAL HEALTH, V6, P21, DOI 10.4081/gh.2011.154
   Kolff CA, 2018, HUM VACC IMMUNOTHER, V14, P1636, DOI 10.1080/21645515.2018.1477458
   Loharikar A, 2016, MMWR-MORBID MORTAL W, V65, P1136, DOI 10.15585/mmwr.mm6541a3
   Makama SD, 2007, POPUL DEV REV, V33, P206
   Mbabazi WB, 2015, HEALTH POLICY PLANN, V30, P638, DOI 10.1093/heapol/czu042
   Metcalf CJE, 2015, EPIDEMIOL INFECT, V143, P1457, DOI 10.1017/S0950268814001988
   Mihigo R, 2017, PAN AFRICAN MED J, V27, DOI [10.116041pamjsuop.201.7.273.12127, DOI 10.11604/116041PAMJSUOP.201.7.273.12127]
   Miller M A, 2000, Int J Infect Dis, V4, P14, DOI 10.1016/S1201-9712(00)90060-2
   National Bureau of Statistics (NBS) and United Nations Children's Fund (UNICEF), 2018, NIG NAT NUTR HLTH SU
   National Population Commision (NPC) [Nigeria] ICF, 2019, NIG DEM HLTH SURVEY2
   Ock M, 2016, J KOREAN MED SCI, V31, pS129, DOI 10.3346/jkms.2016.31.S2.S129
   Odone A, 2015, HUM VACC IMMUNOTHER, V11, P72, DOI 10.4161/hv.34313
   Organizacion Mundial de la Salud, 2013, GLOB VACC ACT PLAN 2
   Ozawa S, 2012, VACCINE, V31, P96, DOI 10.1016/j.vaccine.2012.10.103
   Portnoy A, 2019, LANCET GLOB HEALTH, V7, pE472, DOI 10.1016/S2214-109X(18)30537-0
   Rheingans R, 2018, VACCINE, V36, P7780, DOI 10.1016/j.vaccine.2018.02.008
   Rushby JF, 2001, HEALTH POLICY PLANN, V16, P326, DOI 10.1093/heapol/16.3.326
   Ryman T, 2010, J PUBLIC HEALTH-UK, V32, P18, DOI 10.1093/pubmed/fdp048
   Saha A, 2018, VACCINE, V36, P4742, DOI 10.1016/j.vaccine.2018.04.084
   Touray K, 2016, J INFECT DIS, V213, pS67, DOI 10.1093/infdis/jiv493
   Trumbo SP, 2018, VACCINE, V36, P7674, DOI 10.1016/j.vaccine.2018.10.083
   Uddin MJ, 2010, HEALTH POLICY PLANN, V25, P50, DOI 10.1093/heapol/czp041
   Umeh GC, 2018, VACCINE, V36, P7361, DOI 10.1016/j.vaccine.2018.10.020
   Utazi CE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09611-1
   VanderEnde K, 2018, GLOBAL ROUTINE VACCI, P4
   Wardrop NA, 2018, P NATL ACAD SCI USA, V115, P3529, DOI 10.1073/pnas.1715305115
   Weber EM, 2018, REMOTE SENS ENVIRON, V204, P786, DOI 10.1016/j.rse.2017.09.024
   Woods B, 2016, VALUE HEALTH, V19, P929, DOI 10.1016/j.jval.2016.02.017
   Yourkavitch J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201870
NR 51
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1408
EP 1415
DI 10.1016/j.vaccine.2019.12.002
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900016
PM 31924428
OA Other Gold
DA 2020-05-12
ER

PT J
AU Levillain, F
   Kim, H
   Kwon, KW
   Clark, S
   Cia, F
   Malaga, W
   Lanni, F
   Brodin, P
   Gicquel, B
   Guilhot, C
   Bancroft, GJ
   Williams, A
   Shin, SJ
   Poquet, Y
   Neyrolles, O
AF Levillain, Florence
   Kim, Hongmin
   Kwon, Kee Woong
   Clark, Simon
   Cia, Felipe
   Malaga, Wladimir
   Lanni, Faye
   Brodin, Priscille
   Gicquel, Brigitte
   Guilhot, Christophe
   Bancroft, Gregory J.
   Williams, Ann
   Shin, Sung Jae
   Poquet, Yannick
   Neyrolles, Olivier
TI Preclinical assessment of a new live attenuated Mycobacterium
   tuberculosis Beijing-based vaccine for tuberculosis
SO VACCINE
LA English
DT Article
DE Tuberculosis; Mycobacterium tuberculosis; BCG; Vaccine
ID SCHOOL-AGED CHILDREN; BCG VACCINE; EVOLUTIONARY HISTORY; PROTECTIVE
   IMMUNITY; BOVIS BCG; VIRULENCE; EFFICACY; REVACCINATION; STRAINS;
   IMMUNIZATION
AB Tuberculosis still claims more lives than any other pathogen, and a vaccine better than BCG is urgently needed. One of the challenges for novel TB vaccines is to protect against all Mycobacterium tuberculosis lineages, including the most virulent ones, such as the Beijing lineage. Here we developed a live attenuated M. tuberculosis mutant derived from GC1237, a Beijing strain responsible for tuberculosis outbreaks in the Canary Islands. The mutant strain is inactivated both in the Rv1503c gene, responsible for surface glycolipid synthesis, and in the two-component global regulator PhoPR. This double mutant is as safe as BCG in immunodeficient SCID mice. In immune-competent mice and guinea pigs, the mutant is as protective as BCG against M. tuberculosis strains of common lineage 4 (Euro-American). By contrast, in mice the vaccine is protective against a M. tuberculosis strain of lineage 2 (East-Asian, Beijing), while BCG is not. These results highlight differences in protection efficacy of live attenuated M. tuberculosis-derived vaccine candidates depending on their genetic background, and provide insights for the development of novel live vaccines against TB, especially in East-Asian countries where M. tuberculosis strains of the Beijing family are highly dominant. (C) 2019 Published by Elsevier Ltd.
C1 [Levillain, Florence; Poquet, Yannick; Neyrolles, Olivier] Univ Toulouse, CNRS, UPS, IPBS, Toulouse, France.
   [Kim, Hongmin; Kwon, Kee Woong; Malaga, Wladimir; Guilhot, Christophe; Shin, Sung Jae] Yonsei Univ, Coll Med, Dept Microbiol, Inst Immunol & Immunol Dis, Seoul, South Korea.
   [Clark, Simon; Lanni, Faye; Williams, Ann] Publ Hlth England, Salisbury, Wilts, England.
   [Cia, Felipe; Bancroft, Gregory J.] London Sch Hyg & Trop Med, London, England.
   [Brodin, Priscille] Univ Lille, CNRS, INSERM, CHU Lille,Inst Pasteur Lille,Ctr Infect & Immun L, Lille, France.
   [Gicquel, Brigitte] Inst Pasteur, Unite Genet Mycobacterienne, Paris, France.
   [Gicquel, Brigitte] Shenzhen Nanshan Ctr Chron Dis Control, Dept TB Control & Prevent, Shenzhen, Peoples R China.
RP Neyrolles, O (reprint author), Univ Toulouse, CNRS, UPS, IPBS, Toulouse, France.
EM olivier.neyrolles@ipbs.fr
FU European Commission (contract NEWTBVAC) [241745]; European Commission
   (contract TBVAC2020) [643381]; Centre National de la Recherche
   ScientifiqueCentre National de la Recherche Scientifique (CNRS);
   Universite Paul Sabatier; Agence Nationale de la RechercheFrench
   National Research Agency (ANR) [ANR-11-EQUIPEX-0003]; Fondation pour la
   Recherche MedicaleFondation pour la Recherche Medicale [DEQ2016
   0334902]; Fondation Bettencourt Schueller; Department of Health, UK
FX This work was supported by the European Commission (contracts NEWTBVAC n
   241745 and TBVAC2020 n 643381), Centre National de la Recherche
   Scientifique, Universite Paul Sabatier, Agence Nationale de la Recherche
   (ANR-11-EQUIPEX-0003), Fondation pour la Recherche Medicale (contract
   DEQ2016 0334902), Fondation Bettencourt Schueller. The funding bodies
   did not have a role on the study design, collection, analysis or
   interpretation of the data or the writing of the manuscript or in the
   decision to publish the manuscript.; This work was supported by the
   Department of Health, UK. The views expressed in this publication are
   those of the authors and not necessarily those of the Department of
   Health.
CR Abubakar I, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17370
   Aguilo N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16085
   Alonso H, 2011, TUBERCULOSIS, V91, P117, DOI 10.1016/j.tube.2010.12.007
   Andersen P, 2019, NAT REV IMMUNOL, V19, P550, DOI 10.1038/s41577-019-0174-z
   [Anonymous], 2018, GLOB TUB REP 2018
   Arbues A, 2013, VACCINE, V31, P4867, DOI 10.1016/j.vaccine.2013.07.051
   Aronson NE, 2004, JAMA-J AM MED ASSOC, V291, P2086, DOI 10.1001/jama.291.17.2086
   Bardarov S, 2002, MICROBIOL-SGM, V148, P3007, DOI 10.1099/00221287-148-10-3007
   Barreto ML, 2014, VACCINE, V32, P3759, DOI 10.1016/j.vaccine.2014.05.042
   Barreto ML, 2011, VACCINE, V29, P4875, DOI 10.1016/j.vaccine.2011.05.023
   Bottai D, 2015, VACCINE, V33, P2710, DOI 10.1016/j.vaccine.2015.03.083
   Brodin P, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001100
   Clark S, 2017, J INFECT DIS, V216, P525, DOI 10.1093/infdis/jix030
   de Bree LCJ, 2018, SEMIN IMMUNOL, V39, P35, DOI 10.1016/j.smim.2018.06.002
   Domenech P, 2017, J BACTERIOL, V199, DOI 10.1128/JB.00696-16
   Fallow A, 2010, J BACTERIOL, V192, P2228, DOI 10.1128/JB.01597-09
   Fine PEM, 1996, LANCET, V348, P17
   FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9
   Furin J, 2019, LANCET, V393, P1642, DOI 10.1016/S0140-6736(19)30308-3
   Gagneux S, 2018, NAT REV MICROBIOL, V16, P202, DOI 10.1038/nrmicro.2018.8
   Gonzalo-Asensio J, 2014, P NATL ACAD SCI USA, V111, P11491, DOI 10.1073/pnas.1406693111
   Gonzalo-Asensio J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003496
   Grode L, 2005, J CLIN INVEST, V115, P2472, DOI 10.1172/JCI24617
   Grode L, 2013, VACCINE, V31, P1340, DOI 10.1016/j.vaccine.2012.12.053
   Groschel MI, 2017, CELL REP, V18, P2752, DOI 10.1016/j.celrep.2017.02.057
   Henao-Tamayo M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136500
   Jeon BY, 2008, INFECT IMMUN, V76, P5173, DOI 10.1128/IAI.00019-08
   Kaufmann SHE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01203
   Lopez B, 2003, CLIN EXP IMMUNOL, V133, P30, DOI 10.1046/j.1365-2249.2003.02171.x
   Loxton AG, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00439-16
   Manca C, 2001, P NATL ACAD SCI USA, V98, P5752, DOI 10.1073/pnas.091096998
   Martin C, 2006, VACCINE, V24, P3408, DOI 10.1016/j.vaccine.2006.03.017
   Merker M, 2015, NAT GENET, V47, P242, DOI 10.1038/ng.3195
   Nemes E, 2018, NEW ENGL J MED, V379, P138, DOI [10.1056/NEJMoa1714021, 10.1056/nejmoa1714021]
   Nguipdop-Djomo P, 2016, LANCET INFECT DIS, V16, P219, DOI 10.1016/S1473-3099(15)00400-4
   Niemann S, 2016, MICROBIOL SPECTR, V4
   Nieuwenhuizen NE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01147
   Orgeur M, 2018, CURR OPIN MICROBIOL, V41, P68, DOI 10.1016/j.mib.2017.11.021
   Parwati I, 2010, LANCET INFECT DIS, V10, P103, DOI 10.1016/S1473-3099(09)70330-5
   Perez E, 2001, MOL MICROBIOL, V41, P179, DOI 10.1046/j.1365-2958.2001.02500.x
   Rodrigues LC, 2005, LANCET, V366, P1290, DOI 10.1016/S0140-6736(05)67145-0
   Scriba TJ, 2016, J INFECT DIS, V214, P659, DOI 10.1093/infdis/jiw228
   Spertini F, 2015, LANCET RESP MED, V3, P953, DOI 10.1016/S2213-2600(15)00435-X
   Tameris M, 2019, LANCET RESP MED
   Tsenova L, 2007, VACCINE, V25, P5126, DOI 10.1016/j.vaccine.2006.11.024
   Voss Gerald, 2018, F1000Res, V7, P199, DOI 10.12688/f1000research.13588.1
   Walker K B, 2010, Vaccine, V28, P2259, DOI 10.1016/j.vaccine.2009.12.083
NR 47
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1416
EP 1423
DI 10.1016/j.vaccine.2019.11.085
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900017
PM 31862194
DA 2020-05-12
ER

PT J
AU Jia, R
   Yan, LY
   Guo, JH
AF Jia, Rong
   Yan, Lingyan
   Guo, Jihua
TI Enhancing the immunogenicity of a DNA vaccine against Streptococcus
   mutans by attenuating the inhibition of endogenous miR-9
SO VACCINE
LA English
DT Article
DE DNA vaccine; MicroRNA; miR-9; Immunogenicity
ID MICRORNA SPONGES; HUMAN MONOCYTES; EXPRESSION; CELLS; IMMUNOLOGY; MIRNAS
AB DNA vaccine provides a promising method for preventing and treating diseases. However, the low immunogenicity restricts its application. New approaches are urgent to be explored to enhance the immune response of DNA vaccine. MicroRNAs are endogenous, small non-coding RNAs which play parts in gene expression inhibition. In this study, microRNA-9 (miR-9) was found to inhibit the expression of the GLU-A-P antigen protein encoded by the anti-caries DNA vaccine. Mutation of miR-9 binding sites in the gene fragment encoding GLU-A-P antigen protein significantly increased the expression of antigen protein. Moreover, miR-9 sponge can improve the expression of the GLU-A-P antigen protein. The co-immunization with miR-9 sponge and anti-caries DNA vaccine significantly enhanced the specific immune response in vivo. In conclusion, attenuating the inhibition of endogenous miR-9 enhanced the antigen expression and immunogenicity of the anti-caries DNA vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jia, Rong; Yan, Lingyan; Guo, Jihua] Wuhan Univ, State Key Lab Breeding Base Basic Sci Stomatol Hu, Sch & Hosp Stomatol, 237 Luoyu Rd, Wuhan 430079, Peoples R China.
   [Jia, Rong; Yan, Lingyan; Guo, Jihua] Wuhan Univ, Key Lab Oral Biomed, Sch & Hosp Stomatol, Minist Educ, 237 Luoyu Rd, Wuhan 430079, Peoples R China.
   [Guo, Jihua] Wuhan Univ, Dept Endodont, Sch & Hosp Stomatol, Wuhan, Peoples R China.
RP Guo, JH (reprint author), 237 Luoyu Rd, Wuhan 430079, Peoples R China.
EM jihuaguo@whu.edu.cn
OI Jia, Rong/0000-0001-6960-6199
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81571024, 81170955]
FX This work was supported by Grant 81571024 and 81170955 from the National
   Natural Science Foundation of China.
CR Barnes D, 2008, CELL HOST MICROBE, V4, P239, DOI 10.1016/j.chom.2008.08.003
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bazzoni F, 2009, P NATL ACAD SCI USA, V106, P5282, DOI 10.1073/pnas.0810909106
   Chen X, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1078-2
   Cui M, 2015, CANCER RES, V75, P846, DOI 10.1158/0008-5472.CAN-14-1192
   D'Ippolito E, 2016, CANCER RES, V76, P5562, DOI 10.1158/0008-5472.CAN-16-0140
   Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079
   Ebert MS, 2010, RNA, V16, P2043, DOI 10.1261/rna.2414110
   Garmory HS, 2003, GENET VACCINES THER, V1, P2, DOI DOI 10.1186/1479-0556-1-2
   Gasparini C, 2009, EUR J IMMUNOL, V39, P2215, DOI 10.1002/eji.200939209
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1
   Guo JH, 2004, J DENT RES, V83, P266
   Guo LM, 2009, FEBS J, V276, P5537, DOI 10.1111/j.1742-4658.2009.07237.x
   Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927
   HAMADA S, 1980, MICROBIOL REV, V44, P331, DOI 10.1128/MMBR.44.2.331-384.1980
   Gonzalez-Granado LI, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03148
   Jia R, 2006, VACCINE, V24, P5192, DOI 10.1016/j.vaccine.2006.03.090
   KOGA T, 1990, INFECT IMMUN, V58, P289, DOI 10.1128/IAI.58.2.289-296.1990
   Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303
   Liu MA, 2011, IMMUNOL REV, V239, P62, DOI 10.1111/j.1600-065X.2010.00980.x
   Lukiw WJ, 2012, ALZHEIMERS RES THER, V4, DOI 10.1186/alzrt150
   Lukiw Walter J, 2012, Int J Biochem Mol Biol, V3, P105
   Marin RM, 2013, RNA, V19, P467, DOI 10.1261/rna.035634.112
   Monchois V, 1999, FEMS MICROBIOL REV, V23, P131, DOI 10.1016/S0168-6445(98)00041-2
   Nummer SA, 2018, METHODSX, V5, P304, DOI 10.1016/j.mex.2018.03.011
   Perez JT, 2009, NAT BIOTECHNOL, V27, P572, DOI 10.1038/nbt.1542
   Plaisance V, 2006, J BIOL CHEM, V281, P26932, DOI 10.1074/jbc.M601225200
   Qian DH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00629-3
   Ramachandran D, 2011, FEBS J, V278, P1167, DOI 10.1111/j.1742-4658.2011.08042.x
   Roese-Koerner B, 2016, STEM CELL REP, V7, P207, DOI 10.1016/j.stemcr.2016.06.008
   Romero NB, 2004, HUM GENE THER, V15, P1065, DOI 10.1089/hum.2004.15.1065
   Stachyra A, 2014, ACTA BIOCHIM POL, V61, P515
   Tan XH, 2008, HUM IMMUNOL, V69, P32, DOI 10.1016/j.humimm.2007.11.009
   Tay FC, 2015, ADV DRUG DELIVER REV, V81, P117, DOI 10.1016/j.addr.2014.05.010
   Thulin P, 2013, INT J MOL MED, V31, P1003, DOI 10.3892/ijmm.2013.1311
   Wheatley AK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018225
   WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918
   Zhang Y, 2011, J CELL BIOCHEM, V112, P2435, DOI 10.1002/jcb.23168
NR 38
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1424
EP 1430
DI 10.1016/j.vaccine.2019.11.083
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900018
PM 31917038
DA 2020-05-12
ER

PT J
AU Whiting, G
   Vipond, C
   Facchetti, A
   Chan, H
   Wheeler, JX
AF Whiting, Gail
   Vipond, Caroline
   Facchetti, Alessandra
   Chan, Hannah
   Wheeler, Jun X.
TI Measurement of surface protein antigens, PorA and PorB, in Bexsero
   vaccine using quantitative mass spectrometry
SO VACCINE
LA English
DT Article
DE Bexsero vaccine; Neisseria meningitis serogroup B; MenB; OMV; Isotope
   dilution mass spectrometry
ID MENINGOCOCCAL SEROGROUP-B; STRUCTURAL-CHARACTERIZATION;
   IMMUNE-RESPONSES; QUANTIFICATION; STABILITY; COMPONENT; DISEASE; PORINS
AB Bexsero is a multivalent vaccine containing outer membrane vesicles (OMV) derived from Neisseria meningitidis group B strain NZ98/254 and three recombinant meningococcal proteins, Neisserial adhesin A, Heparin binding antigen and factor H binding protein. OMV production relies on the growth of large-scale cultures of N. meningitidis under controlled conditions. Changes to environmental factors, such as temperature, pH, nutrient availability and trace elements, can impact the growth rate of the meningococcus. Furthermore outer membrane expression levels vary in response to the environmental milieu, thus any changes in environmental conditions can result in changes in OMV protein content. This makes consistent production of OMVs challenging and the ability to measure the protein content of the final product is desirable to ensure product quality. The aim of this work was to develop a mass spectrometry (MS) method for measuring the porin proteins and to evaluate this approach for assessing the batch consistency of Bexsero vaccine. Using isotope dilution MS, we measured the PorA and PorB content in 75 lots of Bexsero vaccine. PorA ranged from 4.0 to 5.95 mu g/dose with an average of 4.8 mu g/dose. PorB ranged from 5.4 to 8.7 mu g/dose with an average of 6.5 mu g/dose. This is the first description of the quantitative characterisation of adjuvanted Bexsero vaccine drug product at the final stage of the production process, once the aluminium adjuvanted vaccine has been packaged into syringes, to assess manufacturing consistency. The significance of our findings to quality control in the future is discussed. Crown Copyright (C) 2019 Published by Elsevier Ltd. All rights reserved.
C1 [Whiting, Gail; Vipond, Caroline; Facchetti, Alessandra; Chan, Hannah; Wheeler, Jun X.] NIBSC, Blanche Lane, Potters Bar EN6 3QG, Herts, England.
RP Whiting, G (reprint author), NIBSC, Blanche Lane, Potters Bar EN6 3QG, Herts, England.
EM gail.whiting@nibsc.org
CR Bai XL, 2011, EXPERT OPIN BIOL TH, V11, P969, DOI 10.1517/14712598.2011.585965
   Electronic Medicines Compendium, BEXS MEN GROUP B VAC
   Finney M, 2008, HUM VACCINES, V4, P23, DOI 10.4161/hv.4.1.4806
   Frasch CE, 2001, METH MOLEC MED, V66, P81, DOI 10.1385/1-59259-148-5:81
   FREDRIKSEN J H, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P67
   Gerber SA, 2003, P NATL ACAD SCI USA, V100, P6940, DOI 10.1073/pnas.0832254100
   Gorringe Andrew R, 2012, Hum Vaccin Immunother, V8, P174, DOI 10.4161/hv.18500
   Holst J, 2013, HUM VACC IMMUNOTHER, V9, P1241, DOI 10.4161/hv.24129
   Lange V, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.61
   Magagnoli C, 2009, VACCINE, V27, P2156, DOI 10.1016/j.vaccine.2009.01.099
   Martino A, 2012, VACCINE, V30, P1330, DOI 10.1016/j.vaccine.2011.12.066
   Peak IR, 2016, J PROTEOME RES, V15, P2356, DOI 10.1021/acs.jproteome.5b00938
   Picotti P, 2012, NAT METHODS, V9, P555, DOI [10.1038/NMETH.2015, 10.1038/nmeth.2015]
   Ruijne N, 2006, CLIN VACCINE IMMUNOL, V13, P797, DOI 10.1128/CVI.00038-06
   Serruto D, 2012, VACCINE, V30, pB87, DOI 10.1016/j.vaccine.2012.01.033
   Tsolakos N, 2010, VACCINE, V28, P3211, DOI 10.1016/j.vaccine.2010.02.023
   van der Ende A, 2000, INFECT IMMUN, V68, P6685, DOI 10.1128/IAI.68.12.6685-6690.2000
   VANDERLEY P, 1991, INFECT IMMUN, V59, P2963, DOI 10.1128/IAI.59.9.2963-2971.1991
   Vipond C, 2005, HUM VACCINES, V1, P80, DOI 10.4161/hv.1.2.1651
   Whiting G, 2017, J PROTEOMICS ENZYMOL, V6, P2, DOI [10.417212470-1289.1000133, DOI 10.4172/2470-1289.1000133]
   Whiting G, 2014, HUM VACC IMMUNOTHER, V10, P1669, DOI 10.4161/hv.28443
   Williams TL, 2008, VACCINE, V26, P2510, DOI 10.1016/j.vaccine.2008.03.014
   Williams TL, 2012, VACCINE, V30, P2475, DOI 10.1016/j.vaccine.2011.12.056
NR 23
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1431
EP 1435
DI 10.1016/j.vaccine.2019.11.082
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900019
PM 31839469
DA 2020-05-12
ER

PT J
AU Salgado, VR
   Fukutani, KF
   Fukutani, E
   Lima, JV
   Rossi, EA
   Barral, A
   de Oliveira, CI
   Nascimento-Carvalho, C
   Van Weyenbergh, J
   Queiroz, ATL
AF Salgado, Vanessa R.
   Fukutani, Kiyoshi F.
   Fukutani, Eduardo
   Lima, Joao V.
   Rossi, Erik A.
   Barral, Aldina
   de Oliveira, Camila I.
   Nascimento-Carvalho, Cristiana
   Van Weyenbergh, Johan
   Queiroz, Artur T. L.
TI Effects of 10-valent pneumococcal conjugate (PCV10) vaccination on the
   nasopharyngeal microbiome
SO VACCINE
LA English
DT Article
DE PCV10; Microbiome; Vaccine
ID HAEMOPHILUS-INFLUENZAE; GUT MICROBIOME; CARRIAGE; HEALTH
AB Pathogenic bacteria, such as Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae and Moraxella catarrhalis, are important vaccine targets. The 10-valent pneumococcal conjugate vaccine (PCV10) acts on 10 differents S. pneumoniae serovars. However, this vaccine could also act on other bacteria genera, leading to dysbiosis. Moreover, the vaccination has also been associated with imbalances in the ratio between commensal and potentially pathogenic bacteria. Despite the wealth of studies assessing the influence of the microbiome on vaccine effects, how vaccination can influence the microbiome remains poorly understood. Herein, we assessed the effects of PCV10 on infant nasopharyngeal microbiome composition. Nasopharyngeal aspirates were collected from children with acute respiratory infection (ARI) aged 6-23 months. Two groups were composed of 48 vaccinated and 36 unvaccinated subjects. 16S ribosomal RNA sequencing was performed to assess bacterial composition and results were analyzed with QIIME. Similar bacterial compositions were observed in the unvaccinated and vaccinated samples. Principal component analysis also indicated a similar bacterial composition between the groups. In addition, bacterial diversity was not different between the vaccinated and unvaccinated samples. Accordingly, our results suggest that PCV10 vaccination promotes a specific response against its targets, thereby preserving the nosocomial microbiome. Although not statistically significant, Streptococcus and Haemophilus genera were increased in the vaccinated group, while Moraxella was decreased. Increases in Streptococcus may be associated with vaccine-target taxa replacement by non-pathogenic species. In sum, we observed that PCV10 vaccination acts by promoting a target-specific action against pathogenic bacteria and also induces commensal bacteria colonization without substantially changing the nasopharyngeal microbiome. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Salgado, Vanessa R.; Fukutani, Eduardo; Rossi, Erik A.; Barral, Aldina; de Oliveira, Camila I.; Queiroz, Artur T. L.] Oswaldo Cruz Fdn FIOCRUZ, Goncalo Moniz Inst, Salvador, BA, Brazil.
   [Fukutani, Kiyoshi F.; Queiroz, Artur T. L.] Fundacao Jose Silveira, MONSTER, Salvador, BA, Brazil.
   [Fukutani, Kiyoshi F.] Fac Tecnol & Ciencia, Salvador, BA, Brazil.
   [Fukutani, Eduardo; Lima, Joao V.; Queiroz, Artur T. L.] Oswaldo Cruz Fdn FIOCRUZ, Ctr Data & Knowledge Integrat Hlth, Goncalo Moniz Inst, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana] Univ Fed Bahia, Postgrad Programme Hlth Sci, Sch Med, Salvador, BA, Brazil.
   [Nascimento-Carvalho, Cristiana] Univ Fed Bahia, Dept Pediat, Sch Med, Salvador, BA, Brazil.
   [Van Weyenbergh, Johan] Katholieke Univ Leuven, Dept Microbiol & Immunol, Rega Inst Med Res, Leuven, Belgium.
RP Van Weyenbergh, J; Queiroz, ATL (reprint author), Oswaldo Cruz Fdn FIOCRUZ, Goncalo Moniz Inst, Salvador, BA, Brazil.
EM artur.queiroz@fiocruz.br
FU program Inova Fiocruz [VPPIS001-FIO18]; Pronex/FAPESB [PNX0019/2009]
FX We thank Ms. Suzane de Oliveira and Mr Olival Rocha for their
   assistance. We also are grateful to Dr. Pablo Ivan Pereira Ramos for his
   support and counsel during the modelling analysis. KFF thanks Dr. Alana
   Alves Farias for her inspiration. The authors would also like to thank
   Andris K. Walter for English language revision and manuscript
   copyediting assistance. AQ acknowledges financial support from the
   program Inova Fiocruz (Project number VPPIS001-FIO18). AB acknowledges
   financial support from the Pronex/FAPESB (Project number PNX0019/2009).
CR Abt MC, 2014, CURR OPIN IMMUNOL, V29, P16, DOI 10.1016/j.coi.2014.03.003
   Andrade DC, 2017, VACCINE, V35, P4105, DOI 10.1016/j.vaccine.2017.06.048
   Biesbroek G, 2014, AM J RESP CRIT CARE, V190, P1283, DOI 10.1164/rccm.201407-1240OC
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Brown EM, 2013, NAT IMMUNOL, V14, P660, DOI 10.1038/ni.2611
   Camilli R, 2015, VACCINE, V33, P4559, DOI 10.1016/j.vaccine.2015.07.009
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   Chaban B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069559
   Cremers AJH, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-44
   Dickson RP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097214
   Dunne EM, 2013, VACCINE, V31, P2333, DOI 10.1016/j.vaccine.2013.03.024
   Feazel LM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128064
   Folsgaard NV, 2013, AM J RESP CRIT CARE, V187, P589, DOI 10.1164/rccm.201207-1297OC
   Frank DN, 2011, TRENDS MICROBIOL, V19, P427, DOI 10.1016/j.tim.2011.06.005
   Fukutani KF, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02475
   Geer LY, 2010, NUCLEIC ACIDS RES, V38, pD492, DOI 10.1093/nar/gkp858
   Gritzfeld JF, 2013, JOVE-J VIS EXP, DOI 10.3791/50115
   Haas BJ, 2011, GENOME RES, V21, P494, DOI 10.1101/gr.112730.110
   Harris VC, 2017, J INFECT DIS, V215, P34, DOI 10.1093/infdis/jiw518
   Hibbing ME, 2010, NAT REV MICROBIOL, V8, P15, DOI 10.1038/nrmicro2259
   Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578
   Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048
   Ichinohe T, 2011, P NATL ACAD SCI USA, V108, P5354, DOI 10.1073/pnas.1019378108
   Kwambana-Adams B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08717-0
   Morris A, 2013, AM J RESP CRIT CARE, V187, P1067, DOI 10.1164/rccm.201210-1913OC
   Perez GF, 2017, J INVEST MED, V65, P984, DOI 10.1136/jim-2017-000414
   Peterson J, 2009, GENOME RES, V19, P2317, DOI 10.1101/gr.096651.109
   Piters WAAD, 2016, ISME J, V10, P97, DOI 10.1038/ismej.2015.99
   Pulendran B, 2014, P NATL ACAD SCI USA, V111, P12300, DOI 10.1073/pnas.1400476111
   Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219
   Reid G, 2011, NAT REV MICROBIOL, V9, P27, DOI 10.1038/nrmicro2473
   Salgado VR, 2016, MEM I OSWALDO CRUZ, V111, P241, DOI 10.1590/0074-02760150436
   Salk HM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162803
   Segal LN, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-19
   Shreiner AB, 2015, CURR OPIN GASTROEN, V31, P69, DOI 10.1097/MOG.0000000000000139
   Smit LAM, 2017, PNEUMONIA, V9, DOI 10.1186/s41479-017-0027-0
   Teo SM, 2015, CELL HOST MICROBE, V17, P704, DOI 10.1016/j.chom.2015.03.008
   van den Bergh MR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047711
   van Gils EJM, 2011, VACCINE, V29, P7595, DOI 10.1016/j.vaccine.2011.08.049
   Vangay P, 2015, CELL HOST MICROBE, V17, P553, DOI 10.1016/j.chom.2015.04.006
   Vesikari T, 2016, J PEDIAT INF DIS SOC, V5, P237, DOI 10.1093/jpids/piw010
   Xu QF, 2012, EMERG INFECT DIS, V18, P1738, DOI 10.3201/eid1811.111904
   Zarco MF, 2012, ORAL DIS, V18, P109, DOI 10.1111/j.1601-0825.2011.01851.x
NR 43
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1436
EP 1443
DI 10.1016/j.vaccine.2019.11.079
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900020
PM 31839468
OA Other Gold
DA 2020-05-12
ER

PT J
AU Mack, I
   Erlanger, IE
   Lang, P
   Sinniger, P
   Perisa, D
   Heininger, U
AF Mack, I.
   Erlanger, I. E.
   Lang, P.
   Sinniger, P.
   Perisa, D.
   Heininger, U.
TI Dose-dependent effectiveness of acellular pertussis vaccine in infants:
   A population-based case-control study
SO VACCINE
LA English
DT Article
DE Acellular pertussis vaccine; Vaccine effectiveness; Dose-dependent;
   Infant; Pertussis
ID CHILDHOOD PERTUSSIS; SURVEILLANCE; CHILDREN; HOSPITALIZATIONS; RISK; AGE
AB Background: Pertussis is a vaccine-preventable disease which is most severe in young infants. More than two decades after the introduction of acelluar pertussis vaccines (aPV) in national immunization programs in many countries worldwide, a resurgence of pertussis has been recognized. Suboptimal effectiveness of aPV has been blamed as one major reason but only few studies have evaluated dose-dependent vaccine effectiveness (VE) provided by aPV in current practice.
   Methods: We performed a population-based retrospective case-control study by comparing pertussis immunization data of children 2.5 months to 2 years of age hospitalized for pertussis and residing in Switzerland with immunization data of a random control sample of children aged 2 years and residing in Switzerland. VE was defined as the percentage of hospitalizations avoided by number of aPV doses. It was calculated as 1-infection rate ratio (IRR)*100.IRR was calculated by dividing infection rates of vaccinated children and infection rates of unvaccinated children. To get dose specific VE, infection rates were stratified by number doses received.
   Results: VE against hospitalization due to pertussis increased significantly with each consecutive aPV dose in a "3 + 1" primary course in infants: 42.1% (95% CI: 11.3-62.6), 83.9% (70.2-92.1), 98.2% (96.1-99.3), and 100% (97.9-100) after the 1st, 2nd, 3rd, and 4th dose, respectively.
   Conclusion: Acellular pertussis vaccines continue to demonstrate protection against hospitalization due to pertussis in infants and young children. Therefore, together with advancing immunization of pregnant women and household contacts, better control of severe pertussis in young infants can be achieved by timely initiation of immunization. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Mack, I.; Heininger, U.] Univ Basel, Childrens Hosp, Paediat Infect Dis & Vaccinol Unit, Basel, Switzerland.
   [Mack, I.; Heininger, U.] Univ Basel, Fac Med, Basel, Switzerland.
   [Erlanger, I. E.] Univ Hosp Basel, Basel, Switzerland.
   [Erlanger, I. E.] Univ Basel, Dept Clin Res, Clin Trial Unit, Basel, Switzerland.
   [Lang, P.; Sinniger, P.] Univ Zurich, Dept Publ Hlth, Epidemiol Biostat & Prevent Inst, Zurich, Switzerland.
   [Perisa, D.] Swiss Fed Off Publ Hlth, Div Infect Dis, Bern, Switzerland.
RP Mack, I (reprint author), Univ Basel, Childrens Hosp, Spitalstr 33, CH-4031 Basel, Switzerland.
EM ines.mack@ukbb.ch
CR Amirthalingam G, 2014, LANCET, V384, P1521, DOI 10.1016/S0140-6736(14)60686-3
   Barug D, 2019, LANCET INFECT DIS, V19, P392, DOI 10.1016/S1473-3099(18)30717-5
   Bisgard KM, 2005, PEDIATRICS, V116, pE285, DOI 10.1542/peds.2004-2759
   Bonhoeffer J, 2005, EUR J PEDIATR, V164, P366, DOI 10.1007/s00431-005-1637-8
   Briand V, 2007, VACCINE, V25, P7224, DOI 10.1016/j.vaccine.2007.07.020
   Bundesamt fur Gesundheit (BAG), BULLETIN, V28/15
   Bundesamt fur Gesundheit (BAG), EMPF PRAV KEUCHH STA
   Bundesamt fur Gesundheit (BAG), 2013, SCHWEIZ IMPFPL 2013
   Bundesamt fur Gesundheit (BAG), 2018, SCHWEIZ LMPFPL 2018
   Bundesamt fur Gesundheit (BAG), 2019, SCHWEIZ IMPFPL 2019
   Campbell H, 2018, J MED MICROBIOL, V67, P1426, DOI 10.1099/jmm.0.000829
   Campbell H, 2012, EMERG INFECT DIS, V18, P38, DOI 10.3201/eid1801.110784
   Cherry JD, 1998, PEDIATRICS, DOI [10.1542/peds.102.4.909, DOI 10.1542/PEDS1024909]
   Cherry JD, 2013, FEIGIN CHERRYS TXB P, P1159
   Donegan K, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4219
   Erb ML, 2019, VACCINE, V1, DOI [10.1016/j.ivacx.2019.100013, DOI 10.1014/J.VARX7019100011]
   Hegerle N, 2014, EXPERT REV VACCINES, V13, P1135, DOI 10.1586/14760584.2014.932254
   Hegerle N, 2013, FUTURE MICROBIOL, V8, P1391, DOI 10.2217/fmb.13.111
   Heininger U, 2012, VACCINE, V30, P1265, DOI 10.1016/j.vaccine.2011.12.048
   HEININGER U, 1992, EUR J PEDIATR, V151, P342, DOI 10.1007/BF02113254
   Heininger U, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155949
   Heininger U, 2014, PEDIATR INFECT DIS J, V33, P147, DOI 10.1097/01.inf.0000435503.44620.74
   Juretzko P, 2002, CLIN INFECT DIS, V35, P162, DOI 10.1086/341027
   Lang P, 2011, PUBLIC HLTH REPOR S2, V126, P97, DOI [10.5167/uzh-54235, DOI 10.5167/UZH-54235]
   Lapidot R, 2016, TROP DIS TRAVEL MED, V2, DOI [10.1186/s40794-016-0043-8, DOI 10.1186/S40794-016-00434-8]
   Misegades LK, 2012, JAMA-J AM MED ASSOC, V308, P2126, DOI 10.1001/jama.2012.14939
   Mooi F, 2007, BORDETELLA MOL MICRO
   Nauta J, 2011, STAT CLIN VACCINE TR, P95
   Quinn HE, 2014, PEDIATRICS, V133, pE513, DOI 10.1542/peds.2013-3181
   Radke S, 2017, VACCINE, V35, P177, DOI 10.1016/j.vaccine.2016.11.004
   Siegrist CA, 2014, REPORT SAGE WORKING
   Simondon F, 1997, VACCINE, V15, P1606, DOI 10.1016/S0264-410X(97)00100-X
   Tauil MD, 2016, VACCINE, V34, P2635, DOI 10.1016/j.vaccine.2016.04.016
   Urwyler P, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-397
   WHO, 2015, WHO POS PAP PERT VAC
   Witt MA, 2013, CLIN INFECT DIS, V56, P1248, DOI 10.1093/cid/cit046
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1444
EP 1449
DI 10.1016/j.vaccine.2019.11.069
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900021
PM 31813648
DA 2020-05-12
ER

PT J
AU Esparza, J
AF Esparza, Jose
TI Early vaccine advocacy: Medals honoring Edward Jenner issued during the
   19th century
SO VACCINE
LA English
DT Article
DE Advocacy; Cowpox; History; Horsepox; Jenner; Medal; Sacco; Smallpox;
   Vaccination; Vaccinia
AB The results from the first vaccination experiments published by Edward Jenner in 1798 were widely disseminated and consequently Jennerian vaccination was rapidly introduced in Europe and elsewhere. One of the reasons for the rapid spread of vaccination was that Jenner championed the procedure as a public health tool and not just as a mean to achieve individual protection. Vaccination was promoted by the highest levels of government in Germany where the vaccine was introduced in 1799 and also in France, where the vaccine arrived in 1800. Medals were used to promote vaccination both rewarding parents of vaccinated children as well as meritorious vaccinators. The first medal mentioning the name of Jenner was minted in Germany in 1803 followed by others, minted in Germany, Italy, France and England. Numerous other vaccine medals were made during the 19th century as an early and little known approach to advocating for vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Esparza, Jose] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA.
RP Esparza, J (reprint author), 11990 Market St,212, Reston, VA 20190 USA.
EM Jose.Esparza5@live.com
CR ALLEN CR, 1981, JAMA-J AM MED ASSOC, V246, P2347
   Baron J., 1838, LIFE E JENNER
   BAXBY D, 1979, J HIST MED ALL SCI, V34, P134
   Bazin H., 2000, ERADICATION SMALLPOX
   Bazin H., 2011, VACCINATION HIST MON
   Cook G C, 1996, J Med Biogr, V4, P71
   Esparza J, 2017, VACCINE, V35, P7222, DOI 10.1016/j.vaccine.2017.11.003
   Esparza JA, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007082
   FENNER F, 1988, SMALLPOX ITS ERADICA
   Garrison FH, 1926, ANN MED HIST, V8, P128
   GRAMICCIA G, 1973, BMJ-BRIT MED J, V4, P724, DOI 10.1136/bmj.4.5894.724
   Hammarsten J F, 1979, Trans Am Clin Climatol Assoc, V90, P44
   Holzmair E., 1937, KATALOG SAMMLUNG J B
   HUERKAMP C, 1985, J CONTEMP HIST, V20, P617, DOI 10.1177/002200948502000407
   JENNER E, 1801, ORIGIN VACCINE INOCU
   Jenner E, 1798, INQUIRY CAUSES EFFEC
   KISCH B, 1948, CIBA Symp, V9, P807
   LeFanu WR, 1951, BIOBIBLIOGRAPHY E JE
   Pearn J, 2019, J MED BIOGR, V27, P108, DOI 10.1177/0967772016676784
   Pfeiffer L, 1882, PESTILENCIA NUMMIS
   REICH J P, 1948, CIBA Symp, V9, P818
   Sacco L, 1809, TRATTATO VACCINAZION
   Schrick L, 2017, NEW ENGL J MED, V377, P1491, DOI 10.1056/NEJMc1707600
   Weiss RA, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0378
NR 24
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1450
EP 1456
DI 10.1016/j.vaccine.2019.11.077
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900022
PM 31839464
DA 2020-05-12
ER

PT J
AU Le Roux, D
   Djokic, V
   Morisse, S
   Chauvin, C
   Dore, V
   Lagree, AC
   Voisin, D
   Villain, Y
   Grasset-Chevillot, A
   Boursin, F
   Su, CL
   Perrot, S
   Vallee, I
   Seche, E
   Blaga, R
AF Le Roux, Delphine
   Djokic, Vitomir
   Morisse, Solen
   Chauvin, Clement
   Dore, Vanessa
   Lagree, Anne-Claire
   Voisin, Deborah
   Villain, Yohan
   Grasset-Chevillot, Aurelie
   Boursin, Fanny
   Su, Chunlei
   Perrot, Sebastien
   Vallee, Isabelle
   Seche, Edouard
   Blaga, Radu
TI Evaluation of immunogenicity and protection of the Mic1-3 knockout
   Toxoplasma gondii live attenuated strain in the feline host
SO VACCINE
LA English
DT Article
DE T. gondii; Mic1-3KO vaccine candidate strain; Definitive host; Immune
   response; Cat; Oocysts
ID GUAR GUM; CATS; VACCINE; IMMUNIZATION; TACHYZOITES; STRATEGIES;
   INVASION; ANIMALS; DIVERSE; OOCYSTS
AB Toxoplasmosis is a zoonotic disease caused by the parasite Toxoplasma gondii. Up to a third of the global human population is estimated to carry a T. gondii infection, which can result in severe complications in immunocompromised individuals and pregnant women. Humans and animals can become infected by ingesting either tissue cysts containing T. gondii bradyzoites, from raw or undercooked meat, or sporulated oocysts from environmental sources. T. gondii oocysts are released in the faeces of cats and other felids, which are the parasite's definitive hosts, leading to environmental contamination. Therefore, vaccination of the feline host against T. gondii is an interesting strategy to interrupt the parasitic life cycle and subsequently limit contamination of intermediate hosts. With this goal in mind, we tested in cats, an attenuated live strain of T. gondii deleted for the Mid and Mic3 genes (Mic1-3KO) that was previously shown to be an efficient vaccine candidate in mouse and sheep models. Subcutaneous or oral vaccination routes induced a high specific antibody titer in the cat sera, indicating that the Mic1-3KO strain is immunogenic for cats. To assess protection induced by the vaccine candidate strain, we followed oocysts shedding by vaccinated cats, after oral challenge with a T. gondii wild-type strain. Surprisingly, a high antibody titer did not prevent cats from shedding oocysts from the challenge strain, regardless of the vaccination route. Our results show that the Mic1-3KO vaccine candidate is immunogenic in the feline host, is well tolerated and safe, but does not confer protection against oocysts shedding after natural infection with wild type T. gondii. This result highlights the particular relationship between T. gondii and its unique definitive host, which indicates the need for further investigations to improve vaccination strategies to limit environmental and livestock contaminations. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Le Roux, Delphine; Djokic, Vitomir; Chauvin, Clement; Lagree, Anne-Claire; Voisin, Deborah; Villain, Yohan; Blaga, Radu] Univ Paris Est, Ecole Natl Vet Alfort, ANSES, UMR BIPAR,INRAE, F-94700 Maisons Alfort, France.
   [Morisse, Solen; Boursin, Fanny; Seche, Edouard] Univ Tours, UFR Sci Pharmaceut, Vitamfero, F-37200 Tours, France.
   [Dore, Vanessa; Perrot, Sebastien] Ecole Natl Vet Alfort, BioPole Alfort, F-94700 Maisons Alfort, France.
   [Grasset-Chevillot, Aurelie; Vallee, Isabelle] Ecole Natl Vet Alfort, INRAE, Lab Sante Anim, UMR BIPAR,Anses, F-94700 Maisons Alfort, France.
   [Su, Chunlei] Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA.
RP Le Roux, D (reprint author), Ecole Natl Vet Alfort, UMR BIPAR, 7 Ave Gen Gaulle, F-94700 Maisons Alfort, France.
EM delphine.le-roux@vet-alfort.fr
OI Perrot, Sebastien/0000-0003-3217-8375; le roux,
   delphine/0000-0003-3252-9155
FU Oseo/BPIFrance [A1206018Q]; scientific council of EnvA; Campus France;
   ANSES
FX The authors thank Dr Darragh Duffy and Dr Bruno Polack for critical
   reading of the manuscript. This work was supported by Oseo/BPIFrance (no
   A1206018Q). C.C. was funded by the scientific council of EnvA and
   V.Dj.'s PhD fellowship was funded by Campus France and ANSES.
CR Aguirre AA, 2019, ECOHEALTH
   Belluco S, 2018, CRIT REV FOOD SCI, V58, P3085, DOI 10.1080/10408398.2017.1352563
   Belluco S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153856
   Belyakov IM, 2009, J IMMUNOL, V183, P6883, DOI 10.4049/jimmunol.0901466
   Bomsel M, 2011, IMMUNITY, V34, P269, DOI 10.1016/j.immuni.2011.01.015
   Cerede O, 2005, J EXP MED, V201, P453, DOI 10.1084/jem.20041672
   Djokic V, 2014, EXP PARASITOL, V147, P67, DOI 10.1016/j.exppara.2014.10.009
   Dubey JP, 2007, VET PARASITOL, V143, P182, DOI 10.1016/j.vetpar.2006.08.024
   Dubey J.P., 2010, TOXOPLASMOSIS ANIMAL
   Dubey J.P., 2019, BIORXIV PREPRINT
   DUBEY JP, 1976, J PROTOZOOL, V23, P537, DOI 10.1111/j.1550-7408.1976.tb03836.x
   Dubey JP, 2005, VET PARASITOL, V133, P289, DOI 10.1016/j.vetpar.2005.06.007
   Dubey JP, 2002, J PARASITOL, V88, P713, DOI 10.1645/0022-3395(2002)088[0713:TILCOT]2.0.CO;2
   FREYRE A, 1993, J PARASITOL, V79, P716, DOI 10.2307/3283610
   Grellet A, 2017, J FELINE MED SURG, V19, P177, DOI 10.1177/1098612X15621353
   Grimm Rainer, 2002, Hist Med Vet, V27, P295
   Herrmann DC, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-39
   Hill D, 2002, CLIN MICROBIOL INFEC, V8, P634, DOI 10.1046/j.1469-0691.2002.00485.x
   HOWE DK, 1995, J INFECT DIS, V172, P1561, DOI 10.1093/infdis/172.6.1561
   Ibekwe VC, 2006, INT J PHARMACEUT, V308, P52, DOI 10.1016/j.ijpharm.2005.10.038
   Innes EA, 2010, ZOONOSES PUBLIC HLTH, V57, P1, DOI 10.1111/j.1863-2378.2009.01276.x
   Innes EA, 2009, PARASITOLOGY, V136, P1887, DOI 10.1017/S0031182009991636
   Ismael AB, 2006, J INFECT DIS, V194, P1176, DOI 10.1086/507706
   Koyama T, 1999, J VET MED SCI, V61, P819, DOI 10.1292/jvms.61.819
   Lelu M, 2012, APPL ENVIRON MICROB, V78, P5127, DOI 10.1128/AEM.00246-12
   Liesenfeld O, 1997, J CLIN MICROBIOL, V35, P174, DOI 10.1128/JCM.35.1.174-178.1997
   Lim SSY, 2014, KOREAN J PARASITOL, V52, P581, DOI 10.3347/kjp.2014.52.6.581
   LIN DS, 1991, J PARASITOL, V77, P272, DOI 10.2307/3283096
   Lindquist HDA, 2003, J PARASITOL, V89, P865, DOI 10.1645/GE-3147RN
   Mahl P, 2014, VET RES, V45, DOI 10.1186/s13567-014-0077-8
   Mateus-Pinilla NE, 1999, J PARASITOL, V85, P855, DOI 10.2307/3285821
   Meek B, 2001, DIAGN MICR INFEC DIS, V41, P131, DOI 10.1016/S0732-8893(01)00291-7
   Mevelec MN, 2010, VET RES, V41, DOI 10.1051/vetres/2010021
   Moire N, 2009, EXP PARASITOL, V123, P111, DOI 10.1016/j.exppara.2009.06.003
   Omata Y, 1997, VET PARASITOL, V73, P1, DOI 10.1016/S0304-4017(97)00126-X
   Opsteegh M, 2015, CLIN INFECT DIS, V60, P101, DOI 10.1093/cid/ciu721
   Ramakrishnan C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37671-8
   Robert-Gangneux F, 2012, CLIN MICROBIOL REV, V25, P264, DOI 10.1128/CMR.05013-11
   Saeij JPJ, 2005, TRENDS PARASITOL, V21, P476, DOI 10.1016/j.pt.2005.08.001
   Sandoval F, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004888
   Sharma G, 2018, CARBOHYD POLYM, V199, P534, DOI 10.1016/j.carbpol.2018.07.053
   Shwab EK, 2014, PARASITOLOGY, V141, P453, DOI 10.1017/S0031182013001844
   Sibley LD, 2011, IMMUNOL REV, V240, P72, DOI 10.1111/j.1600-065X.2010.00990.x
   Sibley LD, 2010, CURR OPIN BIOTECH, V21, P592, DOI 10.1016/j.copbio.2010.05.009
   Su C, 2006, INT J PARASITOL, V36, P841, DOI 10.1016/j.ijpara.2006.03.003
   Tenter AM, 2000, INT J PARASITOL, V30, P1217, DOI 10.1016/S0020-7519(00)00124-7
   Tenter AM, 2009, MEM I OSWALDO CRUZ, V104, P364, DOI 10.1590/S0074-02762009000200033
   Verma R, 2013, HUM VACC IMMUNOTHER, V9, P291, DOI 10.4161/hv.22474
   Yoshida N, 2011, TRENDS PARASITOL, V27, P459, DOI 10.1016/j.pt.2011.06.006
NR 49
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1457
EP 1466
DI 10.1016/j.vaccine.2019.11.076
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900023
PM 31864855
DA 2020-05-12
ER

PT J
AU Kurata, T
   Kanbayashi, D
   Egawa, K
   Kinoshita, M
   Yoshida, H
   Miyazono, M
   Motomura, K
AF Kurata, Takako
   Kanbayashi, Daiki
   Egawa, Kazutaka
   Kinoshita, Masaru
   Yoshida, Hideki
   Miyazono, Masaya
   Motomura, Kazushi
TI A measles outbreak from an index case with immunologically confirmed
   secondary vaccine failure
SO VACCINE
LA English
DT Article
DE Measles outbreak; Vaccination; Vaccine failure
ID ANTIBODIES; IMMUNITY
AB During the elimination stage of measles, the development of such disease in individuals who received measles-containing vaccine (MCV) is a concern from an epidemiological standpoint. A few cases in which measles was transmitted from a patient who received two doses of MCV have been reported. However, whether such transmissions were caused by primary vaccine failure (PVF) or secondary vaccine failure (SVF) remains unclear. All patients suspected of measles in Osaka Prefecture between November and December 2018 were enrolled. Data about age, gender, immunization record, and clinical signs were obtained. Laboratory examinations were performed, which included virus isolation in tissue culture, a nucleic acid test based on virus-specific real-time polymerase chain reaction and humoral responses to the measles virus measuring immunoglobulin (Ig) M, IgG, avidity of IgG, and neutralizing antibody concentration. The measles outbreak comprised 10 laboratory confirmed cases, including three secondary and six tertiary patients. Among them, three secondary patients were unvaccinated. The index case had received two MCV doses, and the six tertiary patients were vaccinated. Both the index and tertiary patients had high specific IgG concentration with high avidity. In particular, the index patient had a markedly high neutralization antibody concentration of 425,590 mIU/mL, which indicated immunological SVF. This study first reported about measles transmission from an individual with SVF who received two vaccination doses. To prevent measles transmission and outbreak particularly in countries where measles was almost eliminated, patients with SVF for measles should be cautiously monitored. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kurata, Takako; Kanbayashi, Daiki; Motomura, Kazushi] Morinomiya Ctr, Osaka Inst Publ Hlth, Higashinari Ku, 1-3-69 Nakamichi, Osaka 5370025, Japan.
   [Egawa, Kazutaka] Tennoji Ctr, Osaka Inst Publ Hlth, Tennoji Ku, 8-34 Tojo Cho, Osaka 5430026, Japan.
   [Kinoshita, Masaru] Osaka Prefectural Govt, Dept Hlth & Med Care, Chuo Ku, 2 Otemae, Osaka 5408570, Japan.
   [Yoshida, Hideki] Osaka City Hlth Ctr, Osaka City Publ Hlth Bur, Abeno Ku, 1-2-7-1000 Asahimachi, Osaka 5450051, Japan.
   [Miyazono, Masaya] Osaka Prefectural Govt, Neyagawa Hlth Ctr, 28-3 Yasaka Cho, Neyagawa, Osaka 5720838, Japan.
RP Kurata, T (reprint author), Morinomiya Ctr, Osaka Inst Publ Hlth, Higashinari Ku, 1-3-69 Nakamichi, Osaka 5370025, Japan.
EM kurata@iph.osaka.jp; Kanbayashi@iph.osaka.jp; egawak@iph.osaka.jp;
   KinoshitaMas@mbox.pref.osaka.lg.jp; h-yoshida@city.osaka.lg.jp;
   miyazono.masaya@city.neyagawa.osaka.jp; motomura@iph.osaka.jp
FU Research Program on Emerging and Re-emerging Infectious Diseases from
   Japan Agency for Medical Research and Development (AMED)Japan Agency for
   Medical Research and Development (AMED) [JP18f1c0108013]; Japan Society
   for the Promotion of Science (JSPS) KAKENHIMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)
   [JP17K09223]
FX This work was partly supported by Research Program on Emerging and
   Re-emerging Infectious Diseases from Japan Agency for Medical Research
   and Development (AMED) [grant numbers JP18f1c0108013] and Japan Society
   for the Promotion of Science (JSPS) KAKENHI [grant number JP17K09223 to
   TK].
CR Avramovich E, 2018, MMWR-MORBID MORTAL W, V67, P1186, DOI 10.15585/mmwr.mm6742a4
   CHEN RT, 1990, J INFECT DIS, V162, P1036, DOI 10.1093/infdis/162.5.1036
   Cherry JD, 2018, CLIN INFECT DIS, V67, P1315, DOI 10.1093/cid/ciy286
   Cohen BJ, 2007, VACCINE, V26, P59, DOI 10.1016/j.vaccine.2007.10.046
   Griffin DE, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8100282
   Hagan Jose E, 2018, MMWR Morb Mortal Wkly Rep, V67, P491, DOI 10.15585/mmwr.mm6717a3
   Hahne SJM, 2016, J INFECT DIS, V214, P1980, DOI 10.1093/infdis/jiw480
   Hamborsky J, 2015, EPIDEMIOLOGY PREVENT, P209
   Hickman CJ, 2011, J INFECT DIS, V204, pS549, DOI 10.1093/infdis/jir106
   Hummel KB, 2006, J VIROL METHODS, V132, P166, DOI 10.1016/j.jviromet.2005.10.006
   Japanese Society for infection prevention and control, GUID VACC HEALTHC WO
   Jones J, 2015, MMWR-MORBID MORTAL W, V64, P832, DOI 10.15585/mmwr.mm6430a5
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   LeBaron CW, 2007, ARCH PEDIAT ADOL MED, V161, P294, DOI 10.1001/archpedi.161.3.294
   Ma R, 2016, VACCINE, V34, P1853, DOI 10.1016/j.vaccine.2015.11.006
   McLean HQ, 2013, MMWR RECOMM REP, V62, P1
   Nakayama T, 2013, J INFECT CHEMOTHER, V19, P787, DOI 10.1007/s10156-013-0641-6
   National Institute Infectious Diseases (NIID) Japan, 2019, INFECT AGENTS SURVEI, V40, P49
   Ono N, 2001, J VIROL, V75, P4399, DOI 10.1128/JVI.75.9.4399-4401.2001
   Ovsyannikova IG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171261
   Patel M., 2019, MMWR MORB MORTAL WKL, V68
   Rosen JB, 2014, CLIN INFECT DIS, V58, P1205, DOI 10.1093/cid/ciu105
   Rota JS, 2011, J INFECT DIS, V204, pS559, DOI 10.1093/infdis/jir098
   Seto J, 2018, EPIDEMIOL INFECT, V146, P1707, DOI 10.1017/S095026881800211X
   Sowers SB, 2016, CLIN VACCINE IMMUNOL, V23, P707, DOI 10.1128/CVI.00268-16
   World Health Organization, GLOB MEASL RUB STRAT
   World Health Organization, 2018, MAN LAB BAS SURV MEA
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1467
EP 1475
DI 10.1016/j.vaccine.2019.11.075
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900024
PM 31831219
DA 2020-05-12
ER

PT J
AU Haber, P
   Moro, PL
   Ng, C
   Dores, GM
   Perez-Vilar, S
   Marquez, PL
   Cano, M
AF Haber, Penina
   Moro, Pedro L.
   Ng, Carmen
   Dores, Graca M.
   Perez-Vilar, Silvia
   Marquez, Paige L.
   Cano, Maria
TI Safety review of tetanus toxoid, reduced diphtheria toxoid, acellular
   pertussis vaccines (Tdap) in adults aged >= 65 years, Vaccine Adverse
   Event reporting System (VAERS), United States, September 2010-December
   2018
SO VACCINE
LA English
DT Review
DE Vaccine safety; Post-licensure surveillance; Tetanus toxoid, reduced
   diphtheria toxoid, acellular pertussis vaccines (Tdap); Vaccine Adverse
   Event Reporting System
ID GUILLAIN-BARRE-SYNDROME; ADVISORY-COMMITTEE; RECOMMENDATIONS;
   ANAPHYLAXIS; POPULATION; GUIDELINES; COLLECTION; OLDER
AB Introduction: The Advisory Committee on Immunization Practices (ACIP) recommends vaccination with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in persons >= 65 years of age. To date, few studies have assessed the safety of Tdap in this population. We aimed to summarize reports submitted to the Vaccine Adverse Event Reporting System (VAERS) following receipt of Tdap in this age group.
   Methods: We searched for and analyzed U.S. VAERS reports of Tdap among individuals >= 65 years of age submitted from September 1, 2010 through December 31, 2018. We classified reports according to concurrent vaccination, seriousness, and outcome (death, non-death) and determined the frequency of reported adverse events (AEs). For serious reports, we reviewed available medical records. Data mining analyses were undertaken to detect disproportionality in reporting.
   Results: VAERS received a total of 1,798 reports following Tdap, of which 104 (6%) were serious. The most common AEs were injection site erythema (26%; n = 468), injection site pain (19%; n = 335), injection site swelling (18%; n = 329), and erythema (18%; n = 321). We identified seven deaths; none were attributed to Tdap. Among serious non-death reports, nervous system disorders (35.1%; n = 34) and infections and infestations (n = 18.6%; n = 18) were most commonly reported. Data mining did not identify any vaccine-AE combination reported more frequently than expected.
   Conclusions: We did not identify any new safety concern over nearly a decade of recommended Tdap use among adults >= 65 years of age. Findings from this post-marketing review are consistent with prior post-marketing observations and pre-licensure studies. Published by Elsevier Ltd.
C1 [Haber, Penina; Moro, Pedro L.; Ng, Carmen; Marquez, Paige L.; Cano, Maria] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
   [Dores, Graca M.; Perez-Vilar, Silvia] US FDA, Div Epidemiol, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA.
   [Perez-Vilar, Silvia] US FDA, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA.
   [Perez-Vilar, Silvia] US FDA, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, Rockville, MD 20857 USA.
RP Haber, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,V18-4, Atlanta, GA 30329 USA.
EM phaber@cdc.gov
CR Anonymous, 2009, Morbidity and Mortality Weekly Report, V58, P357
   Anonymous, 2012, Morbidity and Mortality Weekly Report, V61, P468
   [Anonymous], 2014, ADAMS VICTORS PRINCI
   DeStefano F, 2019, CLIN INFECT DIS, V69, P726, DOI 10.1093/cid/ciz135
   DuMouchel W, 1999, AM STAT, V53, P177, DOI 10.2307/2686093
   Institute of Medicine, 2012, ADVERSE EFFECTS VACC
   Kretsinger Katrina, 2006, Morbidity and Mortality Weekly Report, V55, P1
   Liang JL, 2018, MMWR RECOMM REP, V67, P1, DOI 10.15585/mmwr.rr6702a1
   McNeil MM, 2016, J ALLERGY CLIN IMMUN, V137, P868, DOI 10.1016/j.jaci.2015.07.048
   Moro PL, 2011, VACCINE, V29, P9404, DOI 10.1016/j.vaccine.2011.05.100
   Nordin JD, 2011, VACCINE, V29, P1122, DOI 10.1016/j.vaccine.2010.11.056
   Perez-Vilar S, 2019, VACCINE, V37, P3856, DOI 10.1016/j.vaccine.2019.05.041
   Polakowski LL, 2013, AM J EPIDEMIOL, V178, P962, DOI 10.1093/aje/kwt051
   Ruggeberg JU, 2007, VACCINE, V25, P5675, DOI 10.1016/j.vaccine.2007.02.064
   SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P105, DOI 10.1093/oxfordjournals.aje.a112795
   Sejvar JJ, 2011, NEUROEPIDEMIOLOGY, V36, P123, DOI 10.1159/000324710
   Sejvar JJ, 2011, VACCINE, V29, P599, DOI 10.1016/j.vaccine.2010.06.003
   Seror P, 2017, JOINT BONE SPINE, V84, P153, DOI 10.1016/j.jbspin.2016.03.005
   Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035
   STRATTON KR, 1994, JAMA-J AM MED ASSOC, V271, P1602, DOI 10.1001/jama.271.20.1602
   Su JR, 2019, J ALLERGY CLIN IMMUN, V143, P1465, DOI 10.1016/j.jaci.2018.12.1003
   Szarfman A, 2002, DRUG SAFETY, V25, P381, DOI 10.2165/00002018-200225060-00001
   Tseng HF, 2013, CLIN INFECT DIS, V56, P315, DOI 10.1093/cid/cis871
   Weston WM, 2012, VACCINE, V30, P1721, DOI 10.1016/j.vaccine.2011.12.055
   Zhou Weigong, 2003, MMWR Surveill Summ, V52, P1
NR 25
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1476
EP 1480
DI 10.1016/j.vaccine.2019.11.074
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900025
PM 31883809
DA 2020-05-12
ER

PT J
AU Pike, J
   Marin, M
   Guo, A
   Haselow, D
   Safi, H
   Zhou, FJ
AF Pike, Jamison
   Marin, Mona
   Guo, Angela
   Haselow, Dirk
   Safi, Haytham
   Zhou, Fangjun
TI 2016-2017 Arkansas mumps outbreak in a close-knit community: Assessment
   of the economic impact and response strategies
SO VACCINE
LA English
DT Article
DE Cost of outbreak; Economic burden; Arkansas Marshallese; Mumps
ID IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; PROGRAM; RUBELLA; MEASLES
AB On August 8, 2016, a confirmed case of mumps was reported to the Arkansas Department of Health (ADH) in an adult resident of Springdale, Arkansas. By July 2017, nearly 3,000 cases of mumps were reported to ADH from 37 of the 75 counties in Arkansas. Over 50% of cases were in the Arkansas Marshallese community, a close-knit community characterized by large, and extended families sharing the same living space and communal activities, In a statewide effort, ADH collaborated with CDC, the Republic of the Marshall Island's (RMI) Ministry of Health, and the Arkansas Department of Education (ADE) to rapidly respond to and contain the outbreak. We assessed the economic burden to ADH of the outbreak response in terms of containment and vaccination costs, as well as response costs incurred by CDC, RMI, and ADE. The 2016-2017 Arkansas mumps outbreak was the second largest US mumps outbreak in over 30 years and was unique in size, spread, and population affected. Total public health response costs as a result of the outbreak were over $2.1 million, approximately $725 per case. The costs incurred to control this outbreak reflect the response strategies tailored to the affected populations, including consideration of social, cultural, and political factors in controlling transmission and requirements of distinctive strategies for public health outreach. Aside from the burden these outbreaks have on the affected population, we demonstrate the potential for high economic burden of these outbreaks to public health. Published by Elsevier Ltd.
C1 [Pike, Jamison; Marin, Mona; Guo, Angela; Zhou, Fangjun] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, 1600 Clifton Rd NE, Atlanta, GA 30329 USA.
   [Haselow, Dirk; Safi, Haytham] Arkansas Dept Hlth, Little Rock, AR 72205 USA.
RP Pike, J (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, 1600 Clifton Rd NE, Atlanta, GA 30329 USA.
EM jpike@cdc.gov
OI Pike, Jamison/0000-0002-3442-5627
CR [Anonymous], 2012, REP MARSH ISL 2011 C
   Centers for Disease Control and Prevention, 1989, MMWR-MORBID M      S, V38, P1
   Clemmons N, 2018, MANUAL SURVEILLANCE
   Clemmons NC, 2016, 47 NAT IMM C SEPT 14
   Clemmons NS, 2017, ID WEEK 2017 OCT 4 8
   Duke MR, 2017, MED ANTHROPOL Q, V31, P422, DOI 10.1111/maq.12376
   Fields V.S., 2019, LANCET INFECT DIS
   Haddix AC, 2003, PREVENTION EFFECTIVE
   Kutty PK, 2014, HUM VACC IMMUNOTHER, V10, P1373, DOI 10.4161/hv.28389
   Mahamud A, 2012, VACCINE, V30, P6444, DOI 10.1016/j.vaccine.2012.08.001
   Marin M, 2018, OPEN FORUM INFECT DI, P5
   Marin M, 2018, MMWR-MORBID MORTAL W, V67, P33, DOI 10.15585/mmwr.mm6701a7
   McLean HQ, 2013, MMWR RECOMM REP, V62, P1
   Pike J, 2019, J PUBLIC HLTH MANAGE
   Rubin S., 2017, VACCINES, P663
   Underwood R.A., 2003, AMENDED US COMPACTS
   United States Department of State, 2018, US REL MARSH ISL
   US Department of Labor Bureau of Labor Statistics, 2019, MAY 2018 STAT OCC EM
   Zhou FJ, 2014, PEDIATRICS, V133, P577, DOI 10.1542/peds.2013-0698
   Zhou FJ, 2004, J INFECT DIS, V189, pS131, DOI 10.1086/378987
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1481
EP 1485
DI 10.1016/j.vaccine.2019.11.066
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900026
PM 31818532
DA 2020-05-12
ER

PT J
AU Laconi, A
   Weerts, EAWS
   Bloodgood, JCG
   Marrero, JPD
   Berends, AJ
   Cocciolo, G
   de Wit, JJ
   Verheije, MH
AF Laconi, A.
   Weerts, E. A. W. S.
   Bloodgood, J. C. G.
   Marrero, J. P. Deniz
   Berends, A. J.
   Cocciolo, G.
   de Wit, J. J.
   Verheije, M. H.
TI Attenuated live infectious bronchitis virus QX vaccine disseminates
   slowly to target organs distant from the site of inoculation
SO VACCINE
LA English
DT Article
DE Infectious bronchitis virus; Nephropathogenicity; Broilers; Attenuation;
   Vaccine; Virulence
ID SEROTYPE; STRAIN; PROTECTION; CHALLENGE; GENOTYPES; BROILERS; EFFICACY;
   SAFETY
AB Infectious bronchitis (IB) is a highly contagious respiratory disease of poultry, caused by the avian coronavirus infectious bronchitis virus (IBV). Currently, one of the most relevant genotypes circulating worldwide is IBV-QX (GI-19), for which vaccines have been developed by passaging virulent QX strains in embryonated chicken eggs. Here we explored the attenuated phenotype of a commercially available QX live vaccine, IB Primo QX, in specific pathogens free broilers. At hatch, birds were inoculated with QX vaccine or its virulent progenitor IBV-D388, and postmortem swabs and tissues were collected each day up to eight days post infection to assess viral replication and morphological changes. In the trachea, viral RNA replication and protein expression were comparable in both groups. Both viruses induced morphologically comparable lesions in the trachea, albeit with a short delay in the vaccinated birds. In contrast, in the kidney, QX vaccine viral RNA was nearly absent, which coincided with the lack of any morphological changes in this organ. This was in contrast to high viral RNA titers and abundant lesions in the kidney after IBV D388 infection. Furthermore, QX vaccine showed reduced ability to reach and replicate in conjunctivae and intestines including cloaca, resulting in significantly lower titers and delayed protein expression, respectively. Nephropathogenic IBVs might reach the kidney also via an ascending route from the cloaca, based on our observation that viral RNA was detected in the cloaca one day before detection in the kidney. In the kidney distal tubular segments, collecting ducts and ureter were positive for viral antigen. Taken together, the attenuated phenotype of QX vaccine seems to rely on slower dissemination and lower replication in target tissues other than the site of inoculation. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Laconi, A.; Weerts, E. A. W. S.; Bloodgood, J. C. G.; Marrero, J. P. Deniz; Berends, A. J.; Verheije, M. H.] Univ Utrecht, Fac Vet Med, Dept Pathobiol, Yalelaan 1, NL-3584 CL Utrecht, Netherlands.
   [Cocciolo, G.] Univ Bari, Dept Vet Med, Valenzano, Italy.
   [de Wit, J. J.] GD Anim Hlth, Deventer, Netherlands.
   [Laconi, A.] Univ Padua, Dept Comparat Biomed & Food Sci, Legnaro, PD, Italy.
RP Verheije, MH (reprint author), Univ Utrecht, Fac Vet Med, Dept Pathobiol, Yalelaan 1, NL-3584 CL Utrecht, Netherlands.
EM m.h.verheije@uu.nl
OI Verheije, Helene/0000-0003-1274-2987; Bloodgood,
   Jennifer/0000-0002-9044-8591; Laconi, Andrea/0000-0003-0102-7021
FU Utrecht University (Utrecht, The Netherlands)Netherlands Government; GD
   Animal Health (Deventer, The Netherlands)
FX Utrecht University (Utrecht, The Netherlands) and GD Animal Health
   (Deventer, The Netherlands) financially supported this research. The
   authors have no competing interests to declare.
CR Abro SH, 2012, ARCH VIROL, V157, P1211, DOI 10.1007/s00705-012-1284-0
   Amarasinghe A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181801
   Benyeda Z, 2010, J COMP PATHOL, V143, P276, DOI 10.1016/j.jcpa.2010.04.007
   Bijlenga G, 2004, AVIAN PATHOL, V33, P550, DOI 10.1080/03079450400013154
   Brand JMA, 2011, EFFICACY VACCINATION, V85, P2851, DOI [10.1128/N1.01939-10, DOI 10.1128/N1.01939-10]
   Cavanagh D, 2005, BIRK ADV INFECT DIS, P1
   Chen B, 2007, ANAL LETT, V40, P2465, DOI 10.1080/00032710701583466
   Cook JKA, 2012, AVIAN PATHOL, V41, P239, DOI 10.1080/03079457.2012.680432
   de Wit JJ, 2018, AVIAN PATHOL, V47, P140, DOI 10.1080/03079457.2017.1387231
   de Wit JJ, 2011, AVIAN PATHOL, V40, P463, DOI 10.1080/03079457.2011.599060
   de Wit JJ, 2014, AVIAN PATHOL, V43, P485, DOI 10.1080/03079457.2014.974504
   Dolz R, 2012, VET MICROBIOL, V156, P256, DOI 10.1016/j.vetmic.2011.11.001
   Ganapathy K, 2012, VET REC, V171, P597, DOI 10.1136/vr.101005
   Geerligs HJ, 2011, AVIAN PATHOL, V40, P93, DOI 10.1080/03079457.2010.542742
   Gelb JJ, 1983, AVIAN DIS, V27, P240
   HOFSTAD MS, 1966, AVIAN DIS, V10, P230, DOI 10.2307/1588355
   Jackwood MW, 2003, AVIAN DIS, V47, P627, DOI 10.1637/6094
   Krapei U, 2011, AVIAN DIS DIG, V6, pe60, DOI [10.1637/9662-953317-digest.1, DOI 10.1637/9662-953317-DIGEST.1]
   Laconi A, 2020, J VIROL METHODS, V275, DOI 10.1016/j.jviromet.2019.113771
   Reddy VRAP, 2016, VET RES, V47, P1, DOI [10.1186/s13567-016-0154-9, DOI 10.1186/S13567-016-0154-9]
   Terregino C, 2008, AVIAN PATHOL, V37, P487, DOI 10.1080/03079450802356938
   Valastro V, 2010, VET REC, V167, P865, DOI 10.1136/vr.c6001
   Valastro V, 2016, INFECT GENET EVOL, V39, P349, DOI 10.1016/j.meegid.2016.02.015
   van Beurden SJ, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0775-8
   van der Sluis HJ, 2009, POULTRY SCI, V88, P1242, DOI 10.3382/ps.2008-00155
   Worthington KJ, 2008, AVIAN PATHOL, V37, P247, DOI 10.1080/03079450801986529
   YuDong W, 1998, CHINESE J ANIM Q, V15, P1998
NR 27
TC 0
Z9 0
U1 21
U2 21
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1486
EP 1493
DI 10.1016/j.vaccine.2019.11.064
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900027
PM 31822427
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Ssemaganda, A
   Giddam, AK
   Low, LM
   Liu, XQ
   Ho, MF
   Zaman, M
   Hussein, WM
   Skwarczynski, M
   Toth, I
   Stanisic, DI
   Good, MF
AF Ssemaganda, Aloysious
   Giddam, Ashwini Kumar
   Low, Leanne M.
   Liu, Xue Q.
   Ho, Mei-Fong
   Zaman, Mehfuz
   Hussein, Waleed M.
   Skwarczynski, Mariusz
   Toth, Istvan
   Stanisic, Danielle I.
   Good, Michael F.
TI Mannosylated liposomes formulated with whole parasite P. falciparum
   blood-stage antigens are highly immunogenic in mice
SO VACCINE
LA English
DT Article
DE Whole parasite; Blood-stage; P. falciparum; Mannosylated liposomes;
   Lyophilization; Immunogenicity
ID CD4+ T-CELLS; PLASMODIUM-FALCIPARUM; MALARIA VACCINE; IMMUNE-RESPONSES;
   NEXT-GENERATION; PFSPZ VACCINE; VESICLE SIZE; PROTECTION; ADJUVANTS;
   CHABAUDI
AB The development of a blood-stage malaria vaccine has largely focused on the subunit approach. However, the limited success of this strategy, mainly due to antigenic polymorphism and the failure to maintain potent parasite-specific immune responses, indicates that other approaches must be considered. Whole parasite (WP) vaccines offer many advantages over sub-units; they represent every antigen on the organism, thus limiting the effects of antigenic polymorphism, and similarly they compensate for individual Immune-Response (Ir) gene-regulated non-responsiveness to any particular antigen. From a development perspective, they negate the need to identify and compare the relative efficacies of individual candidate antigens. WP vaccines induce protective immunity that is largely cell-mediated.
   However, WP blood-stage vaccines present a number of challenges for the development pathway. Key issues are cryopreservation and storage and the possible induction of antibodies against red blood cell surface antigens, even if the parasites are grown in blood group O, Rh negative blood. Here, we used a novel adaptation of an immunomagnetic method from STEMCELL (TM) Technologies to remove the red cell membranes from human red blood cells parasitized with P. falciparum. We then used these antigens to construct liposomes which were modified to present mannose on their membrane to target the liposome to antigen presenting cells. We then compared the immunogenicity of freshly prepared and lyophilized liposome vaccines. Following vaccination of mice, liposomes induced significantly lower antibody responses to human red cells but potent strain- and species-transcending cell-mediated immune responses to parasite antigens. These data support transitioning the P. falciparum liposomal vaccine into clinical studies. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ssemaganda, Aloysious; Giddam, Ashwini Kumar; Low, Leanne M.; Liu, Xue Q.; Ho, Mei-Fong; Zaman, Mehfuz; Stanisic, Danielle I.; Good, Michael F.] Griffith Univ, Inst Glyc, Gold Coast Campus,Bldg G26-4-18, Griffith, NSW 4222, Australia.
   [Hussein, Waleed M.; Skwarczynski, Mariusz; Toth, Istvan] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld, Australia.
   [Toth, Istvan] Univ Queensland, Sch Pharm, Brisbane, Qld, Australia.
   [Toth, Istvan] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia.
   [Ssemaganda, Aloysious] Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada.
   [Giddam, Ashwini Kumar] Royal Brisbane & Womens Hosp, Q Pharm, Herston, Qld, Australia.
   [Low, Leanne M.] NIAID, Lab Malaria & Vector Res, NIH, Rockville, MD USA.
RP Stanisic, DI; Good, MF (reprint author), Griffith Univ, Inst Glyc, Gold Coast Campus,Bldg G26-4-18, Griffith, NSW 4222, Australia.
EM d.stanisic@griffith.edu.au; michael.good@grif-fith.edu.au
RI Toth, Istvan/C-1965-2013; Skwarczynski, Mariusz/A-6707-2009
OI Toth, Istvan/0000-0002-4572-397X; Skwarczynski,
   Mariusz/0000-0001-7257-807X; Low, Leanne/0000-0002-1976-3767; Stanisic,
   Danielle/0000-0003-3908-7468
FU Griffith University (Griffith University International Postgraduate
   Research Scholarship); Griffith University (Griffith University
   Postgraduate Research Scholarship); National Health and Medical Research
   Council FellowshipNational Health and Medical Research Council of
   Australia; Queensland Government's Queensland-Chinese Academy of
   Sciences (Q-CAS) Collaborative Science Fund
FX The generous support from Griffith University (Griffith University
   International Postgraduate Research Scholarship and Griffith University
   Postgraduate Research Scholarship) awarded to Aloysious Ssemaganda was
   gratefully acknowledged. We acknowledge support from a National Health
   and Medical Research Council Fellowship awarded to Michael F. Good, and
   from the Queensland Government's Queensland-Chinese Academy of Sciences
   (Q-CAS) Collaborative Science Fund.
CR Arnold MSJ, 2016, ANTIMICROB AGENTS CH, V60, P4361, DOI 10.1128/AAC.02948-15
   Brain MC, 2002, BRIT J HAEMATOL, V118, P899, DOI 10.1046/j.1365-2141.2002.03657.x
   Brewer JM, 2004, J IMMUNOL, V173, P6143, DOI 10.4049/jimmunol.173.10.6143
   Brito LA, 2014, J CONTROL RELEASE, V190, P563, DOI 10.1016/j.jconrel.2014.06.027
   Coler RN, 2009, PARASITE IMMUNOL, V31, P520, DOI 10.1111/j.1365-3024.2009.01142.x
   Copland MJ, 2003, VACCINE, V21, P883, DOI 10.1016/S0264-410X(02)00536-4
   Engwerda CR, 2005, TRENDS PARASITOL, V21, P75, DOI 10.1016/j.pt.2004.11.008
   Epstein JE, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89154
   Ewer KJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3836
   FavilaCastillo L, 1996, PARASITE IMMUNOL, V18, P325, DOI 10.1046/j.1365-3024.1996.d01-117.x
   Genton B, 2002, J INFECT DIS, V185, P820, DOI 10.1086/339342
   Ghaffar KA, 2014, CURR TOP MED CHEM, V14, P1194, DOI 10.2174/1568026614666140329232757
   Giddam AK, 2016, ACTA BIOMATER, DOI [10.1016/j.actbio.2016.08.020, DOI 10.1016/J.ACTBIO.2016.O8.020]
   Good MF, 2013, J CLIN INVEST, V123, P3353, DOI 10.1172/JCI66634
   Henriksen-Lacey M, 2011, J CONTROL RELEASE, V154, P131, DOI 10.1016/j.jconrel.2011.05.019
   Ishizuka AS, 2016, NAT MED, V22, P614, DOI 10.1038/nm.4110
   KUMAR S, 1989, J IMMUNOL, V143, P2017
   LANGHORNE J, 1989, IMMUNOL REV, V112, P71, DOI 10.1111/j.1600-065X.1989.tb00553.x
   Linke A, 1996, EXP PARASITOL, V84, P253, DOI 10.1006/expr.1996.0111
   Low LM, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00587-18
   Lyke KE, 2017, P NATL ACAD SCI USA, V114, P2711, DOI 10.1073/pnas.1615324114
   Moon RW, 2013, P NATL ACAD SCI USA, V110, P531, DOI 10.1073/pnas.1216457110
   Mordmuller B, 2017, NATURE, V542, P445, DOI 10.1038/nature21060
   Neafsey DE, 2015, NEW ENGL J MED, V373, P2025, DOI 10.1056/NEJMoa1505819
   Ogutu BR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004708
   Olotu A, 2016, NEW ENGL J MED, V374, P2519, DOI 10.1056/NEJMoa1515257
   Perrie Y, 2016, ADV DRUG DELIVER REV, V99, P85, DOI 10.1016/j.addr.2015.11.005
   Pinzon-Charry A, 2010, J CLIN INVEST, V120, P2967, DOI 10.1172/JCI39222
   Raja AI, 2016, INFECT IMMUN, V84, P2274, DOI 10.1128/IAI.00157-16
   Seder RA, 2013, SCIENCE, V341, P1359, DOI 10.1126/science.1241800
   Sirima SB, 2011, NEW ENGL J MED, V365, P1062, DOI 10.1056/NEJMc1100670
   Sissoko MS, 2017, LANCET INFECT DIS, V17, P498, DOI [10.1016/s1473-3099(17)30104-4, 10.1016/S1473-3099(17)30104-4]
   Ssemaganda A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00135
   Ssemaganda A, 2018, METALLOMICS, V10, P444, DOI [10.1039/c7mt00311k, 10.1039/C7MT00311K]
   Stanisic DI, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1173-9
   Stanisic DI, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0663-x
   STEVENSON MM, 1993, CLIN EXP IMMUNOL, V92, P77, DOI 10.1111/j.1365-2249.1993.tb05951.x
   Su Z, 2003, INFECT IMMUN, V71, P5178, DOI 10.1128/IAI.71.9.5178-5187.2003
   Thera MA, 2011, NEW ENGL J MED, V365, P1004, DOI 10.1056/NEJMoa1008115
   Ting LM, 2008, NAT MED, V14, P954, DOI 10.1038/nm.1867
   Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8
   VONDERWEID T, 1994, EUR J IMMUNOL, V24, P2285, DOI 10.1002/eji.1830241004
   Vyas SP, 2010, METHODS MOL BIOL, V605, P177, DOI 10.1007/978-1-60327-360-2_12
   Watson DS, 2012, VACCINE, V30, P2256, DOI 10.1016/j.vaccine.2012.01.070
   WINKEL KD, 1991, PARASITE IMMUNOL, V13, P517, DOI 10.1111/j.1365-3024.1991.tb00548.x
   Yap XZ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00032
NR 46
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1494
EP 1504
DI 10.1016/j.vaccine.2019.11.063
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900028
PM 31866187
DA 2020-05-12
ER

PT J
AU Hadjipanayis, A
   van Esso, D
   del Torso, S
   Dornbusch, HJ
   Michailidou, K
   Minicuci, N
   Pancheva, R
   Mujkic, A
   Geitmann, K
   Syridou, G
   Altorjai, P
   Pasinato, A
   Valiulis, A
   Soler, P
   Cirstea, O
   Illy, K
   Mollema, L
   Mazur, A
   Neves, A
   Zavrsnik, J
   Lapii, F
   Efstathiou, E
   Kamphuis, M
   Grossman, Z
AF Hadjipanayis, Adamos
   van Esso, Diego
   del Torso, Stefano
   Dornbusch, Hans Juergen
   Michailidou, Kyriaki
   Minicuci, Nadia
   Pancheva, Ruzha
   Mujkic, Aida
   Geitmann, Karin
   Syridou, Garyfallia
   Altorjai, Peter
   Pasinato, Angela
   Valiulis, Arunas
   Soler, Paul
   Cirstea, Olga
   Illy, Karoly
   Mollema, Liesbeth
   Mazur, Artur
   Neves, Ana
   Zavrsnik, Jernej
   Lapii, Fedir
   Efstathiou, Elisavet
   Kamphuis, Mascha
   Grossman, Zachi
TI Vaccine confidence among parents: Large scale study in eighteen European
   countries
SO VACCINE
LA English
DT Article
DE Vaccine confidence; Vaccine hesitancy
ID COMPLEMENTARY MEDICINE; PRIMARY-CARE; ATTITUDES; HESITANCY; CHILDREN;
   PEDIATRICIANS; IMMUNIZATION; INFECTIONS; KNOWLEDGE; BARRIERS
AB Background: Despite the fact that vaccines save 2-3 million lives worldwide every year, a percentage of children are not getting appropriately vaccinated, thus leading to disease outbreaks. One of the major reasons of low vaccine uptake in Europe is vaccine hesitancy, contributing to the recent measles outbreaks. Monitoring of vaccine hesitancy is valuable in early identification of vaccine concerns.
   Methods: We performed an eighteen country European survey on parents' attitudes and behaviors regarding their children's immunization. Parents having at least one child 1-4 years old were mostly recruited by primary care paediatricians to reply to a web-based questionnaire.
   The questionnaire was developed by the European Academy of Paediatrics Research in Ambulatory Setting Network steering committee, based on similar surveys. An individual level hesitancy score was constructed using the answers to 21 questions, and correlations of the score with socio-demographic characteristics and types of providers were explored. To assess inter country differences, a country level self -reported confidence was defined.
   Results: Fifty six percent and 24% of 5736 respondents defined themselves as "not at all hesitant", and "somewhat hesitant", respectively. Parents who consulted general practitioners were more hesitant than parents who consulted pediatricians (p < 0.05). Consultation with homeopathists was associated with the highest reported hesitancy (p < 0.05). Vaccine confidence was highest in Portugal and Cyprus, and lowest in Bulgaria and Poland.
   Conclusion: The majority of parents in Europe believe in the importance of childhood vaccination. However, significant lack of confidence was found in certain European countries, highlighting the need for continuous monitoring, awareness and response plans. The possible influence of different types of healthcare providers on parental decisions demonstrated for the first time in our survey, calls for further research. Monitoring and continuous medical education efforts aimed mostly at those professionals who might not be likely to recommend vaccination are suggested. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hadjipanayis, Adamos] Larnaca Gen Hosp, Dept Paediat, CY-6042 Inomenon Polition, Larnaca, Cyprus.
   [Hadjipanayis, Adamos] European Univ, Sch Med, 6 Diogenis St, CY-1516 Nicosia, Cyprus.
   [van Esso, Diego] Catalan Inst Hlth, Primary Care Serv, Barcelona, Spain.
   [del Torso, Stefano] ULSS 16, Pediat Clin, Padua, Italy.
   [Dornbusch, Hans Juergen] Med Univ Graz, Graz, Austria.
   [Michailidou, Kyriaki] Cyprus Inst Neurol & Genet, Dept Electron Microscopy Mol Pathol, Nicosia, Cyprus.
   [Michailidou, Kyriaki] Cyprus Inst Neurol & Genet, Cyprus Sch Mol Med, Nicosia, Cyprus.
   [Minicuci, Nadia] CNR, Neurosci Inst, Padua, Italy.
   [Pancheva, Ruzha] Prof Paraskev Stoyanov Med Univ, Fac Publ Hlth, Dept Hyg & Epidemiol, Varna, Bulgaria.
   [Mujkic, Aida] Univ Zagreb, Andrija Stampar Sch Publ Hlth, Sch Med, Zagreb, Croatia.
   [Geitmann, Karin] BVKJ, PCP, D-58095 Hagen, Germany.
   [Syridou, Garyfallia] Thriasio Gen Hosp Elefsina Athens, Dept Paediat, Athens, Greece.
   [Altorjai, Peter] Toth Ilona Healthcare Serv, Primary Paediat Care Off Gorgey Artur Ter 8, H-1212 Budapest, Hungary.
   [Pasinato, Angela] Pediat Libera Scelta, Azienda 8 Berica, Vicenza, Italy.
   [Valiulis, Arunas] Vilnius Univ, Fac Med, Inst Clin Med, Vilnius, Lithuania.
   [Valiulis, Arunas] Vilnius City Clin Hosp, Inst Hlth Sci, Vilnius, Lithuania.
   [Soler, Paul] Mater Dei Hosp Msida, Dept Child & Adolescent Hlth, Msida, Malta.
   [Cirstea, Olga] State Univ Med & Pharm Nicolae Testemitanu Chisin, Dept Pediat, Kishinev, Moldova.
   [Illy, Karoly] Ziekenhuis Rivierenland, Dept Paediat, Tiel, Netherlands.
   [Mollema, Liesbeth] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, Bilthoven, Netherlands.
   [Mazur, Artur] Univ Rzeszow, Fac Med, Rzeszow, Poland.
   [Neves, Ana] Lisbon Univ, Univ Hosp Santa Maria, Dept Pediat, Pediat Allergy Unit,Fac Med, Lisbon, Portugal.
   [Zavrsnik, Jernej] Community Hlth Ctr Dr Adollf Drolc, Maribor, Slovenia.
   [Lapii, Fedir] Natl Med Acad Postgrad Educ, Dept Pediat Infect Dis & Pediat Immunol, Kiev, Ukraine.
   [Efstathiou, Elisavet] Larnaca Gen Hosp, Dept Paediat, Larnax, Cyprus.
   [Kamphuis, Mascha] Dutch Expertise Ctr Child Abuse, Utrecht, Netherlands.
   [Grossman, Zachi] Maccabi Healthcare Serv, Pediat Clin, Tel Aviv, Israel.
RP Hadjipanayis, A (reprint author), 6,25th Martiou St, CY-5380 Derynia, Cyprus.
EM adamos@paidiatros.com; hansjuergen.dornbusch@medunigraz.at;
   kyriakimi@cing.ac.cy; nadia.minicuci@unipd.it; amujkic@snz.hr;
   k.geitmann@web.de; arunas.valiulis@mf.vu.lt; paul.r.soler@gov.mt;
   olga.cirstea@usmf.md; k.illy@zrt.nl; Liesbeth.Mollema@rivm.nl;
   drmazur@poczta.onet.pl; jernej.zavrsnik@zd-mb.si;
   mascha@ajnjeugdartsen.nl; zgrosman@netvision.net.il
RI Hadjipanayis, Adamos/M-6102-2016
OI Hadjipanayis, Adamos/0000-0003-4337-3176; Mazur,
   Artur/0000-0001-5393-3515
CR Attwell K, 2018, SOC SCI MED, V196, P106, DOI 10.1016/j.socscimed.2017.11.022
   Black S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001738
   Chen MF, 2011, J COMMUN HEALTH NURS, V28, P29, DOI 10.1080/07370016.2011.539087
   Chow MYK, 2017, AUST FAM PHYSICIAN, V46, P145
   del Torso S, 2010, CHILD CARE HLTH DEV, V36, P385, DOI 10.1111/j.1365-2214.2010.01086.x
   Dube E, 2016, PLOS CURR, V8, DOI DOI 10.1371/CURRENTS.OUTBREAKS.9E239605F4D320C6AD27CE2AEA5AAAD2
   Dube E, 2018, EXPERT REV VACCINES, V17, P989, DOI 10.1080/14760584.2018.1541406
   Ehrich JHH, 2015, J PEDIATR-US, V167, P471, DOI 10.1016/j.jpeds.2015.03.031
   Esposito S, 2014, CLIN MICROBIOL INFEC, V20, P25, DOI 10.1111/1469-0691.12447
   Frawley JE, 2018, VACCINE, V36, P866, DOI 10.1016/j.vaccine.2017.12.036
   Giambi C, 2018, VACCINE
   Grossman Z, 2016, CHILD CARE HLTH DEV, V42, P928, DOI 10.1111/cch.12374
   Grossman Z, 2018, PEDIAT INFECT DIS J
   Grossman Z, 2012, ACTA PAEDIATR, V101, P935, DOI 10.1111/j.1651-2227.2012.02754.x
   Grossman Z, 2011, PEDIATR INFECT DIS J, V30, P255, DOI 10.1097/INF.0b013e3181faaaa3
   Hadjipanayis A, 2018, EUR J PEDIATR, V177, P675, DOI 10.1007/s00431-018-3108-z
   Hadjipanayis A, 2015, ARCH DIS CHILD, V100, P341, DOI 10.1136/archdischild-2014-306119
   Kirkdale C. L., 2017, Annales Pharmaceutiques Francaises, V75, P9, DOI 10.1016/j.pharma.2016.08.006
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8
   Larson HJSW, 2015, PLOS CURR OUTBREAKS
   Leask J, 2011, NATURE, V473, P443, DOI 10.1038/473443a
   Measles-European Region, 2019, DIS OUTBR NEWS UPTD
   Morin A, 2012, VACCINE, V30, P5921, DOI 10.1016/j.vaccine.2012.07.050
   Opel DJ, 2011, VACCINE, V29, P6598, DOI 10.1016/j.vaccine.2011.06.115
   Opel DJ, 2011, HUM VACCINES, V7, P419, DOI 10.4161/hv.7.4.14120
   Patel MK, 2019, LANCET GLOB HEALTH, V7, pE313, DOI 10.1016/S2214-109X(18)30492-3
   Posfay-Barbe KM, 2005, PEDIATRICS, V116, pE623, DOI 10.1542/peds.2005-0885
   Smith PJ, 2010, PUBLIC HEALTH REP, V125, P534, DOI 10.1177/003335491012500408
   Stefanoff P, 2010, VACCINE, V28, P5731, DOI 10.1016/j.vaccine.2010.06.009
   Swaney SE, 2019, HEALTH PROMOT J AUST, V30, P143, DOI 10.1002/hpja.190
   The SAGE Vaccine Hesitancy Working Group, 2014, REP SAGE WORK GROUP
   van Esso D, 2010, ARCH DIS CHILD, V95, P791, DOI 10.1136/adc.2009.178459
   Verger P, 2016, EUROSURVEILLANCE, V21, P14, DOI 10.2807/1560-7917.ES.2016.21.47.30406
   Verger P, 2015, EBIOMEDICINE, V2, P891, DOI 10.1016/j.ebiom.2015.06.018
   Wardle J, 2016, VACCINE, V34, P4484, DOI 10.1016/j.vaccine.2016.07.026
   World Health Organization, 2014, REP SAGE WORK GROUP
   World Health Organization, 2017, ASS REP GLOB VACC AC
   World Health Organization, 2019, MEASL RUB SURV DAT
NR 41
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1505
EP 1512
DI 10.1016/j.vaccine.2019.11.068
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900029
PM 31848051
DA 2020-05-12
ER

PT J
AU Tricou, V
   Low, JG
   Oh, HM
   Leo, YS
   Kalimuddin, S
   Wijaya, L
   Pang, JX
   Ling, LM
   Lee, TH
   Brose, M
   Hutagalung, Y
   Rauscher, M
   Borkowski, A
   Wallace, D
AF Tricou, Vianney
   Low, Jenny G.
   Oh, Helen M.
   Leo, Yee-Sin
   Kalimuddin, Shirin
   Wijaya, Limin
   Pang, Junxiong
   Ling, Li Min
   Lee, Tau Hong
   Brose, Manja
   Hutagalung, Yanee
   Rauscher, Martina
   Borkowski, Astrid
   Wallace, Derek
TI Safety and immunogenicity of a single dose of a tetravalent dengue
   vaccine with two different serotype-2 potencies in adults in Singapore:
   A phase 2, double-blind, randomised, controlled trial
SO VACCINE
LA English
DT Article
DE Dengue vaccine; Immunogenicity; Safety; Vaccine viremia; Seronegative;
   Singapore
ID HEALTHY-CHILDREN; CANDIDATE; ASIA; TDV
AB Background: Early formulations of Takeda's tetravalent dengue vaccine candidate (TAK-003) have demonstrated notably higher neutralizing antibody responses against serotype 2 than other serotypes. Here, we assessed the immunogenicity and tolerability in adults living in Singapore of two TAK-003 formulations: an early formulation, referred to as HD-TDV, and a new formulation with 10-fold lower serotype 2 potency, referred to as TDV (NCT02425098).
   Methods: Subjects aged 21-45 years were stratified by baseline dengue serostatus and randomised 1:1 to receive a single dose of either HD-TDV or TDV. Immunogenicity was evaluated at Days 15, 30, 90, 180, and 365 post-vaccination as geometric mean titres (GMTs) of neutralising antibodies and seropositivity rates. Viremia was assessed per vaccine strain. Solicited and unsolicited adverse events (AEs) were assessed by severity and causality.
   Results: Of 351 subjects randomised, 176 received HD-TDV and 175 received TDV. Peak GMTs against all serotypes were observed at Day 30, with highest GMTs against DENV-2 in both groups. In subjects seronegative at baseline, the response to DENV-2 was less dominant with TDV (Day 30 GMTs: 813 for TDV, 10,966 for HD-TDV). In these subjects, DENV-4 seropositivity rates and GMTs were higher with TDV (Day 30 GMTs: 58 for TDV, 21 for HD-TDV; seropositivity rates: 76% for TDV, 60% for HD-TDV). Viremia mainly occurred for TDV-2 in both vaccine groups, with a lower incidence in TDV recipients, and mostly resolved by Day 30. Both vaccine formulations showed an acceptable safety profile with similar overall rates of solicited and unsolicited AEs across vaccine groups.
   Conclusions: These results suggest a more balanced immune response with the new formulation TDV compared with the early formulation HD-TDV, particularly in subjects who were seronegative prior to vaccination, and support the choice of the new formulation for the phase 3 efficacy assessment. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Tricou, Vianney; Brose, Manja; Rauscher, Martina; Borkowski, Astrid] Takeda Pharmaceut Int AG, Thurgauerstr 130, CH-8152 Zurich, Switzerland.
   [Low, Jenny G.; Kalimuddin, Shirin; Wijaya, Limin] Singapore Gen Hosp, Singapore, Singapore.
   [Oh, Helen M.] Changi Gen Hosp, Singapore, Singapore.
   [Leo, Yee-Sin] NCID, Singapore, Singapore.
   [Leo, Yee-Sin; Pang, Junxiong; Ling, Li Min; Lee, Tau Hong] Tan Tock Seng Hosp, Singapore, Singapore.
   [Pang, Junxiong] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.
   [Hutagalung, Yanee] Takeda Vaccines Pte Ltd, Singapore, Singapore.
   [Wallace, Derek] Takeda Vaccines Inc, Cambridge, MA USA.
RP Tricou, V (reprint author), Takeda Pharmaceut Int AG, Thurgauerstr 130, CH-8152 Zurich, Switzerland.
EM Vianney.tricou@takeda.com
OI Tricou, Vianney/0000-0002-5465-8647
FU Takeda Vaccines, Inc., Cambridge, MA, USA
FX This clinical trial was sponsored by Takeda Vaccines, Inc., Cambridge,
   MA, USA.
CR [Anonymous], 2016, Wkly Epidemiol Rec, V91, P349
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Biswal S, 2019, NEW ENGL J MED, V381, P2009, DOI 10.1056/NEJMoa1903869
   George SL, 2015, J INFECT DIS, V212, P1032, DOI 10.1093/infdis/jiv179
   Jackson LA, 2018, VACCINE, V36, P3976, DOI 10.1016/j.vaccine.2018.05.028
   Jelitha R, 2015, Med J Malaysia, V70, P67
   Leo YS, 2012, HUM VACC IMMUNOTHER, V8, P1259, DOI 10.4161/hv.21224
   Messina JP, 2014, TRENDS MICROBIOL, V22, P138, DOI 10.1016/j.tim.2013.12.011
   Osorio JE, 2014, LANCET INFECT DIS, V14, P830, DOI 10.1016/S1473-3099(14)70811-4
   Roehrig JT, 2008, VIRAL IMMUNOL, V21, P123, DOI 10.1089/vim.2008.0007
   Rupp R, 2015, VACCINE, V33, P6351, DOI 10.1016/j.vaccine.2015.09.008
   Saez-Llorens X, 2018, LANCET INFECT DIS, V18, P162, DOI 10.1016/S1473-3099(17)30632-1
   Saez-Llorens X, 2017, LANCET INFECT DIS, V17, P615, DOI 10.1016/S1473-3099(17)30166-4
   Sirivichayakul C, 2016, J INFECT DIS, V213, P1562, DOI 10.1093/infdis/jiv762
   van der Schaar HM, 2009, IMMUNOBIOLOGY, V214, P613, DOI 10.1016/j.imbio.2008.11.008
   World Health Organization, GUID CLIN EV DENG VA
   World Health Organization, 2016, DENGUE
   World Health Organization, 2018, WEEKLY EPIDEMIOLOGIC, V93, P337
NR 18
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1513
EP 1519
DI 10.1016/j.vaccine.2019.11.061
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900030
PM 31843269
OA Other Gold
DA 2020-05-12
ER

PT J
AU Sun, XD
   Wagner, AL
   Ji, JH
   Huang, ZY
   Zikmund-Fisher, BJ
   Boulton, ML
   Ren, J
   Prosser, LA
AF Sun, Xiaodong
   Wagner, Abram L.
   Ji, Jiahui
   Huang, Zhuoying
   Zikmund-Fisher, Brian J.
   Boulton, Matthew L.
   Ren, Jia
   Prosser, Lisa A.
TI A conjoint analysis of stated vaccine preferences in Shanghai, China
SO VACCINE
LA English
DT Article
DE China; Conjoint analysis; Discrete choice experiment; Vaccine
   manufacturers
ID CHILDREN YOUNGER; HEALTH; QUALITY
AB It is not clear what kind of preferences parents in China would have for vaccines that could be added to a future immunization schedule. This study's aim was to assess Chinese parents' preferences for attributes of vaccines. We surveyed parents of young infants <= 3 months of age at immunization clinics in Shanghai, China, in 2017. We used a discrete choice experiment (DCE) to present parents with choices between two hypothetical profiles of vaccines which were described using the following attributes: cost, risk of side effect, location of vaccine manufacturer, vaccine testing, vaccine effectiveness, severity of disease, disease prevalence. A logistic regression output estimates of preference utilities. In total, 599 caregivers completed the DCE. Parents expressed lower preference for vaccines with a 30% chance of fever as an adverse event vs a 10% chance (OR: 0.53, 95% CI: 0.44, 0.64), for vaccines only 85% effective vs those 95% effective (OR: 0.55, 95% CI: 0.48, 0.62), and for imported vaccines (OR: 0.74, 95% CI: 0.60, 0.92) and those not tested in Chinese children (OR: 0.45, 95% CI: 0.37, 0.53) compared to domestic vaccines. More affluent groups preferred more expensive vaccines whereas less affluent groups did not express cost-based preferences. Promotion of vaccines in China should focus on parents' stated preferences, which include past testing done in Chinese children - which is, in fact, required of all licensed vaccines in China. Information about these trials could emphasize low risk of adverse events and high effectiveness. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sun, Xiaodong; Huang, Zhuoying; Ren, Jia] Shanghai Municipal Ctr Dis Control & Prevent, Dept Immunizat Program, 1380 West Zhongshan Rd, Shanghai 200336, Peoples R China.
   [Wagner, Abram L.; Ji, Jiahui; Boulton, Matthew L.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, 1415 Washington Hts, Ann Arbor, MI 48109 USA.
   [Zikmund-Fisher, Brian J.] Univ Michigan, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, 1415 Washington Hts, Ann Arbor, MI 48109 USA.
   [Zikmund-Fisher, Brian J.] Univ Michigan, Med Sch, Div Gen Med, Dept Internal Med, 1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA.
   [Boulton, Matthew L.] Univ Michigan, Med Sch, Div Infect Dis, Dept Internal Med, 1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA.
   [Prosser, Lisa A.] Univ Michigan, Med Sch, Dept Pediat, Susan B Meister Child Hlth Evaluat & Res Ctr, Ann Arbor, MI 48109 USA.
RP Wagner, AL (reprint author), 1415 Washington Hts, Ann Arbor, MI 48109 USA.
EM sunxiaodong@scdc.sh.cn; awag@umich.edu; jiahuiji@umich.edu;
   huangzhuoying@scdc.sh.cn; bzikmund@umich.edu; mboulton@umich.edu;
   renjia@scdc.sh.cn; lisapros@umich.edu
OI Wagner, Abram/0000-0003-4691-7802; Zikmund-Fisher,
   Brian/0000-0002-1637-4176
FU Fourth Round of Three-Year Public Health Action Plan of Shanghai, China
   [15GWZKO101]; Office of Global Public Health, University of Michigan,
   Ann Arbor; Susan B. Meister Child Health Evaluation and Research Center;
   MCubed program, University of Michigan, Ann Arbor; PhRMA Foundation
FX This work was supported by The Fourth Round of Three-Year Public Health
   Action Plan of Shanghai, China (No. 15GWZKO101). This study was funded
   by grants from the Office of Global Public Health, University of
   Michigan, Ann Arbor, the Susan B. Meister Child Health Evaluation and
   Research Center, and from the MCubed program, University of Michigan,
   Ann Arbor. ALW has received funding as a Health Outcomes Post Doctoral
   Fellow from the PhRMA Foundation.
CR Bridges JFP, 2011, VALUE HEALTH, V14, P403, DOI 10.1016/j.jval.2010.11.013
   Cameron MP, 2013, VACCINE, V31, P3712, DOI 10.1016/j.vaccine.2013.05.089
   Flood EM, 2011, CLIN PEDIATR, V50, P338, DOI 10.1177/0009922810391247
   Gidengil C, 2012, VACCINE, V30, P3445, DOI 10.1016/j.vaccine.2012.03.022
   Gong P, 2012, LANCET, V379, P843, DOI 10.1016/S0140-6736(11)61878-3
   Guo N, 2017, VACCINE, V35, P2848, DOI 10.1016/j.vaccine.2017.04.006
   Guttier MC, 2017, REV SAUDE PUBL, V51, DOI [10.1590/S1518-8787.2017051006786, 10.1590/s1518-8787.2017051006786]
   Hall J, 2002, HEALTH ECON, V11, P457, DOI 10.1002/hec.694
   Halme M, 2009, PATIENT, V2, P243, DOI 10.2165/11314130-000000000-00000
   Henrikson NB, 2017, PUBLIC HEALTH REP, V132, P451, DOI 10.1177/0033354917711175
   Huang ZY, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197437
   Lin CH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029101
   Makinen M, 2012, HEALTH POLICY PLANN, V27, pII39, DOI 10.1093/heapol/czs036
   Marshall D, 2010, PATIENT, V3, P249, DOI 10.2165/11539650-000000000-00000
   Orme B, 2010, GETTING STARTED CONJ, P57
   Pan XF, 2015, VACCINE, V33, P6164, DOI 10.1016/j.vaccine.2015.09.081
   Poulos C, 2018, VACCINE, V36, P969, DOI 10.1016/j.vaccine.2018.01.004
   Qu F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171438
   Ren J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209117
   Stevenson MA, 2018, GLOB PUBLIC HEALTH, V13, P426, DOI 10.1080/17441692.2016.1245349
   Sun MP, 2010, VACCINE, V28, P1264, DOI 10.1016/j.vaccine.2009.11.015
   Sun XD, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5734-9
   Wagner AL, 2017, VACCINE, V35, P4362, DOI 10.1016/j.vaccine.2017.06.077
   Wagner AL, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0900-2
   Wagner AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097800
   Watt JP, 2009, LANCET, V374, P903, DOI 10.1016/S0140-6736(09)61203-4
   World Health Organization, 2017, SUMM WHO POS PAP REC
   Xu M, 2015, EXPERT REV VACCINES, V14, P763, DOI 10.1586/14760584.2015.1012503
   Yu HJ, 2012, HEALTH AFFAIR, V31, P2545, DOI 10.1377/hlthaff.2011.1272
   Zhang J, 2015, PEDIATR INFECT DIS J, V34, pE233, DOI 10.1097/INF.0000000000000799
   Zheng JS, 2010, VACCINE, V28, pA84, DOI 10.1016/j.vaccine.2010.02.039
NR 31
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1520
EP 1525
DI 10.1016/j.vaccine.2019.11.062
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900031
PM 31822426
DA 2020-05-12
ER

PT J
AU Bertran, K
   Criado, MF
   Lee, DH
   Killmaster, L
   Silva, MSE
   Lucio, E
   Widener, J
   Pritchard, N
   Atkins, E
   Mebatsion, T
   Swayne, DE
AF Bertran, Kateri
   Criado, Miria Ferreira
   Lee, Dong-Hun
   Killmaster, Lindsay
   Silva, Mariana Sa e
   Lucio, Eduardo
   Widener, Justin
   Pritchard, Nikki
   Atkins, Emily
   Mebatsion, Teshome
   Swayne, David E.
TI Protection of White Leghorn chickens by recombinant fowlpox vector
   vaccine with an updated H5 insert against Mexican H5N2 avian influenza
   viruses
SO VACCINE
LA English
DT Article
DE Avian influenza; H5N2; Mexico; Vaccine
ID HEMAGGLUTININ; GLYCOSYLATION; EFFICACY; PCR; EMERGENCE; SITE
AB Despite decades of vaccination, surveillance, and biosecurity measures, H5N2 low pathogenicity avian influenza (LPAI) virus infections continue in Mexico and neighboring countries. One explanation for tenacity of H5N2 LPAI in Mexico is the antigenic divergence of circulating field viruses compared to licensed vaccines due to antigenic drift. Our phylogenetic analysis indicates that the H5N2 LPAI viruses circulating in Mexico and neighboring countries since 1994 have undergone antigenic drift away from vaccine seed strains. Here we evaluated the efficacy of a new recombinant fowlpox virus vector containing an updated H5 insert (rFPV-H5/2016), more relevant to the current strains circulating in Mexico. We tested the vaccine efficacy against a closely related subcluster 4 Mexican H5N2 LPAI (2010 H5/LP) virus and the historic H5N2 HPAI (1995 H5/HP) virus in White Leghorn chickens. The rFPV-H5/2016 vaccine provided hemagglutinin inhibition (HI) titers pre-challenge against viral antigens from both challenge viruses in almost 100% of the immunized birds, with no differences in number of birds seroconverting or HI titers among all tested doses (1.5, 2.0, and 3.1 log(10) mean tissue culture infectious doses/bird). The vaccine conferred 100% clinical protection and a significant decrease in oral and cloacal virus shedding from 1995 H5/HP virus challenged birds when compared to the sham controls at all tested doses. Virus shedding titers from vaccinated 2010 H5/LP virus challenged birds significantly decreased compared to sham birds especially at earlier time points. Our results confirm the efficacy of the new rFPV-H5/2016 against antigenic drift of LPAI virus in Mexico and suggest that this vaccine would be a good candidate, likely as a primer in a prime-boost vaccination program. Published by Elsevier Ltd.
C1 [Bertran, Kateri; Criado, Miria Ferreira; Killmaster, Lindsay; Swayne, David E.] ARS, Exot & Emerging Avian Viral Dis Res Unit, Southeast Poultry Res Lab, US Natl Poultry Res Ctr,USDA, 934 Coll Stn Rd, Athens, GA 30605 USA.
   [Lee, Dong-Hun] Univ Connecticut, Dept Pathobiol & Vet Sci, Storrs, CT 06269 USA.
   [Silva, Mariana Sa e; Atkins, Emily; Mebatsion, Teshome] Boehringer Ingelheim Anim Hlth USA Inc, 1730 Olymp Dr, Athens, GA 30601 USA.
   [Lucio, Eduardo] Boehringer Ingelheim Anim Hlth SA CV, Maiz 49, Mexico City 16090, DF, Mexico.
   [Pritchard, Nikki] Boehringer Ingelheim Anim Hlth USA Inc, 1112 Airport Pkwy, Gainesville, GA 30503 USA.
   [Bertran, Kateri] UAB, IRTA, CReSA, Ctr Recerca Sanitat Anim, Campus UAB, Bellaterra 08193, Spain.
RP Swayne, DE (reprint author), ARS, Exot & Emerging Avian Viral Dis Res Unit, Southeast Poultry Res Lab, US Natl Poultry Res Ctr,USDA, 934 Coll Stn Rd, Athens, GA 30605 USA.
EM kateri.bertran@irta.cat; miria.criado@usda.gov; dong-hun.lee@uconn.edu;
   lindsay.killmaster@usda.gov;
   mariana.sa_e_silva@boehringer-ingelheim.com;
   eduardo.lucio@boehringer-ingelheim.com;
   justin.widener@boehringer-ingelheim.com;
   nikki.pritchard@boehringer-ingelheim.com;
   emily.atkins@boehringer-ingelheim.com;
   teshome.mebatsion@boehringer-ingelheim.com; david.swayne@usda.gov
FU Boehringer Ingelheim Animal Health USA, Inc.Boehringer Ingelheim
   [58-6040-7-002]; U.S. Department of Agriculture, Agricultural Research
   Service CRIS project [6040-32000-066-51S]
FX This work was supported by Trust Fund Cooperative Agreement
   58-6040-7-002 with Boehringer Ingelheim Animal Health USA, Inc. Dr. Lee
   is partially supported by the U.S. Department of Agriculture,
   Agricultural Research Service CRIS project no. 6040-32000-066-51S. The
   authors gratefully acknowledge Scott Lee, Roger Brock, Keith Crawford,
   Jerry Damron, and James Doster for their excellent technical assistance.
   Acknowledgement is also given to Troy Hughes and the BIAH R&D team in
   Gainesville, GA, USA for supplying the vaccine candidate.
CR Abbas MA, 2011, VACCINE, V29, P7424, DOI 10.1016/j.vaccine.2011.07.064
   Bertran K, 2018, VACCINE, V36, P6361, DOI 10.1016/j.vaccine.2018.09.015
   Bosworth B, 2010, COMP IMMUNOL MICROB, V33, pE99, DOI 10.1016/j.cimid.2010.05.002
   Bublot M, 2006, ANN NY ACAD SCI, V1081, P193, DOI 10.1196/annals.1373.023
   Criado MF, 2019, VACCINE, V37, P2232, DOI 10.1016/j.vaccine.2019.03.009
   Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214
   Eggert D, 2010, VACCINE, V28, P4609, DOI 10.1016/j.vaccine.2010.04.081
   Escorcia M, 2010, BMC VET RES, V6, DOI 10.1186/1746-6148-6-57
   Forrest HL, 2013, INFLUENZA OTHER RESP, V7, P1194, DOI 10.1111/irv.12140
   Garcia A, 1998, AVIAN DIS, V42, P248, DOI 10.2307/1592474
   Garcia M, 1996, J GEN VIROL, V77, P1493, DOI 10.1099/0022-1317-77-7-1493
   Herve PL, 2015, VIROLOGY, V486, P134, DOI 10.1016/j.virol.2015.08.033
   HORIMOTO T, 1995, VIROLOGY, V213, P223, DOI 10.1006/viro.1995.1562
   KAWAOKA Y, 1984, VIROLOGY, V139, P303, DOI 10.1016/0042-6822(84)90376-3
   Lee CW, 2004, J VIROL, V78, P8372, DOI [10.1128/JVI.78.15.8372-8381.2004, 10.1128/jvi.78.15.8372-8381.2004]
   Lee CW, 2004, J VIROL METHODS, V119, P151, DOI 10.1016/j.jviromet.2004.03.014
   OIE, 2016, AVIAN INFLUENZA
   Pedersen JC, 2014, METHODS MOL BIOL, V1161, P11, DOI 10.1007/978-1-4939-0758-8_2
   Perdue ML, 1996, VIRUS GENES, V12, P77, DOI 10.1007/BF00370003
   Perez D. R., 2016, Animal influenza, P271
   Slomka MJ, 2010, INFLUENZA OTHER RESP, V4, P277, DOI 10.1111/j.1750-2659.2010.00149.x
   Spackman E, 2002, J CLIN MICROBIOL, V40, P3256, DOI 10.1128/JCM.40.9.3256-3260.2002
   Spackman E, 2014, METHODS MOL BIOL, V1161, P125, DOI 10.1007/978-1-4939-0758-8_12
   Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033
   Stray SJ, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-91
   Suarez DL, 2017, VET MICROBIOL, V206, P144, DOI 10.1016/j.vetmic.2016.11.025
   Swayne DE, 2011, REV SCI TECH OIE, V30, P839
   Swayne D. E., 2008, AVIAN INFLUENZA, P407, DOI DOI 10.1002/9780813818634.CH19
   Swayne DE, 2008, AVIAN INFLUENZA, P287
   Swayne DE, 2020, VET VACCINES LIVESTO
   Tate MD, 2014, VIRUSES-BASEL, V6, P1294, DOI 10.3390/v6031294
   Vander Veen RL, 2013, VET REC, V173, P344, DOI 10.1136/vr.101741
   Villarreal C, 2007, DEV BIOLOGICALS, V130, P53
   Villarreal-Chavez C, 2003, AVIAN DIS, V47, P1002, DOI 10.1637/0005-2086-47.s3.1002
   World Organisation for Animal Health (OIE), UPD AV INFL AN TYP H
   Wu CY, 2017, P NATL ACAD SCI USA, V114, P280, DOI 10.1073/pnas.1617174114
   Yang H, 2016, J VIROL, V90, P5770, DOI 10.1128/JVI.00180-16
   Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114
NR 38
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1526
EP 1534
DI 10.1016/j.vaccine.2019.11.072
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900032
PM 31862196
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Ecarnot, F
   Pedone, C
   Cesari, M
   Maggi, S
   Incalzi, RA
AF Ecarnot, Fiona
   Pedone, Claudio
   Cesari, Matteo
   Maggi, Stefania
   Incalzi, Raffaele Antonelli
TI Knowledge about vaccines and vaccination in older people: Results of a
   national survey by the Italian Society for Gerontology & Geriatrics
SO VACCINE
LA English
DT Article
DE Vaccine; Vaccination; Specialists; Residents; Knowledge; Questionnaire
ID COMMUNITY-ACQUIRED PNEUMONIA; UNITED-STATES; INFLUENZA VACCINATION;
   ZOSTER VACCINE; ATTITUDES; ADULTS; PHYSICIANS; AWARENESS; PROGRAM;
   DISEASE
AB Background: There is wide variation among physicians in the level of knowledge regarding vaccines and vaccination. We sought to compare the level of vaccine knowledge between qualified specialists and postgraduate residents.
   Methods: A questionnaire designed ad hoc by a consensus group was circulated to the Directors of 51 geriatrics internship programs in Italy. It investigated demographics, information sources, knowledge about influenza, pneumonococcal and herpes zoster vaccines and target groups. The proportion of correct responders was compared between residents and qualified specialists, and between best (top quartile) and worst (bottom quartile) performers.
   Results: A total of 459 questionnaires were analyzed; 245 (53%) were females; 253 (55%) were qualified specialists, 206 (45%) were residents. Mean age was 40.3 (SD: 12.8) years, almost 60% worked in acute care wards. On average, 33% of patients asked for information about vaccination. Residents answered significantly better on 7 out of 18 questions, and numerically albeit non-statistically higher correct response rates on a further 8 questions. There were significantly more men among the poor performers (p < 0.001), and significantly more residents among the best performers (p < 0.001). Overall, the rates of correct answers were low, with >50% of correct responses achieved on only 5 out of 18 questions (27.8%); for 2 questions, <20% responded correctly.
   Conclusions: Postgraduate residents in training have an overall better level of knowledge of vaccines, vaccination indications and practices than qualified specialists. This study provides avenues to develop targeted interventions to ensure health care providers are up to date and providing accurate information to patients. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ecarnot, Fiona] Univ Franche Comte, Univ Hosp Besancon, Dept Cardiol, Besancon, France.
   [Ecarnot, Fiona] Univ Franche Comte, EA3920, Besancon, France.
   [Pedone, Claudio; Incalzi, Raffaele Antonelli] Univ Campus Biomed Roma, Unit Geriatr, Rome, Italy.
   [Cesari, Matteo] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy.
   [Cesari, Matteo] Univ Milan, Dept Clin Sci & Community Hlth, Geriatr Unit, Milan, Italy.
   [Maggi, Stefania] CNR, Inst Neurosci, Aging Branch, Padua, Italy.
RP Ecarnot, F (reprint author), Univ Hosp Jean Minjoz, Dept Cardiol, 3 Blvd Fleming, F-25000 Besancon, France.
EM Fiona.ecarnot@univ-fcomte.fr; c.pedone@unicam-pus.it;
   macesari@gmail.com; stefania.maggi@in.cnr.it; r.antonelli@unicampus.it
OI Ecarnot, Fiona/0000-0002-4224-9731
FU MerckMerck & Company
FX This research was partially funded by an unrestricted educational grant
   from Merck.
CR Amirthalingam G, 2018, LANCET PUBLIC HEALTH, V3, pE82, DOI 10.1016/S2468-2667(17)30234-7
   Blasi F, 2017, EUR J INTERN MED, V37, P13, DOI 10.1016/j.ejim.2016.09.024
   Bricout H, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1753-y
   Buxton JA, 2013, CAN FAM PHYSICIAN, V59, pE514
   Caffrey AR, 2018, J AM PHARM ASSOC, V58, P303, DOI 10.1016/j.japh.2017.08.010
   Caruso Brown Amy E, 2017, Narrat Inq Bioeth, V7, P59, DOI 10.1353/nib.2017.0018
   Cordrey K, 2018, CLIN PEDIATR, V57, P327, DOI 10.1177/0009922817727465
   Costantino C, 2016, BMC MED EDUC, V16, DOI 10.1186/s12909-016-0558-8
   Elkin Z, 2013, CORNEA, V32, P976, DOI 10.1097/ICO.0b013e318283453a
   European Centre for Disease Prevention and Control, 2017, SEAS INFL VACC EUR V, DOI [10.2900/153616, DOI 10.2900/153616]
   Fogelberg S, 2018, PHARMACOEPIDEM DR S, V27, P1159, DOI 10.1002/pds.4653
   Ghandora H, 2019, HUM VACC IMMUNOTHER, V15, P700, DOI 10.1080/21645515.2018.1543523
   Gosselin Boucher V, 2019, CLIN RHEUMATOL
   Gurvits GE, 2017, POSTGRAD MED J, V93, P333, DOI 10.1136/postgradmedj-2016-134266
   Hurley LP, 2018, VACCINE, V36, P7408, DOI 10.1016/j.vaccine.2018.09.018
   Hurley LP, 2016, PUBLIC HEALTH REP, V131, P320, DOI 10.1177/003335491613100216
   Kahn KE, 2018, MMWR-MORBID MORTAL W, V67, P1055, DOI 10.15585/mmwr.mm6738a3
   Klett-Tammen CJ, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0502-3
   Korkmaz P, 2019, CENT EUR J PUBL HEAL, V27, P44, DOI 10.21101/cejph.a5231
   Lehmann BA, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0511-7
   Lu PJ, 2018, VACCINE, V36, P890, DOI 10.1016/j.vaccine.2017.12.016
   Lu PJ, 2017, VACCINE, V35, P3104, DOI 10.1016/j.vaccine.2017.04.028
   MacDougall DM, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009062
   Marotta C, 2017, J Prev Med Hyg, V58, pE93
   Nichol KL, 2001, ARCH INTERN MED, V161, P2702, DOI 10.1001/archinte.161.22.2702
   Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042
   Pinchinat S, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-170
   Ridda I, 2008, VACCINE, V26, P5633, DOI 10.1016/j.vaccine.2008.07.070
   Tewell C, 2014, VACCINE, V32, P6025, DOI 10.1016/j.vaccine.2014.08.081
   Torres A, 2018, RESP MED, V137, P6, DOI 10.1016/j.rmed.2018.02.007
   Troeger CE, 2019, LANCET RESP MED, V7, P69, DOI 10.1016/S2213-2600(18)30496-X
   Tsui E, 2018, CORNEA, V37, P947, DOI [10.1097/ICO.0000000000001582, 10]
   Valente N, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011539
NR 33
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1535
EP 1540
DI 10.1016/j.vaccine.2019.11.065
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900033
PM 31822428
DA 2020-05-12
ER

PT J
AU Duong, TN
   Thiem, VD
   Anh, DD
   Cuong, NP
   Thang, TC
   Huong, VM
   Chien, VC
   Phuong, NTL
   Montomoli, E
   Holt, R
   Scorza, FB
   Flores, J
   Tewari, T
AF Tran Nhu Duong
   Vu Dinh Thiem
   Dang Duc Anh
   Nguyen Phu Cuong
   Tran Cong Thang
   Vu Minh Huong
   Vien Chinh Chien
   Nguyen Thi Lan Phuong
   Montomoli, Emanuele
   Holt, Renee
   Scorza, Francesco Berlanda
   Flores, Jorge
   Tewari, Tushar
TI A Phase 2/3 double blinded, randomized, placebo-controlled study in
   healthy adult participants in Vietnam to examine the safety and
   immunogenicity of an inactivated whole virion, alum adjuvanted, A (H5N1)
   influenza vaccine (IVACFLU-A/H5N1)
SO VACCINE
LA English
DT Article
DE Avian A(H5N1) influenza; Vietnam; Safety; immunogenicity
ID VIRUS; ASSAY; HEMAGGLUTININ; INFECTION; TRIAL
AB Background: A global shortfall of vaccines for avian influenza A(H5N1) would occur, especially in low- and-middle income countries, if a pandemic were to occur. To address this issue, development of a pre-pandemic influenza vaccine was initiated in 2012, leveraging a recently established influenza vaccine manufacturing capacity in Vietnam.
   Methods: This was a Phase 2/3, double-blinded, randomized, placebo-controlled study to test the safety and immunogenicity of IVACFLU-A/H5N1 vaccine in healthy adults. Phase 2 was a dose selection study, in which 300 participants were randomized to one of the three groups (15 mcg, 30 mcg, or placebo). Safety and immunogenicity were assessed in all participants. In Phase 3, 630 participants were randomized to receive the IVACFLU-A/H5N1 vaccine dose selected in Phase 2 (15 mcg, n = 525) or placebo (n = 105). Safety was assessed in all Phase 3 participants and immunogenicity was measured in a subset of participants.
   Results: The vaccine was well tolerated and most of the adverse events were mild and of short duration. Mild pain at the injection site was the most common adverse event seen in 60 percent of participants in the vaccine group in Phase 3. In Phase 2, both 15 mcg and 30 mcg doses were immunogenic, so the lower dose was selected for further testing in Phase 3. In Phase 3 overall seroconversion rates were 68 percent for hemagglutination inhibition (HI), 51 percent for microneutralization (MN) and 56 percent for single radial hemolysis (SRH). The seroprotection rates were 44 percent for HI, 41 percent for MN and 55 percent for SRH. The GMT ratio was 5.31 and 3.7 for HI and MN respectively; GMA was 4.75 for the SRH.
   Conclusion: The IVACFLU A/H5N1 was safe and immunogenic. Development of this pandemic avian influenza vaccine is a welcome addition to the limited global pool of these vaccines. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Tran Nhu Duong; Vu Dinh Thiem; Dang Duc Anh] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam.
   [Nguyen Phu Cuong; Tran Cong Thang; Vu Minh Huong] PATH, Hanoi, Vietnam.
   [Vien Chinh Chien; Nguyen Thi Lan Phuong] Inst Vaccines & Med Biol, Nha Trang, Vietnam.
   [Montomoli, Emanuele] Univ Siena, Dept Mol & Dev Med, Siena, Italy.
   [Montomoli, Emanuele] VisMederi Srl, Siena, Italy.
   [Holt, Renee; Scorza, Francesco Berlanda; Flores, Jorge; Tewari, Tushar] PATH, Seattle, WA 98121 USA.
RP Tewari, T (reprint author), PATH, Seattle, WA 98121 USA.
EM ttewari@path.org
FU U.S. Department of Health and Human Services; Office of the Assistant
   Secretary for Preparedness and Response; Biomedical Advanced Research
   and Development Authority, USA [IDSEP130018, IDSEP130015]
FX This project has been funded in whole with Federal funds from the U.S.
   Department of Health and Human Services; Office of the Assistant
   Secretary for Preparedness and Response; Biomedical Advanced Research
   and Development Authority, USA to PATH and WHO (PATH grant number is
   IDSEP130018 and WHO grant number is IDSEP130015).
CR [Anonymous], 2013, GUID CLIN TRIAL INFL
   Banzhoff A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004384
   Bresson JL, 2006, LANCET, V367, P1657, DOI 10.1016/S0140-6736(06)68656-X
   Brodin P, 2015, CELL, V160, P37, DOI 10.1016/j.cell.2014.12.020
   Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0
   Couch RB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049704
   de Jong J C, 2003, Dev Biol (Basel), V115, P63
   Ehrlich HJ, 2008, NEW ENGL J MED, V358, P2573, DOI 10.1056/NEJMoa073121
   European Agency for the Evaluation of Medical Products-Human Medicines Evaluation Unite, 1999, CPMPEWP46397 EUR AG
   Finney DJ, STAT METHODS BIOL AS, P196
   Food and Drug Administration, 2012, LIC PAND INFL VACC D
   Gillard P, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-142
   Jia N, 2008, J VIROL METHODS, V153, P43, DOI 10.1016/j.jviromet.2008.06.016
   Keitel WA, 2009, CURR TOP MICROBIOL, V333, P431, DOI 10.1007/978-3-540-92165-3_21
   McLean KA, 2016, VACCINE, V34, P5410, DOI 10.1016/j.vaccine.2016.08.019
   Nolan T, 2008, VACCINE, V26, P6383, DOI 10.1016/j.vaccine.2008.08.046
   POTTER CW, 1979, BRIT MED BULL, V35, P69, DOI 10.1093/oxfordjournals.bmb.a071545
   Saha S, 2014, B WORLD HEALTH ORGAN, V92, P318, DOI 10.2471/BLT.13.124412
   SCHILD GC, 1975, B WORLD HEALTH ORGAN, V52, P43
   Treanor JJ, 2006, NEW ENGL J MED, V354, P1343, DOI 10.1056/NEJMoa055778
   Trombetta CM, 2014, VACCINES-BASEL, V2, P707, DOI 10.3390/vaccines2040707
   Phan TL, 2016, VACCINE, V34, P5449, DOI 10.1016/j.vaccine.2016.08.055
   van der Velden MVW, 2014, CLIN VACCINE IMMUNOL, V21, P867, DOI 10.1128/CVI.00065-14
   Virk RK, 2016, EXPERT REV ANTI-INFE, V14, P365, DOI 10.1586/14787210.2016.1155450
   Winokur PL, 2015, J INFECT DIS, V212, P525, DOI 10.1093/infdis/jiv087
   WOOD JM, 1977, J BIOL STAND, V5, P237, DOI 10.1016/S0092-1157(77)80008-5
   World Health Organization, GLOB PAND INFL ACT P
   World Health Organization, 2018, INFL CUM NUMB CONF H
   World Health Organization Global Influenza Surveillance Network, 2011, MAN LAB DIAGN VIR SU
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1541
EP 1550
DI 10.1016/j.vaccine.2019.11.059
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900034
PM 31812464
OA Other Gold
DA 2020-05-12
ER

PT J
AU Schneider, R
   Reinau, D
   Schur, N
   Blozik, E
   Fruh, M
   Signorell, A
   Heininger, U
   Schwenkglenks, M
   Meier, CR
AF Schneider, Rahel
   Reinau, Daphne
   Schur, Nadine
   Blozik, Eva
   Fruh, Mathias
   Signorell, Andri
   Heininger, Ulrich
   Schwenkglenks, Matthias
   Meier, Christoph R.
TI Coverage rates and timeliness of nationally recommended vaccinations in
   Swiss preschool children: A descriptive analysis using claims data
SO VACCINE
LA English
DT Article
DE Administrative claims data; Switzerland; Child; Immunisation;
   Vaccination coverage rate; Measles
ID MEASLES; IMMUNIZATION; OUTBREAK; SCHOOL
AB Background: Low vaccination coverage as well as incomplete and delayed vaccinations pose a risk for the individual and population protection from vaccine-preventable diseases.
   Aim: To describe vaccination patterns for nationally recommended basic and supplementary vaccinations in Swiss preschool children.
   Methods: We performed a descriptive study based on administrative claims data from a large Swiss health insurer (Helsana), in cohorts of children born between January 2010 and December 2016. We assessed coverage rates of nationally recommended basic vaccinations (i.e., diphtheria, tetanus, acellular pertussis Haemophilus influenzae type b [Hib], poliomyelitis [IPA, measles, mumps, and rubella [MMR]) and supplementary vaccinations (i.e., pneumococcal conjugate vaccine [PCV] and meningococcal group C conjugate vaccine [MCV]) for each birth cohort at the age of 13, 25, and 37 months. Additionally, we analysed timeliness of vaccinations using inverse Kaplan-Meier curves. Results were extrapolated to the Swiss population.
   Results: The study population comprised 563,216 children. We observed continuously increasing coverage rates for all vaccinations until the 2015 birth cohort. Overall, up-to-date status for the first dose of studied vaccinations at 37 months was as follows: DTaP: 95.4%; Hib: 94.9%; IPV: 95.5%; MMR: 86.8%; PCV: 83.2%; and MCV: 66.7%. On average, however, only seven out of ten children had an up-to-date status for completed basic vaccinations; even less (six out of ten) were up-to-date for recommended supplementary vaccinations at 37 months of age. Moreover, 4% of all analysed children received none of the recommended vaccinations and there were substantial regional differences. Delays in vaccine administration were common. The most frequently postponed basic vaccination was MMR; 22.6% of children vaccinated with the first dose experienced delays relative to age-appropriate standards.
   Conclusion: To avoid future outbreaks and transmission of vaccine-preventable diseases, vaccination coverage in Switzerland must be further improved. In addition, more emphasis should be placed on timely vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Schneider, Rahel; Reinau, Daphne; Meier, Christoph R.] Univ Basel, Dept Pharmaceut Sci, Div Clin Pharm & Epidemiol, Basel Pharmacoepidemiol Unit, Spitalstr 26, CH-4031 Basel, Switzerland.
   [Schneider, Rahel; Reinau, Daphne; Meier, Christoph R.] Univ Hosp Basel, Hosp Pharm, Spitalstr 26, CH-4031 Basel, Switzerland.
   [Schur, Nadine; Schwenkglenks, Matthias] Univ Basel, Inst Pharmaceut Med ECPM, Klingelbergstr 61, CH-4056 Basel, Switzerland.
   [Blozik, Eva; Fruh, Mathias; Signorell, Andri] Helsana Grp, Dept Hlth Sci, Zurichstr 130, CH-8600 Dubendorf, Switzerland.
   [Heininger, Ulrich] Univ Basel, Childrens Hosp, Paediat Infect Dis & Vaccinol, Spitalstr 33, CH-4056 Basel, Switzerland.
   [Heininger, Ulrich] Univ Basel, Med Fac, Spitalstr 33, CH-4056 Basel, Switzerland.
   [Meier, Christoph R.] Boston Collaborat Drug Surveillance Program, MA 11 Muzzey St, St Lexington, MA 02421 USA.
RP Meier, CR (reprint author), Univ Hosp Basel, Hosp Pharm, Spitalstr 26, CH-4031 Basel, Switzerland.
EM christoph.meier@usb.ch
OI Heininger, Ulrich/0000-0001-8901-6778
FU Helsana Group, Zurich, Switzerland
FX This project was funded by Helsana Group, Zurich, Switzerland. The data
   have partially been reported in a document in Switzerland (German
   language) by the Helsana insurance group (Helsana Arzneimittelreport
   2018).
CR [Anonymous], 2019, LANCET, V393, P1669, DOI 10.1016/S0140-6736(19)30903-1
   Bielicki JA, 2013, VACCINE, V31, P5375, DOI 10.1016/j.vaccine.2013.09.025
   Bielicki JA, 2012, PEDIATRICS, V130, pE600, DOI 10.1542/peds.2012-0132
   Dabbagh A, 2018, MMWR-MORBID MORTAL W, V67, P1323, DOI 10.15585/mmwr.mm6747a6
   Dannetun E, 2004, VACCINE, V22, P4228, DOI 10.1016/j.vaccine.2004.04.018
   Dombkowski KJ, 2002, AM J PREV MED, V23, P36, DOI 10.1016/S0749-3797(02)00442-7
   Gemeinsame Einrichtung KVG, 2019, STATISTICS
   Hassidim A., 2008, Morbidity and Mortality Weekly Report, V57, P203
   Heininger U, 2006, EUR J PEDIATR, V165, P124, DOI 10.1007/s00431-005-0014-y
   Hug S, 2012, PEDIATR INFECT DIS J, V31, P217, DOI 10.1097/INF.0b013e31823cbaa5
   John TJ, 2000, EUR J EPIDEMIOL, V16, P601, DOI 10.1023/A:1007626510002
   Kalies H, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-82
   Koch D, 2019, SWISS MED WKLY, V149, DOI 10.4414/smw.2019.20106
   Lang P, 2011, PUBLIC HEALTH REP, V126, P97, DOI 10.1177/00333549111260S212
   Laubereau B, 2002, EPIDEMIOL INFECT, V128, P185, DOI 10.1017/S0950268801006550
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Masserey Spicher V, 2018, BAG B, V9, P12
   Paules CI, 2019, NEW ENGL J MED, V380, P2185, DOI 10.1056/NEJMp1905099
   Pfaff G, 2008, EURO SURVEILL, P13
   Plotkin SA, 2017, VACCINES
   Richard JL, 2019, SWISS MED WKLY, V149, DOI 10.4414/smw.2019.20102
   Rieck T, 2014, HUM VACC IMMUNOTHER, V10, P476, DOI 10.4161/hv.26986
   Rodewald L, 1999, PEDIATRICS, V103, P889
   Schmid D, 2010, EPIDEMIOL INFECT, V138, P415, DOI 10.1017/S0950268809990604
   Stein-Zamir C, 2008, EPIDEMIOL INFECT, V136, P207, DOI 10.1017/S095026880700845X
   Swaney SE, 2018, HLTH PROMOT J AUSTR
   Swiss Federal Office of Public Health, 2019, B BAG, V13, P32
   Swiss Federal Office of Public Health, 2013, B BAG, V17, P263
   Swiss Federal Office of Public Health, 2019, SWISS VACC SCHED 201
   Swiss Federal Office of Public Health, 2018, TAR TARMED
   Swiss Federal Office of Public Health, 2018, B BAG, V24, P10
   Swiss Federal Office of Public Health, 2017, SWISS VACC SCHED 201
   Swiss Federal Office of Public Health, 2010, SWISS VACC SCHED 201
   Swiss Society of Paediatrics, 2017, CHECKL PREV MED CHEC
   WHO, 2018, IMM COV
   WHO Collaborating Centre for Drug Statistics Methodology, 2018, STRUCT PRINC
   Wichmann O, 2007, PEDIATR INFECT DIS J, V26, P782, DOI 10.1097/INF.0b013e318060aca1
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1551
EP 1558
DI 10.1016/j.vaccine.2019.11.057
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900035
PM 31791812
DA 2020-05-12
ER

PT J
AU Rinta-Kokko, H
   Auranen, K
   Toropainen, M
   Nuorti, JP
   Nohynek, H
   Siira, L
   Palmu, AA
AF Rinta-Kokko, Hanna
   Auranen, Kari
   Toropainen, Maija
   Nuorti, J. Pekka
   Nohynek, Hanna
   Siira, Lotta
   Palmu, Arto A.
TI Effectiveness of 10-valent pneumococcal conjugate vaccine estimated with
   three parallel study designs among vaccine-eligible children in Finland
SO VACCINE
LA English
DT Article
DE Ten-valent pneumococcal conjugate vaccine; Invasive pneumococcal
   disease; Vaccine effectiveness; Register study; Study design; National
   vaccination programme
ID DISEASE; COHORT; EFFICACY; IMPACT
AB Background: Ten-valent pneumococcal conjugate vaccine (PCV10) was introduced into the Finnish National Vaccination Programme (NVP) in 9/2010. We estimated the individual-level effectiveness (VE) of PCV10 in children during eight years of vaccine implementation.
   Methods: Data on invasive pneumococcal disease (IPD) were collected from national, population-based surveillance, and vaccination status from the vaccination register. Vaccine-eligible children were followed from six months of age until end of 2018 (born 6/2010 or later, ages 6-102 months). VE was estimated with three parallel approaches: full cohort, nested case-control and indirect cohort designs adjusting with age-group, sex and calendar year.
   Results: VE against PCV10 serotype IPD was estimated at 93% (95% credible interval 87-97%), 98% (90-100%) and 100% (98-100%), and against PCV10-related serotypes at 46% (-13-72%), 51% (-24-79%), and 78% (-7-97%), with the full cohort, nested case-control, and indirect cohort designs, respectively.
   The estimated VE against non-PCV10-related (neither PCV10 nor PCV10-related) serotypes was negative but included zero effectiveness (full cohort VE -67%, -711-52%; nested case-control VE-77%, -929-59%). VE against all IPD was estimated with these two methods at 54% (24-71%) and 61% (26-79%). Over time, VE against PCV10 IPD remained stable but VE against all IPD decreased.
   Discussion: All designs provided estimates that were concordant with each other, but those with the full cohort design were usually the most precise. PCV10 offered sustained high VE against PCV10-serotype IPD on vaccinated children during the first decade after introduction into the programme. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Rinta-Kokko, Hanna] Finnish Inst Hlth & Welf, Dept Publ Hlth Solut, Helsinki, Finland.
   [Auranen, Kari] Univ Turku, Dept Math & Stat, Turku, Finland.
   [Auranen, Kari] Univ Turku, Dept Clin Med, Turku, Finland.
   [Toropainen, Maija; Nuorti, J. Pekka; Nohynek, Hanna; Siira, Lotta] Finnish Inst Hlth & Welf, Dept Hlth Secur, Helsinki, Finland.
   [Nuorti, J. Pekka] Univ Tampere, Fac Social Sci, Hlth Sci Unit, Tampere, Finland.
   [Palmu, Arto A.] Finnish Inst Hlth & Welf, Dept Publ Hlth Solut, Tampere, Finland.
RP Rinta-Kokko, H (reprint author), Finnish Inst Hlth & Welf, Mannerheimintie 166,POB 30, Helsinki 00271, Finland.
EM hanna.rinta-kokko@thl.fi
OI Rinta-Kokko, Hanna/0000-0002-6897-4923
FU GlaxoSmithKline Vaccines; Pfizer, Inc.Pfizer; Sanofi Pasteur, Inc.
FX The authors declare the following financial interests/personal
   relationships which may be considered as potential competing interests:
   The Finnish Institute for Health and Welfare has received research
   funding from GlaxoSmithKline Vaccines for the conduct of a nationwide
   effectiveness trial of the 10-valent pneumococcal conjugate vaccine, and
   from Pfizer, Inc. and Sanofi Pasteur, Inc. for nonpneumococcal research.
   HR-K, AAP, MT, and LS are co -investigators in these studies. The other
   authors have no conflicts to disclose. The current study was entirely
   publicly funded.
CR Andrews N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028435
   Andrews NJ, 2012, VACCINE, V30, P6802, DOI 10.1016/j.vaccine.2012.09.019
   Baum U, 2017, EUROSURVEILL EUROSUR, V22, P17
   BROOME CV, 1980, NEW ENGL J MED, V303, P549, DOI 10.1056/NEJM198009043031003
   De Serres G, 2012, VACCINE, V30, P4067, DOI 10.1016/j.vaccine.2012.04.017
   Deceuninck G, 2015, VACCINE, V33, P2684, DOI 10.1016/j.vaccine.2015.04.005
   Domingues CMAS, 2014, LANCET RESP MED, V2, P464, DOI 10.1016/S2213-2600(14)70060-8
   Dominguez A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183191
   Finnish Institute for Health and Welfare (THL) Finland, VACC REG
   Flasche S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001017
   Gidding HF, 2018, VACCINE, V36, P2650, DOI 10.1016/j.vaccine.2018.03.058
   Guevara M, 2016, EUROSURVEILLANCE, V21, P14, DOI 10.2807/1560-7917.ES.2016.21.14.30186
   HABER M, 1991, INT J EPIDEMIOL, V20, P300, DOI 10.1093/ije/20.1.300
   Hanquet G, 2013, VACCINE, V31, P5634, DOI 10.1016/j.vaccine.2013.07.006
   Jokinen J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120290
   Martinelli D, 2014, HUM VACC IMMUNOTHER, V10, P33, DOI 10.4161/hv.26650
   Nuorti JP, INVASIVE PNEUM UNPUB
   Palmu AA, 2017, PEDIATR INFECT DIS J, V36, P1193, DOI 10.1097/INF.0000000000001705
   Palmu AA, 2013, LANCET, V381, P214, DOI 10.1016/S0140-6736(12)61854-6
   Rinta-Kokko H, 2018, VACCINE, V36, P1934, DOI 10.1016/j.vaccine.2018.03.001
   Ruckinger S, 2010, VACCINE, V28, P5012, DOI 10.1016/j.vaccine.2010.05.021
   Siira L, 2012, J CLIN MICROBIOL, V50, P2727, DOI 10.1128/JCM.00689-12
   Toropainen M, 2018, 11 INT S PNEUM PNEUM
   Verani JR, 2015, VACCINE, V33, P6145, DOI 10.1016/j.vaccine.2015.10.007
   Whitney CG, 2006, LANCET, V368, P1495, DOI 10.1016/S0140-6736(06)69637-2
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1559
EP 1564
DI 10.1016/j.vaccine.2019.11.049
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900036
PM 31791813
DA 2020-05-12
ER

PT J
AU Goss, MD
   Temte, JL
   Barlow, S
   Temte, E
   Bell, C
   Birstler, J
   Chen, GH
AF Goss, Maureen D.
   Temte, Jonathan L.
   Barlow, Shari
   Temte, Emily
   Bell, Cristalyne
   Birstler, Jen
   Chen, Guanhua
TI An assessment of parental knowledge, attitudes, and beliefs regarding
   influenza vaccination
SO VACCINE
LA English
DT Article
DE Vaccine hesitancy; Influenza knowledge, attitudes, and beliefs (KABs);
   Vaccine acceptance; Health behavior; Public health; Vaccine
   decision-making
ID HEALTH; DECISIONS; DETERMINANTS; US
AB Introduction: Seasonal influenza imposes a significant clinical and economic burden. Despite the availability of an annual vaccine to prevent influenza infection and reduce disease severity, influenza vaccination rates remain suboptimal. Research suggests personal experience, perceived effectiveness, and concerns regarding vaccine safety and side effects are the most influential factors in predicting a parent's decision to vaccinate. However, current literature is primarily focused on the vaccine decision-making of healthcare workers and those at high risk for influenza complications.
   Methods: To assess parental attitudes and beliefs regarding the influenza vaccine, a brief mixed-methods survey was developed and optimized for an electronic platform. The Health Belief Model informed survey design and data analysis. Questions were classified into five core concepts: knowledge, barriers, benefits, experience, and severity. Participants were solicited from a population of parents whose children had participated in a school-based influenza surveillance study (n = 244, 73% response rate). We tested associations between responses and children's influenza vaccination status the prior season. Categorical questions were tested using Pearson's chi-squared tests and numerical or ordered questions using Mann Whitney tests. P-values were corrected using the Bonferroni method.
   Results: Doubting effectiveness, concerns about side effects, inconvenience, and believing the vaccine is unnecessary were barriers negatively associated with parents' decision to vaccinate their children during the 2017-18 flu season (p < 0.001). Knowledge that the vaccine is effective in lowering risk, duration, and severity of influenza; receiving the influenza vaccine as an adult; and recognizing the importance of vaccination to prevent influenza transmission in high-risk populations were positively associated with parents' decision to vaccinate (p < 0.001).
   Conclusion: Understanding barriers and motivators behind parents' decision to vaccinate provides valuable insight that has the potential to shape vaccine messaging, recommendations, and policy. The motivation to vaccinate to prevent influenza transmission in high-risk populations is a novel finding that warrants further investigation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Goss, Maureen D.; Temte, Jonathan L.; Barlow, Shari; Temte, Emily; Bell, Cristalyne] Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med & Community Hlth, 1100 Delaplaine Ct, Madison, WI 53715 USA.
   [Birstler, Jen; Chen, Guanhua] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA.
RP Goss, MD (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Family Med & Community Hlth, 1100 Delaplaine Ct, Madison, WI 53715 USA.
EM Maureen.Landsverk@fammed.wisc.edu
OI Temte, Jonathan/0000-0001-7097-583X; Chen, Guanhua/0000-0002-9314-2037;
   Birstler, Jen/0000-0002-5247-0632
FU Department of Family Medicine and Community Health Small Grants Program
   at the University of Wisconsin-Madison
FX This work was supported by the Department of Family Medicine and
   Community Health Small Grants Program at the University of
   Wisconsin-Madison.
CR Ali I, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00173
   [Anonymous], 2018, 2017 18 FLU SEAS FLU
   BECKER MH, 1975, MED CARE, V13, P10, DOI 10.1097/00005650-197501000-00002
   Brown C, 2011, VACCINE, V29, P9488, DOI 10.1016/j.vaccine.2011.10.023
   Brown KF, 2010, VACCINE, V28, P4235, DOI 10.1016/j.vaccine.2010.04.052
   Brunson EK, 2013, VACCINE, V31, P5466, DOI 10.1016/j.vaccine.2013.08.104
   Chapman GB, 1999, PREV MED, V29, P249, DOI 10.1006/pmed.1999.0535
   Chiatti C, 2010, PREV MED, V51, P332, DOI 10.1016/j.ypmed.2010.06.008
   Cowling BJ, 2017, VACCINE, V35, P856, DOI 10.1016/j.vaccine.2016.12.064
   Dini G, 2018, HUM VACC IMMUNOTHER, V14, P772, DOI 10.1080/21645515.2017.1348442
   Fournet N, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5103-8
   Glanz K, 2015, HLTH BEHAV THEORY RE
   Haridi HK, 2017, J HOSP INFECT, V96, P268, DOI 10.1016/j.jhin.2017.02.005
   Harmsen IA, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1183
   Hendrix KS, 2014, PEDIATRICS, V134, pE675, DOI 10.1542/peds.2013-4077
   HODDINOTT SN, 1986, CAN FAM PHYSICIAN, V32, P2366
   JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101
   King JP, 2018, INFLUENZA OTHER RESP, V12, P808, DOI 10.1111/irv.12593
   Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037
   Lehmann BA, 2014, VACCINE, V32, P6986, DOI 10.1016/j.vaccine.2014.10.034
   Leong R., 2015, ANTIMICROB RESIST IN, V4, pP19, DOI [10.118612047-7994-4-S1 -P14, 10.11861/2047-2994-4-S1-P14, DOI 10.1186/2047-2994-4-S1-P14]
   Meszaros JR, 1996, J CLIN EPIDEMIOL, V49, P697, DOI 10.1016/0895-4356(96)00007-8
   Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046
   Nowak GJ, 2015, VACCINE, V33, P2741, DOI 10.1016/j.vaccine.2015.04.064
   Nyhan B, 2015, VACCINE, V33, P459, DOI 10.1016/j.vaccine.2014.11.017
   Nyhan B, 2010, POLIT BEHAV, V32, P303, DOI 10.1007/s11109-010-9112-2
   OLIVER RL, 1979, J CONSUM RES, V6, P113, DOI 10.1086/208755
   Oria PA, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-391
   Shim E, 2012, J R SOC INTERFACE, V9, P2234, DOI 10.1098/rsif.2012.0115
NR 29
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1565
EP 1571
DI 10.1016/j.vaccine.2019.11.040
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900037
PM 31776028
DA 2020-05-12
ER

PT J
AU Penta, MA
   Craciun, IC
   Baban, A
AF Penta, Marcela A.
   Craciun, Irina Catrinel
   Baban, Adriana
TI The power of anticipated regret: Predictors of HPV vaccination and
   seasonal influenza vaccination acceptability among young Romanians
SO VACCINE
LA English
DT Article
DE HPV vaccination; Seasonal flu vaccination; Anticipated regret; Health
   belief model; Young adults; Romania
ID HUMAN-PAPILLOMAVIRUS HPV; HEALTH BEHAVIOR; UNIVERSITY; KNOWLEDGE; WOMEN;
   STUDENTS; INFORMATION; INTENTIONS; HESITANCY; BELIEFS
AB Background: Understanding lay perceptions concerning vaccination and identifying the most important psychological determinants of vaccine acceptability are relevant for health promotion campaigns.
   Methods: This cross-sectional study aimed to identify the psychological determinants of HPV vaccine and seasonal flu vaccine acceptability in a national sample of young adults. An extended version of the health belief model (HBM) provided the main theoretical framework. Four hundred and one adults aged 18-26 (79% women), completed the theory-based survey and were included in analyses. The main outcomes were intentions to vaccinate against HPV and the seasonal flu. Descriptive statistics, bivariate correlations and hierarchical multiple regression were used for data analysis.
   Results: The models predicted 51% and 60% of the variability in intentions to vaccinate against HPV and the seasonal flu, respectively. For both decisional contexts, anticipated inaction regret (assuming one were unvaccinated and later contracted infection) was the strongest predictor of intentions, contributing above and beyond the role of traditional risk belief constructs (HBM constructs). Other shared predictors of intentions were perceived effectiveness of vaccine, perceived vaccine safety, perceived susceptibility to disease and previous vaccine refusal. The study also provides insights into young adults' vaccine-related knowledge and their information-seeking practices.
   Conclusion: Findings outline directions for future research and implications for health communication campaigns. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Penta, Marcela A.; Craciun, Irina Catrinel; Baban, Adriana] Babes Bolyai Univ, Dept Psychol, 37 Republ St, Cluj Napoca 400015, CJ, Romania.
   [Craciun, Irina Catrinel] Free Univ Berlin, Habelschwerdter Allee 45, D-14195 Berlin, Germany.
RP Penta, MA (reprint author), Babes Bolyai Univ, Dept Psychol, 37 Republ St, Cluj Napoca 400015, CJ, Romania.
EM marcelapenta@psychology.ro
CR Bednarczyk RA, 2015, VACCINE, V33, P1659, DOI 10.1016/j.vaccine.2015.02.033
   Betsch C, 2016, MED DECIS MAKING, V36, P811, DOI 10.1177/0272989X15600434
   Brewer NT, 2007, PREV MED, V45, P107, DOI 10.1016/j.ypmed.2007.05.013
   Brewer NT, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1764
   Brewer NT, 2016, HEALTH PSYCHOL, V35, P1264, DOI 10.1037/hea0000294
   Brewer NT, 2011, SEX TRANSM DIS, V38, P197, DOI 10.1097/OLQ.0b013e3181f12dbf
   Cameron KA, 2013, PATIENT EDUC COUNS, V92, P381, DOI 10.1016/j.pec.2013.06.017
   Chapman GB, 2006, HEALTH PSYCHOL, V25, P82, DOI 10.1037/0278-6133.25.1.82
   Christy SM, 2016, J BEHAV MED, V39, P429, DOI 10.1007/s10865-016-9716-z
   Craciun C, 2012, VACCINE, V30, P6789, DOI 10.1016/j.vaccine.2012.09.016
   Donadiki EM, 2014, PUBLIC HEALTH, V128, P268, DOI 10.1016/j.puhe.2013.12.004
   European Centre for Disease Prevention and Control, 2015, SEAS INFL VACC EUR O
   European Centre for Disease Prevention and Control. [ECDC], 2017, SEAS INFL VACC EUR V
   Fazekas KI, 2008, J WOMENS HEALTH, V17, P539, DOI 10.1089/jwh.2007.0489
   Ferguson E, 2007, BRIT J PSYCHOL, V98, P667, DOI 10.1348/000712607X190692
   Gerend MA, 2008, J ADOLESCENT HEALTH, V42, P237, DOI 10.1016/j.jadohealth.2007.08.022
   Gilbert P, 2011, AM J MENS HEALTH, V5, P297, DOI 10.1177/1557988310372802
   Haase N, 2015, J HEALTH COMMUN, V20, P920, DOI 10.1080/10810730.2015.1018605
   Hofman R, 2014, HEALTH EDUC RES, V29, P83, DOI 10.1093/her/cyt092
   Hughes J, 2009, CANCER EPIDEM BIOMAR, V18, P363, DOI 10.1158/1055-9965.EPI-08-0418
   Jones M, 2008, J AM COLL HEALTH, V57, P23, DOI 10.3200/JACH.57.1.23-32
   Juntasopeepun P, 2012, INT J GYNECOL OBSTET, V118, P247, DOI 10.1016/j.ijgo.2012.04.015
   Krawczyk AL, 2012, HEALTH PSYCHOL, V31, P685, DOI 10.1037/a0027012
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Lehmann BA, 2014, VACCINE, V32, P6986, DOI 10.1016/j.vaccine.2014.10.034
   Liao Q, 2013, VACCINE, V31, P4084, DOI 10.1016/j.vaccine.2013.07.009
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   McRee AL, 2010, SEX TRANSM DIS, V37, P234, DOI 10.1097/OLQ.0b013e3181c37e15
   Ratanasiripong NT, 2013, VACCINE, V31, P1370, DOI 10.1016/j.vaccine.2013.01.001
   Reiter PL, 2010, SEX TRANSM INFECT, V86, P241, DOI 10.1136/sti.2009.039065
   Reiter PL, 2009, SOC SCI MED, V69, P475, DOI 10.1016/j.socscimed.2009.05.024
   Rosenthal SL, 2011, VACCINE, V29, P890, DOI 10.1016/j.vaccine.2009.12.063
   Satterwhite CL, 2013, SEX TRANSM DIS, V40, P187, DOI 10.1097/OLQ.0b013e318286bb53
   Sheeran P, 2016, SOC PERSONAL PSYCHOL, V10, P503, DOI 10.1111/spc3.12265
   Shim E, 2012, J R SOC INTERFACE, V9, P2234, DOI 10.1098/rsif.2012.0115
   Voidazan S, 2016, ACTA DERMATOVENER CR, V24, P193
   Weinstein ND, 2007, HEALTH PSYCHOL, V26, P146, DOI 10.1037/0278-6133.26.2.146
   WHO, 2016, EUR HLTH ALL DAT
   Ziarnowski KL, 2009, PREV MED, V48, P411, DOI 10.1016/j.ypmed.2008.10.006
NR 39
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 5
PY 2020
VL 38
IS 6
BP 1572
EP 1578
DI 10.1016/j.vaccine.2019.11.042
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO3JY
UT WOS:000515445900038
PM 31786001
DA 2020-05-12
ER

PT J
AU Tourtelot, E
   Quataert, S
   Glantz, JC
   Perlis, L
   Muthukrishnan, G
   Mosmann, T
AF Tourtelot, Ellen
   Quataert, Sally
   Glantz, J. Christopher
   Perlis, Lauren
   Muthukrishnan, Gowrishankar
   Mosmann, Tim
TI Women who received varicella vaccine versus natural infection have
   different long-term T cell immunity but similar antibody levels
SO VACCINE
LA English
DT Article
DE Varicella-zoster virus; Chickenpox; Pregnancy; Fetal anomalies; Vaccine;
   Flow cytometry; Humoral immunity; Cellular immunity
ID ZOSTER-VIRUS; CYTOMEGALOVIRUS-SEROPOSITIVITY; HEALTHY; IDENTIFICATION
AB Background: Varicella-zoster virus (VZV) infection during pregnancy is associated with serious fetal anomalies. The live-attenuated VZV vaccine was approved in 1995, so many vaccinated women are now of childbearing age. The question of long-term immunity to varicella is critical because breakthrough chickenpox can occur after vaccination.
   Objective: To compare humoral and T cell immunity between women of childbearing age who were immunized by vaccination or chickenpox disease.
   Study design: Non-pregnant females between 18 and 36 years old with a history of VZV immunization (n = 20) or prior chickenpox disease (n = 20) were recruited. IgG antibody titers and T cell responses were measured by flow cytometry-based methods in serum and peripheral blood, respectively.
   Results: There were no significant differences in median antibody titers between vaccinated and chickenpox groups (p = 034). The chickenpox group had significantly higher levels of VZV antigen-specific CD4 T cells (p = 0.004).
   Conclusion: Natural infection induced higher VZV-specific T cell immune responses than vaccination. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Tourtelot, Ellen; Glantz, J. Christopher; Perlis, Lauren] Univ Rochester, Strong Mem Hosp, Dept Obstet & Gynecol, Rochester, NY 14627 USA.
   [Quataert, Sally; Muthukrishnan, Gowrishankar; Mosmann, Tim] Univ Rochester, Strong Mem Hosp, Dept Vaccine Biol & Immunol, Rochester, NY 14627 USA.
RP Tourtelot, E (reprint author), 601 Elmwood Ave,Box 668, Rochester, NY 14642 USA.
EM Ellen_tourtelot@urmc.rochester.edu
FU Mae Stone Goode Foundation; Pilot Grant Department of Obstetrics and
   Gynecology University of Rochester, Rochester, NY
FX Mae Stone Goode Foundation, Pilot Grant Department of Obstetrics and
   Gynecology University of Rochester, Rochester, NY.
CR ARVIN AM, 1986, J INFECT DIS, V154, P422, DOI 10.1093/infdis/154.3.422
   Arvin AM, 2008, J INFECT DIS, V197, pS58, DOI 10.1086/522123
   Asanuma H, 2000, J INFECT DIS, V181, P859, DOI 10.1086/315347
   Breuer J, 2008, J INFECT DIS, V197, pS147, DOI 10.1086/529448
   Chaves SS, 2007, NEW ENGL J MED, V356, P1121, DOI 10.1056/NEJMoa064040
   Chidrawar S, 2009, CLIN EXP IMMUNOL, V155, P423, DOI 10.1111/j.1365-2249.2008.03785.x
   Duncan JR, 2017, VACCINE, V35, P2351, DOI 10.1016/j.vaccine.2017.03.054
   Frey CR, 2003, J INFECT DIS, V188, P40, DOI 10.1086/375828
   Gershon AA, 2010, J CLIN VIROL, V48, pS2, DOI 10.1016/S1386-6532(10)70002-0
   HOPESIMPSON RE, 1965, P ROY SOC MED, V58, P9, DOI 10.1177/003591576505800106
   Khan N, 2002, J IMMUNOL, V169, P1984, DOI 10.4049/jimmunol.169.4.1984
   Krause PR, 2000, NAT MED, V6, P451, DOI 10.1038/74715
   Kuter B, 2004, PEDIATR INFECT DIS J, V23, P132, DOI 10.1097/01.inf.0000109287.97518.67
   Lafer MM, 2011, CLIN VACCINE IMMUNOL, V18, P1194, DOI 10.1128/CVI.05130-11
   Lamoreaux L, 2006, NAT PROTOC, V1, P1507, DOI 10.1038/nprot.2006.268
   Malavige GN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003789
   Marin Mona, 2007, Morbidity and Mortality Weekly Report, V56, P1
   Mosmann TR, 2014, CYTOM PART A, V85, P422, DOI 10.1002/cyto.a.22445
   Ogunjimi B, 2014, CLIN VACCINE IMMUNOL, V21, P417, DOI 10.1128/CVI.00818-13
   Weinberg A, 2010, J INFECT DIS, V201, P1024, DOI 10.1086/651199
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1581
EP 1585
DI 10.1016/j.vaccine.2019.12.067
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900002
PM 31959424
DA 2020-05-12
ER

PT J
AU Jo, SK
   Ahn, BE
   Choi, EH
   Kang, JE
   An, H
   Oh, MD
   Rhie, GE
AF Jo, Su Kyoung
   Ahn, Bo-Eun
   Choi, Eun Hye
   Kang, Ji Eun
   An, Hyonggin
   Oh, Myoung-don
   Rhie, Gi-eun
TI Evaluation of the protective efficacy of recombinant protective antigen
   vaccine (GC1109)-immunized human sera using passive immunization in a
   mouse model
SO VACCINE
LA English
DT Article
DE Anthrax vaccine; Passive immunization; Toxin neutralization assay;
   Survival rate
ID BACILLUS-ANTHRACIS; IMMUNOGENICITY
AB The protective efficacy of human sera from vaccinated individuals with a new recombinant protective antigen anthrax vaccine (GC1109) against lethal spore challenge was evaluated in a mouse model. Eighteen human sera were selected from the vaccinated individuals based on their toxin neutralizing assay (TNA) titer (ED50 of 55 to 668). The selected sera were diluted and passively transferred to AB mice and the mice were subsequently challenged with 100 x LD50 of Bacillus anthracis Sterne spores. The correlation between the survival rate of passively immunized mice and the TNA ED50 of transferred sera was presented (r = 0.873, P-value < 0.001). The estimated TNA titer for 50% survival rate against lethal challenge was 197 (95% confidence interval of 149 and 260). The result suggest that GC1109 is protective against exposure to B. anthracis and the TNA titer of vaccinated serum can be an indicator for protective efficacy. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jo, Su Kyoung; Ahn, Bo-Eun; Choi, Eun Hye; Rhie, Gi-eun] Korea Ctr Dis Control & Prevent, Ctr Lab Control Infect Dis, Div High Risk Pathogens, Cheongju, South Korea.
   [Kang, Ji Eun] GC Pharma, Downstream Proc Res Ctr 2, Yongin, South Korea.
   [An, Hyonggin] Korea Univ, Coll Med, Dept Biostat, Seoul, South Korea.
   [Oh, Myoung-don] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul, South Korea.
   [Oh, Myoung-don] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea.
RP Rhie, GE (reprint author), Korea Ctr Dis Control & Prevent, Ctr Lab Control Infect Dis, Div High Risk Pathogens, Cheongju, South Korea.
EM gerhie@korea.kr
OI An, Hyonggin/0000-0002-0566-758X
FU Research of Korea Centers for Disease Control and Prevention
   [4840-302-210-13, 4840-302-260]
FX This research was supported by Research of Korea Centers for Disease
   Control and Prevention (project numbers 4840-302-210-13 and
   4840-302-260).
CR Campbell JD, 2007, HUM VACCINES, V3, P205, DOI 10.4161/hv.3.5.4459
   Charlton S, 2007, J APPL MICROBIOL, V103, P1453, DOI 10.1111/j.1365-2672.2007.03391.x
   Cybulski RJ, 2009, MOL ASPECTS MED, V30, P490, DOI 10.1016/j.mam.2009.08.006
   Friedlander AM, 2009, VACCINE, V27, pD28, DOI 10.1016/j.vaccine.2009.08.102
   Gorse GJ, 2006, VACCINE, V24, P5950, DOI 10.1016/j.vaccine.2006.05.044
   Hering D, 2004, BIOLOGICALS, V32, P17, DOI 10.1016/j.biologicals.2003.09.003
   Hewetson JF, 2008, VACCINE, V26, P4262, DOI 10.1016/j.vaccine.2008.05.068
   Ivins B, 1995, VACCINE, V13, P1779, DOI 10.1016/0264-410X(95)00139-R
   Joellenbeck LM, ANTHRAX VACCINE IS I, P180
   Kang CK, 2019, VACCINE, V37, P3820, DOI 10.1016/j.vaccine.2019.05.057
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Rhie GE, 2005, FEMS IMMUNOL MED MIC, V45, P331, DOI 10.1016/j.femsim.2005.05.008
   Ritz C, 2005, J STAT SOFTW, V12, P1
   WELKOS SL, 1986, INFECT IMMUN, V51, P795, DOI 10.1128/IAI.51.3.795-800.1986
NR 14
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1586
EP 1588
DI 10.1016/j.vaccine.2019.12.048
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900003
PM 31911031
DA 2020-05-12
ER

PT J
AU Delacruz, WP
   Savona, MR
   Thornton, JA
   Danaher, PJ
AF Delacruz, Wilfred P.
   Savona, Michael R.
   Thornton, Jennifer A.
   Danaher, Patrick J.
TI Evidence of vaccinia dissemination despite lack of major reaction
   following smallpox vaccination
SO VACCINE
LA English
DT Article
DE Vaccinia; Smallpox vaccination; Major reaction; Polymerase chain
   reaction; Immunity
ID PROTECTION; BLOOD; DNA
AB Following vaccinia vaccination, vesicle formation at the site occurs in 95% of primary vaccinees and is thought to indicate virus replication and vaccine efficacy. Little is known about virus replication and immune response in those who do not develop a vesicle. We used PCR to detect vaccinia in various sites following receipt of the smallpox vaccine in those with and without vesicle formation. Among 80 participants, 74 developed and 6 failed to develop a vesicle. Vaccinia DNA was detected in the blood, in the oropharynx, on the dressing, and on the hands of 5%, 11%, 4%, and 0% of those with vesicle formation and of 33%, 17%, 0%, and 17% of those without vesicle formation, respectively (p > 0.05 for each site). The detection of systemic vaccinia DNA in vaccinees without vesicle formation challenges the current understanding that lack of vesicle formation indicates lack of virus replication, the prerequisite to immune response. Published by Elsevier Ltd.
C1 [Delacruz, Wilfred P.; Thornton, Jennifer A.] David Grant US Air Force Med Ctr, Clin Invest Facil, 101 Bodin Circle, Travis AFB, CA 94535 USA.
   [Savona, Michael R.; Danaher, Patrick J.] David Grant US Air Force Med Ctr, Dept Med, 101 Bodin Circle, Travis AFB, CA 94535 USA.
RP Danaher, PJ (reprint author), STVHCS, Med Serv, MC 111,7400 Merton Minter Blvd, San Antonio, TX 78229 USA.
EM wilfred.p.delacruz.mil@mail.mil; michael.savona@vanderbilt.edu;
   jthornton@rippleeffect.com; patrick.danaher@va.gov
CR [Anonymous], 2004, SMALLP VACC DRY CALF, P1
   [Anonymous], 2018, SMALLP VACC VACC LIV
   Belyakov IM, 2003, P NATL ACAD SCI USA, V100, P9458, DOI 10.1073/pnas.1233578100
   Center for Infectious Disease Research and Policy, 2008, US MIL SWITCH NEW SM
   Centers for Disease Control and Prevention, GUID REC SMALLP VACC
   Cheminay C, 2018, VACCINE, V36, P2427, DOI 10.1016/j.vaccine.2018.03.048
   CHERRY JD, 1977, J INFECT DIS, V135, P145, DOI 10.1093/infdis/135.1.145
   Cohen JI, 2007, VACCINE, V25, P4571, DOI 10.1016/j.vaccine.2007.03.044
   Edghill-Smith Y, 2005, NAT MED, V11, P740, DOI 10.1038/nm1261
   Fiore Anthony E., 2011, Morbidity and Mortality Weekly Report, V60, P1
   Frey SE, 2009, VACCINE, V27, P1637, DOI 10.1016/j.vaccine.2008.11.079
   Kelso JM, 2005, JAMA-J AM MED ASSOC, V293, P677, DOI 10.1001/jama.293.6.677
   Law M, 2005, J GEN VIROL, V86, P991, DOI 10.1099/vir.0.80660-0
   Moss B, 2011, IMMUNOL REV, V239, P8, DOI 10.1111/j.1600-065X.2010.00975.x
   Rotz L D, 2001, MMWR Recomm Rep, V50, P1
   Saito T, 2009, JAMA-J AM MED ASSOC, V301, P1025, DOI 10.1001/jama.2009.289
   Savona MR, 2006, JAMA-J AM MED ASSOC, V295, P1898, DOI 10.1001/jama.295.16.1898
   Treanor J, 2006, VACCINE, V24, P6913, DOI 10.1016/j.vaccine.2006.06.006
   Waibel KH, 2004, CLIN INFECT DIS, V39, P1004, DOI 10.1086/423967
   Xia D, 2003, 103 GEN M AM SOC MIC, P175
NR 20
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1589
EP 1592
DI 10.1016/j.vaccine.2019.12.046
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900004
PM 31899026
DA 2020-05-12
ER

PT J
AU Inbal, G
   Markovich, MP
   Dana, W
   Meital, H
   Hartal, M
   Eva, A
AF Inbal, Galor
   Markovich, Michal Perry
   Dana, Wolf
   Meital, Haber
   Hartal, Michael
   Eva, Avramovich
TI Population seroprotection against hepatitis a virus in Israel 18 years
   after introduction of inactivated vaccine into the routine childhood
   vaccination schedule
SO VACCINE
LA English
DT Article
DE Hepatitis A; Hepatitis A vaccine; Serosurvey
ID YOUNG-ADULTS; IMMUNIZATION; CHILDREN; PREVALENCE; ANTIBODIES
AB Vaccine against Hepatitis A virus (HAV) is part of the routine vaccination schedule in Israel since 1999. As of 2016, new recruits to the Israel Defense Forces should have been vaccinated in their childhood. This sero-survey aimed to determine immunity against HAV 18 years after childhood vaccination, and to re-evaluate the need for HAV vaccination booster upon recruitment.
   Two populations were studied: soldiers who were recruited during 2011-2012, who belonged to birth cohorts before childhood vaccination (BCV) was introduced; and recruits from 2017, who belonged to birth cohorts after childhood vaccination (ACV) was introduced.
   Data on 339 BCV recruits and 295 ACV recruits were analyzed. Seropositivity was 35% in the BCV group and 68% in the ACV group (P < 0.0001). Seropositivity rates among ACV subjects enable evaluation of the vaccination program's impact on the population. Our findings do not support discontinuation of HAV vaccination of at risk groups until further evaluation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Inbal, Galor; Markovich, Michal Perry; Meital, Haber; Eva, Avramovich] Israel Def Forces Med Corps, Publ Hlth Branch, Tel Aviv, Israel.
   [Inbal, Galor; Eva, Avramovich] Bar Ilan Univ, Fac Social Sci, Dept Management, Ramat Gan, Israel.
   [Markovich, Michal Perry] Minist Agr & Rural Dev, Israel Vet Serv, Rishon Letsiyon, Israel.
   [Dana, Wolf] Hadassah Hebrew Univ, Dept Clin Microbiol & Infect Dis, Clin Virol Unit, Med Ctr, Jerusalem, Israel.
   [Dana, Wolf] Hebrew Univ Jerusalem, Lautenberg Ctr Gen & Tumor Immunol, Fac Med, Jerusalem, Israel.
   [Hartal, Michael] Myers JDC Brookdale Inst, Jerusalem, Israel.
   [Hartal, Michael] Hebrew Univ Jerusalem, Fac Med, Inst Res Mil Med, Jerusalem, Israel.
RP Inbal, G (reprint author), Israel Def Forces Med Corps, Publ Hlth Branch, Tel Aviv, Israel.
EM inbalraj@gmail.com
CR Bassal R, 2017, EPIDEMIOL INFECT, V145, P2890, DOI [10.1017/S0950268817002126, 10.1017/s0950268817002126]
   Bassal R, 2017, PEDIATR INFECT DIS J, V36, pE248, DOI 10.1097/INF.0000000000001640
   Central Bureau of Statistics, 2019, STAT ABSTRACT ISR 20
   Central bureau of statistics, 2018, IMM ISR 2017
   Dagan R, 2005, JAMA-J AM MED ASSOC, V294, P202, DOI 10.1001/jama.294.2.202
   Dagan R, 2016, PEDIATR INFECT DIS J, V35, pE220, DOI 10.1097/INF.0000000000001176
   DiaSorin S.p.A, HEP RETR HEP A B CHA
   Fischinger S, 2019, SEMIN IMMUNOPATHOL, V41, P239, DOI 10.1007/s00281-018-0726-5
   Gdalevich M, 1998, EPIDEMIOL INFECT, V121, P477, DOI 10.1017/S0950268898001198
   Hartal M, 2015, VACCINE, V33, P4878, DOI 10.1016/j.vaccine.2015.07.058
   Lemon SM, 2018, J HEPATOL, V68, P167, DOI 10.1016/j.jhep.2017.08.034
   Levine H, 2015, EUROSURVEILLANCE, V20, P5, DOI 10.2807/1560-7917.ES2015.20.7.21040
   Lopez EL, 2015, PEDIATR INFECT DIS J, V34, P417, DOI 10.1097/INF.0000000000000605
   Orr N, 2006, VACCINE, V24, P4328, DOI 10.1016/j.vaccine.2006.03.010
   Shahrabani S, 2006, ISRAEL MED ASSOC J, V8, P630
   Stuurman AL, 2017, HUM VACC IMMUNOTHER, V13, P724, DOI 10.1080/21645515.2016.1242539
   Uruena A, 2016, PEDIATR INFECT DIS J, V35, P1339, DOI 10.1097/INF.0000000000001322
   Yitshak-Sade M, 2016, ETHNIC HEALTH, V21, P439, DOI 10.1080/13557858.2015.1068281
   Zahavi A, 2012, J ISRAELI MILITARY M, V2, P5
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1593
EP 1596
DI 10.1016/j.vaccine.2019.12.041
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900005
PM 31932135
DA 2020-05-12
ER

PT J
AU Ritscher, AM
   LeClair-Netzel, M
   Friedlander, NJ
   Stewart, DNH
   Wagner, M
   Kalscheur, N
   Caldera, F
   Hayney, MS
AF Ritscher, Alicia M.
   LeClair-Netzel, Megan
   Friedlander, Nicholas J.
   Stewart, Danielle N. Howard
   Wagner, Mallory
   Kalscheur, Nicole
   Caldera, Freddy
   Hayney, Mary S.
TI Cross-sectional study of hepatitis B antibody status in health care
   workers immunized as children at an academic medical center in Wisconsin
SO VACCINE
LA English
DT Article
DE Hepatitis B vaccine; Health care workers; Anamnestic response; Anti-HBs;
   Bloodborne pathogen
ID IMMUNOLOGICAL MEMORY; ANAMNESTIC RESPONSE; UNITED-STATES; VACCINATION;
   PERSISTENCE; INFANT; STUDENTS; PREVENTION; INFECTION; RISK
AB Individuals who received the hepatitis B vaccine series as young children are entering the healthcare workforce. Our study measured the persistence of antibody to the hepatitis B surface antigen (anti-HBs) at time of employment. Among 986 individuals born in 1991 or more recently with documentation of completion of the hepatitis B vaccine series, 51% had anti-HBs < 10mIU/ml. Of these 507 healthcare workers, 446 (88%) received documented fourth dose of hepatitis B vaccine followed by another anti-HBs >= 28 days post vaccination; 11% (50/446 or 5% of the total population) did not mount an anamnestic response. The non-responders were more likely to be male or complete the vaccine series prior to age 7 months. Measuring anti-HBs at the time of hire in this population of healthcare workers who had documentation of hepatitis B series completion as young children may be unnecessary because of the high rate of hepatitis B vaccine protection. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ritscher, Alicia M.; Friedlander, Nicholas J.; Stewart, Danielle N. Howard; Hayney, Mary S.] Univ Wisconsin, Sch Pharm, 777 Highland Ave, Madison, WI 53705 USA.
   [LeClair-Netzel, Megan; Wagner, Mallory; Kalscheur, Nicole] UW Hlth, Employee Hlth Serv, Madison, WI USA.
   [Caldera, Freddy] Univ Wisconsin, Dept Med, Div Gastroenterol & Hepatol, Sch Med & Publ Hlth, Madison, WI 53705 USA.
RP Hayney, MS (reprint author), Univ Wisconsin, Sch Pharm, 777 Highland Ave, Madison, WI 53705 USA.
EM MLeClair-Netzel@uwhealth.org; nfriedlander@wisc.edu;
   MWagner4@uwhealth.org; NKalscheur2@uwhealth.org;
   fcaldera@medicine.wisc.edu; mary.hayney@wisc.edu
OI Hayney, Mary/0000-0003-3307-5634
CR [Anonymous], 1991, MMWR Recomm Rep, V40, P1
   Bini C, 2018, HUM VACC IMMUNOTHER, V14, P450, DOI 10.1080/21645515.2017.1398297
   Bruce MG, 2016, J INFECT DIS
   Centers for Disease Control and Prevention, 2019, REC IMM SCHED PERS A, V2019, P1
   Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P33
   Dini G, 2017, HUM VACC IMMUNOTHER, V13, P440, DOI 10.1080/21645515.2017.1264788
   Finlayson Teresa J., 2011, Morbidity and Mortality Weekly Report, V60, P1
   Hudu SA, 2013, PATIENT PREFER ADHER, V7, P981, DOI 10.2147/PPA.S49776
   Kinlin LM, 2010, INFECT CONT HOSP EP, V31, P908, DOI 10.1086/655839
   Klinger G, 2018, VACCINE, V36, P2288, DOI 10.1016/j.vaccine.2018.03.028
   Marder E, 2013, MMWR-MORBID MORTAL W, V62, P1
   Marin Mona, 2007, Morbidity and Mortality Weekly Report, V56, P1
   Occupational Safety and Health Administration, 1910, 19101030 OCC SAF HLT
   Poovorawan Y, 2013, HUM VACC IMMUNOTHER, V9, P1679, DOI 10.4161/hv.24844
   Romano L, 2017, HUM VACC IMMUNOTHER, V13, P981, DOI 10.1080/21645515.2017.1264795
   Schillie S, 2018, MMWR RECOMM REP, V67, P1, DOI 10.15585/mmwr.rr6701a1
   Sernia S, 2015, BIOMED RES INT, DOI 10.1155/2015/712020
   Spradling PR, 2015, INFECT CONT HOSP EP, V36, P529, DOI 10.1017/ice.2015.6
   Spradling PR, 2013, CLIN VACCINE IMMUNOL, V20, P559, DOI 10.1128/CVI.00694-12
   Tohme RA, 2011, INFECT CONT HOSP EP, V32, P818, DOI 10.1086/661102
   West DJ, 1996, VACCINE, V14, P1019, DOI 10.1016/0264-410X(96)00062-X
NR 21
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1597
EP 1600
DI 10.1016/j.vaccine.2019.12.036
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900006
PM 31955961
DA 2020-05-12
ER

PT J
AU Jarvis, JR
   Dorey, RB
   Warricker, FDM
   Alwan, NA
   Jones, CE
AF Jarvis, J. R.
   Dorey, R. B.
   Warricker, F. D. M.
   Alwan, N. A.
   Jones, C. E.
TI The effectiveness of influenza vaccination in pregnancy in relation to
   child health outcomes: Systematic review and meta-analysis
SO VACCINE
LA English
DT Review
DE Influenza; Influenza-like illness; Vaccine; Immunisation; Maternal;
   Pregnancy; Infant; Children; Meta-analysis; Systematic review
ID RESPIRATORY-TRACT INFECTION; PANDEMIC INFLUENZA; SEASONAL INFLUENZA;
   OUTPATIENT VISITS; ANTIBODY TRANSFER; YOUNG INFANTS; IMMUNIZATION;
   WOMEN; HOSPITALIZATIONS; ILLNESS
AB Objectives: To determine the effectiveness of influenza vaccination during pregnancy on child health outcomes.
   Design: Systematic review/meta-analysis.
   Data sources: Clinical Trials.gov , Cochrane Library, EMBASE, Medline, Medline in process, PubMed and Web of Science, from 1st January 1996 to 29th June 2018. An updated Medline search was performed 30th June 2018 to 31st October 2019.
   Methods: Randomised controlled trials (RCTs) and observational studies reporting health outcomes of infants and children born to women who received inactivated influenza vaccine during pregnancy. The primary outcome was infant laboratory confirmed influenza (LCI). Secondary outcomes included influenza-like illness (ILI), other respiratory illnesses, primary care, clinic visit or hospitalisations due to influenza illness and long-term respiratory childhood outcomes.
   Results: 19 studies were included; 15 observational studies and 4 primary RCTs with an additional 3 papers reporting secondary outcomes of these RCTs. In a random effects meta-analysis of 2 RCTs including 5742 participants, maternal influenza vaccination was associated with an overall reduction of LCI in infants of 34% (95% confidence interval 15-50%). However, there was no effect of maternal influenza vaccination on ILI in infants <= 6 months old. Two RCTs were excluded from the meta-analysis for the outcome of LCI in infants (different controls used). Both of these studies showed a protective effect for infants from LCI, with a vaccine efficacy of up to 70%.
   Overall observational studies showed an inverse (protective) association between maternal influenza vaccination and infant LCI, hospitalisation and clinic visits due to LCI or ILI in infants and other respiratory illness in infants <= 6 months old.
   Conclusions: This systematic review supports maternal influenza vaccination as a strategy to reduce LCI and influenza-related hospitalisations in young infants. Communicating these benefits to pregnant women may support their decision to accept influenza vaccination in pregnancy and increase vaccine coverage in pregnant women. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Jarvis, J. R.; Dorey, R. B.; Jones, C. E.] Univ Hosp Southampton NHS Fdn Trust, Tremona Rd, Southampton SO16 6YD, Hants, England.
   [Jarvis, J. R.; Alwan, N. A.] Univ Southampton, NIHR Southampton Biomed Res Ctr, C Level West Wing,Mailpoint 218, Southampton SO16 6YD, Hants, England.
   [Jarvis, J. R.; Alwan, N. A.] Univ Hosp Southampton NHS Fdn Trust, Southampton Gen Hosp, C Level West Wing,Mailpoint 218, Southampton SO16 6YD, Hants, England.
   [Warricker, F. D. M.] Salisbury NHS Fdn Trust, Salisbury Dist Hosp, Dept Gastroenterol, Salisbury SP2 8BJ, Wilts, England.
   [Alwan, N. A.] Univ Southampton, Univ Hosp Southampton, Fac Med, Sch Primary Care Populat Sci & Med Educ, AC18,Level C South Acad Block, Southampton SO16 6YD, Hants, England.
   [Dorey, R. B.; Jones, C. E.] Univ Southampton, Fac Med Hlth & Life Sci, Tremona Rd, Southampton SO16 6YD, Hants, England.
RP Jarvis, JR (reprint author), Univ Hosp Southampton NHS Fdn Trust, Tremona Rd, Southampton SO16 6YD, Hants, England.
EM J.Jarvis@soton.ac.uk; r.dorey@soton.ac.uk; frazer.warricker@nhs.net;
   N.A.Alwan@soton.ac.uk; C.E.Jones@soton.ac.uk
RI Alwan, Nisreen/A-5081-2014
OI Alwan, Nisreen/0000-0002-4134-8463; Jones,
   Christine/0000-0003-1523-2368; Dorey, Robert/0000-0002-5257-7333;
   Jarvis, Jessica/0000-0002-8591-5378
FU University of Southampton, National Institute of Health Research (NIHR);
   Health Education England
FX JRJ was supported by the University of Southampton, National Institute
   of Health Research (NIHR) as an Academic Clinical Fellow and through
   Health Education England as a Public Health Registrar in Wessex Deanery.
   JRJs views expressed in this paper are independent of that of her
   funders. The funders had no involvement in the conduct of the research
   (including study design, collection, analysis and interpretation of
   data), preparation of the article or decision to submit for publication,
CR ALVAREZ C, 2016, LANCET INFECT DIS, V16, DOI DOI 10.1186/S12885-016-2261-X
   [Anonymous], 2014, REV MAN REVMAN
   Benowitz I, 2010, CLIN INFECT DIS, V51, P1355, DOI 10.1086/657309
   Black SB, 2004, AM J PERINAT, V21, P333, DOI 10.1055/s-2004-831888
   Chantry CJ, 2006, PEDIATRICS, V117, P425, DOI 10.1542/peds.2004-2283
   Dabrera G, 2014, EUROSURVEILLANCE, V19, P1
   Eberhardt CS, 2017, CLIN INFECT DIS, V64, P1129, DOI 10.1093/cid/cix046
   Eberhardt CS, 2016, CLIN INFECT DIS, V62, P829, DOI 10.1093/cid/ciw027
   Eick A, 2011, ARCH PEDIAT ADOLESC, V165
   FARRINGTON CP, 1993, INT J EPIDEMIOL, V22, P742, DOI 10.1093/ije/22.4.742
   Fell DB, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016526
   Fell DB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160342
   France EK, 2006, ARCH PEDIAT ADOL MED, V160, P1277, DOI 10.1001/archpedi.160.12.1277
   Galvao Tais F, 2013, ISRN Prev Med, V2013, P879493, DOI 10.5402/2013/879493
   Grohskopf LA, 2019, MMWR RECOMM REP, V68, P1, DOI 10.15585/mmwr.rr6803a1
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928
   Hviid A, 2017, JAMA PEDIATR, V171, P239, DOI 10.1001/jamapediatrics.2016.4023
   Jamieson DJ, 2006, EMERG INFECT DIS, V12, P1638, DOI 10.3201/eid1211.060152
   Jarvis J, 2018, PROSPERO INT PROSPEC
   Katz J, 2018, CLIN INFECT DIS, V14, P14, DOI [10.1093/cid/criy090, DOI 10.1093/CID/RIY090]
   Madhi SA, 2014, NEW ENGL J MED, V371, P918, DOI 10.1056/NEJMoa1401480
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Molgaard-Nielsen D, 2019, J INTERN MED, V286, P469, DOI 10.1111/joim.12947
   Mosby LG, 2011, AM J OBSTET GYNECOL, V205, P10, DOI 10.1016/j.ajog.2010.12.033
   Munoz Flor M, 2003, Paediatr Respir Rev, V4, P99, DOI 10.1016/S1526-0542(03)00027-7
   Myers ER, 2011, AM J OBSTET GYNECOL, V204, pS128, DOI 10.1016/j.ajog.2011.04.009
   National Heart Lung and Blood Institute, 2018, STUD QUAL ASS TOOLS
   Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401
   Nunes M, 2016, JAMA PEDIAT, V170
   Nunes MC, 2018, HUM VACC IMMUNOTHER, V14, P758, DOI 10.1080/21645515.2017.1345385
   Nunes MC, 2017, CLIN INFECT DIS, V65, P1066, DOI 10.1093/cid/cix497
   Oboho IK, 2016, J INFECT DIS, V214, P507, DOI 10.1093/infdis/jiw033
   Ohfuji S, 2018, J INFECT DIS, V217, P878, DOI 10.1093/infdis/jix629
   Plant EP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05579-4
   Poehling KA, 2013, PEDIATRICS, V131, P207, DOI 10.1542/peds.2012-1255
   Poehling KA, 2011, AM J OBSTET GYNECOL, V204, pS141, DOI 10.1016/j.ajog.2011.02.042
   Prisma, 2015, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD009982.PUB2/ABSTRACT
   PRISMA PRISMA, 2015, TRANSP REP SYST REV
   Public Health England, 2018, SEAS INFL VACC UPT G
   Rasmussen SA, 2008, EMERG INFECT DIS, V14, P95, DOI 10.3201/eid1401.070667
   Rasmussen SA, 2012, AM J OBSTET GYNECOL, V207, pS3, DOI 10.1016/j.ajog.2012.06.068
   Regan AK, 2016, PEDIATR INFECT DIS J, V35, P1097, DOI 10.1097/INF.0000000000001258
   Shakib JH, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2360
   Steinhoff MC, 2017, LANCET INFECT DIS, V17, P981, DOI 10.1016/S1473-3099(17)30252-9
   Sugimura T, 2016, PEDIATR INT, V58, P709, DOI 10.1111/ped.12888
   Sukumaran L, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-3310
   Walsh LK, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4151
   WHO, 2014, WHO SURV CAS DEF ILI
   Wilcox CR, 2018, VACCINE, V36, P7625, DOI 10.1016/j.vaccine.2018.10.092
   Wilcox CR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01294
   Wiley KE, 2015, QUAL HEALTH RES, V25, P360, DOI 10.1177/1049732314551061
   World Health Organisation, 2012, WKLY EPIDEMIOL REC, V87, P461
   World Health Organisation, 2012, M HELD 6 7 JUN 2012
   Zaman K, 2008, N ENGL J MED, V359
NR 55
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1601
EP 1613
DI 10.1016/j.vaccine.2019.12.056
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900007
PM 31932138
OA Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU Beyer, WEP
   Palache, AM
   Reperant, LA
   Boulfich, M
   Osterhaus, ADME
AF Beyer, Walter E. P.
   Palache, Abraham M.
   Reperant, Leslie A.
   Boulfich, Mimoun
   Osterhaus, Albert D. M. E.
TI Association between vaccine adjuvant effect and pre-seasonal immunity.
   Systematic review and meta-analysis of randomised immunogenicity trials
   comparing squalene-adjuvanted and aqueous inactivated influenza vaccines
SO VACCINE
LA English
DT Review
DE Influenza vaccine; Adjuvant; Squalene; Immunogenicity; Pre-seasonal
   immunity; Meta-analysis
ID SAFETY; EFFICACY; CHILDREN; HISTORY; YOUNG; MF59
AB The immunogenicity benefit of inactivated influenza vaccine (IIV) adjuvanted by squalene over nonadjuvanted aqueous IIV was explored in a meta-analysis involving 49 randomised trials published between 1999 and 2017, and 22,470 eligible persons of all age classes. Most vaccines contained 15 pg viral haemagglutinin per strain. Adjuvanted IIV mostly contained 9.75 mg squalene per dose. Homologous pre- and post-vaccination geometric mean titres (GMTs) of haemagglutination-inhibition (HI) antibody were recorded for 290 single influenza (sub-)type arms. The adjuvant effect was expressed as the ratio of post-vaccination GMTs between squalene-IIV and aqueous IIV (GMTR. 145 estimates). GMTRs > 1.0 favoured squalene-IIV over aqueous IIV. For all influenza (sub-)types, the adjuvant effect proved negatively associated with pre-vaccination GMT and mean age. The adjuvant effect appeared most pronounced in young children (mean age < 2.5 years) showing an average GMTR of 3.7 (95% CI: 2.5 to 5.5). With increasing age, GMTR values gradually decreased towards 1.4 (95% CI: 1.0 to 1.9) in older adults. Heterologous antibody titrations simulating mismatch between vaccine and circulating virus (30 GMTR estimates) again showed a larger adjuvant effect at young age. GMT values and their variances were converted to antibody-predicted protection rates using an evidence-based clinical protection curve. The adjuvant effect was expressed as the protection rate differences, which showed similar age patterns as corresponding GMTR values. However for influenza B, the adjuvant effect lasted longer than for influenza A, possibly due to a generally later influenza B virus exposure. Collectively, this meta-analysis indicates the highest benefit of squalene-IIV over aqueous IIV in young children and decreasing benefit with progressing age. This trend is similar for seasonal influenza (sub-)types and the 2009 pandemic strain, by both homologous and heterologous titration. The impact of pre-seasonal immunity on vaccine effectiveness, and its implications for age-specific vaccination recommendations, are discussed. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Beyer, Walter E. P.; Reperant, Leslie A.; Osterhaus, Albert D. M. E.] Artemis One Hlth, Yalelaan 1, NL-3854 CL Utrecht, Netherlands.
   [Beyer, Walter E. P.] Erasmus MC, Dept Virosci, Rotterdam, Netherlands.
   [Palache, Abraham M.] FluPal Consultancy, Amstelveen, Netherlands.
   [Boulfich, Mimoun] Univ Amsterdam, Amsterdam, Netherlands.
   [Osterhaus, Albert D. M. E.] Univ Vet Med, Hannover, Germany.
RP Osterhaus, ADME (reprint author), Artemis One Hlth, Yalelaan 1, NL-3854 CL Utrecht, Netherlands.
EM Albert.Osterhaus@tiho-hannover.de
OI Beyer, Walter/0000-0001-7075-421X
FU Innovative Medicines Initiative Joint Undertaking (Belgium) from the
   European Union's Seventh Framework Programme (FP/2007-2013) [115672]
FX The FLUCOP project is supported by the Innovative Medicines Initiative
   Joint Undertaking (Belgium) under grant agreement 115672, resources of
   which are composed of financial contribution from the European Union's
   Seventh Framework Programme (FP/2007-2013) and EFPIA companies in kind
   contribution. Parts of this work were presented at the 2018 FLUCOP
   meeting, Ghent, Belgium, April 18 to 20, 2018. FluPal Consultancy B.V.
   provides consulting services to public- and private organisations,
   including Mylan N.V. We thank Jos Nauta, Amsterdam, The Netherlands, for
   the calculation of bootstrap confidence intervals, Laura Taskopru
   Palomino, Amsterdam, The Netherlands, for her contribution to improve
   the search algorithm and to analyse the dose-response relationship of
   squalene, and Dr. David Coyle, Dublin, Ireland, for his support during
   the literature search.
CR Ambrose CS, 2011, INFLUENZA OTHER RESP, V5, P67, DOI 10.1111/j.1750-2659.2010.00183.x
   Beyer WEP, 2017, VACCINE, V35, P4167, DOI 10.1016/j.vaccine.2017.06.038
   Beyer WEP, 2011, VACCINE, V29, P5785, DOI 10.1016/j.vaccine.2011.05.040
   Bodewes R, 2011, CLIN VACCINE IMMUNOL, V18, P469, DOI 10.1128/CVI.00396-10
   Chemick MR, 2008, BOOTSTRAP METHODS GU
   Coudeville L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-18
   De Donato S, 1999, VACCINE, V17, P3094, DOI 10.1016/S0264-410X(99)00138-3
   Domnich A, 2017, VACCINE, V35, P513, DOI 10.1016/j.vaccine.2016.12.011
   Feldstein LR, 2016, VACCINE, V34, P3796, DOI 10.1016/j.vaccine.2016.05.067
   Fukushima W, 2017, VACCINE, V35, P4796, DOI 10.1016/j.vaccine.2017.07.003
   Higgins DA, 1996, VACCINE, V14, P478, DOI 10.1016/0264-410X(95)00240-2
   Hopping AM, 2016, VACCINE, V34, P540, DOI 10.1016/j.vaccine.2015.11.058
   McElhaney JE, 2013, LANCET INFECT DIS, V13, P485, DOI 10.1016/S1473-3099(13)70046-X
   Minutello M, 1999, VACCINE, P1799
   Montana M, 2010, THERAPIE, V65, P533, DOI 10.2515/therapie/2010069
   O'Hagan DT, 2012, VACCINE, V30, P4341, DOI 10.1016/j.vaccine.2011.09.061
   O'Hagan DT, 2013, EXPERT REV VACCINES, V12, P13, DOI [10.1586/erv.12.140, 10.1586/ERV.12.140]
   Pellegrini M, 2009, VACCINE, V27, P6959, DOI 10.1016/j.vaccine.2009.08.101
   Rizzo C, 2018, 1161342 DRIVE
   Sauerbrei A, 2014, EUROSURVEILLANCE, V19, P18, DOI 10.2807/1560-7917.ES2014.19.5.20687
   Song JY, 2013, J MED VIROL, V85, P1591, DOI 10.1002/jmv.23630
   Sutton AJ, 2000, METHODS METAANALYSIS, P58
   Van Buynder PG, 2013, VACCINE, V31, P6122, DOI 10.1016/j.vaccine.2013.07.059
   van de Sandt CE, 2012, VIRUSES-BASEL, V4, P1438, DOI 10.3390/v4091438
   Vesikari T, 2011, NEW ENGL J MED, V365, P1406, DOI 10.1056/NEJMoa1010331
   Zedda L, 2015, PEDIATR INFECT DIS J, V34, P73, DOI 10.1097/INF.0000000000000465
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1614
EP 1622
DI 10.1016/j.vaccine.2019.12.037
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900008
PM 31879122
DA 2020-05-12
ER

PT J
AU Morse-Brady, J
   Hart, AM
AF Morse-Brady, Jesse
   Hart, Ann Marie
TI Prevalence and types of vaccination errors from 2009 to 2018: A
   systematic review of the medical literature
SO VACCINE
LA English
DT Review
DE Vaccination error; Error prevalence; Error type; Vaccine safety
ID EVENT REPORTING SYSTEM; POST-LICENSURE SURVEILLANCE; ADVERSE EVENTS;
   UNITED-STATES; ADMINISTRATION ERRORS; PRIMARY-CARE; VAERS; SAFETY;
   HEALTH; CULTURE
AB Introduction: Vaccination practices and the programmatic factors that influence them are essential for public health. Several barriers impact vaccination efforts, including vaccination errors, which pose the risk of reduced population-wide vaccination efficacy and individual adverse drug events. This study aimed to define the prevalence of vaccination errors documented in English language medical literature between 2009 and 2018 and to identify the common types of errors that occurred during this period.
   Methods: This systematic review followed the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines. The study protocol was registered with the International Prospective Register of Systematic Reviews prior to research activities. The Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, Google Scholar, ProQuest Central, PubMed, Scopus, and Web of Science were searched using predetermined search terms. Included data were from primary studies or retrospective analyses that assessed the prevalence and/or type of vaccination errors and that were peer-reviewed, conducted between 2009 and 2018, and published in English. Data were extracted using the Cochrane Data Extraction and Assessment Template and assessed using the Appraisal tool for Cross-Sectional Studies. Pooled vaccination error prevalence was then calculated.
   Results: Of the 1310 independent records that were identified and screened, 17 studies from five countries met all inclusion criteria. Pooled vaccination error prevalence was calculated to be 1.15 per 10,000 vaccine doses (range, 0.005-141.69 per 10,000 doses). The most commonly reported vaccination errors were "wrong vaccine administered" and "off-schedule administration."
   Conclusions: International rates of vaccination error reporting remain low, with few reports of significant adverse reactions. Vaccination programs should consider the impact of vaccination errors on individual and population health, particularly focusing on the impact of "wrong vaccine" administration. Continued monitoring and promotion of error reporting will enable further understanding of this topic. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Morse-Brady, Jesse; Hart, Ann Marie] Univ Wyoming, Fay W Whitney Sch Nursing, Dept 3065,1000 E Univ Ave, Laramie, WY 82071 USA.
RP Morse-Brady, J (reprint author), Univ Wyoming, Fay W Whitney Sch Nursing, Dept 3065,1000 E Univ Ave, Laramie, WY 82071 USA.
EM jessebrady@alum.bu.edu
CR Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089
   [Anonymous], 2018, PROSPERO INT PROSPEC
   Arana JE, 2018, VACCINE, V36, P1781, DOI 10.1016/j.vaccine.2018.02.034
   Bell EA, 2014, INFECT DIS CHILD
   Braga PC, J NURSING UFPE, V11, P4126
   Bundy DG, 2009, VACCINE, V27, P3890, DOI 10.1016/j.vaccine.2009.04.005
   Chiu P-J, 2010, EPIDEMIOL B, V26, P268
   Downes MJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011458
   Ehreth J, 2003, VACCINE, V21, P596, DOI 10.1016/S0264-410X(02)00623-0
   Evans HP, 2016, HUM VACC IMMUNOTHER, V12, P1280, DOI 10.1080/21645515.2015.1137404
   Green S, 2011, COCHRANE HDB SYSTEMA
   Haas-Gehres A, 2014, J AM PHARM ASSOC, V54, P415, DOI 10.1331/JAPhA.2014.13094
   Haber P, 2016, VACCINE, V34, P6330, DOI 10.1016/j.vaccine.2016.10.052
   Haber P, 2016, VACCINE, V34, P2507, DOI 10.1016/j.vaccine.2016.03.048
   Haber P, 2015, VACCINE, V33, P1987, DOI 10.1016/j.vaccine.2015.01.080
   Harris T, 2016, Can Commun Dis Rep, V42, P181
   Hibbs BF, 2015, VACCINE, V33, P3171, DOI 10.1016/j.vaccine.2015.05.006
   Immunization Action Coalition, 2018, VACC TIM
   Keers RN, 2013, ANN PHARMACOTHER, V47, P237, DOI 10.1345/aph.1R147
   Kellogg KC, 2017, HEALTH CARE MANAGE R, V42, P292, DOI 10.1097/HMR.0000000000000122
   Khatri N, 2009, HEALTH CARE MANAGE R, V34, P312, DOI 10.1097/HMR.0b013e3181a3b709
   Kohn LT, 2000, ERR IS HUMAN BUILDIN
   Lang Sarah, 2014, Qual Prim Care, V22, P139
   Lapkin S, 2016, J NURS MANAGE, V24, P845, DOI 10.1111/jonm.12390
   Lo NC, 2017, JAMA PEDIATR, V171, P887, DOI 10.1001/jamapediatrics.2017.1695
   Mills E, 2005, J CLIN EPIDEMIOL, V58, P1081, DOI 10.1016/j.jclinepi.2005.09.002
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Moher D, 2015, SYST REV-LONDON, V4, DOI 10.1186/2046-4053-4-1
   Moro PL, 2015, VACCINE, V33, P6684, DOI 10.1016/j.vaccine.2015.10.084
   Moro PL, 2013, VACCINE, V31, P4984, DOI 10.1016/j.vaccine.2013.08.001
   Myers TR, 2017, VACCINE, V35, P1758, DOI 10.1016/j.vaccine.2017.02.030
   Office of Disease Prevention and Health Promotion, 2018, OV ADV DRUG EV
   Paparella SF, 2015, J EMERG NURS, V41, P428, DOI 10.1016/j.jen.2015.05.010
   Plotkin S, 2014, P NATL ACAD SCI USA, V111, P12283, DOI 10.1073/pnas.1400472111
   Rees P, 2015, VACCINE, V33, P3873, DOI 10.1016/j.vaccine.2015.06.068
   Rodgers L, 2018, J PEDIATR-US, V193, P164, DOI 10.1016/j.jpeds.2017.09.057
   Rogers J, 2016, AM J HEALTH-SYST PH, V73, pS74, DOI 10.2146/ajhp150311
   Shamseer L, 2015, BMJ-BRIT MED J, V349, DOI [10.1136/bmj.i4086, 10.1136/bmj.g7647]
   Suragh TA, 2018, BRIT J CLIN PHARMACO, V84, P2928, DOI 10.1111/bcp.13736
   Tozzi AE, 2013, VACCINE, V31, P5041, DOI 10.1016/j.vaccine.2013.08.087
   World Health Organization, 2019, GLOB VACC SAF ADV EV
   World Health Organization, 2019, WHO REC ROUT IMM SUM
   World Health Organization, 2018, ASS REP GLOB VACC AC
   Yih WK, 2012, AM J EPIDEMIOL, V175, P1120, DOI 10.1093/aje/kws197
NR 44
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1623
EP 1629
DI 10.1016/j.vaccine.2019.11.078
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900009
PM 31862198
DA 2020-05-12
ER

PT J
AU Gorain, C
   Singh, A
   Bhattacharyya, S
   Kundu, A
   Lahiri, A
   Gupta, S
   Mallick, AI
AF Gorain, Chandan
   Singh, Ankita
   Bhattacharyya, Sudipta
   Kundu, Anirban
   Lahiri, Aritraa
   Gupta, Subhadeep
   Mallick, Amirul, I
TI Mucosal delivery of live Lactococcus lactis expressing functionally
   active JlpA antigen induces potent local immune response and prevent
   enteric colonization of Campylobacter jejuni in chickens
SO VACCINE
LA English
DT Article
DE Campylobacter jejuni; Lactococcus lactis; JlpA; Mucosal immune response;
   Enteric colonization
ID CONTROLLED GENE-EXPRESSION; HETEROLOGOUS PROTEIN; CECAL COLONIZATION;
   IDENTIFICATION; PROTECTION; SECRETION; VACCINES; PERSPECTIVES;
   IMMUNIZATION; ACTIVATION
AB Successful colonization of the mucosal epithelial cells is the key early step for Campylobacter jejuni (C. jejuni) pathogenesis in humans. A set of Surface Exposed Colonization Proteins (SECPs) are known to take leading role in bacterial adhesion and subsequent host pathogenesis. Among the major SECPs, the constitutively expressed C. jejuni surface lipoprotein Jejuni lipoprotein A (JlpA), interacts with intestinal heat shock protein 90 alpha (Hsp90 alpha) and contributes in disease progression by triggering pro-inflammatory responses via activation of NF-kappa B and p38 MAP kinase pathways. In addition to its ability to express on the surface, high sequence conservation of JlpA protein among different Campylobacter spp make it a suitable vaccine target against C. jejuni. Given that chickens are the primary source for C. jejuni infection in humans and persistent cecal colonization significantly contribute in pathogen transmission, we explicitly used chickens as a model to test the immune-protective efficacy of JlpA protein. Taking into account that gastro-intestinal tract is the major site for C. jejuni colonization, we chose to use mucosal (intragastric) route as mode for JlpA antigen delivery. To deliver JlpA via mucosal route, we engineered a food grade Lactic acid producing bacteria, Lactococcus lactis (L. lactis) to express functionally active JlpA protein in the surface. Further, we demonstrated its ability to substantially improve the antigen specific local immune responses in the intestine along with significant immune-protection against enteric colonization of C. jejuni in chickens. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gorain, Chandan; Singh, Ankita; Bhattacharyya, Sudipta; Kundu, Anirban; Lahiri, Aritraa; Gupta, Subhadeep; Mallick, Amirul, I] Indian Inst Sci Educ & Res Kolkata, Dept Biol Sci, Nadia 741246, W Bengal, India.
RP Mallick, AI (reprint author), Indian Inst Sci Educ & Res Kolkata, Dept Biol Sci, Nadia 741246, W Bengal, India.
EM amallick@iiserkol.ac.in
FU Department of Biotechnology, Ministry of Science & Technology, Govt of
   India [BT/PR21437/ADV/90/248/2016]
FX We thank Prof. Luis G Bermudez-Humaran of French National Institute for
   Agricultural Research, Paris, France, for providing pNZ8048 derived
   plasmid backbone and his valuable suggestion to establish L. lactis in
   our lab. We acknowledge Dr. Peter Le, Sunnybrook Research Institute,
   University of Toronto for his help in plasmid construction and Dr. Asish
   Kumar Mukhopadhyay, Scientist F, NICED (ICMR), Kolkata, India for
   providing us human clinical isolate of C. jejuni (BCH71). We acknowledge
   Mr. Avinash Sharma, a former MS student in our lab, for cloning of JlpA
   gene in E. coli. We would like to thank DST-FIST Transmission Electron
   Microscope (TEM) Facility and Central Imaging Facility of IISER Kolkata.
   This work was supported by a grant from Department of Biotechnology,
   Ministry of Science & Technology, Govt of India (Grant No.
   BT/PR21437/ADV/90/248/2016).
CR Annamalai T, 2013, POULTRY SCI, V92, P2201, DOI 10.3382/ps.2012-03004
   Buckley AM, 2010, VACCINE, V28, P1094, DOI 10.1016/j.vaccine.2009.10.018
   CHEN WP, 1993, NUCLEIC ACIDS RES, V21, P2260, DOI 10.1093/nar/21.9.2260
   Connell S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040409
   Cortes-Perez NG, 2005, J DRUG TARGET, V13, P89, DOI 10.1080/10611860400024219
   Cortes-Perez NG, 2003, FEMS MICROBIOL LETT, V229, P37, DOI 10.1016/S0378-1097(03)00778-X
   Davis Lindsay, 2008, Curr Protoc Microbiol, VChapter 8, DOI [10.1002/9780471729259.mc08a02s10, 10.1002/9780471729259.mc08a01s10]
   Davitt CJH, 2015, ADV DRUG DELIVER REV, V91, P52, DOI 10.1016/j.addr.2015.03.007
   De Nardo D, 2009, J IMMUNOL, V183, P8110, DOI 10.4049/jimmunol.0901031
   Flanagan RC, 2009, INFECT IMMUN, V77, P2399, DOI 10.1128/IAI.01266-08
   Forrest Heather L., 2010, Animal Health Research Reviews, V11, P3, DOI 10.1017/S1466252310000071
   Gilbreath JJ, 2011, MICROBIOL MOL BIOL R, V75, P84, DOI 10.1128/MMBR.00035-10
   Grangette C, 2002, VACCINE, V20, P3304, DOI 10.1016/S0264-410X(02)00301-8
   Hanif H, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-574
   HOLO H, 1989, APPL ENVIRON MICROB, V55, P3119, DOI 10.1128/AEM.55.12.3119-3123.1989
   Hu L, 1999, INFECT IMMUN, V67, P4171, DOI 10.1128/IAI.67.8.4171-4182.1999
   Humphrey S, 2014, MBIO, V5, DOI 10.1128/mBio.01364-14
   Janssen R, 2008, CLIN MICROBIOL REV, V21, P505, DOI 10.1128/CMR.00055-07
   Jeon B, 2010, MICROB BIOTECHNOL, V3, P242, DOI 10.1111/j.1751-7915.2009.00118.x
   Jin SM, 2003, CELL MICROBIOL, V5, P165, DOI 10.1046/j.1462-5822.2003.00265.x
   Jin SM, 2001, MOL MICROBIOL, V39, P1225, DOI 10.1046/j.1365-2958.2001.02294.x
   Kawai F, 2012, J STRUCT BIOL, V177, P583, DOI 10.1016/j.jsb.2012.01.001
   Konkel ME, 2005, MOL MICROBIOL, V57, P1022, DOI 10.1111/j.1365-2958.2005.04744.x
   Konkel ME, 2010, J BACTERIOL, V192, P68, DOI 10.1128/JB.00969-09
   Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2
   Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X
   Kumar A, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00405
   Lahiri A, 2019, MOL IMMUNOL, V114, P497, DOI 10.1016/j.molimm.2019.08.015
   Lakdawala SS, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002443
   Larson CL, 2013, EMERG MICROBES INFEC, V2, DOI 10.1038/emi.2013.65
   Lavelle Ed C, 2006, Expert Opin Drug Deliv, V3, P747, DOI 10.1517/17425247.3.6.747
   Layton SL, 2011, CLIN VACCINE IMMUNOL, V18, P449, DOI 10.1128/CVI.00379-10
   Le Loir Y, 2001, APPL ENVIRON MICROB, V67, P4119, DOI 10.1128/AEM.67.9.4119-4127.2001
   Lin TW, 2007, J VIROL, V81, P8730, DOI 10.1128/JVI.00332-07
   Liu J, 2016, LANCET, V388, P1291, DOI 10.1016/S0140-6736(16)31529-X
   Mallick AI, 2007, VACCINE, V25, P7873, DOI 10.1016/j.vaccine.2007.09.008
   McCluskie MJ, 2000, SPRINGER SEMIN IMMUN, V22, P125, DOI 10.1007/s002810000014
   Medina Marcela, 2010, Bioeng Bugs, V1, P313, DOI 10.4161/bbug.1.5.12086
   Meric G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092798
   Mestecky J, 2007, J IMMUNOL, V179, P5633, DOI 10.4049/jimmunol.179.9.5633
   Meunier M, 2016, J IMMUNOL RES, DOI 10.1155/2016/5715790
   Mierau I, 2005, MICROB CELL FACT, V4, DOI 10.1186/1475-2859-4-15
   Mierau I, 2005, MICROB CELL FACT, V4, DOI 10.1186/1475-2859-4-16
   Mokomane M, 2018, THER ADV INFECT DIS, V5, P29, DOI 10.1177/2049936117744429
   Monteville MR, 2003, MICROBIOL-SGM, V149, P153, DOI 10.1099/mic.0.25820-0
   Mukherjee P, 2014, ANTIMICROB AGENTS CH, V58, P4248, DOI 10.1128/AAC.02931-14
   Nothaft H, 2016, SCI REP-UK, V6, DOI 10.1038/srep26511
   Novotny V, 2005, P ROY SOC B-BIOL SCI, V272, P1083, DOI 10.1098/rspb.2004.3023
   Pavot V, 2012, VACCINE, V30, P142, DOI 10.1016/j.vaccine.2011.11.003
   Peng XY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24879-x
   Pontes DS, 2011, PROTEIN EXPRES PURIF, V79, P165, DOI 10.1016/j.pep.2011.06.005
   Quigley BR, 2010, INFECT IMMUN, V78, P1294, DOI 10.1128/IAI.01037-09
   Ribeiro LA, 2002, APPL ENVIRON MICROB, V68, P910, DOI 10.1128/AEM.68.2.910-916.2002
   Sam WIC, 1999, J CLIN PATHOL, V52, P709, DOI 10.1136/jcp.52.9.709
   Shigemori S, 2015, MICROB CELL FACT, V14, DOI 10.1186/s12934-015-0378-2
   Shoaf-Sweeney KD, 2008, APPL ENVIRON MICROB, V74, P6867, DOI 10.1128/AEM.01097-08
   Singh A, 2019, MOL IMMUNOL, V111, P182, DOI 10.1016/j.molimm.2019.04.016
   Singh A, 2019, J MICROBIOL, V57, P298, DOI 10.1007/s12275-019-8165-0
   Spiller S, 2007, J BIOL CHEM, V282, P13190, DOI 10.1074/jbc.M610340200
   Stern NJ, 2006, J FOOD PROTECT, V69, P1034, DOI 10.4315/0362-028X-69.5.1034
   Theoret JR, 2012, CLIN VACCINE IMMUNOL, V19, P1426, DOI 10.1128/CVI.00151-12
   van Wely KHM, 2001, FEMS MICROBIOL REV, V25, P437, DOI 10.1016/S0168-6445(01)00062-6
   Vesa T, 2000, ALIMENT PHARM THERAP, V14, P823
   Watt KA, 2016, ECOL EVOL, V6, P56, DOI 10.1002/ece3.1858
   Wyszynska A, 2004, VACCINE, V22, P1379, DOI 10.1016/j.vaccine.2003.11.001
   Wyszynska A, 2015, APPL MICROBIOL BIOT, V99, P2967, DOI [10.1007/s00253-015-6498-0, 10.1007/s00253-015-6569-2]
   Yan YY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104652
   Yang HT, 2011, J IMMUNOL, V186, P1989, DOI 10.4049/jimmunol.1001003
   Yang WY, 2012, NAT GENET, V44, P725, DOI 10.1038/ng.2285
   Zeng X, 2010, J VACCINES VACCIN, P1
   Zeng XM, 2009, INFECT IMMUN, V77, P5437, DOI 10.1128/IAI.00666-09
   Zhang XW, 2016, J MICROBIOL IMMUNOL, V49, P851, DOI 10.1016/j.jmii.2014.11.009
   Zheng J, 2008, INFECT IMMUN, V76, P4498, DOI 10.1128/IAI.01317-07
   Ziprin RL, 1999, AVIAN DIS, V43, P586, DOI 10.2307/1592660
NR 74
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1630
EP 1642
DI 10.1016/j.vaccine.2019.12.064
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900010
PM 31932136
DA 2020-05-12
ER

PT J
AU Posuwan, N
   Wanlapakorn, N
   Vongpunsawad, S
   Sintusek, P
   Leuridan, E
   Van Damme, P
   Poovorawan, Y
AF Posuwan, Nawarat
   Wanlapakorn, Nasamon
   Vongpunsawad, Sompong
   Sintusek, Palittiya
   Leuridan, Elke
   Van Damme, Pierre
   Poovorawan, Yong
TI Comparison of hepatitis B surface antibody levels induced by the
   pentavalent DTwP-HB-Hib versus the hexavalent DTaP-HB-Hib-IPV vaccine,
   administered to infants at 2, 4, 6, and 18 months of age, following
   monovalent hepatitis B vaccination at birth
SO VACCINE
LA English
DT Article
DE Hepatitis B; Vaccine; Pentavalent; Hexavalent; Immunogenicity
ID VIRUS-INFECTION; PERTUSSIS; IMMUNOGENICITY; IMMUNIZATION; PERSISTENCE;
   DIPHTHERIA; CHILDREN; TETANUS; SAFETY; IMPACT
AB Background: In Thailand, the hepatitis B (HB) vaccine is administered as a tetravalent vaccine (DTwP-HB) to all infants at 2, 4, and 6 months of age, following an initial vaccination with a monovalent HB vaccine at birth. As part of ongoing vaccine evaluation, we aimed to compare the hepatitis B immunogenicity profiles of children who had received either the pentavalent (DTwP-HB-Hib) or the hexavalent (DTaP-HB-Hib-IPV) vaccine.
   Methods: Two groups of infants, whose mothers previously received the tetanus-diphtheria-acellular pertussis vaccine (Tdap), were randomly vaccinated with either pentavalent or hexavalent vaccine at 2, 4, 6, and 18 months of age, following monovalent HB vaccine at birth. Blood samples were obtained at birth, one-month post-primary series immunization (mo 7), pre-booster (mo 18), one-month post-booster (mo 19), and six months post-booster (mo 24). The third group of infants, whose mothers did not receive Tdap, was vaccinated with DTwP-HB-Hib (ER pentavalent group). Levels of HBsAg, anti-HBc, and anti-HBs were evaluated by means of an automated Chemiluminescent Microparticle Immunoassay.
   Results: Anti-HBs levels of >= 10 mIU/ml were achieved in 99.2% (hexavalent group), 99.2% (pentavalent group), and 98.5% (ER pentavalent group) of infants, after four-dose immunization (at 0, 2, 4, 6 months of age). One month after the additional dose given at 18 months of age, anti-HBs levels of >= 10 were observed in 100% (hexavalent group), 99.2% (pentavalent group), and 93.8% (EPI pentavalent group) of infants. At 24 months of age, higher percentages of infants achieving anti-HBs levels >= 10 were found in the hexavalent group (98.3%) compared to the pentavalent group (86.5%).
   Conclusions: Both vaccines were effective in inducing anti-HBs levels of >= 10 mIU/ml, and therefore either can be used as a single formula booster at 18 months of age to simplify vaccine administration under the Expanded Program on Immunization in Thailand. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Posuwan, Nawarat; Wanlapakorn, Nasamon; Vongpunsawad, Sompong; Poovorawan, Yong] Chulalongkorn Univ, Fac Med, Ctr Excellence Clin Virol, Dept Pediat, Bangkok, Thailand.
   [Wanlapakorn, Nasamon] Chulalongkorn Univ, Div Acad Affairs, Fac Med, Bangkok, Thailand.
   [Sintusek, Palittiya] Chulalongkorn Univ, Fac Med, Dept Pediat, Div Gastroenterol & Hepatol, Bangkok, Thailand.
   [Sintusek, Palittiya] King Chulalongkorn Mem Hosp, Dept Pediat, Pediat Liver Dis & Immunol STAR Special Task Forc, Bangkok, Thailand.
   [Sintusek, Palittiya] Chulalongkorn Univ, Fac Med, Bangkok, Thailand.
   [Leuridan, Elke; Van Damme, Pierre] Univ Antwerp, Fac Med & Hlth Sci, Ctr Evaluat Vaccinat, Vaccine & Infect Dis Inst, Univ Pl 1, B-2610 Antwerp, Belgium.
   [Poovorawan, Yong] Royal Soc Thailand, Acad Sci, Bangkok 10300, Thailand.
RP Poovorawan, Y (reprint author), Chulalongkorn Univ, Fac Med, Ctr Excellence Clin Virol, Dept Pediat, Bangkok, Thailand.
EM Yong.P@chula.ac.th
OI Leuridan, Elke/0000-0001-7482-799X; Poovorawan, Yong/0000-0002-2337-6807
FU Health Systems Research Institute (HSRI) [HSRI 61-63];
   Ratchadaphiseksomphot Endowment Fund, Chulalongkorn
   UniversityChulalongkorn University [CUGR(S) 61-36-30-01]; Thrasher
   Research Fund [EWAT 12348]
FX We would like to thank the following institutions and organization for
   their funding and support: the Health Systems Research Institute (HSRI)
   under the HSRI 61-63 contract; Ratchadaphiseksomphot Endowment Fund,
   Chulalongkorn University 2561 (CUGR(S) 61-36-30-01); The Thrasher
   Research Fund award number EWAT 12348.
CR Chunsuttiwat S, 1997, VACCINE, V15, P769, DOI 10.1016/S0264-410X(96)00226-5
   Chunsuttiwat S, 2002, VACCINE, V21, P188, DOI 10.1016/S0264-410X(02)00461-9
   Jourdain G, 2018, NEW ENGL J MED, V378, P911, DOI 10.1056/NEJMoa1708131
   Kosalaraksa P, 2018, HUM VACC IMMUNOTHER, V14, P1257, DOI 10.1080/21645515.2018.1426418
   Kosalaraksa P, 2011, INT J INFECT DIS, V15, pE249, DOI 10.1016/j.ijid.2010.12.004
   Lalwani SK, 2017, HUM VACC IMMUNOTHER, V13, P120, DOI 10.1080/21645515.2016.1225639
   Maertens K, 2017, PEDIATR INFECT DIS J, V36, P1186, DOI 10.1097/INF.0000000000001601
   Merican I, 2000, J GASTROEN HEPATOL, V15, P1356, DOI 10.1046/j.1440-1746.2000.0150121356.x
   POOVORAWAN Y, 1989, JAMA-J AM MED ASSOC, V261, P3278, DOI 10.1001/jama.261.22.3278
   POOVORAWAN Y, 1990, VACCINE, V8, pS56, DOI 10.1016/0264-410X(90)90237-G
   Poovorawan Y, 1999, ASIAN PAC J ALLERGY, V17, P113
   Poovorawan Y, 2000, VACCINE, V19, P943, DOI 10.1016/S0264-410X(00)00216-4
   Poovorawan Y, 1994, VIRAL HEPATITIS LIVE, P526, DOI 10.1007/978-4-431-68255-4_137
   Poovorawan Y, 2008, VACCINE, V26, P1535, DOI 10.1016/j.vaccine.2008.01.028
   Poovorawan Y, 2009, J INFECT DIS, V200, P33, DOI 10.1086/599331
   Poovorawan Yong, 1997, Southeast Asian Journal of Tropical Medicine and Public Health, V28, P496
   Posuwan N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150499
   Quiambao Beatriz, 2012, Hum Vaccin Immunother, V8, P347, DOI 10.4161/hv.18630
   Tharmaphornpilas P, 2009, VACCINE, V27, P6110, DOI 10.1016/j.vaccine.2009.08.034
   Huu TN, 2015, SE ASIAN J TROP MED, V46, P753
   Wanlapakorn N, 2019, CLIN INFECT DIS, DOI [10.1093/cid/ri7778, DOI 10.1093/CID/RI7778]
   Wanlapakorn N, 2018, VACCINE, V36, P1453, DOI 10.1016/j.vaccine.2018.01.059
   *WHO, 2002, HEP B
   Zanetti AR, 2008, VACCINE, V26, P6266, DOI 10.1016/j.vaccine.2008.09.056
NR 24
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1643
EP 1651
DI 10.1016/j.vaccine.2019.12.065
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900011
PM 31948817
DA 2020-05-12
ER

PT J
AU Stinson, JA
   Palmer, CR
   Miller, DP
   Li, AB
   Lightner, K
   Jost, H
   Weldon, WC
   Oberste, MS
   Kluge, JA
   Kosuda, KM
AF Stinson, Jordan A.
   Palmer, Carter R.
   Miller, David P.
   Li, Adrian B.
   Lightner, Kandice
   Jost, Heather
   Weldon, William C.
   Oberste, M. Steven
   Kluge, Jonathan A.
   Kosuda, Kathryn M.
TI Thin silk fibroin films as a dried format for temperature stabilization
   of inactivated polio vaccine
SO VACCINE
LA English
DT Article
DE Silk; Fibroin; Stabilization; Vaccine; Poliovirus
ID WORLDWIDE; ANTIGENS; DELIVERY; RELEASE; ENZYMES
AB Current inactivated polio vaccine (IPV) products are sensitive to both freezing and elevated temperatures and therefore must be shipped and stored between 2 degrees C and 8 degrees C, a requirement that imposes financial and logistical challenges for global distribution. As such, there is a critical need for a robust, thermally stable IPV to support global polio eradication and post-eradication immunization needs. Here, we present the development of air-dried thin films for temperature stabilization of IPV using the biomaterial silk fibroin. Thin-film product compositions were optimized for physical properties as well as poliovirus Dantigen recovery and were tested under accelerated and real-time stability storage conditions. Silk fibroin IPV films maintained 70% D-antigen potency after storage for nearly three years at room temperature, and greater than 50% potency for IPV-2 and IPV-3 serotypes at 45 degrees C for one year. The immunogenicity of silk fibroin IPV films after 2-week storage at 45 degrees C was assessed in Wistar rats and the stressed films generated equivalent neutralizing antibody responses to commercial vaccine for IPV-1 and IPV-2. However, the absence of IPV-3 responses warrants further investigation into the specificity of ELISA for intact IPV-3 D-antigen. By demonstrating immunogenicity post-storage, we offer the air-dried silk film format as a means to increase IPV vaccine access through innovative delivery systems such as microneedles. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Stinson, Jordan A.; Palmer, Carter R.; Miller, David P.; Li, Adrian B.; Kluge, Jonathan A.; Kosuda, Kathryn M.] Vaxess Technol Inc, 790 Mem Dr,Suite 200, Cambridge, MA 02139 USA.
   [Lightner, Kandice] IHRC, 1HRC 2 Ravinia Dr,Suite 1200, Atlanta, GA 30346 USA.
   [Lightner, Kandice] CDC, Atlanta, GA 30333 USA.
   [Jost, Heather; Weldon, William C.; Oberste, M. Steven] Ctr Dis Control & Prevent CDC, Div Viral Dis, 1600 Clifton Rd NE,Mailstop H17-6, Atlanta, GA 30329 USA.
   [Palmer, Carter R.] Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA.
RP Kosuda, KM (reprint author), Vaxess Technol Inc, 790 Mem Dr,Suite 200, Cambridge, MA 02139 USA.
EM kathryn@vaxess.com
FU National Institute of Allergy and Infectious Diseases of the National
   Institutes of Health, United States [R43Al118107]
FX The research reported in this publication was supported in part by the
   National Institute of Allergy and Infectious Diseases of the National
   Institutes of Health, United States under Award Number R43Al118107. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health. The findings and conclusions in this report are those of the
   author(s) and do not necessarily represent the official position of the
   Centers for Disease Control and Prevention.
CR BEALE AJ, 1961, LANCET, V2, P1166
   Edens C, 2015, VACCINE, V33, P4683, DOI 10.1016/j.vaccine.2015.01.089
   Garon JR, 2015, LANCET, V386, P2375, DOI 10.1016/S0140-6736(15)00243-3
   Guziewicz NA, 2013, BIOMATERIALS, V34, P7766, DOI 10.1016/j.biomaterials.2013.06.039
   Kanra G, 1999, VACCINE, V18, P947, DOI 10.1016/S0264-410X(99)00331-X
   Kluge JA, 2016, P NATL ACAD SCI USA, V113, P5892, DOI 10.1073/pnas.1602493113
   Kluge JA, 2016, ACS BIOMATER SCI ENG, V2, P595, DOI 10.1021/acsbiomaterials.5b00556
   Kolluru C, 2019, DRUG DELIV TRANSL RE, V9, P192, DOI 10.1007/s13346-018-00608-9
   Kraan H, 2015, VACCINE, V33, P2030, DOI 10.1016/j.vaccine.2015.03.011
   Kraan H, 2014, PHARM RES-DORDR, V31, P2618, DOI 10.1007/s11095-014-1359-6
   Lawrence BD, 2008, BIOMACROMOLECULES, V9, P1214, DOI 10.1021/bm701235f
   LEBOUVIER GL, 1955, LANCET, V2, P1013
   Li AB, 2017, BIOMACROMOLECULES, V18, P2900, DOI 10.1021/acs.biomac.7b00857
   Li AB, 2015, J CONTROL RELEASE, V219, P416, DOI 10.1016/j.jconrel.2015.09.037
   Lu Q, 2010, MACROMOL BIOSCI, V10, P359, DOI 10.1002/mabi.200900388
   Lu Q, 2010, ACTA BIOMATER, V6, P1380, DOI 10.1016/j.actbio.2009.10.041
   Lu SZ, 2009, BIOMACROMOLECULES, V10, P1032, DOI 10.1021/bm800956n
   Morales M, 2016, MMWR-MORBID MORTAL W, V65, P470, DOI 10.15585/mmwr.mm6518a4
   Muller DA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13011-0
   Perrone GS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4385
   Qi W, 2018, J PHARM SCI-US, V107, P2070, DOI 10.1016/j.xphs.2018.04.019
   Rockwood DN, 2011, NAT PROTOC, V6, P1612, DOI 10.1038/nprot.2011.379
   Sawyer LA, 1997, BIOLOGICALS, V25, P299, DOI 10.1006/biol.1997.0100
   SINGER C, 1989, J BIOL STAND, V17, P137, DOI 10.1016/0092-1157(89)90004-8
   Stinson JA, 2017, ACS BIOMATER SCI ENG, V3, P360, DOI 10.1021/acsbiomaterials.6b00515
   Thurber AE, 2015, BIOMATERIALS, V71, P145, DOI 10.1016/j.biomaterials.2015.08.039
   Tzeng SY, 2016, J CONTROL RELEASE, V233, P101, DOI 10.1016/j.jconrel.2016.05.012
   Wan Y, 2018, J PHARM SCI-US, V107, P1540, DOI 10.1016/j.xphs.2018.01.027
   Weldon WC, 2016, METHODS MOL BIOL, V1387, P145, DOI 10.1007/978-1-4939-3292-4_8
   World Health Organization (WHO), 2018, GLOB WILD POL 2013 2
   Yucel T, 2014, BIOMATERIALS, V35, P8613, DOI 10.1016/j.biomaterials.2014.06.030
   Zhou CZ, 2001, PROTEINS, V44, P119, DOI 10.1002/prot.1078
   Zipursky S, 2014, VACCINE, V32, P1431, DOI 10.1016/j.vaccine.2014.01.038
NR 33
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1652
EP 1660
DI 10.1016/j.vaccine.2019.12.062
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900012
PM 31959422
DA 2020-05-12
ER

PT J
AU Hagedorn, BL
   Gauld, J
   Feasey, N
   Hu, H
AF Hagedorn, Brittany L.
   Gauld, Jillian
   Feasey, Nicholas
   Hu, Hao
TI Cost-effectiveness of using environmental surveillance to target the
   roll-out typhoid conjugate vaccine
SO VACCINE
LA English
DT Article
ID SALMONELLA-TYPHI; FEVER; BURDEN; INCOME; SWABS
C1 [Hagedorn, Brittany L.; Gauld, Jillian; Hu, Hao] Inst Dis Modeling, 3150 139th Ave SE, Bellevue, WA 98005 USA.
   [Feasey, Nicholas] Univ Liverpool Liverpool Sch Trop Med, Pembroke Pl, Liverpool L3 5QA, Merseyside, England.
RP Hagedorn, BL (reprint author), Inst Dis Modeling, 3150 139th Ave SE, Bellevue, WA 98005 USA.
EM bhagedorn@idmod.org
FU Bill and Melinda Gates through the Global Good Fund
FX This work was supported by Bill and Melinda Gates through the Global
   Good Fund. The funders had no role in study design, data collection,
   data analysis, the decision to publish, or preparation of the
   manuscript.
CR Antillon M, 2017, VACCINE, V35, P3506, DOI 10.1016/j.vaccine.2017.05.001
   Antillon M, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005376
   Asghar H, 2014, J INFECT DIS, V210, pS294, DOI 10.1093/infdis/jiu384
   Australasian The, 2018, CLIN GUID
   Berkley S., 2018, VACC ALL M STRAT ADV
   Bershteyn A, 2018, PATHOG DIS, V76, DOI 10.1093/femspd/fty059
   Bilcke J, 2019, LANCET ID, V3099, P1
   Callaghan P, 1968, J HYG LOND
   Cohen J, 2018, SCIENCE, V361, P214, DOI 10.1126/science.361.6399.214
   Crump JA, 2004, B WORLD HEALTH ORGAN, V82, P346
   Feasey NA, 2015, PLOS NEGL TROP DIS, V9
   Gandhi G, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-67
   Gauld JS, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006759
   Jin C, 2017, LANCET, V390, P2472, DOI 10.1016/S0140-6736(17)32149-9
   Karkey A, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004346
   Kroiss SJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208336
   Lo NC, 2018, J INFECT DIS
   Maheswaran H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192991
   Manor Y, 2014, EUROSURVEILLANCE, V19, P31, DOI 10.2807/1560-7917.ES2014.19.7.20708
   Marks F, 2017, LANCET GLOB HLTH
   Medecins Sans Frontieres, 2018, CLIN GUID DIAGN
   Mogasale V, 2014, LANCET GLOB HEALTH, V2, pE570, DOI 10.1016/S2214-109X(14)70301-8
   Murphy JL, 2017, APPL ENV MICROBIOL
   Nair S, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.00167-19
   Qamar FN, 2018, J INFECT DIS
   Saha S, 2019, AM J TROP MED HYG, V100, P43, DOI 10.4269/ajtmh.18-0428
   Sanders MR, 2016, BL HBK DEV PSYCHOL, P100
   SEARS SD, 1984, J INFECT DIS, V149, P640, DOI 10.1093/infdis/149.4.640
   SEARS SD, 1986, APPL ENVIRON MICROB, V51, P425, DOI 10.1128/AEM.51.2.425-426.1986
   Stanaway JD, 2019, LANCET INFECT DIS, V19, P369, DOI 10.1016/S1473-3099(18)30685-6
   Umer MF, 2019, INT J ENV RES PUBLIC, V16, P1365
   World Health Organization, 2018, TYPH VACC WHO POS PA
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1661
EP 1670
DI 10.1016/j.vaccine.2019.12.061
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900013
PM 31917040
OA Other Gold
DA 2020-05-12
ER

PT J
AU Yildirim, M
   Keskinocak, P
   Pelton, S
   Pickering, L
   Yildirim, I
AF Yildirim, Melike
   Keskinocak, Pinar
   Pelton, Stephen
   Pickering, Larry
   Yildirim, Inci
TI Who is at risk of 13-valent conjugated pneumococcal vaccine failure?
SO VACCINE
LA English
DT Article
DE Vaccine failure; 13-valent conjugated pneumococcal vaccine; Children
ID STREPTOCOCCUS-PNEUMONIAE; HAEMOPHILUS-INFLUENZAE; MASSACHUSETTS
   CHILDREN; ADVISORY-COMMITTEE; DISEASE; ERA; RECOMMENDATIONS;
   COLONIZATION; INFECTIONS
AB Background: Despite high vaccine coverage rates in children and efficacy of pneumococcal conjugate vaccines, invasive pneumococcal disease (IPD) episodes due to serotypes included in the vaccine following completion of the recommended course of immunisation (i.e. vaccine failure) have been reported.
   Methods: We used data gathered from a population-based enhanced passive surveillance for IPD in children under 18 years of age in Massachusetts and an ensemble model composed of three machine-learning algorithms to predict probability of 13-valent pneumococcal conjugated vaccine (PCV13) failure and to evaluate potential associated features including age, underlying comorbidity, clinical presentation, and vaccine schedule. Vaccine failure was defined as diagnosis of IPD due to vaccine serotype (VST), in a child who received age recommended doses recommended by Advisory Committee of Immunization Practices.
   Results: During the 7-year study period, between April 01, 2010 and March 31, 2017, we identified 296 IPD cases. There were 107 (36%) IPD cases caused by VST, mostly serotype 19A (49, 17%), 7F (21, 7%), and 3 (18, 6%). Thirty-seven (34%) were in children who were completely vaccinated representing 13% of all IPD cases. Vaccine failure was more likely among children older than 60 months (predicted probability 0.40, observed prevalence 0.37, model prediction accuracy 79%), children presenting with pneumonia (predicted probability 0.27, observed prevalence 0.31, model accuracy 77%), and children with underlying comorbidity (predicted probability 0.24, observed prevalence 0.23, model accuracy 96%). Vaccine failure probability for those >60 months of age and had an underlying risk factor was 45% (observed prevalence 0.33, model accuracy 82%). The likelihood of vaccine failure was lowest among children who had completed 3 primary doses plus one booster dose PCV13 (predicted probability 0.14, observed prevalence 0.14, model prediction accuracy 100%).
   Conclusion: PCV13 vaccine failure is more frequent among older children with underlying comorbidity, and among those who present with pneumococcal pneumonia. Our study provides a preliminary framework to predict the patterns of vaccine failures and may contribute to decision-making processes to optimize PCV immunization schedules. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yildirim, Melike; Keskinocak, Pinar] H Milton Stewart Sch Ind & Syst Engn, Atlanta, GA USA.
   [Keskinocak, Pinar] Georgia Inst Technol, Coll Engn, Atlanta, GA 30332 USA.
   [Pelton, Stephen] Boston Med Ctr, Dept Pediat, Boston, MA USA.
   [Pelton, Stephen] Boston Univ, Dept Epidemiol, Sch Publ Hlth, Boston, MA USA.
   [Pickering, Larry; Yildirim, Inci] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA.
   [Yildirim, Inci] Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA USA.
RP Yildirim, I (reprint author), Emory Univ, Div Pediat Infect Dis, Sch Med, 2015 Uppergate Dr NE Rm 548, Atlanta, GA 30322 USA.; Yildirim, I (reprint author), Emory Univ, Childrens Healthcare Atlanta, Sch Publ Hlth, Dept Epidemiol,Morehouse Sch Med, 2015 Uppergate Dr NE Rm 548, Atlanta, GA 30322 USA.
EM inci.yildirim@emory.edu
CR American Academy of Pediatrics Committee on Infectious Diseases, 2018, RED BOOK REP COMM IN
   Andrews NJ, 2014, LANCET INFECT DIS, V14, P839, DOI 10.1016/S1473-3099(14)70822-9
   Antachopoulos C, 2014, PEDIATR INFECT DIS J, V33, P81, DOI 10.1097/INF.0000000000000041
   Bennett NM, 2013, MMWR-MORBID MORTAL W, V62, P521
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Centers for Disease Control and Prevention (CDC), 2010, MMWR Recomm Rep, V59, P1
   Clinical and Laboratory standard institute (CLSI), 2017, M100S17 CLSI
   Dong YR, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-222
   Efron B., 1993, INTRO BOOTSTRAP
   Friedman JH, 2001, ANN STAT, V29, P1189, DOI 10.1214/aos/1013203451
   Geno KA, 2017, J CLIN MICROBIOL, V55, P1416, DOI 10.1128/JCM.00054-17
   Goldblatt D, 2018, LANCET INFECT DIS, V18, P171, DOI 10.1016/S1473-3099(17)30654-0
   Heath PT, 2000, CLIN INFECT DIS, V31, P973, DOI 10.1086/318132
   Hjuler T, 2008, PEDIATRICS, V122, pE26, DOI 10.1542/peds.2007-1510
   Jain A, 1997, IEEE T PATTERN ANAL, V19, P153, DOI 10.1109/34.574797
   Kaplan SL, 2013, PEDIATR INFECT DIS J, V32, P203, DOI 10.1097/INF.0b013e318275614b
   Ladhani SN, 2013, EMERG INFECT DIS, V19, P61, DOI 10.3201/eid1901.120741
   Lee HY, 2018, J MICROBIOL IMMUNOL, V51, P199, DOI 10.1016/j.jmii.2017.08.022
   Loughrey J, 2004, RES DEV INTELLIGENT
   Martinelli D, 2014, HUM VACC IMMUNOTHER, V10, P33, DOI 10.4161/hv.26650
   McAllister DA, 2019, LANCET GLOB HEALTH, V7, pE47, DOI 10.1016/S2214-109X(18)30408-X
   Moore MR, 2008, J INFECT DIS, V197, P1016, DOI 10.1086/528996
   Moraga-Llop F, 2016, PEDIATR INFECT DIS J, V35, P460, DOI 10.1097/INF.0000000000001041
   Oligbu G, 2016, VACCINE, V34, P6126, DOI 10.1016/j.vaccine.2016.10.050
   Park SY, 2010, J PEDIATR-US, V156, P478, DOI 10.1016/j.jpeds.2009.10.008
   Pelton SI, 2010, VACCINE, V28, P1575, DOI 10.1016/j.vaccine.2009.11.053
   Pilishvili T, 2010, J INFECT DIS, V201, P32, DOI 10.1086/648593
   Roopnarine JL, 2018, HANDBOOK OF INTERNATIONAL PERSPECTIVES ON EARLY CHILDHOOD EDUCATION, P13
   Sa-Leado R, 2008, J CLIN MICROBIOL, V46, P225, DOI 10.1128/JCM.01551-07
   Statens Serum Institut, 2013, STREPT PNEUM TXB DIA
   Team RC, 2017, R LANG ENV STAT COMP
   Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
   Wilson EB, 1927, J AM STAT ASSOC, V22, P209, DOI 10.2307/2276774
   Yildirim I, 2017, VACCINE, V35, P4002, DOI 10.1016/j.vaccine.2017.05.077
   Yildirim I, 2015, INFECT DIS CLIN N AM, V29, P679, DOI 10.1016/j.idc.2015.07.009
   Yildirim I, 2015, PEDIATRICS, V135, P495, DOI 10.1542/peds.2014-2426
   Yildirim I, 2012, PEDIATR INFECT DIS J, V31, P1016, DOI 10.1097/INF.0b013e3182615615
   Yildirim I, 2010, VACCINE, V29, P283, DOI 10.1016/j.vaccine.2010.10.032
NR 39
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1671
EP 1677
DI 10.1016/j.vaccine.2019.12.060
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900014
PM 31974018
DA 2020-05-12
ER

PT J
AU Van Der Meeren, O
   Jongert, E
   Seaton, KE
   Koutsoukos, M
   Aerssens, A
   Brackett, C
   Debois, M
   Janssens, M
   Leroux-Roels, G
   Vela, DM
   Sawant, S
   Yates, NL
   Tomaras, GD
   Leroux-Roels, I
   Roman, F
AF Van Der Meeren, Olivier
   Jongert, Erik
   Seaton, Kelly E.
   Koutsoukos, Marguerite
   Aerssens, Annelies
   Brackett, Caroline
   Debois, Muriel
   Janssens, Michel
   Leroux-Roels, Geert
   Vela, Doris Mesia
   Sawant, Sheetal
   Yates, Nicole L.
   Tomaras, Georgia D.
   Leroux-Roels, Isabel
   Roman, Francois
TI Persistence of vaccine-elicited immune response up to 14 years post-HIV
   gp120-NefTat/AS01(B) vaccination
SO VACCINE
LA English
DT Article
ID RHESUS-MONKEYS; EFFICACY; TRIAL; ANTIBODIES; INFECTION; BINDING;
   AIDSVAX; VIRUS; ALVAC
AB Background: Vaccines eliciting protective and persistent immune responses against multiple human immunodeficiency virus type 1 (HIV-1) clades are needed. This study evaluated the persistence of immune responses induced by an investigational, AS01-adjuvanted HIV-1 vaccine as long as 14 years after vaccination.
   Methods: This phase I, open-label, descriptive, mono-centric, extension study with a single group (NCT03368053) was conducted in adults who received >= 3 doses of the Glade B gp120-NetTat/AS01(B) vaccine candidate 14 years earlier in a previous clinical trial (NCT00434512). Binding responses of serum antibodies targeting a panel of envelope glycoproteins, including gp120, gp140 and V1V2-scaffold antigens and representative of the antigenic diversity of HIV-1, were measured by binding antibody multiplex assay (BAMA). The gp120-specific CD4+/CD8+ T-cell responses were assessed by intracellular cytokine staining assay.
   Results: At Year 14, positive IgG binding antibody responses were detected in 15 out of the 16 antigens from the BAMA V1V2 breadth panel, with positive response rates ranging from 7.1% to 60.7%. The highest response rates were observed for clade B strain V1V2 antigens, with some level of binding antibodies against Glade C strains. Anti-VIV2 IgG3 response magnitude breadth, which correlated with decreased risk of infection in a previous efficacy trial, was of limited amplitude. Response rates to the antigens from the gp120 and gp140 breadth panels ranged from 7.7% to 94.1% and from 15.4% to 96.2% at Year 14, respectively. Following stimulation with gpi 20 peptide pool, highly polyfunctional gp120-specific CD4+ T-cells persisted up to Year 14, with high frequencies of CD4OL tumor necrosis factor alpha (TNF-alpha),CD40L interleukin-2 (IL-2), CD40LTNF-alpha IL-2 and CD4OL interferon gamma (IFN-gamma)TNF-alpha, IL-2 CD4+ T-cells, but no CD8+T-cells detected.
   Conclusions: Persistent antibodies binding to HIV-1 envelope glycoproteins, including the V1V2-scaffold, and gpl 20-specific cellular immunity were observed in volunteers vaccinated 14 years earlier with the gp120-NefTat/AS01(B) vaccine candidate. (C) 2020 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.
C1 [Van Der Meeren, Olivier; Jongert, Erik; Koutsoukos, Marguerite; Debois, Muriel; Janssens, Michel; Vela, Doris Mesia; Roman, Francois] GSK, Rue Inst 89, B-1330 Rixensart, Belgium.
   [Van Der Meeren, Olivier; Jongert, Erik; Koutsoukos, Marguerite; Debois, Muriel; Janssens, Michel; Vela, Doris Mesia; Roman, Francois] GSK, Wavre, Belgium.
   [Seaton, Kelly E.; Brackett, Caroline; Sawant, Sheetal; Yates, Nicole L.; Tomaras, Georgia D.] Duke Univ, Duke Human Vaccine Inst, Durham, NC 27710 USA.
   [Seaton, Kelly E.; Brackett, Caroline; Sawant, Sheetal; Yates, Nicole L.; Tomaras, Georgia D.] Duke Univ, Dept Surg, Durham, NC 27710 USA.
   [Aerssens, Annelies; Leroux-Roels, Geert; Leroux-Roels, Isabel] Univ Ghent, Ctr Vaccinol, Ghent, Belgium.
   [Aerssens, Annelies; Leroux-Roels, Geert; Leroux-Roels, Isabel] Ghent Univ Hosp, Ghent, Belgium.
   [Tomaras, Georgia D.] Duke Univ, Dept Immunol, Durham, NC 27710 USA.
   [Tomaras, Georgia D.] Duke Univ, Dept Mol Genet & Microbiol, Durham, NC 27710 USA.
RP Van Der Meeren, O (reprint author), GSK, Rue Inst 89, B-1330 Rixensart, Belgium.
EM olivier.x.van-der-meeren@gsk.com
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX GlaxoSmithKline Biologicals SA sponsored this study/research and was
   involved in all stages of study conduct, including analysis of the data.
   GlaxoSmithKline Biologicals SA also took in charge all costs associated
   with the development and publication of this manuscript.
CR Barouch DH, 2018, LANCET, V392, P232, DOI [10.1016/S0140-6736(18)31364-3, 10.1016/s0140-6736(18)31364-3]
   Bekker LG, 2018, LANCET HIV, V5, pE366, DOI 10.1016/S2352-3018(18)30071-7
   Bonsignori M, 2012, J VIROL, V86, P11521, DOI 10.1128/JVI.01023-12
   Chung AW, 2015, CELL, V163, P988, DOI 10.1016/j.cell.2015.10.027
   Corey L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7732
   Eckels J, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-145
   Gottardo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075665
   Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425
   Huang YD, 2009, STAT BIOPHARM RES, V1, P81, DOI 10.1198/sbr.2009.0008
   Kim JH, 2015, ANNU REV MED, V66, P423, DOI 10.1146/annurev-med-052912-123749
   Klasse PJ, 2012, AIDS RES HUM RETROV, V28, P1, DOI [10.1089/aid.2011.0053, 10.1089/AID.2011.0053]
   Leroux-Roels I, 2010, VACCINE, V28, P7016, DOI 10.1016/j.vaccine.2010.08.035
   Lewis GK, 2014, P NATL ACAD SCI USA, V111, P15614, DOI 10.1073/pnas.1413550111
   Liao HX, 2013, IMMUNITY, V38, P176, DOI 10.1016/j.immuni.2012.11.011
   Lichterfeld M, 2004, J EXP MED, V200, P701, DOI 10.1084/jem.20041270
   Lin L, 2015, NAT BIOTECHNOL, V33, P610, DOI 10.1038/nbt.3187
   Milligan C, 2015, CELL HOST MICROBE, V17, P500, DOI 10.1016/j.chom.2015.03.002
   Musich T, 2017, J VIROL, V91, DOI [10.1128/JVI.02325-16, 10.1128/jvi.02325-16]
   Perez LG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180720
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Robb ML, 2012, LANCET INFECT DIS, V12, P531, DOI 10.1016/S1473-3099(12)70088-9
   Spearman P, 2019, J INFECT DIS, V219, P1755, DOI 10.1093/infdis/jiz008
   Tay MZ, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005817
   The R Foundation, R PROJECT STAT COMPU
   Tomaras GD, 2017, IMMUNOL REV, V275, P245, DOI 10.1111/imr.12514
   Tomaras GD, 2013, P NATL ACAD SCI USA, V110, P9019, DOI 10.1073/pnas.1301456110
   Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08
   Voss G, 2003, J VIROL, V77, P1049, DOI 10.1128/JVI.77.2.1049-1058.2003
   World Health Organization, DAT SIZ HIV AIDS EP
   World Health Organization, HIV VACC DEV
   Yates NL, 2018, J VIROL, V92, DOI 10.1128/JVI.01843-17
   Yates NL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007730
   Yates NL, 2011, AIDS, V25, P2089, DOI 10.1097/QAD.0b013e32834b348e
   Zolla-Pazner S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087572
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1678
EP 1689
DI 10.1016/j.vaccine.2019.12.058
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900015
PM 31932137
OA Other Gold
DA 2020-05-12
ER

PT J
AU Xu, LL
   Qin, ZQ
   Qiao, L
   Wen, J
   Shao, HB
   Wen, GY
   Pan, ZS
AF Xu, Lulai
   Qin, Zhenqiao
   Qiao, Lei
   Wen, Jie
   Shao, Huabin
   Wen, Guoyuan
   Pan, Zishu
TI Characterization of thermostable Newcastle disease virus recombinants
   expressing the hemagglutinin of H5N1 avian influenza virus as bivalent
   vaccine candidates
SO VACCINE
LA English
DT Article
DE Newcastle disease virus; Hemagglutinin; Highly pathogenic avian
   influenza H5N1 virus; Vector vaccine; Thermostability
ID INFECTIOUS-BRONCHITIS VIRUS; GENE PROTECTS CHICKENS; NEUTRALIZING
   ANTIBODIES; IMMUNE-RESPONSES; VECTORED VACCINE; A H5N1; CHALLENGE;
   IMMUNIZATION; IMMUNOGENICITY; GLYCOPROTEIN
AB Newcastle disease virus (NDV) has been used as a vector in the development of vaccines and gene delivery. In the present study, we generated the thermostable recombinant NDV (rNDV) expressing the different forms of hemagglutinin (HA) of highly pathogenic avian influenza virus (HPAIV) H5N1 based on the full-length cDNA clone of thermostable TS09-C strain. The recombinant thermostable Newcastle disease viruses, rTS-HA, rTS-HA1 and rTS-tPAs/HA1, expressed the HA, HA1 or modified HA1 protein with the tissue plasminogen activator signal sequence (tPAs), respectively. The rNDVs displayed similar thermostability, growth kinetics and pathogenicity compared with the parental TS09-C virus. The tPAs facilitated the expression and secretion of HA1 protein in cells infected with rNDV. Animal studies demonstrated that immunization with rNDVs elicited effective H5N1- and NDV-specific antibody responses and conferred immune protection against lethal H5N1 and NDV challenges in chickens and mice. Importantly, vaccination of rTS-tPAs/HA1 resulted in enhanced protective immunity in chickens and mice. Our study thus provides a novel thermostable NDV-vectored vaccine candidate expressing a soluble form of a heterologous viral protein, which will greatly aid the poultry industry in developing countries. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Xu, Lulai; Qin, Zhenqiao; Qiao, Lei; Wen, Jie; Pan, Zishu] Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China.
   [Shao, Huabin; Wen, Guoyuan] Hubei Acad Agr Sci, Inst Anim Husb & Vet Sci, Key Lab Prevent & Control Agents Anim Bacteriosis, Minist Agr, Wuhan 430064, Peoples R China.
RP Pan, ZS (reprint author), Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China.; Wen, GY (reprint author), Hubei Acad Agr Sci, Inst Anim Husb & Vet Sci, Key Lab Prevent & Control Agents Anim Bacteriosis, Minist Agr, Wuhan 430064, Peoples R China.
EM wgy_524@163.com; zspan@whu.edu.cn
FU National Key Research and Development Program of China [2018YFD0500104];
   Natural Science Foundation of Hubei Province Innovation Group
   [2017CFA022]
FX This study was supported by the National Key Research and Development
   Program of China (No. 2018YFD0500104) and The Natural Science Foundation
   of Hubei Province Innovation Group (2017CFA022).
CR Alexander DJ, 2007, VACCINE, V25, P5637, DOI 10.1016/j.vaccine.2006.10.051
   Alexander DJ, 2012, AVIAN PATHOL, V41, P329, DOI 10.1080/03079457.2012.697991
   Alexander DJ, 2000, REV SCI TECH OIE, V19, P443, DOI 10.20506/rst.19.2.1231
   Ashok MS, 2002, VACCINE, V20, P1563, DOI 10.1016/S0264-410X(01)00492-3
   Basavarajappa MK, 2014, VACCINE, V32, P3555, DOI 10.1016/j.vaccine.2014.04.068
   Bensink Z, 1999, VET MICROBIOL, V68, P131, DOI 10.1016/S0378-1135(99)00069-3
   Bui C, 2016, TRANSBOUND EMERG DIS, V63, P602, DOI [10.1111/tbed.12327, 10.1]
   Bui CM, 2017, PLOS ONE, V12
   Bukreyev A, 2005, J VIROL, V79, P13275, DOI 10.1128/JVI.79.21.13275-13284.2005
   Bukreyev A, 2008, CURR OPIN MOL THER, V10, P46
   Dey S, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5040031
   DiNapoli JM, 2007, J VIROL, V81, P11560, DOI 10.1128/JVI.00713-07
   DiNapoli JM, 2007, P NATL ACAD SCI USA, V104, P9788, DOI 10.1073/pnas.0703584104
   DiNapoli JM, 2010, VACCINE, V29, P17, DOI 10.1016/j.vaccine.2010.10.024
   DiNapoli JM, 2010, J VIROL, V84, P1489, DOI 10.1128/JVI.01946-09
   Echeonwu G, 2008, AFR J BIOTECHNOL, V7, P2688
   Ge JY, 2007, J VIROL, V81, P150, DOI 10.1128/JVI.01514-06
   Golden JW, 2008, VACCINE, V26, P3507, DOI 10.1016/j.vaccine.2008.04.017
   Guan Y, 2013, VIRUS RES, V178, P35, DOI 10.1016/j.virusres.2013.05.012
   Hu ZL, 2017, VACCINE, V35, P6585, DOI 10.1016/j.vaccine.2017.10.010
   Huang Z, 2003, POULTRY SCI, V82, P899, DOI 10.1093/ps/82.6.899
   IDERIS A, 1990, AVIAN PATHOL, V19, P371, DOI 10.1080/03079459008418687
   Jin H, 2007, VACCINE, V25, P8664, DOI 10.1016/j.vaccine.2007.10.032
   Khurana S, 2011, J VIROL, V85, P1246, DOI 10.1128/JVI.02107-10
   Khurana S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011548
   Kim SH, 2018, J CURRENT PROTOCOLS, V48
   Kim SH, 2014, J VIROL, V88, P9718, DOI 10.1128/JVI.01570-14
   Li ZM, 1999, INFECT IMMUN, V67, P4780, DOI 10.1128/IAI.67.9.4780-4786.1999
   Liu QF, 2015, J VIROL, V89, P7401, DOI 10.1128/JVI.00031-15
   Liu XF, 2003, ARCH VIROL, V148, P1387, DOI 10.1007/s00705-003-0014-z
   LOMNICZI B, 1975, ARCH VIROL, V47, P249, DOI 10.1007/BF01317812
   Luo MC, 2011, VACCINE, V29, P2561, DOI 10.1016/j.vaccine.2011.01.060
   Luo MC, 2008, J VIROL METHODS, V154, P121, DOI 10.1016/j.jviromet.2008.08.011
   Maamary J, 2011, J VIROL, V85, P2235, DOI 10.1128/JVI.02036-10
   Nagy A, 2016, VACCINE, V34, P2537, DOI 10.1016/j.vaccine.2016.04.022
   Nayak B, 2010, J VIROL, V84, P2408, DOI 10.1128/JVI.02135-09
   Niqueux E, 2013, VACCINE, V31, P4121, DOI 10.1016/j.vaccine.2013.06.074
   Park MS, 2006, P NATL ACAD SCI USA, V103, P8203, DOI 10.1073/pnas.0602566103
   STEPHENS P, 1968, AUST VET J, V44, P29, DOI 10.1111/j.1751-0813.1967.tb04764.x
   Stevens J, 2004, SCIENCE, V303, P1866, DOI 10.1126/science.1093373
   Tao P, 2009, ANTIVIR RES, V81, P253, DOI 10.1016/j.antiviral.2008.12.009
   Treanor JJ, 2006, NEW ENGL J MED, V354, P1343, DOI 10.1056/NEJMoa055778
   Treanor JJ, 2001, VACCINE, V19, P1732, DOI 10.1016/S0264-410X(00)00395-9
   Veits J, 2006, P NATL ACAD SCI USA, V103, P8197, DOI 10.1073/pnas.0602461103
   Wen GY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172812
   Wen GY, 2015, J GEN VIROL, V96, P1219, DOI 10.1099/vir.0.000067
   Wen GY, 2013, VIRUS GENES, V46, P542, DOI 10.1007/s11262-012-0871-1
   WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0
   WILSON IA, 1990, ANNU REV IMMUNOL, V8, P737, DOI 10.1146/annurev.iy.08.040190.003513
   Yang XZ, 2001, J VIROL, V75, P1165, DOI 10.1128/JVI.75.3.1165-1171.2001
   Zhao J, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0723-7
   Zhao R, 2017, VACCINE, V35, P2435, DOI 10.1016/j.vaccine.2017.03.045
NR 52
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1690
EP 1699
DI 10.1016/j.vaccine.2019.12.054
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900016
PM 31937412
DA 2020-05-12
ER

PT J
AU Duthie, MS
   Frevol, A
   Day, T
   Coler, RN
   Vergara, J
   Rolf, T
   Sagawa, ZK
   Beckmann, AM
   Casper, C
   Reed, SG
AF Duthie, Malcolm S.
   Frevol, Aude
   Day, Tracey
   Coler, Rhea N.
   Vergara, Julie
   Rolf, Tom
   Sagawa, Zachary K.
   Beckmann, Anna Marie
   Casper, Corey
   Reed, Steven G.
TI A phase 1 antigen dose escalation trial to evaluate safety, tolerability
   and immunogenicity of the leprosy vaccine candidate LepVax
   (LEP-F1+GLA-SE) in healthy adults
SO VACCINE
LA English
DT Article
DE Leprosy; Vaccine; Adjuvant; Immunologic; Safety
ID MYCOBACTERIUM-LEPRAE INFECTION; CALMETTE-GUERIN BCG; PREVENTION;
   PROTECTION; TUBERCULOSIS; CHILDREN; CELLS
AB Healthy United States-based adult volunteers with no history of travel to leprosy-endemic countries were enrolled for the first-in-human evaluation of LepVax (LEP-F1 + GLA-SE). In total 24 volunteers participated in an open-label clinical trial, with 21 receiving three injections of LepVax consisting of either 2 mu g or 10 mu g recombinant polyprotein LEP-F1 mixed with 5 mu g of the GLA-SE adjuvant formulation. LepVax doses were provided by intramuscular injection on Days 0, 28, and 56, and safety was evaluated for one year following the final injection. LepVax was safe and well tolerated at both antigen doses. Immunological analyses indicated that similar LEP-F1-specific antibody and Thi cytokine secretion (IFN-gamma, IL-2, TNF) were induced by each of the antigen doses evaluated within LepVax. This clinical trial of the first defined vaccine candidate for leprosy demonstrates that LepVax is safe and immunogenic in healthy subjects and supports its advancement to testing in leprosy-endemic regions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Duthie, Malcolm S.; Frevol, Aude; Day, Tracey; Coler, Rhea N.; Vergara, Julie; Rolf, Tom; Sagawa, Zachary K.; Beckmann, Anna Marie; Casper, Corey; Reed, Steven G.] Infect Dis Res Inst, Seattle, WA USA.
   [Duthie, Malcolm S.; Reed, Steven G.] Host Directed Therapeut, 1616 Eastlake Ave E,Suite 280, Seattle, WA 98102 USA.
   [Duthie, Malcolm S.; Coler, Rhea N.; Beckmann, Anna Marie; Reed, Steven G.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA.
   [Coler, Rhea N.] PAI Life Sci Inc, Seattle, WA USA.
RP Duthie, MS (reprint author), Host Directed Therapeut, 1616 Eastlake Ave E,Suite 280, Seattle, WA 98102 USA.
EM malcolm.duthie@hdtbiocorp.com
FU American Leprosy Missions; Action Damien; Deutsche Lepra;
   Tuberkulosehilfe e.V.
FX This research was conducted with grant funding from the American Leprosy
   Missions, with important contributions from Action Damien, Deutsche
   Lepra- and Tuberkulosehilfe e.V., effect: hope, Fairmed, Fondation Raoul
   Follereau, Netherlands Leprosy Relief, and Secours aux Lepreuz - Leprosy
   Relief Canada.
CR Adams LB, 2002, J INFECT DIS, V185, pS1, DOI 10.1086/338002
   Adams LB, 2012, MEM I OSWALDO CRUZ, V107, P197, DOI 10.1590/S0074-02762012000900028
   [Anonymous], 1995, Wkly Epidemiol Rec, V70, P229
   [Anonymous], 2016, WKLY EPIDEMIOL REC, V92, P501
   Bakker MI, 2005, AM J TROP MED HYG, V72, P443, DOI 10.4269/ajtmh.2005.72.443
   Barreto JG, 2012, MEM I OSWALDO CRUZ, V107, P60, DOI 10.1590/S0074-02762012000900011
   Barreto Mauricio L., 2006, J. Pediatr. (Rio J.), V82, ps45, DOI 10.1590/S0021-75572006000400006
   Bezerra-Santos M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02920
   Billeskov R, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01973
   Coler RN, 2015, CLIN TRANSL IMMUNOL, V4, DOI 10.1038/cti.2015.6
   Coler RN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016333
   CONVIT J, 1992, LANCET, V339, P446, DOI 10.1016/0140-6736(92)91056-E
   Cunha SS, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000167
   Darrah PA, 2007, NAT MED, V13, P843, DOI 10.1038/nm1592
   Fonseca ABD, 2017, INFECT DIS POVERTY, V6, DOI 10.1186/s40249-016-0229-3
   de Souza MM, 2014, T ROY SOC TROP MED H, V108, P495, DOI 10.1093/trstmh/tru093
   Duppre NC, 2008, T ROY SOC TROP MED H, V102, P631, DOI 10.1016/j.trstmh.2008.04.015
   Duppre NC, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001711
   Duthie MS, 2018, NPJ VACCINES, V3, DOI [10.1038/s41541-018-0055-7, 10.1038/s41541-018-0050-z]
   Evans TG, 2001, VACCINE, V19, P2080, DOI 10.1016/S0264-410X(00)00415-1
   Fine PEM, 1996, LANCET, V348, P17
   Frade MAC, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005375
   Hotez PJ, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005896
   Kamal R, 2017, BRIT J DERMATOL, V176, P1388, DOI 10.1111/bjd.14971
   Leung-Theung-Long S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143552
   Macedo ABB, 2012, CLIN EXP IMMUNOL, V167, P505, DOI 10.1111/j.1365-2249.2011.04536.x
   Mazini PS, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00658
   Merle CSC, 2010, EXPERT REV VACCINES, V9, P209, DOI 10.1586/ERV.09.161
   Regules JA, 2016, J INFECT DIS, V214, P762, DOI 10.1093/infdis/jiw237
   Rhodes SJ, 2019, J THEOR BIOL, V465, P51, DOI 10.1016/j.jtbi.2019.01.017
   Rhodes SJ, 2016, VACCINE, V34, P6285, DOI 10.1016/j.vaccine.2016.10.060
   Richardus RA, 2015, VACCINE, V33, P1562, DOI 10.1016/j.vaccine.2015.02.017
   Rodrigues LC, 2007, VACCINE, V25, P6842, DOI 10.1016/j.vaccine.2007.07.032
   Rodrigues LC, 2005, LANCET, V366, P1290, DOI 10.1016/S0140-6736(05)67145-0
   Scollard DM, 2015, CLIN DERMATOL, V33, P46, DOI 10.1016/j.clindermatol.2014.07.008
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   Setia MS, 2006, LANCET INFECT DIS, V6, P162, DOI 10.1016/S1473-3099(06)70412-1
   Sharma SK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03514-1
   Simon M, 2011, DRUG DEVELOP RES, V72, P509, DOI 10.1002/ddr.20457
   Smith CM, 2000, J INFECTION, V41, P137, DOI 10.1053/jinf.2000.0698
   Smith WC, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003658
   Talwar GP, 2016, J TRANSL MED, V1, P69
   Talwar GP, 2017, BIOL-TARGETS THER, V11, P55, DOI 10.2147/BTT.S128308
   WHO, 2018, WKLY EPIDEMIOL REC, V93, P445
   Wilder-Smith EP, 2008, NAT CLIN PRACT NEURO, V4, P656, DOI 10.1038/ncpneuro0941
   Zodpey SP, 2005, PUBLIC HEALTH, V119, P209, DOI 10.1016/j.puhe.2004.04.007
   Zodpey SP, 1999, LEPROSY REV, V70, P287
NR 47
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1700
EP 1707
DI 10.1016/j.vaccine.2019.12.050
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900017
PM 31899025
DA 2020-05-12
ER

PT J
AU Ulziibat, G
   Maygmarsuren, O
   Khishgee, B
   Basan, G
   Sandag, B
   Ruuragc, S
   Limon, G
   Wilsden, G
   Browning, C
   King, DP
   Ludi, AB
   Lyons, NA
AF Ulziibat, Gerelmaa
   Maygmarsuren, Odonchimeg
   Khishgee, Bodisaikhan
   Basan, Ganzorig
   Sandag, Batkhuyag
   Ruuragc, Sodnomdarjaa
   Limon, Georgina
   Wilsden, Ginette
   Browning, Clare
   King, Donald P.
   Ludi, Anna B.
   Lyons, Nicholas A.
TI Immunogenicity of imported foot-and-mouth vaccines in different species
   in Mongolia
SO VACCINE
LA English
DT Article
DE Foot-and-mouth disease; Immunogenicity; Cattle; Sheep; Camels;
   Post-vaccination monitoring
ID DISEASE VIRUS-VACCINE; ALUMINUM-HYDROXIDE GEL; IMMUNE-RESPONSES;
   CAMELUS-DROMEDARIUS; SHEEP; SUSCEPTIBILITY; EPIDEMIOLOGY; ANTIBODIES;
   CHALLENGE; EMULSION
AB Foot-and-mouth disease (FMD) is a high impact viral disease of livestock for which vaccines are extensively used in control. Mongolia has regular incursions of FMD virus that are typically limited to the eastern region although large epidemics are occasionally reported in the normally disease-free western areas. Vaccines are imported and form an important component of the control strategy. In 2015, post-vaccination monitoring guidelines were published by the FAO-OIE recommending approaches for assessing the appropriateness of imported vaccines including small-scale immunogenicity studies. This study used these recommended approaches to guide the use of vaccine adjuvant type and the need for a one or two dose primary course in the national control programme considering cattle, sheep and Bactrian camels and also whether these vaccines were appropriate for the FMD virus lineages considered high risk to Mongolia (A/ASIA/Sea-97; O/SEA/Mya-98; O/ME-SA/PanAsia; O/ME-SA/Ind-2001). The results of these immunogenicity studies indicated that in cattle and sheep, oil-adjuvanted vaccines led to higher and more persistent neutralisation titres that were satisfactory against the target lineages if a two-dose primary course was utilised. In contrast, aqueous-adjuvanted vaccines were associated with lower titres that likely required a booster after 3 months. Levels of antibodies in Bactrian camels were significantly lower although it is unknown how these may correlate with protection under experimental or field exposure conditions. The results of this study have implications for vaccine policy in Mongolia and suggest further studies on the role of Bactrian camels in the epidemiology of FMD are necessary to indicate if further research on FMD vaccines are needed in this species. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Ulziibat, Gerelmaa; Maygmarsuren, Odonchimeg; Basan, Ganzorig; Ruuragc, Sodnomdarjaa] State Cent Vet Lab, Ulaanbaatar, Mongolia.
   [Khishgee, Bodisaikhan; Sandag, Batkhuyag] Gen Author Vet Serv, Govt Bldg 9,Enkhtaivan Ave 16a,3th Khoroo, Ulaanbaatar, Mongolia.
   [Limon, Georgina; Wilsden, Ginette; Browning, Clare; King, Donald P.; Ludi, Anna B.; Lyons, Nicholas A.] Pirbright Inst, Ash Rd, Woking GU24 0NF, Surrey, England.
   [Lyons, Nicholas A.] European Commiss Control Foot & Mouth Dis EuFMD, Food & Agr United Nations, Rome, Italy.
RP Lyons, NA (reprint author), Pirbright Inst, Ash Rd, Woking GU24 0NF, Surrey, England.
EM nl222@cantab.net
OI King, Donald/0000-0002-6959-2708
FU Biotechnology and Biological Sciences Research Council of the United
   KingdomBiotechnology and Biological Sciences Research Council (BBSRC)
   [BB/E/I/00007035, BB/E/I/00007036]; BBSRCBiotechnology and Biological
   Sciences Research Council (BBSRC) [BB/E/I/00007004]; European
   UnionEuropean Union (EU)
FX The authors would like to thank Otgon Choijoo, the participating herder
   from Bayan-Undur sum, Orkhon province, and colleagues from the
   veterinary department of Orkhon province (Orgikhbayar Ouyn-Erdene,
   Urtnast Luvsan, Tugsjargal Otgon and Odsuren Galbadraa) who assisted in
   the implementation of this study. Thanks also go to supporting
   colleagues from the SCVL (Dulam Purevtseren, Tserenjav Jargalsaikhan,
   Amartuvshin Tsolmon, Buyantogtokh Khanui), the General Authority for
   Veterinary Services (including Tsolman Bandi), the Veterinary Drug
   Quality Control Laboratory of Mongolia (Usuhgerel Sukhbaatar) and the
   State Professional Inspection Agency of Mongolia (Zuraash Kadyei).
   Finally thanks to Dr Ruth Farmer for advice on the statistics. The
   Pirbright Institute receives strategic support from the Biotechnology
   and Biological Sciences Research Council of the United Kingdom (projects
   BB/E/I/00007035 and BB/E/I/00007036) and NL was supported by a BBSRC
   funded fellowship (grant code: BB/E/I/00007004). Work at Pirbright was
   also supported by funding provided to the European Commission for the
   Control of FMD (EuFMD) from the European Union and the views expressed
   herein can in no way be taken to reflect the official opinion of the
   European Union.
CR Alexandersen S, 2008, J COMP PATHOL, V139, P187, DOI 10.1016/j.jcpa.2008.06.006
   Auge de Mello P, 1977, B CENTR PANAM FIEBRE, V26, P27
   Barnett PV, 2003, VACCINE, V21, P3240, DOI 10.1016/S0264-410X(03)00219-6
   BARTELING SJ, 1991, VACCINE, V9, P75, DOI 10.1016/0264-410X(91)90261-4
   Clavijo A, 2017, TRANSBOUND EMERG DIS, V64, P31, DOI 10.1111/tbed.12345
   Cox SJ, 2009, VET RES, V40, DOI 10.1051/vetres:2008051
   Cox SJ, 2003, VACCINE, V21, P1336, DOI 10.1016/S0264-410X(02)00691-6
   Diaz-San Segundo F, 2017, VET MICROBIOL, V206, P102, DOI 10.1016/j.vetmic.2016.12.018
   DOEL TR, 1994, VACCINE, V12, P592, DOI 10.1016/0264-410X(94)90262-3
   Doel TR, 1999, VACCINE, V17, P1767, DOI 10.1016/S0264-410X(98)00444-7
   Doel TR, 1996, REV SCI TECH OIE, V15, P883, DOI 10.20506/rst.15.3.955
   Doel TR, 2003, VIRUS RES, V91, P81, DOI 10.1016/S0168-1702(02)00261-7
   FAO and OIE, 2018, PROGR CONTR PATHW FO
   Ferrari G, 2016, FOOT AND MOUTH DIS P
   Fishbourne E, 2017, VACCINE, V35, P2761, DOI 10.1016/j.vaccine.2017.02.047
   Frederiksen T, 2006, OPEN SESS STANDING T, P243
   Gomes I, 1980, B CENTR PANAM FIEBRE, V37-38, P31
   Griffin LM, 2014, J IMMUNOL METHODS, V405, P35, DOI 10.1016/j.jim.2014.01.003
   Johnson Douglas A., 2006, Secheresse (Montrouge), V17, P133
   King DP, 2017, ANN REPORTS 01E FAO
   KITCHING RP, 1995, BRIT VET J, V151, P379, DOI 10.1016/S0007-1935(95)80127-8
   Knight-Jones TJD, 2015, VACCINE, V33, P805, DOI 10.1016/j.vaccine.2014.12.010
   Larska M, 2009, EPIDEMIOL INFECT, V137, P549, DOI 10.1017/S0950268808001088
   Leforban Y, 2002, REV SCI TECH OIE, V21, P477, DOI 10.20506/rst.21.3.1345
   Lyons NA, 2017, VACCINE, V35, P6850, DOI 10.1016/j.vaccine.2017.10.029
   Lyons NA, 2016, FRONT VET SCI, V3, DOI 10.3389/fvets.2016.00102
   McFadden AMJ, 2015, TRANSBOUND EMERG DIS, V62, pE45, DOI 10.1111/tbed.12208
   McKercher PD, 1975, B CENTR PANAM FIEBRE, V19-20, P9
   NAIR SP, 1993, VACCINE, V11, P782, DOI 10.1016/0264-410X(93)90266-Z
   NAIR SP, 1992, COMP IMMUNOL MICROB, V15, P117, DOI 10.1016/0147-9571(92)90110-D
   Nyamsuren D, 2013, J WILDLIFE DIS, V42, P154, DOI [10.7589/0090-3558-42 1.154, DOI 10.7589/0090-3558-421.154]
   Patil PK, 2002, J CLIN MICROBIOL, V40, P4367, DOI 10.1128/JCM.40.11.4367-4371.2002
   Patil PK, 2002, VACCINE, V20, P2781, DOI 10.1016/S0264-410X(02)00184-6
   Patil PK, 2014, VET MICROBIOL, V169, P233, DOI 10.1016/j.vetmic.2014.01.005
   SADIR AM, 1988, EPIDEMIOL INFECT, V100, P135, DOI 10.1017/S0950268800065626
   Shiilegdamba E, 2008, VET RES COMMUN, V32, P201, DOI 10.1007/s11259-007-9018-6
   Sokolov Vladimir E., 1997, Mammalian Species, V571, P1
   SPATH EJA, 1995, VACCINE, V13, P909, DOI 10.1016/0264-410X(95)00009-P
   Sumption K, 2018, OPEN SESS EUFMD STAN, P12
   Sumption K., 2012, FAO OIE GLOB C FOOT
   Ulziibat G, 2018, OPEN SESS EUFMD STAN, P57
   Wernery U, 2004, VET J, V168, P134, DOI 10.1016/j.tvjl.2003.10.005
   Wieland B, 2015, PREV VET MED, V120, P115, DOI 10.1016/j.prevetmed.2014.11.017
NR 43
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1708
EP 1714
DI 10.1016/j.vaccine.2019.12.053
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900018
PM 31926753
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Espul, C
   Cuello, H
   Lo Castro, I
   Bravo, C
   Thollot, Y
   Voznica, J
   Vigne, C
   Coudeville, L
AF Espul, C.
   Cuello, H.
   Lo Castro, I
   Bravo, C.
   Thollot, Y.
   Voznica, J.
   Vigne, C.
   Coudeville, L.
TI Statistical modeling alongside observational data predicts long-term
   immunogenicity of one dose and two doses of pediatric hepatitis A
   vaccine in the Mendoza province of Argentina
SO VACCINE
LA English
DT Article
DE Antibody persistence; Argentina; Hepatitis A vaccine; Single dose;
   Statistical modeling
ID FOLLOW-UP; INDUCED ANTIBODIES; IMMUNE-RESPONSE; PERSISTENCE;
   IMMUNIZATION; CHILDREN; AGE
AB Background: Follow-up for anti-hepatitis A (HA) antibody persistence up to 10 years was conducted after implementation of universal vaccination against HA virus (HAV) in Mendoza, Argentina. Based on these data, statistical modeling was used to predict the antibody persistence to 30 years.
   Methods: A non-interventional study evaluated long-term immunogenicity (geometric mean concentrations [GMCs] and seroprotection rate) following routine vaccination with 1 dose (Group 1: N = 436) or 2 doses (Group 2: N = 108) of HA vaccine. Associated statistical modeling based on a Bayesian approach of mixed effects models on log transformed titers evaluated three models (linear, piecewise linear, and exponential decay, with and without a natural boosting effect).
   Results: From the initial cohort, 9 participants (Group 1) and 1 participant (Group 2) showed antibody titers below the seroprotective threshold and received a booster. At Year 10, 190 (Group 1) and 51 (Group 2) participants remained in the study without a booster dose and all were seroprotected. Regarding statistical modeling, the piecewise linear model showed the best fit and demonstrated high and similar seroprotection for each schedule up to 30 years (89% [1-dose schedule], 85% [2-dose schedule]). The 2-dose schedule showed higher GMC (95% CI) than the 1-dose schedule (Year 10: 352 [271-456] versus 78 [69.8-87.6] mltlimL) and Year 30 (predicted) (37 [13-97] versus 19 [11-34] mlU/mL). Natural boosting had little impact on predicted seroprotection rates at 30 years for the 1-dose schedule (89% [0.8-0.96] and 84% [0.73-0.94] with and without a natural booster, respectively).
   Conclusions: Long-term persistence of anti-HAV antibodies was observed up to 10 years with 1-dose and 2-dose vaccine schedules, supporting booster flexibility. Statistical modeling predicted good persistence of seroprotection for each schedule up to 30 years. Natural boosting had a limited impact on seroprotection rate predictions, enabling extrapolation of these results to non-endemic settings for traveler vaccination. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Espul, C.] Hosp Cent Mendoza, Minist Salud, Mendoza, Argentina.
   [Cuello, H.; Lo Castro, I] Hosp Cent Mendoza, Secc Virol, Mendoza, Argentina.
   [Bravo, C.; Thollot, Y.; Voznica, J.; Vigne, C.; Coudeville, L.] Sanofi Pasteur, Lyon, France.
   [Voznica, J.] Eole Normale Super Paris Saclay, Dept Biol, Cachan, France.
RP Espul, C (reprint author), Hosp Cent Mendoza, Minist Salud, Programa Lucha Hepatitis Virales PRHEVI, Alem 450, RA-5500 Mendoza, Argentina.
EM cespul@mendoza.gov.ar; Catherine.Bravo@sanofi.com;
   Yael.Thollot@sanofi.com; Jakub.Voznica@pasteur.fr;
   claire.vigne@sanofi.com; Laurent.Coudeville@sanofi.com
FU Sanofi Pasteur, France
FX The work was funded by Sanofi Pasteur, France.
CR Brooks SP, 1998, J COMPUT GRAPH STAT, V7, P434, DOI 10.2307/1390675
   Denwood MJ, 2016, J STAT SOFTW, V71, P1, DOI 10.18637/jss.v071.i09
   Desai K, 2012, VACCINE, V30, P2510, DOI 10.1016/j.vaccine.2012.02.005
   Espul C, 2015, J VIRAL HEPATITIS, V22, P453, DOI 10.1111/jvh.12317
   Espul C, 2017, HUM VACC IMMUNOTHER, V13, P2707, DOI 10.1080/21645515.2017.1358326
   Espul C, 2012, HEPATIC MED-EVID RES, V4, P53, DOI 10.2147/HMER.S33847
   Gentile A, 2013, ARCH ARGENT PEDIATR, V111, P155, DOI [10.1590/S0325-00752013000200011, 10.5546/aap.2013.155]
   Hens N, 2014, VACCINE, V32, P1507, DOI 10.1016/j.vaccine.2013.10.088
   Iwarson S, 2002, SCAND J INFECT DIS, V34, P110, DOI 10.1080/00365540110077362
   Lopez E, 2007, J GASTROENTEROL, V42, P152, DOI 10.1007/s00535-006-1984-x
   Lopez EL, 2015, PEDIATR INFECT DIS J, V34, P417, DOI 10.1097/INF.0000000000000605
   Mayorga O, 2016, J INFECT DIS, V214, P1498, DOI 10.1093/infdis/jiw411
   Melgaco JG, 2015, VACCINE, V33, P3813, DOI 10.1016/j.vaccine.2015.06.099
   Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I
   Organization Panamericana de la Salud (OPS) Argentina, BRAK HEP A ARG 2018
   Plummer M., 2003, P 3 INT WORKSH DISTR, V3, P20
   Spiegelhalter DJ, 2002, J ROY STAT SOC B, V64, P583, DOI 10.1111/1467-9868.00353
   Theeten H, 2015, VACCINE, V33, P5723, DOI 10.1016/j.vaccine.2015.07.008
   Van Damme P, 2017, HUM VACC IMMUNOTHER, V13, P972, DOI 10.1080/21645515.2016.1274473
   Van Herck K, 2000, J MED VIROL, V60, P1, DOI 10.1002/(SICI)1096-9071(200001)60:1&lt;1::AID-JMV1&gt;3.0.CO;2-H
   Van Herck K, 2001, J MED VIROL, V63, P1, DOI 10.1002/1096-9071(200101)63:1&lt;1::AID-JMV1000&gt;3.0.CO;2-U
   Vizzotti C, 2015, J PEDIAT INF DIS SOC, V4, pE62, DOI 10.1093/jpids/piu068
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1715
EP 1722
DI 10.1016/j.vaccine.2019.12.049
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900019
PM 31928855
OA Other Gold
DA 2020-05-12
ER

PT J
AU Kim, J
   Kim, T
   Hong, JK
   Lee, HS
   Lee, KN
   Jo, HJ
   Choi, J
   Choi, J
   Lee, SH
   Lee, MH
   Kim, B
   Park, JH
AF Kim, Jaejo
   Kim, Taeseong
   Hong, Jang-Kwan
   Lee, Hyang-Sim
   Lee, Kwang-Nyeong
   Jo, Hye Jun
   Choi, Jieun
   Choi, Jida
   Lee, Seung Heon
   Lee, Myoung-Heon
   Kim, Byounghan
   Park, Jong-Hyeon
TI The interference effect of maternally-derived antibodies on the
   serological performance of pigs immunized with a foot-and-mouth disease
   oil emulsion vaccine
SO VACCINE
LA English
DT Article
DE Foot-and-mouth; Virus; Vaccine; Pig; Maternally-derived antibody;
   Efficacy; Field trial
ID HETEROLOGOUS CHALLENGE; GROWING PIGS; RESPONSES; PROTECTION; VIRUS;
   KOREA; EPIDEMIC; CALVES; AGE
AB To control foot-and-mouth disease (FMD) outbreaks that originated in Jincheon County in South Korea between 2014 and 2015, several commercial vaccines were studied for their efficacy and serological performance in the field. In this study, the efficacy of the O/SKR 7/10 vaccine was evaluated by challenge with the FMD virus (FMDV) O/Jincheon/SKR/2014 (O Jincheon), which has the same O/SEA/Mya-98 lineage as the O/SKR/7/10 strain that was isolated in 2010 in South Korea, in FMD-seronegative pigs. Full protection against the O Jincheon virus was demonstrated as early as 14 days postvaccination, which was explained by the strong serological relationship (r(1) value: >= 0.92) between the O Jincheon and O SKR 2010 viruses. However, in the field trial, no satisfactory serological elevations against FMDV were observed, even in the double-vaccinated groups. Therefore, it can be concluded that the O SKR 7/10 vaccine may need to be improved to overcome the interference effects from the high levels of maternally-derived antibodies generated due to the mandatory nationwide vaccination of sows in South Korea. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Kim, Jaejo; Kim, Taeseong; Lee, Hyang-Sim; Lee, Kwang-Nyeong; Jo, Hye Jun; Choi, Jieun; Choi, Jida; Lee, Seung Heon; Lee, Myoung-Heon; Kim, Byounghan; Park, Jong-Hyeon] Anim & Plant Quarantine Agcy, 177 Hyeoksin 8 Ro, Gimcheon City 39660, Gyeongsangbuk D, South Korea.
   [Hong, Jang-Kwan] Daesung Microbiol Lab, 103 Deogyeong Daero, Uiwang City 16103, Gyeonggi Do, South Korea.
RP Kim, J (reprint author), Anim & Plant Quarantine Agcy, 177 Hyeoksin 8 Ro, Gimcheon City 39660, Gyeongsangbuk D, South Korea.
EM jkim1209@korea.kr
FU APQA's National Animal Disease Research Project
FX We thank the staff of the Center for FMD Vaccine Research at the Animal
   and Plant Quarantine Agency (APQA). This research was supported by a
   grant from the APQA's National Animal Disease Research Project.
CR Alves MP, 2009, CLIN VACCINE IMMUNOL, V16, P1151, DOI 10.1128/CVI.00018-09
   Baldridge MT, 2017, J VIROL, V91, DOI 10.1128/JVI.02079-16
   BARTELING SJ, 1991, VACCINE, V9, P75, DOI 10.1016/0264-410X(91)90261-4
   Brehm KE, 2008, VACCINE, V26, P1681, DOI 10.1016/j.vaccine.2008.01.038
   Brito BP, 2017, TRANSBOUND EMERG DIS, V64, P316, DOI 10.1111/tbed.12373
   Cox SJ, 2003, VACCINE, V21, P1336, DOI 10.1016/S0264-410X(02)00691-6
   Doel TR, 1999, VACCINE, V17, P1767, DOI 10.1016/S0264-410X(98)00444-7
   Doel TR, 2003, VIRUS RES, V91, P81, DOI 10.1016/S0168-1702(02)00261-7
   Elnekave E, 2016, VACCINE, V34, P4927, DOI 10.1016/j.vaccine.2016.07.052
   FRANCIS MJ, 1986, RES VET SCI, V41, P33, DOI 10.1016/S0034-5288(18)30568-X
   HERBERT WJ, 1965, LANCET, V2, P771
   James AD, 2002, REV SCI TECH OIE, V21, P637, DOI 10.20506/rst.21.3.1356
   Kim AY, 2017, J VET MED SCI, V79, P1822, DOI 10.1292/jvms.17-0338
   Kim SM, 2015, J VIROL, V89, P8267, DOI 10.1128/JVI.00766-15
   Kim T, 2019, VACCINE, V37, P1702, DOI 10.1016/j.vaccine.2018.11.080
   Lee HS, 2013, VET MICROBIOL, V164, P239, DOI 10.1016/j.vetmic.2013.02.012
   Liao PC, 2003, VACCINE, V21, P1807, DOI 10.1016/S0264-410X(03)00030-6
   Mahapatra M, 2018, EXPERT REV VACCINES, V17, P577, DOI 10.1080/14760584.2018.1492378
   NICHOLLS MJ, 1984, J HYG-CAMBRIDGE, V92, P105, DOI 10.1017/S0022172400064081
   OIE, 2017, OIE TERR MAN
   Park JN, 2014, VACCINE, V32, P1882, DOI 10.1016/j.vaccine.2014.01.067
   Park JH, 2018, J VET SCI, V19, P271, DOI 10.4142/jvs.2018.19.2.271
   Park JH, 2016, CLIN EXP VACCINE RES, V5, P83, DOI 10.7774/cevr.2016.5.1.83
   Park JH, 2014, EMERG INFECT DIS, V20, P2158, DOI 10.3201/eid2012.130518
   Park JH, 2013, EMERG INFECT DIS, V19, P655, DOI 10.3201/eid1904.121320
   Patil PK, 2002, VET MICROBIOL, V87, P103, DOI 10.1016/S0378-1135(02)00046-9
   Patil PK, 2002, VACCINE, V20, P2781, DOI 10.1016/S0264-410X(02)00184-6
   Paton DJ, 2019, VACCINE, V37, P5515, DOI 10.1016/j.vaccine.2019.07.102
   Sucafusco D, 2014, VACCINE, V32, P6576, DOI 10.1016/j.vaccine.2014.06.056
   안길호, 2013, [Korean Journal of Veterinary Service, 한국가축위생학회지], V36, P15
NR 30
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1723
EP 1729
DI 10.1016/j.vaccine.2019.12.043
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900020
PM 31892447
DA 2020-05-12
ER

PT J
AU McIlhone, KA
   Best, EJ
   Petousis-Harris, H
   Howe, AS
AF McIlhone, Karen A.
   Best, Emma J.
   Petousis-Harris, Helen
   Howe, Anna S.
TI Impact of rotavirus vaccine on paediatric rotavirus hospitalisation and
   intussusception in New Zealand: A retrospective cohort study
SO VACCINE
LA English
DT Article
DE Vaccine safety; Vaccine effectiveness; Post-marketing surveillance;
   Rotavirus; RotaTeq (R); Intussusception
ID ETHNIC DISPARITIES; INFANTS; IMMUNIZATION; DISEASE; TRENDS; PREVENTION;
   RISK; EPIDEMIOLOGY; GUIDELINES; MORTALITY
AB Background: Rotavirus results in a significant burden of hospitalisations and deaths globally. Rotavirus vaccine has been used in New Zealand since July 2014. The aim of this study was to assess the safety and effectiveness of RotaTeq (R) vaccine in New Zealand between 2006 and 2016.
   Methods: A national cohort study of 723,695 children aged less than 6 years was carried out using linked administrative datasets. Study outcomes were hospitalisation for intussusception, rotavirus, and all-cause gastroenteritis. Intussusception hospitalisation rates were calculated from 2006 to 2016, and rotavirus and all-cause gastroenteritis hospitalisation rates from 2011 to 2016. We examined the effect of RotaTeq (R) vaccination on rotavirus and all-cause gastroenteritis hospitalisation rates using Poisson regression. Adjusted incidence rate ratios controlled for sex, year of birth, ethnicity, socioeconomic deprivation, and district health board area.
   Results: Significant reductions in the incidence of rotavirus hospitalisation were seen in all age groups, ethnicities, and deprivation following the introduction of RotaTeq (R). There was a 92.6% reduction in hospitalisation incidence in the vaccinated cohort (p < 0.0001). There was also a 48% reduction in all-cause gastroenteritis hospitalisation incidence in the vaccinated cohort (p < 0.0001). The average annual intussusception rate in children aged less than 3 years was 26.2 per 100,000, with no significant change over time (p = 0.847).
   Conclusions: In New Zealand the introduction of RotaTeq (R) resulted in a significant reduction in rotavirus hospitalisation, and a halving in all-cause gastroenteritis hospitalisation. There has been no change in the overall incidence of intussusception or clear change in patterns of cases, although intussusception cases did occur within risk period immediately post vaccine. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [McIlhone, Karen A.; Petousis-Harris, Helen; Howe, Anna S.] Univ Auckland, Sch Populat Hlth, Dept Gen Practice & Primary Hlth Care, Private Bag 92019,Victoria St West, Auckland 1142, New Zealand.
   [Best, Emma J.] Univ Auckland, Fac Med & Hlth Sci, Dept Paediat, Private Bag 92019,Victoria St West, Auckland 1142, New Zealand.
   [McIlhone, Karen A.] Waikato Populat Hlth Unit, Private Bag 3200, Hamilton 3240, New Zealand.
RP Best, EJ (reprint author), Univ Auckland, Fac Med & Hlth Sci, Dept Paediat Child & Youth Hlth, Sch Med, Auckland, New Zealand.
EM kden027@aucklanduni.ac.nz; e.best@auckland.ac.nz;
   h.petousis-harris@auckland.ac.nz; a.howe@auckland.ac.nz
CR [Anonymous], 1999, MMWR Recomm Rep, V48, P1
   Ardern-Holmes SL, 1999, PEDIATR INFECT DIS J, V18, P614, DOI 10.1097/00006454-199907000-00009
   Atkinson J, 2014, NZDEP2013 INDEX DEPR
   Baker MG, 2012, LANCET, V379, P1112, DOI 10.1016/S0140-6736(11)61780-7
   Bines JE, 2004, VACCINE, V22, P569, DOI 10.1016/j.vaccine.2003.09.016
   Buttery JP, 2011, VACCINE, V29, P3061, DOI 10.1016/j.vaccine.2011.01.088
   Buttery JP, 2007, CURR OPIN INFECT DIS, V20, P253, DOI 10.1097/QCO.0b013e32813aeaac
   Carlin JB, 2013, CLIN INFECT DIS, V57, P1427, DOI 10.1093/cid/cit520
   Centers for Disease Control and Prevention, 1999, MMWR-MORBID MORTAL W, V48, P577
   Centers for Disease Control and Prevention, 2018, GEN BEST PRACT GUID, P1
   Chen E, 2004, NZ MED J, V117, P1
   Chen YE, 2005, ARCH DIS CHILD, V90, P1077, DOI 10.1136/adc.2005.074104
   Clark A, 2019, LANCET GLOB HEALTH, V7, pE1541, DOI 10.1016/S2214-109X(19)30412-7
   Contopoulos-Ioannidis DG, 2015, PEDIATR INFECT DIS J, V34, P712, DOI 10.1097/INF.0000000000000653
   Cortese Margaret M., 2009, Morbidity and Mortality Weekly Report, V58, P1
   Davis P, 2006, LANCET, V367, P1920, DOI 10.1016/S0140-6736(06)68847-8
   Edwards EA, 2017, PEDIATR RADIOL, V47, P1101, DOI 10.1007/s00247-017-3878-x
   Escolano S, 2015, VACCINE, V33, P1017, DOI 10.1016/j.vaccine.2015.01.005
   Halsey NA, 1998, PEDIATRICS, V102, P1483
   Hawken S, 2017, HUM VACC IMMUNOTHER, V13, P703, DOI 10.1080/21645515.2016.1240846
   Health Utilisation Research Alliance (HURA), 2006, J Health Serv Res Policy, V11, P141
   Hobbs MR, 2017, J PAEDIATR CHILD H, V53, P223, DOI 10.1111/jpc.13377
   Jiang JQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055729
   Milne RJ, 2009, VALUE HEALTH, V12, P888, DOI 10.1111/j.1524-4733.2009.00534.x
   Ministry of Health, NZ IMM SCHED
   Ministry of Health, NAT IMM REG
   Ministry of Health, 2018, ANN UPD KEY RES 2016
   Ministry of Health, 2016, IMM COV DAT 1 APR 20
   Ministry of Health, 2017, IMM HDB
   Mueller S, 2012, HEALTH PLACE, V18, P1217, DOI 10.1016/j.healthplace.2012.08.003
   Murphy TV, 2001, NEW ENGL J MED, V344, P564, DOI 10.1056/NEJM200102223440804
   Nakagomi T, 2006, EPIDEMIOL INFECT, V134, P57, DOI 10.1017/S0950268805004644
   Palupi-Baroto R, 2015, AUST NZ J PUBL HEAL, V39, P11, DOI 10.1111/1753-6405.12297
   Parashar UD, 2000, PEDIATRICS, V106, P1413, DOI 10.1542/peds.106.6.1413
   Parashar UD, 2017, VACCINES
   Payne DC, 2015, CLIN INFECT DIS, V60, P163, DOI 10.1093/cid/ciu746
   Rosie B, 2016, NEW ZEAL MED J, V129, P36
   Rumball-Smith J, 2013, INT J QUAL HEALTH C, V25, P248, DOI 10.1093/intqhc/mzt012
   Siegrest CA, 2017, VACCINES, P34
   Simonsen L, 2005, J INFECT DIS, V192, pS36, DOI 10.1086/431512
   Simonsen L, 2001, LANCET, V358, P1224, DOI 10.1016/S0140-6736(01)06346-2
   Tate JE, 2008, PEDIATRICS, V121, pE1125, DOI 10.1542/peds.2007-1590
   Tate JE, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-1082
   Uhlig U, 2014, PEDIATR INFECT DIS J, V33, pE299, DOI [10.1097/INF.0000000000000441, 10.1097]
   Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664
   Webby RJ, 2006, J PAEDIATR CHILD H, V42, P235, DOI 10.1111/j.1440-1754.2006.00844.x
   Yen C, 2012, J INFECT DIS, V206, P41, DOI 10.1093/infdis/jis314
   Yih WK, 2014, NEW ENGL J MED, V370, P503, DOI 10.1056/NEJMoa1303164
NR 48
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1730
EP 1739
DI 10.1016/j.vaccine.2019.12.045
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900021
PM 31889608
DA 2020-05-12
ER

PT J
AU Berezin, EN
   Jarovsky, D
   Cardoso, MRA
   Mantese, OC
AF Berezin, Eitan Naaman
   Jarovsky, Daniel
   Alves Cardoso, Maria Regina
   Mantese, Orlando Cesar
TI Invasive pneumococcal disease among hospitalized children in Brazil
   before and after the introduction of a pneumococcal conjugate vaccine
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; Pneumococcal infections; Pneumococcal vaccines
ID COMMUNITY-ACQUIRED PNEUMONIA; STREPTOCOCCUS-PNEUMONIAE; IMPACT;
   PREVENTION; BURDEN
AB Background: Most of the available data on invasive pneumococcal disease in Latin America are derived from laboratory-based surveillance systems. There is a lack of epidemiological data on the disease severity and mortality from hospitalized patients with pneumococcal infection.
   Methods: In this hospital-based retrospective historical series of hospitalized children with laboratory-confirmed IPD, we evaluated changes in disease episodes, in-hospital fatality rates, and need for intensive care unit admission after the inclusion of PCV10 in the Brazilian vaccination schedule. Invasive pneumococcal strains isolated by culture were serotyped. Changes over time were assessed, and pre-vaccination (2005-2009) to post-vaccination (2011-2015) disease rates and serotypes were compared.
   Results: 260 patients with IPD and positive pneumococcal isolates were identified (198 during the prePCV10 period). When comparing both periods, hospitalizations were reduced from 20 cases to 5 cases per 10,000 pediatric admissions (p < 0.0001). Likewise, fatalities reduced from 6.6 to 2.0 cases per 10,000 pediatric admissions (p < 0.0001). Pneumonia was the most frequent clinical diagnosis (58%) - of which 49.6% had pleural effusion - followed by meningitis (22%) and bacteremia (15.9%). Overall 30% of cases were sent to ICU, with no percentual changes after PCV10. Additional PCV13 serotypes increased from 7% before vaccine introduction to 21% after PCV10 use. Similarly, serotypes not included in PCV13 increased from 11% to 29%.
   Conclusions: There was a significant reduction in the hospitalizations rates, ICU admissions, and fatalities due to IPD after PCV10 introduction in Brazil. Cases due to PCV10 serotypes were reduced, while infections rates caused by non-PCV10 serotypes increased. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Berezin, Eitan Naaman; Jarovsky, Daniel] Pediat Infect Dis Unit, Rua Dr Cesario Mota Jr 112, BR-01221020 Sao Paulo, SP, Brazil.
   [Alves Cardoso, Maria Regina] Univ Sao Paulo, Sch Publ Hlth, Dept Epidemiol, Ave Dr Arnaldo 715, BR-01246904 Sao Paulo, SP, Brazil.
   [Mantese, Orlando Cesar] Univ Fed Uberlandia, Dept Pediat, Ave Para 1720, BR-38405320 Uberlandia, MG, Brazil.
RP Jarovsky, D (reprint author), Alameda Jau 585-121, BR-01420001 Sao Paulo, SP, Brazil.; Berezin, EN; Jarovsky, D (reprint author), Av Roberto Lorenz 482, BR-03178200 Sao Paulo, SP, Brazil.
EM berezin@terra.com.br; daniel@jarovsky.com.br; rcardoso@usp.br
FU Investigator-Initiated Research (IIR) award from Pfizer [WI207554]
FX This research was supported by an Investigator-Initiated Research (IIR)
   award from Pfizer (Pfizer reference #WI207554). The authors were
   responsible for the content of the manuscript and the decision to submit
   for publication. Pfizer had no involvement in the collection,
   statistical analysis, and interpretation of data, in the writing of the
   manuscript, or in the decision to submit the article for publication.
CR Afonso ET, 2013, EMERG INFECT DIS, V19, P589, DOI 10.3201/eid1904.121198
   Andrade AL, 2016, HUM VACC IMMUNOTHER, V12, P285, DOI 10.1080/21645515.2015.1117713
   Angoulvant F, 2014, CLIN INFECT DIS, V58, P918, DOI 10.1093/cid/ciu006
   [Anonymous], 2007, Wkly Epidemiol Rec, V82, P93
   Azarian T, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006966
   Ben-Shimol S, 2012, VACCINE, V30, P6600, DOI 10.1016/j.vaccine.2012.08.012
   Bierrenbach AL, 2018, HUM VACC IMMUNOTHER, V14, P1138, DOI 10.1080/21645515.2017.1391431
   Brandileone MCC, 2018, VACCINE, V36, P2559, DOI 10.1016/j.vaccine.2018.04.010
   Brandileone MCD, 2019, VACCINE, V37, P5357, DOI 10.1016/j.vaccine.2019.07.043
   Brasil. Ministerio da Saude DataSUS, 2018, TABNET WIN32 3 0 IM
   Cassiolato AP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208211
   Pirez MC, 2014, PEDIATR INFECT DIS J, V33, P753, DOI 10.1097/INF.0000000000000294
   Dagan R, 2009, CLIN MICROBIOL INFEC, V15, P16, DOI 10.1111/j.1469-0691.2009.02726.x
   Diaz J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153141
   Domingues CMAS, 2014, LANCET RESP MED, V2, P464, DOI 10.1016/S2213-2600(14)70060-8
   dos Santos SR, 2013, VACCINE, V31, P6150, DOI 10.1016/j.vaccine.2013.05.042
   Feikin DR, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001517
   Grijalva CG, 2010, CLIN INFECT DIS, V50, P805, DOI 10.1086/650573
   Johns Hopkins Bloomberg School of Public Health International Vaccine, 2018, VIEW HUB REP GLOB VA, V29
   Klugman KP, 2018, P NATL ACAD SCI USA, V115, P12896, DOI 10.1073/pnas.1721095115
   Lee GE, 2010, PEDIATRICS, V126, P204, DOI 10.1542/peds.2009-3109
   Loo JD, 2014, PEDIATR INFECT DIS J, V33, pS140, DOI 10.1097/INF.0000000000000082
   Lopez EL, 2018, J PEDIAT INF DIS SOC, V7, P30, DOI 10.1093/jpids/piw089
   Lovgren M, 2007, J CLIN MICROBIOL, V45, P3184, DOI 10.1128/JCM.00789-07
   Ministerio da Saude, 2010, INF TECN VAC PNEUM 1
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Olarte L, 2017, CLIN INFECT DIS, V64, P1699, DOI 10.1093/cid/cix115
   PAHO/WHO, 2017, INF REG SIREVA
   Palmu AA, 2018, ACTA PAEDIATR, V107, P1610, DOI 10.1111/apa.14335
   Palmu AA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172690
   Savulescu C, 2017, LANCET RESP MED, V5, P648, DOI [10.1016/S2213-2600(17)30110-8, 10.1016/s2213-2600(17)30110-8]
   Scotta MC, 2014, VACCINE, V32, P4495, DOI 10.1016/j.vaccine.2014.06.042
   Secretaria de Vigilancia em Saude Ministerio da Saude, 2010, GUIA VIG EP, V1
   Sterky E, 2017, EUR J PEDIATR, V176, P337, DOI 10.1007/s00431-016-2843-2
   Valenzuela MT, 2009, REV PANAM SALUD PUBL, V25, P270, DOI 10.1590/S1020-49892009000300011
   Tomczyk S, 2016, CLIN INFECT DIS, V62, P1119, DOI 10.1093/cid/ciw067
   Ubukata K, 2018, EMERG INFECT DIS, V24, P2010, DOI 10.3201/eid2411.180326
   Verani JR, 2015, VACCINE, V33, P6145, DOI 10.1016/j.vaccine.2015.10.007
   Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X
   Watkins ER, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005034
   Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823
NR 41
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1740
EP 1745
DI 10.1016/j.vaccine.2019.12.038
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900022
PM 31874778
DA 2020-05-12
ER

PT J
AU Su, JR
   Haber, P
   Ng, CS
   Marquez, PL
   Dores, GM
   Perez-Vilar, S
   Cano, MV
AF Su, John R.
   Haber, Penina
   Ng, Carmen S.
   Marquez, Paige L.
   Dores, Graca M.
   Perez-Vilar, Silvia
   Cano, Maria, V
TI Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal
   necrolysis reported after vaccination, 1999-2017
SO VACCINE
LA English
DT Article
DE Erythema multiforme; Stevens Johnson syndrome; Toxic epidermal
   necrolysis; Vaccine; VAERS; Vaccine safety; Surveillance; Data mining
ID RECOMMENDED IMMUNIZATION SCHEDULE; UNITED-STATES; ADVISORY-COMMITTEE;
   SMALLPOX VACCINE; ADVERSE EVENTS; SAFETY; DRUGS; CLASSIFICATION;
   PERTUSSIS; CHILDREN
AB Background: Since the last review of vaccine safety surveillance data for erythema multiforme (EM), Stevens Johnson syndrome (SJS), SJS/TEN, and toxic epidermal necrolysis (TEN) (EM/SJS/TEN), over 37 new vaccines have been introduced in the United States. We sought to describe reported EM/SJS/TEN after vaccines during 1999-2017.
   Methods: We identified U.S. reports of EM/SJS/TEN received by the Vaccine Adverse Event Reporting System (VAERS) during 1999-2017. We stratified analysis by condition (EM, SJS, or TEN), and analyzed reports by serious or non-serious status, sex, age group, time from vaccination to symptom onset, exposure to known causes of EM/SJS/TEN, and vaccines administered. We used Empirical Bayesian data mining to detect vaccine-AE pairs reported more frequently than expected.
   Results: Of 466,027 reports to VAERS during 1999-2017, we identified 984 reports of EM, 89 reports of SJS, 6 reports of SJS/TEN, and 7 reports of TEN. Few reports of EM (9%), and most reports of SJS (52%), SJS/TEN (100%), and TEN (100%) were serious. Overall, 55% of reports described males, 48% described children aged < 4 years; 58% of EM/SJS/TEN occurred <= 7 days after vaccination. Few reports (<= 5%) described exposure to known causes of EM/SJS/TEN. Overall, childhood vaccines (e.g., combined measles, mumps, and rubella vaccine) were most commonly reported. We identified 6 deaths; 4 were exposed to medications associated with EM/SJS/TEN. EM after smallpox vaccine was reported disproportionately among people aged 19-49 years.
   Conclusions: EM/SJS/TEN were rarely reported after vaccination; data mining identified a known association between EM and smallpox vaccine. Published by Elsevier Ltd.
C1 [Su, John R.; Haber, Penina; Ng, Carmen S.; Marquez, Paige L.; Cano, Maria, V] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30329 USA.
   [Dores, Graca M.; Perez-Vilar, Silvia] US FDA, Ctr Biol Evaluat & Res, Off Biostat & Epidemiol, Silver Spring, MD USA.
   [Ng, Carmen S.] Univ Hong Kong, Div Hlth Econ Policy & Management, Sch Publ Hlth, Hong Kong, Peoples R China.
RP Su, JR (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, 1600 Clifton Rd,MS V18-4, Atlanta, GA 30329 USA.
EM ezu2@cdc.gov
OI Dores, Graca/0000-0002-3985-2935
FU Intramural CDC HHS [CC999999]
CR Alerhand S, 2016, PEDIATR EMERG CARE, V32, P472, DOI 10.1097/PEC.0000000000000840
   Ball R, 2001, PEDIATR INFECT DIS J, V20, P219, DOI 10.1097/00006454-200102000-00022
   BASTUJIGARIN S, 1993, ARCH DERMATOL, V129, P92, DOI 10.1001/archderm.129.1.92
   Bessinger GT, 2007, INT J DERMATOL, V46, P460, DOI 10.1111/j.1365-4632.2006.02953.x
   Centers for Disease Control and Prevention, 2017, INFL VACC COV FLUVAX
   Centers for Disease Control and Prevention, US VACC TABL 1
   Centers for Disease Control and Prevention, CDC WOND BRIDG RAC P
   Centers for Diseases Control and Prevention, VACC ADV EV REP SYST
   Chahal D, 2018, DERMATOL ONLINE J, V24
   CHAN HL, 1990, ARCH DERMATOL, V126, P43, DOI 10.1001/archderm.126.1.43
   Criado PR, 2004, J EUR ACAD DERMATOL, V18, P603, DOI 10.1111/j.1468-3083.2004.00989.x
   Daley MF, 2014, VACCINE, V32, P3019, DOI 10.1016/j.vaccine.2014.03.063
   DuMouchel W, 1999, AM STAT, V53, P177, DOI 10.2307/2686093
   Food and Drug Administration, 2018, VACC LIC US US
   Food and Drug Administration, HEPL B
   Frey SE, 2002, NEW ENGL J MED, V346, P1265, DOI 10.1056/NEJMoa020534
   Frey SE, 2003, JAMA-J AM MED ASSOC, V289, P3295, DOI 10.1001/jama.289.24.3295
   Gillis NK, 2017, J INVEST DERMATOL, V137, P2021, DOI 10.1016/j.jid.2017.05.010
   Greenberg RN, 2008, EXPERT OPIN INV DRUG, V17, P555, DOI [10.1517/13543784.17.4.555, 10.1517/13543784.17.4.555 ]
   Hesse EM, 2019, MMWR-MORBID MORTAL W, V68, P91, DOI 10.15585/mmwr.mm6804a4
   HUFF JC, 1988, J AM ACAD DERMATOL, V18, P197, DOI 10.1016/S0190-9622(88)70027-4
   Jarrett B, 2016, BMJ CASE REP
   Katoulis AC, 2010, DERMATOLOGY, V220, P60, DOI 10.1159/000254898
   Kim DK, 2017, ANN INTERN MED, V166, P209, DOI 10.7326/M16-2936
   Leaute-Labreze C, 2000, ARCH DIS CHILD, V83, P347, DOI 10.1136/adc.83.4.347
   Lidholm AG, 2013, CONTACT DERMATITIS, V68, P286, DOI 10.1111/cod.12053
   Miliszewski MA, 2016, AM J MED, V129, P1221, DOI 10.1016/j.amjmed.2016.03.022
   Mockenhaupt M, 2008, J INVEST DERMATOL, V128, P35, DOI 10.1038/sj.jid.5701033
   Oda T, 2017, J INVEST ALLERG CLIN, V27, P274, DOI 10.18176/jiaci.0169
   Olson D, 2017, J PEDIAT INF DIS SOC, V6, pE140, DOI 10.1093/jpids/piw085
   Olson D, 2015, PEDIATRICS, V136, pE386, DOI 10.1542/peds.2015-0278
   Paquet P, 1997, AM J DERMATOPATH, V19, P127, DOI 10.1097/00000372-199704000-00005
   Patel MP, 2014, CLIN KIDNEY J, V7, DOI 10.1093/ckj/sfu027
   Patja A, 2000, PEDIATR INFECT DIS J, V19, P1127, DOI 10.1097/00006454-200012000-00002
   Petersen BW, 2016, MMWR-MORBID MORTAL W, V65, P257, DOI 10.15585/mmwr.mm6510a2
   Raucci U, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068231
   Robinson CL, 2017, MMWR-MORBID MORTAL W, V66, P134, DOI 10.15585/mmwr.mm6605e1
   Rosenblatt AE, 2015, CLIN DERMATOL, V33, P327, DOI 10.1016/j.clindermatol.2014.12.009
   Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035
   Siedner-Weintraub Y, 2017, ACTA DERM-VENEREOL, V97, P489, DOI 10.2340/00015555-2569
   Speirs C J, 1984, Health Trends, V16, P49
   STRATTON KR, 1994, JAMA-J AM MED ASSOC, V271, P1602, DOI 10.1001/jama.271.20.1602
   Szarfman A, 2002, DRUG SAFETY, V25, P381, DOI 10.2165/00002018-200225060-00001
   Tamez RL, 2018, PEDIATR DERMATOL, V35, pE45, DOI 10.1111/pde.13370
   Varricchio F, 2004, PEDIATR INFECT DIS J, V23, P287, DOI 10.1097/00006454-200404000-00002
   Voigt EA, 2016, EXPERT REV VACCINES, V15, P1197, DOI 10.1080/14760584.2016.1175305
   Wang XQ, 2015, J CLIN NEUROSCI, V22, P1005, DOI 10.1016/j.jocn.2015.01.016
   World Health Organization, VACC SAF BAS E LEARN
NR 48
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1746
EP 1752
DI 10.1016/j.vaccine.2019.12.028
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900023
PM 31870573
DA 2020-05-12
ER

PT J
AU Chowdhury, F
   Bhuiyan, TR
   Akter, A
   Bhuiyan, MS
   Khan, AI
   Tauheed, I
   Ahmed, T
   Ferdous, J
   Dash, P
   Basher, SR
   Al Hakim
   Lynch, J
   Kim, JH
   Excler, JL
   Kim, DR
   Clemens, JD
   Qadri, F
AF Chowdhury, Fahima
   Bhuiyan, Taufiqur Rahman
   Akter, Afroza
   Bhuiyan, Md Saruar
   Khan, Ashraful Islam
   Tauheed, Imam
   Ahmed, Tasnuva
   Ferdous, Jannatul
   Dash, Pinki
   Basher, Salima Raiyan
   Al Hakim
   Lynch, Julia
   Kim, Jerome H.
   Excler, Jean-Louis
   Kim, Deok Ryun
   Clemens, John D.
   Qadri, Firdausi
TI Augmented immune responses to a booster dose of oral cholera vaccine in
   Bangladeshi children less than 5 years of age: Revaccination after an
   interval of over three years of primary vaccination with a single dose
   of vaccine
SO VACCINE
LA English
DT Article
DE Oral Cholera Vaccine (OCV); Augmented immune response; Booster dose;
   Primary dose; Shanchol
ID ANTIBODY-SECRETING CELL; SUBUNIT-WHOLE-CELL; VIBRIOCIDAL ANTIBODY;
   DOUBLE-BLIND; B-CELLS; IMMUNOGENICITY; ANTIGEN; SAFETY; PROTECTION;
   INFECTION
AB We have earlier reported that a single dose of oral cholera vaccine (OCV) is protective in adults and children >= 5 years of age and sustained for 2 years. We enrolled participants (n = 240) from this study, between March-September 2017, over 3 years after receiving a primary single dose. Immune responses were measured in placebo group (Primary Immunization group: PI) and compared with those who received a single dose (Booster Immunization group: BI). The children were 4 to <5 years, 5 to <18 years and adults >18 years. Blood was collected at day 0 (before vaccination) and after receiving 1st and 2nd doses of OCV. Overall, the BI and PI groups showed vibriocidal antibody response after 1st and 2nd dose of vaccination in all age groups to V. cholerae O1 and O139. Young children in the BI group showed significantly higher vibriocidal antibody response two weeks after receiving the first dose as compared to PI group to LPS. Elevated plasma IgA responses to LPS after the first dose were observed among the BI group compared to the PI group among the young children. Mucosal antibody responses measured in fecal extracts showed similar increases as that of vibriocidal and LPS responses in the BI group. These results suggest a single boosting dose of OCV generated immune response in primed population >5 years of age who had earlier received OCV. However, young children who had received OCV earlier, boosting after a single dose, resulted in increased immune responses compared to the PI group. Further studies are needed to assess protection obtained from different strategies, especially for young children and to determine the numbers of primary and booster doses needed. In addition, more information is needed regarding the optimum interval between primary and booster doses to plan future interventions for cholera control. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Chowdhury, Fahima; Bhuiyan, Taufiqur Rahman; Akter, Afroza; Bhuiyan, Md Saruar; Khan, Ashraful Islam; Tauheed, Imam; Ahmed, Tasnuva; Ferdous, Jannatul; Dash, Pinki; Basher, Salima Raiyan; Al Hakim; Clemens, John D.; Qadri, Firdausi] Int Ctr Diarrhoeal Dis Res, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.
   [Lynch, Julia; Kim, Jerome H.; Excler, Jean-Louis; Kim, Deok Ryun] Int Vaccine Inst, Seoul, South Korea.
   [Clemens, John D.] UCLA, Fielding Sch Publ Hlth, Los Angeles, CA USA.
   [Clemens, John D.] Korea Univ, Sch Med, Seoul, South Korea.
RP Qadri, F (reprint author), Int Ctr Diarrhoeal Dis Res, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.
EM fqadri@icddrb.org
OI Hakim, Al/0000-0001-9914-7755
FU Bill & Melinda Gates FoundationGates Foundation [OPP52797]; Government
   of Bangladesh [K43 TW010362, R01 A1130378]; Government of Canada [K43
   TW010362, R01 A1130378]; Government of Sweden [K43 TW010362, R01
   A1130378]; Government of UK [K43 TW010362, R01 A1130378]; governments of
   South Korea
FX This study was supported by grant OPP52797 from the Bill & Melinda Gates
   Foundation to the International Vaccine Institute (IVI), Emerging Global
   Leader Award; K43 TW010362, R01 A1130378, core grants from the
   Governments of Bangladesh, Canada, Sweden, and the UK to the
   International Centre for Diarrhoea] Disease Research (icddr,b) and from
   the governments of South Korea to IVI. We thank the staff members of
   icddr,b and IVI for their work in the field, laboratory and data
   management, and the residents of Mirpur for their participation in the
   trial.
CR Abba K, 2010, COCHRANE DB SYST REV, P7
   Ahren C, 1998, INFECT IMMUN, V66, P3311
   Akhtar M, 2017, VACCINE, V35, P321, DOI 10.1016/j.vaccine.2016.11.055
   Aktar A, 2016, CLIN VACCINE IMMUNOL
   Aktar A, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006399
   Alam MM, 2011, CLIN VACCINE IMMUNOL
   Albert MJ, 2003, J INFECT DIS, V187, P909, DOI 10.1086/368132
   Ali M, 2011, J INFECT DIS, V204, P912, DOI 10.1093/infdis/jir416
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P477
   Azman AS, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001867
   Bhattacharya S, 2013, LANCET INFECT DIS, V13, P1050, DOI 10.1016/S1473-3099(13)70273-1
   Bi QF, 2017, LANCET INFECT DIS, V17, P1080, DOI [10.1016/s1473-3099(17)30359-6, 10.1016/S1473-3099(17)30359-6]
   CLEMENS JD, 1987, J INFECT DIS, V155, P79, DOI 10.1093/infdis/155.1.79
   Crotty S, 2004, J IMMUNOL METHODS, V286, P111, DOI 10.1016/j.jim.2003.12.015
   Deen JL, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000173
   Harris JB, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000221
   Kanungo S, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003809
   Kanungo S, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003574
   Kanungo S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096499
   Kanungo S, 2009, VACCINE, V27, P6887, DOI 10.1016/j.vaccine.2009.09.008
   Karlsen TH, 2003, INFECT IMMUN, V71, P3909, DOI 10.1128/IAI.71.7.3909-3913.2003
   Leung DT, 2013, CLIN VACCINE IMMUNOL, V20, P780, DOI 10.1128/CVI.00035-13
   Leung DT, 2012, CLIN VACCINE IMMUNOL
   Lundgren A, 2014, VACCINE, V32, P7077, DOI 10.1016/j.vaccine.2014.10.069
   Luquero FJ, 2018, LANCET INFECT DIS, V18, P947, DOI 10.1016/S1473-3099(18)30465-1
   Luquero FJ, 2014, NEW ENGL J MED, V370, P2111, DOI 10.1056/NEJMoa1312680
   Patel SM, 2012, CLIN VACCINE IMMUNOL
   QADRI F, 1995, CLIN DIAGN LAB IMMUN, V2, P685, DOI 10.1128/CDLI.2.6.685-688.1995
   Qadri F, 2003, INFECT IMMUN, V71, P4808, DOI 10.1128/IAI.71.8.4808-4814.2003
   Qadri F, 2018, LANCET INFECT DIS, V18, P666, DOI 10.1016/S1473-3099(18)30108-7
   Qadri F, 2016, NEW ENGL J MED, V374, P1723, DOI 10.1056/NEJMoa1510330
   Qadri F, 2015, LANCET, V386, P1362, DOI 10.1016/S0140-6736(15)61140-0
   Saha A, 2011, VACCINE, V29, P8285, DOI 10.1016/j.vaccine.2011.08.108
   Sur D, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001289
   Taylor DN, 1999, AM J TROP MED HYG, V61, P869, DOI 10.4269/ajtmh.1999.61.869
   vanLoon FPL, 1996, VACCINE, V14, P162, DOI 10.1016/0264-410X(95)00122-H
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1753
EP 1761
DI 10.1016/j.vaccine.2019.12.034
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900024
PM 31879124
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Olwagen, CP
   Adrian, PV
   Madhi, SA
AF Olwagen, Courtney P.
   Adrian, Peter, V
   Madhi, Shabir A.
TI Evaluation of the impact of HIV-1 infection and density of common
   nasopharyngeal bacterial colonizers in South African children immunized
   with 7-valent pneumococcal conjugate vaccine
SO VACCINE
LA English
DT Article
DE S. pneumoniae; HIV-1 infection; Pneumococcai Conjugate Vaccine; Fluidigm
ID UPPER RESPIRATORY CARRIAGE; STREPTOCOCCUS-PNEUMONIAE;
   STAPHYLOCOCCUS-AUREUS; HAEMOPHILUS-INFLUENZAE; STANDARD METHOD;
   COLONIZATION; INFANTS; COTRIMOXAZOLE; PROPHYLAXIS; ACQUISITION
AB Background: Due to limitations in standard culture methods, the impact of pneumococcal conjugate vaccine (PCV) immunization on nasopharyngeal bacterial carriage density is unclear, including among HIV-infected children.
   Methods: The prevalence and density of serotype/serogroup-specific pneumococcal and other nasopharyngeal colonizing bacteria were investigated in archived swabs of HIV-infected and HIV-uninfected, PCV-7 immunized (at 6, 10 and 14 weeks of age) South African children collected at 9 and 16 months of age. During the course of the study, ACV-immunization of children in Soweto was limited to study-participants, as the vaccine had not been introduced into the public immunization program.
   Results: At 9 months of age, the prevalence of overall pneumococcal colonization was lower in HIV-infected (58.6%) than HIV-uninfected children (69.9%, p = 0.02), mainly due to lower prevalence of non-vaccine-serotype colonization (27.8% vs. 40%, respectively; p = 0.047). The mean-log(10) density of pneumococcal colonization was, however, higher in HIV-infected (4.81 CFU/ml) than HIV-uninfected pneumococcal colonized children (4.44 CFU/ml; p = 0.014); mainly due to higher mean-log(10) density of PCV7-serotype colonization (4.21 vs. 3.72 CFU/ml; p = 0.014). No difference in the prevalence or density of overall pneumococci was found at 16 months of age. The prevalence of non-vaccine serotype colonization remained 1.7 fold higher in HIV-uninfected (60.4%) than HIV-infected children (50.9%, p = 0.049). Other differences included a lower prevalence of H. influenzae colonization in HIV-infected (42.3% and 56%) than HIV-uninfected children (64.2% and 73.4%) at both 9 and 16 months of age respectively; however, the density of colonization was similar.
   Conclusion: Increased carriage density of residual PCV7-serotypes might cause HIV-infected children to have a higher risk of pneumococcal disease. The higher carriage density observed in HIV-infected children could be attributed to a combination of factors, including HIV treatment and impaired host immunity. Additional studies are (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Olwagen, Courtney P.; Adrian, Peter, V; Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, Fac Hlth Sci, Natl Res Fdn,Vaccine Preventable Dis, Johannesburg, South Africa.
   [Olwagen, Courtney P.; Adrian, Peter, V; Madhi, Shabir A.] Univ Witwatersrand, Fac Hlth Sci, Med Res Council, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa.
RP Olwagen, CP (reprint author), Chris Hani Baragwanath Hosp, Resp & Meningeal Pathogens Res Unit, Soweto, South Africa.; Madhi, SA (reprint author), Univ Witwatersrand, Med Res Council, Resp & Meningeal Pathogens Res Unit, Vaccine Preventable Dis, Johannesburg, South Africa.
EM olwagenc@rmpru.co.za; madhis@rmpru.co.za
OI Madhi, Shabir/0000-0002-7629-0636
FU Department for Science and Technology/National Research Foundation
   through the South African Research Chair Initiative; Medical Research
   Council: Respiratory and Meningeal Pathogens Research Unit; PfizerPfizer
FX This study was partially supported financially by grants from the
   Department for Science and Technology/National Research Foundation
   through the South African Research Chair Initiative and Medical Research
   Council: Respiratory and Meningeal Pathogens Research Unit. C.P.O
   received a Robert Austrian Research award in Pneumococcal Vaccinology
   Funded by Pfizer.
CR Azzari C, 2008, J MED MICROBIOL, V57, P1205, DOI 10.1099/jmm.0.2008/000935-0
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Contijoch EJ, 2019, ELIFE, V8, DOI 10.7554/eLife.40553
   Everett DB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017765
   Gill CJ, 2008, B WORLD HEALTH ORGAN, V86, P929, DOI 10.2471/BLT.07.049668
   Grijalva CG, 2014, CLIN INFECT DIS, V58, P1369, DOI 10.1093/cid/ciu148
   Habib M, 2014, JOVE-J VIS EXP, DOI 10.3791/51208
   Hill PC, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-2
   Jallow S, 2017, EXPERT REV VACCINES, V16, P453, DOI 10.1080/14760584.2017.1307740
   Kinabo GD, 2013, TROP MED INT HEALTH, V18, P286, DOI 10.1111/tmi.12057
   Kluytmans J, 1997, CLIN MICROBIOL REV, V10, P505, DOI 10.1128/CMR.10.3.505
   Madhi SA, 2014, SAMJ S AFR MED J, V104, P228, DOI [10.7196/SAMJ.7597, 10.7196/samj.7597]
   Madhi SA, 2007, J INFECT DIS, V196, P1662, DOI 10.1086/522164
   Madhi SA, 2015, VACCINE, V33, P2662, DOI 10.1016/j.vaccine.2015.04.024
   Madhi SA, 2013, VACCINE, V31, P777, DOI 10.1016/j.vaccine.2012.11.076
   Madhi SA, 2010, J INFECT DIS, V202, P355, DOI 10.1086/653704
   McNally LM, 2006, J INFECT DIS, V194, P385, DOI 10.1086/505076
   Nunes MC, 2013, PEDIATR INFECT DIS J, V32, pE192, DOI 10.1097/INF.0b013e31828683a3
   Nunes MC, 2011, AIDS, V25, P453, DOI 10.1097/QAD.0b013e328341b7f1
   O'Brien KL, 2003, PEDIATR INFECT DIS J, V22, P133, DOI 10.1097/00006454-200302000-00009
   O'Brien KL, 2001, J CLIN MICROBIOL, V39, P1021, DOI 10.1128/JCM.39.3.1021-1024.2001
   Olwagen CP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42846-y
   Olwagen CP, 2017, MSPHERE, V2, DOI [10.1128/mSphere.00404-17, 10.1128/msphere.00404-17]
   Pemba L, 2008, J INFECTION, V56, P171, DOI 10.1016/j.jinf.2007.12.003
   Pholwat S, 2016, J CLIN MICROBIOL, V54, P1842, DOI 10.1128/JCM.00613-16
   Satzke C, 2013, VACCINE, V32, P165, DOI 10.1016/j.vaccine.2013.08.062
   Tempia S, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1198-z
   Wolter N, 2014, J INFECT DIS, V210, P1649, DOI 10.1093/infdis/jiu326
   Zar HJ, 2003, J TROP PEDIATRICS, V49, P78, DOI 10.1093/tropej/49.2.78
NR 29
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1762
EP 1769
DI 10.1016/j.vaccine.2019.12.033
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900025
PM 31874779
DA 2020-05-12
ER

PT J
AU Stoecker, C
   Kobayashi, M
   Matanock, A
   Cho, BH
   Pilishvili, T
AF Stoecker, Charles
   Kobayashi, Miwako
   Matanock, Almea
   Cho, Bo-Hyun
   Pilishvili, Tamara
TI Cost-effectiveness of continuing pneumococcal conjugate vaccination at
   age 65 in the context of indirect effects from the childhood
   immunization program
SO VACCINE
LA English
DT Article
DE Vaccinations; Cost-effectiveness; Pneumococcal disease
ID COMMUNITY-ACQUIRED PNEUMONIA; POLYSACCHARIDE VACCINE;
   STREPTOCOCCUS-PNEUMONIAE; ADVISORY-COMMITTEE; UNITED-STATES; ADULTS;
   SEROTYPES; IMPACT; OLDER
AB The findings and conclusions in this report are those of the authors and do not necessarily represent the official positon of the Centers for Disease Control and Prevention.
   Background: Continued indirect effects provided by the childhood pneumococcal conjugate vaccine (13-valent pneumococcal conjugate vaccine [PCV13]) program in the United States have decreased disease in the adult population, reducing the potential direct effects of vaccinating older adults.
   Objective: We examined the incremental cost-effectiveness of continuing to recommend PCV13 in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23) at age 65 compared to a strategy that only included a recommendation for PPSV23 at age 65.
   Methods: We used a probabilistic model following a cohort of 65 year olds in 2019. We used vaccination coverage and disease incidence estimates for healthy adults and adults with chronic medical conditions. We incorporated continued indirect effects from the childhood PCV13 program on adult disease incidence.
   Results: In the base case scenario, continuing to recommend PCV13 at age 65 cost $561,682 per quality-adjusted life year (QALY) gained. In a scenario where PPSV23 provided modest protection against non-invasive pneumococcal pneumonia, costs increased to $2.3 million per QALY. These estimates are larger than our prior estimates for cost-effectiveness of this recommendation in the context of predicted indirect effects due to new data indicating PCV13 provided limited impact on serotype 3, the major cause of the remaining PCV13-type disease. Under our prior assumptions about PCV13 effectiveness against serotype 3 disease, the cost of continuing the recommendation is $207,607 per QALY.
   Conclusion: Indirect effects from the childhood PCV13 program have dramatically increased the cost per QALY of continuing to recommend PCV13 at age 65 after only a few years. (C) 2019 Published by Elsevier Ltd.
C1 [Stoecker, Charles] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Hlth Policy & Management, New Orleans, LA 70118 USA.
   [Kobayashi, Miwako; Matanock, Almea; Cho, Bo-Hyun; Pilishvili, Tamara] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
RP Stoecker, C (reprint author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Hlth Policy & Management, New Orleans, LA 70118 USA.
EM cfstoecker@tulane.edu
CR [Anonymous], 2013, UNPUB
   Black CL, 2017, MMWR-MORBID MORTAL W, V66, P728, DOI 10.15585/mmwr.mm6627a4
   Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544
   Bureau of Labor Statistics, 2012, CONS PRIC IND ALL UR
   Cho BH, 2013, VACCINE, V31, P6011, DOI 10.1016/j.vaccine.2013.10.024
   Cooper D, 2011, VACCINE, V29, P7207, DOI 10.1016/j.vaccine.2011.06.056
   Falkenhorst G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169368
   FINLAND M, 1977, J CLIN MICROBIOL, V5, P154
   Fry AM, 2002, VACCINE, V21, P303, DOI 10.1016/S0264-410X(02)00451-6
   Glied S, 2014, MEDICARE B
   Htar MTT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177985
   Isturiz RE, 2019, VACCINE
   Jain S, 2015, NEW ENGL J MED, V373, P415, DOI 10.1056/NEJMoa1500245
   Linley E, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010004
   Maciosek MV, 2006, AM J PREV MED, V31, P72, DOI 10.1016/j.amepre.2006.03.008
   Melegaro A, 2004, VACCINE, V22, P4203, DOI 10.1016/j.vaccine.2004.05.003
   Nelson JC, 2008, VACCINE, V26, P4947, DOI 10.1016/j.vaccine.2008.07.016
   Palisade Corporation, 2011, RISK 5 7
   Pfizer. Inc, 2016, INT SAL DAT PCV13
   Pilishvili T, 2018, CASE CONTROL STUDY E
   Pilishvili T, 2018, 11 INT S PNEUM PNEUM
   Pilishvili T, 2018, IMPACT 13 VALENT PNE
   Pilishvili T, 2018, 1SPPD 2018 MELB AUST
   Ramirez JA, 2017, CLIN INFECT DIS, V65, P1806, DOI 10.1093/cid/cix647
   Schiffner-Rohe J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146338
   SISK JE, 1986, ANN INTERN MED, V104, P79, DOI 10.7326/0003-4819-104-1-79
   Stoecker C., 2017, Journal of Vaccines and Vaccination, V8, P373, DOI 10.4172/2157-7560.1000373
   Stoecker C, 2016, J GEN INTERN MED, V31, P901, DOI 10.1007/s11606-016-3651-0
   Suaya J, 2018, IDWEEK 2018
   Suaya JA, 2018, VACCINE, V36, P1477, DOI 10.1016/j.vaccine.2018.01.049
   Tomczyk S, 2014, MMWR-MORBID MORTAL W, V63, P822
   Weycker D, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1432-4
   Williams WW, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6501a1
NR 33
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1770
EP 1777
DI 10.1016/j.vaccine.2019.12.029
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900026
PM 31889609
DA 2020-05-12
ER

PT J
AU Sterrett, S
   Peng, BHJ
   Burton, RL
   LaFon, DC
   Westfall, AO
   Singh, S
   Pride, M
   Anderson, AS
   Ippolito, GC
   Schroeder, HW
   Nahm, MH
   Prasad, AK
   Goepfert, P
   Bansal, A
AF Sterrett, Sarah
   Peng, Binghao J.
   Burton, Robert L.
   LaFon, David C.
   Westfall, Andrew O.
   Singh, Suddham
   Pride, Michael
   Anderson, Annaliesa S.
   Ippolito, Gregory C.
   Schroeder, Harry W., Jr.
   Nahm, Moon H.
   Prasad, A. Krishna
   Goepfert, Paul
   Bansal, Anju
TI Peripheral CD4 T follicular cells induced by a conjugated pneumococcal
   vaccine correlate with enhanced opsonophagocytic antibody responses in
   younger individuals
SO VACCINE
LA English
DT Article
DE (3-10): PCV13; PPSV23; CD4 T cells; Pneumococcal antibodies;
   Opsonophagocytic antibodies; T follicular helper cells; Proliferation;
   Polysaccharide; Glycoconjugate and CRM197
ID POLYSACCHARIDE VACCINE; ZWITTERIONIC POLYSACCHARIDES; OLDER-ADULTS;
   PROTEIN; IMMUNIZATION; OPSONIZATION; ACTIVATION; CAPACITY; ABILITY;
   MODEL
AB Background: PCV13 (conjugated polysaccharide) and PPSV23 (polysaccharide only) are two licensed vaccines targeting S. pneumoniae. The role of CD4 T-cell responses in pneumococcal vaccines among healthy participants and their impact on antibodies is not yet known.
   Methods: Ten adults (5 old and 5 young) received PCV13 (prime) and a year later PPSV23 (boost). Blood samples were collected prior to and multiple time points after vaccination. CD4 T cells responding to CRM197, polysaccharide (PS), CRM197 conjugated polysaccharide (CPS), PCV13 and PPSV23 vaccines were measured by flow cytometry. Serum antibodies were analyzed via multiplex opsonophagocytosis (MOPA) and pneumococcal IgG assays.
   Results: Vaccine-specific CD4 T cells were induced in all ten vaccinees post PCV13. Older vaccinees mounted higher peak responses and those specific for PCV13 and conjugated PS-1 were more polyfunctional compared to the younger group. Vaccine-elicited peripheral T follicular helper (Tfh) cells were only detected in the younger group who also exhibited a higher fold change in OPA titers post both vaccines. Importantly, Tfh cells following PCV13 correlated only with PCV13 serotype specific OPA titers after PPSV23 vaccination.
   Conclusions: These findings demonstrate age related differences in immune response and the potential importance of Tfh in modulating functional antibody responses following pneumococcal vaccination. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sterrett, Sarah; Peng, Binghao J.; Burton, Robert L.; LaFon, David C.; Schroeder, Harry W., Jr.; Nahm, Moon H.; Goepfert, Paul; Bansal, Anju] Univ Alabama Birmingham, Dept Med, 845 19th St South,BBRB 557, Birmingham, AL 35294 USA.
   [Sterrett, Sarah; Peng, Binghao J.; Burton, Robert L.; LaFon, David C.; Schroeder, Harry W., Jr.; Nahm, Moon H.; Goepfert, Paul; Bansal, Anju] Univ Alabama Birmingham, Dept Med, 845 19th St South,BBRB 563, Birmingham, AL 35294 USA.
   [Westfall, Andrew O.] Univ Alabama Birmingham, Dept Biostat Birmingham, Birmingham, AL 35294 USA.
   [Schroeder, Harry W., Jr.; Nahm, Moon H.; Goepfert, Paul] Univ Alabama Birmingham, Dept Microbiol Birmingham, Birmingham, AL 35294 USA.
   [Singh, Suddham; Pride, Michael; Anderson, Annaliesa S.; Prasad, A. Krishna] Pfizer Vaccine Res & Dev, Pearl River, NY USA.
   [Ippolito, Gregory C.] Univ Texas Austin, Austin, TX 78712 USA.
RP Bansal, A (reprint author), Univ Alabama Birmingham, Dept Med, 845 19th St South,BBRB 557, Birmingham, AL 35294 USA.; Goepfert, P (reprint author), Univ Alabama Birmingham, Dept Med, 845 19th St South,BBRB 563, Birmingham, AL 35294 USA.
EM pgoepfert@uabmc.edu; anjubansal@uabmc.edu
FU UAB-CCTS [UL1TR001417, 5T32HL105346-09]; Pfizer, USAPfizer
FX Research funding from UAB-CCTS grant UL1TR001417 (PAG), 5T32HL105346-09
   (DCL) and Pfizer, USA supported this work. ASA, SuS and MP are employed
   by Pfizer and as such receive salaries and stocks from Pfizer.
CR Abudulai LN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176641
   Antunes RDS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169086
   Avci FY, 2012, NAT PROTOC, V7, P2180, DOI 10.1038/nprot.2012.138
   Avci FY, 2011, NAT MED, V17, P1602, DOI 10.1038/nm.2535
   Beck SC, 2013, ANN CLIN BIOCHEM, V50, P517, DOI 10.1177/0004563213500241
   Bentebibel SE, 2016, SCI REP-UK, V6, DOI 10.1038/srep26494
   Bentebibel SE, 2011, P NATL ACAD SCI USA, V108, pE488, DOI 10.1073/pnas.1100898108
   Bonten MJM, 2015, NEW ENGL J MED, V372, P1114, DOI 10.1056/NEJMoa1408544
   Burton RL, 2006, CLIN VACCINE IMMUNOL, V13, P1004, DOI 10.1128/CVI.00112-06
   Cabaj JL, 2016, CLIN INFECT DIS, V62, P1521, DOI 10.1093/cid/ciw175
   Chevalier N, 2011, J IMMUNOL, V186, P5556, DOI 10.4049/jimmunol.1002828
   Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004
   Dan JM, 2016, J IMMUNOL, V197, P983, DOI 10.4049/jimmunol.1600318
   Daniels CC, 2013, CLIN VACCINE IMMUNOL, V20, P1549, DOI 10.1128/CVI.00371-13
   Duvall MG, 2008, EUR J IMMUNOL, V38, P350, DOI 10.1002/eji.200737768
   Fedson DS, 2014, HUM VACC IMMUNOTHER, V10, P1322, DOI 10.4161/hv.28797
   Fuery A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133126
   Gonzalez-Fernandez A, 2008, VACCINE, V26, P292, DOI 10.1016/j.vaccine.2007.11.042
   Hajjar J, 2018, J ALLERGY CLIN IMMUN, V142, P1358, DOI 10.1016/j.jaci.2018.06.013
   He J, 2013, IMMUNITY, V39, P770, DOI 10.1016/j.immuni.2013.09.007
   Jackson LA, 2003, NEW ENGL J MED, V348, P1747, DOI 10.1056/NEJMoa022678
   Jackson LA, 2013, VACCINE, V31, P3577, DOI 10.1016/j.vaccine.2013.04.085
   Jha V, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010018
   Johnson JL, 2015, J BIOL CHEM, V290, P5007, DOI 10.1074/jbc.M114.621771
   Kalka-Moll WM, 2000, J IMMUNOL, V164, P719, DOI 10.4049/jimmunol.164.2.719
   Kelly DF, 2004, IMMUNOLOGY, V113, P163, DOI 10.1111/j.1365-2567.2004.01971.x
   LaFon DC, 2018, J IMMUNOL METHODS, V461, P37, DOI 10.1016/j.jim.2018.08.002
   LaFon DC, 2018, J ALLERGY CLIN IMMUN
   Larsen M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042403
   Lee H, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-474
   Locci M, 2013, IMMUNITY, V39, P758, DOI 10.1016/j.immuni.2013.08.031
   Middleton DR, 2017, J IMMUNOL, V199, P598, DOI 10.4049/jimmunol.1700026
   Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012
   Nahm MH, 2000, VACCINE, V18, P2768, DOI 10.1016/S0264-410X(00)00044-X
   Pallotta A, 2016, CLEV CLIN J MED, V83, P427, DOI 10.3949/ccjm.83a.15044
   Park S, 2011, INFECT IMMUN, V79, P314, DOI 10.1128/IAI.00768-10
   Pichichero ME, 2013, HUM VACC IMMUNOTHER, V9, P2505, DOI 10.4161/hv.26109
   Rabian C, 2010, CLIN INFECT DIS, V50, P1174, DOI 10.1086/651418
   Reiss S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186998
   Said MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060273
   Schenkein JG, 2008, VACCINE, V26, P5521, DOI 10.1016/j.vaccine.2008.07.071
   Stephen TL, 2005, INFECT IMMUN, V73, P2184, DOI 10.1128/IAI.73.4.2184-2189.2005
   Stephen TL, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030032
   Tomczyk S, 2014, MMWR-MORBID MORTAL W, V63, P822
   Van Braeckel E, 2013, VACCINE, V31, P3739, DOI 10.1016/j.vaccine.2013.05.021
   Vos Q, 2000, IMMUNOL REV, V176, P154
   Vu DM, 2006, J INFECT DIS, V193, P821, DOI 10.1086/500512
   Wang D, 2008, J BIOPHARM STAT, V18, P307, DOI 10.1080/10543400701697182
   Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598
   Zhang XC, 2013, CLIN VACCINE IMMUNOL, V20, P957, DOI 10.1128/CVI.00223-13
NR 50
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1778
EP 1786
DI 10.1016/j.vaccine.2019.12.023
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900027
PM 31911030
DA 2020-05-12
ER

PT J
AU Accrombessi, M
   Adetola, CV
   Bacharou, S
   Dossou, Y
   Avokpaho, E
   Yakoubou, A
   Koumakpai-Adeothy, S
   Lozes, E
   Issifou, S
AF Accrombessi, Manfred
   Adetola, Crepin Victor
   Bacharou, Salwane
   Dossou, Yannelle
   Avokpaho, Euripide
   Yakoubou, Annatou
   Koumakpai-Adeothy, Sikiratou
   Lozes, Evelyne
   Issifou, Saadou
TI Assessment of the anti-HBs antibody response in Beninese infants
   following 4 doses of HBV vaccine, including administration at birth,
   compared to the standard 3 doses regime; a cross-sectional survey
SO VACCINE
LA English
DT Article
DE Hepatitis B virus; Vaccination scheme; Sustained protective response;
   Benin
ID HEPATITIS-B-VACCINE; NEWBORN-INFANTS; PRETERM INFANTS; IMMUNIZATION;
   TRANSMISSION; PREVENTION; PROTECTION; AFRICA; TRIAL
AB Hepatitis B virus (HBV) infection remains one of the major neglected health issues worldwide. In sub-Saharan Africa (SSA), HBV endemicity is high, with more than 8% of the population being chronic HBV carriers. Recently, WHO recommended that all infants should receive their first dose of the HBV vaccine as soon as possible after birth. Unfortunately, the incorporation of a birth dose of HBV in the expanded programme immunization (EPI) has not occurred in the majority of countries in SSA. From April to September 2017, a cross-sectional survey was conducted in two vaccine units located in southern Benin. We assessed the sustained anti-HBs antibody response in infants induced by a standard scheme of 3 doses of HBV vaccination (6, 10, 14 weeks) in comparison to a scheme of 4 doses with a birth dose included (0, 6, 10, 14 weeks). Blood samples were systematically collected in the first 140 children aged 9 months and their mothers who had consented to participate for the detection of HBs antigen and the quantification of anti-HBs antibodies. The prevalence of HBV infection among infants and mothers was 2.2% and 7.1%, respectively. Infants who received 4 doses of HBV vaccine had a significantly higher level of anti-HBs antibody than those who received 3 doses of vaccine (557.9 UI/L vs. 386.9 UI/L, respectively, P 0.03). We also showed that the scheme of 4 doses was associated with a significantly higher sustained protective response in comparison to the scheme of 3 doses (aOR 2.49, 95% CI 1.03-6.03, P = 0.04). This result provides further evidence of the importance of administering HBV vaccine at birth, but also highlights the importance for the prevention of vertical transmissions. Additional studies are needed to better establish the cost-effectiveness of such a 4 doses immunization strategy before implementing the HBV vaccination at birth in the EPI. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Accrombessi, Manfred; Dossou, Yannelle; Avokpaho, Euripide; Issifou, Saadou] Fondat Rech Sci FORS, Cotonou, Benin.
   [Accrombessi, Manfred; Dossou, Yannelle; Avokpaho, Euripide; Issifou, Saadou] IRCB, Abomey Calavi, Benin.
   [Accrombessi, Manfred] London Sch Hyg & Trop Med, Fac Infect & Trop Dis Dis Control Dept, London, England.
   [Adetola, Crepin Victor] Agence Natl Transfus Sanguine, Lab Antenne Dept, Porto Novo, Benin.
   [Bacharou, Salwane; Yakoubou, Annatou; Koumakpai-Adeothy, Sikiratou; Lozes, Evelyne] Univ Abomey Calavi, EPAC, Abomey Calavi, Benin.
   [Bacharou, Salwane; Koumakpai-Adeothy, Sikiratou] CHU MEL, Unite Vaccinat, Cotonou, Benin.
   [Bacharou, Salwane; Koumakpai-Adeothy, Sikiratou] Unite Vaccinat Ctr Sante Cotonou I, Cotonou, Benin.
RP Accrombessi, M (reprint author), Fondat Rech Sci FORS, Cotonou, Benin.
EM accrombessimanfred@yahoo.fr
OI AVOKPAHO, Euripide/0000-0003-2321-0505
CR [Anonymous], 2009, Wkly Epidemiol Rec, V84, P405
   [Anonymous], 2018, LANCET, V392, P1736, DOI DOI 10.1016/S0140-6736(18)32203-7
   Banatvala J, 2000, VACCINE, V19, P877, DOI 10.1016/S0264-410X(00)00224-3
   Beninese Alliance of Civil Society Organization Against Viral Hepatitis, 2017, STRAT ACT PLAN HEP B
   Chen HL, 2017, J INFECT DIS, V216, pS785, DOI 10.1093/infdis/jix429
   Chen HL, 2012, GASTROENTEROLOGY, V142, P773, DOI 10.1053/j.gastro.2011.12.035
   Das RR, 2009, J TROP PEDIATRICS, V55, P328, DOI 10.1093/tropej/fmp013
   Ekra D, 2008, VACCINE, V26, P2753, DOI 10.1016/j.vaccine.2008.03.018
   Goldstein ST, 2005, INT J EPIDEMIOL, V34, P1329, DOI 10.1093/ije/dyi206
   Howell J, 2014, J VIRAL HEPATITIS, V21, P381, DOI 10.1111/jvh.12263
   Institut National de la Statistique et de l'Analyse Econom- ique (INSAE) ICF, 2019, DEM HLTH SURV BEN 20, P675
   Kodjoh N, 2015, MED SANTE TROP, V25, P141, DOI 10.1684/mst.2015.0439
   Lee C, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004790.pub2
   LEE CY, 1991, PEDIATR INFECT DIS J, V10, P299, DOI 10.1097/00006454-199104000-00007
   Li ZX, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.30
   Linder N, 2002, INFECTION, V30, P136, DOI 10.1007/s15010-002-2068-3
   Losonsky GA, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.2.e14
   MacIntyre CR, 2001, J PAEDIATR CHILD H, V37, P215, DOI 10.1046/j.1440-1754.2001.00639.x
   MARGOLIS HS, 1995, JAMA-J AM MED ASSOC, V274, P1201, DOI 10.1001/jama.274.15.1201
   MARION SA, 1994, AM J EPIDEMIOL, V140, P734, DOI 10.1093/oxfordjournals.aje.a117321
   Omenaca F, 2018, VACCINE, V36, P986, DOI 10.1016/j.vaccine.2018.01.005
   Papageorghiou AT, 2014, LANCET, V384, P869, DOI 10.1016/S0140-6736(14)61490-2
   PONGPIPAT D, 1984, HELV PAEDIATR ACTA, V39, P231
   Schonberger K, 2013, PEDIATR INFECT DIS J, V32, P307, DOI 10.1097/INF.0b013e31827bd1b0
   Schweitzer A, 2015, LANCET, V386, P1546, DOI 10.1016/S0140-6736(15)61412-X
   Trepo C, 2014, LANCET, V384, P2053, DOI 10.1016/S0140-6736(14)60220-8
   WHO Working Group on Hepatitis and HIV Diagnostic Kits, 2003, REP COLL STUD ASS SI
   WONG VCW, 1984, LANCET, V1, P921
   World Health Organization, 2017, GLOB HEP REP 2017
   World Hlth Org, 2019, VACCINE, V37, P223, DOI 10.1016/j.vaccine.2017.07.046
NR 30
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1787
EP 1793
DI 10.1016/j.vaccine.2019.12.031
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900028
PM 31866185
DA 2020-05-12
ER

PT J
AU Fombonne, E
   Goin-Kochel, RP
   O'Roak, BJ
AF Fombonne, Eric
   Goin-Kochel, Robin P.
   O'Roak, Brian J.
CA SPARK Consortium
TI Beliefs in vaccine as causes of autism among SPARK cohort caregivers
SO VACCINE
LA English
DT Article
DE Autism; Autism spectrum disorder; Immunizations; Vaccines; Psychiatric
   disorder; Seizure; Disorder; Sex; Language; Language delay; Regression;
   Intellectual disability; Ethnicity; Social factors
ID SPECTRUM DISORDERS; YOUNGER SIBLINGS; UNITED-STATES; CHILDREN;
   REGRESSION; LANGUAGE; OUTCOMES; RATES
AB Background: Fear of autism has led to a decline in childhood-immunization uptake and to a resurgence of preventable infectious diseases. Identifying characteristics of parents who believe in a causal role of vaccines for autism spectrum disorder (ASD) in their child may help targeting educational activities and improve adherence to the immunization schedule.
   Objectives: To compare caregivers of children with ASD who agree or disagree that vaccines play an etiological role in autism for 1) socio-demographics characteristics and 2) developmental and clinical profiles of their children.
   Methods: Data from 16,525 participants with ASD under age 18 were obtained from SPARK, a national research cohort started in 2016. Caregivers completed questionnaires at registration that included questions on beliefs about the etiologic role of childhood immunizations and other factors in ASD. Data were available about family socio-demographic characteristics, first symptoms of autism, developmental regression, co-occurring psychiatric disorders, seizures, and current levels of functioning.
   Results: Participants with ASD were 80.4% male with a mean age of 8.1 years (SD = 4.1). Overall, 16.5% of caregivers endorsed immunizations as perceived causes of autism. Compared to caregivers who disagreed with vaccines as a cause for ASD, those who believed in vaccine causation came disproportionately from ethnic minority, less educated, and less wealthy backgrounds. More often their children had experienced developmental regression involving language and other skills, were diagnosed earlier, had lost skills during the second year of life, and had worse language, adaptive, and cognitive outcomes.
   Conclusion: One in six caregivers who participate in a national research cohort believe that child immunizations could be a cause of autism in their child. Parent social background (non-White, less educated) and child developmental features (regression in second year, poorer language skills, and worse adaptive outcomes) index caregivers who are more likely to harbor these beliefs and could benefit from targeted educational activities. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fombonne, Eric] Oregon Hlth & Sci Univ, Dept Psychiat, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97239 USA.
   [Fombonne, Eric] Oregon Hlth & Sci Univ, Dept Pediat, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97239 USA.
   [Fombonne, Eric] Oregon Hlth & Sci Univ, Dept Behav Neurosci, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97239 USA.
   [Goin-Kochel, Robin P.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
   [O'Roak, Brian J.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.
RP Fombonne, E (reprint author), Oregon Hlth & Sci Univ, Dept Psychiat, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97239 USA.; Fombonne, E (reprint author), Oregon Hlth & Sci Univ, Dept Pediat, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97239 USA.; Fombonne, E (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM fombonne@ohsu.edu
RI ; Fombonne, Eric/M-4893-2018
OI Kochel, Robin/0000-0001-6666-4369; Fombonne, Eric/0000-0002-8605-3538;
   Michaelson, Jacob/0000-0001-9713-0992
FU Simons Foundation
FX The authors express their thanks to the SPARK team at the Simons
   Foundation and the SPARK cohort participants. We appreciate obtaining
   access to phenotypic data on SFARI Base. Approved researchers can obtain
   the SPARK dataset described in this study by applying at
   httos://base.sfari.org. The SPARK cohort is funded by the Simons
   Foundation. This project was initiated by the authors without specific
   or supplemental funding. The sponsor played no role in designing,
   executing or writing up the results of this analysis.
CR Abu Kuwaik G, 2014, AUTISM, V18, P148, DOI 10.1177/1362361312459111
   [Anonymous], 2014, Transl Neurodegener, V3, P22, DOI 10.1186/2047-9158-3-22
   [Anonymous], 2004, IMM SAF REV VACC AUT
   Barile JP, 2012, J PEDIATR PSYCHOL, V37, P106, DOI 10.1093/jpepsy/jsr048
   Bazzano A, 2012, AJIDD-AM J INTELLECT, V117, P233, DOI 10.1352/1944-7558-117.3.233
   D'Souza Y, 2006, PEDIATRICS, V118, P1664, DOI 10.1542/peds.2006-1262
   De Giacomo A, 1998, EUR CHILD ADOLES PSY, V7, P131, DOI 10.1007/s007870050058
   Durkin MS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011551
   Feliciano P, 2019, NPJ GENOM MED, V4, DOI 10.1038/s41525-019-0093-8
   Feliciano P, 2018, NEURON, V97, P488, DOI 10.1016/j.neuron.2018.01.015
   Fombonne E, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e58
   Fombonne E, DEPENDENT ADUL UNPUB
   Glickman G, 2017, NEW ENGL J MED, V377, P1099, DOI 10.1056/NEJMc1708223
   Godlee Fiona, 2011, BMJ, V342, pc7452, DOI 10.1136/bmj.c7452
   Goin Kochel R.P., 2019, BELIEFS CAUSES UNPUB
   Goin-Kochel RP, 2017, J AUTISM DEV DISORD, V47, P3600, DOI 10.1007/s10803-017-3256-4
   Goin-Kochel RP, 2016, VACCINE, V34, P1335, DOI 10.1016/j.vaccine.2016.02.008
   Goin-Kochel RP, 2014, RES AUTISM SPECT DIS, V8, P890, DOI 10.1016/j.rasd.2014.04.002
   Gust DA, 2008, PEDIATRICS, V122, P718, DOI 10.1542/peds.2007-0538
   Henley SJ, 2014, MMWR-MORBID MORTAL W, V63, P1
   Henrikson NB, 2015, PEDIATRICS, V136, P70, DOI 10.1542/peds.2014-3199
   Hornig M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003140
   Hviid A, 2003, JAMA-J AM MED ASSOC, V290, P1763, DOI 10.1001/jama.290.13.1763
   Hviid A, 2019, ANN INTERN MED, V170, P513, DOI 10.7326/M18-2101
   Kogan MD, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2017-4161
   Lee H, 2010, AM J MED GENET B, V153B, P1119, DOI 10.1002/ajmg.b.31103
   Magiati I, 2014, CLIN PSYCHOL REV, V34, P73, DOI 10.1016/j.cpr.2013.11.002
   Meilleur AAS, 2009, J INTELL DISABIL RES, V53, P115, DOI 10.1111/j.1365-2788.2008.01134.x
   Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365
   Offit PA, 2008, AUTISM FALSE PROPHET
   Opel DJ, 2013, JAMA PEDIATR, V167, P1065, DOI 10.1001/jamapediatrics.2013.2483
   Patel M, 2019, MMWR-MORBID MORTAL W, V68, P402, DOI 10.15585/mmwr.mm6817e1
   Pearson N, 2018, AUTISM RES, V11, P1602, DOI 10.1002/aur.2035
   Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236
   Ratzan SC, 2019, J HEALTH COMMUN, V24, P581, DOI 10.1080/10810730.2019.1622611
   Rosenberg RE, 2013, CLIN PEDIATR, V52, P871, DOI 10.1177/0009922812438435
   Rothman KJ, 2014, J GEN INTERN MED, V29, P1060, DOI 10.1007/s11606-013-2755-z
   Simonoff E, 2008, J AM ACAD CHILD PSY, V47, P921, DOI 10.1097/CHI.0b013e318179964f
   Smeeth L, 2004, LANCET, V364, P963, DOI 10.1016/S0140-6736(04)17020-7
   Tammimies K, 2019, NEUROSCI BIOBEHAV R, V102, P208, DOI 10.1016/j.neubiorev.2019.04.022
   Taylor LE, 2014, VACCINE, V32, P3623, DOI 10.1016/j.vaccine.2014.04.085
   Thompson L, 2019, J AUTISM DEV DISORD, V49, P2281, DOI 10.1007/s10803-018-03871-4
   Verstraeten T, 2003, PEDIATRICS, V112, P1039, DOI 10.1542/peds.112.2.e98
   Wakefield AJ, 2010, LANCET, V375, P445, DOI 10.1016/S0140-6736(10)60175-4
   Wolff ER, 2014, J AM BOARD FAM MED, V27, P458, DOI 10.3122/jabfm.2014.04.130275
   Zerbo O, 2018, JAMA PEDIATR, V172, P469, DOI 10.1001/jamapediatrics.2018.0082
NR 46
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1794
EP 1803
DI 10.1016/j.vaccine.2019.12.026
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900029
PM 31924427
DA 2020-05-12
ER

PT J
AU Jiang, LN
   Wang, J
   Zhang, C
   He, WT
   Mo, JJ
   Zeng, J
   Chen, MM
   Tan, Y
   Ning, CY
AF Jiang, Lina
   Wang, Jing
   Zhang, Chao
   He, Weitao
   Mo, Jianjun
   Zeng, Jun
   Chen, Minmei
   Tan, Yi
   Ning, Chuanyi
TI Effectiveness of enterovirus A71 vaccine in severe hand, foot, and mouth
   disease cases in Guangxi, China
SO VACCINE
LA English
DT Article
DE Enterovirus A71; Inactivated vaccine; Severe hand; Foot and mouth
   disease
ID TEST-NEGATIVE DESIGN; CHILDREN; IMMUNOGENICITY; EFFICACY; SAFETY;
   EPIDEMIOLOGY
AB Background: Hand, foot, and mouth disease (HFMD) caused by enterovirus A71 (EV-A71) is a major public health issue in China that poses severe risks to children's health, especially those under the age of 3. Since 2016, EV71 vaccines developed by three Chinese manufacturers have been approved for use, and clinical trials of these vaccines have demonstrated protection against EV-A71 infection. However, few studies have assessed the effectiveness of these vaccines in real-world settings.
   Methods: A test-negative design case-control study was used to estimate vaccine effectiveness (VE) in cases of severe HFMD. We obtained information including EV-A71 vaccination status from the Local Center for Disease Control and Prevention (CDC) on all severe HFMD cases under 12 years in age in Guangxi, China, from Jan. 1, 2017, to Dec. 31, 2018. Enterovirus infection was laboratory confirmed by local CDCs. Individuals with a positive EV-A71 nucleic acid test result were assigned to the case group, and those with negative EV-A71 nucleic acid test results were assigned to the control group. We estimated VE using logistic regression.
   Results: A total of 2779 severe HFMD cases were enrolled in the study; 838 children were EV-A71 positive cases, and 1941 children were EV-A71 negative controls. The proportion of EV-A71 positive cases aged 6-36 months was lower than that for EV-A71 negative controls. EV-A71 infection was associated with an increased risk of mortality (aOR, 8.8; 95% CI, 1.3-61.6). The adjusted VE was 81.4% and 88.3% for one dose and two doses, respectively.
   Conclusion: Our findings suggest that the rate of EV-A71 has fallen among severe HFMD cases in Guangxi and that the risk for EV-A71 infection in 6-36-month-old children has been reduced by use of the vaccine. Inactivated vaccines performed well in severe HFMD cases in a real-world setting. (C) 2019 Published by Elsevier Ltd.
C1 [Jiang, Lina; Wang, Jing; Zhang, Chao; He, Weitao; Mo, Jianjun; Zeng, Jun; Chen, Minmei; Tan, Yi] Guangxi Ctr Dis Prevent & Control, Inst Acute Communicable Dis Prevent & Control, Nanning 530028, Guangxi, Peoples R China.
   [Ning, Chuanyi] Guangxi Med Univ, Biosafety Level Lab 3, Nanning 530021, Guangxi, Peoples R China.
   [Ning, Chuanyi] Guangxi Med Univ, Nursing Coll, Nanning 530021, Guangxi, Peoples R China.
RP Tan, Y (reprint author), Guangxi Ctr Dis Prevent & Control, 18 Jinzhou Rd, Nanning 530028, Guangxi, Peoples R China.; Ning, CY (reprint author), Guangxi Med Univ, 8 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
EM jcs@gxcdc.com; ningchuanyi@gxmu.edu.cn
RI Ning, Chuanyi/AAF-5601-2020
OI Ning, Chuanyi/0000-0002-8748-2780
FU Guangxi Natural Science FoundationNational Natural Science Foundation of
   Guangxi Province [2017GXNSFAA198369]
FX This work was supported by Guangxi Natural Science Foundation under
   Grant No. 2017GXNSFAA198369.
CR Cao YG, 2019, CENT EUR J IMMUNOL, V44, P1, DOI 10.5114/ceji.2019.84009
   Chang L, 2007, NEW ENGL J MED, V356, P1226, DOI 10.1056/NEJMoa065954
   Chen CW, 2011, VACCINE, V29, P2772, DOI 10.1016/j.vaccine.2011.01.094
   Coleman LA, 2011, VACCINE, V29, P387, DOI 10.1016/j.vaccine.2010.10.082
   Du ZQ, 2019, J MED VIROL, V91, P881, DOI 10.1002/jmv.25393
   Feng S, 2018, AM J EPIDEMIOL, V187, P389, DOI 10.1093/aje/kwx251
   Foppa IM, 2013, VACCINE, V31, P3104, DOI 10.1016/j.vaccine.2013.04.026
   Fukushima W, 2017, VACCINE, V35, P4796, DOI 10.1016/j.vaccine.2017.07.003
   Gu W, 2018, EXPERT REV VACCINES, V17, P257, DOI 10.1080/14760584.2018.1430572
   Gui JJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139109
   Hu YQ, 2015, PEDIATR INFECT DIS J, V34, P951, DOI 10.1097/INF.0000000000000794
   Huang MC, 2006, PEDIATRICS, V118, pE1785, DOI 10.1542/peds.2006-1547
   Huang XY, 2015, SCI REP-UK, V5, DOI 10.1038/srep08904
   Jackson ML, 2018, VACCINE, V36, P751, DOI 10.1016/j.vaccine.2017.12.022
   Jackson ML, 2015, VACCINE, V33, P1313, DOI 10.1016/j.vaccine.2015.01.069
   Ji H, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-248
   [蒋丽娜 Jiang Lina], 2017, [中华疾病控制杂志, Chinese Journal of Disease Control & Prevention], V21, P340
   Li JX, 2016, EXPERT REV VACCINES, V15, P129, DOI 10.1586/14760584.2016.1096782
   Li RC, 2014, NEW ENGL J MED, V370, P829, DOI 10.1056/NEJMoa1303224
   Liu SL, 2015, REV MED VIROL, V25, P115, DOI 10.1002/rmv.1827
   Long LL, 2016, SCI REP-UK, V6, DOI 10.1038/srep23444
   Long L, 2016, INFECT DIS-NOR, V48, P744, DOI 10.1080/23744235.2016.1185801
   Takahashi S, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001958
   Tsai JD, 2014, NEUROPEDIATRICS, V45, P102, DOI 10.1055/s-0033-1360480
   Wang SM, 2009, EXPERT REV ANTI-INFE, V7, P735, DOI [10.1586/eri.09.45, 10.1586/ERI.09.45]
   Wang XY, 2019, ENVIRON TECHNOL, DOI 10.1080/09593330.2019.1687588
   Xie YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088065
   Xing WJ, 2014, LANCET INFECT DIS, V14, P308, DOI 10.1016/S1473-3099(13)70342-6
   Yang B, 2017, EURO SURVEILL, V22
   Yang BY, 2015, PEDIATR INFECT DIS J, V34, P1399, DOI 10.1097/INF.0000000000000900
   Yang F, 2014, CLIN INFECT DIS, V59, P1504, DOI 10.1093/cid/ciu624
   Zhu FC, 2013, LANCET, V381, P2024, DOI 10.1016/S0140-6736(13)61049-1
   Zhu FC, 2014, NEW ENGL J MED, V370, P818, DOI 10.1056/NEJMoa1304923
NR 33
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1804
EP 1809
DI 10.1016/j.vaccine.2019.12.025
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900030
PM 31892446
DA 2020-05-12
ER

PT J
AU Cagol, L
   Seitel, T
   Ehrenberg, S
   Frivolt, K
   Krahl, A
   Lainka, E
   Gerner, P
   Lenhartz, H
   Vermehren, J
   Radke, M
   Trenkel, S
   Mayer, B
   Koletzko, S
   Debatin, KM
   Mertens, T
   Posovszky, C
AF Cagol, Luana
   Seitel, Teresa
   Ehrenberg, Sarah
   Frivolt, Klara
   Krahl, Andreas
   Lainka, Elke
   Gerner, Patrick
   Lenhartz, Henning
   Vermehren, Jan
   Radke, Michael
   Trenkel, Stefan
   Mayer, Benjamin
   Koletzko, Sibylle
   Debatin, Klaus-Michael
   Mertens, Thomas
   Posovszky, Carsten
TI Vaccination rate and immunity of children and adolescents with
   inflammatory bowel disease or autoimmune hepatitis in Germany
SO VACCINE
LA English
DT Article
DE Vaccination; Measles; Varicella zoster virus; Inflammatory bowel
   disease; Crohn's; Ulcerative colitis; Autoimmune hepatitis; Children
ID VARICELLA-ZOSTER-VIRUS; INFLUENZA VACCINE; IMMUNOSUPPRESSED PATIENTS;
   IMMUNIZATION STATUS; RUBELLA; MEASLES; MUMPS; ANTIBODY; THERAPY;
   CYTOMEGALOVIRUS
AB Background and aims: Immunosuppressed patients are at risk of severe infections with vaccination preventable diseases. We evaluated vaccination rate and immunity of children and adolescents with inflammatory bowel disease (IBD) and autoimmune hepatitis (AIH).
   Methods: Immunization rate of 329 children with IBD (n = 300) and AIH (n = 29) was assessed in seven German centres using vaccination certificates, history of chicken pox and by determining anti-varicella zoster virus (VZV) and anti-measles IgG antibodies.
   Results: Of the total cohort 86% received long-term immunosuppression. Four doses of a hexavalent vaccine were documented in 89%, at least one dose of measles, mumps, and rubella (MMR) vaccination was documented in 325 (99%), with 300 (92%) receiving two doses. Anti-measles IgG concentrations were insufficient in 11% of the immunized patients.
   VZV vaccination was officially recommended in Germany since 2004, and implemented in 88% born from 2005 onwards. In patients born earlier VZV catch up vaccination only reached 25% (n = 67). Of 118 patients with documented VZV vaccination 25 (21%) did not display sufficient anti-VZV IgG. Of 198 patients with a history of chicken pox, six had undetectable anti-VZV IgG. Of 29 patients having neither had chicken pox nor VZV vaccination, 20 were found to have sufficient anti-VZV IgG.
   Conclusions: In our cohort vaccination coverage for hexavalent and MMR vaccinations was good, but insufficient for VZV vaccination in patients born before 2005. Neither the vaccination certificate nor the history of chicken pox is reliable to predict VZV immunity indicating a need for serologic investigations and if needed vaccination before initiating immunosuppressive therapy. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Cagol, Luana; Seitel, Teresa; Ehrenberg, Sarah; Debatin, Klaus-Michael; Posovszky, Carsten] Univ Med Ctr Ulm, Dept Pediat & Adolescent Med, Ulm, Germany.
   [Frivolt, Klara; Koletzko, Sibylle] Univ Hosp, Dept Pediat, LMU Munich, Dr von Hauner Childrens Hosp, Munich, Germany.
   [Krahl, Andreas] Darmstadter Kinderklin Prinzessin Margaret, Dieburger Str 31, Darmstadt, Germany.
   [Lainka, Elke] Univ Med Ctr Essen, Dept Pediat & Adolescent Med, Essen, Germany.
   [Gerner, Patrick] Univ Med Ctr Freiburg, Dept Pediat & Adolescent Med, Freiburg, Germany.
   [Lenhartz, Henning] Univ Med Ctr Hamburg Eppendorf, Ctr Obstet & Pediat, Dept Pediat, Hamburg, Germany.
   [Vermehren, Jan] Univ Hosp Regensburg, Univ Childrens Hosp, Regensburg, Germany.
   [Radke, Michael; Trenkel, Stefan] Klinikum Westbrandenburg, Dept Pediat & Adolescent Med, Potsdam, Germany.
   [Mayer, Benjamin] Ulm Univ, Inst Epidemiol & Med Biometry, Ulm, Germany.
   [Koletzko, Sibylle] Univ Warmia & Mazury, Dept Pediat Gastroenterol & Nutr, Sch Med, Coll Med, Olsztyn, Poland.
   [Mertens, Thomas] Univ Med Ctr Ulm, Inst Virol, Ulm, Germany.
RP Posovszky, C (reprint author), Univ Med Ctr Ulm, Pediat Gastroenterol & Nutr, Dept Pediat & Adolescent Med, Eythstr 24, D-89075 Ulm, Germany.
EM carsten.posovszky@uniklinik-ulm.de
RI Posovszky, Carsten/J-5966-2018; Debatin, Klaus-Michael/J-9704-2014
OI Posovszky, Carsten/0000-0002-9487-8812; Debatin,
   Klaus-Michael/0000-0002-8397-1886
FU German Crohn and Colitis Organization
FX This work was supported by an award (Ludwig-Demling research prize in
   2015) of the German Crohn and Colitis Organization to Carsten Posovszky
   donated by the Falk Foundation e.V.
CR Agarwal N, 2012, VACCINE, V30, P1413, DOI 10.1016/j.vaccine.2011.11.109
   Ansari F, 2011, J PEDIATR GASTR NUTR, V53, P386, DOI 10.1097/MPG.0b013e31821e1917
   Asanuma H, 2000, J INFECT DIS, V181, P859, DOI 10.1086/315347
   Balint A, 2015, SCAND J GASTROENTERO, V50, P174, DOI 10.3109/00365521.2014.928902
   Bayer O, 2007, VACCINE, V25, P6655, DOI 10.1016/j.vaccine.2007.07.010
   Beretta-Piccoli BT, 2017, WORLD J GASTROENTERO, V23, P6030, DOI 10.3748/wjg.v23.i33.6030
   Buderus S, 2015, DTSCH ARZTEBL INT, V112, P121, DOI 10.3238/arztebl.2015.0121
   Caldera F, 2019, DIGEST DIS SCI, V64, P189, DOI 10.1007/s10620-018-5321-z
   Caldera F, 2018, DIGEST DIS SCI, V63, P1532, DOI 10.1007/s10620-018-5043-2
   Chaves SS, 2007, NEW ENGL J MED, V356, P1121, DOI 10.1056/NEJMoa064040
   Corica D, 2017, J CLIN GASTROENTEROL, V51, P100, DOI 10.1097/MCG.0000000000000696
   Crawford NW, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-87
   Croce E, 2017, VACCINE, V35, P1216, DOI 10.1016/j.vaccine.2017.01.048
   Cullen G, 2012, INFLAMM BOWEL DIS, V18, P2392, DOI 10.1002/ibd.22950
   Davidkin I, 2008, J INFECT DIS, V197, P950, DOI 10.1086/528993
   deBruyn JCC, 2019, INFLAMM BOWEL DIS, V25, P1218, DOI 10.1093/ibd/izy366
   Della Corte C, 2012, EUR J GASTROEN HEPAT, V24, P739, DOI 10.1097/MEG.0b013e328353750c
   DEUTSCH DE, 1995, J PEDIATR GASTR NUTR, V20, P351, DOI 10.1097/00005176-199504000-00016
   Dipasquale V, 2017, VACCINE, V35, P6070, DOI 10.1016/j.vaccine.2017.09.031
   Floreani A, 2018, J AUTOIMMUN, V95, P133, DOI 10.1016/j.jaut.2018.10.020
   Guariso G, 2017, WORLD J GASTROENTERO, V23, P5469, DOI 10.3748/wjg.v23.i30.5469
   Horstkotter N, 2017, BZGA FORSCHUNGSBERIC
   Krysan Damian J, 2004, J Pediatr, V145, P416, DOI 10.1016/j.jpeds.2004.06.035
   Lawrance IC, 2010, J GASTROEN HEPATOL, V25, P1732, DOI 10.1111/j.1440-1746.2010.06407.x
   Leung VS, 2004, AM J GASTROENTEROL, V99, P2503, DOI 10.1111/j.1572-0241.2004.41389_7.x
   Liese JG, 2008, PEDIATR INFECT DIS J, V27, P119, DOI 10.1097/INF.0b013e3181586665
   Longuet R, 2014, EUR J PEDIATR, V173, P603, DOI 10.1007/s00431-013-2207-0
   Lu Y, 2010, J PEDIATR GASTR NUTR, V50, P562, DOI 10.1097/MPG.0b013e3181bab351
   Lu Y, 2009, INFLAMM BOWEL DIS, V15, P1417, DOI 10.1002/ibd.20941
   Lu Y, 2009, AM J GASTROENTEROL, V104, P444, DOI 10.1038/ajg.2008.120
   Mamula P, 2007, CLIN GASTROENTEROL H, V5, P851, DOI 10.1016/j.cgh.2007.02.035
   Manns MP, 2015, J HEPATOL, V62, pS100, DOI 10.1016/j.jhep.2015.03.005
   Marder E, 2013, MMWR-MORBID MORTAL W, V62, P1
   Marin AC, 2015, WORLD J GASTROENTERO, V21, P11273, DOI 10.3748/wjg.v21.i40.11273
   Marin Mona, 2007, Morbidity and Mortality Weekly Report, V56, P1
   Melmed GY, 2006, AM J GASTROENTEROL, V101, P1834, DOI 10.1111/j.1572-0241.2006.00646.x
   Melmed GY, 2010, AM J GASTROENTEROL, V105, P148, DOI 10.1038/ajg.2009.523
   Naganuma M, 2013, INFLAMM BOWEL DIS, V19, P418, DOI 10.1002/ibd.23027
   Parker S, 2013, INFLAMM BOWEL DIS, V19, P1809, DOI 10.1097/MIB.0b013e31828c8512
   Plans P, 2013, EUR J CLIN MICROBIOL, V32, P961, DOI 10.1007/s10096-013-1836-6
   Poethko-Muller C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042867
   Rahier JF, 2014, J CROHNS COLITIS, V8, P443, DOI 10.1016/j.crohns.2013.12.013
   Rahier JF, 2010, RHEUMATOLOGY, V49, P1815, DOI 10.1093/rheumatology/keq183
   Reiter S., 2012, EPIDEMIOLOGISCHES B
   Robert-Koch-Institut, 2018, EMPF STAND IMPFK STI, P335
   Robert-Koch-Institut, 2016, EPID B, P129
   Robert-Koch-Institut, 2012, EP B, P135
   Rubin LG, 2014, CLIN INFECT DIS, V58, pE44, DOI 10.1093/cid/cit684
   Scheinberg M, 2010, ARTHRIT CARE RES, V62, P896, DOI 10.1002/acr.20045
   Seagle EE, 2018, VACCINE, V36, P818, DOI 10.1016/j.vaccine.2017.12.075
   Soon IS, 2013, CAN J GASTROENTEROL, V27, P213, DOI 10.1155/2013/539524
   Teich N, 2011, DTSCH ARZTEBL INT, V108, P105, DOI 10.3238/arztebl.2011.0105
   Vazquez M, 2004, JAMA-J AM MED ASSOC, V291, P851, DOI 10.1001/jama.291.7.851
   Wallace KL, 2014, WORLD J GASTROENTERO, V20, P6, DOI 10.3748/wjg.v20.i1.6
   Wasan SK, 2011, INFLAMM BOWEL DIS, V17, P2536, DOI 10.1002/ibd.21667
   Waszczuk K, 2015, EUR J GASTROEN HEPAT, V27, P249, DOI 10.1097/MEG.0000000000000280
   Wilckens V, 2011, SCAND J GASTROENTERO, V46, P855, DOI 10.3109/00365521.2011.574734
   Xu XR, 2014, WORLD J GASTROENTERO, V20, P3255, DOI 10.3748/wjg.v20.i12.3255
NR 58
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1810
EP 1817
DI 10.1016/j.vaccine.2019.12.024
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900031
PM 31879123
OA Other Gold
DA 2020-05-12
ER

PT J
AU Nakano, S
   Fujisawa, T
   Ito, Y
   Chang, B
   Matsumura, Y
   Yamamoto, M
   Suga, S
   Ohnishi, M
   Nagao, M
AF Nakano, Satoshi
   Fujisawa, Takao
   Ito, Yutaka
   Chang, Bin
   Matsumura, Yasufumi
   Yamamoto, Masaki
   Suga, Shigeru
   Ohnishi, Makoto
   Nagao, Miki
TI Nationwide surveillance of paediatric invasive and non-invasive
   pneumococcal disease in Japan after the introduction of the 13-valent
   conjugated vaccine, 2015-2017
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; PCV7; PCV13; Japan; Serotype replacement; 12F
ID STREPTOCOCCUS-PNEUMONIAE; ANTIMICROBIAL SUSCEPTIBILITY; RESISTANCE; PCV7
AB Streptococcus pneumoniae is still one of the major causes of morbidity and mortality worldwide. In Japan, pneumococcal conjugate vaccine (PCV)7 and PCV13 were licensed in 2010 and 2013, respectively. We conducted a nationwide paediatric invasive pneumococcal disease (IPD) and non-IPD surveillance study in Japan between 2015 and 2017. We collected 498 IPD isolates and 231 non-IPD isolates from a total of 187 medical institutions in japan. We performed serotyping, antimicrobial susceptibility testing and multi-locus sequencing typing (MLST) for the collected isolates. Among the 498 1PD isolates, the most prevalent serotype was 24F, followed by 12F, 15A and 15B/C. However, 12F increased and 24F significantly decreased during the study period (p < 0.001), resulting in 12F becoming the most prevalent serotype in 2017. Among the IPD isolates, the PCV7 and PCV13 coverage rates were 0.8% and 9.2%, respectively. The most prevalent serotype among the non-IPD isolates was 15A, followed by 35B, 15B/C and 19A. The overall resistance rates to penicillin (PG), cefotaxime (CTX), meropenem (MEM), erythromycin (EM) and levofloxacin (LFX) were 40.5%, 12.2%, 19.4%, 91.8% and 0.5%, respectively. PG, CTX and MEM resistance rates were significantly higher in non-IPD isolates than in IPD isolates (p < 0.001). Serotype 15A-CC63 and serotype 35B-CC558 tended to be multi-drug resistant. In conclusion, the PCV13 coverage rate was significantly lower than that in a previous surveillance study in Japan between 2012 and 2014, and IPD cases attributable to serotype 19A also decreased. We should note the rapid increase in the prevalence of serotype 12F in IPD cases and the spread of the multi-drug resistant serotype 15A-CC63 and 35B-CC558 lineages. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Nakano, Satoshi; Matsumura, Yasufumi; Yamamoto, Masaki; Nagao, Miki] Kyoto Univ, Grad Sch Med, Dept Clin Lab Med, Kyoto, Japan.
   [Fujisawa, Takao; Suga, Shigeru] Natl Hosp Org Mie Natl Hosp, Dept Clin Res, Tsu, Mie, Japan.
   [Ito, Yutaka] Nagoya City Univ, Grad Sch Med Sci, Dept Resp Med Allergy & Rheumatol, Nagoya, Aichi, Japan.
   [Chang, Bin; Ohnishi, Makoto] Natl Inst Infect Dis, Dept Bacteriol 1, Tokyo, Japan.
RP Nakano, S (reprint author), 54 Shogoin Kawahara Cho,Sakyo Ku, Kyoto 6068507, Japan.
EM snakano@kuhp.kyoto-u.ac.jp
OI Nakano, Satoshi/0000-0002-8987-0250
FU PfizerPfizer
FX This study was supported by internal funding and research funding from
   Pfizer for the surveillance study entitled "Clonarity analysis of S.
   pneumoniae isolated from children with pneumococcal infection in Japan".
CR Pinto TCA, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00486
   Camilli R, 2017, VACCINE, V35, P4587, DOI 10.1016/j.vaccine.2017.07.010
   Chancey ST, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00026
   Chen C, 2019, LANCET GLOB HEALTH, V7, pE58, DOI 10.1016/S2214-109X(18)30422-4
   Chiba N, 2014, EMERG INFECT DIS, V20, P1132, DOI 10.3201/eid2007.131485
   Chochua S, 2017, EMERG INFECT DIS, V23, P922, DOI 10.3201/eid2306.170071
   CLSI, 2008, M100S18 CLSI
   Demczuk WHB, 2018, VACCINE, V36, P4701, DOI 10.1016/j.vaccine.2018.06.018
   Emory University, PNEUM MOL EP NETW PM
   Enright MC, 1998, MICROBIOL-UK, V144, P3049, DOI 10.1099/00221287-144-11-3049
   Fenoll A, 2018, VACCINE, V36, P7993, DOI 10.1016/j.vaccine.2018.10.098
   Francisco AP, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-152
   Golden AR, 2019, J ANTIMICROB CHEMOTH, V74, P39, DOI 10.1093/jac/dkz286
   Hauser C, 2016, EUROSURVEILLANCE, V21
   Ikuse T, 2018, EPIDEMIOL INFECT, V146, DOI 10.1017/S0950268818002133
   Mackenzie GA, 2016, LANCET INFECT DIS, V16, P703, DOI 10.1016/S1473-3099(16)00054-2
   Metcalf BJ, 2015, CLIN MICROBIOL INFEC
   Nakano S, 2019, ANTIMICROB AGENTS CH, P63
   Nakano S, 2018, EMERG INFECT DIS, V24, P275, DOI 10.3201/eid2402.171268
   Nakano S, 2016, VACCINE, V34, P67, DOI 10.1016/j.vaccine.2015.11.015
   Ohkusu M, 2019, J MED MICROBIOL
   Park DC, 2019, ANN LAB MED, V39, P537, DOI 10.3343/alm.2019.39.6.537
   Sader HS, 2019, OPEN FORUM INFECT DI, V6, pS14, DOI 10.1093/ofid/ofy263
   Satzke C, 2013, VACCINE, V32, P165, DOI 10.1016/j.vaccine.2013.08.062
   Suga S, VACCINE
   Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4
   Ubukata K, 2018, EMERG INFECT DIS, V24, P2010, DOI 10.3201/eid2411.180326
   Waight PA, 2015, LANCET INFECT DIS, V15, P535, DOI 10.1016/S1473-3099(15)70044-7
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1818
EP 1824
DI 10.1016/j.vaccine.2019.12.022
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900032
PM 31882246
DA 2020-05-12
ER

PT J
AU Anyiwe, K
   Richardson, M
   Brophy, J
   Sander, B
AF Anyiwe, Kika
   Richardson, Marina
   Brophy, Jason
   Sander, Beate
TI Assessing adolescent immunization options for pertussis in Canada: A
   cost-utility analysis
SO VACCINE
LA English
DT Article
DE Pertussis; Cost-utility analysis; Economic evaluation; Adolescent
   immunization; Booster vaccine
ID UNITED-STATES; RISK-FACTORS; STRATEGIES; VACCINE; IMPACT; ADULTS;
   EPIDEMIOLOGY; MENINGITIS; FRACTURES; DURATION
AB Background: Adolescent tetanus, diphtheria and pertussis (Tdap) immunization helps prevent pertussis infection. Timing of Tdap receipt represents an important facet of successful adolescent pertussis immunization. Potential strategies for timing of vaccine administration are each associated with different benefits - including disease prevention - and costs. The objective of this study was to assess the cost-utility of adolescent pertussis immunization strategies in Canada.
   Methods: A cost-utility analysis was conducted using a pertussis disease history-simulating Markov model, with adolescents (beginning at age 10 years) as the cohort of interest. The model assessed three Tdap vaccination strategies: (1) immunization of 10 year olds, (2) removal of adolescent vaccination, and (3) immunization of 14 year olds (status quo). The analysis was conducted from a healthcare payer perspective and used a lifetime time horizon. Primary outcomes included life years, quality-adjusted life years (QALYs), health system costs, and an incremental cost-effectiveness ratio (ICER). Costs and outcomes were discounted at 1.5 percent annually. Deterministic and probabilistic sensitivity analyses were performed to assess parameter uncertainty.
   Results: The current recommended adolescent immunization strategy (at age 14) resulted in an average of 40.4432 expected QALYs and $26.28 per individual. This strategy was dominated by immunization at 10 years and no immunization. Compared to no immunization, immunizing adolescents at age 10 had an ICER of $74,899 per QALY. Results were most sensitive to the incidence of pertussis and the utility of moderate or severe pertussis. At a cost-effectiveness threshold of $50,000/QALY, removal of adolescent vaccination represented the most cost-effective strategy in 78% of simulations.
   Conclusion: Analysis assumes a policy context where immunization of pregnant women is recommended. Findings suggest that alternate adolescent Tdap vaccine strategies - either immunization of 10 year olds, or removal of the adolescent vaccine - are more cost-effective than the current practice of immunizing 14 year olds. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Anyiwe, Kika; Richardson, Marina; Sander, Beate] Univ Toronto, Inst Hlth Policy Management & Evaluat, 155 Coll St, Toronto, ON M5T 3M6, Canada.
   [Anyiwe, Kika; Richardson, Marina; Sander, Beate] Univ Hlth Network, Toronto Gen Hosp, THETA Collaborat, 200 Elizabeth St, Toronto, ON M5G 2C4, Canada.
   [Brophy, Jason] Univ Ottawa, Dept Pediat, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.
   [Brophy, Jason] Childrens Hosp Eastern Ontario, Div Infect Dis, Res Inst, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.
   [Sander, Beate] ICES, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
   [Sander, Beate] Publ Hlth Ontario, 480 Univ Ave,Suite 300, Toronto, ON M5G 1V2, Canada.
RP Anyiwe, K (reprint author), Toronto Gen Hosp, Eaton Bldg,10th Floor,Room 248,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.
EM k.anyiwe@mail.utoronto.ca
CR Adachi JD, 2010, MAYO CLIN PROC, V85, P806, DOI 10.4065/mcp.2010.0082
   [Anonymous], 2017, ONT SCHED BEN LAB SE
   [Anonymous], 2018, IMM COV REP SCH PUP
   [Anonymous], 2015, ONT SCHED PHYS BEN
   [Anonymous], 2018, REP CAS 1991 2016 CA
   [Anonymous], 2017, ONT CAS COST IN
   [Anonymous], 2018, PERT WHOOP COUGH
   [Anonymous], DRUG PROGR POL STRAT
   [Anonymous], 2018, CDC VACC PRIC LIST
   [Anonymous], 2018, UPD IMM PREGN TET TO
   AOYAMA T, 1992, AM J DIS CHILD, V146, P163, DOI 10.1001/archpedi.1992.02160140029015
   CADTH, 2017, GUID EC EV HLTH TECH
   Cohen E, 2012, PEDIATRICS, V130, pE1463, DOI 10.1542/peds.2012-0175
   Czupryna P, 2018, EPIDEMIOL INFECT, V146, P1663, DOI [10.1017/S0950268818002005, 10.1017/s0950268818002005]
   D'Ailly PN, 2016, J SPORT MED PHYS FIT, V56, P744
   De Serres G, 2000, J INFECT DIS, V182, P174, DOI 10.1086/315648
   Deeks S L, 2014, Can Commun Dis Rep, V40, P42
   Desjardins M, 2018, Can Commun Dis Rep, V44, P190, DOI [10.14745/ccdr.44i09a01, 10.14745/ccdr.v44i09a01]
   Ebell MH, 2017, J AM BOARD FAM MED, V30, P308, DOI 10.3122/jabfm.2017.03.160330
   Feagan BG, 2000, CAN MED ASSOC J, V162, P1415
   Fernandes EG, 2019, HUM VACC IMMUNOTHER, V15, P14, DOI 10.1080/21645515.2018.1509646
   Forsyth K, 2015, PEDIATRICS, V135, pE1475, DOI 10.1542/peds.2014-3925
   Guertin JR, 2018, CAN MED ASSOC J, V190, pE155, DOI 10.1503/cmaj.170317
   Halperin SA, 1999, CLIN INFECT DIS, V28, P1238, DOI 10.1086/514792
   HALPERIN SA, 1989, J PEDIATR-US, V115, P686, DOI 10.1016/S0022-3476(89)80643-2
   Hasbun R, 2017, CLIN INFECT DIS, V65, P359, DOI 10.1093/cid/cix319
   Iskedjian M, 2004, VACCINE, V22, P4215, DOI 10.1016/j.vaccine.2004.04.025
   Iskedjian Michael, 2005, Paediatr Drugs, V7, P123, DOI 10.2165/00148581-200507020-00005
   JENKINSON D, 1988, BRIT MED J, V296, P612, DOI 10.1136/bmj.296.6622.612
   Kamiya H, 2016, VACCINE, V34, P1832, DOI 10.1016/j.vaccine.2016.02.027
   Klein NP, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3326
   Klein NP, 2013, PEDIATRICS, V131, pE1716, DOI 10.1542/peds.2012-3836
   Lee GM, 2005, PEDIATRICS, V115, P1675, DOI 10.1542/peds.2004-2509
   Lee Grace M, 2005, Health Qual Life Outcomes, V3, P17, DOI 10.1186/1477-7525-3-17
   Liu BC, 2012, CLIN INFECT DIS, V55, P1450, DOI 10.1093/cid/cis627
   McGirr A., 2017, PERTUSSIS PERSISTENC
   McNamara LA, 2017, CLIN INFECT DIS, V65, P811, DOI 10.1093/cid/cix421
   Neumann PJ, 2014, NEW ENGL J MED, V371, P796, DOI 10.1056/NEJMp1405158
   Oostenbrink R, 2002, J CLIN EPIDEMIOL, V55, P791, DOI 10.1016/S0895-4356(02)00448-1
   Purdy KW, 2004, CLIN INFECT DIS, V39, P20, DOI 10.1086/421091
   Rothstein E, 2005, PEDIATR INFECT DIS J, V24, P544
   Rozenbaum MH, 2012, EPIDEMIOL INFECT, V140, P1503, DOI 10.1017/S0950268811002354
   Sander B, 2016, VACCINE, V34, P1936, DOI 10.1016/j.vaccine.2016.02.016
   Schwartz KL, 2016, CAN MED ASSOC J, V188, pE399, DOI 10.1503/cmaj.160193
   Statistics Canada, TABL 18 10 0004 13 C
   Statistics Canada Life Tables, 2018, LIF TABL CAN PROV TE
   Stey AM, 2014, SURGERY, V155, P1081, DOI 10.1016/j.surg.2014.03.041
   Thampi N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119271
   Wendelboe Aaron M, 2005, Pediatr Infect Dis J, V24, pS58, DOI 10.1097/01.inf.0000160914.59160.41
NR 49
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1825
EP 1833
DI 10.1016/j.vaccine.2019.12.021
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900033
PM 31889607
DA 2020-05-12
ER

PT J
AU Offeddu, V
   Low, MSF
   Surendran, S
   Kembhavi, G
   Tam, CC
AF Offeddu, Vittoria
   Low, Mabel Sheau Fong
   Surendran, Shilpa
   Kembhavi, Gayatri
   Tam, Clarence C.
TI Acceptance and feasibility of school-based seasonal influenza
   vaccination in Singapore: A qualitative study
SO VACCINE
LA English
DT Article
DE Influenza; Influenza vaccine; School-based vaccination
ID CHILDREN; SURVEILLANCE; TRANSMISSION; SATURATION; INTERVIEWS;
   PROTECTION; MORBIDITY; ATTITUDES
AB Introduction: Influenza is a major cause of disease in children. School-based seasonal influenza vaccination can be a cost-effective tool to improve vaccine uptake among children, and can bring substantial health and economic benefits to the broader community. The acceptance and feasibility of school-based influenza vaccination are likely to be highly context-specific, but limited data exist from tropical settings with year-round influenza transmission. We conducted a qualitative study to assess acceptability and feasibility of a school-based seasonal influenza vaccination programme in Singapore.
   Methods: We conducted qualitative in-depth interviews with key stakeholders, including healthcare professionals, representatives of relevant ministries, preschool principals and parents to understand their perspectives on a proposed school-based seasonal influenza vaccination programme. Interviews were transcribed verbatim and analysed using thematic analysis.
   Results: We conducted 40 interviews. Although preschool-aged children are currently the recommended age group for vaccination, stakeholders suggested introducing the programme in primary and/or secondary schools, where existing vaccination infrastructure would facilitate delivery. However, more comprehensive evidence on the local influenza burden and transmission patterns among children is required to develop an evidence-based, locally relevant rationale for a school-based vaccination programme and effectively engage policy-makers, school staff, and parents. Extensive, age-appropriate public education and awareness campaigns would increase the acceptability of the programme among stakeholders. Stakeholders indicated that an opt-out programme with free or subsidised vaccination would be the most likely to achieve high vaccine coverage and make access to vaccination more equitable.
   Conclusions: Overall, participants were supportive of a free or subsidised school-based influenza vaccination programme in primary and/or secondary schools, although children in this age group are not currently a recommended group for vaccination. However, a better informed, evidence-based rationale to estimate the programme's impact in Singapore is currently lacking. Extensive, age-appropriate public education and awareness campaigns will help ensure full support across key stakeholder groups. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Offeddu, Vittoria; Surendran, Shilpa; Kembhavi, Gayatri; Tam, Clarence C.] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Tahir Fdn Bldg MD1,12 Sci Dr 2, Singapore 117549, Singapore.
   [Surendran, Shilpa] Natl Univ Hlth Syst, Singapore 117549, Singapore.
   [Low, Mabel Sheau Fong] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Cambridge, MA 02138 USA.
   [Surendran, Shilpa; Tam, Clarence C.] London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Kembhavi, Gayatri] Ctr Evidence & Implementat, 55 Duxton Rd, Singapore 089519, Singapore.
RP Tam, CC (reprint author), Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Tahir Fdn Bldg MD1,12 Sci Dr 2, Singapore 117549, Singapore.
EM vittoria.offeddu@nus.edu.sg; e0178075@u.nus.edu; clarence.tam@nus.edu.sg
OI Tam, Clarence/0000-0003-1697-286X
FU Singapore Ministry of Education Academic Research Fund (MOE AcRF) Tier 1
   GrantMinistry of Education, Singapore
FX This study was supported by the Singapore Ministry of Education Academic
   Research Fund (MOE AcRF) Tier 1 Grant (FY2015). The funding source was
   not involved in study design, data collection, data analysis,
   interpretation of research findings, or manuscript completion and
   submission.
CR Ali ST, 2018, EMERG INFECT DIS, V24, P2071, DOI 10.3201/eid2411.180612
   Ang LW, 2017, EPIDEMIOL INFECT, V145, P775, DOI 10.1017/S0950268816002491
   Ang LW, 2016, J MED VIROL, V88, P2069, DOI 10.1002/jmv.24566
   Brousseau N, 2015, EPIDEMIOL INFECT, V143, P3405, DOI 10.1017/S0950268815000667
   Brown DS, 2014, VACCINE, V32, P1043, DOI 10.1016/j.vaccine.2014.01.003
   Cowling BJ, 2016, VACCINE, V34, P61, DOI 10.1016/j.vaccine.2015.11.016
   Davis MM, 2008, PEDIATRICS, V122, pE260, DOI 10.1542/peds.2007-2963
   Esposito S, 2003, VACCINE, V21, P3162, DOI 10.1016/S0264-410X(03)00253-6
   Fusch P, 2015, THE QUALITATIVE REPO, V20
   Gargano LM, 2015, J COMMUN HEALTH, V40, P660, DOI 10.1007/s10900-014-9982-z
   Gattas VL, 2015, INFLUENZA OTHER RESP, V9, P323, DOI 10.1111/irv.12328
   Glezen WP, 2006, J CLIN VIROL, V37, P237, DOI 10.1016/j.jcv.2006.08.020
   Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903
   HealthHub-Singapore Minstry of Health, 2019, FLU VACC
   Helmeke C, 2015, PLOS ONE, P10, DOI [10.1371/journal.pone.0122910e0122910, DOI 10.1371/JOUMALDONE.0122.910E0122910]
   Hennink MM, 2017, QUAL HEALTH RES, V27, P591, DOI 10.1177/1049732316665344
   Huang KE, 2014, EPIDEMIOLOGY, V25, P203, DOI 10.1097/EDE.0000000000000055
   Hull HF, 2010, PEDIATR INFECT DIS J, V29, P910, DOI 10.1097/INF.0b013e3181e05579
   Hurwitz ES, 2000, JAMA-J AM MED ASSOC, V284, P1677, DOI 10.1001/jama.284.13.1677
   Kang GJ, 2017, VACCINE, V35, P1987, DOI 10.1016/j.vaccine.2017.03.014
   King JC, 2006, NEW ENGL J MED, V355, P2523, DOI 10.1056/NEJMoa055414
   King JC, 2005, PEDIATRICS, V116, pE868, DOI 10.1542/peds.2005-1301
   Lafond KE, 2016, PLOS MED, P13, DOI [10.1371/journal.pmed.1001977e1001977, DOI 10.1371/JOURNAL.PMED1001977E1001977]
   Lind C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093490
   Low MSF, 2017, VACCINE, V35, P6096, DOI 10.1016/j.vaccine.2017.09.060
   MacDougall D, 2014, BMJ OPEN, DOI [10.1136/bmjopen-2014-005189e005189, DOI 10.1136/HRNJOPEN-7014-00918CLE005189]
   Meeyai A, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001829
   Middelberg APJ, 2011, VACCINE, V29, P7154, DOI 10.1016/j.vaccine.2011.05.075
   Middleman AB, 2012, HUM VACC IMMUNOTHER, V8, P1395, DOI 10.4161/hv.21575
   Middleman AB, 2012, VACCINE, V30, P4993, DOI 10.1016/j.vaccine.2012.05.022
   Middleman AB, 2010, J ADOLESCENT HEALTH, V47, P249, DOI 10.1016/j.jadohealth.2010.01.009
   Offutt-Powell TN, 2014, EPIDEMIOL INFECT, V142, P134, DOI 10.1017/S0950268813000782
   Pannaraj PS, 2014, CLIN INFECT DIS, V59, P325, DOI 10.1093/cid/ciu340
   Pebody R G, 2015, Euro Surveill, V20, P21025, DOI 10.2807/1560-7917.ES2015.20.5.21025
   Pebody RG, 2014, EUROSURVEILLANCE, V19
   Perman S, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4168-0
   Piedra PA, 2007, PEDIATRICS, V120, pE553, DOI 10.1542/peds.2006-2836
   Pitman RJ, 2013, VACCINE, V31, P927, DOI 10.1016/j.vaccine.2012.12.010
   Principi N, 2003, PEDIATR INFECT DIS J, V22, pS207, DOI 10.1097/01.inf.0000092188.48726.e4
   Saunders B, 2018, QUAL QUANT, V52, P1893, DOI 10.1007/s11135-017-0574-8
   Singapore Ministry of Health, 2014, MOH PAND READ RESP P
   Tran CH, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0114479e114479, DOI 10.1371/JOURNALPONP0114479E114479]
   Troeger CE, 2019, LANCET RESP MED, V7, P69, DOI 10.1016/S2213-2600(18)30496-X
   Tsang TK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08036-6
   Viboud C, 2004, BRIT J GEN PRACT, V54, P684
   WHO, 2012, VACC INFL
   Williams V, 2012, J SCH NURS, V28, P256, DOI 10.1177/1059840512438776
   Worby CJ, 2015, EPIDEMICS-NETH, V13, P10, DOI 10.1016/j.epidem.2015.04.003
   Yin JK, 2017, CLIN INFECT DIS, V65, P719, DOI 10.1093/cid/cix420
   Zahari M, 2018, INT SOC INFLUENZA OT
NR 50
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1834
EP 1841
DI 10.1016/j.vaccine.2019.12.020
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900034
PM 31862193
DA 2020-05-12
ER

PT J
AU Hansen, PR
   Schmidtblaicher, M
   Brewer, NT
AF Hansen, Peter R.
   Schmidtblaicher, Matthias
   Brewer, Noel T.
TI Resilience of HPV vaccine uptake in Denmark: Decline and recovery
SO VACCINE
LA English
DT Article
DE HPV vaccination; Resilience; Vaccine hesitancy; Safety
ID HUMAN-PAPILLOMAVIRUS; COVERAGE; CRISIS; HEALTH
AB Background: Immunization programs' resilience to shocks is central to their success, but little empirical evidence documents resilience in action. We sought to characterize the decline of HPV vaccination in Denmark after negative media coverage and recovery during a national information campaign.
   Methods: We conducted a population-based retrospective cohort study of all girls born in Denmark from 1997 to 2006 (N = 328,779), aged 12-15. The outcome measure was HPV vaccine uptake (first dose), as reported to the Danish national health registry from 2009 to 2019, when HPV vaccine was freely available to girls in primary care clinics in Denmark. Events that created 4 natural time periods for study were HPV vaccine reaching the uptake of other vaccines in the national program (2009), some negative media coverage of HPV vaccination (2013), extensive negative media coverage (2015), and a national information campaign about the vaccine's safety and effectiveness (2017-2019).
   Results: In the period with some negative media coverage, HPV vaccine uptake fell to 83.6% (95% CI:78.0%-89.7%) of baseline uptake. In the period with extensive negative media coverage, uptake fell even further to 49.6% (95% CI:44.5%-55.2%) of baseline uptake. After the information campaign, HPV vaccine uptake recovered to its baseline level (109.2%, 95% CI:90.1%-132.4%) due in part to catch-up doses. Despite the recovery, an estimated 26,000 fewer girls initiated the vaccine than if uptake had not declined.
   Conclusions: The experience in Denmark offers one of the first opportunities to document how a nation grappled with negative media coverage of HPV vaccination and the steadying impact of action by national authorities. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hansen, Peter R.] Univ N Carolina, Dept Econ, Gardner Hall CB 3305, Chapel Hill, NC 27599 USA.
   [Hansen, Peter R.] Copenhagen Business Sch, Dept Finance, Copenhagen, Denmark.
   [Schmidtblaicher, Matthias] European Univ Inst, Dept Econ, Florence, Italy.
   [Schmidtblaicher, Matthias] QuantCo Inc, Boston, MA USA.
   [Brewer, Noel T.] Univ N Carolina, Dept Hlth Behav, Gillings Sch Global Publ Hlth, Chapel Hill, NC 27599 USA.
   [Brewer, Noel T.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
RP Hansen, PR (reprint author), Univ N Carolina, Dept Econ, Gardner Hall CB 3305, Chapel Hill, NC 27599 USA.
EM hansen@unc.edu
CR ANDERSON RM, 1985, NATURE, V318, P323, DOI 10.1038/318323a0
   [Anonymous], 2013, LAEG KRIT DOBB INT H
   Arbyn M, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009069.pub3
   Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521
   Brewer NT, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1764
   Brewer NT, 2008, RISK ANAL, V28, P1737, DOI 10.1111/j.1539-6924.2008.01118.x
   Bruni L, 2016, LANCET GLOB HEALTH, V4, pE453, DOI 10.1016/S2214-109X(16)30099-7
   Centers for Disease Control and Prevention (CDC), MMWR MORB MORTAL WKL
   Corcoran B, 2018, LANCET, V391, P2103, DOI 10.1016/S0140-6736(18)30854-7
   Danish Health Authority, 2009, ARSR ARB TASK FORC V
   Danish Health Authority, 2014, CHANG DENM CHILDH VA
   Engholm G, 2010, ACTA ONCOL, V49, P725, DOI 10.3109/02841861003782017
   Faasse K, 2017, VACCINE, V35, P6872, DOI 10.1016/j.vaccine.2017.10.004
   Giuliano AR, 2007, J INFECT DIS, V196, P1153, DOI 10.1086/521679
   Hanley SJB, 2015, LANCET, V385, P2571, DOI 10.1016/S0140-6736(15)61152-7
   Hansen PR, 2019, J BUS ECON STAT, DOI 10.1080/07350015.2019.1623045
   Krause TG, 2012, EUROSURVEILLANCE, V17, P5
   National Health Service, 2009, NHS IMM STAT ENGL 20
   Oliver SE, 2017, J INFECT DIS, V216, P594, DOI 10.1093/infdis/jix244
   Paul KT, 2016, SOC SCI MED, V153, P193, DOI 10.1016/j.socscimed.2016.02.006
   Phillips A, 2018, DRUG SAFETY, V41, P329, DOI 10.1007/s40264-017-0625-z
   Rechel B, 2013, LANCET, V381, P1235, DOI 10.1016/S0140-6736(12)62086-8
   Saslow D, 2018, ACAD PEDIATR, V18, pS11, DOI 10.1016/j.acap.2017.06.003
   Smith MJ, 2008, PEDIATRICS, V121, pE836, DOI 10.1542/peds.2007-1760
   Suppli CH, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6268-x
   The Castro CJ, 2018, J GLOB ONCOL, V4, ps169, DOI [10.1200/jgo.18.78400, DOI 10.1200/IG0.18.78400]
   Vorsters A, 2018, VACCINE, V36, P5219, DOI 10.1016/j.vaccine.2018.06.066
   Vorsters A, 2017, PAPILLOMAVIRUS RES, V4, P45, DOI 10.1016/j.pvr.2017.07.001
   WHO, 2019, WHO FACT SHEET 2019
   Wooldridge JM, 1999, J ECONOMETRICS, V90, P77, DOI 10.1016/S0304-4076(98)00033-5
NR 30
TC 2
Z9 2
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1842
EP 1848
DI 10.1016/j.vaccine.2019.12.019
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900035
PM 31918860
DA 2020-05-12
ER

PT J
AU Puente-Massaguer, E
   Lecina, M
   Godia, F
AF Puente-Massaguer, Eduard
   Lecina, Marti
   Godia, Francesc
TI Application of advanced quantification techniques in nanoparticle-based
   vaccine development with the Sf9 cell baculovirus expression system
SO VACCINE
LA English
DT Article
DE Flow virometry; Nanoparticle tracking analysis; Confocal microscopy;
   Baculovirus expression vector system; Virus-like particle; Statistical
   design; Sf9 cells
ID VIRUS-LIKE PARTICLES; RESPONSE-SURFACE METHODOLOGY; TRANSIENT
   TRANSFECTION; TRACKING ANALYSIS; VLP PRODUCTION; TYPE-1 GAG;
   OPTIMIZATION; SIZE; DENSITY; INFECTION
AB Nanoparticles generated by recombinant technologies are receiving increased interest in several applications, particularly the use of virus like particles (VLPs) for the generation of safer vaccines. The characterization and quantification of these nanoparticles with complex structures is very relevant for a better comprehension of the production systems and should circumvent the limitations of the most conventional quantification techniques often used. Here, we applied confocal microscopy, flow virometry and nanoparticle tracking analysis (NTA) to assess the production process of Gag virus-like particles (VLPs) in the Sf9 cell/baculovirus expression vector system (BEVS). These novel techniques were implemented in an optimization workflow based on Design of Experiments (DoE) and desirability functions to determine the best production conditions. A higher level of sensitivity was observed for NTA and confocal microscopy but flow virometry proved to be more accurate. Interestingly, extracellular vesicles were detected as an important source of contamination of this system. The synergistic interplay of viable cell concentration at infection (CCI), multiplicity of infection (MOI) and time of harvest (TOH) was assessed on five objective responses: VLP assembly, baculovirus infection, VLP production, cell viability and VLP productivity. Two global optimal conditions were defined, one targeting the maximal yield of VLPs and the other providing a balance between production and assembled VLPs. In both cases, a low MOl proved to be the best condition to achieve the highest VLP production and productivity yields. Cryo-EM analysis of nanoparticles produced in these conditions showed the typical size and morphology of HIV-1 VLPs. This study presents an integrative approach based on the combination of DoE and direct nanoparticle quantification techniques to comprehensively optimize the production of VLPs and other viral-based biotherapeutics. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Puente-Massaguer, Eduard; Godia, Francesc] Univ Autonoma Barcelona, Dept Engn Quim Biol & Ambiental, Barcelona, Spain.
   [Lecina, Marti] Univ Ramon Llull, IQS Sch Engn, Barcelona, Spain.
RP Puente-Massaguer, E (reprint author), Univ Autonoma Barcelona, Dept Engn Quim Biol & Ambiental, Escola Engn, Barcelona, Spain.
RI Puente-Massaguer, Eduard/T-7482-2018
OI Puente-Massaguer, Eduard/0000-0002-2816-7051
FU FPU grant from Ministerio de Educacion, Cultura y Deporte of SpainGerman
   Research Foundation (DFG) [FPU15/03577]
FX The authors thank Dr. Nick Berrow (Institute for Research in
   Biomedicine, Barcelona, Spain) for providing the Sf9 cell line. Marta
   Martinez-Calle developed the BV-GageGFP. Angel Calvache (Beckman
   Coulter) facilitated the access to the CytoFlex LX flow cytometer. The
   technical support of Monica Roldan and Marti de Cabo from Servei de
   Microscopia of Universitat Autonoma de Barcelona (UAB) with the confocal
   fluorescence microscope and the cryo-EM, and Paolo Saccardo from
   Plataforma de Produccion de Proteinas, CIBER de Bioingenieria,
   Biomateriales y Nanomedicina (CIBER-BBN) of UAB with baculovirus
   titration are also appreciated. Eduard Puente-Massaguer is a recipient
   of an FPU grant from Ministerio de Educacion, Cultura y Deporte of Spain
   (FPU15/03577). The research group is recognized as 2017 SGR 898 by
   Generalitat de Catalunya.
CR Bernal V, 2009, BIOTECHNOL BIOENG, V104, P162, DOI 10.1002/bit.22364
   Bezerra MA, 2008, TALANTA, V76, P965, DOI 10.1016/j.talanta.2008.05.019
   Bukzem AL, 2016, INT J BIOL MACROMOL, V85, P615, DOI 10.1016/j.ijbiomac.2016.01.017
   Carinhas N, 2009, APPL MICROBIOL BIOT, V81, P1041, DOI 10.1007/s00253-008-1727-4
   Cervera L, 2017, BIOTECHNOL BIOENG, V114, P2507, DOI 10.1002/bit.26367
   Cervera L, 2015, APPL MICROBIOL BIOT, V99, P9935, DOI 10.1007/s00253-015-6842-4
   Cervera L, 2013, J BIOTECHNOL, V166, P152, DOI 10.1016/j.jbiotec.2013.05.001
   Chojnacki J, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0424-3
   Cruz PE, 1998, BIOTECHNOL BIOENG, V60, P408, DOI 10.1002/(SICI)1097-0290(19981120)60:4<408::AID-BIT2>3.3.CO;2-C
   Deml L, 2005, MOL IMMUNOL, V42, P259, DOI 10.1016/j.molimm.2004.06.028
   Deo VK, 2015, MOL PHARMACEUT, V12, P839, DOI 10.1021/mp500860x
   DERRINGER G, 1980, J QUAL TECHNOL, V12, P214
   Donaldson B, 2018, EXPERT REV VACCINES, V17, P833, DOI 10.1080/14760584.2018.1516552
   Fuenmayor J, 2018, APPL MICROBIOL BIOT, V102, P4477, DOI 10.1007/s00253-018-8930-8
   Fuenmayor J, 2018, APPL MICROBIOL BIOT, V102, P165, DOI 10.1007/s00253-017-8605-x
   Gardiner C, 2014, J EXTRACELL VESICLES, V3, P1
   GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8
   Gonzalez-Dominguez I., 2020, QUANTIFICATION HIV 1
   Haynes JR, 2009, VACCINE, V27, P530, DOI 10.1016/j.vaccine.2008.11.011
   Hermida-Matsumoto L, 2000, J VIROL, V74, P8670, DOI 10.1128/JVI.74.18.8670-8679.2000
   Honary S, 2014, PHARM DEV TECHNOL, V19, P987, DOI 10.3109/10837450.2013.846375
   Hu CMJ, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-016-0321-6
   Huynh HT, 2015, APPL MICROBIOL BIOT, V99, P1687, DOI 10.1007/s00253-014-6260-z
   Ikonomou L, 2004, CYTOTECHNOLOGY, V44, P67, DOI 10.1023/B:CYTO.0000043413.53044.fa
   Inamdar K.FlodererC, 2019, VIRUSES, V11, P1
   Kessans SA, 2013, PLANT BIOTECHNOL J, V11, P681, DOI 10.1111/pbi.12058
   Kushnir N, 2012, VACCINE, V31, P58, DOI 10.1016/j.vaccine.2012.10.083
   Lippe R., 2017, J VIROL, V92, P1
   Lua LHL, 2014, BIOTECHNOL BIOENG, V111, P425, DOI 10.1002/bit.25159
   Maranga L, 2003, BIOTECHNOL BIOENG, V84, P245, DOI 10.1002/bit.10773
   McVey MJ, 2018, J EXTRACELL VESICLES, V7, P1
   Mena JA, 2011, EXPERT REV VACCINES, V10, P1063, DOI [10.1586/erv.11.24, 10.1586/ERV.11.24]
   Pillay S, 2009, BIOTECHNOL PROGR, V25, P1153, DOI 10.1002/btpr.187
   Puente-Massaguer E, 2019, ENG LIFE SCI, V19, P315, DOI 10.1002/elsc.201800168
   Puente-Massaguer E, 2018, APPL MICROBIOL BIOT, V102, P10495, DOI 10.1007/s00253-018-9423-5
   Sakuragi S, 2002, P NATL ACAD SCI USA, V99, P7956, DOI 10.1073/pnas.082281199
   Sanders RW, 2017, IMMUNOL REV, V275, P161, DOI 10.1111/imr.12481
   Steppert P, 2017, J CHROMATOGR A, V1487, P89, DOI 10.1016/j.chroma.2016.12.085
   van der Pol E, 2014, J THROMB HAEMOST, V12, P1182, DOI 10.1111/jth.12602
   Van der Pol E, 2012, J THROMB HAEMOST, V10, P919, DOI 10.1111/j.1538-7836.2012.04683.x
   Vestad B, 2017, J EXTRACELL VESICLES, V6, P1, DOI 10.1080/20013078.2017.1344087
   Vicente T, 2011, J INVERTEBR PATHOL, V107, pS42, DOI 10.1016/j.jip.2011.05.004
NR 42
TC 3
Z9 3
U1 10
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1849
EP 1859
DI 10.1016/j.vaccine.2019.11.087
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900036
PM 31911032
DA 2020-05-12
ER

PT J
AU Nath, B
   Vandna
   Saini, HM
   Prasad, M
   Kumar, S
AF Nath, Barnali
   Vandna
   Saini, Hari Mohan
   Prasad, Minakshi
   Kumar, Sachin
TI Evaluation of Japanese encephalitis virus E and NS1 proteins
   immunogenicity using a recombinant Newcastle disease virus in mice
SO VACCINE
LA English
DT Article
DE Newcastle disease virus; Envelope protein; Viral vector; Neutralization;
   Vaccine
ID SWINE-FEVER VIRUS; PROTECTIVE IMMUNITY; ESCHERICHIA-COLI; DNA
   IMMUNIZATION; FUSION PROTEIN; VACCINE; GENOME; SA14-14-2; FLAVIVIRUSES;
   CHALLENGE
AB Japanese encephalitis (JE) is the most important cause of acute encephalitis syndrome (AES). Japanese encephalitis virus (JEV), the prototype member of the JE serocomplex, belongs to the genus Flavivirus. The immunogenic proteins envelope (E) and non-structural protein 1 (NS1) of JEV are widely explored for the development of vaccines and diagnostics against JEV. However, there are underlying concerns such as the risk of reversion of live-attenuated vaccines to high virulence, the incomplete inactivation of pathogens in inactivated vaccines and partial vaccine coverage. Newcastle disease virus (NDV) is an efficient viral vaccine vector to express several human and animal immunogenic proteins. In the present study, we have developed a recombinant NDV (rNDV), individually expressing the E and NS1 proteins of JEV (rNDV-Ejev and rNDV-NS1jev). The recovered rNDV-Ejev and rNDV-NS1jev were characterized in 9-day-old SPF embryonated chicken eggs and in cell culture. The vaccination of rNDV-Ejev and rNDV-NS1jev showed effective immunity against JEV upon intranasal immunization in BALB/c mice. The rNDVs vaccination produced effective neutralization antibody titers against both NDV and JEV. The cytokine profiling of the vaccinated mice showed an effective Th1 and Th2 mediated immune response. The study also provided an insight that E, when used in combination with NS1 could reduce the efficacy of only E based immunization in mice. Our results suggested rNDV-Ejev to be a promising live viral vectored vaccine against JEV. This study implies an alternative and economical strategy for the development of a recombinant vaccine against JEV. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Nath, Barnali; Kumar, Sachin] Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Gauhati 781039, Assam, India.
   [Vandna; Saini, Hari Mohan] Maharshi Dayanand Univ, Ctr Med Biotechnol, Rohtak 124001, Haryana, India.
   [Prasad, Minakshi] Lala Lajpat Rai Univ Vet & Anim Sci, Coll Vet Sci, Hisar 125004, Haryana, India.
RP Kumar, S (reprint author), Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Gauhati 781039, Assam, India.
EM sachinku@iitg.ac.in
FU Department of Biotechnology [BT/562/NE/U-Excel/2016]
FX The NDV research in our laboratory is currently supported by the
   Department of Biotechnology, Govt. of India (BT/562/NE/U-Excel/2016
CR Alexander D J, 1974, Avian Pathol, V3, P269, DOI 10.1080/03079457409353840
   ALEXANDER DJ, 1977, AVIAN PATHOL, V6, P9, DOI 10.1080/03079457708418208
   [Anonymous], 2005, Wkly Epidemiol Rec, V80, P242
   Ashok MS, 1999, VACCINE, V18, P68, DOI 10.1016/S0264-410X(99)00180-2
   Beasley DWC, 2008, EXPERT OPIN BIOL TH, V8, P95, DOI 10.1517/14712598.8.1.95
   Beckham D, 2015, ENCEPHALITIS, P1144
   Bukreyev A, 2008, CURR OPIN MOL THER, V10, P46
   Calvert AE, 2014, VACCINE, V32, P258, DOI 10.1016/j.vaccine.2013.11.016
   Campbell GL, 2011, B WORLD HEALTH ORGAN, V89, P766, DOI 10.2471/BLT.10.085233
   CHAMBERS TJ, 1990, ANNU REV MICROBIOL, V44, P649, DOI 10.1146/annurev.mi.44.100190.003245
   Chang GJJ, 2000, J VIROL, V74, P4244, DOI 10.1128/JVI.74.9.4244-4252.2000
   Chanthavanich P, 2018, HUM VACC IMMUNOTHER, V14, P900, DOI 10.1080/21645515.2017.1414763
   Chen HW, 1999, J VIROL, V73, P10137, DOI 10.1128/JVI.73.12.10137-10145.1999
   Connor Bradley, 2017, Trop Dis Travel Med Vaccines, V3, P14, DOI 10.1186/s40794-017-0057-x
   DUESBERG PH, 1965, P NATL ACAD SCI USA, V54, P794, DOI 10.1073/pnas.54.3.794
   Ferguson M, 2007, VACCINE, V25, P5233, DOI 10.1016/j.vaccine.2007.05.034
   Fischer Marc, 2010, Morbidity and Mortality Weekly Report, V59, P1
   Foumillier A, 2001, J VIROL, V75, P12088
   Gauger PC, 2014, METHODS MOL BIOL, V1161, P313, DOI 10.1007/978-1-4939-0758-8_26
   HAIGWOOD NL, 1992, J VIROL, V66, P172, DOI 10.1128/JVI.66.1.172-182.1992
   Halstead SB, 1992, ARBOVIRUSES PACIFIC
   Halstead SB, 2011, EXPERT REV VACCINES, V10, P355, DOI [10.1586/ERV.11.7, 10.1586/erv.11.7]
   Huang Z, 2003, POULTRY SCI, V82, P899, DOI 10.1093/ps/82.6.899
   Ishikawa T, 2011, VACCINE, V29, P7444, DOI 10.1016/j.vaccine.2011.07.058
   JAN LR, 1993, AM J TROP MED HYG, V48, P412, DOI 10.4269/ajtmh.1993.48.412
   Kaleta EF, 1988, NEWCASTLE DIS DEV VE
   Kaur R, 2003, J NEUROVIROL, V9, P421, DOI 10.1080/13550280390218454
   Khattar SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078521
   Kim SH, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8070183
   KIMURAKURODA J, 1988, J IMMUNOL, V141, P3606
   KONISHI E, 1992, VIROLOGY, V188, P714, DOI 10.1016/0042-6822(92)90526-U
   KONISHI E, 1991, VIROLOGY, V185, P401, DOI 10.1016/0042-6822(91)90788-D
   Kumar R, 2019, ARCH VIROL, V164, P3007, DOI 10.1007/s00705-019-04425-4
   Kumar R, 2018, PROCESS BIOCHEM, V66, P113, DOI 10.1016/j.procbio.2017.12.001
   Kumar R, 2016, VET IMMUNOL IMMUNOP, V172, P50, DOI 10.1016/j.vetimm.2016.03.004
   Kumar S, 2011, J VIROL, V85, P6521, DOI 10.1128/JVI.00367-11
   Lin YL, 1998, J VIROL, V72, P191, DOI 10.1128/JVI.72.1.191-200.1998
   Lindenbach BD, 2007, FLAVIVIRIDAE VIRUSES
   Lobigs M, 2012, EXPERT REV VACCINES, V11, P177, DOI [10.1586/erv.11.180, 10.1586/ERV.11.180]
   Luca VC, 2012, J VIROL, V86, P2337, DOI 10.1128/JVI.06072-11
   Mackenzie JS, 2004, NAT MED, V10, pS98, DOI 10.1038/nm1144
   MASON PW, 1991, VIROLOGY, V180, P294, DOI 10.1016/0042-6822(91)90034-9
   MASON PW, 1989, J GEN VIROL, V70, P2037, DOI 10.1099/0022-1317-70-8-2037
   McMinn PC, 1997, J GEN VIROL, V78, P2711, DOI 10.1099/0022-1317-78-11-2711
   Monath T. P., 1996, FLAVIVIRUSES
   Monath TP, 2002, CURR TOP MICROBIOL, V267, P105
   Monath TP, 1990, FLAVIVIRUSES
   Nascimento IP, 2012, BRAZ J MED BIOL RES, V45, P1102, DOI 10.1590/S0100-879X2012007500142
   Nath B, 2017, MICROB PATHOGENESIS, V111, P187, DOI 10.1016/j.micpath.2017.08.046
   Nja MacLachlan, 2016, FENNERS VET VIROLOGY, P602
   Oliveira ARS, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2354-7
   Pearce JC, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay009
   Rastogi M, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0590-7
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Sakai Y, 1999, FEBS LETT, V456, P221, DOI 10.1016/S0014-5793(99)00960-6
   Samal SK, 2011, BIOLOGY OF PARAMYXOVIRUSES, P69
   Schweitzer BK, 2009, LABMEDICINE, V40, P493, DOI 10.1309/LM5YWS85NJPCWESW
   SEIF SA, 1995, VACCINE, V13, P1515, DOI 10.1016/0264-410X(95)00097-K
   Seif SA, 1996, VIRUS RES, V43, P91, DOI 10.1016/0168-1702(96)01323-8
   Solomon T, 2003, J VIROL, V77, P3091, DOI 10.1128/JVI.77.5.3091-3098.2003
   SRIVASTAVA AK, 1995, VACCINE, V13, P1251, DOI 10.1016/0264-410X(94)00059-V
   SUMIYOSHI H, 1987, VIROLOGY, V161, P497, DOI 10.1016/0042-6822(87)90144-9
   Tsai Theodore F., 2000, Vaccine, V18, P1, DOI 10.1016/S0264-410X(00)00037-2
   Unni SK, 2011, MICROBES INFECT, V13, P312, DOI 10.1016/j.micinf.2011.01.002
   Verma SK, 2009, VACCINE, V27, P6905, DOI 10.1016/j.vaccine.2009.09.006
   Wertz GW, 2002, J VIROL, V76, P7642, DOI 10.1128/JVI.76.15.7642-7650.2002
   WHO, 2007, 58 M WHO EXP COMM BI
   Wilder-Smith A, 2010, CURR OPIN INFECT DIS, V23, P426, DOI 10.1097/QCO.0b013e32833c1d01
   Yu YX, 2010, VACCINE, V28, P3635, DOI 10.1016/j.vaccine.2010.02.105
   Yun SI, 2014, HUM VACC IMMUNOTHER, V10, P263, DOI 10.4161/hv.26902
NR 70
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 11
PY 2020
VL 38
IS 7
BP 1860
EP 1868
DI 10.1016/j.vaccine.2019.11.088
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KO0BB
UT WOS:000515209900037
PM 31955960
DA 2020-05-12
ER

PT J
AU Plotkin, SA
   Offit, PA
   DeStefano, F
   Larson, HJ
   Arora, NK
   Zuber, PLF
   Fombonne, E
   Sejvar, J
   Lambert, PH
   Hviid, A
   Halsey, N
   Garcon, N
   Peden, K
   Pollard, AJ
   Markowitz, LE
   Glanz, J
AF Plotkin, Stanley A.
   Offit, Paul A.
   DeStefano, Frank
   Larson, Heidi J.
   Arora, Narendra Kumar
   Zuber, Patrick L. F.
   Fombonne, Eric
   Sejvar, James
   Lambert, Paul Henri
   Hviid, Anders
   Halsey, Neal
   Garcon, Nathalie
   Peden, Keith
   Pollard, Andrew J.
   Markowitz, Lauri E.
   Glanz, Jason
TI The science of vaccine safety: Summary of meeting at Wellcome Trust
SO VACCINE
LA English
DT Article
DE Safety; Autism; Encephalopathy; Adjuvants; DNA
ID GUILLAIN-BARRE-SYNDROME; PERVASIVE DEVELOPMENTAL DISORDERS;
   HUMAN-PAPILLOMAVIRUS VACCINATION; THIMEROSAL-CONTAINING VACCINES;
   QUADRIVALENT HPV VACCINATION; ACTIVATED H-RAS; T-CELL;
   MULTIPLE-SCLEROSIS; INFLUENZA A(H1N1); UNITED-KINGDOM
AB Vaccines are everywhere hugely successful but are also under attack. The reason for the latter is the perception by some people that vaccines are unsafe. However that may be, vaccine safety, life any other scientific subject, must be constantly studied. It was from this point of view that a meeting was organized at the Wellcome Trust in London in May 2019 to assess some aspects of vaccine safety as subjects for scientific study. The objective of the meeting was to assess what is known beyond reasonable doubt and conversely what areas need additional studies. Although the meeting could not cover all aspects of vaccine safety science, many of the most important issues were addressed by a group of about 30 experts to determine what is already known and what additional studies are merited to assess the safety of the vaccines currently in use. The meeting began with reviews of the current situation in different parts of the world, followed by reviews of specific controversial areas, including the incidence of certain conditions after vaccination and the safety of certain vaccine components. Lastly, information about the human papillomavirus vaccine was considered because its safety has been particularly challenged by vaccine opponents. The following is a summary of the meeting findings. In addition to this summary, the meeting organizers will explore opportunities to perform studies that would enlarge knowledge of vaccine safety.
C1 [Plotkin, Stanley A.] Univ Penn, Vaxconsult, 4650 Wismer Rd, Doylestown, PA 18902 USA.
   [Offit, Paul A.] Childrens Hosp Philadelphia, Vaccine Educ Ctr Div Infect Dis, Philadelphia, PA 19104 USA.
   [DeStefano, Frank] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA.
   [Larson, Heidi J.] London Sch Hyg & Trop Med, Vaccine Confidence Project, London, England.
   [Arora, Narendra Kumar] INCLEN Trust Int New Delhi, Vaccine Hesitancy Cluster, New Delhi, India.
   [Zuber, Patrick L. F.] WHO, SAV, Access Med Vaccines & Pharmaceut, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.
   [Fombonne, Eric] Oregon Hlth & Sci Univ, Inst Dev & Disabil, Portland, OR 97201 USA.
   [Sejvar, James] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA.
   [Lambert, Paul Henri] Univ Geneva, Ctr Vaccinol, Geneva, Switzerland.
   [Hviid, Anders] Statens Serum Inst, Dept Epidemiol Res, Copenhagen, Denmark.
   [Halsey, Neal] Johns Hopkins Bloomberg Sch Publ Hlth, Inst Vaccine Safety, Baltimore, MD 21205 USA.
   [Garcon, Nathalie] BIOASTER, 40 Ave Tony Garnier, Lyon, France.
   [Peden, Keith] US FDA, Lab DNA Viruses, Div Viral Prod, Off Vaccines Res & Review,Ctr Biol Evaluat & Revi, Silver Spring, MD 20993 USA.
   [Pollard, Andrew J.] Univ Oxford, Childrens Hosp, St Cross Coll, Dept Paediat, Room 02-46-07,Level 2, Oxford OX3 9DU, England.
   [Markowitz, Lauri E.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Glanz, Jason] Colorado Sch Publ Hlth, Kaiser Permanente Colorado, Inst Hlth Res, Dept Epidemiol, Aurora, CO USA.
RP Plotkin, SA (reprint author), Univ Penn, Vaxconsult, 4650 Wismer Rd, Doylestown, PA 18902 USA.
EM Stanley.plotkin@vaxconsult.com; offit@email.chop.edu;
   Heidi.larson@ishtm.ac.uk; nkarora@inclentrust.org; fombonne@ohsu.edu;
   Zea3@cdc.gov; paul.lambert@unige.ch; aii@ssi.dk; nhalsey1@jhu.edu;
   keith.peden@fda.hhs.gov; lem2@cdc.gov
RI Fombonne, Eric/M-4893-2018
OI Fombonne, Eric/0000-0002-8605-3538
FU World Health OrganizationWorld Health Organization [001]
CR Ahmed SS, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2354
   Andrews N, 2004, PEDIATRICS, V114, P584, DOI 10.1542/peds.2003-1177-L
   Andrews N, 2017, VACCINE, V35, P1729, DOI 10.1016/j.vaccine.2017.01.076
   [Anonymous], 2019, TIMES INDIA
   Arnheim-Dahlstom L, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5906
   Asturias EJ, 2016, VACCINE, V34, P3342, DOI 10.1016/j.vaccine.2016.05.018
   Autran B, 2009, EXPERT REV VACCINES, V8, P705, DOI 10.1586/ERV.09.40
   Bahri P, 2018, BRIT J CLIN PHARMACO, V84, P1696, DOI 10.1111/bcp.13587
   Bahri P, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0850-4
   Barroso-Sousa R, 2018, JAMA ONCOL, V4, P173, DOI 10.1001/jamaoncol.2017.3064
   Belongia Edward A, 2003, Clin Med Res, V1, P87
   Bergfors E, 2017, CLIN TRANSL MED, V6, DOI 10.1186/s40169-016-0129-y
   Bernard-Valnet R, 2016, P NATL ACAD SCI USA, V113, P10956, DOI 10.1073/pnas.1603325113
   BISTONI F, 1986, INFECT IMMUN, V51, P668, DOI 10.1128/IAI.51.2.668-674.1986
   Burgos-Barragan G, 2017, NATURE, V548, P549, DOI 10.1038/nature23481
   Chaturvedi S, 2009, INDIAN PEDIATR, V46, P115
   Chen W, 2004, PSYCHOL MED, V34, P543, DOI 10.1017/S0033291703001259
   Christensen J, 2013, JAMA-J AM MED ASSOC, V309, P1696, DOI 10.1001/jama.2013.2270
   Clarkson TW, 2003, NEW ENGL J MED, V349, P1731, DOI 10.1056/NEJMra022471
   D'Souza Y, 2006, PEDIATRICS, V118, P1664, DOI 10.1542/peds.2006-1262
   Da Silva FT, 2015, HUM VACC IMMUNOTHER, V11, P1814, DOI 10.1080/21645515.2015.1043501
   Da Silva FT, 2013, VACCINE, V31, P1870, DOI 10.1016/j.vaccine.2013.01.042
   de Wit E, 2018, J INFECT DIS, V217, P1237, DOI 10.1093/infdis/jiy003
   Deceuninck G, 2018, EXPERT REV VACCINES, V17, P99, DOI 10.1080/14760584.2018.1388168
   Dempsey AF, 2011, PEDIATRICS, V128, P848, DOI 10.1542/peds.2011-0400
   Donahue JG, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-1808
   Elwood JM, 2018, VACCINE, V36, P5796, DOI 10.1016/j.vaccine.2018.07.074
   European Centre for Disease Prevention and Control, 2015, RAP LIT REV MOT HES
   European Commission, 2018, STAT VACC CONF EU
   European Medicines Agency, 2016, HPV VACC EMA CONF EV
   European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP), 2005, GUID ADJ VACC HUM US
   Feiring B, 2017, VACCINE, V35, P4203, DOI 10.1016/j.vaccine.2017.06.031
   Fernandes GC, 2007, VACCINE, V25, P3124, DOI 10.1016/j.vaccine.2007.01.078
   Fombonne E, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e58
   Fombonne E, 2006, PEDIATRICS, V118, pE139, DOI 10.1542/peds.2005-2993
   Food and Drug Administration, COMM INGR US LIC VAC
   Gabay C, 2011, ARTHRITIS RHEUM-US, V63, P3383, DOI 10.1002/art.30574
   Garcon N, 2011, PERSPECT VACCINOL, P89, DOI DOI 10.1016/J.PERVAC.2011.05.004
   Gee J, 2017, VACCINE, V35, P5756, DOI 10.1016/j.vaccine.2017.09.009
   Genovese C, 2018, J Prev Med Hyg, V59, pE194, DOI 10.15167/2421-4248/jpmh2018.59.3.998
   Glanz JM, 2018, JAMA-J AM MED ASSOC, V319, P906, DOI 10.1001/jama.2018.0708
   Glanz Jason M, 2016, Vaccine, V34 Suppl 1, pA1, DOI 10.1016/j.vaccine.2015.10.082
   Global Advisory Committee on Vaccine Safety (GACVS), 2012, WEEKLY EPIDEMIOLOGIC, V87, P277
   Goodridge HS, 2016, NAT REV IMMUNOL, V16, P392, DOI 10.1038/nri.2016.43
   Gurnani V, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4782
   Han F, 2011, ANN NEUROL, V70, P410, DOI 10.1002/ana.22587
   Hem SL, 2002, VACCINE, V20, pS40, DOI 10.1016/S0264-410X(02)00170-6
   HEMACHUDHA T, 1987, NEW ENGL J MED, V316, P369, DOI 10.1056/NEJM198702123160703
   Heron J, 2004, PEDIATRICS, V114, P577, DOI 10.1542/peds.2003-1176-L
   Hertz-Picciotto I, 2010, ENVIRON HEALTH PERSP, V118, P161, DOI 10.1289/ehp.0900736
   Hicks DJ, 2012, CLIN EXP IMMUNOL, V169, P199, DOI 10.1111/j.1365-2249.2012.04592.x
   Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170
   Hornig M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003140
   Hultman CM, 2011, MOL PSYCHIATR, V16, P1203, DOI 10.1038/mp.2010.121
   Hviid A, 2018, J INTERN MED, V283, P154, DOI 10.1111/joim.12694
   Hviid A, 2003, JAMA-J AM MED ASSOC, V290, P1763, DOI 10.1001/jama.290.13.1763
   Hviid A, 2019, ANN INTERN MED
   IOM (Institute of Medicine), 2013, COMM ASS STUD HLTH O
   Jayaraman K, 2019, PEDIATR INFECT DIS J, V38, P198, DOI 10.1097/INF.0000000000002198
   Jiang HY, 2019, VACCINE, V37, P3031, DOI 10.1016/j.vaccine.2019.04.049
   Kaden D, 2010, WHO GUIDELINES INDOO
   Kandasamy R, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5225
   Karafillakis E, 2017, VACCINE, V35, P4840, DOI 10.1016/j.vaccine.2017.07.061
   Klein NP, 2019, VACCINE, V37, P1938, DOI 10.1016/j.vaccine.2019.02.051
   Klein NP, 2009, BMJ CASE REP
   Knobel DL, 2017, VACCINE, V35, P3844, DOI 10.1016/j.vaccine.2017.05.095
   Koyuncu OO, 2013, CELL HOST MICROBE, V13, P379, DOI 10.1016/j.chom.2013.03.010
   Larson H, 2015, NATURE, V528, P9, DOI 10.1038/528009a
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   LaRussa PS, 2011, PEDIATRICS, V127, pS65, DOI 10.1542/peds.2010-1722J
   Leake JAD, 2004, PEDIATR INFECT DIS J, V23, P756, DOI 10.1097/01.inf.0000133048.75452.dd
   Leroux-Roels G, 2011, UNDERSTANDING MODERN, V1, P115
   Leroux-Roels G, 2016, CLIN IMMUNOL, V169, P16, DOI 10.1016/j.clim.2016.05.007
   Lopez-Lopez JA, 2019, INT J EPIDEMIOL
   LUELMO F, 1982, AM REV RESPIR DIS, V125, P70
   Mahmud SM, 2018, EMERG INFECT DIS, V24, P1267, DOI 10.3201/eid2407.161783
   Arias LHM, 2015, VACCINE, V33, P3773, DOI 10.1016/j.vaccine.2015.05.013
   Maure CG, 2014, B WORLD HEALTH ORGAN, V92, P695, DOI 10.2471/BLT.14.138875
   McCarthy NL, 2017, VACCINE, V35, P6643, DOI 10.1016/j.vaccine.2017.10.034
   McMahon AW, 2007, VACCINE, V25, P1727, DOI 10.1016/j.vaccine.2006.11.027
   McNeil MM, 2014, VACCINE, V32, P5390, DOI 10.1016/j.vaccine.2014.07.073
   Nguyen M, 2012, PHARMACOEPIDEM DR S, V21, P291, DOI 10.1002/pds.2323
   Miller E, 2001, ARCH DIS CHILD, V84, P227, DOI 10.1136/adc.84.3.227
   Mitkus RJ, 2011, VACCINE, V29, P9538, DOI 10.1016/j.vaccine.2011.09.124
   Monath TP, 2015, J CLIN VIROL, V64, P160, DOI 10.1016/j.jcv.2014.08.030
   Mouchet J, 2018, PHARMACOL RES, V132, P108, DOI 10.1016/j.phrs.2018.04.007
   Mrozek-Budzyn D, 2015, EUR J PEDIATR, V174, P383, DOI 10.1007/s00431-014-2412-5
   Munoz DC, 2015, INT J PUBLIC HEALTH, V60, P767, DOI 10.1007/s00038-015-0715-6
   Murphy TV, 2001, NEW ENGL J MED, V344, P564, DOI 10.1056/NEJM200102223440804
   Naleway AL, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-0943
   Nathanson N, 2010, AM J EPIDEMIOL, V172, P1213, DOI 10.1093/aje/kwq320
   Nelson KB, 2003, PEDIATRICS, V111, P674, DOI 10.1542/peds.111.3.674
   Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098
   Nohynek H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033536
   O'Connor D, 2013, CLIN INFECT DIS, V57, P860, DOI 10.1093/cid/cit373
   Offit PA, 2005, CUTTER INCIDENT AM 1
   Parra M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066115
   Petricciani J, 2001, Dev Biol (Basel), V106, P275
   Petricciani J, 2008, BIOLOGICALS, V36, P359, DOI 10.1016/j.biologicals.2008.06.004
   Pichichero ME, 2008, PEDIATRICS, V121, pE208, DOI 10.1542/peds.2006-3363
   Price CS, 2010, PEDIATRICS, V126, P656, DOI 10.1542/peds.2010-0309
   Sakaguchi M, 1997, J ALLERGY CLIN IMMUN, V99, P263, DOI 10.1016/S0091-6749(97)70108-8
   Scheller NM, 2017, NEW ENGL J MED, V376, P1223, DOI 10.1056/NEJMoa1612296
   Scheller NM, 2015, JAMA-J AM MED ASSOC, V313, P54, DOI 10.1001/jama.2014.16946
   SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P105, DOI 10.1093/oxfordjournals.aje.a112795
   Schurink-van't Klooster TM, 2018, VACCINE, V36, P6796, DOI 10.1016/j.vaccine.2018.09.019
   Sheng L, 2008, BIOLOGICALS, V36, P184, DOI 10.1016/j.biologicals.2007.11.003
   Sheng-Fowler L, 2010, INT J BIOL SCI, V6, P151
   Sheng-Fowler L, 2009, BIOLOGICALS, V37, P259, DOI 10.1016/j.biologicals.2009.04.002
   Sheng-Fowler L, 2009, BIOLOGICALS, V37, P190, DOI 10.1016/j.biologicals.2009.02.015
   Shimabukuro TT, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-1791
   Shimabukuro TT, 2015, VACCINE, V33, P4398, DOI 10.1016/j.vaccine.2015.07.035
   Shoenfeld Y, 2013, CLIN REV ALLERG IMMU, V45, P149, DOI 10.1007/s12016-013-8385-8
   Siddiqui M, 2017, VACCINE, V35, P5352, DOI 10.1016/j.vaccine.2017.08.033
   Skufca J, 2018, VACCINE, V36, P5926, DOI 10.1016/j.vaccine.2018.06.074
   Smeeth L, 2004, LANCET, V364, P963, DOI 10.1016/S0140-6736(04)17020-7
   Spiering MJ, 2015, ALCOHOL RES-CURR REV, V37, P171
   Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820
   Stensballe LG, 2017, ARCH DIS CHILD, V102, P224, DOI 10.1136/archdischild-2016-310760
   Takaba H, 2017, TRENDS IMMUNOL, V38, P805, DOI 10.1016/j.it.2017.07.010
   Taylor LE, 2014, VACCINE, V32, P3623, DOI 10.1016/j.vaccine.2014.04.085
   Tesoriero C, 2016, P NATL ACAD SCI USA, V113, pE368, DOI 10.1073/pnas.1521463112
   Thompson WW, 2007, NEW ENGL J MED, V357, P1281, DOI 10.1056/NEJMoa071434
   Tielemans SMAJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3862
   Tozzi AE, 2009, PEDIATRICS, V123, P475, DOI 10.1542/peds.2008-0795
   Trogstad L, 2017, VACCINE, V35, P1879, DOI 10.1016/j.vaccine.2017.02.053
   van Riel D, 2014, J INFECT DIS, V210, P419, DOI 10.1093/infdis/jiu097
   Verstraeten T, 2003, PEDIATRICS, V112, P1039, DOI 10.1542/peds.112.2.e98
   Wellcome Trust, GLOB MON 2018 DOES W
   Whitaker HJ, 2018, BIOMETRICAL J, V60, P1110, DOI 10.1002/bimj.201800019
   WHO, 2013, WEEKLY EPIDEMIOLOGIC
   Willhite CC, 2014, CRIT REV TOXICOL, V44, P1, DOI 10.3109/10408444.2014.934439
   World Health Organization, 2018, WKLY EPIDEMIOL REC, V93, P21
   World Health Organization, 2007, WKLY EPIDEMIOL REC, V82, P22
   World Health Organization, SAF UPD HPV VACC
   World Health Organization, 2010, WHO WEEKLY EPIDEMIOL, V85, P288
   World Health Organization (WHO), 2013, WHO TECHN REP SER, V987
   Yih WK, 2018, AM J EPIDEMIOL, V187, P1269, DOI 10.1093/aje/kwy023
   Zerbo O, 2018, JAMA PEDIATR, V172, P469, DOI 10.1001/jamapediatrics.2018.0082
   Zuber PLF, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-001053
NR 140
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 1869
EP 1880
DI 10.1016/j.vaccine.2020.01.024
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000001
PM 31987690
DA 2020-05-12
ER

PT J
AU Pacheco, FC
   Franca, GVA
   Elidio, GA
   Leal, MB
   de Oliveira, C
   Guilhem, DB
AF Pacheco, Flavia C.
   Franca, Giovanny V. A.
   Elidio, Guilherme A.
   Leal, Mariana B.
   de Oliveira, Cesar
   Guilhem, Dirce B.
TI Measles-containing vaccines in Brazil: Coverage, homogeneity of coverage
   and associations with contextual factors at municipal level
SO VACCINE
LA English
DT Article
DE Vaccination coverage; Measles-Mumps-Rubella Vaccine; Measles; Public
   Health; Brazil
ID VACCINATION
AB We aimed to (i) describe both the coverage and the homogeneity of coverage of the first and second doses of measles-containing vaccines (MCV) in Brazil in 2017, and (ii) to investigate the potential influence of contextual factors at municipal level. All 5570 Brazilian municipalities were included. The North and Center-West regions presented the lowest coverages of the first and second doses of MCV, respectively, We found significant associations of both first and second doses of MCV with population size, coverage of Family Health Strategy (FHS) and other indicators of living conditions and inequalities. Monitoring the homogeneity of MCV coverage at national, regional and state levels is essential, as it allows identifying areas at higher risk of measles spread that should be targeted for vaccination. Targeting large cities i.e. 100,000 or more inhabitants, especially poor neighborhoods and areas with low FHS coverage, could lead to improvements in coverage homogeneity. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Pacheco, Flavia C.; Franca, Giovanny V. A.; Elidio, Guilherme A.; Guilhem, Dirce B.] Univ Brasilia, Postgrad Program Hlth Sci, Brasilia, DF, Brazil.
   [Pacheco, Flavia C.; Franca, Giovanny V. A.; Elidio, Guilherme A.] Minist Hlth, Secretariat Hlth Surveillance, Brasilia, DF, Brazil.
   [Leal, Mariana B.] Minist Hlth, Secretariat Hlth Care, Brasilia, DF, Brazil.
   [de Oliveira, Cesar] UCL, Dept Epidemiol & Publ Hlth, London, England.
RP Pacheco, FC (reprint author), SRTVN Quadra 701,Via W 5 Norte,LoteD, BR-70719040 Brasilia, DF, Brazil.
EM fpcaselli@gmail.com
RI Araujo de Franca, Giovanny Vinicius/L-7385-2018
OI Araujo de Franca, Giovanny Vinicius/0000-0002-7530-2017
FU National Council for Scientific and Technological Development -
   CNPqNational Council for Scientific and Technological Development
   (CNPq); Research Productivity Grant 1-D (2016-2020)
FX DBG receives funding from the National Council for Scientific and
   Technological Development - CNPq and Research Productivity Grant 1-D
   (2016-2020).
CR Abadura SA, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2315-z
   American Pan. Health Organization/World Health Organization, 2018, PAHO URG RAP INCR VA
   [Anonymous], 2013, NAT IMM PROGR NIP 40
   Antai D, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-181
   Succi RCD, 2018, J PEDIAT-BRAZIL, V94, P574, DOI 10.1016/j.jped.2018.01.008
   Domingues CMAS, 2013, EPIDEMIOL SERV SAUDE, V22, P9, DOI 10.5123/S1679-49742013000100002
   Domingues CMAS, 2012, REV INST MED TROP SP, V54, pS22, DOI 10.1590/S0036-46652012000700009
   Elidio GA, 2019, EURO SURVEILL, P24
   ibge, 2011, CENS DEM 2010 CAR PO
   Konstantyner T, 2011, VACCINE, V29, P9298, DOI 10.1016/j.vaccine.2011.10.020
   Ministerio da Sadde. Secretaria de Vigilancia em Saude, 2019, B EP VIG EP SAR BRAS, V50
   Ministry of Health, 2019, 372019 MIN HLTH
   Pacheco FC, 2019, VACCINE, V37, P2651, DOI 10.1016/j.vaccine.2019.04.019
   Pacheco FC, 2019, INT J INFECT DIS, V82, P51, DOI 10.1016/j.ijid.2019.03.014
   Pan American Health Organization World Health Organization, 2016, REG AM IS DECL FREE
   Sato APS, 2018, REV SAUDE PUBL, V52, DOI [10.11606/S1518-8787.2018052001199, 10.11606/s1518-8787.2018052001199]
   Tauil MD, 2016, VACCINE, V34, P2635, DOI 10.1016/j.vaccine.2016.04.016
   Tertuliano GC, 2011, CIENC SAUDE COLETIVA, V16, P523, DOI 10.1590/S1413-81232011000200015
   Victora CG, 2011, LANCET, V377, P2042, DOI 10.1016/S0140-6736(11)60055-X
   Wiysonge CS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037905
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 1881
EP 1887
DI 10.1016/j.vaccine.2020.01.030
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000002
PM 31980195
DA 2020-05-12
ER

PT J
AU Derbise, A
   Guillas, C
   Gerke, C
   Carniel, E
   Pizarro-Cerda, J
   Demeure, CE
AF Derbise, Anne
   Guillas, Chloe
   Gerke, Christiane
   Carniel, Elisabeth
   Pizarro-Cerda, Javier
   Demeure, Christian E.
TI Subcutaneous vaccination with a live attenuated Yersinia
   pseudotuberculosis plague vaccine
SO VACCINE
LA English
DT Article
DE Bubonic plague; Pneumonic plague; Live vaccine; Yersinia pestis;
   Yersinia pseudotuberculosis; Subcutaneous
ID MICE
AB A single oral inoculation to mice of the live attenuated Yersinia pseudotuberculosis VTnF1 strain producing an F1 pseudocapsule protects against bubonic and pneumonic plague. However oral vaccination can fail in humans exposed to frequent intestinal infections. We evaluated in mice the efficacy of subcutaneous vaccine injection as an alternative way to induce protective immunity, while reducing the dose and avoiding strain release in nature. A single subcutaneous dose of up to 10(8) CFU induced dose-dependent antibody production. At the dose of 10(7) CFU, i.e. 10 times less than via the oral route, it caused a modest skin reaction and protected 100% against bubonic and 80% against pneumonic plague, caused by high doses of Yersinia pestis. Bacteria migrating to lymph nodes and spleen, but not feces, were rapidly eliminated. Thus, subcutaneous injection of VTnF1 would represent a good alternative when dissemination in nature and human intestinal responsiveness are limitations. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Derbise, Anne; Guillas, Chloe; Carniel, Elisabeth; Pizarro-Cerda, Javier; Demeure, Christian E.] Inst Pasteur, Yersinia Res Unit, 28 Rue Dr Roux, F-75724 Paris, France.
   [Gerke, Christiane] Inst Pasteur, Vaccine Programs, 28 Rue Dr Roux, F-75724 Paris, France.
   [Carniel, Elisabeth] Pasteur Ctr Cameroon, Yaounde 1274, Cameroon.
   [Guillas, Chloe] Hop Europeen Georges Pompidou, PARCC, INSERM UMR 970, 56 Rue Leblanc, F-75015 Paris, France.
RP Demeure, CE (reprint author), Inst Pasteur, Yersinia Res Unit, 28 Rue Dr Roux, F-75724 Paris, France.
EM cdemeure@pasteur.fr
FU ANR Emergence grantFrench National Research Agency (ANR)
   [ANR12-EMMA-0011-01]; Institut Pasteur Accelerating Preclinical
   Candidates - GPF-Vaccinology 2015 grant [GPFVacc2-08]
FX The project was supported by an ANR Emergence grant (ANR12-EMMA-0011-01)
   and an Institut Pasteur Accelerating Preclinical Candidates -
   GPF-Vaccinology 2015 grant (GPFVacc2-08). The authors would like to
   thank the Institut Pasteur Central animal facility team for their
   support with mouse hosting and care.
CR Demeure CE, 2019, VACCINE, V37, P123, DOI 10.1016/j.vaccine.2018.11.022
   Derbise A, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004162
   Derbise A, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001528
   DynPort Vaccine Company, 2011, REC PLAG VACC RF1V H
   Feodorova VA, 2011, VACCINES BACTERIAL B, P175
   Frey J, 2007, VACCINE, V25, P5598, DOI 10.1016/j.vaccine.2006.11.058
   Holmgren J, 2012, CURR OPIN IMMUNOL, V24, P343, DOI 10.1016/j.coi.2012.03.014
   Iannelli V., 2019, WHICH VACCINES CAN B
   Jiangsu Province CDC, 2015, IMM SAF SUB PLAG VAC
   Kabashima K, 2019, NAT REV IMMUNOL, V19, P19, DOI 10.1038/s41577-018-0084-5
   Kashem SW, 2017, ANNU REV IMMUNOL, V35, P469, DOI 10.1146/annurev-immunol-051116-052215
   Kupper TS, 2004, NAT REV IMMUNOL, V4, P211, DOI 10.1038/nri1310
   Levine MM, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-129
   LINDBERG AA, 1995, DEV BIOL STAND, V84, P211
   Mikshis NI, 2019, PROBLEMS PARTICUL DA, V1, P50
   Minor P, 2009, VACCINE, V27, P2649, DOI 10.1016/j.vaccine.2009.02.071
   Olson RM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217440
   Quereda JJ, 2017, MBIO, V8, DOI 10.1128/mBio.00259-17
   Rossi O, 2014, J BIOL CHEM, V289, P24922, DOI 10.1074/jbc.M114.566570
   Southam DS, 2002, AM J PHYSIOL-LUNG C, V282, pL833, DOI 10.1152/ajplung.00173.2001
   Warren HS, 2010, J INFECT DIS, V201, P223, DOI 10.1086/649557
   WHO, 2019, WKLY EPIDEMIOL REC, V94, P289
   Zhao ZQ, 2008, INFECT IMMUN, V76, P2157, DOI 10.1128/IAI.01495-07
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 1888
EP 1892
DI 10.1016/j.vaccine.2020.01.014
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000003
PM 31964555
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Daly, C
   Molodecky, NA
   Sreevatsava, M
   Belayneh, AD
   Chandio, SA
   Partridge, J
   Shaikh, A
   Laghari, M
   Agbor, J
   Safdar, RM
   Bullo, UF
   Malik, SM
   Mahamud, A
AF Daly, Catherine
   Molodecky, Natalia A.
   Sreevatsava, Meghana
   Belayneh, Asalif D.
   Chandio, Shoukat A.
   Partridge, Jeff
   Shaikh, Ahmed
   Laghari, Mumtaz
   Agbor, John
   Safdar, Rana M.
   Bullo, Umar Farooq
   Malik, Safi M.
   Mahamud, Abdirahman
TI Needle-free injectors for mass administration of fractional dose
   inactivated poliovirus vaccine in Karachi, Pakistan: A survey of
   caregiver and vaccinator acceptability
SO VACCINE
LA English
DT Article
DE Fractional-dose IPV; Jet injector; Needle-free; Pakistan; Polio
ID IMMUNOGENICITY; TRIAL
AB The first large-scale vaccination campaign using needle-free jet injectors to administer fractional doses of inactivated poliovirus vaccine (fIPV) was conducted in Karachi, Pakistan, in February 2019. Data on acceptability of jet injectors were collected from 610 vaccinators and 4898 caregivers during the first four days of the campaign. Of those with prior needle and syringe experience, both vaccinators and caregivers expressed a strong preference for jet injectors (578/592 (97.6%1 and 4792/4813 [99.6%], respectively), citing ease of use, appearance, and child's response to vaccination. Among caregivers, 4638 (94.7%) stated they would be more likely to bring their child for vaccination in a future campaign that used jet injectors. Mean vaccine coverage among towns administering fIPV was 98.7% - an increase by 18.4% over the preceding campaign involving full-dose IPV. Our findings demonstrate the strong acceptability of fIPV jet injectors and highlight the potential value of this method in future mass campaigns. (C) 2019 Published by Elsevier Ltd.
C1 [Daly, Catherine; Molodecky, Natalia A.; Sreevatsava, Meghana; Mahamud, Abdirahman] WHO, Islamabad, Pakistan.
   [Molodecky, Natalia A.; Mahamud, Abdirahman] Natl Emergency Operat Ctr Polio Eradicat, Islamabad, Pakistan.
   [Belayneh, Asalif D.] WHO, Sindh, Pakistan.
   [Chandio, Shoukat A.] United Nat Childrens Fund UNICEF, Sindh, Pakistan.
   [Partridge, Jeff] Bill & Melinda Gates Fdn, Seattle, WA USA.
   [Shaikh, Ahmed] Bill & Melinda Gates Fdn, Sindh, Pakistan.
   [Laghari, Mumtaz] Natl Stop Transmiss Polio N STOP Program, Sindh, Pakistan.
   [Agbor, John] United Nat Childrens Fund UNICEF, Islamabad, Pakistan.
   [Safdar, Rana M.; Malik, Safi M.] Minist Natl Hlth Serv Regulat & Coordinat, Islamabad, Pakistan.
   [Bullo, Umar Farooq] Minist Natl Hlth Serv Regulat & Coordinat, Sindh, Pakistan.
RP Daly, C (reprint author), WHO, Natl Inst Hlth, Natl Pk Rd, Islamabad, Pakistan.
EM dalyc@who.int
FU World Health Organization, Pakistan
FX The survey was funded by the World Health Organization, Pakistan. The
   jet injectors were purchased by the Bill and Melinda Gates Foundations
   for the Pakistan polio programme. A representative from Pharmajet
   accompanied polio programme staff during the first three days of field
   visits but was not involved in data collection or interpretation of
   results.
CR Anand A, 2017, VACCINE, V35, P2993, DOI 10.1016/j.vaccine.2017.03.008
   Clarke E, 2016, LANCET GLOB HEALTH, V4, pE534, DOI 10.1016/S2214-109X(16)30075-4
   Global Polio Eradication Initiative, 2019, TECHN ADV GROUP M PO
   Government of Pakistan Bureau of Statistics, POP CENS
   Hsu C, 2018, MMWR-MORBID MORTAL W, V67, P1242, DOI 10.15585/mmwr.mm6744a5
   Jafari H, 2014, SCIENCE, V345, P922, DOI 10.1126/science.1255006
   John J, 2014, LANCET, V384, P1505, DOI 10.1016/S0140-6736(14)60934-X
   Mbaeyi C, 2018, MMWR-MORBID MORTAL W, V67, P690, DOI 10.15585/mmwr.mm6724a5
   Resik S, 2015, VACCINE, V33, P307, DOI 10.1016/j.vaccine.2014.11.025
   Sheikh MA, 2014, MMWR-MORBID MORTAL W, V63, P237
   Shirreff G, 2017, EMERG INFECT DIS, V23, P258, DOI 10.3201/eid2302.161210
   Snider CJ, 2019, LANCET, V393, P2624, DOI 10.1016/S0140-6736(19)30503-3
   Yousafzai MT, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00395
NR 13
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 1893
EP 1898
DI 10.1016/j.vaccine.2019.12.059
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000004
PM 31983581
DA 2020-05-12
ER

PT J
AU Mohanty, S
   Joyce, CM
   Delamater, PL
   Klein, NP
   Salmon, D
   Omer, SB
   Buttenheim, AM
AF Mohanty, Salini
   Joyce, Caroline M.
   Delamater, Paul L.
   Klein, Nicola P.
   Salmon, Daniel
   Omer, Saad B.
   Buttenheim, Alison M.
TI Homeschooling parents in California: Attitudes, beliefs and behaviors
   associated with child's vaccination status
SO VACCINE
LA English
DT Article
DE Homeschool; Vaccine hesitancy; Immunization mandates; California
ID VACCINES
AB Background: Senate Bill 277 (SB277) banned nonmedical exemptions from school-entry vaccination requirements for children attending classroom-based schools in California, but excluded homeschooled children from vaccination requirements. Thus, it was hypothesized that more parents would choose to homeschool to avoid vaccination requirements in response to SB277. There is limited literature on the vaccine attitudes, beliefs, and behaviors among the homeschooling population in the US, despite an overall increase in homeschooling nationwide and documented vaccine-preventable disease outbreaks within the homeschooled child population.
   Methods: Between November 2018 and January 2019, we conducted a cross-sectional online survey among homeschooling parents with at least one child in grades K-8 who is currently enrolled in one of the legally-acceptable mechanisms to homeschool in California: (1) home-based private school satellite program (PSP), or (2) public or charter independent study program (ISP) with no classroom-based instruction.
   Results: Among 140 homeschooling parents from 8 schools in California, 71% reported that their youngest child in grade K-8 was up-to-date on immunizations at kindergarten-entry and 56% reported that they made the decision to homeschool their child after the implementation of SB277. Compared to homeschooling parents whose child was up-to-date at kindergarten entry, homeschooling parents whose child was not up-to-date at kindergarten entry reported higher concerns over vaccine safety and effectiveness, more frequently cited immunization mandates as a reason to homeschool, and were more likely to report having considered moving out of California due to immunization mandates.
   Conclusion: There was variation in vaccine attitudes and beliefs within the homeschooling population in this sample. Immunization mandates were a factor in the decision to homeschool for some parents in this sample, supporting the hypothesis that vaccine-hesitant parents considered homeschooling as a way to avoid immunization mandates such as SB277. Future studies should explore the complexities around vaccine attitudes, beliefs and behaviors among homeschooling populations. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Mohanty, Salini; Joyce, Caroline M.; Buttenheim, Alison M.] Univ Penn, Dept Family & Community Hlth, Sch Nursing, 418 Curie Blvd, Philadelphia, PA 19104 USA.
   [Delamater, Paul L.] Univ N Carolina, Dept Geog, Chapel Hill, NC 27515 USA.
   [Delamater, Paul L.] Univ N Carolina, Carolina Populat Ctr, Chapel Hill, NC 27515 USA.
   [Klein, Nicola P.] Kaiser Permanente Vaccine Study Ctr, Oakland, CA USA.
   [Salmon, Daniel] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Inst Vaccine Safety, Dept Int Hlth & Hlth Behav Soc, Baltimore, MD USA.
   [Omer, Saad B.] Yale Univ, Yale Inst Global Hlth, New Haven, CT USA.
   [Omer, Saad B.] Yale Univ, Sch Med, Dept Med, Infect Dis, New Haven, CT 06510 USA.
   [Omer, Saad B.] Yale Univ, Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA.
   [Buttenheim, Alison M.] Univ Penn, Ctr Hlth Incentives & Behav Econ, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Buttenheim, AM (reprint author), Univ Penn, Dept Family & Community Hlth, Sch Nursing, 418 Curie Blvd, Philadelphia, PA 19104 USA.
EM smohanty@upenn.edu; abutt@nursing.upenn.edu
OI Delamater, Paul/0000-0003-3627-9739
FU National Institute of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [801A1125405]
FX This work was supported through the National Institute of Allergy and
   Infectious Diseases (801A1125405 PI: SB Omer).
CR California Department of Education, SCH ATT REV BOARDS
   California Department of Education, PUBL SCH DISTR DAT F
   California Department of Education, FIL STRUCT PUBL SCH
   California Homeschool Network, LEG OPT
   California Homeschool Network, PRIV SCH SAT PROGR
   Centers for Disease Control and Prevention, STAT VACC REQ
   Choi BK, 2010, J PEDIATR HEALTH CAR, V24, P42, DOI 10.1016/j.pedhc.2009.02.002
   Collom E, 2005, EDUC URBAN SOC, V37, P307, DOI 10.1177/0013124504274190
   Delamater PL, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-3301
   Gaither Milton, 2017, Pro-Posições, V28, P213, DOI 10.1590/1980-6248-2015-0171
   Huseman J., 2015, PRO PUBLICA     0827
   Johnson MG, 2013, PEDIATRICS, V132, pE1686, DOI 10.1542/peds.2013-1636
   Kennedy AM, 2005, J SCHOOL HEALTH, V75, P276, DOI 10.1111/j.1746-1561.2005.00037.x
   Kennedy AM, 2005, PUBLIC HEALTH REP, V120, P252, DOI 10.1177/003335490512000306
   Khalili D, 2007, J LAW MED ETHICS, V35, P471, DOI 10.1111/j.1748-720X.2007.00169.x
   McCoy JD, 2019, VACCINE, V37, P5770, DOI 10.1016/j.vaccine.2018.09.036
   McDonald P, 2019, VACCINE, V37, P742, DOI 10.1016/j.vaccine.2018.12.018
   Mello MM, 2015, NEW ENGL J MED, V373, P785, DOI 10.1056/NEJMp1508701
   Mohanty S, 2018, PEDIATRICS
   Mohanty S, 2019, AM J PUBLIC HEALTH, V109, P96, DOI 10.2105/AJPH.2018.304768
   National Center for Education Statistics, HOM US 2012
   National Center for Education Statistics, NUMB PERC HOM STUD A
   Oladejo O, 2016, VACCINE, V34, P4964, DOI 10.1016/j.vaccine.2016.08.046
   Opel DJ, 2013, JAMA PEDIATR, V167, P1065, DOI 10.1001/jamapediatrics.2013.2483
   Opel DJ, 2011, VACCINE, V29, P6598, DOI 10.1016/j.vaccine.2011.06.115
   Parker AA, 2006, NEW ENGL J MED, V355, P447, DOI 10.1056/NEJMoa060775
   Salmon DA, 2005, ARCH PEDIAT ADOL MED, V159, P470, DOI 10.1001/archpedi.159.5.470
   Salmon DA, 2008, HUM VACCINES, V4, P286, DOI 10.4161/hv.4.4.5752
   Thorpe EL, 2012, VACCINE, V30, P1149, DOI 10.1016/j.vaccine.2011.12.019
   Troupe D., 2017, Californian Journal of Health Promotion, V15, P46
NR 30
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 1899
EP 1905
DI 10.1016/j.vaccine.2020.01.026
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000005
PM 31982257
DA 2020-05-12
ER

PT J
AU Musa, S
   Skrijelj, V
   Kulo, A
   Habersaat, KB
   Smjecanin, M
   Primorac, E
   Becirovic, D
   Jackson, C
AF Musa, Sanjin
   Skrijelj, Venesa
   Kulo, Aida
   Habersaat, Katrine Bach
   Smjecanin, Mirsad
   Primorac, Emilija
   Becirovic, Darija
   Jackson, Cath
TI Identifying barriers and drivers to vaccination: A qualitative interview
   study with health workers in the Federation of Bosnia and Herzegovina
SO VACCINE
LA English
DT Article
DE Vaccination; Immunization; Immunisation; Health worker; Bosnia and
   Herzegovina; Tailoring Immunization Programmes (TIP)
ID HESITANCY
AB Background: Vaccination coverage in Bosnia and Herzegovina has been declining over recent years. A World Health Organization Tailoring Immunization Programmes (TIP) project is underway to gain insights into the underlying reasons for this, to develop tailored interventions. As part of TIP, this study aimed to investigate the views of health workers on their barriers and drivers to positive childhood vaccination practices.
   Methods: Face-to-face qualitative interviews explored 38 health workers' views on vaccination coverage, their vaccination attitudes, and system, programme and institutional influences on their vaccination practices. The data were analysed using content analysis and organised by the COM (Capability, Opportunity and Motivation) factors.
   Findings: Very few differences in barriers and drivers were evident between high and low coverage primary care centres or across different professional roles.
   Capability: Drivers included awareness of the risks of low vaccination coverage, regular use of the Rulebook and Order, knowledge of how to advise parents on mild side effects and recognition of the importance of good communication with parents. Key barriers were the use of false contraindications to postpone vacination and poor skills in tailoring communication with parents.
   Opportunity: Drivers were sufficient time for adminstering vaccination and good availability of vaccines. Several barriers were evident: lack of implementation of mandatory vaccination, no uniform recall and reminder system or system for detecting under-vaccinated children, staff shortages and lack of time to discuss vaccination with parents.
   Motivation: Drivers were a belief in the value, safety and effectiveness of vaccination and seeing that they have an important role to play. Barriers were a tendency to blame external factors e.g. anti-vax movement and a fear of being blamed for adverse events.
   Conclusions: The study identified complex and inter-related barriers and drivers to health worker positive vaccination practices. These insights will now inform a process to identify and prioritize interventions. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Musa, Sanjin; Smjecanin, Mirsad; Primorac, Emilija] Inst Publ Hlth Federat Bosnia & Herzegovina, Marsala Tita 9, Sarajevo 71000, Bosnia & Herceg.
   [Skrijelj, Venesa] Univ Sarajevo, Med Fac, Dept Publ Hlth & Prevent Med, Cekalusa 90, Sarajevo 71000, Bosnia & Herceg.
   [Kulo, Aida; Becirovic, Darija] Univ Sarajevo, Inst Pharmacol Clin Pharmacol & Toxicol, Med Fac, Cekalusa 90, Sarajevo 71000, Bosnia & Herceg.
   [Habersaat, Katrine Bach] WHO, Reg Off Europe, Marmorvej 51, DK-2100 Copenhagen OE, Denmark.
   [Jackson, Cath] Valid Res Ltd, Suite 19,Sandown House,Sandbeck Way, Wetherby LS22 7DN, W Yorkshire, England.
   [Skrijelj, Venesa] Gen Hosp Prim Dr Abdulah Nakas, Kranjceviceva 12, Sarajevo 71000, Bosnia & Herceg.
RP Musa, S (reprint author), Inst Publ Hlth Federat Bosnia & Herzegovina, Marsala Tita 9, Sarajevo 71000, Bosnia & Herceg.
EM s.musa@zzjzfbih.ba
RI Kulo, Aida/AAC-3341-2020
OI kulo cesic, Aida/0000-0002-5891-3780
FU US Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
FX The Tailoring Immunization Programmes (TIP) work by the WHO Regional
   Office for Europe and its application in Member States is supported by
   the US Centers for Disease Control and Prevention.
CR Ames HMR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011787.pub2
   Berry NJ, 2018, VACCINE, V36, P6480, DOI 10.1016/j.vaccine.2017.10.077
   Berry NJ, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0783-2
   Colquhoun HL, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0560-5
   Dube E, 2018, VACCINE, V36, P1509, DOI 10.1016/j.vaccine.2017.12.012
   Elo S, 2008, J ADV NURS, V62, P107, DOI 10.1111/j.1365-2648.2007.04569.x
   Habersaat KB, 2020, BUNDESGESUNDHEITSBLA, V63, P32, DOI 10.1007/s00103-019-03063-0
   JC Jacobsen Vann, 2018, COCHRANE DB SYST REV, V18, DOI 10.1002/14651858 CD003941 pub3
   John Hopkins Center for Communication Programs, 2018, INT COMM IMM PACK
   Karafillakis E, 2016, VACCINE, V34, P5013, DOI 10.1016/j.vaccine.2016.08.029
   Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022
   Leask J, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-154
   Lee C, 2016, J INFECTION, V72, P659, DOI 10.1016/j.jinf.2016.04.002
   MacDonald NE, 2018, VACCINE, V36, P5811, DOI 10.1016/j.vaccine.2018.08.042
   Magic I, 2006, MAT SOCIOMEDICA, V18, P13
   Michie S, 2014, BEHAV CHANGE WHEEL G
   Omer SB, 2019, NATURE, V571, P469, DOI 10.1038/d41586-019-02232-0
   Omer SB, 2017, JAMA PEDIATR, V171, P929, DOI 10.1001/jamapediatrics.2017.2219
   Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042
   Radovanovic Z., 2017, SRP ARK CELOK LEK, V145, P46, DOI [10.2298/SARH.16121404611, DOI 10.2298/SARH.161214046R]
   Ritchie J., 2014, QUALITATIVE RES PRAC
   Strategic Advisory Group of Experts on Immunization, 2014, SAGE WORK GROUP VACC
   UNICEF, 2017, KNOWL ATT PRACT REL
   World Health Organization, 2018, WHO EPIDATA NO 10 20
   World Health Organization Regional Office for Europe, 2019, TAIL IMM PROGR TIP
   World Health Organization Regional Office for Europe, 2017, 31 M REG CERT COMM P
   World Health Organization Regional Office for Europe, 2014, EUR VACC ACT PLAN 20
   Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 1906
EP 1914
DI 10.1016/j.vaccine.2020.01.025
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000006
PM 31980190
OA Other Gold
DA 2020-05-12
ER

PT J
AU Izac, JR
   O'Bier, NS
   Oliver, LD
   Camire, AC
   Earnhart, CG
   Rhodes, DVL
   Young, BF
   Parnham, SR
   Davies, C
   Marconi, RT
AF Izac, Jerilyn R.
   O'Bier, Nathaniel S.
   Oliver, Lee D., Jr.
   Camire, Andrew C.
   Earnhart, Christopher G.
   Rhodes, DeLacy V. LeBlanc
   Young, Brandon F.
   Parnham, Stuart R.
   Davies, Christopher
   Marconi, Richard T.
TI Development and optimization of OspC chimeritope vaccinogens for Lyme
   disease
SO VACCINE
LA English
DT Article
DE Borreliella burgdorferi; Chimeritope; Ticks; Lyme vaccine; Borrelia
ID SURFACE PROTEIN-C; ELICITS BACTERICIDAL ANTIBODY; H-BINDING PROTEIN;
   BORRELIA-BURGDORFERI; CRYSTAL-STRUCTURE; NORTH-AMERICAN; IDENTIFICATION;
   SPIROCHETE; TICKS; MICE
AB Experimental Outer surface protein (Osp) C based subunit chimeritope vaccinogens for Lyme disease (LD) were assessed for immunogenicity, structure, ability to elicit antibody (Ab) responses to divergent OspC proteins, and bactericidal activity. Chimeritopes are chimeric epitope based proteins that consist of linear epitopes derived from multiple proteins or multiple variants of a protein. An inherent advantage to chimeritope vaccinogens is that they can be constructed to trigger broadly protective Ab responses. Three OspC chimeritope proteins were comparatively assessed: Chv1, Chv2 and Chv3. The Chv proteins possess the same set of 18 linear epitopes derived from 9 OspC type proteins but differ in the physical ordering of epitopes or by the presence or absence of linkers. All Chv proteins were immunogenic in mice and rats eliciting high titer Ab. Immunoblot and enzyme linked immunosorbent assays demonstrated that the Chv proteins elicit IgG that recognizes a diverse array of OspC type proteins. The panel included OspC proteins produced by N. American and European strains of the LD spirochetes. Rat anti-Chv antisera uniformly labeled intact, non-permeabilized Borreliella burgdorferi demonstrating that vaccinal Ab can bind to targets that are naturally presented on the spirochete cell surface. Vaccinal Ab also displayed potent complement dependent-Ab mediated killing activity. This study highlights the ability of OspC chimeritopes to serve as vaccinogens that trigger potentially broadly protective Ab responses. In addition to the current use of an OspC chimeritope in a canine LD vaccine, chimeritopes can serve as key components of human LD subunit vaccines. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Izac, Jerilyn R.; O'Bier, Nathaniel S.; Oliver, Lee D., Jr.; Camire, Andrew C.; Earnhart, Christopher G.; Marconi, Richard T.] Virginia Commonwealth Univ Med Ctr, Dept Microbiol & Immunol, Richmond, VA 23298 USA.
   [Rhodes, DeLacy V. LeBlanc] Berry Coll, Dept Biol, Mt Berry, GA USA.
   [Young, Brandon F.; Davies, Christopher] Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.
   [Parnham, Stuart R.] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.
RP Marconi, RT (reprint author), Virginia Commonwealth Univ Med Ctr, Dept Microbiol & Immunol, Richmond, VA 23298 USA.
EM Richard.marconi@vcuhealth.org
FU Steven and Alexandra Cohen Foundation; Christian Foundation; Zoetis; VCU
   VETAR (Value and Efficiency Teaching and Research); NIH, NIAIDUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R01 A1072683, R01A1141801, R56A1127801]
FX This study was supported in part by awards, grants or donations from the
   NIH, NIAID (RO1A1141801 and R56A1127801), Steven and Alexandra Cohen
   Foundation, The Christian Foundation, Zoetis, and the VCU VETAR (Value
   and Efficiency Teaching and Research) to RTM and by a grant to JAC and
   RTM from NIH, NIAID (R01 A1072683).
CR Ball EC, 2016, SAB00193
   Barthold SW, 1997, CLIN INFECT DIS, V25, pS9, DOI 10.1086/516166
   Bauer Y, 2001, EUR J IMMUNOL, V31, P767, DOI 10.1002/1521-4141(200103)31:3&lt;767::AID-IMMU767&gt;3.0.CO;2-M
   Baum E, 2016, PLOS ONE, V8
   BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302
   BISSETT ML, 1987, J CLIN MICROBIOL, V25, P2296, DOI 10.1128/JCM.25.12.2296-2301.1987
   Bowser NH, 2018, VET SCI, V5
   Brisson D, 2008, P ROY SOC B-BIOL SCI, V275, P227, DOI 10.1098/rspb.2007.1208
   Brown EL, 2005, VACCINE, V23, P3687, DOI 10.1016/j.vaccine.2005.02.006
   Buckles EL, 2006, CLIN VACCINE IMMUNOL, V13, P1162, DOI 10.1128/CVI.00099-06
   BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737
   CEVENINI R, 1992, FEMS MICROBIOL LETT, V90, P147, DOI 10.1111/j.1574-6968.1992.tb05142.x
   Earnhart CG, 2005, INFECT IMMUN, V73, P7869, DOI 10.1128/IAI.73.12.7869-7877.2005
   Earnhart CG, 2007, HUM VACCINES, V3, P281, DOI 10.4161/hv.4661
   Earnhart CG, 2007, CLIN VACCINE IMMUNOL, V14, P628, DOI 10.1128/CVI.00409-06
   Earnhart CG, 2007, VACCINE, V25, P3419, DOI 10.1016/j.vaccine.2006.12.051
   Earnhart CG, 2007, VACCINE, V25, P466, DOI 10.1016/j.vaccine.2006.07.052
   Earnhart CG, 2010, MOL MICROBIOL, V76, P393, DOI 10.1111/j.1365-2958.2010.07103.x
   Edmondson DG, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00306-16, 10.1128/cvi.00306-16]
   Eicken C, 2001, J BIOL CHEM, V276, P10010, DOI 10.1074/jbc.M010062200
   FIKRIG E, 1992, P NATL ACAD SCI USA, V89, P5418, DOI 10.1073/pnas.89.12.5418
   Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551
   Gilmore RD, 1999, INFECT IMMUN, V67, P5463, DOI 10.1128/IAI.67.10.5463-5469.1999
   Gilmore RD, 1996, INFECT IMMUN, V64, P2234, DOI 10.1128/IAI.64.6.2234-2239.1996
   Golovchenko M, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0538-y
   Heyman P, 2010, EXPERT REV ANTI-INFE, V8, P33, DOI [10.1586/eri.09.118, 10.1586/ERI.09.118]
   Hsieh CL, 2017, ELIFE, V6, DOI 10.7554/eLife.30051
   Iyer R, 2015, MOL MICROBIOL, V95, P509, DOI 10.1111/mmi.12882
   Izac JR, 2019, VACCINE, V37, P2401, DOI 10.1016/j.vaccine.2019.02.007
   Izac JR, 2017, VACCINE, V35, P3178, DOI 10.1016/j.vaccine.2017.04.079
   Izac JR, 2019, VET CLIN N AM SMALL
   Jobe DA, 2003, CLIN DIAGN LAB IMMUN, V10, P573, DOI 10.1128/CDLI.10.4.573-578.2003
   Jobe DA, 2011, CLIN VACCINE IMMUNOL, V18, P1034, DOI 10.1128/CVI.00063-11
   Kumaran D, 2001, EMBO J, V20, P971, DOI 10.1093/emboj/20.5.971
   LaFleur RL, 2009, CLIN VACCINE IMMUNOL, V16, P253, DOI 10.1128/CVI.00373-08
   Little SE, 2010, TRENDS PARASITOL, V26, P213, DOI 10.1016/j.pt.2010.01.006
   Littman MP, 2018, J VET INTERN MED, V32, P887, DOI 10.1111/jvim.15085
   Lovrich SD, 2005, CLIN DIAGN LAB IMMUN, V12, P746, DOI 10.1128/CDLI.12.6.746-751.2005
   Lovrich SD, 2007, CLIN VACCINE IMMUNOL, V14, P635, DOI 10.1128/CVI.00431-06
   Mallory KL, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftw105
   MARCONI RT, 1992, J GEN MICROBIOL, V138, P533, DOI 10.1099/00221287-138-3-533
   MARCONI RT, 1992, J BACTERIOL, V174, P241, DOI 10.1128/jb.174.1.241-244.1992
   Marconi RT, 2010, BORRELIA MOL BIOL HO, P467
   Mathiesen MJ, 1998, J CLIN MICROBIOL, V36, P3474, DOI 10.1128/JCM.36.12.3474-3479.1998
   Mead PS, 2015, INFECT DIS CLIN N AM, V29, P187, DOI 10.1016/j.idc.2015.02.010
   Miller DP, 2012, J BIOL CHEM, V287, P12715, DOI 10.1074/jbc.M112.339721
   Neary JM, 2001, INFECT IMMUN, V69, P773, DOI 10.1128/IAI.69.2.773-778.2001
   Nelson CA, 2015, EMERG INFECT DIS, V21, P1625, DOI 10.3201/eid2109.150417
   Nowling JM, 1999, INFECT IMMUN, V67, P443, DOI 10.1128/IAI.67.1.443-445.1999
   OLIVER JH, 1993, J MED ENTOMOL, V30, P54, DOI 10.1093/jmedent/30.1.54
   Oliver LD, 2016, VET J, V218, P27, DOI 10.1016/j.tvjl.2016.11.001
   Parenti D, 1999, Conn Med, V63, P570
   Pritt BS, 2016, LANCET INFECT DIS
   Probert WS, 1997, J INFECT DIS, V175, P400, DOI 10.1093/infdis/175.2.400
   PROBERT WS, 1994, INFECT IMMUN, V62, P1920, DOI 10.1128/IAI.62.5.1920-1926.1994
   Radolf JD, 2012, NAT REV MICROBIOL, V10, P87, DOI 10.1038/nrmicro2714
   Ramamoorthy R, 1998, INFECT IMMUN, V66, P5119, DOI 10.1128/IAI.66.11.5119-5124.1998
   Rhodes DVL, 2013, VET J, V198, P412, DOI 10.1016/j.tvjl.2013.07.019
   Rousselle JC, 1998, J INFECT DIS, V178, P733, DOI 10.1086/515382
   Scheiblhofer S, 2003, MICROBES INFECT, V5, P939, DOI 10.1016/S1286-4579(03)00182-5
   Schwan TG, 2003, BIOCHEM SOC T, V31, P108, DOI 10.1042/BST0310108
   Schwan TG, 2000, J CLIN MICROBIOL, V38, P382
   Seinost G, 1999, INFECT IMMUN, V67, P3518, DOI 10.1128/IAI.67.7.3518-3524.1999
   Steere AC, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.90
   Strle K, 2011, AM J PATHOL, V178, P2726, DOI 10.1016/j.ajpath.2011.02.018
   Sung SY, 2000, INFECT IMMUN, V68, P1319, DOI 10.1128/IAI.68.3.1319-1327.2000
   Sung SY, 2001, J BACTERIOL, V183, P5855, DOI 10.1128/JB.183.20.5855-5861.2001
   Swei A, 2012, VECTOR-BORNE ZOONOT, V12, P623, DOI 10.1089/vbz.2011.0783
   Tilly K, 2007, INFECT IMMUN, V75, P1517, DOI 10.1128/IAI.01725-06
   Welsch JA, 2003, J INFECT DIS, V188, P1730, DOI 10.1086/379375
   Welsch JA, 2008, J INFECT DIS, V197, P1053, DOI 10.1086/528994
   Xiang XW, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00131
   Yang CK, 2006, MOL ENDOCRINOL, V20, P3251, DOI 10.1210/me.2006-0200
   Zundorf Ilse, 2008, Pharm Unserer Zeit, V37, P38, DOI 10.1002/pauz.200790128
NR 74
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 1915
EP 1924
DI 10.1016/j.vaccine.2020.01.027
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000007
PM 31959423
OA Other Gold
DA 2020-05-12
ER

PT J
AU Castilla, J
   Portillo, ME
   Casado, I
   Pozo, F
   Navascues, A
   Adelantado, M
   Ibanez, CG
   Ezpeleta, C
   Martinez-Baz, I
AF Castilla, Jesus
   Eugenia Portillo, Maria
   Casado, Itziar
   Pozo, Francisco
   Navascues, Ana
   Adelantado, Marta
   Gomez Ibanez, Carlos
   Ezpeleta, Carmen
   Martinez-Baz, Ivan
CA Primary Hlth Care Sentinel Network
   Network Influenza Surveillance Hos
TI Effectiveness of the current and prior influenza vaccinations in
   Northern Spain, 2018-2019
SO VACCINE
LA English
DT Article
DE Influenza; Influenza vaccine; Influenza-like illness; Case-control
   study; Vaccine effectiveness; Repeated vaccination
ID VACCINE EFFECTIVENESS; SEASON PROTECTION; UNITED-STATES; VIRUS;
   CHILDREN; HEMAGGLUTININ; A(H3N2); ILLNESS; CANADA
AB Background: The population targeted for influenza vaccination can be repeatedly vaccinated over successive seasons, and vaccines received in previous seasons may retain preventive effect. This study aims to estimate the effectiveness of inactivated influenza vaccines received in the current and prior seasons in the 2018-2019 season.
   Methods: Influenza-like illness patients attended by sentinel general practitioners or admitted to hospitals in Navarre, Spain, were tested for influenza. Vaccination status in the current and three prior seasons was obtained from the vaccination registry. The test-negative design was used to estimate the vaccine effectiveness.
   Results: A total of 381 influenza A(H1N1)pdm09 cases, 341 A(H3N2) cases and 1222 controls were analysed. As compared to individuals unvaccinated in the current and three prior seasons, the influenza vaccine effectiveness against A(H1N1)pdm09 was 57% (95% confidence interval ICI]: 40%, 70%) for current season vaccination regardless of prior doses and 48% (95%Cl: 14%, 68%) for vaccination in prior seasons but not in the current season. These estimates were 12% (95%CI: -23%, 37%) and 27% (95%CI: -22%, 56%), respectively, against influenza A(H3N2). Individuals vaccinated with the two A(H1N1)pdm09 strains in influenza vaccines since 2009, A/Michigan/45/2015 and A/California/07/2009, had higher protection (68%; 95%CI: 53%, 77%) than those vaccinated with A/Michigan/45/2015 only (29%, p = 0.020) or with A/California/07/2009 only (34%, p = 0.005).
   Conclusion: These results suggest moderate effectiveness of influenza vaccination against A(H1N1) pdm09 and low effectiveness against A(H3N2) influenza in the 2018-2019 season. Vaccination in prior seasons maintained a notable protective effect. Strains included in previous vaccines were as effective as the current vaccine strain, and both added their effects against influenza A(H1N1)pdm09. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Castilla, Jesus; Casado, Itziar; Gomez Ibanez, Carlos; Martinez-Baz, Ivan] Inst Salud Publ Navarra IdiSNA, Pamplona, Spain.
   [Castilla, Jesus; Casado, Itziar; Pozo, Francisco; Martinez-Baz, Ivan] CIBERESP, Madrid, Spain.
   [Eugenia Portillo, Maria; Navascues, Ana; Adelantado, Marta; Ezpeleta, Carmen] Complejo Hosp Navarra IdiSNA, Pamplona, Spain.
   [Pozo, Francisco] Inst Salud Carlos III, WHO Natl Influenza Ctr Madrid, Ctr Nacl Microbiol, Majadahonda, Spain.
RP Castilla, J (reprint author), Inst Salud Publ, Leyre 15, Pamplona 31003, Spain.
EM jcastilc@navarra.es
RI Casado, Itziar/B-1341-2017
OI Casado, Itziar/0000-0001-6879-4984
FU I-MOVE Network (Influenza Monitoring Vaccine Effectiveness in Europe) -
   European Centre for Disease Prevention and Control; Carlos III Institute
   of HealthInstituto de Salud Carlos III; European Regional Development
   FundEuropean Union (EU) [PI17/00868]
FX This study was supported by the I-MOVE Network (Influenza Monitoring
   Vaccine Effectiveness in Europe) funded by the European Centre for
   Disease Prevention and Control; and by the Carlos III Institute of
   Health with the European Regional Development Fund (PI17/00868).
CR AGUILAR I, 2010, EUROSURVEILLANCE, V17, P20154
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P117
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P97
   [Anonymous], 2018, WHO WKLY EPIDEMIOL R, V93, P133
   Belongia Edward A, 2017, Expert Rev Vaccines, V16, P1, DOI 10.1080/14760584.2017.1334554
   Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8
   Castilla J, 2016, EUROSURVEILLANCE, V21, P10, DOI 10.2807/1560-7917.ES.2016.21.22.30243
   Castilla J, 2017, EUROSURVEILLANCE, V22, P11, DOI 10.2807/1560-7917.ES.2017.22.7.30465
   Castilla J, 2018, EURO SURVEILL, V201
   Castilla J, 2016, VACCINE, V34, P1350, DOI 10.1016/j.vaccine.2016.01.054
   Chiu SS, 2019, EUROSURVEILLANCE, V24, P2, DOI 10.2807/1560-7917.ES.2019.24.5.1900056
   Consejo Interterritorial del Sistema Nacional de Salud, REC VAC FRENT GRIP T
   Doyle JD, 2019, MMWR-MORBID MORTAL W, V68, P135, DOI 10.15585/mmwr.mm6806a2
   European Centre for Disease Prevention and Control, 2019, INFL VIR CHAR SUMM E
   European Centre for Disease prevention and Control (ECDC), SEAS INFL 2018 2019
   Fu CX, 2015, VACCINE, V33, P2917, DOI 10.1016/j.vaccine.2015.04.063
   Gaglani M, 2016, J INFECT DIS, V213, P1546, DOI 10.1093/infdis/jiv577
   Gherasim A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179160
   Instituto de Salud Carlos III, INF VIG GRIP ESP TEM
   Jimenez-Jorge S, 2012, VACCINE, V30, P3595, DOI 10.1016/j.vaccine.2012.03.048
   Kissling E, 2019, EURO SURVEILL, V24
   Kissling E, 2019, EUROSURVEILLANCE, V24, P31, DOI 10.2807/1560-7917.ES.2019.24.48.1900604
   Martinez-Baz I, 2019, J INFECT DIS, V220, P1136, DOI 10.1093/infdis/jiz266
   Martinez-Baz I, 2017, J INFECT DIS, V215, P847, DOI 10.1093/infdis/jix055
   McLean HQ, 2015, J INFECT DIS, V211, P1529, DOI 10.1093/infdis/jiu647
   McLean HQ, 2014, CLIN INFECT DIS, V59, P1375, DOI 10.1093/cid/ciu680
   Ohmit SE, 2015, J INFECT DIS, V211, P1519, DOI 10.1093/infdis/jiu650
   Ohmit SE, 2014, CLIN INFECT DIS, V58, P319, DOI 10.1093/cid/cit736
   Ohmit SE, 2013, CLIN INFECT DIS, V56, P1363, DOI 10.1093/cid/cit060
   Petrie JG, 2015, J INFECT DIS, V212, P1914, DOI 10.1093/infdis/jiv313
   Ramsay LC, 2019, BMC MED, V17, DOI 10.1186/s12916-018-1239-8
   Skowronski DM, 2019, EUROSURVEILLANCE, V24, P6, DOI 10.2807/1560-7917.ES.2019.24.4.1900055
   Skowronski DM, 2017, J INFECT DIS, V215, P1059, DOI 10.1093/infdis/jix074
   Skowronski DM, 2015, J INFECT DIS, V212, P726, DOI 10.1093/infdis/jiv177
   Skowronski DM, 2012, CLIN INFECT DIS, V55, P332, DOI 10.1093/cid/cis431
   Sullivan SG, 2013, CLIN INFECT DIS, V57, P474, DOI 10.1093/cid/cit255
   Syrjanen RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108538
   Thompson MG, 2016, PEDIATR INFECT DIS J, V35, P299, DOI 10.1097/INF.0000000000001006
   Thompson MG, 2016, VACCINE, V34, P981, DOI 10.1016/j.vaccine.2015.10.119
   Thompson MG, 2014, CLIN INFECT DIS, V58, P449, DOI 10.1093/cid/cit750
   Valenciano M, 2010, VACCINE, V28, P7381, DOI 10.1016/j.vaccine.2010.09.010
   World Health Organization (WHO), 2019, ADD REC COMP INFL VI
NR 42
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 1925
EP 1932
DI 10.1016/j.vaccine.2020.01.028
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000008
PM 31982263
DA 2020-05-12
ER

PT J
AU Kazakova, A
   Kakkola, L
   Ziegler, T
   Syrjanen, R
   Pakkila, H
   Waris, M
   Soukka, T
   Julkunen, I
AF Kazakova, Anna
   Kakkola, Laura
   Ziegler, Thedi
   Syrjanen, Ritva
   Pakkila, Henna
   Waris, Matti
   Soukka, Tero
   Julkunen, Ilkka
TI Pandemic influenza A(H1N1 pdm09) vaccine induced high levels of
   influenza-specific IgG and IgM antibodies as analyzed by enzyme
   immunoassay and dual-mode multiplex microarray immunoassay methods
SO VACCINE
LA English
DT Article
DE Antibodies; Influenza A; Pandemic; Vaccine; Immunoassay; Multiplex
ID BEAD ARRAY ASSAYS; PROTEIN MICROARRAY; SERUM ANTIBODIES; INHIBITION
   ASSAY; H1N1 INFLUENZA; VIRUSES; REPRODUCIBILITY; TECHNOLOGIES;
   SENSITIVITY; EVALUATE
AB Influenza A viruses continue to circulate throughout the world as yearly epidemics or occasional pandemics. Influenza infections can be prevented by seasonal multivalent or monovalent pandemic vaccines. In the present study, we describe a novel multiplex microarray immunoassay (MAIA) for simultaneous measurement of virus-specific IgG and IgM antibodies using Pandemrix-vaccinated adult sera collected at day 0 and 28 and 180 days after vaccination as the study material. MAIA showed excellent correlation with a conventional enzyme immunoassay (EIA) in both IgG and IgM anti-influenza A antibodies and good correlation with hemagglutination inhibition (HI) test. Pandemrix vaccine induced 5-30 fold increases in anti-H1N1pdm09 influenza antibodies as measured by HI, EIA or MAIA. A clear increase in virus-specific IgG antibodies was found in 93-97% of vaccinees by MAIA and EIA. Virus-specific IgM antibodies were found in 90-92% of vaccinees by MAIA and EIA, respectively and IgM antibodies persisted for up to 6 months after vaccination in 55-62% of the vaccinees. Pandemic influenza vaccine induced strong anti-influenza A IgG and IgM responses that persisted several months after vaccination. MAIA was demonstrated to be an excellent method for simultaneous measurement of antiviral IgG and IgM antibodies against multiple virus antigens. Thus the method is well suitable for large scale epidemiological and vaccine immunity studies. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Kazakova, Anna; Kakkola, Laura; Waris, Matti; Julkunen, Ilkka] Univ Turku, Inst Biomed Virol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.
   [Ziegler, Thedi] Univ Turku, Res Ctr Child Psychiat, Itainen Pitkakatu 1, FIN-20520 Turku, Finland.
   [Syrjanen, Ritva] Natl Inst Hlth & Welf, Mannerheimintie 166, Helsinki 00300, Finland.
   [Pakkila, Henna; Soukka, Tero] Univ Turku, Dept Biotechnol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.
   [Waris, Matti; Julkunen, Ilkka] Turku Univ Hosp, Clin Microbiol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.
RP Julkunen, I (reprint author), Univ Turku, Inst Biomed, Medisiina D,Floor D7,Unit 7A,Kiinamyllynkatu 10, FIN-20520 Turku, Finland.
EM ilkka.julkunen@utu.fi
OI Kakkola, Laura/0000-0001-9271-4059; Kazakova, Anna/0000-0001-6205-2031
FU THL; Medical Research Council of the Academy of FinlandAcademy of
   Finland; University of Turku; Ministry of Social Affairs and Health,
   Finland
FX The study was supported by THL, University of Turku, Ministry of Social
   Affairs and Health, Finland and the Medical Research Council of the
   Academy of Finland. The funding organizations have no role in the design
   of the study and data analysis and presentation.
CR Ayling Kieran, 2018, Methods Mol Biol, V1781, P327, DOI 10.1007/978-1-4939-7828-1_17
   Baldo V, 2006, EUR J EPIDEMIOL, V21, P843, DOI 10.1007/s10654-006-9071-4
   Bucukovski J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134484
   Coudeville L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-18
   de Jong J C, 2003, Dev Biol (Basel), V115, P63
   Desbien AL, 2013, BIOTECHNIQUES, V54, P345, DOI 10.2144/000114041
   Elshal MF, 2006, METHODS, V38, P317, DOI 10.1016/j.ymeth.2005.11.010
   Engin Evren Doruk, 2019, J Immunoassay Immunochem, V40, P109, DOI 10.1080/15321819.2018.1563551
   Fineberg HV, 2014, NEW ENGL J MED, V370, P1335, DOI 10.1056/NEJMra1208802
   Freidl GS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108043
   Gall A, 2009, J CLIN MICROBIOL, V47, P327, DOI 10.1128/JCM.01330-08
   Haveri A, 2019, VACCINE, V37, P2731, DOI 10.1016/j.vaccine.2019.03.078
   HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610
   Itell HL, 2018, VACCINE, V36, P5600, DOI 10.1016/j.vaccine.2018.07.048
   Jorquera PA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39276-1
   Kale V, 2016, ANAL CHEM, V88, P4470, DOI 10.1021/acs.analchem.6b00337
   Kazakova A, 2019, MSPHERE, V4, DOI 10.1128/mSphere.00447-19
   Khan SS, 2004, CYTOM PART B-CLIN CY, V61B, P35, DOI 10.1002/cyto.b.20021
   Kutsaya A, 2016, EPIDEMIOL INFECT, V144, P1622, DOI 10.1017/S0950268815003143
   Leng SX, 2008, J GERONTOL A-BIOL, V63, P879, DOI 10.1093/gerona/63.8.879
   Meade P, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.98
   Nakajima R, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00592-18
   Negm OH, 2015, CLIN VACCINE IMMUNOL, V22, P1033, DOI 10.1128/CVI.00190-15
   Pedersen JC, 2014, METHODS MOL BIOL, V1161, P11, DOI 10.1007/978-1-4939-0758-8_2
   Plotkin SA, VACCINES
   Price JV, 2013, PLOS ONE, P8, DOI DOI 10.1371/JORNAL.PONE.0064555
   Puzelli S, 2005, J INFECT DIS, V192, P1318, DOI 10.1086/444390
   SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467
   Schepp RM, 2019, MSPHERE, V4, DOI 10.1128/mSphere.00236-19
   Schepp RM, 2017, J VIROL METHODS, V241, P15, DOI 10.1016/j.jviromet.2016.12.006
   Selvarajah S, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/820304
   Shu LL, 1996, EPIDEMIOL INFECT, V117, P179, DOI 10.1017/S0950268800001291
   Sikkema RS, 2016, EUROSURVEILLANCE, V21, P8, DOI 10.2807/1560-7917.ES.2016.21.44.30388
   Smits GP, 2012, CLIN VACCINE IMMUNOL, V19, P396, DOI 10.1128/CVI.05537-11
   Stevens J, 2006, NAT REV MICROBIOL, V4, P857, DOI 10.1038/nrmicro1530
   Syrjanen RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108538
   Tighe PJ, 2015, PROTEOM CLIN APPL, V9, P406, DOI 10.1002/prca.201400130
   Trombetta CM, 2014, VACCINES-BASEL, V2, P707, DOI 10.3390/vaccines2040707
   van Gageldonk PGM, 2008, J IMMUNOL METHODS, V335, P79, DOI 10.1016/j.jim.2008.02.018
   Wagner R, 2012, VACCINE, V30, P4113, DOI 10.1016/j.vaccine.2012.02.077
   Walker WT, 2010, EXPERT REV VACCINES, V9, P1385, DOI [10.1586/erv.10.141, 10.1586/ERV.10.141]
   Webster RG, 2002, VACCINE, V20, pS16, DOI 10.1016/S0264-410X(02)00123-8
   Wood JM, 2012, VACCINE, V30, P210, DOI 10.1016/j.vaccine.2011.11.019
   World Health Organization Global Influenza Surveillance Network, 2011, MAN LAB DIAGN VIR SU
   Yamazaki Y, 2009, ARCH VIROL, V154, P421, DOI 10.1007/s00705-009-0319-7
   Yasrebi H, 2016, BRIEF BIOINFORM, V17, P771, DOI 10.1093/bib/bbv092
   Yuk CS, 2004, BIOTECHNOL LETT, V26, P1563, DOI 10.1023/B:BILE.0000045653.92719.a4
NR 47
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 1933
EP 1942
DI 10.1016/j.vaccine.2020.01.022
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000009
PM 31987689
DA 2020-05-12
ER

PT J
AU Wasko, I
   Golebiewska, A
   Kiedrowska, M
   Ronkiewicz, P
   Wrobel-Pawelczyk, I
   Kuch, A
   Hong, E
   Skoczynska, A
AF Wasko, Izabela
   Golebiewska, Agnieszka
   Kiedrowska, Marlena
   Ronkiewicz, Patrycja
   Wrobel-Pawelczyk, Izabela
   Kuch, Alicja
   Hong, Eva
   Skoczynska, Anna
TI Genetic variability of Polish serogroup B meningococci (2010-2016)
   including the 4CMenB vaccine component genes
SO VACCINE
LA English
DT Article
DE Neisseria meningitidis; invasive meningococcal disease; molecular
   epidemiology; Bexsero (R) Antigen Sequence Type
ID H BINDING-PROTEIN; INVASIVE NEISSERIA-MENINGITIDIS; PREDICTED STRAIN
   COVERAGE; MULTICOMPONENT VACCINE; ANTIGEN; BEXSERO(R); DIVERSITY;
   DISEASE; CANDIDATE; VARIANTS
AB Neisseria meningitidis serogroup B (MenB) has recently become the major cause of invasive meningococcal disease in Poland. Therefore, the purpose of this study was to characterize MenB isolates, responsible for invasive meningococcal disease in 2010-2016, by MIST and sequencing of genes encoding proteins used as 4CMenB vaccine antigens. Two methods of coverage estimation were performed: extrapolation of MATS results of Polish meningococci 2010-2011 (exMATS) and gMATS, which combines genotyping and MATS results.
   Among 662 isolates 20 clonal complexes (CC) were detected, of which the most frequent were CC32, CC41/44 and CC18, accounting for 31.9%, 16.5% and 12.7%, respectively. A total of 111 combinations of PorA variable regions (VR1/VR2) were found, with P1.7,16 (15.0%) and P1.22,14 (13.6%) being prevalent. Vaccine variant VR2:4 was detected in 7.3% of isolates, mainly representing CC41/44 and non-assigned CC. Eighty five fHbp alleles encoding 74 peptide subvariants were revealed. Subvariant 1.1, a component of 4CMenB, was prevalent (24.2%) and found generally in CC32. Typing of the nhba gene revealed 102 alleles encoding 87 peptides. The most frequent was peptide 3 (22.4%), whereas vaccine peptide 2 was detected in 9.8%, mostly among CC41/44. The nadA gene was detected in 34.0% of isolates and the most prevalent was peptide 1 (variant NadA-1; 71.6%), found almost exclusively in CC32 meningococci. Vaccine peptide 8 (variant NadA-2/3) was identified once. Consequently, 292 completed BAST profiles were revealed. Regarding vaccine coverage, 39.7% of isolates had at least one 4CMenB vaccine variant, but according to exMATS and gMATS the coverage was 83.3% and 86.6%, respectively.
   In conclusion, Polish MenB (2010-2016) was highly diverse according to MLST and gene alleles encoding 4CMenB vaccine antigens. Some correlations between clonal complexes and variants of examined proteins/BAST profiles were revealed and a high coverage of 4CMenB vaccine was estimated. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Wasko, Izabela; Golebiewska, Agnieszka; Kiedrowska, Marlena; Ronkiewicz, Patrycja; Wrobel-Pawelczyk, Izabela; Kuch, Alicja; Skoczynska, Anna] Natl Med Inst, Natl Reference Ctr Bacterial Meningitis, Warsaw, Poland.
   [Hong, Eva] Inst Pasteur, Invas Bacterial Infect Unit, Paris, France.
RP Wasko, I (reprint author), Natl Med Inst, Natl Reference Ctr Bacterial Meningitis, Warsaw, Poland.
OI Wasko, Izabela/0000-0001-5494-3635
FU National Science Centre, Poland [2012/07/N/NZ7/04315]; Ministry of
   HealthMinistry of Health - Turkey; Ministry of Science and Higher
   EducationMinistry of Science and Higher Education, Poland
FX The study was partially supported by The National Science Centre, Poland
   grant to IWa (Poland grant 2012/07/N/NZ7/04315), Ministry of Health
   within the framework of the National Program of Antibiotic Protection
   (NPOA), by the Ministry of Science and Higher Education within the
   framework of Mikrobank 2 Program and DS 5.24.
CR Abad R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150721
   Bambini S, 2009, VACCINE, V27, P2794, DOI 10.1016/j.vaccine.2009.02.098
   Brehony C, 2016, VACCINE, V34, P4690, DOI 10.1016/j.vaccine.2016.08.015
   Caesar NM, 2013, MICROB PATHOGENESIS, V57, P33, DOI 10.1016/j.micpath.2013.02.003
   Comanducci M, 2002, J EXP MED, V195, P1445, DOI 10.1084/jem.20020407
   de Filippis I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033016
   ECDC, ANN EP REP MEN DIS
   European ECDC. Centre for Disease Prevention and Control, 2017, EXP OP INTR MEN B 4C
   Harrison LH, 2009, VACCINE, V27, pB51, DOI 10.1016/j.vaccine.2009.04.063
   HUNTER PR, 1988, J CLIN MICROBIOL, V26, P2465, DOI 10.1128/JCM.26.11.2465-2466.1988
   Jandova Z, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167762
   Ladhani SN, 2015, J INFECTION, V71, P611, DOI 10.1016/j.jinf.2015.09.035
   Law DKS, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0469-6
   Law DKS, 2014, J MED MICROBIOL, V63, P1490, DOI 10.1099/jmm.0.079921-0
   Lucidarme J, 2011, CLIN VACCINE IMMUNOL, V18, P1002, DOI 10.1128/CVI.00055-11
   Lucidarme J, 2010, CLIN VACCINE IMMUNOL, V17, P919, DOI 10.1128/CVI.00027-10
   Medini D, 2015, VACCINE, V33, P2629, DOI 10.1016/j.vaccine.2015.04.015
   Mowlaboccus S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158315
   Murphy E, 2009, J INFECT DIS, V200, P379, DOI 10.1086/600141
   Muzzi A, 2019, VACCINE, V37, P991, DOI 10.1016/j.vaccine.2018.12.061
   NIPH-NIH, REP CAS INF DIS POIS
   NRCBM, INV MEN DIS POL 2018
   O'Connor L, 2015, EUROSURVEILLANCE, V20, DOI 10.2807/1560-7917.ES2015.20.21.21139
   Panatto D, 2011, EXPERT REV VACCINES, V10, P1337, DOI [10.1586/erv.11.103, 10.1586/ERV.11.103]
   Parikh SR, 2017, LANCET INFECT DIS, V17, P754, DOI 10.1016/S1473-3099(17)30170-6
   Presa J, 2019, INFECT DIS THER, V8, P307, DOI 10.1007/s40121-019-0254-1
   Racloz VN, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-175
   Rajam G, 2017, MSPHERE, V2, DOI [10.1128/mSphere.00261-17, 10.1128/msphere.00261-17]
   Rodrigues CMC, 2018, EMERG INFECT DIS, V24, P673, DOI 10.3201/eid2404.171480
   Serruto D, 2012, VACCINE, V30, pB87, DOI 10.1016/j.vaccine.2012.01.033
   Shi FL, 2017, VACCINE, V35, P2343, DOI 10.1016/j.vaccine.2017.03.057
   Simoes MJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176177
   Skoczynska A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071943
   Stephens DS, 2009, VACCINE, V27, pB71, DOI 10.1016/j.vaccine.2009.04.070
   Thabuis A, 2018, EUROSURVEILLANCE, V23, P17, DOI 10.2807/1560-7917.ES.2018.23.28.1700590
   Tsang RSW, 2015, CAN J INFECT DIS MED, V26, P299, DOI 10.1155/2015/393659
   Tzanakaki G, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-111
   Vogel U, 2013, LANCET INFECT DIS, V13, P416, DOI 10.1016/S1473-3099(13)70006-9
   Wasko I, 2016, VACCINE, V34, P510, DOI 10.1016/j.vaccine.2015.11.070
   Wasko I, 2015, POL J MICROBIOL, V64, P313, DOI 10.5604/17331331.1185912
   Watson PS, 2016, VACCINE, V34, P875, DOI 10.1016/j.vaccine.2015.11.057
   Whittaker R, 2017, VACCINE, V35, P2034, DOI 10.1016/j.vaccine.2017.03.007
NR 42
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 1943
EP 1952
DI 10.1016/j.vaccine.2020.01.021
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000010
PM 31980191
OA Other Gold
DA 2020-05-12
ER

PT J
AU Chromikova, V
   Tan, J
   Aslam, S
   Rajabhathor, A
   Bermudez-Gonzalez, M
   Ayllon, J
   Simon, V
   Garcia-Sastre, A
   Salaun, B
   Nachbagauer, R
   Krammer, F
AF Chromikova, Veronika
   Tan, Jessica
   Aslam, Sadaf
   Rajabhathor, Arvind
   Bermudez-Gonzalez, Maria
   Ayllon, Juan
   Simon, Viviana
   Garcia-Sastre, Adolfo
   Salaun, Bruno
   Nachbagauer, Raffael
   Krammer, Florian
TI Activity of human serum antibodies in an influenza virus hemagglutinin
   stalk-based ADCC reporter assay correlates with activity in a CD107a
   degranulation assay
SO VACCINE
LA English
DT Article
DE Influenza hemagglutinin; ADCC; ADCP; Effector functions; Stalk
   antibodies
ID DEPENDENT CELLULAR CYTOTOXICITY; MONOCLONAL-ANTIBODIES; MEDIATED
   CYTOTOXICITY; FC-RECEPTOR; NK CELLS; VACCINE; ACTIVATION; INFECTION;
   RELEASE; PROTECTION
AB The stalk of the influenza virus hemagglutinin (HA) is an attractive target for antibody-based universal influenza virus vaccine development. While antibodies that target this part of the virus can be neutralizing, it has been shown in recent years that Fc receptor-mediated effector functions are of significant importance for the protective effect of anti-stalk antibodies. Several assays to measure Fc-Fc receptor interaction-based effector functions like antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis exist, but they suffer from limitations such as low throughput and high run-to-run variability. Reporter assays for antibody-dependent cellular cytotoxicity based on reporter cells that express luciferase upon engagement of human Fc gamma RIIIa with the Fc of antigen-bound antibodies have been developed as well. These reporter assays can be used in a higher throughput setting with limited run-to-run assay variability but since they express only one Fc receptor, their biological relevance is unclear. Here we optimized an antibody-dependent cellular cytotoxicity reporter assay to measure the activity of antibodies to the conserved stalk domain of H1 hemagglutinin. The assay was then correlated to a CD107a-based degranulation assay, and a strong and significant correlation could be observed. This data suggests that the Fc gamma RIIIa-based reporter assay is a good substitute for functional assays, especially in settings where larger sample numbers need to be analyzed. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Chromikova, Veronika; Tan, Jessica; Aslam, Sadaf; Rajabhathor, Arvind; Bermudez-Gonzalez, Maria; Ayllon, Juan; Simon, Viviana; Garcia-Sastre, Adolfo; Nachbagauer, Raffael; Krammer, Florian] Icahn Sch Med Mt Sinai, Dept Microbiol, Box 1124, New York, NY 10029 USA.
   [Salaun, Bruno] GlaxoSmithKline, Rixensart, Belgium.
   [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Global Hlth & Emerging Pathogens Inst, New York, NY 10029 USA.
   [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY 10029 USA.
   [Garcia-Sastre, Adolfo] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
   [Tan, Jessica] Icahn Sch Med Mt Sinai, Grad Sch Biol Sci, New York, NY 10029 USA.
RP Krammer, F (reprint author), Icahn Sch Med Mt Sinai, Dept Microbiol, Box 1124, New York, NY 10029 USA.
EM florian.krammer@mssm.edu
OI Nachbagauer, Raffael/0000-0001-5568-5420
FU GlaxoSmith-KlineGlaxoSmithKline; NIAID Centers of Excellence for
   Influenza Research and Surveillance (CEIRS) [HHSN272201400008C]
FX Work in the Krammer laboratory was supported by GlaxoSmith-Kline as well
   as funding from the NIAID Centers of Excellence for Influenza Research
   and Surveillance (CEIRS, HHSN272201400008C). We would like to thank Dr.
   Patrick Wilson from the University of Chicago for providing plasmids for
   human mAb expression, the Icahn School of Medicine Flow Cytometry Core
   for access to the flow cytometers and Dr. Evren Azeloglu for assistance
   with fluorescence microscopy. We would also like to thank Elena Hirsch
   for expert sample processing as well as the study participants.
CR Achkar JM, 2018, CURR OPIN IMMUNOL, V53, P30, DOI 10.1016/j.coi.2018.04.004
   Arunkumar GA, 2019, J VIROL, V93, DOI 10.1128/JVI.01696-18
   Barrow AD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00909
   Bernstein DI, 2019, LANCET INFECT DIS
   Broussas Matthieu, 2013, Methods Mol Biol, V988, P305, DOI 10.1007/978-1-62703-327-5_19
   Chai N, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005702
   Chen CJ, 2016, J VIROL, V90, P3789, DOI 10.1128/JVI.03060-15
   Choi Angela, 2019, Immunohorizons, V3, P133, DOI 10.4049/immunohorizons.1900022
   Chromikova V, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183315
   Chung AW, 2009, J IMMUNOL, V182, P1202, DOI 10.4049/jimmunol.182.2.1202
   Co MDT, 2014, VIRAL IMMUNOL, V27, P375, DOI 10.1089/vim.2014.0061
   Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669
   Cox F, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00399
   Cox F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145243
   de Vries RD, 2018, J INFECT DIS, V217, P3, DOI 10.1093/infdis/jix546
   DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443
   Dreyfus C, 2012, SCIENCE, V337, P1343, DOI 10.1126/science.1222908
   Duehr J, 2017, J VIROL, V91, DOI 10.1128/JVI.00652-17
   Dunand CJH, 2016, CELL HOST MICROBE, V19, P800, DOI 10.1016/j.chom.2016.05.014
   Dunand CJH, 2015, J CLIN INVEST, V125, P1255, DOI 10.1172/JCI74374
   El Bakkouri K, 2011, J IMMUNOL, V186, P1022, DOI 10.4049/jimmunol.0902147
   Ermler ME, 2017, J VIROL, V91, DOI 10.1128/JVI.00286-17
   Florek NW, 2014, J VIROL
   Gomez-Roman VR, 2006, J IMMUNOL METHODS, V308, P53, DOI 10.1016/j.jim.2005.09.018
   Gunn BM, 2016, TRENDS MOL MED, V22, P969, DOI 10.1016/j.molmed.2016.09.002
   Hanson QM, 2015, BIOCHEMISTRY-US, V54, P2931, DOI 10.1021/acs.biochem.5b00299
   Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425
   He WQ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00928-3
   He WQ, 2016, P NATL ACAD SCI USA, V113, P11931, DOI 10.1073/pnas.1609316113
   Hessell AJ, 2007, NATURE, V449, P101, DOI 10.1038/nature06106
   Horner H, 2007, J IMMUNOL, V179, P337, DOI 10.4049/jimmunol.179.1.337
   Hsieh YT, 2017, J IMMUNOL METHODS, V441, P56, DOI 10.1016/j.jim.2016.12.002
   Huber VC, 2001, J IMMUNOL, V166, P7381, DOI 10.4049/jimmunol.166.12.7381
   JACOBS DB, 1983, J IMMUNOL METHODS, V62, P101, DOI 10.1016/0022-1759(83)90115-1
   Jacobsen H, 2017, MBIO, V8, DOI 10.1128/mBio.01463-17
   Jegaskanda S, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020027
   Jegaskanda S, 2016, J INFECT DIS, V214, P945, DOI 10.1093/infdis/jiw262
   Jegaskanda S, 2013, J VIROL, V87, P5512, DOI 10.1128/JVI.03030-12
   Jegaskanda S, 2013, J IMMUNOL, V190, P1837, DOI 10.4049/jimmunol.1201574
   KATO K, 1991, JPN J CANCER RES, V82, P206, DOI 10.1111/j.1349-7006.1991.tb01830.x
   Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581
   Lee-MacAry AE, 2001, J IMMUNOL METHODS, V252, P83, DOI 10.1016/S0022-1759(01)00336-2
   Leon PE, 2016, P NATL ACAD SCI USA, V113, pE5944, DOI 10.1073/pnas.1613225113
   Li GM, 2012, P NATL ACAD SCI USA, V109, P9047, DOI 10.1073/pnas.1118979109
   Maecker HT, 2012, NAT REV IMMUNOL, V12, P191, DOI 10.1038/nri3158
   Martinez-Sobrido L, 2010, J VIROL, V84, P2157, DOI 10.1128/JVI.01433-09
   Nachbagauer R, 2016, MBIO, V7, DOI 10.1128/mBio.01996-15
   Ng S, 2019, NAT MED, V25, P962, DOI 10.1038/s41591-019-0463-x
   ORTALDO JR, 1992, J LEUKOCYTE BIOL, V52, P483
   Roman VROG6mz, 2014, ANTIBODY FC LINKING
   Saphire EO, 2018, NAT IMMUNOL, V19, P1169, DOI 10.1038/s41590-018-0233-9
   Saphire EO, 2018, CELL, V174, P938, DOI 10.1016/j.cell.2018.07.033
   Sivori S, 2019, CELL MOL IMMUNOL, V16, P430, DOI 10.1038/s41423-019-0206-4
   Tan GS, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005578
   Thulin NK, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030036
   TIMONEN T, 1977, J IMMUNOL METHODS, V18, P123, DOI 10.1016/0022-1759(77)90163-6
   Tudor D, 2011, AIDS, V25, P751, DOI 10.1097/QAD.0b013e32834507bd
   Van den Hoecke S, 2017, J VIROL, V91, DOI 10.1128/JVI.02500-16
   Wang TT, 2018, CURR OPIN IMMUNOL, V53, P124, DOI 10.1016/j.coi.2018.04.026
   Wohlbold TJ, 2017, NAT MICROBIOL, V2, P1415, DOI 10.1038/s41564-017-0011-8
   Wohlbold TJ, 2015, MBIO, V6, DOI 10.1128/mBio.02556-14
NR 61
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 1953
EP 1961
DI 10.1016/j.vaccine.2020.01.008
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000011
PM 31959425
DA 2020-05-12
ER

PT J
AU Fadlyana, E
   Dhamayanti, M
   Tarigan, R
   Sari, RM
   Bachtiar, NS
   Kartasasmita, CB
   Rusmil, K
AF Fadlyana, Eddy
   Dhamayanti, Meita
   Tarigan, Rodman
   Sari, Rini Mulia
   Bachtiar, Novilia Sjafri
   Kartasasmita, Cissy B.
   Rusmil, Kusnandi
TI Immunogenicity and safety profile of a primary dose of bivalent oral
   polio vaccine given simultaneously with DTwP-Hb-Hib and inactivated
   poliovirus vaccine at the 4th visit in Indonesian infants
SO VACCINE
LA English
DT Article
DE bOPV; IPV; Immunogenicity; Pentabio; Safety
AB In this study, we aimed to evaluate the immunological protectivity of infants following four doses of bivalent oral polio vaccine (bOPV; Bio Farma), which were given simultaneously with DTwP-Hb-Hib (Pentabio (R)), along with one dose of inactivated poliovirus vaccine (IPV) at the fourth visit. A total of 143 newborn infants who fulfilled the inclusion criteria were enrolled and completed the study. Subjects received the first dose of bOPV at birth. On days 60, 90 and 120, bOPV was given simultaneously with Pentabio (R). On day 120, one dose of IPV was also administered. Serum samples for serology analysis were collected before the first dose of bOPV (at day 0), before the second dose of bOPV (at day 60) and 30 days after the last dose of bOPV. In addition, the intensity, duration and relationship of each adverse event to the trial vaccines were assessed. Seroprotection rates after the fourth dose of bOPV were 100%, 91.6% and 99.3% for poliovirus P1, P2 and P3, respectively. Seroconversion rates after the fourth dose of bOPV were 100.0%, 93.3% and 100% for poliovirus P1, P2 and P3, respectively. There were no severe adverse events, and systemic reactions were generally mild during the 1-28 day post-vaccination period. Collectively, our findings indicate that bOPV given simultaneously with Pentabio (R) and one dose of IPV at the 4th visit was immunogenic and well tolerated. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Fadlyana, Eddy; Dhamayanti, Meita; Tarigan, Rodman; Kartasasmita, Cissy B.; Rusmil, Kusnandi] Univ Padjadjaran, Dept Child Hlth, Fac Med, Hasan Sadikin Hosp, Jl Pasteur 38, Bandung, Indonesia.
   [Sari, Rini Mulia; Bachtiar, Novilia Sjafri] PT Bio Farma, Bandung, Indonesia.
RP Fadlyana, E (reprint author), Univ Padjadjaran, Dept Child Hlth, Fac Med, Hasan Sadikin Hosp, Jl Pasteur 38, Bandung, Indonesia.
EM edfadlyana@yahoo.com; rini.mulia@biofarma.co.id; novilia@biofarma.co.id
OI Dhamayanti, Meita/0000-0001-9661-0708
FU PT Bio Farma (Persero) [00912/DIR/111/2016, PO - 00010835]
FX This study was funded by PT Bio Farma (Persero); the MOU number is
   00912/DIR/111/2016, PO - 00010835.
CR [Anonymous], 2016, OPV OR POL VACC BIV
   [Anonymous], 2014, WORLD HEAL ORGAN TEC
   Expert Committee on Biological Standardization, 2016, GUID CLIN EV VACC RE, P1
   Global Polio Eradication Initiative, THIS WEEK GPEI
   Global Polio Eradication Initiative, 2013, POL ER ENDG STRAT PL, P1
   Grassly NC, 2014, J INFECT DIS, V210, pS439, DOI 10.1093/infdis/jit601
   ICH CCP, 2016, GUID GOOD CLIN PRACT
   Kew OM, 2005, ANNU REV MICROBIOL, V59, P587, DOI 10.1146/annurev.micro.58.030603.123625
   Kong H, 2013, WMA DECLARATION HELS, P29
   Minor P, 2009, VACCINE, V27, P2649, DOI 10.1016/j.vaccine.2009.02.071
   PT Bio Farma, 2018, PENT VACC DTP HB HIB
   Rusmil K, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0525-2
   Rusmil Kusnandi, 2006, ANTIBODY RESPONSE SA
   Saleem AF, 2018, J INFECT DIS, V217, P443, DOI 10.1093/infdis/jix577
   Sutter RW, 2015, LANCET, V386, P2413, DOI 10.1016/S0140-6736(15)00237-8
   SWARTZ TA, 1989, EUR J EPIDEMIOL, V5, P143, DOI 10.1007/BF00156819
   Tanuwidjaja Suganda, 2008, COMP EVALUATION IMMU
   Wahjuhono G, 2014, J INFECT DIS, V210, pS347, DOI 10.1093/infdis/jiu060
   WHO, 2014, VACCINE, V32, P4117, DOI 10.1016/j.vaccine.2014.04.023
   (WHO) WHO, WHOEPIGEN939
   (WHO) WHO, 2015, VACC ASS PAR POL VAP
   (WHO) WHO, 2014, BACKGR TECHN RAT INT
   (WHO) WHO, 2018, POL VACC IN IPV SHAN
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 1962
EP 1967
DI 10.1016/j.vaccine.2020.01.007
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000012
PM 31982261
OA Other Gold
DA 2020-05-12
ER

PT J
AU Lai, E
   Tan, HY
   Kunasekaran, M
   Chughtai, AA
   Trent, M
   Poulos, C
   MacIntyre, CR
AF Lai, Elisa
   Tan, Hao Yi
   Kunasekaran, Mohana
   Chughtai, Abrar Ahmad
   Trent, Mallory
   Poulos, Christopher
   MacIntyre, C. Raina
TI Influenza vaccine coverage and predictors of vaccination among aged care
   workers in Sydney Australia
SO VACCINE
LA English
DT Article
DE Aged care workers; Influenza vaccine; Coverage; Long-term care
   facilities; Nursing homes; Occupational health
ID LONG-TERM-CARE; ANTIBODY-RESPONSE; HEALTH; MORTALITY; RATES; STAFF;
   IMMUNIZATION; DISPARITIES; FACILITIES; RESIDENTS
AB Aged care facilities (ACFs) are residential communities with a concentration of vulnerable individuals with increased risk of severe influenza infection and complications such as outbreaks, hospitalisations and deaths. Aged care workers (ACW) are potential sources of influenza introduction and transmission in ACFs. Little is known about vaccine uptake among ACW. This study aimed to measure the vaccine uptake rate among Australian ACW and evaluate the demographic determinants of uptake during the influenza season of 2018.
   146 ACWs were recruited from 7 facilities of a multisite aged care provider in Sydney. ACWs completed a questionnaire regarding their demographic, occupational and vaccination status. Vaccine coverage was calculated and variables were examined against their 2018 influenza vaccination status in statistical analysis.
   ACWs in our study were predominantly from a non-health occupational background with a large proportion of migrant workers (56%, 75/134). Vaccine coverage in 2018 was 48% (65/135). The strongest determinants of vaccine uptake were previous year vaccination history (Odds Ratio [OR] 10.49, 95% CI 3.33-33.10), workplace immunisation programs for employees (OR 7.87, 95% CI 2.47-25.10), casual work as employment status (OR 0.14, 95% CI 0.02-0.77), and presence of comorbidities (OR 4.04, 95% CI 1.23-13.32).
   ACW are a unique and understudied group who are critical to infection control in ACF5. Few ACWs have formal health training, and many are migrants who may lack access to subsidised health care and face out of pocket costs for vaccination. Vaccine coverage among ACW were below recommended levels. Provision of influenza vaccine for staff in workplaces is highly effective in raising vaccine coverage amongst ACWs. More research on the aged care sector workforce is needed in order to evaluate the determinants of vaccine uptake among Australian ACWs. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Lai, Elisa; Kunasekaran, Mohana; Trent, Mallory; MacIntyre, C. Raina] Univ New South Wales, Fac Med, Kirby Inst, Biosecur Program, Sydney, NSW, Australia.
   [Tan, Hao Yi; Chughtai, Abrar Ahmad; Poulos, Christopher] Univ New South Wales, Fac Med, Sch Publ Hlth & Community Med, Sydney, NSW, Australia.
   [Poulos, Christopher] HammondCare, Res & Aged Care Clin Serv, St Leonards, NSW, Australia.
   [MacIntyre, C. Raina] Arizona State Univ, Coll Publ Serv & Community Solut, Tempe, AZ 85287 USA.
RP Lai, E (reprint author), Univ New South Wales, Fac Med, Kirby Inst, Wallace Wurth Bldg Room 644, Kensington, NSW 2052, Australia.
EM elisa.lai@student.unsw.edu.au
FU NHMRC Centre of Research Excellence in Integrated Systems for Epidemic
   Response (ISER)National Health and Medical Research Council of Australia
   [1107393]; NHMRCNational Health and Medical Research Council of
   Australia [1137582]
FX The authors declare the following financial interests/personal
   relationships which may be considered as potential competing interests:
   This work was supported by a grant from the NHMRC Centre of Research
   Excellence in Integrated Systems for Epidemic Response (ISER) under the
   grant ID 1107393. Professor C Raina Maclntyre is supported by a NHMRC
   Principal Research Fellowship of grant ID 1137582.
CR Amodio E, 2014, J HOSP INFECT, V86, P182, DOI 10.1016/j.jhin.2014.01.005
   Andrew MK, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-36
   [Anonymous], 2013, BMJ-BRIT MED J, V347, pf6705, DOI DOI 10.1136/BMJ.F6705
   Asciak R, 2013, MULTIDISCIP RESP MED, V8, DOI 10.1186/2049-6958-8-68
   Australian Government Department of Health, 2017, 2017 INFL SEAS AUSTR
   Australian Government Department of Human Services, MED CARD EL 2018
   Australian Technical Advisory Group on Immunisation (ATAGI), 2017, AUSTR IMM HDB
   Budhwani H, 2016, PUBLIC HEALTH, V138, P146, DOI 10.1016/j.puhe.2016.04.003
   Carman WF, 2000, LANCET, V355, P93, DOI 10.1016/S0140-6736(99)05190-9
   Chambers C, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy211
   Charles C, 1999, SOC SCI MED, V49, P651, DOI 10.1016/S0277-9536(99)00145-8
   Cohn AC, 2013, MMWR RECOMM REP, V62, P1
   COLES FB, 1992, J AM GERIATR SOC, V40, P589, DOI 10.1111/j.1532-5415.1992.tb02108.x
   Communicable Diseases Network Australia (CDNA), 2017, GUID PREV CONTR PUBL
   Cruijff M, 1999, VACCINE, V17, P426, DOI 10.1016/S0264-410X(98)00213-8
   Daugherty JD, 2015, AM J INFECT CONTROL, V43, P100, DOI 10.1016/j.ajic.2014.08.021
   Demicheli V, 2014, COCHRANE DATABASE SY, V3
   DiazGranados CA, 2016, CLIN INFECT DIS, V62, P1092, DOI 10.1093/cid/ciw085
   Elias C, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4556-5
   Gaillat J, 2009, EUR J CLIN MICROBIOL, V28, P1077, DOI 10.1007/s10096-009-0751-3
   Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105
   Gravenstein S, 2018, HUM VACC IMMUNOTHER, V14, P736, DOI 10.1080/21645515.2017.1398872
   Groenewold M, 2012, J AM MED DIR ASSOC, V13, DOI 10.1016/j.jamda.2011.02.008
   Halliday L, 2003, AUST NZ J PUBL HEAL, V27, P70, DOI 10.1111/j.1467-842X.2003.tb00383.x
   Hayward AC, 2006, BRIT MED J, V333, P1241, DOI 10.1136/bmj.39010.581354.55
   Healy J, 2005, DO AGED CARE WORKER
   Hopping AM, 2016, VACCINE, V34, P540, DOI 10.1016/j.vaccine.2015.11.058
   Huhtinen E, 2019, AUSTRALAS J AGEING, V38, P60, DOI 10.1111/ajag.12595
   Hunt G, 2018, MANDATORY VACCINE PR
   Lansbury LE, 2017, INFLUENZA OTHER RESP, V11, P356, DOI 10.1111/irv.12464
   Lee SJ, 2013, AM J INFECT CONTROL, V41, pE65, DOI 10.1016/j.ajic.2012.10.014
   Leekha S, 2007, INFECT CONT HOSP EP, V28, P1071, DOI 10.1086/520101
   Lester RT, 2003, INFECT CONT HOSP EP, V24, P839, DOI 10.1086/502146
   Looijmans-van den Akker I, 2009, VACCINE, V27, P4724, DOI 10.1016/j.vaccine.2009.05.013
   Marin A, 2012, ECOL SOC, V17, DOI 10.5751/ES-04562-170113
   Moran A, 2019, VACCINE, V37, P705, DOI 10.1016/j.vaccine.2018.12.029
   Nace DA, 2007, J AM MED DIR ASSOC, V8, P128, DOI 10.1016/j.jamda.2006.09.014
   Newall AT, 2010, EPIDEMIOL INFECT, V138, P836, DOI 10.1017/S095026880999118X
   Newall AT, 2008, VACCINE, V26, P2135, DOI 10.1016/j.vaccine.2008.01.051
   NSW Health, INFL INF HEALTHC WOR
   Ofstead CL, 2017, VACCINE, V35, P2390, DOI 10.1016/j.vaccine.2017.03.041
   Ojha RP, 2015, AM J PUBLIC HEALTH, V105, pE35, DOI 10.2105/AJPH.2015.302736
   Person CJ, 2013, AM J INFECT CONTROL, V41, P743, DOI 10.1016/j.ajic.2012.09.025
   Petrie JG, 2017, UNTANGLING EFFECTS P
   Potter J, 1997, J INFECT DIS, V175, P1, DOI 10.1093/infdis/175.1.1
   Remschmidt C, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1154-y
   Restivo V, 2018, HUM VACC IMMUNOTHER, V14, P724, DOI 10.1080/21645515.2017.1321722
   Seale H, 2009, INFLUENZA OTHER RESP, V3, P15, DOI 10.1111/j.1750-2659.2008.00063.x
   Tan HY, 2019, VACCINE, V37, P6329, DOI 10.1016/j.vaccine.2019.09.021
   Telford R, 2003, HEALTH EDUC RES, V18, P743, DOI 10.1093/her/cyf059
   Tennant E, 2019, AUST NZ J PUBL HEAL, DOI 10.1111/1753-6405.12933
   Thomas RE, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005187.pub5
   Travers J, 2015, GERIATR NURS, V36, P355, DOI 10.1016/j.gerinurse.2015.05.001
   Van den Dool C, 2008, VACCINE, V26, P1297, DOI 10.1016/j.vaccine.2007.12.045
   Wendelboe AM, 2011, INFECT CONT HOSP EP, V32, P990, DOI 10.1086/661916
   Whitaker JA, 2018, VACCINE, V36, P5940, DOI 10.1016/j.vaccine.2018.08.040
   Wilde JA, 1999, JAMA-J AM MED ASSOC, V281, P908, DOI 10.1001/jama.281.10.908
   Yue X, 2019, J AM MED DIR ASSOC, V20, P718, DOI 10.1016/j.jamda.2018.11.029
NR 58
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 1968
EP 1974
DI 10.1016/j.vaccine.2020.01.004
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000013
PM 31983582
DA 2020-05-12
ER

PT J
AU Opriessnig, T
   Karuppannan, AK
   Halbur, PG
   Calvert, JG
   Nitzel, GP
   Matzinger, SR
   Meng, XJ
AF Opriessnig, Tanja
   Karuppannan, Anbu K.
   Halbur, Patrick G.
   Calvert, Jay G.
   Nitzel, Gregory P.
   Matzinger, Shannon R.
   Meng, Xiang-Jin
TI Porcine circovirus type 2a or 2b based experimental vaccines provide
   protection against PCV2d/porcine parvovirus 2 co-challenge
SO VACCINE
LA English
DT Article
DE Cross-protection; Co-challenge; Porcine circovirus (PCV); PCV2a; PCV2b;
   PCV2d; Porcine parvovirus 2 (PPV2); Vaccination
ID COMMERCIAL PCV2A-BASED VACCINE; RESPIRATORY SYNDROME VIRUS;
   NONPATHOGENIC PCV1; 2A-BASED VACCINE; PIGS; INFECTION; DISEASE; MUTANT;
   ASSOCIATION; GENOTYPES
AB With the discovery of Porcine circovirus type 2d (PCV2d) in the USA in 2012 and subsequent genotype shift from the previously predominant PCV2b to PCV2d in the face of widespread PCV2a vaccination, concerns over PCV2 vaccine efficacy were raised. The objective of this study was to evaluate the efficacy of two similarly produced PCV2 vaccines, one containing the PCV2a capsid and the other one containing the PCV2b capsid, in the conventional pig model against PCV2d/porcine parvovirus 2 (PPV2) co-challenge. A co-challenge was added since there is evidence that PPV2 may exacerbate PCV2 infection and since PCV2 only rarely causes disease in experimentally infected pigs, hence vaccine efficacy can be difficult to assess. In brief, sixty 3-week-old-pigs from a PCV2 seropositive farm without evidence of active virus replication (no PCV2 viremia, low antibody titers with no evidence of increase after two consecutive bleedings) were blocked by PCV2 antibody titer and then randomly divided into three groups with 20 pigs each, a non-vaccinated group (challenge control), a PCV2a vaccinated group (VAC2a) and a PCV2b vaccinated group (VAC2b). Vaccinations were done at 4 and again at 6 weeks of age. At 8 weeks of age, all pigs were challenged with a PCV2d strain via intranasal and intramuscular routes of inoculation followed by intramuscular administration of PPV2 one day later. PCV2 vaccination, regardless of PCV2 genotype, resulted in significantly higher humoral and cellular immunity compared to non-vaccinated challenge control pigs as evidenced by increased numbers of interferon (IFN) gamma secreting cells after PCV2d stimulation of peripheral blood mononuclear cells collected prior to challenge. Furthermore, PCV2a and PCV2b vaccinations both reduced PCV2d viremia and PCV2-associated pathological lesions. Under the study conditions, the PCV2a and PCV2b vaccine preparations each induced immune responses and clinical protection against a heterologous PCV2d/PPV2 co-challenge. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Opriessnig, Tanja] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland.
   [Opriessnig, Tanja] Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland.
   [Opriessnig, Tanja; Karuppannan, Anbu K.; Halbur, Patrick G.] Iowa State Univ, Coll Vet Med, Dept Vet Diagnost & Prod Anim Med, Ames, IA USA.
   [Calvert, Jay G.; Nitzel, Gregory P.] Zoetis Inc, Vet Med Res & Dev, Kalamazoo, MI USA.
   [Matzinger, Shannon R.; Meng, Xiang-Jin] Virginia Polytech Inst & State Univ, Virginia Maryland Coll Vet Med, Dept Biomed Sci & Pathobiol, Blacksburg, VA 24061 USA.
RP Opriessnig, T (reprint author), Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland.; Opriessnig, T (reprint author), Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland.
EM Tanja.Opriessnig@roslin.ed.ac.uk
OI Karuppannan, Anbu Kumar/0000-0003-3020-4867
FU Zoetis Inc, Kalamazoo, MI, USA; Roslin Institute Strategic Programme
   Control of Infectious Diseases [BBS/E/D/20002173, BBS/E/D/20002174]
FX This work was supported by a Research Services Agreement with Zoetis
   Inc, Kalamazoo, MI, USA. We would also like to acknowledge Biotechnology
   and Biological Sciences Research Council (BBSRC) support of the Roslin
   Institute Strategic Programme Control of Infectious Diseases
   (BBS/E/D/20002173 and BBS/E/D/20002174).
CR Afghah Z, 2017, VET MICROBIOL, V206, P21, DOI 10.1016/j.vetmic.2016.10.002
   Allan GM, 2000, J VET DIAGN INVEST, V12, P3, DOI 10.1177/104063870001200102
   Beach NM, 2010, VACCINE, V29, P221, DOI 10.1016/j.vaccine.2010.10.050
   Carman S, 2008, CAN J VET RES, V72, P259
   Cui J, 2017, TRANSBOUND EMERG DIS, V64, P1945, DOI 10.1111/tbed.12593
   Fenaux M, 2003, J VIROL, V77, P11232, DOI 10.1128/JVI.77.20.11232-11243.2003
   Fort M, 2008, VACCINE, V26, P1063, DOI 10.1016/j.vaccine.2007.12.019
   Gagnon CA, 2007, CAN VET J, V48, P811
   Gerber PF, 2013, RES VET SCI, V95, P775, DOI 10.1016/j.rvsc.2013.06.004
   Guo LJ, 2015, VACCINE, V33, P3752, DOI 10.1016/j.vaccine.2015.05.056
   HALBUR PG, 1995, VET PATHOL, V32, P648, DOI 10.1177/030098589503200606
   Hijikata M, 2001, JPN J INFECT DIS, V54, P244
   Huan CC, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00455
   Karuppannan AK, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9050099
   Kolyvushko O, 2019, VET SCI
   Li JZ, 2017, ARCH VIROL, V162, P235, DOI 10.1007/s00705-016-3099-x
   Matzinger SR, 2016, VIROLOGY, V498, P82, DOI 10.1016/j.virol.2016.08.011
   Opriessnig T, 2008, VET MICROBIOL, V131, P103, DOI 10.1016/j.vetmic.2008.03.002
   Opriessnig T, 2008, J GEN VIROL, V89, P2482, DOI 10.1099/vir.0.2008/001081-0
   Opriessnig T, 2008, CLIN VACCINE IMMUNOL, V15, P397, DOI 10.1128/CVI.00416-07
   Opriessnig T, 2006, VET PATHOL, V43, P281, DOI 10.1354/vp.43-3-281
   Opriessnig T, 2004, VET PATHOL, V41, P624, DOI 10.1354/vp.41-6-624
   Opriessnig T, 2013, VET PATHOL, V50, P23, DOI 10.1177/0300985812450726
   Opriessnig T, 2003, VET PATHOL, V40, P521, DOI 10.1354/vp.40-5-521
   Opriessnig T, 2018, METHODSX, V5, P403, DOI 10.1016/j.mex.2018.03.010
   Opriessnig T, 2017, VACCINE, V35, P248, DOI 10.1016/j.vaccine.2016.11.085
   Opriessnig T, 2014, J GEN VIROL, V95, P2495, DOI 10.1099/vir.0.066423-0
   Opriessnig T, 2014, VET MICROBIOL, V173, P9, DOI 10.1016/j.vetmic.2014.06.024
   Opriessnig T, 2014, VACCINE, V32, P4342, DOI 10.1016/j.vaccine.2014.06.004
   Opriessnig T, 2014, VACCINE, V32, P230, DOI 10.1016/j.vaccine.2013.11.010
   Opriessnig T, 2013, VET MICROBIOL, V163, P177, DOI 10.1016/j.vetmic.2012.12.019
   Opriessnig T, 2013, VACCINE, V31, P487, DOI 10.1016/j.vaccine.2012.11.030
   Opriessnig T, 2012, VIRUS RES, V164, P20, DOI 10.1016/j.virusres.2011.09.014
   Opriessnig T, 2010, VET MICROBIOL, V142, P177, DOI 10.1016/j.vetmic.2009.09.056
   Park KH, 2019, VET MICROBIOL, V231, P87, DOI 10.1016/j.vetmic.2019.03.002
   Rose N, 2016, VACCINE, V34, P3738, DOI 10.1016/j.vaccine.2016.06.005
   Sorden SD, 1999, J VET DIAGN INVEST, V11, P528, DOI 10.1177/104063879901100607
   Xiao CT, 2015, J GEN VIROL, V96, P1830, DOI 10.1099/vir.0.000100
   Xiao CT, 2013, VET MICROBIOL, V161, P325, DOI 10.1016/j.vetmic.2012.07.038
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 1975
EP 1981
DI 10.1016/j.vaccine.2020.01.013
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000014
PM 31974016
DA 2020-05-12
ER

PT J
AU Hall, C
   Abramovitz, LM
   Bukowinski, AT
   Ricker, AA
   Khodr, ZG
   Gumbs, GR
   Wells, NY
   Conlin, AMS
AF Hall, Clinton
   Abramovitz, Lisa M.
   Bukowinski, Anna T.
   Ricker, Ashley A.
   Khodr, Zeina G.
   Gumbs, Gia R.
   Wells, Natalie Y.
   Conlin, Ava Marie S.
TI Safety of tetanus, diphtheria, and acellular pertussis vaccination among
   pregnant active duty US military women
SO VACCINE
LA English
DT Article
DE Vaccine safety; Pregnancy; Tdap; Maternal immunization; Military
ID MATERNAL TDAP VACCINATION; BIRTH-DEFECTS; IMMUNIZATION; OUTCOMES;
   INFANTS; RISK; RECOMMENDATIONS
AB Background: The tetanus, diphtheria, and acellular pertussis (Tdap) vaccine was approved for U.S. adults in 2005 and recommended for administration in every pregnancy in 2012, with optimal timing between 27 and 36 weeks' gestation. In the military, however, a current Tdap vaccination status is compulsory for service, and active duty women may be inadvertently exposed in early pregnancy. Safety data in this population are limited.
   Objectives: To assess safety of inadvertent (0-13 weeks' gestation) and recommended (27-36 weeks' gestation) exposure to the Tdap vaccine in pregnancy.
   Methods: Pregnancies and live births from Department of Defense Birth and Infant Health Research program data were linked with military personnel immunization records to determine pregnancy Tdap vaccine exposure among active duty women, 2006-2014. Multivariable Cox and generalized linear regression models estimated associations between Tdap vaccine exposure and adverse pregnancy or infant outcomes.
   Results: Of 145,883 pregnancies, 1272 were exposed to the Tdap vaccine in the first trimester and 9438 between 27 and 36 weeks' gestation. Neither inadvertent nor recommended vaccine exposure were associated with spontaneous abortion, preeclampsia, or preterm labor. Among 117,724 live born infants, 984 were exposed to the Tdap vaccine in the first trimester and 9352 between 27 and 36 weeks' gestation. First trimester exposure was not associated with birth defects, growth problems in utero, growth problems in infancy, preterm birth, or low birth weight. Tdap vaccine exposure between 27 and 36 weeks' gestation was not associated with any adverse infant outcome.
   Conclusions: Among a population of active duty women in the U.S. military who received the Tdap vaccine during pregnancy, we detected no increased risks for adverse maternal, fetal, or infant outcomes. Our findings corroborate existing literature on the safety of exposure to the Tdap vaccine in pregnancy. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Hall, Clinton; Abramovitz, Lisa M.; Bukowinski, Anna T.; Khodr, Zeina G.; Gumbs, Gia R.] Leidos Inc, 140 Sylvester Rd, San Diego, CA 92106 USA.
   [Hall, Clinton; Abramovitz, Lisa M.; Bukowinski, Anna T.; Ricker, Ashley A.; Khodr, Zeina G.; Gumbs, Gia R.; Wells, Natalie Y.; Conlin, Ava Marie S.] Naval Hlth Res Ctr, Deployment Hlth Res Dept, 140 Sylvester Rd, San Diego, CA 92106 USA.
   [Ricker, Ashley A.] Innovat Employee Solut, 140 Sylvester Rd, San Diego, CA 92106 USA.
RP Hall, C (reprint author), Naval Hlth Res Ctr, Deployment Hlth Res Dept, 140 Sylvester Rd, San Diego, CA 92106 USA.
EM clinton.j.hall15.ctr@mail.mil
OI Ricker, Ashley/0000-0002-5549-2247
CR Abu Raya B, 2014, VACCINE, V32, P5787, DOI 10.1016/j.vaccine.2014.08.038
   Anonymous, 2011, Morbidity and Mortality Weekly Report, V60, P1424
   Barrett John P, 2012, J Registry Manag, V39, P69
   Baxter R, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4091
   Berenson AB, 2016, HUM VACC IMMUNOTHER, V12, P1965, DOI 10.1080/21645515.2016.1157241
   Bukowinski Anna T, 2017, MSMR, V24, P39
   Conlin AMS, 2018, VACCINE, V36, P2855, DOI 10.1016/j.vaccine.2018.03.061
   Conlin AMS, 2017, VACCINE, V35, P4414, DOI 10.1016/j.vaccine.2017.06.032
   Conlin AMS, 2013, OBSTET GYNECOL, V121, P511, DOI 10.1097/AOG.0b013e318280d64e
   Dabrera G, 2015, CLIN INFECT DIS, V60, P333, DOI 10.1093/cid/ciu821
   DeSilva M, 2017, VACCINE, V35, P3655, DOI 10.1016/j.vaccine.2017.05.041
   DeSilva M, 2016, JAMA-J AM MED ASSOC, V316, P1823, DOI 10.1001/jama.2016.14432
   Donegan K, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4219
   Gkentzi D, 2017, ARCH DIS CHILD-FETAL, V102, pF456, DOI 10.1136/archdischild-2016-312341
   Griffin JB, 2018, VACCINE, V36, P5173, DOI 10.1016/j.vaccine.2018.07.011
   Healy CM, 2013, CLIN INFECT DIS, V56, P539, DOI 10.1093/cid/cis923
   Howards PP, 2007, AM J EPIDEMIOL, V165, P444, DOI 10.1093/aje/kwk027
   Kharbanda EO, 2014, JAMA-J AM MED ASSOC, V312, P1897, DOI 10.1001/jama.2014.14825
   Kharbanda EO, 2017, PHARMACOEPIDEM DR S, V26, P412, DOI 10.1002/pds.4153
   Kharbanda EO, 2016, VACCINE, V34, P968, DOI 10.1016/j.vaccine.2015.12.046
   Khodr ZG, 2017, VACCINE, V35, P5603, DOI 10.1016/j.vaccine.2017.08.041
   Kraemer S, 2000, BRIT MED J, V321, P1609, DOI 10.1136/bmj.321.7276.1609
   Layton JB, 2017, VACCINE, V35, P4072, DOI 10.1016/j.vaccine.2017.06.071
   Mathews T J, 2005, Natl Vital Stat Rep, V53, P1
   McIntyre PB, 2014, LANCET, V384, P1484, DOI 10.1016/S0140-6736(14)60977-6
   McMillan M, 2017, OBSTET GYNECOL, V129, P560, DOI 10.1097/AOG.0000000000001888
   Morgan JL, 2015, OBSTET GYNECOL, V125, P1433, DOI 10.1097/AOG.0000000000000862
   Munoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633
   Nieves DJ, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.EI10-0008-2015
   Powell KR, 2006, PEDIATRICS, V117, P965, DOI 10.1542/peds.2005-3038
   Ryan MAK, 2001, TERATOLOGY, V64, pS26, DOI 10.1002/tera.1081
   Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131
   Sever LE, 2004, GUIDELINES CONDUCTIN
   Shakib JH, 2013, J PEDIATR-US, V163, P1422, DOI 10.1016/j.jpeds.2013.06.021
   Skoff TH, 2017, CLIN INFECT DIS, V65, P1977, DOI 10.1093/cid/cix724
   U.S. Department of Health and Human Services Centers for Disease Control and Prevention National Center for Health Statistics Division of Vital Statistics, DIV VIT STAT BIRTHS
   Vilajeliu A, 2015, VACCINE, V33, P1056, DOI 10.1016/j.vaccine.2014.12.062
   Walls T, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009536
   Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 1982
EP 1988
DI 10.1016/j.vaccine.2020.01.009
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000015
PM 31952872
DA 2020-05-12
ER

PT J
AU Tian, KY
   Guo, HF
   Li, N
   Zhang, YH
   Wang, Z
   Wang, BY
   Yang, X
   Li, YT
   Zhao, J
AF Tian, Kai-yue
   Guo, Hui-fang
   Li, Ning
   Zhang, Yu-han
   Wang, Zeng
   Wang, Baiyu
   Yang, Xia
   Li, Yong-tao
   Zhao, Jun
TI Protection of chickens against hepatitis-hydropericardium syndrome and
   Newcastle disease with a recombinant Newcastle disease virus vaccine
   expressing the fowl adenovirus serotype 4 fiber-2 protein
SO VACCINE
LA English
DT Article
DE Newcastle disease; Hepatitis-hydropericardium syndrome; Recombinant NDV;
   LaSota vaccine strain; Fowl adenovirus serotype 4; Fiber-2
ID AVIAN INFLUENZA; EFFICACY
AB Newcastle disease (ND) is one of the most important and devastating avian diseases with considerable threat to the global poultry industry. Hepatitis-hydropericardium syndrome (HHS), caused by virulent fowl adenovirus serotype 4 (FAdV-4), is another highly infectious disease in chickens with severe economic impact. The effective way to combat ND and HHS is by vaccinating the poultry. In the present study, a recombinant NDV LaSota vaccine strain expressing full length fiber-2 gene of FAdV-4 (rLaSota-fiber2) was generated using reverse genetics. The FAdV-4 fiber-2 protein was expressed as a soluble form rather than NDV membrane-anchored form. The rLaSota-fiber2 was genetically stable, and it showed growth patterns in embryonated eggs comparable to that of parental rLaSota virus. Since our unpublished data demonstrated that delivery of live rLaSota-fiber2 in drinking water or ocular delivery of the vaccine didn't produce protection against hypervirulent FAdV-4 challenge, even though the vaccine provide full protection against NDV challenge, the efficacy of the rLaSota-fiber2 was evaluated by delivering the vaccine intramuscularly in this study. Single-dose intramuscular vaccination of 2-week-old SPF White Leghorn chicks with the live or inactivated rLaSota-fiber2 provided complete protection against virulent NDV challenge. However, single-dose intramuscular vaccination with the live rLaSota-fiber2 vaccine provided better protection against virulent FAdV-4 challenge and significantly reduced faecal viral shedding comparing to the inactivated vaccine. These results indicate that the NDV-vectored FAdV-4 vaccine is a promising bivalent vaccine candidate to control both HHS and ND. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Tian, Kai-yue; Guo, Hui-fang; Li, Ning; Zhang, Yu-han; Wang, Zeng; Wang, Baiyu; Yang, Xia; Li, Yong-tao; Zhao, Jun] Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou, Henan, Peoples R China.
RP Zhao, J (reprint author), Henan Agr Univ, Coll Anim Sci & Vet Med, Zhengzhou, Henan, Peoples R China.
EM zhaoj@henau.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31772771]
FX This work was supported by the National Natural Science Foundation of
   China [grant number 31772771].
CR ABDULAZIZ TA, 1991, VET REC, V129, P272, DOI 10.1136/vr.129.12.272
   Abozeid HH, 2019, VET RES, V50, DOI 10.1186/s13567-019-0631-5
   Amarasinghe GK, 2017, ARCH VIROL, V162, P2493, DOI 10.1007/s00705-017-3311-7
   Asrani RK, 1997, VET REC, V141, P271, DOI 10.1136/vr.141.11.271
   Bello MB, 2018, BIOMED RES INT, DOI 10.1155/2018/7278459
   Chen L, 2018, VACCINE, V36, P1203, DOI 10.1016/j.vaccine.2018.01.028
   Cornelissen LAHM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044447
   Feichtner F, 2018, AVIAN PATHOL, V47, P73, DOI 10.1080/03079457.2017.1372561
   Ge JY, 2015, VACCINE, V33, P2457, DOI 10.1016/j.vaccine.2015.03.091
   Ge JY, 2014, VACCINE, V32, P1514, DOI 10.1016/j.vaccine.2014.01.020
   Harrach B., 2012, VIRUS TAXONOMY, P125, DOI DOI 10.1016/B978-0-12-384684-6.00009-4
   Hess M, 1999, AVIAN PATHOL, V28, P433, DOI 10.1080/03079459994443
   Hu HX, 2018, VACCINE, V36, P4846, DOI 10.1016/j.vaccine.2018.06.055
   Khattar SK, 2015, MBIO, V6, DOI 10.1128/mBio.01005-15
   Kim SH, 2017, VACCINE, V35, P4133, DOI 10.1016/j.vaccine.2017.06.055
   Li G, 2019, VIRUSES, V3
   Liu YK, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.115
   Meulemans G, 2001, AVIAN PATHOL, V30, P655, DOI 10.1080/03079450120092143
   Miller PJ, 2013, DIS POULTRY
   Murulitharan K, 2013, VIRUS GENES, V46, P431, DOI 10.1007/s11262-012-0874-y
   Nagy A, 2016, VACCINE, V34, P2537, DOI 10.1016/j.vaccine.2016.04.022
   Nakamura K, 1999, AVIAN DIS, V43, P414, DOI 10.2307/1592638
   Office International des, 2017, TERRES ANIM HLTH COD, V10, P1
   Pallister J, 1996, J VIROL, V70, P5115, DOI 10.1128/JVI.70.8.5115-5122.1996
   Peeters BPH, 1999, J VIROL, V73, P5001, DOI 10.1128/JVI.73.6.5001-5009.1999
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Ruan SF, 2018, INFECT GENET EVOL, V61, P145, DOI 10.1016/j.meegid.2018.03.031
   Schachner A, 2018, AVIAN PATHOL, V47, P111, DOI 10.1080/03079457.2017.1385724
   Schachner A, 2014, VACCINE, V32, P1086, DOI 10.1016/j.vaccine.2013.12.056
   Schonewille E, 2010, AVIAN DIS, V54, P905, DOI 10.1637/8999-072309-Reg.1
   Toro H, 1999, AVIAN DIS, V43, P262, DOI 10.2307/1592616
   Wang XL, 2018, VIRUS RES, V245, P1, DOI 10.1016/j.virusres.2017.12.003
   Ye JQ, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.50
   Yi JZ, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-202
   Zhao J, 2018, VET REC, V182, P381, DOI 10.1136/vr.104517
   Zhao J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133073
   Zhao R, 2017, VACCINE, V35, P2435, DOI 10.1016/j.vaccine.2017.03.045
   Zhao TK, 2018, NPJ COMPUT MATER, V4, DOI 10.1038/s41524-018-0069-8
NR 38
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 1989
EP 1997
DI 10.1016/j.vaccine.2020.01.006
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000016
PM 31948818
DA 2020-05-12
ER

PT J
AU Ma, P
   Luo, ZW
   Qian, J
   Yan, ZF
   Zhang, LM
   Martin, LS
   Wang, ZY
   Xia, H
   Yu, FF
   Jiang, W
AF Ma, Ping
   Luo, Zhenwu
   Qian, Jing
   Yan, Zhongfang
   Zhang, Lumin
   Martin, Lisa
   Wang, Ziyu
   Xia, Huan
   Yu, Fangfang
   Jiang, Wei
TI Decreased ratio of influenza-specific IgG versus IgM in response to
   influenza vaccination in antiretroviral-treated HIV-infected African
   Americans compared to Caucasians, and its direct correlation with the
   percentages of peripheral Tfh cells
SO VACCINE
LA English
DT Article
DE HIV disease; B cells; Antibody responses; Influenza vaccine
ID PLASMACYTOID DENDRITIC CELLS; HUMAN-IMMUNODEFICIENCY-VIRUS; MONOCYTE
   ACTIVATION; BLACK-MEN; SEX; NONRESPONDERS; IMMUNIZATION; BIOMARKERS;
   MORTALITY; CHILDREN
AB Background: Racial differences have been observed in the rate of bacterial infection and disease progression in HIV. Here, we evaluate racial differences in seasonal influenza vaccine responses.
   Methods: 16 healthy controls (9 Caucasians (CC) and 7 African Americans (AA)) and 26 antiretroviral therapy (ART)-treated aviremic HIV+ subjects (11 CC and 15 AA) were enrolled in the current study. Blood was collected at pre-vaccination (DO) and day 14 (D14) following seasonal influenza vaccination. Serologic responses were characterized in plasma by ELISA. B and T cells were assessed by flow cytometry ex vivo.
   Results: The absolute counts of CD4+ CD3+ T cells and CD19+ B cells were similar in healthy controls and HIV-infected individuals, and similar in CC and AA in the two study groups. However, the percentage of peripheral T follicular helper (pTfh) cells was decreased in HIV+ AA compared to HIV+ CC. There were no racial differences in IgG antibody responses against vaccination in the two study groups. However, the ratio of anti-influenza-specific IgG versus IgM induction following vaccination was decreased in HIV+ AA compared to HIV+ CC, which was directly correlated with the percentages of pTfh cells. This racial difference and correlation were not demonstrable in healthy controls.
   Conclusion: Here we report that HIV + AA has decreased fold induction of IgG versus IgM after influenza vaccination, which may suggest impaired class-switching from IgM to IgG in AA HIV-infected individuals. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Ma, Ping; Qian, Jing; Yan, Zhongfang; Wang, Ziyu; Xia, Huan; Yu, Fangfang] Nankai Univ, Peoples Hosp 2, Sch Med, Dept Infect Dis, Tianjin 300192, Peoples R China.
   [Ma, Ping] Tianjin STD & AIDS Prevent & Treatment Assoc, Tianjin 300192, Peoples R China.
   [Luo, Zhenwu; Jiang, Wei] Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
   [Zhang, Lumin] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.
   [Martin, Lisa; Jiang, Wei] Med Univ South Carolina, Dept Med, Div Infect Dis, Charleston, SC 29425 USA.
RP Ma, P; Jiang, W (reprint author), 173 Ashley Ave,BSB207, Charleston, SC 29425 USA.
EM 30917046@nankai.edu.cn; jianw@musc.edu
FU National magaproject on Key Infectious Diseases [2017ZX10202102005004];
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI1288864]
FX This work was supported by the National magaproject on Key Infectious
   Diseases 2017ZX10202102005004 and NIH grant A11288864.
CR Aberg JA, 2004, CLIN INFECT DIS, V39, P609, DOI 10.1086/423390
   Alcendor DJ, 2016, AM J REPROD IMMUNOL, V76, P99, DOI 10.1111/aji.12497
   Bickel M, 2010, AIDS, V24, pF31, DOI 10.1097/QAD.0b013e3283398da1
   Bonduelle O, 2013, J IMMUNOL, V191, P623, DOI 10.4049/jimmunol.1203483
   Brown CH, 2013, JAIDS-J ACQ IMM DEF, V63, pS72, DOI 10.1097/QAI.0b013e31829372bd
   Cagigi A, 2013, CLIN EXP IMMUNOL, V174, P274, DOI 10.1111/cei.12173
   Cagigi A, 2013, VACCINE, V31, P2231, DOI 10.1016/j.vaccine.2013.03.002
   Cagigi A, 2010, LANCET INFECT DIS, V10, P499, DOI 10.1016/S1473-3099(10)70117-1
   COHEN JP, 1989, JAMA-J AM MED ASSOC, V261, P245, DOI 10.1001/jama.1989.03420020097023
   Davalos DM, 2010, J NATL MED ASSOC, V102, P1131, DOI 10.1016/S0027-9684(15)30767-7
   Egli A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004556
   Frasca D, 2014, CURR OPIN IMMUNOL, V29, P112, DOI 10.1016/j.coi.2014.05.008
   Frasca D, 2012, INT IMMUNOL, V24, P175, DOI 10.1093/intimm/dxr123
   Freedman BI, 2014, CLIN J AM SOC NEPHRO, V9, P2006, DOI 10.2215/CJN.01330214
   Fuller JD, 1999, CLIN INFECT DIS, V28, P541, DOI 10.1086/515170
   Furman D, 2014, P NATL ACAD SCI USA, V111, P869, DOI 10.1073/pnas.1321060111
   George VK, 2015, J INFECT DIS
   Imp BM, 2017, J INFECT DIS, V215, P114, DOI 10.1093/infdis/jiw506
   Iwajomo OH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078592
   Jiang W., 2018, CELL MOL IMMUNOL
   Kim JH, 2012, AIDS RES HUM RETROV, V28, P235, DOI [10.1089/AID.2011.0040, 10.1089/aid.2011.0040]
   Lai H, 2012, INT J CARDIOL, V158, P211, DOI 10.1016/j.ijcard.2011.01.032
   Lederman MM, 2011, J INFECT DIS, V204, P1217, DOI 10.1093/infdis/jir507
   Levy ME, 2014, AIDS BEHAV, V18, P972, DOI 10.1007/s10461-014-0719-x
   Luo ZW, 2016, VACCINE, V34, P1945, DOI 10.1016/j.vaccine.2015.12.038
   Malaspina A, 2005, J INFECT DIS, V191, P1442, DOI 10.1086/429298
   Matthews DD, 2016, AIDS BEHAV, V20, P7, DOI 10.1007/s10461-015-1158-z
   Maulsby C, 2014, AIDS BEHAV, V18, P10, DOI 10.1007/s10461-013-0476-2
   McCarty B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01901
   McKibben RA, 2015, J INFECT DIS, V211, P1219, DOI 10.1093/infdis/jiu594
   Naicker S, 2010, CLIN NEPHROL, V74, pS51
   Oramasionwu CU, 2012, MED CARE, V50, P920, DOI 10.1097/MLR.0b013e31826c85d1
   Pallikkuth S, 2012, BLOOD, V120, P985, DOI 10.1182/blood-2011-12-396648
   Pallikkuth S, 2011, J ALLERGY CLIN IMMUN, V128, P1279, DOI 10.1016/j.jaci.2011.05.033
   Pallikkuth S, 2011, J IMMUNOL, V186, P6173, DOI 10.4049/jimmunol.1100264
   Parmigiani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079816
   Ramirez LA, 2014, J INFECT DIS, V210, P646, DOI 10.1093/infdis/jiu132
   Rangnekar AS, 2012, ALIMENT PHARM THER, V36, P104, DOI 10.1111/j.1365-2036.2012.05145.x
   Reidy KJ, 2018, CURR OPIN PEDIATR, V30, P252, DOI 10.1097/MOP.0000000000000603
   Rihana N, 2018, CANCER CONTROL, V25, DOI 10.1177/1073274818797955
   SCHERLE PA, 1986, J EXP MED, V164, P1114, DOI 10.1084/jem.164.4.1114
   Siegrist CA, 2009, NAT REV IMMUNOL, V9, P185, DOI 10.1038/nri2508
   So-Armah KA, 2016, JAIDS-J ACQ IMM DEF, V72, P206, DOI 10.1097/QAI.0000000000000954
   Tami-Maury I, 2011, J PUBLIC HEALTH DENT, V71, P257, DOI 10.1111/j.1752-7325.2011.00256.x
   Tan Y, 2014, EUR J IMMUNOL, V44, P285, DOI 10.1002/eji.201343657
   Tebas P, 2010, AIDS, V24, P2187, DOI 10.1097/QAD.0b013e32833c6d5c
   Thomas JM, 2014, J VIROL, V88, P10758, DOI 10.1128/JVI.01501-14
   Tsang JS, 2014, CELL, V157, P499, DOI 10.1016/j.cell.2014.03.031
   Valour F, 2014, VACCINE, V32, P4558, DOI 10.1016/j.vaccine.2014.06.015
   Vigano A, 1998, AIDS RES HUM RETROV, V14, P727, DOI 10.1089/aid.1998.14.727
   Zhang LM, 2014, J VIROL, V88, P11430, DOI 10.1128/JVI.00682-14
NR 51
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 1998
EP 2004
DI 10.1016/j.vaccine.2020.01.002
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000017
PM 31948820
DA 2020-05-12
ER

PT J
AU Batista, ICA
   Quinan, BR
   Alves, EAR
   Jangola, STG
   Oliveira, ES
   Colombarolli, SG
   Ferreira, JGG
   Rocha, ESD
   Kroon, EG
   de Assis, RR
   de Oliveira, JG
   Fiuza, JA
   Calzavara-Silva, CE
AF Andrade Batista, Izabella Cristina
   Quinan, Barbara Resende
   Rocha Alves, Erica Alessandra
   Gaze Jangola, Soraya Torres
   Oliveira, Eneida Santos
   Colombarolli, Stella Garcia
   Goulart Ferreira, Jorge Gomes
   de Oliveira Rocha, Eliseu Soares
   Kroon, Erna Geessien
   de Assis, Rafael Ramiro
   de Oliveira, Jaquelline Germano
   Fiuza, Jacqueline Araujo
   Calzavara-Silva, Carlos Eduardo
TI Design and production of dengue virus chimeric proteins useful for
   developing tetravalent vaccines
SO VACCINE
LA English
DT Article
DE Dengue; Tetravalent vaccine; Chimeric proteins
ID CD8(+) T-CELLS; ENVELOPE GLYCOPROTEIN; MONOCLONAL-ANTIBODIES;
   IMMUNE-RESPONSE; DOMAIN-III; MICE; ENCEPHALITIS; INFECTION; EPITOPES;
   CD4(+)
AB Dengue virus (DENV) is a Flavivirus estimated to cause 390 million infections/year. Currently, there is no anti-viral specific treatment for dengue, and efficient DENV vector control is still unfeasible. Here, we designed and produced chimeric proteins containing potential immunogenic epitopes from the four DENV serotypes in an attempt to further compose safer, balanced tetravalent dengue vaccines.
   For this, South American DENV isolate sequences were downloaded from the NCBI/Virus Variation/ Dengue virus databases and intraserotype-aligned to generate four consensuses. Four homologous DENV sequences were retrieved using BLAST and then interserotype-aligned. In parallel, sequences were subjected to linear B epitope prediction analysis. Regions of the envelope and NS1 proteins that are highly homologous among the four DENV serotypes, non-conserved antigenic regions and the most antigenic epitopes found in the C, prM, E and NS1 DENV proteins were used to construct 11 chimeric peptides. Genes encoding the chimeric proteins were commercially synthesized, and proteins were expressed, purified by affinity chromatography and further subjected to ELISA assays using sera from individuals infected with DENVs 1, 2, 3 or 4. As a proof-of-concept, the chimeric EnvEpII protein was selected to immunize BALB/c and C57BL/6 mice strains. The immunization with EnvEpII protein associated with aluminum induced an increased number of T CD4(+) and CD8(+) cells, high production of IgG(1) and IgG(2) antibodies, and increased levels of IL-2 and IL-17 cytokines, in both mouse strains. Because the EnvEpII protein associated with aluminum induced an efficient cellular response by stimulating the production of IL-2, IL-4, IL-17 and induced a robust humoral response in mice, we conclude that it resembles an efficient specific response against DENV infection. Although further experiments are required, our results indicate that epitope selection by bioinformatic tools is efficient to create recombinant proteins that can be used as candidates for the development of vaccines against infectious diseases. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Andrade Batista, Izabella Cristina; Rocha Alves, Erica Alessandra; Gaze Jangola, Soraya Torres; Oliveira, Eneida Santos; Colombarolli, Stella Garcia; Goulart Ferreira, Jorge Gomes; de Oliveira, Jaquelline Germano; Fiuza, Jacqueline Araujo; Calzavara-Silva, Carlos Eduardo] Fundacao Oswaldo Cruz, IRR, Grp Imunol Celular & Mol, Av Augusto de Lima 1715, Belo Horizonte, MG, Brazil.
   [de Oliveira Rocha, Eliseu Soares] Katal Biotecnol, R Leiria 1160, BR-31255100 Belo Horizonte, MG, Brazil.
   [Kroon, Erna Geessien] Univ Fed Minas Gerais, ICB, Dept Microbiol, Av Presidente Antonio Carlos 6627, Belo Horizonte, MG, Brazil.
   [Quinan, Barbara Resende] Univ Fed Minas Gerais, Hosp Clin, Av Prof Alfredo Balena 110, BR-30130100 Belo Horizonte, MG, Brazil.
   [de Assis, Rafael Ramiro] Univ Calif Irvine, Dept Physiol, Vaccine Res & Dev Ctr, Irvine, CA 92717 USA.
RP Fiuza, JA; Calzavara-Silva, CE (reprint author), Fundacao Oswaldo Cruz, IRR, Grp Imunol Celular & Mol, Av Augusto de Lima 1715, Belo Horizonte, MG, Brazil.
EM izabellaandradeb@gmail.com; quinanb@gmail.com; erica.alves@fiocruz.br;
   soraya.gaze@cpqrr.fiocruz.br; eneida.oliveira@fiocruz.br;
   stella_colom-barolli@hotmail.com; jorgekorps@yahoo.com.br;
   eliseubiologia@gmail.com; ernagkroon@gmail.cozm; rramirod@hs.uci.edu;
   jaquelline.oliveira@fiocruz.br; jacqueline.fiuza@fiocruz.br;
   carlos.calzavara@fio-cruz.br
FU Conselho Nacional de Pesquisa (CNPq)National Council for Scientific and
   Technological Development (CNPq) [305618/2013-0, 439979/2016-1,
   401779/2015-7]; Fundacdo de Pesquisa de Minas Gerais (FAPEMIG) [CBB -
   APQ-0741-11]
FX This work was supported by Conselho Nacional de Pesquisa (CNPq)
   (305618/2013-0; 439979/2016-1, 401779/2015-7) and Fundacdo de Pesquisa
   de Minas Gerais (FAPEMIG) (CBB - APQ-0741-11).
CR Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050
   Amorim JH, 2016, VIROLOGY, V487, P41, DOI 10.1016/j.virol.2015.10.006
   [Anonymous], 2003, QLAEXPRESSIONIST HDB, P63
   Artimo P, 2012, NUCLEIC ACIDS RES, V40, pW597, DOI 10.1093/nar/gks400
   Avirutnan P, 2011, MBIO, V2, DOI 10.1128/mBio.00276-11
   Back Anne Tuiskunen, 2013, Infect Ecol Epidemiol, V3, DOI 10.3402/iee.v3i0.19839
   Bashyam HS, 2006, J IMMUNOL, V176, P2817, DOI 10.4049/jimmunol.176.5.2817
   Belkaid Y, 2002, J IMMUNOL, V168, P3992, DOI 10.4049/jimmunol.168.8.3992
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156
   Buddhari D, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003230
   Chaturvedi UC, 2009, INDIAN J MED RES, V129, P1
   Crill WD, 2004, J VIROL, V78, P13975, DOI 10.1128/JVI.78.24.13975-13986.2004
   Rocha ESD, 2013, J VIROL METHODS, V187, P114, DOI 10.1016/j.jviromet.2012.09.012
   Gagnon SJ, 1996, J VIROL, V70, P141, DOI 10.1128/JVI.70.1.141-147.1996
   Gil L, 2009, INT IMMUNOL, V21, P1175, DOI 10.1093/intimm/dxp082
   Gromowski GD, 2008, J VIROL, V82, P8828, DOI 10.1128/JVI.00606-08
   Guy B, 2016, NAT REV MICROBIOL, V14, P45, DOI 10.1038/nrmicro.2015.2
   Halstead SB, 2003, ADV VIRUS RES, V60, P421, DOI 10.1016/S0065-3527(03)60011-4
   HALSTEAD SB, 1977, J EXP MED, V146, P201, DOI 10.1084/jem.146.1.201
   HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8
   Hazenbos WLW, 1998, J IMMUNOL, V161, P3026
   HENCHAL EA, 1990, CLIN MICROBIOL REV, V3, P376, DOI 10.1128/CMR.3.4.376-396.1990
   HENCHAL EA, 1988, J GEN VIROL, V69, P2101, DOI 10.1099/0022-1317-69-8-2101
   Jacobs MG, 2000, FASEB J, V14, P1603, DOI 10.1096/fj.14.11.1603
   Jain A, 2013, J CLIN IMMUNOL, V33, P613, DOI 10.1007/s10875-012-9855-0
   KAUFMAN BM, 1987, AM J TROP MED HYG, V36, P427, DOI 10.4269/ajtmh.1987.36.427
   Kuhn RJ, 2002, CELL, V108, P717, DOI 10.1016/S0092-8674(02)00660-8
   KURANE I, 1991, J VIROL, V65, P1823, DOI 10.1128/JVI.65.4.1823-1828.1991
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Lai CY, 2008, J VIROL, V82, P6631, DOI 10.1128/JVI.00316-08
   Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2
   Mackenzie JM, 1996, VIROLOGY, V220, P232, DOI 10.1006/viro.1996.0307
   Rathakrishnan A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052215
   Remy Melissa M., 2014, Inflammation & Allergy Drug Targets, V13, P262
   RICE CM, 1985, SCIENCE, V229, P726, DOI 10.1126/science.4023707
   Rivino L, 2016, EXPERT REV VACCINES, V15, P443, DOI 10.1586/14760584.2016.1116948
   Rivino L, 2013, J VIROL, V87, P2693, DOI 10.1128/JVI.02675-12
   Robinson CR, 1998, P NATL ACAD SCI USA, V95, P5929, DOI 10.1073/pnas.95.11.5929
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   SCHLESINGER JJ, 1987, J GEN VIROL, V68, P853, DOI 10.1099/0022-1317-68-3-853
   Sjatha F, 2014, MICROBIOL IMMUNOL, V58, P126, DOI 10.1111/1348-0421.12125
   Stothard P, 2000, BIOTECHNIQUES, V28, P1102, DOI 10.2144/00286ir01
   Suzarte E, 2015, INT IMMUNOL, V27, P367, DOI 10.1093/intimm/dxv011
   Valdes I, 2009, VIROLOGY, V394, P249, DOI 10.1016/j.virol.2009.08.029
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   Weiskopf D, 2015, J VIROL, V89, P120, DOI 10.1128/JVI.02129-14
   Yauch LE, 2014, ADV VIRUS RES, V88, P315, DOI 10.1016/B978-0-12-800098-4.00007-6
   Yauch LE, 2010, J IMMUNOL, V185, P5405, DOI 10.4049/jimmunol.1001709
   Yoshida T, 2013, ARCH VIROL, V158, P1209, DOI 10.1007/s00705-013-1618-6
   Zellweger RM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003723
   Zuest R, 2015, VACCINE, V33, P1474, DOI 10.1016/j.vaccine.2015.01.074
   2009, ALC INJ EM DEPT, P1
NR 53
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 2005
EP 2015
DI 10.1016/j.vaccine.2020.01.003
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000018
PM 31982262
DA 2020-05-12
ER

PT J
AU Abdellrazeq, GS
   Fry, LM
   Elnaggar, MM
   Bannantine, JP
   Schneider, DA
   Chamberlin, WM
   Mahmoud, AHA
   Park, KT
   Hulubei, V
   Davis, WC
AF Abdellrazeq, Gaber S.
   Fry, Lindsay M.
   Elnaggar, Mahmoud M.
   Bannantine, John P.
   Schneider, David A.
   Chamberlin, William M.
   Mahmoud, Asmaa H. A.
   Park, Kun-Taek
   Hulubei, Victoria
   Davis, William C.
TI Simultaneous cognate epitope recognition by bovine CD4 and CD8 T cells
   is essential for primary expansion of antigen-specific cytotoxic T-cells
   following ex vivo stimulation with a candidate Mycobacterium avium
   subsp. paratuberculosis peptide vaccine
SO VACCINE
LA English
DT Article
DE Bovine; Dendritic cells; T cells; Paratuberculosis; Mycobacterium avium
   subsp. paratuberculosis; Cognate epitope recognition; Cytotoxicity;
   Vaccination; Propidium monoazide
ID DENDRITIC CELLS; HELPER; MECHANISMS; MUTANTS; BIOLOGY; IMMUNE; MEMORY;
   PCR
AB Studies in cattle show CD8 cytotoxic T cells (CTL), with the ability to kill intracellular bacteria, develop following stimulation of monocyte-depleted peripheral blood mononuclear cells (mdPBMC) with antigen presenting cells (APC, i.e. conventional dendritic cells [cDC] and monocyte-derived DC [MoDC]) pulsed with MMP, a membrane protein from Mycobacterium avium subsp. paratuberculosis (Map) encoded by MAP2121c. CTL activity was diminished if CD4 T cells were depleted from mdPBMC before antigen (Ag) presentation by APC, suggesting simultaneous cognate recognition of MMP epitopes presented by MHC I and MHC II molecules to CD4 and CD8 T cells is essential for development of CTL activity. To explore this possibility, studies were conducted with mdPBMC cultures in the presence of monoclonal antibodies (mAbs) specific for MHC class I and MHC class II molecules. The CTL response of mdPBMC to MMP-pulsed APC was completely blocked in the presence of mAbs to both MHC I and II molecules and also blocked in the presence of mAbs to either MHC I or MHC II alone. The results demonstrate simultaneous cognate recognition of Ag by CD4 and CD8 T cells is essential for delivery of CD4 T cell help to CD8 T cells to elicit development of CTL. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Abdellrazeq, Gaber S.; Elnaggar, Mahmoud M.; Mahmoud, Asmaa H. A.; Hulubei, Victoria; Davis, William C.] Washington State Univ, Dept Vet Microbiol & Pathol, Pullman, WA 99164 USA.
   [Abdellrazeq, Gaber S.; Elnaggar, Mahmoud M.] Alexandria Univ, Fac Vet Med, Dept Microbiol, Alexandria, Egypt.
   [Fry, Lindsay M.; Schneider, David A.] ARS, USDA, Anim Dis Res Unit, Pullman, WA USA.
   [Bannantine, John P.] ARS, USDA, Natl Anim Dis Ctr, Ames, IA USA.
   [Mahmoud, Asmaa H. A.] Minist Agr & Land Reclamat, Gen Org Vet Serv, Vet Quarantine Alexandria, Cairo, Egypt.
   [Park, Kun-Taek] Inje Univ, Dept Biotechnol, Injero 197, Kimhae Si, Gyeongsangnam D, South Korea.
RP Davis, WC (reprint author), Washington State Univ, Dept Vet Microbiol & Pathol, Pullman, WA 99164 USA.
EM davisw@wsu.edu
RI ; Schneider, David/A-2833-2010
OI Elnaggar, Mahmoud/0000-0003-4501-7722; Park, Kun
   Taek/0000-0001-6177-0373; Schneider, David/0000-0001-9659-6731
FU State Univ.
FX Support was provided by the Wash. State Univ. Monoclonal Antibody
   Center.
CR Abdellrazeq GS, 2019, VACCINE, V37, P2783, DOI 10.1016/j.vaccine.2019.04.040
   Abdellrazeq GS, 2018, VET RES, V49, DOI 10.1186/s13567-018-0549-3
   Allen AJ, 2009, CLIN VACCINE IMMUNOL, V16, P453, DOI 10.1128/CVI.00347-08
   Bachmann MF, 1998, J IMMUNOL, V161, P5791
   Behrens G, 2004, IMMUNOL CELL BIOL, V82, P84, DOI 10.1111/j.1440-1711.2004.01211.x
   Bennett SRM, 1998, NATURE, V393, P478
   Bevan MJ, 2004, NAT REV IMMUNOL, V4, P595, DOI 10.1038/nri1413
   Blander JM, 2018, ANNU REV IMMUNOL, V36, P717, DOI 10.1146/annurev-immunol-041015-055523
   Cruz FM, 2017, ANNU REV IMMUNOL, V35, P149, DOI 10.1146/annurev-immunol-041015-055254
   Dahl JL, 2003, P NATL ACAD SCI USA, V100, P10026, DOI 10.1073/pnas.1631248100
   Davis WC, 2017, EXPERT REV GASTROENT, P1
   Elnaggar MM, 2016, VET IMMUNOL IMMUNOP, V178, P57, DOI 10.1016/j.vetimm.2016.06.010
   Janssen EM, 2003, NATURE, V421, P852, DOI 10.1038/nature01441
   JOHNE HA, 1895, DTSCH Z TIERMED PATH, V21, P438
   Kim J, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/218752
   Kralik P, 2010, INT J FOOD MICROBIOL, V141, pS80, DOI 10.1016/j.ijfoodmicro.2010.03.018
   Leite FL, 2015, VET MICROBIOL, V175, P275, DOI 10.1016/j.vetmic.2014.11.009
   Li LL, 2005, P NATL ACAD SCI USA, V102, P12344, DOI 10.1073/pnas.0505662102
   Naser SA, 2014, WORLD J GASTROENTERO, V20, P7403, DOI 10.3748/wjg.v20.i23.7403
   Park KT, 2008, APPL ENVIRON MICROB, V74, P1687, DOI 10.1128/AEM.01208-07
   Park KT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165247
   Park KT, 2015, VET IMMUNOL IMMUNOP, V168, P118, DOI 10.1016/j.vetimm.2015.09.002
   Park KT, 2015, VET IMMUNOL IMMUNOP, V163, P216, DOI 10.1016/j.vetimm.2014.12.008
   Park KT, 2014, J MICROBIOL METH, V99, P58, DOI 10.1016/j.mimet.2014.02.003
   Park KT, 2011, VACCINE, V29, P4709, DOI 10.1016/j.vaccine.2011.04.090
   Planesse C, 2015, CYTOKINE, V73, P190, DOI 10.1016/j.cyto.2015.01.028
   RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0
   Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989
   Schonenbrucher H, 2008, APPL ENVIRON MICROB, V74, P2751, DOI 10.1128/AEM.02534-07
   Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305
   Shugart JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064878
   Singh S. V., 2014, Journal of Public Health and Epidemiology, V6, P20
   Singh SV, 2016, FRONT MED-LAUSANNE, V3, DOI 10.3389/fmed.2016.00049
   Smith CM, 2004, NAT IMMUNOL, V5, P1143, DOI 10.1038/ni1129
   Sun JC, 2003, SCIENCE, V300, P339, DOI 10.1126/science.1083317
   Taracha ELN, 1997, J IMMUNOL, V159, P4539
   Theisen Derek, 2017, F1000Res, V6, P98, DOI 10.12688/f1000research.9997.1
   Walburger A, 2004, SCIENCE, V304, P1800, DOI 10.1126/science.1099384
NR 38
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 2016
EP 2025
DI 10.1016/j.vaccine.2019.12.052
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000019
PM 31902643
DA 2020-05-12
ER

PT J
AU Bettinger, JA
   Liberator, P
   Halperin, SA
   Vaudry, W
   Sadarangani, M
   Hao, L
   Lambert, N
   Jansen, KU
   Anderson, AS
   Tsang, R
AF Bettinger, Julie A.
   Liberator, Paul
   Halperin, Scott A.
   Vaudry, Wendy
   Sadarangani, Manish
   Hao, Li
   Lambert, Nathaniel
   Jansen, Kathrin U.
   Anderson, Annaliesa S.
   Tsang, Raymond
CA Canadian Immunization Monitoring P
TI Estimated susceptibility of Canadian meningococcal B isolates to a
   meningococcal serogroup B vaccine (MenB-FHbp)
SO VACCINE
LA English
DT Article
DE Factor H binding protein; Invasive meningococcal disease; Neisseria
   meningitidis
ID NEISSERIA-MENINGITIDIS; IMPACT; DISEASE; QUEBEC
AB Background: Invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) remains a health risk in Canada and globally. Two MenB vaccines are now approved for use. An understanding of the genotype of Canadian strains and the potential strain coverage conferred by the MenB-FHbp vaccine is needed to inform immunization policies.
   Methods: Serogroup B Neisseria meningitidis strains responsible for meningococcal disease in Canada from 2006 to 2012 were collected as part of the Canadian Immunization Monitoring Program Active surveillance network. Genotypic analysis was done on MenB isolates from 2006 to 2012 with determination of fHbp surface expression for a subset of isolates: those occurring from 2010 to 2012.
   Results: Two clonal complexes (cc269 and cc41/44) were observed in 68.8% of the 276 isolates. A total of 50 different fHbp peptides were identified among isolates from 2006 to 2012. Surface expression of fHbp was detected on 95% of MenB isolates from 2010 to 2012 and 91% of isolates expressed fHbp at levels that are predicted to be susceptible to the bactericidal immune response elicited by the MenB-FHbp vaccine. Some regional differences were observed, particularly in isolates from British Columbia and Quebec.
   Conclusion: The majority of MenB isolates responsible for meningococcal disease in Canada expressed fHbp at levels predicted to be sufficient for complement mediated bactericidal activity in the presence of MenB-FHbp induced serum antibodies. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Bettinger, Julie A.; Sadarangani, Manish] BC Childrens Hosp, Vaccine Evaluat Ctr, Vancouver, BC V5Z 4H4, Canada.
   [Bettinger, Julie A.; Sadarangani, Manish] Univ British Columbia, Vancouver, BC V5Z 4H4, Canada.
   [Liberator, Paul; Hao, Li; Lambert, Nathaniel; Jansen, Kathrin U.; Anderson, Annaliesa S.] Pfizer Inc, Vaccine Res & Dev, Pearl River, NY 10965 USA.
   [Halperin, Scott A.] IWK Hlth Ctr, Canadian Ctr Vaccinol, Halifax, NS B3K 6R8, Canada.
   [Halperin, Scott A.] Dalhousie Univ, Halifax, NS B3K 6R8, Canada.
   [Vaudry, Wendy] Stollery Childrens Hosp, Edmonton, AB T6G 1C9, Canada.
   [Vaudry, Wendy] Univ Alberta, Edmonton, AB T6G 1C9, Canada.
   [Lambert, Nathaniel] Juno Therapeut, Seattle, WA 98102 USA.
   [Tsang, Raymond] Publ Hlth Agcy Canada, Natl Microbiol Lab, Winnipeg, MB R3E 3R2, Canada.
RP Bettinger, JA (reprint author), BC Childrens Hosp, A5-950 West 28th St, Vancouver, BC V5Z 4H4, Canada.
EM jbettinger@bcchr.ubc.ca
OI Sadarangani, Manish/0000-0002-9985-6452
FU Sanofi-Pasteur; Novartis Vaccines Diagnostics; PfizerPfizer
FX The Canadian Immunization Monitoring Program, Active (IMPACT) is a
   national surveillance initiative managed by the Canadian Paediatric
   Society and conducted by the IMPACT network of pediatric investigators.
   IMPACT meningococcal surveillance was supported by a grant from
   Sanofi-Pasteur (2002-2011) and Novartis Vaccines & Diagnostics (2012).
   The additional typing and laboratory testing performed in this study was
   supported by a grant from Pfizer.
CR [Anonymous], 2018, MEN VACC CAN IMM GUI
   Bai XL, 2010, EXPERT REV VACCINES, V9, P1203, DOI 10.1586/ERV.10.116
   Bettinger JA, 2013, VACCINE, V32, P124, DOI 10.1016/j.vaccine.2013.03.063
   Bettinger JA, 2013, PEDIATR INFECT DIS J, V32, pE20, DOI 10.1097/INF.0b013e3182706b89
   Borrow R, 2005, VACCINE, V23, P2222, DOI 10.1016/j.vaccine.2005.01.051
   Brehony C, 2009, MICROBIOL-SGM, V155, P4155, DOI 10.1099/mic.0.027995-0
   De Wals P, 2017, CLIN INFECT DIS, V64, P1263, DOI 10.1093/cid/cix154
   DeSerres G, 2016, RAPPORT FINAL SURVEI
   Fletcher LD, 2004, INFECT IMMUN, V72, P2088, DOI 10.1128/IAI.72.4.2088-2100.2004
   Frasch CE, 2009, VACCINE, V27, pB112, DOI 10.1016/j.vaccine.2009.04.065
   Gilca R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050659
   Giuliani MM, 2006, P NATL ACAD SCI USA, V103, P10834, DOI 10.1073/pnas.0603940103
   GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307
   Hoiseth SK, 2013, PEDIATR INFECT DIS J, V32, P1096, DOI 10.1097/INF.0b013e31829aa63b
   Jolley KA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-595
   Langley JM, 2016, VACCINE, V34, P4046, DOI 10.1016/j.vaccine.2016.06.025
   Le Saux Nicole, 2009, Can J Infect Dis Med Microbiol, V20, pe130
   Lucidarme J, 2011, CLIN VACCINE IMMUNOL, V18, P1002, DOI 10.1128/CVI.00055-11
   Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140
   McNeil LK, 2018, MBIO, V9, DOI 10.1128/mBio.00036-18
   McNeil LK, 2009, VACCINE, V27, P3417, DOI 10.1016/j.vaccine.2009.01.075
   Murphy E, 2009, J INFECT DIS, V200, P379, DOI 10.1086/600141
   National Institute for Health and Care Excellence, 2014, ADD CLIN GUID 37 POS, P1, DOI DOI 10.17226/18385
   Sadarangani M, 2015, CLIN INFECT DIS, V60, pE27, DOI 10.1093/cid/civ028
   Sadarangani M, 2014, CLIN INFECT DIS, V59, P1208, DOI 10.1093/cid/ciu597
   Scheifele D, 2009, PAED CHILD HEALT-CAN, V14, P33, DOI 10.1093/pch/14.1.33
   Serruto D, 2012, VACCINE, V30, pB87, DOI 10.1016/j.vaccine.2012.01.033
   Zhou JW, 2012, J CLIN MICROBIOL, V50, P1545, DOI 10.1128/JCM.06835-11
   Zlotnick GW, 2015, HUM VACC IMMUNOTHER, V11, P5, DOI 10.4161/hv.34293
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 2026
EP 2033
DI 10.1016/j.vaccine.2019.12.051
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000020
PM 31983586
OA Other Gold
DA 2020-05-12
ER

PT J
AU Fan, ST
   Liao, Y
   Jiang, GR
   Jiang, L
   Wang, LC
   Xu, XL
   Feng, M
   Yang, EX
   Zhang, Y
   Cui, W
   Li, QH
AF Fan, Shengtao
   Liao, Yun
   Jiang, Guorun
   Jiang, Li
   Wang, Lichun
   Xu, Xingli
   Feng, Min
   Yang, Erxia
   Zhang, Ying
   Cui, Wei
   Li, Qihan
TI Study of integrated protective immunity induced in rhesus macaques by
   the intradermal administration of a bivalent EV71-CA16 inactivated
   vaccine
SO VACCINE
LA English
DT Article
DE Enterovirus type 71 (EV71); Coxsackievirus A 16 (CA16); Bivalent
   vaccine; Rhesus macaques
ID COXSACKIEVIRUS A16 INFECTIONS; ENTEROVIRUS 71; MOUTH-DISEASE; EV71
   VACCINE; HAND; FOOT; EPIDEMIOLOGY; CHINA
AB Enterovirus type 71 (EV71) and coxsackievirus A 16 (CA16) are recognized as the major pathogens responsible for human hand-foot-mouth disease. To develop a bivalent EV71-CA16 vaccine, rhesus macaques immunized with two doses of this vaccine via the intradermal route were challenged with EV71 or CA16, and their clinical symptoms, viral shedding, neutralizing antibodies, IFN-gamma-specific ELISpots, and tissue viral load were examined longitudinally. Specific immunity against EV71 and CA16 was observed in the macaques, which exhibited controlled proliferation of the EV71 and CA16 viruses and upregulated expression of immune-related genes compared with the controls. Furthermore, broad protection against EV71 and CA16 challenge without immunopathological effects was observed in all the immunized macaques. These studies suggest that the bivalent EV71-CA16 inactivated vaccine was effective against wildtype EV71 or CA16 viral challenge in rhesus macaques. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Fan, Shengtao; Liao, Yun; Jiang, Guorun; Wang, Lichun; Xu, Xingli; Feng, Min; Zhang, Ying; Li, Qihan] Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Yunnan Key Lab Vaccine Res & Dev Severe Infect Di, Kunming 650118, Yunnan, Peoples R China.
   [Jiang, Li; Yang, Erxia; Cui, Wei] Aimei Convac BioPharm Jiangsu Co Ltd, Taizhou 225300, Jiangsu, Peoples R China.
RP Li, QH (reprint author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Biol, Yunnan Key Lab Vaccine Res & Dev Severe Infect Di, Kunming 650118, Yunnan, Peoples R China.
EM liqihan@imbcams.com.cn
FU PUMC Youth Fund; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [3332016115]; CAMS Initiative for Innovative Medicine [2016-12M-1-019];
   National Science and Technology Major Project [2018ZX10101001]; National
   Natural Science FoundationNational Natural Science Foundation of China
   [31700931]; Yunnan Key Laboratory of Vaccine Research & Development in
   Severe Infectious Diseases and Major Science and Technology Special
   Projects of Yunnan Province [2019FB101, 2017ZF020, 2017FB018]; State
   Project for Essential Drug Research and Development [2017ZX09307013-2,
   2016ZX09101120-2, 2018ZX09737011-002]; Technical innovation talents of
   Yunnan Province; Medical Reserve Talents plan of Yunnan health and
   Health Committee [H-2017035]; Aimei Convac BioPharm (Jiangsu) Co., Ltd.
FX This study was founded by the PUMC Youth Fund, Fundamental Research
   Funds for the Central Universities (3332016115), the CAMS Initiative for
   Innovative Medicine (2016-12M-1-019), the State Project for Essential
   Drug Research and Development (2017ZX09307013-2 and 2016ZX09101120-2 and
   2018ZX09737011-002), the National Science and Technology Major Project
   (2018ZX10101001), the National Natural Science Foundation (31700931),
   and funds from the Yunnan Key Laboratory of Vaccine Research &
   Development in Severe Infectious Diseases and Major Science and
   Technology Special Projects of Yunnan Province (2019FB101, 2017ZF020 and
   2017FB018). This study is also supported by Technical innovation talents
   of Yunnan Province and Medical Reserve Talents plan of Yunnan health and
   Health Committee (H-2017035). This study was also supported by Aimei
   Convac BioPharm (Jiangsu) Co., Ltd.
CR Aswathyraj S, 2016, MED MICROBIOL IMMUN, V205, P397, DOI 10.1007/s00430-016-0465-y
   Barao I, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00402
   Cai YC, 2014, VACCINE, V32, P2406, DOI 10.1016/j.vaccine.2014.03.012
   Campos M, 2003, INT J PARASITOL, V33, P655, DOI 10.1016/S0020-7519(03)00066-3
   Dong CH, 2010, HUM VACCINES, V6, P1028, DOI 10.4161/hv.6.12.12982
   Eberl G, 2015, SCIENCE, V348, DOI 10.1126/science.aaa6566
   Esposito S, 2018, EUR J CLIN MICROBIOL, V37, P391, DOI 10.1007/s10096-018-3206-x
   Fan ST, 2019, NPJ VACCINES, V4, DOI [10.1038/s41541-019-0108-6, 10.1038/s41541-019-0141-5]
   Frydenberg Alexis, 2003, Aust Fam Physician, V32, P594
   Hassel C, 2015, EUROSURVEILLANCE, V20, P2, DOI 10.2807/1560-7917.ES.2015.20.34.30005
   Jubelt B, 2014, HAND CLINIC, V123, P379, DOI 10.1016/B978-0-444-53488-0.00018-3
   Ku ZQ, 2014, VACCINE, V32, P4296, DOI 10.1016/j.vaccine.2014.06.025
   Li RC, 2014, NEW ENGL J MED, V370, P829, DOI 10.1056/NEJMoa1303224
   Liu BH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138207
   Liu SL, 2015, REV MED VIROL, V25, P115, DOI 10.1002/rmv.1827
   Mao Q, 2018, CHIN J VIRAL DIS, V8, P481
   Mao QY, 2016, EXPERT REV VACCINES, V15, P599, DOI 10.1586/14760584.2016.1138862
   Mao QY, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.73
   McIntyre Mary G., 2012, Morbidity and Mortality Weekly Report, V61, P213
   Okayasu H, 2017, J INFECT DIS, V216, pS161, DOI 10.1093/infdis/jix038
   Robinette ML, 2015, NAT IMMUNOL, V16, P306, DOI 10.1038/ni.3094
   Signore A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050681
   Song J, 2018, ARCH VIROL, V163, P135, DOI 10.1007/s00705-017-3592-x
   Song J, 2016, VIRUS RES, V214, P1, DOI 10.1016/j.virusres.2016.01.002
   Sun SY, 2014, HUM VACC IMMUNOTHER, V10, P2885, DOI 10.4161/hv.29823
   Takahashi S, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001958
   Tseng SY, 2002, CURR OPIN CELL BIOL, V14, P575, DOI 10.1016/S0955-0674(02)00370-8
   Wang JJ, 2017, VIROLOGY, V500, P198, DOI 10.1016/j.virol.2016.10.031
   Wang JJ, 2014, VACCINE, V32, P4436, DOI 10.1016/j.vaccine.2014.06.062
   Wang XL, 2019, HUM VACC IMMUNOTHER, V15, P1183, DOI 10.1080/21645515.2019.1581539
   Xing WJ, 2014, LANCET INFECT DIS, V14, P308, DOI 10.1016/S1473-3099(13)70342-6
   Yang EX, 2014, HUM VACC IMMUNOTHER, V10, P1266, DOI 10.4161/hv.28083
   Zhang Y, 2015, VACCINE, V33, P6290, DOI 10.1016/j.vaccine.2015.09.047
   Zhang Y, 2011, LAB INVEST, V91, P1337, DOI 10.1038/labinvest.2011.82
   Zhao T, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00171
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 2034
EP 2044
DI 10.1016/j.vaccine.2019.12.057
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000021
PM 31982260
DA 2020-05-12
ER

PT J
AU Nguyen, TTM
   Lafond, KE
   Nguyen, TX
   Tran, PD
   Nguyen, HM
   Ha, VTC
   Do, TT
   Ha, NT
   Seward, JF
   McFarland, JW
AF Thoa Thi Minh Nguyen
   Lafond, Kathryn E.
   Tung Xuan Nguyen
   Phu Dac Tran
   Hang Minh Nguyen
   Van Thi Cam Ha
   Thu Thi Do
   Nga Thu Ha
   Seward, Jane F.
   McFarland, Jeffrey W.
TI Acceptability of seasonal influenza vaccines among health care workers
   in Vietnam in 2017
SO VACCINE
LA English
DT Article
DE Influenza vaccination; Health care workers; Acceptability
ID VACCINATION; KNOWLEDGE; ATTITUDES; IMMUNIZATION
AB Introduction: A demonstration project in Vietnam provided 11,000 doses of human seasonal influenza vaccine free of charge to healthcare workers (HCWs) in 4 provinces of Vietnam. Through this project, we conducted an acceptability survey to identify the main reasons that individuals chose to be vaccinated or not to inform and improve future immunization activities.
   Methods: We conducted a descriptive cross-sectional survey from May to August 2017 among HCWs at 13 selected health facilities. We employed logistic regression to determine the association between demographic and professional factors, and the decision to receive seasonal influenza vaccine. We performed post-hoc pairwise comparisons among reasons for and against vaccination using Chi square and Fisher's exact tests (for cell sizes <5).
   Results: A total of 1,450 HCWs participated in the survey, with a higher proportion of females than males (74% versus 26%). The median age of the participating HCWs was 35 years (median range 25.8-44.2). Among those surveyed, 700 (48%) HCWs were vaccinated against seasonal influenza during the first half of 2017. Younger HCWs under 30 and 30-39 years old were less likely to get vaccinated against seasonal influenza than HCWs >= 50 years old (OR = 0.5; 95%CI 0.4-0.8 and OR = 0.6; 95%CI 0.4-0.8 respectively). Nurses and other employees were more likely to get seasonal influenza vaccination than physicians (OR = 1.5; 95%0 1.0-2.4 and OR = 2.0; 95%CI 1.2-3.2 respectively). The most common reason for accepting vaccination was fear of getting influenza (66%) and the most common reason for not getting vaccinated was concern about vaccine side effects (23%).
   Conclusion: Acceptability of seasonal influenza vaccines in this setting varied among HCWs by age group and job category. Interventions to increase acceptance of vaccine among HCWs in this setting where influenza vaccine is being introduced free for the first time should include targeted risk communication on vaccine safety and efficacy. Published by Elsevier Ltd.
C1 [Thoa Thi Minh Nguyen; Nga Thu Ha; McFarland, Jeffrey W.] US Ctr Dis Control & Prevent, Influenza Div, Hanoi, Vietnam.
   [Lafond, Kathryn E.] US Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
   [Tung Xuan Nguyen; Phu Dac Tran; Hang Minh Nguyen; Van Thi Cam Ha; Thu Thi Do] Minist Hlth, Gen Dept Prevent Med, Hanoi, Vietnam.
   [Seward, Jane F.] Task Force Global Hlth, Atlanta, GA USA.
RP Nguyen, TTM (reprint author), US Ctr Dis Control & Prevent, Influenza Div, Hanoi, Vietnam.
EM ksi1@cdc.gov
FU U.S. CDC via Influenza Division's cooperative agreementUnited States
   Department of Health & Human ServicesCenters for Disease Control &
   Prevention - USA; GDPM [IP000821]
FX The authors would like to thank all of the individuals from GDPM, all
   implementing health facilities and health care workers who participated
   in the vaccination campaign and other colleagues supporting us in
   reviewing this paper. Specifically, we would like to recognize Lauren
   Beacham, Rachael Porter and Philip Gould from U.S. CDC Atlanta for their
   advice in statistics and manuscript review. Financial support for this
   work came from the U.S. CDC via Influenza Division's cooperative
   agreement with GDPM, IP000821.
CR Bali NK, 2013, INFLUENZA OTHER RESP, V7, P540, DOI 10.1111/j.1750-2659.2012.00416.x
   Bellia C, 2013, INFLUENZA OTHER RESP, V7, P97, DOI 10.1111/irv.12088
   Blank PR, 2009, J INFECTION, V58, P446, DOI 10.1016/j.jinf.2009.04.001
   Dominguez ZC, 2016, REV ROL ENFERM, V39, P8
   Cozza V, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2067-9
   Europe ROf, 2015, GUID INCR HLT CAR WO
   Ha NT, INFLUENZA VACCINATIO
   Heininger U, 2003, PEDIATR INFECT DIS J, V22, P391, DOI 10.1097/00006454-200305000-00001
   Hollmeyer HG, 2009, VACCINE, V27, P3935, DOI 10.1016/j.vaccine.2009.03.056
   Hudu S A, 2016, Med J Malaysia, V71, P231
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Jaiyeoba O, 2014, AM J INFECT CONTROL, V42, P69, DOI 10.1016/j.ajic.2013.06.020
   Khazaeipour Z, 2010, J INFECT DEV COUNTR, V4, P636, DOI 10.3855/jidc.1152
   Kien VanPhi PDT, 2016, VIETNAM MED RES J, V104, P61
   Lee PH, 2017, AM J INFECT CONTROL, V45, P575, DOI 10.1016/j.ajic.2016.05.038
   Maltezou HC, 2008, VACCINE, V26, P1408, DOI 10.1016/j.vaccine.2008.01.049
   Ministry of Health, 2017, HLTH STAT YB 2015
   Ministry of Health, 2011, GUID SEAS INFL DIAGN
   Rachiotis G, 2010, EURO SURVEILL, V15
   Riphagen-Dalhuisen J, 2012, OCCUP ENVIRON MED, V69, P230, DOI 10.1136/oemed-2011-100134
   Rondy M, 2017, J INFECTION, V75, P381, DOI 10.1016/j.jinf.2017.09.010
   Shahbic HE, 2010, SAUDI MED J, V31, P1157
   Song Y, 2017, VACCINE, V35, P4060, DOI 10.1016/j.vaccine.2017.06.054
   Sundaram N, 2018, VACCINE, V36, P1996, DOI 10.1016/j.vaccine.2018.02.102
   To SH, 2018, SLOVINS FORMULA WHAT
   Torun SD, 2010, VACCINE, V28, P5703, DOI 10.1016/j.vaccine.2010.06.049
   Virseda S, 2010, VACCINE, V28, P4751, DOI 10.1016/j.vaccine.2010.04.101
   World Health Organization (WHO), 2018, SEAS INFL
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 2045
EP 2050
DI 10.1016/j.vaccine.2019.12.047
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000022
PM 32001072
OA Other Gold
DA 2020-05-12
ER

PT J
AU Inguva, S
   Barnard, M
   Ward, LM
   Yang, Y
   Pittman, E
   Banahan, BF
   Kirby, TR
   Noble, SL
AF Inguva, Sushmitha
   Barnard, Marie
   Ward, Lori M.
   Yang, Yi
   Pittman, Eric
   Banahan, Benjamin F., III
   Kirby, Terri R.
   Noble, Sara L.
TI Factors influencing Human papillomavirus (HPV) vaccination series
   completion in Mississippi Medicaid
SO VACCINE
LA English
DT Article
DE Human papillomavirus; Medicaid; Immunization; Vaccine initiation;
   Vaccine series completion; Sociodemographic factors; Geographic factors
ID ADOLESCENT GIRLS; 3-DOSE REGIMEN; INITIATION; IMPACT; RATES; BOYS
AB Purpose: To identify factors associated with Human Papillomavirus (HPV) vaccine series completion among vaccine initiators in Mississippi Medicaid.
   Methods: 2013-2018 Mississippi Medicaid administrative claims data were analyzed. Female and male beneficiaries aged 9 to 26 years who initiated HPV vaccination in the identification period were assessed for completion of age-appropriate number of recommended doses within a period of 12 months. Sex-stratified multivariable logistic regression was used to examine factors associated with HPV vaccine series completion in the study sample.
   Results: A total of 18,110 female and 18,186 male beneficiaries initiated HPV vaccine between January 1, 2014 and June 30, 2017. Most of the initiators belonged to ages 11 to 12 years, African American race, managed care plans and Central Mississippi public health region. The vaccine series completion rate was 34% for females and 30% for males. Younger age at initiation was a significant predictor of vaccine series completion in both sexes. Specifically, initiators in age groups 9 to 10 and 11 to 12 years, respectively, had greater odds of completion, while initiators aged 15 to 26 years had lower odds of completion compared to initiators aged 13 to 14 years. Female and male beneficiaries in managed care plans (vs. feefor-service) and of African American race (vs. Caucasians) had lower odds of completing the vaccine series, Female and male beneficiaries who initiated HPV vaccine series with a pediatrician had the highest completion rates.
   Conclusion: HPV vaccination series completion rate in Mississippi Medicaid was suboptimal despite the high HPV-related cancer incidence in the state. HPV vaccine series completion is influenced by various sociodemographic factors. There is a need for robust education and public health programs to encourage completion of recommended doses. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Inguva, Sushmitha; Barnard, Marie; Yang, Yi] Univ Mississippi, Sch Pharm, Dept Pharm Adm, University, MS 38677 USA.
   [Ward, Lori M.] Univ Mississippi, Med Ctr, John D Bower Sch Populat Hlth, Dept Populat Hlth Sci, Jackson, MS 39216 USA.
   [Pittman, Eric; Banahan, Benjamin F., III] Univ Mississippi, Ctr Pharmaceut Mkt & Management, Res Inst Pharmaceut Sci, University, MS 38677 USA.
   [Kirby, Terri R.; Noble, Sara L.] Mississippi Div Medicaid, Jackson, MS 39201 USA.
RP Inguva, S (reprint author), Univ Mississippi, Dept Pharm Adm, POB 1848, University, MS 38677 USA.
EM singuva@go.olemiss.edu
CR Ackerson B, 2017, VACCINE, V35, P897, DOI 10.1016/j.vaccine.2017.01.007
   American Cancer Society, 2016, HPV VACC
   Baroy J, 2016, J AM PHARM ASSOC, V56, P418, DOI 10.1016/j.japh.2016.03.006
   Bednarczyk RA, 2012, PEDIATRICS, V130, P798, DOI 10.1542/peds.2012-1516
   Centers for Disease Control and Prevention, 2016, GRAD REC ASS DEV EV
   Centers for Disease Control and Prevention (CDC), 2010, FDA LIC BIV HUM PAP, V59
   Centers for Disease Control and Prevention (CDC), 2018, CDC MAN CANC AR LINK
   Centers for Disease Control and Prevention (CDC), 2007, MORB MORTAL WKLY REP, V56
   Centers for Disease Control and Prevention (CDC), 2018, HUM PAP HPV QUEST AN
   Centers for Disease Control and Prevention (CDC), 2016, VACC CHILDR PROGR
   Centers for Disease Control and Prevention (CDC), 2018, HPV ASS CANC RAT STA
   Centers for Disease Control and Prevention (CDC), 2018, CANC ASS HUM PAP HPV
   Chao C, 2009, MAYO CLIN PROC, V84, P864, DOI [10.4065/84.10.864, 10.1016/S0025-6196(11)60503-X]
   Chou B, 2011, OBSTET GYNECOL, V118, P14, DOI 10.1097/AOG.0b013e318220ebf3
   Cook RL, 2010, J ADOLESCENT HEALTH, V47, P596, DOI 10.1016/j.jadohealth.2010.09.015
   Cowburn S, 2014, AM J PUBLIC HEALTH, V104, pE71, DOI 10.2105/AJPH.2014.302007
   Daley EM, 2017, PAPILLOMAVIRUS RES, V3, P142, DOI 10.1016/j.pvr.2017.04.004
   Gold R, 2013, J ADOLESCENT HEALTH, V52, P427, DOI 10.1016/j.jadohealth.2012.09.009
   Gorjana R, 2017, PREV MED, V95, P26, DOI 10.1016/j.ypmed.2016.11.019
   Henry KA, 2016, CANCER EPIDEM BIOMAR, V25, P309, DOI 10.1158/1055-9965.EPI-15-0658
   Hirth JM, 2012, CANCER-AM CANCER SOC, V118, P5623, DOI 10.1002/cncr.27598
   Isenor JE, 2016, VACCINE, V34, P5708, DOI 10.1016/j.vaccine.2016.08.085
   Iversen OE, 2016, JAMA-J AM MED ASSOC, V316, P2411, DOI 10.1001/jama.2016.17615
   Johnson KL, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-53
   Kessels SJM, 2012, VACCINE, V30, P3546, DOI 10.1016/j.vaccine.2012.03.063
   Layton JB, 2019, VACCINE, V37, P2892, DOI 10.1016/j.vaccine.2019.02.074
   Laz Tabassum H Rahman, 2013, CANCER, V119, P1386, DOI [10.1002/cncr 27894, DOI 10.1002/CNCR.27894]
   Liu G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125001
   Marchand E, 2013, J COMMUNITY HLTH, V38, P371, DOI [101038/jid 2014.371, DOI 10.1038/JID2014.371]
   Markowitz L, 2018, ADV COMM IMM PRACT M, P1
   Meites E, 2016, MMWR-MORBID MORTAL W, V65, P1405, DOI 10.15585/mmwr.mm6549a5
   Mississippi Division of Medicaid, ADM COD TITL 23 224
   Mississippi Division of Medicaid (MS-DOM), 2018, MISS MED 2017 ENR RE
   Monnat SM, 2016, MATERN CHILD HLTH J, V20, P315, DOI 10.1007/s10995-015-1831-x
   Rahman M, 2014, HUM VACC IMMUNOTHER, V10, P2163, DOI 10.4161/hv.29633
   Smith LM, 2015, CAN MED ASSOC J, V187, pE74, DOI 10.1503/cmaj.140900
   Spencer JC, 2018, AM J PUBLIC HEALTH, V108, P946, DOI 10.2105/AJPH.2018.304408
   St Sauver JL, 2016, PREV MED, V89, P327, DOI 10.1016/j.ypmed.2016.02.039
   Viens LJ, 2016, MMWR-MORBID MORTAL W, V65, P661, DOI 10.15585/mmwr.mm6526a1
   Walling EB, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-3863
   Widdice LE, 2011, PEDIATRICS, V127, P77, DOI 10.1542/peds.2010-0812
NR 41
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 2051
EP 2057
DI 10.1016/j.vaccine.2019.12.030
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000023
PM 31980196
DA 2020-05-12
ER

PT J
AU Bradshaw, AS
   Treise, D
   Shelton, SS
   Cretul, M
   Raisa, A
   Bajalia, A
   Peek, D
AF Bradshaw, Amanda S.
   Treise, Debbie
   Shelton, Summer S.
   Cretul, Matthew
   Raisa, Aantaki
   Bajalia, Alexis
   Peek, Daisha
TI Propagandizing anti-vaccination: Analysis of Vaccines Revealed
   documentary series
SO VACCINE
LA English
DT Article
DE Anti-vaccination documentaries; Propaganda; Vaccine hesitancy; Childhood
   vaccination; Social media; Media effects
ID UNITED-STATES; WEB 2.0; IMMUNIZATION; AUTISM
AB Politically charged health propaganda films may have public health ramifications through decreased vaccination uptake, especially with expansive dissemination potential on social media. The nine-episode documentary series Vaccines Revealed, touted as foremost truth within the largest anti-vaccination closed Facebook group, advocates for non-medical childhood vaccination exemptions - a policy actively opposed by the American Academy of Pediatrics. This series is recommended specifically to parents who are on the fence about whether or not to vaccinate their children as well as new, first-time, and expectant mothers.
   Fourteen 'expert' panelists included: six M.D,'s who reportedly prefer natural approaches for everything from chiropractic to cardiology practice, a vaccine injury attorney, two professors, one psychiatrist, the founder of natural search engine Greenmedinfo.com, a nationally-recognized clinical research expert on the HPV vaccine, the president of the National Vaccine Information Center, and three parents of vaccine-injured children. Additionally, voiceover clips from an epidemiologist and former senior scientist at the CDC were played throughout the series as evidence of governmental conspiracy. Inclusion of these testimonies, particularly from white coat doctors, led to a perception of high source credibility.
   Qualitative analysis of this documentary series revealed five overarching themes: (perceived) solidified science, collusion and conspiracy, canary in the coal mine, fear appeals, and the morality and necessity of individual choice.
   As opposed to formulating a priori theoretical assumptions, grounded theory allowed an integrative theoretical explanation to emerge from the data. Researchers expanded cognitive dissonance, parasocial interaction, and social identification theories and described how viewers of Vaccines Revealed could come to align their views on vaccinations with those of the panelists featured in the videos. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bradshaw, Amanda S.; Treise, Debbie; Cretul, Matthew; Raisa, Aantaki; Bajalia, Alexis; Peek, Daisha] Univ Florida, Gainesville, FL 32611 USA.
   [Shelton, Summer S.] Idaho State Univ, Pocatello, ID 83209 USA.
RP Bradshaw, AS (reprint author), 2319 NW 44th Pl, Gainesville, FL 32605 USA.
EM abradshaw1@ufl.edu
RI Bradshaw, Amanda/AAL-1630-2020
CR AAP Policy Statement, 2016, MED VERS NONM IMM EX
   Altheide DL, 1987, QUALITATIVE SOCIOLOG, V10, P65, DOI DOI 10.1007/BF00988269
   [Anonymous], 2018, VACCINE GLOSSARY TER
   Baker JP, 2008, AM J PUBLIC HEALTH, V98, P244, DOI 10.2105/AJPH.2007.113159
   Bessi A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159641
   Bradshaw AS, 2020, HEALTH COMMUN, DOI 10.1080/10410236.2020.1712037
   Brown B, 2016, CINEMATOGRAPHY: THEORY AND PRACTICE: IMAGE MAKING FOR CINEMATOGRAPHERS AND DIRECTORS, 3RD EDITION, P259
   Creswell J.W., 2013, QUALITATIVE INQUIRY
   Dominus S., 2011, NY TIMES MAGAZINE
   Duggan M., 2015, PARENTS SOCIAL MEDIA
   Festinger L, 2009, THEORY COGNITIVE DIS
   Festinger L., 1957, THEORY COGNITIVE DIS
   Fields E. E, 1988, QUALITATIVE SOCIOLOG, V11, P183, DOI DOI 10.1007/BF00988954
   Glaser B. G., 1967, DISCOVERY GROUNDED T
   GLASER BG, 1965, SOC PROBL, V12, P436, DOI 10.1525/sp.1965.12.4.03a00070
   Green MC, 2004, DISCOURSE PROCESS, V38, P247, DOI 10.1207/s15326950dp3802_5
   Hill HA, 2019, MMWR-MORBID MORTAL W, V68, P913, DOI 10.15585/mmwr.mm6841e2
   Hofstede G, 2010, CULTURES ORG SOFTWAR
   Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687
   Jones Abbey M, 2012, Adv Prev Med, V2012, P932741, DOI 10.1155/2012/932741
   Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112
   Kaufman SR, 2010, ETHOS, V38, P8, DOI 10.1111/j.1548-1352.2009.01079.x
   Kelman H. C., 1958, J CONFLICT RESOLUT, V2, P51, DOI [DOI 10.1177/002200275800200106, 10.1177/002200275800200106]
   KELMAN HC, 1961, PUBLIC OPIN QUART, V25, P57, DOI 10.1086/266996
   Leask J, 2011, NATURE, V473, P443, DOI 10.1038/473443a
   Moran M. B., 2016, Journal of Communication in Healthcare, V9, P151, DOI 10.1080/17538068.2016.1235531
   Phillip L, 2017, VACCINE SKEPTIC ROBE
   Samuel L, 2017, VACCINE EXEMPTIONS A
   Smith TC, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx146
   Sobo EJ, 2016, MED ANTHROPOL, V35, P529, DOI 10.1080/01459740.2016.1145219
   Strauss A, 2008, BASICS QUALITATIVE R, P1
   Vaccines Revealed, 2017, MEET SOME EXPERTS FE
   Ventola C Lee, 2016, P T, V41, P426
   Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0
   Wang E, 2014, AM J PUBLIC HEALTH, V104, pE62, DOI 10.2105/AJPH.2014.302190
   Ward PR, 2017, UNDERSTANDING PERCEI
   Whitney C. G., 2014, MMWR-MORBID MORTAL W, V63, P352
NR 37
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 2058
EP 2069
DI 10.1016/j.vaccine.2019.12.027
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000024
PM 31980194
DA 2020-05-12
ER

PT J
AU Giese, H
   Neth, H
   Moussaid, M
   Betsch, C
   Gaissmaier, W
AF Giese, Helge
   Neth, Hansjoerg
   Moussaid, Mehdi
   Betsch, Cornelia
   Gaissmaier, Wolfgang
TI The echo in flu-vaccination echo chambers: Selective attention trumps
   social influence
SO VACCINE
LA English
DT Article
DE Amplification of risk; Diffusion chain; Opinion dynamics; Vaccine
   hesitancy; Social media; Polarization
ID WEB 2.0; RISK; AMPLIFICATION; INFORMATION; BIAS
AB Background: Online discussions may impact the willingness to get vaccinated. This experiment tests how groups of individuals with consistent and inconsistent attitudes towards flu vaccination attend to and convey information online, and how they alter their corresponding risk perceptions.
   Methods: Out of 1859 MTurkers, we pre-selected 208 people with negative and 221 people with positive attitudes towards flu vaccinations into homogeneous or heterogeneous 3-link experimental diffusion chains. We assessed (i) which information about flu vaccinations participants conveyed to the subsequent link, (ii) how flu-vaccination related perceptions were altered by incoming messages, and (iii) how participants perceived incoming information.
   Results: Participants (i) selectively conveyed attitude-consistent information, but exhibited no overall anti-vaccination bias, (ii) were reluctant to alter their flu-vaccination related perceptions in response to messages, and (iii) evaluated incoming information consistent with their prior attitudes as more convincing.
   Discussion: Flu-vaccination related perceptions are resilient against contradictions and bias online communication. Contrary to expectations, there was no sign of amplification of anti-vaccine attitudes by online communication. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Giese, Helge; Neth, Hansjoerg; Gaissmaier, Wolfgang] Univ Konstanz, Dept Psychol, POB 43, D-78457 Constance, Germany.
   [Moussaid, Mehdi] Max Planck Inst Human Dev, Ctr Adapt Rational, Berlin, Germany.
   [Betsch, Cornelia] Univ Erfurt, Ctr Empir Res Econ & Behav Sci CEREB, Erfurt, Germany.
RP Giese, H (reprint author), Univ Konstanz, Dept Psychol, POB 43, D-78457 Constance, Germany.
EM helge.giese@uni-konstanz.de
OI Giese, Helge/0000-0001-7609-0215; Betsch, Cornelia/0000-0002-2856-7303
FU German Research Foundation (DFG Research Unit)German Research Foundation
   (DFG) [FOR 2374]; German Research Foundation Centre of Excellence 2117
   "Centre for the Advanced Study of Collective Behaviour" [422037984]
FX This work was supported by the German Research Foundation under Grant
   FOR 2374 (DFG Research Unit) and the German Research Foundation Centre
   of Excellence 2117 "Centre for the Advanced Study of Collective
   Behaviour" (ID: 422037984). We would like to thank Larissa Baer and
   Joachim Gassert for their support in rating the material.
CR Aiken L.S., 1991, MULTIPLE REGRESSION
   Bartlett Frederic. C, 1932, REMEMBERING STUDY EX
   Betsch C, 2015, P NATL ACAD SCI USA, V112, pE6725, DOI 10.1073/pnas.1516350112
   Betsch C, 2013, HEALTH PSYCHOL, V32, P146, DOI 10.1037/a0027387
   Betsch C, 2012, VACCINE, V30, P3727, DOI 10.1016/j.vaccine.2012.02.025
   Betsch C, 2011, MED DECIS MAKING, V31, P742, DOI 10.1177/0272989X11400419
   Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521
   Brown KF, 2010, VACCINE, V28, P4181, DOI 10.1016/j.vaccine.2010.04.012
   Conner M, 2005, PREDICTING HLTH BEHA, V2, P170, DOI DOI 10.1348/014466699164121
   Festinger L., 1957, THEORY COGNITIVE DIS
   Hart W, 2009, PSYCHOL BULL, V135, P555, DOI 10.1037/a0015701
   Horne Z, 2015, P NATL ACAD SCI USA, V112, P10321, DOI 10.1073/pnas.1504019112
   KASPERSON RE, 1988, RISK ANAL, V8, P177, DOI 10.1111/j.1539-6924.1988.tb01168.x
   Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112
   Leask J, 2011, NATURE, V473, P443, DOI 10.1038/473443a
   Miton H, 2015, TRENDS COGN SCI, V19, P633, DOI 10.1016/j.tics.2015.08.007
   Moussaid M, 2015, P NATL ACAD SCI USA, V112, P5631, DOI 10.1073/pnas.1421883112
   Nyhan B, 2015, VACCINE, V33, P459, DOI 10.1016/j.vaccine.2014.11.017
   Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365
   Omer SB, 2017, JAMA PEDIATR, V171, P929, DOI 10.1001/jamapediatrics.2017.2219
   Pluviano S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181640
   Porter RM, 2018, VACCINE, V36, P2494, DOI 10.1016/j.vaccine.2018.01.040
   RENN O, 1992, J SOC ISSUES, V48, P137, DOI 10.1111/j.1540-4560.1992.tb01949.x
   Renner B, 2012, VACCINE, V30, P7019, DOI 10.1016/j.vaccine.2012.09.064
   Salathe M, 2013, EPJ DATA SCI, V2, DOI 10.1140/epjds16
   Schmidt AL, 2018, VACCINE, V36, P3606, DOI 10.1016/j.vaccine.2018.05.040
   Siegrist M, 2001, RISK ANAL, V21, P199, DOI 10.1111/0272-4332.211102
NR 27
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 2070
EP 2076
DI 10.1016/j.vaccine.2019.11.038
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000025
PM 31864854
DA 2020-05-12
ER

PT J
AU Adamson, PJ
   Wang, JJ
   Anosova, NG
   Colella, AD
   Chataway, TK
   Kleanthous, H
   Gordon, TP
   Gordon, DL
AF Adamson, Penelope J.
   Wang, Jing J.
   Anosova, Natalie G.
   Colella, Alex D.
   Chataway, Timothy K.
   Kleanthous, Harry
   Gordon, Tom P.
   Gordon, David L.
TI Proteomic profiling of precipitated Clostridioides difficile toxin A and
   B antibodies
SO VACCINE
LA English
DT Article
DE C. difficile; Vaccination; Serum antibody repertoire; Proteomics; Mass
   spectrometric sequencing
ID AUTOANTIBODY PROTEOMES; SJOGRENS-SYNDROME; INFECTION; EPIDEMIOLOGY;
   CANDIDATE; DISEASE; BEZLOTOXUMAB; PROTECTION; DIAGNOSIS; VACCINE
AB Clostridioides difficile infection is the leading cause of nosocomial diarrhoea globally. Immune responses to toxins produced by C. difficile are important in disease progression and outcome. Here, we analysed the anti-toxin A and anti-toxin B serum antibody proteomes following natural infection or vaccination with a C. difficile toxoid A/toxoid B vaccine using a modified miniaturised proteomic approach based on de novo mass spectrometric sequencing. Analysis of immunoglobulin variable region (IgV) subfamily expression in immunoprecipitated toxin A and toxin B antibodies from four and seven participants of a vaccine trial, respectively, revealed a polyclonal proteome with restricted IGHV, IGKV and IGLV subfamily usage. No dominant IGHV subfamily was observed in the toxin A response, however the dominant anti-toxin B heavy (H)-chain was encoded by IGHV3-23. Light (L)-chain usage was convergent for both anti-toxin A and anti-toxin B proteomes with IGKV3-11, 3-15, 3-20 and 4-1 shared among all subjects in both cohorts. Peptide mapping of common IgV families showed extensive public and private amino acid substitutions. The cohort responses to toxin A and toxin B showed limited similarity in shared IGHV subfamilies. L-chain subfamily usage was more similar in the anti-toxin A and anti-toxin B responses, however the mutational signatures for each subfamily were toxin-dependent. Samples taken both post vaccination (n = 5) or at baseline, indicating previous exposure (n = 2), showed similar anti-toxin B IgV subfamily usage and mutational profiles. In summary, this study provides the first sequence-based proteomic analysis of the antibody response to the major disease-mediating toxins of C difficile, toxin A and toxin B, and demonstrates that despite the potential for extreme diversity, the immunoglobulin repertoire can raise convergent responses to specific pathogens whether through natural infection or following vaccination. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Adamson, Penelope J.; Gordon, David L.] Flinders Univ S Australia, Dept Microbiol & Infect Dis, Bedford Pk, SA 5042, Australia.
   [Adamson, Penelope J.; Wang, Jing J.; Gordon, Tom P.; Gordon, David L.] SA Pathol, Flinders Med Ctr, Bedford Pk, SA 5042, Australia.
   [Wang, Jing J.; Gordon, Tom P.] Flinders Univ S Australia, Dept Immunol, Bedford Pk, SA 5042, Australia.
   [Anosova, Natalie G.; Kleanthous, Harry] Sanofi Pasteur, Cambridge, MA USA.
   [Colella, Alex D.; Chataway, Timothy K.] Flinders Univ S Australia, Flinders Med Ctr, Flinders Prote Facil, Bedford Pk, SA 5042, Australia.
RP Adamson, PJ (reprint author), Flinders Univ S Australia, Dept Microbiol & Infect Dis, Bedford Pk, SA 5042, Australia.; Adamson, PJ (reprint author), SA Pathol, Flinders Med Ctr, Bedford Pk, SA 5042, Australia.
EM penelope.adamson@sa.gov.au; jing.wang@flinders.edu.au;
   Natalie.Anosova@sanofi.com; Alexander.Colella@sa.gov.au;
   tim.chataway@flinders.edu.au; Harold.Kleanthous@sanofi.com;
   t.gordon@flinders.edu.au; d.gordon@flinders.edu.au
FU Australian National Health and Medical Research Council Early Career
   FellowshipNational Health and Medical Research Council of Australia
   [1090759]; Sanofi Pasteur
FX This work was supported by an Australian National Health and Medical
   Research Council Early Career Fellowship (grant 1090759) to JJW and by
   Sanofi Pasteur.
CR Adamson PJ, 2017, VACCINE, V35, P5576, DOI 10.1016/j.vaccine.2017.08.053
   Aktories K, 2017, ANNU REV MICROBIOL, V71, P281, DOI 10.1146/annurev-micro-090816-093458
   Al Kindi MA, 2016, CLIN EXP IMMUNOL, V184, P29, DOI 10.1111/cei.12750
   Al Kindi MA, 2016, AUTOIMMUN REV, V15, P405, DOI 10.1016/j.autrev.2016.01.008
   Al Kindi MA, 2015, J AUTOIMMUN, V57, P77, DOI 10.1016/j.jaut.2014.12.005
   Anosova NG, 2015, CLIN VACCINE IMMUNOL, V22, P711, DOI 10.1128/CVI.00763-14
   Archibald LK, 2004, J INFECT DIS, V189, P1585, DOI 10.1086/383045
   Arnaout R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022365
   ARONSSON B, 1985, INFECTION, V13, P97, DOI 10.1007/BF01642866
   Babcock GJ, 2006, INFECT IMMUN, V74, P6339, DOI 10.1128/IAI.00982-06
   BARTLETT JG, 1977, J INFECT DIS, V136, P701, DOI 10.1093/infdis/136.5.701
   BARTLETT JG, 1978, GASTROENTEROLOGY, V75, P778
   Bezay N, 2016, VACCINE, V34, P2585, DOI 10.1016/j.vaccine.2016.03.098
   Bloomfield LE, 2016, INFECT DIS THER, V5, P231, DOI 10.1007/s40121-016-0117-y
   Carter GP, 2015, MBIO, V6, DOI 10.1128/mBio.00551-15
   de Bruyn G, 2016, VACCINE, V34, P2170, DOI 10.1016/j.vaccine.2016.03.028
   Foglia G, 2012, VACCINE, V30, P4307, DOI 10.1016/j.vaccine.2012.01.056
   Freeman J, 2010, CLIN MICROBIOL REV, V23, P529, DOI 10.1128/CMR.00082-09
   Greenberg RN, 2012, VACCINE, V30, P2245, DOI 10.1016/j.vaccine.2012.01.065
   Humphreys DP, 2014, CLIN VACCINE IMMUNOL, V21, P913, DOI 10.1128/CVI.00116-14
   Hussack G, 2016, CLIN EXP GASTROENTER, V9, P209, DOI 10.2147/CEG.S84017
   Hussack G, 2010, TOXINS, V2, P998, DOI 10.3390/toxins2050998
   Janezic S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167101
   Kelly CP, 2011, J MED MICROBIOL, V60, P1070, DOI 10.1099/jmm.0.030015-0
   Kuehne SA, 2010, NATURE, V467, P711, DOI 10.1038/nature09397
   Kyne L, 2000, NEW ENGL J MED, V342, P390, DOI 10.1056/NEJM200002103420604
   Kyne L, 2001, LANCET, V357, P189, DOI 10.1016/S0140-6736(00)03592-3
   Lawson PA, 2016, ANAEROBE, V40, P95, DOI 10.1016/j.anaerobe.2016.06.008
   Leav BA, 2010, VACCINE, V28, P965, DOI 10.1016/j.vaccine.2009.10.144
   Lee J, 2016, NAT MED, V22, P1456, DOI 10.1038/nm.4224
   Lyras D, 2009, NATURE, V458, P1176, DOI 10.1038/nature07822
   Martin JSH, 2016, NAT REV GASTRO HEPAT, V13, P206, DOI 10.1038/nrgastro.2016.25
   Monaghan TM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074452
   Napolitano LM, 2017, SURGERY, V162, P325, DOI 10.1016/j.surg.2017.01.018
   Natarajan M, 2013, ANAEROBE, V22, P1, DOI 10.1016/j.anaerobe.2013.05.005
   Negm OH, 2015, CLIN VACCINE IMMUNOL, V22, P1033, DOI 10.1128/CVI.00190-15
   Orth P, 2014, J BIOL CHEM, V289, P18008, DOI 10.1074/jbc.M114.560748
   Sheldon E, 2016, VACCINE, V34, P2082, DOI 10.1016/j.vaccine.2016.03.010
   Tabbaa OM, 2018, GASTROENTEROL RES, V11, P397, DOI 10.14740/gr1091
   Vedantam G, 2012, GUT MICROBES, V3, P121, DOI 10.4161/gmic.19399
   Wang JJ, 2018, CLIN EXP IMMUNOL, V194, P273, DOI 10.1111/cei.13197
   Wang JJ, 2018, ARTHRITIS RHEUMATOL, V70, P1617, DOI 10.1002/art.40539
   Wang JJ, 2016, CLIN IMMUNOL, V173, P57, DOI 10.1016/j.clim.2016.09.001
   WARNY M, 1994, INFECT IMMUN, V62, P384, DOI 10.1128/IAI.62.2.384-389.1994
   Wilcox MH, 2017, NEW ENGL J MED, V376, P305, DOI 10.1056/NEJMoa1602615
NR 45
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 2077
EP 2087
DI 10.1016/j.vaccine.2019.10.096
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000026
PM 31718902
OA Other Gold
DA 2020-05-12
ER

PT J
AU Florek, K
   Mutschler, J
   McLean, HQ
   King, JP
   Flannery, B
   Belongia, EA
   Friedrich, TC
AF Florek, Kelsey
   Mutschler, James
   McLean, Huong Q.
   King, Jennifer P.
   Flannery, Brendan
   Belongia, Edward A.
   Friedrich, Thomas C.
TI Antibody-dependent cell-mediated cytotoxicity antibody responses to
   inactivated and live-attenuated influenza vaccination in children during
   2014-15
SO VACCINE
LA English
DT Article
DE ADCC; Influenza vaccine; Antigenic drift; Children
ID SEASONAL INFLUENZA; UNITED-STATES; VIRUS; PROTECTION; INFECTION;
   CORRELATE; VACCINES
AB Background: Seasonal influenza vaccines aim to induce strain-specific neutralizing antibodies. Non-neutralizing antibodies may be more broadly cross-reactive and still protect through mechanisms including antibody-dependent cell-mediated cytotoxicity (ADCC). Influenza vaccines may stimulate ADCC antibodies in adults, but whether they do so in children is unknown. Here we examined how vaccination affects cross-reactive ADCC antibody responses in children after receipt of inactivated trivalent vaccine (IIV3) or quadrivalent live-attenuated vaccine (LAIV4).
   Methods: Children aged 5-17 were recruited in fall 2014 to provide pre- and post-vaccination serum samples. Children aged 5-9 received LAIV4 based on then-current recommendation, and older children were randomly assigned to IIV3 or LAIV4. We used microtiter-plate-based flow cytometry with an NK cell line to examine ADCC antibody responses to the 2014-15 H3N2 vaccine component (A/Texas/50/2012 [TX12]) and a drifted strain, A/Switzerland/9715293/2013 (SW13). Responses were stratified by two-season (2013-14 and 2014-15) vaccine sequence.
   Results: Eighty-five children received LAIV4 and 45 received IIV3. Prevaccination ADCC activity was highest in children who had received any vaccine in the prior season. Increase in ADCC antibody responses against the vaccine strain TX12 following vaccination was greatest for participants who received IIV3 in 2014-15 and LAIV4 in the prior season (geometric mean fold rise [MFR] = 1.6, 95% CI.
   1.23-2.11). This group also had a detectable ADCC response to the drifted SW13 strain. There was a modest ADCC response against SW13 in LAIV4 recipients who were unvaccinated in the previous season (MFR 1.18, 95% CI 1.10-1.25). There were no significant changes in 2014-15 ADCC response to vaccination among children who had received IIV3 in 2013-14.
   Conclusions: Vaccinating children with IIV3 after prior receipt of LAIV4 generated a modest increase in ADCC antibodies, including some cross-reactivity with an emerging drift variant. Other vaccine-induced ADCC responses were minimal and not affected by vaccine type or sequence. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Florek, Kelsey] Wisconsin State Lab Hyg, Madison, WI 53714 USA.
   [Mutschler, James; Friedrich, Thomas C.] Univ Wisconsin, Dept Pathobiol Sci, Sch Vet Med, Madison, WI 53706 USA.
   [McLean, Huong Q.; King, Jennifer P.; Belongia, Edward A.] Marshfield Clin Res Inst, Ctr Clin Epidemiol & Populat Hlth, 1000 North Oak Ave, Marshfield, WI 54449 USA.
   [Flannery, Brendan] Ctr Dis Control & Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA.
   [Friedrich, Thomas C.] Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA.
RP Friedrich, TC (reprint author), Univ Wisconsin, Dept Pathobiol Sci, Sch Vet Med, Madison, WI 53706 USA.; Belongia, EA (reprint author), Marshfield Clin Res Inst, Ctr Clin Epidemiol & Populat Hlth, 1000 North Oak Ave, Marshfield, WI 54449 USA.
EM belongia.edward@marshfieldclinic.org; thomasf@primate.wisc.edu
OI McLean, Huong/0000-0003-2725-6439; Belongia, Edward/0000-0001-7478-0415
FU Centers for Disease Control and Prevention (CDC)United States Department
   of Health & Human ServicesCenters for Disease Control & Prevention -
   USA; Marshfield Clinic Research Institute [U01 IP000471]; National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; NIH National Research
   Service AwardUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [T32 GM07215]
FX We thank the Centers for Disease Control and Prevention (CDC) for
   providing the H3 recombinant HAs. The study was supported by the Centers
   for Disease Control and Prevention (CDC) through a cooperative agreement
   with the Marshfield Clinic Research Institute (U01 IP000471) to E.A.B.
   and by the National Institutes of Health. K.F. was supported by the NIH
   National Research Service Award T32 GM07215.
CR Alpert MD, 2012, J VIROL, V86, P12039, DOI 10.1128/JVI.01650-12
   Ana-Sosa-Batiz F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154461
   Black S, 2011, PEDIATR INFECT DIS J, V30, P1081, DOI 10.1097/INF.0b013e3182367662
   Boudreau CM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00440
   de Vries RD, 2018, J INFECT DIS, V218, P614, DOI 10.1093/infdis/jiy214
   de Vries RD, 2017, VACCINE, V35, P238, DOI 10.1016/j.vaccine.2016.11.082
   DiLillo DJ, 2016, J CLIN INVEST, V126, P605, DOI 10.1172/JCI84428
   DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443
   Dunand CJH, 2016, CELL HOST MICROBE, V19, P800, DOI 10.1016/j.chom.2016.05.014
   Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103
   Florek NW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181738
   Florek NW, 2014, J VIROL, V88, P13418, DOI 10.1128/JVI.01219-14
   Grohskopf LA, 2014, MMWR-MORBID MORTAL W, V63, P691
   HASHIMOTO G, 1983, J INFECT DIS, V148, P785, DOI 10.1093/infdis/148.5.785
   HOBSON D, 1972, J HYG-CAMBRIDGE, V70, P767, DOI 10.1017/S0022172400022610
   Huber VC, 2001, J IMMUNOL, V166, P7381, DOI 10.4049/jimmunol.166.12.7381
   Islam S, 2019, SCAND J IMMUNOL, V90, DOI 10.1111/sji.12801
   Jegaskanda S, 2016, J INFECT DIS, V214, P945, DOI 10.1093/infdis/jiw262
   Jegaskanda S, 2013, J VIROL, V87, P13706, DOI 10.1128/JVI.01666-13
   Jegaskanda S, 2013, J VIROL, V87, P5512, DOI 10.1128/JVI.03030-12
   KAZATCHKINE MD, 1984, J CLIN INVEST, V74, P976, DOI 10.1172/JCI111518
   King JC, 2009, VACCINE, V27, P6589, DOI 10.1016/j.vaccine.2009.08.032
   King JP, 2018, INFLUENZA OTHER RESP, V12, P808, DOI 10.1111/irv.12593
   Leon PE, 2016, P NATL ACAD SCI USA, V113, pE5944, DOI 10.1073/pnas.1613225113
   McLean Huong Q, 2020, J Pediatric Infect Dis Soc, V9, P173, DOI 10.1093/jpids/piz001
   McLean HQ, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.3742
   Ohmit SE, 2011, J INFECT DIS, V204, P1879, DOI 10.1093/infdis/jir661
   Russell CA, 2008, VACCINE, V26, pD31, DOI 10.1016/j.vaccine.2008.07.078
   Thulin NK, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030036
   Vanderven HA, 2018, J INFECT DIS, V217, P12, DOI 10.1093/infdis/jix554
   Vanderven HA, 2017, CURR OPIN VIROL, V22, P89, DOI 10.1016/j.coviro.2016.12.002
   Wickham H, 2016, GGPLOT2 ELEGANT GRAP
   Yang H, 2015, VIROLOGY, V477, P18, DOI 10.1016/j.virol.2014.12.024
   Zhong WM, 2016, VIRAL IMMUNOL, V29, P259, DOI 10.1089/vim.2016.0003
   Zimmerman RK, 2016, CLIN INFECT DIS, V63, P1564, DOI 10.1093/cid/ciw635
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 2088
EP 2094
DI 10.1016/j.vaccine.2019.10.060
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000027
PM 31753674
DA 2020-05-12
ER

PT J
AU Perrett, KP
   Halperin, SA
   Nolan, T
   Pancorbo, CM
   Tapiero, B
   Martinon-Torres, F
   Stranak, Z
   Virta, M
   Vanderkooi, OG
   Kosina, P
   Pardilla, MBE
   Garcia, IC
   Zuccotti, GV
   Kostanyan, L
   Meyer, N
   Ceregido, MA
   Cheuvart, B
   Kuriyakose, SO
   Fernandez, MM
   Zambrano, MAR
   Garcia, AM
   de la Fuente, JEA
   Marin, MDC
   Fernandez-Miranda, MD
   Espinar, YR
   Marchisio, PG
   Manzoni, P
   Mesaros, N
AF Perrett, Kirsten P.
   Halperin, Scott A.
   Nolan, Terry
   Martinez Pancorbo, Cristina
   Tapiero, Bruce
   Martinon-Torres, Federico
   Stranak, Zbynek
   Virta, Miia
   Vanderkooi, Otto G.
   Kosina, Pavel
   Encinas Pardilla, Maria Begona
   Cristobal Garcia, Ignacio
   Zuccotti, Gian Vincenzo
   Kostanyan, Lusine
   Meyer, Nadia
   Ceregido, Maria Angeles
   Cheuvart, Brigitte
   Kuriyakose, Sherine O.
   Marcos Fernandez, Manuel
   Rodriguez Zambrano, Miguel Angel
   Martin Garcia, Adrian
   Asenjo de la Fuente, Juan Eloy
   Camacho Marin, Maria Dolores
   de la Calle Fernandez-Miranda, Maria
   Romero Espinar, Yolanda
   Marchisio, Paola Giovanna
   Manzoni, Paolo
   Mesaros, Narcisa
TI Immunogenicity, transplacental transfer of pertussis antibodies and
   safety following pertussis immunization during pregnancy: Evidence from
   a randomized, placebo-controlled trial
SO VACCINE
LA English
DT Article
DE Tdap; Adult formulation acellular pertussis vaccine; Maternal
   immunization
ID MATERNAL TDAP VACCINATION; TETANUS; DIPHTHERIA; INFANTS; BIRTH; RISK;
   RESPONSES; MOTHERS; ASSAY
AB Background: Pertussis immunization during pregnancy is recommended in many countries. Data from large randomized controlled trials are needed to assess the immunogenicity, reactogenicity and safety of this approach.
   Methods: This phase IV, observer-blind, randomized, placebo-controlled, multicenter trial assessed immunogenicity, transplacental transfer of maternal pertussis antibodies, reactogenicity and safety of a reduced-antigen-content diphtheria-tetanus-three-component acellular pertussis vaccine (Tdap) during pregnancy. Women received Tdap or placebo at 27-36 weeks' gestation with crossover <= 72-hourpostpartum immunization. Immune responses were assessed before the pregnancy dose and 1 month after, and from the umbilical cord at delivery. Superiority (primary objective) was reached if the lower limits of the 95% confidence intervals (Cis) of the pertussis geometric mean concentration (GMC) ratios (Tdap/control) in cord blood were >= 1.5. Solicited and unsolicited adverse events (AEs) and pregnancy-I neonate-related AEs of interest were recorded.
   Results: 687 pregnant women were vaccinated (Tdap: N = 341 control: N = 346). Superiority of the pertussis immune response (maternally transferred pertussis antibodies in cord blood) was demonstrated by the GMC ratios (Tdap/control): 16.1 (95% CI: 13.5-19.2) for anti-filamentous hemagglutinin, 20.7 (15.9-26.9) for anti-pertactin and 8.5 (7.0-10.2) for anti-pertussis toxoid. Rates of pregnancy-/neonate-related AEs of interest, solicited general and unsolicited AEs were similar between groups. None of the serious AEs reported throughout the study were considered related to maternal Tdap vaccination.
   Conclusions: Tdap vaccination during pregnancy resulted in high levels of pertussis antibodies in cord blood, was well tolerated and had an acceptable safety profile. This supports the recommendation of Tdap vaccination during pregnancy to prevent early-infant pertussis disease. (C) 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.
C1 [Perrett, Kirsten P.; Nolan, Terry] Univ Melbourne, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   [Perrett, Kirsten P.; Nolan, Terry] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia.
   [Halperin, Scott A.] Dalhousie Univ, Canadian Ctr Vaccinol, Halifax, NS, Canada.
   [Martinez Pancorbo, Cristina] Inst Hispalense Pediat, Inst Sevillano Mujer, Seville, Spain.
   [Tapiero, Bruce] Univ Montreal, CHU St Justine, Montreal, PQ, Canada.
   [Martinon-Torres, Federico] Univ Santiago de Compostela, Translat Pediat & Infect Dis Pediat Dept, Hosp Clin, Santiago De Compostela, Spain.
   [Martinon-Torres, Federico] Univ Santiago de Compostela, Genet Vaccines & Pediat Res Grp, Inst Invest Sanitaria Santiago de Compostela, Santiago De Compostela, Spain.
   [Stranak, Zbynek] Inst Care Mother & Child, Prague, Czech Republic.
   [Virta, Miia] Tampere Univ, Tampere Vaccine Res Ctr, Tampere, Finland.
   [Vanderkooi, Otto G.] Univ Calgary, Alberta Childrens Hosp, Calgary, AB, Canada.
   [Kosina, Pavel] Univ Hosp, Hradec Kralove, Czech Republic.
   [Encinas Pardilla, Maria Begona] Hosp Univ Puerta Hierro, Majadahonda, Spain.
   [Cristobal Garcia, Ignacio] Univ Francisco de Vitoria, Madrid, Spain.
   [Zuccotti, Gian Vincenzo] Osped Bambini Vittore Buzzi, Milan, Italy.
   [Zuccotti, Gian Vincenzo] Univ Milan, Milan, Italy.
   [Kostanyan, Lusine] GSK, Modis, Wavre, Belgium.
   [Meyer, Nadia; Ceregido, Maria Angeles; Cheuvart, Brigitte; Mesaros, Narcisa] GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
   [Kuriyakose, Sherine O.] GSK, Bangalore, Karnataka, India.
   [Marcos Fernandez, Manuel] Hosp Monteprincipe, Boadilla Del Monte, Spain.
   [Rodriguez Zambrano, Miguel Angel] Hosp HM Puerta Sur, Mostoles, Spain.
   [Martin Garcia, Adrian] Nuevo Hosp Univ Burgos, Burgos, Spain.
   [Asenjo de la Fuente, Juan Eloy; Camacho Marin, Maria Dolores] Hosp Clin San Carlos, Madrid, Spain.
   [de la Calle Fernandez-Miranda, Maria] Hosp La Paz, Madrid, Spain.
   [Romero Espinar, Yolanda] Hosp Quironsalud Malaga, Malaga, Spain.
   [Marchisio, Paola Giovanna] Univ Milan, Milan, Italy.
   [Manzoni, Paolo] Osped Ostetr Ginecol St Anna, Turin, Italy.
   [Manzoni, Paolo] Infermi Hosp, Dept Maternal Infant Pediat Hlth, Biella, Italy.
RP Mesaros, N (reprint author), GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
EM kirsten.perrett@rch.org.au; scott.halperin@dal.ca;
   t.nolan@unimelb.edu.au; b.tapiero@umontreal.ca;
   federico.martinon.torres@sergas.es; z.stranak@seznam.cz;
   miia.virta@staff.uta.fi; ovanderk@ucalgary.ca; kosinpav@seznam.cz;
   icristobalg@sego.es; gianvincenzo.zuccotti@unimi.it;
   lusine.x.kostanyan@gsk.com; nadia.x.meyer@gsk.com;
   maria-angeles.x.ceregido@gsk.com; brigitte.cheuvart@gsk.com;
   sherine.o.kuriyakose@gsk.com; mmarcos@egom.es;
   eloyasenjo@telefonica.net; paola.marchisio@unimi.it;
   narcisa.x.mesaros@gsk.com
RI Martinon-Torres, Federico/E-4982-2016; de+la+Calle, Maria/AAE-4900-2020;
   Nolan, Terry/A-2236-2008; perrett, kirsten/P-8813-2019
OI Martinon-Torres, Federico/0000-0002-9023-581X; Nolan,
   Terry/0000-0001-6018-3863; perrett, kirsten/0000-0002-5683-996X
FU GlaxoSmithKline Biologicals S.A.GlaxoSmithKline
FX This work was supported by GlaxoSmithKline Biologicals S.A., which was
   the funding source, was involved in all stages of the study conduct and
   analysis and paid for all costs associated with the development and
   publishing of this manuscript.
CR Abu Raya B, 2014, VACCINE, V32, P5787, DOI 10.1016/j.vaccine.2014.08.038
   Amirthalingam G, 2014, LANCET, V384, P1521, DOI 10.1016/S0140-6736(14)60686-3
   Anonymous, 2011, Morbidity and Mortality Weekly Report, V60, P1424
   Australian Government Department of Health, IMM PREGN WHOOP COUG
   Barug D, 2019, LANCET INFECT DIS, V19, P392, DOI 10.1016/S1473-3099(18)30717-5
   Belloni C, 2003, PEDIATRICS, V111, P1042, DOI 10.1542/peds.111.5.1042
   CAMARGO ME, 1984, J CLIN MICROBIOL, V20, P772, DOI 10.1128/JCM.20.4.772-774.1984
   Dabrera G, 2015, CLIN INFECT DIS, V60, P333, DOI 10.1093/cid/ciu821
   de Greeff SC, 2012, EPIDEMIOLOGY, V23, P852, DOI 10.1097/EDE.0b013e31826c2b9e
   Department of Health and Social Care, 2012, WHOOP COUGH VACC PRO
   DeSilva M, 2017, VACCINE, V35, P3655, DOI 10.1016/j.vaccine.2017.05.041
   Donegan K, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4219
   Eberhardt CS, 2016, CLIN INFECT DIS, V62, P829, DOI 10.1093/cid/ciw027
   Frew PM, 2014, CLIN INFECT DIS, V59, pS400, DOI 10.1093/cid/ciu726
   Furuta M, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1559-2
   Gall SA, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.11.024
   Gkentzi D, 2017, ARCH DIS CHILD-FETAL, V102, pF456, DOI 10.1136/archdischild-2016-312341
   Government of Canada National Advisory Committee on Immunization, UPD IMM PREGN TDAP V
   Hoang HTT, 2016, VACCINE, V34, P151, DOI 10.1016/j.vaccine.2015.10.098
   Halperin SA, 2018, CLIN INFECT DIS, V67, P1063, DOI 10.1093/cid/ciy244
   Hardy-Fairbanks AJ, 2013, PEDIATR INFECT DIS J, V32, P1257, DOI 10.1097/INF.0b013e3182a09b6a
   Healy CM, 2011, CLIN INFECT DIS, V52, P157, DOI 10.1093/cid/ciq001
   Kharbanda EO, 2014, JAMA-J AM MED ASSOC, V312, P1897, DOI 10.1001/jama.2014.14825
   Kharbanda EO, 2016, VACCINE, V34, P968, DOI 10.1016/j.vaccine.2015.12.046
   Layton JB, 2017, VACCINE, V35, P4072, DOI 10.1016/j.vaccine.2017.06.071
   Maertens K, 2016, VACCINE, V34, P142, DOI 10.1016/j.vaccine.2015.10.100
   Masseria C, 2017, PEDIATR INFECT DIS J, V36, pE54, DOI 10.1097/INF.0000000000001440
   McMillan M, 2017, OBSTET GYNECOL, V129, P560, DOI 10.1097/AOG.0000000000001888
   MELVILLESMITH ME, 1983, J BIOL STAND, V11, P137, DOI 10.1016/S0092-1157(83)80038-9
   Munoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633
   Munoz FM, 2013, VACCINE, V31, P4274, DOI 10.1016/j.vaccine.2013.07.042
   Naidu MA, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.03.002
   Perrett K, 2017, PEDIATR DRUGS, V19, P313, DOI 10.1007/s40272-017-0231-7
   Perrett KP, 2019, VACCINE
   Petousis-Harris H, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010911
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Public Health England, 2016, TIM PERT VACC PREGN
   Ranstam J, 2008, ACTA RADIOL, V49, P644, DOI 10.1080/02841850802075082
   Sancovski M, 2019, HUM VACC IMMUNOTHER, V15, P2873, DOI 10.1080/21645515.2019.1627161
   Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131
   Perez JZV, 2017, HUM VACC IMMUNOTHER, V13, P128, DOI 10.1080/21645515.2016.1232786
   Wood N, 2018, JAMA PEDIATR, V172, P1045, DOI 10.1001/jamapediatrics.2018.2349
   Wood N, 2010, PEDIATR INFECT DIS J, V29, P209, DOI 10.1097/INF.0b013e3181bc98d5
   World Health Organization, 2018, WKLY EPIDEMIOL REC
NR 44
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 2095
EP 2104
DI 10.1016/j.vaccine.2019.10.105
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000028
PM 31776029
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Perrett, KP
   Halperin, SA
   Nolan, T
   Martinez, AC
   Martinon-Torres, F
   Garcia-Sicilia, J
   Virta, M
   Vanderkooi, OG
   Zuccotti, GV
   Manzoni, P
   Kostanyan, L
   Meyer, N
   Ceregido, MA
   Cheuvart, B
   Kuriyakose, SO
   Stranak, Z
   Arribas, JMM
   Ortega, MJC
   Miranda-Valdivieso, M
   Novas, BA
   Amador, JTR
   Omenaca, F
   Baca, M
   Marchisio, PG
   Mesaros, N
AF Perrett, Kirsten P.
   Halperin, Scott A.
   Nolan, Terry
   Carmona Martinez, Alfonso
   Martinon-Torres, Federico
   Garcia-Sicilia, Jose
   Virta, Miia
   Vanderkooi, Otto G.
   Zuccotti, Gian Vincenzo
   Manzoni, Paolo
   Kostanyan, Lusine
   Meyer, Nadia
   Ceregido, Maria Angeles
   Cheuvart, Brigitte
   Kuriyakose, Sherine O.
   Stranak, Zbynek
   Merino Arribas, Jose M.
   Cilleruelo Ortega, Maria Jose
   Miranda-Valdivieso, Mariano
   Arias Novas, Begona
   Ramos Amador, Jose Tomas
   Omenaca, Felix
   Baca, Manuel
   Marchisio, Paola Giovanna
   Mesaros, Narcisa
TI Impact of tetanus-diphtheria-acellular pertussis immunization during
   pregnancy on subsequent infant immunization seroresponses: follow-up
   from a large randomized placebo-controlled trial
SO VACCINE
LA English
DT Article
DE Tdap vaccine; Pertussis; Maternal immunization; Blunting; Infants
ID CAPSULAR POLYSACCHARIDE; ANTIBODY-RESPONSES; CONTAINING VACCINE; TDAP
   IMMUNIZATION; SERUM ANTIBODIES; IMMUNE-RESPONSES; MATERNAL TETANUS;
   PROTECTIVE LEVEL; MOTHERS; IMMUNOGENICITY
AB Background: Pertussis immunization during pregnancy results in high pertussis antibody concentrations in young infants but may interfere with infant immune responses to post-natal immunization.
   Methods: This phase IV, multi-country, open-label study assessed the immunogenicity and safety of infant primary vaccination with DTaP-HepB-IPV/Hib and 13-valent pneumococcal conjugate vaccine PCV13). Enrolled infants (6-14 weeks old) were born to mothers who were randomized to receive reduced-antigen-content diphtheria-tetanus-three-component acellular pertussis vaccine (Tdap group) or placebo (control group) during pregnancy (27(0/7)-36(6/7) weeks' gestation) with crossover immunization postpartum. All infants received 2 or 3 DTaP-HepB-IPV/Hib and PCV13 doses according to national schedules. Immunogenicity was assessed in infants pre- and 1 month post-primary vaccination. The primary objective was to assess seroprotection/vaccine response rates for DTaP-HepB-IPV/Hib antigens 1 month post-primary vaccination.
   Results: 601 infants (Tdap group: 296; control group: 305) were vaccinated. One month post-priming, seroprotection rates were 100% (diphtheria; tetanus), >= 98.5% (hepatitis B), >= 95.9% (polio) and >= 94.5% (Hib) in both groups. Vaccine response rates for pertussis antigens were significantly lower in infants whose mothers received pregnancy Tdap (37.5-77.1%) versus placebo (90.0-99.2%). Solicited and unsolicited adverse event rates were similar between groups. Serious adverse events occurred in 2.4% (Tdap group) and 5.6% (control group) of infants, none were vaccination-related.
   Conclusions: Pertussis antibodies transferred during pregnancy may decrease the risk of pertussis infection in the first months of life but interfere with the infant's ability to produce pertussis antibodies, the clinical significance of which remains unknown. Safety and reactogenicity results were consistent with previous experience. (C) 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.
C1 [Perrett, Kirsten P.; Nolan, Terry] Univ Melbourne, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   [Perrett, Kirsten P.; Nolan, Terry] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia.
   [Halperin, Scott A.] Dalhousie Univ, Canadian Ctr Vaccinol, Halifax, NS, Canada.
   [Carmona Martinez, Alfonso] Inst Hispalense Pediat, Seville, Spain.
   [Martinon-Torres, Federico] Univ Santiago de Compostela, Hosp Clin, Translat Pediat & Infect Dis Pediat Dept, Santiago De Compostela, Spain.
   [Martinon-Torres, Federico] Univ Santiago de Compostela, Genet Vaccines & Pediat Res Grp, Inst Invest Sanitaria Santiago de Compostela, Santiago De Compostela, Spain.
   [Garcia-Sicilia, Jose] Hosp Univ Madrid Sanchinarro, Madrid, Spain.
   [Virta, Miia] Tampere Univ, Tampere Vaccine Res Ctr, Tampere, Finland.
   [Vanderkooi, Otto G.] Univ Calgary, Alberta Childrens Hosp, Calgary, AB, Canada.
   [Zuccotti, Gian Vincenzo] Osped Bambini Vittore Buzzi, Milan, Italy.
   [Zuccotti, Gian Vincenzo] Univ Milan, Milan, Italy.
   [Manzoni, Paolo] Osped Ostetr Cinecol St Anna, Turin, Italy.
   [Manzoni, Paolo] Hosp Infermi, Dept Maternal Infant Pediat Hlth, Biella, Italy.
   [Kostanyan, Lusine] GSK, Modis, Wavre, Belgium.
   [Meyer, Nadia; Ceregido, Maria Angeles; Cheuvart, Brigitte; Mesaros, Narcisa] GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
   [Kuriyakose, Sherine O.] GSK, Bangalore, Karnataka, India.
   [Stranak, Zbynek] Inst Care Mother & Child, Prague, Czech Republic.
   [Merino Arribas, Jose M.] Nuevo Hosp Univ Burgos, Burgos, Spain.
   [Cilleruelo Ortega, Maria Jose] Hosp Univ Puerta Hierro, Majadahonda, Majadahonda, Spain.
   [Miranda-Valdivieso, Mariano] Hosp Antequera, Malaga, Spain.
   [Arias Novas, Begona] Hosp La Zarzuela, Aravaca, Spain.
   [Ramos Amador, Jose Tomas] Hosp Clin San Carlos, Madrid, Spain.
   [Omenaca, Felix] Hosp La Paz, Neonatol, Madrid, Spain.
   [Baca, Manuel] Hosp Quiron Malaga, Malaga, Spain.
   [Marchisio, Paola Giovanna] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Unita Pediat Cure Altamente Intens, Milan, Italy.
RP Mesaros, N (reprint author), GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
EM kirsten.perrett@rch.org.au; scott.halperin@dal.ca;
   t.nolan@unimelb.edu.au; alfonsocarmona@ihppediatria.com;
   federico.martinon.torres@sergas.es; jgarcia-sicilia@telefonica.net;
   miia.virta@staff.uta.fi; ovanderk@ucalgary.ca;
   gianvincenzo.zuccotti@unimi.it; lusine.x.kostanyan@gsk.com;
   nadia.x.meyer@gsk.com; maria-angeles.x.ceregido@gsk.com;
   brigitte.cheuvart@gsk.com; sherine.o.kuriyakose@gsk.com;
   z.stranak@seznam.cz; mjose.cilleruelo@salud.madrid.org;
   mariano.miranda@andaluciajunta.es; barias@sanitas.es;
   josetomas.ramos@salud.madrid.org; pediatra@manuelbaca.com;
   paola.marchisio@unimi.it; narcisa.x.mesaros@gsk.com
RI Martinon-Torres, Federico/E-4982-2016; perrett, kirsten/P-8813-2019;
   Nolan, Terry/A-2236-2008
OI Martinon-Torres, Federico/0000-0002-9023-581X; perrett,
   kirsten/0000-0002-5683-996X; Nolan, Terry/0000-0001-6018-3863
FU GlaxoSmithKline Biologicals S.A.GlaxoSmithKline
FX This work was supported by GlaxoSmithKline Biologicals S.A., which was
   the funding source, was involved in all stages of the study conduct and
   analysis and paid for all costs associated with the development and
   publishing of this manuscript.
CR Abu Raya B, 2014, VACCINE, V32, P5787, DOI 10.1016/j.vaccine.2014.08.038
   Amirthalingam G, 2016, CLIN INFECT DIS, V63, pS236, DOI 10.1093/cid/ciw559
   Amirthalingam G, 2014, LANCET, V384, P1521, DOI 10.1016/S0140-6736(14)60686-3
   ANDERSON P, 1984, J INFECT DIS, V149, P1034, DOI 10.1093/infdis/149.6.1034
   [Anonymous], 1991, MMWR Recomm Rep, V40, P1
   Barug D, 2019, LANCET INFECT DIS, V19, P392, DOI 10.1016/S1473-3099(18)30717-5
   Baxter R, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4091
   Becker-Dreps S, 2018, AM J PREV MED, V55, P159, DOI 10.1016/j.amepre.2018.04.013
   Bellido-Blasco J, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.22.30545
   Cabore RN, 2017, VIRULENCE, V8, P1245, DOI 10.1080/21505594.2017.1296998
   CAMARGO ME, 1984, J CLIN MICROBIOL, V20, P772, DOI 10.1128/JCM.20.4.772-774.1984
   Dabrera G, 2015, CLIN INFECT DIS, V60, P333, DOI 10.1093/cid/ciu821
   Edwards KM, 2015, VACCINE, V33, P6469, DOI 10.1016/j.vaccine.2015.07.085
   Fernandes EG, 2019, VACCINE, V37, P5481, DOI 10.1016/j.vaccine.2019.03.049
   Feyssaguet M, 2019, VACCINE, V37, P2208, DOI 10.1016/j.vaccine.2019.03.011
   Hoang HTT, 2016, VACCINE, V34, P151, DOI 10.1016/j.vaccine.2015.10.098
   Halperin SA, 2018, CLIN INFECT DIS, V67, P1063, DOI 10.1093/cid/ciy244
   Hardy-Fairbanks AJ, 2013, PEDIATR INFECT DIS J, V32, P1257, DOI 10.1097/INF.0b013e3182a09b6a
   Jack AD, 1999, J INFECT DIS, V179, P489, DOI 10.1086/314578
   KAYHTY H, 1983, J INFECT DIS, V147, P1100
   Ladhani SN, 2015, CLIN INFECT DIS, V61, P1637, DOI 10.1093/cid/civ695
   Maertens K, 2017, PEDIATR INFECT DIS J, V36, P1186, DOI 10.1097/INF.0000000000001601
   Maertens K, 2016, CLIN INFECT DIS, V63, pS197, DOI 10.1093/cid/ciw551
   Maertens K, 2016, VACCINE, V34, P142, DOI 10.1016/j.vaccine.2015.10.100
   Masseria C, 2017, PEDIATR INFECT DIS J, V36, pE54, DOI 10.1097/INF.0000000000001440
   MELVILLESMITH ME, 1983, J BIOL STAND, V11, P137, DOI 10.1016/S0092-1157(83)80038-9
   Munoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633
   Niewiesk S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00446
   Perrett KP, 2019, VACCINE
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Romanin V, 2020, CLIN INFECT DIS, V70, P380, DOI 10.1093/cid/ciz217
   Saul N, 2018, VACCINE, V36, P1887, DOI 10.1016/j.vaccine.2018.02.047
   Siber GR, 2007, VACCINE, V25, P3816, DOI 10.1016/j.vaccine.2007.01.119
   Skoff TH, 2017, CLIN INFECT DIS, V65, P1977, DOI 10.1093/cid/cix724
   Perez JZV, 2017, HUM VACC IMMUNOTHER, V13, P128, DOI 10.1080/21645515.2016.1232786
   Voysey M, 2017, JAMA PEDIATR, V171, P637, DOI 10.1001/jamapediatrics.2017.0638
   World Health Organization, 2018, WKLY EPIDEMIOL REC
   World Health Organization Expanded Programme on Immunization, 1993, GUID WHO EPI COLL ST
   World Health Organization SAGE pertussis working group, 2014, BACKGR PAP
NR 39
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 18
PY 2020
VL 38
IS 8
BP 2105
EP 2114
DI 10.1016/j.vaccine.2019.10.104
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KS7ME
UT WOS:000518490000029
PM 31776027
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Balemans, C
   Hulsen, MA
   Anderson, PD
AF Balemans, Caroline
   Hulsen, Martien A.
   Anderson, Patrick D.
TI On the validity of 2D analysis of non-isothermal sintering in SLS
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Finite element method; Temperature-dependent viscous flow; Coalescence;
   3D printing; SLS
ID VISCOUS-FLOW; STOKES-FLOW; SIMULATION; DRIVEN; MODEL; COALESCENCE
AB Selective laser sintering (SLS) is an important additive manufacturing method for polymers and is increasingly used for industrial applications. To improve the quality of printed products a thorough understanding of the process is necessary. Simulations are a convenient way to assess the sintering in detail. In literature several numerical studies can be found on the sintering process of two particles. Both 2D and 3D geometries are used and sometimes the assumption of axisymmetry is made. If the effect of the laser beam in temperature-dependent sintering is taken into account, axisymmetry cannot be assumed anymore and full 3D simulations are required. However, these simulations are complex and computationally expensive. In this work, we assess if 2D simulations are representative for the 3D case of the temperature-dependent sintering process of two viscous particles. We find that 2D simulations are a good alternative for 3D simulations for the sintering problem of two particles, if the correct geometrical scaling factors are taken into account. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Balemans, Caroline; Hulsen, Martien A.; Anderson, Patrick D.] Eindhoven Univ Technol, Dept Mech Engn, Polymer Technol, NL-5600 MB Eindhoven, Netherlands.
   [Balemans, Caroline] Brightlands Mat Ctr, NL-6167 RD Geleen, Netherlands.
RP Anderson, PD (reprint author), Eindhoven Univ Technol, Dept Mech Engn, Polymer Technol, NL-5600 MB Eindhoven, Netherlands.
EM P.D.Anderson@tue.nl
CR Balemans C, 2018, ADDIT MANUF, V24, P528, DOI 10.1016/j.addma.2018.09.005
   Balemans C, 2017, APPL SCI-BASEL, V7, DOI 10.3390/app7050516
   Bellehumeur CT, 1998, RHEOL ACTA, V37, P270, DOI 10.1007/s003970050114
   Brandrup J., 1999, POLYM HDB
   Diller T., 2010, P 21 ANN INT SOL FRE, P539
   Djohari H, 2009, CHEM ENG SCI, V64, P3799, DOI 10.1016/j.ces.2009.05.018
   Eshelby J., 1949, MET T, V185, P796
   Frenkel J., 1945, J PHYS USSR, V9, P385
   Garabedian RS, 2001, J COLLOID INTERF SCI, V234, P248, DOI 10.1006/jcis.2000.7297
   Hooper R, 2000, CHEM ENG SCI, V55, P5733, DOI 10.1016/S0009-2509(00)00224-4
   HOPPER RW, 1990, J FLUID MECH, V213, P349, DOI 10.1017/S002211209000235X
   Hulsen M.A., 2019, TFEM TOOLKIT FINITE
   JAGOTA A, 1988, ACTA METALL MATER, V36, P2551, DOI 10.1016/0001-6160(88)90200-3
   JAGOTA A, 1990, J AM CERAM SOC, V73, P173, DOI 10.1111/j.1151-2916.1990.tb05117.x
   KUIKEN HK, 1990, J FLUID MECH, V214, P503, DOI 10.1017/S0022112090000234
   Laumer T, 2016, POLYM TEST, V56, P207, DOI 10.1016/j.polymertesting.2016.10.010
   MARTINEZHERRERA JI, 1995, J AM CERAM SOC, V78, P645, DOI 10.1111/j.1151-2916.1995.tb08226.x
   MARTINEZHERRERA JI, 1994, AICHE J, V40, P1794, DOI 10.1002/aic.690401104
   MAZUR S, 1994, PROG ORG COAT, V24, P225, DOI 10.1016/0033-0655(94)85016-X
   Pokluda O, 1997, AICHE J, V43, P3253, DOI 10.1002/aic.690431213
   ROSS JW, 1981, J APPL PHYS, V52, P3884, DOI 10.1063/1.329235
   Scribben E, 2006, RHEOL ACTA, V45, P825, DOI 10.1007/s00397-005-0039-1
   Singh AK, 2010, RAPID PROTOTYPING J, V16, P441, DOI 10.1108/13552541011083362
   Sun M., 1991, P SOL FREEF FABR S A
   VANDEVORST GAL, 1993, J FLUID MECH, V257, P667
   VANDEVORST GAL, 1992, J COMPUT PHYS, V100, P50, DOI 10.1016/0021-9991(92)90309-M
   VANDEVORST GAL, 1992, COMPUTING, V49, P239, DOI 10.1007/BF02238931
   VANDEVORST GAL, 1994, ENG ANAL BOUND ELEM, V14, P193, DOI 10.1016/0955-7997(94)90096-5
   Verbelen L, 2016, EUR POLYM J, V75, P163, DOI 10.1016/j.eurpolymj.2015.12.014
   Wakai F, 2016, ACTA MATER, V109, P292, DOI 10.1016/j.actamat.2016.03.006
   Yuan M., 2011, P SOL FREEF FABR S, P427
   Zhou H, 1998, J AM CERAM SOC, V81, P533
NR 32
TC 1
Z9 1
U1 12
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115365
DI 10.1016/j.ces.2019.115365
PG 11
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600005
DA 2020-05-12
ER

PT J
AU Cao, ZK
   Guo, R
   Du, P
   Mei, JL
   Zhang, X
   Xu, CM
   Liu, J
   Jiang, GY
   Li, HP
   Duan, AJ
AF Cao, Zhengkai
   Guo, Rong
   Du, Peng
   Mei, Jinlin
   Zhang, Xia
   Xu, Chunming
   Liu, Jian
   Jiang, Guiyuan
   Li, Huiping
   Duan, Aijun
TI Synthesis of highly ordered Al-Zr-SBA-16 composites and their
   application in dibenzothiophene hydrodesulfurization
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Modification; HYD selectivity; Hierarchical reaction steps; HDS
   performance
ID NIMO CATALYSTS; MESOPOROUS SILICA; DIFFERENT MORPHOLOGIES; HDS ACTIVITY;
   DEEP HDS; SOL-GEL; SBA-16; AL; ALUMINA; 4,6-DIMETHYLDIBENZOTHIOPHENE
AB Serial Al-Zr-SBA-16 composites are successfully prepared through a two-step synthetic method. The influences of Al and Zr species on the properties of Al-Zr-SBA-16 composites and NiMo corresponding catalysts are investigated by various measurements. The results showed that a series of Al-Zr-SBA-16 supports maintained the intact structure and highly ordered degree. Al and Zr modification could increase the proportion of inactive Mo (Td) and Mo(Oh) species, respectively. The DBT HDS evaluation results revealed that NiMo/AZ-2.5 presented the highest HDS efficiency of 96.2%. The reasons should be ascribed to the factors that the higher dispersion degree of active metals, the highest proportion of MoS 2 and NiMoS active phases over NiMo/AZ-2.5 sulfide catalyst, and the highest selectivity of hydrogenation (HYD) route. In addition, principle of hierarchical reaction steps in HYD route was also proposed to explain the reason why the HYD/DDS (direct desulfurization) ratio and HDS efficiency were the highest for NiMo/AZ-2.5 catalyst. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Cao, Zhengkai; Mei, Jinlin; Xu, Chunming; Liu, Jian; Jiang, Guiyuan; Li, Huiping; Duan, Aijun] China Univ Petr, State Key Lab Heavy Oil Proc, Beijing 102249, Peoples R China.
   [Cao, Zhengkai; Guo, Rong; Zhang, Xia] SINOPEC, Dalian Res Inst Petr & Petrochem, Dalian 116041, Liaoning, Peoples R China.
   [Du, Peng] City Univ Hong Kong, Dept Mat Sci & Engn, Kowloon, Hong Kong, Peoples R China.
RP Duan, AJ (reprint author), China Univ Petr, State Key Lab Heavy Oil Proc, Beijing 102249, Peoples R China.; Zhang, X (reprint author), SINOPEC, Dalian Res Inst Petr & Petrochem, Dalian 116041, Liaoning, Peoples R China.
EM zhangxia@tju.edu.cn; duanaijun@cup.edu.cn
OI DU, PENG/0000-0002-4760-6857
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21676298, 21878330, U1463207, 21503152, 21808079];
   CNPC Key Research Project [GCP201401]; KLGCP [GCP201401]; Key Research
   and Development Program of Shandong Province [2019GSF109115]
FX The authors acknowledge the financial supports from the National Natural
   Science Foundation of China (No. 21676298, 21878330, U1463207 and
   21503152), CNPC Key Research Project and KLGCP (GCP201401), Key Research
   and Development Program of Shandong Province (No. 2019GSF109115) and
   National Natural Science Foundation of China (No. 21808079). We also
   thank the senior engineers including Chunyan Yang, Wenya Yang and Guoli
   Zhao for helping us to carry out the measurement of H<INF>2</INF>-TPD,
   TEM and CO-IR respectively.
CR Adachi M, 1996, J CATAL, V162, P66, DOI 10.1006/jcat.1996.0260
   Amezcua JC, 2005, CATAL TODAY, V107-08, P578, DOI 10.1016/j.cattod.2005.07.018
   Badoga S, 2014, IND ENG CHEM RES, V53, P2137, DOI 10.1021/ie400695m
   Basha SJS, 2006, APPL CATAL A-GEN, V308, P91, DOI 10.1016/j.apcata.2006.04.013
   Biswas P, 2011, IND ENG CHEM RES, V50, P7882, DOI 10.1021/ie102429j
   Cao Z., 2016, ENERG FUEL, V31, P805
   Cao ZK, 2016, CHEM ENG SCI, V155, P141, DOI 10.1016/j.ces.2016.08.001
   Carvalho WA, 1997, ZEOLITES, V18, P408, DOI 10.1016/S0144-2449(97)00031-6
   Chen SY, 2010, J CATAL, V270, P196, DOI 10.1016/j.jcat.2009.12.020
   CORDERO RL, 1991, APPL CATAL, V74, P125
   Ding WJ, 2015, CHEM ENG J, V266, P213, DOI 10.1016/j.cej.2014.12.040
   Du YC, 2009, MICROPOR MESOPOR MAT, V121, P185, DOI 10.1016/j.micromeso.2009.01.030
   DUTOIT DCM, 1995, J CATAL, V153, P165, DOI 10.1006/jcat.1995.1118
   Ewald S, 2019, APPL CATAL A-GEN, V570, P376, DOI 10.1016/j.apcata.2018.10.033
   Gallo JMR, 2010, LANGMUIR, V26, P5791, DOI 10.1021/la903661q
   Gao DW, 2015, APPL CATAL B-ENVIRON, V165, P269, DOI 10.1016/j.apcatb.2014.10.034
   Gutierrez OY, 2008, CATAL TODAY, V130, P292, DOI 10.1016/j.cattod.2007.10.110
   Gutierrez OY, 2007, J CATAL, V249, P140, DOI 10.1016/j.jcat.2007.04.014
   Hamdy M.S., 2010, CHEMISTRY, V12, P620
   Huirache-Acuna R, 2017, FUEL, V198, P145, DOI 10.1016/j.fuel.2016.09.042
   Huirache-Acuna R, 2015, FUEL, V149, P149, DOI 10.1016/j.fuel.2014.08.045
   Huirache-Acuna R, 2012, APPL CATAL B-ENVIRON, V125, P473, DOI 10.1016/j.apcatb.2012.05.034
   Huirache-Acuna R, 2009, APPL CATAL B-ENVIRON, V92, P168, DOI 10.1016/j.apcatb.2009.07.012
   Jiang N, 2007, STUD SURF SCI CATAL, V165, P901
   Kim TW, 2004, J PHYS CHEM B, V108, P11480, DOI 10.1021/jp048582k
   Klimova T, 2004, CATAL TODAY, V98, P141, DOI 10.1016/j.cattod.2004.07.028
   Kruk M, 2008, MICROPOR MESOPOR MAT, V114, P64, DOI 10.1016/j.micromeso.2007.12.015
   Kumar A, 2012, J CATAL, V293, P126, DOI 10.1016/j.jcat.2012.06.012
   Kunisada N, 2004, APPL CATAL A-GEN, V269, P43, DOI 10.1016/j.apcata.2004.03.051
   Lai WK, 2013, J CATAL, V303, P80, DOI 10.1016/j.jcat.2013.03.001
   Lecrenay E, 1998, APPL CATAL A-GEN, V175, P237, DOI 10.1016/S0926-860X(98)00224-5
   Liu Y, 2014, SOLID STATE COMMUN, V178, P16, DOI 10.1016/j.ssc.2013.09.030
   Lizama LY, 2009, J MATER SCI, V44, P6617, DOI 10.1007/s10853-009-3613-6
   Merida-Robles J, 1999, J MOL CATAL A-CHEM, V145, P169, DOI 10.1016/S1381-1169(99)00048-5
   Minesso A, 2002, J SOL-GEL SCI TECHN, V24, P197, DOI 10.1023/A:1015328506642
   PERI JB, 1984, J CATAL, V86, P84, DOI 10.1016/0021-9517(84)90350-6
   Poncelet G, 2005, APPL CATAL A-GEN, V288, P232, DOI 10.1016/j.apcata.2005.04.052
   Qu LL, 2003, J CATAL, V215, P7, DOI 10.1016/S0021-9517(02)00181-1
   Riegel B, 1997, J NON-CRYST SOLIDS, V211, P294, DOI 10.1016/S0022-3093(96)00639-4
   Shah AT, 2009, J COLLOID INTERF SCI, V336, P707, DOI 10.1016/j.jcis.2009.04.026
   SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603
   Toledo-Antonio JA, 2017, APPL CATAL B-ENVIRON, V213, P106, DOI 10.1016/j.apcatb.2017.05.011
   Valencia D, 2011, CATAL TODAY, V166, P91, DOI 10.1016/j.cattod.2010.08.006
   Wang HY, 2015, APPL CATAL A-GEN, V502, P157, DOI 10.1016/j.apcata.2015.05.028
   WILLIAMS CC, 1991, J PHYS CHEM-US, V95, P8781, DOI 10.1021/j100175a067
   Zepeda TA, 2008, MICROPOR MESOPOR MAT, V111, P157, DOI 10.1016/j.micromeso.2007.07.025
   Zepeda TA, 2016, APPL CATAL B-ENVIRON, V180, P569, DOI 10.1016/j.apcatb.2015.07.013
   Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548
   Zhao DY, 1998, J AM CHEM SOC, V120, P6024, DOI 10.1021/ja974025i
   Zhao L, 2006, J COLLOID INTERF SCI, V304, P84, DOI 10.1016/j.jcis.2006.08.042
   Zhou WW, 2018, APPL CATAL B-ENVIRON, V238, P212, DOI 10.1016/j.apcatb.2018.07.042
   Zhou WW, 2017, CHEM ENG J, V330, P605, DOI 10.1016/j.cej.2017.08.005
   Zhou XF, 2014, J MATER CHEM A, V2, P6823, DOI 10.1039/c3ta14859a
NR 53
TC 0
Z9 0
U1 18
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115415
DI 10.1016/j.ces.2019.115415
PG 14
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600028
DA 2020-05-12
ER

PT J
AU Dong, CS
   Rassame, S
   Zhang, LZ
   Hibiki, T
AF Dong, Chuanshuai
   Rassame, Somboon
   Zhang, Lizhi
   Hibiki, Takashi
TI Drift-flux correlation for upward two-phase flow in inclined pipes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Drift-flux model; Void fraction; Upward two-phase flows; Inclined pipe
ID VOID FRACTION; SLUG FLOW; MODEL; VELOCITY; TUBE
AB In view of the practical importance of the drift-flux model to predict void fraction for gas-liquid flow in various engineering fields including chemical engineering, this study aims at developing a drift-flux correlation with a wide range of applicability for upward two-phase flows in inclined pipes. Firstly, over 3000 experimental data of void fraction were collected from 14 sources. Then, the correlations of distribution parameter and void-fraction-weighted-mean drift velocity were established. The comparison between the collected database and correlations indicated none of the existing correlations could predict the whole database satisfactorily. Therefore, the dependence of drift-flux parameters on inclination angles was comprehensively analysed, and a new drift-flux correlation was developed. The newly-developed drift-flux correlation demonstrated superior performance to existing correlations. More than 95% of the predicted void fraction were predicted within +/- 20% error. In summary, the newly-developed drift-flux correlation is useful to predict void fraction in various engineering fields including chemical engineering. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Dong, Chuanshuai; Zhang, Lizhi] South China Univ Technol, Sch Chem & Chem Engn, Key Lab Enhanced Heat Transfer & Energy Conservat, Guangzhou 510640, Peoples R China.
   [Rassame, Somboon] Chulalongkorn Univ, Fac Engn, Dept Nucl Engn, Bangkok 10330, Thailand.
   [Hibiki, Takashi] Purdue Univ, Sch Nucl Engn, 400 Cent Dr, W Lafayette, IN 47907 USA.
RP Rassame, S (reprint author), Chulalongkorn Univ, Fac Engn, Dept Nucl Engn, Bangkok 10330, Thailand.
EM somboon.ra@chula.ac.th
FU China MOST-Japan JICA International Cooperation Key Project of the
   National Key Research and Development Program [2017YFE0116100]; National
   Science Fund for Distinguished Young Scholars of ChinaNational Natural
   Science Foundation of ChinaNational Science Fund for Distinguished Young
   Scholars [51425601]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [51906071];
   Postdoctoral Science Foundation of ChinaChina Postdoctoral Science
   Foundation [2019M652889]; National Natural Science Foundation of
   GuangdongNational Natural Science Foundation of Guangdong Province
   [2019A1515011536]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [D2191890]; Key Laboratory of Advanced Reactor Engineering and Safety,
   Ministry of Education [ares-2019-09]
FX This project is supported by the China MOST-Japan JICA International
   Cooperation Key Project of the National Key Research and Development
   Program (No. 2017YFE0116100). It is also supported by the National
   Science Fund for Distinguished Young Scholars of China (No. 51425601).
   This project is also supported by the National Natural Science
   Foundation of China (No. 51906071), the Postdoctoral Science Foundation
   of China (No. 2019M652889), the National Natural Science Foundation of
   Guangdong (No. 2019A1515011536), the Fundamental Research Funds for the
   Central Universities (No. D2191890) and Key Laboratory of Advanced
   Reactor Engineering and Safety, Ministry of Education (No.
   ares-2019-09).
CR BChexal B., 1991, NSAC139 EPRI
   Beggs H.D., 1972, THESIS
   Bhagwat SM, 2016, EXP THERM FLUID SCI, V79, P301, DOI 10.1016/j.expthermflusci.2016.08.004
   Bhagwat SM, 2014, INT J MULTIPHAS FLOW, V59, P186, DOI 10.1016/j.ijmultiphaseflow.2013.11.001
   Colebrook C.F., 1939, J I CIV ENG LONDON
   Dong CS, 2019, INT J MULTIPHAS FLOW, V119, P28, DOI 10.1016/j.ijmultiphaseflow.2019.07.004
   FRANCA F, 1992, INT J MULTIPHAS FLOW, V18, P787, DOI 10.1016/0301-9322(92)90059-P
   Hibiki T, 2003, INT J HEAT MASS TRAN, V46, P1773, DOI 10.1016/S0017-9310(02)00473-8
   Hibiki T, 2002, INT J HEAT MASS TRAN, V45, P707, DOI 10.1016/S0017-9310(01)00195-8
   HIBIKI T, 2019, EXP COMPUT MULTIPHAS, V1, P85
   Hibiki T, 2017, PROG NUCL ENERG, V97, P38, DOI 10.1016/j.pnucene.2017.01.003
   ISHII M., 1977, ANL7747
   KATAOKA I, 1987, INT J HEAT MASS TRAN, V30, P1927
   Kokal S.L., 1987, THESIS
   Luo W, 2016, INT J HEAT TECHNOL, V34, P455, DOI 10.18280/ijht.340315
   Mukherjee H., 1979, THESIS
   Ottens M, 2001, CHEM ENG RES DES, V79, P581, DOI 10.1205/02638760152424361
   Oyewole A.L., 2009, THESIS
   Payne G.A., 1979, INT J PET TECHNOL, P1198
   Perez H., 2008, THESIS
   Rassame S, 2018, INT J HEAT FLUID FL, V69, P33, DOI 10.1016/j.ijheatfluidflow.2017.11.002
   Spedding P.L., 1998, INT J HEAT MASS TRAN, V30, P3194
   Wen Y, 2017, INT J HEAT TECHNOL, V35, P713, DOI 10.18280/ijht.350404
   Wiesche S.A.D., 2015, P ASME JSME KSME 201
   Yan CX, 2014, NUCL ENG DES, V273, P155, DOI 10.1016/j.nucengdes.2014.03.019
   YEOH GH, 2019, EXP COMPUT MULTIPHAS, V1, P3
   Zhao QB, 2019, INT J MULTIPHAS FLOW, V113, P33, DOI 10.1016/j.ijmultiphaseflow.2018.12.016
   ZUBER N, 1965, J HEAT TRANSF, V87, P453, DOI 10.1115/1.3689137
NR 28
TC 1
Z9 1
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115395
DI 10.1016/j.ces.2019.115395
PG 20
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600018
DA 2020-05-12
ER

PT J
AU Duan, XZ
   Huang, ZK
   Qian, G
   He, K
   Zhang, J
   Mleczko, L
   Zhou, XG
AF Duan, Xuezhi
   Huang, Zikun
   Qian, Gang
   He, Kuan
   Zhang, Jing
   Mleczko, Leslaw
   Zhou, Xinggui
TI Unprecedented yield of methyl-esterification with in-situ generated
   diazomethane in a microchannel reactor with methanol as solvent
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Microreaction technology; Methyl-esterfication; Diazomethane; Solvent
   effects; Transesterification
ID IRON-CATALYZED CYCLOPROPANATION; MICROREACTION TECHNOLOGY; ONE-POT;
   FLOW; CHEMISTRY; DIAZO; CONVERSION; MECHANISM; SYSTEMS
AB Continuous synthesis of diazomethane followed by the in-situ methylesterfication has been seen as promising approach for broader use of chemical routes based on highly reactive component. In several studies proof-of-concept has been achieved. However, the yield of target product has been low. In this work, we report an underlying mechanism of the solvent effects on the low ester yields, mainly arising from the transesterification of the methyl ester products. When methanol was used as solvent, unprecedented high ester yield of above 99.5% was obtained. This overcomes the obstacle to practical application of methylesterfication with in-situ generated diazomethane. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Duan, Xuezhi; Huang, Zikun; Qian, Gang; He, Kuan; Zhang, Jing; Zhou, Xinggui] East China Univ Sci & Technol, State Key Lab Chem Engn, 130 Meilong Rd, Shanghai 200237, Peoples R China.
   [Mleczko, Leslaw] Bayer AG, Engn & Technol, D-51368 Leverkusen, Germany.
RP Duan, XZ; Zhou, XG (reprint author), East China Univ Sci & Technol, State Key Lab Chem Engn, 130 Meilong Rd, Shanghai 200237, Peoples R China.
EM xzduan@ecust.edu.cn; xgzhou@ecust.edu.cn
OI Mleczko, Leslaw/0000-0002-9039-1310
FU Bayer Technology Services GmbH; 111 Project of Ministry of Education of
   ChinaMinistry of Education, China - 111 Project [B08021]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [21991103, 21991104]
FX This work was financially supported by the Bayer Technology Services
   GmbH and the 111 Project of Ministry of Education of China (B08021) the
   National Natural Science Foundation of China (21991103 and 21991104).
CR Adamo A, 2016, SCIENCE, V352, P61, DOI 10.1126/science.aaf1337
   Antkowiak WZ, 2001, TETRAHEDRON, V57, P2799, DOI 10.1016/S0040-4020(01)00122-3
   ARNDT F., 1943, ORG SYNTH, V2, P165
   Barkawi LS, 2010, NAT PROTOC, V5, P1619, DOI 10.1038/nprot.2010.119
   Black T. H., 1983, ALDRICHIM ACTA, V16, P3
   Choi S.B., 1991, MICROMECHANICAL SENS, V32, P123
   De Boer T. J., 1963, ORG SYNTH, V4, P250
   Deadman BJ, 2015, CHEM-EUR J, V21, P2298, DOI 10.1002/chem.201404348
   Denmark SE, 1997, J ORG CHEM, V62, P3375, DOI 10.1021/jo970044z
   Di Gioia ML, 2003, J ORG CHEM, V68, P7416, DOI 10.1021/jo034233v
   Eistert B, 1941, ANGEW CHEM-GER EDIT, V54, P124, DOI 10.1002/ange.19410540904
   Ferstl W. F., 2004, CHEM-ING-TECH, V76, P1326, DOI DOI 10.1002/CITE.200490233
   Forbes DC, 2000, TETRAHEDRON LETT, V41, P9943, DOI 10.1016/S0040-4039(00)01791-3
   Fu M, 2019, J FLOW CHEM, V9, P89, DOI 10.1007/s41981-019-00030-3
   Gutmann B, 2015, ANGEW CHEM INT EDIT, V54, P6688, DOI 10.1002/anie.201409318
   Hartman RL, 2011, ANGEW CHEM INT EDIT, V50, P7502, DOI 10.1002/anie.201004637
   HECHT SM, 1973, J ORG CHEM, V38, P1821, DOI 10.1021/jo00950a011
   Hessel V, 2005, CHEM ENG SCI, V60, P2479, DOI 10.1016/j.ces.2004.11.033
   Holladay JD, 2004, CHEM REV, V104, P4767, DOI 10.1021/cr020721b
   Hopps H.B., 1970, ALDRICHIM ACTA, V3, P7
   Huisgen R, 2000, EUR J ORG CHEM, V2000, P1685
   Igarashi M, 2004, J NUTR SCI VITAMINOL, V50, P121, DOI 10.3177/jnsv.50.121
   Jahnisch K, 2004, ANGEW CHEM INT EDIT, V43, P406, DOI 10.1002/anie.200300577
   Kaschel J, 2012, ANGEW CHEM INT EDIT, V51, P7085, DOI 10.1002/anie.201203829
   Kozyrev AN, 1999, ANGEW CHEM INT EDIT, V38, P126, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<126::AID-ANIE126>3.0.CO;2-U
   Kuhnel E, 2007, ANGEW CHEM INT EDIT, V46, P7075, DOI 10.1002/anie.200702131
   Leggio A, 2001, J ORG CHEM, V66, P2246, DOI 10.1021/jo0012391
   Lei YX, 2002, J ORG CHEM, V67, P6971, DOI 10.1021/jo0203802
   LEVAI A, 1997, CHEM HETEROCYCL COMP, V33, P647, DOI DOI 10.1007/BF02291794
   Longstreet AR, 2013, ACCOUNTS CHEM RES, V46, P327, DOI 10.1021/ar300144x
   Lowe H, 1999, ELECTROCHIM ACTA, V44, P3679, DOI 10.1016/S0013-4686(99)00071-7
   Maas G, 2009, ANGEW CHEM INT EDIT, V48, P8186, DOI 10.1002/anie.200902785
   Masami Y., 1981, CHEM PHARM BULL, V29, P1475
   Mason BP, 2007, CHEM REV, V107, P2300, DOI 10.1021/cr050944c
   Mastronardi F, 2013, ORG LETT, V15, P5590, DOI 10.1021/ol4027914
   Maurya RA, 2011, ANGEW CHEM INT EDIT, V50, P5952, DOI 10.1002/anie.201101977
   MCKAY AF, 1948, J AM CHEM SOC, V70, P1974, DOI 10.1021/ja01185a516
   Mineno T, 2006, CHEM PHARM BULL, V54, P918, DOI 10.1248/cpb.54.918
   Moore JA, 1973, ORG SYN COLL, V5, P351
   Morandi B, 2012, SCIENCE, V335, P1471, DOI 10.1126/science.1218781
   Muray E, 2000, J ORG CHEM, V65, P388, DOI 10.1021/jo991227j
   Pace V, 2010, J ORG CHEM, V75, P5760, DOI 10.1021/jo101105g
   Pashkova A, 2015, CATAL TODAY, V248, P128, DOI 10.1016/j.cattod.2014.03.012
   Pechmann H.V., 1895, CHEM BER, V28, P855
   Pechmann H. V., 1894, BER DTSCH CHEM GES, V27, P1888
   Pennemann H, 2004, CHEM ENG SCI, V59, P4789, DOI 10.1016/j.ces.2004.07.049
   Pizey J.S., 1974, SYNTHETIC REAGENTS, V2, P65
   Proctor LD, 2002, ORG PROCESS RES DEV, V6, P884, DOI 10.1021/op020049k
   Rodriguez-Garcia C, 2001, J AM CHEM SOC, V123, P6157, DOI 10.1021/ja015676o
   Rossi E, 2012, ORG PROCESS RES DEV, V16, P1146, DOI 10.1021/op200110a
   Struempel M, 2008, GREEN CHEM, V10, P41, DOI 10.1039/b710554a
   Su YH, 2011, AICHE J, V57, P1409, DOI 10.1002/aic.12367
   Tietze LF, 2008, ARKIVOC, P193, DOI 10.3998/ark.5550190.0009.816
   Wang K, 2015, AICHE J, V61, P1959, DOI 10.1002/aic.14797
   Westermann T, 2016, ORG PROCESS RES DEV, V20, P487, DOI 10.1021/acs.oprd.5b00205
   Wiles C, 2011, CHEM COMMUN, V47, P6512, DOI 10.1039/c1cc00089f
   Wu W, 2007, CHEM ENG SCI, V62, P5127, DOI 10.1016/j.ces.2006.11.024
   Yamamoto N, 2011, J ORG CHEM, V76, P2937, DOI 10.1021/jo2003264
   Yang CF, 2019, J TAIWAN INST CHEM E, V98, P94, DOI 10.1016/j.jtice.2018.06.022
   Yoshida J, 2013, CHEM COMMUN, V49, P9896, DOI 10.1039/c3cc44709j
   Zhang J, 2010, J HAZARD MATER, V181, P1024, DOI 10.1016/j.jhazmat.2010.05.117
   Zhang JS, 2014, AICHE J, V60, P2724, DOI 10.1002/aic.14450
NR 62
TC 0
Z9 0
U1 9
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115397
DI 10.1016/j.ces.2019.115397
PG 6
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600019
DA 2020-05-12
ER

PT J
AU Farsi, A
   Xiang, J
   Latham, JP
   Carlsson, M
   Stitt, EH
   Marigo, M
AF Farsi, Ado
   Xiang, J.
   Latham, J. P.
   Carlsson, M.
   Stitt, E. H.
   Marigo, M.
TI Strength and fragmentation behaviour of complex-shaped catalyst pellets:
   A numerical and experimental study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fracture; Crushing; Simulations; FDEM; Catalyst supports
ID MODEL; BREAKAGE
AB The effects of catalyst support shapes on their final strength and fragmentation behaviour are investigated. Uniaxial compression tests by diametrical loading of solid and four-holed discs with high-speed video recordings are employed to investigate strengths and pellet crushing behaviours. The combined finite-discrete element method (FDEM) is employed to simulate the effects of geometrical features and loading orientation on the pre- and post-failure behaviour of catalysts. A comparison with experimental results is also presented and the remarkable agreement in failure evolution and mode is discussed. A methodology to derive representative fragment size distributions from defined pellet shapes and material properties is introduced, providing a further tool to understand the strength and fragmentation behaviour of catalyst supports. The results suggest that fixed-bed reactors made with solid cylindrical catalysts will be more likely to be affected by pressure drops caused by the choking effect of a significant portion of fines than if it was made with catalyst supports with four holes. Two designs of four-hole catalyst supports sintered with different porosities have also been studied, showing different fragment size distributions and fines production. Characterisation of fines production for different catalyst support designs will improve prediction of reactor clogging and pressure drops. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Farsi, Ado; Xiang, J.; Latham, J. P.] Imperial Coll London, Dept Earth Sci & Engn, Appl Modelling & Computat Grp, South Kensington Campus, London SW7 2AZ, England.
   [Carlsson, M.; Stitt, E. H.; Marigo, M.] Johnson Matthey, POB 1,Belasis Ave, Billingham TS23 1LB, Cleveland, England.
RP Farsi, A (reprint author), Imperial Coll London, Dept Earth Sci & Engn, Appl Modelling & Computat Grp, South Kensington Campus, London SW7 2AZ, England.
EM ado.farsi@imperial.ac.uk
RI Xiang, Jiansheng/AAK-8487-2020
OI Xiang, Jiansheng/0000-0002-1343-3628
FU Engineering and Physical Sciences Research Council (EPSRC)Engineering &
   Physical Sciences Research Council (EPSRC); Impact Acceleration Account
   grant [EP/R511547/1]; Johnson Matthey
FX The authors wish to thank James Bower for the nanoindentation tests and
   Daniel Curry for his help in sample preparation. This research was
   supported by the Engineering and Physical Sciences Research Council
   (EPSRC) with a Case studentship in collaboration with Johnson Matthey
   and the Impact Acceleration Account grant (Ref: EP/R511547/1).
CR Antonyuk S, 2005, CHEM ENG SCI, V60, P4031, DOI 10.1016/j.ces.2005.02.038
   Beeckman JWL, 2017, CHEM ENG TECHNOL, V40, P1844, DOI 10.1002/ceat.201600550
   BIENIAWSKI ZT, 1978, INT J ROCK MECH MIN, V15, P99
   Brown NJ, 2014, GRANUL MATTER, V16, P299, DOI 10.1007/s10035-014-0494-4
   Cleary PW, 2017, MINER ENG, V100, P49, DOI 10.1016/j.mineng.2016.10.005
   David E., 2015, ARCH MAT SCI ENG, V73, P5
   Farnell P., 2014, AICHE SAF S, P71
   Farsi A., 2017, 5 INT C PART BAS MET
   Farsi A., 2017, FULL DEFLECTION PROF, V7, P46190
   Jimenez-Herrera N, 2018, ADV POWDER TECHNOL, V29, P692, DOI 10.1016/j.apt.2017.12.006
   Kun F, 1996, COMPUT METHOD APPL M, V138, P3, DOI 10.1016/S0045-7825(96)01012-2
   Li YD, 2000, IND ENG CHEM RES, V39, P838, DOI 10.1021/ie990418+
   Osborne S., 2013, NITROGEN SYNGAS, V321, P1
   Pham HN, 1999, POWDER TECHNOL, V103, P95, DOI 10.1016/S0032-5910(98)00177-6
   Potyondy DO, 2004, INT J ROCK MECH MIN, V41, P1329, DOI 10.1016/j.ijrmms.2004.09.011
   Rostrup-Nielsen JR, 2002, CATTECH, V6, P150, DOI 10.1023/A:1020163012266
   Stitt H., 2016, 1 CFDEM PROJ US M
   Tancret F, 2018, MATER SCI TECH-LOND, V34, P1333, DOI 10.1080/02670836.2018.1449177
   Tavares LM, 2007, HANDB POWD TECHNOL, V12, P3, DOI 10.1016/S0167-3785(07)12004-2
   Unland G, 2007, HANDB POWD TECHNOL, V12, P117, DOI 10.1016/S0167-3785(07)12007-8
   Wang QZ, 2004, INT J ROCK MECH MIN, V41, P245, DOI 10.1016/S1365-1609(03)00093-5
   Wu DF, 2003, CHEM ENG SCI, V58, P3995, DOI 10.1016/S0009-2509(03)00286-0
NR 22
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115409
DI 10.1016/j.ces.2019.115409
PG 18
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600023
DA 2020-05-12
ER

PT J
AU Gong, SG
   Gao, NN
   Han, LC
   Luo, HA
AF Gong, Shenggao
   Gao, Ningning
   Han, Luchang
   Luo, He'an
TI A theoretical model for bubble coalescence by coupling film drainage
   with approach processes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bubble coalescence; Critical coalescence velocity; Film drainage;
   Approach; Turbulence
ID INTERFACIAL AREA TRANSPORT; POPULATION BALANCE MODEL; MASS-TRANSFER;
   STABILITY CONDITION; REGIME TRANSITION; APPROACH VELOCITY; DROPLET
   BREAKAGE; ENERGY-SPECTRUM; TURBULENCE; FLOW
AB An improved theoretical model for simulating bubble coalescence caused by turbulence was developed. Unlike the previous models, this improved model simulated the film drainage and approach processes between two bubbles simultaneously in the condition of fully mobile interfaces, considering the influence of the variation of approach velocity, film thickness, film area/radius and interaction forces etc. with time on the bubble coalescence. The lubrication form drag force caused by flattening of colliding surface was introduced to model the approach process. The initial film thickness and radius required for film drainage process were estimated by the expressions validated by experimental data. The critical coalescence velocities for determining coalescence predicted by the improved model were consistent with available experimental data. Moreover, the proposed improved model was used to predict the size distribution in a bubble column, and a good agreement between simulated and experimental results was obtained. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Gong, Shenggao; Gao, Ningning] Hunan Inst Technol, Sch Mat & Chem Engn, Hengyang 421002, Hunan, Peoples R China.
   [Gong, Shenggao; Han, Luchang; Luo, He'an] Xiangtan Univ, Sch Chem Engn, Xiangtan 411105, Hunan, Peoples R China.
RP Gong, SG; Han, LC (reprint author), Xiangtan Univ, Sch Chem Engn, Xiangtan 411105, Hunan, Peoples R China.
EM gongshenggao0827@163.com; han_119_lulu@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21676224]; Scientific Research Fund of Hunan
   Provincial Education DepartmentHunan Provincial Education Department
   [18A076, 19C0536]; Hunan Provincial Innovation Foundation for
   Postgraduate [CX2013B273]; Characteristic Application Discipline of
   Material Science and Engineering in Hunan Province (Hunan Provincial
   Education Department Notice) [[2018]469]; Scientific Research Foundation
   for Doctors of Hunan Institute of Technology [HQ17010, 2017HY019]
FX The authors acknowledge the financial support from the National Natural
   Science Foundation of China (21676224), the Scientific Research Fund of
   Hunan Provincial Education Department (18A076, 19C0536), the Hunan
   Provincial Innovation Foundation for Postgraduate (CX2013B273), the
   Characteristic Application Discipline of Material Science and
   Engineering in Hunan Province (Hunan Provincial Education Department
   Notice (Grants No [2018]469)), and the Scientific Research Foundation
   for Doctors of Hunan Institute of Technology (HQ17010, 2017HY019).
CR Agahzamin S, 2019, CHEM ENG SCI, V193, P421, DOI 10.1016/j.ces.2018.08.052
   Bazhlekov I, 2016, J COMPUT APPL MATH, V293, P7, DOI 10.1016/j.cam.2015.04.013
   Ceylan K, 2001, POWDER TECHNOL, V119, P250, DOI 10.1016/S0032-5910(01)00261-3
   Chen C, 2019, CHEM ENG SCI, V193, P171, DOI 10.1016/j.ces.2018.08.048
   CHEN JD, 1984, AICHE J, V30, P622, DOI 10.1002/aic.690300413
   Chen P, 2005, AICHE J, V51, P696, DOI 10.1002/aic.10381
   Chesters A. K., 1975, International Journal of Multiphase Flow, V2, P191, DOI 10.1016/0301-9322(75)90008-7
   Chesters AK, 2000, J COLLOID INTERF SCI, V230, P229, DOI 10.1006/jcis.2000.7074
   CHESTERS AK, 1982, APPL SCI RES, V38, P353, DOI 10.1007/BF00385965
   Cheung SCP, 2013, NUCL ENG DES, V265, P120, DOI 10.1016/j.nucengdes.2013.08.049
   Colin C., 2004, 5 INT C MULT FLOW
   Coons JE, 2003, ADV COLLOID INTERFAC, V105, P3, DOI 10.1016/S0001-8686(03)00003-4
   COULALOGLOU CA, 1977, CHEM ENG SCI, V32, P1289, DOI 10.1016/0009-2509(77)85023-9
   Danov KD, 1999, J COLLOID INTERF SCI, V211, P291, DOI 10.1006/jcis.1998.5973
   DANOV KD, 1993, LANGMUIR, V9, P1731, DOI 10.1021/la00031a021
   Das SK, 2015, CHEM ENG SCI, V137, P22, DOI 10.1016/j.ces.2015.04.026
   Das SK, 2016, CHEM ENG SCI, V152, P140, DOI 10.1016/j.ces.2016.05.039
   Datta S, 2019, AICHE J, V65, P829, DOI 10.1002/aic.16457
   Del Castillo LA, 2011, J COLLOID INTERF SCI, V356, P316, DOI 10.1016/j.jcis.2010.12.057
   Derksen JJ, 2012, AICHE J, V58, P2589, DOI 10.1002/aic.12761
   Duineveld PC, 1998, APPL SCI RES, V58, P409
   Elghobashi S, 2019, ANNU REV FLUID MECH, V51, P217, DOI 10.1146/annurev-fluid-010518-040401
   Feng ZG, 2001, J FLUID ENG-T ASME, V123, P841, DOI 10.1115/1.1412458
   Firouzi M, 2015, ADV COLLOID INTERFAC, V222, P305, DOI 10.1016/j.cis.2014.07.005
   Gong SG, 2018, CHEM ENG SCI, V176, P377, DOI 10.1016/j.ces.2017.10.045
   Hagesaether L, 1999, CHEM ENG SCI, V54, P4749, DOI 10.1016/S0009-2509(99)00191-8
   Han LC, 2015, AICHE J, V61, P2147, DOI 10.1002/aic.14830
   Hibiki T, 2000, INT J HEAT MASS TRAN, V43, P2711, DOI 10.1016/S0017-9310(99)00325-7
   Horn RG, 2011, ADV COLLOID INTERFAC, V168, P85, DOI 10.1016/j.cis.2011.05.006
   Israelachvili JN, 2011, INTERMOLECULAR AND SURFACE FORCES, 3RD EDITION, P1
   Jeelani SAK, 1998, J COLLOID INTERF SCI, V206, P83, DOI 10.1006/jcis.1998.5699
   Kamp AM, 2001, INT J MULTIPHAS FLOW, V27, P1363, DOI 10.1016/S0301-9322(01)00010-6
   Kamp J, 2014, CHEM ENG RES DES, V92, P635, DOI 10.1016/j.cherd.2013.12.023
   Karakashev SI, 2008, LANGMUIR, V24, P11587, DOI 10.1021/la801456j
   KIRKPATRICK RD, 1974, CHEM ENG SCI, V29, P2363, DOI 10.1016/0009-2509(74)80013-8
   Klaseboer E, 2000, J COLLOID INTERF SCI, V229, P274, DOI 10.1006/jcis.2000.6987
   Komrakova AE, 2015, AICHE J, V61, P2618, DOI 10.1002/aic.14821
   Kumar S, 1996, CHEM ENG SCI, V51, P1311, DOI 10.1016/0009-2509(96)88489-2
   KUMAR S, 1993, CHEM ENG SCI, V48, P2025, DOI 10.1016/0009-2509(93)80079-6
   Lehr F, 2002, AICHE J, V48, P2426, DOI 10.1002/aic.690481103
   Li DY, 2017, AICHE J, V63, P2293, DOI 10.1002/aic.15557
   Li J., 1994, PARTICLE FLUID 2 PHA
   Lu JK, 2019, CHEM ENG SCI, V196, P493, DOI 10.1016/j.ces.2018.11.002
   Lucas D, 2005, INT J MULTIPHAS FLOW, V31, P1304, DOI 10.1016/j.ijmultiphaseflow.2005.07.004
   Lucas D, 2010, INT J THERM SCI, V49, P664, DOI 10.1016/j.ijthermalsci.2009.11.008
   Luo H, 1996, CHEM ENG COMMUN, V145, P145, DOI 10.1080/00986449608936473
   Luo H., 1993, THESIS
   MARTIN H, 1980, CHEM-ING-TECH, V52, P199, DOI 10.1002/cite.330520303
   Morel C, 2010, INT J MULTIPHAS FLOW, V36, P25, DOI 10.1016/j.ijmultiphaseflow.2009.09.003
   OOLMAN TO, 1986, CHEM ENG COMMUN, V43, P237, DOI 10.1080/00986448608911334
   Podgorska W, 2005, CHEM ENG SCI, V60, P2115, DOI 10.1016/j.ces.2004.10.035
   Pope S. B., 2000, TURBULENT FLOWS
   PRINCE MJ, 1990, AICHE J, V36, P1425, DOI 10.1002/aic.690360915
   PRINCE MJ, 1990, AICHE J, V36, P1485, DOI 10.1002/aic.690361004
   Ribeiro CP, 2007, CHEM ENG J, V126, P23, DOI 10.1016/j.cej.2006.08.029
   Ribeiro CP, 2006, CHEM ENG SCI, V61, P5704, DOI 10.1016/j.ces.2006.04.043
   Schiller L, 1933, Z VER DTSCH ING, V77, P318
   Shen JB, 2015, CAN J CHEM ENG, V93, P2266, DOI 10.1002/cjce.22329
   Solsvik J, 2016, IND ENG CHEM RES, V55, P1449, DOI 10.1021/acs.iecr.5b04077
   Soo S.L., 1970, FLUID DYNAMICS MULTI
   SOVOVA H, 1981, CHEM ENG SCI, V36, P1567, DOI 10.1016/0009-2509(81)85117-2
   Svendsen HF, 1996, CAN J CHEM ENG, V74, P321, DOI 10.1002/cjce.5450740302
   Syed AH, 2017, FRONT CHEM, V5, DOI 10.3389/fchem.2017.00068
   Toro-Mendoza J., 2010, PHYS REV E, V81
   VRIJ A, 1968, J AM CHEM SOC, V90, P3074, DOI 10.1021/ja01014a015
   Wang TF, 2006, AICHE J, V52, P125, DOI 10.1002/aic.10611
   Wang TF, 2005, CHEM ENG SCI, V60, P6199, DOI 10.1016/j.ces.2005.04.027
   Wilczek M, 2011, J FLUID MECH, V676, P191, DOI 10.1017/jfm.2011.39
   Wu Q, 1998, INT J HEAT MASS TRAN, V41, P1103, DOI 10.1016/S0017-9310(97)00167-1
   Yaminsky VV, 2010, LANGMUIR, V26, P8061, DOI 10.1021/la904481d
   Yang N, 2007, CHEM ENG SCI, V62, P6978, DOI 10.1016/j.ces.2007.08.034
   Yang N, 2017, CHEM ENG SCI, V170, P241, DOI 10.1016/j.ces.2017.01.026
   Yang N, 2010, CHEM ENG SCI, V65, P517, DOI 10.1016/j.ces.2009.06.014
NR 73
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115387
DI 10.1016/j.ces.2019.115387
PG 20
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600013
DA 2020-05-12
ER

PT J
AU Jung, H
   Yoon, S
   Kim, Y
   Lee, JH
   Park, H
   Kim, D
   Kim, J
   Kang, S
AF Jung, Hokyo
   Yoon, Serin
   Kim, Youngjae
   Lee, Jun Ho
   Park, Hyungmin
   Kim, Dongjoo
   Kim, Jungwoo
   Kang, Seongwon
TI Development and evaluation of data-driven modeling for bubble size in
   turbulent air-water bubbly flows using artificial multi-layer neural
   networks
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Turbulent bubbly flows; Bubble size; Two-fluid model; Artificial neural
   network
ID INTERFACIAL AREA CONCENTRATION; 2-PHASE FLOW; SINGLE BUBBLES;
   CLOSURE-MODEL; HEAT-TRANSFER; TRANSPORT; COALESCENCE; SIMULATION;
   PREDICTION; VELOCITY
AB In the present study, we consider a new reliable model of the bubble size based on multi-layer artificial neural networks (ANN). A multi-layer ANN is used to establish a function for the bubble size without any assumption on the form. In the training procedure, the proposed ANN is trained using data sets collected from open literature and experiments performed in the present study. An excellent agreement was obtained between the trained ANN and experimental data in the bubble size. Also, sensitivity analyses along with principal component analysis and random forest method provide important physical parameters for the bubble size. Next, in order to rigorously evaluate the prediction capability of the present model, flow simulations were conducted for turbulent bubbly flows, for which experimental data are available. The present validation results show that a regime-adaptive data-driven model for the bubble size achieves successful estimation for both wall and core peaking regimes. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jung, Hokyo; Yoon, Serin; Kim, Youngjae; Kang, Seongwon] Sogang Univ, Dept Mech Engn, Seoul 04107, South Korea.
   [Lee, Jun Ho; Park, Hyungmin] Seoul Natl Univ, Dept Mech & Aerosp Engn, Seoul 08826, South Korea.
   [Kim, Jungwoo] Seoul Natl Univ Sci & Technol, Dept Mech Syst Design Engn, Seoul 01811, South Korea.
   [Kim, Dongjoo] Kumoh Natl Inst Technol, Dept Mech Engn, Gumi 39177, Gyeongbuk, South Korea.
RP Kang, S (reprint author), Sogang Univ, Dept Mech Engn, Seoul 04107, South Korea.; Kim, J (reprint author), Seoul Natl Univ Sci & Technol, Dept Mech Syst Design Engn, Seoul 01811, South Korea.
EM hokyo@sogang.ac.kr; serin@sogang.ac.kr; kyj136@sogang.ac.kr;
   junho20699@snu.ac.kr; hminpark@snu.ac.kr; kdj@kumoh.ac.kr;
   kimjw@seoultech.ac.kr; skang@sogang.ac.kr
FU National Research Foundation of Korea (NRF) - Korea government (MSIP)
   [2017M2A8A4018482, 2017R1A2B3008273]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grants funded by the Korea government (MSIP) (No. 2017M2A8A4018482
   and 2017R1A2B3008273). We are very grateful to anonymous reviewers for
   their insightful comments.
CR Al-Rawahi Nabeel, 2012, Multiphase Science and Technology, V24, P89, DOI 10.1615/MultScienTechn.v24.i2.10
   Aoyama S, 2017, INT J MULTIPHAS FLOW, V96, P113, DOI 10.1016/j.ijmultiphaseflow.2017.07.003
   BREIMAN L, 1992, INT STAT REV, V60, P291, DOI 10.2307/1403680
   Burns A. D., 2004, EULERIAN MULTIPHASE, V4, P1
   Chang CW, 2019, INT J THERM SCI, V135, P559, DOI 10.1016/j.ijthermalsci.2018.09.002
   Cheung SCP, 2007, CHEM ENG SCI, V62, P4659, DOI 10.1016/j.ces.2007.05.030
   Chuang TJ, 2015, PROG NUCL ENERG, V85, P415, DOI 10.1016/j.pnucene.2015.07.008
   Dawes B., 2018, BOOST C LIB
   Doup B, 2013, NUCL ENG DES, V263, P273, DOI 10.1016/j.nucengdes.2013.05.022
   du Cluzeau A, 2019, J FLUID MECH, V866, P132, DOI 10.1017/jfm.2019.100
   Geisser S., 1993, PREDICTIVE INFERENCE
   Hibiki T, 2001, INT J HEAT MASS TRAN, V44, P3443, DOI 10.1016/S0017-9310(00)00365-3
   Hibiki T, 2000, INT J HEAT MASS TRAN, V43, P2711, DOI 10.1016/S0017-9310(99)00325-7
   Hibiki T, 1998, NUCL ENG DES, V184, P287, DOI 10.1016/S0029-5493(98)00203-9
   Hibiki T, 2002, CHEM ENG SCI, V57, P3967, DOI 10.1016/S0009-2509(02)00263-4
   Hibiki T, 2001, INT J HEAT MASS TRAN, V44, P1869, DOI 10.1016/S0017-9310(00)00232-5
   Hosokawa S, 2009, CHEM ENG SCI, V64, P5308, DOI 10.1016/j.ces.2009.09.017
   ISHII M, 1979, AICHE J, V25, P843, DOI 10.1002/aic.690250513
   ISHII M, 1984, NUCL ENG DES, V82, P107, DOI 10.1016/0029-5493(84)90207-3
   Julia JE, 2008, NUCL ENG DES, V238, P156, DOI 10.1016/j.nucengdes.2007.05.005
   KATAOKA I, 1986, INT J MULTIPHAS FLOW, V12, P505, DOI 10.1016/0301-9322(86)90057-1
   Kim BJ, 2014, NUCL SCI ENG, V178, P225, DOI 10.13182/NSE13-57
   Kim J., 2015, NURETH 16
   Kim M, 2016, EXP FLUIDS, V57, DOI 10.1007/s00348-016-2144-6
   Kingma DP, 2014, ADAM METHOD STOCHAST
   KOCAMUSTAFAOGULLARI G, 1994, NUCL ENG DES, V148, P437, DOI 10.1016/0029-5493(94)90124-4
   Kohavi R., 1995, IJCAI-95. Proceedings of the Fourteenth International Joint Conference on Artificial Intelligence, P1137
   Krepper E, 2018, NUCL ENG DES, V340, P388, DOI 10.1016/j.nucengdes.2018.09.042
   Lau YM, 2013, CHEM ENG SCI, V94, P20, DOI 10.1016/j.ces.2013.02.043
   Liao YX, 2015, CHEM ENG SCI, V122, P336, DOI 10.1016/j.ces.2014.09.042
   Lin CH, 2014, PROG NUCL ENERG, V74, P91, DOI 10.1016/j.pnucene.2014.01.015
   Ling J, 2016, J FLUID MECH, V807, P155, DOI 10.1017/jfm.2016.615
   Liu Y, 2018, APPL THERM ENG, V144, P305, DOI 10.1016/j.applthermaleng.2018.08.041
   Lo S., 2012, J COMPUT MULTIPHASE, V4, P299, DOI DOI 10.1260/1757-482X.4.3.299
   Lu C., 2010, THESIS, DOI 10.17077/etd.ic0r4r98
   Lucas D, 2007, CHEM ENG SCI, V62, P4146, DOI 10.1016/j.ces.2007.04.035
   Ma M., 2017, THESIS
   Ma M, 2016, INT J MULTIPHAS FLOW, V85, P336, DOI 10.1016/j.ijmultiphaseflow.2016.06.021
   Ma M, 2015, PHYS FLUIDS, V27, DOI 10.1063/1.4930004
   Mi Y, 2001, NUCL ENG DES, V204, P87, DOI 10.1016/S0029-5493(00)00325-3
   Millies M, 1996, INT J MULTIPHAS FLOW, V22, P1073, DOI 10.1016/0301-9322(96)00031-6
   Monros-Andreu G, 2013, EPJ WEB CONF, V45, DOI 10.1051/epjconf/20134501105
   Mukin RV, 2014, INT J MULTIPHAS FLOW, V62, P52, DOI 10.1016/j.ijmultiphaseflow.2014.02.008
   Nguyen V.T., 2012, J COMPUT MULTIPH FLO, V4, P327
   Park IK, 2013, J NUCL SCI TECHNOL, V50, P813, DOI 10.1080/00223131.2013.808001
   Rzehak R, 2017, CHEM ENG SCI, V157, P147, DOI 10.1016/j.ces.2016.04.056
   Sathe MJ, 2010, CHEM ENG SCI, V65, P2431, DOI 10.1016/j.ces.2009.11.014
   SATO Y, 1981, INT J MULTIPHAS FLOW, V7, P167, DOI 10.1016/0301-9322(81)90003-3
   Schlegel JP, 2015, CHEM ENG SCI, V131, P172, DOI 10.1016/j.ces.2015.04.004
   Singh AP, 2017, AIAA J, V55, P2215, DOI 10.2514/1.J055595
   Tomiyama A, 2002, CHEM ENG SCI, V57, P1849, DOI 10.1016/S0009-2509(02)00085-4
   Tryggvason G, 2016, NUCL SCI ENG, V184, P312, DOI 10.13182/NSE16-10
   WELLEK RM, 1966, AICHE J, V12, P854, DOI 10.1002/aic.690120506
   YEONG BAK JIN, 2016, 에너지공학, V25, P69
   Yun BJ, 2012, NUCL ENG DES, V253, P351, DOI 10.1016/j.nucengdes.2011.08.067
   Ziegenhein T, 2017, CAN J CHEM ENG, V95, P170, DOI 10.1002/cjce.22647
NR 56
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115357
DI 10.1016/j.ces.2019.115357
PG 21
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600003
DA 2020-05-12
ER

PT J
AU Karim, AM
   Suszynski, WJ
   Pujari, S
   Francis, LF
   Carvalho, MS
AF Karim, Alireza Mohammad
   Suszynski, Wieslaw J.
   Pujari, Saswati
   Francis, Lorraine F.
   Carvalho, Marcio S.
TI Delaying breakup and avoiding air entrainment in curtain coating using a
   two-layer liquid structure
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Curtain coating; Viscoelasticity; Liquid sheet breakup; Two-layer
   coating; Capillary hydrodynamics
ID HYDRODYNAMIC ASSIST; VISCOSITY; FILAMENT; FLOW
AB Successful curtain coating is limited by two flow instabilities, the breakup of the liquid curtain below a critical flow rate and air entrainment above a maximum substrate speed. These limitations make thin film coating at high speed a great challenge. Previous work has shown that the curtain breakup can be delayed to lower flow rates if the flowing liquid has viscoelastic behavior. However, viscoelastic stresses near the dynamic contact line destabilize the flow in that region, leading to the onset of air entrainment at lower web speeds. We propose and experimentally validate the use of a two-layer curtain coating configuration, with a shear-thinning liquid as the bottom layer and a viscoelastic liquid as the top layer, that expands the processing window and enables thin coating at high speeds. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Karim, Alireza Mohammad; Suszynski, Wieslaw J.; Francis, Lorraine F.; Carvalho, Marcio S.] Univ Minnesota, Dept Chem Engn & Mat Sci, 421 Washington Ave SE, Minneapolis, MN 55455 USA.
   [Pujari, Saswati] Dow Chem Co USA, 400 Arcola Rd, Collegeville, PA 19426 USA.
   [Carvalho, Marcio S.] Pontificia Univ Catolica Rio de Janeiro, Dept Mech Engn, Rua Marques Sao Vicente 225, BR-22453900 Rio De Janeiro, RJ, Brazil.
RP Francis, LF; Carvalho, MS (reprint author), Pontificia Univ Catolica Rio de Janeiro, Dept Mech Engn, Rua Marques Sao Vicente 225, BR-22453900 Rio De Janeiro, RJ, Brazil.
EM lfrancis@umn.edu; msc@puc-rio.br
RI Karim, Alireza Mohammad/AAI-5651-2020
OI Karim, Alireza Mohammad/0000-0002-2031-9057
FU Dow Chemical Company
FX This research was supported by the Dow Chemical Company.
CR Barcock R.A., 2011, US Pat, Patent No. [7976904 B2, 7976904]
   Becerra M, 2011, CHEM ENG PROCESS, V50, P445, DOI 10.1016/j.cep.2010.11.011
   BLAKE TD, 1994, AICHE J, V40, P229, DOI 10.1002/aic.690400205
   Choinski E.J., 1978, US Pat, Patent No. 4113903
   Christanti Y, 2001, J NON-NEWTON FLUID, V100, P9, DOI 10.1016/S0377-0257(01)00135-5
   Cohu O, 1998, AICHE J, V44, P2360, DOI 10.1002/aic.690441104
   Cooper-White JJ, 2002, J NON-NEWTON FLUID, V106, P29, DOI 10.1016/S0377-0257(02)00084-8
   Dontula P, 1998, AICHE J, V44, P1247, DOI 10.1002/aic.690440603
   Entov VM, 1997, J NON-NEWTON FLUID, V72, P31, DOI 10.1016/S0377-0257(97)00022-0
   Ghosh T., 2013, US Pat, Patent No. [8552132 B2, 8552132]
   Karim AM, 2019, J NON-NEWTON FLUID, V263, P69, DOI 10.1016/j.jnnfm.2018.11.009
   Karim AM, 2018, J NON-NEWTON FLUID, V257, P83, DOI 10.1016/j.jnnfm.2018.03.019
   Katagiri Y., 2002, European Pat, Patent No. [1236518A2, 1236518]
   KHAGRAM M, 1985, J RHEOL, V29, P191, DOI 10.1122/1.549788
   Liu CY, 2016, J FLUID MECH, V789, P285, DOI 10.1017/jfm.2015.739
   Marston JO, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2378562
   Marston JO, 2007, EXP FLUIDS, V42, P483, DOI 10.1007/s00348-007-0258-6
   McKinley GH, 2000, J RHEOL, V44, P653, DOI 10.1122/1.551105
   Miyamoto K., 1997, LIQUID FILM COATING
   Oliveira MSN, 2006, J NON-NEWTON FLUID, V137, P137, DOI 10.1016/j.jnnfm.2006.01.014
   Romero OJ, 2004, J NON-NEWTON FLUID, V118, P137, DOI 10.1016/j.jnnfm.2004.03.004
   Seevaratnam GK, 2007, PHYS FLUIDS, V19, DOI 10.1063/1.2432107
   Wei Y, 2007, J COLLOID INTERF SCI, V313, P274, DOI 10.1016/j.jcis.2007.04.020
NR 23
TC 1
Z9 1
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115376
DI 10.1016/j.ces.2019.115376
PG 6
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600008
DA 2020-05-12
ER

PT J
AU Li, B
   Wang, ZT
   Vivacqua, V
   Ghadiri, M
   Wang, JF
   Zhang, W
   Wang, DB
   Liu, HL
   Sun, ZQ
   Wang, ZB
AF Li, Bin
   Wang, Zhentao
   Vivacqua, Vincenzino
   Ghadiri, Mojtaba
   Wang, Junfeng
   Zhang, Wei
   Wang, Dongbao
   Liu, Hailong
   Sun, Zhiqian
   Wang, Zhenbo
TI Drop-interface electrocoalescence mode transition under a direct current
   electric field
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Electrocoalescence; Drop-interface coalescence; Level-set method;
   Interface; Electrohydrodynamics
ID IN-OIL EMULSION; WATER DROPS; HIGH-FREQUENCY; LEVEL-SET; COALESCENCE;
   DEMULSIFICATION; DEFORMATION; PARAMETERS; SEPARATION; BREAKUP
AB The electrocoalescence of a water drop at the water/oil interface in the presence of externally direct current electric fields was numerically analyzed with the finite element method by solving the Navier-Stokes and charge conservation equations. The proprietary software Comsol Multiphysics was used for this purpose, and the interface motion was captured by the Level-Set method. Good agreement was obtained between numerical and experimental results in the literature. The effects of the electric field strength, droplet size, oil phase permittivity, surface tension, bulk viscosity, water phase conductivity, and drop-interface distance were systematically assessed. Three coalescence modes were obtained: complete coalescence, including typical complete coalescence and complete coalescence with upheaval; partial coalescence, including typical partial coalescence and jet-like partial coalescence; and noncoalescence, including typical non-coalescence and breakup of bouncing-off droplet non-coalescence. The pressure gradients between the drop and the bridge rather than the sign of the pressure determined the coalescence. There is a critical non-dimensional drop-interface distance of electrocoalescence modes that has negligible dependence on the non-dimensional water phase conductivity. The ratio of the Weber Number (describing electric field effects) and the Ohnesorge Number (describing physical properties) was found to well describe the coalescence process. The outcome of this work is potentially useful for optimizing the design of compact and efficient oil-water separators. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Li, Bin; Wang, Zhentao; Wang, Junfeng; Zhang, Wei; Wang, Dongbao; Liu, Hailong] Jiangsu Univ, Sch Energy & Power Engn, Zhenjiang 212013, Jiangsu, Peoples R China.
   [Li, Bin; Vivacqua, Vincenzino; Ghadiri, Mojtaba] Univ Leeds, Sch Chem & Proc Engn, Leeds LS2 9JT, W Yorkshire, England.
   [Sun, Zhiqian; Wang, Zhenbo] China Univ Petr East China, State Key Lab Heavy Oil, Qingdao 266580, Peoples R China.
RP Wang, JF (reprint author), Jiangsu Univ, Sch Energy & Power Engn, Zhenjiang 212013, Jiangsu, Peoples R China.
EM wangjunfeng@ujs.edu.cn
OI Ghadiri, Mojtaba/0000-0003-0479-2845
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51761145011, 51506078]; China Scholarship
   CouncilChina Scholarship Council [201606450040]; State Key Laboratory of
   Heavy Oil Processing [SLKZZ-2017013]
FX The financial support of National Natural Science Foundation of China
   (No. 51761145011, and No. 51506078), China Scholarship Council (No.
   201606450040), and State Key Laboratory of Heavy Oil Processing
   (SLKZZ-2017013) for supporting the first author to carry out the
   research work at the University of Leeds is gratefully acknowledged.
CR Aryafar H, 2010, PHYS FLUIDS, V22, DOI 10.1063/1.3480116
   Aryafar H, 2009, LANGMUIR, V25, P12460, DOI 10.1021/la902758u
   Aryafar H, 2007, PHYS FLUIDS, V19, DOI 10.1063/1.2774682
   Atten P, 2010, IEEE T IND APPL, V46, P1578, DOI 10.1109/TIA.2010.2050984
   Bartlett CT, 2015, J FLUID MECH, V763, P369, DOI 10.1017/jfm.2014.664
   Bird JC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.164502
   Blanchette F, 2006, NAT PHYS, V2, P254, DOI 10.1038/nphys268
   Blanchette F, 2009, J FLUID MECH, V620, P333, DOI 10.1017/S0022112008004801
   Charles G.E., 1960, Journal of Colloid Science, V15, P105, DOI 10.1016/0095-8522(60)90012-X
   Choi SW, 2017, APPL SURF SCI, V397, P57, DOI 10.1016/j.apsusc.2016.11.088
   Collins RT, 2008, NAT PHYS, V4, P149, DOI 10.1038/nphys807
   Eow JS, 2002, SEP PURIF TECHNOL, V29, P63, DOI 10.1016/S1383-5866(02)00093-X
   Eow JS, 2001, CHEM ENG J, V84, P173, DOI 10.1016/S1385-8947(00)00386-7
   Gennes P. G. D., 2004, CAPILLARITY WETTING
   Ghadiri M, 2006, CHEM ENG SCI, V61, P2290, DOI 10.1016/j.ces.2005.05.009
   GOTO M, 1989, J CHEM ENG JPN, V22, P401, DOI 10.1252/jcej.22.401
   Hamlin BS, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.094501
   Helmensdorfer S, 2013, EPL-EUROPHYS LETT, V104, DOI 10.1209/0295-5075/104/34001
   HIRATO T, 1991, MATER T JIM, V32, P257, DOI 10.2320/matertrans1989.32.257
   Holto J, 2009, C ELECT INSUL DIEL P, P208
   Huang X, 2017, INT J MULTIPHAS FLOW, V96, P123, DOI 10.1016/j.ijmultiphaseflow.2017.07.007
   Huo Y., 2015, EXP FLUIDS, V65, P1
   Karyappa RB, 2014, J FLUID MECH, V754, P550, DOI 10.1017/jfm.2014.402
   Li B, 2017, CHEM ENG RES DES, V127, P180, DOI 10.1016/j.cherd.2017.09.024
   Li B, 2017, POWDER TECHNOL, V316, P338, DOI 10.1016/j.powtec.2017.03.024
   Li B, 2016, J ELECTROSTAT, V80, P22, DOI 10.1016/j.elstat.2016.01.003
   Lu J, 2016, PHYS REV E, V93, DOI 10.1103/PhysRevE.93.023111
   Luo SR, 2016, PHYS CHEM CHEM PHYS, V18, P29786, DOI 10.1039/c6cp06085d
   Luo XM, 2018, CHEM ENG SCI, V191, P350, DOI 10.1016/j.ces.2018.07.002
   Mhatre S, 2015, CHEM ENG RES DES, V96, P177, DOI 10.1016/j.cherd.2015.02.012
   Mhatre S, 2019, CHEM ENG RES DES, V141, P540, DOI 10.1016/j.cherd.2018.11.019
   MOHAMMED RA, 1994, COLLOID SURFACE A, V83, P261, DOI 10.1016/0927-7757(93)02706-K
   Mousavi SH, 2014, CHEM ENG SCI, V120, P130, DOI 10.1016/j.ces.2014.08.055
   Mousavichoubeh M, 2011, CHEM ENG PROCESS, V50, P338, DOI 10.1016/j.cep.2010.09.017
   Mousavichoubeh M, 2011, CHEM ENG SCI, V66, P5330, DOI 10.1016/j.ces.2011.07.019
   Olsson E, 2005, J COMPUT PHYS, V210, P225, DOI 10.1016/j.jcp.2005.04.007
   Osher S., 2003, LEVEL SET METHODS DY
   Pillai R, 2017, CHEM ENG SCI, V169, P273, DOI 10.1016/j.ces.2016.07.022
   Pillai R., 2015, 11 INT C CFD MIN PRO
   Ristenpart WD, 2009, NATURE, V461, P377, DOI 10.1038/nature08294
   ROMMEL W, 1992, SEPAR SCI TECHNOL, V27, P129, DOI 10.1080/01496399208018870
   Saranin VA, 2011, J EXP THEOR PHYS+, V112, P896, DOI 10.1134/S1063776111040212
   Sethian J.A., 1999, LEVEL SET METHODS FA
   Shadloo MS, 2013, COMPUT MECH, V52, P693, DOI 10.1007/s00466-013-0841-z
   Sun DZ, 1999, COLLOID SURFACE A, V150, P69
   TAYLOR G, 1964, PROC R SOC LON SER-A, V280, P383, DOI 10.1098/rspa.1964.0151
   Taylor SE, 1996, CHEM ENG RES DES, V74, P526
   Teigen K.E., 2008, CFD2008 6 INT C COMP
   Tian HM, 2011, ELECTROPHORESIS, V32, P2245, DOI 10.1002/elps.201100036
   Vivacqua V, 2016, CHEM ENG RES DES, V114, P180, DOI 10.1016/j.cherd.2016.08.019
   Vivacqua V, 2015, CHEM ENG RES DES, V104, P658, DOI 10.1016/j.cherd.2015.10.006
   Wang JF, 2014, SCI REP-UK, V4, DOI 10.1038/srep07123
   Wang ZT, 2018, AIP ADV, V8, DOI 10.1063/1.5045747
   Yu K, 2018, J COLLOID INTERF SCI, V527, P346, DOI 10.1016/j.jcis.2018.05.035
   Yue PT, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2364144
NR 55
TC 2
Z9 2
U1 21
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115360
DI 10.1016/j.ces.2019.115360
PG 14
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600004
DA 2020-05-12
ER

PT J
AU Li, C
   Lin, J
   Shen, LM
   Bao, NZ
AF Li, Chang
   Lin, Jie
   Shen, Liming
   Bao, Ningzhong
TI Quantitative analysis and kinetic modeling of ultrasound-assisted
   exfoliation and breakage process of graphite oxide
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Graphene oxide; Ultrasonic exfoliation; Relative single-layer fraction;
   Lateral size distribution; Kapur function
ID WALLED CARBON NANOTUBES; GRAPHENE OXIDE; CHEMICAL ROUTE; SIZE;
   DISPERSIONS; MECHANISMS; LENGTH; SONOFRAGMENTATION; IDENTIFICATION;
   VISCOSITY
AB Ultrasonic exfoliation is the most widely used delamination technique for producing graphene oxide. In this work, the exfoliation of graphite oxide suspension is conveniently monitored via real-time measurement of viscosity and then quantitatively described by using the relative single-layer fraction (alpha) for the first time, by which the full exfoliation is achieved with a time scale of minutes. Lateral size evolution is demonstrated using lognormal distribution based on statistical analysis. With the quantization of relative single-layer fraction and lateral size distribution, a prototype database has been built to efficiently integrate experimental data tested under different process conditions (suspension concentration, ultrasonic frequency, and ultrasonic power density), which can be used as reference guides for process optimization and product control. The selection and breakage functions (S-i and B-ij) of ultrasound-assisted exfoliation are calculated and the breakage mechanisms of graphite oxide are found attributed mainly to sheet fracture. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Li, Chang; Lin, Jie; Shen, Liming; Bao, Ningzhong] Nanjing Tech Univ, Coll Chem Engn, State Key Lab Mat Oriented Chem Engn, Nanjing 210009, Jiangsu, Peoples R China.
   [Bao, Ningzhong] Jiangsu Ind Technol Res Inst, Inst Graphene, Nanjing 210009, Jiangsu, Peoples R China.
RP Shen, LM; Bao, NZ (reprint author), Nanjing Tech Univ, Coll Chem Engn, State Key Lab Mat Oriented Chem Engn, Nanjing 210009, Jiangsu, Peoples R China.
EM lshen@njtech.edu.cn; nzhbao@njtech.edu.cn
RI Li, Chang/A-8690-2019
OI Li, Chang/0000-0003-1341-2672
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51425202, 51772150]; Key Research and Development
   Program of Jiangsu Province [BE2017006-4, BE2018008-1]; Natural Science
   Foundation of Jiangsu ProvinceJiangsu Planned Projects for Postdoctoral
   Research FundsNatural Science Foundation of Jiangsu Province
   [BK20160093]; Priority Academic Program Development of Jiangsu Higher
   Education Institutions (PAPD)
FX This research was supported by the National Natural Science Foundation
   of China (No. 51425202, No. 51772150), the Key Research and Development
   Program of Jiangsu Province (No. BE2017006-4, No. BE2018008-1), the
   Natural Science Foundation of Jiangsu Province (No. BK20160093), and the
   Project Funded by the Priority Academic Program Development of Jiangsu
   Higher Education Institutions (PAPD).
CR Alzorqi I, 2015, AICHE J, V61, P1483, DOI 10.1002/aic.14776
   Bao NZ, 2004, J MATER SCI, V39, P469, DOI 10.1023/B:JMSC.0000011500.98619.0c
   Berthiaux H, 1996, CHEM ENG SCI, V51, P4509, DOI 10.1016/0009-2509(96)00275-8
   Brotchie A, 2009, PHYS REV LETT, V102, DOI 10.1103/PhysRevLett.102.084302
   Bunch JS, 2008, NANO LETT, V8, P2458, DOI 10.1021/nl801457b
   Chen J, 2015, CARBON, V81, P826, DOI 10.1016/j.carbon.2014.10.033
   Chua CK, 2014, CHEM SOC REV, V43, P291, DOI 10.1039/c3cs60303b
   Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849
   Ghosh S, 2010, NAT MATER, V9, P555, DOI [10.1038/NMAT2753, 10.1038/nmat2753]
   Gilje S, 2007, NANO LETT, V7, P3394, DOI 10.1021/nl0717715
   Hagenson LC, 1998, CHEM ENG SCI, V53, P131, DOI 10.1016/S0009-2509(97)00193-0
   He DF, 2014, AICHE J, V60, P2757, DOI 10.1002/aic.14499
   Hennart SLA, 2009, CHEM ENG SCI, V64, P4123, DOI 10.1016/j.ces.2009.06.031
   Huang X, 2012, CHEM SOC REV, V41, P666, DOI 10.1039/c1cs15078b
   Hung AH, 2014, ACS NANO, V8, P10168, DOI 10.1021/nn502986e
   Jordens J, 2016, CRYST GROWTH DES, V16, P6167, DOI 10.1021/acs.cgd.6b00088
   Joshi RK, 2014, SCIENCE, V343, P752, DOI 10.1126/science.1245711
   KAPUR PC, 1970, CHEM ENG SCI, V25, P1111, DOI 10.1016/0009-2509(70)85055-2
   Kim HN, 2017, CHEM-EUR J, V23, P2778, DOI 10.1002/chem.201605857
   Kim HW, 2013, SCIENCE, V342, P91, DOI 10.1126/science.1236098
   Kim SG, 2017, CARBON, V125, P280, DOI 10.1016/j.carbon.2017.09.054
   Kumar P, 2014, CARBON, V80, P453, DOI 10.1016/j.carbon.2014.08.085
   Li C, 2019, CHEM ENG SCI, V200, P127, DOI 10.1016/j.ces.2019.01.045
   Li C, 2018, CHEM ENG SCI, V176, P319, DOI 10.1016/j.ces.2017.10.028
   Lin XY, 2012, ACS NANO, V6, P10708, DOI 10.1021/nn303904z
   Liscio A, 2017, 2D MATER, V4, DOI 10.1088/2053-1583/aa57ff
   Medhekar NV, 2010, ACS NANO, V4, P2300, DOI 10.1021/nn901934u
   MENACHO JM, 1986, POWDER TECHNOL, V49, P87, DOI 10.1016/0032-5910(86)85010-0
   Merouani S, 2013, ULTRASON SONOCHEM, V20, P815, DOI 10.1016/j.ultsonch.2012.10.015
   Mkhoyan KA, 2009, NANO LETT, V9, P1058, DOI 10.1021/nl8034256
   Mueller S, 2010, P ROY SOC A-MATH PHY, V466, P1201, DOI 10.1098/rspa.2009.0445
   Narayan R, 2016, ADV MATER, V28, P3045, DOI [10.1002/adma.201505122, 10.1002/adma.201670110]
   Ogino I, 2014, CHEM MATER, V26, P3334, DOI 10.1021/cm501305c
   Pan SY, 2011, ACS NANO, V5, P4073, DOI 10.1021/nn200666r
   Paredes JI, 2008, LANGMUIR, V24, P10560, DOI 10.1021/la801744a
   Park S, 2009, NAT NANOTECHNOL, V4, P217, DOI [10.1038/nnano.2009.58, 10.1038/NNANO.2009.58]
   Parra-Vasquez ANG, 2007, MACROMOLECULES, V40, P4043, DOI 10.1021/ma062003n
   Parra-Vasquez ANG, 2014, AICHE J, V60, P1499, DOI 10.1002/aic.14325
   Partoens B, 2006, PHYS REV B, V74, DOI 10.1103/PhysRevB.74.075404
   Pokhrel N, 2016, ULTRASON SONOCHEM, V29, P104, DOI 10.1016/j.ultsonch.2015.07.023
   Potapov AV, 1997, POWDER TECHNOL, V93, P13, DOI 10.1016/S0032-5910(97)03242-7
   Raccichini R, 2015, NAT MATER, V14, P271, DOI 10.1038/nmat4170
   Raman V, 2011, AICHE J, V57, P2025, DOI 10.1002/aic.12415
   Stafford J, 2018, AICHE J, V64, P3246, DOI 10.1002/aic.16174
   Stankovich S, 2006, CARBON, V44, P3342, DOI 10.1016/j.carbon.2006.06.004
   Su CL, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2315
   Su CY, 2009, CHEM MATER, V21, P5674, DOI 10.1021/cm902182y
   Talyzin AV, 2017, CARBON, V115, P430, DOI 10.1016/j.carbon.2016.12.097
   Tao Y, 2014, ULTRASON SONOCHEM, V21, P1461, DOI 10.1016/j.ultsonch.2014.01.029
   Thompson LH, 1999, IND ENG CHEM RES, V38, P1215, DOI 10.1021/ie9804172
   Titelman GI, 2005, CARBON, V43, P641, DOI 10.1016/j.carbon.2004.10.035
   Toch K, 2015, AICHE J, V61, P880, DOI 10.1002/aic.14680
   Varinot C, 1997, CHEM ENG SCI, V52, P3605, DOI 10.1016/S0009-2509(97)89693-5
   Wang Y, 2010, J AM CHEM SOC, V132, P9274, DOI 10.1021/ja103169v
   Xia ZY, 2013, ADV FUNCT MATER, V23, P4684, DOI 10.1002/adfm.201203686
   Xiouras C, 2018, CRYST GROWTH DES, V18, P3051, DOI 10.1021/acs.cgd.8b00201
   Xu HX, 2013, CHEM SOC REV, V42, P2555, DOI 10.1039/c2cs35282f
   Yao YB, 2014, MACROMOLECULES, V47, P3093, DOI 10.1021/ma5003497
   Zeiger BW, 2011, J AM CHEM SOC, V133, P14530, DOI 10.1021/ja205867f
   Zhang L, 2009, CARBON, V47, P3365, DOI 10.1016/j.carbon.2009.07.045
   Zhao JP, 2010, ACS NANO, V4, P5245, DOI 10.1021/nn1015506
   Zhou YN, 2015, AICHE J, V61, P1947, DOI 10.1002/aic.14792
NR 62
TC 0
Z9 0
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115414
DI 10.1016/j.ces.2019.115414
PG 13
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600027
DA 2020-05-12
ER

PT J
AU Liu, L
   Wang, K
   Bai, BF
AF Liu, Li
   Wang, Ke
   Bai, Bofeng
TI Comparative investigation of liquid film thickness and interfacial wave
   properties of swirling gas-liquid flows
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Swirling gas-liquid flow; Liquid film thickness; Interfacial wave
   properties; Image processing; Statistical analysis
ID WATER 2-PHASE FLOW; CRITICAL HEAT-FLUX; ANNULAR-FLOW; SEPARATION
   PERFORMANCE; PRESSURE-DROP; SLUG FLOW; PATTERN; TUBE; COCURRENT
AB The liquid film in swirling flows plays an important role in mass, momentum and heat transfer, whose properties differ from those in non-swirling regimes. In this paper, we employ the image processing and statistical analysis to compare the liquid film thickness and wave properties of swirling gas column, swirling intermittent and swirling annular flow. The results indicate that the film thickness is intimately linked to the flow regimes, i.e., uniform in swirling gas column flow, gradual thickening in swirling intermittent flow, and increasing up to a maximum point and decreasing thereafter in swirling annular flow. Additionally, the wave frequency is proportional to j(g) but inversely proportional to j(l) in swirling gas column flow, which is to the contrary in swirling intermittent flow. In swirling annular flow, the waves show less correlation at a finite time and the frequency decreases with j(g), but the influence of j(l) depends on flow distance. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Li] Shanghai Jiao Tong Univ, Sch Nucl Sci & Engn, Shanghai 200240, Peoples R China.
   [Liu, Li; Bai, Bofeng] Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Xian 710049, Shaanxi, Peoples R China.
   [Wang, Ke] China Univ Petr, Beijing Key Lab Proc Fluid Filtrat & Separat, Beijing 102249, Peoples R China.
RP Bai, BF (reprint author), Xi An Jiao Tong Univ, State Key Lab Multiphase Flow Power Engn, Xian 710049, Shaanxi, Peoples R China.
EM bfbai@mail.xjtu.edu.cn
RI Wang, Ke/L-1921-2015
OI Wang, Ke/0000-0002-7447-2356
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51906147]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2019T120341,
   2019M651495]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 51906147). L. Liu was also supported by the China
   Postdoctoral Science Foundation (Grant No. 2019T120341 and 2019M651495).
CR Alamu MB, 2011, NUCL ENG DES, V241, P5079, DOI 10.1016/j.nucengdes.2011.08.015
   Baghernejad Y, 2019, INT J MULTIPHAS FLOW, V111, P101, DOI 10.1016/j.ijmultiphaseflow.2018.11.012
   Belt RJ, 2010, INT J MULTIPHAS FLOW, V36, P570, DOI 10.1016/j.ijmultiphaseflow.2010.03.004
   Chang SW, 2009, EXP THERM FLUID SCI, V33, P1087, DOI 10.1016/j.expthermflusci.2009.06.005
   FRYER PJ, 1982, INT J MULTIPHAS FLOW, V8, P285, DOI 10.1016/0301-9322(82)90037-4
   Funahashi H, 2018, NUCL ENG DES, V330, P97, DOI 10.1016/j.nucengdes.2018.01.043
   Funahashi H, 2016, NUCL ENG DES, V308, P205, DOI 10.1016/j.nucengdes.2016.08.030
   Hamdani A, 2016, J MECH SCI TECHNOL, V30, P3897, DOI 10.1007/s12206-016-0801-6
   Hreiz R, 2014, CHEM ENG RES DES, V92, P2231, DOI 10.1016/j.cherd.2014.02.029
   Hreiz R, 2014, INT J MULTIPHAS FLOW, V58, P15, DOI 10.1016/j.ijmultiphaseflow.2013.08.006
   Imao S, 1996, INT J HEAT FLUID FL, V17, P444, DOI 10.1016/0142-727X(96)00057-4
   Jafari M, 2017, APPL THERM ENG, V124, P883, DOI 10.1016/j.applthermaleng.2017.06.095
   Kanizawa FT, 2012, INT J MULTIPHAS FLOW, V47, P50, DOI 10.1016/j.ijmultiphaseflow.2012.07.003
   KATAOKA H, 2008, J POWER ENERGY SYST, V2, P1120
   Kataoka H, 2009, J ENG GAS TURB POWER, V131, DOI 10.1115/1.3078701
   Kim CH, 2005, INT J HEAT MASS TRAN, V48, P2868, DOI 10.1016/j.ijheatmasstransfer.2005.01.039
   Kohler W., 1986, P 8 INT HEAT TRANSF, V5, P2861
   Liang FC, 2017, AICHE J, V63, P2348, DOI 10.1002/aic.15570
   Liu L, 2020, INT J MULTIPHAS FLOW, V122, DOI 10.1016/j.ijmultiphaseflow.2019.103113
   Liu L, 2019, CHEM ENG SCI, V199, P405, DOI 10.1016/j.ces.2019.01.039
   Liu L, 2019, CHEM ENG SCI, V199, P588, DOI 10.1016/j.ces.2019.01.037
   Liu L, 2017, INTERFACIAL PHENOM H, V5, P9, DOI 10.1615/InterfacPhenomHeatTransfer.2018021108
   Liu L, 2016, NUCL ENG DES, V298, P229, DOI 10.1016/j.nucengdes.2016.01.001
   Liu LN, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.2.025003
   Liu W., 2014, P ASME FEDSM 2014 CH
   Liu W, 2019, CHEM ENG SCI, V202, P392, DOI 10.1016/j.ces.2019.03.058
   Liu XF, 2015, INT J MULTIPHAS FLOW, V73, P227, DOI 10.1016/j.ijmultiphaseflow.2015.03.012
   Matas JP, 2014, PHYS FLUIDS, V26, DOI 10.1063/1.4871395
   Matsubayashi T, 2012, NUCL ENG DES, V249, P63, DOI 10.1016/j.nucengdes.2011.05.036
   NAMIE S, 1993, INT J MULTIPHAS FLOW, V19, P91, DOI 10.1016/0301-9322(93)90025-P
   Namie S., 1991, 3RD ASME JSME THERM, V2, P223
   Ng SY, 2006, CHEM ENG RES DES, V84, P884, DOI [10.1205/cherd05063, 10.1205/cherd.05063]
   Ofuchi CY, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19010193
   Park Y, 2010, NUCL ENG DES, V240, P3405, DOI 10.1016/j.nucengdes.2010.07.015
   Raeiszadeh F, 2018, CHEM ENG RES DES, V137, P10, DOI 10.1016/j.cherd.2018.07.002
   Raeiszadeh F, 2016, INT J MULTIPHAS FLOW, V81, P1, DOI 10.1016/j.ijmultiphaseflow.2016.01.002
   Rocha AD, 2015, INT J HEAT FLUID FL, V53, P81, DOI 10.1016/j.ijheatfluidflow.2015.02.003
   Shakutsui H, 2010, JPN J MULTIPHASE FLO, V24, P305
   Takeshima K., 2002, Heat Transfer-Asian Research, V31, P639, DOI 10.1002/htj.10066
   Takeshima K., 2002, Heat Transfer-Asian Research, V31, P652, DOI 10.1002/htj.10067
   TOMIDA T, 1987, IND ENG CHEM RES, V26, P1472, DOI 10.1021/ie00067a034
   WHALLEY PB, 1979, INT J MULTIPHAS FLOW, V5, P211, DOI 10.1016/0301-9322(79)90018-1
   WHALLEY PB, 1980, INT J MULTIPHAS FLOW, V6, P345, DOI 10.1016/0301-9322(80)90026-9
   Xiong ZQ, 2014, ANN NUCL ENERGY, V63, P138, DOI 10.1016/j.anucene.2013.07.026
   Yue T, 2019, CHEM ENG J, V358, P806, DOI 10.1016/j.cej.2018.10.018
   Zadrazil I, 2014, INT J MULTIPHAS FLOW, V60, P87, DOI 10.1016/j.ijmultiphaseflow.2013.11.008
   Zhang Z., 2018, ADV MECH ENG, V10, P1, DOI DOI 10.1109/TGRS.2018.2830100
   Zhou C, 2019, J PETROL SCI ENG, V173, P965, DOI 10.1016/j.petrol.2018.10.091
NR 48
TC 1
Z9 1
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115407
DI 10.1016/j.ces.2019.115407
PG 14
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600022
DA 2020-05-12
ER

PT J
AU Lv, L
   Zhang, J
   Xu, JC
AF Lv, Li
   Zhang, Jun
   Xu, Junchao
TI Microscopic visualization of heterogeneous nucleation process on smooth
   spherical particle: Method and results
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Heterogeneous nucleation; Super-hydrophobic/fine particle surface;
   Microscopic visualization; Environmental Scanning Electron Microscopy
   (ESEM); Supersaturation
ID WATER-VAPOR; FINE PARTICLES; SUBMICROMETER PARTICLES; FLUE-GAS;
   CONDENSATION; SIO2; AGGLOMERATION; CIRCULATION; ACTIVATION; REMOVAL
AB Heterogeneous nucleation is a very fundamental step in vapor condensation. However, it is scarcely possible to directly visualize the nucleation process because it is very quick and complicated. In present work, a method is proposed to create a mixed surface, where the hydrophilic SiO2 particle is dispersed on the super-hydrophobic substrate for a direct visualization of the nucleation process. The time-resolved images are recorded by Environmental Scanning Electron Microscopy (ESEM) system. The results indicate that only one embryo drop forms at a random point of a single particle surface and subsequently grows up and finally wraps the single particle. For multiple particles, the embryo drop occurs on the junction of particles and continues to enlarge to finally wrap all the particles. The numerical analysis shows that the nucleation ability of SiO2 is qualitatively consistent with the theoretical prediction, and quantitatively, the experimental S-cr is much smaller than the predicted results. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lv, Li; Zhang, Jun] Southeast Univ, Key Lab Energy Thermal Convers & Control, Minist Educ, Nanjing 210096, Peoples R China.
   [Xu, Junchao] Anhui Univ Technol, Sch Energy & Environm, Maanshan 243002, Peoples R China.
RP Zhang, J (reprint author), Southeast Univ, Key Lab Energy Thermal Convers & Control, Minist Educ, Nanjing 210096, Peoples R China.
EM junzhang@seu.edu.cn
RI Xu, Junchao/S-7444-2017
OI Xu, Junchao/0000-0002-1179-741X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51576043]; Research Innovation Program for College
   Graduates of Jiangsu Province, China [KYLX16_0202]; Major State Basic
   Research Development Program of ChinaNational Basic Research Program of
   China [2013CB228504]
FX The authors would like to acknowledge the research grant from National
   Natural Science Foundation of China (No.51576043), the Research
   Innovation Program for College Graduates of Jiangsu Province, China
   (KYLX16_0202), and the Major State Basic Research Development Program of
   China (No. 2013CB228504).
CR Abyzov AS, 2013, J CHEM PHYS, V138, DOI 10.1063/1.4802201
   Bao JJ, 2013, FUEL, V108, P73, DOI 10.1016/j.fuel.2010.12.037
   Chen C., 1993, J COLLOID INTERF SCI, V157, P456
   CHEN CC, 1993, IND ENG CHEM RES, V32, P1509, DOI 10.1021/ie00019a027
   Chen CC, 1998, J COLLOID INTERF SCI, V198, P354, DOI 10.1006/jcis.1997.5298
   Chen CC, 2000, J CHEM PHYS, V112, P9967, DOI 10.1063/1.481633
   Cui L, 2018, APPL ENERG, V225, P656, DOI 10.1016/j.apenergy.2018.04.084
   de Joannon M, 2013, FUEL PROCESS TECHNOL, V107, P113, DOI 10.1016/j.fuproc.2012.10.004
   de la Mora JF, 2011, AEROSOL SCI TECH, V45, P543, DOI 10.1080/02786826.2010.550341
   Fan FX, 2009, CHEM ENG PROCESS, V48, P1353, DOI 10.1016/j.cep.2009.06.011
   Fan Y, 2013, CHEM ENG SCI, V102, P387, DOI 10.1016/j.ces.2013.08.040
   FLETCHER NH, 1958, J CHEM PHYS, V29, P572, DOI 10.1063/1.1744540
   Glushchuk A, 2017, INT J HEAT MASS TRAN, V108, P2130, DOI 10.1016/j.ijheatmasstransfer.2017.01.067
   He YP, 2019, ATMOS ENVIRON, V197, P141, DOI 10.1016/j.atmosenv.2018.10.035
   Hogrefe OV, 2002, AEROSOL SCI TECH, V36, P239, DOI 10.1080/027868202753504092
   KUSAKA I, 1995, J CHEM PHYS, V103, P8993, DOI 10.1063/1.470089
   Lazaridis M, 2000, ATMOS RES, V55, P103, DOI 10.1016/S0169-8095(00)00059-4
   [刘锦辉 Liu Jinhui], 2011, [燃料化学学报, Journal of Fuel Chemistry and Technology], V39, P1, DOI 10.1016/S1872-5813(11)60007-8
   Oberli L, 2014, ADV COLLOID INTERFAC, V210, P47, DOI 10.1016/j.cis.2013.10.018
   Olga V.S., 2000, NEW APPARATUS F STUD
   PORSTENDORFER J, 1985, AEROSOL SCI TECH, V4, P65, DOI 10.1080/02786828508959039
   Smorodin VY, 2006, ATMOS RES, V82, P591, DOI 10.1016/j.atmosres.2006.02.015
   Tammaro M, 2012, CHEM ENG SCI, V74, P124, DOI 10.1016/j.ces.2012.02.023
   Varanasi KK, 2009, APPL PHYS LETT, V95, DOI 10.1063/1.3200951
   Volmer M, 1926, Z PHYS CHEM-STOCH VE, V119, P277
   Wang ZT, 2019, ATMOS POLLUT RES, V10, P759, DOI 10.1016/j.apr.2018.12.003
   Wang ZT, 2017, APPL THERM ENG, V118, P765, DOI 10.1016/j.applthermaleng.2017.03.007
   Wu H, 2016, ENERG FUEL, V30, P6103, DOI 10.1021/acs.energyfuels.6b00673
   Xu JC, 2017, CHEM ENG J, V330, P979, DOI 10.1016/j.cej.2017.08.047
   Xu JC, 2017, POWDER TECHNOL, V305, P71, DOI 10.1016/j.powtec.2016.09.078
   Yan JP, 2016, CHEM ENG J, V290, P319, DOI 10.1016/j.cej.2016.01.075
   Yang LJ, 2010, CHEM ENG J, V156, P25, DOI 10.1016/j.cej.2009.09.026
   Yu Y, 2019, ENVIRON RES, V169, P173, DOI 10.1016/j.envres.2018.11.010
   Zhang H, 2018, PARTICUOLOGY, V38, P71, DOI 10.1016/j.partic.2017.06.002
NR 34
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115411
DI 10.1016/j.ces.2019.115411
PG 11
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600025
DA 2020-05-12
ER

PT J
AU Ma, PC
   Liang, D
   Zhu, CY
   Fu, TT
   Ma, YG
AF Ma, Pengcheng
   Liang, Di
   Zhu, Chunying
   Fu, Taotao
   Ma, Youguang
TI An effective method to facile coalescence of microdroplet in the
   symmetrical T-junction with expanded convergence
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Microchannel; Droplet; Coalescence; Flow patterns
ID EQUAL-SIZED DROPS; IONIC LIQUIDS; FLOW; MICROCHANNEL; DEFORMATION;
   BREAKUP; EXTRACTION; DYNAMICS; DEVICES
AB The coalescence process of microdroplets in the expanded convergence of symmetrical T-junction was investigated. Five types of droplet coalescence regimes were observed. The existence of expanded convergence slows down the moving speed of droplets, which accordingly allows a certain time difference between the two microdroplets arriving at the convergence for coalescence, and the maximum allowable arriving time difference of the two droplets was predicted. The passive coalescence of two droplets is mainly described by the liquid film draining model. The critical capillary number (Ca-c), which determines whether symmetrical colliding droplets would coalesce, decreases with the increase of the viscosity of the dispersed phase, it means that the increase of the viscosity of dispersed phase is not conducive to coalescence. A correlation equation was proposed to predict the critical capillary number, which may provide valuable guidance for the design and application of microdevices. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ma, Pengcheng; Liang, Di; Zhu, Chunying; Fu, Taotao; Ma, Youguang] Tianjin Univ, Sch Chem Engn & Technol, State Key Lab Chem Engn, Tianjin 300072, Peoples R China.
   [Ma, Pengcheng] Wanhua Chem Grp Co Ltd, Yantai 264002, Shandong, Peoples R China.
RP Zhu, CY; Ma, YG (reprint author), Tianjin Univ, Sch Chem Engn & Technol, State Key Lab Chem Engn, Tianjin 300072, Peoples R China.
EM zhchy971@tju.edu.cn; ygma@tju.edu.cn
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China [21576186, 21776200, 91634105]; aid of Opening
   Project of State Key Laboratory of Chemical Engineering, China
   [SKL-ChE-17B02]
FX The work was supported by the National Nature Science Foundation of
   China (Nos. 21576186, 21776200, 91634105), and the aid of Opening
   Project of State Key Laboratory of Chemical Engineering, China (No.
   SKL-ChE-17B02).
CR Baldessari F, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2158427
   Baldessari F, 2007, J COLLOID INTERF SCI, V307, P188, DOI 10.1016/j.jcis.2006.11.018
   Baroud CN, 2007, LAB CHIP, V7, P1029, DOI 10.1039/b702472j
   Baroud CN, 2010, LAB CHIP, V10, P2032, DOI 10.1039/c001191f
   Belder D, 2005, ANGEW CHEM INT EDIT, V44, P3521, DOI 10.1002/anie.200500620
   Christopher GF, 2009, LAB CHIP, V9, P1102, DOI 10.1039/b813062k
   Cubaud T, 2004, PHYS FLUIDS, V16, P4575, DOI 10.1063/1.1813871
   Du Z, 2007, CHEM-EUR J, V13, P2130, DOI 10.1002/chem.200601234
   Egatz-Gomez A, 2007, APPL SURF SCI, V254, P330, DOI 10.1016/j.apsusc.2007.07.121
   Frenz L, 2008, ANGEW CHEM INT EDIT, V47, P6817, DOI 10.1002/anie.200801360
   Fu TT, 2012, CHEM ENG SCI, V84, P207, DOI 10.1016/j.ces.2012.08.039
   Fu TT, 2010, MICROFLUID NANOFLUID, V8, P467, DOI 10.1007/s10404-009-0471-0
   Gunes DZ, 2010, J COLLOID INTERF SCI, V343, P79, DOI 10.1016/j.jcis.2009.11.035
   Guo RW, 2019, CHEM ENG J, V373, P1203, DOI 10.1016/j.cej.2019.05.124
   Hallett JP, 2011, CHEM REV, V111, P3508, DOI 10.1021/cr1003248
   Hu YT, 2000, PHYS FLUIDS, V12, P484, DOI 10.1063/1.870254
   Jin BJ, 2010, J MICROMECH MICROENG, V20, DOI 10.1088/0960-1317/20/3/035003
   Kang MG, 2004, ETRI J, V26, P647, DOI 10.4218/etrij.04.0103.0152
   Kilpelainen I, 2007, J AGR FOOD CHEM, V55, P9142, DOI 10.1021/jf071692e
   Kohler JM, 2004, CHEM ENG J, V101, P201, DOI 10.1016/j.cej.2003.11.025
   Leshansky AM, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3078515
   Liao YX, 2010, CHEM ENG SCI, V65, P2851, DOI 10.1016/j.ces.2010.02.020
   Lin SCS, 2012, LAB CHIP, V12, P2766, DOI [10.1039/C2LC90076A, 10.1039/c2lc90076a]
   Link DR, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.054503
   Liu K, 2007, MICROFLUID NANOFLUID, V3, P239, DOI 10.1007/s10404-006-0121-8
   Liu ZM, 2015, EXP FLUIDS, V56, DOI 10.1007/s00348-015-1901-2
   Ma R, 2018, J IND ENG CHEM, V65, P272, DOI 10.1016/j.jiec.2018.04.038
   Mazutis L, 2009, ANAL CHEM, V81, P4813, DOI 10.1021/ac900403z
   Hoang PH, 2011, J AM CHEM SOC, V133, P14765, DOI 10.1021/ja2054429
   Rother MA, 2001, PHYS FLUIDS, V13, P1178, DOI 10.1063/1.1358871
   Song CE, 2000, CHEM COMMUN, P1743, DOI 10.1039/b004645k
   Song H, 2003, ANGEW CHEM INT EDIT, V42, P768, DOI 10.1002/anie.200390203
   Song H, 2006, ANAL CHEM, V78, P4839, DOI 10.1021/ac0601718
   Tan YC, 2004, LAB CHIP, V4, P292, DOI 10.1039/b403280m
   Tan YC, 2007, MICROFLUID NANOFLUID, V3, P495, DOI 10.1007/s10404-006-0136-1
   Teh SY, 2008, LAB CHIP, V8, P198, DOI 10.1039/b715524g
   Utada AS, 2005, SCIENCE, V308, P537, DOI 10.1126/science.1109164
   Visser AE, 2001, CHEM COMMUN, P135, DOI 10.1039/b008041l
   Wang K, 2013, CHEM ENG J, V227, P90, DOI 10.1016/j.cej.2012.09.060
   Wang K, 2013, AICHE J, V59, P643, DOI 10.1002/aic.13825
   Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058
   Yang H, 2001, PHYS FLUIDS, V13, P1087, DOI 10.1063/1.1358873
   Yang L, 2012, MICROFLUID NANOFLUID, V12, P715, DOI 10.1007/s10404-011-0912-4
   Yeo LY, 2003, J COLLOID INTERF SCI, V257, P93, DOI 10.1016/S0021-9797(02)00033-4
   Yoon Y, 2005, J FLUID MECH, V525, P355, DOI 10.1017/S0022112004002824
   Zagnoni M, 2009, LAB CHIP, V9, P2652, DOI 10.1039/b906298j
   Zhu CY, 2018, CHEM ENG TECHNOL, V41, P541, DOI 10.1002/ceat.201600658
NR 47
TC 0
Z9 0
U1 21
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115389
DI 10.1016/j.ces.2019.115389
PG 11
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600014
DA 2020-05-12
ER

PT J
AU Morsch, P
   Ginisty, P
   Anlauf, H
   Nirschl, H
AF Morsch, Patrick
   Ginisty, Pascal
   Anlauf, Harald
   Nirschl, Hermann
TI Factors influencing backwashing operation in the liquid phase after cake
   filtration
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Regeneration filter; Backwashing filter; Filter cake discharge; Liquid
   discharge; Filter cake thickness; Cohesion; Adhesion
ID FILTER MEDIA
AB The separation of solids from process streams takes place in almost every process plant. In particular, cake-forming filtration in the liquid environment is advancing as a widespread method of separating low-concentration suspensions from their solids content and offers energy advantages over other separation principles. In addition to the actual separation performance, the filter fabrics must be regularly replaced or regenerated. The reason for this is the growing resistance because of the increasing filter cake thicknesses. Considering the reduction of disposable products, the regeneration of the fabrics is an interesting possibility to reduce costs and to guarantee a stable process control. This can be achieved by means of filter cake discharge. In the course of this regeneration, the filter cake should be discharged as completely as possible so that the fabric reaches the required initial filtrate flow of the previous filtration cycle again.
   Investigations concerning cake discharge have shown that the regeneration step can be divided into different discharge mechanisms (complete, partial, resuspended) which result in different cleaning qualities. In the context of this study, backwashing processes with different backwashing parameters (pressure, cake thickness) as well as different particle shapes and their influence on the regeneration quality of filter fabrics are presented and discussed.
   The focus of this work is the investigation of the backwashing process "cake discharge" as a subsequent and necessary step in cake-forming filtration. Within the scope of this study, a test setup was designed which allows the variation of different process variables and tissue-particle combinations. The experimental setup is kept simple and allows easy reproduction of experiments. The aim is the integrated consideration of the influencing variables on the regeneration quality. The variables cake thickness, particle shape and backwash pressure were investigated within the scope of this study.
   A significant influence of backwash quality on the examined multifilament filter fabric for particle systems <= 20 mu m can be attributed to the particle shape and filter cake thickness. Here, a good regeneration quality can be achieved after exceeding a defined filter cake resistance. This depends significantly on the specific filter cake resistance and thus determines the required cake thickness. Particle systems which, due to their shape and size, have a lower specific cake resistance therefore require a higher cake thickness for a good cleaning result. As a rule of thumb, the absolute filter cake resistance can be estimated with >= 4 . 10(10) m(-1). A possible influence of the backwash pressure was investigated and can be denied in the range of 0.1-2 bar. The necessary backwash volume in l/m(2) was constant over this pressure range. Only the regeneration time decreased, which, relative to the filtration time, is considered insignificant. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Morsch, Patrick; Anlauf, Harald; Nirschl, Hermann] Karlsruhe Inst Technol, Inst Mech Proc Engn & Mech, Proc Machines, Str Forum 8, D-76131 Karlsruhe, Germany.
   [Ginisty, Pascal] IFTS, CEOPS, Rue Marcel Pagnol, F-47510 Foulayronnes, France.
RP Morsch, P (reprint author), Karlsruhe Inst Technol, Inst Mech Proc Engn & Mech, Proc Machines, Str Forum 8, D-76131 Karlsruhe, Germany.
EM patrick.morsch@kit.edu; pascal.ginisty@ifts-sls.com;
   harald.anlauf@kit.edu; hermann.nirschl@kit.edu
FU German Federation of Industrial Research Associations (AiF) within the
   programme for promoting the Industrial Collective Research (IGF) of the
   German Ministry of Economic Affairs and Energy (BMWi) [18591 N]
FX The IGF Project 18591 N is supported via German Federation of Industrial
   Research Associations (AiF) within the programme for promoting the
   Industrial Collective Research (IGF) of the German Ministry of Economic
   Affairs and Energy (BMWi), based on a resolution of the German
   Parliament. The authors would also like to thank all colleagues and
   students for the support in writing this paper.
CR Alles C.M., 2001, PROCESS STRATEGIES C
   AMIRTHARAJAH A, 1985, WATER RES, V19, P581, DOI 10.1016/0043-1354(85)90063-6
   Burdick GM, 2005, THIN SOLID FILMS, V488, P116, DOI 10.1016/j.tsf.2005.04.112
   Charleton A.J., 1983, FILTRATION SEPARATIO, V20
   Fitzpatrick C.S., 1998, FILTR SEPARAT, V35, P1
   Leipert C., 2012, F S INT EDITION, V11
   Morris K., 1987, FILTRATION SEPARATIO, V24
   Muller H.R., 1987, FILTRATION SEPARATIO, V24
   Ripperger S., 2008, FILTRIEREN SEPARIERE, V22
   Rushton A., 1972, FILTR SEP, P9
   Rushton A., 2008, SOLID LIQUID FILTRAT
   Stahl S, 2013, SEP PURIF TECHNOL, V110, P196, DOI 10.1016/j.seppur.2013.02.003
   Stahl S, 2008, CHEM ENG TECHNOL, V31, P1577, DOI 10.1002/ceat.200800300
   Weidemann C, 2014, J FOOD ENG, V132, P29, DOI 10.1016/j.jfoodeng.2014.02.005
NR 14
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115372
DI 10.1016/j.ces.2019.115372
PG 12
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600006
DA 2020-05-12
ER

PT J
AU Cao, NYP
   Celse, B
   Guillaume, D
   Guibard, I
   Thybaut, JW
AF Ngoc-Yen-Phuong Cao
   Celse, Benoit
   Guillaume, Denis
   Guibard, Isabelle
   Thybaut, Joris W.
TI Stabilization time modeling for hydroprocessing: Identification of the
   dominant factors
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Hydrocarbon; Hydrotreating; Stabilization; Transient data
ID HYDRODENITROGENATION; HYDROCRACKING; KINETICS; HYDRODESULFURIZATION;
   RECONSTRUCTION
AB Hydroprocessing stabilization has been assessed using experimental data acquired at transient conditions. These data were obtained from a hydrotreating pilot plant in a wide range of operating conditions. It has been found that the stabilization evolution follows a first-order response and could be characterized by a stabilization time tau. A linear model was developed to relate tau to its most influential parameters. The model can then be combined with online transient data to predict the steady-state performance. By testing against new data with other feedstocks, the model has been found to provide a good prediction of the stabilization evolution and the ultimate steady-state hydrotreating performance. It is, hence, possible to "online" calculate the steady-state performance without the need to reach this steady state. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ngoc-Yen-Phuong Cao; Celse, Benoit; Guillaume, Denis; Guibard, Isabelle] IFP Energies Nouvelles, Rond Point Echangeur Solaize, BP 3, F-69360 Solaize, France.
   [Thybaut, Joris W.] Univ Ghent, Lab Chem Technol, Technol Pk 125, B-9052 Ghent, Belgium.
RP Celse, B (reprint author), IFP Energies Nouvelles, Rond Point Echangeur Solaize, BP 3, F-69360 Solaize, France.
EM benoit.celse@ifpen.fr
RI Thybaut, Joris/O-5026-2017
OI Thybaut, Joris/0000-0002-4187-7904; Celse, Benoit/0000-0002-2503-6734;
   Cao, Ngoc Yen Phuong/0000-0003-2647-1807
CR Bahmani M., 2010, IRAN J CHEM ENG, V7
   Bates D.M., 1988, NONLINEAR REGRESSION
   Becker PJ, 2015, FUEL, V139, P133, DOI 10.1016/j.fuel.2014.08.032
   Bonnardot J., 1998, KINETIC MODELLING HY
   Charon-Revellin N, 2011, OIL GAS SCI TECHNOL, V66, P479, DOI 10.2516/ogst/2010005
   de Oliveira LP, 2016, OIL GAS SCI TECHNOL, V71, DOI 10.2516/ogst/2016011
   Doukeh R, 2018, CR CHIM, V21, P277, DOI 10.1016/j.crci.2017.07.001
   Elizalde I, 2016, REACT KINET MECH CAT, V118, P299, DOI 10.1007/s11144-016-0995-8
   Elkamel A, 1999, PET SCI TECHNOL, V17, P931, DOI 10.1080/10916469908949757
   Esmaeel SA, 2016, APPL PETROCHEM RES, V6, P117, DOI 10.1007/s13203-015-0142-x
   FURNIVAL GM, 1974, TECHNOMETRICS, V16, P499, DOI 10.2307/1267601
   Jarullah AT, 2011, FUEL, V90, P2165, DOI 10.1016/j.fuel.2011.01.025
   Lababidi HMS, 2011, ENERG FUEL, V25, P1939, DOI 10.1021/ef200153p
   LAND AH, 1960, ECONOMETRICA, V28, P497, DOI 10.2307/1910129
   Garcia CL, 2010, CATAL TODAY, V150, P279, DOI 10.1016/j.cattod.2009.08.002
   Nguyen MT, 2015, IND ENG CHEM RES, V54, P9278, DOI 10.1021/acs.iecr.5b02175
   Nguyen MT, 2017, IND ENG CHEM RES, V56, P11088, DOI 10.1021/acs.iecr.7b02993
   Oyekunle LO, 2009, PETROL SCI TECHNOL, V27, P557, DOI 10.1080/10916460802104156
   Raghuveer CS, 2016, FUEL, V171, P253, DOI 10.1016/j.fuel.2015.12.042
   Sadighi S., 2013, B CHEM REACT ENG CAT, V8, DOI [10.9767/bcrec.8.2.4722.125-136, DOI 10.9767/BCREC.8.2.4722.125-136]
   Sadighi S., 2018, PET COAL, V60, P358
   Sau M, 2005, CATAL TODAY, V109, P112, DOI 10.1016/j.cattod.2005.08.007
   Schweitzer JM, 1999, CHEM ENG SCI, V54, P2441, DOI 10.1016/S0009-2509(99)00006-8
   Smith C.A., 2016, 1 COURSE DIFFERENTIA
   Tang X, 2013, OIL SHALE, V30, P517, DOI 10.3176/oil.2013.4.05
   Treese S. A., 2015, HDB PETROLEUM PROCES
   Tukey J, 1977, EXPLORATORY DATA ANA
NR 27
TC 0
Z9 0
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115392
DI 10.1016/j.ces.2019.115392
PG 10
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600016
DA 2020-05-12
ER

PT J
AU Nyalosaso, JL
   Potdevin, A
   Reveret, F
   Disseix, P
   Mahiou, R
   Chadeyron, G
AF Nyalosaso, Jeff L.
   Potdevin, Audrey
   Reveret, Francois
   Disseix, Pierre
   Mahiou, Rachid
   Chadeyron, Genevieve
TI Enhancement of light extraction in Y3Al5O12:Tb3+ thin films through
   nanopatterning
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Sol-gel process; Langmuir-Blodgett; LEDs; Surface nanostructuring; Light
   extraction
ID PHOSPHORS; EFFICIENCY; LUMINESCENCE; EXCITATION; CRYSTALS; DESIGN; LEDS
AB Light extraction is a key parameter to improve the performances of optical devices. Nanopatterned Y3Al5O12:Tb3+ luminescent coatings usable in such devices have been elaborated and have shown enhanced emission efficiency compared to their unpatterned counterparts. These nanostructured films were obtained by using the colloidal lithography combined with the Langmuir-Blodgett technique. It is the first time to our knowledge that this patterning technique is directly applied on YAG matrix. Resulting nanostructuring is a hexagonal network capable of modifying the light travelling path within the substrate. Conventional and angular-resolved photoluminescence were investigated on both unpatterned and patterned samples. Due to the nanostructuring, the extraction efficiency is improved by 26% and 131% depending on the crystallinity of the sample. Noticeably, nanostructuring is found to have an influence on the angular distribution of photoluminescence whose intensity has been evaluated to its maximum normal to the film surface. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Nyalosaso, Jeff L.; Potdevin, Audrey; Mahiou, Rachid; Chadeyron, Genevieve] Univ Clermont Auvergne, CNRS, SIGMA Clermont, ICCF, F-63000 Clermont Ferrand, France.
   [Reveret, Francois; Disseix, Pierre] Univ Clermont Auvergne, CNRS, SIGMA Clermont, Inst Pascal, F-63000 Clermont Ferrand, France.
RP Potdevin, A (reprint author), Univ Clermont Auvergne, CNRS, SIGMA Clermont, ICCF, F-63000 Clermont Ferrand, France.
EM audrey.potdevin@sigma-clermont.fr
RI Potdevin, Audrey/AAK-2046-2020
OI Potdevin, Audrey/0000-0003-4728-3952; NYALOSASO,
   Jeff/0000-0003-3753-1633
FU Region Auvergne-Rhone-AlpesRegion Auvergne-Rhone-Alpes; European
   CommunityEuropean Community (EC) [RII3-CT-2004-506008]
FX This work was supported by the Region Auvergne-Rhone-Alpes (Optilum
   project); European Community for its financial support during the access
   to VUV spectroscopy facilities DESY (Contract RII3-CT-2004-506008).
CR Ai B, 2017, ADV MATER INTERFACES, V4, DOI 10.1002/admi.201600271
   Akaltun Y, 2011, OPT COMMUN, V284, P2307, DOI 10.1016/j.optcom.2010.12.094
   Bardosova M, 2010, ADV MATER, V22, P3104, DOI 10.1002/adma.200903708
   Blasse G, 1994, LUMINESCENT MAT
   Brinker C.J., 2013, SOL GEL SCI PHYS CHE
   Cho JY, 2014, THIN SOLID FILMS, V570, P326, DOI 10.1016/j.tsf.2014.03.065
   Cho JY, 2007, THIN SOLID FILMS, V515, P3373, DOI 10.1016/j.tsf.2006.09.029
   Colson P, 2013, J NANOMATER, V2013, P21, DOI DOI 10.1155/2013/948510
   Colson P, 2011, LANGMUIR, V27, P12800, DOI 10.1021/la202284a
   Devys L, 2014, ADV OPT MATER, V2, P81, DOI 10.1002/adom.201300304
   Ding P, 2017, OPT QUANT ELECTRON, V49, DOI 10.1007/s11082-017-1035-2
   Do YR, 2005, ELECTROCHEM SOLID ST, V8, pH43, DOI 10.1149/1.1887191
   Dorenbos P, 2003, J PHYS-CONDENS MAT, V15, P6249, DOI 10.1088/0953-8984/15/36/313
   Fang CY, 2013, ADV FUNCT MATER, V23, P1412, DOI 10.1002/adfm.201201949
   Ge ZY, 2015, APPL OPTICS, V54, P6025, DOI 10.1364/AO.54.006025
   Geng C, 2014, SMALL, V10, P1668, DOI 10.1002/smll.201303599
   Gorsky S, 2019, APL PHOTONICS, V4, DOI [10.1063/1.5124302, 10.1063/1.5052637]
   Khan MA, 2019, ULTRAMICROSCOPY, V196, P1, DOI 10.1016/j.ultramic.2018.09.003
   Khanna V.K., 2014, FUNDAMENTALS SOLID S
   Kim JS, 2016, ADV OPT MATER, V4, P1081, DOI 10.1002/adom.201500734
   Ko KY, 2008, J PHYS CHEM C, V112, P7594, DOI 10.1021/jp800115r
   Kumar P, 2011, OPT COMMUN, V284, P4874, DOI 10.1016/j.optcom.2011.06.062
   Lee YK, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2763974
   Lenef A, 2018, ECS J SOLID STATE SC, V7, pR3211, DOI 10.1149/2.0271801jss
   Liang XG, 2019, ADV MATER TECHNOL-US, V4, DOI 10.1002/admt.201800541
   Mao A, 2013, OPT LETT, V38, P2796, DOI 10.1364/OL.38.002796
   Mayolet A, 1995, OPT MATER, V4, P757, DOI 10.1016/0925-3467(95)00024-0
   McKittrick J, 2014, J AM CERAM SOC, V97, P1327, DOI 10.1111/jace.12943
   Mergel D, 2000, THIN SOLID FILMS, V371, P218, DOI 10.1016/S0040-6090(00)01015-4
   Narendran N, 2005, PHYS STATUS SOLIDI A, V202, pR60, DOI 10.1002/pssa.200510015
   Park BK, 2012, J ELECTROCHEM SOC, V159, pJ96, DOI 10.1149/2.031204jes
   Park CH, 2000, J MATER SCI LETT, V19, P335, DOI 10.1023/A:1006727116993
   Piquette A, 2016, ECS J SOLID STATE SC, V5, pR3146, DOI 10.1149/2.0191601jss
   Potdevin A, 2007, J APPL PHYS, V102, DOI 10.1063/1.2784998
   Potdevin A, 2006, J NON-CRYST SOLIDS, V352, P2510, DOI 10.1016/j.jnoncrysol.2006.03.046
   Potdevin A, 2006, J MATER SCI, V41, P2201, DOI 10.1007/s10853-006-7182-7
   Potdevin A, 2016, RSC ADV, V6, P41962, DOI 10.1039/c6ra06444b
   Potdevin A, 2011, MATER CHEM PHYS, V130, P500, DOI 10.1016/j.matchemphys.2011.07.019
   Potdevin A, 2009, THIN SOLID FILMS, V517, P4610, DOI 10.1016/j.tsf.2009.02.087
   Potdevin A, 2010, DALTON T, V39, P8718, DOI [10.1039/c005452f, 10.1039/c0dt00090f]
   Potdevin A, 2010, CHEM PHYS LETT, V490, P50, DOI 10.1016/j.cplett.2010.03.003
   Reculusa S, 2003, CHEM MATER, V15, P598, DOI 10.1021/cm021242w
   Revaux A, 2011, NANOTECHNOLOGY, V22, DOI 10.1088/0957-4484/22/36/365701
   SCHNITZER I, 1993, APPL PHYS LETT, V63, P2174, DOI 10.1063/1.110575
   Shionoya S., 1998, PHOSPHOR HDB
   Sohn KS, 2004, APPL PHYS LETT, V85, P55, DOI 10.1063/1.1766392
   Sun H., 2016, IEEE PHOTONICS J, V8, P1, DOI DOI 10.HTTPS://D0I.0RG/10.1109/JPH0T.2016.2527019
   Szabo Z, 2013, PHOTONIC NANOSTRUCT, V11, P1, DOI 10.1016/j.photonics.2012.06.009
   Tian Y, 2018, SMALL METHODS, V2, DOI 10.1002/smtd.201800104
   Ulman A., 2013, INTRO ULTRATHIN ORGA
   Vogel N, 2015, CHEM REV, V115, P6265, DOI 10.1021/cr400081d
   Vogel N, 2012, SOFT MATTER, V8, P4044, DOI 10.1039/c1sm06650a
   Wang S, 2016, OPT EXPRESS, V24, P17522, DOI 10.1364/OE.24.017522
   Wang SG, 2016, SCI REP-UK, V6, DOI 10.1038/srep28872
   Yang XY, 2014, ADV FUNCT MATER, V24, P5977, DOI 10.1002/adfm.201400190
   Youn W, 2015, ACS APPL MATER INTER, V7, P8974, DOI 10.1021/acsami.5b01533
   Zhang G, 2009, CHEM-ASIAN J, V4, P236, DOI 10.1002/asia.200800298
   Zhmakin AI, 2011, PHYS REP, V498, P189, DOI 10.1016/j.physrep.2010.11.001
   Zimmerer G, 2007, RADIAT MEAS, V42, P859, DOI 10.1016/j.radmeas.2007.02.050
NR 59
TC 0
Z9 0
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115416
DI 10.1016/j.ces.2019.115416
PG 11
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600029
DA 2020-05-12
ER

PT J
AU Palodkar, AV
   Jana, AK
AF Palodkar, Avinash, V
   Jana, Amiya K.
TI Clathrate hydrate dynamics with synthetic- and bio-surfactant in porous
   media: Model formulation and validation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Clathrate hydrate; Synthetic surfactant; Biosurfactant; Formation and
   growth; Porous media; Experimental validation
ID UNSTIRRED GAS/LIQUID SYSTEM; NATURAL-GAS STORAGE; PHASE-EQUILIBRIUM;
   METHANE; CO2; KINETICS; SDS; SEPARATION; INHIBITOR; MECHANISM
AB In this contribution, we formulate a model to gain physical insight into the hydration process in presence of biosurfactant and porous media. This hydrate model addresses several practically relevant issues, including renewal of surface where hydrates form, uneven size and shape of internal pores in the porous material, hydrate formation in the interstitial and interior pore spaces of the unconsolidated porous particles, surface tension effect, and impeding nature of the salt ions present in seawater towards the hydrate formation and growth. The proposed model is illustrated by the formation and growth process of methane and carbon dioxide gases in presence of biosurfactant (the rhamnolipids solution produced from Pseudomonas aeruginosa) and porous silica gel. In addition, here we consider one of the most efficient and preferred synthetic surface active agents, namely sodium dodecyl sulfate. The proposed formulation has shown an excellent agreement (quantified with the percentage absolute average relative deviation) with the experimental data of the methane and carbon-dioxide gas hydrates formation and growth at diverse conditions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Palodkar, Avinash, V; Jana, Amiya K.] Indian Inst Technol Kharagpur, Dept Chem Engn, Energy & Proc Engn Lab, Kharagpur 721302, W Bengal, India.
RP Jana, AK (reprint author), Indian Inst Technol Kharagpur, Dept Chem Engn, Energy & Proc Engn Lab, Kharagpur 721302, W Bengal, India.
EM akjana@che.iitkgp.ac.in
OI Palodkar, Avinash V./0000-0001-8080-7354
CR Aman ZM, 2016, CHEM SOC REV, V45, P1678, DOI 10.1039/c5cs00791g
   Arora A., 2014, J PET ENV BIOTECHNOL, V5, P1
   Arora A, 2016, SCI REP-UK, V6, DOI 10.1038/srep20893
   Banat IM, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00697
   Dong HS, 2019, ACS SUSTAIN CHEM ENG, V7, P7932, DOI 10.1021/acssuschemeng.9b00651
   Duan ZH, 2006, AM MINERAL, V91, P1346, DOI 10.2138/am.2006.2017
   Erdogan ST, 2016, J MATER CIVIL ENG, V28, DOI 10.1061/(ASCE)MT.1943-5533.0001575
   Eslamimanesh A, 2012, J CHEM THERMODYN, V46, P62, DOI 10.1016/j.jct.2011.10.006
   Ganji H, 2007, FUEL, V86, P434, DOI 10.1016/j.fuel.2006.07.032
   Gayet P, 2005, CHEM ENG SCI, V60, P5751, DOI 10.1016/j.ces.2005.04.069
   HOLDER GD, 1984, ANNU REV ENERGY, V9, P427, DOI 10.1146/annurev.eg.09.110184.002235
   Kang SP, 2010, CHEM ENG SCI, V65, P1840, DOI 10.1016/j.ces.2009.11.027
   Karaaslan U, 2000, ENERG FUEL, V14, P1103, DOI 10.1021/ef000069s
   Karaaslan U, 2002, ENERG FUEL, V16, P1387, DOI 10.1021/ef0200222
   Kezirian MT, 2017, ENERGIES, V10, DOI 10.3390/en10060828
   Koh CA, 2002, CHEM SOC REV, V31, P157, DOI 10.1039/b008672j
   Kuhs WF, 2000, GEOPHYS RES LETT, V27, P2929, DOI 10.1029/2000GL006112
   Kumar A, 2015, IND ENG CHEM RES, V54, P12217, DOI 10.1021/acs.iecr.5b03476
   Kumar A, 2015, CHEM ENG SCI, V122, P78, DOI 10.1016/j.ces.2014.09.019
   Kumar A, 2014, IND ENG CHEM RES, V53, P9849, DOI 10.1021/ie5001955
   Kumar A, 2013, FUEL, V105, P664, DOI 10.1016/j.fuel.2012.10.031
   Kumar P., 2016, SCI REP, V6
   Lanoil BD, 2001, APPL ENVIRON MICROB, V67, P5143, DOI 10.1128/AEM.67.11.5143-5153.2001
   LASDON LS, 1974, REV FR AUTOMAT INFOR, V8, P73
   LEWIS MA, 1991, WATER RES, V25, P101, DOI 10.1016/0043-1354(91)90105-Y
   Li XS, 2012, ENERG FUEL, V26, P2518, DOI 10.1021/ef3000399
   Makogon YF, 2007, J PETROL SCI ENG, V56, P14, DOI 10.1016/j.petrol.2005.10.009
   Mimachi H, 2014, CHEM ENG SCI, V118, P208, DOI 10.1016/j.ces.2014.07.050
   Okutani K, 2008, CHEM ENG SCI, V63, P183, DOI 10.1016/j.ces.2007.09.012
   Palodkar AV, 2019, ENERG FUEL, V33, P1433, DOI 10.1021/acs.energyfuels.8b03245
   Palodkar AV, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34926-2
   Palodkar AV, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06717-8
   Palodkar AV, 2016, ENERG FUEL, V30, P7656, DOI 10.1021/acs.energyfuels.6b01397
   Pan Z, 2018, J NAT GAS SCI ENG, V56, P266, DOI 10.1016/j.jngse.2018.06.018
   Park KN, 2011, DESALINATION, V274, P91, DOI 10.1016/j.desal.2011.01.084
   Partoon B, 2013, ASIA-PAC J CHEM ENG, V8, P916, DOI 10.1002/apj.1736
   Ricaurte M, 2013, IND ENG CHEM RES, V52, P899, DOI 10.1021/ie3025888
   Rogers R.E., 2003, OFFSH TECHN C HOUST
   Rogers RE, 2003, CAN J CHEM ENG, V81, P973
   Ruppel C.D., 2018, GAS HYDRATE NATURE, DOI [10.3133/fs20173080, DOI 10.3133/FS20173080]
   Sassen R, 1998, GEOLOGY, V26, P851, DOI 10.1130/0091-7613(1998)026<0851:BMOISF>2.3.CO;2
   Sloan ED, 2008, CHEM IND-SER, V119, pXIX
   Sloan ED, 2003, NATURE, V426, P353, DOI 10.1038/nature02135
   Storr MT, 2004, J AM CHEM SOC, V126, P1569, DOI 10.1021/ja035243g
   Sun ZG, 2003, ENERG CONVERS MANAGE, V44, P2733, DOI 10.1016/S0196-8904(03)00048-7
   Thakre N, 2019, J PHYS CHEM A, V123, P2762, DOI 10.1021/acs.jpca.8b12335
   Thakre N, 2017, APPL ENERG, V205, P749, DOI 10.1016/j.apenergy.2017.08.083
   Torre JP, 2012, CHEM ENG SCI, V82, P1, DOI 10.1016/j.ces.2012.07.025
   Veluswamy HP, 2015, CHEM ENG SCI, V132, P202, DOI 10.1016/j.ces.2015.03.061
   Watanabe K, 2005, CHEM ENG SCI, V60, P4846, DOI 10.1016/j.ces.2005.03.043
   Zerpa LE, 2011, IND ENG CHEM RES, V50, P188, DOI 10.1021/ie100873k
   Zhang JS, 2008, J PHYS CHEM C, V112, P12381, DOI 10.1021/jp801963c
   Zhang LX, 2017, CHEM ENG J, V308, P40, DOI 10.1016/j.cej.2016.09.047
   Zhong DL, 2013, ENERG FUEL, V27, P7252, DOI 10.1021/ef401491e
NR 54
TC 0
Z9 0
U1 10
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115386
DI 10.1016/j.ces.2019.115386
PG 11
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600012
DA 2020-05-12
ER

PT J
AU Ramirez-Correa, F
   Gomez-Garcia, MA
   Dobrosz-Gomez, I
   Rojas-Sierra, CA
AF Ramirez-Correa, Fernando
   Angel Gomez-Garcia, Miguel
   Dobrosz-Gomez, Izabela
   Alberto Rojas-Sierra, Carlos
TI An adaptive WENO algorithm for one-dimensional convection-dominated
   partial differential equations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Convection-dominated PDEs; Finite volume method; WENO scheme; Adaptive
   grid refinement; Dynamic simulation
ID ESSENTIALLY NONOSCILLATORY SCHEMES; NUMERICAL-SIMULATION;
   CONSERVATION-LAWS; GRID ADAPTATION; SOLVING PDES; RESOLUTION; EFFICIENT;
   TRACKING
AB In this work, a versatile numerical algorithm was proposed for solving one-dimensional nonlinear convection-dominated partial differential equations as these found in the simulation of diverse chemical engineering applications. The proposed algorithm uses a fully adaptive scheme, in which both the grid spacing and the time discretization are dynamically adjusted. It uses a finite volume discretization with a variable number of grid cells and an explicit time integration with time-step control. The high-order Weighted Essentially Non-Oscillatory (WENO) scheme on non-uniform grid was combined with a grid refinement technique based on the equitable distribution principle and a spatial regularization procedure. The time-stepping procedure as well as some implementation issues are minutely discussed. The capability and efficiency of the new algorithm was demonstrated through the numerical simulation of five chemical engineering applications: the Viscous Burgers Equation, a Chromatographic column, the Buckley-Leverett Equation, and two examples of reaction-convection systems. For all analyzed cases, it was verified that the number of grid cells required to capture steep gradients can be greatly reduced with the proposed grid adaptation scheme. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ramirez-Correa, Fernando] Univ Cent, Fac Ingn & Ciencias Basicas, Dept Ingn Ambiental, Bogota, Colombia.
   [Angel Gomez-Garcia, Miguel] Univ Nacl Colombia, Fac Ingn & Arquitectura, Dept Ingn Quim, Sede Manizales, Colombia.
   [Dobrosz-Gomez, Izabela] Univ Nacl Colombia, Fac Ciencias Exactas & Nat, Dept Fis & Quim, Sede Manizales, Colombia.
   [Alberto Rojas-Sierra, Carlos] Univ Autonoma Manizales, Fac Ingn, Dept Fis & Matemat, Manizales, Colombia.
RP Gomez-Garcia, MA (reprint author), Univ Nacl Colombia, Fac Ingn & Arquitectura, Dept Ingn Quim, Sede Manizales, Colombia.
EM magomez@unal.edu.co
FU Universidad Autonoma de Manizales [466-065]
FX C.A Rojas-Sierra acknowledges the financial support of the Universidad
   Autonoma de Manizales through the research project Cod. 466-065 (in
   applied mathematics).
CR Alhumaizi K, 2004, COMPUT CHEM ENG, V28, P1759, DOI 10.1016/j.compchemeng.2004.02.032
   Alhumaizi K, 2003, COMPUT CHEM ENG, V27, P579, DOI 10.1016/S0098-1354(02)00238-7
   Bouaswaig AE, 2009, CHEM ENG SCI, V64, P3214, DOI 10.1016/j.ces.2009.03.040
   Brown SF, 2018, COMPUT CHEM ENG, V110, P69, DOI 10.1016/j.compchemeng.2017.12.006
   Coimbra MD, 2000, J COMPUT APPL MATH, V115, P169, DOI 10.1016/S0377-0427(99)00171-5
   Cruz P, 2003, CHEM ENG SCI, V58, P1777, DOI 10.1016/S0009-2509(03)00015-0
   Cruz P, 2002, AICHE J, V48, P774, DOI 10.1002/aic.690480412
   Cruz P, 2001, CHEM ENG SCI, V56, P3305, DOI 10.1016/S0009-2509(00)00551-0
   Domingues MO, 2009, INT J NUMER METH ENG, V78, P652, DOI 10.1002/nme.2501
   Domingues MO, 2009, APPL NUMER MATH, V59, P2303, DOI 10.1016/j.apnum.2008.12.018
   Donat R, 2018, APPL NUMER MATH, V123, P22, DOI 10.1016/j.apnum.2017.08.008
   Ferm L, 2006, J SCI COMPUT, V26, P83, DOI 10.1007/s10915-004-4801-9
   Finlayson B.A., 1992, NUMERICAL METHODS FO
   Gorguis A, 2006, APPL MATH COMPUT, V173, P126, DOI 10.1016/j.amc.2005.02.045
   Guiochon G., 2006, FUNDAMENTALS PREPARA
   Harten A, 1997, J COMPUT PHYS, V131, P3, DOI 10.1006/jcph.1996.5632
   HIRSCH C, 1990, NUMERICAL COMPUTATIO, V2
   Hu FX, 2015, APPL NUMER MATH, V91, P11, DOI 10.1016/j.apnum.2014.10.008
   Huang W, 2011, PROCEEDINGS OF THE ASME TURBO EXPO 2011, VOL 2, PTS A AND B, P17
   Javeed S, 2011, COMPUT CHEM ENG, V35, P2294, DOI 10.1016/j.compchemeng.2010.10.002
   Jiang GS, 1996, J COMPUT PHYS, V126, P202, DOI 10.1006/jcph.1996.0130
   KAUTSKY J, 1980, SIAM J SCI STAT COMP, V1, P499, DOI 10.1137/0901036
   Kurganov A, 2000, J COMPUT PHYS, V160, P241, DOI 10.1006/jcph.2000.6459
   Leveque R. J., 2002, FINITE VOLUME METHOD, P558, DOI DOI 10.1017/CBO9780511791253
   Lim YI, 2001, COMPUT CHEM ENG, V25, P653, DOI 10.1016/S0098-1354(01)00646-9
   LIU XD, 1994, J COMPUT PHYS, V115, P200, DOI 10.1006/jcph.1994.1187
   Liu Y, 2000, CHEM ENG SCI, V55, P1729, DOI 10.1016/S0009-2509(99)00462-5
   Meyer K, 2019, COMPUT CHEM ENG, V124, P172, DOI 10.1016/j.compchemeng.2019.02.017
   Meyer K, 2018, COMPUT CHEM ENG, V109, P68, DOI 10.1016/j.compchemeng.2017.10.023
   Qamar S, 2006, COMPUT CHEM ENG, V30, P1119, DOI 10.1016/j.compchemeng.2006.02.012
   Rice R.G., 2012, APPL MATH MODELING C
   Ruthven D., 1993, PRESSURE SWING ADSOR, DOI [10.1016/j.chroma.2008.07.069, DOI 10.1016/J.CHROMA.2008.07.069]
   Saucez P, 2004, J COMPUT APPL MATH, V168, P413, DOI 10.1016/j.cam.2003.12.012
   Saucez P, 1996, J COMPUT PHYS, V128, P274, DOI 10.1006/jcph.1996.0210
   Seidel-Morgenstern A, 2004, J CHROMATOGR A, V1037, P255, DOI 10.1016/j.chroma.2003.11.108
   Shampine LF, 2005, J SCI COMPUT, V25, P3, DOI 10.1007/s10915-004-4629-3
   Shipilova O, 2008, J CHROMATOGR A, V1204, P62, DOI 10.1016/j.chroma.2008.07.069
   Shu C. W., 1998, LECT NOTES MATH, P325, DOI DOI 10.1007/BFB0096355
   Shu CW, 2009, SIAM REV, V51, P82, DOI 10.1137/070679065
   Smit J, 2005, CHEM ENG SCI, V60, P2609, DOI 10.1016/j.ces.2004.12.017
   Stoer J., 1983, INTRO NUMERICAL ANAL, DOI [10.1007/978-0-387-21738-3, DOI 10.1007/978-0-387-21738-3]
   Vande Wouwer A., 2001, ADAPTIVE METHOD LINE, DOI [10.1201/9781420035612, DOI 10.1201/9781420035612]
   Wang R, 2008, APPL MATH COMPUT, V196, P433, DOI 10.1016/j.amc.2007.06.024
   Zhang TH, 2008, COMPUT CHEM ENG, V32, P2403, DOI 10.1016/j.compchemeng.2008.01.002
NR 44
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115391
DI 10.1016/j.ces.2019.115391
PG 18
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600015
DA 2020-05-12
ER

PT J
AU Scala, M
   Garnet, L
   Malbec, LM
   Li, HZ
AF Scala, Marco
   Garnet, Lionel
   Malbec, Louis-Marie
   Li, Huai-Zhi
TI Hydrodynamics of gas-liquid dispersion in transparent Sulzer static
   mixers SMX (TM)
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Hydrodynamics; Sulzer static mixer SMX (TM); Multiphase flow; G-L
   dispersions; Process intensification; Particle image velocimetry (PIV)
ID RESIDENCE TIME DISTRIBUTION; NON-NEWTONIAN FLUIDS; MASS-TRANSFER;
   BUBBLE-COLUMN; FLOW STRUCTURE; PRESSURE-DROP; 2-PHASE PIV; PERFORMANCE;
   VELOCITY; KENICS
AB The gas-liquid hydrodynamics in a Sulzer SMX (TM) static mixer was investigated in the present work through two different optical techniques: Backlight Shadowgraph Technique (BST) and Particle Image Velocimetry (Ply). 3D printed static mixers were manufactured using transparent plastic in order to provide optical access. The normal-heptane was used as the continuous liquid phase. Three different lengths of mixers and different gaseous nitrogen flow rates were investigated. The flow pattern in an empty tube without the mixing device was used as a reference. Bubble diameter distributions at the inlet and outlet of the SMX mixer were evaluated. The velocity fields inside the mixers were quantified. The gas holdup was also examined. These original results allow to appreciate the SMX static mixer's performance and thus to open new industrial applications involving gas-liquid flows such as striping and purification of liquids by a gas. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Scala, Marco; Garnet, Lionel] IFPEN Rond Point Echangeur Solaize, BP 3, F-69360 Solaize, France.
   [Malbec, Louis-Marie] IFP Energies Nouvelles, 1 & 4 Ave Bois Preau, F-92852 Rueil Malmaison, France.
   [Li, Huai-Zhi] LRGP CNRS, 1 Rue Grandville,BP 20451, F-54001 Nancy, France.
RP Scala, M (reprint author), IFPEN Rond Point Echangeur Solaize, BP 3, F-69360 Solaize, France.
EM Marco.scala@ifpen.fr; Lionel.gamet@ifp.fr; Louis-marie.malbec@ifp.fr;
   Huai-Zhi.Li@univ-lorraine.fr
RI Li, Huai/S-2162-2019
OI Li, Huai/0000-0001-7129-6660
CR Al Taweel AM, 2005, CHEM ENG SCI, V60, P6378, DOI 10.1016/j.ces.2005.03.011
   Alekseev KA, 2017, THEOR FOUND CHEM EN+, V51, P266, DOI 10.1134/S0040579517030010
   Ayati AA, 2015, INT J MULTIPHAS FLOW, V74, P45, DOI 10.1016/j.ijmultiphaseflow.2015.03.024
   Bouaifi M, 2001, CHEM ENG PROCESS, V40, P97, DOI 10.1016/S0255-2701(00)00129-X
   Boyer C, 2002, CHEM ENG SCI, V57, P3185, DOI 10.1016/S0009-2509(02)00193-8
   Brox T., 2004, P EUR C COMP VIS ECC, P3024
   Buffo A, 2016, MEAS SCI TECHNOL, V27, DOI 10.1088/0957-0233/27/4/045301
   Byrde O, 1999, CHEM ENG J, V72, P163, DOI 10.1016/S1385-8947(98)00145-4
   CHEN RC, 1992, CHEM ENG SCI, V47, P3615, DOI 10.1016/0009-2509(92)85077-O
   CHISTI Y, 1990, CAN J CHEM ENG, V68, P45, DOI 10.1002/cjce.5450680106
   Clift R., 1978, BUBBLES DROP PARTICL
   Das MD, 2013, CHEM ENG SCI, V101, P329, DOI 10.1016/j.ces.2013.06.047
   Deen NG, 2002, CAN J CHEM ENG, V80, P638
   Deen NG, 2002, CHEM ENG TECHNOL, V25, P97, DOI 10.1002/1521-4125(200201)25:1<97::AID-CEAT97>3.0.CO;2-7
   DEEN NG, 2000, 10 INT S APPL LAS TE
   Deen NG, 2010, EXP FLUIDS, V49, P525, DOI 10.1007/s00348-010-0827-y
   Delnoij E, 1999, CHEM ENG SCI, V54, P5159, DOI 10.1016/S0009-2509(99)00233-X
   Delnoij E, 2000, CHEM ENG SCI, V55, P3385, DOI 10.1016/S0009-2509(99)00595-3
   Engel V, 2001, CHEM ENG TECHNOL, V24, P459, DOI 10.1002/1521-4125(200105)24:5<459::AID-CEAT459>3.0.CO;2-D
   Fradette L, 2006, CHEM ENG SCI, V61, P3506, DOI 10.1016/j.ces.2005.12.022
   Funfschilling D, 2001, CHEM ENG SCI, V56, P1137, DOI 10.1016/S0009-2509(00)00332-8
   Ghanem A, 2014, CHEM ENG RES DES, V92, P205, DOI 10.1016/j.cherd.2013.07.013
   GRUND G, 1992, CHEM ENG SCI, V47, P3509, DOI 10.1016/0009-2509(92)85064-I
   HARMATHY TZ, 1960, AICHE J, V6, P281, DOI 10.1002/aic.690060222
   Heyouni A, 2002, CHEM ENG SCI, V57, P3325, DOI 10.1016/S0009-2509(02)00202-6
   Hobbs DM, 1998, CHEM ENG SCI, V53, P3199, DOI 10.1016/S0009-2509(98)00115-8
   Kazakis NA, 2008, CHEM ENG J, V137, P265, DOI 10.1016/j.cej.2007.04.040
   Keshav TR, 2008, CHEM ENG PROCESS, V47, P2275, DOI 10.1016/j.cep.2007.12.015
   Kovats P, 2018, HEAT MASS TRANSFER, V54, P453, DOI 10.1007/s00231-017-2142-0
   Lage PLC, 1999, POWDER TECHNOL, V101, P142, DOI 10.1016/S0032-5910(98)00165-X
   Laupsien D, 2017, CHEM ENG TECHNOL, V40, P1484, DOI 10.1002/ceat.201600690
   Lemenand T, 2003, INT J MULTIPHAS FLOW, V29, P813, DOI 10.1016/S0301-9322(03)00032-6
   Li HZ, 1997, CHEM ENG RES DES, V75, P792, DOI 10.1205/026387697524461
   Link J, 2004, CAN J CHEM ENG, V82, P30
   Liu SP, 2006, AICHE J, V52, P150, DOI 10.1002/aic.10608
   Liu ZL, 2005, CHEM ENG SCI, V60, P3537, DOI 10.1016/j.ces.2004.03.049
   Lunde K, 1998, APPL SCI RES, V58, P387
   Luo SJ, 2008, CHEM ENG J, V144, P227, DOI 10.1016/j.cej.2008.01.026
   Madhuranthakam CMR, 2009, CHEM ENG SCI, V64, P3320, DOI 10.1016/j.ces.2009.04.001
   Madhuranthakam CMR, 2009, IND ENG CHEM RES, V48, P719, DOI 10.1021/ie801407y
   Meijer HEH, 2012, PROG POLYM SCI, V37, P1333, DOI 10.1016/j.progpolymsci.2011.12.004
   MENDELSON HD, 1967, AICHE J, V13, P250, DOI 10.1002/aic.690130213
   Montante G, 2016, CHEM ENG SCI, V141, P250, DOI 10.1016/j.ces.2015.11.009
   Mougin G, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.014502
   Paglianti A, 2013, CHEM ENG SCI, V97, P376, DOI 10.1016/j.ces.2013.04.042
   PAHL MH, 1982, INT CHEM ENG, V22, P197
   Park T, 2014, INT J NAV ARCH OCEAN, V6, P27, DOI 10.2478/IJNAOE-2013-0161
   Paul E.L., 2004, HDB IND MIXING SCI P
   RAFFEL M, 1998, EXP FLUID MECH, P1
   Rauline D, 2000, CHEM ENG RES DES, V78, P389, DOI 10.1205/026387600527284
   Rauline D, 1998, CAN J CHEM ENG, V76, P527, DOI 10.1002/cjce.5450760325
   Raymond F, 2000, CHEM ENG SCI, V55, P943, DOI 10.1016/S0009-2509(99)00385-1
   Regner M, 2006, CHEM ENG SCI, V61, P6133, DOI 10.1016/j.ces.2006.05.044
   SAFFMAN PG, 1956, J FLUID MECH, V1, P249, DOI 10.1017/S0022112056000159
   Perez JAS, 2006, CHEM ENG J, V124, P1, DOI 10.1016/j.cej.2006.07.002
   Sathe M, 2013, CHEM ENG SCI, V100, P52, DOI 10.1016/j.ces.2013.01.004
   Sathe MJ, 2010, CHEM ENG SCI, V65, P2431, DOI 10.1016/j.ces.2009.11.014
   Settles GS, 2001, SCHLIEREN SHADOWGRAP, P143
   Singh MK, 2009, MACROMOL RAPID COMM, V30, P362, DOI 10.1002/marc.200800710
   Sobieszuk P, 2012, CHEM ENG TECHNOL, V35, P1346, DOI 10.1002/ceat.201100643
   Stokes G.G., 1850, T CAMBRIDGE PHILOS S, V9, P8
   Thakur RK, 2003, CHEM ENG RES DES, V81, P787, DOI 10.1205/026387603322302968
   Tizaoui C, 2010, CHEM ENG J, V162, P557, DOI 10.1016/j.cej.2010.05.061
   Tomiyama A, 1998, JSME INT J B-FLUID T, V41, P472, DOI 10.1299/jsmeb.41.472
   Tomiyama A., 2002, WORKSH MEAS TECHN MT
   Tripathi MK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7268
   Ugwu CU, 2002, APPL MICROBIOL BIOT, V58, P600, DOI 10.1007/s00253-002-0940-9
   Voulgaropoulos V, 2017, EXP FLUIDS, V58, DOI 10.1007/s00348-017-2445-4
   Wallis G. B., 1974, International Journal of Multiphase Flow, V1, P491, DOI 10.1016/0301-9322(74)90003-2
   WILD G, 2003, INT J CHEM REACT ENG, V1, P1
   Willems P, 2010, J MEMBRANE SCI, V362, P143, DOI 10.1016/j.memsci.2010.06.029
   Zaruba A, 2005, FLOW MEAS INSTRUM, V16, P277, DOI 10.1016/j.flowmeasinst.2005.03.009
NR 72
TC 0
Z9 0
U1 10
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115398
DI 10.1016/j.ces.2019.115398
PG 12
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600020
DA 2020-05-12
ER

PT J
AU Sepulveda, J
   Montillet, A
   Della Valle, D
   Loisel, C
   Riaublanc, A
AF Sepulveda, Julian
   Montillet, Agnes
   Della Valle, Dominique
   Loisel, Catherine
   Riaublanc, Alain
TI Deformation of gas-liquid interfaces in a non-Newtonian fluid at high
   throughputs inside a microfluidic device and effect of an expansion on
   bubble breakup mechanisms
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bubble breakup; Microfluidics; Tip-streaming; Two-phase flow; Foams;
   Non-Newtonian fluid
ID WHEY-PROTEIN ISOLATE; SWIRLING FLOW; DYNAMICS; FOAMS; EMULSIONS;
   VISCOSITY; DROPLETS; LAYERS; DROPS
AB This work is focused on the development of a compact continuous process for the production of food foams with controlled properties. Cross-shaped channels of infra millimeter size are used and the two-phase flow pattern is analyzed in order to identify the mechanisms of bubble deformation and breakup at very high velocities [similar to 2-20 m s(-1)]. Two different microcrochannel designs are used, differing by the presence of an abrupt expansion in one of the devices. Similar breakup mechanisms are observed in both devices in the cross-shaped channels and an additional local elongational flow was identified in the expansion. The expansion was found to intensify bubble breakup. All the experiments are carried out with the same gas content and the same liquid mix prepared from biosourced molecules (xanthan gum and whey proteins). A dimensional analysis is proposed in order to model the diameter of bubbles at the moment of their formation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sepulveda, Julian; Montillet, Agnes] Univ Nantes, CNRS, LUNAM, GEPEA,UMR6144, St Nazaire, France.
   [Della Valle, Dominique; Loisel, Catherine] ONIRIS, Nantes, France.
   [Loisel, Catherine] ONIRIS, GEPEA, UMR CNRS 6144, Nantes, France.
   [Riaublanc, Alain] INRA, UR1268 Biopolymeres Interact Assemblages, Nantes, France.
RP Montillet, A (reprint author), Univ Nantes, CNRS, LUNAM, GEPEA,UMR6144, St Nazaire, France.
EM Agnes.Montillet@univ-nantes.fr
FU regional programme "Food for Tomorrow/Cap Aliment; Research, Education
   and Innovation in Pays de la Loire" by French Region Pays de la Loire;
   European Regional Development Fund (FEDER)European Union (EU)
FX This work was carried out with the financial support of the regional
   programme "Food for Tomorrow/Cap Aliment; Research, Education and
   Innovation in Pays de la Loire", which is supported by the French Region
   Pays de la Loire and the European Regional Development Fund (FEDER). We
   would like to especially thank two members of the technical team of the
   GEPEA laboratory, Christophe COUDEL and Jean-Luc HAUSER, for the help
   provided during the development of the experimental setup.
CR Afzal A, 2014, CHEM ENG SCI, V116, P263, DOI 10.1016/j.ces.2014.05.021
   Anna SL, 2016, ANNU REV FLUID MECH, V48, P285, DOI 10.1146/annurev-fluid-122414-034425
   Bandara T, 2015, CHEM ENG SCI, V126, P283, DOI 10.1016/j.ces.2014.12.007
   BARTHESBIESEL D, 1973, J FLUID MECH, V61, P1, DOI 10.1017/S0022112073000534
   Benichou A, 2007, FOOD HYDROCOLLOID, V21, P379, DOI 10.1016/j.foodhyd.2006.04.013
   Berton-Carabin CC, 2018, ANNU REV FOOD SCI T, V9, P551, DOI 10.1146/annurev-food-030117-012405
   Borwankar RP, 1997, CURR OPIN COLLOID IN, V2, P584, DOI 10.1016/S1359-0294(97)80049-0
   Butt H.-J., 2003, PHYS CHEM INTERFACES, DOI [10.1002/467676, DOI 10.1002/467676]
   Campbell G.M., 2008, BUBBLES FOOD 2 NOVEL
   Cantat I., 2013, FOAMS STRUCTURE DYNA
   Castrejon-Pita AA, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.074506
   Cengel Y. A., 2014, FLUID MECH FUNDAMENT
   Comolet R., 1994, MECANIQUE EXPT FLUID
   Cubaud T, 2004, PHYS FLUIDS, V16, P4575, DOI 10.1063/1.1813871
   de Bruijn R.A., 1989, THESIS
   DEBRUIJN RA, 1993, CHEM ENG SCI, V48, P277, DOI 10.1016/0009-2509(93)80015-I
   Delaplace G., 2015, DIMENSIONAL ANAL FOO
   Drenckhan W, 2015, ADV COLLOID INTERFAC, V222, P228, DOI 10.1016/j.cis.2015.04.001
   Driessen T, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4811849
   Eggers J, 2008, REP PROG PHYS, V71, DOI 10.1088/0034-4885/71/3/036601
   Francis F.J., 2000, ENCY FOOD SCI TECHNO, V2
   Fu TT, 2015, CHEM ENG SCI, V135, P343, DOI 10.1016/j.ces.2015.02.016
   Gaillard T., 2016, THESIS
   Ganan-Calvo AM, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysLettRev.96.124504
   Garstecki P, 2004, APPL PHYS LETT, V85, P2649, DOI 10.1063/1.1796526
   GRACE HP, 1982, CHEM ENG COMMUN, V14, P225, DOI 10.1080/00986448208911047
   Haase S, 2016, INT J MULTIPHAS FLOW, V87, P197, DOI 10.1016/j.ijmultiphaseflow.2016.08.003
   HALLETT WLH, 1984, CAN J CHEM ENG, V62, P149, DOI 10.1002/cjce.5450620123
   Hessel V., 2009, MICROPROCESS ENG COM
   Jain S.S., 2017, ARXIV170106157PHYSIC
   JANSSEN JJM, 1994, AICHE J, V40, P1929, DOI 10.1002/aic.690401202
   Jeong WC, 2012, LAB CHIP, V12, P1446, DOI 10.1039/c2lc00018k
   Kandlikar S.G., 2014, HEAT TRANSFER FLUID
   Laporte M, 2014, J FOOD ENG, V128, P119, DOI 10.1016/j.jfoodeng.2013.12.017
   Leal LG, 2004, PHYS FLUIDS, V16, P1833, DOI 10.1063/1.1701892
   Lieu B.K., 2014, THESIS
   Link DR, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.054503
   Mak H, 2007, CHEM ENG SCI, V62, P6726, DOI 10.1016/j.ces.2007.07.009
   Marmottant P, 2004, PHYS FLUIDS, V16, P2732, DOI 10.1063/1.1756030
   Mary G, 2013, CHEM ENG RES DES, V91, P2579, DOI 10.1016/j.cherd.2013.05.020
   Moyle TM, 2012, PHYS FLUIDS, V24, DOI 10.1063/1.4746253
   Muller-Fischer N, 2008, EXP FLUIDS, V45, P917, DOI 10.1007/s00348-008-0509-1
   Muijlwijk K., 2017, THESIS
   Muijlwijk K, 2016, TRENDS FOOD SCI TECH, V49, P51, DOI 10.1016/j.tifs.2016.01.004
   Muller-Fischer N, 2005, COLLOID SURFACE A, V263, P353, DOI 10.1016/j.colsurfa.2004.12.057
   Perez-Fuentes L, 2017, MATERIALS, V10, DOI 10.3390/ma10080893
   Pipe CJ, 2009, MECH RES COMMUN, V36, P110, DOI 10.1016/j.mechrescom.2008.08.009
   Puerta-Gomez A.F., 2014, THESIS
   Rayleigh L., 1879, P LOND MATH SOC, V10, P4, DOI DOI 10.1112/PLMS/S1-10.1.4
   Ruzicka MC, 2008, CHEM ENG RES DES, V86, P835, DOI 10.1016/j.cherd.2008.03.007
   Sadek C, 2015, FOOD HYDROCOLLOID, V48, P8, DOI 10.1016/j.foodhyd.2015.01.014
   Schramm L.L., 2014, EMULSIONS FOAMS SUSP
   Stevenson P., 2012, FOAM ENG FUNDAMENTAL, DOI [10.1002/9781119954620.fmatter, DOI 10.1002/9781119954620.FMATTER]
   Stone HA, 2004, ANNU REV FLUID MECH, V36, P381, DOI 10.1146/annurev.fluid.36.050802.122124
   STONE HA, 1994, ANNU REV FLUID MECH, V26, P65, DOI 10.1146/annurev.fluid.26.1.65
   Taylor GI, 1934, P R SOC LOND A-CONTA, V146, P0501, DOI 10.1098/rspa.1934.0169
   Tsamopoulos J, 2008, J FLUID MECH, V601, P123, DOI 10.1017/S0022112008000517
   Utada AS, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.094502
   Utada AS, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.014502
   Van Hoeve W., 2011, THESIS
   Vial C., 2013, EMULSIONS ALIMENTAIR
   Walstra P., 2003, FOOD SCI TECHNOLOGY
   Weaire D, 2008, ADV COLLOID INTERFAC, V137, P20, DOI 10.1016/j.cis.2007.04.001
   Weaire D., 1999, PHYS FOAMS
   Wyatt NB, 2011, POLYMER, V52, P2437, DOI 10.1016/j.polymer.2011.03.053
NR 65
TC 0
Z9 0
U1 14
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115377
DI 10.1016/j.ces.2019.115377
PG 12
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600009
DA 2020-05-12
ER

PT J
AU Severo, IA
   Depra, MC
   Dias, RR
   Barin, JS
   de Menezes, CR
   Wagner, R
   Zepka, LQ
   Jacob-Lopes, E
AF Severo, Ihana A.
   Depra, Mariany C.
   Dias, Rosangela R.
   Barin, Juliano S.
   de Menezes, Cristiano R.
   Wagner, Roger
   Zepka, Leila Q.
   Jacob-Lopes, Eduardo
TI Bio-combustion of petroleum coke: The process integration with
   photobioreactors. Part II - Sustainability metrics and bioeconomy
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Biological carbon capture and utilization; Microalgae; Combustion; Life
   cycle assessment; Circular bioeconomy; Carbon credits
ID LIFE-CYCLE ASSESSMENT; OXY-FUEL COMBUSTION; CARBON-DIOXIDE; BIOFUEL
   PRODUCTION; MICROALGAE CULTIVATION; ENERGY; WATER; CO2
AB In this study, we evaluated the sustainability metrics and bioeconomy of the integrated bio-combustion system. Based on previous experiments, inventory data were standardized for a functional unit of 1 kg of mass, 1 MJ of energy, 1 m(3) of water, and a stream factor of 0.90. The impact categories resulted in a net energy ratio of 0.71, greenhouse gas emissions of 0.70 kg(GHG)/kg(fuet), global warming potential of 12,523.60 kgCO(2)(eq)/yr, water footprint of 56.40 m(3)/m(3)/yr, acidification potential of 33 kgSO(2eq)/yr, eutrophication potential of 4.42 x 10(-3) kgN(eq)/yr, and ozone depletion potential of 2.15 x 10(-)(8) kgCFC-11(eq)/yr. Regarding the utilities, fuel consumption cost was reduced close to 40%, and the oxygen and volatile organic compounds productions were responsible for the majority revenue generation. Besides, both avoided and captured carbons obtained potential revenues through carbon credits. The current contribution of the integrated process has shown improved environmental performance and is a promising approach towards circular bioeconomy. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Severo, Ihana A.; Depra, Mariany C.; Dias, Rosangela R.; Barin, Juliano S.; de Menezes, Cristiano R.; Wagner, Roger; Zepka, Leila Q.; Jacob-Lopes, Eduardo] Univ Fed Santa Maria, UFSM, Bioproc Intensificat Grp, Roraima Ave 1000, BR-97105900 Santa Maria, RS, Brazil.
RP Jacob-Lopes, E (reprint author), Univ Fed Santa Maria, UFSM, Bioproc Intensificat Grp, Roraima Ave 1000, BR-97105900 Santa Maria, RS, Brazil.
EM jacoblopes@pq.cnpq.br
RI Wagner, Roger/I-1538-2014
OI Wagner, Roger/0000-0002-6176-7913; Aguiar Severo,
   Ihana/0000-0001-5429-6052
FU National Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordination of Improvement of Higher Education Personnel
   (CAPES), (Brazil)CAPES [001]; InterCement Brazil S/A
FX Funding for this research has been provided by the National Council for
   Scientific and Technological Development (CNPq), Coordination of
   Improvement of Higher Education Personnel (CAPES), Finance Code 001
   (Brazil), and InterCement Brazil S/A. The authors are grateful to Seiiti
   Suzuki for technical support.
CR [Anonymous], 2006, 14040 ISO
   Arastoopour H, 2019, CHEM ENG SCI, V203, P247, DOI 10.1016/j.ces.2019.03.069
   Baleta J, 2019, J CLEAN PROD, V215, P1424, DOI 10.1016/j.jclepro.2019.01.035
   Batan L, 2013, ALGAL RES, V2, P196, DOI 10.1016/j.algal.2013.02.003
   Batterham RJ, 2006, CHEM ENG SCI, V61, P4188, DOI 10.1016/j.ces.2005.10.016
   CMR, 2019, IND CHEM PRIC A Z
   Collet P, 2015, APPL ENERG, V154, P1089, DOI 10.1016/j.apenergy.2015.03.056
   Oliveira FAC, 2019, SOL ENERGY, V183, P677, DOI 10.1016/j.solener.2019.03.064
   Czyrnek-Deletre MM, 2017, RENEW ENERG, V105, P436, DOI 10.1016/j.renene.2016.11.043
   Depra MC, 2019, CHEM ENG RES DES, V144, P1, DOI 10.1016/j.cherd.2019.01.023
   EPA, 2016, GREENH GAS INV GUID
   European Commission-Joint Research Centre, 2010, INT REF LIF CYCL DAT
   Farooq W, 2015, BIORESOURCE TECHNOL, V184, P73, DOI 10.1016/j.biortech.2014.10.140
   Glassman I., 2015, COMBUSTION
   Grierson S, 2013, ALGAL RES, V2, P299, DOI 10.1016/j.algal.2013.04.004
   Hauschild M. Z., 1998, ENV ASSESSMENT PRODU, V2
   Hoekstra AY, 2011, WATER-SUI, V3, P21, DOI 10.3390/w3010021
   Hulatt CJ, 2011, BIORESOURCE TECHNOL, V102, P5775, DOI 10.1016/j.biortech.2011.02.025
   IHEA, 2015, IMPR PROC HEAT SYST
   Jacob A, 2015, APPL ENERG, V148, P396, DOI 10.1016/j.apenergy.2015.03.077
   Jacob-Lopes E., 2017, Patent WO, Patent No. [WO 2017/112984 A1, 2017112984, 2017/112984 A1]
   Jacob-Lopes E, 2013, J CO2 UTIL, V2, P1, DOI 10.1016/j.jcou.2013.06.001
   Jacob-Lopes E, 2010, ENERG CONVERS MANAGE, V51, P894, DOI 10.1016/j.enconman.2009.11.027
   Jorquera O, 2010, BIORESOURCE TECHNOL, V101, P1406, DOI 10.1016/j.biortech.2009.09.038
   Klemes JJ, 2013, WOODHEAD PUBL SER EN, P1, DOI 10.1533/9780857097255
   Koiwanit J, 2014, INT J GREENH GAS CON, V28, P257, DOI 10.1016/j.ijggc.2014.07.001
   Laratte B, 2014, SCI TOTAL ENVIRON, V481, P588, DOI 10.1016/j.scitotenv.2014.02.020
   Merchuk J. C., 2019, COMPREHENSIVE BIOTEC, P320, DOI [10.1016/B978-0-444-64046-8.00081-1, DOI 10.1016/B978-0-444-64046-8.00081-1]
   Mullinger P., 2014, IND PROCESS FURNACES
   Perez-Fortes M, 2016, APPL ENERG, V161, P718, DOI 10.1016/j.apenergy.2015.07.067
   Perez-Lopez P, 2017, APPL ENERG, V205, P1151, DOI 10.1016/j.apenergy.2017.08.102
   Santos AB, 2016, J APPL PHYCOL, V28, P1561, DOI 10.1007/s10811-015-0740-0
   Severo IA, 2018, CHEM ENG SCI, V177, P422, DOI 10.1016/j.ces.2017.12.001
   Severo IA, 2018, GREEN ENERGY TECHNOL, P271, DOI 10.1007/978-3-319-69093-3_13
   Slade R, 2013, BIOMASS BIOENERG, V53, P29, DOI 10.1016/j.biombioe.2012.12.019
   Sun CH, 2019, ENERGY, V171, P1033, DOI 10.1016/j.energy.2019.01.074
   Tredici MR, 2015, APPL ENERG, V154, P1103, DOI 10.1016/j.apenergy.2015.01.086
   Turns S, 2011, INTRO COMBUSTION CON
   Turton R., 2009, ANAL SYNTHESIS DESIG
   Ulrich GD, 2006, CHEM ENG-NEW YORK, V113, P66
   Valderrama C, 2012, J CLEAN PROD, V25, P60, DOI 10.1016/j.jclepro.2011.11.055
   Varbanov PS, 2018, ENERGY, V146, P1, DOI 10.1016/j.energy.2018.01.122
   Verma R, 2018, ENVIRON DEV, V27, P95, DOI 10.1016/j.envdev.2018.07.004
   Walmsley TG, 2019, RENEW SUST ENERG REV, V107, P507, DOI 10.1016/j.rser.2019.03.039
   Wang CA, 2019, J ENERGY INST, V92, P1023, DOI 10.1016/j.joei.2018.07.004
   Wiesberg IL, 2017, J ENVIRON MANAGE, V203, P988, DOI 10.1016/j.jenvman.2017.03.005
   World Bank Group, 2015, STAT TRENDS CARB PRI, DOI [10.1596/978-1-4648-1292-7, DOI 10.1596/978-1-4648-1292-7, 10.1596/978-1-4648-1292-7.]
   World Energy Council, 2016, WORLD ENERGY RESOURC
   Ye CS, 2018, ALGAL RES, V34, P154, DOI 10.1016/j.algal.2018.07.013
   Yin CG, 2016, APPL ENERG, V162, P742, DOI 10.1016/j.apenergy.2015.10.149
NR 50
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115412
DI 10.1016/j.ces.2019.115412
PG 10
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600026
DA 2020-05-12
ER

PT J
AU Siginer, DA
   Letelier, MF
   Jacobs, P
   Aguirre, A
   Boutaous, M
AF Siginer, Dennis A.
   Letelier, Mario F.
   Jacobs, Patricio
   Aguirre, Alejandro
   Boutaous, Mhamed
TI Forced convection of elastoviscoplastic fluids in non-circular tubes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Forced convection in tubes with non-circular cross-sections;
   Elastoviscoplastic, viscoplastic and viscoelastic fluids; Triangular and
   square cross sections; Transversal field; Elasticity and plasticity;
   Yield stress
ID NONLINEAR VISCOELASTIC FLUIDS; HEAT-TRANSFER; TRANSVERSAL FIELD; FLOW
AB An analytical study of the forced convection of an elastoviscoplastic fluid in tubes of arbitrary cross section is presented. The constitutive structure of the fluid is described by a frame indifferent linear combination of the Modified Phan-Thien-Tanner model of non-linear viscoelastic fluids and the Bingham model of non-linear plastic fluids. Arbitrary tube cross sections are modeled by a continuous one-to-one mapping of the circular base contour into a wide spectrum family of non-circular tube contours. Field variables are expanded into double asymptotic series in terms of the elasticity measure Weissenberg number WI, and a mapping parameter leading to a set of linearized hierarchical momentum balance, constitutive structure and thermal field equations which are solved successively up to and including the third order in Wi for the velocity and temperature fields. The general algorithm developed is applied to the study of forced convection in tubes with exact equilateral triangular and approximately square cross sections. The analysis also yields the solution of the forced convection of linear (Newtonian) fluids in non-circular tubes and the forced convection in circular tubes of the family of non-linear fluids (viscoplastic, viscoelastic, elastoviscoplastic) described by the constitutive structure under consideration thereby providing as well validation for the computations carried out for non-linear fluids in non-circular cross-sections. A thorough comparison of the velocity and thermal fields of the Newtonian, viscoplastic, viscoelastic and elastoviscoplastic fluids in tubes of equilateral triangular and pseudo square cross-sectional tubes is presented as specific cases. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Siginer, Dennis A.; Letelier, Mario F.; Jacobs, Patricio; Aguirre, Alejandro] Univ Santiago Chile, Ctr Invest Creatividad & Educ Super, Santiago, Chile.
   [Siginer, Dennis A.; Letelier, Mario F.; Jacobs, Patricio; Aguirre, Alejandro] Univ Santiago Chile, Dept Ingn Mecan, Santiago, Chile.
   [Siginer, Dennis A.] Bostwana Int Univ Sci & Technol, Dept Math & Stat Sci, Dept Mech Energy & Ind Engn, Dept Chem Mat & Met Engn, Palapye, Botswana.
   [Boutaous, Mhamed] Univ Lyon, CNRS, INSA Lyon, CETHIL,UMR5008, F-69621 Villeurbanne, France.
RP Siginer, DA (reprint author), Univ Santiago Chile, Ctr Invest Creatividad & Educ Super, Santiago, Chile.; Siginer, DA (reprint author), Univ Santiago Chile, Dept Ingn Mecan, Santiago, Chile.; Siginer, DA (reprint author), Bostwana Int Univ Sci & Technol, Dept Math & Stat Sci, Dept Mech Energy & Ind Engn, Dept Chem Mat & Met Engn, Palapye, Botswana.
EM dennis.siginer@usach.cl
FU DICYT at USACH; FONDECYTComision Nacional de Investigacion Cientifica y
   Tecnologica (CONICYT)CONICYT FONDECYT [1130346]
FX The authors gratefully acknowledge the financial support of DICYT at
   USACH and of FONDECYT through Grant 1130346
CR Mendes PRD, 2007, J NON-NEWTON FLUID, V147, P109, DOI 10.1016/j.jnnfm.2007.07.010
   Ericksen J.L., 1956, Q APPL MATH, V14, P319
   Gao SX, 1996, INT J HEAT MASS TRAN, V39, P1317, DOI 10.1016/0017-9310(95)00041-0
   Green A.E., 1956, QUART APPL MATH, V14, P299
   Korobkin A, 2011, J ENG MATH, V69, P111, DOI 10.1007/s10665-010-9427-3
   Kuiken HK, 2001, J ENG MATH, V39, P1
   Langlois W.E., 1963, REND MATEMATICA ROMA, V22, P169
   Letelier M, 2018, MECCANICA, V53, P161, DOI 10.1007/s11012-017-0716-z
   Letelier MF, 2018, APPL MATH MODEL, V54, P768, DOI 10.1016/j.apm.2017.10.008
   Letelier MF, 2017, APPL MATH MODEL, V46, P572, DOI 10.1016/j.apm.2017.01.058
   Letelier MF, 2017, INT J NONLIN MECH, V88, P1, DOI 10.1016/j.ijnonlinmec.2016.09.012
   Letelier MF, 2017, INT J THERM SCI, V111, P369, DOI 10.1016/j.ijthermalsci.2016.05.034
   OLIVER DR, 1969, TRANS INST CHEM ENG, V47, pT18
   Pinho FT, 2000, INT J HEAT MASS TRAN, V43, P2273, DOI 10.1016/S0017-9310(99)00303-8
   Saramito P, 2007, J NON-NEWTON FLUID, V145, P1, DOI 10.1016/j.jnnfm.2007.04.004
   Saramito P, 2009, J NON-NEWTON FLUID, V158, P154, DOI 10.1016/j.jnnfm.2008.12.001
   Siginer D.A., 2014, MONOGRAPH, V9783
   Siginer D.A., 2015, MONOGRAPH
   Siginer DA, 2019, INT J THERM SCI, V141, P150, DOI 10.1016/j.ijthermalsci.2019.03.019
   Siginer DA, 2011, INT J HEAT MASS TRAN, V54, P2188, DOI 10.1016/j.ijheatmasstransfer.2010.11.041
   Siginer DA, 2011, INT J ENG SCI, V49, P443, DOI 10.1016/j.ijengsci.2010.11.001
   Siginer DA, 2010, INT J ENG SCI, V48, P1544, DOI 10.1016/j.ijengsci.2010.07.010
   Smith WR, 2017, J ENG MATH, V102, P1, DOI 10.1007/s10665-016-9883-5
NR 23
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115318
DI 10.1016/j.ces.2019.115318
PG 17
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600001
DA 2020-05-12
ER

PT J
AU Tang, WQ
   Yu, HP
   Cai, C
   Zhao, T
   Lu, CJ
   Zhao, SL
   Lu, XH
AF Tang, Weiqiang
   Yu, Hongping
   Cai, Cheng
   Zhao, Teng
   Lu, Changjie
   Zhao, Shuangliang
   Lu, Xiaohua
TI Solvent effects on a derivative of 1,3,4-oxadiazole tautomerization
   reaction in water: A reaction density functional theory study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Reaction density functional theory; Solvent effect; Tautomerization
   reaction; Oxadiazole
ID PROTON-TRANSFER; FREE-ENERGY; SOLVATION DYNAMICS; CHEMICAL-REACTIONS;
   MOLECULES; CONTINUUM; DESIGN
AB In this work, we investigate the simple and water assisted tautomerization reaction in a derivative of 1,3,4-oxadiazole by means of the proposed multiscale reaction density functional theory (RxDFT). The complete scheme and reaction pathways among four different tautomers are investigated, and the free energy profiles of four corresponding tautomerization reactions in the absence and presence of 1-3 water molecules are calculated. The results show that the presence of liquid water considerably reduces the free energy barriers of the tautomerization reactions, but imposes negligible impact on the reaction free energies. The solvent effects are ascribed primarily to the assistance of water molecules, and then to the difference in solvation free energy. The satisfactory accuracy and low computational cost of RxDFT highlight its great potential for studying solvent effect on chemical reactions in solution compared with ab initio or QM/MM method. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tang, Weiqiang; Yu, Hongping; Cai, Cheng; Zhao, Teng; Lu, Changjie; Zhao, Shuangliang] East China Univ Sci & Technol, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.
   [Tang, Weiqiang; Yu, Hongping; Cai, Cheng; Zhao, Teng; Lu, Changjie; Zhao, Shuangliang] East China Univ Sci & Technol, Sch Chem Engn, Shanghai 200237, Peoples R China.
   [Lu, Xiaohua] Nanjing Tech Univ, Coll Chem Engn, State Key Lab Mat Oriented Chem Engn, Nanjing 210009, Peoples R China.
RP Zhao, SL (reprint author), East China Univ Sci & Technol, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.; Zhao, SL (reprint author), East China Univ Sci & Technol, Sch Chem Engn, Shanghai 200237, Peoples R China.
EM szhao@ecust.edu.cn
RI Tang, Weiqiang/P-3435-2018; Zhao, Shuangliang/B-6139-2017
OI Tang, Weiqiang/0000-0002-7726-4130; Zhao,
   Shuangliang/0000-0002-9547-4860
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21878078, U1707602, 51621002]; 111 Project of
   ChinaMinistry of Education, China - 111 Project [B08021]
FX This work is supported by National Natural Science Foundation of China
   (Nos. 21878078, and U1707602), and National Natural Science Foundation
   of China for Innovative Research Groups (No. 51621002), and the 111
   Project of China (No. B08021).
CR ABRAHAM MH, 1993, PURE APPL CHEM, V65, P2503, DOI 10.1351/pac199365122503
   Arslan NB, 2014, CHEM PHYS, V439, P1, DOI 10.1016/j.chemphys.2014.05.006
   Berendsen HJC, 1981, INTERMOLECULAR FORCE, V14, P331, DOI DOI 10.1007/978-94-015-7658-1_21
   Bhattacharyya K, 2003, ACCOUNTS CHEM RES, V36, P95, DOI 10.1021/ar020067m
   Bondock S, 2012, EUR J MED CHEM, V48, P192, DOI 10.1016/j.ejmech.2011.12.013
   Carey F. A., 2004, ORGANIC CHEM
   Chahkandi B, 2013, J MOL GRAPH MODEL, V44, P120, DOI 10.1016/j.jmgm.2013.04.002
   Clarke CJ, 2018, CHEM REV, V118, P747, DOI 10.1021/acs.chemrev.7b00571
   Dalessandro EV, 2018, QUIM NOVA, V41, P628, DOI 10.21577/0100-4042.20170224
   England JL, 2011, ANNU REV PHYS CHEM, V62, P257, DOI 10.1146/annurev-physchem-032210-103531
   Ensing B, 2001, J PHYS CHEM A, V105, P3300, DOI 10.1021/jp003468x
   EVANS R, 1979, ADV PHYS, V28, P143, DOI 10.1080/00018737900101365
   Fershtat LL, 2016, TETRAHEDRON LETT, V57, P5685, DOI 10.1016/j.tetlet.2016.11.023
   Frisch MJ, 2009, GAUSSIAN 09 REVISION
   FUKUI K, 1981, ACCOUNTS CHEM RES, V14, P363, DOI 10.1021/ar00072a001
   Ghiran D., 1974, FRAMACIA BUCHAREST, V22, P141
   Ghosh D, 2015, J PHYS CHEM B, V119, P5650, DOI 10.1021/acs.jpcb.5b00021
   Hirata F, 2001, COMPUTATIONAL BIOCHEMISTRY AND BIOPHYSICS, P417
   Hirata F., 2003, MOL THEORY SOLVATION, P24
   KWIATKOWSKI JS, 1986, ADV QUANTUM CHEM, V18, P85, DOI 10.1016/S0065-3276(08)60048-9
   LAIDLER KJ, 1983, J PHYS CHEM-US, V87, P2657, DOI 10.1021/j100238a002
   Laino T, 2005, J CHEM THEORY COMPUT, V1, P1176, DOI 10.1021/ct050123f
   MEGHEZZI H, 1992, J MOL STRUC-THEOCHEM, V89, P175
   MENNUCCI B, 2007, CONTINUUM SOLVATION
   MIERTUS S, 1981, CHEM PHYS, V55, P117, DOI 10.1016/0301-0104(81)85090-2
   MIERTUS S, 1982, CHEM PHYS, V65, P239, DOI 10.1016/0301-0104(82)85072-6
   Mohammed OF, 2005, SCIENCE, V310, P83, DOI 10.1126/science.1117756
   Naka K, 1999, THEOR CHEM ACC, V102, P165, DOI 10.1007/s002140050487
   Omar FA, 1996, EUR J MED CHEM, V31, P819, DOI 10.1016/0223-5234(96)83976-6
   Qing LY, 2019, LANGMUIR, V35, P4254, DOI 10.1021/acs.langmuir.9b00088
   Reichardt C., 2011, SOLVENTS SOLVENT EFF
   Rini M, 2004, J CHEM PHYS, V121, P9593, DOI 10.1063/1.1804172
   ROSENFELD Y, 1989, PHYS REV LETT, V63, P980, DOI 10.1103/PhysRevLett.63.980
   SCHLEGEL HB, 1982, J COMPUT CHEM, V3, P214, DOI 10.1002/jcc.540030212
   Sharma R., 2015, RES REV J CHEM
   Shivakumar D, 2009, J CHEM THEORY COMPUT, V5, P919, DOI 10.1021/ct800445x
   Siwick BJ, 2007, J AM CHEM SOC, V129, P13412, DOI 10.1021/ja069265p
   Struebing H, 2017, CHEM ENG SCI, V159, P69, DOI 10.1016/j.ces.2016.09.032
   Struebing H, 2013, NAT CHEM, V5, P952, DOI [10.1038/NCHEM.1755, 10.1038/nchem.1755]
   Tang WQ, 2018, J PHYS CHEM C, V122, P20745, DOI 10.1021/acs.jpcc.8b05383
   Thompson WH, 2011, ANNU REV PHYS CHEM, V62, P599, DOI 10.1146/annurev-physchem-032210-103330
   Tomasi J, 2005, CHEM REV, V105, P2999, DOI 10.1021/cr9904009
   Udagawa T, 2017, RSC ADV, V7, P9328, DOI 10.1039/c6ra28271g
   Welton T, 2015, P ROY SOC A-MATH PHY, V471, DOI 10.1098/rspa.2015.0502
   YALE HL, 1966, J MED CHEM, V9, P478, DOI 10.1021/jm00322a007
   Yu YX, 2002, J CHEM PHYS, V117, P10156, DOI 10.1063/1.1520530
   Zborowski K, 2003, J MOL STRUC-THEOCHEM, V639, P87, DOI 10.1016/S0166-1280(03)00586-4
   Zhao S., 2015, ADV CHEM ENG, V47, P1
   Zhao SL, 2013, J CHEM PHYS, V139, DOI 10.1063/1.4813400
   Zhao SL, 2011, J PHYS CHEM B, V115, P6971, DOI 10.1021/jp201949k
   Zhao SL, 2011, J CHEM PHYS, V134, DOI 10.1063/1.3589142
NR 51
TC 1
Z9 1
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115380
DI 10.1016/j.ces.2019.115380
PG 8
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600011
DA 2020-05-12
ER

PT J
AU Tang, YN
   Wang, S
   Zhou, X
   Wu, Y
   Xian, SK
   Li, Z
AF Tang, Yuning
   Wang, Sa
   Zhou, Xin
   Wu, Ying
   Xian, Shikai
   Li, Zhong
TI Room temperature synthesis of Cu(Qc)(2) and its application for ethane
   capture from light hydrocarbons
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE RT-Cu(Qc)(2); Room-temperature synthesis; Ethane-capturing; Adsorption
ID METAL-ORGANIC FRAMEWORK; HIGHLY SELECTIVE SEPARATION; PREFERENTIAL
   ADSORPTION; HIGH-CAPACITY; CU-BTC; ETHYLENE; ADSORBENTS; COMPOSITES;
   PERFORMANCES; CONVERSION
AB A facile and efficient room-temperature synthesis approach was proposed to prepare MOF material Cu (Qc)(2) (henceforth called RT-Cu(Qc)(2)) with ultramicropores. RT-Cu(Qc)(2) was successfully synthesized at room-temperature by means of (Zn, Cu) hydroxyl double salt as intermediate within 1-12 h. The resulting RT-Cu(Qc)(2) exhibited excellent water vapor stability and its C2H6 uptake reached 2.19 mmol/g at 288 K and 1 bar. Its C2H6/C2H4 and C2H6/CH4 uptake ratio at 298 K and 1 bar were up to 3.70 and 22.67, superior to benchmark MAF-49, Cu(Qc)(2) and ZIF-7. Its IAST-predicted C2H6/C2H4 and C2H6/CH4 selectivity reached 4.1 (1:1 v:v) and 35.9 (1:9 v:v) at 288 K and 1 bar, higher than most of ethane-capturing MOFs. Molecular simulation revealed well-defined host-guest match between Cu(Qc) 2 and ethane. Fixed bed experiments confirmed that ethane/ethylene or ethane/methane mixtures can be completely separated using RT-Cu(Qc)(2). RT-Cu(Qc)(2) has great potential for separation of ethane/ethylene and the recovery of ethane from natural gas. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tang, Yuning; Wang, Sa; Zhou, Xin; Wu, Ying; Xian, Shikai; Li, Zhong] South China Univ Technol, Sch Chem & Chem Engn, Guangzhou 510640, Peoples R China.
   [Li, Zhong] South China Univ Technol, State Key Lab Subtrop Bldg Sci China, Guangzhou 510640, Peoples R China.
RP Zhou, X; Li, Z (reprint author), South China Univ Technol, Sch Chem & Chem Engn, Guangzhou 510640, Peoples R China.
EM xinzhou@scut.edu.cn; cezhli@scut.edu.cn
RI Zhou, Xin/K-4037-2014
OI Zhou, Xin/0000-0002-4317-7354
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21436005, U1662136, 21808067]; Guangdong Province
   Science and Technology Project [2016A020221006]; China Postdoctoral
   Science FoundationChina Postdoctoral Science Foundation [2018M640785]
FX We gratefully acknowledge the National Natural Science Foundation of
   China (No. 21436005; No. U1662136; NO. 21808067), the Guangdong Province
   Science and Technology Project (No. 2016A020221006), and the China
   Postdoctoral Science Foundation (2018M640785).
CR Bachman JE, 2017, J AM CHEM SOC, V139, P15363, DOI 10.1021/jacs.7b06397
   Banerjee D, 2015, COMMENT INORG CHEM, V35, P18, DOI 10.1080/02603594.2014.976704
   Bao Z., 2018, ANGEW CHEM INT EDIT, V130, P16252
   Bao ZB, 2011, LANGMUIR, V27, P13554, DOI 10.1021/la2030473
   Bloch ED, 2012, SCIENCE, V335, P1606, DOI 10.1126/science.1217544
   Chen KJ, 2016, ANGEW CHEM INT EDIT, V55, P10268, DOI 10.1002/anie.201603934
   Chen YW, 2019, CRYSTENGCOMM, V21, P165, DOI 10.1039/c8ce01489b
   Chen YW, 2018, CHEM ENG SCI, V175, P110, DOI 10.1016/j.ces.2017.09.032
   Flores JG, 2018, DALTON T, V47, P4639, DOI 10.1039/c7dt04701k
   Garcia-Perez E, 2009, LANGMUIR, V25, P1725, DOI 10.1021/la803085h
   Geier SJ, 2013, CHEM SCI, V4, P2054, DOI 10.1039/c3sc00032j
   Gucuyener C, 2010, J AM CHEM SOC, V132, P17704, DOI 10.1021/ja1089765
   Guesh K, 2017, CRYST GROWTH DES, V17, P1806, DOI 10.1021/acs.cgd.6b01776
   Hartmann M, 2015, LANGMUIR, V31, P12382, DOI 10.1021/acs.langmuir.5b02907
   He YB, 2012, ENERG ENVIRON SCI, V5, P9107, DOI 10.1039/c2ee22858k
   He YB, 2012, CHEM COMMUN, V48, P6493, DOI 10.1039/c2cc31792c
   He YB, 2012, CHEM-EUR J, V18, P613, DOI 10.1002/chem.201102734
   Li H, 2017, CHEM ENG J, V307, P537, DOI 10.1016/j.cej.2016.08.128
   Li JR, 2009, CHEM SOC REV, V38, P1477, DOI 10.1039/b802426j
   Li LB, 2018, SCIENCE, V362, P443, DOI 10.1126/science.aat0586
   Liang WW, 2018, AICHE J, V64, P3390, DOI 10.1002/aic.16182
   Liang WW, 2017, CHEM ENG SCI, V162, P192, DOI 10.1016/j.ces.2017.01.003
   Liang WW, 2016, CHEM ENG SCI, V148, P275, DOI 10.1016/j.ces.2016.04.016
   Liao PQ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9697
   Lin RB, 2018, J AM CHEM SOC, V140, P12940, DOI 10.1021/jacs.8b07563
   Ma C, 2017, CHEM ENG SCI, V172, P612, DOI 10.1016/j.ces.2017.07.020
   Meng S, 2014, J MATER CHEM A, V2, P14536, DOI 10.1039/c4ta00984c
   MYERS AL, 1965, AICHE J, V11, P121, DOI 10.1002/aic.690110125
   Pires J, 2014, ACS APPL MATER INTER, V6, P12093, DOI 10.1021/am502686g
   Sholl DS, 2016, NATURE, V532, P435, DOI 10.1038/532435a
   Sun XJ, 2014, RSC ADV, V4, P56216, DOI 10.1039/c4ra08598a
   Wang XJ, 2019, CHEM ENG J, V358, P1114, DOI 10.1016/j.cej.2018.10.109
   Wang XJ, 2016, CHEM ENG SCI, V155, P338, DOI 10.1016/j.ces.2016.08.026
   Wu YF, 2019, ACS SUSTAIN CHEM ENG, V7, P1557, DOI 10.1021/acssuschemeng.8b05321
   Xian SK, 2013, SEP SCI TECHNOL, V48, P1479, DOI 10.1080/01496395.2012.738756
   Xu F, 2016, CHEM ENG J, V303, P231, DOI 10.1016/j.cej.2016.05.143
   Yang R T, 2003, ADSORBENTS FUNDAMENT
   Yang SH, 2015, NAT CHEM, V7, P121, DOI 10.1038/nchem.2114
   Yuan BQ, 2019, CHEM ENG J, V355, P679, DOI 10.1016/j.cej.2018.08.201
   Zhang YF, 2017, IND ENG CHEM RES, V56, P8689, DOI 10.1021/acs.iecr.7b01420
   Zhao JJ, 2015, J AM CHEM SOC, V137, P13756, DOI 10.1021/jacs.5b08752
NR 41
TC 2
Z9 2
U1 40
U2 40
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115355
DI 10.1016/j.ces.2019.115355
PG 9
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600002
DA 2020-05-12
ER

PT J
AU Taris, A
   Grosso, M
   Brundu, M
   Guida, V
AF Taris, Alessandra
   Grosso, Massimiliano
   Brundu, Mariarosa
   Guida, Vincenzo
TI Dissolution of surfactant mixtures investigated through hyperspectral
   imaging and multivariate curve resolution
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Surfactant dissolution; Multivariate curve resolution; Hyperspectral
   imaging; Diffusion models
ID QUALITY-CONTROL; PHASE-DIAGRAM; TIME; TRANSFORMATIONS; MECHANISMS;
   KINETICS; BEHAVIOR; RATES; MCR
AB Linear solvent penetration experiments are used to study the dissolution of mixed surfactant pastes consisting of two surfactants and water by means of confocal Raman microscopy. During the experiment, Raman spectra were collected along with space and over time. The resulting hyperspectral data were then processed by means of Multivariate Curve Resolution - Alternating Least Square (MCR-ALS) technique to estimate the evolution of the spatial profile of the surfactant concentrations over time. We show that hyperspectral imaging coupled with MCR-ALS can provide a detailed description of the dissolution process. The experimental concentration profiles are analyzed using a diffusive model with concentration-dependent diffusion coefficient, showing a quantitative agreement. We show that the additional information extracted by confocal Raman microscopy enables a more sophisticated analysis of linear penetration experiments when compared to the traditional approach of surfactant mesophases front propagation tracking even in absence of a detailed phase diagram. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Taris, Alessandra; Grosso, Massimiliano] Univ Cagliari, Dipartimento Ingn Meccan Chim & Mat, Via Marengo 2, I-09123 Cagliari, Italy.
   [Brundu, Mariarosa; Guida, Vincenzo] Procter & Gamble Eurocor NV, Temselaan 100, B-1853 Strombeek Bever, Belgium.
RP Grosso, M (reprint author), Univ Cagliari, Dipartimento Ingn Meccan Chim & Mat, Via Marengo 2, I-09123 Cagliari, Italy.
EM massimiliano.grosso@dimcm.unica.it
CR Alexandrino GL, 2015, EUR J PHARM BIOPHARM, V93, P224, DOI 10.1016/j.ejpb.2015.03.034
   Amirabadi S, 2018, POLYM TEST, V68, P61, DOI 10.1016/j.polymertesting.2018.03.047
   Bates D. M., 2007, NONLINEAR REGRESSION
   CAFFREY M, 1987, BIOPHYS J, V51, P37, DOI 10.1016/S0006-3495(87)83309-X
   Camacho J, 2008, J CHEMOMETR, V22, P299, DOI 10.1002/cem.1113
   Castaldo RI, 2019, SOFT MATTER, V15, P8352, DOI 10.1039/c9sm01481k
   Chen BH, 2000, LANGMUIR, V16, P5276, DOI 10.1021/la9913497
   Chen BH, 2001, COLLOID SURFACE A, V183, P191, DOI 10.1016/S0927-7757(01)00547-7
   de Juan A, 2009, COMPREHENSIVE CHEMOMETRICS: CHEMICAL AND BIOCHEMICAL DATA ANALYSIS, VOLS 1-4, pA325
   DEVOTTA I, 1994, CHEM ENG SCI, V49, P645, DOI 10.1016/0009-2509(94)85010-0
   Dietzek B., 2010, CONFOCAL RAMAN MICRO
   Everall NJ, 2009, APPL SPECTROSC, V63, p245A, DOI 10.1366/000370209789379196
   Gosselin R, 2009, IND ENG CHEM RES, V48, P3033, DOI 10.1021/ie800997x
   Gowen AA, 2011, ANAL CHIM ACTA, V705, P272, DOI 10.1016/j.aca.2011.06.031
   Gradzielski M, 2003, CURR OPIN COLLOID IN, V8, P337, DOI 10.1016/S1359-0294(03)00080-3
   Imura T, 2007, LANGMUIR, V23, P1659, DOI 10.1021/la0620814
   Jaumot J, 2015, CHEMOMETR INTELL LAB, V140, P1, DOI 10.1016/j.chemolab.2014.10.003
   KEKICHEFF P, 1989, J COLLOID INTERF SCI, V131, P112, DOI 10.1016/0021-9797(89)90151-3
   Kocherbitov V, 2006, J PHYS CHEM B, V110, P13649, DOI 10.1021/jp060934v
   Lagarias JC, 1998, SIAM J OPTIMIZ, V9, P112, DOI 10.1137/S1052623496303470
   Laughlin RG, 2000, J PHYS CHEM B, V104, P7354, DOI 10.1021/jp994220e
   Laughlin RG, 2001, CURR OPIN COLLOID IN, V6, P405, DOI 10.1016/S1359-0294(01)00108-X
   Borba FDL, 2017, ANALYST, V142, P1106, DOI 10.1039/c6an02340a
   MAEDER M, 1987, ANAL CHEM, V59, P527, DOI 10.1021/ac00130a035
   MILLER CA, 1993, COLLOID SURFACE A, V74, P169, DOI 10.1016/0927-7757(93)80263-E
   Miller CA, 2008, ADV POLYM SCI, V218, P3, DOI 10.1007/12_2008_160
   Osorio JG, 2014, CHEM ENG SCI, V108, P244, DOI 10.1016/j.ces.2013.12.027
   PEPPAS NA, 1994, MACROMOLECULES, V27, P5626, DOI 10.1021/ma00098a017
   Pereira AC, 2009, IND ENG CHEM RES, V48, P988, DOI 10.1021/ie071610b
   Poulos AS, 2017, SOFT MATTER, V13, P5332, DOI 10.1039/c7sm01096f
   Prats-Montalban JM, 2011, CHEMOMETR INTELL LAB, V107, P1, DOI 10.1016/j.chemolab.2011.03.002
   Rehder S, 2013, EUR J PHARM SCI, V48, P97, DOI 10.1016/j.ejps.2012.10.001
   Reis MS, 2015, CHEMOMETR INTELL LAB, V142, P36, DOI 10.1016/j.chemolab.2015.01.008
   Rodgers TL, 2011, J PHYS CHEM B, V115, P10218, DOI 10.1021/jp111464b
   SKEEL RD, 1990, SIAM J SCI STAT COMP, V11, P1, DOI 10.1137/0911001
   Tang YJ, 2015, APPL SPECTROSC, V69, P1319, DOI 10.1366/14-07721
   Taris A, 2017, J APPL CRYSTALLOGR, V50, P451, DOI 10.1107/S1600576717001753
   Tauler R, 2009, COMPREHENSIVE CHEMOMETRICS: CHEMICAL AND BIOCHEMICAL DATA ANALYSIS, VOLS 1-4, pA473
   Tres F, 2015, MOL PHARMACEUT, V12, P1512, DOI 10.1021/mp500829v
   Tronci S, 2011, J PROCESS CONTR, V21, P1250, DOI 10.1016/j.jprocont.2011.07.014
   Warren PB, 2001, CURR OPIN COLLOID IN, V6, P287, DOI 10.1016/S1359-0294(01)00095-4
   Windig W, 1997, CHEMOMETR INTELL LAB, V36, P3, DOI 10.1016/S0169-7439(96)00061-5
   Yue X, 2017, J MOL LIQ, V227, P161, DOI 10.1016/j.molliq.2016.12.010
NR 43
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115378
DI 10.1016/j.ces.2019.115378
PG 10
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600010
DA 2020-05-12
ER

PT J
AU Varsakelis, C
   Papalexandris, MV
AF Varsakelis, C.
   Papalexandris, M., V
TI Bridging the gap between the Darcy-Brinkman equations and the Nielsen
   model for tortuosity in polymer-filled systems
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Polymer filled systems; Tortuosity; Darcy-Brinkman equation; Porous
   media
ID BARRIER PROPERTIES; TRANSPORT-PROPERTIES; MASS-TRANSPORT;
   NANOCOMPOSITES; PERMEABILITY; CONVECTION; FLOW; DIFFUSION
AB The present study establishes the link between the well-known Nielsen model for the calculation of tortuosity in polymer-filled systems and the Darcy-Brinkman equation for flows in porous media. Based on the fact that the polymer-filled system is a porous medium, with properties fixed by the volume fraction and the geometry of the fillers, we employ the Darcy-Brinkman equations to compute an expression for tortuosity. This expression is then directly linked to the interphasial drag coefficient. Finally, we prove that the Nielsen model constitutes a special case of our derived formula. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Varsakelis, C.; Papalexandris, M., V] UCLouvain, Inst Mech Mat & Civil Engn, Pl Levant 2, B-1348 Louvain La Neuve, Belgium.
RP Varsakelis, C (reprint author), UCLouvain, Inst Mech Mat & Civil Engn, Pl Levant 2, B-1348 Louvain La Neuve, Belgium.
EM christos.varsakelis@uclouvain.be; miltos@uclouvain.be
CR Antoniadis PD, 2015, PHYS FLUIDS, V27, DOI 10.1063/1.4905558
   Antoniadis PD, 2016, INT J HEAT MASS TRAN, V96, P643, DOI 10.1016/j.ijheatmasstransfer.2016.01.056
   Barrer J.P.R.M., 1961, BR J APPL PHYS, V12, P691
   Benyahia S, 2006, POWDER TECHNOL, V162, P166, DOI 10.1016/j.powtec.2005.12.014
   BRYDGES WT, 1975, J MATER SCI, V10, P2044, DOI 10.1007/BF00557482
   Choudalakis G, 2009, EUR POLYM J, V45, P967, DOI 10.1016/j.eurpolymj.2009.01.027
   Churakov SV, 2018, AM J SCI, V318, P921, DOI 10.2475/09.2018.03
   Cui YB, 2015, RSC ADV, V5, P63669, DOI 10.1039/c5ra10333a
   CUSSLER EL, 1988, J MEMBRANE SCI, V38, P161, DOI 10.1016/S0376-7388(00)80877-7
   Denn MM, 2014, ANNU REV CHEM BIOMOL, V5, P203, DOI 10.1146/annurev-chembioeng-060713-040221
   Dunkerley E, 2010, MACROMOLECULES, V43, P10536, DOI 10.1021/ma1018846
   ERGUN S, 1952, CHEM ENG PROG, V48, P89
   Fredrickson GH, 1999, J CHEM PHYS, V110, P2181, DOI 10.1063/1.477829
   GOODMAN MA, 1972, ARCH RATION MECH AN, V44, P249
   Gusev AA, 2001, ADV MATER, V13, P1641, DOI 10.1002/1521-4095(200111)13:21<1641::AID-ADMA1641>3.0.CO;2-P
   Hooman K, 2008, J COMPUT APPL MATH, V211, P57, DOI 10.1016/j.cam.2006.11.005
   Kelliher JP, 2011, PHYSICA D, V240, P619, DOI 10.1016/j.physd.2010.11.012
   Kladias N, 1991, J THERMOPHYS HEAT TR, V5, P560, DOI 10.2514/3.301
   Lape NK, 2004, J MEMBRANE SCI, V236, P29, DOI 10.1016/j.memsci.2003.12.026
   Lasseux D, 2017, CR MECANIQUE, V345, P660, DOI 10.1016/j.crme.2017.06.005
   Lundberg J., 2008, P P 49 SCAND C SIM M
   Minelli M, 2011, J MEMBRANE SCI, V381, P10, DOI 10.1016/j.memsci.2011.06.036
   Monsorno D, 2017, J NON-NEWTON FLUID, V247, P229, DOI 10.1016/j.jnnfm.2017.08.002
   Morris B.A., 2017, SCI TECHNOLOGY FLEXI
   Nielsen L. E., 1967, J MACROMOL SCI CHEM, V1, P929, DOI DOI 10.1080/10601326708053745
   Papalexandris MV, 2015, INT J HEAT MASS TRAN, V88, P42, DOI 10.1016/j.ijheatmasstransfer.2015.04.049
   Passman S.L., 1984, THEORY MULTIPHASE MI, P286
   Paul DR, 2008, POLYMER, V49, P3187, DOI 10.1016/j.polymer.2008.04.017
   Picard E, 2007, J MEMBRANE SCI, V292, P133, DOI 10.1016/j.memsci.2007.01.030
   Prasianakis NI, 2013, COMMUN COMPUT PHYS, V13, P851, DOI 10.4208/cicp.341011.310112s
   Ray SS, 2003, PROG POLYM SCI, V28, P1539, DOI 10.1016/j.progpolymsci.2003.08.002
   Luna CMR, 2017, PARTICUOLOGY, V33, P129, DOI 10.1016/j.partic.2016.08.008
   Rosen T, 2012, J ELECTROCHEM SOC, V159, pF536, DOI 10.1149/2.005209jes
   Stanly R, 2018, CHEM ENG SCI, V188, P132, DOI 10.1016/j.ces.2018.05.030
   Tan B, 2016, J MEMBRANE SCI, V514, P595, DOI 10.1016/j.memsci.2016.05.026
   Varsakelis C, 2017, NONLINEARITY, V30, P1449, DOI 10.1088/1361-6544/aa5ecf
   Wolf C, 2018, J MEMBRANE SCI, V556, P393, DOI 10.1016/j.memsci.2018.03.085
   Yang YK, 2019, CEMENT CONCRETE COMP, V96, P55, DOI 10.1016/j.cemconcomp.2018.11.008
NR 38
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115394
DI 10.1016/j.ces.2019.115394
PG 7
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600017
DA 2020-05-12
ER

PT J
AU Winkler, M
   Sonner, H
   Gleiss, M
   Nirschl, H
AF Winkler, Marvin
   Sonner, Heiko
   Gleiss, Marco
   Nirschl, Hermann
TI Fractionation of ultrafine particles: Evaluation of separation
   efficiency by UV-vis spectroscopy
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Solid-liquid separation; Centrifugation; Fractionation; Colloidal
   particles; UV-vis spectroscopy; Machine learning
ID OPTICAL-PROPERTIES; SIZE; GOLD; NANOPARTICLES
AB Centrifugation is an established tool in solids process technology to handle classification of particulate products. However, dispersions with strict specifications for product-relevant properties often require a different approach. Fractionation is necessary when both geometric and material properties matter. Due to their high throughput and centrifugal acceleration, semi-continuous tubular centrifuges are suitable for the effective performance of such tasks. In order to monitor this mechanism for several size and density fractions, the separation efficiency is correlated with optical properties. Titanium dioxide and pigment particles serve as experimental products. Coarser size fractions are separated and overflow samples are analysed with analytical centrifugation and UV-vis spectroscopy. Each extinction spectrum is labeled with distinctive target values and a regression model is build. Finally, mixtures are processed and targets determined using the machine learning algorithm. It is discussed to what extent the advanced methodology can be applied to multidimensional unit operations such as density fractionation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Winkler, Marvin; Sonner, Heiko; Gleiss, Marco; Nirschl, Hermann] Karlsruhe Inst Technol, Inst Mech Proc Engn & Mech, Campus Sued,Str Forum 8, D-76131 Karlsruhe, Germany.
RP Winkler, M (reprint author), Karlsruhe Inst Technol, Inst Mech Proc Engn & Mech, Campus Sued,Str Forum 8, D-76131 Karlsruhe, Germany.
EM marvin.winkler2@kit.edu
FU German Research Foundation (Deutsche Forschungsgemeinschaft - DFG)German
   Research Foundation (DFG) [2045]
FX Funding by the German Research Foundation (Deutsche
   Forschungsgemeinschaft - DFG) in the priority program 2045 "Highly
   specific and multidimensional fractionation of fine particle systemes
   with technical relevance." is greatly acknowledged.
CR Akthakul A, 2005, ADV MATER, V17, P532, DOI 10.1002/adma.200400636
   Barbe CJ, 1997, J AM CERAM SOC, V80, P3157
   Bentolila L A, 2005, Discov Med, V5, P213
   Bohren C.F., 2004, ABSORPTION SCATTERIN
   Buitinck L., 2013, ARXIV13090238
   Butler KT, 2018, NATURE, V559, P547, DOI 10.1038/s41586-018-0337-2
   Chen X, 2007, CHEM REV, V107, P2891, DOI 10.1021/cr0500535
   Flegler A, 2016, RSC ADV, V6, pS7236, DOI 10.1039/c6ra09553d
   GIPPEL CJ, 1995, HYDROL PROCESS, V9, P83, DOI 10.1002/hyp.3360090108
   Haiss W, 2007, ANAL CHEM, V79, P4215, DOI 10.1021/ac0702084
   HALPERIN WP, 1986, REV MOD PHYS, V58, P533, DOI 10.1103/RevModPhys.58.533
   Hassan PA, 2015, LANGMUIR, V31, P3, DOI 10.1021/la501789z
   Hendel T, 2014, ANAL CHEM, V86, P11115, DOI 10.1021/ac502053s
   Hoppe H, 2004, J MATER RES, V19, P1924, DOI 10.1557/JMR.2004.0252
   Konrath M, 2016, CHEM ENG SCI, V147, P65, DOI 10.1016/j.ces.2016.03.025
   Konrath M, 2014, ADV POWDER TECHNOL, V25, P991, DOI 10.1016/j.apt.2014.01.022
   Langergraber G, 2003, WATER SCI TECHNOL, V47, P63
   Mantele W, 2017, SPECTROCHIM ACTA A, V173, P965, DOI 10.1016/j.saa.2016.09.037
   Muller F, 2010, CHEM ENG TECHNOL, V33, P1419, DOI 10.1002/ceat.200900540
   Naiim M, 2015, SOFT MATTER, V11, P28, DOI 10.1039/c4sm01995d
   Novak JP, 2001, ANAL CHEM, V73, P5758, DOI 10.1021/ac010812t
   Otto M.V., 2017, CHEMOMETRICS STAT CO, DOI [10.1002/9783527699377, DOI 10.1002/9783527699377]
   Paramelle D, 2014, ANALYST, V139, P4855, DOI 10.1039/c4an00978a
   Pfaff G, 1999, CHEM REV, V99, P1963, DOI 10.1021/cr970075u
   Pilania G, 2013, SCI REP-UK, V3, DOI 10.1038/srep02810
   Pillai S, 2010, SOL ENERG MAT SOL C, V94, P1481, DOI 10.1016/j.solmat.2010.02.046
   Rogel-Salazar J., 2017, DATA SCI ANAL PYTHON
   Rossel RAV, 2006, GEODERMA, V137, P70, DOI 10.1016/j.geoderma.2006.07.004
   Spelter LE, 2012, CHEM ENG TECHNOL, V35, P1486, DOI 10.1002/ceat.201200050
   Stahl S, 2008, CHEM ENG TECHNOL, V31, P1577, DOI 10.1002/ceat.200800300
   Sun XM, 2009, ANGEW CHEM INT EDIT, V48, P939, DOI 10.1002/anie.200805047
   Sun YG, 2002, SCIENCE, V298, P2176, DOI 10.1126/science.1077229
   Van Eerdenbrugh B, 2011, PHARM RES-DORDR, V28, P1643, DOI 10.1007/s11095-011-0399-4
   VanderPlas J, 2016, PYTHON DATA SCI HDB
   Walter J, 2015, ANAL CHEM, V87, P3396, DOI 10.1021/ac504649c
   Wiley BJ, 2007, NANO LETT, V7, P1032, DOI 10.1021/nl070214f
   WOHRLE D, 1991, ADV MATER, V3, P129, DOI 10.1002/adma.19910030303
   Xia YN, 2009, ANGEW CHEM INT EDIT, V48, P60, DOI 10.1002/anie.200802248
NR 38
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115374
DI 10.1016/j.ces.2019.115374
PG 13
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600007
DA 2020-05-12
ER

PT J
AU Zhang, YN
   Wu, P
   Jeantet, R
   Dupont, D
   Delaplace, G
   Chen, XD
   Xiao, J
AF Zhang, Yanan
   Wu, Peng
   Jeantet, Romain
   Dupont, Didier
   Delaplace, Guillaume
   Chen, Xiao Dong
   Xiao, Jie
TI How motility can enhance mass transfer and absorption in the duodenum:
   Taking the structure of the villi into account
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Motility; Small intestine; Villi; Mass transfer and absorption;
   Numerical simulation; Moving mesh method
ID SMALL-INTESTINE; FLOW; DIGESTION; ILEUM; CONTRACTIONS; MODEL; TRANSPORT;
   CHYME; ACID
AB Given the complex motility of the intestinal wall featuring villous structure, the mechanisms by which the motility can enhance mass transfer and absorption in the small intestine have been a mystery. In this work, the challenging task to couple the intestinal lumen flow and the contraction movement of the villi is tackled by a multi-physics model. The effects of motility of an entire duodenum on the mass transfer and absorption under the influence of ambient flow can be systematically explored. It is revealed that the top of the villi plays a major role in mass absorption. For a rat duodenum, the pendular movement can enhance mass transfer and absorption by up to about 72%. With the introduction of ambient flow, although the absorption amount increases, the enhancement of mass transfer by pendular activity is inhibited. Specifically, the average enhancement factor decreases sharply from similar to 1.35 to similar to 1.05. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Yanan; Wu, Peng; Chen, Xiao Dong; Xiao, Jie] Soochow Univ, Coll Chem Chem Engn & Mat Sci, Sch Chem & Environm Engn, Suzhou 215123, Jiangsu, Peoples R China.
   [Jeantet, Romain; Dupont, Didier] INRA, STLO, UMR 1253, Agrocampus Quest, F-35000 Rennes, France.
   [Delaplace, Guillaume] INRA, Team PIHM, UMET, UMR 8207, 369 Rue Jules Guesde, F-59651 Villeneuve Dascq, France.
RP Xiao, J (reprint author), Soochow Univ, Coll Chem Chem Engn & Mat Sci, Sch Chem & Environm Engn, Suzhou 215123, Jiangsu, Peoples R China.
EM jie.xiao@suda.edu.cn
OI Xiao, Jie/0000-0001-7842-7862
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21978184]; Natural Science Foundation of Jiangsu
   ProvinceJiangsu Planned Projects for Postdoctoral Research FundsNatural
   Science Foundation of Jiangsu Province [BK20170062]; National Key
   Research and Development Program of China (International S&T Cooperation
   Program, ISTCP) [2016YFE0101200]; COFCO Nutrition and Health Research
   Institute (Beijing); Jiangsu Specially-Appointed Professors Program;
   Jiangsu Innovation and Entrepreneurship (Shuang Chuang) Program;
   Priority Academic Program Development (PAPD) of Jiangsu Higher Education
   Institutions
FX This work was supported by the research funds from the National Natural
   Science Foundation of China (No. 21978184), the Natural Science
   Foundation of Jiangsu Province (Grant No. BK20170062), the National Key
   Research and Development Program of China (International S&T Cooperation
   Program, ISTCP, No. 2016YFE0101200), the COFCO Nutrition and Health
   Research Institute (Beijing), and the "Jiangsu Specially-Appointed
   Professors Program", "Jiangsu Innovation and Entrepreneurship (Shuang
   Chuang) Program", "Priority Academic Program Development (PAPD) of
   Jiangsu Higher Education Institutions".
CR Baklis S., 2009, ROYAL SOC CHEM, V21, P377
   BARRY RE, 1976, J MAMMAL, V57, P273, DOI 10.2307/1379688
   Bornhorst GM, 2016, J FOOD SCI, V81, pR534, DOI 10.1111/1750-3841.13216
   Canto MIF, 1996, GASTROINTEST ENDOSC, V44, P1, DOI 10.1016/S0016-5107(96)70221-3
   CHRISTENSEN J, 1971, NEW ENGL J MED, V285, P85, DOI 10.1056/NEJM197107082850205
   de Loubens C, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0027
   Delaplace G, 2018, CHEM ENG SCI, V192, P1071, DOI 10.1016/j.ces.2018.08.023
   Fonseca M.R.J., 2012, ENG UNDERSTANDING SM
   Gouseti O, 2014, FOOD HYDROCOLLOID, V42, P378, DOI 10.1016/j.foodhyd.2014.06.004
   GRIVEL ML, 1972, J PHYSIOL-LONDON, V227, P611, DOI 10.1113/jphysiol.1972.sp010050
   Guseinov TS, 2008, B EXP BIOL MED+, V145, P755, DOI 10.1007/s10517-008-0187-2
   Gwynne RM, 2004, J PHYSIOL-LONDON, V556, P557, DOI 10.1113/jphysiol.2003.057182
   Holm M, 2001, DIGEST DIS SCI, V46, P1765, DOI 10.1023/A:1010674109111
   Janssen J, 2013, APPLIED DIFFUSION PROCESSES FROM ENGINEERING TO FINANCE, P219
   Janssen PWM, 2007, J PHYSIOL-LONDON, V582, P1239, DOI 10.1113/jphysiol.2007.134403
   Jeffrey B, 2003, AM J PHYSIOL-GASTR L, V285, pG907, DOI 10.1152/ajpgi.00062.2003
   Lammers WJEP, 1996, NEUROGASTROENT MOTIL, V8, P207, DOI 10.1111/j.1365-2982.1996.tb00259.x
   Leiper JB, 2015, NUTR REV, V73, P57, DOI 10.1093/nutrit/nuv032
   Lentle RG, 2018, FOOD FUNCT, V9, P4069, DOI [10.1039/C8FO00722E, 10.1039/c8fo00722e]
   Lentle RG, 2015, J COMP PHYSIOL B, V185, P369, DOI 10.1007/s00360-015-0889-5
   Lentle RG, 2013, NEUROGASTROENT MOTIL, V25, P881, DOI 10.1111/nmo.12203
   Lentle RG, 2012, NEUROGASTROENT MOTIL, V24, DOI 10.1111/j.1365-2982.2012.01923.x
   Lentle RG, 2008, J COMP PHYSIOL B, V178, P257, DOI 10.1007/s00360-007-0217-9
   Lentle RG, 2007, J COMP PHYSIOL B, V177, P543, DOI 10.1007/s00360-007-0153-8
   Lim I.Y.F., 2015, THESIS
   Lim YF, 2015, FOOD FUNCT, V6, P1787, DOI [10.1039/c5fo00285k, 10.1039/C5FO00285K]
   Lim YF, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.1008
   Lim YF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100140
   Liu MH, 2018, CHEM ENG TECHNOL, V41, P1051, DOI 10.1002/ceat.201600617
   MELVILLE J, 1975, AM J PHYSIOL, V228, P1887
   Moxon TE, 2016, J FOOD ENG, V176, P110, DOI 10.1016/j.jfoodeng.2015.10.019
   Riahi DN, 2011, APPL APPL MATH, V6, P428
   Schulze KS, 2015, ACTA PHYSIOL, V213, P394, DOI 10.1111/apha.12407
   Schulze-Delrieu K, 1999, AM J PHYSIOL-GASTR L, V276, pG1417
   Stoll BR, 2000, CHEM ENG SCI, V55, P473, DOI 10.1016/S0009-2509(99)00308-5
   Tharakan A, 2010, J FOOD SCI, V75, pE339, DOI 10.1111/j.1750-3841.2010.01659.x
   Wang YX, 2017, PHYS REV E, V95, DOI 10.1103/PhysRevE.95.062412
   Wang YX, 2010, PHILOS T R SOC A, V368, P2863, DOI 10.1098/rsta.2010.0090
   Wright ND, 2016, J FOOD ENG, V171, P129, DOI 10.1016/j.jfoodeng.2015.10.013
   Xiao J, 2018, CHEM ENG SCI, V181, P272, DOI 10.1016/j.ces.2018.02.019
NR 40
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115406
DI 10.1016/j.ces.2019.115406
PG 13
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600021
DA 2020-05-12
ER

PT J
AU Zhu, LT
   Yang, YN
   Pan, DT
   Luo, ZH
AF Zhu, Li-Tao
   Yang, Ya-Nan
   Pan, De-Tao
   Luo, Zheng-Hong
TI Capability assessment of coarse-grid simulation of gas-particle riser
   flow using sub-grid drag closures
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Computational fluid dynamics; Mesoscale riser flow; Sub-grid drag model;
   Coarse-grid simulation; Capability assessment
ID FILTERED 2-FLUID MODELS; BOUNDARY-CONDITIONS; HEAT-TRANSFER; SOLID
   FLOWS; INDEPENDENCE BEHAVIOR; NUMERICAL-SIMULATION; CFD SIMULATIONS;
   VALIDATION; FLUID; VERIFICATION
AB Our prior work developed an effective material-property-dependent sub-grid model (SGM) for efficient coarse-grid riser flow simulations. To apply this SGM for the purpose of designing and scaling-up riser reactors reliably, quantitative assessment in its predictive capability is required. Here, we quantify the influence of various model parameters with respect to time-averaging, grid resolution, time step, discretization scheme for convection terms, and solid-wall slip condition by implementing extensive three-dimensional coarse-grid simulations. Moreover, we compare several crucial SGM-based coarse-grid and coarse-grained methods to reveal their advantages and disadvantages. Detailed parametric sensitivity analyses demonstrate that the accurate determination of SGM appears to play a dominant role in successfully predicting hydrodynamics. The optimal selection of the other model parameters is suggested to realize a compromise between computation speed and accuracy. Overall, this fundamental study helps to quantitatively understand the predictability of SGMs for coarse-grid simulations of large-scale riser reactors. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhu, Li-Tao; Yang, Ya-Nan; Pan, De-Tao; Luo, Zheng-Hong] Shanghai Jiao Tong Univ, Sch Chem & Chem Engn, Dept Chem Engn, State Key Lab Met Matrix Composites, Shanghai 200240, Peoples R China.
RP Pan, DT; Luo, ZH (reprint author), Shanghai Jiao Tong Univ, Sch Chem & Chem Engn, Dept Chem Engn, State Key Lab Met Matrix Composites, Shanghai 200240, Peoples R China.
EM pandetao@sjtu.edu.cn; luozh@sjtu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [91834303, U1862201, 21776173, 21625603]; Program of
   Shanghai Subject Chief Scientist [18XD1402000]
FX The authors thank the National Natural Science Foundation of China (No.
   91834303, U1862201, 21776173 and 21625603), the Program of Shanghai
   Subject Chief Scientist (No. 18XD1402000).
CR Ahmad N, 2019, CHEM ENG SCI, V200, P257, DOI 10.1016/j.ces.2019.02.016
   Almuttahar A, 2008, POWDER TECHNOL, V185, P11, DOI 10.1016/j.powtec.2007.09.010
   Arastoopour H, 2019, CHEM ENG SCI, V203, P247, DOI 10.1016/j.ces.2019.03.069
   Benyahia S, 2012, AICHE J, V58, P427, DOI 10.1002/aic.12603
   Chen XZ, 2018, CHEM ENG SCI, V192, P864, DOI 10.1016/j.ces.2018.08.019
   Cloete JH, 2019, CHEM ENG SCI, V207, P379, DOI 10.1016/j.ces.2019.06.006
   Cloete S, 2018, CHEM ENG SCI, V182, P93, DOI 10.1016/j.ces.2018.02.032
   Cloete S, 2016, POWDER TECHNOL, V289, P65, DOI 10.1016/j.powtec.2015.11.011
   Cloete S, 2015, POWDER TECHNOL, V269, P153, DOI 10.1016/j.powtec.2014.08.055
   Cornelissen JT, 2007, CHEM ENG SCI, V62, P6334, DOI 10.1016/j.ces.2007.07.014
   Coroneo M, 2011, CHEM ENG SCI, V66, P2317, DOI 10.1016/j.ces.2011.02.019
   Deen NG, 2014, CHEM ENG SCI, V116, P710, DOI 10.1016/j.ces.2014.05.039
   Fullmer WD, 2016, AICHE J, V62, P11, DOI 10.1002/aic.15052
   Gao X, 2018, AICHE J, V64, P3565, DOI 10.1002/aic.16341
   Gao X, 2018, CHEM ENG SCI, V184, P33, DOI 10.1016/j.ces.2018.03.038
   Gao X, 2017, ALGAL RES, V24, P1, DOI 10.1016/j.algal.2017.03.009
   Gao X, 2012, CHEM ENG SCI, V78, P98, DOI 10.1016/j.ces.2012.03.030
   Ge W, 2019, COMPUT CHEM ENG, V126, P68, DOI 10.1016/j.compchemeng.2019.03.042
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Grace JR, 2004, POWDER TECHNOL, V139, P99, DOI 10.1016/j.powtec.2003.10.006
   Gungor A, 2013, COMPUT CHEM ENG, V48, P234, DOI 10.1016/j.compchemeng.2012.09.012
   Hamidouche Z, 2019, CHEM ENG SCI, V193, P102, DOI 10.1016/j.ces.2018.08.032
   Harshe YM, 2004, CHEM ENG SCI, V59, P5145, DOI 10.1016/j.ces.2004.09.005
   Herbert P, 1999, AICHE SYM S, V95, P61
   Heynderickx GJ, 2004, IND ENG CHEM RES, V43, P4635, DOI 10.1021/ie034122m
   Hong K, 2018, ADV POWDER TECHNOL, V29, P488, DOI 10.1016/j.apt.2018.02.024
   Hu SW, 2019, CHEM ENG SCI, V205, P14, DOI 10.1016/j.ces.2019.04.033
   Jain D, 2015, CHEM ENG SCI, V137, P685, DOI 10.1016/j.ces.2015.07.025
   Jiang Y, 2018, POWDER TECHNOL, V346, P403
   JOHNSON PC, 1987, J FLUID MECH, V176, P67, DOI 10.1017/S0022112087000570
   Karthik GM, 2018, AICHE J, V64, P4162, DOI 10.1002/aic.16386
   Lan XY, 2012, CHEM ENG SCI, V69, P419, DOI 10.1016/j.ces.2011.10.064
   Lane WA, 2018, CHEM ENG SCI, V176, P409, DOI 10.1016/j.ces.2017.11.018
   Lane WA, 2016, CHEM ENG SCI, V151, P7, DOI 10.1016/j.ces.2016.05.005
   Li TW, 2017, AICHE J, V63, P1203, DOI 10.1002/aic.15507
   Li TW, 2014, CHEM ENG SCI, V120, P10, DOI 10.1016/j.ces.2014.08.041
   Li TW, 2014, POWDER TECHNOL, V254, P115, DOI 10.1016/j.powtec.2014.01.022
   Li TW, 2012, AICHE J, V58, P2058, DOI 10.1002/aic.12728
   Li TW, 2012, CHEM ENG SCI, V84, P746, DOI 10.1016/j.ces.2012.09.024
   Li TW, 2010, POWDER TECHNOL, V203, P447, DOI 10.1016/j.powtec.2010.06.005
   Liu XH, 2012, CHEM ENG PROG, V108, P28
   Liu YX, 2019, CHEM ENG J, V370, P1154, DOI 10.1016/j.cej.2019.03.267
   Lu BN, 2019, REV CHEM ENG, V35, P879, DOI 10.1515/revce-2017-0023
   Lu BN, 2011, CHEM ENG SCI, V66, P4624, DOI 10.1016/j.ces.2011.06.026
   Lu LQ, 2014, CHEM ENG SCI, V120, P67, DOI 10.1016/j.ces.2014.08.004
   Luo H, 2017, CHEM ENG J, V326, P47, DOI 10.1016/j.cej.2017.04.145
   Milioli CC, 2013, AICHE J, V59, P3265, DOI 10.1002/aic.14130
   Moliner C, 2019, CHEM ENG SCI, V207, P39, DOI 10.1016/j.ces.2019.06.008
   Mouallem J, 2019, AICHE J, DOI 10.1002/aic.16763
   Mouallem J, 2018, CHEM ENG SCI, V182, P200, DOI 10.1016/j.ces.2018.02.039
   Nikolopoulos A, 2017, CHEM ENG SCI, V163, P189, DOI 10.1016/j.ces.2017.01.052
   Oberkampf WL, 2008, NUCL ENG DES, V238, P716, DOI 10.1016/j.nucengdes.2007.02.032
   Oberkampf WL, 2002, PROG AEROSP SCI, V38, P209, DOI 10.1016/S0376-0421(02)00005-2
   Ozarkar SS, 2015, POWDER TECHNOL, V284, P159, DOI 10.1016/j.powtec.2015.06.028
   Ozel A, 2017, PHYS FLUIDS, V29, DOI 10.1063/1.5000516
   Ozel A, 2016, CHEM ENG SCI, V155, P258, DOI 10.1016/j.ces.2016.08.014
   Partopour B, 2019, CHEM ENG SCI, V198, P224, DOI 10.1016/j.ces.2018.10.005
   Radl S, 2014, CHEM ENG SCI, V117, P416, DOI 10.1016/j.ces.2014.07.011
   Sakai M, 2014, CHEM ENG J, V244, P33, DOI 10.1016/j.cej.2014.01.029
   Sarkar A, 2016, CHEM ENG SCI, V152, P443, DOI 10.1016/j.ces.2016.06.023
   Schneiderbauer S, 2018, AICHE J, V64, P1591, DOI 10.1002/aic.16142
   Schneiderbauer S, 2017, AICHE J, V63, P3544, DOI 10.1002/aic.15684
   Schneiderbauer S, 2014, AICHE J, V60, P839, DOI 10.1002/aic.14321
   Schneiderbauer S, 2013, AICHE J, V59, P4077, DOI 10.1002/aic.14155
   Schneiderbauer S, 2012, CHEM ENG SCI, V80, P279, DOI 10.1016/j.ces.2012.06.041
   Schneiderbauer S, 2012, INT J MULTIPHAS FLOW, V43, P149, DOI 10.1016/j.ijmultiphaseflow.2012.03.006
   Soleimani A, 2015, INT J MULTIPHAS FLOW, V71, P94, DOI 10.1016/j.ijmultiphaseflow.2014.12.008
   Syamlal M, 2017, AICHE J, V63, P5343, DOI 10.1002/aic.15868
   Utikar RP, 2017, ACS SUSTAIN CHEM ENG, V5, P3607, DOI 10.1021/acssuschemeng.6b03017
   Vila Alija, 2019, Chemical Engineering Science: X, V2, P31, DOI 10.1016/j.cesx.2019.100015
   Wang J., 2019, CHEM ENG J
   Wang JW, 2009, CHEM ENG SCI, V64, P622, DOI 10.1016/j.ces.2008.09.028
   Wang W, 2007, CHEM ENG SCI, V62, P208, DOI 10.1016/j.ces.2006.08.017
   Wen C.Y., 1966, CHEM ENG PROGR S SER, V62, P100, DOI DOI 10.1016/S0032-0633(98)00014-2
   Xie J, 2018, ADV POWDER TECHNOL, V29, P2859, DOI 10.1016/j.apt.2018.08.007
   Xiong QG, 2018, CHEM ENG PROCESS, V127, P206, DOI 10.1016/j.cep.2018.04.005
   Yan WC, 2018, J CLEAN PROD, V178, P476, DOI 10.1016/j.jclepro.2018.01.009
   Zhu LT, 2019, CHEM ENG J, V374, P531, DOI 10.1016/j.cej.2019.05.194
   Zhu LT, 2019, CHEM ENG SCI, V204, P228, DOI 10.1016/j.ces.2019.04.026
   Zhu LT, 2019, CHEM ENG SCI, V196, P478, DOI 10.1016/j.ces.2018.11.026
   Zhu LT, 2018, CHEM ENG SCI, V192, P759, DOI 10.1016/j.ces.2018.08.026
   Zhu LT, 2017, IND ENG CHEM RES, V56, P1090, DOI 10.1021/acs.iecr.6b04026
   Zhu LT, 2016, IND ENG CHEM RES, V55, P11887, DOI 10.1021/acs.iecr.6b02819
   Zhu LT, 2016, CHEM ENG SCI, V143, P369, DOI 10.1016/j.ces.2016.01.006
NR 84
TC 1
Z9 1
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD FEB 23
PY 2020
VL 213
AR 115410
DI 10.1016/j.ces.2019.115410
PG 16
WC Engineering, Chemical
SC Engineering
GA KF8DN
UT WOS:000509467600024
DA 2020-05-12
ER

PT J
AU Hills, SL
   Fischer, M
   Biggerstaff, BJ
AF Hills, Susan L.
   Fischer, Marc
   Biggerstaff, Brad J.
TI Perceptions among the US population of value of Japanese encephalitis
   (JE) vaccination for travel to JE-endemic countries
SO VACCINE
LA English
DT Article
DE Japanese encephalitis; Vaccine; Risk perception; Travel
ID ADVISORY-COMMITTEE; IMMUNIZATION; SAFETY; RECOMMENDATIONS;
   IMMUNOGENICITY; VACCINES; IC51
AB Introduction: Japanese encephalitis (JE) is a rare but potentially severe disease among travelers. JE vaccine in the United States costs $500-$600 for a 2-dose series and is safe and effective but rare serious adverse events can occur. Our survey investigated likelihood of vaccine receipt for travel.
   Methods: An electronically-administered survey was conducted among U.S. adults. Participants were presented a hypothetical scenario on travel to a JE-endemic country and JE vaccine characteristics and responded on likelihood of vaccination.
   Results: Overall, 6384 (59%) of 10,904 persons completed the questions. Population estimates indicated 32% would be likely and 42% were unlikely to be vaccinated, and 26% were unsure. Among those likely to get vaccinated, important factors were disease risk and severity, and vaccine safety. Among those unlikely, cost, disease risk, and possibility of serious side effects ranked highest.
   Conclusions: There is population heterogeneity in perception of JE disease risk and value of vaccination. Published by Elsevier Ltd.
C1 [Hills, Susan L.; Fischer, Marc; Biggerstaff, Brad J.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA.
RP Hills, SL (reprint author), Ctr Dis Control & Prevent, 3156 Rampart Rd, Ft Collins, CO 80521 USA.
EM shills@cdc.gov
CR Benoit CM, 2013, J TRAVEL MED, V20, P346, DOI 10.1111/jtm.12056
   Dubischar KL, 2017, PEDIATR INFECT DIS J, V36, P898, DOI 10.1097/INF.0000000000001615
   Dubischar-Kastner K, 2010, VACCINE, V28, P6463, DOI 10.1016/j.vaccine.2010.07.040
   GfK, KNOWLEDGEPANEL METH
   Heffelfinger JD, 2017, MMWR-MORBID MORTAL W, V66, P579, DOI 10.15585/mmwr.mm6622a3
   Hills SL, 2019, MMWR RECOMM REP, V68, P1
   Hills SL, 2010, AM J TROP MED HYG, V82, P930, DOI 10.4269/ajtmh.2010.09-0676
   Lee G, 2018, MMWR-MORBID MORTAL W, V67, P1271, DOI 10.15585/mmwr.mm6745a4
   LUMLEY T, 2015, J SURVEY STAT METHOD, V3, P1, DOI DOI 10.1093/jssam/smu021
   Lumley T., 2004, J STAT SOFTW, V9, P1, DOI DOI 10.18637/JSS.V009.I08
   Marshall H, 2009, J PAEDIATR CHILD H, V45, P297, DOI 10.1111/j.1440-1754.2009.01494.x
   Poulos C, 2018, VACCINE, V36, P969, DOI 10.1016/j.vaccine.2018.01.004
   Shlim DR, 2002, CLIN INFECT DIS, V35, P183, DOI 10.1086/341247
   Siddiqui M, 2013, HUM VACC IMMUNOTHER, V9, P2643, DOI 10.4161/hv.27243
   Solomon T, 2000, J NEUROL NEUROSUR PS, V68, P405, DOI 10.1136/jnnp.68.4.405
   Tauber E, 2008, J INFECT DIS, V198, P493, DOI 10.1086/590116
   Tauber E, 2007, LANCET, V370, P1847, DOI 10.1016/S0140-6736(07)61780-2
   United States Census Bureau, CURR POP SURV
   Voumard R, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0654-y
   Walker WL, 2018, VACCINE, V36, P4369, DOI 10.1016/j.vaccine.2018.04.038
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2117
EP 2121
DI 10.1016/j.vaccine.2020.01.048
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900003
PM 31992482
DA 2020-05-12
ER

PT J
AU Pilaev, M
   Shen, Y
   Carbonneau, J
   Venable, MC
   Rheaume, C
   Lavigne, S
   Couture, C
   Guarne, A
   Hamelin, ME
   Boivin, G
AF Pilaev, Martin
   Shen, Yao
   Carbonneau, Julie
   Venable, Marie-Christine
   Rheaume, Chantal
   Lavigne, Sophie
   Couture, Christian
   Guarne, Alba
   Hamelin, Marie-Eve
   Boivin, Guy
TI Evaluation of pre- and post-fusion Human metapneumovirus F proteins as
   subunit vaccine candidates in mice
SO VACCINE
LA English
DT Article
DE Balb/C; hMPV; Fusion protein; Pre-fusion; Vaccine; Immunisation
ID INFECTION
AB Human metapneumovirus (hMPV) is an important respiratory pathogen especially in young children and elderly subjects. Our objective was to assess the immunogenicity and protection conferred by predominant pre- and post-fusion (F) hMPV-F constructs in Balb/C mice. Immunizations without adjuvant were not immunogenic whereas alum-adjuvanted hMPV-F proteins, regardless of their conformations, generated comparable neutralizing antibody titers with undetectable pulmonary viral titers following viral challenge. In conclusion, we found no apparent advantage for mixtures of predominant pre-fusion F proteins over post-fusion conformations for hMPV vaccination in opposite to recent data obtained with the human respiratory syncytial virus. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Pilaev, Martin; Carbonneau, Julie; Venable, Marie-Christine; Rheaume, Chantal; Hamelin, Marie-Eve; Boivin, Guy] CHU Quebec, Infect Dis Res Ctr, Quebec City, PQ, Canada.
   [Pilaev, Martin; Carbonneau, Julie; Venable, Marie-Christine; Rheaume, Chantal; Hamelin, Marie-Eve; Boivin, Guy] Laval Univ, Quebec City, PQ, Canada.
   [Shen, Yao; Guarne, Alba] McGill Univ, Dept Biochem, Montreal, PQ, Canada.
   [Lavigne, Sophie; Couture, Christian] Laval Univ, Quebec Heart & Lung Inst, Quebec City, PQ, Canada.
RP Boivin, G (reprint author), CHU Quebec, Infect Dis Res Ctr, Quebec City, PQ, Canada.; Boivin, G (reprint author), Laval Univ, Quebec City, PQ, Canada.
EM Guy.Boivin@crchudequebec.ulaval.ca
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR) [273261, PJT-155491]
FX This study was supported by grants from Canadian Institutes of Health
   Research No. 273261 to GB and PJT-155491 to AG.
CR Aerts L, 2015, J GEN VIROL, V96, P767, DOI 10.1099/vir.0.000031
   Alvarez R, 2005, J VIROL, V79, P5971, DOI 10.1128/JVI.79.10.5971-5978.2005
   Battles MB, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01708-9
   Cseke G, 2007, J VIROL, V81, P698, DOI 10.1128/JVI.00844-06
   Davis CR, 2016, J PEDIAT INF DIS SOC, V5, P303, DOI 10.1093/jpids/piv027
   Hamelin ME, 2007, J GEN VIROL, V88, P3391, DOI 10.1099/vir.0.83250-0
   Hamelin ME, 2005, J VIROL, V79, P8894, DOI 10.1128/JVI.79.14.8894-8903.2005
   Klimpel GR, 1996, MED MICROBIOLOGY
   Lambert SL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119509
   Mas V, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005859
   McLellan JS, 2015, CURR OPIN VIROL, V11, P70, DOI 10.1016/j.coviro.2015.03.002
   McLellan JS, 2013, SCIENCE, V342, P592, DOI 10.1126/science.1243283
   McLellan JS, 2013, SCIENCE, V340, P1113, DOI 10.1126/science.1234914
   Mousa JJ, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2016.271
   Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006
   Shafagati Nazly, 2018, F1000Res, V7, P135, DOI 10.12688/f1000research.12625.1
   van den Hoogen BG, 2001, NAT MED, V7, P719, DOI 10.1038/89098
   Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166
NR 18
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2122
EP 2127
DI 10.1016/j.vaccine.2020.01.047
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900004
PM 32007293
DA 2020-05-12
ER

PT J
AU Suntarattiwong, P
   Vandepitte, WP
   Singhamatr, P
   Chotpitayasunondh, T
AF Suntarattiwong, Piyarat
   Vandepitte, Warunee Punpanich
   Singhamatr, Pon
   Chotpitayasunondh, Tawee
TI Seroprotection rate in adults after 1-dose, 2-dose, and 3-dose series of
   a reduced-diphtheria-tetanus toxoid vaccine (Td) during a diphtheria
   outbreak in Thailand
SO VACCINE
LA English
DT Article
DE Diphtheria outbreak; Diphtheria toxoid vaccine; Diphtheria; Adult
   vaccination; Thailand immunization program
ID SEROPREVALENCE; IMMUNITY; CHILDREN
AB To evaluate seroprotection of different dosing strategies of reduced-diphtheria-tetanus-toxoid vaccine (Td) for adults during a diphtheria outbreak in Thailand, we enrolled 160 healthcare workers and 161 adults aged 20-60 years old and measured diphtheria antitoxin (DAT) level before administration of a Td vaccine. We scheduled a second Td at 4-8 weeks and a third Td at 6-12 months interval. DAT was measured 4 weeks after each dose. DAT levels of >= 0.1 and >= 1 IU/mL were considered as seroprotective and long-term seroprotective. Persons achieving long-term seroprotection were not given a further dose.
   The baseline seroprotection rate was 32.6%, which increased to 87.1% (95% confidence interval, 83.4-90.8%) after one dose. The seroprotection rate increased slightly with additional doses. The immune response was lowest among persons 30-49 years of age. We suggest 1-dose Td for adults during a diphtheria outbreak, and a 2-dose series being considered for those born before 1980. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Suntarattiwong, Piyarat; Vandepitte, Warunee Punpanich; Chotpitayasunondh, Tawee] Queen Sirikit Natl Inst Child Hlth, 420-8 Rajavithi Rd, Bangkok 10400, Thailand.
   [Suntarattiwong, Piyarat; Vandepitte, Warunee Punpanich] Rangsit Univ, Coll Med, Bangkok, Thailand.
   [Singhamatr, Pon] Queen Sirikit Natl Inst Child Hlth, Dept Pathol, Bangkok, Thailand.
RP Suntarattiwong, P (reprint author), Queen Sirikit Natl Inst Child Hlth, 420-8 Rajavithi Rd, Bangkok 10400, Thailand.
EM dr.piyarat.suntarattiwong@gmail.com
FU Department of Medical Services Research Fund, Thai Ministry of Public
   Health
FX This work was supported by the Department of Medical Services Research
   Fund, Thai Ministry of Public Health.
CR Acosta AM, 2020, HUNTERS TROPICAL MED, P439
   Hughes GJ, 2015, PEDIATR INFECT DIS J, V34, P1152, DOI 10.1097/INF.0000000000000846
   Kimberlin DW, 2018, RED BOOK 2018 REPORT, P319
   Kurugol Z, 2011, VACCINE, V29, P4341, DOI 10.1016/j.vaccine.2011.04.016
   Mahomed S, 2017, EPIDEMIOL INFECT, V145, P2100, DOI [10.1017/S0950268817000851, 10.1017/s0950268817000851]
   Sangal L, 2017, FRONT PUBLIC HEALTH, V5, DOI 10.3389/fpubh.2017.00218
   Sein C, 2016, VACCINE, V34, P4321, DOI 10.1016/j.vaccine.2016.06.074
   Suntarattiwong P, 2019, INT J INFECT DIS, V81, P43, DOI 10.1016/j.ijid.2019.01.031
   Tharmaphornpilas P, 2001, J INFECT DIS, V184, P1035, DOI 10.1086/323453
   Tiwari TSP, 2018, PLOTKINS VACCINES, DOI [10.1016/B978-0-323-35761-6.00019-5, DOI 10.1016/B978-0-323-35761-6.00019-5]
   Wanlapakorn N, 2014, SE ASIAN J TROP MED, V45, P1132
   World Hlth Org, 2018, VACCINE, V36, P199, DOI 10.1016/j.vaccine.2017.08.024
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2128
EP 2131
DI 10.1016/j.vaccine.2020.01.040
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900005
PM 31987691
DA 2020-05-12
ER

PT J
AU Akpalu, Y
   Sullivan, SJ
   Regan, AK
AF Akpalu, Yao
   Sullivan, Seth J.
   Regan, Annette K.
TI Association between health insurance coverage and uptake of seasonal
   influenza vaccine in Brazos County, Texas
SO VACCINE
LA English
DT Article
DE Influenza vaccine; Vaccination; Health insurance; Vaccination coverage
ID UNITED-STATES; CARE; ACCESS
AB Background: Lack of health insurance may limit access to influenza vaccination, resulting in higher risk of infection.
   Methods: The Brazos County Health Department obtained medical records summarizing vaccination and health insurance status of all influenza cases occurring in December 2017 (n = 417). The odds of influenza vaccination were estimated for those with public or private health insurance as compared to uninsured individuals using multivariate logistic regression analysis adjusted for age and race.
   Results: Health insurance coverage among Brazos County residents with influenza was 62.4%. Public and private health insurance was associated with higher odds of influenza vaccination compared to no insurance (aOR: 2.05; 95% CI: 1.00-4.21 and aOR: 1.77; 95% CI: 1.07-2.92, respectively), particularly among adults 18-64 years of age.
   Conclusions: Influenza vaccination is strongly associated with health insurance. Expansion of programs that facilitate access to health services or provide free influenza vaccines may improve influenza prevention among the uninsured. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Akpalu, Yao; Sullivan, Seth J.] Brazos Cty Hlth Dist, 201 North Texas Avenue, Bryan, TX 77803 USA.
   [Regan, Annette K.] Texas A&M Univ, Sch Publ Hlth, College Stn, TX 77843 USA.
   [Regan, Annette K.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA.
RP Regan, AK (reprint author), Texas A&M Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 1266 TAMU, College Stn, TX 77843 USA.
EM a_regan@tamu.edu
CR Akpalu Y, 2019, INFECT DIS, V12, DOI [10.1177/1178633719863815, DOI 10.1177/1178633719863815.EC0LLECTI0N]
   Berchick ER, 2018, HLTH INSURANCE COVER
   Blinn College District, 2017, BLINN ENR 18977 STUD
   Budhwani H, 2016, PUBLIC HEALTH, V138, P146, DOI 10.1016/j.puhe.2016.04.003
   Centers for Disease Control and Prevention, EST INFL ILLN MED VI
   Centers for Disease Control and Prevention, 2018, INFL SEAS VACC COV R
   Fox J. B., 2010, Morbidity and Mortality Weekly Report, V59, P1448
   Gilstad-Hayden K, 2015, PREV MED, V74, P97, DOI 10.1016/j.ypmed.2015.02.008
   Grohskopf LA, 2018, MMWR RECOMM REP, V67, DOI 10.15585/mmwr.rr6703a1
   Hadley J, 2007, JAMA-J AM MED ASSOC, V297, P1073, DOI 10.1001/jama.297.10.1073
   Hoffman C, 2008, ANN NY ACAD SCI, V1136, P149, DOI 10.1196/annals.1425.007
   McMorrow S, 2014, AM J PUBLIC HEALTH, V104, P2392, DOI 10.2105/AJPH.2013.301569
   Office of Disease Prevention and Health Promotion (ODPHP), 2018, HLTH PEOPL 2020 OBJ
   Rolfes MA, 2018, INFLUENZA OTHER RESP, V12, P132, DOI 10.1111/irv.12486
   Stone K, 2018, VACCINE, V36, P6001, DOI 10.1016/j.vaccine.2018.08.030
   Texas A&M University, 2017, ENR PROF SPRING 2017
   Tian C, 2018, J PUBLIC HLTH, DOI [10.1093/pubmed/fdy189, DOI 10.1093/PITHMED/FDYL89]
   US Census Bureau, 2019, HLTH INS HIST TABL H
   US Census Bureau, 2019, QUICKFACTS BRAZ COUN
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2132
EP 2135
DI 10.1016/j.vaccine.2020.01.029
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900006
PM 32008878
DA 2020-05-12
ER

PT J
AU Thompson, KM
   Orenstein, WA
   Hinman, AR
AF Thompson, Kimberly M.
   Orenstein, Walter A.
   Hinman, Alan R.
TI Performance of the United States Vaccine Injury Compensation Program
   (VICP): 1988-2019
SO VACCINE
LA English
DT Review
DE Vaccine; Safety; Injury compensation; Vaccine Injury Compensation
   Program (VICP)
AB The United States (US) highly values the individual and societal benefits of vaccination and invests significantly in vaccine development and use as part of its national vaccine enterprise. In 1986, recognizing the small, but non -zero risks associated with vaccines, the US created a mechanism to collect excise taxes on each dose of vaccine to fund a national Vaccine Injury Compensation Program (VICP). The VICP includes a system for those claiming serious injuries from vaccines to seek compensation, and a process to pay individuals with legitimate claims and their legal counsel. Given the maturity of the VICP, we review experience with the vaccines and injuries covered, claims, and economics of the fund. Our review shows the excellent safety track record of vaccines, provides some evidence of injuries related specifically to vaccine delivery, and discusses the financial health of the fund. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Thompson, Kimberly M.] Kid Risk Inc, 7512 Dr Phillips Blvd 50-523, Orlando, FL 32819 USA.
   [Orenstein, Walter A.] Emory Univ, Atlanta, GA 30322 USA.
   [Hinman, Alan R.] Task Force Global Hlth, Atlanta, GA USA.
RP Thompson, KM (reprint author), Kid Risk Inc, 7512 Dr Phillips Blvd 50-523, Orlando, FL 32819 USA.
EM kimt@kidrisk.org
OI Thompson, Kimberly/0000-0002-0849-9147
FU US Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [5NU2RGH001913-03-00]
FX The lead author acknowledges support from Cooperative Agreement Number
   5NU2RGH001913-03-00 funded by the US Centers for Disease Control and
   Prevention. Its contents are solely the responsibility of the authors
   and do not necessarily represent the official views of the US Centers
   for Disease Control and Prevention or the Department of Health and Human
   Services. We thank James Goodson, Julie Jenks, Narayan Nair, Paul Rota,
   and Ward Sorensen for helpful information, discussions, and comments.
CR Atanasoff S, 2010, VACCINE, V28, P8049, DOI 10.1016/j.vaccine.2010.10.005
   Cook KM, 2011, PEDIATRICS, V127, pS74, DOI 10.1542/peds.2010-1722K
   Department of Health and Human Services HSRA, 2019, DAT STAT
   Evans G, 1999, VACCINE, V17, pS25, DOI 10.1016/S0264-410X(99)00291-1
   Hesse EM, 2020, VACCINE, V38, P1076, DOI 10.1016/j.vaccine.2019.11.032
   HINMAN AR, 1989, FOOD DRUG LAW J, V44, P633
   Marcuse EK, 1997, PEDIATRICS, V100, P1015
   Meissner HC, 2019, JAMA-J AM MED ASSOC, V321, P343, DOI 10.1001/jama.2018.20421
   National Vaccine Advisory Committee, 1997, US VACC INJ COMP TRU
   National Vaccine Advisory Committee, 1996, VACC SAF SEPT
   Roush SW, 2007, JAMA-J AM MED ASSOC, V298, P2155, DOI 10.1001/jama.298.18.2155
   Treadway Johnson M, 1998, USE EXPERT TESTIMONY
   U.S. Court of Federal Claims Office of Special Masters, 2010, BACKGR US ONL AUT P
   U.S. Court of Federal Claims Office of Special Masters, 2012, OMN AUT P
   U.S. Department of the Treasury, 2019, US DEP TREAS TREAS B
   US Department of Health and Human Services Health Resources and Services Administration, 2017, VACC INJ TABL
   Zhou FJ, 2014, PEDIATRICS, V133, P577, DOI 10.1542/peds.2013-0698
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2136
EP 2143
DI 10.1016/j.vaccine.2020.01.042
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900007
PM 31982259
DA 2020-05-12
ER

PT J
AU Huneycutt, B
   Lurie, N
   Rotenberg, S
   Wilder, R
   Hatchett, R
AF Huneycutt, Brenda
   Lurie, Nicole
   Rotenberg, Sara
   Wilder, Richard
   Hatchett, Richard
TI Finding equipoise: CEPI revises its equitable access policy
SO VACCINE
LA English
DT Review
DE Vaccine development; Emerging infectious diseases; Epidemic
   preparedness; Equitable Access
AB Launched at Davos in January 2017 with funding from sovereign investors and philanthropic institutions, the Coalition for Epidemic Preparedness Innovations (CEPI) is an innovative partnership between public, private, philanthropic, and civil organisations whose mission is to stimulate, finance and co-ordinate vaccine development against diseases with epidemic potential in cases where market incentives fail. As of December 2019, CEPI has committed to investing up to $706 million in vaccine development. This includes 19 vaccine candidates against its priority pathogens (Lassa fever virus, Middle East respiratory syndrome coronavirus, Nipah virus, Chikungunya, Rift Valley fever) and three vaccine platforms to develop vaccines against Disease X, a novel or unanticipated pathogen.
   As an entity largely supported by public funds, ensuring equitable access to vaccines whose development it supports in low- and middle-income countries is CEPI's primary focus. CEPI developed an initial equitable access policy shortly after its formation, with key stakeholders expressing strong views about its content and prescriptive nature. The CEPI board instructed that it be revisited after a year. This paper describes the process of revising the policy, and how key issues were resolved. CEPI will continue to take an iterative, rather than prescriptive, approach to its policy-one that reflects the needs of multiple stakeholders and ensures it can meet its equitable access goals. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Huneycutt, Brenda; Lurie, Nicole; Wilder, Richard; Hatchett, Richard] Coalit Epidem Preparedness Innovat, 1901 Penn Ave NW,Suite 1003, Washington, DC 20006 USA.
   [Huneycutt, Brenda] FasterCures, 730 15th St NW, Washington, DC 20005 USA.
   [Rotenberg, Sara] Georgetown Univ, Dept Int Hlth, 3700 Reservoir Rd NW, Washington, DC 20057 USA.
RP Lurie, N (reprint author), Coalit Epidem Preparedness Innovat, 1901 Penn Ave NW,Suite 1003, Washington, DC 20006 USA.
EM nicole.lurie@cepi.net
CR Coalition for Epidemic Preparedness Innovations, CEPIS EQ ACC POL
   Coalition for Epidemic Preparedness Innovations, ADV EQ ACC EP VACC C
   Coalition for Epidemic Preparedness Innovations, FUND AGR TERMS COND
NR 3
TC 0
Z9 0
U1 8
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2144
EP 2148
DI 10.1016/j.vaccine.2019.12.055
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900008
PM 32005536
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Liu, J
   Clayton, K
   Gao, WB
   Li, Y
   Zealey, C
   Budylowski, P
   Schwartz, J
   Yue, FY
   Bie, Y
   Rini, J
   Ostrowski, M
AF Liu, Jun
   Clayton, Kiera
   Gao, Wenbo
   Li, Yu
   Zealey, Chris
   Budylowski, Patrick
   Schwartz, Jordan
   Yue, Feng Yun
   Bie, Yuan
   Rini, James
   Ostrowski, Mario
TI Trimeric HIV-1 gp140 fused with APRIL, BAFF, and CD40L on the mucosal
   gp140-specific antibody responses in mice
SO VACCINE
LA English
DT Article
DE HIV; Vaccine; Adjuvant; Mucosa; Antibody; TNFSF
ID IMMUNOGLOBULIN-A; GENITAL-TRACT; T-CELL; NEUTRALIZING ANTIBODIES;
   ENVELOPE GLYCOPROTEINS; BONE-MARROW; B-CELLS; VACCINE; SURVIVAL;
   RECEPTORS
AB HIV-1 envelope (Env)-specific antibody present at mucosal surfaces can block entry of HIV-1 into these portals and thus should be elicited by an HIV-1 preventive vaccine. Since three molecules of tumor necrosis factor superfamily (TNFSF), APRIL, BAFF, and CD40L, could promote mucosal antibody responses, we made fusion constructs of them with an HIV-1 gp140 [rimer and tested the mucosal gp140-specific antibody elicited by the fusion constructs in mice using a DNA prime-protein boost vaccination regimen. The fusion constructs formed trimers and displayed both broadly neutralizing antibody epitopes and non-broadly neutralizing antibody epitopes. Compared with the control construct, trimeric gp140, trimeric gp140-APRIL and gp140-BAFF fusion proteins mildly promoted B cell proliferation in vitro, enhanced HIV-1 gp140-binding IgG responses in vaginal lavage or fecal pellets, respectively, and decreased HIV-1 gp140-binding IgA in sera. Gp140-APRIL also augmented HIV-1 gp140-binding IgG in sera. Surprisingly, gp140-CD40L did not promote B cell proliferation in vitro and inhibited mucosal and systemic HIV-1 gp140-binding IgG or IgA. These results suggest that APRIL and BAFF should be further explored as molecular adjuvants for HIV-1 vaccines to enhance mucosal antibody responses, but covalent fusion of TNFSFs to gp140 may hinder their adjuvancy due to steric interactions. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Liu, Jun; Ostrowski, Mario] Univ Toronto, Clin Sci Div, Toronto, ON, Canada.
   [Clayton, Kiera; Gao, Wenbo; Li, Yu; Zealey, Chris; Schwartz, Jordan; Yue, Feng Yun; Bie, Yuan; Ostrowski, Mario] Univ Toronto, Dept Immunol, Toronto, ON, Canada.
   [Ostrowski, Mario] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
   [Rini, James] Univ Toronto, Dept Biochem, Toronto, ON, Canada.
   [Budylowski, Patrick] Univ Toronto, Inst Med Sci, Toronto, ON, Canada.
   [Li, Yu] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA.
   [Zealey, Chris] Sixsense Strategy Grp, Toronto, ON, Canada.
RP Liu, J; Ostrowski, M (reprint author), Room 6368,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.
EM junut.liu@gmail.com; mario.ostrowski@gmail.com
OI Li, Yu/0000-0002-1893-9046
FU CIHRCanadian Institutes of Health Research (CIHR)
FX This work was supported by CIHR. We think NIH AIDS reagent program to
   provide some key reagent.
CR Barouch DH, 2012, NATURE, V482, P89, DOI 10.1038/nature10766
   Belnoue E, 2008, BLOOD, V111, P2755, DOI 10.1182/blood-2007-09-110858
   Bomsel M, 2011, IMMUNITY, V34, P269, DOI 10.1016/j.immuni.2011.01.015
   Bossen C, 2008, BLOOD, V111, P1004, DOI 10.1182/blood-2007-09-110874
   Bossen C, 2006, SEMIN IMMUNOL, V18, P263, DOI 10.1016/j.smim.2006.04.006
   Bunker JJ, 2015, IMMUNITY, V43, P541, DOI 10.1016/j.immuni.2015.08.007
   Burton DR, 2016, ANNU REV IMMUNOL, V34, P635, DOI 10.1146/annurev-immunol-041015-055515
   Castigli E, 2005, J EXP MED, V201, P35, DOI 10.1084/jem.20032000
   Choi RY, 2012, AIDS, V26, P2155, DOI 10.1097/QAD.0b013e328359b99b
   EIgnieti R, 2009, IMMUNOL REV, V229, P152
   Georgiev IS, 2015, J VIROL, V89, P5318, DOI 10.1128/JVI.03451-14
   Gustafson CE, 2014, MUCOSAL IMMUNOL, V7, P467, DOI 10.1038/mi.2013.64
   Haase AT, 2011, ANNU REV MED, V62, P127, DOI 10.1146/annurev-med-080709-124959
   Hapfelmeier S, 2010, SCIENCE, V328, P1705, DOI 10.1126/science.1188454
   Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425
   He B, 2007, IMMUNITY, V26, P812, DOI 10.1016/j.immuni.2007.04.014
   Hirbod T, 2008, AIDS, V22, P727, DOI 10.1097/QAD.0b013e3282f56b64
   Hirbod T, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004416
   Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302
   Huard B, 2008, J CLIN INVEST, V118, P2887, DOI 10.1172/JCI33760
   Ingold K, 2005, J EXP MED, V201, P1375, DOI 10.1084/jem.20042309
   Isik G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107683
   Jacque E, 2015, J EXP MED, V212, P883, DOI 10.1084/jem.20142127
   Kalled SL, 2006, SEMIN IMMUNOL, V18, P290, DOI 10.1016/j.smim.2006.06.002
   Kim M, 2016, CELL HOST MICROBE, V20, P202, DOI 10.1016/j.chom.2016.07.001
   Li QS, 2014, J IMMUNOL, V193, P3113, DOI 10.4049/jimmunol.1400820
   Li ZL, 2011, P NATL ACAD SCI USA, V108, P4388, DOI 10.1073/pnas.1012861108
   Litinskiy MB, 2002, NAT IMMUNOL, V3, P822, DOI 10.1038/ni829
   Liu J, 2008, VACCINE, V26, P4062, DOI 10.1016/j.vaccine.2008.05.018
   Liu YF, 2002, CELL, V108, P383, DOI 10.1016/S0092-8674(02)00631-1
   Lopez-Fraga M, 2001, EMBO REP, V2, P945, DOI 10.1093/embo-reports/kve198
   Lycke NY, 2017, MUCOSAL IMMUNOL, V10, P1361, DOI 10.1038/mi.2017.62
   Mackay F, 2009, NAT REV IMMUNOL, V9, P491, DOI 10.1038/nri2572
   Macpherson AJ, 2008, MUCOSAL IMMUNOL, V1, P11, DOI 10.1038/mi.2007.6
   Medina-Ramirez M, 2017, J EXP MED, V214, P2573, DOI 10.1084/jem.20161160
   Melchers M, 2012, J VIROL, V86, P2488, DOI 10.1128/JVI.06259-11
   Mesin L, 2011, J IMMUNOL, V187, P2867, DOI 10.4049/jimmunol.1003181
   Mestecky J, 2011, AM J REPROD IMMUNOL, V65, P361, DOI 10.1111/j.1600-0897.2010.00923.x
   Moldoveanu Z, 2005, J IMMUNOL, V175, P4127, DOI 10.4049/jimmunol.175.6.4127
   Moor K, 2017, NATURE, V544, P498, DOI 10.1038/nature22058
   MOORE JP, 1988, AIDS RES HUM RETROV, V4, P369, DOI 10.1089/aid.1988.4.369
   Ng LG, 2004, J IMMUNOL, V173, P807, DOI 10.4049/jimmunol.173.2.807
   O'Connor BP, 2004, J EXP MED, V199, P91, DOI 10.1084/jem.20031330
   Parr MB, 1998, IMMUNOLOGY, V95, P208
   Pavot V, 2014, AIDS, V28, P1701, DOI 10.1097/QAD.0000000000000308
   Pedersen GK, 2014, VACCINE, V32, P4550, DOI 10.1016/j.vaccine.2014.06.009
   Prodger JL, 2014, MUCOSAL IMMUNOL, V7, P634, DOI 10.1038/mi.2013.83
   Roederer M, 2001, CYTOMETRY, V45, P194, DOI 10.1002/1097-0320(20011101)45:3<194::AID-CYTO1163>3.0.CO;2-C
   Rolink AG, 2002, EUR J IMMUNOL, V32, P2004, DOI 10.1002/1521-4141(200207)32:7<2004::AID-IMMU2004>3.0.CO;2-5
   Ruskin MW, 2015, MUCOSAL IMMUNOLOGY, P429
   Sakai F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105370
   Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618
   Sarzotti-Kelsoe M, 2014, J IMMUNOL METHODS, V409, P131, DOI 10.1016/j.jim.2013.11.022
   SHROFF KE, 1995, INFECT IMMUN, V63, P3904, DOI 10.1128/IAI.63.10.3904-3913.1995
   Steichen JM, 2016, IMMUNITY, V45, P483, DOI 10.1016/j.immuni.2016.08.016
   TAKAHASHI H, 1988, P NATL ACAD SCI USA, V85, P3105, DOI 10.1073/pnas.85.9.3105
   Tezuka H, 2007, NATURE, V448, P929, DOI 10.1038/nature06033
   Tezuka H, 2011, IMMUNITY, V34, P247, DOI 10.1016/j.immuni.2011.02.002
   Tomaras GD, 2013, P NATL ACAD SCI USA, V110, P9019, DOI 10.1073/pnas.1301456110
   Vaccari M, 2016, NAT MED, V22, P762, DOI 10.1038/nm.4105
   VanCott TC, 1998, J IMMUNOL, V160, P2000
   Woof J, 2015, MUCOSAL IMMUNOLOGY, P287
   Wozniak KL, 2002, INFECT IMMUN, V70, P5790, DOI 10.1128/IAI.70.10.5790-5799.2002
   Wu W, 2017, MUCOSAL IMMUNOL, V10, P946, DOI 10.1038/mi.2016.114
   Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884
   Yang LF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01631
   Yang XZ, 2002, J VIROL, V76, P4634, DOI 10.1128/JVI.76.9.4634-4642.2002
   Yu G, 2000, NAT IMMUNOL, V1, P252, DOI 10.1038/79802
NR 68
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2149
EP 2159
DI 10.1016/j.vaccine.2020.01.050
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900009
PM 32014267
DA 2020-05-12
ER

PT J
AU Petit, B
   Epaulard, O
AF Petit, Benoit
   Epaulard, Olivier
TI Men having sex with men and the HPV vaccine in France: A low vaccine
   coverage that may be due to its infrequent proposal by physicians
SO VACCINE
LA English
DT Article
DE Vaccine; HPV; Vaccine coverage; MSM
ID HUMAN-PAPILLOMAVIRUS VACCINATION
AB Introduction: In France, the human papilloma (HPV) vaccine is recommended to all female adolescents, and since 2016 to men having sex with men (MSM) under the age of 27. Here, we aimed to explore HPV vaccine coverage in adult MSM living in France.
   Methods: We elaborated an anonymous online questionnaire targeting MSM and disseminated it between October 7, 2018 and January 15, 2019 by various means, including a Facebook (R) discussion forum for pre-exposure prophylaxis (PrEP) users.
   Results: Overall, 2094 participants completed the questionnaire (mean age 35.4 +/- 11 years); 25.8% were in the age class targeted by the HPV vaccine recommendation; 16.1% were in a PrEP program. On a 1-10 scale, they evaluated being "in favor of vaccination" at a median of 10, and general vaccine usefulness and harmfulness at medians of 10 and 2, respectively; 62.4% considered that the HPV vaccine was rather not or not at all dangerous. Those using PrEP had better perceptions of vaccination in general and of the HPV vaccine in particular. For the 1728 participants with a family physician, he/she had proposed the HPV vaccine in 9.9% of cases (9.1% of those in the targeted age class [<27 years]). Overall, 1994 knew their HPV vaccine status; 8.0% had received at least 1 dose of the vaccine, including 17.9% of those in the targeted age class (and 52.2% among the 40 participants in this age group who received PrEP). When the 1935 participants who declared to be unvaccinated against HPV were asked whether they would accept to be vaccinated, 34.4% answered "rather yes" and 45.5% "definitely yes".
   Conclusion: HPV vaccine coverage is low among French MSM. Our results suggest that this trend has more to do with the infrequent proposals made by clinicians than with negative vaccine perceptions. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Petit, Benoit; Epaulard, Olivier] Ctr Hosp Univ Grenoble Alpes, Serv Malad Infect, CS10217, F-38043 Grenoble 09, France.
   [Petit, Benoit; Epaulard, Olivier] Univ Grenoble Alpes, Federat Infectiol Multidisciplinaire Arc Alpin, Grenoble, France.
   [Epaulard, Olivier] UMR 5075 CEA CNRS UGA, Virus Humains Persistants Team, Inst Biol Struct, Grenoble, France.
RP Epaulard, O (reprint author), Ctr Hosp Univ Grenoble Alpes, Serv Malad Infect, CS10217, F-38043 Grenoble 09, France.
EM OEpaulard@chu-grenoble.fr
CR Alberts CJ, 2019, VACCINE, V37, P2849, DOI 10.1016/j.vaccine.2019.03.048
   Ali H, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2032
   Australian Institute of Health and Welfare, 2018, CERV SCREEN AUSTR
   Chow EPF, 2019, VACCINE, V37, P6907, DOI [10.1016/j.vaccine.2019.09.052, 10.1016/j.vaccine.2019.09]
   Collange F, 2016, VACCINE, V34, P762, DOI 10.1016/j.vaccine.2015.12.054
   De Santis S, 2017, J STOMATOL ORAL MAXI, V118, P103, DOI 10.1016/j.jormas.2017.02.004
   Dillner J, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3493
   European Medicine Agency, 2006, GARD SUMM PROD CHAR
   European Medicine Agency, 2017, GARDASIL9 SUMM PROD
   European_Medicine_Agency, 2007, CERV SUMM PROD CHAR
   Fairley CK, 2017, SEX HEALTH, V14, P123, DOI 10.1071/SH16067
   Gault G, 2019, MED MALADIES INFECT, V49, P38, DOI 10.1016/j.medmal.2018.11.001
   Goldstone SE, 2013, VACCINE, V31, P3849, DOI 10.1016/j.vaccine.2013.06.057
   Haut Conseil a la Sante Publique, 2016, GUID VACC HUM PAP IN
   Haute Autorite de Sante, 2019, WID HPV VACC POL MAL
   Hull B, 2018, COMMUN DIS INTELL, V2019
   Karafillakis E, 2019, HUM VACC IMMUNOTHER, V15, P1615, DOI 10.1080/21645515.2018.1564436
   Koch J, 2016, EUROSURVEILLANCE, V21, P12, DOI 10.2807/1560-7917.ES.2016.21.5.30122
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Lefevre H, 2018, ARCH DIS CHILD, V103, P740, DOI 10.1136/archdischild-2017-313887
   McGrath L, 2019, SEX TRANSM INFECT, V95, P181, DOI 10.1136/sextrans-2018-053619
   Middleman A, 2016, HUM VACC IMMUNOTHER, V12, P1599, DOI 10.1080/21645515.2016.1168953
   Oliver SE, 2017, JAIDS-J ACQ IMM DEF, V75, pS370, DOI [10.1097/QAI.0000000000001413, 10.1097/qai.0000000000001413]
   Palefsky JM, 2011, NEW ENGL J MED, V365, P1576, DOI 10.1056/NEJMoa1010971
   Patel C, 2018, EUROSURVEILLANCE, V23, P1
   Pillsbury AJ, 2017, CLIN INFECT DIS, V65, P827, DOI 10.1093/cid/cix436
   Potherat G, 2019, B EPIDEMIOLOGIQUE HE, V2019, P204
   Shapiro GK, 2017, VACCINE, V35, P5700, DOI 10.1016/j.vaccine.2017.07.079
   Shield KD, 2018, EUR J EPIDEMIOL, V33, P263, DOI 10.1007/s10654-017-0334-z
   World Hlth Org, 2017, VACCINE, V35, P5753, DOI 10.1016/j.vaccine.2017.05.069
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2160
EP 2165
DI 10.1016/j.vaccine.2020.01.049
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900010
PM 32008880
DA 2020-05-12
ER

PT J
AU Baker, M
   Jankosky, C
   Yih, WK
   Gruber, S
   Li, LL
   Cocoros, NM
   Lipowicz, H
   Coronel-Moreno, C
   DeLuccia, S
   Lin, ND
   McMahill-Walraven, CN
   Menschik, D
   Selvan, MS
   Selvam, N
   Tilney, RC
   Zichittella, L
   Lee, GM
   Kawai, AT
AF Baker, Meghan
   Jankosky, Christopher
   Yih, W. Katherine
   Gruber, Susan
   Li, Lingling
   Cocoros, Noelle M.
   Lipowicz, Hana
   Coronel-Moreno, Claudia
   DeLuccia, Sandra
   Lin, Nancy D.
   McMahill-Walraven, Cheryl N.
   Menschik, David
   Selvan, Mano S.
   Selvam, Nandini
   Tilney, Rong Chen
   Zichittella, Lauren
   Lee, Grace M.
   Kawai, Alison Tse
TI The risk of febrile seizures following influenza and 13-valent
   pneumococcal conjugate vaccines
SO VACCINE
LA English
DT Article
DE Febrile seizure; 13-valent pneumococcal conjugate vaccine; PCV13;
   Influenza vaccine
ID SAFETY; SURVEILLANCE
AB Background: Evidence on the risk of febrile seizures after inactivated influenza vaccine (11V) and 13-valent pneumococcal conjugate vaccine (PCV13) is mixed. In the FDA-sponsored Sentinel Initiative, we examined risk of febrile seizures after IIV and PCV13 in children 6-23 months of age during the 2013-14 and 2014-15 influenza seasons.
   Methods: Using claims data and a self-controlled risk interval design, we compared the febrile seizure rate in a risk interval (0-1 days) versus control interval (14-20 days). In exploratory analyses, we assessed whether the effect of IIV was modified by concomitant PCV13 administration.
   Results: Adjusted for age, calendar time and concomitant administration of the other vaccine, the incidence rate ratio (IRR) for risk of febrile seizures following IIV was 1.12 (95% CI 0.80, 1.56) and following PCV13 was 1.80 (95% CI 1.29, 2.52). The attributable risk for febrile seizures following PCV13 ranged from 0.33 to 5.16 per 100,000 doses by week of age.
   The age and calendar-time adjusted IRR comparing exposed to unexposed time was numerically larger for concomitant 11V and PCV13 (IRR 2.80, 95% CI 1.63, 4.83), as compared to PCV13 without concomitant IIV (IRR 1.54, 95% CI 1.04, 2.28), and the IRR for IIV without concomitant PCV13 suggested no independent effects of IIV (1RR 0.94, 95% CI 0.63, 1.42). Taken together, this suggests a possible interaction between IIV and PCV13, though our study was not sufficiently powered to provide a precise estimate of the interaction.
   Conclusions: We found an elevated risk of febrile seizures after PCV13 vaccine but not after IIV. The risk of febrile seizures after PCV13 is low compared to the overall risk in this population of children, and the risk should be interpreted in the context of the importance of preventing pneumococcal infections. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Baker, Meghan; Yih, W. Katherine; Gruber, Susan; Li, Lingling; Cocoros, Noelle M.; Lipowicz, Hana; Coronel-Moreno, Claudia; DeLuccia, Sandra; Tilney, Rong Chen; Zichittella, Lauren; Lee, Grace M.; Kawai, Alison Tse] Harvard Med Sch, Dept Populat Med, 401 Pk Dr,Suite 401 East, Boston, MA 02215 USA.
   [Baker, Meghan; Yih, W. Katherine; Gruber, Susan; Li, Lingling; Cocoros, Noelle M.; Lipowicz, Hana; Coronel-Moreno, Claudia; DeLuccia, Sandra; Tilney, Rong Chen; Zichittella, Lauren; Lee, Grace M.; Kawai, Alison Tse] Harvard Pilgrim Hlth Care Inst, 401 Pk Dr,Suite 401 East, Boston, MA 02215 USA.
   [Baker, Meghan] Brigham & Womens Hosp, Dept Med, Div Infect Dis, 75 Francis St, Boston, MA 02115 USA.
   [Jankosky, Christopher; Menschik, David] FDA Ctr Biol Evaluat & Res, Silver Spring, MD USA.
   [Lin, Nancy D.] Optuminsight Life Sci, Boston, MA USA.
   [McMahill-Walraven, Cheryl N.] Aetna, Blue Bell, PA USA.
   [Selvan, Mano S.] Humana Healthcare Res, Alexandria, VA USA.
   [Selvam, Nandini] HealthCore Inc, Alexandria, VA USA.
   [Jankosky, Christopher] Act Hlth Sci LLC, Las Vegas, NV USA.
   [Gruber, Susan] Putnam Data Sci LLC, Cambridge, MA USA.
   [Li, Lingling] Karyopharm Therapeut Inc, Newton, MA USA.
   [Selvam, Nandini] IQVIA Govt Solut, Fairfax, VA USA.
   [Tilney, Rong Chen; Zichittella, Lauren; Kawai, Alison Tse] RTI Int, Waltham, MA USA.
   [Lee, Grace M.] Stanford Univ, Lucile Salter Packard Childrens Hosp, Stanford, CA 94305 USA.
   [Selvam, Nandini] Humana Inc, Comprehens Hlth Insights, Louisville, KY USA.
RP Baker, M (reprint author), Harvard Med Sch, Dept Populat Med, 401 Pk Dr,Suite 401 East, Boston, MA 02215 USA.; Baker, M (reprint author), Harvard Pilgrim Hlth Care Inst, 401 Pk Dr,Suite 401 East, Boston, MA 02215 USA.
EM meghan_baker@harvardpilgrim.org
FU Food and Drug Administration through Department of Health and Human
   Services [HHSF223200910006I, HHSF22301018T]
FX This work was supported by the Food and Drug Administration through
   Department of Health and Human Services Contract Number
   HHSF223200910006I, Task Order Number HHSF22301018T, USA.
CR Glanz JM, 2011, ARCH PEDIAT ADOL MED, V165, P749, DOI 10.1001/archpediatrics.2011.112
   Greene SK, 2010, AM J EPIDEMIOL, V171, P177, DOI 10.1093/aje/kwp345
   Hambidge SJ, 2006, JAMA-J AM MED ASSOC, V296, P1990, DOI 10.1001/jama.296.16.1990
   Hodgson ES, 2008, PEDIATRICS, V121, P1281, DOI 10.1542/peds.2008-0939
   Kawai A, 2014, ASSESSMENT FEBRILE S
   Kawai AT, 2019, VACCINE, V37, P4172, DOI 10.1016/j.vaccine.2019.05.042
   Klein NP, 2010, PEDIATRICS, V126, pE1, DOI 10.1542/peds.2010-0665
   Lee GM, 2011, AM J PREV MED, V41, P121, DOI 10.1016/j.amepre.2011.04.004
   Manfredini R, 2004, J PEDIATR-US, V145, P838, DOI 10.1016/j.jpeds.2004.06.079
   McDanel JS, 2013, ANTIMICROB AGENTS CH, V57, P552, DOI 10.1128/AAC.01623-12
   Rowhani-Rahbar A, 2012, VACCINE, V31, P271, DOI 10.1016/j.vaccine.2012.07.024
   Tse A, 2012, VACCINE, V30, P2024, DOI 10.1016/j.vaccine.2012.01.027
   Vestergaard M, 2009, BRAIN DEV-JPN, V31, P372, DOI 10.1016/j.braindev.2008.11.012
   Whitwell J, 2016, J NEUROCHEM, V138, P239
   Yih WK, 2016, PHARMACOEPIDEM DR S, V25, P481, DOI 10.1002/pds.3908
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2166
EP 2171
DI 10.1016/j.vaccine.2020.01.046
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900011
PM 32019703
OA Green Published
DA 2020-05-12
ER

PT J
AU Bovay, A
   Nassiri, S
   Maby-El Hajjami, H
   Mondejar, PM
   Akondy, RS
   Ahmed, R
   Lawson, B
   Speiser, DE
   Marraco, SAF
AF Bovay, Amandine
   Nassiri, Sina
   Maby-El Hajjami, Helene
   Mondejar, Paula Marcos
   Akondy, Rama S.
   Ahmed, Rafi
   Lawson, Benton
   Speiser, Daniel E.
   Marraco, Silvia A. Fuertes
TI Minimal immune response to booster vaccination against Yellow Fever
   associated with pre-existing antibodies
SO VACCINE
LA English
DT Article
DE Yellow fever virus vaccine; YF-17D; Booster vaccination; Primary
   vaccination; Innate response; Adaptive response
ID ARTHROPOD-BORNE VIRUSES; T-CELL RESPONSES; 17D; PERSISTENCE; DYNAMICS;
   EFFECTOR; MONKEYS
AB Ever since its development in the 1930's, the live-attenuated Yellow Fever virus vaccine YF-17D has been highly effective. Despite the increasing knowledge on the immune biology of the YF-17D vaccine, most studies have focused only on a few types of immune cells and pathways or mainly on the primary adaptive immune response to YF-17D vaccination. Here, we examined humoral, innate and adaptive cellular responses in a longitudinal YF-17D vaccination study in Switzerland, comparing both primary and booster vaccination. In contrast to the strong innate and adaptive immune response to the primary vaccination, we find that the response to boosting is much reduced. Our data show an inverse association of neutralizing antibodies at baseline with vaccine virus replication and with the immune response upon boosting. These results suggest that booster vaccination may not have major immunological effects when neutralizing antibodies are present. Importantly, our study population was healthy adults in a nonendemic country and ultimately booster vaccine requirement must be assessed based on additional epidemiological and public health considerations in endemic areas. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Bovay, Amandine; Nassiri, Sina; Maby-El Hajjami, Helene; Mondejar, Paula Marcos; Speiser, Daniel E.; Marraco, Silvia A. Fuertes] Univ Lausanne, CHUV, Dept Oncol, Lausanne, Switzerland.
   [Nassiri, Sina] Swiss Inst Bioinformat, Bioinformat Core Facil, Lausanne, Switzerland.
   [Akondy, Rama S.; Ahmed, Rafi; Lawson, Benton] Emory Univ, Emory Vaccine Ctr, Dept Microbiol & Immunol, Atlanta, GA 30322 USA.
   [Lawson, Benton] NCIRD, Ctr Dis Control, OID, CTR, Atlanta, GA USA.
RP Marraco, SAF (reprint author), Univ Lausanne, CHUV, Dept Oncol, Lausanne, Switzerland.
EM silvia.fuertesmarraco@unil.ch
OI Bovay, Amandine/0000-0001-6947-9812
FU University of Lausanne; Quealth Foundation; Swiss National Science
   FoundationSwiss National Science Foundation (SNSF) [310030B1 79570]
FX This study was supported by the University of Lausanne, the Quealth
   Foundation, and the Swiss National Science Foundation (grant 310030B1
   79570).
CR Akondy RS, 2017, NATURE, V552, P362, DOI 10.1038/nature24633
   Akondy RS, 2015, P NATL ACAD SCI USA, V112, P3050, DOI 10.1073/pnas.1500475112
   Akondy RS, 2009, J IMMUNOL, V183, P7919, DOI 10.4049/jimmunol.0803903
   Bassi MR, 2015, J IMMUNOL, V194, P1141, DOI 10.4049/jimmunol.1402605
   Blom K, 2013, J IMMUNOL, V190, P2150, DOI 10.4049/jimmunol.1202234
   Brodin P, 2015, CELL, V160, P37, DOI 10.1016/j.cell.2014.12.020
   Caldas IR, 2014, VACCINE, V32, P4977, DOI 10.1016/j.vaccine.2014.07.021
   Campi-Azevedo AC, 2016, HUM VACC IMMUNOTHER, V12, P491, DOI 10.1080/21645515.2015.1082693
   CHRISTENSON B, 1994, VACCINE, V12, P129, DOI 10.1016/0264-410X(94)90049-3
   Co MDT, 2009, IMMUNOLOGY, V128, pe718, DOI 10.1111/j.1365-2567.2009.03070.x
   Co MDT, 2002, VIROLOGY, V293, P151, DOI 10.1006/viro.2001.1255
   Collaborative Grp, 2019, VACCINE, V37, P5129, DOI 10.1016/j.vaccine.2019.05.048
   Neves PCD, 2009, VACCINE, V27, P5543, DOI 10.1016/j.vaccine.2009.07.028
   de Melo AB, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0001938
   de Noronha TG, 2019, VACCINE, V37, P7147, DOI 10.1016/j.vaccine.2019.09.051
   Domingo C, 2019, LANCET INFECT DIS, V19, P1363, DOI 10.1016/S1473-3099(19)30323-8
   dos Santos AP, 2005, MEM I OSWALDO CRUZ, V100, P331, DOI 10.1590/S0074-02762005000300021
   Ferreira CD, 2018, EXPERT REV VACCINES, V17, P79, DOI 10.1080/14760584.2018.1406800
   Gotuzzo E, 2013, AM J TROP MED HYG, V89, P434, DOI 10.4269/ajtmh.13-0264
   Hepburn MJ, 2006, VACCINE, V24, P2843, DOI 10.1016/j.vaccine.2005.12.055
   Hou J, 2017, J IMMUNOL, V199, P1476, DOI 10.4049/jimmunol.1700083
   James EA, 2013, J VIROL, V87, P12794, DOI 10.1128/JVI.01160-13
   Kareko BW, 2019, J INFECT DIS
   Koblischke M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09331-w
   Kohler S, 2012, EUR J IMMUNOL, V42, P2363, DOI 10.1002/eji.201142306
   Kongsgaard M, 2017, SCI REP, V7, P1
   Luiza M, 2008, VACCINE
   Marquardt N, 2015, J IMMUNOL, V195, P3262, DOI 10.4049/jimmunol.1401811
   Marraco SAF, 2015, GENOM DATA, V5, P297, DOI 10.1016/j.gdata.2015.06.024
   Martins MA, 2007, CLIN EXP IMMUNOL, V148, P90, DOI 10.1111/j.1365-2249.2006.03317.x
   MASON RA, 1973, APPL MICROBIOL, V25, P539, DOI 10.1128/AEM.25.4.539-544.1973
   MASON RA, 1972, APPL MICROBIOL, V23, P908, DOI 10.1128/AEM.23.5.908-913.1972
   Miller JD, 2008, IMMUNITY, V28, P710, DOI 10.1016/j.immuni.2008.02.020
   Miyaji KT, 2017, REV INST MED TROP SP, V59, DOI [10.1590/s1678-9946201759002, 10.1590/S1678-9946201759002]
   Muyanja E, 2014, J CLIN INVEST, V124, P15
   Niedrig M, 1999, TROP MED INT HEALTH, V4, P867, DOI 10.1046/j.1365-3156.1999.00496.x
   Perfetto SP, 2006, NAT PROTOC, V1, P1522, DOI 10.1038/nprot.2006.250
   POLAND JD, 1981, B WORLD HEALTH ORGAN, V59, P895
   Pulendran B, 2011, NAT IMMUNOL, V12, P509, DOI 10.1038/ni.2039
   Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688
   ROSENZWEIG EC, 1963, AM J TROP MED HYG, V12, P230, DOI 10.4269/ajtmh.1963.12.230
   Silva ML, 2011, VACCINE, V29, P583, DOI 10.1016/j.vaccine.2010.08.046
   Team RC, 2018, R LANG ENV STAT COMP
   Vasconcelos PFC, 2019, LANCET INFECT DIS, V19, P1275, DOI 10.1016/S1473-3099(19)30411-6
   WHO, 2015, VACCINE, V33, P76, DOI 10.1016/j.vaccine.2014.05.040
   Wieten RW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149871
   WISSEMAN CL, 1962, AM J TROP MED HYG, V11, P570, DOI 10.4269/ajtmh.1962.11.570
   Zinkernagel RM, 2003, ANNU REV IMMUNOL, V21, P515, DOI 10.1146/annurev.immunol.21.120601.141045
   Zinkernagel RM, 2001, SCIENCE, V293, P251, DOI 10.1126/science.1063005
NR 49
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2172
EP 2182
DI 10.1016/j.vaccine.2020.01.045
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900012
PM 32008879
OA Other Gold
DA 2020-05-12
ER

PT J
AU Kalok, A
   Loh, SYE
   Chew, KT
   Aziz, NHA
   Shah, SA
   Ahmad, S
   Ismail, NAM
   Mahdy, ZA
AF Kalok, Aida
   Loh, Sweet Yi Esther
   Chew, Kah Teik
   Aziz, Nor Haslinda Abdul
   Shah, Shamsul Azhar
   Ahmad, Shuhaila
   Ismail, Nor Azlin Mohamed
   Mahdy, Zaleha Abdullah
TI Vaccine hesitancy towards childhood immunisation amongst urban pregnant
   mothers in Malaysia
SO VACCINE
LA English
DT Article
DE Vaccine hesitancy; PACV; Childhood immunisation; Pregnant mothers
ID PARENT ATTITUDES; HEALTH
AB Background: Vaccine hesitancy is a complex behaviour which involves various degrees of indecision about specific vaccines or vaccination uptake. Access to antenatal care had been associated with positive vaccine behavior.
   Objective: To determine the prevalence of vaccine hesitancy towards childhood immunisation amongst urban pregnant mothers and the associated socio-demographic factors.
   Methods: A cross-sectional study was conducted among 1081 women who received antenatal care at a teaching hospital in Kuala Lumpur. Vaccine hesitancy was assessed using the Parent Attitudes about Childhood Vaccines (PACV) Survey in both English and validated Malay versions. The sociodemographic data of the mothers and their partners, source of vaccine information and reasons for hesitancy were analysed.
   Results: Eighty-six (8.0%) pregnant mothers were vaccine hesitant. Ethnicity, religion, number of children, educational level and employment status were significantly associated with vaccine hesitancy. Multivariable analysis showed that a low level of education was the most significant risk factor (p < 0.001), followed by religion (p = 0.03). Health professionals was the main source of information about vaccine. The non-vaccine hesitant women were more likely to seek information from health professionals, and health books and magazine. Fear of adverse side effects of vaccines was the predominant concern for all participants (58%) whilst fear of vaccination pain, preference for alternative medicine and lack of trust in the pharmaceutical industry were significant reasons given by the vaccine hesitant group. Partners' ethnicity, a low educational level and a low income were significantly associated with vaccine hesitancy amongst pregnant mothers.
   Conclusion: Prevalence of vaccine hesitancy amongst urban Malaysian pregnant women was relatively low. Muslim mothers are less likely to be vaccine hesitant. Educational level of mothers and their partners are the common determinant of vaccine hesitancy amongst antenatal mothers. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Kalok, Aida; Loh, Sweet Yi Esther; Chew, Kah Teik; Aziz, Nor Haslinda Abdul; Ahmad, Shuhaila; Ismail, Nor Azlin Mohamed; Mahdy, Zaleha Abdullah] Univ Kebangsaan Malaysia, Natl Univ Malaysia, Fac Med, Dept Obstet & Gynaecol,Med Ctr, Kuala Lumpur, Malaysia.
   [Shah, Shamsul Azhar] Univ Kebangsaan Malaysia, Natl Univ Malaysia, Fac Med, Dept Community Hlth,Med Ctr, Kuala Lumpur, Malaysia.
RP Kalok, A (reprint author), UKM Med Ctr, Fac Med, Dept Obstet & Gynaecol, Jalan Yaacob Latiff, Kuala Lumpur 56000, Malaysia.
EM aidahani.mohdkalok@ppukm.ukm.edu.my
RI Kalok, Aida/T-1014-2019
FU Universiti Kebangsaan Malaysia [FF-2016-422]
FX This study was funded by a fundamental grant of Universiti Kebangsaan
   Malaysia (Research Code: FF-2016-422). The authors would like to express
   our gratitude to Dr Douglas.] Opel for permission to use the PACV
   questionnaire in this study. The authors also wish to thank all patients
   who participated in this study.
CR Ahmed A, 2018, J INFECT PUBLIC HEAL, V11, P153, DOI 10.1016/j.jiph.2017.09.007
   Alabbad AA, 2018, J INFECT PUBLIC HEAL, V11, P491, DOI 10.1016/j.jiph.2017.09.002
   Arriola CS, 2018, VACCINE, V36, P3686, DOI 10.1016/j.vaccine.2018.05.013
   Aslam M, 2012, WORLD DEV, V40, P2014, DOI 10.1016/j.worlddev.2012.05.007
   Azizi FSM, 2017, VACCINE, V35, P2955, DOI 10.1016/j.vaccine.2017.04.010
   Babalola S, 2009, J CHILD HEALTH CARE, V13, P46, DOI 10.1177/1367493508098380
   Beaton DE, 2000, SPINE, V25, P3186, DOI 10.1097/00007632-200012150-00014
   Brunson EK, 2013, VACCINE, V31, P5466, DOI 10.1016/j.vaccine.2013.08.104
   Centers for Disease Control and Prevention Control, 2015, PROV RES VACC CONV P
   D'Alessandro A, 2018, HUM VACC IMMUNOTHER, V14, P1573, DOI 10.1080/21645515.2018.1483809
   Dasgupta P, 2018, INDIAN J PUBLIC HLTH, V62, P253, DOI 10.4103/ijph.IJPH_397_17
   Dube E, 2014, VACCINE, V32, P6649, DOI 10.1016/j.vaccine.2014.09.039
   Esposito S, 2014, CLIN MICROBIOL INFEC, V20, P25, DOI 10.1111/1469-0691.12447
   Gellin BG, 2000, PEDIATRICS, V106, P1097, DOI 10.1542/peds.106.5.1097
   GUILLEMIN F, 1993, J CLIN EPIDEMIOL, V46, P1417, DOI 10.1016/0895-4356(93)90142-N
   Gust DA, 2008, PEDIATRICS, V122, P718, DOI 10.1542/peds.2007-0538
   Henrikson NB, 2017, PUBLIC HEALTH REP, V132, P451, DOI 10.1177/0033354917711175
   Kumar D, 2016, ISR J HEALTH POLICY, V5, DOI 10.1186/s13584-016-0062-y
   Larson H, 2012, DRUG SAFETY, V35, P1053, DOI 10.2165/11635880-000000000-00000
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Larson HJ, 2015, PLOS CURR, V7, DOI DOI 10.1371/CURRENTS.OUTBREAKS.CE0F6177BC97332602A8E3FE7D7F7CC4
   May CC, 2016, THE MALAY MAIL
   Napolitano F, 2018, HUM VACC IMMUNOTHER, V14, P1558, DOI 10.1080/21645515.2018.1463943
   Napolitano F, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2138-2
   Opel DJ, 2013, JAMA PEDIATR, V167, P1065, DOI 10.1001/jamapediatrics.2013.2483
   Opel DJ, 2011, VACCINE, V29, P6598, DOI 10.1016/j.vaccine.2011.06.115
   Opel DJ, 2011, HUM VACCINES, V7, P419, DOI 10.4161/hv.7.4.14120
   Pandey S, 2012, HEALTH EDUC J, V71, P642, DOI 10.1177/0017896911419343
   Razak Ahmad VD, 2019, STAR ONLINE
   Salmon DA, 2015, VACCINE, V33, pD66, DOI 10.1016/j.vaccine.2015.09.035
   Sia D, 2008, SANTE, V17, P201
   Smith PJ, 2011, PUBLIC HEALTH REP, V126, P135, DOI 10.1177/00333549111260S215
   Strelitz B, 2015, VACCINE, V33, P1802, DOI 10.1016/j.vaccine.2015.02.034
   Tabacchi G, 2017, HUM VACC IMMUNOTHER, V13, P339, DOI 10.1080/21645515.2017.1264733
   WHO UNICEF World Bank, 2009, STATE WORLD VACCINES
   Williams SE, 2016, CLIN PEDIATR, V55, P537, DOI 10.1177/0009922815615823
   World Health Organization, 2014, REP SAGE WORK GROUP
NR 38
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2183
EP 2189
DI 10.1016/j.vaccine.2020.01.043
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900013
PM 32001070
DA 2020-05-12
ER

PT J
AU Aziz, AB
   Ali, M
   Basunia, AU
   Yunus, M
   Clemens, J
   Zaman, K
AF Aziz, Asma Binte
   Ali, Mohammad
   Basunia, Ahsan-ul Habib
   Yunus, Md
   Clemens, John
   Zaman, K.
TI Impact of vaccination on the risk factors for acute rotavirus diarrhea:
   An analysis of the data of a cluster randomized trial conducted in a
   rural area of Bangladesh
SO VACCINE
LA English
DT Article
DE Rotavirus; Rotarix vaccine; Risk factors; Matlab; Bangladesh; Cluster
   randomized trial
ID YOUNG-CHILDREN; DISEASE
AB Background: Rotavirus is one of the causes of severe diarrhea and death in young children. To control the disease, safe and effective vaccines are being used in several countries. We assessed the impact of vaccination on the risk factors for acute rotavirus diarrhea (ARD) in Bangladesh.
   Methods: We used the data of a cluster-randomized trial. The clusters were 142 villages, 71 in each of the two arms of study. The infants were offered human rotavirus vaccine (HRV), Rotarix, over three-year period. We divided the time period into two equal periods (T1 and T2). A generalized estimating equation with logit-link function was used to evaluate the risk factors by arm and by period.
   Results: Among 10,917 children, 5,759 (53%) were in the HRV villages. We had 359 cases; 44% in the HRV villages. Mean age of attack was similar between the arms of study in T1, but significantly higher in HRV villages than that in the non-HRV villages in T2. In HRV villages, males were at a higher risk of having ARD than females in Ti, but not in 12. In contrast, males were at a higher risk of having ARD in both the time periods in non-HRV villages. In HRV-villages, children having literate mother were at significantly higher risk of having ARD in T1 but not in T2; whereas children in the non-HRV villages had a higher risk of having ARD in T2. Children living in an area with higher phone users had more cases than their counterpart in non-HRV villages, but not in HRV villages.
   Conclusion: Our study illustrates that several risk factors for ARD varied between the two arms of study as well as between the two periods of study. Assessing post-vaccination risk factors is, therefore, important for understanding the impact of vaccination and undertaking post-vaccination control measures. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Aziz, Asma Binte; Basunia, Ahsan-ul Habib; Yunus, Md; Clemens, John; Zaman, K.] Icddr B, Dhaka, Bangladesh.
   [Ali, Mohammad] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Aziz, AB (reprint author), Icddr B, Dhaka, Bangladesh.
EM asma.aziz@icddrb.org
FU Gavi, the Vaccine Alliance [GAV.1141-02]; Bill and Melinda Gates
   Foundation through the Delivering Oral Vaccine Effectively (DOVE)
   project [OPP1148763]
FX This study was funded by Gavi, the Vaccine Alliance
   (http://www.gavi.org) under grant GAV.1141-02 to, Dhaka who donated the
   start-up funds PATH's Rotavirus Vaccine Program (RVP) as primary
   sponsor; the UNICEF, and GlaxoSmithKline (GSK) who donated vaccine for
   the project. icddr,b acknowledges with gratitude the commitment of RVP,
   the UNICEF and GSK to its research efforts. icddr,b is also grateful to
   the Governments of Bangladesh, Canada, Sweden and the UK for providing
   core/unrestricted support. Mohammad Ali's time was funded by the Bill
   and Melinda Gates Foundation through the Delivering Oral Vaccine
   Effectively (DOVE) project, administered by the Johns Hopkins Bloomberg
   School of Public Health (OPP1148763).
CR Adams NL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191633
   Ali M, 2005, B WORLD HEALTH ORGAN, V83, P604
   [Anonymous], 2009, Wkly Epidemiol Rec, V84, P533
   [Anonymous], 2009, WHOIVB0817
   Armah GE, 2010, LANCET, V376, P606, DOI 10.1016/S0140-6736(10)60889-6
   Awoyemi T. T., 2011, Journal of Human Ecology, V35, P1
   Banerjee I, 2006, J CLIN MICROBIOL, V44, P2468, DOI 10.1128/JCM.01882-05
   BECKER S, 1986, ECOL FOOD NUTR, V18, P251, DOI 10.1080/03670244.1986.9990930
   Binka FN, 2003, TROP MED INT HEALTH, V8, P840
   Burnett E, 2018, PEDIATR DRUGS, V20, P223, DOI 10.1007/s40272-018-0283-3
   Carrel M, 2011, INT J HEALTH GEOGR, V10, DOI 10.1186/1476-072X-10-41
   Chan J, 2011, VACCINE, V29, P1242, DOI 10.1016/j.vaccine.2010.11.087
   Chowdhury F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130105
   Clark AM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188267
   Clark A, 2019, LANCET INFECT DIS, V19, P717, DOI 10.1016/S1473-3099(19)30126-4
   DEZOYSA I, 1985, B WORLD HEALTH ORGAN, V63, P569
   Emch M, 1999, SOC SCI MED, V49, P519, DOI 10.1016/S0277-9536(99)00146-X
   GBD 2016 Diarrhoeal Disease Collaborators, 2018, LANCET INFECT DIS, V18, P1211
   Ghazi HO, 2005, SAUDI ARABIA J PAK M, V55, P231
   Glass RI, 2006, LANCET, V368, P323, DOI 10.1016/S0140-6736(06)68815-6
   International Centre for Diarrhoeal Disease Research Bangladesh, 2012, HLTH DEM SURV SYST M
   International Vaccine Access Center (IVAC) Johns Hopkins Bloomberg School of Public Health, 2019, VIEW HUB GLOB VACC I
   Linhares AC, 2006, J PEDIAT, V82, P25
   Lopman BA, 2018, J INFECT DIS, V217, P851, DOI 10.1093/infdis/jix670
   Madhi SA, 2016, MALAWI MED J, V28, P108, DOI 10.1056/NEJMoa0904797
   Merga N, 2015, J HEALTH POPUL NUTR, V33, P20
   Nakawesi JS, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-69
   Nazia N, 2018, SPAT SPATIO-TEMPORAL, V24, P1, DOI 10.1016/j.sste.2017.09.001
   Nguyen TV, 2004, J CLIN MICROBIOL, V42, P5745, DOI 10.1128/JCM.42.12.5745-5750.2004
   Parashar UD, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7204
   Patel M, 2013, J INFECT DIS, V208, P284, DOI 10.1093/infdis/jit166
   Pollard SL, 2015, VACCINE, V33, P3795, DOI 10.1016/j.vaccine.2015.06.064
   Salim H, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-54
   Satter SM, 2017, PEDIATR INFECT DIS J, V36, P168, DOI 10.1097/INF.0000000000001381
   Staat MA, 2002, PEDIATR INFECT DIS J, V21, P221, DOI 10.1097/00006454-200203000-00012
   Taniuchi M, 2016, VACCINE, V34, P3068, DOI 10.1016/j.vaccine.2016.04.080
   Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013
   Van Damme P, 2007, J INFECT DIS, V195, pS4, DOI 10.1086/516714
   WHO, 2005, TREATM DIARRH MAN PH
   World Health Organization, ROT DEATHS COUNTR 20
   Zaman K, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002282
   Zaman K, 2010, LANCET, V376, P615, DOI 10.1016/S0140-6736(10)60755-6
NR 42
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2190
EP 2197
DI 10.1016/j.vaccine.2020.01.041
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900014
PM 31983585
DA 2020-05-12
ER

PT J
AU Uziel, Y
   Moshe, V
   Onozo, B
   Kulcsar, A
   Trobert-Sipos, D
   Akikusa, JD
   Pileggi, GS
   Maritsi, D
   Kasapcopur, O
   Rodrigues, M
   Smerla, R
   Rigante, D
   Makay, B
   Atsali, E
   Wulffraat, N
   Toplak, N
AF Uziel, Yosef
   Moshe, Veronica
   Onozo, Beata
   Kulcsar, Andrea
   Trobert-Sipos, Diana
   Akikusa, Jonathan D.
   Pileggi, Gecilmara Salviato
   Maritsi, Despoina
   Kasapcopur, Ozgur
   Rodrigues, Mariana
   Smerla, Roubini
   Rigante, Donato
   Makay, Balahan
   Atsali, Erato
   Wulffraat, Nico
   Toplak, Natasa
CA PReS Working Party Vaccination Stu
TI Live attenuated MMR/V booster vaccines in children with rheumatic
   diseases on immunosuppressive therapy are safe: Multicenter,
   retrospective data collection
SO VACCINE
LA English
DT Article
DE Vaccination; Biologic therapies; Juvenile idiopathic arthritis - JIA;
   Measles, mumps, rubella booster; Varicella booster; Immunocompromised
ID JUVENILE IDIOPATHIC ARTHRITIS; VARICELLA VACCINATION; RUBELLA; MEASLES;
   MUMPS; METHOTREXATE; EFFICACY
AB Purpose: To collect retrospective data of patients with Juvenile Idiopathic Arthritis (JIA) and other rheumatic diseases who received live attenuated booster measles-mumps-rubella (MMR) or measles-mumps-rubellavaricella (MMR/V) during treatment with immunosuppressive therapy.
   Results: Data from 13 pediatric rheumatology centers in 10 countries, including 234 patients, were collected. Mean age at diagnosis was 5 +/- 2.7 years, 67% were girls. Among them, 211 (90.2%) had JIA and 110 (47%) were in remission on medication. Disease activity was low in 37%, high in 8%, and moderate in 8%. One hundred-twenty-four received MMR/V booster while on methotrexate (MTX); 3 reported local mild adverse events (AE). Among 62 on MTX + biologics and 9 patients who received a combination of 2 disease modifying antirheumatic drugs (DMARDs), 9 reported mild AE. Among 39 on biologics, 1 reported fever one day after booster vaccination. No vaccine-related infection of measles, rubella, mumps or varicella was reported, none of the patients developed disease flare, including those with high disease activity.
   Conclusions: In this retrospective study, live-attenuated MMRIV booster vaccines were safe for children with rheumatic diseases, on immunosuppressive therapies. This strengthens the Paediatric Rheumatology European Society (PReS) recommendation that vaccination with live attenuated vaccines in patients on immunosuppressive therapies can be considered individually, weighing the benefit of vaccination against the risk of inducing infection through vaccination. These data provide the basis for a prospective data collection study, planned by the PReS vaccination study group. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Uziel, Yosef; Moshe, Veronica] Tel Aviv Univ, Pediat Rheumatol Unit, Dept Pediat, Meir Med Ctr,Sackler Fac Med, Kefar Sava, Israel.
   [Onozo, Beata] Borsod Abauj Zemplen Cty Cent Hosp, Dept Pediat, Miskolc, Hungary.
   [Kulcsar, Andrea] South Pest Cent Hosp Natl Inst Hematol & Infect D, Dept Special Immunizat Serv, Budapest, Hungary.
   [Trobert-Sipos, Diana] South Pest Cent Hosp Natl Inst Hematol & Infect D, Dept Pediat, Budapest, Hungary.
   [Akikusa, Jonathan D.] Royal Childrens Hosp, Dept Paediat, Melbourne, Vic, Australia.
   [Pileggi, Gecilmara Salviato] Univ Sao Paulo, Univ Hosp Ctr, Sch Med Ribeirao Preto, Clin Res Unit, Sao Paulo, Brazil.
   [Maritsi, Despoina] Natl & Kapodistrian Univ Athens, Athens Med Sch, Dept Pediat 2, Athens, Greece.
   [Kasapcopur, Ozgur] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Dept Pediat Rheumatol, Istanbul, Turkey.
   [Rodrigues, Mariana] Sao Joao Univ Hosp, Porto Fac Med, Paediat Rheumatol Unit, Porto, Portugal.
   [Smerla, Roubini] Univ Athens, Dept Paediat, Athens, Greece.
   [Rigante, Donato] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Inst Pediat, Rome, Italy.
   [Makay, Balahan] Izmir Behcet Uz Childrens Hosp, Dept Pediat Rheumatol, Izmir, Turkey.
   [Atsali, Erato] Natl & Kapodistrian Univ Athens, Athens Med Sch, Dept Pediat 3, Pediat Rheumatol Unit, Athens, Greece.
   [Wulffraat, Nico] Wilhelmina Childrens Hosp, Divisie Kinderen, Utrecht, Netherlands.
   [Toplak, Natasa] Univ Ljubljana, Univ Childrens Hosp, Univ Med Ctr Ljubljana, Dept Allergol Rheumatol & Clin Immunol,Fac Med, Ljubljana, Slovenia.
RP Uziel, Y (reprint author), Meir Med Ctr, Dept Pediat, 49 Tchernichovsky St, IL-4428164 Kefar Sava, Israel.
EM uziely@zahav.net.il
RI Kasapcopur, Ozgur/A-8888-2018
OI Kasapcopur, Ozgur/0000-0002-1125-7720
CR Borte S, 2009, RHEUMATOLOGY, V48, P144, DOI 10.1093/rheumatology/ken436
   Doran MF, 2002, ARTHRITIS RHEUM, V46, P2287, DOI 10.1002/art.10524
   Fessler BJ, 2002, BEST PRACT RES CL RH, V16, P281, DOI 10.1053/berh.2001.0226
   Giancane G, 2019, ANN RHEUM DIS, V78, P629, DOI 10.1136/annrheumdis-2019-eular.6773
   Groot N, 2017, VACCINE, V35, P2818, DOI 10.1016/j.vaccine.2017.04.015
   Groot N, 2015, CURR RHEUMATOL REP, V17, DOI 10.1007/s11926-015-0519-y
   Heijstek MW, 2011, ANN RHEUM DIS, V70, P1704, DOI 10.1136/ard.2011.150193
   Heijstek MW, 2007, ANN RHEUM DIS, V66, P1384, DOI 10.1136/ard.2006.063586
   Heijstek MW, 2013, JAMA-J AM MED ASSOC, V309, P2449, DOI 10.1001/jama.2013.6768
   Heijstek MW, 2012, ANN RHEUM DIS, V71, P948, DOI 10.1136/annrheumdis-2011-200637
   Jeyaratnam J, 2018, PEDIATR RHEUMATOL, V16, DOI 10.1186/s12969-018-0235-z
   Moraitis E, 2019, ANN RHEUM DIS, V78, P1343, DOI 10.1136/annrheumdis-2019-eular.8063
   O'Donnell S, 2019, EMERG MED J, V36, P310, DOI 10.1136/emermed-2019-208490
   Pileggi GS, 2010, ARTHRIT CARE RES, V62, P1034, DOI 10.1002/acr.20183
   Toplak N, 2015, VACCINE, V33, P4056, DOI 10.1016/j.vaccine.2015.06.086
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
   Wulffraat NM, 2018, MED MATTERSRHEUMATOL
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2198
EP 2201
DI 10.1016/j.vaccine.2020.01.037
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900015
PM 31987692
DA 2020-05-12
ER

PT J
AU King, JP
   Hanson, KE
   Donahue, JG
   Glanz, JM
   Klein, NP
   Naleway, AL
   DeStefano, F
   Weintraub, E
   Belongia, EA
AF King, Jennifer P.
   Hanson, Kayla E.
   Donahue, James G.
   Glanz, Jason M.
   Klein, Nicola P.
   Naleway, Allison L.
   DeStefano, Frank
   Weintraub, Eric
   Belongia, Edward A.
TI Survey of influenza vaccine knowledge, attitudes, and beliefs among
   pregnant women in the 2016-17 season
SO VACCINE
LA English
DT Article
DE Influenza; Pregnancy; Vaccination; Knowledge
ID UNITED-STATES; IMMUNIZATION; SAFETY; COVERAGE
AB Objectives: Influenza vaccination coverage among pregnant women in the United States is suboptimal. We surveyed women who were pregnant during the 2016-17 influenza season to assess knowledge and attitudes regarding influenza vaccination.
   Methods: We identified and sampled pregnant women to include approximately equal numbers of vaccinated and unvaccinated women from strata defined by vaccination status and trimester from four integrated health systems in the Vaccine Safety Datalink (VSD). Potential participants were contacted via mail and telephone to complete a standardized survey. Characteristics and responses of women vaccinated and unvaccinated during pregnancy were compared.
   Results: The survey was completed by 510 (48%) of 1062 contacted women: 500 were included in the analysis. Vaccine receipt while pregnant was associated with primigravida status (p = 0.02), college degree (p = 0.01), employment in health care (p < 0.01), and history of routine annual influenza vaccination (p < 0.01). Among 330 vaccinated women, the primary reasons for vaccination included protection of self and baby from influenza (n = 233, 71%), and medical professional recommendation (n = 46, 14%). Multiple reasons were given for nonvaccination, but concern about 'negative effects' was cited most often (n = 44, 29%). Vaccinated women were significantly more likely to believe that influenza vaccines are safe and effective, and to recognize the potential for harm from influenza infection. Nearly all women reported receiving at least one influenza vaccination recommendation from a healthcare provider.
   Conclusions: Vaccinated pregnant women were more likely to receive routine annual influenza vaccine compared to those not vaccinated. Recommendations by obstetric providers should be supplemented with efforts to encourage women of childbearing age to receive annual vaccination. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [King, Jennifer P.; Hanson, Kayla E.; Donahue, James G.; Belongia, Edward A.] Marshfield Clin Res Inst, Ctr Clin Epidemiol & Populat Hlth, 1000 N Oak Ave,ML2, Marshfield, WI 54449 USA.
   [Glanz, Jason M.] Kaiser Permanente Colorado, Inst Hlth Res, 10065 E Harvard Ave 300, Denver, CO 80231 USA.
   [Klein, Nicola P.] Kaiser Permanente Northern Calif, Div Res, Vaccine Study Ctr, 2000 Broadway, Oakland, CA 94612 USA.
   [Naleway, Allison L.] Kaiser Permanente Northwest, Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA.
   [DeStefano, Frank; Weintraub, Eric] Ctr Dis Control & Prevent, Immunizat Safety Off, 1600 Clifton Rd NE,MS V18-4, Atlanta, GA 30333 USA.
RP King, JP (reprint author), Marshfield Clin Res Inst, Ctr Clin Epidemiol & Populat Hlth, 1000 N Oak Ave,ML2, Marshfield, WI 54449 USA.
EM king.jennifer@marshfieldresearch.org;
   hanson.kayla@marshfieldresearch.org;
   donahue.james@marshfieldresearch.org; jason.m.glanz@kp.org;
   nicola.klein@kp.org; allison.naleway@kpchr.org; fxd1@cdc.gov;
   eiw8@cdc.gov; belongia.edward@marshfieldclinic.org
FU Centers for Disease Control and Prevention (CDC), United StatesUnited
   States Department of Health & Human ServicesCenters for Disease Control
   & Prevention - USA [200-2012-53587/0007]
FX This study was supported by the Centers for Disease Control and
   Prevention (CDC), United States under contract 200-2012-53587/0007. CDC
   scientists participated in interpretation of the data, and preparation,
   review, and approval of the manuscript for publication. The findings and
   conclusions in this report are those of the authors and do not
   necessarily represent the official position of the Centers for Disease
   Control and Prevention.
CR Agresti A., 1990, CATEGORICAL DATA ANA
   American College of Obstetricians and Gynecologists, 2014, OBSTET GYNECOL, V124, P648
   [Anonymous], 2018, Obstet Gynecol, V131, pe109, DOI 10.1097/AOG.0000000000002588
   Baggs J, 2011, PEDIATRICS, V127, pS45, DOI 10.1542/peds.2010-1722H
   Bednarczyk RA, 2012, AM J OBSTET GYNECOL, V207, pS38, DOI 10.1016/j.ajog.2012.07.002
   Bettinger JA, 2016, J OBSTET GYNAECOL CA, V38, P1045, DOI 10.1016/j.jogc.2016.08.004
   Bloom-Feshbach K, 2011, J INFECT DIS, V204, P1157, DOI 10.1093/infdis/jir510
   Chamberlain AT, 2016, VACCINE, V34, P1597, DOI 10.1016/j.vaccine.2016.01.058
   Chamberlain AT, 2015, SAFETY PLOS CURR, V7
   Deshpande JV, 1995, STAT ANAL NONNORMAL
   Ding H, 2017, MMWR-MORBID MORTAL W, V66, P1016, DOI 10.15585/mmwr.mm6638a2
   Ding HL, 2015, MMWR-MORBID MORTAL W, V64, P1000, DOI 10.3201/mmwr.mm6436a2
   Eppes C, 2013, VACCINE, V31, P2874, DOI 10.1016/j.vaccine.2013.04.031
   Frew PM, 2014, HUM VACC IMMUNOTHER, V10, P2576, DOI 10.4161/hv.32248
   Groom HC, 2016, AM J PREV MED, V50, P480, DOI 10.1016/j.amepre.2015.08.017
   Harper Scott A., 2004, Morbidity and Mortality Weekly Report, V53, P1
   Henninger M, 2013, OBSTET GYNECOL, V121, P741, DOI 10.1097/AOG.0b013e3182878a5a
   Lutz CS, 2018, VACCINE, V36, P7445, DOI 10.1016/j.vaccine.2018.10.046
   Meharry PM, 2013, MATERN CHILD HLTH J, V17, P156, DOI 10.1007/s10995-012-0957-3
   Omer SB, 2012, HUM VACC IMMUNOTHER, V8, P130, DOI 10.4161/hv.8.1.18601
   Panda B, 2011, J MATERN-FETAL NEO M, V24, P402, DOI 10.3109/14767058.2010.497882
   Sayakhot P, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0856-5
   Siston AM, 2010, JAMA-J AM MED ASSOC, V303, P1517, DOI 10.1001/jama.2010.479
   Stark LM, 2016, INFECT DIS OBSTET GY, V2016
   Tamma PD, 2009, AM J OBSTET GYNECOL, V201, P547, DOI 10.1016/j.ajog.2009.09.034
   U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion, 2010, HLTH PEOPL 2020
NR 26
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2202
EP 2208
DI 10.1016/j.vaccine.2020.01.039
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900016
PM 31992481
DA 2020-05-12
ER

PT J
AU Sato, R
   Belel, A
AF Sato, Ryoko
   Belel, Abdullahi
TI The effect of performance-based financing on child vaccinations in
   northern Nigeria
SO VACCINE
LA English
DT Article
DE Performance-Based Financing; Child vaccinations; Nigeria
ID HEALTH-CARE; IMMUNIZATION; SERVICES; COVERAGE
AB Vaccination is known to be one of the most cost-effective ways to avert child deaths. However, in Nigeria, the vaccination completion rate among children is extremely low and the child mortality rate is one of the highest in the world. National immunization coverage survey shows that the low vaccination rate in Nigeria is partly attributed to service delivery issues. This paper evaluates the effect of Performance-Based Financing (PBF), an incentive scheme where health facilities are funded based on their performance, on the quantity of vaccinations carried out in Adamawa state. Under the Nigeria State Health Investment Project (NSHIP), half of the Local Government Areas (LGAs) in Adamawa State were randomly assigned to receive PBF intervention between 2015 and 2018. The Difference-in Differences (DiD) technique as well as ANCOVA analysis are used to evaluate the effect of PBF on vaccination service delivery indicators. We find that the PBF intervention significantly increased the quantity of full vaccination cases as compared to the comparison group, although the effect size was small. On the other hand, if health facilities receive intensified PEI (Polio Eradication Initiative) concurrently, the effectiveness of PBF in increasing the number of full vaccination cases do not differ significantly from health facilities that are not under PBF. Rather than providing conditional financial incentives such as PBF to health facilities, simply providing unconditional financial and technical assistance to strengthen routine immunization programs might be sufficient to increase the quantity of vaccination service provision. The positive effect of PBF on vaccination provision was not sustainable, either. Future work should explore how we can strengthen the health system in a cost-effective and sustainable way. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Sato, Ryoko; Belel, Abdullahi] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.
RP Sato, R (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA.
EM rsato@hsph.harvard.edu
CR Ataguba JE, 2016, HEALTH POLICY PLANN, V31, P1212, DOI 10.1093/heapol/czw053
   Basinga P, 2011, LANCET, V377, P1421, DOI 10.1016/S0140-6736(11)60177-3
   Bright T, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2180-9
   de Walque D, 2017, LOOKING PERFORMANCE
   Eeshani Loevinsohn Benjamin Kandpal, 2019, IMPACT EVALUATION NI
   Eichler R, 2013, J HEALTH POPUL NUTR, V31, P36
   Falisse JB, 2015, HEALTH POLICY PLANN, V30, P1251, DOI 10.1093/heapol/czu132
   Kieny MP, 2017, B WORLD HEALTH ORGAN, V95, P537, DOI 10.2471/BLT.16.187476
   McKenzie D, 2012, J DEV ECON, V99, P210, DOI 10.1016/j.jdeveco.2012.01.002
   Meessen B, 2011, B WORLD HEALTH ORGAN, V89, P153, DOI 10.2471/BLT.10.077339
   National Immunization Coverage Survey (NICS), 2018, 2018 NAT BRIEF
   Oku A, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4020-6
   Ozawa S, 2016, HEALTH AFFAIR, V35, P199, DOI 10.1377/hlthaff.2015.1086
   Sibeudu Florence T, 2017, BMC Res Notes, V10, P78, DOI 10.1186/s13104-017-2407-1
   Stokes-Prindle C, 2012, LANDSCAPE ANAL ROUTI
   UNICEF, 2017, UNICEF DAT
   World Bank, 2017, WORLD BANK OP DAT
   World Health Organization, 2019, CHILDR RED MORT
NR 18
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2209
EP 2215
DI 10.1016/j.vaccine.2020.01.033
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900017
PM 31983583
DA 2020-05-12
ER

PT J
AU Cunha, GK
   de Matos, MB
   Trettim, JP
   Rubin, BB
   Quevedo, LD
   Pinheiro, KAT
   Coelho, FMD
   Pinheiro, RT
AF Cunha, Gabriela Kurz
   de Matos, Mariana Bonati
   Trettim, Jessica Puchalski
   Rubin, Barbara Borges
   Quevedo, Luciana de Avila
   Tavares Pinheiro, Karen Amaral
   da Cunha Coelho, Fabio Monteiro
   Pinheiro, Ricardo Tavares
TI Thimerosal-containing vaccines and deficit in child development:
   Population-based study in southern Brazil
SO VACCINE
LA English
DT Article
DE Thimerosal; Vaccination; Child development
ID NEURODEVELOPMENTAL DISORDERS; UNITED-KINGDOM; EXPOSURE; INFANTS; COHORT;
   SUPPORT; SAFETY; RISK
AB Background: The discussion on the safety of thimerosal-containing vaccines (TCVs) and their impact on child development its very relevant. Methods: This is a cohort study with mother-child dyads who received prenatal care in the Unified Health System. The domains of motor, cognitive and language development were evaluated in children between 24 and 36 months of age. Data on vaccination were obtained through the child's immunization record. A linear regression analysis was carried out considering possible confounders. Results: In bivariate analyses, motor and language development were associated with TCVs (p < 0.05). However, in the multivariate analysis, this association was not maintained (p > 0.05). These results indicate that the use of TCVs is not associated with child development. The importance of this study is summarized in transmitting relevant information regarding public health, based on reliable data. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Cunha, Gabriela Kurz; de Matos, Mariana Bonati; Trettim, Jessica Puchalski; Rubin, Barbara Borges; Quevedo, Luciana de Avila; Pinheiro, Ricardo Tavares] Catholic Univ Pelotas UCPel, Postgrad Programme Hlth & Behav, Goncalves Chaves 377-411 C, BR-96015560 Pelotas, RS, Brazil.
   [Tavares Pinheiro, Karen Amaral] Univ Fed Rio Grande, Ave Italia S-N,Km 9, Rio Grande, RS, Brazil.
   [da Cunha Coelho, Fabio Monteiro] Fed Univ Pelotas UFPel, Ave Duque de Caxias 250, BR-25096020 Pelotas, RS, Brazil.
RP Cunha, GK; de Matos, MB (reprint author), Catholic Univ Pelotas UCPel, Postgrad Programme Hlth & Behav, Goncalves Chaves 377-411 C, BR-96015560 Pelotas, RS, Brazil.
EM gabriellakcunha@hotmail.com; marianabonatidematos@gmail.com
OI Borges Rubin, Barbara/0000-0003-2062-1480
FU National Council of Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [Process474786/2012-9 Edital Universal 1412012]
FX National Council of Scientific and Technological Development (CNPq)
   -Process474786/2012-9 Edital Universal 1412012.
CR Amorim P., 2000, REV BRAS PSIQUIATR, V22, P106, DOI DOI 10.1590/S1516-44462000000300003
   Andrews N, 2004, PEDIATRICS, V114, P584, DOI 10.1542/peds.2003-1177-L
   Bayley N., 1993, BAYLEY SCALES INFANT
   Beck A. T., 1996, BECK DEPRESSION INVE, V78, P490, DOI DOI 10.1037/T00742-000
   Beck AT, 1988, FREMDBEURTEILUNGSVER, V7
   Dorea JG, 2013, CURR MED CHEM, V20, P4060
   Geier DA, 2018, INT J HYG ENVIR HEAL, V221, P677, DOI 10.1016/j.ijheh.2018.03.004
   Geier DA, 2015, CLIN CHIM ACTA, V444, P212, DOI 10.1016/j.cca.2015.02.030
   Heron J, 2004, PEDIATRICS, V114, P577, DOI 10.1542/peds.2003-1176-L
   Cavalcante KRLJ, 2017, EPIDEMIOL SERV SAUDE, V26, P617, DOI 10.5123/S1679-49742017000300018
   Luhm KR, 2011, REV SAUDE PUBL, V45, P90, DOI 10.1590/s0034-89102010005000054
   Mrozek-Budzyn D, 2015, EUR J PEDIATR, V174, P383, DOI 10.1007/s00431-014-2412-5
   Mrozek-Budzyn D, 2012, NEUROTOXICOL TERATOL, V34, P592, DOI 10.1016/j.ntt.2012.10.001
   Nanoff C, 2019, INT J HYG ENVIR HEAL, V222, P307, DOI 10.1016/j.ijheh.2018.10.003
   Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x
   Sabanathan S, 2015, ARCH DIS CHILD, V100, P482, DOI 10.1136/archdischild-2014-308114
   Temporão José Gomes, 2003, Hist. cienc. saude-Manguinhos, V10, P601, DOI 10.1590/S0104-59702003000500008
   Verstraeten T, 2003, PEDIATRICS, V112, P1039, DOI 10.1542/peds.112.2.e98
   Young HA, 2008, J NEUROL SCI, V271, P110, DOI 10.1016/j.jns.2008.04.002
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2216
EP 2220
DI 10.1016/j.vaccine.2019.12.044
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900018
PM 32014269
DA 2020-05-12
ER

PT J
AU Sandhu, SK
   Hua, W
   MaCurdy, TE
   Franks, RL
   Avagyan, A
   Chillarige, Y
   Wernecke, M
   Kelman, J
   Ball, R
AF Sandhu, Sukhminder K.
   Hua, Wei
   MaCurdy, Thomas E.
   Franks, Riley L.
   Avagyan, Armen
   Chillarige, Yoganand
   Wernecke, Michael
   Kelman, Jeffrey
   Ball, Robert
TI Comparison of alpha-spending plans for near real-time monitoring for
   Guillain-Barre Syndrome after influenza vaccination during the 2010/11
   influenza season
SO VACCINE
LA English
DT Article
DE Alpha-spending; Sequential test; Guillain-Barre Syndrome; Immunization;
   Influenza; Vaccine
ID POST-MARKET DRUG; MEDICARE POPULATION; SAFETY SURVEILLANCE;
   SEQUENTIAL-ANALYSIS; ASSOCIATION; RECEIPT; SYSTEM; H1N1
AB Background: Near real-time surveillance of the influenza vaccine, which is administered to a large proportion of the US population every year, is essential to enscure safety of the vaccine. For efficient near real-time surveillance, it is key to select appropriate parameters such as monitoring start date, number of interim tests and a scheme for spending a pre-defined total alpha across the entire influenza season. Guillain-Barre Syndrome, shown to be associated with the 1976 influenza vaccine, is used to evaluate how choices of these parameters can affect whether or not a signal is detected and the time to signal. FDA has been monitoring for the risk of GBS after influenza vaccination for every influenza season since 2008.
   Methods: Using Medicare administrative data and the Updating Sequential Probability Ratio Test methodology to account for claims delay, we evaluated a number of different alpha-spending plans by varying several parameters.
   Results: For relative risks of 5 or greater, almost all alpha-spending plans have 100% power: however, for relative risks of 1.5 or lower, the constant and O'Brien-Fleming plans have increasingly more power. For RRs of 1.5 and greater, the Pocock plan signals earliest but would not signal at a RR of 1.25, as observed in prior influenza seasons. There were no remarkable differences across the different plans in regards to monitoring start dates defined by the number of vaccinations: reducing the number of interim tests improves performance only marginally.
   Conclusions: A constant alpha-spending plan appears to be robust, in terms of power and time to detect a signal, across a range of these parameters, including alternate monitoring start dates based on either cumulative vaccinations or GBS claims observed, frequency of monitoring, hypothetical relative risks, and vaccine uptake patterns. Published by Elsevier Ltd.
C1 [Sandhu, Sukhminder K.; Hua, Wei; Ball, Robert] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA.
   [MaCurdy, Thomas E.] Stanford Univ, Stanford, CA 94305 USA.
   [MaCurdy, Thomas E.; Franks, Riley L.; Avagyan, Armen; Chillarige, Yoganand; Wernecke, Michael] Acumen LLC, Burlingame, CA USA.
   [Kelman, Jeffrey] Ctr Medcare & Medicaid Serv, Washington, DC USA.
RP Sandhu, SK (reprint author), US PHS, 10903 New Hampshire Ave Bldg 22,Room 2472, Silver Spring, MD 20993 USA.; Sandhu, SK (reprint author), US FDA, CDER OSE OPE DEPI I, 10903 New Hampshire Ave Bldg 22,Room 2472, Silver Spring, MD 20993 USA.
EM sukhminder.sandhu@fda.hhs.gov
FU FDA's Center for Biologics Evaluation and Research
FX This work was funded by FDA's Center for Biologics Evaluation and
   Research.
CR Belongia EA, 2010, PEDIATR INFECT DIS J, V29, P1, DOI 10.1097/INF.0b013e3181af8605
   Burwen DR, 2007, PHARMACOEPIDEM DR S, V16, P753, DOI 10.1002/pds.1390
   Burwen DR, 2012, AM J PUBLIC HEALTH, V102, P1921, DOI 10.2105/AJPH.2011.300510
   Burwen DR, 2010, AM J PREV MED, V39, P296, DOI 10.1016/j.amepre.2010.05.022
   CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8
   Cook AJ, 2012, PHARMACOEPIDEM DR S, V21, P72, DOI 10.1002/pds.2320
   COPELAND KT, 1977, AM J EPIDEMIOL, V105, P488, DOI 10.1093/oxfordjournals.aje.a112408
   Davis RL, 2005, EPIDEMIOLOGY, V16, P336, DOI 10.1097/01.ede.0000155506.05636.a4
   Franks R, 2014, STAT ANAL DATA MIN, V7, P368, DOI 10.1002/sam.11234
   Greene SK, 2012, AM J EPIDEMIOL, V175, P1100, DOI 10.1093/aje/kws195
   Greene SK, 2010, AM J EPIDEMIOL, V171, P177, DOI 10.1093/aje/kwp345
   Haber P, 2004, JAMA-J AM MED ASSOC, V292, P2478, DOI 10.1001/jama.292.20.2478
   Haber P, 2013, VACCINE
   Immunization Safety Review. Committee BoHPaDP, 2001, I MED
   Jennison C, 2000, GROUP SEQUENTIAL MET
   Klein NP, 2010, PEDIATR INFECT DIS J, V29, P613, DOI 10.1097/INF.0b013e3181d581f9
   LANGMUIR AD, 1984, AM J EPIDEMIOL, V119, P841, DOI 10.1093/oxfordjournals.aje.a113809
   Lee GM, 2011, AM J PREV MED, V41, P121, DOI 10.1016/j.amepre.2011.04.004
   Lieu TA, 2007, MED CARE, V45, pS89, DOI 10.1097/MLR.0b013e3180616c0a
   Maro JC, 2014, PHARMACOEPIDEM DR S, V23, P839, DOI 10.1002/pds.3618
   Martin D, 2013, DRUG SAFETY, V36, P547, DOI 10.1007/s40264-013-0051-9
   OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245
   POCOCK SJ, 1977, BIOMETRIKA, V64, P191, DOI 10.1093/biomet/64.2.191
   Polakowski LL, 2013, AM J EPIDEMIOL, V178, P962, DOI 10.1093/aje/kwt051
   SAFRANEK TJ, 1991, AM J EPIDEMIOL, V133, P940, DOI 10.1093/oxfordjournals.aje.a115973
   Sandhu SK, 2009, COMP ALPHA SPENDING
   Sandhu SK, 2011, VACCINES, P2009
   Sandhu SK, 2017, VACCINE, V35, P2986, DOI 10.1016/j.vaccine.2017.03.087
   SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P105, DOI 10.1093/oxfordjournals.aje.a112795
   Silva IR, 2015, BIOMETRICS, V71, P851, DOI 10.1111/biom.12324
   Silva IR, 2019, STAT MED, V38, P2126, DOI 10.1002/sim.8097
   Silva IR, 2018, STAT MED, V37, P107, DOI 10.1002/sim.7504
NR 32
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2221
EP 2228
DI 10.1016/j.vaccine.2019.12.032
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900019
PM 31932134
DA 2020-05-12
ER

PT J
AU Angelidou, A
   Conti, MG
   Diray-Arce, J
   Benn, CS
   Shann, F
   Netea, MG
   Liu, M
   Potluri, LP
   Sanchez-Schmitz, G
   Husson, R
   Ozonoff, A
   Kampmann, B
   van Haren, SD
   Levy, O
AF Angelidou, Asimenia
   Conti, Maria-Giulia
   Diray-Arce, Joann
   Benn, Christine S.
   Shann, Frank
   Netea, Mihai G.
   Liu, Mark
   Potluri, Lakshmi Prasad
   Sanchez-Schmitz, Guzman
   Husson, Robert
   Ozonoff, Al
   Kampmann, Beate
   van Haren, Simon Daniel
   Levy, Ofer
TI Licensed Bacille Calmette-Guerin (BCG) formulations differ markedly in
   bacterial viability, RNA content and innate immune activation
SO VACCINE
LA English
DT Article
DE BCG vaccine formulation; Viability; Colony forming units; Cytokine;
   Chemokine; Cord blood
ID MYCOBACTERIUM-BOVIS; VACCINE STRAIN; GENE-EXPRESSION; GUINEA-BISSAU;
   TUBERCULOSIS; INFANTS; PROTECTION; RESPONSES; IMMUNOGENICITY; MORBIDITY
AB Background: Bacille Calmette-Guerin (BCG), the live attenuated tuberculosis vaccine, is manufactured under different conditions across the globe generating formulations that may differ in clinical efficacy. Innate immune recognition of live BCG contributes to immunogenicity suggesting that differences in BCG viability may contribute to divergent activity of licensed formulations.
   Methods: We compared BCG-Denmark (DEN), -Japan (JPN), -India (IND), -Bulgaria (BUL) and -USA in vitro with respect to a) viability as measured by colony-forming units (CFU), mycobacterial membrane integrity, and RNA content, and b) cytokine/chemokine production in newborn cord and adult peripheral blood.
   Results: Upon culture, relative growth was BCG-USA > JPN >> DEN > BUL = IND. BCG-IND and -BUL demonstrated >1000-fold lower growth than BCG JPN in 7H9 medium and >10-fold lower growth in commercial Middlebrook 7H11 medium. BCG-IND demonstrated significantly decreased membrane integrity, lower RNA content, and weaker IFN-gamma inducing activity in whole blood compared to other BCGs. BCG-induced whole blood cytokines differed significantly by age, vaccine formulation and concentration. BCG-induced cytokine production correlated with CFU, suggesting that mycobacterial viability may contribute to BCG-induced immune responses.
   Conclusions: Licensed BCG vaccines differ markedly in their content of viable mycobacteria possibly contributing to formulation-dependent activation of innate and adaptive immunity and distinct protective effects. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Angelidou, Asimenia] Harvard Med Sch, Boston Childrens Hosp, Div Newborn Med, Boston, MA 02115 USA.
   [Angelidou, Asimenia; Conti, Maria-Giulia; Diray-Arce, Joann; Liu, Mark; Potluri, Lakshmi Prasad; Sanchez-Schmitz, Guzman; Husson, Robert; Ozonoff, Al; van Haren, Simon Daniel; Levy, Ofer] Harvard Med Sch, Boston Childrens Hosp, Div Infect Dis, Precis Vaccines Program, Boston, MA 02115 USA.
   [Conti, Maria-Giulia] Sapienza Univ Rome, Dept Pediat, I-00185 Rome, Italy.
   [Benn, Christine S.] Univ Southern Denmark, Odense Univ Hosp, Odense Patient Data Explorat Network, OPEN,Inst Clin Res, DK-5000 Odense C, Denmark.
   [Shann, Frank] Univ Melbourne, Royal Childrens Hosp, Dept Pediat, Parkville, Vic 3052, Australia.
   [Netea, Mihai G.] Radboud Univ Nijmegen, Dept Internal Med, Med Ctr, Nijmegen, Netherlands.
   [Netea, Mihai G.] Radboud Univ Nijmegen, Radboud Ctr Infect Dis, Med Ctr, Nijmegen, Netherlands.
   [Netea, Mihai G.] Univ Bonn, Life & Med Sci Inst LIMES, Dept Genom & Immunoregulat, D-53115 Bonn, Germany.
   [Kampmann, Beate] London Sch Hyg & Trop Med, Vaccine Ctr, Fac Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
   [Kampmann, Beate] Gambia London Sch Hyg & Trop Med, Med Res Council Unit, Vaccines & Immun Theme, POB 273, Banjul, Gambia.
   [Angelidou, Asimenia; Sanchez-Schmitz, Guzman; Husson, Robert; Ozonoff, Al; van Haren, Simon Daniel; Levy, Ofer] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.
   [Levy, Ofer] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
RP Levy, O (reprint author), Boston Childrens Hosp, 4 Blackfan Circle, Boston, MA 02115 USA.
EM Asimenia.Angelidou@childrens.harvard.edu;
   MariaGiulia.Conti@childrens.harvard.edu;
   Joann.Arce@childrens.harvard.edu; CB@ssi.dk; shannf@netspace.net.au;
   Mihai.Netea@radboudumc.nl; LakshmiPrasad.Potluri@childrens.harvard.edu;
   Guzman.Sanchez-Schmitz@childrens.harvard.edu;
   Robert.Husson@childrens.harvard.edu; Al.Ozonoff@childrens.harvard.edu;
   bkampmann@mrc.gm; Simon.VanHaren@childrens.harvard.edu;
   Ofer.Levy@childrens.harvard.edu
RI Potluri, Lakshmi-Prasad/D-3318-2013
OI Potluri, Lakshmi-Prasad/0000-0001-5260-6678
FU National Institute of Allergy and Infectious Diseases (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U01Al124284]; Human Immunology Project Consortium
   (HIPC) [U19A1118608]; American Academy of Pediatrics; Sapienza
   University of Rome; Admeto Pettinnari e Paolo Andreini graduate
   scholarship; Danish National Research FoundationDanmarks
   Grundforskningsfond [DNRF108]; Spinoza grant of the Netherlands
   Organization for Scientific Research; UK Research and Innovation (UKRI)
   [MC_UP_A900/1122, MR/K011944/1]; Precision Vaccines Program at Boston
   Children's Hospital
FX This work was supported in part by grants from the National Institute of
   Allergy and Infectious Diseases (NIAID), including those on Molecular
   Mechanisms of Combination Adjuvants (grant number U01Al124284 to SvH)
   and the Human Immunology Project Consortium (HIPC; grant number
   U19A1118608). AA received the Marshall Klaus Perinatal Research Award
   from the American Academy of Pediatrics. MGC was sponsored by Sapienza
   University of Rome and was a recipient of the Admeto Pettinnari e Paolo
   Andreini graduate scholarship for specialization courses in Italy and
   abroad. CSB received funding from the Danish National Research
   Foundation (DNRF108). MGN was supported by a Spinoza grant of the
   Netherlands Organization for Scientific Research. BK is funded by UK
   Research and Innovation (UKRI) (grant number MC_UP_A900/1122;
   MR/K011944/1) and is a co-investigator of HIPC. AA, AO, GSS, OL, and SvH
   were in part supported by the Precision Vaccines Program at Boston
   Children's Hospital.
CR Anderson EJ, 2012, VACCINE, V30, P2083, DOI 10.1016/j.vaccine.2012.01.053
   Behr MA, 1999, VACCINE, V17, P915, DOI 10.1016/S0264-410X(98)00277-1
   Benmerzoug S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26984-3
   Berendsen MLT, 2019, J PEDIAT INFECT DIS, DOI [10.1093/jpids/piy147, DOI 10.1093/JNIDS/PIY142]
   Biering-Sorensen S, 2017, CLIN INFECT DIS, V65, P1183, DOI 10.1093/cid/cix525
   Biering-Sorensen S, 2015, VACCINE, V33, P2056, DOI 10.1016/j.vaccine.2015.02.056
   Cernuschi T, 2018, VACCINE, V36, P498, DOI 10.1016/j.vaccine.2017.12.010
   Chambers MA, 1997, J IMMUNOL, V158, P1742
   Corner LAL, 2012, VET MICROBIOL, V156, P162, DOI 10.1016/j.vetmic.2011.10.016
   Curtis N, 2019, PEDIATR INFECT DIS J, V38, P195, DOI 10.1097/INF.0000000000002230
   Dagg B, 2014, VACCINE, V32, P6390, DOI 10.1016/j.vaccine.2014.09.065
   Dai FY, 2017, HUM VACC IMMUNOTHER, V13, P1425, DOI 10.1080/21645515.2017.1279771
   Davids V, 2006, J INFECT DIS, V193, P531, DOI 10.1086/499825
   DENIS M, 1990, IMMUNOL LETT, V24, P203, DOI 10.1016/0165-2478(90)90049-V
   Dowling DJ, 2017, J ALLERGY CLIN IMMUN, V140, P1339, DOI 10.1016/j.jaci.2016.12.985
   Favorov M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032567
   Fletcher HA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11290
   Frankel H, 2016, VACCINE, V34, P4586, DOI 10.1016/j.vaccine.2016.07.022
   Funch KM, 2018, HUM VACC IMMUNOTHER, V14, P2434, DOI 10.1080/21645515.2017.1421879
   Gheorghiu M, 1996, DEV BIOL STAND, V87, P251
   GHEORGHIU M, 1983, ANN INST PASTEUR IMM, VC134, P125, DOI 10.1016/S0769-2625(83)80157-3
   Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170
   Hoffman RJE, 2013, HEMATOLOGY DIAGNOSIS, P311
   Jayaraman K, 2019, PEDIATR INFECT DIS J, V38, P198, DOI 10.1097/INF.0000000000002198
   Jensen KJ, 2015, J INFECT DIS, V211, P956, DOI 10.1093/infdis/jiu508
   de Castro MJ, 2015, CLIN INFECT DIS, V60, P1611, DOI 10.1093/cid/civ144
   Kagina BMN, 2010, AM J RESP CRIT CARE, V182, P1073, DOI 10.1164/rccm.201003-0334OC
   Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517
   KROGER L, 1994, PEDIATR INFECT DIS J, V13, P113, DOI 10.1097/00006454-199402000-00007
   Mangtani P, 2014, CLIN INFECT DIS, V58, P470, DOI 10.1093/cid/cit790
   McAuliffe L, 2006, MICROBIOL-SGM, V152, P913, DOI 10.1099/mic.0.28604-0
   Means TK, 1999, J IMMUNOL, V163, P3920
   Messina NL, 2018, TUBERCULOSIS, V111, P188, DOI 10.1016/j.tube.2018.06.001
   Moorlag SJCFM, 2018, IMMUNOL REV, V281, P28, DOI 10.1111/imr.12617
   OSBORN TW, 1983, TUBERCLE, V64, P1, DOI 10.1016/0041-3879(83)90044-2
   Ponte C, 2018, HUM VACC IMMUNOTHER, V14, P28, DOI 10.1080/21645515.2017.1382788
   Ritz N, 2012, AM J RESP CRIT CARE, V185, P213, DOI 10.1164/rccm.201104-0714OC
   Roy RB, 2019, LANCET INFECT DIS, V19, pE96, DOI 10.1016/S1473-3099(18)30157-9
   Sanchez-Schmitz G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02634
   Sander LE, 2011, NATURE, V474, P385, DOI 10.1038/nature10072
   Schaltz-Buchholzer Frederik, 2019, Clin Infect Dis, DOI 10.1093/cid/ciz1080
   Scheid A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00029
   Shann F, 2015, CLIN INFECT DIS, V61, P960, DOI 10.1093/cid/civ454
   Storgaard L, 2015, CLIN INFECT DIS, V61, P950, DOI 10.1093/cid/civ452
   Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3
   Turner J, 1996, IMMUNOLOGY, V87, P339, DOI 10.1046/j.1365-2567.1996.512590.x
   Ugolini M, 2018, NAT IMMUNOL, V19, P386, DOI 10.1038/s41590-018-0068-4
   UNICEF, 2015, BCG VACC CURR SUPPL
   van den Biggelaar AHJ, 2009, J ALLERGY CLIN IMMUN, V124, P544, DOI 10.1016/j.jaci.2009.03.040
   Vouret-Craviari V, 1997, CYTOKINE, V9, P992, DOI 10.1006/cyto.1997.0242
   White GP, 2002, J IMMUNOL, V168, P2820, DOI 10.4049/jimmunol.168.6.2820
   Wu B, 2007, INFECT IMMUN, V75, P3658, DOI 10.1128/IAI.00244-07
   Yamamoto S, 2007, JPN J INFECT DIS, V60, P331
NR 53
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2229
EP 2240
DI 10.1016/j.vaccine.2019.11.060
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900020
PM 32005538
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Laing, SK
   Griffiths, U
   Raza, AA
   Zulu, F
   Yakubu, A
   Bessias, S
   Ozawa, S
AF Laing, Sarah K.
   Griffiths, Ulla
   Raza, Azhar Abid
   Zulu, Flint
   Yakubu, Ahmadu
   Bessias, Sophia
   Ozawa, Sachiko
TI An investment case for maternal and neonatal tetanus elimination
SO VACCINE
LA English
DT Article
DE Tetanus; Maternal child health; Neonatal mortality; Vaccination;
   Elimination; Cost-effectiveness
ID COST-EFFECTIVENESS; NEWBORN BABIES; IMMUNIZATION; HEALTH; INTERVENTIONS;
   PREVENTION; STRATEGIES; DELIVERY
AB Introduction: Globally, 13 countries have yet to eliminate maternal and neonatal tetanus. While efforts have improved access to tetanus toxoid containing vaccines (TTCVs) and increased clean delivery practices, reaching elimination targets (<1 case of neonatal tetanus per 1000 live births per district per year) may require significant resources to reach the remaining high risk and hard-to-reach districts.
   Methods: We estimated the cost to achieve maternal and neonatal tetanus elimination (MNTE) in three years in the remaining 13 countries: Afghanistan, Angola, Central African Republic, Democratic Republic of the Congo, Guinea, Mali, Nigeria, Pakistan, Papua New Guinea, Somalia, South Sudan, Sudan, and Yemen. Costs were estimated for: (1) vaccination campaigns using standard TTCVs and TT-Uniject (TM) targeting women of reproductive age in high risk areas, (2) additional vaccinations delivered to pregnant women at antenatal care (ANC) clinics, (3) clean delivery and umbilical cord care promotion, (4) neonatal tetanus surveillance strengthening, and (5) validation activities. We forecasted the averted mortality to assess the cost-effectiveness of achieving MNTE.
   Results: It will cost an estimated US$197.7 million to realize MNTE over three years. These costs include $161.4 million for vaccination campaigns, $6.1 million for routine vaccination during ANC, $23.3 million for promotion of clean delivery practices, $4 million for surveillance, and $3 million for validation of MNTE. Achieving MNTE will avert approximately 70,000 neonatal deaths over ten years of vaccine protection, resulting in approximately 4.4 million life years gained. It will cost $2,900 per death averted and $45 per life year gained.
   Conclusion: Maternal and neonatal tetanus can be eliminated with significant financial investment, high prioritization, and strong political will. While substantial costs must be incurred to reach hard-to-reach populations, MNTE should be accomplished as a matter of health equity, and will significantly contribute to reaching the United Nations' Sustainable Development Goals. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Laing, Sarah K.] Duke Univ, Duke Global Hlth Inst, Durham, NC USA.
   [Griffiths, Ulla; Raza, Azhar Abid; Zulu, Flint] UNICEF, Hlth Sect, New York, NY USA.
   [Yakubu, Ahmadu] UNICEF, Immunizat Coverage & Equ, New York, NY USA.
   [Bessias, Sophia] Univ N Carolina, Enterprise Analyt & Data Sci, Hlth Care, Chapel Hill, NC 27515 USA.
   [Ozawa, Sachiko] Univ N Carolina, Div Practice Adv & Clin Educ, UNC Eshelman Sch Pharm, Chapel Hill, NC 27515 USA.
   [Ozawa, Sachiko] Univ N Carolina, Dept Maternal & Child Hlth, UNC Gillings Sch Global Publ Hlth, Chapel Hill, NC 27515 USA.
RP Ozawa, S (reprint author), Univ N Carolina, Practice Adv & Clin Educ, UNC Eshelman Sch Pharm, CB 7574,Beard Hall 115H, Chapel Hill, NC 27599 USA.
EM ozawa@unc.edu
CR Adam T, 2005, BMJ-BRIT MED J, V331, P1107, DOI 10.1136/bmj.331.7525.1107
   [Anonymous], 1995, Vaccine Wkly, P12
   [Anonymous], 2014, NIG DEM HLTH SURV 20
   Bhutta ZA, 2014, LANCET, V384, P347, DOI 10.1016/S0140-6736(14)60792-3
   Bill Melinda Gates Foundation. World Health Organization UNICEF, 2017, TOT SYST EFF COMP AN
   Bleck TP, 2005, CLOSTRIDIUM TETANI T, P2817
   Burgess C, 2017, LANCET, V389, P1380, DOI 10.1016/S0140-6736(17)30635-9
   Central Bureau of Statistics (Sudan) Federal Ministry of Health (Sudan) UNICEF, 2016, SUD MULT IND CLUST S
   Central Statistics Organization/Afghanistan Ministry of Public Health/ Afghanistan ICF, 2017, AFGH DEM HLTH SURV 2
   COLLIER LH, 1979, LANCET, V1, P1364
   Consultoria de Servicos Estudos e Presquisas-COSEP-Consultoria Lda Consultoria de Gesdo e Administracao em Saude-Consadde Lda Macro International, 2007, ANG MAL IND SURV 200
   Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6
   Demicheli V, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002959.pub3
   Expanded programme on immunization. Global Advisory Group-Part II, 1994, RELEVE EPIDEMIOLOGIQ, V69, P29
   Expanded programme on immunization. Global Advisory Group-Part II, 1994, RELEVE EPIDEMIOLOGIQ, V69, P34
   FAUVEAU V, 1993, INT J GYNECOL OBSTET, V40, P3, DOI 10.1016/0020-7292(93)90765-O
   Galazka A, 1998, THERMOSTABILITY VACC
   Glenton C, 2013, TROP MED INT HEALTH, V18, P1002, DOI 10.1111/tmi.12126
   Griffiths UK, 2004, B WORLD HEALTH ORGAN, V82, P643
   Heinrichs G, 2011, WOMENS HLTH DEV WORL
   Institut National de la Statistique des Etudes Economiques et Demographiques-INSEED/Tchad Minisdre de la Sante Publique-MSP/Tchad ICF International, 2016, ENQ DEM SANT IND MUL
   Joshi N, 2004, Indian J Med Sci, V58, P472
   Kenya National Bureau of Statistics MoHK National AIDS Control Council/Kenya Kenya Medical Research Institute National Council for Population and Development/Kenya and ICF International, 2015, KEN DEM HLTH SURV 20
   Khan AA, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-322
   Khan KS, 2006, LANCET, V367, P1066, DOI 10.1016/S0140-6736(06)68397-9
   Khan R, 2015, IN J WOMENS HEALTH, V7, P171, DOI 10.2147/IJWH.S50539
   Koenig MA, 1998, AM J PUBLIC HEALTH, V88, P903, DOI 10.2105/AJPH.88.6.903
   Levine MM, 2016, CLIN VACCINE IMMUNOL, V23, P532, DOI 10.1128/CVI.00259-16
   Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6
   Minisdre du Plan et Suivi de la Mise en ceuvre de la Revolution de la Modernite-MPSMRM/Congo Minisdre de la Sante Publique-MSP/Congo ICF International, 2014, REP DEM CONG ENQ DEM
   Ministry of Health South Sudan National Bureau of Statistics South Sudan, 2013, S SUD HOUS HLTH SURV
   Ministry of Public Health Population Yemen Central Statistical Organization Yemen Pan Arab Program for Family Health ICF International, 2015, YEM NAT HLTH DEM SUR
   National Statistical Office (Papua New Guinea), 2009, PAP NEW GUIN DEM HLT
   Navaneetham K, 1982, SOC SCI MED, V2002, P1849
   NEWELL KW, 1966, B WORLD HEALTH ORGAN, V35, P863
   Nisar N, 2003, J Pak Med Assoc, V53, P47
   Ozawa S, 2019, VACCINE, V37, P5525, DOI 10.1016/j.vaccine.2019.06.081
   Pakistan Bureau of Statistics, 2014, PAK SOC LIV STAND ME
   Pakistan Bureau of Statistics, 2015, PAK SOC LIV STAND ME
   Pallikadavath S, 1982, SOC SCI MED, V2004, P1147
   QUIROGA R, 1998, PAN AM J PUBLIC HLTH, V4, P20
   Raza SA, 2013, INT J GYNECOL OBSTET, V120, P148, DOI 10.1016/j.ijgo.2012.07.030
   Ridpath Alison Delano, 2017, Pan Afr Med J, V27, P24, DOI 10.11604/pamj.supp.2017.27.3.11783
   Roper MH, 2007, LANCET, V370, P1947, DOI 10.1016/S0140-6736(07)61261-6
   SAGE Working Group on Maternal and Neonatal Tetanus, 2016, VACC SCHED US PREV N
   Samake S, 2007, ENQUETE DEMOGRAPHIQU
   SCHOFIELD F, 1986, REV INFECT DIS, V8, P144
   Steinglass RB, 1993, DIS CONTROL PRIORITI, P189
   Stenberg K, 2014, LANCET, V383, P1333, DOI 10.1016/S0140-6736(13)62231-X
   Sutanto A, 1999, B WORLD HEALTH ORGAN, V77, P119
   Thwaites CL, 2015, BRIT MED BULL, V116, P69, DOI 10.1093/bmb/ldv044
   Thwaites CL, 2015, LANCET, V385, P362, DOI 10.1016/S0140-6736(14)60236-1
   UNICEF, 2019, MAT NEWB HLTH
   UNICEF, 2004, EL MAT NEON TET
   UNICEF PATH, 2003, INTR TT UN MAT NEON
   UNICEF Somalia Support Centre, 2006, MULT IND CLUST SURV
   United Nations, 2018, SUST DEV KNOWL PLATF
   United Nations Population D, 2017, POP GROWTH RAT
   Vandelaer J, 2003, VACCINE, V21, P3442, DOI 10.1016/S0264-410X(03)00347-5
   Vandelaer J, 2008, B WORLD HEALTH ORGAN, P161, DOI DOI 10.2471/BLT.07.042127
   VOLK VK, 1962, PUBLIC HEALTH REP, V77, P185, DOI 10.2307/4591451
   Whitman Cynthia, 1992, World Health Statistics Quarterly, V45, P248
   WHO, 2003, WHO REC STAND SURV S
   World Health Organization, 2004, GLOB EP INF DIS
   World Health Organization, 2016, REP SAGE WORK GROUP
   World Health Organization, 2019, PROT ALL TET GUID SU
   World Health Organization, 2018, MAT NEON TET EL MNTE
   World Health Organization, 1999, FIELD MAN NEON TETN
   World Health Organization Child Health Epidemiology Reference Group (WHO-CHERG), 2016, DIS BURD MORT EST 20
   World Health Organization Strategic Advisory Group of Experts in Immunization, 2016, M STRAT ADV GROUP EX, P561
   World Health Organization UNICEF UNFPA, 2000, MAT NEON TET EL 2005
NR 71
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2241
EP 2249
DI 10.1016/j.vaccine.2019.11.052
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900021
PM 31980197
DA 2020-05-12
ER

PT J
AU Plotkin, SA
AF Plotkin, Stanley A.
TI Updates on immunologic correlates of vaccine-induced protection
SO VACCINE
LA English
DT Article
DE Correlates; Antibodies; Cell mediated immunity
ID INFLUENZAE TYPE-B; CD4(+) T-CELLS; IMMUNE-RESPONSES; ANTIBODY-TITERS;
   SEROLOGICAL CORRELATE; PERTUSSIS VACCINES; MATERNAL ANTIBODY; CONJUGATE
   VACCINE; CLINICAL-TRIALS; VIRUS-INFECTION
AB Correlates of protection (Cops) are increasingly important in the development and licensure of vaccines. Although the study of CoPs was initially directed at identifying a single immune function that could explain vaccine efficacy, it has become increasingly clear that there are often multiple functions responsible for efficacy. This review is meant to supplement prior articles on the subject, illustrating both simple and complex CoPs. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Plotkin, Stanley A.] Univ Penn, Vaxconsult, Pediat, 4650 Wismer Rd, Doylestown, PA 18902 USA.
RP Plotkin, SA (reprint author), Univ Penn, Vaxconsult, Pediat, 4650 Wismer Rd, Doylestown, PA 18902 USA.
EM Stanley.plotkin@vaxconsult.com
CR Abbink P, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4163
   Almudevar A, 2018, VACCINE, V36, P1133, DOI 10.1016/j.vaccine.2018.01.021
   Amanna IJ, 2008, HUM VACCINES, V4, P316, DOI 10.4161/hv.4.4.5751
   Andrews N, 2003, CLIN DIAGN LAB IMMUN, V10, P780, DOI 10.1128/CDLI.10.5.780-786.2003
   Angel J, 2014, HUM VACC IMMUNOTHER, V10, P3659, DOI 10.4161/hv.34361
   Angel J, 2012, CURR OPIN VIROL, V2, P419, DOI 10.1016/j.coviro.2012.05.003
   Arevalillo JM, 2017, J BIOMED INFORM, V74, P1, DOI 10.1016/j.jbi.2017.08.005
   Atmar RL, 2015, CLIN VACCINE IMMUNOL, V22, P923, DOI 10.1128/CVI.00196-15
   Baker CJ, 2014, J INFECT DIS, V209, P781, DOI 10.1093/infdis/jit549
   Bancroft T, 2016, CELL IMMUNOL, V304, P35, DOI 10.1016/j.cellimm.2016.05.002
   Battles MB, 2019, NAT REV MICROBIOL, V17, P233, DOI 10.1038/s41579-019-0149-x
   Behet MC, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-136
   Belshe RB, 2000, J INFECT DIS, V181, P1133, DOI 10.1086/315323
   Bentebibel SE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005191
   Bhatt K, 2015, CLIN VACCINE IMMUNOL, V22, P258, DOI 10.1128/CVI.00721-14
   Black S, 2011, PEDIATR INFECT DIS J, V30, P1081, DOI 10.1097/INF.0b013e3182367662
   Bradfute SB, 2011, VIRUSES-BASEL, V3, P982, DOI 10.3390/v3070982
   Buurman ET, 2019, J INFECT DIS, DOI [10.1093/infdis/iiz062, DOI 10.1093/INFRLISLJIZ062]
   Campbell H, 2010, CLIN VACCINE IMMUNOL, V17, P840, DOI 10.1128/CVI.00529-09
   Chaudhri G, 2006, J VIROL, V80, P6339, DOI 10.1128/JVI.00116-06
   Chaudhri G, 2015, J VIROL, V89, P1889, DOI 10.1128/JVI.02572-14
   Chen LG, 2014, CLIN VACCINE IMMUNOL, V21, P1512, DOI 10.1128/CVI.00469-14
   Cheuvart B, 2014, HUM VACC IMMUNOTHER, V10, P505, DOI 10.4161/hv.27097
   Christensen SR, 2019, J VIROL, V93, DOI [10.1128/JVI.02134-18, 10.1128/jvi.02134-18]
   Clarke E, 2015, MUCOSAL IMMUNOL, V8, P1, DOI 10.1038/mi.2014.114
   Cooper LV, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182575
   Coudeville L, 2010, HUM VACCINES, V6, P841, DOI 10.4161/hv.6.10.12636
   Coudeville L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-18
   Cowling BJ, 2018, CLIN INFECT DIS, DOI [10.1093/cid/civ759, DOI 10.1093/CID/RIY759]
   Cunningham AL, 2018, J INFECT DIS, V217, P1750, DOI 10.1093/infdis/jiy095
   Dangor Z, 2015, VACCINE, V33, P6793, DOI 10.1016/j.vaccine.2015.10.019
   Day PM, 2010, CELL HOST MICROBE, V8, P260, DOI 10.1016/j.chom.2010.08.003
   de Cassan SC, 2010, CLIN VACCINE IMMUNOL, V17, P1066, DOI 10.1128/CVI.00047-10
   Desselberger U, 2011, J INFECT DIS, V203, P188, DOI 10.1093/infdis/jiq031
   Doll KL, 2014, IMMUNOL RES, V59, P166, DOI 10.1007/s12026-014-8525-0
   Edghill-Smith Y, 2005, J INFECT DIS, V191, P372, DOI 10.1086/427265
   Epstein JE, 2011, SCIENCE, V334, P475, DOI 10.1126/science.1211548
   Falsey AR, 2008, J INFECT DIS, V198, P1317, DOI 10.1086/592168
   Fernandez J, 2000, J INFECT DIS, V182, P1553, DOI 10.1086/315870
   Fletcher HA, 2007, CURR MOL MED, V7, P319, DOI 10.2174/156652407780598520
   Forrest BD, 2008, CLIN VACCINE IMMUNOL, V15, P1042, DOI 10.1128/CVI.00397-07
   Franco MA, 2006, VACCINE, V24, P2718, DOI 10.1016/j.vaccine.2005.12.048
   Fries L, 2017, IMMUN AGEING, V14, DOI 10.1186/s12979-017-0090-7
   Fuentes S, 2015, J VIROL, V89, P8193, DOI 10.1128/JVI.00133-15
   Gilbert PB, 2018, J INFECT DIS, V218, pS99, DOI 10.1093/infdis/jiy421
   Gilbert PB, 2014, J INFECT DIS, V210, P1573, DOI 10.1093/infdis/jiu279
   Glass RI, 2018, VACCINE, V36, P2233, DOI 10.1016/j.vaccine.2018.03.008
   GLEZEN WP, 1981, J PEDIATR-US, V98, P708, DOI 10.1016/S0022-3476(81)80829-3
   Goldblatt D, 2010, PEDIATR INFECT DIS J, V29, P401, DOI 10.1097/INF.0b013e3181c67f04
   Gooch KE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38885-0
   GRANOFF DM, 1995, ANN NY ACAD SCI, V754, P278, DOI 10.1111/j.1749-6632.1995.tb44461.x
   Groome MJ, 2017, LANCET INFECT DIS, V17, P843, DOI [10.1016/S1473-3099(17)30242-6, 10.1016/s1473-3099(17)30242-6]
   Grund S, 2013, J VIROL METHODS, V193, P558, DOI 10.1016/j.jviromet.2013.07.032
   Habibi MS, 2015, AM J RESP CRIT CARE, V191, P1040, DOI 10.1164/rccm.201412-2256OC
   Hansen SG, 2018, NAT MED, V24, P130, DOI 10.1038/nm.4473
   Harris JB, 2018, J INFECT DIS, V218, pS141, DOI 10.1093/infdis/jiy414
   Heeney Jonathan L, 2006, Nat Immunol, V7, P1281, DOI 10.1038/ni1206-1281
   Holmgren J, 2017, VACCINE, V35, P3355, DOI 10.1016/j.vaccine.2017.05.005
   Hope JC, 2011, CLIN VACCINE IMMUNOL, V18, P373, DOI 10.1128/CVI.00543-10
   Horowitz A, 2012, J IMMUNOL, V188, P5054, DOI 10.4049/jimmunol.1102710
   Ionin B, 2013, CLIN VACCINE IMMUNOL, V20, P1016, DOI 10.1128/CVI.00099-13
   Jahrling PB, 2007, J INFECT DIS, V196, pS400, DOI 10.1086/520587
   Jochems SP, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006665
   John S, 2018, VACCINE, V36, P1689, DOI 10.1016/j.vaccine.2018.01.029
   Jokinen JT, 2004, J INFECT DIS, V190, P545, DOI 10.1086/422531
   Kapil P, 2019, CURR OPIN IMMUNOL, V59, P72, DOI 10.1016/j.coi.2019.03.006
   Kemp TJ, 2011, VACCINE, V29, P2011, DOI 10.1016/j.vaccine.2011.01.001
   Kennedy RB, 2009, CURR OPIN IMMUNOL, V21, P314, DOI 10.1016/j.coi.2009.04.004
   Korenkov D, 2018, EXPERT REV VACCINES, V17, P977, DOI 10.1080/14760584.2018.1541407
   Kulkarni PS, 2018, VIRAL IMMUNOL, V31, P195, DOI 10.1089/vim.2017.0147
   Kurtis JD, 2018, CLIN INFECT DIS, DOI [10.1093/rid/civ728, DOI 10.1093/RID/CIY728]
   Laidlaw BJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003207
   Lappalainen S, 2014, HUM VACC IMMUNOTHER, V10, P2039, DOI 10.4161/hv.28858
   Le Doare K, 2019, LANCET INFECT DIS, V19, pE162, DOI 10.1016/S1473-3099(18)30659-5
   Lee YT, 2017, J BIOMED NANOTECHNOL, V13, P95, DOI 10.1166/jbn.2017.2341
   Leroux-Roels G, 2019, VACCINE, V37, P2694, DOI 10.1016/j.vaccine.2019.04.011
   Levin MJ, 2019, HUM VACC IMMUNOTHER, V15, P772, DOI 10.1080/21645515.2018.1560918
   Levin MJ, 2018, J CLIN INVEST, V128, P4429, DOI [10.1172/JCI121484, 10.1172/jci121484]
   McAleer JP, 2014, IMMUNOL REV, V260, P129, DOI 10.1111/imr.12183
   McCall MBB, 2018, SEMIN IMMUNOL, V39, P52, DOI 10.1016/j.smim.2018.08.002
   Medaglini D, 2018, SEMIN IMMUNOL, V39, P65, DOI 10.1016/j.smim.2018.07.003
   Meyer M, 2019, TRENDS MICROBIOL, V27, P8, DOI 10.1016/j.tim.2018.08.008
   Millar EV, 2007, CLIN INFECT DIS, V44, P1173, DOI 10.1086/513199
   Monto AS, 2015, J INFECT DIS, V212, P1191, DOI 10.1093/infdis/jiv195
   Moormann AM, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0134-1
   Moris P, 2018, HUM VACC IMMUNOTHER, V14, P17, DOI 10.1080/21645515.2017.1381809
   Nahrendorf W, 2014, J INFECT DIS, V210, P1981, DOI 10.1093/infdis/jiu354
   Ohmit SE, 2011, J INFECT DIS, V204, P1879, DOI 10.1093/infdis/jir661
   Ojal J, 2017, VACCINE, V35, P4652, DOI 10.1016/j.vaccine.2017.05.088
   Panchanathan V, 2006, J VIROL, V80, P6333, DOI 10.1128/JVI.00115-06
   Permar SR, 2018, J VIROL, V92, DOI 10.1128/JVI.00030-18
   Petrie JG, 2019, VACCINE, V37, P1284, DOI 10.1016/j.vaccine.2019.01.055
   Petrie JG, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020017
   Piedra PA, 2016, METHODS MOL BIOL, V1442, P77, DOI 10.1007/978-1-4939-3687-8_7
   Pinto LA, 2018, VACCINE, V36, P4792, DOI 10.1016/j.vaccine.2017.11.089
   Plotkin SA, 2001, PEDIATR INFECT DIS J, V20, P63, DOI 10.1097/00006454-200101000-00013
   Plotkin SA, 2008, CLIN INFECT DIS, V47, P401, DOI 10.1086/589862
   Plotkin SA, 2013, CLIN INFECT DIS, V56, P1458, DOI 10.1093/cid/cit048
   Plotkin SA, 2012, CLIN INFECT DIS, V54, P1615, DOI 10.1093/cid/cis238
   Plotkin SA, 2010, CLIN VACCINE IMMUNOL, V17, P1055, DOI 10.1128/CVI.00131-10
   Premkumar P, 2014, VACCINE, V32, pA55, DOI 10.1016/j.vaccine.2014.04.077
   Ramani S, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005334
   Reber A, 2013, EXPERT REV VACCINES, V12, P519, DOI [10.1586/erv.13.35, 10.1586/ERV.13.35]
   SARKAR JK, 1975, B WORLD HEALTH ORGAN, V52, P307
   Satti I, 2019, EXPERT REV VACCINES, V18, P43, DOI 10.1080/14760584.2019.1552140
   Schiffer JM, 2015, VACCINE, V33, P3709, DOI 10.1016/j.vaccine.2015.05.091
   Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274
   Shedlock DJ, 2013, MOL THER, V21, P1432, DOI 10.1038/mt.2013.61
   Shimanovich AA, 2017, CLIN VACCINE IMMUNOL, V24, P1, DOI 10.1128/CVI.00412-16
   Solans L, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03068
   Sullivan NJ, 2009, NAT REV MICROBIOL, V7, P393, DOI 10.1038/nrmicro2129
   Sullivan NL, 2018, J VIROL, V92, DOI 10.1128/JVI.00269-18
   Sztein MB, 2007, CLIN INFECT DIS, V45, pS15, DOI 10.1086/518140
   Taranger J, 2000, J INFECT DIS, V181, P1010, DOI 10.1086/315318
   Tesfalem H, 2018, NDT&E INT, V100, P1, DOI 10.1016/j.ndteint.2018.07.007
   Tomaras GD, 2017, IMMUNOL REV, V275, P245, DOI 10.1111/imr.12514
   Townsend K, 2014, VACCINE, V32, P5650, DOI 10.1016/j.vaccine.2014.08.010
   Trombetta CM, 2016, EXPERT REV VACCINES, V15, P967, DOI 10.1586/14760584.2016.1164046
   Tsang TK, 2014, J INFECT DIS, V210, P684, DOI 10.1093/infdis/jiu186
   van Els C, 2014, HUM VACC IMMUNOTHER, V10, P1935, DOI 10.4161/hv.28639
   van Riet E, 2012, VACCINE, V30, P5893, DOI 10.1016/j.vaccine.2012.04.109
   Vekemans J, 2019, VACCINE, V37, P3190, DOI 10.1016/j.vaccine.2019.04.039
   Villafana T, 2017, EXPERT REV VACCINES, V16, P737, DOI 10.1080/14760584.2017.1333425
   Vipond C, 2012, VACCINE, V30, pB10, DOI 10.1016/j.vaccine.2011.12.060
   Vogelzang A, 2014, J INFECT DIS, V210, P1928, DOI 10.1093/infdis/jiu347
   Ward BJ, 2018, HUM VACC IMMUNOTHER, V14, P647, DOI 10.1080/21645515.2017.1413518
   WARD KA, 1983, J GEN VIROL, V64, P1867, DOI 10.1099/0022-1317-64-9-1867
   Warfel JM, 2014, EXPERT REV VACCINES, V13, P1241, DOI 10.1586/14760584.2014.946016
   Warfield KL, 2018, J INFECT DIS, V218, pS553, DOI 10.1093/infdis/jiy316
   White MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061065
   Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612
   Yang K, 2014, CURR OPIN VIROL, V6, P78, DOI 10.1016/j.coviro.2014.03.009
NR 132
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2250
EP 2257
DI 10.1016/j.vaccine.2019.10.046
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900022
PM 31767462
DA 2020-05-12
ER

PT J
AU Ashbaugh, HR
   Cherry, JD
   Hoff, NA
   Doshi, RH
   Alfonso, VH
   Gadoth, A
   Mukadi, P
   Higgins, SG
   Budd, R
   Randall, C
   Mwamba, GN
   Okitolonda-Wemakoy, E
   Muyembe-Tamfum, JJ
   Gerber, SK
   Rimoin, AW
AF Ashbaugh, Hayley R.
   Cherry, James D.
   Hoff, Nicole A.
   Doshi, Reena H.
   Alfonso, Vivian H.
   Gadoth, Adva
   Mukadi, Patrick
   Higgins, Stephen G.
   Budd, Roger
   Randall, Christina
   Mwamba, Guillaume Ngoie
   Okitolonda-Wemakoy, Emile
   Muyembe-Tamfum, Jean Jacques
   Gerber, Sue K.
   Rimoin, Anne W.
TI Measles antibody levels among vaccinated and unvaccinated children 6-59
   months of age in the Democratic Republic of the Congo, 2013-2014
SO VACCINE
LA English
DT Article
ID IMMUNITY; RESPONSES; IMMUNIZATION; ELIMINATION; INFECTION; OUTBREAK;
   COVERAGE; PROGRESS; INFANTS; BLOOD
AB Background: Measles is endemic in the Democratic Republic of the Congo (DRC), and 89-94% herd immunity is required to halt its transmission. Much of the World Health Organization African Region, including the DRC, has vaccination coverage below the 95% level required to eliminate measles, heightening concern of inadequate measles immunity.
   Methods: We assessed 6706 children aged 6-59 months whose mothers were selected for interview in the 2013-2014 DRC Demographic and Health Survey. History of measles was obtained by maternal report, and classification of children who had measles was completed using maternal recall and measles immunoglobulin G serostatus obtained from a multiplex chemiluminescent automated immunoassay dried blood spot analysis. A logistic regression model was used to identify associations of covariates with measles and seroprotection, and vaccine effectiveness (VE) was calculated.
   Results: Out of our sample, 64% of children were seroprotected. Measles vaccination was associated with protection against measles (OR: 0.15, 95% CI: 0.03, 0.81) when administered to children 12 months of age or older. Vaccination was predictive of seroprotection at all ages. VE was highest (88%) among children 12-24 months of age.
   Conclusion: Our results demonstrated lower than expected seroprotection against measles among vaccinated children. Understanding the factors that affect host immunity to measles will aid in developing more efficient and effective immunization programs in DRC. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Ashbaugh, Hayley R.; Hoff, Nicole A.; Doshi, Reena H.; Gadoth, Adva; Rimoin, Anne W.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Box 951772,650 Charles Young Dr South, Los Angeles, CA 90095 USA.
   [Cherry, James D.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Alfonso, Vivian H.] McKing Consulting, Atlanta, GA 30341 USA.
   [Mukadi, Patrick] Kinshasa Univ, Sch Med, Kinshasa, DEM REP CONGO.
   [Higgins, Stephen G.] Lentigen Technol Inc, Gaithersburg, MD 20878 USA.
   [Budd, Roger; Randall, Christina] DYNEX Technol Inc, Chantilly, VA 20151 USA.
   [Mwamba, Guillaume Ngoie] Minist Publ Hlth, Expanded Program Immunizat, Kinshasa, DEM REP CONGO.
   [Okitolonda-Wemakoy, Emile] Kinshasa Sch Publ Hlth, Kinshasa, DEM REP CONGO.
   [Muyembe-Tamfum, Jean Jacques] Natl Inst Biomed Res, Kinshasa, DEM REP CONGO.
   [Gerber, Sue K.] Bill & Melinda Gates Fdn, Seattle, WA 98109 USA.
RP Ashbaugh, HR; Rimoin, AW (reprint author), Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Box 951772,650 Charles Young Dr South, Los Angeles, CA 90095 USA.; Cherry, JD (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
EM hashbaugh@ucla.edu; JCherry@mednet.ucla.edu; arimoin@ucla.edu
FU Faucett Catalyst Fund; Estimating Population Immunity by Bill and
   Melinda Gates Foundation [OPP1066684]
FX This work was supported by the Faucett Catalyst Fund and the Estimating
   Population Immunity to Poliovirus in the Democratic Republic of the
   Congo Grant by the Bill and Melinda Gates Foundation [Grant No.
   OPP1066684].
CR ADU FD, 1992, B WORLD HEALTH ORGAN, V70, P457
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P205
   [Anonymous], 2014, ENQ DEM SANT REP DEM
   Ashbaugh HR, 2018, VACCINE, V36, P587, DOI 10.1016/j.vaccine.2017.11.049
   Ashbaugh HR, 2018, J PEDIAT INFECT DIS
   Avramovich E, 2018, MMWR-MORBID MORTAL W, V67, P1186, DOI 10.15585/mmwr.mm6742a4
   CARNEY JM, 1980, AM J DIS CHILD, V134, P824, DOI 10.1001/archpedi.1980.02130210008003
   Carter ED, 2018, J GLOB HEALTH, V8, DOI 10.7189/jogh.08.010602
   CHEN RT, 1990, J INFECT DIS, V162, P1036, DOI 10.1093/infdis/162.5.1036
   Cherry JD, 2018, CLIN INFECT DIS, V67, P1315, DOI 10.1093/cid/ciy286
   CHERRY JD, 1972, J PEDIATR-US, V81, P217, DOI 10.1016/S0022-3476(72)80287-7
   CUTTS FT, 1995, BIOLOGICALS, V23, P95
   Dabbagh A, 2018, MMWR-MORBID MORTAL W, V67, P1323, DOI 10.15585/mmwr.mm6747a6
   de Francisco A, 1998, VACCINE, V16, P564, DOI 10.1016/S0264-410X(97)00245-4
   de Vries RD, 2015, VIRUSES-BASEL, V7, P699, DOI 10.3390/v7020699
   Doshi Reena H, 2017, Pediatr Infect Dis J, V36, P462, DOI 10.1097/INF.0000000000001483
   Doshi RH, 2015, VACCINE, V33, P6786, DOI 10.1016/j.vaccine.2015.10.020
   Doshi RH, 2015, VACCINE, V33, P3407, DOI 10.1016/j.vaccine.2015.04.067
   Gerard SP, 2014, PUBLIC HEALTH ACTION, V4, P6, DOI 10.5588/pha.13.0099
   Haralambieva IH, 2015, TRENDS MOL MED, V21, P789, DOI 10.1016/j.molmed.2015.10.005
   Higgins SG, 2019, MSPHERE, V4, DOI 10.1128/mSphere.00112-19
   HOBCRAFT J, 1983, POPUL INDEX, V49, P585, DOI 10.2307/2737284
   Holzmann H, 2016, MED MICROBIOL IMMUN, V205, P201, DOI 10.1007/s00430-016-0451-4
   ICF International, 2012, DEM HLTH SURV METH
   Leuridan E, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1626
   Masresha BG, 2017, MMWR-MORBID MORTAL W, V66, P436, DOI 10.15585/mmwr.mm6617a2
   Mercader S, 2006, J VIROL METHODS, V137, P140, DOI 10.1016/j.jviromet.2006.06.018
   Miles M, 2013, VACCINE, V31, P1560, DOI 10.1016/j.vaccine.2012.10.089
   Ministere du Plan et Suivi de la Mise en oeuvre de la Revolution de la Modernite (MPSMRM) Ministere de la Sante Publique (MSP) et ICF International, 2015, DEM HLTH SURV DRC DH
   NEUMANN CG, 1975, AM J CLIN NUTR, V28, P89
   Niewiesk S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00446
   Oyedele OO, 2005, J TROP PEDIATRICS, V51, P45, DOI 10.1093/tropej/fmh073
   Regional Committee for Africa, 2017, PROGR MEASL EL AFR R
   Rosen JB, 2014, CLIN INFECT DIS, V58, P1205, DOI 10.1093/cid/ciu105
   Rutstein S., 2008, DHS WEALTH INDEX APP
   Rutstein SO, 2006, DEMOGRAPHIC HLTH SUR
   Strebel PM, 2017, VACCINES
   Taurisano P, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00235
   Thompson KM, 2016, RISK ANAL, V36, P1383, DOI 10.1111/risa.12637
   Whittle H, 1999, PEDIATR INFECT DIS J, V18, P53, DOI 10.1097/00006454-199901000-00013
   Whittle HC, 1999, LANCET, V353, P98, DOI 10.1016/S0140-6736(98)02364-2
   World Health Organization, IMMUNOLOGICAL BASIS
   Zhang XW, 2012, VACCINE, V30, P752, DOI 10.1016/j.vaccine.2011.11.078
NR 43
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2258
EP 2265
DI 10.1016/j.vaccine.2019.09.047
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900023
PM 32057333
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Trucas, M
AF Trucas, Marcello
TI The Falconi's needle against anti-vaccination: A minimally invasive tool
   in the nineteenth century
SO VACCINE
LA English
DT Article
DE Smallpox; Anti-vaccination; Needle; Falconi; Rubin; Invasiveness
ID SMALLPOX VACCINE
AB The history of Giovanni Falconi's career and his vaccination campaigns is two hundred years old. It is however very relevant today because of the widespread negative social opinion against vaccination at that time, opinions which seem to have re-emerged even in the current century. In his very important role of "Vaccine Conservator" (a sort of national supervisor for the quality of vaccinations), he clashed with the prejudice of the people and with the anti-scientific attitudes of some of his illustrious colleagues. He investigated how to simplify the procedure with a smallpox needle that became known as "Falconi's Needle" or "Falconian Needle". Falconi also made several experiments on smallpox vaccine preparation and was a supporter of the use of "animal" and "humanized" formulas despite the prejudice regarding the latter. Due to his profound anatomical knowledge and the strength of mind that characterized him, he was able to follow evidence-based scientific principles in his methods. Thanks to this he managed to convince people not to oppose vaccinations. He also succeeded in bringing the number of vaccinated people to exceed the number of newborns, a great achievement that led to remarkable progress in Italy and the rescue of thousands of lives throughout Europe. Unfortunately, it was not possible to find a copy of this instrument, which required the author to have the needle reconstructed. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Trucas, Marcello] Univ Cagliari, Dept Biomed Sci, Cittadella Univ Blocco A,Sestu Km 0-700, I-09042 Monserrato, Italy.
RP Trucas, M (reprint author), Univ Cagliari, Dept Biomed Sci, Cittadella Univ Blocco A,Sestu Km 0-700, I-09042 Monserrato, Italy.
EM marcello.trucas@uniroma1.it
CR [Anonymous], 1857, DIRITTO         0605
   Atzeni V., 1951, RICERCHE DOCUMENTI V, pn1
   Barouk MA, 1995, FAVOLOSO INNESTO STO
   Depaul. Travoux Academiques, 1867, B GEN THERAPEUTIQUE
   Derrick Baxby, 2002, VACCINE, V20, P2140, DOI [10.1016/SO264-410X(02)00028-2, DOI 10.1016/SO264-410)02)0002R-7]
   Dubos R., 1962, PASTEUR SCI MODERNA, P98
   Falconi G., 1871, SARDEGNA MED, pIX
   Falconi G., QUESTIONE VACCINICA
   Falconi G., 1858, PRESSE MED BELG 0523
   Falconi G., 1873, AGO VACCINICO VACCIN, pXI
   Falconi G., 1871, SIG SINDACO COMUNALE
   Falconi G., 1864, RELAZIONE ISPEZIONE
   FENNER F, 1988, SMALLPOX ITS ERADICA
   Fodde S., 1979, ALMANACCO CAGLIARI
   Gatti A., 1764, REFLEXIONS PREJUGES
   Goodall Archibald L, 1942, Glasgow Med J, V138, P143
   Imbriani E., 2014, INDOMENEO, P221
   Koblentz GD, 2017, HEALTH SECUR, V24, DOI [10.1089/hs.2017.0061, DOI 10.1089/HT.2017.0061]
   Kupferschmidt K, 2017, SCIENCE, V357, P115, DOI 10.1126/science.357.6347.115
   Lai I., 1994, F GIOVANNI DIZIONARI, V44
   LEAKE J. P., 1927, Public Health Reports, V42, P221, DOI 10.2307/4578155
   Masnata G., 1871, VAJUOLO ARABO VACCIN
   Murphy FA, 2005, EMERG INFECT DIS, V11, P1086
   National Research Council, 2011, PROT FRONTL BIOD RES, DOI [10.17226/13112., DOI 10.17226/13112]
   PARISH H. J., 1941, Proceedings of the Royal Society of Medicine, V34, P247
   Parish HJ, 1944, BMJ-BRIT MED J, V1944, P781
   PATTANAYAK S, 1970, B WORLD HEALTH ORGAN, V42, P305
   Phelps A, 2017, VACCINE, V35, P3889, DOI 10.1016/j.vaccine.2017.05.058
   Piras A., 1863, SARDEGNA MED    0916, P81
   Rolleston H., 1928, REPORT COMMITTEE VAC
   Tripi B., 1861, AGO CRUNATO DOTTOR F
   Trucas M., 2017, VAIOLO ALTRO G FALCO
   Vivanet F., 1861, G JORDAN SARDEGNA
NR 33
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 24
PY 2020
VL 38
IS 9
BP 2266
EP 2272
DI 10.1016/j.vaccine.2019.12.063
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT0UL
UT WOS:000518725900024
PM 31928854
DA 2020-05-12
ER

PT J
AU Ranshing, SS
   Cherian, SS
   Agarwal, MS
   Jagtap, AS
   Patil, CM
   Gopalkrishna, V
AF Ranshing, Sujata S.
   Cherian, Sarah S.
   Agarwal, Megha S.
   Jagtap, Anuradha S.
   Patil, Chinmayee M.
   Gopalkrishna, Varanasi
TI Full genome based sequence and structural characterization of an unusual
   group A rotavirus G12P[11] isolated from neonates in Pune, western India
SO VACCINE
LA English
DT Article
DE Rotavirus; Neonates; Reassortant; G12P[11] strains; Genome;
   Age-restricted tropism
ID INFECTION; NEWBORNS; STRAINS; DELHI
AB Studies conducted at neonatal intensive care units in Pune, western India, suggested early exposure to rotaviruses and predominance of unusual human-bovine-like G12P[11] strains. The whole genome sequencing and phylogenetic analyses of a naturally attenuated, culture adapted neonatal strain, (NIV-1740121) revealed multiple-gene reassortment events, containing ROTAVAC (R) vaccine strain, 116E-like VP4, VP6, NSP3, NSP5 genes, VP7 gene of G12 origin and VP3 gene of porcine ancestry in a human Wa-like backbone. Analysis of 3D structure modeling of the VP7 and VP4 proteins with respect to 116E suggested amino acid variations in the major neutralizing epitopes of VP7, contributed to a modified charge density. Visualization of receptor-glycan interaction structures of NIV-1740121 and 116E VP8* showed type I glycan binds with a similar conformation at the same active site as represented in the available crystal structure of G10P[11]VP8*. The study adds to the knowledge of age restricted tropism of P[11] strains in neonates. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Ranshing, Sujata S.; Jagtap, Anuradha S.; Patil, Chinmayee M.; Gopalkrishna, Varanasi] ICMR Natl Inst Virol, Enter Viruses Grp, 20-A,Dr Ambedkar Rd, Pune 411001, Maharashtra, India.
   [Cherian, Sarah S.; Agarwal, Megha S.] ICMR Natl Inst Virol, Bioinformat & Data Management, Pune, Maharashtra, India.
RP Gopalkrishna, V (reprint author), ICMR Natl Inst Virol, Enter Viruses Grp, 20-A,Dr Ambedkar Rd, Pune 411001, Maharashtra, India.
EM gopalvk58@hotmail.com
CR Armah GE, 2010, LANCET, V376, P606, DOI 10.1016/S0140-6736(10)60889-6
   BHAN MK, 1993, J INFECT DIS, V168, P282, DOI 10.1093/infdis/168.2.282
   CICIRELLO HG, 1994, PEDIATR INFECT DIS J, V13, P720, DOI 10.1097/00006454-199408000-00008
   DAS M, 1993, VIROLOGY, V194, P374, DOI 10.1006/viro.1993.1271
   Gomara MI, 2004, J CLIN MICROBIOL, V42, P2541, DOI 10.1128/JCM.42.6.2541-2547.2004
   GOUVEA V, 1990, J CLIN MICROBIOL, V28, P276, DOI 10.1128/JCM.28.2.276-282.1990
   HOSHINO Y, 1995, VIROLOGY, V209, P274, DOI 10.1006/viro.1995.1255
   Hu LY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9346
   Lopman BA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041720
   Matthijnssens J, 2006, J VIROL, V80, P3801, DOI 10.1128/JVI.80.8.3801-3810.2006
   Matthijnssens J, 2008, ARCH VIROL, V153, P1621, DOI 10.1007/s00705-008-0155-1
   Matthijnssens J, 2011, ARCH VIROL, V156, P1397, DOI 10.1007/s00705-011-1006-z
   Ramani S, 2008, PEDIATR INFECT DIS J, V27, P719, DOI 10.1097/INF.0b013e3181715170
   Ranshing SS, 2003, J CLIN MICROBIOL, V41, P5267, DOI 10.1128/JCM.41.11.5267-5269.2003
   Ranshing SS, 2019, INFECT GENET EVOL, V70, P45, DOI 10.1016/j.meegid.2019.02.014
   Ray P, 2007, J CLIN MICROBIOL, V45, P3824, DOI 10.1128/JCM.01288-07
   Rippinger CM, 2010, VIROLOGY, V405, P201, DOI 10.1016/j.virol.2010.06.005
   Wylie KM, 2017, J PEDIATR INFECT DIS, V6, P346, DOI 10.1093/jpids/piw065
   Zaman K, 2010, LANCET
NR 19
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2020
VL 38
IS 10
BP 2275
EP 2291
DI 10.1016/j.vaccine.2020.01.081
PG 17
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KR5KP
UT WOS:000517657600003
PM 32029320
DA 2020-05-12
ER

PT J
AU Ballard, SB
   Tallant, A
   Guerra, RG
   Quigley, D
   Stiegmann, R
   Mirelman, AJ
   Riddle, MS
   Gilman, RH
   Aliaga-Colquechagua, F
   Bausch, DG
   Blazes, DL
   Bern, C
   Cabrera, L
   Calderon, M
   Cordova-Rafael, B
   Heitzinger, K
   Jennings, MC
   Kosek, M
   Loayza, L
   Luna, CG
   Mayta, H
   Meza, R
   Neira, K
   Pajuelo, M
   Parreira, K
   Pollett, S
   Quispe, J
   Rappoport, L
   Reaves, EJ
   Rocha, C
   Rothstein, J
   Saito, M
   Sanchez, G
   Silva, ME
   Simons, MP
   Steinberg, HE
   Tilley, DH
   Verastegui, M
AF Ballard, Sarah-Blythe
   Tallant, Aaron
   Guerra, Rosio G.
   Quigley, Dawn
   Stiegmann, Regan
   Mirelman, Andrew J.
   Riddle, Mark S.
   Gilman, Robert H.
   Aliaga-Colquechagua, Fabiola
   Bausch, Daniel G.
   Blazes, David L.
   Bern, Caryn
   Cabrera, Lilia
   Calderon, Maritza
   Cordova-Rafael, Briasaida
   Heitzinger, Kristen
   Jennings, Mary Carol
   Kosek, Margaret
   Loayza, Luis
   Luna, C. Giannina
   Mayta, Holger
   Meza, Rina
   Neira, Karen
   Pajuelo, Monica
   Parreira, Karen
   Pollett, Simon
   Quispe, Jose
   Rappoport, Laura
   Reaves, Erik J.
   Rocha, Claudio
   Rothstein, Jessica
   Saito, Mayuko
   Sanchez, Gerardo
   Silva, Maria E.
   Simons, Mark P.
   Steinberg, Hannah E.
   Tilley, Drake H.
   Verastegui, Manuela
CA Norovirus Working Grp Peru
TI Application of a cost-effectiveness analysis of pathogen-specific
   vaccines against gastroenteritis to a military population in a
   developing country setting
SO VACCINE
LA English
DT Article
DE Gastroenteritis; Vaccine; Cost-effectiveness analysis; Low- and
   middle-income countries; Military; Peru
ID DIARRHEA
AB Vaccine implementation planning in low- and middle-income countries (LMIC) often focuses on children without considering special adult populations. We adapted an economic model developed by the United States Department of Defense (DoD) to evaluate the cost-effectiveness of vaccine acquisition strategies for Campylobacter-, ETEC-, Shigella-, and norovirus-associated gastroenteritis. We compared implementation costs with current medical management in the Peruvian armed forces, a special population of low- and middle-income (LMIC) adults with a high incidence of infectious gastroenteritis. Pathogen-specific vaccine implementation resulted in calculated cost-effectiveness ratio (CER) per duty day lost averted (CERDDL) of $13,741; $1,272; $301; and $803, and a CER per diarrhea day averted of $2,130; $215; $51; and $199 for Campylobacter, ETEC, Shigella, and norovirus, respectively. These estimates compare favorably to CERDDL estimates from high-income military population and suggest that implementing vaccines gastroenteritis may be cost-effective in the Peruvian military population. Published by Elsevier Ltd.
C1 [Ballard, Sarah-Blythe; Gilman, Robert H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St,Rm W5519, Baltimore, MD 25101 USA.
   [Ballard, Sarah-Blythe; Quigley, Dawn; Stiegmann, Regan; Riddle, Mark S.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biostat, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.
   [Tallant, Aaron] Naval Med Ctr Portsmouth, Dept Internal Med, 620 John Paul Jones Circle, Portsmouth, VA 23518 USA.
   [Guerra, Rosio G.] Alerta DISAMAR Syst, Trop & Infect Dis Area, Transmissible Dis Serv, Peruvian Navy Med Ctr,Peruvian Navy Hlth Director, Cuadra 36 S-N Ave Venezuela, Bellavista, Callao, Peru.
   [Mirelman, Andrew J.] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England.
RP Ballard, SB (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St,Rm W5519, Baltimore, MD 25101 USA.
EM sballar3@jhu.edu; aaron.m.tallant.mil@mail.mil;
   rosio.guerra.fn@mail.mil; dawn.quigley@usuhs.edu;
   regan.stiegmann@usuhs.edu; andrew.mirelman@york.ac.uk;
   mark.riddle@usuhs.edu; rgilman1@jhu.edu
OI Mirelman, Anat/0000-0002-1520-2292; Ballard,
   Sarah-Blythe/0000-0003-3581-5771
FU National Institutes of Health Fogarty International Center through the
   Fogarty Global Health Fellows UJMT Consortium [1R25 TW009340-01]; US
   Fulbright Program; Pat Tillman Foundation; Thrasher Research Fund Early
   Career Award; Johns Hopkins Bloomberg School of Public Health Procter &
   Gamble Fellowship; R. Bradley Sack Family Award; National Institute of
   Allergy and Infections DiseasesUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R21 A1099737]; US
   Department of Defense Global Emerging Infections Surveillance and
   Response SystemUnited States Department of Defense [847705 82000 25GB
   B0016]
FX This work was supported by the National Institutes of Health Fogarty
   International Center through the Fogarty Global Health Fellows UJMT
   Consortium [grant number 1R25 TW009340-01]; the US Fulbright Program;
   the Pat Tillman Foundation; the Thrasher Research Fund Early Career
   Award; the Johns Hopkins Bloomberg School of Public Health Procter &
   Gamble Fellowship; the R. Bradley Sack Family Award; the National
   Institute of Allergy and Infections Diseases [grant number R21
   A1099737]; and the US Department of Defense Global Emerging Infections
   Surveillance and Response System [work number 847705 82000 25GB B0016].
CR Alsentzer E, 2014, ISDS C
   [Anonymous], 2008, PAN AM HLTH ORG IMMU, V300
   [Anonymous], 2016, GLOBAL FIRE POWER
   Ballard SB, 2015, CURR OPIN INFECT DIS, V28, P408, DOI 10.1097/QCO.0000000000000197
   Ballard SB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131646
   Clark AD, 2009, J INFECT DIS, V200, pS114, DOI 10.1086/605043
   Mirelman AJ, 2015, VACCINE, V33, P3084, DOI 10.1016/j.vaccine.2015.05.004
   Riddle MS, 2008, VACCINE, V26, P2490, DOI 10.1016/j.vaccine.2008.03.008
   Riddle MS, 2008, J EVAL CLIN PRACT, V14, P266, DOI 10.1111/j.1365-2753.2007.00848.x
   Tallant A, 2014, VACCINE, V32, P5156, DOI 10.1016/j.vaccine.2014.07.070
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2020
VL 38
IS 10
BP 2292
EP 2297
DI 10.1016/j.vaccine.2020.01.075
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KR5KP
UT WOS:000517657600004
PM 32019702
DA 2020-05-12
ER

PT J
AU Hales, C
   Jochems, SP
   Robinson, R
   Solorzano, C
   Carniel, B
   Pojar, S
   Reine, J
   German, EL
   Nikolaou, E
   Mitsi, E
   Hyder-Wright, AD
   Hill, H
   Adler, H
   Connor, V
   Zaidi, S
   Lowe, C
   Fan, XJ
   Wang, DL
   Gordon, SB
   Rylance, J
   Ferreira, DM
AF Hales, Caz
   Jochems, Simon P.
   Robinson, Rachel
   Solorzano, Carla
   Carniel, Beatriz
   Pojar, Sherin
   Reine, Jesus
   German, Esther L.
   Nikolaou, Elissavet
   Mitsi, Elena
   Hyder-Wright, Angela D.
   Hill, Helen
   Adler, Hugh
   Connor, Victoria
   Zaidi, Seher
   Lowe, Catherine
   Fan, Xiaojing
   Wang, Duolao
   Gordon, Stephen B.
   Rylance, Jamie
   Ferreira, Daniela M.
TI Symptoms associated with influenza vaccination and experimental human
   pneumococcal colonisation of the nasopharynx
SO VACCINE
LA English
DT Article
DE Controlled human infection challenge model; Influenza vaccination;
   Pneumococcal inoculation; Live attenuated influenza vaccine;
   Pneumococcus colonisation; Streptococcus pneumoniae; Symptoms
ID STREPTOCOCCUS-PNEUMONIAE; CARRIAGE; EFFICACY; COINFECTION; INFECTION;
   SEVERITY; BACTERIA; RHINITIS; CHILDREN; SAFETY
AB Background: Nasopharyngeal colonisation by S. pneumoniae is a prerequisite for invasive pneumococcal infections. Influenza co-infection leads to increased susceptibility to secondary pneumonia and mortality during influenza epidemics. Increased bacterial load and impaired immune responses to pneumococcus caused by influenza play a role in this increased susceptibility. Using an Experimental Human Challenge Model and influenza vaccines, we examined symptoms experienced by healthy adults during nasal co-infection with S. pneumoniae and live attenuated influenza virus.
   Methods: Randomised, blinded administration of Live Attenuated Influenza Vaccine (LAW) or Tetravalent Inactivated Influenza Vaccine (TN) either preceded bacterial inoculation or followed it, separated by a 3 day interval. The presence and density of S. pneumoniae was determined from nasal washes. Participants completed a symptom questionnaire from the first intervention until 6 days post second intervention.
   Results: The timing and type of influenza vaccination and presence of S. pneumoniae in the nasopharynx significantly affected symptom reporting. In the study where influenza vaccination preceded bacterial inoculation: nasal symptoms were less common in the LAIV group than the TIV group (OR 0.57, p < 0.01); with colonisation status only affecting the TIV group where more symptoms were reported by colonised participants compared to non-colonised participants following inoculation (n = 12/23 [52.17%] vs n = 13/38 [34.21%], respectively; p < 0.05). In the study where influenza vaccination followed bacterial inoculation: no difference was seen in the symptoms reported between the LAIV and TIV groups following inoculation and subsequent vaccination; and symptoms were unaffected by colonisation status.
   Conclusion: Symptoms experienced during live viral vaccination and bacterial co-infection in the nasopharynx are directly affected by the precedence of the pathogen acquisition. Symptoms were directly affected by nasal pneumococcal colonisation but only when TIV was given prior to bacterial exposure. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Hales, Caz; Robinson, Rachel; Hyder-Wright, Angela D.; Adler, Hugh; Connor, Victoria; Zaidi, Seher; Lowe, Catherine; Rylance, Jamie] Royal Liverpool & Broadgreen Univ Hosp Trust, Prescot St, Liverpool L7 8XP, Merseyside, England.
   [Hales, Caz; Jochems, Simon P.; Robinson, Rachel; Solorzano, Carla; Carniel, Beatriz; Pojar, Sherin; Reine, Jesus; German, Esther L.; Nikolaou, Elissavet; Mitsi, Elena; Hyder-Wright, Angela D.; Hill, Helen; Adler, Hugh; Connor, Victoria; Zaidi, Seher; Lowe, Catherine; Fan, Xiaojing; Wang, Duolao; Gordon, Stephen B.; Rylance, Jamie; Ferreira, Daniela M.] Univ Liverpool Liverpool Sch Trop Med, Dept Clin Sci, Pembroke Pl, Liverpool L3 5QA, Merseyside, England.
RP Hales, C (reprint author), Univ Liverpool Liverpool Sch Trop Med, 3rd Floor,Pembroke Pl, Liverpool L3 5QA, Merseyside, England.
EM Caz.hales@lstmed.ac.uk
OI Gordon, Stephen/0000-0001-6576-1116; Wang, Duolao/0000-0003-2788-2464;
   Reine, Jesus/0000-0001-7462-2054; Ferreira, Daniela
   M/0000-0002-0594-0902; Mitsi, Elena/0000-0001-7586-6050; Pojar,
   Sherin/0000-0002-7746-3279; Jochems, Simon/0000-0002-4835-1032
FU Bill and Melinda Gates FoundationGates Foundation [OPP1117728]; UK
   Medical Research CouncilMedical Research Council UK (MRC)
   [MR/M011569/1]; Liverpool School of Tropical Medicine; Royal Liverpool
   and Broad green University Hospitals NHS Trust, UK
FX The study was funded by the Bill and Melinda Gates Foundation (grant
   OPP1117728) and the UK Medical Research Council (grant MR/M011569/1).
   The study was co-sponsored by the Liverpool School of Tropical Medicine
   and the Royal Liverpool and Broad green University Hospitals NHS Trust,
   UK.
CR Adetifa IMO, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030548
   Adler H, 2019, J INFECT DIS, V219, P1989, DOI 10.1093/infdis/jiz034
   Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002
   Block SL, 2011, VACCINE, V29, P9391, DOI 10.1016/j.vaccine.2011.09.109
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   DeMuri GP, 2018, CLIN INFECT DIS, V66, P1045, DOI 10.1093/cid/cix941
   DIAMOND L, 1995, J ALLERGY CLIN IMMUN, V95, P1139, DOI 10.1016/S0091-6749(95)70219-9
   Ferreira DM, 2013, AM J RESP CRIT CARE, V187, P855, DOI 10.1164/rccm.201212-2277OC
   Glennie S, 2016, MUCOSAL IMMUNOL, V9, P56, DOI 10.1038/mi.2015.35
   Goldblatt D, 2005, J INFECT DIS, V192, P387, DOI 10.1086/431524
   GRAY BM, 1980, J INFECT DIS, V142, P923, DOI 10.1093/infdis/142.6.923
   Gritzfeld JF, 2014, CLIN MICROBIOL INFEC, V20, pO1145, DOI 10.1111/1469-0691.12752
   Gritzfeld JF, 2013, JOVE-J VIS EXP, DOI 10.3791/50115
   Groves R, 2009, SURVEY METHODOLOGY
   Henriquez KM, 2015, J MED VIROL, V87, P330, DOI 10.1002/jmv.24042
   Jochems SP, 2018, NAT IMMUNOL, V19, P1299, DOI 10.1038/s41590-018-0231-y
   Morens DM, 2008, J INFECT DIS, V198, P962, DOI 10.1086/591708
   Pennington SH, 2016, AM J RESP CRIT CARE, V194, P1523, DOI 10.1164/rccm.201512-2467OC
   Rhorer J, 2009, VACCINE, V27, P1101, DOI 10.1016/j.vaccine.2008.11.093
   Rodrigues F, 2013, PEDIATR INFECT DIS J, V32, P227, DOI 10.1097/INF.0b013e31827687fc
   Rylance J, 2019, AM J RESP CRIT CARE, V199, P1160, DOI 10.1164/rccm.201811-2081LE
   Short KR, 2012, MBIO, V3, DOI 10.1128/mBio.00255-12
   Siegel SJ, 2014, CELL HOST MICROBE, V16, P55, DOI 10.1016/j.chom.2014.06.005
   Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/erv.12.53, 10.1586/ERV.12.53]
   Spector SL, 2003, ANN ALLERG ASTHMA IM, V91, P105, DOI 10.1016/S1081-1206(10)62160-6
   Thors V, 2016, AM J RESP CRIT CARE, V193, P1401, DOI 10.1164/rccm.201510-2000OC
   Tocheva AS, 2011, VACCINE, V29, P4400, DOI 10.1016/j.vaccine.2011.04.004
   Trimble A, 2019, PNEUMOCOCCAL COLONIS
   Trombetta CM, 2018, HUM VACC IMMUNOTHER, V14, P657, DOI 10.1080/21645515.2017.1423153
   WADOWSKY RM, 1995, INFECT IMMUN, V63, P1153, DOI 10.1128/IAI.63.4.1153-1157.1995
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2020
VL 38
IS 10
BP 2298
EP 2306
DI 10.1016/j.vaccine.2020.01.070
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KR5KP
UT WOS:000517657600005
PM 32035708
OA Green Published, Green Accepted, Other Gold
DA 2020-05-12
ER

PT J
AU Perry, MR
   Ionin, B
   Barnewall, RE
   Vassar, ML
   Reece, JJ
   Park, S
   Lemiale, L
   Skiadopoulos, MH
   Shearer, JD
   Savransky, V
AF Perry, Mark R.
   Ionin, Boris
   Barnewall, Roy E.
   Vassar, Michelle L.
   Reece, Joshua J.
   Park, Sukjoon
   Lemiale, Laurence
   Skiadopoulos, Mario H.
   Shearer, Jeffry D.
   Savransky, Vladimir
TI Development of a guinea pig inhalational anthrax model for evaluation of
   post-exposure prophylaxis efficacy of anthrax vaccines
SO VACCINE
LA English
DT Article
DE Anthrax; Animal model; Post-exposure prophylaxis; Ciprofloxacin; Vaccine
ID PROTECTIVE ANTIGEN; DOUBLE-BLIND; CPG 7909; IMMUNOGENICITY; AV7909;
   SURVIVAL; SAFETY
AB A next-generation anthrax vaccine candidate, AV7909, is being developed for post-exposure prophylaxis (PEP) of inhalational anthrax in combination with the recommended course of antimicrobial therapy. Clinical efficacy studies of anthrax countermeasures in humans are not ethical or feasible, therefore, licensure of AV7909 for PEP is being pursued under the US Food and Drug Administration (FDA) Animal Rule, which requires that evidence of effectiveness be demonstrated in an animal model of anthrax, where results of studies in such a model can establish reasonable likelihood of AV7909 to produce clinical benefit in humans. Initial development of a PEP model for inhalational anthrax included evaluation of post-exposure ciprofloxacin pharmacokinetics (PK), tolerability and survival in guinea pigs treated with various ciprofloxacin dosing regimens. Three times per day (TID) intraperitoneal (IP) dosing with 7.5 mg/kg of ciprofloxacin initiated 1 day following inhalational anthrax challenge and continued for 14 days was identified as a well tolerated partially curative ciprofloxacin treatment regimen. The added benefit of AV7909 vaccination was evaluated in guinea pigs given the partially curative ciprofloxacin treatment regimen. Groups of ciprofloxacin-treated guinea pigs were vaccinated.
   1 and 8 days post-challenge with serial dilutions of AV7909, a 1:16 dilution of AVA, or normal saline. A group of untreated guinea pigs was included as a positive control to confirm lethal B. anthracis exposure. Post-exposure vaccination with the AV7909 anthrax vaccine candidate administered in combination with the partially curative ciprofloxacin treatment significantly increased survival of guinea pigs compared to ciprofloxacin treatment alone. These results suggest that the developed model can be useful in demonstrating added value of the vaccine for PEP. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Perry, Mark R.; Barnewall, Roy E.; Vassar, Michelle L.] Battelle Biomed Res Ctr, 1425 Plain City Georgesville Rd,JM7, West Jefferson, OH 46162 USA.
   [Ionin, Boris; Reece, Joshua J.; Park, Sukjoon; Lemiale, Laurence; Skiadopoulos, Mario H.; Shearer, Jeffry D.; Savransky, Vladimir] Emergent BioSolut Inc, 300 Profess Dr, Gaithersburg, MD 20879 USA.
RP Savransky, V (reprint author), Emergent BioSolut Inc, 300 Profess Dr, Gaithersburg, MD 20879 USA.
EM savranskyv@ebsi.com
FU National Institute of Allergy and Infectious Diseases, National
   Institutes of Health, Department of Health and Human ServicesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [HHSN272200800051C]
FX The authors thank Greg Stark, Mike Anderson, and Nancy Niemuth for
   statistical analysis of the data. This project was funded, in whole or
   in part, with federal funds from the National Institute of Allergy and
   Infectious Diseases, National Institutes of Health, Department of Health
   and Human Services, under contract HHSN272200800051C.
CR Abrami L, 2004, J CELL BIOL, V166, P645, DOI 10.1083/jcb.200312072
   Altboum Z, 2002, INFECT IMMUN, V70, P6231, DOI 10.1128/IAI.70.11.6231-6241.2002
   [Anonymous], 2010, VACC REL BIOL PROD A
   Bader MS, 2017, CLEV CLIN J MED, V84, P65, DOI 10.3949/ccjm.84a.15049
   Bader MS, 2013, AM FAM PHYSICIAN, V88, P25
   Bann JG, 2004, NATURE, V430, P843, DOI 10.1038/430843a
   BRACHMAN PS, 1962, AM J PUBLIC HEALTH N, V52, P632, DOI 10.2105/AJPH.52.4.632
   Brossier F, 2001, TOXICON, V39, P1747, DOI 10.1016/S0041-0101(01)00161-1
   CBER, 2002, ANTHR VACC EFF TEST
   CDER and CBER, 2015, PROD DEV AN RUL GUID
   Collier RJ, 2003, ANNU REV CELL DEV BI, V19, P45, DOI 10.1146/annurev.cellbio.19.111301.140655
   Fellows PF, 2001, VACCINE, V20, P635, DOI 10.1016/S0264-410X(01)00411-X
   Gu ML, 2007, VACCINE, V25, P526, DOI 10.1016/j.vaccine.2006.07.056
   GUYTON AC, 1947, AM J PHYSIOL, V150, P70
   HENDERSON D. W., 1956, JOUR HYG, V54, P28
   Hopkins RJ, 2016, VACCINE, V34, P2096, DOI 10.1016/j.vaccine.2016.03.006
   Hopkins RJ, 2013, VACCINE, V31, P3051, DOI 10.1016/j.vaccine.2013.04.063
   Inglesby TV, 2000, JAMA-J AM MED ASSOC, V283, P1963
   Inglesby TV, 2002, JAMA-J AM MED ASSOC, V288, P1849
   Ionin B, 2013, CLIN VACCINE IMMUNOL, V20, P1016, DOI 10.1128/CVI.00099-13
   IVINS BE, 1986, INFECT IMMUN, V52, P454, DOI 10.1128/IAI.52.2.454-458.1986
   Kao LM, 2006, ANTIMICROB AGENTS CH, V50, P3535, DOI 10.1128/AAC.00090-06
   Leffel EK, 2012, CLIN VACCINE IMMUNOL, V19, P1158, DOI 10.1128/CVI.00240-12
   lonin B, 2010, 8 ANN BIOD VACC THER
   Quinn CP, 2012, CLIN VACCINE IMMUNOL, V19, P1730, DOI 10.1128/CVI.00324-12
   Rankin R, 2001, ANTISENSE NUCLEIC A, V11, P333, DOI 10.1089/108729001753231713
   ROSS JM, 1955, BRIT J EXP PATHOL, V36, P336
   ROSS JM, 1957, J PATHOL BACTERIOL, V73, P485, DOI 10.1002/path.1700730219
   Rynkiewicz D, 2011, VACCINE, V29, P6313, DOI 10.1016/j.vaccine.2011.05.047
   Savransky V, 2017, VACCINE, V35, P4952, DOI 10.1016/j.vaccine.2017.07.076
   Savransky V, 2013, INFECT IMMUN, V81, P1152, DOI 10.1128/IAI.01289-12
   Semenova VA, 2012, J IMMUNOL METHODS, V376, P97, DOI 10.1016/j.jim.2011.12.002
   Turnbull PCB, 2004, J CLIN MICROBIOL, V42, P3626, DOI [10.1128/JCM.42.8.3626-3634.2004, 10.1128/jcm.42.8.3626-3634.2004]
NR 33
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2020
VL 38
IS 10
BP 2307
EP 2314
DI 10.1016/j.vaccine.2020.01.068
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KR5KP
UT WOS:000517657600006
PM 32029323
OA Other Gold
DA 2020-05-12
ER

PT J
AU Wantuch, PL
   Sun, LN
   LoPilato, RK
   Mousa, JJ
   Haltiwanger, RS
   Avci, FY
AF Wantuch, Paeton L.
   Sun, Lina
   LoPilato, Rachel K.
   Mousa, Jarrod J.
   Haltiwanger, Robert S.
   Avci, Fikri Y.
TI Isolation and characterization of new human carrier peptides from two
   important vaccine immunogens
SO VACCINE
LA English
DT Article
DE CRM197; Tetanus toxoid; MHC class II; T cell; B cell; Glycoconjugate
   vaccines; Carrier protein
ID T-CELL EPITOPES; HUMAN CD4(+) CELLS; CLASS-II; CONJUGATE VACCINES;
   IMMUNE-RESPONSES; HIGH-RESOLUTION; HLA ALLELES; TETANUS; POLYSACCHARIDE;
   BINDING
AB In the preparation of glycoconjugate vaccines in clinical practice, two highly immunogenic carrier proteins, CRM197 and tetanus toxoid (TT), are predominantly conjugated with the capsular polysaccharides (CPSs) of bacterial pathogens. In addition, TT has long been used as an effective vaccine to prevent tetanus. While these carrier proteins play an important role in immunogenicity and vaccine design alike, their defined human major histocompatibility complex class II (MHCII) T cell epitopes are inadequately characterized. In this current work, we use mass spectrometry to identify the peptides from these carrier proteins that are naturally processed and presented by human B cells via MHCII pathway. The MHCII-presented peptides are screened for their T cell stimulation using primary CD4+ T cells from four healthy adult donors. These combined methods reveal a subset of eleven CD4+ T cell epitopes that proliferate and stimulate human T cells with diverse MHCII allelic repertoire. Six of these peptides stand out as potential immunodominant epitopes by responding in three or more donors. Additionally, we provide evidence of these natural epitopes eliciting more significant T cell responses in donors than previously published TT peptides selected from T cell epitope screening. This study serves toward understanding carrier protein immune responses and thus enables the use of these peptides in developing novel knowledge-based vaccines to combat persisting problems in glycoconjugate vaccine design. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Wantuch, Paeton L.; Sun, Lina; LoPilato, Rachel K.; Haltiwanger, Robert S.; Avci, Fikri Y.] Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.
   [Wantuch, Paeton L.; Sun, Lina; Avci, Fikri Y.] Univ Georgia, Ctr Mol Med, Athens, GA 30602 USA.
   [LoPilato, Rachel K.; Haltiwanger, Robert S.] Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA.
   [Mousa, Jarrod J.] Univ Georgia, Coll Vet Med, Ctr Vaccines & Immunol, Athens, GA 30602 USA.
   [Mousa, Jarrod J.] Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA.
RP Avci, FY (reprint author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.
EM avci@uga.edu
OI Avci, Fikri/0000-0002-1902-7532
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01A1123383,
   R01GM061126, K01OD026569]
FX We would like to thank Andrew Lees from Fina Biosolutions, LLC for
   providing CRM<INF>197</INF> and Tetanus Toxoid heavy chain proteins.
   Support for this work was provided by National Institutes of Health
   grants R01A1123383 (FA), R01GM061126 (RSH) and K01OD026569 (JJM).
CR Antunes RDS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169086
   Avci FY, 2013, CURR TOP MED CHEM, V13, P2535, DOI 10.2174/15680266113136660180
   Avci FY, 2011, NAT MED, V17, P1602, DOI 10.1038/nm.2535
   Avelos AM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00092
   Baraldo K, 2005, INFECT IMMUN, V73, P5835, DOI 10.1128/IAI.73.9.5835-5841.2005
   Bentley G, 2009, TISSUE ANTIGENS, V74, P393, DOI 10.1111/j.1399-0039.2009.01345.x
   BIXLER GS, 1989, ADV EXP MED BIOL, V251, P175
   Bozzacco L, 2011, J PROTEOME RES, V10, P5016, DOI 10.1021/pr200503g
   Cai H, 2013, ANGEW CHEM INT EDIT, V52, P6106, DOI 10.1002/anie.201300390
   Castelli FA, 2002, J IMMUNOL, V169, P6928, DOI 10.4049/jimmunol.169.12.6928
   Cobb BA, 2004, CELL, V117, P677, DOI 10.1016/j.cell.2004.05.001
   DEMOTZ S, 1993, EUR J IMMUNOL, V23, P425, DOI 10.1002/eji.1830230219
   DEMOTZ S, 1989, J IMMUNOL, V142, P394
   DEVELASCO EA, 1995, INFECT IMMUN, V63, P961, DOI 10.1128/IAI.63.3.961-968.1995
   DiCarluccio AR, 2019, JOVE-J VIS EXP, V148
   Diethelm-Okita BM, 2000, J INFECT DIS, V181, P1001, DOI 10.1086/315324
   DiethelmOkita BM, 1997, J INFECT DIS, V175, P382, DOI 10.1093/infdis/175.2.382
   ETLINGER HM, 1990, SCIENCE, V249, P423, DOI 10.1126/science.1696030
   Falugi F, 2001, EUR J IMMUNOL, V31, P3816, DOI 10.1002/1521-4141(200112)31:12<3816::AID-IMMU3816>3.0.CO;2-K
   Fink AL, 2018, P NATL ACAD SCI USA, V115, P12477, DOI 10.1073/pnas.1805268115
   Fink AL, 2015, PHYSIOLOGY, V30, P408, DOI 10.1152/physiol.00035.2015
   Fischinger S, 2019, SEMIN IMMUNOPATHOL, V41, P239, DOI 10.1007/s00281-018-0726-5
   Fujita Y, 2011, CHEM CENT J, V5, DOI 10.1186/1752-153X-5-48
   Goldblatt D, 2000, CLIN EXP IMMUNOL, V119, P1, DOI 10.1046/j.1365-2249.2000.01109.x
   Gonzalez-Galarza FF, 2015, NUCLEIC ACIDS RES, V43, pD784, DOI 10.1093/nar/gku1166
   HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610
   Jackson DC, 2002, CURR DRUG TARGETS, V3, P175, DOI 10.2174/1389450024605436
   Kerblat I, 2000, IMMUNOLOGY, V100, P178, DOI 10.1046/j.1365-2567.2000.00032.x
   Leonard EG, 2003, INFECT IMMUN, V71, P4186, DOI 10.1128/IAI.71.7.4186-4189.2003
   Mack SJ, 2013, TISSUE ANTIGENS, V81, P194, DOI 10.1111/tan.12093
   Maiers M, 2007, HUM IMMUNOL, V68, P779, DOI 10.1016/j.humimm.2007.04.005
   McFarland BJ, 1999, BIOCHEMISTRY-US, V38, P16663, DOI 10.1021/bi991393l
   Micoli F, 2018, MOLECULES, V23, DOI 10.3390/molecules23061451
   Middleton DR, 2017, J IMMUNOL, V199, P598, DOI 10.4049/jimmunol.1700026
   Murphy K, 2017, JANEWAY'S IMMUNOBIOLOGY, 9TH EDITION, P1
   PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209
   Pichichero ME, 2013, HUM VACC IMMUNOTHER, V9, P2505, DOI 10.4161/hv.26109
   Raju R, 1995, EUR J IMMUNOL, V25, P3207, DOI 10.1002/eji.1830251202
   Rappuoli R, 2019, P NATL ACAD SCI USA, V116, P14, DOI 10.1073/pnas.1819612116
   Riaz MK, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010195
   Rodrigues-da-Silva RN, 2019, VACCINE, V37, P306, DOI 10.1016/j.vaccine.2018.10.016
   SCHUTZE MP, 1987, CELL IMMUNOL, V104, P79, DOI 10.1016/0008-8749(87)90008-6
   SCHUTZE MP, 1985, J IMMUNOL, V135, P2319
   Scott CA, 1998, IMMUNITY, V8, P319, DOI 10.1016/S1074-7613(00)80537-3
   Slingluff CL, 2011, CANCER J, V17, P343, DOI 10.1097/PPO.0b013e318233e5b2
   Snook AE, 2016, HUM GENE THER METHOD, V27, P238, DOI 10.1089/hgtb.2016.114
   Southwood S, 1998, J IMMUNOL, V160, P3363
   Sun LN, 2016, GLYCOBIOLOGY, V26, P1029, DOI 10.1093/glycob/cww062
   Sun XM, 2019, P NATL ACAD SCI USA, V116, P193, DOI 10.1073/pnas.1816401115
   van Lith M, 2010, J BIOL CHEM, V285, P40800, DOI 10.1074/jbc.M110.148155
   Wantuch PL, 2018, HUM VACC IMMUNOTHER, V14, P2303, DOI 10.1080/21645515.2018.1470726
   Wantuch PL, 2019, HUM VACC IMMUNOTHER, P1
   Zeigler DF, 2019, VACCINE, V37, P1584, DOI 10.1016/j.vaccine.2019.02.003
NR 53
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2020
VL 38
IS 10
BP 2315
EP 2325
DI 10.1016/j.vaccine.2020.01.065
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KR5KP
UT WOS:000517657600007
PM 32005537
DA 2020-05-12
ER

PT J
AU Avalos, LA
   Ferber, J
   Zerbo, O
   Naleway, AL
   Bulkley, J
   Thompson, M
   Cragan, J
   Williams, J
   Odouli, R
   Kauffman, TL
   Ball, S
   Shifflett, P
   Li, DK
AF Avalos, Lyndsay A.
   Ferber, Jeannette
   Zerbo, Ousseny
   Naleway, Allison L.
   Bulkley, Joanna
   Thompson, Mark
   Cragan, Janet
   Williams, Jennifer
   Odouli, Roxana
   Kauffman, Tia L.
   Ball, Sarah
   Shifflett, Pat
   Li, De-Kun
TI Trivalent inactivated influenza vaccine (IIV3) during pregnancy and
   six-month infant development
SO VACCINE
LA English
DT Article
DE Trivalent inactivated influenza vaccine (IIV3); Pregnancy; Infant
   development; Ages and Stages (ASQ)
ID H1N1 INFLUENZA; NEONATAL OUTCOMES; RISK; IMMUNIZATION; ACTIVATION;
   INFECTION; AUTISM; RESPONSES; CHILDREN; DELIVERY
AB Objective: Despite recommendations by professional organizations that all pregnant women receive inactivated influenza vaccine, safety concerns remain a barrier. Our objective was to assess the effect of trivalent influenza vaccines (IIV3) during pregnancy on parent report 6-month infant development.
   Methods: We conducted a multi-site prospective birth cohort study during the 2010-2011 influenza season and followed pregnant women and their newborns through 6 months of age. Information on IIV3 during pregnancy was ascertained from the EHR and self-report. The Ages and Stages Questionnaire-3 (ASQ-3) was completed by the mother to assess 6-month infant neurodevelopment in five domains (communication, gross motor, fine motor, problem-solving, and personal adaptive skills). Scores for each domain above the cut-off point indicating typical development were categorized as "on schedule" while scores in the zones indicating the need for either monitoring or further assessment were categorized as "not on schedule". Multivariable logistic regression was conducted.
   Results: Of the 1225 infant-mother pairs, 65% received IIV3 during pregnancy. In bivariate analysis, infants of women who received IIV3 during pregnancy were moderately-less likely to need monitoring or further assessment in the personal social domain compared with infants of unvaccinated women (10.0% vs. 14.1%, p = 0.033; crude OR (cOR): 0.68(95%CI:0.48,0.97)). However, after controlling for potential confounders, the findings were no longer statistically significant (aOR:0.72,95%CI: 0.49,1.06,p = 0.46). No significant unadjusted or adjusted associations emerged in any other ASQ-3 domain.
   Conclusion: There was no significant association between IIV3 exposure during pregnancy and 6-month infant development. Studies of IIV3 during pregnancy to assess longer-term developmental outcomes are indicated. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Avalos, Lyndsay A.; Ferber, Jeannette; Zerbo, Ousseny; Odouli, Roxana; Li, De-Kun] Kaiser Permanente Northern Calif, Div Res, 2000 Broadway, Oakland, CA 94612 USA.
   [Naleway, Allison L.; Bulkley, Joanna; Kauffman, Tia L.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA.
   [Thompson, Mark] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
   [Cragan, Janet; Williams, Jennifer] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA.
   [Ball, Sarah; Shifflett, Pat] Abt Associates Inc, Cambridge, MA USA.
RP Avalos, LA (reprint author), Kaiser Permanente Northern Calif, Div Res, 2000 Broadway, Oakland, CA 94612 USA.
EM Lyndsay.A.Avalos@kp.org
FU Centers for Disease Control and Prevention (CDC)United States Department
   of Health & Human ServicesCenters for Disease Control & Prevention - USA
   [200-2010-F-33132]; National Institutes of Mental HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Mental Health (NIMH) [K01MH103444]
FX This study was funded by the Centers for Disease Control and Prevention
   (CDC; Contract 200-2010-F-33132 to Abt Associates Inc). Investigators
   from the CDC were involved in the study design, interpretation of the
   analysis and made significant contributions to various drafts of the
   manuscript. The CDC provided approval for submission of this manuscript
   for publication. Participation on this study by Lyndsay A. Avalos was
   funded by National Institutes of Mental Health (K01MH103444).
CR Bauman MD, 2014, BIOL PSYCHIAT, V75, P332, DOI 10.1016/j.biopsych.2013.06.025
   Bodnar TS, 2018, BRAIN BEHAV IMMUN
   Chambers CD, 2013, VACCINE, V31, P5026, DOI 10.1016/j.vaccine.2013.08.097
   Christian LM, 2013, AM J REPROD IMMUNOL, V70, P45, DOI 10.1111/aji.12117
   Diseases COI, 2017, PEDIATRICS, V140
   Fatemi SH, 1998, SYNAPSE, V29, P84, DOI 10.1002/(SICI)1098-2396(199805)29:1<84::AID-SYN8>3.3.CO;2-N
   Fatemi SH, 1999, MOL PSYCHIATR, V4, P145, DOI 10.1038/sj.mp.4000520
   Goines PE, 2011, MOL AUTISM, V2, DOI 10.1186/2040-2392-2-13
   Gollenberg AL, 2010, CHILD CARE HLTH DEV, V36, P485, DOI 10.1111/j.1365-2214.2009.01041.x
   Grohskopf LA, 2018, MMWR RECOMM REP, V67, DOI 10.15585/mmwr.rr6703a1
   Haberg SE, 2013, NEW ENGL J MED, V368, P333, DOI 10.1056/NEJMoa1207210
   He XS, 2006, J VIROL, V80, P11756, DOI 10.1128/JVI.01460-06
   He XS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002574
   Hsiao EY, 2012, P NATL ACAD SCI USA, V109, P12776, DOI 10.1073/pnas.1202556109
   Jones KL, 2017, MOL PSYCHIATR, V22, P273, DOI 10.1038/mp.2016.77
   Kallen B, 2012, BJOG-INT J OBSTET GY, V119, P1583, DOI 10.1111/j.1471-0528.2012.03470.x
   Limbos MM, 2011, J DEV BEHAV PEDIATR, V32, P499, DOI 10.1097/DBP.0b013e31822552e9
   Malkova NV, 2012, BRAIN BEHAV IMMUN, V26, P607, DOI 10.1016/j.bbi.2012.01.011
   Meharry PM, 2013, MATERN CHILD HLTH J, V17, P156, DOI 10.1007/s10995-012-0957-3
   Munoz FM, 2018, VACCINE, V36, P8054, DOI 10.1016/j.vaccine.2018.10.088
   Naleway AL, 2014, VACCINE, V32, P3122, DOI 10.1016/j.vaccine.2014.04.021
   Nawa H, 2006, NEUROSCI RES, V56, P2, DOI 10.1016/j.neures.2006.06.002
   Omer SB, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000441
   Patterson PH, 2011, TRENDS MOL MED, V17, P389, DOI 10.1016/j.molmed.2011.03.001
   Rasmussen SA, 2012, AM J OBSTET GYNECOL, V207, pS3, DOI 10.1016/j.ajog.2012.06.068
   Richards JL, 2013, CLIN INFECT DIS, V56, P1216, DOI 10.1093/cid/cit045
   Sammon CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051734
   Sandler AD, 2001, PEDIATRICS, V107
   Schanzer DL, 2007, J OBSTET GYNAECOL CA, V29, P622, DOI 10.1016/S1701-2163(16)32559-2
   Short SJ, 2010, BIOL PSYCHIAT, V67, P965, DOI 10.1016/j.biopsych.2009.11.026
   Smith SEP, 2007, J NEUROSCI, V27, P10695, DOI 10.1523/JNEUROSCI.2178-07.2007
   Squires J., 2009, AGES STAGES QUESTION
   Steinhoff MC, 2012, CAN MED ASSOC J, V184, P645, DOI 10.1503/cmaj.110754
   Thompson M, 2011, AM J OBSTET GYNECOL, V204, pS69, DOI 10.1016/j.ajog.2011.01.006
   Wu YY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1252-z
   Xia YC, 2014, BRAIN BEHAV IMMUN, V42, P212, DOI 10.1016/j.bbi.2014.06.202
   Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630
   Zerbo O, 2017, JAMA PEDIATR, V171, P601, DOI 10.1001/jamapediatrics.2017.0737
NR 38
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2020
VL 38
IS 10
BP 2326
EP 2332
DI 10.1016/j.vaccine.2020.01.059
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KR5KP
UT WOS:000517657600008
PM 32033850
DA 2020-05-12
ER

PT J
AU Stoppato, M
   Gaspar, C
   Regeimbal, J
   Nunez, RG
   Giuntini, S
   Schiller, ZA
   Gawron, MA
   Pondish, JR
   Martin, JC
   Schneider, MI
   Klempner, MS
   Cavacini, LA
   Wang, Y
AF Stoppato, Matteo
   Gaspar, Carlos
   Regeimbal, James
   Nunez, Rosa G.
   Giuntini, Serena
   Schiller, Zachary A.
   Gawron, Melissa A.
   Pondish, Jessica R.
   Martin, Joseph C., III
   Schneider, Matthew, I
   Klempner, Mark S.
   Cavacini, Lisa A.
   Wang, Yang
TI Oral administration of an anti-CfaE secretory IgA antibody protects
   against Enterotoxigenic Escherichia coli diarrheal disease in a nonhuman
   primate model
SO VACCINE
LA English
DT Article
DE ETEC diarrhea; SIgA; dIgA, nonhuman primates
ID IMMUNITY
AB Enterotoxigenic Escherichia coil (ETEC) is a leading cause of diarrhea-associated illness in developing countries. There is currently no vaccine licensed to prevent ETEC and the development of an efficacious prophylaxis would provide an intervention with significant impact. Recent studies suggested that effective protection could be achieved by inducing immunity to block colonization of ETEC. Here, we evaluated the efficacy of secretory (s) IgA2 and dimeric (d) IgA2 of an anti-colonization factor antigen antibody, 68-61, in the Aorus nancymaae nonhuman primate (NHP) ETEC challenge model via oral and parental delivery. Thirty-nine animals were distributed across 3 groups of 13, and challenged with 5.0x10(11) colony forming unit (CFU) of H10407 on Day 0. Group 1 received a dIgA2 68-61 subcutaneously on day 0. Group 2 received a SIgA2 68-61 orally on days 1, 0, and +1, and Group 3 received an irrelevant SIgA2 antibody orally on days 1, 0, and +1. All animals were observed for symptoms of diarrhea, and stools were collected for ETEC colony counts. Anti-CfaE SIgA2 treatment significantly lowered the attack rate, resulting in a protective efficacy of 74.1% (p = 0.025) in Group 2 as compared to Group 3. The anti-CfaE dIgA2 treatment group had reduced diarrheal attack rate, although the reduction did not reach significance (57.1%; p = 0.072) as compared to the irrelevant SIgA2 Group 3. Our results demonstrated the feasibility of oral administration of SIgA as a potential immunoprophylaxis against enteric infections. To our knowledge, this is the first study to demonstrate the efficacy of administrated SIgA in a nonhuman primate model. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Stoppato, Matteo; Regeimbal, James; Nunez, Rosa G.; Giuntini, Serena; Schiller, Zachary A.; Gawron, Melissa A.; Pondish, Jessica R.; Martin, Joseph C., III; Schneider, Matthew, I; Klempner, Mark S.; Cavacini, Lisa A.; Wang, Yang] Univ Massachusetts, Sch Med, MassBiol, 460 Walk Hill St, Boston, MA 02126 USA.
   [Gaspar, Carlos] Naval Med Res Unit 6, Lima, Peru.
   [Stoppato, Matteo] Sana Biotechnol Inc, Cambridge, MA USA.
   [Giuntini, Serena] Staidson Biopharma, Richmond, CA USA.
   [Gawron, Melissa A.; Martin, Joseph C., III] Scholar Rock, Cambridge, MA USA.
   [Pondish, Jessica R.] Morph Therapeut, Waltham, MA USA.
   [Schneider, Matthew, I] Dragonfly Therapeut, Waltham, MA USA.
RP Klempner, MS; Cavacini, LA; Wang, Y (reprint author), Univ Massachusetts, Sch Med, MassBiol, 460 Walk Hill St, Boston, MA 02126 USA.
EM mark.klempner@umassmed.edu; lisa.cavacini@umassmed.edu;
   yang.wang@umassmed.edu
OI Schiller, Zachary/0000-0002-4185-2416
FU Defense Advanced Research Project AgencyUnited States Department of
   DefenseDefense Advanced Research Projects Agency (DARPA)
   [DARPA-BAA-13-03]
FX This work was supported by the Defense Advanced Research Project Agency
   (DARPA-BAA-13-03) to MK.
CR Brandtzaeg P, 2003, VACCINE, V21, P3382, DOI 10.1016/S0264-410X(03)00338-4
   Brandtzaeg P, 2007, VACCINE, V25, P5467, DOI 10.1016/j.vaccine.2006.12.001
   Giuntini S, 2018, INFECT IMMUN
   Isidean SD, 2011, VACCINE, V29, P6167, DOI 10.1016/j.vaccine.2011.06.084
   Jones FR, 2006, VACCINE, V24, P3786, DOI 10.1016/j.vaccine.2005.07.029
   Luiz WB, 2015, INFECT IMMUN, V83, P4555, DOI 10.1128/IAI.00858-15
   Madhavan TPV, 2015, ADV APPL MICROBIOL, V90, P155, DOI 10.1016/bs.aambs.2014.09.003
   Nakanishi K, 2019, PLANTA, V250, P1255, DOI 10.1007/s00425-019-03215-1
   Paul M, 2014, MABS-AUSTIN, V6, P1585, DOI 10.4161/mabs.36336
   Rollenhagen JE, 2018, INFECT IMMUN
   Savarino Si.McKenzieR.TribbleDR, 2017, J INFECT DIS, P24
   Savarino SJ, 2019, J INFECT DIS, V220, P505, DOI 10.1093/infdis/jiz135
   Savarino SJ, 2017, J INFECT DIS, V216, P7, DOI 10.1093/infdis/jix144
   Sears CL, 1996, MICROBIOL REV, V60, P167, DOI 10.1128/MMBR.60.1.167-215.1996
   Stelwagen K, 2009, J ANIM SCI, V87, P3, DOI 10.2527/jas.2008-1377
   Turula H, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10050237
   Wenzel H, 2017, VACCINE, V35, P6798, DOI 10.1016/j.vaccine.2017.08.030
   Woof JM, 2011, MUCOSAL IMMUNOL, V4, P590, DOI 10.1038/mi.2011.39
   Zhang WP, 2012, EXPERT REV VACCINES, V11, P677, DOI [10.1586/erv.12.37, 10.1586/ERV.12.37]
NR 19
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2020
VL 38
IS 10
BP 2333
EP 2339
DI 10.1016/j.vaccine.2020.01.064
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KR5KP
UT WOS:000517657600009
PM 32008877
DA 2020-05-12
ER

PT J
AU Choi, KY
   El-Hamdi, NS
   McGregor, A
AF Choi, K. Yeon
   El-Hamdi, Nadia S.
   McGregor, Alistair
TI Neutralizing antibodies to gB based CMV vaccine requires full length
   antigen but reduced virus neutralization on non-fibroblast cells limits
   vaccine efficacy in the guinea pig model
SO VACCINE
LA English
DT Article
DE Guinea pig; Cytomegalovirus; Vaccines; Glycoprotein gB; Neutralization;
   Congenital infection
ID CYTOMEGALOVIRUS GLYCOPROTEIN-B; RHESUS CYTOMEGALOVIRUS; INFECTION;
   COMPLEX; IDENTIFICATION; EXPRESSION; PREVENTION; PROTECTION; HOMOLOGS;
   PLACENTA
AB Cytomegalovirus is a leading cause of congenital disease and a vaccine is a high priority. The viral gB glycoprotein is essential for infection on all cell types. The guinea pig is the only small animal model for congenital CMV (cCMV), but requires guinea pig cytomegalovirus (GPCMV). Various GPCMV gB vaccine strategies have been investigated but not with a full length protein. Previous GPCMV gB vaccines have failed to fully protect against cCMV, with approximately 50% efficacy. In an effort to define the basis of GPCMV gB based vaccine failure, we evaluated recombinant defective Ad vectors encoding GPCMV gB full length (gBwt), or truncated protein lacking transmembrane domain (gBTMD). Both candidate vaccines evoked high anti-gB titers and neutralized virus infection on fibroblast cells but had varying weaker results on non-fibroblasts (renal epithelial and placental trophoblasts). Non-fibroblast cells are dependent upon the viral pentamer complex (PC) for endocytic pathway cell entry. In contrast, fibroblasts cells that express the viral receptor platelet derived growth factor receptor alpha (PDGFRA) to enable entry by direct cell fusion independent of the PC. Anti-gBwt sera was approximately 2-fold (renal epithelial) to 3 fold (fibroblasts) more effective at neutralizing virus compared to anti-gBTMD sera. Both gB vaccines were weakest against virus neutralization on trophoblasts. Knockout of PDGFRA cell receptor on fibroblast cells (GPKO) rendered virus dependent upon the PC pathway for cell entry and anti-gB GPCMV NAso was more similar to epithelial cells. In a gBwt vaccine protection study, vaccination of animals significantly reduced, but did not prevent dissemination of wild type GPCMV challenge virus to target organs. Depletion of complement in vivo had limited impact on vaccine efficacy. Overall, a full length gB antigen has the potential to improve neutralizing antibody titer but fails to fully prevent virus dissemination and likely congenital infection. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Choi, K. Yeon; El-Hamdi, Nadia S.; McGregor, Alistair] Texas A&M Univ, Coll Med, Dept Microbial Pathogenesis & Immunol, Bryan, TX 77807 USA.
RP McGregor, A (reprint author), Texas A&M Univ, Coll Med, Dept Microbial Pathogenesis & Immunol, Bryan, TX 77807 USA.
EM mcgalistair2013@tamu.edu
FU NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01AI098984, R01AI100933]; NICHDUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD) [R01HD090065]
FX We are grateful to Jim Choi and Darijana Horvat for their technical
   assistance on specific aspects of this study. We thank Dr. Britt (UAB)
   for the generous gift of anti-gB mouse monoclonal antibody. Research was
   supported by funding from NIAID (R01AI098984: R01AI100933) and NICHD
   (R01HD090065).
CR Abel K, 2011, J VIROL, V85, P2878, DOI 10.1128/JVI.00883-10
   Auerbach M, 2013, VIROLOGY, V441, P75, DOI 10.1016/j.virol.2013.03.008
   Baraniak I, 2018, P NATL ACAD SCI USA, V115, P6273, DOI 10.1073/pnas.1800224115
   Boppana SB, 1996, VIROLOGY, V222, P293, DOI 10.1006/viro.1996.0424
   Britt WJ, 2005, J VIROL, V79, P4066, DOI 10.1128/JVI.79.7.4066-4079.2005
   BRITT WJ, 1990, J VIROL, V64, P1079, DOI 10.1128/JVI.64.3.1079-1085.1990
   BRITT WJ, 1994, VIROLOGY, V201, P294, DOI 10.1006/viro.1994.1294
   Burke HG, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005227
   Cardin RD, 2016, VACCINE, V34, P1993, DOI 10.1016/j.vaccine.2016.03.005
   Chiuppesi F, 2015, J VIROL, V89, P11884, DOI 10.1128/JVI.01701-15
   Choi KY, 2019, J VIROL, V93, DOI 10.1128/JVI.01442-19
   Choi KY, 2016, J VIROL, V90, P7902, DOI 10.1128/JVI.00283-16
   Coleman S, 2015, PLOS ONE, V10, DOI [10.1371/ journal.pone 0135567e0135567, DOI 10.1371/JOURNAL.PHONE.0135567E0135567]
   Coleman S, 2017, VIROLOGY, V509, P205, DOI 10.1016/j.virol.2017.06.008
   Coleman S, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005755
   Cui XH, 2008, VACCINE, V26, P5760, DOI 10.1016/j.vaccine.2008.07.092
   Cui XL, 2018, VACCINE, V36, P5580, DOI 10.1016/j.vaccine.2018.07.056
   Freed DC, 2013, P NATL ACAD SCI USA, V110, pE4997, DOI 10.1073/pnas.1316517110
   GRIFFITH BP, 1985, J VIROL, V55, P402, DOI 10.1128/JVI.55.2.402-409.1985
   Ha S, 2017, J VIROL, V91, DOI 10.1128/JVI.02033-16
   Hashimoto K, 2013, VACCINE, V31, P3199, DOI 10.1016/j.vaccine.2013.04.078
   Kanai K, 2011, J GEN VIROL, V92, P1005, DOI 10.1099/vir.0.027789-0
   Kaufmann P, 2004, GUINEA PIG CAVIA PRO
   MARSHALL GS, 1992, J INFECT DIS, V165, P381, DOI 10.1093/infdis/165.2.381
   McGregor A, 2004, VIRUS RES, V101, P101, DOI 10.1016/j.virusres.2003.12.030
   McGregor A, CYTOMEGALOVIRUSES MO
   Mess A, 2007, PLACENTA, V28, P812, DOI 10.1016/j.placenta.2007.02.005
   Pass RF, 2009, NEW ENGL J MED, V360, P1191, DOI 10.1056/NEJMoa0804749
   PLEYER U, 1992, INVEST OPHTH VIS SCI, V33, P2212
   Ross Shannon A, 2005, Semin Pediatr Infect Dis, V16, P44, DOI 10.1053/j.spid.2004.09.011
   Ryckman BJ, 2008, P NATL ACAD SCI USA, V105, P14118, DOI 10.1073/pnas.0804365105
   Schleiss MR, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00268-17
   Schleiss MR, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-139
   Schleiss MR, 2004, J INFECT DIS, V189, P1374, DOI 10.1086/382751
   Schleiss MR, 2003, J VIROL METHODS, V108, P59, DOI 10.1016/S0166-0934(02)00258-6
   Schleiss MR, 2017, VECTOR CLIN VACCINE, V24, DOI [10.1128/CVI.00300-16, DOI 10.1128/CVI.22322-16]
   Scrivano L, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001256
   Swanson EC, 2015, VACCINE, V33, P4013, DOI 10.1016/j.vaccine.2015.06.019
   WOOLF NK, 1989, J INFECT DIS, V160, P929, DOI 10.1093/infdis/160.6.929
   Wu YQ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006281
   Xing Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005856
   Yamada S, 2014, J GEN VIROL, V95, P1376, DOI 10.1099/vir.0.064527-0
   Yue YJ, 2003, J GEN VIROL, V84, P3371, DOI 10.1099/vir.0.19508-0
   Yue YJ, 2008, ADV VIRUS RES, V72, P207, DOI 10.1016/S0065-3527(08)00405-3
   Zhang K, 2017, ONCOTARGET, V8, P30422, DOI 10.18632/oncotarget.16503
NR 45
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2020
VL 38
IS 10
BP 2340
EP 2349
DI 10.1016/j.vaccine.2020.01.063
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KR5KP
UT WOS:000517657600010
PM 32008881
DA 2020-05-12
ER

PT J
AU Madhi, SA
   Moreira, M
   Koen, A
   van Niekerk, N
   de Gouveia, L
   Jose, L
   Cutland, CL
   Francois, N
   Schoonbroodt, S
   Ruiz-Guinazu, J
   Yarzabal, JP
   Borys, D
   Schuerman, L
AF Madhi, Shabir A.
   Moreira, Marta
   Koen, Anthonet
   van Niekerk, Nadia
   de Gouveia, Linda
   Jose, Lisa
   Cutland, Clare L.
   Francois, Nancy
   Schoonbroodt, Sonia
   Ruiz-Guinazu, Javier
   Yarzabal, Juan Pablo
   Borys, Dorota
   Schuerman, Lode
TI Impact of HIV status and vaccination schedule on bacterial
   nasopharyngeal carriage following infant immunisation with the
   pneumococcal non-typeable Haemophilus influenzae protein D conjugate
   vaccine in South Africa
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; Nasopharyngeal carriage; Pneumococcal
   conjugate vaccine; Vaccination schedule; HIV; Infants
ID STREPTOCOCCUS-PNEUMONIAE; DISEASE; CHILDREN; PHID-CV10; EFFICACY
AB Background: Nasopharyngeal carriage (NPC) of Streptococcus pneumoniae is a precondition for pneumococcal disease and a source of transmission. This trial evaluated NPC of S. pneumoniae and other pathogens post-vaccination with the pneumococcal non-typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine (PHiD-CV) in human immunodeficiency virus (HIV)-infected (HIV+), HIV-exposed-uninfected (HEU), and HIV-unexposed-uninfected (HUU) South African children.
   Methods: In this phase III, open, single-centre, controlled study (ClinicalTrials.gov: NCT00829010), 484 children were stratified by HIV status: 83 HIV+, 101 HEU, and 300 HUU. HIV+ and HEU children received a 3 + 1 PHiD-CV vaccination schedule: primary vaccination, age 6110/14 weeks, and booster dose, age 9-10 months. HUU infants were randomised (1:1:1) to 3-dose priming and booster (HU11/3+1); 3-dose priming without booster (HUU/3+0); or 2-dose priming and booster (HUU/2+1). Bacterial NPC was assessed 8 times up to 24-27 months of age.
   Results: Overall pneumococcal carriage rates were similar across 3+1 groups irrespective of HIV status; trends towards higher carriage rates in the HIV+ than HEU and HUU/3+1 groups were observed at 24-27 months of age. In HUU children, carriage of any pneumococcal serotype was similar for the three different dosing schedules at all timepoints; carriage of vaccine-type pneumococci tended to be lower at 16-19 months and 24-27 months of age in children who had received a booster dose (HUU/2+1 and HUU/3+1 groups) than in the HUU/3+0 group. Carriage rates of NTHi, Staphylococcus aureus and Moraxella catarrhalis were comparable between all groups.
   Conclusions: HIV infection or exposure did not seem to alter the effect of PHiD-CV on pneumococcal NPC in children during their first 2 years of life. NPC prevalence of vaccine-type pneumococci following vaccination series tended to be lower in children who had received a booster dose in comparison to those who had not. (C) 2020 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.
C1 [Madhi, Shabir A.; Koen, Anthonet; van Niekerk, Nadia; Jose, Lisa; Cutland, Clare L.] Univ Witwatersrand, Fac Hlth Sci, Med Res Council Resp & Meningeal Pathogens Res Un, Johannesburg, South Africa.
   [Madhi, Shabir A.; Koen, Anthonet; van Niekerk, Nadia; Jose, Lisa; Cutland, Clare L.] Univ Witwatersrand, Dept Sci & Technol, Fac Hlth Sci, Natl Res Fdn Vaccine Preventable Dis, Johannesburg, South Africa.
   [Moreira, Marta; Francois, Nancy; Schoonbroodt, Sonia; Ruiz-Guinazu, Javier; Yarzabal, Juan Pablo; Borys, Dorota; Schuerman, Lode] GSK, Wavre, Belgium.
   [de Gouveia, Linda] Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Johannesburg, South Africa.
RP Madhi, SA (reprint author), Chris Hani Baragwanath Acad Hosp, Resp & Meningeal Pathogens Res Unit, Chris Hani Rd,Nurses Residence 11th Floor, ZA-2013 Bertsham, Gauteng, South Africa.
EM madhis@rmpru.co.za; koena@rmpru.co.za; lindad@nicd.ac.za;
   josel@rmpru.co.za; cutlandc@rmpru.co.za; nancy.a.francois@gsk.com;
   sonia.j.schoonbroodt@gsk.com; javier.x.ruiz@gsk.com;
   juan.p.yarzabal@gsk.com; dorota.d.borys@gsk.com; lode.schuerman@gsk.com
OI Madhi, Shabir/0000-0002-7629-0636
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX This work was supported by GlaxoSmithKline Biologicals SA.
   GlaxoSmithKline Biologicals SA was involved in all stages of the study
   conduct and analysis. GlaxoSmithKline Biologicals SA also took
   responsibility for all costs associated with the development and
   publishing of the present manuscript.
CR Adegbola RA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103293
   Davis SM, 2013, VACCINE, V32, P133, DOI 10.1016/j.vaccine.2013.05.005
   Flasche S, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001839
   Hamaluba M, 2015, LANCET INFECT DIS, V15, P405, DOI 10.1016/S1473-3099(15)70007-1
   Hammitt LL, 2014, LANCET GLOB HEALTH, V2, pE397, DOI 10.1016/S2214-109X(14)70224-4
   Hammitt LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085459
   Loo JD, 2014, PEDIATR INFECT DIS J, V33, pS161, DOI 10.1097/INF.0000000000000084
   Madhi SA, 2017, EXPERT REV VACCINES, V16, P641, DOI 10.1080/14760584.2017.1321990
   Madhi SA, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005881
   Madhi SA, 2015, VACCINE, V33, P2662, DOI 10.1016/j.vaccine.2015.04.024
   Madhi SA, 2012, VACCINE, V30, pC21, DOI 10.1016/j.vaccine.2012.05.055
   Mehr S, 2012, PAEDIATR RESPIR REV, V13, P258, DOI 10.1016/j.prrv.2011.12.001
   Nunes MC, 2015, VACCINE, V33, P628, DOI 10.1016/j.vaccine.2014.12.023
   Nzenze SA, 2017, AM J EPIDEMIOL, V186, P435, DOI 10.1093/aje/kwx048
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Odutola A, 2017, VACCINE, V35, P2531, DOI 10.1016/j.vaccine.2017.03.071
   Palmu AA, 2014, LANCET RESP MED, V2, P717, DOI 10.1016/S2213-2600(14)70139-0
   Palmu AA, 2013, LANCET, V381, P214, DOI 10.1016/S0140-6736(12)61854-6
   Prymula R, 2011, VACCINE, V29, P1959, DOI 10.1016/j.vaccine.2010.12.086
   Saez-Llorens X, 2017, HUM VACC IMMUNOTHER, V13, P1213, DOI 10.1080/21645515.2017.1287640
   Schoub BD, 2010, VACCINE, V28, pA31, DOI 10.1016/j.vaccine.2010.02.029
   Simell B, 2012, EXPERT REV VACCINES, V11, P841, DOI [10.1586/erv.12.53, 10.1586/ERV.12.53]
   Usuf E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085001
   van den Bergh MR, 2013, CLIN INFECT DIS, V56, pE30, DOI 10.1093/cid/cis922
   Vesikari T, 2016, J PEDIAT INF DIS SOC, V5, P237, DOI 10.1093/jpids/piw010
   World Health Organization, CAS DEF HIV SURV REV
   World Health Organization, 2019, PNEUM CONJ VACC INF
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2020
VL 38
IS 10
BP 2350
EP 2360
DI 10.1016/j.vaccine.2020.01.062
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KR5KP
UT WOS:000517657600011
PM 32035706
OA Other Gold
DA 2020-05-12
ER

PT J
AU Kuba, Y
   Kyan, H
   Iha, Y
   Kato, T
   Oyama, M
   Miyahira, M
   Kakita, T
   Takara, T
   Yamauchi, M
   Kamiya, H
   Sunagawa, T
   Kawakami, Y
   Nidaira, M
   Kudaka, J
   Yamakawa, M
   Itokazu, T
   Itokazu, K
AF Kuba, Yumani
   Kyan, Hisako
   Iha, Yoshiyuki
   Kato, Takashi
   Oyama, Minori
   Miyahira, Masato
   Kakita, Tetsuya
   Takara, Taketoshi
   Yamauchi, Miyuki
   Kamiya, Hajime
   Sunagawa, Tomimasa
   Kawakami, Yoshino
   Nidaira, Minoru
   Kudaka, Jun
   Yamakawa, Munesada
   Itokazu, Toru
   Itokazu, Kiyomasa
TI Emergent measles-containing vaccination recommendation for aged 6-11
   months and detection of vaccine-associated measles during a large
   measles outbreak in Okinawa, Japan, in 2018
SO VACCINE
LA English
DT Article
DE Measles; Outbreak; Vaccine-associated measles; Infants; Emergent
   vaccination; Outbreak response
ID MATERNAL ANTIBODIES; INFANTS; VIRUS; NETHERLANDS; EPIDEMIC
AB Okinawa Prefecture, Japan, experienced a large measles outbreak from March to May 2018. During this outbreak, there were 99 laboratory-confirmed cases and 14 vaccine-associated measles cases. In addition to the reinforcement of routine immunization, Okinawa prefectural government introduced emergent measles-containing vaccination recommendations for infants aged 6-11 months as part of the outbreak response. Increased concern exists in Okinawa about measles in infants following a previous outbreak from 1998 to 2001, when nine children including four infants died. Of 8062 infants aged 6-11 months who received measles-containing vaccine (MCV), six developed vaccine-associated measles; incidence was 0.74 per 1000 doses (95%CI 0.27-1.62). This was similar to that of first dose routine immunization recipients at one year of age (IR 0.60, 95%CI 0.20-1.78). Among 14 vaccine-associated measles cases, throat swab samples showed the highest positive rate (92.9%) by real-time reverse transcription polymerase chain reaction (RT-qPCR), followed by urine (25.0%) and whole blood (7.7%) samples. Furthermore, one throat swab sample classified as equivocal by RT-qPCR was positive by conventional RT-PCR (RT-PCR). During an outbreak, it is critical to distinguish between cases with measles-like symptoms caused by wild circulating virus and those caused by vaccine-derived virus as accurately and urgently as possible because the public health response will be quite different.
   No infant deaths were observed during this outbreak, and no severe adverse events following immunization were seen among infants 6-11 months old who were given MCV as a public health response. Thus, we conclude that introduction of emergent MCV was effective and describing the characteristics of vaccine-associated measles cases during a measles outbreak will be helpful for future outbreak response efforts. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Kuba, Yumani; Kyan, Hisako; Iha, Yoshiyuki; Kato, Takashi; Oyama, Minori; Miyahira, Masato; Kakita, Tetsuya; Takara, Taketoshi; Yamauchi, Miyuki; Itokazu, Kiyomasa] Okinawa Prefectural Inst Hlth & Environm, 17-1 Kanekadan, Uruma, Okinawa 9042241, Japan.
   [Kamiya, Hajime; Sunagawa, Tomimasa] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Tokyo, Japan.
   [Kawakami, Yoshino; Nidaira, Minoru; Kudaka, Jun; Yamakawa, Munesada; Itokazu, Toru] Okinawa Prefectural Govt, Reg Hlth Div, Dept Publ Hlth & Med Care, Naha, Okinawa, Japan.
RP Kuba, Y (reprint author), Okinawa Prefectural Inst Hlth & Environm, 17-1 Kanekadan, Uruma, Okinawa 9042241, Japan.
EM kubayuma@pref.okinawa.lg.jp
CR [Anonymous], 2013, Wkly Epidemiol Rec, V88, P89
   Ashimine K., 2010, JMAJ - Japan Medical Association Journal, V53, P19
   Ashimine K, 2005, DAY JAPAN BECOMES ME
   Brugha R, 1996, EPIDEMIOL INFECT, V117, P519, DOI 10.1017/S0950268800059203
   Caceres VM, 2000, CLIN INFECT DIS, V31, P110, DOI 10.1086/313926
   Campbell H, 2007, INT J EPIDEMIOL, V36, P1334, DOI 10.1093/ije/dym207
   Center of National Institute Of Infection Diseases Ministry of Health Labour and Welfare, 2018, IASR
   Davis RL, 1997, PEDIATRICS, V100, P767, DOI 10.1542/peds.100.5.767
   Guerra FM, 2018, VACCINE, V36, P1248, DOI 10.1016/j.vaccine.2018.01.002
   Hamabata H, 2005, DAY JAPAN BECOMES ME, P116
   Kaic B, 2010, EUROSURVEILLANCE, V15, P8
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Komabayashi K, 2018, JPN J INFECT DIS, V71, P413, DOI [10.7883/yoken.JJID.2018.083, 10.7883/yoken.jjid.2018.083]
   Leuridan E, 2007, VACCINE, V25, P6296, DOI 10.1016/j.vaccine.2007.06.020
   Lochlainn LMN, 2017, VACCINE, V35, P5828, DOI 10.1016/j.vaccine.2017.09.018
   MALDONADO YA, 1995, PEDIATRICS, V96, P447
   Morfin F, 2002, VACCINE, V20, P1541, DOI 10.1016/S0264-410X(01)00495-9
   Moss WJ, 2017, LANCET, V390, P2490, DOI 10.1016/S0140-6736(17)31463-0
   Nic Lochlainn L, MEASLES VACCINATION
   Okinawa prefectural government, GUID MEASL OUTBR RES
   Roy F, 2017, J CLIN MICROBIOL, V55, P735, DOI 10.1128/JCM.01879-16
   Taiwan Center for Disease Control, 2018, TAIW CDC ADV PUBL DE
   The National Institute of Infection Diseases, MAN DET MEASL VIR VE
   van den Hof S, 2002, J INFECT DIS, V186, P1483, DOI 10.1086/344894
   Waaijenborg S, 2013, J INFECT DIS, V208, P10, DOI 10.1093/infdis/jit143
   Watanabe A, 2017, WEST PAC SURVEILL RE, V8, DOI 10.5365/wpsar.2016.7.4.007
   Wendorf KA, 2017, CLIN INFECT DIS, V65, P226, DOI 10.1093/cid/cix302
   World Health Organization, RESP MEASL OUTBR MEA
   World Health Organization, 2006, WEEKLY EPIDEMIOLOGIC, V81, P17
   World Health Organization, INF VACC SAF 2 S
   World Health Organization, GLOB MEASL RUB STRAT
   World Health Organization, 2009, IMM BAS IMM SER MOD
   World Health Organization Western Pacific Reagional Office, BUR DAR CAMB JAP VER
   Woudenberg T, 2017, EUROSURVEILLANCE, V22, P11, DOI 10.2807/1560-7917.ES.2017.22.3.30443
NR 34
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2020
VL 38
IS 10
BP 2361
EP 2367
DI 10.1016/j.vaccine.2020.01.067
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KR5KP
UT WOS:000517657600012
PM 32037227
DA 2020-05-12
ER

PT J
AU Vanderven, HA
   Barr, I
   Reynaldi, A
   Wheatley, AK
   Wines, BD
   Davenport, MP
   Hogarth, PM
   Kent, SJ
AF Vanderven, Hillary A.
   Barr, Ian
   Reynaldi, Arnold
   Wheatley, Adam K.
   Wines, Bruce D.
   Davenport, Miles P.
   Hogarth, P. Mark
   Kent, Stephen J.
TI Fc functional antibody responses to adjuvanted versus unadjuvanted
   seasonal influenza vaccination in community-dwelling older adults
SO VACCINE
LA English
DT Article
DE Influenza; vaccine; Inactivated influenza vaccine; Adjuvanted influenza
   vaccine; Hemagglutination inhibition; Antibody-dependent cellular
   cytotoxicity; Fc receptor; Older adults
ID DEPENDENT CELLULAR CYTOTOXICITY; MEDIATED CYTOTOXICITY; LONG-TERM;
   VIRUS; IMMUNOGENICITY; PROTECTION; HEMAGGLUTININ; ACTIVATION; INFECTION;
   DISEASE
AB Background: Seasonal influenza vaccination with a standard trivalent influenza vaccine (TIV) induces a modest, and cross-reactive, Fc functional antibody response in older adults. Recent improvements to influenza vaccines include a quadrivalent influenza vaccine (QIV) and a TIV adjuvanted with the squalene-based oil-in-water emulsion MF59.
   Methods: Pre- and post-vaccination serum samples from older adults vaccinated with QJV (n = 27) and adjuvanted TIV (n = 44) were studied using hemagglutination inhibition (HAI) assays and dimeric Fc-gamma receptor IIIa binding ELISAs, as a surrogate of antibody-dependent cellular cytotoxicity (ADCC).
   Results: We found that the unadjuvanted QIV elicited a stronger HAI response against the H1N1 vaccine virus than the adjuvanted TIV. Post-vaccination levels of HA-specific ADCC antibodies were similar for older adults vaccinated with QIV and adjuvanted TIV. The ADCC response to influenza vaccination was largely determined by pre-vaccination or baseline levels of these antibodies, with older adults with low baseline levels of ADCC activity demonstrating greater post-vaccination rises.
   Conclusions: In this cohort of community-dwelling older adults, the QIV was at least as good as the adjuvanted TIV in the induction of ADCC and HAI responses. Further studies on how these antibody responses translate to efficacy in preventing influenza infections are warranted. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Vanderven, Hillary A.] James Cook Univ, Coll Publ Hlth Med & Vet Sci, Biomed, Douglas, Qld, Australia.
   [Vanderven, Hillary A.; Barr, Ian; Wheatley, Adam K.; Kent, Stephen J.] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia.
   [Barr, Ian] Peter Doherty Inst Infect & Immun, WHO Collaborating Ctr Reference & Res Influenza, Melbourne, Vic, Australia.
   [Reynaldi, Arnold; Davenport, Miles P.] Univ New South Wales Australia, Kirby Inst Infect & Immun, Infect Analyt Program, Sydney, NSW, Australia.
   [Wheatley, Adam K.; Kent, Stephen J.] Univ Melbourne, Australian Res Council, Ctr Excellence Convergent Bionano Sci & Technol, Parkville, Vic, Australia.
   [Wines, Bruce D.; Hogarth, P. Mark] Burnet Inst, Immune Therapies Lab, Melbourne, Vic, Australia.
   [Kent, Stephen J.] Monash Univ, Melbourne Sexual Hlth Ctr, Clayton, Vic, Australia.
   [Kent, Stephen J.] Monash Univ, Dept Infect Dis, Alfred Hlth, Cent Clin Sch, Clayton, Vic, Australia.
RP Kent, SJ (reprint author), Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Melbourne, Vic, Australia.
EM skent@unimelb.edu.au
RI Kent, Stephen/AAL-5101-2020; Vanderven, Hillary A/Y-5768-2018
OI Kent, Stephen/0000-0002-8539-4891; 
FU Australian National Health and Medical Research CouncilNational Health
   and Medical Research Council of Australia [1052979]; James Cook
   University; Australian Government Department of HealthAustralian
   GovernmentDepartment of Health & Ageing
FX This work was supported by the Australian National Health and Medical
   Research Council (award number 1052979 to SJ.K.) and James Cook
   University (laboratory start-up funding to H.A.V.). The Melbourne WHO
   Collaborating Centre for Reference and Research on Influenza is
   supported by the Australian Government Department of Health.
CR Ansaldi F, 2008, VACCINE, V26, P1525, DOI 10.1016/j.vaccine.2008.01.019
   Arriola C, 2017, CLIN INFECT DIS, V65, P1289, DOI 10.1093/cid/cix468
   Atmar RL, 2007, VACCINE, V25, P5367, DOI 10.1016/j.vaccine.2007.05.002
   Australian Minister of Health, 2018, GROUND BREAK FLU VAC
   Bernstein DI, 2008, J INFECT DIS, V197, P667, DOI 10.1086/527489
   Bruhns P, 2012, BLOOD, V119, P5640, DOI 10.1182/blood-2012-01-380121
   Centers for Disase Control and Prevention, 2017, INFL VACC US 2017 18
   Centers for Disease Control and Prevention, 2016, EST INFL ILLN HOSP A
   Cox F, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00399
   Curtis D, 2015, VACCINE, V33, P4790, DOI 10.1016/j.vaccine.2015.07.082
   de Bruijn IA, 1999, J INFECT DIS, V179, P31, DOI 10.1086/314540
   DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727
   DiLillo DJ, 2016, J CLIN INVEST, V126, P605, DOI 10.1172/JCI84428
   DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443
   Dunand CJH, 2016, CELL HOST MICROBE, V19, P800, DOI 10.1016/j.chom.2016.05.014
   EPSTEIN SL, 1993, J IMMUNOL, V150, P5484
   Falsey AR, 2009, J INFECT DIS, V200, P172, DOI 10.1086/599790
   Foppa IM, 2015, VACCINE, V33, P3003, DOI 10.1016/j.vaccine.2015.02.042
   Frasca D, 2008, J IMMUNOL, V180, P5283, DOI 10.4049/jimmunol.180.8.5283
   Frasca D, 2010, VACCINE, V28, P8077, DOI 10.1016/j.vaccine.2010.10.023
   Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105
   Gravenstein S, 2017, LANCET RESP MED, V5, P738, DOI 10.1016/S2213-2600(17)30235-7
   GREENBERG SB, 1978, INFECT IMMUN, V20, P640, DOI 10.1128/IAI.20.3.640-645.1978
   GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008
   HASHIMOTO G, 1983, INFECT IMMUN, V42, P214, DOI 10.1128/IAI.42.1.214-218.1983
   HASHIMOTO G, 1983, J INFECT DIS, V148, P785, DOI 10.1093/infdis/148.5.785
   He WQ, 2016, P NATL ACAD SCI USA, V113, P11931, DOI 10.1073/pnas.1609316113
   Huang KYA, 2017, SCI REP-UK, V7, DOI 10.1038/srep40027
   Iob A, 2005, EPIDEMIOL INFECT, V133, P687, DOI 10.1017/S0950268805003936
   Jegaskanda S, 2016, J INFECT DIS, V214, P945, DOI 10.1093/infdis/jiw262
   Jegaskanda S, 2013, J INFECT DIS, V208, P1051, DOI 10.1093/infdis/jit294
   Jegaskanda S, 2013, J VIROL, V87, P5512, DOI 10.1128/JVI.03030-12
   Jegaskanda S, 2013, J IMMUNOL, V190, P1837, DOI 10.4049/jimmunol.1201574
   Khurana S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000624
   Kositanont U, 2012, VIRAL IMMUNOL, V25, P471, DOI 10.1089/vim.2012.0024
   Kristensen AB, 2016, J VIROL, V90, P5724, DOI 10.1128/JVI.00285-16
   Leon PE, 2016, P NATL ACAD SCI USA, V113, pE5944, DOI 10.1073/pnas.1613225113
   Monto AS, 2015, J INFECT DIS, V212, P1191, DOI 10.1093/infdis/jiv195
   Murasko DM, 2002, EXP GERONTOL, V37, P427, DOI 10.1016/S0531-5565(01)00210-8
   Nunes MC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0210124
   Ohmit SE, 2011, J INFECT DIS, V204, P1879, DOI 10.1093/infdis/jir661
   Podda A, 2001, VACCINE, V19, P2673, DOI 10.1016/S0264-410X(00)00499-0
   Song JY, 2013, J MED VIROL, V85, P1591, DOI 10.1002/jmv.23630
   Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333
   Treanor JJ, 2016, NEW ENGL J MED, V375, P1261, DOI 10.1056/NEJMcp1512870
   Tsai TF, 2013, INFECT CHEMOTHER, V45, P159, DOI 10.3947/ic.2013.45.2.159
   Van Buynder PG, 2013, VACCINE, V31, P6122, DOI 10.1016/j.vaccine.2013.07.059
   Vanderven HA, 2018, J INFECT DIS, V217, P12, DOI 10.1093/infdis/jix554
   Vanderven HA, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92750
   Vanderven HA, 2016, EBIOMEDICINE, V8, P277, DOI 10.1016/j.ebiom.2016.04.029
   Vu T, 2002, VACCINE, V20, P1831, DOI 10.1016/S0264-410X(02)00041-5
   Wang TT, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000796
   Wines BD, 2016, J IMMUNOL, V197, P1507, DOI 10.4049/jimmunol.1502551
   World Health Organization, 2018, INFL SEAS
   Yasuhara A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17986-8
NR 55
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2020
VL 38
IS 10
BP 2368
EP 2377
DI 10.1016/j.vaccine.2020.01.066
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KR5KP
UT WOS:000517657600013
PM 32035709
DA 2020-05-12
ER

PT J
AU Novotny, LA
   Bakaletz, LO
AF Novotny, Laura A.
   Bakaletz, Lauren O.
TI Transcutaneous immunization with a nontypeable Haemophilus influenzae
   dual adhesin-directed immunogen induces durable and boostable immunity
SO VACCINE
LA English
DT Article
DE Otitis media; Type IV pilus; PilA; chimV4; dmLT
ID OUTER-MEMBRANE PROTEIN; IV PILUS EXPRESSION; OTITIS-MEDIA;
   EPITHELIAL-CELLS; P5-HOMOLOGOUS ADHESIN; PASSIVE-IMMUNIZATION; VACCINE;
   NASOPHARYNX; PROTECTION; ADHERENCE
AB Otitis media (OM) is a very common pediatric disease and nontypeable Haemophilus influenzae (NTHI) is the predominant causative agent. We've developed a chimeric immunogen, chimV4, that simultaneously targets two NTHI adhesins, OMP P5 and the type IV pilus. Transcutaneous immunization (TCI) via bandaid with chimV4 plus the adjuvant dmLT provides significant protection against experimental NTHI-induced OM in chinchilla models. Herein, we now examined the durability and boostability of the induced immune response. Bandaid immunization with chimV4+dmLT followed by two sequential middle ear challenges with NTHI resulted in rapid bacterial clearance and significantly accelerated disease resolution. Moreover, TCI with chimV4+dmLT significantly increased mature B-cell phenotypes and antibody-secreting cells within nasal-associated lymphoid tissues, a response that was further augmented upon TCI two months later. Thus, bandaid immunization induced durable and boostable immunity. The simplicity and non-invasive nature of TCI with chimV4+dmLT supports its utility as a highly effective additional immunization strategy for NTHI-induced OM. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Novotny, Laura A.; Bakaletz, Lauren O.] Nationwide Childrens Hosp, Ctr Microbial Pathogenesis, Abigail Wexner Res Inst, Columbus, OH 43205 USA.
   [Bakaletz, Lauren O.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA.
RP Bakaletz, LO (reprint author), 700 Childrens Dr,W591, Columbus, OH 43205 USA.
EM lauren.bakaletz@nationwidechildrens.org
FU National Institutes of Health/National Institute on Deafness and Other
   Communication DisordersUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Deafness & Other Communication Disorders (NIDCD) [RO1 DC003915]
FX This work was funded by the National Institutes of Health/National
   Institute on Deafness and Other Communication Disorders [grant number
   RO1 DC003915] to LOB. We are grateful to Dr. John D. Clements for the
   sharing of his vast expertise in noninvasive immunization strategies,
   his guidance and collaboration throughout the development and refinement
   of TCI strategies and for generously providing dmLT. We thank Stephen L
   Toone, Dr. Kenneth L. Brockman and Joseph A. Jurcisek for technical
   assistance with chinchilla studies, Dr. Binh L Phong for critical
   manuscript review, the Animal Resource Core at the Abigail Wexner
   Research Institute at Nationwide Children's Hospital for outstanding
   chinchilla husbandry and Jennifer Neelans for assistance in manuscript
   submission.
CR Arya J, 2016, J CONTROL RELEASE, V240, P135, DOI 10.1016/j.jconrel.2015.11.019
   Avadhanula V, 2006, INFECT IMMUN, V74, P830, DOI 10.1128/IAI.74.2.830-838.2006
   Bakaletz LO, 1999, INFECT IMMUN, V67, P2746, DOI 10.1128/IAI.67.6.2746-2762.1999
   Bakaletz LO, 2005, INFECT IMMUN, V73, P1635, DOI 10.1128/IAI.73.3.1635-1643.2005
   Blais N, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00022-19
   Bookwalter JE, 2008, INFECT IMMUN, V76, P48, DOI 10.1128/IAI.00980-07
   Brandtzaeg P, 2011, AM J RESP CRIT CARE, V183, P1595, DOI 10.1164/rccm.201011-1783OC
   Brown JR, 2019, MSPHERE, V4, DOI 10.1128/mSphere.00254-19
   Carruthers MD, 2012, J BACTERIOL, V194, P1927, DOI 10.1128/JB.06540-11
   Centers for Disease Control and Prevention, 2009, REC IMM SCHED PERS A
   Cerquetti M, 2016, HUM VACC IMMUNOTHER, V12, P2357, DOI 10.1080/21645515.2016.1174354
   Clements JD, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00215-18
   Duell BL, 2016, FEBS LETT, V590, P3840, DOI 10.1002/1873-3468.12351
   Engelke L, 2015, VACCINE, V33, P4663, DOI 10.1016/j.vaccine.2015.05.012
   Giudice EL, 2006, ADV DRUG DELIVER REV, V58, P68, DOI 10.1016/j.addr.2005.12.003
   Harrison A, 2005, J BACTERIOL, V187, P4627, DOI 10.1128/JB.187.13.4627-4636.2005
   Jalalvand F, 2018, EXPERT REV VACCINES, V17, P503, DOI 10.1080/14760584.2018.1484286
   Jurcisek JA, 2003, CELLS TISSUES ORGANS, V174, P136, DOI 10.1159/000071154
   Jurcisek JA, 2007, MOL MICROBIOL, V65, P1288, DOI 10.1111/j.1365-2958.2007.05864.x
   Jurcisek JA, 2007, J BACTERIOL, V189, P3868, DOI 10.1128/JB.01935-06
   Kennedy BJ, 2000, INFECT IMMUN, V68, P2756, DOI 10.1128/IAI.68.5.2756-2765.2000
   Kiyono H, 2004, NAT REV IMMUNOL, V4, P699, DOI 10.1038/nri1439
   Kyd JM, 2003, INFECT IMMUN, V71, P4691, DOI 10.1128/IAI.71.8.4691-4699.2003
   Leroux-Roels G, 2016, VACCINE, V34, P3156, DOI 10.1016/j.vaccine.2016.04.051
   Levin C, 2015, HUM VACC IMMUNOTHER, V11, P27, DOI 10.4161/hv.34299
   Levine MM, 2011, VACCINE, V29, pD116, DOI 10.1016/j.vaccine.2011.11.090
   Marwah H, 2016, DRUG DELIV, V23, P564, DOI 10.3109/10717544.2014.935532
   Miyamoto N, 1996, MICROB PATHOGENESIS, V21, P343, DOI 10.1006/mpat.1996.0067
   Mokrzan EM, 2016, J BACTERIOL, V198, P2619, DOI 10.1128/JB.01022-15
   Murphy TF, 2015, CLIN VACCINE IMMUNOL, V22, P459, DOI 10.1128/CVI.00089-15
   Novotny LA, 2011, MUCOSAL IMMUNOL, V4, P456, DOI 10.1038/mi.2011.6
   Novotny LA, 2003, J IMMUNOL, V171, P1978, DOI 10.4049/jimmunol.171.4.1978
   Novotny LA, 2002, VACCINE, V20, P3590, DOI 10.1016/S0264-410X(02)00306-7
   Novotny LA, 2000, INFECT IMMUN, V68, P2119, DOI 10.1128/IAI.68.4.2119-2128.2000
   Novotny LA, 2006, VACCINE, V24, P4804, DOI 10.1016/j.vaccine.2006.03.021
   Novotny LA, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00563-16
   Novotny LA, 2015, CLIN VACCINE IMMUNOL, V22, P867, DOI 10.1128/CVI.00090-15
   Novotny LA, 2013, VACCINE, V31, P3417, DOI 10.1016/j.vaccine.2012.10.033
   Novotny LA, 2009, VACCINE, V28, P279, DOI 10.1016/j.vaccine.2009.08.017
   Paap CM, 1996, ANN PHARMACOTHER, V30, P1291, DOI 10.1177/106002809603001114
   Parhi R, 2015, CURR DRUG DELIV, V12, P122, DOI 10.2174/1567201811666140515145329
   Pasparakis M, 2014, NAT REV IMMUNOL, V14, P289, DOI 10.1038/nri3646
   Prymula R, 2009, EXPERT REV VACCINES, V8, P1479, DOI 10.1586/ERV.09.113
   SIRAKOVA T, 1994, INFECT IMMUN, V62, P2002, DOI 10.1128/IAI.62.5.2002-2020.1994
   Van Damme P, 2019, VACCINE, V37, P3113, DOI 10.1016/j.vaccine.2019.04.041
   Wilkinson TMA, 2019, VACCINE, V37, P6102, DOI 10.1016/j.vaccine.2019.07.100
   Ysebaert C, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00345-19
   Zheng ZC, 2018, HUM VACC IMMUNOTHER, V14, P1717, DOI 10.1080/21645515.2018.1461296
NR 48
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2020
VL 38
IS 10
BP 2378
EP 2386
DI 10.1016/j.vaccine.2020.01.052
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KR5KP
UT WOS:000517657600014
PM 32001071
DA 2020-05-12
ER

PT J
AU Lu, Y
   Landreth, S
   Liu, GQ
   Brownlie, R
   Gaba, A
   Littel-van den Hurk, SV
   Gerdts, V
   Zhou, Y
AF Lu, Yao
   Landreth, Shelby
   Liu, GuanQun
   Brownlie, Robert
   Gaba, Amit
   Littel-van den Hurk, Sylvia van Drunen
   Gerdts, Volker
   Zhou, Yan
TI Innate immunemodulator containing adjuvant formulated HA based vaccine
   protects mice from lethal infection of highly pathogenic avian influenza
   H5N1 virus
SO VACCINE
LA English
DT Article
DE Influenza A virus H5N1; Adjuvant; Recombinant HA vaccine
ID COMBINATION ADJUVANT; IMMUNOGENICITY; GLYCOSYLATION; ANTIGENICITY;
   IMMUNIZATION; RESPONSES; IMMUNITY; SAFETY
AB The highly pathogenic avian influenza (HPAI) H5N1 viruses and their spillover into the human population pose substantial economic and public health threats. Although antiviral drugs have some effect in treating influenza infection, vaccination is still the most effective intervention to prevent possible pandemic outbreaks. We have developed a novel H5 influenza vaccine to improve the world's pandemic preparedness. We produced a hemagglutinin (HA) of HPAI H5N1 virus A/Alberta/01/2014 (AB14) using both mammalian (m) and bacterial (b) expression systems. The purified recombinant proteins were formulated with a proprietary adjuvant (TriAdj) and their efficacy as vaccine candidates was evaluated in mice. Intramuscular delivery of two doses of TriAdj formulated mammalian expressed HA (m-HA/TriAdj) was shown to provide full protection against a lethal challenge of AB14 in mice. In contrast, bacterially expressed HA with TriAdj (b-HA/TriAdj), b-HA without adjuvant, and m-HA without adjuvant resulted in no protection in immunized mice. Furthermore, m-HA/TriAdj elicited significantly higher levels of balanced Th1 and Th2 responses and neutralizing antibody titres. All the mice in the m-HA/TriAdj group survived a lethal AB14 H5N1 challenge and showed no signs of disease or infection as demonstrated by no loss of body weight or detectable virus in the lungs. Our results suggest that m-HA formulated with TriAdj has potential to protect against pandemic H5N1 in the event of its cross over to the human host. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Lu, Yao; Landreth, Shelby; Liu, GuanQun; Brownlie, Robert; Gaba, Amit; Littel-van den Hurk, Sylvia van Drunen; Gerdts, Volker; Zhou, Yan] Univ Saskatchewan, Vaccine & Infect Dis Org Int Vaccine Ctr VIDO Int, Saskatoon, SK, Canada.
   [Lu, Yao; Gerdts, Volker; Zhou, Yan] Univ Saskatchewan, Western Coll Vet Med, Dept Vet Microbiol, Saskatoon, SK, Canada.
   [Littel-van den Hurk, Sylvia van Drunen] Univ Saskatchewan, Coll Med, Dept Microbiol & Immunol, Saskatoon, SK, Canada.
RP Zhou, Y (reprint author), Univ Saskatchewan, VIDO InterVac, 120 Vet Rd, Saskatoon, SK S7N 5E3, Canada.
EM yan.zhou@usask.ca
RI Liu, GuanQun L./AAJ-2681-2020
OI Liu, GuanQun L./0000-0003-2520-7625
FU Public Health Agency of Canada
FX This work was supported by Public Health Agency of Canada funding to
   Y.Z.
CR Abe Y, 2004, J VIROL, V78, P9605, DOI 10.1128/JVI.78.18.9605-9611.2004
   Altmann F, 1999, GLYCOCONJUGATE J, V16, P109, DOI 10.1023/A:1026488408951
   Andrianov AK, 2006, BIOMACROMOLECULES, V7, P394, DOI 10.1021/bm050790a
   Belshe RB, 2014, JAMA-J AM MED ASSOC, V312, P1420, DOI 10.1001/jama.2014.12609
   Benton DJ, 2018, P NATL ACAD SCI USA, V115, P10112, DOI 10.1073/pnas.1810927115
   Biesova Z, 2009, VACCINE, V27, P6234, DOI 10.1016/j.vaccine.2009.07.107
   Bright RA, 2003, VIROLOGY, V308, P270, DOI 10.1016/S0042-6822(03)00008-4
   Cohet C, 2019, VACCINE, V37, P3006, DOI 10.1016/j.vaccine.2019.04.048
   Cox RJ, 2013, HUM VACC IMMUNOTHER, V9, P405, DOI 10.4161/hv.22908
   de Vries RD, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030046
   Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320
   Fouchier RAM, 2005, J VIROL, V79, P2814, DOI 10.1128/JVI.79.5.2814-2822.2005
   Frey SE, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz107
   Garg R, 2015, VACCINE, V33, P1338, DOI 10.1016/j.vaccine.2015.01.041
   Garg R, 2014, J GEN VIROL, V95, P1043, DOI 10.1099/vir.0.062570-0
   Greenfield NJ, 2006, NAT PROTOC, V1, P2876, DOI 10.1038/nprot.2006.202
   Hutter J, 2013, J IMMUNOL, V190, P220, DOI 10.4049/jimmunol.1201060
   Jonges M, 2010, J CLIN MICROBIOL, V48, P928, DOI 10.1128/JCM.02045-09
   Karber G, 1931, N-S ARCH EX PATH PH, V162, P480, DOI 10.1007/BF01863914
   Keitel W, 2010, VACCINE, V28, P840, DOI 10.1016/j.vaccine.2009.10.019
   Krammer F, 2015, NAT REV DRUG DISCOV, V14, P167, DOI 10.1038/nrd4529
   Levast B, 2014, VACCINES-BASEL, V2, P297, DOI 10.3390/vaccines2020297
   Lin SC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020052
   Liu GQ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05745-w
   Lu Y, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020193
   Niyonsaba F, 2013, J LEUKOCYTE BIOL, V94, P159, DOI 10.1189/jlb.1012497
   Polewicz M, 2011, VACCINE, V29, P7718, DOI 10.1016/j.vaccine.2011.07.135
   Sadat SMA, 2017, VACCINE, V35, P3466, DOI 10.1016/j.vaccine.2017.05.029
   Sansyzbay AR, 2013, CLIN VACCINE IMMUNOL, V20, P1314, DOI 10.1128/CVI.00096-13
   Sato M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37830-x
   Shi ST, 2019, VACCINE, V37, P3167, DOI 10.1016/j.vaccine.2019.04.055
   Short KR, 2015, ONE HEALTH, V1, P1, DOI [10.1016/j.onehlt.2015.03.001, 10.1016/j.onehit.2015.03.001]
   Soema PC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00525
   Spearman C, 1908, BRIT J PSYCHOL, V2, P227, DOI 10.1111/j.2044-8295.1908.tb00176.x
   Sun XJ, 2017, VIROLOGY, V508, P164, DOI 10.1016/j.virol.2017.05.010
   Talaat KR, 2014, J INFECT DIS, V209, P1860, DOI 10.1093/infdis/jiu123
   Treanor JJ, 2001, VACCINE, V19, P1732, DOI 10.1016/S0264-410X(00)00395-9
   Van Kerkhove MD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014582
   Wang CC, 2009, P NATL ACAD SCI USA, V106, P18137, DOI 10.1073/pnas.0909696106
   Wang SH, 2019, VACCINE, V37, P1591, DOI 10.1016/j.vaccine.2019.02.002
   WHO, 2019, CAND VACC VIR POT TE
   WHO, 2019, CUM NUMB CONF HUM CA
   Wong SS, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0017-5
NR 43
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2020
VL 38
IS 10
BP 2387
EP 2395
DI 10.1016/j.vaccine.2020.01.051
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KR5KP
UT WOS:000517657600015
PM 32014270
DA 2020-05-12
ER

PT J
AU Matthias, KA
   Reveille, A
   Connolly, KL
   Jerse, AE
   Gao, YMS
   Bash, MC
AF Matthias, Kathryn A.
   Reveille, Alexandra
   Connolly, Kristie L.
   Jerse, Ann E.
   Gao, Yamei S.
   Bash, Margaret C.
TI Deletion of major porins from meningococcal outer membrane vesicle
   vaccines enhances reactivity against heterologous serogroup B Neisseria
   meningitidis strains
SO VACCINE
LA English
DT Article
DE Neisseria meningitidis; serogroup B; OMV; Porin; Vaccine; Bactericidal
   antibody
ID ANTIBODY-BINDING; BACTERICIDAL ANTIBODIES; PHASE VARIATION;
   IMMUNOGENICITY; PORA; PROTEIN; SAFETY; CHILDREN; DISEASE; HETEROGENEITY
AB Detergent-extracted detoxified outer membrane vesicle (dOMV) vaccines are effective at preventing invasive serogroup B meningococcal (MenB) disease caused by the homologous Neisseria meningitidis strain from which they are produced, but offer limited protection from heterologous strains. Differences in vaccine efficacy are partially due to strain-specific variations in the antigenic sequence types and expression levels of outer membrane proteins (OMPs), including the immunodominant OMP PorA. In this study, dOMV vaccines deficient in major OMPs, including PorA, PorB, and RmpM were isolated and used to immunize rabbits and mice. Serum samples were obtained from each animal and tested for antibody responses against five MenB strains. Immunization with wild type dOMVs elicited antibodies to major antigens including PorA, PorB, RmpM, and lipooligosaccharide (LOS), and demonstrated limited bactericidal activity against heterologous strains. In contrast, OMP-deficient dOMV vaccines elicited broadly cross-reactive bactericidal antibodies, with PorA/PorB-dual deficient dOMVs inducing antibodies exhibiting the greatest cross-reactivity. Enhanced killing of heterologous strains correlated with binding to unique protein bands in immunoblots, suggestive of improved immunogenicity of antigens under-represented in the wild type vaccine. Published by Elsevier Ltd.
C1 [Matthias, Kathryn A.; Reveille, Alexandra; Bash, Margaret C.] US FDA, Lab Bacterial Polysaccharides, Div Bacterial Parasit & Allergen Prod, Ctr Biol Evaluat & Res, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA.
   [Connolly, Kristie L.; Jerse, Ann E.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.
   [Gao, Yamei S.] US FDA, Ctr Biol Evaluat, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA.
   [Gao, Yamei S.] US FDA, Res Electron Microscopy Lab, Div Viral Prod, Ctr Biol Evaluat & Res, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA.
RP Bash, MC (reprint author), US FDA, Lab Bacterial Polysaccharides, Div Bacterial Parasit & Allergen Prod, Ctr Biol Evaluat & Res, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA.
EM kathryn.matthias@fda.hhs.gov; alexandra.reveille@fda.hhs.gov;
   kristie.connolly.ctr@usuhs.edu; annjerse1@usuhs.edu;
   yamei.gao@fda.hhs.gov; margaret.bash@fda.hhs.gov
FU National Institutes of Allergy and Infectious DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [AAI14024-001-03000, AAI14024-001 -03002]
FX This work was supported by the National Institutes of Allergy and
   Infectious Diseases [interagency agreement numbers AAI14024-001-03000,
   AAI14024-001 -03002 to A. E. J.].
CR Alcala B, 2004, J MED MICROBIOL, V53, P515, DOI 10.1099/jmm.0.05517-0
   Arigita C, 2003, VACCINE, V21, P950, DOI 10.1016/S0264-410X(02)00546-7
   BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S
   Boutriau D, 2007, CLIN VACCINE IMMUNOL, V14, P65, DOI 10.1128/CVI.00230-06
   Caron F, 2011, LANCET INFECT DIS, V11, P455, DOI 10.1016/S1473-3099(11)70027-5
   Cartwright K, 1999, VACCINE, V17, P2612, DOI 10.1016/S0264-410X(99)00044-4
   Christodoulides M, 2017, PATHOG DIS, V75, DOI 10.1093/femspd/ftx033
   de Kleijn ED, 2001, J INFECT DIS, V184, P98, DOI 10.1086/320993
   de Kleijn ED, 2000, VACCINE, V18, P1456, DOI 10.1016/S0264-410X(99)00423-5
   DEMORAES JC, 1992, LANCET, V340, P1074
   Donets M, 2008, 16 INT PATH NEISS C
   FINNE J, 1987, J IMMUNOL, V138, P4402
   Frasch CE, 2003, MED INTELL UNIT, P229
   FREDRIKSEN J H, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P67
   Fukasawa LO, 2004, FEMS IMMUNOL MED MIC, V41, P205, DOI 10.1016/j.femsim.2004.03.005
   Gorringe AR, 2009, CLIN VACCINE IMMUNOL, V16, P1113, DOI 10.1128/CVI.00118-09
   Granoff DM, 2010, CLIN INFECT DIS, V50, pS54, DOI 10.1086/648966
   Granoff DM, 2009, VACCINE, V27, pB117, DOI 10.1016/j.vaccine.2009.04.066
   HITCHCOCK PJ, 1983, J BACTERIOL, V154, P269, DOI 10.1128/JB.154.1.269-277.1983
   Klimentova J, 2015, MICROBIOL RES, V170, P1, DOI 10.1016/j.micres.2014.09.006
   Koeberling O, 2008, J INFECT DIS, V198, P262, DOI 10.1086/589308
   Koeberling O, 2009, CLIN VACCINE IMMUNOL, V16, P156, DOI 10.1128/CVI.00403-08
   MANDRELL RE, 1984, J IMMUNOL METHODS, V67, P1, DOI 10.1016/0022-1759(84)90080-2
   Matthias KA, 2017, MOL MICROBIOL, V105, P934, DOI 10.1111/mmi.13747
   Nagaputra JC, 2014, CLIN VACCINE IMMUNOL, V21, P234, DOI 10.1128/CVI.00561-13
   Oliver KJ, 2002, INFECT IMMUN, V70, P3621, DOI 10.1128/IAI.70.7.3621-3626.2002
   Peeters CCAM, 1996, VACCINE, V14, P1009, DOI 10.1016/0264-410X(96)00001-1
   Petousis-Harris H, 2018, HUM VACC IMMUNOTHER, V14, P1058, DOI 10.1080/21645515.2017.1381810
   Prevention UCfDCa, 2018, ENHANCED MENINGOCOCC
   QI HL, 1994, INFECT IMMUN, V62, P2432, DOI 10.1128/IAI.62.6.2432-2439.1994
   Sandbu S, 2007, CLIN VACCINE IMMUNOL, V14, P1062, DOI 10.1128/CVI.00094-07
   SIERRA G V G, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P195
   Steeghs L, 2004, J ENDOTOXIN RES, V10, P113, DOI 10.1179/096805104225004059
   Tan K, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00783
   Tappero JW, 1999, JAMA-J AM MED ASSOC, V281, P1520, DOI 10.1001/jama.281.16.1520
   Tauseef I, 2013, INFECT IMMUN, V81, P1374, DOI 10.1128/IAI.01358-12
   van der Ende A, 2003, J INFECT DIS, V187, P869, DOI 10.1086/367899
   van der Pol L, 2015, BIOTECHNOL J, V10, P1689, DOI 10.1002/biot.201400395
   VanDerVoort ER, 1996, INFECT IMMUN, V64, P2745, DOI 10.1128/IAI.64.7.2745-2751.1996
   WEDEGE E, 1988, J IMMUNOL METHODS, V113, P51, DOI 10.1016/0022-1759(88)90381-X
   Weynants V, 2009, INFECT IMMUN, V77, P2084, DOI 10.1128/IAI.01108-08
   Weynants VE, 2007, INFECT IMMUN, V75, P5434, DOI 10.1128/IAI.00411-07
   Wong S, 2007, PEDIATR INFECT DIS J, V26, P345, DOI 10.1097/01.inf.0000258697.05341.2c
   WYLE FA, 1972, J INFECT DIS, V126, P514, DOI 10.1093/infdis/126.5.514
   Zhang L, 2016, VACCINE, V34, P4250, DOI 10.1016/j.vaccine.2016.05.049
NR 45
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2020
VL 38
IS 10
BP 2396
EP 2405
DI 10.1016/j.vaccine.2020.01.038
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KR5KP
UT WOS:000517657600016
PM 32037226
DA 2020-05-12
ER

PT J
AU Muhsen, K
   Haklai, Z
   Applbaum, Y
   Gordon, ES
   Shteiman, A
   Glatman-Freedman, A
   Leshem, E
AF Muhsen, Khitam
   Haklai, Ziona
   Applbaum, Yael
   Gordon, Ethel-Sherry
   Shteiman, Ada
   Glatman-Freedman, Aharona
   Leshem, Eyal
TI Effects of rotavirus vaccine on all-cause acute gastroenteritis and
   rotavirus hospitalizations in Israel: A nationwide analysis
SO VACCINE
LA English
DT Article
DE Rotavirus vaccines; Acute gastroenteritis; Hospitalizations; Impact;
   Israel
ID CHILDREN LESS-THAN-5 YEARS; UNIVERSAL IMMUNIZATION; IMPACT; AGE;
   MORTALITY; EFFICACY; SAFETY; BURDEN
AB Background: In December 2010, the pentavalent rotavirus vaccine (RotaTeq) was added to the national immunization program in Israel. The study aim was to examine national reductions in all-cause acute gastroenteritis (AGE) and rotavirus gastroenteritis (RVGE) hospitalizations among children aged 0-59 months following the introduction of universal rotavirus immunization in Israel.
   Methods: We extracted data from the Israel National Hospital Discharge Database. Hospitalization rates were calculated by dividing the annual number of all-cause AGE and RVGE hospitalizations by the number of children aged 0-59 months residing Israel. To assess rate reductions, we compared the mean hospitalization rate for the pre-vaccine years (2002-2008) with that for the universal vaccination years (2011-2017). Interrupted time-series analyses were undertaken. During 2008-2010 rotavirus vaccines were partially available.
   Results: A total of 131,116 AGE hospitalizations were reported, of which 13,111 (10.0%) were coded as RVGE hospitalizations. The average annual all-cause AGE hospitalization rate during the pre-vaccine period was 147.9 (95% CI 146.7-149.0) per 10,000 children aged 0-59 months, and declined by 38.7-53.0% during the universal vaccination years. The average annual pre-vaccine RVGE hospitalization rate was 16.9 (95% CI 16.5-17.3) per 10,000 children, and declined by 89.1% during 2016-2017.
   Findings from interrupted time-series analyses showed significant impact of introducing universal rotavirus immunization on the declines of all-cause AGE and RVGE hospitalizations rates. A multivariable Autoregressive Integrated Moving Average model showed that the variable "immunization period" was a significant predictor of RVGE hospitalizations (t = 7.3, p < 0.001) for the universal vaccination years.
   The declines in hospitalizations rates of all-cause AGE were lower among Arab children compared to Jewish children, but the declines in RVGE rates were similar between the groups.
   Conclusions: National hospitalization data demonstrated substantial and consistent reductions in all-cause AGE and RVGE hospitalizations following the implementation of universal rotavirus vaccination program. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Muhsen, Khitam; Glatman-Freedman, Aharona] Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Dept Epidemiol & Prevent Med, IL-6139001 Tel Aviv, Israel.
   [Haklai, Ziona; Applbaum, Yael; Gordon, Ethel-Sherry; Shteiman, Ada] Israel Minist Hlth, Div Hlth Informat, Jerusalem, Israel.
   [Glatman-Freedman, Aharona] Israel Minist Hlth, Israel Ctr Dis Control, Ramat Gan, Israel.
   [Leshem, Eyal] Sheba Med Ctr, Div Infect Dis, Ramat Gan, Israel.
   [Leshem, Eyal] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
RP Muhsen, K (reprint author), Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Dept Epidemiol & Prevent Med, IL-6139001 Tel Aviv, Israel.
EM kmuhsen@tauex.tau.ac.il
CR Armah GE, 2010, LANCET, V376, P606, DOI 10.1016/S0140-6736(10)60889-6
   Badur S, 2019, HUM VACC IMMUNOTHER, P1
   Banajeh SM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1165-8
   Benhafid M, 2015, J MED VIROL, V87, P944, DOI 10.1002/jmv.24122
   Burnett E, 2017, J INFECT DIS, V215, P1666, DOI 10.1093/infdis/jix186
   Feldman M, 2014, EC CHARACTERISTICS U
   Sanchez FG, 2016, HUM VACC IMMUNOTHER, V12, P1035, DOI 10.1080/21645515.2015.1118592
   Givon-Lavi N, 2015, VACCINE, V33, P1934, DOI 10.1016/j.vaccine.2015.02.062
   Gurovich N, 2004, ULTRAORTHODOX JEWS G
   Haklai Z, 2014, STUD HEALTH TECHNOL, V197, P59, DOI 10.3233/978-1-61499-389-6-59
   Hegazi MA, 2017, MEDICINE, V96
   Hungerford D, 2018, BMC MED, V16, DOI 10.1186/s12916-017-0989-z
   International vaccine access center (IVAC), 2017, VIEW HUB REP GLOB VA
   Israel Central Bureau of Statistics, 2016, STAT ABSTR ISR 2016
   Israel Central Bureau of Statistics, 2013, SEL DEM CHAR POP REL
   Leshem E, 2018, J PEDIAT INF DIS SOC, V7, P257, DOI 10.1093/jpids/pix057
   Leshem E, 2015, JAMA-J AM MED ASSOC, V313, P2282, DOI 10.1001/jama.2015.5571
   Muhsen K, 2018, CLIN MICROBIOL INFEC, V24, P53, DOI 10.1016/j.cmi.2017.04.018
   Muhsen K, 2015, EURO SURVEILL, V20
   Muhsen K, 2017, HUM VACC IMMUNOTHER, V13, P1722, DOI 10.1080/21645515.2017.1297908
   Muhsen K, 2016, VACCINE, V34, P5916, DOI 10.1016/j.vaccine.2016.10.021
   Muhsen K, 2015, HUM VACC IMMUNOTHER, V11, P2475, DOI 10.1080/21645515.2015.1056951
   Muhsen K, 2009, J INFECT DIS, V200, pS254, DOI 10.1086/605425
   Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I
   Pindyck T, 2018, EXPERT REV VACCINES, V17, P593, DOI 10.1080/14760584.2018.1489724
   PORATH A, 1995, INT J QUAL HEALTH C, V7, P281, DOI 10.1093/intqhc/7.3.281
   Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434
   Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013
   Troeger C, 2018, LANCET INFECT DIS, V18, P1211, DOI 10.1016/S1473-3099(18)30362-1
   Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664
   WHO, 2019, WHO VACC PREV DIS MO
   World Health Organization Immunization, 2017, VACC NAT IMM PROGR U
   Zaki A, 2017, ARAB J GASTROENTEROL, V18, P140, DOI 10.1016/j.ajg.2017.09.008
   Zaman K, 2010, LANCET, V376, P615, DOI 10.1016/S0140-6736(10)60755-6
NR 34
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2020
VL 38
IS 10
BP 2406
EP 2415
DI 10.1016/j.vaccine.2020.01.034
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KR5KP
UT WOS:000517657600017
PM 32029322
DA 2020-05-12
ER

PT J
AU Boyle, J
   Berman, L
   Nowak, GJ
   Iachan, R
   Middleton, D
   Deng, YY
AF Boyle, John
   Berman, Lew
   Nowak, Glen J.
   Iachan, Ronaldo
   Middleton, Deirdre
   Deng, Yangyang
TI An assessment of parents' childhood immunization beliefs, intentions,
   and behaviors using a smartphone panel
SO VACCINE
LA English
DT Article
DE Survey research; Nonprobability sampling; Vaccine hesitancy; Attitudes
   and beliefs
ID INFLUENZA VACCINATION COVERAGE; UNITED-STATES; ATTITUDES
AB Introduction: It is important to quickly identify parent beliefs, intentions, and behaviors toward childhood vaccination, especially parents of children 19 to 35 months. This paper describes parental immunization beliefs, intentions, and behaviors; assesses the relationships between beliefs and intentions regarding child immunization and actual behaviors; and assesses whether beliefs, intentions, and/or behaviors varied across demographic subgroups.
   Methods: A sample of parents, ages 18 and older, from a mobile panel with people residing in the U.S. were invited to answer immunization behavior, intention, and belief questions using a smartphone app that was not vaccine specific. 10,000 panel members with a child under 18 were sent invitations. 1029 surveys were completed by a respondent with a child 19 to 35 months. The survey instrument replicated many NIS questions and had similar sequencing.
   Findings: Respondents reported that most children received all recommended vaccines, except flu vaccine, suggesting some may not understand the immunization schedule. Demographics closely associated with immunization behaviors were respondents' education and household income. There is strong agreement that vaccines are effective, important to community health, and the child's health. There is concern about the number of shots received, disease prevention, and ingredient safety. Some belief remains about vaccines causing learning disabilities. Positive beliefs about the benefits of childhood vaccines and concomitant risks vary with demographics.
   Conclusions: This survey provided insights into beliefs and behaviors of parents regarding childhood vaccination. It found evidence of differences in beliefs, particularly related to delaying or declining recommended childhood vaccinations. The survey was conducted in a few days and at lower cost than traditional methods. This serves as a model for health agencies where rapid results or inexpensive approaches are needed. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Boyle, John; Berman, Lew; Iachan, Ronaldo; Middleton, Deirdre; Deng, Yangyang] ICF, 530 Gaither Rd,Suite 500, Rockville, MD 20850 USA.
   [Nowak, Glen J.] Univ Georgia, Grady Coll, Ctr Hlth & Risk Commun, 120 Hooper St, Athens, GA 30047 USA.
RP Middleton, D (reprint author), 530 Gaither Rd,Suite 500, Rockville, MD 20850 USA.
EM Deirdre.Middleton@icf.com
OI Nowak, Glen/0000-0002-9153-2189
CR [Anonymous], INT TECHN MOB FACT S
   Atkinson KM, 2016, HUM VACC IMMUNOTHER, V12, P2654, DOI 10.1080/21645515.2016.1194146
   Bednarczyk RA, 2018, HEALTH PSYCHOL, V37, P316, DOI 10.1037/hea0000596
   Black CL, 2017, MMWR-MORBID MORTAL W, V66, P1009, DOI 10.15585/mmwr.mm6638a1
   Ding H, 2017, MMWR-MORBID MORTAL W, V66, P1016, DOI 10.15585/mmwr.mm6638a2
   Frew PM, 2019, VACCINE, V37, P325, DOI 10.1016/j.vaccine.2018.09.043
   Gibson DG, 2017, LANCET GLOB HEALTH, V5, pE428, DOI [10.1016/S2214-109X(17)30072-4, 10.1016/s2214-109x(17)30072-4]
   Kazi AM, 2017, LANCET GLOB HEALTH, V5, pE377, DOI 10.1016/S2214-109X(17)30088-8
   Kennedy A, 2011, PEDIATRICS, V127, pS92, DOI 10.1542/peds.2010-1722N
   National Immunization Survey, 2018, NATL IMMUNIZATION SU
   Opel DJ, 2011, HUM VACCINES, V7, P419, DOI 10.4161/hv.7.4.14120
   Orenstein WA, 2015, PUBLIC HEALTH REP, V130, P573
   Quinn SC, 2019, HUM VACC IMMUNOTHER, DOI 10.1080/21645515.2019.1646578
   Sanders C, 2019, J HLTH SOC SCI, V4, P149
NR 14
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2020
VL 38
IS 10
BP 2416
EP 2423
DI 10.1016/j.vaccine.2020.01.032
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KR5KP
UT WOS:000517657600018
PM 32035710
OA Other Gold
DA 2020-05-12
ER

PT J
AU Lasseter, G
   Al-Janabi, H
   Trotter, CL
   Carroll, FE
   Christensen, H
AF Lasseter, G.
   Al-Janabi, H.
   Trotter, C. L.
   Carroll, F. E.
   Christensen, H.
TI Understanding the role of peace of mind in childhood vaccination: A
   qualitative study with members of the general public
SO VACCINE
LA English
DT Article
DE Vaccination; Peace of mind; Public opinion; Health Belief Model;
   Qualitative; Focus group
ID HEALTH BELIEF MODEL; INFLUENZA; DETERMINANTS; VACCINES
AB Background: Recent debates on the introduction of new childhood vaccines in the UK have suggested that 'peace of mind' (PoM) might influence decision making. The aim of this study is to ascertain the importance of 'PoM' in individuals' decision making.
   Methods: Four focus groups were conducted in the UK. Participants were 22 females and 2 males, aged 18-74 years, with a selection of non-parents, parents, guardians and foster carers. Data were analysed using an inductive thematic framework approach and conceptualised using the Health Belief Model, which provided an overview of participants' perceptions and behaviours about childhood vaccinations.
   Results: Vaccine associated PoM was associated with individuals' perceptions of disease severity, with individuals feeling more reassurance after obtaining vaccinations against diseases that they considered to be severe compared to relatively mild diseases. Conversely, concerns about vaccination side-effects reduced participants PoM, but the duration of this effect varied between individuals. Other factors, such as social pressure and the emotional anxiety related to children's feelings, or physical reactions, to vaccinations also negatively impacted on participants' vaccine associated PoM.
   Conclusion: Vaccine associated PoM was a consideration for some participants seeking vaccinations but was only a minor motivating factor for these individuals. These differences stemmed from whether participants received PoM from the uptake of a vaccination because they perceived some intrinsic benefit from it or, conversely, they considered vaccinations as a routine health intervention. Overall, vaccine related PoM varied between participants in magnitude and fluctuated over time, even in the same individuals. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Lasseter, G.; Christensen, H.] Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, Avon, England.
   [Al-Janabi, H.] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England.
   [Trotter, C. L.] Univ Cambridge, Dept Vet Med, Cambridge, England.
   [Carroll, F. E.] Royal Coll Obstetricians & Gynaecologists, London, England.
RP Lasseter, G (reprint author), Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, Avon, England.
EM gemma.lasseter@bristol.ac.uk
FU Meningitis Research FoundationMeningitis Research Foundation (MRF)
   [1506.1]; National Institute for Health Research Health Protection
   Research Unit (NIHR HPRU) in Evaluation of Interventions at the
   University of Bristol; Public Health England; NIHR Career Development
   Fellowship [CDF-15-08-025]
FX This work was supported by the Meningitis Research Foundation (grant
   number 1506.1) via a charitable donation from Pfizer Limited. GL, HC and
   CT are supported by the National Institute for Health Research Health
   Protection Research Unit (NIHR HPRU) in Evaluation of Interventions at
   the University of Bristol in partnership with Public Health England. HA
   is supported by a NIHR Career Development Fellowship (CDF-15-08-025).
   The views expressed are those of the author(s) and not necessarily those
   of the NHS, the NIHR, the Department of Health or Public Health England.
CR [Anonymous], 2016, COST EFFECTIVENESS M
   Beutels P, 2008, LANCET INFECT DIS, V8, P727, DOI 10.1016/S1473-3099(08)70258-5
   Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107
   Blagden S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181817
   Bond L, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-943
   Boyatzis R. E., 1998, TRANSFORMING QUALITA
   Bricout H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220230
   Ferrer HB, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-700
   Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117
   Gallagher S, 2006, J PUBLIC HEALTH-UK, V28, P139, DOI 10.1093/pubmed/fdl008
   GLASER BG, 1965, SOC PROBL, V12, P436, DOI 10.1525/sp.1965.12.4.03a00070
   Gorjana R, 2017, PREV MED, V95, P26, DOI 10.1016/j.ypmed.2016.11.019
   Gravetter F. J., 2012, RES METHODS BEHAV SC
   Herdman M, 2016, VALUE HEALTH, V19, P255, DOI 10.1016/j.jval.2015.11.003
   Hilyard KM, 2014, HEALTH EDUC BEHAV, V41, P307, DOI 10.1177/1090198113515244
   Hounsome L, 2018, INT BREASTFEED J, V13, DOI 10.1186/s13006-018-0145-1
   JANZ NK, 1984, HEALTH EDUC QUART, V11, P1, DOI 10.1177/109019818401100101
   Jit M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0446-9
   Jones CL, 2015, HEALTH COMMUN, V30, P566, DOI 10.1080/10410236.2013.873363
   KITZINGER J, 1995, BRIT MED J, V311, P299, DOI 10.1136/bmj.311.7000.299
   Lasseter G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197374
   Leask J, 2001, AUST NZ J PUBL HEAL, V25, P152, DOI 10.1111/j.1753-6405.2001.tb01838.x
   [Meningitis Research Foundation Committee P. UK], 2018, WRITT EV SUBM MEN RE
   Meszaros JR, 1996, J CLIN EPIDEMIOL, V49, P697, DOI 10.1016/0895-4356(96)00007-8
   Ozawa S, 2016, HEALTH AFFAIR, V35, P199, DOI 10.1377/hlthaff.2015.1086
   Park M, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1130-7
   Patton M.Q., 2002, QUALITATIVE RES EVAL
   Patty NJS, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4879-2
   Poland CM, 2011, VACCINE, V29, P6145, DOI 10.1016/j.vaccine.2011.07.131
   Rabiee F, 2004, P NUTR SOC, V63, P655, DOI 10.1079/PNS2004399
   Ritchie J., 2003, QUALITATIVE RES PRAC
   Sadique MZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054149
   Serpell L, 2006, VACCINE, V24, P4041, DOI 10.1016/j.vaccine.2006.02.037
   Setbon M, 2010, EUR J PUBLIC HEALTH, V20, P490, DOI 10.1093/eurpub/ckq054
   Smith PJ, 2011, PUBLIC HEALTH REP, V126, P135, DOI 10.1177/00333549111260S215
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042
NR 36
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 28
PY 2020
VL 38
IS 10
BP 2424
EP 2432
DI 10.1016/j.vaccine.2019.12.009
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KR5KP
UT WOS:000517657600019
PM 32033847
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Azman, AS
   Moore, SM
   Lessler, J
AF Azman, Andrew S.
   Moore, Sean M.
   Lessler, Justin
TI Surveillance and the global fight against cholera: Setting priorities
   and tracking progress
SO VACCINE
LA English
DT Article
C1 [Azman, Andrew S.; Lessler, Justin] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA.
   [Moore, Sean M.] Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA.
   [Moore, Sean M.] Univ Notre Dame, Eck Inst Global Hlth, Notre Dame, IN 46556 USA.
RP Azman, AS (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA.
EM azman@jhu.edu
OI Azman, Andrew/0000-0001-8662-9077; Lessler, Justin/0000-0002-9741-8109
FU Bill & Melinda Gates Foundation, Seattle, WAGates Foundation
   [OPP1171700, OPP1191944]; National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [R01 AI135115]
FX This work was supported by the Bill & Melinda Gates Foundation, Seattle,
   WA [OPP1171700], [OPP1191944] and National Institutes of Health (R01
   AI135115).
CR [Anonymous], 2015, WKLY EPIDEMIOL REC, V91, P433
   Bi Q, 2017, LANCET INFECT DIS, DOI [10.1016/S1473-3099(17)30359-6, DOI 10.1061/S1473-3099(17)30359-6]
   Global Task Force for Cholera Control, 2017, END CHOL
   Lessler J, 2018, LANCET, V391, P1908, DOI [10.1016/S0140-6736(17)33050-7, 10.1016/s0140-6736(17)33050-7]
   Luquero FJ, 2016, EMERG INFECT DIS, V22, P410, DOI 10.3201/eid2203.141970
   Matapo B, 2016, MED J ZAMBIA, V43, P116
   Organization WH, 2016, WORLD MAL REP 2015
   POLLITZER R, 1954, Bull World Health Organ, V10, P421
   Pullan RL, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001626
   WHO, 2011, PREV CONTR CHOL OUTB
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A28
EP A30
DI 10.1016/j.vaccine.2019.06.037
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500007
PM 31266671
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Chatterjee, P
   Kanungo, S
   Bhattacharya, SK
   Dutta, S
AF Chatterjee, Pranab
   Kanungo, Suman
   Bhattacharya, Sujit K.
   Dutta, Shanta
TI Mapping cholera outbreaks and antibiotic resistant Vibrio cholerae in
   India: An assessment of existing data and a scoping review of the
   literature
SO VACCINE
LA English
DT Review
DE Cholera; Vibrio; Outbreaks; Antibiotics; Antimicrobials; Antimicrobial
   resistance; Oral cholera vaccines
ID DOUBLE-BLIND; DIARRHEA; KOLKATA; THERAPY; VACCINE; BURDEN; EFFICACY;
   SLUMS
AB Although fluid and electrolyte replenishment remains the mainstay of clinical management of cholera, antibiotics are an important component of the strategy for clinical management of moderate to severe cases of cholera. The emergence of antibiotic resistance (ABR) in Vibrio cholerae has led to difficulties in case management. The past decade has also seen the development of cheap and effective oral cholera vaccines (OCVs). In addition to the two-dose strategy for widespread immunization, OCVs have also been shown to be effective in containing outbreaks using a single-dose schedule. In this scoping review we map the states and union territories (SUTs) of India which are prone to cholera outbreaks followed by a scoping review of peer-reviewed publications about ABR outbreaks of cholera employing the Arksey and O'Malley framework. Using the data reported by the Integrated Disease Surveillance Program (IDSP), we identified 559 outbreaks of cholera between 2009 and 2017, affecting 27 SUTs. We defined SUTs which had reported outbreaks in at least three out of the last five years (2012-2016) or had experienced two or more outbreaks in the same year in at least two of the last five years to be outbreak-prone. The scoping review identified 62 ABR outbreaks, with four SUTs accounting for two-thirds of them: West Bengal (14), Maharashtra (10), Odisha (10) and Delhi (7). Overall, this scoping review suggests that there is an increasing trend of ABR in Vibrio cholerae isolated from outbreaks in India. This opens up avenues for exploring the role of antibiotic stewardship in the clinical management of diarrhea, the institution of vaccination as an infection prevention intervention to reduce selection pressure, and the deployment of high quality surveillance systems which report accurate, real-time data allowing appropriate and timely public health responses. It is crucial to counter the issue of ABR in cholera before it assumes a menacing magnitude. (C) 2019 Published by Elsevier Ltd.
C1 [Chatterjee, Pranab; Kanungo, Suman] Indian Council Med Res, Natl Inst Cholera & Enter Dis, Div Epidemiol, P-33 CIT Rd, Kolkata 700010, India.
   [Bhattacharya, Sujit K.] Glocal Hosp, Krishnanagore, W Bengal, India.
   [Dutta, Shanta] Indian Council Med Res, Natl Inst Cholera & Enter Dis, Div Bacteriol, Kolkata, India.
   [Dutta, Shanta] Indian Council Med Res, Natl Inst Cholera & Enter Dis, P-33 CIT Rd, Kolkata 700010, India.
RP Kanungo, S (reprint author), ICMR, Natl Inst Cholera & Enter Dis, P-33 CIT Rd, Kolkata 700010, India.
EM pranab.chatterjee@icmr.gov.in; sumankanungo@gmail.com
RI Chatterjee, Pranab/P-6272-2017
OI Chatterjee, Pranab/0000-0001-6443-608X; Dutta,
   Shanta/0000-0002-6897-7390
CR Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832
   Arksey H, 2005, INT J SOC RES METHOD, V8, P19, DOI DOI 10.1080/1364557032000119616
   Azman AS, 2016, LANCET GLOB HEALTH, V4, pE856, DOI 10.1016/s2214-109x(16)30211-x
   Azman AS, 2016, NEW ENGL J MED, V375, DOI 10.1056/NEJMc1607285
   Bergstrom CT, 2004, P NATL ACAD SCI USA, V101, P13285, DOI 10.1073/pnas.0402298101
   Bhattacharya S, 2013, LANCET INFECT DIS, V13, P1050, DOI 10.1016/S1473-3099(13)70273-1
   Central Bureau of Health Intelligence, NAT HLTH PROF 2005
   Chauhan AS, 2018, ANTIMICROB RESIST IN, V7, DOI 10.1186/s13756-018-0354-9
   Das B, 2020, VACCINE, V38, pA83, DOI 10.1016/j.vaccine.2019.06.031
   Daudt HML, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-48
   Dellit TH, 2007, CLIN INFECT DIS, V44, P159, DOI 10.1086/510393
   Doron S, 2011, MAYO CLIN PROC, V86, P1113, DOI 10.4065/mcp.2011.0358
   Dutta D, 2013, EMERG INFECT DIS, V19, P464, DOI 10.3201/eid1903.121156
   Ganguly NK, 2011, INDIAN J MED RES, V134, P281
   Garg P, 2000, EPIDEMIOL INFECT, V124, P393, DOI 10.1017/S0950268899003957
   Ginsburg AS, 2017, LANCET GLOB HEALTH, V5, pE1176, DOI 10.1016/S2214-109X(17)30364-9
   Global Task Force on Cholera Control, 2017, END CHOL GLOB ROADM
   Gore SM, 1992, BMJ-BRIT MED J, V304
   Guerrant RL, 2003, CLIN INFECT DIS, V37, P398, DOI 10.1086/376619
   HAYASHI F, 1982, MICROBIOL IMMUNOL, V26, P479, DOI 10.1111/j.1348-0421.1982.tb00201.x
   Integrated Disease Surveillance Project, 2008, TRAIN MAN STAT DISTR
   Kakkar M, 2017, BMJ-BRIT MED J, V358, P25, DOI 10.1136/bmj.j2687
   Kanungo S, 2014, EPIDEMIOL INFECT, V142, P314, DOI 10.1017/S0950268813001076
   Kanungo S, 2010, B WORLD HEALTH ORGAN, V88, P185, DOI 10.2471/BLT.09.073460
   Kelly-Hope LA, 2008, EMERG INFECT DIS, V14, P1004, DOI 10.3201/eid1406.080027
   Khuntia HK, 2010, J MICROBIOL IMMUNOL, V43, P133, DOI 10.1016/S1684-1182(10)60021-7
   Kitaoka M, 2011, J MED MICROBIOL, V60, P397, DOI 10.1099/jmm.0.023051-0
   Kotwani A, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-99
   Kotwani A, 2010, FAM PRACT, V27, P684, DOI 10.1093/fampra/cmq059
   Kuwahara S, 1978, Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi, V11, P99
   Kyaw MH, 2006, NEW ENGL J MED, V354, P1455, DOI 10.1056/NEJMoa051642
   Lee CR, 2013, INT J ENV RES PUB HE, V10, P4274, DOI 10.3390/ijerph10094274
   Leibovici-Weissman Y, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008625.pub2
   Letchumanan V, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00033
   Letchumanan V, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01417
   Levac D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-69
   LINDENBA.J, 1967, B WORLD HEALTH ORGAN, V36, P871
   LINDENBAUM J, 1967, B WORLD HEALTH ORGAN, V37, P529
   Lipsitch M, 2016, MBIO, V7, DOI 10.1128/mBio.00428-16
   Longini IM, 2007, PLOS MED, V4, P1776, DOI 10.1371/journal.pmed.0040336
   Manjusha S., 2011, INT FOOD RES J, V18, P1171
   Munn Z, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0611-x
   Murugaiah C, 2011, CRIT REV MICROBIOL, V37, P337, DOI 10.3109/1040841X.2011.603288
   Musekiwa A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003754.pub3
   Nair GB, 2010, GUT PATHOG, V2, DOI 10.1186/1757-4749-2-4
   National Centre for Disease Control, 2017, IMPL SUMM REP DEPUY
   National Centre for Disease Control DG of HS, NAT CTR DIS CONTR DG
   Nelson EJ, 2011, NEW ENGL J MED, V364, P5, DOI 10.1056/NEJMp1013771
   ONeill J, 2016, REV ANTIMICROBIAL RE
   Pan-American Health Organization World Health Organization, PAHO WHO EXP CONS PA
   Panda S, 2020, VACCINE, V38, pA148, DOI 10.1016/j.vaccine.2019.07.029
   Parker LA, 2017, LANCET INFECT DIS, V17, pE123, DOI 10.1016/S1473-3099(16)30472-8
   Qadri F, 2016, NEW ENGL J MED, V374, P1723, DOI 10.1056/NEJMoa1510330
   RAHAMAN MM, 1976, ANTIMICROB AGENTS CH, V10, P610, DOI 10.1128/AAC.10.4.610
   REIS EC, 1994, PEDIATRICS, V93, P708
   Reyburn R, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000952
   Rijal N, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4432-2
   Saha D, 2006, NEW ENGL J MED, V354, P2452, DOI 10.1056/NEJMoa054493
   Singh J, 1995, J DIARRHOEAL DIS RES, V13, P229
   Soto SM, 2009, CLIN MICROBIOL INFEC, V15, P26, DOI 10.1111/j.1469-0691.2008.02694.x
   Sur D, 2005, ARCH DIS CHILD, V90, P1175, DOI 10.1136/adc.2004.071316
   Sur D, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001289
   Tacconelli E, 2018, LANCET INFECT DIS, V18, pE99, DOI 10.1016/S1473-3099(17)30485-1
   United Nations News Service Section, 2017, UN ANN INT GROUP COO, P3
   van Loon HJ, 2005, AM J RESP CRIT CARE, V171, P480, DOI 10.1164/rccm.200401-070OC
   Vashishtha VM, 2001, BMJ-BRIT MED J, V323, P81
   von Gottberg A, 2014, NEW ENGL J MED, V371, P1889, DOI 10.1056/NEJMoa1401914
   Warren DK, 2004, CRIT CARE MED, V32, P2450, DOI 10.1097/01.CCM.0000147685.79487.28
   World Health Organization, 2016, UN HIGH LEV M ANT RE, P3
   Zuckerman JN, 2007, LANCET INFECT DIS, V7, P521, DOI 10.1016/S1473-3099(07)70138-X
NR 70
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A93
EP A104
DI 10.1016/j.vaccine.2019.12.003
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500015
PM 31883807
OA Other Gold
DA 2020-05-12
ER

PT J
AU Das, B
   Verma, J
   Kumar, P
   Ghosh, A
   Ramamurthy, T
AF Das, Bhabatosh
   Verma, Jyoti
   Kumar, Pawan
   Ghosh, Amit
   Ramamurthy, Thandavarayan
TI Antibiotic resistance in Vibrio cholerae: Understanding the ecology of
   resistance genes and mechanisms
SO VACCINE
LA English
DT Article
DE Antimicrobial resistance (AMR); Multidrug resistance (MDR); Integrating
   conjugative element (ICE); Plasmids; Integron; Cholera
ID EL-TOR STRAINS; CONJUGATIVE ELEMENTS; MOLECULAR-MECHANISMS;
   ESCHERICHIA-COLI; DRUG-RESISTANCE; TRIMETHOPRIM-SULFAMETHOXAZOLE;
   CHROMOSOMAL INTEGRATION; BACTERIAL-RESISTANCE; ANTIMICROBIAL AGENTS;
   EVOLUTION
AB The unique genetic makeup and remarkable competency of Vibrio cholerae are the key factors that help the cholera pathogen adapt rapidly to adverse environmental conditions and resist the detrimental effect of antimicrobial agents. In the last few decades, V. cholerae that causes acute watery diarrhoeal disease cholera has emerged as a notorious multidrug resistant (MDR) enteric pathogen. Although chromosomal mutations can contribute to antimicrobial resistance (AMR), the frequent acquisition of extrachromosomal mobile genetic elements (MGEs) from closely/distantly related bacterial species are major players in V. cholerae drug resistance. Whole genome sequence analysis of clinical and environmental V. cholerae strains revealed that the genome of most of the recent isolates harbour integrating conjugative elements (ICEs), plasmids, superintegron, transposable elements and insertion sequences, which are the key carriers of genetic traits encoding antimicrobial resistance function. Different antimicrobial resistance genes identified in V. cholerae can contribute in antibiotic resistance by facilitating one of the following three mechanisms; (i) reduced permeability or active efflux of the antibiotics, (ii) alteration of the antibiotic targets by introducing post-transcriptional/translational modifications and (iii) hydrolysis or chemical modification of antibiotics. Here, we present an overview of the present insights on the emergence and mechanisms of AMR in V. cholerae. (C) 2019 Elsevier Ltd.
C1 [Das, Bhabatosh; Verma, Jyoti; Kumar, Pawan; Ramamurthy, Thandavarayan] Translat Hlth Sci & Technol Inst, Ctr Human Microbial Ecol, Mol Genet Lab, NCR Biotech Sci Cluster, 3rd Milestone,Faridabad Gurgaon Expressway, Faridabad 121001, Haryana, India.
   [Ghosh, Amit] Natl Inst Cholera & Enter Dis, P33 CIT Rd,Scheme 60, Kolkata 700010, India.
RP Das, B (reprint author), Translat Hlth Sci & Technol Inst, Ctr Human Microbial Ecol, Mol Genet Lab, NCR Biotech Sci Cluster, 3rd Milestone,Faridabad Gurgaon Expressway, Faridabad 121001, Haryana, India.
EM bhabatosh@thsti.res.in
OI KUMAR, PAWAN/0000-0002-7488-8474; Das, Bhabatosh/0000-0002-2447-5380
FU Department of Biotechnology (DBT)Department of Biotechnology (DBT) India
   [BT/MB/THSTI/HMC-SFC/2011]; Department of Science and
   TechnologyDepartment of Science & Technology (India) [SB/FT/LS-309/2012]
FX Department of Biotechnology (DBT), Govt. of India, India (Grant No.
   BT/MB/THSTI/HMC-SFC/2011) and Department of Science and Technology
   (Grant No. SB/FT/LS-309/2012), Govt. of India, India. Funding agencies
   have no role in writing the review.
CR Abdelwahab H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162578
   Alekshun MN, 2007, CELL, V128, P1037, DOI 10.1016/j.cell.2007.03.004
   AMARO C, 1988, APPL ENVIRON MICROB, V54, P2771, DOI 10.1128/AEM.54.11.2771-2776.1988
   Aminov RI, 2007, FEMS MICROBIOL LETT, V271, P147, DOI 10.1111/j.1574-6968.2007.00757.x
   Andersson DI, 2010, NAT REV MICROBIOL, V8, P260, DOI 10.1038/nrmicro2319
   Armshaw P, 2013, MICROBIAL PATHOGENS, P439
   Bag S, 2019, MICROB ECOL, V77, P546, DOI 10.1007/s00248-018-1228-7
   Banerjee R, 2014, INFECT GENET EVOL, V23, P32, DOI 10.1016/j.meegid.2014.01.006
   Baysarowich J, 2008, P NATL ACAD SCI USA, V105, P4886, DOI 10.1073/pnas.0711939105
   Beaber JW, 2002, J BACTERIOL, V184, P4259, DOI 10.1128/JB.184.15.4259-4269.2002
   Biskri L, 2005, J BACTERIOL, V187, P1740, DOI 10.1128/JB.187.5.1740-1750.2005
   Blair JMA, 2015, NAT REV MICROBIOL, V13, P42, DOI 10.1038/nrmicro3380
   Burrus V, 2003, J BACTERIOL, V185, P5045, DOI 10.1128/JB.185.17.5045-5054.2003
   Burrus V, 2006, APPL ENVIRON MICROB, V72, P3054, DOI 10.1128/AEM.72.4.3054-3057.2006
   Carattoli A, 2013, INT J MED MICROBIOL, V303, P298, DOI 10.1016/j.ijmm.2013.02.001
   CARPENTER C C, 1964, J Indian Med Assoc, V43, P309
   Carraro N, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005298
   CASH RA, 1973, J INFECT DIS, V128, pS749, DOI 10.1093/infdis/128.Supplement_3.S749
   CHAKRAVARTI H S, 1954, J Indian Med Assoc, V23, P331
   CHAUDHURI R. N., 1950, INDIAN MED GAZ, V85, P398
   Clemens JD, 2017, LANCET
   COETZEE JN, 1972, J GEN MICROBIOL, V72, P543, DOI 10.1099/00221287-72-3-543
   Darley E, 2012, LANCET, V380, P1358, DOI 10.1016/S0140-6736(12)60911-8
   Das B, 2007, ARCH MICROBIOL, V188, P677, DOI 10.1007/s00203-007-0275-0
   Das B, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3535
   Das B, 2016, CURR OPIN INFECT DIS, V29, P520, DOI 10.1097/QCO.0000000000000306
   Das B, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00650
   Das B, 2011, P NATL ACAD SCI USA, V108, P2516, DOI 10.1073/pnas.1017061108
   Das B, 2010, P NATL ACAD SCI USA, V107, P4377, DOI 10.1073/pnas.0910212107
   Davies BW, 2012, CELL, V149, P358, DOI 10.1016/j.cell.2012.01.053
   DAVIES J, 1995, GENETICS, V139, P1465
   De Pascale G, 2010, CHEMBIOCHEM, V11, P1325, DOI 10.1002/cbic.201000067
   DUTTA JK, 1978, T ROY SOC TROP MED H, V72, P40, DOI 10.1016/0035-9203(78)90297-3
   Everett MJ, 1996, ANTIMICROB AGENTS CH, V40, P2380, DOI 10.1128/AAC.40.10.2380
   Fischbach MA, 2009, SCIENCE, V325, P1089, DOI 10.1126/science.1176667
   Fonseca EL, 2013, J MED MICROBIOL, V62, P1628, DOI 10.1099/jmm.0.062661-0
   GHARAGOZLOO RA, 1970, BMJ-BRIT MED J, V4, P281, DOI 10.1136/bmj.4.5730.281
   Ghosh A, 2011, INDIAN J MED RES, V133, P225
   Gillings MR, 2014, MICROBIOL MOL BIOL R, V78, P257, DOI 10.1128/MMBR.00056-13
   Grados P, 1996, Bull Pan Am Health Organ, V30, P36
   HALL RM, 1995, MOL MICROBIOL, V15, P593, DOI 10.1111/j.1365-2958.1995.tb02368.x
   Hassan F, 2010, NATURE, V467, P982, DOI 10.1038/nature09469
   Hay ID, 2019, EMBO REP, V20, DOI 10.15252/embr.201847427
   HEDGES RW, 1975, MOL GEN GENET, V140, P69, DOI 10.1007/BF00268990
   Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000
   Higgins CF, 2007, NATURE, V446, P749, DOI 10.1038/nature05630
   Hochhut B, 1999, MOL MICROBIOL, V32, P99, DOI 10.1046/j.1365-2958.1999.01330.x
   Holmes AH, 2016, LANCET, V387, P176, DOI 10.1016/S0140-6736(15)00473-0
   Hooper DC, 2001, CLIN INFECT DIS, V32, pS9, DOI 10.1086/319370
   Hoshino Y, 2010, J ANTIBIOT, V63, P23, DOI 10.1038/ja.2009.116
   Izard T, 2000, EMBO J, V19, P2690, DOI 10.1093/emboj/19.11.2690
   Johnson CM, 2015, ANNU REV GENET, V49, P577, DOI 10.1146/annurev-genet-112414-055018
   Karaolis DKR, 1999, NATURE, V399, P375, DOI 10.1038/20715
   KARCHMER A W, 1970, Bulletin of the World Health Organization, V43, P373
   Kobayashi S, 2000, ANTIMICROB AGENTS CH, V44, P647, DOI 10.1128/AAC.44.3.647-650.2000
   Kuma GK, 2014, INT J INFECT CONTROL, V10, pi3
   MacLean RC, 2015, CURR BIOL, V25, pR764, DOI 10.1016/j.cub.2015.07.006
   Marin MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108728
   Marrero J, 2007, J BACTERIOL, V189, P3302, DOI 10.1128/JB.01902-06
   Martinez JL, 2008, SCIENCE, V321, P365, DOI 10.1126/science.1159483
   Mazel D, 2006, NAT REV MICROBIOL, V4, P608, DOI 10.1038/nrmicro1462
   McArthur AG, 2013, ANTIMICROB AGENTS CH, V57, P3348, DOI 10.1128/AAC.00419-13
   McGrath M, 2014, J ANTIMICROB CHEMOTH, V69, P292, DOI 10.1093/jac/dkt364
   MHALU FS, 1979, LANCET, V1, P345
   Midonet C, 2014, P NATL ACAD SCI USA, V111, P16848, DOI 10.1073/pnas.1404047111
   Mohapatra H, 2008, ENVIRON MICROBIOL, V10, P866, DOI 10.1111/j.1462-2920.2007.01502.x
   Morar M, 2012, BIOCHEMISTRY-US, V51, P1740, DOI 10.1021/bi201790u
   Mori T, 2008, APPL ENVIRON MICROB, V74, P6803, DOI 10.1128/AEM.00873-08
   Mukhtar TA, 2001, BIOCHEMISTRY-US, V40, P8877, DOI 10.1021/bi0106787
   Mutreja A, 2011, NATURE, V477, P462, DOI 10.1038/nature10392
   Nair GB, 2002, J CLIN MICROBIOL, V40, P3296, DOI 10.1128/JCM.40.9.3296-3299.2002
   NAKAYA R, 1960, BIOCHEM BIOPH RES CO, V3, P654, DOI 10.1016/0006-291X(60)90081-4
   NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064
   Nizami S Q, 1998, J Pak Med Assoc, V48, P171
   Olaitan AO, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00643
   Pant A, 2016, J BACTERIOL, V198, P268, DOI 10.1128/JB.00674-15
   Partridge SR, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00088-17
   PASTORE G, 1977, CHEMOTHERAPY, V23, P121, DOI 10.1159/000221980
   PIERCE NF, 1968, BMJ-BRIT MED J, V3, P277, DOI 10.1136/bmj.3.5613.277
   Quilici ML, 2010, EMERG INFECT DIS, V16, P1804, DOI 10.3201/eid1611.100568
   Ramirez MS, 2010, DRUG RESIST UPDATE, V13, P151, DOI 10.1016/j.drup.2010.08.003
   REIMANN HA, 1946, AM J TROP MED, V26, P631
   Rowe-Magnus DA, 2002, MOL MICROBIOL, V43, P1657, DOI 10.1046/j.1365-2958.2002.02861.x
   Saha D, 2006, NEW ENGL J MED, V354, P2452, DOI 10.1056/NEJMoa054493
   Schwarz S, 2004, FEMS MICROBIOL REV, V28, P519, DOI 10.1016/j.femsre.2004.04.001
   SIDDIQUE AK, 1991, LANCET, V337, P1125, DOI 10.1016/0140-6736(91)92789-5
   SIDDIQUE AK, 1995, LANCET, V345, P359, DOI 10.1016/S0140-6736(95)90344-5
   Spagnoletti M, 2014, MBIO, V5, DOI 10.1128/mBio.01356-14
   Spanogiannopoulos P, 2012, ANTIMICROB AGENTS CH, V56, P5061, DOI 10.1128/AAC.01166-12
   SPEER BS, 1989, J BACTERIOL, V171, P148, DOI 10.1128/jb.171.1.148-153.1989
   Thungapathra M, 2002, ANTIMICROB AGENTS CH, V46, P2948, DOI 10.1128/AAC.46.9.2948-2955.2002
   TOWNER KJ, 1980, B WORLD HEALTH ORGAN, V58, P747
   Uylangco C V, 1965, J Philipp Med Assoc, V41, P763
   Verma J, 2019, P NATL ACAD SCI USA, V116, P6226, DOI 10.1073/pnas.1900141116
   VILA J, 1994, ANTIMICROB AGENTS CH, V38, P2477, DOI 10.1128/AAC.38.10.2477
   von Wintersdorff CJH, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00173
   Waldor MK, 1996, J BACTERIOL, V178, P4157, DOI 10.1128/jb.178.14.4157-4165.1996
   Walsh TR, 2011, LANCET INFECT DIS, V11, P355, DOI 10.1016/S1473-3099(11)70059-7
   Wang RZ, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00144
   Wang RB, 2012, INT J ANTIMICROB AG, V40, P361, DOI 10.1016/j.ijantimicag.2012.06.010
   WATANABE T, 1963, BACTERIOL REV, V27, P87, DOI 10.1128/MMBR.27.1.87-115.1963
   Wozniak RAF, 2010, NAT REV MICROBIOL, V8, P552, DOI 10.1038/nrmicro2382
   Wozniak RAF, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000786
   Wright GD, 1999, CURR OPIN MICROBIOL, V2, P499, DOI 10.1016/S1369-5274(99)00007-7
   Yu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038633
   ZAHRINGER U, 1993, FEMS MICROBIOL LETT, V110, P331, DOI 10.1016/0378-1097(93)90124-K
NR 106
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A83
EP A92
DI 10.1016/j.vaccine.2019.06.031
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500014
PM 31272870
OA Other Gold
DA 2020-05-12
ER

PT J
AU Das, M
   Singh, H
   Kumar, CPG
   John, D
   Panda, S
   Mehendale, SM
AF Das, Madhuchhanda
   Singh, Harpreet
   Kumar, C. P. Girish
   John, Denny
   Panda, Samiran
   Mehendale, Sanjay M.
TI Non-vaccine strategies for cholera prevention and control: India's
   preparedness for the global roadmap
SO VACCINE
LA English
DT Article
DE Cholera; Prevention; Control; WASH; Disease model
ID TRANSMISSION DYNAMICS; EPIDEMIC; OUTBREAKS; CLIMATE; HAITI
AB Background: Recently World Health Organization's Global Task Force on Cholera Control (GTFCC) has published a global roadmap for prevention and control of cholera. We review preparedness of existing governmental non-vaccine programs and strategies for cholera prevention and control in India. We also describe strengths and gaps in the context of implementation of the global roadmap.
   Methods: We reviewed published literature on non-vaccine based strategies for prevention and control of cholera in India and analyzed strengths and weaknesses of Government of India's major anti-cholera and ante-diarrhea initiatives under Integrated Disease Surveillance Program (IDSP), National Rural Health Mission (NRHM), and other disease surveillance platforms.
   Results: The first strategy of the WHO global roadmap, namely, preparedness for early detection and outbreak containment, has been addressed by the IDSP. NRHM complements IDSP activities by focusing on sanitation, hygiene, nutrition, and safe drinking water. We identified the need to adopt stricter case definitions and data validation protocols.
   Multi-sectoral approach to prevent cholera occurrences and re-occurrences [the second suggested strategy in the global roadmap], highlights identification of hotspots and implementing strategies based on transmission dynamics. We recommend development of comprehensive models by integrating data sources beyond the national programs to eliminate cholera hotspots in India.
   Implementing the third proposed strategy in the global roadmap, coordinated technical support, resource mobilization, and partnerships at local and global levels, has major challenges in India due to structural issues related to health systems and health programs.
   Conclusion: Even with a robust public health infrastructure, absence of a national cholera program might have resulted in lack of specific focus and concerted efforts for cholera prevention and control in India. A National Taskforce for Cholera Control must develop India-specific 'National Cholera Prevention and Response Road Map' with an appropriate administrative and financially viable framework for its implementation. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Das, Madhuchhanda; Singh, Harpreet; Mehendale, Sanjay M.] Indian Council Med Res, Post Box 4911, New Delhi 110029, India.
   [Kumar, C. P. Girish] ICMR Natl Inst Epidemiol, Chennai, Tamil Nadu, India.
   [John, Denny] Campbell Collaborat, New Delhi, India.
   [Panda, Samiran] ICMR Natl AIDS Res Inst, Pune, Maharashtra, India.
RP Mehendale, SM (reprint author), Indian Council Med Res, Post Box 4911, New Delhi 110029, India.
EM sanjaymehendale.hq@icmr.gov.in
RI John, Denny/J-7815-2017
OI John, Denny/0000-0002-4486-632X; Singh, Harpreet/0000-0002-5838-1884
CR Abhiyan Swachh Bharat, 2019, SWACHH BHARAT ABHIYA
   Abrams JY, 2013, EPIDEMIOL INFECT, V141, P1276, DOI 10.1017/S0950268812001793
   Ali M, 2017, PLOS ONE, DOI [10.1371/journal, DOI 10.1371/JOURNAL.PONE.0183100E0183100]
   Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832
   Andrews JR, 2011, LANCET, V377, P1248, DOI 10.1016/S0140-6736(11)60273-0
   [Anonymous], 2017, 5 M IN DIARRH ENT DI
   [Anonymous], INT DIS SURV PROGR
   [Anonymous], 2017, HLTH STAT IND NAT HL
   [Anonymous], 2019, IND VER SWACHH BHAR
   [Anonymous], 2018, HLTH STAT IND NAT HL
   Board CPC, NAT WAT QUAL MON PRO
   Centre for Disease Control, 2015, PLANN EM STRAT ID EN
   Chao DL, 2014, CURR TOP MICROBIOL, V379, P195, DOI 10.1007/82_2013_307
   Debnath F, 2018, CLIN EPIDEMIOL GLOB, V6, P163, DOI 10.1016/j.cegh.2017.10.006
   Fletcher-Lartey SM, 2016, PARASITOLOGY, V143, P401, DOI 10.1017/S0031182015001869
   Fung ICH, 2014, EMERG THEMES EPIDEMI, V11, DOI 10.1186/1742-7622-11-1
   Global Task Force on Cholera Control, 2017, END CHOL GLOB ROADM
   Hartley DM, 2005, PLOS MED, V3, DOI [10.1371Viurnal.pmed.0030007e7, DOI 10.1371/JOURNAL.PMED.00300007E7]
   Tong HV, 2017, TROP MED INT HEALTH, V22, P1063, DOI 10.1111/tmi.12923
   Jayakumar K, 2013, ARCH APPL SCI RES, V5, P93
   Jutla A, 2013, AM J TROP MED HYG, V89, P597, DOI 10.4269/ajtmh.12-0721
   Kanungo S, 2010, B WORLD HEALTH ORGAN, V88, P185, DOI 10.2471/BLT.09.073460
   King AA, 2008, NATURE, V454, P877, DOI 10.1038/nature07084
   Koelle K, 2009, CLIN MICROBIOL INFEC, V15, P29, DOI 10.1111/j.1469-0691.2008.02686.x
   Kroiss SJ, 2017, VACCINE, V35, P5674, DOI 10.1016/j.vaccine.2017.08.048
   Lessler J, 2017, AM J TROP MED HYG, V96, P1270, DOI 10.4269/ajtmh.16-0427
   Mishra M, 2015, AM J INFECT DIS MICR, V3, P141
   Mukherjee R, 2011, J HEALTH POPUL NUTR, V29, P421
   National Centre for Disease Control (NCDC), NCDC ANN REP 2016 17
   Nijeeshi TP, 2016, TIMES INDIA
   Nishiura H, 2017, THEOR BIOL MED MODEL, V14, DOI 10.1186/s12976-017-0061-x
   Okuonghae D, 2016, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01530
   Pascual M, 2008, CLIM RES, V36, P131, DOI 10.3354/cr00730
   Rajiv G., 2017, TIMES INDIA
   Ramamurthy T, 2014, CURR TOP MICROBIOL, V379, P49, DOI 10.1007/82_2014_368
   Real LA, 2007, CURR TOP MICROBIOL, V315, P33
   Siettos CI, 2013, VIRULENCE, V4, P295, DOI 10.4161/viru.24041
   Sun GQ, 2017, COMMUN NONLINEAR SCI, V45, P235, DOI 10.1016/j.cnsns.2016.10.007
   White K, 2017, LANCET, V390, P1947, DOI 10.1016/S0140-6736(17)32677-6
   WHO, 2017, UN WAT GLOB AN ASS S
   Wisner B, 2002, ENV HLTH EMERGENCIES
   World Health Organization (WHO) and the United Nations Children's Fund (UNICEF), 2017, PROGR DRINK WAT SAN
NR 42
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A167
EP A174
DI 10.1016/j.vaccine.2019.08.010
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500025
PM 31443992
OA Other Gold
DA 2020-05-12
ER

PT J
AU Deen, J
   Mengel, MA
   Clemens, JD
AF Deen, Jacqueline
   Mengel, Martin A.
   Clemens, John D.
TI Epidemiology of cholera
SO VACCINE
LA English
DT Article
DE Cholera; Vibrio cholerae; Pandemics; Transmission; Epidemiology
ID EL-TOR CHOLERA; VIBRIO-CHOLERAE; ORAL CHOLERA; IMMUNE-RESPONSES;
   RISK-FACTORS; FIELD-TRIAL; BLOOD-GROUP; TRANSMISSION; OUTBREAK; VACCINE
AB Cholera is an ancient disease that remains a public health problem in many impoverished locations around the world. Seven pandemics of cholera have been recorded since the first pandemic in 1817, the last of which is on going. Overcrowding, poverty, insufficient water and sanitation facilities increase the risk for cholera outbreaks. The epidemiology of cholera in the areas in Asia, Africa and the Americas where the disease occurs continues to evolve. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Deen, Jacqueline] Univ Philippines, Inst Child Hlth & Human Dev, Natl Inst Hlth, Pedro Gil St, Manila 1000, Philippines.
   [Deen, Jacqueline] Johns Hopkins Bloomberg Sch Publ Hlth, DOVE, Baltimore, MD 21205 USA.
   [Mengel, Martin A.] Global Hlth Consulting, Calle Isabel de Villena 99, Valencia 46011, Spain.
   [Clemens, John D.] Iccdr B, GPO Box 128, Dhaka 1000, Bangladesh.
   [Clemens, John D.] UCLA Fielding Sch Publ Hlth, 650 Charles E Young Dr South, Los Angeles, CA 90095 USA.
RP Deen, J (reprint author), Univ Philippines, Manila, Philippines.
EM deen.jacqueline@gmail.com
FU Bill and Melinda Gates FoundationGates Foundation; Wellcome
   TrustWellcome Trust; Globvac
FX JDC is supported by the Bill and Melinda Gates Foundation, the Wellcome
   Trust, and Globvac, as well as by the governments of Bangladesh, Canada,
   Sweden, and the United Kingdom, which provide core support to the
   icddr,b.
CR Ackers ML, 1998, INT J EPIDEMIOL, V27, P330, DOI 10.1093/ije/27.2.330
   Adagbada AO, 2012, PAN AFR MED J, V12
   Ahmed Mesbah Uddin, 2018, BMC Proc, V12, P62, DOI 10.1186/s12919-018-0158-1
   Ako AA, 2009, WATER SCI TECHNOL, V59, P2321, DOI 10.2166/wst.2009.268
   Ali M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183100
   Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832
   Almagro-Moreno S, 2013, MICROBIOL SPECTR, V1, DOI 10.1128/microbiolspec.OH-0003-2012
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P521
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P437
   [Anonymous], 1993, Lancet, V342, P387
   [Anonymous], 1971, BMJ-BRIT MED J, V3, P266
   Armah FA, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018.e00931
   Azman AS, 2015, LANCET, V385, P851, DOI 10.1016/S0140-6736(15)60178-7
   Azman AS, 2013, J INFECTION, V66, P432, DOI 10.1016/j.jinf.2012.11.013
   Azman AS, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001901
   BAINE WB, 1974, LANCET, V2, P1370
   Banerjee R, 2014, INFECT GENET EVOL, V23, P32, DOI 10.1016/j.meegid.2014.01.006
   Bhattacharya S, 2013, LANCET INFECT DIS, V13, P1050, DOI 10.1016/S1473-3099(13)70273-1
   Bi QF, 2017, LANCET INFECT DIS, V17, P1080, DOI [10.1016/s1473-3099(17)30359-6, 10.1016/S1473-3099(17)30359-6]
   Bi QF, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004400
   Blake A, 2018, INFECT DIS POVERTY, V7, DOI 10.1186/s40249-018-0393-8
   BOELAERT M, 1995, LANCET, V345, P1567, DOI 10.1016/S0140-6736(95)91111-1
   Bompangue D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000436
   Bwire G, 2015, AM J TROP MED HYG, V93, P534, DOI 10.4269/ajtmh.14-0730
   CLEMENS JD, 1989, J INFECT DIS, V159, P770, DOI 10.1093/infdis/159.4.770
   CLEMENS JD, 1990, AM J EPIDEMIOL, V131, P400, DOI 10.1093/oxfordjournals.aje.a115515
   CLEMENS JD, 1991, J INFECT DIS, V163, P1235, DOI 10.1093/infdis/163.6.1235
   Colombara DV, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-440
   Colombara DV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054395
   COLOMBO MM, 1993, EUR J EPIDEMIOL, V9, P563, DOI 10.1007/BF00209537
   COOPER DB, 1986, SOC SCI HIST, V10, P467, DOI 10.2307/1171027
   CVJETANOVIC B, 1972, NATURE, V239, P137, DOI 10.1038/239137a0
   de Magny GC, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-20
   de Magny GC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044577
   Desai SN, 2016, LANCET GLOB HEALTH, V4, pE223, DOI 10.1016/S2214-109X(16)00037-1
   Didelot X, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005072
   Domman D, 2017, SCIENCE, V358, P789, DOI 10.1126/science.aao2136
   Eisenberg MC, 2013, J THEOR BIOL, V324, P84, DOI 10.1016/j.jtbi.2012.12.021
   Farhana I, 2016, WORLD J MICROB BIOT, V32, DOI 10.1007/s11274-016-2100-x
   FARUQUE ASG, 1994, T ROY SOC TROP MED H, V88, P439, DOI 10.1016/0035-9203(94)90423-5
   Faruque SM, 2006, P NATL ACAD SCI USA, V103, P6350, DOI 10.1073/pnas.0601277103
   Fernandez MAL, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-442
   Finger F, 2016, P NATL ACAD SCI USA, V113, P6421, DOI 10.1073/pnas.1522305113
   Flach CF, 2007, INFECT IMMUN, V75, P2343, DOI 10.1128/IAI.01900-06
   Fotedar R, 2001, ACTA TROP, V78, P31, DOI 10.1016/S0001-706X(00)00162-5
   Frerichs RR, 2012, CLIN MICROBIOL INFEC, V18, pE158, DOI 10.1111/j.1469-0691.2012.03841.x
   GLASS RI, 1985, J INFECT DIS, V151, P236, DOI 10.1093/infdis/151.2.236
   GLASS RI, 1985, AM J EPIDEMIOL, V121, P791, DOI 10.1093/oxfordjournals.aje.a114050
   GLASS RI, 1982, AM J EPIDEMIOL, V116, P959, DOI 10.1093/oxfordjournals.aje.a113498
   GOODGAME RW, 1975, ANN INTERN MED, V82, P101, DOI 10.7326/0003-4819-82-1-101
   Griffith DC, 2006, AM J TROP MED HYG, V75, P973, DOI 10.4269/ajtmh.2006.75.973
   Guevart E, 2006, Med Trop (Mars), V66, P283
   Guillaume Y, 2018, J INFECT DIS, V218, pS167, DOI 10.1093/infdis/jiy491
   Gujral L, 2013, J INFECT DIS, V208, pS107, DOI 10.1093/infdis/jit212
   Harris JB, 2012, LANCET, V379, P2466, DOI 10.1016/S0140-6736(12)60436-X
   Harris JB, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000221
   Hartley DM, 2006, PLOS MED, V3, P63, DOI 10.1371/journal.pmed.0030007
   Hays JN, 2005, EPIDEMICS PANDEMICS
   HOLMGREN J, 1983, PROG ALLERGY, V33, P106
   Hsiao A, 2014, NATURE, V515, P423, DOI 10.1038/nature13738
   Huq A, 2005, APPL ENVIRON MICROB, V71, P4645, DOI 10.1128/AEM.71.8.4645-4654.2005
   Ivers LC, 2012, AM J TROP MED HYG, V86, P36, DOI 10.4269/ajtmh.2012.11-0435
   Joo I, 1974, CHOLERA, P333
   Jutla A, 2013, AM J TROP MED HYG, V89, P597, DOI 10.4269/ajtmh.12-0721
   Kanungo S, 2010, B WORLD HEALTH ORGAN, V88, P185, DOI 10.2471/BLT.09.073460
   Karlsson EK, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006338
   Khatib AM, 2012, LANCET INFECT DIS, V12, P837, DOI 10.1016/S1473-3099(12)70196-2
   Koelle K, 2009, CLIN MICROBIOL INFEC, V15, P29, DOI 10.1111/j.1469-0691.2008.02686.x
   Koelle K, 2006, P R SOC B, V273, P2879, DOI 10.1098/rspb.2006.3668
   Kuhlmann FM, 2016, AM J TROP MED HYG, V95, P440, DOI 10.4269/ajtmh.16-0161
   KUSTNER HGV, 1981, S AFR MED J, V60, P87
   Lam C, 2010, EMERG INFECT DIS, V16, P1130, DOI 10.3201/eid1607.100131
   Lantagne D, 2014, CURR TOP MICROBIOL, V379, P145, DOI 10.1007/82_2013_331
   Lantagne D, 2012, J DISASTER RES, V7, P759, DOI 10.20965/jdr.2012.p0759
   LaRocque RC, 2009, GENES IMMUN, V10, P267, DOI 10.1038/gene.2009.2
   Jimenez ML, 2011, EMERG INFECT DIS, V17, P2172, DOI 10.3201/eid1711.111263
   Lawoyin TO, 1999, EUR J EPIDEMIOL, V15, P367, DOI 10.1023/A:1007547117763
   Legros D, 2000, E AFR MED J, V77, P347
   Legros D, 2018, J INFECT DIS, V218, pS137, DOI 10.1093/infdis/jiy486
   Lessler J, 2018, LANCET, V391, P1908, DOI [10.1016/S0140-6736(17)33050-7, 10.1016/s0140-6736(17)33050-7]
   Leung DT, 2012, EXPERT REV ANTI-INFE, V10, P435, DOI [10.1586/ERI.12.23, 10.1586/eri.12.23]
   Losonsky GA, 1996, INFECT IMMUN, V64, P10, DOI 10.1128/IAI.64.1.10-15.1996
   Luquero FJ, 2016, EMERG INFECT DIS, V22, P410, DOI 10.3201/eid2203.141970
   Luquero FJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019005
   Manga N M, 2008, Med Trop (Mars), V68, P589
   Martin S, 2014, B WORLD HEALTH ORGAN, V92, P881, DOI 10.2471/BLT.14.139949
   Mengel MA, 2014, CURR TOP MICROBIOL, V379, P117, DOI 10.1007/82_2014_369
   Merrell DS, 2002, NATURE, V417, P642, DOI 10.1038/nature00778
   Ministry of Health DRC, 2012, SIT EP CHOL REP DEM
   Moore S, 2014, CLIN MICROBIOL INFEC, V20, P373, DOI 10.1111/1469-0691.12610
   MOSLEY WH, 1968, B WORLD HEALTH ORGAN, V38, P335
   Mukhopadhyay AK, 2014, CURR TOP MICROBIOL, V379, P17, DOI 10.1007/82_2014_363
   Mutreja A, 2011, NATURE, V477, P462, DOI 10.1038/nature10392
   Nair GB, 2002, J CLIN MICROBIOL, V40, P3296, DOI 10.1128/JCM.40.9.3296-3299.2002
   Nelson EJ, 2009, NAT REV MICROBIOL, V7, P693, DOI 10.1038/nrmicro2204
   Nkoko DB, 2011, EMERG INFECT DIS, V17, P2026, DOI 10.3201/eid1711.110170
   Osei FB, 2008, INT J HEALTH GEOGR, V7, DOI 10.1186/1476-072X-7-44
   Penrose K, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000631
   Pollitzer R., 1959, CHOLERA
   Rebaudet S, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002898
   Sack DA, 2004, LANCET, V363, P223, DOI 10.1016/S0140-6736(03)15328-7
   Safa A, 2008, EMERG INFECT DIS, V14, P987, DOI 10.3201/eid1406.080129
   Sasaki S, 2008, AM J TROP MED HYG, V79, P414, DOI 10.4269/ajtmh.2008.79.414
   Sasaki S, 2009, AM J PUBLIC HEALTH, V99, P1982, DOI 10.2105/AJPH.2008.151076
   Sauvageot D, 2017, VACCINE, V35, P5194, DOI 10.1016/j.vaccine.2017.07.104
   Sauvageot D, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004679
   Schaetti C, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-99
   Sengupta S., 2016, UN APOLOGIZES ROLE H
   Shultz A, 2009, AM J TROP MED HYG, V80, P640, DOI 10.4269/ajtmh.2009.80.640
   Siddique AK, 2010, EPIDEMIOL INFECT, V138, P347, DOI 10.1017/S0950268809990550
   Silva AJ, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004330
   Sugimoto JD, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003314
   Sundaram N, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2710-0
   SWERDLOW DL, 1992, LANCET, V340, P28, DOI 10.1016/0140-6736(92)92432-F
   Swerdlow DL, 1997, EPIDEMIOL INFECT, V118, P207, DOI 10.1017/S0950268896007352
   TANAMAL STW, 1959, AM J TROP MED HYG, V8, P72, DOI 10.4269/ajtmh.1959.8.72
   UNHCR, 2019, FLOOD WORS HUM NEEDS
   Utsalo SJ, 1999, EUR J EPIDEMIOL, V15, P379, DOI 10.1023/A:1007541317104
   Van Heyningen WE, 1983, CHOLERA AM SCI EXPER
   VANLOON FPL, 1990, J CLIN EPIDEMIOL, V43, P1361, DOI 10.1016/0895-4356(90)90103-V
   von Seidlein L, 2008, TROP MED INT HEALTH, V13, P683, DOI 10.1111/j.1365-3156.2008.02051.x
   Weil AA, 2014, AM J TROP MED HYG, V91, P738, DOI 10.4269/ajtmh.14-0095
   Weil AA, 2009, CLIN INFECT DIS, V49, P1473, DOI 10.1086/644779
   WEIL O, 1992, REV EPIDEMIOL SANTE, V40, P145
   Weill FX, 2019, NATURE, V565, P230, DOI 10.1038/s41586-018-0818-3
   Weill FX, 2017, SCIENCE, V358, P785, DOI 10.1126/science.aad5901
   WHO, 2009, EUROPEAN HEALTH REPORT 2009: HEALTH AND HEALTH SYSTEMS, P1
   World Health Organization, MAJ CHOL OUTBR 2017
   World Health Organization, 2018, WEEKLY EPIDEMIOLOGIC, V93, P489
   You YA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071173
   2014, HLTH PEOPL WHAT, P1
NR 131
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A31
EP A40
DI 10.1016/j.vaccine.2019.07.078
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500008
PM 31395455
OA Other Gold
DA 2020-05-12
ER

PT J
AU Ganesan, D
   Sen Gupta, S
   Legros, D
AF Ganesan, Divya
   Sen Gupta, Sanjukta
   Legros, Dominique
TI Cholera surveillance and estimation of burden of cholera
SO VACCINE
LA English
DT Article
DE Cholera; Disease burden; Reporting; Barriers; WHO; Surveillance
ID CHALLENGES; PREVENTION; INDIA
AB Cholera continues to be poorly controlled in multiple epidemic and endemic areas across the globe, with estimated annual incidence of 1.3-4.0 million cases, resulting in 21,000 to 143,000 deaths worldwide in 2015. The usual approach for patient diagnosis and cholera surveillance is clinical examination of cases of acute watery diarrhea (AWD), confirmed by positive culture or polymerase chain reaction tests. Rapid diagnostic tests (RDTs) are used in regions with limited laboratory capacities but have been found to demonstrate large variations in performance, ranging in sensitivity from 58% to 100% and in specificity from 60% to 100%. Most countries rely on hospital-based surveillance of diarrheal disease to compute the cholera burden. The World Health Organization (WHO) recommends that countries assess public health events involving cholera against the International Health Regulations 2005 criteria and determine need for official notification using the standard case definition. Cholera is an often under-recognized and under reported problem because of differences in case definitions, reluctance by authorities to acknowledge and report cholera, inadequacies in hospital surveillance systems, lack of effective diagnostic tests and commonalities in clinical presentation of cholera with other AWD etiologies. The resulting gap in burden data impairs economic analysis of disease impact and identification of areas for targeted control interventions. There is an urgent need to strengthen surveillance data by supplementing reported numbers with estimates from literature reviews and data from modelling studies, developing better-performing RDTs, enhancing monitoring and evaluation processes of in-country surveillance systems, and encouraging countries to report cholera cases by "rewarding" better reporting with technical support and improved access to vaccines. It is imperative that immediate steps are taken towards strengthening surveillance and reporting systems globally, especially in cholera-prone and resource-limited areas, where it will enable countries to articulate their demand for resources more accurately. (C) 2019 Published by Elsevier Ltd.
C1 [Ganesan, Divya] Global Hlth Strategies, 18-1 Qutab Inst Area, New Delhi 110016, India.
   [Sen Gupta, Sanjukta] Translat Hlth Sci & Technol Inst, NCR Biotech Sci Cluster, 3rd Milestone,Faridabad Gurgaon Expressway, Faridabad 121001, Haryana, India.
   [Legros, Dominique] WHO, Global Task Force Cholera Control, Ave Appia 20, CH-1211 Geneva 27, Switzerland.
   [Ganesan, Divya] Emory Univ, Rollins Sch Publ Hlth, 1518 Clifton Rd, Atlanta, GA 30322 USA.
RP Legros, D (reprint author), WHO, Ave Appia 20, CH-1211 Geneva 27, Switzerland.
EM legrosd@who.int
FU World Health OrganizationWorld Health Organization [001]
CR Adokiya MN, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1397-y
   Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832
   Ali M, 2012, B WORLD HEALTH ORGAN, V90, P209, DOI 10.2471/BLT.11.093427
   [Anonymous], 2016, Wkly Epidemiol Rec, V91, P433
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P517
   [Anonymous], 2013, Wkly Epidemiol Rec, V88, P321
   [Anonymous], 2012, Wkly Epidemiol Rec, V87
   [Anonymous], 2011, Wkly Epidemiol Rec, V86, P325
   [Anonymous], PREV CONTR CHOL OUTB
   [Anonymous], 2014, MAN PROC PHIL INT DI
   [Anonymous], 2007, WHO STAT REL INT TRA
   [Anonymous], 2016, CHOL SURV DET REP CA
   Azman AS, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004230
   Camacho A, 2018, LANCET GLOB HEALTH, V6, pE680, DOI 10.1016/S2214-109X(18)30230-4
   Cash RA, 2000, B WORLD HEALTH ORGAN, V78, P1358
   Chao DL, 2014, CURR TOP MICROBIOL, V379, P195, DOI 10.1007/82_2013_307
   Debes AK, 2016, AM J TROP MED HYG, V94, P537, DOI 10.4269/ajtmh.15-0496
   Dick MH, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001845
   Fung ICH, 2014, EMERG THEMES EPIDEMI, V11, DOI 10.1186/1742-7622-11-1
   Grad YH, 2012, EPIDEMIOLOGY, V23, P523, DOI 10.1097/EDE.0b013e3182572581
   Kanungo S, 2010, B WORLD HEALTH ORGAN, V88, P185, DOI 10.2471/BLT.09.073460
   Kasolo F, 2013, BIOSECUR BIOTERROR, V11, P163, DOI 10.1089/bsp.2013.0032
   Kirigia JM, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-8
   Legros D., 2016, MANUAL CHILDHOOD INF, P484
   Lopez AL, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003440
   Lukwago L, 2013, HEALTH POLICY PLANN, V28, P30, DOI 10.1093/heapol/czs022
   Morris JG, UPTODATE
   Norwood PF, 2016, NEGLECTED TROPICAL D, P1
   Ramamurthy T, 2014, CURR TOP MICROBIOL, V379, P49, DOI 10.1007/82_2014_368
   Raut DK, 2014, GLOB J MED PUBLIC HL, V3
   Sen Gupta S, 2016, INDIAN J MED RES, V143, P545, DOI 10.4103/0971-5916.187102
   Sultan MA, 2017, 5 IN DIARRH ENT DIS
   Sur Dipika, 2016, Indian J Public Health, V60, P171, DOI 10.4103/0019-557X.188995
   Talavera A, 2009, J INFECT DEV COUNTR, V3, P408, DOI 10.3855/jidc.410
   WHO, 2014, WKLY EPIDEMIOL REC, V89, P345
   WHO UNICEF, 2015, PROGR SAN DRINK WAT
   Zuckerman JN, 2007, LANCET INFECT DIS, V7, P521, DOI 10.1016/S1473-3099(07)70138-X
NR 37
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A13
EP A17
DI 10.1016/j.vaccine.2019.07.036
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500004
PM 31326254
OA Other Gold
DA 2020-05-12
ER

PT J
AU Haldar, P
AF Haldar, Pradeep
TI Programmatic Preparations and challenges for OCV introduction in India
SO VACCINE
LA English
DT Article
DE Cholera vaccine; Use in endemic countries; Shortage of vaccines
AB Cholera mainly affects the marginalized with inequitable access to care, potable water and improved sanitation. An estimated 411 million people in India are at risk from cholera, with 675,188 cases and 20,256 deaths occurring annually. Given the global elimination plan for cholera by 2030, a multi-stakeholder strategy is required. The National Technical Advisory Group on Immunization (NTAGI) Working Group on Cholera met in 2016 to review the evidence for cholera burden in India and successful oral cholera vaccine (OCV) implementation in other countries. Based on NTAGI's recommendations, the Ministry of Health and Family Welfare will implement cholera control measures and decide on OCV's addition to India's Universal Immunization Programme (UIP). Key steps for OCV introduction will include choosing the vaccine formulation, developing vaccine delivery strategy, ensuring sufficient resources, engaging OCV manufacturers to ensure a sustainable supply, and developing a post-introduction evaluation strategy. (C) 2019 Elsevier Ltd.
C1 [Haldar, Pradeep] Govt India, Dept Hlth & Family Welf, Minist Hlth & Family Welf, Room 105-D, New Delhi 110011, India.
RP Haldar, P (reprint author), Govt India, Dept Hlth & Family Welf, Minist Hlth & Family Welf, Room 105-D, New Delhi 110011, India.
EM pradeephaldar@yahoo.co.in
CR Ali M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183100
   Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P477
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P437
   Deen J, 2016, INDIAN J MED RES, V144, P149, DOI 10.4103/0971-5916.194997
   Deutsch N, 2017, J INFECT DIS, V216, pS260, DOI 10.1093/infdis/jix068
   Global Task Force on Cholera Control, END CHOL GLOB ROADM
   John TJ, 2010, VACCINE, V28, pA88, DOI 10.1016/j.vaccine.2010.02.041
NR 8
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A175
EP A177
DI 10.1016/j.vaccine.2019.06.047
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500026
PM 31307875
OA Other Gold
DA 2020-05-12
ER

PT J
AU Islam, MS
   Zaman, MH
   Islam, MS
   Ahmed, N
   Clemens, JD
AF Islam, M. Sirajul
   Zaman, M. H.
   Islam, M. Shafiqul
   Ahmed, Niyaz
   Clemens, J. D.
TI Environmental reservoirs of Vibrio cholerae
SO VACCINE
LA English
DT Article
DE Environmental reservoir; Cholera; Vibrio cholerae; Cyanobacteria;
   Climate variability; Cholera seasonality
ID BLUE-GREEN-ALGA; ENDEMIC CHOLERA; FRESH-WATER; SURFACE-WATER; AQUATIC
   ENVIRONMENT; GENETIC DIVERSITY; RURAL BANGLADESH; EL-TOR; O1;
   SEASONALITY
AB The environmental reservoir of Vibrio cholerae, the causative agent of cholera, has been a topic of scientific investigation ever since the discovery of the bacterium itself. While the bacteria can be isolated from both clinical and environmental sources during epidemics, it evades isolation by conventional culture techniques during the period between successive epidemics. The problem is identifying the location and mode of survival and multiplication of V. cholerae during this inter-epidemic period. This information is crucial not only for epidemiological reasons, but also because the seasonality of cholera epidemics is plausibly mediated by the climate-regulated activity of the reservoir. This article focuses on the epidemiological importance of the environmental reservoir of V. cholerae, considering several investigations made on different types of aquatic fauna (zooplanktons, crustaceans, etc.) and flora (macrophytes and microphytes). After evaluating different lines of evidence, we make the case that certain species of cyanobacteria (Anabaena variabilis, Microcystis aeruginosa) can act as inter-epidemic reservoirs of V. cholerae. Physiological and functional aspects of this association are also discussed. We then present a hypothesis, expanding upon a previously published conceptual model, of how the climate-regulated seasonality of cholera epidemics is mediated by the effect of climatic factors on algal bloom and other local abiotic variables in the water, using Bangladesh as a model. Finally, another aspect of the climate-dependence of disease patterns is briefly explored: large-scale environmental signatures associated with cholera, and recent modelling efforts to predict cholera outbreaks based on coastal phytoplankton. The review, therefore, serves not only as a study of the identity of the inter-epidemic reservoir of V. cholerae, but also explores different ways in which the reservoir and the pathogen behaviour is affected by the climate, and the possible consequences it may have on disease pattern. (C) 2019 Elsevier Ltd.
C1 [Islam, M. Sirajul; Zaman, M. H.; Islam, M. Shafiqul; Ahmed, Niyaz; Clemens, J. D.] Int Ctr Diarrhoeal Dis Res, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.
RP Islam, MS (reprint author), Int Ctr Diarrhoeal Dis Res, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.
EM sislam@icddrb.org
FU icddr,b; Government of Bangladesh
FX We gratefully acknowledge the financial support of icddr,b. icddr,b is
   also grateful to the Government of Bangladesh, Canada, Sweden and the UK
   for providing core/unrestricted support.
CR ABOU-GAREEB A. H., 1960, JOUR HYG, V58, P21
   Alam MT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124098
   Alam MT, 2014, EMERG INFECT DIS, V20, P356, DOI 10.3201/eid2003.131293
   Almagro-Moreno S, 2013, MICROBIOL SPECTR, V1, DOI 10.1128/microbiolspec.OH-0003-2012
   AMAKO K, 1987, APPL ENVIRON MICROB, V53, P603, DOI 10.1128/AEM.53.3.603-605.1987
   AZURIN JC, 1967, B WORLD HEALTH ORGAN, V37, P745
   BAKER RM, 1983, APPL ENVIRON MICROB, V46, P930, DOI 10.1128/AEM.46.4.930-940.1983
   Baracchini T, 2017, ADV WATER RESOUR, V108, P357, DOI 10.1016/j.advwatres.2016.11.012
   BELLY RT, 1973, J PHYCOL, V9, P123, DOI 10.1111/j.0022-3646.1973.00123.x
   BISGAARD M, 1978, ACTA PATH MICRO IM B, V86, P261
   BLAKE PA, 1980, NEW ENGL J MED, V302, P305, DOI 10.1056/NEJM198002073020601
   BOCKEMUHL J, 1986, J APPL BACTERIOL, V60, P435, DOI 10.1111/j.1365-2672.1986.tb05089.x
   BOURKE ATC, 1986, MED J AUSTRALIA, V144, P229, DOI 10.5694/j.1326-5377.1986.tb115883.x
   BRAYTON PR, 1987, APPL ENVIRON MICROB, V53, P2862, DOI 10.1128/AEM.53.12.2862-2865.1987
   Bwire G, 2018, FRONT MICROBIAL, V9
   CHAN ECS, 1969, CAN J MICROBIOL, V15, P409, DOI 10.1139/m69-073
   Colwell R, 1990, ADV CHOLERA RELATED, P327
   Colwell Rita R., 1994, P117
   COLWELL RR, 1985, BIO-TECHNOL, V3, P817, DOI 10.1038/nbt0985-817
   DASTIDAR SG, 1968, INDIAN J MED RES, V56, P654
   de Magny GC, 2008, P NATL ACAD SCI USA, V105, P17676, DOI 10.1073/pnas.0809654105
   DEPAOLA A, 1992, LANCET, V339, P624, DOI 10.1016/0140-6736(92)90917-R
   Emch M, 2008, INT J HEALTH GEOGR, V7, DOI 10.1186/1476-072X-7-31
   Fogg G, 1955, INT VEREIN THEORET A, V12, P219
   FOGG GE, 1958, NATURE, V181, P789, DOI 10.1038/181789a0
   Gangarosa E, 1974, CHOLERA, P381
   GANGAROSA EJ, 1966, B WORLD HEALTH ORGAN, V34, P363
   GLASS RI, 1982, AM J EPIDEMIOL, V116, P959, DOI 10.1093/oxfordjournals.aje.a113498
   Hashizume M, 2010, EPIDEMIOLOGY, V21, P706, DOI 10.1097/EDE.0b013e3181e5b053
   Hayes CA, 2017, ENVIRON MICROBIOL, V19, P4154, DOI 10.1111/1462-2920.13866
   He Y, 2015, MAR POLLUT BULL, V101, P526, DOI 10.1016/j.marpolbul.2015.10.062
   Hill VR, 2011, EMERG INFECT DIS, V17, P2147, DOI 10.3201/eid1711.110748
   HOOD MA, 1981, APPL ENVIRON MICROB, V41, P559, DOI 10.1128/AEM.41.2.559-560.1981
   Hood MA, 1984, ECOLOGY VIBRIO CHOLE
   HOSSELL JC, 1979, FRESHWATER BIOL, V9, P319, DOI 10.1111/j.1365-2427.1979.tb01516.x
   HUGHES JM, 1982, B WORLD HEALTH ORGAN, V60, P395
   HUQ A, 1983, APPL ENVIRON MICROB, V45, P275, DOI 10.1128/AEM.45.1.275-283.1983
   Isa A R, 1990, Med J Malaysia, V45, P187
   Islam M. A., 1988, Bangladesh Veterinarian, V5, P41
   Islam MS, 2009, T ROY SOC TROP MED H, V103, P1165, DOI 10.1016/j.trstmh.2009.04.016
   Islam MS, 2015, T ROY SOC TROP MED H, V109, P572, DOI 10.1093/trstmh/trv057
   ISLAM MS, 1990, MICROBIOL IMMUNOL, V34, P557, DOI 10.1111/j.1348-0421.1990.tb01032.x
   Islam MS, 2004, CAN J MICROBIOL, V50, P127, DOI 10.1139/W03-114
   ISLAM MS, 1994, J DIARRHOEAL DIS RES, V12, P87
   ISLAM MS, 1993, LANCET, V342, P430, DOI 10.1016/0140-6736(93)92840-P
   Islam MS, 2002, CAN J MICROBIOL, V48, P793, DOI [10.1139/w02-073, 10.1139/W02-073]
   ISLAM MS, 1993, J DIARRHOEAL DIS RES, V11, P197
   Islam MS, 1999, T ROY SOC TROP MED H, V93, P36, DOI 10.1016/S0035-9203(99)90171-2
   ISLAM MS, 1989, J TROP MED HYG, V92, P396
   ISLAM MS, 1984, J MED MICROBIOL, V18, pR8
   ISLAM MS, 1994, T ROY SOC TROP MED H, V88, P298, DOI 10.1016/0035-9203(94)90085-X
   ISLAM MS, 1990, T ROY SOC TROP MED H, V84, P422, DOI 10.1016/0035-9203(90)90345-F
   ISLAM MS, 1994, APPL ENVIRON MICROB, V60, P1684, DOI 10.1128/AEM.60.5.1684-1686.1994
   ISLAM MS, 1992, WORLD J MICROB BIOT, V8, P160, DOI 10.1007/BF01195838
   ISLAM MS, 1994, J DIARRHOEAL DIS RES, V12, P245
   Islam MS, 1983, P 2 AS C DIARR DIS C, P23
   Islam MS, 1987, THESIS
   Islam MS, 1995, INT J ENVIRON STUD, V46, P217, DOI DOI 10.1080/00207239508710962
   Islam MS, 1978, P 3 ANN SCI C BANGL, P52
   Islam MS, 1981, BANGLADESH J MICROBI, V1, P70
   ISLAM S, 1990, J TROP MED HYG, V93, P133
   Jutla AS, 2013, ENVIRON MODELL SOFTW, V47, P148, DOI 10.1016/j.envsoft.2013.05.008
   Kabore S, 2018, RES MICROBIOL, V169, P1, DOI 10.1016/j.resmic.2017.08.004
   Kamal A., 1974, 7 PANDEMIC CHOLERA, P1
   KANEKO T, 1978, MICROBIAL ECOL, V4, P135, DOI 10.1007/BF02014284
   KANEKO T, 1973, J BACTERIOL, V113, P24, DOI 10.1128/JB.113.1.24-32.1973
   KAPER J, 1979, APPL ENVIRON MICROB, V37, P91, DOI 10.1128/AEM.37.1.91-103.1979
   KAYSNER CA, 1987, APPL ENVIRON MICROB, V53, P1344, DOI 10.1128/AEM.53.6.1344-1348.1987
   KHAN MU, 1984, TROP GEOGR MED, V36, P335
   Koch R, 1884, Br Med J, V2, P453
   Kokashvili T, 2013, Georgian Med News, P55
   LEE JV, 1982, J APPL BACTERIOL, V52, P281, DOI 10.1111/j.1365-2672.1982.tb04852.x
   Lobitz B, 2000, P NATL ACAD SCI USA, V97, P1438, DOI 10.1073/pnas.97.4.1438
   Longini IM, 2002, J INFECT DIS, V186, P246
   MARTIN AR, 1969, AM J EPIDEMIOL, V89, P572, DOI 10.1093/oxfordjournals.aje.a120970
   MCCORMACK WM, 1969, AM J EPIDEMIOL, V89, P393, DOI 10.1093/oxfordjournals.aje.a120953
   Merson MH, 1980, CHOLERA RELATED DIAR, P34
   MILLER CJ, 1985, LANCET, V1, P261
   MILLER CJ, 1982, LANCET, V1, P1216
   NALIN DR, 1976, LANCET, V2, P958
   OGG JE, 1989, APPL ENVIRON MICROB, V55, P95, DOI 10.1128/AEM.55.1.95-99.1989
   PAERL HW, 1978, LIMNOL OCEANOGR, V23, P927, DOI 10.4319/lo.1978.23.5.0927
   PAERL HW, 1978, MICROBIAL ECOL, V4, P215, DOI 10.1007/BF02015078
   PAERL HW, 1976, J PHYCOL, V12, P431, DOI 10.1111/j.0022-3646.1976.00431.x
   Panja G., 1947, INDIAN JOUR MED RES, V35, P1
   Pollitzer R., 1959, MONOGRAPH SERIES, V43, P1019
   Pretzer C, 2017, ENVIRON MICROBIOL, V19, P328, DOI 10.1111/1462-2920.13612
   RAI R N, 1991, Journal of Communicable Diseases, V23, P44
   Read W, 1941, INDIAN J MED RES, V29
   Rebaudet S, 2013, J INFECT DIS, V208, pS98, DOI 10.1093/infdis/jit202
   RHODES JB, 1986, APPL ENVIRON MICROB, V51, P1216, DOI 10.1128/AEM.51.6.1216-1219.1986
   ROGERS RC, 1980, B WORLD HEALTH ORGAN, V58, P665
   SACK RB, 1973, J INFECT DIS, V127, P709, DOI 10.1093/infdis/127.6.709
   SACK RB, 1964, INDIAN J MED RES, V52, P848
   SALMASO S, 1980, LANCET, V2, P1124
   SAMADI AR, 1983, T ROY SOC TROP MED H, V77, P853, DOI 10.1016/0035-9203(83)90306-1
   SCHNEIDER DR, 1982, J INFECT DIS, V145, P474, DOI 10.1093/infdis/145.4.474
   SOCHARD MR, 1979, APPL ENVIRON MICROB, V37, P750, DOI 10.1128/AEM.37.4.750-759.1979
   SPIRA WM, 1981, APPL ENVIRON MICROB, V42, P550, DOI 10.1128/AEM.42.3.550-553.1981
   Sugimoto JD, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003314
   Sun SY, 2015, ISME J, V9, P1812, DOI 10.1038/ismej.2014.265
   SWAROOP S, 1951, Indian J Med Res, V39, P141
   Takemura T, 2017, INFECT GENET EVOL, V54, P146, DOI 10.1016/j.meegid.2017.06.017
   TAMPLIN ML, 1991, LANCET, V338, P1216, DOI 10.1016/0140-6736(91)92089-K
   TAMPLIN ML, 1990, APPL ENVIRON MICROB, V56, P1977, DOI 10.1128/AEM.56.6.1977-1980.1990
   TWEDT RM, 1981, APPL ENVIRON MICROB, V41, P1475, DOI 10.1128/AEM.41.6.1475-1478.1981
   VENKATESWARAN K, 1989, APPL ENVIRON MICROB, V55, P2613, DOI 10.1128/AEM.55.10.2613-2618.1989
   Venkatraman K, 1941, INDIAN J MED RES, V29
   Visser IJR, 1999, VET REC, V144, P451, DOI 10.1136/vr.144.16.451
   Ward CH, 1964, STUDIES BACTERIA ASS
   WEISSMAN JB, 1974, AM J EPIDEMIOL, V100, P487, DOI 10.1093/oxfordjournals.aje.a112061
   WEST PA, 1982, J APPL BACTERIOL, V52, P435, DOI 10.1111/j.1365-2672.1982.tb05074.x
   World Health Organization, 2017, CHOL FACT SHEET
NR 113
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A52
EP A62
DI 10.1016/j.vaccine.2019.06.033
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500011
PM 31285087
OA Other Gold
DA 2020-05-12
ER

PT J
AU Islam, MT
   Chowdhury, F
   Qadri, F
   Sur, D
   Ganguly, NK
AF Islam, Md Taufiqul
   Chowdhury, Fahima
   Qadri, Firdausi
   Sur, Dipika
   Ganguly, N. K.
TI Trials of the killed oral cholera vaccine (Shanchol) in India and
   Bangladesh: Lessons learned and way forward
SO VACCINE
LA English
DT Article
DE Oral cholera vaccine (OCV); Clinical trial; India; Bangladesh
ID CAMPAIGN; EFFICACY; SAFETY
AB Cholera has been endemic in India and Bangladesh for the greater part of recorded history, giving this region the reputation of being the 'homeland of cholera'. The causative organism Vibrio cholerae O1 has been responsible for large epidemics and pandemics. Bangladesh and India have conducted several sequential studies of Oral Cholera Vaccine (OCV) to ascertain its safety, efficacy, effectiveness, field feasibility and acceptance in high-risk urban populations. The objective of this article is to illustrate the experience of OCV use in these endemic settings, its major challenges, and how policymakers can grant vaccine licenses as well as implement its use in the national immunization programme. The relevant aspects of the OCV studies, such as boosting the effect of vaccine, single-dose versus double-dose trials and thermal stability of the vaccine during delivery have generated strong evidence for recommendation of vaccine use in these settings. Studies have shown that a single dose is effective for children of five years of age and older age groups. The locally manufactured vaccine in India is thermostable and can be delivered in field settings without use of cold chain. The vaccine delivery is feasible and the protective efficacy (PE) of this vaccine above five years of age against cholera was 53-65%. Administration of an OCV boosting regimen elicits an immune response similar to those who received a two-dose vaccine five years back. OCV can be used as a preemptive measure in endemic settings, in natural calamities and during political instability when there is total disruption as well as collapse of safe water supply, sanitation and hygiene (WASH) facilities and other control measures. Clear identification of areas and target population (who will gain benefit from the OCVs) is required to be developed in endemic settings. (C) 2019 Published by Elsevier Ltd.
C1 [Islam, Md Taufiqul; Chowdhury, Fahima; Qadri, Firdausi] Icddr B, Dhaka, Bangladesh.
   [Sur, Dipika; Ganguly, N. K.] Translat Hlth Sci & Technol Inst, Faridabad, Haryana, India.
RP Qadri, F (reprint author), Icddr B, Infect Dis Div, Enter & Resp Infect, 68 Shaheed Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.
EM fqadri@icddrb.org
CR Akanda AS, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL039312
   Ali M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183100
   Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P477
   [Anonymous], 2011, WHA64, P16
   Barua Dhiman, 1992, P1
   Bharati K, CHOLERA OUTBREAK, P87
   Bhattacharya S, 2013, LANCET INFECT DIS, V13, P1050, DOI 10.1016/S1473-3099(13)70273-1
   D'Cor NA, 2016, INT J INFECT DIS, V45, P417, DOI 10.1016/j.ijid.2016.02.890
   Kanungo S, 2010, B WORLD HEALTH ORGAN, V88, P185, DOI 10.2471/BLT.09.073460
   Kanungo S, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003809
   Kanungo S, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003574
   Kanungo S, 2009, VACCINE, V27, P6887, DOI 10.1016/j.vaccine.2009.09.008
   Kar SK, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002629
   Khan AI, 2017, VACCINE, V35, P1538, DOI 10.1016/j.vaccine.2017.01.080
   Khatib AM, 2012, LANCET INFECT DIS, V12, P837, DOI 10.1016/S1473-3099(12)70196-2
   Legros D, 2018, J INFECT DIS, V218, pS137, DOI 10.1093/infdis/jiy486
   Luquero FJ, 2015, LANCET GLOB HEALTH, V3, pE120, DOI 10.1016/S2214-109X(15)70015-X
   Massing LA, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006369
   Montgomery M, 2018, B WORLD HEALTH ORGAN, V96, P371, DOI 10.2471/BLT.18.213678
   Organization W.H., 2013, GUID ACC OR CHOL VAC
   Qadri F, 2018, LANCET INFECT DIS, V18, P666, DOI 10.1016/S1473-3099(18)30108-7
   Qadri F, 2016, NEW ENGL J MED, V374, P1723, DOI 10.1056/NEJMoa1510330
   Qadri F, 2015, LANCET, V386, P1362, DOI 10.1016/S0140-6736(15)61140-0
   Saha A, 2016, VACCINE, V34, P1551, DOI 10.1016/j.vaccine.2016.02.020
NR 25
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A127
EP A131
DI 10.1016/j.vaccine.2019.06.082
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500019
PM 31301917
OA Other Gold
DA 2020-05-12
ER

PT J
AU Lonappan, S
   Golecha, R
   Nair, GB
AF Lonappan, Sophia
   Golecha, Ria
   Nair, G. Balakrish
TI Contrasts, contradictions and control of cholera
SO VACCINE
LA English
DT Article
DE Oral cholera vaccine; Cholera; Outbreak; Forecast; Global Task Force on
   Cholera Control
AB Cholera has been extremely pervasive during the past four decades and continues to remain a significant public health concern. The disease has plagued humankind in the form of seven pandemics since the last two centuries. There is considerable scientific evidence based on research on cholera and its etiologic agent Vibrio cholerae, however we are still unable to accurately forecast and pre-empt the occurrence of cholera outbreaks. The commentary discusses the contrasts and contradictions of cholera, its control and its unpredictable nature. Through a multi-sectoral approach and broad stakeholder collaboration cholera control is possible with meticulous country-level planning for early detection and response to outbreaks. The commentary reiterates that every potential death on account of cholera is preventable because of the available knowledge and tools to effectively prevent and treat cholera. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Lonappan, Sophia; Golecha, Ria] Global Hlth Strategies, New Delhi, India.
   [Nair, G. Balakrish] Rajiv Gandhi Ctr Biotechnol, Microbiome Lab, Thiruvananthapuram 695014, Kerala, India.
RP Nair, GB (reprint author), Rajiv Gandhi Ctr Biotechnol, Microbiome Lab, Thiruvananthapuram 695014, Kerala, India.
EM gbnair_2000@yahoo.com
CR Luquero FJ, 2016, EMERG INFECT DIS, V22, P410, DOI 10.3201/eid2203.141970
   Qadri F, 2018, LANCET, V391, P1877, DOI 10.1016/S0140-6736(18)30993-0
   Sarkar BL, 2012, INDIAN J MED RES, V135, P246
   Sen Gupta S, 2016, INDIAN J MED RES, V143, P545, DOI 10.4103/0971-5916.187102
   Sobsey MD, 2008, ENVIRON SCI TECHNOL, V42, P4261, DOI 10.1021/es702746n
   von Seidlein L, 2017, CHOLERA YEMEN WHY AR
   Weigel J, 2012, AM Q
   Weill FX, 2017, SCIENCE, V358, P785, DOI 10.1126/science.aad5901
   WHO, 2016, WORLD HLTH ORG WEEKL
   WHO, 2017, 2 1 BILL PEOPL LACK
   WHO, 2017, CHOLERA COUNT REACH
   World Health Organization Global Taskforce on Cholera Control, 2017, GLOB TASKF CHOL CONT
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A4
EP A6
DI 10.1016/j.vaccine.2019.08.022
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500002
PM 31451324
OA Other Gold
DA 2020-05-12
ER

PT J
AU Lopez, AL
   Dutta, S
   Qadri, F
   Sovann, L
   Pandey, BD
   Bin Hamzah, WM
   Memon, I
   Iamsirithaworn, S
   Dang, DA
   Chowdhury, F
   Heng, S
   Kanungo, S
   Mogasale, V
   Sultan, A
   Ylade, M
AF Lopez, Anna Lena
   Dutta, Shanta
   Qadri, Firdausi
   Sovann, Ly
   Pandey, Basu Dev
   Bin Hamzah, Wan Mansor
   Memon, Iqbal
   Iamsirithaworn, Sopon
   Duc Anh Dang
   Chowdhury, Fahima
   Heng, Seng
   Kanungo, Suman
   Mogasale, Vittal
   Sultan, Ashraf
   Ylade, Michelle
TI Cholera in selected countries in Asia
SO VACCINE
LA English
DT Article
DE Vibrio; Acute watery diarrhea; Burden; South Asia; Southeast Asia
ID EL-TOR STRAINS; VIBRIO-CHOLERAE; SOUTH-INDIA; WEST-BENGAL; OUTBREAK; O1;
   EPIDEMIC; POPULATION; EMERGENCE; CHILDREN
AB Introduction: Although the current pandemic of cholera originated in Asia, reports of cholera cases and outbreaks in the region are sparse. To provide a sub-regional assessment of cholera in South and Southeast Asia, we collated published and unpublished data from existing surveillance systems from Bangladesh, Cambodia, India, Malaysia, Nepal, Pakistan, Philippines, Thailand and Vietnam.
   Methods: Data from existing country surveillance systems on diarrhea, acute watery diarrhea, suspected cholera and/or confirmed cholera in nine selected Asian countries (Bangladesh, Cambodia, India, Malaysia, Nepal, Pakistan, Philippines, Thailand and Vietnam) from 2011 to 2015 (or 2016, when available) were collated. We reviewed annual cholera reports from WHO and searched PubMed and/or ProMED to complement data, where information is not completely available.
   Results: From 2011 to 2016, confirmed cholera cases were identified in at least one year of the 5- or 6-year period in the countries included. Surveillance for cholera exists in most countries, but cases are not always reported. India reported the most number of confirmed cases with a mean of 5964 cases annually. The mean number of cases per year in the Philippines, Pakistan, Bangladesh, Malaysia, Nepal and Thailand were 760, 592, 285, 264, 148 and 88, respectively. Cambodia and Vietnam reported 51 and 3 confirmed cholera cases in 2011, with no subsequent reported cases.
   Discussion and conclusion: We present consolidated results of available surveillance in nine Asian countries and supplemented these with publication searches. There is paucity of readily accessible data on cholera in these countries. We highlight the continuing existence of the disease even in areas with improved sanitation and access to safe drinking water. Continued vigilance and improved surveillance in countries should be strongly encouraged. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Lopez, Anna Lena; Ylade, Michelle] Univ Philippines Manila, Inst Child Hlth & Human Dev, Natl Inst Hlth, NIH Bldg,Room 112,623 Pedro Gil St, Manila 1000, Philippines.
   [Dutta, Shanta; Kanungo, Suman] Natl Inst Cholera & Enter Dis, Indian Council Med Res, Kolkata, India.
   [Qadri, Firdausi; Chowdhury, Fahima] Int Ctr Diarrheal Dis Res, Dhaka, Bangladesh.
   [Sovann, Ly; Heng, Seng] Minist Hlth, Phnom Penh, Cambodia.
   [Pandey, Basu Dev] Minist Hlth, Dept Hlth Serv, Kathmandu, Nepal.
   [Bin Hamzah, Wan Mansor] Minist Hlth, Putrajaya, Malaysia.
   [Memon, Iqbal] Sir Syed Coll Med Sci, Karachi, Pakistan.
   [Iamsirithaworn, Sopon] Thailand Minist Publ Hlth US CDC Collaborat, Dept Dis Control, Nonthaburi, Thailand.
   [Duc Anh Dang] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam.
   [Mogasale, Vittal] Int Vaccine Inst, Seoul, South Korea.
   [Sultan, Ashraf] Midc Hosp, Lahore, Pakistan.
RP Lopez, AL (reprint author), Univ Philippines Manila, Inst Child Hlth & Human Dev, Natl Inst Hlth, NIH Bldg,Room 112,623 Pedro Gil St, Manila 1000, Philippines.
EM allopez2@up.edu.ph
OI Dutta, Shanta/0000-0002-6897-7390
CR ALBERT MJ, 1993, LANCET, V341, P704
   Ali M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183100
   Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832
   Allam Ramesh R, 2015, Indian J Community Med, V40, P283, DOI 10.4103/0970-0218.164408
   [Anonymous], 2016, Wkly Epidemiol Rec, V91, P433
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P517
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P539
   [Anonymous], 2013, Wkly Epidemiol Rec, V88, P321
   [Anonymous], 2012, Wkly Epidemiol Rec, V87
   Anti DD, 2014, PLOS MED, V11, pe1001712
   Bangladesh Bureau of Statistics, 2015, POP PROJ BANGL DYN T
   Bhattacharya D, 2015, JPN J INFECT DIS, V68, P347, DOI 10.7883/yoken.JJID.2014.257
   Biswas DK, 2014, J TROP MED, DOI 10.1155/2014/764530
   Cholera 2015, 2016, WEEKLY EPIDEMIOLOGIC, V91, P433
   Das SK, 2014, TROP MED INT HEALTH, V19, P240, DOI 10.1111/tmi.12231
   Datta SS, 2012, J HEALTH POPUL NUTR, V30, P109, DOI 10.3329/jhpn.v30i1.11290
   Deepthi R, 2013, J INFECT PUBLIC HEAL, V6, P35, DOI 10.1016/j.jiph.2012.05.003
   Dey S, 2014, INDIAN J MED RES, V140, P420
   Fredrick T, 2015, J HEALTH POPUL NUTR, V33, P31
   Goel AK, 2011, J MICROBIOL, V49, P280, DOI 10.1007/s12275-011-0317-9
   Hu DL, 2016, P NATL ACAD SCI USA, V113, pE7730, DOI 10.1073/pnas.1608732113
   Jain M, 2016, J PATHOG, DOI 10.1155/2016/1695410
   Jain M, 2011, ACTA TROP, V117, P152, DOI 10.1016/j.actatropica.2010.12.002
   JMP, WHO UNICEF JOINT MON
   Kanungo S, 2010, B WORLD HEALTH ORGAN, V88, P185, DOI 10.2471/BLT.09.073460
   Kar SK, 2015, INT J INFECT DIS, V33, P45, DOI 10.1016/j.ijid.2014.12.025
   Kumar P, 2014, INFECT GENET EVOL, V25, P93, DOI 10.1016/j.meegid.2014.03.020
   Kumar P, 2014, CLIN MICROBIOL INFEC, V20, pO292, DOI 10.1111/1469-0691.12393
   Liu J, 2016, LANCET, V388, P1291, DOI 10.1016/S0140-6736(16)31529-X
   Lopez AL, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003440
   Mahanta Bhupendra Narayan, 2013, Indian J Community Med, V38, P240, DOI 10.4103/0970-0218.120160
   Mridha P, 2011, J HEALTH POPUL NUTR, V29, P9
   Mutreja A, 2011, NATURE, V477, P462, DOI 10.1038/nature10392
   Nair GB, 2006, J CLIN MICROBIOL, V44, P4211, DOI 10.1128/JCM.01304-06
   National Centre for Disease Control, 2017, INT DIS SURV PROGR
   Oxford Economics, 2010, EC IMP CHOL EP MOZ B
   RAMAMURTHY T, 1993, LANCET, V341, P703, DOI 10.1016/0140-6736(93)90480-5
   Roy S, 2012, J MED MICROBIOL, V61, P1574, DOI 10.1099/jmm.0.049692-0
   Sabatinelli Guido, 2012, Morbidity and Mortality Weekly Report, V61, P1002
   Sack DA, 2004, LANCET, V363, P223, DOI 10.1016/S0140-6736(03)15328-7
   Sekar R, 2012, INDIAN J MED RES, V135, P678
   Shah HD, 2012, J POSTGRAD MED, V58, P14, DOI 10.4103/0022-3859.93247
   Sonia Barve, 2012, National Journal of Community Medicine, V3, P104
   Talavera A, 2009, J INFECT DEV COUNTR, V3, P408, DOI 10.3855/jidc.410
   Uthappa CK, 2015, J HEALTH POPUL NUTR, V33, P7
   WHO, 2014, REL EP HEBD SECT HYG, V89, P345
   WHO, 2004, CHOL OUTBR ASS OUTBR
   WHO, 2010, WHO STAT REL INT TRA
NR 48
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A18
EP A24
DI 10.1016/j.vaccine.2019.07.035
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500005
PM 31326255
OA Other Gold
DA 2020-05-12
ER

PT J
AU Lubogo, M
   Mohamed, AM
   Ali, AH
   Ali, AH
   Popal, GR
   Kiongo, D
   Bile, KM
   Malik, M
   Abubakar, A
AF Lubogo, Mutaawe
   Mohamed, Ahmed M.
   Ali, Abdullahi H.
   Ali, Aden H.
   Popal, Ghulam R.
   Kiongo, David
   Bile, Khalif Mohamud
   Malik, Mamunur
   Abubakar, Abdinasir
TI Oral cholera vaccination coverage in an acute emergency setting in
   Somalia, 2017
SO VACCINE
LA English
DT Article
DE Cholera; Oral cholera vaccine; Outbreaks; Vaccine coverage; Households;
   Somalia
ID STOP TRANSMISSION; SOUTH SUDAN; OUTBREAK
AB The first oral cholera vaccination (OCV) campaign in Somalia was implemented between March and October 2017. It was the first time the Ministry of Health had introduced and used OCV as part of the cholera prevention and control strategies. The Ministry of Health aimed to cover 1.1 million people >= 1 year with 2 doses of the OCV in 11 high-risk districts. Overall, 2-dose administrative OCV coverage in all targeted districts was 95.5%. Following the campaign, a random sample survey was conducted in 9 out of 11 districts to evaluate coverage, awareness, reasons for non-vaccination, the water and sanitation status of households, and any resulting adverse events. The survey was conducted in 2 phases. Of the 3,715 eligible individuals in the first phase, 92.5% (95% CI 91.4-93.6%) received 2 doses of the OCV and 7.0% (95% CI 6.0-8.2%) 1 dose. In the second phase, of 1,926 individuals, 94.1% (95% CI 92.9-95.1%) received 2 doses and 2.6% (95% CI 2.0-3.4%) 1 dose. Despite challenges, this experience shows that OCV campaigns can be implemented in acute humanitarian settings through existing immunization structures. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Lubogo, Mutaawe; Popal, Ghulam R.] WHO, Somalia Country Off, Mogadishu, Somalia.
   [Mohamed, Ahmed M.; Ali, Abdullahi H.; Ali, Aden H.] Fed Minist Hlth, Mogadishu, Somalia.
   [Malik, Mamunur; Abubakar, Abdinasir] WHO Eastern Mediterranean Reg, Cairo, Egypt.
RP Abubakar, A (reprint author), WHO, Reg Off Eastern Mediterranean, Infect Hazard Management Unit, Monazamet El Seha El Alamia St, Cairo 11371, Egypt.
EM abubakara@who.int
OI abubakar, abdinasir/0000-0002-5131-5518
FU World Health OrganizationWorld Health Organization [001]
CR Abubakar A, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001901
   [Anonymous], 2010, Wkly Epidemiol Rec, V85, P117
   Azman AS, 2016, LANCET GLOB HEALTH, V4, pE856, DOI 10.1016/s2214-109x(16)30211-x
   Azman AS, 2016, NEW ENGL J MED, V375, DOI 10.1056/NEJMc1607285
   Azman AS, 2016, EMERG INFECT DIS, V22, P1067, DOI 10.3201/eid2206.151592
   Cabrera A, 2017, ANN PHARMACOTHER, V51, P584, DOI 10.1177/1060028017698162
   Lam E, 2017, EMERG INFECT DIS, V23, P38, DOI 10.3201/eid2301.160881
   Lessler J, 2018, LANCET, V391, P1908, DOI [10.1016/S0140-6736(17)33050-7, 10.1016/s0140-6736(17)33050-7]
   Michael CA, 2017, J INFECT DIS, V216, pS373, DOI 10.1093/infdis/jix014
   Msyamboza Kelias Phiri, 2016, Pan Afr Med J, V23, P203, DOI 10.11604/pamj.2016.23.203.8346
   Reliefweb Internet, 2017, HUM B SOM
   Tchoualeu DD, 2017, J INFECT DIS, V216, pS362, DOI 10.1093/infdis/jiw563
   World Health Organization, 2017, EP PAND PRON DIS NIF
   World Health. Organization, 2008, TRAIN MIDL MAN MLM M
   World Health Organization, 2017, CHOL SIT SOM
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A141
EP A147
DI 10.1016/j.vaccine.2020.01.015
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500021
PM 31980193
OA Other Gold
DA 2020-05-12
ER

PT J
AU Luby, SP
   Davis, J
   Brown, RR
   Gorelick, SM
   Wong, THF
AF Luby, Stephen P.
   Davis, Jennifer
   Brown, Rebekah R.
   Gorelick, Steven M.
   Wong, Tony H. F.
TI Broad approaches to cholera control in Asia: Water, sanitation and
   handwashing
SO VACCINE
LA English
DT Article
DE Cholera; Sanitation; Asia; Drinking water; Government
ID DRINKING-WATER; WASTE-WATER; BANGLADESH; IMPACT; DIARRHEA; QUALITY;
   HYGIENE; PRIVATIZATION; DISINFECTION; EXPERIENCE
AB Cholera has been eliminated as a public health problem in high-income countries that have implemented sanitation system separating the community's fecal waste from their drinking water and food supply. These expensive, highly-engineered systems, first developed in London over 150 years ago, have not reached low-income high-risk communities across Asia. Barriers to their implementation in communities at highest risk for cholera include the high capital and operating costs for this technological approach, limited capacity and perverse incentives of local governments, and a decreasing availability of water. Interim solutions including household level water treatment, constructing latrines and handwashing promotion have only marginally reduced the risk of cholera and other fecally transmitted diseases. Increased research to develop and policy flexibility to implement a new generation of solutions that are designed specifically to address the physical, financial and political constraints of low-income communities offers the best prospect for reducing the burden of cholera across Asia. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Luby, Stephen P.; Davis, Jennifer; Gorelick, Steven M.] Stanford Univ, Woods Inst Environm, Stanford, CA 94305 USA.
   [Brown, Rebekah R.] Monash Univ, Monash Sustainable Dev Inst, Clayton, Vic, Australia.
   [Wong, Tony H. F.] Monash Univ, Cooperat Res Ctr Water Sensit Cities, Clayton, Vic, Australia.
RP Luby, SP (reprint author), Stanford Univ, Y2E2,MC 4205,473 Via Ortega, Stanford, CA 94305 USA.
EM sluby@stanford.edu
OI Brown, Rebekah/0000-0002-8689-7562
CR Alcayaga S, 1993, REV CHIL INFECTOL, V1, P5
   Asian Development Bank, 2016, AS WAT DEV OUTL 2016
   Baietti A, 2006, CHARACTERISTICS WELL
   Bartone CR, 2011, FEAR CHOLERA FULL WA
   BRISCOE J, 1978, AM J CLIN NUTR, V31, P2100
   Briscoe J., 2006, PAKISTANS WATER EC R
   Brown R, 2011, WATER RESOUR MANAG, V25, P4037, DOI 10.1007/s11269-011-9886-y
   Brown RR, 2008, ENVIRON MANAGE, V41, P221, DOI 10.1007/s00267-007-9046-6
   Budds J, 2003, ENVIRON URBAN, V15, P87, DOI 10.1177/095624780301500222
   Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P783
   Clasen T, 2014, LANCET GLOB HEALTH, V2, pE645, DOI 10.1016/S2214-109X(14)70307-9
   Clasen TF, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004794.pub3
   Colwell RR, 2003, P NATL ACAD SCI USA, V100, P1051, DOI 10.1073/pnas.0237386100
   Conroy RM, 2001, ARCH DIS CHILD, V85, P293, DOI 10.1136/adc.85.4.293
   Curtis VA, 2009, HEALTH EDUC RES, V24, P655, DOI 10.1093/her/cyp002
   Davis J, 2004, WORLD DEV, V32, P53, DOI 10.1016/j.worlddev.2003.07.003
   DEB BC, 1986, B WORLD HEALTH ORGAN, V64, P127
   Dreibelbis R, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1015
   Ercumen A, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007323
   Ferreccio C, 1995, ENVIRON SUST DEV P, P160
   Frauendorfer R., 2010, ISSUES CHALLENGES RE
   Galiani S, 2005, J POLIT ECON, V113, P83, DOI 10.1086/426041
   George CM, 2016, EMERG INFECT DIS, V22, P233, DOI [10.3201/eid2202.151175, 10.3201/eid2202.15117]
   Gleick P. H., 2012, THE WORLDS WATER, DOI [10.5822/978-1-59726-228-6_6, DOI 10.5822/978-1-59726-228-6_6]
   Grant SB, 2012, SCIENCE, V337, P681, DOI 10.1126/science.1216852
   Habitat UN, 2013, STAT WORLDS CIT 2012
   Hackenbroch K, 2012, PLAN THEORY PRACT, V13, P397, DOI 10.1080/14649357.2012.694265
   Hailu D, 2012, WORLD DEV, V40, P2564, DOI 10.1016/j.worlddev.2012.05.032
   Halliday S., 1999, GREAT STINK LONDON
   Hoque MA, 2007, HYDROGEOL J, V15, P1523, DOI 10.1007/s10040-007-0226-5
   Horng LM, 2016, J HOSP INFECT, V94, P286, DOI 10.1016/j.jhin.2016.08.016
   Hossain S, 2013, ENVIRON URBAN, V25, P209, DOI 10.1177/0956247812465803
   Huang X, 2016, WATER RES, V92, P164, DOI 10.1016/j.watres.2016.01.040
   Hueso A, 2013, WATER POLICY, V15, P1001, DOI 10.2166/wp.2013.032
   Hulland KRS, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-877
   Huttinger A, 2017, INT J ENV RES PUB HE, V14, DOI 10.3390/ijerph14121584
   icddr b, 2014, ICDDR B BANGL NAT HY
   Jeandron A, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001893
   Jena M, 2008, EC POLIT WKLY, P88
   Kar K., 2008, HDB COMMUNITY LED TO
   Karkey A, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004346
   KHAN MU, 1981, INT J EPIDEMIOL, V10, P23, DOI 10.1093/ije/10.1.23
   Killingsworth JR, 1999, HEALTH POLICY PLANN, V14, P152, DOI 10.1093/heapol/14.2.152
   Kingdom B, CHALLENGE REDUCING N
   Kumpel E, 2014, ENVIRON SCI TECHNOL, V48, P2766, DOI 10.1021/es405054u
   Kumpel E, 2013, WATER RES, V47, P5176, DOI 10.1016/j.watres.2013.05.058
   Lanata CF, 2003, INT J ENVIRON HEAL R, V13, pS175, DOI 10.1080/0960312031000102921
   Lantagne DS, 2017, ENVIRON SCI TECHNOL, V46, P11352
   Lau JTF, 2003, J EPIDEMIOL COMMUN H, V57, P864, DOI 10.1136/jech.57.11.864
   Lee Ellen J., 2005, Journal of Water and Health, V3, P109
   LEVINE RJ, 1976, LANCET, V2, P86
   Lijadu K., KENYAN NONPROFITS IN
   Lin A, 2018, CLIN INFECT DIS
   Luby SP, 2008, AM J TROP MED HYG, V78, P382, DOI 10.4269/ajtmh.2008.78.382
   Luby SP, 2018, LANCET GLOB HEALTH, V6, pE302, DOI 10.1016/S2214-109X(17)30490-4
   Luckin W, 1977, Med Hist, V21, P32
   McCrickard LS, 2017, CHOLERA MORTALITY UR, V23
   McIntosh AC, 2003, ASIAN WATER SUPPLIES
   McKenzie D, 2009, WATER POLICY, V11, P442, DOI 10.2166/wp.2009.056
   Melosi MV, 2000, SANITARY CITY
   Mguni P, 2015, WATER POLICY, V17, P126, DOI 10.2166/wp.2014.047
   Mutikanga HE, 2011, WATER ENVIRON J, V25, P327, DOI 10.1111/j.1747-6593.2010.00225.x
   Najnin N, 2017, INT J EPIDEMIOL, V46, P2056, DOI 10.1093/ije/dyx187
   Nguyen VD, 2014, AM J TROP MED HYG, V90, P518, DOI 10.4269/ajtmh.13-0567
   Otaki Y, 2007, J WATER HEALTH, V5, P259, DOI [10.2166/wh.2007.005b, 10.2166/wh.2007.005]
   Pachauri R. K., 2014, CLIMATE CHANGE 2014
   Patrick M, 2017, AM J TROP MED HYG, V97, P84, DOI 10.4269/ajtmh.16-0692
   Patrick M, 2013, AM J TROP MED HYG, V89, P647, DOI 10.4269/ajtmh.13-0308
   Paul RC, 2016, EPIDEMIOL INFECT, V144, P927, DOI 10.1017/S0950268815002174
   Peal A, 2014, J WATER SANIT HYG DE, V4, P563, DOI 10.2166/washdev.2014.026
   Qadri F, 2015, LANCET, V386, P1362, DOI 10.1016/S0140-6736(15)61140-0
   Rahman MM, 2000, ENVIRON GEOL, V40, P31, DOI 10.1007/s002540000152
   Rebaudet S, 2013, J INFECT DIS, V208, pS46, DOI 10.1093/infdis/jit195
   Rodell M, 2009, NATURE, V460, P999, DOI 10.1038/nature08238
   Rosa G, 2010, AM J TROP MED HYG, V82, P289, DOI 10.4269/ajtmh.2010.09-0382
   Rubin GJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2651
   Sato T, 2013, AGR WATER MANAGE, V130, P1, DOI 10.1016/j.agwat.2013.08.007
   Segerfeldt F, 2005, WATER SALE BUSINESS
   Sima LC, 2013, ECOL ECON, V87, P137, DOI 10.1016/j.ecolecon.2012.12.011
   Smith AH, 2000, B WORLD HEALTH ORGAN, V78, P1093
   Sochan G, 2007, HUMANIT TECHNOL REV, V26, P27
   SOMMER A, 1972, LANCET, V2, P985
   Srinivasan V, 2013, GLOBAL ENVIRON CHANG, V23, P229, DOI 10.1016/j.gloenvcha.2012.10.002
   Stockman LJ, 2007, EMERG INFECT DIS, V13, P1077, DOI 10.3201/eid1307.060767
   Sur D, 2009, NEW ENGL J MED, V361, P335, DOI 10.1056/NEJMoa0807521
   Taylor DL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135676
   Thornbury W., 1878, VICTORIA EMBANKMENT, P322
   Tien JH, 2010, J ROY SOC INTERFACE
   Tilmans S, 2014, J WATER SANIT HYG DE, V4, P449, DOI 10.2166/washdev.2014.138
   United Nations General Assembly, 2010, ARES64292 UN GEN ASS
   Verhoeven JTA, 1999, ECOL ENG, V12, P5, DOI 10.1016/S0925-8574(98)00050-0
   WADE R, 1985, WORLD DEV, V13, P467, DOI 10.1016/0305-750X(85)90052-X
   Wang A, 2016, MMWR-MORBID MORTAL W, V65, P2
   WHO/UNICEF, 2014, PROGR JWSSM PROGR DR
   Winblad U., 1997, ECOLOGICAL APPROACH
   Wolf J, 2014, TROP MED INT HEALTH, V19, P928, DOI 10.1111/tmi.12331
   Wolfe M, 2018, AM J TROP MED HYG, V99, P534, DOI 10.4269/ajtmh.17-0897
   Wong THF, 2009, WATER SCI TECHNOL, V60, P673, DOI 10.2166/wst.2009.436
   Wong THF, 2006, AUSTRALAS J WAT RESO, V10, P213, DOI 10.1080/13241583.2006.11465296
   World Bank, 2019, EV POT CONT BAS SAN
   World Economic Forum Water Initiative, 2012, WAT SEC WAT FOOD EN
   Zhang QF, 2009, J AM WATER RESOUR AS, V45, P1238, DOI 10.1111/j.1752-1688.2009.00357.x
NR 102
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A110
EP A117
DI 10.1016/j.vaccine.2019.07.084
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500017
PM 31383486
OA Other Gold
DA 2020-05-12
ER

PT J
AU Mogasale, V
   Kanungo, S
   Pati, S
   Lynch, J
   Dutta, S
AF Mogasale, Vittal
   Kanungo, Suman
   Pati, Sanghamitra
   Lynch, Julia
   Dutta, Shanta
TI The history of OCV in India and barriers remaining to programmatic
   introduction
SO VACCINE
LA English
DT Article
DE Cholera vaccine; Clinical trial; Vaccine introduction
ID ORAL CHOLERA VACCINE; WHOLE-CELL; KOLKATA; TRANSMISSION; ODISHA; SLUMS;
   HAITI
AB Cholera-endemic Eastern India has played an important role in the development of oral cholera vaccines (OCV) through conduct of pivotal trials in Kolkata which led to the registration of the first low-cost bivalent killed whole cell OCV in India in 2009, and subsequent prequalification by the World Health Organization prequalification in 2011. Odisha hosted an influential early demonstration project for use of the vaccine in a high-risk population and provided data and lessons that were crucial input in the Vaccine Investment Strategy developed by Gavi, the Vaccine Alliance in 2013. With Gavi's decision to finance an OCV stockpile, the demand for OCV surged and vaccine has been deployed with great success worldwide in areas of need in response to outbreaks and disasters, most notably in Africa. However, although India is considered one of the highest burden countries, no further use of OCV has occurred since the demonstration project in Odisha in 2011. In this paper we will summarize the important contributions of India to the development and use of OCV and discuss the possible barriers to OCV introduction as a public health tool to control cholera. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Mogasale, Vittal] Int Vaccine Inst, Policy & Econ Res Dept, Publ Hlth Access & Vaccine Epidemiol PAVE Unit, Seoul, South Korea.
   [Kanungo, Suman; Dutta, Shanta] Indian Council Med Res, Natl Inst Cholera & Enter Dis, P-33 CIT Rd, Kolkata 700010, India.
   [Pati, Sanghamitra] Indian Council Med Res, Reg Med Res Ctr, Bhubaneswar, India.
   [Lynch, Julia] Int Vaccine Inst, Dev & Delivery Unit, Seoul, South Korea.
RP Dutta, S (reprint author), Indian Council Med Res, Natl Inst Cholera & Enter Dis, P-33 CIT Rd, Kolkata 700010, India.
EM shanta1232001@yahoo.co.in
OI Dutta, Shanta/0000-0002-6897-7390; Mogasale, Vittal/0000-0003-0596-8072
FU Government of the Republic of KoreaKorean Government; Government of the
   Sweden; Government of the India
FX Authors did,not receive any financial resources for this work. The
   International Vaccine Institute receives core funding from the
   Governments of the Republic of Korea, Sweden and India. Contribution of
   Dr. B.B. Pal, Scientist, RMRC, Bhubneswar and Dr. P. Chatterjee,
   Scientist, ICMR-NICED in reviewing the article is gratefully
   acknowledged.
CR Ali M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183100
   Ali M, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002120
   Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832
   Ali M, 2013, CLIN INFECT DIS, V56, P1123, DOI 10.1093/cid/cit009
   Anh DD, 2007, VACCINE, V25, P1149, DOI 10.1016/j.vaccine.2006.09.049
   Ann Levin DD, 2012, INVESTMENT CASE ACCE
   Azman AS, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau6242
   Balakrishnan VS, 2017, LANCET INFECT DIS, V17, P700, DOI 10.1016/S1473-3099(17)30352-3
   Bhattacharya S, 2013, LANCET INFECT DIS, V13, P1050, DOI 10.1016/S1473-3099(13)70273-1
   Cholera WHO, 2018, VACCINE, V36, P3418
   Anh DD, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001712
   Desai SN, 2017, HUM VACC IMMUNOTHER, V13, P579, DOI 10.1080/21645515.2016.1245250
   Desai SN, 2016, LANCET GLOB HEALTH, V4, pE223, DOI 10.1016/S2214-109X(16)00037-1
   Haldar P, 2020, VACCINE, V38, pA175, DOI 10.1016/j.vaccine.2019.06.047
   Islam MS, 2015, T ROY SOC TROP MED H, V109, P572, DOI 10.1093/trstmh/trv057
   Ivers LC, 2017, NEW ENGL J MED, V376, P101, DOI 10.1056/NEJMp1614104
   Ivers LC, 2015, LANCET GLOB HEALTH, V3, pE162, DOI 10.1016/S2214-109X(14)70368-7
   Jelinek T, 2008, EXPERT REV VACCINES, V7, P561, DOI 10.1586/14760584.7.5.561
   Jeuland M, 2009, VALUE HEALTH, V12, P899, DOI 10.1111/j.1524-4733.2009.00562.x
   John TJ, 2010, VACCINE, V28, pA88, DOI 10.1016/j.vaccine.2010.02.041
   Kanungo S, 2010, B WORLD HEALTH ORGAN, V88, P185, DOI 10.2471/BLT.09.073460
   Kanungo S, 2009, VACCINE, V27, P6887, DOI 10.1016/j.vaccine.2009.09.008
   Kar SK, 2014, HUM VACC IMMUNOTHER, V10, P2834, DOI 10.4161/21645515.2014.971655
   Kar SK, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002629
   Kim JH, 2016, VACCINE, V34
   Kupferschmidt K, 2017, SCIENCE, V356, P1316, DOI 10.1126/science.356.6345.1316
   Lahariya C, 2014, INDIAN J MED RES, V139, P491
   Legros D, 2018, J INFECT DIS, V218, pS137, DOI 10.1093/infdis/jiy486
   Lopez AL, 2012, COUNTRY INVESTMENT C, pIVI
   Lopez Anna Lena, 2014, Ther Adv Vaccines, V2, P123, DOI 10.1177/2051013614537819
   Mahalanabis D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002323
   Mogasale V, 2020, VACCINE, V38, pAl 60
   Mogasale V, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005124
   Mogasale V, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004072
   Mogasale V, 2013, LANCET, V382, P6
   Mutreja A, 2011, NATURE, V477, P462, DOI 10.1038/nature10392
   Nelson CB, 2014, VACCINE, V32, P7033, DOI 10.1016/j.vaccine.2014.05.028
   Panda S, 2020, VACCINE, V38, pA148, DOI 10.1016/j.vaccine.2019.07.029
   POLLITZER R, 1954, Bull World Health Organ, V10, P421
   Poulos C, 2012, EPIDEMIOL INFECT, V140, P500, DOI 10.1017/S0950268811000513
   Sachdeva A, 2017, INDIAN PEDIATR, V54, P445, DOI 10.1007/s13312-017-1044-z
   Saha A, 2017, EXPERT REV VACCINES, V16, P235, DOI 10.1080/14760584.2017.1249470
   Sarkar BL, 2012, INDIAN J MED RES, V135, P246
   Severe K, 2016, AM J TROP MED HYG, V94, P1136, DOI 10.4269/ajtmh.15-0700
   Shin S, 2011, CLIN INFECT DIS, V52, P1343, DOI 10.1093/cid/cir141
   Sur D, 2005, ARCH DIS CHILD, V90, P1175, DOI 10.1136/adc.2004.071316
   Teshome S, 2018, HUM VACC IMMUNOTHER, V14, P2427, DOI 10.1080/21645515.2018.1460295
   Weill FX, 2017, SCIENCE, V358, P785, DOI 10.1126/science.aad5901
   Wierzba TF, 2015, VACCINE, V33, P2463, DOI 10.1016/j.vaccine.2015.03.073
   World Hlth Org, 2018, VACCINE, V36, P3418, DOI 10.1016/j.vaccine.2017.09.034
NR 50
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A41
EP A45
DI 10.1016/j.vaccine.2020.01.016
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500009
PM 31982258
OA Other Gold
DA 2020-05-12
ER

PT J
AU Mogasale, V
   Mogasale, VV
   Hsiao, A
AF Mogasale, Vittal
   Mogasale, Vijayalaxmi V.
   Hsiao, Amber
TI Economic burden of cholera in Asia
SO VACCINE
LA English
DT Article
DE Cholera; Economic burden; Cost of illness; Treatment costs; Lost
   productivity
ID VACCINES
AB Background: The economic burden data can provide a basis to inform investments in cholera control and prevention activities. However, treatment costs and productivity loss due to cholera are not well studied.
   Methods: We included Asian countries that either reported cholera cases to the World Health Organization (WHO) in 2015 or were considered cholera endemic in 2015 global burden of disease study. Public health service delivery costs for hospitalization and outpatient costs, out-of-pocket costs to patients and households, and lost productivity were extracted from literature. A probabilistic multivariate sensitivity analysis was conducted for key outputs using Monte Carlo simulation. Scenario analyses were conducted using data from the WHO cholera reports and conservative and liberal disease burden estimates.
   Results: Our analysis included 14 Asian countries that were estimated to have a total of 850,000 cholera cases and 25,500 deaths in 2015 While, the WHO cholera report documented around 60,000 cholera cases and 28 deaths. We estimated around $20.2 million (374.4 million) in out-of-pocket expenditures, $8.5 million (1530.1 million) in public sector costs, and $12.1 million (1543.7 million) in lost productivity in 2015. Lost productivity due to premature deaths was estimated to be $985.7 million (1$3,638.6 million). Our scenario analyses excluding mortality costs showed that the economic burden ranged from 20.3% ($8.3 million) to 139.3% ($57.1 million) in high and low scenarios when compared to the base case scenario ($41 million) and was least at 10.1% ($4.1 million) when estimated based on cholera cases reported to WHO.
   Conclusion: The economic burden of cholera in Asia provides a better understanding of financial offsets that can be achieved, and the value of investments on cholera control measures. With a clear understanding of the limitations of the underlying assumptions, the information may be used in economic evaluations and policy decisions. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Mogasale, Vittal] Int Vaccine Inst, Policy & Econ Res Dept, Publ Hlth Access & Vaccine Epidemiol Unit, SNU Res Pk,1 Gwanak Ro, Seoul 08826, South Korea.
   [Mogasale, Vijayalaxmi V.] Yenepoya Med Coll & Res Ctr, Dept Pediat, Mangalore, India.
   [Hsiao, Amber] Tech Univ Berlin, Dept Hlth Care Management, Berlin, Germany.
RP Mogasale, V (reprint author), Int Vaccine Inst, Policy & Econ Res Dept, Publ Hlth Access & Vaccine Epidemiol Unit, SNU Res Pk,1 Gwanak Ro, Seoul 08826, South Korea.
EM vmogasale@ivi.int
OI Mogasale, Vittal/0000-0003-0596-8072
FU Government of the Republic of KoreaKorean Government; Government of the
   Republic of Sweden; Government of the Republic of India
FX Authors did not receive any financial resources for this work. The
   International Vaccine Institute receives core funding from the
   Governments of the Republic of Korea, Sweden and India.
CR Agtini MD, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-89
   Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832
   [Anonymous], 2008, CHOOS INT AR COST EF
   Barendregt JJ, 2010, ERSATZ
   Bartsch SM, 2014, HUM VACC IMMUNOTHER, V10, P1568, DOI 10.4161/hv.28885
   Cholera 2015, 2016, WEEKLY EPIDEMIOLOGIC, V91, P433
   Hsiao A, 2018, VACCINE, V36, P4404, DOI 10.1016/j.vaccine.2018.05.120
   Hsiao A, 2017, B WORLD HEALTH ORGAN, V95, P303, DOI [10.2471/BLT.16.175166, 10.2471/blt.16.175166]
   Kim JH, 2016, VACCINE, V34, P2113, DOI 10.1016/j.vaccine.2016.03.004
   Kirigia JM, 2009, BMC INT HEALTH HUM R, V9, DOI 10.1186/1472-698X-9-8
   Legros D, 2018, J INFECT DIS, V218, pS137, DOI 10.1093/infdis/jiy486
   Lucas MES, 2005, NEW ENGL J MED, V352, P757, DOI 10.1056/NEJMoa043323
   Mogasale V, 2015, PLOS NEGLECT TROP D, V9
   Mogasale V, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005124
   Mogasale V, 2013, LANCET, V382, P6
   POLLITZER R, 1954, Bull World Health Organ, V10, P421
   Poulos C, 2012, EPIDEMIOL INFECT, V140, P500, DOI 10.1017/S0950268811000513
   RiskAMP, 2017, OV BET PERT DISTR MO
   Sarker AR, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-518
   Sur D, 2005, ARCH DIS CHILD, V90, P1175, DOI 10.1136/adc.2004.071316
   Teoh SL, 2018, HUM VACC IMMUNOTHER, V14, P420, DOI 10.1080/21645515.2017.1392422
   UN, 2014, COMP MACR GEOGR CONT
   WHO, 2017, PART COMM RED CHOL D
   WHO Publication, 2010, VACCINE, V28, P4687, DOI 10.1016/j.vaccine.2010.05.008
   Wierzba TF, 2015, VACCINE, V33, P2463, DOI 10.1016/j.vaccine.2015.03.073
   WorldBank, 2017, GDP DEFL ANN WORLD B
   WorldBank, 2017, LIF EXP BIRTH TOT YE
   WorldBank, 2017, WORLD BANK COUNTR LE
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A160
EP A166
DI 10.1016/j.vaccine.2019.09.099
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500024
PM 31611097
OA Other Gold
DA 2020-05-12
ER

PT J
AU Mutreja, A
   Dougan, G
AF Mutreja, Ankur
   Dougan, Gordon
TI Molecular epidemiology and intercontinental spread of cholera
SO VACCINE
LA English
DT Article
DE Cholera; Vibrio; Genomics; Vaccine; Epidemiology; Spread; Transmission;
   Outbreak; Epidemic; Pandemic
ID VIBRIO-CHOLERAE; TRANSMISSION; OUTBREAK
AB Whole genome sequence analysis has revealed the phylogenetic structure of Vibrio cholerae and has shown that the current seventh pandemic is highly clonal, emerging from a single source. Such analysis has the potential to become a powerful public health tool as we build public sequence databases, and as the speed of sequencing and analysis increases. Examples of such studies, as applied to different settings of the disease cholera, are described and discussed. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Mutreja, Ankur; Dougan, Gordon] Univ Cambridge, Dept Med, Cambridge CB2 0QQ, England.
   [Mutreja, Ankur] Translat Hlth Sci & Technol Inst, Faridabad 121001, Haryana, India.
   [Mutreja, Ankur; Dougan, Gordon] Wellcome Trust Sanger Inst, Cambridge CB10 1S, England.
RP Mutreja, A (reprint author), Univ Cambridge, Addenbrookes Hosp, Dept Med, Level 5, Cambridge CB2 0QQ, England.
EM am872@medschl.cam.ac.uk
OI Mutreja, Ankur/0000-0002-1118-8075
FU Wellcome, DBTWellcome Trust DBT India Alliance; EPSRCEngineering &
   Physical Sciences Research Council (EPSRC)
FX This work was supported by Wellcome, DBT and EPSRC.
CR Bryant JM, 2013, LANCET RESP MED, V1, P786, DOI 10.1016/S2213-2600(13)70231-5
   Chin CS, 2011, NEW ENGL J MED, V364, P33, DOI 10.1056/NEJMoa1012928
   Chun J, 2009, P NATL ACAD SCI USA, V106, P15442, DOI 10.1073/pnas.0907787106
   Devault AM, 2014, NEW ENGL J MED, V370, P334, DOI 10.1056/NEJMoa1308663
   Domman D, 2017, SCIENCE, V358, P789, DOI 10.1126/science.aao2136
   Dutilh BE, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-654
   Harris SR, 2010, SCIENCE, V327, P469, DOI 10.1126/science.1182395
   Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000
   Hendriksen RS, 2011, MBIO, V2, DOI 10.1128/mBio.00157-11
   Holt KE, 2012, NAT GENET, V44, P1056, DOI 10.1038/ng.2369
   Hu DL, 2016, P NATL ACAD SCI USA, V113, pE7730, DOI 10.1073/pnas.1608732113
   Kiiru J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074829
   Mutreja A, 2011, NATURE, V477, P462, DOI 10.1038/nature10392
   Shah MA, 2014, EMERG INFECT DIS, V20, P13, DOI 10.3201/.eid2001.130428
   Spagnoletti M, 2014, MBIO, V5, DOI 10.1128/mBio.01356-14
   Weill FX, 2019, NATURE, V565, P230, DOI 10.1038/s41586-018-0818-3
   Weill FX, 2017, SCIENCE, V358, P785, DOI 10.1126/science.aad5901
NR 17
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A46
EP A51
DI 10.1016/j.vaccine.2019.07.038
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500010
PM 31345641
OA Other Gold
DA 2020-05-12
ER

PT J
AU Nayyar, A
   Privor-Dumm, L
AF Nayyar, Anjali
   Privor-Dumm, Lois
TI Cholera control and prevention: Role of evidence-based advocacy and
   communications
SO VACCINE
LA English
DT Article
DE Communications; Cholera control; India; Advocacy; Policy outreach
ID VACCINES
AB Evidence-based communications and policy outreach are critical elements in building awareness about a disease, build public momentum and decision making and resource mobilization. In India, communications and advocacy played an important role in managing diseases like HIV/AIDS, pneumonia, tuberculosis, etc. and addressing barriers to adoption of new health interventions. These learnings from the past, can help India manage cholera more effectively through a strong advocacy and communications strategy involving multiple stakeholders and partners, with a focus on engaging decision makers. The article discusses strategic communications and advocacy programs for cholera that can be instrumental in paving the way for cholera vaccine use to combat this public health problem and its social and economic impact. (C) 2019 Published by Elsevier Ltd.
C1 [Nayyar, Anjali] Global Hlth Strategies, New Delhi, India.
   [Privor-Dumm, Lois] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Nayyar, A (reprint author), 18-1,2nd,3rd & 4th Floor,Aruna Asaf Ali Marg, New Delhi 110067, India.
EM ANayyar@globalhealthstrategies.com
OI Privor-Dumm, Lois/0000-0001-9807-2544
CR Hajjeh R, 2011, PHILOS T R SOC B, V366, P2827, DOI 10.1098/rstb.2011.0046
   Jeuland M, 2009, VALUE HEALTH, V12, P899, DOI 10.1111/j.1524-4733.2009.00562.x
   Jeuland M, 2009, WORLD BANK ECON REV, V23, P235, DOI 10.1093/wber/lhp006
   Mohammad Ali, IDENTIFICATION BURDE, DOI [10.1371/journalpone.0183100, DOI 10.1371/JOURNALPONE.0183100]
   Sen Gupta S, 2016, INDIAN J MED RES, V143, P545, DOI 10.4103/0971-5916.187102
   Sur Dipika, 2016, Indian J Public Health, V60, P171, DOI 10.4103/0019-557X.188995
   Wolfe CM, 2018, AM J TROP MED HYG, V99, P19
NR 7
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A178
EP A180
DI 10.1016/j.vaccine.2019.06.042
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500027
PM 31262588
OA Other Gold
DA 2020-05-12
ER

PT J
AU Panda, S
   Chatterjee, P
   Deb, A
   Kanungo, S
   Dutta, S
AF Panda, Samiran
   Chatterjee, Pranab
   Deb, Alok
   Kanungo, Suman
   Dutta, Shanta
TI Preventing cholera in India: Synthesizing evidences through a systematic
   review for policy discussion on the use of oral cholera vaccine
SO VACCINE
LA English
DT Review
DE India; Vulnerability; Cholera; Vaccine; Hygiene & sanitation; Systematic
   review for policy discussion
ID ACUTE DIARRHEAL DISEASE; VIBRIO-CHOLERAE; WEST-BENGAL; CHILDHOOD
   DIARRHEA; DRINKING-WATER; CARE SEEKING; CYCLONE AILA; SOUTH-INDIA;
   OUTBREAK; KOLKATA
AB y Development of oral cholera vaccines (OCVs) experienced exciting times over the last two decades. A two-dose OCV, found efficacious through field trials, has obtained license for use in India. However, the current policy discussion revolves around 'to use or not to use' this vaccine covering entire population in the country, which has its own cost implications. We conducted a systematic review to address this conundrum. The disease burden and distribution, potential impact, programmatic issues, and competing priorities were kept in consideration. Peer reviewed articles and 'Integrated Disease Surveillance Program' data, generated by Government of India, were accessed. Our synthesis highlights that cholera burden estimates for India have been hamstrung by their extrapolation from a single incidence study conducted in Kolkata. Heterogeneity of 685 Indian districts regarding vulnerability to cholera is also obvious. Analysis of outbreak reports indicated that some settlements and sub-populations were more vulnerable to diarrhea/cholera than others. Infrastructure failure leading to contamination of drinking water and behavioral issues were of concern. Investment in safe water, sanitation and hygiene (WASH) and addressing inequity of health services pertaining to vulnerable population groups are the needs of the hour. OCV could play an important role as one of the elements in such multi-component cholera prevention effort. OCV administration through public health system in Odisha identified logistic challenges, with low uptake of the second dose at 46%, while 61% of the target population received the first dose. We identified accumulating global evidence on the advantage and efficacy of single-dose based approach, where the same OCV, as licensed in India, was used. The short-lasting nature of cholera outbreaks in India also argue in favor of such pragmatism. Failure to implement multi-component prevention strategy today runs the risk of perpetuating inequity, recurring cholera outbreaks in future, and its retinue of costs. (C) 2019 Published by Elsevier Ltd.
C1 [Panda, Samiran; Chatterjee, Pranab; Deb, Alok; Kanungo, Suman; Dutta, Shanta] ICMR, NICED, P-33 CIT Rd, Kolkata 700010, India.
RP Panda, S (reprint author), ICMR, Natl AIDS Res Inst, MIDC, 73,G Block, Pune 411026, Maharashtra, India.
EM director@nariindia.org
RI Chatterjee, Pranab/P-6272-2017
OI Chatterjee, Pranab/0000-0001-6443-608X; Dutta,
   Shanta/0000-0002-6897-7390
CR ALBERT MJ, 1993, LANCET, V341, P704
   Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832
   Ali M, 2013, CLIN INFECT DIS, V56, P1123, DOI 10.1093/cid/cit009
   Allam Ramesh R, 2015, Indian J Community Med, V40, P283, DOI 10.4103/0970-0218.164408
   [Anonymous], 2010, Wkly Epidemiol Rec, V85, P117
   Avachat SS, 2011, AUSTRALAS MED J, V4, P72, DOI 10.4066/AMJ.2011.524
   Azman AS, 2016, LANCET GLOB HEALTH, V4, pE856, DOI 10.1016/s2214-109x(16)30211-x
   Azman AS, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001867
   Azman AS, 2016, NEW ENGL J MED, V375, DOI [10 1056/NEIMc1607285e12., 10.1056/NEIMc1607285e12, DOI 10.1056/NEIMC1607285E12]
   Batabyal P, 2012, JPN J INFECT DIS, V65, P358, DOI 10.7883/yoken.65.358
   Bhattacharya S, 2013, LANCET INFECT DIS, V13, P1050, DOI 10.1016/S1473-3099(13)70273-1
   Bhunia R, 2011, T ROY SOC TROP MED H, V105, P214, DOI 10.1016/j.trstmh.2010.12.008
   Bhunia R, 2009, INDIAN J GASTROENTER, V28, P62, DOI 10.1007/s12664-009-0020-5
   Biswas DK, 2014, J TROP MED, DOI 10.1155/2014/764530
   Boisson S, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001497
   Charles RC, 2011, CURR OPIN INFECT DIS, V24, P472, DOI 10.1097/QCO.0b013e32834a88af
   CHATTERJEE HN, 1953, LANCET, V265, P1045
   Clasen T, 2014, LANCET GLOB HEALTH, V2, pE645, DOI 10.1016/S2214-109X(14)70307-9
   Clemens J, 2014, CURR TOP MICROBIOL, V379, P231, DOI 10.1007/82_2013_353
   Das A, 2009, EPIDEMIOL INFECT, V137, P906, DOI 10.1017/S0950268808001611
   Das A, 2009, J HEALTH POPUL NUTR, V27, P646
   Datta SS, 2012, J HEALTH POPUL NUTR, V30, P109, DOI 10.3329/jhpn.v30i1.11290
   de Magny GC, 2008, P NATL ACAD SCI USA, V105, P17676, DOI 10.1073/pnas.0809654105
   DE SN, 1953, J PATHOL BACTERIOL, V66, P559, DOI 10.1002/path.1700660228
   DE SN, 1959, NATURE, V183, P1533, DOI 10.1038/1831533a0
   Deen JL, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000173
   Deepthi R, 2013, J INFECT PUBLIC HEAL, V6, P35, DOI 10.1016/j.jiph.2012.05.003
   Dey S, 2014, INDIAN J MED RES, V140, P420
   Dongre AR, 2010, INDIAN J PEDIATR, V77, P503, DOI 10.1007/s12098-010-0063-8
   Duthade M. M., 2010, Journal of Communicable Diseases, V42, P165
   Ercumen A, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001892
   Farmer P, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001145
   Feldman M, 2015, SLEISENGER FORDTRANS
   Fredrick T, 2015, J HEAL POPUL NUTR, V2015, P31
   Graves PM, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000974.pub2
   Heijnen M, 2015, AM J TROP MED HYG, V93, P263, DOI 10.4269/ajtmh.14-0812
   Jacob J, 2016, INDIAN PEDIATR, V53, P642, DOI 10.1007/s13312-016-0903-3
   Jadhav J, 2010, AUSTRALAS MED J, V3, P803, DOI 10.4066/AMJ.2010.247
   Jeuland M, 2009, VALUE HEALTH, V12, P899, DOI 10.1111/j.1524-4733.2009.00562.x
   Johnson S., 2006, GHOST MAP STORY LOND
   Kanungo S, 2010, B WORLD HEALTH ORGAN, V88, P185, DOI 10.2471/BLT.09.073460
   KAPER JB, 1990, RES MICROBIOL, V141, P901, DOI 10.1016/0923-2508(90)90128-D
   Kar SK, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002629
   Khuntia HK, 2010, J MICROBIOL IMMUNOL, V43, P133, DOI 10.1016/S1684-1182(10)60021-7
   Koley H, 2014, JPN J INFECT DIS, V67, P221, DOI 10.7883/yoken.67.221
   Kotloff KL, 2013, LANCET, V382, P209, DOI 10.1016/S0140-6736(13)60844-2
   Kulkarni R D, 2007, Indian J Med Microbiol, V25, P76
   Kumar M, 2008, OPEN J EPIDEMIOL, V4, P243, DOI [10.42361ojepi.2014.44031, DOI 10.4236/OJEPI.2014.44031]
   Kumar P, 2009, J MED MICROBIOL, V58, P234, DOI 10.1099/jmm.0.002089-0
   Kumar R, 2014, INDIAN J PEDIATR, V81, P1347, DOI 10.1007/s12098-014-1495-3
   Kumar S, 2013, HEALTH ECON, V22, P410, DOI 10.1002/hec.2809
   Lavanya V, 2013, J PUBLIC HEALTH-HEID, V21, P481, DOI 10.1007/s10389-013-0573-8
   MAHALANABIS D, 1973, JOHNS HOPKINS MED J, V132, P197
   Mahanta Bhupendra Narayan, 2013, Indian J Community Med, V38, P240, DOI 10.4103/0970-0218.120160
   Martin S, 2014, B WORLD HEALTH ORGAN, V92, P881, DOI 10.2471/BLT.14.139949
   Masthi NRR, 2015, INDIAN J MED RES, V142, P533, DOI 10.4103/0971-5916.171277
   Ministry of Drinking Water and Sanitation, 2017, ANN REP 2016 2017 MI
   Moors E, 2013, SCI TOTAL ENVIRON, P468, DOI [10.1016/j scitotenv.2013.07.02, DOI 10.1016/JSCITOTENV.2013.07.02]
   Mridha P, 2011, J HEALTH POPUL NUTR, V29, P9
   Mukherjee R, 2011, J HEALTH POPUL NUTR, V29, P421
   NALIN DR, 1968, LANCET, V2, P370
   National Centre for Disease Control, 2017, IMPL SUMM REP DEPUY
   National Sample Survey Office, 2016, SWACHHT STAT REP
   Panda S, 2011, INDIAN J MED RES, V133, P395
   Parker LA, 2017, LANCET INFECT DIS, V17, pE123, DOI 10.1016/S1473-3099(16)30472-8
   Patil SB, 2011, J GLOB INFECT DIS, V3, P361, DOI 10.4103/0974-777X.91060
   Patil SR, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001709
   Poulos C, 2012, EPIDEMIOL INFECT, V140, P500, DOI 10.1017/S0950268811000513
   Qadri F, 2016, NEW ENGL J MED, V374, P1723, DOI 10.1056/NEJMoa1510330
   Rajaraman D, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1179
   Rajendran K, 2011, INDIAN J MED RES, V133, P138
   RAMAMURTHY T, 1993, LANCET, V341, P703, DOI 10.1016/0140-6736(93)90480-5
   Reyburn R, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000952
   Rheingans R, 2012, CLIN INFECT DIS, V55, pS327, DOI 10.1093/cid/cis764
   Rosenberg Charles, 1987, CHOLERA YEARS US 183
   Roy S, 2012, J MED MICROBIOL, V61, P1574, DOI 10.1099/jmm.0.049692-0
   Ruiz-Moreno D, 2007, ECOHEALTH, V4, P52, DOI 10.1007/s10393-006-0079-8
   Sarkar R, 2007, T ROY SOC TROP MED H, V101, P587, DOI 10.1016/j.trstmh.2006.11.005
   Sarpal S, 2014, MED J DR DY PATIL U, V7, P147, DOI [10.4103/0975-2870.126320, DOI 10.4103/0975-2870.126320]
   Sebastian T, 2015, CLIN EPIDEMIOL GLOB, V3, P144, DOI 10.1016/j.cegh.2015.05.001
   Sekar R, 2012, INDIAN J MED RES, V135, P678
   Sen Gupta S, 2016, INDIAN J MED RES, V143, P545, DOI 10.4103/0971-5916.187102
   Shah HD, 2012, J POSTGRAD MED, V58, P14, DOI 10.4103/0022-3859.93247
   Sharma J., 2014, INT J PHARM BIOSCIEN, V5, P37
   Shroff B. D., 2011, National Journal of Community Medicine, V2, P371
   Sinclair D, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008603.pub2
   Singh CH, 2009, J PUBLIC HEALTH-HEID, V17, P401, DOI 10.1007/s10389-009-0268-3
   Srivastava NM, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-61
   Sugunan AP, 2007, J PUBLIC HEALTH-UK, V29, P308, DOI 10.1093/pubmed/fdm032
   Sur D, 2005, ARCH DIS CHILD, V90, P1175, DOI 10.1136/adc.2004.071316
   Sur D, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001289
   Sur D, 2009, LANCET, V374, P1694, DOI 10.1016/S0140-6736(09)61297-6
   Tambe PV, 2008, J HEALTH POPUL NUTR, V26, P139
   Tripurari Kumar, 2017, Journal of Communicable Diseases, V49, P35, DOI 10.24321/0019.5138.201705
   UNICEF, 2013, STAT WORLDS CHILDR 2
   Uthappa CK, 2015, J HEALTH POPUL NUTR, V33, DOI 10.1186/s41043-015-0021-1
   Wierzba TF, 2015, VACCINE, V33, P2463, DOI 10.1016/j.vaccine.2015.03.073
   World Health Organization, 1992, MAN PAT CHOL
   2013, WORLD MAL REP 2013, P1
NR 99
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A148
EP A156
DI 10.1016/j.vaccine.2019.07.029
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500022
PM 31405636
OA Other Gold
DA 2020-05-12
ER

PT J
AU Pant, A
   Das, B
   Bhadra, RK
AF Pant, Archana
   Das, Bhabatosh
   Bhadra, Rupak K.
TI CTX phage of Vibrio cholerae: Genomics and applications
SO VACCINE
LA English
DT Article
DE Vibrio cholerae; CTX phi; Mobile genetic elements; Prophage; Dimer
   resolution site; Vector; Cholera vaccine
ID MOBILE GENETIC ELEMENTS; PHI; INTEGRATION; EVOLUTION; REPLICATION;
   ACQUISITION; DIVERSITY; MECHANISM
AB The bipartite genome of Vibrio cholerae is divided into two circular non-homologous chromosomes, which harbor several genetic elements like phages, plasmids, transposons, integrative conjugative elements, and pathogenic islands that encode functions responsible for disease development, antimicrobial resistance, and subsistence in hostile environments. These elements are highly heterogeneous, mobile in nature, and encode their own mobility functions or exploit host-encoded enzymes for intra- and inter-cellular movements. The key toxin of V. cholerae responsible for the life-threatening diarrheal disease cholera, the cholera toxin, is coded by part of the genome of a filamentous phage, CTX phi. The replicative genome of CTX phi. is divided into two distinct modular structures and has adopted a unique strategy for its irreversible integration into the V. cholerae chromosomes. CTX phi exploits two host-encoded tyrosine recombinases, XerC and XerD, for its integration in the highly conserved dimer resolution site (dif) of V. cholerae chromosomes. CTX phi can replicate only in the limited number of Vibrio species. In contrast, the phage integration into the bacterial chromosome does not rely on its replication and could integrate to the dif site of large numbers of gram-negative bacteria. Recent pangenomic analysis revealed that like CTX phi, the bacterial dif site is the integration spot for several other mobile genetic elements such as plasmids and genomic islands. In this review we discuss about current molecular insights into CTX phi genomics and its replication and integration mechanisms into hosts. Particular emphasis has been given on the exploitation of CTX phi genomics knowledge in developing genetic tools and designing environmentally safe recombinant live oral cholera vaccine strains. (C) 2019 Elsevier Ltd.
C1 [Pant, Archana; Das, Bhabatosh] Translat Hlth Sci & Technol Inst, Ctr Human Microbial Ecol, Mol Genet Lab, NCR Biotech Sci Cluster, 3rd Milestone,Faridabad Gurgaon Expressway, Faridabad 121001, Haryana, India.
   [Pant, Archana; Das, Bhabatosh] Manipal Acad Higher Educ, Sch Life Sci, Manipal 576104, Karnataka, India.
   [Bhadra, Rupak K.] CSIR, Indian Inst Chem Biol, Infect Dis & Immunol Div, 4 Raja SC Mullick Rd, Kolkata 700032, India.
RP Das, B (reprint author), Translat Hlth Sci & Technol Inst, Ctr Human Microbial Ecol, Mol Genet Lab, NCR Biotech Sci Cluster, 3rd Milestone,Faridabad Gurgaon Expressway, Faridabad 121001, Haryana, India.; Bhadra, RK (reprint author), CSIR, Indian Inst Chem Biol, Infect Dis & Immunol Div, 4 Raja SC Mullick Rd, Kolkata 700032, India.
EM bhabatosh@thsti.res.in; rupakbhadra@iicb.res.in
OI Das, Bhabatosh/0000-0002-2447-5380
FU Department of Biotechnology [BT/MB/THSTI/HMC-SFC/2011]; CSIRCouncil of
   Scientific & Industrial Research (CSIR) - India [MLP118]
FX Department of Biotechnology, Govt. of India (Grant No.
   BT/MB/THSTI/HMC-SFC/2011) and CSIR (MLP118). The funding agency had no
   role in writing the review.
CR Baik YO, 2015, VACCINE, V33, P6360, DOI 10.1016/j.vaccine.2015.08.075
   Boyd EF, 2000, J BACTERIOL, V182, P5530, DOI 10.1128/JB.182.19.5530-5538.2000
   Calain P, 2004, VACCINE, V22, P2444, DOI 10.1016/j.vaccine.2003.11.070
   Cambray G, 2010, ANNU REV GENET, V44, P141, DOI 10.1146/annurev-genet-102209-163504
   Carnoy C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006531
   Chun J, 2009, P NATL ACAD SCI USA, V106, P15442, DOI 10.1073/pnas.0907787106
   Clemens JD, 2017, LANCET, V390, P1539, DOI 10.1016/S0140-6736(17)30559-7
   Das B, 2016, CURR OPIN INFECT DIS, V29, P520, DOI 10.1097/QCO.0000000000000306
   Das B, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00650
   Das B, 2014, J BACTERIOL, V196, P4071, DOI 10.1128/JB.01966-14
   Das B, 2013, TRENDS MICROBIOL, V21, P23, DOI 10.1016/j.tim.2012.10.003
   Das B, 2011, INDIAN J MED RES, V133, P195
   Das B, 2011, P NATL ACAD SCI USA, V108, P2516, DOI 10.1073/pnas.1017061108
   Das B, 2010, P NATL ACAD SCI USA, V107, P4377, DOI 10.1073/pnas.0910212107
   Davies BW, 2012, CELL, V149, P358, DOI 10.1016/j.cell.2012.01.053
   Davis BM, 2000, P NATL ACAD SCI USA, V97, P8572, DOI 10.1073/pnas.140109997
   Domman D, 2017, SCIENCE, V358, P789, DOI 10.1126/science.aao2136
   Dziejman M, 2002, P NATL ACAD SCI USA, V99, P1556, DOI 10.1073/pnas.042667999
   Faruque SM, 2012, VIRULENCE, V3, P556, DOI 10.4161/viru.22351
   Faruque SM, 2004, P NATL ACAD SCI USA, V101, P2123, DOI 10.1073/pnas.0308485100
   Faruque SM, 2003, TRENDS MICROBIOL, V11, P505, DOI 10.1016/j.tim.2003.09.003
   Faruque SM, 2003, P NATL ACAD SCI USA, V100, P1304, DOI 10.1073/pnas.0337468100
   Frost LS, 2005, NAT REV MICROBIOL, V3, P722, DOI 10.1038/nrmicro1235
   Halder K, 2010, MICROBIOL-SGM, V156, P99, DOI 10.1099/mic.0.032458-0
   Hassan F, 2010, NATURE, V467, P982, DOI 10.1038/nature09469
   Hay ID, 2019, EMBO REP, V20, DOI 10.15252/embr.201847427
   Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000
   Hengge R, 2009, NAT REV MICROBIOL, V7, P263, DOI 10.1038/nrmicro2109
   Henry M, 2012, VIROLOGY, V434, P151, DOI 10.1016/j.virol.2012.09.017
   Huber KE, 2002, NATURE, V417, P656, DOI 10.1038/nature00782
   Kim EJ, 2017, P NATL ACAD SCI USA, V114, P2343, DOI 10.1073/pnas.1701335114
   Kim EJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004384
   Kimsey HH, 2004, J BIOL CHEM, V279, P2640, DOI 10.1074/jbc.M311109200
   Kupferschmidt K, 2018, SCIENCE, V359, P620, DOI 10.1126/science.359.6376.620
   Levine MM, 2017, EXPERT REV VACCINES, V16, P197, DOI 10.1080/14760584.2017.1291348
   Maiti D, 2006, MICROBIOL-SGM, V152, P3633, DOI 10.1099/mic.0.2006/000117-0
   Martinez E, 2016, BACTERIOPHAGE, V6
   Midonet C, 2014, P NATL ACAD SCI USA, V111, P16848, DOI 10.1073/pnas.1404047111
   Mutreja A, 2011, NATURE, V477, P462, DOI 10.1038/nature10392
   Pant A, 2015, J BACTERIOL, V198, P1
   Park JY, 2017, SCI REP-UK, V7, DOI 10.1038/srep44929
   Quinones M, 2005, MOL CELL, V17, P291, DOI 10.1016/j.molcel.2004.11.046
   RHINE JA, 1994, MOL MICROBIOL, V13, P1013, DOI 10.1111/j.1365-2958.1994.tb00492.x
   Val ME, 2005, MOL CELL, V19, P559, DOI 10.1016/j.molcel.2005.07.002
   Verma J, 2019, P NATL ACAD SCI USA, V116, P6226, DOI 10.1073/pnas.1900141116
   Waldor MK, 1997, MOL MICROBIOL, V24, P917, DOI 10.1046/j.1365-2958.1997.3911758.x
   Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910
   Weill FX, 2017, SCIENCE, V358, P785, DOI 10.1126/science.aad5901
   Wozniak RAF, 2010, NAT REV MICROBIOL, V8, P552, DOI 10.1038/nrmicro2382
   Yosef I, 2015, P NATL ACAD SCI USA, V112, P7267, DOI 10.1073/pnas.1500107112
NR 50
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A7
EP A12
DI 10.1016/j.vaccine.2019.06.034
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500003
PM 31272871
OA Other Gold
DA 2020-05-12
ER

PT J
AU Pezzoli, L
   Cavailler, P
   Mengel, M
   Matzger, H
   Lorenson, T
   Sur, D
   Luquero, F
   Grais, R
   Ko, M
   Soble, A
   Rouzier, V
   Pape, JW
   Buckee, C
   Qadri, F
   Mahoney, F
   Kall, JJ
   Landegger, J
   Gayer, M
   Lynch, J
   Azman, AS
   Sack, D
   Henkens, M
   Ciglenecki, I
   Hall, R
   Ivers, LC
   Diggle, E
   Weiss, M
   Hinman, A
   Maim, K
   Mirza, I
   Papowitz, H
   Gimeno, G
   Ramos, M
   Levine, MM
   Date, K
   Sreenivasan, N
AF Pezzoli, Lorenzo
   Cavailler, Philippe
   Mengel, Martin
   Matzger, Helen
   Lorenson, Tina
   Sur, Dipika
   Luquero, Francisco
   Grais, Rebecca
   Ko, Melissa
   Soble, Adam
   Rouzier, Vanessa
   Pape, Jean William
   Buckee, Caroline
   Qadri, Firdausi
   Mahoney, Frank
   Kall, Jill John
   Landegger, Justine
   Gayer, Michelle
   Lynch, Julia
   Azman, Andrew S.
   Sack, David
   Henkens, Myriam
   Ciglenecki, Iza
   Hall, Robert
   Ivers, Louise C.
   Diggle, Emma
   Weiss, Mitchell
   Hinman, Alan
   Maim, Kahindo
   Mirza, Imran
   Papowitz, Heather
   Gimeno, Guillermo
   Ramos, Monica
   Levine, Myron M.
   Date, Kashmira
   Sreenivasan, Nandini
CA Oral Cholera Vaccine Working Grp G
TI Global oral cholera vaccine use, 2013-2018
SO VACCINE
LA English
DT Article
DE Oral Cholera Vaccine; Vaccination Campaigns; Global Task Force on
   Cholera Control; Cholera Elimination; End Cholera
ID CONTROLLED TEMPERATURE CHAIN; MASS VACCINATION; WHOLE-CELL; HUMANITARIAN
   CRISIS; PREGNANT-WOMEN; COVERAGE; SAFETY; HAITI; CAMPAIGN;
   IMMUNOGENICITY
AB Vaccination is a key intervention to prevent and control cholera in conjunction with water, sanitation and hygiene activities. An oral cholera vaccine (OCV) stockpile was established by the World Health Organization (WHO) in 2013. We reviewed its use from July 2013 to all of 2018 in order to assess its role in cholera control. We computed information related to OCV deployments and campaigns conducted including setting, target population, timelines, delivery strategy, reported adverse events, coverage achieved, and costs.
   In 2013-2018, a total of 83,509,941 OCV doses have been requested by 24 countries, of which 55,409,160 were approved and 36,066,010 eventually shipped in 83 deployments, resulting in 104 vaccination campaigns in 22 countries. OCVs had in general high uptake (mean administrative coverage 1st dose campaign at 90.3%; 2nd dose campaign at 88.2%; mean survey-estimated two-dose coverage at 69.9%, at least one dose at 84.6%) No serious adverse events were reported. Campaigns were organized quickly (five days median duration). In emergency settings, the longest delay was from the occurrence of the emergency to requesting OCV (median: 26 days). The mean cost of administering one dose of vaccine was 2.98 USD.
   The OCV stockpile is an important public health resource. OCVs were generally well accepted by the population and their use demonstrated to be safe and feasible in all settings. OCV was an inexpensive intervention, although timing was a limiting factor for emergency use. The dynamic created by the establishment of the OCV stockpile has played a role in the increased use of the vaccine by setting in motion a virtuous cycle by which better monitoring and evaluation leads to better campaign organization, better cholera control, and more requests being generated. Further work is needed to improve timeliness of response and contextualize strategies for OCV delivery in the various settings. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Pezzoli, Lorenzo] WHO, Cholera Team, Focal Point Vaccinat Infect Hazard Management IHM, Geneva, Switzerland.
   [Cavailler, Philippe; Mengel, Martin] Agence Med Prevent, Paris, France.
   [Matzger, Helen; Lorenson, Tina] Bill & Melinda Gates Fdn, Seattle, WA USA.
   [Luquero, Francisco; Grais, Rebecca] Epicentre, Paris, France.
   [Ko, Melissa; Soble, Adam] Gavi, Geneva, Switzerland.
   [Rouzier, Vanessa; Pape, Jean William] GHESKIO, Port Au Prince, Haiti.
   [Buckee, Caroline] Harvard Univ, Cambridge, MA 02138 USA.
   [Qadri, Firdausi] Icddr B, Dhaka, Bangladesh.
   [Mahoney, Frank] Int Federat Red Cross & Red Crescent Soc IFRC, Geneva, Switzerland.
   [Kall, Jill John] IMC, Los Angeles, CA USA.
   [Landegger, Justine; Gayer, Michelle] Int Rescue Comm, New York, NY USA.
   [Lynch, Julia] Int Vaccine Inst, Seoul, South Korea.
   [Azman, Andrew S.; Sack, David] Johns Hopkins Univ, Baltimore, MD 21218 USA.
   [Henkens, Myriam; Ciglenecki, Iza] Med Sans Frontieres, Geneva, Switzerland.
   [Hall, Robert] NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Ivers, Louise C.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
   [Diggle, Emma] Save Children, London, England.
   [Weiss, Mitchell] Swiss Trop & Publ Hlth Inst, Geneva, Switzerland.
   [Hinman, Alan] Task Force Global Hlth, Atlanta, GA USA.
   [Maim, Kahindo] UNHCR, Geneva, Switzerland.
   [Mirza, Imran; Papowitz, Heather] UNICEF, Program Div, New York, NY USA.
   [Gimeno, Guillermo] UNICEF, Supply Div, New York, NY USA.
   [Ramos, Monica] UNICEF, WASH, New York, NY USA.
   [Levine, Myron M.] Univ Maryland, College Pk, MD 20742 USA.
   [Date, Kashmira; Sreenivasan, Nandini] US Ctr Dis Control & Prevent, Atlanta, GA USA.
RP Pezzoli, L (reprint author), WHO, Cholera Team, Focal Point Vaccinat Infect Hazard Management IHM, Geneva, Switzerland.
FU Bill and Melinda Gates FoundationGates Foundation
FX We are grateful to countries and partners for requesting and using OCV.
   We wish to thank Gavi for the support with the stockpile and for
   providing the operational costs, and the European Union/ECHO for
   covering implementation costs and monitoring and evaluation activities
   of selected campaigns, and the Bill and Melinda Gates Foundation for
   supporting the GTFCC. A special acknowledgement goes to Malika Bouhenia
   (WHO) for her revision of the manuscript.
CR Abubakar A, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001901
   Alberti KP, 2008, T ROY SOC TROP MED H, V102, P251, DOI 10.1016/j.trstmh.2007.10.015
   Ali M, 2005, LANCET, V366, P44, DOI 10.1016/S0140-6736(05)66550-6
   Ali M, 2008, PEDIATR INFECT DIS J, V27, P33, DOI 10.1097/INF.0b013e318149dffd
   Ali M, 2017, LANCET INFECT DIS, V17, P538, DOI [10.1016/s1473-3099(16)30523-0, 10.1016/S1473-3099(16)30523-0]
   Ali M, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002120
   Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832
   Ali M, 2013, CLIN INFECT DIS, V56, P1123, DOI 10.1093/cid/cit009
   Anh DD, 2007, VACCINE, V25, P1149, DOI 10.1016/j.vaccine.2006.09.049
   Anh Dang Duc, 2011, PLoS Negl Trop Dis, V5, pe1006, DOI 10.1371/journal.pntd.0001006
   [Anonymous], 2016, Wkly Epidemiol Rec, V91, P305
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P521
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P477
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P437
   [Anonymous], 2014, Wkly Epidemiol Rec, V89, P214
   AS Azman, 2015, PLOS MED, V12
   Azman AS, 2016, LANCET GLOB HEALTH, V4, pE856, DOI 10.1016/s2214-109x(16)30211-x
   Azman AS, 2016, EMERG INFECT DIS, V22, P1067, DOI 10.3201/eid2206.151592
   Azman AS, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001901
   Baik YO, 2014, J KOREAN MED SCI, V29, P494, DOI 10.3346/jkms.2014.29.4.494
   Bhattacharya S, 2013, LANCET INFECT DIS, V13, P1050, DOI 10.1016/S1473-3099(13)70273-1
   Bi Q, 2017, LANCET INFECT DIS
   Chao DL, 2011, P NATL ACAD SCI USA, V108, P7081, DOI 10.1073/pnas.1102149108
   Ciglenecki I, 2017, LANCET INFECT DIS, V17, P480, DOI 10.1016/S1473-3099(17)30184-6
   Ciglenecki I, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001512
   Clemens JD, 2017, LANCET
   Clemens J, 2014, CURR TOP MICROBIOL, V379, P231, DOI 10.1007/82_2013_353
   Deen J, 2016, LANCET INFECT DIS, V16, P125, DOI 10.1016/S1473-3099(15)00298-4
   Dellepiane N, 2015, VACCINE, V33, P52, DOI 10.1016/j.vaccine.2013.11.066
   Desai SN, 2017, HUM VACC IMMUNOTHER, V13, P579, DOI 10.1080/21645515.2016.1245250
   Desai SN, 2016, LANCET GLOB HEALTH, V4, pE223, DOI 10.1016/S2214-109X(16)00037-1
   Desai SN, 2015, AM J TROP MED HYG, V93, P527, DOI 10.4269/ajtmh.14-0683
   Emch M, 2006, INT J EPIDEMIOL, V35, P1044, DOI 10.1093/ije/dyl100
   Grandesso F, 2019, VACCINE, V37, P3668, DOI 10.1016/j.vaccine.2019.05.044
   Grout L, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004274
   Hashim R, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001743
   Hsiao A, 2017, B WORLD HEALTH ORGAN, V95, P303, DOI [10.2471/BLT.16.175166, 10.2471/blt.16.175166]
   Ivers LC, 2015, LANCET GLOB HEALTH, V3, pE162, DOI 10.1016/S2214-109X(14)70368-7
   Ivers LC, 2013, AM J TROP MED HYG, V89, P617, DOI 10.4269/ajtmh.13-0183
   Ivers LC, 2012, LANCET, V379, P2026, DOI 10.1016/S0140-6736(12)60832-0
   Kahn AL, 2017, VACCINE, V35, P2214, DOI 10.1016/j.vaccine.2016.10.091
   Kanungo S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099381
   Kar SK, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002629
   Khan AI, 2017, VACCINE, V35, P1538, DOI 10.1016/j.vaccine.2017.01.080
   Khatib AM, 2012, LANCET INFECT DIS, V12, P837, DOI 10.1016/S1473-3099(12)70196-2
   Kirpich A, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005482
   Koo D, 1996, Bull Pan Am Health Organ, V30, P134
   Lam E, 2017, EMERG INFECT DIS, V23, P38, DOI 10.3201/eid2301.160881
   Lam E, 2015, HUM VACC IMMUNOTHER, V11, P2627, DOI 10.1080/21645515.2015.1096457
   Lippi D, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.PoH-0012-2015
   Lucas MES, 2005, NEW ENGL J MED, V352, P757, DOI 10.1056/NEJMoa043323
   Luquero FJ, 2014, NEW ENGL J MED, V370, P2111, DOI 10.1056/NEJMoa1312680
   Luquero FJ, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002465
   M'bangombe M, 2018, B WORLD HEALTH ORGAN, V96, P428, DOI 10.2471/BLT.17.207175
   Martin S, 2014, B WORLD HEALTH ORGAN, V92, P881, DOI 10.2471/BLT.14.139949
   Mengel MA, 2014, T ROY SOC TROP MED H, V108, P391, DOI 10.1093/trstmh/tru077
   Mogasale V, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005124
   Mogasale V, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004072
   Moro PL, 2017, LANCET INFECT DIS, V17, P469, DOI 10.1016/S1473-3099(17)30055-5
   Msyamboza Kelias Phiri, 2016, Pan Afr Med J, V23, P203, DOI 10.11604/pamj.2016.23.203.8346
   Munier Aline, 2017, BMC Proc, V11, P2, DOI 10.1186/s12919-016-0068-z
   Naficy A, 1998, JAMA-J AM MED ASSOC, V279, P521, DOI 10.1001/jama.279.7.521
   Parker LA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005652
   Peprah D, 2016, VACCINE, V34, P3823, DOI 10.1016/j.vaccine.2016.05.038
   Phares CR, 2016, VACCINE, V34, P128, DOI 10.1016/j.vaccine.2015.10.112
   Poncin M, 2018, B WORLD HEALTH ORGAN, V96, P86, DOI 10.2471/BLT.16.189241
   Porta MI, 2014, T ROY SOC TROP MED H, V108, P810, DOI 10.1093/trstmh/tru153
   Pugliese-Garcia M, 2018, VACCINE, V36, P5617, DOI [10.1016/j.vaccine.2018.07.042, 10.1016/j.vaccine.2017.10.108]
   Qadri F, 2015, LANCET, V386, P1362, DOI 10.1016/S0140-6736(15)61140-0
   Root ED, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022971
   Routh JA, 2017, AM J TROP MED HYG, V97, P37, DOI 10.4269/ajtmh.16-1023
   Rouzier V, 2013, AM J TROP MED HYG, V89, P671, DOI 10.4269/ajtmh.13-0171
   Saha A, 2017, EXPERT REV VACCINES, V16, P235, DOI 10.1080/14760584.2017.1249470
   Saha A, 2016, VACCINE, V34, P1551, DOI 10.1016/j.vaccine.2016.02.020
   Sarker AR, 2015, VACCINE, V33, P4916, DOI 10.1016/j.vaccine.2015.07.042
   Sauvageot D, 2017, VACCINE, V35, P5194, DOI 10.1016/j.vaccine.2017.07.104
   Schaetti C, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001844
   Scobie HM, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005210
   Severe K, 2016, AM J TROP MED HYG, V94, P1136, DOI 10.4269/ajtmh.15-0700
   Sundaram N, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2710-0
   Sur D, 2009, LANCET, V374, P1694, DOI 10.1016/S0140-6736(09)61297-6
   Tohme RA, 2015, EMERG INFECT DIS, V21, P984, DOI 10.3201/eid2106.141797
   Toole MJ, 1997, ANNU REV PUBL HEALTH, V18, P283, DOI 10.1146/annurev.publhealth.18.1.283
   Troeger C, 2014, AM J TROP MED HYG, V91, P1181, DOI 10.4269/ajtmh.14-0159
   World Health Organization, 2018, WEEKLY EPIDEMIOLOGIC, V93, P489
   Yen C, 2015, LANCET INFECT DIS, V15, P340, DOI 10.1016/S1473-3099(14)70999-5
   Zipursky S, 2014, VACCINE, V32, P1431, DOI 10.1016/j.vaccine.2014.01.038
NR 87
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A132
EP A140
DI 10.1016/j.vaccine.2019.08.086
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500020
PM 31519444
OA Other Gold
DA 2020-05-12
ER

PT J
AU Pietroni, MAC
AF Pietroni, M. A. C.
TI Case management of cholera
SO VACCINE
LA English
DT Article
DE Cholera; Case management; Treatment
AB Cholera still affects about three million people a year and kills approximately 100,000. Cholera can be effectively managed in the majority of cases with oral rehydration solution alone. Up to one third of patients present with severe dehydration, which can be diagnosed clinically, and will require rapid intravenous rehydration with Ringers Lactate or other appropriate fluid before being managed with oral rehydration solution. Antibiotics reduce the duration of illness and should be used in patients with severe dehydration. Resistance is common and local sensitivities should guide the choice of antibiotic. All children between six months and five years should receive zinc supplements. Effective case management with strict attention to detail including infection control and the use of protocolized approaches can reduce the mortality to around 1% even in resource poor settings. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Pietroni, M. A. C.] Gloucetsershire Royal Hosp NHS Fdn Trust, Gloucester, England.
   [Pietroni, M. A. C.] Univ Bristol, Fac Hlth Sci, Bristol, Avon, England.
   [Pietroni, M. A. C.] Icddr B, Publ Hlth South Gloucestershire, Dhaka, Bangladesh.
RP Pietroni, MAC (reprint author), Gloucestershire Royal Hosp, Div Med, Great Western Rd, Gloucester GL1 3NN, England.
EM mark.pietroni@nhs.net
CR Alam NH, 2006, JAMA-J AM MED ASSOC, V296, P567, DOI 10.1001/jama.296.5.567
   Alam Nure H, 2003, Paediatr Drugs, V5, P151, DOI 10.2165/00148581-200305030-00002
   Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832
   Ali M, 2012, B WORLD HEALTH ORGAN, V90, P209, DOI 10.2471/BLT.11.093427
   Harris JB, 2017, APPROACH CHILD ACUTE
   LaRocque R, 2017, UPTODATE
   Pietroni MAC, 2017, CHOLERA METHOD CONNS, P497
   Roy SK, 1997, ARCH DIS CHILD, V77, P196, DOI 10.1136/adc.77.3.196
   Saha D, 2006, NEW ENGL J MED, V354, P2452, DOI 10.1056/NEJMoa054493
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A105
EP A109
DI 10.1016/j.vaccine.2019.09.098
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500016
PM 31668817
OA Other Gold
DA 2020-05-12
ER

PT J
AU Ramamurthy, T
   Das, B
   Chakraborty, S
   Mukhopadhyay, AK
   Sack, DA
AF Ramamurthy, Thandavarayan
   Das, Bhabatosh
   Chakraborty, Subhra
   Mukhopadhyay, Asish K.
   Sack, David A.
TI Diagnostic techniques for rapid detection of Vibrio cholerae O1/O139
SO VACCINE
LA English
DT Article
DE Culture methods; Rapid diagnostic tests; PCR; ELISA; Point-of-care
   facilities; Cholera toxin; Viable but non-culturable
ID LINKED-IMMUNOSORBENT-ASSAY; O139 SYNONYM BENGAL; COAGGLUTINATION TEST;
   NONCULTURABLE STATE; ESCHERICHIA-COLI; WATER SAMPLES; DIPSTICK TEST;
   REAL-TIME; EL-TOR; ENVIRONMENTAL SURVEILLANCE
AB Cholera caused by the toxigenic Vibrio cholerae is still a major public health problem in many countries. This disease is mainly due to poor sanitation, hygiene and consumption of unsafe water. Several recent epidemics of cholera showed its increasing intensity, duration and severity of the illness. This indicates an urgent need for effective management and preventive measures in controlling the outbreaks and epidemics. In preventing and spread of epidemic cholera, rapid diagnostic tests (RDTs) are useful in screening suspected stool specimens, water/food samples. Several RDTs developed recently are considered as investigative tools in confirming cholera cases, as the culture techniques are difficult to establish and/or maintain. The usefulness of RDTs will be more at the point-of-care facilities as it helps to make appropriate decisions in the management of outbreaks or epidemiological surveillance by the public health authorities. Apart from RDTs, several other tests are available for the direct detection of either V. cholerae or its cholera toxin. Viable but non-culturable (VBNC) state of V. cholerae poses a great challenge in developing RDTs. The aim of this article is to provide an overview of current knowledge about RDT and other techniques with reference to their status and future potentials in detecting cholera/V. cholerae. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Ramamurthy, Thandavarayan; Das, Bhabatosh] Translat Hlth Sci & Technol Inst, Faridabad, Haryana, India.
   [Chakraborty, Subhra; Sack, David A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth Program Global Dis Epidemiol & Cont, Baltimore, MD USA.
   [Mukhopadhyay, Asish K.] Natl Inst Cholera & Enter Dis, Div Bacteriol, Kolkata, India.
RP Ramamurthy, T (reprint author), Translat Hlth Sci & Technol Inst, Ctr Human Microbial Ecol, NCR Biotech Sci Cluster, 3rd Milestone, Faridabad 121001, Haryana, India.
EM tramu@thsti.res.in
OI Sack, David/0000-0002-9338-5119; Das, Bhabatosh/0000-0002-2447-5380
FU Bill & Melinda Gates FoundationGates Foundation [01131126286];
   Department of Biotechnology, GOI [BT/MB/THSTI/HMC-SFC/2011]
FX The work was supported in part by the Bill & Melinda Gates Foundation
   (Investment ID-01131126286) and the Department of Biotechnology, GOI
   (Grant No. BT/MB/THSTI/HMC-SFC/2011) to Translational Health Science and
   Technology Institute, Faridabad, Haryana, India.
CR Abu Sayeed M, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006286
   ADAMS LB, 1988, J CLIN MICROBIOL, V26, P1801, DOI 10.1128/JCM.26.9.1801-1809.1988
   Ahn S, 2008, ANAL BIOANAL CHEM, V391, P473, DOI 10.1007/s00216-007-1551-1
   Alam M, 2007, P NATL ACAD SCI USA, V104, P17801, DOI 10.1073/pnas.0705599104
   Ang GY, 2012, BIOSENS BIOELECTRON, V38, P151, DOI 10.1016/j.bios.2012.05.019
   Archibald MM, 2015, BIOSENS BIOELECTRON, V74, P406, DOI 10.1016/j.bios.2015.06.069
   Aulet O, 2007, REV SOC BRAS MED TRO, V40, P385, DOI 10.1590/S0037-86822007000400002
   Bejhed RS, 2015, BIOSENS BIOELECTRON, V66, P405, DOI 10.1016/j.bios.2014.11.048
   BHADRA RK, 1991, ZBL BAKT-INT J MED M, V275, P467
   Bolanos HM, 2004, REV PANAM SALUD PUBL, V16, P233, DOI 10.1590/S1020-49892004001000002
   Boncy J, 2013, DIAGN MICR INFEC DIS, V76, P521, DOI 10.1016/j.diagmicrobio.2013.03.010
   BRAMUCCI MG, 1978, J CLIN MICROBIOL, V8, P252
   Briquaire R, 2017, J MICROBIOL METH, V133, P23, DOI 10.1016/j.mimet.2016.12.014
   Bwire G, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2824-8
   Chaicumpa W, 1998, J CLIN MICROBIOL, V36, P3595, DOI 10.1128/JCM.36.12.3595-3600.1998
   Chaiyanan S, 2001, SYST APPL MICROBIOL, V24, P331, DOI 10.1078/0723-2020-00032
   Chakraborty S, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00320
   Chen WX, 2014, CLIN BIOCHEM, V47, P448, DOI 10.1016/j.clinbiochem.2013.12.022
   Chmelik J, 2007, EUR J MASS SPECTROM, V13, P347, DOI 10.1255/ejms.891
   Clemens JD, 2017, LANCET
   Colwell R R, 2000, J Infect Chemother, V6, P121, DOI 10.1007/PL00012151
   COLWELL RR, 1992, FEMS MICROBIOL LETT, V97, P215, DOI 10.1016/0378-1097(92)90339-P
   Debes AK, 2016, AM J TROP MED HYG, V94, P537, DOI 10.4269/ajtmh.15-0496
   Deurenberg RH, 2017, J BIOTECHNOL, V243, P16, DOI 10.1016/j.jbiotec.2016.12.022
   Dick MH, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001845
   Faruque SM, 2006, P NATL ACAD SCI USA, V103, P6350, DOI 10.1073/pnas.0601277103
   Fykse EM, 2007, APPL ENVIRON MICROB, V73, P1457, DOI 10.1128/AEM.01635-06
   Garner CE, 2009, T ROY SOC TROP MED H, V103, P1171, DOI 10.1016/j.trstmh.2009.02.004
   George CM, 2014, TROP MED INT HEALTH, V19, P301, DOI 10.1111/tmi.12252
   GHOSAL S C, 1952, Bull World Health Organ, V7, P371
   Ghosh-Banerjee J, 2010, J CLIN MICROBIOL, V48, P4283, DOI 10.1128/JCM.00799-10
   Goel AK, 2005, FOLIA MICROBIOL, V50, P448, DOI 10.1007/BF02931428
   Gubala AJ, 2006, J MICROBIOL METH, V65, P278, DOI 10.1016/j.mimet.2005.07.017
   Hao M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179937
   Harris JR, 2009, TROP MED INT HEALTH, V14, P1117, DOI 10.1111/j.1365-3156.2009.02335.x
   HASAN JAK, 1994, FEMS MICROBIOL LETT, V120, P143, DOI 10.1016/0378-1097(94)00191-X
   HASAN JAK, 1995, J CLIN MICROBIOL, V33, P2935, DOI 10.1128/JCM.33.11.2935-2939.1995
   HEJTMANCIK KE, 1977, INFECT IMMUN, V17, P621, DOI 10.1128/IAI.17.3.621-628.1977
   JESUDASON MV, 1984, J CLIN MICROBIOL, V19, P712, DOI 10.1128/JCM.19.5.712-713.1984
   Jin DZ, 2008, J MICROBIOL METH, V75, P365, DOI 10.1016/j.mimet.2008.06.020
   Jin DZ, 2013, J CLIN MICROBIOL, V51, P3968, DOI 10.1128/JCM.01959-13
   Kahler AM, 2015, AM J TROP MED HYG, V92, P118, DOI 10.4269/ajtmh.13-0601
   Kalluri P, 2006, TROP MED INT HEALTH, V11, P49, DOI 10.1111/j.1365-3156.2005.01539.x
   Kanoktippornchai B, 2014, SE ASIAN J TROP MED, V45, P375
   KAPER JB, 1995, CLIN MICROBIOL REV, V8, P48, DOI 10.1128/CMR.8.1.48
   Keddy KH, 2013, J INFECT DIS, V208, pS23, DOI 10.1093/infdis/jit196
   Kelly MT, 1991, MANUAL CLIN MICROBIO
   Lam S Y, 1983, J Diarrhoeal Dis Res, V1, P87
   Ley B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036930
   Martinez-Govea A, 2001, CLIN DIAGN LAB IMMUN, V8, P768, DOI 10.1128/CDLI.8.4.768-771.2001
   Martinez-Pino I, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002366
   Mishra A, 2011, LETT APPL MICROBIOL, V53, P124, DOI 10.1111/j.1472-765X.2011.03077.x
   MIYAGI K, 1994, MICROBIOL IMMUNOL, V38, P301, DOI 10.1111/j.1348-0421.1994.tb01780.x
   Mizunoe Y, 2000, FEMS MICROBIOL LETT, V186, P115, DOI 10.1016/S0378-1097(00)00129-4
   Mukherjee P, 2010, JPN J INFECT DIS, V63, P234
   Mwaba J, 2018, TROP MED INT HEALTH, V23, P834, DOI 10.1111/tmi.13084
   NAIR GB, 1995, J CLIN MICROBIOL, V33, P2186, DOI 10.1128/JCM.33.8.2186-2187.1995
   Nato F, 2003, CLIN DIAGN LAB IMMUN, V10, P476, DOI 10.1128/CDLI.10.3.476-478.2003
   Ontweka LN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168257
   Paauw A, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-158
   PACUSZKA T, 1978, J BIOL CHEM, V253, P5103
   Page AL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037360
   Pan I H, 1965, Taiwan Yi Xue Hui Za Zhi, V64, P313
   Panutdaporn N, 2006, INT J FOOD MICROBIOL, V106, P241, DOI 10.1016/j.ijfoodmicro.2005.06.022
   Pengsuk C, 2011, J MICROBIOL METH, V87, P224, DOI 10.1016/j.mimet.2011.07.022
   Probert CSJ, 2011, BIOCHEM SOC T, V39, P1079, DOI 10.1042/BST0391079
   QADRI F, 1994, J CLIN MICROBIOL, V32, P1589, DOI 10.1128/JCM.32.6.1589-1590.1994
   QADRI F, 1995, J CLIN MICROBIOL, V33, P732, DOI 10.1128/JCM.33.3.732-734.1995
   RAHMAN M, 1987, J CLIN MICROBIOL, V25, P2204, DOI 10.1128/JCM.25.11.2204-2206.1987
   RAMAMURTHY T, 1990, LANCET, V336, P375, DOI 10.1016/0140-6736(90)91917-Y
   RAMAMURTHY T, 1992, J CLIN MICROBIOL, V30, P1783, DOI 10.1128/JCM.30.7.1783-1786.1992
   Ramamurthy T, 2003, MICROBES INFECT, V5, P329, DOI 10.1016/S1286-4579(03)00035-2
   RAMAMURTHY T, 1993, LANCET, V341, P703, DOI 10.1016/0140-6736(93)90480-5
   Rashid M, 2017, TROP MED INT HEALTH, V22, P205, DOI 10.1111/tmi.12797
   RAVEL J, 1995, MICROBIOL-UK, V141, P377, DOI 10.1099/13500872-141-2-377
   Reissbrodt R, 2002, APPL ENVIRON MICROB, V68, P4788, DOI 10.1128/AEM.68.10.4788-4794.2002
   Righetto L, 2015, EPIDEMIOL INFECT, V143, P2330, DOI 10.1017/S0950268814003252
   Rohani M Y, 1998, Malays J Pathol, V20, P31
   Safa A, 2008, EMERG INFECT DIS, V14, P987, DOI 10.3201/eid1406.080129
   Saha PK, 1996, J CLIN MICROBIOL, V34, P1114, DOI 10.1128/JCM.34.5.1114-1117.1996
   SALLES CA, 1981, J APPL BACTERIOL, V51, P433, DOI 10.1111/j.1365-2672.1981.tb01263.x
   Sanchez J, 2008, CELL MOL LIFE SCI, V65, P1347, DOI 10.1007/s00018-008-7496-5
   Sanchez J, 2011, INDIAN J MED RES, V133, P153
   Senoh M, 2015, MICROBIOLOGYOPEN, V4, P589, DOI 10.1002/mbo3.264
   Senoh M, 2014, MICROBIOLOGYOPEN, V3, P239, DOI 10.1002/mbo3.164
   Senoh M, 2012, MICROBIOL IMMUNOL, V56, P342, DOI 10.1111/j.1348-0421.2012.00440.x
   Sheng LP, 2015, TALANTA, V139, P167, DOI 10.1016/j.talanta.2015.02.054
   SHIMADA T, 1994, CURR MICROBIOL, V28, P175, DOI 10.1007/BF01571061
   SHIRAI H, 1991, J CLIN MICROBIOL, V29, P2517, DOI 10.1128/JCM.29.11.2517-2521.1991
   Sinha S, 2001, INDIAN J MED RES, V114, P83
   SUPAWAT K, 1994, ASIAN PAC J ALLERGY, V12, P155
   Taneja N, 2016, LETT APPL MICROBIOL, V62, P452, DOI 10.1111/lam.12574
   Thattiyaphong A, 2013, SE ASIAN J TROP MED, V44, P448
   Tobin-D'Angelo M, 2008, CLIN INFECT DIS, V47, P1035, DOI 10.1086/591973
   Wai SN, 1996, FEMS MICROBIOL LETT, V136, P187
   Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910
   Wang J, 2014, BIOMED RES INT, DOI DOI 10.1155/2014/648520
   Wang XY, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-17
   World Health Organization, 2018, WEEKLY EPIDEMIOLOGIC, V93, P489
   YAM WC, 1992, J CLIN MICROBIOL, V30, P2518, DOI 10.1128/JCM.30.9.2518-2520.1992
   Yamai S, 1997, Kansenshogaku Zasshi, V71, P1037
   Yamasaki Eiki, 2017, Methods Mol Biol, V1600, P1, DOI 10.1007/978-1-4939-6958-6_1
   Yamazaki W, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-94
   Yu CY, 2015, BIOSENS BIOELECTRON, V70, P282, DOI 10.1016/j.bios.2015.03.048
   Yu CY, 2011, J MICROBIOL METH, V86, P277, DOI 10.1016/j.mimet.2011.04.020
   Yu J, 2019, ANAL BIOANAL CHEM, V411, P647, DOI 10.1007/s00216-018-1472-1
   Zamani P, 2016, BIOSENS BIOELECTRON, V79, P213, DOI 10.1016/j.bios.2015.12.018
   Zarocostas J, 2017, LANCET, V389, P2274, DOI 10.1016/S0140-6736(17)31581-7
   Zhou C, 2016, ANAL BIOCHEM, V494, P68, DOI 10.1016/j.ab.2015.10.011
   2017, LANCET GASTROENTEROL, V2, P619
NR 110
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A73
EP A82
DI 10.1016/j.vaccine.2019.07.099
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500013
PM 31427135
OA Other Gold
DA 2020-05-12
ER

PT J
AU Ray, A
   Sarkar, K
   Haldar, P
   Ghosh, R
AF Ray, Arindam
   Sarkar, Kaushik
   Haldar, Pradeep
   Ghosh, Rajshankar
TI Oral cholera vaccine delivery strategy in India: Routine or campaign?-A
   scoping review
SO VACCINE
LA English
DT Review
DE Vibrio cholera; India; South Asia; Oral cholera vaccine
ID COST-EFFECTIVENESS; VIBRIO-CHOLERAE; WHOLE-CELL; EPIDEMIC CHOLERA;
   ENDEMIC CHOLERA; HAITI; INTERVENTIONS; POPULATION; BANGLADESH;
   PREVENTION
AB Oral Cholera Vaccine (OCV) has been recognized as an adjunct tool for prevention and control of cholera. However, policy directions are currently unavailable in India to guide the vaccine delivery. We conducted a scoping review to inform the policy about the scopes and challenges of different strategic choices of OCV delivery in India in light of current evidences, highlighting the scope of new research. Methods: Adopting the Arksey and O'Malley Framework for review, we searched for literatures on "efficacy", "effectiveness", and "cost" of oral cholera vaccine delivery through different strategies in Pubmed and Scopus.
   Results: We found that the protective efficacy of OCV depends on its coverage. Evidence on effectiveness of OCV are available for both reactive and pre-vaccination campaigns. Reactive high-risk vaccination is more effective than reactive ring and mass vaccination. Pre-vaccination campaigns are more effective than reactive vaccination when vaccine availability is adequate. Pre-vaccination through school campaigns in 1-14 years age group have been cost effective in India. Vaccination campaigns in under-5 children are also cost effective in spite of low efficacy due to the scope of averting a higher number of cases. However, no evidence is available regarding efficacy and effectiveness of OCV in children <1 year as well as the effectiveness of delivering OCV through routine immunization.
   Conclusion: Little evidence exist to depict mass-campaign as more economic and effective than routine expanded programme on immunization (EPI) session for delivery of OCV. Considering operational feasibility, it needs to be explored whether OCV delivery strategy is compatible with India's current EPI, if it can be introduced in routine immunization at measles containing vaccine age-schedule, optionally preceded by a campaign in targeted hot-spots in the 1-14 year age-group. Safety and efficacy data of OCV during infancy as well as hot-spot surveillance are pre-requisites for formulation of such EPI policy. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Ray, Arindam; Ghosh, Rajshankar] Bill & Melinda Gates Fdn, Delhi, India.
   [Sarkar, Kaushik] Malaria No More, Prayatna, India.
   [Haldar, Pradeep] Govt India, Delhi, India.
RP Ray, A (reprint author), Bill & Melinda Gates Fdn, Delhi, India.
EM Arindam.ray@gatesfoundation.org
RI Ray, Arindam/AAN-1525-2020
OI Ray, Arindam/0000-0002-5955-0352
CR Abubakar A, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001901
   Albert MJ, 2003, J INFECT DIS, V187, P909, DOI 10.1086/368132
   Ali M, 2005, LANCET, V366, P44, DOI 10.1016/S0140-6736(05)66550-6
   Ali M, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002120
   Ali M, 2016, VACCINE, V34, P479, DOI 10.1016/j.vaccine.2015.12.004
   Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832
   [Anonymous], 2017, HINDU
   Arksey H, 2005, INT J SOC RES METHOD, V8, P19, DOI DOI 10.1080/1364557032000119616
   Baik YO, 2015, VACCINE, V33, P6360, DOI 10.1016/j.vaccine.2015.08.075
   Baxter K, 2008, HEALTH SOC CARE COMM, V16, P197, DOI 10.1111/j.1365-2524.2007.00742.x
   Bhattacharya S, 2013, LANCET INFECT DIS, V13, P1050, DOI 10.1016/S1473-3099(13)70273-1
   Chao DL, 2011, P NATL ACAD SCI USA, V108, P7081, DOI 10.1073/pnas.1102149108
   Charles RC, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002828
   CHOLERA, 2008, CHOLERA CONTINUING C, V12
   Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025
   Cravioto A., 2017, CONCLUSIONS SAGE WOR
   de Magny GC, 2008, P NATL ACAD SCI USA, V105, P17676, DOI 10.1073/pnas.0809654105
   Desai SN, 2014, HUM VACC IMMUNOTHER, V10, P1457, DOI 10.4161/hv.29199
   Dimitrov DT, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003343
   Dutta D, 2013, EMERG INFECT DIS, V19, P464, DOI 10.3201/eid1903.121156
   Farmer P, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001145
   Fedson D S, 1998, Dev Biol Stand, V95, P195
   Greenhalgh T, 2005, BRIT MED J, V331, P1064, DOI 10.1136/bmj.38636.593461.68
   International Vaccine Institute, 2012, COUNTR INV CAS STUD
   Ivers LC, 2013, AM J TROP MED HYG, V89, P617, DOI 10.4269/ajtmh.13-0183
   Ivers LC, 2010, LANCET, V376, P2048, DOI 10.1016/S0140-6736(10)62243-X
   Jason B, 2012, LANCET, V379, P2466, DOI DOI 10.1016/S0140-6736(12)60436-X.CHOLERA
   Jeuland M, 2009, VALUE HEALTH, V12, P899, DOI 10.1111/j.1524-4733.2009.00562.x
   John J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004616
   Johri M, 2013, VACCINE, V31, P1259, DOI 10.1016/j.vaccine.2012.09.044
   Kanungo S, 2010, B WORLD HEALTH ORGAN, V88, P185, DOI 10.2471/BLT.09.073460
   Kar SK, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002629
   Kessels SJM, 2012, VACCINE, V30, P3546, DOI 10.1016/j.vaccine.2012.03.063
   Khan IA, 2013, VACCINE, V31, P6058, DOI 10.1016/j.vaccine.2013.10.021
   Khatib AM, 2012, LANCET INFECT DIS, V12, P837, DOI 10.1016/S1473-3099(12)70196-2
   Kim SY, 2011, SAMJ S AFR MED J, V101, P659
   Kulkarni T., 2017, HINDU
   Lantagne DS, 2012, ENVIRON SCI TECHNOL, V46, P11352, DOI 10.1021/es301842u
   Lee JS, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003810
   Legros D, 2018, J INFECT DIS, V218, pS137, DOI 10.1093/infdis/jiy486
   Lessler J, 2018, LANCET, V391, P1908, DOI [10.1016/S0140-6736(17)33050-7, 10.1016/s0140-6736(17)33050-7]
   Levac D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-69
   Lippi D, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.PoH-0012-2015
   Longini IM, 2007, PLOS MED, V4, P1776, DOI 10.1371/journal.pmed.0040336
   Luquero FJ, 2014, NEW ENGL J MED, V370, P2111, DOI 10.1056/NEJMoa1312680
   Matsuda F, 2011, VACCINE, V29, P1855, DOI 10.1016/j.vaccine.2010.12.133
   Ministry of Heath & Family Welfare. Government of India, 2017, HLTH MIN LAUNCH SING
   Mookerjee S, 2014, ENVIRON MONIT ASSESS, V186, P6241, DOI 10.1007/s10661-014-3851-1
   Murray J, 1998, B WORLD HEALTH ORGAN, V76, P343
   National Vector Borne Disease Control Programme. Directorate General of Health Services. Ministry of Health & Family Welfare. Government of India, 2014, AC ENC SYNDR OP GUID
   Nelson CB, 2014, VACCINE, V32, P7033, DOI 10.1016/j.vaccine.2014.05.028
   Nygren BL, 2014, AM J TROP MED HYG, V91, P1023, DOI 10.4269/ajtmh.14-0331
   Pal BB, 2019, J CLIN MICROBIOL, V57, DOI 10.1128/JCM.01877-18
   Pham MT, 2014, RES SYNTH METHODS, V5, P371, DOI 10.1002/jrsm.1123
   Poljak M, 2013, VACCINE, V31, pH59, DOI 10.1016/j.vaccine.2013.03.029
   Pollock M, 2016, SYST REV, V5, DOI 10.1186/s13643-016-0367-5
   Pratham Education Foundation, 2017, ANN STAT ED REP 2016
   Qadri F, 2016, NEW ENGL J MED, V374, P1723, DOI 10.1056/NEJMoa1510330
   Qadri F, 2015, LANCET, V386, P1362, DOI 10.1016/S0140-6736(15)61140-0
   Root ED, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022971
   Rouzier V, 2013, AM J TROP MED HYG, V89, P671, DOI 10.4269/ajtmh.13-0171
   Ryan ET, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001003
   Saha A, 2011, VACCINE, V29, P8285, DOI 10.1016/j.vaccine.2011.08.108
   Sarkar BL, 2012, INDIAN J MED RES, V135, P246
   Schaetti C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041527
   Sen Gupta S, 2016, INDIAN J MED RES, V143, P545, DOI 10.4103/0971-5916.187102
   Severe K, 2016, AM J TROP MED HYG, V94, P1136, DOI 10.4269/ajtmh.15-0700
   SHEPARD DS, 1989, B WORLD HEALTH ORGAN, V67, P649
   Sodha SV, 2015, BRIT MED BULL, V113, P5, DOI 10.1093/bmb/ldv001
   Sreedevi A, 2018, J POSTGRAD MED, V64, P202, DOI 10.4103/jpgm.JPGM_104_18
   Srivastava RN, 2012, INDIAN PEDIATR, V49, P501
   Tappero JW, 2011, EMERG INFECT DIS, V17, P2087, DOI 10.3201/eid1711.110827
   Tauxe Robert, 1994, P321
   Taylor DL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135676
   Trach DD, 1997, LANCET, V349, P231, DOI 10.1016/S0140-6736(96)06107-7
   Troeger C, 2014, AM J TROP MED HYG, V91, P1181, DOI 10.4269/ajtmh.14-0159
   Uddin MJ, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1758-x
   UNICEF, 2016, OR CHOL VACC MARK SU
   Thiem VD, 2011, CLIN VACCINE IMMUNOL, V18, P730, DOI 10.1128/CVI.00532-10
   WHO, 2010, OR CHOL VACC MASS IM
   WHO, ADD OR CHOL VACC MAS
   Wierzba TF, 2015, VACCINE, V33, P2463, DOI 10.1016/j.vaccine.2015.03.073
   World Health Organization, 2016, WKLY EPIDEMIOL REC W, V91, P297, DOI [10.1371/jour, DOI 10.1371/JOUR]
   World Health Organization, 2014, PRINC CONS ADD VACC
   World Health Organization, 2017, CHOL VACC WHO POS PA, V34
NR 85
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A184
EP A193
DI 10.1016/j.vaccine.2019.07.082
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500029
PM 31377080
OA Other Gold
DA 2020-05-12
ER

PT J
AU Sekhar, A
   Kang, G
AF Sekhar, Amrita
   Kang, Gagandeep
TI Pathways to a policy for cholera control in India
SO VACCINE
LA English
DT Article
DE Cholera; India; Policy; Vaccine
ID COST-EFFECTIVENESS; VACCINES
AB Cholera is endemic in southern Asia, but available control mechanisms have either not been applied or have been ineffective. Oral killed cholera vaccines are now available, are pre-qualified by the World Health Organization (WHO) and are being stock-piled by the Gavi Alliance. Although cholera vaccines have been tested, manufactured and licensed in India for several years, they are not in use in public health programmes for either endemic disease or outbreaks. The National Technical Advisory Group on Immunization (NTAGI) is the advisory body that considers disease burden, vaccine performance, cost-effectiveness and potential for introduction into national programmes, reporting to the Ministry of Health. The NTAGI also takes into account the recommendations of the WHO and is now considering cholera vaccines. Policies for cholera control are urgently needed, and the availability and affordability of an oral cholera vaccine in India offers new opportunities to control an important public health problem. (C) 2019 Elsevier Ltd.
C1 [Sekhar, Amrita; Kang, Gagandeep] Translat Hlth Sci & Technol Inst, 3rd Milestone, Faridabad 121001, Haryana, India.
RP Kang, G (reprint author), Translat Hlth Sci & Technol Inst, 3rd Milestone, Faridabad 121001, Haryana, India.
EM gkang@thsti.res.in
OI Kang, Gagandeep/0000-0002-3656-564X
CR Allan M, 2016, EPIDEMICS-NETH, V14, P1, DOI 10.1016/j.epidem.2015.08.001
   [Anonymous], 2010, Wkly Epidemiol Rec, V85, P117
   Bi QF, 2017, LANCET INFECT DIS, V17, P1080, DOI [10.1016/s1473-3099(17)30359-6, 10.1016/S1473-3099(17)30359-6]
   Clemens JD, 2017, LANCET, V390, P1539, DOI 10.1016/S0140-6736(17)30559-7
   Jesudason MV, 2000, EPIDEMIOL INFECT, V124, P201, DOI 10.1017/S095026889900357X
   Jeuland M, 2009, VALUE HEALTH, V12, P899, DOI 10.1111/j.1524-4733.2009.00562.x
   John TJ, 2010, VACCINE, V28, pA88, DOI 10.1016/j.vaccine.2010.02.041
   SHUKLA BN, 1995, FEMS IMMUNOL MED MIC, V12, P113, DOI 10.1111/j.1574-695X.1995.tb00182.x
   Troeger C, 2014, AM J TROP MED HYG, V91, P1181, DOI 10.4269/ajtmh.14-0159
   World Health Organization, MUCH WOULD IT COST A
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A157
EP A159
DI 10.1016/j.vaccine.2019.06.036
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500023
PM 31266672
OA Other Gold
DA 2020-05-12
ER

PT J
AU Sen Gupta, S
   Gupta, SK
AF Sen Gupta, Sanjukta
   Gupta, Satish Kumar
TI Social mobilization for cholera prevention & control in India: Building
   on the existing framework
SO VACCINE
LA English
DT Article
DE Social mobilisation; Communications; Existing framework; Cholera
   prevention
AB Social mobilization is an important component of the delivery of vaccines and has to be carried out at different levels. It plays a very critical role in success of a campaign, as was shown by the Polio eradication program in India that was supported by SMNet, a platform created for the purpose. Learnings from this has been used for other vaccine deployments in India as well. In addition, there is a social mobilization effort for routine immunization. A guideline for social mobilization was created by UNICEF specifically for cholera vaccine use during Haiti epidemic in 2010. Since there is a need to develop a roadmap for cholera control in India, especially in the known hotspots, and after natural disasters, we suggest a possible strategy that could be built on the existing framework available in India. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Sen Gupta, Sanjukta] Translat Hlth Sci & Technol Inst, NCR Biotech Sci Cluster, 3rd Milestone,Faridabad Gurgaon Expressway, Faridabad 121001, Haryana, India.
   [Gupta, Satish Kumar] UNICEF, Yangon, Myanmar.
RP Gupta, SK (reprint author), UNICEF, Yangon, Myanmar.
EM sgupta@unicef.org
CR [Anonymous], 2011, UNICEF STRATEGY SOCI
   [Anonymous], 2017, COMM GUID MEASL RUB
   Cholera, 2018, WEEKLY EPIDEMIOLOGIC, V93, P489
   Deen J, 2018, HUM VACC IMMUNOTHER, V14, P2069, DOI 10.1080/21645515.2018.1462068
   Deutsch N, 2017, J INFECT DIS, V216, pS260, DOI 10.1093/infdis/jix068
   Immunization Division Department of Family Welfare Ministry of Health and Family Welfare Government of India, 2010, OP GUID JAP ENC VACC
   Kar SK, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002629
   Siddique Anisur Rahman, 2016, Indian Pediatr, V53 Suppl 1, pS50
NR 8
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A181
EP A183
DI 10.1016/j.vaccine.2019.07.047
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500028
PM 31331775
OA Other Gold
DA 2020-05-12
ER

PT J
AU Sen Gupta, S
   Ganguly, NK
AF Sen Gupta, Sanjukta
   Ganguly, Nirmal Kumar
TI Opportunities and challenges for cholera control in India
SO VACCINE
LA English
DT Article
DE India; Cholera prevention; Opportunities; Challenges
AB The Indo Gangetic delta is homeland for cholera for almost two centuries now and there is evidence of global spread from this area. With migration of people to more urban areas within the country and increase in international travel, it is time for action against cholera in India, given its capacity to present itself in epidemic proportions. The Global roadmap to end cholera by 2030 was launched by the WHO Global Task force for Cholera Control which has led to renewed vigor and convergence of stakeholders across the world against the disease. There is also an emphasis on cleanliness and improved sanitation by the current government. The article discusses the unique opportunity for India in the current scenario, to act against diseases like cholera and challenges that are anticipated in deployment of interventions due to suboptimal surveillance and shortage of vaccines. (C) 2019 Published by Elsevier Ltd.
C1 [Sen Gupta, Sanjukta; Ganguly, Nirmal Kumar] Translat Hlth Sci & Technol Inst, Policy Ctr Biomed Res, NCR Biotech Biosci Cluster, Faridabad Gurgaon Expressway, Faridabad 121001, India.
RP Ganguly, NK (reprint author), Translat Hlth Sci & Technol Inst, Policy Ctr Biomed Res, NCR Biotech Biosci Cluster, Faridabad Gurgaon Expressway, Faridabad 121001, India.
EM nkganguly@nii.ac.in
FU Bill and Melinda Gates FoundationGates Foundation [OPP116283]
FX We acknowledge funding for the work carried out for creation of a
   National Roadmap for prevention and control of cholera in India from the
   Bill and Melinda Gates Foundation, Grant ID: OPP116283.
CR Ali M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183100
   Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832
   Bhunia R, 2011, T ROY SOC TROP MED H, V105, P214, DOI 10.1016/j.trstmh.2010.12.008
   David S, 2016, INT J INFECT DIS, V47, P42, DOI 10.1016/j.ijid.2016.01.010
   Desai SN, 2017, HUM VACC IMMUNOTHER, V13, P579, DOI 10.1080/21645515.2016.1245250
   Mutreja A, 2011, NATURE, V477, P462, DOI 10.1038/nature10392
   Pal BB, 2018, JPN J INFECT DIS, V71, P99, DOI 10.7883/yoken.JJID.2017.193
   Ramamurthy T, 2014, CURR TOP MICROBIOL, V379, P49, DOI 10.1007/82_2014_368
   Sen Gupta S, 2016, INDIAN J MED RES, V143, P545, DOI 10.4103/0971-5916.187102
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A25
EP A27
DI 10.1016/j.vaccine.2019.06.032
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500006
PM 31266674
OA Other Gold
DA 2020-05-12
ER

PT J
AU Shaikh, H
   Lynch, J
   Kim, J
   Excler, JL
AF Shaikh, Hanif
   Lynch, Julia
   Kim, Jerome
   Excler, Jean-Louis
TI Current and future cholera vaccines
SO VACCINE
LA English
DT Article
DE Cholera; Prevention; Vaccine; Oral cholera vaccine; Parenteral cholera
   vaccine; WHO prequalification; Stockpile
ID SUBUNIT-WHOLE-CELL; MASS VACCINATION CAMPAIGN; VIBRIO-CHOLERAE;
   B-SUBUNIT; EL-TOR; CVD 103-HGR; CROSS-PROTECTION; ORAL VACCINES; FIELD
   TRIAL; VITAMIN-A
AB Cholera remains a major global public health problem that is primarily linked to insufficient access to safe water and proper sanitation. Oral Cholera Vaccine (OCV) has been recommended as an additional public health tool along with WASH in cholera endemic countries and in areas at risk for outbreaks. The new generation OCV is safe and offers good protection in older children and adults while limited protection in younger children less than five years of age has been observed. The combination of direct vaccine protection and vaccine herd immunity effects makes OCV highly cost-effective and, therefore, attractive for use in developing countries. Additionally, in recent studies OCV was safe in pregnant women, supporting its use in pregnant women in cholera endemic countries. However, knowledge need to be developed for current vaccines for their prolonged duration of protection and vaccines need improvements for better immune response in younger children. A single dose vaccination regimen would be more cost-effective and easier to deliver. Recent approaches have focused on designing genetically attenuated cholera strains for use in single-dose cholera vaccines. The global demand for OCV has been boosted by the WHO recommendation to use OCV and is driven largely by epidemics and outbreaks and has been increasing due to the availability of cheaper easy-to-use vaccines, feasibility of mass OCV vaccination campaigns, demonstration of protection to underserved population in precarious situations, and vaccine costs being borne by Gavi (Vaccine Alliance). For rapid access in emergency and equitable distribution of OCV in cholera-endemic low-income countries, a global OCV stockpile was established in 2013 with support from the Global Alliance for Vaccines and Immunization. The three WHO-prequalified vaccines are Dukoral (R), Shanchol (TM), Euvichol (R) (and Euvichol (R) Plus presentation), the latter two being included in the stockpile. (C) 2019 The Author(s). Published by Elsevier Ltd.
C1 [Shaikh, Hanif; Lynch, Julia; Kim, Jerome; Excler, Jean-Louis] Int Vaccine Inst, Seoul, South Korea.
   [Shaikh, Hanif] KEM Hosp Res Ctr, Pune, Maharashtra, India.
RP Shaikh, H (reprint author), KEM Hosp, KEM Hosp Res Ctr, 3rd Floor,TDH Bldg, Pune 411001, Maharashtra, India.
EM hanifshaikh.pune@gmail.com
OI Shaikh, MohammadHanif/0000-0002-8958-5644
CR Ahmed T, 2009, VACCINE, V27, P1433, DOI 10.1016/j.vaccine.2008.12.036
   ALBERT MJ, 1993, LANCET, V342, P387
   ALBERT MJ, 1994, J INFECT DIS, V169, P230, DOI 10.1093/infdis/169.1.230
   Albert MJ, 2003, J INFECT DIS, V187, P909, DOI 10.1086/368132
   Ali M, 2005, LANCET, V366, P44, DOI 10.1016/S0140-6736(05)66550-6
   Ali M, 2017, LANCET INFECT DIS, V17, P538, DOI [10.1016/s1473-3099(16)30523-0, 10.1016/S1473-3099(16)30523-0]
   Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832
   Ali M, 2013, CLIN INFECT DIS, V56, P1123, DOI 10.1093/cid/cit009
   Ali M, 2011, J INFECT DIS, V204, P912, DOI 10.1093/infdis/jir416
   Anh DD, 2007, VACCINE, V25, P1149, DOI 10.1016/j.vaccine.2006.09.049
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P477
   [Anonymous], 2010, Wkly Epidemiol Rec, V85, P117
   AYANGADE O, 1981, International Journal of Gynecology and Obstetrics, V19, P403, DOI 10.1016/0020-7292(81)90025-4
   Azman AS, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001867
   Baik YO, 2015, VACCINE, V33, P6360, DOI 10.1016/j.vaccine.2015.08.075
   Baik YO, 2014, J KOREAN MED SCI, V29, P494, DOI 10.3346/jkms.2014.29.4.494
   Bhattacharya S, 2013, LANCET INFECT DIS, V13, P1050, DOI 10.1016/S1473-3099(13)70273-1
   Calain P, 2004, VACCINE, V22, P2444, DOI 10.1016/j.vaccine.2003.11.070
   Cannell JJ, 2006, EPIDEMIOL INFECT, V134, P1129, DOI 10.1017/S0950268806007175
   Cassani B, 2012, MOL ASPECTS MED, V33, P63, DOI 10.1016/j.mam.2011.11.001
   Charles RC, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002828
   Chen Q, 1996, Zhonghua Yu Fang Yi Xue Za Zhi, V30, P330
   Chen WH, 2016, CLIN INFECT DIS, V62, P1329, DOI 10.1093/cid/ciw145
   Chen WH, 2014, CLIN VACCINE IMMUNOL, V21, P66, DOI 10.1128/CVI.00601-13
   Chowdhury F, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004183
   Chowdhury FR, 2017, ANN CLIN MICROB ANTI, V16, DOI 10.1186/s12941-017-0185-1
   Chowdhury R, 2014, 2014 14TH INTERNATIONAL CONFERENCE ON INNOVATIONS FOR COMMUNITY SERVICES (I4CS), P9, DOI 10.1109/I4CS.2014.6860546
   Ciglenecki I, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002368
   CLEMENS J D, 1988, Southeast Asian Journal of Tropical Medicine and Public Health, V19, P417
   CLEMENS JD, 1986, LANCET, V2, P124
   CLEMENS JD, 1987, J INFECT DIS, V155, P79, DOI 10.1093/infdis/155.1.79
   CLEMENS JD, 1988, J INFECT DIS, V158, P372, DOI 10.1093/infdis/158.2.372
   Clemens JD, 2013, VACCINES, P141
   Clemens J, 2011, NAT REV GASTRO HEPAT, V8, P701, DOI 10.1038/nrgastro.2011.174
   Clemens JD, 2017, LANCET, V390, P1539, DOI 10.1016/S0140-6736(17)30559-7
   Clemens JD, 2011, P NATL ACAD SCI USA, V108, P8529, DOI 10.1073/pnas.1105807108
   Clements JD, 2016, CLIN VACCINE IMMUNOL, V23, P438, DOI 10.1128/CVI.00214-16
   Deen JL, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000173
   Desai SN, 2017, HUM VACC IMMUNOTHER, V13, P579, DOI 10.1080/21645515.2016.1245250
   Desai SN, 2016, LANCET GLOB HEALTH, V4, pE223, DOI 10.1016/S2214-109X(16)00037-1
   Diop SA, 2007, MED MALADIES INFECT, V37, P816, DOI 10.1016/j.medmal.2007.05.010
   Feeley JC, 1980, CHOLERA RELATED DIAR, P204
   Ferreras E, 2018, NEW ENGL J MED, V378, P577, DOI 10.1056/NEJMc1711583
   Garcia L, 2005, INFECT IMMUN, V73, P3018, DOI 10.1128/IAI.73.5.3018-3024.2005
   GARG S, 1993, J INFECTION, V27, P108, DOI 10.1016/0163-4453(93)94398-U
   Ghosh-Banerjee J, 2010, J CLIN MICROBIOL, V48, P4283, DOI 10.1128/JCM.00799-10
   GLASS RI, 1985, J INFECT DIS, V151, P236, DOI 10.1093/infdis/151.2.236
   Grout L, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004274
   Hashim R, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001743
   HOLMGREN J, 1992, VACCINE, V10, P911, DOI 10.1016/0264-410X(92)90324-D
   HONDA T, 1979, P NATL ACAD SCI USA, V76, P2052, DOI 10.1073/pnas.76.4.2052
   Hubbard TP, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aap8423
   JOHNSON JA, 1994, INFECT IMMUN, V62, P2108, DOI 10.1128/IAI.62.5.2108-2110.1994
   Jutla Antarpreet, 2017, Curr Environ Health Rep, V4, P99, DOI 10.1007/s40572-017-0132-5
   Jutla A, 2013, AM J TROP MED HYG, V89, P597, DOI 10.4269/ajtmh.12-0721
   Kanungo S, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003574
   Kanungo S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099381
   Kanungo S, 2009, VACCINE, V27, P6887, DOI 10.1016/j.vaccine.2009.09.008
   KAPER JB, 1995, CLIN MICROBIOL REV, V8, P48, DOI 10.1128/CMR.8.1.48
   Karlsson SL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108521
   Khan AI, 2017, VACCINE, V35, P1538, DOI 10.1016/j.vaccine.2017.01.080
   Khan P K, 1969, Int Surg, V51, P138
   Khatib AM, 2012, LANCET INFECT DIS, V12, P837, DOI 10.1016/S1473-3099(12)70196-2
   Kim JH, 2016, VACCINE, V34, P2113, DOI 10.1016/j.vaccine.2016.03.004
   Leung DT, 2012, EXPERT REV ANTI-INFE, V10, P435, DOI [10.1586/ERI.12.23, 10.1586/eri.12.23]
   Levin A, 2012, INVESTMENT CASE ACCE
   LEVINE MM, 1993, VACCINE, V11, P207, DOI 10.1016/0264-410X(93)90019-T
   LEVINE MM, 1988, LANCET, V2, P468, DOI 10.1016/S0140-6736(88)90120-1
   LEVINE MM, 1979, T ROY SOC TROP MED H, V73, P3, DOI 10.1016/0035-9203(79)90119-6
   Levine MM, 2017, EXPERT REV VACCINES, V16, P197, DOI 10.1080/14760584.2017.1291348
   Longini IM, 2007, PLOS MED, V4, P1776, DOI 10.1371/journal.pmed.0040336
   Lopez Anna Lena, 2014, Ther Adv Vaccines, V2, P123, DOI 10.1177/2051013614537819
   Luquero FJ, 2015, LANCET GLOB HEALTH, V3, pE120, DOI 10.1016/S2214-109X(15)70015-X
   Luquero FJ, 2014, NEW ENGL J MED, V370, P2111, DOI 10.1056/NEJMoa1312680
   Lyer A. S., 2016, SCI REPORT, V6, P35742
   Mahalanabis D, 2009, VACCINE, V27, P4850, DOI 10.1016/j.vaccine.2009.05.065
   Mahalanabis D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002323
   Martin S, 2014, B WORLD HEALTH ORGAN, V92, P881, DOI 10.2471/BLT.14.139949
   MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0
   Nair GB, 2002, J CLIN MICROBIOL, V40, P3296, DOI 10.1128/JCM.40.9.3296-3299.2002
   Nair GB, 2014, CURR TOP MICROBIOL I, V379, P34
   Naylor C, 2015, EBIOMEDICINE, V2, P1759, DOI 10.1016/j.ebiom.2015.09.036
   Odevall L, 2018, VACCINE, V36, P6606, DOI 10.1016/j.vaccine.2018.09.026
   OGUNBODE O, 1972, OBSTET GYNECOL, V39, P441
   OWEN RL, 1986, J INFECT DIS, V153, P1108, DOI 10.1093/infdis/153.6.1108
   Plotkin SA, 2012, CLIN INFECT DIS, V54, P1615, DOI 10.1093/cid/cis238
   Qadri F, 2005, INFECT IMMUN, V73, P6577, DOI 10.1128/IAI.73.10.6577-6583.2005
   Qadri F, 2004, VACCINE, V22, P416, DOI 10.1016/j.vaccine.2003.07.005
   Qadri F, 2016, NEW ENGL J MED, V374, P1723, DOI 10.1056/NEJMoa1510330
   Ryan ET, 2006, EXPERT REV VACCINES, V5, P483, DOI 10.1586/14760584.5.4.483
   Sack DA, 1997, J INFECT DIS, V176, P201, DOI 10.1086/514025
   Sack DA, 2004, LANCET, V363, P223, DOI 10.1016/S0140-6736(03)15328-7
   Safa A, 2008, EMERG INFECT DIS, V14, P987, DOI 10.3201/eid1406.080129
   SAGE Working Group on Oral Cholera Vaccines World Health Organization (WHO) Secretariat Centers for Disease Control and Prevention, 2017, BACKGR PAP WHOL CELL, P107
   Saha A, 2016, VACCINE, V34, P1551, DOI 10.1016/j.vaccine.2016.02.020
   Saha A, 2011, VACCINE, V29, P8285, DOI 10.1016/j.vaccine.2011.08.108
   Saha D, 2004, J INFECT DIS, V189, P2318, DOI 10.1086/421275
   Saluja T, 2020, HUM VACC IMMUNOTHER, V16, P42, DOI 10.1080/21645515.2019.1644882
   Sharma NC, 2007, INDIAN J MED RES, V125, P633
   Sit B, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007417
   SUHARYONO, 1992, LANCET, V340, P689, DOI 10.1016/0140-6736(92)92231-4
   Sur D, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001289
   Sur D, 2009, LANCET, V374, P1694, DOI 10.1016/S0140-6736(09)61297-6
   SVENNERHOLM AM, 1977, SCAND J IMMUNOL, V6, P1345
   Talavera A, 2009, J INFECT DEV COUNTR, V3, P408, DOI 10.3855/jidc.410
   Taylor DN, 2000, J INFECT DIS, V181, P1667, DOI 10.1086/315462
   Trach DD, 2002, B WORLD HEALTH ORGAN, V80, P2
   Trach DD, 1997, LANCET, V349, P231, DOI 10.1016/S0140-6736(96)06107-7
   Valera R, 2009, VACCINE, V27, P6564, DOI 10.1016/j.vaccine.2009.08.042
   World Health Organization, 2017, WEEKL UPD CHOL 06 JU
   World Health Organization, 2019, WHO PREQ VACC CHOL I
   World Health Organization, 2004, GUID PROD CONTR IN C, V924, P9
   World Health Organization, 2012, WHO TECHN WORK GROUP
   Xiong MWL, 1998, J 1 MILITARY MED U, P329
NR 114
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A118
EP A126
DI 10.1016/j.vaccine.2019.12.011
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500018
PM 31879125
OA Other Gold
DA 2020-05-12
ER

PT J
AU Taneja, N
   Mishra, A
   Batra, N
   Gupta, P
   Mahindroo, J
   Mohan, B
AF Taneja, Neelam
   Mishra, Arti
   Batra, Nitya
   Gupta, Parakriti
   Mahindroo, Jaspreet
   Mohan, Balvinder
TI Inland cholera in freshwater environs of north India
SO VACCINE
LA English
DT Article
DE Cholera outbreak; Freshwater; Sporadic cholera; Vibrio cholerae
ID NONCULTURABLE VIBRIO-CHOLERAE; NON-CULTURABLE STATE; EL-TOR; VIRULENCE
   GENES; PATHOGENICITY ISLAND; AQUATIC ENVIRONMENT; INFECTIOUS-DISEASE;
   GLOBAL CLIMATE; SEROTYPE INABA; O1 BIOTYPE
AB In the freshwater environment of north India, cholera appears seasonally in form of clusters as well as sporadically, accounting for a significant piece of the puzzle of cholera epidemiology. We describe a number of cholera outbreaks with an average attack rate of 96.5/1000 but an overall low case fatality (0.17). Clinical cholera cases coincided with high rainfall and elevated temperatures, whereas isolation of V. cholerae non-O1 non-O139 from water was dependent on temperature (p < 0.05) but was independent of rainfall and pH (p > 0.05). However, isolation from plankton samples correlated with increased temperature and pH (p < 0.05). A lag period of almost a month was observed between rising temperature and increased isolation of V. cholerae from the environment, which in succession was followed by an appearance of cholera cases in the community a month later. Our results suggested that the aquatic environment can harbor highly divergent V. cholerae strains and serve as a reservoir for multiple V. cholera virulence-associated genes that may be exchanged via mobile genetic elements. In agreement with PFGE, AFLP data also proved that the V. cholerae O1 population was not clonal but was closely related. Our investigation did not support the concept that seasonal cholera outbreaks occur by movement of a single clonal strain across the region, as the clinical isolates from the same years were clearly different, implying that continuous evolution of V. cholerae O1 strains occurs in the cholera endemic area. Interestingly, the viable but non-culturable (VBNC) V. cholerae O1 cells were demonstrated in 2.21% samples from natural water bodies in addition to 40.69% samples from cholera-affected areas respectively. This suggests that aquatic environs do harbor the pathogenic O1 strain, though the isolation of culturable V. cholerae O1 is a rare event in the presence of relatively abundant non-O1 non-O139 isolates. (C) 2019 Published by Elsevier Ltd.
C1 [Taneja, Neelam; Mishra, Arti; Batra, Nitya; Gupta, Parakriti; Mahindroo, Jaspreet; Mohan, Balvinder] Postgrad Inst Med Educ & Res, Dept Med Microbiol, Chandigarh, India.
RP Taneja, N (reprint author), Postgrad Inst Med Educ & Res, Dept Med Microbiol, Chandigarh, India.
EM drneelampgi@yahoo.com
FU WHO India office; ICMRIndian Council of Medical Research (ICMR);
   Department of Science and Technology ChandigarhDepartment of Science &
   Technology (India)
FX We acknowledge the help and support provided by local health authorities
   in investigating and managing the outbreaks of cholera. We also
   acknowledge the financial support of WHO India office, ICMR and
   Department of Science and Technology Chandigarh in carrying out most of
   this work. Technical support for PFGE and reference strains were
   provided by NICED, Kolkata (kind courtesy Dr. Ramamurthy and Dr. Nair).
   Dr. Ram Kumar of Institute of Himalayan Bioresource and Technology,
   Palampur, Himachal Pradesh provided technical help for AFLP work.
CR Alam M, 2007, P NATL ACAD SCI USA, V104, P17801, DOI 10.1073/pnas.0705599104
   Ali M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183100e0183100
   Ali M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003832
   Allam Ramesh R, 2015, Indian J Community Med, V40, P283, DOI 10.4103/0970-0218.164408
   Asakura H, 2007, ENVIRON MICROBIOL, V9, P869, DOI 10.1111/j.1462-2920.2006.01206.x
   BAKER RM, 1983, APPL ENVIRON MICROB, V46, P930, DOI 10.1128/AEM.46.4.930-940.1983
   Bhattacharya D, 2015, JPN J INFECT DIS, V68, P347, DOI 10.7883/yoken.JJID.2014.257
   Binsztein N, 2004, APPL ENVIRON MICROB, V70, P7481, DOI 10.1128/AEM.70.12.7481-7486.2004
   Chaiyanan S, 2007, ENVIRON MICROBIOL, V9, P393, DOI 10.1111/j.1462-2920.2006.01150.x
   Chakraborty S, 2000, APPL ENVIRON MICROB, V66, P4022, DOI 10.1128/AEM.66.9.4022-4028.2000
   Chattejee SN, 2003, BBA-MOL BASIS DIS, V1639, P65, DOI 10.1016/j.bbadis.2003.08.004
   Chatterjee SN, 2004, BBA-MOL BASIS DIS, V1690, P93, DOI 10.1016/j.bbadis.2004.06.006
   COLWELL RR, 1985, BIO-TECHNOL, V3, P817, DOI 10.1038/nbt0985-817
   Colwell RR, 1996, WORLD J MICROB BIOT, V12, P28, DOI 10.1007/BF00327795
   Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025
   COLWELL RR, 1977, SCIENCE, V198, P394, DOI 10.1126/science.910135
   de Magny GC, 2008, P NATL ACAD SCI USA, V105, P17676, DOI 10.1073/pnas.0809654105
   Deen JL, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000173
   Dey S, 2014, INDIAN J MED RES, V140, P420
   Dutta B, 2006, J CLIN MICROBIOL, V44, P3391, DOI 10.1128/JCM.00632-06
   Epstein SS, 2009, MICROBIOL MONOGR, V10, P131, DOI 10.1007/7171_2009_2
   Faruque SM, 2004, P NATL ACAD SCI USA, V101, P2123, DOI 10.1073/pnas.0308485100
   Faruque SM, 1998, MICROBIOL MOL BIOL R, V62, P1301, DOI 10.1128/MMBR.62.4.1301-1314.1998
   Faruque SM, 2000, INFECT IMMUN, V68, P4795, DOI 10.1128/IAI.68.8.4795-4801.2000
   Gonzalez-Escalona N, 2006, ENVIRON MICROBIOL, V8, P658, DOI 10.1111/j.1462-2920.2005.00943.x
   Hasan NA, 2013, APPL ENVIRON MICROB, V79, P5782, DOI 10.1128/AEM.01113-13
   Hoshino K, 1998, FEMS IMMUNOL MED MIC, V20, P201, DOI 10.1111/j.1574-695X.1998.tb01128.x
   HUQ A, 1984, APPL ENVIRON MICROB, V48, P420, DOI 10.1128/AEM.48.2.420-424.1984
   Huq A, 2005, APPL ENVIRON MICROB, V71, P4645, DOI 10.1128/AEM.71.8.4645-4654.2005
   HUQ A, 1983, APPL ENVIRON MICROB, V45, P275, DOI 10.1128/AEM.45.1.275-283.1983
   Imamura D, 2015, MICROBIOL IMMUNOL, V59, P305, DOI 10.1111/1348-0421.12246
   ISLAM MS, 1994, J DIARRHOEAL DIS RES, V12, P87
   Kanungo S, 2010, B WORLD HEALTH ORGAN, V88, P185, DOI 10.2471/BLT.09.073460
   Karaolis DKR, 1998, P NATL ACAD SCI USA, V95, P3134, DOI 10.1073/pnas.95.6.3134
   Kell DB, 1998, ANTON LEEUW INT J G, V73, P169, DOI 10.1023/A:1000664013047
   Kimani RW, 2014, AFR J LAB MED, V3, DOI 10.4102/ajlm.v3i1.41
   Kong IS, 2004, FEMS MICROBIOL ECOL, V67, P3928
   Li MR, 2003, APPL ENVIRON MICROB, V69, P1728, DOI 10.1128/AEM.69.3.1728-1738.2003
   Lipp EK, 2002, CLIN MICROBIOL REV, V15, P757, DOI 10.1128/CMR.15.4.757-770.2002
   Mahapatra T, 2014, JPN J INFECT DIS, V67, P145, DOI 10.7883/yoken.67.145
   Merrell DS, 2002, NATURE, V417, P642, DOI 10.1038/nature00778
   Mishra A, 2012, J APPL MICROBIOL, V112, P945, DOI 10.1111/j.1365-2672.2012.05255.x
   Mishra A, 2012, J APPL MICROBIOL, V112, P225, DOI 10.1111/j.1365-2672.2011.05191.x
   Mishra A, 2011, LETT APPL MICROBIOL, V53, P124, DOI 10.1111/j.1472-765X.2011.03077.x
   Mishra A, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-249
   Nelson EJ, 2009, NAT REV MICROBIOL, V7, P693, DOI 10.1038/nrmicro2204
   Oliver JD, 2010, FEMS MICROBIOL REV, V34, P415, DOI 10.1111/j.1574-6976.2009.00200.x
   Oliver JD, 2000, NONCULTURABLE MICROORGANISMS IN THE ENVIRONMENT, P277
   Pal BB, 2010, INT J INFECT DIS, V14, pE384, DOI 10.1016/j.ijid.2009.06.020
   Puri S, 2014, MED J DY PATIL U, V7, P147
   Ramamurthy T, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00103
   Ramamurthy T, 2014, CURR TOP MICROBIOL, V379, P49, DOI 10.1007/82_2014_368
   Ravel J, 1985, MICROBIOL, V141, P377
   de Menezes FGR, 2014, REV INST MED TROP SP, V56, P427, DOI 10.1590/S0036-46652014000500010
   Senoh M, 2015, MICROBIOLOGYOPEN, V4, P589, DOI 10.1002/mbo3.264
   Sharma C, 1997, J INFECT DIS, V175, P1134, DOI 10.1086/516453
   Singh DV, 2001, APPL ENVIRON MICROB, V67, P910, DOI 10.1128/AEM.67.2.910-921.2001
   Siriphap A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169324
   Sung HH, 2006, J FOOD DRUG ANAL, V14, P265
   Takemura T, 2017, INFECT GENET EVOL, V54, P146, DOI 10.1016/j.meegid.2017.06.017
   Taneja N, 2005, JPN J INFECT DIS, V58, P238
   Taneja N, 2003, INDIAN J MED RES, V117, P243
   Taneja Neelam, 2007, J Commun Dis, V39, P241
   Taneja N, 2012, INDIAN J MED RES, V136, P656
   Taneja N, 2009, EMERG INFECT DIS, V15, P352, DOI 10.3201/eid1502.080943
   Uthappa CK, 2015, J HEALTH POPUL NUTR, V33, DOI 10.1186/s41043-015-0021-1
   Vora GJ, 2005, P NATL ACAD SCI USA, V102, P19109, DOI 10.1073/pnas.0505033102
   Wai SN, 1999, FEMS MICROBIOL LETT, V180, P123, DOI 10.1111/j.1574-6968.1999.tb08786.x
   Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910
   Wu B, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00404
   XU HS, 1982, MICROBIAL ECOL, V8, P313, DOI 10.1007/BF02010671
   Yamai S, 1997, Kansenshogaku Zasshi, V71, P1037
NR 72
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD FEB 29
PY 2020
VL 38
SU 1
BP A63
EP A72
DI 10.1016/j.vaccine.2019.06.038
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WY
UT WOS:000518877500012
PM 31279566
OA Other Gold
DA 2020-05-12
ER

PT J
AU Adib, SD
   Lescan, M
   Renovanz, M
   Schuhmann, MU
   Trakolis, L
   Bongers, M
   Tatagiba, M
   Dobele, A
   Grozinger, G
AF Adib, Sasan Darius
   Lescan, Mario
   Renovanz, Mirjam
   Schuhmann, Martin U.
   Trakolis, Leonidas
   Bongers, Malte
   Tatagiba, Marcos
   Doebele, Alexander
   Groezinger, Gerd
TI Intracardial Catheter Migration of a Ventriculoperitoneal Shunt:
   Pathophysiology and Interdisciplinary Management
SO WORLD NEUROSURGERY
LA English
DT Article
DE Interdisciplinary management; Interventional snaring; Interventional
   therapy; Intracardial migration; Pathophysiology; Ventriculoperitoneal
   shunt; VP shunt
ID DISTAL CATHETER; CARDIAC MIGRATION; PULMONARY-ARTERY; FOREIGN-BODIES;
   HEART; COMPLICATION; RETRIEVAL; REMOVAL; VEIN
AB BACKGROUND: Intracardial migration of a ventriculoperitoneal (VP) shunt (ICMVP) is a rare complication that has been described in only single case reports. Here we report the successful interdisciplinary management of an ICMVP and provide a review of the relevant literature.
   CASE DESCRIPTION: A 38-year-old-patient with shunt-dependent hydrocephalus caused due to a Blake's pouch cyst presented in our hydrocephalus outpatient clinic with thoracic pain and nocturnal cough at 7 months after VP shunt implantation (with initially a proper location on computed tomography scan of the head and X-ray of the abdomen). A new X-ray of the abdomen and the thorax revealed a dislocated shunt with migration of the distal catheter into the superior cava vein, right atrium, and right heart ventricle, with some loops in both pulmonary arteries. The catheter was successfully removed by an interdisciplinary team in general anesthesia under ultrasound, X-ray guidance, and cardiovascular parameter control by withdrawing the shunt into the superior cava vein and removing the remnant portion of the distal catheter (with a knot) by interventional snaring. Cardiac and vascular surgeons were on standby.
   CONCLUSIONS: The management of an ICMVP is complex and carries a high risk for severe potential complications. Two different pathophysiological mechanisms have been discussed in the literature, including gradual erosion into an adjacent vein and transvenous catheter placement of the initial shunt secondary to subcostal placement of shunt tunneling instruments. The suction effect of the venous system results in gradual pulling of the catheter into the venous system.
C1 [Adib, Sasan Darius; Renovanz, Mirjam; Schuhmann, Martin U.; Trakolis, Leonidas; Tatagiba, Marcos] Univ Tubingen, Dept Neurosurg, Tubingen, Germany.
   [Lescan, Mario] Univ Tubingen, Dept Thorac & Cardiovasc Surg, Tubingen, Germany.
   [Bongers, Malte; Groezinger, Gerd] Univ Tubingen, Dept Diagnost & Intervent Radiol, Tubingen, Germany.
   [Doebele, Alexander] Univ Tubingen, Dept Anesthesiol & Intens Care Med, Tubingen, Germany.
RP Adib, SD (reprint author), Univ Tubingen, Dept Neurosurg, Tubingen, Germany.
EM sasan_adib2002@yahoo.de
OI Adib, Sasan Darius/0000-0002-1879-8490
CR Aboukais R, 2015, NEUROCHIRURGIE, V61, P43, DOI 10.1016/j.neuchi.2014.10.109
   Anegawa S, 1986, Neurol Med Chir (Tokyo), V26, P256, DOI 10.2176/nmc.26.256
   Chong JY, 2008, J KOREAN NEUROSURG S, V44, P170, DOI 10.3340/jkns.2008.44.3.170
   DEAN DF, 1972, J NEUROL NEUROSUR PS, V35, P474, DOI 10.1136/jnnp.35.4.474
   Di Roio C, 2000, INTENS CARE MED, V26, P818, DOI 10.1007/s001340051255
   Dossani RH, 2017, ANN VASC SURG, V45, P305, DOI 10.1016/j.avsg.2017.06.040
   Fewel ME, 2004, J NEUROSURG, V100, P206, DOI 10.3171/ped.2004.100.2.0206
   FISHER RG, 1978, AM J ROENTGENOL, V130, P541, DOI 10.2214/ajr.130.3.541
   Frahm-Jensen G, 2015, J CLIN NEUROSCI, V22, P771, DOI 10.1016/j.jocn.2014.10.020
   Frazier JL, 2002, NEUROSURGERY, V51, P819, DOI 10.1097/00006123-200209000-00042
   GRABENWOEGER F, 1988, BRIT J RADIOL, V61, P1014, DOI 10.1259/0007-1285-61-731-1014
   GROSFELD JL, 1974, J PEDIATR SURG, V9, P311, DOI 10.1016/S0022-3468(74)80286-1
   Hajdarpasic E, 2019, WORLD NEUROSURG, V126, P172, DOI 10.1016/j.wneu.2019.02.176
   Haralampopoulos F, 1996, SURG NEUROL, V46, P21, DOI 10.1016/0090-3019(96)00052-3
   Hermann EJ, 2009, ACTA NEUROCHIR, V151, P647, DOI 10.1007/s00701-009-0282-9
   Imamura H, 2002, NEUROL MED-CHIR, V42, P181, DOI 10.2176/nmc.42.181
   James CA, 1997, PEDIATR RADIOL, V27, P330, DOI 10.1007/s002470050142
   Kang JK, 1996, CHILD NERV SYST, V12, P176, DOI 10.1007/BF00266827
   Kano T, 2010, NEUROL MED-CHIR, V50, P945, DOI 10.2176/nmc.50.945
   Kim MS, 2005, SURG NEUROL, V63, P185, DOI 10.1016/j.surneu.2004.04.022
   Kubo S, 2002, NEUROL MED-CHIR, V42, P572, DOI 10.2176/nmc.42.572
   KURITA A, 1972, JPN HEART J, V13, P464
   Lyon K, 2016, WORLD NEUROSURG, V92, DOI 10.1016/j.wneu.2016.05.024
   Manix Marc, 2014, J La State Med Soc, V166, P21
   MORELL RC, 1994, J NEUROSURG ANESTH, V6, P132
   Nguyen HS, 2010, CHILD NERV SYST, V26, P1113, DOI 10.1007/s00381-010-1146-6
   Nordbeck P, 2010, CLIN RES CARDIOL, V99, P677, DOI 10.1007/s00392-010-0195-x
   PORTNOY HD, 1973, J NEUROSURG, V39, P775, DOI 10.3171/jns.1973.39.6.0775
   PRICE HI, 1981, NEURORADIOLOGY, V21, P273, DOI 10.1007/BF02100159
   Ralston A, 2017, CHILD NERV SYST, V33, P703, DOI 10.1007/s00381-016-3324-7
   Rizk E, 2009, J NEUROSURG-PEDIATR, V3, P525, DOI 10.3171/2009.2.PEDS08482
   Rodriguez-Sanchez JA, 2003, NEUROSURGERY, V52, P1510, DOI 10.1227/01.NEU.0000068351.22859.59
   Ruggiero C, 2010, CHILD NERV SYST, V26, P957, DOI 10.1007/s00381-009-1052-y
   Ryugo Masahiro, 2009, Ann Vasc Dis, V2, P51, DOI 10.3400/avd.AVDcr08038
   SAKODA TH, 1971, J NEUROSURG, V35, P95, DOI 10.3171/jns.1971.35.1.0095
   SELLS CJ, 1973, J PEDIATR-US, V83, P823, DOI 10.1016/S0022-3476(73)80376-2
   TAUB E, 1994, NEUROSURGERY, V34, P181
   TOUHO H, 1987, NEUROSURGERY, V21, P258, DOI 10.1227/00006123-198708000-00027
   UFLACKER R, 1986, RADIOLOGY, V160, P731, DOI 10.1148/radiology.160.3.3737911
   Wei QT, 2012, CHILD NERV SYST, V28, P1959, DOI 10.1007/s00381-012-1814-9
   Zairi F, 2012, BRIT J NEUROSURG, V26, P545, DOI 10.3109/02688697.2011.641612
NR 41
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.089
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600138
PM 31877393
DA 2020-05-12
ER

PT J
AU Agarwal, N
   Agarwal, P
   Taylor, TM
   Mortimer, AR
   Stacy, JD
   Spatola, M
   Mazzola, CA
   Orrico, KO
   Heary, RF
AF Agarwal, Nitin
   Agarwal, Prateek
   Taylor, Tavis M.
   Mortimer, Adrienne R.
   Stacy, Jason D.
   Spatola, Mark
   Mazzola, Catherine A.
   Orrico, Katie O.
   Heary, Robert F.
TI Contributions to the Neurosurgery Political Action Committee
   (NeurosurgeryPAC): A Historical Perspective
SO WORLD NEUROSURGERY
LA English
DT Article
DE Advocacy; NeurosurgeryPAC; Political action committee
AB BACKGROUND: The political action committee (PAC) of the American Association of Neurological Surgeons, known as NeurosurgeryPAC, was formed in August 2005 to strengthen neurosurgical advocacy efforts. Since its establishment, NeurosurgeryPAC has made nonpartisan, direct campaign contributions to hundreds of candidates for the U.S. Senate and U.S. House of Representatives.
   METHODS: Historical contribution data for 2005-2018 was obtained from NeurosurgeryPAC. Data analyzed by year, and a 2-year election cycle included total amount raised, number of contributors, average donation, and percent participation. NeurosurgeryPAC contribution amounts for election cycles were also compared with those of other physician PACs.
   RESULTS: NeurosurgeryPAC has raised $2,953,870 since its inception in 2005, for an average of $210,991 per year. For this fundraising, the average annual donation amount is $796 per donor. The number of unique contributors per cycle has varied from 316-504, with an average of 389 individuals per annum and a participation rate of 7.8%. To date, the total amount raised in election years (S1,605,940) is 16.1% higher than that raised in nonelection years ($1,347,930). Among 28 physician PACs, NeurosurgeryPAC has ranked as high as 13 and as low as 17 in total hard money contributions. The orthopedic, neurology and general surgery PACs have consistently ranked higher than NeurosurgeryPAC, whereas the otolaryngology, spine, and plastic surgery PACs have ranked lower.
   CONCLUSIONS: Since its creation, NeurosurgeryPAC has collected a steady stream of donations to support political candidates. These donations have helped lawmakers who are supportive of policy issues important to neurosurgery, particularly physician reimbursement, medical liability reform, and graduate medical education. However, there remains a significant opportunity to increase the neurosurgeon participation rate in this vital organization. It is truly through advocacy that we will be able to positively affect the future of neurologic surgery in the United States.
C1 [Agarwal, Nitin; Taylor, Tavis M.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15261 USA.
   [Agarwal, Prateek] Univ Penn, Perelman Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA.
   [Mortimer, Adrienne R.; Orrico, Katie O.] Amer Assoc Neurol Surg, Washington, DC USA.
   [Stacy, Jason D.] North Mississippi Med Ctr, Tupelo, MS USA.
   [Spatola, Mark] Orange Pk Med Ctr, Dept Neurol Surg, Orange Pk, FL USA.
   [Mazzola, Catherine A.] New Jersey Pediat Neurosci Inst, Morristown, NJ USA.
   [Heary, Robert F.] Rutgers New Jersey Med Ctr, Dept Neurol Surg, Newark, NJ USA.
RP Agarwal, N (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15261 USA.
EM agarwaln@upmc.edu
OI Agarwal, Nitin/0000-0003-0256-3897
CR American Association of Neurological Surgeons, 2012, C NEUR SURG SOC NEUR
   Attenello FJ, 2018, J NEUROSURG, V129, P1349, DOI 10.3171/2017.9.JNS17996
   Babu M, FINANCIAL IMPACT NEU
   Bliss M., 2007, HARVEY CUSHING LIFE
   LoPresti M, 2019, J NEUROSURG-PEDIATR, V24, P338, DOI 10.3171/2019.4.PEDS1911
   OpenSecrets.org, INS
   OpenSecrets.org, HLTH PROF
   Rovit RL, 2001, J NEUROSURG, V95, P354, DOI 10.3171/jns.2001.95.2.0354
   The Society of BritishNeurological Surgeons (SBNS), HISTORY
   Zaidi HA, 2017, NEUROSURGERY, V80, P146, DOI 10.1093/neuros/nyw009
   Zusman EE, 2017, NEUROSURGERY, V80, pS34, DOI 10.1093/neuros/nyw151
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.082
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600149
PM 31874292
DA 2020-05-12
ER

PT J
AU Almeida, ND
   Lee, R
   Bestourous, D
   Klein, AL
   Parekh, NR
   Sack, K
   Sherman, JH
AF Almeida, Neil D.
   Lee, Ryan
   Bestourous, Daniel
   Klein, Andrea L.
   Parekh, Neil R.
   Sack, Kenneth
   Sherman, Jonathan H.
TI Perioperative Complications Associated with Severity of Anemia in
   Geriatric Patients Undergoing Spinal Procedures
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anemia; Complications; Geriatrics; Hematocrit; NSQIP; Spinal surgery;
   Transfusions
ID SURGICAL SITE INFECTION; RISK-FACTORS; PREOPERATIVE ANEMIA; SURGERY;
   OUTCOMES; COLON
AB OBJECTIVE: To investigate preoperative baseline anemia, stratified by severity as a function of hematocrit level, as a risk factor for perioperative complications in geriatric patients undergoing spinal procedures.
   BACKGROUND: Previous literature has examined the impact of anemia on risk for complications and adverse outcomes in patients undergoing elective spinal procedures. However, there is a paucity of literature analyzing the impact of anemia in the geriatric population, specifically.
   METHODS: The American College of Surgeons-National Surgical Quality Improvement Database was used to identify patients older than 65 years who had undergone elective spinal procedures and were subsequently stratified into 3 separate cohorts based on hematocrit levels: severe/moderate (hematocrit level <30%), mild (30%-37%), and no anemia (>38%). These patient samples were then analyzed using multivariate analyses to assess severity of anemia as a risk factor for complications in elderly patients undergoing spinal procedures.
   RESULTS: When anemia classes were analyzed as separate independent risk factors for complications, mild anemia (class II) was a significant risk factor for the same complications as moderate/severe anemia (class III/IV), with the exception of 2 complications, compared with nonanemic patients. Mild anemia was independently associated with wound dehiscence (odds ratio, 1.521; 95% confidence interval, 1.126-2.054; P = 0.006), whereas moderate/severe anemia did not show an increased risk for wound dehiscence. However, moderate/severe anemia independently increased the risk for deep venous thromboembolism (odds ratio, 1.437; 95% confidence interval, 1.028-2.011; P = 0.034), compared with mild anemia. Both categories of anemia independently increased the risk for additional complications such as deep incisional surgical site infection, organ/space surgical site infection, pneumonia, unplanned intubation, ventilator dependence, progressive renal insufficiency, acute renal failure, urinary tract infections, cardiac arrest, myocardial infarctions, blood transfusions, systemic sepsis, reoperation, extended length of stay of >= 5 days, unplanned readmission, and mortality.
   CONCLUSIONS: This study indicated that patients with preoperative baseline anemia were at risk for requiring transfusions, renal failure, and infectious complications. Physicians should be cognizant of anemia as a risk factor affecting numerous perioperative complications and adverse outcomes to work toward improving health-related quality of life.
C1 [Almeida, Neil D.; Lee, Ryan; Bestourous, Daniel; Klein, Andrea L.; Parekh, Neil R.] George Washington Univ, Sch Med & Hlth Sci, Washington, DC 20052 USA.
   [Sack, Kenneth; Sherman, Jonathan H.] George Washington Univ Hosp, Dept Neurosurg, Washington, DC 20037 USA.
RP Sherman, JH (reprint author), George Washington Univ Hosp, Dept Neurosurg, Washington, DC 20037 USA.
EM jsherman0620@gmail.com
OI Bestourous, Daniel/0000-0002-4830-2660
CR Anderson DJ, 2014, INFECT CONTROL HO S2, V9, P66
   Carson JL, 2016, JAMA-J AM MED ASSOC, V316, P2025, DOI 10.1001/jama.2016.9185
   Epstein Nancy E, 2011, Surg Neurol Int, V2, P188, DOI 10.4103/2152-7806.91408
   Fei Q, 2016, WORLD NEUROSURG, V95, P507, DOI 10.1016/j.wneu.2015.05.059
   Frakes JM, 2015, J GERIATR ONCOL, V6, P127, DOI 10.1016/j.jgo.2014.11.005
   Gregory JR, 2018, SPINE DEFORM, V6, P736
   Kaye ID, 2018, INT J SPINE SURG, V12, P638, DOI 10.14444/5079
   Kishida N, 2015, ANN SURG ONCOL, V22, P3094, DOI 10.1245/s10434-014-4350-x
   Leichtle SW, 2011, J AM COLL SURGEONS, V212, P187, DOI 10.1016/j.jamcollsurg.2010.09.013
   Li H, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012924
   Liu L, 2018, GASTROENT RES PRACT, DOI 10.1155/2018/2417028
   Lu VM, 2018, SPINE, V43, pE958
   Musallam KM, 2011, LANCET, V378, P1396, DOI 10.1016/S0140-6736(11)61381-0
   Patel MS, 2009, MED CLIN N AM, V93, P1095, DOI 10.1016/j.mcna.2009.05.007
   Sanoufa M, 2015, J Perioper Pract, V25, P267
   Seicean A, 2013, SPINE, V38, P1331, DOI 10.1097/BRS.0b013e3182912c6b
   Shander A, 2004, AM J MED, V116, P58, DOI 10.1016/j.amjmed.2003.12.013
   Soroceanu A, 2016, SPINE, V41, P1718, DOI 10.1097/BRS.0000000000001636
   Stancu SM, 2019, SURG INFECT, V20, P39, DOI 10.1089/sur.2018.146
   Wang Z, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0948-1
   Yao RN, 2018, J CLIN NEUROSCI, V52, P5, DOI 10.1016/j.jocn.2018.03.023
   Yeo HL, 2016, J SURG RES, V205, P11, DOI 10.1016/j.jss.2016.04.038
   Yeramaneni S, 2016, CURR REV MUSCULOSKE, V9, P327, DOI 10.1007/s12178-016-9352-9
   Yu PX, 2018, AESTHET PLAST SURG, V42, P511, DOI 10.1007/s00266-018-1087-0
   Zhang L, 2018, THER CLIN RISK MANAG, V14, P2161, DOI 10.2147/TCRM.S181477
   Zuckerman Scott L, 2018, J Spine Surg, V4, P333, DOI 10.21037/jss.2018.05.28
NR 26
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.159
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600035
PM 31841719
DA 2020-05-12
ER

PT J
AU Arikan, F
   Errando, N
   Lagares, A
   Gandara, D
   Gabarros, A
   Lopez-Ojeda, P
   Ibanez, J
   Brell, M
   Gomez, PA
   Fernandez-Alen, JA
   Morera, J
   Horcajadas, A
   Vanaclocha, V
   Llacer, JL
   Bano-Ruiz, E
   Goncalves-Estella, JM
   Torne, R
   Hoyos, JA
   Sarabia, R
   Arrese, I
   Rodriguez-Boto, G
   de la Lama, A
   Dominguez, J
   Martin-Laez, R
   Santamarta-Gomez, D
   Delgado-Lopez, PD
   Ley-Urzaiz, L
   Mateo, O
   Iza, B
   Orduna-Martinez, J
   Lorente-Munoz, FD
   Munoz-Hernandez, F
   Iglesias, J
   Vilalta, J
AF Arikan, Fuat
   Errando, Nacho
   Lagares, Alfonso
   Gandara, Dario
   Gabarros, Andreu
   Lopez-Ojeda, Pablo
   Ibanez, Javier
   Brell, Marta
   Gomez, Pedro A.
   Fernandez-Alen, Jose A.
   Morera, Jesus
   Horcajadas, Angel
   Vanaclocha, Vicente
   Llacer, Jose L.
   Bano-Ruiz, Elena
   Goncalves-Estella, Jesus M.
   Torne, Ramon
   Hoyos, Jhon A.
   Sarabia, Rosario
   Arrese, Ignacio
   Rodriguez-Boto, Gregorio
   de la Lama, Adolfo
   Dominguez, Jaime
   Martin-Laez, Ruben
   Santamarta-Gomez, David
   Delgado-Lopez, Pedro D.
   Ley-Urzaiz, Luis
   Mateo, Olga
   Iza, Begona
   Orduna-Martinez, Javier
   de Asis Lorente-Munoz, Francisco
   Munoz-Hernandez, Fernando
   Iglesias, Jone
   Vilalta, Jordi
TI Variability of Clinical and Angiographic Results Based on the Treatment
   Preference (Endovascular or Surgical) of Centers Participating in the
   Subarachnoid Hemorrhage Database of the Working Group of the Spanish
   Society of Neurosurgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clip; Coil; Endovascular treatment; Hospital practice variation;
   Intracranial aneurysm; Subarachnoid hemorrhage; Surgery
ID RUPTURED INTRACRANIAL ANEURYSMS; HEALTH-CARE PROFESSIONALS; POOR-GRADE;
   MULTICENTER DATABASE; UNITED-STATES; MANAGEMENT; MORTALITY; OUTCOMES;
   ASSOCIATION; PATHOLOGY
AB OBJECTIVES: Since the introduction of endovascular treatment for cerebral aneurysms, hospitals in which subarachnoid hemorrhage is treated show different availability and/or preferences towards both treatment modalities. The main aim is to evaluate the clinical and angiographic results according to the hospital's treatment preferences applied.
   METHODS: This study was conducted based on use of the subarachnoid hemorrhage database of the Vascular Pathology Group of the Spanish Neurosurgery Society. Centers were classified into 3 subtypes according to an index in the relationship between endovascular and surgical treatment as: endovascular preference, high endovascular preference, and elevated surgical preference. The clinical results and angiographic results were evaluated among the 3 treatment strategies.
   RESULTS: From November 2004 to December 2017, 4282 subarachnoid hemorrhage patients were selected for the study: 630 (14.7%) patients from centers with surgical preference, 2766 (64.6%) from centers with endovascular preference, and 886 (20.7%) from centers with high endovascular preference. The surgical preference group obtained the best angiographic results associated with a greater complete exclusion (odds ratio: 1.359; 95% confidence interval: 1.025-1.801; P = 0.033). The surgical preference subgroup obtained the best outcome at discharge (65.45%), followed by the high endovascular preference group (61.5%) and the endovascular preference group (57.8%) (odds ratio: 1.359; 95% confidence interval: 1.025-1.801; P = 0.033).
   CONCLUSIONS: In Spain, there is significant variability in aneurysm exclusion treatment in aneurysmal subarachnoid hemorrhage. Surgical centers offer better results for both surgical and endovascular patients. A multidisciplinary approach and the maintenance of an elevated quality of surgical competence could be responsible for these results.
C1 [Arikan, Fuat; Gandara, Dario; Vilalta, Jordi] Univ Hosp Vall dHebron, Neurosurg Dept, Barcelona, Spain.
   [Arikan, Fuat; Gandara, Dario; Vilalta, Jordi] Res Inst Vall dHebron, Neurotraumatol Neurosurg Res Unit UNINN, Barcelona, Spain.
   [Arikan, Fuat; Errando, Nacho; Gandara, Dario] Univ Autonoma Barcelona, Barcelona, Spain.
   [Lagares, Alfonso; Gomez, Pedro A.; Fernandez-Alen, Jose A.] Univ Complutense Madrid, Neurosurg Dept, Hosp 12 Octubre, Imas12, Madrid, Spain.
   [Gabarros, Andreu; Lopez-Ojeda, Pablo] Univ Hosp Bellvitge, Neurosurg Dept, Barcelona, Spain.
   [Gabarros, Andreu; Lopez-Ojeda, Pablo] Univ Barcelona, Barcelona, Spain.
   [Ibanez, Javier; Brell, Marta] Univ Hosp Son Espases, Neurosurg Dept, Palma De Mallorca, Spain.
   [Morera, Jesus] Doctor Negrin Univ Hosp, Neurosurg Dept, Las Palmas Gran Canaria, Spain.
   [Horcajadas, Angel] Virgen de las Nieves Univ Hosp, Neurosurg Dept, Granada, Spain.
   [Vanaclocha, Vicente] Gen Univ Hosp Consortium Valencia, Neurosurg Dept, Valencia, Spain.
   [Llacer, Jose L.] Hosp Ribera, Neurosurg Dept, Alzira, Spain.
   [Bano-Ruiz, Elena] Hosp Gen Univ Alicante, Neurosurg Dept, Alicante, Spain.
   [Goncalves-Estella, Jesus M.] Univ Hosp Salamanca, Neurosurg Dept, Salamanca, Spain.
   [Torne, Ramon; Hoyos, Jhon A.] Univ Barcelona, Hosp Clin Barcelona, Dept Neurol Surg, Barcelona, Spain.
   [Torne, Ramon] Augusti Pi & Sunyer Biomed Res Inst IDIBAPS, Barcelona, Spain.
   [Sarabia, Rosario; Arrese, Ignacio] Univ Hosp Rio Hortega, Neurosurg Dept, Neurovasc Unit UNVRH, Valladolid, Spain.
   [Rodriguez-Boto, Gregorio] Univ Complutense Madrid, Univ Hosp Clin San Carlos, Neurosurg Dept, Madrid, Spain.
   [Rodriguez-Boto, Gregorio] Autonomous Univ, Univ Hosp Puerta Hierro Majadahonda, Neurosurg Dept, Madrid, Spain.
   [de la Lama, Adolfo] Complejo Hosp Vigo, Neurosurg Dept, Vigo, Spain.
   [Dominguez, Jaime] Hosp Univ Nuestra Senora Candelaria, Neurosurg Dept, Santa Cruz De Tenerife, Spain.
   [Martin-Laez, Ruben] Univ Hosp Marques Valdecilla, Dept Neurosurg & Surg Spine Unit, Santander, Spain.
   [Santamarta-Gomez, David] Univ Hosp Leon, Neurosurg Dept, Leon, Spain.
   [Delgado-Lopez, Pedro D.] Univ Hosp Burgos, Neurosurg Dept, Burgos, Spain.
   [Ley-Urzaiz, Luis] Univ Hosp Ramon & Cajal, Neurosurg Dept, Madrid, Spain.
   [Mateo, Olga; Iza, Begona] Univ Hosp Gregorio Maranon, Neurosurg Dept, Madrid, Spain.
   [Orduna-Martinez, Javier; de Asis Lorente-Munoz, Francisco] Miguel Servet Univ Hosp, Neurosurg Dept, Zaragoza, Spain.
   [Munoz-Hernandez, Fernando] Hosp Santa Creu & Sant Pau, Neurosurg Dept, Barcelona, Spain.
   [Iglesias, Jone] Univ Hosp Cruces, Neurosurg Dept, Baracaldo, Spain.
RP Arikan, F (reprint author), Univ Hosp Vall dHebron, Neurosurg Dept, Barcelona, Spain.; Arikan, F (reprint author), Res Inst Vall dHebron, Neurotraumatol Neurosurg Res Unit UNINN, Barcelona, Spain.; Arikan, F (reprint author), Univ Autonoma Barcelona, Barcelona, Spain.
EM farikan@vhebron.net
RI ALEN, JOSE A FERNANDEZ/G-4990-2018; Arikan, Fuat/F-8900-2016; Lagares,
   Alfonso/B-2969-2011; Horcajadas, Angel/AAN-1765-2020
OI ALEN, JOSE A FERNANDEZ/0000-0002-3321-983X; Arikan,
   Fuat/0000-0002-9459-0915; Lagares, Alfonso/0000-0003-3996-0554; Munoz
   Hernandez, Fernando/0000-0002-5827-0519
CR Bakker NA, 2010, NEUROSURGERY, V66, P961, DOI 10.1227/01.NEU.0000368152.67151.73
   Bardach NS, 2002, STROKE, V33, P1851, DOI 10.1161/01.STR.0000019126.43079.7B
   Barker FG, 2003, NEUROSURGERY, V52, P995, DOI 10.1227/01.NEU.0000057743.56678.5F
   Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395
   Bergui M, 2004, NEURORADIOLOGY, V46, P161, DOI 10.1007/s00234-003-1143-5
   Berman MF, 2003, STROKE, V34, P2200, DOI 10.1161/01.STR.0000086528.32334.06
   Cross DT, 2003, J NEUROSURG, V99, P810, DOI 10.3171/jns.2003.99.5.0810
   Darsaut TE, 2019, J NEUROSURG, V131, P25, DOI 10.3171/2018.1.JNS172645
   Darsaut TE, 2013, J NEUROSURG, V119, P1642, DOI 10.3171/2013.5.JNS13917
   Toledo P, 2009, IEEE T INF TECHNOL B, V13, P794, DOI 10.1109/TITB.2009.2020434
   GUGLIELMI G, 1991, J NEUROSURG, V75, P1, DOI 10.3171/jns.1991.75.1.0001
   Janardhan Vallabh, 2002, Neurosurg Focus, V13, pe1
   Johnston SC, 2002, STROKE, V33, P2536, DOI 10.1161/01.STR.0000034708.66191.7D
   Koivisto T, 2000, STROKE, V31, P2369, DOI 10.1161/01.STR.31.10.2369
   Lagares A, 2008, NEUROCIRUGIA, V19, P405
   Lagares A, 2005, ACTA NEUROCHIR, V147, P5, DOI 10.1007/s00701-004-0417-y
   Lagares A, 2011, NEUROCIRUGIA, V22, P93
   Lagares A, 2002, STROKE, V33, P2153, DOI 10.1161/01.STR.0000029275.02637.27
   Lagares A, 2001, ACTA NEUROCHIR, V143, P665, DOI 10.1007/s007010170044
   Lagares A, 2015, NEUROCIRUGIA, V26, P167, DOI 10.1016/j.neucir.2014.11.005
   Molyneux A, 2013, J NEUROSURG, V119, P139, DOI 10.3171/2012.11.JNS121406
   Munoz-Sanchez MA, 2003, REV NEUROLOGIA, V36, P301, DOI 10.33588/rn.3604.2002430
   Natarajan SK, 2008, AM J NEURORADIOL, V29, P753, DOI 10.3174/ajnr.A0895
   Prestigiacomo Charles J, 2006, Neurosurgery, V59, pS39
   Prestigiacomo CJ, 2006, NEUROSURGERY S3, V59, pS13
   Qureshi AI, 2005, NEUROSURGERY, V57, P1, DOI 10.1227/01.NEU.0000163081.55025.CD
   Ross J, 2002, J CLIN NEUROSCI, V9, P648, DOI 10.1054/jocn.2002.1100
   Sarabia R, 2010, NEUROCIRUGIA, V21, P441
   Shea AM, 2007, NEUROSURGERY, V61, P1131, DOI 10.1227/01.neu.0000306090.30517.ae
   Spetzler RF, 2013, J NEUROSURG, V119, P139
   Suzuki S, 2006, J NEUROSURG, V105, P664, DOI 10.3171/jns.2006.105.5.664
   Vilalta J, 1999, MED CLIN-BARCELONA, V113, P478
NR 32
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.163
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600038
PM 31811967
DA 2020-05-12
ER

PT J
AU Bao, DS
   Li, L
   Gong, M
   Xiang, Z
AF Bao, DingSu
   Li, Lang
   Gong, Min
   Xiang, Zhou
TI Treatment of Atlantoaxial Tuberculosis with Neurological Impairment: A
   Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Atlantoaxial joint; Conservation; Craniovertebral junction; Surgery;
   Treatment
ID CRANIOVERTEBRAL JUNCTION TUBERCULOSIS; SPINAL TUBERCULOSIS; MANAGEMENT;
   DISLOCATION; CHILDREN; EXPERIENCE; FIXATION
AB BACKGROUND: Tuberculosis (TB) in the atlantoaxial joint is a rare disease. However, the treatment of atlantoaxial TB with neurologic impairment is controversial. The aim of this review is to provide clinical outcomes of surgical and nonsurgical management of atlantoaxial TB.
   METHODS: Databases including PubMed, Embase, and the Cochrane Central Register of Controlled Trials were searched for English literature describing the treatment of atlantoaxial TB with neurologic deficits. The outcomes of conservative and surgical treatment approaches, including treatment failure, death, changes in neurologic impairment, and complications, were compared by performing odds ratio (OR) analysis.
   RESULTS: Overall, 24 studies (247 patients) meeting the inclusion criteria were analyzed. Ninety-four patients (38%) were treated conservatively and 153 (62%) patients were treated surgically. The rate of poor outcomes was greater in the conservative group (14.89%) than in the surgery group (1.3%) (OR, 0.081; 95% confidence interval [CI], 0.016-0.39).There was no significant difference in mortality between the conservative (1.06%) and surgery (3.27%) groups (OR, 3.28; 95% CI, 0.494-27.381). There was no significant difference in muscle power improvement between the 2 treatments (conservative, 95.7%; surgery:, 94.8%; OR, 1.353; 95% CI, 0.291-4.925).
   CONCLUSIONS: Conservative and surgical treatments both significantly improved neurologic deficits in most patients. Compared with conservative treatment, surgical treatment reduced treatment failures without significantly increasing the rates of neurologic deficit improvement or mortality.
C1 [Bao, DingSu; Li, Lang; Gong, Min; Xiang, Zhou] Sichuan Univ, West China Hosp, Dept Orthopaed, Chengdu, Peoples R China.
   [Bao, DingSu] Southwest Med Univ, Hosp Tradit Chinese Med, Luzhou, Peoples R China.
   [Li, Lang] Hosp Chengdu Off Peoples Govt Tibetan Autonomous, Chengdu, Sichuan, Peoples R China.
RP Xiang, Z (reprint author), Sichuan Univ, West China Hosp, Dept Orthopaed, Chengdu, Peoples R China.
EM xiangzhou15@hotmail.com
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China [31870961]; Foundation of Sino-German center for
   Research promotion [GZ1219]
FX This work was supported by National Nature Science Foundation of China
   (number 31870961) and Foundation of Sino-German center for Research
   promotion (GZ1219).
CR Akhaddar A, 1999, REV RHUM, V66, P739
   Arora S, 2011, J BONE JOINT SURG AM, V93A, P540, DOI 10.2106/JBJS.J.00634
   Arunkumar MJ, 2002, J NEUROSURG, V97, P166, DOI 10.3171/spi.2002.97.2.0166
   Bapat MR, 2007, EUR SPINE J, V16, P187, DOI 10.1007/s00586-006-0071-6
   Behari S, 2003, NEUROSURGERY, V52, P72, DOI 10.1097/00006123-200301000-00009
   Chadha M, 2007, SPINE, V32, P1629, DOI 10.1097/BRS.0b013e318074d41e
   Chatterjee S, 2015, CHILD NERV SYST, V31, P1341, DOI 10.1007/s00381-015-2695-5
   Chaudhary K, 2012, SPINE, V37, pE836, DOI 10.1097/BRS.0b013e31824a4c8f
   Dhammi IK, 2001, EUR SPINE J, V10, P540, DOI 10.1007/s005860100340
   Edwards RJ, 2000, BRIT J NEUROSURG, V14, P19
   FANG D, 1983, J BONE JOINT SURG BR, V65, P47
   Goel A, 2016, J CRANIOVERTEBRAL JU, V7, P129, DOI 10.4103/0974-8237.188418
   Gupta SK, 2006, NEUROSURGERY, V58, P1144, DOI 10.1227/01.NEU.0000215950.85745.33
   HOFFMAN EB, 1993, J BONE JOINT SURG BR, V75, P233
   Jain AK, 2000, NEUROL INDIA, V48, P132
   Jutte PC, 2006, COCHRANE DB SYST REV, V5
   Kalra SK, 2007, J NEUROSURG, V107, P111, DOI 10.3171/PED-07/08/111
   Khandelwal N, 1991, NEURORADIOLOGY, P106
   Kotil K, 2007, J CLIN NEUROSCI, V14, P540, DOI 10.1016/j.jocn.2006.03.005
   Krishnan A, 2001, J COMPUT ASSIST TOMO, V25, P171, DOI 10.1097/00004728-200103000-00003
   LAL AP, 1992, BRIT J NEUROSURG, V6, P529, DOI 10.3109/02688699209002369
   LIFESO R, 1987, J BONE JOINT SURG BR, V69, P183
   Mandavia R, 2017, JRSM OPEN, V8
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Pandya S K, 1970, Neurol India, V18, P147
   Qureshi MA, 2013, EUR SPINE J, V22, P612, DOI 10.1007/s00586-012-2497-3
   Shukla D, 2005, SURG NEUROL, V63, P101, DOI 10.1016/j.surneu.2004.03.019
   Sinha S, 2003, NEUROSURGERY, V52, P331, DOI 10.1227/01.NEU.0000043930.28934.FE
   Sridharan S, 2017, INT J MYCOBACT, V6, P127, DOI 10.4103/ijmy.ijmy_55_17
   Teegala R, 2008, NEUROSURGERY, V63, P946, DOI 10.1227/01.NEU.0000327696.77814.1E
   TULI SM, 1974, CLIN ORTHOP RELAT R, P209
   Wang B, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891-019-2539-7
   Xing S, 2016, SPINE, V41, P104, DOI 10.1097/BRS.0000000000001169
   Yadav YR, 2013, J NEUROL SURG PART A, V74, P162, DOI 10.1055/s-0032-1327441
   Zhang HQ, 2013, EUR SPINE J, V22, P616, DOI 10.1007/s00586-012-2470-1
NR 35
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.09.073
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600094
PM 31550536
DA 2020-05-12
ER

PT J
AU Baydin, S
   Baran, O
   Gungor, A
   Kuruoglu, E
   Tanriover, N
AF Baydin, Serhat
   Baran, Oguz
   Gungor, Abuzer
   Kuruoglu, Enis
   Tanriover, Necmettin
TI Vascularization of the Subthalamic Nucleus: Highlighting the
   Significance of the Premamillary Artery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral arteries; Deep brain stimulation; Fiber dissection;
   Microsurgical anatomy; Parkinson disease; Subthalamic nucleus
ID ANTERIOR CHOROIDAL ARTERY; MICROSURGICAL ANATOMY; HYPERPHAGIA;
   STIMULATION; HEMICHOREA; PATIENT; LESIONS
AB BACKGROUND: The need for a better understanding of the subthalamic nucleus (STN)'s vascular anatomy is still evident because revealing its vascular supply may increase insight in the pathogenesis of related disorders, such as STN ischemia. The mechanisms under motor, behavioral, and cognitive changes following deep brain stimulation treatment may also be explained by its pattern of vascularization. The primary goal of this study was to delineate the vascularization of the STN and highlight the predominant perforating arteries supplying its territory.
   METHODS: Fiber dissections were performed with the modified Klingler technique under 6-40x magnification by preserving all vascular structures.
   RESULTS: The thalamic and subthalamic regions were dissected from medial to lateral in silicone-injected cadavers. The STN was revealed as a biconvex-shaped structure surrounded by dense inferolateral bundles of myelinated fibers, the zona incerta, bordering the superolateral portion of the red nucleus. The ventral limit of the STN was the substantia nigra, and the internal capsule traversed from its inferior to anterolateral side. The premamillary artery, a large perforator arising from the posterior communicating artery, constantly supplied the STN and was followed proximally along the anterior third ventricular floor toward its origin. The premamillary artery was found to be one of the posterior perforators of the posterior communicating artery in all hemispheres.
   CONCLUSIONS: The 3-dimensional microsurgical anatomy of the deep-seated STN region is complex, and the additional knowledge on its vascularization should improve our understanding of its surgical anatomy.
C1 [Baydin, Serhat; Kuruoglu, Enis] Ondokuz Mayis Univ, Med Fac, Dept Neurosurg, Samsun, Turkey.
   [Baran, Oguz] Haseki Res & Training Hosp, Neurosurg Clin, Istanbul, Turkey.
   [Gungor, Abuzer] Acibadem Univ, Dept Neurosurg, Med Fac, Istanbul, Turkey.
   [Tanriover, Necmettin] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey.
RP Tanriover, N (reprint author), Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Neurosurg, Istanbul, Turkey.
EM nctan27@yahoo.com
OI gungor, abuzer/0000-0002-2792-7610
CR Barutca S, 2003, NEUROL MED-CHIR, V43, P457, DOI 10.2176/nmc.43.457
   Baunez C, 2011, NEUROSCIENCE, V198, P193, DOI 10.1016/j.neuroscience.2011.09.059
   Baunez C, 2002, J NEUROSCI, V22, P562, DOI 10.1523/JNEUROSCI.22-02-00562.2002
   Cerrato P, 2004, J NEUROL NEUROSUR PS, V75, P1364, DOI 10.1136/jnnp.2003.027607
   Chabardes S, 2013, WORLD NEUROSURG, V80, DOI 10.1016/j.wneu.2012.03.010
   Chung SJ, 2004, J NEUROL, V251, P725, DOI 10.1007/s00415-004-0412-5
   Cipolla M. J., 2009, CEREBRAL CIRCULATION
   Cooper IS, 1953, PSYCHIAT QUART, V27, P317, DOI 10.1007/BF01562492
   Cruz Gloria M, 2014, Tecnura, V18, P80, DOI 10.14483/udistrital.jour.tecnura.2014.DSE1.a07
   DEWEY RB, 1989, ARCH NEUROL-CHICAGO, V46, P862, DOI 10.1001/archneur.1989.00520440044020
   Duvernoy HM, 2000, HUMAN BRAINSTEM VESS
   Etemadifar M, 2012, CASE REP MED, DOI 10.1155/2012/768580
   Fahn S, 2011, PRINCIPLES PRACTICE
   Finley KH, 1936, ARCH NEURO PSYCHIATR, V36, P118, DOI 10.1001/archneurpsyc.1936.02260070126010
   Funkiewiez A, 2004, J NEUROL NEUROSUR PS, V75, P834, DOI 10.1136/jnnp.2002.009803
   Grandas Francisco, 2011, Handb Clin Neurol, V100, P249, DOI 10.1016/B978-0-444-52014-2.00017-3
   Gungor A, 2019, J NEUROSURG, V130, P716, DOI 10.3171/2017.10.JNS171513
   Hamani C, 2004, BRAIN, V127, P4, DOI 10.1093/brain/awh029
   Herzog J, 2003, MOVEMENT DISORD, V18, P1382, DOI 10.1002/mds.10530
   LEE MS, 1994, MOVEMENT DISORD, V9, P493, DOI 10.1002/mds.870090502
   Nambu A, 2002, NEUROSCI RES, V43, P111, DOI 10.1016/S0168-0102(02)00027-5
   Nougaret S, 2013, FRONT COMPUT NEUROSC, V7, DOI 10.3389/fncom.2013.00135
   Park J, 2016, J MOV DISORD, V9, P71, DOI 10.14802/jmd.16005
   Percheron G, 1982, STEREOTAXY HUMAN BRA, P218
   Postuma RB, 2003, LANCET NEUROL, V2, P661, DOI 10.1016/S1474-4422(03)00554-4
   Rhoton AL, 2002, NEUROSURGERY, V51, pS53, DOI 10.1227/01.NEU.0000028484.12422.23
   Shimizu Satoru, 2006, Neurosurgery, V58, pE1000, DOI 10.1227/01.NEU.0000210247.37628.43
   Shukla AW, 2014, NEUROTHERAPEUTICS, V11, P47, DOI 10.1007/s13311-013-0235-0
   Tan SKH, 2006, J CHEM NEUROANAT, V31, P155, DOI 10.1016/j.jchemneu.2006.01.001
   Tanriover N, 2014, J NEUROSURG, V120, P1217, DOI 10.3171/2014.1.JNS131325
   Temel Y, 2005, PROG NEUROBIOL, V76, P393, DOI 10.1016/j.pneurobio.2005.09.005
   Tykocki T, 2012, ARCH MED SCI, V8, P805, DOI 10.5114/aoms.2012.31135
   ZEAL AA, 1978, J NEUROSURG, V48, P534, DOI 10.3171/jns.1978.48.4.0534
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.062
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600066
PM 31863894
DA 2020-05-12
ER

PT J
AU Calafiore, R
   Mouchtouris, N
   Flomenberg, N
   Harrop, JS
AF Calafiore, Rebecca
   Mouchtouris, Nikolaos
   Flomenberg, Neal
   Harrop, James S.
TI Epstein-Barr Virus-Associated Smooth Muscle Tumor of the Spine After
   Bone Marrow Transplant: Case Report and Review of Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Bone marrow transplant; Epstein-Barr virus; Smooth muscle tumor; Spine
ID SEVERE COMBINED IMMUNODEFICIENCY; LEIOMYOSARCOMA; LEIOMYOMATOSIS; AIDS
AB BACKGROUND: Epstein-Barr virus-associated smooth muscle tumors (SMTs) are rare neoplasms that have been found to develop in immunocompromised patients. Three distinct groups of affected patients have been described: (1) human immunodeficiency virus-infected patients, (2) post-transplant patients, and (3) patients with congenital immunodeficiency. The tumors can develop anywhere in the body, with 17 reported cases occurring in the spinal canal, all in patients with human immunodeficiency virus infection.
   CASE DESCRIPTION: We report the first case of Epstein-Barr virus-associated SMT affecting the spinal canal in a post-bone marrow transplant adult patient. Interestingly, unlike other reported cases, the patient described here had not been receiving immunosuppressive therapy in the 2 years prior to diagnosis of the tumor.
   CONCLUSIONS: Despite the growing number of case reports, this diagnosis presents a challenge, as the pathophysiology and optimal treatment regimens are not well understood. Results of a literature review of Epstein-Barr virus-associated SMT of the spine as well as a discussion of the presentation, management, and prognosis of this condition is presented here.
C1 [Calafiore, Rebecca] Univ Connecticut, Sch Med, Farmington, CT USA.
   [Mouchtouris, Nikolaos; Harrop, James S.] Thomas Jefferson Univ Hosp, Dept Neurol Surg, Philadelphia, PA 19107 USA.
   [Flomenberg, Neal] Thomas Jefferson Univ Hosp, Dept Med Oncol, Philadelphia, PA 19107 USA.
RP Harrop, JS (reprint author), Thomas Jefferson Univ Hosp, Dept Neurol Surg, Philadelphia, PA 19107 USA.
EM james.harrop@jefferson.edu
OI Calafiore, Rebecca/0000-0003-1567-1942; Mouchtouris,
   Nikolaos/0000-0001-9495-9391
CR Atluri S, 2007, J PEDIAT HEMATOL ONC, V29, P166, DOI 10.1097/MPH.0b013e31803b95b3
   Choi SH, 1997, NEUROSURGERY, V40, P1080, DOI 10.1097/00006123-199705000-00038
   Dekate J, 2016, ARCH PATHOL LAB MED, V140, P718, DOI 10.5858/arpa.2015-0120-RS
   Deyrup AT, 2006, AM J SURG PATHOL, V30, P75, DOI 10.1097/01.pas.0000178088.69394.7b
   Ehresman JS, 2018, J CLIN NEUROSCI, V52, P145, DOI 10.1016/j.jocn.2018.03.009
   Gallien S, 2008, ONCOLOGY-BASEL, V74, P167, DOI 10.1159/000151364
   Hayase E, 2014, TRANSPLANTATION, V97, pE1, DOI 10.1097/01.TP.0000437912.60638.23
   Hussein K, 2014, EUR J CANCER, V50, P2417, DOI 10.1016/j.ejca.2014.06.006
   Issarachaikul R, 2014, INTERNAL MED, V53, P2391, DOI 10.2169/internalmedicine.53.2674
   Jonigk D, 2012, AM J TRANSPLANT, V12, P1908, DOI 10.1111/j.1600-6143.2012.04011.x
   Karpinski NC, 1999, BRAIN PATHOL, V9, P609, DOI 10.1111/j.1750-3639.1999.tb00609.x
   Lohan R, 2013, CLIN IMAG, V37, P564, DOI 10.1016/j.clinimag.2012.09.019
   Monforte-Munoz H, 2003, PEDIATR DEVEL PATHOL, V6, P449, DOI 10.1007/s10024-003-8096-x
   Morgello S, 1997, J NEUROSURG, V86, P883, DOI 10.3171/jns.1997.86.5.0883
   Penney SW, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27585
   Ritter AM, 2000, J NEUROSURG, V92, P688, DOI 10.3171/jns.2000.92.4.0688
   Stubbins RJ, 2019, TRANSPL INFECT DIS, V21, DOI 10.1111/tid.13010
   Suankratay C, 2005, CLIN INFECT DIS, V40, P1521, DOI 10.1086/429830
   Wilaisakditipakorn T, 2015, CASE REP, V2015
   Wujanto C, 2019, INT J STD AIDS, V30, P605, DOI 10.1177/0956462418821569
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.160
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600132
PM 31809898
DA 2020-05-12
ER

PT J
AU Catapano, JS
   Mezher, AW
   Wang, DJ
   Whiting, AC
   Mooney, MA
   Bohl, MA
   Sheehy, JP
   DiDomenico, JD
   Sarris, CE
   Smith, KA
   Lawton, MT
   Zabramski, JM
AF Catapano, Joshua S.
   Mezher, Andrew W.
   Wang, Derrick J.
   Whiting, Alexander C.
   Mooney, Michael A.
   Bohl, Michael A.
   Sheehy, John P.
   DiDomenico, Joseph D.
   Sarris, Christina E.
   Smith, Kris A.
   Lawton, Michael T.
   Zabramski, Joseph M.
TI Laparoscopic-Assisted Ventriculoperitoneal Shunt Placement and Reduction
   in Operative Time and Total Hospital Charges
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hospital charges; Laparoscopic-assisted ventriculoperitoneal shunt
   placement; Normal pressure hydrocephalus; Operative time
ID SURGICAL-TREATMENT; HYDROCEPHALUS; COMPLICATIONS; LAPAROTOMY
AB OBJECTIVE: In ventriculoperitoneal shunt (VPS) placement, distal placement of the peritoneal catheter will typically be performed by a neurosurgeon. More recently, laparoscopic-assisted (LA) placement of the distal peritoneal catheter by general surgeons has become common. The present study examined whether LA placement of a VPS (LAVPS) is associated with a reduced operative time, lower hospital costs, and fewer distal revisions.
   METHODS: A retrospective review was performed of the data from all patients who had received a new VPS at our institution from 2013 to 2016. Age, sex, diagnosis, previous abdominal surgery, operative time, anesthesia grade, incidence of 30-day shunt failure, and total hospital charges were analyzed.
   RESULTS: A total of 680 patients had undergone first-time VPS placement, including 199 with LAVPS and 481 with non-LAVPS placement (non-LAVPS). The mean age of the LAVPS patients was significantly older than that of the non-LAVPS patients (64.1 vs. 59.3 years; P = 0.002). The mean operative time was shorter in the LAVPS group than in the non-LAVPS group (55 vs. 75 minutes; P< 0.001). Distal shunt revision within 30 days occurred more often for the non-LAVPS patients (6 of 481 [1.2%]) than for the LAVPS patients (0 of 199 [0%]). A subset analysis of patients with normal-pressure hydrocephalus found decreased total hospital charges in the LAVPS group ($67,124 vs. $80,890; P = 0.009).
   CONCLUSIONS: Compared with non-LAVPS, LAVPS was associated with significantly shorter operative times and fewer distal shunt revisions within 30 days. The findings from a subset analysis supported a decrease in total hospital charges. Additional studies are needed; however, these data suggest that LAVPS is a safer, less-expensive alternative to non-LAVPS.
C1 [Catapano, Joshua S.; Mezher, Andrew W.; Wang, Derrick J.; Whiting, Alexander C.; Mooney, Michael A.; Bohl, Michael A.; Sheehy, John P.; DiDomenico, Joseph D.; Sarris, Christina E.; Smith, Kris A.; Lawton, Michael T.; Zabramski, Joseph M.] St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ 85013 USA.
RP Zabramski, JM (reprint author), St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ 85013 USA.
EM Neuropub@barrowneuro.org
OI Whiting, Alexander/0000-0002-4585-5219; Mezher,
   Andrew/0000-0002-9072-9510
CR Baird C, 1999, PEDIATR NEUROSURG, V31, P269, DOI 10.1159/000028874
   Greenberg MS, 2016, HDB NEUROSURGERY
   He ML, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS1637
   Mwachaka PM, 2010, PEDIATR NEUROSURG, V46, P1, DOI 10.1159/000314050
   Naftel RP, 2011, J NEUROSURG, V115, P151, DOI 10.3171/2011.1.JNS101492
   Paff M, 2018, INTERDISCIP NEUROSUR, V13, P66, DOI 10.1016/j.inat.2018.04.004
   Park YS, 2010, J KOREAN NEUROSURG S, V48, P325, DOI 10.3340/jkns.2010.48.4.325
   Patwardhan RV, 2005, NEUROSURGERY, V56, P139, DOI 10.1227/01.NEU.0000146206.40375.41
   Phan S, 2016, CLIN NEUROL NEUROSUR, V140, P26, DOI 10.1016/j.clineuro.2015.10.025
   PUDENZ RH, 1981, SURG NEUROL, V15, P15, DOI 10.1016/S0090-3019(81)80084-5
   Rachel RA, 1999, PEDIATR NEUROSURG, V30, P296, DOI 10.1159/000028814
   SCARFF JE, 1963, J NEUROL NEUROSUR PS, V26, P1, DOI 10.1136/jnnp.26.1.1
   Vinchon M, 2002, NEUROPEDIATRICS, V33, P169, DOI 10.1055/s-2002-34490
   Wu Y, 2007, NEUROSURGERY, V61, P557, DOI 10.1227/01.NEU.0000290903.07943.AF
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.086
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600074
PM 31874294
DA 2020-05-12
ER

PT J
AU Catapano, JS
   Whiting, AC
   Mezher, AW
   Przybylowski, CJ
   See, AP
   Labib, MA
   Fredrickson, VL
   Cavalcanti, DD
   Lawton, MT
   Ducruet, AF
   Albuquerque, FC
   Sanai, N
AF Catapano, Joshua S.
   Whiting, Alexander C.
   Mezher, Andrew W.
   Przybylowski, Colin J.
   See, Alfred P.
   Labib, Mohamed A.
   Fredrickson, Vance L.
   Cavalcanti, Daniel D.
   Lawton, Michael T.
   Ducruet, Andrew F.
   Albuquerque, Felipe C.
   Sanai, Nader
TI Postembolization Change in Magnetic Resonance Imaging Contrast
   Enhancement of Meningiomas Is a Better Predictor of Intraoperative Blood
   Loss Than Angiography
SO WORLD NEUROSURGERY
LA English
DT Article
DE Embolization; Endovascular procedures; Meningiomas
ID POLYVINYL-ALCOHOL PARTICLES; SKULL-BASE MENINGIOMAS; PREOPERATIVE
   EMBOLIZATION; INTRACRANIAL MENINGIOMAS; SURGICAL RESECTION; MORTALITY;
   EFFICACY; TRANSFUSION
AB BACKGROUND: Preoperative embolization of meningiomas to reduce tumor vascularity and intraoperative blood loss remains controversial. Incomplete devascularization on angiography is not significantly correlated with intraoperative estimated blood loss (EBL). Magnetic resonance imaging (MRI) may provide a better assessment of devascularization and prediction of EBL.
   METHODS: We retrospectively analyzed patients undergoing preoperative embolization for intracranial meningiomas. Cohorts based on postembolization devascularization (>50% vs. <= 50%) were compared.
   RESULTS: Of 84 patients with meningioma undergoing preoperative embolization, 35 (42%) had a postembolization MRI before resection and met study inclusion criteria. The mean tumor diameter was 4.9 +/- 1.3 cm, and mean intraoperative EBL was 576 +/- 341 mL Compared with MRI, angiography overestimated devascularization in 22 patients (63%). Using pre- versus postembolization MRIs, 17 (49%) patients had a >50% decrease in enhancement, which was associated with lower mean intraoperative blood loss (444 +/- 255 mL) compared with 17 patients with <= 50% devascularization (700 +/- 374 mL) (P = 0.03). On angiography, the 22 (63%) patients who demonstrated >50% devascularization during embolization did not statistically differ in intraoperative EBL when compared with 13 (37%) patients with <50% angiographic devascularization. Patients with a <= 50% decrease in contrast enhancement on postembolization MRI were 9 times more likely to lose >500 mL blood intraoperatively during resection (95% confidence interval 1.6-54, P = 0.01).
   CONCLUSIONS: Postembolization contrast-enhanced MRI is a better predictor of intraoperative blood loss during meningioma resection than postembolization angiography, which overestimates the degree of embolic devascularization. Postembolization preoperative MRI is warranted for optimal patient management.
C1 [Catapano, Joshua S.; Whiting, Alexander C.; Mezher, Andrew W.; Przybylowski, Colin J.; See, Alfred P.; Labib, Mohamed A.; Fredrickson, Vance L.; Cavalcanti, Daniel D.; Lawton, Michael T.; Ducruet, Andrew F.; Albuquerque, Felipe C.; Sanai, Nader] St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
RP Sanai, N (reprint author), St Josephs Hosp, Barrow Neurol Inst, Dept Neurosurg, Phoenix, AZ 85013 USA.
EM Neuropub@barrowneuro.org
OI Whiting, Alexander/0000-0002-4585-5219; Mezher,
   Andrew/0000-0002-9072-9510; Cavalcanti, Daniel/0000-0002-2284-9297
CR Bendszus M, 2000, NEUROSURGERY, V47, P1306, DOI 10.1097/00006123-200012000-00008
   Bendszus M, 2005, AM J NEURORADIOL, V26, P1413
   Bendszus M, 2003, NEURORADIOLOGY, V45, P451, DOI 10.1007/s00234-003-1005-1
   Bendszus M, 2000, AM J NEURORADIOL, V21, P255
   Boulos P T, 2001, Neurosurg Focus, V10, pE5
   CARSON JL, 1988, LANCET, V1, P727
   Chun JY, 2002, NEUROSURGERY, V50, P1231, DOI 10.1097/00006123-200206000-00010
   DEAN BL, 1994, AM J NEURORADIOL, V15, P1675
   Dubel GJ, 2013, SEMIN INTERVENT RAD, V30, P263, DOI 10.1055/s-0033-1353479
   Ilyas A, 2019, J CLIN NEUROSCI, V59, P259, DOI 10.1016/j.jocn.2018.06.022
   Kai Y, 2006, AM J NEURORADIOL, V27, P1146
   Kim LJ, 2006, NEUROSURGERY, V58, P106, DOI 10.1227/01.NEU.0000192161.95893.D7
   Kim LI, 2006, NEUROSURGERY, V59, P98, DOI 10.1227/01.NEU.0000220215.71485.07
   Kominami S, 2012, INTERV NEURORADIOL, V18, P133, DOI 10.1177/159101991201800202
   Lacobucci M, 2017, DIAGN INTERV IMAG, V98, P307, DOI 10.1016/j.diii.2016.08.006
   Law-ye B, 2013, ACTA NEUROCHIR, V155, P707, DOI 10.1007/s00701-013-1632-1
   Martin AJ, 2007, AM J NEURORADIOL, V28, P1771, DOI 10.3174/ajnr.A0647
   Oka H, 1998, J NEURO-ONCOL, V40, P67, DOI 10.1023/A:1006196420398
   Pollak JS, 2001, J VASC INTERV RADIOL, V12, P907, DOI 10.1016/S1051-0443(07)61568-1
   Przybylowski CJ, 2018, WORLD NEUROSURG, V116, pE371, DOI 10.1016/j.wneu.2018.04.208
   Quinones-Hinojosa A, 2009, CAN J NEUROL SCI, V36, P623, DOI 10.1017/S0317167100008143
   Raper DMS, 2014, AM J NEURORADIOL, V35, P1798, DOI 10.3174/ajnr.A3919
   Rosen CL, 2002, ACTA NEUROCHIR, V144, P1157, DOI 10.1007/s00701-002-0965-y
   Shah AH, 2013, J NEUROSURG, V119, P364, DOI 10.3171/2013.3.JNS121328
   Singla A, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.9.FOCUS13351
   Vaidya Sandeep, 2008, Semin Intervent Radiol, V25, P204, DOI 10.1055/s-0028-1085930
   WAKHLOO AK, 1993, AM J NEURORADIOL, V14, P571
   Waldron JS, 2011, NEUROSURGERY, V68, P162, DOI 10.1227/NEU.0b013e3181fe2de9
   Wang YC, 2016, SCI REP, V6, P654
   Wu WC, 2012, ANN SURG, V255, P708, DOI 10.1097/SLA.0b013e31824a55b9
   Wu WC, 2010, ANN SURG, V252, P11, DOI 10.1097/SLA.0b013e3181e3e43f
   Yoon N, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.1.FOCUS17686
NR 32
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.104
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600081
PM 31884126
DA 2020-05-12
ER

PT J
AU Cepeda, S
   Barrena, C
   Arrese, I
   Fernandez-Perez, G
   Sarabia, R
AF Cepeda, Santiago
   Barrena, Cristina
   Arrese, Ignacio
   Fernandez-Perez, Gabriel
   Sarabia, Rosario
TI Intraoperative Ultrasonographic Elastography: A Semi-Quantitative
   Analysis of Brain Tumor Elasticity Patterns and Peritumoral Region
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain tumor; Elastography; Ultrasound
ID SHEAR-WAVE ELASTOGRAPHY; REAL-TIME ELASTOGRAPHY; ULTRASOUND
   ELASTOGRAPHY; EFSUMB GUIDELINES; LIVER FIBROSIS; CLINICAL-USE;
   RECOMMENDATIONS; US
AB BACKGROUND: Ultrasonographic elastography imaging visualizes the elastic properties of tissues to distinguish pathologic and healthy areas. Real-time elastography measures relative tissue hardness by evaluating changes in local strain in response to external forces.
   OBJECTIVE: We aimed to determine the elastographic patterns of different brain tumor types and establish differences between their peritumoral regions.
   METHODS: We prospectively enrolled patients undergoing craniotomy along with intraoperative ultrasonographic elastography for supratentorial brain tumors in March 2018-May 2019. The elastograms were semi-quantitatively analyzed offline based on the mean tissue elasticity of the tumors, peritumoral regions, and healthy parenchyma.
   RESULTS: We examined 37 lesions in 36 patients. The pathologic diagnoses comprised 11 meningiomas (29.7%), 4 low-grade gliomas (LGGs; 10.8%), 16 high-grade gliomas (HGGs; 43.2%), and 6 metastases (16.2%). The median MTE values observed after manual segmentation of the whole tumor were as follows: meningiomas, 119.9 (36.6); HGGs, 77.9 (18.9); LGGs, 91 (19.5); metastases, 103.9 (35.6); tumor types significantly differed (H = 18.2; P < 0.001). The peritumoral MTE values were as follows: meningiomas, 120.1 (36.3); HGGs, 86.3 (20.9); LGGs, 94.8 (7.38); and metastases, 116.3 (22). The intergroup differences were significant (H = 17.43; P < 0.001). Using receiver operating characteristic curves, we obtained an optimal cutoff point of 92.22 (whole tumors) and 109.6 (peritumoral regions). Values below these cutoff points were correlated with a high probability of being a glioma.
   CONCLUSIONS: We objectively describe the elastographic patterns of different types of brain tumors (i.e., gliomas, metastases, and meningiomas). We have identified differences in both the tumors and the peritumoral areas of these histologic types.
C1 [Cepeda, Santiago; Barrena, Cristina; Arrese, Ignacio; Sarabia, Rosario] Univ Hosp Rio Hortega, Dept Neurosurg, Valladolid, Spain.
   [Fernandez-Perez, Gabriel] Univ Hosp Rio Hortega, Dept Radiol, Valladolid, Spain.
   [Sarabia, Rosario] Univ Valladolid, Valladolid, Spain.
RP Cepeda, S (reprint author), Univ Hosp Rio Hortega, Dept Neurosurg, Valladolid, Spain.
EM cepeda_santiago@hotmail.com
OI Cepeda, Santiago/0000-0003-1667-8548
CR Bamber J, 2013, ULTRASCHALL MED, V34, P169, DOI 10.1055/s-0033-1335205
   Bavu E, 2011, ULTRASOUND MED BIOL, V37, P1361, DOI 10.1016/j.ultrasmedbio.2011.05.016
   Berg WA, 2012, RADIOLOGY, V262, P435, DOI 10.1148/radiol.11110640
   Bhatia KSS, 2012, EUR RADIOL, V22, P2397, DOI 10.1007/s00330-012-2495-1
   Box G, 2016, CANCER RES, V75, P1216
   Chakraborty A., 2007, DEV INTRAOPERATIVE U
   Chakraborty A, 2006, ULTRASOUND, V14, P43, DOI 10.1179/174313406X82461
   Chan HW, 2016, THESIS
   Chauvet D, 2016, ULTRASCHALL MED, V37, P584, DOI 10.1055/s-0034-1399152
   Cicchetti D., 1994, PSYCHOL ASSESSMENTS, V6, P284, DOI [DOI 10.1037/1040-3590.6.4.284, 10.1037/1040-3590.6.4.284]
   Cosgrove D, 2013, ULTRASCHALL MED, V34, P238, DOI 10.1055/s-0033-1335375
   Ferraioli G, 2014, J ULTRAS MED, V33, P197, DOI 10.7863/ultra.33.2.197
   Gennisson J-L, 2013, Diagn Interv Imaging, V94, P487, DOI 10.1016/j.diii.2013.01.022
   Gheonea DI, 2010, WORLD J GASTROENTERO, V16, P1720, DOI 10.3748/wjg.v16.i14.1720
   Hothorn T, 2008, J STAT SOFTW, V28, P1
   Jakola AS, 2011, J NEUROSURG, V114, P1622, DOI 10.3171/2011.1.JNS101657
   Kim HJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24377-0
   Lopez-Raton M, 2014, J STAT SOFTW, V61, P1
   OPHIR J, 1991, ULTRASONIC IMAGING, V13, P111, DOI 10.1016/0161-7346(91)90079-W
   Orlacchio A, 2012, ULTRASOUND MED BIOL, V38, P537, DOI 10.1016/j.ultrasmedbio.2011.12.023
   Paparo F, 2014, ULTRASOUND MED BIOL, V40, P1923, DOI 10.1016/j.ultrasmedbio.2014.03.021
   Park SH, 2016, CLIN MOL HEPATOL, V22, P406, DOI 10.3350/cmh.2016.0106
   Pepin KM, 2018, AM J NEURORADIOL, V39, P31, DOI 10.3174/ajnr.A5415
   Prada F, 2019, OPER NEUROSURG, V17, P227, DOI 10.1093/ons/opy323
   Reiss-Zimmermann M, 2015, CLIN NEURORADIOL, V25, P371, DOI 10.1007/s00062-014-0311-9
   Sarvazyan P., 1995, ACOUST IMAGING, V21, P223, DOI DOI 10.1007/978-1-4615-1943-0_23
   Scholz M, 2005, J ULTRAS MED, V24, P985, DOI 10.7863/jum.2005.24.7.985
   Selbekk T, 2005, ULTRASOUND MED BIOL, V31, P45, DOI 10.1016/j.ultrasmedbio.2004.09.011
   Selbekk T, 2012, BMC MED IMAGING, V12, DOI 10.1186/1471-2342-12-11
   Sigrist RMS, 2017, THERANOSTICS, V7, P1303, DOI 10.7150/thno.18650
   Tanter M, 2009, IEEE T MED IMAGING, V28, P1881, DOI 10.1109/TMI.2009.2021471
   Wu DF, 2018, CLIN NEUROL NEUROSUR, V175, P84, DOI 10.1016/j.clineuro.2018.10.009
NR 32
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.133
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600030
PM 31790843
DA 2020-05-12
ER

PT J
AU Chen, H
   Chen, RD
   Yang, HK
   Li, H
   Wang, JH
   Yu, JS
AF Chen, Hao
   Chen, Rudong
   Yang, Hongkuan
   Li, Hua
   Wang, Junhong
   Yu, Jiasheng
TI Resolution of Trigeminal Neuralgia After Surgical Disconnection of a
   Foramen Magnum Dural Arteriovenous Fistula
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dural arteriovenous fistula; Foramen magnum; Surgical disconnection;
   Trigeminal neuralgia
ID CRANIOCERVICAL JUNCTION; DIAGNOSTIC EVALUATION; MALFORMATION;
   MANAGEMENT; EMBOLIZATION; ANGIOGRAPHY; MYELOPATHY; ANEURYSM
AB BACKGROUND: Trigeminal neuralgia (TN) resulting from dural arteriovenous (DAVFs) is rare. TN caused by a foramen magnum DAVF has not been reported yet. We report a patient with TN caused by a foramen magnum DAVF treated with surgical disconnection.
   CASE DESCRIPTION: A 35-year-old man was admitted to our hospital with a TN. Magnetic resonance imaging showed an abnormal flow void in the posterior fossa and a vascular structure next to the root entry zone of the right trigeminal nerve. Digital subtraction angiography showed a Cognard type IV DAVF located at the foramen magnum. The fistula was disconnected surgically. The patient was rendered completely pain-free, and the fistula did not recur during 4-year follow-up.
   CONCLUSIONS: DAVF is a rare cause of TN. Surgical disconnection is an effective treatment method for TN caused by a foramen magnum DAVF.
C1 [Chen, Hao; Chen, Rudong; Yang, Hongkuan; Li, Hua; Wang, Junhong; Yu, Jiasheng] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan, Peoples R China.
RP Yu, JS (reprint author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan, Peoples R China.
EM yujiasheng2000@sina.com
FU Natural Science Foundation of Hubei Province, ChinaNatural Science
   Foundation of Hubei Province [2018CFB458]
FX This work was supported by the Natural Science Foundation of Hubei
   Province, China (Grant Number 2018CFB458).
CR Akhaddar A, 2010, HEADACHE, V50, P861, DOI 10.1111/j.1526-4610.2009.01555.x
   Barker FG, 1996, NEW ENGL J MED, V334, P1077, DOI 10.1056/NEJM199604253341701
   Beynon C, 2012, CLIN NEUROL NEUROSUR, V114, P696, DOI 10.1016/j.clineuro.2011.11.022
   Chen G, 2011, ACTA NEUROCHIR SUPPL, V110, P99, DOI 10.1007/978-3-7091-0356-2_18
   COGNARD C, 1995, RADIOLOGY, V194, P671, DOI 10.1148/radiology.194.3.7862961
   Lucas CD, 2007, ACTA NEUROCHIR, V149, P1249, DOI 10.1007/s00701-007-1367-y
   Du R, 2003, NEUROSURGERY, V53, P216, DOI 10.1227/01.NEU.0000069535.42897.1F
   Elhammady MS, 2017, HAND CLINIC, V143, P99, DOI 10.1016/B978-0-444-63640-9.00009-6
   Fukutome K, 2017, WORLD NEUROSURG, V98, DOI 10.1016/j.wneu.2016.11.033
   GAENSLER EHL, 1990, AM J NEURORADIOL, V11, P518
   Ge HJ, 2016, INTERV NEURORADIOL, V22, P600, DOI 10.1177/1591019916654430
   Gilard V, 2013, NEUROCHIRURGIE, V59, P210, DOI 10.1016/j.neuchi.2013.06.003
   Gronseth G, 2008, NEUROLOGY, V71, P1183, DOI 10.1212/01.wnl.0000326598.83183.04
   Guo LM, 2010, EUR J NEUROL, V17, P684, DOI 10.1111/j.1468-1331.2009.02895.x
   HARDERS A, 1982, ACTA NEUROCHIR, V66, P95, DOI 10.1007/BF01809308
   Hiramatsu R, 2015, TURK NEUROSURG, V25, P971, DOI 10.5137/1019-5149.JTN.11860-14.3
   Hurst RW, 1999, SKULL BASE SURG, V9, P1, DOI 10.1055/s-2008-1058166
   Ito M, 1996, SURG NEUROL, V45, P370, DOI 10.1016/0090-3019(95)00438-6
   Jiang LD, 2019, WORLD NEUROSURG, V121, P243, DOI 10.1016/j.wneu.2018.08.176
   Kim H, 2018, INT J TOUR RES, V20, P126, DOI 10.1002/jtr.2169
   Kim MS, 2003, SURG NEUROL, V59, P512, DOI 10.1016/S0090-3019(03)00077-6
   Kinouchi H, 1998, J NEUROSURG, V89, P755, DOI 10.3171/jns.1998.89.5.0755
   Kulwin C, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.2.FOCUS1217
   Liang GB, 2013, J NEURORADIOLOGY, V40, P134, DOI 10.1016/j.neurad.2012.09.001
   Llacer JL, 2016, NEUROCIRUGIA, V27, P199, DOI 10.1016/j.neucir.2016.01.006
   Lu XJ, 2014, J NEUROINTERV SURG, V6, pE45, DOI 10.1136/neurintsurg-2013-010984.rep
   Mascalchi M, 1996, AM J NEURORADIOL, V17, P1137
   Matsushige T, 2006, SURG NEUROL, V66, P519, DOI 10.1016/j.surneu.2006.01.022
   MENDELOWITSCH A, 1990, EUR NEUROL, V30, P338, DOI 10.1159/000117368
   Mendes GAC, 2016, CLIN NEURORADIOL, V26, P117, DOI 10.1007/s00062-015-0417-8
   Mendes GAC, 2015, INTERV NEURORADIOL, V21, P244, DOI 10.1177/1591019915582942
   Motebejane MS, 2018, OPER NEUROSURG, V15, P262, DOI 10.1093/ons/opx229
   NEWTON TH, 1969, RADIOLOGY, V93, P1071, DOI 10.1148/93.5.1071
   Niwa J, 1997, SURG NEUROL, V48, P627, DOI 10.1016/S0090-3019(96)00552-6
   Oishi H, 1999, NEURORADIOLOGY, V41, P463, DOI 10.1007/s002340050785
   Okromelidze L, 2019, WORLD NEUROSURG, V122, P607, DOI 10.1016/j.wneu.2018.11.177
   OTT D, 1993, HEADACHE, V33, P503, DOI 10.1111/j.1526-4610.1993.hed3309503.x
   Pop R, 2015, INTERV NEURORADIOL, V21, P724, DOI 10.1177/1591019915609783
   Prasad S, 2009, NEUROLOGIST, V15, P87, DOI 10.1097/NRL.0b013e3181775ac3
   Raheja A, 2017, OPER NEUROSURG, V13, P644, DOI 10.1093/ons/opx055
   Rahme R, 2007, ACTA NEUROCHIR, V149, P937, DOI 10.1007/s00701-007-1251-9
   Reddy GD, 2014, NEUROL CLIN, V32, P539, DOI 10.1016/j.ncl.2013.11.008
   Reinges MHT, 2001, J NEUROL, V248, P197, DOI 10.1007/s004150170226
   Santillan A, 2013, CLIN NEUROL NEUROSUR, V115, P241, DOI 10.1016/j.clineuro.2012.11.021
   Sattur MG, 2019, OPER NEUROSURG, V17, pE203, DOI 10.1093/ons/opz030
   Seo H, 1991, SHINKEINAIKA, V34, P429
   SYMON L, 1984, J NEUROSURG, V60, P238, DOI 10.3171/jns.1984.60.2.0238
   Takami T, 2005, J CLIN NEUROSCI, V12, P580, DOI 10.1016/j.jocn.2005.02.003
   Tolle Thomas, 2006, Pain Pract, V6, P153, DOI 10.1111/j.1533-2500.2006.00079.x
   Tomak PR, 2003, NEUROSURGERY, V52, P750, DOI 10.1227/01.NEU.0000053221.22954.85
   VINUELA F, 1986, J NEUROSURG, V64, P554, DOI 10.3171/jns.1986.64.4.0554
   Wakuta N, 2013, MED BULL FUKUOKA UNI, V40, P61
   Wang JY, 2015, J CLIN NEUROSCI, V22, P1701, DOI 10.1016/j.jocn.2015.05.014
   WILLINSKY R, 1990, NEURORADIOLOGY, V32, P114, DOI 10.1007/BF00588560
   Yoshida S, 1999, NEUROL MED-CHIR, V39, P376, DOI 10.2176/nmc.39.376
   Zhao JJ, 2016, J NEUROINTERV SURG, V8, P648, DOI 10.1136/neurintsurg-2015-011775
NR 56
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.07.063
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600135
PM 31306835
DA 2020-05-12
ER

PT J
AU Chen, L
   Liu, H
   Hong, Y
   Yang, Y
   Hu, LY
AF Chen, Lin
   Liu, Hao
   Hong, Ying
   Yang, Yi
   Hu, Lingyun
TI Minimally Invasive Decompression and Intracorporeal Bone Grafting
   Combined with Temporary Percutaneous Short-Segment Pedicle Screw
   Fixation for Treatment of Thoracolumbar Burst Fracture with Neurological
   Deficits
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intracorporeal bone grafting; Minimally invasive surgery; Short-segment
   percutaneous fixation; Thoracolumbar burst fracture
ID SPINAL-CORD-INJURY; POSTERIOR DISTRACTION; INSTRUMENTATION; MANAGEMENT;
   STABILIZATION; REDUCTION; LIGAMENTOTAXIS; CLASSIFICATION; EPIDEMIOLOGY;
   CORPECTOMY
AB OBJECTIVE: We evaluated the clinical and radiographic outcomes of patients with thoracolumbar burst fractures and neurological deficits treated with minimally invasive decompression and intracorporeal bone grafting combined with percutaneous short-segment stabilization.
   METHODS: Patients with thoracolumbar burst fractures and neurological deficits underwent minimally invasive decompression and intracorporeal bone grafting combined with percutaneous short-segment stabilization. Instrumentation was removed approximately 1 year after vertebral fracture union. The clinical and radiographic outcomes were analyzed.
   RESULTS: The mean operative duration and intraoperative bleeding volume were 135 +/- 63 minutes and 120 +/- 200 ml, respectively. The average American Spinal Injury Association impairment scale scores had significantly improved at the final follow-up examination. The visual analog scale score had decreased from 7.8 +/- 1.1 preoperatively to <2.9 +/- 1.3 (P < 0.05) at 1 week postoperatively. The Oswestry disability index had decreased from 86.1 +/- 8.8 preoperatively to 15.9 +/- 6.4 (P < 0.05) at 1 year postoperatively. The canal stenosis index had improved from 43.4% +/- 12.0% to 93.8% +/- 4.8% (P < 0.05). The sagittal Cobb angle had been corrected from 17.8 degrees +/- 7.5 degrees to 4.0 degrees +/- 1.9 degrees (P < 0.05) and remained at 4.9 degrees +/- 2.0 degrees (P > 0.05) at 1 year postoperatively. The sagittal index had been corrected from 16.6 degrees +/- 6.1 degrees to 0.3 degrees +/- 4.6 degrees (P < 0.05) and remained at 1.5 degrees +/- 4.5 degrees (P > 0.05) at 1 year postoperatively. The anterior vertebral height had increased from 49.3% +/- 11.1% to 97.6% +/- 6.5% (P < 0.05) and remained at 95.7% +/- 6.0% (P> 0.05) at 1 year postoperatively. After implant removal, the total kyphosis correction losses were 1.5 degrees +/- 0.8 degrees for the Cobb angle, 2.0 degrees +/- 1.1 degrees for the sagittal index, and 3.4% +/- 2.1% for the anterior vertebral height. One pullout screw and one broken rod were found in 1 patient each.
   CONCLUSION: Minimally invasive decompression and intracorporeal bone grafting combined with percutaneous short-segment fixation yielded satisfactory results in decompression and immediate kyphosis correction. Additionally, this procedure resulted in maintenance of the vertebral height and prevented late correction loss after implant removal.
C1 [Chen, Lin; Liu, Hao; Hong, Ying; Yang, Yi; Hu, Lingyun] Sichuan Univ, West China Hosp, Dept Orthoped, Chengdu, Peoples R China.
RP Liu, H (reprint author), Sichuan Univ, West China Hosp, Dept Orthoped, Chengdu, Peoples R China.
EM liuhao6304@126.com
CR Aebi M, 2013, EUR SPINE J, V22, P2147, DOI 10.1007/s00586-013-3062-4
   Aebi M, 2010, EUR SPINE J, V19, P2, DOI 10.1007/s00586-009-1114-6
   Alanay A, 2001, SPINE, V26, P213, DOI 10.1097/00007632-200101150-00017
   Aono H, 2017, SPINE J, V17, P1113, DOI 10.1016/j.spinee.2017.03.022
   Arlet V, 2009, EUR SPINE J, V18, P282, DOI 10.1007/s00586-008-0848-x
   Charles YP, 2017, SPINE, V42, pE523, DOI 10.1097/BRS.0000000000001888
   Charles YP, 2012, EUR SPINE J, V21, P2214, DOI 10.1007/s00586-012-2306-z
   CRUTCHER JP, 1991, J SPINAL DISORD, V4, P39
   DEGREIF J, 1994, UNFALLCHIRURG, V97, P250
   EBELKE DK, 1991, SPINE, V16, pS428
   Fan SW, 2010, EUR SPINE J, V19, P316, DOI 10.1007/s00586-009-1191-6
   FARCY JPC, 1990, SPINE, V15, P958, DOI 10.1097/00007632-199009000-00022
   Fitschen-Oestern S, 2015, INJURY, V46, pS63, DOI 10.1016/S0020-1383(15)30020-6
   Fuentes S, 2010, EUR SPINE J, V19, P1281, DOI 10.1007/s00586-010-1444-4
   He DW, 2013, EUR SPINE J, V22, P2256, DOI 10.1007/s00586-013-2972-5
   Jeon CH, 2015, SPINE, V40, pE627, DOI 10.1097/BRS.0000000000000870
   Jeong WJ, 2013, ORTHOPEDICS, V36, pE567, DOI 10.3928/01477447-20130426-17
   Kim CW, 2010, SPINE, V35, pS281, DOI 10.1097/BRS.0b013e3182022d32
   Knop C, 2001, SPINE, V26, P88, DOI 10.1097/00007632-200101010-00016
   Lee JK, 2013, ACTA NEUROCHIR, V155, P2305, DOI 10.1007/s00701-013-1859-x
   Lenehan B, 2012, SPINE, V37, P321, DOI 10.1097/BRS.0b013e31822e5ff8
   Li KC, 2014, SPINE, V39, P433, DOI 10.1097/BRS.0000000000000186
   Maciejczak A, 2007, NEUROSURGERY, V60, P232, DOI 10.1227/01.NEU.0000255399.08033.B3
   MCCORMACK T, 1994, SPINE, V19, P1741, DOI 10.1097/00007632-199408000-00014
   MCLAIN RF, 1993, J BONE JOINT SURG AM, V75A, P162, DOI 10.2106/00004623-199302000-00002
   Meves R, 2006, SPINE, V31, P2137, DOI 10.1097/01.brs.0000231730.34754.9e
   Mueller LA, 2006, ARCH ORTHOP TRAUM SU, V126, P364, DOI 10.1007/s00402-005-0065-6
   Pesenti S, 2015, BIOMED RES INT, DOI 10.1155/2015/639542
   Phan K, 2015, CLIN NEUROL NEUROSUR, V135, P85, DOI 10.1016/j.clineuro.2015.05.016
   Pickett GE, 2006, SPINE, V31, P799, DOI 10.1097/01.brs.0000207258.80129.03
   Proietti L, 2014, ORTHOP TRAUMATOL-SUR, V100, P455, DOI 10.1016/j.otsr.2014.06.003
   Shawky A, 2013, EUR SPINE J, V22, P2211, DOI 10.1007/s00586-013-2835-0
   Shi R, 2011, SPINE, V36, pE598, DOI 10.1097/BRS.0b013e3181e04b8f
   Smith WD, 2010, SPINE, V35, pS338, DOI 10.1097/BRS.0b013e3182023113
   Steib JP, 2010, EUR SPINE J, V19, P66, DOI 10.1007/s00586-009-1119-1
   Taylor H, 2002, SPINE, V27, P2758, DOI 10.1097/00007632-200212150-00004
   Vanek P, 2014, J NEUROSURG-SPINE, V20, P150, DOI 10.3171/2013.11.SPINE13479
   Wang XB, 2017, CLIN SPINE SURG, V30, pE317, DOI 10.1097/BSD.0000000000000192
   Wood KB, 2014, SPINE J, V14, P145, DOI 10.1016/j.spinee.2012.10.041
   Xu GJ, 2013, EUR SPINE J, V22, P2176, DOI 10.1007/s00586-013-2987-y
   Zhang W, 2016, SPINE, V41, pB23, DOI 10.1097/BRS.0000000000001814
NR 41
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.123
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600025
PM 31786380
DA 2020-05-12
ER

PT J
AU Chiu, PY
   Chi, JE
   Kao, FC
   Hsieh, MK
   Tsai, TT
AF Chiu, Ping-Yeh
   Chi, Jia-En
   Kao, Fu-Cheng
   Hsieh, Ming-Kei
   Tsai, Tsung-Ting
TI Minimally Invasive Surgery Combining Cortical Bone Trajectory Screws and
   Pedicle Screws to Treat Spondylodiskitis: Technical Notes and
   Preliminary Results
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cortical bone trajectory screws; Lumbar interbody fusion; Minimally
   invasive surgery; Pedicle screws; Spondylodiskitis
ID LUMBAR INTERBODY FUSION; PYOGENIC SPONDYLODISCITIS; VERTEBRAL
   OSTEOMYELITIS; SURGICAL-TREATMENT; INSTRUMENTATION; FIXATION;
   STABILIZATION; DEBRIDEMENT; DIAGNOSIS; DISCITIS
AB OBJECTIVE: Various surgical techniques for treating spondylodiskitis have been proposed, but the most appropriate surgical treatment remains controversial. In this study, we propose a new hybrid approach combining the use of cortical bone trajectory screws and pedicle screws with the technique of transforaminal lumbar interbody debridement and fusion. With this method, we can shorten the length of the segment that needs to be fixed, minimize the extent of surgical dissection, and reduce the risk of adjacent level degeneration.
   METHODS: Patients with clinical and radiographic evidences of single-level lumbar spondylodiskitis seen between January and December of 2017 were included in the study. Demographic data, including age and sex, were recorded. The intraoperative details, results of culture, functional outcome, radiologic outcome, and length of hospital stay were recorded.
   RESULTS: The mean age of 15 patients was 62.8 years. The mean operative time was 135 minutes, and the mean blood loss was 260 mL. The culture rate was 80%. The mean Numeric Rating Scale score and Oswestry Disability Index score significantly improved from 6.60 to 2.47 and from 21.20 to 10.20, respectively. No major perioperative complications occurred.
   CONCLUSIONS: With the proposed hybrid approach using cortical bone trajectory and pedicle screws with the transforaminal lumbar interbody debridement and fusion technique, the damaged anterior column can be debrided and reconstructed, and spinal stabilization can also be achieved.
C1 [Tsai, Tsung-Ting] Chang Gung Mem Hosp, Bone & Joint Res Ctr, Dept Orthopaed Surg, Spine Sect, Taoyuan, Taiwan.
   Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
RP Tsai, TT (reprint author), Chang Gung Mem Hosp, Bone & Joint Res Ctr, Dept Orthopaed Surg, Spine Sect, Taoyuan, Taiwan.
EM tsai1129@gmail.com
OI Hsieh, Ming-kai/0000-0002-9154-8850; Tsai,
   Tsung-Ting/0000-0002-7776-7627
FU Chang Gung Memorial Hospital, Linkou [CORPG3H0271]
FX This study was supported by Chang Gung Memorial Hospital, Linkou (grant
   no. CORPG3H0271).
CR Akpolat YT, 2016, SPINE, V41, pE335, DOI 10.1097/BRS.0000000000001233
   An HS, 2006, CLIN ORTHOP RELAT R, P27, DOI 10.1097/01.blo.0000203452.36522.97
   Berbari EF, 2015, CLIN INFECT DIS, V61, P859, DOI 10.1093/cid/civ633
   Calvert GC, 2015, J NEUROSURG-SPINE, V22, P166, DOI 10.3171/2014.10.SPINE14371
   Chen YR, 2016, CUREUS, V8, DOI 10.7759/cureus.714
   D'Aliberti G, 2012, EUR SPINE J, V21, pS75, DOI 10.1007/s00586-012-2238-7
   Delgado-Fernandez J, 2017, ASIAN SPINE J, V11, P817, DOI 10.4184/asj.2017.11.5.817
   Endres S, 2012, J ORTHOP SURG-HONG K, V20, P1
   Fritzell P, 2002, SPINE, V27, P1131, DOI 10.1097/00007632-200206010-00002
   Glennie RA, 2015, J CLIN NEUROSCI, V22, P972, DOI 10.1016/j.jocn.2015.01.010
   Grados F, 2007, JOINT BONE SPINE, V74, P133, DOI 10.1016/j.jbspin.2006.11.002
   Guerado E, 2012, INT ORTHOP, V36, P413, DOI 10.1007/s00264-011-1441-1
   Karlsson MK, 2002, ARCH ORTHOP TRAUM SU, V122, P522, DOI 10.1007/s00402-002-0440-5
   Lee GW, 2015, SPINE J, V15, P1519, DOI 10.1016/j.spinee.2015.02.038
   Lee JS, 2006, J BONE JOINT SURG BR, V88B, P765, DOI 10.1302/0301-620X.88B6
   Lin CP, 2012, SPINE, V37, pE1572, DOI 10.1097/BRS.0b013e31827399b8
   Lu ML, 2015, EUR SPINE J, V24, P555, DOI 10.1007/s00586-014-3585-3
   Masuda T, 2006, ARCH ORTHOP TRAUM SU, V126, P339, DOI 10.1007/s00402-006-0114-9
   Matsukawa K, 2015, J NEUROSURG-SPINE, V23, P471, DOI 10.3171/2015.1.SPINE141103
   Mohamed AS, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.6.FOCUS14142
   Nasto LA, 2014, SPINE J, V14, P1139, DOI 10.1016/j.spinee.2013.07.479
   OGA M, 1993, SPINE, V18, P1890, DOI 10.1097/00007632-199310000-00028
   Perez-Orribo L, 2013, SPINE, V38, P635, DOI 10.1097/BRS.0b013e318279a95e
   Phan Kevin, 2017, J Spine Surg, V3, P679, DOI 10.21037/jss.2017.11.03
   Quinones-Hinojosa Alfredo, 2004, Neurosurg Focus, V17, pE1, DOI 10.3171/foc.2004.17.6.1
   Rath SA, 1996, NEUROSURGERY, V38, P926, DOI 10.1097/00006123-199605000-00013
   Rayes M, 2010, J NEUROSURG-SPINE, V12, P647, DOI 10.3171/2009.12.SPINE09428
   REDFERN RM, 1988, J NEUROL NEUROSUR PS, V51, P803, DOI 10.1136/jnnp.51.6.803
   Ruf M, 2007, SPINE, V32, pE275, DOI 10.1097/01.brs.0000261034.83395.7f
   Sakaura H, 2018, J NEUROSURG-SPINE, V28, P57, DOI 10.3171/2017.5.SPINE161154
   Santoni BG, 2009, SPINE J, V9, P366, DOI 10.1016/j.spinee.2008.07.008
   Snyder LA, 2016, WORLD NEUROSURG, V88, P205, DOI 10.1016/j.wneu.2015.12.065
   Sobottke R, 2008, DTSCH ARZTEBL INT, V105, P181, DOI 10.3238/arztebl.2008.0181
   Tai CL, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-84
   Takata Y, 2014, J MED INVESTIG, V61, P388, DOI 10.2152/jmi.61.388
   Tay Bobby K-B, 2002, J Am Acad Orthop Surg, V10, P188
   Yan DL, 2008, EUR SPINE J, V17, P1311, DOI 10.1007/s00586-008-0739-1
   Zaveri GR, 2009, J SPINAL DISORD TECH, V22, P257, DOI 10.1097/BSD.0b013e31818859d0
   Zhang RX, 2020, J NAT GAS SCI ENG, V73, DOI 10.1016/j.jngse.2019.103057
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.165
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600037
PM 31809891
DA 2020-05-12
ER

PT J
AU Craven, CL
   Pradini-Santos, L
   Goel, A
   Thorne, L
   Watkins, LD
   Toma, AK
AF Craven, Claudia L.
   Pradini-Santos, Laura
   Goel, Aimee
   Thorne, Lewis
   Watkins, Laurence D.
   Toma, Ahmed K.
TI Approach to Slitlike Ventricles: Parietal-Occipital versus Frontal Burr
   Catheter Entry Sites
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hydrocephalus; Keen point; Kochers point; Navigation; Slit ventricle;
   Ventriculoperitoneal shunt
ID PLACEMENT
AB BACKGROUND: Slit ventricles can be a challenging target during shunt catheter insertion. Traditionally, the frontal approach has been considered optimal for small ventricles. At this center, routine use of electromagnetic (EM) stereotactic guidance (Stealth, Medtronic, Dublin, Ireland) has enabled a parietooccipital (P-O) burr hole approach to the frontal horns. We compare shunt placement and revisions required for patients with slit ventricles who had shunts inserted via a P-O approach versus frontal shunt.
   METHODS: We studied a retrospective cohort of patients with slit ventricles and a ventricular shunt inserted using EM guidance between 2012 and 2018. Slitlike ventricles were defined as the widest point of the lateral ventricle <3 mm. Outcome measures included placement accuracy and survival using the Kaplan-Meier curve. Optimal final catheter tip location was considered to be the frontal horn of the ipsilateral lateral ventricle.
   RESULTS: Eighty-two patients (77 female, 5 male) aged 34.9 +/- 10.8 years (mean +/- standard deviation) had ventricular shunts inserted for idiopathic intracranial hypertension (n = 63), chiari/syrinx (n = 8), congenital (n = 10), and pseudomeningocele (n = 1). Of those identified, 35 had primary P-O shunts and 46 had frontal shunts. Overall, 94% of cases had the catheter tip sitting in the frontal horn. The P-O approach was just as accurate as the frontal approach. Eight P-O shunts and 9 frontal shunts required revision over a 60-month period. There was no significant different in shunt survival between the 2 approaches (P = 0.37).
   CONCLUSIONS: EM-guided placement has enabled the P-O approach to be as safe and with equivalent survival to frontal approach. The accuracy of shunt placement between the 2 approaches was similar.
C1 [Craven, Claudia L.; Pradini-Santos, Laura; Goel, Aimee; Thorne, Lewis; Watkins, Laurence D.; Toma, Ahmed K.] Natl Hosp Neurol & Neurosurg, Victor Horsley Dept Neurosurg, London, England.
RP Craven, CL (reprint author), Natl Hosp Neurol & Neurosurg, Victor Horsley Dept Neurosurg, London, England.
EM claudia.craven@gmail.com
OI Thorne, Lewis/0000-0002-7692-0378; CRAVEN, CLAUDIA/0000-0002-6199-0090
CR Bhargav AG, 2019, WORLD NEUROSURG, V126, pE1017, DOI 10.1016/j.wneu.2019.03.027
   Dickerman RD, 2005, J CLIN NEUROSCI, V12, P781, DOI 10.1016/j.jocn.2004.12.005
   Drake JM, 1995, THE SHUNT BOOK
   Duong Jason, 2019, Surg Neurol Int, V10, P21, DOI 10.4103/sni.sni_3_18
   Hermann EJ, 2017, STEREOT FUNCT NEUROS, V95, P26, DOI 10.1159/000453277
   Krombach G, 2000, MINIM INVAS NEUROSUR, V43, P171, DOI 10.1055/s-2000-11376
   Reig AS, 2010, STEREOT FUNCT NEUROS, V88, P75, DOI 10.1159/000271822
   Sekhar LN, 2002, NEUROSURG CLIN N AM, V13, P401, DOI 10.1016/S1042-3680(02)00026-8
   Thurtell MJ, 2013, CURR TREAT OPTION NE, V15, P1, DOI 10.1007/s11940-012-0207-4
   Whitehead WE, 2017, J NEUROSURG-PEDIATR, V19, P157, DOI 10.3171/2016.8.PEDS16229
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.030
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600052
PM 31843723
DA 2020-05-12
ER

PT J
AU Dahl, RH
   Eskesen, V
   Benndorf, G
AF Dahl, Rasmus Holmboe
   Eskesen, Vagn
   Benndorf, Goetz
TI Dural Arteriovenous Fistula of the Vein of Trolard Mimicking a Cavernous
   Sinus Fistula
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cavernous sinus fistula; Digital subtraction angiography; Endovascular
   treatment; Proptosis; Superior anastomotic vein; Superior ophthalmic
   vein; Vein of Trolard
AB BACKGROUND: Arteriovenous fistulas (AVFs) involving the cavernous sinus usually become clinically apparent due to eye symptoms. Although rare, the same symptoms can be associated with AVFs located remote from the cavernous sinus when the shunt drains into its tributaries. We report the unusual case of a dural AVF in which such communication was not immediately obvious from the diagnostic angiogram.
   CASE DESCRIPTION: A 61-year-old male presented with increasing lid swelling, proptosis, and redness of the right eye for 1 month. Digital subtraction angiography showed no evidence of a cavernous sinus fistula but revealed a dural AVF between the right middle meningeal artery and the vein of Trolard. The fistula had a minor drainage through a small superficial middle cerebral vein toward the middle cranial fossa. Late venous-phase images eventually revealed faint opacification of the right cavernous sinus and superior ophthalmic vein. Endovascular treatment was performed by transarterial embolization with complete occlusion of the AVF obtained after 2 sessions.
   CONCLUSIONS: Dural AVFs involving cortical veins may cause atypical symptoms suggesting a cavernous sinus fistula due to remote venous drainage. Understanding venous anatomy helps to correlate vascular pathology and clinical symptoms and thus allows efficient and safe treatment.
C1 [Dahl, Rasmus Holmboe; Benndorf, Goetz] Univ Hosp Rigshosp, Dept Radiol, Copenhagen, Denmark.
   [Eskesen, Vagn] Univ Hosp Rigshosp, Dept Neurosurg, Copenhagen, Denmark.
   [Dahl, Rasmus Holmboe] Univ Hosp Aalborg, Dept Neurol, Aalborg, Denmark.
   [Benndorf, Goetz] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA.
RP Benndorf, G (reprint author), Univ Hosp Rigshosp, Dept Radiol, Copenhagen, Denmark.; Benndorf, G (reprint author), Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA.
EM bnndrf@gmail.com
OI Dahl, Rasmus Holmboe/0000-0002-2014-7400
CR BARNWELL SL, 1990, AM J NEURORADIOL, V11, P511
   Benndorf G, 2003, NEUROSURGERY, V53, P222, DOI 10.1227/01.NEU.0000068873.63576.5E
   COGNARD C, 1995, RADIOLOGY, V194, P671, DOI 10.1148/radiology.194.3.7862961
   Daou B, 2015, OPER NEUROSURG, V11, pE579, DOI 10.1227/NEU.0000000000000932
   Ellis JA, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.2.FOCUS1223
   Feyissa AM, 2014, J NEUROL SCI, V338, P229, DOI 10.1016/j.jns.2014.01.008
   Gross BA, 2017, J NEUROSURG, V126, P1884, DOI 10.3171/2016.5.JNS16331
   Kiyosue H, 2001, J NEUROSURG, V94, P630, DOI 10.3171/jns.2001.94.4.0630
   Kobkitsuksakul C, 2016, DIAGN INTERV RADIOL, V22, P555, DOI 10.5152/dir.2016.16073
   Kurosu A, 1998, BRIT J NEUROSURG, V12, P176, DOI 10.1080/02688699845375
   LASJAUNIAS P, 1986, J NEUROSURG, V64, P724, DOI 10.3171/jns.1986.64.5.0724
   Liu HM, 2001, NEURORADIOLOGY, V43, P405, DOI 10.1007/s002340100551
   Robert T, 2016, AM J NEURORADIOL, V37, P1870, DOI 10.3174/ajnr.A4831
   Spitze A, 2014, NEURO-OPHTHALMOLOGY, V38, P29, DOI 10.3109/01658107.2013.830628
   Tan AP, 2014, J NEUROINTERV SURG, V6, pE49, DOI 10.1136/neurintsurg-2013-010939.rep
   van Rooij WJ, 2007, AM J NEURORADIOL, V28, P651
NR 16
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.014
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600106
PM 31715406
DA 2020-05-12
ER

PT J
AU Dai, JB
   Del Signore, AG
   Govindaraj, S
   Bederson, JB
   Iloreta, AMC
   Shrivastava, RK
AF Dai, Jennifer B.
   Del Signore, Anthony G.
   Govindaraj, Satish
   Bederson, Joshua B.
   Iloreta, Alfred M. C.
   Shrivastava, Raj K.
TI Investigation of Skull-Based Cerebrospinal Fluid Leak Repair: A
   Single-Institution Comprehensive Study of 116 Cases Over 10 Years
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebrospinal fluid leak; Cerebrospinal fluid rhinorrhea; Cerebrospinal
   fluid otorrhea; Endoscopic surgery; Skull-based surgery; Surgical
   outcome
ID IDIOPATHIC INTRACRANIAL HYPERTENSION; BETA-TRACE PROTEIN; ENDOSCOPIC
   REPAIR; RISK-FACTORS; RHINORRHEA; MANAGEMENT; ENCEPHALOCELES;
   IDENTIFICATION; DIAGNOSIS; PRESSURE
AB BACKGROUND: Cerebrospinal fluid (CSF) leaks have been historically difficult to diagnose and treat because their cause can widely vary. There are insufficient diagnostic predictors and no clinically accepted standards for their treatment. This large institutional study reports on the diagnosis, management, and outcomes of patients presenting with CSF leak over 10 years and aims to identify potential comorbidities and risk factors for primary and recurrent leaks.
   METHODS: Patients diagnosed with CSF leak from 2007 to 2017 were analyzed retrospectively. The data included medical history, body mass index, surgical treatment, and postoperative outcomes.
   RESULTS: A total of 116 cases were identified. The location of leaks was 91 CSF rhinorrhea and 28 CSF otor-rhea (3 both). The average BMI for females was greater than that of males (P = 0.01). Causes of leak were 64 noniatrogenic, 47 iatrogenic, and 9 traumatic. A total of 108 patients underwent surgical treatment. Sixty-nine were treated by endoscopic approaches, 42 involved open approaches, and 83 involved the placement of a lumbar drain. Eighteen patients had a ventriculoperitoneal shunt and 6 had a lumbar-peritoneal shunt. A total of 78 patients (72.22%) had an associated encephalocele with the CSF leak. The average length of stay was 7.73 days (0.76). The average length of follow-up was 1.58 years (0.22). The primary repair rate was 80.17% (n = 93) and the overall repair outcome was 99.14% (n = 115).
   CONCLUSIONS: The overall CSF repair outcome was 99.14% over 10 years at a single institution. Despite this high percentage, CSF leaks continue to be a complex problem and require vigorous multidisciplinary work with close follow-up and use of multiple imaging strategies.
C1 [Dai, Jennifer B.; Bederson, Joshua B.; Shrivastava, Raj K.] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
   [Del Signore, Anthony G.; Govindaraj, Satish; Iloreta, Alfred M. C.] Icahn Sch Med Mt Sinai, Dept Otolaryngol, New York, NY 10029 USA.
RP Dai, JB (reprint author), Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA.
EM jennifer.dai@icahn.mssm.edu
CR Andrews LE, 2014, HORM RES PAEDIAT, V81, P217, DOI 10.1159/000357730
   Bachmann G, 2002, NEUROSURGERY, V50, P571, DOI 10.1097/00006123-200203000-00027
   Badia L, 2001, AM J RHINOL, V15, P117, DOI 10.2500/105065801781543736
   Baker EH, 2005, EMERG MED J, V22, P556, DOI 10.1136/emj.2004.022111
   Banks CA, 2009, OTOLARYNG HEAD NECK, V140, P826, DOI 10.1016/j.otohns.2008.12.060
   Berdahl JP, 2012, INVEST OPHTH VIS SCI, V53, P1422, DOI 10.1167/iovs.11-8220
   Billington CJ, 2000, ARCH INTERN MED, V160, P898, DOI 10.1001/archinte.160.7.898
   Burns JA, 1996, LARYNGOSCOPE, V106, P1080, DOI 10.1097/00005537-199609000-00007
   Chaaban MR, 2014, LARYNGOSCOPE, V124, P70, DOI 10.1002/lary.24160
   Copeland WR, 2015, J NEUROSURG, V122, P312, DOI 10.3171/2014.10.JNS14432
   Curtin HD, 2003, HEAD NECK IMAGING
   Gafoor VA, 2017, ANN INDIAN ACAD NEUR, V20, P220, DOI 10.4103/aian.AIAN_32_17
   Gassner HG, 1999, AM J RHINOL, V13, P439, DOI 10.2500/105065899781329610
   GBD Obesity Collaborators, 2017, NEW ENGL J MED, V377, P13, DOI [DOI 10.1056/NEJMoa1614362, 10.1056/NEJMoa1614362]
   Hornby C, 2018, NEURO-OPHTHALMOLOGY, V42, P99, DOI 10.1080/01658107.2017.1334218
   Jacob A, 2007, OTOL NEUROTOL, V28, P934, DOI 10.1097/MAO.0b013e31814619bd
   Janecka IP, 1997, SKULL BASE SURG ANAT
   Janfaza P, SURG ANATOMY HEAD NE
   Kutz JW, 2008, LARYNGOSCOPE, V118, P2195, DOI 10.1097/MLG.0b013e318182f833
   Lanza DC, 1996, LARYNGOSCOPE, V106, P1119, DOI 10.1097/00005537-199609000-00015
   Lee DH, 2011, J CRANIOFAC SURG, V22, P1266, DOI 10.1097/SCS.0b013e31821c6ad3
   Lindstrom DR, 2004, LARYNGOSCOPE, V114, P969, DOI 10.1097/00005537-200406000-00003
   Lloyd KM, 2008, RADIOLOGY, V248, P725, DOI 10.1148/radiol.2483070362
   Lobo BC, 2017, LARYNSCOPE INVESTIG, V2, P215, DOI 10.1002/lio2.75
   Mirza S, 2005, LARYNGOSCOPE, V115, P1774, DOI 10.1097/01.mlg.0000175679.68452.75
   Patel PN, 2018, OTOLARYNG HEAD NECK, V158, P952, DOI 10.1177/0194599818756272
   Perez MA, 2013, J NEURO-OPHTHALMOL, V33, P327, DOI 10.1097/WNO.0b013e318299c292
   Prickett KK, 2011, ARCH OTOLARYNGOL, V137, P457, DOI 10.1001/archoto.2011.12
   Quatre R, 2017, J NEUROL SURG PART B, V78, P419, DOI 10.1055/s-0037-1603731
   Rao AK, 2005, OTOL NEUROTOL, V26, P1171, DOI 10.1097/01.mao.0000179526.17285.cc
   Reddy M, 2017, RADIOL CLIN N AM, V55, P167, DOI 10.1016/j.rcl.2016.08.005
   Roehm PC, 2018, J NEUROSURG, V128, P1880, DOI 10.3171/2017.1.JNS161947
   Russel A, 2017, OTOL NEUROTOL, V38, P248, DOI 10.1097/MAO.0000000000001267
   Sampaio MH, 2009, AMJ RHINOL ALLERGY, V23, P585, DOI 10.2500/ajra.2009.23.3409
   Schlosser RJ, 2003, AM J RHINOL, V17, P191, DOI 10.1177/194589240301700403
   Silver RI, 2007, AM J RHINOL, V21, P257, DOI 10.2500/ajr.2007.21.3026
   Stucken EZ, 2012, OTOL NEUROTOL, V33, P1412, DOI 10.1097/MAO.0b013e318268d350
   Tahir Muhammad Zubair, 2011, Surg Neurol Int, V2, P174, DOI 10.4103/2152-7806.90689
   Thompson D, 1999, ARCH INTERN MED, V159, P2177, DOI 10.1001/archinte.159.18.2177
   Woodworth BA, 2008, OTOLARYNG HEAD NECK, V138, P715, DOI 10.1016/j.otohns.2008.02.010
   Yang ZJ, 2011, J NEUROSURG, V115, P165, DOI 10.3171/2011.3.JNS101447
   ZLAB M K, 1992, Ear Nose and Throat Journal, V71, P314
   Zuckerman J, 2005, AM J RHINOL, V19, P582, DOI 10.1177/194589240501900609
   Zuckerman JD, 2008, AM J RHINOL, V22, P151, DOI 10.2500/ajr.2008.22.3150
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.09.133
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600002
PM 31604132
DA 2020-05-12
ER

PT J
AU Delavari, N
   Mureb, MC
   Yaun, A
   Wisoff, JH
   Harter, DH
   Hidalgo, ET
AF Delavari, Nader
   Mureb, Monica C.
   Yaun, Amanda
   Wisoff, Jeffrey H.
   Harter, David H.
   Hidalgo, E. Teresa
TI Intrareservoir Administration of Alteplase to Treat a Distal
   Ventriculoatrial Shunt Obstruction
SO WORLD NEUROSURGERY
LA English
DT Article
DE Alteplase; Tissue plasminogen activator; Ventriculoatrial shunt
AB BACKGROUND: Ventriculoatrial shunts can be afflicted with distal malfunctions due to thrombus formation at the distal tip. Distal tip thrombus formation may occur more commonly in oncologic patients who are predisposed to hypercoagulability.
   CASE DESCRIPTION: A patient who had a ventriculoatrial shunt placed for leptomeningeal carcinomatosis presented with headaches and confusion and was found to have a partial distal shunt obstruction. Intrareservoir administration of alteplase resulted in resolution of her symptoms. Nuclear medicine shunt patency test demonstrated restoration of distal flow.
   CONCLUSIONS: Intrareservoir administration of alteplase can be a useful nonoperative treatment strategy for ventriculoatrial shunt malfunction. This strategy may be particularly useful in cases with higher perioperative risk, such as patients with advanced metastatic cancer.
C1 [Delavari, Nader; Mureb, Monica C.; Yaun, Amanda; Wisoff, Jeffrey H.; Harter, David H.; Hidalgo, E. Teresa] NYU, Sch Med, Dept Neurosurg, New York, NY 10016 USA.
RP Delavari, N (reprint author), NYU, Sch Med, Dept Neurosurg, New York, NY 10016 USA.
EM Teresa.Hidalgo@nyumc.org
RI Hidalgo, Eveline Teresa/AAK-9820-2020
OI Hidalgo, Eveline Teresa/0000-0002-0053-8658; Wisoff,
   Jeffrey/0000-0003-3303-2220; Yaun, Amanda/0000-0002-3395-0032
CR Deitcher SR, 2002, J CLIN ONCOL, V20, P317, DOI 10.1200/JCO.20.1.317
   Hanley DF, 2017, LANCET, V389, P603, DOI 10.1016/S0140-6736(16)32410-2
   Hudgins RJ, 1996, PEDIATR NEUROSURG, V25, P315, DOI 10.1159/000121146
   Jones J, 2016, J CLIN NEUROSCI, V34, P281, DOI 10.1016/j.jocn.2016.05.011
NR 4
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.013
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600146
PM 31715416
DA 2020-05-12
ER

PT J
AU Deng, JJ
   Ma, MY
   Wang, DJ
   Zhu, HD
   Hua, LY
   Sun, SC
   Chen, H
   Cheng, HX
   Qian, ZR
   Xie, Q
   Zhang, T
   Gong, Y
AF Deng, Jiaojiao
   Ma, Mengyin
   Wang, Daijun
   Zhu, Hongda
   Hua, Lingyang
   Sun, Shuchen
   Chen, Hong
   Cheng, Haixia
   Qian, Zhi Rong
   Xie, Qing
   Zhang, Tao
   Gong, Ye
TI Expression and Clinical Significance of Immune Checkpoint Regulator
   B7-H3 (CD276) in Human Meninninma
SO WORLD NEUROSURGERY
LA English
DT Article
DE B7-H3; Checkpoint; Immunotherapy; Meningioma; PD-L1; VISTA
ID MODULATORY MOLECULE PD-L1; PROSTATE-CANCER; MENINGIOMAS; RADIATION;
   PATHWAYS; ANDROGEN; THERAPY; TUMORS
AB BACKGROUND: The high expression across multiple tumor types and restricted expression in normal tissues make B7-H3 an attractive target for immunotherapy. So far, little is known about the clinical significance of B7-H3 expression in meningiomas. We conducted this study to address this issue in a cohort of 242 patients from a single institution.
   METHODS: Expression profiles of immune checkpoint proteins (programmed death-ligand 1, B7-H3, lymphocyte activation gene-3, programmed death 1, and V-domain Ig suppressor of T cell activation) were explored by immunohistochemistry in a meningioma test cohort (n = 8). Role of B7-H3 expression was further assessed in an expanded patient cohort (n = 234) using immunohistochemical tissue microarray analysis.
   RESULTS: B7-H3 expression was significantly greater than all immune checkpoint proteins studied in the tested cohort. B7-H3 was detected with different degrees in all meningioma specimens, predominantly on tumor cell membranes and in cytoplasm. Tumors were classified as B7-H3 high or low group depending on immunohistochemistry histoscore (median histoscore 111.06; range, 7.313-212.008). B7-H3 expression was statistically correlated with patient sex (P = 0.0297), tumor histopathologic subtypes (P = 0.0262), and radiotherapy after surgery (P = 0.0028). However, no significant differences were observed in patient age, tumor location, and grade and extent of resection between groups. Similarly, there was no significant difference in progression-free survival and overall survival between B7-H3 high and low group.
   CONCLUSIONS: Our study indicates variable expression and clinical role of B7-H3 in meningiomas, suggesting its potential as an immunotherapeutic target in the future.
C1 [Deng, Jiaojiao; Wang, Daijun; Zhu, Hongda; Hua, Lingyang; Sun, Shuchen; Xie, Qing; Gong, Ye] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
   [Ma, Mengyin] Fudan Univ, Huashan Hosp, Dept Lab Med, Shanghai, Peoples R China.
   [Chen, Hong; Cheng, Haixia; Zhang, Tao] Fudan Univ, Huashan Hosp, Dept Neuropathol, Shanghai, Peoples R China.
   [Gong, Ye] Fudan Univ, Huashan Hosp, Dept Crit Care Med, Shanghai, Peoples R China.
   [Qian, Zhi Rong] Sun Yat Sen Univ, Affiliated Hosp 7, Guangzhou, Peoples R China.
RP Gong, Y (reprint author), Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
EM drgongye@163.com
FU National Key R&D Program of China [2018YFC1312600, 2018YFC1312604];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81772674]; Science and Technology Commission of
   Shanghai MunicipalityScience & Technology Commission of Shanghai
   Municipality (STCSM) [18140900200]
FX This study was supported by grants from the National Key R&D Program of
   China (2018YFC1312600, 2018YFC1312604 to Y. Gong), National Natural
   Science Foundation of China (81772674 to Y. Gong), and Science and
   Technology Commission of Shanghai Municipality (18140900200 to Y. Gong).
CR Benzon B, 2017, PROSTATE CANCER P D, V20, P28, DOI 10.1038/pcan.2016.49
   Bi WL, 2016, J NEUROSURG, V125, P525, DOI 10.3171/2015.6.JNS15591
   Castellanos JR, 2017, AM J CLIN EXP IMMUNO, V6, P66
   Chapoval AI, 2001, NAT IMMUNOL, V2, P269, DOI 10.1038/85339
   Chavin G, 2009, CLIN CANCER RES, V15, P2174, DOI 10.1158/1078-0432.CCR-08-2262
   Clark VE, 2013, SCIENCE, V339, P1077, DOI 10.1126/science.1233009
   Du ZM, 2015, ONCOTARGET, V6, P4704, DOI 10.18632/oncotarget.3082
   Fang LJ, 2013, NEURO-ONCOLOGY, V15, P1479, DOI 10.1093/neuonc/not110
   Goldbrunner R, 2016, LANCET ONCOL, V17, pE383, DOI 10.1016/S1470-2045(16)30321-7
   Gupta S, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2018.1.FOCUS17754
   Han SJ, 2016, J NEURO-ONCOL, V130, P543, DOI 10.1007/s11060-016-2256-0
   Hua LY, 2018, J NEUROSURG, V128, P1698, DOI 10.3171/2017.2.JNS162566
   Johnson MD, 2018, J CLIN NEUROSCI, V57, P149, DOI 10.1016/j.jocn.2018.08.023
   Kasten BB, 2017, NUCL MED BIOL, V47, P23, DOI 10.1016/j.nucmedbio.2017.01.003
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Majzner RG, 2019, CLIN CANCER RES, V25, P2560, DOI 10.1158/1078-0432.CCR-18-0432
   MAXWELL M, 1993, J NEUROSURG, V78, P456, DOI 10.3171/jns.1993.78.3.0456
   Parker AS, 2011, INT J RADIAT ONCOL, V79, P1343, DOI 10.1016/j.ijrobp.2010.01.061
   Picarda E, 2016, CLIN CANCER RES, V22, P3425, DOI 10.1158/1078-0432.CCR-15-2428
   Powderly J, 2015, J IMMUNOTHER CANC S2, V3, pO8, DOI DOI 10.1186/2051-1426-3-S2-O8
   Proctor DT, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1512943
   Sun J, 2010, CANCER IMMUNOL IMMUN, V59, P1163, DOI 10.1007/s00262-010-0841-1
   Tang C, 2014, CANCER IMMUNOL RES, V2, P831, DOI 10.1158/2326-6066.CIR-14-0069
   Yeo W, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1334-6
NR 24
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.10.044
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600003
PM 31629137
DA 2020-05-12
ER

PT J
AU Di Pascuale, I
   Brito, N
   Zerpa, J
   Roa, C
   Faria, G
AF Di Pascuale, Italo
   Brito, Nafxiel
   Zerpa, Jose
   Roa, Cesar
   Faria, Gustavo
TI Hypoglossal Nerve Schwannoma? Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Hypoglossal nerve; Neurilemmoma; Schwannoma
AB BACKGROUND: Hypoglossal schwannomas are rare, benign intracranial neoplasms; they represent 5% of all nonvestibular schwannomas.
   CASE DESCRIPTION: A 22-year-old male patient had presented 4 months before admission with left-sided hearing loss, an increase in the base of support with lateralization to the left, and dysphagia to solids. Physical examination on admission showed hypotrophy of the tongue and deviation to the left. Magnetic resonance imaging showed evidence of an extraaxial lesion compressing the medulla oblongata and pons, which protruded through the hypoglossal canal. The patient was prepared for surgical treatment in 2 stages: in the first surgery, a left retrosigmoidal approach with total resection of the intracranial lesion was performed. The biopsy reported a schwannoma, and correlating the signs, symptoms, and imaging, the diagnosis of a hypoglossal nerve schwannoma was established. In the second surgery, a lateral cervical approach was performed, with subtotal resection of the lesion, leaving a remnant adhered to the nerve in the hypoglossal canal.
   CONCLUSIONS: Hypoglossal schwannomas are a rare entity, in which surgery is the most viable option with high cure rates. However, its complete resection, without leaving permanent neurologic sequels, is a challenge.
C1 [Di Pascuale, Italo; Brito, Nafxiel; Zerpa, Jose; Roa, Cesar; Faria, Gustavo] Hosp Univ Caracas, Dept Neurosurg, Caracas, Venezuela.
RP Brito, N (reprint author), Hosp Univ Caracas, Dept Neurosurg, Caracas, Venezuela.
EM nafxiel@gmail.com
OI Brito, Nafxiel/0000-0003-1742-7273
CR Baghel PS, 2013, NEUROL INDIA, V61, P324, DOI 10.4103/0028-3886.115092
   Bindal S, 2019, J CLIN NEUROSCI, V62, P162, DOI 10.1016/j.jocn.2018.11.037
   De Martel T, 1933, ARS MED, V9, P416
   Deora H, 2018, J NEUROSCI RURAL PRA, V9, P258, DOI 10.4103/jnrp.jnrp_469_17
   DUCATMAN BS, 1986, CANCER-AM CANCER SOC, V57, P2006, DOI 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6
   Fornaro R, 2017, MOL CLIN ONCOL, V7, P288, DOI 10.3892/mco.2017.1297
   Heda Shruti, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr-2018-225544
   Illuminati G, 2017, INT J SURG CASE REP, V34, P20, DOI 10.1016/j.ijscr.2017.03.005
   Kadri Paulo A S, 2004, Neurosurg Focus, V17, pE9
   Kuo LT, 2008, SURG NEUROL, V70, P34, DOI 10.1016/j.surneu.2007.11.023
   Nonaka Y, 2011, NEUROSURGERY, V69, P121, DOI 10.1227/NEU.0b013e31822a547b
   POLLOCK BE, 1993, NEUROSURGERY, V33, P597, DOI 10.1227/00006123-199310000-00006
   Suri A, 2014, J NEUROL SURG PART B, V75, P159, DOI 10.1055/s-0033-1356924
   Yasumatsu Ryuji, 2013, Int J Otolaryngol, V2013, P973045, DOI 10.1155/2013/973045
   Yu ZY, 2016, ONCOL LETT, V11, P283, DOI 10.3892/ol.2015.3911
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.006
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600134
PM 31821912
DA 2020-05-12
ER

PT J
AU DiGiorgio, AM
   Wittenberg, BA
   Crutcher, CL
   Kennamer, B
   Greene, CS
   Velander, AJ
   Wilson, JD
   Tender, GC
   Culicchia, F
   Hunt, JP
AF DiGiorgio, Anthony M.
   Wittenberg, Blake A.
   Crutcher, Clifford L., II
   Kennamer, Brooke
   Greene, Clarence S.
   Velander, Alan J.
   Wilson, Jason D.
   Tender, Gabriel C.
   Culicchia, Frank
   Hunt, John P.
TI The Impact of Drug and Alcohol Intoxication on Glasgow Coma Scale
   Assessment in Patients with Traumatic Brain Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Glasgow coma scale; Intoxication; Traumatic brain injury
ID SUBSTANCE USE; SCORE; ASSOCIATION; PREDICTORS; DEATHS; MILD
AB BACKGROUND: The effect of intoxicating substances on assessment of Glasgow Coma Scale (GCS) in the trauma setting has not been completely elucidated.
   METHODS: A trauma registry was queried for patients with blunt head trauma in 2013-2017. Initial GCS score and toxicology screening from the database were reviewed. Next recorded GCS score from the neurosurgery evaluation and change in GCS score (Delta GCS) were compared.
   RESULTS: We reviewed 468 patients. In 217 (46.4%) patients, no toxic substances were found, whereas >1 toxic substance was found in 104 (22.2%) patients. Alcohol level above the legal limit was found in 109 (23.3%) patients, marijuana was found in 105 (22.4%) patients, benzodiazepines were found in 94 (20.1%) patients, opiates were found in 48 (10.3%) patients, and cocaine was found in 41 (8.8%) patients. Mean change in GCS score was significantly higher in impaired patients compared with patients with a negative screening test (1.74 +/- 2.4 vs. 0.75 +/- 2.7, P < 0.001); this is despite both groups having a similar initial GCS score (6.23 +/- 3.86 in impaired group vs. 6.47 +/- 3.52 in sober group, P = 0.677). Initial GCS score was 3 in 187 patients, of whom 150 had a positive toxicology screen. Change in GCS score was significantly higher in the impaired group (2.75 +/- 2.7 vs. 1.19 +/- 1.8, P < 0.001).
   CONCLUSIONS: Intoxicating substances can confound GCS assessment in trauma patients. This can have effects on patient care as well as performance metrics and predictive analytics. These patients should be screened, and intoxicating substances should be reversed or allowed to wear off before GCS score is recorded for benchmarking or quality reporting.
C1 [DiGiorgio, Anthony M.; Crutcher, Clifford L., II; Greene, Clarence S.; Velander, Alan J.; Wilson, Jason D.; Tender, Gabriel C.; Culicchia, Frank] Louisiana State Univ, Dept Neurosurg, Hlth Sci Ctr, New Orleans, LA 70112 USA.
   [Hunt, John P.] Louisiana State Univ, Dept Gen Surg, Hlth Sci Ctr, New Orleans, LA USA.
   [Wittenberg, Blake A.] Univ Colorado, Dept Neurosurg, Denver, CO USA.
   [Kennamer, Brooke] Univ Arizona, Div Neurosurg, Dept Surg, Coll Med,Maricopa Med Ctr, Phoenix, AZ USA.
   [Hunt, John P.] Univ Med Ctr New Orleans, Norman E McSwain Jr MD, Spirit Char Trauma Ctr, New Orleans, LA USA.
   [DiGiorgio, Anthony M.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA.
RP DiGiorgio, AM (reprint author), Louisiana State Univ, Dept Neurosurg, Hlth Sci Ctr, New Orleans, LA 70112 USA.; DiGiorgio, AM (reprint author), San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA.
EM amdigiorgio@gmail.com
OI Tender, Gabriel/0000-0002-6367-004X
CR Baum J, 2016, WORLD NEUROSURG, V90, P525, DOI 10.1016/j.wneu.2015.12.012
   Demetriades D, 2004, J AM COLL SURGEONS, V199, P687, DOI 10.1016/j.jamcollsurg.2004.07.017
   Demetriades D, 2004, ARCH SURG-CHICAGO, V139, P1066, DOI 10.1001/archsurg.139.10.1066
   Guly H, 2004, TRAUMA, V6, P205
   Hadjizacharia P, 2011, EUR J TRAUMA EMERG S, V37, P169, DOI 10.1007/s00068-010-0038-5
   Hemmila MR, 2010, J TRAUMA, V68, P253, DOI 10.1097/TA.0b013e3181cfc8e6
   Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384
   London JA, 2007, ARCH SURG-CHICAGO, V142, P633, DOI 10.1001/archsurg.142.7.633
   National Institute on Alcohol Abuse and Alcoholism, 2019, ALC US DIS
   National Institute on Drug Abuse, 2015, DRUGFACTS NAT TRENDS
   Newgard CD, 2013, J AM COLL SURGEONS, V216, P147, DOI 10.1016/j.jamcollsurg.2012.08.017
   Parker CM, 2019, NEW ENGL J MED, V380, P1, DOI 10.1056/NEJMp1813836
   Reith FCM, 2017, INJURY, V48, P1932, DOI 10.1016/j.injury.2017.05.038
   RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907
   RIVARA FP, 1989, J TRAUMA, V29, P462, DOI 10.1097/00005373-198904000-00008
   Rotondo MF, 2014, RESOURCES OPTIMAL CA, P109
   Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3
   Rundhaug NP, 2015, J NEUROSURG, V122, P211, DOI 10.3171/2014.9.JNS14322
   Soderstrom CA, 1997, JAMA-J AM MED ASSOC, V277, P1769, DOI 10.1001/jama.277.22.1769
   Sperry JL, 2006, J TRAUMA, V61, P1305, DOI 10.1097/01.ta.0000240113.13552.96
   TEASDALE G, 1974, LANCET, V2, P81
   Teasdale G, 2014, LANCET NEUROL, V13, P844, DOI 10.1016/S1474-4422(14)70120-6
   Valadka AB, 2001, NEUROSURGERY, V48, P17, DOI 10.1097/00006123-200101000-00004
   Whaley CC, 2019, WORLD NEUROSURG, V130, P454, DOI 10.1016/j.wneu.2019.06.124
   Yue JK, 2017, J CLIN NEUROSCI, V45, P293, DOI 10.1016/j.jocn.2017.07.022
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.095
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600079
PM 31881342
DA 2020-05-12
ER

PT J
AU Dominguez, L
   Saway, B
   Benko, MJ
   Guilliams, E
   Marvin, EA
   Entwistle, JJ
AF Dominguez, Lisette
   Saway, Brian
   Benko, Michael J.
   Guilliams, Evin
   Marvin, Eric A.
   Entwistle, John J.
TI Ruptured Distal Superior Cerebellar Artery Aneurysm After Gamma Knife
   Radiosurgery for Trigeminal Neuralgia: A Case Report and Review of the
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Aneurysm rupture; Gamma knife radiosurgery; GKRS; Radiation-induced
   aneurysm; SCA aneurysm; Trigeminal neuralgia
ID ARTERIOVENOUS-MALFORMATION; INTRACRANIAL ANEURYSMS; VESTIBULAR
   SCHWANNOMA; SURGERY; IRRADIATION
AB BACKGROUND: Intracranial aneurysm formation after Gamma Knife radiosurgery (GKRS) is a rare complication that has only recently been reported in the literature. We report the case of a fatal distal superior cerebellar artery (SCA) aneurysm rupture in a woman treated twice with GKRS for trigeminal neuralgia along with a review of the literature regarding radiation-induced aneurysms.
   CASE DESCRIPTION: A 77-year-old white woman with a history of refractory right-sided trigeminal neuralgia treated with GKRS in 2001, and again in 2006 after a relapse, presented to our emergency department with complaints of a sudden-onset severe headache associated with vomiting, right eye vision loss, left-sided facial droop, and left-sided weakness with no history of hypertension or smoking prior to presentation. Initial head computed tomography scan without contrast demonstrated an intraparenchymal hemorrhage centered in the right middle cerebellar peduncle with subarachnoid hemorrhage in the basal cisterns and extension into the fourth ventricle causing early hydrocephalus. Head computed tomography angiography (CIA) demonstrated a distal right SCA aneurysm adjacent to the hemorrhage. The patient's mental status deteriorated into coma after suspected rerupture during the CTA requiring immediate intubation, external ventricular drain placement, and emergent cerebral angiogram with coil embolization. Ultimately, the patient never recovered despite medical and surgical management; therefore, care was withdrawn in accordance with her known wishes.
   CONCLUSIONS: The pathophysiologic association of aneurysm formation after GKRS remains to be elucidated, but given the potentially fatal consequences of aneurysm rupture, we advocate for further research and propose serial vascular imaging during the postradiosurgery follow-up period for iatrogenic aneurysm formation surveillance.
C1 [Dominguez, Lisette] Mayo Clin, Sch Grad Med Educ, Jacksonville, FL 32224 USA.
   [Saway, Brian; Benko, Michael J.; Guilliams, Evin; Marvin, Eric A.; Entwistle, John J.] Virginia Tech, Dept Surg, Div Neurosurg, Carilion Sch Med, Roanoke, VA USA.
   [Saway, Brian; Benko, Michael J.; Guilliams, Evin; Marvin, Eric A.; Entwistle, John J.] Fralin Biomed Res Inst, Roanoke, VA USA.
RP Dominguez, L (reprint author), Mayo Clin, Sch Grad Med Educ, Jacksonville, FL 32224 USA.
EM Lisette.Dominguez.DO@gmail.com
OI Dominguez, Lisette/0000-0001-5184-6506; Saway, Brian/0000-0002-7101-0981
CR Akai T, 2015, J NEUROL SURG REP, V76, P105, DOI 10.1055/s-0035-1549223
   Akamatsu Y, 2009, J NEUROSURG, V110, P543, DOI 10.3171/2008.8.JNS08177
   Bozboga M, 1996, ACTA NEUROCHIR, V138, P1013, DOI 10.1007/BF01411293
   Cahan WG, 1998, CANCER-AM CANCER SOC, V82, P8, DOI 10.1002/(SICI)1097-0142(19980101)82:1<8::AID-CNCR3>3.0.CO;2-W
   Danet M, 2001, AM J NEURORADIOL, V22, P717
   Dho YS, 2017, STEREOT FUNCT NEUROS, V95, P379, DOI 10.1159/000481666
   Elaimy Ameer L, 2013, Surg Neurol Int, V4, P92, DOI 10.4103/2152-7806.115163
   GACS G, 1983, J NEUROSURG, V58, P63, DOI 10.3171/jns.1983.58.1.0063
   Gronseth G, 2008, NEUROLOGY, V71, P1183, DOI 10.1212/01.wnl.0000326598.83183.04
   Huang PP, 2001, AM J NEURORADIOL, V22, P1346
   Hughes JD, 2015, OTOL NEUROTOL, V36, P1428, DOI 10.1097/MAO.0000000000000807
   Joanes V, 1998, ACTA NEUROCHIR, V140, P1077, DOI 10.1007/s007010050217
   Kellner CP, 2015, J NEUROINTERV SURG, V7, pE21, DOI 10.1136/neurintsurg-2014-011206.rep
   Kondziolka D, 1998, ARCH NEUROL-CHICAGO, V55, P1524, DOI 10.1001/archneur.55.12.1524
   LOCKSLEY HB, 1966, J NEUROSURG, V25, P219, DOI 10.3171/jns.1966.25.2.0219
   Lorenzoni J, 2011, CLIN NEUROL NEUROSUR, V113, P758, DOI 10.1016/j.clineuro.2011.08.013
   Nanney AD, 2014, WORLD NEUROSURG, V81, P511, DOI 10.1016/j.wneu.2013.10.044
   NILSSON A, 1978, ACTA RADIOL ONCOL, V17, P150, DOI 10.3109/02841867809127916
   Pan HC, 2010, J NEUROSURG, V113, P191, DOI 10.3171/2010.8.GKS10879
   Park KY, 2009, J NEUROSURG, V110, P540, DOI 10.3171/2008.9.JNS08860
   Sheehan J, 2005, J NEUROSURG, V102, P434, DOI 10.3171/jns.2005.102.3.0434
   Sheehan JP, 2014, WORLD NEUROSURG, V81, P487, DOI 10.1016/j.wneu.2013.11.003
   Stone HB, 2003, LANCET ONCOL, V4, P529, DOI 10.1016/S1470-2045(03)01191-4
   Sunderland G, 2014, BRIT J NEUROSURG, V28, P536, DOI 10.3109/02688697.2013.847168
   Takao T, 2006, ACTA NEUROCHIR, V148, P1317, DOI 10.1007/s00701-006-0912-4
   Uchikawa H, 2017, WORLD NEUROSURG, V99, DOI 10.1016/j.wneu.2016.11.069
   Yamamoto M, 1995, SURG NEUROL, V44, P421, DOI 10.1016/0090-3019(95)00260-X
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.10.136
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600093
PM 31734428
DA 2020-05-12
ER

PT J
AU Ehresman, J
   Ahmed, AK
   Lubelski, D
   Pennington, Z
   Jiang, BW
   Zygourakis, C
   Cottrill, E
   Theodore, N
AF Ehresman, Jeff
   Ahmed, A. Karim
   Lubelski, Daniel
   Pennington, Zachary
   Jiang, Bowen
   Zygourakis, Corinna
   Cottrill, Ethan
   Theodore, Nicholas
TI Assessment of a Triage Protocol for Emergent Neurosurgical Cases at a
   Single Institution
SO WORLD NEUROSURGERY
LA English
DT Article
DE Emergent; Level; Neurosurgical; Protocol; Trauma; Triage; Urgent
ID DEDICATED OPERATING-ROOM; SURGERY; MORTALITY; ACCESS; TRAUMA
AB BACKGROUND: Level I trauma centers use patient triaging systems to deploy neurosurgical resources and pursue good outcomes; however, data describing the effectiveness these triage systems are lacking. We reviewed the leveling protocol (cases designated urgent and emergent) of a regional Level I trauma center to obtain epidemiologic data about the efficiency of that system and identify areas for improvement.
   METHODS: We retrospectively reviewed leveled neurosurgical cases from January 2015 to October 2017, assessing surgery date, neurosurgical procedure, posted surgical urgency level (levels 1-3, with 1 being most urgent), and post-to-room (PTR) time (i.e., the time between initial leveling and admission of the patient to the operating room). Mean PTR times were compared between case types using one-way analysis of variance with post hoc Tukey honestly significant difference analysis.
   RESULTS: Of 1469 cases, 577 (39.3%) were shunt placement or revision, 231 (15.7%) were craniectomy or craniotomy for hematoma, 147 (10.0%) were craniectomy or craniotomy for tumor, and 514 (35.0%) were for other indications. Among level 1 cases, PTR time was lowest for craniotomies to evacuate intracranial hematoma (mean 16.2 minutes) and highest for spinal decompression procedures and wound washouts (mean 36.2 and 42.4 minutes, respectively).
   CONCLUSIONS: To our knowledge, this is the first study of variability in PTR timing as a function of surgical urgency or indication. The most common leveled cases were craniectomies or craniotomies to relieve increased intracranial pressure, which were also the most common level 1 cases. Significant variability occurred within each leveling category; thus, further investigation is required.
C1 [Ehresman, Jeff; Ahmed, A. Karim; Lubelski, Daniel; Pennington, Zachary; Jiang, Bowen; Cottrill, Ethan; Theodore, Nicholas] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
   [Zygourakis, Corinna] Stanford Univ, Med Ctr, Dept Neurosurg, Palo Alto, CA 94304 USA.
RP Theodore, N (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
EM Theodore@jhmi.edu
OI Theodore, Nicholas/0000-0001-5355-2683; Cottrill,
   Ethan/0000-0001-5991-7962; Ehresman, Jeff/0000-0002-8900-8935;
   Pennington, Zachary/0000-0001-8012-860X
CR Aarabi B, 2013, NEUROSURGERY, V72, P195, DOI 10.1227/NEU.0b013e318276f64b
   Ahmed K, 2019, CUREUS, V11, DOI 10.7759/cureus.3973
   [Anonymous], 2017, J Intensive Care Soc, V18, P236, DOI 10.1177/1751143716685246
   Brasel KJ, 1998, J TRAUMA, V44, P832, DOI 10.1097/00005373-199805000-00015
   Catena Fausto, 2007, World J Emerg Surg, V2, P3, DOI 10.1186/1749-7922-2-3
   Chern JJ, 2010, J NEUROSURG-PEDIATR, V6, P318, DOI 10.3171/2010.7.PEDS09534
   Chowdhury S, 2018, WORLD J EMERG SURG, V13, DOI 10.1186/s13017-018-0166-5
   Eko FN, 2013, N AM J MED SCI, V5, P22, DOI 10.4103/1947-2714.106186
   Heng M, 2013, CAN J SURG, V56, P167, DOI 10.1503/cjs.019711
   Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215
   Kowalsky RJ, 2018, J PHYS ACT HEALTH, V15, P788, DOI [10.3171/2017.7.JNS17555, 10.1123/jpah.2017-0639]
   McIsaac DI, 2017, CAN MED ASSOC J, V189, pE905, DOI 10.1503/cmaj.160576
   McManus ML, 2004, ANESTHESIOLOGY, V100, P1271, DOI 10.1097/00000542-200405000-00032
   McManus ML, 2003, ANESTHESIOLOGY, V98, P1491, DOI 10.1097/00000542-200306000-00029
   Schechtman D, 2017, J TRAUMA ACUTE CARE, V82, P58, DOI 10.1097/TA.0000000000001302
   van Veen-Berkx E, 2016, AM J SURG, V211, P122, DOI 10.1016/j.amjsurg.2015.06.021
   Wilson JR, 2017, GLOB SPINE J, V7, p95S, DOI 10.1177/2192568217701716
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.005
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600044
PM 31821911
DA 2020-05-12
ER

PT J
AU Eksi, MS
   Ozcan-Eksi, EE
   Huet, SE
   Dinc, T
   Ozmen, BB
   Akcal, MA
AF Eksi, Murat Sakir
   Ozcan-Eksi, Emel Ece
   Huet, Sibel Emilie
   Dinc, Taha
   Ozmen, Berk Baris
   Akcal, Mehmet Akif
TI Prevalence of Thoracic Scoliosis in Adolescents in Turkey: Analysis of
   1065 Chest Radiographs
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adolescent; Chest radiograph; Prevalence; Screening; Thoracic scoliosis
ID SCHOOL SCREENING-PROGRAM; IDIOPATHIC SCOLIOSIS; FOLLOW-UP; CLINICAL
   EFFECTIVENESS; STRUCTURAL SCOLIOSIS; TRUNK ASYMMETRIES; BACK-PAIN;
   CHILDREN; STUDENTS; COHORT
AB BACKGROUND: School scoliosis screening programs (SSSPs) are widely used for reporting the prevalence and improving the awareness of scoliosis. Thus, scoliosis could be prevented and/or treated in a timely manner. However, mild scoliosis (10 degrees-20 degrees) could be missed in SSSPs. Previously obtained plain chest radiographs could be used as an adjunct to SSSPs to detect the exact prevalence of scoliosis. In this study, we aimed to detect the prevalence of thoracic scoliosis in adolescents in Turkey using posteroanterior chest radiographs.
   METHODS: We conducted a cross-sectional radiologic study evaluating plain chest radiographs in adolescents who visited the emergency department or outpatient clinics at a community-based hospital. We also reviewed the literature regarding scoliosis screening in adolescents using the PubMed/MEDLINE search engine.
   RESULTS: We included 1065 adolescents. Thoracic scoliosis was detected on plain posteroanterior chest radiographs in 10.4% of the adolescents. The prevalence of thoracic scoliosis was significantly larger in females compared with males (12.3% vs. 8.6%; P = 0.047). We retrieved 140 articles regarding scoliosis screening in adolescents from the literature. Each continent had different scoliosis prevalence (according to Cobb angle >= 10 degrees verified on a radiograph).
   CONCLUSIONS: SSSPs help detection of the prevalence of scoliosis and the factors associated with scoliosis in adolescents. However, patients with small-angle curves could be missed in SSSPs. Our results showed that plain posteroanterior chest radiographs could be used as an adjunct to SSSPs to accurately detect prevalence of scoliosis in adolescents.
C1 [Eksi, Murat Sakir] Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Neurosurg, Istanbul, Turkey.
   [Huet, Sibel Emilie; Dinc, Taha; Ozmen, Berk Baris] Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Istanbul, Turkey.
   [Ozcan-Eksi, Emel Ece] Bahcesehir Univ, Sch Med, Dept Phys Med & Rehabil, Istanbul, Turkey.
   [Akcal, Mehmet Akif] Antalya Ataturk State Hosp, Clin Orthoped Surg, Antalya, Turkey.
RP Eksi, MS (reprint author), Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Neurosurg, Istanbul, Turkey.
EM muratsakireksi@gmail.com
RI Eksi, Murat Sakir/I-3699-2012
OI Eksi, Murat Sakir/0000-0002-3036-0061
CR ABOBAKR A, 1992, ANN SAUDI MED, V12, P555, DOI 10.5144/0256-4947.1992.555
   ADLER NS, 1984, WESTERN J MED, V141, P631
   Adobor RD, 2011, SCOLIOSIS SPINAL DIS, V6, DOI 10.1186/1748-7161-6-23
   ALTURAIKI MH, 1994, SAUDI MED J, V15, P277
   Ascani E, 1977, Ital J Orthop Traumatol, V3, P111
   Aulisa AG, 2019, J PEDIATR ORTHOP B, V28, P271, DOI 10.1097/BPB.0000000000000611
   BAKER EA, 1970, AM J NURS, V70, P766, DOI 10.2307/3421218
   BELLYEI A, 1977, ACTA ORTHOP SCAND, V48, P177, DOI 10.3109/17453677708985131
   BREMBERG S, 1986, J PEDIATR ORTHOPED, V6, P564, DOI 10.1097/01241398-198609000-00007
   BROOKS HL, 1975, J BONE JOINT SURG AM, V57, P968, DOI 10.2106/00004623-197557070-00015
   BURWELL RG, 1983, J BONE JOINT SURG BR, V65, P452
   CARTER OD, 1987, INT J EPIDEMIOL, V16, P537, DOI 10.1093/ije/16.4.537
   CHAN A, 1986, MED J AUSTRALIA, V145, P379, DOI 10.5694/j.1326-5377.1986.tb112390.x
   Chen BH, 1990, J CERVICODYNIA LUMBO, V11, P1
   Chen CW, 2010, MED INNOVATION CHINA, V7, P44
   Chen JB, 2016, EUR SPINE J, V25, P3082, DOI 10.1007/s00586-015-4215-4
   Chen LD, 2012, MED INNOVATION CHINA, V09, P89
   [程斌 CHENG Bin], 2006, [中国脊柱脊髓杂志, Chinese Journal of Spine and Spinal Cord], V16, P180
   Chowanska J, 2012, SCOLIOSIS SPINAL DIS, V7, DOI 10.1186/1748-7161-7-9
   Cilli K, 2009, ACTA ORTHOP TRAUMATO, V43, P426, DOI 10.3944/AOTT.2009.426
   COLLIS DK, 1969, J BONE JOINT SURG AM, VA 51, P425, DOI 10.2106/00004623-196951030-00001
   CUCEKPLENICAR M, 1995, ST HEAL T, V15, P275
   Danielsson AJ, 2012, SPINE, V37, P755, DOI 10.1097/BRS.0b013e318231493c
   DARUWALLA JS, 1985, J BONE JOINT SURG BR, V67, P182
   David Rami, 1996, Harefuah, V130, P297
   de Souza FI, 2013, ACTA ORTOP BRAS, V21, P223, DOI 10.1590/S1413-78522013000400008
   Deepak AS, 2017, MALAYS ORTHOP J, V11, P41, DOI 10.5704/MOJ.1703.018
   Deng N, 2006, 1 INT C CHIN ORTH AS, P581
   DICKSON RA, 1983, BMJ-BRIT MED J, V286, P615, DOI 10.1136/bmj.286.6365.615
   DICKSON RA, 1980, BRIT MED J, V281, P265, DOI 10.1136/bmj.281.6235.265
   Dong ZQ, 2009, ACTA ACAD MED JIANGX, V49, P129
   Du Q, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1140-6
   Du QJ, 2010, LINGNAN MOD CLIN SUR, V10, P52
   Fan HW, 2016, SPINE, V41, P259, DOI 10.1097/BRS.0000000000001197
   Fazey G., 1988, NURS TIMES, V8, P58
   Fong DYT, 2015, SPINE J, V15, P825, DOI 10.1016/j.spinee.2015.01.019
   Fong DYT, 2010, SPINE, V35, P1061, DOI 10.1097/BRS.0b013e3181bcc835
   FRANCIS RS, 1988, PHYS THER, V68, P1513
   Gao WR, 2004, HEBEI MED, V10, P1073
   GOLDBERG CJ, 1995, SPINE, V20, P1368, DOI 10.1097/00007632-199506000-00007
   GORE DR, 1981, PEDIATRICS, V67, P196
   Grauers A, 2014, SPINE, V39, P886, DOI 10.1097/BRS.0000000000000312
   Grivas T B, 2002, Stud Health Technol Inform, V91, P76
   Grivas TB, 2008, DISABIL REHABIL, V30, P752, DOI 10.1080/09638280802041086
   Grivas Theodoros B, 2002, Stud Health Technol Inform, V91, P71
   Grivas TB, 2006, SCOLIOSIS SPINAL DIS, V1, DOI 10.1186/1748-7161-1-9
   Guo YW, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000006481, 10.1097/md.0000000000006481]
   Gurr J F, 1977, Can Nurse, V73, P24
   Hansen T B, 1994, Ugeskr Laeger, V156, P4979
   HARLIN VK, 1977, J SCHOOL HEALTH, V47, P348, DOI 10.1111/j.1746-1561.1977.tb01083.x
   HARREBY M, 1995, SPINE, V20, P2298, DOI 10.1097/00007632-199511000-00007
   HEINE J, 1981, Z ORTHOP GRENZGEB, V119, P340, DOI 10.1055/s-2008-1051633
   Huang Nan-qi, 2011, Zhonghua Liu Xing Bing Xue Za Zhi, V32, P138
   Huang SC, 1997, SPINE, V22, P1985, DOI 10.1097/00007632-199709010-00007
   JUMA AHA, 1989, SAUDI MED J, V10, P213
   Kamtsiuris P, 2007, BUNDESGESUNDHEITSBLA, V50, P686, DOI 10.1007/s00103-007-0230-x
   Kapoor M, 2008, J PEDIATR ORTHOP B, V17, P281, DOI 10.1097/BPB.0b013e328311d4d8
   Karachalios T, 1999, SPINE, V24, P2318, DOI 10.1097/00007632-199911150-00006
   Kasper M J, 1993, Arthritis Care Res, V6, P126, DOI 10.1002/art.1790060304
   Ke Y, 2012, J PRACT MED, V28, P832
   KERET D, 1986, Harefuah, V110, P565
   Keskin D, 1997, EUR J PHYS MED REHAB, V7, P42
   Koga Y, 1986, Nihon Seikeigeka Gakkai Zasshi, V60, P61
   Komang-Agung IS, 2017, MALAYS ORTHOP J, V11, P17, DOI 10.5704/MOJ.1711.011
   Koukourakis I, 1997, J SPINAL DISORD, V10, P527
   Kuroki H, 2018, J ORTHOP SCI, V23, P609, DOI 10.1016/j.jos.2018.03.005
   Labelle H, 2013, SCOLIOSIS SPINAL DIS, V8, DOI 10.1186/1748-7161-8-17
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   LAULUND T, 1982, ACTA ORTHOP SCAND, V53, P765, DOI 10.3109/17453678208992289
   Lee CF, 2010, SPINE, V35, pE1492, DOI 10.1097/BRS.0b013e3181ecf3fe
   Lee JY, 2014, YONSEI MED J, V55, P773, DOI 10.3349/ymj.2014.55.3.773
   Leone A, 2010, RADIOL MED, V115, P238, DOI 10.1007/s11547-009-0429-z
   LI HP, 1985, J BONE JOINT SURG AM, V67A, P1202, DOI 10.2106/00004623-198567080-00009
   Li Q, 1999, CHIN J ORTHOP, V19, P265
   Li WP, 2001, CHIN J PEDIAT SURG, V22, P104
   Li YJ, 1999, CHIN J SCH DOCTOR, V13, P415
   Liang XQ, 2005, MATERN CHILD HLTH J, V20, P1496
   Liston C, 1981, Aust J Physiother, V27, P37, DOI 10.1016/S0004-9514(14)60744-3
   Liu RT, 2001, OCCUP HLTH, V17, P75
   [刘尚礼 Liu Shangli], 2002, [中国脊柱脊髓杂志, Chinese Journal of Spine and Spinal Cord], V12, P41
   Liu W, 2011, ORTHOP J CHIN, V19, P1244
   LONSTEIN JE, 1982, J BONE JOINT SURG AM, V64, P481, DOI 10.2106/00004623-198264040-00002
   LONSTEIN JE, 1977, CLIN ORTHOP RELAT R, P33
   [芦淼 Lu Miao], 2010, [中国矫形外科杂志, Orthopedic Journal of China], V18, P591
   Luk KDK, 2010, SPINE, V35, P1607, DOI 10.1097/BRS.0b013e3181c7cb8c
   Ma X, 1995, Zhonghua Liu Xing Bing Xue Za Zhi, V16, P109
   Meng LQ, 2003, J MED THEORY PRACT, V16, P516
   Miller M J, 1978, AORN J, V27, P1006, DOI 10.1016/S0001-2092(07)62912-3
   Minehisa K, 1999, RIGAKURYOHO KAGAKU, V14, P69
   Minghelli B, 2014, PEDIATR ENDOCR REV P, V11, P374
   MORAIS T, 1985, AM J PUBLIC HEALTH, V75, P1377, DOI 10.2105/AJPH.75.12.1377
   Motohashi R, 1999, YOBO IGAKU JANARU, P13
   NEGRI V, 1982, Acta Bio-Medica de l'Ateneo Parmense, V53, P41
   Nery LS, 2010, SAO PAULO MED J, V128, P69, DOI 10.1590/S1516-31802010000200005
   NEWMAN DC, 1977, ILLINOIS MED J, V151, P31
   NISSINEN M, 1993, ACTA PAEDIATR, V82, P77, DOI 10.1111/j.1651-2227.1993.tb12521.x
   Nussinovitch M, 2002, PUBLIC HEALTH, V116, P30, DOI 10.1038/sj/ph/1900812
   OBRIEN JP, 1977, PRACTITIONER, V219, P739
   Ogilvie JW, 2006, SPINE, V31, P679, DOI 10.1097/01.brs.0000202527.25356.90
   OHTSUKA Y, 1988, SPINE, V13, P1251, DOI 10.1097/00007632-198811000-00008
   Ostojic Z, 2006, COLLEGIUM ANTROPOL, V30, P59
   Penha PJ, 2018, SPINE, V43, P1710, DOI 10.1097/BRS.0000000000002725
   Pokharel RK, 2013, NEPAL ORTHOP ASS J, V3, P14
   Pruijs J E, 1996, Eur Spine J, V5, P374, DOI 10.1007/BF00301964
   PRUIJS JEH, 1992, SPINE, V17, P431, DOI 10.1097/00007632-199204000-00009
   Ramirez N, 1997, J BONE JOINT SURG AM, V79A, P364, DOI 10.2106/00004623-199703000-00007
   RANDALL FM, 1983, ALA J MED SCI, V20, P395
   Ratahi ED, 2002, J PEDIATR ORTHOPED, V22, P784, DOI 10.1097/00004694-200211000-00018
   Redondo Granado M J, 1999, An Esp Pediatr, V50, P129
   ROGALA EJ, 1978, J BONE JOINT SURG AM, V60, P173, DOI 10.2106/00004623-197860020-00005
   Sakullertphasuk Wimonrat, 2015, Journal of the Medical Association of Thailand, V98, pS18
   Scoliosis Research Society, SRS POSNA AAOS AAP P
   SELLS CJ, 1974, AM J NURS, V74, P60, DOI 10.2307/3469590
   SHANDS AR, 1955, J BONE JOINT SURG AM, V37, P1243, DOI 10.2106/00004623-195537060-00012
   Shannak A, 1986, JORDAN MED J, V21, P219
   Smyrnis Panagiotis, 2015, Spine Deform, V3, P253, DOI 10.1016/j.jspd.2014.10.002
   SMYRNIS PN, 1979, J BONE JOINT SURG BR, V61, P215
   Soucacos PN, 1997, J BONE JOINT SURG AM, V79A, P1498, DOI 10.2106/00004623-199710000-00006
   Stirling AJ, 1996, J BONE JOINT SURG AM, V78A, P1330, DOI 10.2106/00004623-199609000-00006
   Sugita K, 2000, Nihon Koshu Eisei Zasshi, V47, P320
   Sugita K, 1997, Nihon Koshu Eisei Zasshi, V44, P167
   Suh SW, 2011, EUR SPINE J, V20, P1087, DOI 10.1007/s00586-011-1695-8
   Sun R, 2009, GUIZHOU MED J, V33, P73
   Tan CM, 1988, GUANGXI MED J, V10, P314
   Tanchev P, 1996, ORTHOP TRAUMA B, V33, P69
   Tang ZY, 2007, 3 S CHIN SPIN SURG S, P198
   Teng HR, 1989, CHIN J SCH HLTH, V10, P58
   TORELL G, 1981, J BONE JOINT SURG AM, V63, P337, DOI 10.2106/00004623-198163030-00002
   Ueno M, 2011, J ORTHOP SCI, V16, P1, DOI 10.1007/s00776-010-0009-z
   Ugras AA, 2010, J BACK MUSCULOSKELET, V23, P45, DOI 10.3233/BMR-2010-0247
   Urrutia J, 2018, J PEDIATR ORTHOP B, V27, P159, DOI 10.1097/BPB.0000000000000466
   Urrutia J, 2014, SPINE, V39, P149, DOI 10.1097/BRS.0000000000000095
   Urrutia J, 2011, EUR SPINE J, V20, P2223, DOI 10.1007/s00586-011-1829-z
   Velezis MJ, 2002, J PEDIATR ORTHOPED, V22, P788, DOI 10.1097/00004694-200211000-00019
   Wang XS, 1998, NEW CHIN MED, V29, P534
   Wang Y, 2013, J TRADIT CHIN ORTHOP, V25, P25
   Wang Y P, 1996, Zhonghua Liu Xing Bing Xue Za Zhi, V17, P160
   [王振堂 WANG Zhentang], 2007, [中国脊柱脊髓杂志, Chinese Journal of Spine and Spinal Cord], V17, P440
   Weinstein SL, 2003, JAMA-J AM MED ASSOC, V289, P559, DOI 10.1001/jama.289.5.559
   Weinstein SL, 1999, SPINE, V24, P2592, DOI 10.1097/00007632-199912150-00006
   WILLNER S, 1982, ACTA ORTHOP SCAND, V53, P233, DOI 10.3109/17453678208992208
   WILLNER S, 1984, SPINE, V9, P644, DOI 10.1097/00007632-198409000-00017
   WILLNER S, 1984, J PEDIATR ORTHOPED, V4, P452, DOI 10.1097/01241398-198408000-00012
   Wong HK, 2005, SPINE, V30, P1188, DOI 10.1097/01.brs.0000162280.95076.bb
   WYNNE-DAVIES R, 1968, Journal of Bone and Joint Surgery British Volume, V50B, P24
   Yamamoto S, 2015, ASIAN SPINE J, V9, P407, DOI 10.4184/asj.2015.9.3.407
   Yang Q, 2005, CHIN J PRACT MED, V5
   Yawn BP, 1999, JAMA-J AM MED ASSOC, V282, P1427, DOI 10.1001/jama.282.15.1427
   Yawn BP, 2000, SPINE, V25, P2387, DOI 10.1097/00007632-200009150-00019
   Yong F, 2009, ANN ACAD MED SINGAP, V38, P1056
   Yu ZT, 1995, CHIN J ORTHOP, V15, P418
   ZHANG GP, 1988, CHINESE MED J-PEKING, V101, P151
   Zhang HQ, 2015, SPINE, V40, P41, DOI 10.1097/BRS.0000000000000664
   Zhang S, 2003, ORTHOP J CHIN, V11, P1712
   Zhang SJ, 2011, J DIS MONIT CONTROL, V05, P131
   Zhang WZ, 1996, CHIN J SCH DOCTOR, V10, P362
   Zheng Y, 2017, J REHABIL MED, V49, P512, DOI 10.2340/16501977-2240
   Zheng Y, 2016, J REHABIL MED, V48, P547, DOI 10.2340/16501977-2098
   Zhou BW, 1984, ACTA ACAD MED QINGDA, V36, P87
   [周惠清 ZHOU Huiqing], 2008, [中国脊柱脊髓杂志, Chinese Journal of Spine and Spinal Cord], V18, P824
   丁绍省, 2005, [中国医学影像学杂志, Chinese Journal of Medical Imaging], V13, P470
NR 161
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.057
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600063
PM 31863897
DA 2020-05-12
ER

PT J
AU Er, K
   Schmieder, K
   Brenke, C
   Miller, D
   Parpaley, Y
   Gierthmuehlen, M
AF Er, Kadir
   Schmieder, Kirsten
   Brenke, Christopher
   Miller, Dorothea
   Parpaley, Yaroslav
   Gierthmuehlen, Mortimer
TI Brainatomy: A Novel Way of Teaching Sphenoid Bone Anatomy With a
   Simplified 3-Dimensional Model
SO WORLD NEUROSURGERY
LA English
DT Article
DE Mnemonic; Neuroanatomy; Neurosurgery; Skullbase; Sphecoid; Sphenoid
   bone; Teaching
ID MICROSURGICAL ANATOMY
AB BACKGROUND: The diagnosis and treatment of diseases at and around the sphenoid bone demands throughout understanding of its anatomy in 3-dimensional (3-D) space. However, despite the complex anatomic nature of the sphenoid bone, the current educational resources for its 3-D anatomy are insufficient for fast and long-term retention of the anatomic relationships.
   OBJECTIVE: To provide a simplified 3-D model of the sphenoid bone that anyone can easily learn and recall as an internal mental model.
   METHODS: Various studies on the anatomy of the sphenoid bone were analyzed. The collected data included the shape, foramina, canals, fissures, and minute details of the sphenoid bone. The gained detailed knowledge was subsequently used to create a 3-D model of the sphenoid hone with the help of 3-D computer software. A live lecture was given with this same software and simultaneously recorded with a microphone and a computer-screen recorder. A novel approach in lecturing, building the sphenoid bone from the scratch in a piecemeal fashion, was utilized.
   RESULTS: The sphenoid bone was recreated as an horizontally elongated box without a superior and posterior wall. All its foramina, canals, and fissures are visually easy to follow. Understanding its neuroanatomic terminologies based on their anatomic nature and relationships is enhanced.
   CONCLUSIONS: This simplified 3-D model, along with the video lecture, will enhance the efficiency of studying sphenoid bone anatomy. The educational resources of this study can be obtained by medical students, radiologists, neurologists, neurosurgeons, neuroscientists, or anyone else seeking for fundamental understanding of sphenoid bone anatomy.
C1 [Er, Kadir; Schmieder, Kirsten; Brenke, Christopher; Miller, Dorothea; Parpaley, Yaroslav; Gierthmuehlen, Mortimer] Univ Hosp Bochum, Dept Neurosurg, Bochum, Germany.
RP Er, K (reprint author), Univ Hosp Bochum, Dept Neurosurg, Bochum, Germany.
EM er.kadir.do@gmail.com
CR Abbassy M, 2016, OTOLARYNG CLIN N AM, V49, P141, DOI 10.1016/j.otc.2015.08.002
   Cheng Y, 2016, SURG RADIOL ANAT, V38, P541, DOI 10.1007/s00276-015-1597-2
   Dagtekin A, 2014, TURK NEUROSURG, V24, P484, DOI 10.5137/1019-5149.JTN.8738-13.1
   FUJII K, 1979, J NEUROSURG, V50, P31, DOI 10.3171/jns.1979.50.1.0031
   Hofmann E, 2012, CLIN NEURORADIOL, V22, P123, DOI 10.1007/s00062-011-0083-4
   Joo W, 2012, NEUROSURGERY, V70, P300, DOI 10.1227/NEU.0b013e3182431767
   Kerr RG, 2012, J NEUROL SURG PART B, V73, P424, DOI 10.1055/s-0032-1329626
   Meng QG, 2015, INT J CLIN EXP MED, V8, P15601
   Seoane E, 1998, NEUROSURGERY, V42, P869, DOI 10.1097/00006123-199804000-00108
   Wang WH, 2019, J NEUROSURG, V131, P1571, DOI 10.3171/2018.6.JNS181117
NR 10
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.10.128
PG 21
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600008
PM 31678451
DA 2020-05-12
ER

PT J
AU Eroglu, U
   Bahadir, B
   Tomlinson, SB
   Ugur, HC
   Sayaci, EY
   Attar, A
   Caglar, YS
   Gadol, AAC
AF Eroglu, Umit
   Bahadir, Burak
   Tomlinson, Samuel B.
   Ugur, Hasan Caglar
   Sayaci, Emre Yagiz
   Attar, Ayhan
   Caglar, Yusuf Sukru
   Gadol, Aaron A. Cohen
TI Microsurgical Management of Ventral Intradural-Extramedullary Cervical
   Meningiomas: Technical Considerations and Outcomes
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior; Cervical; Meningioma; Outcomes; Spine; Surgical technique;
   Ventral
ID SPINAL MENINGIOMAS; SURGICAL-MANAGEMENT; ANTERIOR APPROACH
AB OBJECTIVE: Cervical meningiomas are uncommon intradural-extramedullary tumors that have a tendency to be situated anterior to the spinal cord. The optimal surgical corridor to reach purely ventral cervical meningiomas has not been established. This article presents a series of patients with ventral cervical meningiomas treated via 1 of 2 microneurosurgical approaches: the anterior approach with corpectomy and fusion or the posterolateral approach.
   METHODS: Eight patients who underwent surgical resection of solitary, histopathologically confirmed, intradural-extramedullary cervical meningiomas of purely ventral location were retrospectively examined. Preoperative and postoperative Nurick scores quantified the degree of ambulatory function. Patients were followed for an average of 2.1 years after surgery. Postoperative imaging was performed to determine the extent of resection and to assess for tumor recurrence.
   RESULTS: Two patients with lower cervical meningiomas underwent resection via an anterior approach with single-level corpectomy and fusion. Six patients were treated via a posterolateral approach including ipsilateral hemilaminectomy and partial facetectomy without fusion. No intraoperative or postoperative complications were observed. Gross total resection was achieved in 8 of 8 patients, although 1 patient exhibited tumor recurrence. Improvement in ambulatory function was observed in all patients.
   CONCLUSIONS: Purely ventral cervical meningiomas are uncommon and pose unique technical challenges for neurosurgeons. We document favorable outcomes from 2 cases of lower cervical meningioma treated via an anterior approach and 6 cases of upper cervical tumors treated via a posterolateral approach. This series demonstrates operative considerations for effectively managing ventral cervical meningiomas.
C1 [Eroglu, Umit; Ugur, Hasan Caglar; Sayaci, Emre Yagiz; Attar, Ayhan; Caglar, Yusuf Sukru] Ankara Univ, Sch Med, Dept Neurosurg, Ankara, Turkey.
   [Bahadir, Burak] Ankara Sehir Hosp, Ankara, Turkey.
   [Tomlinson, Samuel B.] Univ Rochester, Med Ctr, Sch Med & Dent, Rochester, NY 14642 USA.
   [Gadol, Aaron A. Cohen] Indiana Univ, Dept Neurosurg, Indianapolis, IN 46204 USA.
RP Gadol, AAC (reprint author), Indiana Univ, Dept Neurosurg, Indianapolis, IN 46204 USA.
EM acohenmd@gmail.com
OI Eroglu, Umit/0000-0001-8623-071X
CR Aboul-Enein HA, 2015, CLIN NEUROL NEUROSUR, V139, P152, DOI 10.1016/j.clineuro.2015.10.008
   Alexander H, 2010, J CLIN NEUROSCI, V17, P374, DOI 10.1016/j.jocn.2009.06.037
   Angevine PD, 2011, J NEUROSURG-SPINE, V15, P28, DOI 10.3171/2011.3.SPINE1095
   Banczerowski Peter, 2003, Ideggyogy Sz, V56, P115
   Cohen-Gadol AA, 2003, J NEUROSURG, V98, P258, DOI 10.3171/spi.2003.98.3.0258
   CROCKARD HA, 1991, NEUROSURGERY, V28, P88
   Fraioli MF, 2015, TECHNOL CANCER RES T, V14, P505, DOI 10.1177/1533034614500418
   Ghasem Alexander, 2017, Spinal Cord Ser Cases, V3, P17092, DOI 10.1038/s41394-017-0017-8
   Giroux J C, 1978, Neurosurgery, V2, P128
   Gottfried Oren N, 2003, Neurosurg Focus, V14, pe2, DOI 10.3171/foc.2003.14.6.2
   HELSETH A, 1989, J NEUROSURG, V71, P842, DOI 10.3171/jns.1989.71.6.0842
   Kim CH, 2011, SPINE, V36, pE531, DOI 10.1097/BRS.0b013e3181dc8426
   LENELLE J, 1986, NEUROCHIRURGIE, V32, P262
   LEVY WJ, 1982, J NEUROSURG, V57, P804, DOI 10.3171/jns.1982.57.6.0804
   Lonjon N, 2016, WORLD NEUROSURG, V89, P464, DOI 10.1016/j.wneu.2016.01.029
   Notani Naoki, 2017, Eur J Orthop Surg Traumatol, V27, P181, DOI 10.1007/s00590-016-1860-1
   Pai S Balaji, 2018, Asian J Neurosurg, V13, P651, DOI 10.4103/ajns.AJNS_273_16
   Payer M, 2005, ACTA NEUROCHIR, V147, P555, DOI 10.1007/s00701-005-0502-x
   Postalci L, 2011, TURK NEUROSURG, V21, P449, DOI [10.5137/1019-5149.JTN .3518-10.2, 10.5137/1019-5149.JTN.3518-10.2]
   Roux FX, 1996, SURG NEUROL, V46, P458, DOI 10.1016/S0090-3019(96)00199-1
   Sandalcioglu IE, 2008, EUR SPINE J, V17, P1035, DOI 10.1007/s00586-008-0685-y
   Schaller B, 2005, J NEURO-ONCOL, V75, P157, DOI 10.1007/s11060-005-1469-4
   SOLERO CL, 1989, NEUROSURGERY, V25, P153, DOI 10.1227/00006123-198908000-00001
   Takami T, 2015, J CRANIOVERTEBRAL JU, V6, P173, DOI 10.4103/0974-8237.167862
   Tola S, 2016, CLIN NEUROL NEUROSUR, V148, P35, DOI 10.1016/j.clineuro.2016.06.015
NR 25
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.145
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600090
PM 31901496
DA 2020-05-12
ER

PT J
AU Faried, A
   Hermanto, Y
   Tjahjono, FP
   Valentino, A
   Arifin, MZ
AF Faried, Ahmad
   Hermanto, Yulius
   Tjahjono, Firman P.
   Valentino, Andrea
   Arifin, Muhammad Z.
TI Identification of Periostin as a Potential Biomarker in Gliomas by
   Database Mining
SO WORLD NEUROSURGERY
LA English
DT Article
DE CGGA; Glioma; Periostin (POSTN); Prognosis; TCGA
ID GENOMIC ANALYSIS; STEM-CELLS; GLIOBLASTOMA; CLASSIFICATION; CANCER;
   PROGRESSION; RESISTANCE; LANDSCAPE; SUBTYPES; REVEALS
AB BACKGROUND: Bioinformatics analysis integrating microenvironmental factors and single cell analysis segregated the glioblastoma (GBM) subtype into 3 subtypes: proneural, classic, and mesenchymal. Mesenchymal GBM tends to have the worst survival but benefits from aggressive treatment protocols. Therefore, it is clinically meaningful to identify relevant biomarkers to distinguish the mesenchymal subtype. Moreover, in developing nations with limited resources, rigorous examinations are costly and inefficient for patient care.
   METHODS: In this study, we analyzed The Cancer Genome Atlas (TCGA)-Glioblastoma and TCGA-Low-Grade Glioma RNA sequencing (RNAseq) cohorts and confirmed that the mesenchymal subtype was associated with the worst prognosis.
   RESULTS: We identified periostin (POSTN) as a mesenchymal subtype biomarker with prognostic value across histologic grades and confirmed the reliability of POSTN by gene expression meta-analysis combining TCGA, Chinese Glioma Genome Atlas (CGGA) and REMBRANDT (Repository for Molecular Brain Neoplasia Data) GBM cohorts (hazard ratio, 1.71 [range, 1.47-2.07], n = 693) and LGG cohorts (hazard ratio, 2.55 [range, 1.61-4.05], n = 1226).
   CONCLUSIONS: By using available online glioma databases, our study provided an insight into the expression of POSTN as an independent predictor for patients with glioma (GBM and LGG) and could be useful for diagnostic simplification to identify high-risk groups.
C1 [Faried, Ahmad; Tjahjono, Firman P.; Arifin, Muhammad Z.] Univ Padjadjaran, Dept Neurosurg, Fac Med, Dr Hasan Sadikin Hosp, Bandung, West Java, Indonesia.
   [Faried, Ahmad; Hermanto, Yulius] Univ Padjadjaran, Fac Med, Oncol & Stem Cell Working Grp, Dr Hasan Sadikin Hosp, Bandung, West Java, Indonesia.
   [Valentino, Andrea] Univ Riau, Fac Med, Dept Surg, Neurosurg Div,Arifin Achmad Hosp, Pekanbaru, Riau, Indonesia.
RP Faried, A (reprint author), Univ Padjadjaran, Dept Neurosurg, Fac Med, Dr Hasan Sadikin Hosp, Bandung, West Java, Indonesia.; Faried, A (reprint author), Univ Padjadjaran, Fac Med, Oncol & Stem Cell Working Grp, Dr Hasan Sadikin Hosp, Bandung, West Java, Indonesia.
EM faried.fkup@gmail.com
OI Hermanto, Yulius/0000-0003-2937-8130
CR Aldape K, 2015, ACTA NEUROPATHOL, V129, P829, DOI 10.1007/s00401-015-1432-1
   Behnan J, 2019, BRAIN, V142, P847, DOI 10.1093/brain/awz044
   Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001
   Brat DJ, 2015, NEW ENGL J MED, V372, P2481, DOI 10.1056/NEJMoa1402121
   Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507
   Gonzalez-Gonzalez L, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00225
   Guan XW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091216
   Huang J, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00242
   Li T, 2017, CANCER RES, V77, P108
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Madhavan S, 2009, MOL CANCER RES, V7, P157, DOI 10.1158/1541-7786.MCR-08-0435
   Murtagh F, 2014, J CLASSIF, V31, P274, DOI 10.1007/s00357-014-9161-z
   Olar A, 2014, J PATHOL, V232, P165, DOI 10.1002/path.4282
   Park SY, 2016, MOL CANCER THER, V15, P2187, DOI 10.1158/1535-7163.MCT-15-0427
   Pencheva N, 2017, CELL REP, V20, P48, DOI 10.1016/j.celrep.2017.06.036
   Szklarczyk D, 2018, NUCLEIC ACIDS RES, V47, P607
   Szopa W, 2017, BIOMED RES INT, DOI 10.1155/2017/8013575
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   van den Bent MJ, 2017, NEURO-ONCOLOGY, V19, P614, DOI 10.1093/neuonc/now277
   Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020
   Wang HJ, 2013, INT J ONCOL, V42, P1716, DOI 10.3892/ijo.2013.1847
   Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003
   Wang Z, 2012, CELL STEM CELL, V10, P111, DOI 10.1016/j.stem.2012.01.002
   Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126
   Yi L, 2018, MOL MED REP, V18, P741, DOI 10.3892/mmr.2018.9011
   Yin W, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00419
   Zanotto-Filho A, 2017, CANCER LETT, V390, P176, DOI 10.1016/j.canlet.2016.12.015
   Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090
NR 30
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.077
PG 27
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600018
PM 31785437
DA 2020-05-12
ER

PT J
AU Fierstra, J
   Anon, J
   Mendelowitsch, I
   Fandino, J
   Diepers, M
   Remonda, L
   Marbacher, S
AF Fierstra, Jorn
   Anon, Javier
   Mendelowitsch, Itai
   Fandino, Javier
   Diepers, Michael
   Remonda, Luca
   Marbacher, Serge
TI Amended Intraoperative Neuronavigation: Three-Dimensional Vascular
   Roadmapping with Selective Rotational Digital Subtraction Angiography
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebrovascular neuronavigation; Intraoperative selective rotational
   digital subtraction angiography (3D-iDSA)
ID GUIDANCE
AB BACKGROUND: Accuracy of intraoperative cerebrovascular neuronavigation is difficult to maintain because of the ongoing need for brain shift correction. By including 3-dimensional rotational intraoperative digital subtraction angiography (3D-iDSA), the intraoperative cerebrovascular neuronavigation can be updated and upgraded throughout the microneurosurgical procedure. The aim of this technical note is to demonstrate the feasibility and advantage of updating and upgrading the accuracy of targeted cerebrovascular neuronavigation with an intraoperative 3D-DSA dataset.
   METHODS: A preoperative diagnostic selective 3D-DSA was registered with the neuronavigation software, followed by the automated segmentation of the vascular object of interest (an aneurysm in this case). After acquiring additional 3D-iDSA volumes, these steps were repeated, thereby updating the cerebrovascular roadmap and neuronavigation accuracy (i.e., brain shift correction).
   RESULTS: This technique was applied successfully in a patient who underwent elective microneurosurgical clipping of a right-sided middle cerebral artery (MCA) bifurcation aneurysm in a hybrid neurosurgical operating setting. After clipping of the MCA aneurysm, a selective 3D WA was performed that was then used to update the projection and accuracy of the initial 3D neurovascular object of interest (i.e., the aneurysm). In this revised rotational view, the projection refined the target segments of the clipped MCA aneurysm, the accuracy of clipping, and brain shift correction.
   CONCLUSIONS: 3D-iDSA vascular segmentations can update and upgrade the intraoperative neurovascular roadmap by thereby enhancing accuracy of cerebrovascular neuronavigation, as well as correcting brain shift. This technique is feasible within the hybrid operation room. Evaluation in larger series is required to support these findings.
C1 [Fierstra, Jorn; Mendelowitsch, Itai; Fandino, Javier; Marbacher, Serge] Kantonsspital Aarau, Dept Neurosurg, Aarau, Switzerland.
   [Anon, Javier; Diepers, Michael; Remonda, Luca] Kantonsspital Aarau, Div Intervent Neuroradiol, Aarau, Switzerland.
   [Fierstra, Jorn] Univ Zurich, Univ Hosp Zurich, Dept Neurosurg, Clin Neurosci Ctr, Zurich, Switzerland.
RP Fierstra, J (reprint author), Kantonsspital Aarau, Dept Neurosurg, Aarau, Switzerland.; Fierstra, J (reprint author), Univ Zurich, Univ Hosp Zurich, Dept Neurosurg, Clin Neurosci Ctr, Zurich, Switzerland.
EM jorn.fierstra@usz.ch
OI Fierstra, Jorn/0000-0001-6220-0727
CR Ayad M, 2007, NEUROSURGERY, V61, P55, DOI 10.1227/01.NEU.0000279998.18825.A9
   Cabrilo I, 2014, ACTA NEUROCHIR, V156, P1769, DOI 10.1007/s00701-014-2183-9
   Cabrilo I, 2014, OPER NEUROSURG, V10, P252, DOI 10.1227/NEU.0000000000000328
   Fandino J, 2013, ACTA NEUROCHIR SUPPL, V115, P113, DOI 10.1007/978-3-7091-1192-5_24
   Gonzalez LF, 2010, NEUROSURGERY, V67, P471, DOI 10.1227/01.NEU.0000372205.53792.E4
   Marbacher Serge, 2019, Neurosurgery, DOI 10.1093/neuros/nyz487
   Marbacher S, 2019, J NEUROSURG, V131, P64, DOI 10.3171/2018.1.JNS172253
   Raabe A, 2006, J NEUROSURG, V105, P406, DOI 10.3171/jns.2006.105.3.406
   Schaller K, 2011, ACTA NEUROCHIR SUPPL, V109, P111, DOI 10.1007/978-3-211-99651-5_18
   Stidd DA, 2014, J NEUROSURG, V121, P745, DOI 10.3171/2014.6.JNS132386
NR 10
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.055
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600130
PM 31863893
DA 2020-05-12
ER

PT J
AU Fluss, R
   Chan, AW
   Ligas, BA
   Rahme, R
   Ortiz, RA
   Ellis, JA
   Langer, DJ
AF Fluss, Rose
   Chan, Amber W.
   Ligas, Barbara A.
   Rahme, Ralph
   Ortiz, Rafael A.
   Ellis, Jason A.
   Langer, David J.
TI Monitoring Treatment Effectiveness in Intracranial Arteriovenous Shunt
   Lesions: Emerging Role of Quantitative Magnetic Resonance Venography for
   Intracranial Arteriovenous Shunts
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous malformation; Blood flow; Dural arteriovenous fistula;
   Embolization; Quantitative magnetic resonance venography
ID MALFORMATION HEMODYNAMICS; CAROTID-ARTERY; ANGIOGRAPHY
AB BACKGROUND: Quantitative magnetic resonance angiography (qMRA) using noninvasive optimal vessel analysis (NOVA) is a novel noninvasive imaging technique that is being increasingly used to measure blood flow in extracranial and intracranial arteries. By providing important quantitative flow data, NOVA qMRA can facilitate the management of cerebrovascular disease. While the same technology can also be applied to measure flow in intracranial and extracranial veins, NOVA quantitative MRV (qMRV) is only rarely used in neurovascular practice.
   CASE DESCRIPTION: We report interesting qMRV data in 2 patients with symptomatic intracranial arteriovenous shunts: a 61-year-old man with a left transverse-sigmoid dural arteriovenous fistula and a 40-year-old woman with a left parietal arteriovenous malformation. In each patient, NOVA qMRV demonstrated significant reduction of intracranial venous outflow after therapeutic obliteration of the shunt lesion, heralding marked clinical improvement.
   CONCLUSIONS: To the best of our knowledge, this is the first report of successful clinical application of NOVA qMRV in adult patients with intracranial arteriovenous malformations or dural arteriovenous fistulas. We propose that NOVA qMRV is a promising technique for noninvasive measurement of intracranial and extracranial venous blood flow and for monitoring treatment effectiveness in patients with intracranial arteriovenous shunt lesions.
C1 [Fluss, Rose; Rahme, Ralph] SBH Hlth Syst, Div Neurosurg, Bronx, NY USA.
   [Fluss, Rose] Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Chan, Amber W.; Ligas, Barbara A.; Rahme, Ralph; Ortiz, Rafael A.; Ellis, Jason A.; Langer, David J.] Zucker Sch Med Hofstra Northwell, Dept Neurosurg, Lenox Hill Hosp, New York, NY 11549 USA.
   [Rahme, Ralph] CUNY, Sch Med, New York, NY 10031 USA.
RP Langer, DJ (reprint author), Zucker Sch Med Hofstra Northwell, Dept Neurosurg, Lenox Hill Hosp, New York, NY 11549 USA.
EM dlanger@northwell.edu
OI Rahme, Ralph/0000-0003-1796-7296
CR Alaraj A, 2015, STROKE, V46, P942, DOI 10.1161/STROKEAHA.114.008569
   Calderon-Arnulphi M, 2011, AM J NEURORADIOL, V32, P1552, DOI 10.3174/ajnr.A2546
   Esfahani DR, 2015, NEUROSURGERY, V77, P254, DOI 10.1227/NEU.0000000000000771
   Furtado SV, 2019, J CLIN NEUROSCI, V61, P219, DOI 10.1016/j.jocn.2018.09.023
   GELWAN MJ, 1988, NEUROSURGERY, V22, P1079, DOI 10.1227/00006123-198806010-00020
   Langer DJ, 2006, J NEUROSURG, V104, P41, DOI 10.3171/ped.2006.104.1.41
   MacIntosh PW, 2014, SURV OPHTHALMOL, V59, P664, DOI 10.1016/j.survophthal.2014.01.010
   Rahme R, 2018, OPER NEUROSURG, V15, pE94, DOI 10.1093/ons/opy010
   SCHIFFER J, 1984, SURG NEUROL, V22, P524, DOI 10.1016/0090-3019(84)90316-1
   Shakur SF, 2018, J NEUROINTERV SURG, V10, P156, DOI 10.1136/neurintsurg-2017-012991
   Shakur SF, 2017, STROKE, V48, P1088, DOI 10.1161/STROKEAHA.116.015666
   Shakur SF, 2016, J CLIN NEUROSCI, V33, P119, DOI 10.1016/j.jocn.2016.02.034
   White TG, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2018.11.FOCUS18536
   Zhu FP, 2018, J NEUROSURG, V129, P677, DOI 10.3171/2017.5.JNS163112
NR 14
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.10.088
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600098
PM 31655230
DA 2020-05-12
ER

PT J
AU Foreman, PM
   Salem, MM
   Griessenauer, CJ
   Dmytriw, AA
   Parra-Farinas, C
   Nicholson, P
   Limbucci, N
   Kuhn, AL
   Puri, AS
   Renieri, L
   Nappini, S
   Kicielinski, KP
   Bugarini, A
   Pereira, VM
   Marotta, TR
   Schirmer, CM
   Ogilvy, CS
   Thomas, AJ
AF Foreman, Paul M.
   Salem, Mohamed M.
   Griessenauer, Christoph J.
   Dmytriw, Adam A.
   Parra-Farinas, Carmen
   Nicholson, Patrick
   Limbucci, Nicola
   Kuhn, Anna Luisa
   Puri, Ajit S.
   Renieri, Leonardo
   Nappini, Sergio
   Kicielinski, Kimberly P.
   Bugarini, Alejandro
   Pereira, Vitor Mendes
   Marotta, Thomas R.
   Schirmer, Clemens M.
   Ogilvy, Christopher S.
   Thomas, Ajith J.
TI Flow Diversion for Treatment of Partially Thrombosed Aneurysms: A
   Multicenter Cohort
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Complication; Flow diverter; Occlusion; Pipeline; Thrombosed
   aneurysm; Thrombus
ID PIPELINE EMBOLIZATION DEVICE; INTRACRANIAL ANEURYSMS; VERTEBRAL ARTERY;
   RUPTURE MECHANISM; GROWTH-MECHANISM; GIANT ANEURYSM; FOLLOW-UP;
   SYMPTOMS; OUTCOMES
AB BACKGROUND: Partially thrombosed intracranial aneurysms (PTIA) represent a unique subset of intracranial aneurysms with an ill-defined natural history, posing challenges to standard management strategies. This study aims to assess the efficacy of flow diversion in the treatment of this pathology.
   METHODS: A retrospective review of patients with flow-diverted PTIA at 6 cerebrovascular centers was performed. Clinical and radiographic data were collected from the medical records, with the primary outcome of aneurysmal occlusion and secondary outcomes of clinical status and complications.
   RESULTS: Fifty patients with 51 PTIA treated with flow diversion were included. Median age was 56.5 years. Thirty-three (64.7%) aneurysms were saccular and 16 (31.4%) were fusiform/dolichoectatic. The most common location was the internal carotid artery (54.9%) followed by the vertebral and basilar arteries (17.7% and 17.7%, respectively). Last imaging follow-up was performed at a median of 25.1 (interquartile range, 12.8-43) months. Complete occlusion at last radiographic follow-up was achieved in 37 (77.1%) aneurysms. Pretreatment aneurysm thrombosis of >50% was associated with a significantly lower rate of complete aneurysm occlusion (58.8 vs. 87.1%, P = 0.026) with a trend toward better functional outcome (modified Rankin scale <2) at last follow-up in patients with <50% pretreatment aneurysm thrombosis (96.8 vs. 82.4; P = 0.08). Ischemic complications occurred in 5 (9.8%) patients, producing symptoms in 4 (7.8%) and resultant mortality in 2 (4.2%) patients.
   CONCLUSIONS: Flow diversion treatment of PTIA has adequate efficacy along with a reasonable safety profile. Aneurysms harboring large amounts of pretreatment thrombus were associated with lower rates of complete occlusion.
C1 [Foreman, Paul M.; Griessenauer, Christoph J.; Bugarini, Alejandro; Schirmer, Clemens M.] Geisinger Hlth Syst, Dept Neurosurg, Danville, PA 17822 USA.
   [Foreman, Paul M.; Griessenauer, Christoph J.; Bugarini, Alejandro; Schirmer, Clemens M.] Geisinger Hlth Syst, Neurosci Inst, Danville, PA 17822 USA.
   [Salem, Mohamed M.; Kicielinski, Kimberly P.; Ogilvy, Christopher S.; Thomas, Ajith J.] Harvard Teaching Hosp, Beth Israel Deaconess Med Ctr, Div Neurosurg, Dept Radiol, Boston, MA USA.
   [Kuhn, Anna Luisa] Harvard Teaching Hosp, Beth Israel Deaconess Med Ctr, Div Neuroradiol, Dept Radiol, Boston, MA USA.
   [Puri, Ajit S.] Univ Massachusetts, Dept Radiol, Div Neuroimaging & Intervent, Mod Ctr, Worcester, MA 01605 USA.
   [Foreman, Paul M.] Orlando Hlth, Neurosci & Rehabil Lostinite, Orlando, FL 32806 USA.
   [Griessenauer, Christoph J.] Paracelsus Med Univ, Res Inst Neurointervent, Salzburg, Austria.
   [Dmytriw, Adam A.; Nicholson, Patrick; Pereira, Vitor Mendes] Univ Hlth Network, Toronto Western Hosp, Dept Med Imaging, Toronto, ON, Canada.
   [Parra-Farinas, Carmen; Marotta, Thomas R.] St Michaels Hosp, Dept Intervent Neuroradiol, Toronto, ON, Canada.
   [Limbucci, Nicola; Renieri, Leonardo; Nappini, Sergio] Univ Florence, Dept Intervent Neuroradiol, Florence, Italy.
RP Foreman, PM (reprint author), Geisinger Hlth Syst, Dept Neurosurg, Danville, PA 17822 USA.; Foreman, PM (reprint author), Geisinger Hlth Syst, Neurosci Inst, Danville, PA 17822 USA.; Foreman, PM (reprint author), Orlando Hlth, Neurosci & Rehabil Lostinite, Orlando, FL 32806 USA.
EM pforeman@geisinger.edu
OI Dmytriw, Adam/0000-0003-0131-5699; Nicholson,
   Patrick/0000-0001-7182-5112
CR Becske T, 2017, NEUROSURGERY, V80, P40, DOI 10.1093/neuros/nyw014
   Becske T, 2013, RADIOLOGY, V267, P858, DOI 10.1148/radiol.13120099
   Cho YD, 2010, NEURORADIOLOGY, V52, P751, DOI 10.1007/s00234-009-0622-8
   Chow M, 2012, AJNR Am J Neuroradiol, V33, pE46, DOI 10.3174/ajnr.A2532
   Chyatte D, 1999, NEUROSURGERY, V45, P1137, DOI 10.1097/00006123-199911000-00024
   Ferns SP, 2010, AM J NEURORADIOL, V31, P1197, DOI 10.3174/ajnr.A2057
   Guresir E, 2018, WORLD NEUROSURG, V118, pE834, DOI 10.1016/j.wneu.2018.07.063
   Iihara K, 2003, J NEUROSURG, V98, P407, DOI 10.3171/jns.2003.98.2.0407
   Kim SJ, 2000, INTERV NEURORADIOL, V6, P13, DOI 10.1177/159101990000600103
   Krings T, 2007, INTERV NEURORADIOL, V13, P117, DOI 10.1177/159101990701300201
   Krings T, 2005, NEURORADIOLOGY, V47, P931, DOI 10.1007/s00234-005-1438-9
   Kulcsar Z, 2011, AM J NEURORADIOL, V32, P20, DOI 10.3174/ajnr.A2370
   Lawton MT, 2005, NEUROSURGERY, V56, P441, DOI 10.1227/01.NEU.0000153927.70897.A2
   NAGAHIRO S, 1995, J NEUROSURG, V82, P796, DOI 10.3171/jns.1995.82.5.0796
   Nelson PK, 2011, AM J NEURORADIOL, V32, P34, DOI 10.3174/ajnr.A2421
   SCHUBIGER O, 1987, NEURORADIOLOGY, V29, P266, DOI 10.1007/BF00451765
   Szikora I, 2013, AM J NEURORADIOL, V34, P935, DOI 10.3174/ajnr.A3547
   Turowski B, 2011, NEURORADIOLOGY, V53, P37, DOI 10.1007/s00234-010-0676-7
   Yang K, 2014, ACTA NEUROCHIR, V156, P1669, DOI 10.1007/s00701-014-2147-0
   Yasui T, 1998, NEUROL MED-CHIR, V38, P860, DOI 10.2176/nmc.38.860
   Zanaty M, 2015, J CLIN NEUROSCI, V22, P105, DOI 10.1016/j.jocn.2014.05.033
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.084
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600019
PM 31760188
DA 2020-05-12
ER

PT J
AU Garton, ALA
   Gupta, VP
   Sudesh, S
   Zhou, H
   Christophe, BR
   Connolly, ES
AF Garton, Andrew L. A.
   Gupta, Vivek P.
   Sudesh, Saurabh
   Zhou, Henry
   Christophe, Brandon R.
   Connolly, E. Sander, Jr.
TI The Intracerebral Hemorrhage Score: Changing perspectives on Mortality
   and Disability
SO WORLD NEUROSURGERY
LA English
DT Article
DE Disability; Functional outcomes; ICH Score; Intracerebral hemorrhage;
   Mortality; Surgery; Withdrawal of care
ID PERIHEMATOMAL EDEMA; INTRAVENTRICULAR HEMORRHAGE; OUTCOMES; VALIDATION;
   PREDICTION; VOLUME
AB BACKGROUND: Intracerebral hemorrhage (ICH) remains a devastating diagnosis. While the ICH Score continues to be used in the clinical setting to prognosticate outcomes, contemporary improvements in management have reduced mortality rates for each scoring tier. The aims of this study were to examine mortality rates within ICH Score strata and examine if these findings are stable when major disability is included in categorizing poor outcomes.
   METHODS: From a single-institution cohort built be-tween 2009 and 2016, 582 patients were extracted based on the criteria for complete ICH Score, discharge mortality, and functional status for survivors. Mortality rates were stratified by ICH Score and compared with both historical and similar contemporary cohorts. Poor outcome was defined as severe disability (modified Rankin Scale score 5) in addition to death, stratified by ICH Score, and compared. A secondary analysis of patients with ICH Score of 2 was performed in light of the primary results.
   RESULTS: Mortality rates stratified by ICH Score were notably lower than expected for low- and moderate-grade ICH compared with the original cohort. However, when defining a poor outcome as including severe disability (modified Rankin Scale score 5) in addition to death, the rates for poor outcomes were higher for patients with ICH Score of 2 (51.16% vs. 26%, P = 0.017) and no different for any other score group compared with the original cohort.
   CONCLUSIONS: Though the original ICH Score over-estimates mortality for low-grade and moderate-grade hemorrhages, it may underpredict severe disability.
C1 [Garton, Andrew L. A.] New York Presbyterian Hosp, Dept Neurosurg, Weill Cornell Med Ctr, New York, NY 10032 USA.
   [Gupta, Vivek P.] Washington Univ, Sch Med, Dept Neurosurg, St Louis, MO USA.
   [Sudesh, Saurabh; Zhou, Henry; Christophe, Brandon R.; Connolly, E. Sander, Jr.] Columbia Univ, Dept Neurosurg, Vagelos Coll Phys & Surg, New York, NY USA.
RP Garton, ALA (reprint author), New York Presbyterian Hosp, Dept Neurosurg, Weill Cornell Med Ctr, New York, NY 10032 USA.
EM garton.ala@gmail.com
OI Gupta, Vivek/0000-0003-4814-2094; Garton, Andrew/0000-0003-4206-9084
CR Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766
   Boulouis G, 2017, J NEUROL NEUROSUR PS, V88, P339, DOI 10.1136/jnnp-2016-315346
   BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987
   Chan E, 2015, STROKE, V46, P653, DOI 10.1161/STROKEAHA.114.008470
   Cheung RTF, 2003, STROKE, V34, P1717, DOI 10.1161/01.STR.0000078657.22835.B9
   Christensen MC, 2009, STROKE, V40, P1677, DOI 10.1161/STROKEAHA.108.538967
   Fernandes H, 2002, STROKE, V33, P1455, DOI 10.1161/01.STR.0000018666.74574.9B
   Flaherty ML, 2006, NEUROLOGY, V66, P1182, DOI 10.1212/01.wnl.0000208400.08722.7c
   Gonzalez-Perez A, 2013, NEUROLOGY, V81, P559, DOI 10.1212/WNL.0b013e31829e6eff
   Grunwald Z, 2017, NEUROCRIT CARE, V26, P205, DOI 10.1007/s12028-016-0321-3
   Gupta VP, 2017, WORLD NEUROSURG, V101, P577, DOI 10.1016/j.wneu.2017.02.082
   Han JX, 2018, WORLD NEUROSURG, V109, pE601, DOI 10.1016/j.wneu.2017.10.039
   Hanger HC, 2000, CLIN REHABIL, V14, P417, DOI 10.1191/0269215500cr330oa
   Hanley DF, 2016, LANCET NEUROL, V15, P1226, DOI 10.1016/S1474-4422(16)30234-4
   Hemphill JC, 2009, NEUROLOGY, V73, P1088, DOI 10.1212/WNL.0b013e3181b8b332
   Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891
   Hung MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075605
   Hwang BY, 2010, NEUROCRIT CARE, V13, P141, DOI 10.1007/s12028-010-9382-x
   James ML, 2017, NEUROLOGY, V89, P1011, DOI 10.1212/WNL.0000000000004255
   Ji RJ, 2013, CRIT CARE, V17, DOI 10.1186/cc13130
   Jolink WMT, 2015, NEUROLOGY, V85, P1318, DOI 10.1212/WNL.0000000000002015
   Leasure AC, 2019, STROKE, V50, P2016, DOI 10.1161/STROKEAHA.119.024838
   Lekander I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174861
   Maas MB, 2013, NEUROLOGY, V80, P1295, DOI 10.1212/WNL.0b013e31828ab2a7
   Mar J, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0230-8
   McCracken DJ, 2019, NEUROSURGERY, V84, P741, DOI 10.1093/neuros/nyy193
   Murthy SB, 2015, STROKE, V46, P3088, DOI 10.1161/STROKEAHA.115.010054
   Phan TG, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00064
   Poon MTC, 2014, J NEUROL NEUROSUR PS, V85, P660, DOI 10.1136/jnnp-2013-306476
   Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8
   Rodriguez-Luna D, 2016, STROKE, V47, P350, DOI 10.1161/STROKEAHA.115.011295
   Rost NS, 2008, STROKE, V39, P2304, DOI 10.1161/STROKEAHA.107.512202
   Sallinen H, 2019, BRAIN BEHAV, V9, DOI 10.1002/brb3.1270
   Satopaa J, 2017, J NEUROL SCI, V379, P103, DOI 10.1016/j.jns.2017.05.034
   Sembill JA, 2017, NEUROLOGY, V89, P423, DOI 10.1212/WNL.0000000000004174
   Siddiqui FM, 2017, STROKE, V48, P2098, DOI 10.1161/STROKEAHA.117.017358
   Stern-Nezer S, 2017, NEUROREHABILITATION, V41, P179, DOI 10.3233/NRE-171470
   TUHRIM S, 1991, ANN NEUROL, V29, P658, DOI 10.1002/ana.410290614
   VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604
   Witsch J, 2016, ANN NEUROL, V80, P46, DOI 10.1002/ana.24675
   Wu YN, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00682
   Zahuranec DB, 2014, NEUROLOGY, V82, P2180, DOI 10.1212/WNL.0000000000000519
NR 42
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.074
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600068
PM 31870822
DA 2020-05-12
ER

PT J
AU Goel, A
   Jadhav, N
   Shah, A
   Rai, S
   Vutha, R
AF Goel, Atul
   Jadhav, Neha
   Shah, Abhidha
   Rai, Survendra
   Vutha, Ravikiran
TI Chiari Malformation and Syringomyelia Associated with Hirayama Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Atlantoaxial instability; Chiari formation; Hirayama disease;
   Syringomyelia
ID ATLANTOAXIAL INSTABILITY; MUSCULAR-ATROPHY; FIXATION; PLATE
AB BACKGROUND: To the best of our knowledge, the presence of Chiari formation and Hirayama disease in the same patient has not been previously reported. On the basis of the presented case, we have attempted to identify the common pathogenesis of both of these clinical entities.
   CASE DESCRIPTION: We have reported a case of a 23-year-old male patient had who presented with complaints of pain in the nape of neck and shoulders of 9 months' duration, weakness and stiffness in all 4 limbs, and wasting and weakness of muscles of both hands of 6 months' duration. The investigations showed Chiari formation and syringomyelia. Additional investigations depicted the characteristic radiological features associated with Hirayama disease. The patient was treated by atlantoaxial and multisegmental subaxial cervical spinal fixation.
   CONCLUSIONS: Spinal instability seems to be the nodal point of the pathogenesis of both Chiari formation and Hirayama disease.
C1 [Goel, Atul; Jadhav, Neha; Shah, Abhidha; Rai, Survendra; Vutha, Ravikiran] King Edward Mem Hosp, Dept Neurosurg, Mumbai, Maharashtra, India.
   [Goel, Atul; Jadhav, Neha; Shah, Abhidha; Rai, Survendra; Vutha, Ravikiran] Seth Gordhandas Sunderdas Med Coll, Mumbai, Maharashtra, India.
   [Goel, Atul] Lilavati Hosp & Res Ctr, Dept Neurosurg, Mumbai, Maharashtra, India.
RP Goel, A (reprint author), King Edward Mem Hosp, Dept Neurosurg, Mumbai, Maharashtra, India.; Goel, A (reprint author), Seth Gordhandas Sunderdas Med Coll, Mumbai, Maharashtra, India.; Goel, A (reprint author), Lilavati Hosp & Res Ctr, Dept Neurosurg, Mumbai, Maharashtra, India.
EM atulgoel62@hotmail.com
CR GOEL A, 1994, ACTA NEUROCHIR, V129, P47, DOI 10.1007/BF01400872
   Goel A, 2002, NEUROSURGERY, V51, P1351, DOI 10.1097/00006123-200212000-00004
   Goel A, 2019, NEUROSPINE, V16, P186, DOI 10.14245/ns.1938138.069
   Goel Atul, 2019, Acta Neurochir Suppl, V125, P101, DOI 10.1007/978-3-319-62515-7_15
   Goel A, 2017, WORLD NEUROSURG, V99, P186, DOI 10.1016/j.wneu.2016.11.143
   Goel A, 2015, J NEUROSURG-SPINE, V22, P116, DOI 10.3171/2014.10.SPINE14176
   Goel A, 2014, J CRANIOVERTEBRAL JU, V5, P3, DOI 10.4103/0974-8237.135206
   Guo X, 2014, J SPINAL DISORD TECH, V27, pE241, DOI 10.1097/BSD.0000000000000098
   Hirayama K, 2000, NEUROLOGY, V54, P1922, DOI 10.1212/WNL.54.10.1922
   Hirayama K, 1972, Rinsho Shinkeigaku, V12, P313
   Hirayama K, 1959, PSYCHIATR NEUROL JAP, V61, P2190
   Ito H, 2014, J NEUROSURG-SPINE, V21, P743, DOI 10.3171/2014.7.SPINE13955
   Nagaoka M, 1980, No To Shinkei, V32, P821
   Paredes I, 2014, J NEUROSURG-SPINE, V20, P191, DOI 10.3171/2013.10.SPINE13508
   Pradhan S, 2009, NEUROLOGY, V72, P2083, DOI 10.1212/WNL.0b013e3181aa5364
   ROYCAMILLE R, 1972, NOUV PRESSE MED, V1, P2484
   Shah A, 2019, WORLD NEUROSURG, V127, pE644, DOI 10.1016/j.wneu.2019.03.236
   Tokumaru Y, 2001, Rinsho Shinkeigaku, V41, P173
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.101
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600142
PM 31881343
DA 2020-05-12
ER

PT J
AU Gomez-Paz, S
   Maragkos, GA
   Salem, MM
   Ascanio, LC
   Lee, M
   Enriquez-Marulanda, A
   Orrego-Gonzalez, E
   Kicielinski, K
   Moore, JM
   Ogilvy, CS
   Thomas, AJ
AF Gomez-Paz, Santiago
   Maragkos, Georgios A.
   Salem, Mohamed M.
   Ascanio, Luis C.
   Lee, Michelle
   Enriquez-Marulanda, Alejandro
   Orrego-Gonzalez, Eduardo
   Kicielinski, Kimberly
   Moore, Justin M.
   Ogilvy, Christopher S.
   Thomas, Ajith J.
TI Symptomatic Hemorrhage From Cerebral Cavernous Malformations: Evidence
   from a Cohort Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cavernoma; Cavernous hemangioma; Cavernous malformation; Cerebrovascular
   malformations; Vascular malformation
ID NATURAL-HISTORY; BRAIN-STEM; PROPRANOLOL; MANAGEMENT; ANGIOMA
AB OBJECTIVE: Patients with a cerebral cavernous malformation (CCM) can have intracranial hemorrhages ranging from insignificant and chronic microbleeds to life-threatening hemorrhage. Management decisions and patient counseling are based on a heterogeneous body of evidence. We sought to improve the literature by providing our results based on the standardized definitions and aimed to delineate differences in the symptomatic burden for CCMs, based on their anatomic location and presence of developmental venous anomalies. This evidence will aid in clinical decision making and patient counseling.
   METHODS: A retrospective cohort analysis between 1990 and 2018 was performed, including patients with a diagnosis of a CCM. The primary outcome was acute symptomatic hemorrhages.
   RESULTS: We identified 438 patients harboring 632 CCMs. Mean age at diagnosis was 50 years (standard deviation +/- 17 years). Median follow-up was 26 months (interquartile range, 7-72 hours). Multiple lesions were encountered in 64 patients (15%). An initial symptomatic presentation was observed in 64% of the patients. There were 438 supratentorial lesions (69%) and 194 infratentorial lesions (31%). A symptomatic hemorrhage was observed in 25% of the supratentorial lesions and 29% of the infratentorial lesions (P < 0.001). A linear mixed-effects regression model showed a significant difference in developing a symptomatic hemorrhage at diagnosis or follow-up between CCMs with an infratentorial location and those with a supratentorial location (odds ratio, 1.81; 95% confidence interval, 1.17-2.81; P = 0.008).
   CONCLUSIONS: Infratentorial cavernous malformations are more likely to present with symptomatic hemorrhages at diagnosis or during follow-up when accounting for size differences between lesions.
C1 [Gomez-Paz, Santiago; Maragkos, Georgios A.; Salem, Mohamed M.; Ascanio, Luis C.; Lee, Michelle; Enriquez-Marulanda, Alejandro; Orrego-Gonzalez, Eduardo; Kicielinski, Kimberly; Moore, Justin M.; Ogilvy, Christopher S.; Thomas, Ajith J.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Neurosurg Serv, Boston, MA 02115 USA.
RP Thomas, AJ (reprint author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Neurosurg Serv, Boston, MA 02115 USA.
EM athomas6@bidmc.harvard.edu
OI Gomez-Paz, Santiago/0000-0003-2283-3612; Ascanio,
   Luis/0000-0001-9914-1599; Orrego Gonzalez, Eduardo
   Esteban/0000-0002-8406-4153; Maragkos, Georgios/0000-0003-2156-7391;
   Enriquez-Marulanda, Alejandro/0000-0001-6091-390X
CR Abla AA, 2011, NEUROSURGERY, V68, P403, DOI 10.1227/NEU.0b013e3181ff9cde
   AIBA T, 1995, J NEUROSURG, V83, P56, DOI 10.3171/jns.1995.83.1.0056
   Berti I, 2014, CLIN PEDIATR, V53, P189, DOI 10.1177/0009922813492885
   Bulters D, 2018, NAT REV NEUROL, V14, P416, DOI 10.1038/s41582-018-0020-0
   Clatterbuck RE, 2001, J NEUROL NEUROSUR PS, V71, P188, DOI 10.1136/jnnp.71.2.188
   DELCURLING O, 1991, J NEUROSURG, V75, P702, DOI 10.3171/jns.1991.75.5.0702
   Ellis JA, 2017, HAND CLINIC, V143, P283, DOI 10.1016/B978-0-444-63640-9.00027-8
   Flemming KD, 2017, JAMA NEUROL, V74, P801, DOI 10.1001/jamaneurol.2017.0439
   Goldberg J, 2019, J NEUROSURG, V130, P1931, DOI 10.3171/2017.12.JNS172404
   Gross BA, 2017, J NEUROSURG, V126, P1079, DOI 10.3171/2016.3.JNS152419
   Horne MA, 2016, LANCET NEUROL, V15, P166, DOI 10.1016/S1474-4422(15)00303-8
   Jeon JS, 2014, J NEUROL NEUROSUR PS, V85, P1366, DOI 10.1136/jnnp-2013-306844
   Kashefiolasl S, 2018, NEUROLOGY, V90, pE856, DOI 10.1212/WNL.0000000000005066
   KONDZIOLKA D, 1995, J NEUROSURG, V83, P820, DOI 10.3171/jns.1995.83.5.0820
   Labouge P, 2007, LANCET NEUROL, V6, P237, DOI 10.1016/S1474-4422(07)70053-4
   Miquel J, 2014, J AM ACAD DERMATOL, V70, pE83, DOI 10.1016/j.jaad.2013.11.006
   OTTEN P, 1989, NEUROCHIRURGIE, V35, P82
   Porter PJ, 1997, J NEUROSURG, V87, P190, DOI 10.3171/jns.1997.87.2.0190
   Porter RW, 1999, J NEUROSURG, V90, P50, DOI 10.3171/jns.1999.90.1.0050
   RIGAMONTI D, 1987, J NEUROSURG, V67, P518, DOI 10.3171/jns.1987.67.4.0518
   RIGAMONTI D, 1991, NEUROSURGERY, V28, P60, DOI 10.1227/00006123-199101000-00010
   Salman RAS, 2008, STROKE, V39, P3222, DOI 10.1161/STROKEAHA.108.515544
   SIMARD JM, 1986, NEUROSURGERY, V18, P162
   Stapleton CJ, 2018, STROKE, V49, P1029, DOI 10.1161/STROKEAHA.117.017074
   TOMLINSON FH, 1994, NEUROSURGERY, V34, P792, DOI 10.1227/00006123-199405000-00002
   TRUWIT CL, 1992, AM J ROENTGENOL, V159, P1299, DOI 10.2214/ajr.159.6.1442406
   Tu J, 2005, J NEUROSURG, V103, P903, DOI 10.3171/jns.2005.103.5.0903
   Wang CC, 2003, SURG NEUROL, V59, P444, DOI 10.1016/S0090-3019(03)00187-3
   Zabramski JM, 2016, WORLD NEUROSURG, V88, P631, DOI 10.1016/j.wneu.2015.11.003
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.035
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600056
PM 31843731
DA 2020-05-12
ER

PT J
AU Gong, S
   Xu, MT
   Tao, YQ
   Jin, H
   Liu, Y
   Sun, X
   Wang, SM
   Yang, XW
   Wang, Y
   Yuan, LJ
   Song, WL
AF Gong, Shun
   Xu, Menting
   Tao, Yingqun
   Jin, Hai
   Liu, Yang
   Sun, Xiao
   Wang, Shimiao
   Yang, Xingwang
   Wang, Yu
   Yuan, Lijia
   Song, Weilong
TI Comparison of Subthalamic Nucleus and Globus Pallidus Internus Deep
   Brain Stimulation Surgery on Parkinson Disease-Related Pain
SO WORLD NEUROSURGERY
LA English
DT Article
DE Deep brain stimulation; Globus pallidus internus; Pain; Parkinson
   disease; Subthalamic nucleus
ID SENSORY THRESHOLDS; FOLLOW-UP; DYSTONIA; SCALE
AB OBJECTIVE: To analyze and compare the effects of subthalamic nucleus (STN) deep brain stimulation (DBS) and globus pallidus internus (GPi)-DBS on Parkinson disease (PD)-related pain.
   METHODS: A retrospective study was performed of 64 patients (28 who underwent GPi-DBS and 36 who underwent STN-DBS) with PD-related pain in our hospital between January 2017 and July 2019. A numerical rating scale (NRS) was used to evaluate the degree of pain preoperatively and 4 months after operation, and the unified PD scale III (UPDRS-III) was completed simultaneously to assess motor symptoms.
   RESULTS: The average NRS score of all 64 patients after surgery was 1.09 +/- 1.39, which was significantly lower than that before operation (4.44 +/- 1.67; P < 0.0001). The improvement rate of NRS was 75 +/- 27% in the 28 GPi-DBS patients and 79 +/- 27% in the 36 STN-DBS patients, with no significant difference (P = 0.577). The improvements in NRS and UPDRS-III were significantly correlated in the STN-DBS group (r = 0.3707, P = 0.026) but not significantly correlated in the GPi-DBS group (P = 0.516).
   CONCLUSIONS: Both GPi-DBS and STN-DBS were effective for analyzing PD-related pain and seemed to have similar efficacy. This study provides an important first-step toward determining different DBS targets for controlling PD-related pain. Follow-up prospective research is an appropriate next step on the path to multicenter clinical trials.
C1 [Gong, Shun; Xu, Menting; Tao, Yingqun; Jin, Hai; Liu, Yang; Sun, Xiao; Wang, Shimiao; Yang, Xingwang; Wang, Yu; Yuan, Lijia; Song, Weilong] Gen Hosp Northern Theater Command, PLA Inst Neurol, Dept Neurosurg, Shenyang, Peoples R China.
RP Tao, YQ (reprint author), Gen Hosp Northern Theater Command, PLA Inst Neurol, Dept Neurosurg, Shenyang, Peoples R China.
EM yingquntao@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81870890]; Key Program of Scientific Natural
   Funding of Liaoning Province [20170540935]
FX This work was supported by the National Natural Science Foundation of
   China (Grant 81870890) and the Key Program of Scientific Natural Funding
   of Liaoning Province (Grant 20170540935).
CR Anderson BL, 2019, CUREUS, V11, DOI 10.7759/cureus.3838
   Becerra L, 2006, ANESTH ANALG, V103, P208, DOI 10.1213/01.ane.0000221457.71536.e0
   Beiske AG, 2009, PAIN, V141, P173, DOI 10.1016/j.pain.2008.12.004
   Belasen A, 2017, J NEUROSURG, V126, P397, DOI 10.3171/2016.2.JNS152231
   Belasen A, 2016, NEUROMODULATION, V19, P698, DOI 10.1111/ner.12453
   Chaudhuri KR, 2015, MOVEMENT DISORD, V30, P1623, DOI 10.1002/mds.26270
   Dafsari HS, 2018, BRAIN STIMUL, V11, P867, DOI 10.1016/j.brs.2018.02.015
   de Andrade DC, 2012, PAIN, V153, P1107, DOI 10.1016/j.pain.2012.02.016
   Dellapina E, 2012, PAIN, V153, P2267, DOI 10.1016/j.pain.2012.07.026
   DiMarzio M, 2018, NEUROMODULATION, V21, P617, DOI 10.1111/ner.12778
   Eggink F, 2018, PARKINSONISM RELAT D, V55, P26, DOI 10.1016/j.parkreldis.2018.06.024
   Hogg E, 2017, INT REV NEUROBIOL, V134, P1045, DOI [10.1016/bs.irn.2017.05.022, 10.1016/bs.im.2017.05.022]
   Holland MT, 2018, J CLIN NEUROSCI, V50, P190, DOI 10.1016/j.jocn.2018.01.036
   Honey CR, 1999, J NEUROSURG, V91, P198, DOI 10.3171/jns.1999.91.2.0198
   Hong L, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012378
   Hunsche S, 2013, STEREOT FUNCT NEUROS, V91, P328, DOI 10.1159/000350024
   Jung YJ, 2015, JAMA NEUROL, V72, P504, DOI 10.1001/jamaneurol.2015.8
   Khemani P, 2015, JAMA NEUROL, V72, P499, DOI 10.1001/jamaneurol.2015.36
   Kim HJ, 2012, NEUROSURGERY, V70, P18, DOI 10.1227/NEU.0b013e3182266664
   Liu Y, 2014, J NEUROSURG, V121, P709, DOI 10.3171/2014.4.JNS131711
   Loher TJ, 2002, J NEUROL NEUROSUR PS, V73, P395, DOI 10.1136/jnnp.73.4.395
   Marques A, 2013, NEUROLOGY, V81, P633, DOI 10.1212/WNL.0b013e3182a08d00
   Odekerken VJJ, 2013, LANCET NEUROL, V12, P37, DOI 10.1016/S1474-4422(12)70264-8
   Picillo M, 2016, BRAIN STIMUL, V9, P425, DOI 10.1016/j.brs.2016.02.004
   Rana AQ, 2017, CLIN NEUROL NEUROSUR, V160, P1, DOI 10.1016/j.clineuro.2017.05.022
   Russmann H, 2003, ARCH NEUROL-CHICAGO, V60, P351, DOI 10.1001/archneur.60.3.351
   Scherder E, 2005, NEUROSCI BIOBEHAV R, V29, P1047, DOI 10.1016/j.neubiorev.2005.03.001
   Sophie M, 2012, CNS DRUGS, V26, P937, DOI 10.1007/s40263-012-0005-2
   Surucu O, 2013, PAIN, V154, P1477, DOI 10.1016/j.pain.2013.03.008
   Valkovic P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136541
   Wong JK, 2019, PARKINSONISM RELAT D, V58, P56, DOI 10.1016/j.parkreldis.2018.08.017
   Xu F, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.4.FOCUS1815
NR 32
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.026
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600013
PM 31733388
DA 2020-05-12
ER

PT J
AU Guo, S
   Gerganov, V
   Giordano, M
   Samii, A
   Samii, M
AF Guo, Shunyu
   Gerganov, Venelin
   Giordano, Mario
   Samii, Amir
   Samii, Madjid
TI Elderly Patients with Frontobasal and Suprasellar Meningiomas: Safety
   and Efficacy of Tumor Removal via Frontolateral Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Elderly; Frontolateral approach; Frontobasal; Meningiomas; Suprasellar
ID OLFACTORY GROOVE MENINGIOMAS; INTRACRANIAL MENINGIOMAS; STEREOTACTIC
   RADIOSURGERY; RECURRENCE; SURGERY; EPIDEMIOLOGY
AB OBJECTIVE: Many neurosurgeons prefer conservative treatments in the elderly because of higher rates of mortality and morbidity after surgery. We aim to evaluate safety and efficacy of surgery in elderly patients with frontobasal and suprasellar meningiomas with a simple operative procedure, the frontolateral approach.
   METHODS: Retrospective analysis was made in consecutive patients with meningiomas operated via frontolateral approach. They were divided into 2 groups: elderly group (age >= 65 years) and young group (age < 65 years). Multivariate logistic regression analysis was performed for postoperative complications and Karnofsky Performance Scale score (KPS).
   RESULTS: The study comprises 128 patients operated over a 19-year period, of which 35 patients were in the elderly group and 93 patients were in the young group. More elderly patients presented with American Society of Anesthesiology (ASA) class II and III (57.1% vs. 43%). Gross resection was achieved in 31 cases in the elderly and 85 cases in young group (88.6% vs. 90.3%, P = 0.17). Postoperative KPS in both groups was improved (85.7% vs. 91.4%, P = 0.18). One death occurred in elderly group (2.9%, P = 0.27). Approach-related and medical morbidity in the elderly group was slightly higher than in the young group without significant difference (respectively, 11.4% and 14.3% vs. 9.7% and 8.6%, P = 0.18). Multivariate logistic regression showed increasing age was not associated with approach-related morbidity (odds ratio [OR]: 1.39, P = 0.53), medical morbidity (OR: 1.94, P = 0.88), and improvement of KPS (OR: 0.32, P = 0.25).
   CONCLUSIONS: Frontobasal and suprasellar meningiomas in elderly patients can be treated surgically with acceptably low morbidity and mortality rates via the frontolateral approach. Preoperative KPS score <= 60 and ASA classification >= III predict an unfavorable postoperative outcome.
C1 [Guo, Shunyu; Gerganov, Venelin; Giordano, Mario; Samii, Amir; Samii, Madjid] Int Neurosci Inst, Dept Neurosurg, Hannover, Germany.
RP Guo, S (reprint author), Int Neurosci Inst, Dept Neurosurg, Hannover, Germany.
EM guo@ini-hannover.de
FU China Scholarship Council (CSC)China Scholarship Council [201708440234]
FX Great gratitude for the support from China Scholarship Council (CSC no.
   201708440234). Special thanks to colleagues in the neurosurgery clinic
   and document stations at the International Neuroscience Institute.
CR ARIENTA C, 1990, ACTA NEUROCHIR, V107, P47, DOI 10.1007/BF01402612
   BROCK M, 1978, NEUROCHIRURGIA, V21, P185
   Brokinkel B, 2017, J NEUROSURG, V126, P1201, DOI 10.3171/2016.2.JNS152611
   Cahill KS, 2011, J NEUROSURG, V115, P259, DOI 10.3171/2011.3.JNS101748
   Cohen-Inbar O, 2010, ACTA NEUROCHIR, V152, P87, DOI 10.1007/s00701-009-0552-6
   DJINDJIAN M, 1988, ACTA NEUROCHIR, V90, P121, DOI 10.1007/BF01560565
   Dolecek TA, 2015, CANCER-AM CANCER SOC, V121, P2400, DOI 10.1002/cncr.29379
   Giordano M, 2018, WORLD NEUROSURG, V114, pE1002, DOI 10.1016/j.wneu.2018.03.131
   Grossman R, 2011, WORLD NEUROSURG, V75, P279, DOI 10.1016/j.wneu.2010.09.003
   Hasegawa H, 2018, OPER NEUROSURG, V14, P341, DOI 10.1093/ons/opx109
   Hernesniemi J, 2005, ACT NEUR S, V94, P17
   Ikawa F, 2017, NEUROL MED-CHIR, V57, P521, DOI 10.2176/nmc.ra.2017-0011
   MAURICEWILLIAMS RS, 1992, BRIT J NEUROSURG, V6, P131, DOI 10.3109/02688699209002915
   Nakamura M, 2006, NEUROSURGERY, V58, P626, DOI 10.1227/01.NEU.0000197104.78684.5D
   Nakamura M, 2003, NEUROSURGERY, V53, P62, DOI 10.1227/01.NEU.0000068730.76856.58
   Nakamura M, 2007, NEUROSURGERY, V60, P844, DOI 10.1227/01.NEU.0000255453.20602.80
   Nakamura M, 2006, NEUROSURGERY, V59, P1019, DOI 10.1227/01.NEU.0000245600.92322.06
   Ostrom QT, 2018, NEURO-ONCOLOGY, V20, P1, DOI 10.1093/neuonc/noy131
   PAPO I, 1983, ACTA NEUROCHIR, V67, P195, DOI 10.1007/BF01401421
   Patil CG, 2010, J NEUROL NEUROSUR PS, V81, P502, DOI 10.1136/jnnp.2009.185074
   Pollock BE, 2003, INT J RADIAT ONCOL, V55, P1000, DOI 10.1016/S0360-3016(02)04356-0
   Roser F, 2007, J CLIN NEUROSCI, V14, P224, DOI 10.1016/j.jocn.2005.12.004
   Sacko O, 2007, NEUROSURGERY, V61, P950, DOI 10.1227/01.neu.0000303190.80049.7d
   Salma A, 2011, NEUROSURGERY S, V68, P364
   Salma A, 2011, NEUROSURGERY, V68, P364, DOI 10.1227/NEU.0b013e318211721f
   SEKHAR LN, 1992, J NEUROSURG, V76, P198, DOI 10.3171/jns.1992.76.2.0198
   SIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22
   Spektor S, 2005, NEUROSURGERY, V57, P268, DOI 10.1227/01.NEU.0000176409.70668.EB
   Starke RM, 2015, J NEUROSURG, V122, P363, DOI 10.3171/2014.10.JNS14198
   Thompson N, 1977, RECONSTRUCTIVE PLAST, P293
   Tin-Chung Poon M, 2013, INT J SURG, V11, P656
   Zhao XC, 2018, J CLIN NEUROSCI, V56, P143, DOI 10.1016/j.jocn.2018.06.011
NR 32
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.029
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600053
PM 31843725
DA 2020-05-12
ER

PT J
AU Gutierrez, S
   Huynh, T
   Iwanaga, J
   Dumont, AS
   Bui, CJ
   Tubbs, RS
AF Gutierrez, Santiago
   Huynh, Trong
   Iwanaga, Joe
   Dumont, Aaron S.
   Bui, C. J.
   Tubbs, R. Shane
TI A Review of the History, Anatomy, and Development of the C1 Spinal Nerve
SO WORLD NEUROSURGERY
LA English
DT Review
DE C1 spinal nerve; Development; Occipital neuralgia; Review; Suboccipital
   nerve
ID ACCESSORY NERVE; POSTERIOR ROOT; CLINICAL ANATOMY; HYPOGLOSSAL;
   CONNECTIONS; GANGLION
AB The C1 spinal nerve is a fascinating anatomic structure owing to its wide range of variations. Throughout history, understanding of the cranial and spinal nerves has probably influenced the current conception of this nerve among anatomists. Located at the craniocervical junction, the C1 spinal nerve contributes to the motor innervation of deep cervical muscles through the cervical (anterior) and Cruveilhier's (posterior) plexuses. Sensory functions of this nerve are more enigmatic; despite investigations into its dorsal rootlets, a dorsal root ganglion, and the relationships between this nerve and adjacent cranial and spinal nerves, there is still no consensus regarding its true anatomy. In this article, we review the available literature and discuss some of the developmental models that could potentially explain the wide range of variations and functions of the C1 nerve.
C1 [Gutierrez, Santiago] Pontificia Univ Javeriana, Bogota, Colombia.
   [Huynh, Trong] Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ USA.
   [Iwanaga, Joe; Dumont, Aaron S.; Tubbs, R. Shane] Tulane Univ, Sch Med, Dept Neurosurg, 1430 Tulane Ave, New Orleans, LA 70112 USA.
   [Tubbs, R. Shane] Tulane Univ, Sch Med, Dept Struct & Cellular Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA.
   [Bui, C. J.] Ochsner Med Ctr, Dept Neurosurg, New Orleans, LA USA.
   [Tubbs, R. Shane] St Georges Univ, Dept Anat Sci, St Georges, Grenada.
RP Iwanaga, J (reprint author), Tulane Univ, Sch Med, Dept Neurosurg, 1430 Tulane Ave, New Orleans, LA 70112 USA.
EM iwanagajoeca@gmail.com
OI Gutierrez-Gomez, Santiago/0000-0003-1326-8308
CR Benninger B, 2010, NEUROL RES INT, V2010, DOI 10.1155/2010/476018
   Brazis PW, 2011, LOCALIZATION CLIN NE
   Butera G., 2003, NEUROMORFOFISIOLOGIA
   Campos D., 2012, Journal of Morphological Sciences, V29, P65
   Catala M, 2013, HAND CLINIC, V115, P29, DOI 10.1016/B978-0-444-52902-2.00003-5
   Cho KH, 2015, CHILD NERV SYST, V31, P95, DOI 10.1007/s00381-014-2546-9
   Dobson J., 1962, ANATOMICAL EPONYMS
   Edwards B, 2018, CUREUS, V10, DOI 10.7759/cureus.2172
   Erhart EA, 1974, NEUROANATOMIA
   Ericsson R, 2013, J ANAT, V222, P67, DOI 10.1111/j.1469-7580.2012.01530.x
   HOLLIGER A, 1955, Arch Anat Histol Embryol, V38, P1
   Hollinshead WH, 1982, ANATOMY SURG HEAD NE
   Iwanaga J, 2017, WORLD NEUROSURG, V100, P590, DOI 10.1016/j.wneu.2017.01.038
   Kazzander G, 1891, ANAT ANZEIGER, V6, P444
   KURATANI S, 1988, AM J ANAT, V182, P155, DOI 10.1002/aja.1001820206
   Lake S, 2018, CUREUS, V10, DOI 10.7759/cureus.2933
   Lang J., 1993, CLIN ANATOMY CERVICA
   Latarjet M, 2004, ANATOMIA HUMANA
   LIM TM, 1987, DEVELOPMENT, V100, P525
   Offiah CE, 2017, INSIGHTS IMAGING, V8, P29, DOI 10.1007/s13244-016-0530-5
   Oh CS, 2002, CLIN ANAT, V15, P267, DOI 10.1002/ca.10026
   Orhan M, 2009, SURG RADIOL ANAT, V31, P107, DOI 10.1007/s00276-008-0414-6
   OUAKNINE G, 1973, J NEUROSURG, V38, P189, DOI 10.3171/jns.1973.38.2.0189
   Shoja MM, 2018, CLIN ANAT, V31, P488, DOI 10.1002/ca.23048
   Swanson LW, 2015, NEUROANATOMICAL TERM
   Tada MN, 2015, ZOOL LETT, V1, DOI 10.1186/s40851-014-0006-8
   Testut L, 1977, TRATADO ANATOMIA HUM, V3
   Tubbs RS, 2007, CLIN ANAT, V20, P624, DOI 10.1002/ca.20472
   Tubbs RS, 2011, J NEUROSURG, V115, P929, DOI 10.3171/2011.5.JNS102058
   Tubbs RS, 2009, J NEUROSURG-SPINE, V10, P390, DOI 10.3171/2008.12.SPINE08661
   Tubbs R, 2009, SURG RADIOL ANAT, V31, P173, DOI 10.1007/s00276-008-0422-6
   Verberne ME, 1999, ANAT RECORD, V255, P407
   WILLIAMS PL, 1995, GRAYS ANATOMY ANATOM
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.024
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600161
PM 31838236
DA 2020-05-12
ER

PT J
AU Hafez, A
   Elsharkawy, A
   Schwartz, C
   Muhammad, S
   Laakso, A
   Niemela, M
   Lehecka, M
AF Hafez, Ahmad
   Elsharkawy, Ahmed
   Schwartz, Christoph
   Muhammad, Sajjad
   Laakso, Aki
   Niemela, Mika
   Lehecka, Martin
TI Comparison of Conventional Microscopic and Exoscopic Experimental Bypass
   Anastomosis. A Technical Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE 3D exoscope; Bypass; Continuous suture; Interrupted suture; Practical
   bypass scale
ID HIGH-DEFINITION EXOSCOPE; MICRONEUROSURGERY; SIMULATION; NEUROSURGERY;
   EXPERIENCE; MODEL
AB BACKGROUND: Recently, the use of digital exoscopes been increasingly promoted as an alternative to microscopes. The aim of this study is to compare experimental bypass quality in both visualization methods.
   METHODS: This study used two hundred 1-mm chicken wing vessels, which were used for either exoscopic or microscopic (100 samples each) bypass procedures. All procedures were recorded between July 2018 and September 2018. The bypass quality was evaluated according to our published practical scale (time, stitch distribution, intima-intima attachment, and orifice size).
   RESULTS: Both methods are effective in doing bypass aring (practical scale score was good, 86% vs. 85%; P = 0.84). There were no significant differences regarding intima-intima attachment (P = 0.26) and orifice size (P = 0.25). However, suturing time (P< 0.001) was less using the microscope, whereas stitch distribution (P = 0.001) was better using the exoscope. Different suturing techniques (interrupted vs. continuous) had overall comparable results (P = 0.55).
   CONCLUSIONS: Both methods produced equally satisfactory results in experimental bypass procedures. The exoscope has the potential for better 3-dimensional visualization and sharing the surgeon's view with others for teaching purposes.
C1 [Hafez, Ahmad; Elsharkawy, Ahmed; Schwartz, Christoph; Muhammad, Sajjad; Laakso, Aki; Niemela, Mika; Lehecka, Martin] Helsinki Univ Hosp, Dept Neurosurg, Helsinki, Finland.
   [Elsharkawy, Ahmed] Tanta Univ, Dept Neurosurg, Tanta, Egypt.
   [Schwartz, Christoph] Paracelsus Med Univ, Dept Neurosurg, Salzburg, Austria.
   [Muhammad, Sajjad] Heinrich Heine Univ, Med Fac, Dept Neurosurg, Dusseldorf, Germany.
RP Hafez, A (reprint author), Helsinki Univ Hosp, Dept Neurosurg, Helsinki, Finland.
EM ext-ahmad.hafez@hus.fi
OI Muhammad, Sajjad/0000-0002-6734-7979; Lehecka,
   Martin/0000-0003-4088-1116; Laakso, Aki/0000-0002-5312-4926
CR Aboud E, 2002, J NEUROSURG, V97, P1367, DOI 10.3171/jns.2002.97.6.1367
   Aboud E, 2015, J NEUROSURG, V123, P1339, DOI 10.3171/2014.12.JNS141551
   Aboud ET, 2011, J TRAUMA, V71, P1484, DOI 10.1097/TA.0b013e3182396337
   Belykh Evgenii, 2018, Surg Neurol Int, V9, P115, DOI 10.4103/sni.sni_36_18
   Birch K, 2014, J CLIN NEUROSCI, V21, P1245, DOI 10.1016/j.jocn.2013.10.026
   Chalouhi N, 2015, J NEUROSURG, V123, P1113, DOI 10.3171/2014.10.JNS141564
   Choudhury Nusrat, 2013, World Neurosurg, V80, pe9, DOI 10.1016/j.wneu.2012.08.022
   Chowdhry SA, 2014, NEUROSURGERY, V74, pS198, DOI 10.1227/NEU.0000000000000225
   Eivazi S, 2017, ACTA NEUROCHIR, V159, P959, DOI 10.1007/s00701-017-3185-1
   Ezra DG, 2009, OPHTHALMOLOGY, V116, P257, DOI 10.1016/j.ophtha.2008.09.038
   Hafez A, 2019, WORLD NEUROSURG, V121, pE111, DOI 10.1016/j.wneu.2018.09.031
   Hafez Ahmad, 2017, Surg Neurol Int, V8, P295, DOI 10.4103/sni.sni_322_17
   Harnof S, 2013, ISR MED ASSOC J, V15, P489
   Herlan S, 2019, OPER NEUROSURG, V17, P518, DOI 10.1093/ons/opz081
   Hernesniemi J, 2005, SURG NEUROL, V64, P195, DOI 10.1016/j.surneu.2005.04.031
   Higurashi M, 2014, J CLIN NEUROSCI, V21, P554, DOI 10.1016/j.jocn.2013.07.029
   Khalessi AA, 2019, OPER NEUROSURG, V16, P717, DOI 10.1093/ons/opy320
   Krishnan KG, 2017, WORLD NEUROSURG, V97, P652, DOI 10.1016/j.wneu.2016.09.037
   Kwan K, 2019, OPER NEUROSURG, V16, P619, DOI 10.1093/ons/opy196
   Lipsman N, 2017, WORLD NEUROSURG, V99, P381, DOI 10.1016/j.wneu.2016.12.039
   Mokhtari P, 2017, WORLD NEUROSURG, V108, P230, DOI 10.1016/j.wneu.2017.08.132
   Muhammad S, 2019, ACTA NEUROCHIR, V161, P1515, DOI 10.1007/s00701-019-03976-4
   Nishiyama K, 2017, J KOREAN NEUROSURG S, V60, P289, DOI 10.3340/jkns.2017.0202.003
   Nossek E, 2019, OPER NEUROSURG, V17, P157, DOI 10.1093/ons/opy342
   Regelsberger J, 2011, CENT EUR NEUROSURG, V72, P192, DOI 10.1055/s-0030-1261906
   Rehder R, 2016, CHILD NERV SYST, V32, P43, DOI 10.1007/s00381-015-2923-z
   Ricciardi L, 2019, WORLD NEUROSURG, V127, P653, DOI 10.1016/j.wneu.2019.04.078
   Rossini Z, 2017, WORLD NEUROSURG, V107, P663, DOI 10.1016/j.wneu.2017.08.083
   Sack J, 2018, OPER NEUROSURG, V14, P395, DOI 10.1093/ons/opx145
   Sarkiss CA, 2016, WORLD NEUROSURG, V89, P1, DOI 10.1016/j.wneu.2015.12.052
   Yadav YR, 2016, J NEUROL SURG PART A, V77, P146, DOI 10.1055/s-0034-1376190
   Yasargil MG, 2010, J NEUROSURG, V112, P1163, DOI 10.3171/2009.7.JNS091124
   Yasargil MG, 1999, NEUROSURGERY, V45, P1025
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.154
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600033
PM 31805406
DA 2020-05-12
ER

PT J
AU Hatano, K
   Kawamura, D
   Ohashi, H
   Hamaguchi, T
   Hattanmaru, Y
   Tani, S
   Murayama, Y
AF Hatano, Keisuke
   Kawamura, Daichi
   Ohashi, Hiroki
   Hamaguchi, Takayuki
   Hattanmaru, Yoshiyasu
   Tani, Satoshi
   Murayama, Yuichi
TI Total Spinal Epidural "Blood Patch" Application Through a Racz Catheter
   in Spontaneous Intracranial Hypotension
SO WORLD NEUROSURGERY
LA English
DT Article
DE Epidural blood patch; Racz catheter; Spontaneous intracranial
   hypotension
ID CEREBROSPINAL-FLUID LEAKS; EFFICACY
AB BACKGROUND: Epidural "blood patch" (EBP) is a standard treatment of itaneous intracranial hypotension (SIH). In recent years, there are some reports of Racz catheter use for EBP performance at upper cervical spine levels. However, the practical use of Racz catheter for single-entry multisite EBP has never been reported until now.
   CASE DESCRIPTION: We treated a 60-year-old man diagnosed with SIH presenting with cerebrospinal fluid leaks from the cervical to the sacral segments. We discuss the advantages of the single-entry multisite EBP and the convenience of Racz catheter use in such cases.
   CONCLUSIONS: The Racz catheter can be a convenient means to deliver large-volume EBPs from a single entry point in the treatment of SIH.
C1 [Hatano, Keisuke; Kawamura, Daichi; Ohashi, Hiroki; Tani, Satoshi; Murayama, Yuichi] Jikei Univ, Dept Neurosurg, Sch Med, Minato Ku, Tokyo, Japan.
   [Hamaguchi, Takayuki; Hattanmaru, Yoshiyasu] Jikei Univ, Dept Anesthesiol, Sch Med, Minato Ku, Tokyo, Japan.
RP Hatano, K (reprint author), Jikei Univ, Dept Neurosurg, Sch Med, Minato Ku, Tokyo, Japan.
EM hatakenosuke@gmail.com
CR Berroir S, 2004, NEUROLOGY, V63, P1950, DOI 10.1212/01.WNL.0000144339.34733.E9
   Cho KI, 2011, NEUROLOGY, V76, P1139, DOI 10.1212/WNL.0b013e318212ab43
   Griauzde J, 2014, AM J NEURORADIOL, V35, P1841, DOI 10.3174/ajnr.A3945
   Kanao-Kanda M, 2019, J CLIN ANESTH, V57, P122, DOI 10.1016/j.jclinane.2019.04.022
   Kwon SY, 2014, PAIN PHYSICIAN, V17, pE381
   Mokri B, 1999, MAYO CLIN PROC, V74, P1113, DOI 10.4065/74.11.1113
   Murphy David, 2015, Asian J Neurosurg, V10, P262, DOI 10.4103/1793-5482.161168
   Ohtonari T, 2018, WORLD NEUROSURG, V118, pE276, DOI 10.1016/j.wneu.2018.06.171
   Ohtonari T, 2012, J NEUROSURG, V116, P1049, DOI 10.3171/2012.1.JNS111568
   RACZ GB, 1982, JAMA-J AM MED ASSOC, V248, P579, DOI 10.1001/jama.248.5.579
   Sencakova D, 2001, NEUROLOGY, V57, P1921, DOI 10.1212/WNL.57.10.1921
   Yoshida H, 2014, J NEUROSURG-SPINE, V21, P432, DOI 10.3171/2014.5.SPINE13549
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.169
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600119
PM 31816456
DA 2020-05-12
ER

PT J
AU He, JQ
   Iv, M
   Li, G
   Zhang, M
   Gephart, MH
AF He, Joy Qiyue
   Iv, Michael
   Li, Gordon
   Zhang, Michael
   Gephart, Melanie Hayden
TI Noncontrast T2-Weighted Magnetic Resonance Imaging Sequences for
   Long-Term Monitoring of Asymptomatic Convexity Meningiomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Contrast; Gadolinium; Long-term follow-up; Meningioma; MRI
ID NEPHROGENIC SYSTEMIC FIBROSIS; RESPIRATORY-DISTRESS-SYNDROME;
   HIGH-SIGNAL INTENSITY; DENTATE NUCLEUS; GADOLINIUM DEPOSITION;
   GLOBUS-PALLIDUS; CONTRAST; BRAIN; IMAGES; GADODIAMIDE
AB BACKGROUND: Gadolinium-based contrast agents (GBCAs) used to enhance magnetic resonance imaging (MRI) scans have been linked to tissue deposition, including in the brain. The management of indolent tumors such as meningiomas requires frequent MRI scans to monitor for interval growth. Given concern regarding GBCA deposition, we sought to determine if noncontrast MRI scans in patients with asymptomatic meningiomas were equivalent to GBCA-enhanced MRI scans in surveillance monitoring.
   METHODS: This institutional review hoard-approved retrospective chart review included 106 MRI sequences from 18 patients. Inclusion criteria were adult patients with asymptomatic meningiomas who received baseline contrast-enhanced and noncontrast axial brain MRI scan. Exclusion criteria included the following: 1) baseline or follow-up axial images were not available for review, 2) baseline scan was obtained without contrast, and 3) diagnosis of meningioma was uncertain. Percent tumor growth was measured by comparing cross-sectional area at maximum tumor diameter from the earliest and most recent scans. For each patient, change in tumor size over time was compared using T1 + contrast, T2, and T2 fluid-attenuated inversion recovery (FLAIR) sequences. These were compared with a qualitative consensus reading by a neurosurgeon and a neuroradiologist.
   RESULTS: Measured change of greater than 10% was taken to represent tumor growth. In 17 out of 18 patients, measurement of noncontrast studies (T2 and T2 FLAIR) matched consensus. For one patient, imaging on T2 suggested 11% growth, whereas T2 FLAIR and overall consensus was stability.
   CONCLUSIONS: Our study provides evidence that noncontrasted MRI scans are equivalent to contrast-weighted MRI scans to follow change in tumor size over time in asymptomatic meningiomas.
C1 [He, Joy Qiyue; Li, Gordon; Zhang, Michael; Gephart, Melanie Hayden] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA.
   [Iv, Michael] Stanford Univ, Dept Radiol Neuroimaging & Neurointervent, Stanford, CA 94305 USA.
RP Gephart, MH (reprint author), Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA.
EM mghayden@stanford.edu
OI Zhang, Michael/0000-0002-7067-0689
CR Canavese C, 2008, J NEPHROL, V21, P324
   Collidge TA, 2007, RADIOLOGY, V245, P168, DOI 10.1148/radiol.2451070353
   Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218
   Errante Y, 2014, INVEST RADIOL, V49, P685, DOI 10.1097/RLI.0000000000000072
   Forsting M, 2010, EUR J RADIOL, V74, pE187, DOI 10.1016/j.ejrad.2009.06.005
   Grobner T, 2006, NEPHROL DIAL TRANSPL, V21, P1104, DOI 10.1093/ndt/gfk062
   Kanda T, 2015, RADIOLOGY, V276, P228, DOI 10.1148/radiol.2015142690
   Kanda T, 2014, RADIOLOGY, V270, P834, DOI 10.1148/radiol.13131669
   Kerget B, 2018, RESPIR MED CASE REP, V25, P336, DOI 10.1016/j.rmcr.2018.10.018
   Lancelot E, 2016, INVEST RADIOL, V51, P691, DOI 10.1097/RLI.0000000000000280
   Marckmann P, 2006, J AM SOC NEPHROL, V17, P2359, DOI 10.1681/ASN.2006060601
   McDonald RJ, 2017, RADIOLOGY, V285, P536, DOI 10.1148/radiol.2017161594
   McDonald RJ, 2017, RADIOLOGY, V285, P546, DOI 10.1148/radiol.2017161595
   McDonald RJ, 2015, RADIOLOGY, V275, P772, DOI 10.1148/radiol.15150025
   Murata N, 2016, MAGN RESON IMAGING, V34, P1359, DOI 10.1016/j.mri.2016.08.025
   Murata N, 2016, INVEST RADIOL, V51, P447, DOI 10.1097/RLI.0000000000000252
   Oya S, 2011, J NEUROSURG, V114, P1250, DOI 10.3171/2010.12.JNS101623
   Park J, 2015, YONSEI MED J, V56, P1155, DOI 10.3349/ymj.2015.56.4.1155
   Prybylski JP, 2019, MAGN RESON IMAGING, V55, P140, DOI 10.1016/j.mri.2018.10.006
   Radbruch A, 2015, INVEST RADIOL, V50, P805, DOI 10.1097/RLI.0000000000000227
   Sanyal S, 2011, NEPHROL DIAL TRANSPL, V26, P3616, DOI 10.1093/ndt/gfr085
   Schad SG, 2013, J CUTAN PATHOL, V40, P935, DOI 10.1111/cup.12214
   Sherry AD, 2009, J MAGN RESON IMAGING, V30, P1240, DOI 10.1002/jmri.21966
   Stratta P, 2008, CURR MED CHEM, V15, P1229, DOI 10.2174/092986708784310396
   Tamrazi B, 2016, NEUROSURG CLIN N AM, V27, P137, DOI 10.1016/j.nec.2015.11.004
NR 25
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.051
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600014
PM 31734418
DA 2020-05-12
ER

PT J
AU Huang, AE
   Noland, SS
   Spinner, RJ
   Bishop, AT
   Shin, AY
AF Huang, Alice E.
   Noland, Shelley S.
   Spinner, Robert J.
   Bishop, Allen T.
   Shin, Alexander Y.
TI Outcomes of Reconstructive Surgery in Traumatic Brachial Plexus Injury
   with Concomitant Vascular Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult traumatic brachial plexus; Surgical outcomes; Vascular injury
ID SCAPULOTHORACIC DISSOCIATION; NERVE INJURIES; SURGICAL-TREATMENT;
   AVULSION INJURIES; UPPER-LIMB; MANAGEMENT; SHOULDER; RESTORATION;
   LESIONS; REPAIR
AB OBJECTIVE: To investigate functional outcome from reconstructive surgery in adult traumatic brachial plexus injury (AT-BPI) with associated vascular lesions.
   METHODS: A retrospective review was performed of 325 patients with AT-BPI who underwent reconstructive surgery between 2001 and 2012. Patients with (vascular group) and without (control group) vascular injuries were identified by review of medical documentation. Patient presentation, characteristics of nerve and associated lesions, and surgical management were evaluated to identify prognostic variables. Postoperative muscle strength, range of motion, and patient-reported disability scores were analyzed to determine long-term outcome.
   RESULTS: Sixty-eight patients had a concomitant vascular injury. There were no significant differences in age or sex between the control and vascular groups. The vascular group was more likely to have pan-plexus lesions (P < 0.0001), with significantly more associated upper extremity injuries (P < 0.0001). The control group underwent more nerve transfers, whereas the vascular group underwent more nerve grafting (P = 0.003). Complete outcome data were obtained in 139 patients, which included 111 control (43% of all control subjects) and 28 vascular patients (41%). There was no significant difference in patient-reported disability scores between the 2 groups. However, 73% of control subjects had grade 3 or greater postoperative elbow flexion, whereas only 43% of vascular patients achieved this strength (P = 0.003). Control patients demonstrated a greater increase in strength of shoulder abduction as well (P = 0.004). Shoulder external rotation strength was grade 0 in most patients, with no difference between the 2 groups.
   CONCLUSIONS: Concomitant vascular injury leads to worse functional outcome after reconstructive surgery of traumatic brachial plexus injury.
C1 [Huang, Alice E.; Spinner, Robert J.; Bishop, Allen T.; Shin, Alexander Y.] Mayo Clin, Dept Orthoped Surg, Rochester, MN 55905 USA.
   [Spinner, Robert J.; Bishop, Allen T.; Shin, Alexander Y.] Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
   [Noland, Shelley S.] Mayo Clin, Dept Plast Surg, Scottsdale, AZ USA.
RP Shin, AY (reprint author), Mayo Clin, Dept Orthoped Surg, Rochester, MN 55905 USA.; Shin, AY (reprint author), Mayo Clin, Dept Neurol Surg, Rochester, MN 55905 USA.
EM shin.alexander@mayo.edu
OI Bishop, Allen/0000-0001-9856-6448
CR BALLARD JL, 1992, AM J SURG, V164, P316, DOI 10.1016/S0002-9610(05)80895-5
   Brown KR, 2001, ANN VASC SURG, V15, P43, DOI 10.1007/BF02693799
   BROWN PW, 1972, SURG CLIN N AM, V52, P1137
   Brucker PU, 2005, INJURY, V36, P1147, DOI 10.1016/j.injury.2004.12.053
   Campbell WW, 2008, CLIN NEUROPHYSIOL, V119, P1951, DOI 10.1016/j.clinph.2008.03.018
   Damschen DD, 1997, J TRAUMA, V42, P537, DOI 10.1097/00005373-199703000-00024
   Elhassan B, 2012, J BONE JOINT SURG AM, V94A, P1391, DOI 10.2106/JBJS.J.01913
   Eser F, 2009, NEUROL INDIA, V57, P434, DOI 10.4103/0028-3886.55614
   Galanakos SP, 2011, MICROSURG, V31, P253, DOI 10.1002/micr.20845
   Giuffre JL, 2010, J HAND SURG-AM, V35A, P678, DOI 10.1016/j.jhsa.2010.01.021
   GOLDIE BS, 1992, J HAND SURG-BRIT EUR, V17B, P86, DOI 10.1016/0266-7681(92)90018-W
   GRAHAM JM, 1982, ANN SURG, V195, P232, DOI 10.1097/00000658-198202000-00020
   Hudak PL, 1996, AM J IND MED, V29, P602, DOI 10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L
   Iriz Erkan, 2004, Ann Thorac Cardiovasc Surg, V10, P373
   JOHNSON SF, 1991, J TRAUMA, V31, P1546, DOI 10.1097/00005373-199111000-00016
   KELBEL JM, 1986, CLIN ORTHOP RELAT R, P210
   KLINE DG, 1983, J NEUROSURG, V58, P631, DOI 10.3171/jns.1983.58.5.0631
   Kline DG, 1998, J NEUROSURG, V89, P13, DOI 10.3171/jns.1998.89.1.0013
   KLINE DG, 1975, SURGERY, V78, P54
   Lam WL, 2015, J HAND SURG-EUR VOL, V40, P573, DOI 10.1177/1753193414553753
   Lee L, 1998, Am J Orthop (Belle Mead NJ), V27, P699
   Lin PH, 2003, AM J SURG, V185, P580, DOI 10.1016/S0002-9610(03)00070-9
   Manord JD, 1998, J VASC SURG, V27, P43, DOI 10.1016/S0741-5214(98)70290-3
   Masmejean EH, 2000, J HAND SURG-BRIT EUR, V25B, P336, DOI 10.1054/jhsb.2000.0393
   Merrell GA, 2001, J HAND SURG-AM, V26A, P303, DOI 10.1053/jhsu.2001.21518
   Millesi H, 1977, J Hand Surg Am, V2, P367
   NAGANO A, 1989, J HAND SURG-AM, V14A, P980, DOI 10.1016/S0363-5023(89)80047-4
   NARAKAS AO, 1993, CLIN NEUROL NEUROSUR, V95, pS56
   Noland SS, 2019, J AM ACAD ORTHOP SUR, V27, P705, DOI 10.5435/JAAOS-D-18-00433
   ORECK SL, 1984, J BONE JOINT SURG AM, V66A, P758, DOI 10.2106/00004623-198466050-00016
   Pannell William C, 2017, Hand (N Y), V12, P501, DOI 10.1177/1558944716675294
   Rasulic L, 2017, NEUROSURG REV, V40, P241, DOI 10.1007/s10143-016-0755-2
   Razmadze A, 1999, EUR J VASC ENDOVASC, V18, P235, DOI 10.1053/ejvs.1999.0857
   Rhee PC, 2011, J BONE JOINT SURG AM, V93A, P2271, DOI [10.2106/JBJS.J.00922, 10.2106/JBJSJ.00922]
   Rich N, 1978, VASCULAR TRAUMA
   Riess KP, 2007, J TRAUMA, V63, P1021, DOI 10.1097/01.ta.0000233764.54922.55
   Secer HI, 2007, J NEUROSURG, V107, P776, DOI 10.3171/JNS-07/10/0776
   SELECKI BR, 1982, AUST NZ J SURG, V52, P111, DOI 10.1111/j.1445-2197.1982.tb06081.x
   Sen RK, 2009, ACTA ORTHOP BELG, V75, P14
   SHAW AD, 1995, INJURY, V26, P515, DOI 10.1016/0020-1383(95)00090-V
   Shi LG, 2013, PAK J MED SCI, V29, P64, DOI 10.12669/pjms.291.2619
   Shin AY, 2005, J AM ACAD ORTHOP SUR, V13, P382, DOI 10.5435/00124635-200510000-00003
   Songcharoen P, 1996, J HAND SURG-AM, V21A, P387, DOI 10.1016/S0363-5023(96)80349-2
   Stanec S, 1997, INJURY, V28, P463, DOI 10.1016/S0020-1383(97)00086-7
   STURM JT, 1987, ANN EMERG MED, V16, P404, DOI 10.1016/S0196-0644(87)80359-1
   Suzuki K, 2007, J RECONSTR MICROSURG, V23, P295, DOI 10.1055/s-2007-985205
   Terzis JK, 1999, PLAST RECONSTR SURG, V104, P1221, DOI 10.1097/00006534-199910000-00001
   VISSER PA, 1980, AM J SURG, V140, P596
   Zelle BA, 2004, J BONE JOINT SURG AM, V86A, P2, DOI 10.2106/00004623-200401000-00002
NR 49
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.166
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600039
PM 31837496
DA 2020-05-12
ER

PT J
AU Huang, YZ
   Zhao, TX
   Reidler, JS
   Chen, XJ
   Zhang, HW
   Shao, HY
   Jin, MR
   Zhang, J
AF Huang, Yazeng
   Zhao, Tingxiao
   Reidler, Jay S.
   Chen, Xinji
   Zhang, Hengwei
   Shao, Haiyu
   Jin, Mengran
   Zhang, Jun
TI The Top 100 Most-Cited Articles on Kyphoplasty and Vertebroplasty
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bibliometric study; Citation analysis; Kyphoplasty; Top cited;
   Vertebroplasty; Web of Science
ID VERTEBRAL COMPRESSION FRACTURES; QUALITY-OF-LIFE; PERCUTANEOUS
   VERTEBROPLASTY; BALLOON KYPHOPLASTY; RANDOMIZED-TRIAL; TASK-FORCE;
   EFFICACY; MANAGEMENT; SAFETY; SPINE
AB INTRODUCTION: Over the last several decades, both percutaneous kyphoplasty (PKP) and percutaneous vertebroplasty (PVP) have been used for pain relief in patients with osteoporotic vertebral compression fractures. The purpose of our study was to use citation analysis to identify and review the top 100 most-cited publications regarding PKP and PVP.
   METHODS: All databases of the Web of Science were searched using the keywords "kyphoplasty" and "vertebroplasty." All publications with >100 citations were identified and the results were ranked in descending order of citations. The 100 most-cited publications were included for analysis.
   RESULTS: A total of 6271 publications on PKP and PVP were identified. The number of citations of the 100 most-cited studies ranged from 735 to 109, with a mean of 225.3 citations per study. The most productive period was 2001-2010, which produced 79 of the top 100 publications. Thirteen journals published these 100 studies, with Spine publishing the largest number (23) of studies. Most of the identified articles originated in the United States, with France and Switzerland found to be the next most heavily represented countries of origin of the 11 countries that produced them. Most of the studies focused on treatment of osteoporotic vertebral compression fractures, followed by pathologic fractures caused by tumors.
   CONCLUSIONS: We identified the 100 most-cited publications on PKP and PVP and performed a bibliometric analysis characterizing distinguishing features of these studies. This list can help guide clinical decision making and future research directions as clinicians and researchers continue to explore these controversial therapeutic techniques.
C1 [Huang, Yazeng; Chen, Xinji; Shao, Haiyu; Jin, Mengran; Zhang, Jun] Zhejiang Prov Peoples Hosp, Dept Spine Surg, Hangzhou, Zhejiang, Peoples R China.
   [Huang, Yazeng; Chen, Xinji; Shao, Haiyu; Jin, Mengran; Zhang, Jun] Hangzhou Med Coll, Peoples Hosp, Hangzhou, Zhejiang, Peoples R China.
   [Huang, Yazeng; Zhao, Tingxiao] Bengbu Med Coll, Bengbu, Anhui, Peoples R China.
   [Reidler, Jay S.] Columbia Univ, New York Presbyterian & Spine Hosp, Irving Med Ctr, New York, NY USA.
   [Zhang, Hengwei] Chinese Acad Med Sci, Peking Union Med Coll, Suzhou Inst Syst Med, Suzhou, Jiangsu, Peoples R China.
RP Zhang, J (reprint author), Zhejiang Prov Peoples Hosp, Dept Spine Surg, Hangzhou, Zhejiang, Peoples R China.; Zhang, J (reprint author), Hangzhou Med Coll, Peoples Hosp, Hangzhou, Zhejiang, Peoples R China.
EM spinezhangjun@aliyun.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31771560]; Zhejiang Provincial Health Bureau
   Science Foundation of China [2018KY017]
FX This study was supported by grants from National Natural Science
   Foundation of China (31771560), and Zhejiang Provincial Health Bureau
   Science Foundation of China (2018KY017).
CR Alvarez L, 2006, SPINE, V31, P1113
   Astur N, 2019, GLOB SPINE J, V9, P348, DOI 10.1177/2192568218768774
   Baerlocher MO, 2014, J VASC INTERV RADIOL, V25, P165, DOI 10.1016/j.jvir.2013.09.004
   Belkoff SM, 2001, SPINE, V26, P1537, DOI 10.1097/00007632-200107150-00007
   Belkoff SM, 2001, SPINE, V26, P151, DOI 10.1097/00007632-200101150-00008
   Berenson J, 2011, LANCET ONCOL, V12, P225, DOI 10.1016/S1470-2045(11)70008-0
   Bouza C, 2006, EUR SPINE J, V15, P1050, DOI 10.1007/s00586-005-0048-x
   Buchbinder R, 2009, NEW ENGL J MED, V361, P557, DOI 10.1056/NEJMoa0900429
   Clark W, 2016, LANCET, V388, P1408, DOI 10.1016/S0140-6736(16)31341-1
   Clarke BL, 2019, J BONE MINER RES, V34, P1, DOI 10.1002/jbmr.3651
   Deramond H, 1998, RADIOL CLIN N AM, V36, P533, DOI 10.1016/S0033-8389(05)70042-7
   Diamond TH, 2003, AM J MED, V114, P257, DOI 10.1016/S0002-9343(02)01524-3
   Dudeney S, 2002, J CLIN ONCOL, V20, P2382, DOI 10.1200/JCO.2002.09.097
   Ebeling PR, 2019, J BONE MINER RES, V34, P3, DOI 10.1002/jbmr.3653
   Farrokhi MR, 2011, J NEUROSURG-SPINE, V14, P561, DOI 10.3171/2010.12.SPINE10286
   Filippiadis DK, 2017, CARDIOVASC INTER RAD, V40, P1815, DOI 10.1007/s00270-017-1779-x
   Fourney DR, 2003, J NEUROSURG, V98, P21, DOI 10.3171/spi.2003.98.1.0021
   Fribourg D, 2004, SPINE, V29, P2270, DOI 10.1097/01.brs.0000142469.41565.2a
   GALIBERT P, 1987, NEUROCHIRURGIE, V33, P166
   Garfin SR, 2001, SPINE, V26, P1511, DOI 10.1097/00007632-200107150-00002
   Garfin SR, 2006, SPINE, V31, P2213, DOI 10.1097/01.brs.0000232803.71640.ba
   Germaneau A, 2016, J MECH BEHAV BIOMED, V59, P291, DOI 10.1016/j.jmbbm.2016.02.002
   Gill J Brian, 2007, Pain Physician, V10, P583
   Hochmuth K, 2006, EUR RADIOL, V16, P998, DOI 10.1007/s00330-005-0067-3
   Jensen ME, 1997, AM J NEURORADIOL, V18, P1897
   Jessup RL, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3801-7
   Kallmes DF, 2009, NEW ENGL J MED, V361, P569, DOI 10.1056/NEJMoa0900563
   Klazen CAH, 2010, LANCET, V376, P1085, DOI 10.1016/S0140-6736(10)60954-3
   Laratta Joseph L, 2017, J Spine Surg, V3, P364, DOI 10.21037/jss.2017.08.02
   Lieberman I, 2003, CLIN ORTHOP RELAT R, pS176, DOI 10.1097/01.blo.0000093841.72468.a8
   Lieberman IH, 2001, SPINE, V26, P1631, DOI 10.1097/00007632-200107150-00026
   Liu J, 2019, WORLD NEUROSURG, V122, pE1381, DOI 10.1016/j.wneu.2018.11.062
   Murphy KJ, 2000, NEUROIMAG CLIN N AM, V10, P535
   Padovani B, 1999, AM J NEURORADIOL, V20, P375
   Rajah G, 2015, J NEUROSURG-SPINE, V23, P228, DOI 10.3171/2014.11.SPINE14909
   Rodriguez AJ, 2017, J BONE MINER RES, V32, P1935, DOI 10.1002/jbmr.3170
   Rousing R, 2010, SPINE, V35, P478, DOI 10.1097/BRS.0b013e3181b71bd1
   Sorensen ST, 2019, SPINE J, V19, P1067, DOI 10.1016/j.spinee.2019.02.012
   Taylor RS, 2007, EUR SPINE J, V16, P1085, DOI 10.1007/s00586-007-0308-z
   Teyssedou S, 2014, ORTHOP TRAUMATOL-SUR, V100, pS169, DOI 10.1016/j.otsr.2013.11.005
   Tohmeh AG, 1999, SPINE, V24, P1772, DOI 10.1097/00007632-199909010-00004
   Trout AT, 2006, AM J NEURORADIOL, V27, P217
   Tsoumakidou G, 2017, CARDIOVASC INTER RAD, V40, P331, DOI 10.1007/s00270-017-1574-8
   Voggenreiter G, 2005, SPINE, V30, P2806, DOI 10.1097/01.brs.0000190885.85675.a0
   Voormolen MHJ, 2007, AM J NEURORADIOL, V28, P555
   Wang HK, 2010, PAIN MED, V11, P1659, DOI 10.1111/j.1526-4637.2010.00959.x
   Wood KB, 2014, SPINE J, V14, P145, DOI 10.1016/j.spinee.2012.10.041
   Zhang J, 2017, TURK NEUROSURG, V27, P460, DOI 10.5137/1019-5149.JTN.13032-14.2
NR 48
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.014
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600051
PM 31837493
DA 2020-05-12
ER

PT J
AU Ikeda, H
   Sano, N
   Torikoshi, S
   Otsuka, R
   Tsujimoto, Y
   Yamashita, T
   Hayase, M
   Toda, H
AF Ikeda, Hiroyuki
   Sano, Noritaka
   Torikoshi, Sadaharu
   Otsuka, Ryotaro
   Tsujimoto, Yoshitaka
   Yamashita, Tomoyuki
   Hayase, Makoto
   Toda, Hiroki
TI Dissection of the Vertebral Artery Fenestration Limb Presenting with
   Occlusion After Rupture
SO WORLD NEUROSURGERY
LA English
DT Article
DE Dissection; Fenestration; Internal trapping; Occlusion; Vertebral artery
ID ENDOVASCULAR TREATMENT; MEDULLARY INFARCTION; ANEURYSM
AB BACKGROUND: Dissection of a vertebral artery (VA) fenestration is extremely rare. We herein present the first case of a patient who presented with the dissection of a VA fenestration limb accompanied by occlusion after rupture, who was treated with internal trapping of the dissected limb and the parent artery proximal to the fenestration.
   CASE DESCRIPTION: A 55-year-old man presented with sudden headache and altered consciousness. Computed tomography at admission showed subarachnoid hemorrhage. Angiography showed occlusion of the inner limb of the vertebrobasilar junction fenestration, and the occluded ends had a tapered shape, suggesting the occlusion of the dissection of the inner limb after rupture. Angiography immediately before embolization revealed inner limb recanalization with an irregular string sign; thus only the inner limb was embolized. Angiography after embolization showed near-complete suppression of the blood flow in the inner limb; however, a slight antegrade flow through the coil mass was observed in the late phase. The procedure was finished with the expectation of complete occlusion over time with natural heparin reversal. Angiography 8 days after embolization revealed a significant increase in antegrade blood flow through the coil mass within the inner limb. Therefore additional embolization of the parent artery proximal to the fenestration was performed, which achieved complete occlusion.
   CONCLUSIONS: The embolization length was limited and the antegrade blood flow through the other limb remained during internal trapping for the dissected VA fenestration limb; therefore careful observation of the blood flow to the dissected segment after embolization is necessary.
C1 [Ikeda, Hiroyuki; Sano, Noritaka; Torikoshi, Sadaharu; Otsuka, Ryotaro; Tsujimoto, Yoshitaka; Yamashita, Tomoyuki; Hayase, Makoto; Toda, Hiroki] Fukui Red Cross Hosp, Dept Neurosurg, Fukui, Japan.
RP Ikeda, H (reprint author), Fukui Red Cross Hosp, Dept Neurosurg, Fukui, Japan.
EM rocky@kuhp.kyoto-u.ac.jp
OI Ikeda, Hiroyuki/0000-0001-5710-7456; Toda, Hiroki/0000-0002-1596-4131
CR Bernard TJ, 2007, J NEUROL SCI, V260, P279, DOI 10.1016/j.jns.2007.04.032
   de Andrade GC, 2005, ARQ NEURO-PSIQUIAT, V63, P352, DOI 10.1590/S0004-282X2005000200031
   Endo H, 2013, J NEUROSURG, V118, P131, DOI 10.3171/2012.9.JNS12566
   Guo X, 2018, WORLD NEUROSURG, V115, pE592, DOI 10.1016/j.wneu.2018.04.106
   Hayashi T, 2000, NEUROL MED-CHIR, V40, P164, DOI 10.2176/nmc.40.164
   Ikeda H, 2016, INTERV NEURORADIOL, V22, P67, DOI 10.1177/1591019915609127
   Kubo M, 2005, SURG NEUROL, V63, P244, DOI 10.1016/j.surneu.2004.02.038
   Matsumoto Y, 2008, J CLIN NEUROSCI, V15, P700, DOI 10.1016/j.jocn.2007.04.016
   Nicola D, 2016, CAN J NEUROL SCI, V43, P329, DOI 10.1017/cjn.2015.329
   SASAKI O, 1991, J NEUROSURG, V75, P874, DOI 10.3171/jns.1991.75.6.0874
   Satow T, 2014, NEUROL MED-CHIR, V54, P98, DOI 10.2176/nmc.oa.2013-0184
   Sawada M, 2005, J NEUROSURG, V102, P161, DOI 10.3171/jns.2005.102.1.0161
   Sim E, 2001, SPINE, V26, pE139, DOI 10.1097/00007632-200103150-00007
   Takahara Kenta, 2017, No Shinkei Geka, V45, P1075, DOI 10.11477/mf.1436203650
   Uchino A, 2012, NEURORADIOLOGY, V54, P445, DOI 10.1007/s00234-011-0903-x
   Uda T, 2009, NEUROL SURG TOKYO, V37, P1111
   Yasui T, 1997, SURG NEUROL, V47, P149, DOI 10.1016/S0090-3019(96)00193-0
   ZHANG QJ, 1994, STROKE, V25, P1273, DOI 10.1161/01.STR.25.6.1273
NR 18
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.133
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600157
PM 31901498
DA 2020-05-12
ER

PT J
AU Jiang, QL
   Wang, PJ
   Liu, HX
   Huang, LL
   Kang, XK
AF Jiang, Qun-Long
   Wang, Pei-Jian
   Liu, Hui-Xin
   Huang, Li-Li
   Kang, Xiao-Kui
TI Dual versus Single Antiplatelet Therapy in Carotid Artery
   Endarterectomy: Direct Comparison of Complications Related to
   Antiplatelet Therapy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Antiplatelet therapy; Carotid endarterectomy; Meta-analysis
ID TRANSIENT ISCHEMIC ATTACK; COLLABORATIVE METAANALYSIS; MINOR STROKE;
   DOUBLE-BLIND; EARLY RISK; CLOPIDOGREL; SURGERY; ASPIRIN; PREVENTION
AB BACKGROUND: Dual and single antiplatelet therapies are routinely used in carotid artery endarterectomy (CEA). However, the efficacy and safety of these therapies are controversial. The present study aimed to comprehensively compare the clinical outcomes between dual and single antiplatelet therapies in CEA.
   METHODS: This study retrieved available academic studies evaluating the complications related to antiplatelet therapy between dual and single antiplatelet therapies in CEA from the databases of ScienceDirect, the Cochrane Library, EMBASE, and PubMed. References to previous reviews and related clinical trials were manually checked to retrieve potential literature that was not included in our electronic search results.
   RESULTS: A total of 10 articles (1 randomized controlled trial, 9 non-randomized controlled trials) were included in the study. The overall number of patients in the dual antiplatelet group was 14,280, and the number of patients in the single antiplatelet group was 125,850. The results revealed that the single antiplatelet group had a lower incidence of 30-day death (rate difference [RD] 0.002; 95% confidence interval [CI] 0.000-0.003; P = 0.014), neck hematoma (odds ratio [OR] 2.120; 95% CI 1.431-3.142; P < 0.001), myocardial infarction (RD 0.004; 95% CI 0.001-0.007; P = 0.003), and major bleeding (RD 0.005; 95% CI 0.002-0.008; P < 0.001). Meanwhile, the single antiplatelet group was associated with a shorter operation time (weighted mean difference 4.000; 95% CI = 2.564-5.436; P < 0.001). However, there was no significant difference in the rate of postoperative transient ischemic attack (P = 0.215), stroke (P = 0.130), or length of stay (P = 0.563).
   CONCLUSIONS: Based on current evidence, using single antiplatelet therapy in CEA may reduce operation time and the incidences of 30-day death, neck hematoma, major bleeding, and myocardial infarction without increasing the risks of transient ischemic attack, stroke, or a longer operation time.
C1 [Jiang, Qun-Long; Wang, Pei-Jian; Kang, Xiao-Kui] Liaocheng Peoples Hosp, Dept Neurosurg, Liaocheng, Shandong, Peoples R China.
   [Liu, Hui-Xin] Liaocheng Peoples Hosp, Dept Med Examinat, Liaocheng, Shandong, Peoples R China.
   [Huang, Li-Li] Liaocheng Peoples Hosp, Dept Endocrinol, Liaocheng, Shandong, Peoples R China.
RP Kang, XK (reprint author), Liaocheng Peoples Hosp, Dept Neurosurg, Liaocheng, Shandong, Peoples R China.
EM xiaokuikang@163.com
CR Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
   Barboza Miguel A, 2016, J Vasc Interv Neurol, V9, P5
   Barkat M, 2017, EUR J VASC ENDOVASC, V53, P53, DOI 10.1016/j.ejvs.2016.10.011
   BARNETT HJM, 1995, NEW ENGL J MED, V332, P238, DOI 10.1056/NEJM199501263320408
   Batchelder A, 2015, EUR J VASC ENDOVASC, V50, P412, DOI 10.1016/j.ejvs.2015.07.019
   Chechik O, 2012, VASCULAR, V20, P193, DOI 10.1258/vasc.2011.oa0336
   Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1
   Coull AJ, 2004, BMJ-BRIT MED J, V328, P326, DOI 10.1136/bmj.37991.635266.44
   Diener HC, 2004, LANCET, V364, P331, DOI 10.1016/S0140-6736(04)16721-4
   Filsoufi F, 2008, J CARDIOTHOR VASC AN, V22, P60, DOI 10.1053/j.jvca.2007.10.009
   Fleming MD, 2009, ANN VASC SURG, V23, P612, DOI 10.1016/j.avsg.2009.06.004
   Gonzalez-Sanchez A, 2018, MICROBIOLOGYOPEN, V7, DOI 10.1002/mbo3.573
   Hale B, 2013, VASCULAR, V21, P197, DOI 10.1177/1708538113478763
   Hayes PD, 2003, J VASC SURG, V38, P1226, DOI 10.1016/j.jvs.2003.05.001
   Illuminati G, 2017, ANN VASC SURG, V40, P39, DOI 10.1016/j.avsg.2016.09.012
   Johnston SC, 2000, JAMA-J AM MED ASSOC, V284, P2901, DOI 10.1001/jama.284.22.2901
   Jones DW, 2016, J VASC SURG, V63, P1262, DOI 10.1016/j.jvs.2015.12.020
   Kakisis JD, 2012, EUR J VASC ENDOVASC, V44, P238, DOI 10.1016/j.ejvs.2012.04.015
   Kennedy J, 2007, LANCET NEUROL, V6, P961, DOI 10.1016/S1474-4422(07)70250-8
   KRETSCHMER G, 1990, ANN SURG, V211, P317, DOI 10.1097/00000658-199003000-00002
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   LINDBLAD B, 1993, STROKE, V24, P1125, DOI 10.1161/01.STR.24.8.1125
   Lovett JK, 2003, STROKE, V34, pE138, DOI 10.1161/01.STR.0000080935.01264.91
   Noronen K, 2012, EUR J VASC ENDOVASC, V44, P261, DOI 10.1016/j.ejvs.2012.06.014
   Oldag A, 2012, LANGENBECK ARCH SURG, V397, P1275, DOI 10.1007/s00423-012-0967-z
   Payne DA, 2004, CIRCULATION, V109, P1476, DOI 10.1161/01.CIR.0000121739.05643.E6
   Petty GW, 1999, STROKE, V30, P2513, DOI 10.1161/01.STR.30.12.2513
   Rothwell PM, 2007, LANCET, V370, P1432, DOI 10.1016/S0140-6736(07)61448-2
   Saadeh C, 2013, J VASC SURG, V58, P1586, DOI 10.1016/j.jvs.2013.05.092
   Sharpe RY, 2010, EUR J VASC ENDOVASC, V40, P162, DOI 10.1016/j.ejvs.2010.04.004
   Stone DH, 2011, J VASC SURG, V54, P779, DOI 10.1016/j.jvs.2011.03.003
   Zimmermann A, 2018, J VASC SURG, V68, P1753, DOI 10.1016/j.jvs.2018.01.063
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.070
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600071
PM 31870823
DA 2020-05-12
ER

PT J
AU Johnson, MD
   Matur, AV
   Asghar, F
   Nasser, R
   Cheng, JS
   Prestigiacomo, CJ
AF Johnson, Mark D.
   Matur, Abhijith, V
   Asghar, Ferhan
   Nasser, Rani
   Cheng, Joseph S.
   Prestigiacomo, Charles J.
TI Right Versus Left Approach to Anterior Cervical Discectomy and Fusion:
   An Anatomic Versus Historic Debate
SO WORLD NEUROSURGERY
LA English
DT Article
DE ACDF; Anterior cervical discectomy and fusion; Cloward; History;
   Recurrent laryngeal nerve palsy; Robinson; Smith
ID RECURRENT LARYNGEAL NERVE; SPINE SURGERY; INTERBODY FUSION; REMOVAL;
   INJURY; PALSY; DISC; DISEASE
AB The debate over the influence approach sidedness has on the risk of recurrent laryngeal nerve palsy (RLNP) following anterior cervical discectomy and fusion (ACDF) has its origins with the introduction of the procedure for radicular pain in the 1950s. The recurrent laryngeal nerves follow disparate courses in the lower neck secondary to differences in embryogenesis. Because of these differences, some authors believe a right-sided approach increases the risk of RLNP. However, modern surgical series have not shown a clear risk of RLNP with a right-versus left-sided approach. By looking at the historical context surrounding the introduction of ACDF, we propose the dogmatic view of an increased risk of RLNP with a right-sided approach likely arose from a combination of theoretical anatomic risk and the early surgical experience of a pioneer of the procedure.
C1 [Johnson, Mark D.; Nasser, Rani; Cheng, Joseph S.; Prestigiacomo, Charles J.] Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA.
   [Johnson, Mark D.; Matur, Abhijith, V; Asghar, Ferhan; Nasser, Rani; Cheng, Joseph S.; Prestigiacomo, Charles J.] Univ Cincinnati, Coll Med, Dept Neurol Surg, Cincinnati, OH 45267 USA.
   [Asghar, Ferhan] Univ Cincinnati, Dept Orthoped Surg, Coll Med, Cincinnati, OH USA.
RP Prestigiacomo, CJ (reprint author), Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA.; Prestigiacomo, CJ (reprint author), Univ Cincinnati, Coll Med, Dept Neurol Surg, Cincinnati, OH 45267 USA.
EM presticj@ucmail.uc.edu
CR Apfelbaum RI, 2000, SPINE, V25, P2906, DOI 10.1097/00007632-200011150-00012
   ARONSON N, 1968, J NEUROSURG, V29, P397, DOI 10.3171/jns.1968.29.4.0397
   Audu P, 2006, ANESTHESIOLOGY, V105, P898, DOI 10.1097/00000542-200611000-00009
   BAILEY RW, 1960, J BONE JOINT SURG AM, V42, P565, DOI 10.2106/00004623-196042040-00001
   Baron EM, 2003, ANN OTO RHINOL LARYN, V112, P921, DOI 10.1177/000348940311201102
   Bartels RHMA, 2018, J NEUROSURG-SPINE, V28, P395, DOI 10.3171/2017.7.SPINE17182
   Beutler WJ, 2001, SPINE, V26, P1337, DOI 10.1097/00007632-200106150-00014
   Burkhardt BW, 2016, WORLD NEUROSURG, V92, P371, DOI 10.1016/j.wneu.2016.05.036
   Cloward RB, 2007, J NEUROSURG-SPINE, V6, P496, DOI 10.3171/spi.2007.6.5.496
   CLOWARD RB, 1973, J NEUROSURG, V38, P527, DOI 10.3171/jns.1973.38.4.0527
   CLOWARD RB, 1988, SPINE, V13, P823, DOI 10.1097/00007632-198807000-00020
   Derakhshan A, 2017, GLOB SPINE J, V7, P1155, DOI 10.1177/2192568216688194
   DEREYMAEKER A., 1958, REV NEUROL, V99, P597
   Ebraheim NA, 1997, SPINE, V22, P2664, DOI 10.1097/00007632-199711150-00015
   Erwood MS, 2016, J NEUROSURG-SPINE, V25, P198, DOI 10.3171/2015.9.SPINE15187
   ESPERSEN JO, 1984, ACTA NEUROCHIR, V70, P97, DOI 10.1007/BF01406047
   Gokaslan ZL, 2017, GLOB SPINE J, V7, P535, DOI 10.1177/2192568216687547
   Gross CG, 1998, NEUROSCIENTIST, V4, P216, DOI 10.1177/107385849800400317
   Haller JM, 2012, SPINE, V37, P97, DOI 10.1097/BRS.0b013e31821f3e86
   HEENEMAN H, 1973, LARYNGOSCOPE, V83, P17, DOI 10.1288/00005537-197301000-00002
   HORSEY WJ, 1977, PARAPLEGIA, V15, P110, DOI 10.1038/sc.1977.16
   Jung A, 2010, NEUROSURGERY, V67, P10, DOI 10.1227/01.NEU.0000370203.26164.24
   Kaplan EL, 2009, WORLD J SURG, V33, P386, DOI 10.1007/s00268-008-9798-z
   Kilburg C, 2006, J NEUROSURG-SPINE, V4, P273, DOI 10.3171/spi.2006.4.4.273
   Maiti TK, 2016, WORLD NEUROSURG, V89, P562, DOI 10.1016/j.wneu.2015.06.061
   Miscusi M, 2007, J Neurosurg Sci, V51, P61
   Monfared A, 2010, OTOL NEUROTOL, V31, P691, DOI 10.1097/MAO.0b013e3181c0e98e
   Moore KL, 2016, DEV HUMAN CLIN ORIEN, P155
   Netterville JL, 1966, ANN OTO RHINOL LARYN, V105, P85
   ROBINSON RA, 1962, J BONE JOINT SURG AM, V44, P1569, DOI 10.2106/00004623-196244080-00007
   ROBINSON RA, 1955, B JOHNS HOPKINS HOSP, V96, P223
   ROBINSON RA, 1975, CLIN ORTHOP RELAT R, P78
   SMITH GW, 1958, J BONE JOINT SURG AM, V40, P607, DOI 10.2106/00004623-195840030-00009
   Staartjes VE, 2018, WORLD NEUROSURG, V116, pE1047, DOI 10.1016/j.wneu.2018.05.162
   Tan TP, 2014, SPINE J, V14, P1332, DOI 10.1016/j.spinee.2014.02.017
   Tew J M Jr, 1976, Clin Neurosurg, V23, P424
   Viers A, 2012, J NEUROSURG, V117, P800, DOI 10.3171/2012.7.JNS111873
   Weisberg NK, 1997, OTOLARYNG HEAD NECK, V116, P317, DOI 10.1016/S0194-5998(97)70266-3
NR 38
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.052
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600120
PM 31857270
DA 2020-05-12
ER

PT J
AU Kawashima, M
   Hasegawa, H
   Kurita, H
   Suzuki, K
   Shin, M
   Ikemura, M
   Saito, N
AF Kawashima, Mariko
   Hasegawa, Hirotaka
   Kurita, Hiroki
   Suzuki, Kaima
   Shin, Masahiro
   Ikemura, Masako
   Saito, Nobuhito
TI Ectopic Recurrence of Arteriovenous Malformation After Radiosurgery:
   Case Report and Insight Regarding Pathogenesis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous malformation; Endoglin; Gamma Knife; Stereotactic
   radiosurgery
ID HEREDITARY HEMORRHAGIC TELANGIECTASIA; GAMMA-KNIFE SURGERY;
   ENDOTHELIAL-CELLS; MOYAMOYA-DISEASE; ENDOGLIN CD105; GROWTH-FACTOR;
   CHILDREN; EXPRESSION; RESECTION; BRAIN
AB BACKGROUND: While prior studies reporting de novo arteriovenous malformations after birth are not uncommon, reports of ectopic recurrence of arteriovenous malformation after radiotherapy are scarce.
   CASE DESCRIPTION: An 8-year-old girl with a ruptured cerebellar arteriovenous malformation was treated with stereotactic radiosurgery. The nidus was completely obliterated 17 months after stereotactic radiosurgery; however, 20 years later she had a rupture of a recurrent nidus that occurred adjacent to the original nidus, accompanied by a radiation-induced cyst. Surgical resection was performed, and subsequent pathologic examination revealed 2 different compartments: a typical nidus and a postirradiated degenerated nidus with an encapsulated hematoma. Immunohistochemical stains showed increased expression of Ki-67 and decreased expression of endoglin in endothelial cells in the recurrent nidus.
   CONCLUSIONS: Depletion in endoglin may lead to the formation of vessel formations in the presence of angiogenic stimuli. This case serves as a strong reminder of the importance of long-term follow-up after stereotactic radiosurgery, especially for pediatric cases.
C1 [Kawashima, Mariko; Hasegawa, Hirotaka; Shin, Masahiro; Saito, Nobuhito] Univ Tokyo Hosp, Dept Neurosurg, Tokyo, Japan.
   [Ikemura, Masako] Univ Tokyo Hosp, Dept Pathol, Tokyo, Japan.
   [Kurita, Hiroki; Suzuki, Kaima] Saitama Med Univ, Int Med Ctr, Dept Cerebrovasc Surg, Saitama, Japan.
   [Kurita, Hiroki; Suzuki, Kaima] Saitama Med Univ, Int Med Ctr, Stroke Ctr, Saitama, Japan.
RP Hasegawa, H (reprint author), Univ Tokyo Hosp, Dept Neurosurg, Tokyo, Japan.
EM hirohasegawa-tky@umin.ac.jp
RI Hasegawa, Hirotaka/AAJ-2034-2020
OI Hasegawa, Hirotaka/0000-0002-3585-2188
CR Aboukais R, 2017, J NEUROSURG, V126, P1088, DOI 10.3171/2016.3.JNS152846
   Akimoto H, 2003, NEUROSURGERY, V52, P228, DOI 10.1097/00006123-200301000-00030
   Ali MJ, 2003, PEDIATR NEUROSURG, V39, P32, DOI 10.1159/000070878
   Andaluz N, 2004, SURG NEUROL, V62, P324, DOI 10.1016/j.surneu.2003.11.030
   Bristol RE, 2006, J NEUROSURG, V105, P88, DOI 10.3171/ped.2006.105.2.88
   Burrows FJ, 1995, CLIN CANCER RES, V1, P1623
   CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027
   Chen WQ, 2014, STROKE, V45, P900, DOI 10.1161/STROKEAHA.113.003655
   Dallas NA, 2008, CLIN CANCER RES, V14, P1931, DOI 10.1158/1078-0432.CCR-07-4478
   Fonsatti E, 2004, J TRANSL MED, V2, P654
   Fujimura M, 2014, J NEUROSURG-PEDIATR, V13, P647, DOI 10.3171/2014.3.PEDS13610
   Gaballah M, 2014, J NEUROSURG-PEDIATR, V13, P222, DOI 10.3171/2013.10.PEDS13291
   Gonzalez LF, 2005, J NEUROSURG, V102, P726, DOI 10.3171/jns.2005.102.4.0726
   GOUGOS A, 1990, J BIOL CHEM, V265, P8361
   Hashimoto N, 1999, CRIT REV NEUROSURG, V9, P141, DOI 10.1007/s003290050123
   Hashimoto T, 2001, NEUROSURGERY, V49, P124, DOI 10.1097/00006123-200107000-00019
   Hatva E, 1996, J NEUROPATH EXP NEUR, V55, P1124, DOI 10.1097/00005072-199611000-00003
   HLADKY JP, 1994, CHILD NERV SYST, V10, P328, DOI 10.1007/BF00335172
   Kader A, 1996, J NEUROSURG, V85, P14, DOI 10.3171/jns.1996.85.1.0014
   KARAMITOPOULOU E, 1994, ACTA NEUROPATHOL, V87, P47
   Klimo P, 2007, CHILD NERV SYST, V23, P31, DOI 10.1007/s00381-006-0245-x
   KONDZIOLKA D, 1992, CAN J NEUROL SCI, V19, P40, DOI 10.1017/S0317167100042517
   Lang SS, 2012, J NEUROSURG-PEDIATR, V9, P497, DOI 10.3171/2012.1.PEDS11453
   Leblanc GG, 2009, STROKE, V40, pE694, DOI 10.1161/STROKEAHA.109.563692
   Mahajan A, 2010, NEUROSURG REV, V33, P115, DOI 10.1007/s10143-009-0227-z
   Maher CO, 2009, J NEUROS-PEDIATR, V4, P12, DOI 10.3171/2009.1.PEDS08329
   Mahmoud M, 2010, CIRC RES, V106, P1425, DOI 10.1161/CIRCRESAHA.109.211037
   Matsubara S, 2000, STROKE, V31, P2653, DOI 10.1161/01.STR.31.11.2653
   MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345
   Miller DW, 1999, INT J CANCER, V81, P568, DOI 10.1002/(SICI)1097-0215(19990517)81:4<568::AID-IJC11>3.3.CO;2-O
   Morgenstern PF, 2016, J NEUROSURG-PEDIATR, V17, P134, DOI 10.3171/2015.6.PEDS14708
   Mullan S, 1996, J NEUROSURG, V85, P1, DOI 10.3171/jns.1996.85.1.0001
   Nassiri F, 2011, ANTICANCER RES, V31, P2283
   O'Shaughnessy BA, 2005, J NEUROSURG, V102, P238, DOI 10.3171/jns.2005.102.2.0238
   Rodriguez-Arias C, 2000, CHILD NERV SYST, V16, P363, DOI 10.1007/s003810050532
   Schmit BP, 1996, J NEUROSURG, V84, P677, DOI 10.3171/jns.1996.84.4.0677
   Shuto T, 2015, ACTA NEUROCHIR, V157, P293, DOI 10.1007/s00701-014-2298-z
   Sonstein WJ, 1996, J NEUROSURG, V85, P838, DOI 10.3171/jns.1996.85.5.0838
   Stevens J, 2009, AM J NEURORADIOL, V30, P111, DOI 10.3174/ajnr.A1255
   Sure U, 2001, J NEUROSURG, V94, P970, DOI 10.3171/jns.2001.94.6.0972
   Takagi Y, 2010, WORLD NEUROSURG, V73, P100, DOI 10.1016/j.surneu.2009.07.008
   ten Dijke P, 2008, ANGIOGENESIS, V11, P79, DOI 10.1007/s10456-008-9101-9
   Torsney E, 2003, CIRCULATION, V107, P1653, DOI 10.1161/01.CIR.0000058170.92267.00
   Tual-Chalot S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098646
   Yun JH, 2012, J NEUROSURG, V117, P120, DOI 10.3171/2012.8.GKS12994
NR 45
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.156
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600105
PM 31841722
DA 2020-05-12
ER

PT J
AU Kikuta, S
   Iwanaga, J
   Watanabe, K
   Haladaj, R
   Wysiadecki, G
   Dumont, AS
   Tubbs, RS
AF Kikuta, Shogo
   Iwanaga, Joe
   Watanabe, Koichi
   Haladaj, Robert
   Wysiadecki, Grzegorz
   Dumont, Aaron S.
   Tubbs, R. Shane
TI Posterior Sacrococcygeal Plexus: Application to Spine Surgery and Better
   Understanding Low-Back Pain
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anatomy; Entrapment; Low-back pain; Middle clunial nerve; Posterior
   sacrococcygeal plexus; Sacral dorsal rami; Surgery
ID SUPERIOR CLUNEAL NERVE; ENTRAPMENT NEUROPATHY; ANATOMY
AB OBJECTIVE: The sacral dorsal rami form the posterior sacrococcygeal plexus (PSCP), which has been scantly studied. This study's goal was to clarify the PSCP s detailed anatomy and discuss its clinical relevance.
   METHODS: Ten sides of 5 fresh-frozen cadavers were dissected for this research. After the muscles covering the sacrum were removed, the PSCP was identified and traced under the operating microscope until the entire plexus was exposed. The contributions to this plexus and its relations to surrounding anatomic structures were recorded.
   RESULTS: The PSCP was found on all sides and was composed of a medial trunk (MT), communicating branches, and a lateral trunk. Each sacral dorsal ramus's MT formed a series of loops created by adjacent sacral dorsal rami placed between the transverse tubercles and the posterior sacral foramina. The MT, communicating branches, and lateral trunk demonstrated potential entrapment sites.
   CONCLUSIONS: To our knowledge, this is the first anatomic study that provides detailed images that indicate 3 potential sites where surrounding structures could entrap the PSCP. Knowledge of its detailed anatomy might help in better understanding low-back pain, targeting pain sources and guide spine surgeons for avoiding injury to these nerves.
C1 [Iwanaga, Joe; Dumont, Aaron S.; Tubbs, R. Shane] Tulane Univ, Sch Med, Dept Neurosurg, 1430 Tulane Ave, New Orleans, LA 70112 USA.
   [Kikuta, Shogo; Iwanaga, Joe] Kurume Univ, Dent & Oral Med Ctr, Sch Med, Kurume, Fukuoka, Japan.
   [Iwanaga, Joe; Watanabe, Koichi] Kurume Univ, Div Gross & Clin Anat, Sch Med, Dept Anat, Kurume, Fukuoka, Japan.
   [Haladaj, Robert; Wysiadecki, Grzegorz] Med Univ Lodz, Dept Normal & Clin Anat, Lodz, Poland.
   [Tubbs, R. Shane] St Georges Univ, Dept Anat Sci, St Georges, Grenada.
RP Iwanaga, J (reprint author), Tulane Univ, Sch Med, Dept Neurosurg, 1430 Tulane Ave, New Orleans, LA 70112 USA.; Iwanaga, J (reprint author), Kurume Univ, Dent & Oral Med Ctr, Sch Med, Kurume, Fukuoka, Japan.; Iwanaga, J (reprint author), Kurume Univ, Div Gross & Clin Anat, Sch Med, Dept Anat, Kurume, Fukuoka, Japan.
EM iwanagajoeca@gmail.com
RI Wysiadecki, Grzegorz/S-9744-2016
OI Wysiadecki, Grzegorz/0000-0003-3631-2295; Kikuta,
   Shogo/0000-0002-2236-2884
CR Aota Y, 2016, WORLD J ORTHOP, V7, P167, DOI 10.5312/wjo.v7.i3.167
   Berthelot JM, 1996, J RHEUMATOL, V23, P2179
   GROB KR, 1995, Z RHEUMATOL, V54, P117
   Henry Brandon Michael, 2017, Folia Med Cracov, V57, P105
   Horwitz MT, 1939, ANAT REC, V74, P91, DOI 10.1002/ar.1090740110
   Iwanaga J, 2018, WORLD NEUROSURG, V116, pE766, DOI 10.1016/j.wneu.2018.05.087
   Konno T, 2017, J PAIN RES, V10, P1431, DOI 10.2147/JPR.S135382
   Mahli Ahmet, 2002, Spine (Phila Pa 1976), V27, pE478, DOI 10.1097/00007632-200211150-00018
   Maigne JY, 1997, SPINE, V22, P1156, DOI 10.1097/00007632-199705150-00017
   Matsumoto J, 2018, J NEUROSURG-SPINE, V29, P208, DOI 10.3171/2017.12.SPINE17991
   McGrath C, 2009, JOINT BONE SPINE, V76, P57, DOI 10.1016/j.jbspin.2008.02.015
   McGrath MC, 2005, SURG RADIOL ANAT, V27, P327, DOI 10.1007/s00276-005-0331-x
   Standring S., 2015, GRAYS ANATOMY BOOK A
   STRONG E K, 1957, Ind Med Surg, V26, P417
   Talu GK, 2000, REGION ANESTH PAIN M, V25, P648, DOI 10.1053/rapm.2000.18189
   Tomaszewski KA, 2017, CLIN ANAT, V30, P14, DOI 10.1002/ca.22800
   Tubbs RS, 2010, J NEUROSURG-SPINE, V13, P356, DOI 10.3171/2010.3.SPINE09747
   Willard F, 1998, LONG POSTERIOR INTER
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.061
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600067
PM 31863883
DA 2020-05-12
ER

PT J
AU Kim, H
   Jo, K
AF Kim, Hoon
   Jo, KwangWook
TI Laboratory Predictors of Contrast-Induced Nephropathy After
   Neurointervention: A Prospective 3-Year Observational Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acute kidney injury; Contrast-induced nephropathy; hsCRP;
   Neurointervention; Neutrophil gelatinase-associated lipocalin
ID C-REACTIVE PROTEIN; ACUTE KIDNEY INJURY; GELATINASE-ASSOCIATED
   LIPOCALIN; MYOCARDIAL-INFARCTION; RENAL-FUNCTION; IMPACT; RISK;
   EPIDEMIOLOGY; BIOMARKER; DISEASE
AB OBJECTIVE: The purpose of this study was to assess the natural course of contrast-induced nephropathy (CIN) and to determine the predictive abilities of preprocedural high-sensitivity C-reactive protein (hs-CRP) and urine neutrophil gelatinase-associated lipocalin for CIN after neurointervention procedures.
   METHODS: We prospectively enrolled 176 patients who underwent an elective neurointervention procedure (diagnostic angiography or endovascular surgery). CIN was defined as an increase in serum creatinine of more than 0.5 mg/dL or an increase of at least 25% from the baseline value within 48 hours of contrast media exposure. The predictive value of hs-CRP and serial urine NGAL (baseline, 6, 24, and 48 hours) for the risk of CIN was assessed using multivariate logistic regression.
   RESULTS: CIN occurred in 17 patients (9.46%). Multivariate analysis revealed that the CIN incidence was significantly associated with high baseline hs-CRP. All patients with CIN had creatinine return to baseline levels within 7 days. No patients required dialysis or suffered permanent sequelae as a result of a creatinine increase. During the 3-year follow-up period, no cerebro- or cardiovascular events occurred in the CIN group. However, 3 patients in the non-CIN group suffered a vascular event. One was a myocardial infarction, and 2 were ischemic strokes.
   CONCLUSIONS: The incidence of CIN after neurointervention procedures was relatively high (9.46%). The natural course of CIN was favorable, however, and did not affect cerebrovascular events. Additionally, patients with CIN typically recovered with supportive care within 7 days. Elevated preprocedural hs-CRP levels (>5 mg/dL) were a significant and independent predictor of CIN after neurointervention procedures.
C1 [Kim, Hoon; Jo, KwangWook] Catholic Univ Korea, Bucheon St Marys Hosp, Coll Med, Dept Neurosurg, Seoul, South Korea.
RP Jo, K (reprint author), Catholic Univ Korea, Bucheon St Marys Hosp, Coll Med, Dept Neurosurg, Seoul, South Korea.
EM jkw94@naver.com
FU Institute of Clinical Medicine Research of Bucheon St. Mary's Hospital,
   Research Fund
FX This work was supported by the Institute of Clinical Medicine Research
   of Bucheon St. Mary's Hospital, Research Fund, 2012.
CR Albeladi FI, 2017, NEPHRON EXTRA, V7, P62, DOI 10.1159/000477469
   Andreucci M, 2014, BIOMED RES INT, DOI 10.1155/2014/741018
   Bachorzewska-Gajewska H, 2006, AM J NEPHROL, V26, P287, DOI 10.1159/000093961
   Banerjee G, 2016, J NEUROL, V263, P760, DOI 10.1007/s00415-016-8040-4
   Celik T, 2005, CORONARY ARTERY DIS, V16, P293, DOI 10.1097/00019501-200508000-00006
   Chen WB, 2015, BIOMED RES INT, DOI 10.1155/2015/593060
   den Elzen WPJ, 2006, NEPHROL DIAL TRANSPL, V21, P1588, DOI 10.1093/ndt/gfk092
   Devarajan P, 2007, CONTRIB NEPHROL, V156, P203
   Filiopoulos V, 2014, RENAL FAILURE, V36, P979, DOI 10.3109/0886022X.2014.900429
   Haase M, 2009, AM J KIDNEY DIS, V54, P1012, DOI 10.1053/j.ajkd.2009.07.020
   Han SS, 2017, ANN THORAC SURG, V104, P804, DOI 10.1016/j.athoracsur.2017.01.075
   Hardiek K, 2001, AM J PHYSIOL-RENAL, V280, pF61
   Hirsch R, 2007, PEDIATR NEPHROL, V22, P2089, DOI 10.1007/s00467-007-0601-4
   Liu Y, 2012, J NEPHROL, V25, P332, DOI 10.5301/jn.5000007
   McCullough PA, 2006, AM J CARDIOL, V98, p5K, DOI 10.1016/j.amjcard.2006.01.019
   McIlroy DR, 2010, ANESTHESIOLOGY, V112, P998, DOI 10.1097/ALN.0b013e3181cded3f
   Nguyen MT, 2008, PEDIATR NEPHROL, V23, P2151, DOI 10.1007/s00467-007-0470-x
   Nusca A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197833
   Owens CD, 2007, J VASC SURG, V45, P2, DOI 10.1016/j.jvs.2006.08.048
   Pannu N, 2006, JAMA-J AM MED ASSOC, V295, P2765, DOI 10.1001/jama.295.23.2765
   Sarnak MJ, 2003, CIRCULATION, V108, P2154, DOI 10.1161/01.CIR.0000095676.90936.80
   Schulz S, 2016, CYTOKINE, V88, P71, DOI 10.1016/j.cyto.2016.08.021
   Shacham Y, 2015, CLIN EXP NEPHROL, V19, P838, DOI 10.1007/s10157-014-1071-1
   Sidhu RB, 2008, AM J CARDIOL, V102, P1482, DOI 10.1016/j.amjcard.2008.07.037
   Song W, 2014, CLIN INTERV AGING, V9, P85, DOI 10.2147/CIA.S55157
   Tropeano F, 2016, J CARDIOVASC PHARM T, V21, P159, DOI 10.1177/1074248415599062
   Tsirpanlis G, 2005, KIDNEY BLOOD PRESS R, V28, P55, DOI 10.1159/000082165
   Vrsalovic M, 2015, CROAT MED J, V56, P351, DOI 10.3325/cmj.2015.56.351
   Weisbord SD, 2008, ARCH INTERN MED, V168, P1325, DOI 10.1001/archinte.168.12.1325
   Yuan Y, 2017, CLIN CARDIOL, V40, P719, DOI 10.1002/clc.22722
   Zhang JW, 2014, ANGIOLOGY, V65, P402, DOI 10.1177/0003319713482177
NR 31
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.10.166
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600010
PM 31698123
DA 2020-05-12
ER

PT J
AU Kim, MS
   Rho, MH
   Hong, HP
   Park, HJ
   Chung, PW
   Won, YS
AF Kim, Myung Sub
   Rho, Myung Ho
   Hong, Hyun Pyo
   Park, Hee Jin
   Chung, Pil Wook
   Won, Yu Sam
TI Comparison of Embolic Protection with Proximal and Distal Protection
   Devices: Periprocedural Complications, Clinical Outcomes, and Cerebral
   Embolic Lesions on Diffusion-Weighted Magnetic Resonance Imaging
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid artery stenting; Cerebral protection device; Diffusion-weighted
   magnetic resonance imaging; Distal filter protection; Proximal balloon
   occlusion
ID CAROTID STENT THROMBOSIS; BALLOON ANGIOPLASTY; FILTER PROTECTION; ARTERY
   STENOSIS; HIGH-RISK; ENDARTERECTOMY; OCCLUSION; STROKE; PLAQUE
AB OBJECTIVE: Two main types of embolic protection devices have been used during carotid artery stenting (CAS): distal protection devices (DPDs) and proximal protection devices (PPDs). We compared the complications, clinical outcomes, and new ischemic lesions on diffusion-weighted magnetic resonance imaging (DWI) studies between patients who had undergone CAS using a DPD or PPD.
   METHODS: We performed a retrospective review of the data from patients who had undergone CAS from March 2010 to January 2016. The periprocedural and 30-day adverse events and new ischemic lesions on DWI studies after CAS were evaluated.
   RESULTS: CAS was performed in 103 patients (DPD, n = 60; PPD, n = 43). The number of patients with new ischemic lesions was greater in the DPD than in the PPD group (78% vs. 56%; P = 0.014). Most lesions (>90%) were tiny (<= 3 mm), and the average number of new tiny lesions per patient was significantly greater in the DPD than in the PPD group (mean, 9.6 vs. 4.0; P = 0.008). No significant differences in the periprocedural or 30-day adverse rates were noted between the 2 groups. Intolerance during the procedure occurred in 5 patients (12%) in the PPD group, 4 of whom had poor collateral circulation.
   CONCLUSIONS: The number of new ischemic lesions per patient and the incidence of ischemic lesions found on DWI were significantly greater in the DPD than in the PPD group. The lack of differences in the periprocedural and 30-day adverse rates between the 2 groups suggests that cerebral microemboli might not be associated with the clinical outcomes. For patients with poor collateral status, DPDs should be used preferentially to avoid the neurologic compromise associated with PPDs.
C1 [Kim, Myung Sub; Rho, Myung Ho; Hong, Hyun Pyo; Park, Hee Jin] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Dept Radiol, Seoul, South Korea.
   [Chung, Pil Wook] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Dept Neurol, Seoul, South Korea.
   [Won, Yu Sam] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Dept Neurosurg, Seoul, South Korea.
RP Rho, MH (reprint author), Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Dept Radiol, Seoul, South Korea.
EM rhomh96@gmail.com
CR Akkaya E, 2014, INT J CARDIOL, V176, P478, DOI 10.1016/j.ijcard.2014.07.241
   Biasi GM, 2004, CIRCULATION, V110, P756, DOI 10.1161/01.CIR.0000138103.91187.E3
   Bijuklic K, 2012, J AM COLL CARDIOL, V59, P1383, DOI 10.1016/j.jacc.2011.11.035
   Chaturvedi S, 2005, NEUROLOGY, V65, P794, DOI 10.1212/01.wnl.0000176036.07558.82
   Chaturvedi S, 2001, STROKE, V32, P2700
   Coggia M, 2000, J VASC SURG, V31, P550
   Ederle J, 2009, STROKE, V40, P1373, DOI 10.1161/STROKEAHA.108.531228
   Giri J, 2015, JACC-CARDIOVASC INTE, V8, P609, DOI 10.1016/j.jcin.2015.02.001
   Hauth EAM, 2005, AM J NEURORADIOL, V26, P2336
   Iyer V, 2007, J VASC SURG, V46, P251, DOI 10.1016/j.jvs.2007.04.053
   Kastrup A, 2008, AM J NEURORADIOL, V29, P608, DOI 10.3174/ajnr.A0871
   Kastrup A, 2003, CEREBROVASC DIS, V15, P84, DOI 10.1159/000067134
   Kastrup A, 2003, STROKE, V34, P813, DOI 10.1161/01.STR.0000058160.53040.5F
   Kolominsky-Rabas PL, 2001, STROKE, V32, P2735, DOI 10.1161/hs1201.100209
   Maggio P, 2013, J NEUROL SCI, V328, P58, DOI 10.1016/j.jns.2013.02.019
   Maleux G, 2006, AM J NEURORADIOL, V27, P1830
   Montorsi P, 2011, J AM COLL CARDIOL, V58, P1656, DOI 10.1016/j.jacc.2011.07.015
   Nicosia A, 2010, J ENDOVASC THER, V17, P275, DOI 10.1583/09-2943.1
   Omran J, 2017, CATHETER CARDIO INTE, V89, P923, DOI 10.1002/ccd.26842
   Rapp JH, 2000, J VASC SURG, V32, P68, DOI 10.1067/mva.2000.107315
   Reimers B, 2005, J ENDOVASC THER, V12, P156, DOI 10.1583/04-1400MR.1
   Roh HG, 2005, AM J NEURORADIOL, V26, P376
   Steiner-Boker S, 2004, AM J NEURORADIOL, V25, P1411
   Takaya N, 2005, CIRCULATION, V111, P2768, DOI 10.1161/CIRCULATIONAHA.104.504167
   Tendera M, 2011, EUR HEART J, V32, P2851, DOI 10.1093/eurheartj/ehr211
   Theron JG, 1996, RADIOLOGY, V201, P627, DOI 10.1148/radiology.201.3.8939208
   Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.121
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600088
PM 31899400
DA 2020-05-12
ER

PT J
AU Kim, SS
   Park, H
   Lee, KH
   Jung, S
   Yoon, CH
   Kim, SK
   Ryu, KH
   Baek, HJ
   Hwang, SH
   Kwon, OK
AF Kim, Seung Soo
   Park, Hyun
   Lee, Kwang Ho
   Jung, Seunguk
   Yoon, Chang Hyo
   Kim, Sung Kwon
   Ryu, Kyeong Hwa
   Baek, Hye Jin
   Hwang, Soo Hyun
   Kwon, O-Ki
TI Utility of Low-Profile Visualized Intraluminal Support Junior Stent as a
   Rescue Therapy for Treating Ruptured Intracranial Aneurysms During
   Complicated Coil Embolization
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endovascular; LVIS Jr.; Protrusion; Rescue treatment; Stent;
   Subarachnoid hemorrhage
ID WIDE-NECKED ANEURYSMS; GUGLIELMI DETACHABLE COILS; SELF-EXPANDABLE
   STENT; ENDOVASCULAR TREATMENT; CEREBRAL ANEURYSMS; SUBARACHNOID
   HEMORRHAGE; PLACEMENT; EVENTS; RISK; HEMODYNAMICS
AB BACKGROUND: Coil protrusion occasionally occurs during embolization and can lead to thromboembolic complications. We aimed to evaluate the efficacy of rescue stenting procedures with a low-profile stent system (LVIS Jr.) for treating ruptured intracranial aneurysms during complicated coil embolization.
   METHODS: We performed a retrospective review to identify patients who had subarachnoid hemorrhage and were treated with LVIS Jr. stent rescue therapy. We enrolled 15 patients with intracranial aneurysms and evaluated the technical success and immediate post-procedural clinical and angiographic outcomes.
   RESULTS: All 15 patients underwent successful rescuestent treatment, and no thrombotic or hemorrhagic complications occurred. Immediate postprocedural angiography revealed complete aneurysm occlusion in 40% (6/15) of the patients, whereas 60% (9) of the patients had a residual neck. Among the 12 patients who underwent follow-up angiography, 10 (83.3%) patients had complete aneurysm occlusion, 1 (8.3%) had a residual neck, and 1 (8.3%) showed an increase in the filling status of the aneurysm. There were no thrombotic complications during the follow-up period.
   CONCLUSIONS: Our findings indicate that LVIS Jr. stent rescue therapy is clinically useful for handling coil protrusion during the embolization of ruptured intracranial aneurysms.
C1 [Kim, Seung Soo; Kim, Sung Kwon] Gyeongsang Natl Univ, Changwon Hosp, Dept Neurosurg, Changwon Si, Gyeongsangnam D, South Korea.
   [Jung, Seunguk; Yoon, Chang Hyo] Gyeongsang Natl Univ, Changwon Hosp, Dept Neurol, Changwon Si, Gyeongsangnam D, South Korea.
   [Park, Hyun; Lee, Kwang Ho; Hwang, Soo Hyun] Gyeongsang Natl Univ, Sch Med, Gyeongsang Natl Univ Hosp, Dept Neurosurg, Jinju Si, South Korea.
   [Ryu, Kyeong Hwa; Baek, Hye Jin] Gyeongsang Natl Univ, Sch Med, Dept Radiol, Changwon Hosp, Chang Won, South Korea.
   [Kwon, O-Ki] Seoul Natl Univ, Dept Neurosurg, Bundang Hosp, Sungnam Si, Gyeonggi Do, South Korea.
RP Park, H (reprint author), Gyeongsang Natl Univ, Sch Med, Gyeongsang Natl Univ Hosp, Dept Neurosurg, Jinju Si, South Korea.
EM 1coo3004@naver.com
OI Kim, Seung Soo/0000-0002-2114-4594; Lee, Kwangho/0000-0001-8366-0669
CR Abdihalim M, 2011, AM J NEURORADIOL, V32, P1392, DOI 10.3174/ajnr.A2572
   Amenta PS, 2012, NEUROSURGERY, V70, P1415, DOI 10.1227/NEU.0b013e318246a4b1
   Chalouhi N, 2012, NEUROSURGERY, V71, P710, DOI 10.1227/NEU.0b013e31826213f9
   Chung JH, 2018, NEUROL RES, V40, P78, DOI 10.1080/01616412.2017.1398881
   Derdeyn CP, 2002, J NEUROSURG, V96, P837, DOI 10.3171/jns.2002.96.5.0837
   Dinc H, 2006, NEURORADIOLOGY, V48, P269, DOI 10.1007/s00234-006-0051-x
   Fessler RD, 2000, NEUROSURGERY, V46, P248
   Fiorella D, 2005, NEUROSURGERY, V57, P1218, DOI 10.1227/01.NEU.0000186036.35823.10
   Fourie P, 2003, AM J NEURORADIOL, V24, P630
   Frontera JA, 2006, NEUROSURGERY, V59, P21, DOI 10.1227/01.NEU.0000218821.34014.1B
   Jankowitz B, 2008, INTERV NEURORADIOL, V14, P385, DOI 10.1177/159101990801400404
   Klotzsch C, 1998, AM J NEURORADIOL, V19, P1315
   Kono K, 2013, AM J NEURORADIOL, V34, P1980, DOI 10.3174/ajnr.A3479
   Krischek O, 2011, MINIM INVAS NEUROSUR, V54, P21, DOI 10.1055/s-0031-1271681
   Kwon OK, 2005, AM J NEURORADIOL, V26, P894
   Lanzino G, 1999, J NEUROSURG, V91, P538, DOI 10.3171/jns.1999.91.4.0538
   Lavine SD, 2000, NEUROSURGERY, V46, P1013, DOI 10.1097/00006123-200004000-00051
   Liang XD, 2016, J NEUROINTERV SURG, V8, P1148, DOI 10.1136/neurintsurg-2015-012055
   Lubicz B, 2006, NEUROSURGERY, V58, P451, DOI 10.1227/01.NEU.0000200346.39119.3D
   Luo CB, 2008, AM J NEURORADIOL, V29, P1951, DOI 10.3174/ajnr.A1268
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Pelz DM, 1998, AM J NEURORADIOL, V19, P1541
   Phatouros CC, 1999, NEURORADIOLOGY, V41, P324, DOI 10.1007/s002340050757
   Pierot L, 2008, STROKE, V39, P2497, DOI 10.1161/STROKEAHA.107.512756
   Rordorf G, 2001, AM J NEURORADIOL, V22, P5
   Schutz A, 2005, NEURORADIOLOGY, V47, P874, DOI 10.1007/s00234-005-1430-4
   Shobayashi Y, 2013, J NEUROINTERV SURG, V5, pIII38, DOI 10.1136/neurintsurg-2012-010488
   STANDARD SC, 1994, NEUROSURGERY, V35, P994, DOI 10.1227/00006123-199411000-00038
   Sugiu K, 2002, J NEUROSURG, V96, P373, DOI 10.3171/jns.2002.96.2.0373
   Tateshima S, 2009, J NEUROSURG, V111, P22, DOI 10.3171/2009.2.JNS081324
   van Amerongen MJ, 2014, AM J NEURORADIOL, V35, P1655, DOI 10.3174/ajnr.A3700
   Wanke I, 2008, NEURORADIOLOGY, V50, P991, DOI 10.1007/s00234-008-0460-0
   Wermer MJH, 2007, STROKE, V38, P1404, DOI 10.1161/01.STR.0000260955.51401.cd
   Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401
   Workman MJ, 2002, AM J NEURORADIOL, V23, P1568
   Yoo E, 2009, AM J NEURORADIOL, V30, P1028, DOI 10.3174/ajnr.A1482
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.110
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600085
PM 31887464
DA 2020-05-12
ER

PT J
AU Kimura, R
   Hayashi, Y
   Sasagawa, Y
   Kobayashi, M
   Oishi, M
   Kinoshita, M
   Nakada, M
AF Kimura, Ryouken
   Hayashi, Yasuhiko
   Sasagawa, Yasuo
   Kobayashi, Masaaki
   Oishi, Masahiro
   Kinoshita, Masashi
   Nakada, Mitsutoshi
TI Progressively Enlarged Convexity Arachnoid Cysts in Elderly Patients: A
   Report of 2 Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arachnoid cyst; Convexity; Elderly; Enlarge; Symptomatic
ID NATURAL-HISTORY; PREVALENCE; FOSSA
AB BACKGROUND: Generally, enlargement of arachnoid cysts (ACs) has been found mostly in cases occurring during early childhood. Therefore, progressively enlarged ACs found to be symptomatic in elderly patients are extremely rare, and the mechanisms have remained unexplored.
   CASE DESCRIPTION: Our first patient was a 72-year-old woman with memory disturbance, who had presented with a large cyst beneath the right temporal convexity 9 years previously. The annual follow-up magnetic resonance imaging (MRI) studies had revealed that the cyst had progressively enlarged. In addition, her memory disturbance had become advanced. Endoscopic cyst fenestration was performed between the cyst and lateral ventricle, resulting in a reduction of her symptoms. Our second patient was a 79-year-old woman with unsteadiness, who had presented with a large cyst under the right parietal convexity 6 years previously. The annual follow-up MRI studies had shown that the cyst had gradually enlarged. She subsequently developed left hemiparesis. Because the pyramidal tract was located between the cyst and ventricle, a cyst-ventricle shunt was placed to allow the cystic fluid into the lateral ventricle, with complete resolution of her symptoms. In both cases, MRI showed obliteration of the subdural spaces around the cysts. Endoscopic observations revealed that the arachnoid membrane was lined under the surrounding brain, leading to the diagnosis of an AC.
   CONCLUSION: The establishment of stable communication between a cyst and the normal cerebrospinal fluid space is important to treat symptomatic ACs characterized by progressive enlargement, even in elderly patients. The 1-way entry of the cerebrospinal fluid into the cyst and the closure of the surrounding subdural space might result in AC enlargement internally.
C1 [Kimura, Ryouken; Hayashi, Yasuhiko; Sasagawa, Yasuo; Kobayashi, Masaaki; Oishi, Masahiro; Kinoshita, Masashi; Nakada, Mitsutoshi] Kanazawa Univ, Grad Sch Med Sci, Dept Neurosurg, Kanazawa, Ishikawa, Japan.
RP Hayashi, Y (reprint author), Kanazawa Univ, Grad Sch Med Sci, Dept Neurosurg, Kanazawa, Ishikawa, Japan.
EM yhayashi@kanazawa-med.ac.jp
OI Oishi, Masahiro/0000-0002-9776-2399; Hayashi,
   Yasuhiko/0000-0001-5998-3329
CR Al-Holou WN, 2013, J NEUROSURG, V118, P222, DOI 10.3171/2012.10.JNS12548
   Al-Holou WN, 2010, J NEUROSURG-PEDIATR, V5, P578, DOI 10.3171/2010.2.PEDS09464
   Alexiou GA, 2010, NEUROSURGERY, V67, P1632, DOI 10.1227/NEU.0b013e3181f94476
   ARTICO M, 1995, ACTA NEUROCHIR, V132, P75, DOI 10.1007/BF01404851
   Berle M, 2010, FLUIDS BARRIERS CNS, V7, DOI 10.1186/1743-8454-7-8
   Clifton W, 2018, WORLD NEUROSURG, V116, P329, DOI 10.1016/j.wneu.2018.05.046
   Couvreur T, 2015, WORLD NEUROSURG, V84, DOI 10.1016/j.wneu.2015.04.053
   De Keersmaecker B, 2015, EUR J PAEDIATR NEURO, V19, P114, DOI 10.1016/j.ejpn.2014.12.008
   Di Rocco F, 2005, J NEUROSURG, V103, P54, DOI 10.3171/ped.2005.103.1.0054
   DYCK P, 1977, ARCH NEUROL-CHICAGO, V34, P276, DOI 10.1001/archneur.1977.00500170030004
   Fulkerson DH, 2011, J NEUROSURG-PEDIATR, V7, P549, DOI 10.3171/2011.2.PEDS10457
   GALASSI E, 1982, SURG NEUROL, V17, P363, DOI 10.1016/0090-3019(82)90315-9
   GO KG, 1984, J NEUROSURG, V60, P803, DOI 10.3171/jns.1984.60.4.0803
   Hayashi Yasuhiko, 2015, Surg Neurol Int, V6, P7, DOI 10.4103/2152-7806.149611
   Helland CA, 2006, J NEUROSURG, V105, P385, DOI 10.3171/ped.2006.105.5.385
   Marques IB, 2014, ACTA MEDICA PORT, V27, P137, DOI 10.20344/amp.2017
   Oertel JMK, 2010, NEUROSURGERY, V67, P824, DOI 10.1227/01.NEU.0000377852.75544.E4
   WATANABE M, 1994, SURG NEUROL, V42, P346, DOI 10.1016/0090-3019(94)90408-1
   Yokoyama K, 2019, WORLD NEUROSURG, V130, P154, DOI 10.1016/j.wneu.2019.07.029
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.112
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600145
PM 31887463
DA 2020-05-12
ER

PT J
AU Kimura, T
   Kamide, T
   Onodera, K
   Tabata, S
   Shibata, A
   Suzuki, K
   Takeda, R
   Ikeda, T
   Kikkawa, Y
   Iihoshi, S
   Kohyama, S
   Kurita, H
AF Kimura, Tatsuki
   Kamide, Tomoya
   Onodera, Koki
   Tabata, Shinya
   Shibata, Aoto
   Suzuki, Kaima
   Takeda, Ririko
   Ikeda, Toshiki
   Kikkawa, Yuichiro
   Iihoshi, Satoshi
   Kohyama, Shinya
   Kurita, Hiroki
TI Clinical Features of Neurogenic Pulmonary Edema in Patients with
   Subarachnoid Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Central nervous system injury; Neurogenic pulmonary edema;
   Subarachnoid hemorrhage; Vertebral artery dissection; WFNS grade
AB OBJECTIVE: Neurogenic pulmonary edema (NPE) is a clinical syndrome characterized by acute onset after central nervous system injury. Here, we investigated the clinical features of NPE in patients with subarachnoid hemorrhage (SAH).
   METHODS: We retrospectively analyzed a total of 350 patients with SAH who were treated at our hospital from April 2014 to September 2017. Patient demographics, aneurysm size and location, clinical characteristics, and patient outcomes were reviewed and compared between an NPE and a non-NPE group.
   RESULTS: Sixteen patients (4.6%) presented with NPE at admission. Ten of these (62.5%) recovered from NPE immediately, and ventilatory support was withdrawn within 2 days from onset. A univariate analysis showed that patients with NPE were younger (P = 0.04), had a higher rate of vertebral artery dissection (P < 0.01), more severe World Federation of Neurosurgical Societies (WFNS) grades (P = 0.01), and lower systolic blood pressure on admission (P = 0.01). A multivariate analysis revealed significant differences in the frequency of vertebral artery dissection (odds ratio 4.83, 95% confidence interval 1.50-15.56, P < 0.01) and in WFNS grades (odds ratio 3.73, 95% confidence interval 1.02-13.66, P = 0.04) between the groups. No significant group differences were found in other factors including heart rate, radiographic sign (Fisher grade), aneurysm size and location, blood sample tests on admission, and neurologic outcomes.
   CONCLUSIONS: Vertebral artery dissection and severe WENS grade on admission were confirmed as significant risk factors for NPE. However, neurologic outcomes at discharge did not differ between groups, suggesting that poor outcomes due to NPE could be reduced by appropriate diagnosis and treatment.
C1 [Kimura, Tatsuki; Kamide, Tomoya; Onodera, Koki; Tabata, Shinya; Shibata, Aoto; Suzuki, Kaima; Takeda, Ririko; Ikeda, Toshiki; Kikkawa, Yuichiro; Iihoshi, Satoshi; Kohyama, Shinya; Kurita, Hiroki] Saitama Med Univ, Int Med Ctr, Dept Neurosurg, Hidaka, Japan.
RP Kamide, T (reprint author), Saitama Med Univ, Int Med Ctr, Dept Neurosurg, Hidaka, Japan.
EM kamide@med.kanazawa-u.ac.jp
CR Baumann A, 2007, ACTA ANAESTH SCAND, V51, P447, DOI 10.1111/j.1399-6576.2007.01276.x
   Canovas D, 2012, EUR J NEUROL, V19, P457, DOI 10.1111/j.1468-1331.2011.03542.x
   Cavallo C, 2018, WORLD NEUROSURG, V119, pE366, DOI 10.1016/j.wneu.2018.07.166
   Chaari A, 2015, AM J EMERG MED, V33, DOI 10.1016/j.ajem.2014.12.009
   Chen WL, 2016, NEUROCRIT CARE, V25, P71, DOI 10.1007/s12028-015-0237-3
   GARCIAURIA J, 1981, J NEUROSURG, V54, P632, DOI 10.3171/jns.1981.54.5.0632
   Gokyar A, 2018, WORLD NEUROSURG, V115, pE476, DOI 10.1016/j.wneu.2018.04.075
   Inamasu J, 2012, ACTA NEUROCHIR, V154, P2179, DOI 10.1007/s00701-012-1515-x
   Manto A, 2014, NEURORADIOL J, V27, P356, DOI 10.15274/NRJ-2014-10035
   Meguro T, 2016, TURK NEUROSURG, V26, P849, DOI 10.5137/1019-5149.JTN.13870-15.1
   Muroi C, 2008, J NEUROSURG ANESTH, V20, P188, DOI 10.1097/ANA.0b013e3181778156
   Nastasovic T, 2017, ACTA NEUROCHIR, V159, P705, DOI 10.1007/s00701-017-3091-6
   Ochiai H, 2001, NEUROL MED-CHIR, V41, P529, DOI 10.2176/nmc.41.529
   Ogura T, 2012, NEUROL RES, V34, P484, DOI 10.1179/1743132812Y.0000000033
   Rajagopal R, 2017, INDIAN J CRIT CARE M, V21, P329, DOI 10.4103/ijccm.IJCCM_431_16
   Sedy J, 2008, PHYSIOL RES, V57, P499
   Yamagishi T, 2014, J EMERG MED, V46, P683, DOI 10.1016/j.jemermed.2013.11.094
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.060
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600060
PM 31863887
DA 2020-05-12
ER

PT J
AU Krafft, PR
   Noureldine, MHA
   Greenberg, MS
   Alikhani, P
AF Krafft, Paul R.
   Noureldine, Mohammad Hassan A.
   Greenberg, Mark S.
   Alikhani, Puya
TI Minimally Invasive Lateral Retropleural Approach to the Thoracic Spine
   for Salvage of a Subsided Expandable Interbody Cage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior column; Cylindrical; Endcap; Expandable cage; Instrumentation;
   Rectangular; Subsidence
ID TITANIUM MESH CAGE; CLINICAL-OUTCOMES; CORPECTOMY; RECONSTRUCTION
AB BACKGROUND: Cylindrical expandable cages are commonly used as interbody grafts after cervical, thoracic, or lumbar corpectomy in patients with osteomyelitis. Unfortunately, there is a high incidence of hardware subsidence due to small-diameter footplates. Newer expandable intervertebral cages with large rectangular endcaps use the anatomic strength of the vertebral epiphyseal ring to prevent subsidence.
   CASE DESCRIPTION: A 67-year-old man with medically refractory thoracic osteomyelitis and discitis presented to our service for further management of debilitating back pain secondary to a persistent infection and associated progressive spinal kyphotic deformity. lie underwent a transpedicular 19-10 corpectomy, placement of an expandable interbody cage, and posterior instrumented spinal fusion from T7 to T12. On postoperative day 2, upright thoracic radiographs demonstrated cage subsidence of >50% into the T8 vertebral body. The patient was returned to the operating room for hardware revision and placement of an expandable intervertebral cage with rectangular endcaps through a minimally invasive lateral retropleural approach to the thoracic spine. The patient tolerated the procedure well, and no evidence of subsidence occurred after the revision after 2 years of follow-up.
   CONCLUSIONS: Expandable intervertebral cages with rectangular endcaps can be used to prevent and/or correct preexisting cage subsidence in patients in need of anterior column instrumentation, especially in those with bone-weakening pathologies. Prospective studies should be entertained to evaluate subsidence rates in cages with cylindrical versus rectangular endcaps.
C1 [Krafft, Paul R.; Greenberg, Mark S.; Alikhani, Puya] Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Tampa, FL 33620 USA.
   [Noureldine, Mohammad Hassan A.] Johns Hopkins Univ, Sch Med, Inst Brain Protect Sci, Johns Hopkins All Childrens Hosp, St Petersburg, FL USA.
RP Krafft, PR (reprint author), Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Tampa, FL 33620 USA.
EM pkrafft@usf.edu
CR Arts MP, 2008, NEUROSURGERY, V63, P537, DOI 10.1227/01.NEU.0000325260.00628.DC
   Bailey CS, 2011, SPINE, V36, P124, DOI 10.1097/BRS.0b013e3181cc8a32
   Bartels RHMA, 2006, NEUROSURGERY, V58, P502, DOI 10.1227/01.NEU.0000197258.30821.50
   Chen Y, 2008, J SPINAL DISORD TECH, V21, P489, DOI 10.1097/BSD.0b013e318158de22
   Cunningham BW, 2002, CLIN ORTHOP RELAT R, P73
   Deukmedjian AR, 2014, J CLIN NEUROSCI, V21, P1632, DOI 10.1016/j.jocn.2013.12.028
   Fang TL, 2012, J NEUROSURG-SPINE, V17, P271, DOI 10.3171/2012.7.SPINE111086
   Holland CM, 2015, CLIN NEUROL NEUROSUR, V129, P37, DOI 10.1016/j.clineuro.2014.11.022
   Karikari IO, 2014, J SPINAL DISORD TECH, V27, P1, DOI 10.1097/BSD.0b013e31825bd26d
   Kim HW, 2011, J KOREAN NEUROSURG S, V50, P348, DOI 10.3340/jkns.2011.50.4.348
   Lau D, 2013, NEUROSURGERY, V72, P529, DOI 10.1227/NEU.0b013e318282a558
   Nakase H, 2006, J SPINAL DISORD TECH, V19, P353, DOI 10.1097/01.bsd.0000210113.09521.aa
   Pee YH, 2008, J NEUROSURG-SPINE, V8, P405, DOI 10.3171/SPI/2008/8/5/405
   Pekmezci M, 2012, SPINE, V37, pE1177, DOI 10.1097/BRS.0b013e3182647c0b
   Schomacher M, 2014, CLIN NEUROL NEUROSUR, V127, P65, DOI 10.1016/j.clineuro.2014.09.027
   Wilke HJ, 2000, SPINE, V25, P2762, DOI 10.1097/00007632-200011010-00008
NR 16
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.008
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600104
PM 31841720
DA 2020-05-12
ER

EF